"Authors","Author full names","Author(s) ID","Title","Year","Source title","Volume","Issue","Art. No.","Page start","Page end","Page count","Cited by","DOI","Link","Affiliations","Authors with affiliations","Abstract","Author Keywords","Index Keywords","Molecular Sequence Numbers","Chemicals/CAS","Tradenames","Manufacturers","Funding Details","Funding Texts","References","Correspondence Address","Editors","Publisher","Sponsors","Conference name","Conference date","Conference location","Conference code","ISSN","ISBN","CODEN","PubMed ID","Language of Original Document","Abbreviated Source Title","Document Type","Publication Stage","Open Access","Source","EID"

"Nozu T.; Miyagishi S.; Ishioh M.; Takakusaki K.; Okumura T.","Nozu, Tsukasa (12765917900); Miyagishi, Saori (56538237900); Ishioh, Masatomo (57202513969); Takakusaki, Kaoru (7004150214); Okumura, Toshikatsu (7202327796)","12765917900; 56538237900; 57202513969; 7004150214; 7202327796","Peripheral apelin mediates visceral hypersensitivity and impaired gut barrier in a rat irritable bowel syndrome model","2022","Neuropeptides","94","","102248","","","","4","10.1016/j.npep.2022.102248","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85129563627&doi=10.1016%2fj.npep.2022.102248&partnerID=40&md5=4ce6f239a105fae8b8d8855131ee83b4","Department of Regional Medicine and Education, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Hokkaido, Asahikawa, 078-8510, Japan; Center for Medical Education, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Hokkaido, Asahikawa, 078-8510, Japan; Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Hokkaido, Asahikawa, 078-8510, Japan; Division of Neuroscience, Department of Physiology, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Hokkaido, Asahikawa, 078-8510, Japan; Department of General Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Hokkaido, Asahikawa, 078-8510, Japan","Nozu T., Department of Regional Medicine and Education, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Hokkaido, Asahikawa, 078-8510, Japan, Center for Medical Education, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Hokkaido, Asahikawa, 078-8510, Japan; Miyagishi S., Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Hokkaido, Asahikawa, 078-8510, Japan; Ishioh M., Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Hokkaido, Asahikawa, 078-8510, Japan; Takakusaki K., Division of Neuroscience, Department of Physiology, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Hokkaido, Asahikawa, 078-8510, Japan; Okumura T., Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Hokkaido, Asahikawa, 078-8510, Japan, Department of General Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Hokkaido, Asahikawa, 078-8510, Japan","Growing evidence indicates that visceral hypersensitivity and impaired gut barrier play an important role in the pathophysiology of irritable bowel syndrome (IBS). In animal models, these changes are known to be mediated via corticotropin-releasing factor (CRF)-Toll like receptor 4 (TLR4)-proinflammatory cytokine signaling. Apelin, an endogenous ligand of APJ, was reported to modulate CRF-induced enhanced colonic motility. In this context, we hypothesized that apelin also modulates visceral sensation and gut barrier, and tested this hypothesis. We measured visceral pain threshold in response to colonic balloon distention by abdominal muscle contractions assessed by electromyogram in rats. Colonic permeability was estimated by quantifying the absorbed Evans blue in colonic tissue. Intraperitoneal (ip) administration of [Ala13]-apelin-13, an APJ antagonist, blocked lipopolysaccharide (LPS)- or CRF-induced visceral hypersensitivity and colonic hyperpermeability (IBS model) in a dose-response manner. These inhibitory effects were blocked by compound C, an AMPK inhibitor, NG-nitro-L-arginine methyl ester, a nitric oxide (NO) synthesis inhibitor or naloxone in the LPS model. On the other hand, ip [Pyr1]-apelin-13, an APJ agonist, caused visceral hypersensitivity and colonic hyperpermeability, and these effects were reversed by astressin, a CRF receptor antagonist, TAK-242, a TLR4 antagonist or anakinra, an interleukin-1 receptor antagonist. APJ system modulated CRF-TLR4-proinflammatory cytokine signaling to cause visceral hypersensitivity and colonic hyperpermeability. APJ antagonist blocked these GI changes in IBS models, which were mediated via AMPK, NO and opioid signaling. Apelin may contribute to the IBS pathophysiology, and the inhibition of apelinergic signaling may be a promising therapeutic option for IBS. © 2022 Elsevier Ltd","Apelin; Corticotropin-releasing factor; Gut barrier; Lipopolysaccharide; Visceral sensation","AMP-Activated Protein Kinases; Animals; Apelin; Colon; Corticotropin-Releasing Hormone; Cytokines; Irritable Bowel Syndrome; Lipopolysaccharides; Rats; Rats, Sprague-Dawley; Toll-Like Receptor 4; anakinra; apelin; astressin; butorphanol tartrate; corticotropin releasing factor; dimethyl sulfoxide; interleukin 1 receptor blocking agent; lipopolysaccharide; medetomidine; midazolam; n,n dimethylformamide; naloxone; nitric oxide; toll like receptor 4; apelin; cytokine; hydroxymethylglutaryl coenzyme A reductase kinase; lipopolysaccharide; toll like receptor 4; abdominal wall musculature; adult; animal experiment; animal model; Article; colon tissue; cytokine signaling; electromyogram; gastrointestinal tract; irritable colon; male; nonhuman; pathophysiology; protein phosphorylation; rat; signal transduction; upregulation; visceral hyperalgesia; visceral pain; animal; colon; Sprague Dawley rat","","anakinra, 143090-92-0; astressin, 170809-51-5; butorphanol tartrate, 58786-99-5; corticotropin releasing factor, 9015-71-8, 178359-01-8, 79804-71-0, 86297-72-5, 86784-80-7; dimethyl sulfoxide, 67-68-5; medetomidine, 119717-21-4, 86347-14-0, 86347-15-1; midazolam, 59467-70-8, 59467-96-8; n,n dimethylformamide, 68-12-2; naloxone, 357-08-4, 465-65-6; nitric oxide, 10102-43-9; toll like receptor 4, 203811-83-0; hydroxymethylglutaryl coenzyme A reductase kinase, 172522-01-9, 72060-32-3; AMP-Activated Protein Kinases, ; Apelin, ; Corticotropin-Releasing Hormone, ; Cytokines, ; Lipopolysaccharides, ; Toll-Like Receptor 4, ","","","Akiyama Life Science Foundation; Japan Society for the Promotion of Science, KAKEN, (26120012, 26460287, 26460955)","This work was partially supported by the Japan Society for the Promotion of Science KAKENHI, Grant-in-Aid for Scientific Research (C) [26460287 (TN) and 26460955 (TO)], Scientific Research on Innovative Areas [26120012 (KT)], and the research grant from the Akiyama Life Science Foundation (TN). ","Al-Chaer E.D., Kawasaki M., Pasricha P.J., A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development, Gastroenterology, 119, pp. 1276-1285, (2000); Belmonte L., Beutheu Youmba S., Bertiaux-Vandaele N., Antonietti M., Lecleire S., Zalar A., Gourcerol G., Leroi A.M., Dechelotte P., Coeffier M., Ducrotte P., Role of toll like receptors in irritable bowel syndrome: differential mucosal immune activation according to the disease subtype, PLoS One, 7, (2012); Bulbul M., Sinen O., Birsen I., Izgut-Uysal V., Peripheral apelin-13 administration inhibits gastrointestinal motor functions in rats: the role of cholecystokinin through CCK(1) receptor-mediated pathway, Neuropeptides, 63, pp. 91-97, (2017); Bulbul M., Sinen O., Izgut-Uysal V.N., Akkoyunlu G., Ozturk S., Uysal F., Peripheral apelin mediates stress-induced alterations in gastrointestinal motor functions depending on the nutritional status, Clin. Exp. Pharmacol. Physiol., 46, pp. 29-39, (2019); Bulbul M., Sinen O., Bayramoglu O., Akkoyunlu G., Enteric apelin enhances the stress-induced stimulation of colonic motor functions, Stress, 23, pp. 201-212, (2020); Camilleri M., Lasch K., Zhou W., Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome, Am. J. Physiol. Gastrointest. Liver Physiol., 303, pp. G775-G785, (2012); Chatoo M., Li Y., Ma Z., Coote J., Du J., Chen X., Involvement of Corticotropin-releasing factor and receptors in immune cells in irritable bowel syndrome, Front. Endocrinol. (Lausanne), 9, (2018); Chen L., Tao Y., Jiang Y., Apelin activates the expression of inflammatory cytokines in microglial BV2 cells via PI-3K/Akt and MEK/Erk pathways, Sci. China Life Sci., 58, pp. 531-540, (2015); Creekmore A.L., Hong S., Zhu S., Xue J., Wiley J.W., Chronic stress-associated visceral hyperalgesia correlates with severity of intestinal barrier dysfunction, Pain, 159, pp. 1777-1789, (2018); Dlugosz A., Nowak P., D'Amato M., Mohammadian Kermani G., Nystrom J., Abdurahman S., Lindberg G., Increased serum levels of lipopolysaccharide and antiflagellin antibodies in patients with diarrhea-predominant irritable bowel syndrome, Neurogastroenterol. Motil., 27, pp. 1747-1754, (2015); Ferre S., Casado V., Devi L.A., Filizola M., Jockers R., Lohse M.J., Milligan G., Pin J.P., Guitart X., G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives, Pharmacol. Rev., 66, pp. 413-434, (2014); Ferreira S.H., Duarte I.D., Lorenzetti B.B., The molecular mechanism of action of peripheral morphine analgesia: stimulation of the cGMP system via nitric oxide release, Eur. J. Pharmacol., 201, pp. 121-122, (1991); Fukudo S., Nomura T., Hongo M., Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome, Gut, 42, pp. 845-849, (1998); Han S., Wang G., Qiu S., de la Motte C., Wang H.Q., Gomez G., Englander E.W., Greeley G.H., Increased colonic apelin production in rodents with experimental colitis and in humans with IBD, Regul. Pept., 142, pp. 131-137, (2007); Han S., Wang G., Qi X., Englander E.W., Greeley G.H., Involvement of a Stat3 binding site in inflammation-induced enteric apelin expression, Am. J. Physiol. Gastrointest. Liver Physiol., 295, pp. G1068-G1078, (2008); Igarashi S., Nozu T., Ishioh M., Kumei S., Saito T., Toki Y., Hatayama M., Yamamoto M., Shindo M., Tanabe H., Okumura T., Centrally administered orexin prevents lipopolysaccharide and colchicine induced lethality via the vagal cholinergic pathway in a sepsis model in rats, Biochem. Pharmacol., (2020); Jing N., Fang B., Li Z., Tian A., Exogenous activation of cannabinoid-2 receptor modulates TLR4/MMP9 expression in a spinal cord ischemia reperfusion rat model, J. Neuroinflammation, 17, (2020); Kanazawa M., Hongo M., Fukudo S., Visceral hypersensitivity in irritable bowel syndrome, J. Gastroenterol. Hepatol., 26, pp. 119-121, (2011); Kim J., Kwak H.J., Cha J.Y., Jeong Y.S., Rhee S.D., Kim K.R., Cheon H.G., Metformin suppresses lipopolysaccharide (LPS)-induced inflammatory response in murine macrophages via activating transcription factor-3 (ATF-3) induction, J. Biol. Chem., 289, pp. 23246-23255, (2014); Kocak E., Akbal E., Koklu S., Ergul B., Can M., The colonic tissue levels of TLR2, TLR4 and nitric oxide in patients with irritable bowel syndrome, Intern. Med., 55, pp. 1043-1048, (2016); Kroncke K.D., Fehsel K., Suschek C., Kolb-Bachofen V., Inducible nitric oxide synthase-derived nitric oxide in gene regulation, cell death and cell survival, Int. Immunopharmacol., 1, pp. 1407-1420, (2001); Larauche M., Mulak A., Kim Y.S., Labus J., Million M., Tache Y., Visceral analgesia induced by acute and repeated water avoidance stress in rats: sex difference in opioid involvement, Neurogastroenterol. Motil., 24, pp. 1031-e1547, (2012); Li Y., Chen J., Bai B., Du H., Liu Y., Liu H., Heterodimerization of human apelin and kappa opioid receptors: roles in signal transduction, Cell. Signal., 24, pp. 991-1001, (2012); Liebregts T., Adam B., Bredack C., Roth A., Heinzel S., Lester S., Downie-Doyle S., Smith E., Drew P., Talley N.J., Holtmann G., Immune activation in patients with irritable bowel syndrome, Gastroenterology, 132, pp. 913-920, (2007); Luo Q., Liu G., Chen G., Guo D., Xu L., Hang M., Jin M., Apelin protects against sepsis-induced cardiomyopathy by inhibiting the TLR4 and NLRP3 signaling pathways, Int. J. Mol. Med., 42, pp. 1161-1167, (2018); Martucci C., Franchi S., Lattuada D., Panerai A.E., Sacerdote P., Differential involvement of RelB in morphine-induced modulation of chemotaxis, NO, and cytokine production in murine macrophages and lymphocytes, J. Leukoc. Biol., 81, pp. 344-354, (2007); McKernan D.P., Gaszner G., Quigley E.M., Cryan J.F., Dinan T.G., Altered peripheral toll-like receptor responses in the irritable bowel syndrome, Aliment. Pharmacol. Ther., 33, pp. 1045-1052, (2011); Meares G.P., Hughes K.J., Naatz A., Papa F.R., Urano F., Hansen P.A., Benveniste E.N., Corbett J.A., IRE1-dependent activation of AMPK in response to nitric oxide, Mol. Cell. Biol., 31, pp. 4286-4297, (2011); Mearin F., Lacy B.E., Chang L., Chey W.D., Lembo A.J., Simren M., Spiller R., Bowel disorders, Gastroenterology, 150, pp. 1393-1407, (2016); Mertz H., Naliboff B., Munakata J., Niazi N., Mayer E.A., Altered rectal perception is a biological marker of patients with irritable bowel syndrome, Gastroenterology, 109, pp. 40-52, (1995); Mughal A., Sun C., O'Rourke, S.T, Apelin reduces nitric oxide-induced relaxation of cerebral arteries by inhibiting activation of large-conductance, calcium-activated K channels, J. Cardiovasc. Pharmacol., 71, pp. 223-232, (2018); Ness T.J., Gebhart G.F., Colorectal distension as a noxious visceral stimulus: physiologic and pharmacologic characterization of pseudaffective reflexes in the rat, Brain Res., 450, pp. 153-169, (1988); Nozaki-Taguchi N., Yamamoto T., The interaction of FK409, a novel nitric oxide releaser, and peripherally administered morphine during experimental inflammation, Anesth. Analg., 86, pp. 367-373, (1998); Nozu T., Okumura T., Corticotropin-releasing factor receptor type 1 and type 2 interaction in irritable bowel syndrome, J. Gastroenterol., 50, pp. 819-830, (2015); Nozu T., Miyagishi S., Nozu R., Takakusaki K., Okumura T., Lipopolysaccharide induces visceral hypersensitivity: role of interleukin-1, interleukin-6, and peripheral corticotropin-releasing factor in rats, J. Gastroenterol., 52, pp. 72-80, (2017); Nozu T., Miyagishi S., Nozu R., Takakusaki K., Okumura T., Repeated water avoidance stress induces visceral hypersensitivity; role of IL-1, IL-6 and peripheral corticotropin-releasing factor, J. Gastroenterol. Hepatol., 32, pp. 1958-1965, (2017); Nozu T., Miyagishi S., Nozu R., Takakusaki K., Okumura T., Altered colonic sensory and barrier functions by CRF: roles of TLR4 and IL-1, J. Endocrinol., 239, pp. 241-252, (2018); Nozu T., Miyagishi S., Kumei S., Nozu R., Takakusaki K., Okumura T., Metformin inhibits visceral allodynia and increased gut permeability induced by stress in rats, J. Gastroenterol. Hepatol., 34, pp. 186-193, (2019); Nozu T., Miyagishi S., Nozu R., Takakusaki K., Okumura T., Butyrate inhibits visceral allodynia and colonic hyperpermeability in rat models of irritable bowel syndrome, Sci. Rep., 9, (2019); Nozu T., Miyagishi S., Nozu R., Takakusaki K., Okumura T., Losartan improves visceral sensation and gut barrier in a rat model of irritable bowel syndrome, Neurogastroenterol. Motil., 32, (2020); Nozu T., Miyagishi S., Ishioh M., Takakusaki K., Okumura T., Phlorizin attenuates visceral hypersensitivity and colonic hyperpermeability in a rat model of irritable bowel syndrome, Biomed. Pharmacother., 139, (2021); Obreja O., Rathee P.K., Lips K.S., Distler C., Kress M., IL-1 beta potentiates heat-activated currents in rat sensory neurons: involvement of IL-1RI, tyrosine kinase, and protein kinase C, FASEB J., 16, pp. 1497-1503, (2002); O'Carroll A.M., Lolait S.J., Harris L.E., Pope G.R., The apelin receptor APJ: journey from an orphan to a multifaceted regulator of homeostasis, J. Endocrinol., 219, pp. R13-R35, (2013); O'Dowd B.F., Heiber M., Chan A., Heng H.H., Tsui L.C., Kennedy J.L., Shi X., Petronis A., George S.R., Nguyen T., A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11, Gene, 136, pp. 355-360, (1993); Okumura T., Nozu T., Kumei S., Takakusaki K., Ohhira M., Ghrelin acts centrally to induce an antinociceptive action during colonic distension through the orexinergic, dopaminergic and opioid systems in conscious rats, Brain Res., 1686, pp. 48-54, (2018); Ortiz-Lucas M., Saz-Peiro P., Sebastian-Domingo J.J., Irritable bowel syndrome immune hypothesis. Part two: the role of cytokines, Rev. Esp. Enferm. Dig., 102, pp. 711-717, (2010); Piche T., Barbara G., Aubert P., Bruley Des Varannes S., Dainese R., Nano J.L., Cremon C., Stanghellini V., De Giorgio R., Galmiche J.P., Neunlist M., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Sinagra E., Pompei G., Tomasello G., Cappello F., Morreale G.C., Amvrosiadis G., Rossi F., Lo Monte A.I., Rizzo A.G., Raimondo D., Inflammation in irritable bowel syndrome: myth or new treatment target? World, J. Gastroenterol., 22, pp. 2242-2255, (2016); Sun X., Iida S., Yoshikawa A., Senbonmatsu R., Imanaka K., Maruyama K., Nishimura S., Inagami T., Senbonmatsu T., Non-activated APJ suppresses the angiotensin II type 1 receptor, whereas apelin-activated APJ acts conversely, Hypertens. Res., 34, pp. 701-706, (2011); Susaki E., Wang G., Cao G., Wang H.Q., Englander E.W., Greeley G.H., Apelin cells in the rat stomach, Regul. Pept., 129, pp. 37-41, (2005); Suzuki T., Yoshinaga N., Tanabe S., Interleukin-6 (IL-6) regulates claudin-2 expression and tight junction permeability in intestinal epithelium, J. Biol. Chem., 286, pp. 31263-31271, (2011); Tache Y., Kiank C., Stengel A., A role for corticotropin-releasing factor in functional gastrointestinal disorders, Curr. Gastroenterol. Rep., 11, pp. 270-277, (2009); Taheri S., Murphy K., Cohen M., Sujkovic E., Kennedy A., Dhillo W., Dakin C., Sajedi A., Ghatei M., Bloom S., The effects of centrally administered apelin-13 on food intake, water intake and pituitary hormone release in rats, Biochem. Biophys. Res. Commun., 291, pp. 1208-1212, (2002); Tang Q.L., Lai M.L., Zhong Y.F., Wang A.M., Su J.K., Zhang M.Q., Antinociceptive effect of berberine on visceral hypersensitivity in rats, World J. Gastroenterol., 19, pp. 4582-4589, (2013); Tatemoto K., Hosoya M., Habata Y., Fujii R., Kakegawa T., Zou M.X., Kawamata Y., Fukusumi S., Hinuma S., Kitada C., Kurokawa T., Onda H., Fujino M., Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor, Biochem. Biophys. Res. Commun., 251, pp. 471-476, (1998); Wang G., Kundu R., Han S., Qi X., Englander E.W., Quertermous T., Greeley G.H., Ontogeny of apelin and its receptor in the rodent gastrointestinal tract, Regul. Pept., 158, pp. 32-39, (2009); Yang J.P., Yao M., Jiang X.H., Wang L.N., Establishment of model of visceral pain due to colorectal distension and its behavioral assessment in rats, World J. Gastroenterol., 12, pp. 2781-2784, (2006); Yang J., Shang B., Shi H., Zhu S., Lu G., Dai F., The role of toll-like receptor 4 and mast cell in the ameliorating effect of electroacupuncture on visceral hypersensitivity in rats, Neurogastroenterol. Motil., 31, (2019); Yu Y., Liu Z.Q., Liu X.Y., Yang L., Geng X.R., Yang G., Liu Z.G., Zheng P.Y., Yang P.C., Stress-derived Corticotropin releasing factor breaches epithelial endotoxin tolerance, PLoS One, 8, (2013); Zhang J.M., An J., Cytokines, inflammation, and pain, Int. Anesthesiol. Clin., 45, pp. 27-37, (2007); Zhang Z.X., Li E., Yan J.P., Fu W., Shen P., Tian S.W., You Y., Apelin attenuates depressive-like behavior and neuroinflammation in rats co-treated with chronic stress and lipopolysaccharide, Neuropeptides, 77, (2019)","T. Nozu; Department of Regional Medicine and Education, Asahikawa Medical University, Hokkaido, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Japan; email: tnozu@asahikawa-med.ac.jp","","Churchill Livingstone","","","","","","01434179","","NRPPD","35526468","English","Neuropeptides","Article","Final","","Scopus","2-s2.0-85129563627"

"Xia Y.; Peng S.; Lin M.; Duan H.; Yuan F.; Shao M.; Tan W.; Luo H.","Xia, Yuan (58339820300); Peng, Shuai (57222312400); Lin, Mengjuan (57189383265); Duan, Houyu (57211590548); Yuan, Fangting (57219728258); Shao, Ming (57800815600); Tan, Wei (57199664684); Luo, Hesheng (24348352500)","58339820300; 57222312400; 57189383265; 57211590548; 57219728258; 57800815600; 57199664684; 24348352500","Apigenin attenuates visceral hypersensitivity in water avoidance stress rats by modulating the microbiota-gut-brain axis and inhibiting mast cell activation","2023","Biomedicine and Pharmacotherapy","167","","115562","","","","4","10.1016/j.biopha.2023.115562","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85173045062&doi=10.1016%2fj.biopha.2023.115562&partnerID=40&md5=08240467a5d1ce830eda98163fd4b410","Department of Gastroenterology, Renmin Hospital of Wuhan University, Hubei Province, Wuhan, China; Key Laboratory of Hubei Province for Digestive System Diseases, Renmin Hospital of Wuhan University, Hubei Province, Wuhan, China","Xia Y., Department of Gastroenterology, Renmin Hospital of Wuhan University, Hubei Province, Wuhan, China, Key Laboratory of Hubei Province for Digestive System Diseases, Renmin Hospital of Wuhan University, Hubei Province, Wuhan, China; Peng S., Department of Gastroenterology, Renmin Hospital of Wuhan University, Hubei Province, Wuhan, China, Key Laboratory of Hubei Province for Digestive System Diseases, Renmin Hospital of Wuhan University, Hubei Province, Wuhan, China; Lin M., Department of Gastroenterology, Renmin Hospital of Wuhan University, Hubei Province, Wuhan, China, Key Laboratory of Hubei Province for Digestive System Diseases, Renmin Hospital of Wuhan University, Hubei Province, Wuhan, China; Duan H., Department of Gastroenterology, Renmin Hospital of Wuhan University, Hubei Province, Wuhan, China, Key Laboratory of Hubei Province for Digestive System Diseases, Renmin Hospital of Wuhan University, Hubei Province, Wuhan, China; Yuan F., Department of Gastroenterology, Renmin Hospital of Wuhan University, Hubei Province, Wuhan, China, Key Laboratory of Hubei Province for Digestive System Diseases, Renmin Hospital of Wuhan University, Hubei Province, Wuhan, China; Shao M., Department of Gastroenterology, Renmin Hospital of Wuhan University, Hubei Province, Wuhan, China, Key Laboratory of Hubei Province for Digestive System Diseases, Renmin Hospital of Wuhan University, Hubei Province, Wuhan, China; Tan W., Department of Gastroenterology, Renmin Hospital of Wuhan University, Hubei Province, Wuhan, China, Key Laboratory of Hubei Province for Digestive System Diseases, Renmin Hospital of Wuhan University, Hubei Province, Wuhan, China; Luo H., Department of Gastroenterology, Renmin Hospital of Wuhan University, Hubei Province, Wuhan, China, Key Laboratory of Hubei Province for Digestive System Diseases, Renmin Hospital of Wuhan University, Hubei Province, Wuhan, China","Visceral hypersensitivity (VH) and gut microbiota dysbiosis significantly contribute to the occurrence and development of irritable bowel syndrome (IBS), exacerbated by stress. Apigenin, a natural flavonoid derived from plants, possesses a range of beneficial properties. However, additional research is necessary to investigate its potential in alleviating symptoms of IBS and elucidating its underlying mechanisms of action. Our study confirms that apigenin effectively reverses mast cell and microglial activation, regulates the composition and abundance of the gut microbiota, improves intestinal barrier function in rats induced with water-avoidance stress, and mitigates VH and colonic hypermotility. Furthermore, in vitro studies suggest a potential role of dysbiotic gut microbiota in activating mast cells at the cellular level. Notably, apigenin inhibits mast cell degranulation through the toll-like receptor 4 (TLR4) / myeloid differentiation primary response gene 88 (MyD88) / nuclear factor-kappa B (NF-κB) pathway. In conclusion, this study discusses the potential therapeutic effects of apigenin in alleviating VH and modulating the gut-brain axis in water-avoidance stress rats, providing a novel or alternative treatment approach for IBS. © 2023 The Authors","Apigenin; Gut-brain axis; Irritable bowel syndrome; Mast cell; Toll-like receptors; Visceral hypersensitivity","Animals; Apigenin; Brain-Gut Axis; Irritable Bowel Syndrome; Mast Cells; Rats; Water; anesthetic agent; apigenin; beta n acetylhexosaminidase; immunoglobulin enhancer binding protein; myeloid differentiation factor 88; occludin; protein ZO1; toll like receptor 4; water; apigenin; water; abdominal reflex; abdominal wall musculature; Actinobacteria; anesthesia; animal cell; animal experiment; animal model; animal tissue; Article; Bifidobacterium; brain tissue; brain-gut axis; cell activation; cell viability; clinical feature; colon tissue; comparative study; controlled study; diarrhea; Enterococcus; enzyme linked immunosorbent assay; Escherichia; Firmicutes; immunofluorescence; in vitro study; intestinal dysmotility; intestine function; irritable colon; limit of quantitation; Limosilactobacillus; male; mast cell; mast cell degranulation; microbial diversity; microglia; nonhuman; operational taxonomic unit; pathogenesis; physiological stress; prophylaxis; Proteobacteria; rat; rat model; RBL-2H3 cell line; Shigella; signal transduction; Sprague Dawley rat; Streptococcus; visceral hyperalgesia; water avoidance stress; Western blotting; withdrawal reflex; animal; brain-gut axis; irritable colon; mast cell; metabolism","","apigenin, 520-36-5; beta n acetylhexosaminidase, 37211-57-7, 9012-33-3, 9027-52-5; occludin, 176304-61-3; toll like receptor 4, 203811-83-0; water, 7732-18-5; Apigenin, ; Water, ","","","National Natural Science Foundation of China, NSFC, (82000505)","This work was supported by the National Natural Science Foundation of China [NSFC: 82000505 ]. ","Melchior C., Colomier E., Trindade I.A., Khadija M., Hreinsson J.P., Tornblom H., Simren M., Irritable bowel syndrome: factors of importance for disease-specific quality of life, United European, Gastroenterol. J., 10, 7, pp. 754-764, (2022); Enck P., Aziz Q., Barbara G., Farmer A.D., Fukudo S., Mayer E.A., Niesler B., Quigley E.M., Rajilic-Stojanovic M., Schemann M., Schwille-Kiuntke J., Simren M., Zipfel S., Spiller R.C., Irritable bowel syndrome, Nat. Rev. Dis. Prim., 2, (2016); Uranga J.A., Martinez V., Abalo R., Mast cell regulation and irritable bowel syndrome: effects of food components with potential nutraceutical use, Molecules, 25, 18, (2020); Li Y.J., Li J., Dai C., The role of intestinal microbiota and mast cell in a rat model of visceral hypersensitivity, J. Neurogastroenterol. Motil., 26, 4, pp. 529-538, (2020); Sundin J., Nordlander S., Eutamene H., Alquier-Bacquie V., Cartier C., Theodorou V., Le Neve B., Tornblom H., Simren M., Ohman L., Colonic mast cell numbers, symptom profile, and mucosal expression of elements of the epithelial barrier in irritable bowel syndrome, Neurogastroenterol. Motil., 31, 11, (2019); Barreau F., Salvador-Cartier C., Houdeau E., Bueno L., Fioramonti J., Long-term alterations of colonic nerve-mast cell interactions induced by neonatal maternal deprivation in rats, Gut, 57, 5, pp. 582-590, (2008); Guilarte M., Santos J., de Torres I., Alonso C., Vicario M., Ramos L., Martinez C., Casellas F., Saperas E., Malagelada J.R., Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum, Gut, 56, 2, pp. 203-209, (2007); Guilarte M., Vicario M., Martinez C., de Torres I., Lobo B., Pigrau M., Gonzalez-Castro A., Rodino-Janeiro B.K., Salvo-Romero E., Fortea M., Pardo-Camacho C., Antolin M., Saperas E., Azpiroz F., Santos J., Alonso-Cotoner C., Peripheral corticotropin-releasing factor triggers jejunal mast cell activation and abdominal pain in patients with diarrhea-predominant irritable bowel syndrome, Am. J. Gastroenterol., 115, 12, pp. 2047-2059, (2020); Zhang J.D., Liu J., Zhu S.W., Fang Y., Wang B., Jia Q., Hao H.F., Kao J.Y., He Q.H., Song L.J., Liu F., Zhu B.L., Owyang C., Duan L.P., Berberine alleviates visceral hypersensitivity in rats by altering gut microbiome and suppressing spinal microglial activation, Acta Pharm. Sin., 42, 11, pp. 1821-1833, (2021); Shimbori C., De Palma G., Baerg L., Lu J., Verdu E.F., Reed D.E., Vanner S., Collins S.M., Bercik P., Gut bacteria interact directly with colonic mast cells in a humanized mouse model of IBS, Gut Microbes, 14, 1, (2022); Zhang L., Song J., Bai T., Wang R., Hou X., Sustained pain hypersensitivity in the stressed colon: role of mast cell-derived nerve growth factor-mediated enteric synaptic plasticity, Neurogastroenterol. Motil., 30, 9, (2018); Salehi B., Venditti A., Sharifi-Rad M., Kregiel D., Sharifi-Rad J., Durazzo A., Lucarini M., Santini A., Souto E.B., Novellino E., Antolak H., Azzini E., Setzer W.N., Martins N., The therapeutic potential of apigenin, Int J. Mol. Sci., 20, 6, (2019); Yao L., Fan Z., Han S., Sun N., Che H., Apigenin attenuates the allergic reactions by competitively binding to ER with estradiol, Front Pharm., 11, (2020); Shao H., Jing K., Mahmoud E., Huang H., Fang X., Yu C., apigenin sensitizes colon cancer cells to antitumor activity of ABT-263, Mol. Cancer Ther., 12, 12, pp. 2640-2650, (2013); Che D.N., Cho B.O., Shin J.Y., Kang H.J., Kim J.S., Oh H., Kim Y.S., Jang S.I., apigenin Inhibits IL-31 Cytokine in Human Mast Cell and Mouse Skin Tissues, Molecules, 24, 7, (2019); Grabauskas G., Wu X., Gao J., Li J.Y., Turgeon D.K., Owyang C., Prostaglandin E(2), produced by mast cells in colon tissues from patients with irritable bowel syndrome, contributes to visceral hypersensitivity in mice, Gastroenterology, 158, 8, pp. 2195-2207, (2020); Wang M., Firrman J., Zhang L., Arango-Argoty G., Tomasula P., Liu L., Xiao W., Yam K., Apigenin impacts the growth of the gut microbiota and alters the gene expression of enterococcus, Molecules, 22, 8, (2017); Yuan F., Tan W., Ren H., Yan L., Wang Y., Luo H., The effects of short-chain fatty acids on rat colonic hypermotility induced by water avoidance stress, Drug Des. Devel Ther., 14, pp. 4671-4684, (2020); Zhang T., Su J., Guo B., Wang K., Li X., Liang G., apigenin protects blood-brain barrier and ameliorates early brain injury by inhibiting TLR4-mediated inflammatory pathway in subarachnoid hemorrhage rats, Int Immunopharmacol., 28, 1, pp. 79-87, (2015); Ford A.C., Lacy B.E., Talley N.J., Irritable bowel syndrome, N. Engl. J. Med, 376, 26, pp. 2566-2578, (2017); Hillestad E.M.R., van der Meeren A., Nagaraja B.H., Bjorsvik B.R., Haleem N., Benitez-Paez A., Sanz Y., Hausken T., Lied G.A., Lundervold A., Berentsen B., Gut bless you: the microbiota-gut-brain axis in irritable bowel syndrome, World J. Gastroenterol., 28, 4, pp. 412-431, (2022); Spiller R., Impact of diet on symptoms of the irritable bowel syndrome, Nutrients, 13, 2, (2021); Xiao L., Liu Q., Luo M., Xiong L., Gut Microbiota-Derived Metabolites in Irritable Bowel Syndrome, Front Cell Infect. Microbiol, 11, (2021); Kim J.H., Jeun E.J., Hong C.P., Kim S.H., Jang M.S., Lee E.J., Moon S.J., Yun C.H., Im S.H., Jeong S.G., Park B.Y., Kim K.T., Seoh J.Y., Kim Y.K., Oh S.J., Ham J.S., Yang B.G., Jang M.H., Extracellular vesicle-derived protein from Bifidobacterium longum alleviates food allergy through mast cell suppression, J. Allergy Clin. Immunol., 137, 2, (2016); Garcia-Rodriguez K.M., Goenka A., Thomson D.D., Bahri R., Tontini C., Salcman B., Hernandez-Pando R., Bulfone-Paus S., Bacillus Calmette-Guerin-Induced Human Mast Cell Activation Relies on IL-33 Priming, Int J. Mol. Sci., 23, 14, (2022); Yue S.J., Liu J., Wang W.X., Wang A.T., Yang X.Y., Guan H.S., Wang C.Y., Yan D., Berberine treatment-emergent mild diarrhea associated with gut microbiota dysbiosis, Biomed. Pharm., 116, (2019); Zou Y.T., Zhou J., Zhu J.H., Wu C.Y., Shen H., Zhang W., Zhou S.S., Xu J.D., Mao Q., Zhang Y.Q., Long F., Li S.L., Gut Microbiota Mediates the Protective Effects of Traditional Chinese Medicine Formula Qiong-Yu-Gao against Cisplatin-Induced Acute Kidney Injury, Microbiol Spectr., 10, 3, (2022); Shang Q., Liu S., Liu H., Mahfuz S., Piao X., Impact of sugar beet pulp and wheat bran on serum biochemical profile, inflammatory responses and gut microbiota in sows during late gestation and lactation, J. Anim. Sci. Biotechnol., 12, 1, (2021); Coeffier M., Gloro R., Boukhettala N., Aziz M., Lecleire S., Vandaele N., Antonietti M., Savoye G., Bole-Feysot C., Dechelotte P., Reimund J.M., Ducrotte P., Increased proteasome-mediated degradation of occludin in irritable bowel syndrome, Am. J. Gastroenterol., 105, 5, pp. 1181-1188, (2010); Hou Q., Zhu S., Zhang C., Huang Y., Guo Y., Li P., Chen X., Wen Y., Han Q., Liu F., Berberine improves intestinal epithelial tight junctions by upregulating A20 expression in IBS-D mice, Biomed. Pharm., 118, (2019); Lee K.J., Kim Y.B., Kim J.H., Kwon H.C., Kim D.K., Cho S.W., The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors, J. Gastroenterol. Hepatol., 23, 11, pp. 1689-1694, (2008); Pisipati S., Connor B.A., Riddle M.S., Updates on the epidemiology, pathogenesis, diagnosis, and management of postinfectious irritable bowel syndrome, Curr. Opin. Infect. Dis., 33, 5, pp. 411-418, (2020); Akbar A., Yiangou Y., Facer P., Walters J.R., Anand P., Ghosh S., Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain, Gut, 57, 7, pp. 923-929, (2008); Winston J.H., Xu G.Y., Sarna S.K., Adrenergic stimulation mediates visceral hypersensitivity to colorectal distension following heterotypic chronic stress, Gastroenterology, 138, 1, (2010); Xu X.J., Zhang Y.L., Liu L., Pan L., Yao S.K., Increased expression of nerve growth factor correlates with visceral hypersensitivity and impaired gut barrier function in diarrhoea-predominant irritable bowel syndrome: a preliminary explorative study, Aliment Pharm. Ther., 45, 1, pp. 100-114, (2017); Imran M., Aslam Gondal T., Atif M., Shahbaz M., Batool Qaisarani T., Hanif Mughal M., Salehi B., Martorell M., Sharifi-Rad J., Apigenin as an anticancer agent, Phytother. Res, 34, 8, pp. 1812-1828, (2020); LoVerde D., Iweala O.I., Eginli A., Krishnaswamy G., Anaphylaxis, Chest, 153, 2, pp. 528-543, (2018); Folkerts J., Redegeld F., Folkerts G., Blokhuis B., van den Berg M.P.M., de Bruijn M.J.W., van IJcken W.F.J., Junt T., Tam S.Y., Galli S.J., Hendriks R.W., Standhouders R., Maurer M., Butyrate inhibits human mast cell activation via epigenetic regulation of FcepsilonRI-mediated signaling, Allergy, 75, 8, pp. 1966-1978, (2020); He-Yang J., Zhang W., Liu J., Xue P., Zhou X., Human breast milk oligosaccharides attenuate necrotizing enterocolitis in rats by suppressing mast cell accumulation, DPPI activity and TLR4 expression in ileum tissue, and regulating mitochondrial damage of Caco-2 cells, Int Immunopharmacol., 88, (2020)","W. Tan; Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China; email: tanwei_2000@163.com","","Elsevier Masson s.r.l.","","","","","","07533322","","BIPHE","37801900","English","Biomed. Pharmacother.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85173045062"

"Leite G.; de Freitas Germano J.; Morales W.; Weitsman S.; Barlow G.M.; Parodi G.; Pimentel M.L.; Villanueva-Millan M.J.; Sanchez M.; Ayyad S.; Rezaie A.; Mathur R.; Pimentel M.","Leite, Gabriela (57211561751); de Freitas Germano, Juliana (57194106499); Morales, Walter (57117524600); Weitsman, Stacy (56705105600); Barlow, Gillian M (55300614800); Parodi, Gonzalo (57211562499); Pimentel, Maya L (57217180122); Villanueva-Millan, Maria Jesus (54901742500); Sanchez, Maritza (57215506242); Ayyad, Sarah (57990747300); Rezaie, Ali (10044809800); Mathur, Ruchi (7202179697); Pimentel, Mark (7006799213)","57211561751; 57194106499; 57117524600; 56705105600; 55300614800; 57211562499; 57217180122; 54901742500; 57215506242; 57990747300; 10044809800; 7202179697; 7006799213","Cytolethal distending toxin B inoculation leads to distinct gut microtypes and IBS-D-like microRNA-mediated gene expression changes in a rodent model","2024","Gut Microbes","16","1","2293170","","","","1","10.1080/19490976.2023.2293170","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85180384970&doi=10.1080%2f19490976.2023.2293170&partnerID=40&md5=9c4aa0a9259c94bafc319b4ccd181fcc","Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles, CA, United States; Karsh Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai, Los Angeles, CA, United States; Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Cedars-Sinai, Los Angeles, CA, United States","Leite G., Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles, CA, United States; de Freitas Germano J., Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles, CA, United States; Morales W., Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles, CA, United States; Weitsman S., Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles, CA, United States; Barlow G.M., Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles, CA, United States; Parodi G., Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles, CA, United States; Pimentel M.L., Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles, CA, United States; Villanueva-Millan M.J., Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles, CA, United States; Sanchez M., Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles, CA, United States; Ayyad S., Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles, CA, United States; Rezaie A., Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles, CA, United States, Karsh Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai, Los Angeles, CA, United States; Mathur R., Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles, CA, United States, Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Cedars-Sinai, Los Angeles, CA, United States; Pimentel M., Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles, CA, United States, Karsh Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai, Los Angeles, CA, United States","Diarrhea-predominant irritable bowel syndrome (IBS-D), associated with increased intestinal permeability, inflammation, and small intestinal bacterial overgrowth, can be triggered by acute gastroenteritis. Cytolethal distending toxin B (CdtB) is produced by gastroenteritis-causing pathogens and may underlie IBS-D development, through molecular mimicry with vinculin. Here, we examine the effects of exposure to CdtB alone on gut microbiome composition, host intestinal gene expression, and IBS-D-like phenotypes in a rat model. CdtB-inoculated rats exhibited increased anti-CdtB levels, which correlated with increased stool wet weights, pro-inflammatory cytokines (TNFα, IL2) and predicted microbial metabolic pathways including inflammatory responses, TNF responses, and diarrhea. Three distinct ileal microbiome profiles (microtypes) were identified in CdtB-inoculated rats. The first microtype (most like controls) had altered relative abundance (RA) of genera Bifidobacterium, Lactococcus, and Rothia. The second had lower microbial diversity, higher Escherichia-Shigella RA, higher absolute E. coli abundance, and altered host ileal tissue expression of immune-response and TNF-response genes compared to controls. The third microtype had higher microbial diversity, higher RA of hydrogen sulfide (H2S)-producer Desulfovibrio, and increased expression of H2S-associated pain/serotonin response genes. All CdtB-inoculated rats exhibited decreased ileal expression of cell junction component mRNAs, including vinculin-associated proteins. Significantly, cluster-specific microRNA-mRNA interactions controlling intestinal permeability, visceral hypersensitivity/pain, and gastrointestinal motility genes, including several previously associated with IBS were seen. These findings demonstrate that exposure to CdtB toxin alone results in IBS-like phenotypes including inflammation and diarrhea-like stool, decreased expression of intestinal barrier components, and altered ileal microtypes that influenced changes in microRNA-modulated gene expression and predicted metabolic pathways consistent with specific IBS-D symptoms. © 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.","cytolethal distending toxin; gut microbiome; host gene expression; Irritable bowel syndrome; microRNAs","Animals; Diarrhea; Escherichia coli; Gastroenteritis; Gastrointestinal Microbiome; Gene Expression; Inflammation; Irritable Bowel Syndrome; Pain; Rats; Rodentia; Vinculin; cytolethal distending toxin; gamma interferon; interleukin 18; interleukin 2; interleukin 5; interleukin 8; lipopolysaccharide; messenger RNA; microRNA; occludin; RNA 16S; serotonin; tachykinin; tumor necrosis factor; cytolethal distending toxin; vinculin; animal model; animal tissue; Article; bacterial load; bacterial overgrowth; bacterial translocation; Bacteroides; Bifidobacterium; bioinformatics; blood sampling; cell junction; cluster analysis; cyanobacterium; cytotoxicity; Desulfovibrio; diarrhea; discriminant analysis; DNA extraction; DNA isolation; dysbiosis; enzyme linked immunosorbent assay; Escherichia; Escherichia coli; Eubacterium; feces analysis; feces microflora; gastroenteritis; gene expression; gene expression profiling; gene ontology; gene sequence; ileum; ileum tissue; immune response; inflammation; intestine flora; intestine mucosa permeability; irritable colon; Lactobacillus; Lactococcus; male; microbial diversity; microbiome; molecular mimicry; natural killer cell; nociception; nonhuman; principal component analysis; Pseudomonas; pyrosequencing; quality control; quality of life; rat; Rothia; Ruminococcus; Shigella; upregulation; animal; gastroenteritis; gene expression; genetics; pain; rodent","","gamma interferon, 82115-62-6; interleukin 18, 189304-55-0; interleukin 2, 85898-30-2; interleukin 8, 114308-91-7; occludin, 176304-61-3; serotonin, 50-67-9; cytolethal distending toxin, ; Vinculin, ","Agilent 210, Agilent; KAPA, Hoffmann La Roche, Switzerland; Luminex FlexMap 3D, Luminex, United States; MagAttract, Qiagen; MiSeq, Illumina; Qubit 4, Invitrogen","Agilent; Hoffmann La Roche, Switzerland; Illumina; Invitrogen; Luminex, United States; Qiagen","Bausch Health Inc.; Georgianna Atol Charitable Trust; John and Geraldine Cusenza Family Foundation; Monica Lester Charitable Trust; Thomas Wurster and David Allen; Tull Family Foundation; National Philanthropic Trust, NPT; Bausch Health, BHC","Funding text 1: This study was funded in part by funds from Bausch Health Companies Inc and the National Philanthropic Trust to MP. These sponsors played no role in the study design or in the collection, analysis, and interpretation of data. The authors would also like to thank the following donors for their support: The Gottesdiener foundation, Frank Lee, Joel Levine, the Monica Lester Charitable Trust, the Elias, Genevieve, and Georgianna Atol Charitable Trust, the Tull Family Foundation, Thomas Wurster and David Allen, and the John and Geraldine Cusenza Family Foundation.; Funding text 2: MP and AR are consultants for, and have received grant support from, Bausch Health Inc. The remaining authors have no relevant conflicts of interest to disclose. ","Ford A.C., Lacy B.E., Talley N.J., Longo D.L., Irritable bowel syndrome, N Engl J Med, 376, 26, pp. 2566-2525, (2017); Ford A.C., Sperber A.D., Corsetti M., Camilleri M., Irritable bowel syndrome, Lancet, 396, pp. 1675-1688, (2020); Sperber A.D., Bangdiwala S.I., Drossman D.A., Ghoshal U.C., Simren M., Tack J., Whitehead W.E., Dumitrascu D.L., Fang X., Fukudo S., Et al., Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation global study, Gastroenterology, 160, pp. 99-114 e3, (2021); Lacy B.E., Mearin F., Chang L., Chey W.D., Lembo A.J., Simren M., Spiller R., Bowel disorders, Gastroenterology, 150, pp. 1393-1407, (2016); Pimentel M., Saad R.J., Long M.D., Rao S.S.C., ACG clinical guideline: small intestinal bacterial overgrowth, Am J Gastroenterol, 115, pp. 165-178, (2020); Shah E.D., Riddle M.S., Chang C., Pimentel M., Estimating the contribution of acute gastroenteritis to the overall prevalence of irritable bowel syndrome, J Neurogastroenterol Motil, 18, pp. 200-204, (2012); Villanueva-Millan M.J., Leite G., Wang J., Morales W., Parodi G., Pimentel M.L., Barlow G.M., Mathur R., Rezaie A., Sanchez M., Et al., Methanogens and hydrogen sulfide producing bacteria guide distinct gut microbe profiles and irritable bowel syndrome subtypes, Am J Gastroenterol, 117, 12, pp. 2055-2066, (2022); Klem F., Wadhwa A., Prokop L.J., Sundt W.J., Farrugia G., Camilleri M., Singh S., Grover M., Prevalence, risk factors, and outcomes of irritable bowel syndrome after infectious enteritis: a systematic review and meta-analysis, Gastroenterology, 152, pp. 1042-1054, (2017); Takakura W., Kudaravalli P., Chatterjee C., Pimentel M., Riddle M.S., Campylobacter infection and the link with irritable bowel syndrome: on the pathway towards a causal association, Pathog Dis, 80, (2022); Pimentel M., Chatterjee S., Chang C., Low K., Song Y., Liu C., Morales W., Ali L., Lezcano S., Conklin J., Et al., A new rat model links two contemporary theories in irritable bowel syndrome, Dig Dis Sci, 53, 4, pp. 982-989, (2008); Pokkunuri V., Pimentel M., Morales W., Jee S.-R., Alpern J., Weitsman S., Marsh Z., Low K., Hwang L., Khoshini R., Et al., Role of cytolethal distending toxin in altered stool form and bowel phenotypes in a rat model of post-infectious irritable bowel syndrome, J Neurogastroenterol Motil, 18, 4, pp. 434-442, (2012); Pimentel M., Morales W., Pokkunuri V., Brikos C., Kim S.M., Kim S.E., Triantafyllou K., Weitsman S., Marsh Z., Marsh E., Et al., Autoimmunity links vinculin to the pathophysiology of chronic functional bowel changes following Campylobacter jejuni infection in a rat model, Dig Dis Sci, 60, 5, pp. 1195-1205, (2015); Pickett C.L., Whitehouse C.A., The cytolethal distending toxin family, Trends Microbiol, 7, 7, pp. 292-297, (1999); Morales W., Triantafyllou K., Parodi G., Weitsman S., Park S.C., Rezaie A., Pichetshote N., Lin E., Pimentel M., Immunization with cytolethal distending toxin B produces autoantibodies to vinculin and small bowel bacterial changes in a rat model of postinfectious irritable bowel syndrome, Neurogastroenterol Motil, 32, (2020); Farzaei M.H., Bahramsoltani R., Abdollahi M., Rahimi R., The role of visceral hypersensitivity in irritable bowel syndrome: pharmacological targets and novel treatments, J Neurogastroenterol Motil, 22, pp. 558-574, (2016); Sikander A., Rana S.V., Prasad K.K., Role of serotonin in gastrointestinal motility and irritable bowel syndrome, Clin Chim Acta, 403, 1-2, pp. 47-55, (2009); Hyland N.P., Quigley E.M., Brint E., Microbiota-host interactions in irritable bowel syndrome: epithelial barrier, immune regulation and brain-gut interactions, World J Gastroenterol, 20, 27, pp. 8859-8866, (2014); Bravo-Vazquez L.A., Medina-Rios I., Marquez-Gallardo L.D., Reyes-Munoz J., Serrano-Cano F.I., Pathak S., Banerjee A., Bandyopadhyay A., Duttaroy A.K., Paul S., Et al., Functional implications and clinical potential of MicroRNAs in irritable bowel syndrome: a concise review, Dig Dis Sci, 68, 1, pp. 38-53, (2023); Leite G., Morales W., Weitsman S., Celly S., Parodi G., Mathur R., Barlow G.M., Sedighi R., Millan M.J.V., Rezaie A., Et al., The duodenal microbiome is altered in small intestinal bacterial overgrowth, Plos One, 15, 7, (2020); Fernandez-Calleja J.M.S., Konstanti P., Swarts H.J.M., Bouwman L.M.S., Garcia-Campayo V., Billecke N., Oosting A., Smidt H., Keijer J., van Schothorst E.M., Et al., Non-invasive continuous real-time in vivo analysis of microbial hydrogen production shows adaptation to fermentable carbohydrates in mice, Sci Rep, 8, 1, (2018); Klapholz B., Brown N.H., Talin - the master of integrin adhesions, J Cell Sci, 130, pp. 2435-2446, (2017); Parsanathan R., Jain S.K., Hydrogen sulfide regulates circadian-clock genes in C2C12 myotubes and the muscle of high-fat-diet-fed mice, Arch Biochem Biophys, 672, (2019); Kim D.S., Anantharam P., Padhi P., Thedens D.R., Li G., Transcriptomic profile analysis of brain inferior colliculus following acute hydrogen sulfide exposure, Toxicology, 430, (2020); Bravo-Vazquez L.A., Medina-Rios I., Marquez-Gallardo L.D., Reyes-Munoz J., Serrano-Cano F.I., Pathak S., Banerjee A., Bandyopadhyay A., Duttaroy A.K., Paul S., Et al., Functional implications and clinical potential of MicroRNAs in irritable bowel syndrome: a concise review, Dig Dis Sci, 68, pp. 38-53, (2022); Singh R., Zogg H., Ro S., Role of microRnas in disorders of gut–brain interactions: clinical insights and therapeutic alternatives, J Pers Med, 11, (2021); Park C., Lee M.Y., Slivano O.J., Park P.J., Ha S., Berent R.M., Fuchs R., Collins N.C., Yu T.J., Syn H., Park J., Loss of serum response factor induces microRNA-mediated apoptosis in intestinal smooth muscle cells, Cell Death Dis, 6, (2015); Hou Q., Huang Y., Zhang C., Zhu S., Li P., Chen X., Hou Z., Liu F., MicroRNA-200a targets cannabinoid receptor 1 and serotonin transporter to increase visceral hyperalgesia in diarrhea-predominant irritable bowel syndrome rats, J Neurogastroenterol Motil, 24, pp. 656-668, (2018); Chao G., Wang Y., Zhang S., Yang W., Ni Z., Zheng X., MicroRNA-29a increased the intestinal membrane permeability of colonic epithelial cells in irritable bowel syndrome rats, Oncotarget, 8, pp. 85828-85837, (2017); Nakata K., Sugi Y., Narabayashi H., Kobayakawa T., Nakanishi Y., Tsuda M., Hosono A., Kaminogawa S., Hanazawa S., Takahashi K., Et al., Commensal microbiota-induced microRNA modulates intestinal epithelial permeability through the small GTPase ARF4, J Biol Chem, 292, 37, pp. 15426-15433, (2017); Mahurkar-Joshi S., Rankin C.R., Videlock E.J., Soroosh A., Verma A., Khandadash A., Iliopoulos D., Pothoulakis C., Mayer E.A., Chang L., Et al., The colonic mucosal MicroRNAs, MicroRNA-219a-5p, and MicroRNA-338-3p are downregulated in irritable bowel syndrome and are associated with barrier function and MAPK signaling, Gastroenterology, 160, 7, pp. 2409-2422, (2021); Fourie N.H., Peace R.M., Abey S.K., Sherwin L.B., Rahim-Williams B., Smyser P.A., Wiley J.W., Henderson W.A., Elevated circulating miR-150 and miR-342-3p in patients with irritable bowel syndrome, Exp Mol Pathol, 96, pp. 422-425, (2014); Ye D., Guo S., Al-Sadi R., Ma T.Y., MicroRNA regulation of intestinal epithelial tight junction permeability, Gastroenterology, 141, pp. 1323-1333, (2011); Zhu H., Xiao X., Shi Y., Wu Y., Huang Y., Li D., Xiong F., He G., Chai Y., Tang H., Et al., Inhibition of miRNA‑29a regulates intestinal barrier function in diarrhea‑predominant irritable bowel syndrome by upregulating ZO‑1 and CLDN1, Exp Ther Med, 20, (2020); Fei L., Wang Y., microRNA-495 reduces visceral sensitivity in mice with diarrhea-predominant irritable bowel syndrome through suppression of the PI3K/AKT signaling pathway via PKIB, Iubmb Life, 72, 7, pp. 1468-1480, (2020); Zhang Y., Wu X., Wu J., Li S., Han S., Lin Z., Ding S., Jia X., Gong W., Decreased expression of microRNA-510 in intestinal tissue contributes to post-infectious irritable bowel syndrome via targeting PRDX1, Am J Transl Res, 11, pp. 7385-7397, (2019); Tao W., Dong X., Kong G., Fang P., Huang X., Bo P., Elevated circulating hsa-miR-106b, hsa-miR-26a, and hsa-miR-29b in type 2 diabetes mellitus with diarrhea-predominant irritable bowel syndrome, Gastroenterol Res Pract, 2016, pp. 1-9, (2016); Guo J., Lu G., Chen L., Geng H., Wu X., Chen H., Li Y., Yuan M., Sun J., Pei L., Et al., Regulation of serum microRNA expression by acupuncture in patients with diarrhea-predominant irritable bowel syndrome, Acupunct Med, 40, 1, pp. 34-42, (2022); Gao J., Xiong T., Grabauskas G., Owyang C., Mucosal serotonin reuptake transporter expression in irritable bowel syndrome is modulated by gut microbiota via mast cell–prostaglandin E2, Gastroenterology, 162, 7, pp. 1962-1974, (2022); Singh P., Lembo A., Emerging role of the gut microbiome in irritable bowel syndrome, Gastroenterol Clin North Am, 50, 3, pp. 523-545, (2021); Higashi T., Arnold T.R., Stephenson R.E., Dinshaw K., Miller A., Maintenance of the epithelial barrier and remodeling of cell-cell junctions during Cytokinesis, Curr Biol, 26, pp. 1829-1842, (2016); Goult B.T., Zacharchenko T., Bate N., Tsang R., Hey F., Gingras A.R., Elliott P.R., Roberts G.C.K., Ballestrem C., Critchley D.R., Et al., RIAM and vinculin binding to talin are mutually exclusive and regulate adhesion assembly and turnover, J Biol Chem, 288, 12, pp. 8238-8249, (2013); Konishi S., Yano T., Tanaka H., Mizuno T., Kanoh H., Tsukita K., Namba T., Tamura A., Yonemura S., Gotoh S., Et al., Vinculin is critical for the robustness of the epithelial cell sheet paracellular barrier for ions, Life Sci Alli, 2, (2019); Yao M., Qiu W., Liu R., Efremov A.K., Cong P., Seddiki R., Payre M., Lim C.T., Ladoux B., Mege R.-M., Et al., Force-dependent conformational switch of α-catenin controls vinculin binding, Nat Commun, 5, 1, (2014); Twiss F., Le Duc Q., Van Der Horst S., Tabdili H., Van Der Krogt G., Wang N., Rehmann H., Huveneers S., Leckband D.E., De Rooij J., Et al., Vinculin-dependent cadherin mechanosensing regulates efficient epithelial barrier formation, Biol Open, 1, 11, pp. 1128-1140, (2012); Linsalata M., Riezzo G., D'Attoma B., Clemente C., Orlando A., Russo F., Noninvasive biomarkers of gut barrier function identify two subtypes of patients suffering from diarrhoea predominant-IBS: a case-control study, BMC Gastroenterol, 18, (2018); Hanning N., Edwinson A.L., Ceuleers H., Peters S.A., De Man J.G., Hassett L.C., De Winte B.Y., Grover M., Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review, Therap Adv Gastroenterol, 14, (2021); Shefa U., Kim M.S., Jeong N.Y., Jung J., Antioxidant and cell-signaling functions of hydrogen sulfide in the central nervous System, Oxid Med Cell Longev, 2018, pp. 1-17, (2018); Koh S.J., Choi Y., Kim B.G., Lee K.L., Kim D.W., Kim J.H., Kim J.W., Kim J.S., Matricellular protein periostin mediates intestinal inflammation through the activation of nuclear factor κB signaling, Plos One, 11, (2016); Cui X.F., Zhou W.M., Yang Y., Zhou J., Li X.L., Lin L., Zhang H.J., Epidermal growth factor upregulates serotonin transporter and its association with visceral hypersensitivity in irritable bowel syndrome, World J Gastroenterol, 20, pp. 13521-13529, (2014); Crowell M.D., Role of serotonin in the pathophysiology of the irritable bowel syndrome, Br J Pharmacol, 141, 8, pp. 1285-1293, (2004); Pyleris E., Giamarellos-Bourboulis E.J., Tzivras D., Koussoulas V., Barbatzas C., Pimentel M., The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome, Dig Dis Sci, 57, pp. 1321-1329, (2012); Leite G., Rezaie A., Mathur R., Barlow G.M., Rashid M., Hosseini A., Wang J., Parodi G., Villanueva-Millan M.J., Sanchez M., Et al., Defining small intestinal bacterial overgrowth by culture and high throughput sequencing, Clin Gastroenterol Hepatol, (2023); Chassaing B., Raja S.M., Lewis J.D., Srinivasan S., Gewirtz A.T., Colonic microbiota encroachment correlates with dysglycemia in humans, Cell Mol Gastroenterol Hepatol, 4, pp. 205-221, (2017); Rolhion N., Chassaing B., When pathogenic bacteria meet the intestinal microbiota, Philos Trans R Soc Lond B Biol Sci, 371, (2016); Yang W., Xu H.W., Lu X.R., Xu Q.-F., Tao M.-H., Dai Y.-M., Overexpression of miR-122 impairs intestinal barrier function and aggravates acute pancreatitis by downregulating occludin expression, Biochem Genet, 60, pp. 382-394, (2022); Jingushi K., Kashiwagi Y., Ueda Y., Kitae K., Hase H., Nakata W., Fujita K., Uemura M., Nonomura N., Tsujikawa K., Et al., High miR-122 expression promotes malignant phenotypes in ccRCC by targeting occludin, Int J Oncol, 51, 1, pp. 289-297, (2017); Liu L., Zhu M., Liu X., Fei L., Shen J., Chen D., miR-122-5p regulates the tight junction of the blood-testis barrier of mice via occludin: miR-122-5p can regulate the tight junction, Basic Clin Androl, 31, (2021); Barbara G., De Giorgio R., Stanghellini V., Cremon C., Corinaldesi R., A role for inflammation in irritable bowel syndrome?, Gut, 51 Suppl 1, pp. i41-i44, (2002); Barbara G., Stanghellini V., De Giorgio R., Cremon C., Cottrell G.S., Santini D., Pasquinelli G., Morselli-Labate A.M., Grady E.F., Bunnett N.W., Et al., Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome, Gastroenterology, 126, 3, pp. 693-702, (2004); Barbara G., Wang B., Stanghellini V., de Giorgio R., Cremon C., Di Nardo G., Trevisani M., Campi B., Geppetti P., Tonini M., Et al., Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome, Gastroenterology, 132, 1, pp. 26-37, (2007); Holzer P., Holzer-Petsche U., Tachykinin receptors in the gut: physiological and pathological implications, Curr Opin Pharmacol, 1, 6, pp. 583-590, (2001); Tack J., Drossman D.A., What’s new in Rome IV?, Neurogastroenterol Motil, 29, (2017); Steinhoff M.S., von Mentzer B., Geppetti P., Pothoulakis C., Bunnett N.W., Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease, Physiol Rev, 94, pp. 265-301, (2014); Fritz N., Berens S., Dong Y., Martinez C., Schmitteckert S., Houghton L.A., Goebel-Stengel M., Wahl V., Kabisch M., Gotze D., Et al., The serotonin receptor 3E variant is a risk factor for female IBS-D, J Mol Med (Berl), 100, 11, pp. 1617-1627, (2022); Mogilyansky E., Rigoutsos I., The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease, Cell Death Differ, 20, 12, pp. 1603-1614, (2013); Wu S., Yuan C., Liu S., Zhang Q., Yang Z., Sun F., Zhan S., Zhu S., Zhang S., Irritable bowel syndrome and long-term risk of cancer: a prospective cohort study among 0.5 million adults in UK biobank, Am J Gastroenterol, 117, pp. 785-793, (2022); Morales W., Rezaie A., Barlow G., Pimentel M., Second-generation biomarker testing for irritable bowel syndrome using plasma anti-CdtB and anti-vinculin levels, Dig Dis Sci, 64, pp. 3115-3121, (2019); Klindworth A., Pruesse E., Schweer T., Peplies J., Quast C., Horn M., Glockner F.O., Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation sequencing-based diversity studies, Nucleic Acids Res, 41, (2013); Leite G.G.S., Morales W., Weitsman S., Celly S., Parodi G., Mathur R., Sedighi R., Barlow G.M., Rezaie A., Pimentel M., Et al., Optimizing microbiome sequencing for small intestinal aspirates: validation of novel techniques through the REIMAGINE study, BMC Microbiol, 19, 1, (2019); 16S metagenomic sequencing library preparation, (2013); CLC Genomics Workbench 23.0.5 product manual; Lu Y., Zhou G., Ewald J., Pang Z., Shiri T., Xia J., MicrobiomeAnalyst 2.0: comprehensive statistical, functional and integrative analysis of microbiome data, Nucleic Acids Res, 51, pp. W310-W318, (2023); Martin M., Cutadapt removes adapter sequences from high-throughput sequencing reads, EMBnet Journal, 17, (2011); Andrews S., FastQC: a quality control tool for high throughput sequence data, (2010); Dobin A., Davis C.A., Schlesinger F., Drenkow J., Zaleski C., Jha S., Batut P., Chaisson M., Gingeras T.R., STAR: ultrafast universal RNA-seq aligner, Bioinformatics, 29, pp. 15-21, (2013); Anders S., Pyl P.T., Huber W., Htseq–a Python framework to work with high-throughput sequencing data, Bioinformatics, 31, pp. 166-169, (2015); Love M.I., Huber W., Anders S., Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2, Genome Biol, 15, 12, (2014); Alexa A., Rahnenfuhrer J., topGO: enrichment analysis for gene ontology, R package version 1.38.1, (2019); Mitchell A.L., Attwood T.K., Babbitt P.C., Blum M., Bork P., Bridge A., Brown S.D., Chang H.-Y., El-Gebali S., Fraser M.I., Et al., InterPro in 2019: improving coverage, classification and access to protein sequence annotations, Nucleic Acids Res, 47, D1, pp. D351-D360, (2019); Geer L.Y., Marchler-Bauer A., Geer R.C., Han L., He J., He S., Liu C., Shi W., Bryant S.H., The NCBI BioSystems database, Nucleic Acids Res, 38, pp. D492-D496, (2010); Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Et al., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles, Proc Natl Acad Sci USA, 102, 43, pp. 15545-15550, (2005); Liberzon A., Subramanian A., Pinchback R., Thorvaldsdottir H., Tamayo P., Mesirov J.P., Molecular signatures database (MSigDB) 3.0, Bioinformatics, 27, pp. 1739-1740, (2011); Fabregat A., Jupe S., Matthews L., Sidiropoulos K., Gillespie M., Garapati P., Haw R., Jassal B., Korninger F., May B., Et al., The reactome pathway knowledgebase, Nucleic Acids Res, 46, D1, pp. D649-D655, (2018); Slenter D.N., Kutmon M., Hanspers K., Riutta A., Windsor J., Nunes N., Melius J., Cirillo E., Coort S.L., Digles D., Et al., WikiPathways: a multifaceted pathway database bridging metabolomics to other omics research, Nucleic Acids Res, 46, D1, pp. D661-D667, (2018); Robinson M.D., Oshlack A., A scaling normalization method for differential expression analysis of RNA-seq data, Genome Biol, 11, 3, (2010); Ge S.X., Jung D., Yao R., Valencia A., ShinyGO: a graphical gene-set enrichment tool for animals and plants, Bioinformatics, 36, 8, pp. 2628-2629, (2020); Svoronos A.A., Campbell S.G., Engelman D.M., MicroRNA function can be reversed by altering target gene expression levels, iScience, 24, (2021); Salmena L., Poliseno L., Tay Y., Kats L., Pandolfi P., A ceRNA hypothesis: the Rosetta stone of a hidden RNA language?, Cell, 146, pp. 353-358, (2011)","M. Pimentel; Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles, United States; email: mark.pimentel@cshs.org","","Taylor and Francis Ltd.","","","","","","19490976","","","38108386","English","Gut Microbes","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85180384970"

"Kang X.; Zhang H.; Li X.; Zhang K.; Huang Z.; Li Y.; Ren X.; Chai Y.","Kang, Xueling (58909753400); Zhang, Honglin (57211166289); Li, Xiaying (58910751800); Zhang, Kai (57212137034); Huang, Zhansheng (58909954300); Li, Yuanyuan (57884981400); Ren, Xiaoxuan (24473473500); Chai, Yemao (57817027600)","58909753400; 57211166289; 58910751800; 57212137034; 58909954300; 57884981400; 24473473500; 57817027600","Electroacupuncture Improving Intestinal Barrier Function in Rats with Irritable Bowel Syndrome Through Regulating Aquaporins","2024","Digestive Diseases and Sciences","69","4","","1143","1155","12","0","10.1007/s10620-024-08288-x","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85186190307&doi=10.1007%2fs10620-024-08288-x&partnerID=40&md5=27f9eaa35140c70b05a17c30f1c045f0","School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, 100029, China; School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China; School of Chinese Materia Medica, Beijing University of Chinese Medicine, No. 11 Beisanhuan East Road, Chaoyang District, Beijing, 100029, China","Kang X., School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, 100029, China; Zhang H., School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, 100029, China; Li X., School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China; Zhang K., School of Chinese Materia Medica, Beijing University of Chinese Medicine, No. 11 Beisanhuan East Road, Chaoyang District, Beijing, 100029, China; Huang Z., School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China; Li Y., School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, 100029, China; Ren X., School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, 100029, China; Chai Y., School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, 100029, China","Background: Intestinal mucosal barrier dysfunction plays a crucial role in the pathogenesis of irritable bowel syndrome with diarrhea (IBS-D). In order to explore the mechanism of electroacupuncture (EA) treatment on intestinal mucosal barrier, this study observed the effect of EA on aquaporins (AQPs), tight junctions (TJs), NF-κB pathway and the gut microbiota in IBS-D rats. Methods: The IBS-D model was established by acetic acid enema combined with chronic restraint method. The effects of EA on the treatment of IBS-D were examined by the abdominal withdrawal reflex score, Bristol's fecal character score, fecal water content, small intestine propulsion rate and HE staining. AQPs, TJs and inflammation-related molecular mechanisms were explored. The fecal samples were applied for 16S rRNA sequencing to assess the effect of EA intervention to the intestinal bacterial abundance. Results: EA reduced intestinal sensitization, restored intestinal motility and improved inflammatory cell infiltration. Furthermore, EA improved intestinal inflammation and flora environment significantly, inhibited NF-κB signaling and inflammatory factors (IL-1β and TNF-α). It can also increase the gene and protein expression of AQPs (AQP1, AQP3, and AQP8) and the gene levels of TJs (ZO-1 and Occludin). Conclusion: EA has an inhibitory effect on the NF-κB signaling pathway, and regulates the proteins of AQP1, AQP3, AQP8, and TJs to restore the balance of water metabolism and intestinal permeability in IBS-D, which also restored the function of the intestinal mucosa by regulating the intestinal flora. Graphical Abstract: Irritable bowel syndrome with predominant diarrhea (IBS-D) is a common gastrointestinal disease in clinical practice, which was affected by intestinal mucosal barrier dysfunction, intestinal mucosal inflammation production and abnormal intestinal flora, then there is currently no specific drug for treating IBS-D. Electroacupuncture (EA), as a non-pharmacological therapy, has good therapeutic effects in treating IBS-D. Aquaporins (AQPs) are distributed in the intestinal mucosa of the intestine and are important factors in mediating water–liquid transmembrane transport. Changes in AQPs expression have been identified as a common factor in the etiology of certain gastrointestinal diseases. AQP1, AQP3, and AQP8 are distributed in the distal colon. EA can inhibit NF-κB signaling pathway, and regulate the proteins of AQP1, AQP3, AQP8, and TJs to restore the balance of water metabolism and intestinal permeability in IBS-D, which also can restore the function of the intestinal mucosa by regulating the intestinal flora. (Figure presented.). © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024.","Acupuncture; Aquaporins; Gut microbiota; Intestinal barrier function; Irritable bowel syndrome; NF-κB","Animals; Aquaporins; Diarrhea; Electroacupuncture; Inflammation; Intestinal Barrier Function; Irritable Bowel Syndrome; NF-kappa B; Rats; RNA, Ribosomal, 16S; Water; acetic acid; aquaporin; aquaporin 1; aquaporin 3; aquaporin 8; genomic DNA; immunoglobulin enhancer binding protein; interleukin 1beta; messenger RNA; occludin; protein ZO1; RNA 16S; tumor necrosis factor; aquaporin; immunoglobulin enhancer binding protein; RNA 16S; water; acupuncture; animal experiment; animal model; animal tissue; apical membrane; Article; Bacteroidaceae; cell infiltration; colon mucosa; controlled study; descending colon; diarrhea; electroacupuncture; enteritis; Enterococcaceae; enzyme linked immunosorbent assay; gene expression; immunohistochemistry; intestine; intestine flora; intestine function; intestine motility; intestine mucosa; intestine mucosa permeability; irritable colon; Lachnospiraceae; Lactobacillaceae; loose feces; male; microbial diversity; NF kB signaling; nonhuman; optical density; Prevotellaceae; protein expression; protein expression level; protein function; protein localization; rat; real time polymerase chain reaction; RNA sequencing; Ruminococcaceae; shangjuxu acupoint; small intestine; tianshu acupoint; water content; water metabolism; Western blotting; withdrawal reflex; animal; inflammation; metabolism","","acetic acid, 127-08-2, 127-09-3, 64-19-7, 71-50-1, 6131-90-4; aquaporin, 215587-75-0; aquaporin 1, 146410-94-8, 149348-86-7; occludin, 176304-61-3; water, 7732-18-5; Aquaporins, ; NF-kappa B, ; RNA, Ribosomal, 16S, ; Water, ","","","Beijing University of Chinese Medicine, BUCM, (2020-JYB-XJSJJ-016); Beijing University of Chinese Medicine, BUCM","This research was supported by New Teacher Initiation Fund Project of Beijing University of Chinese Medicine (No. 2020-JYB-XJSJJ-016). ","Aziz I., Simren M., The overlap between irritable bowel syndrome and organic gastrointestinal diseases, Lancet Gastroenterol Hepatol, 6, pp. 139-148, (2021); Ghoshal U.C., Pros and cons while looking through an Asian window on the Rome IV criteria for irritable bowel syndrome: Pros, J Neurogastroenterol Motil, 23, pp. 334-340, (2017); Oka P., Parr H., Barberio B., Et al., Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis, Lancet Gastroenterol Hepatol, 5, pp. 908-917, (2020); Trinkley K.E., Nahata M.C., Medication management of irritable bowel syndrome, Digestion, 89, pp. 253-267, (2014); Canavan C., West J., Card T., Calculating total health service utilisation and costs from routinely collected electronic health records using the example of patients with irritable bowel syndrome before and after their first gastroenterology appointment, Pharmacoeconomics, 34, pp. 181-194, (2016); Camilleri M., Lasch K., Zhou W., Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome, Am J Physiol Gastrointest Liver Physiol, 303, pp. G775-G785, (2012); Laforenza U., Water channel proteins in the gastrointestinal tract, Mol Aspects Med, 33, pp. 642-650, (2012); Kalita A., Das M., Baro M.R., Das B., Exploring the role of Aquaporins (AQPs) in LPS induced systemic inflammation and the ameliorative effect of Garcinia in male Wistar rat, Inflammopharmacology, 29, pp. 801-823, (2021); Zhao G.X., Dong P.P., Peng R., Et al., Expression, localization and possible functions of aquaporins 3 and 8 in rat digestive system, Biotech Histochem, 91, pp. 269-276, (2016); Singh S.K., Binder H.J., Boron W.F., Geibel J.P., Fluid absorption in isolated perfused colonic crypts, J Clin Investig, 96, pp. 2373-2379, (1995); Yano T., Kanoh H., Tamura A., Tsukita S., Apical cytoskeletons and junctional complexes as a combined system in epithelial cell sheets, Ann NY Acad Sci, 1405, pp. 32-43, (2017); Vermette D., Hu P., Canarie M.F., Funaro M., Glover J., Pierce R.W., Tight junction structure, function, and assessment in the critically ill: a systematic review, Intensive Care Med Exp, 6, (2018); Fischbarg J., Fluid transport across leaky epithelia: central role of the tight junction and supporting role of aquaporins, Physiol Rev, 90, pp. 1271-1290, (2010); Yuan Y., Wang X., Huang S., Wang H., Shen G., Low-level inflammation, immunity, and brain–gut axis in IBS: unraveling the complex relationships, Gut Microbes, 15, (2023); Vivinus-Nebot M., Frin-Mathy G., Bzioueche H., Et al., Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation, Gut, 63, pp. 744-752, (2014); Chao G., Zhang S., Aquaporins 1, 3 and 8 expression in irritable bowel syndrome rats' colon via NF-κB pathway, Oncotarget, 8, pp. 47175-47183, (2017); Rabitti S., Giovanardi C.M., Colussi D., Acupuncture and related therapies for the treatment of gastrointestinal diseases, J Clin Gastroenterol, 55, pp. 207-217, (2021); Zhu X., Liu Z., Qin Y., Et al., Analgesic effects of electroacupuncture at ST25 and CV12 in a rat model of postinflammatory irritable bowel syndrome visceral pain, Acupunct Med, 36, pp. 240-246, (2018); Li J., Lu J., Sun J., Et al., Acupuncture with regulating mind and spleen for diarrhea irritable bowel syndrome and sleep quality: a randomized controlled trial, Zhongguo Zhen Jiu, 37, pp. 9-13, (2017); Hou Y.J., Wang K., Jiang H.L., Et al., Study on the mechanism of electroacupuncture repairing intestinal barrier via regulating mast cell in rats with diarrhea-predominant irritable bowel syndrome, Zhen Ci Yan Jiu, 48, pp. 281-286, (2023); Mengzhu S., Yujie Z., Yafang S., Et al., Electroacupuncture alleviates water avoidance stress-induced irritable bowel syndrome in mice by improving intestinal barrier functions and suppressing the expression of inflammatory cytokines, J Tradit Chin Med, 43, pp. 494-500, (2023); Chao G., Wang Z., Yang Y., Zhang S., LncRNA H19 as a competing endogenous RNA to regulate AQP expression in the intestinal barrier of IBS-D patients, Front Physiol, 11, (2021); Williams C.L., Villar R.G., Peterson J.M., Burks T.F., Stress-induced changes in intestinal transit in the rat: a model for irritable bowel syndrome, Gastroenterology, 94, pp. 611-621, (1988); La J.H., Kim T.W., Sung T.S., Et al., Visceral hypersensitivity and altered colonic motility after subsidence of inflammation in a rat model of colitis, World J Gastroenterol, 9, pp. 2791-2795, (2003); Lewis S.J., Heaton K.W., Stool form scale as a useful guide to intestinal transit time, Scand J Gastroenterol, 32, pp. 920-924, (1997); Camilleri M., Ford A.C., Irritable bowel syndrome: pathophysiology and current therapeutic approaches, Handb Exp Pharmacol, 239, pp. 75-113, (2017); Wu I.X.Y., Wong C.H.L., Ho R.S.T., Et al., Acupuncture and related therapies for treating irritable bowel syndrome: overview of systematic reviews and network meta-analysis, Ther Adv Gastroenterol, 12, (2019); Huang J., Lu M., Zheng Y., Et al., Quality of evidence supporting the role of acupuncture for the treatment of irritable bowel syndrome, Pain Res Manag, 2021, (2021); Sun J.W., Sun M.L., Li D., Et al., Efficacy of acupuncture based on acupoint combination theory for irritable bowel syndrome: a study protocol for a multicenter randomized controlled trial, Trials, 22, (2021); Zhou Z.X., Ma H.F., Yang Y.C., Chen J.T., Feng Y.H., Effect of electroacupuncture on colonic motility and RhoA and ROCK protein expression in IBS-D rats, Zhen Ci Yan Jiu, 47, pp. 611-616, (2022); Li X., Ren K., Hong X., Et al., Ameliorating effects of electroacupuncture on the low-grade intestinal inflammation in rat model of diarrhea-predominant irritable bowel syndrome, J Gastroenterol Hepatol, 37, pp. 1963-1974, (2022); Su Q., Tun H.M., Liu Q., Et al., Gut microbiome signatures reflect different subtypes of irritable bowel syndrome, Gut Microbes, 15, (2023); Sun M.Z., Zhang Y.J., Song Y.F., Et al., Electroacupuncture at Tianshu (ST25) and Zusanli (ST36) alleviates stress-induced irritable bowel syndrome in mice by modulating gut microbiota and corticotropin-releasing factor, J Tradit Chin Med, 42, pp. 732-740, (2022); Piche T., Tight junctions and IBS—the link between epithelial permeability, low-grade inflammation, and symptom generation?, Neurogastroenterol Motil, 26, pp. 296-302, (2014); Ivashkin V., Poluektov Y., Kogan E., Et al., Disruption of the pro-inflammatory, anti-inflammatory cytokines and tight junction proteins expression, associated with changes of the composition of the gut microbiota in patients with irritable bowel syndrome, PLoS ONE, 16, (2021); Martens E.C., Neumann M., Desai M.S., Interactions of commensal and pathogenic microorganisms with the intestinal mucosal barrier, Nat Rev Microbiol, 16, pp. 457-470, (2018); Salman M.M., Kitchen P., Yool A.J., Bill R.M., Recent breakthroughs and future directions in drugging aquaporins, Trends Pharmacol Sci, 43, pp. 30-42, (2022); Wagner K., Unger L., Salman M.M., Et al., Signaling mechanisms and pharmacological modulators governing diverse aquaporin functions in human health and disease, Int J Mol Sci, 23, (2022); Camilleri M., Carlson P., Chedid V., Et al., Aquaporin expression in colonic mucosal biopsies from irritable bowel syndrome with diarrhea, Clin Transl Gastroenterol, 10, (2019); Wang J.P., Hou X.H., Expression of aquaporin 8 in colonic epithelium with diarrhoea-predominant irritable bowel syndrome, Chin Med J, 120, pp. 313-316, (2007); Buckley A., Turner J.R., Cell biology of tight junction barrier regulation and mucosal disease, Cold Spring Harb Perspect Biol, 10, (2018); Wang H.Y., Chi C., Xu Y.Q., Et al., Occludin endocytosis is involved in the disruption of the intestinal epithelial barrier in a mouse model of alcoholic steatohepatitis, J Dig Dis, 20, pp. 476-485, (2019); Zhang W., Xu Y., Chen Z., Xu Z., Xu H., Knockdown of aquaporin 3 is involved in intestinal barrier integrity impairment, FEBS Lett, 585, pp. 3113-3119, (2011); Dong L.W., Chen Y.Y., Chen C.C., Et al., Adenosine 2A receptor contributes to the facilitation of post-infectious irritable bowel syndrome by γδ T cells via the PKA/CREB/NF-κB signaling pathway, World J Gastroenterol, 29, pp. 1475-1491, (2023); Wang L., Lei J., Zhao Z., Jia J., Wang L., Therapeutic effects of paeoniflorin on irritable bowel syndrome in rats, J Vet Sci, 24, (2023); Zou L., Ruan J.R., Chen J.Y., Et al., Moxibustion relieves colonic inflammation by up-regulating expression of miR-345-3p/miR-216a-5p and down-regulating NF-κB p65 in colonic tissue of rats with diarrhea-predominant irritable bowel syndrome, Zhen Ci Yan Jiu, 48, pp. 226-232, (2023)","Y. Chai; School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, 100029, China; email: 201901020@bucm.edu.cn","","Springer","","","","","","01632116","","DDSCD","38421507","English","Dig. Dis. Sci.","Article","Final","","Scopus","2-s2.0-85186190307"

"Jin X.; Hu Y.; Lin T.; Gao F.; Xu Z.; Hou X.; Yin Y.; Kan S.; Zhu H.; Chen D.","Jin, Xueli (57736997800); Hu, Yongjia (57855175200); Lin, Ting (57855800900); Gao, Fei (57216622610); Xu, Ziqi (58099877800); Hou, Xiao (57856426700); Yin, Yu (56664962000); Kan, Shidong (35205618600); Zhu, Hui (57211883191); Chen, Daijie (35073629800)","57736997800; 57855175200; 57855800900; 57216622610; 58099877800; 57856426700; 56664962000; 35205618600; 57211883191; 35073629800","Selenium-enriched Bifidobacterium longum DD98 relieves irritable bowel syndrome induced by chronic unpredictable mild stress in mice","2023","Food and Function","14","11","","5355","5374","19","6","10.1039/d2fo03408e","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85162818640&doi=10.1039%2fd2fo03408e&partnerID=40&md5=78fda1c68fadec17612b3f951f95342a","School of Pharmacy, Shanghai Jiao Tong University, No. 800 Dongchuan Road, Minhang District, China; State Key Laboratory of Microbial Metabolism, Shanghai Jiao Tong University, No. 800 Dongchuan Road, Minhang District, China","Jin X., School of Pharmacy, Shanghai Jiao Tong University, No. 800 Dongchuan Road, Minhang District, China, State Key Laboratory of Microbial Metabolism, Shanghai Jiao Tong University, No. 800 Dongchuan Road, Minhang District, China; Hu Y., School of Pharmacy, Shanghai Jiao Tong University, No. 800 Dongchuan Road, Minhang District, China; Lin T., School of Pharmacy, Shanghai Jiao Tong University, No. 800 Dongchuan Road, Minhang District, China; Gao F., School of Pharmacy, Shanghai Jiao Tong University, No. 800 Dongchuan Road, Minhang District, China; Xu Z., School of Pharmacy, Shanghai Jiao Tong University, No. 800 Dongchuan Road, Minhang District, China; Hou X., School of Pharmacy, Shanghai Jiao Tong University, No. 800 Dongchuan Road, Minhang District, China; Yin Y., School of Pharmacy, Shanghai Jiao Tong University, No. 800 Dongchuan Road, Minhang District, China; Kan S., School of Pharmacy, Shanghai Jiao Tong University, No. 800 Dongchuan Road, Minhang District, China; Zhu H., School of Pharmacy, Shanghai Jiao Tong University, No. 800 Dongchuan Road, Minhang District, China; Chen D., School of Pharmacy, Shanghai Jiao Tong University, No. 800 Dongchuan Road, Minhang District, China, State Key Laboratory of Microbial Metabolism, Shanghai Jiao Tong University, No. 800 Dongchuan Road, Minhang District, China","Irritable bowel syndrome (IBS) is a functional intestinal disorder without clear pathological mechanisms. Classical treatments for IBS are not always effective and are usually accompanied by side effects. Selenium-enriched Bifidobacterium longum DD98 (Se-B. longum DD98) is a selenized probiotic strain which has shown many beneficial effects on the gastrointestinal tract, but its effects on IBS and the underlying mechanism are unclear. This study aims to investigate the relieving effects of Se-B. longum DD98 on chronic unpredictable mild stress (CUMS)-induced IBS in mice. The model mice were treated with saline, B. longum DD98, or Se-B. longum DD98 while receiving CUMS. The results suggest that Se-B. longum DD98 significantly relieved the intestinal symptoms of IBS mice and reduced intestinal permeability and inflammation. The depression and anxiety-like behaviors of IBS mice were also improved by Se-B. longum DD98. In addition, the expression of serotonin (5-HT), γ-aminobutyric acid (GABA), neuropeptide Y (NPY), and brain-derived neurotrophic factor (BDNF), which are indicators closely related to mood and brain-gut axis, were up-regulated in mice treated with Se-B. longum DD98. Furthermore, the 16S rRNA sequencing study showed that Se-B. longum DD98 effectively restored the relative abundance of intestinal microbes (e.g., Lactobacillus, Desulfovibrio, Akkermansia) and regulated the impaired diversity of gut microbiota in IBS mice. These results suggest that Se-B. longum DD98 positively acts on the brain-gut axis by improving intestinal functions and regulating mood-associated behaviors and indicators of IBS mice. Therefore, this Se-enriched probiotic strain could be considered a promising candidate for the alleviation of CUMS-induced IBS. © 2023 The Royal Society of Chemistry.","","Animals; Bifidobacterium longum; Intestines; Irritable Bowel Syndrome; Mice; Probiotics; RNA, Ribosomal, 16S; Selenium; Amino acids; Mammals; Probiotics; RNA; Selenium compounds; probiotic agent; RNA 16S; selenium; Beneficial effects; Bifidobacterium longum; Gastrointestinal tract; Intestinal inflammation; Intestinal permeabilities; Irritable bowel syndromes; Probiotic strain; Side effect; Stress-induced; γ-Aminobutyric acid; animal; Bifidobacterium longum; intestine; irritable colon; metabolism; microbiology; mouse; Selenium","","selenium, 7782-49-2; RNA, Ribosomal, 16S, ; Selenium, ","","","Science and Technology Talent Project of Shanghai, (17XD1423200); National Natural Science Foundation of China, NSFC, (81872775); National Natural Science Foundation of China, NSFC; Ministry of Industry and Information Technology of the People's Republic of China, MIIT, (CEIEC-2020-ZM02-0165); Ministry of Industry and Information Technology of the People's Republic of China, MIIT; National Key Research and Development Program of China, NKRDPC, (2018YFA0901904); National Key Research and Development Program of China, NKRDPC","This work was supported by grants from the National Key Research and Development Program of China (No. 2018YFA0901904), the Science and Technology Talent Project of Shanghai (No. 17XD1423200), the National Natural Science Foundation of China (No. 81872775), and funding from the Consumer Products Group of Ministry of Industry and Information Technology of China (No. CEIEC-2020-ZM02-0165).","Foster J.A., Neufeld K.A.M., Gut-brain: how the microbiome influences anxiety and depression, Trends Neurosci., 36, pp. 305-312, (2013); Yu Y.B., Zhao D.Y., Qi Q.Q., Long X., Li X., Chen F.X., Zuo X.L., BDNF modulates intestinal barrier integrity through regulating the expression of tight junction proteins, Neurogastroenterol. Motil., 29, (2017); Lopez-Perez A.E., Nurgali K., Abalo R., Painful neurotrophins and their role in visceral pain, Behav. Pharmacol., 29, pp. 120-139, (2018); Rasmusson A.M., The gut peptide neuropeptide Y and post-traumatic stress disorder, Curr. Opin. Endocrinol., Diabetes Obes., 24, pp. 3-8, (2017); Abedpoor N., Taghian F., Hajibabaie F., Cross Brain-Gut Analysis Highlighted Hub Genes and LncRNA Networks Differentially Modified During Leucine Consumption and Endurance Exercise in Mice with Depression-Like Behaviors, Mol. Neurobiol., 59, pp. 4106-4123, (2022); Fetissov S.O., Neuropeptide-like signaling in the microbiota-gut-brain axis, Behav. Brain Sci., 42, (2019); Jeffery I.B., O'Toole P.W., Ohman L., Claesson M.J., Deane J., Quigley E.M.M., Simren M., An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota, Gut, 61, pp. 997-1006, (2012); Peyton L., Greene J., Irritable bowel syndrome: current and emerging treatment options, P T, 39, pp. 567-578, (2014); Fitzgerald I., O'Dwyer S., Brooks M., Sahm L., Crowley E., Dhubhlaing C.N., Worth the Weight? Olanzapine Prescribing in Schizophrenia. A Review of Weight Gain and Other Cardiometabolic Side Effects of Olanzapine, Front. Mol. Psychiatry, 12, (2021); Bertholon F., Krajewski Y., el Allali A., Adverse effects: priapism caused by paroxetine, Ann. Med.-Psychol., 154, pp. 145-146, (1996); Mermi O., Atmaca M., Peripheral Edema Related to Paroxetine Discontinuation: A Case Report, Klin. Psikofarmakol. Bul., 25, pp. 291-294, (2015); Nicholson S.D., Extra pyramidal side effects associated with paroxetine, West Engl. Med. J., 107, pp. 90-91, (1992); Neve J., Vertongen F., Molle L., Selenium deficiency, Clin. Endocrinol. Metab., 14, pp. 629-656, (1985); Fairweather-Tait S.J., Bao Y., Broadley M.R., Collings R., Ford D., Hesketh J.E., Hurst R., Selenium in human health and disease, Antioxid. Redox Signal., 14, pp. 1337-1383, (2011); Mangiapane E., Pessione A., Pessione E., Selenium and selenoproteins: an overview on different biological systems, Curr. Protein Pept. Sci., 15, pp. 598-607, (2014); Rannem T., Ladefoged K., Hylander E., Hegnhoj J., Staun M., Selenium depletion in patients with gastrointestinal diseases: Are there any predictive factors?, Scand. J. Gastroenterol., 33, pp. 1057-1061, (1998); Ye R.H., Huang J.Q., Wang Z.X., Chen Y.X., Dong Y.L., Trace Element Selenium Effectively Alleviates Intestinal Diseases, Int. J. Mol. Sci., 22, (2021); Burk R.F., Hill K.E., Motley A.K., Winfrey V.P., Kurokawa S., Mitchell S.L., Zhang W.Q., Selenoprotein P and apolipoprotein E receptor-2 interact at the blood-brain barrier and also within the brain to maintain an essential selenium pool that protects against neurodegeneration, FASEB J., 28, pp. 3579-3588, (2014); Solovyev N., Drobyshev E., Blume B., Michalke B., Selenium at the Neural Barriers: A Review, Front. Neurosci., 15, (2021); Alim I., Caulfield J.T., Chen Y.X., Swarup V., Geschwind D.H., Ivanova E., Seravalli J., Ai Y.X., Sensing L.H., Ste Marie E.J., Hondal R.J., Mukherjee S., Cave J.W., Sagdullaev B.T., Karuppagounder S.S., Ratan R.R., Selenium Drives a Transcriptional Adaptive Program to Block Ferroptosis and Treat Stroke, Cell, 177, pp. 1262-1279, (2019); Amani H., Habibey R., Shokri F., Hajmiresmail S.J., Akhavans O., Mashaghi A., Pazoki-Toroudi H., Selenium nanoparticles for targeted stroke therapy through modulation of inflammatory and metabolic signaling, Sci. Rep., 9, (2019); Malyar R.M., Naseri E., Li H., Ali I., Farid R.A., Liu D., Maroof K., Nasim M., Banuree S.A.H., Huang K., Waldron K.J., Chen X., Hepatoprotective Effects of Selenium-Enriched Probiotics Supplementation on Heat-Stressed Wistar Rat Through Anti-Inflammatory and Antioxidant Effects, Biol. Trace Elem. Res., 199, pp. 3445-3456, (2021); Darwish A.M., Khattab A.E.A., Abd El-Razik K.A., Othman S.I., Allam A.A., Abu-Taweel G.M., Effectiveness of new selenium-enriched mutated probiotics in reducing inflammatory effects of piroxicam medication in liver and kidney, Inflammopharmacology, 30, pp. 2097-2106, (2022); Ibrahim H.A., Zhu Y., Wu C., Lu C., Ezekwe M.O., Liao S.F., Huang K., Selenium-enriched probiotics improves murine male fertility compromised by high fat diet, Biol. Trace Elem. Res., 147, pp. 251-260, (2012); Yang J., Huang K., Qin S., Wu X., Zhao Z., Chen F., Antibacterial action of selenium-enriched probiotics against pathogenic Escherichia coli, Dig. Dis Sci., 54, pp. 246-254, (2009); Pophaly S.D., Poonam, Singh P., Kumar H., Tomar S.K., Singh R., Selenium enrichment of lactic acid bacteria and bifidobacteria: A functional food perspective, Trends Food Sci. Technol., 39, pp. 135-145, (2014); Lach G., Schellekens H., Dinan T.G., Cryan J.F., Anxiety, Depression, and the Microbiome: A Role for Gut Peptides, Neurotherapeutics, 15, pp. 36-59, (2018); Long-Smith C., O'Riordan K.J., Clarke G., Stanton C., Dinan T.G., Cryan J.F., Annual Review of Pharmacology and Toxicology, 60, pp. 477-502, (2020); Pittayanon R., Lau J.T., Yuan Y.H., Leontiadis G.I., Tse F., Surette M., Moayyedi P., Gut Microbiota in Patients With Irritable Bowel Syndrome-A Systematic Review, Gastroenterology, 157, pp. 97-108, (2019); El-Salhy M., Hatlebakk J.G., Hausken T., Diet in Irritable Bowel Syndrome (IBS): Interaction with Gut Microbiota and Gut Hormones, Nutrients, 11, (2019); Tian P.J., O'Riordan K.J., Lee Y.K., Wang G., Zhao J.X., Zhang H., Cryan J.F., Chen W., Towards a psychobiotic therapy for depression: Bifidobacterium breve CCFM1025 reverses chronic stress-induced depressive symptoms and gut microbial abnormalities in mice, Neurobiol. Stress, 12, (2020); Dale H.F., Rasmussen S.H., Asiller O.O., Lied G.A., Probiotics in Irritable Bowel Syndrome: An Up-to-Date Systematic Review, Nutrients, 11, (2019); Kasaikina M.V., Kravtsova M.A., Lee B.C., Seravalli J., Peterson D.A., Walter J., Legge R., Benson A.K., Hatfield D.L., Gladyshev V.N., Dietary selenium affects host selenoproteome expression by influencing the gut microbiota, FASEB J., 25, pp. 2492-2499, (2011); Hui Z., Yan Z., Yan Q., Rui J., Junliang Z., Zhixiang Q., Chunzhen W., Jun T., Lei S., Daijie C., Preparation and characterization of selenium enriched-Bifidobacterium longum DD98, and its repairing effects on antibiotic-induced intestinal dysbacteriosis in mice, Food Funct., 10, pp. 4975-4984, (2019); Zhu H., Lu C.Y., Gao F., Qian Z.X., Yin Y., Kan S.D., Chen D.J., Selenium-enriched Bifidobacterium longum DD98 attenuates irinotecan-induced intestinal and hepatic toxicity in vitro and in vivo, Biomed. Pharmacother., 143, (2021); Hu Y.J., Jin X.L., Gao F., Lin T., Zhu H., Hou X., Yin Y., Kan S.D., Chen D.J., Selenium-enriched Bifidobacterium longum DD98 effectively ameliorates dextran sulfate sodium-induced ulcerative colitis in mice, Front. Microbiol., 13, (2022); Zhu H., Bierla K., Jin X., Szpunar J., Chen D., Lobinski R., Identification of γ-Glutamyl-Selenomethionine as the Principal Selenium Metabolite in a Selenium-Enriched Probiotic, Bifidobacterium longum, by Two-Dimensional HPLC-ICP MS and HPLC-ESI Orbitrap MS, J. Agric. Food Chem., 70, pp. 6726-6736, (2022); Antoniuk S., Bijata M., Ponimaskin E., Wlodarczyk J., Chronic unpredictable mild stress for modeling depression in rodents: Meta-analysis of model reliability, Neurosci. Biobehav. Rev., 99, pp. 101-116, (2019); Shi H.L., Liu C.H., Ding L.L., Zheng Y., Fei X.Y., Lu L., Zhou X.M., Yuan J.Y., Xie J.Q., Alterations in serotonin, transient receptor potential channels and protease-activated receptors in rats with irritable bowel syndrome attenuated by Shugan decoction, World J. Gastroenterol., 21, pp. 4852-4863, (2015); Zielinska M., Jarmuz A., Wasilewski A., Cami-Kobeci G., Husbands S., Fichna J., Methyl-orvinol-Dual activity opioid receptor ligand inhibits gastrointestinal transit and alleviates abdominal pain in the mouse models mimicking diarrhea-predominant irritable bowel syndrome, Pharmacol. Rep., 69, pp. 350-357, (2017); Christianson J.A., Gebhart G.F., Assessment of colon sensitivity by luminal distension in mice, Nat. Protoc., 2, pp. 2624-2631, (2007); Zhang C., Zhou X., Zhou X., Effect of Acute Brief Social Isolation on Visceral Pain, J. Pain. Res., 15, pp. 3547-3553, (2022); Kraeuter A.K., Guest P.C., Sarnyai Z., The Open Field Test for Measuring Locomotor Activity and Anxiety-Like Behavior, Methods Mol. Biol., 1916, pp. 99-103, (2019); Campos A.C., Fogaca M.V., Aguiar D.C., Guimaraes F.S., Animal models of anxiety disorders and stress, Rev. Bras. Psiquiatr., 35, pp. S101-S111, (2013); Planaguma J., Leypoldt F., Mannara F., Gutierrez-Cuesta J., Martin-Garcia E., Aguilar E., Titulaer M.J., Petit-Pedrol M., Jain A., Balice-Gordon R., Lakadamyali M., Graus F., Maldonado R., Dalmau J., Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice, Brain, 138, pp. 94-109, (2015); Schmittgen T.D., Livak K.J., Analyzing real-time PCR data by the comparative C(T) method, Nat. Protoc., 3, pp. 1101-1108, (2008); Zhang L., Wang Y., Xia X.Y., Shi C.H., Chen W., Song N., Fu X.J., Zhou R., Xu Y.F., Huang L., Zhu H., Han Y.L., Qin C., Altered Gut Microbiota in a Mouse Model of Alzheimer's Disease, J. Alzheimer's Dis., 60, pp. 1241-1257, (2017); Bruijstens A.L., Molenaar S., Wong Y.Y.M., Kraaij R., Neuteboom R.F., Gut microbiota analysis in pediatric-onset multiple sclerosis compared to pediatric monophasic demyelinating syndromes and pediatric controls, Eur. J. Neurol., (2022); Yanrong L., Xiangxiang Q., Huaijie J., Sirui C., Weiwei S., Xiaoxia W., The association between gut microbiota composition and BMI in Chinese male college students, as analysed by next-generation sequencing, Br. J. Nutr., 122, pp. 986-995, (2019); Brzozowski B., Mazur-Bialy A., Pajdo R., Kwiecien S., Bilski J., Zwolinska-Wcislo M., Mach T., Brzozowski T., Mechanisms by which Stress Affects the Experimental and Clinical Inflammatory Bowel Disease (IBD): Role of Brain-Gut Axis, Curr. Neuropharmacol., 14, pp. 892-900, (2016); Long Y., Du L., Kim J.J., Chen B., Zhu Y., Zhang Y., Yao S., He H., Zheng X., Huang Z., Dai N., MLCK-mediated intestinal permeability promotes immune activation and visceral hypersensitivity in PI-IBS mice, Neurogastroenterol. Motil., 30, (2018); Lambert G.P., Stress-induced gastrointestinal barrier dysfunction and its inflammatory effects, J. Anim. Sci., 87, pp. E101-E108, (2009); Balmus I.M., Ciobica A., Cojocariu R., Luca A.C., Gorgan L., Irritable Bowel Syndrome and Neurological Deficiencies: Is There A Relationship? The Possible Relevance of the Oxidative Stress Status, Medicina, 56, (2020); Ghosh S., Whitley C.S., Haribabu B., Jala V.R., Regulation of Intestinal Barrier Function by Microbial Metabolites, Cell. Mol. Gastroenterol. Hepatol., 11, pp. 1463-1482, (2021); Ulluwishewa D., Anderson R.C., McNabb W.C., Moughan P.J., Wells J.M., Roy N.C., Regulation of Tight Junction Permeability by Intestinal Bacteria and Dietary Components1,2, J. Nutr., 141, pp. 769-776, (2011); Carroll I.M., Ringel-Kulka T., Keku T.O., Chang Y.H., Packey C.D., Sartor R.B., Ringel Y., Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome, Am. J. Physiol., 301, pp. G799-G807, (2011); Qiang-Song W., Yi-Lun W., Wen-Yan Z., Kuang-Dai L., Xiong-Fei L., Yuan-Lu C., Puerarin from Pueraria lobata alleviates the symptoms of irritable bowel syndrome-diarrhea, Food Funct., 12, pp. 2211-2224, (2021); Osadchiy V., Martin C.R., Mayer E.A., The Gut-Brain Axis and the Microbiome: Mechanisms and Clinical Implications, Clin. Gastroenterol. Hepatol., 17, pp. 322-332, (2019); Dinan T.G., Cryan J.F., The Microbiome-Gut-Brain Axis in Health and Disease, Gastroenterol. Clin. North Am., 46, pp. 77-89, (2017); Mayer E.A., Savidge T., Shulman R.J., Brain-Gut Microbiome Interactions and Functional Bowel Disorders, Gastroenterology, 146, pp. 1500-1512, (2014); Trinkley K.E., Nahata M.C., Medication Management of Irritable Bowel Syndrome, Digestion, 89, pp. 253-267, (2014); Avery J.C., Hoffmann P.R., Selenium, Selenoproteins, and Immunity, Nutrients, 10, (2018); Rayman M.P., Selenium intake, status, and health: a complex relationship, Hormones, 19, pp. 9-14, (2020); Bron P.A., Kleerebezem M., Brummer R.J., Cani P.D., Mercenier A., MacDonald T.T., Garcia-Rodenas C.L., Wells J.M., Can probiotics modulate human disease by impacting intestinal barrier function?, Br. J. Nutr., 117, pp. 93-107, (2017); Yan F., Polk D.B., Probiotics and Probiotic-Derived Functional Factors-Mechanistic Insights Into Applications for Intestinal Homeostasis, Front. Immunol., 11, (2020); Plaza-Diaz J., Ruiz-Ojeda F.J., Vilchez-Padial L.M., Gil A., Evidence of the Anti-Inflammatory Effects of Probiotics and Synbiotics in Intestinal Chronic Diseases, Nutrients, 9, (2017); Li B., Liang L., Deng H., Guo J., Shu H., Zhang L., Efficacy and Safety of Probiotics in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis, Front. Pharmacol., 11, (2020); Didari T., Mozaffari S., Nikfar S., Abdollahi M., Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis, World J. Gastroenterol., 21, pp. 3072-3084, (2015); Horvat I.B., Gobin I., Kresovic A., Hauser G., How can probiotic improve irritable bowel syndrome symptoms, World J. Gastrointest. Surg., 13, pp. 923-940, (2021); Xi L., Qingqing L., Jiaoyan Y., Ruitao Z., Ting S., Wei J., Na H., Peng Y., Li L., Jing R., Qinhui W., Yan W., Qi Y., Costunolide ameliorates intestinal dysfunction and depressive behaviour in mice with stress-induced irritable bowel syndrome via colonic mast cell activation and central 5-hydroxytryptamine metabolism, Food Funct., 12, pp. 4142-4151, (2021); Krammer L., Sowa A.S., Lorentz A., Mast Cells in Irritable Bowel Syndrome: A Systematic Review, J. Gastrointestin. Liver Dis., 28, pp. 463-472, (2019); Grabauskas G., Wu X.Y., Gao J., Li J.Y., Turgeon D.K., Owyang C., Prostaglandin E-2, Produced by Mast Cells in Colon Tissues From Patients With Irritable Bowel Syndrome, Contributes to Visceral Hypersensitivity in Mice, Gastroenterology, 158, pp. 2195-2207, (2020); Feng B., La J.H., Schwartz E.S., Gebhart G.F., Neural and neuro-immune mechanisms of visceral hypersensitivity in irritable bowel syndrome, Am. J. Physiol.: Gastrointest. Liver Physiol., 302, pp. G1085-G1098, (2012); Brzozowski B., Mazur-Bialy A., Pajdo R., Kwiecien S., Bilski J., Zwolinska-Wcislo M., Mach T., Brzozowski T., Mechanisms by which Stress Affects the Experimental and Clinical Inflammatory Bowel Disease (IBD): Role of Brain-Gut Axis, Curr. Neuropharmacol., 14, pp. 892-900, (2016); Michielan A., D'Inca R., Intestinal Permeability in Inflammatory Bowel Disease: Pathogenesis, Clinical Evaluation, and Therapy of Leaky Gut, Mediators Inflammation, 2015, (2015); Long Y., Du L., Kim J.J., Chen B., Zhu Y., Zhang Y., Yao S., He H., Zheng X., Huang Z., Dai N., MLCK-mediated intestinal permeability promotes immune activation and visceral hypersensitivity in PI-IBS mice, Neurogastroenterol. Motil., 30, (2018); He Y., Yue Y., Zheng X., Zhang K., Chen S.H., Du Z.Y., Curcumin, Inflammation, and Chronic Diseases: How Are They Linked?, Molecules, 20, pp. 9183-9213, (2015); Balmus I.M., Ilie O.D., Ciobica A., Cojocariu R.O., Stanciu C., Trifan A., Cimpeanu M., Cimpeanu C., Gorgan L., Irritable Bowel Syndrome between Molecular Approach and Clinical Expertise-Searching for Gap Fillers in the Oxidative Stress Way of Thinking, Medicina, 56, (2020); Miao L., St Clair D.K., Regulation of superoxide dismutase genes: implications in disease, Free Radicals Biol. Med., 47, pp. 344-356, (2009); De Luca C., Mikhal'chik E.V., Suprun M.V., Papacharalambous M., Truhanov A.I., Korkina L.G., Skin Antiageing and Systemic Redox Effects of Supplementation with Marine Collagen Peptides and Plant-Derived Antioxidants: A Single-Blind Case-Control Clinical Study, Oxid. Med. Cell. Longevity, 2016, (2016); Goyal M.M., Basak A., Human catalase: looking for complete identity, Protein Cell, 1, pp. 888-897, (2010); Vlasova I.I., Peroxidase Activity of Human Hemoproteins: Keeping the Fire under Control, Molecules, 23, (2018); Yang S.Y., Zhang C.Y., Xu W.Q., Li D.T., Feng Y., Wu J.Y., Luo W., Du X.G., Du Z.J., Huang X.L., Heat Stress Decreases Intestinal Physiological Function and Facilitates the Proliferation of Harmful Intestinal Microbiota in Sturgeons, Front. Microbiol., 13, (2022); Sinha A.K., Romano N., Shrivastava J., Monico J., Bishop W.M., Oxidative stress, histopathological alterations and anti-oxidant capacity in different tissues of largemouth bass (Micropterus salmoides) exposed to a newly developed sodium carbonate peroxyhydrate granular algaecide formulated with hydrogen peroxide, Aquat. Toxicol., 218, (2020); Jiang W.D., Feng L., Qu B., Wu P., Kuang S.Y., Jiang J., Tang L., Tang W.N., Zhang Y.A., Zhou X.Q., Liu Y., Changes in integrity of the gill during histidine deficiency or excess due to depression of cellular anti-oxidative ability, induction of apoptosis, inflammation and impair of cell-cell tight junctions related to Nrf2, TOR and NF-κB signaling in fish, Fish Shellfish Immunol., 56, pp. 111-122, (2016); Mete R., Tulubas F., Oran M., Yilmaz A., Avci B.A., Yildiz K., Turan C.B., Gurel A., The role of oxidants and reactive nitrogen species in irritable bowel syndrome: A potential etiological explanation, Med. Sci. Monit., 19, pp. 762-766, (2013); Chimienti G., Orlando A., Lezza A.M.S., D'Attoma B., Notarnicola M., Gigante I., Pesce V., Russo F., The Ketogenic Diet Reduces the Harmful Effects of Stress on Gut Mitochondrial Biogenesis in a Rat Model of Irritable Bowel Syndrome, Int. J. Mol. Sci., 22, (2021); Hardy G., Hardy I., Manzanares W., Selenium supplementation in the critically ill, Nutr. Clin. Pract., 27, pp. 21-33, (2012); Lackner J.M., Ma C.X., Keefer L., Brenner D.M., Gudleski G.D., Satchidanand N., Firth R., Sitrin M.D., Katz L., Krasner S.S., Ballou S.K., Naliboff B.D., Mayer E.A., Type, Rather Than Number, of Mental and Physical Comorbidities Increases the Severity of Symptoms in Patients With Irritable Bowel Syndrome, Clin. Gastroenterol. Hepatol., 11, pp. 1147-1157, (2013); Chen M.J., Ruan G.C., Chen L., Ying S.H., Li G.H., Xu F.H., Xiao Z.F., Tian Y.T., Lv L.L., Ping Y., Cheng Y., Wei Y.L., Neurotransmitter and Intestinal Interactions: Focus on the Microbiota-Gut-Brain Axis in Irritable Bowel Syndrome, Front. Endocrinol., 13, (2022); Artigas F., Serotonin receptors involved in antidepressant effects, Pharmacol. Ther., 137, pp. 119-131, (2013); Fogaca M.V., Duman R.S., Cortical GABAergic Dysfunction in Stress and Depression: New Insights for Therapeutic Interventions, Front. Cell. Neurosci., 13, (2019); Castren E., Monteggia L.M., Brain-Derived Neurotrophic Factor Signaling in Depression and Antidepressant Action, Biol. Psychiatry, 90, pp. 128-136, (2021); Sram R.J., Veleminsky M., Veleminsky M., Stejskalova J., The impact of air pollution to central nervous system in children and adults, Neuro. Endocrinol. Lett., 38, pp. 389-396, (2017); Cohen H., Liu T.M., Kozlovsky N., Kaplan Z., Zohar J., Mathe A.A., The Neuropeptide Y (NPY)-ergic System is Associated with Behavioral Resilience to Stress Exposure in an Animal Model of Post-Traumatic Stress Disorder, Neuropsychopharmacology, 37, pp. 350-363, (2012); Simren M., Stotzer P.O., Sjovall H., Abrahamsson H., Bjornsson E.S., Abnormal levels of neuropeptide Y and peptide YY in the colon in irritable bowel syndrome, Eur. J. Gastroenterol. Hepatol., 15, pp. 55-62, (2003); Naderi M., Puar P., Zonouzi-Marand M., Chivers D.P., Niyogi S., Kwong R.W.M., A comprehensive review on the neuropathophysiology of selenium, Sci. Total Environ., 767, (2021); Bogatov N.V., Selenium deficiency and its dietary correction in patients with irritable bowel syndrome and chronic catarrhal colitis, Vopr. Pitan., 76, pp. 35-39, (2007); Hillestad E.M.R., van der Meeren A., Nagaraja B.H., Bjorsvik B.R., Haleem N., Benitez-Paez A., Sanz Y., Hausken T., Lied G.A., Lundervold A., Berentsen B., Gut bless you: The microbiota-gut-brain axis in irritable bowel syndrome, World J. Gastroenterol., 28, pp. 412-431, (2022); Ahluwalia B., Iribarren C., Magnusson M.K., Sundin J., Clevers E., Savolainen O., Ross A.B., Tornblom H., Simren M., Ohman L., A Distinct Faecal Microbiota and Metabolite Profile Linked to Bowel Habits in Patients with Irritable Bowel Syndrome, Cells, 10, (2021); Hove H., Mortensen P.B., Colonic lactate metabolism and D-lactic acidosis, Dig. Dis. Sci., 40, pp. 320-330, (1995); Tana C., Umesaki Y., Imaoka A., Handa T., Kanazawa M., Fukudo S., Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome, Neurogastroenterol. Motil., 22, (2010); Wu Z., Liu H., Yan E., Zhang X., Wang Y., Huang C., He T., Miao L., Yang L., Jiang R., Qi C., Liu C., Wang D., Yang C., Desulfovibrio confers resilience to the comorbidity of pain and anxiety in a mouse model of chronic inflammatory pain, Psychopharmacology, 240, pp. 87-100, (2023); Hong Y., Sheng L., Zhong J., Tao X., Zhu W., Ma J., Yan J., Zhao A., Zheng X., Wu G., Li B., Han B., Ding K., Zheng N., Jia W., Li H., Desulfovibrio vulgaris, a potent acetic acid-producing bacterium, attenuates nonalcoholic fatty liver disease in mice, Gut Microbes, 13, (2021); Wouw M.V.D., Schellekens H., Dinan T.G., Cryan J.F., Microbiota-gut-brain axis: modulator of host metabolism and appetite, J. Nutr., 147, pp. 727-745, (2017); Woting A., Blaut M., The Intestinal Microbiota in Metabolic Disease, Nutrients, 8, (2016); Cheng D., Xie M.Z., A review of a potential and promising probiotic candidate-Akkermansia muciniphila, J. Appl. Microbiol., 130, pp. 1813-1822, (2021); Naito Y., Uchiyama K., Takagi T., A next-generation beneficial microbe: Akkermansia muciniphila, J. Clin. Biochem. Nutr., 63, pp. 33-35, (2018); Jiang H.Y., Ling Z.X., Zhang Y.H., Mao H.J., Ma Z.P., Yin Y., Wang W.H., Tang W.X., Tan Z.L., Shi J.F., Li L.J., Ruan B., Altered fecal microbiota composition in patients with major depressive disorder, Brain, Behav., Immun., 48, pp. 186-194, (2015); Valles-Colomer M., Falony G., Darzi Y., Tigchelaar E.F., Wang J., Tito R.Y., Schiweck C., Kurilshikov A., Joossens M., Wijmenga C., Claes S., Van Oudenhove L., Zhernakova A., Vieira-Silva S., Raes J., The neuroactive potential of the human gut microbiota in quality of life and depression, Nat. Microbiol., 4, pp. 623-632, (2019); Ait-Belgnaoui A., Colom A., Braniste V., Ramalho L., Marrot A., Cartier C., Houdeau E., Theodorou V., Tompkins T., Probiotic gut effect prevents the chronic psychological stress-induced brain activity abnormality in mice, Neurogastroenterol. Motil., 26, pp. 510-520, (2014); Xu Y., Wang N., Tan H.Y., Li S., Zhang C., Feng Y.B., Function of Akkermansia muciniphila in Obesity: Interactions With Lipid Metabolism, Immune Response and Gut Systems, Front. Microbiol., 11, (2020); Goodrich J.K., Waters J.L., Poole A.C., Sutter J.L., Koren O., Blekhman R., Beaumont M., Van Treuren W., Knight R., Bell J.T., Spector T.D., Clark A.G., Ley R.E., Human genetics shape the gut microbiome, Cell, 159, pp. 789-799, (2014); Lee J., d'Aigle J., Atadja L., Quaicoe V., Honarpisheh P., Ganesh B.P., Hassan A., Graf J., Petrosino J., Putluri N., Zhu L., Durgan D.J., Bryan R.M., McCullough L.D., Venna V.R., Gut Microbiota-Derived Short-Chain Fatty Acids Promote Poststroke Recovery in Aged Mice, Circ. Res., 127, pp. 453-465, (2020); Palmnas-Bedard M.S.A., Costabile G., Vetrani C., Aberg S., Hjalmarsson Y., Dicksved J., Riccardi G., Landberg R., The human gut microbiota and glucose metabolism: a scoping review of key bacteria and the potential role of SCFAs, Am. J. Clin. Nutr., 116, pp. 862-874, (2022)","H. Zhu; School of Pharmacy, Shanghai Jiao Tong, University, No. 800 Dongchuan Road, Minhang District, China; email: julie19930@sjtu.edu.cn; D. Chen; School of Pharmacy, Shanghai Jiao Tong University, No. 800 Dongchuan Road, Minhang District, China; email: chen_lab@sjtu.edu.cn","","Royal Society of Chemistry","","","","","","20426496","","","37212199","English","Food. Funct.","Article","Final","","Scopus","2-s2.0-85162818640"

"Kim J.E.; Song H.J.; Choi Y.J.; Jin Y.J.; Roh Y.J.; Seol A.; Park S.H.; Park J.M.; Kang H.G.; Hwang D.Y.","Kim, Ji Eun (55850180200); Song, Hee Jin (57747007100); Choi, Yun Ju (55819466900); Jin, You Jeong (57323040500); Roh, Yu Jeong (57748302000); Seol, Ayun (57746686300); Park, So Hae (49662037700); Park, Ju Min (57202266137); Kang, Hyun Gu (55194469400); Hwang, Dae Youn (57714752500)","55850180200; 57747007100; 55819466900; 57323040500; 57748302000; 57746686300; 49662037700; 57202266137; 55194469400; 57714752500","Improvement of the intestinal epithelial barrier during laxative effects of phlorotannin in loperamide-induced constipation of SD rats","2023","Laboratory Animal Research","39","1","1","","","","2","10.1186/s42826-022-00152-1","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85149222170&doi=10.1186%2fs42826-022-00152-1&partnerID=40&md5=5e674dff511ad28f4c08ff77b19c0f45","Department of Biomaterials Science (BK21 FOUR Program), College of Natural Resources and Life Science/Life and Industry Convergence Research Institute/Laboratory Animal Resources Center, Pusan National University, Miryang, 50463, South Korea; Department of Food Science and Nutrition, College of Human Ecology, Pusan National University, Busan, 46241, South Korea; Veterinary Medical Center, Department of Veterinary Theriogenology, College of Veterinary Medicine, Chungbuk National University, Cheongju, 28644, South Korea","Kim J.E., Department of Biomaterials Science (BK21 FOUR Program), College of Natural Resources and Life Science/Life and Industry Convergence Research Institute/Laboratory Animal Resources Center, Pusan National University, Miryang, 50463, South Korea; Song H.J., Department of Biomaterials Science (BK21 FOUR Program), College of Natural Resources and Life Science/Life and Industry Convergence Research Institute/Laboratory Animal Resources Center, Pusan National University, Miryang, 50463, South Korea; Choi Y.J., Department of Biomaterials Science (BK21 FOUR Program), College of Natural Resources and Life Science/Life and Industry Convergence Research Institute/Laboratory Animal Resources Center, Pusan National University, Miryang, 50463, South Korea; Jin Y.J., Department of Biomaterials Science (BK21 FOUR Program), College of Natural Resources and Life Science/Life and Industry Convergence Research Institute/Laboratory Animal Resources Center, Pusan National University, Miryang, 50463, South Korea; Roh Y.J., Department of Biomaterials Science (BK21 FOUR Program), College of Natural Resources and Life Science/Life and Industry Convergence Research Institute/Laboratory Animal Resources Center, Pusan National University, Miryang, 50463, South Korea; Seol A., Department of Biomaterials Science (BK21 FOUR Program), College of Natural Resources and Life Science/Life and Industry Convergence Research Institute/Laboratory Animal Resources Center, Pusan National University, Miryang, 50463, South Korea; Park S.H., Department of Biomaterials Science (BK21 FOUR Program), College of Natural Resources and Life Science/Life and Industry Convergence Research Institute/Laboratory Animal Resources Center, Pusan National University, Miryang, 50463, South Korea; Park J.M., Department of Food Science and Nutrition, College of Human Ecology, Pusan National University, Busan, 46241, South Korea; Kang H.G., Veterinary Medical Center, Department of Veterinary Theriogenology, College of Veterinary Medicine, Chungbuk National University, Cheongju, 28644, South Korea; Hwang D.Y., Department of Biomaterials Science (BK21 FOUR Program), College of Natural Resources and Life Science/Life and Industry Convergence Research Institute/Laboratory Animal Resources Center, Pusan National University, Miryang, 50463, South Korea","Background: Disruptions of the intestinal epithelial barrier (IEB) are frequently observed in various digestive diseases, including irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). This study assessed the improvement in the IEB during the laxative activity of phlorotannin (Pt) harvested from Ecklonia cava in constipation by examining the changes in the expression of the regulatory proteins for the tight junction (TJ) and adherens junction (AJ), and inflammatory cytokines in Sprague Dawley (SD) rats with loperamide (Lm)-induced constipation after a Pt treatment. Results: The Pt treatment induced laxative activity, including the improvement of feces-related parameters, gastrointestinal transit rate, and histological structure of the mid colon in Lm-treated SD rats. In addition, significant recovery effects were detected in the histology of IEB, including the mucus layer, epithelial cells, and lamina propria in the mid colon of Lm + Pt treated SD rats. The expression levels of E-cadherin and p120-catenin for AJ and the ZO-1, occludin, and Claudin-1 genes for TJ in epithelial cells were improved remarkably after the Pt treatment, but the rate of increase was different. Furthermore, the Pt treatment increased the expression level of several inflammatory cytokines, such as TNF-α, IL-6, IL-1β, IL-13, and IL-4 in Lm + Pt treated SD rats. Conclusions: These results provide the first evidence that the laxative activity of Pt in SD rats with Lm-induced constipation phenotypes involve improvements in the IEB. © 2023, The Author(s).","Adherens junction; Constipation; Intestinal epithelial barrier; Laxative effects; Phlorotannins; Tight junction","","","","","","Pusan National University, PNU; Ministry of Education, MOE, (2020R1l1A1A01052277); National Research Foundation of Korea, NRF; Ministry of Education, Kenya, MOE, (F21YY8109033)","Funding text 1: This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2020R1l1A1A01052277). This research was also supported by the BK21 FOUR project through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Korea (F21YY8109033). ; Funding text 2: The authors wish to thank Jin Hyang Hwang, the animal technician, for directing the animal use and care at the Laboratory Animal Resources Center in Pusan National University.","Veiga-Fernandes H., Mucida D., Neuro-immune interactions at barrier surfaces, Cell, 165, pp. 801-811, (2016); Salvo Romero E., Alonso Cotoner C., Pardo Camacho C., Casado Bedmar M., Vicario M., The intestinal barrier function and its involvement in digestive disease, Rev Esp Enferm Dig, 107, pp. 686-696, (2015); Anderson J.M., Van Itallie C.M., Physiology and function of the tight junction, Cold Spring Harb Perspect Biol, 1, (2009); Koval M., Differential pathways of Claudin oligomerization and integration into tight junctions, Tissue Barriers, 1, (2013); Lu Z., Ding L., Lu Q., Chen Y.H., Claudins in intestines: distribution and functional significance in health and diseases, Tissue Barriers, 1, (2013); Ivanov A.I., Naydenov N.G., Dynamics and regulation of epithelial adherens junctions: recent discoveries and controversies, Int Rev Cell Mol Biol, 303, pp. 27-99, (2013); Takeichi M., Dynamic contacts: rearranging adherens junctions to drive epithelial remodeling, Nat Rev Mol Cell Biol, 15, pp. 397-410, (2014); Troyanovsky S., Adherens junction assembly, Subcell Biochem, 60, pp. 89-108, (2012); Hartsock A., Nelson W.J., Adherens and tight junctions: Structure, function and connections to the actin cytoskeleton, Biochim Biophys Acta, 1778, pp. 660-669, (2008); Vivinus-Nebot M., Frin-Mathy G., Bzioueche H., Dainese R., Bernard G., Anty R., Et al., Functional bowel symptoms in quiescent inflammatory bowel diseases: Role of epithelial barrier disruption and low-grade inflammation, Gut, 63, pp. 744-752, (2014); Xu C.M., Li X.M., Qin B.Z., Liu B., Effect of tight junction protein of intestinal epithelium and permeability of colonic mucosa in pathogenesis of injured colonic barrier during chronic recovery stage of rats with inflammatory bowel disease, Asian Pac J Trop Med, 9, pp. 148-152, (2016); Michielan A., D'Inca R., Intestinal permeability in inflammatory bowel disease: pathogenesis, clinical evaluation, and therapy of leaky gut, Mediators Inflamm, 2015, (2015); Zeissig S., Burgel N., Gunzel D., Richter J., Mankertz J., Wahnschaffe U., Et al., Changes in expression and distribution of Claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn’s disease, Gut, 56, pp. 61-72, (2007); Morampudi V., Bhinder G., Wu X., Dai C., Sham H.P., Vallance B.A., Et al., DNBS/TNBS colitis models: providing insights into inflammatory bowel disease and effects of dietary fat, J Vis Exp, 84, (2014); Schwerbrock N.M., Makkink M.K., van der Sluis M., Buller H.A., Einerhand A.W., Sartor R.B., Et al., Interleukin 10-deficient mice exhibit defective colonic Muc2 synthesis before and after induction of colitis by commensal bacteria, Inflamm Bowel Dis, 10, pp. 811-823, (2004); Grover M., Camilleri M., Hines J., Burton D., Ryks M., Wadhwa A., Et al., Cmannitol as a novel biomarker for measurement of intestinal permeability, Neurogastroenterol Motil, 28, pp. 1114-1119, (2016); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Lecleire S., Antonietti M., Gourcerol G., Et al., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am J Gastroenterol, 106, pp. 2165-2173, (2011); Hou Q., Huang Y., Zhu S., Li P., Chen X., Hou Z., Et al., MiR-144 increases intestinal permeability in IBS-D rats by targeting OCLN and ZO1, Cell Physiol Biochem, 44, pp. 2256-2268, (2017); Silva S.D., Robbe-Masselot C., Ait-Belgnaoui A., Mancuso A., Mercade-Loubiere M., Salvador-Cartier C., Et al., Stress disrupts intestinal mucus barrier in rats via mucin O-glycosylation shift: prevention by a probiotic treatment, Am J Physiol Gastrointest Liver Physiol, 307, pp. G420-G429, (2014); Kim J.E., Choi Y.J., Lee S.J., Gong J.E., Jin Y.J., Park S.H., Et al., Laxative effects of phlorotannins derived from Ecklonia cava, in loperamide-induced constipation of SD rats, Molecules, 26, (2021); Gillois K., Leveque M., Theodorou V., Robert H., Mercier-Bonin M., Mucus: an underestimated gut target for environmental pollutants and food additives, Microorganisms, 6, (2018); Johansson M.E.V., Hansson G.C., Immunological aspects of intestinal mucus and mucins, Nat Rev Immunol, 16, pp. 639-649, (2016); Barbara G., Barbaro M.R., Fuschi D., Palombo M., Falangone F., Cremon C., Et al., Inflammatory and microbiota-related regulation of the intestinal epithelial barrier, Front Nutr, 8, (2021); Slifer Z.M., Blikslager A.T., The integral role of tight junction proteins in the repair of injured intestinal epithelium, Int J Mol Sci, 21, (2020); Zwiers A., Fuss I.J., Leijen S., Mulder C.J., Kraal G., Bouma G., Increased expression of the tight junction molecule Claudin-18 A1 in both experimental colitis and ulcerative colitis, Inflamm Bowel Dis, 14, pp. 1652-1659, (2008); Yamamoto-Furusho J.K., Mendivil E.J., Fonseca-Camarillo G., Differential expression of occludin in patients with ulcerative colitis and healthy controls, Inflamm Bowel Dis, 18, (2012); Caviglia G.P., Dughera F., Ribaldone D.G., Rosso C., Abate M.L., Pellicano R., Et al., Serum zonulin in patients with inflammatory bowel disease: a pilot study, Minerva Med, 110, pp. 95-100, (2019); Kong W.M., Gong J., Dong L., Xu J.R., Changes of tight junction Claudin-1,-3,-4 protein expression in the intestinal mucosa in patients with irritable bowel syndrome, Nan Fang Yi Ke Da Xue Xue Bao, 27, pp. 1345-1347, (2007); Marchiando A.M., Graham W.V., Turner J.R., Epithelial barriers in homeostasis and disease, Annu Rev Pathol, 5, pp. 119-144, (2010); Catalioto R.M., Maggi C.A., Giuliani S., Intestinal epithelial barrier dysfunction in disease and possible therapeutical interventions, Curr Med Chem, 18, pp. 398-426, (2011); Luissint A.C., Parkos C.A., Nusrat A., Inflammation and the intestinal barrier: leukocyte-epithelial cell interactions, cell junction remodeling, and mucosal repair, Gastroenterology, 151, pp. 616-632, (2016); Menard S., Cerf-Bensussan N., Heyman M., Multiple facets of intestinal permeability and epithelial handling of dietary antigens, Mucosal Immunol, 3, pp. 247-259, (2010); Oshima T., Miwa H., Joh T., Changes in the expression of Claudins in active ulcerative colitis, J Gastroenterol Hepatol, 23, pp. S146-S150, (2008); Prasad S., Mingrino R., Kaukinen K., Hayes K.L., Powell R.M., MacDonald T.T., Et al., Inflammatory processes have differential effects on Claudins 2, 3 and 4 in colonic epithelial cells, Lab Invest, 85, pp. 1139-1162, (2005); Madsen K.L., Malfair D., Gray D., Doyle J.S., Jewell L.D., Fedorak R.N., Interleukin-10 gene-deficient mice develop a primary intestinal permeability defect in response to enteric microflora, Inflamm Bowel Dis, 5, pp. 262-270, (1999); Oshima T., Laroux F.S., Coe L.L., Morise Z., Kawachi S., Bauer P., Et al., Interferon-γ and interleukin-10 reciprocally regulate endothelial junction integrity and barrier function, Microvasc Res, 61, pp. 130-143, (2001); Albert-Bayo M., Paracuellos I., Gonzalez-Castro A.M., Rodriguez-Urrutia A., Rodriguez-Lagunas M.J., Alonso-Cotoner C., Et al., Intestinal mucosal mast cells: key modulators of barrier function and homeostasis, Cells, 8, (2019); Al-Sadi R., Ye D., Boivin M., Guo S., Hashimi M., Ereifej L., Et al., Interleukin-6 modulation of intestinal epithelial tight junction permeability is mediated by JNK pathway, PLoS ONE, 9, (2014); Kucharzik T., Walsh S.V., Chen J., Parkos C.A., Nusrat A., Neutrophil transmigration in inflammatory bowel disease is associated with differential expression of epithelial intercellular junction proteins, Am J Pathol, 159, pp. 2001-2009, (2001); Gassler N., Rohr C., Schneider A., Kartenbeck J., Bach A., Obermuller N., Et al., Inflammatory bowel disease is associated with changes of enterocytic junctions, Am J Physiol Gastrointest Liver Physiol, 281, pp. 216-228, (2001); Choi Y.J., Kim J.E., Lee S.J., Gong J.E., Jin Y.J., Seo S., Et al., Inflammatory response in the mid colon of ICR mice treated with polystyrene microplastics for two weeks, Lab Anim Res, 37, (2021); Lee H.S., Jeong M.S., Ko S.C., Heo S.Y., Kang H.W., Kim S.W., Et al., Fabrication and biological activity of polycaprolactone/phlorotannin endotracheal tube to prevent tracheal stenosis: an in vitro and in vivo study, J Biomed Mater Res B Appl Biomater, 108, pp. 1046-1056, (2020); Kim J.E., Go J., Koh E.K., Song S.H., Sung J.E., Lee H.A., Et al., Gallotannin-enriched extract isolated from Galla Rhois may be a functional candidate with laxative effects for treatment of loperamide-induced constipation of SD rats, PLoS ONE, 11, (2016); Abbas S., Bashir S., Khan A., Mehmood M.H., Gilani A.H., Gastrointestinal stimulant effect ofUrginea indica Kunth. and involvement of muscarinic receptors, Phytother Res, 26, pp. 704-708, (2012); He S., Liu F., Xu L., Yin P., Li D., Mei C., Et al., Protective effects of ferulic acid against heat stress-induced intestinal epithelial barrier dysfunction in vitro and in vivo, PLoS ONE, 11, (2016); Song B.R., Lee S.J., Kim J.E., Choi H.J., Bae S.J., Choi Y.J., Et al., Anti-inflammatory effects of Capparis ecuadorica extract in phthalic-anhydride-induced atopic dermatitis of IL-4/Luc/CNS-1 transgenic mice, Pharm Biol, 58, pp. 1263-1276, (2020); Bae S.J., Kim J.E., Choi H.J., Choi Y.J., Lee S.J., Gong J.E., Et al., α-Linolenic acid-enriched cold-pressed perilla oil suppress high-fat diet-induced hepatic steatosis through amelioration of the ER stress-mediated autophagy, Molecules, 25, (2020); Livak K.J., Schmittgen T.D., Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method, Methods, 25, pp. 402-408, (2001)","D.Y. Hwang; Department of Biomaterials Science (BK21 FOUR Program), College of Natural Resources and Life Science/Life and Industry Convergence Research Institute/Laboratory Animal Resources Center, Pusan National University, Miryang, 50463, South Korea; email: dyhwang@pusan.ac.kr","","BioMed Central Ltd","","","","","","17386055","","","","English","Lab Anim Res","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85149222170"

"Jang J.-H.; Jang S.-Y.; Ahn S.; Oh J.-Y.; Yeom M.; Ko S.-J.; Park J.-W.; Kwon S.-K.; Kim K.; Lee I.-S.; Hahm D.-H.; Park H.-J.","Jang, Jae-Hwan (56583200900); Jang, Sun-Young (57892329500); Ahn, Sora (57194058949); Oh, Ju-Young (57191963711); Yeom, Mijung (57763862500); Ko, Seok-Jae (52363719300); Park, Jae-Woo (57193414960); Kwon, Soon-Kyeong (35201193400); Kim, Kyuseok (37059026300); Lee, In-Seon (55575603100); Hahm, Dae-Hyun (13309892700); Park, Hi-Joon (7601566951)","56583200900; 57892329500; 57194058949; 57191963711; 57763862500; 52363719300; 57193414960; 35201193400; 37059026300; 55575603100; 13309892700; 7601566951","Chronic Gut Inflammation and Dysbiosis in IBS: Unraveling Their Contribution to Atopic Dermatitis Progression","2024","International Journal of Molecular Sciences","25","5","2753","","","","0","10.3390/ijms25052753","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85187683750&doi=10.3390%2fijms25052753&partnerID=40&md5=8967fdcc9a9955da1805a53a627fd6a2","Jaseng Spine and Joint Research Institute, Jaseng Medical Foundation, Seoul, 05854, South Korea; Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul, 02447, South Korea; Department of Anatomy and Information Sciences, College of Korean Medicine, Kyung Hee University, Seoul, 02447, South Korea; Acupuncture & Meridian Science Research Center, Kyung Hee University, Seoul, 02447, South Korea; Department of Gastroenterology, College of Korean Medicine, Kyung Hee University, Seoul, 02447, South Korea; Division of Applied Life Science (BK21), Gyeongsang National University, Jinju, 52828, South Korea; Department of Ophthalmology, Otorhinolaryngology, and Dermatology of Korean Medicine, College of Korean Medicine, Kyung Hee University, Seoul, 02447, South Korea; Department of Meridian & Acupoint, College of Korean Medicine, Kyung Hee University, Seoul, 02447, South Korea; Department of Physiology, School of Medicine, Kyung Hee University, Seoul, 02447, South Korea; Department of KHU-KIST Convergence Science & Technology, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul, 02447, South Korea","Jang J.-H., Jaseng Spine and Joint Research Institute, Jaseng Medical Foundation, Seoul, 05854, South Korea; Jang S.-Y., Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul, 02447, South Korea, Department of Anatomy and Information Sciences, College of Korean Medicine, Kyung Hee University, Seoul, 02447, South Korea; Ahn S., Department of Anatomy and Information Sciences, College of Korean Medicine, Kyung Hee University, Seoul, 02447, South Korea, Acupuncture & Meridian Science Research Center, Kyung Hee University, Seoul, 02447, South Korea; Oh J.-Y., Department of Anatomy and Information Sciences, College of Korean Medicine, Kyung Hee University, Seoul, 02447, South Korea, Acupuncture & Meridian Science Research Center, Kyung Hee University, Seoul, 02447, South Korea; Yeom M., Acupuncture & Meridian Science Research Center, Kyung Hee University, Seoul, 02447, South Korea; Ko S.-J., Department of Gastroenterology, College of Korean Medicine, Kyung Hee University, Seoul, 02447, South Korea; Park J.-W., Department of Gastroenterology, College of Korean Medicine, Kyung Hee University, Seoul, 02447, South Korea; Kwon S.-K., Division of Applied Life Science (BK21), Gyeongsang National University, Jinju, 52828, South Korea; Kim K., Department of Ophthalmology, Otorhinolaryngology, and Dermatology of Korean Medicine, College of Korean Medicine, Kyung Hee University, Seoul, 02447, South Korea; Lee I.-S., Acupuncture & Meridian Science Research Center, Kyung Hee University, Seoul, 02447, South Korea, Department of Meridian & Acupoint, College of Korean Medicine, Kyung Hee University, Seoul, 02447, South Korea; Hahm D.-H., Acupuncture & Meridian Science Research Center, Kyung Hee University, Seoul, 02447, South Korea, Department of Physiology, School of Medicine, Kyung Hee University, Seoul, 02447, South Korea; Park H.-J., Department of Anatomy and Information Sciences, College of Korean Medicine, Kyung Hee University, Seoul, 02447, South Korea, Acupuncture & Meridian Science Research Center, Kyung Hee University, Seoul, 02447, South Korea, Department of KHU-KIST Convergence Science & Technology, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul, 02447, South Korea","Emerging evidence suggests a link between atopic dermatitis (AD) and gastrointestinal disorders, particularly in relation to gut microbial dysbiosis. This study explored the potential exacerbation of AD by gut inflammation and microbial imbalances using an irritable bowel syndrome (IBS) mouse model. Chronic gut inflammation was induced in the model by intrarectal injection of 2,4,6-trinitrobenzene sulfonic acid (TNBS), followed by a 4-week development period. We noted significant upregulation of proinflammatory cytokines in the colon and evident gut microbial dysbiosis in the IBS mice. Additionally, these mice exhibited impaired gut barrier function, increased permeability, and elevated systemic inflammation markers such as IL-6 and LPS. A subsequent MC903 challenge on the right cheek lasting for 7 days revealed more severe AD symptoms in IBS mice compared to controls. Further, fecal microbial transplantation (FMT) from IBS mice resulted in aggravated AD symptoms, a result similarly observed with FMT from an IBS patient. Notably, an increased abundance of Alistipes in the feces of IBS mice correlated with heightened systemic and localized inflammation in both the gut and skin. These findings collectively indicate that chronic gut inflammation and microbial dysbiosis in IBS are critical factors exacerbating AD, highlighting the integral relationship between gut and skin health. © 2024 by the authors.","atopic dermatitis; gut microbial dysbiosis; irritable bowel syndrome; systemic inflammation","Animals; Dermatitis, Atopic; Dysbiosis; Fecal Microbiota Transplantation; Feces; Gastrointestinal Microbiome; Humans; Inflammation; Irritable Bowel Syndrome; Mice; calcipotriol; endotoxin; interleukin 22; interleukin 31; interleukin 6; lipopolysaccharide; macrophage elastase; messenger RNA; occludin; protein ZO1; RNA 16S; trinitrobenzenesulfonic acid; Alistipes; animal experiment; animal model; animal tissue; Article; atopic dermatitis; body weight; comparative study; controlled study; descending colon; disease exacerbation; dysbiosis; fecal microbiota transplantation; in vivo study; intestine flora; irritable colon; male; mouse; nonhuman; upregulation; animal; atopic dermatitis; dysbiosis; feces; human; inflammation; physiology","","calcipotriol, 112828-00-9, 112965-21-6; interleukin 22, 457106-70-6, 478219-35-1, 554460-75-2; macrophage elastase, ; occludin, 176304-61-3; trinitrobenzenesulfonic acid, 16655-63-3, 2508-19-2","","","National Research Foundation of Korea, NRF, (NRF-2021R1A2C2006818, 2022M3A9B6017813); National Research Foundation of Korea, NRF","This research was supported by grants from the National Research Foundation of Korea funded by the Korean government (grant numbers: NRF-2021R1A2C2006818 and 2022M3A9B6017813).","Yang G., Seok J.K., Kang H.C., Cho Y.Y., Lee H.S., Lee J.Y., Skin Barrier Abnormalities and Immune Dysfunction in Atopic Dermatitis, Int. J. Mol. Sci, 21, (2020); Nutten S., Atopic dermatitis: Global epidemiology and risk factors, Ann. Nutr. Metab, 66, pp. 8-16, (2015); Langan S.M., Irvine A.D., Weidinger S., Atopic dermatitis, Lancet, 396, pp. 345-360, (2020); Fyhrquist N., Werner P., Alenius H., Host-microbiome interactions in atopic and allergic diseases, Curr. Opin. Toxicol, 35, (2023); Wang X., Li Y., Wu L., Xiao S., Ji Y., Tan Y., Jiang C., Zhang G., Dysregulation of the gut-brain-skin axis and key overlapping inflammatory and immune mechanisms of psoriasis and depression, Biomed. Pharmacother, 137, (2021); Shi N., Li N., Duan X., Niu H., Interaction between the gut microbiome and mucosal immune system, Mil. Med. Res, 4, (2017); Ungar B., Garcet S., Gonzalez J., Dhingra N., Correa da Rosa J., Shemer A., Krueger J.G., Suarez-Farinas M., Guttman-Yassky E., An Integrated Model of Atopic Dermatitis Biomarkers Highlights the Systemic Nature of the Disease, J. Investig. Dermatol, 137, pp. 603-613, (2017); Vich Vila A., Imhann F., Collij V., Jankipersadsing S.A., Gurry T., Mujagic Z., Kurilshikov A., Bonder M.J., Jiang X., Tigchelaar E.F., Et al., Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome, Sci. Transl. Med, 10, (2018); Chen Y., Feng S., Li Y., Zhang C., Chao G., Zhang S., Gut microbiota and intestinal immunity—A crosstalk in irritable bowel syndrome, Immunology, (2024); Kiecolt-Glaser J.K., Wilson S.J., Bailey M.L., Andridge R., Peng J., Jaremka L.M., Fagundes C.P., Malarkey W.B., Laskowski B., Belury M.A., Marital distress, depression, and a leaky gut: Translocation of bacterial endotoxin as a pathway to inflammation, Psychoneuroendocrinology, 98, pp. 52-60, (2018); Passeron T., Piche T., Skin manifestations associated with irritable bowel syndrome, J. Eur. Acad. Dermatol. Venereol, 34, pp. e651-e652, (2020); Jo U.H., Lee J.Y., Lee H., Kim D.Y., Kang S., Koh S.J., Park H., Various skin manifestations related to inflammatory bowel disease: A nationwide cross-sectional study on the Korean population, J. Dermatol, 48, pp. 431-438, (2021); Zhao Q., Yang W.R., Wang X.H., Li G.Q., Xu L.Q., Cui X., Liu Y., Zuo X.L., Clostridium butyricum alleviates intestinal low-grade inflammation in TNBS-induced irritable bowel syndrome in mice by regulating functional status of lamina propria dendritic cells, World J. Gastroenterol, 25, pp. 5469-5482, (2019); Mohammad S., Thiemermann C., Role of Metabolic Endotoxemia in Systemic Inflammation and Potential Interventions, Front. Immunol, 11, (2021); Wilson S.R., The L., Batia L.M., Beattie K., Katibah G.E., McClain S.P., Pellegrino M., Estandian D.M., Bautista D.M., The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch, Cell, 155, pp. 285-295, (2013); Wang X.P., Schunck M., Kallen K.J., Neumann C., Trautwein C., Rose-John S., Proksch E., The interleukin-6 cytokine system regulates epidermal permeability barrier homeostasis, J. Investig. Dermatol, 123, pp. 124-131, (2004); Chopra R., Silverberg J.I., Assessing the severity of atopic dermatitis in clinical trials and practice, Clin. Dermatol, 36, pp. 606-615, (2018); Kaya Islamoglu Z.G., Unal M., Kucuk A., Atopic Dermatitis in Adults and Irritable Bowel Syndrome: A Cross-sectional Study, Indian J. Dermatol, 64, pp. 355-359, (2019); Ivashkin V., Poluektov Y., Kogan E., Shifrin O., Sheptulin A., Kovaleva A., Kurbatova A., Krasnov G., Poluektova E., Disruption of the pro-inflammatory, anti-inflammatory cytokines and tight junction proteins expression, associated with changes of the composition of the gut microbiota in patients with irritable bowel syndrome, PLoS ONE, 16, (2021); Li M., Hener P., Zhang Z., Kato S., Metzger D., Chambon P., Topical vitamin D3 and low-calcemic analogs induce thymic stromal lymphopoietin in mouse keratinocytes and trigger an atopic dermatitis, Proc. Natl. Acad. Sci. USA, 103, pp. 11736-11741, (2006); Lee H., Lee J.H., Koh S.-J., Park H., Bidirectional relationship between atopic dermatitis and inflammatory bowel disease: A systematic review and meta-analysis, J. Am. Acad. Dermatol, 83, pp. 1385-1394, (2020); Altomare A., Del Chierico F., Rocchi G., Emerenziani S., Nuglio C., Putignani L., Angeletti S., Lo Presti A., Ciccozzi M., Russo A., Et al., Association between Dietary Habits and Fecal Microbiota Composition in Irritable Bowel Syndrome Patients: A Pilot Study, Nutrients, 13, (2021); Song Y.F., Pei L.X., Chen L., Geng H., Yuan M.Q., Xu W.L., Wu J., Zhou J.Y., Sun J.H., Electroacupuncture Relieves Irritable Bowel Syndrome by Regulating IL-18 and Gut Microbial Dysbiosis in a Trinitrobenzene Sulfonic Acid-Induced Post-Inflammatory Animal Model, Am. J. Chin. Med, 48, pp. 77-90, (2020); Nourrisson C., Scanzi J., Brunet J., Delbac F., Dapoigny M., Poirier P., Prokaryotic and Eukaryotic Fecal Microbiota in Irritable Bowel Syndrome Patients and Healthy Individuals Colonized With Blastocystis, Front. Microbiol, 12, (2021); Lin H., Guo Q., Wen Z., Tan S., Chen J., Lin L., Chen P., He J., Wen J., Chen Y., The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors, Microb. Cell Fact, 20, (2021); Frank D.N., St Amand A.L., Feldman R.A., Boedeker E.C., Harpaz N., Pace N.R., Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases, Proc. Natl. Acad. Sci. USA, 104, pp. 13780-13785, (2007); Wang W., Chen L., Zhou R., Wang X., Song L., Huang S., Wang G., Xia B., Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease, J. Clin. Microbiol, 52, pp. 398-406, (2014); Saulnier D.M., Riehle K., Mistretta T.A., Diaz M.A., Mandal D., Raza S., Weidler E.M., Qin X., Coarfa C., Milosavljevic A., Et al., Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome, Gastroenterology, 141, pp. 1782-1791, (2011); Thingholm L.B., Ruhlemann M.C., Koch M., Fuqua B., Laucke G., Boehm R., Bang C., Franzosa E.A., Hubenthal M., Rahnavard A., Et al., Obese Individuals with and without Type 2 Diabetes Show Different Gut Microbial Functional Capacity and Composition, Cell Host Microbe, 26, pp. 252-264.e210, (2019); Escobedo G., Lopez-Ortiz E., Torres-Castro I., Gut microbiota as a key player in triggering obesity, systemic inflammation and insulin resistance, Rev. Investig. Clin, 66, pp. 450-459, (2014); Zhang Y., Chen L., Hu M., Kim J.J., Lin R., Xu J., Fan L., Qi Y., Wang L., Liu W., Et al., Dietary type 2 resistant starch improves systemic inflammation and intestinal permeability by modulating microbiota and metabolites in aged mice on high-fat diet, Aging, 12, pp. 9173-9187, (2020); Tobin M.C., Moparty B., Farhadi A., DeMeo M.T., Bansal P.J., Keshavarzian A., Atopic irritable bowel syndrome: A novel subgroup of irritable bowel syndrome with allergic manifestations, Ann. Allergy Asthma Immunol, 100, pp. 49-53, (2008); Kristek M., Collins L.E., DeCourcey J., McEvoy F.A., Loscher C.E., Soluble factors from colonic epithelial cells contribute to gut homeostasis by modulating macrophage phenotype, Innate Immun, 21, pp. 358-369, (2015); Kaur H., Erickson A., Moreau R., Divergent regulation of inflammatory cytokines by mTORC1 in THP-1-derived macrophages and intestinal epithelial Caco-2 cells, Life Sci, 284, (2021); Rose-John S., IL-6 trans-signaling via the soluble IL-6 receptor: Importance for the pro-inflammatory activities of IL-6, Int. J. Biol. Sci, 8, pp. 1237-1247, (2012); Diehl S., Rincon M., The two faces of IL-6 on Th1/Th2 differentiation, Mol. Immunol, 39, pp. 531-536, (2002); Doganci A., Sauer K., Karwot R., Finotto S., Pathological role of IL-6 in the experimental allergic bronchial asthma in mice, Clin. Rev. Allergy Immunol, 28, pp. 257-270, (2005); David Boothe W., Tarbox J.A., Tarbox M.B., Atopic Dermatitis: Pathophysiology, Adv. Exp. Med. Biol, 1027, pp. 21-37, (2017); Choi Y.J., Lee H.J., Lee D.H., Woo S.Y., Lee K.H., Yun S.T., Kim J.M., Kim H.J., Kim J.W., Therapeutic effects and immunomodulation of suanbo mineral water therapy in a murine model of atopic dermatitis, Ann. Dermatol, 25, pp. 462-470, (2013); Yeom M., Ahn S., Jang S.-Y., Jang J.-H., Lee Y., Hahm D.-H., Park H.-J., Acupuncture attenuates comorbid anxiety- and depressive-like behaviors of atopic dermatitis through modulating neuroadaptation in the brain reward circuit in mice, Biol. Res, 55, (2022); Szymaszkiewicz A., Wlodarczyk J., Wasilewski A., Di Marzo V., Storr M., Fichna J., Zielinska M., Desensitization of transient receptor potential vanilloid type-1 (TRPV1) channel as promising therapy of irritable bowel syndrome: Characterization of the action of palvanil in the mouse gastrointestinal tract, Naunyn-Schmiedeberg’s Arch. Pharmacol, 393, pp. 1357-1364, (2020); Sharma D., Sangar M., Park J.L., Kang S.G., Ham K.S., Roasted garlic protects against leaky gut syndrome in dextran sodium sulfate-induced colitis mice, Food Sci. Biotechnol, 31, pp. 1335-1342, (2022); Jang J.H., Song E.M., Do Y.H., Ahn S., Oh J.Y., Hwang T.Y., Ryu Y., Jeon S., Song M.Y., Park H.J., Acupuncture alleviates chronic pain and comorbid conditions in a mouse model of neuropathic pain: The involvement of DNA methylation in the prefrontal cortex, Pain, 162, pp. 514-530, (2021); Jang J.-H., Yeom M.-J., Ahn S., Oh J.-Y., Ji S., Kim T.-H., Park H.-J., Acupuncture inhibits neuroinflammation and gut microbial dysbiosis in a mouse model of Parkinson’s disease, Brain Behav. Immun, 89, pp. 641-655, (2020); Hamilton M.J., Weingarden A.R., Sadowsky M.J., Khoruts A., Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection, Am. J. Gastroenterol, 107, pp. 761-767, (2012); Schuijt T.J., Lankelma J.M., Scicluna B.P., de Sousa e Melo F., Roelofs J.J., de Boer J.D., Hoogendijk A.J., de Beer R., de Vos A., Belzer C., Et al., The gut microbiota plays a protective role in the host defence against pneumococcal pneumonia, Gut, 65, pp. 575-583, (2016)","H.-J. Park; Department of Anatomy and Information Sciences, College of Korean Medicine, Kyung Hee University, Seoul, 02447, South Korea; email: acufind@khu.ac.kr","","Multidisciplinary Digital Publishing Institute (MDPI)","","","","","","16616596","","","38473999","English","Int. J. Mol. Sci.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85187683750"

"Abdellah S.A.; Gal C.; Laterza L.; Velenza V.; Settanni C.R.; Napoli M.; Schiavoni E.; Mora V.; Petito V.; Gasbarrini A.","Abdellah, Samira Ait (57190169470); Gal, Caroline (57221644730); Laterza, Lucrezia (55428675300); Velenza, Venanzio (58299234600); Settanni, Carlo Romano (57189993230); Napoli, Marco (57203000868); Schiavoni, Elisa (57188980383); Mora, Vincenzina (57203530618); Petito, Valentina (41961464200); Gasbarrini, Antonio (58589716200)","57190169470; 57221644730; 55428675300; 58299234600; 57189993230; 57203000868; 57188980383; 57203530618; 41961464200; 58589716200","Effect of a Multistrain Probiotic on Leaky Gut in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Pilot Study","2023","Digestive Diseases","41","3","","489","499","10","3","10.1159/000526712","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85149019547&doi=10.1159%2f000526712&partnerID=40&md5=aa9815c5dcfb6df48e60a78932b5f8e6","PiLeJe Laboratoire, Paris, France; Cemad, Digestive Disease Center, Fondazione Policlinico Universitario A. Gemelli Irccs, Università Cattolica Del Sacro Cuore, Roma, Italy; Department of Diagnostic Imaging, Oncological Radiotherapy and Hematology, Fondazione Policlinico Universitario A. Gemelli Irccs, Università Cattolica Del Sacro Cuore, Roma, Italy","Abdellah S.A., PiLeJe Laboratoire, Paris, France; Gal C., PiLeJe Laboratoire, Paris, France; Laterza L., Cemad, Digestive Disease Center, Fondazione Policlinico Universitario A. Gemelli Irccs, Università Cattolica Del Sacro Cuore, Roma, Italy; Velenza V., Department of Diagnostic Imaging, Oncological Radiotherapy and Hematology, Fondazione Policlinico Universitario A. Gemelli Irccs, Università Cattolica Del Sacro Cuore, Roma, Italy; Settanni C.R., Cemad, Digestive Disease Center, Fondazione Policlinico Universitario A. Gemelli Irccs, Università Cattolica Del Sacro Cuore, Roma, Italy; Napoli M., Cemad, Digestive Disease Center, Fondazione Policlinico Universitario A. Gemelli Irccs, Università Cattolica Del Sacro Cuore, Roma, Italy; Schiavoni E., Cemad, Digestive Disease Center, Fondazione Policlinico Universitario A. Gemelli Irccs, Università Cattolica Del Sacro Cuore, Roma, Italy; Mora V., Cemad, Digestive Disease Center, Fondazione Policlinico Universitario A. Gemelli Irccs, Università Cattolica Del Sacro Cuore, Roma, Italy; Petito V., Cemad, Digestive Disease Center, Fondazione Policlinico Universitario A. Gemelli Irccs, Università Cattolica Del Sacro Cuore, Roma, Italy; Gasbarrini A., Cemad, Digestive Disease Center, Fondazione Policlinico Universitario A. Gemelli Irccs, Università Cattolica Del Sacro Cuore, Roma, Italy","Background: A probiotic mixture prevented epithelial barrier impairment in various experimental models. The objective was to evaluate its effects in patients suffering from IBS with diarrhea (IBS-D) with confirmed leaky gut. Methods: IBS-D patients with increased intestinal permeability measured by radionuclide tracers were enrolled in this pilot, open-label, prospective, interventional, single-center, Phase IV study. Patients received two capsules of a multistrain probiotic a day for 30 days and were evaluated by repeated intestinal permeability tests, the Bristol Stool Scale, and patient-perceived quality of life and satisfaction. Results: Of the 30 enrolled patients (mean age: 42.1 [SD: 13.1] years; female: 60%), 27 completed the study (full analysis set [FAS]), and 18 had no major protocol violation (per protocol set [PPS]). On D30, an improvement of intestinal permeability was observed in 81.5% of patients in FAS, normalization being observed in 37% of the participants (44% in PPS). The mean intestinal permeability was significantly decreased: baseline minus D30, 3.4 (95% CI: 1.7, 5.2); the IBS-QOL total score was significantly increased: D30 minus baseline, 8.0 (95% CI: 3.0, 12.9); and stool consistency was significantly improved. On D15 and D30, 96.3% of patients claimed that their IBS symptoms had been satisfactory alleviated, and a significant improvement was reported for the following VAS-IBS items: abdominal pain, diarrhea, and impact of gastrointestinal problems in daily life. Compliance and tolerance were satisfactory. Conclusion: The multistrain probiotic tested may reduce intestinal permeability in a considerable proportion of patients and may improve abdominal pain, stool consistency, and quality of life. These results pave the way for larger, placebo-controlled clinical studies.  © 2023 S. Karger AG. All rights reserved.","Intestinal permeability; Irritable bowel syndrome; Leaky gut syndrome; Probiotics; Quality of life","Abdominal Pain; Adult; Diarrhea; Female; Humans; Irritable Bowel Syndrome; Pilot Projects; Probiotics; Prospective Studies; Quality of Life; Treatment Outcome; acetylsalicylic acid; C reactive protein; lactibiane tolrance; multistrain probiotics; nonsteroid antiinflammatory agent; probiotic agent; protein glutamine gamma glutamyltransferase antibody; radioisotope; tracer; unclassified drug; abdominal pain; adult; aged; Article; bacterial strain; bloating; blood pressure; blood sampling; body temperature; breathing rate; Bristol Stool Scale; colonoscopy; constipation; diarrhea; digestive system disease; disease assessment; drug safety; drug tolerability; enzyme linked immunosorbent assay; female; flatulence; follow up; gastrointestinal tumor; heart rate; human; Irritable Bowel Syndrome Quality of Life; irritable colon; lactose intolerance; leaky gut; leaky gut; major clinical study; male; open study; patient-reported outcome; pilot study; prospective study; psychological well-being; quality of life; satisfaction; urinary excretion; visual analog scale; young adult; clinical trial; complication; diarrhea; irritable colon; phase 4 clinical trial; treatment outcome","","acetylsalicylic acid, 493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1; C reactive protein, 9007-41-4","lactibiane tolrance, PiLeJe Laboratoire","PiLeJe Laboratoire","PiLeJe Laboratoire","This study was sponsored by PiLeJe Laboratoire","Moayyedi P., Mearin F., Azpiroz F., Andresen V., Barbara G., Corsetti M., Et al., Irritable bowel syndrome diagnosis and management: a simplified algorithm for clinical practice, United European Gastroenterol J., 5, 6, pp. 773-788, (2017); Oka P., Parr H., Barberio B., Black C.J., Savarino E.V., Ford A.C., Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis, Lancet Gastroenterol Hepatol., 5, 10, pp. 908-917, (2020); Barbara G., Zecchi L., Barbaro R., Cremon C., Bellacosa L., Marcellini M., Et al., Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome, J Clin Gastroenterol., 46, pp. S52-S55, (2012); Ishaque S.M., Khosruzzaman S.M., Ahmed D.S., Sah M.P., A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-KultR) in the management of diarrhea-predominant irritable bowel syndrome, BMC Gastroenterol., 18, 1, (2018); Quigley E.M.M., Fried M., Gwee K.-A., Khalif I., Hungin P., Lindberg G., Et al., Irritable bowel syndrome: a global perspective, (2015); Vasant D.H., Paine P.A., Black C.J., Houghton L.A., Everitt H.A., Corsetti M., Et al., British Society of Gastroenterology guidelines on the management of irritable bowel syndrome, Gut., 70, 7, pp. 1214-1240, (2021); Gecse K., Roka R., Sera T., Rosztoczy A., Annahazi A., Izbeki F., Et al., Leaky gut in patients with diarrhea-predominant irritable bowel syndrome and inactive ulcerative colitis, Digestion., 85, 1, pp. 40-46, (2012); La Fata G., Weber P., Mohajeri M.H., Probiotics and the gut immune system: indirect regulation, Probiotics Antimicrob Proteins., 10, 1, pp. 11-21, (2018); Nebot-Vivinus M., Harkat C., Bzioueche H., Cartier C., Plichon-Dainese R., Moussa L., Et al., Multispecies probiotic protects gut barrier function in experimental models, World J Gastroenterol., 20, 22, pp. 6832-6843, (2014); Hanning N., Edwinson A.L., Ceuleers H., Peters S.A., De Man J.G., Hassett L.C., Et al., Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review, Therap Adv Gastroenterol., 14, (2021); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain., 146, 1-2, pp. 41-46, (2009); Lacy B.E., Mearin F., Chang L., Chey W.D., Lembo A.J., Simren M., Et al., Bowel disorders, Gastroenterology., 150, 6, pp. 1393e5-1407e5, (2016); Bengtsson M., Ohlsson B., Ulander K., Development and psychometric testing of the visual analogue scale for irritable bowel syndrome (VAS-IBS), BMC Gastroenterol., 7, (2007); Patrick D.L., Drossman D.A., Frederick I.O., DiCesare J., Puder K.L., Quality of life in persons with irritable bowel syndrome: development and validation of a new measure, Dig Dis Sci., 43, 2, pp. 400-411, (1998); Andrae D.A., Patrick D.L., Drossman D.A., Covington P.S., Evaluation of the irritable bowel syndrome quality of life (IBS-QOL) questionnaire in diarrheal-predominant irritable bowel syndrome patients, Health Qual Life Outcomes., 11, (2013); Bjarnason I., Peters T.J., Veall N., A persistent defect in intestinal permeability in coeliac disease demonstrated by a 51Cr-labelled EDTA absorption test, Lancet., 1, 8320, pp. 323-325, (1983); Resnick R.H., Royal H., Marshall W., Barron R., Werth T., Intestinal permeability in gastrointestinal disorders, Use of oral [99mTc]DTPA. Dig Dis Sci., 35, 2, pp. 205-211, (1990); Scarpellini E., Valenza V., Gabrielli M., Lauritano E.C., Perotti G., Merra G., Et al., Intestinal permeability in cirrhotic patients with and without spontaneous bacterial peritonitis: is the ring closed?, Am J Gastroenterol., 105, 2, pp. 323-327, (2010); Fasano A., Intestinal permeability and its regulation by zonulin: diagnostic and therapeutic implications, Clin Gastroenterol Hepatol., 10, pp. 1096-1100, (2012); Tripathi A., Lammers K.M., Goldblum S., Shea-Donohue T., Netzel-Arnett S., Buzza M.S., Et al., Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2, Proc Natl Acad Sci U S A., 106, 39, pp. 16799-16804, (2009); Singh P., Silvester J., Chen X., Xu H., Sawhney V., Rangan V., Et al., Serum zonulin is elevated in IBS and correlates with stool frequency in IBS-D, United European Gastroenterol J., 7, 5, pp. 709-715, (2019); Lewis S.J., Heaton K.W., Stool form scale as a useful guide to intestinal transit time, Scand J Gastroenterol., 32, 9, pp. 920-924, (1997); Skrzydlo-Radomanska B., Prozorow-Krol B., Cichoz-Lach H., Majsiak E., Bierla J.B., Kanarek E., Et al., The effectiveness and safety of multistrain probiotic preparation in patients with diarrhea-predominant irritable bowel syndrome: a randomized controlled study, Nutrients., 13, 3, (2021); Lewis E.D., Antony J.M., Crowley D.C., Piano A., Bhardwaj R., Tompkins T.A., Et al., Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in alleviating symptoms of Irritable Bowel Syndrome (IBS): a randomized, placebo-controlled study, Nutrients., 12, 4, (2020); Martoni C.J., Srivastava S., Leyer G.J., Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 improve abdominal pain severity and symptomology in irritable bowel syndrome: randomized controlled trial, Nutrients., 12, 2, (2020); Zeng J., Li Y.-Q., Zuo X.-L., Zhen Y.-B., Yang J., Liu C.-H., Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome, Aliment Pharmacol Ther., 28, 8, pp. 994-1002, (2008); Boonma P., Shapiro J.M., Hollister E.B., Badu S., Wu Q., Weidler E.M., Et al., Probiotic VSL#3 treatment reduces colonic permeability and abdominal pain symptoms in patients with irritable bowel syndrome, Front Pain Res., 2, (2021); Bonfrate L., Di Palo D.M., Celano G., Albert A., Vitellio P., De Angelis M., Et al., Effects of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 in IBS patients, Eur J Clin Invest., 50, 3, (2020); Caviglia G.P., Tucci A., Pellicano R., Fagoonee S., Rosso C., Abate M.L., Et al., Clinical response and changes of cytokines and zonulin levels in patients with diarrhoea-predominant irritable bowel syndrome treated with Bifidobacterium longum ES1 for 8 or 12 weeks: a preliminary report, J Clin Med., 9, (2020); Moser A.M., Spindelboeck W., Halwachs B., Strohmaier H., Kump P., Gorkiewicz G., Et al., Effects of an oral synbiotic on the gastrointestinal immune system and microbiota in patients with diarrhea-predominant irritable bowel syndrome, Eur J Nutr., 58, 7, pp. 2767-2778, (2019); Talley N.J., Holtmann G.J., Jones M., Koloski N.A., Walker M.M., Burns G., Et al., Zonulin in serum as a biomarker fails to identify the IBS, functional dyspepsia and non-coeliac wheat sensitivity, Gut., 69, 9, pp. 1-3, (2020); Massier L., Chakaroun R., Kovacs P., Heiker J.T., Blurring the picture in leaky gut research: How shortcomings of zonulin as a biomarker mislead the field of intestinal permeability, Gut., 70, 9, pp. 1801-1802, (2021); Scheffler L., Crane A., Heyne H., Tonjes A., Schleinitz D., Ihling C.H., Et al., Widely used commercial ELISA does not detect precursor of haptoglobin2, but recognizes properdin as a potential second member of the zonulin family, Front Endocrinol., 9, (2018); Ajamian M., Steer D., Rosella G., Gibson P.R., D'Auria S., Serum zonulin as a marker of intestinal mucosal barrier function: may not be what it seems, PLoS One., 14, 1, (2019); Meira De-Faria F., Bednarska O., Strom M., Soderholm J.D., Walter S.A., Keita A.V., Colonic paracellular permeability and circulating zonulin-related proteins, Scand J Gastroenterol., 56, 4, pp. 424-431, (2021); Drouault-Holowacz S., Foligne B., Dennin V., Goudercourt D., Terpend K., Burckel A., Et al., Anti-inflammatory potential of the probiotic dietary supplement lactibiane tolerance: in vitro and in vivo considerations, Clin Nutr., 25, 6, pp. 994-1003, (2006); Rossi M., Sganga G., Mazzone M., Valenza V., Guarneri S., Portale G., Et al., Cardiopulmonary bypass in man: role of the intestine in a selflimiting inflammatory response with demonstrable bacterial translocation, Ann Thorac Surg., 77, 2, pp. 612-618, (2004)","S.A. Abdellah; PiLeJe Laboratoire, Paris, France; email: s.aitabdellah@pileje.com","","S. Karger AG","","","","","","02572753","","DIDIE","36007493","English","Dig. Dis.","Article","Final","All Open Access; Hybrid Gold Open Access","Scopus","2-s2.0-85149019547"

"Ke W.; Wu J.; Li H.; Huang S.; Li H.; Wang Y.; Wu Y.; Yuan J.; Zhang S.; Tang H.; Lei K.","Ke, Wei (58024459000); Wu, Jinjun (56007120400); Li, Hongbin (59178113600); Huang, Siyu (57204075645); Li, Huibiao (57204629373); Wang, Yongfu (58024459100); Wu, Yingxiu (57219923150); Yuan, Jie (58134906000); Zhang, Shuncong (56292041600); Tang, Hongmei (15519827300); Lei, Kaijun (57478804300)","58024459000; 56007120400; 59178113600; 57204075645; 57204629373; 58024459100; 57219923150; 58134906000; 56292041600; 15519827300; 57478804300","Network pharmacology and experimental validation to explore the mechanism of Changji'an Formula against irritable bowel syndrome with predominant diarrhea","2024","Heliyon","10","12","e33102","","","","0","10.1016/j.heliyon.2024.e33102","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85196265408&doi=10.1016%2fj.heliyon.2024.e33102&partnerID=40&md5=a20569888967f8f98887dbe4c573cf5b","Foshan Hospital of Traditional Chinese Medicine, Guangdong, Foshan, 528000, China; The Eighth Clinical Medical College of Guangzhou University of Chinese Medicine, Guangdong, Foshan, 528000, China; School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangdong, Guangzhou, 510006, China; The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangdong, Guangzhou, 510405, China; Guangdong Provincial Key Laboratory of Advanced Drug Delivery Systems and Guangdong Provincial Engineering Center of Topical Precise Drug Delivery System, Guangdong Pharmaceutical University, Guangdong, Guangzhou, 510006, China; The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong, Guangzhou, 510405, China; The First Affiliated Hospital of Zhengzhou University, Henan, Zhengzhou, 450052, China; Foshan Clinical Medical School, Guangzhou University of Chinese Medicine, Guangdong, Foshan, 528000, China","Ke W., Foshan Hospital of Traditional Chinese Medicine, Guangdong, Foshan, 528000, China, The Eighth Clinical Medical College of Guangzhou University of Chinese Medicine, Guangdong, Foshan, 528000, China; Wu J., School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangdong, Guangzhou, 510006, China; Li H., The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangdong, Guangzhou, 510405, China; Huang S., Guangdong Provincial Key Laboratory of Advanced Drug Delivery Systems and Guangdong Provincial Engineering Center of Topical Precise Drug Delivery System, Guangdong Pharmaceutical University, Guangdong, Guangzhou, 510006, China; Li H., The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong, Guangzhou, 510405, China; Wang Y., The First Affiliated Hospital of Zhengzhou University, Henan, Zhengzhou, 450052, China; Wu Y., Foshan Hospital of Traditional Chinese Medicine, Guangdong, Foshan, 528000, China; Yuan J., Foshan Clinical Medical School, Guangzhou University of Chinese Medicine, Guangdong, Foshan, 528000, China; Zhang S., The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong, Guangzhou, 510405, China; Tang H., The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong, Guangzhou, 510405, China; Lei K., Foshan Hospital of Traditional Chinese Medicine, Guangdong, Foshan, 528000, China, The Eighth Clinical Medical College of Guangzhou University of Chinese Medicine, Guangdong, Foshan, 528000, China","Changji'an Formula (CJAF) is a Chinese herbal compound, which is effective against irritable bowel syndrome with predominant diarrhea (IBS-D) in clinic. However, the molecular mechanism has not been well defined. In the current study, the potential targets and signaling pathways of CJAF against IBS-D were predicted using network pharmacology analysis. The pharmacological mechanisms of CJAF against IBS-D and the potential mechanism were validated by using an IBS-D mouse model induced by enema with trinitrobenzene-sulfonic acid (TNBS) plus with restraint stress and further intervened with CJAF. A total of 232 active compounds of CJAF were obtained, a total of 397 potential targets for the active ingredients were retrieved and a total of 219 common targets were obtained as the potential targets of CJAF against IBS-D. GO and KEGG enrichment analyses showed that multiple targets were enriched and could be experimentally validated in a mouse model of IBS-D. The mechanisms were mainly converged on the immune and inflammatory pathways, especially the NF-κB, TNF and IL-17 signaling pathway, which were closely involved in the treatment of CJAF against IBS-D. Animal experiment showed that CJAF alleviated visceral hypersensitivity and diarrhea symptom of IBS-D. CJAF also restored the histological and ultrastructure damage of IBS-D. The result of western blot showed that CJAF upregulated colonic tight junction proteins of ZO-1, Occludin and Claudin-1. Further results demonstrated that CJAF inhibited the protein expression of NF-κB/NLRP3 inflammasome pathway targets and downregulated proinflammatory mediators of IL-1β, IL-18, TNF-α. In conclusion, CJAF could effectively reduce inflammatory response and alleviate visceral hypersensitivity as well as diarrhea symptom of IBS-D by inhibiting the NF-κB/NLRP3 signaling pathway. This study not only reveals the mechanism of CJAF against IBS-D, but also provides a novel therapeutic strategy for IBS-D. © 2024 The Author(s)","Changji'an Formula; intestinal epithelial barrier; irritable bowel syndrome; network pharmacology; NF-κB/NLRP3 signaling pathway","","","","","","Lingnan Medical Research Center of Guangzhou University of Chinese Medicine; National Natural Science Foundation of China, NSFC, (81673842); Natural Science Foundation of Guangdong Province, (2019A1515011745); Special projects in key areas of colleges and universities in Guangdong province, (2023ZDZX2019); Pharmaceutical Research Special Fund of Guangdong Hospital Association, (2021YXZD02)","Funding text 1: We thank the Lingnan Medical Research Center of Guangzhou University of Chinese Medicine for providing experimental platform for us.; Funding text 2: This work was supported by the National Natural Science Foundation of China (project number: 81673842 ), the Natural Science Foundation of Guangdong Province (project number: 2019A1515011745 ), Special projects in key areas of colleges and universities in Guangdong province (Biomedicine and Health) (project number: 2023ZDZX2019 ), and Pharmaceutical Research Special Fund of Guangdong Hospital Association in 2021 (project number: 2021YXZD02 ). ","Chey W.D., Kurlander J., Eswaran S., Irritable bowel syndrome: a clinical review, JAMA, 313, 9, pp. 949-958, (2015); Singh P., Staller K., Barshop K., Dai E., Newman J., Yoon S., Castel S., Kuo B., Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation, World Journal of Gastroenterology, 21, 26, pp. 8103-8109, (2015); Mearin F., Lacy B.E., Chang L., Chey W.D., Lembo A.J., Simren M., Spiller R., Bowel Disorders, Gastroenterology, (2016); Ford A.C., Lacy B.E., Talley N.J., Irritable Bowel Syndrome, The New England Journal of Medicine, 376, 26, pp. 2566-2578, (2017); Chen J., Yu Y., He J., Discussion and consideration on the essence of ‘stagnation of liver qi and spleen deficiency’ in diarrhea-predominant irritable bowel syndrome, China Journal of Traditional Chinese Medicine and Pharmacy, 35, pp. 5698-5703, (2020); Chen Z., Treatment of 87 patients with irritable bowel syndrome by traditional Chinese medicine, Liaoning Journal of Traditional Chinese Medicine, 42, (1988); Gong Y., Chen X., Treating 30 Cases of Diarrhea Type Irritable Bowel Syndrome with Tongxie Yaofang plus Four Noble Drugs Decoction, Journal of Practical Traditional Chinese Internal Medicine, 25, pp. 52-54, (2011); Zhuo B., Ning X., Zhang Y., Effect of Tongxie Yaofang combined with Sijunzi Decoction on immune function of patients with IBS-D, Guangdong Medical Journal, 38, pp. 3669-3671+3675, (2017); Liu S., Clinical efficacy of Tongxiyaofang combined with Sijunzi Decoction in the treatment of irritable bowel syndrome and its influence on immune function, Chin J of Clinical Rational Drug Use, 12, pp. 157-159, (2019); Wen P., Lai Y., Treatment of 42 patients with IBS-D (spleen deficiency and liver depression syndrome) with Sijunzi decoction combined with Tongxie Yaofang, Fujian Journal of TCM, 45, pp. 30-31, (2014); Chai Y., Huang Y., Tang H., Wang T., Liu Y., Zhong R., Effect of Shugan Jianpi Method (Changji'an Fomulation) on IBS-D Immune Function, Chinese Journal of Experimental Traditional Medical Formulae, 22, pp. 93-98, (2016); Shi Y., Tang H., Wu Y., Zhu H., He G., Xiong F., Zhang Y., Effect of Changji'an Prescription on Intestinal Permeability of IBS-D Rats, Chinese Journal of Experimental Traditional Medical Formulae, 25, pp. 80-85, (2019); Hopkins A.L., Network pharmacology: the next paradigm in drug discovery, Nature Chemical Biology, 4, 11, pp. 682-690, (2008); Frantz S., Drug discovery: playing dirty, Nature, 437, 7061, pp. 942-943, (2005); Shou X., Wang Y., Zhang X., Zhang Y., Yang Y., Duan C., Yang Y., Jia Q., Yuan G., Shi J., Shi S., Cui H., Hu Y., Network Pharmacology and Molecular Docking Analysis on Molecular Mechanism of Qingzi Zhitong Decoction in the Treatment of Ulcerative Colitis, Frontiers In Pharmacology, 13, (2022); Chen Y., Chu F., Lin J., Su Z., Liao M., Li T., Li Y., Johnson N., Zheng H., Ding X., The mechanisms of action of WeiChang'An Pill (WCAP) treat diarrhoea-predominant irritable bowel syndrome (IBS-D) using network pharmacology approach and in vivo studies, Journal of Ethnopharmacology, 275, (2021); Tan X., Pei W., Xie C., Wang Z., Mao T., Zhao X., Kou F., Lu Q., Sun Z., Xue X., Li J., Network Pharmacology Identifies the Mechanisms of Action of Tongxie Anchang Decoction in the Treatment of Irritable Bowel Syndrome with Diarrhea Predominant, Evidence-based Complementary and Alternative Medicine : ECAM., 2020, (2020); Zhen Z., Xia L., You H., Jingwei Z., Shasha Y., Xinyi W., Wenjing L., Xin Z., Chaomei F., An Integrated Gut Microbiota and Network Pharmacology Study on Fuzi-Lizhong Pill for Treating Diarrhea-Predominant Irritable Bowel Syndrome, Frontiers In Pharmacology, 12, (2021); Liao Y., Ding Y., Yu L., Xiang C., Yang M., Exploring the mechanism of Alisma orientale for the treatment of pregnancy induced hypertension and potential hepato-nephrotoxicity by using network pharmacology, network toxicology, molecular docking and molecular dynamics simulation, Frontiers In Pharmacology, 13, (2022); An L., Lin Y., Li L., Kong M., Lou Y., Wu J., Liu Z., Integrating Network Pharmacology and Experimental Validation to Investigate the Effects and Mechanism of Astragalus Flavonoids Against Hepatic Fibrosis, Frontiers In Pharmacology, 11, (2020); Wu Y., Tang H., Wang Y., Zhang Y., Huang Y., Gan J., Simultaneous determination of ten constituents in lyophilized powder of Changji'an Prescription by UHPLC-MS/MS, Chinese Traditional Patent Medicine, 43, pp. 2302-2307, (2021); Lembo A., Sultan S., Chang L., Heidelbaugh J.J., Smalley W., Verne G.N., AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea, Gastroenterology, 163, 1, pp. 137-151, (2022); Xu D., Gao J., Gillilland M., Wu X., Song I., Kao J.Y., Owyang C., Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats, Gastroenterology, 146, 2, (2014); Tang H., Liao X., He J., Li D., Yan X., Determination of paeoniflorin, palmatine hydrochloride and berberine hydrochloride in Changji'an Preparation by HPLC, Chinese Traditional Patent Medicine, 34, pp. 853-857, (2012); Ke W., Wang Y., Huang S., Liu S., Zhu H., Xie X., Yang H., Lu Q., Gan J., He G., Che F., Wan X., Tang H., Paeoniflorin alleviates inflammatory response in IBS-D mouse model via downregulation of the NLRP3 inflammasome pathway with involvement of miR-29a, Heliyon, 8, 12, (2022); Kang D.J., Kakiyama G., Betrapally N.S., Herzog J., Nittono H., Hylemon P.B., Zhou H., Carroll I., Yang J., Gillevet P.M., Jiao C., Takei H., Pandak W.M., Iida T., Heuman D.M., Fan S., Fiehn O., Kurosawa T., Sikaroodi M., Sartor R.B., Bajaj J.S., Rifaximin Exerts Beneficial Effects Independent of its Ability to Alter Microbiota Composition, Clinical and Translational Gastroenterology, 7, 8, (2016); Aguilera-Lizarraga J., Florens M.V., Viola M.F., Jain P., Decraecker L., Appeltans I., Cuende-Estevez M., Fabre N., Van Beek K., Perna E., Balemans D., Stakenborg N., Theofanous S., Bosmans G., Mondelaers S.U., Matteoli G., Ibiza Martinez S., Lopez-Lopez C., Jaramillo-Polanco J., Talavera K., Alpizar Y.A., Feyerabend T.B., Rodewald H.-R., Farre R., Redegeld F.A., Si J., Raes J., Breynaert C., Schrijvers R., Bosteels C., Lambrecht B.N., Boyd S.D., Hoh R.A., Cabooter D., Nelis M., Augustijns P., Hendrix S., Strid J., Bisschops R., Reed D.E., Vanner S.J., Denadai-Souza A., Wouters M.M., Boeckxstaens G.E., Local immune response to food antigens drives meal-induced abdominal pain, Nature, 590, 7844, pp. 151-156, (2021); Yuan F., Tan W., Ren H., Yan L., Wang Y., Luo H., The Effects of Short-Chain Fatty Acids on Rat Colonic Hypermotility Induced by Water Avoidance Stress, Drug Design, Development and Therapy, 14, pp. 4671-4684, (2020); Al-Chaer E.D., Kawasaki M., Pasricha P.J., A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development, Gastroenterology, 119, 5, pp. 1276-1285, (2000); Obermeier F., Kojouharoff G., Hans W., Scholmerich J., Gross V., Falk W., Interferon-gamma (IFN-gamma)- and tumour necrosis factor (TNF)-induced nitric oxide as toxic effector molecule in chronic dextran sulphate sodium (DSS)-induced colitis in mice, Clinical and Experimental Immunology, 116, 2, pp. 238-245, (1999); Miglietta S., Borghini R., Relucenti M., Sorrentino V., Chen R., Li X., Fazi F., Donato G., Familiari G., Petrozza V., Picarelli A., New Insights into Intestinal Permeability in Irritable Bowel Syndrome-Like Disorders: Histological and Ultrastructural Findings of Duodenal Biopsies, Cells, 10, 10, (2021); Farzaei M.H., Bahramsoltani R., Abdollahi M., Rahimi R., The Role of Visceral Hypersensitivity in Irritable Bowel Syndrome: Pharmacological Targets and Novel Treatments, Journal of Neurogastroenterology and Motility, 22, 4, pp. 558-574, (2016); Lembo T., Munakata J., Mertz H., Niazi N., Kodner A., Nikas V., Mayer E.A., Evidence for the hypersensitivity of lumbar splanchnic afferents in irritable bowel syndrome, Gastroenterology, 107, 6, pp. 1686-1696, (1994); Awad F., Assrawi E., Louvrier C., Jumeau C., Georgin-Lavialle S., Grateau G., Amselem S., Giurgea I., Karabina S.-A., Inflammasome biology, molecular pathology and therapeutic implications, Pharmacology & Therapeutics, 187, pp. 133-149, (2018); Kaminsky L.W., Al-Sadi R., Ma T.Y., IL-1β and the Intestinal Epithelial Tight Junction Barrier, Frontiers In Immunology, 12, (2021); Matricon J., Meleine M., Gelot A., Piche T., Dapoigny M., Muller E., Ardid D., Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome, Alimentary Pharmacology & Therapeutics, 36, 11-12, pp. 1009-1031, (2012); Scuderi S.A., Casili G., Lanza M., Filippone A., Paterniti I., Esposito E., Campolo M., Modulation of NLRP3 Inflammasome Attenuated Inflammatory Response Associated to Diarrhea-Predominant Irritable Bowel Syndrome, Biomedicines, 8, 11, (2020); Bauernfeind F.G., Horvath G., Stutz A., Alnemri E.S., MacDonald K., Speert D., Fernandes-Alnemri T., Wu J., Monks B.G., Fitzgerald K.A., Hornung V., Latz E., Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression, Journal of Immunology (Baltimore, Md, 183, 2, pp. 787-791, (2009); Hayden M.S., Ghosh S., Signaling to NF-kappaB, Genes & Development, 18, 18, pp. 2195-2224, (2004); Schroder K., Tschopp J., The inflammasomes, Cell, 140, 6, pp. 821-832, (2010); Song H.P., Hou X.Q., Li R.Y., Yu R., Li X., Zhou S.N., Huang H.Y., Cai X., Zhou C., Atractylenolide I stimulates intestinal epithelial repair through polyamine-mediated Ca2+ signaling pathway, Phytomedicine : International Journal of Phytotherapy and Phytopharmacology., 28, pp. 27-35, (2017); Hanning N., Edwinson A.L., Ceuleers H., Peters S.A., De Man J.G., Hassett L.C., De Winter B.Y., Grover M., Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review, Therapeutic Advances In Gastroenterology, 14, (2021); Zhang X.J., Li Z., Leung W.M., Liu L., Xu H.X., Bian Z.X., The analgesic effect of paeoniflorin on neonatal maternal separation-induced visceral hyperalgesia in rats, The Journal of Pain, 9, 6, pp. 497-505, (2008); Li J., Ren S., Li M., Bi J., Yang G., Li E., Paeoniflorin protects against dextran sulfate sodium (DSS)-induced colitis in mice through inhibition of inflammation and eosinophil infiltration, International Immunopharmacology, 97, (2021); Jiang X.G., Sun K., Liu Y.Y., Yan L., Wang M.X., Fan J.Y., Mu H.N., Li C., Chen Y.Y., Wang C.S., Han J.Y., Astragaloside IV ameliorates 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis implicating regulation of energy metabolism, Scientific Reports, 7, (2017); Liu B., Luo M., Meng D., Pan H., Shen H., Shen J., Yao M., Xu L., Tetrahydropalmatine exerts analgesic effects by promoting apoptosis and inhibiting the activation of glial cells in rats with inflammatory pain, Molecular Pain, 17, (2021); Zhang J.D., Liu J., Zhu S.W., Fang Y., Wang B., Jia Q., Hao H.-F., Kao J.Y., He Q.H., Song L.J., Liu F., Zhu B.L., Owyang C., Duan L.P., Berberine alleviates visceral hypersensitivity in rats by altering gut microbiome and suppressing spinal microglial activation, Acta Pharmacologica Sinica, 42, 11, pp. 1821-1833, (2021); Yu Z.C., Cen Y.X., Wu B.H., Wei C., Xiong F., Li D.F., Liu T.T., Luo M.H., Guo L.L., Li Y.X., Wang L.S., Wang J.Y., Yao J., Berberine prevents stress-induced gut inflammation and visceral hypersensitivity and reduces intestinal motility in rats, World Journal of Gastroenterology, 25, 29, pp. 3956-3971, (2019); Chen X., Fang D., Li L., Chen L., Li Q., Gong F., Fang M., Glycyrrhizin ameliorates experimental colitis through attenuating interleukin-17-producing T cell responses via regulating antigen-presenting cells, Immunologic Research, 65, 3, pp. 666-680, (2017); Kudo T., Okamura S., Zhang Y., Masuo T., Mori M., Topical application of glycyrrhizin preparation ameliorates experimentally induced colitis in rats, World Journal of Gastroenterology, 17, 17, pp. 2223-2228, (2011); Liu Y., Xiang J., Liu M., Wang S., Lee R.J., Ding H., Protective effects of glycyrrhizic acid by rectal treatment on a TNBS-induced rat colitis model, The Journal of Pharmacy and Pharmacology, 63, 3, pp. 439-446, (2011); Qin H.-Y., Wu J.C.Y., Tong X.-D., Sung J.J.Y., Xu H.-X., Bian Z.-X., Systematic review of animal models of post-infectious/post-inflammatory irritable bowel syndrome, Journal of Gastroenterology, 46, 2, pp. 164-174, (2011); Bashashati M., Rezaei N., Shafieyoun A., McKernan D.P., Chang L., Ohman L., Quigley E.M., Schmulson M., Sharkey K.A., Simren M., Cytokine imbalance in irritable bowel syndrome: a systematic review and meta-analysis, Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society, 26, 7, pp. 1036-1048, (2014); Katoh M., Multi-layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β-catenin signaling activation, International Journal of Molecular Medicine, 42, 2, pp. 713-725, (2018); Sofi F., Whittaker A., Gori A.M., Cesari F., Surrenti E., Abbate R., Gensini G.F., Benedettelli S., Casini A., Effect of Triticum turgidum subsp. turanicum wheat on irritable bowel syndrome: a double-blinded randomised dietary intervention trial, The British Journal of Nutrition, 111, 11, pp. 1992-1999, (2014); Bashashati M., Moradi M., Sarosiek I., Interleukin-6 in irritable bowel syndrome: A systematic review and meta-analysis of IL-6 (-G174C) and circulating IL-6 levels, Cytokine, 99, pp. 132-138, (2017); O'Malley D., Liston M., Hyland N.P., Dinan T.G., Cryan J.F., Colonic soluble mediators from the maternal separation model of irritable bowel syndrome activate submucosal neurons via an interleukin-6-dependent mechanism, American Journal of Physiology. Gastrointestinal and Liver Physiology, 300, 2, pp. G241-G252, (2011); Vesely P.W., Staber P.B., Hoefler G., Kenner L., Translational regulation mechanisms of AP-1 proteins, Mutation Research, 682, 1, (2009); Liaqat H., Parveen A., Kim S.Y., Antidepressive Effect of Natural Products and Their Derivatives Targeting BDNF-TrkB in Gut-Brain Axis, International Journal of Molecular Sciences, 23, 23, (2022); Fukumoto M., Takeuchi T., Koubayashi E., Harada S., Ota K., Kojima Y., Higuchi K., Induction of brain-derived neurotrophic factor in enteric glial cells stimulated by interleukin-1β via a c-Jun N-terminal kinase pathway, Journal of Clinical Biochemistry and Nutrition, 66, 2, pp. 103-109, (2020); Latz E., The inflammasomes: mechanisms of activation and function, Current Opinion In Immunology, 22, 1, pp. 28-33, (2010); Ting J.P.Y., Lovering R.C., Alnemri E.S., Bertin J., Boss J.M., Davis B.K., Flavell R.A., Girardin S.E., Godzik A., Harton J.A., Hoffman H.M., Hugot J.-P., Inohara N., Mackenzie A., Maltais L.J., Nunez G., Ogura Y., Otten L.A., Philpott D., Reed J.C., Reith W., Schreiber S., Steimle V., Ward P.A., The NLR gene family: a standard nomenclature, Immunity, 28, 3, pp. 285-287, (2008); Petrilli V., Dostert C., Muruve D.A., Tschopp J., The inflammasome: a danger sensing complex triggering innate immunity, Current Opinion In Immunology, 19, 6, pp. 615-622, (2007); Suzuki T., Regulation of intestinal epithelial permeability by tight junctions, Cellular and Molecular Life Sciences : CMLS, 70, 4, pp. 631-659, (2013); Martinez C., Lobo B., Pigrau M., Ramos L., Gonzalez-Castro A.M., Alonso C., Guilarte M., Guila M., de Torres I., Azpiroz F., Santos J., Vicario M., Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, 8, pp. 1160-1168, (2013); Sun X.Q., Fu X.B., Zhang R., Lu Y., Deng Q., Jiang X.G., Sheng Z.Y., Relationship between plasma D(-)-lactate and intestinal damage after severe injuries in rats, World Journal of Gastroenterology, 7, 4, pp. 555-558, (2001); Xia B., Wu W., Fang W., Wen X., Xie J., Zhang H., Heat stress-induced mucosal barrier dysfunction is potentially associated with gut microbiota dysbiosis in pigs, Animal Nutrition (Zhongguo Xu Mu Shou Yi Xue Hui), 8, 1, pp. 289-299, (2022); Lembo A., Pimentel M., Rao S.S., Schoenfeld P., Cash B., Weinstock L.B., Paterson C., Bortey E., Forbes W.P., Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome, Gastroenterology, 151, 6, pp. 1113-1121, (2016); Drolia R., Tenguria S., Durkes A.C., Turner J.R., Bhunia A.K., Listeria Adhesion Protein Induces Intestinal Epithelial Barrier Dysfunction for Bacterial Translocation, Cell Host & Microbe, 23, 4, (2018); Qin Z., Shi D.D., Li W., Cheng D., Zhang Y.-D., Zhang S., Tsoi B., Zhao J., Wang Z., Zhang Z.J., Berberine ameliorates depression-like behaviors in mice via inhibiting NLRP3 inflammasome-mediated neuroinflammation and preventing neuroplasticity disruption, Journal of Neuroinflammation, 20, 1, (2023); Principi N., Cozzali R., Farinelli E., Brusaferro A., Esposito S., Gut dysbiosis and irritable bowel syndrome: The potential role of probiotics, The Journal of Infection, 76, 2, pp. 111-120, (2018); Margolis K.G., Cryan J.F., Mayer E.A., The Microbiota-Gut-Brain Axis: From Motility to Mood, Gastroenterology, 160, 5, pp. 1486-1501, (2021); El-Salhy M., Hatlebakk J.G., Gilja O.H., Brathen Kristoffersen A., Hausken T., Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study, Gut, 69, 5, pp. 859-867, (2020); Shi Y.Y., Tang H.M., Wu Y.X., Zhu H., He G.D., Xiong F., Et al., Effect of Changji'an Prescription on Intestinal Permeability of IBS-D Ｒats, Chinese Journal of Experimental Traditional Medical Formulae, 25, pp. 80-85, (2019); Zhu H., Chai Y., Zhang Y., Wang Y., Gan J., Zhou Y., Et al., Effects of Changji'an Formula on Ultrastructure of Colonic Mucosa and Levels of ZO- 1 and CLDN1 in Model Rats with IBS-D, Traditional Chinese Drug Research and Clinical Pharmacology, 32, 7, pp. 905-911, (2021); Guo J., Zhang F., Gao J., Guan X., Liu B., Wang X., Qin Z., Tang K., Liu S., Proteomics-based screening of the target proteins associated with antidepressant-like effect and mechanism of Saikosaponin A, Journal of Cellular and Molecular Medicine, 24, 1, pp. 174-188, (2020)","K. Lei; Pharmaceutical Department, Foshan Hospital of Traditional Chinese Medicine, Foshan, No.6 Qinren Road, Chancheng District, Guangdong, 528000, China; email: leikj@fshtcm.com.cn; H. Tang; Pharmaceutical Department, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 16 Ji Chang Road, Guangdong, 510405, China; email: yxb@gzucm.edu.cn","","Elsevier Ltd","","","","","","24058440","","","","English","Heliyon","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85196265408"

"Xu Y.; Yao R.; Zhao W.; Zhu J.; Yao J.; Zhang G.; Liu D.","Xu, Yan (58459840900); Yao, Ru (59029013100); Zhao, Wenxue (58423369300); Zhu, Jianguo (58366205200); Yao, Jingchun (57193604202); Zhang, Guimin (58297616700); Liu, Dongguang (58429640400)","58459840900; 59029013100; 58423369300; 58366205200; 57193604202; 58297616700; 58429640400","Spirocyclopiperazinium salt compound DXL-A-24 improves visceral sensation and gut microbiota in a rat model of irritable bowel syndrome","2023","Heliyon","9","6","e16544","","","","3","10.1016/j.heliyon.2023.e16544","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85160690644&doi=10.1016%2fj.heliyon.2023.e16544&partnerID=40&md5=14b025ac6d1210617405024141b90d94","From the Center for New Drug Pharmacology, Lunan Pharmaceutical Group Corporation, Linyi, China","Xu Y., From the Center for New Drug Pharmacology, Lunan Pharmaceutical Group Corporation, Linyi, China; Yao R., From the Center for New Drug Pharmacology, Lunan Pharmaceutical Group Corporation, Linyi, China; Zhao W., From the Center for New Drug Pharmacology, Lunan Pharmaceutical Group Corporation, Linyi, China; Zhu J., From the Center for New Drug Pharmacology, Lunan Pharmaceutical Group Corporation, Linyi, China; Yao J., From the Center for New Drug Pharmacology, Lunan Pharmaceutical Group Corporation, Linyi, China; Zhang G., From the Center for New Drug Pharmacology, Lunan Pharmaceutical Group Corporation, Linyi, China; Liu D., From the Center for New Drug Pharmacology, Lunan Pharmaceutical Group Corporation, Linyi, China","Irritable bowel syndrome (IBS) is characterized by visceral pain, impaired intestinal barrier and a disorder of the microbiota. DXL-A-24 has analgesic and anti-inflammatory effects by inhibiting neuropeptides and inflammatory factors. In this study, we used chronic unpredictable mild stress (CUMS) induced IBS model, to assess the action of DXL-A-24 on visceral hypersensitivity, barrier function and microbiota. Visceral sensation was assessed by colorectal distension in a model of IBS. The expressions of substance P (SP) and calcitonin gene-related peptide (CGRP) were detected by immunohistochemistry and western blot, the contents of diamine oxidase (DAO) and D-lactic acid were detected by ELISA, and 16S rRNA to detect the diversity of gut microbiota. CUMS reduced visceral pain threshold and increased colonic permeability of rats. DXL-A-24 for 28 days inhibited these changes. DXL-A-24 also decreased the expression of SP, CGRP in colon and D-LA, DAO in serum. Besides, DXL-A-24 increased the richness and diversity of intestinal microbiota. In conclusions, DXL-A-24 reduced visceral sensitivity, improved intestinal barrier and regulated gut microbiota in rats with IBS. © 2023","Gut barrier; Irritable bowel syndrome; Microbiota; Visceral hypersensitivity","","","","","","Lunan Pharmaceutical Group Corporation","This work was supported by Lunan Pharmaceutical Group Corporation. ","Ford A.C., Lacy B.E., Talley N.J., Irritable bowel syndrome, N. Engl. J. Med., 376, 26, pp. 2566-2578, (2017); Raskov H., Burcharth J., Pommergaard H.C., Rosenberg J., Irritable bowel syndrome, the microbiota and the gut-brain axis, Gut Microbes, 7, 5, pp. 365-383, (2016); Salvo Romero E., Alonso Cotoner C., Pardo Camacho C., Casado Bedmar M., Vicario M., The intestinal barrier function and its involvement in digestive disease, Rev. Esp. Enferm. Dig., 107, 11, pp. 686-696, (2015); Li N., Liu Q., Li R.T., Sun Q., Jiang Y.M., Ye J., Anti-arthritic effect of the spirocyclopiperazinium salt compound LXM-15 in rats and its underlying mechanism, Inflammation, 43, 3, pp. 903-915, (2020); Gao X., Sun Q., Zhang W., Jiang Y., Li R., Ye J., Anti-inflammatory effect and mechanism of the spirocyclopiperazinium salt compound LXM-15 in rats and mice, Inflamm. Res., 67, 4, pp. 363-370, (2018); Yang H., Sun Q., Liang Y., Jiang Y., Li R., Ye J., Antinociception of the spirocyclopiperazinium salt compound LXM-15 via activating α7 nAChR and M4 mAChR and inhibiting CaMKIIα/cAMP/CREB/CGRP signalling pathway in mice, Regul. Toxicol. Pharmacol., 94, pp. 108-114, (2018); Wang D., Yang H., Liang Y., Wang X., Du X., Li R., Jiang Y., Ye J., Antinociceptive Effect of spirocyclopiperazinium salt compound DXL-A-24 and the underlying mechanism, Neurochem. Res., 44, 12, pp. 2786-2795, (2019); Liu Q., Gao X., Wang T., Wang X., Li R., Jiang Y., Ye J., Effect and underlying mechanisms of spirocyclopiperazinium salt compound DXL-A-24 in rats following spinal nerve ligation, Brain Res., 1800, (2023); Fan J., Chang H., Dong S., Yan X., Wang J., Hong Y., Establishment and evaluation of a novel rat model of chronic stress-induced irritable bowel syndrome, Acta Labor. Anim. Sci. Sin., 18, 2, pp. 91-95+88, (2010); Yang J.P., Yao M., Jiang X.H., Wang L.N., Establishment of model of visceral pain due to colorectal distension and its behavioral assessment in rats, World J. Gastroenterol., 12, 17, pp. 2781-2784, (2006); Shi H.L., Liu C.H., Ding L.L., Zheng Y., Fei X.Y., Lu L., Zhou X.M., Yuan J.Y., Xie J.Q., Alterations in serotonin, transient receptor potential channels and protease-activated receptors in rats with irritable bowel syndrome attenuated by Shugan decoction, World J. Gastroenterol., 21, 16, pp. 4852-4863, (2015); Qin H.Y., Cheng C.W., Tang X.D., Bian Z.X., Impact of psychological stress on irritable bowel syndrome, World J. Gastroenterol., 20, 39, pp. 14126-14131, (2014); Sun H., Ma Y., An S., Wang Z., Altered gene expression signatures by calcitonin gene-related peptide promoted mast cell activity in the colon of stress-induced visceral hyperalgesia mice, Neurogastroenterol. Motil., 33, 6, (2021); Siiskonen H., Harvima I., Mast cells and sensory nerves contribute to neurogenic inflammation and pruritus in chronic skin inflammation, Front. Cell Neurosci., 13, (2019); Noor-Mohammadi E., Ligon C.O., Mackenzie K., Stratton J., Shnider S., Greenwood-Van Meerveld B., A Monoclonal Anti-Calcitonin Gene-Related Peptide Antibody Decreases Stress-Induced Colonic Hypersensitivity, J. Pharmacol. Exp. Ther., 379, 3, pp. 270-279, (2021); Al-Qudah M., Alkahtani R., Akbarali H.I., Murthy K.S., Grider J.R., Stimulation of synthesis and release of brain-derived neurotropic factor from intestinal smooth muscle cells by substance P and pituitary adenylate cyclase-activating peptide, Neurogastroenterol. Motil., 27, 8, pp. 1162-1174, (2015); Weinstock J.V., The role of substance P, hemokinin and their receptor in governing mucosal inflammation and granulomatous responses, Front. Biosci., 9, pp. 1936-1943, (2004); Holzer P., Holzer-Petsche U., Tachykinin receptors in the gut: physiological and pathological implications, Curr. Opin. Pharmacol., 1, 6, pp. 583-590, (2001); Galland L., The gut microbiome and the brain, J. Med. Food, 17, 12, pp. 1261-1272, (2014); Li H.C., Fan X.J., Chen Y.F., Tu J.M., Pan L.Y., Chen T., Yin P.H., Peng W., Feng D.X., Early prediction of intestinal mucosal barrier function impairment by elevated serum procalcitonin in rats with severe acute pancreatitis, Pancreatology, 16, 2, pp. 211-217, (2016); Zhuang X., Tian Z., Li L., Zeng Z., Chen M., Xiong L., Fecal microbiota alterations associated with diarrhea-predominant irritable bowel syndrome, Front. Microbiol., 9, (2018); Carroll I.M., Ringel-Kulka T., Siddle J.P., Ringel Y., Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome, Neurogastroenterol. Motil., 24, 6, pp. 521-30 e248, (2012); O'Mahony S.M., Marchesi J.R., Scully P., Codling C., Ceolho A.M., Quigley E.M., Cryan J.F., Dinan T.G., Early life stress alters behavior, immunity, and microbiota in rats: implications for irritable bowel syndrome and psychiatric illnesses, Biol. Psychiatry, 65, 3, pp. 263-267, (2009); Enqi W., Jingzhu S., Lingpeng P., Yaqin L., Comparison of the gut microbiota disturbance in rat models of irritable bowel syndrome induced by maternal separation and multiple early-life adversity, Front. Cell Infect. Microbiol., 10, (2021); Bennet S.M., Ohman L., Simren M., Gut microbiota as potential orchestrators of irritable bowel syndrome, Gut Liver, 9, 3, pp. 318-331, (2015); Chen W., Liu F., Ling Z., Tong X., Xiang C., Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer, PLoS One, 7, 6, (2012); Han Y.W., Redline R.W., Li M., Yin L., Hill G.B., McCormick T.S., Fusobacterium nucleatum induces premature and term stillbirths in pregnant mice: implication of oral bacteria in preterm birth, Infect. Immun., 72, 4, pp. 2272-2279, (2004); Shang F.M., Liu H.L., Fusobacterium nucleatum and colorectal cancer: a review, World J. Gastrointest. Oncol., 10, 3, pp. 71-81, (2018); Shin N.R., Whon T.W., Bae J.W., Proteobacteria: microbial signature of dysbiosis in gut microbiota, Trends Biotechnol., 33, 9, pp. 496-503, (2015); Moratalla A., Gomez-Hurtado I., Santacruz A., A M., Peiro G., Zapater P., Gonzalez-Navajas J.M., Gimenez P., Such J., Sanz Y., Frances R., Protective effect of Bifidobacterium pseudocatenulatum CECT7765 against induced bacterial antigen translocation in experimental cirrhosis, Liver Int., 34, 6, pp. 850-858, (2014); Kassinen A., Krogius-Kurikka L., Makivuokko H., Rinttila T., Paulin L., Corander J., Malinen E., Apajalahti J., Palva A., The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects, Gastroenterology, 133, 1, pp. 24-33, (2007); Kerckhoffs A.P., Samsom M., van der Rest M.E., de Vogel J., Knol J., Ben-Amor K., Akkermans L.M., Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients, World J. Gastroenterol., 15, 23, pp. 2887-2892, (2009); Rajilic-Stojanovic M., Biagi E., Heilig H.G., Kajander K., Kekkonen R.A., Tims S., de Vos W.M., Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome, Gastroenterology, 141, 5, pp. 1792-1801, (2011); Rigsbee L., Agans R., Shankar V., Kenche H., Khamis H.J., Michail S., Paliy O., Quantitative profiling of gut microbiota of children with diarrhea-predominant irritable bowel syndrome, Am. J. Gastroenterol., 107, 11, pp. 1740-1751, (2012); Malinen E., Rinttila T., Kajander K., Matto J., Kassinen A., Krogius L., Saarela M., Korpela R., Palva A., Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR, Am. J. Gastroenterol., 100, 2, pp. 373-382, (2005); Duboc H., Rainteau D., Rajca S., Humbert L., Farabos D., Maubert M., Grondin V., Jouet P., Bouhassira D., Seksik P., Sokol H., Coffin B., Sabate J.M., Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome, Neurogastroenterol. Motil., 24, 6, pp. 513-520, (2012); O'Callaghan J., O'Toole P.W., Lactobacillus: host-microbe relationships, Curr. Top. Microbiol. Immunol., 358, pp. 119-154, (2013); Ponnusamy K., Choi J.N., Kim J., Lee S.Y., Lee C.H., Microbial community and metabolomic comparison of irritable bowel syndrome faeces, J. Med. Microbiol., 60, pp. 817-827, (2011); Kassinen A., Krogius-Kurikka L., Makivuokko H., Rinttila T., Paulin L., Corander J., Malinen E., Apajalahti J., Palva A., The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects, Gastroenterology, 133, 1, pp. 24-33, (2007); Mack A., Bobardt J.S., Hass A., Nichols K.B., Schmid R.M., Stein-Thoeringer C.K., Changes in gut microbial metagenomic pathways associated with clinical outcomes after the elimination of malabsorbed sugars in an IBS cohort, Gut Microbes, 11, 3, pp. 620-631, (2020); Devriese S., Eeckhaut V., Geirnaert A., Van den Bossche L., Hindryckx P., Van de Wiele T., Van Immerseel F., Ducatelle R., De Vos M., Laukens D., Reduced mucosa-associated butyricicoccus activity in patients with ulcerative colitis correlates with aberrant claudin-1 expression, J. Crohns Colitis, 11, 2, pp. 229-236, (2017); Eeckhaut V., Machiels K., Perrier C., Romero C., Maes S., Flahou B., Steppe M., Haesebrouck F., Sas B., Ducatelle R., Vermeire S., Van Immerseel F., Butyricicoccus pullicaecorum in inflammatory bowel disease, Gut, 62, 12, pp. 1745-1752, (2013); Kong C., Gao R., Yan X., Huang L., Qin H., Probiotics improve gut microbiota dysbiosis in obese mice fed a high-fat or high-sucrose diet, Nutrition, 60, pp. 175-184, (2019); Perez-Burillo S., Pastoriza S., Fernandez-Arteaga A., Luzon G., Jimenez-Hernandez N., D'Auria G., Francino M.P., Rufian-Henares J.A., Spent coffee grounds extract, rich in mannooligosaccharides, promotes a healthier gut microbial community in a dose-dependent manner, J. Agric. Food Chem., 67, 9, pp. 2500-2509, (2019); Pittayanon R., Lau J.T., Yuan Y., Leontiadis G.I., Tse F., Surette M., Moayyedi P., Gut microbiota in patients with irritable bowel syndrome-a systematic review, Gastroenterology, 157, 1, pp. 97-108, (2019)","D. Liu; Lunan Pharmaceutical Group Corporation, Linyi, Shandong, 276000, China; email: liudongguang0176@163.com","","Elsevier Ltd","","","","","","24058440","","","","English","Heliyon","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85160690644"

"Sun J.; Zhang M.; Liu W.; Liu Y.; Zhang D.; Fan X.; Zhang J.; Li T.; Lu M.","Sun, Jing (58485206300); Zhang, Mengqiu (58302524500); Liu, Wei (58480217200); Liu, Youqian (57244836400); Zhang, Dongjian (56484812800); Fan, Xinyu (57226534707); Zhang, Jian (55922439400); Li, Tian (57217011478); Lu, Min (56553533900)","58485206300; 58302524500; 58480217200; 57244836400; 56484812800; 57226534707; 55922439400; 57217011478; 56553533900","Evaluation of the effectiveness and mechanism of action of the Chang-Kang-Fang formula combined with bifid triple viable capsules on diarrhea-predominant irritable bowel syndrome","2023","Frontiers in Microbiology","14","","1160783","","","","3","10.3389/fmicb.2023.1160783","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85164749336&doi=10.3389%2ffmicb.2023.1160783&partnerID=40&md5=984338a5c1bb3f68e601d8edb0510c91","Department of Central laboratory, Nanjing Lishui District Hospital of Traditional Chinese Medicine, Nanjing, China; Department of TCMs Pharmaceuticals, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China; School of Third Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing, China; Suqian Hospital of Traditional Chinese Medicine, Suqian, China; Department of Gastroenterology, Nanjing Lishui District Hospital of Traditional Chinese Medicine, Nanjing, China; Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China","Sun J., Department of Central laboratory, Nanjing Lishui District Hospital of Traditional Chinese Medicine, Nanjing, China, Department of TCMs Pharmaceuticals, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China; Zhang M., School of Third Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing, China, Suqian Hospital of Traditional Chinese Medicine, Suqian, China; Liu W., School of Third Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing, China; Liu Y., Department of Gastroenterology, Nanjing Lishui District Hospital of Traditional Chinese Medicine, Nanjing, China; Zhang D., School of Third Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing, China, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China; Fan X., Department of Gastroenterology, Nanjing Lishui District Hospital of Traditional Chinese Medicine, Nanjing, China, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China; Zhang J., School of Third Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing, China; Li T., Department of Central laboratory, Nanjing Lishui District Hospital of Traditional Chinese Medicine, Nanjing, China; Lu M., School of Third Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing, China","Introduction: The Chang-Kang-Fang (CKF) formula, a traditional Chinese herbal formula, can decrease serotonin (5-HT) levels and treat irritable bowel syndrome (IBS). Probiotics have a better synergistic effect on diarrhea-predominant IBS (IBS-D) when combined with 5-HT3 receptor antagonists. The present study aimed to elucidate the efficacy and the mechanisms of action of the CKF formula combined with bifid triple viable capsules (PFK) against IBS-D. Methods: The rat models of IBS-D were induced by gavage with senna decoction plus restraint stress. The CKF formula, PFK and their combination were administered to the rats. Their effects were evaluated based on general condition of the rats and the AWR score. The levels of 5-HT and fos protein in the colon and hippocampus were measured by immunohistochemistry. The levels of SP and VIP, as well as ZO-1 and occludin in the colon, were determined by enzyme-linked immunosorbent assay and immunohistochemistry. The intestinal microbiota in faeces was analyzed by 16S rRNA high-throughput sequencing. Results: The results showed that the oral CKF formula combined with PFK (CKF + PFK) could significantly relieve the symptoms of IBS-D, including elevating the weight rate and decreasing the AWR score. Compared with the MC group, administration of CKF + PFK significantly reduced the expression of fos in the colon and hippocampus and that of 5-HT, SP and VIP in the colon and increased the levels of 5-HT in the hippocampus and ZO-1 and occludin in the colon. The above indexes exhibited statistical significance in the CKF + PFK group relative to those in the other groups. Moreover, treatment with CKF + PFK improved the diversity of intestinal microbiota and the abundance of Firmicutes, Lachnospiraceae and Ruminococcaceae but decreased those of Bacteroidetes and Prevotellaceae. Conclusions: The CKF formula combined with PFK may have a synergistic effect on IBS-D by slowing gastrointestinal motility, lowering visceral hypersensitivity, enhancing the intestinal barrier function and modulating the composition of intestinal microbiota. Copyright © 2023 Sun, Zhang, Liu, Liu, Zhang, Fan, Zhang, Li and Lu.","bifid triple viable capsule; Chang-Kang-Fang; diarrhea-predominant irritable bowel syndrome; intestinal microbiota; serotonin","bifid triple viable capsule; occludin; probiotic agent; protein fos; protein ZO1; RNA 16S; serotonin; serotonin 3 antagonist; unclassified drug; vasoactive intestinal polypeptide; abdominal withdrawal reflex; animal experiment; animal model; animal tissue; Article; Bacteroidetes; Chang Kang Fang; comparative effectiveness; diarrhea; down regulation; enzyme linked immunosorbent assay; epithelium cell; feces; Firmicutes; gastrointestinal motility; gene sequence; high throughput sequencing; hippocampus; immobilization stress; immunohistochemistry; intestine flora; irritable colon; Lachnospiraceae; male; microbial community; microcapsule; monotherapy; nonhuman; operational taxonomic unit; physiological stress; polymerase chain reaction; Prevotellaceae; protein expression; Proteobacteria; quality control; rat; Ruminococcaceae; synergistic effect; visceral hyperalgesia","","occludin, 176304-61-3; serotonin, 50-67-9; vasoactive intestinal polypeptide, 37221-79-7","MiSeq, Illumina, United States","Illumina, United States","Jiangsu Cadre Health Research Project; Jiangsu Province Traditional Chinese Medicine Science and Technology Development Project, (ZD201708); Nanjing Hilshou Biotechnology Co.; Nanjing Lishui District Hospital of Traditional Chinese Medicine, (lzy2019yj002); Jiangsu Commission of Health, (BJ20026)","Funding text 1: This research was supported by Jiangsu Province Traditional Chinese Medicine Science and Technology Development Project (ZD201708) (design of the study, analysis of data, collection of data), Jiangsu Cadre Health Research Project, Jiangsu Commission of Health (BJ20026) (writing the manuscript), Nanjing Lishui District Hospital of Traditional Chinese Medicine (lzy2019yj002) (interpretation of data). ; Funding text 2: We thank Nanjing Hilshou Biotechnology Co., LTD for targeting capsule technology support.","Al-Chaer E.D., Kawasaki M., Pasricha P.J., A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development, Gastroenterology, 119, pp. 1276-1285, (2000); Altomare A., Di Rosa C., Imperia E., Emerenziani S., Cicala M., Guarino M.P.L., Diarrhea predominant-irritable bowel syndrome (ibs-d): effects of different nutritional patterns on intestinal dysbiosis and symptoms, Nutrients, 13, (2021); Bearcroft C.P., Perrett D., Farthing M.J.G., Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study, Gut, 42, pp. 42-46, (1998); Bu F.-L., Chen R.-L., Lin Z.-Y., Cao H.-J., Robinson N., Liang N., Et al., Chinese herbal medicine versus probiotics for irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials, Eur. J. Integr. Med, 38, (2020); Chao G., Wang Z., Yang Y., Zhang S., LncRNA H19 as a Competing Endogenous RNA to Regulate AQP Expression in the Intestinal Barrier of IBS-D Patients, Front. Physiol, 11, (2021); Chapman C.M.C., Gibson G.R., Rowland I., Health benefits of probiotics: are mixtures more effective than single strains?, Eur. J. Nutr, 50, pp. 1-17, (2011); Chen M.-Y., Qiu Z.-W., Tang H.-M., Zhuang K.-H., Cai Q.-Q., Chen X.-L., Et al., Efficacy and safety of bifid triple viable plus aminosalicylic acid for the treatment of ulcerative colitis: a systematic review and meta-analysis, Medicine, 98, (2019); Choi Y.-D., Sung T.-S., Kim H.-J., La J.-H., Kim T.-W., Yang I.-S., Increased 5-hydroxytryptamine mediates post-inflammatory visceral hypersensitivity via the 5-hydroxytryptamine 3 receptor in rats, Dig. Dis. Sci, 53, pp. 2909-2916, (2008); Choung R.S., Locke G.R., Epidemiology of IBS, Gastroenterol. Clin. N. Am, 40, pp. 1-10, (2011); Cibert-Goton V., Lam C., Lingaya M., Falcone Y., Wood J.N., Bulmer D.C., Et al., Pain severity correlates with biopsy-mediated colonic afferent activation but not psychological scores in patients with IBS-D, Clin. Transl. Gastroenterol, 12, (2021); Compare D., Rocco A., Coccoli P., Angrisani D., Sgamato C., Iovine B., Et al., Lactobacillus casei DG and its postbiotic reduce the inflammatory mucosal response: an ex-vivo organ culture model of post-infectious irritable bowel syndrome, BMC Gastroenterol, 17, (2017); Espley R.V., Butts C.A., Laing W.A., Martell S., Smith H., McGhie T.K., Et al., Dietary flavonoids from modified apple reduce inflammation markers and modulate gut microbiota in mice, J. Nutr, 144, pp. 146-154, (2014); Fan X., Lu M., Ren J., The effect of Chang-Kang-Fang formula on SERT and 5-HT3 receptors in the intestinal tissues of IBS-D rats, Acta Chin. Med. Pharmacol, 47, pp. 12-18, (2019); Flores-Ramos M., Moreno J., Heinze G., Aguilera-Perez R., Pellicer Graham F., Gonadal hormone levels and platelet tryptophan and serotonin concentrations in perimenopausal women with or without depressive symptoms, Gynecol. Endocrinol, 30, pp. 232-235, (2014); Foley S., Garsed K., Singh G., Duroudier N.P., Swan C., Hall I.P., Et al., Impaired uptake of serotonin by platelets from patients with irritable bowel syndrome correlates with duodenal immune activation, Gastroenterology, 140, pp. 1434-1443.e1, (2011); Gao J., Xiong T., Grabauskas G., Owyang C., Mucosal serotonin reuptake transporter (SERT) expression in IBS is modulated by gut microbiota via mast cell–prostaglandin E2, Gastroenterology, 162, pp. 1962-1974.e6, (2022); Geng Q., Yu Z., Shu-Kun, Serotonin transporter and cholecystokinin in diarrhea-predominant irritable bowel syndrome: associations with abdominal pain, visceral hypersensitivity and psychological performance, World J. Clin. Cases, 8, pp. 1632-1641, (2020); Ghoshal U.C., Srivastava D., Irritable bowel syndrome and small intestinal bacterial overgrowth: meaningful association or unnecessary hype, World J. Gastroenterol, 20, pp. 2482-2491, (2014); Hou Q., Huang Y., Zhang C., Zhu S., Li P., Chen X., Et al., MicroRNA-200a targets cannabinoid receptor 1 and serotonin transporter to increase visceral hyperalgesia in diarrhea-predominant irritable bowel syndrome rats, J. Neurogastroenterol. Motil, 24, pp. 656-668, (2018); Hou Q., Huang Y., Zhu S., Li P., Chen X., Hou Z., Et al., MiR-144 increases intestinal permeability in ibs-d rats by targeting OCLN and ZO1, Cell. Physiol. Biochem, 44, pp. 2256-2268, (2017); Houghton L.A., Atkinson W., Whitaker R.P., Whorwell P.J., Rimmer M.J., Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome, Gut, 52, pp. 663-670, (2003); Houghton L.A., Brown H., Atkinson W., Morris J., Fell C., Whorwell P.J., Et al., 5-hydroxytryptamine signalling in irritable bowel syndrome with diarrhoea: effects of gender and menstrual status, Aliment. Pharmacol. Ther, 30, pp. 919-929, (2009); Ishaque S.M., Khosruzzaman S.M., Ahmed D.S., Sah M.P., A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult(R)) in the management of diarrhea-predominant irritable bowel syndrome, BMC Gastroenterol, 18, (2018); Jiang X., Yang S., Zhou X., Zhang Y., Effects of mesalazine combined with bifid triple viable on intestinal flora, immunoglobulin and levels of cal, MMP-9, and MPO in feces of patients with ulcerative colitis, Eur. Rev. Med. Pharmacol. Sci, 24, pp. 935-942, (2020); Jie R., Xinyu F., Zhiwei F., Sheng J., Min L., Effect of Changkang formula on MC in rats with IBS-D, Information on Traditional Chinese Medicine, 37, (2020); Ko S.J., Ryu B., Kim J., Hong B.G., Park J.W., Effect of herbal extract granules combined with probiotic mixture on irritable bowel syndrome with diarrhea study protocol for a randomized controlled trial, Trials, 12, (2011); Koloski N.A., Talley N.J., Huskic S.S., Boyce P.M., Predictors of conventional and alternative health care seeking for irritable bowel syndrome and functional dyspepsia, Aliment. Pharmacol. Ther, 17, pp. 841-851, (2003); Kruijer W., Schubert D., Verma I.M., Induction of the proto-oncogene fos by nerve growth factor, Proc. Natl. Acad. Sci. U. S. A, 82, pp. 7330-7334, (1985); Kwak D.S., Jun D.W., Seo J.G., Chung W.S., Park S.-E., Lee K.N., Et al., Short-term probiotic therapy alleviates small intestinal bacterial overgrowth, but does not improve intestinal permeability in chronic liver disease, Eur. J. Gastroenterol. Hepatol, 26, pp. 1353-1359, (2014); Lacy B.E., Chey W.D., Cash B.D., Lembo A.J., Dove L.S., Covington P.S., Eluxadoline efficacy in IBS-D patients who report prior loperamide use, Am. J. Gastroenterol, 112, pp. 924-932, (2017); Lacy B.E., Harris L.A., Chang L., Lucak S., Gutman C., Dove L.S., Et al., Impact of patient and disease characteristics on the efficacy and safety of eluxadoline for IBS-D: a subgroup analysis of phase III trials, Ther. Adv. Gastroenterol, 12, (2019); Lewis S.J., Heaton K.W., Stool form scale as a useful guide to intestinal transit time, Scand. J. Gastroenterol, 32, pp. 920-924, (1997); Li J., Cui H., Cai Y., Lin J., Song X., Zhou Z., Et al., Tong-Xie-Yao-Fang regulates 5-ht level in diarrhea predominant irritable bowel syndrome through gut microbiota modulation, Front. Pharmacol, 9, (2018); Li L., Cui H., Li T., Qi J., Chen H., Gao F., Et al., Synergistic effect of berberine-based chinese medicine assembled nanostructures on diarrhea-predominant irritable bowel syndrome in vivo, Front. Pharmacol, 11, (2020); Li X., Shen M., Effects of changkang prescription on SP and VIP in diarrheal irritable bowel syndrome rats, Chin. J. Exp. Tradit. Med. Formulae, 21, pp. 112-115, (2015); Liang S.-B., Liang C.-H., Yang S.-H., Li Y.-Q., Tian Z.-Y., Robinson N., Et al., Clinical effects and safety of compound glutamine entersoluble capsules for diarrhea-predominant irritable bowel syndrome: a systematic review and meta-analysis, Eur. J. Integr. Med, 32, (2019); Liang D., Longgui N., Guoqiang X., Efficacy of different probiotic protocols in irritable bowel syndrome: a network meta-analysis, Medicine, 98, (2019); Linsalata M., Riezzo G., Clemente C., D'Attoma B., Russo F., Noninvasive biomarkers of gut barrier function in patients suffering from diarrhea predominant-ibs: an update, Dis. Markers, 2020, pp. 2886268-2886212, (2020); Liu L.S., Shenoy M., Pasricha P.J., The analgesic effects of the GABAB receptor agonist, baclofen, in a rodent model of functional dyspepsia, Neurogastroenterol. Motil, 23, pp. 356-e161, (2011); Lu Z., Duan L., Liu Y., Leng Y., Wang K.J., A meta-analysis of the prevalence and risk factors of irritable bowel syndrome in Chinese community, Zhonghua Nei Ke Za Zhi, 53, pp. 969-975, (2014); Magzal F., Even C., Haimov I., Agmon M., Asraf K., Shochat T., Et al., Associations between fecal short-chain fatty acids and sleep continuity in older adults with insomnia symptoms, Sci. Rep, 11, (2021); Mao Q., Shi L., Wang Z.G., Luo Y.H., Wang Y.Y., Li X., Et al., Chemical profiles and pharmacological activities of Chang-Kang-Fang, a multi-herb Chinese medicinal formula, for treating irritable bowel syndrome, J. Ethnopharmacol, 201, pp. 123-135, (2017); Marciani L., Wright J., Foley S., Hoad C.L., Totman J.J., Bush D., Et al., Effects of a 5-HT(3) antagonist, ondansetron, on fasting and postprandial small bowel water content assessed by magnetic resonance imaging, Aliment. Pharmacol. Ther, 32, pp. 655-663, (2010); Mayer E.A., Nance K., Chen S., The Gut–Brain Axis, Annu. Rev. Med, 73, pp. 439-453, (2022); Min Y.W., Rhee P.-L., The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D), Ther. Adv. Gastroenterol, 8, pp. 136-142, (2015); Moore N.A., Sargent B.J., Manning D.D., Guzzo P.R., Partial agonism of 5-HT3 receptors: a novel approach to the symptomatic treatment of IBS-D, ACS Chem. Neurosci, 4, pp. 43-47, (2013); Nebot-Vivinus M., Harkat C., Bzioueche H., Cartier C., Plichon-Dainese R., Moussa L., Et al., Multispecies probiotic protects gut barrier function in experimental models, World J. Gastroenterol, 20, pp. 6832-6843, (2014); Pham V.T., Calatayud M., Rotsaert C., Seifert N., Richard N., Van den Abbeele P., Et al., Antioxidant vitamins and prebiotic Fos and Xos differentially shift microbiota composition and function and improve intestinal epithelial barrier in vitro, Nutrients, 13, (2021); Preston K., Krumian R., Hattner J., de Montigny D., Stewart M., Gaddam S., Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2 improve quality-of-life and IBS symptoms: a double-blind, randomised, placebo-controlled study, Benef Microbes, 9, pp. 697-706, (2018); Roberts A., Grafton G., Powell A.D., Brock K., Chen C., Xie D., Et al., CSTI-300 (SMP-100); a novel 5-HT3 receptor partial agonist with potential to treat patients with irritable bowel syndrome or carcinoid syndrome, J. Pharmacol. Exp. Ther, 373, pp. 122-134, (2020); Sabo C.M., Dumitrascu D.L., Microbiota and the irritable bowel syndrome, Minerva Gastroenterol, 67, pp. 377-384, (2021); Sadler R., Cramer J.V., Heindl S., Kostidis S., Betz D., Zuurbier K.R., Et al., Short-chain fatty acids improve poststroke recovery via immunological mechanisms, J. Neurosci, 40, pp. 1162-1173, (2020); Sanchez B., Delgado S., Blanco-Miguez A., Lourenco A., Gueimonde M., Margolles A., Probiotics, gut microbiota, and their influence on host health and disease, Mol. Nutr. Food Res, 61, (2017); Schnadower D., Finkelstein Y., Freedman S.B., Ondansetron and probiotics in the management of pediatric acute gastroenteritis in developed countries, Curr. Opin. Gastroenterol, 31, pp. 1-6, (2015); Skrzydlo-Radomanska B., Prozorow-Krol B., Cichoz-Lach H., Majsiak E., Bierla J.B., Kanarek E., Et al., The effectiveness and safety of multi-strain probiotic preparation in patients with diarrhea-predominant irritable bowel syndrome: a randomized controlled study, Nutrients, 13, (2021); Spiller R., Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease, Neurogastroenterol. Motil, 19, pp. 25-31, (2007); Su T., Liu R., Lee A., Long Y., Du L., Lai S., Et al., Altered intestinal microbiota with increased abundance of prevotella is associated with high risk of diarrhea-predominant irritable bowel syndrome, Gastroenterol. Res. Pract, 2018, (2018); Sun J., Wu X., Meng Y., Cheng J., Ning H., Peng Y., Et al., Electro-acupuncture decreases 5-HT, CGRP and increases NPY in the brain-gut axis in two rat models of Diarrhea-predominant irritable bowel syndrome(D-IBS), BMC Complement. Altern. Med, 15, (2015); Tang X.-D., Lu B., Li Z.-H., Wei W., Meng L.-N., Li B.-S., Et al., Therapeutic effect of chang’an i recipe on irritable bowel syndrome with diarrhea: a multicenter randomized double-blind placebo-controlled clinical trial, Chin. J. Integr. Med, 24, pp. 645-652, (2018); Tarrerias A.L., Costil V., Vicari F., Letard J.C., Adenis-Lamarre P., Aisene A., Et al., The effect of inactivated Lactobacillus LB fermented culture medium on symptom severity: observational investigation in 297 patients with diarrhea-predominant irritable bowel syndrome, Dig. Dis, 29, pp. 588-591, (2011); Vacca M., Celano G., Calabrese F.M., Portincasa P., Gobbetti M., De Angelis M., The controversial role of human gut lachnospiraceae, Microorganisms, 8, (2020); van Tilburg M.A., Palsson O.S., Levy R.L., Feld A.D., Turner M.J., Drossman D.A., Et al., Complementary and alternative medicine use and cost in functional bowel disorders: a six month prospective study in a large HMO, BMC Complement. Altern. Med, 8, (2008); Wu K.-Q., Sun W.-J., Li N., Chen Y.-Q., Wei Y.-L., Chen D.-F., Small intestinal bacterial overgrowth is associated with Diarrhea-predominant irritable bowel syndrome by increasing mainly Prevotella abundance, Scand. J. Gastroenterol, 54, pp. 1419-1425, (2019); Wu H., Zhan K., Rao K., Zheng H., Qin S., Tang X., Et al., Comparison of five diarrhea-predominant irritable bowel syndrome (IBS-D) rat models in the brain-gut-microbiota axis, Biomed. Pharmacother, 149, (2022); Xie S.-Z., Liu B., Ye H.-Y., Li Q.-M., Pan L.-H., Zha X.-Q., Et al., Dendrobium huoshanense polysaccharide regionally regulates intestinal mucosal barrier function and intestinal microbiota in mice, Carbohydr. Polym, 206, pp. 149-162, (2019); Xu X.J., Liu L., Yao S.K., Nerve growth factor and diarrhea-predominant irritable bowel syndrome (IBS-D): a potential therapeutic target?, J Zhejiang Univ Sci B, 17, pp. 1-9, (2016); Yu F.-Y., Huang S.-G., Zhang H.-Y., Ye H., Chi H.-G., Zou Y., Et al., Comparison of 5-hydroxytryptophan signaling pathway characteristics in diarrhea-predominant irritable bowel syndrome and ulcerative colitis, World J. Gastroenterol, 22, pp. 3451-3459, (2016); Zaleski A., Banaszkiewicz A., Walkowiak J., Butyric acid in irritable bowel syndrome, Prz. Gastroenterol, 6, pp. 350-353, (2013); Zhang X., Zhao Y., Zhang M., Pang X., Xu J., Kang C., Et al., Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats, PLoS One, 7, (2012); Zhao J., Observation and research on the effect of probiotics in the treatment of ulcerative colitis, China Pract Med, 13, pp. 84-85, (2018); Zheng Y., Ching J., Cheng C.W., Lam W.C., Chan K.L., Zhang X., Et al., Efficacy and safety of Chinese medicine JCM-16021 for diarrhea-predominant irritable bowel syndrome: study protocol for a multi-center, randomized, double-blind, placebo controlled clinical trial, Chin. Med, 16, (2021); Zheng Y., Yu T., Tang Y., Xiong W., Shen X., Jiang L., Et al., Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials, PLoS One, 12, (2017); Zhou Y., Han S., He Y., Clinical effects and safety of tongxieyaofang on diarrhea predominant irritable bowel syndrome: a meta-analysis of randomized trails, Evid. Based Complement. Alternat. Med, 2019, pp. 4893876-4893811, (2019); Zhu X., Liu Z., Niu W., Wang Y., Zhang A., Qu H., Et al., Effects of Electroacupuncture at St25 and Bl25 in a Sennae-induced rat model of diarrhoea-predominant irritable bowel syndrome, Acupunct. Med, 35, pp. 216-223, (2017)","T. Li; Department of Central laboratory, Nanjing Lishui District Hospital of Traditional Chinese Medicine, Nanjing, China; email: littian26@163.com; M. Lu; School of Third Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing, China; email: lumin@jsatcm.com","","Frontiers Media SA","","","","","","1664302X","","","","English","Front. Microbiol.","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85164749336"

"Marchix J.; Quénéhervé L.; Bordron P.; Aubert P.; Durand T.; Oullier T.; Blondeau C.; Ait Abdellah S.; Bruley des Varannes S.; Chaffron S.; Coron E.; Neunlist M.","Marchix, Justine (54929796800); Quénéhervé, Lucille (55342915000); Bordron, Philippe (37078852500); Aubert, Philippe (56652397900); Durand, Tony (56059320200); Oullier, Thibauld (54420888000); Blondeau, Claude (55607676300); Ait Abdellah, Samira (57190169470); Bruley des Varannes, Stanislas (57193752746); Chaffron, Samuel (15759198300); Coron, Emmanuel (22134096900); Neunlist, Michel (6701416352)","54929796800; 55342915000; 37078852500; 56652397900; 56059320200; 54420888000; 55607676300; 57190169470; 57193752746; 15759198300; 22134096900; 6701416352","Could the Microbiota Be a Predictive Factor for the Clinical Response to Probiotic Supplementation in IBS-D? A Cohort Study","2023","Microorganisms","11","2","277","","","","3","10.3390/microorganisms11020277","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85149025268&doi=10.3390%2fmicroorganisms11020277&partnerID=40&md5=3889aa29d40a282fa8b43b48c4319c21","Nantes Université, CHU Nantes, INSERM, The Enteric Nervous System in Gut and Brain Diseases, IMAD, Nantes, F-44000, France; Gastroenterology Department, University Hospital of Brest, Brest, 29200, France; PiLeJe Laboratoire, 31-35 rue de la Fédération, Paris, 75015, France; Nantes Université, CHU Nantes, INSERM, Département de Gastroentérologie, CIC 1413, IMAD, Nantes, F-44000, France; Nantes Université, École Centrale Nantes, CNRS, LS2N, UMR 6004, Nantes, F-44000, France; Gastroenterology and Hepatology Department, University Hospital of Geneva (HUG), Geneva, 1211, Switzerland","Marchix J., Nantes Université, CHU Nantes, INSERM, The Enteric Nervous System in Gut and Brain Diseases, IMAD, Nantes, F-44000, France; Quénéhervé L., Nantes Université, CHU Nantes, INSERM, The Enteric Nervous System in Gut and Brain Diseases, IMAD, Nantes, F-44000, France, Gastroenterology Department, University Hospital of Brest, Brest, 29200, France; Bordron P., Nantes Université, CHU Nantes, INSERM, The Enteric Nervous System in Gut and Brain Diseases, IMAD, Nantes, F-44000, France; Aubert P., Nantes Université, CHU Nantes, INSERM, The Enteric Nervous System in Gut and Brain Diseases, IMAD, Nantes, F-44000, France; Durand T., Nantes Université, CHU Nantes, INSERM, The Enteric Nervous System in Gut and Brain Diseases, IMAD, Nantes, F-44000, France; Oullier T., Nantes Université, CHU Nantes, INSERM, The Enteric Nervous System in Gut and Brain Diseases, IMAD, Nantes, F-44000, France; Blondeau C., PiLeJe Laboratoire, 31-35 rue de la Fédération, Paris, 75015, France; Ait Abdellah S., PiLeJe Laboratoire, 31-35 rue de la Fédération, Paris, 75015, France; Bruley des Varannes S., Nantes Université, CHU Nantes, INSERM, The Enteric Nervous System in Gut and Brain Diseases, IMAD, Nantes, F-44000, France, Nantes Université, CHU Nantes, INSERM, Département de Gastroentérologie, CIC 1413, IMAD, Nantes, F-44000, France; Chaffron S., Nantes Université, École Centrale Nantes, CNRS, LS2N, UMR 6004, Nantes, F-44000, France; Coron E., Nantes Université, CHU Nantes, INSERM, The Enteric Nervous System in Gut and Brain Diseases, IMAD, Nantes, F-44000, France, Nantes Université, CHU Nantes, INSERM, Département de Gastroentérologie, CIC 1413, IMAD, Nantes, F-44000, France, Gastroenterology and Hepatology Department, University Hospital of Geneva (HUG), Geneva, 1211, Switzerland; Neunlist M., Nantes Université, CHU Nantes, INSERM, The Enteric Nervous System in Gut and Brain Diseases, IMAD, Nantes, F-44000, France","Background: Increasing evidence suggests the beneficial effects of probiotics in irritable bowel syndrome (IBS), but little is known about how they can impact the gut microbiota. Our objective was to evaluate the effects of a multistrain probiotic on IBS symptoms, gut permeability and gut microbiota in patients with diarrhoea-predominant IBS (IBS-D). Methods: Adults with IBS-D were enrolled in an open-label trial to receive a multistrain probiotic for 4 weeks. Abdominal pain, stool frequency, quality of life, gut permeability, and the luminal and adherent microbiota from colonic biopsies were evaluated before and after supplementation. Results: Probiotics significantly improved symptoms and quality of life, despite having no impact on permeability in the global population. In the population stratified by the response, the diarrhoea responders displayed reduced colonic permeability after supplementation. The luminal and adherent microbiota were specifically altered depending on the patients’ clinical responses regarding pain and diarrhoea. Interestingly, we identified a microbial signature in IBS-D patients that could predict a response or lack of response to supplementation. Conclusions: The multistrain probiotic improved the symptoms of IBS-D patients and induced distinct effects on the gut microbiota according to the patient’s clinical response and initial microbiota composition. Our study further supports the need to develop individualised probiotic-based approaches regarding IBS. © 2023 by the authors.","diarrhoea; intestinal permeability; irritable bowel syndrome; microbiota; probiotics","","","","","","Conseil Régional des Pays de la Loire, (ANR-19-CE14-0024)","This study was funded by PiLeJe Laboratoire and supported in part by the Région Pays de la Loire (MibioGate) and ANR Microbiautism (ANR-19-CE14-0024).","Ducrotte P., Sawant P., Jayanthi V., Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome, World J. Gastroenterol, 18, pp. 4012-4018, (2012); Sperber A.D., Bangdiwala S.I., Drossman D.A., Ghoshal U.C., Simren M., Tack J., Whitehead W.E., Dumitrascu D.L., Fang X., Fukudo S., Et al., Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study, Gastroenterology, 160, pp. 99-114.e3, (2021); Carroll I.M., Ringel-Kulka T., Keku T.O., Chang Y.-H., Packey C.D., Sartor R.B., Ringel Y., Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome, Am. J. Physiol. Gastrointest. Liver Physiol, 301, pp. G799-G807, (2011); Carroll I.M., Ringel-Kulka T., Siddle J.P., Ringel Y., Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome, Neurogastroenterol. Motil, 24, (2012); Pozuelo M., Panda S., Santiago A., Mendez S., Accarino A., Santos J., Guarner F., Azpiroz F., Manichanh C., Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel Syndrome, Sci. Rep, 5, (2015); Liu H.-N., Wu H., Chen Y.-Z., Chen Y.-J., Shen X.-Z., Liu T.-T., Altered molecular signature of intestinal microbiota in irritable bowel syndrome patients compared with healthy controls: A systematic review and meta-analysis, Dig. Liver Dis, 49, pp. 331-337, (2017); Lee B.J., Bak Y.-T., Irritable bowel syndrome, gut microbiota and probiotics, J. Neurogastroenterol. Motil, 17, pp. 252-266, (2011); Alard J., Peucelle V., Boutillier D., Breton J., Kuylle S., Pot B., Holowacz S., Grangette C., New probiotic strains for inflammatory bowel disease management identified by combining in vitro and in vivo approaches, Benef. Microbes, 9, pp. 317-331, (2018); Carco C., Young W., Gearry R.B., Talley N.J., McNabb W.C., Roy N.C., Increasing Evidence That Irritable Bowel Syndrome and Functional Gastrointestinal Disorders Have a Microbial Pathogenesis, Front. Cell. Infect. Microbiol, 10, (2020); Barbara G., Zecchi L., Barbaro R., Cremon C., Bellacosa L., Marcellini M., de Giorgio R., Corinaldesi R., Stanghellini V., Mucosal Permeability and Immune Activation as Potential Therapeutic Targets of Probiotics in Irritable Bowel Syndrome, J. Clin. Gastroenterol, 46, pp. S52-S55, (2012); Ishaque S.M., Khosruzzaman S.M., Ahmed D.S., Sah M.P., A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult<sup>®</sup>) in the management of diarrhea-predominant irritable bowel syndrome, BMC Gastroenterol, 18, (2018); Tiequn B., Guanqun C., Shuo Z., Therapeutic effects of Lactobacillus in treating irritable bowel syndrome: A meta-analysis, Intern Med, 54, pp. 243-249, (2015); Li B., Liang L., Deng H., Guo J., Shu H., Zhang L., Efficacy and Safety of Probiotics in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis, Front. Pharmacol, 11, (2020); Sun J.-R., Kong C.-F., Qu X.-K., Deng C., Lou Y.-N., Jia L.-Q., Efficacy and safety of probiotics in irritable bowel syndrome: A systematic review and meta-analysis, Saudi J. Gastroenterol, 26, pp. 66-77, (2020); Zhang T., Zhang C., Zhang J., Sun F., Duan L., Efficacy of Probiotics for Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis, Front. Cell. Infect. Microbiol, 12, (2022); Hungin A.P., Mulligan C., Pot B., Whorwell P., Agreus L., Fracasso P., Lionis C., Mendive J., Philippart de Foy J.M., Rubin G., Et al., Systematic review: Probiotics in the management of lower gastrointestinal symptoms in clinical practice—An evidence-based international guide, Aliment. Pharmacol. Ther, 38, pp. 864-886, (2013); Murakami K., Habukawa C., Nobuta Y., Moriguchi N., Takemura T., The effect of Lactobacillus brevis KB290 against irritable bowel syndrome: A placebo-controlled double-blind crossover trial, Biopsychosoc. Med, 6, (2012); Shin S.P., Choi Y.M., Kim W.H., Hong S.P., Park J.-M., Kim J., Kwon O., Lee E.H., Hahm K.B., A double blind, placebo-controlled, randomized clinical trial that breast milk derived-Lactobacillus gasseri BNR17 mitigated diarrhea-dominant irritable bowel syndrome, J. Clin. Biochem. Nutr, 62, pp. 179-186, (2018); Lewis E.D., Antony J.M., Crowley D.C., Piano A., Bhardwaj R., Tompkins T.A., Evans M., Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in Alleviating Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled Study, Nutrients, 12, (2020); Martoni C.J., Srivastava S., Leyer G.J., Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial, Nutrients, 12, (2020); Clinical Decision Support Tool: IBS Treatment, Gastroenterology, 163, (2022); Tap J., Derrien M., Tornblom H., Brazeilles R., Cools-Portier S., Dore J., Storsrud S., Le Neve B., Ohman L., Simren M., Identification of an Intestinal Microbiota Signature Associated with Severity of Irritable Bowel Syndrome, Gastroenterology, 152, pp. 111-123.e8, (2017); Nebot-Vivinus M., Harkat C., Bzioueche H., Cartier C., Plichon-Dainese R., Moussa L., Eutamene H., Pishvaie D., Holowacz S., Seyrig C., Et al., Multispecies probiotic protects gut barrier function in experimental models, World J. Gastroenterol, 20, pp. 6832-6843, (2014); Slim K., Bousquet J., Kwiatkowski F., Lescure G., Pezet D., Chipponi J., Première validation de la version française de l’index de qualité de vie pour les maladies digestives (GIQLI), Gastroenterol. Clin. Biol, 23, pp. 25-31, (1999); Pimentel M., Cash B.D., Lembo A., Wolf R.A., Israel R.J., Schoenfeld P., Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity, Dig. Dis. Sci, 62, pp. 2455-2463, (2017); Sequeira I.R., Lentle R.G., Kruger M.C., Hurst R.D., Hogan S.P., Standardising the Lactulose Mannitol Test of Gut Permeability to Minimise Error and Promote Comparability, PLoS ONE, 9, (2014); Meurette G., Blanchard C., Duchalais-Dassonneville E., Coquenlorge S., Aubert P., Wong M., Lehur P.-A., Neunlist M., Sacral nerve stimulation enhances epithelial barrier of the rectum: Results from a porcine model, Neurogastroenterol. Motil, 24, (2012); Queneherve L., David G., Bourreille A., Hardouin J.B., Rahmi G., Neunlist M., Bregeon J., Coron E., Quantitative assessment of mucosal architecture using computer-based analysis of confocal laser endomicroscopy in inflammatory bowel diseases, Gastrointest. Endosc, 89, pp. 626-636, (2019); Bolyen E., Rideout J.R., Dillon M.R., Bokulich N.A., Abnet C.C., Al-Ghalith G.A., Alexander H., Alm E.J., Arumugam M., Asnicar F., Et al., Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2, Nat. Biotechnol, 37, pp. 852-857, (2019); Love M.I., Huber W., Anders S., Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2, Genome Biol, 15, (2014); Sisson G., Ayis S., Sherwood R.A., Bjarnason I., Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome—A 12 week double-blind study, Aliment. Pharmacol. Ther, 40, pp. 51-62, (2014); Skrzydlo-Radomanska B., Prozorow-Krol B., Cichoz-Lach H., Majsiak E., Bierla J.B., Kanarek E., Sowinska A., Cukrowska B., The Effectiveness and Safety of Multi-Strain Probiotic Preparation in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Controlled Study, Nutrients, 13, (2021); Hanning N., Edwinson A.L., Ceuleers H., Peters S.A., de Man J.G., Hassett L.C., de Winter B.Y., Grover M., Intestinal barrier dysfunction in irritable bowel syndrome: A systematic review, Ther. Adv. Gastroenterol, 14, (2021); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Gecse K., Roka R., Sera T., Rosztoczy A., Annahazi A., Izbeki F., Nagy F., Molnar T., Szepes Z., Pavics L., Et al., Leaky gut in patients with diarrhea-predominant irritable bowel syndrome and inactive ulcerative colitis, Digestion, 85, pp. 40-46, (2012); Boonma P., Shapiro J.M., Hollister E.B., Badu S., Wu Q., Weidler E.M., Abraham B.P., Devaraj S., Luna R.A., Versalovic J., Et al., Probiotic VSL#3 Treatment Reduces Colonic Permeability and Abdominal Pain Symptoms in Patients with Irritable Bowel Syndrome, Front. Pain Res, 2, (2021); Zeng J., Li Y.-Q., Zuo X.-L., Zhen Y.-B., Yang J., Liu C.-H., Clinical trial: Effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome, Aliment. Pharmacol. Ther, 28, pp. 994-1002, (2008); Caviglia G.P., Tucci A., Pellicano R., Fagoonee S., Rosso C., Abate M.L., Olivero A., Armandi A., Vanni E., Saracco G.M., Et al., Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum ES1 for 8 or 12 Weeks: A Preliminary Report, J. Clin. Med, 9, (2020); Ait Abdellah S., Gal C., Laterza L., Velenza V., Settanni C.R., Napoli M., Schiavoni E., Mora V., Petito V., Gasbarrini A., Effect of a multistrain probiotic on leaky gut in patients with diarrhea-predominant irritable bowel syndrome (IBS-D): A pilot study, Dig. Dis, (2022); Rajilic-Stojanovic M., Biagi E., Heilig H.G.H.J., Kajander K., Kekkonen R.A., Tims S., de Vos W.M., Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome, Gastroenterology, 141, pp. 1792-1801, (2011); Hod K., Dekel R., Aviv Cohen N., Sperber A., Ron Y., Boaz M., Berliner S., Maharshak N., The effect of a multispecies probiotic on microbiota composition in a clinical trial of patients with diarrhea-predominant irritable bowel syndrome, Neurogastroenterol. Motil, 30, (2018); Michail S., Kenche H., Gut microbiota is not modified by Randomized, Double-blind, Placebo-controlled Trial of VSL#3 in Diarrhea-predominant Irritable Bowel Syndrome, Probiotics Antimicrob. Proteins, 3, pp. 1-7, (2011); Shin S.Y., Park S., Moon J.M., Kim K., Kim J.W., Chun J., Lee T.H., Choi C.H., Compositional Changes in the Gut Microbiota of Responders and Non-responders to Probiotic Treatment Among Patients with Diarrhea-predominant Irritable Bowel Syndrome: A Post Hoc Analysis of a Randomized Clinical Trial, J. Neurogastroenterol. Motil, 28, pp. 642-654, (2022); Wang T., Teng K., Liu Y., Shi W., Zhang J., Dong E., Zhang X., Tao Y., Zhong J., Lactobacillus plantarum PFM 105 Promotes Intestinal Development Through Modulation of Gut Microbiota in Weaning Piglets, Front. Microbiol, 10, (2019); Deleu S., Machiels K., Raes J., Verbeke K., Vermeire S., Short chain fatty acids and its producing organisms: An overlooked therapy for IBD?, EBioMedicine, 66, (2021); Mazzawi T., Hausken T., Hov J.R., Valeur J., Sangnes D.A., El-Salhy M., Gilja O.H., Hatlebakk J.G., Lied G.A., Clinical response to fecal microbiota transplantation in patients with diarrhea-predominant irritable bowel syndrome is associated with normalization of fecal microbiota composition and short-chain fatty acid levels, Scand. J. Gastroenterol, 54, pp. 690-699, (2019); El-Salhy M., Mazzawi T., Hausken T., Hatlebakk J.G., Irritable bowel syndrome patients who are not likely to respond to fecal microbiota transplantation, Neurogastroenterol. Motil, 34, (2022); Pittayanon R., Lau J.T., Yuan Y., Leontiadis G.I., Tse F., Surette M., Moayyedi P., Gut Microbiota in Patients with Irritable Bowel Syndrome-A Systematic Review, Gastroenterology, 157, pp. 97-108, (2019); Janda J.M., Abbott S.L., The Genus Hafnia: From Soup to Nuts, Clin. Microbiol. Rev, 19, pp. 12-28, (2006)","M. Neunlist; Nantes Université, CHU Nantes, INSERM, The Enteric Nervous System in Gut and Brain Diseases, IMAD, Nantes, F-44000, France; email: michel.neunlist@univ-nantes.fr","","MDPI","","","","","","20762607","","","","English","Microorg.","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85149025268"

"Nozu T.; Miyagishi S.; Ishioh M.; Takakusaki K.; Okumura T.","Nozu, Tsukasa (12765917900); Miyagishi, Saori (56538237900); Ishioh, Masatomo (57202513969); Takakusaki, Kaoru (7004150214); Okumura, Toshikatsu (7202327796)","12765917900; 56538237900; 57202513969; 7004150214; 7202327796","Imeglimin prevents visceral hypersensitivity and colonic hyperpermeability in irritable bowel syndrome rat model","2023","Journal of Pharmacological Sciences","153","1","","26","30","4","1","10.1016/j.jphs.2023.07.002","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85164402833&doi=10.1016%2fj.jphs.2023.07.002&partnerID=40&md5=6394f66b7e08ca7cf557cf58404632da","Department of Regional Medicine and Education, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Center for Medical Education, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Division of Neuroscience, Department of Physiology, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Department of General Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan","Nozu T., Department of Regional Medicine and Education, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan, Center for Medical Education, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan, Department of General Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Miyagishi S., Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Ishioh M., Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Takakusaki K., Division of Neuroscience, Department of Physiology, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Okumura T., Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan, Department of General Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan","Visceral hypersensitivity and leaky gut, which are mediated via corticotropin-releasing factor (CRF) and Toll-like receptor 4 are key pathophysiology of irritable bowel syndrome (IBS). Metformin was reported to improve these gastrointestinal (GI) changes. In this study, we attempted to determine the effects of imeglimin, which was synthesized from metformin on GI function in IBS rat models. Imeglimin blocked lipopolysaccharide- or CRF-induced visceral hypersensitivity and colonic hyperpermeability. These effects were prevented by compound C or naloxone. These results suggest that imeglimin may be effective for the treatment of IBS by improved visceral sensation and colonic barrier via AMPK and opioid receptor. © 2023 The Authors","Colonic permeability; Imeglimin; Visceral sensation","Animals; Colon; Corticotropin-Releasing Hormone; Irritable Bowel Syndrome; Metformin; Rats; 2 chloro 5 nitrobenzanilide; corticotropin releasing factor; dopamine 2 receptor; dorsomorphin; hydroxymethylglutaryl coenzyme A reductase kinase; imeglimin; lipopolysaccharide; metformin; mitochondrial DNA; mitochondrial permeability transition pore; naloxone; nitric oxide; opiate receptor; peroxisome proliferator activated receptor gamma; pioglitazone; reactive oxygen metabolite; toll like receptor 4; twymeeg; corticotropin releasing factor; imeglimin; metformin; adipocyte; antidiabetic activity; Article; cardiac muscle cell; colonic hyperpermeability; cytokine production; endothelium cell; enzyme inhibition; human; in vivo study; intestine mucosa permeability; irritable colon; limit of quantitation; mitochondrion; muscle cell; nonhuman; oxidative stress; sensation; signal transduction; visceral hyperalgesia; visceral sensation; animal; colon; rat","","corticotropin releasing factor, 9015-71-8, 178359-01-8, 79804-71-0, 86297-72-5, 86784-80-7; dorsomorphin, 1219168-18-9, 866405-64-3; hydroxymethylglutaryl coenzyme A reductase kinase, 172522-01-9, 72060-32-3; imeglimin, 775351-65-0; metformin, 1115-70-4, 657-24-9; naloxone, 357-08-4, 465-65-6; nitric oxide, 10102-43-9; pioglitazone, 105355-27-9, 111025-46-8, 1266523-09-4, 105390-47-4, 112529-15-4; toll like receptor 4, 203811-83-0; Corticotropin-Releasing Hormone, ; imeglimin, ; Metformin, ","twymeeg, Sumitomo, Japan","Sumitomo, Japan","Akiyama Life Science Foundation; Japan Society for the Promotion of Science, KAKEN, (22K08790, 26120012, 26460955)","This work was partially supported by the Japan Society for the Promotion of Science KAKENHI , Grant-in-Aid for Scientific Research (C) [ 22K08790 (TN) and 26460955 (TO)], Scientific Research on Innovative Areas [ 26120012 (KT)], and the research grant from the Akiyama Life Science Foundation (TN).","Nozu T., Miyagishi S., Nozu R., Et al., Altered colonic sensory and barrier functions by CRF: roles of TLR4 and IL-1, J Endocrinol, 239, 2, pp. 241-252, (2018); Nozu T., Miyagishi S., Kumei S., Et al., Metformin inhibits visceral allodynia and increased gut permeability induced by stress in rats, J Gastroenterol Hepatol, 34, 1, pp. 186-193, (2019); Nozu T., Miyagishi S., Ishioh M., Et al., Imipramine improves visceral sensation and gut barrier in rat models of irritable bowel syndrome, Eur J Pharmacol, 887, (2020); Nozu T., Miyagishi S., Nozu R., Et al., Pioglitazone improves visceral sensation and colonic permeability in a rat model of irritable bowel syndrome, J Pharmacol Sci, 139, 2019, pp. 46-49, (2018); Fouqueray P., Leverve X., Fontaine E., Et al., Imeglimin - a new oral anti-diabetic that targets the three key defects of type 2 diabetes, J Diabetes Metabol, 2, 4, (2011); Yaribeygi H., Maleki M., Sathyapalan T., Et al., Molecular mechanisms by which imeglimin improves glucose homeostasis, J Diabetes Res, 2020, (2020); Yaribeygi H., Atkin S.L., Sahebkar A., Mitochondrial dysfunction in diabetes and the regulatory roles of antidiabetic agents on the mitochondrial function, J Cell Physiol, 234, 6, pp. 8402-8410, (2019); Yakes F.M., Van Houten B., Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress, Proc Natl Acad Sci USA, 94, 2, pp. 514-519, (1997); Kepp O., Galluzzi L., Kroemer G., Mitochondrial control of the NLRP3 inflammasome, Nat Immunol, 12, 3, pp. 199-200, (2011); Lee H.J., Oh Y.K., Rhee M., Et al., The role of STAT1/IRF-1 on synergistic ROS production and loss of mitochondrial transmembrane potential during hepatic cell death induced by LPS/d-GalN, J Mol Biol, 369, 4, pp. 967-984, (2007); Cao S., Zhang Q., Wang C., Et al., LPS challenge increased intestinal permeability, disrupted mitochondrial function and triggered mitophagy of piglets, Innate Immun, 24, 4, pp. 221-230, (2018); Barreto-Torres G., Parodi-Rullan R., Javadov S., The role of PPARalpha in metformin-induced attenuation of mitochondrial dysfunction in acute cardiac ischemia/reperfusion in rats, Int J Mol Sci, 13, 6, pp. 7694-7709, (2012); Li J., Wang Y., Wang Y., Et al., Pharmacological activation of AMPK prevents Drp1-mediated mitochondrial fission and alleviates endoplasmic reticulum stress-associated endothelial dysfunction, J Mol Cell Cardiol, 86, pp. 62-74, (2015); Martucci C., Franchi S., Lattuada D., Et al., Differential involvement of RelB in morphine-induced modulation of chemotaxis, NO, and cytokine production in murine macrophages and lymphocytes, J Leukoc Biol, 81, 1, pp. 344-354, (2007); Nozu T., Okumura T., Pathophysiological commonality between irritable bowel syndrome and metabolic syndrome: role of corticotropin-releasing factor-toll-like receptor 4-proinflammatory cytokine signaling, J. Neurogastroenterol. Motil., 28, 2, pp. 173-184, (2022)","T. Nozu; Department of Regional Medicine and Education, Asahikawa Medical University, Asahikawa, 2-1-1-1 Midorigaoka-Higashi, 078-8510, Japan; email: tnozu@sea.plala.or.jp","","Japanese Pharmacological Society","","","","","","13478613","","JPSTG","37524451","English","J. Pharmacol. Sci.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85164402833"

"Lu M.; Fan X.; Zheng Y.; Kong W.; Ji R.; Xie H.","Lu, Min (56553533900); Fan, Xinyu (57226534707); Zheng, Yuanyuan (57473427500); Kong, Weiqian (57473427600); Ji, Ruyi (57473427700); Xie, Hui (57473692400)","56553533900; 57226534707; 57473427500; 57473427600; 57473427700; 57473692400","Chang-Kang-Fang ameliorates irritable bowel syndrome with diarrhea in rat by regulating gut microbiota and improving intestinal barrier","2022","ScienceAsia","48","2","","151","158","7","0","10.2306/scienceasia1513-1874.2022.021","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85125600878&doi=10.2306%2fscienceasia1513-1874.2022.021&partnerID=40&md5=170967d06d2362f0e6e50d031b057d63","Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China; Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210023, China; Nanjing Lishui District Hospital of Traditional Chinese Medicine, Nanjing, 210023, China; Clinical College of Jiangsu Health Vocational College, Nanjing, 210023, China; Third Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, 210023, China","Lu M., Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210023, China; Fan X., Nanjing Lishui District Hospital of Traditional Chinese Medicine, Nanjing, 210023, China, Clinical College of Jiangsu Health Vocational College, Nanjing, 210023, China; Zheng Y., Third Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, 210023, China; Kong W., Third Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, 210023, China; Ji R., Third Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, 210023, China; Xie H., Third Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, 210023, China","Chang-Kang-Fang formula (CKF), a multi-herb traditional Chinese medicinal formula, has been clinically used for treatment of irritable bowel syndrome with diarrhea (IBS-D). Though we have reported the compounds of CKF and their therapeutic effect on IBS-D rats, the exact underlying mechanism is still not clear. The aim of this study was to clearly define the effect of CKF on IBS-D by regulating gut microbiota and promoting intestinal barrier. IBS-D rats were established by psychosocial stress (restraint) combined with the peripheral stimulation (senna leaf gavage) stress. The changes of body weight and the number of fecal pellets were investigated during the experiment. The effect on intestinal sensitivity was assessed based on the abdominal withdrawal reflex (AWR) scores and the intestinal permeability, the expression of zona occludens 1 (ZO-1), measured by immunohistochemistry. The composition of gut microbiota was detected through 16S rRNA. The administration of CKF significantly had therapeutic effects on IBS-D rats based on the decreased AWR scores and the increased number of pellets. However, the changes of body weight were not observed. In addition, CKF could up-regulate the expression of ZO-1 in the colon and rebalance the gut microbiota of IBS-D by increasing the abundance of Lactobacillus, Allobaculum, Roseburia, and Lachnospiraceae_NK4A136. CKF potentially alleviated IBS-D through regulating gut microbiota and improving the intestinal barrier function. © 2022 Science Society of Thailand under Royal Patronage. All rights reserved.","Diarrhea predominant irritable bowel syndrome; Gut microbiota; TCM","","","","","","Jiangsu Health Vocational College University, (JKC201958); Jiangsu Provincial ?; Major Science and Technology Project of Jiangsu Province Administration of Traditional Chinese Medicine, (WSN-040, ZD201708); Natural Science Foundation of Jiangsu Province, (BK20161608)","Funding text 1: Acknowledgements: This work was supported by Major Science and Technology Project of Jiangsu Province Administration of Traditional Chinese Medicine (ZD201708); the Jiangsu Provincial “six talent peaks” High talents the fourteenth batch (WSN-040); the Natural Science Foundation of Jiangsu Province (BK20161608); Jiangsu Health Vocational College University level scientific research projects(JKC201958).; Funding text 2: Acknowledgements: This work was supported by Major Science and Technology Project of Jiangsu Province Administration of Traditional Chinese Medicine (ZD201708); the Jiangsu Provincial ?six talent peaks? High talents the fourteenth batch (WSN-040); the Natural Science Foundation of Jiangsu Province (BK20161608); Jiangsu Health Vocational College University level scientific research projects(JKC201958).","Lovell RM, Ford AC, Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis, Clin Gastroenterol Hepatol, 10, pp. 712-721, (2012); Enck P, Aziz Q, Barbara G, Farmer AD, Fukudo S, Mayer EA, Niesler B, Quigley EM, Irritable bowel syndrome, Nat Rev Dis Primers, 2, (2016); Ford AC, Sperber AD, Corsetti M, Camilleri M, Irritable bowel syndrome, Lancet, 396, pp. 1675-1688, (2020); Ford AC, Lacy BE, Talley NJ, Irritable bowel syndrome, N Engl J Med, 376, pp. 2566-2578, (2017); Zhu HM, Li L, Li SY, Yan Q, Li F, Effect of water extract from Berberis heteropoda Schrenk roots on diarrhea-predominant irritable bowel syndrome by adjusting intestinal flora, J Ethnopharmacol, 237, pp. 182-191, (2019); Turner JR, Intestinal mucosal barrier function in health and disease, Nat Rev Immunol, 9, pp. 799-809, (2009); Yu C, Xi L, Zhao Y, Feng A, Zha L, Yang H, Chen M, Zhang Y, Et al., Artificial cultivation and nutritional evaluation of proteins from a wild Ganoderma gibbosum strain, ScienceAsia, 46, pp. 548-556, (2020); Mao Q, Shi L, Wang ZG, Luo YH, Wang YY, Li X, Lu M, Ju JM, Et al., Chemical profiles and pharmacological activities of Chang-Kang-Fang, a multi-herb Chinese medicinal formula, for treating irritable bowel syndrome, J Ethnopharmacol, 201, pp. 123-135, (2017); Vila VA, Imhann F, Collij V, Jankipersadsing SA, Gurry T, Mujagic Z, Kurilshikov A, Bonder MJ, Et al., Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome, Sci Transl Med, 10, (2018); Liu HN, Wu H, Chen YZ, Chen YJ, Shen XZ, Liu TT, Altered molecular signature of intestinal microbiota in irritable bowel syndrome patients compared with healthy controls: A systematic review and meta-analysis, Dig Liver Dis, 49, pp. 331-337, (2017); Arzani M, Jahromi SR, Ghorbani Z, Vahabizad F, Martelletti P, Ghaemi A, Sacco S, TOgha M, Et al., Gut-brain axis and migraine headache: a comprehensive review, J Headache Pain, 21, (2020); Kennedy PJ, Cryan JF, Dinan TG, Clarke G, Irritable bowel syndrome: a microbiome-gut-brain axis disorder?, World J Gastroenterol, 20, pp. 14105-14125, (2014); Nobaek S, Johansson ML, Molin G, Ahrne S, Jeppsson B, Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome, Am J Gastroenterol, 95, pp. 1231-1238, (2000); Martoni CJ, Srivastava S, Leyer GJ, Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 improve abdominal pain severity and symptomology in irritable bowel syndrome: Randomized controlled trial, Nutrients, 12, (2020); Labus JS, Sohn W, Lee OY, Lee SP, Lee KN, Jun DW, Yoon BC, Choi HS, Et al., Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial, J Gastroenterol Hepatol, 29, pp. 52-59, (2014); Labus JS, Hollister EB, Jacobs J, Kirbach K, Oezguen N, Gupta A, Acosta J, Luna RA, Et al., Differences in gut microbial composition correlate with regional brain volumes in irritable bowel syndrome, Microbiome, 5, (2017); Li J, Cui H, Cai Y, Lin J, Song X, Zhou Z, Xiong W, Zhou H, Et al., Tong-Xie-Yao-Fang regulates 5-HT level in diarrhea predominant irritable bowel syndrome through gut microbiota modulation, Front Pharmacol, 9, (2018)","H. Xie; Third Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, 210023, China; email: xiehuitcm@163.com","","Science Society of Thailand under Royal Patronage","","","","","","15131874","","","","English","ScienceAsia","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85125600878"

"Torres-Maravilla E.; Holowacz S.; Delannoy J.; Lenoir L.; Jacouton E.; Gervason S.; Meynier M.; Boucard A.-S.; Carvalho F.A.; Barbut F.; Bermúdez-Humarán L.G.; Langella P.; Waligora-Dupriet A.-J.","Torres-Maravilla, Edgar (56922108200); Holowacz, Sophie (56200615700); Delannoy, Johanne (57186421200); Lenoir, Loïc (56801539100); Jacouton, Elsa (56641711900); Gervason, Sandie (57209348857); Meynier, Maëva (57217062090); Boucard, Anne-Sophie (57208299895); Carvalho, Frédéric A. (16041688200); Barbut, Frédéric (7005710294); Bermúdez-Humarán, Luis G. (6602243913); Langella, Philippe (7003598187); Waligora-Dupriet, Anne-Judith (6506915359)","56922108200; 56200615700; 57186421200; 56801539100; 56641711900; 57209348857; 57217062090; 57208299895; 16041688200; 7005710294; 6602243913; 7003598187; 6506915359","Serpin-positive Bifidobacterium breve CNCM I-5644 improves intestinal permeability in two models of irritable bowel syndrome","2022","Scientific Reports","12","1","19776","","","","4","10.1038/s41598-022-21746-8","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85142172749&doi=10.1038%2fs41598-022-21746-8&partnerID=40&md5=f264846ad4c81d0a219480059c3d4b44","INRAE, AgroParisTech, Micalis Institute, Université Paris-Saclay, Jouy-en-Josas, 78350, France; Université Paris Cité, INSERM, 3PHM, Paris, F-75006, France; PiLeJe Laboratoire, 37 Quai de Grenelle, Paris Cedex 15, 75015, France; INSERM UMR 1107 NeuroDol, University of Clermont Auvergne, Clermont-Ferrand, 63001, France; National Reference Laboratory for C. Difficile, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Paris, 75012, France","Torres-Maravilla E., INRAE, AgroParisTech, Micalis Institute, Université Paris-Saclay, Jouy-en-Josas, 78350, France, Université Paris Cité, INSERM, 3PHM, Paris, F-75006, France; Holowacz S., PiLeJe Laboratoire, 37 Quai de Grenelle, Paris Cedex 15, 75015, France; Delannoy J., Université Paris Cité, INSERM, 3PHM, Paris, F-75006, France; Lenoir L., PiLeJe Laboratoire, 37 Quai de Grenelle, Paris Cedex 15, 75015, France; Jacouton E., PiLeJe Laboratoire, 37 Quai de Grenelle, Paris Cedex 15, 75015, France; Gervason S., INSERM UMR 1107 NeuroDol, University of Clermont Auvergne, Clermont-Ferrand, 63001, France; Meynier M., INSERM UMR 1107 NeuroDol, University of Clermont Auvergne, Clermont-Ferrand, 63001, France; Boucard A.-S., INRAE, AgroParisTech, Micalis Institute, Université Paris-Saclay, Jouy-en-Josas, 78350, France; Carvalho F.A., INSERM UMR 1107 NeuroDol, University of Clermont Auvergne, Clermont-Ferrand, 63001, France; Barbut F., Université Paris Cité, INSERM, 3PHM, Paris, F-75006, France, National Reference Laboratory for C. Difficile, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Paris, 75012, France; Bermúdez-Humarán L.G., INRAE, AgroParisTech, Micalis Institute, Université Paris-Saclay, Jouy-en-Josas, 78350, France; Langella P., INRAE, AgroParisTech, Micalis Institute, Université Paris-Saclay, Jouy-en-Josas, 78350, France; Waligora-Dupriet A.-J., Université Paris Cité, INSERM, 3PHM, Paris, F-75006, France","Probiotic supplementation can help to mitigate the pathogenesis of irritable bowel syndrome (IBS) by reinforcing the intestinal barrier, and reducing both inflammation and proteolytic activity. Here, a combination of in vitro tests was performed on 33 Bifidobacterium strains as probiotic candidates for IBS. In addition to the classical tests performed, the detection of the serine protease inhibitor (serpin) enzyme capable of decreasing the high proteolytic activity found in IBS patients was included. Three serpin-positive strains were selected: Bifidobacterium breve CNCM I-5644, Bifidobacterium longum subsp. infantis CNCM I-5645 and B. longum CNCM I-5646 for their immunomodulation properties and protection of intestinal epithelial integrity in vitro. Furthermore, we found that B. breve CNCM I-5644 strain prevented intestinal hyperpermeability by upregulating Cingulin and Tight Junction Protein 1 mRNA levels and reducing pro-inflammatory markers. The ability of CNCM I-5644 strain to restore intestinal hyperpermeability (FITC-dextran) was shown in the murine model of low-grade inflammation induced by dinitrobenzene sulfonic acid (DNBS). This effect of this strain was corroborated in a second model of IBS, the neonatal maternal separation model in mice. Altogether, these data suggest that serpin-positive B. breve CNCM I-5644 may partially prevent disorders associated with increased barrier permeability such as IBS. © 2022, The Author(s).","","Animals; Bifidobacterium breve; Bifidobacterium longum subspecies infantis; Inflammation; Irritable Bowel Syndrome; Maternal Deprivation; Mice; Permeability; Serpins; serine proteinase inhibitor; animal; Bifidobacterium breve; Bifidobacterium longum subsp. infantis; inflammation; irritable colon; maternal deprivation; mouse; permeability","","Serpins, ","","","INRAE Infectiology of Fishes and Rodents Facility, (IERP-UE907); Jouy-en-Josas Research Center; National Distributed Research Infrastructure for the Control of Animal and Zoonotic Emerging Infectious Diseases; Université de Paris; Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement, INRAE","Funding text 1: The reported study was supported by the National Research Institute for Agriculture, Food and Environment (INRAE), Paris University and a contract with PiLeJe Laboratoire. ; Funding text 2: We would like to thank Claude Blondeau for his help for the writing assistance, technical editing, language editing, and proofreading of the manuscript. We wish to thank the staff of the INRAE Infectiology of Fishes and Rodents Facility (IERP-UE907, Jouy-en-Josas Research Center, France) in which animal experiments have been performed. IERP Facility belongs to the National Distributed Research Infrastructure for the Control of Animal and Zoonotic Emerging Infectious Diseases through In vivo Investigation.","Lacy B.E., Et al., ACG clinical guideline: Management of irritable bowel syndrome, Am. Coll. Gastroenterol., 116, pp. 17-44, (2021); Qin H.-Y., Cheng C.-W., Tang X.-D., Bian Z.-X., Impact of psychological stress on irritable bowel syndrome, World J. Gastroenterol., 20, pp. 14126-14131, (2014); Jeffery I.B., Et al., Differences in fecal microbiomes and metabolomes of people with vs without irritable bowel syndrome and bile acid malabsorption, Gastroenterology, 158, pp. 1016-1028.e1018, (2020); Ticho A.L., Malhotra P., Dudeja P.K., Gill R.K., Alrefai W.A., Bile acid receptors and gastrointestinal functions, Liver Res., 3, pp. 31-39, (2019); Chong P.P., Et al., The microbiome and irritable bowel syndrome—A review on the pathophysiology, current research and future therapy, Front. Microbiol., 10, (2019); Wang L., Et al., Gut microbial dysbiosis in the irritable bowel syndrome: A systematic review and meta-analysis of case-control studies, J. Acad. Nutr. Diet., 120, pp. 565-586, (2020); Distrutti E., Monaldi L., Ricci P., Fiorucci S., Gut microbiota role in irritable bowel syndrome: New therapeutic strategies, World J. Gastroenterol., 22, pp. 2219-2241, (2016); Rodino-Janeiro B.K., Vicario M., Alonso-Cotoner C., Pascua-Garcia R., Santos J., A review of microbiota and irritable bowel syndrome: Future in therapies, Adv. Ther., 35, pp. 289-310, (2018); Thevaranjan N., Et al., Age-associated microbial dysbiosis promotes intestinal permeability, systemic inflammation, and macrophage dysfunction, Cell Host Microbe, 21, pp. 455-466.e454, (2017); Bischoff S.C., Et al., Intestinal permeability—A new target for disease prevention and therapy, BMC Gastroenterol., 14, (2014); Edogawa S., Et al., Serine proteases as luminal mediators of intestinal barrier dysfunction and symptom severity in IBS, Gut, 69, pp. 62-73, (2020); Jablaoui A., Et al., Fecal serine protease profiling in inflammatory bowel diseases, Front. Cell. Infect. Microbiol., 10, (2020); Rolland-Fourcade C., Et al., Epithelial expression and function of trypsin-3 in irritable bowel syndrome, Gut, 66, pp. 1767-1778, (2017); Burns G., Et al., Immune activation in functional gastrointestinal disorders, Gastroenterol. Hepatol., 15, pp. 539-548, (2019); Alessandri G., Ossiprandi M.C., MacSharry J., van Sinderen D., Ventura M., Bifidobacterial dialogue with its human host and consequent modulation of the immune system, Front. Immunol., (2019); McCarville J.L., Et al., A commensal Bifidobacterium longum strain prevents gluten-related immunopathology in mice through expression of a serine protease inhibitor, Appl. Environ. Microbiol., 83, pp. e01323-e1317, (2017); Ivanov D., Et al., A serpin from the gut bacterium Bifidobacterium longum inhibits eukaryotic elastase-like serine proteases, J. Biol. Chem., 281, pp. 17246-17252, (2006); Marshall N.C., Finlay B.B., Overall C.M., Sharpening host defenses during infection: Proteases cut to the chase, Mol. Cell. Proteom., 16, pp. S161-S171, (2017); Martin R., Et al., The commensal bacterium Faecalibacterium prausnitzii is protective in DNBS-induced chronic moderate and severe colitis models, Inflamm. Bowel Dis., 20, pp. 417-430, (2014); Martin R., Et al., Faecalibacterium prausnitzii prevents physiological damages in a chronic low-grade inflammation murine model, BMC Microbiol., 15, (2015); Larauche M., Mulak A., Tache Y., Stress and visceral pain: From animal models to clinical therapies, Exp. Neurol., 233, pp. 49-67, (2012); Schell M.A., Et al., The genome sequence of Bifidobacterium longum reflects its adaptation to the human gastrointestinal tract, Proc. Natl. Acad. Sci. U.S.A., 99, pp. 14422-14427, (2002); Buhner S., Et al., Protease signaling through protease activated receptor 1 mediate nerve activation by mucosal supernatants from irritable bowel syndrome but not from ulcerative colitis patients, PLoS ONE, 13, (2018); Liebregts T., Et al., Immune activation in patients with irritable bowel syndrome, Gastroenterology, 132, pp. 913-920, (2007); Cremon C., Et al., Mucosal immune activation in irritable bowel syndrome: Gender-dependence and association with digestive symptoms, Am. J. Gastroenterol., 104, pp. 392-400, (2009); Barbara G., Et al., Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome, Gastroenterology, 126, pp. 693-702, (2004); Barbara G., Et al., Rome foundation working team report on post-infection irritable bowel syndrome, Gastroenterology, 156, pp. 46-58.e47, (2019); Bermudez-Humaran L.G., Et al., Serine protease inhibitors protect better than IL-10 and TGF-β anti-inflammatory cytokines against mouse colitis when delivered by recombinant lactococci, Microb. Cell Factories, 14, (2015); Ceuleers H., Et al., Newly developed serine protease inhibitors decrease visceral hypersensitivity in a post-inflammatory rat model for irritable bowel syndrome, Br. J. Pharmacol., 175, pp. 3516-3533, (2018); Ruiz L., Delgado S., Ruas-Madiedo P., Sanchez B., Margolles A., Bifidobacteria and their molecular communication with the immune system, Front. Microbiol., 8, (2017); Levy M., Thaiss C.A., Elinav E., Metabolites: Messengers between the microbiota and the immune system, Genes Dev., 30, pp. 1589-1597, (2016); Haub S., Et al., Enhancement of intestinal inflammation in mice lacking interleukin 10 by deletion of the serotonin reuptake transporter, Neurogastroenterol. Motil., 22, pp. 826-e229, (2010); Mauras A., Et al., A new Bifidobacteria Expression SysTem (BEST) to produce and deliver interleukin-10 in Bifidobacterium bifidum, Front. Microbiol., 9, (2018); Biancheri P., Di Sabatino A., Corazza G.R., MacDonald T.T., Proteases and the gut barrier, Cell Tissue Res., 351, pp. 269-280, (2013); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Piche T., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: Involvement of soluble mediators, Gut, 58, (2009); Engevik M.A., Et al., Bifidobacterium dentium fortifies the intestinal mucus layer via autophagy and calcium signaling pathways, MBio, (2019); Martin R., Et al., The infant-derived Bifidobacterium bifidum strain CNCM I-4319 strengthens gut functionality, Microorganisms, 8, (2020); Martin R., Et al., Bifidobacterium animalis ssp. lactis CNCM-I2494 restores gut barrier permeability in chronically low-grade inflamed mice, Front. Microbiol., 7, (2016); Schossleitner K., Et al., Evidence that cingulin regulates endothelial barrier function in vitro and in vivo, Arterioscler. Thromb. Vasc. Biol., 36, pp. 647-654, (2016); Soroosh A., Et al., miR-24 Is elevated in ulcerative colitis patients and regulates intestinal epithelial barrier function, Am. J. Pathol., 189, pp. 1763-1774, (2019); Sultana R., McBain A.J., O'Neill C.A., Strain-dependent augmentation of tight-junction barrier function in human primary epidermal keratinocytes by Lactobacillus and Bifidobacterium lysates, Appl. Environ. Microbiol., 79, pp. 4887-4894, (2013); Kiu R., Et al., Bifidobacterium breve UCC2003 induces a distinct global transcriptomic programme in neonatal murine intestinal epithelial cells, bioRxiv, (2020); Din A.U., Et al., Inhibitory effect of Bifidobacterium bifidum ATCC 29521 on colitis and its mechanism, J. Nutr. Biochem., 79, (2020); O'Malley D., Dinan T.G., Cryan J.F., Interleukin-6 modulates colonic transepithelial ion transport in the stress-sensitive wistar kyoto rat, Front. Pharmacol., 3, (2012); Stallhofer J., Et al., Lipocalin-2 Is a disease activity marker in inflammatory bowel disease regulated by IL-17A, IL-22, and TNF-α and modulated by IL23R genotype status, Inflamm. Bowel Dis., 21, pp. 2327-2340, (2015); Roka R., Et al., A pilot study of fecal serine-protease activity: A pathophysiologic factor in diarrhea-predominant irritable bowel syndrome, Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc., 5, pp. 550-555, (2007); Van Spaendonk H., Et al., Regulation of intestinal permeability: The role of proteases, World J. Gastroenterol., 23, pp. 2106-2123, (2017); Zhao J., Et al., A protease inhibitor against acute stress-induced visceral hypersensitivity and paracellular permeability in rats, Eur. J. Pharmacol., 654, pp. 289-294, (2011); Sinagra E., Et al., Inflammation in irritable bowel syndrome: Myth or new treatment target?, World J. Gastroenterol., 22, pp. 2242-2255, (2016); Larauche M., Mulak A., Tache Y., Stress-related alterations of visceral sensation: Animal models for irritable bowel syndrome study, J. Neurogastroenterol. Motil., 17, pp. 213-234, (2011); Lo Presti A., Et al., Fecal and mucosal microbiota profiling in irritable bowel syndrome and inflammatory bowel disease, Front. Microbiol., 10, (2019); Fukui H., Et al., Effect of probiotic Bifidobacterium bifidum G9–1 on the relationship between gut microbiota profile and stress sensitivity in maternally separated rats, Sci. Rep., 8, (2018); Miquel S., Et al., Anti-nociceptive effect of Faecalibacterium prausnitzii in non-inflammatory IBS-like models, Sci. Rep., 6, (2016); Ait-Belgnaoui A., Et al., Bifidobacterium longum and Lactobacillus helveticus synergistically suppress stress-related visceral hypersensitivity through hypothalamic-pituitary-adrenal axis modulation, J. Neurogastroenterol. Motil., 24, pp. 138-146, (2018); Buckley A., Turner J.R., Cell biology of tight junction barrier regulation and mucosal disease, Cold Spring Harb Perspect. Biol., 10, (2018); Amasheh M., Et al., Regulation of mucosal structure and barrier function in rat colon exposed to tumor necrosis factor alpha and interferon gamma in vitro: A novel model for studying the pathomechanisms of inflammatory bowel disease cytokines, Scand. J. Gastroenterol., 44, pp. 1226-1235, (2009); Zheng G., Et al., Corticosterone mediates stress-related increased intestinal permeability in a region-specific manner, Neurogastroenterol. Motil., 25, pp. e127-e139, (2013); Neau E., Et al., Three novel candidate probiotic strains with prophylactic properties in a murine model of cow's milk allergy, Appl. Environ. Microbiol., 82, pp. 1722-1733, (2016); Kechaou N., Et al., Identification of one novel candidate probiotic Lactobacillus plantarum strain active against influenza virus infection in mice by a large-scale screening, Appl. Environ. Microbiol., 79, pp. 1491-1499, (2013); Laval L., Et al., Lactobacillus rhamnosus CNCM I-3690 and the commensal bacterium Faecalibacterium prausnitzii A2–165 exhibit similar protective effects to induced barrier hyper-permeability in mice, Gut Microb., 6, pp. 1-9, (2015); Prisciandaro L.D., Et al., Probiotic factors partially prevent changes to caspases 3 and 7 activation and transepithelial electrical resistance in a model of 5-fluorouracil-induced epithelial cell damage, Support. Care Cancer Off. J. Multinatl. Assoc. Support. Care Cancer, 20, pp. 3205-3210, (2012); Barone M., Et al., A versatile new model of chemically induced chronic colitis using an outbred murine strain, Front. Microbiol., 9, (2018); Maeda S., Et al., Intestinal protease-activated receptor-2 and fecal serine protease activity are increased in canine inflammatory bowel disease and may contribute to intestinal cytokine expression, J. Vet. Med. Sci., 76, pp. 1119-1127, (2014)","P. Langella; INRAE, AgroParisTech, Micalis Institute, Université Paris-Saclay, Jouy-en-Josas, 78350, France; email: philippe.langella@inrae.fr; A.-J. Waligora-Dupriet; Université Paris Cité, INSERM, 3PHM, Paris, F-75006, France; email: anne-judith.waligora@u-paris.fr","","Nature Research","","","","","","20452322","","","36396717","English","Sci. Rep.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85142172749"

"Nozu T.; Arie H.; Miyagishi S.; Ishioh M.; Takakusaki K.; Okumura T.","Nozu, Tsukasa (12765917900); Arie, Hideyuki (57210962418); Miyagishi, Saori (56538237900); Ishioh, Masatomo (57202513969); Takakusaki, Kaoru (7004150214); Okumura, Toshikatsu (7202327796)","12765917900; 57210962418; 56538237900; 57202513969; 7004150214; 7202327796","Tranilast alleviates visceral hypersensitivity and colonic hyperpermeability by suppressing NLRP3 inflammasome activation in irritable bowel syndrome rat models","2024","International Immunopharmacology","133","","112099","","","","0","10.1016/j.intimp.2024.112099","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85190809478&doi=10.1016%2fj.intimp.2024.112099&partnerID=40&md5=b23cdc564232fffe4d24af12d7eb86ff","Department of Regional Medicine and Education, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Hokkaido, Asahikawa, 078-8510, Japan; Center for Medical Education, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Hokkaido, Asahikawa, 078-8510, Japan; Department of General Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Hokkaido, Asahikawa, 078-8510, Japan; Division of Neuroscience, Department of Physiology, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Hokkaido, Asahikawa, 078-8510, Japan; Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Hokkaido, Asahikawa, 078-8510, Japan","Nozu T., Department of Regional Medicine and Education, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Hokkaido, Asahikawa, 078-8510, Japan, Center for Medical Education, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Hokkaido, Asahikawa, 078-8510, Japan, Department of General Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Hokkaido, Asahikawa, 078-8510, Japan; Arie H., Department of Regional Medicine and Education, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Hokkaido, Asahikawa, 078-8510, Japan; Miyagishi S., Department of General Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Hokkaido, Asahikawa, 078-8510, Japan; Ishioh M., Department of General Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Hokkaido, Asahikawa, 078-8510, Japan; Takakusaki K., Division of Neuroscience, Department of Physiology, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Hokkaido, Asahikawa, 078-8510, Japan; Okumura T., Department of General Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Hokkaido, Asahikawa, 078-8510, Japan, Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Hokkaido, Asahikawa, 078-8510, Japan","Visceral hypersensitivity resulting from compromised gut barrier with activated immune system is a key feature of irritable bowel syndrome (IBS). Corticotropin-releasing factor (CRF) and Toll-like receptor 4 (TLR4) activate proinflammatory cytokine signaling to induce these changes, which is one of the mechanisms of IBS. As activation of the NLRP3 inflammasome by lipopolysaccharide (LPS) or TLR4 leads to release interleukin (IL)-1β, the NLRP3 inflammasome may be involved in the pathophysiology of IBS. Tranilast, an anti-allergic drug has been demonstrated to inhibit the NLRP3 inflammasome, and we evaluated the impact of tranilast on visceral hypersensitivity and colonic hyperpermeability induced by LPS or CRF (IBS rat model). Visceral pain threshold caused by colonic balloon distention was measured by monitoring abdominal muscle contractions electrophysiologically. Colonic permeability was determined by quantifying the absorbed Evans blue within the colonic tissue. Colonic protein levels of NLRP3 and IL-1β were assessed by immunoblot or ELISA. Intragastric administration of tranilast (20–200 mg/kg) for 3 days inhibited LPS (1 mg/kg)-induced visceral hypersensitivity and colonic hyperpermeability in a dose-dependent manner. Simultaneously, tranilast also abolished these alterations induced by CRF (50 µg/kg). LPS increased colonic protein levels of NLRP3 and IL-1β, and tranilast inhibited these changes. β-hydroxy butyrate, an NLRP3 inhibitor, also abolished visceral hypersensitivity and colonic hyperpermeability caused by LPS. In contrast, IL-1β induced similar GI alterations to LPS, which were not modified by tranilast. In conclusion, tranilast improved visceral pain and colonic barrier by suppression of the NLRP3 inflammasome in IBS rat models. Tranilast may be useful for IBS treating. © 2024 Elsevier B.V.","Gut barrier; Irritable bowel syndrome; NLRP3 inflammasome; Tranilast; Visceral pain; β-hydroxy butyrate","Animals; Colon; Disease Models, Animal; Hyperalgesia; Inflammasomes; Interleukin-1beta; Irritable Bowel Syndrome; Lipopolysaccharides; Male; NLR Family, Pyrin Domain-Containing 3 Protein; ortho-Aminobenzoates; Permeability; Rats; Rats, Sprague-Dawley; Visceral Pain; beta actin; butorphanol tartrate; corticotropin releasing factor; cryopyrin; Evans blue; immunoglobulin enhancer binding protein; inflammasome; interleukin 1beta; interleukin 1beta converting enzyme; isoflurane; lipopolysaccharide; medetomidine; midazolam; nitric oxide; peroxisome proliferator activated receptor gamma; tranilast; anthranilic acid derivative; cryopyrin; inflammasome; interleukin 1beta; lipopolysaccharide; Nlrp3 protein, rat; tranilast; abdominal wall musculature; abdominal withdrawal reflex; anesthesia; animal experiment; animal model; animal tissue; Article; ascending colon; colon tissue; controlled study; electromyography; enzyme linked immunosorbent assay; immunoblotting; intestinal dysmotility; irritable colon; laparotomy; male; nonhuman; pain threshold; pathogenesis; protein expression; protein expression level; quantitative analysis; radioimmunoprecipitation; rat; rat model; signal transduction; Sprague Dawley rat; visceral hyperalgesia; visceral pain; withdrawal reflex; animal; colon; disease model; drug effect; hyperalgesia; irritable colon; metabolism; permeability; Sprague Dawley rat; visceral pain","","butorphanol tartrate, 58786-99-5; corticotropin releasing factor, 9015-71-8, 178359-01-8, 79804-71-0, 86297-72-5, 86784-80-7; Evans blue, 314-13-6; interleukin 1beta converting enzyme, 122191-40-6, 187414-12-6; isoflurane, 26675-46-7; medetomidine, 119717-21-4, 86347-14-0, 86347-15-1; midazolam, 59467-70-8, 59467-96-8; nitric oxide, 10102-43-9; tranilast, 53902-12-8; Inflammasomes, ; Interleukin-1beta, ; Lipopolysaccharides, ; NLR Family, Pyrin Domain-Containing 3 Protein, ; Nlrp3 protein, rat, ; ortho-Aminobenzoates, ; tranilast, ","","","Akiyama Life Science Foundation; Scientific Research on Innovative Areas; Japan Society for the Promotion of Science, JSPS, (22K08790, 26460955, 26120012); Japan Society for the Promotion of Science, JSPS","This work was partially supported by the Japan Society for the Promotion of Science KAKENHI, Grant-in-Aid for Scientific Research (C) [22K08790 (TN) and 26460955 (TO)], Scientific Research on Innovative Areas [26120012 (KT)], and the research grant from the Akiyama Life Science Foundation (TN). ","Enck P., Aziz Q., Barbara G., Farmer A.D., Fukudo S., Mayer E.A., Niesler B., Quigley E.M., Rajilic-Stojanovic M., Schemann M., Schwille-Kiuntke J., Simren M., Zipfel S., Spiller R.C., Irritable bowel syndrome, Nat. Rev. Dis. Primers, 2, (2016); Fukudo S., Stress and visceral pain: focusing on irritable bowel syndrome, Pain, 154, pp. S63-S70, (2013); Schaper S.J., Stengel A., Emotional stress responsivity of patients with IBS - a systematic review, J. Psychosom. Res., 153, (2022); Nozu T., Okumura T., Corticotropin-releasing factor receptor type 1 and type 2 interaction in irritable bowel syndrome, J. Gastroenterol., 50, 8, pp. 819-830, (2015); Azpiroz F., Bouin M., Camilleri M., Mayer E.A., Poitras P., Serra J., Spiller R.C., Mechanisms of hypersensitivity in IBS and functional disorders, Neurogastroenterol. Motil., 19, 1, pp. 62-88, (2007); Piche T., Barbara G., Aubert P., Bruley des Varannes S., Dainese R., Nano J.L., Cremon C., Stanghellini V., De Giorgio R., Galmiche J.P., Neunlist M., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators, Gut, 58, 2, pp. 196-201, (2009); Nozu T., Okumura T., Pathophysiological commonality between irritable bowel syndrome and metabolic syndrome: role of corticotropin-releasing factor-toll-like receptor 4-proinflammatory cytokine signaling, J. Neurogastroenterol. Motil., 28, 2, pp. 173-184, (2022); Suzuki T., Yoshinaga N., Tanabe S., Interleukin-6 (IL-6) regulates claudin-2 expression and tight junction permeability in intestinal epithelium, J. Biol. Chem., 286, 36, pp. 31263-31271, (2011); Nozu T., Miyagishi S., Nozu R., Takakusaki K., Okumura T., Repeated water avoidance stress induces visceral hypersensitivity; role of IL-1, IL-6 and peripheral corticotropin-releasing factor, J. Gastroenterol. Hepatol., 32, 12, pp. 1958-1965, (2017); Nozu T., Miyagishi S., Nozu R., Takakusaki K., Okumura T., Altered colonic sensory and barrier functions by CRF: roles of TLR4 and IL-1, J. Endocrinol., 239, 2, pp. 241-252, (2018); Zhen Y., Zhang H., NLRP3 inflammasome and inflammatory bowel disease, Front. Immunol., 10, (2019); Yang Y., Wang H., Kouadir M., Song H., Shi F., Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors, Cell Death Dis., 10, 2, (2019); Zahid A., Li B., Kombe A.J.K., Jin T., Tao J., Pharmacological inhibitors of the NLRP3 inflammasome, Front. Immunol., 10, (2019); Pae H.O., Jeong S.O., Koo B.S., Ha H.Y., Lee K.M., Chung H.T., Tranilast, an orally active anti-allergic drug, up-regulates the anti-inflammatory heme oxygenase-1 expression but down-regulates the pro-inflammatory cyclooxygenase-2 and inducible nitric oxide synthase expression in RAW264.7 macrophages, Biochem. Biophys. Res. Commun., 371, 3, pp. 361-365, (2008); Yamanashi T., Iwata M., Kamiya N., Tsunetomi K., Kajitani N., Wada N., Iitsuka T., Yamauchi T., Miura A., Pu S., Shirayama Y., Watanabe K., Duman R.S., Kaneko K., Beta-hydroxybutyrate, an endogenic NLRP3 inflammasome inhibitor, attenuates stress-induced behavioral and inflammatory responses, Sci. Rep., 7, 1, (2017); Nozu T., Miyagishi S., Nozu R., Takakusaki K., Okumura T., Lipopolysaccharide induces visceral hypersensitivity: role of interleukin-1, interleukin-6, and peripheral corticotropin-releasing factor in rats, J. Gastroenterol., 52, 1, pp. 72-80, (2017); Nozu T., Miyagishi S., Nozu R., Takakusaki K., Okumura T., Losartan improves visceral sensation and gut barrier in a rat model of irritable bowel syndrome, Neurogastroenterol. Motil., 32, 6, (2020); Umemura K., Kikuchi S., Suzuki Y., Nakashima M., Inhibitory effect of tranilast on hypertrophic collagen production in the spontaneously hypertensive rat heart, Jpn. J. Pharmacol., 78, 2, pp. 161-167, (1998); Ness T.J., Gebhart G.F., Colorectal distension as a noxious visceral stimulus: physiologic and pharmacologic characterization of pseudaffective reflexes in the rat, Brain Res., 450, 1-2, pp. 153-169, (1988); Al-Chaer E.D., Kawasaki M., Pasricha P.J., A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development, Gastroenterology, 119, 5, pp. 1276-1285, (2000); Yang J.P., Yao M., Jiang X.H., Wang L.N., Establishment of model of visceral pain due to colorectal distension and its behavioral assessment in rats, World J. Gastroenterol., 12, 17, pp. 2781-2784, (2006); Okumura T., Nozu T., Kumei S., Takakusaki K., Ohhira M., Ghrelin acts centrally to induce an antinociceptive action during colonic distension through the orexinergic, dopaminergic and opioid systems in conscious rats, Brain Res., 1686, pp. 48-54, (2018); Sastre E., Caracuel L., Xavier F.E., Balfagon G., Blanco-Rivero J., Opposite effect of mast cell stabilizers ketotifen and tranilast on the vasoconstrictor response to electrical field stimulation in rat mesenteric artery, PLoS One, 8, 8, (2013); Zhuo Y., Zhuo J., Tranilast treatment attenuates cerebral ischemia-reperfusion injury in rats through the inhibition of inflammatory responses mediated by NF-kappaB and PPARs, Clin. Transl. Sci., 12, 2, pp. 196-202, (2019); Youm Y.H., Nguyen K.Y., Grant R.W., Goldberg E.L., Bodogai M., Kim D., D'Agostino D., Planavsky N., Lupfer C., Kanneganti T.D., Kang S., Horvath T.L., Fahmy T.M., Crawford P.A., Biragyn A., Alnemri E., Dixit V.D., The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease, Nat. Med., 21, 3, pp. 263-269, (2015); Kelley N., Jeltema D., Duan Y., He Y., The NLRP3 inflammasome: an overview of mechanisms of activation and regulation, Int. J. Mol. Sci., 20, 13, (2019); Dlugosz A., Nowak P., D'Amato M., Mohammadian Kermani G., Nystrom J., Abdurahman S., Lindberg G., Increased serum levels of lipopolysaccharide and antiflagellin antibodies in patients with diarrhea-predominant irritable bowel syndrome, Neurogastroenterol. Motil., 27, 12, pp. 1747-1754, (2015); Ortiz-Lucas M., Saz-Peiro P., Sebastian-Domingo J.J., Irritable bowel syndrome immune hypothesis. Part two: the role of cytokines, Rev. Esp. Enferm. Dig., 102, 12, pp. 711-717, (2010); Fukudo S., Nomura T., Hongo M., Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome, Gut, 42, 6, pp. 845-849, (1998); Yu Y., Liu Z.Q., Liu X.Y., Yang L., Geng X.R., Yang G., Liu Z.G., Zheng P.Y., Yang P.C., Stress-derived corticotropin releasing factor breaches epithelial endotoxin tolerance, PLoS One, 8, 6, (2013); Obreja O., Rathee P.K., Lips K.S., Distler C., Kress M., IL-1 beta potentiates heat-activated currents in rat sensory neurons: involvement of IL-1RI, tyrosine kinase, and protein kinase C, FASEB J., 16, 12, pp. 1497-1503, (2002); Yuan P.Q., Wu S.V., Wang L., Tache Y., Corticotropin releasing factor in the rat colon: expression, localization and upregulation by endotoxin, Peptides, 31, 2, pp. 322-331, (2010); Ke W., Wang Y., Huang S., Liu S., Zhu H., Xie X., Yang H., Lu Q., Gan J., He G., Che F., Wan X., Tang H., Paeoniflorin alleviates inflammatory response in IBS-D mouse model via downregulation of the NLRP3 inflammasome pathway with involvement of miR-29a, Heliyon, 8, 12, (2022); Scuderi S.A., Casili G., Lanza M., Filippone A., Paterniti I., Esposito E., Campolo M., Modulation of NLRP3 inflammasome attenuated inflammatory response associated to Diarrhea-predominant irritable bowel syndrome, Biomedicines, 8, 11, (2020); Xiong Y., Wei H., Chen C., Jiao L., Zhang J., Tan Y., Zeng L., Coptisine attenuates post-infectious IBS via Nrf2-dependent inhibition of the NLPR3 inflammasome, Mol. Med. Rep., 26, 6, (2022); Liu J.J., Kay T.M., Davis E.M., Lou Y., Kao D., Claggett B., Fedorak R.N., Irvin R.T., Epithelial cell extrusion zones observed on confocal laser endomicroscopy correlates with immunohistochemical staining of mucosal biopsy samples, Dig. Dis. Sci., 61, 7, pp. 1895-1902, (2016); Chen S., Wang Y., Pan Y., Liu Y., Zheng S., Ding K., Mu K., Yuan Y., Li Z., Song H., Jin Y., Fu J., Novel role for tranilast in regulating NLRP3 ubiquitination, vascular inflammation, and atherosclerosis, J. Am. Heart Assoc., 9, 12, (2020); Huang Y., Jiang H., Chen Y., Wang X., Yang Y., Tao J., Deng X., Liang G., Zhang H., Jiang W., Zhou R., Tranilast directly targets NLRP3 to treat inflammasome-driven diseases, EMBO Mol. Med., 10, 4, (2018); Cao J., Peng Q., NLRP3 inhibitor tranilast attenuates gestational diabetes mellitus in a genetic mouse model, Drugs R D, 22, 1, pp. 105-112, (2022); Yu H., Zhou Y., Duan Y., Gao Y., Fang N., Zhang J., Li Y., Tranilast treats cold-related hypertension by reducing the expression of NLRP3 inflammasome, Frigid Zone Medicine, 1, 2, pp. 95-101, (2021); Azuma H., Banno K., Yoshimura T., Pharmacological properties of N-(3',4'-dimethoxycinnamoyl) anthranilic acid (N-5'), a new anti-atopic agent, Br. J. Pharmacol., 58, 4, pp. 483-488, (1976); Stanisor O.I., van Diest S.A., Yu Z., Welting O., Bekkali N., Shi J., de Jonge W.J., Boeckxstaens G.E., van den Wijngaard R.M., Stress-induced visceral hypersensitivity in maternally separated rats can be reversed by peripherally restricted histamine-1-receptor antagonists, PLoS One, 8, 6, (2013); Nozu T., Miyagishi S., Nozu R., Takakusaki K., Okumura T., Pioglitazone improves visceral sensation and colonic permeability in a rat model of irritable bowel syndrome, J. Pharmacol. Sci., 139, 2019, pp. 46-49, (2018); Nozu T., Miyagishi S., Ishioh M., Takakusaki K., Okumura T., Phlorizin attenuates visceral hypersensitivity and colonic hyperpermeability in a rat model of irritable bowel syndrome, Biomed. Pharmacother., 139, (2021); Shao B.Z., Xu Z.Q., Han B.Z., Su D.F., Liu C., NLRP3 inflammasome and its inhibitors: a review, Front. Pharmacol., 6, (2015); Kanazawa M., Fukudo S., Effects of fasting therapy on irritable bowel syndrome, Int. J. Behav. Med., 13, 3, pp. 214-220, (2006)","T. Nozu; Department of Regional Medicine and Education, Asahikawa Medical University, Asahikawa, 2-1-1-1 Midorigaoka-Higashi, Hokkaido, 078-8510, Japan; email: tnozu@sea.plala.or.jp","","Elsevier B.V.","","","","","","15675769","","IINMB","38643709","English","Int. Immunopharmacol.","Article","Final","","Scopus","2-s2.0-85190809478"

"Awad K.; Barmeyer C.; Bojarski C.; Nagel O.; Lee I.-F.M.; Schweiger M.R.; Schulzke J.-D.; Bücker R.","Awad, Karem (57188694305); Barmeyer, Christian (6506742657); Bojarski, Christian (8764110100); Nagel, Oliver (56444576700); Lee, In-Fah M. (55246172200); Schweiger, Michal R. (9240082000); Schulzke, Jörg-Dieter (35502556700); Bücker, Roland (10043068400)","57188694305; 6506742657; 8764110100; 56444576700; 55246172200; 9240082000; 35502556700; 10043068400","Impaired Intestinal Permeability of Tricellular Tight Junctions in Patients with Irritable Bowel Syndrome with Mixed Bowel Habits (IBS-M)","2023","Cells","12","2","236","","","","12","10.3390/cells12020236","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85146784888&doi=10.3390%2fcells12020236&partnerID=40&md5=ab146542ae7556f9649e490350560437","Clinical Physiology, Charité—Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, 12203, Germany; Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité—Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, 12203, Germany; Institute for Translational Epigenetics, Medical Faculty, University of Cologne, Cologne, 50931, Germany","Awad K., Clinical Physiology, Charité—Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, 12203, Germany; Barmeyer C., Clinical Physiology, Charité—Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, 12203, Germany; Bojarski C., Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité—Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, 12203, Germany; Nagel O., Clinical Physiology, Charité—Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, 12203, Germany; Lee I.-F.M., Clinical Physiology, Charité—Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, 12203, Germany; Schweiger M.R., Institute for Translational Epigenetics, Medical Faculty, University of Cologne, Cologne, 50931, Germany; Schulzke J.-D., Clinical Physiology, Charité—Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, 12203, Germany, Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité—Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, 12203, Germany; Bücker R., Clinical Physiology, Charité—Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, 12203, Germany","Background: The underlying pathophysiology of irritable bowel syndrome (IBS) is still unclear. Our aim was to investigate the pathophysiological mechanisms of diarrhea, constipation, and antigen uptake in mixed-type IBS (IBS-M). Methods: Colonoscopic biopsies were obtained from IBS-M patients. Epithelial transport and barrier function of colonic mucosae were characterized in Ussing chambers using impedance spectroscopy. Mucosal permeability to macromolecules was measured. Western blotting for tight junction (TJ) proteins was performed and their subcellular localization was visualized by confocal microscopy. RNA-sequencing was performed for gene expression and signaling pathway analysis. Results: In IBS-M, epithelial resistance and ENaC-dependent sodium absorption were unchanged, while short-circuit current reflecting chloride secretion was reduced. Concomitantly, epithelial permeability for fluorescein and FITC-dextran-4000 increased. TJ protein expression of occludin decreased, whereas claudins were unaltered. Confocal microscopy revealed the de-localization of tricellulin from tricellular TJs. Involved pathways were detected as proinflammatory cytokine pathways, LPS, PGE2, NGF, and vitamin D. Conclusions: Decreased anion secretion explains constipation in IBS-M, while ion permeability and sodium absorption were unaltered. Reduced occludin expression resulted in the delocalization of tricellulin from the tricellular TJ, leading to increased macromolecular permeability that contributes to antigen influx into the mucosa and perpetuates a low-grade inflammatory process. © 2023 by the authors.","intestinal barrier function; irritable bowel syndrome; leaky gut; occludin; RNA-seq; tight junctions; tricellulin","Constipation; Habits; Humans; Irritable Bowel Syndrome; MARVEL Domain Containing 2 Protein; Occludin; Permeability; Tight Junction Proteins; Tight Junctions; beta actin; claudin 1; claudin 2; claudin 3; claudin 4; claudin 5; claudin 8; colony stimulating factor; epithelial sodium channel; gamma interferon; interleukin 1beta; interleukin 4; lipopolysaccharide; occludin; protein ZO1; tight junction protein; tricellulin; occludin; tight junction protein; tricellulin; anion transport; apoptosis rate; Article; cellular distribution; CFTR  gene; chloride secretion; CLCA1 gene; colonoscopy; confocal laser scanning microscopy; constipation; controlled study; diarrhea; female; gene; gene expression; gene expression profiling; high throughput sequencing; human; human tissue; immunofluorescence microscopy; immunohistochemistry; impedance spectroscopy; intestine mucosa permeability; ion permeability; irritable colon; male; morphometry; mRNA expression level; pathway analysis; protein expression; protein localization; RNA sequencing; SCNN1A gene; SCNN1B gene; SCNN1G gene; signal transduction; SLC12A2 gene; sodium absorption; stimulated emission depletion microscopy; surface area; transepithelial resistance; tricellular junction; TUNEL assay; Western blotting; constipation; habit; metabolism; permeability; tight junction","","claudin 1, 329338-06-9; colony stimulating factor, 62683-29-8; gamma interferon, 82115-62-6; occludin, 176304-61-3; MARVEL Domain Containing 2 Protein, ; Occludin, ; Tight Junction Proteins, ","LSM 780, Carl Zeiss, Germany; NovaSeq 6000, Illumina; mirVana, Ambion, United States","Ambion, United States; Carl Zeiss, Germany; Illumina","Deutsche Forschungsgemeinschaft, DFG, (559/11-5, GRK 2318-2 C1); Charité – Universitätsmedizin Berlin","This research was funded by the Deutsche Forschungsgemeinschaft (DFG) grant GRK 2318-2 C1 and DFG Schu 559/11-5. Thanks to Dorothee Günzel and Jörg Piontek for the support and the grant for the STED microscope supported by the DFG. The APC was funded by the German Research Foundation and the Open Access Publication Fund of the Charité—Universitätsmedizin Berlin.","Lovell R.M., Ford A.C., Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis, Clin. Gastroenterol. Hepatol, 10, pp. 712-721, (2012); Drossman D.A., The functional gastrointestinal disorders and the Rome III process, Gastroenterology, 130, pp. 1377-1390, (2006); Choung R.S., Locke G.R., Epidemiology of IBS, Gastroenterol. Clin. N. Am, 40, pp. 1-10, (2011); Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Oka P., Parr H., Barberio B., Black C.J., Savarino E.V., Ford A.C., Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: A systematic review and meta-analysis, Lancet Gastroenterol. Hepatol, 5, pp. 908-917, (2020); Schulzke J.D., Gunzel D., John L.J., Fromm M., Perspectives on tight junction research, Ann. N. Y. Acad. Sci, 1257, pp. 1-19, (2012); Tsukita S., Tanaka H., Tamura A., The Claudins: From Tight Junctions to Biological Systems, Trends Biochem. Sci, 44, pp. 141-152, (2019); Sonoda N., Furuse M., Sasaki H., Yonemura S., Katahira J., Horiguchi Y., Tsukita S., Clostridium perfringens enterotoxin fragment removes specific claudins from tight junction strands: Evidence for direct involvement of claudins in tight junction barrier, J. Cell Biol, 147, pp. 195-204, (1999); Van Itallie C., Rahner C., Anderson J.M., Regulated expression of claudin-4 decreases paracellular conductance through a selective decrease in sodium permeability, J. Clin. Investig, 107, pp. 1319-1327, (2001); Amasheh S., Meiri N., Gitter A.H., Schoneberg T., Mankertz J., Schulzke J.D., Fromm M., Claudin-2 expression induces cation-selective channels in tight junctions of epithelial cells, J. Cell Sci, 115, pp. 4969-4976, (2002); Tsukita S., Furuse M., Claudin-based barrier in simple and stratified cellular sheets, Curr. Opin. Cell Biol, 14, pp. 531-536, (2002); Wen H., Watry D.D., Marcondes M.C., Fox H.S., Selective decrease in paracellular conductance of tight junctions: Role of the first extracellular domain of claudin-5, Mol. Cell. Biol, 24, pp. 8408-8417, (2004); Matter K., Balda M.S., Occludin and the functions of tight junctions, Int. Rev. Cytol, 186, pp. 117-146, (1999); Krug S.M., Bojarski C., Fromm A., Lee I.M., Dames P., Richter J.F., Fromm M., Schulzke J.D., Tricellulin is regulated via interleukin-13-receptor α2, affects macromolecule uptake, and is decreased in ulcerative colitis, Mucosal Immunol, 11, pp. 345-356, (2018); Hu J.E., Bojarski C., Branchi F., Fromm M., Krug S., Leptin Downregulates Angulin-1 in Active Crohn’s Disease via STAT3, Int. J. Mol. Sci, 21, (2020); Tsukita S., Furuse M., Itoh M., Structural and signalling molecules come together at tight junctions, Curr. Opin. Cell Biol, 11, pp. 628-633, (1999); Hasler W.L., Grabauskas G., Singh P., Owyang C., Mast cell mediation of visceral sensation and permeability in IBS, Neurogastroenterol. Motil, 34, (2022); Piche T., Tight junctions and IBS--the link between epithelial permeability, low-grade inflammation, and symptom generation?, Neurogastroenterol. Motil, 26, pp. 296-302, (2014); Dunlop S.P., Hebden J., Campbell E., Naesdal J., Olbe L., Perkins A., Spiller R.C., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am. J. Gastroenterol, 101, pp. 1288-1294, (2006); Barmeyer C., Erko I., Awad K., Fromm A., Bojarski C., Meissner S., Loddenkemper C., Kerick M., Siegmund B., Fromm M., Et al., Epithelial barrier dysfunction in lymphocytic colitis through cytokine-dependent internalization of claudin-5 and -8, J. Gastroenterol, 52, pp. 1090-1100, (2017); Fromm M., Krug S.M., Zeissig S., Richter J.F., Rosenthal R., Gunzel R., Schulzke J.-D., High-resolution analysis of barrier function, Ann. N. Y. Acad. Sci, 1165, pp. 74-81, (2009); Tai Y.H., Tai C.Y., The conventional short-circuiting technique under-short-circuits most epithelia, J. Membr. Biol, 59, pp. 173-177, (1981); Peters S.A., Edogawa S., Sundt W.J., Dyer R.B., Dalenberg D.A., Mazzone A., Singh R.J., Moses N., Smyrk T.C., Weber C., Et al., Constipation-Predominant Irritable Bowel Syndrome Females Have Normal Colonic Barrier and Secretory Function, Am. J. Gastroenterol, 112, pp. 913-923, (2017); Schulzke J.D., Fromm M., Hegel U., Riecken E.-O., Ion transport and enteric nervous system (ENS) in rat rectal colon: Mechanical stretch causes electrogenic Cl-secretion via plexus Meissner and amiloride-sensitive electrogenic Na-absorption is not affected by intramural neurons, Pflugers Arch, 414, pp. 216-221, (1989); Schmitz H., Fromm M., Bode H., Scholz P., Riecken E.O., Schulzke J.D., Tumor necrosis factor-alpha induces Cl- and K+ secretion in human distal colon driven by prostaglandin E2, Am. J. Physiol, 271, pp. G669-G674, (1996); Grabauskas G., Wu X., Gao J., Li J.-Y., Turgeon D.K., Owyang C., Prostaglandin E2, Produced by Mast Cells in Colon Tissues from Patients with Irritable Bowel Syndrome, Contributes to Visceral Hypersensitivity in Mice, Gastroenterology, 158, pp. 2195-2207.e6, (2020); Menzies I.S., Laker M.F., Pounder R., Heyer S., Bull J., Wheeler P., Creamer B., Abnormal intestinal permeability to sugars in villous atrophy, Lancet, 2, pp. 1107-1109, (1979); Wheeler P.G., Menzies I.S., Creamer B., Effect of hyperosmolar stimuli and coeliac disease on the permeability of the human gastrointestinal tract, Clin. Sci. Mol. Med, 54, pp. 495-501, (1978); Burgel N., Bojarski C., Mankertz J., Zeitz M., Fromm M., Schulzke J., Mechanisms of diarrhea in collagenous colitis, Gastroenterology, 123, pp. 433-443, (2002); Heller F., Florian P., Bojarski C., Richter J., Christ M., Hillenbrand B., Mankertz J., Gitter A.H., Burgel N., Fromm M., Et al., Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution, Gastroenterology, 129, pp. 550-564, (2005); Bucker R., Schulz E., Gunzel D., Bojarski C., Lee I.F.M., John L.J., Wiegand S., Janssen T., Wieler L., Dobrindt U., Et al., α-Haemolysin of Escherichia coli in IBD: A potentiator of inflammatory activity in the colon, Gut, 63, pp. 1893-1901, (2014); Schulz E., Schumann M., Schneemann M., Dony V., Fromm A., Nagel O., Schulzke J.-D., Bucker R., Escherichia coli Alpha-Hemolysin HlyA Induces Host Cell Polarity Changes, Epithelial Barrier Dysfunction and Cell Detachment in Human Colon Carcinoma Caco-2 Cell Model via PTEN-Dependent Dysregulation of Cell Junctions, Toxins, 13, (2021); Bucker R., Krug S.M., Moos V., Bojarski C., Schweiger M.R., Kerick M., Fromm A., Janssen S., Fromm M., Hering N., Et al., Campylobacter jejuni impairs sodium transport and epithelial barrier function via cytokine release in human colon, Mucosal Immunol, 11, pp. 474-485, (2018); Buschmann M.M., Shen L., Rajapakse H., Raleigh D.R., Wang Y., Wang Y., Lingaraju A., Zha J., Abbott E., McAuley E., Et al., Occludin OCEL-domain interactions are required for maintenance and regulation of the tight junction barrier to macromolecular flux, Mol. Biol. Cell, 24, pp. 3056-3068, (2013); Krug S.M., Amasheh S., Richter J.F., Milatz S., Gunzel D., Westphal J.K., Huber O., Schulzke J.D., Fromm M., Tricellulin forms a barrier to macromolecules in tricellular tight junctions without affecting ion permeability, Mol. Biol. Cell, 20, pp. 3713-3724, (2009); Ikenouchi J., Sasaki H., Tsukita S., Furuse M., Tsukita S., Loss of occludin affects tricellular localization of tricellulin, Mol. Biol. Cell, 19, pp. 4687-4693, (2008); Gwee K.A., Collins S.M., Read N.W., Rajnakova A., Deng Y., Graham J.C., McKendrick M.W., Moochhala S.M., Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome, Gut, 52, pp. 523-526, (2003); Macsharry J., O'Mahony L., Fanning A., Bairead E., Sherlock G., Tiesman J., Fulmer A., Kiely B., Dinan T.G., Shanahan F., Et al., Mucosal cytokine imbalance in irritable bowel syndrome, Scand. J. Gastroenterol, 43, pp. 1467-1476, (2008); Lobo de Sa F.D., Heimesaat M.M., Bereswill S., Nattramilarasu P.K., Schulzke J.D., Bucker R., Resveratrol Prevents Campylobacter jejuni-Induced Leaky gut by Restoring Occludin and Claudin-5 in the Paracellular Leak Pathway, Front. Pharmacol, 12, (2021); Mankertz J., Tavalali S., Schmitz H., Mankertz A., Riecken E.O., Fromm M., Schulzke J.D., Expression from the human occludin promoter is affected by tumor necrosis factor alpha and interferon gamma, J. Cell Sci, 113, pp. 2085-2090, (2000); Hughes P.A., Harrington A.M., Castro J., Liebregts T., Adam B., Grasby D.J., Isaacs N.J., Maldeniya L., Martin C.M., Persson J., Et al., Sensory neuro-immune interactions differ between irritable bowel syndrome subtypes, Gut, 62, pp. 1456-1465, (2013); Miryan M., Soleimani D., Alavinejad P., Abbaspour M., Ostadrahimi A., Effects of propolis supplementation on irritable bowel syndrome with constipation (IBS-C) and mixed (IBS-M) stool pattern: A randomized, double-blind clinical trial, Food Sci. Nutr, 10, pp. 1899-1907, (2022)","J.-D. Schulzke; Clinical Physiology, Charité—Universitätsmedizin Berlin, Berlin, Campus Benjamin Franklin, 12203, Germany; email: joerg.schulzke@charite.de","","MDPI","","","","","","20734409","","","36672170","English","Cells","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85146784888"

"Iribarren C.; Nordlander S.; Sundin J.; Isaksson S.; Savolainen O.; Törnblom H.; Magnusson M.K.; Simrén M.; Öhman L.","Iribarren, Cristina (57200549137); Nordlander, Sofia (24780774900); Sundin, Johanna (56332687100); Isaksson, Stefan (21639681500); Savolainen, Otto (56011360600); Törnblom, Hans (7801453693); Magnusson, Maria K. (35248805000); Simrén, Magnus (57202571330); Öhman, Lena (14820629200)","57200549137; 24780774900; 56332687100; 21639681500; 56011360600; 7801453693; 35248805000; 57202571330; 14820629200","Fecal luminal factors from patients with irritable bowel syndrome induce distinct gene expression of colonoids","2022","Neurogastroenterology and Motility","34","10","e14390","","","","6","10.1111/nmo.14390","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85128884996&doi=10.1111%2fnmo.14390&partnerID=40&md5=895e7637fc93563dcb19b6ff523f39be","Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Chalmers Mass Spectrometry Infrastructure, Department of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden; Center for Functional GI and Motility Disorders, University of North Carolina, Chapel Hill, NC, United States","Iribarren C., Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Nordlander S., Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Sundin J., Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Isaksson S., Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Savolainen O., Chalmers Mass Spectrometry Infrastructure, Department of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden; Törnblom H., Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Magnusson M.K., Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Simrén M., Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, Center for Functional GI and Motility Disorders, University of North Carolina, Chapel Hill, NC, United States; Öhman L., Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden","Background: Alteration of the host-microbiota cross talk at the intestinal barrier may participate in the pathophysiology of irritable bowel syndrome (IBS). Therefore, we aimed to determine effects of fecal luminal factors from IBS patients on the colonic epithelium using colonoids. Methods: Colon-derived organoid monolayers, colonoids, generated from a healthy subject, underwent stimulation with fecal supernatants from healthy subjects and IBS patients with predominant diarrhea, phosphate-buffered saline (PBS), or lipopolysaccharide (LPS). Cytokines in cell cultures and fecal LPS were measured by ELISA and mRNA gene expression of monolayers was analyzed using Qiagen RT2 Profiler PCR Arrays. The fecal microbiota profile was determined by the GA-map™ dysbiosis test and the fecal metabolite profile was analyzed by untargeted liquid chromatography/mass spectrometry. Key results: Colonoid monolayers stimulated with fecal supernatants from healthy subjects (n = 7), PBS (n = 4) or LPS (n = 3) presented distinct gene expression profiles, with some overlap (R2Y = 0.70, Q2= 0.43). Addition of fecal supernatants from healthy subjects and IBS patients (n = 9) gave rise to different gene expression profiles of the colonoid monolayers (R2Y = 0.79, Q2= 0.64). Genes (n = 22) related to immune response (CD1D, TLR5) and barrier integrity (CLDN15, DSC2) contributed to the separation. Levels of proinflammatory cytokines in colonoid monolayer cultures were comparable when stimulated with fecal supernatants from either donor types. Fecal microbiota and metabolite profiles, but not LPS content, differed between the study groups. Conclusions: Fecal luminal factors from IBS patients induce a distinct colonic epithelial gene expression, potentially reflecting the disease pathophysiology. The culture of colonoids from healthy subjects with fecal supernatants from IBS patients may facilitate the exploration of IBS related intestinal micro-environmental and barrier interactions. © 2022 The Authors. Neurogastroenterology & Motility published by John Wiley & Sons Ltd.","colonoids; epithelial barrier; host-microbiota cross talk; intestinal microenvironment; irritable bowel syndrome","Cytokines; Diarrhea; Feces; Gene Expression; Humans; Irritable Bowel Syndrome; Lipopolysaccharides; Phosphates; RNA, Messenger; Toll-Like Receptor 5; CD1d antigen; cytokine; lipopolysaccharide; messenger RNA; phosphate buffered saline; toll like receptor 5; cytokine; lipopolysaccharide; messenger RNA; phosphate; toll like receptor 5; adult; Article; clinical article; colon epithelium; colonoid; controlled study; cytokine release; diarrhea; digestive system disease assessment; DNA determination; enzyme linked immunosorbent assay; feces microflora; female; gene expression; gene expression profiling; human; immune response; immunofluorescence; irritable bowel syndrome severity scoring system; irritable colon; liquid chromatography-mass spectrometry; male; metabolite; microenvironment; monolayer culture; protein expression; scoring system; supernatant; chemistry; feces; gene expression; metabolism","","phosphate, 14066-19-4, 14265-44-2; Cytokines, ; Lipopolysaccharides, ; Phosphates, ; RNA, Messenger, ; Toll-Like Receptor 5, ","","","Centre for Cellular Imaging at the University of Gothenburg, (VR‐RFI 2016‐00968); Faculty of Medicine at University of Gothenburg; Hubrecht Institute for Developmental Biology and Stem Cell Research; Menarini; Regional Executive Board; Sahlgrenska Academy at University of Gothenburg; Swedish government, (ALFGBG‐722331, ALFGBG‐723921); AstraZeneca; AbbVie; Västra Götalandsregionen, (VGFOUREG-931919); Västra Götalandsregionen; Baylor College of Medicine; Takeda Pharmaceutical Company, TPC; Universiteit Utrecht, UU; Kyowa Hakko Kirin; Shire; Ferring Pharmaceuticals; Medicinska Forskningsrådet, MFR, (2018‐02566, 2019‐01052); Medicinska Forskningsrådet, MFR","Funding text 1: The study was funded by Swedish Medical Research Council (grants no. 2019-01052 (LÖ) and 2018-02566 (MS)), Sahlgrenska Academy at University of Gothenburg (LÖ), Faculty of Medicine at University of Gothenburg (MS), grants from the Swedish state under the agreement between the Swedish government and the county councils; the ALF-agreement (ALFGBG-723921 (LÖ), ALFGBG-722331 (MS)) and Regional Executive Board, Region Västra Götaland (grant no. VGFOUREG-931919 (LÖ)) and Swedish Fund for Research without Animal Experiments (LÖ)Key points Cross talk between the luminal factors and the epithelial layer likely participates in the pathogenesis of irritable bowel syndrome (IBS). It may be explored in vitro using human colon crypt-derived organoid monolayers and fecal supernatants. Fecal luminal factors from healthy subjects and IBS induce distinct gene expression profiles of colon crypt-derived organoid monolayers. Here, we present a unique model of colonoid monolayers to evaluate IBS-specific regulation of colonic epithelium, which may provide improved understanding of the pathophysiology of IBS. Cross talk between the luminal factors and the epithelial layer likely participates in the pathogenesis of irritable bowel syndrome (IBS). It may be explored in vitro using human colon crypt-derived organoid monolayers and fecal supernatants. Fecal luminal factors from healthy subjects and IBS induce distinct gene expression profiles of colon crypt-derived organoid monolayers. Here, we present a unique model of colonoid monolayers to evaluate IBS-specific regulation of colonic epithelium, which may provide improved understanding of the pathophysiology of IBS. The authors gratefully acknowledge Daisy Jonkers and Pan Xu for sharing their knowledge isolating colonic crypts and passaging colonoids; and Gaelle Noel and Julie In, for their help regarding the expansion of colonoids, transwell cultures and immunofluorescence staining. Further, the authors acknowledge the contribution of Inga Rimkute and Baylor College of Medicine (Houston, Texas, USA) for specific advice on growing colonoids into monolayers. Additionally, the authors thank Hans Clevers group from Hubrecht Institute for Developmental Biology and Stem Cell Research (Utrecht University, Utrecht, Netherlands) for providing Noggin and Wnt-3A cell lines together with protocols for conditioned media. Chalmers Mass Spectrometry Infrastructure is acknowledged for performing on the metabolomics analyses. Last, the authors acknowledge the Centre for Cellular Imaging at the University of Gothenburg and the National Microscopy Infrastructure, NMI (VR-RFI 2016-00968) for the support and assistance in microscopy.; Funding text 2: The authors gratefully acknowledge Daisy Jonkers and Pan Xu for sharing their knowledge isolating colonic crypts and passaging colonoids; and Gaelle Noel and Julie In, for their help regarding the expansion of colonoids, transwell cultures and immunofluorescence staining. Further, the authors acknowledge the contribution of Inga Rimkute and Baylor College of Medicine (Houston, Texas, USA) for specific advice on growing colonoids into monolayers. Additionally, the authors thank Hans Clevers group from Hubrecht Institute for Developmental Biology and Stem Cell Research (Utrecht University, Utrecht, Netherlands) for providing Noggin and Wnt‐3A cell lines together with protocols for conditioned media. Chalmers Mass Spectrometry Infrastructure is acknowledged for performing on the metabolomics analyses. Last, the authors acknowledge the Centre for Cellular Imaging at the University of Gothenburg and the National Microscopy Infrastructure, NMI (VR‐RFI 2016‐00968) for the support and assistance in microscopy. ; Funding text 3: The study was funded by Swedish Medical Research Council (grants no. 2019‐01052 (LÖ) and 2018‐02566 (MS)), Sahlgrenska Academy at University of Gothenburg (LÖ), Faculty of Medicine at University of Gothenburg (MS), grants from the Swedish state under the agreement between the Swedish government and the county councils; the ALF‐agreement (ALFGBG‐723921 (LÖ), ALFGBG‐722331 (MS)) and Regional Executive Board, Region Västra Götaland (grant no. VGFOUREG‐931919 (LÖ)) and Swedish Fund for Research without Animal Experiments (LÖ) Key points ; Funding text 4: CI, SN, JS, SI, OS and MKM do not have conflict of interest to declare. HT has served as advisory board member for Almirall, Allergan, and Shire. MS has received unrestricted research grants from Danone, Ferring Pharmaceuticals and Glycom (now DSM); served as advisory board member for Almirall, Allergan, Albireo, AstraZeneca, Danone, Nestlé, Glycom (now part of DSM), Menarini, and Shire, as well as a speaker for AlfaSigma, Allergan, Almirall, Alimentary Health, Biocodex, Kyowa Kirin, Menarini, Tillotts, Takeda and Shire. LÖ has received a financial support for research by Genetic Analysis AS, Biocodex, Danone Research and AstraZeneca and served as Consultant/Advisory Board member for Genetic Analysis AS, and as a speaker for Biocodex, Ferring Pharmaceuticals, Takeda, AbbVie, and Meda. ","Ohman L., Tornblom H., Simren M., Crosstalk at the mucosal border: importance of the gut microenvironment in IBS, Nat Rev Gastroenterol Hepatol, 12, 1, pp. 36-49, (2015); Martinez C., Gonzalez-Castro A., Vicario M., Santos J., Cellular and molecular basis of intestinal barrier dysfunction in the irritable bowel syndrome, Gut Liv, 6, 3, pp. 305-315, (2012); Vancamelbeke M., Vermeire S., The intestinal barrier: a fundamental role in health and disease, Expert Rev Gastroenterol Hepatol, 11, 9, pp. 821-834, (2017); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, 1-2, pp. 41-46, (2009); Shulman R.J., Jarrett M.E., Cain K.C., Broussard E.K., Heitkemper M.M., Associations among gut permeability, inflammatory markers, and symptoms in patients with irritable bowel syndrome, J Gastroenterol, 49, 11, pp. 1467-1476, (2014); Bennet S.M.P., Sundin J., Magnusson M.K., Et al., Altered intestinal antibacterial gene expression response profile in irritable bowel syndrome is linked to bacterial composition and immune activation, Neurogastroenterol Motil, 30, 12, (2018); Tap J., Derrien M., Tornblom H., Et al., Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome, Gastroenterology, 152, 1, pp. 111-123 e8, (2017); Sundin J., Aziz I., Nordlander S., Et al., Evidence of altered mucosa-associated and fecal microbiota composition in patients with Irritable Bowel Syndrome, Sci Rep, 10, 1, (2020); Zhang W.-X., Zhang Y.U., Qin G., Et al., Altered profiles of fecal metabolites correlate with visceral hypersensitivity and may contribute to symptom severity of diarrhea-predominant irritable bowel syndrome, World J Gastroenterol, 25, 43, pp. 6416-6429, (2019); Lee J.S., Kim S.-Y., Chun Y.S., Et al., Characteristics of fecal metabolic profiles in patients with irritable bowel syndrome with predominant diarrhea investigated using 1H-NMR coupled with multivariate statistical analysis, Neurogastroenterol Motil, 3, (2020); Ahluwalia B., Iribarren C., Magnusson M.K., Et al., A distinct faecal microbiota and metabolite profile linked to bowel habits in patients with irritable bowel syndrome, Cells, 10, 6, (2021); Ludidi S., Jonkers D., Elamin E., Et al., The intestinal barrier in irritable bowel syndrome: subtype-specific effects of the systemic compartment in an in vitro model, PLoS One, 10, 5, (2015); Edogawa S., Edwinson A.L., Peters S.A., Et al., Serine proteases as luminal mediators of intestinal barrier dysfunction and symptom severity in IBS, Gut, 69, 1, pp. 62-73, (2020); Piche T., Barbara G., Aubert P., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators, Gut, 58, 2, pp. 196-201, (2009); Wilms E., Troost F.J., Elizalde M., Et al., Intestinal barrier function is maintained with aging – a comprehensive study in healthy subjects and irritable bowel syndrome patients, Sci Rep, 10, 1, (2020); Altay G., Larranaga E., Tosi S., Et al., Self-organized intestinal epithelial monolayers in crypt and villus-like domains show effective barrier function, Sci Rep, 9, 1, (2019); Castellanos-Gonzalez A., Cabada M.M., Nichols J., Gomez G., White A.C., Human primary intestinal epithelial cells as an improved in vitro model for Cryptosporidium parvum infection, Infect Immun, 81, 6, pp. 1996-2001, (2013); Noel G., Baetz N.W., Staab J.F., Et al., A primary human macrophage-enteroid co-culture model to investigate mucosal gut physiology and host-pathogen interactions, Sci Rep, 7, 1, (2017); In J.G., Foulke-Abel J., Clarke E., Kovbasnjuk O., Human colonoid monolayers to study interactions between pathogens, commensals, and host intestinal epithelium, J Vis Exp, 146, (2019); Sato T., Stange D.E., Ferrante M., Et al., Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium, Gastroenterology, 141, 5, pp. 1762-1772, (2011); George M.M., Rahman M., Connors J., Stadnyk A.W., Opinion: are organoids the end of model evolution for studying host intestinal epithelium/microbe interactions?, Microorganisms, 7, 10, (2019); Kashfi S.M.H., Almozyan S., Jinks N., Koo B.K., Nateri A.S., Morphological alterations of cultured human colorectal matched tumour and healthy organoids, Oncotarget, 9, 12, pp. 10572-10584, (2018); Heaton K.W., O'Donnell L.J., An office guide to whole-gut transit time. Patients’ recollection of their stool form, J Clin Gastroenterol, 19, 1, pp. 28-30, (1994); Francis C.Y., Morris J., Whorwell P.J., The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress, Aliment Pharmacol Ther, 11, 2, pp. 395-402, (1997); Iribarren C., Tornblom H., Aziz I., Et al., Human milk oligosaccharide supplementation in irritable bowel syndrome patients: a parallel, randomized, double-blind, placebo-controlled study, Neurogastroenterol Motil, 32, 10, (2020); Lacy B.E., Mearin F., Chang L., Et al., Bowel disorders, Gastroenterology, 150, 6, pp. 1393-1407.e5, (2016); In J., Foulke-Abel J., Zachos N.C., Et al., Enterohemorrhagic Escherichia coli reduces mucus and intermicrovillar bridges in human stem cell-derived colonoids, Cell Mol Gastroenterol Hepatol, 2, 1, pp. 48-62.e3, (2016); Haileselassie Y., Johansson M.A., Zimmer C.L., Et al., Lactobacilli regulate Staphylococcus aureus 161:2-induced pro-inflammatory T-cell responses in vitro, PLoS One, 8, 10, (2013); Zheng R., Brunius C., Shi L., Et al., Prediction and evaluation of the effect of pre-centrifugation sample management on the measurable untargeted LC-MS plasma metabolome, Anal Chim Acta, 1182, (2021); Klavus A., Kokla M., Noerman S., Et al., “Notame”: workflow for non-targeted LC–MS metabolic profiling, Metabolites, 10, 4, (2020); Casen C., Vebo H.C., Sekelja M., Et al., Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD, Aliment Pharmacol Ther, 42, 1, pp. 71-83, (2015); James S.C., Fraser K., Young W., McNabb W.C., Roy N.C., Gut microbial metabolites and biochemical pathways involved in irritable bowel syndrome: effects of diet and nutrition on the microbiome, J Nutr, 150, 5, pp. 1012-1021, (2019); d'Aldebert E., Quaranta M., Sebert M., Et al., Characterization of human colon organoids from inflammatory bowel disease patients, Front Cell Dev Biol, 8, (2020); Liu L., Saitz-Rojas W., Smith R., Et al., Mucus layer modeling of human colonoids during infection with enteroaggragative E. coli, Sci Rep, 10, 1, (2020); Zhang J., Huang Y.-J., Yoon J.Y., Et al., Primary human colonic mucosal barrier crosstalk with super oxygen-sensitive Faecalibacterium prausnitzii in continuous culture, Med, 2, 1, pp. 74-98.e9, (2021); Aguilera-Lizarraga J., Florens M.V., Van Brussel T., Et al., Expression of immune-related genes in rectum and colon descendens of irritable bowel syndrome patients is unrelated to clinical symptoms, Neurogastroenterol Motil, 31, 6, (2019); Zhen Y., Chu C., Zhou S., Qi M., Shu R., Imbalance of tumor necrosis factor-α, interleukin-8 and interleukin-10 production evokes barrier dysfunction, severe abdominal symptoms and psychological disorders in patients with irritable bowel syndrome-associated diarrhea, Mol Med Rep, 12, 4, pp. 5239-5245, (2015); Huang X., Yang Y., Targeting the TLR9-MyD88 pathway in the regulation of adaptive immune responses, Expert Opin Ther Targets, 14, 8, pp. 787-796, (2010); Bel S., Pendse M., Wang Y., Et al., Paneth cells secrete lysozyme via secretory autophagy during bacterial infection of the intestine, Science, 357, 6355, pp. 1047-1052, (2017); Olszak T., Neves J.F., Dowds C.M., Et al., Protective mucosal immunity mediated by epithelial CD1d and IL-10, Nature, 509, 7501, pp. 497-502, (2014); Wang Y., Liu L., Moore D.J., Et al., An LGG-derived protein promotes IgA production through upregulation of APRIL expression in intestinal epithelial cells, Mucosal Immunol, 10, 2, pp. 373-384, (2017); Luissint A.-C., Parkos C.A., Nusrat A., Inflammation and the intestinal barrier: leukocyte-epithelial cell interactions, cell junction remodeling, and mucosal repair, Gastroenterology, 151, 4, pp. 616-632, (2016); Han X., Lee A., Huang S., Gao J., Spence J.R., Owyang C., Lactobacillus rhamnosus GG prevents epithelial barrier dysfunction induced by interferon-gamma and fecal supernatants from irritable bowel syndrome patients in human intestinal enteroids and colonoids, Gut Microbes, 10, 1, pp. 59-76, (2019); Menard S., Cerf-Bensussan N., Heyman M., Multiple facets of intestinal permeability and epithelial handling of dietary antigens, Mucosal Immunol, 3, 3, pp. 247-259, (2010); Serena G., Huynh D., Lima R.S., Et al., Intestinal epithelium modulates macrophage response to gliadin in celiac disease, Front Nutr, 6, (2019); Wang Y., Kim R., Hwang S.-H.J., Dutton J., Sims C.E., Allbritton N.L., Analysis of interleukin 8 secretion by a stem-cell-derived human-intestinal-epithelial-monolayer platform, Anal Chem, 90, 19, pp. 11523-11530, (2018); Maasfeh L., Hartlova A., Isaksson S., Et al., Impaired luminal control of intestinal macrophage maturation in patients with ulcerative colitis during remission, Cell Mol Gastroenterol Hepatol, 12, 4, pp. 1415-1432, (2021); Pittayanon R., Lau J.T., Yuan Y., Et al., Gut microbiota in patients with irritable bowel syndrome - a systematic review, Gastroenterology, 157, 1, pp. 97-108, (2019); Krogius-Kurikka L., Lyra A., Malinen E., Et al., Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers, BMC Gastroenterol, 9, (2009); Mei L., Zhou J., Su Y., Et al., Gut microbiota composition and functional prediction in diarrhea-predominant irritable bowel syndrome, BMC Gastroenterol, 21, 1, (2021); Kerckhoffs A.P.M., Ben-Amor K., Samsom M., Et al., Molecular analysis of faecal and duodenal samples reveals significantly higher prevalence and numbers of Pseudomonas aeruginosa in irritable bowel syndrome, J Med Microbiol, 60, pp. 236-245, (2011); Maharshak N., Ringel Y., Katibian D., Et al., Fecal and mucosa-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome, Dig Dis Sci, 63, 7, pp. 1890-1899, (2018); Leclercq S., Matamoros S., Cani P.D., Et al., Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity, Proc Natl Acad Sci USA, 111, 42, pp. E4485-E4493, (2014); Altomare A., Di Rosa C., Imperia E., Emerenziani S., Cicala M., Guarino M.P.L., Diarrhea predominant-irritable bowel syndrome (IBS-D): effects of different nutritional patterns on intestinal dysbiosis and symptoms, Nutrients, 13, 5, (2021); Tailford L.E., Crost E.H., Kavanaugh D., Juge N., Mucin glycan foraging in the human gut microbiome, Front Genet, 6, (2015); Taverniti V., Guglielmetti S., Methodological issues in the study of intestinal microbiota in irritable bowel syndrome, World J Gastroenterol, 20, 27, pp. 8821-8836, (2014); Lee J.S., Wang R.X., Alexeev E.E., Et al., Hypoxanthine is a checkpoint stress metabolite in colonic epithelial energy modulation and barrier function, J Biol Chem, 293, 16, pp. 6039-6051, (2018); Zhou S.-Y., Gillilland M., Wu X., Et al., FODMAP diet modulates visceral nociception by lipopolysaccharide-mediated intestinal inflammation and barrier dysfunction, J Clin Invest, 128, 1, pp. 267-280, (2018)","L. Öhman; Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; email: lena.ohman@microbio.gu.se","","John Wiley and Sons Inc","","","","","","13501925","","NMOTE","35485994","English","Neurogastroenterol. Motil.","Article","Final","All Open Access; Hybrid Gold Open Access","Scopus","2-s2.0-85128884996"

"Sun M.; Zhang Y.; Song Y.; Guo J.; Wang Y.; Xin C.; Gu D.; Sun J.; Pei L.","Sun, Mengzhu (57223130073); Zhang, Yujie (57223142525); Song, Yafang (57207466549); Guo, Jing (57221092084); Wang, Yuhang (57211463803); Xin, Chen (59116571400); Gu, Dongmei (57219743075); Sun, Jianhua (57211454192); Pei, Lixia (53985252400)","57223130073; 57223142525; 57207466549; 57221092084; 57211463803; 59116571400; 57219743075; 57211454192; 53985252400","Electroacupuncture alleviates water avoidance stress-induced irritable bowel syndrome in mice by improving intestinal barrier functions and suppressing the expression of inflammatory cytokines","2023","Journal of Traditional Chinese Medicine","43","3","","494","500","6","2","10.19852/j.cnki.jtcm.2023.03.001","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85159554533&doi=10.19852%2fj.cnki.jtcm.2023.03.001&partnerID=40&md5=504215f1b22069e85928a3c0af50312b","Department of acupuncture, Affiliated Hospital of Nanjing University of Chinese Meidicne, Nanjing, 210023, China; Department of acupuncture, Jiangsu Province Hospital of Chinese Medicine, Nanjing, 210029, China","Sun M., Department of acupuncture, Affiliated Hospital of Nanjing University of Chinese Meidicne, Nanjing, 210023, China; Zhang Y., Department of acupuncture, Affiliated Hospital of Nanjing University of Chinese Meidicne, Nanjing, 210023, China; Song Y., Department of acupuncture, Affiliated Hospital of Nanjing University of Chinese Meidicne, Nanjing, 210023, China; Guo J., Department of acupuncture, Affiliated Hospital of Nanjing University of Chinese Meidicne, Nanjing, 210023, China; Wang Y., Department of acupuncture, Affiliated Hospital of Nanjing University of Chinese Meidicne, Nanjing, 210023, China; Xin C., Department of acupuncture, Affiliated Hospital of Nanjing University of Chinese Meidicne, Nanjing, 210023, China; Gu D., Department of acupuncture, Affiliated Hospital of Nanjing University of Chinese Meidicne, Nanjing, 210023, China; Sun J., Department of acupuncture, Jiangsu Province Hospital of Chinese Medicine, Nanjing, 210029, China; Pei L., Department of acupuncture, Jiangsu Province Hospital of Chinese Medicine, Nanjing, 210029, China","OBJECTIVE: To evaluate the effects and related mechanisms of electroacupuncture (EA) on irritable bowel syndrome (IBS). METHODS: Male C57BL/6 mice were randomly allocated into normal, model, and EA groups. Experimental IBS mice models were established by exposure to water avoidance stress (WAS). Mice in the EA group were treated with EA at bilateral Tianshu (ST 25) and Zusanli (ST 36) for 7 consecutive days, 15 min each day. Abdominal withdrawal reflex (AWR) tests and intestinal motility tests were performed to evaluate visceral sensitivity and intestinal motility of mice. Expression levels of tight junction proteins (TJPs) and inflammatory cytokines in colon tissues were determined through immunofluorescence, real-time polymerase chain reactions (PCR) and Western blot assays. RESULTS: EA alleviated visceral hypersensitivity and intestinal hypermotility in WAS-induced IBS mice. Moreover, EA promoted the expression of zonula occludens (ZO)-1, claudin-1, and occludin while suppressing the expression of interleukin (IL)-8, interferon (IFN)-γ, and tumor necrosis factor (TNF)-αin water avoidance stress (WAS)-induced irritable bowel syndrome (IBS) mice. CONCLUSION: EA alleviated WAS-induced IBS in mice by promoting intestinal barrier functions and suppressing the expression of inflammatory cytokines. © 2023 JTCM. All rights reserved.","electroacupuncture; inflammatory cytokines; intestinal barrier function; irritable bowel syndrome; tight junction proteins","Acupuncture Points; Animals; Cytokines; Electroacupuncture; Irritable Bowel Syndrome; Male; Mice; Mice, Inbred C57BL; Rats; Rats, Sprague-Dawley; Water; claudin 1; cytokine; gamma interferon; interleukin 8; occludin; protein ZO1; tight junction protein; tumor necrosis factor; water; cytokine; water; animal experiment; animal model; animal tissue; antiinflammatory activity; Article; avoidance behavior; C57BL 6 mouse; colon tissue; controlled study; electroacupuncture; gene sequence; histopathology; immunofluorescence; intestinal dysmotility; intestine function; intestine motility; irritable colon; male; mouse; mRNA expression level; nonhuman; physiological stress; protein expression; real time polymerase chain reaction; tianshu acupoint; treatment duration; treatment outcome; visceral hyperalgesia; Western blotting; withdrawal reflex; zusanli acupoint; acupuncture point; animal; C57BL mouse; genetics; rat; Sprague Dawley rat","","claudin 1, 329338-06-9; gamma interferon, 82115-62-6; interleukin 8, 114308-91-7; occludin, 176304-61-3; water, 7732-18-5; Cytokines, ; Water, ","","","Jiangsu Provincial Administration, (SLJ0206); Nanjing University of Traditional Chinese Medicine; Peak Talent Project of Jiangsu Province Hospital, (y2018rc05); Research and Practice Innovation Program for Postgraduates of Jiangsu Province, (KYCX20_1469); National Natural Science Foundation of China, NSFC, (81804193); National Natural Science Foundation of China, NSFC; Nanjing University of Chinese Medicine, NJUCM","Funding text 1: Supported by the Research and Practice Innovation Program for Postgraduates of Jiangsu Province (Mechanism of Electroacupuncture Regulating Bile Acid Receptor to Alleviate Visceral Hypersensitivity in Irritable Bowel Syndrome; No. KYCX20_1469), the National Natural Science Fund (Mechanism of Electroacupuncture Regulating CRF-NLRP6 Inflammasome-Related Pathways in Intestinal Flora Immune Dialogue; No. 81804193), the Leading Talents Project of Jiangsu Provincial Administration of TCM (Clinical Effect and Mechanism of Acupuncture and Moxibustion on Irritable Bowel Syndrome; No. SLJ0206), and the Peak Talent Project of Jiangsu Province Hospital of TCM (Clinical Effect and Mechanism of Acupuncture and Moxibustion in the Treatment of Functional Gastrointestinal Diseases; No. y2018rc05) We are thankful to the Experimental Animal Center of Nanjing University of Traditional Chinese Medicine for providing the necessary study facilities.; Funding text 2: SUN Mengzhu, ZHANG Yujie, SONG Yafang, GUO Jing, WANG Yuhang, XIN Chen, GU Dongmei, Department of acupuncture, Affiliated Hospital of Nanjing University of Chinese Meidicne, Nanjing 210023, China SUN Jianhua, PEI Lixia, Department of acupuncture, Jiangsu Province Hospital of Chinese Medicine, Nanjing 210029, China Supported by the Research and Practice Innovation Program for Postgraduates of Jiangsu Province (Mechanism of Electroacupuncture Regulating Bile Acid Receptor to Alleviate Visceral Hypersensitivity in Irritable Bowel Syndrome; No. KYCX20_1469), the National Natural Science Fund (Mechanism of Electroacupuncture Regulating CRF-NLRP6 Inflammasome-Related Pathways in Intestinal Flora Immune Dialogue; No. 81804193), the Leading Talents Project of Jiangsu Provincial Administration of TCM (Clinical Effect and Mechanism of Acupuncture and Moxibustion on Irritable Bowel Syndrome; No. SLJ0206), and the Peak Talent Project of Jiangsu Province Hospital of TCM (Clinical Effect and Mechanism of Acupuncture and Moxibustion in the Treatment of Functional Gastrointestinal Diseases; No. y2018rc05) Correspondence to: PEI Lixia, Department of acupuncture, Jiangsu Province Hospital of Chinese Medicine, Nanjing 210029, China. plx11801758@163.com; SUN Jianhua, Department of acupuncture, Jiangsu Province Hospital of Chinese Medicine, Nanjing 210029, China. drjhsun@sina.com Telephone: +86-13851402838; +86-13914722816 DOI: 10.19852/j.cnki.jtcm.2023.03.001 Received: February 12, 2021 Accepted: May 7, 2021 Available online: April 28, 2023","Sultan S, Malhotra A., Irritable bowel syndrome, Ann Intern Med, 166, pp. C81-C96, (2017); Posserud I, Syrous A, Lindstrom L, Et al., Altered rectal perception in irritable bowel syndrome is associated with symptom severity, Gastroenterology, 133, pp. 1113-1123, (2007); Vancamelbeke M, Vermeire S., The intestinal barrier: a fundamental role in health and disease, Expert Rev Gastroenterol Hepatol, 11, pp. 821-834, (2017); Bertiaux-Vandaele N, Youmba SB, Belmonte L, Et al., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am J Gastroenterol, 106, pp. 2165-2173, (2011); Nozu T, Miyagishi S, Nozu R, Et al., Losartan improves visceral sensation and gut barrier in a rat model of irritable bowel syndrome, Neurogastroenterol Motil, 32, (2020); Nusrat A, Turner JR, Madara JL., Molecular physiology and pathophysiology of tight junctions. IV. Regulation of tight junctions by extracellular stimuli: nutrients, cytokines, and immune cells, Am J Physiol Gastrointest Liver Physiol, 279, pp. G851-G857, (2000); Patel SR, Singh A, Misra V, Et al., Levels of interleukins 2, 6, 8, and 10 in patients with irritable bowel syndrome, Indian J Pathol Microbiol, 60, pp. 385-389, (2017); de Souza HS, Fiocchi C., Immunopathogenesis of IBD: current state of the art, Nat Rev Gastroenterol Hepatol, 13, pp. 13-27, (2016); Neurath MF., Cytokines in inflammatory bowel disease, Nat Rev Immunol, 14, pp. 329-342, (2014); Madara JL, Stafford J., Interferon-gamma directly affects barrier function of cultured intestinal epithelial monolayers, J Clin Invest, 83, pp. 724-727, (1989); Mullin JM, Laughlin KV, Marano CW, Et al., Modulation of tumor necrosis factor-induced increase in renal (LLC-PK1) transepithelial permeability, Am J Physiol, 263, pp. F915-F924, (1992); Milard M, Penhoat A, Durand A, Et al., Acute effects of milk polar lipids on intestinal tight junction expression: towards an impact of sphingomyelin through the regulation of IL-8 secretion?, J Nutr Biochem, 65, pp. 128-138, (2019); Song YF, Geng H, Chen L, Et al., Electroacupuncture relieves irritable bowel syndrome by increasing expression of nucleotide-binding oligomerization domain protein-like receptor family pyrin domain containing 6 in water-avoidance stress mice, J Tradit Chin Med, 40, pp. 407-413, (2020); Fourie NH, Wang D, Abey SK, Et al., Structural and functional alterations in the colonic microbiome of the rat in a model of stress induced irritable bowel syndrome, Gut Microbes, 8, pp. 33-45, (2017); Ren X, Liu L, Gamallat Y, Et al., Enteromorpha and polysaccharides from enteromorpha ameliorate loperamideinduced constipation in mice, Biomed Pharmacother, 96, pp. 1075-1081, (2017); Rojas-Macias V, Rodriguez-Fandino O, Jimenez-Ponce F, Et al., External validity of a relevant model for irritable bowel syndrome (IBS) using chronic stress by water avoidance in Wistar rats, Rev Gastroenterol Mex, 75, pp. 421-426, (2010); Song YF, Pei LX, Chen L, Et al., Electroacupuncture relieves irritable bowel syndrome by regulating IL-18 and gut microbial dysbiosis in a trinitrobenzene sulfonic acid-induced post-inflammatory animal model, Am J Chin Med, 48, pp. 77-90, (2020); Chen Y, Zhao Y, Luo DN, Et al., Electroacupuncture regulates disorders of gut-brain interaction by decreasing corticotropinreleasing factor in a rat model of IBS, Gastroenterol Res Pract, (2019); Zhang F, Ma Z, Weng Z, Et al., P2X3 receptor in primary afferent neurons mediates the relief of visceral hypersensitivity by electroacupuncture in an irritable bowel syndrome rat model, Gastroenterol Res Pract, (2020); Du MH, Luo HM, Hu S, Et al., Electroacupuncture improves gut barrier dysfunction in prolonged hemorrhagic shock rats through vagus anti-inflammatory mechanism, World J Gastroenterol, 19, pp. 5988-5999, (2013); Pope JL, Bhat AA, Sharma A, Et al., Claudin-1 regulates intestinal epithelial homeostasis through the modulation of Notch-signalling, Gut, 63, pp. 622-634, (2014); Coeffier M, Gloro R, Boukhettala N, Et al., Increased proteasomemediated degradation of occludin in irritable bowel syndrome, Am J Gastroenterol, 105, pp. 1181-1188, (2010); Piche T., Tight junctions and IBS-the link between epithelial permeability, low-grade inflammation, and symptom generation?, Neurogastroenterol Motil, 26, pp. 296-302, (2014); Bertiaux-Vandaele N, Youmba SB, Belmonte L, Et al., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am J Gastroenterol, 106, pp. 2165-2173, (2011); Sinagra E, Morreale GC, Mohammadian G, Et al., New therapeutic perspectives in irritable bowel syndrome: targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond, World J Gastroenterol, 23, pp. 6593-6627, (2017); Choghakhori R, Abbasnezhad A, Hasanvand A, Et al., Inflammatory cytokines and oxidative stress biomarkers in irritable bowel syndrome: association with digestive symptoms and quality of life, Cytokine, 93, pp. 34-43, (2017); Ji LJ, Li F, Zhao P, Et al., Silencing interleukin 1alpha underlies a novel inhibitory role of miR-181c-5p in alleviating low-grade inflammation of rats with irritable bowel syndrome, J Cell Biochem, 120, pp. 15268-15279, (2019); Yang J, Shang B, Shi H, Et al., The role of toll-like receptor 4 and mast cell in the ameliorating effect of electroacupuncture on visceral hypersensitivity in rats, Neurogastroenterol Motil, 31, (2019); Xu D, Gao J, Gillilland MR, Et al., Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats, Gastroenterology, 146, pp. 484-496, (2014); de Magalhaes SF, Manzo LP, de Faria FM, Et al., Inflammatory pain in peripheral tissue depends on the activation of the TNF-alpha type 1 receptor in the primary afferent neuron, Eur J Neurosci, 53, pp. 376-389, (2021); Zhen Y, Chu C, Zhou S, Et al., Imbalance of tumor necrosis factor-alpha, interleukin-8 and interleukin-10 production evokes barrier dysfunction, severe abdominal symptoms and psychological disorders in patients with irritable bowel syndrome-associated diarrhea, Mol Med Rep, 12, pp. 5239-5245, (2015); Barbaro MR, Di Sabatino A, Cremon C, Et al., Interferon-gamma is increased in the gut of patients with irritable bowel syndrome and modulates serotonin metabolism, Am J Physiol Gastrointest Liver Physiol, 310, pp. G439-G447, (2016)","J. Sun; Department of acupuncture, Jiangsu Province Hospital of Chinese Medicine, Nanjing, 210029, China; email: drjhsun@sina.com; L. Pei; Department of acupuncture, Jiangsu Province Hospital of Chinese Medicine, Nanjing, 210029, China; email: plx11801758@163.com","","Journal of Traditional Chinese Medicine","","","","","","02552922","","JTCME","37147750","English","J. Trad. Chin. Med.","Article","Final","","Scopus","2-s2.0-85159554533"

"Omarova S.; Awad K.; Moos V.; Püning C.; Gölz G.; Schulzke J.-D.; Bücker R.","Omarova, Sholpan (58163484800); Awad, Karem (57188694305); Moos, Verena (6602224334); Püning, Christoph (57216042644); Gölz, Greta (12647649300); Schulzke, Jörg-Dieter (35502556700); Bücker, Roland (10043068400)","58163484800; 57188694305; 6602224334; 57216042644; 12647649300; 35502556700; 10043068400","Intestinal Barrier in Post-Campylobacter jejuni Irritable Bowel Syndrome","2023","Biomolecules","13","3","449","","","","8","10.3390/biom13030449","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85151221533&doi=10.3390%2fbiom13030449&partnerID=40&md5=76988cd8cc2619e91c8cd6610d39b029","Clinical Physiology, Charité–Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, 12203, Germany; Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité–Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, 12203, Germany; Department of Veterinary Medicine, Center for Veterinary Public Health, Institute of Food Safety and Food Hygiene, Freie Universität Berlin, Berlin, 14163, Germany","Omarova S., Clinical Physiology, Charité–Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, 12203, Germany; Awad K., Clinical Physiology, Charité–Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, 12203, Germany; Moos V., Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité–Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, 12203, Germany; Püning C., Department of Veterinary Medicine, Center for Veterinary Public Health, Institute of Food Safety and Food Hygiene, Freie Universität Berlin, Berlin, 14163, Germany; Gölz G., Department of Veterinary Medicine, Center for Veterinary Public Health, Institute of Food Safety and Food Hygiene, Freie Universität Berlin, Berlin, 14163, Germany; Schulzke J.-D., Clinical Physiology, Charité–Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, 12203, Germany, Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité–Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, 12203, Germany; Bücker R., Clinical Physiology, Charité–Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, 12203, Germany","Background: Campylobacter jejuni (C. jejuni) is one of the most common causes of bacterial gastroenteritis worldwide. One sequela of this infection is the development of post-infectious irritable bowel syndrome (PI-IBS). It has been suggested that a dysfunctional intestinal barrier may promote IBS development. We aimed to test this hypothesis against the background of the leaky gut concept for low-grade inflammation in PI-IBS. Methods: We identified patients with persistent PI-IBS symptoms after C. jejuni infection. During sigmoidoscopy, forceps biopsies were obtained for electrophysiological measurements of epithelial transport and barrier function in miniaturized Ussing devices. C. jejuni absence was checked by PCR and cytokine production with immunohistochemistry. Results: In PI-IBS, the epithelial resistance of the colon epithelium was unaltered, reflecting an intact paracellular pathway. In contrast, temperature-dependent horseradish peroxidase (HRP, 44 kDa) permeation increased. Short-circuit current (Isc) reflecting active anion secretion and ENaC-dependent electrogenic sodium absorption was unaffected. Early endosome antigen-1 (EEA1) and IL-4 levels increased. C. jejuni is not incorporated into the resident microbiota of the colon mucosa in PI-IBS. Conclusions: In PI-IBS after C. jejuni infection, macromolecule uptake via endocytosis was enhanced, leading to low-grade inflammation with pro-inflammatory cytokine release. The findings will allow C. jejuni-induced pathomechanisms to be targeted during infection and, thereafter to reduce sequelae such as PI-IBS. © 2023 by the authors.","antigen entry; barrier function; Campylobacter jejuni; cytokine; endocytosis; irritable bowel syndrome; leaky gut; permeability; post-infectious irritable bowel syndrome; tight junction; transcytosis","Campylobacter Infections; Campylobacter jejuni; Cytokines; Humans; Inflammation; Irritable Bowel Syndrome; aldosterone; amiloride; early endosome antigen 1; epithelial sodium channel; gamma interferon; horseradish peroxidase; interleukin 10; interleukin 1beta; interleukin 22; interleukin 4; interleukin 6; tumor necrosis factor; cytokine; antigen entry; Article; biological functions; biopsy technique; Campylobacter enteritis; clinical feature; colon biopsy; colon epithelium; colon mucosa; colonoscopy; controlled study; DNA extraction; electric resistance; electrogenic anion secretion; electrogenic sodium absorption; electrophysiology; endocytosis; epithelial resistance; forceps biopsies; human; human tissue; immunohistochemistry; impedance spectroscopy; inflamed subepithelium; intestinal barrier; intestine cell; irritable colon; leaky gut; low grade inflammation; microflora; multiplex polymerase chain reaction; overall resistance defect; paracellular pathway; pathological anatomy; permeability barrier; post campylobacter jejuni irritable bowel syndrome; resident microbiota; short circuit current; sigmoidoscopy; signal transduction; sodium absorption; tight junction; transcytosis; transepithelial resistance; Campylobacter jejuni; campylobacteriosis; complication; inflammation; metabolism; microbiology","","aldosterone, 52-39-1, 6251-69-0; amiloride, 2016-88-8, 2609-46-3; gamma interferon, 82115-62-6; interleukin 22, 457106-70-6, 478219-35-1, 554460-75-2; Cytokines, ","CFX96, Biorad, United States; DNeasy, Qiagen, Germany; QIAamp, Qiagen, Germany","Biorad, United States; Qiagen, Germany; Qiagen, Germany","Sonnenfeld-Stiftung Berlin; Deutsche Forschungsgemeinschaft, DFG, (559/11-5–175142815, GRK 2318–318905415); Bundesministerium für Bildung und Forschung, BMBF, (IP2/01KI2007A, IP8/01KI2007D)","This research was funded by the Deutsche Forschungsgemeinschaft (Schu 559/11-5–175142815 and GRK 2318–318905415 (C01)) and the Sonnenfeld-Stiftung Berlin. This research was partly supported by the German Federal Ministry of Education and Research (BMBF) in frame of the zoonoses research consortium PAC-Campylobacter (project IP2/01KI2007A and project IP8/01KI2007D).","Spiller R.C., Jenkins D., Thornley J.P., Hebden J.M., Wright T., Skinner M., Neal K.R., Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, pp. 804-811, (2000); Kaakoush N.O., Castano-Rodriguez N., Global Epidemiology of Campylobacter Infection, Clin. Microbiol. Rev, 28, pp. 687-720, (2015); Lovell R.M., Ford A.C., Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis, Clin. Gastroenterol. Hepatol, 10, pp. 712-721, (2012); Scallan Walter E.J., Crim S.M., Bruce B.B., Griffin P.M., Postinfectious Irritable Bowel Syndrome After Campylobacter Infection, Am. J. Gastroenterol, 114, pp. 1649-1656, (2019); Bucker R., Krug S.M., Moos V., Bojarski C., Schweiger M.R., Kerick M., Fromm A., Janssen S., Fromm M., Hering N.A., Et al., Campylobacter jejuni impairs sodium transport and epithelial barrier function via cytokine release in human colon, Mucosal. Immunol, 11, pp. 474-485, (2018); de Sa F.D.L., Heimesaat M.M., Bereswill S., Nattramilarasu P.K., Schulzke J.D., Bucker R., Resveratrol prevents Campylobacter jejuni-induced leaky gut by restoring occludin and claudin-5 in the paracellular leak pathway, Front. Pharmacol, 12, (2021); Lobo de Sa F.D., Butkevych E., Nattramilarasu P.K., Fromm A., Mousavi S., Moos V., Golz J.C., Stingl K., Kittler S., Seinige D., Et al., Curcumin Mitigates Immune-Induced Epithelial Barrier Dysfunction by Campylobacter jejuni, Int. J. Mol. Sci, 20, (2019); Lobo de Sa F.D., Backert S., Nattramilarasu P.K., Mousavi S., Sandle G.I., Bereswill S., Heimesaat M.M., Schulzke J.D., Bucker R., Vitamin D Reverses Disruption of Gut Epithelial Barrier Function Caused by Campylobacter jejuni, Int. J. Mol. Sci, 22, (2021); Mayr A.M., Lick S., Bauer J., Tharigen D., Busch U., Huber I., Rapid detection and differentiation of Campylobacter jejuni, Campylobacter coli and Campylobacter lari in food, using multiplex real-time PCR, J. Food Prot, 73, pp. 241-250, (2010); Burgel N., Bojarski C., Mankertz J., Zeitz M., Fromm M., Schulzke J.D., Mechanisms of diarrhea in collagenous colitis, Gastroenterology, 123, pp. 433-443, (2002); Barmeyer C., Erko I., Fromm A., Bojarski C., Loddenkemper C., Dames P., Kerick M., Siegmund B., Fromm M., Schweiger M.R., Et al., ENaC dysregulation through activation of MEK1/2 contributes to impaired sodium absorption in lymphocytic colitis, Inflamm. Bowel Dis, 22, pp. 539-547, (2016); Bucker R., Schulz E., Gunzel D., Bojarski C., Lee I.F., John L.J., Wiegand S., Janssen T., Wieler L.H., Dobrindt U., Et al., α-Haemolysin of Escherichia coli in IBD: A potentiator of inflammatory activity in the colon, Gut, 63, pp. 1893-1901, (2014); John L., Mechanisms of Macromolecular Transcytosis during Crohn’s Disease: Investigations on the Cell Model T84 and Human Colon Biopsies, Ph.D. Dissertation, (2014); Berin M.C., Yang P.C., Ciok L., Waserman S., Perdue M.H., Role for IL-4 in macromolecular transport across human intestinal epithelium, Am. J. Physiol, 276, pp. C1046-C1052, (1999); Cohen E., Ophir I., Henis Y.I., Bacher A., Ben Shaul Y., Effect of temperature on the assembly of tight junctions and on the mobility of lipids in membranes of HT29 cells, J. Cell Sci, 97, pp. 119-125, (1990); Punnonen E.L., Ryhanen K., Marjomaki V.S., At reduced temperature, endocytic membrane traffic is blocked in multivesicular carrier endosomes in rat cardiac myocytes, Eur. J. Cell Biol, 75, pp. 344-352, (1998); Schinnerling K., Geelhaar-Karsch A., Allers K., Friebel J., Conrad K., Loddenkemper C., Kuhl A., Erben U., Ignatius R., Moos V., Et al., Role of dendritic cells in the pathogenesis of Whipple’s disease, Infect. Immun, 83, pp. 482-491, (2015); Buschmann M.M., Shen L., Rajapakse H., Raleigh D.R., Wang Y., Wang Y., Lingaraju A., Zha J., Abbott E., McAuley E.M., Et al., Occludin OCEL-domain interactions are required for maintenance and regulation of the tight junction barrier to macromolecular flux, Mol. Biol. Cell, 24, pp. 3056-3068, (2013); Krug S.M., Amasheh S., Richter J.F., Milatz S., Gunzel D., Westphal J.K., Huber O., Schulzke J.D., Fromm M., Tricellulin forms a barrier to macromolecules in tricellular tight junctions without affecting ion permeability, Mol. Biol. Cell, 20, pp. 3713-3724, (2009); Bellono N.W., Bayrer J.R., Leitch D.B., Castro J., Zhang C., O'Donnell T.A., Brierley S.M., Ingraham H.A., Julius D., Enterochromaffin Cells Are Gut Chemosensors that Couple to Sensory Neural Pathways, Cell, 170, pp. 185-198, (2017); Ng Q.X., Soh A.Y.S., Loke W., Lim D.Y., Yeo W.S., The role of inflammation in irritable bowel syndrome (IBS), J. Inflamm. Res, 11, pp. 345-349, (2018); Lobo de Sa F.D., Schulzke J.D., Bucker R., Diarrheal Mechanisms and the Role of Intestinal Barrier Dysfunction in Campylobacter Infections, Curr. Top. Microbiol. Immunol, 431, pp. 203-231, (2021); Miner-Williams W.M., Stevens B.R., Moughan P.J., Are intact peptides absorbed from the healthy gut in the adult human?, Nutr. Res. Rev, 27, pp. 308-329, (2014); Matysiak-Budnik T., Candalh C., Dugave C., Namane A., Cellier C., Cerf-Bensussan N., Heyman M., Alterations of the intestinal transport and processing of gliadin peptides in celiac disease, Gastroenterology, 125, pp. 696-707, (2003); Krug S.M., Bojarski C., Fromm A., Lee I.M., Dames P., Richter J.F., Turner J.R., Fromm M., Schulzke J.D., Tricellulin is regulated via interleukin-13-receptor α2, affects macromolecule uptake, and is decreased in ulcerative colitis, Mucosal Immunol, 11, pp. 345-356, (2018); Gwee K.A., Collins S.M., Read N.W., Rajnakova A., Deng Y., Graham J.C., McKendrick M.W., Moochhala S.M., Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome, Gut, 52, pp. 523-526, (2003); Macsharry J., O'Mahony L., Fanning A., Bairead E., Sherlock G., Tiesman J., Fulmer A., Kiely B., Dinan T.G., Shanahan F., Et al., Mucosal cytokine imbalance in irritable bowel syndrome, Scand. J. Gastroenterol, 43, pp. 1467-1476, (2008); Awad K., Epitheliale Barrierefunktion des Kolons Beim DIARRHOE-Dominanten und Beim Mischtyp-Reizdarmsyndrom, Ph.D. Dissertation, (2022); Brooks P.T., Brakel K.A., Bell J.A., Bejcek C.E., Gilpin T., Brudvig J.M., Mansfield L.S., Transplanted human fecal microbiota enhanced Guillain Barré syndrome autoantibody responses after Campylobacter jejuni infection in C57BL/6 mice, Microbiome, 5, (2017); Parthasarathy G., Mansfield L.S., Recombinant interleukin-4 enhances Campylobacter jejuni invasion of intestinal pig epithelial cells (IPEC-1), Microb. Pathog, 47, pp. 38-46, (2009); Edwards L.A., Nistala K., Mills D.C., Stephenson H.N., Zilbauer M., Wren B.W., Dorrell N., Lindley K.J., Wedderburn L.R., Bajaj-Elliott M., Delineation of the innate and adaptive T-cell immune outcome in the human host in response to Campylobacter jejuni infection, PLoS ONE, 5, (2010); Brand S., Beigel F., Olszak T., Zitzmann K., Eichhorst S.T., Otte J.M., Diepolder H., Marquardt A., Jagla W., Popp A., Et al., IL-22 is increased in active Crohn’s disease and promotes proinflammatory gene expression and intestinal epithelial cell migration, Am. J. Physiol. Gastrointest Liver Physiol, 290, pp. G827-G838, (2006); Yuki N., Kuwabara S., Axonal Guillain-Barré syndrome: Carbohydrate mimicry and pathophysiology, J. Peripher. Nerv. Syst, 12, pp. 239-249, (2007); Morales W., Triantafyllou K., Parodi G., Weitsman S., Park S.C., Rezaie A., Pichetshote N., Lin E., Pimentel M., Immunization with cytolethal distending toxin B produces autoantibodies to vinculin and small bowel bacterial changes in a rat model of postinfectious irritable bowel syndrome, Neurogastroenterol. Motil, 32, (2020); Pimentel M., Morales W., Pokkunuri V., Brikos C., Kim S.M., Kim S.E., Triantafyllou K., Weitsman S., Marsh Z., Marsh E., Et al., Autoimmunity Links Vinculin to the Pathophysiology of Chronic Functional Bowel Changes Following Campylobacter jejuni Infection in a Rat Model, Dig Dis. Sci, 60, pp. 1195-1205, (2015); Barbara G., Wang B., Stanghellini V., de Giorgio R., Cremon C., Di Nardo G., Trevisani M., Campi B., Geppetti P., Tonini M., Et al., Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome, Gastroenterology, 132, pp. 26-37, (2007)","R. Bücker; Clinical Physiology, Charité–Universitätsmedizin Berlin, Berlin, Campus Benjamin Franklin, 12203, Germany; email: roland-felix.buecker@charite.de","","MDPI","","","","","","2218273X","","","36979384","English","Biomolecules","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85151221533"

"Meynier M.; Daugey V.; Mallaret G.; Gervason S.; Meleine M.; Barbier J.; Aissouni Y.; Lolignier S.; Bonnet M.; Ardid D.; De Vos W.M.; Van Hul M.; Suenaert P.; Brochot A.; Cani P.D.; Carvalho F.A.","Meynier, Maëva (57217062090); Daugey, Valentine (58793530700); Mallaret, Geoffroy (57221844941); Gervason, Sandie (57209348857); Meleine, Mathieu (53464003400); Barbier, Julie (57195961481); Aissouni, Youssef (6508190769); Lolignier, Stéphane (24076257000); Bonnet, Mathilde (36051650700); Ardid, Denis (6603953203); De Vos, Willem M. (35495729400); Van Hul, Matthias (24400419500); Suenaert, Peter (6506787503); Brochot, Amandine (57191440247); Cani, Patrice D. (6507917827); Carvalho, Frédéric A. (16041688200)","57217062090; 58793530700; 57221844941; 57209348857; 53464003400; 57195961481; 6508190769; 24076257000; 36051650700; 6603953203; 35495729400; 24400419500; 6506787503; 57191440247; 6507917827; 16041688200","Pasteurized akkermansia muciniphila improves irritable bowel syndrome-like symptoms and related behavioral disorders in mice","2024","Gut Microbes","16","1","2298026","","","","2","10.1080/19490976.2023.2298026","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85181520039&doi=10.1080%2f19490976.2023.2298026&partnerID=40&md5=43d31eb54593dfd3eb60043bcff3b1fa","NeuroDol, UMR 1107 INSERM, University of Clermont Auvergne, Clermont-Ferrand, France; M2iSH, UMR 1071 INSERM, UMR1382 INRAé, University of Clermont Auvergne, Clermont-Ferrand, France; Laboratory of Microbiology, Wageningen University, Wageningen, Netherlands; Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland; The Akkermansia Company™, Mont-Saint-Guibert, Belgium; Metabolism and Nutrition Research group, Louvain Drug Research Institute (LDRI), UCLouvain, Université Catholique de Louvain, Brussels, Belgium; WELBIO-Walloon Excellence in Life Sciences and Biotechnology, WELBIO department, WEL Research Institute, Wavre, Belgium; Institute of Experimental and Clinical Research (IREC), UCLouvain, Université catholique de Louvain, Brussels, Belgium","Meynier M., NeuroDol, UMR 1107 INSERM, University of Clermont Auvergne, Clermont-Ferrand, France, M2iSH, UMR 1071 INSERM, UMR1382 INRAé, University of Clermont Auvergne, Clermont-Ferrand, France; Daugey V., NeuroDol, UMR 1107 INSERM, University of Clermont Auvergne, Clermont-Ferrand, France; Mallaret G., NeuroDol, UMR 1107 INSERM, University of Clermont Auvergne, Clermont-Ferrand, France; Gervason S., NeuroDol, UMR 1107 INSERM, University of Clermont Auvergne, Clermont-Ferrand, France; Meleine M., NeuroDol, UMR 1107 INSERM, University of Clermont Auvergne, Clermont-Ferrand, France; Barbier J., NeuroDol, UMR 1107 INSERM, University of Clermont Auvergne, Clermont-Ferrand, France; Aissouni Y., NeuroDol, UMR 1107 INSERM, University of Clermont Auvergne, Clermont-Ferrand, France; Lolignier S., NeuroDol, UMR 1107 INSERM, University of Clermont Auvergne, Clermont-Ferrand, France; Bonnet M., M2iSH, UMR 1071 INSERM, UMR1382 INRAé, University of Clermont Auvergne, Clermont-Ferrand, France; Ardid D., NeuroDol, UMR 1107 INSERM, University of Clermont Auvergne, Clermont-Ferrand, France; De Vos W.M., Laboratory of Microbiology, Wageningen University, Wageningen, Netherlands, Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland, The Akkermansia Company™, Mont-Saint-Guibert, Belgium; Van Hul M., Metabolism and Nutrition Research group, Louvain Drug Research Institute (LDRI), UCLouvain, Université Catholique de Louvain, Brussels, Belgium, WELBIO-Walloon Excellence in Life Sciences and Biotechnology, WELBIO department, WEL Research Institute, Wavre, Belgium; Suenaert P., The Akkermansia Company™, Mont-Saint-Guibert, Belgium; Brochot A., The Akkermansia Company™, Mont-Saint-Guibert, Belgium; Cani P.D., Metabolism and Nutrition Research group, Louvain Drug Research Institute (LDRI), UCLouvain, Université Catholique de Louvain, Brussels, Belgium, WELBIO-Walloon Excellence in Life Sciences and Biotechnology, WELBIO department, WEL Research Institute, Wavre, Belgium, Institute of Experimental and Clinical Research (IREC), UCLouvain, Université catholique de Louvain, Brussels, Belgium; Carvalho F.A., NeuroDol, UMR 1107 INSERM, University of Clermont Auvergne, Clermont-Ferrand, France","Gut–brain communications disorders in irritable bowel syndrome (IBS) are associated with intestinal microbiota composition, increased gut permeability, and psychosocial disturbances. Symptoms of IBS are difficult to medicate, and hence much research is being made into alternative approaches. This study assesses the potential of a treatment with pasteurized Akkermansia muciniphila for alleviating IBS-like symptoms in two mouse models of IBS with different etiologies. Two clinically relevant animal models were used to mimic IBS-like symptoms in C57BL6/J mice: the neonatal maternal separation (NMS) paradigm and the Citrobacter rodentium infection model. In both models, gut permeability, colonic sensitivity, fecal microbiota composition and colonic IL-22 expression were evaluated. The cognitive performance and emotional state of the animals were also assessed by several tests in the C. rodentium infection model. The neuromodulation ability of pasteurized A. muciniphila was assessed on primary neuronal cells from mice dorsal root ganglia using a ratiometric calcium imaging approach. The administration of pasteurized A. muciniphila significantly reduced colonic hypersensitivity in both IBS mouse models, accompanied by a reinforcement of the intestinal barrier function. Beneficial effects of pasteurized A. muciniphila treatment have also been observed on anxiety-like behavior and memory defects in the C. rodentium infection model. Finally, a neuroinhibitory effect exerted by pasteurized A. muciniphila was observed on neuronal cells stimulated with two algogenic substances such as capsaicin and inflammatory soup. Our findings demonstrate novel anti-hyperalgesic and neuroinhibitory properties of pasteurized A. muciniphila, which therefore may have beneficial effects in relieving pain and anxiety in subjects with IBS. © 2024 The Author(s). Published with license by Taylor & Francis Group, LLC.","anxiety-like disorders; colonic hypersensitivity; IBS; memory impairment; neuroinhibition; Pasteurized akkermansia muciniphila","Akkermansia muciniphila; Animals; Gastrointestinal Microbiome; Humans; Irritable Bowel Syndrome; Maternal Deprivation; Mice; Verrucomicrobia; calcium; capsaicin; claudin 2; fluorescein isothiocyanate dextran; interleukin 22; occludin; protein ZO1; RNA 16S; acclimatization; Akkermansia muciniphila; animal experiment; animal model; animal tissue; anxiety disorder; area under the curve; Article; behavior disorder; Citrobacter rodentium; colony forming unit; colorectal distension test; controlled study; diagnostic test; diagnostic test accuracy study; elevated plus maze test; female; fluorometry; hole board test; hypersensitivity; irritable colon; male; memory disorder; mouse; nerve cell inhibition; nonhuman; novel object recognition test; Y-maze test; Akkermansia muciniphila; animal; human; intestine flora; irritable colon; maternal deprivation; physiology; Verrucomicrobia","","calcium, 7440-70-2, 14092-94-5; capsaicin, 404-86-4; fluorescein isothiocyanate dextran, 60842-46-8; interleukin 22, 457106-70-6, 478219-35-1, 554460-75-2; occludin, 176304-61-3","C1000, Biorad, United States; CFX96, Biorad, United States; Distender Series II, GJ Electronics; Ethovision XT 15, Noldus; GraphPad Prism version 10.1.1, Graphpad, United States; LabChart 7, AdInstruments, France; PCU-2000, Millar, United States; QIAamp, Qiagen, Germany; QX manager software 2.1, Biorad, United States; model 600, Millar, United States","AdInstruments, France; Biorad, United States; Biorad, United States; Biorad, United States; GJ Electronics; Graphpad, United States; Millar, United States; Millar, United States; Noldus; Qiagen, Germany","Akkermansia Company™; Clermont Auvergne Métropole; French Ministère de la Recherche et de la Technologie; Waalse Gewest, (8206); Institut National de la Santé et de la Recherche Médicale, Inserm; Fonds De La Recherche Scientifique - FNRS, FNRS, (40007505, WELBIO-CR-2022A-02); European Regional Development Fund, ERDF, (16-IDEX-0001-CAP 20-25); Région Auvergne-Rhône-Alpes","This work was supported by co-financing from The Akkermansia Company™ (Belgium) and supported by a research agreement from the Walloon Region (agreement 8206), the French Ministère de la Recherche et de la Technologie (NeuroDol laboratory [INSERM 1107]), the Region Auvergne-Rhône-Alpes and FEDER, No. Thématiques émergentes, Pack Ambition Recherche; the French Government IDEX-ISITE Initiative, No. 16-IDEX-0001-CAP 20-25, and the Clermont Auvergne Métropole, No “Recherche-Action” project. P.D.C. is research director for the FNRS and recipient of a Projet de Recherche PDR-convention: FNRS T.0030.21 and FRFS-WELBIO: WELBIO-CR-2022A-02, EOS: program no. 40007505. Abdelkrim Alloui (Animal Facilities) for animal care.","Drossman D.A., Hasler W.L., Rome IV—functional GI disorders: disorders of gut-brain interaction, Gastroenterology, 150, 6, pp. 1257-1221, (2016); Hillestad E.M.R., van der Meeren A., Nagaraja B.H., Bjorsvik B.R., Haleem N., Benitez-Paez A., Sanz Y., Hausken T., Lied G.A., Lundervold A., Et al., Gut bless you: the microbiota-gut-brain axis in irritable bowel syndrome, World J Gastroentero, 28, 4, pp. 412-431, (2022); Barbara G., Grover M., Bercik P., Corsetti M., Ghoshal U.C., Ohman L., Rajilic-Stojanovic M., Rome foundation working team report on post-infection irritable bowel syndrome, Gastroenterology, 156, 1, pp. 46-58, (2019); Nicholl B.I., Halder S.L., Macfarlane G.J., Thompson D.G., O'Brien S., Musleh M., McBeth J., Psychosocial risk markers for new onset irritable bowel syndrome–results of a large prospective population-based study, Pain, 137, 1, pp. 147-155, (2008); Camilleri M., Boeckxstaens G., Irritable bowel syndrome: treatment based on pathophysiology and biomarkers, Gut, 72, 3, pp. 590-599, (2023); Barreau F., Ferrier L., Fioramonti J., Bueno L., New insights in the etiology and pathophysiology of irritable bowel syndrome: contribution of neonatal stress models, Pediatr Res, 62, 3, pp. 240-245, (2007); Mallaret G., Lashermes A., Meleine M., Boudieu L., Barbier J., Aissouni Y., Gelot A., Chassaing B., Gewirtz A.T., Ardid D., Et al., Involvement of toll-like receptor 5 in mouse model of colonic hypersensitivity induced by neonatal maternal separation, World J Gastroenterol, 28, 29, pp. 3903-3916, (2022); Hanning N., Edwinson A.L., Ceuleers H., Peters S.A., De Man J.G., Hassett L.C., De Winter B.Y., Grover M., Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review, Therap Adv Gastroenterol, 14, (2021); Mondelaers S.U., Theofanous S.A., Florens M.V., Perna E., Aguilera-Lizarraga J., Boeckxstaens G., Wouters M., Effect of genetic background and postinfectious stress on visceral sensitivity in citrobacter rodentium-infected mice, Neurogastroent Motil, 28, 5, pp. 647-658, (2016); Collins J.W., Keeney K.M., Crepin V.F., Rathinam V.A.K., Fitzgerald K.A., Finlay B.B., Frankel G., Citrobacter rodentium: infection, inflammation and the microbiota, Nat Rev Microbiol, 12, 9, pp. 612-623, (2014); Meynier M., Baudu E., Rolhion N., Defaye M., Daugey V., Modoux M., Wawrzyniak I., Villeger R., Meleine M., Borras Nogues E., Et al., AhR/IL-22 pathway as new target for the treatment of post-infectious irritable bowel syndrome symptoms, Gut Microbes, 14, 1, (2022); Ibeakanma C., Miranda-Morales M., Richards M., Bautista-Cruz F., Martin N., Hurlbut D., Vanner S., Citrobacter rodentium colitis evokes post-infectious hyperexcitability of mouse nociceptive colonic dorsal root ganglion neurons, J Physiol, 587, 14, pp. 3505-3521, (2009); Dinan T.G., Cryan J.F., The microbiome-gut-brain axis in health and disease, Gastroenterol Clin North Am, 46, 1, pp. 77-89, (2017); Derrien M., Vaughan E.E., Plugge C.M., de Vos W.M., Akkermansia municiphila gen. Nov., sp. Nov., a human intestinal mucin-degrading bacterium, Int J Syst Evol Microbiol, 54, 5, pp. 1469-1476, (2004); Everard A., Belzer C., Geurts L., Ouwerkerk J.P., Druart C., Bindels L.B., Guiot Y., Derrien M., Muccioli G.G., Delzenne N.M., Et al., Cross-talk between akkermansia muciniphila and intestinal epithelium controls diet-induced obesity, Proceedings of the National Academy of Sciences of the United States of America, 110, pp. 9066-9071, (2013); Cani P.D., Depommier C., Derrien M., Everard A., de Vos W.M., Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms, Nat Rev Gastroenterol Hepatol, 19, 10, pp. 625-637, (2022); Karlsson C.L.J., Onnerfalt J., Xu J., Molin G., Ahrne S., Thorngren-Jerneck K., The microbiota of the gut in preschool children with normal and excessive body weight, Obesity, 20, 11, pp. 2257-2261, (2012); Everard A., Lazarevic V., Derrien M., Girard M., Muccioli G.M., Neyrinck A.M., Possemiers S., Van Holle A., Francois P., De Vos W.M., Et al., Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice, Diabetes, 60, 11, pp. 2775-2786, (2011); Plovier H., Everard A., Druart C., Depommier C., Van Hul M., Geurts L., Chilloux J., Ottman N., Duparc T., Lichtenstein L., Et al., A purified membrane protein from akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice, Nat Med, 23, 1, pp. 107-113, (2017); Depommier C., Van Hul M., Everard A., Delzenne N.M., De Vos W.M., Cani P.D., Pasteurized akkermansia muciniphila increases whole-body energy expenditure and fecal energy excretion in diet-induced obese mice, Gut Microbes, 11, 5, pp. 1231-1245, (2020); Depommier C., Everard A., Druart C., Plovier H., Van Hul M., Vieira-Silva S., Falony G., Raes J., Maiter D., Delzenne N.M., Et al., Supplementation with akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study, Nat Med, 25, 7, pp. 1096-1103, (2019); Xu D., Chen V.L., Steiner C.A., Berinstein J.A., Eswaran S., Waljee A.K., Higgins P.D.R., Owyang C., Efficacy of fecal microbiota transplantation in irritable bowel syndrome: a systematic review and meta-analysis, Am J Gastroenterol, 114, 7, pp. 1043-1050, (2019); Ford A.C., Harris L.A., Lacy B.E., Quigley E.M.M., Moayyedi P., Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome, Aliment Pharmacol Ther, 48, 10, pp. 1044-1060, (2018); Cruz-Aguliar R.M., Wantia N., Clavel T., Vehreschild M.J.G.T., Buch T., Bajbouj M., Haller D., Busch D., Schmid R.M., Stein-Thoeringer C.K., An open-labeled study on fecal microbiota transfer in irritable bowel syndrome patients reveals improvement in abdominal pain associated with the relative abundance of akkermansia muciniphila, Digestion, 100, 2, pp. 127-138, (2019); Miquel S., Martin R., Lashermes A., Gillet M., Meleine M., Gelot A., Eschalier A., Ardid D., Bermudez-Humaran L.G., Sokol H., Et al., Anti-nociceptive effect of Faecalibacterium prausnitzii in non-inflammatory IBS-like models, Sci Rep, 6, 1, (2016); Xin Y., Wang J., Chu T., Zhou Y., Liu C., Xu A., Electroacupuncture alleviates neuroinflammation by inhibiting the HMGB1 signaling pathway in rats with sepsis-associated encephalopathy, Brain Sci, 12, 12, (2022); Iban-Arias R., Trageser K.J., Yang E.-J., Griggs E., Radu A., Naughton S., Al Rahim M., Tatsunori O., Raval U., Palmieri J., Et al., Exposure to world trade center dust exacerbates cognitive impairment and evokes a central and peripheral pro-inflammatory transcriptional profile in an animal model of alzheimer’s disease, J Alzheimers Dis, 91, 2, pp. 779-794, (2022); Perez-Berezo T., Pujo J., Martin P., Le Faouder P., Galano J.-M., Guy A., Knauf C., Tabet J.C., Tronnet S., Barreau F., Et al., Identification of an analgesic lipopeptide produced by the probiotic Escherichia coli strain nissle 1917, Nat Commun, 8, 1, (2017); Perez-Burgos A., Wang L., McVey Neufeld K.-A., Mao Y.-K., Ahmadzai M., Janssen L.J., Stanisz A.M., Bienenstock J., Kunze W.A., The TRPV1 channel in rodents is a major target for antinociceptive effect of the probiotic lactobacillus reuteri DSM 17938, J Physiol, 593, pp. 3943-3957, (2015); Simren M., Tornblom H., Palsson O.S., van Tilburg M.A.L., Van Oudenhove L., Tack J., Whitehead W.E., Visceral hypersensitivity is associated with GI symptom severity in functional GI disorders: consistent findings from five different patient cohorts, Gut, 67, pp. 255-262, (2018); Ford A.C., Sperber A.D., Corsetti M., Camilleri M., Irritable bowel syndrome, Lancet, 396, pp. 1675-1688, (2020); Drossman D.A., Tack J., Ford A.C., Szigethy E., Tornblom H., Van Oudenhove L., Neuromodulators for functional gastrointestinal disorders (disorders of gut−brain interaction): a Rome foundation working team report, Gastroenterology, 154, 4, pp. 1140-1171, (2018); Camilleri M., Boeckxstaens G., Dietary and pharmacological treatment of abdominal pain in IBS, Gut, 66, 5, pp. 966-974, (2017); Wilmes L., Collins J.M., O'Riordan K.J., O'Mahony S.M., Cryan J.F., Clarke G., Of bowels, brain and behavior: a role for the gut microbiota in psychiatric comorbidities in irritable bowel syndrome, Neurogastroenterol Motil, 33, 3, (2021); Coutinho S.V., Plotsky P.M., Sablad M., Miller J.C., Zhou H., Bayati A.I., McRoberts J.A., Mayer E.A., Neonatal maternal separation alters stress-induced responses to viscerosomatic nociceptive stimuli in rat, Am J Physiol Gastrointest Liver Physiol, 282, 2, pp. G307-G316, (2002); Meleine M., Boudieu L., Gelot A., Muller E., Lashermes A., Matricon J., Silberberg C., Theodorou V., Eschalier A., Ardid D., Et al., Comparative effects of α2δ-1 ligands in mouse models of colonic hypersensitivity, World J Gastroenterol, 22, 31, pp. 7111-7123, (2016); Chen Y., Xiao S., Gong Z., Zhu X., Yang Q., Li Y., Gao S., Dong Y., Shi Z., Wang Y., Et al., Wuji wan formula ameliorates diarrhea and disordered colonic motility in post-inflammation irritable bowel syndrome rats by modulating the gut microbiota, Front Microbiol, 8, (2017); Jacobs J.P., Gupta A., Bhatt R.R., Brawer J., Gao K., Tillisch K., Lagishetty V., Firth R., Gudleski G.D., Ellingson B.M., Et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement, Microbiome, 9, 1, (2021); Morais L.H., Schreiber H.L., Mazmanian S.K., The gut microbiota–brain axis in behaviour and brain disorders, Nat Rev Microbiol, 19, 4, pp. 241-255, (2021); Ji N.-N., Jiang H., Xia M., The influence of the enriched environment in different periods on neonatal maternal separation-induced visceral pain, anxiousness, and depressive behaviors, Transl Pediatr, 11, 9, pp. 1562-1569, (2022); Pontifex M.G., Connell E., Le Gall G., Pourtau L., Gaudout D., Angeloni C., Zallocco L., Ronci M., Giusti L., Muller M., Et al., Saffron extract (Safr’inside™) improves anxiety related behaviour in a mouse model of low-grade inflammation through the modulation of the microbiota and gut derived metabolites, Food Funct, 13, 23, pp. 12219-12233, (2022); Sun Y., Zhu H., Cheng R., Tang Z., Zhang M., Outer membrane protein Amuc_1100 of akkermansia muciniphila alleviates antibiotic-induced anxiety and depression-like behavior in mice, Physiol Behavior, 258, (2023); Bae M., Cassilly C.D., Liu X., Park S.-M., Tusi B.K., Chen X., Kwon J., Filipcik P., Bolze A.S., Liu Z., Et al., Akkermansia muciniphila phospholipid induces homeostatic immune responses, Nature, 608, 7921, pp. 168-173, (2022); Gu Z., Pei W., Shen Y., Wang L., Zhu J., Zhang Y., Fan S., Wu Q., Li L., Zhang Z., Akkermansia muciniphila and its outer protein Amuc_1100 regulates tryptophan metabolism in colitis, Food Funct, 12, 20, pp. 10184-10195, (2021); Bachmann R., Van Hul M., Baldin P., Leonard D., Delzenne N.M., Belzer C., Ouwerkerk J.P., Repsilber D., Rangel I., Kartheuser A., Et al., Akkermansia muciniphila reduces peritonitis and improves intestinal tissue wound healing after a colonic transmural defect by a MyD88-dependent mechanism, Cells, 11, 17, (2022); Lapointe T.K., Basso L., Iftinca M.C., Flynn R., Chapman K., Dietrich G., Vergnolle N., Altier C., TRPV1 sensitization mediates postinflammatory visceral pain following acute colitis, Am J Physiol-Gastr L, 309, 2, pp. G87-G99, (2015); Akbar A., Yiangou Y., Facer P., Walters J.R.F., Anand P., Ghosh S., Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain, Gut, 57, 7, pp. 923-929, (2008); Najjar S.A., Davis B.M., Albers K.M., Epithelial–neuronal communication in the colon: implications for visceral pain, Trends Neurosci, 43, 3, pp. 170-181, (2020); Jalanka J., Lam C., Bennett A., Hartikainen A., Crispie F., Finnegan L.A., Cotter P.D., Spiller R., Colonic gene expression and fecal microbiota in diarrhea-predominant irritable bowel syndrome: increased toll-like receptor 4 but minimal inflammation and no response to Mesalazine, J Neurogastroenterol Motil, 27, 2, pp. 279-291, (2021); Barbara G., Wang B., Stanghellini V., de Giorgio R., Cremon C., Di Nardo G., Trevisani M., Campi B., Geppetti P., Tonini M., Et al., Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome, Gastroenterology, 132, 1, pp. 26-37, (2007); Sugiuar T., Bielefeldt K., Gebhart G.F., TRPV1 function in mouse colon sensory neurons is enhanced by metabotropic 5-hydroxytryptamine receptor activation, J Neurosci, 24, 43, pp. 9521-9530, (2004); Mistry S., Paule C.C., Varga A., Photiou A., Jenes A., Avelino A., Buluwela L., Nagy I., Prolonged exposure to bradykinin and prostaglandin E2 increases TRPV1 mRNA but does not alter TRPV1 and TRPV1b protein expression in cultured rat primary sensory neurons, Neurosci Lett, 564, pp. 89-93, (2014); Wouters M.M., Balemans D., Van Wanrooy S., Dooley J., Cibert-Goton V., Alpizar Y.A., Valdez-Morales E.E., Nasser Y., Van Veldhoven P.P., Vanbrabant W., Et al., Histamine receptor H1–mediated sensitization of TRPV1 mediates visceral hypersensitivity and symptoms in patients with irritable bowel syndrome, Gastroenterology, 150, 4, pp. 875-887, (2016); Shen W., Shen M., Zhao X., Zhu H., Yang Y., Lu S., Tan Y., Li G., Li M., Wang J., Et al., Anti-obesity effect of capsaicin in mice fed with high-fat diet is associated with an increase in population of the gut bacterium akkermansia muciniphila, Front Microbiol, 8, (2017); Gong T., Wang H., Liu S., Zhang M., Xie Y., Liu X., Capsaicin regulates lipid metabolism through modulation of bile acid/gut microbiota metabolism in high-fat-fed SD rats, Food Nutr Res, 66, (2022); Fried D.E., Gulbransen B.D., In situ Ca2+ imaging of the enteric nervous system, J Vis Exp, (2015); Dinan T.G., Cryan J.F., The impact of gut microbiota on brain and behaviour: implications for psychiatry, Curr Opin Clin Nutr Metab Care, 18, 6, pp. 552-558, (2015); Zimmermann M., Ethical guidelines for investigations of experimental pain in conscious animals, Pain, 16, 2, pp. 109-110, (1983); Larauche M., Gourcerol G., Million M., Adelson D.W., Tache Y., Repeated psychological stress-induced alterations of visceral sensitivity and colonic motor functions in mice: influence of surgery and postoperative single housing on visceromotor responses, Stress, 13, 4, pp. 344-355, (2010); Picard E., Carvalho F.A., Agosti F., Bourinet E., Ardid D., Eschalier A., Daulhac L., Mallet C., Inhibition of cav 3.2 calcium channels: a new target for colonic hypersensitivity associated with low-grade inflammation, Br J Pharmacol, 176, 7, pp. 950-963, (2019); Rodriguez Echandia E.L., Broitman S.T., Foscolo M.R., Effect of the chronic ingestion of chlorimipramine and desipramine on the hole board response to acute stresses in male rats, Pharmacol Biochem Behav, 26, 2, pp. 207-210, (1987); Sierksma A.S.R., Van Den Hove D.L.A., Pfau F., Philippens M., Bruno O., Fedele E., Ricciarelli R., Steinbusch H.W.M., Vanmierlo T., Prickaerts J., Improvement of spatial memory function in APPswe/PS1dE9 mice after chronic inhibition of phosphodiesterase type 4D, Neuropharmacology, 77, pp. 120-130, (2014); Barre A., Berthoux C., De Bundel D., Valjent E., Bockaert J., Marin P., Becamel C., Presynaptic serotonin 2A receptors modulate thalamocortical plasticity and associative learning, Proceedings of the National Academy of Sciences of the United States of America, 113, pp. E1382-E1391, (2016); Bolyen E., Rideout J.R., Dillon M.R., Bokulich N.A., Abnet C.C., Al-Ghalith G.A., Alexander H., Alm E.J., Arumugam M., Asnicar F., Et al., Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2, Nat Biotechnol, 37, 8, pp. 852-857, (2019); Callahan B.J., McMurdie P.J., Rosen M.J., Han A.W., Johnson A.J.A., Holmes S.P., DADA2: High-resolution sample inference from Illumina amplicon data, Nat Methods, 13, 7, pp. 581-583, (2016); Quast C., Pruesse E., Yilmaz P., Gerken J., Schweer T., Yarza P., Peplies J., Glockner F.O., The SILVA ribosomal RNA gene database project: improved data processing and web-based tools, Nucleic Acids Res, 41, D1, pp. D590-D596, (2013)","F.A. Carvalho; NeuroDol UMR 1107 INSERM, University of Clermont-Auvergne, Clermont-Ferrand, 28 place Henri Dunant, BP 38, 63000, France; email: frederic.carvalho@inserm.fr","","Taylor and Francis Ltd.","","","","","","19490976","","","38170633","English","Gut Microbes","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85181520039"

"Wang Y.; Ke W.; Gan J.; Zhu H.; Xie X.; He G.; Liu S.; Huang Y.; Tang H.","Wang, Yongfu (58024459100); Ke, Wei (58024459000); Gan, Jianfeng (58024855800); Zhu, He (57208025933); Xie, Xiangyu (58025057100); He, Guodong (58023864400); Liu, Shan (57201523353); Huang, Yusheng (57200676463); Tang, Hongmei (15519827300)","58024459100; 58024459000; 58024855800; 57208025933; 58025057100; 58023864400; 57201523353; 57200676463; 15519827300","MicroRNA-29b-3p promotes intestinal permeability in IBS-D via targeting TRAF3 to regulate the NF-κB-MLCK signaling pathway","2023","PLoS ONE","18","7 July","e0287597","","","","2","10.1371/journal.pone.0287597","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85164299008&doi=10.1371%2fjournal.pone.0287597&partnerID=40&md5=c8e9f86a4ada49a3478dc2d2dc4bf4db","Department of Traditional Chinese Medicine, The First Affiliated Hospital of Zhengzhou University, Henan, Zhengzhou, China; The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, China; The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangdong, Guangzhou, China; Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangdong, Guangzhou, China; The Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangdong, Guangzhou, China","Wang Y., Department of Traditional Chinese Medicine, The First Affiliated Hospital of Zhengzhou University, Henan, Zhengzhou, China; Ke W., The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, China, The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangdong, Guangzhou, China, Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangdong, Guangzhou, China; Gan J., The Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangdong, Guangzhou, China; Zhu H., The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangdong, Guangzhou, China; Xie X., The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, China, The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangdong, Guangzhou, China, Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangdong, Guangzhou, China; He G., The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, China, The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangdong, Guangzhou, China, Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangdong, Guangzhou, China; Liu S., The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, China, The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangdong, Guangzhou, China, Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangdong, Guangzhou, China; Huang Y., The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangdong, Guangzhou, China, Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangdong, Guangzhou, China; Tang H., The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangdong, Guangzhou, China","Irritable bowel syndrome with predominant diarrhea (IBS-D) is characterized by increased intestinal permeability. Previous studies have shown that the microRNA-29 gene is involved in the regulation of intestinal permeability in patients with IBS-D. NF-κB was proved to play a key role in inflammatory response of intestine and resultant disruption of tight junction integrity, whose activity could be inhibited by TNF Receptor-Associated Factor 3 (TRAF3). However, the exact mechanism that induces increased intestinal permeability in IBS-D patients has not been clarified. In this study, we found that microRNA-29b-3p (miR-29b-3p) was significantly upregulated, while TRAF3 was decreased and the NF-κB-MLCK pathway was activated within the colonic tissue of IBS-D patients. Subsequently, we confirmed the targeting relationship between miR-29b-3p and TRAF3 through a double-luciferase reporter assay. Lentivirus transfection of NCM460 cells with miR-29b-3p-overexpressing and -silencing vectors demonstrated that the expression of TRAF3 was negatively correlated with the level of miR-29b-3p. The NF-κB/MLCK pathway was activated in the miR-29b-3p-overexpressing group and inhibited to some extent in the miR-29b-3p-silencing group. Results in WT and miR-29 knockout mice showed that miR-29b-3p levels were increased, TRAF3 levels were decreased, and the NF-κB/MLCK signaling was activated in the WT IBS-D group as compared with the WT control group. The protein levels of TRAF3 and TJs in the miR-29b-/- IBS-D group were partially recovered and NF-κB/MLCK pathway indicators were, to a certain extent, decreased as compared with the WT IBS-D group. These results suggested that miR-29b-3p deletion enhances the TRAF3 level in IBS-D mice and alleviates the high intestinal permeability. In brief, through the analysis of intestinal tissue samples from IBS-D patients and miR-29b-/- IBS-D mice, we showed that miR-29b-3p is involved in the pathogenesis of intestinal hyperpermeability in IBS-D via targeting TRAF3 to regulate the NF-κB-MLCK signaling pathway. Copyright: © 2023 Wang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.","","Animals; Intestines; Irritable Bowel Syndrome; Mice; MicroRNAs; NF-kappa B; Permeability; Signal Transduction; TNF Receptor-Associated Factor 3; immunoglobulin enhancer binding protein; lentivirus vector; microRNA 29b; microRNA 29b 3p; myosin light chain kinase; tumor necrosis factor receptor associated factor 3; unclassified drug; immunoglobulin enhancer binding protein; microRNA; MIRN29 microRNA, mouse; tumor necrosis factor receptor associated factor 3; adult; animal experiment; animal model; animal tissue; Article; case control study; clinical article; clinical feature; colon tissue; controlled study; demographics; diarrhea; disease severity; enteritis; expression vector; female; gene overexpression; gene silencing; gene targeting; genetic transfection; histopathology; human; human cell; human tissue; intestinal hyperpermeability; intestine function disorder; intestine mucosa permeability; irritable colon; knockout mouse; Lentivirus; luciferase assay; male; molecular pathology; mouse; NCM460 cell line; NF kB MLCK signaling pathway; nonhuman; protein expression level; protein targeting; real time reverse transcription polymerase chain reaction; signal transduction; tight junction; upregulation; wild type mouse; animal; genetics; intestine; metabolism; pathology; permeability; signal transduction","","myosin light chain kinase, 51845-53-5; MicroRNAs, ; MIRN29 microRNA, mouse, ; NF-kappa B, ; TNF Receptor-Associated Factor 3, ","","","","","Lovell RM, Ford AC., Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis, Clin Gastroenterol Hepatol, 10, pp. 712-721, (2012); Oka P, Parr H, Barberio B, Black CJ, Savarino E V., Ford AC., Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis, Lancet Gastroenterol Hepatol, 5, pp. 908-917, (2020); Ford AC, Sperber AD, Corsetti M, Camilleri M., Series Functional Gastrointestinal Disorders 2 Irritable bowel syndrome, Lancet, 6736, pp. 1-14, (2020); Holtmann GJ, Ford AC, Talley NJ., Pathophysiology of irritable bowel syndrome, Lancet Gastroenterol Hepatol, 1, pp. 133-146, (2016); Hanning N, Edwinson AL, Ceuleers H, Peters SA, De Man JG, Hassett LC, Et al., Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review, Therap Adv Gastroenterol, 14, pp. 1-31, (2021); Ye X, Sun M., AGR2 ameliorates tumor necrosis factor-α-induced epithelial barrier dysfunction via suppression of NF-κB p65-mediatedMLCK/p-MLC pathway activation, Int J Mol Med, 39, pp. 1206-1214, (2017); Van Itallie CM, Anderson JM., Claudins and epithelial paracellular transport, Annu Rev Physiol, 68, pp. 403-429, (2006); Steinbacher T, Kummer D, Ebnet K., Junctional adhesion molecule-A: functional diversity through molecular promiscuity, Cell Mol Life Sci, 75, pp. 1393-1409, (2018); Bertrand J, Ghouzali I, Guerin C, Bole-feysot C, Gouteux M, Dechelotte P, Et al., Glutamine Restores Tight Junction Protein Claudin-1 Expression in Colonic Mucosa of Patients With Diarrhea-Predominant Irritable Bowel Syndrome, (2015); Heinemann U., Structural Features of Tight-Junction Proteins, pp. 1-24, (2019); D'Antongiovanni V, Pellegrini C, Fornai M, Colucci R, Blandizzi C, Antonioli L, Et al., Intestinal epithelial barrier and neuromuscular compartment in health and disease, World J Gastroenterol, 26, pp. 1564-1579, (2020); Li W, Gao M, Han T., Lycium barbarum polysaccharides ameliorate intestinal barrier dysfunction and inflammation through the MLCK-MLC signaling pathway in Caco-2 cells, Food Funct, 11, pp. 3741-3748, (2020); Taniguchi K, Karin M., NF-B, inflammation, immunity and cancer: Coming of age, Nat Rev Immunol, 18, pp. 309-324, (2018); Giridharan S, Srinivasan M., Mechanisms of NF-κB p65 and strategies for therapeutic manipulation, J Inflamm Res, 11, pp. 407-419, (2018); Jin Y, Blikslager AT., The regulation of intestinal mucosal barrier by myosin light chain Kinase/Rho kinases, Int J Mol Sci, 21, pp. 15-17, (2020); Treiber T, Treiber N, Meister G., Regulation of microRNA biogenesis and its crosstalk with other cellular pathways, Nat Rev Mol Cell Biol, 20, pp. 5-20, (2019); Guo D, Yang J, Ling F, Tu L, Li J, Chen Y, Et al., Elemental Diet Enriched with Amino Acids Alleviates Mucosal Inflammatory Response and Prevents Colonic Epithelial Barrier Dysfunction in Mice with DSS-Induced Chronic Colitis, J Immunol Res, 2020, (2020); Zhou Q, Costinean S, Croce CM, Brasier AR, Merwat S, Larson SA, Et al., MicroRNA 29 targets nuclear factor-κB-repressing factor and claudin 1 to increase intestinal permeability, Gastroenterology, 148, pp. 158-169, (2015); Nourbakhsh M, Hauser H., Constitutive silencing of IFN-β promoter is mediated by NRF (NF-κBrepressing factor), a nuclear inhibitor of NF-κB, EMBO J, 18, pp. 6415-6425, (1999); Yang M, Jia W, Wang D, Han F, Niu W, Zhang H, Et al., Effects and Mechanism of Constitutive TL1A Expression on Intestinal Mucosal Barrier in DSS-Induced Colitis, Dig Dis Sci, 64, pp. 1844-1856, (2019); Drossman DA, Hasler WL., Rome IV—Functional GI disorders: Disorders of gut-brain interaction, Gastroenterology, 150, pp. 1257-1261, (2016); Zhu H, Xiao X, Chai Y, Li D, Yan X, Tang H., MiRNA-29a modulates visceral hyperalgesia in irritable bowel syndrome by targeting HTR7, Biochem Biophys Res Commun, 511, pp. 671-678, (2019); Al-Chaer ED, Kawasaki M, Pasricha PJ., A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development, Gastroenterology, 119, pp. 1276-1285, (2000); Liang J, Liang J, Hao H, Lin H, Wang P, Wu Y, Et al., The extracts of Morinda officinalis and its hairy roots attenuate dextran sodium sulfate-induced chronic ulcerative colitis in mice by regulating inflammation and lymphocyte apoptosis, Front Immunol, 8, pp. 1-17, (2017); Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F., An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation, J Exp Med, 190, pp. 995-1003, (1999); Wang Y, Liu J, Huang Z, Li Y, Liang Y, Luo C, Et al., Coptisine ameliorates DSS-induced ulcerative colitis via improving intestinal barrier dysfunction and suppressing inflammatory response, Eur J Pharmacol, 896, (2021); Lobo B, Ramos L, Martinez C, Guilarte M, Gonzalez-Castro AM, Alonso-Cotoner C, Et al., Downregulation of mucosal mast cell activation and immune response in diarrhoea-irritable bowel syndrome by oral disodium cromoglycate: A pilot study, United Eur Gastroenterol J, 5, pp. 887-897, (2017); Wen ZS, Du M, Tang Z, Zhou TY, Zhang ZS, Song HH, Et al., Low molecular seleno-aminopolysaccharides protect the intestinal mucosal barrier of rats under weaning stress, Int J Mol Sci, 20, (2019); Lv M, Zhong Z, Huang M, Tian Q, Jiang R, Chen J., lncRNA H19 regulates epithelial–mesenchymal transition and metastasis of bladder cancer by miR-29b-3p as competing endogenous RNA, Biochim Biophys Acta—Mol Cell Res, 1864, pp. 1887-1899, (2017); Dai Y, Mao Z, Han X, Xu Y, Xu L, Yin L, Et al., MicroRNA-29b-3p reduces intestinal ischaemia/reperfusion injury via targeting of TNF receptor-associated factor 3, Br J Pharmacol, 176, pp. 3264-3278, (2019); Scuderi SA, Casili G, Lanza M, Filippone A, Paterniti I, Esposito E, Et al., Modulation of nlrp3 inflammasome attenuated inflammatory response associated to diarrhea-predominant irritable bowel syndrome, Biomedicines, 8, pp. 1-16, (2020); Demircan M, Cetin S, Uguralp S, Sezgin N, Karaman A, Gozukara EM., Plasma D-lactic acid level: A useful marker to distinguish perforated from acute simple appendicitis, Asian J Surg, 27, pp. 303-305, (2004); Miyoshi J, Miyamoto H, Goji T, Taniguchi T, Tomonari T, Sogabe M, Et al., Serum diamine oxidase activity as a predictor of gastrointestinal toxicity and malnutrition due to anticancer drugs, J Gastroenterol Hepatol, 30, pp. 1582-1590, (2015); Stevens BR, Goel R, Seungbum K, Richards EM, Holbert RC, Pepine CJ, Et al., Altered Gut Microbiome in Anxiety or Depression, Gut, 67, pp. 1555-1557, (2018); Pinto-Sanchez MI, Ford AC, Avila CA, Verdu EF, Collins SM, Morgan D, Et al., Anxiety and depression increase in a stepwise manner in parallel with multiple FGIDs and symptom severity and frequency, Am J Gastroenterol, 110, pp. 1038-1048, (2015); Bradesi S, Schwetz I, Ennes HS, Lamy CMR, Ohning G, Fanselow M, Et al., Repeated exposure to water avoidance stress in rats: A new model for sustained visceral hyperalgesia, Am J Physiol—Gastrointest Liver Physiol, 289, (2005); Yan B, Guo Q, Fu FJ, Wang Z, Yin Z, Wei YB, Et al., The role of miR-29b in cancer: Regulation, function, and signaling, Onco Targets Ther, 8, pp. 539-548, (2015); Hu J, Zhu XH, Zhang XJ, Wang PX, Zhang R, Zhang P, Et al., Targeting TRAF3 signaling protects against hepatic ischemia/reperfusions injury, J Hepatol, 64, pp. 146-159, (2016); Sun Y, Zhou Y, Shi Y, Zhang Y, Liu K, Liang R, Et al., Expression of miRNA-29 in Pancreatic β Cells Promotes Inflammation and Diabetes via TRAF3, Cell Rep, 34, (2021); Zhang B, Shetti D, Fan C, Wei K., miR-29b-3p promotes progression of MDA-MB-231 triple-negative breast cancer cells through downregulating TRAF3, Biol Res, 52, (2019); Profile C, E-mediated I, Irritable W, Syndrome B, Diarrhea W., Cytokine Profile and Immunoglobulin E-mediated Serological Food Hypersensitivity in Patients With Irritable Bowel Syndrome With Diarrhea, 24, pp. 415-421, (2018); A AW., Role of NF- k B activation in intestinal immune homeostasis, Int Jl Med Microbiol, 300, pp. 49-56, (2010); Nighot M, Rawat M, Al-Sadi R, Castillo EF, Nighot P, Ma TY., Lipopolysaccharide-Induced Increase in Intestinal Permeability Is Mediated by TAK-1 Activation of IKK and MLCK/MYLK Gene, Am J Pathol, 189, pp. 797-812, (2019); Ma TY, Boivin MA, Ye D, Pedram A, Said HM, Thomas Y, Et al., Mechanism of TNF- α modulation of Caco-2 intestinal epithelial tight junction barrier: role of myosin light-chain kinase protein expression, 1, pp. 422-430, (2005); Marchiando AM, Shen L, Graham WV, Edelblum KL, Carrie A, Guan Y, Et al., NIH Public Access, 140, pp. 1208-1218, (2012)","Y. Huang; The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China; email: hys1125@gzucm.edu.cn; H. Tang; The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China; email: yxb@gzucm.edu.cn","","Public Library of Science","","","","","","19326203","","POLNC","37428806","English","PLoS ONE","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85164299008"

"Langlois L.D.; Oddoux S.; Aublé K.; Violette P.; Déchelotte P.; Noël A.; Coëffier M.","Langlois, Ludovic D. (58869571200); Oddoux, Sarah (57225291827); Aublé, Kanhia (58222029100); Violette, Paul (57734216600); Déchelotte, Pierre (57201760610); Noël, Antoine (57221445829); Coëffier, Moïse (6603081357)","58869571200; 57225291827; 58222029100; 57734216600; 57201760610; 57221445829; 6603081357","Effects of Glutamine, Curcumin and Fish Bioactive Peptides Alone or in Combination on Intestinal Permeability in a Chronic-Restraint Stress Model","2023","International Journal of Molecular Sciences","24","8","7220","","","","3","10.3390/ijms24087220","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85156197877&doi=10.3390%2fijms24087220&partnerID=40&md5=92df7794dce22002e73d1fbd68ad7435","Univ Rouen Normandie, Inserm, ADEN UMR1073 “Nutrition, Inflammation and Microbiota-Gut-Brain Axis”, Rouen, 76000, France; Laboratoire DIELEN, Tourlaville, F-50110, France; Nutrition Department, CHU Rouen, Rouen, 76000, France","Langlois L.D., Univ Rouen Normandie, Inserm, ADEN UMR1073 “Nutrition, Inflammation and Microbiota-Gut-Brain Axis”, Rouen, 76000, France, Laboratoire DIELEN, Tourlaville, F-50110, France; Oddoux S., Laboratoire DIELEN, Tourlaville, F-50110, France; Aublé K., Univ Rouen Normandie, Inserm, ADEN UMR1073 “Nutrition, Inflammation and Microbiota-Gut-Brain Axis”, Rouen, 76000, France; Violette P., Laboratoire DIELEN, Tourlaville, F-50110, France; Déchelotte P., Univ Rouen Normandie, Inserm, ADEN UMR1073 “Nutrition, Inflammation and Microbiota-Gut-Brain Axis”, Rouen, 76000, France, Nutrition Department, CHU Rouen, Rouen, 76000, France; Noël A., Laboratoire DIELEN, Tourlaville, F-50110, France; Coëffier M., Univ Rouen Normandie, Inserm, ADEN UMR1073 “Nutrition, Inflammation and Microbiota-Gut-Brain Axis”, Rouen, 76000, France, Nutrition Department, CHU Rouen, Rouen, 76000, France","Irritable bowel syndrome (IBS), a multifactorial intestinal disorder, is often associated with a disruption in intestinal permeability as well as an increased expression of pro-inflammatory markers. The aim of this study was to first test the impact of treatment with glutamine (Gln), a food supplement containing natural curcumin extracts and polyunsaturated n-3 fatty acids (Cur); bioactive peptides from a fish protein hydrolysate (Ga); and a probiotic mixture containing Bacillus coagulans, Lactobacillus acidophilus, Lactobacillus gasseri and Lactobacillus helveticus. These compounds were tested alone on a stress-based IBS model, the chronic-restraint stress model (CRS). The combination of Gln, Cur and Ga (GCG) was also tested. Eight-week-old C57Bl/6 male mice were exposed to restraint stress for two hours every day for four days and received different compounds every day one week before and during the CRS procedure. Plasma corticosterone levels were measured as a marker of stress, and colonic permeability was evaluated ex vivo in Ussing chambers. Changes in the gene expression of tight junction proteins (occludin, claudin-1 and ZO 1) and inflammatory cytokines (IL1β, TNFα, CXCL1 and IL10) were assessed using RT-qPCR. The CRS model led to an increase in plasma corticosterone and an increase in colonic permeability compared with unstressed animals. No change in plasma corticosterone concentrations was observed in response to CRS with the different treatments (Gln, Cur, Ga or GCG). Stressed animals treated with Gln, Cur and Ga alone and in combination showed a decrease in colonic permeability when compared to the CRS group, while the probiotic mixture resulted in an opposite response. The Ga treatment induced an increase in the expression of the anti-inflammatory cytokine IL-10, and the GCG treatment was able to decrease the expression of CXCL1, suggesting the synergistic effect of the combined mixture. In conclusion, this study demonstrated that a combined administration of glutamine, a food supplement containing curcumin and polyunsaturated n-3 fatty acids, and bioactive peptides from a fish hydrolysate was able to reduce colonic hyperpermeability and reduce the inflammatory marker CXCL1 in a stress-based model of IBS and could be of interest to patients suffering from IBS. © 2023 by the authors.","curcumin; fish bioactive peptides; glutamine; intestinal permeability; stress","Animals; Corticosterone; Curcumin; Cytokines; Fatty Acids, Omega-3; Glutamine; Intestinal Mucosa; Irritable Bowel Syndrome; Male; Mice; Permeability; alpha tocopherol; claudin 1; colecalciferol; corticosterone; curcumega; curcumin; CXCL1 chemokine; docosahexaenoic acid; fish protein; gabolysat; glutamine; icosapentaenoic acid; interleukin 10; interleukin 1beta; interleukin 8; isoflurane; messenger RNA; occludin; probiotic agent; protein hydrolysate; protein ZO1; tight junction protein; tumor necrosis factor; unclassified drug; corticosterone; curcumin; cytokine; glutamine; omega 3 fatty acid; adult; animal experiment; animal model; animal tissue; Article; Bacillus coagulans; blood sampling; colon mucosa; combination drug therapy; controlled study; corticosterone blood level; dietary supplement; drug potentiation; human; immobilization stress; intestine mucosa permeability; irritable colon; Lactobacillus acidophilus; Lactobacillus gasseri; Lactobacillus helveticus; male; mouse; nonhuman; real time polymerase chain reaction; animal; intestine mucosa; irritable colon; metabolism; permeability","","alpha tocopherol, 1406-18-4, 1406-70-8, 52225-20-4, 58-95-7, 59-02-9; claudin 1, 329338-06-9; colecalciferol, 1406-16-2, 67-97-0; corticosterone, 50-22-6; curcumin, 458-37-7; docosahexaenoic acid, 25167-62-8, 32839-18-2; glutamine, 56-85-9, 6899-04-3; icosapentaenoic acid, 10417-94-4, 1553-41-9, 25378-27-2, 32839-30-8; interleukin 8, 114308-91-7; isoflurane, 26675-46-7; occludin, 176304-61-3; protein hydrolysate, 76773-71-2, 9015-54-7; Corticosterone, ; Curcumin, ; Cytokines, ; Fatty Acids, Omega-3, ; Glutamine, ","curcumega; gabolysat","","Laboratoire Dielen; Region Normandy, (21E00021)","This work was funded by the Region Normandy via the program Impulsion Innovation, grant no. 21E00021, and by Laboratoire Dielen.","Canavan C., West J., Card T., The Epidemiology of Irritable Bowel Syndrome, Clin. Epidemiol, 6, pp. 71-80, (2014); Le Pluart D., Sabate J.-M., Bouchoucha M., Hercberg S., Benamouzig R., Julia C., Functional Gastrointestinal Disorders in 35,447 Adults and Their Association with Body Mass Index. Aliment, Pharmacol. Ther, 41, pp. 758-767, (2015); Kopczynska M., Mokros L., Pietras T., Malecka-Panas E., Quality of Life and Depression in Patients with Irritable Bowel Syndrome, Przeglad Gastroenterol, 13, pp. 102-108, (2018); Talley N.J., Zinsmeister A.R., Melton L.J., Irritable Bowel Syndrome in a Community: Symptom Subgroups, Risk Factors, and Health Care Utilization, Am. J. Epidemiol, 142, pp. 76-83, (1995); Longstreth G.F., Irritable Bowel Syndrome: A Multibillion-Dollar Problem, Gastroenterology, 109, pp. 2029-2031, (1995); Spiller R.C., Jenkins D., Thornley J.P., Hebden J.M., Wright T., Skinner M., Neal K.R., Increased Rectal Mucosal Enteroendocrine Cells, T Lymphocytes, and Increased Gut Permeability Following Acute Campylobacter Enteritis and in Post-Dysenteric Irritable Bowel Syndrome, Gut, 47, pp. 804-811, (2000); Coeffier M., Gloro R., Boukhettala N., Aziz M., Lecleire S., Vandaele N., Antonietti M., Savoye G., Bole-Feysot C., Dechelotte P., Et al., Increased Proteasome-Mediated Degradation of Occludin in Irritable Bowel Syndrome, Am. J. Gastroenterol, 105, pp. 1181-1188, (2010); Zhou Q., Zhang B., Verne G.N., Intestinal Membrane Permeability and Hypersensitivity in the Irritable Bowel Syndrome, Pain, 146, pp. 41-46, (2009); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Lecleire S., Antonietti M., Gourcerol G., Leroi A.-M., Dechelotte P., Menard J.-F., Ducrotte P., Et al., The Expression and the Cellular Distribution of the Tight Junction Proteins Are Altered in Irritable Bowel Syndrome Patients with Differences According to the Disease Subtype, Am. J. Gastroenterol, 106, pp. 2165-2173, (2011); Collins S.M., Denou E., Verdu E.F., Bercik P., The Putative Role of the Intestinal Microbiota in the Irritable Bowel Syndrome, Dig. Liver Dis, 41, pp. 850-853, (2009); De Palma G., Lynch M.D.J., Lu J., Dang V.T., Deng Y., Jury J., Umeh G., Miranda P.M., Pigrau Pastor M., Sidani S., Et al., Transplantation of Fecal Microbiota from Patients with Irritable Bowel Syndrome Alters Gut Function and Behavior in Recipient Mice, Sci. Transl. Med, 9, (2017); Walter S.A., Aardal-Eriksson E., Thorell L.H., Bodemar G., Hallbook O., Pre-Experimental Stress in Patients with Irritable Bowel Syndrome: High Cortisol Values Already before Symptom Provocation with Rectal Distensions, Neurogastroenterol. Motil, 18, pp. 1069-1077, (2006); Vanuytsel T., van Wanrooy S., Vanheel H., Vanormelingen C., Verschueren S., Houben E., Salim Rasoel S., Tomicronth J., Holvoet L., Farre R., Et al., Psychological Stress and Corticotropin-Releasing Hormone Increase Intestinal Permeability in Humans by a Mast Cell-Dependent Mechanism, Gut, 63, pp. 1293-1299, (2014); Ghouzali I., Lemaitre C., Bahlouli W., Azhar S., Bole-Feysot C., Meleine M., Ducrotte P., Dechelotte P., Coeffier M., Targeting Immunoproteasome and Glutamine Supplementation Prevent Intestinal Hyperpermeability, Biochim. Biophys. Acta Gen. Subj, 1861, pp. 3278-3288, (2017); Barreau F., Cartier C., Leveque M., Ferrier L., Moriez R., Laroute V., Rosztoczy A., Fioramonti J., Bueno L., Pathways Involved in Gut Mucosal Barrier Dysfunction Induced in Adult Rats by Maternal Deprivation: Corticotrophin-Releasing Factor and Nerve Growth Factor Interplay, J. Physiol, 580, pp. 347-356, (2007); L'Huillier C., Jarbeau M., Achamrah N., Belmonte L., Amamou A., Nobis S., Goichon A., Salameh E., Bahlouli W., do Rego J.-L., Et al., Glutamine, but Not Branched-Chain Amino Acids, Restores Intestinal Barrier Function during Activity-Based Anorexia, Nutrients, 11, (2019); Achamrah N., Dechelotte P., Coeffier M., Glutamine and the Regulation of Intestinal Permeability: From Bench to Bedside, Curr. Opin. Clin. Nutr. Metab. Care, 20, pp. 86-91, (2017); Zhou Q., Costinean S., Croce C.M., Brasier A.R., Merwat S., Larson S.A., Basra S., Verne G.N., MicroRNA 29 Targets Nuclear Factor-ΚB–Repressing Factor and Claudin 1 to Increase Intestinal Permeability, Gastroenterology, 148, pp. 158-169.e8, (2015); Zhou Q., Verne M.L., Fields J.Z., Lefante J.J., Basra S., Salameh H., Verne G.N., Randomised Placebo-Controlled Trial of Dietary Glutamine Supplements for Postinfectious Irritable Bowel Syndrome, Gut, 68, pp. 996-1002, (2019); Lubbad A., Oriowo M.A., Khan I., Curcumin Attenuates Inflammation through Inhibition of TLR-4 Receptor in Experimental Colitis, Mol. Cell. Biochem, 322, pp. 127-135, (2009); Ng Q.X., Soh A.Y.S., Loke W., Venkatanarayanan N., Lim D.Y., Yeo W.-S., A Meta-Analysis of the Clinical Use of Curcumin for Irritable Bowel Syndrome (IBS), J. Clin. Med, 7, (2018); Freret T., Largilliere S., Nee G., Coolzaet M., Corvaisier S., Boulouard M., Fast Anxiolytic-Like Effect Observed in the Rat Conditioned Defensive Burying Test, after a Single Oral Dose of Natural Protein Extract Products, Nutrients, 13, (2021); Bernet F., Montel V., Noel B., Dupouy J.P., Diazepam-like Effects of a Fish Protein Hydrolysate (Gabolysat PC60) on Stress Responsiveness of the Rat Pituitary-Adrenal System and Sympathoadrenal Activity, Psychopharmacology, 149, pp. 34-40, (2000); Oddoux S., Violette P., Cornet J., Akkoyun-Farinez J., Besnier M., Noel A., Rouillon F., Effect of a Dietary Supplement Combining Bioactive Peptides and Magnesium on Adjustment Disorder with Anxiety: A Clinical Trial in General Practice, Nutrients, 14, (2022); Colomier E., Algera J., Melchior C., Pharmacological Therapies and Their Clinical Targets in Irritable Bowel Syndrome with Diarrhea, Front. Pharmacol, 11, (2020); Asfaha S., Dubeykovskiy A.N., Tomita H., Yang X., Stokes S., Shibata W., Friedman A.N., Ariyama H., Dubeykovskaya Z.A., Muthupalani S., Et al., Mice that express human interleukin-8 have increased mobilization of immature myeloid cells, which exacerbates inflammation and accelerates colon carcinogenesis, Gastroenterology, 144, pp. 155-166, (2013); Hol J., Wilhelmsen L., Haraldsen G., The murine IL-8 homologues KC, MIP-2, and LIX are found in endothelial cytoplasmic granules but not in Weibel-Palade bodies, J. Leukoc. Biol, 87, pp. 501-508, (2010); Larauche M., Moussaoui N., Biraud M., Bae W.K., Duboc H., Million M., Tache Y., Brain Corticotropin-Releasing Factor Signaling: Involvement in Acute Stress-Induced Visceral Analgesia in Male Rats, Neurogastroenterol. Motil, 31, (2019); Greenwood-Van Meerveld B., Johnson A.C., Stress-Induced Chronic Visceral Pain of Gastrointestinal Origin, Front. Syst. Neurosci, 11, (2017); Saw C.L.L., Huang Y., Kong A.-N., Synergistic Anti-Inflammatory Effects of Low Doses of Curcumin in Combination with Polyunsaturated Fatty Acids: Docosahexaenoic Acid or Eicosapentaenoic Acid, Biochem. Pharmacol, 79, pp. 421-430, (2010); Rastgoo S., Ebrahimi-Daryani N., Agah S., Karimi S., Taher M., Rashidkhani B., Hejazi E., Mohseni F., Ahmadzadeh M., Sadeghi A., Et al., Glutamine Supplementation Enhances the Effects of a Low FODMAP Diet in Irritable Bowel Syndrome Management, Front. Nutr, 8, (2021); Cao W., Wang C., Chin Y., Chen X., Gao Y., Yuan S., Xue C., Wang Y., Tang Q., DHA-Phospholipids (DHA-PL) and EPA-Phospholipids (EPA-PL) Prevent Intestinal Dysfunction Induced by Chronic Stress, Food Funct, 10, pp. 277-288, (2019); Lobo de Sa F.D., Backert S., Nattramilarasu P.K., Mousavi S., Sandle G.I., Bereswill S., Heimesaat M.M., Schulzke J.-D., Bucker R., Vitamin D Reverses Disruption of Gut Epithelial Barrier Function Caused by Campylobacter Jejuni, Int. J. Mol. Sci, 22, (2021); Thomson A., Smart K., Somerville M.S., Lauder S.N., Appanna G., Horwood J., Sunder Raj L., Srivastava B., Durai D., Scurr M.J., Et al., The Ussing Chamber System for Measuring Intestinal Permeability in Health and Disease, BMC Gastroenterol, 19, (2019); Fitzgerald A.J., Rai P.S., Marchbank T., Taylor G.W., Ghosh S., Ritz B.W., Playford R.J., Reparative Properties of a Commercial Fish Protein Hydrolysate Preparation, Gut, 54, pp. 775-781, (2005); Gupta A.K., Maity C., Efficacy and Safety of Bacillus Coagulans LBSC in Irritable Bowel Syndrome: A Prospective, Interventional, Randomized, Double-Blind, Placebo-Controlled Clinical Study [CONSORT Compliant], Medicine, 100, (2021); Sadrin S., Sennoune S., Gout B., Marque S., Moreau J., Zinoune K., Grillasca J.-P., Pons O., Maixent J.-M., A 2-Strain Mixture of Lactobacillus Acidophilus in the Treatment of Irritable Bowel Syndrome: A Placebo-Controlled Randomized Clinical Trial, Dig. Liver Dis, 52, pp. 534-540, (2020); Kim J.Y., Park Y.J., Lee H.J., Park M.Y., Kwon O., Effect of Lactobacillus Gasseri BNR17 on Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Trial, Food Sci. Biotechnol, 27, pp. 853-857, (2018); Ait-Belgnaoui A., Payard I., Rolland C., Harkat C., Braniste V., Theodorou V., Tompkins T.A., Bifidobacterium Longum and Lactobacillus Helveticus Synergistically Suppress Stress-Related Visceral Hypersensitivity through Hypothalamic-Pituitary-Adrenal Axis Modulation, J. Neurogastroenterol. Motil, 24, pp. 138-146, (2018); Ligaarden S.C., Axelsson L., Naterstad K., Lydersen S., Farup P.G., A Candidate Probiotic with Unfavourable Effects in Subjects with Irritable Bowel Syndrome: A Randomised Controlled Trial, BMC Gastroenterol, 10, (2010); Zhu F., He H., Fan L., Ma C., Xu Z., Xue Y., Wang Y., Zhang C., Zhou G., Blockade of CXCR2 Suppresses Proinflammatory Activities of Neutrophils in Ulcerative Colitis, Am. J. Transl. Res, 12, pp. 5237-5251, (2020); Faucher P., Dries A., Mousset P.Y., Leboyer M., Dore J., Beracochea D., Synergistic Effects of Lacticaseibacillus Rhamnosus GG, Glutamine, and Curcumin on Chronic Unpredictable Mild Stress-Induced Depression in a Mouse Model, Benef. Microbes, 13, pp. 253-264, (2022); Moreno-Martinez S., Tendilla-Beltran H., Sandoval V., Flores G., Terron J.A., Chronic Restraint Stress Induces Anxiety-like Behavior and Remodeling of Dendritic Spines in the Central Nucleus of the Amygdala, Behav. Brain Res, 416, (2022); Kilkenny C., Parsons N., Kadyszewski E., Festing M.F.W., Cuthill I.C., Fry D., Hutton J., Altman D.G., Survey of the Quality of Experimental Design, Statistical Analysis and Reporting of Research Using Animals, PLoS ONE, 4, (2009); Tian L., Zeng K., Shao W., Yang B.B., Fantus I.G., Weng J., Jin T., Short-Term Curcumin Gavage Sensitizes Insulin Signaling in Dexamethasone-Treated C57BL/6 Mice, J. Nutr, 145, pp. 2300-2307, (2015); Nair A.B., Jacob S., A Simple Practice Guide for Dose Conversion between Animals and Human, J. Basic Clin. Pharm, 7, pp. 27-31, (2016); Coeffier M., Claeyssens S., Hecketsweiler B., Lavoinne A., Ducrotte P., Dechelotte P., Enteral Glutamine Stimulates Protein Synthesis and Decreases Ubiquitin MRNA Level in Human Gut Mucosa, Am. J. Physiol. Gastrointest. Liver Physiol, 285, pp. G266-G273, (2003)","M. Coëffier; Univ Rouen Normandie, Inserm, ADEN UMR1073 “Nutrition, Inflammation and Microbiota-Gut-Brain Axis”, Rouen, 76000, France; email: moise.coeffier@univ-rouen.fr","","Multidisciplinary Digital Publishing Institute (MDPI)","","","","","","16616596","","","37108383","English","Int. J. Mol. Sci.","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85156197877"

"Kovaleva A.; Poluektova E.; Maslennikov R.; Karchevskaya A.; Shifrin O.; Kiryukhin A.; Tertychnyy A.; Kovalev L.; Kovaleva M.; Lobanova O.; Kudryavtseva A.; Krasnov G.; Fedorova M.; Ivashkin V.","Kovaleva, Aleksandra (57224547897); Poluektova, Elena (57205199117); Maslennikov, Roman (57204125411); Karchevskaya, Anna (57845159500); Shifrin, Oleg (6507547844); Kiryukhin, Andrey (57212314548); Tertychnyy, Aleksandr (57209460072); Kovalev, Leonid (7004540939); Kovaleva, Marina (6701467064); Lobanova, Olga (57484405500); Kudryavtseva, Anna (35083706800); Krasnov, George (24492185500); Fedorova, Maria (58098836200); Ivashkin, Vladimir (57201595785)","57224547897; 57205199117; 57204125411; 57845159500; 6507547844; 57212314548; 57209460072; 7004540939; 6701467064; 57484405500; 35083706800; 24492185500; 58098836200; 57201595785","Effect of Rebamipide on the Intestinal Barrier, Gut Microbiota Structure and Function, and Symptom Severity Associated with Irritable Bowel Syndrome and Functional Dyspepsia Overlap: A Randomized Controlled Trial","2023","Journal of Clinical Medicine","12","18","6064","","","","4","10.3390/jcm12186064","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85172813571&doi=10.3390%2fjcm12186064&partnerID=40&md5=8fc5b2a8a46ed7412ce9c949242c491e","Department of Introduction to Internal Diseases, Gastroenterology and Hepatology, Sechenov University, Pogodinskaya Str., 1, Bld. 1, Moscow, 119435, Russian Federation; The Scientific Community for Human Microbiome Research, Pogodinskaya Str., 1, Bld. 1, Moscow, 119435, Russian Federation; Laboratory of General and Clinical Neurophysiology, Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, 5A Butlerova Str, Moscow, 117485, Russian Federation; N.N. Burdenko National Medical Research Center of Neurosurgery, 16, 4th Tverskaya-Yamskaya St, Moscow, 125047, Russian Federation; Endoscopy Unit, The Second University Clinic, Sechenov University, Pogodinskaya Str., 1, Bld. 1, Moscow, 119435, Russian Federation; Institute of Clinical Morphology and Digital Pathology, Sechenov University, Trubetskaya Str., 8, Bld. 2, Moscow, 119048, Russian Federation; Laboratory of Structural Biochemistry of Protein, A.N. Bach Institute of Biochemistry, Research Center of Biotechnology, Russian Academy of Sciences, Leninsky Prospekt, 33, Bld. 2, Moscow, 119071, Russian Federation; Laboratory of Postgenomic Research, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Vavilova Str., 32, Bld. 1, Moscow, 119991, Russian Federation","Kovaleva A., Department of Introduction to Internal Diseases, Gastroenterology and Hepatology, Sechenov University, Pogodinskaya Str., 1, Bld. 1, Moscow, 119435, Russian Federation; Poluektova E., Department of Introduction to Internal Diseases, Gastroenterology and Hepatology, Sechenov University, Pogodinskaya Str., 1, Bld. 1, Moscow, 119435, Russian Federation, The Scientific Community for Human Microbiome Research, Pogodinskaya Str., 1, Bld. 1, Moscow, 119435, Russian Federation; Maslennikov R., Department of Introduction to Internal Diseases, Gastroenterology and Hepatology, Sechenov University, Pogodinskaya Str., 1, Bld. 1, Moscow, 119435, Russian Federation, The Scientific Community for Human Microbiome Research, Pogodinskaya Str., 1, Bld. 1, Moscow, 119435, Russian Federation; Karchevskaya A., Department of Introduction to Internal Diseases, Gastroenterology and Hepatology, Sechenov University, Pogodinskaya Str., 1, Bld. 1, Moscow, 119435, Russian Federation, Laboratory of General and Clinical Neurophysiology, Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, 5A Butlerova Str, Moscow, 117485, Russian Federation, N.N. Burdenko National Medical Research Center of Neurosurgery, 16, 4th Tverskaya-Yamskaya St, Moscow, 125047, Russian Federation; Shifrin O., Department of Introduction to Internal Diseases, Gastroenterology and Hepatology, Sechenov University, Pogodinskaya Str., 1, Bld. 1, Moscow, 119435, Russian Federation; Kiryukhin A., Endoscopy Unit, The Second University Clinic, Sechenov University, Pogodinskaya Str., 1, Bld. 1, Moscow, 119435, Russian Federation; Tertychnyy A., Institute of Clinical Morphology and Digital Pathology, Sechenov University, Trubetskaya Str., 8, Bld. 2, Moscow, 119048, Russian Federation; Kovalev L., Laboratory of Structural Biochemistry of Protein, A.N. Bach Institute of Biochemistry, Research Center of Biotechnology, Russian Academy of Sciences, Leninsky Prospekt, 33, Bld. 2, Moscow, 119071, Russian Federation; Kovaleva M., Laboratory of Structural Biochemistry of Protein, A.N. Bach Institute of Biochemistry, Research Center of Biotechnology, Russian Academy of Sciences, Leninsky Prospekt, 33, Bld. 2, Moscow, 119071, Russian Federation; Lobanova O., Institute of Clinical Morphology and Digital Pathology, Sechenov University, Trubetskaya Str., 8, Bld. 2, Moscow, 119048, Russian Federation; Kudryavtseva A., Laboratory of Postgenomic Research, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Vavilova Str., 32, Bld. 1, Moscow, 119991, Russian Federation; Krasnov G., Laboratory of Postgenomic Research, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Vavilova Str., 32, Bld. 1, Moscow, 119991, Russian Federation; Fedorova M., Laboratory of Postgenomic Research, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Vavilova Str., 32, Bld. 1, Moscow, 119991, Russian Federation; Ivashkin V., Department of Introduction to Internal Diseases, Gastroenterology and Hepatology, Sechenov University, Pogodinskaya Str., 1, Bld. 1, Moscow, 119435, Russian Federation, The Scientific Community for Human Microbiome Research, Pogodinskaya Str., 1, Bld. 1, Moscow, 119435, Russian Federation","Treatment of functional digestive disorders is not always effective. Therefore, a search for new application points for potential drugs is perspective. Our aim is to evaluate the effect of rebamipide on symptom severity, intestinal barrier status, and intestinal microbiota composition and function in patients with diarrheal variant of irritable bowel syndrome overlapping with functional dyspepsia (D-IBSoFD). Sixty patients were randomized to receive trimebutine (TRI group), trimebutine + rebamipide (T + R group), or rebamipide (REB group) for 2 months. At the beginning and end of the study, patients were assessed for general health (SF-36), severity of digestive symptoms (Gastrointestinal Symptom Rating and 7 × 7 scales), state of the intestinal barrier, and composition (16S rRNA gene sequencing) and function (short-chain fatty acid fecal content) of the gut microbiota. The severity of most digestive symptoms was reduced in the REB and T + R groups to levels similar to that observed in the TRI group. The duodenal and sigmoidal lymphocytic and sigmoidal eosinophilic infiltration was decreased only in the REB and T + R groups, not in the TRI group. Serum zonulin levels were significantly decreased only in the REB group. A decrease in intraepithelial lymphocytic infiltration in the duodenum correlated with a decrease in the severity of rumbling and flatulence, while a decrease in infiltration within the sigmoid colon correlated with improved stool consistency and decreased severity of the sensation of incomplete bowel emptying. In conclusion, rebamipide improves the intestinal barrier condition and symptoms in D-IBSoFD. The rebamipide effects are not inferior to those of trimebutine. © 2023 by the authors.","dysbiosis; functional bowel disease; gut microbiota; intestinal permeability; minimal inflammation","biological marker; fatty acid binding protein; fatty acid binding protein 1; haptoglobin; mucin 2; placebo; rebagit; rebamipide; RNA 16S; short chain fatty acid; trimebutine; unclassified drug; zonulin; abdominal discomfort; abdominal pain; adult; Article; clinical outcome; controlled study; diarrhea; digestive system function disorder; disease severity; drug effect; drug efficacy; duodenum; dysbiosis; dyspepsia; enzyme linked immunosorbent assay; eosinophil; eructation; feces; female; flatulence; gastrointestinal symptom; gastrointestinal symptom rating scale; gene sequence; heartburn; human; human tissue; incomplete bowel emptying; inflammation; intestine flora; intestine mucosa; intestine mucosa permeability; intraepithelial lymphocyte; irritable colon; liquid feces; loose feces; lymphocytic infiltration; major clinical study; male; nonhuman; outcome assessment; permeability barrier; protein blood level; randomized controlled trial; Short Form 36; sigmoid; treatment response","","haptoglobin, 9087-69-8; rebamipide, 111911-87-6; trimebutine, 39133-31-8","2100 Bioanalyzer, Agilent, United States; Agencourt AMPure XP, Beckman Coulter, United States; Applied Biosystems 2720, Thermo, United States; BenchMark XT, Ventana, United States; DNA 1000 Kit, Agilent, United States; I-view detection kit, Ventana, United States; MagNA Pure Compact Nucleic Acid Isolation Kit I, Hoffmann La Roche; MagNA Pure LC, Hoffmann La Roche; MiSeq Reagent Kit v3, Illumina, United States; MiSeq, Illumina, United States; NanoDrop 1000, Thermo, United States; Nextera XT Index Kit, Illumina, United States; QuantiT dsDNA High-Sensitivity Assay Kit; Qubit 2.0, Invitrogen, United States; rebagit","Agilent, United States; Agilent, United States; Beckman Coulter, United States; Hoffmann La Roche; Hoffmann La Roche; Illumina, United States; Illumina, United States; Illumina, United States; Invitrogen, United States; Thermo, United States; Thermo, United States; Ventana, United States; Ventana, United States","","","Enck P., Azpiroz F., Boeckxstaens G., Elsenbruch S., Feinle-Bisset C., Holtmann G., Lackner J.M., Ronkainen J., Schemann M., Stengel A., Et al., Functional Dyspepsia, Nat. Rev. Dis. Primers, 3, (2017); Talley N.J., Walker M.M., Holtmann G., Functional Dyspepsia, Curr. Opin. Gastroenterol, 32, pp. 467-473, (2016); Stanghellini V., Functional Dyspepsia and Irritable Bowel Syndrome: Beyond Rome IV, Dig. Dis, 35, pp. 14-17, (2017); von Wulffen M., Talley N.J., Hammer J., McMaster J., Rich G., Shah A., Koloski N., Kendall B.J., Jones M., Holtmann G., Overlap of Irritable Bowel Syndrome and Functional Dyspepsia in the Clinical Setting: Prevalence and Risk Factors, Dig. Dis. Sci, 64, pp. 480-486, (2018); Choi Y.J., Kim N., Yoon H., Shin C.M., Park Y.S., Kim J.-W., Kim Y.S., Lee D.H., Jung H.C., Overlap between Irritable Bowel Syndrome and Functional Dyspepsia Including Subtype Analyses, J. Gastroenterol. Hepatol, 32, pp. 1553-1561, (2017); Yao X., Yang Y.S., Cui L.H., Sun G., Peng L.H., Wang W.F., Hyder Q., Zhang X.L., The Overlap of Upper Functional Gastrointestinal Disorders with Irritable Bowel Syndrome in Chinese Outpatients: A Multicenter Study, J. Gastroenterol. Hepatol, 31, pp. 1584-1593, (2016); Ford A.C., Marwaha A., Lim A., Moayyedi P., Systematic Review and Meta-Analysis of the Prevalence of Irritable Bowel Syndrome in Individuals with Dyspepsia, Clin. Gastroenterol. Hepatol, 8, pp. 401-409, (2010); Mekhdiyev S.N., Mekhdieva O.A., Berko O.M., Overlap of Functional Gastrointestinal Disorders: Common Mechanisms of Pathogenesis as a Key to Rational Therapy, Russ. J. Gastroenterol. Hepatol. Coloproctol, 32, pp. 95-103, (2022); Fan K., Talley N.J., Functional Dyspepsia and Duodenal Eosinophilia: A New Model, J. Dig. Dis, 18, pp. 667-677, (2017); Sarkar M.A.M., Akhter S., Khan M.R., Saha M., Roy P.K., Association of Duodenal Eosinophilia with Helicobacter Pylori-Negative Functional Dyspepsia, Arab. J. Gastroenterol, 21, pp. 19-23, (2020); Wauters L., Burns G., Ceulemans M., Walker M.M., Vanuytsel T., Keely S., Talley N.J., Duodenal Inflammation: An Emerging Target for Functional Dyspepsia?, Expert Opin. Ther. Targets, 24, pp. 511-523, (2020); Lee K.J., Tack J., Duodenal Implications in the Pathophysiology of Functional Dyspepsia, J. Neurogastroenterol. Motil, 16, pp. 251-257, (2010); Ivashkin V.T., Maev I.V., Trukhmanov A.S., Sheptulin A.A., Lapina T.L., Simanenkov V.I., Sokolov K.A., Inflammation, Impaired Motor Function and Visceral Hypersensitivity: The Main Mechanisms of Functional Disorders of the Gastrointestinal Tract (Materials of the Expert Council and Literature Review), Russ. J. Gastroenterol. Hepatol. Coloproctol, 32, pp. 7-14, (2022); Puthanmadhom Narayanan S., O'Brien D.R., Sharma M., Smyrk T.C., Graham R.P., Grover M., Bharucha A.E., Duodenal Mucosal Barrier in Functional Dyspepsia, Clin. Gastroenterol. Hepatol, 20, pp. 1019-1028.e3, (2022); Vanheel H., Vicario M., Vanuytsel T., Van Oudenhove L., Martinez C., Keita A.V., Pardon N., Santos J., Soderholm J.D., Tack J., Et al., Impaired Duodenal Mucosal Integrity and Low-Grade Inflammation in Functional Dyspepsia, Gut, 63, pp. 262-271, (2013); Nojkov B., Zhou S.-Y., Dolan R.D., Davis E.M., Appelman H.D., Guo X., Jackson K., Sturm M.B., Wang T.D., Owyang C., Et al., Evidence of Duodenal Epithelial Barrier Impairment and Increased Pyroptosis in Patients with Functional Dyspepsia on Confocal Laser Endomicroscopy and “Ex Vivo” Mucosa Analysis, Am. J. Gastroenterol, 115, pp. 1891-1901, (2020); Wauters L., Ceulemans M., Schol J., Farre R., Tack J., Vanuytsel T., The Role of Leaky Gut in Functional Dyspepsia, Front. Neurosci, 16, (2022); Farre R., Vicario M., Abnormal Barrier Function in Gastrointestinal Disorders, Gastrointest. Pharmacol, 239, pp. 193-217, (2016); Mujagic Z., Ludidi S., Keszthelyi D., Hesselink M.A.M., Kruimel J.W., Lenaerts K., Hanssen N.M.J., Conchillo J.M., Jonkers D.M.A.E., Masclee A.A.M., Small Intestinal Permeability Is Increased in Diarrhoea Predominant IBS, While Alterations in Gastroduodenal Permeability in All IBS Subtypes Are Largely Attributable to Confounders, Aliment. Pharmacol. Ther, 40, pp. 288-297, (2014); Linsalata M., Riezzo G., D'Attoma B., Clemente C., Orlando A., Russo F., Noninvasive Biomarkers of Gut Barrier Function Identify Two Subtypes of Patients Suffering from Diarrhoea Predominant-IBS: A Case-Control Study, BMC Gastroenterol, 18, (2018); Linsalata M., Riezzo G., Clemente C., D'Attoma B., Russo F., Noninvasive Biomarkers of Gut Barrier Function in Patients Suffering from Diarrhea Predominant-IBS: An Update, Dis. Markers, 2020, (2020); Iakupova A.A., Abdulkhakov S.R., Zalyalov R.K., Safin A.G., Abdulkhakov R.A., Intestinal Permeability Assays: A Review, Russ. J. Gastroenterol. Hepatol. Coloproctol, 31, pp. 20-30, (2021); Jakobsson H.E., Rodriguez-Pineiro A.M., Schutte A., Ermund A., Boysen P., Bemark M., Sommer F., Backhed F., Hansson G.C., Johansson M.E.V., The Composition of the Gut Microbiota Shapes the Colon Mucus Barrier, EMBO Rep, 16, pp. 164-177, (2015); Grondin J.A., Kwon Y.H., Far P.M., Haq S., Khan W.I., Mucins in Intestinal Mucosal Defense and Inflammation: Learning from Clinical and Experimental Studies, Front. Immunol, 11, (2020); Shin A., Preidis G.A., Shulman R., Kashyap P.C., The Gut Microbiome in Adult and Pediatric Functional Gastrointestinal Disorders, Clin. Gastroenterol. Hepatol, 17, pp. 256-274, (2019); Ma W., Drew D.A., Staller K., The Gut Microbiome and Colonic Motility Disorders: A Practical Framework for the Gastroenterologist, Curr. Gastroenterol. Rep, 24, pp. 115-126, (2022); Singh R., Zogg H., Wei L., Bartlett A., Ghoshal U.C., Rajender S., Ro S., Gut Microbial Dysbiosis in the Pathogenesis of Gastrointestinal Dysmotility and Metabolic Disorders, J. Neurogastroenterol. Motil, 27, pp. 19-34, (2021); Ivashkin V.T., Maev I.V., Abdulganieva D.I., Alekseenko S.A., Gorelov A.V., Zakharova I.N., Zolnikova O.Y., Ivashkina N.Y., Korochanskaya N.V., Mammayev S.N., Et al., Practical Recommendations of Scientific Society for the Study of Human Microbiome and the Russian Gastroenterological Association on Use of Probiotics, Prebiotics, Synbiotics and Functional Foods in Treatment and Prevention of Gastroenterological Diseases in Children and Adults, Russ. J. Gastroenterol. Hepatol. Coloproctol, 31, pp. 65-91, (2021); Maslennikov R., Ivashkin V., Efremova I., Poluektova E., Shirokova E., Probiotics in Hepatology: An Update, World J. Hepatol, 13, pp. 1154-1166, (2021); Arakawa T., Higuchi K., Fujiwara Y., Watanabe T., Tominaga K., Sasaki E., Oshitani N., Yoshikawa T., Tarnawski A.S., 15th Anniversary of Rebamipide: Looking Ahead to the New Mechanisms and New Applications, Dig. Dis. Sci, 50, pp. S3-S11, (2005); Kleine A., Kluge S., Peskar B.M., Stimulation of Prostaglandin Biosynthesis Mediates Gastroprotective Effect of Rebamipide in Rats, Dig. Dis. Sci, 38, pp. 1441-1449, (1993); Gweon T.-G., Park J.-H., Kim B.-W., Choi Y.K., Kim J.S., Park S.M., Kim C.W., Kim H.-G., Chung J.-W., Incheon and Western Kyonggi Gastrointestinal Study Additive Effects of Rebamipide Plus Proton Pump Inhibitors on the Expression of Tight Junction Proteins in a Rat Model of Gastro-Esophageal Reflux Disease, Gut Liver, 12, pp. 46-50, (2018); Jaafar M.H., Safi S.Z., Tan M.-P., Rampal S., Mahadeva S., Efficacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta-Analysis, Dig. Dis. Sci, 63, pp. 1250-1260, (2017); Naryzhny S.N., Legina O.K., Zonulin—Regulation of Tight Contacts in the Brain and Intestine—Facts and Hypotheses, Biomeditsinskaya Khimiya, 68, pp. 309-320, (2022); Yang Y.J., Bang C.S., Baik G.H., Park T.Y., Shin S.P., Suk K.T., Kim D.J., Prokinetics for the Treatment of Functional Dyspepsia: Bayesian Network Meta-Analysis, BMC Gastroenterol, 17, (2017); Kountouras J., Doulberis M., Papaefthimiou A., Polyzos S.A., Gastroesophageal Reflux Disease, Irritable Bowel Syndrome and Functional Dyspepsia as Overlapping Conditions: Focus on Effect of Trimebutine, Ann. Gastroenterol, 32, (2019); Salvioli B., Trimebutine: A State-of-the-Art Review, Minerva Gastroenterol. Dietol, 65, pp. 229-238, (2019); Moayyedi P.M., Lacy B.E., Andrews C.N., Enns R.A., Howden C.W., Vakil N., ACG and CAG Clinical Guideline: Management of Dyspepsia, Am. J. Gastroenterol, 112, pp. 988-1013, (2017); Fukudo S., Kaneko H., Akiho H., Inamori M., Endo Y., Okumura T., Kanazawa M., Kamiya T., Sato K., Chiba T., Et al., Evidence-Based Clinical Practice Guidelines for Irritable Bowel Syndrome, J. Gastroenterol, 50, pp. 11-30, (2014); Brazier J.E., Harper R., Jones N.M., O'Cathain A., Thomas K.J., Usherwood T., Westlake L., Validating the SF-36 Health Survey Questionnaire: New Outcome Measure for Primary Care, BMJ, 305, pp. 160-164, (1992); Ivashkin V., Sheptulin A., Shifrin O., Poluektova E., Pavlov C., Ivashkin K., Drozdova A., Lyashenko O., Korolev A., Clinical Validation of the “7 × 7” Questionnaire for Patients with Functional Gastrointestinal Disorders, J. Gastroenterol. Hepatol, 34, pp. 1042-1048, (2018); Svedlund J., Sjdin I., Dotevall G., GSRS—A Clinical Rating Scale for Gastrointestinal Symptoms in Patients with Irritable Bowel Syndrome and Peptic Ulcer Disease, Dig. Dis. Sci, 33, pp. 129-134, (1988); Fouhy F., Deane J., Rea M.C., O'Sullivan O., Ross R.P., O'Callaghan G., Plant B.J., Stanton C., The effects of freezing on faecal microbiota as determined using MiSeq sequencing and culture-based investigations, PLoS ONE, 10, (2015); Zheng W., Tsompana M., Ruscitto A., Sharma A., Genco R., Sun Y., Buck M.J., An accurate and efficient experimental approach for characterization of the complex oral microbiota, Microbiome, 3, (2015); Parikh H.I., Koparde V.N., Bradley S.P., Buck G.A., Sheth N.U., MeFiT: Merging and filtering tool for illumina paired-end reads for 16S rRNA amplicon sequencing, BMC Bioinform, 17, (2016); Callahan B.J., McMurdie P.J., Rosen M.J., Han A.W., Johnson A.J., Holmes S.P., DADA2: High-resolution sample inference from Illumina amplicon data, Nat. Methods, 13, pp. 581-583, (2016); Quast C., Pruesse E., Yilmaz P., Gerken J., Schweer T., Yarza P., Peplies J., Glockner F.O., The SILVA ribosomal RNA gene database project: Improved data processing and web-based tools, Nucleic Acids Res, 41, pp. D590-D596, (2013); Fernandes A.D., Macklaim J.M., Linn T.G., Reid G., Gloor G.B., ANOVA-like differential expression (ALDEx) analysis for mixed population RNA-Seq, PLoS ONE, 8, (2013); Funaoka H., Kanda T., Kajiura S., Ohkaru Y., Fujii H., Development of a High-Specificity Sandwich ELISA System for the Quantification of Human Intestinal Fatty Acid-Binding Protein (I-FABP) Concentrations, Immunol. Investig, 40, pp. 223-242, (2011); Poynard T., Regimbeau C., Benhamou Y., Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome, Aliment. Pharmacol. Ther, 15, pp. 355-361, (2001); Ruepert L., Quartero A.O., de Wit N.J., van der Heijden G.J., Rubin G., Muris J.W., Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome, Cochrane Database Syst. Rev, 2013, (2011)","R. Maslennikov; Department of Introduction to Internal Diseases, Gastroenterology and Hepatology, Sechenov University, Moscow, Pogodinskaya Str., 1, Bld. 1, 119435, Russian Federation; email: maslennikov_r_v@staff.sechenov.ru","","Multidisciplinary Digital Publishing Institute (MDPI)","","","","","","20770383","","","","English","J. Clin. Med.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85172813571"

"Rodiño-Janeiro B.K.; Pigrau M.; Salvo-Romero E.; Nieto A.; Expósito E.; González-Castro A.M.; Galán C.; de Torres I.; Pribic T.; Hernández L.; Lobo B.; Fortea M.; Gallart M.; Pardo-Camacho C.; Guagnozzi D.; Santos J.; Alonso-Cotoner C.","Rodiño-Janeiro, Bruno K. (35729142300); Pigrau, Marc (37009212800); Salvo-Romero, Eloísa (56830611700); Nieto, Adoración (57191341801); Expósito, Elba (57220056948); González-Castro, Ana M. (54796498900); Galán, Carmen (57205368870); de Torres, Inés (7003506754); Pribic, Teodora (57192113868); Hernández, Laura (59035058800); Lobo, Beatriz (7003936898); Fortea, Marina (56830396500); Gallart, Milagros (57213292987); Pardo-Camacho, Cristina (57192877965); Guagnozzi, Danila (6506135584); Santos, Javier (7402389020); Alonso-Cotoner, Carmen (57220113655)","35729142300; 37009212800; 56830611700; 57191341801; 57220056948; 54796498900; 57205368870; 7003506754; 57192113868; 59035058800; 7003936898; 56830396500; 57213292987; 57192877965; 6506135584; 7402389020; 57220113655","Acute Stress Regulates Sex-Related Molecular Responses in the Human Jejunal Mucosa: Implications for Irritable Bowel Syndrome","2023","Cells","12","3","423","","","","1","10.3390/cells12030423","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85147822338&doi=10.3390%2fcells12030423&partnerID=40&md5=0f56334059b4867951834ba9298476fd","Department of Gastroenterology, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain; Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain; Laboratory of Translational Mucosal Immunology, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain; Facultad de Medicina, Universitat Autònoma de Barcelona, Barcelona, 08193, Spain; Department of Pathology, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERHED), Instituto de Salud Carlos III, Madrid, 28029, Spain","Rodiño-Janeiro B.K., Department of Gastroenterology, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain, Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain; Pigrau M., Department of Gastroenterology, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain, Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain; Salvo-Romero E., Department of Gastroenterology, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain, Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain, Laboratory of Translational Mucosal Immunology, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain; Nieto A., Department of Gastroenterology, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain, Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain; Expósito E., Department of Gastroenterology, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain, Laboratory of Translational Mucosal Immunology, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain; González-Castro A.M., Department of Gastroenterology, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain, Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain, Laboratory of Translational Mucosal Immunology, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain; Galán C., Department of Gastroenterology, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain, Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain; de Torres I., Facultad de Medicina, Universitat Autònoma de Barcelona, Barcelona, 08193, Spain, Department of Pathology, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain; Pribic T., Department of Gastroenterology, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain, Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain; Hernández L., Department of Gastroenterology, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain, Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain; Lobo B., Department of Gastroenterology, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain, Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain, Facultad de Medicina, Universitat Autònoma de Barcelona, Barcelona, 08193, Spain; Fortea M., Department of Gastroenterology, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain, Laboratory of Translational Mucosal Immunology, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain; Gallart M., Department of Gastroenterology, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain, Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain; Pardo-Camacho C., Department of Gastroenterology, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain, Laboratory of Translational Mucosal Immunology, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain; Guagnozzi D., Department of Gastroenterology, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain, Laboratory of Translational Mucosal Immunology, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain, Facultad de Medicina, Universitat Autònoma de Barcelona, Barcelona, 08193, Spain, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERHED), Instituto de Salud Carlos III, Madrid, 28029, Spain; Santos J., Department of Gastroenterology, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain, Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain, Facultad de Medicina, Universitat Autònoma de Barcelona, Barcelona, 08193, Spain, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERHED), Instituto de Salud Carlos III, Madrid, 28029, Spain; Alonso-Cotoner C., Department of Gastroenterology, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain, Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain, Facultad de Medicina, Universitat Autònoma de Barcelona, Barcelona, 08193, Spain, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERHED), Instituto de Salud Carlos III, Madrid, 28029, Spain","Irritable bowel syndrome (IBS) is a prevalent gastrointestinal disorder linked to intestinal barrier dysfunction and life stress. We have previously reported that female sex per se determines an increased susceptibility to intestinal barrier dysfunction after cold pain stress (CPS). We aimed to identify sex-related molecular differences in response to CPS in healthy subjects to understand the origin of sex bias predominance in IBS. In 13 healthy males and 21 females, two consecutive jejunal biopsies were obtained using Watson’s capsule, at baseline, and ninety minutes after CPS. Total mucosal RNA and protein were isolated from jejunal biopsies. Expression of genes related to epithelial barrier (CLDN1, CLDN2, OCLN, ZO-1, and ZO-3), mast cell (MC) activation (TPSAB1, SERPINA1), and the glucocorticoid receptor (NR3C1) were analyzed using RT-qPCR. NR3C1, ZO-1 and OCLN protein expression were evaluated through immunohistochemistry and western blot, and mucosal inflammation through MC, lymphocyte, and eosinophil numbering. Autonomic, hormonal, and psychological responses to CPS were monitored. We found an increase in jejunal MCs, a reduced CLDN1 and OCLN expression, and an increased CLDN2 and SERPINA1 expression 90 min after CPS. We also found a significant decrease in ZO-1, OCLN, and NR3C1 gene expression, and a decrease in OCLN protein expression only in females, when compared to males. CPS induced a significant increase in blood pressure, plasma cortisol and ACTH, and subjective stress perception in all participants. Specific and independent sex-related molecular responses in epithelial barrier regulation are unraveled by acute stress in the jejunum of healthy subjects and may partially explain female predominance in IBS. © 2023 by the authors.","acute stress; human; intestinal barrier; irritable bowel syndrome; sex","Biopsy; Female; Humans; Intestinal Mucosa; Intestines; Irritable Bowel Syndrome; Jejunum; Male; corticotropin; hydrocortisone; occludin; protein ZO1; acute stress; adult; Article; Beck Depression Inventory; blood pressure; blood sampling; chemiluminescence immunoassay; CLDN1 gene; CLDN2 gene; cluster analysis; depression; diastolic blood pressure; eosinophil; female; fluoroscopy; gene; gene expression; gene expression level; hand pain; heart rate; human; human experiment; hydrocortisone blood level; immunohistochemistry; irritable colon; jejunum biopsy; jejunum mucosa; male; middle aged; nociception; NR3C1 gene; OCLN gene; Perceived Stress Scale; prospective study; protein expression; protein expression level; protein isolation; real time polymerase chain reaction; RNA isolation; SERPINA1 gene; sex; sham procedure; Social Readjustment Rating Scale; systolic blood pressure; TPSAB1 gene; visual analog scale; Western blotting; ZO-1 gene; ZO-3 gene; biopsy; genetics; intestine; intestine mucosa; jejunum; metabolism; pathology","","corticotropin, 11136-52-0, 9002-60-2, 9061-27-2; hydrocortisone, 50-23-7; occludin, 176304-61-3","ADVIA Centaur, Siemens Healthcare Diagnostics, Germany; Omron M4-I, Omron, Netherlands","Omron, Netherlands; Siemens Healthcare Diagnostics, Germany","Fondo de Investigación Sanitaria; Ministerio de Economía y Competitividad, MINECO, (CD15/00010, CM08/00229, CM10/00155, EII2011-0035, FI12/00254, MV17-00043); Ministerio de Economía y Competitividad, MINECO; Institute of Environmental Science and Research, ESR, (CIBEREHD CB06/04/0021, PI12/00314, PI15/00301, PI17/0190, PRED-VHIR-2014-018, PRED-VHIR-2016-53 34); Institute of Environmental Science and Research, ESR; Instituto de Salud Carlos III, ISCIII; European Regional Development Fund, ERDF; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, CIBEREHD","Supported in part by Fondo Europeo de Desarrollo Regional (FEDER), Fondo de Investigación Sanitaria and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Subdirección General de Investigación Sanitaria, Ministerio de Economiá y Competitividad: CM08/00229 (BL); CM10/00155 (MP); EII2011-0035, CD15/00010, and MV17-00043 (BKRJ.); FI12/00254 (ESR.), PI17/0190 (JS), PI12/00314 and PI15/00301 (CAC), CIBEREHD CB06/04/0021 (JS, CAC.); Vall d’Hebron Institut de Recerca, Programa de becas predoctorales Amics de Vall d’Hebron: PRED-VHIR-2014-018 (MF), PRED-VHIR-2016-53 34 (CPC.).","Nater U.M., Maloney E., Heim C., Reeves W.C., Cumulative Life Stress in Chronic Fatigue Syndrome, Psychiatry Res, 189, pp. 318-320, (2011); Enck P., Aziz Q., Barbara G., Farmer A.D., Fukudo S., Mayer E.A., Niesler B., Quigley E.M.M., Rajilic-Stojanovic M., Schemann M., Et al., Irritable Bowel Syndrome, Nat. Rev. Dis. Prim, 2, (2016); Galvez-Sanchez C.M., Duschek S., Reyes Del Paso G.A., Psychological Impact of Fibromyalgia: Current Perspectives, Psychol. Res. Behav. Manag, 12, pp. 117-127, (2019); Gupta A., Bhatt R.R., Naliboff B.D., Kutch J.J., Labus J.S., Vora P.P., Alaverdyan M., Schrepf A., Lutgendorf S., Mayer E.A., Et al., Impact of Early Adverse Life Events and Sex on Functional Brain Networks in Patients with Urological Chronic Pelvic Pain Syndrome (UCPPS): A MAPP Research Network Study, PLoS ONE, 14, (2019); Lacy B.E., Mearin F., Chang L., Chey W.D., Lembo A.J., Simren M., Spiller R., Bowel Disorders, Gastroenterology, 150, pp. 1393-1407, (2016); Sperber A.D., Bangdiwala S.I., Drossman D.A., Ghoshal U.C., Simren M., Tack J., Whitehead W.E., Dumitrascu D.L., Fang X., Fukudo S., Et al., Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study, Gastroenterology, 160, pp. 99-114, (2021); Chey W.D., Food: The Main Course to Wellness and Illness in Patients with Irritable Bowel Syndrome, Am. J. Gastroenterol, 111, pp. 366-371, (2016); Dinan T.G., Cryan J., Shanahan F., Keeling P.W.N., Quigley E.M.M., IBS: An Epigenetic Perspective, Nat. Rev. Gastroenterol. Hepatol, 7, pp. 465-471, (2010); Henstrom M., D'Amato M., Genetics of Irritable Bowel Syndrome, Mol. Cell. Pediatr, 3, (2016); Gazouli M., Wouters M.M., Kapur-Pojskic L., Bengtson M.-B., Friedman E., Nikcevic G., Demetriou C.A., Mulak A., Santos J., Niesler B., Lessons Learned—Resolving the Enigma of Genetic Factors in IBS, Nat. Rev. Gastroenterol. Hepatol, 13, pp. 77-87, (2016); Rodino-Janeiro B.K., Pardo-Camacho C., Santos J., Martinez C., Mucosal RNA and Protein Expression as the next Frontier in IBS: Abnormal Function despite Morphologically Intact Small Intestinal Mucosa, Am. J. Physiol. Gastrointest. Liver Physiol, 316, pp. G701-G719, (2019); Guilarte M., Santos J., de Torres I., Alonso C., Vicario M., Ramos L., Martinez C., Casellas F., Saperas E., Malagelada J.R., Diarrhoea-Predominant IBS Patients Show Mast Cell Activation and Hyperplasia in the Jejunum, Gut, 56, pp. 203-209, (2007); Guilarte M., Vicario M., Martinez C., de Torres I., Lobo B., Pigrau M., Gonzalez-Castro A., Rodino-Janeiro B.K., Salvo-Romero E., Fortea M., Et al., Peripheral Corticotropin-Releasing Factor Triggers Jejunal Mast Cell Activation and Abdominal Pain in Patients With Diarrhea-Predominant Irritable Bowel Syndrome, Am. J. Gastroenterol, 115, pp. 2047-2059, (2020); Vicario M., Gonzalez-Castro A.M., Martinez C., Lobo B., Pigrau M., Guilarte M., de Torres I., Mosquera J.L., Fortea M., Sevillano-Aguilera C., Et al., Increased Humoral Immunity in the Jejunum of Diarrhoea-Predominant Irritable Bowel Syndrome Associated with Clinical Manifestations, Gut, 64, pp. 1379-1388, (2015); Martin-Vinas J.J., Quigley E.M.M., Immune Response in Irritable Bowel Syndrome: A Systematic Review of Systemic and Mucosal Inflammatory Mediators, J. Dig. Dis, 17, pp. 572-581, (2016); Martinez C., Rodino-Janeiro B.K., Lobo B., Stanifer M.L., Klaus B., Granzow M., Gonzalez-Castro A.M., Salvo-Romero E., Alonso-Cotoner C., Pigrau M., Et al., MiR-16 and MiR-125b Are Involved in Barrier Function Dysregulation through the Modulation of Claudin-2 and Cingulin Expression in the Jejunum in IBS with Diarrhoea, Gut, 66, pp. 1537-1538, (2017); Bashashati M., Moossavi S., Cremon C., Barbaro M.R., Moraveji S., Talmon G., Rezaei N., Hughes P.A., Bian Z.X., Choi C.H., Et al., Colonic Immune Cells in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis, Neurogastroenterol. Motil, 30, (2018); Mavrangelos C., Campaniello M.A., Andrews J.M., Bampton P.A., Hughes P.A., Longitudinal Analysis Indicates Symptom Severity Influences Immune Profile in Irritable Bowel Syndrome, Gut, 67, pp. 398-399, (2018); Martinez C., Gonzalez-Castro A., Vicario M., Santos J., Cellular and Molecular Basis of Intestinal Barrier Dysfunction in the Irritable Bowel Syndrome, Gut Liver, 6, pp. 305-315, (2012); Martinez C., Lobo B., Pigrau M., Ramos L., Gonzalez-Castro A.M., Alonso C., Guilarte M., Guila M., de Torres I., Azpiroz F., Et al., Diarrhoea-Predominant Irritable Bowel Syndrome: An Organic Disorder with Structural Abnormalities in the Jejunal Epithelial Barrier, Gut, 62, pp. 1160-1168, (2013); Vanuytsel T., van Wanrooy S., Vanheel H., Vanormelingen C., Verschueren S., Houben E., Salim Rasoel S., Tomicronth J., Holvoet L., Farre R., Et al., Psychological Stress and Corticotropin-Releasing Hormone Increase Intestinal Permeability in Humans by a Mast Cell-Dependent Mechanism, Gut, 63, pp. 1293-1299, (2014); Rodino-Janeiro B.K., Alonso-Cotoner C., Pigrau M., Lobo B., Vicario M., Santos J., Role of Corticotropin-Releasing Factor in Gastrointestinal Permeability, J. Neurogastroenterol. Motil, 21, pp. 33-50, (2015); Barclay G.R., Turnberg L.A., Effect of Psychological Stress on Salt and Water Transport in the Human Jejunum, Gastroenterology, 93, pp. 91-97, (1987); Barclay G.R., Turnberg L.A., Effect of Cold-Induced Pain on Salt and Water Transport in the Human Jejunum, Gastroenterology, 94, pp. 994-998, (1988); Santos J., Saperas E., Nogueiras C., Mourelle M., Antolin M., Cadahia A., Malagelada J.R., Release of Mast Cell Mediators into the Jejunum by Cold Pain Stress in Humans, Gastroenterology, 114, pp. 640-648, (1998); Zheng G., Victor Fon G., Meixner W., Creekmore A., Zong Y., KDame M., Colacino J., Dedhia P.H., Hong S., Wiley J.W., Chronic Stress and Intestinal Barrier Dysfunction: Glucocorticoid Receptor and Transcription Repressor HES1 Regulate Tight Junction Protein Claudin-1 Promoter, Sci. Rep, 7, (2017); Alonso C., Guilarte M., Vicario M., Ramos L., Rezzi S., Martinez C., Lobo B., Martin F.-P., Pigrau M., Gonzalez-Castro A.M., Et al., Acute Experimental Stress Evokes a Differential Gender-Determined Increase in Human Intestinal Macromolecular Permeability, Neurogastroenterol. Motil, 24, pp. 740-746, (2012); Holmes T.H., Rahe R.H., The Social Readjustment Rating Scale, J. Psychosom. Res, 11, pp. 213-218, (1967); Cohen S., Kamarck T., Mermelstein R., A Global Measure of Perceived Stress, J. Health Soc. Behav, 24, pp. 385-396, (1983); Beck A.T., Ward C.H., Mendelson M., Mock J., Erbaugh J., An Inventory for Measuring Depression, Arch. Gen. Psychiatry, 4, pp. 561-571, (1961); Lovallo W., The Cold Pressor Test and Autonomic Function: A Review and Integration, Psychophysiology, 12, pp. 268-282, (1975); Naliboff B.D., Benton D., Solomon G.F., Morley J.E., Fahey J.L., Bloom E.T., Makinodan T., Gilmore S.L., Immunological Changes in Young and Old Adults during Brief Laboratory Stress, Psychosom. Med, 53, pp. 121-132, (1991); Alonso C., Guilarte M., Vicario M., Ramos L., Ramadan Z., Antolin M., Martinez C., Rezzi S., Saperas E., Kochhar S., Et al., Maladaptive Intestinal Epithelial Responses to Life Stress May Predispose Healthy Women to Gut Mucosal Inflammation, Gastroenterology, 135, pp. 163-172, (2008); Bekhbat M., Neigh G.N., Sex Differences in the Neuro-Immune Consequences of Stress: Focus on Depression and Anxiety, Brain Behav. Immun, 67, pp. 1-12, (2018); Meester I., Rivera-Silva G.F., Gonzalez-Salazar F., Immune System Sex Differences May Bridge the Gap Between Sex and Gender in Fibromyalgia, Front. Neurosci, 13, (2019); Zheng G., Wu S.-P., Hu Y., Smith D.E., Wiley J.W., Hong S., Corticosterone Mediates Stress-Related Increased Intestinal Permeability in a Region-Specific Manner, Neurogastroenterol. Motil, 25, pp. e127-e139, (2013); Matsuo K., Zhang X., Ono Y., Nagatomi R., Acute Stress-Induced Colonic Tissue HSP70 Expression Requires Commensal Bacterial Components and Intrinsic Glucocorticoid, Brain Behav. Immun, 23, pp. 108-115, (2009); Creekmore A.L., Hong S., Zhu S., Xue J., Wiley J.W., Chronic Stress-Associated Visceral Hyperalgesia Correlates with Severity of Intestinal Barrier Dysfunction, Pain, 159, pp. 1777-1789, (2018); Zong Y., Zhu S., Zhang S., Zheng G., Wiley J.W., Hong S., Chronic Stress and Intestinal Permeability: Lubiprostone Regulates Glucocorticoid Receptor-Mediated Changes in Colon Epithelial Tight Junction Proteins, Barrier Function, and Visceral Pain in the Rodent and Human, Neurogastroenterol. Motil, 31, (2018); Kawedia J.D., Nieman M.L., Boivin G.P., Melvin J.E., Kikuchi K.-I., Hand A.R., Lorenz J.N., Menon A.G., Interaction between Transcellular and Paracellular Water Transport Pathways through Aquaporin 5 and the Tight Junction Complex, Proc. Natl. Acad. Sci. USA, 104, pp. 3621-3626, (2007); Lee H.S., Kim D.-K., Kim Y.B., Lee K.J., Effect of Acute Stress on Immune Cell Counts and the Expression of Tight Junction Proteins in the Duodenal Mucosa of Rats, Gut Liver, 7, pp. 190-196, (2013); Hu C.H., Xiao K., Luan Z.S., Song J., Early Weaning Increases Intestinal Permeability, Alters Expression of Cytokine and Tight Junction Proteins, and Activates Mitogen-Activated Protein Kinases in Pigs, J. Anim. Sci, 91, pp. 1094-1101, (2013); Van Itallie C.M., Fanning A.S., Bridges A., Anderson J.M., ZO-1 Stabilizes the Tight Junction Solute Barrier through Coupling to the Perijunctional Cytoskeleton, Mol. Biol. Cell, 20, pp. 3930-3940, (2009); Schulzke J.D., Gitter A.H., Mankertz J., Spiegel S., Seidler U., Amasheh S., Saitou M., Tsukita S., Fromm M., Epithelial Transport and Barrier Function in Occludin-Deficient Mice, Biochim. Biophys. Acta Biomembr, 1669, pp. 34-42, (2005); Saitou M., Fujimoto K., Doi Y., Itoh M., Fujimoto T., Furuse M., Takano H., Noda T., Tsukita S., Occludin-Deficient Embryonic Stem Cells Can Differentiate into Polarized Epithelial Cells Bearing Tight Junctions, J. Cell Biol, 141, pp. 397-408, (1998); Raleigh D.R., Boe D.M., Yu D., Weber C.R., Marchiando A.M., Bradford E.M., Wang Y., Wu L., Schneeberger E.E., Shen L., Et al., Occludin S408 Phosphorylation Regulates Tight Junction Protein Interactions and Barrier Function, J. Cell Biol, 193, pp. 565-582, (2011); Buschmann M.M., Shen L., Rajapakse H., Raleigh D.R., Wang Y., Wang Y., Lingaraju A., Zha J., Abbott E., McAuley E.M., Et al., Occludin OCEL-Domain Interactions Are Required for Maintenance and Regulation of the Tight Junction Barrier to Macromolecular Flux, MBoC, 24, pp. 3056-3068, (2013); Tamura A., Hayashi H., Imasato M., Yamazaki Y., Hagiwara A., Wada M., Noda T., Watanabe M., Suzuki Y., Tsukita S., Loss of Claudin-15, but Not Claudin-2, Causes Na+ Deficiency and Glucose Malabsorption in Mouse Small Intestine, Gastroenterology, 140, pp. 913-923, (2011); Van Itallie C.M., Holmes J., Bridges A., Gookin J.L., Coccaro M.R., Proctor W., Colegio O.R., Anderson J.M., The Density of Small Tight Junction Pores Varies among Cell Types and Is Increased by Expression of Claudin-2, J. Cell. Sci, 121, pp. 298-305, (2008); Inai T., Kobayashi J., Shibata Y., Claudin-1 Contributes to the Epithelial Barrier Function in MDCK Cells, Eur. J. Cell Biol, 78, pp. 849-855, (1999); Zuo L., Kuo W.-T., Turner J.R., Tight Junctions as Targets and Effectors of Mucosal Immune Homeostasis, Cell. Mol. Gastroenterol. Hepatol, 10, pp. 327-340, (2020); Meddings J.B., Swain M.G., Environmental Stress-Induced Gastrointestinal Permeability Is Mediated by Endogenous Glucocorticoids in the Rat, Gastroenterology, 119, pp. 1019-1028, (2000); Yu Y., Liu Z.-Q., Liu X.-Y., Yang L., Geng X.-R., Yang G., Liu Z.-G., Zheng P.-Y., Yang P.-C., Stress-Derived Corticotropin Releasing Factor Breaches Epithelial Endotoxin Tolerance, PLoS ONE, 8, (2013); Bangasser D.A., Valentino R.J., Sex Differences in Stress-Related Psychiatric Disorders: Neurobiological Perspectives, Front. Neuroendocrinol, 35, pp. 303-319, (2014); Vicario M., Guilarte M., Alonso C., Yang P., Martinez C., Ramos L., Lobo B., Gonzalez A., Guila M., Pigrau M., Et al., Chronological Assessment of Mast Cell-Mediated Gut Dysfunction and Mucosal Inflammation in a Rat Model of Chronic Psychosocial Stress, Brain Behav. Immun, 24, pp. 1166-1175, (2010); Soderholm J.D., Yang P.-C., Ceponis P., Vohra A., Riddell R., Sherman P.M., Perdue M.H., Chronic Stress Induces Mast Cell-Dependent Bacterial Adherence and Initiates Mucosal Inflammation in Rat Intestine, Gastroenterology, 123, pp. 1099-1108, (2002); Kaushik S., Kaur J., Effect of Chronic Cold Stress on Intestinal Epithelial Cell Proliferation and Inflammation in Rats, Stress, 8, pp. 191-197, (2005); Santos J., Yang P.C., Soderholm J.D., Benjamin M., Perdue M.H., Role of Mast Cells in Chronic Stress Induced Colonic Epithelial Barrier Dysfunction in the Rat, Gut, 48, pp. 630-636, (2001); Smith F., Clark J.E., Overman B.L., Tozel C.C., Huang J.H., Rivier J.E.F., Blikslager A.T., Moeser A.J., Early Weaning Stress Impairs Development of Mucosal Barrier Function in the Porcine Intestine, Am. J. Physiol. Gastrointest. Liver Physiol, 298, pp. G352-G363, (2010); Santos J., Yates D., Guilarte M., Vicario M., Alonso C., Perdue M.H., Stress Neuropeptides Evoke Epithelial Responses via Mast Cell Activation in the Rat Colon, Psychoneuroendocrinology, 33, pp. 1248-1256, (2008); Santos J., Benjamin M., Yang P.C., Prior T., Perdue M.H., Chronic Stress Impairs Rat Growth and Jejunal Epithelial Barrier Function: Role of Mast Cells, Am. J. Physiol. Gastrointest. Liver Physiol, 278, pp. G847-G854, (2000); Wallon C., Yang P.-C., Keita A.V., Ericson A.-C., McKay D.M., Sherman P.M., Perdue M.H., Soderholm J.D., Corticotropin-Releasing Hormone (CRH) Regulates Macromolecular Permeability via Mast Cells in Normal Human Colonic Biopsies in Vitro, Gut, 57, pp. 50-58, (2008); Jacob C., Yang P.-C., Darmoul D., Amadesi S., Saito T., Cottrell G.S., Coelho A.-M., Singh P., Grady E.F., Perdue M., Et al., Mast Cell Tryptase Controls Paracellular Permeability of the Intestine. Role of Protease-Activated Receptor 2 and Beta-Arrestins, J. Biol. Chem, 280, pp. 31936-31948, (2005); Goldblum S.E., Rai U., Tripathi A., Thakar M., De Leo L., Di Toro N., Not T., Ramachandran R., Puche A.C., Hollenberg M.D., Et al., The Active Zot Domain (Aa 288-293) Increases ZO-1 and Myosin 1C Serine/Threonine Phosphorylation, Alters Interaction between ZO-1 and Its Binding Partners, and Induces Tight Junction Disassembly through Proteinase Activated Receptor 2 Activation, FASEB J, 25, pp. 144-158, (2011); Vergnolle N., Protease Inhibition as New Therapeutic Strategy for GI Diseases, Gut, 65, pp. 1215-1224, (2016); Ray K., IBS: The Power of Protease Activity in IBS, Nat. Rev. Gastroenterol. Hepatol, 14, (2017); Rolland-Fourcade C., Denadai-Souza A., Cirillo C., Lopez C., Jaramillo J.O., Desormeaux C., Cenac N., Motta J.-P., Larauche M., Tache Y., Et al., Epithelial Expression and Function of Trypsin-3 in Irritable Bowel Syndrome, Gut, 66, pp. 1767-1778, (2017); Lau C., Lytle C., Straus D.S., DeFea K.A., Apical and Basolateral Pools of Proteinase-Activated Receptor-2 Direct Distinct Signaling Events in the Intestinal Epithelium, Am. J. Physiol. Cell Physiol, 300, pp. C113-C123, (2011); Greene C.M., Marciniak S.J., Teckman J., Ferrarotti I., Brantly M.L., Lomas D.A., Stoller J.K., McElvaney N.G., A1-Antitrypsin Deficiency, Nat. Rev. Dis. Primers, 2, (2016); Geboes K., Ray M.B., Rutgeerts P., Callea F., Desmet V.J., Vantrappen G., Morphological Identification of Alpha-I-Antitrypsin in the Human Small Intestine, Histopathology, 6, pp. 55-60, (1982); Henley D.E., Lightman S.L., New Insights into Corticosteroid-Binding Globulin and Glucocorticoid Delivery, Neuroscience, 180, pp. 1-8, (2011); Bolton J.L., Hayward C., Direk N., Lewis J.G., Hammond G.L., Hill L.A., Anderson A., Huffman J., Wilson J.F., Campbell H., Et al., Genome Wide Association Identifies Common Variants at the SERPINA6/SERPINA1 Locus Influencing Plasma Cortisol and Corticosteroid Binding Globulin, PLoS Genet, 10, (2014); Mackey E., Ayyadurai S., Pohl C.S., D'Costa S., Li Y., Moeser A.J., Sexual Dimorphism in the Mast Cell Transcriptome and the Pathophysiological Responses to Immunological and Psychological Stress, Biol. Sex Differ, 7, (2016)","J. Santos; Department of Gastroenterology, Vall d’Hebron Hospital Universitari, Barcelona, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, 08035, Spain; email: javier.santos@vhir.org; C. Alonso-Cotoner; Department of Gastroenterology, Vall d’Hebron Hospital Universitari, Barcelona, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, 08035, Spain; email: caralons@vhebron.net","","MDPI","","","","","","20734409","","","36766765","English","Cells","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85147822338"

"Kovaleva A.; Poluektova E.; Maslennikov R.; Karchevskaya A.; Shifrin O.; Kiryukhin A.; Tertychnyy A.; Kovalev L.; Kovaleva M.; Lobanova O.; Kudryavtseva A.; Krasnov G.; Ivashkin V.","Kovaleva, Aleksandra (57224547897); Poluektova, Elena (57205199117); Maslennikov, Roman (57204125411); Karchevskaya, Anna (57845159500); Shifrin, Oleg (6507547844); Kiryukhin, Andrey (57212314548); Tertychnyy, Aleksandr (57209460072); Kovalev, Leonid (7004540939); Kovaleva, Marina (6701467064); Lobanova, Olga (57484405500); Kudryavtseva, Anna (35083706800); Krasnov, George (24492185500); Ivashkin, Vladimir (57201595785)","57224547897; 57205199117; 57204125411; 57845159500; 6507547844; 57212314548; 57209460072; 7004540939; 6701467064; 57484405500; 35083706800; 24492185500; 57201595785","Intestinal Barrier and Gut Microbiota in Patients with Overlapping Irritable Bowel Syndrome and Functional Dyspepsia","2023","Digestive Diseases and Sciences","68","11","","4166","4174","8","1","10.1007/s10620-023-08117-7","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85172406139&doi=10.1007%2fs10620-023-08117-7&partnerID=40&md5=5130ccd8d21e2f08b49f8e1c7b765c52","Sechenov University, Moscow, 119435, Russian Federation; A.N. Bach Institute of Biochemistry, Leninsky Prospekt, 33, Bld. 2, Moscow, 119071, Russian Federation; Engelhardt Institute of Molecular Biology, Vavilova St., 32, Bld. 1, Moscow, 119991, Russian Federation","Kovaleva A., Sechenov University, Moscow, 119435, Russian Federation; Poluektova E., Sechenov University, Moscow, 119435, Russian Federation; Maslennikov R., Sechenov University, Moscow, 119435, Russian Federation; Karchevskaya A., Sechenov University, Moscow, 119435, Russian Federation; Shifrin O., Sechenov University, Moscow, 119435, Russian Federation; Kiryukhin A., Sechenov University, Moscow, 119435, Russian Federation; Tertychnyy A., Sechenov University, Moscow, 119435, Russian Federation; Kovalev L., A.N. Bach Institute of Biochemistry, Leninsky Prospekt, 33, Bld. 2, Moscow, 119071, Russian Federation; Kovaleva M., A.N. Bach Institute of Biochemistry, Leninsky Prospekt, 33, Bld. 2, Moscow, 119071, Russian Federation; Lobanova O., Sechenov University, Moscow, 119435, Russian Federation; Kudryavtseva A., Engelhardt Institute of Molecular Biology, Vavilova St., 32, Bld. 1, Moscow, 119991, Russian Federation; Krasnov G., Engelhardt Institute of Molecular Biology, Vavilova St., 32, Bld. 1, Moscow, 119991, Russian Federation; Ivashkin V., Sechenov University, Moscow, 119435, Russian Federation","Background: Disturbances in the intestinal barrier and gut dysbiosis have been observed in patients with functional bowel diseases. Aims: To investigate the correlation between biomarkers of intestinal barrier disorders at different layers and the severity of symptoms in patients with overlapping diarrhea-predominant irritable bowel syndrome and functional dyspepsia (IDFO), as well as with gut microbiota taxa. Methods: This study included 45 patients with IDFO and 16 healthy controls. Endoscopy with biopsy of the duodenum and sigmoid colon (SC) was performed to count intraepithelial lymphocytes (IELs) and mucosal eosinophils (subepithelial layer), assess fatty acid binding protein (FABP; epithelial layer) level, and stain for mucin-2 (MUC-2; pre-epithelial layer). Composition of the gut microbiota was evaluated using 16S rRNA gene sequencing. Results: Patients with IDFO exhibited an increase in biomarkers of intestinal barrier disorders at all layers studied. IEL count in the duodenum was correlated with the severity of bloating (r = 0.336; p = 0.024) and, in the SC, was correlated with tenesmus severity (r = 0.303; p = 0.042). FABP-1 level in the SC was correlated with the severity of diarrhea (r = 0.577; p = 0.001), and FABP-5 concentration in the SC was correlated with abdominal distension (r = 0.477; p = 0.010). MUC-2 concentration in the duodenum was correlated with the severity of heartburn (r = 0.572; p = 0.025) and burning sensation in the epigastrium (r = 0.518; p = 0.048). All biomarkers of intestinal barrier permeability were correlated with the abundance of some gut microbiota taxa. Conclusion: Patients with IDFO exhibited disrupted intestinal barrier function in all layers, which was associated with clinical symptom severity and changes in the gut microbiota. Graphical Abstract: [Figure not available: see fulltext.]. © 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.","Diarrhea; Dysbiosis; Functional digestive disease; Gut barrier; Microbiome; Microbiota","Biomarkers; Diarrhea; Dysbiosis; Dyspepsia; Gastrointestinal Microbiome; Humans; Irritable Bowel Syndrome; RNA, Ribosomal, 16S; fatty acid binding protein; fatty acid binding protein 1; fatty acid binding protein 5; mucin 2; RNA 16S; unclassified drug; biological marker; RNA 16S; abdominal distension; adult; Article; bloating; burning sensation; clinical article; colon biopsy; colon mucosa; controlled study; diarrhea; disease severity; duodenum biopsy; dyspepsia; endoscopy; eosinophil; female; gastrointestinal symptom rating scale; heartburn; human; human cell; intestine endoscopy; intestine epithelium; intestine flora; intestine mucosa permeability; intraepithelial lymphocyte; irritable colon; male; nonhuman; observational study; retrospective study; RNA sequencing; sigmoid; stain; tenesmus; dysbiosis; genetics","","Biomarkers, ; RNA, Ribosomal, 16S, ","","","","","Lacy B.E., Mearin F., Chang L., Chey W.D., Et al., Bowel disorders, Gastroenterology., 150, pp. 1393-1407, (2016); Ivashkin V.T., Maev I.V., Shelygin Y.A., Et al., Diagnosis and treatment of irritable bowel syndrome: clinical recommendations of the Russian gastroenterological association and association of coloproctologists of Russia, Russ J Gastroenterol Hepatol Coloproctol., 31, pp. 74-95, (2021); Enck P., Azpiroz F., Boeckxstaens G., Et al., Functional dyspepsia, Nat Rev Dis Primers., 3, (2017); Scaldaferri F., Pizzoferrato M., Gerardi V., Lopetuso L., Gasbarrini A., The gut barrier: new acquisitions and therapeutic approaches, J Clin Gastroenterol., 46, pp. S12-S17, (2012); Schneeberger E.E., Lynch R.D., The tight junction: a multifunctional complex, Am J Physiol Cell Physiol., 286, pp. C1213-C1228, (2004); Fukui H., Increased intestinal permeability and decreased barrier function: does it really influence the risk of inflammation?, Inflamm Intest Dis., 1, pp. 135-145, (2016); Salim S.Y., Soderholm J.D., Importance of disrupted intestinal barrier in inflammatory bowel diseases, Inflamm Bowel Dis., 17, pp. 362-381, (2011); Jakobsson H.E., Rodriguez-Pineiro A.M., Schutte A., Et al., The composition of the gut microbiota shapes the colon mucus barrier, EMBO Rep., 16, pp. 164-177, (2015); Groschwitz K.R., Hogan S.P., Intestinal barrier function: molecular regulation and disease pathogenesis, J Allergy Clin Immunol., 124, pp. 3-20, (2009); Simanenkov V.I., Maev I.V., Tkacheva O.N., Et al., Increased epithelial permeability syndrome in clinical practice multidisciplinary national consensus, Cardiovasc Ther Prev., 20, (2021); Kovaleva A.L., Poluektova E.A., Shifrin O.S., Intestinal barrier, intestinal permeability, nonspecific inflammation and their role in forming functional diseases of gastrointestinal tract, Russ J Gastroenterol Hepatol Coloproctol., 30, pp. 52-59, (2020); Schoultz I., Keita A.V., The Intestinal barrier and current techniques for the assessment of gut permeability, Cells., 9, (2020); Sinagra E., Pompei G., Tomasello G., Et al., Inflammation in irritable bowel syndrome: myth or new treatment target?, World J Gastroenterol., 22, pp. 2242-2255, (2016); Wibowo A.A., Pardjianto B., Sumitro S.B., Kania N., Handono K., Decreased expression of MUC2 due to a decrease in the expression of lectins and apoptotic defects in colitis patients, Biochem Biophys Rep., 19, (2019); Du L., Chen B., Kim J.J., Chen X., Dai N., Micro-inflammation in functional dyspepsia: a systematic review and meta-analysis, Neurogastroenterol Motil., 30, (2018); Taki M., Oshima T., Li M., Et al., Duodenal low-grade inflammation and expression of tight junction proteins in functional dyspepsia, Neurogastroenterol Motil., 31, (2019); Lee J.Y., Kim N., Choi Y.J., Et al., Expression of tight junction proteins according to functional dyspepsia subtype and sex, J Neurogastroenterol Motil., 26, pp. 248-258, (2020); Ivashkin V.T., Mayev I.V., Sheptulin A.A., Et al., Diagnosis and treatment of the functional dyspepsia: clinical guidelines of the Russian Gastroenterological Association, Russ J Gastroenterol Hepatol Coloproctol\., 27, pp. 50-61, (2017); Humes D.J., Changing epidemiology: does it increase our understanding?, Dig Dis., 30, pp. 6-11, (2012); Ivashkin V.T., Sheptulin A.A., Poluektova E.A., Et al., Opportunities of 7x7 Scale (7 symptoms per 7 Days) to evaluate dynamics in symptoms of functional dyspepsia and irritable bowel syndrome, Russ J Gastroenterol Hepatol Coloproctol., 26, pp. 24-33, (2016); Revicki D.A., Wood M., Wiklund I., Crawley J., Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease, Qual Life Res., 7, pp. 75-83, (1998); Jung H.K., Talley N.J., Role of the duodenum in the pathogenesis of functional dyspepsia: a paradigm shift, J Neurogastroenterol Motil., 24, pp. 345-354, (2018); Lacy B.E., Cangemi D.J., Updates in functional dyspepsia and bloating, Curr Opin Gastroenterol., 38, pp. 613-619, (2022); Adriaanse M.P., Tack G.J., Passos V.L., Et al., Serum I-FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies, Aliment Pharmacol Ther., 37, pp. 482-490, (2013); Adriaanse M.P.M., Mubarak A., Riedl R.G., Et al., Progress towards non-invasive diagnosis and follow-up of celiac disease in children; a prospective multicentre study to the usefulness of plasma I-FABP, Sci Rep., 7, (2017); Shi H., Wan J., Liu W., Su B., An analysis for the clinical difference between post infectious irritable bowel syndrome and non post infectious irritable bowel syndrome, Zhonghua Nei Ke Za Zhi., 54, pp. 326-329, (2015); Li B., Reynolds J.M., Stout R.D., Bernlohr D.A., Suttles J., Regulation of Th17 differentiation by epidermal fatty acid-binding protein, J Immunol., 182, pp. 7625-7633, (2009); Grondin J.A., Kwon Y.H., Far P.M., Haq S., Khan W.I., Mucins in intestinal mucosal defense and inflammation: learning from clinical and experimental studies, Front Immunol., 11, (2020); Ivashkin V.T., Trukhmanov A.S., Gonik M.I., Using rebamipide in treating gastroesophageal reflux disease, Therapeutic Archive., 92, pp. 98-104, (2020); Arakawa T., Higuchi K., Fujiwara Y., Et al., 15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications, Dig Dis Sci., 50, pp. S3-S11, (2005); Kleine A., Kluge S., Peskar B.M., Stimulation of prostaglandin biosynthesis mediates gastroprotective effect of rebamipide in rats, Dig Dis Sci., 38, pp. 1441-1449, (1993); Gweon T.G., Park J.H., Kim B.W., Et al., Additive Effects of rebamipide plus proton pump inhibitors on the expression of tight junction proteins in a rat model of gastro-esophageal reflux disease, Gut Liver., 12, pp. 46-50, (2018)","R. Maslennikov; Sechenov University, Moscow, 119435, Russian Federation; email: maslennikov_r_v@staff.sechenov.ru","","Springer","","","","","","01632116","","DDSCD","37752368","English","Dig. Dis. Sci.","Article","Final","","Scopus","2-s2.0-85172406139"

"Wang Y.; Qiao M.; Yao X.; Feng Z.; Hu R.; Chen J.; Liu L.; Liu J.; Sun Y.; Guo Y.","Wang, Yanrong (57966568500); Qiao, Mingbiao (58605553500); Yao, Xue (57225089706); Feng, Zhonghui (58166331200); Hu, Ruiqi (57966568600); Chen, Jianguo (57377700200); Liu, Lei (55580861800); Liu, Jinbo (56156489500); Sun, Yueshan (57212583832); Guo, Yuanbiao (57203710897)","57966568500; 58605553500; 57225089706; 58166331200; 57966568600; 57377700200; 55580861800; 56156489500; 57212583832; 57203710897","Lidocaine ameliorates intestinal barrier dysfunction in irritable bowel syndrome by modulating corticotropin-releasing hormone receptor 2","2023","Neurogastroenterology and Motility","35","11","e14677","","","","0","10.1111/nmo.14677","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85171691965&doi=10.1111%2fnmo.14677&partnerID=40&md5=a88b7214a966f18a2531bb202c44fa73","Department of Laboratory Medicine, Sichuan Tianfu New Area People's Hospital, Chengdu, China; Department of Pathology, De Yang People's Hospital, Deyang, China; Medical Research Center, The Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, The Second Chengdu Hospital Affiliated to Chongqing Medical University, Chengdu, China; Center of Gastrointestinal and Minimally Invasive Surgery, Department of General Surgery, The Third People's Hospital of Chengdu, The Second Chengdu Hospital Affiliated to Chongqing Medical University, Chengdu, China; Department of Clinical Laboratory, The Affiliated Hospital of Southwest Medical University, Luzhou, China","Wang Y., Department of Laboratory Medicine, Sichuan Tianfu New Area People's Hospital, Chengdu, China; Qiao M., Department of Pathology, De Yang People's Hospital, Deyang, China; Yao X., Medical Research Center, The Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, The Second Chengdu Hospital Affiliated to Chongqing Medical University, Chengdu, China; Feng Z., Center of Gastrointestinal and Minimally Invasive Surgery, Department of General Surgery, The Third People's Hospital of Chengdu, The Second Chengdu Hospital Affiliated to Chongqing Medical University, Chengdu, China; Hu R., Department of Clinical Laboratory, The Affiliated Hospital of Southwest Medical University, Luzhou, China; Chen J., Department of Clinical Laboratory, The Affiliated Hospital of Southwest Medical University, Luzhou, China; Liu L., Medical Research Center, The Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, The Second Chengdu Hospital Affiliated to Chongqing Medical University, Chengdu, China; Liu J., Department of Clinical Laboratory, The Affiliated Hospital of Southwest Medical University, Luzhou, China; Sun Y., Medical Research Center, The Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, The Second Chengdu Hospital Affiliated to Chongqing Medical University, Chengdu, China; Guo Y., Medical Research Center, The Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, The Second Chengdu Hospital Affiliated to Chongqing Medical University, Chengdu, China","Background: Intestinal barrier dysfunction is a prevalent pathogenic factor underlying various disorders. Currently there is no effective resolution. Previous studies have reported the potential anti-inflammatory properties of lidocaine and its ability to alleviate visceral hypersensitivity in individuals with irritable bowel syndrome (IBS). Therefore, our study will further verify the effect of lidocaine on intestinal barrier dysfunction in IBS and investigate the underlying mechanisms. Methods: In this study, we investigated the role of lidocaine by assessing visceral hypersensitivity, body weight, inflammatory factors, fluorescein isothiocyanate-dextran 4000 (FD4) flux, tight junctions (TJs) and spleen and thymus index in rats subjected to water avoidance stress (WAS) to mimic intestinal barrier dysfunction in IBS with and without lidocaine. In vitro, we investigated the role of corticotropin-releasing hormone receptor 2 (CRHR2) in lidocaine-treated Caco2 cells using small interfering RNA (siRNA) targeting CRHR2. Key Results: In WAS rats, lidocaine significantly restored weight loss, damaged TJs, spleen index and thymus index and inhibited abdominal hypersensitivity as well as blood levels of markers indicating intestinal permeability, such as diamine oxidase (DAO), D-lactic acid (D-Lac) and lipopolysaccharide (LPS). Consequently, the leakage of FD4 flux from intestine was significantly attenuated in lidocaine group, and levels of intestinal inflammatory factors (IL-1β, IFN-γ, TNF-α) were reduced. Interestingly, lidocaine significantly suppressed corticotropin-releasing hormone (CRH) levels in lamina propria cells, while the CRH receptor CRHR2 was upregulated in intestinal epithelial cells. In vitro, lidocaine enhanced the expression of CRHR2 on Caco-2 intestinal epithelial cells and restored disrupted TJs and the epithelial barrier caused by LPS. Conversely, these effects were diminished by a CRHR2 antagonist and siRNA-CRHR2, suggesting that the protective effect of lidocaine depends on CRHR2. Conclusions and Inferences: Lidocaine ameliorates intestinal barrier dysfunction in IBS by potentially modulating the expression of CRHR2 on intestinal epithelial cells. © 2023 John Wiley & Sons Ltd.","corticotropin-releasing hormone receptor 2; intestinal barrier; lidocaine; stress; tight junctions","Animals; Caco-2 Cells; Corticotropin-Releasing Hormone; Humans; Irritable Bowel Syndrome; Lidocaine; Lipopolysaccharides; Rats; Receptors, Corticotropin-Releasing Hormone; RNA, Small Interfering; amine oxidase (copper containing); corticotropin releasing factor receptor 2; fluorescein isothiocyanate dextran; gamma interferon; interleukin 1beta; lactic acid; lidocaine; lipopolysaccharide; small interfering RNA; tumor necrosis factor; corticotropin releasing factor; corticotropin releasing factor receptor; lidocaine; animal cell; animal experiment; animal model; animal tissue; antigen retrieval; Article; body weight; body weight loss; brain tissue; Caco-2 cell line; colon tissue; controlled study; drug effect; electromyogram; experimental test; human; human cell; immunofluorescence; immunohistochemistry; in vitro study; inflammation; intestinal barrier dysfunction; intestine epithelium cell; intestine function disorder; irritable colon; lamina propria; male; nonhuman; protein expression; rat; spleen index; thymus index; tight junction; upregulation; visceral hyperalgesia; water avoidance stress; animal; metabolism","","amine oxidase (copper containing), 9001-53-0, 9014-75-9; fluorescein isothiocyanate dextran, 60842-46-8; gamma interferon, 82115-62-6; lactic acid, 113-21-3, 50-21-5; lidocaine, 137-58-6, 24847-67-4, 56934-02-2, 73-78-9; corticotropin releasing factor, 9015-71-8, 178359-01-8, 79804-71-0, 86297-72-5, 86784-80-7; Corticotropin-Releasing Hormone, ; Lidocaine, ; Lipopolysaccharides, ; Receptors, Corticotropin-Releasing Hormone, ; RNA, Small Interfering, ","","","Sichuan Province Science and Technology Support Program, (2023JDRC0088); Sichuan Province Science and Technology Support Program; Science and Technology Department of Sichuan Province, SPDST, (2022YFS0340); Science and Technology Department of Sichuan Province, SPDST; Chengdu Science and Technology Bureau, (2021-YF05-00585-SN); Chengdu Science and Technology Bureau","Funding text 1: This work was supported by the Foundation of Science and Technology Department of Sichuan Province (2022YFS0340), the Sichuan Science and Technology program (2023JDRC0088) and Chengdu Science and Technology Bureau (2021-YF05-00585-SN).; Funding text 2: This work was supported by the Foundation of Science and Technology Department of Sichuan Province (2022YFS0340), the Sichuan Science and Technology program (2023JDRC0088) and Chengdu Science and Technology Bureau (2021‐YF05‐00585‐SN). ","Mearin F., Lacy B.E., Chang L., Et al., Bowel Disorders, Gastroenterology, S0016-5085, 16, pp. 00222-00225, (2016); Sperber A.D., Epidemiology and burden of irritable bowel syndrome: an international perspective, Gastroenterol Clin North Am, 50, pp. 489-503, (2021); Collins S.M., Piche T., Rampal P., The putative role of inflammation in the irritable bowel syndrome, Gut, 49, pp. 743-745, (2001); Price D.D., Zhou Q., Moshiree B., Robinson M.E., Verne G.N., Peripheral and central contributions to hyperalgesia in irritable bowel syndrome, J Pain, 7, pp. 529-535, (2006); Ng Q.X., Soh A.Y.S., Loke W., Lim D.Y., Yeo W.S., The role of inflammation in irritable bowel syndrome (IBS), J Inflamm Res, 11, pp. 345-349, (2018); Miglietta S., Borghini R., Relucenti M., Et al., New insights into intestinal permeability in irritable bowel syndrome-like disorders: histological and ultrastructural findings of duodenal biopsies, Cell, 10, (2021); Su T., Liu R., Lee A., Et al., Altered intestinal microbiota with increased abundance of Prevotella is associated with high risk of diarrhea-predominant irritable bowel syndrome, Gastroenterol Res Pract, 2018, pp. 6961783-6961789, (2018); Aguilera-Lizarraga J., Hussein H., Boeckxstaens G.E., Immune activation in irritable bowel syndrome: what is the evidence?, Nat Rev Immunol, 22, pp. 674-686, (2022); Vancamelbeke M., Vermeire S., The intestinal barrier: a fundamental role in health and disease, Expert Rev Gastroenterol Hepatol, 11, pp. 821-834, (2017); Ge P., Luo Y., Okoye C.S., Et al., Intestinal barrier damage, systemic inflammatory response syndrome, and acute lung injury: a troublesome trio for acute pancreatitis, Biomed Pharmacother, 132, (2020); Camilleri M., Management options for irritable bowel syndrome, Mayo Clin Proc, 93, pp. 1858-1872, (2018); Jeong D.Y., Kim S., Son M.J., Et al., Induction and maintenance treatment of inflammatory bowel disease: a comprehensive review, Autoimmun Rev, 18, pp. 439-454, (2019); Camilleri M., Madsen K., Spiller R., Greenwood-Van Meerveld B., Verne G.N., Intestinal barrier function in health and gastrointestinal disease, Neurogastroenterol Motil, 24, pp. 503-512, (2012); Odenwald M.A., Turner J.R., The intestinal epithelial barrier: a therapeutic target?, Nat Rev Gastroenterol Hepatol, 14, pp. 9-21, (2017); Buckley A., Turner J.R., Cell biology of tight junction barrier regulation and mucosal disease, Cold Spring Harb Perspect Biol, 10, (2018); Gasbarrini G., Montalto M., Structure and function of tight junctions. Role in intestinal barrier, Ital J Gastroenterol Hepatol, 31, pp. 481-488, (1999); Otani T., Furuse M., Tight junction structure and function revisited, Trends Cell Biol, 30, pp. 805-817, (2020); Kimura H., Sawada N., Tobioka H., Et al., Bacterial lipopolysaccharide reduced intestinal barrier function and altered localization of 7H6 antigen in IEC-6 rat intestinal crypt cells, J Cell Physiol, 171, pp. 284-290, (1997); Liu Y., Meng F., Wang S., Xia S., Wang R., Vitamin D3 mitigates lipopolysaccharide-induced oxidative stress, tight junction damage and intestinal inflammatory response in yellow catfish, Pelteobagrus fulvidraco, Comp Biochem Physiol C Toxicol Pharmacol, 243, (2021); Rodino-Janeiro B.K., Alonso-Cotoner C., Pigrau M., Lobo B., Vicario M., Santos J., Role of corticotropin-releasing factor in gastrointestinal permeability, J Neurogastroenterol Motil, 21, pp. 33-50, (2015); Stengel A., Tache Y., Corticotropin-releasing factor signaling and visceral response to stress, Exp Biol Med (Maywood), 235, pp. 1168-1178, (2010); Valentino R.J., Foote S.L., Page M.E., The locus coeruleus as a site for integrating corticotropin-releasing factor and noradrenergic mediation of stress responses, Ann N Y Acad Sci, 697, pp. 173-188, (1993); Kano M., Muratsubaki T., Van Oudenhove L., Et al., Altered brain and gut responses to corticotropin-releasing hormone (CRH) in patients with irritable bowel syndrome, Sci Rep, 7, (2017); Hoffman J.M., Baritaki S., Ruiz J.J., Sideri A., Pothoulakis C., Corticotropin-releasing hormone receptor 2 signaling promotes mucosal repair responses after colitis, Am J Pathol, 186, pp. 134-144, (2016); Bruce J.K., Burns G.L., Sinn Soh W., Et al., Defects in NLRP6, autophagy and goblet cell homeostasis are associated with reduced duodenal CRH receptor 2 expression in patients with functional dyspepsia, Brain Behav Immun, 101, pp. 335-345, (2022); Li B., Lee C., Filler T., Et al., Inhibition of corticotropin-releasing hormone receptor 1 and activation of receptor 2 protect against colonic injury and promote epithelium repair, Sci Rep, 7, (2017); Berk T., Silberstein S.D., The use and method of action of intravenous lidocaine and its metabolite in headache disorders, Headache, 58, pp. 783-789, (2018); Verne G.N., Sen A., Price D.D., Intrarectal lidocaine is an effective treatment for abdominal pain associated with diarrhea-predominant irritable bowel syndrome, J Pain, 6, pp. 493-496, (2005); Verne G.N., Robinson M.E., Vase L., Price D.D., Reversal of visceral and cutaneous hyperalgesia by local rectal anesthesia in irritable bowel syndrome (IBS) patients, Pain, 105, pp. 223-230, (2003); Letzen J.E., Craggs J.G., Perlstein W.M., Price D.D., Robinson M.E., Functional connectivity of the default mode network and its association with pain networks in irritable bowel patients assessed via lidocaine treatment, J Pain, 14, pp. 1077-1087, (2013); Teng X., Liu Y., Wang L., Wang G., Lidocaine exerts anticancer activity in bladder cancer by targeting isoprenylcysteine carboxylmethyltransferase (ICMT), Transl Androl Urol, 10, pp. 4219-4230, (2021); Okada S., Hagan J.B., Kato M., Et al., Lidocaine and its analogues inhibit IL-5-mediated survival and activation of human eosinophils, J Immunol, 160, pp. 4010-4017, (1998); Bednarska O., Biskou O., Israelsen H., Winberg M.E., Walter S., Keita A.V., A postbiotic fermented oat gruel may have a beneficial effect on the colonic mucosal barrier in patients with irritable bowel syndrome, Front Nutr, 9, (2022); Cojocariu R., Ciobica A., Balmus I.M., Et al., Antioxidant capacity and behavioral relevance of a polyphenolic extract of Chrysanthellum americanum in a rat model of irritable bowel syndrome, Oxid Med Cell Longev, 2019, (2019); Zhang C., Zhu H., Jie H., Ding H., Sun H., Arbutin ameliorated ulcerative colitis of mice induced by dextran sodium sulfate (DSS), Bioengineered, 12, pp. 11707-11715, (2021); Fukudome I., Kobayashi M., Dabanaka K., Et al., Diamine oxidase as a marker of intestinal mucosal injury and the effect of soluble dietary fiber on gastrointestinal tract toxicity after intravenous 5-fluorouracil treatment in rats, Med Mol Morphol, 47, pp. 100-107, (2014); Sun S., Liu W., Li Y., CADM1 enhances intestinal barrier function in a rat model of mild inflammatory bowel disease by inhibiting the STAT3 signaling pathway, J Bioenerg Biomembr, 52, pp. 343-354, (2020); Bagalagel A., Diri R., Noor A., Et al., Curative effects of fucoidan on acetic acid induced ulcerative colitis in rats via modulating aryl hydrocarbon receptor and phosphodiesterase-4, BMC Complement Med Ther, 22, (2022); Ford A.C., Sperber A.D., Corsetti M., Camilleri M., Irritable bowel syndrome, Lancet, 396, pp. 1675-1688, (2020); Li X., Lv H., Shi F., Song J., Zhang Z., The potential therapeutic effects of hydroxypropyl cellulose on acute murine colitis induced by DSS, Carbohydr Polym, 289, (2022); Fritsch Fredin M., Elgbratt K., Svensson D., Jansson L., Melgar S., Hultgren H.E., Dextran sulfate sodium-induced colitis generates a transient thymic involution–Impact on thymocyte subsets, Scand J Immunol, 65, pp. 421-429, (2007); Zhou X., Li J., Guo J., Et al., Gut-dependent microbial translocation induces inflammation and cardiovascular events after ST-elevation myocardial infarction, Microbiome, 6, (2018); Bischoff S.C., Barbara G., Buurman W., Et al., Intestinal permeability–A new target for disease prevention and therapy, BMC Gastroenterol, 14, (2014); la Fleur S.E., Wick E.C., Idumalla P.S., Grady E.F., Bhargava A., Role of peripheral corticotropin-releasing factor and urocortin II in intestinal inflammation and motility in terminal ileum, Proc Natl Acad Sci U S A, 102, pp. 7647-7652, (2005); Im E., Rhee S.H., Park Y.S., Fiocchi C., Tache Y., Pothoulakis C., Corticotropin-releasing hormone family of peptides regulates intestinal angiogenesis, Gastroenterology, 138, pp. 2457-2467, (2010); Wei C.X., Wu J.H., Huang Y.H., Wang X.Z., Li J.Y., Lactobacillus plantarum improves LPS-induced Caco2 cell line intestinal barrier damage via cyclic AMP-PKA signaling, PLoS One, 17, (2022); Jiang Y., Song J., Xu Y., Et al., Piezo1 regulates intestinal epithelial function by affecting the tight junction protein claudin-1 via the ROCK pathway, Life Sci, 275, (2021); Karnina R., Arif S.K., Hatta M., Bukhari A., Molecular mechanisms of lidocaine, Ann Med Surg (Lond), 69, (2021); Weibel S., Jokinen J., Pace N.L., Et al., Efficacy and safety of intravenous lidocaine for postoperative analgesia and recovery after surgery: a systematic review with trial sequential analysis, Br J Anaesth, 116, pp. 770-783, (2016); Gammaitoni A.R., Alvarez N.A., Galer B.S., Pharmacokinetics and safety of continuously applied lidocaine patches 5%, Am J Health Syst Pharm, 59, pp. 2215-2220, (2002); Wang H.L., Zhang W.H., Lei W.F., Zhou C.Q., Ye T., The inhibitory effect of lidocaine on the release of high mobility group box 1 in lipopolysaccharide-stimulated macrophages, Anesth Analg, 112, pp. 839-844, (2011); Chen L.J., Ding Y.B., Ma P.L., Et al., The protective effect of lidocaine on lipopolysaccharide-induced acute lung injury in rats through NF-kappaB and p38 MAPK signaling pathway and excessive inflammatory responses, Eur Rev Med Pharmacol Sci, 22, pp. 2099-2108, (2018); Froicu M., Zhu Y., Cantorna M.T., Vitamin D receptor is required to control gastrointestinal immunity in IL-10 knockout mice, Immunology, 117, pp. 310-318, (2006); Nakanishi M., Tazawa H., Tsuchiya N., Sugimura T., Tanaka T., Nakagama H., Mouse strain differences in inflammatory responses of colonic mucosa induced by dextran sulfate sodium cause differential susceptibility to PhIP-induced large bowel carcinogenesis, Cancer Sci, 98, pp. 1157-1163, (2007); Oh M.J., Choi H.D., Ha S.K., Choi I., Park H.Y., Immunomodulatory effects of polysaccharide fraction isolated from Fagopyrum esculentum on innate immune system, Biochem Biophys Res Commun, 496, pp. 1210-1216, (2018); Hao W., Hao C., Wu C., Xu Y., Jin C., Aluminum induced intestinal dysfunction via mechanical, immune, chemical and biological barriers, Chemosphere, 288, (2022); Michielan A., D'Inca R., Intestinal permeability in inflammatory bowel disease: pathogenesis, clinical evaluation, and therapy of leaky gut, Mediators Inflamm, 2015, (2015); Zhou Q., Verne G.N., Intestinal hyperpermeability: a gateway to multi-organ failure?, J Clin Invest, 128, pp. 4764-4766, (2018); Holmberg F.E.O., Pedersen J., Jorgensen P., Soendergaard C., Jensen K.B., Nielsen O.H., Intestinal barrier integrity and inflammatory bowel disease: stem cell-based approaches to regenerate the barrier, J Tissue Eng Regen Med, 12, pp. 923-935, (2018); Yu K., Ma Y., Zhang Z., Et al., AhR activation protects intestinal epithelial barrier function through regulation of Par-6, J Mol Histol, 49, pp. 449-458, (2018); Guo S., Al-Sadi R., Said H.M., Ma T.Y., Lipopolysaccharide causes an increase in intestinal tight junction permeability in vitro and in vivo by inducing enterocyte membrane expression and localization of TLR-4 and CD14, Am J Pathol, 182, pp. 375-387, (2013); He S., Guo Y., Zhao J., Xu X., Wang N., Liu Q., Ferulic acid ameliorates lipopolysaccharide-induced barrier dysfunction via MicroRNA-200c-3p-mediated activation of PI3K/AKT pathway in Caco-2 cells, Front Pharmacol, 11, (2020); Hill L.T., Kidson S.H., Michell W.L., Corticotropin-releasing factor is present in intestinal tissue of patients with gastrointestinal dysfunction following shock and abdominal surgery, Nutrition, 29, pp. 650-654, (2013); Yuan P.Q., Wu S.V., Wang L., Tache Y., Corticotropin releasing factor in the rat colon: expression, localization and upregulation by endotoxin, Peptides, 31, pp. 322-331, (2010); Takada M., Nishida K., Kataoka-Kato A., Et al., Probiotic Lactobacillus casei strain Shirota relieves stress-associated symptoms by modulating the gut-brain interaction in human and animal models, Neurogastroenterol Motil, 28, pp. 1027-1036, (2016); Gareau M.G., Silva M.A., Perdue M.H., Pathophysiological mechanisms of stress-induced intestinal damage, Curr Mol Med, 8, pp. 274-281, (2008); Tucci S., Cheeta S., Seth P., File S.E., Corticotropin releasing factor antagonist, alpha-helical CRF(9-41), reverses nicotine-induced conditioned, but not unconditioned, anxiety, Psychopharmacology (Berl), 167, pp. 251-256, (2003)","Y. Sun; Medical Research Center, The Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, The Second Chengdu Hospital Affiliated to Chongqing Medical University, Chengdu, Sichuan, 610031, China; email: sysnjsdx@163.com; Y. Guo; Medical Research Center, The Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, The Second Chengdu Hospital Affiliated to Chongqing Medical University, Chengdu, China; email: guo.ybiao@yahoo.com","","John Wiley and Sons Inc","","","","","","13501925","","NMOTE","37736684","English","Neurogastroenterol. Motil.","Article","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-85171691965"

"Pardo-Camacho C.; Mall J.-P.G.; Martínez C.; Pigrau M.; Expósito E.; Albert-Bayo M.; Melón-Ardanaz E.; Nieto A.; Rodiño-Janeiro B.; Fortea M.; Guagnozzi D.; Rodriguez-Urrutia A.; Torres I.; Santos-Briones I.; Azpiroz F.; Lobo B.; Alonso-Cotoner C.; Santos J.; González-Castro A.M.; Vicario M.","Pardo-Camacho, Cristina (57192877965); Mall, John-Peter Ganda (57195053310); Martínez, Cristina (17534584700); Pigrau, Marc (37009212800); Expósito, Elba (57220056948); Albert-Bayo, Mercé (57222520754); Melón-Ardanaz, Elisa (57766286400); Nieto, Adoración (57191341801); Rodiño-Janeiro, Bruno (35729142300); Fortea, Marina (56830396500); Guagnozzi, Danila (6506135584); Rodriguez-Urrutia, Amanda (35337676400); Torres, Inés de (57205310649); Santos-Briones, Ignacio (57765848400); Azpiroz, Fernando (57207592894); Lobo, Beatriz (7003936898); Alonso-Cotoner, Carmen (57220113655); Santos, Javier (7402389020); González-Castro, Ana M. (54796498900); Vicario, Maria (6603267769)","57192877965; 57195053310; 17534584700; 37009212800; 57220056948; 57222520754; 57766286400; 57191341801; 35729142300; 56830396500; 6506135584; 35337676400; 57205310649; 57765848400; 57207592894; 7003936898; 57220113655; 7402389020; 54796498900; 6603267769","Mucosal Plasma Cell Activation and Proximity to Nerve Fibres Are Associated with Glycocalyx Reduction in Diarrhoea-Predominant Irritable Bowel Syndrome: Jejunal Barrier Alterations Underlying Clinical Manifestations","2022","Cells","11","13","2046","","","","5","10.3390/cells11132046","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85132923608&doi=10.3390%2fcells11132046&partnerID=40&md5=dcb3e77970c6336d3a44ec7f99badfcf","Laboratory of Translational Mucosal Immunology, Digestive System Research Unit, Vall d’Hebron Institut de Recerca, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain; Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d’Hebron Institut de Recerca, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain; Facultat de Medicina, Universitat Autònoma de Barcelona, Bellaterra, 08193, Spain; Department of Biomedical and Clinical Sciences, Linköping University, Linköping, 58185, Sweden; Vascular and Renal Translational Research Group, Lleida Institute for Biomedical Research Dr. Pifarré. Foundation (IRBLleida), Av. Alcalde Rovira Roure 80, Lleida, 25198, Spain; Department of Gastroenterology, Vall d’Hebron Hospital Universitari, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain; Department of Mental Health, Vall d’Hebron Hospital Universitari, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, 28029, Spain; Department of Pathology, Hospital Universitari Vall d’Hebrón, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain; Facultat Ciències de la Salut, Universitat Ramon LLull-Blanquerna, C/Padilla 326, Barcelona, 08025, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Madrid, 28029, Spain; Department of Gastrointestinal Health, Nestlé Institute of Health Sciences, Société des Produits Nestlé S.A., Nestlé Research, Vers-chez-les-Blanc, Lausanne, 1000, Switzerland","Pardo-Camacho C., Laboratory of Translational Mucosal Immunology, Digestive System Research Unit, Vall d’Hebron Institut de Recerca, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain, Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d’Hebron Institut de Recerca, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain, Facultat de Medicina, Universitat Autònoma de Barcelona, Bellaterra, 08193, Spain; Mall J.-P.G., Laboratory of Translational Mucosal Immunology, Digestive System Research Unit, Vall d’Hebron Institut de Recerca, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, 58185, Sweden; Martínez C., Vascular and Renal Translational Research Group, Lleida Institute for Biomedical Research Dr. Pifarré. Foundation (IRBLleida), Av. Alcalde Rovira Roure 80, Lleida, 25198, Spain; Pigrau M., Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d’Hebron Institut de Recerca, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain, Facultat de Medicina, Universitat Autònoma de Barcelona, Bellaterra, 08193, Spain; Expósito E., Laboratory of Translational Mucosal Immunology, Digestive System Research Unit, Vall d’Hebron Institut de Recerca, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain, Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d’Hebron Institut de Recerca, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain; Albert-Bayo M., Laboratory of Translational Mucosal Immunology, Digestive System Research Unit, Vall d’Hebron Institut de Recerca, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain; Melón-Ardanaz E., Laboratory of Translational Mucosal Immunology, Digestive System Research Unit, Vall d’Hebron Institut de Recerca, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain; Nieto A., Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d’Hebron Institut de Recerca, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain, Department of Gastroenterology, Vall d’Hebron Hospital Universitari, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain; Rodiño-Janeiro B., Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d’Hebron Institut de Recerca, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain; Fortea M., Laboratory of Translational Mucosal Immunology, Digestive System Research Unit, Vall d’Hebron Institut de Recerca, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain; Guagnozzi D., Laboratory of Translational Mucosal Immunology, Digestive System Research Unit, Vall d’Hebron Institut de Recerca, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain, Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d’Hebron Institut de Recerca, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain, Department of Gastroenterology, Vall d’Hebron Hospital Universitari, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain; Rodriguez-Urrutia A., Facultat de Medicina, Universitat Autònoma de Barcelona, Bellaterra, 08193, Spain, Department of Mental Health, Vall d’Hebron Hospital Universitari, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, 28029, Spain; Torres I., Facultat de Medicina, Universitat Autònoma de Barcelona, Bellaterra, 08193, Spain, Department of Pathology, Hospital Universitari Vall d’Hebrón, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain; Santos-Briones I., Facultat Ciències de la Salut, Universitat Ramon LLull-Blanquerna, C/Padilla 326, Barcelona, 08025, Spain; Azpiroz F., Department of Gastroenterology, Vall d’Hebron Hospital Universitari, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Madrid, 28029, Spain; Lobo B., Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d’Hebron Institut de Recerca, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain, Facultat de Medicina, Universitat Autònoma de Barcelona, Bellaterra, 08193, Spain, Department of Gastroenterology, Vall d’Hebron Hospital Universitari, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain; Alonso-Cotoner C., Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d’Hebron Institut de Recerca, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain, Facultat de Medicina, Universitat Autònoma de Barcelona, Bellaterra, 08193, Spain, Department of Gastroenterology, Vall d’Hebron Hospital Universitari, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Madrid, 28029, Spain; Santos J., Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d’Hebron Institut de Recerca, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain, Facultat de Medicina, Universitat Autònoma de Barcelona, Bellaterra, 08193, Spain, Department of Gastroenterology, Vall d’Hebron Hospital Universitari, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Madrid, 28029, Spain; González-Castro A.M., Laboratory of Translational Mucosal Immunology, Digestive System Research Unit, Vall d’Hebron Institut de Recerca, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain, Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d’Hebron Institut de Recerca, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain; Vicario M., Laboratory of Translational Mucosal Immunology, Digestive System Research Unit, Vall d’Hebron Institut de Recerca, Passeig Vall d’Hebron 119-129, Barcelona, 08035, Spain, Department of Gastrointestinal Health, Nestlé Institute of Health Sciences, Société des Produits Nestlé S.A., Nestlé Research, Vers-chez-les-Blanc, Lausanne, 1000, Switzerland","Irritable bowel syndrome (IBS) is a disorder of brain-gut interaction characterised by abdominal pain and changes in bowel habits. In the diarrhoea subtype (IBS-D), altered epithelial barrier and mucosal immune activation are associated with clinical manifestations. We aimed to further evaluate plasma cells and epithelial integrity to gain understanding of IBS-D pathophysiology. One mucosal jejunal biopsy and one stool sample were obtained from healthy controls and IBS-D patients. Gastrointestinal symptoms, stress, and depression scores were recorded. In the jejunal mucosa, RNAseq and gene set enrichment analyses were performed. A morphometric analysis by electron microscopy quantified plasma cell activation and proximity to enteric nerves and glycocalyx thickness. Immunoglobulins concentration was assessed in the stool. IBS-D patients showed differential expression of humoral pathways compared to controls. Activation and proximity of plasma cells to nerves and IgG concentration were also higher in IBS-D. Glycocalyx thickness was lower in IBS-D compared to controls, and this reduction correlated with plasma cell activation, proximity to nerves, and clinical symptoms. These results support humoral activity and loss of epithelial integrity as important contributors to gut dysfunction and clinical manifestations in IBS-D. Additional studies are needed to identify the triggers of these alterations to better define IBS-D pathophysiology. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.","IBS-D; intestinal barrier dysfunction; intestinal glycocalyx; intestinal plasma cells; mucosal nerve fibres; mucosal ultrastructure","Diarrhea; Glycocalyx; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Nerve Fibers; Plasma Cells; immunoglobulin A; immunoglobulin E; immunoglobulin G; immunoglobulin G1; immunoglobulin G2; immunoglobulin G3; immunoglobulin G4; immunoglobulin M; mucin; syndecan 1; ubiquitin thiolesterase; abdominal distension; abdominal pain; adult; Article; Beck Depression Inventory; bristol stool chart score; cell activation; cellular parameters; cohort analysis; controlled study; depression; diarrhea; dyspepsia; enzyme linked immunosorbent assay; feces analysis; female; gastrointestinal symptom; gene; gene expression; gene expression profiling; gene set enrichment analysis; glycocalyx; glycocalyx thickness; histology; human; human tissue; immunofluorescence assay; immunohistochemistry; intestine epithelium cell; intestine innervation; irritable colon; jejunum biopsy; major clinical study; male; mental stress; middle aged; morphometry; MUC17 gene; Perceived Stress Scale; prospective study; quality of life; real time reverse transcription polymerase chain reaction; RNA sequencing; satisfaction; signal transduction; Social Readjustment Rating Scale; transmission electron microscopy; complication; diarrhea; glycocalyx; intestine mucosa; metabolism; nerve fiber; pathology; plasma cell","","immunoglobulin E, 37341-29-0; immunoglobulin G, 97794-27-9, 308067-58-5; immunoglobulin M, 9007-85-6; syndecan 1, 128559-86-4; ubiquitin thiolesterase, 86480-67-3","ABI PRISM, Applied Biosystems; JEM-1400, Jeol, Japan","Applied Biosystems; Jeol, Japan","Bioinformatics Unit of Bellvitge Biomedical Research Institute; European Union’s Horizon research and innovation programme 2020, (848228); Fondo de Investigación Sanitaria; MT Casaus; Generalitat de Catalunya, (2014 SGR 1285, PRED-VHIR-2016-34); Generalitat de Catalunya; Agència de Gestió d'Ajuts Universitaris i de Recerca, AGAUR; Ministerio de Educación, Cultura y Deporte, MECD; Ministerio de Economía y Competitividad, MINECO, (CP18/00116, PI15/00301, PI17/01443, PI19/01643, PRED-VHIR-2014-018); Ministerio de Economía y Competitividad, MINECO; Linköpings Universitet, LiU; Vetenskapsrådet, VR, (2019-00653); Vetenskapsrådet, VR; Instituto de Salud Carlos III, ISCIII; Dirección General de Investigación Científica y Técnica, DGICT, (SAF 2016-76648-R); Dirección General de Investigación Científica y Técnica, DGICT; European Regional Development Fund, ERDF; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, CIBEREHD","Funding text 1: This study was funded in part by Fondo Europeo de Desarrollo Regional (FEDER), Fondo de Investigación Sanitaria and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Subdirección General de Investigación Sani-taria, Ministerio de Economía y Competitividad: CP18/00116 (C.M.), PI19/01643 (B.L.); PI17/01443 (D.G.); PI15/00301 (C.A.-C.), PI17/0190 (J.S.), PI19/01643 & CPII16/00031, (M.V.); CIBEREHD CB06/04/0021 (F.A., C.A.-C., J.S., M.V.); Ministerio de Educación, Dirección General de Investigación: SAF 2016-76648-R (F.A.); Agència de Gestió d’Ajuts Universitaris i de Recerca, de la Generalitat de Catalunya: 2014 SGR 1285 (F.A.); Vall d’Hebron Institut de Recerca, Programa de becas pre-doctorales Amics de Vall d’Hebron: PRED-VHIR-2016-34 (C.P.-C.), PRED-VHIR-2014-018 (M.F.), the Swedish Research Council dnr 2019-00653 (J.-P.G.M.), and the European Union’s Horizon research and innovation programme 2020, grant no. 848228 (E.E., A.R.-U., B.L., C.A.-C., J.S.).Acknowledgments: The authors thank MT Casaus and P Rodríguez for assistance in the performance of jejunal biopsies; J Heredia and G Santaliestra for secretarial assistance; A. Sanchez-Chardi and F. Cardoso from Servei de Microscòpia of Universitat Autònoma de Barcelona for excellent technical support; and JL Mosquera from Bioinformatics Unit of Bellvitge Biomedical Research Institute (Bellvitge, Spain) for RNAseq bioinformatic analysis. Authors would also like to thank Associate Professor Åsa V. Keita at Linköping University (Sweden) for her support during the project.; Funding text 2: Funding: This study was funded in part by Fondo Europeo de Desarrollo Regional (FEDER), Fondo de Investigación Sanitaria and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Subdirección General de Investigación Sanitaria, Ministerio de Economía y Competitividad: CP18/00116 (C.M.), PI19/01643 (B.L.); PI17/01443 (D.G.); PI15/00301 (C.A.-C.), PI17/0190 (J.S.), PI19/01643 & CPII16/00031, (M.V.); CIBEREHD CB06/04/0021 (F.A., C.A.-C., J.S., M.V.); Ministerio de Educación, Dirección General de Investigación: SAF 2016-76648-R (F.A.); Agència de Gestió d’Ajuts Universitaris i de Recerca, de la Generalitat de Catalunya: 2014 SGR 1285 (F.A.); Vall d’Hebron Institut de Recerca, Programa de becas pre-doctorales Amics de Vall d’Hebron: PRED-VHIR-2016-34 (C.P.-C.), PRED-VHIR-2014-018 (M.F.), the Swedish Research Council dnr 2019-00653 (J.-P.G.M.), and the European Union’s Horizon research and innovation programme 2020, grant no. 848228 (E.E., A.R.-U., B.L., C.A.-C., J.S.).","Drossman D.A., Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV, Gastroenterology, 150, pp. 1262-1279, (2016); Barbara G., Cremon C., De Giorgio R., Dothel G., Zecchi L., Bellacosa L., Carini G., Stanghellini V., Corinaldesi R., Mechanisms underlying visceral hypersensitivity in irritable bowel syndrome, Curr. Gastroenterol. Rep, 13, pp. 308-315, (2011); Enck P., Aziz Q., Barbara G., Farmer A.D., Fukudo S., Mayer E.A., Niesler B., Quigley E.M., Rajilic-Stojanovic M., Schemann M., Et al., Irritable bowel syndrome, Nat. Rev. Dis. Primers, 2, (2016); Ford A.C., Sperber A.D., Corsetti M., Camilleri M., Irritable bowel syndrome, Lancet, 396, pp. 1675-1688, (2020); Sibelli A., Chalder T., Everitt H., Workman P., Windgassen S., Moss-Morris R., A systematic review with meta-analysis of the role of anxiety and depression in irritable bowel syndrome onset, Psychol. Med, 46, pp. 3065-3080, (2016); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Lecleire S., Antonietti M., Gourcerol G., Leroi A.M., Dechelotte P., Menard J.F., Ducrotte P., Et al., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am. J. Gastroenterol, 106, pp. 2165-2173, (2011); Piche T., Barbara G., Aubert P., Bruley des Varannes S., Dainese R., Nano J.L., Cremon C., Stanghellini V., De Giorgio R., Galmiche J.P., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: Involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Martinez C., Lobo B., Pigrau M., Ramos L., Gonzalez-Castro A.M., Alonso C., Guilarte M., Guila M., de Torres I., Azpiroz F., Et al., Diarrhoea-predominant irritable bowel syndrome: An organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, pp. 1160-1168, (2013); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Farre R., Vicario M., Abnormal Barrier Function in Gastrointestinal Disorders, Handb. Exp. Pharmacol, 239, pp. 193-217, (2017); Bashashati M., Moossavi S., Cremon C., Barbaro M.R., Moraveji S., Talmon G., Rezaei N., Hughes P.A., Bian Z.X., Choi C.H., Et al., Colonic immune cells in irritable bowel syndrome: A systematic review and meta-analysis, Neurogastroenterol. Motil, 30, (2018); Robles A., Perez Ingles D., Myneedu K., Deoker A., Sarosiek I., Zuckerman M.J., Schmulson M.J., Bashashati M., Mast cells are increased in the small intestinal mucosa of patients with irritable bowel syndrome: A systematic review and meta-analysis, Neurogastroenterol. Motil, 31, (2019); Vicario M., Gonzalez-Castro A.M., Martinez C., Lobo B., Pigrau M., Guilarte M., de Torres I., Mosquera J.L., Fortea M., Sevillano-Aguilera C., Et al., Increased humoral immunity in the jejunum of diarrhoea-predominant irritable bowel syndrome associated with clinical manifestations, Gut, 64, pp. 1379-1388, (2015); Liu Y., Yuan X., Li L., Lin L., Zuo X., Cong Y., Li Y., Increased Ileal Immunoglobulin A Production and Immunoglobulin A-Coated Bacteria in Diarrhea-Predominant Irritable Bowel Syndrome, Clin. Transl. Gastroenterol, 11, (2020); Dlugosz A., Nowak P., D'Amato M., Mohammadian Kermani G., Nystrom J., Abdurahman S., Lindberg G., Increased serum levels of lipopolysaccharide and antiflagellin antibodies in patients with diarrhea-predominant irritable bowel syndrome, Neurogastroenterol. Motil, 27, pp. 1747-1754, (2015); Martinez C., Vicario M., Ramos L., Lobo B., Mosquera J.L., Alonso C., Sanchez A., Guilarte M., Antolin M., de Torres I., Et al., The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations, Am. J. Gastroenterol, 107, pp. 736-746, (2012); Rodino-Janeiro B.K., Martinez C., Fortea M., Lobo B., Pigrau M., Nieto A., Gonzalez-Castro A.M., Salvo-Romero E., Guagnozzi D., Pardo-Camacho C., Et al., Decreased TESK1-mediated cofilin 1 phosphorylation in the jejunum of IBS-D patients may explain increased female predisposition to epithelial dysfunction, Sci. Rep, 8, (2018); Hanning N., Edwinson A.L., Ceuleers H., Peters S.A., De Man J.G., Hassett L.C., De Winter B.Y., Grover M., Intestinal barrier dysfunction in irritable bowel syndrome: A systematic review, Ther. Adv. Gastroenterol, 14, pp. 1-31, (2021); Pelaseyed T., Bergstrom J.H., Gustafsson J.K., Ermund A., Birchenough G.M., Schutte A., van der Post S., Svensson F., Rodriguez-Pineiro A.M., Nystrom E.E., Et al., The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system, Immunol. Rev, 260, pp. 8-20, (2014); Grondin J.A., Kwon Y.H., Far P.M., Haq S., Khan W.I., Mucins in Intestinal Mucosal Defense and Inflammation: Learning From Clinical and Experimental Studies, Front. Immunol, 11, (2020); Basivireddy J., Jacob M., Ramamoorthy P., Balasubramanian K.A., Alterations in the intestinal glycocalyx and bacterial flora in response to oral indomethacin, Int. J. Biochem. Cell Biol, 37, pp. 2321-2332, (2005); Layunta E., Javerfelt S., Dolan B., Arike L., Pelaseyed T., IL-22 promotes the formation of a MUC17 glycocalyx barrier in the postnatal small intestine during weaning, Cell Rep, 34, (2021); Wu J., Yin Y., Qin M., Li K., Liu F., Zhou X., Song X., Li B., Vagus Nerve Stimulation Protects Enterocyte Glycocalyx After Hemorrhagic Shock Via the Cholinergic Anti-Inflammatory Pathway, Shock, 56, pp. 832-839, (2021); Drossman D.A., The functional gastrointestinal disorders and the Rome III process, Gastroenterology, 130, pp. 1377-1390, (2006); Francis C.Y., Morris J., Whorwell P.J., The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress, Aliment. Pharmacol. Ther, 11, pp. 395-402, (1997); Lewis S.J., Heaton K.W., Stool form scale as a useful guide to intestinal transit time, Scand. J. Gastroenterol, 32, pp. 920-924, (1997); Beck A.T., Ward C.H., Mendelson M., Mock J., Erbaugh J., An inventory for measuring depression, Arch. Gen. Psychiatry, 4, pp. 561-571, (1961); Holmes T.H., Rahe R.H., The Social Readjustment Rating Scale, J. Psychosom. Res, 11, pp. 213-218, (1967); Cohen S., Kamarck T., Mermelstein R., A global measure of perceived stress, J. Health Soc. Behav, 24, pp. 385-396, (1983); Guilarte M., Santos J., de Torres I., Alonso C., Vicario M., Ramos L., Martinez C., Casellas F., Saperas E., Malagelada J.R., Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum, Gut, 56, pp. 203-209, (2007); Martinez C., Rodino-Janeiro B.K., Lobo B., Stanifer M.L., Klaus B., Granzow M., Gonzalez-Castro A.M., Salvo-Romero E., Alonso-Cotoner C., Pigrau M., Et al., miR-16 and miR-125b are involved in barrier function dysregulation through the modulation of claudin-2 and cingulin expression in the jejunum in IBS with diarrhoea, Gut, 66, pp. 1537-1538, (2017); Love M.I., Huber W., Anders S., Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2, Genome Biol, 15, (2014); Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Et al., Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles, Proc. Natl. Acad. Sci. USA, 102, pp. 15545-15550, (2005); Ferguson A., Murray D., Quantitation of intraepithelial lymphocytes in human jejunum, Gut, 12, pp. 988-994, (1971); Kirk S.J., Cliff J.M., Thomas J.A., Ward T.H., Biogenesis of secretory organelles during B cell differentiation, J. Leukoc. Biol, 87, pp. 245-255, (2010); Vivinus-Nebot M., Dainese R., Anty R., Saint-Paul M.C., Nano J.L., Gonthier N., Marjoux S., Frin-Mathy G., Bernard G., Hebuterne X., Et al., Combination of allergic factors can worsen diarrheic irritable bowel syndrome: Role of barrier defects and mast cells, Am. J. Gastroenterol, 107, pp. 75-81, (2012); Sun W.W., Krystofiak E.S., Leo-Macias A., Cui R., Sesso A., Weigert R., Ebrahim S., Kachar B., Nanoarchitecture and dynamics of the mouse enteric glycocalyx examined by freeze-etching electron tomography and intravital microscopy, Commun. Biol, 3, (2020); Fang J., Wang H., Zhou Y., Zhang H., Zhou H., Zhang X., Slimy partners: The mucus barrier and gut microbiome in ulcerative colitis, Exp. Mol. Med, 53, pp. 772-787, (2021); Qin X., Damage of the Mucus Layer: The Possible Shared Critical Common Cause for Both Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS), Inflamm. Bowel Dis, 23, pp. E11-E12, (2017); Aerssens J., Camilleri M., Talloen W., Thielemans L., Gohlmann H.W., Van Den Wyngaert I., Thielemans T., De Hoogt R., Andrews C.N., Bharucha A.E., Et al., Alterations in mucosal immunity identified in the colon of patients with irritable bowel syndrome, Clin. Gastroenterol. Hepatol, 6, pp. 194-205, (2008); Jabbar K.S., Dolan B., Eklund L., Wising C., Ermund A., Johansson A., Tornblom H., Simren M., Hansson G.C., Association between Brachyspira and irritable bowel syndrome with diarrhoea, Gut, 70, pp. 1117-1129, (2021); Wang S.H., Dong L., Luo J.Y., Gong J., Li L., Lu X.L., Han S.P., Decreased expression of serotonin in the jejunum and increased numbers of mast cells in the terminal ileum in patients with irritable bowel syndrome, World J. Gastroenterol, 13, pp. 6041-6047, (2007); Ford A.C., Lacy B.E., Harris L.A., Quigley E.M.M., Moayyedi P., Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis, Am. J. Gastroenterol, 114, pp. 21-39, (2019); Hansen M.B., Witte A.B., The role of serotonin in intestinal luminal sensing and secretion, Acta Physiol, 193, pp. 311-323, (2008); Arabyan N., Park D., Foutouhi S., Weis A.M., Huang B.C., Williams C.C., Desai P., Shah J., Jeannotte R., Kong N., Et al., Salmonella Degrades the Host Glycocalyx Leading to Altered Infection and Glycan Remodeling, Sci. Rep, 6, (2016); Bednarska O., Walter S.A., Casado-Bedmar M., Strom M., Salvo-Romero E., Vicario M., Mayer E.A., Keita A.V., Vasoactive Intestinal Polypeptide and Mast Cells Regulate Increased Passage of Colonic Bacteria in Patients With Irritable Bowel Syndrome, Gastroenterology, 153, pp. 948-960, (2017); Martino C., Kellman B.P., Sandoval D.R., Clausen T.M., Marotz C.A., Song S.J., Wandro S., Zaramela L.S., Salido Benitez R.A., Zhu Q., Et al., Bacterial modification of the host glycosaminoglycan heparan sulfate modulates SARS-CoV-2 infectivity, bioRxiv, (2020); Wang L., Alammar N., Singh R., Nanavati J., Song Y., Chaudhary R., Mullin G.E., Gut Microbial Dysbiosis in the Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Case-Control Studies, J. Acad. Nutr. Diet, 120, pp. 565-586, (2020); Saffouri G.B., Shields-Cutler R.R., Chen J., Yang Y., Lekatz H.R., Hale V.L., Cho J.M., Battaglioli E.J., Bhattarai Y., Thompson K.J., Et al., Small intestinal microbial dysbiosis underlies symptoms associated with functional gastrointestinal disorders, Nat. Commun, 10, (2019); Qin H.Y., Cheng C.W., Tang X.D., Bian Z.X., Impact of psychological stress on irritable bowel syndrome, World J. Gastroenterol, 20, pp. 14126-14131, (2014); Rengarajan S., Knoop K.A., Rengarajan A., Chai J.N., Grajales-Reyes J.G., Samineni V.K., Russler-Germain E.V., Ranganathan P., Fasano A., Sayuk G.S., Et al., A Potential Role for Stress-Induced Microbial Alterations in IgA-Associated Irritable Bowel Syndrome with Diarrhea, Cell Rep. Med, 1, (2020); Vicario M., Guilarte M., Alonso C., Yang P., Martinez C., Ramos L., Lobo B., Gonzalez A., Guila M., Pigrau M., Et al., Chronological assessment of mast cell-mediated gut dysfunction and mucosal inflammation in a rat model of chronic psychosocial stress, Brain Behav. Immun, 24, pp. 1166-1175, (2010); Da Silva S., Robbe-Masselot C., Ait-Belgnaoui A., Mancuso A., Mercade-Loubiere M., Salvador-Cartier C., Gillet M., Ferrier L., Loubiere P., Dague E., Et al., Stress disrupts intestinal mucus barrier in rats via mucin O-glycosylation shift: Prevention by a probiotic treatment, Am. J. Physiol. Gastrointest. Liver Physiol, 307, pp. G420-G429, (2014); Chassaing B., Koren O., Goodrich J.K., Poole A.C., Srinivasan S., Ley R.E., Gewirtz A.T., Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome, Nature, 519, pp. 92-96, (2015); Jakobsson H.E., Rodriguez-Pineiro A.M., Schutte A., Ermund A., Boysen P., Bemark M., Sommer F., Backhed F., Hansson G.C., Johansson M.E., The composition of the gut microbiota shapes the colon mucus barrier, EMBO Rep, 16, pp. 164-177, (2015); Fenton C.G., Taman H., Florholmen J., Sorbye S.W., Paulssen R.H., Transcriptional Signatures That Define Ulcerative Colitis in Remission, Inflamm. Bowel Dis, 27, pp. 94-105, (2021); Mockl L., The Emerging Role of the Mammalian Glycocalyx in Functional Membrane Organization and Immune System Regulation, Front. Cell Dev. Biol, 8, (2020); Mole C.M., Bene M.C., Montagne P.M., Seilles E., Faure G.C., Light chains of immunoglobulins in human secretions, Clin. Chim. Acta, 224, pp. 191-197, (1994); Dlugosz A., Tornblom H., Mohammadian G., Morgan G., Veress B., Edvinsson B., Sandstrom G., Lindberg G., Chlamydia trachomatis antigens in enteroendocrine cells and macrophages of the small bowel in patients with severe irritable bowel syndrome, BMC Gastroenterol, 10, (2010); Lobo B., Ramos L., Martinez C., Guilarte M., Gonzalez-Castro A.M., Alonso-Cotoner C., Pigrau M., de Torres I., Rodino-Janeiro B.K., Salvo-Romero E., Et al., Downregulation of mucosal mast cell activation and immune response in diarrhoea-irritable bowel syndrome by oral disodium cromoglycate: A pilot study, United Eur. Gastroenterol. J, 5, pp. 887-897, (2017); Nozu T., Miyagishi S., Nozu R., Takakusaki K., Okumura T., Lipopolysaccharide induces visceral hypersensitivity: Role of interleukin-1, interleukin-6, and peripheral corticotropin-releasing factor in rats, J. Gastroenterol, 52, pp. 72-80, (2017); Ferrante A., Beard L.J., Feldman R.G., IgG subclass distribution of antibodies to bacterial and viral antigens, Pediatr. Infect. Dis. J, 9, pp. S16-S24, (1990); Goldenberg H.B., McCool T.L., Weiser J.N., Cross-reactivity of human immunoglobulin G2 recognizing phosphorylcholine and evidence for protection against major bacterial pathogens of the human respiratory tract, J. Infect. Dis, 190, pp. 1254-1263, (2004); Kluber P., Meurer S.K., Lambertz J., Schwarz R., Zechel-Gran S., Braunschweig T., Hurka S., Domann E., Weiskirchen R., Depletion of Lipocalin 2 (LCN2) in Mice Leads to Dysbiosis and Persistent Colonization with Segmented Filamentous Bacteria, Int. J. Mol. Sci, 22, (2021); Waters L.R., Ahsan F.M., Wolf D.M., Shirihai O., Teitell M.A., Initial B Cell Activation Induces Metabolic Reprogramming and Mitochondrial Remodeling, iScience, 5, pp. 99-109, (2018); Kimata H., Yoshida A., Ishioka C., Fujimoto M., Furusho K., Vasoactive intestinal peptide enhances immunoglobulin production and growth in human plasma cells via mechanisms that may involve protein kinase C, J. Clin. Endocrinol. Metab, 81, pp. 3024-3032, (1996); Scicchitano R., Biennenstock J., Stanisz A.M., In vivo immunomodulation by the neuropeptide substance P, Immunology, 63, pp. 733-735, (1988); Xu X.J., Zhang Y.L., Liu L., Pan L., Yao S.K., Increased expression of nerve growth factor correlates with visceral hypersensitivity and impaired gut barrier function in diarrhoea-predominant irritable bowel syndrome: A preliminary explorative study, Aliment. Pharmacol. Ther, 45, pp. 100-114, (2017); Zhang X., Lei B., Yuan Y., Zhang L., Hu L., Jin S., Kang B., Liao X., Sun W., Xu F., Et al., Brain control of humoral immune responses amenable to behavioural modulation, Nature, 581, pp. 204-208, (2020); Lakhan S.E., Kirchgessner A., Neuroinflammation in inflammatory bowel disease, J. Neuroinflamm, 7, (2010); Akbar A., Yiangou Y., Facer P., Walters J.R., Anand P., Ghosh S., Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain, Gut, 57, pp. 923-929, (2008); Sohn W., Lee O.Y., Lee S.P., Lee K.N., Jun D.W., Lee H.L., Yoon B.C., Choi H.S., Sim J., Jang K.S., Mast cell number, substance P and vasoactive intestinal peptide in irritable bowel syndrome with diarrhea, Scand. J. Gastroenterol, 49, pp. 43-51, (2014); Liu S., Neurotrophic factors in enteric physiology and pathophysiology, Neurogastroenterol. Motil, 30, (2018); Saruta M., Takahashi K., Suzuki T., Torii A., Kawakami M., Sasano H., Urocortin 1 in colonic mucosa in patients with ulcerative colitis, J. Clin. Endocrinol. Metab, 89, pp. 5352-5361, (2004); Yamato S., Kurematsu A., Amano T., Ariga H., Ando T., Komaki G., Wada K., Urocortin 1: A putative excitatory neurotransmitter in the enteric nervous system, Neurogastroenterol. Motil, 32, (2020); Brandt R., Timm S., Gorenflos Lopez J.L., Kwame Abledu J., Kuebler W.M., Hackenberger C.P.R., Ochs M., Lopez-Rodriguez E., Metabolic Glycoengineering Enables the Ultrastructural Visualization of Sialic Acids in the Glycocalyx of the Alveolar Epithelial Cell Line hAELVi, Front. Bioeng. Biotechnol, 8, (2020); Alonso-Cotoner C., Abril-Gil M., Albert-Bayo M., Mall J.G., Exposito E., Gonzalez-Castro A.M., Lobo B., Santos J., The Role of Purported Mucoprotectants in Dealing with Irritable Bowel Syndrome, Functional Diarrhea, and Other Chronic Diarrheal Disorders in Adults, Adv. Ther, 38, pp. 2054-2076, (2021); Azzini E., Maiani G., Garaguso I., Polito A., Foddai M.S., Venneria E., Durazzo A., Intorre F., Palomba L., Rauseo M.L., Et al., The Potential Health Benefits of Polyphenol-Rich Extracts from Cichorium intybus L. Studied on Caco-2 Cells Model, Oxidative Med. Cell. Longev, 2016, (2016); Kong C., Elderman M., Cheng L., de Haan B.J., Nauta A., de Vos P., Modulation of Intestinal Epithelial Glycocalyx Development by Human Milk Oligosaccharides and Non-Digestible Carbohydrates, Mol. Nutr. Food Res, 63, (2019)","A.M. González-Castro; Laboratory of Translational Mucosal Immunology, Digestive System Research Unit, Vall d’Hebron Institut de Recerca, Barcelona, Passeig Vall d’Hebron 119-129, 08035, Spain; email: ana.maria.gonzalez@vhir.org; M. Vicario; Laboratory of Translational Mucosal Immunology, Digestive System Research Unit, Vall d’Hebron Institut de Recerca, Barcelona, Passeig Vall d’Hebron 119-129, 08035, Spain; email: maria.vicarioperez@rd.nestle.com","","MDPI","","","","","","20734409","","","35805133","English","Cells","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85132923608"

"Huang Y.-Q.; Liu J.-L.; Chen G.-X.; Shen D.-T.; Zhu W.; Chen X.-L.; Liu F.-B.; Hou Q.-K.","Huang, Yong-quan (57195074253); Liu, Jia-lin (59062469300); Chen, Geng-xin (57195345532); Shen, Dan-ting (57205137273); Zhu, Wang (58182879800); Chen, Xin-lin (55357650100); Liu, Feng-bin (55799656200); Hou, Qiu-ke (35573727700)","57195074253; 59062469300; 57195345532; 57205137273; 58182879800; 55357650100; 55799656200; 35573727700","Berberine Enhances Intestinal Mucosal Barrier Function by Promoting Vitamin D Receptor Activity","2024","Chinese Journal of Integrative Medicine","30","2","","143","151","8","3","10.1007/s11655-023-3547-x","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85152466162&doi=10.1007%2fs11655-023-3547-x&partnerID=40&md5=ad5d70e38e5f29a778d078720e149a28","Graduate School, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China; Department of Orthopedics, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510006, China; Department of Preventive Medicine and Health Statistics, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China; Department of Gastroenterology, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China","Huang Y.-Q., Graduate School, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China, Department of Orthopedics, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510006, China; Liu J.-L., Graduate School, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China; Chen G.-X., Department of Orthopedics, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510006, China; Shen D.-T., Graduate School, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China; Zhu W., Graduate School, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China; Chen X.-L., Department of Preventive Medicine and Health Statistics, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China; Liu F.-B., Department of Gastroenterology, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China; Hou Q.-K., Department of Gastroenterology, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China","Objective: To evaluate if berberine can act on vitamin D receptors (VDR) and thereby regulate the expression of tight junction proteins (TJPs) in irritable bowel syndrame-diarrhea-predominant (IBS-D) rats. Methods: The newborn rats were induced into IBS-D rat model via neonatal maternal separation combined with acetic acid chemical stimulation. After modeling, the model was evaluated and rats were divided into the control group and berberine treatment groups (0.85, 1.7 and 3.4 mg/kg, once a day for 2 weeks). The distal colon was obtained and colonic epithelial cells (CECs) were isolated and cultured after IBS-D model evaluation. The vitamin D receptor response element (VDRE) reporter gene was determined in the CECs of IBS-D rats to analyze the effect of berberine on the VDRE promoter. VDR overexpression or silencing technology was used to analyze whether VDR plays a role in promoting intestinal barrier repair, and to determine which region of VDR plays a role in berberine-regulated intestinal TJPs. Results: The IBS-D rat model was successfully constructed and the symptoms were improved by berberine in a dose-dependent manner (P<0.05). The activity of VDRE promoter was also effectively promoted by berberine (P<0.05). Berberine increased the expression of TJPs in IBS-D CECs (P<0.05). VDR expression was significantly increased after transfection of different domains of VDR when compared to normal control and basic plasmid groups (all P<0.05). RT-qPCR and Western blot results showed that compared with the blank group, expressions of occludin and zonula occludens-1 were significantly higher in VDR containing groups (all P<0.05). Berberine plus pCMV-Myc-VDR-N group exerted the highest expression levels of occludin and zonula occludens-1 (P<0.05). Conclusion: Berberine enhances intestinal mucosal barrier function of IBS-D rats by promoting VDR activity, and the main site of action is the N-terminal region of VDR. © 2023, The Chinese Journal of Integrated Traditional and Western Medicine Press and Springer-Verlag GmbH Germany, part of Springer Nature.","berberine; Chinese medicine; intestinal mucosal barrier; irritable bowel syndrome-diarrhea-predominant; tight junction proteins; vitamin D receptors","Animals; Berberine; Diarrhea; Intestinal Barrier Function; Intestinal Mucosa; Irritable Bowel Syndrome; Maternal Deprivation; Occludin; Rats; Receptors, Calcitriol; acetic acid; berberine; diazepam; ketamine; occludin; penicillin derivative; phosphate buffered saline; protein ZO1; tight junction protein; vitamin D receptor; berberine; calcitriol receptor; animal cell; animal experiment; animal model; Article; chemical stimulation; controlled study; dose response; female; genetic transfection; intestinal barrier function; irritable colon; male; maternal deprivation; newborn; nonhuman; permeability; protein expression; rat; rat model; reporter gene; transepithelial resistance; water content; Western blotting; animal; diarrhea; genetics; intestine mucosa; irritable colon; metabolism","","acetic acid, 127-08-2, 127-09-3, 64-19-7, 71-50-1, 6131-90-4; berberine, 2086-83-1, 633-65-8; diazepam, 439-14-5, 11100-37-1, 53320-84-6; ketamine, 1867-66-9, 6740-88-1, 81771-21-3; occludin, 176304-61-3; Berberine, ; Occludin, ; Receptors, Calcitriol, ","","","National Natural Science Foundation of China, NSFC, (82004387, 82174303); National Natural Science Foundation of China, NSFC","Supported by the National Natural Science Foundation (No. 82174303, 82004387) ","Zhuang X., Tian Z., Luo M., Xiong L., Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome, BMC Gastroenterol, 20, (2020); Zhou Y., Han S., He Y., Clinical effects and safety of Tongxieyaofang on diarrhea predominant irritable bowel syndrome: a meta-analysis of randomized trails, Evid Based Complement Alternat Med, 2019, (2019); Lee H., Park J.H., Park D.I., Kim H.J., Cho Y.K., Sohn C.I., Et al., Mucosal mast cell count is associated with intestinal permeability in patients with diarrhea predominant irritable bowel syndrome, J Neurogastroenterol Motil, 19, pp. 244-250, (2013); Zhang C., Huang Y., Li P., Chen X., Liu F., Hou Q., Ginger relieves intestinal hypersensitivity of diarrhea predominant irritable bowel syndrome by inhibiting proinflammatory reaction, BMC Complement Med Ther, 20, (2020); Zhang Y., Li Y., Hao Z., Li X., Bo P., Gong W., Association of the serotonin receptor 3E gene as a functional variant in the MicroRNA-510 target site with diarrhea predominant irritable bowel syndrome in Chinese women, J Neurogastroenterol Motil, 22, pp. 272-281, (2016); Yu Y.C., Li J., Zhang M., Pan J.C., Yu Y., Zhang J.B., Et al., Resveratrol improves brain-gut axis by regulation of 5-HT-dependent signaling in the rat model of irritable bowel syndrome, Front Cell Neurosci, 13, (2019); Abbasnezhad A., Amani R., Hajiani E., Alavinejad P., Cheraghian B., Ghadiri A., Effect of vitamin D on gastrointestinal symptoms and health-related quality of life in irritable bowel syndrome patients: a randomized double-blind clinical trial, Neurogastroenterol Motil, 28, pp. 1533-1544, (2016); Hou Q., Huang Y., Zhu S., Li P., Chen X., Hou Z., Et al., MiR-144 increases intestinal permeability in IBS-D rats by targeting OCLN and ZO1, Cell Physiol Biochem, 44, pp. 2256-2268, (2017); Shao J., Zeng D., Tian S., Liu G., Fu J., Identification of the natural product berberine as an antiviral drug, AMB Express, 10, (2020); Zhang D., Jiang L., Wang M., Jin M., Zhang X., Liu D., Et al., Berberine inhibits intestinal epithelial barrier dysfunction in colon caused by peritoneal dialysis fluid by improving cell migration, J Ethnopharmacol, 264, (2021); Yu M., Jin X., Liang C., Bu F., Pan D., He Q., Et al., Berberine for diarrhea in children and adults: a systematic review and meta-analysis, Ther Adv Gastroenterol, 13, (2020); Hou Q., Zhu S., Zhang C., Huang Y., Guo Y., Li P., Et al., Berberine improves intestinal epithelial tight junctions by upregulating A20 expression in IBS-D mice, Biomed Pharmacother, 118, (2019); Nakamichi Y., Udagawa N., Horibe K., Mizoguchi T., Yamamoto Y., Nakamura T., Et al., VDR in osteoblast-lineage cells primarily mediates vitamin D treatment-induced increase in bone mass by suppressing bone resorption, J Bone Miner Res, 32, pp. 1297-1308, (2017); Borzouei S., Sheikh V., Ghasemi M., Zamani A., Telikani Z., Zareighane Z., Et al., Anti-inflammatory effect of combined sitagliptin and vitamin D3 on cytokines profile in patients with type 2 diabetes mellitus, J Interferon Cytokine Res, 39, pp. 293-301, (2019); Gallo D., Mortara L., Gariboldi M.B., Cattaneo S.A.M., Rosetti S., Gentile L., Et al., Immunomodulatory effect of vitamin D and its potential role in the prevention and treatment of thyroid autoimmunity: a narrative review, J Endocrinol Invest, 43, pp. 413-429, (2020); Thornton K.A., Marin C., Mora-Plazas M., Villamor E., Vitamin D deficiency associated with increased incidence of gastrointestinal and ear infections in school-age children, Pediatr Infect Dis J, 32, pp. 585-593, (2013); Cantorna M.T., Snyder L., Arora J., Vitamin A and vitamin D regulate the microbial complexity, barrier function, and the mucosal immune responses to ensure intestinal homeostasis, Crit Rev Biochem Mol Biol, 54, pp. 184-192, (2019); Kong J., Zhang Z., Musch M.W., Ning G., Sun J., Hart J., Et al., Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier, Am J Physiol Gastrointest Liver Physiol, 294, pp. G208-G216, (2008); Khalighi S.M., Mokhtare M., Janani L., Faghihi Kashani A.H., Masoodi M., Agah S., Et al., Vitamin D3 supplementation in diarrhea-predominant irritable bowel syndrome patients: the effects on symptoms improvement, serum corticotropin-releasing hormone, and interleukin-6—a randomized clinical trial, Complement Med Res, 27, pp. 302-309, (2020); Khalighi Sikaroudi M., Mokhtare M., Shidfar F., Janani L., Faghihi Kashani A., Masoodi M., Et al., Effects of vitamin D3 supplementation on clinical symptoms, quality of life, serum serotonin (5-hydroxytryptamine), 5-hydroxy-indole acetic acid, and ratio of 5-HIAA/5-HT in patients with diarrhea-predominant irritable bowel syndrome: a randomized clinical trial, EXCLI J, 19, pp. 652-667, (2020); Miura K., Oshima T., Ito C., Horikawa T., Yamada M., Tomita T., Et al., Vitamin D receptor is overexpressed in the duodenum of patients with irritable bowel syndrome, J Gastroenterol Hepatol, 36, pp. 951-958, (2021); He L., Liu T., Shi Y., Tian F., Hu H., Deb D.K., Et al., Gut epithelial vitamin D receptor regulates microbiota-dependent mucosal inflammation by suppressing intestinal epithelial cell apoptosis, Endocrinology, 159, pp. 967-979, (2018); Wang F.Y., Su M., Zheng Y.Q., Wang X.G., Kang N., Chen T., Et al., Herbal prescription Chang’ an II repairs intestinal mucosal barrier in rats with post-inflammation irritable bowel syndrome, Acta Pharmacol Sin, 36, pp. 708-715, (2015); Hou Q., Huang Y., Zhu Z., Liao L., Chen X., Han Q., Et al., Tong-Xie-Yao-Fang improves intestinal permeability in diarrhoea-predominant irritable bowel syndrome rats by inhibiting the NF-kappaB and notch signalling pathways, BMC Complement Altern Med, 19, (2019); Blake M.R., Raker J.M., Whelan K., Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome, Aliment Pharmacol Ther, 44, pp. 693-703, (2016); Hou Q., Huang Y., Zhang C., Zhu S., Li P., Chen X., Et al., MicroRNA-200a targets cannabinoid receptor 1 and serotonin transporter to increase visceral hyperalgesia in diarrhea-predominant irritable bowel syndrome rats, J Neurogastroenterol Motil, 24, pp. 656-668, (2018); Hou Q.K., Huang Y.Q., Luo Y.W., Wang B., Liu Y.M., Deng R.D., Et al., (+)-Cholesten-3-one induces osteogenic differentiation of bone marrow mesenchymal stem cells by activating vitamin D receptor, Exp Ther Med, 13, pp. 1841-1849, (2017); Tash B.R., Bewley M.C., Russo M., Keil J.M., Griffin K.A., Sundstrom J.M., Et al., The occludin and ZO-1 complex, defined by small angle X-ray scattering and NMR, has implications for modulating tight junction permeability, Proc Natl Acad Sci U S A, 109, pp. 10855-10860, (2012); Billings S.D., Walsh S.V., Fisher C., Nusrat A., Weiss S.W., Folpe A.L., Aberrant expression of tight junction-related proteins ZO-1, claudin-1 and occludin in synovial sarcoma: an immunohistochemical study with ultrastructural correlation, Mod Pathol, 17, pp. 141-149, (2004); Visconti B., Paolino G., Carotti S., Pendolino A.L., Morini S., Richetta A.G., Et al., Immunohistochemical expression of VDR is associated with reduced integrity of tight junction complex in psoriatic skin, J Eur Acad Dermatol Venereol, 29, pp. 2038-2042, (2015); Chen B., Zhu W.F., Mu Y.Y., Liu B., Li H.Z., He X.F., Association between vitamin D receptor BsmI, FokI, and Cdx2 polymorphisms and osteoporosis risk: an updated meta-analysis, Biosci Rep, 40, (2020); Stobaugh D.J., Deepak P., Ehrenpreis E.D., Increased risk of osteoporosis-related fractures in patients with irritable bowel syndrome, Osteoporos Int, 24, pp. 1169-1175, (2013); Shi S., Feng J., Zhou L., Li Y., Shi H., Risk factors for vitamin D deficiency in inflammatory bowel disease: a systematic review and meta-analysis, Turk J Gastroenterol, 32, pp. 508-518, (2021); Linsalata M., Riezzo G., Orlando A., D'Attoma B., Prospero L., Tutino V., Et al., The relationship between low serum vitamin D levels and altered intestinal barrier function in patients with IBS diarrhoea undergoing a long-term low-FODMAP diet: novel observations from a clinical trial, Nutrients, 13, (2021); Li L., Cui H., Li T., Qi J., Chen H., Gao F., Et al., Synergistic effect of berberine-based Chinese medicine assembled nanostructures on diarrhea-predominant irritable bowel syndrome in vivo, Front Pharmacol, 11, (2020); Li Y.C., Chen Y., Du J., Critical roles of intestinal epithelial vitamin D receptor signaling in controlling gut mucosal inflammation, J Steroid Biochem Mol Biol, 148, pp. 179-183, (2015); Barbalho S.M., Goulart R.A., Araujo A.C., Guiguer E.L., Bechara M.D., Irritable bowel syndrome: a review of the general aspects and the potential role of vitamin D, Expert Rev Gastroenterol Hepatol, 13, pp. 345-359, (2019); Fang X., Miao X.L., Liu J.L., Zhang D.W., Wang M., Zhao D.D., Et al., Berberine induces cell apoptosis through cytochrome C/apoptotic protease-activating factor 1/Caspase-3 and apoptosis inducing factor pathway in mouse insulinoma cells, Chin J Integr Med, 25, pp. 853-860, (2019); Yue S.J., Wang W.X., Zhang L., Liu J., Feng W.W., Gao H., Et al., Anti-obesity and gut microbiota modulation effect of Astragalus Polysaccharides combined with berberine on high-fat diet-fed obese mice, Chin J Integr Med, (2021); Yao Y., Chen H., Yan L., Wang W., Wang D., Berberine alleviates type 2 diabetic symptoms by altering gut microbiota and reducing aromatic amino acids, Biomed Pharmacother, 131, (2020)","Q.-K. Hou; Department of Gastroenterology, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China; email: houqiuke@gzucm.edu.cn","","Springer Science and Business Media Deutschland GmbH","","","","","","16720415","","","37046128","English","Chin. J. Integr. Med.","Article","Final","","Scopus","2-s2.0-85152466162"

"Tao E.; Wu Y.; Hu C.; Zhu Z.; Ye D.; Long G.; Chen B.; Guo R.; Shu X.; Zheng W.; Zhang T.; Jia X.; Du X.; Fang M.; Jiang M.","Tao, Enfu (57188721251); Wu, Yuhao (58136887300); Hu, Chenmin (57559943700); Zhu, Zhenya (57480252000); Ye, Diya (57219930107); Long, Gao (57201640175); Chen, Bo (55673224900); Guo, Rui (57194716253); Shu, Xiaoli (14519820600); Zheng, Wei (57201637334); Zhang, Ting (57198705875); Jia, Xinyi (57205193870); Du, Xiao (57218300356); Fang, Marong (8664493500); Jiang, Mizu (7401861132)","57188721251; 58136887300; 57559943700; 57480252000; 57219930107; 57201640175; 55673224900; 57194716253; 14519820600; 57201637334; 57198705875; 57205193870; 57218300356; 8664493500; 7401861132","Early life stress induces irritable bowel syndrome from childhood to adulthood in mice","2023","Frontiers in Microbiology","14","","1255525","","","","0","10.3389/fmicb.2023.1255525","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85174277827&doi=10.3389%2ffmicb.2023.1255525&partnerID=40&md5=c3ee2a6d587308ca22e2a5106853ef46","Pediatric Endoscopy Center and Gastrointestinal Laboratory, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China; Department of Neonatology and NICU, Wenling Maternal and Child Health Care Hospital, Wenling, China; Department of Gastroenterology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China; Institute of Neuroscience and Gastrointestinal Laboratory, Children’s Hospital, Zhejiang University School of Medicine, Hangzhou, China","Tao E., Pediatric Endoscopy Center and Gastrointestinal Laboratory, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China, Department of Neonatology and NICU, Wenling Maternal and Child Health Care Hospital, Wenling, China; Wu Y., Pediatric Endoscopy Center and Gastrointestinal Laboratory, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China; Hu C., Pediatric Endoscopy Center and Gastrointestinal Laboratory, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China; Zhu Z., Pediatric Endoscopy Center and Gastrointestinal Laboratory, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China; Ye D., Pediatric Endoscopy Center and Gastrointestinal Laboratory, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China; Long G., Pediatric Endoscopy Center and Gastrointestinal Laboratory, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China; Chen B., Pediatric Endoscopy Center and Gastrointestinal Laboratory, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China; Guo R., Pediatric Endoscopy Center and Gastrointestinal Laboratory, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China; Shu X., Pediatric Endoscopy Center and Gastrointestinal Laboratory, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China; Zheng W., Pediatric Endoscopy Center and Gastrointestinal Laboratory, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China, Department of Gastroenterology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China; Zhang T., Pediatric Endoscopy Center and Gastrointestinal Laboratory, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China; Jia X., Pediatric Endoscopy Center and Gastrointestinal Laboratory, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China, Department of Gastroenterology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China; Du X., Pediatric Endoscopy Center and Gastrointestinal Laboratory, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China, Department of Gastroenterology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China; Fang M., Institute of Neuroscience and Gastrointestinal Laboratory, Children’s Hospital, Zhejiang University School of Medicine, Hangzhou, China; Jiang M., Pediatric Endoscopy Center and Gastrointestinal Laboratory, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China, Department of Gastroenterology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China","Background: Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal disorder. Traditionally, early life stress (ELS) is predisposed to IBS in adult. However, whether ELS induces IBS in early life remains unclear. Methods: Separated cohort studies were conducted in neonatal male pups of C57BL/6 mice by maternal separation (MS) model. MS and non-separation mice were scheduled to be evaluated for prime IBS-phenotypes, including visceral hypersensitivity, intestinal motility, intestinal permeability, and anxiety-like behavior. Ileal contents and fecal samples were collected and analyzed by 16S rRNA gene sequencing and bacterial community analyses. Subcellular structures of intestinal epithelial, such as epithelial tight junctions and mitochondria, were observed under transmission electron microscopy. Results: MS induced visceral hypersensitivity and decreased total intestinal transit time from childhood to adulthood. In addition, MS induced intestinal hyperpermeability and anxiety-like behavior from adolescence to adulthood. Besides, MS affected intestinal microbial composition from childhood to adulthood. Moreover, MS disrupted intestinal mitochondrial structure from childhood to adulthood. Conclusion: The study showed for the first time that MS induced IBS from early life to adulthood in mice. The disrupted intestinal mitochondrial structure and the significant dysbiosis of intestinal microbiota in early life may contribute to the initiation and progress of IBS from early life to adulthood. Copyright © 2023 Tao, Wu, Hu, Zhu, Ye, Long, Chen, Guo, Shu, Zheng, Zhang, Jia, Du, Fang and Jiang.","brain-gut-microbiota axis; early life stress; irritable bowel syndrome; maternal separation; visceral hypersensitivity","RNA 16S; Actinobacteria; adolescence; adulthood; animal experiment; animal model; anxiety; Article; Blautia; brain-gut axis; childhood; Clostridiales; cohort analysis; decapitation; dysbiosis; early life stress; elevated plus maze test; feces; female; fluorescence intensity; gastrointestinal disease; gene sequence; gestational age; intestine epithelium cell; intestine flora; intestine motility; intestine transit time; irritable colon; Lachnospiraceae; Lactobacillus; male; maternal deprivation; microbial community; microbial diversity; mitochondrion; mouse; newborn; nonhuman; open field test; physiological stress; tight junction; transmission electron microscopy; visceral hyperalgesia","","","EM UC7, Leica, United States; G2 Spirit","Leica, United States","National Clinical Research Center for Child Health, (G20A0008Z)","The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by a project from the National Clinical Research Center for Child Health (G20A0008Z). ","Black C.J., Ford A.C., Global burden of irritable bowel syndrome: trends, predictions and risk factors, Nat. Rev. Gastroenterol. Hepatol, 17, pp. 473-486, (2020); Borre Y.E., O'keeffe G.W., Clarke G., Stanton C., Dinan T.G., Cryan J.F., Microbiota and neurodevelopmental windows: implications for brain disorders, Trends Mol. Med, 20, pp. 509-518, (2014); Botschuijver S., Van Diest S.A., Van Thiel I.A.M., Saia R.S., Strik A.S., Yu Z., Et al., Miltefosine treatment reduces visceral hypersensitivity in a rat model for irritable bowel syndrome via multiple mechanisms, Sci. Rep, 9, (2019); Bradford K., Shih W., Videlock E.J., Presson A.P., Naliboff B.D., Mayer E.A., Et al., Association between early adverse life events and irritable bowel syndrome, Clin. Gastroenterol. Hepatol, 10, (2012); Brandsma E., Kloosterhuis N.J., Koster M., Dekker D.C., Gijbels M.J.J., Van Der Velden S., Et al., A Proinflammatory gut microbiota increases systemic inflammation and accelerates atherosclerosis, Circ. Res, 124, pp. 94-100, (2019); Brierley S.M., Greenwood-Van Meerveld B., Sarnelli G., Sharkey K.A., Storr M., Tack J., Targeting the endocannabinoid system for the treatment of abdominal pain in irritable bowel syndrome, Nat. Rev. Gastroenterol. Hepatol, 20, pp. 5-25, (2023); Bulbul M., Sinen O., Centrally administered neuropeptide-S alleviates gastrointestinal Dysmotility induced by neonatal maternal separation, Neurogastroenterol. Motil, 34, (2021); Burke N.N., Finn D.P., Mcguire B.E., Roche M., Psychological stress in early life as a predisposing factor for the development of chronic pain: clinical and preclinical evidence and neurobiological mechanisms, J. Neurosci. Res, 95, pp. 1257-1270, (2017); Canakis A., Haroon M., Weber H.C., Irritable bowel syndrome and gut microbiota, Curr. Opin. Endocrinol. Diabetes Obes, 27, pp. 28-35, (2020); Cao H., Liu X., An Y., Zhou G., Liu Y., Xu M., Et al., Dysbiosis contributes to chronic constipation development via regulation of serotonin transporter in the intestine, Sci. Rep, 7, (2017); Chang C.S., Liao Y.C., Huang C.T., Lin C.M., Cheung C.H.Y., Ruan J.W., Et al., Identification of a gut microbiota member that ameliorates DSS-induced colitis in intestinal barrier enhanced Dusp6-deficient mice, Cell Rep, 37, (2021); Chen S., Chen F., Amin N., Ren Q., Ye S., Hu Z., Et al., Defects of parvalbumin-positive interneurons in the ventral dentate gyrus region are implicated depression-like behavior in mice, Brain Behav. Immun, 99, pp. 27-42, (2021); Chen M., Ruan G., Chen L., Ying S., Li G., Xu F., Et al., Neurotransmitter and intestinal interactions: focus on the microbiota-gut-brain Axis in irritable bowel syndrome, Front. Endocrinol, 13, (2022); Chen S., Wang J., Dong N., Fang Q., Zhang Y., Chen C., Et al., Polysaccharides from natural Cordyceps sinensis attenuated dextran sodium sulfate-induced colitis in C57BL/6J mice, Food Funct, 14, pp. 720-733, (2023); Collins J.M., Hyland N.P., Clarke G., Fitzgerald P., Julio-Pieper M., Bulmer D.C., Et al., Beta 3-adrenoceptor agonism ameliorates early-life stress-induced visceral hypersensitivity in male rats, J. Neurochem, (2023); Cruz B., Conceicao L.L.D., Mendes T.A.O., Ferreira C., Goncalves R.V., Peluzio M., Use of the synbiotic VSL#3 and yacon-based concentrate attenuates intestinal damage and reduces the abundance of Candidatus Saccharimonas in a colitis-associated carcinogenesis model, Food Res. Int, 137, (2020); Egerton S., Donoso F., Fitzgerald P., Gite S., Fouhy F., Whooley J., Et al., Investigating the potential of fish oil as a nutraceutical in an animal model of early life stress, Nutr. Neurosci, 25, pp. 356-378, (2020); Eisner V., Cupo R.R., Gao E., Csordas G., Slovinsky W.S., Paillard M., Et al., Mitochondrial fusion dynamics is robust in the heart and depends on calcium oscillations and contractile activity, Proc. Natl. Acad. Sci. U. S. A, 114, pp. E859-E868, (2017); Emami N.K., White M.B., Calik A., Kimminau E.A., Dalloul R.A., Managing broilers gut health with antibiotic-free diets during subclinical necrotic enteritis, Poult. Sci, 100, (2021); Favoretto C.A., Bertagna N.B., Righi T., Rodolpho B.T., Anjos-Santos A., Silva F.B.R., Et al., Impacts of maternal separation stress on ethanol-related responses, anxiety-and depressive-like behaviors in adolescent mice, Neurosci. Lett, 809, (2023); Gao Y., Ding P., Wang J., Zhang C., Ji G., Wu T., Application of metabolomics in irritable bowel syndrome in recent 5 years, Int. Immunopharmacol, 124, (2023); Gu Z., Zhu Y., Jiang S., Xia G., Li C., Zhang X., Et al., Tilapia head glycolipids reduce inflammation by regulating the gut microbiota in dextran sulphate sodium-induced colitis mice, Food Funct, 11, pp. 3245-3255, (2020); Guerbette T., Boudry G., Lan A., Mitochondrial function in intestinal epithelium homeostasis and modulation in diet-induced obesity, Mol. Metab, 63, (2022); Han L., Zhao L., Zhou Y., Yang C., Xiong T., Lu L., Et al., Altered metabolome and microbiome features provide clues in understanding irritable bowel syndrome and depression comorbidity, ISME J, 16, pp. 983-996, (2022); Han H., Zhou Y., Liu Q., Wang G., Feng J., Zhang M., Effects of Ammonia on gut microbiota and growth performance of broiler chickens, Animals (Basel), 11, (2021); Hollis F., Van Der Kooij M.A., Zanoletti O., Lozano L., Canto C., Sandi C., Mitochondrial function in the brain links anxiety with social subordination, Proc. Natl. Acad. Sci. U. S. A, 112, pp. 15486-15491, (2015); Hu L., Jin L., Xia D., Zhang Q., Ma L., Zheng H., Et al., Nitrate ameliorates dextran sodium sulfate-induced colitis by regulating the homeostasis of the intestinal microbiota, Free Radic. Biol. Med, 152, pp. 609-621, (2020); Huang J., Huang J., Li Y., Wang Y., Wang F., Qiu X., Et al., Sodium alginate modulates immunity, intestinal mucosal barrier function, and gut microbiota in cyclophosphamide-induced immunosuppressed BALB/c mice, J. Agric. Food Chem, 69, pp. 7064-7073, (2021); Huang S.T., Song Z.J., Liu Y., Luo W.C., Yin Q., Zhang Y.M., BNST (AV) (GABA)-PVN (CRF) circuit regulates visceral hypersensitivity induced by maternal separation in Vgat-Cre mice, Front. Pharmacol, 12, (2021); Ibrahim A., Hugerth L.W., Hases L., Saxena A., Seifert M., Thomas Q., Et al., Colitis-induced colorectal cancer and intestinal epithelial estrogen receptor beta impact gut microbiota diversity, Int. J. Cancer, 144, pp. 3086-3098, (2019); Ju T., Naliboff B.D., Shih W., Presson A.P., Liu C., Gupta A., Et al., Risk and protective factors related to early adverse life events in irritable bowel syndrome, J. Clin. Gastroenterol, 54, pp. 63-69, (2020); Kan L., Guo F., Liu Y., Pham V.H., Guo Y., Wang Z., Probiotics Bacillus licheniformis improves intestinal health of subclinical necrotic enteritis-challenged broilers, Front. Microbiol, 12, (2021); Kasahara T., Takata A., Kato T.M., Kubota-Sakashita M., Sawada T., Kakita A., Et al., Depression-like episodes in mice harboring mtDNA deletions in paraventricular thalamus, Mol. Psychiatry, 21, pp. 39-48, (2016); Khorjahani A., Peeri M., Azarbayjani M.A., The therapeutic effect of exercise on anxiety and bowel oxidative stress in the maternal separation animal model, Basic Clin. Neurosci, 11, pp. 69-78, (2020); Kuti D., Winkler Z., Horvath K., Juhasz B., Paholcsek M., Stagel A., Et al., Gastrointestinal (non-systemic) antibiotic rifaximin differentially affects chronic stress-induced changes in colon microbiome and gut permeability without effect on behavior, Brain Behav. Immun, 84, pp. 218-228, (2020); Lacy B.E., Pimentel M., Brenner D.M., Chey W.D., Keefer L.A., Long M.D., Et al., ACG clinical guideline: Management of Irritable Bowel Syndrome, Am. J. Gastroenterol, 116, pp. 17-44, (2021); Lam J., Katti P., Biete M., Mungai M., Ashshareef S., Neikirk K., Et al., A universal approach to analyzing transmission Electron microscopy with ImageJ, Cells, 10, (2021); Laursen M.F., Bahl M.I., Licht T.R., Settlers of our inner surface - factors shaping the gut microbiota from birth to toddlerhood, FEMS Microbiol. Rev, 45, (2021); Lee S.H., Jung E.-M., Adverse effects of early-life stress: focus on the rodent neuroendocrine system, Neural Regen. Res, 19, pp. 336-341, (2024); Leyrolle Q., Decoeur F., Briere G., Amadieu C., Quadros A.R.A.A., Voytyuk I., Et al., Maternal dietary omega-3 deficiency worsens the deleterious effects of prenatal inflammation on the gut-brain axis in the offspring across lifetime. Neuropsychopharmacology: official publication of the American college of, Neuropsychopharmacology, 46, pp. 579-602, (2021); Li Y.-C., Wang Q., Li M.-G., Hu S.-F., Xu G.-Y., A paraventricular hypothalamic nucleus input to ventral of lateral septal nucleus controls chronic visceral pain, Pain, 164, pp. 625-637, (2023); Litvak Y., Byndloss M.X., Baumler A.J., Colonocyte metabolism shapes the gut microbiota, Science, 362, (2018); Liu L., Cheng S., Qi X., Meng P., Yang X., Pan C., Et al., Mitochondria-wide association study observed significant interactions of mitochondrial respiratory and the inflammatory in the development of anxiety and depression, Transl. Psychiatry, 13, (2023); Liu X.L., Zhao Y.C., Zhu H.Y., Wu M., Zheng Y.N., Yang M., Et al., Taxifolin retards the D-galactose-induced aging process through inhibiting Nrf2-mediated oxidative stress and regulating the gut microbiota in mice, Food Funct, 12, pp. 12142-12158, (2021); Low E.X.S., Mandhari M., Herndon C.C., Loo E.X.L., Tham E.H., Siah K.T.H., Parental, perinatal, and childhood risk factors for development of irritable bowel syndrome: a systematic review, J Neurogastroenterol. Motil, 26, pp. 437-446, (2020); Maltz R.M., Keirsey J., Kim S.C., Mackos A.R., Gharaibeh R.Z., Moore C.C., Et al., Prolonged restraint stressor exposure in outbred CD-1 mice impacts microbiota, colonic inflammation, and short chain fatty acids, PLoS One, 13, (2018); Martin-Gallausiaux C., Marinelli L., Blottiere H.M., Larraufie P., Lapaque N., SCFA: mechanisms and functional importance in the gut, Proc. Nutr. Soc, 80, pp. 37-49, (2021); Matsumoto H., Shiotani A., Katsumata R., Fukushima S., Handa Y., Osawa M., Et al., Mucosa-associated microbiota in patients with irritable bowel syndrome: a comparison of subtypes, Digestion, 102, pp. 49-56, (2021); Mcnamara M.P., Singleton J.M., Cadney M.D., Ruegger P.M., Borneman J., Garland T., Early-life effects of juvenile Western diet and exercise on adult gut microbiome composition in mice, J. Exp. Biol, 224, (2021); Mishima Y., Ishihara S., Enteric microbiota-mediated serotonergic signaling in pathogenesis of irritable bowel syndrome, Int. J. Mol. Sci, 22, (2021); Oh J.K., Vasquez R., Hwang I.C., Oh Y.N., Kim S.H., Kang S.H., Et al., Cudrania tricuspidata combined with Lacticaseibacillus rhamnosus modulate gut microbiota and alleviate obesity-associated metabolic parameters in obese mice, Microorganisms, 9, (2021); Osadchiy V., Martin C.R., Mayer E.A., The gut-brain Axis and the microbiome: mechanisms and clinical implications, Clin. Gastroenterol. Hepatol, 17, pp. 322-332, (2019); Pagliai G., Russo E., Niccolai E., Dinu M., Di Pilato V., Magrini A., Et al., Influence of a 3-month low-calorie Mediterranean diet compared to the vegetarian diet on human gut microbiota and SCFA: the CARDIVEG study, Eur. J. Nutr, 59, pp. 2011-2024, (2020); Park H.J., Kim S.A., Kang W.S., Kim J.W., Early-life stress modulates gut microbiota and peripheral and central inflammation in a sex-dependent manner, Int. J. Mol. Sci, 22, (2021); Park S.H., Videlock E.J., Shih W., Presson A.P., Mayer E.A., Chang L., Adverse childhood experiences are associated with irritable bowel syndrome and gastrointestinal symptom severity, Neurogastroenterol. Motil, 28, pp. 1252-1260, (2016); Petitfils C., Maurel S., Payros G., Hueber A., Agaiz B., Gazzo G., Et al., Identification of bacterial lipopeptides as key players in IBS, Gut, 72, pp. 939-950, (2023); Picard M., Mcewen B.S., Psychological stress and mitochondria: a systematic review, Psychosom. Med, 80, pp. 141-153, (2018); Rashidi A., Peled J.U., Ebadi M., Rehman T.U., Elhusseini H., Marcello L.T., Et al., Protective effect of intestinal Blautia against neutropenic fever in allogeneic transplant recipients, Clin. Infect. Dis. Off. Public. Infect. Dis. Soc. Am, 75, pp. 1912-1920, (2022); Rath E., Moschetta A., Haller D., Mitochondrial function - gatekeeper of intestinal epithelial cell homeostasis, Nat. Rev. Gastroenterol. Hepatol, 15, pp. 497-516, (2018); Ratsika A., Codagnone M.C., O'mahony S., Stanton C., Cryan J.F., Priming for life: early life nutrition and the microbiota-gut-brain Axis, Nutrients, 13, (2021); Riba A., Olier M., Lacroix-Lamande S., Lencina C., Bacquie V., Harkat C., Et al., Early life stress in mice is a suitable model for irritable bowel syndrome but does not predispose to colitis nor increase susceptibility to enteric infections, Brain Behav. Immun, 73, pp. 403-415, (2018); Rincel M., Darnaudery M., Maternal separation in rodents: a journey from gut to brain and nutritional perspectives, Proc. Nutr. Soc, 79, pp. 113-132, (2020); Rosario D., Bidkhori G., Lee S., Bedarf J., Hildebrand F., Le Chatelier E., Et al., Systematic analysis of gut microbiome reveals the role of bacterial folate and homocysteine metabolism in Parkinson's disease, Cell Rep, 34, (2021); Saulnier D.M., Riehle K., Mistretta T.A., Diaz M.A., Mandal D., Raza S., Et al., Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome, Gastroenterology, 141, pp. 1782-1791, (2011); Schmitt C.C., Aranias T., Viel T., Chateau D., Le Gall M., Waligora-Dupriet A.J., Et al., Intestinal invalidation of the glucose transporter GLUT2 delays tissue distribution of glucose and reveals an unexpected role in gut homeostasis, Mol. Metab, 6, pp. 61-72, (2017); Song Y.F., Pei L.X., Chen L., Geng H., Yuan M.Q., Xu W.L., Et al., Electroacupuncture relieves irritable bowel syndrome by regulating IL-18 and gut microbial Dysbiosis in a Trinitrobenzene sulfonic acid-induced post-inflammatory animal model, Am. J. Chin. Med, 48, pp. 77-90, (2020); Sperber A.D., Bangdiwala S.I., Drossman D.A., Ghoshal U.C., Simren M., Tack J., Et al., Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome foundation global study, Gastroenterology, 160, pp. 99-114.e3, (2021); Sun D., Ge X., Tang S., Liu Y., Sun J., Zhou Y., Et al., Bacterial characteristics of intestinal tissues from patients with Crohn's disease, Front. Cell. Infect. Microbiol, 11, (2021); Takihara H., Okuda S., Glycan-related genes in human gut microbiota exhibit differential distribution and diversity in carbohydrate degradation and glycan synthesis, Front. Mol. Biosci, 10, (2023); Tao E., Long G., Yang T., Chen B., Guo R., Ye D., Et al., Maternal separation induced visceral hypersensitivity evaluated via novel and small size distention balloon in post-weaning mice, Front. Neurosci, 15, (2022); Tao E., Zhu Z., Hu C., Long G., Chen B., Guo R., Et al., Potential roles of Enterochromaffin cells in early life stress-induced irritable bowel syndrome, Front. Cell. Neurosci, 16, (2022); Tesfaye M., Jaholkowski P., Hindley G.F.L., Shadrin A.A., Rahman Z., Bahrami S., Et al., Shared genetic architecture between irritable bowel syndrome and psychiatric disorders reveals molecular pathways of the gut-brain axis, Genome Med, 15, (2023); Torres-Maravilla E., Holowacz S., Delannoy J., Lenoir L., Jacouton E., Gervason S., Et al., Serpin-positive Bifidobacterium breve CNCM I-5644 improves intestinal permeability in two models of irritable bowel syndrome, Sci. Rep, 12, (2022); Toubal A., Kiaf B., Beaudoin L., Cagninacci L., Rhimi M., Fruchet B., Et al., Mucosal-associated invariant T cells promote inflammation and intestinal dysbiosis leading to metabolic dysfunction during obesity, Nat. Commun, 11, (2020); Van Orten-Luiten A.C.B., De Roos N.M., Majait S., Witteman B.J.M., Witkamp R.F., Effects of Cannabidiol chewing gum on perceived pain and well-being of irritable bowel syndrome patients: a placebo-controlled crossover exploratory intervention study with symptom-driven dosing, Cann. Cannab. Res, 7, pp. 436-444, (2022); Vicario M., Alonso C., Guilarte M., Serra J., Martinez C., Gonzalez-Castro A.M., Et al., Chronic psychosocial stress induces reversible mitochondrial damage and corticotropin-releasing factor receptor type-1 upregulation in the rat intestine and IBS-like gut dysfunction, Psychoneuroendocrinology, 37, pp. 65-77, (2012); Wang J., Duan G., Zhan T., Dong Z., Zhang Y., Chen Y., Et al., Upregulation of Netrin-1 in the hippocampus mediates the formation of visceral hypersensitivity induced by maternal separation, Front. Mol. Neurosci, 15, (2022); Wang J., Zhang C., Guo C., Li X., Chitosan ameliorates DSS-induced ulcerative colitis mice by enhancing intestinal barrier function and improving microflora, Int. J. Mol. Sci, 20, (2019); Wei W., Jiang W., Tian Z., Wu H., Ning H., Yan G., Et al., Fecal g. Streptococcus and g. Eubacterium_coprostanoligenes_group combined with sphingosine to modulate the serum dyslipidemia in high-fat diet mice, Clin. Nutr, 40, pp. 4234-4245, (2021); Wong H.L.X., Qin H.Y., Tsang S.W., Zuo X., Che S., Chow C.F.W., Et al., Early life stress disrupts intestinal homeostasis via NGF-TrkA signaling, Nat. Commun, 10, (2019); Wu K., Gao J.H., Hua R., Peng X.H., Wang H., Zhang Y.M., Predisposition of neonatal maternal separation to visceral hypersensitivity via downregulation of small-conductance calcium-activated Potassium Channel subtype 2 (SK2) in mice, Neural Plast, 2020, pp. 8876230-8876215, (2020); Wu F., Lei H., Chen G., Chen C., Song Y., Cao Z., Et al., In vitro and in vivo studies reveal that Hesperetin-7-O-glucoside, a naturally occurring Monoglucoside, exhibits strong anti-inflammatory capacity, J. Agric. Food Chem, 69, pp. 12753-12762, (2021); Wu Y., Ran L., Yang Y., Gao X., Peng M., Liu S., Et al., Deferasirox alleviates DSS-induced ulcerative colitis in mice by inhibiting ferroptosis and improving intestinal microbiota, Life Sci, 314, (2023); Xiao L., Liu Q., Luo M., Xiong L., Gut microbiota-derived metabolites in irritable bowel syndrome, Front. Cell. Infect. Microbiol, 11, (2021); Xie X.Q., Geng Y., Guan Q., Ren Y., Guo L., Lv Q., Et al., Influence of short-term consumption of Hericium erinaceus on serum biochemical markers and the changes of the gut microbiota: a pilot study, Nutrients, 13, (2021); Xu Y., Yu Y., Shen Y., Li Q., Lan J., Wu Y., Et al., Effects of Bacillus subtilis and Bacillus licheniformis on growth performance, immunity, short chain fatty acid production, antioxidant capacity, and cecal microflora in broilers, Poult. Sci, 100, (2021); Yang D.-F., Huang W.-C., Wu C.W., Huang C.-Y., Yang Y.C.S.H., Tung Y.-T., Acute sleep deprivation exacerbates systemic inflammation and psychiatry disorders through gut microbiota dysbiosis and disruption of circadian rhythms, Microbiol. Res, 268, (2023); Yao Y., Cai X., Fei W., Ye Y., Zhao M., Zheng C., The role of short-chain fatty acids in immunity, inflammation and metabolism, Crit. Rev. Food Sci. Nutr, 62, pp. 1-12, (2020); Ye D., Hu Y., Zhu N., Gu W., Long G., Tao E., Et al., Exploratory investigation of intestinal structure and function after stroke in mice, Mediat. Inflamm, 2021, pp. 1315797-1315712, (2021); Yi L., Zhang H., Sun H., Zhou L., Chen Y., Xuan L., Et al., Maternal separation induced visceral hypersensitivity from childhood to adulthood, J. Neurogastroenterol. Motil, 23, pp. 306-315, (2017); Yoon C.H., Ryu J.S., Moon J., Kim M.K., Association between aging-dependent gut microbiome dysbiosis and dry eye severity in C57BL/6 male mouse model: a pilot study, BMC Microbiol, 21, (2021); Yu Y.B., Zuo X.L., Zhao Q.J., Chen F.X., Yang J., Dong Y.Y., Et al., Brain-derived neurotrophic factor contributes to abdominal pain in irritable bowel syndrome, Gut, 61, pp. 685-694, (2012); Yuan Y., Lu L., Bo N., Chaoyue Y., Haiyang Y., Allicin ameliorates intestinal barrier damage via microbiota-regulated short-chain fatty acids-TLR4/MyD88/NF-κB Cascade response in acrylamide-induced rats, J. Agric. Food Chem, 69, pp. 12837-12852, (2021); Zhang Z.-W., Gao C.-S., Zhang H., Yang J., Wang Y.-P., Pan L.-B., Et al., Morinda officinalis oligosaccharides increase serotonin in the brain and ameliorate depression via promoting 5-hydroxytryptophan production in the gut microbiota, Acta Pharm. Sin. B, 12, pp. 3298-3312, (2022); Zhang H., Geng X., Li Z., Li Y., Xu K., Wu H., Et al., Paeonol at certain doses alleviates aggressive and anxiety-like behaviours in two premenstrual dysphoric disorder rat models, Front. Psych, 11, (2020); Zhang J.D., Liu J., Zhu S.W., Fang Y., Wang B., Jia Q., Et al., Berberine alleviates visceral hypersensitivity in rats by altering gut microbiome and suppressing spinal microglial activation, Acta Pharmacol. Sin, 42, pp. 1821-1833, (2021); Zhang Y., Zhang J., Duan L., The role of microbiota-mitochondria crosstalk in pathogenesis and therapy of intestinal diseases, Pharmacol. Res, 186, (2022); Zhang Y., Zhang H., Zhang W., Zhang Y., Wang W., Nie L., LncRNA XIST modulates 5-hydroxytrytophan-induced visceral hypersensitivity by epigenetic silencing of the SERT gene in mice with diarrhea-predominant IBS, Cell. Signal, 73, (2020); Zhang Q., Zhong D., Sun R., Zhang Y., Pegg R.B., Zhong G., Prevention of loperamide induced constipation in mice by KGM and the mechanisms of different gastrointestinal tract microbiota regulation, Carbohydr. Polym, 256, (2021); Zhao X., Jiang L., Fang X., Guo Z., Wang X., Shi B., Et al., Host-microbiota interaction-mediated resistance to inflammatory bowel disease in pigs, Microbiome, 10, (2022); Zhou L., Wu Z., Li Y., Xiao L., Wang H., Wang G., Brief maternal separation promotes resilience to anxiety-like and depressive-like behaviors in female C57BL/6J offspring with Imiquimod-induced psoriasis, Brain Sci, 12, (2022); Zhou Y., Zhang F., Mao L., Feng T., Wang K., Xu M., Et al., Bifico relieves irritable bowel syndrome by regulating gut microbiota dysbiosis and inflammatory cytokines, Eur. J. Nutr, 62, pp. 139-155, (2023); Zhuang X., Tian Z., Li L., Zeng Z., Chen M., Xiong L., Fecal microbiota alterations associated with diarrhea-predominant irritable bowel syndrome, Front. Microbiol, 9, (2018); Zitkovsky E.K., Daniels T.E., Tyrka A.R., Mitochondria and early-life adversity, Mitochondrion, 57, pp. 213-221, (2021)","M. Jiang; Pediatric Endoscopy Center and Gastrointestinal Laboratory, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China; email: mizu@zju.edu.cn","","Frontiers Media SA","","","","","","1664302X","","","","English","Front. Microbiol.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85174277827"

"Linsalata M.; Prospero L.; Riezzo G.; Orlando A.; D'Attoma B.; Ignazzi A.; Russo F.","Linsalata, Michele (6603600075); Prospero, Laura (57207799778); Riezzo, Giuseppe (7004144336); Orlando, Antonella (23767683100); D'Attoma, Benedetta (8554891800); Ignazzi, Antonia (57206193613); Russo, Francesco (59133987100)","6603600075; 57207799778; 7004144336; 23767683100; 8554891800; 57206193613; 59133987100","Somatization is associated with altered serum levels of vitamin D, serotonin, and brain-derived neurotrophic factor in patients with predominant diarrhea irritable bowel syndrome","2023","Neurogastroenterology and Motility","35","3","e14512","","","","2","10.1111/nmo.14512","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85144160885&doi=10.1111%2fnmo.14512&partnerID=40&md5=1320e9642c7a1b00fb6d1d76931f8fe9","Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte, Italy","Linsalata M., Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte, Italy; Prospero L., Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte, Italy; Riezzo G., Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte, Italy; Orlando A., Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte, Italy; D'Attoma B., Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte, Italy; Ignazzi A., Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte, Italy; Russo F., Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte, Italy","Background: Patients with irritable bowel syndrome (IBS) often show psychological disorders, including somatization, usually driven by an altered gut–brain axis. These changes are also accompanied by modifications in the circulating levels of vitamin D (VD) and neurotransmitters such as serotonin (5-HT) and brain-derived neurotrophic factor (BDNF). The present study aimed to evaluate the relationship between gastrointestinal (GI) symptoms and circulating levels of VD, 5-HT, and BDNF in IBS patients with diarrhea (IBS-D) categorized according to somatization. Methods: Fifty-three IBS-D patients were recruited and profiled for GI symptoms by validated questionnaires. The fasting serum concentrations of VD, 5-HT, and BDNF were assessed. The health of the intestinal barrier, minimal inflammation, and dysbiosis was also evaluated. Key Results: Thirty patients showed high somatization scores, IBS-D(S+), and 23 low somatization scores, IBS-D(S-). IBS-D(S+) patients reported higher “Abdominal pain” and the “Abdominal pain duration in days” scores, lower serum VD levels and increased 5-HT and BDNF concentrations than IBS-D(S-). Besides, in IBS-D(S+) patients, the GI symptoms correlated with 5HT, BDNF, and VD concentrations. These parameters were associated with impaired small intestinal permeability and increased inflammation markers. Conclusions and Inferences: These data support the multifactorial IBS pathogenesis in which organic and psychological factors interact. An active role by VD, 5-HT, and BDNF in affecting the clinical and biochemical profiles in IBS-D(S+) patients may be conceivable. Therefore, the routine VD estimation and the assay of circulating levels of 5-HT and BDNF could be considered a new approach for managing these patients. © 2022 The Authors. Neurogastroenterology & Motility published by John Wiley & Sons Ltd.","5-HT; abdominal pain; BDNF; gastrointestinal symptom profile; inflammation; irritable bowel syndrome; vitamin D","Abdominal Pain; Brain-Derived Neurotrophic Factor; Diarrhea; Humans; Inflammation; Irritable Bowel Syndrome; Serotonin; Vitamin D; 25 hydroxyvitamin D; amine oxidase (copper containing); brain derived neurotrophic factor; C reactive protein; fatty acid binding protein 2; indole; interleukin 10; interleukin 6; interleukin 8; lactulose; lipopolysaccharide; mannitol; serotonin; skatole; tumor necrosis factor; brain derived neurotrophic factor; serotonin; vitamin D; abdominal distension; abdominal pain; acid regurgitation; adult; anxiety disorder; Article; bacterial translocation; biochemical analysis; blood cell count; borborygmus; chemoluminescence; colonoscopy; colorimetry; defecation habit; defecation urgency; depression; diarrhea; dysbiosis; dyspepsia; enzyme linked immunosorbent assay; epigastrium sucking sensation; eructation; fasting; fecal parasite testing; feces culture; female; flatulence; follicular phase; gastrointestinal symptom; gastrointestinal symptom rating scale; gastroscopy; Global Severity Index; halitosis; heartburn; high performance liquid chromatography; human; IBS Severity Scoring System; indigestion; inflammation; irritable colon; liver function test; loose feces; major clinical study; male; membrane permeability; occult blood test; pathogenesis; physical examination; protein blood level; psychological aspect; questionnaire; somatization; Symptom Checklist 90-Revised; thyroid function; urine level; urine sampling; urine volume; vitamin blood level; abdominal pain; complication; diarrhea; irritable colon","","25 hydroxyvitamin D, 64719-49-9; amine oxidase (copper containing), 9001-53-0, 9014-75-9; brain derived neurotrophic factor, 218441-99-7; C reactive protein, 9007-41-4; indole, 120-72-9; interleukin 8, 114308-91-7; lactulose, 4618-18-2, 58166-24-8; mannitol, 69-65-8, 87-78-5; serotonin, 50-67-9; skatole, 83-34-1; Brain-Derived Neurotrophic Factor, ; Serotonin, ; Vitamin D, ","Indican Assay Kit, Abnova","Abnova","Italian Ministry of Health RC 2020","This research was funded by the Italian Ministry of Health RC 2020–2021, Prog. N° 16 (DDG n. 700/2020). ","Schmulson M.J., Drossman D.A., What is new in Rome IV, J Neurogastroenterol Motil, 23, 2, pp. 151-163, (2017); Lydiard R.B., Falsetti S.A., Experience with anxiety and depression treatment studies: implications for designing irritable bowel syndrome clinical trials, Am J Med, 107, 5A, pp. 65 S-73 S, (1999); Peter J., Fournier C., Durdevic M., Et al., A microbial signature of psychological distress in irritable bowel syndrome, Psychosom Med, 80, 8, pp. 698-709, (2018); Lipowski Z.J., Somatization: the concept and its clinical application, Am J Psychiatry, 145, 11, pp. 1358-1368, (1988); Shiha M.G., Asghar Z., Thoufeeq M., Et al., Increased psychological distress and somatization in patients with irritable bowel syndrome compared with functional diarrhea or functional constipation, based on Rome IV criteria, Neurogastroenterol Motil, 33, 10, (2021); Grinsvall C., van Oudenhove L., Dupont P., Et al., Altered structural covariance of insula, cerebellum and prefrontal cortex is associated with somatic symptom levels in irritable bowel syndrome (IBS), Brain Sci, 11, 12, (2021); Prospero L., Riezzo G., Linsalata M., Et al., Somatization in patients with predominant diarrhoea irritable bowel syndrome: the role of the intestinal barrier function and integrity, BMC Gastroenterol, 21, 1, (2021); Linsalata M., Riezzo G., Orlando A., Et al., The relationship between low serum vitamin D levels and altered intestinal barrier function in patients with IBS Diarrhoea undergoing a long-term low-FODMAP diet: novel observations from a clinical trial, Nutrients, 13, 3, (2021); Anglin R.E., Samaan Z., Walter S.D., McDonald S.D., Vitamin D deficiency and depression in adults: systematic review and meta-analysis, Br J Psychiatry, 202, pp. 100-107, (2013); Chen L., Zhu H., Harshfield G.A., Et al., Serum 25-Hydroxyvitamin D concentrations are associated with mental health and psychosocial stress in young adults, Nutrients, 12, 7, (2020); Berk M., Williams L.J., Jacka F.N., Et al., So depression is an inflammatory disease, but where does the inflammation come from?, BMC Med, 11, (2013); Srivastava S., Bhatia M.S., Gautam P., 25 Hydroxyvitamin D levels, quality of life, and disability in long-standing patients of somatization, Ind Psychiatry J, 27, 1, pp. 87-91, (2018); Ancona A., Petito C., Iavarone I., Et al., The gut-brain axis in irritable bowel syndrome and inflammatory bowel disease, Dig Liver Dis, 53, 3, pp. 298-305, (2021); Goltz A., Janowitz D., Hannemann A., Et al., Association of Brain-Derived neurotrophic factor and vitamin D with depression and obesity: a population-based study, Neuropsychobiology, 76, 4, pp. 171-181, (2017); Huiberts L.M., Smolders K., Effects of vitamin D on mood and sleep in the healthy population: interpretations from the serotonergic pathway, Sleep Med Rev, 55, (2021); Martinowich K., Lu B., Interaction between BDNF and serotonin: role in mood disorders, Neuropsychopharmacology, 33, 1, pp. 73-83, (2008); Garvin B., Wiley J.W., The role of serotonin in irritable bowel syndrome: implications for management, Curr Gastroenterol Rep, 10, 4, pp. 363-368, (2008); Spiller R., Aziz Q., Creed F., Et al., Guidelines on the irritable bowel syndrome: mechanisms and practical management, Gut, 56, 12, pp. 1770-1798, (2007); Atkinson W., Lockhart S., Whorwell P.J., Keevil B., Houghton L.A., Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome, Gastroenterology, 130, 1, pp. 34-43, (2006); Koopman N., Katsavelis D., Hove A.S.T., Brul S., Jonge W.J., Seppen J., The multifaceted role of serotonin in intestinal homeostasis, Int J Mol Sci, 22, 17, (2021); Yu Y.B., Zhao D.Y., Qi Q.Q., Et al., BDNF modulates intestinal barrier integrity through regulating the expression of tight junction proteins, Neurogastroenterol Motil, 29, 3, (2017); Russo F., Chimienti G., Riezzo G., Et al., Adipose tissue-derived biomarkers of intestinal barrier functions for the characterization of Diarrhoea-predominant IBS, Dis Markers, 2018, (2018); Weaver K.R., Boulineaux C.M., Robinson J.M., Butler K., Heitkemper M.M., Henderson W.A., Sex Hormones, BDNF, Leptin, and TGF-beta1 in females with IBS: a pilot investigation, Biol Res Nurs, 23, 2, pp. 231-237, (2021); Schmulson M., Lee O.Y., Chang L., Naliboff B., Mayer E.A., Symptom differences in moderate to severe IBS patients based on predominant bowel habit, Am J Gastroenterol, 94, 10, pp. 2929-2935, (1999); Francis C.Y., Morris J., Whorwell P.J., The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress, Aliment Pharmacol Ther, 11, 2, pp. 395-402, (1997); Kulich K.R., Madisch A., Pacini F., Et al., Reliability and validity of the gastrointestinal symptom rating scale (GSRS) and quality of life in reflux and dyspepsia (QOLRAD) questionnaire in dyspepsia: a six-country study, Health Qual Life Outcomes, 6, (2008); Derogatis L.R., Lipman R.S., Covi L., SCL-90: an outpatient psychiatric rating scale—preliminary report, Psychopharmacol Bull, 9, 1, pp. 13-28, (1973); Hildenbrand A.K., Nicholos E.G., Aggarwall R., Brody-Bizar E., Daly B.P., Symptom Checklist-90-revised (SCL-90-R), The Encyclopedia of Clinical Psychology, pp. 1-5, (2015); Jensen H.H., Mortensen E.L., Lotz M., Scl-90-R symptom profiles and outcome of short-term psychodynamic group therapy, ISRN Psychiatry, 2013, (2013); Linsalata M., D'Attoma B., Orlando A., Guerra V., Russo F., Comparison of an enzymatic assay with liquid chromatography-pulsed amperometric detection for the determination of lactulose and mannitol in urine of healthy subjects and patients with active celiac disease, Clin Chem Lab Med, 52, 4, pp. e61-e64, (2014); Linsalata M., Riezzo G., D'Attoma B., Clemente C., Orlando A., Russo F., Noninvasive biomarkers of gut barrier function identify two subtypes of patients suffering from diarrhoea predominant-IBS: a case-control study, BMC Gastroenterol, 18, 1, (2018); Camilleri M., Diagnosis and treatment of irritable bowel syndrome: a review, JAMA, 325, 9, pp. 865-877, (2021); Shiha M.G., Aziz I., Review article: physical and psychological comorbidities associated with irritable bowel syndrome, Aliment Pharmacol Ther, 54, pp. S12-S23, (2021); Whitehead W.E., Palsson O., Jones K.R., Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications?, Gastroenterology, 122, 4, pp. 1140-1156, (2002); Rhee S.H., Pothoulakis C., Mayer E.A., Principles and clinical implications of the brain-gut-enteric microbiota axis, Nat Rev Gastroenterol Hepatol, 6, 5, pp. 306-314, (2009); Aziz M.N.M., Kumar J., Muhammad Nawawi K.N., Raja Ali R.A., Mokhtar N.M., Irritable bowel syndrome, depression, and neurodegeneration: a bidirectional communication from gut to brain, Nutrients, 13, 9, (2021); Mayer E.A., Labus J., Aziz Q., Et al., Role of brain imaging in disorders of brain-gut interaction: a Rome working team report, Gut, 68, 9, pp. 1701-1715, (2019); Gros M., Gros B., Mesonero J.E., Latorre E., Neurotransmitter dysfunction in irritable bowel syndrome: emerging approaches for management, J Clin Med, 10, 15, (2021); Williams C.E., Williams E.A., Corfe B.M., Vitamin D status in irritable bowel syndrome and the impact of supplementation on symptoms: what do we know and what do we need to know?, Eur J Clin Nutr, 72, 10, pp. 1358-1363, (2018); Barbalho S.M., Goulart R.A., Araujo A.C., Guiguer E.L., Bechara M.D., Irritable bowel syndrome: a review of the general aspects and the potential role of vitamin D, Expert Rev Gastroenterol Hepatol, 13, 4, pp. 345-359, (2019); Khalighi Sikaroudi M., Mokhtare M., Shidfar F., Et al., Effects of vitamin D3 supplementation on clinical symptoms, quality of life, serum serotonin (5-hydroxytryptamine), 5-hydroxy-indole acetic acid, and ratio of 5-HIAA/5-HT in patients with diarrhea-predominant irritable bowel syndrome: a randomized clinical trial, EXCLI J, 19, pp. 652-667, (2020); Luo M., Zhuang X., Tian Z., Xiong L., Alterations in short-chain fatty acids and serotonin in irritable bowel syndrome: a systematic review and meta-analysis, BMC Gastroenterol, 21, 1, (2021); di Tommaso N., Gasbarrini A., Ponziani F.R., Intestinal Barrier in Human Health and Disease, Int J Environ Res Public Health, 18, 23, (2021); Mishima Y., Ishihara S., Enteric microbiota-mediated serotonergic signaling in pathogenesis of irritable bowel syndrome, Int J Mol Sci, 22, 19, (2021); Homberg J.R., Molteni R., Calabrese F., Riva M.A., The serotonin-BDNF duo: developmental implications for the vulnerability to psychopathology, Neurosci Biobehav Rev, 43, pp. 35-47, (2014); Katsui R., Kojima Y., Kuniyasu H., Et al., A new possibility for repairing the anal dysfunction by promoting regeneration of the reflex pathways in the enteric nervous system, Am J Physiol Gastrointest Liver Physiol, 294, 4, pp. G1084-G1093, (2008); Grider J.R., Piland B.E., Gulick M.A., Qiao L.Y., Brain-derived neurotrophic factor augments peristalsis by augmenting 5-HT and calcitonin gene-related peptide release, Gastroenterology, 130, 3, pp. 771-780, (2006); Zhang Y., Bi Y.X., Chen J., Et al., Association of Peroxiredoxin 1 and brain-derived neurotrophic factor serum levels with depression and anxiety symptoms in patients with irritable bowel syndrome, Gen Hosp Psychiatry, 68, pp. 59-64, (2021); Caviedes A., Lafourcade C., Soto C., Wyneken U., BDNF/NF-kappaB signaling in the neurobiology of depression, Curr Pharm des, 23, 21, pp. 3154-3163, (2017)","F. Russo; Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte, Via Turi 27, (Ba), 70013, Italy; email: francesco.russo@irccsdebellis.it","","John Wiley and Sons Inc","","","","","","13501925","","NMOTE","36520620","English","Neurogastroenterol. Motil.","Article","Final","All Open Access; Hybrid Gold Open Access","Scopus","2-s2.0-85144160885"

"Hou Y.; Zhao Y.; Jiang H.; Wang K.; Zhang W.; Zhou S.; Li Y.; Zheng Q.","Hou, Yujun (57221710391); Zhao, Ying (57215065894); Jiang, Huiling (57221711465); Wang, Kai (57353229500); Zhang, Wei (59063263800); Zhou, Siyuan (55321777500); Li, Ying (55916594900); Zheng, Qianhua (56178980000)","57221710391; 57215065894; 57221711465; 57353229500; 59063263800; 55321777500; 55916594900; 56178980000","Maintenance of Intestinal Homeostasis in Diarrhea-Predominant Irritable Bowel Syndrome by Electroacupuncture Through Submucosal Enteric Glial Cell-Derived S-Nitrosoglutathione","2022","Frontiers in Physiology","13","","917579","","","","5","10.3389/fphys.2022.917579","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85138294868&doi=10.3389%2ffphys.2022.917579&partnerID=40&md5=727bb7f480cec5cf62a8ad9cc5b772a9","Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, China; Department of Rehabilitation Medicine, West China Hospital, Sichuan University, China; Department of Traditional Chinese Medicine, the People's Hospital of Shifang, Shifang, China","Hou Y., Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, China; Zhao Y., Department of Rehabilitation Medicine, West China Hospital, Sichuan University, China; Jiang H., Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, China; Wang K., Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, China; Zhang W., Department of Traditional Chinese Medicine, the People's Hospital of Shifang, Shifang, China; Zhou S., Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, China; Li Y., Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, China; Zheng Q., Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, China","Objective: To determine whether electroacupuncture (EA) maintains intestinal homeostasis in diarrhea-predominant irritable bowel syndrome (IBS-D) rats by repairing intestinal barrier function through enteric glial cell (EGC)-derived S-nitrosoglutathione (GSNO). Methods: Sprague–Dawley rats were randomly divided into a control group (n = 10) and an IBS-D group (n = 20). These rats received senna solution by gavage and chronic unpredictable mild stress for 14 days and were further divided into a model group (n = 10) and an EA group (n = 10). Rats in the EA group were electroacupunctured at ST25 (Tianshu), ST36 (Zusanli), and LR3 (Taichong) for 20 min every day for 14 days. The abdominal withdrawal reflex (AWR), the percentage of time spent in open arms (OT%) in the elevated plus maze test, and the diarrhea index (DI) were measured. Histopathological examination was performed to evaluate the pathological features of the colon after sacrificing the rats. Transmission electron microscopy was used to observe the EGC in the muscle and submucosal layers. Enzyme-linked immunosorbent assay was performed to detect GSNO expression in the colon. Double immunofluorescence labeling was used to detect the colocalized GFAP and GSNO expressions in the muscle and submucosal layers. Plasma FITC-dextran was used to measure intestinal permeability, whereas western blot was used to detect ZO-1 and occludin expressions in the colon. Results: OT% and ZO-1 and occludin expressions were significantly lower than those of the control group, whereas AWR scores, DI, GSNO expression in the colon, colocalized GFAP and GSNO expressions in the submucosal layer, and intestinal permeability were significantly higher than those of the control group. Structural EGC abnormalities were observed in the model group. After EA treatment, OT% and ZO-1 and occludin expressions increased significantly, whereas AWR scores, DI, GSNO expression, colocalized GFAP and GSNO expressions in the submucosal layer, and intestinal permeability decreased significantly. The EGC structure was then restored to its normal state. Conclusion: EA treatment downregulates the submucosal EGC–derived GSNO expressions, repairs the intestinal barrier by upregulating the ZO-1 and occludin expression, and improves IBS-D symptoms, including visceral hypersensitivity, anxiety, and diarrhea, suggesting a potential role for EGC-derived GSNO in the regulation of intestinal homeostasis in IBS-D rats. Copyright © 2022 Hou, Zhao, Jiang, Wang, Zhang, Zhou, Li and Zheng.","electroacupuncture; enteric glial cell; intestinal barrier; irritable bowel syndrome; occludin; S-nitrosothiols; ZO-1","fluorescein isothiocyanate dextran; glial fibrillary acidic protein; occludin; protein ZO1; s nitrosoglutathione; Senna extract; abdominal withdrawal reflex; animal cell; animal experiment; animal model; animal tissue; anxiety; Article; chronic unpredictable mild stress; chronic unpredictable stress; clinical feature; colon tissue; controlled study; diarrhea; diarrhea index; down regulation; electroacupuncture; elevated plus maze test; enteric glia cell; enzyme linked immunosorbent assay; female; glia cell; histopathology; homeostasis; immunofluorescence assay; intestinal homeostasis; intestine cell; intestine mucosa permeability; intestine muscle; intestine parameters; irritable colon; nonhuman; permeability barrier; protein analysis; protein expression; protein polymorphism; protein structure; rat; reflex; Sprague Dawley rat; submucosa; taichong acupoint; therapy effect; tianshu acupoint; time spent in open arms; tissue repair; transmission electron microscopy; treatment duration; upregulation; visceral hyperalgesia; Western blotting; zusanli acupoint","","fluorescein isothiocyanate dextran, 60842-46-8; occludin, 176304-61-3; s nitrosoglutathione, 57564-91-7; Senna extract, 57828-25-8","","","National Natural Science Fund of China Youth Foundation Project, (81804207); Project of Xinglin Scholar Discipline Talent Scientific Research Promotion Program of Chengdu University of Traditional Chinese Medicine, (QJRC2021014); National Key Research and Development Program of China, NKRDPC, (YFC1712103); National Key Research and Development Program of China, NKRDPC","This work was supported by the National Natural Science Fund of China Youth Foundation Project (81804207), Project of Xinglin Scholar Discipline Talent Scientific Research Promotion Program of Chengdu University of Traditional Chinese Medicine (QJRC2021014), and National Key Research and Development Program of China (YFC1712103), which provided the authors with funding support. ","Aggarwal A., Singh I., Sandhir R., Protective Effect of S-Nitrosoglutathione Administration Against Hyperglycemia Induced Disruption of Blood Brain Barrier Is Mediated by Modulation of Tight Junction Proteins and Cell Adhesion Molecules, Neurochem. Int, 118, pp. 205-216, (2018); Al-Chaer E.D., Kawasaki M., Pasricha P.J., A New Model of Chronic Visceral Hypersensitivity in Adult Rats Induced by Colon Irritation during Postnatal Development, Gastroenterology, 119, pp. 1276-1285, (2000); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Lecleire S., Antonietti M., Gourcerol G., Et al., The Expression and the Cellular Distribution of the Tight Junction Proteins Are Altered in Irritable Bowel Syndrome Patients with Differences According to the Disease Subtype, Am. J. Gastroenterol, 106, pp. 2165-2173, (2011); Black C.J., Ford A.C., Global Burden of Irritable Bowel Syndrome: Trends, Predictions and Risk Factors, Nat. Rev. Gastroenterol. Hepatol, 17, pp. 473-486, (2020); Boesmans W., Hao M.M., Fung C., Li Z., Van den Haute C., Tack J., Et al., Structurally Defined Signaling in Neuro‐glia Units in the Enteric Nervous System, Glia, 67, pp. 1167-1178, (2019); Bonetti J., Zhou Y., Parent M., Clarot I., Yu H., Fries-Raeth I., Et al., Intestinal Absorption of S-Nitrosothiols: Permeability and Transport Mechanisms, Biochem. Pharmacol, 155, pp. 21-31, (2018); Broniowska K.A., Diers A.R., Hogg N., S-Nitrosoglutathione, Biochimica Biophysica Acta (BBA) - General Subj, 1830, pp. 3173-3181, (2013); Camilleri M., Leaky Gut: Mechanisms, Measurement and Clinical Implications in Humans, Gut, 68, pp. 1516-1526, (2019); Camilleri M., Madsen K., Spiller R., Van Meerveld B.G., Verne G.N., Intestinal Barrier Function in Health and Gastrointestinal Disease, Neurogastroenterol. Motil, 24, pp. 503-512, (2012); Cheadle G.A., Costantini T.W., Lopez N., Bansal V., Eliceiri B.P., Coimbra R., Enteric Glia Cells Attenuate Cytomix-Induced Intestinal Epithelial Barrier Breakdown, Plos One, 8, (2013); Chen Y., Zhao Y., Luo D.N., Zheng H., Li Y., Zhou S.Y., Electroacupuncture Regulates Disorders of Gut-Brain Interaction by Decreasing Corticotropin-Releasing Factor in a Rat Model of IBS, Gastroenterol. Res. Pract, 2019, (2019); Chey W.D., Kurlander J., Eswaran S., Irritable Bowel Syndrome: A Clinical Review, JAMA, 313, pp. 949-958, (2015); da Silva M.V., Marosti A.R., Mendes C.E., Palombit K., Castelucci P., Submucosal Neurons and Enteric Glial Cells Expressing the P2X7 Receptor in Rat Experimental Colitis, Acta Histochem, 119, pp. 481-494, (2017); Dolatabadi F., Abdolghaffari A.H., Farzaei M.H., Baeeri M., Ziarani F.S., Eslami M., Et al., The Protective Effect of Melissa officinalis L. in Visceral Hypersensitivity in Rat Using 2 Models of Acid-Induced Colitis and Stress-Induced Irritable Bowel Syndrome: A Possible Role of Nitric Oxide Pathway, J. Neurogastroenterol. Motil, 24, pp. 490-501, (2018); Flamant M., Aubert P., Rolli-Derkinderen M., Bourreille A., Neunlist M.R., Mahe M.M., Et al., Enteric Glia Protect Against Shigella Flexneri Invasion In intestinal Epithelial Cells: a Role for S-Nitrosoglutathione, Gut, 60, pp. 473-484, (2011); Ford A.C., Sperber A.D., Corsetti M., Camilleri M., Irritable Bowel syndrome, Lancet, 396, pp. 1675-1688, (2020); Fukudo S., Okumura T., Inamori M., Okuyama Y., Kanazawa M., Kamiya T., Et al., Evidence-Based Clinical Practice Guidelines for Irritable Bowel Syndrome 2020, J. Gastroenterol, 56, pp. 193-217, (2021); Groschwitz K.R., Hogan S.P., Intestinal Barrier Function: Molecular Regulation and Disease Pathogenesis, J. Allergy Clin. Immunol, 124, pp. 3-20, (2009); Hagbom M., De Faria F.M., Winberg M.E., Westerberg S., Nordgren J., Sharma S., Et al., Neurotrophic Factors Protect the Intestinal Barrier from Rotavirus Insult in Mice, mBio, 11, pp. e02834-e2819, (2020); Hanning N., Edwinson A.L., Ceuleers H., Peters S.A., De Man J.G., Hassett L.C., Et al., Intestinal Barrier Dysfunction in Irritable Bowel Syndrome: A Systematic Review, Ther. Adv. Gastroenterol, 14, (2021); Hou Q., Zhu S., Zhang C., Huang Y., Guo Y., Li P., Et al., Berberine Improves Intestinal Epithelial Tight Junctions by Upregulating A20 Expression in Ibs-D Mice, Biomed. Pharmacother, 118, (2019); Hu S., Zhao Z.-K., Liu R., Wang H.-B., Gu C.-Y., Luo H.-M., Et al., Electroacupuncture Activates Enteric Glial Cells and Protects the Gut Barrier In Hemorrhaged Rats, World J. Gastroenterol, 21, pp. 1468-1478, (2015); Huang J., Lu M., Zheng Y., Ma J., Ma X., Wang Y., Et al., Quality of Evidence Supporting the Role of Acupuncture for the Treatment of Irritable Bowel Syndrome, Pain Res. Manag, 2021, (2021); Kraeuter A.-K., Guest P.C., Sarnyai Z., The Elevated Plus Maze Test for Measuring Anxiety-Like Behavior in Rodents, Methods Mol. Biol, 1916, pp. 69-74, (2019); Li Z., Zhang X., Zhou H., Liu W., Li J., Exogenous S-Nitrosoglutathione Attenuates Inflammatory Response and Intestinal Epithelial Barrier Injury in Endotoxemic Rats, J. Trauma Acute Care Surg, 80, pp. 977-984, (2016); Meir M., Flemming S., Burkard N., Wagner J., Germer C.-T., Schlegel N., The Glial Cell-Line Derived Neurotrophic Factor: A Novel Regulator Of Intestinal Barrier Function In Health And Disease, Am. J. Physiology-Gastrointestinal Liver Physiology, 310, pp. G1118-G1123, (2016); Neunlist M., Van L., Mahe M.M., Derkinderen P., des Varannes S.B., Rolli-Derkinderen M., The Digestive Neuronal-Glial-Epithelial Unit: A New Actor In Gut Health And Disease, Nat. Rev. Gastroenterol. Hepatol, 10, pp. 90-100, (2013); Pei L., Chen H., Guo J., Chen L., Wu X., Xu W., Et al., Effect of Acupuncture And Its Influence on Visceral Hypersensitivity In IBS-D Patients: Study Protocol for a Randomized Controlled Trial, Med. Baltim, 97, (2018); Pei L., Geng H., Guo J., Yang G., Wang L., Shen R., Et al., Effect of Acupuncture in Patients With Irritable Bowel Syndrome: A Randomized Controlled Trial, Mayo Clin. Proc, 95, pp. 1671-1683, (2020); Pinto-Sanchez M.I., Hall G.B., Ghajar K., Nardelli A., Bolino C., Lau J.T., Et al., Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome, Gastroenterology, 153, pp. 448-459, (2017); Quigley E.M.M., Fried M., Gwee K.-A., Khalif I., Hungin A.P.S., Lindberg G., Et al., World Gastroenterology Organisation Global Guidelines Irritable Bowel Syndrome: A Global Perspective Update September 2015, J. Clin. Gastroenterol, 50, pp. 704-713, (2016); Saha L., Irritable Bowel Syndrome: Pathogenesis, Diagnosis, Treatment, and Evidence-Based Medicine, World J. Gastroenterol, 20, pp. 6759-6773, (2014); Savidge T.C., Newman P., Pothoulakis C., Ruhl A., Neunlist M., Bourreille A., Et al., Enteric Glia Regulate Intestinal Barrier Function and Inflammation Via Release of S-Nitrosoglutathione, Gastroenterology, 132, pp. 1344-1358, (2007); Song Y.-F., Pei L.-X., Chen L., Geng H., Yuan M.-Q., Xu W.-L., Et al., Electroacupuncture Relieves Irritable Bowel Syndrome by Regulating IL-18 and Gut Microbial Dysbiosis in a Trinitrobenzene Sulfonic Acid-Induced Post-Inflammatory Animal Model, Am. J. Chin. Med, 48, pp. 77-90, (2020); Sun J., Wu X., Meng Y., Cheng J., Ning H., Peng Y., Et al., Electro-Acupuncture Decreases 5-HT, CGRP and Increases NPY in the Brain-Gut Axis in two rat Models of Diarrhea-Predominant Irritable Bowel Syndrome(D-IBS), BMC Complement. Altern. Med, 15, (2015); Turan I., Sayan Ozacmak H., Ozacmak V.H., Barut F., Ozacmak I.D., The Effects of S-Nitrosoglutathione on Intestinal Ischemia Reperfusion Injury and Acute Lung Injury in Rats: Roles Of Oxidative Stress And NF-κB, Tissue cell, 52, pp. 35-41, (2018); Unno N., Wang H., Menconi M.J., Tytgat S.H., Larkin V., Inhibition of Inducible Nitric Oxide Synthase Ameliorates Endotoxin-Induced Gut Mucosal Barrier Dysfunction In Rats, Gastroenterology, 113, pp. 1246-1257, (1997); Van Sebille Y.Z.A., Gibson R.J., Wardill H.R., Secombe K.R., Ball I.A., Keefe D.M.K., Et al., Dacomitinib‐Induced Diarrhoea is Associated With Altered Gastrointestinal Permeability and Disruption in Ileal Histology in Rats, Int. J. Cancer, 140, pp. 2820-2829, (2017); Wang L., Xian J., Sun M., Wang X., Zang X., Zhang X., Et al., Acupuncture for Emotional Symptoms in Patients With Functional Gastrointestinal Disorders: A Systematic Review And Meta-Analysis, Plos One, 17, (2022); Wang P., Du C., Chen F.-X., Li C.-Q., Yu Y.-B., Han T., Et al., BDNF Contributes to IBS-like Colonic Hypersensitivity via Activating the Enteroglia-Nerve Unit, Sci. Rep, 6, (2016); Wang X.Y., Wang H., Guan Y.Y., Cai R.L., Shen G.M., Acupuncture for Functional Gastrointestinal Disorders: A Systematic Review And Meta‐Analysis, J. Gastroenterology Hepatology, 36, pp. 3015-3026, (2021); Wang Z., Ocadiz-Ruiz R., Sundaresan S., Ding L., Hayes M., Sahoo N., Et al., Isolation of Enteric Glial Cells from the Submucosa and Lamina Propria of the Adult Mouse, JoVE, (2018); Yang X., Sheng L., Guan Y., Qian W., Hou X., Synaptic Plasticity: The New Explanation of Visceral Hypersensitivity in Rats With Trichinella spiralis infection?, Dig. Dis. Sci, 54, pp. 937-946, (2009); Yu Y.-B., Li Y., Enteric Glial Cells and Their Role in The Intestinal Epithelial Barrier, World J. Gastroenterol, 20, pp. 11273-11280, (2014); Zhang M., Liu Y., Zhao M., Tang W., Wang X., Dong Z., Et al., Depression and Anxiety Behaviour in A Rat Model Of Chronic Migraine, J. Headache Pain, 18, (2017); Zhao Y., Jiang H.L., Shi Y., Zhang W., Zhang L.X., Hou Y.J., Et al., Electroacupuncture Alleviates Visceral Hypersensitivity in IBS-D Rats by Inhibiting EGCs Activity through Regulating BDNF/TrkB Signaling Pathway, Evid. Based Complement. Altern. Med, 2022, (2022); Zhu J., Yu L., Fan Y., Zhang H., Li F., Li X., Et al., Camelina sativa Oil Treatment Alleviates Castor Oil-Induced Diarrhea in ICR Mice by Regulating Intestinal Flora Composition, Evid. Based Complement. Altern. Med, 2022, (2022)","Y. Li; Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, China; email: liying@cdutcm.edu.cn; Q. Zheng; Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, China; email: zhengqianhua@cdutcm.edu.cn","","Frontiers Media S.A.","","","","","","1664042X","","","","English","Front. Physiol.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85138294868"

"Rodríguez-Sojo M.J.; Garcia-Garcia J.; Ruiz-Malagón A.J.; Diez-Echave P.; Hidalgo-García L.; Molina-Tijeras J.A.; González-Lozano E.; López-Escanez L.; Rodríguez-Cabezas M.E.; Rodríguez-Sánchez M.J.; Rodríguez-Nogales A.; Mediavilla C.; Galvez J.","Rodríguez-Sojo, María Jesús (57219963817); Garcia-Garcia, Jorge (57222272619); Ruiz-Malagón, Antonio Jesús (57211626330); Diez-Echave, Patricia (57203976100); Hidalgo-García, Laura (56957125300); Molina-Tijeras, José Alberto (57205398368); González-Lozano, Elena (58025289200); López-Escanez, Laura (58047074200); Rodríguez-Cabezas, María Elena (6602880894); Rodríguez-Sánchez, Maria José (57893513100); Rodríguez-Nogales, Alba (55603925700); Mediavilla, Cristina (6603428888); Galvez, Julio (7102940760)","57219963817; 57222272619; 57211626330; 57203976100; 56957125300; 57205398368; 58025289200; 58047074200; 6602880894; 57893513100; 55603925700; 6603428888; 7102940760","Beneficial Effects of Limosilactobacillus fermentum in the DCA Experimental Model of Irritable Bowel Syndrome in Rats","2023","Nutrients","15","1","24","","","","1","10.3390/nu15010024","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85145914602&doi=10.3390%2fnu15010024&partnerID=40&md5=b6c6f1e70316a2f31b8068a242d1178a","Departamento de Farmacología, Centro de Investigación Biomédica (CIBM), Universidad de Granada, Granada, 18071, Spain; Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, 18071, Spain; Servicio de Digestivo, Hospital Universitario Virgen de las Nieves, Granada, 18071, Spain; Department of Psychobiology, Mind, Brain, and Behavior Research Center (CIMCYC), University of Granada, Granada, 18071, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, 08036, Spain","Rodríguez-Sojo M.J., Departamento de Farmacología, Centro de Investigación Biomédica (CIBM), Universidad de Granada, Granada, 18071, Spain, Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, 18071, Spain; Garcia-Garcia J., Departamento de Farmacología, Centro de Investigación Biomédica (CIBM), Universidad de Granada, Granada, 18071, Spain; Ruiz-Malagón A.J., Departamento de Farmacología, Centro de Investigación Biomédica (CIBM), Universidad de Granada, Granada, 18071, Spain, Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, 18071, Spain; Diez-Echave P., Departamento de Farmacología, Centro de Investigación Biomédica (CIBM), Universidad de Granada, Granada, 18071, Spain, Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, 18071, Spain; Hidalgo-García L., Departamento de Farmacología, Centro de Investigación Biomédica (CIBM), Universidad de Granada, Granada, 18071, Spain, Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, 18071, Spain; Molina-Tijeras J.A., Departamento de Farmacología, Centro de Investigación Biomédica (CIBM), Universidad de Granada, Granada, 18071, Spain, Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, 18071, Spain; González-Lozano E., Departamento de Farmacología, Centro de Investigación Biomédica (CIBM), Universidad de Granada, Granada, 18071, Spain, Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, 18071, Spain; López-Escanez L., Departamento de Farmacología, Centro de Investigación Biomédica (CIBM), Universidad de Granada, Granada, 18071, Spain, Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, 18071, Spain; Rodríguez-Cabezas M.E., Departamento de Farmacología, Centro de Investigación Biomédica (CIBM), Universidad de Granada, Granada, 18071, Spain, Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, 18071, Spain; Rodríguez-Sánchez M.J., Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, 18071, Spain, Servicio de Digestivo, Hospital Universitario Virgen de las Nieves, Granada, 18071, Spain; Rodríguez-Nogales A., Departamento de Farmacología, Centro de Investigación Biomédica (CIBM), Universidad de Granada, Granada, 18071, Spain, Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, 18071, Spain; Mediavilla C., Department of Psychobiology, Mind, Brain, and Behavior Research Center (CIMCYC), University of Granada, Granada, 18071, Spain; Galvez J., Departamento de Farmacología, Centro de Investigación Biomédica (CIBM), Universidad de Granada, Granada, 18071, Spain, Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, 18071, Spain, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, 08036, Spain","Limosilactobacillus fermentum CECT5716, a probiotic strain isolated from human milk, has reported beneficial effects on different gastrointestinal disorders. Moreover, it has shown its ability to restore altered immune responses, in association with microbiome modulation in different pathological conditions. Therefore, our aim was to assess the effects of a Limosilacbacillus fermentum CECT5716 in a rat experimental model of irritable bowel syndrome (IBS) that resembles human IBS. The experimental IBS was induced by deoxycholic acid (DCA) in rats and then, Limosilactobacillus fermentum CECT5716 (109 CFU/day/rat) was administered. Behavioral studies, hyperalgesia and intestinal hypersensitivity determinations were performed and the impact of the probiotic on the inflammatory and intestinal barrier integrity was evaluated. Additionally, the gut microbiota composition was analyzed. Limosilactobacillus fermentum CECT5716 attenuated the anxiety-like behavior as well as the visceral hypersensitivity and referred pain. Moreover, this probiotic ameliorated the gut inflammatory status, re-establishing the altered intestinal permeability, reducing the mast cell degranulation and re-establishing the gut dysbiosis in experimental IBS. Therefore, our results suggest a potential use of Limosilactobacillus fermentum CECT5716 in clinical practice for the management of IBS patients. © 2022 by the authors.","IBS rat model; Intestine anti-inflammatory activity; Limosilactobacillus fermentum CECT5716; probiotic; visceral analgesia","Animals; Humans; Hyperalgesia; Irritable Bowel Syndrome; Limosilactobacillus fermentum; Milk, Human; Probiotics; Rats; deoxycholic acid; gabapentin; probiotic agent; rifaximin; probiotic agent; adult; animal cell; animal experiment; animal model; animal tissue; antiinflammatory activity; anxiety disorder; Article; behavior assessment; colony forming unit; controlled study; gene expression profiling; human; human cell; intestine flora; intestine mucosa permeability; irritable colon; Lactobacillus fermentum; male; mast cell degranulation; nonhuman; rat; referred pain; species composition; visceral hyperalgesia; animal; breast milk; hyperalgesia; irritable colon","","deoxycholic acid, 83-44-3; gabapentin, 60142-96-3; rifaximin, 80621-81-4, 88747-56-2","","","CIBER-EHD; Instituto de Salud Carlos III, ISCIII, (PI19/01058, PI20/01447); Junta de Andalucía, (A-CTS-447-UGR18, CTS 164)","This study was supported by the Junta de Andalucía (A-CTS-447-UGR18 and CTS 164), and by the Instituto de Salud Carlos III (ISCIII) (PI19/01058, PI20/01447; CIBER-EHD).","Mearin F., Lacy B.E., Chang L., Chey W.D., Lembo A.J., Simren M., Spiller R., Bowel Disorders, Gastroenterology, 150, pp. 1393-1407, (2016); Ford A.C., Lacy B.E., Talley N.J., Irritable Bowel Syndrome, N. Engl. J. Med, 376, pp. 2566-2578, (2017); Black C.J., Ford A.C., Global burden of irritable bowel syndrome: Trends, predictions and risk factors, Nat. Rev. Gastroenterol. Hepatol, 17, pp. 473-486, (2020); Lee Y.J., Park K.S., Irritable bowel syndrome: Emerging paradigm in pathophysiology, World J. Gastroenterol, 20, pp. 2456-2469, (2014); Uranga J.A., Martinez V., Abalo R., Mast Cell Regulation and Irritable Bowel Syndrome: Effects of Food Components with Potential Nutraceutical Use, Molecules, 25, (2020); Zamani M., Alizadeh-Tabari S., Zamani V., Systematic review with meta-analysis: The prevalence of anxiety and depression in patients with irritable bowel syndrome, Aliment. Pharm, 50, pp. 132-143, (2019); Van Oudenhove L., Crowell M.D., Drossman D.A., Halpert A.D., Keefer L., Lackner J.M., Murphy T.B., Naliboff B.D., Levy R.L., Biopsychosocial Aspects of Functional Gastrointestinal Disorders, Gastroenterology, 150, pp. 1355-1367.e2, (2016); Coss-Adame E., Rao S.S., Brain and gut interactions in irritable bowel syndrome: New paradigms and new understandings, Curr. Gastroenterol. Rep, 16, (2014); Foster J.A., Rinaman L., Cryan J.F., Stress & the gut-brain axis: Regulation by the microbiome, Neurobiol. Stress, 7, pp. 124-136, (2017); Bellini M., Gambaccini D., Stasi C., Urbano M.T., Marchi S., Usai-Satta P., Irritable bowel syndrome: A disease still searching for pathogenesis, diagnosis and therapy, World J. Gastroenterol, 20, pp. 8807-8820, (2014); Camilleri M., Boeckxstaens G., Dietary and pharmacological treatment of abdominal pain in IBS, Gut, 66, pp. 966-974, (2017); Bordbar G., Miri M.B., Omidi M., Shoja S., Akhavan M., Efficacy and Safety of a Novel Herbal Medicine in the Treatment of Irritable Bowel Syndrome: A Randomized Double-Blinded Clinical Trial, Gastroenterol. Res. Pr, 2020, (2020); Camilleri M., Diagnosis and Treatment of Irritable Bowel Syndrome: A Review, Jama, 325, pp. 865-877, (2021); Bond D.M., Morris J.M., Nassar N., Study protocol: Evaluation of the probiotic Lactobacillus Fermentum CECT5716 for the prevention of mastitis in breastfeeding women: A randomised controlled trial, BMC Pregnancy Childbirth, 17, (2017); Pastor-Villaescusa B., Blanco-Rojo R., Olivares M., Evaluation of the Effect of Limosilactobacillus fermentum CECT5716 on Gastrointestinal Infections in Infants: A Systematic Review and Meta-Analysis, Microorganisms, 9, (2021); Rodriguez-Nogales A., Algieri F., Vezza T., Garrido-Mesa N., Olivares M., Comalada M., Riccardi C., Utrilla M.P., Rodriguez-Cabezas M.E., Galvez J., The viability of Lactobacillus fermentum CECT5716 is not essential to exert intestinal anti-inflammatory properties, Food Funct, 6, pp. 1176-1184, (2015); Rodriguez-Nogales A., Algieri F., Garrido-Mesa J., Vezza T., Utrilla M.P., Chueca N., Garcia F., Olivares M., Rodriguez-Cabezas M.E., Galvez J., Differential intestinal anti-inflammatory effects of Lactobacillus fermentum and Lactobacillus salivarius in DSS mouse colitis: Impact on microRNAs expression and microbiota composition, Mol. Nutr. Food Res, 61, (2017); Molina-Tijeras J.A., Diez-Echave P., Vezza T., Hidalgo-Garcia L., Ruiz-Malagon A.J., Rodriguez-Sojo M.J., Romero M., Robles-Vera I., Garcia F., Plaza-Diaz J., Et al., Lactobacillus fermentum CECT5716 ameliorates high fat diet-induced obesity in mice through modulation of gut microbiota dysbiosis, Pharm. Res, 167, (2021); Robles-Vera I., Toral M., de la Visitacion N., Sanchez M., Romero M., Olivares M., Jimenez R., Duarte J., The Probiotic Lactobacillus fermentum Prevents Dysbiosis and Vascular Oxidative Stress in Rats with Hypertension Induced by Chronic Nitric Oxide Blockade, Mol. Nutr. Food Res, 62, (2018); Lee K.J., Kim J.H., Cho S.W., Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome, Aliment. Pharm, 22, pp. 981-988, (2005); Pimentel M., Park S., MIrocha J., Kane S.V., Kong Y., The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: A randomized trial, Ann. Intern. Med, 145, pp. 557-563, (2006); Menees S.B., Maneerattannaporn M., Kim H.M., Chey W.D., The efficacy and safety of rifaximin for the irritable bowel syndrome: A systematic review and meta-analysis, Am. J. Gastroenterol, 107, pp. 28-35, (2012); Rodriguez-Nogales A., Algieri F., Vezza T., Garrido-Mesa J., Molina-Tijeras J.A., ROdriguez-Cabezas M.E., Utrilla M.P., Pischel I., Galvez J., Calcium Pyruvate Exerts Beneficial Effects in an Experimental Model of Irritable Bowel Disease Induced by DCA in Rats, Nutrients, 11, (2019); Keszthelyi D., Troost F.J., Masclee A.A., Irritable bowel syndrome: Methods, mechanisms, and pathophysiology. Methods to assess visceral hypersensitivity in irritable bowel syndrome, Am. J. Physiol. Gastrointest. Liver Physiol, 303, pp. G141-G154, (2012); Zhang C., Rui Y.-Y., Zhou Y.-Y., Ju Z., Zhang H.-H., Hu C.-Y., Xiao Y., Xu G.-Y., Adrenergic β2-receptors mediates visceral hypersensitivity induced by heterotypic intermittent stress in rats, PLoS ONE, 9, (2014); Vezza T., Algieri F., Rodriguez-Nogales A., Garrido-Mesa J., Utrilla M.P., Talhaoui N., Gomez-Caravaca A.M., Segura-Carretero A., Rodriguez-Cabezas M.E., Monteleone G., Immunomodulatory properties of Olea europaea leaf extract in intestinal inflammation, Mol. Nutr. Food Res, 61, (2017); Schindelin J., Arganda-Carreras I., Frise E., Kaynig V., Longair M., Pietzsch T., Preibisch S., Rueden C., Saalfeld S., Schmid B., Fiji: An open-source platform for biological-image analysis, Nat. Methods, 9, pp. 676-682, (2012); Mane J., Loren V., Pedrosa E., Ojanguren I., Xaus J., Cabre E., Domenech E., Gassull M.A., Lactobacillus fermentum CECT 5716 prevents and reverts intestinal damage on TNBS-induced colitis in mice, Inflamm. Bowel Dis, 15, pp. 1155-1163, (2009); (2019); Lucak S., Chang L., Halpert A., Harris L.A., Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: Evidence-based treatment in practice, Ther. Adv. Gastroenterol, 10, pp. 253-275, (2017); Patel S., Doerfler B., Boutros K., Ng S., Manuel M., DeSimone E., Review of Treatment Options for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation, Int. J. Gen. Med, 14, pp. 1457-1468, (2021); Nee J., Lembo A., Review Article: Current and future treatment approaches for IBS with diarrhoea (IBS-D) and IBS mixed pattern (IBS-M), Aliment. Pharm, 54, pp. S63-S74, (2021); Jiang H.-Y., Zhang X., Yu Z.-H., Zhang Z., Deng M., Zhao J.-H., Ruan B., Altered gut microbiota profile in patients with generalized anxiety disorder, J. Psychiatr. Res, 104, pp. 130-136, (2018); Elsenbruch S., Abdominal pain in Irritable Bowel Syndrome: A review of putative psychological, neural and neuro-immune mechanisms, Brain Behav. Immun, 25, pp. 386-394, (2011); Traub R.J., Tang B., Ji Y., Pandya S., Yfnatis H., Sun Y., A rat model of chronic postinflammatory visceral pain induced by deoxycholic acid, Gastroenterology, 135, pp. 2075-2083, (2008); Guthrie E., Barlow J., Fernandes L., Ratcliffe J., Read N., Thompson D.G., Tomenson B., Creed F., Changes in tolerance to rectal distension correlate with changes in psychological state in patients with severe irritable bowel syndrome, Psychosom. Med, 66, pp. 578-582, (2004); Trinkley K.E., Nahata M.C., Medication management of irritable bowel syndrome, Digestion, 89, pp. 253-267, (2014); Ait-Belgnaoui A., Payard I., Rolland C., Harkat C., Braniste V., Theodorou V., Tompkins T.A., Bifidobacterium longum and Lactobacillus helveticus Synergistically Suppress Stress-related Visceral Hypersensitivity Through Hypothalamic-Pituitary-Adrenal Axis Modulation, J. Neurogastroenterol. Motil, 24, pp. 138-146, (2018); Eutamene H., Lamine F., Chabo C., Theodorou V., Rochat F., Bergonzelli G.E., Corthesy-Theulaz I., Fioramonti J., Bueno L., Synergy between Lactobacillus paracasei and its bacterial products to counteract stress-induced gut permeability and sensitivity increase in rats, J. Nutr, 137, pp. 1901-1907, (2007); McGrath J.C., Drummond G.B., McLachlan E.M., Kilkenny C., Wainwright C.L., Guidelines for reporting experiments involving animals: The ARRIVE guidelines, Br. J. Pharm, 160, pp. 1573-1576, (2010); Wang B., Mao Y.-K., Diorio C., Wang L., Huizinga J.D., Bienenstock J., Kunze W., Lactobacillus reuteri ingestion and IK(Ca) channel blockade have similar effects on rat colon motility and myenteric neurones, Neurogastroenterol. Motil, 22, pp. 98-107, (2010); Verdu E.F., Bercik P., Verma-Gandhu M., Huang X.-X., Blennerhassett P., Jackson W., Mao Y., Wang L., Rochat F., Collins S.M., Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice, Gut, 55, pp. 182-190, (2006); Ng Q.X., Soh A.Y.S., Loke W., Lim D.Y., Yeo W.-S., The role of inflammation in irritable bowel syndrome (IBS), J. Inflamm. Res, 11, pp. 345-349, (2018); Hassanin T.M., Fouad Y., Mohamed F.E., Abdel-Hafeez E.H., Hassnine A., Colonic mucosal eosinophilia and immunohistochemical expression of COX-2 and NF-kB in patients with irritable bowel syndrome, Eur. J. Gastroenterol. Hepatol, 34, pp. 512-517, (2022); Holzer P., TRPV1: A new target for treatment of visceral pain in IBS?, Gut, 57, pp. 882-884, (2008); Dasgupta Y., Golovine K., Nieborowska-Skorska M., Luo L., Matlawska-Wasowska K., Mullighan C.G., Skorski T., Drugging DNA repair to target T-ALL cells, Leuk. Lymphoma, 59, pp. 1746-1749, (2018); Lee J., Lee B.J., Lee Y.M., Park H., Kim J.H., Kim W.J., Self-Assembled Nanoconstructs Modified with Amplified Aptamers Inhibited Tumor Growth and Retinal Vascular Hyperpermeability via Vascular Endothelial Growth Factor Capturing, Mol. Pharm, 14, pp. 1460-1468, (2017); Grabauskas G., Wu X., Gao J., Li J.-Y., Turgeon D.K., Owyang C., Prostaglandin E(2), Produced by Mast Cells in Colon Tissues From Patients With Irritable Bowel Syndrome, Contributes to Visceral Hypersensitivity in Mice, Gastroenterology, 158, pp. 2195-2207.e6, (2020); Akbar A., Yiangou Y., Facer P., Walters J.R., Anand P., Ghosh S., Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain, Gut, 57, pp. 923-929, (2008); Perez-Burgos A., Wang L., Neufeld K.-A.M., Mao Y.-K., Ahmadzai M., Janssen L.J., Stanisz A.M., Bienenstock J., Kunze W.A., The TRPV1 channel in rodents is a major target for antinociceptive effect of the probiotic Lactobacillus reuteri DSM 17938, J. Physiol, 593, pp. 3943-3957, (2015); Yang C.Q., Guo X.-S., Wei Z.-B., Zhao L., Zhao G.-T., Sheng S.-T., Rifaximin Improves Visceral Hyperalgesia via TRPV1 by Modulating Intestinal Flora in the Water Avoidance Stressed Rat, Gastroenterol. Res. Pr, 2020, (2020); Ribatti D., Vacca A., Dammacco F., The role of the vascular phase in solid tumor growth: A historical review, Neoplasia, 1, pp. 293-302, (1999); Chen L., Deng H., Cui H., Fang J., Zuo Z., Deng J., Li Y., Wang X., Zhao L., Inflammatory responses and inflammation-associated diseases in organs, Oncotarget, 9, pp. 7204-7218, (2018); Casado-Bedmar M., Keita A.V., Potential neuro-immune therapeutic targets in irritable bowel syndrome, Ther. Adv. Gastroenterol, 13, (2020); Carabotti M., Scirocco A., Maselli M.A., Severi C., The gut-brain axis: Interactions between enteric microbiota, central and enteric nervous systems, Ann. Gastroenterol, 28, pp. 203-209, (2015); Bischoff S.C., Kramer S., Human mast cells, bacteria, and intestinal immunity, Immunol. Rev, 217, pp. 329-337, (2007); O'Sullivan M., Clayton N., Breslin N.P., Harman I., Bountra C., McLaren A., O'morain C.A., Increased mast cells in the irritable bowel syndrome, Neurogastroenterol. Motil, 12, pp. 449-457, (2000); Camilleri M., Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome, Expert Opin Pharm, 14, pp. 1151-1160, (2013); Klooker T.K., Braak B., Koopman K.E., Welting O., Wouters M.M., van der Heide S., Schemann M., Bischoff S.C., van den Wijingaard E.M., Boeckxstaerns G.E., The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome, Gut, 59, pp. 1213-1221, (2010); Buhner S., Li Q., Vignali S., Barbara G., De Giorgio R., Stanghellini V., Cremon C., Zeller F., Langer R., Daniel H., Et al., Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome, Gastroenterology, 137, pp. 1425-1434, (2009); Barbara G., Stanghellini V., De Giorgio R., Cremon C., Cottrell G.S., Santini D., Pasquinelli G., Morselli-Labate A.M., Grady E.F., Bunnett N.W., Et al., Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome, Gastroenterology, 126, pp. 693-702, (2004); Harata G., He F., Takahashi K., Hosono A., Miyazawa K., Yoda K., Hiramatsu M., Kaminogawa S., Human Lactobacillus Strains from the Intestine can Suppress IgE-Mediated Degranulation of Rat Basophilic Leukaemia (RBL-2H3) Cells, Microorganisms, 4, (2016); Forsythe P., Wang B., Khambati I., Kunze W.A., Systemic effects of ingested Lactobacillus rhamnosus: Inhibition of mast cell membrane potassium (IKCa) current and degranulation, PLoS ONE, 7, (2012); Kawahara T., Inhibitory effect of heat-killed Lactobacillus strain on immunoglobulin E-mediated degranulation and late-phase immune reactions of mouse bone marrow-derived mast cells, Anim. Sci. J, 81, pp. 714-721, (2010); Piche T., Tight junctions and IBS--the link between epithelial permeability, low-grade inflammation, and symptom generation?, Neurogastroenterol. Motil, 26, pp. 296-302, (2014); Zeng H., Umar S., Rust B., Lazarova D., Bordonario M., Secondary Bile Acids and Short Chain Fatty Acids in the Colon: A Focus on Colonic Microbiome, Cell Proliferation, Inflammation, and Cancer, Int. J. Mol. Sci, 20, (2019); Vancamelbeke M., Vermeire S., The intestinal barrier: A fundamental role in health and disease, Expert Rev. Gastroenterol. Hepatol, 11, pp. 821-834, (2017); Chen X., Oshima T., Tomita T., Fukui H., Watari J., Matsumoto T., Miwa H., Acidic bile salts modulate the squamous epithelial barrier function by modulating tight junction proteins, Am. J. Physiol. Gastrointest. Liver Physiol, 301, pp. G203-G209, (2011); Ghosh S., Whitley C.S., Haribabu B., Jala V.R., Regulation of Intestinal Barrier Function by Microbial Metabolites, Cell Mol. Gastroenterol. Hepatol, 11, pp. 1463-1482, (2021); Duan R., Zhu S., Wang B., Duan L., Alterations of Gut Microbiota in Patients With Irritable Bowel Syndrome Based on 16S rRNA-Targeted Sequencing: A Systematic Review, Clin. Transl. Gastroenterol, 10, (2019); Jeffery I.B., Das A., OHerlihy E., Coughlan S., Cisek K., Moore M., Bradley F., Carty T., Pradhan M., Dwibedi C., Et al., Differences in Fecal Microbiomes and Metabolomes of People With vs Without Irritable Bowel Syndrome and Bile Acid Malabsorption, Gastroenterology, 158, pp. 1016-1028.e8, (2020); Tap J., Derrien M., Tornblom H., Brazeilles R., Cools-Portier S., Dore J., Storsrud S., Le Neve B., Ohman L., Simren M., Identification of an Intestinal Microbiota Signature Associated With Severity of Irritable Bowel Syndrome, Gastroenterology, 152, pp. 111-123.e8, (2017); Su T., Liu R., Lee A., Long Y., Du L., LAi S., Chen X., Wang L., Si J., Owyang C., Et al., Altered Intestinal Microbiota with Increased Abundance of Prevotella Is Associated with High Risk of Diarrhea-Predominant Irritable Bowel Syndrome, Gastroenterol. Res. Pr, 2018, (2018); Kovatcheva-Datchary P., Nilsson A., Akrami R., Lee Y.S., De Vadder F., Arora T., Hallen A., Martens E., Bjorck I., Backhed F., Dietary Fiber-Induced Improvement in Glucose Metabolism Is Associated with Increased Abundance of Prevotella, Cell Metab, 22, pp. 971-982, (2015); Staudacher H.M., Irving P.M., Lomer M.C.E., Whelan K., Mechanisms and efficacy of dietary FODMAP restriction in IBS, Nat. Rev. Gastroenterol. Hepatol, 11, pp. 256-266, (2014); Chen J., Wright K., Davis J.M., Jeraldo P., Marietta E.V., Murray J., Nelson H., Matteson E.L., Taneja V., An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis, Genome Med, 8, (2016); Menees S., Chey W., The gut microbiome and irritable bowel syndrome, F1000Res, 7, (2018); Bailey M.T., Dowd S.E., Galley J.D., Hufnagle A.R., Allen R.G., Lyte M., Exposure to a social stressor alters the structure of the intestinal microbiota: Implications for stressor-induced immunomodulation, Brain Behav. Immun, 25, pp. 397-407, (2011); Kuti D., Dowd S.E., Galley J.D., Hufnagle A.R., Allen R.G., Lyte M., Gastrointestinal (non-systemic) antibiotic rifaximin differentially affects chronic stress-induced changes in colon microbiome and gut permeability without effect on behavior, Brain Behav. Immun, 84, pp. 218-228, (2020); Bercik P., The microbiota-gut-brain axis: Learning from intestinal bacteria?, Gut, 60, pp. 288-289, (2011); Smith K.B., Murray E., Gregory J.G., Liang J., Ismail N., Pubertal probiotics mitigate lipopolysaccharide-induced programming of the hypothalamic-pituitary-adrenal axis in male mice only, Brain Res. Bull, 177, pp. 111-118, (2021)","A. Rodríguez-Nogales; Departamento de Farmacología, Centro de Investigación Biomédica (CIBM), Universidad de Granada, Granada, 18071, Spain; email: albarn@ugr.es; M.J. Rodríguez-Sánchez; Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, 18071, Spain; email: mjrs2188@gmail.com","","MDPI","","","","","","20726643","","","36615683","English","Nutrients","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85145914602"

"Bootz-Maoz H.; Pearl A.; Melzer E.; Malnick S.; Sharon E.; Bennet Y.; Tsentsarevsky R.; Abuchatzera S.; Amidror S.; Aretz E.; Azriel S.; Gam Ze Letova C.; Naama M.; Shoval I.; Yaron O.; Karako-Lampert S.; Bel S.; Yissachar N.","Bootz-Maoz, Hadar (57970591500); Pearl, Ayelet (57266289300); Melzer, Ehud (7006188330); Malnick, Stephen (7005572437); Sharon, Efrat (57265949600); Bennet, Yifat (57969661500); Tsentsarevsky, Rotem (57970360600); Abuchatzera, Shlomi (57266061200); Amidror, Sivan (57215692576); Aretz, Elana (57266635600); Azriel, Shalhevet (55362650600); Gam Ze Letova, Chen (57321224600); Naama, Maria (57969901100); Shoval, Irit (25634529400); Yaron, Orly (57220352504); Karako-Lampert, Sarit (8221376300); Bel, Shai (37025474200); Yissachar, Nissan (13008478500)","57970591500; 57266289300; 7006188330; 7005572437; 57265949600; 57969661500; 57970360600; 57266061200; 57215692576; 57266635600; 55362650600; 57321224600; 57969901100; 25634529400; 57220352504; 8221376300; 37025474200; 13008478500","Diet-induced modifications to human microbiome reshape colonic homeostasis in irritable bowel syndrome","2022","Cell Reports","41","7","111657","","","","10","10.1016/j.celrep.2022.111657","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85142157389&doi=10.1016%2fj.celrep.2022.111657&partnerID=40&md5=d686a7ed7a255ceabc805c2ae3263668","The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, 5290002, Israel; Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat-Gan, 5290002, Israel; Department of Gastroenterology and Liver Disease, Kaplan Medical Center, Rehovot, Israel; Department of Internal Medicine, Kaplan Medical Center, Rehovot, Israel; Hadassah Medical Center, the Hebrew University, Jerusalem, Israel; Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel","Bootz-Maoz H., The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, 5290002, Israel, Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat-Gan, 5290002, Israel; Pearl A., The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, 5290002, Israel, Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat-Gan, 5290002, Israel; Melzer E., Department of Gastroenterology and Liver Disease, Kaplan Medical Center, Rehovot, Israel, Hadassah Medical Center, the Hebrew University, Jerusalem, Israel; Malnick S., Department of Internal Medicine, Kaplan Medical Center, Rehovot, Israel, Hadassah Medical Center, the Hebrew University, Jerusalem, Israel; Sharon E., The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, 5290002, Israel, Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat-Gan, 5290002, Israel; Bennet Y., The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, 5290002, Israel, Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat-Gan, 5290002, Israel; Tsentsarevsky R., The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, 5290002, Israel, Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat-Gan, 5290002, Israel; Abuchatzera S., The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, 5290002, Israel, Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat-Gan, 5290002, Israel; Amidror S., The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, 5290002, Israel, Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat-Gan, 5290002, Israel; Aretz E., Department of Gastroenterology and Liver Disease, Kaplan Medical Center, Rehovot, Israel; Azriel S., The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, 5290002, Israel, Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat-Gan, 5290002, Israel; Gam Ze Letova C., The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, 5290002, Israel, Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat-Gan, 5290002, Israel; Naama M., Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel; Shoval I., The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, 5290002, Israel; Yaron O., The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, 5290002, Israel; Karako-Lampert S., The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, 5290002, Israel; Bel S., Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel; Yissachar N., The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, 5290002, Israel, Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat-Gan, 5290002, Israel","Changes in microbiome composition are associated with a wide array of human diseases, turning the human microbiota into an attractive target for therapeutic intervention. Yet, clinical translation of these findings requires the establishment of causative connections between specific microbial taxa and their functional impact on host tissues. Here, we infuse gut organ cultures with longitudinal microbiota samples collected from therapy-naive patients with irritable bowel syndrome (IBS) under a low-fermentable oligo-, di-, mono-saccharides and polyols (FODMAP) diet. We show that post-diet microbiota regulates intestinal expression of inflammatory and neuro-muscular gene sets. Specifically, we identify Bifidobacterium adolescentis as a diet-sensitive pathobiont that alters tight junction integrity and disrupts gut barrier functions. Collectively, we present a pathway discovery platform for mechanistic dissection and identification of functional diet-host-microbiota modules. Our data support the hypothesis that the gut microbiota mediates the beneficial effects of a low-FODMAP diet and reinforce the potential feasibility of microbiome-based therapies in IBS. © 2022 The Author(s)","CP: Microbiology; gut microbiota; intestinal epithelial barrier; irritable bowel syndrome; low-FODMAP diet","Diet, Carbohydrate-Restricted; Gastrointestinal Microbiome; Homeostasis; Humans; Irritable Bowel Syndrome; adult; animal cell; animal experiment; animal model; animal tissue; Article; Bifidobacterium adolescentis; clinical article; cohort analysis; colon; controlled study; enteritis; female; gene control; gene expression; gene set analysis; genetic association; homeostasis; human; human cell; intestine flora; irritable colon; longitudinal study; low FODMAP diet; male; microbial identification; microdissection; mouse; neuromuscular function; nonhuman; organ culture; regulator gene; signal transduction; species composition; tight junction; homeostasis; low carbohydrate diet","","","","","Gassner Fund for Medical Research, Israel; Broad Institute, (2615/18); Israel Science Foundation, ISF, (1384/18)","We thank Ron Unger for helpful advice, Sara Gerstein for assistance with organ cultures, the Mathis/Benoist lab for microbial strains, Shani Brown and Sondra Turjeman for critical editing of the manuscript, and members of the Yissachar lab for insightful discussions. This work was supported by the Israel Science Foundation (grant no. 1384/18 ), the Israel Science Foundation —Broad Institute Joint Program (grant no. 2615/18 ), and the Gassner Fund for Medical Research, Israel. ","Enck P., Aziz Q., Barbara G., Farmer A.D., Fukudo S., Mayer E.A., Niesler B., Quigley E.M.M., Rajilic-Stojanovic M., Schemann M., Et al., Irritable bowel syndrome, Nat. Rev. Dis. Primers, 2, (2016); Palsson O.S., Whitehead W.E., van Tilburg M.A.L., Chang L., Chey W., Crowell M.D., Keefer L., Lembo A.J., Parkman H.P., Rao S.S., Et al., Rome IV diagnostic questionnaires and tables for investigators and clinicians, Gastroenterology, (2016); Mars R.A.T., Yang Y., Ward T., Houtti M., Priya S., Lekatz H.R., Tang X., Sun Z., Kalari K.R., Korem T., Et al., Longitudinal multi-omics reveals subset-specific mechanisms underlying irritable bowel syndrome, Cell, 182, pp. 1460-1473.e17, (2020); Moayyedi P., Simren M., Bercik P., Evidence-based and mechanistic insights into exclusion diets for IBS, Nat. Rev. Gastroenterol. Hepatol., 17, pp. 406-413, (2020); Altobelli E., Del Negro V., Angeletti P.M., Latella G., Low-FODMAP diet improves irritable bowel syndrome symptoms: a meta-analysis, Nutrients, 9, (2017); Staudacher H.M., Irving P.M., Lomer M.C.E., Whelan K., Mechanisms and efficacy of dietary FODMAP restriction in IBS, Nat. Rev. Gastroenterol. Hepatol., 11, pp. 256-266, (2014); Staudacher H.M., Whelan K., The low FODMAP diet: recent advances in understanding its mechanisms and efficacy in IBS, Gut, 66, pp. 1517-1527, (2017); Nanayakkara W.S., Skidmore P.M., O'Brien L., Wilkinson T.J., Gearry R.B., Efficacy of the low FODMAP diet for treating irritable bowel syndrome: the evidence to date, Clin. Exp. Gastroenterol., 9, pp. 131-142, (2016); Halmos E.P., Christophersen C.T., Bird A.R., Shepherd S.J., Gibson P.R., Muir J.G., Diets that differ in their FODMAP content alter the colonic luminal microenvironment, Gut, 64, pp. 93-100, (2015); Hustoft T.N., Hausken T., Ystad S.O., Valeur J., Brokstad K., Hatlebakk J.G., Lied G.A., Effects of varying dietary content of fermentable short-chain carbohydrates on symptoms, fecal microenvironment, and cytokine profiles in patients with irritable bowel syndrome, Neuro Gastroenterol. Motil., 29, (2017); McIntosh K., Reed D.E., Schneider T., Dang F., Keshteli A.H., De Palma G., Madsen K., Bercik P., Vanner S., FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial, Gut, 66, pp. 1241-1251, (2017); Bennet S.M.P., Bohn L., Storsrud S., Liljebo T., Collin L., Lindfors P., Tornblom H., Ohman L., Simren M., Multivariate modelling of faecal bacterial profiles of patients with IBS predicts responsiveness to a diet low in FODMAPs, Gut, 67, pp. 872-881, (2018); Yissachar N., Zhou Y., Ung L., Lai N.Y., Mohan J.F., Ehrlicher A., Weitz D.A., Kasper D.L., Chiu I.M., Mathis D., Benoist C., An intestinal organ culture system uncovers a role for the nervous system in microbe-immune crosstalk, Cell, 168, pp. 1135-1148.e12, (2017); Pittayanon R., Lau J.T., Yuan Y., Leontiadis G.I., Tse F., Surette M., Moayyedi P., Gut microbiota in patients with irritable bowel syndrome-A systematic review, Gastroenterology, 157, pp. 97-108, (2019); Staudacher H.M., Lomer M.C.E., Anderson J.L., Barrett J.S., Muir J.G., Irving P.M., Whelan K., Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome, J. Nutr., 142, pp. 1510-1518, (2012); Staudacher H.M., Lomer M.C.E., Farquharson F.M., Louis P., Fava F., Franciosi E., Scholz M., Tuohy K.M., Lindsay J.O., Irving P.M., Whelan K., A diet low in FODMAPs reduces symptoms in patients with irritable bowel syndrome and A probiotic restores Bifidobacterium species: a randomized controlled trial, Gastroenterology, 153, pp. 936-947, (2017); Duscha A., Gisevius B., Hirschberg S., Yissachar N., Stangl G.I., Eilers E., Bader V., Haase S., Kaisler J., David C., Et al., Propionic acid shapes the multiple sclerosis disease course by an immunomodulatory mechanism, Cell, 180, pp. 1067-1080.e16, (2020); Zhou Y., Zhou B., Pache L., Chang M., Khodabakhshi A.H., Tanaseichuk O., Benner C., Chanda S.K., Metascape provides a biologist-oriented resource for the analysis of systems-level datasets, Nat. Commun., 10, (2019); Tan T.G., Sefik E., Geva-Zatorsky N., Kua L., Naskar D., Teng F., Pasman L., Ortiz-Lopez A., Jupp R., Wu H.-J.J., Et al., Identifying species of symbiont bacteria from the human gut that, alone, can induce intestinal Th17 cells in mice, Proc. Natl. Acad. Sci. USA, 113, pp. E8141-E8150, (2016); Eftychi C., Schwarzer R., Vlantis K., Wachsmuth L., Basic M., Wagle P., Neurath M.F., Becker C., Bleich A., Pasparakis M., Temporally distinct functions of the cytokines IL-12 and IL-23 drive chronic colon inflammation in response to intestinal barrier impairment, Immunity, 51, pp. 367-380.e4, (2019); Atarashi K., Tanoue T., Ando M., Kamada N., Nagano Y., Narushima S., Suda W., Imaoka A., Setoyama H., Nagamori T., Et al., Th17 cell induction by adhesion of microbes to intestinal epithelial cells, Cell, 163, pp. 367-380, (2015); Zhou S.-Y., Gillilland M., Wu X., Leelasinjaroen P., Zhang G., Zhou H., Ye B., Lu Y., Owyang C., FODMAP diet modulates visceral nociception by lipopolysaccharide-mediated intestinal inflammation and barrier dysfunction, J. Clin. Invest., 128, pp. 267-280, (2018); Mazmanian S.K., Round J.L., Kasper D.L., A microbial symbiosis factor prevents intestinal inflammatory disease, Nature, 453, pp. 620-625, (2008); Tsai P.-Y., Zhang B., He W.-Q., Zha J.-M., Odenwald M.A., Singh G., Tamura A., Shen L., Sailer A., Yeruva S., Et al., IL-22 upregulates epithelial claudin-2 to drive diarrhea and enteric pathogen clearance, Cell Host Microbe, 21, pp. 671-681.e4, (2017); Johansson M.E.V., Phillipson M., Petersson J., Velcich A., Holm L., Hansson G.C., The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria, Proc. Natl. Acad. Sci. USA, 105, pp. 15064-15069, (2008); Yu R., Zuo F., Ma H., Chen S., Exopolysaccharide-producing Bifidobacterium adolescentis strains with similar adhesion property induce differential regulation of inflammatory immune response in Treg/Th17 Axis of DSS-colitis mice, Nutrients, 11, (2019); Fanning S., Hall L.J., Cronin M., Zomer A., MacSharry J., Goulding D., Motherway M.O., Shanahan F., Nally K., Dougan G., van Sinderen D., Bifidobacterial surface-exopolysaccharide facilitates commensal-host interaction through immune modulation and pathogen protection, Proc. Natl. Acad. Sci. USA, 109, pp. 2108-2113, (2012); Hughes K.R., Harnisch L.C., Alcon-Giner C., Mitra S., Wright C.J., Ketskemety J., van Sinderen D., Watson A.J.M., Hall L.J., Bifidobacterium breve reduces apoptotic epithelial cell shedding in an exopolysaccharide and MyD88-dependent manner, Open Biol., 7, (2017); Kaminsky L.W., Al-Sadi R., Ma T.Y., IL-1β and the intestinal epithelial tight junction barrier, Front. Immunol., 12, (2021); Cox S.R., Lindsay J.O., Fromentin S., Stagg A.J., McCarthy N.E., Galleron N., Ibraim S.B., Roume H., Levenez F., Pons N., Et al., Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial, Gastroenterology, 158, pp. 176-188.e7, (2020); Zeevi D., Korem T., Zmora N., Israeli D., Rothschild D., Weinberger A., Ben-Yacov O., Lador D., Avnit-Sagi T., Lotan-Pompan M., Et al., Personalized nutrition by prediction of glycemic responses, Cell, 163, pp. 1079-1094, (2015); Rothschild D., Weissbrod O., Barkan E., Kurilshikov A., Korem T., Zeevi D., Costea P.I., Godneva A., Kalka I.N., Bar N., Et al., Environment dominates over host genetics in shaping human gut microbiota, Nature, 555, pp. 210-215, (2018); El-Salhy M., Hatlebakk J.G., Gilja O.H., Brathen Kristoffersen A., Hausken T., Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study, Gut, 69, pp. 859-867, (2020); Valdez-Palomares F., Nambo-Venegas R., Uribe-Garcia J., Mendoza-Vargas A., Granados-Portillo O., Meraz-Cruz N., Palacios-Gonzalez B., Intestinal microbiota fingerprint in subjects with irritable bowel syndrome responders to a low FODMAP diet, Food Funct., 12, pp. 3206-3218, (2021); Santacruz A., Marcos A., Warnberg J., Marti A., Martin-Matillas M., Campoy C., Moreno L.A., Veiga O., Redondo-Figuero C., Garagorri J.M., Et al., Interplay between weight loss and gut microbiota composition in overweight adolescents, Obesity, 17, pp. 1906-1915, (2009); Modesto M., Checcucci A., Mattarelli P., Identification of bifidobacteria by the phosphoketolase assay, Methods Mol. Biol., 2278, pp. 141-148, (2021); Febbraio M.A., Karin M., “Sweet death”: fructose as a metabolic toxin that targets the gut-liver axis, Cell Metab., 33, pp. 2316-2328, (2021); Herman M.A., Birnbaum M.J., Molecular aspects of fructose metabolism and metabolic disease, Cell Metab., 33, pp. 2329-2354, (2021); Todoric J., Di Caro G., Reibe S., Henstridge D.C., Green C.R., Vrbanac A., Ceteci F., Conche C., McNulty R., Shalapour S., Et al., Fructose stimulated de novo lipogenesis is promoted by inflammation, Nat. Metab., 2, pp. 1034-1045, (2020); Manfredo Vieira S., Hiltensperger M., Kumar V., Zegarra-Ruiz D., Dehner C., Khan N., Costa F.R.C., Tiniakou E., Greiling T., Ruff W., Et al., Translocation of a gut pathobiont drives autoimmunity in mice and humans, Science, 359, pp. 1156-1161, (2018); Thaiss C.A., Levy M., Grosheva I., Zheng D., Soffer E., Blacher E., Braverman S., Tengeler A.C., Barak O., Elazar M., Et al., Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection, Science, 359, pp. 1376-1383, (2018); Buckley A., Turner J.R., Cell biology of tight junction barrier regulation and mucosal disease, Cold Spring Harb. Perspect. Biol., 10, (2018); Luissint A.-C., Parkos C.A., Nusrat A., Inflammation and the intestinal barrier: leukocyte-epithelial cell interactions, cell junction remodeling, and mucosal repair, Gastroenterology, 151, pp. 616-632, (2016); Khor B., Gardet A., Xavier R.J., Genetics and pathogenesis of inflammatory bowel disease, Nature, 474, pp. 307-317, (2011); Clemente M.G., De Virgiliis S., Kang J.S., Macatagney R., Musu M.P., Di Pierro M.R., Drago S., Congia M., Fasano A., Early effects of gliadin on enterocyte intracellular signalling involved in intestinal barrier function, Gut, 52, pp. 218-223, (2003); Martinez C., Lobo B., Pigrau M., Ramos L., Gonzalez-Castro A.M., Alonso C., Guilarte M., Guila M., de Torres I., Azpiroz F., Et al., Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, pp. 1160-1168, (2013); Dunlop S.P., Hebden J., Campbell E., Naesdal J., Olbe L., Perkins A.C., Spiller R.C., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am. J. Gastroenterol., 101, pp. 1288-1294, (2006); Piche T., Barbara G., Aubert P., Bruley des Varannes S., Dainese R., Nano J.L., Cremon C., Stanghellini V., De Giorgio R., Galmiche J.P., Neunlist M., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Aguilera-Lizarraga J., Florens M.V., Viola M.F., Jain P., Decraecker L., Appeltans I., Cuende-Estevez M., Fabre N., Van Beek K., Perna E., Et al., Local immune response to food antigens drives meal-induced abdominal pain, Nature, 590, pp. 151-156, (2021); Martinez C., Gonzalez-Castro A., Vicario M., Santos J., Cellular and molecular basis of intestinal barrier dysfunction in the irritable bowel syndrome, Gut Liver, 6, pp. 305-315, (2012); Martinez C., Rodino-Janeiro B.K., Lobo B., Stanifer M.L., Klaus B., Granzow M., Gonzalez-Castro A.M., Salvo-Romero E., Alonso-Cotoner C., Pigrau M., Et al., miR-16 and miR-125b are involved in barrier function dysregulation through the modulation of claudin-2 and cingulin expression in the jejunum in IBS with diarrhoea, Gut, 66, pp. 1537-1538, (2017); De Palma G., Lynch M.D.J., Lu J., Dang V.T., Deng Y., Jury J., Umeh G., Miranda P.M., Pigrau Pastor M., Sidani S., Et al., Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice, Sci. Transl. Med., 9, (2017); DeSantis T.Z., Hugenholtz P., Larsen N., Rojas M., Brodie E.L., Keller K., Huber T., Dalevi D., Hu P., Andersen G.L., Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB, Appl. Environ. Microbiol., 72, pp. 5069-5072, (2006); Parks D.H., Chuvochina M., Rinke C., Mussig A.J., Chaumeil P.-A., Hugenholtz P., GTDB: an ongoing census of bacterial and archaeal diversity through a phylogenetically consistent, rank normalized and complete genome-based taxonomy, Nucleic Acids Res., 50, pp. D785-D794, (2022); Quast C., Pruesse E., Yilmaz P., Gerken J., Schweer T., Yarza P., Peplies J., Glockner F.O., The SILVA ribosomal RNA gene database project: improved data processing and web-based tools, Nucleic Acids Res., 41, pp. D590-D596, (2013); Love M.I., Huber W., Anders S., Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2, Genome Biol., 15, (2014); Drossman D.A., Hasler W.L., Rome IV—functional GI disorders: disorders of gut-brain interaction, Gastroenterology, 150, pp. 1257-1261, (2016); Francis C.Y., Morris J., Whorwell P.J., The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress, Aliment. Pharmacol. Ther., 11, pp. 395-402, (1997); Lewis S.J., Heaton K.W., Stool form scale as a useful guide to intestinal transit time, Scand. J. Gastroenterol., 32, pp. 920-924, (1997); Matsuki T., Watanabe K., Tanaka R., Oyaizu H., Rapid identification of human intestinal bifidobacteria by 16S rRNA-targeted species- and group-specific primers, FEMS Microbiol. Lett., 167, pp. 113-121, (1998); Salter S.J., Cox M.J., Turek E.M., Calus S.T., Cookson W.O., Moffatt M.F., Turner P., Parkhill J., Loman N.J., Walker A.W., Reagent and laboratory contamination can critically impact sequence-based microbiome analyses, BMC Biol., 12, (2014); Dobin A., Davis C.A., Schlesinger F., Drenkow J., Zaleski C., Jha S., Batut P., Chaisson M., Gingeras T.R., STAR: ultrafast universal RNA-seq aligner, Bioinformatics, 29, pp. 15-21, (2013); Anders S., Pyl P.T., Huber W., HTSeq–a Python framework to work with high-throughput sequencing data, Bioinformatics, 31, pp. 166-169, (2015); Howe K.L., Achuthan P., Allen J., Allen J., Alvarez-Jarreta J., Amode M.R., Armean I.M., Azov A.G., Bennett R., Bhai J., Et al., Ensembl 2021, Nucleic Acids Res., 49, pp. D884-D891, (2021); Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Mesirov J.P., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles, Proc. Natl. Acad. Sci. USA, 102, pp. 15545-15550, (2005)","N. Yissachar; The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, 5290002, Israel; email: nissan.yissachar@biu.ac.il","","Elsevier B.V.","","","","","","22111247","","","36384106","English","Cell Rep.","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85142157389"

"Xu W.; Zhang Z.; Lu Y.; Li M.; Li J.; Tao W.","Xu, Weidong (57454238900); Zhang, Zhiyi (57453877000); Lu, Ye (57979814700); Li, Mengxi (57979262800); Li, Jiayao (57216911717); Tao, Wenhua (57219926856)","57454238900; 57453877000; 57979814700; 57979262800; 57216911717; 57219926856","Traditional Chinese medicine Tongxie Yaofang treating irritable bowel syndrome with diarrhea and type 2 diabetes mellitus in rats with liver-depression and spleen-deficiency: A preliminary study","2022","Frontiers in Nutrition","9","","968930","","","","9","10.3389/fnut.2022.968930","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85142520790&doi=10.3389%2ffnut.2022.968930&partnerID=40&md5=686ba5df33f554a46f381d62279875fb","Department of Traditional Chinese Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, China; School of Pharmacy, Jiangsu University, Zhenjiang, China","Xu W., Department of Traditional Chinese Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, China, School of Pharmacy, Jiangsu University, Zhenjiang, China; Zhang Z., School of Pharmacy, Jiangsu University, Zhenjiang, China; Lu Y., Department of Traditional Chinese Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, China, School of Pharmacy, Jiangsu University, Zhenjiang, China; Li M., Department of Traditional Chinese Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, China; Li J., School of Pharmacy, Jiangsu University, Zhenjiang, China; Tao W., Department of Traditional Chinese Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, China","Tongxie Yaofang (TXYF), a Traditional Chinese Medicine (TCM) with four components as follows: Rhizoma Atractylodis Macrocephalae (baizhu), Radix Paeoniae Alba (baishao), Pericarpium Citri Reticulatae (chenpi) and Radix Saposhnikovia Divaricata (fangfeng), benefits irritable bowel syndrome (IBS). Nonetheless, proofs of this formula ameliorating D-IBS and T2DM are required. This research aimed at investigating the efficacy of TXYF in treating inflammation in rats with D-IBS and T2DM using animal models. In this study, gavage with high-fat diet, fasciculation, and senna was given to develop rat models with target diseases. To determine intestinal inflammations, major inflammatory factors, and intestinal permeability proteins, H&E staining, ELISA, and immunohistochemistry methods were employed, respectively. This study also utilized Western blot to discover potential inflammatory targets. Results of this research illustrates that TXYF treatment reduced the level of TNF-α, IL-1β, and IL-6, and raised the IL-10 concentration in liver-depressed spleende ficient rats with D-IBS and T2DM, indicating controlled inflammatory reactions. Staining analysis also showed improved disease states of animal models. Furthermore, efficient rebounds of claudin-1, an intestinal permeability-associated protein, were detected. Moreover, TXYF may treat D-IBS and T2DM in rats via the rage pathway. Copyright © 2022 Xu, Zhang, Lu, Li, Li and Tao.","D-IBS; inflammation; RAGE; T2DM; TXYF","","","","","","National Natural Science Foundation of China, NSFC, (81904166)","This study was funded by the National Natural Science Foundation of China (81904166). ","Altomare A., Di Rosa C., Imperia E., Emerenziani S., Cicala M., Guarino M.P.L., Diarrhea predominant-irritable bowel syndrome (IBS-D): effects of different nutritional patterns on intestinal dysbiosis and symptoms, Nutrients, 13, 1506, (2021); Wang H., Zhou G., Luo L., Crusius J.B.A., Yuan A., Kou J., Et al., Serological screening for celiac disease in adult Chinese patients with diarrhea predominant irritable bowel syndrome, Medicine (Baltimore), 94, e1779, (2015); Devanarayana N.M., Rajindrajith S., Pathmeswaran A., Abegunasekara C., Gunawardena N.K., Benninga M.A., Epidemiology of irritable bowel syndrome in children and adolescents in Asia, J Pediatr Gastroenterol Nutr, 60, pp. 792-798, (2015); Wei X., Chen M., Wang J., The epidemiology of irritable bowel syndrome and functional constipation of Guangzhou residents, Zhonghua Nei Ke Za Zhi, 40, pp. 517-520, (2001); Gao H.X., Regier E.E., Close K.L., International diabetes federation world diabetes congress 2015, J Diabetes, 8, pp. 300-302, (2016); Gulcan E., Taser F., Toker A., Korkmaz U., Alcelik A., Increased frequency of prediabetes in patients with irritable bowel syndrome, Am J Med Sci, 338, pp. 116-119, (2009); Tao W.-H., Correlation between irritable bowel syndrome and diabetes, World Chin J Dig, 24, pp. 1770-1774, (2016); Martinez C., Lobo B., Pigrau M., Ramos L., Gonzalez-Castro A.M., Alonso C., Et al., Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, pp. 1160-1168, (2013); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Lecleire S., Antonietti M., Gourcerol G., Et al., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am J Gastroenterol, 106, pp. 2165-2173, (2011); Inai T., Kobayashi J., Shibata Y., Claudin-1 contributes to the epithelial barrier function in MDCK cells, Eur J Cell Biol, 78, pp. 849-855, (1999); Bischoff S.C., Barbara G., Buurman W., Ockhuizen T., Schulzke J.D., Serino M., Et al., Intestinal permeability–a new target for disease prevention and therapy, BMC Gastroenterol, 14, 189, (2014); Coeffier M., Dechelotte P., Ducrotte P., Intestinal permeability in patients with diarrhea-predominant irritable bowel syndrome: is there a place for glutamine supplementation?, Gastroenterology, 148, pp. 1079-1080, (2015); Mujagic Z., Ludidi S., Keszthelyi D., Hesselink M.A., Kruimel J.W., Lenaerts K., Et al., Small intestinal permeability is increased in diarrhoea predominant IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to confounders, Aliment Pharmacol Ther, 40, pp. 288-297, (2014); Shulman R.J., Jarrett M.E., Cain K.C., Broussard E.K., Heitkemper M.M., Associations among gut permeability, inflammatory markers, and symptoms in patients with irritable bowel syndrome, J Gastroenterol, 49, pp. 1467-1476, (2014); Hirabara S.M., Gorjao R., Vinolo M.A., Rodrigues A.C., Nachbar R.T., Curi R., Molecular targets related to inflammation and insulin resistance and potential interventions, J Biomed Biotechnol, 2012, (2012); Maynard C.L., Weaver C.T., Diversity in the contribution of interleukin-10 to T-cell-mediated immune regulation, Immunol Rev, 226, pp. 219-233, (2008); Wang H., Shi P., Zuo L., Dong J., Zhao J., Liu Q., Et al., Dietary non-digestible polysaccharides ameliorate intestinal epithelial barrier dysfunction in IL-10 knockout mice, J Crohns Colitis, 10, pp. 1076-1086, (2016); Boontanrart M., Hall S.D., Spanier J.A., Hayes C.E., Olson J.K., Vitamin D3 alters microglia immune activation by an IL-10 dependent SOCS3 mechanism, J Neuroimmunol, 292, pp. 126-136, (2016); Hua M.C., Lai M.W., Kuo M.L., Yao T.C., Huang J.L., Chen S.M., Decreased interleukin-10 secretion by peripheral blood mononuclear cells in children with irritable bowel syndrome, J Pediatr Gastroenterol Nutr, 52, pp. 376-381, (2011); Schmulson M., Pulido-London D., Rodriguez O., Morales-Rochlin N., Martinez-Garcia R., Gutierrez-Ruiz M.C., Et al., Lower serum IL-10 is an independent predictor of IBS among volunteers in Mexico, Am J Gastroenterol, 107, pp. 747-753, (2012); Acharya A.B., Thakur S., Muddapur M.V., Evaluation of serum interleukin-10 levels as a predictor of glycemic alteration in chronic periodontitis and type 2 diabetes mellitus, J Indian Soc Periodontol, 19, pp. 388-392, (2015); Wang S.S., Wang X.R., Yang R.Y., Xu Y., Li M.Y., [Efficacy and mechanism of acupuncture combined with tongxieyaofang for diarrhea-type irritable bowel syndrome of liver depression and spleen deficiency], Zhongguo Zhen Jiu, 40, pp. 605-609, (2020); Zhang J., Deng H., Bai J., Zhou X., Zhao Y., Zhu Y., Et al., Health-promoting properties of barley: a review of nutrient and nutraceutical composition, functionality, bioprocessing, and health benefits, Crit Rev Food Sci Nutr, (2022); Li M., Bao X., Zhang X., Ren H., Cai S., Hu X., Et al., Exploring the phytochemicals and inhibitory effects against α-glucosidase and dipeptidyl peptidase-IV in Chinese pickled chili pepper: insights into mechanisms by molecular docking analysis, LWT, 162, (2022); Aziz M.N.M., Kumar J., Muhammad Nawawi K.N., Raja Ali R.A., Mokhtar N.M., Irritable bowel syndrome, depression, and neurodegeneration: a bidirectional communication from gut to Brain, Nutrients, 13, 3061, (2021); Vahora I.S., Tsouklidis N., Kumar R., Soni R., Khan S., How serotonin level fluctuation affects the effectiveness of treatment in irritable bowel syndrome, Cureus, 12, e9871, (2020); Vincenzi A., Goettert M.I., Volken de Souza C.F., An evaluation of the effects of probiotics on tumoral necrosis factor (TNF-alpha) signaling and gene expression, Cytokine Growth Factor Rev, 57, pp. 27-38, (2021); Yang W.L., Chen S.Y., Ho C.Y., Yen G.C., Citrus flavonoids suppress IL-5 and ROS through distinct pathways in PMA/ionomycin-induced EL-4 cells, Food Funct, 11, pp. 824-833, (2020); Cai H., Xu Y., Xie L., Duan Y., Zhou J., Liu J., Et al., Investigation on spectrum-effect correlation between constituents absorbed into blood and bioactivities of baizhu shaoyao San before and after processing on ulcerative colitis rats by UHPLC/Q-TOF-MS/MS coupled with gray correlation analysis, Molecules, 24, 940, (2019); Zhou Y., Tao H., Wang A., Zhong Z., Wu X., Wang M., Et al., Chinese herb pair paeoniae radix alba and atractylodis macrocephalae rhizoma suppresses LPS-induced inflammatory response through inhibiting MAPK and NF-kappaB pathway, Chin Med, 14, 2, (2019); Shang Z., Li M., Zhang W., Cai S., Hu X., Yi J., Analysis of phenolic compounds in pickled chayote and their effects on antioxidant activities and cell protection, Food Res Int, 157, (2022); Body-Malapel M., Djouina M., Waxin C., Langlois A., Gower-Rousseau C., Zerbib P., Et al., The RAGE signaling pathway is involved in intestinal inflammation and represents a promising therapeutic target for inflammatory bowel diseases, Mucosal Immunol, 12, pp. 468-478, (2019); Schmidt A.M., Yan S.D., Yan S.F., Stern D.M., The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses, J Clin Investig, 108, pp. 949-955, (2001)","W. Tao; Department of Traditional Chinese Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, China; email: taowh@ujs.edu.con","","Frontiers Media S.A.","","","","","","2296861X","","","","English","Front. Nutr.","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85142520790"

"Linsalata M.; Riezzo G.; Orlando A.; D’Attoma B.; Prospero L.; Ignazzi A.; Losurdo G.; Di Leo A.; Giannelli G.; Russo F.","Linsalata, Michele (6603600075); Riezzo, Giuseppe (7004144336); Orlando, Antonella (23767683100); D’Attoma, Benedetta (57205751185); Prospero, Laura (57207799778); Ignazzi, Antonia (57206193613); Losurdo, Giuseppe (56516483500); Di Leo, Alfredo (56962705200); Giannelli, Gianluigi (7005015716); Russo, Francesco (59133987100)","6603600075; 7004144336; 23767683100; 57205751185; 57207799778; 57206193613; 56516483500; 56962705200; 7005015716; 59133987100","The Role of Intestinal Barrier Function in Overweight Patients with IBS with Diarrhea Undergoing a Long-Term Low Fermentable Oligo-, Di-, and Monosaccharide and Polyol Diet","2023","Nutrients","15","21","4683","","","","0","10.3390/nu15214683","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85176903096&doi=10.3390%2fnu15214683&partnerID=40&md5=1ec6663ab1a7417938956356e76afd22","Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS “S. de Bellis, Metropolitan, 70013, Italy; Section of Gastroenterology, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, Bari, 70124, Italy; Scientific Direction, National Institute of Gastroenterology IRCCS “S. de Bellis”, Metropolitan, 70013, Italy","Linsalata M., Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS “S. de Bellis, Metropolitan, 70013, Italy; Riezzo G., Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS “S. de Bellis, Metropolitan, 70013, Italy; Orlando A., Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS “S. de Bellis, Metropolitan, 70013, Italy; D’Attoma B., Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS “S. de Bellis, Metropolitan, 70013, Italy; Prospero L., Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS “S. de Bellis, Metropolitan, 70013, Italy; Ignazzi A., Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS “S. de Bellis, Metropolitan, 70013, Italy; Losurdo G., Section of Gastroenterology, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, Bari, 70124, Italy; Di Leo A., Section of Gastroenterology, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, Bari, 70124, Italy; Giannelli G., Scientific Direction, National Institute of Gastroenterology IRCCS “S. de Bellis”, Metropolitan, 70013, Italy; Russo F., Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS “S. de Bellis, Metropolitan, 70013, Italy","Overweight and obesity have been suggested as significant factors in irritable bowel syndrome (IBS) development. However, the relationship between overweight/obesity and IBS is unclear. It is known that a modified intestinal barrier, especially the permeability of the small intestine (s-IP), can play a significant role in the pathogenesis of both obesity and IBS. Moreover, dietary interventions are essential for treating both pathologies. We evaluated the gastrointestinal (GI) symptoms and the urinary and circulating markers of GI barrier function and integrity, the markers of intestinal dysbiosis and bacterial translocation, in 40 IBS patients with predominant diarrhea (IBS-D) (32 females and 8 males; mean age = 43.5 ± 1.4 years), categorized using their Body Mass Index levels as normal (NW) and overweight (OW). Evaluations were performed before and after 12 weeks of a Low FODMAP Diet (LFD). At the baseline, OW patients showed a significantly higher s-IP than NW. After an LFD, a significant improvement of s-IP in OW patients occurred, along with a significant decrease in markers of epithelial integrity and bacterial translocation. Our findings highlight the close relationship between overweight and the intestinal barrier and support their involvement in IBS-D pathophysiology. Furthermore, the positive role of an LFD in managing overweight IBS-D was highlighted. © 2023 by the authors.","gastrointestinal symptoms; intestinal barrier; irritable bowel syndrome; low FODMAP diet; overweight","Adult; Diarrhea; Diet; Disaccharides; Female; Fermentation; Humans; Irritable Bowel Syndrome; Male; Monosaccharides; Obesity; Oligosaccharides; Overweight; amine oxidase (copper containing); biological marker; fatty acid binding protein 2; indican; lipopolysaccharide; tight junction protein; unclassified drug; zonulin; disaccharide; monosaccharide; oligosaccharide; polyol; abdominal distension; abdominal pain; adult; age; Article; attitude assessment; bacterial translocation; body mass; Bristol stool form scale; caloric intake; case control study; clinical evaluation; cohort analysis; comparative study; controlled clinical trial; controlled study; defecation habit; diarrhea; digestive system disease assessment; disease severity assessment; dysbiosis; energy expenditure; female; gastrointestinal symptom; gastrointestinal symptom rating scale; gender; human; IBS diet adherence report scale; IBS symptom severity scale; intestine function; intestine mucosa permeability; irritable bowel syndrome with diarrhea; irritable colon; long term care; low FODMAP diet; major clinical study; male; obese patient; obesity; pain intensity; quality of life; small intestine; complication; diarrhea; diet; fermentation; irritable colon; microbiology; obesity","","amine oxidase (copper containing), 9001-53-0, 9014-75-9; indican, 1336-79-4, 487-94-5; Disaccharides, ; Monosaccharides, ; Oligosaccharides, ; polyol, ","2005 Stata Statistical software release 9, StataCorp, United States; Bodygram PLUS Software v. 1.0, akern, Italy; SECA mod. 220, Intermed, Italy; SECA mod. 700, Intermed, Italy; mod-201 SECA tape","Intermed, Italy; Intermed, Italy; StataCorp, United States; akern, Italy","Italian Ministry of Health RC 2020, (2020012064, 700/2020)","This research was funded by the Italian Ministry of Health RC 2020–2021, Prog. N° 16 (DDG n. 700/2020) Workflow ID n. 2020012064—1 December 2020.","Camilleri M., Diagnosis and Treatment of Irritable Bowel Syndrome: A Review, JAMA, 325, pp. 865-877, (2021); Yanping W., Gao X., Cheng Y., Liu M., Liao S., Zhou J., Hao J., Jiang G., Lu Y., Qu T., Et al., The interaction between obesity and visceral hypersensitivity, J. Gastroenterol. Hepatol, 38, pp. 370-377, (2023); Pickett-Blakely O., Obesity and irritable bowel syndrome: A comprehensive review, Gastroenterol Hepatol, 10, pp. 411-416, (2014); Pugliese G., Muscogiuri G., Barrea L., Laudisio D., Savastano S., Colao A., Irritable bowel syndrome: A new therapeutic target when treating obesity?, Hormones, 18, pp. 395-399, (2019); Rusu F., Obesity and irritable bowel syndrome: Coincidence or association?, J. Gastrointest. Liver Dis, 27, (2018); Svedberg P., Johansson S., Wallander M., Hamelin B., Pedersen N.L., Extra-intestinal manifestations associated with irritable bowel syndrome: A twin study, Aliment. Pharmacol. Ther, 16, pp. 975-983, (2002); Aasbrenn M., Hogestol I., Eribe I., Kristinsson J., Lydersen S., Mala T., Farup P.G., Prevalence and predictors of irritable bowel syndrome in patients with morbid obesity: A cross-sectional study, BMC Obes, 4, (2017); Sherwin L.B., Ozoji O.M., Boulineaux C.M., Joseph P.V., Fourie N.H., Abey S.K., Zhang X., Henderson W.A., Gender and Weight Influence Quality of Life in Irritable Bowel Syndrome, J. Clin. Med, 6, (2017); Akhondi N., Montazerin S.M., Soltani S., Saneei P., Keshteli A.H., Esmaillzadeh A., Adibi P., General and abdominal obesity in relation to the prevalence of irritable bowel syndrome, Neurogastroenterol. Motil, 31, (2019); Seethaler B., Basrai M., Neyrinck A.M., Nazare J.-A., Walter J., Delzenne N.M., Bischoff S.C., Biomarkers for assessment of intestinal permeability in clinical practice, Am. J. Physiol. Liver Physiol, 321, pp. G11-G17, (2021); Farre R., Fiorani M., Abdu Rahiman S., Matteoli G., Intestinal Permeability, Inflammation and the Role of Nutrients, Nutrients, 12, (2020); Matricon J., Meleine M., Gelot A., Piche T., Dapoigny M., Muller E., Ardid D., Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome, Aliment. Pharmacol. Ther, 36, pp. 1009-1031, (2012); Hanning N., Edwinson A.L., Ceuleers H., Peters S.A., De Man J.G., Hassett L.C., De Winter B.Y., Grover M., Intestinal barrier dysfunction in irritable bowel syndrome: A systematic review, Ther. Adv. Gastroenterol, 14, (2021); Linsalata M., Riezzo G., Clemente C., D'attoma B., Russo F., Noninvasive Biomarkers of Gut Barrier Function in Patients Suffering from Diarrhea Predominant-IBS: An Update, Dis. Markers, 2020, (2020); Chelakkot C., Ghim J., Ryu S.H., Mechanisms regulating intestinal barrier integrity and its pathological implications, Exp. Mol. Med, 50, pp. 1-9, (2018); Damms-Machado A., Louis S., Schnitzer A., Volynets V., Rings A., Basrai M., Bischoff S.C., Gut permeability is related to body weight, fatty liver disease, and insulin resistance in obese individuals undergoing weight reduction, Am. J. Clin. Nutr, 105, pp. 127-135, (2017); Sadik R., Bjornsson E., Simren M., The relationship between symptoms, body mass index, gastrointestinal transit and stool frequency in patients with irritable bowel syndrome, Eur. J. Gastroenterol. Hepatol, 22, pp. 102-108, (2010); Camilleri M., Leaky gut: Mechanisms, measurement and clinical implications in humans, Gut, 68, pp. 1516-1526, (2019); Fasano A., Zonulin and Its Regulation of Intestinal Barrier Function: The Biological Door to Inflammation, Autoimmunity, and Cancer, Physiol. Rev, 91, pp. 151-175, (2011); Zhang L., Fan X., Zhong Z., Xu G., Shen J., Association of plasma diamine oxidase and intestinal fatty acid–binding protein with severity of disease in patient with heat stroke, Am. J. Emerg. Med, 33, pp. 867-871, (2015); Inczefi O., Bacsur P., Resal T., Keresztes C., Molnar T., The Influence of Nutrition on Intestinal Permeability and the Microbiome in Health and Disease, Front. Nutr, 9, (2022); Aasbrenn M., Lydersen S., Farup P.G., A Conservative Weight Loss Intervention Relieves Bowel Symptoms in Morbidly Obese Subjects with Irritable Bowel Syndrome: A Prospective Cohort Study, J. Obes, 2018, (2018); Linsalata M., Riezzo G., Orlando A., D'attoma B., Prospero L., Tutino V., Notarnicola M., Russo F., The Relationship between Low Serum Vitamin D Levels and Altered Intestinal Barrier Function in Patients with IBS Diarrhoea Undergoing a Long-Term Low-FODMAP Diet: Novel Observations from a Clinical Trial, Nutrients, 13, (2021); Svedlund J., Sjodin I., Dotevall G., GSRS–A Clinical Rating Scale for Gastrointestinal Symptoms in Patients with Irritable Bowel Syndrome and Peptic Ulcer Disease, Dig. Dis. Sci, 33, pp. 129-134, (1988); Schmulson M.J., A Drossman D., What Is New in Rome IV, J. Neurogastroenterol. Motil, 23, pp. 151-163, (2017); Verdu E.F., Armstrong D., A Murray J., Between Celiac Disease and Irritable Bowel Syndrome: The “No Man’s Land” of Gluten Sensitivity, Am. J. Gastroenterol, 104, pp. 1587-1594, (2009); Blake M.R., Raker J.M., Whelan K., Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome, Aliment. Pharmacol. Ther, 44, pp. 693-703, (2016); Francis C.Y., Morris J., Whorwell P.J., The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress, Aliment. Pharmacol. Ther, 11, pp. 395-402, (1997); Minguez Perez M., Benages Martinez A., The Bristol scale—A useful system to assess stool form?, Rev. Esp. Enferm. Dig, 101, pp. 305-311, (2009); Orlando A., Tutino V., Notarnicola M., Riezzo G., Linsalata M., Clemente C., Prospero L., Martulli M., D'attoma B., De Nunzio V., Et al., Improved Symptom Profiles and Minimal Inflammation in IBS-D Patients Undergoing a Long-Term Low-FODMAP Diet: A Lipidomic Perspective, Nutrients, 12, (2020); Khalil S.F., Mohktar M.S., Ibrahim F., The Theory and Fundamentals of Bioimpedance Analysis in Clinical Status Monitoring and Diagnosis of Diseases, Sensors, 14, pp. 10895-10928, (2014); Maagaard L., Ankersen D.V., Vegh Z., Burisch J., Jensen L., Pedersen N., Munkholm P., Follow-up of patients with functional bowel symptoms treated with a low FODMAP diet, World J. Gastroenterol, 22, pp. 4009-4019, (2016); The Monash University Low FODMAP App, (2017); Hilsden R., Meddings J., Sutherland L., Intestinal permeability changes in response to acetylsalicylic acid in relatives of patients with Crohn’s disease, Gastroenterology, 110, pp. 1395-1403, (1996); Simeoni M., Citraro M.L., Cerantonio A., Deodato F., Provenzano M., Cianfrone P., Capria M., Corrado S., Libri E., Comi A., Et al., An open-label, randomized, placebo-controlled study on the effectiveness of a novel probiotics administration protocol (ProbiotiCKD) in patients with mild renal insufficiency (stage 3a of CKD), Eur. J. Nutr, 58, pp. 2145-2156, (2018); Emerenziani S., Guarino M.P.L., Asensio L.M.T., Altomare A., Ribolsi M., Balestrieri P., Cicala M., Role of Overweight and Obesity in Gastrointestinal Disease, Nutrients, 12, (2019); Mansueto P., Soresi M., La Blasca F., Fayer F., D'alcamo A., Carroccio A., Body Mass Index and Associated Clinical Variables in Patients with Non-Celiac Wheat Sensitivity, Nutrients, 11, (2019); Gasmi A., Mujawdiya P.K., Pivina L., Dosa A., Semenova Y., Benahmed A.G., Bjorklund G., Relationship between Gut Microbiota, Gut Hyperpermeability and Obesity, Curr. Med. Chem, 28, pp. 827-839, (2021); Bashir M., Meddings J., Alshaikh A., Jung D., Le K., Amin R., Ratakonda S., Sharma S., Granja I., Satti M., Et al., Enhanced gastrointestinal passive paracellular permeability contributes to the obesity-associated hyperoxaluria, Am. J. Physiol. Liver Physiol, 316, pp. G1-G14, (2019); Bull M.J., Plummer N.T., Part 2: Treatments for Chronic Gastrointestinal Disease and Gut Dysbiosis, Integr. Med, 14, pp. 25-33, (2015); Sarmiento-Andrade Y., Suarez R., Quintero B., Garrochamba K., Chapela S.P., Gut microbiota and obesity: New insights, Front. Nutr, 9, (2022); Ajamian M., Rosella G., Newnham E.D., Biesiekierski J.R., Muir J.G., Gibson P.R., Effect of Gluten Ingestion and FODMAP Restriction on Intestinal Epithelial Integrity in Patients with Irritable Bowel Syndrome and Self-Reported Non-Coeliac Gluten Sensitivity, Mol. Nutr. Food Res, 65, (2020); Harvie R.M., Chisholm A.W., Bisanz J.E., Burton J.P., Herbison P., Schultz K., Schultz M., Long-term irritable bowel syndrome symptom control with reintroduction of selected FODMAPs, World J. Gastroenterol, 23, pp. 4632-4643, (2017); Tahapary D.L., Fatya A.I., Kurniawan F., Marcella C., Rinaldi I., Tarigan T.J.E., Harbuwono D.S., Yunir E., Soewondo P., Purnamasari D., Increased intestinal-fatty acid binding protein in obesity-associated type 2 diabetes mellitus, PLoS ONE, 18, (2023); Altomare A., Di Rosa C., Imperia E., Emerenziani S., Cicala M., Guarino M.P.L., Diarrhea Predominant-Irritable Bowel Syndrome (IBS-D): Effects of Different Nutritional Patterns on Intestinal Dysbiosis and Symptoms, Nutrients, 13, (2021)","F. Russo; Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS “S. de Bellis, Metropolitan, 70013, Italy; email: francesco.russo@irccsdebellis.it","","Multidisciplinary Digital Publishing Institute (MDPI)","","","","","","20726643","","","37960336","English","Nutrients","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85176903096"

"Peruhova M.; Mihova A.; Altankova I.; Velikova T.","Peruhova, Milena (57219107674); Mihova, Antoaneta (6507547182); Altankova, Iskra (6603179662); Velikova, Tsvetelina (55987966500)","57219107674; 6507547182; 6603179662; 55987966500","Specific Immunoglobulin E and G to Common Food Antigens and Increased Serum Zonulin in IBS Patients: A Single-Center Bulgarian Study","2022","Antibodies","11","2","23","","","","2","10.3390/antib11020023","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85128463512&doi=10.3390%2fantib11020023&partnerID=40&md5=f6980f266827285d7d2aa9d560389a32","Medical Faculty, Sofia University St. Kliment Ohridski, Sofia, 1407, Bulgaria; Laboratory of Clinical Immunology, University Hospital Lozenetz, Sofia University St. Kliment Ohridski, Sofia, 1407, Bulgaria","Peruhova M., Medical Faculty, Sofia University St. Kliment Ohridski, Sofia, 1407, Bulgaria; Mihova A., Laboratory of Clinical Immunology, University Hospital Lozenetz, Sofia University St. Kliment Ohridski, Sofia, 1407, Bulgaria; Altankova I., Laboratory of Clinical Immunology, University Hospital Lozenetz, Sofia University St. Kliment Ohridski, Sofia, 1407, Bulgaria; Velikova T., Laboratory of Clinical Immunology, University Hospital Lozenetz, Sofia University St. Kliment Ohridski, Sofia, 1407, Bulgaria","Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder whose pathogenesis is considered multifactorial, including abnormal gut motility, visceral hyperreactivity, psychological factors, disturbances in the brain-gut axis, leaky gut, oxidative stress, etc. We aimed to investigate serum levels of specific immunoglobulin E and G to common food antigens and zonulin and to assess their use in clinical practice for patients with IBS. Material and methods. We included 23 participants, 15 with IBS (diagnosed according to the Rome IV criteria) and 8 healthy controls. We investigated serum levels of specific IgG antibodies to 24 food antigens, specific IgE antibodies to 20 food antigens, anti-celiac antibodies, fecal calprotectin and serum zonulin by ELISA. Results. Food-specific positive IgG antibodies were significantly higher in patients with IBS than in controls (p = 0.007). IgE-mediated allergic reactions were found in five patients with IBS; no one had anti-TG antibodies. One-third of IBS patients demonstrated a low degree of chronic inflammation (positive fecal calprotectin test > 50 ng/mL) without specific bacterial infection. Serum levels of zonulin in IBS patients were higher than in healthy controls (0.378 ± 0.13 vs. 0.250 ± 0.14 ng/mL, p = 0.0315). However, no correlations between clinical symptoms and zonulin levels were found. Conclusion. The mechanisms of IgG hypersensitivity and low degree inflammation in IBS and elevated zonulin may contribute to multifactor pathogenesis in IBS. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.","IgE-mediated hypersensitivity; IgG-mediated hypersensitivity; irritable bowel syndrome; leaky gut; zonulin","calgranulin; Clostridium difficile toxin A; Clostridium difficile toxin B; food antigen; gliadin; gliadin antibody; immunoglobulin E; immunoglobulin G; probiotic agent; protein; unclassified drug; Zonulin; abdominal pain; adult; anxiety; Article; bacterial infection; blood sampling; brain-gut axis; clinical article; constipation; diarrhea; enzyme linked immunosorbent assay; fatigue; female; flatulence; headache; Helicobacter pylori; human; immune deficiency; immunoaffinity chromatography; immunoblotting; immunoglobulin blood level; insomnia; irritable colon; male; migraine; nausea and vomiting; oxidative stress; pruritus; questionnaire; rash; retrospective study; urticaria","","gliadin, 9007-90-3; immunoglobulin E, 37341-29-0; immunoglobulin G, 97794-27-9, 308067-58-5; protein, 67254-75-5","","","University Hospitals, UH, (80-10-160/25.04.2018); Sofia University","Funding: This research was funded by Sofia University St. Kliment Ohridski and supported by the University Hospital “Lozenetz”, grant number № 80-10-160/25.04.2018.","Balmus I.-M., Ilie O.-D., Ciobica A., Cojocariu R.-O., Stanciu C., Trifan A., Cimpeanu M., Cimpeanu C., Gorgan L., Irritable Bowel Syndrome between Molecular Approach and Clinical Expertise—Searching for Gap Fillers in the Oxidative Stress Way of Thinking, Medicina, 56, (2020); Li F.X., Patten S.B., Hilsden R.J., Sutherland L.R., Irritable bowel syndrome and health-related quality of life: A population-based study in Calgary, Alberta, Can. J. Gastroenterol. Hepatol, 17, pp. 259-263, (2003); Lovell R.M., Ford A.C., Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis, Clin. Gastroenterol. Hepatol, 10, pp. 712-721, (2012); Foxx-Orenstein A.E., New and emerging therapies for the treatment of irritable bowel syndrome: An update for gastroenterologists, Ther. Adv. Gastroenterol, 9, pp. 354-375, (2016); Adriani A., Ribaldone D.G., Astegiano M., Durazzo M., Saracco G.M., Pellicano R., Irritable bowel syndrome: The clinical approach, Panminerva Med, 60, pp. 213-222, (2018); Choung R.S., Talley N.J., Food Allergy and Intolerance in IBS, Gastroenterol. Hepatol, 2, pp. 756-760, (2006); Elsenbruch S., Abdominal pain in irritable bowel syndrome: A review of putative psychological, neural and neuro-immune mechanisms, Brain Behav. Immun, 25, pp. 386-394, (2011); Velikova T., Kukov A., Georgieva V., Peruhova M., Yurukova N., Mihova A., Mehandziyska-Marinova T., Mizgova G., Terzieva V., Zhelezova G., Et al., Methods for detection of food intolerance, Recent Adv. Food Sci, 1, pp. 106-119, (2018); Dainese R., Galliani E.A., De Lazzari F., Leo V.D., Naccarato R., Discrepancies between reported food intolerance and sensitization test findings in irritable bowel syndrome patients, Am. J. Gastroenterol, 94, pp. 1892-1897, (1999); Gwynn C.M., Smith J.M., Leon G.L., Stanworth D.R., Role of IgG4 subclass in childhood allergy, Lancet, 1, pp. 910-911, (1978); Husby S., Oxelius V.A., Teisner B., Jensenius J.C., Svehag S.-E., Humoral immunity to dietary antigens in healthy adults. Occurrence, isotype and IgG subclass distribution of serum antibodies to protein antigens, Int. Arch. Allergy Appl. Immunol, 77, pp. 416-422, (1985); Barnes R.M., Harvey M.M., Blears J., Finn R., Johnson P., IgG subclass of human serum antibodies reactive with dietary proteins, Int. Arch. Allergy Appl. Immunol, 81, pp. 141-147, (1986); Hunter J.O., Food elimination in IBS: The case for IgG testing remains doubtful, Gut, 54, (2005); Barnes R.M., Lewis-Jones M.S., Allan S., Dixon T.A., Vickers C.F.H., Development and isotype diversity of antibodies to inhalant and dietary antigens in childhood atopic eczema, Clin. Exp. Dermatol, 18, pp. 211-216, (1993); Ishikawa R., Tsujimura Y., Obata K., Dixon T.A., Vickers C.F.H., IgG-mediated systemic anaphylaxis to protein antigen can be induced even under conditions of limited amounts of antibody and antigen, Biochem. Biophys. Res. Commun, 402, pp. 742-746, (2010); Tsujimura Y., Obata K., Mukai K., Shindou H., Shindou M., Nishikado H., Kawano Y., Kawano Y., Shimizu T., Karasuyama H., Basophils play a pivotal role in immunoglobulin-G-mediated but not immunoglobulin-E-mediated systemic anaphylaxis, Immunity, 28, pp. 581-589, (2008); Brandtzaeg P., Food allergy: Separating the science from the mythology, Nat. Rev. Gastroenterol. Hepatol, 7, pp. 380-400, (2010); Vojdani A., Detection of IgE, IgG, IgA and IgM antibodies against raw and processed food antigens, Nutr. Metab, 6, (2009); Bock S.A., AAAAI Support of the EAACI Position Paper on IgG4; Position Statement, J. Allergy Clin. Immunol, 125, (2010); Fasano A., All disease begins in the (leaky) gut: Role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases, F1000Research, 9, (2020); Fasano A., Zonulin, regulation of tight junctions, and autoimmune diseases, Ann. N. Y. Acad. Sci, 1258, pp. 25-33, (2012); Stevens B.R., Goel R., Seungbum K., Richards E.M., Holbert R.C., Pepine C.J., Raizada M.K., Increased human intestinal barrier permeability plasma biomarkers zonulin and FABP2 correlated with plasma LPS and altered gut microbiome in anxiety or depression, Gut, 67, pp. 1555-1557, (2018); Paterson B.M., Lammers K.M., Arrieta M.C., Fasano A., Meddings J.B., The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: A proof of concept study, Aliment. Pharmacol. Ther, 26, pp. 757-766, (2007); Sturgeon C., Lan J., Fasano A., Zonulin transgenic mice show altered gut permeability and increased morbidity/mortality in the DSS colitis model, Ann. N. Y. Acad. Sci, 1397, pp. 130-142, (2017); Velikova T.V., Altankova I., Peruhova M., Mihova A., Kukov A., Georgieva V., Yurukova N., Mizgova G., Mehandzhiyska-Marinova T., Terzieva V., Et al., Prevalence of Specific IgG to Food Antigens in Bulgarian IBS Patients: A Preliminary Study, Mathews J. Nutr. Diet, 3, (2018); Velikova T.V., Altankova I., Mihova A., Terzieva V., Georgieva V., Kukov A., Yurukova N., Mehandzhiyska-Marinova T., Mizgova G., Zhelezova G., Et al., IgG-mediated immune reactivity in patients with Irritable Bowel Syndrome: A pilot study, Yearbook of Bulgarian Association for Clinical Immunology, 12, pp. 31-71, (2018); Schur P.H., Rosen F., Norman M.E., Immunoglobulin subclasses in normal children, Pediatr. Res, 13, pp. 181-183, (1979); Bentley S.J., Pearson D.J., Rix K.J., Food hypersensitivity in irritable bowel syndrome, Lancet, 2, pp. 295-297, (1983); Zar S., Mincher L., Benson M.J., Kumar D., Food-specific IgG4 antibodyguided exclusion diet improves symptoms and rectal compliance in irritable bowel syndrome, Scand. J. Gastroenterol, 40, pp. 800-807, (2005); Zeng Q., Dong S.Y., Wu L.X., Li H., Sun Z.-J., Li J.-B., Jiang H.-X., Chen Z.-H., Wang Q.-B., Chen W.-W., Variable food-specific IgG antibody levels in healthy and symptomatic Chinese adults, PLoS ONE, 8, (2013); Ligaarden S.C., Lydersen S., Farup P.G., IgG and IgG4 antibodies in subjects with irritable bowel syndrome: A case control study in the general population, BMC Gastroenterol, 12, (2012); Kvehaugen A.S., Tveiten D., Farup P.G., Is perceived intolerance to milk and wheat associated with the corresponding IgG and IgA food antibodies? A cross sectional study in subjects with morbid obesity and gastrointestinal symptoms, BMC Gastroenterol, 18, (2018); Wilders-Truschnig M., Mangge H., Lieners C., Gruber H.-J., Mayer C., Marz W., IgG antibodies against food antigens are correlated with inflammation and intima media thickness in obese juveniles, Exp. Clin. Endocrinol. Diabetes, 116, pp. 241-245, (2008); Aydinlar E.I., Dikmen P.Y., Tiftikci A., Saruc M., Aksu M., Gunsoy H.G., Tozun N., IgG-based elimination diet in migraine plus irritable bowel syndrome, Headache, 53, pp. 514-525, (2013); Drisko J., Bischoff B., Hall M., McCallum R., Treating irritable bowel syndrome with a food elimination diet followed by food challenge and probiotics, J. Am. Coll. Nutr, 25, pp. 514-522, (2006); Atkinson W., Sheldon T.A., Shaath N., Whorwell P.J., Food elimination based on IgG antibodies in irritable bowel syndrome: A randomised controlled trial, Gut, 53, pp. 1459-1464, (2004); Singh P., Silvester J., Chen X., Xu H., Sawhney V., Rangan V., Iturrino J., Nee J., Duerksen D.R., Lembo A., Serum zonulin is elevated in, I.B.S.; correlates with stool frequency in, I.B.S.-D, United Eur. Gastroenterol. J, 7, pp. 709-715, (2019); Caviglia G.P., Rosso C., Ribaldone D.G., Dughera F., Fagoonee S., Astegiano M., Pellicano R., Physiopathology of intestinal barrier and the role of zonulin, Minerva Biotecnol, 31, pp. 83-92, (2019); Barbaro M.R., Cremon C., Caio G., de Giorgio R., Volta U., Stanghellini V., Barbara G., 247 Zonulin serum levels are increased in non-celiac gluten sensitivity and irritable bowel syndrome with diarrhea, Gastroenterology, 148, (2015); Prospero L., Riezzo G., Linsalata M., Orlando A., D'Attoma B., Russo F., Psychological and Gastrointestinal Symptoms of Patients with Irritable Bowel Syndrome Undergoing a Low-FODMAP Diet: The Role of the Intestinal Barrier, Nutrients, 13, (2021); Tripathi A., Lammers K.M., Goldblum S., Shea-Donohue T., Netzel-Arnett S., Buzza M.S., Antalis T.M., Vogel S.N., Zhao A., Yang S., Et al., Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2, Proc. Natl. Acad. Sci. USA, 106, pp. 16799-16804, (2009); Koch W., Latz W., Eichinger M., Gschwendner C., Teige B., Schomig A., Kastrati A., Haptoglobin gene subtyping by restriction enzyme analysis, Clin. Chem, 49, pp. 1937-1940, (2003); Meira de-Faria F., Bednarska O., Strom M., Soderholm J.D., Walter S.A., Keita A.V., Colonic paracellular permeability and circulating zonulin-related proteins, Scand. J. Gastroenterol, 56, pp. 424-431, (2021); Scheffler L., Crane A., Heyne H., Tonjes A., Schleinitz D., Ihling C.H., Stumvoll M., Freire R., Fiorentino M., Fasano A., Et al., Widely used commercial ELISA does not detect precursor of haptoglobin2, but recognizes properdin as a potential second member of the zonulin family, Front. Endocrinol, 9, (2018); Ajamian M., Steer D., Rosella G., Gibson P.R., Serum zonulin as a marker of intestinal mucosal barrier function: May not be what it seems, PLoS ONE, 14, (2019); Talley N.J., Holtmann G.J., Jones M., Koloski N.A., Walker M.M., Burns G., Potter M.D.E., Shah A., Keely S., Zonulin in serum as a biomarker fails to identify the IBS, functional dyspepsia and non-coeliac wheat sensitivity, Gut, 69, pp. 1719-1722, (2020)","T. Velikova; Laboratory of Clinical Immunology, University Hospital Lozenetz, Sofia University St. Kliment Ohridski, Sofia, 1407, Bulgaria; email: tsvelikova@medfac.mu-sofia.bg","","MDPI","","","","","","20734468","","","","English","Antibodies","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85128463512"

"Valibouze C.; Dubuquoy C.; Chavatte P.; Genin M.; Maquet V.; Modica S.; Desreumaux P.; Rousseaux C.","Valibouze, Caroline (57216955115); Dubuquoy, Caroline (16678426600); Chavatte, Philippe (7004730680); Genin, Michaël (55627397100); Maquet, Veronique (6603820646); Modica, Salvatore (57208187463); Desreumaux, Pierre (54978202100); Rousseaux, Christel (8415396600)","57216955115; 16678426600; 7004730680; 55627397100; 6603820646; 57208187463; 54978202100; 8415396600","Chitin-glucan improves important pathophysiological features of irritable bowel syndrome","2024","World Journal of Gastroenterology","30","16","","2258","2271","13","0","10.3748/wjg.v30.i16.2258","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85191863150&doi=10.3748%2fwjg.v30.i16.2258&partnerID=40&md5=331eab2a4e4138298b4d785da318cf0a","Department of Digestive Surgery and Transplantation, Lille University, Lille, 59037, France; Intestinal Biotech Development, Faculté de Médicine, Lille, 59045, France; U1286-INFINITE-Institute for Translational Research in Inflammation, Université de Lille, Lille, 59000, France; ULR 2694-METRICS, Évaluation des Technologies de Santé et des Pratiques Médicales, University of Lille, Lille, 59000, France; KitoZyme SA, Institution Société Anonyme, Zone 2, Parc des Hauts Sarts, Rue de Milmort, Herstal, 4040, Belgium; Hepato-Gastroenterology Department, Lille University Hospital, Lille, 59037, France","Valibouze C., Department of Digestive Surgery and Transplantation, Lille University, Lille, 59037, France; Dubuquoy C., Intestinal Biotech Development, Faculté de Médicine, Lille, 59045, France; Chavatte P., U1286-INFINITE-Institute for Translational Research in Inflammation, Université de Lille, Lille, 59000, France; Genin M., ULR 2694-METRICS, Évaluation des Technologies de Santé et des Pratiques Médicales, University of Lille, Lille, 59000, France; Maquet V., KitoZyme SA, Institution Société Anonyme, Zone 2, Parc des Hauts Sarts, Rue de Milmort, Herstal, 4040, Belgium; Modica S., KitoZyme SA, Institution Société Anonyme, Zone 2, Parc des Hauts Sarts, Rue de Milmort, Herstal, 4040, Belgium; Desreumaux P., Hepato-Gastroenterology Department, Lille University Hospital, Lille, 59037, France; Rousseaux C., Intestinal Biotech Development, Faculté de Médicine, Lille, 59045, France","BACKGROUND Irritable bowel syndrome (IBS) is one of the most frequent and debilitating conditions leading to gastroenterological referrals. However, recommended treatments remain limited, yielding only limited therapeutic gains. Chitin-glucan (CG) is a novel dietary prebiotic classically used in humans at a dosage of 1.5-3.0 g/d and is considered a safe food ingredient by the European Food Safety Authority. To provide an alternative approach to managing patients with IBS, we performed preclinical molecular, cellular, and animal studies to evaluate the role of chitin-glucan in the main pathophysiological mechanisms involved in IBS. AIM To evaluate the roles of CG in visceral analgesia, intestinal inflammation, barrier function, and to develop computational molecular models. METHODS Visceral pain was recorded through colorectal distension (CRD) in a model of long-lasting colon hypersensitivity induced by an intra-rectal administration of TNBS [15 milligrams (mg)/kilogram (kg)] in 33 Sprague-Dawley rats. Intracolonic pressure was regularly assessed during the 9 wk-experiment (weeks 0, 3, 5, and 7) in animals receiving CG (n = 14) at a human equivalent dose (HED) of 1.5 g/d or 3.0 g/d and compared to negative control (tap water, n = 11) and positive control (phloroglucinol at 1.5 g/d HED, n = 8) groups. The anti-inflammatory effect of CG was evaluated using clinical and histological scores in 30 C57bl6 male mice with colitis induced by dextran sodium sulfate (DSS) administered in their drinking water during 14 d. HT-29 cells under basal conditions and after stimulation with lipopolysaccharide (LPS) were treated with CG to evaluate changes in pathways related to analgesia (µ-opioid receptor (MOR), cannabinoid receptor 2 (CB2), peroxisome proliferator-activated receptor alpha, inflammation [interleukin (IL)-10, IL-1b, and IL-8] and barrier function [mucin 2-5AC, claudin-2, zonula occludens (ZO)-1, ZO-2] using the real-time PCR method. Molecular modelling of CG, LPS, lipoteichoic acid (LTA), and phospholipomannan (PLM) was developed, and the ability of CG to chelate microbial pathogenic lipids was evaluated by docking and molecular dynamics simulations. Data were expressed as the mean ± SEM. RESULTS Daily CG orally-administered to rats or mice was well tolerated without including diarrhea, visceral hypersensitivity, or inflammation, as evaluated at histological and molecular levels. In a model of CRD, CG at a dosage of 3 g/d HED significantly decreased visceral pain perception by 14% after 2 wk of administration (P < 0.01) and reduced inflammation intensity by 50%, resulting in complete regeneration of the colonic mucosa in mice with DSS-induced colitis. To better reproduce the characteristics of visceral pain in patients with IBS, we then measured the therapeutic impact of CG in rats with TNBS-induced inflammation to long-lasting visceral hypersensitivity. CG at a dosage of 1.5 g/d HED decreased visceral pain perception by 20% five weeks after colitis induction (P < 0.01). When the CG dosage was increased to 3.0 g/d HED, this analgesic effect surpassed that of the spasmolytic agent phloroglucinol, manifesting more rapidly within 3 wk and leading to a 50% inhibition of pain perception (P < 0.0001). The underlying molecular mechanisms contributing to these analgesic and anti-inflammatory effects of CG involved, at least in part, a significant induction of MOR, CB2 receptor, and IL-10, as well as a significant decrease in pro-inflammatory cytokines IL-1b and IL-8. CG also significantly upregulated barrier-related genes including muc5AC, claudin-2, and ZO-2. Molecular modelling of CG revealed a new property of the molecule as a chelator of microbial pathogenic lipids, sequestering gram-negative LPS and gram-positive LTA bacterial toxins, as well as PLM in fungi at the lowesr energy conformations. CONCLUSION CG decreased visceral perception and intestinal inflammation through master gene regulation and direct binding of microbial products, suggesting that CG may constitute a new therapeutic strategy for patients with IBS or IBS-like symptoms. © The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.","Abdominal pain; Chitin-glucan; Inflammation; Intestinal barrier; Irritable bowel syndrome; Microbial cell walls chelation; Molecular modelling","Animals; Chitin; Colitis; Colon; Disease Models, Animal; Glucans; HT29 Cells; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Male; Mice; Prebiotics; Rats; Rats, Sprague-Dawley; Trinitrobenzenesulfonic Acid; Visceral Pain; cannabinoid 2 receptor; chitin glucan; claudin 2; dextran sulfate; interleukin 10; interleukin 1beta; interleukin 8; lipopolysaccharide; lipoteichoic acid; mu opiate receptor; mucin 2; mucin 5AC; phloroglucinol; phospholipid; phospholipomannan; polysaccharide; protein ZO1; protein ZO2; unclassified drug; chitin; glucan; prebiotic agent; trinitrobenzenesulfonic acid; analgesic activity; animal experiment; animal model; animal tissue; antiinflammatory activity; Article; colitis; colon mucosa; controlled study; drug tolerability; gene expression; histopathology; human; human cell; hypersensitivity; inflammation; intestinal barrier function; irritable colon; male; molecular docking; molecular model; nonhuman; pathophysiology; rat; real time polymerase chain reaction; tissue regeneration; upregulation; visceral pain; animal; colon; disease model; drug effect; HT-29 cell line; intestine mucosa; irritable colon; metabolism; mouse; pathology; Sprague Dawley rat; visceral pain","","dextran sulfate, 9011-18-1, 9042-14-2; interleukin 8, 114308-91-7; lipoteichoic acid, 56411-57-5; phloroglucinol, 108-73-6; chitin, 1398-61-4; glucan, 9012-72-0, 9037-91-6; trinitrobenzenesulfonic acid, 16655-63-3, 2508-19-2; Chitin, ; Glucans, ; Prebiotics, ; Trinitrobenzenesulfonic Acid, ","","","","","Camilleri M, Choi MG., Review article: irritable bowel syndrome, Aliment Pharmacol Ther, 11, pp. 3-15, (1997); Fortea J, Prior M., Irritable bowel syndrome with constipation: a European-focused systematic literature review of disease burden, J Med Econ, 16, pp. 329-341, (2013); Sethi S, Wadhwa V, LeClair J, Mikami S, Park R, Jones M, Sethi N, Brown A, Lembo A., In-patient discharge rates for the irritable bowel syndrome - an analysis of national trends in the United States from 1997 to 2010, Aliment Pharmacol Ther, 38, pp. 1338-1346, (2013); Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, Moshiree B., ACG Clinical Guideline: Management of Irritable Bowel Syndrome, Am J Gastroenterol, 116, pp. 17-44, (2021); Vasant DH, Paine PA, Black CJ, Houghton LA, Everitt HA, Corsetti M, Agrawal A, Aziz I, Farmer AD, Eugenicos MP, Moss-Morris R, Yiannakou Y, Ford AC., British Society of Gastroenterology guidelines on the management of irritable bowel syndrome, Gut, 70, pp. 1214-1240, (2021); Moayyedi P, Andrews CN, MacQueen G, Korownyk C, Marsiglio M, Graff L, Kvern B, Lazarescu A, Liu L, Paterson WG, Sidani S, Vanner S., Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS), J Can Assoc Gastroenterol, 2, pp. 6-29, (2019); Fukudo S, Okumura T, Inamori M, Okuyama Y, Kanazawa M, Kamiya T, Sato K, Shiotani A, Naito Y, Fujikawa Y, Hokari R, Masaoka T, Fujimoto K, Kaneko H, Torii A, Matsueda K, Miwa H, Enomoto N, Shimosegawa T, Koike K., Evidence-based clinical practice guidelines for irritable bowel syndrome 2020, J Gastroenterol, 56, pp. 193-217, (2021); Lembo A, Sultan S, Chang L, Heidelbaugh JJ, Smalley W, Verne GN., AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea, Gastroenterology, 163, pp. 137-151, (2022); Chang L, Sultan S, Lembo A, Verne GN, Smalley W, Heidelbaugh JJ., AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation, Gastroenterology, 163, pp. 118-136, (2022); Savarino E, Zingone F, Barberio B, Marasco G, Akyuz F, Akpinar H, Barboi O, Bodini G, Bor S, Chiarioni G, Cristian G, Corsetti M, Di Sabatino A, Dimitriu AM, Drug V, Dumitrascu DL, Ford AC, Hauser G, Nakov R, Patel N, Pohl D, Sfarti C, Serra J, Simren M, Suciu A, Tack J, Toruner M, Walters J, Cremon C, Barbara G., Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility, United European Gastroenterol J, 10, pp. 556-584, (2022); Jakobsson Ung E, Ringstrom G, Sjovall H, Simren M., How patients with long-term experience of living with irritable bowel syndrome manage illness in daily life: a qualitative study, Eur J Gastroenterol Hepatol, 25, pp. 1478-1483, (2013); Bertram S, Kurland M, Lydick E, Locke GR, Yawn BP., The patient's perspective of irritable bowel syndrome, J Fam Pract, 50, pp. 521-525, (2001); Scientific opinion on the safety of ‘Chitin-glucan’ as a novel food ingredient, EFSA J, 8, (2010); Berecochea-Lopez A, Decorde K, Ventura E, Godard M, Bornet A, Teissedre PL, Cristol JP, Rouanet JM., Fungal chitin-glucan from Aspergillus niger efficiently reduces aortic fatty streak accumulation in the high-fat fed hamster, an animal model of nutritionally induced atherosclerosis, J Agric Food Chem, 57, pp. 1093-1098, (2009); Neyrinck AM, Possemiers S, Verstraete W, De Backer F, Cani PD, Delzenne NM., Dietary modulation of clostridial cluster XIVa gut bacteria (Roseburia spp.) by chitin-glucan fiber improves host metabolic alterations induced by high-fat diet in mice, J Nutr Biochem, 23, pp. 51-59, (2012); Calatayud M, Verstrepen L, Ghyselinck J, Van den Abbeele P, Marzorati M, Modica S, Ranjanoro T, Maquet V., Chitin Glucan Shifts Luminal and Mucosal Microbial Communities, Improve Epithelial Barrier and Modulates Cytokine Production In Vitro, Nutrients, 13, (2021); Rodriguez J, Neyrinck AM, Zhang Z, Seethaler B, Nazare JA, Robles Sanchez C, Roumain M, Muccioli GG, Bindels LB, Cani PD, Maquet V, Laville M, Bischoff SC, Walter J, Delzenne NM., Metabolite profiling reveals the interaction of chitin-glucan with the gut microbiota, Gut Microbes, 12, (2020); Martin R, Rios-Covian D, Huillet E, Auger S, Khazaal S, Bermudez-Humaran LG, Sokol H, Chatel JM, Langella P., Faecalibacterium: a bacterial genus with promising human health applications, FEMS Microbiol Rev, 47, (2023); Johnson AC, Farmer AD, Ness TJ, Greenwood-Van Meerveld B., Critical evaluation of animal models of visceral pain for therapeutics development: A focus on irritable bowel syndrome, Neurogastroenterol Motil, 32, (2020); Brenna O, Furnes MW, Drozdov I, van Beelen Granlund A, Flatberg A, Sandvik AK, Zwiggelaar RT, Marvik R, Nordrum IS, Kidd M, Gustafsson BI., Relevance of TNBS-colitis in rats: a methodological study with endoscopic, histologic and Transcriptomic [corrected] characterization and correlation to IBD, PLoS One, 8, (2013); Zimmermann M., Ethical guidelines for investigations of experimental pain in conscious animals, Pain, 16, pp. 109-110, (1983); Bourdu S, Dapoigny M, Chapuy E, Artigue F, Vasson MP, Dechelotte P, Bommelaer G, Eschalier A, Ardid D., Rectal instillation of butyrate provides a novel clinically relevant model of noninflammatory colonic hypersensitivity in rats, Gastroenterology, 128, pp. 1996-2008, (2005); Rousseaux C, Thuru X, Gelot A, Barnich N, Neut C, Dubuquoy L, Dubuquoy C, Merour E, Geboes K, Chamaillard M, Ouwehand A, Leyer G, Carcano D, Colombel JF, Ardid D, Desreumaux P., Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors, Nat Med, 13, pp. 35-37, (2007); Cooper HS, Murthy SN, Shah RS, Sedergran DJ., Clinicopathologic study of dextran sulfate sodium experimental murine colitis, Lab Invest, 69, pp. 238-249, (1993); Dieleman LA, Palmen MJ, Akol H, Bloemena E, Pena AS, Meuwissen SG, Van Rees EP., Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines, Clin Exp Immunol, 114, pp. 385-391, (1998); Funakoshi T, Yamashita K, Ichikawa N, Fukai M, Suzuki T, Goto R, Oura T, Kobayashi N, Katsurada T, Ichihara S, Ozaki M, Umezawa K, Todo S., A novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin, ameliorates inflammatory colonic injury in mice, J Crohns Colitis, 6, pp. 215-225, (2012); Clark M, Cramer RD, Van Opdenbosch N., Validation of the general purpose Tripos 5.2 force field, J Comput Chem, 10, pp. 982-1012, (1989); Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, Spiller R., Bowel Disorders, Gastroenterology, (2016); Drossman DA., Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV, Gastroenterology, (2016); Esquerre N, Basso L, Dubuquoy C, Djouina M, Chappard D, Blanpied C, Desreumaux P, Vergnolle N, Vignal C, Body-Malapel M., Aluminum Ingestion Promotes Colorectal Hypersensitivity in Rodents, Cell Mol Gastroenterol Hepatol, 7, pp. 185-196, (2019); Jafri W, Yakoob J, Hussain S, Jafri N, Islam M., Phloroglucinol in irritable bowel syndrome, J Pak Med Assoc, 56, pp. 5-8, (2006); Annahazi A, Roka R, Rosztoczy A, Wittmann T., Role of antispasmodics in the treatment of irritable bowel syndrome, World J Gastroenterol, 20, pp. 6031-6043, (2014); Shin SY, Cha BK, Kim WS, Park JY, Kim JW, Choi CH., The Effect of Phloroglucinol in Patients With Diarrhea-predominant Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled Trial, J Neurogastroenterol Motil, 26, pp. 117-127, (2020); Philippe D, Chakass D, Thuru X, Zerbib P, Tsicopoulos A, Geboes K, Bulois P, Breisse M, Vorng H, Gay J, Colombel JF, Desreumaux P, Chamaillard M., Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation, Gut, 55, pp. 815-823, (2006); Philippe D, Dubuquoy L, Groux H, Brun V, Chuoi-Mariot MT, Gaveriaux-Ruff C, Colombel JF, Kieffer BL, Desreumaux P., Anti-inflammatory properties of the mu opioid receptor support its use in the treatment of colon inflammation, J Clin Invest, 111, pp. 1329-1338, (2003); Wright K, Rooney N, Feeney M, Tate J, Robertson D, Welham M, Ward S., Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing, Gastroenterology, 129, pp. 437-453, (2005); Kasatkina LA, Rittchen S, Sturm EM., Neuroprotective and Immunomodulatory Action of the Endocannabinoid System under Neuroinflammation, Int J Mol Sci, 22, (2021); Xu B, Zhang Q, Chen D, Zhang M, Zhang R, Zhao W, Qiu Y, Xu K, Xiao J, Niu J, Shi Y, Li N, Fang Q., OCP002, a Mixed Agonist of Opioid and Cannabinoid Receptors, Produces Potent Antinociception With Minimized Side Effects, Anesth Analg, 136, pp. 373-386, (2023); Luo Y, Xie C, Brocker CN, Fan J, Wu X, Feng L, Wang Q, Zhao J, Lu D, Tandon M, Cam M, Krausz KW, Liu W, Gonzalez FJ., Intestinal PPARα Protects Against Colon Carcinogenesis via Regulation of Methyltransferases DNMT1 and PRMT6, Gastroenterology, 157, pp. 744-759, (2019); Drewes AM, Olesen AE, Farmer AD, Szigethy E, Rebours V, Olesen SS., Gastrointestinal pain, Nat Rev Dis Primers, 6, (2020); Ford AC, Talley NJ., Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review, J Gastroenterol, 46, pp. 421-431, (2011); Bugbee E, Wang AA, Gommerman JL., Under the influence: environmental factors as modulators of neuroinflammation through the IL-10/IL-10R axis, Front Immunol, 14, (2023); Dunlop SP, Hebden J, Campbell E, Naesdal J, Olbe L, Perkins AC, Spiller RC., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Rao AS, Camilleri M, Eckert DJ, Busciglio I, Burton DD, Ryks M, Wong BS, Lamsam J, Singh R, Zinsmeister AR., Urine sugars for in vivo gut permeability: validation and comparisons in irritable bowel syndrome-diarrhea and controls, Am J Physiol Gastrointest Liver Physiol, 301, pp. G919-G928, (2011); Inaba R, Vujakovic S, Bergstrom K., The gut mucus network: A dynamic liaison between microbes and the immune system, Semin Immunol, 69, (2023); Martinez-Maqueda D, Miralles B, Recio I., HT29 Cell Line, The Impact of Food Bioactives on Health: in vitro and ex vivo models [Internet], (2015); Bentzer P, Russell JA, Walley KR., Advances in Sepsis Research, Clin Chest Med, 36, pp. 521-530, (2015); Cinel I, Opal SM., Molecular biology of inflammation and sepsis: a primer, Crit Care Med, 37, pp. 291-304, (2009); Howell CA, Kemppinen A, Allgar V, Dodd M, Knowles CH, McLaughlin J, Pandya P, Whorwell P, Markaryan E, Yiannakou Y., Double-blinded randomised placebo controlled trial of enterosgel (polymethylsiloxane polyhydrate) for the treatment of IBS with diarrhoea (IBS-D), Gut, 71, pp. 2430-2438, (2022); Rosa RD, Vergnes A, de Lorgeril J, Goncalves P, Perazzolo LM, Saune L, Romestand B, Fievet J, Gueguen Y, Bachere E, Destoumieux-Garzon D., Functional divergence in shrimp anti-lipopolysaccharide factors (ALFs): from recognition of cell wall components to antimicrobial activity, PLoS One, 8, (2013); Yang Y, Boze H, Chemardin P, Padilla A, Moulin G, Tassanakajon A, Pugniere M, Roquet F, Destoumieux-Garzon D, Gueguen Y, Bachere E, Aumelas A., NMR structure of rALF-Pm3, an anti-lipopolysaccharide factor from shrimp: model of the possible lipid A-binding site, Biopolymers, 91, pp. 207-220, (2009); Perez S, Wertz JL., Chitin and Chitosans in the bioeconomy, (2022); Ngo DH, Kim SK., Antioxidant effects of chitin, chitosan, and their derivatives, Adv Food Nutr Res, 73, pp. 15-31, (2014); Gonzalez-Fernandez C, Basauri A, Fallanza M, Bringas E, Oostenbrink C, Ortiz I., Fighting Against Bacterial Lipopolysaccharide-Caused Infections through Molecular Dynamics Simulations: A Review, J Chem Inf Model, 61, pp. 4839-4851, (2021)","C. Rousseaux; Intestinal Biotech Development, Faculté de Médicine, Pole Recherche Amphi JK, Lille, Bd du Pr Jules Leclercq, 59045, France; email: crousseaux@ibd-biotech.com","","Baishideng Publishing Group Inc","","","","","","10079327","","WJGAF","38690023","English","World J. Gastroenterol.","Article","Final","All Open Access; Hybrid Gold Open Access","Scopus","2-s2.0-85191863150"

"Ciriza de Los Ríos C.; Aparicio Cabezudo M.; Zatarain Vallés A.; Rey E.","Ciriza de Los Ríos, Constanza (6602108091); Aparicio Cabezudo, Marta (56113649600); Zatarain Vallés, Ana (57205761877); Rey, Enrique (7103353498)","6602108091; 56113649600; 57205761877; 7103353498","Practical approach to irritable bowel syndrome-diarrhea beyond low-FODMAP diet","2022","Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva","114","8","","481","488","7","0","10.17235/reed.2022.8749/2022","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85135419412&doi=10.17235%2freed.2022.8749%2f2022&partnerID=40&md5=fbe215b182a6da2de6922ef9fb486871","Aparato Digestivo, Hospital Clínico San Carlos, Spain; Aparato Digestivo, Hospital Clínico San Carlos, Spain","Ciriza de Los Ríos C., Aparato Digestivo, Hospital Clínico San Carlos, Spain; Aparicio Cabezudo M., Aparato Digestivo, Hospital Clínico San Carlos, Spain; Zatarain Vallés A., Aparato Digestivo, Hospital Clínico San Carlos, Spain; Rey E., Aparato Digestivo, Hospital Clínico San Carlos, Spain","Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by abdominal pain and altered defecation, usually accompanied by abdominal bloating or distension. The integrated model of bidirectional interaction between the central, autonomic, enteric nervous system, the microbiome, and the gut barrier allows a better understanding of the pathophysiology of IBS, as well as consideration of potential therapeutic strategies. IBS with predominant diarrhea (IBS-D) represents a therapeutic challenge. Dietary changes or restrictions are most commonly used by patients in an attempt at symptom control. Therefore, a number of diets, especially low-FODMAP diet, have increasingly gained interest as a therapy for IBS-D or mixed IBS. However, this kind of diet, while effective, is not exempt of problems. It is therefore necessary that other therapeutic options be considered while bearing pathophysiological mechanisms and general symptom management in mind.","","Diarrhea; Diet; Fermentation; Gastrointestinal Diseases; Humans; Irritable Bowel Syndrome; Monosaccharides; Oligosaccharides; monosaccharide; oligosaccharide; complication; diarrhea; diet; fermentation; gastrointestinal disease; human; irritable colon","","Monosaccharides, ; Oligosaccharides, ","","","","","","","","NLM (Medline)","","","","","","11300108","","","35694883","English","Rev Esp Enferm Dig","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85135419412"

"Wei Y.; Fan Y.; Huang S.; Lv J.; Zhang Y.; Hao Z.","Wei, Yuanyuan (57272898300); Fan, Yimeng (57223671808); Huang, Sijuan (58672703200); Lv, Jianyu (58672550500); Zhang, Yannan (57273393600); Hao, Zhihui (55565872500)","57272898300; 57223671808; 58672703200; 58672550500; 57273393600; 55565872500","Baizhu shaoyao decoction restores the intestinal barrier and brain–gut axis balance to alleviate diarrhea-predominant irritable bowel syndrome via FoxO1/FoxO3a","2024","Phytomedicine","122","","155163","","","","3","10.1016/j.phymed.2023.155163","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85175352430&doi=10.1016%2fj.phymed.2023.155163&partnerID=40&md5=ca5faeae018c81408898dfa334e9a56f","National Key Laboratory of Veterinary Public Health Security, College of Veterinary Medicine, China Agricultural University, No. 2 Yuanmingyuan West Road, 100193, Beijing, China; Key Biology Laboratory of Chinese Veterinary Medicine, Ministry of Agriculture and Rural Affairs, Beijing, 100193, China; National Center of Technology Innovation for Medicinal Function of Food, National Food and Strategic Reserves Administration, Beijing, 100193, China","Wei Y., National Key Laboratory of Veterinary Public Health Security, College of Veterinary Medicine, China Agricultural University, No. 2 Yuanmingyuan West Road, 100193, Beijing, China, Key Biology Laboratory of Chinese Veterinary Medicine, Ministry of Agriculture and Rural Affairs, Beijing, 100193, China, National Center of Technology Innovation for Medicinal Function of Food, National Food and Strategic Reserves Administration, Beijing, 100193, China; Fan Y., National Key Laboratory of Veterinary Public Health Security, College of Veterinary Medicine, China Agricultural University, No. 2 Yuanmingyuan West Road, 100193, Beijing, China, Key Biology Laboratory of Chinese Veterinary Medicine, Ministry of Agriculture and Rural Affairs, Beijing, 100193, China, National Center of Technology Innovation for Medicinal Function of Food, National Food and Strategic Reserves Administration, Beijing, 100193, China; Huang S., National Key Laboratory of Veterinary Public Health Security, College of Veterinary Medicine, China Agricultural University, No. 2 Yuanmingyuan West Road, 100193, Beijing, China, Key Biology Laboratory of Chinese Veterinary Medicine, Ministry of Agriculture and Rural Affairs, Beijing, 100193, China, National Center of Technology Innovation for Medicinal Function of Food, National Food and Strategic Reserves Administration, Beijing, 100193, China; Lv J., National Key Laboratory of Veterinary Public Health Security, College of Veterinary Medicine, China Agricultural University, No. 2 Yuanmingyuan West Road, 100193, Beijing, China, Key Biology Laboratory of Chinese Veterinary Medicine, Ministry of Agriculture and Rural Affairs, Beijing, 100193, China, National Center of Technology Innovation for Medicinal Function of Food, National Food and Strategic Reserves Administration, Beijing, 100193, China; Zhang Y., National Key Laboratory of Veterinary Public Health Security, College of Veterinary Medicine, China Agricultural University, No. 2 Yuanmingyuan West Road, 100193, Beijing, China, Key Biology Laboratory of Chinese Veterinary Medicine, Ministry of Agriculture and Rural Affairs, Beijing, 100193, China, National Center of Technology Innovation for Medicinal Function of Food, National Food and Strategic Reserves Administration, Beijing, 100193, China; Hao Z., National Key Laboratory of Veterinary Public Health Security, College of Veterinary Medicine, China Agricultural University, No. 2 Yuanmingyuan West Road, 100193, Beijing, China, Key Biology Laboratory of Chinese Veterinary Medicine, Ministry of Agriculture and Rural Affairs, Beijing, 100193, China, National Center of Technology Innovation for Medicinal Function of Food, National Food and Strategic Reserves Administration, Beijing, 100193, China","Background: Diarrhea-predominant irritable bowel syndrome (IBS-D) is a common functional gastrointestinal disease. Besides, baizhu shaoyao decoction (BSD) is an effective treatment for IBS-D; however, its mechanism of action remains unclear. Purpose: This study aims to assess the ability of BSD to therapy IBS-D and to elucidate the underlying mechanism. Methods: First, comprehensive analyses, including ADME (absorption, distribution, metabolism, excretion) screening, Venn analysis, Gene Ontology (GO) analysis, and network construction, were performed to characterize IBS-D-related pathways and explore the synergistic effects of BSD active compounds. Next, an IBS-D model was constructed using a three-factor superposition method of neonatal maternal separation, chronic immobilization stress stimulation, and Sennae folium aqueous extract lavage. Moreover, the impact of BSD was assessed based on the body weight, fecal water content, and abdominal withdrawal reflex (AWR), and the results of the open field test, sucrose preference test, intestinal permeability assessment, transmission electron microscopy, and TdT-mediated dUTP nick-end labeling (TUNEL) analysis. The factors that regulate the BSD effects on IBS-D were estimated using immunoblotting, quantitative reverse transcription polymerase chain reaction (q-RTPCR), immunohistochemistry, and transcriptome sequencing analyses. Results: We found that BSD improved depressive behavior, brain–gut peptide levels, and intestinal permeability induced by IBS-D by increasing the abundance of intestinal tight junctions. In addition, BSD reduced secretory immunoglobulin A levels and the number of intestinal mast cells in IBS-D rats. Network pharmacology and transcriptome sequencing analysis further revealed that the forkhead box O (FoxO) signaling pathway contributed to the BSD-induced alleviation of IBS-D, as BSD regulated the protein and mRNA levels of FoxO1, glycogen synthase kinase 3β, and FoxO3a. Importantly, a FoxO1 inhibitor effectively alleviated IBS-D symptoms in rats, whereas a FoxO3a agonist had the opposite effects. Conclusion: These results demonstrate that BSD alleviates depression and intestinal symptoms by regulating brain–gut peptide expression and restoring the intestinal barrier function via the FoxO signaling pathway. Furthermore, our study uses serum pharmacochemistry technology to analyze the in vivo components of TCM formula under effective condition, solving the problem of the discovery of the effective components of TCM to some extent. © 2023 Elsevier GmbH","Baizhu shaoyao decoction; Brain–gut axis; FoxO signal pathway; Intestinal barrier; Irritable bowel syndrome; Predominant diarrhea","Animals; Brain-Gut Axis; Diarrhea; Irritable Bowel Syndrome; Maternal Deprivation; Peptides; Rats; amine oxidase (copper containing); baizhu shaoyao decoction; Chinese medicinal formula; cholecystokinin; claudin 1; gastrointestinal polypeptide; glial maturation factor beta; glycogen synthase kinase 3beta; lactic acid; messenger RNA; neuropeptide Y; pinaverium bromide; protein ZO1; secretory immunoglobulin; Senna extract; serotonin; substance P; thrombocyte activating factor; transcription factor FKHR; transcription factor FKHRL1; tryptase; unclassified drug; vasoactive intestinal polypeptide; Atractylodes macrocephala extract; peptide; animal cell; animal experiment; animal model; animal tissue; Article; brain-gut axis; controlled study; diarrhea; drug mechanism; feces; histopathology; human; immobilization stress; immunoblotting; immunohistochemistry; in vivo study; intestine mucosa permeability; irritable colon; male; mast cell; maternal deprivation; mRNA expression level; newborn; nonhuman; open field test; permeability barrier; protein expression; rat; real time reverse transcription polymerase chain reaction; regulatory mechanism; signal transduction; sucrose preference test; systems pharmacology; tight junction; transcription regulation; transcriptome sequencing; transmission electron microscopy; TUNEL assay; upregulation; water content; withdrawal reflex; animal; brain-gut axis; diarrhea; irritable colon; metabolism","","amine oxidase (copper containing), 9001-53-0, 9014-75-9; cholecystokinin, 9011-97-6, 93443-27-7; claudin 1, 329338-06-9; glycogen synthase kinase 3alpha, ; glycogen synthase kinase 3beta, ; lactic acid, 113-21-3, 50-21-5; neuropeptide Y, 82785-45-3, 83589-17-7; pinaverium bromide, 53251-94-8; Senna extract, 57828-25-8; serotonin, 50-67-9; substance P, 33507-63-0; thrombocyte activating factor, 64176-80-3, 65154-06-5; tryptase, 97501-93-4; vasoactive intestinal polypeptide, 37221-79-7; Baizhu, ; Peptides, ","","","Key Project at Central Government Level, China Academy of Chinese Medical Sciences, (2060302); State Key Research and Development Plan , China, (2022YFD1801105); State Key Research and Development Plan, China","Funding text 1: The research was supported by the Key Project at Central Government Level, China Academy of Chinese Medical Sciences (grant number 2060302 ) and the State Key Research and Development Plan , China (grant number 2022YFD1801105 ). ; Funding text 2: The research was supported by the Key Project at Central Government Level, China Academy of Chinese Medical Sciences (grant number 2060302) and the State Key Research and Development Plan, China (grant number 2022YFD1801105).","Abbas Z., Yakoob J., Jafri W., Ahmad Z., Azam Z., Usman M.W., Shamim S., Islam M., Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: a randomized trial, Eur. J. Gastroenterol. Hepatol., 26, pp. 630-639, (2014); Akbar A., Yiangou Y., Facer P., Walters J.R., Anand P., Ghosh S., Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain, Gut, 57, pp. 923-929, (2008); Bardou P., Mariette J., Escudie F., Djemiel C., Klopp C., jvenn: an interactive Venn diagram viewer, BMC Bioinformatics, 15, (2014); Bertrand J., Ghouzali I., Guerin C., Bole-Feysot C., Gouteux M., Dechelotte P., Ducrotte P., Coeffier M., Glutamine restores tight junction protein claudin-1 expression in colonic mucosa of patients with diarrhea-predominant irritable bowel syndrome, JPEN J. Parenter. Enteral Nutr., 40, pp. 1170-1176, (2016); Black C.J., Burr N.E., Camilleri M., Earnest D.L., Quigley E.M., Moayyedi P., Houghton L.A., Ford A.C., Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis, Gut, 69, pp. 74-82, (2020); Camilleri M., Diagnosis and treatment of irritable bowel syndrome: a review, JAMA, 325, pp. 865-877, (2021); Camilleri M., Boeckxstaens G., Dietary and pharmacological treatment of abdominal pain in IBS, Gut, 66, pp. 966-974, (2017); Chen M., Tang T.C., Wang Y., Shui J., Xiao X.H., Lan X., Yu P., Zhang C., Wang S.H., Yao J., Zheng H., Huang D.Q., Randomised clinical trial: tong-Xie-Yao-Fang granules versus placebo for patients with diarrhoea-predominant irritable bowel syndrome, Aliment. Pharmacol. Ther., 48, pp. 160-168, (2018); Cheng L., Luo Q.Q., Chen S.L., The role of intestinal mast cell infiltration in irritable bowel syndrome, J. Dig. Dis., 22, pp. 143-151, (2021); Coeffier M., Gloro R., Boukhettala N., Aziz M., Lecleire S., Vandaele N., Antonietti M., Savoye G., Bole-Feysot C., Dechelotte P., Reimund J.M., Ducrotte P., Increased proteasome-mediated degradation of occludin in irritable bowel syndrome, Am. J. Gastroenterol., 105, pp. 1181-1188, (2010); Daitoku H., Sakamaki J., Fukamizu A., Regulation of FoxO transcription factors by acetylation and protein-protein interactions, Biochim. Biophys. Acta, 1813, pp. 1954-1960, (2011); Dalal S.R., Chang E.B., The microbial basis of inflammatory bowel diseases, J. Clin. Invest., 124, pp. 4190-4196, (2014); Fan Y., Zhao Q., Wei Y., Wang H., Ga Y., Zhang Y., Hao Z., Pingwei san ameliorates spleen deficiency-induced diarrhea through intestinal barrier protection and gut microbiota modulation, Antioxidants (Basel), (2023); Ford A.C., Sperber A.D., Corsetti M., Camilleri M., Irritable bowel syndrome, Lancet, 396, pp. 1675-1688, (2020); Gao C., Liu C., Wei Y., Wang Q., Ni X., Wu S., Fang Y., Hao Z., The acute oral toxicity test of ethanol extract of salt-processed Psoraleae Fructus and its acute hepatotoxicity and nephrotoxicity risk assessment, J. Ethnopharmacol., 309, (2023); Gao J., Xiong T., Grabauskas G., Owyang C., Mucosal serotonin reuptake transporter expression in irritable bowel syndrome is modulated by gut microbiota via mast cell-prostaglandin E2, Gastroenterology, 162, pp. 1962-1974.e1966, (2022); Gawali N.B., Bulani V.D., Gursahani M.S., Deshpande P.S., Kothavade P.S., Juvekar A.R., Agmatine attenuates chronic unpredictable mild stress-induced anxiety, depression-like behaviours and cognitive impairment by modulating nitrergic signalling pathway, Brain Res., 1663, pp. 66-77, (2017); Grabauskas G., Wu X., Gao J., Li J.Y., Turgeon D.K., Owyang C., Prostaglandin E(2), produced by mast cells in colon tissues from patients with irritable bowel syndrome, contributes to visceral hypersensitivity in mice, Gastroenterology, 158, pp. 2195-2207.e2196, (2020); Gracie D.J., Hamlin P.J., Ford A.C., The influence of the brain-gut axis in inflammatory bowel disease and possible implications for treatment, Lancet. Gastroenterol. Hepatol. (N Y), 4, pp. 632-642, (2019); Green C.L., Lamming D.W., Fontana L., Molecular mechanisms of dietary restriction promoting health and longevity, Nat. Rev. Mol. Cell Biol., 23, pp. 56-73, (2022); Gui T., Burgering B.M.T., FOXOs: masters of the equilibrium, FEBS J., 289, pp. 7918-7939, (2022); Hajjar S., Nathan N., Joseph J., Mottawea W., Ariana A., Pyatibrat S., Harper M.E., Alain T., Blais A., Russell R.C., Sad S., Foxo3a tempers excessive glutaminolysis in activated T cells to prevent fatal gut inflammation in the murine IL-10(-/-) model of colitis, Cell Death Differ., 29, pp. 585-599, (2022); Han Y., Wang X., Cheng X., Zhao M., Zhao T., Guo L., Liu D., Wu K., Fan M., Shi M., Zhu L., Close homolog of L1 deficiency exacerbated intestinal epithelial barrier function in mouse model of dextran sulfate sodium-induced colitis, Front. Physiol., 11, (2020); Hossain Z., Hirata T., Molecular mechanism of intestinal permeability: interaction at tight junctions, Mol. Biosyst., 4, pp. 1181-1185, (2008); Hou Q., Huang Y., Zhu S., Li P., Chen X., Hou Z., Liu F., MiR-144 increases intestinal permeability in IBS-D rats by targeting OCLN and ZO1, Cell. Physiol. Biochem., 44, pp. 2256-2268, (2017); Hou Q., Huang Y., Zhu Z., Liao L., Chen X., Han Q., Liu F., Tong-Xie-Yao-Fang improves intestinal permeability in diarrhoea-predominant irritable bowel syndrome rats by inhibiting the NF-κB and notch signalling pathways, BMC Complement. Altern. Med., 19, (2019); Huang W., Jiang S.M., Jia L., You L.Q., Huang Y.X., Gong Y.M., Wang G.Q., Effect of amitriptyline on gastrointestinal function and brain-gut peptides: a double-blind trial, World J. Gastroenterol., 19, pp. 4214-4220, (2013); Ji M., Huang H., Lan X., Correlation between intestinal microflora in irritable bowel syndrome and severity, Dis. Markers, 2022, (2022); Lackner J.M., Ma C.X., Keefer L., Brenner D.M., Gudleski G.D., Satchidanand N., Firth R., Sitrin M.D., Katz L., Krasner S.S., Ballou S.K., Naliboff B.D., Mayer E.A., Type, rather than number, of mental and physical comorbidities increases the severity of symptoms in patients with irritable bowel syndrome, Clin. Gastroenterol. Hepatol., 11, pp. 1147-1157, (2013); Lee K.N., Lee O.Y., The role of mast cells in irritable bowel syndrome, Gastroenterol. Res. Pract., 2016, (2016); Li L., Cui H., Li T., Qi J., Chen H., Gao F., Tian X., Mu Y., He R., Lv S., Chu F., Xu B., Wang P., Lei H., Xu H., Wang C., Synergistic effect of berberine-based chinese medicine assembled nanostructures on diarrhea-predominant irritable bowel syndrome in vivo, Front. Pharmacol., 11, (2020); Li Y.J., Dai C., Jiang M., Mechanisms of probiotic VSL#3 in a rat model of visceral hypersensitivity involves the mast cell-PAR2-TRPV1 pathway, Dig. Dis. Sci., 64, pp. 1182-1192, (2019); Liu Y., Wang Y., Li X., Jia Y., Wang J., Ao X., FOXO3a in cancer drug resistance, Cancer Lett., 540, (2022); Liu Y., Yuan X., Li L., Lin L., Zuo X., Cong Y., Li Y., Increased ileal immunoglobulin A production and immunoglobulin A-coated bacteria in diarrhea-predominant irritable bowel syndrome, Clin. Transl. Gastroenterol., 11, (2020); Ma X., Wang X., Kang N., Chen T., Ji H., Lv L., Yin X., Tian Y., Zheng R., Duan Y., Wang F., Tang X., The effect of Tong-Xie-Yao-Fang on intestinal mucosal mast cells in postinfectious irritable bowel syndrome rats, Evid Based Complement. Alternat. Med., 2017, (2017); Munjal A., Dedania B., Cash B., Update on Pharmacotherapy for Irritable Bowel Syndrome, Curr. Gastroenterol. Rep., 21, (2019); Nam Y., Min Y.S., Sohn U.D., Recent advances in pharmacological research on the management of irritable bowel syndrome, Arch. Pharm. Res., 41, pp. 955-966, (2018); Piche T., Tight junctions and IBS–the link between epithelial permeability, low-grade inflammation, and symptom generation?, Neurogastroenterol. Motil., 26, pp. 296-302, (2014); Pinho-Ribeiro F.A., Verri W.A., Chiu I.M., Nociceptor Sensory Neuron-Immune Interactions in Pain and Inflammation, Trends Immunol., 38, pp. 5-19, (2017); Qin W., Zhao W., Ho L., Wang J., Walsh K., Gandy S., Pasinetti G.M., Regulation of forkhead transcription factor FoxO3a contributes to calorie restriction-induced prevention of Alzheimer's disease-type amyloid neuropathology and spatial memory deterioration, Ann. N. Y. Acad. Sci., 1147, pp. 335-347, (2008); Ru J., Li P., Wang J., Zhou W., Li B., Huang C., Li P., Guo Z., Tao W., Yang Y., Xu X., Li Y., Wang Y., Yang L., TCMSP: a database of systems pharmacology for drug discovery from herbal medicines, J. Cheminform., 6, (2014); Schou W.S., Ashina S., Amin F.M., Goadsby P.J., Ashina M., Calcitonin gene-related peptide and pain: a systematic review, J. Headache Pain, 18, (2017); Skrzydlo-Radomanska B., Prozorow-Krol B., Cichoz-Lach H., Majsiak E., Bierla J.B., Kosikowski W., Szczerbinski M., Gantzel J., Cukrowska B., The effectiveness of synbiotic preparation containing lactobacillus and bifidobacterium probiotic strains and short chain fructooligosaccharides in patients with diarrhea predominant irritable bowel syndrome-a randomized double-blind, placebo-controlled study, Nutrients, 12, (2020); Sperber A.D., Bangdiwala S.I., Drossman D.A., Ghoshal U.C., Simren M., Tack J., Whitehead W.E., Dumitrascu D.L., Fang X., Fukudo S., Kellow J., Okeke E., Quigley E.M.M., Schmulson M., Whorwell P., Archampong T., Adibi P., Andresen V., Benninga M.A., Bonaz B., Bor S., Fernandez L.B., Choi S.C., Corazziari E.S., Francisconi C., Hani A., Lazebnik L., Lee Y.Y., Mulak A., Rahman M.M., Santos J., Setshedi M., Syam A.F., Vanner S., Wong R.K., Lopez-Colombo A., Costa V., Dickman R., Kanazawa M., Keshteli A.H., Khatun R., Maleki I., Poitras P., Pratap N., Stefanyuk O., Thomson S., Zeevenhooven J., Palsson O.S., Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome foundation global study, Gastroenterology, 160, pp. 99-114.e113, (2021); Sun J., Wu X., Meng Y., Cheng J., Ning H., Peng Y., Pei L., Zhang W., Electro-acupuncture decreases 5-HT, CGRP and increases NPY in the brain-gut axis in two rat models of Diarrhea-predominant irritable bowel syndrome(D-IBS), BMC Complement. Altern. Med., 15, (2015); Wang F.Y., Su M., Zheng Y.Q., Wang X.G., Kang N., Chen T., Zhu E.L., Bian Z.X., Tang X.D., Herbal prescription Chang'an II repairs intestinal mucosal barrier in rats with post-inflammation irritable bowel syndrome, Acta Pharmacol. Sin., 36, pp. 708-715, (2015); Wang Y., Chen N., Niu F., Li Y., Guo K., Shang X., E F., Yang C., Yang K., Li X., Probiotics therapy for adults with diarrhea-predominant irritable bowel syndrome: a systematic review and meta-analysis of 10 RCTs, Int. J. Colorectal Dis., 37, pp. 2263-2276, (2022); Wang Y., Huang Y.Q., Zhu S.L., Zhang C.R., Chen X.L., Hou Q.K., Liu F.B., Efficacy of Tong-Xie-Yao-Fang granule and its impact on whole transcriptome profiling in diarrhea-predominant irritable bowel syndrome patients: study protocol for a randomized controlled trial, Trials, 21, (2020); Wei Y., Gao C., Wang H., Zhang Y., Gu J., Zhang X., Gong X., Hao Z., Mori fructus aqueous extracts attenuates liver injury by inhibiting ferroptosis via the Nrf2 pathway, J. Anim. Sci. Biotechnol., 14, (2023); Wei Y.Y., Wang H.R., Fan Y.M., Gu J.H., Zhang X.Y., Gong X.H., Hao Z.H., Acute liver injury induced by carbon tetrachloride reversal by Gandankang aqueous extracts through nuclear factor erythroid 2-related factor 2 signaling pathway, Ecotoxicol. Environ. Saf., 251, (2023); Welgan P., Meshkinpour H., Hoehler F., The effect of stress on colon motor and electrical activity in irritable bowel syndrome, Psychosom. Med., 47, pp. 139-149, (1985); Whitehead W.E., Palsson O.S., Simren M., Irritable bowel syndrome: what do the new Rome IV diagnostic guidelines mean for patient management?, Expert Rev. Gastroenterol. Hepatol., 11, pp. 281-283, (2017); Willcox B.J., Donlon T.A., He Q., Chen R., Grove J.S., Yano K., Masaki K.H., Willcox D.C., Rodriguez B., Curb J.D., FOXO3A genotype is strongly associated with human longevity, Proc. Natl. Acad. Sci. U. S. A., 105, pp. 13987-13992, (2008); Woo J.K., Choi S., Kang J.H., Kim D.E., Hurh B.S., Jeon J.E., Kim S.Y., Oh S.H., Fermented barley and soybean (BS) mixture enhances intestinal barrier function in dextran sulfate sodium (DSS)-induced colitis mouse model, BMC Complement. Altern. Med., 16, (2016); Wouters M.M., Vicario M., Santos J., The role of mast cells in functional GI disorders, Gut, 65, pp. 155-168, (2016); Wu Y., He H., Cheng Z., Bai Y., Ma X., The role of neuropeptide Y and peptide YY in the development of obesity via gut-brain axis, Curr. Protein Pept. Sci., 20, pp. 750-758, (2019); Yan J., Miao Z.W., Lu J., Ge F., Yu L.H., Shang W.B., Liu L.N., Sun Z.G., Acupuncture plus Chinese herbal medicine for irritable bowel syndrome with diarrhea: a systematic review and meta-analysis, Evid. Based Complement. Alternat. Med., 2019, (2019); Yin Y., Wang J., Zhao X., Wu X., Zou H., Qin Z., Cao J., Overexpressed FOXO3 improves inflammatory status in mice by affecting NLRP3-mediated cell coronation in necrotizing colitis mice, Biomed. Pharmacother., 125, (2020); Zhang M., Zheng Y., Li X., Wu H., Liu P., Zhang K., Shi Z., Lv M., Wang F., Tang X., Tong-Xie-Yao-Fang alleviates diarrhea-predominant irritable bowel syndrome in rats via the GCN2/PERK-eIF2α-ATF4 signaling pathway, Phytomedicine, 107, (2022); Zhou Y., Zhou B., Pache L., Chang M., Khodabakhshi A.H., Tanaseichuk O., Benner C., Chanda S.K., Metascape provides a biologist-oriented resource for the analysis of systems-level datasets, Nat. Commun., 10, (2019)","Z. Hao; National Key Laboratory of Veterinary Public Health Security, College of Veterinary Medicine, China Agricultural University, No. 2 Yuanmingyuan West Road, 100193, China; email: haozhihui@cau.edu.cn","","Elsevier GmbH","","","","","","09447113","","PYTOE","37924689","English","Phytomedicine","Article","Final","","Scopus","2-s2.0-85175352430"

"Nozu T.; Okumura T.","Nozu, Tsukasa (12765917900); Okumura, Toshikatsu (7202327796)","12765917900; 7202327796","Pathophysiological Commonality Between Irritable Bowel Syndrome and Metabolic Syndrome: Role of Corticotropin-releasing Factor–Toll-like Receptor 4–Proinflammatory Cytokine Signaling","2022","Journal of Neurogastroenterology and Motility","28","2","","173","184","11","9","10.5056/jnm21002","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85128625983&doi=10.5056%2fjnm21002&partnerID=40&md5=d3033a4e3eeef46d1541a966cb616760","Department of Regional Medicine and Education, Asahikawa Medical University, Hokkaido, Asahikawa, Japan; Center for Medical Education, Asahikawa Medical University, Hokkaido, Asahikawa, Japan; Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Hokkaido, Asahikawa, Japan; Department of General Medicine, Asahikawa Medical University, Hokkaido, Asahikawa, Japan","Nozu T., Department of Regional Medicine and Education, Asahikawa Medical University, Hokkaido, Asahikawa, Japan, Center for Medical Education, Asahikawa Medical University, Hokkaido, Asahikawa, Japan; Okumura T., Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Hokkaido, Asahikawa, Japan, Department of General Medicine, Asahikawa Medical University, Hokkaido, Asahikawa, Japan","Irritable bowel syndrome (IBS) displays chronic abdominal pain with altered defecation. Most of the patients develop visceral hypersensitivity possibly resulting from impaired gut barrier and altered gut microbiota. We previously demonstrated that colonic hyperpermeability with visceral hypersensitivity in animal IBS models, which is mediated via corticotropin-releasing factor (CRF)–Toll-like receptor 4 (TLR4)–proinflammatory cytokine signaling. CRF impairs gut barrier via TLR4. Leaky gut induces bacterial translocation resulting in dysbiosis, and increases lipopolysaccharide (LPS). Activation of TLR4 by LPS increases the production of proinflammatory cytokines, which activate visceral sensory neurons to induce visceral hypersensitivity. LPS also activates CRF receptors to further increase gut permeability. Metabolic syndrome (MS) is a cluster of cardiovascular risk factors, including insulin resistance, obesity, dyslipidemia, and hypertension, and recently several researchers suggested the possibility that impaired gut barrier and dysbiosis with low-grade systemic inflammation are involved in MS. Moreover, TLR4–proinflammatory cytokine contributes to the development of insulin resistance and obesity. Thus, the existence of pathophysiological commonality between IBS and MS is expected. This review discusses the potential mechanisms of IBS and MS with reference to gut barrier and microbiota, and explores the possibility of existence of a pathophysiological link between these diseases with a focus on CRF, TLR4, and proinflammatory cytokine signaling. We also review epidemiological data supporting this possibility, and discuss the potential of therapeutic application of the drugs used for MS to IBS treatment. This notion may pave the way for exploring novel therapeutic approaches for these disorders. © 2022 The Korean Society of Neurogastroenterology and Motility.","Gut barrier; Irritable bowel syndrome; Metabolic syndrome; Microbiota; Toll-like receptor 4","corticotropin releasing factor; fatty acid; oxidized low density lipoprotein; toll like receptor 4; Article; brain-gut axis; cytokine signaling; epidemiological data; human; immune system; intestine flora; irritable colon; metabolic syndrome X; nonhuman; pathophysiology","","corticotropin releasing factor, 9015-71-8, 178359-01-8, 79804-71-0, 86297-72-5, 86784-80-7; toll like receptor 4, 203811-83-0","","","","","Drossman DA, Camilleri M, Mayer EA, Whitehead WE., AGA technical review on irritable bowel syndrome, Gastroenterology, 123, pp. 2108-2131, (2002); Tache Y, Kiank C, Stengel A., A role for corticotropin-releasing factor in functional gastrointestinal disorders, Curr Gastroenterol Rep, 11, pp. 270-277, (2009); Nozu T, Okumura T., Corticotropin-releasing factor receptor type 1 and type 2 interaction in irritable bowel syndrome, J Gastroenterol, 50, pp. 819-830, (2015); Tache Y, Million M., Role of corticotropin-releasing factor signaling in stress-related alterations of colonic motility and hyperalgesia, J Neurogastroenterol Motil, 21, pp. 8-24, (2015); Lozano R, Naghavi M, Foreman K, Et al., Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010, Lancet, 380, pp. 2095-2128, (2012); Festi D, Schiumerini R, Eusebi LH, Marasco G, Taddia M, Colecchia A., Gut microbiota and metabolic syndrome, World J Gastroenterol, 20, pp. 16079-16094, (2014); Wellen KE, Hotamisligil GS., Inflammation, stress, and diabetes, J Clin Invest, 115, pp. 1111-1119, (2005); Cani PD, Amar J, Iglesias MA, Et al., Metabolic endotoxemia initiates obesity and insulin resistance, Diabetes, 56, pp. 1761-1772, (2007); Mayer EA, Savidge T, Shulman RJ., Brain-gut microbiome interactions and functional bowel disorders, Gastroenterology, 146, pp. 1500-1512, (2014); Camilleri M, Lasch K, Zhou W., Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome, Am J Physiol Gastrointest Liver Physiol, 303, pp. G775-G785, (2012); Nozu T, Miyagishi S, Nozu R, Takakusaki K, Okumura T., Altered colonic sensory and barrier functions by CRF: roles of TLR4 and IL-1, J Endocrinol, 239, pp. 241-252, (2018); Cryan JF, O'Mahony SM., The microbiome-gut-brain axis: from bowel to behavior, Neurogastroenterol Motil, 23, pp. 187-192, (2011); Fukudo S, Nomura T, Muranaka M, Taguchi F., Brain-gut response to stress and cholinergic stimulation in irritable bowel syndrome. A preliminary study, J Clin Gastroenterol, 17, pp. 133-141, (1993); Mayer EA, Naliboff BD, Chang L, Coutinho SV. V., Stress and irritable bowel syndrome, Am J Physiol Gastrointest Liver Physiol, 280, pp. G519-G524, (2001); Fukudo S, Nomura T, Hongo M., Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome, Gut, 42, pp. 845-849, (1998); Lee C, Doo E, Choi JM, Et al., The increased level of depression and anxiety in irritable bowel syndrome patients compared with healthy controls: systematic review and meta-analysis, J Neurogastroenterol Motil, 23, pp. 349-362, (2017); Fond G, Loundou A, Hamdani N, Et al., Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis, Eur Arch Psychiatry Clin Neurosci, 264, pp. 651-660, (2014); Kellow JE, Delvaux M, Azpiroz F, Camilleri M, Quigley EM, Thompson DG., Principles of applied neurogastroenterology: physiology/motility-sensation, Gut, 45, pp. II17-II24, (1999); Delvaux M., Role of visceral sensitivity in the pathophysiology of irritable bowel syndrome, Gut, 51, pp. i67-i71, (2002); Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA., Altered rectal perception is a biological marker of patients with irritable bowel syndrome, Gastroenterology, 109, pp. 40-52, (1995); Bouin M, Plourde V, Boivin M, Et al., Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds, Gastroenterology, 122, pp. 1771-1777, (2002); Kanazawa M, Hongo M, Fukudo S., Visceral hypersensitivity in irritable bowel syndrome, J Gastroenterol Hepatol, 26, pp. 119-121, (2011); Nozu T, Kudaira M, Kitamori S, Uehara A., Repetitive rectal painful distention induces rectal hypersensitivity in patients with irritable bowel syndrome, J Gastroenterol, 41, pp. 217-222, (2006); Farzaei MH, Bahramsoltani R, Abdollahi M, Rahimi R., The role of visceral hypersensitivity in irritable bowel syndrome: pharmacological targets and novel treatments, J Neurogastroenterol Motil, 22, pp. 558-574, (2016); Camilleri M, Gorman H., Intestinal permeability and irritable bowel syndrome, Neurogastroenterol Motil, 19, pp. 545-552, (2007); Dlugosz A, Nowak P, D'Amato M, Et al., Increased serum levels of lipopolysaccharide and antiflagellin antibodies in patients with diarrhea-predominant irritable bowel syndrome, Neurogastroenterol Motil, 27, pp. 1747-1754, (2015); Ortiz-Lucas M, Saz-Peiro P, Sebastian-Domingo JJ., Irritable bowel syndrome immune hypothesis. Part two: the role of cytokines, Rev Esp Enferm Dig, 102, pp. 711-717, (2010); Sinagra E, Pompei G, Tomasello G, Et al., Inflammation in irritable bowel syndrome: myth or new treatment target?, World J Gastroenterol, 22, pp. 2242-2255, (2016); Liebregts T, Adam B, Bredack C, Et al., Immune activation in patients with irritable bowel syndrome, Gastroenterology, 132, pp. 913-920, (2007); Nozu T, Miyagishi S, Nozu R, Takakusaki K, Okumura T., Lipopolysaccharide induces visceral hypersensitivity: role of interleukin-1, interleukin-6, and peripheral corticotropin-releasing factor in rats, J Gastroenterol, 52, pp. 72-80, (2017); Avila M, Gonzalez-Espinosa C., Signaling through toll-like receptor 4 and mast cell-dependent innate immunity responses, IUBMB Life, 63, pp. 873-880, (2011); Boyer J, Saint-Paul MC, Dadone B, Et al., Inflammatory cell distribution in colon mucosa as a new tool for diagnosis of irritable bowel syndrome: a promising pilot study, Neurogastroenterol Motil, 30, (2018); Creekmore AL, Hong S, Zhu S, Xue J, Wiley JW., Chronic stress-associated visceral hyperalgesia correlates with severity of intestinal barrier dysfunction, Pain, 159, pp. 1777-1789, (2018); Nozu T, Miyagishi S, Kumei S, Nozu R, Takakusaki K, Okumura T., Lovastatin inhibits visceral allodynia and increased colonic permeability induced by lipopolysaccharide or repeated water avoidance stress in rats, Eur J Pharmacol, 818, pp. 228-234, (2017); Nozu T, Miyagishi S, Nozu R, Takakusaki K, Okumura T., Pioglitazone improves visceral sensation and colonic permeability in a rat model of irritable bowel syndrome, J Pharmacol Sci, 139, pp. 46-49, (2018); Nozu T, Miyagishi S, Kumei S, Nozu R, Takakusaki K, Okumura T., Metformin inhibits visceral allodynia and increased gut permeability induced by stress in rats, J Gastroenterol Hepatol, 34, pp. 186-193, (2019); Nozu T, Miyagishi S, Nozu R, Takakusaki K, Okumura T., Dehydroepiandrosterone sulfate improves visceral sensation and gut barrier in a rat model of irritable bowel syndrome, Eur J Pharmacol, 852, pp. 198-206, (2019); Nozu T, Miyagishi S, Nozu R, Takakusaki K, Okumura T., Butyrate inhibits visceral allodynia and colonic hyperpermeability in rat models of irritable bowel syndrome, Sci Rep, 9, (2019); Nozu T, Miyagishi S, Nozu R, Takakusaki K, Okumura T., Losartan improves visceral sensation and gut barrier in a rat model of irritable bowel syndrome, Neurogastroenterol Motil, 32, (2020); Nozu T, Kudaira M., Corticotropin-releasing factor induces rectal hypersensitivity after repetitive painful rectal distention in healthy humans, J Gastroenterol, 41, pp. 740-744, (2006); Barreau F, Cartier C, Leveque M, Et al., Pathways involved in gut mucosal barrier dysfunction induced in adult rats by maternal deprivation: corticotrophin-releasing factor and nerve growth factor interplay, J Physiol, 580, pp. 347-356, (2007); Santos J, Saunders PR, Hanssen NP, Et al., Corticotropin-releasing hormone mimics stress-induced colonic epithelial pathophysiology in the rat, Am J Physiol, 277, pp. G391-G399, (1999); Saunders PR, Santos J, Hanssen NP, Yates D, Groot JA, Perdue MH., Physical and psychological stress in rats enhances colonic epithelial permeability via peripheral CRH, Dig Dis Sci, 47, pp. 208-215, (2002); Soderholm JD, Yates DA, Gareau MG, Yang PC, MacQueen G, Perdue MH., Neonatal maternal separation predisposes adult rats to colonic barrier dysfunction in response to mild stress, Am J Physiol Gastrointest Liver Physiol, 283, pp. G1257-G1263, (2002); Hillhouse EW, Grammatopoulos DK., The molecular mechanisms underlying the regulation of the biological activity of corticotropin-releasing hormone receptors: implications for physiology and pathophysiology, Endocr Rev, 27, pp. 260-286, (2006); Perrin MH, Vale WW., Corticotropin releasing factor receptors and their ligand family, Ann N Y Acad Sci, 885, pp. 312-328, (1999); Nozu T, Takakusaki K, Okumura T., A balance theory of peripheral corticotropin-releasing factor receptor type 1 and type 2 signaling to induce colonic contractions and visceral hyperalgesia in rats, Endocrinology, 155, pp. 4655-4664, (2014); Nozu T, Miyagishi S, Nozu R, Takakusaki K, Okumura T., Repeated water avoidance stress induces visceral hypersensitivity: role of IL-1, IL-6 and peripheral corticotropin-releasing factor, J Gastroenterol Hepatol, 32, pp. 1958-1965, (2017); Overman EL, Rivier JE, Moeser AJ., CRF induces intestinal epithelial barrier injury via the release of mast cell proteases and TNF-alpha, PLoS One, 7, (2012); Barbara G, Wang B, Stanghellini V, Et al., Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome, Gastroenterology, 132, pp. 26-37, (2007); Bhattarai Y, Muniz Pedrogo DA, Kashyap PC., Irritable bowel syndrome: a gut microbiota-related disorder?, Am J Physiol Gastrointest Liver Physiol, 312, pp. G52-G62, (2017); Tap J, Derrien M, Tornblom H, Et al., Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome, Gastroenterology, 152, pp. 111-123, (2017); O'Mahony SM, Marchesi JR, Scully P, Et al., Early life stress alters behavior, immunity, and microbiota in rats: implications for irritable bowel syndrome and psychiatric illnesses, Biol Psychiatry, 65, pp. 263-267, (2009); Xu D, Gao J, Gillilland M, Et al., Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats, Gastroenterology, 146, pp. 484-496, (2014); Salguero MV, Al-Obaide MAI, Singh R, Siepmann T, Vasylyeva TL., Dysbiosis of gram-negative gut microbiota and the associated serum lipopolysaccharide exacerbates inflammation in type 2 diabetic patients with chronic kidney disease, Exp Ther Med, 18, pp. 3461-3469, (2019); Bailey MT, Dowd SE, Galley JD, Hufnagle AR, Allen RG, Lyte M., Exposure to a social stressor alters the structure of the intestinal microbiota: implications for stressor-induced immunomodulation, Brain Behav Immun, 25, pp. 397-407, (2011); Santos J, Yang PC, Soderholm JD, Benjamin M, Perdue MH., Role of mast cells in chronic stress induced colonic epithelial barrier dysfunction in the rat, Gut, 48, pp. 630-636, (2001); Ait-Belgnaoui A, Durand H, Cartier C, Et al., Prevention of gut leakiness by a probiotic treatment leads to attenuated HPA response to an acute psychological stress in rats, Psychoneuroendocrinology, 37, pp. 1885-1895, (2012); Kelly JR, Kennedy PJ, Cryan JF, Dinan TG, Clarke G, Hyland NP., Breaking down the barriers: the gut microbiome, intestinal permeability and stress-related psychiatric disorders, Front Cell Neurosci, 9, (2015); Ploger S, Stumpff F, Penner GB, Et al., Microbial butyrate and its role for barrier function in the gastrointestinal tract, Ann N Y Acad Sci, 1258, pp. 52-59, (2012); Zhang J, Song L, Wang Y, Et al., Beneficial effect of butyrate-producing Lachnospiraceae on stress-induced visceral hypersensitivity in rats, J Gastroenterol Hepatol, 34, pp. 1368-1376, (2019); Crouzet L, Gaultier E, Del'Homme C, Et al., The hypersensitivity to colonic distension of IBS patients can be transferred to rats through their fecal microbiota, Neurogastroenterol Motil, 25, pp. e272-e282, (2013); Zong Y, Zhu S, Zhang S, Zheng G, Wiley JW, Hong S., Chronic stress and intestinal permeability: lubiprostone regulates glucocorticoid receptor-mediated changes in colon epithelial tight junction proteins, barrier function, and visceral pain in the rodent and human, Neurogastroenterol Motil, (2019); Cryan JF, Dinan TG., Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour, Nat Rev Neurosci, 13, pp. 701-712, (2012); Audhya T, Jain R, Hollander CS., Receptor-mediated immunomodulation by corticotropin-releasing factor, Cell Immunol, 134, pp. 77-84, (1991); Hojo M, Ohkusa T, Tomeoku H, Et al., Corticotropin-releasing factor secretion from dendritic cells stimulated by commensal bacteria, World J Gastroenterol, 17, pp. 4017-4022, (2011); Zheng PY, Feng BS, Oluwole C, Et al., Psychological stress induces eosinophils to produce corticotrophin releasing hormone in the intestine, Gut, 58, pp. 1473-1479, (2009); Yu Y, Liu ZQ, Liu XY, Et al., Stress-derived corticotropin releasing factor breaches epithelial endotoxin tolerance, PLoS One, 8, (2013); Obreja O, Rathee PK, Lips KS, Distler C, Kress M., IL-1 beta potentiates heat-activated currents in rat sensory neurons: involvement of IL-1RI, tyrosine kinase, and protein kinase C, FASEB J, 16, pp. 1497-1503, (2002); Suzuki T, Yoshinaga N, Tanabe S., Interleukin-6 (IL-6) regulates claudin-2 expression and tight junction permeability in intestinal epithelium, J Biol Chem, 286, pp. 31263-31271, (2011); Liu L, Zhu G., Gut-brain axis and mood disorder, Front Psychiatry, 9, (2018); Calarge CA, Devaraj S, Shulman RJ., Gut permeability and depressive symptom severity in unmedicated adolescents, J Affect Disord, 246, pp. 586-594, (2019); Uehara A, Gottschall PE, Dahl RR, Arimura A., Interleukin-1 stimulates ACTH release by an indirect action which requires endogenous corticotropin releasing factor, Endocrinology, 121, pp. 1580-1582, (1987); Dabke K, Hendrick G, Devkota S., The gut microbiome and metabolic syndrome, J Clin Invest, 129, pp. 4050-4057, (2019); Araujo JR, Tomas J, Brenner C, Sansonetti PJ., Impact of high-fat diet on the intestinal microbiota and small intestinal physiology before and after the onset of obesity, Biochimie, 141, pp. 97-106, (2017); Jakobsdottir G, Xu J, Molin G, Ahrne S, Nyman M., High-fat diet reduces the formation of butyrate, but increases succinate, inflammation, liver fat and cholesterol in rats, while dietary fibre counteracts these effects, PLoS One, 8, (2013); Gao F, Lv YW, Long J, Et al., Butyrate improves the metabolic disorder and gut microbiome dysbiosis in mice induced by a high-fat diet, Front Pharmacol, 10, (2019); Rogero MM, Calder PC., Obesity, inflammation, toll-like receptor 4 and fatty acids, Nutrients, 10, (2018); Kim KA, Gu W, Lee IA, Joh EH, Kim DH., High fat diet-induced gut microbiota exacerbates inflammation and obesity in mice via the TLR4 signaling pathway, PLoS One, 7, (2012); Rehman K, Akash MS., Mechanisms of inflammatory responses and development of insulin resistance: how are they interlinked?, J Biomed Sci, 23, (2016); Gregor MF, Hotamisligil GS., Inflammatory mechanisms in obesity, Annu Rev Immunol, 29, pp. 415-445, (2011); Kallio KA, Hatonen KA, Lehto M, Salomaa V, Mannisto S, Pussinen PJ., Endotoxemia, nutrition, and cardiometabolic disorders, Acta Diabetol, 52, pp. 395-404, (2015); Jialal I, Kaur H, Devaraj S., Toll-like receptor status in obesity and metabolic syndrome: a translational perspective, J Clin Endocrinol Metab, 99, pp. 39-48, (2014); Miura K, Ishioka M, Iijima K., The roles of the gut microbiota and toll-like receptors in obesity and nonalcoholic fatty liver disease, J Obes Metab Syndr, 26, pp. 86-96, (2017); Ahmad R, Al-Mass A, Atizado V, Et al., Elevated expression of the toll like receptors 2 and 4 in obese individuals: its significance for obesity-induced inflammation, J Inflamm (Lond), 9, (2012); Nakarai H, Yamashita A, Nagayasu S, Et al., Adipocyte-macrophage interaction may mediate LPS-induced low-grade inflammation: potential link with metabolic complications, Innate Immun, 18, pp. 164-170, (2012); Hotamisligil GS, Shargill NS, Spiegelman BM., Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance, Science, 259, pp. 87-91, (1993); Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW, Obesity is associated with macrophage accumulation in adipose tissue, J Clin Invest, 112, pp. 1796-1808, (2003); Lin Y, Lee H, Berg AH, Lisanti MP, Shapiro L, Scherer PE., The lipopolysaccharide-activated toll-like receptor (TLR)-4 induces synthesis of the closely related receptor TLR-2 in adipocytes, J Biol Chem, 275, pp. 24255-24263, (2000); Daemen S, Schilling JD., The interplay between tissue niche and macrophage cellular metabolism in obesity, Front Immunol, 10, (2019); Farrell GC, van Rooyen D, Gan L, Chitturi S., NASH is an inflammatory disorder: pathogenic, prognostic and therapeutic implications, Gut Liver, 6, pp. 149-171, (2012); Frost RA, Nystrom GJ, Lang CH., Lipopolysaccharide stimulates nitric oxide synthase-2 expression in murine skeletal muscle and C<sub>2</sub>C<sub>12</sub> myoblasts via toll-like receptor-4 and c-Jun NH(2)-terminal kinase pathways, Am J Physiol Cell Physiol, 287, pp. C1605-C1615, (2004); Frost RA, Nystrom GJ, Lang CH., Lipopolysaccharide and proinflammatory cytokines stimulate interleukin-6 expression in C2C12 myoblasts: role of the Jun NH<sub>2</sub>-terminal kinase, Am J Physiol Regul Integr Comp Physiol, 285, pp. R1153-R1164, (2003); Williams KH, Shackel NA, Gorrell MD, McLennan SV, Twigg SM., Diabetes and nonalcoholic fatty liver disease: a pathogenic duo, Endocr Rev, 34, pp. 84-129, (2013); Kolodziejczyk AA, Zheng D, Shibolet O, Elinav E., The role of the microbiome in NAFLD and NASH, EMBO Mol Med, 11, (2019); Rocha DM, Caldas AP, Oliveira LL, Bressan J, Hermsdorff HH., Saturated fatty acids trigger TLR4-mediated inflammatory response, Atherosclerosis, 244, pp. 211-215, (2016); Suganami T, Tanimoto-Koyama K, Nishida J, Et al., Role of the toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages, Arterioscler Thromb Vasc Biol, 27, pp. 84-91, (2007); Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS., TLR4 links innate immunity and fatty acid-induced insulin resistance, J Clin Invest, 116, pp. 3015-3025, (2006); Fessler MB, Rudel LL, Brown JM., Toll-like receptor signaling links dietary fatty acids to the metabolic syndrome, Curr Opin Lipidol, 20, pp. 379-385, (2009); Zhang N, Liang H, Farese RV, Li J, Musi N, Hussey SE., Pharmacological TLR4 inhibition protects against acute and chronic fat-induced insulin resistance in rats, PLoS One, 10, (2015); Hopps E, Noto D, Caimi G, Averna MR., A novel component of the metabolic syndrome: the oxidative stress, Nutr Metab Cardiovasc Dis, 20, pp. 72-77, (2010); Neves AL, Coelho J, Couto L, Leite-Moreira A, Roncon-Albuquerque R, Metabolic endotoxemia: a molecular link between obesity and cardiovascular risk, J Mol Endocrinol, 51, pp. R51-R64, (2013); Linna MS, Ahotupa M, Kukkonen-Harjula K, Fogelholm M, Vasankari TJ., Co-existence of insulin resistance and high concentrations of circulating oxidized LDL lipids, Ann Med, 47, pp. 394-398, (2015); Liu HQ, Qiu Y, Mu Y, Et al., A high ratio of dietary n-3/n-6 polyunsaturated fatty acids improves obesity-linked inflammation and insulin resistance through suppressing activation of TLR4 in SD rats, Nutr Res, 33, pp. 849-858, (2013); Barreau F, Ferrier L, Fioramonti J, Bueno L., Neonatal maternal deprivation triggers long term alterations in colonic epithelial barrier and mucosal immunity in rats, Gut, 53, pp. 501-506, (2004); Yi L, Zhang H, Sun H, Et al., Maternal separation induced visceral hypersensitivity from childhood to adulthood, J Neurogastroenterol Motil, 23, pp. 306-315, (2017); Clarke G, O'Mahony SM, Hennessy AA, Et al., Chain reactions: early-life stress alters the metabolic profile of plasma polyunsaturated fatty acids in adulthood, Behav Brain Res, 205, pp. 319-321, (2009); Chua CS, Huang SY, Cheng CW, Et al., Fatty acid components in Asian female patients with irritable bowel syndrome, Medicine (Baltimore), 96, (2017); Bale TL, Anderson KR, Roberts AJ, Lee KF, Nagy TR, Vale WW., Corticotropin-releasing factor receptor-2-deficient mice display abnormal homeostatic responses to challenges of increased dietary fat and cold, Endocrinology, 144, pp. 2580-2587, (2003); Tache Y, Bonaz B., Corticotropin-releasing factor receptors and stress-related alterations of gut motor function, J Clin Invest, 117, pp. 33-40, (2007); Li C, Chen P, Vaughan J, Lee KF, Vale W., Urocortin 3 regulates glucose-stimulated insulin secretion and energy homeostasis, Proc Natl Acad Sci USA, 104, pp. 4206-4211, (2007); Kuperman Y, Issler O, Regev L, Et al., Perifornical urocortin-3 mediates the link between stress-induced anxiety and energy homeostasis, Proc Natl Acad Sci USA, 107, pp. 8393-8398, (2010); Chrousos GP., The role of stress and the hypothalamic-pituitary-adrenal axis in the pathogenesis of the metabolic syndrome: neuro-endocrine and target tissue-related causes, Int J Obes Relat Metab Disord, 24, pp. S50-S55, (2000); Rosmond R., Role of stress in the pathogenesis of the metabolic syndrome, Psychoneuroendocrinology, 30, pp. 1-10, (2005); Tramullas M, Finger BC, Dinan TG, Cryan JF., Obesity takes its toll on visceral pain: high-fat diet induces toll-like receptor 4-dependent visceral hypersensitivity, PLoS One, 11, (2016); Pickett-Blakely O., Obesity and irritable bowel syndrome: a comprehensive review, Gastroenterol Hepatol (NY), 10, pp. 411-416, (2014); Aasbrenn M, Lydersen S, Farup PG., A conservative weight loss intervention relieves bowel symptoms in morbidly obese subjects with irritable bowel syndrome: a prospective cohort study, J Obes, 2018, (2018); Lee CG, Lee JK, Kang YS, Et al., Visceral abdominal obesity is associated with an increased risk of irritable bowel syndrome, Am J Gastroenterol, 110, pp. 310-319, (2015); Despres JP, Lemieux I., Abdominal obesity and metabolic syndrome, Nature, 444, pp. 881-887, (2006); Guo Y, Niu K, Momma H, Et al., Irritable bowel syndrome is positively related to metabolic syndrome: a population-based cross-sectional study, PLoS One, 9, (2014); Cholongitas E, Pipili C, Dasenaki M., Gastro-oesophageal reflux disease and irritable bowel syndrome significantly associated with metabolic syndrome, Scand J Gastroenterol, 43, pp. 1405-1406, (2008); Basilisco G, Camboni G, Bozzani A, Vita P, Doldi S, Bianchi PA., Orocecal transit delay in obese patients, Dig Dis Sci, 34, pp. 509-512, (1989); Sadik R, Bjornsson E, Simren M., The relationship between symptoms, body mass index, gastrointestinal transit and stool frequency in patients with irritable bowel syndrome, Eur J Gastroenterol Hepatol, 22, pp. 102-108, (2010); Eswaran S, Tack J, Chey WD., Food: the forgotten factor in the irritable bowel syndrome, Gastroenterol Clin North Am, 40, pp. 141-162, (2011); Chirila I, Petrariu FD, Ciortescu I, Mihai C, Drug VL., Diet and irritable bowel syndrome, J Gastrointestin Liver Dis, 21, pp. 357-362, (2012); Kaptoge S, Seshasai SR, Gao P, Et al., Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis, Eur Heart J, 35, pp. 578-589, (2014); Nozu T, Miyagishi S, Kumei S, Nozu R, Takakusaki K, Okumura T., Glucagon-like peptide-1 analog, liraglutide improves visceral sensation and gut permeability in rats, J Gastroenterol Hepatol, 33, pp. 232-239, (2018)","T. Nozu; Department of Regional Medicine and Education, Asahikawa Medical University, Hokkaido, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Japan; email: tnozu@sea.plala.or.jp","","Korean Society of Neurogastroenterology and Motility","","","","","","20930879","","","","English","J. Neurogastroenterology Motil.","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85128625983"

"Mas-Orea X.; Rey L.; Battut L.; Bories C.; Petitfils C.; Abot A.; Gheziel N.; Wemelle E.; Blanpied C.; Motta J.-P.; Knauf C.; Barreau F.; Espinosa E.; Aloulou M.; Cenac N.; Serino M.; Mouledous L.; Fazilleau N.; Dietrich G.","Mas-Orea, Xavier (57211444773); Rey, Lea (58696013100); Battut, Louise (57226566961); Bories, Cyrielle (57783690200); Petitfils, Camille (57211474816); Abot, Anne (53981156300); Gheziel, Nadine (58648489000); Wemelle, Eve (57209714256); Blanpied, Catherine (6701693619); Motta, Jean-Paul (36098189300); Knauf, Claude (6602748894); Barreau, Frederick (6507191901); Espinosa, Eric (7102688338); Aloulou, Meryem (23984365500); Cenac, Nicolas (6602478958); Serino, Matteo (22235461800); Mouledous, Lionel (6603207664); Fazilleau, Nicolas (6507439759); Dietrich, Gilles (24377963200)","57211444773; 58696013100; 57226566961; 57783690200; 57211474816; 53981156300; 58648489000; 57209714256; 6701693619; 36098189300; 6602748894; 6507191901; 7102688338; 23984365500; 6602478958; 22235461800; 6603207664; 6507439759; 24377963200","Proenkephalin deletion in hematopoietic cells induces intestinal barrier failure resulting in clinical feature similarities with irritable bowel syndrome in mice","2023","Communications Biology","6","1","1168","","","","2","10.1038/s42003-023-05542-2","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85176803035&doi=10.1038%2fs42003-023-05542-2&partnerID=40&md5=cb32c514f461ad63c369ed0e8e6c66be","IRSD, Université de Toulouse, INSERM, INRAE, ENVT, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France; INFINITy, Université de Toulouse, INSERM U1291, CNRS U5051, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France; Research Center on Animal Cognition (CRCA), Center of Integrative Biology (CBI), Université de Toulouse, CNRS UMR-5169, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France; Enterosys SAS, Labège, France","Mas-Orea X., IRSD, Université de Toulouse, INSERM, INRAE, ENVT, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France; Rey L., IRSD, Université de Toulouse, INSERM, INRAE, ENVT, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France; Battut L., IRSD, Université de Toulouse, INSERM, INRAE, ENVT, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France; Bories C., INFINITy, Université de Toulouse, INSERM U1291, CNRS U5051, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France; Petitfils C., IRSD, Université de Toulouse, INSERM, INRAE, ENVT, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France; Abot A., IRSD, Université de Toulouse, INSERM, INRAE, ENVT, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France, Enterosys SAS, Labège, France; Gheziel N., IRSD, Université de Toulouse, INSERM, INRAE, ENVT, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France, INFINITy, Université de Toulouse, INSERM U1291, CNRS U5051, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France; Wemelle E., IRSD, Université de Toulouse, INSERM, INRAE, ENVT, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France; Blanpied C., IRSD, Université de Toulouse, INSERM, INRAE, ENVT, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France; Motta J.-P., IRSD, Université de Toulouse, INSERM, INRAE, ENVT, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France; Knauf C., IRSD, Université de Toulouse, INSERM, INRAE, ENVT, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France; Barreau F., IRSD, Université de Toulouse, INSERM, INRAE, ENVT, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France; Espinosa E., IRSD, Université de Toulouse, INSERM, INRAE, ENVT, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France; Aloulou M., INFINITy, Université de Toulouse, INSERM U1291, CNRS U5051, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France; Cenac N., IRSD, Université de Toulouse, INSERM, INRAE, ENVT, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France; Serino M., IRSD, Université de Toulouse, INSERM, INRAE, ENVT, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France; Mouledous L., Research Center on Animal Cognition (CRCA), Center of Integrative Biology (CBI), Université de Toulouse, CNRS UMR-5169, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France; Fazilleau N., INFINITy, Université de Toulouse, INSERM U1291, CNRS U5051, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France; Dietrich G., IRSD, Université de Toulouse, INSERM, INRAE, ENVT, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France","Opioid-dependent immune-mediated analgesic effects have been broadly reported upon inflammation. In preclinical mouse models of intestinal inflammatory diseases, the local release of enkephalins (endogenous opioids) by colitogenic T lymphocytes alleviate inflammation-induced pain by down-modulating gut-innervating nociceptor activation in periphery. In this study, we wondered whether this immune cell-derived enkephalin-mediated regulation of the nociceptor activity also operates under steady state conditions. Here, we show that chimeric mice engrafted with enkephalin-deficient bone marrow cells exhibit not only visceral hypersensitivity but also an increase in both epithelial paracellular and transcellular permeability, an alteration of the microbial topography resulting in increased bacteria-epithelium interactions and a higher frequency of IgA-producing plasma cells in Peyer’s patches. All these alterations of the intestinal homeostasis are associated with an anxiety-like behavior despite the absence of an overt inflammation as observed in patients with irritable bowel syndrome. Thus, our results show that immune cell-derived enkephalins play a pivotal role in maintaining gut homeostasis and normal behavior in mice. Because a defect in the mucosal opioid system remarkably mimics some major clinical symptoms of the irritable bowel syndrome, its identification might help to stratify subgroups of patients. © 2023, The Author(s).","","Analgesics, Opioid; Animals; Enkephalins; Humans; Inflammation; Irritable Bowel Syndrome; Mice; Pain; enkephalin; narcotic analgesic agent; proenkephalin; animal; genetics; human; inflammation; irritable colon; mouse; pain","","proenkephalin, 90880-95-8; Analgesics, Opioid, ; Enkephalins, ; proenkephalin, ","","","Anne-Laure Iscache; French government, (ANR-11-EQPX-0003); Toulouse III; US006/INSERM, Toulouse, MetaToul; Université Paul Sabatier; Equipex; Agence Nationale de la Recherche, ANR, (NOCICEPOP-ANR-22-CE14-0011-01); Institut National de la Santé et de la Recherche Médicale, Inserm; Fondation pour la Recherche Médicale, FRM; Ministère de l'Enseignement supérieur, de la Recherche et de l'Innovation","Funding text 1: The authors wish to thank the animal care facility, Genetoul, anexplo, US006/INSERM, Toulouse, MetaToul (Toulouse metabolomics & fluxomics facilities, www.metatoul.fr) which is part of the French National Infrastructure for Metabolomics and Fluxomics MetaboHUB-ANR-11-INBS-0010 and the platform Aninfimip, an EquipEx (‘Equipement d’Excellence’) supported by the French government through the Investments for the Future program (ANR-11-EQPX-0003). We gratefully acknowledge the technical assistance provided by the INFINITy (INSERM 1291) personnel of both the flow cytometry (F.E. L’Faqihi-Olive, V. Duplan-Eche and Anne-Laure Iscache) and cellular imaging (S. Allart and S. Lachambre) core facilities connected to ‘Toulouse Réseau Imagerie’ network. This work was supported by the Institut National de la Santé et de la Recherche Médicale (INSERM), the Université Paul Sabatier, Toulouse III, the Association François Aupetit (G.D.) and the French Agence Nationale de la Recherche (NOCICEPOP-ANR-22-CE14-0011-01, G.D.). X.M.O., L.R., N.G., C.P. and E.W. were supported by scholarship from « Ministère de l’Enseignement Supérieur, de la Recherche et de l’Innovation » and L.B. by The Fondation pour la Recherche Médicale.; Funding text 2: The authors wish to thank the animal care facility, Genetoul, anexplo, US006/INSERM, Toulouse, MetaToul (Toulouse metabolomics & fluxomics facilities, www.metatoul.fr ) which is part of the French National Infrastructure for Metabolomics and Fluxomics MetaboHUB-ANR-11-INBS-0010 and the platform Aninfimip, an EquipEx (‘Equipement d’Excellence’) supported by the French government through the Investments for the Future program (ANR-11-EQPX-0003). We gratefully acknowledge the technical assistance provided by the INFINITy (INSERM 1291) personnel of both the flow cytometry (F.E. L’Faqihi-Olive, V. Duplan-Eche and Anne-Laure Iscache) and cellular imaging (S. Allart and S. Lachambre) core facilities connected to ‘Toulouse Réseau Imagerie’ network. This work was supported by the Institut National de la Santé et de la Recherche Médicale (INSERM), the Université Paul Sabatier, Toulouse III, the Association François Aupetit (G.D.) and the French Agence Nationale de la Recherche (NOCICEPOP-ANR-22-CE14-0011-01, G.D.). X.M.O., L.R., N.G., C.P. and E.W. were supported by scholarship from « Ministère de l’Enseignement Supérieur, de la Recherche et de l’Innovation » and L.B. by The Fondation pour la Recherche Médicale. ","Guerrero-Alba R., Et al., Co-expression of mu and delta opioid receptors by mouse colonic nociceptors, Br. J. Pharm., 175, pp. 2622-2634, (2018); Hockley J.R.F., Et al., Single-cell RNAseq reveals seven classes of colonic sensory neuron, Gut, 68, pp. 633-644, (2019); DiCello J.J., Et al., Inflammation-associated changes in DOR expression and function in the mouse colon, Am. J. Physiol. Gastrointest. Liver Physiol., 315, pp. G544-G559, (2018); Pol O., Alameda F., Puig M.M., Inflammation enhances mu-opioid receptor transcription and expression in mice intestine, Mol. Pharm., 60, pp. 894-899, (2001); Pol O., Palacio J.R., Puig M.M., The expression of delta- and kappa-opioid receptor is enhanced during intestinal inflammation in mice, J. Pharm. Exp. Ther., 306, pp. 455-462, (2003); Valle L., Pol O., Puig M.M., Intestinal inflammation enhances the inhibitory effects of opioids on intestinal permeability in mice, J. Pharm. Exp. Ther., 296, pp. 378-387, (2001); IL-4 induces M2 macrophages to produce sustained analgesia via opioids, JCI Insight, 5, (2020); Garcia-Dominguez M., Et al., The Chemokine CCL4 (MIP-1beta) Evokes Antinociceptive Effects in Mice: a Role for CD4(+) Lymphocytes and Met-Enkephalin, Mol. Neurobiol., 56, pp. 1578-1595, (2019); Machelska H., Celik M.O., Immune cell-mediated opioid analgesia, Immunol. Lett., 227, pp. 48-59, (2020); Shime H., Et al., Proenkephalin(+) regulatory T cells expanded by ultraviolet B exposure maintain skin homeostasis with a healing function, Proc. Natl Acad. Sci. USA, 117, pp. 20696-20705, (2020); Rittner H.L., Et al., Mycobacteria attenuate nociceptive responses by formyl peptide receptor triggered opioid peptide release from neutrophils, PLoS Pathog., 5, (2009); Basso L., Et al., Mobilization of CD4+ T lymphocytes in inflamed mucosa reduces pain in colitis mice: toward a vaccinal strategy to alleviate inflammatory visceral pain, Pain, 159, pp. 331-341, (2018); Basso L., Bourreille A., Dietrich G., Intestinal inflammation and pain management, Curr. Opin. Pharm., 25, pp. 50-55, (2015); Basso L., Et al., T-lymphocyte-derived enkephalins reduce Th1/Th17 colitis and associated pain in mice, J. Gastroenterol., 53, pp. 215-226, (2018); Boue J., Et al., Endogenous regulation of visceral pain via production of opioids by colitogenic CD4(+) T cells in mice, Gastroenterology, 146, pp. 166-175, (2014); Basso L., Et al., Endogenous control of inflammatory visceral pain by T cell-derived opioids in IL-10-deficient mice, Neurogastroenterol. Motil., 32, (2020); Mas-Orea X., Et al., Delta opioid receptors on nociceptive sensory neurons mediate peripheral endogenous analgesia in colitis, J. Neuroinflammation, 19, (2022); Sathaliyawala T., Et al., Distribution and compartmentalization of human circulating and tissue-resident memory T cell subsets, Immunity, 38, pp. 187-197, (2013); Ansaldo E., Farley T.K., Belkaid Y., Control of immunity by the microbiota, Annu. Rev. Immunol., 39, pp. 449-479, (2021); Beura L.K., Et al., CD4(+) resident memory T cells dominate immunosurveillance and orchestrate local recall responses, J. Exp. Med., 216, pp. 1214-1229, (2019); Boue J., Blanpied C., Brousset P., Vergnolle N., Dietrich G., Endogenous opioid-mediated analgesia is dependent on adaptive T cell response in mice, J. Immunol., 186, pp. 5078-5084, (2011); Verma-Gandhu M., Et al., CD4+ T-cell modulation of visceral nociception in mice, Gastroenterology, 130, pp. 1721-1728, (2006); Motta J.P., Et al., Active thrombin produced by the intestinal epithelium controls mucosal biofilms, Nat. Commun., 10, (2019); Baddack-Werncke U., Et al., Cytotoxic T cells modulate inflammation and endogenous opioid analgesia in chronic arthritis, J. Neuroinflammation, 14, (2017); Basso L., Et al., Endogenous analgesia mediated by CD4(+) T lymphocytes is dependent on enkephalins in mice, J. Neuroinflammation, 13, (2016); Basso L., Boue J., Bourreille A., Dietrich G., Endogenous regulation of inflammatory pain by T-cell-derived opioids: when friend turns to foe, Inflamm. Bowel Dis., 20, pp. 1870-1877, (2014); Boue J., Et al., Immune conditions associated with CD4+ T effector-induced opioid release and analgesia, Pain, 153, pp. 485-493, (2012); Valdez-Morales E., Et al., Release of endogenous opioids during a chronic IBD model suppresses the excitability of colonic DRG neurons, Neurogastroenterol. Motil., 25, pp. 39-46.e34, (2013); Verma-Gandhu M., Et al., Visceral pain perception is determined by the duration of colitis and associated neuropeptide expression in the mouse, Gut, 56, pp. 358-364, (2007); Hegazy A.N., Et al., Circulating and tissue-resident CD4(+) T cells with reactivity to intestinal microbiota are abundant in healthy individuals and function is altered during inflammation, Gastroenterology, 153, pp. 1320-1337 e1316, (2017); Abdullah N., Defaye M., Altier C., Neural control of gut homeostasis, Am. J. Physiol. Gastrointest. Liver Physiol., 319, pp. G718-G732, (2020); Guo R., Chen L.H., Xing C., Liu T., Pain regulation by gut microbiota: molecular mechanisms and therapeutic potential, Br. J. Anaesth., 123, pp. 637-654, (2019); Pinho-Ribeiro F.A., Verri W.A., Chiu I.M., Nociceptor sensory neuron-immune interactions in pain and inflammation, Trends Immunol., 38, pp. 5-19, (2017); Johansson M.E., Et al., Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis, Gut, 63, pp. 281-291, (2014); Etxeberria U., Et al., Pterostilbene-induced changes in gut microbiota composition in relation to obesity, Mol. Nutr. Food Res., 61, (2017); Wright D.P., Rosendale D.I., Robertson A.M., Prevotella enzymes involved in mucin oligosaccharide degradation and evidence for a small operon of genes expressed during growth on mucin, FEMS Microbiol. Lett., 190, pp. 73-79, (2000); Han L., Et al., Altered metabolome and microbiome features provide clues in understanding irritable bowel syndrome and depression comorbidity, ISME J., 16, pp. 983-996, (2022); Su T., Et al., Altered intestinal microbiota with increased abundance of prevotella is associated with high risk of diarrhea-predominant irritable bowel syndrome, Gastroenterol. Res Pr., 2018, (2018); Baumgartner M., Et al., Mucosal biofilms are an endoscopic feature of irritable bowel syndrome and ulcerative colitis, Gastroenterology, 161, pp. 1245-1256 e1220, (2021); Edelblum K.L., Et al., The microbiome activates CD4 T-cell-mediated immunity to compensate for increased intestinal permeability, Cell Mol. Gastroenterol. Hepatol., 4, pp. 285-297, (2017); Buhner S., Et al., Genetic basis for increased intestinal permeability in families with Crohn’s disease: role of CARD15 3020insC mutation?, Gut, 55, pp. 342-347, (2006); Secondulfo M., Et al., Intestinal permeability in Crohn’s disease patients and their first degree relatives, Dig. Liver Dis., 33, pp. 680-685, (2001); Hanning N., Et al., Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review, Ther. Adv. Gastroenterol., 14, (2021); McOmber M., Et al., Increased Gut permeability in first-degree relatives of children with irritable bowel syndrome or functional abdominal pain, Clin. Gastroenterol. Hepatol., 18, pp. 375-384.e371, (2020); Inczefi O., Et al., Targeted intestinal tight junction hyperpermeability alters the microbiome, behavior, and visceromotor responses, Cell Mol. Gastroenterol. Hepatol., 10, pp. 206-208.e203, (2020); Rincel M., Et al., Pharmacological restoration of gut barrier function in stressed neonates partially reverses long-term alterations associated with maternal separation, Psychopharmacology, 236, pp. 1583-1596, (2019); Powell N., Walker M.M., Talley N.J., The mucosal immune system: master regulator of bidirectional gut-brain communications, Nat. Rev. Gastroenterol. Hepatol., 14, pp. 143-159, (2017); Aguilera-Lizarraga J., Hussein H., Boeckxstaens G.E., Immune activation in irritable bowel syndrome: what is the evidence?, Nat. Rev. Immunol., 22, pp. 674-686, (2022); Hughes P.A., Et al., Sensory neuro-immune interactions differ between irritable bowel syndrome subtypes, Gut, 62, pp. 1456-1465, (2013); Hughes P.A., Et al., Immune derived opioidergic inhibition of viscerosensory afferents is decreased in irritable bowel syndrome patients, Brain Behav. Immun., 42, pp. 191-203, (2014); Faria A.M.C., Reis B.S., Mucida D., Tissue adaptation: implications for gut immunity and tolerance, J. Exp. Med., 214, pp. 1211-1226, (2017); Lapiere A., Et al., Prophylactic Faecalibacterium prausnitzii treatment prevents the acute breakdown of colonic epithelial barrier in a preclinical model of pelvic radiation disease, Gut Microbes, 12, pp. 1-15, (2020); Zhang J., Gong J.F., Zhang W., Zhu W.M., Li J.S., Effects of transplanted bone marrow mesenchymal stem cells on the irradiated intestine of mice, J. Biomed. Sci., 15, pp. 585-594, (2008); Goldsmith J.R., Uronis J.M., Jobin C., Mu opioid signaling protects against acute murine intestinal injury in a manner involving Stat3 signaling, Am. J. Pathol., 179, pp. 673-683, (2011); Gralnek I.M., Hays R.D., Kilbourne A., Naliboff B., Mayer E.A., The impact of irritable bowel syndrome on health-related quality of life, Gastroenterology, 119, pp. 654-660, (2000); Ford A.C., Sperber A.D., Corsetti M., Camilleri M., Irritable bowel syndrome, Lancet, 396, pp. 1675-1688, (2020); Sabate J.M., Et al., Healthcare use by 30,000 patients with irritable bowel syndrome (IBS) in France: a 5-year retrospective and 1-year prospective national observational study, BMC Gastroenterol., 19, (2019); Kavelaars A., Heijnen C.J., T cells as guardians of pain resolution, Trends Mol. Med., 27, pp. 302-313, (2021); Lembo T., Et al., Irritable bowel syndrome patients show altered sensitivity to exogenous opioids, Pain, 87, pp. 137-147, (2000); Machelska H., Celik M.O., Opioid receptors in immune and glial cells-implications for pain control, Front. Immunol., 11, (2020); Koester S.T., Li N., Lachance D.M., Dey N., Marker-based assays for studying gut transit in gnotobiotic and conventional mouse models, STAR Protoc., 2, (2021); Abot A., Et al., Identification of new enterosynes using prebiotics: roles of bioactive lipids and mu-opioid receptor signaling in humans and mice, Gut, 70, pp. 1078-1087, (2021); Love M.I., Huber W., Anders S., Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2, Genome Biol., 15, (2014); Le Faouder P., Et al., LC-MS/MS method for rapid and concomitant quantification of pro-inflammatory and pro-resolving polyunsaturated fatty acid metabolites, J. Chromatogr. B Anal. Technol. Biomed. Life Sci., 932, pp. 123-133, (2013); Pujo J., Et al., Bacteria-derived long chain fatty acid exhibits anti-inflammatory properties in colitis, Gut, 70, pp. 1088-1097, (2021); Bautzova T., Et al., 5-oxoETE triggers nociception in constipation-predominant irritable bowel syndrome through MAS-related G protein-coupled receptor D, Sci. Signal, 11, (2018); Jung C., Et al., Yersinia pseudotuberculosis disrupts intestinal barrier integrity through hematopoietic TLR-2 signaling, J. Clin. Investig., 122, pp. 2239-2251, (2012); Mas-Orea X., Et al., Peripheral Opioid Receptor Blockade Enhances Epithelial Damage in Piroxicam-Accelerated Colitis in IL-10-Deficient Mice, Int. J. Mol. Sci., 22, (2021); Petitfils C., Identification of bacterial lipopeptides as key players in IBS, Gut, (2022); Serino M., Et al., Metabolic adaptation to a high-fat diet is associated with a change in the gut microbiota, Gut, 61, pp. 543-553, (2012); Segata N., Et al., Metagenomic biomarker discovery and explanation, Genome Biol., 12, (2011); Kawamoto S., Et al., Foxp3(+) T cells regulate immunoglobulin a selection and facilitate diversification of bacterial species responsible for immune homeostasis, Immunity, 41, pp. 152-165, (2014); Surget A., Et al., Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal, Biol. Psychiatry, 64, pp. 293-301, (2008)","G. Dietrich; IRSD, Université de Toulouse, INSERM, INRAE, ENVT, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France; email: gilles.dietrich@inserm.fr","","Nature Research","","","","","","23993642","","","37968381","English","Commun. Biolog.","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85176803035"

"Ke W.; Wang Y.; Huang S.; Liu S.; Zhu H.; Xie X.; Yang H.; Lu Q.; Gan J.; He G.; Che F.; Wan X.; Tang H.","Ke, Wei (58024459000); Wang, Yongfu (58024459100); Huang, Siyu (58023658700); Liu, Shan (57201523353); Zhu, He (57208025933); Xie, Xiangyu (58025057100); Yang, Huifei (57860401500); Lu, Qin (58024459200); Gan, Jianfeng (58024855800); He, Guodong (58023864400); Che, Fei (58024663200); Wan, Xin (58025057300); Tang, Hongmei (15519827300)","58024459000; 58024459100; 58023658700; 57201523353; 57208025933; 58025057100; 57860401500; 58024459200; 58024855800; 58023864400; 58024663200; 58025057300; 15519827300","Paeoniflorin alleviates inflammatory response in IBS-D mouse model via downregulation of the NLRP3 inflammasome pathway with involvement of miR-29a","2022","Heliyon","8","12","e12312","","","","6","10.1016/j.heliyon.2022.e12312","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85144345132&doi=10.1016%2fj.heliyon.2022.e12312&partnerID=40&md5=0c51bf8d7b740e7b2084cc1884ee86d5","The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China; The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China; Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China; Department of Traditional Chinese Medicine, The First Affiliated Hospital of Zhengzhou University, Henan, Zhengzhou, 450052, China; Guangdong Provincial Key Laboratory of Advanced Drug Delivery Systems and Guangdong Provincial Engineering Center of Topical Precise Drug Delivery System, Guangdong Pharmaceutical University, Guangdong, Guangzhou, 510006, China; Guangzhou Liwan District Hospital of Traditional Chinese Medicine, Guangdong, Guangzhou, 510160, China","Ke W., The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China, Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China; Wang Y., Department of Traditional Chinese Medicine, The First Affiliated Hospital of Zhengzhou University, Henan, Zhengzhou, 450052, China; Huang S., The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China, Guangdong Provincial Key Laboratory of Advanced Drug Delivery Systems and Guangdong Provincial Engineering Center of Topical Precise Drug Delivery System, Guangdong Pharmaceutical University, Guangdong, Guangzhou, 510006, China; Liu S., The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China, Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China; Zhu H., The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China; Xie X., The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China, Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China; Yang H., The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China, Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China; Lu Q., The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China, Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China; Gan J., The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China, Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China; He G., The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China, Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China; Che F., The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China, Guangzhou Liwan District Hospital of Traditional Chinese Medicine, Guangdong, Guangzhou, 510160, China; Wan X., The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China, Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China; Tang H., The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China","Paeoniflorin has been traditionally used to treat pain and immunologic derangement in China. However, its detailed mechanism remains to be illuminated. We investigated the mechanism by which paeoniflorin alleviates the inflammatory response in a mouse model of irritable bowel syndrome with predominant diarrhea (IBS-D). C57BL/6 wild type (WT) and miR-29a knockout (KO) mice were randomly divided into control, model, rifaximin, and paeoniflorin groups (n = 7). IBS-D model was induced by single intracolonic instillation of 0.1 mL trinitro-benzene-sulfonic acid (TNBS, 50 mg/mL) combined with restraint stress for seven consecutive days. The treatment groups received rifaximin (100 mg/kg) and paeoniflorin (50 mg/kg) via intragastric administration for seven days, respectively. The results showed that the fecal water content, fecal pellet output, visceral sensitivity, and histopathological score after paeoniflorin treatment were lower than those of the model group in both WT and miR-29a KO mice (P < 0.05). In both lineage mice, damage was observed in the colon tissues of model group, while paeoniflorin treatment partially ameliorated the tissue damage. Serum levels of DAO, DLA, IL-1β, IL-18, TNF-α, and MPO were decreased after paeoniflorin treatment (P < 0.05), with miR-29a KO mice in a lower level compared with that of WT mice. RT-PCR showed that the relative expression of miR-29a, NF-κB (p65), NLRP3, ASC, caspase-1, IL-1β, and TNF-α was downregulated while NKRF was upregulated after paeoniflorin treatment (P < 0.05). Immunohistochemistry showed that intestinal epithelial protein levels of NLRP3, ASC, and caspase-1 decreased while those of Claudin-1 and ZO-1 increased in the paeoniflorin treatment group (P < 0.05). In general, compared with WT mice, NLRP3 inflammasome pathway targets was in much lower expression level than miR-29a KO mice. In conclusion, paeoniflorin could inhibit abnormal activation of the NLRP3 inflammasome pathway by inhibiting miR-29a in IBS-D, thereby relieving the inflammatory response of the intestinal mucosa and reconstructing the intestinal epithelial barrier. © 2022 The Author(s)","irritable bowel syndrome; miR-29a; NLRP3 inflammasome; Paeoniflorin","","","","","","National Natural Science Foundation of China, NSFC, (81673842); Natural Science Foundation of Guangdong Province, (2019A1515011745, 2021A1515110727)","This work was supported by the following three funding programs: 1. the National Natural Science Foundation of China, China (grant no. 81673842); 2. Natural Science Foundation of Guangdong Province, China (grant no. 2019A1515011745); 3. Natural Science Foundation of Guangdong Province, China (grant no. 2021A1515110727). ","Mearin F., Lacy B.E., Chang L., Et al., Bowel disorders, Gastroenterology, S0016-5085, 16, pp. 222-225, (2016); Oka P., Parr H., Barberio B., Et al., Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis, Lancet Gastroenterol. Hepatol., 5, 10, pp. 908-917, (2020); Canavan C., West J., Card T., Review article: the economic impact of the irritable bowel syndrome, Aliment. Pharmacol. Ther., 40, 9, pp. 1023-1034, (2014); Drossman D.A., Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV, Gastroenterology, S0016-5085, 16, pp. 223-227, (2016); Harvey J.M., Sibelli A., Chalder T., Et al., Desperately seeking a cure: treatment seeking and appraisal in irritable bowel syndrome, Br. J. Health Psychol., 23, 3, pp. 561-579, (2018); Talley N.J., What causes functional gastrointestinal disorders? A proposed disease model, Am. J. Gastroenterol., 115, 1, pp. 41-48, (2020); Martin-Vinas J.J., Quigley E.M., Immune response in irritable bowel syndrome: a systematic review of systemic and mucosal inflammatory mediators, J Dig Dis, 17, 9, pp. 572-581, (2016); Bashashati M., Moossavi S., Cremon C., Et al., Colonic immune cells in irritable bowel syndrome: a systematic review and meta-analysis, Neuro Gastroenterol. Motil., 30, 1, (2018); Ohman L., Simren M., Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions, Nat. Rev. Gastroenterol. Hepatol., 7, 3, pp. 163-173, (2010); Zhen Y., Zhang H., NLRP3 inflammasome and inflammatory bowel disease, Front. Immunol., 10, (2019); Scuderi S.A., Casili G., Lanza M., Et al., Modulation of NLRP3 inflammasome attenuated inflammatory response associated to diarrhea-predominant irritable bowel syndrome, Biomedicines, 8, 11, (2020); Vanaja S.K., Rathinam V.A., Fitzgerald K.A., Mechanisms of inflammasome activation: recent advances and novel insights, Trends Cell Biol., 25, 5, pp. 308-315, (2015); de Almeida L., Khare S., Misharin A.V., Et al., The PYRIN domain-only protein POP1 inhibits inflammasome assembly and ameliorates inflammatory disease, Immunity, 43, 2, pp. 264-276, (2015); Barbara G., Barbaro M.R., Fuschi D., Et al., Inflammatory and microbiota-related regulation of the intestinal epithelial barrier, Front. Nutr., 8, (2021); Matricon J., Meleine M., Gelot A., Et al., Review article: associations between immune activation, intestinal permeability and the irritable bowel syndrome, Aliment. Pharmacol. Ther., 36, 11-12, pp. 1009-1031, (2012); Pimentel M., Lembo A., Chey W.D., Et al., Rifaximin therapy for patients with irritable bowel syndrome without constipation, N. Engl. J. Med., 364, 1, pp. 22-32, (2011); Xu D., Gao J., Gillilland M., Et al., Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats, Gastroenterology, 146, 2, pp. 484-496 e4, (2014); Lu T.X., Rothenberg M.E., MicroRNA, J. Allergy Clin. Immunol., 141, 4, pp. 1202-1207, (2018); Zhou Q., Souba W.W., Croce C.M., Et al., MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome, Gut, 59, 6, pp. 775-784, (2010); Zhou Q., Costinean S., Croce C.M., Et al., MicroRNA 29 targets nuclear factor-kappaB-repressing factor and Claudin 1 to increase intestinal permeability, Gastroenterology, 148, 1, pp. 158-169 e8, (2015); Bauernfeind F.G., Horvath G., Stutz A., Et al., Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression, J. Immunol., 183, 2, pp. 787-791, (2009); Chen M., Tang T.C., Wang Y., Et al., Randomised clinical trial: Tong-Xie-Yao-Fang granules versus placebo for patients with diarrhoea-predominant irritable bowel syndrome, Aliment. Pharmacol. Ther., 48, 2, pp. 160-168, (2018); Wang G., Li T.Q., Wang L., Et al., Tong-xie-ning, a Chinese herbal formula, in treatment of diarrhea-predominant irritable bowel syndrome: a prospective, randomized, double-blind, placebo-controlled trial, Chin. Med. J. (Engl.)., 119, 24, pp. 2114-2119, (2006); Luo X., Wang X., Huang S., Et al., Paeoniflorin ameliorates experimental colitis by inhibiting gram-positive bacteria-dependent MDP-NOD2 pathway, Int. Immunopharm., 90, (2021); Fan Q., Guan X., Hou Y., Et al., Paeoniflorin modulates gut microbial production of indole-3-lactate and epithelial autophagy to alleviate colitis in mice, Phytomedicine, 79, (2020); Wu X.X., Huang X.L., Chen R.R., Et al., Paeoniflorin prevents intestinal barrier disruption and inhibits lipopolysaccharide (LPS)-Induced inflammation in Caco-2 cell monolayers, Inflammation, 42, 6, pp. 2215-2225, (2019); Zhang X.J., Li Z., Leung W.M., Et al., The analgesic effect of paeoniflorin on neonatal maternal separation-induced visceral hyperalgesia in rats, J. Pain, 9, 6, pp. 497-505, (2008); Zhu H., Xiao X., Chai Y., Et al., MiRNA-29a modulates visceral hyperalgesia in irritable bowel syndrome by targeting HTR7, Biochem. Biophys. Res. Commun., 511, 3, pp. 671-678, (2019); Williams C.L., Villar R.G., Peterson J.M., Et al., Stress-induced changes in intestinal transit in the rat: a model for irritable bowel syndrome, Gastroenterology, 94, 3, pp. 611-621, (1988); Kang D.J., Kakiyama G., Betrapally N.S., Et al., Rifaximin exerts beneficial effects independent of its ability to alter microbiota composition, Clin. Transl. Gastroenterol., 7, 8, (2016); Zhang J., Dou W., Zhang E., Et al., Paeoniflorin abrogates DSS-induced colitis via a TLR4-dependent pathway, Am. J. Physiol. Gastrointest. Liver Physiol., 306, 1, pp. G27-36, (2014); Aguilera-Lizarraga J., Florens M.V., Viola M.F., Et al., Local immune response to food antigens drives meal-induced abdominal pain, Nature, 590, 7844, pp. 151-156, (2021); Al-Chaer E.D., Kawasaki M., Pasricha P.J., A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development, Gastroenterology, 119, 5, pp. 1276-1285, (2000); Asseman C., Mauze S., Leach M.W., Et al., An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation, J. Exp. Med., 190, 7, pp. 995-1004, (1999); Zhang F., Wang W., Niu J., Et al., Heat-shock transcription factor 2 promotes sodium butyrate-induced autophagy by inhibiting mTOR in ulcerative colitis, Exp. Cell Res., 388, 1, (2020); Esposito E., Impellizzeri D., Mazzon E., Et al., Neuroprotective activities of palmitoylethanolamide in an animal model of Parkinson's disease, PLoS One, 7, 8, (2012); Rangan V., Nee J., Singh P., Et al., Fecal urgency: clinical and manometric characteristics in patients with and without diarrhea, Dig. Dis. Sci., 65, 12, pp. 3679-3687, (2020); Shamshiri H., Paragomi P., Paydar M.J., Et al., Antinociceptive effect of chronic lithium on visceral hypersensitivity in a rat model of diarrhea-predominant irritable bowel syndrome: the role of nitric oxide pathway, J. Gastroenterol. Hepatol., 24, 4, pp. 672-680, (2009); Ford A.C., Lacy B.E., Harris L.A., Et al., Effect of antidepressants and psychological therapies in irritable bowel syndrome: an updated systematic review and meta-analysis, Am. J. Gastroenterol., 114, 1, pp. 21-39, (2019); Bonaz B., Lane R.D., Oshinsky M.L., Et al., Diseases, disorders, and comorbidities of interoception, Trends Neurosci., 44, 1, pp. 39-51, (2021); Blake M.R., Raker J.M., Whelan K., Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome, Aliment. Pharmacol. Ther., 44, 7, pp. 693-703, (2016); Farzaei M.H., Bahramsoltani R., Abdollahi M., Et al., The role of visceral hypersensitivity in irritable bowel syndrome: pharmacological targets and novel treatments, J Neurogastroenterol Motil, 22, 4, pp. 558-574, (2016); Benvenutti R.C., Dalla Vecchia C.A., Locateli G., Et al., Gastroprotective activity of hydroalcoholic extract of the leaves of Urera baccifera in rodents, J. Ethnopharmacol., 250, (2020); Sun X.Q., Fu X.B., Zhang R., Et al., Relationship between plasma D(-)-lactate and intestinal damage after severe injuries in rats, World J. Gastroenterol., 7, 4, pp. 555-558, (2001); Xia B., Wu W., Fang W., Et al., Heat stress-induced mucosal barrier dysfunction is potentially associated with gut microbiota dysbiosis in pigs, Anim Nutr, 8, 1, pp. 289-299, (2022); Pellegrini C., Antonioli L., Lopez-Castejon G., Et al., Canonical and non-canonical activation of NLRP3 inflammasome at the crossroad between immune tolerance and intestinal inflammation, Front. Immunol., 8, (2017); Gu Q.Y., Zhang J., Feng Y.C., Role of NLRP3 inflammasome in Bifidobacterium longum-regulated visceral hypersensitivity of postinfectious irritable bowel syndrome, Artif. Cell Nanomed. Biotechnol., 44, 8, pp. 1933-1937, (2016); Awad F., Assrawi E., Louvrier C., Et al., Inflammasome biology, molecular pathology and therapeutic implications, Pharmacol. Ther., 187, pp. 133-149, (2018); Vallabhapurapu S., Karin M., Regulation and function of NF-kappaB transcription factors in the immune system, Annu. Rev. Immunol., 27, pp. 693-733, (2009); Heinemann U., Schuetz A., Structural features of tight-junction proteins, Int. J. Mol. Sci., 20, 23, (2019); Barmeyer C., Schulzke J.D., Fromm M., Claudin-related intestinal diseases, Semin. Cell Dev. Biol., 42, pp. 30-38, (2015); Sugita K., Kabashima K., Tight junctions in the development of asthma, chronic rhinosinusitis, atopic dermatitis, eosinophilic esophagitis, and inflammatory bowel diseases, J. Leukoc. Biol., 107, 5, pp. 749-762, (2020); Suzuki T., Regulation of intestinal epithelial permeability by tight junctions, Cell. Mol. Life Sci., 70, 4, pp. 631-659, (2013); Rawat M., Nighot M., Al-Sadi R., Et al., IL1B increases intestinal tight junction permeability by up-regulation of MIR200C-3p, which degrades occludin mRNA, Gastroenterology, 159, 4, pp. 1375-1389, (2020); Martinez C., Rodino-Janeiro B.K., Lobo B., Et al., miR-16 and miR-125b are involved in barrier function dysregulation through the modulation of claudin-2 and cingulin expression in the jejunum in IBS with diarrhoea, Gut, 66, 9, pp. 1537-1538, (2017)","H. Tang; The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China; email: tanghongmei2000@163.com","","Elsevier Ltd","","","","","","24058440","","","","English","Heliyon","Article","Final","All Open Access; Green Open Access","Scopus","2-s2.0-85144345132"

"Cui L.; Hua Y.; Zou S.; Gu C.; Li H.","Cui, Li (55189436500); Hua, Yongzhi (57223416459); Zou, Shuting (58731982700); Gu, Chao (57226658841); Li, Hui (57196364139)","55189436500; 57223416459; 58731982700; 57226658841; 57196364139","Combination of fenchone and sodium hyaluronate ameliorated constipation-predominant irritable bowel syndrome and underlying mechanisms","2024","Chemical Biology and Drug Design","103","1","e14397","","","","0","10.1111/cbdd.14397","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85178242854&doi=10.1111%2fcbdd.14397&partnerID=40&md5=9f457953cac4b58f9c843ec43012e906","Department of Gastroenterology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China; Digestive Department, Nanjing Lishui District Hospital of Traditional Chinese Medicine, Nanjing, China","Cui L., Department of Gastroenterology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China; Hua Y., Department of Gastroenterology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China, Digestive Department, Nanjing Lishui District Hospital of Traditional Chinese Medicine, Nanjing, China; Zou S., Department of Gastroenterology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China; Gu C., Department of Gastroenterology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China; Li H., Department of Gastroenterology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China","We sought to explore the protective effect of the combination of fenchone (FE) and sodium hyaluronate (SH) on ice water-induced IBS-C rats and the potential mechanism. The neurotransmitter levels, including substance P (SP), motilin (MTL), 5-hydroxytryptamine (5-HT), and vasoactive intestinal peptide (VIP), were determined by ELISA methods. The stem cell factors (SCF)/c-Kit signaling pathway-related protein and mRNA levels were determined by western blot and reverse transcription quantitative polymerase chain reaction (RT-qPCR) analyses, respectively. The expressions of tight ZO-1, Occludin, and Claudin-1 were also measured by western blot assay and immunofluorescence staining. The 16S rRNA gene sequence was used to measure the composition of gut microbiota. The co-administration of FE and SH improved the body weight, number of fecal pellets, fecal moisture, abdominal with drawal reflex score, and gastrointestinal transit rate in IBS-C rats. The unique efficacy of combination depended on the regulation of balance between excitatory and inhibitory neurotransmitters, enhancement of intestinal barrier function, and activation of SCF/c-Kit pathway. The gut microbiota structure was also restored. The ability of FE combined with SH to regulate SCF/c-Kit signaling pathway, enhance intestinal barrier function, and modulate gut microbiota contributes to their efficacy in managing IBS-C in rats. © 2023 John Wiley & Sons Ltd.","constipation-predominant irritable bowel syndrome; fenchone; gut microbiota; SCF/c-kit signaling pathway; sodium hyaluronate","Animals; Camphanes; Constipation; Hyaluronic Acid; Irritable Bowel Syndrome; Norbornanes; Rats; RNA, Ribosomal, 16S; activated carbon; bicyclic monoterpenoid; claudin 1; cytokine; essential oil; fenchone; glycerol; hyaluronic acid; interleukin 18; interleukin 1beta; linaclotide; messenger RNA; motilin; neurotransmitter; occludin; RNA 16S; serotonin; stem cell factor; substance P; tight junction protein; tumor necrosis factor; unclassified drug; vasoactive intestinal polypeptide; camphane derivative; fenchone; hyaluronic acid; norbornane derivative; abdominal wall musculature; animal experiment; animal model; Article; body weight; cell nucleus; chemical structure; clinical practice; colon motility; colon tissue; constipation; controlled study; enzyme linked immunosorbent assay; fluid intake; food intake; gastrointestinal transit; gene sequence; genetic profile; homeostasis; ileocecal valve; immune response; immunofluorescence; immunohistochemistry; intestine flora; intestine motility; irritable colon; male; microbial diversity; myoelectricity; nonhuman; population abundance; protein expression level; quantitative analysis; rat; real time polymerase chain reaction; real time reverse transcription polymerase chain reaction; remission; signal transduction; Simpson index; species diversity; Sprague Dawley rat; upregulation; visceral hyperalgesia; water content; water treatment; Western blotting; withdrawal reflex; animal; constipation; irritable colon","","activated carbon, 64365-11-3, 82228-96-4; claudin 1, 329338-06-9; glycerol, 56-81-5; hyaluronic acid, 31799-91-4, 9004-61-9, 9067-32-7; interleukin 18, 189304-55-0; linaclotide, 851199-59-2, 851199-60-5; motilin, 52906-92-0; occludin, 176304-61-3; serotonin, 50-67-9; substance P, 33507-63-0; vasoactive intestinal polypeptide, 37221-79-7; Camphanes, ; fenchone, ; Hyaluronic Acid, ; Norbornanes, ; RNA, Ribosomal, 16S, ","","","Jiangsu Provincial TCM Science and Technology Development Plan Project, (MS2021025); National Administration of Traditional Chinese Medicine, (2022GJJZDYJS‐01); Social Development Project of Jiangsu Province, (BE2022817); National Natural Science Foundation of China, NSFC, (81403121); National Natural Science Foundation of China, NSFC","This work was financially supported by the National Natural Science Foundation of China (81403121), Jiangsu Provincial TCM Science and Technology Development Plan Project (MS2021025), Social Development Project of Jiangsu Province (BE2022817), and Central government financial transfer payment for local projects from National Administration of Traditional Chinese Medicine (2022GJJZDYJS‐01). ","Bai Y., Liu F., Zheng L., Wan Y., Fan J., Deng J., Li Q., Xie Y., Guo P., Yajieshaba"" prevents acute alcoholic liver injury and repairs the intestinal mucosal barrier, Journal of Ethnopharmacology, 318, (2023); Bonetti A., Piva A., Grilli E., Botanicals as a zinc oxide alternative to protect intestinal cells from an Escherichia coli F4 infection in vitro by modulation of enterocyte inflammatory response and bacterial virulence, Frontiers in Veterinary Science, 10, (2023); Chen I.J., Wong C.S., Shea nut oil extracts enhance the intra-articular sodium hyaluronate effectiveness on surgically induced OA progression in rats, Nutrients, 12, 4, (2020); DuPont A.W., Jiang Z.D., Harold S.A., Snyder N., Galler G.W., Garcia-Torres F., DuPont H.L., Motility abnormalities in irritable bowel syndrome, Digestion, 89, 2, pp. 119-123, (2014); Faghihi A., Zohalinezhad M.E., Najafi Kalyani M., Comparison of the effects of abdominal massage and Oral Administration of Sweet Almond oil on constipation and quality of life among elderly individuals: A single-blind clinical trial, BioMed Research International, 2022, (2022); Feng J., Gao J., Zhou S., Liu Y., Zhong Y., Shu Y., Meng M.S., Yan J., Sun D., Fang Q., Sun D., Role of stem cell factor in the regulation of ICC proliferation and detrusor contraction in rats with an underactive bladder, Molecular Medicine Reports, 16, 2, pp. 1516-1522, (2017); Filippone A., Ardizzone A., Bova V., Lanza M., Casili G., Cuzzocrea S., Esposito E., Campolo M., Paterniti I., A combination of xyloglucan, pea protein and Chia seed ameliorates intestinal barrier integrity and mucosa functionality in a rat model of constipation-predominant irritable bowel syndrome, Journal of Clinical Medicine, 11, 23, (2022); Fiorino G., Gilardi D., Naccarato P., Sociale O.R., Danese S., Safety and efficacy of sodium hyaluronate (IBD98E) in the induction of clinical and endoscopic remission in subjects with distal ulcerative colitis, Digestive and Liver Disease, 46, 4, pp. 330-334, (2014); Furgala A., Ciesielczyk K., Przybylska-Felus M., Jablonski K., Gil K., Zwolinska-Wcislo M., Postprandial effect of gastrointestinal hormones and gastric activity in patients with irritable bowel syndrome, Scientific Reports, 13, 1, (2023); Ge C., Luo X., Wu L., Lv Y., Hu Z., Yu D., Liu B., Plant essential oils improve growth performance by increasing antioxidative capacity, enhancing intestinal barrier function, and modulating gut microbiota in Muscovy ducks, Poultry Science, 102, 8, (2023); Gong Y., Liang X., Dai Y., Huang X., Su Q., Ma Y., Chen F., Wang S., Prokinetic effects of Citrus reticulata and Citrus aurantium extract with/without Bupleurum chinense using multistress-induced delayed gastric emptying models, Pharmaceutical Biology, 61, 1, pp. 345-355, (2023); Hao M., Song J., Zhai X., Cheng N., Xu C., Gui S., Chen J., Improvement of loperamide-hydrochloride-induced intestinal motility disturbance by Platycodon grandiflorum polysaccharides through effects on gut microbes and colonic serotonin, Frontiers in Cellular and Infection Microbiology, 13, (2023); Hollister E.B., Cain K.C., Shulman R.J., Jarrett M.E., Burr R.L., Ko C., Zia J., Han C.J., Heitkemper M.M., Relationships of microbiome markers with extraintestinal, psychological distress and gastrointestinal symptoms, and quality of life in women with irritable bowel syndrome, Journal of Clinical Gastroenterology, 54, 2, pp. 175-183, (2020); Hou Y., Dong L., Lu X., Shi H., Xu B., Zhong W., Ma L., Wang S., Yang C., He X., Zhao Y., Wang S., Distinctions between fecal and intestinal mucosal microbiota in subgroups of irritable bowel syndrome, Digestive Diseases and Sciences, 67, 12, pp. 5580-5592, (2022); Hu J., Gao W.Y., Gao Y., Ling N.S., Huang L.Q., Liu C.X., M3 muscarinic receptor- and Ca2+ influx-mediated muscle contractions induced by croton oil in isolated rabbit jejunum, Journal of Ethnopharmacology, 129, 3, pp. 377-380, (2010); Hu L., Nomura S., Sato Y., Takagi K., Ishii T., Honma Y., Watanabe K., Mizukami Y., Muto J., Anti-inflammatory effects of differential molecular weight hyaluronic acids on UVB-induced calprotectin-mediated keratinocyte inflammation, Journal of Dermatological Science, 107, 1, pp. 24-31, (2022); Jacobs J.P., Lagishetty V., Hauer M.C., Labus J.S., Dong T.S., Toma R., Vuyisich M., Naliboff B.D., Lackner J.M., Gupta A., Tillisch K., Mayer E.A., Multi-omics profiles of the intestinal microbiome in irritable bowel syndrome and its bowel habit subtypes, Microbiome, 11, 1, (2023); Jung S.M., Ha A.W., Choi S.J., Kim S.Y., Kim W.K., Effect of Bacillus coagulans SNZ 1969 on the improvement of bowel movement in loperamide-treated SD rats, Nutrients, 14, 18, pp. 1-13, (2022); Karaus M., Sarna S.K., Ammon H.V., Wienbeck M., Effects of oral laxatives on colonic motor complexes in dogs, Gut, 28, 9, pp. 1112-1119, (1987); Keskin I., Gunal Y., Ayla S., Kolbasi B., Sakul A., Kilic U., Gok O., Koroglu K., Ozbek H., Effects of Foeniculum vulgare essential oil compounds, fenchone and limonene, on experimental wound healing, Biotechnic & Histochemistry, 92, 4, pp. 274-282, (2017); Kim M., Sowndhararajan K., Kim S., The chemical composition and biological activities of essential oil from Korean native thyme Bak-Ri-hyang (Thymus quinquecostatus Celak.), Molecules, 27, 13, (2022); Kojima R., Doihara H., Nozawa K., Kawabata-Shoda E., Yokoyama T., Ito H., Characterization of two models of drug-induced constipation in mice and evaluation of mustard oil in these models, Pharmacology, 84, 4, pp. 227-233, (2009); Lee J.W., Kim H.H., Hyaluronic acid solution injection for upper and lower gastrointestinal bleeding after failed conventional endoscopic therapy, Digestive Endoscopy, 26, 2, pp. 285-290, (2014); Meligy A.M.A., El-Hamid M.I.A., Yonis A.E., Elhaddad G.Y., Abdel-Raheem S.M., El-Ghareeb W.R., Mohamed M.H.A., Ismail H., Ibrahim D., Liposomal encapsulated oregano, cinnamon, and clove oils enhanced the performance, bacterial metabolites antioxidant potential, and intestinal microbiota of broiler chickens, Poultry Science, 102, 6, (2023); Meunier M., Scandolera A., Chapuis E., Lapierre L., Sandre J., Brunner G., Lovchik M., Reynaud R., The anti-wrinkles properties of sodium acetylated hyaluronate, Journal of Cosmetic Dermatology, 21, 7, pp. 2749-2762, (2022); Parthasarathy G., Chen J., Chen X., Chia N., O'Connor H.M., Wolf P.G., Gaskins H.R., Bharucha A.E., Relationship between microbiota of the colonic mucosa vs feces and symptoms, colonic transit, and methane production in female patients with chronic constipation, Gastroenterology, 150, 2, pp. 367-379 e361, (2016); Pessoa M.L.S., Silva L.M.O., Araruna M.E.C., Serafim C.A.L., Junior E.B.A., Silva A.O., Pessoa M.M.B., Neto H.D., Lima E.O., Batista L.M., Antifungal activity and antidiarrheal activity via antimotility mechanisms of (−)-fenchone in experimental models, World Journal of Gastroenterology, 26, 43, pp. 6795-6809, (2020); Picon P.D., Picon R.V., Costa A.F., Sander G.B., Amaral K.M., Aboy A.L., Henriques A.T., Randomized clinical trial of a phytotherapic compound containing Pimpinella anisum, Foeniculum vulgare, Sambucus nigra, and Cassia augustifolia for chronic constipation, BMC Complementary and Alternative Medicine, 10, (2010); Rangan V., Ballou S., Shin A., Camilleri M., Nee J., Iturrino J., Singh P., Patel R., Lembo A., Use of treatments for irritable bowel syndrome and patient satisfaction based on the IBS in America survey, Gastroenterology, 158, 3, pp. 786-788 e781, (2020); Reigstad C.S., Salmonson C.E., Rainey J.F., Szurszewski J.H., Linden D.R., Sonnenburg J.L., Farrugia G., Kashyap P.C., Gut microbes promote colonic serotonin production through an effect of short-chain fatty acids on enterochromaffin cells, The FASEB Journal, 29, 4, pp. 1395-1403, (2015); Saravanaperumal S.A., Gibbons S.J., Malysz J., Sha L., Linden D.R., Szurszewski J.H., Farrugia G., Extracellular Cl(−) regulates electrical slow waves and setting of smooth muscle membrane potential by interstitial cells of Cajal in mouse jejunum, Experimental Physiology, 103, 1, pp. 40-57, (2018); Sedky A.A., Magdy Y., Tadalafil versus linaclotide in gastrointestinal dysfunction and depressive behavior in constipation-predominant irritable bowel syndrome, Life Sciences, 256, (2020); Shang X.E.F.F., Guo K.L., Li Y.F., Zhao H.L., Wang Y., Chen N., Nian T., Yang C.Q., Yang K.H., Li X.X., Effectiveness and safety of probiotics for patients with constipation-predominant irritable bowel syndrome: A systematic review and meta-analysis of 10 randomized controlled trials, Nutrients, 14, 12, (2022); Slavchev I., Dobrikov G.M., Valcheva V., Ugrinova I., Pasheva E., Dimitrov V., Antimycobacterial activity generated by the amide coupling of (−)-fenchone derived aminoalcohol with cinnamic acids and analogues, Bioorganic & Medicinal Chemistry Letters, 24, 21, pp. 5030-5033, (2014); Tan W., Lee G., Chen J.H., Huizinga J.D., Relationships between distention-, butyrate- and pellet-induced stimulation of peristalsis in the mouse colon, Frontiers in Physiology, 11, (2020); Tang S., Liu W., Zhao Q., Li K., Zhu J., Yao W., Gao X., Combination of polysaccharides from Astragalus membranaceus and Codonopsis pilosula ameliorated mice colitis and underlying mechanisms, Journal of Ethnopharmacology, 264, (2021); Tian H., Cui J., Ye C., Zhao J., Yang B., Xu Y., Ji S., Wang L., Lv X., Ma C., Zhou S., Li N., Wang X., Qin H., Chen Q., Depletion of butyrate-producing microbes of the firmicutes predicts nonresponse to FMT therapy in patients with recurrent Clostridium difficile infection, Gut Microbes, 15, 1, (2023); van Muijlwijk G.H., van Mierlo G., Jansen P., Vermeulen M., Bleumink-Pluym N.M.C., Palm N.W., van Putten J.P.M., de Zoete M.R., Identification of Allobaculum mucolyticum as a novel human intestinal mucin degrader, Gut Microbes, 13, 1, (2021); Vanuytsel T., Bercik P., Boeckxstaens G., Understanding neuroimmune interactions in disorders of gut-brain interaction: From functional to immune-mediated disorders, Gut, 72, 4, pp. 787-798, (2023); Vedantam G., Viswanathan V.K., Unlocking the gates to inflammatory bowel disease: The role of Enterococcus faecalis gelatinase, Gastroenterology, 141, 3, pp. 795-798, (2011); Wang L., Alammar N., Singh R., Nanavati J., Song Y., Chaudhary R., Mullin G.E., Gut microbial dysbiosis in the irritable bowel syndrome: A systematic review and meta-analysis of case-control studies, Journal of the Academy of Nutrition and Dietetics, 120, 4, pp. 565-586, (2020); Wang X., Xiao Y., Xu X., Guo L., Yu Y., Li N., Xu C., Characteristics of fecal microbiota and machine learning strategy for fecal invasive biomarkers in pediatric inflammatory bowel disease, Frontiers in Cellular and Infection Microbiology, 11, (2021); Wen Y., Li J., Long Q., Yue C.C., He B., Tang X.G., The efficacy and safety of probiotics for patients with constipation-predominant irritable bowel syndrome: A systematic review and meta-analysis based on seventeen randomized controlled trials, International Journal of Surgery, 79, pp. 111-119, (2020); Yokoi A., Kamata N., The usefulness of olive oil enema in children with severe chronic constipation, Journal of Pediatric Surgery, 56, 7, pp. 1141-1144, (2021); Zhang D., Lu R., Wang M., Ji J., Zhang S., Wang S., Zhang D., Chen M., Effects of Banxia Xiexin decoction on apoptosis of interstitial cells of Cajal via regulation of MiR-451-5p: An in vivo and in vitro study, Journal of Ethnopharmacology, 314, (2023); Zhao Y., Zou D.W., Gut microbiota and irritable bowel syndrome, Journal of Digestive Diseases, 24, pp. 312-320, (2023); Zhu Y., Yang Y., Guo J., Zhang W., Zhu Z., Xie B., Yu J., Cheng J., Abdominal manual therapy repairs interstitial cells of Cajal and increases colonic c-kit expression when treating bowel dysfunction after spinal cord injury, BioMed Research International, 2017, (2017)","C. Gu; Department of Gastroenterology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China; email: gcsunny@163.com; H. Li; Department of Gastroenterology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China; email: jessica20110215@163.com","","John Wiley and Sons Inc","","","","","","17470277","","CBDDA","38030381","English","Chem. Biol. Drug Des.","Article","Final","","Scopus","2-s2.0-85178242854"

"Holst L.M.; Iribarren C.; Sapnara M.; Savolainen O.; Törnblom H.; Wettergren Y.; Strid H.; Simrén M.; Magnusson M.K.; Öhman L.","Holst, Luiza Moraes (57817488700); Iribarren, Cristina (57200549137); Sapnara, Maria (12809030200); Savolainen, Otto (56011360600); Törnblom, Hans (7801453693); Wettergren, Yvonne (6602286642); Strid, Hans (6601963141); Simrén, Magnus (57202571330); Magnusson, Maria K. (35248805000); Öhman, Lena (14820629200)","57817488700; 57200549137; 12809030200; 56011360600; 7801453693; 6602286642; 6601963141; 57202571330; 35248805000; 14820629200","Fecal Luminal Factors from Patients with Gastrointestinal Diseases Alter Gene Expression Profiles in Caco-2 Cells and Colonoids","2022","International Journal of Molecular Sciences","23","24","15505","","","","4","10.3390/ijms232415505","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85144722564&doi=10.3390%2fijms232415505&partnerID=40&md5=0717802c18ffb1b467fb025747760679","Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, 405 30, Sweden; Chalmers Mass Spectrometry Infrastructure, Department of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, 412 96, Sweden; Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, 70210, Finland; Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, 405 30, Sweden; Department of Surgery, Institute of Clinical Sciences, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, 405 30, Sweden; Department of Internal Medicine, Södra Älvsborgs Hospital, Borås, 501 82, Sweden","Holst L.M., Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, 405 30, Sweden; Iribarren C., Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, 405 30, Sweden; Sapnara M., Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, 405 30, Sweden; Savolainen O., Chalmers Mass Spectrometry Infrastructure, Department of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, 412 96, Sweden, Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, 70210, Finland; Törnblom H., Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, 405 30, Sweden; Wettergren Y., Department of Surgery, Institute of Clinical Sciences, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, 405 30, Sweden; Strid H., Department of Internal Medicine, Södra Älvsborgs Hospital, Borås, 501 82, Sweden; Simrén M., Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, 405 30, Sweden; Magnusson M.K., Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, 405 30, Sweden; Öhman L., Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, 405 30, Sweden","Previous in vitro studies have shown that the intestinal luminal content, including metabolites, possibly regulates epithelial layer responses to harmful stimuli and promotes disease. Therefore, we aimed to test the hypothesis that fecal supernatants from patients with colon cancer (CC), ulcerative colitis (UC) and irritable bowel syndrome (IBS) contain distinct metabolite profiles and establish their effects on Caco-2 cells and human-derived colon organoids (colonoids). The metabolite profiles of fecal supernatants were analyzed by liquid chromatography–mass spectrometry and distinguished patients with CC (n = 6), UC (n = 6), IBS (n = 6) and healthy subjects (n = 6). Caco-2 monolayers and human apical-out colonoids underwent stimulation with fecal supernatants from different patient groups and healthy subjects. Their addition did not impair monolayer integrity, as measured by transepithelial electrical resistance; however, fecal supernatants from different patient groups and healthy subjects altered the gene expression of Caco-2 monolayers, as well as colonoid cultures. In conclusion, the stimulation of Caco-2 cells and colonoids with fecal supernatants derived from CC, UC and IBS patients altered gene expression profiles, potentially reflecting the luminal microenvironment of the fecal sample donor. This experimental approach allows for investigating the crosstalk at the gut barrier and the effects of the gut microenvironment in the pathogenesis of intestinal diseases. © 2022 by the authors.","Caco-2; colon cancer; fecal metabolites; gut barrier; host–microbial crosstalk; irritable bowel syndrome; organoids; ulcerative colitis","adult; Article; Caco-2 cell line; colonoid; controlled study; feces analysis; gastrointestinal disease; gene expression profiling; human; human cell; irritable colon; liquid chromatography-mass spectrometry; microenvironment; monolayer culture; supernatant; transepithelial resistance; ulcerative colitis","","","","","Apotekare Hedbergs foundation; Faculty of Medicine at University of Gothenburg; Magnus Simrén, (ALFGBG-965619); Martina Lundgren’s foundation; Regional Executive Board; Sahlgrenska Academy at University of Gothenburg; Swedish government, (ALFGBG-722331, ALFGBG-723921); Västra Götalandsregionen, (F2021-007, S2020-033, VGFOUREG-931919, VGFOUREG-940815); Adlerbertska Stiftelserna; Medicinska Forskningsrådet, MFR, (2018-02566, 2019-01052)","The study was funded by the Swedish Medical Research Council (grant no. 2019-01052 (L.Ö.) and 2018-02566 (Magnus Simrén)), Apotekare Hedbergs foundation (M.K.M.), Wilhelm and Martina Lundgren’s foundation (M.K.M.), Adlerbertska foundation (M.K.M.), Sahlgrenska Academy at University of Gothenburg (L.Ö.), Faculty of Medicine at University of Gothenburg (Magnus Simrén), grants from the Swedish state under the agreement between the Swedish government and the county councils; the ALF-agreement (ALFGBG-723921 (L.Ö.); ALFGBG-722331 (Magnus Simrén) ALFGBG-965619(M.M.)) and Regional Executive Board, Region Västra Götaland (grant no. VGFOUREG-931919 (L.Ö.) and grant no. VGFOUREG-940815 (M.M.)) and Swedish Fund for Research without Animal Experiments S2020-033, F2021-007 (L.Ö.).","Zhou A., Yuan Y., Yang M., Huang Y., Li X., Li S., Yang S., Tang B., Crosstalk Between the Gut Microbiota and Epithelial Cells Under Physiological and Infectious Conditions, Front. Cell. Infect. Microbiol, 12, (2022); Genua F., Raghunathan V., Jenab M., Gallagher W.M., Hughes D.J., The Role of Gut Barrier Dysfunction and Microbiome Dysbiosis in Colorectal Cancer Development, Front. Oncol, 11, (2021); Zhou Q., Zhang B., Verne N.G., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); McCole D.F., IBD Candidate Genes and Intestinal Barrier Regulation, Inflamm. Bowel Dis, 20, pp. 1829-1849, (2014); Ahmad R., Sorrell M.F., Batra S.K., Dhawan P., Singh A.B., Gut permeability and mucosal inflammation: Bad, good or context dependent, Mucosal Immunol, 10, pp. 307-317, (2017); Barrett J.C., Lee J.C., Lees C.W., Prescott N.J., Anderson C.A., Phillips A., Wesley E., Parnell K., Zhang H., Et al., Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region, Nat. Genet, 41, pp. 1330-1334, (2009); Anderson C.A., Boucher G., Lees C.W., Franke A., D'Amato M., Taylor K.D., Lee J.C., Goyette P., Imielinski M., Latiano A., Et al., Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47, Nat. Genet, 43, pp. 246-252, (2011); Grivennikov S.I., Inflammation and colorectal cancer: Colitis-associated neoplasia, Semin. Immunopathol, 35, pp. 229-244, (2012); Terzic J., Grivennikov S., Karin E., Karin M., Inflammation and colon cancer, Gastroenterology, 138, pp. 2101-2114.e5, (2010); Chen Y., Zhang M., Ren F., A Role of Exopolysaccharide Produced by Streptococcus thermophilus in the Intestinal Inflammation and Mucosal Barrier in Caco-2 Monolayer and Dextran Sulphate Sodium-Induced Experimental Murine Colitis, Molecules, 24, (2019); Sharma M., Chandel D., Shukla G., Antigenotoxicity and Cytotoxic Potentials of Metabiotics Extracted from Isolated Probiotic, Lactobacillus rhamnosus MD 14 on Caco-2 and HT-29 Human Colon Cancer Cells, Nutr. Cancer, 72, pp. 110-119, (2019); Co J.Y., Margalef-Catala M., Li X., Mah A.T., Kuo C.J., Monack D.M., Amieva M.R., Controlling Epithelial Polarity: A Human Enteroid Model for Host-Pathogen Interactions, Cell Rep, 26, pp. 2509-2520.e4, (2019); Sato T., Stange D.E., Ferrante M., Vries R.G.J., Van Es J.H., Van Den Brink S., Van Houdt W.J., Pronk A., Van Gorp J., Siersema P.D., Et al., Long-term Expansion of Epithelial Organoids From Human Colon, Adenoma, Adenocarcinoma, and Barrett’s Epithelium, Gastroenterology, 141, pp. 1762-1772, (2011); Noel G., Baetz N.W., Staab J.F., Donowitz M., Kovbasnjuk O., Pasetti M.F., Zachos N.C., A primary human macrophage-enteroid co-culture model to investigate mucosal gut physiology and host-pathogen interactions, Sci. Rep, 7, (2017); Sato T., Vries R.G., Snippert H.J., Van De Wetering M., Barker N., Stange D.E., Van Es J.H., Abo A., Kujala P., Peters P.J., Et al., Single Lgr5 Stem Cells Build Crypt-Villus Structures in Vitro without a Mesenchymal Niche, Nature, 459, pp. 262-265, (2009); McCracken K.W., Howell J.C., Wells J.M., Spence J.R., Generating human intestinal tissue from pluripotent stem cells in vitro, Nat. Protoc, 6, pp. 1920-1928, (2011); Silva-Almeida C., Ewart M.-A., Wilde C., 3D gastrointestinal models and organoids to study metabolism in human colon cancer, Semin. Cell Dev. Biol, 98, pp. 98-104, (2019); Ojo B.A., VanDussen K.L., Rosen M.J., The Promise of Patient-Derived Colon Organoids to Model Ulcerative Colitis, Inflamm. Bowel Dis, 28, pp. 299-308, (2021); Cristobal A., van den Toorn H.W., van de Wetering M., Clevers H., Heck A.J.R., Mohammed S., Personalized Proteome Profiles of Healthy and Tumor Human Colon Organoids Reveal Both Individual Diversity and Basic Features of Colorectal Cancer, Cell Rep, 18, pp. 263-274, (2017); Kashfi S.M.H., Almozyan S., Jinks N., Koo B.-K., Nateri A.S., Morphological alterations of cultured human colorectal matched tumour and healthy organoids, Oncotarget, 9, pp. 10572-10584, (2018); Iribarren C., Nordlander S., Sundin J., Isaksson S., Savolainen O., Tornblom H., Magnusson M.K., Simren M., Fecal luminal factors from patients with irritable bowel syndrome induce distinct gene expression of colonoids, Neurogastroenterol. Motil, 34, (2022); Pearce S.C., Weber G.J., Doherty L.A., Soares J.W., Human iPSC colon organoid function is improved by exposure to fecal fermentates, FASEB Bioadv, 4, pp. 468-484, (2022); Zhang J., Hernandez-Gordillo V., Trapecar M., Wright C., Taketani M., Schneider K., Chen W.L.K., Stas E., Breault D.T., Carrier R.L., Et al., Coculture of primary human colon monolayer with human gut bacteria, Nat. Protoc, 16, pp. 3874-3900, (2021); Kim K., Castro E.J.T., Shim H., Advincula J.V.G., Kim Y.-W., Differences Regarding the Molecular Features and Gut Microbiota Between Right and Left Colon Cancer, Ann. Coloproctology, 34, pp. 280-285, (2018); Tong M., Li X., Parfrey L.W., Roth B., Ippoliti A., Wei B., Borneman J., McGovern D.P.B., Frank D.N., Li E., Et al., A Modular Organization of the Human Intestinal Mucosal Microbiota and Its Association with Inflammatory Bowel Disease, PLoS ONE, 8, (2013); Frank D.N., St Amand A.L., Feldman R.A., Boedeker E.C., Harpaz N., Pace N.R., Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases, Proc. Natl. Acad. Sci. USA, 104, pp. 13780-13785, (2007); Pittayanon R., Lau J.T., Yuan Y., Leontiadis G.I., Tse F., Surette M., Moayyedi P., Gut Microbiota in Patients With Irritable Bowel Syndrome—A Systematic Review, Gastroenterology, 157, pp. 97-108, (2019); Tap J., Derrien M., Tornblom H., Brazeilles R., Cools-Portier S., Dore J., Storsrud S., Le Neve B., Ohman L., Simren M., Identification of an Intestinal Microbiota Signature Associated With Severity of Irritable Bowel Syndrome, Gastroenterology, 152, pp. 111-123.e8, (2017); Lee J.S., Wang R.X., Alexeev E.E., Colgan S.P., Intestinal Inflammation as a Dysbiosis of Energy Procurement: New Insights into an Old Topic, Gut Microbes, 13, (2021); Dorrestein P.C., Mazmanian S.K., Knight R., Finding the Missing Links among Metabolites, Microbes, and the Host, Immunity, 40, pp. 824-832, (2014); Le Gall G., Guttula K., Kellingray L., Tett A.J., Ten Hoopen R., Kemsley K.E., Savva G.M., Ibrahim A., Narbad A., Metabolite quantification of faecal extracts from colorectal cancer patients and healthy controls, Oncotarget, 9, pp. 33278-33289, (2018); Ahluwalia B., Iribarren C., Magnusson M., Sundin J., Clevers E., Savolainen O., Ross A., Tornblom H., Simren M., A Distinct Faecal Microbiota and Metabolite Profile Linked to Bowel Habits in Patients with Irritable Bowel Syndrome, Cells, 10, (2021); Le Gall G., Noor S.O., Ridgway K., Scovell L., Jamieson C., Johnson I.T., Colquhoun I.J., Kemsley E.K., Narbad A., Metabolomics of fecal extracts detects altered metabolic activity of gut microbiota in ulcerative colitis and irritable bowel syndrome, J. Proteome Res, 10, pp. 4208-4218, (2011); Hilgers A.R., Conradi R.A., Burton P.S., Caco-2 Cell Monolayers as a Model for Drug Transport Across the Intestinal Mucosa, Pharm. Res, 7, pp. 902-910, (1990); Korecka A., Dona A., Lahiri S., Tett A.J., Al-Asmakh M., Braniste V., D'Arienzo R., Abbaspour A., Reichardt N., Fujii-Kuriyama Y., Et al., Bidirectional communication between the Aryl hydrocarbon Receptor (AhR) and the microbiome tunes host metabolism, npj Biofilms Microbiomes, 2, (2016); Chen T., Kim C.Y., Kaur A., Lamothe L., Shaikh M., Keshavarzian A., Hamaker B.R., Dietary fibre-based SCFA mixtures promote both protection and repair of intestinal epithelial barrier function in a Caco-2 cell model, Food Funct, 8, pp. 1166-1173, (2017); Simon-Assmann P., Turck N., Sidhoum-Jenny M., Gradwohl G., Kedinger M., In vitro models of intestinal epithelial cell differentiation, Cell Biol. Toxicol, 23, pp. 241-256, (2006); Sambuy Y., De Angelis I., Ranaldi G., Scarino M.L., Stammati A., Zucco F., The Caco-2 cell line as a model of the intestinal barrier: Influence of cell and culture-related factors on Caco-2 cell functional characteristics, Cell Biol. Toxicol, 21, pp. 1-26, (2005); Tsai P.-Y., Zhang B., He W.-Q., Zha J.-M., Odenwald M.A., Singh G., Tamura A., Shen L., Sailer A., Yeruva S., Et al., IL-22 Upregulates Epithelial Claudin-2 to Drive Diarrhea and Enteric Pathogen Clearance, Cell Host Microbe, 21, pp. 671-681.e4, (2017); Hanning N., Edwinson A.L., Ceuleers H., Peters S.A., De Man J.G., Hassett L.C., De Winter B.Y., Grover M., Intestinal barrier dysfunction in irritable bowel syndrome: A systematic review, Ther. Adv. Gastroenterol, 14, (2021); Nicchitta C.V., Come forth CD1d: Hsp110 in the regulation of intestinal epithelial CD1d expression, J. Clin. Investig, 112, pp. 646-648, (2003); Eftychi C., Schwarzer R., Vlantis K., Wachsmuth L., Basic M., Wagle P., Neurath M.F., Becker C., Bleich A., Pasparakis M., Temporally Distinct Functions of the Cytokines IL-12 and IL-23 Drive Chronic Colon Inflammation in Response to Intestinal Barrier Impairment, Immunity, 51, pp. 367-380.e4, (2019); Greving C.N.A., Towne J.E., A Role for IL-12 in IBD after All?, Immunity, 51, pp. 209-211, (2019); Alotaibi A.G., Li J.V., Gooderham N.J., Tumour necrosis factor-α (TNF-α) enhances dietary carcinogen-induced DNA damage in colorectal cancer epithelial cells through activation of JNK signaling pathway, Toxicology, 457, (2021); Roulis M., Armaka M., Manoloukos M., Apostolaki M., Kollias G., Intestinal epithelial cells as producers but not targets of chronic TNF suffice to cause murine Crohn-like pathology, Proc. Natl. Acad. Sci. USA, 108, pp. 5396-5401, (2011); Xu H.-M., Zhao H.-L., Guo G.-J., Xu J., Zhou Y.-L., Huang H.-L., Nie Y.-Q., Characterization of short-chain fatty acids in patients with ulcerative colitis: A meta-analysis, BMC Gastroenterol, 22, (2022); Gomes S.D., Oliveira C.S., Azevedo-Silva J., Casanova M.R., Barreto J., Pereira H., Chaves S.R., Rodrigues L.R., Casal M., Corte-Real M., Et al., The Role of Diet Related Short-Chain Fatty Acids in Colorectal Cancer Metabolism and Survival: Prevention and Therapeutic Implications, Curr. Med. Chem, 27, pp. 4087-4108, (2020); Sun Q., Jia Q., Song L., Duan L., Alterations in fecal short-chain fatty acids in patients with irritable bowel syndrome: A systematic review and meta-analysis, Medicine, 98, (2019); Song X., Gao H., Lin Y., Yao Y., Zhu S., Wang J., Liu Y., Yao X., Meng G., Shen N., Et al., Alterations in the Microbiota Drive Interleukin-17C Production from Intestinal Epithelial Cells to Promote Tumorigenesis, Immunity, 40, pp. 140-152, (2014); Grivennikov S., Karin E., Terzic J., Mucida D., Yu G., Vallabhapurapu S., Scheller J., Rose-John S., Cheroutre H., Eckmann L., Et al., IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer, Cancer Cell, 15, pp. 103-113, (2009); Guthrie L., Spencer S.P., Perelman D., Van Treuren W., Han S., Yu F.B., Sonnenburg E.D., Fischbach M.A., Meyer T.W., Sonnenburg J.L., Impact of a 7-day homogeneous diet on interpersonal variation in human gut microbiomes and metabolomes, Cell Host Microbe, 30, pp. 863-874.e4, (2022); Ohman L., Lasson A., Strombeck A., Isaksson S., Hesselmar M., Simren M., Strid H., Magnusson M.K., Fecal microbiota dynamics during disease activity and remission in newly diagnosed and established ulcerative colitis, Sci. Rep, 11, pp. 1-8, (2021); Rajilic-Stojanovic M., Heilig H.G.H.J., Tims S., Zoetendal E.G., de Vos W.M., Long-term monitoring of the human intestinal microbiota composition, Environ. Microbiol, 15, pp. 1146-1159, (2012); Mars R.A., Yang Y., Ward T., Houtti M., Priya S., Lekatz H.R., Tang X., Sun Z., Kalari K.R., Korem T., Et al., Longitudinal Multi-omics Reveals Subset-Specific Mechanisms Underlying Irritable Bowel Syndrome, Cell, 183, pp. 1137-1140, (2020); Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); O'Sullivan B., Brierley J., Byrd D., Bosman F., Kehoe S., Kossary C., Pineros M., Van Eycken E., Weir H.K., Gospodarowicz M., The TNM classification of malignant tumours-towards common understanding and reasonable expectations, Lancet Oncol, 18, pp. 849-851, (2017); Sturm A., Maaser C., Calabrese E., Annese V., Fiorino G., Kucharzik T., Vavricka S.R., Verstockt B., Van Rheenen P., Tolan D., Et al., ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects, J. Crohn’s Colitis, 13, pp. 273-284, (2018); Francis C.Y., Morris J., Whorwell P., The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress, Aliment. Pharmacol. Ther, 11, pp. 395-402, (1997); Lewis S.J., Heaton K.W., Stool Form Scale as a Useful Guide to Intestinal Transit Time, Scand. J. Gastroenterol, 32, pp. 920-924, (1997); Zheng R., Brunius C., Shi L., Zafar H., Paulson L., Landberg R., Naluai T., Prediction and evaluation of the effect of pre-centrifugation sample management on the measurable untargeted LC-MS plasma metabolome, Anal. Chim. Acta, 1182, (2021); Stekhoven D.J., Buhlmann P., MissForest-non-parametric missing value imputation for mixed-type data, Bioinformatics, 28, pp. 112-118, (2012); Mosmann T., Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays, J. Immunol. Methods, 65, pp. 55-63, (1983); Tolosa L., Donato M.T., Gomez-Lechon M.J., General Cytotoxicity Assessment by Means of the MTT Assay, Methods Mol. Biol, 1250, pp. 333-348, (2014); Co J.Y., Margalef-Catala M., Monack D.M., Amieva M.R., Controlling the polarity of human gastrointestinal organoids to investigate epithelial biology and infectious diseases, Nat. Protoc, 16, pp. 5171-5192, (2021)","L. Öhman; Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, 405 30, Sweden; email: lena.ohman@microbio.gu.se","","MDPI","","","","","","16616596","","","","English","Int. J. Mol. Sci.","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85144722564"

"Fan X.; Shi J.; Liu Y.; Zhang M.; Lu M.; Qu D.","Fan, Xinyu (57226534707); Shi, Jiachen (58127241100); Liu, Ye (58302577000); Zhang, Mengqiu (58302524500); Lu, Min (56553533900); Qu, Ding (55924162600)","57226534707; 58127241100; 58302577000; 58302524500; 56553533900; 55924162600","Cannabidiol-Decorated Berberine-Loaded Microemulsions Improve IBS-D Therapy Through Ketogenic Diet-Induced Cannabidiol Receptors Overexpression","2023","International Journal of Nanomedicine","18","","","2839","2853","14","2","10.2147/IJN.S402871","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85160973727&doi=10.2147%2fIJN.S402871&partnerID=40&md5=d050cd4bbaa1ab488595f44337d92d88","Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China; Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China; The Second Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, China","Fan X., Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China; Shi J., Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China; Liu Y., The Second Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, China; Zhang M., Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China; Lu M., Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China; Qu D., Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China","Background: Berberine (BR) shows promise as a candidate for treating irritable bowel syndrome with diarrhea (IBS-D). However, the undesired physicochemical properties and poor oral absorption limit its clinical translation. A ketogenic diet (KD) can induce intestinal overexpression of cannabidiol (CB) receptors, which may offer a potential target for IBS-D-specific delivery of BR. Methods: The microemulsions loaded with BR and decorated with cannabidiol (CBD/BR-MEs) were developed through a one-step emulsion method. The pharmaceutical behaviors of the CBD/BR-MEs were measured using dynamic light scattering and high-performance liquid chromatography. The efficacy of the anti-IBS-D therapy was evaluated by assessing fecal water content, Bristol score, and AWR score. The intestinal permeability were assessed through immunofluorescent staining of CB1 and ZO-1, respectively. The signaling of CREB/BDNF/c-Fos was also studied along with immunofluorescent and immunohistochemical examination of brain sections. Results: The CBD/BR-MEs, which had a particle size of approximately 30 nm and a surface density of 2% (wt%) CBD, achieved greater than 80% (wt%) encapsulation efficiency of BR. The pharmacokinetics performance of CBD/BR-MEs was significantly improved in the KD-fed IBS-D rats than the standard diet-fed ones, which is highly related to intestinal expression of CB1 receptors. The treatment with CBD/BR-MEs and KD exhibited evident comprehensive advantages over the other groups in terms of anti-IBS-D efficacy. CBD/BR-MEs and KD synergistically decreased intestinal permeability. Moreover, the treatment with CBD/BR-MEs and KD not only blocked the CREB/BDNF/c-Fos signaling in the brain but also decreased the levels of neurotrophic factors, neurotransmitters, and inflammatory cytokines in the serum of IBS-D model rats. Conclusion: Such a design represents the first attempt at IBS-D-targeted drug delivery for improved oral absorption and efficacy through KD-induced target exposure, which holds promising potential for the treatment of IBS-D. © 2023 Fan et al.","berberine; CB1 receptors; irritable bowel syndrome-diarrhea; ketogenic diet; microemulsion","Animals; Berberine; Brain-Derived Neurotrophic Factor; Cannabidiol; Diarrhea; Diet, Ketogenic; Irritable Bowel Syndrome; Rats; berberine; cannabidiol; cannabinoid 1 receptor; neurotransmitter; neurotrophic factor; berberine; brain derived neurotrophic factor; cannabidiol; animal cell; animal experiment; animal model; Article; diarrhea; drug absorption; drug delivery system; drug distribution; drug efficacy; drug formulation; high performance liquid chromatography; intestine mucosa permeability; irritable colon; male; microemulsion; nanoencapsulation; nonhuman; particle size; photon correlation spectroscopy; rat; water content; animal; diarrhea; ketogenic diet; metabolism","","berberine, 2086-83-1, 633-65-8; cannabidiol, 13956-29-1; brain derived neurotrophic factor, 218441-99-7; Berberine, ; Brain-Derived Neurotrophic Factor, ; Cannabidiol, ","","","Jiangsu Provincial Cadre Health Research Project, (BJ20026); National Natural Science Foundation of China, NSFC, (81873017, 82173980); Natural Science Foundation of Jiangsu Province, (BK20211389); Six Talent Peaks Project in Jiangsu Province, (WSN-040, YY-028-2019); Graduate Research and Innovation Projects of Jiangsu Province, (SJCX22-0841)","Funding text 1: This work was also supported by Graduate Research and Practice Innovation Project of Jiangsu Province (SJCX22-0841).; Funding text 2: This work was supported by National Natural Science Foundation of China (82173980 and 81873017), Natural Science Foundation of Jiangsu Province of China (BK20211389), the Six Talent Peak Project of Jiangsu Province (WSN-040; YY-028-2019), and the Jiangsu Provincial Cadre Health Research Project (BJ20026).","Chey WD, Kurlander J, Eswaran S., Irritable bowel syndrome: a clinical review, JAMA, 313, 9, pp. 949-958, (2015); Enck P, Aziz Q, Barbara G, Et al., Irritable bowel syndrome, Nat Rev Dis Primers, 2, (2016); Singh P, Staller K, Barshop K, Et al., Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation, World j Gastroenterol, 21, 26, pp. 8103-8109, (2015); Gracie DJ, Hamlin PJ, Ford AC., The influence of the brain-gut axis in inflammatory bowel disease and possible implications for treatment, lancet Gastroenterol Hepatol, 4, 8, pp. 632-642, (2019); Shi C, Dawulieti J, Shi F, Et al., A nanoparticulate dual scavenger for targeted therapy of inflammatory bowel disease, Sci Adv, 8, 4, (2022); Barbaro MR, Cremon C., Non-Celiac Gluten Sensitivity in the Context of Functional Gastrointestinal Disorders, Nutrients, 12, 12, (2020); Martin CR, Osadchiy V, Kalani A, Mayer EA., The Brain-Gut-Microbiome Axis, Cell Mol Gastroenterol Hepatol, 6, 2, pp. 133-148, (2018); Pinto-Sanchez MI, Hall GB, Ghajar K, Et al., Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: a Pilot Study in Patients With Irritable Bowel Syndrome, Gastroenterology, 153, 2, pp. 448-459, (2017); Xu J, Xu J, Shi T, Et al., Restores Intestinal Homeostasis in Colitis by Regulating Redox Balance, Immune Responses, and the Gut Microbiome, Adv Mater, 35, 3, (2023); Zhang W, Xu JH, Yu T, Chen QK., Effects of berberine and metformin on intestinal inflammation and gut microbiome composition in db/db mice, Biomed Pharmacother, 118, (2019); Lu Y, Huang J, Zhang Y, Et al., Therapeutic Effects of Berberine Hydrochloride on Stress-Induced Diarrhea-Predominant Irritable Bowel Syndrome Rats by Inhibiting Neurotransmission in Colonic Smooth Muscle, Front Pharmacol, 12, (2021); Wang Y, Tong Q, Ma SR, Et al., Oral berberine improves brain dopa/dopamine levels to ameliorate Parkinson’s disease by regulating gut microbiota, Signal Transduction and Targeted Therapy, 6, 1, (2021); Qu D, Wang L, Qin Y, Et al., Non-triggered sequential-release liposomes enhance anti-breast cancer efficacy of STS and celastrol-based microemulsion, Biomaterials sci, 6, 12, pp. 3284-3299, (2018); Su X, Gao C, Shi F, Et al., A microemulsion co-loaded with Schizandrin A-docetaxel enhances esophageal carcinoma treatment through overcoming multidrug resistance, Drug Deliv, 24, 1, pp. 10-19, (2017); Gui SY, Wu L, Peng DY, Liu QY, Yin BP, Shen JZ., Preparation and evaluation of a microemulsion for oral delivery of berberine, Die Pharmazie, 63, 7, pp. 516-519, (2008); Ang QY, Alexander M, Newman JC, Et al., Ketogenic Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells, Cell, 181, 6, pp. 1263-1275, (2020); Gigante I, Tutino V, Russo F., Cannabinoid Receptors Overexpression in a Rat Model of Irritable Bowel Syndrome (IBS) after Treatment with a Ketogenic Diet, International Journal of Molecular Sciences, 22, 6, (2021); Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM., Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor, Br J Pharmacol, 172, 20, pp. 4790-4805, (2015); Pertwee RG., The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin, Br J Pharmacol, 153, 2, pp. 199-215, (2008); Fathalipour S, Ataei B, Janati F., Aqueous suspension of biocompatible reduced graphene oxide-Au NPs composite as an effective recyclable catalyst in a Betti reaction, Mater Sci Eng C Mater Biol Appl, 97, pp. 356-366, (2019); Zhong L, Xu L, Liu Y, Et al., Transformative hyaluronic acid-based active targeting supramolecular nanoplatform improves long circulation and enhances cellular uptake in cancer therapy, Acta pharmaceutica Sinica B, 9, 2, pp. 397-409, (2019); Zuo Z, Li M, Han T, Et al., A platelet-cloaking tetramethylprazine-loaded microemulsion for improved therapy of myocardial ischaemia/reperfusion injury, J Drug Target, 30, 6, pp. 646-656, (2022); Chen Y, Wang S, Hu Q, Zhou L., Self-Emulsifying System Coloaded with Paclitaxel and Coix Seed Oil Deeply Penetrated to Enhance Efficacy of Cervical Cancer, Curr Drug Deliv, 2, (2022); Maulvi FA, Desai AR, Choksi HH, Et al., Effect of surfactant chain length on drug release kinetics from microemulsion-laden contact lenses, Int J Pharm, 524, 1–2, pp. 193-204, (2017); Bao CH, Wang CY, Li GN, Et al., Effect of mild moxibustion on intestinal microbiota and NLRP6 inflammasome signaling in rats with post-inflammatory irritable bowel syndrome, World j Gastroenterol, 25, 32, pp. 4696-4714, (2019); Al-Chaer ED, Kawasaki M, Pasricha PJ., A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development, Gastroenterology, 119, 5, pp. 1276-1285, (2000); Zhou Q, Verne ML, Fields JZ, Et al., Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome, Gut, 68, 6, pp. 996-1002, (2019); Pleguezuelos-Manzano C, Puschhof J, van den Brink S, Geurts V, Beumer J, Clevers H., Establishment and Culture of Human Intestinal Organoids Derived from Adult Stem Cells, Curr Protocols Immunol, 130, 1, (2020); Mohammadi S, Morell-Perez C, Wright CW, Et al., Assessing donor-to-donor variability in human intestinal organoid cultures, Stem Cell Reports, 16, 9, pp. 2364-2378, (2021); Lin J, Huang L, Xiang R, Et al., Blood compatibility evaluations of CaCO<sub>3</sub> particles, Biomed Mater, 16, 5, (2021); Mohamed AS, Fahmy SR, Soliman AM, Gaafar KM., Effects of 3 Rodent Beddings on Biochemical Measures in Rats and Mice, J Am Assoc Lab Anim Sci, 57, 5, pp. 443-446, (2018); Chen Y, Qu D, Fu R, Et al., A Tf-modified tripterine-loaded coix seed oil microemulsion enhances anti-cervical cancer treatment, Int J Nanomedicine, 13, pp. 7275-7287, (2018); Cheng MB, Wang JC, Li YH, Et al., Characterization of water-in-oil microemulsion for oral delivery of earthworm fibrinolytic enzyme, J Controlled Release, 129, 1, pp. 41-48, (2008); Raskov H, Burcharth J, Pommergaard HC, Rosenberg J., Irritable bowel syndrome, the microbiota and the gut-brain axis, Gut Microbes, 7, 5, pp. 365-383, (2016); Ford AC, Sperber AD, Corsetti M, Camilleri M., Irritable bowel syndrome, Lancet, 396, 10263, pp. 1675-1688, (2020); Li H, Wang T, Shi C, Et al., Inhibition of GALR1 in PFC Alleviates Depressive-Like Behaviors in Postpartum Depression Rat Model by Upregulating CREB-BNDF and 5-HT Levels, Front Psychiatry, 9, (2018); Rosa K, Delgado-Herrera L, Zeiher B, Et al., Psychometric assessment of the IBS-D Daily Symptom Diary and Symptom Event Log, Quality Res, 25, 12, pp. 3197-3208, (2016)","M. Lu; Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 100 Shizi Street, Hongshan Road, 210028, China; email: lmxlsr6666@163.com; D. Qu; Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 100 Shizi Street, Hongshan Road, 210028, China; email: quding1985@hotmail.com","","Dove Medical Press Ltd","","","","","","11769114","","","37273286","English","Int. J. Nanomed.","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85160973727"

"Liu S.; Huang Q.; Huang Q.; Wang Y.; Li S.; Wang J.; Wu Q.","Liu, Shuqing (57328859000); Huang, Qin (57580354000); Huang, Qianhui (58242170800); Wang, Yuemei (57329632400); Li, Sihui (57205653161); Wang, Junmeng (57211091292); Wu, Qiaofeng (15761512600)","57328859000; 57580354000; 58242170800; 57329632400; 57205653161; 57211091292; 15761512600","The protective effects of electroacupuncture on intestinal barrier lesions in IBS and UC model","2023","Scientific Reports","13","1","7276","","","","1","10.1038/s41598-023-34182-z","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85158901031&doi=10.1038%2fs41598-023-34182-z&partnerID=40&md5=7f9fdf235e33b724aa7a44259bb412c4","Acupuncture and Moxibustion School, Chengdu University of Traditional Chinese Medicine, Sichuan, Chengdu, 610075, China","Liu S., Acupuncture and Moxibustion School, Chengdu University of Traditional Chinese Medicine, Sichuan, Chengdu, 610075, China; Huang Q., Acupuncture and Moxibustion School, Chengdu University of Traditional Chinese Medicine, Sichuan, Chengdu, 610075, China; Huang Q., Acupuncture and Moxibustion School, Chengdu University of Traditional Chinese Medicine, Sichuan, Chengdu, 610075, China; Wang Y., Acupuncture and Moxibustion School, Chengdu University of Traditional Chinese Medicine, Sichuan, Chengdu, 610075, China; Li S., Acupuncture and Moxibustion School, Chengdu University of Traditional Chinese Medicine, Sichuan, Chengdu, 610075, China; Wang J., Acupuncture and Moxibustion School, Chengdu University of Traditional Chinese Medicine, Sichuan, Chengdu, 610075, China; Wu Q., Acupuncture and Moxibustion School, Chengdu University of Traditional Chinese Medicine, Sichuan, Chengdu, 610075, China","Irritable bowel syndrome (IBS) and ulcerative colitis (UC) are two intestinal diseases with different pathological changes. Electroacupuncture (EA) at Zusanli (ST36) on both IBS and UC is widely used in clinic practice. But it is unclear whether acupuncture at one acupoint can treat two different intestinal diseases at different layers of intestinal barrier. To address this question, we explored three intestinal barrier lesions in IBS and UC mice with the aid of transcriptome data analysis and studied the efficacy of EA at ST36 on them. The transcriptome data analysis showed that both UC and IBS had disrupted intestinal barrier in various layers. And both UC and IBS had epithelial barrier lesions with reduction of ZO-1, Occludin and Claudin-1, while UC rather than IBS had the destruction of the mucus barrier with less MUC2 expression. As to the vascular barrier, UC showed a higher CD31 level and mesenteric blood flow reduction, while IBS showed a lower PV-1 level. EA at ST36 can significantly improve the above lesions of intestinal barrier of IBS and UC. Our results gave more details about the comprehensive protective effect of EA for UC and IBS. We guess the effect of acupuncture may be a kind of homeostasis regulation. © 2023, The Author(s).","","Acupuncture Points; Animals; Colitis, Ulcerative; Electroacupuncture; Intestines; Irritable Bowel Syndrome; Mice; acupuncture point; animal; electroacupuncture; intestine; irritable colon; mouse; pathology; procedures; ulcerative colitis","","","","","Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Medicine; National Natural Science Foundation of China, NSFC, (81873383, 82174511, 82174512); Department of Science and Technology of Sichuan Province, SPDST, (2021ZYD0081, 2022ZDZX0033); National Key Research and Development Program of China, NKRDPC, (2019YFC1709001, 2022YFC3500703, ZYYCXTD-D-202003)","Funding text 1: This work was supported by the National Natural Science Foundation of China (No. 82174512, 82174511 and 81873383), the National Key R&D Program of China (No. 2022YFC3500703 and 2019YFC1709001), Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine. (No: ZYYCXTD-D-202003), and Fund of Science and Technology Department of Sichuan Province, China (No.2021ZYD0081 and 2022ZDZX0033). We would like to thank Jiayi Sun at Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Medicine, for the assistance with confocal laser scanning microscopy. ; Funding text 2: This work was supported by the National Natural Science Foundation of China (No. 82174512, 82174511 and 81873383), the National Key R&D Program of China (No. 2022YFC3500703 and 2019YFC1709001), Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine. (No: ZYYCXTD-D-202003), and Fund of Science and Technology Department of Sichuan Province, China (No.2021ZYD0081 and 2022ZDZX0033). We would like to thank Jiayi Sun at Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Medicine, for the assistance with confocal laser scanning microscopy.","Ford A.C., Sperber A.D., Corsetti M., Camilleri M., Irritable bowel syndrome, Lancet, 396, pp. 1675-1688, (2020); Kobayashi T., Et al., Ulcerative colitis, Nat. Rev. Dis. Primers, 6, (2020); Gecse K., Et al., Leaky gut in patients with diarrhea-predominant irritable bowel syndrome and inactive ulcerative colitis, Digestion, 85, pp. 40-46, (2012); Merga Y., Campbell B.J., Rhodes J.M., Mucosal barrier, bacteria and inflammatory bowel disease: Possibilities for therapy, Dig. Dis., 32, pp. 475-483, (2014); Brescia P., Rescigno M., The gut vascular barrier: A new player in the gut-liver-brain axis, Trends Mol. Med., 27, pp. 844-855, (2021); Schneider A., Et al., Acupuncture treatment in irritable bowel syndrome, Gut, 55, pp. 649-654, (2006); Lux G., Et al., Acupuncture inhibits vagal gastric acid secretion stimulated by sham feeding in healthy subjects, Gut, 35, pp. 1026-1029, (1994); Li Y., Et al., Use acupuncture to treat functional constipation: Study protocol for a randomized controlled trial, Trials, 13, (2012); Gao X., Yuan J., Li H., Ren S., Clinical research on acupuncture and moxibustion treatment of chronic atrophic gastritis, J. Tradit. Chin. Med., 27, pp. 87-91, (2007); Joos S., Et al., Acupuncture and moxibustion in the treatment of ulcerative colitis: A randomized controlled study, Scand. J. Gastroenterol., 41, pp. 1056-1063, (2006); Zhu Y., Et al., CD39/CD73/A2a adenosine metabolic pathway: Targets for moxibustion in treating dss-induced ulcerative colitis, Am. J. Chin. Med., 49, pp. 661-676, (2021); Ji J., Et al., Review of clinical studies of the treatment of ulcerative colitis using acupuncture and moxibustion, Gastroenterol. Res. Pract., 2016, (2016); Jiang X., Guo X., Zhou J., Ye S., Acupuncture and moxibustion in the treatment of adult diarrhea irritable bowel syndrome: A network meta-analysis, Comput. Math. Methods Med., 2022, (2022); Hou Y., Et al., Maintenance of intestinal homeostasis in diarrhea-predominant irritable bowel syndrome by electroacupuncture through submucosal enteric glial cell-derived S-nitrosoglutathione, Front. Physiol., 13, (2022); Chen Y., Et al., Electroacupuncture regulates disorders of gut-brain interaction by decreasing corticotropin-releasing factor in a rat model of IBS, Gastroenterol. Res. Pract., 2019, (2019); Song Y., Et al., Electroacupuncture relieves irritable bowel syndrome by increasing expression of nucleotide-binding oligomerization domain protein-like receptor family pyrin domain containing 6 in water-avoidance stress mice, J. Tradit. Chin. Med., 40, pp. 407-413, (2020); Wu H.G., Et al., Experimental study on influence of acupuncture and moxibustion therapy on apoptosis of colonic epithelial cells in rats of ulcerative colitis, Zhongguo Zhen Jiu, 25, pp. 119-122, (2005); Bootz-Maoz H., Et al., Diet-induced modifications to human microbiome reshape colonic homeostasis in irritable bowel syndrome, Cell Rep., 41, (2022); Fang K., Et al., Temporal genomewide expression profiling of DSS colitis reveals novel inflammatory and angiogenesis genes similar to ulcerative colitis, Physiol. Genomics, 43, pp. 43-56, (2011); Pelaseyed T., Et al., The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system, Immunol. Rev., 260, pp. 8-20, (2014); Wibowo A.A., Pardjianto B., Sumitro S.B., Kania N., Handono K., Decreased expression of MUC2 due to a decrease in the expression of lectins and apoptotic defects in colitis patients, Biochem. Biophys. Rep., 19, (2019); Wenzel U.A., Et al., Spontaneous colitis in Muc2-deficient mice reflects clinical and cellular features of active ulcerative colitis, PLoS One, 9, (2014); Da Silva S., Et al., Stress disrupts intestinal mucus barrier in rats via mucin O-glycosylation shift: prevention by a probiotic treatment, Am. J. Physiol. Gastrointest. Liver Physiol., 307, pp. G420-G429, (2014); Furuse M., Molecular basis of the core structure of tight junctions, Cold Spring Harb. Perspect. Biol., 2, (2010); Hou Q., Et al., Berberine improves intestinal epithelial tight junctions by upregulating A20 expression in IBS-D mice, Biomed. Pharmacother., 118, (2019); Wang J., Zhang C., Guo C., Li X., Chitosan ameliorates DSS-induced ulcerative colitis mice by enhancing intestinal barrier function and improving microflora, Int. J. Mol. Sci., (2019); Su L., Et al., Targeted epithelial tight junction dysfunction causes immune activation and contributes to development of experimental colitis, Gastroenterology, 136, pp. 551-563, (2009); Zeissig S., Et al., Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease, Gut, 56, pp. 61-72, (2007); Garcia-Carbonell R., Et al., Elevated A20 promotes TNF-induced and RIPK1-dependent intestinal epithelial cell death, Proc. Natl. Acad. Sci. U. S. A., 115, pp. E9192-e9200, (2018); Spadoni I., Et al., A gut-vascular barrier controls the systemic dissemination of bacteria, Science, 350, pp. 830-834, (2015); Bertocchi A., Et al., Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver, Cancer Cell, 39, pp. 708-724.e711, (2021); Shue E.H., Et al., Plasmalemmal vesicle associated protein-1 (PV-1) is a marker of blood-brain barrier disruption in rodent models, BMC Neurosci., 9, (2008); Sajib S., Zahra F.T., Lionakis M.S., German N.A., Mikelis C.M., Mechanisms of angiogenesis in microbe-regulated inflammatory and neoplastic conditions, Angiogenesis, 21, pp. 1-14, (2018); Tian Y., Zheng Y., Teng G., Li J., Wang H., Imbalanced mucosal microcirculation in the remission stage of ulcerative colitis using probe-based confocal laser endomicroscopy, BMC Gastroenterol., 19, (2019); Jonefjall B., Ohman L., Simren M., Strid H., IBS-like symptoms in patients with ulcerative colitis in deep remission are associated with increased levels of serum cytokines and poor psychological well-being, Inflamm. Bowel Dis., 22, pp. 2630-2640, (2016); Yang J., Et al., The role of toll-like receptor 4 and mast cell in the ameliorating effect of electroacupuncture on visceral hypersensitivity in rats, Neurogastroenterol Motil, 31, (2019); Sun J., Et al., Regulating the balance of Th17/Treg via electroacupuncture and moxibustion: An ulcerative colitis mice model based study, Evid. Based Complement. Altern. Med., 2017, (2017); Liu S., Et al., Somatotopic organization and intensity dependence in driving distinct NPY-expressing sympathetic pathways by electroacupuncture, Neuron, 108, pp. 436-450.e437, (2020); Oh J.E., Kim S.N., Anti-inflammatory effects of acupuncture at ST36 point: A literature review in animal studies, Front. Immunol., 12, (2021); Xia L., Et al., The synergistic effect of electroacupuncture and bone mesenchymal stem cell transplantation on repairing thin endometrial injury in rats, Stem. Cell Res. Ther., 10, (2019); Liu S., Et al., A neuroanatomical basis for electroacupuncture to drive the vagal-adrenal axis, Nature, 598, pp. 641-645, (2021); Lu M.J., Yu Z., He Y., Yin Y., Xu B., Electroacupuncture at ST36 modulates gastric motility via vagovagal and sympathetic reflexes in rats, World J. Gastroenterol., 25, pp. 2315-2326, (2019); Percie du Sert N., Et al., Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 2.0, PLoS Biol, 18, (2020); Zhang N., Et al., Electroacupuncture and moxibustion regulate hippocampus glia and mitochondria activation in DSS-induced colitis mice, Evid. Based Complement. Altern. Med., 2020, (2020)","Q. Wu; Acupuncture and Moxibustion School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 610075, China; email: wuqiaofeng@cdutcm.edu.cn","","Nature Research","","","","","","20452322","","","37142764","English","Sci. Rep.","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85158901031"

"Zhao Y.; Zhan J.; Sun C.; Zhu S.; Zhai Y.; Dai Y.; Wang X.; Gao X.","Zhao, Yucui (57929201600); Zhan, Jiaguo (58284590300); Sun, Congying (57929138600); Zhu, Shixiao (58857940200); Zhai, Yue (58857745400); Dai, Yongna (57217080459); Wang, Xiaoying (56013824000); Gao, Xiumei (7403872165)","57929201600; 58284590300; 57929138600; 58857940200; 58857745400; 57217080459; 56013824000; 7403872165","Sishen Wan enhances intestinal barrier function via regulating endoplasmic reticulum stress to improve mice with diarrheal irritable bowel syndrome","2024","Phytomedicine","129","","155541","","","","0","10.1016/j.phymed.2024.155541","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85189512466&doi=10.1016%2fj.phymed.2024.155541&partnerID=40&md5=7be350af59dbc075b906cb01496b87da","Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, China; School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, China; State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China; School of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China","Zhao Y., Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, China, School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, China, State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China; Zhan J., Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, China, School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, China, State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China; Sun C., Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, China, School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, China, State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China; Zhu S., Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, China, School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, China, State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China; Zhai Y., Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, China, School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, China, State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China; Dai Y., Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, China, School of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China; Wang X., Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, China, School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, China, State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China; Gao X., Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, China","Background: Diarrheal irritable bowel syndrome (IBS-D), characterized primarily by the presence of diarrhea and abdominal pain, is a clinical manifestation resulting from a multitude of causative factors. Furthermore, Sishen Wan (SSW) has demonstrated efficacy in treating IBS-D. Nevertheless, its mechanism of action remains unclear. Methods: A model of IBS-D was induced by a diet containing 45 % lactose and chronic unpredictable mild stress. Additionally, the impact of SSW was assessed by measuring body weight, visceral sensitivity, defecation parameters, intestinal transport velocity, intestinal neurotransmitter levels, immunohistochemistry, and transmission electron microscopy analysis. Immunofluorescent staining was used to detect the expression of Mucin 2 (MUC2) and Occludin in the colon. Western blotting was used to detect changes in proteins related to tight junction (TJ), autophagy, and endoplasmic reticulum (ER) stress in the colon. Finally, 16S rRNA amplicon sequencing was used to monitor the alteration of gut microbiota after SSW treatment. Results: Our study revealed that SSW administration resulted in reduced visceral sensitivity, improved defecation parameters, decreased intestinal transport velocity, and reduced intestinal permeability in IBS-D mice. Furthermore, SSW promotes the secretion of colonic mucus by enhancing autophagy and inhibiting ER stress. SSW treatment caused remodeling of the gut microbiome by increasing the abundance of Blautia, Muribaculum and Ruminococcus torques group. Conclusion: SSW can improve intestinal barrier function by promoting autophagy and inhibiting ER stress, thus exerting a therapeutic effect on IBS-D. © 2024 Elsevier GmbH","Colonic mucus; Diarrheal irritable bowel syndrome; Endoplasmic reticulum stress; Sishen Wan","Animals; Autophagy; Colon; Diarrhea; Disease Models, Animal; Drugs, Chinese Herbal; Endoplasmic Reticulum Stress; Gastrointestinal Microbiome; Intestinal Barrier Function; Intestinal Mucosa; Irritable Bowel Syndrome; Male; Mice; Mice, Inbred C57BL; Mucin-2; Occludin; Permeability; Tight Junctions; beclin 1; Chinese medicinal formula; claudin 2; digestive tract agent; Evodia fruit; lactose; microtubule associated protein; microtubule associated protein 1A 1B light chain; mucin 2; neurotransmitter; occludin; RNA 16S; Schisandra chinensis extract; sequestosome 1; sishen wan; unclassified drug; herbaceous agent; mucin 2; occludin; abdominal pain; abdominal wall musculature; Akkermansia; amplicon; animal experiment; animal model; animal tissue; Article; autophagy (cellular); Bacteroides; Bifidobacterium; Blautia; body weight; chronic unpredictable stress; colon tissue; controlled study; Cullen corylifolium; defecation; diarrhea; drug efficacy; drug mechanism; drug synthesis; endoplasmic reticulum stress; enzyme linked immunosorbent assay; feces microflora; immunofluorescence assay; immunohistochemistry; intestinal barrier function; intestine absorption; intestine brush border; intestine flora; intestine motility; intestine mucosa permeability; intestine transit time; irritable colon; Lactobacillus; male; metabolic disorder; microbial community; mouse; mucus secretion; Muribaculum; muscle contraction; neutrophil chemotaxis; nonhuman; nutmeg; protein expression; Ruminococcus; Shannon index; tight junction; transmission electron microscopy; viscera; Western blotting; animal; C57BL mouse; colon; disease model; drug effect; drug therapy; intestinal barrier function; intestine flora; intestine mucosa; metabolism; permeability","","lactose, 10039-26-6, 16984-38-6, 63-42-3, 64044-51-5; occludin, 176304-61-3; Drugs, Chinese Herbal, ; Mucin-2, ; Occludin, ","","","National Natural Science Foundation of China, NSFC, (82192914); National Natural Science Foundation of China, NSFC","This work was supported by the National Natural Science Foundation of China under Grant No. 82192914 . ","Alvarado D.M., Chen B., Iticovici M., Thaker A.I., Dai N., VanDussen K.L., Shaikh N., Lim C.K., Guillemin G.J., Tarr P.I., Ciorba M.A., Epithelial indoleamine 2,3-dioxygenase 1 modulates aryl hydrocarbon receptor and notch signaling to increase differentiation of secretory cells and alter mucus-associated microbiota, Gastroenterology, 157, pp. 1093-1108.e1011, (2019); Annahazi A., Roka R., Rosztoczy A., Wittmann T., Role of antispasmodics in the treatment of irritable bowel syndrome, World J. Gastroenterol., 20, pp. 6031-6043, (2014); Camilleri M., Magnus Y., Carlson P., Wang X.J., Chedid V., Maselli D., Taylor A., McKinzie S., Kengunte Nagaraj N., Busciglio I., Nair A., Differential mRNA expression in ileal and colonic biopsies in irritable bowel syndrome with diarrhea or constipation, Am. J. Physiol. Gastrointest. Liver. Physiol., 323, pp. G88-g101, (2022); Canavan C., West J., Card T., Review article: the economic impact of the irritable bowel syndrome, Aliment. Pharmacol. Ther., 40, pp. 1023-1034, (2014); Cantero-Recasens G., Burballa C., Ohkawa Y., Fukuda T., Harada Y., Curwin A.J., Brouwers N., Thun G.A., Gu J., Gut I., Taniguchi N., Malhotra V., The ulcerative colitis-associated gene FUT8 regulates the quantity and quality of secreted mucins, Proc. Natl. Acad. Sci. U S A, 119, (2022); Chen Q., Zhang H., Sun C.Y., He Q.Y., Zhang R.R., Luo B.F., Zhou Z.H., Chen X.F., Evaluation of two laboratory model methods for diarrheal irritable bowel syndrome, Mol. Med., 29, (2023); Cheng S., Ma X., Geng S., Jiang X., Li Y., Hu L., Li J., Wang Y., Han X., Fecal microbiota transplantation beneficially regulates intestinal mucosal autophagy and alleviates gut barrier injury, mSystems, 3, (2018); Chi L., Khan I., Lin Z., Zhang J., Lee M.Y.S., Leong W., Hsiao W.L.W., Zheng Y., Fructo-oligosaccharides from Morinda officinalis remodeled gut microbiota and alleviated depression features in a stress rat model, Phytomedicine, 67, (2020); Donohoe D.R., Garge N., Zhang X., Sun W., O'Connell T.M., Bunger M.K., Bultman S.J., The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon, Cell Metab., 13, pp. 517-526, (2011); Flacco M.E., Manzoli L., De Giorgio R., Gasbarrini A., Cicchetti A., Bravi F., Altini M., Caio G.P., Ursini F., Costs of irritable bowel syndrome in European countries with universal healthcare coverage: a meta-analysis, Eur. Rev. Med. Pharmacol. Sci., 23, pp. 2986-3000, (2019); Ford A.C., Sperber A.D., Corsetti M., Camilleri M., Irritable bowel syndrome, Lancet, 396, pp. 1675-1688, (2020); Gao J., Xiong T., Grabauskas G., Owyang C., Mucosal serotonin reuptake transporter expression in irritable bowel syndrome is modulated by gut microbiota via mast cell-prostaglandin E2, Gastroenterology, 162, pp. 1962-1974.e1966, (2022); Gecse K., Roka R., Ferrier L., Leveque M., Eutamene H., Cartier C., Ait-Belgnaoui A., Rosztoczy A., Izbeki F., Fioramonti J., Wittmann T., Bueno L., Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity, Gut, 57, pp. 591-599, (2008); Goodoory V.C., Ng C.E., Black C.J., Ford A.C., Direct healthcare costs of Rome IV or Rome III-defined irritable bowel syndrome in the United Kingdom, Aliment. Pharmacol. Ther., 56, pp. 110-120, (2022); Halmos E.P., Power V.A., Shepherd S.J., Gibson P.R., Muir J.G., A diet low in FODMAPs reduces symptoms of irritable bowel syndrome, Gastroenterology, 146, pp. 67-75.e65, (2014); Hanning N., Edwinson A.L., Ceuleers H., Peters S.A., De Man J.G., Hassett L.C., De Winter B.Y., Grover M., Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review, Therap. Adv. Gastroenterol., 14, (2021); Hu W.D., Hong L.L., Wang W., Wang H.D., Jiang M.T., Li X.H., Xu X.Y., Hu Y., Wang S.Y., Wang Y., Zou Y.D., Wang X.Y., Gao X.M., Yang W.Z., Unveiling the chemical components variation of Sishen formula induced by different prescription ratios by the advanced liquid chromatography/mass spectrometry approaches, Arab. J. Chem., 17, (2024); Imhann F., Vich Vila A., Bonder M.J., Fu J., Gevers D., Visschedijk M.C., Spekhorst L.M., Alberts R., Franke L., van Dullemen H.M., Ter Steege R.W.F., Huttenhower C., Dijkstra G., Xavier R.J., Festen E.A.M., Wijmenga C., Zhernakova A., Weersma R.K., Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease, Gut, 67, pp. 108-119, (2018); Jacobs J.P., Lagishetty V., Hauer M.C., Labus J.S., Dong T.S., Toma R., Vuyisich M., Naliboff B.D., Lackner J.M., Gupta A., Tillisch K., Mayer E.A., Multi-omics profiles of the intestinal microbiome in irritable bowel syndrome and its bowel habit subtypes, Microbiome, 11, (2023); Jin X., Hu Y., Lin T., Gao F., Xu Z., Hou X., Yin Y., Kan S., Zhu H., Chen D., Selenium-enriched Bifidobacterium longum DD98 relieves irritable bowel syndrome induced by chronic unpredictable mild stress in mice, Food Funct., 14, pp. 5355-5374, (2023); Kamphuis J.B.J., Guiard B., Leveque M., Olier M., Jouanin I., Yvon S., Tondereau V., Riviere P., Gueraud F., Chevolleau S., Noguer-Meireles M.H., Martin J.F., Debrauwer L., Eutamene H., Theodorou V., Lactose and fructo-oligosaccharides increase visceral sensitivity in mice via glycation processes, increasing mast cell density in colonic mucosa, Gastroenterology, 158, pp. 652-663.e656, (2020); Kaser A., Lee A.H., Franke A., Glickman J.N., Zeissig S., Tilg H., Nieuwenhuis E.E., Higgins D.E., Schreiber S., Glimcher L.H., Blumberg R.S., XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease, Cell, 134, pp. 743-756, (2008); Ke X., You K., Pichaud M., Haiser H.J., Graham D.B., Vlamakis H., Porter J.A., Xavier R.J., Gut bacterial metabolites modulate endoplasmic reticulum stress, Genome Biol., 22, (2021); Kennelly J.P., Carlin S., Ju T., van der Veen J.N., Nelson R.C., Buteau J., Thiesen A., Richard C., Willing B.P., Jacobs R.L., Intestinal phospholipid disequilibrium initiates an ER stress response that drives goblet cell necroptosis and spontaneous colitis in mice, Cell Mol. Gastroenterol. Hepatol., 11, pp. 999-1021, (2021); Larabi A., Barnich N., Nguyen H.T.T., New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD, Autophagy, 16, pp. 38-51, (2020); Lembo A., Sultan S., Chang L., Heidelbaugh J.J., Smalley W., Verne G.N., AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with diarrhea, Gastroenterology, 163, pp. 137-151, (2022); Linsalata M., Riezzo G., Orlando A., D'Attoma B., Prospero L., Tutino V., Notarnicola M., Russo F., The relationship between low serum vitamin D levels and altered intestinal barrier function in patients with ibs diarrhoea undergoing a long-term low-FODMAP diet: novel observations from a clinical trial, Nutrients, 13, (2021); Liu L., Saitz-Rojas W., Smith R., Gonyar L., In J.G., Kovbasnjuk O., Zachos N.C., Donowitz M., Nataro J.P., Ruiz-Perez F., Mucus layer modeling of human colonoids during infection with enteroaggragative E. coli, Sci. Rep., 10, (2020); Liu S., Zhao S., Cheng Z., Ren Y., Shi X., Mu J., Ge X., Dai Y., Li L., Zhang Z., Akkermansia muciniphila protects against antibiotic-associated diarrhea in mice, Probiotics. Antimicrob. Proteins, (2023); Liu X., Mao B., Gu J., Wu J., Cui S., Wang G., Zhao J., Zhang H., Chen W., Blautia-a new functional genus with potential probiotic properties?, Gut. Microbes, 13, pp. 1-21, (2021); Martinez C., Lobo B., Pigrau M., Ramos L., Gonzalez-Castro A.M., Alonso C., Guilarte M., Guila M., de Torres I., Azpiroz F., Santos J., Vicario M., Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, pp. 1160-1168, (2013); Martinon F., Chen X., Lee A.H., Glimcher L.H., TLR activation of the transcription factor XBP1 regulates innate immune responses in macrophages, Nat. Immunol., 11, pp. 411-418, (2010); Mayer E.A., Ryu H.J., Bhatt R.R., The neurobiology of irritable bowel syndrome, Mol. Psychiatry, 28, pp. 1451-1465, (2023); Naama M., Telpaz S., Awad A., Ben-Simon S., Harshuk-Shabso S., Modilevsky S., Rubin E., Sawaed J., Zelik L., Zigdon M., Asulin N., Turjeman S., Werbner M., Wongkuna S., Feeney R., Schroeder B.O., Nyska A., Nuriel-Ohayon M., Bel S., Autophagy controls mucus secretion from intestinal goblet cells by alleviating ER stress, Cell Host. Microbe, 31, pp. 433-446.e434, (2023); Oka P., Parr H., Barberio B., Black C.J., Savarino E.V., Ford A.C., Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis, Lancet Gastroenterol. Hepatol., 5, pp. 908-917, (2020); Paton A.W., Beddoe T., Thorpe C.M., Whisstock J.C., Wilce M.C., Rossjohn J., Talbot U.M., Paton J.C., AB5 subtilase cytotoxin inactivates the endoplasmic reticulum chaperone BiP, Nature, 443, pp. 548-552, (2006); Petitfils C., Maurel S., Payros G., Hueber A., Agaiz B., Gazzo G., Marrocco R., Auvray F., Langevin G., Motta J.P., Floch P., Tremblay-Franco M., Galano J.M., Guy A., Durand T., Lachambre S., Durbec A., Hussein H., Decraecker L., Bertrand-Michel J., Saoudi A., Oswald E., Poisbeau P., Dietrich G., Melchior C., Boeckxstaens G., Serino M., Le Faouder P., Cenac N., Identification of bacterial lipopeptides as key players in IBS, Gut, 72, pp. 939-950, (2023); Seewoo B.J., Chua E.G., Arena-Foster Y., Hennessy L.A., Gorecki A.M., Anderton R., Rodger J., Changes in the rodent gut microbiome following chronic restraint stress and low-intensity rTMS, Neurobiol. Stress., 17, (2022); Skrzydlo-Radomanska B., Prozorow-Krol B., Cichoz-Lach H., Majsiak E., Bierla J.B., Kosikowski W., Szczerbinski M., Gantzel J., Cukrowska B., The effectiveness of synbiotic preparation containing lactobacillus and bifidobacterium probiotic strains and short chain fructooligosaccharides in patients with diarrhea predominant irritable bowel syndrome-a randomized double-blind, placebo-controlled study, Nutrients, 12, pp. 1-19, (2020); Sperber A.D., Bangdiwala S.I., Drossman D.A., Ghoshal U.C., Simren M., Tack J., Whitehead W.E., Dumitrascu D.L., Fang X., Fukudo S., Kellow J., Okeke E., Quigley E.M.M., Schmulson M., Whorwell P., Archampong T., Adibi P., Andresen V., Benninga M.A., Bonaz B., Bor S., Fernandez L.B., Choi S.C., Corazziari E.S., Francisconi C., Hani A., Lazebnik L., Lee Y.Y., Mulak A., Rahman M.M., Santos J., Setshedi M., Syam A.F., Vanner S., Wong R.K., Lopez-Colombo A., Costa V., Dickman R., Kanazawa M., Keshteli A.H., Khatun R., Maleki I., Poitras P., Pratap N., Stefanyuk O., Thomson S., Zeevenhooven J., Palsson O.S., Worldwide prevalence and burden of functional gastrointestinal disorders, results of rome foundation global study, Gastroenterology, 160, pp. 99-114.e113, (2021); Wang H.Y., Zhao H.M., Wang Y., Liu Y., Lu X.Y., Liu X.K., Chen F., Ge W., Zuo Z.Y., Liu D.Y., Sishen Wan(®) Ameliorated trinitrobenzene-sulfonic-acid-induced chronic colitis via NEMO/NLK signaling pathway, Front. Pharmacol., 10, (2019); Wang L., Chai M., Wang J., Yu Q., Wang G., Zhang H., Zhao J., Chen W., Bifidobacterium longum relieves constipation by regulating the intestinal barrier of mice, Food Funct., 13, pp. 5037-5049, (2022); Wang L.X., Zhao Q., Zhang Y., Xue R., Li S., Li Y., Yu J.J., Li J.C., Zhang Y.Z., Network pharmacology and pharmacological evaluation for deciphering novel indication of Sishen Wan in insomnia treatment, Phytomedicine, 108, (2023); Wang Q., Wang C., Abdullah, Tian W., Qiu Z., Song M., Cao Y., Xiao J., Hydroxytyrosol alleviates dextran sulfate sodium-induced colitis by modulating inflammatory responses, intestinal barrier, and microbiome, J. Agric. Food Chem., 70, pp. 2241-2252, (2022); Wei Y., Fan Y., Huang S., Lv J., Zhang Y., Hao Z., Baizhu shaoyao decoction restores the intestinal barrier and brain-gut axis balance to alleviate diarrhea-predominant irritable bowel syndrome via FoxO1/FoxO3a, Phytomedicine, 122, (2024); Xia X., Lin H., Luo F., Wu X., Zhu L., Chen S., Luo H., Ye F., Peng X., Zhang Y., Yang G., Lin Q., Oryzanol ameliorates DSS-stimulated gut barrier damage via targeting the gut microbiota accompanied by the TLR4/NF-κB/NLRP3 cascade response in vivo, J. Agric. Food Chem., 70, pp. 15747-15762, (2022); Xie Y., Zhan X., Tu J., Xu K., Sun X., Liu C., Ke C., Cao G., Zhou Z., Liu Y., Atractylodes oil alleviates diarrhea-predominant irritable bowel syndrome by regulating intestinal inflammation and intestinal barrier via SCF/c-kit and MLCK/MLC2 pathways, J. Ethnopharmacol., 272, (2021); Xiong R., Li W., Li Y., Zheng K., Zhang T., Gao M., Li Y., Hu L., Hu C., Er Shen Wan extract reduces diarrhea and regulates AQP 4 and NHE 3 in a rat model of spleen-kidney Yang deficiency-induced diarrhea, Biomed. PharmacOther, 98, pp. 834-846, (2018); Yao D., Dai W., Dong M., Dai C., Wu S., MUC2 and related bacterial factors: Therapeutic targets for ulcerative colitis, EBioMedicine, 74, (2021); Zhai L., Huang C., Ning Z., Zhang Y., Zhuang M., Yang W., Wang X., Wang J., Zhang L., Xiao H., Zhao L., Asthana P., Lam Y.Y., Chow C.F.W., Huang J.D., Yuan S., Chan K.M., Yuan C.S., Lau J.Y., Wong H.L.X., Bian Z.X., Ruminococcus gnavus plays a pathogenic role in diarrhea-predominant irritable bowel syndrome by increasing serotonin biosynthesis, Cell Host. Microbe, 31, pp. 33-44.e35, (2023)","Y. Dai; Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, inghai District, No.10 Poyanghu Road, Tianjin, 301617, China; email: daiyongna@tjutcm.edu.cn","","Elsevier GmbH","","","","","","09447113","","PYTOE","38579640","English","Phytomedicine","Article","Final","","Scopus","2-s2.0-85189512466"

"Maqoud F.; Orlando A.; Tricarico D.; Antonacci M.; Di Turi A.; Giannelli G.; Russo F.","Maqoud, Fatima (57189688787); Orlando, Antonella (23767683100); Tricarico, Domenico (7003562407); Antonacci, Marina (57468115900); Di Turi, Annamaria (56180925800); Giannelli, Gianluigi (7005015716); Russo, Francesco (57201476097)","57189688787; 23767683100; 7003562407; 57468115900; 56180925800; 7005015716; 57201476097","Anti-Inflammatory Effects of a Novel Acetonitrile–Water Extract of Lens Culinaris against LPS-Induced Damage in Caco-2 Cells","2024","International Journal of Molecular Sciences","25","7","3802","","","","0","10.3390/ijms25073802","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85190364768&doi=10.3390%2fijms25073802&partnerID=40&md5=854905ef63177c43adfb00b1b3e1982d","Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS “Saverio de Bellis”, BA, Castellana Grotte, 70013, Italy; Section of Pharmacology, Department of Pharmacy-Pharmaceutical Sciences, University of Bari ‘Aldo Moro’, BA, Bari, 70121, Italy; Scientific Direction, National Institute of Gastroenterology IRCCS “Saverio de Bellis”, BA, Castellana Grotte, 70013, Italy","Maqoud F., Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS “Saverio de Bellis”, BA, Castellana Grotte, 70013, Italy; Orlando A., Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS “Saverio de Bellis”, BA, Castellana Grotte, 70013, Italy; Tricarico D., Section of Pharmacology, Department of Pharmacy-Pharmaceutical Sciences, University of Bari ‘Aldo Moro’, BA, Bari, 70121, Italy; Antonacci M., Section of Pharmacology, Department of Pharmacy-Pharmaceutical Sciences, University of Bari ‘Aldo Moro’, BA, Bari, 70121, Italy; Di Turi A., Section of Pharmacology, Department of Pharmacy-Pharmaceutical Sciences, University of Bari ‘Aldo Moro’, BA, Bari, 70121, Italy; Giannelli G., Scientific Direction, National Institute of Gastroenterology IRCCS “Saverio de Bellis”, BA, Castellana Grotte, 70013, Italy; Russo F., Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS “Saverio de Bellis”, BA, Castellana Grotte, 70013, Italy","Natural compounds like flavonoids preserve intestinal mucosal integrity through their antioxidant, anti-inflammatory, and antimicrobial properties. Additionally, some flavonoids show prebiotic abilities, promoting the growth and activity of beneficial gut bacteria. This study investigates the protective impact of Lens culinaris extract (LE), which is abundant in flavonoids, on intestinal mucosal integrity during LPS-induced inflammation. Using Caco-2 cells as a model for the intestinal barrier, the study found that LE did not affect cell viability but played a cytoprotective role in the presence of LPS. LE improved transepithelial electrical resistance (TEER) and tight junction (TJ) protein levels, which are crucial for barrier integrity. It also countered the upregulation of pro-inflammatory genes TRPA1 and TRPV1 induced by LPS and reduced pro-inflammatory markers like TNF-α, NF-κB, IL-1β, and IL-8. Moreover, LE reversed the LPS-induced upregulation of AQP8 and TLR-4 expression. These findings emphasize the potential of natural compounds like LE to regulate the intestinal barrier and reduce inflammation’s harmful effects on intestinal cells. More research is required to understand their mechanisms and explore therapeutic applications, especially for gastrointestinal inflammatory conditions. © 2024 by the authors.","aquaporin; ATP-sensitive K<sup>+</sup> channels; calcium-activated K<sup>+</sup> channels; functional gastrointestinal disorders; intestinal dismicrobism; ion channels; irritable bowel syndrome (IBS); transient receptor potential; transporters; voltage-dependent sodium channels","Acetonitriles; Caco-2 Cells; Flavonoids; Humans; Inflammation; Lens Plant; Lipopolysaccharides; acetonitrile; cytoprotective agent; immunoglobulin enhancer binding protein; interleukin 1beta; interleukin 8; lipopolysaccharide; occludin; plant extract; protein ZO1; tight junction protein; toll like receptor 4; tumor necrosis factor; acetonitrile; acetonitrile derivative; flavonoid; lipopolysaccharide; antiinflammatory activity; Article; Caco-2 cell line; cell protection; cell viability; controlled study; electric resistance; human; human cell; intestinal barrier function; intestine mucosa; lentil; lipopolysaccharide-induced inflammation; mRNA expression level; MTT assay; nonhuman; protein expression; tight junction; upregulation; Western blotting; Caco-2 cell line; inflammation","","acetonitrile, 75-05-8; interleukin 8, 114308-91-7; occludin, 176304-61-3; toll like receptor 4, 203811-83-0; acetonitrile, ; Acetonitriles, ; Flavonoids, ; Lipopolysaccharides, ","","","Ministero della Salute, (RC 2022–2024, DDG_661_23.12.2022); Ministero della Salute","This research was funded by the Italian Ministry of Health RC 2022\u20132024, Prog. N. 19 (DDG_661_23.12.2022).","Barrett K.E., New ways of thinking about (and teaching about) intestinal epithelial function, Adv. Physiol. Educ, 32, pp. 25-34, (2008); Runkle E.A., Mu D., Tight junction proteins: From barrier to tumorigenesis, Cancer Lett, 337, pp. 41-48, (2013); Hodges K., Gill R., Infectious diarrhea: Cellular and molecular mechanisms, Gut Microbes, 1, pp. 4-21, (2010); Maqoud F., Tricarico D., Mallamaci R., Orlando A., Russo F., The Role of Ion Channels in Functional Gastrointestinal Disorders (FGID): Evidence of Channelopathies and Potential Avenues for Future Research and Therapeutic Targets, Int. J. Mol. Sci, 24, (2023); Ikarashi N., Kon R., Sugiyama K., Aquaporins in the Colon as a New Therapeutic Target in Diarrhea and Constipation, Int. J. Mol. Sci, 17, (2016); Putt K.K., Pei R., White H.M., Bolling B.W., Yogurt inhibits intestinal barrier dysfunction in Caco-2 cells by increasing tight junctions, Food Funct, 8, pp. 406-414, (2017); Holst O., Ulmer A.J., Brade H., Flad H.-D., Rietschel E.T., Biochemistry and cell biology of bacterial endotoxins, FEMS Immunol. Med. Microbiol, 16, pp. 83-104, (1996); Straub R.H., TRPV1, TRPA1, and TRPM8 channels in inflammation, energy redirection, and water retention: Role in chronic inflammatory diseases with an evolutionary perspective, J. Mol. Med, 92, pp. 925-937, (2014); Ciesielska A., Matyjek M., Kwiatkowska K., TLR4 and CD14 trafficking and its influence on LPS-induced pro-inflammatory signaling, Cell. Mol. Life Sci, 78, pp. 1233-1261, (2021); Kanda Y., Yamasaki Y., Sasaki-Yamaguchi Y., Ida-Koga N., Kamisuki S., Sugawara F., Nagumo Y., Usui T., TRPA1-dependent reversible opening of tight junction by natural compounds with an α,β-unsaturated moiety and capsaicin, Sci. Rep, 8, (2018); Noda S., Tanabe S., Suzuki T., Naringenin enhances intestinal barrier function through the expression and cytoskeletal association of tight junction proteins in Caco-2 cells, Mol. Nutr. Food Res, 57, pp. 2019-2028, (2013); Mahmoud A.M., Yang W., Bosland M.C., Soy isoflavones and prostate cancer: A review of molecular mechanisms, J. Steroid Biochem. Mol. Biol, 140, pp. 116-132, (2014); Toschi A., Rossi B., Tugnoli B., Piva A., Grilli E., Nature-Identical Compounds and Organic Acids Ameliorate and Prevent the Damages Induced by an Inflammatory Challenge in Caco-2 Cell Culture, Molecules, 25, (2020); Bialkowski S., Toschi A., Yu L.-E., Schlitzkus L., Mann P., Grilli E., Li Y., Effects of microencapsulated blend of organic acids and botanicals on growth performance, intestinal barrier function, inflammatory cytokines, and endocannabinoid system gene expression in broiler chickens, Poult. Sci, 102, (2023); Di Turi A., Antonacci M., Dibenedetto J.R., Maqoud F., Leonetti F., Centoducati G., Colonna N., Tricarico D., Molecular Composition and Biological Activity of a Novel Acetonitrile–Water Extract of Lens Culinaris Medik in Murine Native Cells and Cell Lines Exposed to Different Chemotherapeutics Using Mass Spectrometry, Cells, 12, (2023); Antonacci M., Dibenedetto J.R., Maqoud F., Centoducati G., Colonna N., Leonetti F., Tricarico D., Counteractions of a Novel Hydroalcoholic Extract from Lens Culinaria against the Dexamethasone-Induced Osteoblast Loss of Native Murine Cells, Cells, 11, (2022); Bueno L., Fioramonti J., Protease-activated receptor 2 and gut permeability: A review, Neurogastroenterol. Motil, 20, pp. 580-587, (2008); Fan J., Li B.-R., Zhang Q., Zhao X.-H., Wang L., Pretreatment of IEC-6 cells with quercetin and myricetin resists the indomethacin-induced barrier dysfunction via attenuating the calcium-mediated JNK/Src activation, Food Chem. Toxicol, 147, (2021); Felix K., Tobias S., Jan H., Nicolas S., Michael M., Measurements of transepithelial electrical resistance (TEER) are affected by junctional length in immature epithelial monolayers, Histochem. Cell Biol, 156, pp. 609-616, (2021); An L., Wirth U., Koch D., Schirren M., Drefs M., Koliogiannis D., Niess H., Andrassy J., Guba M., Bazhin A.V., Et al., The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases, J. Gastrointest. Surg, 26, pp. 671-683, (2022); Ghosh S.S., Wang J., Yannie P.J., Ghosh S., Intestinal Barrier Dysfunction, LPS Translocation, and Disease Development, J. Endocr. Soc, 4, (2020); Maleki S.J., Crespo J.F., Cabanillas B., Anti-inflammatory effects of flavonoids, Food Chem, 299, (2019); Serafini M., Peluso I., Raguzzini A., Flavonoids as anti-inflammatory agents, Proc. Nutr. Soc, 69, pp. 273-278, (2010); Joo M., Kim H.S., Kwon T.H., Palikhe A., Zaw T.S., Jeong J.H., Sohn U.D., Anti-inflammatory Effects of Flavonoids on TNBS-induced Colitis of Rats, Korean J. Physiol. Pharmacol. Off. J. Korean Physiol. Soc. Korean Soc. Pharmacol, 19, pp. 43-50, (2015); Amasheh M., Schlichter S., Amasheh S., Mankertz J., Zeitz M., Fromm M., Schulzke J.D., Quercetin Enhances Epithelial Barrier Function and Increases Claudin-4 Expression in Caco-2 Cells, J. Nutr, 138, pp. 1067-1073, (2008); DiGuilio K.M., Rybakovsky E., Valenzano M.C., Nguyen H.H., Del Rio E.A., Newberry E., Spadea R., Mullin J.M., Quercetin improves and protects Calu-3 airway epithelial barrier function, Front. Cell Dev. Biol, 11, (2023); Junyuan Z., Hui X., Chunlan H., Junjie F., Qixiang M., Yingying L., Lihong L., Xingpeng W., Yue Z., Quercetin protects against intestinal barrier disruption and inflammation in acute necrotizing pancreatitis through TLR4/MyD88/p38 MAPK and ERS inhibition, Pancreatology, 18, pp. 742-752, (2018); Li J., Tian R., Liang G., Shi R., Hu J., Jiang Z., Interaction mechanism of flavonoids with whey protein isolate: A spectrofluorometric and theoretical investigation, Food Chem, 355, (2021); Wang R., Tu L., Pan D., Gao X., Du L., Cai Z., Wu J., Dang Y., A Comparative Study of Binding Interactions between Proteins and Flavonoids in Angelica Keiskei: Stability, α-Glucosidase Inhibition and Interaction Mechanisms, Int. J. Mol. Sci, 24, (2023); Tunisi L., Forte N., Fernandez-Rilo A.C., Mavaro I., Capasso R., D'Angelo L., Milic N., Cristino L., Di Marzo V., Palomba L., Orexin-A Prevents Lipopolysaccharide-Induced Neuroinflammation at the Level of the Intestinal Barrier, Front. Endocrinol, 10, (2019); He C., Deng J., Hu X., Zhou S., Wu J., Xiao D., Darko K.O., Huang Y., Tao T., Peng M., Et al., Vitamin A inhibits the action of LPS on the intestinal epithelial barrier function and tight junction proteins, Food Funct, 10, pp. 1235-1242, (2019); Al-Sadi R., Boivin M., Ma T., Mechanism of cytokine modulation of epithelial tight junction barrier, Front. Biosci. (Landmark Ed.), 14, pp. 2765-2778, (2009); Capaldo C.T., Nusrat A., Cytokine regulation of tight junctions, Biochim. Biophys. Acta (BBA) Biomembr, 1788, pp. 864-871, (2009); Zhu C., Chen Z., Jiang Z., Expression, Distribution and Role of Aquaporin Water Channels in Human and Animal Stomach and Intestines, Int. J. Mol. Sci, 17, (2016); Kruger C., Jorns A., Kaynert J., Waldeck-Weiermair M., Michel T., Elsner M., Lenzen S., The importance of aquaporin-8 for cytokine-mediated toxicity in rat insulin-producing cells, Free Radic. Biol. Med, 174, pp. 135-143, (2021); Safe S., Jayaraman A., Chapkin R.S., Howard M., Mohankumar K., Shrestha R., Flavonoids: Structure–function and mechanisms of action and opportunities for drug development, Toxicol. Res, 37, pp. 147-162, (2021); Scala R., Maqoud F., Zizzo N., Passantino G., Mele A., Camerino G.M., McClenaghan C., Harter T.M., Nichols C.G., Tricarico D., Consequences of SUR2[A478V] Mutation in Skeletal Muscle of Murine Model of Cantu Syndrome, Cells, 10, (2021); Scala R., Maqoud F., Antonacci M., Dibenedetto J.R., Perrone M.G., Scilimati A., Castillo K., Latorre R., Conte D., Bendahhou S., Et al., Bisphosphonates Targeting Ion Channels and Musculoskeletal Effects, Front. Pharmacol, 13, (2022); Conte E., Romano A., De Bellis M., de Ceglia M., Carratu M.R., Gaetani S., Maqoud F., Tricarico D., Camerino C., Oxtr/TRPV1 expression and acclimation of skeletal muscle to cold-stress in male mice, J. Endocrinol, 249, pp. 135-148, (2021); Maqoud F., Scala R., Tragni V., Pierri C.L., Perrone M.G., Scilimati A., Tricarico D., Zoledronic Acid as a Novel Dual Blocker of KIR6.1/2-SUR2 Subunits of ATP-Sensitive K<sup>+</sup> Channels: Role in the Adverse Drug Reactions, Pharmaceutics, 13, (2021); Maqoud F., Cetrone M., Mele A., Tricarico D., Molecular structure and function of big calcium-activated potassium channels in skeletal muscle: Pharmacological perspectives, Physiol. Genom, 49, pp. 306-317, (2017); Maqoud F., Vacca E., Tommaseo-Ponzetta M., From Morocco to Italy: How Women’s Bodies Reflect their Change of Residence, Coll. Antropol, 40, pp. 9-15, (2016)","F. Russo; Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS “Saverio de Bellis”, Castellana Grotte, BA, 70013, Italy; email: francesco.russo@irccsdebellis.it","","Multidisciplinary Digital Publishing Institute (MDPI)","","","","","","16616596","","","38612611","English","Int. J. Mol. Sci.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85190364768"

"Frieling T.; Gjini B.; Melchior I.; Euler P.; Kreysel C.; Kalde S.; Krummen B.; Kiesslich R.; Hemmerlein B.","Frieling, Thomas (56253543400); Gjini, Besmir (57999111300); Melchior, Ilka (37081575200); Euler, Philipp (57219446514); Kreysel, Christian (35170027600); Kalde, Sigrid (6507669661); Krummen, Britta (57209271853); Kiesslich, Ralf (22234423500); Hemmerlein, Bernhard (55951725600)","56253543400; 57999111300; 37081575200; 57219446514; 35170027600; 6507669661; 57209271853; 22234423500; 55951725600","Endoscopic laser endomicroscopy and leaky gut in patients with functional gastrointestinal symptoms and food intolerance","2022","Zeitschrift fur Gastroenterologie","61","11","","1465","1471","6","4","10.1055/a-1959-3200","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85144742507&doi=10.1055%2fa-1959-3200&partnerID=40&md5=cc15ec687d0ba37c5fc38b604ee903bb","Medizinische Klinik II, HELIOS Klinikum Krefeld, Krefeld, Germany; Helios Dr. Horst Schmidt Kliniken Wiesbaden GmbH, Wiesbaden, Germany; Institut für Pathologie, HELIOS Klinikum Krefeld, Krefeld, Germany","Frieling T., Medizinische Klinik II, HELIOS Klinikum Krefeld, Krefeld, Germany; Gjini B., Medizinische Klinik II, HELIOS Klinikum Krefeld, Krefeld, Germany; Melchior I., Medizinische Klinik II, HELIOS Klinikum Krefeld, Krefeld, Germany; Euler P., Medizinische Klinik II, HELIOS Klinikum Krefeld, Krefeld, Germany; Kreysel C., Medizinische Klinik II, HELIOS Klinikum Krefeld, Krefeld, Germany; Kalde S., Medizinische Klinik II, HELIOS Klinikum Krefeld, Krefeld, Germany; Krummen B., Medizinische Klinik II, HELIOS Klinikum Krefeld, Krefeld, Germany; Kiesslich R., Helios Dr. Horst Schmidt Kliniken Wiesbaden GmbH, Wiesbaden, Germany; Hemmerlein B., Institut für Pathologie, HELIOS Klinikum Krefeld, Krefeld, Germany","Background Intestinal epithelial barrier dysfunction (leaky gut syndrome, LGS) is thought to play a major role in the pathogenesis of disorders of the gut brain axis. Endoscopic confocal laser endomicroscopy (eCLE) is an objective measure to test duodenal permeability. We applied this technique in patients with functional gastrointestinal symptoms and food intolerance to characterize the proportion of patients with LGS. Material and Methods In an observational study, we evaluated 85 patients with functional gastrointestinal symptoms and food intolerance. Gastrointestinal symptoms were classified according to Rom IV into functional abdominal pain (FAP), irritable bowel syndrome (IBS), irritable bowel syndrome diarrhea dominant (IBS-D), irritable bowel syndrome constipation dominant (IBS-C), irritable bowel syndrome with mixed stool (IBS-M), functional abdominal bloating (FAB), functional diarrhea (FD) and unclassified (NC). During eCLE, spontaneous transfer of intravenously applied fluorescein into duodenal lumen (LGS) and following duodenal food challenge (DFC) were analyzed. Blood analysis comprised parameters of mast cell function, histology of duodenal mucosal biopsies analysis of mucosal inflammation, intraepithelial lymphocytes (IELs) as well as number, distribution and morphology of mast cells. Results 24 patients (9 IBS, 9 FAP, 3 FAB, 1 FD, 2 NC), showed LGS, 50 patients (14 IBS-D, 4 IBS-C, 3 IBS-M, 23 FAP, 3 FAB, 3 NC) had no LGS but responded to DFC and 11 patients (6 NC, 3 FAP, 1 FAB, 1 FD) had no LGS and no response to DFC. The proportion of subgroups with/or without spontaneous leakage of fluorescein (+LGS/-LGS) were IBS-LGS/IBS+LGS 67%/33%, FAP-LGS/FAP+LGS 72%/28%,FAB-LGS/FAB+LGS 50%/50%, NC-LGS/NC+LGS 60%/40%. Subgroup analysis revealed no significant differences for all parameters tested. Conclusion As a proof of concept, the results of our study indicate that eCLE is a clinical useful tool to evaluate patients with disorders of the gut brain axis and those suspicious of LGS. However, the clinical significance of LGS remains unclear. The study should be an incentive to perform a randomized study including healthy controls. © 2022 Georg Thieme Verlag. All rights reserved.","disorders of the gut-brain-axis; Endoscopic laser endomicroscopy (eCLE); food intolerance; functional gastrointestinal symptoms; irritable bowel syndrome (IBS); leaky gut syndrome","Abdominal Pain; Diarrhea; Fluoresceins; Food Intolerance; Gastrointestinal Diseases; Humans; Irritable Bowel Syndrome; fluorescein; fluorescein derivative; abdominal pain; Article; bloating; blood analysis; cell function; confocal laser scanning microscopy; constipation; diarrhea; endoscopic laser endomicroscopy; female; gastrointestinal symptom; human; human tissue; immunohistochemistry; intraepithelial lymphocyte; irritable colon; major clinical study; male; mast cell; microscopy; mucosa inflammation; nutritional intolerance; observational study; complication; diarrhea; gastrointestinal disease; irritable colon; nutritional intolerance","","fluorescein, 2321-07-5, 91316-42-6; Fluoresceins, ","","","","","Fukui H., Increased intestinal permeability and decreased barrier function: Does it really influence the risk of inflammation?, Inflamm Intest Dis, 1, pp. 135-145, (2016); Yoshimoto T., Oshima T., Huang X., Microinflammation in the intestinal mucosa and symptoms of irritable bowel syndrome, J Gastroenterol, 57, pp. 62-69, (2022); Vanuytsel T., Van Wanrooy S., Vanheel H., Psychological stress and corticotropin-releasuing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism, Gut, 63, pp. 1293-1299, (2014); Wauters L., Talley N.J., Walker M.M., Novel concepts in the pathophysiology and treatment of functional dyspepsia, Gut, 69, pp. 591-600, (2020); Vanheel H., Vicario M., Vanuytsel T., Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia, Gut, 63, pp. 262-271, (2014); Talley N.J., Walker M.M., Aro P., Non-ulcer dyspepsia and duodenal eosinophilia: An adult endoscopic population-based case-control study, Clin Gastroenterol Hepatol, 5, pp. 1175-1183, (2007); Vanheel H., Vicario M., Boesmans W., Activation of eosinophils and mast cells in functional dyspepsia: An ultrastructural evaluation, Sci Rep, 8, (2018); Cirillo C., Bessissow T., Desmet A.S., Evidence for neuronal and structural changes in submucous ganglia of patients with functional dyspepsia, Am J Gastroenterol, 110, pp. 1205-1215, (2015); Kindt S., Tertychnyy A., De Hertogh G., Intestinal immune activation in presumed post-infectious functional dyspepsia, Neurogastroenterol Motil, 21, (2009); Taki M., Oshima T., Li M., Duodenal low-grade inflammation and expression of tight junction proteins in functional dyspepsia, Neurogastroenterol Motil, 31, (2019); Miglietta S., Borghini R., Relucenti M., New insights into intestinal permeability in irritable Bowel syndrome-like disorders: Histological and ultrastructural findings of duodenal biopsies, Cells, 10, (2021); Obrenovich M.E.M., Leaky gut, leaky brain?, Microorganisms, 6, (2018); Tack J., Schol J., Van Den Houte K., Pradigm shift. Functional dyspepsia-a leaky gut disorder?, Am J Gastroenterol, 116, pp. 274-275, (2020); Nojkov B., Zhou S.Y., Dolan R.D., Evidence of duodenal epithelial barrier impairment and increased pyroptosis in patients with functional dyspepsia on confocal laser endomicroscopy and ex vivo mucosa analysis, Am J Gastroenterol, 115, pp. 1891-1901, (2020); Wauters L., Ceulemans M., Schol J., The Role of Leaky Gut in Functional Dyspepsia, Front. Neurosci, (2022); Beeckmans D., Farre R., Riethorst D., Relationship between bile salts, bacterial translocation, and duodenal mucosal integrity in functional dyspepsia, Neurogastroenterol Motil, 32, (2020); Vanheel H., Carbone F., Valvekens L., Pathophysiological abnormalities in functional dyspepsia subgroups according to the rome III criteria, Am J Gastroenterol, 112, pp. 132-140, (2017); Binienda A., Twardowska A., Makaro A., Dietary Carbohydrates and Lipids in the Pathogenesis of Leaky Gut Syndrome: An Overview, Int J Mol Sci, 21, (2020); Fritscher-Ravens A., Schuppan D., Ellrichmann M., Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome, Gastroenterology, 147, pp. 1012-1020, (2014); Fritscher-Ravens A., Pflaum T., Mosinger M., Many patients with irritable bowel syndrome have atypical food allergies not associated with immunoglobulin e, Gastroenterology, 157, pp. 109-118, (2019); Drossman D.A., Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV, Gastroenterology, (2016); Wyatt J., Oberhuber G., Pongratz S., Increased gastric and intestinal permeability in patients with Crohn's disease, Am J Gastroenterol, 92, pp. 1891-1896, (1997); Oriishi T., Sata M., Toyonaga A., Evaluation of intestinal permeability in patients with inflammatory bowel disease using lactulose and measuring antibodies to lipid A, Gut, 36, pp. 891-896, (1995); Vivinus-Nebot M., Frin-Mathy G., Bzioueche H., Functional bowel symptoms in quiescent inflammatory bowel diseases: Role of epithelial barrier disruption and low-grade inflammation, Gut, 63, pp. 744-752, (2014); Buning C., Geissler N., Prager M., Increased small intestinal permeability in ulcerative colitis: Rather genetic than environmental and a risk factor for extensive disease?, Inflamm Bowel Dis, 18, pp. 1932-1939, (2012); Gerova V.A., Stoynov S.G., Katsarov D.S., Increased intestinal permeability in inflammatory bowel diseases assessed by iohexol test, World J Gastroenterol, 17, pp. 2211-2215, (2011); Camilleri M., Lasch K., Zhou W., Irritable bowel syndrome: Methods, mechanisms, and pathophysiology. the confluence of increased permeability, inflammation, and pain in irritable bowel syndrome, Am J Physiol Gastrointest Liver Physiol, 303, pp. G775-G785, (2012); Piche T., Barbara G., Aubert P., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: Involvement of soluble mediators, Gut, 58, pp. 196-220, (2009); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am J Gastroenterol, 106, pp. 2165-2173, (2011); Waugh E., Waugh N., Cummins E., Faecal Calprotectin Testing for Differentiating Amongst Inflammatory and Non-inflammatory Bowel Diseases: Systematic Review and Economic EvaluationHealth Technology Assessment, 17, (2013)","T. Frieling; Medizinische Klinik II, HELIOS Klinikum Krefeld, Krefeld, Lutherplatz 40, 47805, Germany; email: thomas.frieling@helios-gesundheit.de","","Georg Thieme Verlag","","","","","","00442771","","ZGASA","36417920","English","Z. Gastroenterol.","Article","Final","","Scopus","2-s2.0-85144742507"

"Olyaiee A.; Yadegar A.; Mirsamadi E.S.; Sadeghi A.; Mirjalali H.","Olyaiee, Alireza (57789669300); Yadegar, Abbas (26658798500); Mirsamadi, Elnaz Sadat (50761257100); Sadeghi, Amir (57746270700); Mirjalali, Hamed (35311420300)","57789669300; 26658798500; 50761257100; 57746270700; 35311420300","Profiling of the fecal microbiota and circulating microRNA-16 in IBS subjects with Blastocystis infection : a case–control study","2023","European Journal of Medical Research","28","1","483","","","","1","10.1186/s40001-023-01441-8","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85175822681&doi=10.1186%2fs40001-023-01441-8&partnerID=40&md5=1376bb45611e1fa8468c9ef047e242da","Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran; Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Department of Microbiology, Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran","Olyaiee A., Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran; Yadegar A., Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Mirsamadi E.S., Department of Microbiology, Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; Sadeghi A., Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Mirjalali H., Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran","Irritable bowel syndrome (IBS) is a prevalent gastrointestinal (GI) tract disorder. Although the main reason for IBS is not clear, the interaction between intestinal microorganisms and the gut barrier seems to play an important role in pathogenesis of IBS. The current study aimed to investigate the effect of Blastocystis on the gut microbiota profile and the circulation levels of microRNA (mir)-16 of IBS patients compared to healthy subjects. Stool and blood samples were collected from 80 participants including 40 samples from each IBS and healthy group. Upon DNA extraction from stool samples, barcoding region and quantitative real-time PCR were analyzed to investigate Blastocystis and the microbiota profile, respectively. RNA was extracted from serum samples of included subjects and the expression of mir-16 was evaluated using stem-loop protocol and qreal-time PCR. Significant changes between IBS patients and healthy controls was observed in Firmicutes, Actinobacteria, Faecalibacterium, and Alistipes. In IBS patients, the relative abundance of Bifidobacteria was directly correlated with the presence of Blastocystis, while Alistipes was decreased with Blastocystis. Lactobacillus was significantly increased in Blastocystis carriers. In healthy subjects, the relative abundance of Bifidobacteria was decreased, but Alistipes was increased in Blastocystis carriers. The changes in the Firmicutes/Bacteroidetes ratio was not significant in different groups. The relative expression of mir-16 in Blastocystis-negative IBS patients and healthy carriers was significantly overexpressed compared to control group. The presence of Blastocystis, decreased the relative expression of mir-16 in IBS patients compared to Blastocystis-negative IBS patients. The present study revealed that Blastocystis has the ability to change the abundance of some phyla/genera of bacteria in IBS and healthy subjects. Moreover, Blastocystis seems to modulate the relative expression of microRNAs to control the gut atmosphere, apply its pathogenicity, and provide a favor niche for its colonization. © 2023, The Author(s).","Blastocystis; Fecal microbiota; IBS; MicroRNA; mir-16","Blastocystis; Blastocystis Infections; Case-Control Studies; Circulating MicroRNA; Humans; Irritable Bowel Syndrome; Microbiota; MicroRNAs; microRNA 16; circulating microRNA; microRNA; MIRN16 microRNA, human; Actinobacteria; adult; Alistipes; Article; bacterial colonization; Bifidobacteriaceae; Blastocystis; blastocystosis; blood sampling; clinical article; controlled study; disease association; DNA extraction; Faecalibacterium; feces analysis; feces microflora; female; Firmicutes; gene expression; gene function; genetic association; genetic code; human; irritable colon; Lactobacillus; male; molecular pathology; nonhuman; phylum; population abundance; real time polymerase chain reaction; RNA extraction; Blastocystis; case control study; microbiology; microflora","","Circulating MicroRNA, ; MicroRNAs, ; MIRN16 microRNA, human, ","","","","","Olyaiee A., Sadeghi A., Yadegar A., Mirsamadi E.S., Mirjalali H., Gut microbiota shifting in irritable bowel syndrome: the mysterious role of Blastocystis sp, Front Med (Lausanne), 9, (2022); Mei L., Zhou J., Su Y., Mao K., Wu J., Zhu C., He L., Cui Y., Gut microbiota composition and functional prediction in diarrhea-predominant irritable bowel syndrome, BMC Gastroenterol, 21, (2021); Johnsen P.H., Hilpusch F., Valle P.C., Goll R., The effect of fecal microbiota transplantation on IBS related quality of life and fatigue in moderate to severe non-constipated irritable bowel: Secondary endpoints of a double blind, randomized, placebo-controlled trial, EBioMedicine, 51, (2020); Nagel R., Traub R.J., Allcock R.J., Kwan M.M., Bielefeldt-Ohmann H., Comparison of faecal microbiota in Blastocystis-positive and Blastocystis-negative irritable bowel syndrome patients, Microbiome, 4, (2016); Dale H.F., Lied G.A., Gut microbiota and therapeutic approaches for dysbiosis in irritable bowel syndrome: recent developments and future perspectives, Turk J Med Sci, 50, pp. 1632-1641, (2020); Zhao L., Yang W., Chen Y., Huang F., Lu L., Lin C., Huang T., Ning Z., Zhai L., Zhong L.L., Et al., A Clostridia-rich microbiota enhances bile acid excretion in diarrhea-predominant irritable bowel syndrome, J Clin Invest, 130, pp. 438-450, (2020); Gasbarrini A., Lauritano E.C., Garcovich M., Sparano L., Gasbarrini G., New insights into the pathophysiology of IBS: intestinal microflora, gas production and gut motility, Eur Rev Med Pharmacol Sci, 12, pp. 111-117, (2008); Rajilic-Stojanovic M., Biagi E., Heilig H.G., Kajander K., Kekkonen R.A., Tims S., de Vos W.M., Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome, Gastroenterology, 141, pp. 1792-1801, (2011); Shankar V., Reo N.V., Paliy O., Simultaneous fecal microbial and metabolite profiling enables accurate classification of pediatric irritable bowel syndrome, Microbiome, 3, (2015); Fagoonee S., Pellicano R., Does the microbiota play a pivotal role in the pathogenesis of irritable bowel syndrome?, J Clin Med, 8, (2019); Nieves-Ramirez M., Partida-Rodriguez O., Laforest-Lapointe I., Reynolds L., Brown E., Valdez-Salazar A., Moran-Silva P., Rojas-Velazquez L., Morien E., Parfrey L., Asymptomatic intestinal colonization with protist Blastocystis is strongly associated with distinct microbiome ecological patterns, Msystems, 3, pp. e00007-e00018, (2018); Nemati S., Zali M.R., Johnson P., Mirjalali H., Karanis P., Molecular prevalence and subtype distribution of Blastocystis sp. in Asia and in Australia, J Water Health, 19, pp. 687-704, (2021); Cifre S., Gozalbo M., Ortiz V., Soriano J.M., Merino J.F., Trelis M., Blastocystis subtypes and their association with Irritable Bowel Syndrome, Med Hypotheses, 116, pp. 4-9, (2018); Dogruman-Al F., Simsek Z., Boorom K., Ekici E., Sahin M., Tuncer C., Kustimur S., Altinbas A., Comparison of methods for detection of Blastocystis infection in routinely submitted stool samples, and also in IBS/IBD Patients in Ankara, Turkey PLoS One, 5, (2010); Beghini F., Pasolli E., Truong T.D., Putignani L., Caccio S.M., Segata N., Large-scale comparative metagenomics of Blastocystis, a common member of the human gut microbiome, ISME J, 11, pp. 2848-2863, (2017); Asnicar F., Berry S.E., Valdes A.M., Nguyen L.H., Piccinno G., Drew D.A., Leeming E., Gibson R., Le Roy C., Khatib H.A., Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals, Nat Med, 27, pp. 321-332, (2021); Karamati S.A., Mirjalali H., Niyyati M., Yadegar A., Asadzadeh Aghdaei H., Haghighi A., Seyyed Tabaei S.J., Association of Blastocystis ST6 with higher protease activity among symptomatic subjects, BMC Microbiol, 21, (2021); Mirza H., Wu Z., Teo J.D., Tan K.S., Statin pleiotropy prevents rho kinase-mediated intestinal epithelial barrier compromise induced by Blastocystis cysteine proteases, Cell Microbiol, 14, pp. 1474-1484, (2012); Mohammad Rahimi H., Yadegar A., Asadzadeh Aghdaei H., Mirjalali H., Zali M.R., Modulation of microRNAs and claudin-7 in Caco-2 cell line treated with Blastocystis sp., subtype 3 soluble total antigen, BMC Microbiol, 22, (2022); Chatterjee B., Sarkar M., Bose S., Alam M.T., Chaudhary A.A., Dixit A.K., Tripathi P.P., Srivastava A.K., MicroRNAs: Key modulators of inflammation-associated diseases, Seminars in Cell & Developmental Biology, (2023); Martinez C., Rodino-Janeiro B.K., Lobo B., Stanifer M.L., Klaus B., Granzow M., Gonzalez-Castro A.M., Salvo-Romero E., Alonso-Cotoner C., Pigrau M., miR-16 and miR-125b are involved in barrier function dysregulation through the modulation of claudin-2 and cingulin expression in the jejunum in IBS with diarrhoea, Gut, 66, pp. 1537-1538, (2017); Norouzi M., Pirestani M., Arefian E., Dalimi A., Sadraei J., Mirjalali H., Exosomes secreted by Blastocystis subtypes affect the expression of proinflammatory and anti-inflammatory cytokines (TNFα, IL-6, IL-10, IL-4), Front Med (Lausanne), 9, (2022); Gholam-Mostafaei F.S., Azimirad M., Naseri K., Nabavi-Rad A., Asadzadeh Aghdaei H., Shahrokh S., Ebrahimi Daryani N., Yadegar A., Zali M.R., Intestinal microbiota changes pre-and post-fecal microbiota transplantation for treatment of recurrent Clostridioides difficile infection among Iranian patients with concurrent inflammatory bowel disease, Front Microbiol, 14, (2023); De Gregoris T.B., Aldred N., Clare A.S., Burgess J.G., Improvement of phylum-and class-specific primers for real-time PCR quantification of bacterial taxa, J Microbiol Method, 86, pp. 351-356, (2011); Moszak M., Szulinska M., Bogdanski P., You are what you eat—the relationship between diet, microbiota, and metabolic disorders—a review, Nutrients, 12, (2020); Thursby E., Juge N., Introduction fo the human gut flora, Biochem J, 474, pp. 1823-1836, (2017); Hermann-Bank M.L., Skovgaard K., Stockmarr A., Larsen N., Molbak L., The gut microbiotassay: a high-throughput qPCR approach combinable with next generation sequencing to study gut microbial diversity, BMC Genomic, 14, pp. 1-14, (2013); Springham N., Robert G., Experience based co-design reduces formal complaints on an acute mental health ward, BMJ Open Qual, 4, u209153, (2015); Keshavarz Azizi Raftar S., Ashrafian F., Yadegar A., Lari A., Moradi H.R., Shahriary A., Azimirad M., Alavifard H., Mohsenifar Z., Davari M., The protective effects of live and pasteurized Akkermansia muciniphila and its extracellular vesicles against HFD/CCl4-induced liver injury, Microbiol Spect, 9, pp. e00484-e1421, (2021); Wang I.-K., Lai H.-C., Yu C.-J., Liang C.-C., Chang C.-T., Kuo H.-L., Yang Y.-F., Lin C.-C., Lin H.-H., Liu Y.-L., Real-time PCR analysis of the intestinal microbiotas in peritoneal dialysis patients, Appl Environ Microbiol, 78, pp. 1107-1112, (2012); Quigley E.M., Gut bacteria in health and disease, Gastroenterol Hepatol, 9, (2013); Vigsnaes L.K., Brynskov J., Steenholdt C., Wilcks A., Licht T.R., Gram-negative bacteria account for main differences between faecal microbiota from patients with ulcerative colitis and healthy controls, Beneficial Microb, 3, pp. 287-297, (2012); Tap J., Derrien M., Tornblom H., Brazeilles R., Cools-Portier S., Dore J., Storsrud S., Le Neve B., Ohman L., Simren M., Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome, Gastroenterology, 152, pp. 111-123, (2017); Zhuang X., Tian Z., Li L., Zeng Z., Chen M., Xiong L., Fecal microbiota alterations associated with diarrhea-predominant irritable bowel syndrome, Front Microbiol, 9, (2018); Deng L., Wojciech L., Gascoigne N.R., Peng G., Tan K.S., New insights into the interactions between Blastocystis, the gut microbiota, and host immunity, PLoS Pathog, 17, (2021); Kim M.J., Lee Y.J., Kim T.J., Won E.J., Gut microbiome profiles in colonizations with the enteric protozoa Blastocystis in Korean populations, Microorganisms, 10, (2021); Stensvold C.R., Sorland B.A., Berg R., Andersen L.O., van der Giezen M., Bowtell J.L., El-Badry A.A., Belkessa S., Kurt O., Nielsen H.V., Stool microbiota diversity analysis of Blastocystis-positive and Blastocystis-negative individuals, Microorganisms, 10, (2022); Olivo-Diaz A., Romero-Valdovinos M., Gudino-Ramirez A., Reyes-Gordillo J., Jimenez-Gonzalez D.E., Ramirez-Miranda M.E., Martinez-Flores W.A., Martinez-Hernandez F., Flisser A., Maravilla P., Findings related to IL-8 and IL-10 gene polymorphisms in a Mexican patient population with irritable bowel syndrome infected with Blastocystis, Parasitol Res, 111, pp. 487-491, (2012); Ismail M.H., Molan A.L., Abbas S.K., Serological levels of cytokines in irritable bowel syndrome (IBS) patients and non-IBS subjects with and without Blastocystis spp. infection, Ann Parasitol, 68, pp. 77-85, (2022); Nagel R., Traub R.J., Kwan M.M., Bielefeldt-Ohmann H., Blastocystis specific serum immunoglobulin in patients with irritable bowel syndrome (IBS) versus healthy controls, Parasit Vectors, 8, (2015); Chen H., Ou R., Tang N., Su W., Yang R., Yu X., Zhang G., Jiao J., Zhou X., Alternation of the gut microbiota in irritable bowel syndrome: an integrated analysis based on multicenter amplicon sequencing data, J Transl Med, 21, (2023); Lee S.M., Kim N., Yoon H., Kim Y.S., Choi S.I., Park J.H., Lee D.H., Compositional and functional changes in the gut microbiota in irritable bowel syndrome patients, Gut Liver, 15, pp. 253-261, (2021); Lopetuso L.R., Petito V., Graziani C., Schiavoni E., Paroni Sterbini F., Poscia A., Gaetani E., Franceschi F., Cammarota G., Sanguinetti M., Et al., Gut microbiota in health, diverticular disease, irritable bowel syndrome, and inflammatory bowel diseases: time for microbial marker of gastrointestinal disorders, Dig Dis, 36, pp. 56-65, (2018); Barandouzi Z.A., Lee J., Maas K., Starkweather A.R., Cong X.S., Altered gut microbiota in irritable bowel syndrome and its association with food components, J Pers Med, 11, (2021); Carroll I.M., Ringel-Kulka T., Keku T.O., Chang Y.H., Packey C.D., Sartor R.B., Ringel Y., Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome, Am J Physiol Gastrointest Liver Physiol, 301, pp. G799-G807, (2011); Parker B.J., Wearsch P.A., Veloo A.C.M., Rodriguez-Palacios A., The genus alistipes: gut bacteria with emerging implications to inflammation, cancer, and mental health, Front Immunol, 11, (2020); O'Riordan K.J., Collins M.K., Moloney G.M., Knox E.G., Aburto M.R., Fulling C., Morley S.J., Clarke G., Schellekens H., Cryan J.F., Short chain fatty acids: microbial metabolites for gut-brain axis signalling, Mol Cell Endocrinol, 546, (2022); Oliphant K., Allen-Vercoe E., Macronutrient metabolism by the human gut microbiome: major fermentation by-products and their impact on host health, Microbiome, 7, (2019); Jiang W., Wu J., Zhu S., Xin L., Yu C., Shen Z., The role of short chain fatty acids in irritable bowel syndrome, J Neurogastroenterol Motil, 28, pp. 540-548, (2022); Sun Q., Jia Q., Song L., Duan L., Alterations in fecal short-chain fatty acids in patients with irritable bowel syndrome: A systematic review and meta-analysis, Medicine (Baltimore), 98, (2019); Gargari G., Taverniti V., Gardana C., Cremon C., Canducci F., Pagano I., Barbaro M.R., Bellacosa L., Castellazzi A.M., Valsecchi C., Et al., Fecal clostridiales distribution and short-chain fatty acids reflect bowel habits in irritable bowel syndrome, Environ Microbiol, 20, pp. 3201-3213, (2018); Dalile B., Van Oudenhove L., Vervliet B., Verbeke K., The role of short-chain fatty acids in microbiota-gut-brain communication, Nat Rev Gastroenterol Hepatol, 16, pp. 461-478, (2019); Deng L., Wojciech L., Png C.W., Kioh D.Y.Q., Gu Y., Aung T.T., Malleret B., Chan E.C.Y., Peng G., Zhang Y., Et al., Colonization with two different Blastocystis subtypes in DSS-induced colitis mice is associated with strikingly different microbiome and pathological features, Theranostics, 13, pp. 1165-1179, (2023); Deng L., Wojciech L., Png C.W., Koh E.Y., Aung T.T., Kioh D.Y.Q., Chan E.C.Y., Malleret B., Zhang Y., Peng G., Et al., Experimental colonization with Blastocystis ST4 is associated with protective immune responses and modulation of gut microbiome in a DSS-induced colitis mouse model, Cell Mol Life Sci, 79, (2022); Mayneris-Perxachs J., Arnoriaga-Rodriguez M., Garre-Olmo J., Puig J., Ramos R., Trelis M., Burokas A., Coll C., Zapata-Tona C., Pedraza S., Et al., Presence of Blastocystis in gut microbiota is associated with cognitive traits and decreased executive function, Isme J, 16, pp. 2181-2197, (2022); Schoultz I., Keita A.V., The intestinal barrier and current techniques for the assessment of gut permeability, Cells, 2020, (1909); Lee S.H., Intestinal permeability regulation by tight junction: implication on inflammatory bowel diseases, Intestin Res, 13, (2015); Koziel M.J., Ziaja M., Piastowska-Ciesielska A.W., Intestinal barrier, claudins and mycotoxins, Toxins, 13, (2021); Zhao X., Zeng H., Lei L., Tong X., Yang L., Yang Y., Li S., Zhou Y., Luo L., Huang J., Tight junctions and their regulation by non-coding RNAs, Int J Biol Sci, 17, (2021); Xi M., Zhao P., Li F., Bao H., Ding S., Ji L., Yan J., MicroRNA-16 inhibits the TLR4/NF-κB pathway and maintains tight junction integrity in irritable bowel syndrome with diarrhea, J Biol Chem, 298, 11, (2022)","H. Mirjalali; Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran; email: hamed_mirjalali@hotmail.com","","BioMed Central Ltd","","","","","","09492321","","","37932792","English","Eur. J. Med. Res.","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85175822681"

"Bednarska O.; Biskou O.; Israelsen H.; Winberg M.E.; Walter S.; Keita Å.V.","Bednarska, Olga (55789563900); Biskou, Olga (55920107600); Israelsen, Hans (6601965903); Winberg, Martin E. (20434962500); Walter, Susanna (23053245700); Keita, Åsa V. (13104052600)","55789563900; 55920107600; 6601965903; 20434962500; 23053245700; 13104052600","A postbiotic fermented oat gruel may have a beneficial effect on the colonic mucosal barrier in patients with irritable bowel syndrome","2022","Frontiers in Nutrition","9","","1004084","","","","5","10.3389/fnut.2022.1004084","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85144496618&doi=10.3389%2ffnut.2022.1004084&partnerID=40&md5=707bb5166e1b50c54b4ef6a3bbd7533e","Department of Gastroenterology, Linköping University Hospital, Linköping, Sweden; Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden; Nordic Rebalance A/S, Hillerød, Denmark; Department of Health, Medicine, and Caring Sciences, Linköping University, Linköping, Sweden","Bednarska O., Department of Gastroenterology, Linköping University Hospital, Linköping, Sweden; Biskou O., Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden; Israelsen H., Nordic Rebalance A/S, Hillerød, Denmark; Winberg M.E., Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden; Walter S., Department of Gastroenterology, Linköping University Hospital, Linköping, Sweden, Department of Health, Medicine, and Caring Sciences, Linköping University, Linköping, Sweden; Keita Å.V., Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden","Background: Impaired intestinal permeability and microbial dysbiosis are important pathophysiological mechanisms underlying irritable bowel syndrome (IBS). ReFerm®, also called Profermin®, is a postbiotic product of oat gruel fermented with Lactobacillus plantarum 299v. In this study, we investigated whether ReFerm® has a beneficial effect on the intestinal epithelial barrier function in patients with IBS. Materials and methods: Thirty patients with moderate to severe IBS-diarrhoea (IBS-D) or IBS-mixed (IBS-M) were treated with enema containing ReFerm® or placebo. The patients underwent sigmoidoscopy with biopsies obtained from the distal colon at baseline and after 14 days of treatment with ReFerm® or placebo twice daily. The biopsies were mounted in Ussing chambers, and paracellular and transcellular permeabilities were measured for 120 min. In addition, the effects of ReFerm® or placebo on the epithelial barrier were investigated in vitro using Caco-2 cells. Results: ReFerm® reduced paracellular permeability (p < 0.05) and increased transepithelial resistance (TER) over time (p < 0.01), whereas the placebo had no significant effect in patients. In ReFerm®-treated Caco-2 cells, paracellular and transcellular permeabilities were decreased compared to the control (p < 0.05) and placebo (p < 0.01). TER was increased in Caco-2 ReFerm®-treated cells, and normalised TER was increased in ReFerm®-treated Caco-2 cells compared to control (p < 0.05) and placebo-treated (p < 0.05) cells. Conclusion: ReFerm® significantly reduced paracellular permeability and improved TER in colonic biopsies collected from patients with IBS and in a Caco-2 cell model. Our results offer new insights into the potential benefits of ReFerm® in IBS management. Further studies are needed to identify the molecular mechanisms underlying the barrier-protective properties of ReFerm®. Clinical trial registration: [https://clinicaltrials.gov/], identifier [NCT05475314]. Copyright © 2022 Bednarska, Biskou, Israelsen, Winberg, Walter and Keita.","fermented oats; gut permeability; IBS–irritable bowel syndrome; intestinal barrier; postbiotics","","","","","","Richard Julin Foundation, (2022-00270); Region Östergötland, (RÖ-969343); Bengt Ihres Foundation","This study was funded by “P. Håkanssons Stiftelse, Eslöv, Sweden” (OBe), “ALF Grants, Region Östergötland” (LIO-938303 OBe and RÖ-960493 ÅK), “Grants from Region Östergötland” RÖ-969343 (ÅK), “Bengt Ihre Foundation” (OBe), “Ruth and Richard Julin Foundation” 2022-00270 (ÅK), and “Mucosa Infection and Inflammation Center-MIIC” (ÅK/SW). Nordic Rebalance provided ReFerm and placebo and partially financed the study (HI). ® ","Mearin F., Lacy B.E., Chang L., Chey W.D., Lembo A.J., Simren M., Et al., Bowel disorders, ROME IV, Functional Gastrointestinal Disorders-Disorders of gut-brain interactions, (2016); Palsson O.S., Whitehead W.E., van Tilburg M.A., Chang L., Chey W., Crowell M.D., Et al., Rome IV diagnostic questionnaires and tables for investigators and clinicians, Gastroenterology, (2016); Drossman D.A., Hasler W.L., Rome IV-functional GI disorders: disorders of gut-brain interaction, Gastroenterology, 150, pp. 1257-1261, (2016); Sperber A.D., Bangdiwala S.I., Drossman D.A., Ghoshal U.C., Simren M., Tack J., Et al., Worldwide prevalence and burden of functional gastrointestinal disorders, results of rome foundation global study, Gastroenterology, 160, pp. 99-114.e3, (2021); Canavan C., West J., Card T., Review article: the economic impact of the irritable bowel syndrome, Aliment Pharmacol Ther, 40, pp. 1023-1034, (2014); Singh P., Staller K., Barshop K., Dai E., Newman J., Yoon S., Et al., Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation, World J Gastroenterol, 21, pp. 8103-8109, (2015); Buono J.L., Carson R.T., Flores N.M., Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea, Health Qual Life Outcomes, 15, 35, (2017); Simren M., Svedlund J., Posserud I., Bjornsson E.S., Abrahamsson H., Health-related quality of life in patients attending a gastroenterology outpatient clinic: functional disorders versus organic diseases, Clin Gastroenterol Hepatol, 4, pp. 187-195, (2006); Tillisch K., Labus J.S., Naliboff B.D., Bolus R., Shetzline M., Mayer E.A., Et al., Characterization of the alternating bowel habit subtype in patients with irritable bowel syndrome, Am J Gastroenterol, 100, pp. 896-904, (2005); Palsson O.S., Baggish J.S., Turner M.J., Whitehead W.E., IBS patients show frequent fluctuations between loose/watery and hard/lumpy stools: implications for treatment, Am J Gastroenterol, 107, pp. 286-295, (2012); Enck P., Aziz Q., Barbara G., Farmer A.D., Fukudo S., Mayer E.A., Et al., Irritable bowel syndrome, Nat Rev Dis Primers, 2, (2016); Quigley E.M.M., The gut-brain axis and the microbiome: clues to pathophysiology and opportunities for novel management strategies in irritable bowel syndrome (IBS), J Clin Med, 7, 6, (2018); Camilleri M., Lasch K., Zhou W., Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome, Am J Physiol Gastrointest Liver Physiol, 303, pp. G775-G785, (2012); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Lecleire S., Antonietti M., Gourcerol G., Et al., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am J Gastroenterol, 106, pp. 2165-2173, (2011); Vasant D.H., Paine P.A., Black C.J., Houghton L.A., Everitt H.A., Corsetti M., Et al., British society of gastroenterology guidelines on the management of irritable bowel syndrome, Gut, 70, pp. 1214-1240, (2021); Eckmann L., Defence molecules in intestinal innate immunity against bacterial infections, Curr Opin Gastroenterol, 21, pp. 147-151, (2005); Yi H., Hu W., Chen S., Lu Z., Wang Y., Cathelicidin-WA improves intestinal epithelial barrier function and enhances host defense against enterohemorrhagic Escherichia coli O157:H7 infection, J Immunol, 198, pp. 1696-1705, (2017); Andrews C.N., Sidani S., Marshall J.K., Clinical management of the microbiome in irritable bowel syndrome, J Can Assoc Gastroenterol, 4, pp. 36-43, (2021); Mack D.R., Ahrne S., Hyde L., Wei S., Hollingsworth M.A., Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro, Gut, 52, pp. 827-833, (2003); Servin A.L., Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens, FEMS Microbiol Rev, 28, pp. 405-440, (2004); Huang J.Y., Lee S.M., Mazmanian S.K., The human commensal Bacteroides fragilis binds intestinal mucin, Anaerobe, 17, pp. 137-141, (2011); Chung H.G., Min Y.W., Lee C., Hong S.N., Won J.Y., Jang J.A., Et al., Effects of novel probiotics in a murine model of irritable bowel syndrome, Korean J Gastroenterol, 75, pp. 141-146, (2020); Waugh A.W.G., Rae F., Macfarlane S., Doyle J.S.G., Churchill T.A., Sydora B.C., Et al., Effect of Lactobacillus plantarum 299v treatment in an animal model of irritable bowel syndrome, Microb Ecol Health Dis, 21, 5, (2009); Nordstrom E.A., Teixeira C., Montelius C., Jeppsson B., Larsson N., Lactiplantibacillus plantarum 299v (LP299V(R)): three decades of research, Benef Microbes, 12, pp. 441-465, (2021); Goossens D., Jonkers D., Russel M., Thijs A., van den Bogaard A., Stobberingh E., Et al., Survival of the probiotic, L. plantarum 299v and its effects on the faecal bacterial flora, with and without gastric acid inhibition, Dig Liver Dis, 37, pp. 44-50, (2005); Holst B., Glenting J., Holmstrom K., Israelsen H., Vrang A., Antonsson M., Et al., Molecular switch controlling expression of the mannose-specific Adhesin, Msa, in Lactobacillus plantarum, Appl Environ Microbiol, 85, e02954-18, (2019); Anderson R.C., Cookson A.L., McNabb W.C., Kelly W.J., Roy N.C., Lactobacillus plantarum DSM 2648 is a potential probiotic that enhances intestinal barrier function, FEMS Microbiol Lett, 309, pp. 184-192, (2010); Barnett A.M., Roy N.C., Cookson A.L., McNabb W.C., Metabolism of caprine milk carbohydrates by probiotic bacteria and Caco-2:HT29(-)MTX epithelial co-cultures and their impact on intestinal barrier integrity, Nutrients, 10, 949, (2018); Nordstrom E.A., Teixeira C., Montelius C., Jeppsson B., Larsson N., Lactiplantibacillus plantarum 299v (LP299V(§)): three decades of research, Benef Microbes, 12, pp. 441-465, (2021); Nobaek S., Johansson M.L., Molin G., Ahrne S., Jeppsson B., Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome, Am J Gastroenterol, 95, pp. 1231-1238, (2000); Niedzielin K., Kordecki H., Birkenfeld B., A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome, Eur J Gastroenterol Hepatol, 13, pp. 1143-1147, (2001); Ducrotte P., Sawant P., Jayanthi V., Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome, World J Gastroenterol, 18, pp. 4012-4018, (2012); Sen S., Mullan M.M., Parker T.J., Woolner J.T., Tarry S.A., Hunter J.O., Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome, Dig Dis Sci, 47, pp. 2615-2620, (2002); Stevenson C., Blaauw R., Fredericks E., Visser J., Roux S., Randomized clinical trial: effect of Lactobacillus plantarum 299 v on symptoms of irritable bowel syndrome, Nutrition, 30, pp. 1151-1157, (2014); Ligaarden S.C., Axelsson L., Naterstad K., Lydersen S., Farup P.G., A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial, BMC Gastroenterol, 10, 16, (2010); Salminen S., Collado M.C., Endo A., Hill C., Lebeer S., Quigley E.M.M., Et al., The international scientific association of probiotics and prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics, Nat Rev Gastroenterol Hepatol, 18, pp. 649-667, (2021); Compare D., Rocco A., Coccoli P., Angrisani D., Sgamato C., Iovine B., Et al., Lactobacillus casei DG and its postbiotic reduce the inflammatory mucosal response: an ex-vivo organ culture model of post-infectious irritable bowel syndrome, BMC Gastroenterol, 17, 53, (2017); Tarrerias A.L., Costil V., Vicari F., Letard J.C., Adenis-Lamarre P., Aisene A., Et al., The effect of inactivated Lactobacillus LB fermented culture medium on symptom severity: observational investigation in 297 patients with diarrhea-predominant irritable bowel syndrome, Dig Dis, 29, pp. 588-591, (2011); Krag A., Munkholm P., Israelsen H., von Ryberg B., Andersen K.K., Bendtsen F., Profermin is efficacious in patients with active ulcerative colitis–a randomized controlled trial, Inflamm Bowel Dis, 19, pp. 2584-2592, (2013); Francis C.Y., Morris J., Whorwell P.J., The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress, Aliment Pharmacol Ther, 11, pp. 395-402, (1997); Krag A., Israelsen H., von Ryberg B., Andersen K.K., Bendtsen F., Safety and efficacy of Profermin<sup>®</sup> to induce remission in ulcerative colitis, World J Gastroenterol, 18, pp. 1773-1780, (2012); Wiklund I.K., Fullerton S., Hawkey C.J., Jones R.H., Longstreth G.F., Mayer E.A., Et al., An irritable bowel syndrome-specific symptom questionnaire: development and validation, Scand J Gastroenterol, 38, pp. 947-954, (2003); Labus J.S., Bolus R., Chang L., Wiklund I., Naesdal J., Mayer E.A., Et al., The visceral sensitivity index: development and validation of a gastrointestinal symptom-specific anxiety scale, Aliment Pharmacol Ther, 20, pp. 89-97, (2004); Zigmond A.S., Snaith R.P., The hospital anxiety and depression scale, Acta Psychiatr Scand, 67, pp. 361-370, (1983); Bjelland I., Dahl A.A., Haug T.T., Neckelmann D., The validity of the hospital anxiety and depression scale. An updated literature review, J Psychosom Res, 52, pp. 69-77, (2002); Krarup A.L., Peterson E., Ringstrom G., Tornblom H., Hjortswang H., Simren M., The short health scale: a simple, valid, reliable, and responsive way of measuring subjective health in patients with irritable bowel syndrome, J Clin Gastroenterol, 49, pp. 565-570, (2015); Grass G.M., Sweetana S.A., In vitro measurement of gastrointestinal tissue permeability using a new diffusion cell, Pharm Res, 5, pp. 372-376, (1988); Keita A.V., Gullberg E., Ericson A.C., Salim S.Y., Wallon C., Kald A., Et al., Characterization of antigen and bacterial transport in the follicle-associated epithelium of human ileum, Lab Invest, 86, pp. 504-516, (2006); Ganda Mall J.P., Casado-Bedmar M., Winberg M.E., Brummer R.J., Schoultz I., Keita A.V., A β-glucan-based dietary fiber reduces mast cell-induced hyperpermeability in ileum from patients with Crohn’s disease and control subjects, Inflamm Bowel Dis, 24, pp. 166-178, (2017); Bednarska O., Walter S.A., Casado-Bedmar M., Strom M., Salvo-Romero E., Vicario M., Et al., Vasoactive intestinal polypeptide and mast cells regulate increased passage of colonic bacteria in patients with irritable bowel syndrome, Gastroenterology, 153, pp. 948-60.e3, (2017); Hanning N., Edwinson A.L., Ceuleers H., Peters S.A., De Man J.G., Hassett L.C., Et al., Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review, Therap Adv Gastroenterol, 14, (2021); Matricon J., Meleine M., Gelot A., Piche T., Dapoigny M., Muller E., Et al., Review article: associations between immune activation, intestinal permeability and the irritable bowel syndrome, Aliment Pharmacol Ther, 36, pp. 1009-1031, (2012); Klooker T.K., Braak B., Koopman K.E., Welting O., Wouters M.M., van der Heide S., Et al., The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome, Gut, 59, pp. 1213-1221, (2010); Zhou Q., Verne M.L., Fields J.Z., Lefante J.J., Basra S., Salameh H., Et al., Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome, Gut, 68, pp. 996-1002, (2019); Zhang T., Zhang C., Zhang J., Sun F., Duan L., Efficacy of probiotics for irritable bowel syndrome: a systematic review and network meta-analysis, Front Cell Infect Microbiol, 12, (2022); Marlicz W., Skonieczna-Zydecka K., Krynicka P., Loniewski I., Rydzewska G., Probiotics in irritable bowel syndrome - is the quest for the right strain over? Rapid review of existing guidelines and recommendations, Prz Gastroenterol, 16, pp. 369-382, (2021); Ortiz-Lucas M., Tobias A., Saz P., Sebastian J.J., Effect of probiotic species on irritable bowel syndrome symptoms: a bring up to date meta-analysis, Rev Esp Enferm Dig, 105, pp. 19-36, (2013); Ohman L., Simren M., Intestinal microbiota and its role in irritable bowel syndrome (IBS), Curr Gastroenterol Rep, 15, 323, (2013); Spiller R., Garsed K., Postinfectious irritable bowel syndrome, Gastroenterology, 136, pp. 1979-1988, (2009); Raskov H., Burcharth J., Pommergaard H.C., Rosenberg J., Irritable bowel syndrome, the microbiota and the gut-brain axis, Gut Microbes, 7, pp. 365-383, (2016); Saffouri G.B., Shields-Cutler R.R., Chen J., Yang Y., Lekatz H.R., Hale V.L., Et al., Small intestinal microbial dysbiosis underlies symptoms associated with functional gastrointestinal disorders, Nat Commun, 10, 2012, (2019); Xiao L., Liu Q., Luo M., Xiong L., Gut microbiota-derived metabolites in irritable bowel syndrome, Front Cell Infect Microbiol, 11, (2021); Schoultz I., Keita A.V., The intestinal barrier and current techniques for the assessment of gut permeability, Cells, 9, 1909, (2020); Karczewski J., Troost F.J., Konings I., Dekker J., Kleerebezem M., Brummer R.J., Et al., Regulation of human epithelial tight junction proteins by Lactobacillus plantarum in vivo and protective effects on the epithelial barrier, Am J Physiol Gastrointest Liver Physiol, 298, pp. G851-G859, (2010); Qin H., Zhang Z., Hang X., Jiang Y., L. plantarum prevents enteroinvasive Escherichia coli-induced tight junction proteins changes in intestinal epithelial cells, BMC Microbiol, 9, 63, (2009); Zhou Y., Qin H., Zhang M., Shen T., Chen H., Ma Y., Et al., Lactobacillus plantarum inhibits intestinal epithelial barrier dysfunction induced by unconjugated bilirubin, Br J Nutr, 104, pp. 390-401, (2010); Zhou X., Qi W., Hong T., Xiong T., Gong D., Xie M., Et al., Exopolysaccharides from Lactobacillus plantarum NCU116 regulate intestinal barrier function via STAT3 signaling pathway, J Agric Food Chem, 66, pp. 9719-9727, (2018); Kim Y.S., Kim N., Sex-gender differences in irritable bowel syndrome, J Neurogastroenterol Motil, 24, pp. 544-558, (2018); Patel J., Maji B., Moorthy N., Maiti S., Xanthan gum derivatives: review of synthesis, properties and diverse applications, RSC Adv, 10, pp. 27103-27136, (2020); Elsenbruch S., Enck P., Placebo effects and their determinants in gastrointestinal disorders, Nat Rev Gastroenterol Hepatol, 12, pp. 472-485, (2015)","Å.V. Keita; Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden; email: asa.keita@liu.se","","Frontiers Media S.A.","","","","","","2296861X","","","","English","Front. Nutr.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85144496618"

"Awad K.; Barmeyer C.; Bojarski C.; Nagel O.; Lee I.-F.M.; Schweiger M.R.; Schulzke J.-D.; Bücker R.","Awad, Karem (57188694305); Barmeyer, Christian (6506742657); Bojarski, Christian (8764110100); Nagel, Oliver (56444576700); Lee, In-Fah M. (55246172200); Schweiger, Michal R. (9240082000); Schulzke, Jörg-Dieter (35502556700); Bücker, Roland (10043068400)","57188694305; 6506742657; 8764110100; 56444576700; 55246172200; 9240082000; 35502556700; 10043068400","Epithelial Barrier Dysfunction in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) via Downregulation of Claudin-1","2023","Cells","12","24","2846","","","","2","10.3390/cells12242846","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85180645476&doi=10.3390%2fcells12242846&partnerID=40&md5=f90f0281ab39682838b1059689ef6595","Clinical Physiology/Nutritional Medicine, Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité—Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, 12203, Germany; Institute for Translational Epigenetics, Medical Faculty, University of Cologne, Cologne, 50931, Germany","Awad K., Clinical Physiology/Nutritional Medicine, Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité—Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, 12203, Germany; Barmeyer C., Clinical Physiology/Nutritional Medicine, Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité—Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, 12203, Germany; Bojarski C., Clinical Physiology/Nutritional Medicine, Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité—Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, 12203, Germany; Nagel O., Clinical Physiology/Nutritional Medicine, Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité—Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, 12203, Germany; Lee I.-F.M., Clinical Physiology/Nutritional Medicine, Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité—Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, 12203, Germany; Schweiger M.R., Institute for Translational Epigenetics, Medical Faculty, University of Cologne, Cologne, 50931, Germany; Schulzke J.-D., Clinical Physiology/Nutritional Medicine, Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité—Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, 12203, Germany; Bücker R., Clinical Physiology/Nutritional Medicine, Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité—Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, 12203, Germany","Background: In patients with diarrhea-predominant irritable bowel syndrome (IBS-D), the diarrheal mechanisms are largely unknown, and they were examined in this study on colon biopsies. Methods: Electrophysiological measurements were used for monitoring functional changes in the diarrheic colon specimens. In parallel, tight junction protein expression was analyzed by Western blot and confocal laser-scanning microscopy, and signaling pathway analysis was performed using RNA sequencing and bioinformatics. Results: Epithelial resistance was decreased, indicating an epithelial leak flux diarrheal mechanism with a molecular correlate of decreased claudin-1 expression, while induction of active anion secretion and impairment of active sodium absorption via the epithelial sodium channel, ENaC, were not detected. The pathway analysis revealed activation of barrier-affecting cytokines TNF-α, IFN-γ, IL-1β and IL-4. Conclusions: Barrier dysfunction as a result of epithelial tight junction changes plays a role in IBS-D as a pathomechanism inducing a leak flux type of diarrhea. © 2023 by the authors.","claudin-1; intestinal barrier function; irritable bowel syndrome; leaky gut; RNA-seq; tight junctions; tricellulin","Claudin-1; Diarrhea; Down-Regulation; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; androstanolone; claudin 1; claudin 2; claudin 3; claudin 4; claudin 5; cystic fibrosis transmembrane conductance regulator; epithelial sodium channel; gamma interferon; interleukin 13; interleukin 1beta; interleukin 4; kruppel like factor 4; microRNA; occludin; prostaglandin E2; protein ZO1; small interfering RNA; testosterone; tight junction protein; transcriptome; tumor necrosis factor; uvomorulin; claudin 1; adult; apoptosis; Article; bioinformatics; clinical article; colon biopsy; colonoscopy; confocal laser scanning microscopy; confocal microscopy; controlled study; diarrhea; down regulation; electric resistance; epithelium; female; gene expression; gene ontology; histology; homeostasis; human; human cell; human tissue; immune response; immunoblotting; immunofluorescence; impedance spectroscopy; irritable colon; jejunum; male; microscopy; morphometry; protein expression; RNA isolation; RNA sequencing; scanning electron microscopy; signal transduction; signaling pathway analysis; sodium absorption; sodium transport; tight junction; transcytosis; transepithelial resistance; TUNEL assay; upregulation; Western blotting; diarrhea; down regulation; genetics; intestine mucosa; irritable colon; metabolism; pathology","","androstanolone, 521-18-6; claudin 1, 329338-06-9; cystic fibrosis transmembrane conductance regulator, 126880-72-6; gamma interferon, 82115-62-6; interleukin 13, 148157-34-0; occludin, 176304-61-3; prostaglandin E2, 363-24-6; testosterone, 58-22-0; uvomorulin, 112956-45-3; Claudin-1, ","Zeiss LSM 780, Carl Zeiss, Germany; ZeissLSM ZEN software version 2.5.75., Carl Zeiss, Germany","Carl Zeiss, Germany; Carl Zeiss, Germany","Deutsche Forschungsgemeinschaft, DFG, (559/11-5—175142815, GRK 2318—318905415); Charité – Universitätsmedizin Berlin","This research was funded by the Deutsche Forschungsgemeinschaft (DFG) grant GRK 2318—318905415 (project C1) and DFG Schu 559/11-5—175142815. The authors express their gratitude to Dorothee Günzel and Jörg Piontek for the support and the grant for the STED microscope supported by the DFG. The APC was funded by the German Research Foundation and the Open Access Publication Fund of the Charité—Universitätsmedizin Berlin.","Anbazhagan A.N., Priyamvada S., Alrefai W.A., Dudeja P.K., Pathophysiology of IBD associated diarrhea, Tissue Barriers, 6, (2018); Karnsakul W., Lifschitz C., Diarrheal (diarrhoeal) diseases, Encycl. Food Sci. Nutr, pp. 1804-1813, (2003); Lovell R.M., Ford A.C., Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis, Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc, 10, pp. 712-721.e4, (2012); Choung R.S., Locke G.R., Epidemiology of IBS, Gastroenterol. Clin. N. Am, 40, pp. 1-10, (2011); Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Drossman D.A., The functional gastrointestinal disorders and the Rome III process, Gastroenterology, 130, pp. 1377-1390, (2006); Oka P., Parr H., Barberio B., Black C.J., Savarino E.V., Ford A.C., Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: A systematic review and meta-analysis, Lancet Gastroenterol. Hepatol, 5, pp. 908-917, (2020); Hanning N., Edwinson A.L., Ceuleers H., Peters S.A., De Man J.G., Hassett L.C., De Winter B.Y., Grover M., Intestinal barrier dysfunction in irritable bowel syndrome: A systematic review, Ther. Adv. Gastroenterol, 14, (2021); Xi M., Zhao P., Li F., Bao H., Ding S., Ji L., Yan J., MicroRNA-16 inhibits the TLR4/NF-κB pathway and maintains tight junction integrity in irritable bowel syndrome with diarrhea, J. Biol. Chem, 298, (2022); Cheng P., Yao J., Wang C., Zhang L., Kong W., Molecular and cellular mechanisms of tight junction dysfunction in the irritable bowel syndrome, Mol. Med. Rep, 12, pp. 3257-3264, (2015); Ishimoto H., Oshima T., Sei H., Yamasaki T., Kondo T., Tozawa K., Tomita T., Ohda Y., Fukui H., Watari J., Et al., Claudin-2 expression is upregulated in the ileum of diarrhea predominant irritable bowel syndrome patients, J. Clin. Biochem. Nutr, 60, pp. 146-150, (2017); Cording J., Berg J., Kading N., Bellmann C., Tscheik C., Westphal J.K., Milatz S., Gunzel D., Wolburg H., Piontek J., Et al., In tight junctions, claudins regulate the interactions between occludin, tricellulin and marvelD3, which, inversely, modulate claudin oligomerization, J. Cell Sci, 126, pp. 554-564, (2013); Tsukita S., Tanaka H., Tamura A., The Claudins: From Tight Junctions to Biological Systems, Trends Biochem. Sci, 44, pp. 141-152, (2019); Sonoda N., Furuse M., Sasaki H., Yonemura S., Katahira J., Horiguchi Y., Tsukita S., Clostridium perfringens enterotoxin fragment removes specific claudins from tight junction strands: Evidence for direct involvement of claudins in tight junction barrier, J. Cell Biol, 147, pp. 195-204, (1999); Van Itallie C., Rahner C., Anderson J.M., Regulated expression of claudin-4 decreases paracellular conductance through a selective decrease in sodium permeability, J. Clin. Investig, 107, pp. 1319-1327, (2001); Enck A.H., Berger U.V., Yu A.S., Claudin-2 is selectively expressed in proximal nephron in mouse kidney, Am. J. Physiol. Renal. Physiol, 281, (2001); Tsukita S., Furuse M., Claudin-based barrier in simple and stratified cellular sheets, Curr. Opin. Cell Biol, 14, pp. 531-536, (2002); Wen H., Watry D.D., Marcondes M.C., Fox H.S., Selective decrease in paracellular conductance of tight junctions: Role of the first extracellular domain of claudin-5, Mol. Cell. Biol, 24, pp. 8408-8417, (2004); Tsukita S., Furuse M., Itoh M., Structural and signalling molecules come together at tight junctions, Curr. Opin. Cell Biol, 11, pp. 628-633, (1999); Hasler W.L., Grabauskas G., Singh P., Owyang C., Mast cell mediation of visceral sensation and permeability in irritable bowel syndrome, Neurogastroenterol. Motil, 34, (2022); Piche T., Tight junctions and IBS—The link between epithelial permeability, low-grade inflammation, and symptom generation?, Neurogastroenterol. Motil, 26, pp. 296-302, (2014); Pimentel M., Lembo A., Microbiome and Its Role in Irritable Bowel Syndrome, Dig. Dis. Sci, 65, pp. 829-839, (2020); Burgel N., Bojarski C., Mankertz J., Zeitz M., Fromm M., Schulzke J.D., Mechanisms of diarrhea in collagenous colitis, Gastroenterology, 123, pp. 433-443, (2002); Awad K., Barmeyer C., Bojarski C., Nagel O., Lee I.M., Schweiger M.R., Schulzke J.D., Bucker R., Impaired Intestinal Permeability of Tricellular Tight Junctions in Patients with Irritable Bowel Syndrome with Mixed Bowel Habits (IBS-M), Cells, 12, (2023); Barmeyer C., Erko I., Fromm A., Bojarski C., Loddenkemper C., Dames P., Kerick M., Siegmund B., Fromm M., Schweiger M.R., Et al., ENaC Dysregulation Through Activation of MEK1/2 Contributes to Impaired Na<sup>+</sup> Absorption in Lymphocytic Colitis, Inflamm. Bowel Dis, 22, pp. 539-547, (2016); Tai Y.H., Tai C.Y., The conventional short-circuiting technique under-short-circuits most epithelia, J. Membr. Biol, 59, pp. 173-177, (1981); Greig E.R., Boot-Handford R.P., Mani V., Sandle G.I., Decreased expression of apical Na+ channels and basolateral Na<sup>+</sup>, K<sup>+</sup>-ATPase in ulcerative colitis, J. Pathol, 204, pp. 84-92, (2004); Bucker R., Krug S.M., Moos V., Bojarski C., Schweiger M.R., Kerick M., Fromm A., Janssen S., Fromm M., Hering N.A., Et al., Campylobacter jejuni impairs sodium transport and epithelial barrier function via cytokine release in human colon, Mucosal Immunol, 11, pp. 474-485, (2018); Martinez C., Lobo B., Pigrau M., Ramos L., Gonzalez-Castro A.M., Alonso C., Guilarte M., Guila M., de Torres I., Azpiroz F., Et al., Diarrhoea-predominant irritable bowel syndrome: An organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, pp. 1160-1168, (2013); Zhou Q., Costinean S., Croce C.M., Brasier A.R., Merwat S., Larson S.A., Basra S., Verne G.N., MicroRNA 29 targets nuclear factor-κB-repressing factor and Claudin 1 to increase intestinal permeability, Gastroenterology, 148, pp. 158-169.e8, (2015); Coeffier M., Gloro R., Boukhettala N., Aziz M., Lecleire S., Vandaele N., Antonietti M., Savoye G., Bole-Feysot C., Dechelotte P., Et al., Increased proteasome-mediated degradation of occludin in irritable bowel syndrome, Am. J. Gastroenterol, 105, pp. 1181-1188, (2010); Bertrand J., Ghouzali I., Guerin C., Bole-Feysot C., Gouteux M., Dechelotte P., Ducrotte P., Coeffier M., Glutamine Restores Tight Junction Protein Claudin-1 Expression in Colonic Mucosa of Patients with Diarrhea-Predominant Irritable Bowel Syndrome, JPEN J. Parenter Enter. Nutr, 40, pp. 1170-1176, (2016); Huang H., Zhao P., Xi M., Li F., Ji L., Mechanism of QingHuaZhiXie Prescription Regulating TLR4-IECs Pathway in the Intervention of Diarrhea Predominant Irritable Bowel Syndrome, Evid. Based Complement. Altern. Med, 2021, (2021); Omarova S., Awad K., Moos V., Puning C., Golz G., Schulzke J.D., Bucker R., Intestinal Barrier in Post-Campylobacter jejuni Irritable Bowel Syndrome, Biomolecules, 13, (2023)","J.-D. Schulzke; Clinical Physiology/Nutritional Medicine, Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité—Universitätsmedizin Berlin, Berlin, Campus Benjamin Franklin, 12203, Germany; email: joerg.schulzke@charite.de","","Multidisciplinary Digital Publishing Institute (MDPI)","","","","","","20734409","","","38132165","English","Cells","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85180645476"

"Torres-Maravilla E.; Carvalho F.A.; Holowacz S.; Delannoy J.; Lenoir L.; Jacouton E.; Barbut F.; Langella P.; Bermúdez-Humarán L.G.; Waligora-Dupriet A.-J.","Torres-Maravilla, E. (56922108200); Carvalho, F.A. (16041688200); Holowacz, S. (56200615700); Delannoy, J. (57186421200); Lenoir, L. (56801539100); Jacouton, E. (56641711900); Barbut, F. (7005710294); Langella, P. (7003598187); Bermúdez-Humarán, L.G. (6602243913); Waligora-Dupriet, A-J (6506915359)","56922108200; 16041688200; 56200615700; 57186421200; 56801539100; 56641711900; 7005710294; 7003598187; 6602243913; 6506915359","Screening of probiotic strains to improve visceral hypersensitivity in irritable bowel syndrome by using in vitro and in vivo approaches","2024","Beneficial microbes","15","3","","293","310","17","0","10.1163/18762891-bja00006","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85195227914&doi=10.1163%2f18762891-bja00006&partnerID=40&md5=fcc1a66a38cfe6c67d7e7ecbf898604e","AgroParisTech, Micalis Institute, Université Paris-Saclay, France; INSERM, UMRS 1139, Paris, 75006, France; INSERM U1107 NeuroDol, Université Clermont Auvergne, Clermont-Ferrand, France; PiLeJe Laboratoire, 31-35 Rue de la Fédération, Paris, 75015, France; Service de Microbiologie de l'environnement, UHLIN (Unité d'Hygiène et de Lutte contre les Infections Nosocomiales), National Reference Laboratory for Clostridium difficile, Groupe Hospitalier de l'Est Parisien (HUEP) Site Saint-Antoine, Paris, 75012, France","Torres-Maravilla E., AgroParisTech, Micalis Institute, Université Paris-Saclay, France, INSERM, UMRS 1139, Paris, 75006, France; Carvalho F.A., INSERM U1107 NeuroDol, Université Clermont Auvergne, Clermont-Ferrand, France; Holowacz S., PiLeJe Laboratoire, 31-35 Rue de la Fédération, Paris, 75015, France; Delannoy J., INSERM, UMRS 1139, Paris, 75006, France; Lenoir L., PiLeJe Laboratoire, 31-35 Rue de la Fédération, Paris, 75015, France; Jacouton E., PiLeJe Laboratoire, 31-35 Rue de la Fédération, Paris, 75015, France; Barbut F., INSERM, UMRS 1139, Paris, 75006, France, Service de Microbiologie de l'environnement, UHLIN (Unité d'Hygiène et de Lutte contre les Infections Nosocomiales), National Reference Laboratory for Clostridium difficile, Groupe Hospitalier de l'Est Parisien (HUEP) Site Saint-Antoine, Paris, 75012, France; Langella P., AgroParisTech, Micalis Institute, Université Paris-Saclay, France; Bermúdez-Humarán L.G., AgroParisTech, Micalis Institute, Université Paris-Saclay, France; Waligora-Dupriet A.-J., INSERM, UMRS 1139, Paris, 75006, France","Oral administration of probiotics has been proposed as a promising biotherapy to prevent and treat different diseases related to gastrointestinal disorders, such as irritable bowel syndrome (IBS). Due to the increasing research area on the characterisation of new probiotic bacterial strains, it is necessary to perform suitable in vitro experiments, using pertinent cellular models, in order to establish appropriate readout profiles based on IBS symptoms and subtypes. In this work, a collection of 30 candidate strains, belonging mainly to the Lactobacillus and Bifidobacterium genera, were screened using three different sets of in vitro experiments with different readouts to identify promising probiotic strains with: (1) the ability to inhibit the synthesis of IL-8 production by TNF-α stimulated HT-29 cells, (2) immunomodulatory properties quantified as increased IL-10 levels in peripheral blood mononuclear cell (PBMCs), and (3) the ability to maintain epithelial barrier integrity by increasing the trans-epithelial/endothelial electrical resistance (TEER) values in Caco-2 cells. Based on these criteria, three strains were selected: Lactobacillus gasseri PI41, Lacticaseibacillus rhamnosus PI48 and Bifidobacterium animalis subsp. lactis PI50, and tested in a murine model of low-grade inflammation induced by dinitrobenzene sulfonic acid (DNBS), which mimics some of the symptoms of IBS. Among the three strains, L. gasseri PI41 improved overall host well-being by preventing body weight loss in DNBS-treated mice and restored gut homeostasis by normalising the intestinal permeability and reducing pro-inflammatory markers. Therefore, the potential of this strain was confirmed in a second murine model known to reproduce IBS symptoms: the neonatal maternal separation (NMS) model. The PI41 strain was effective in preventing intestinal permeability and reducing colonic hypersensitivity. In conclusion, the set of in vitro experiments combined with in vivo assessments allowed us to identify a promising probiotic candidate strain, L. gasseri PI41, in the context of IBS.","","Animals; Bifidobacterium; Bifidobacterium animalis; Caco-2 Cells; Disease Models, Animal; HT29 Cells; Humans; Interleukin-10; Interleukin-8; Irritable Bowel Syndrome; Lacticaseibacillus rhamnosus; Lactobacillus; Lactobacillus gasseri; Leukocytes, Mononuclear; Male; Mice; Probiotics; interleukin 10; interleukin 8; probiotic agent; animal; Bifidobacterium; Bifidobacterium animalis; Caco-2 cell line; disease model; HT-29 cell line; human; immunology; irritable colon; Lactobacillus; Lactobacillus gasseri; Lactobacillus rhamnosus; male; metabolism; microbiology; mononuclear cell; mouse; physiology; therapy","","interleukin 8, 114308-91-7; Interleukin-10, ; Interleukin-8, ","","","","","","","","","","","","","","18762891","","","38677716","English","Benef Microbes","Article","Final","","Scopus","2-s2.0-85195227914"

"Cui L.; Zou S.; Liu J.; Lv H.; Li H.; Zhang Z.","Cui, Li (55189436500); Zou, Shuting (58731982700); Liu, Jing (59062363500); Lv, Huixia (35364715600); Li, Hui (57196364139); Zhang, Zhenhai (55658029100)","55189436500; 58731982700; 59062363500; 35364715600; 57196364139; 55658029100","Potential effects of sodium hyaluronate on constipation-predominant irritable bowel syndrome","2024","International Immunopharmacology","127","","111404","","","","0","10.1016/j.intimp.2023.111404","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85180612456&doi=10.1016%2fj.intimp.2023.111404&partnerID=40&md5=781ed588099957e204192fe429660b5b","Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210028, China; School of Pharmacy, China Pharmaceutical University, Nanjing, 211198, China","Cui L., Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210028, China; Zou S., Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210028, China; Liu J., Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210028, China; Lv H., School of Pharmacy, China Pharmaceutical University, Nanjing, 211198, China; Li H., Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210028, China; Zhang Z., Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210028, China","Treatment strategies for constipation-predominant irritable bowel syndrome (IBS-C) continue to improve. However, effective drugs are still lacking. Herein, we explored whether sodium hyaluronate (SH) could be used to treat IBS-C. The effects of SH with different molecular weights were compared in a rat model of IBS-C. Low-molecular-weight SH (LMW-SH, 5 ∼ 10 kDa), medium-molecular-weight SH (MMW-SH, 200 ∼ 400 kDa), and high-molecular-weight SH (HMW-SH, 1300 ∼ 1500 kDa) were screened for efficacy in IBS-C using the following indicators: body weight, number of fecal pellets, fecal moisture, visceral hypersensitivity, and gastrointestinal transit rate. H-HMW-SH was the most effective in improving IBS-C symptoms. The ELISA kits indicated that H-HMW-SH reduced the levels of pro-inflammatory cytokines IL-1β, IL-18, and TNF-α in IBS-C rats. In addition, both western blot and immunofluorescence analyses showed that H-HMW-SH increased the protein expressions of claudin-1, occludin and zonula occludens-1. Furthermore, H-HMW-SH restored the balance of intestinal flora in different intestinal contents (duodenum, jejunum, ileum, and colon) and feces of rats with IBS-C. Overall, our study illustrates the therapeutic potential of H-HMW-SH in the treatment of IBS-C. © 2023 Elsevier B.V.","Constipation-predominant irritable bowel syndrome; Gut barrier; Gut microbiota; Inflammatory cytokines; Molecular weight; Sodium hyaluronate","Animals; Claudin-1; Constipation; Cytokines; Diarrhea; Hyaluronic Acid; Irritable Bowel Syndrome; Rats; claudin 1; hyaluronic acid; interleukin 18; interleukin 1beta; linaclotide; occludin; protein ZO1; tumor necrosis factor; ultraha; claudin 1; cytokine; hyaluronic acid; animal experiment; animal model; Article; body weight; colon; constipation; controlled study; digestive tract parameters; drug efficacy; drug megadose; duodenum; fecal moisture; fecal pellet; gastrointestinal transit; ileum; immunofluorescence; intestine flora; irritable colon; jejunum; low drug dose; male; microbial community; microbial diversity; molecular weight; nonhuman; protein expression; rat; rat model; species richness; visceral hyperalgesia; Western blotting; animal; constipation; diarrhea; irritable colon; metabolism","","claudin 1, 329338-06-9; hyaluronic acid, 31799-91-4, 9004-61-9, 9067-32-7; interleukin 18, 189304-55-0; linaclotide, 851199-59-2, 851199-60-5; occludin, 176304-61-3; Claudin-1, ; Cytokines, ; Hyaluronic Acid, ","ultraha, Bloomage Biotech, China","Bloomage Biotech, China","Jiangsu Provincial TCM Science and Technology Development Plan Project, (MS2021025); Natural Science Foundation of Nanjing University of Chinese Medicine, (XZR2020025); Social Development Project of Jiangsu Province, (BE2022817); National Natural Science Foundation of China, NSFC, (81403121); National Natural Science Foundation of China, NSFC","This work was financially supported by the National Natural Science Foundation of China ( 81403121 ), Social Development Project of Jiangsu Province ( BE2022817 ), Jiangsu Provincial TCM Science and Technology Development Plan Project ( MS2021025 ), and the Natural Science Foundation of Nanjing University of Chinese Medicine ( XZR2020025 ).","Liu J., Lv C., Wang W., Huang Y., Wang B., Tian J., Sun C., Yu Y., Slow, deep breathing intervention improved symptoms and altered rectal sensitivity in patients with constipation-predominant irritable bowel syndrome, Front. Neurosci., 16, (2022); Xiao L., Liu Q., Luo M., Xiong L., Gut microbiota-derived metabolites in irritable bowel syndrome, Front. Cell. Infect. Microbiol., 11, (2021); Pimentel M., Lembo A., Microbiome and its role in irritable bowel syndrome, Dig. Dis. Sci., 65, 3, pp. 829-839, (2020); Mertz H., Morgan V., Tanner G., Pickens D., Price R., Shyr Y., Kessler R., Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention, Gastroenterology, 118, 5, pp. 842-848, (2000); Attaluri A., Jackson M., Valestin J., Rao S.S., Methanogenic flora is associated with altered colonic transit but not stool characteristics in constipation without IBS, Am. J. Gastroenterol., 105, 6, pp. 1407-1411, (2010); Wen Y., Li J., Long Q., Yue C.C., He B., Tang X.G., The efficacy and safety of probiotics for patients with constipation-predominant irritable bowel syndrome: a systematic review and meta-analysis based on seventeen randomized controlled trials, Int. J. Surg., 79, pp. 111-119, (2020); Filippone A., Ardizzone A., Bova V., Lanza M., Casili G., Cuzzocrea S., Esposito E., Campolo M., Paterniti I., A combination of xyloglucan, pea protein and chia seed ameliorates intestinal barrier integrity and mucosa functionality in a rat model of constipation-predominant irritable bowel syndrome, J. Clin. Med., 11, 23, (2022); Schmulson M., Pulido-London D., Rodriguez O., Morales-Rochlin N., Martinez-Garcia R., Gutierrez-Ruiz M.C., Lopez-Alvarenga J.C., Robles-Diaz G., Gutierrez-Reyes G., Lower serum IL-10 is an independent predictor of IBS among volunteers in Mexico, Am. J. Gastroenterol., 107, 5, pp. 747-753, (2012); Bashashati M., Moradi M., Sarosiek I., Interleukin-6 in irritable bowel syndrome: a systematic review and meta-analysis of IL-6 (-G174C) and circulating IL-6 levels, Cytokine, 99, pp. 132-138, (2017); Macsharry J., O'Mahony L., Fanning A., Bairead E., Sherlock G., Tiesman J., Fulmer A., Kiely B., Dinan T.G., Shanahan F., Quigley E.M., Mucosal cytokine imbalance in irritable bowel syndrome, Scand. J. Gastroenterol., 43, 12, pp. 1467-1476, (2008); Ohman L., Isaksson S., Lundgren A., Simren M., Sjovall H., A controlled study of colonic immune activity and beta7+ blood T lymphocytes in patients with irritable bowel syndrome, Clin. Gastroenterol. Hepatol., 3, 10, pp. 980-986, (2005); Lazaridis N., Germanidis G., Current insights into the innate immune system dysfunction in irritable bowel syndrome, Ann. Gastroenterol., 31, 2, pp. 171-187, (2018); Wojdasiewicz P., Poniatowski L.A., Szukiewicz D., The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis, Mediators Inflamm., 2014, (2014); Korner E., Lorentz A., Fecal microbiota transplantation in patients with irritable bowel syndrome: an overview of current studies, J. Appl. Microbiol., (2023); Chen H., Ou R., Tang N., Su W., Yang R., Yu X., Zhang G., Jiao J., Zhou X., Alternation of the gut microbiota in irritable bowel syndrome: an integrated analysis based on multicenter amplicon sequencing data, J. Transl. Med., 21, 1, (2023); Kim G.H., Lee K., Shim J.O., Gut bacterial dysbiosis in irritable bowel syndrome: a case-control study and a cross-cohort analysis using publicly available data sets, Microbiol. Spectr., 11, 1, (2023); Jacobs J.P., Lagishetty V., Hauer M.C., Labus J.S., Dong T.S., Toma R., Vuyisich M., Naliboff B.D., Lackner J.M., Gupta A., Tillisch K., Mayer E.A., Multi-omics profiles of the intestinal microbiome in irritable bowel syndrome and its bowel habit subtypes, Microbiome, 11, 1, (2023); Rangan V., Ballou S., Shin A., Camilleri M., Gastroenterology, 158, 3, pp. 786-788, (2020); Chircov C., Grumezescu A.M., Bejenaru L.E., Hyaluronic acid-based scaffolds for tissue engineering, Rom. J. Morphol. Embryol., 59, 1, pp. 71-76, (2018); Hu L., Nomura S., Sato Y., Takagi K., Ishii T., Honma Y., Watanabe K., Mizukami Y., Muto J., Anti-inflammatory effects of differential molecular weight Hyaluronic acids on UVB-induced calprotectin-mediated keratinocyte inflammation, J. Dermatol. Sci., 107, 1, pp. 24-31, (2022); Jiang D., Liang J., Noble P.W., Hyaluronan as an immune regulator in human diseases, Physiol. Rev., 91, 1, pp. 221-264, (2011); Noble P.W., Hyaluronan and its catabolic products in tissue injury and repair, Matrix Biol., 21, 1, pp. 25-29, (2002); Cyphert J.M., Trempus C.S., Garantziotis S., Size matters: molecular weight specificity of hyaluronan effects in cell biology, Int J Cell Biol, 2015, (2015); Heldin P., Lin C.Y., Kolliopoulos C., Chen Y.H., Skandalis S.S., Regulation of hyaluronan biosynthesis and clinical impact of excessive hyaluronan production, Matrix Biol., 78-79, pp. 100-117, (2019); Fiorino G., Gilardi D., Naccarato P., Sociale O.R., Danese S., Safety and efficacy of sodium hyaluronate (IBD98E) in the induction of clinical and endoscopic remission in subjects with distal ulcerative colitis, Dig. Liver Dis., 46, 4, pp. 330-334, (2014); Lee J.W., Kim H.H., Hyaluronic acid solution injection for upper and lower gastrointestinal bleeding after failed conventional endoscopic therapy, Dig. Endosc., 26, 2, pp. 285-290, (2014); Witting M., Boreham A., Brodwolf R., Vavrova K., Alexiev U., Friess W., Hedtrich S., Interactions of hyaluronic Acid with the skin and implications for the dermal delivery of biomacromolecules, Mol. Pharm., 12, 5, pp. 1391-1401, (2015); Sedky A.A., Magdy Y., Tadalafil versus linaclotide in gastrointestinal dysfunction and depressive behavior in constipation-predominant irritable bowel syndrome, Life Sci., 256, (2020); Sharman S.K., Islam B.N., Hou Y., Usry M., Bridges A., Singh N., Sridhar S., Rao S., Browning D.D., Sildenafil normalizes bowel transit in preclinical models of constipation, PLoS One, 12, 4, (2017); Pecundo M.H., Chang A.C.G., Chen T., Dela Cruz T.E.E., Ren H., Li N., Full-Length 16S rRNA and ITS gene sequencing revealed rich microbial flora in roots of Cycas spp. in China, Evol Bioinform Online, 17, (2021); Zhang D., Li H., Luo X., Liu D., Wei Q., Ye X., Integrated 16S rDNA, metabolomics, and TNF-alpha/NF-kappaB signaling pathway analyses to explain the modulatory effect of Poria cocos aqueous extract on anxiety-like behavior, Phytomedicine, 104, (2022); Diop K., Diop A., Levasseur A., Mediannikov O., Robert C., Armstrong N., Couderc C., Bretelle F., Raoult D., Fournier P.E., Fenollar F., Microbial culturomics broadens human vaginal flora diversity: genome sequence and description of Prevotella lascolaii sp. nov. isolated from a patient with bacterial vaginosis, OMICS, 22, 3, pp. 210-222, (2018); Cui L., Guan X., Ding W., Luo Y., Wang W., Bu W., Song J., Tan X., Sun E., Ning Q., Liu G., Jia X., Feng L., Scutellaria baicalensis Georgi polysaccharide ameliorates DSS-induced ulcerative colitis by improving intestinal barrier function and modulating gut microbiota, Int. J. Biol. Macromol., 166, pp. 1035-1045, (2021); Li X., Lv H., Shi F., Song J., Zhang Z., The potential therapeutic effects of hydroxypropyl cellulose on acute murine colitis induced by DSS, Carbohydr. Polym., 289, (2022); Ng S.C., Lam E.F., Lam T.T., Chan Y., Law W., Tse P.C., Kamm M.A., Sung J.J., Chan F.K., Wu J.C., Effect of probiotic bacteria on the intestinal microbiota in irritable bowel syndrome, J. Gastroenterol. Hepatol., 28, 10, pp. 1624-1631, (2013); Giamarellos-Bourboulis E., Tang J., Pyleris E., Pistiki A., Barbatzas C., Brown J., Lee C.C., Harkins T.T., Kim G., Weitsman S., Barlow G.M., Funari V.A., Pimentel M., Molecular assessment of differences in the duodenal microbiome in subjects with irritable bowel syndrome, Scand. J. Gastroenterol., 50, 9, pp. 1076-1087, (2015); Maharshak N., Ringel Y., Katibian D., Lundqvist A., Sartor R.B., Carroll I.M., Ringel-Kulka T., Fecal and Mucosa-Associated Intestinal Microbiota in Patients with Diarrhea-Predominant Irritable Bowel Syndrome, Dig. Dis. Sci., 63, 7, pp. 1890-1899, (2018); Liu M., Yang Y., Zhu W., Wu J., Yu X., Li W., Specific TLR-mediated HSP70 activation plays a potential role in host defense against the intestinal parasite Giardia duodenalis, Front. Microbiol., 14, (2023); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Lecleire S., Antonietti M., Gourcerol G., Leroi A.M., Dechelotte P., Menard J.F., Ducrotte P., Coeffier M., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am. J. Gastroenterol., 106, 12, pp. 2165-2173, (2011); Annahazi A., Ferrier L., Bezirard V., Leveque M., Eutamene H., Ait-Belgnaoui A., Coeffier M., Ducrotte P., Roka R., Inczefi O., Gecse K., Rosztoczy A., Molnar T., Ringel-Kulka T., Ringel Y., Piche T., Theodorou V., Wittmann T., Bueno L., Luminal cysteine-proteases degrade colonic tight junction structure and are responsible for abdominal pain in constipation-predominant IBS, Am. J. Gastroenterol., 108, 8, pp. 1322-1331, (2013); Wu Y., Zheng Y., Wang X., Tang P., Guo W., Ma H., Zhang A., Li D., Xie Y., Wang C.Z., Yao H., Wan J.Y., Yuan C.S., Ginseng-containing Sijunzi decoction ameliorates ulcerative colitis by orchestrating gut homeostasis in microbial modulation and intestinal barrier integrity, Am. J. Chin. Med., pp. 1-23, (2023); Loayza J.J.J., Kang S., Schooth L., Teh J.J., de Klerk A., Noon E.K., Zhang J., Hu J., Hamilton A.L., Wilson-O'Brien A., Trakman G.L., Lin W., Ching J., Or L., Sung J.J.Y., Yu J., Ng S.C., Kamm M.A., Morrison M., Effect of food additives on key bacterial taxa and the mucosa-associated microbiota in Crohn's disease. The ENIGMA study, Gut Microbes, 15, 1, (2023); Qi B., Zhang Y., Ren D., Qin X., Wang N., Yang X., Fu brick tea alleviates constipation via regulating the aquaporins-mediated water transport system in association with gut microbiota, J. Agric. Food Chem., 71, 8, pp. 3862-3875, (2023); Yang Y., Li M., Liu Q., Zhao Q., Zeng J., Wang Q., Zhao Y., Du F., Chen Y., Shen J., Luo H., Wang S., Li W., Chen M., Li X., Wang F., Sun Y., Gu L., Xiao Z., Du Y., Wu X., Starch from Pueraria lobata and the amylose fraction alleviates dextran sodium sulfate induced colitis in mice, Carbohydr. Polym., 302, (2023); Llewellyn S.R., Britton G.J., Contijoch E.J., Vennaro O.H., Mortha A., Colombel J.F., Grinspan A., Clemente J.C., Merad M., Faith J.J., Interactions between diet and the intestinal microbiota alter intestinal permeability and colitis severity in Mice, Gastroenterology, 154, 4, pp. 1037-1046, (2018); Brierley S.M., Linden D.R., Neuroplasticity and dysfunction after gastrointestinal inflammation, Nat. Rev. Gastroenterol. Hepatol., 11, 10, pp. 611-627, (2014); Rajilic-Stojanovic M., Biagi E., Heilig H.G., Kajander K., Kekkonen R.A., Tims S., de Vos W.M., Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome, Gastroenterology, 141, 5, pp. 1792-1801, (2011); Jeffery I.B., O'Toole P.W., Ohman L., Claesson M.J., Deane J., Quigley E.M., Simren M., An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota, Gut, 61, 7, pp. 997-1006, (2012); Hou Y., Dong L., Lu X., Shi H., Xu B., Zhong W., Ma L., Wang S., Yang C., He X., Zhao Y., Wang S., Distinctions between fecal and intestinal mucosal microbiota in subgroups of irritable bowel syndrome, Dig. Dis. Sci., 67, 12, pp. 5580-5592, (2022); Gomaa E.Z., Human gut microbiota/microbiome in health and diseases: a review, Antonie Van Leeuwenhoek, 113, 12, pp. 2019-2040, (2020); Sinn D.H., Song J.H., Kim H.J., Lee J.H., Son H.J., Chang D.K., Kim Y.H., Kim J.J., Rhee J.C., Rhee P.L., Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome, Dig. Dis. Sci., 53, 10, pp. 2714-2718, (2008); Ouwehand A.C., Invernici M.M., Furlaneto F.A.C., Messora M.R., (2018); Wang L., Alammar N., Singh R., Nanavati J., Song Y., Chaudhary R., Mullin G.E., Gut microbial dysbiosis in the irritable bowel syndrome: a systematic review and meta-analysis of case-control studies, J. Acad. Nutr. Diet., 120, 4, pp. 565-586, (2020); Ji M., Huang H., Lan X., Correlation between intestinal microflora in irritable bowel syndrome and severity, Dis. Markers, 2022, (2022); Guardado R., Asensi V., Torres J.M., Perez F., Blanco A., Maradona J.A., Carton J.A., Post-surgical enterococcal meningitis: clinical and epidemiological study of 20 cases, Scand. J. Infect. Dis., 38, 8, pp. 584-588, (2006); Zhao J., Bai M., Ning X., Qin Y., Wang Y., Yu Z., Dong R., Zhang Y., Sun S., Expansion of Escherichia-Shigella in gut is associated with the onset and response to immunosuppressive therapy of IgA nephropathy, J Am Soc Nephrol, 33, 12, pp. 2276-2292, (2022); Chen J., Wright K., Davis J.M., Jeraldo P., Marietta E.V., Murray J., Nelson H., Matteson E.L., Taneja V., An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis, Genome Med., 8, 1, (2016); Sheh A., The gastrointestinal microbiota of the common marmoset (Callithrix jacchus), ILAR J., 61, 2-3, pp. 188-198, (2020); Belzer C., Chia L.W., Aalvink S., Chamlagain B., Piironen V., Knol J., de Vos W.M., Microbial metabolic networks at the mucus layer lead to diet-independent butyrate and vitamin B(12) production by intestinal symbionts, MBio, 8, 5, (2017); Kang C., Wang B., Kaliannan K., Wang X., Lang H., Hui S., Huang L., Zhang Y., Zhou M., Chen M., Mi M., Gut microbiota mediates the protective effects of dietary capsaicin against chronic low-grade inflammation and associated obesity induced by high-fat diet, MBio, 8, 3, (2017); Quigley E.M.M., Markinson L., Stevenson A., Treasure F.P., Lacy B.E., Randomised clinical trial: efficacy and safety of the live biotherapeutic product MRx1234 in patients with irritable bowel syndrome, Aliment. Pharmacol. Ther., 57, 1, pp. 81-93, (2023); Kocak E., Akbal E., Koklu S., Ergul B., Can M., The colonic tissue levels of TLR2, TLR4 and nitric oxide in patients with irritable bowel syndrome, Intern. Med., 55, 9, pp. 1043-1048, (2016); Wood J.D., Neuropathophysiology of irritable bowel syndrome, J. Clin. Gastroenterol., 35, 1, pp. S11-S22, (2002)","H. Lv; School of Pharmacy, China Pharmaceutical University, Nanjing, 211198, China; email: lvhuixia@163.com","","Elsevier B.V.","","","","","","15675769","","IINMB","38128311","English","Int. Immunopharmacol.","Article","Final","","Scopus","2-s2.0-85180612456"

"Ozaka S.; Sonoda A.; Ariki S.; Minata M.; Kamiyama N.; Hidano S.; Sachi N.; Ito K.; Kudo Y.; Dewayani A.; Chalalai T.; Ozaki T.; Soga Y.; Fukuda C.; Mizukami K.; Ishizawa S.; Nishiyama M.; Fujitsuka N.; Mogami S.; Kubota K.; Murakami K.; Kobayashi T.","Ozaka, Sotaro (56094787900); Sonoda, Akira (7004117592); Ariki, Shimpei (57218213616); Minata, Mizuki (57226804532); Kamiyama, Naganori (57188694955); Hidano, Shinya (6508296343); Sachi, Nozomi (57195370979); Ito, Kanako (57226796472); Kudo, Yoko (35332411600); Dewayani, Astri (57218165232); Chalalai, Thanyakorn (57194543524); Ozaki, Takashi (57195284895); Soga, Yasuhiro (57216298878); Fukuda, Chiaki (57195366124); Mizukami, Kazuhiro (7005239531); Ishizawa, Shiori (57202194061); Nishiyama, Mitsue (24339049800); Fujitsuka, Naoki (7005396694); Mogami, Sachiko (54883734200); Kubota, Kunitsugu (35074382700); Murakami, Kazunari (57214336895); Kobayashi, Takashi (36067140500)","56094787900; 7004117592; 57218213616; 57226804532; 57188694955; 6508296343; 57195370979; 57226796472; 35332411600; 57218165232; 57194543524; 57195284895; 57216298878; 57195366124; 7005239531; 57202194061; 24339049800; 7005396694; 54883734200; 35074382700; 57214336895; 36067140500","Saireito, a Japanese herbal medicine, alleviates leaky gut associated with antibiotic-induced dysbiosis in mice","2022","PLoS ONE","17","6 June","e0269698","","","","2","10.1371/journal.pone.0269698","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85132155385&doi=10.1371%2fjournal.pone.0269698&partnerID=40&md5=946f7c15bac947270ed7289371f82e7e","Department of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Japan; Department of Gastroenterology, Faculty of Medicine, Oita University, Yufu, Japan; Tsumura Advanced Technology Research Laboratories, Tsumura & Co., Ibaraki, Japan; Tsumura Kampo Research Laboratories, Tsumura & Co., Ibaraki, Japan","Ozaka S., Department of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Japan, Department of Gastroenterology, Faculty of Medicine, Oita University, Yufu, Japan; Sonoda A., Department of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Japan, Department of Gastroenterology, Faculty of Medicine, Oita University, Yufu, Japan; Ariki S., Department of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Japan, Department of Gastroenterology, Faculty of Medicine, Oita University, Yufu, Japan; Minata M., Department of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Japan; Kamiyama N., Department of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Japan; Hidano S., Department of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Japan; Sachi N., Department of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Japan; Ito K., Department of Gastroenterology, Faculty of Medicine, Oita University, Yufu, Japan; Kudo Y., Department of Gastroenterology, Faculty of Medicine, Oita University, Yufu, Japan; Dewayani A., Department of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Japan; Chalalai T., Department of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Japan; Ozaki T., Department of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Japan; Soga Y., Department of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Japan; Fukuda C., Department of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Japan; Mizukami K., Department of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Japan, Department of Gastroenterology, Faculty of Medicine, Oita University, Yufu, Japan; Ishizawa S., Tsumura Advanced Technology Research Laboratories, Tsumura & Co., Ibaraki, Japan; Nishiyama M., Tsumura Advanced Technology Research Laboratories, Tsumura & Co., Ibaraki, Japan; Fujitsuka N., Tsumura Kampo Research Laboratories, Tsumura & Co., Ibaraki, Japan; Mogami S., Tsumura Kampo Research Laboratories, Tsumura & Co., Ibaraki, Japan; Kubota K., Tsumura Kampo Research Laboratories, Tsumura & Co., Ibaraki, Japan; Murakami K., Department of Gastroenterology, Faculty of Medicine, Oita University, Yufu, Japan; Kobayashi T., Department of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Japan","Antibiotics disrupt normal gut microbiota and cause dysbiosis, leading to a reduction in intestinal epithelial barrier function. Disruption of the intestinal epithelial barrier, which is known as “leaky gut”, results in increased intestinal permeability and contributes to the development or exacerbation of gastrointestinal diseases such as inflammatory bowel disease and irritable bowel syndrome. We have previously reported on a murine model of intestinal epithelial barrier dysfunction associated with dysbiosis induced by the administration of ampicillin and vancomycin. Saireito, a traditional Japanese herbal medicine, is often used to treat autoimmune disorders including ulcerative colitis; the possible mechanism of action and its efficacy, however, remains unclear. In this study, we examined the efficacy of Saireito in our animal model for leaky gut associated with dysbiosis. C57BL/6 mice were fed a Saireito diet for the entirety of the protocol (day1-28). To induce colitis, ampicillin and vancomycin were administered in drinking water for the last seven consecutive days (day22-28). As previously demonstrated, treatment with antibiotics caused fecal occult bleeding, cecum enlargement with black discoloration, colon inflammation with epithelial cell apoptosis, and upregulation of pro-inflammatory cytokines. Oral administration of Saireito significantly improved antibiotics-induced fecal occult bleeding and cecum enlargement by suppressing inflammation in the colon. Furthermore, Saireito treatment ensured the integrity of the intestinal epithelial barrier by suppressing apoptosis and inducing cell adhesion proteins including ZO-1, occludin, and E-cadherin in intestinal epithelial cells, which in turn decreased intestinal epithelial permeability. Moreover, the reduced microbial diversity seen in the gut of mice treated with antibiotics was remarkably improved with the administration of Saireito. In addition, Saireito altered the composition of gut microbiota in these mice. These results suggest that Saireito alleviates leaky gut caused by antibiotic-induced dysbiosis. Our findings provide a potentially new therapeutic strategy for antibiotic-related gastrointestinal disorders. Copyright: © 2022 Ozaka et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.","","Ampicillin; Animals; Anti-Bacterial Agents; Colitis; Colitis, Ulcerative; Disease Models, Animal; Drugs, Chinese Herbal; Dysbiosis; Herbal Medicine; Inflammation; Intestinal Mucosa; Japan; Mice; Mice, Inbred C57BL; Vancomycin; acetic acid; ampicillin; antibiotic agent; butyric acid; daikenchuto; fluorescein isothiocyanate dextran; genomic DNA; interleukin 12p40; interleukin 13; interleukin 1beta; interleukin 6; lactoferrin; occludin; propionic acid; protein ZO1; RNA 16S; sairei to; secretory leukocyte proteinase inhibitor; short chain fatty acid; uvomorulin; valeric acid; vancomycin; antiinfective agent; herbaceous agent; vancomycin; animal cell; animal experiment; animal model; animal tissue; apoptosis; Article; blood sampling; cell adhesion; cell culture; cell infiltration; cervical spine dislocation; controlled study; DNA extraction; dysbiosis; female; herbal medicine; histology; immunohistochemistry; inflammatory bowel disease; intestine flora; irritable colon; mass fragmentography; metagenome; mouse; mRNA expression level; nonhuman; occult blood; real time reverse transcription polymerase chain reaction; RNA extraction; scoring system; sequence analysis; TUNEL assay; ulcerative colitis; animal; C57BL mouse; colitis; disease model; dysbiosis; herbal medicine; inflammation; intestine mucosa; Japan; metabolism; ulcerative colitis","","acetic acid, 127-08-2, 127-09-3, 64-19-7, 71-50-1, 6131-90-4; ampicillin, 69-52-3, 69-53-4, 7177-48-2, 74083-13-9, 94586-58-0; butyric acid, 107-92-6, 156-54-7, 461-55-2; daikenchuto, 110445-34-6; fluorescein isothiocyanate dextran, 60842-46-8; interleukin 13, 148157-34-0; lactoferrin, 55599-62-7; occludin, 176304-61-3; propionic acid, 72-03-7, 79-09-4; sairei to, 308068-64-6; uvomorulin, 112956-45-3; valeric acid, 10023-74-2, 109-52-4; vancomycin, 1404-90-6, 1404-93-9; Ampicillin, ; Anti-Bacterial Agents, ; Drugs, Chinese Herbal, ; sairei-to, ; Vancomycin, ","EnVision, Agilent; Infinite 200 PRO, Tecan, Switzerland; LightCycler 96, Hoffmann La Roche, Switzerland; MiSeq, Illumina, United States; PureLink, Thermo, United States; QuantStudio 7, Thermo, United States; TQ8040, Shimadzu, Japan","Agilent; Hoffmann La Roche, Switzerland; Illumina, United States; Shimadzu, Japan; Tecan, Switzerland; Thermo, United States; Thermo, United States","Four Seasons Ladies Clinic; Tsumura & Co.; Taiju Life Social Welfare Foundation; Japan Society for the Promotion of Science, KAKEN, (17K08889, 20K07394, 20K16028, 20K16499, 20K17025, 20K18482, 21K07984); Oita University","This work was supported by Oita University President’s Strategic Discretionary Fund to S.O., S.A., N.K., and N.S., Taiju Life Social Welfare Foundation (http://www.kousei-zigyodan. or.jp/igakukenkyu_zyosei.html) (to N.K.), Four Seasons Ladies Clinic Research Grant (https:// fourseasons096.com/) (to T.K.), Tsumura & Co. (https://www.tsumura.co.jp/) (to K.M.) and Japan Society for the Promotion of Science [grant number (17K08889, 21K07984 to T.K.), (20K18482 to N.K.), (20K17025 to S.A.), (20K16499 to N.S.), (20K16028 to S.O.), (20K07394 to K.M.)]. In this study, we received the financial support from Tsumura & Co. Co-authors include employees of the company (Shiori Ishizawa, Mitsue Nishiyama, Naoki, Fujitsuka, Sachiko Mogami, and Kunitsugu Kubota) that solely provide Saireito and contribute data analysis of gut microbiota (Fig. 6, S2 Fig). We thank Ms. Aiko Yasuda (Oita University), Ms. Mami Koya (Oita University) and Ms. Kumiko Sakai (Oita University) for excellent technical assistance.","Strati F, Pujolassos M, Burrello C, Giuffre MR, Lattanzi G, Caprioli F, Et al., Antibiotic-associated dysbiosis affects the ability of the gut microbiota to control intestinal inflammation upon fecal microbiota transplantation in experimental colitis models, Microbiome, 9, 1, (2021); Kamada N, Seo S, Chen G, Nunez G., Role of the gut microbiota in immunity and inflammatory disease, Nature Reviews Immunology, 13, 5, pp. 321-335, (2013); Keeney K, Yurist-Doutsch S, Arrieta M, Finlay B., Effects of Antibiotics on Human Microbiota and Subsequent Disease, Annual Review of Microbiology, 68, pp. 217-235, (2014); Sturgeon C, Fasano A., Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases, Tissue Barriers, 4, 4, (2016); Pakravan N, Kermanian F, Mahmoudi E., Filtered Kombucha tea ameliorates the leaky gut syndrome in young and old mice model of colitis, Iran J Basic Med Sci, 22, 10, pp. 1158-1165, (2019); Zhu L, Li J, Wei C, Luo T, Deng Z, Fan Y, Et al., A polysaccharide from Fagopyrum esculentum Moench bee pollen alleviates microbiota dysbiosis to improve intestinal barrier function in antibiotic-treated mice, Food Funct, 11, 12, pp. 10519-10533, (2020); Mu Q, Kirby J, Reilly CM, Luo XM., Leaky Gut As a Danger Signal for Autoimmune Diseases, Front Immunol, 8, (2017); Paray BA, Albeshr MF, Jan AT, Rather IA., Leaky Gut and Autoimmunity: An Intricate Balance in Individuals Health and the Diseased State, Int J Mol Sci, 21, 24, (2020); Camilleri M., Leaky gut: mechanisms, measurement and clinical implications in humans, Gut, 68, 8, pp. 1516-1526, (2019); Fukui H., Increased Intestinal Permeability and Decreased Barrier Function: Does It Really Influence the Risk of Inflammation?, Inflamm Intest Dis, 1, 3, pp. 135-145, (2016); Fasano A., Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer, Physiol Rev, 91, 1, pp. 151-175, (2011); Sonoda A, Kamiyama N, Ozaka S, Gendo Y, Ozaki T, Hirose H, Et al., Oral administration of antibiotics results in fecal occult bleeding due to metabolic disorders and defective proliferation of the gut epithelial cell in mice, Genes Cells, 23, 12, pp. 1043-1055, (2018); Ohno S., Roles of Kampo medicine in treating rheumatic diseases, J Trad Med, 24, pp. 73-80, (2007); Kimura K, Nanba S, Tojo A, Matsuoka H, Sugimoto T., Effects of sairei-to on the relapse of steroid-dependent nephrotic syndrome, Am J Chin Med, 18, pp. 45-50, (1990); Endo M, Oikawa T, Hoshino T, Hatori T, Matsumoto T, Hanawa T., Supression of murine colitis by Kampo medicines, with special reference to the efficacy of saireito, J Trad Med, 26, pp. 110-121, (2009); Kato S, Hayashi S, Kitahara Y, Nagasawa K, Aono H, Shibata J, Et al., Saireito (TJ-114), a Japanese traditional herbal medicine, reduces 5-fluorouracil-induced intestinal mucositis in mice by inhibiting cytokine-mediated apoptosis in intestinal crypt cells, PLoS One, 10, 1, (2015); Watanabe T, Yamamoto T, Yoshida M, Fujiwara K, Kageyama-Yahara N, Kuramoto H, Et al., The traditional herbal medicine saireito exerts its inhibitory effect on murine oxazolone-induced colitis via the induction of Th1-polarized immune responses in the mucosal immune system of the colon, Int Arch Allergy Immunol, 151, 2, pp. 98-106, (2010); Dohi T, Ejima C, Kato R, Kawamura YI, Kawashima R, Mizutani N, Et al., Therapeutic potential of follistatin for colonic inflammation in mice, Gastroenterology, 128, 2, pp. 411-423, (2005); Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, Et al., Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells, Nature, 504, 7480, pp. 446-450, (2013); Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Et al., QIIME allows analysis of high-throughput community sequencing data, Nat Methods, 7, 5, pp. 335-336, (2010); Roopchand DE, Carmody RN, Kuhn P, Moskal K, Rojas-Silva P, Turnbaugh PJ, Et al., Dietary Polyphenols Promote Growth of the Gut Bacterium Akkermansia muciniphila and Attenuate High-Fat Diet-Induced Metabolic Syndrome, Diabetes, 64, 8, pp. 2847-2858, (2015); Martini E, Krug SM, Siegmund B, Neurath MF, Becker C., Mend Your Fences: The Epithelial Barrier and its Relationship With Mucosal Immunity in Inflammatory Bowel Disease, Cell Mol Gastroenterol Hepatol, 4, 1, pp. 33-46, (2017); Chelakkot C, Ghim J, Ryu SH., Mechanisms regulating intestinal barrier integrity and its pathological implications, Exp Mol Med, 50, 8, pp. 1-9, (2018); Ho S, Pothoulakis C, Koon HW., Antimicrobial peptides and colitis, Curr Pharm Des, 19, 1, pp. 40-47, (2013); Johansson ME, Phillipson M, Petersson J, Velcich A, Holm L, Hansson GC., The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria, Proc Natl Acad Sci U S A, 105, 39, pp. 15064-15069, (2008); Vancamelbeke M, Vanuytsel T, Farre R, Verstockt S, Ferrante M, Van Assche G, Et al., Genetic and Transcriptomic Bases of Intestinal Epithelial Barrier Dysfunction in Inflammatory Bowel Disease, Inflamm Bowel Dis, 23, 10, pp. 1718-1729, (2017); Luissint AC, Parkos CA, Nusrat A., Inflammation and the Intestinal Barrier: Leukocyte-Epithelial Cell Interactions, Cell Junction Remodeling, and Mucosal Repair, Gastroenterology, 151, 4, pp. 616-632, (2016); Dannappel M, Vlantis K, Kumari S, Polykratis A, Kim C, Wachsmuth L, Et al., RIPK1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis, Nature, 513, 7516, pp. 90-94, (2014); Shi Y, Kellingray L, Zhai Q, Gall GL, Narbad A, Zhao J, Et al., Structural and Functional Alterations in the Microbial Community and Immunological Consequences in a Mouse Model of Antibiotic-Induced Dysbiosis, Front Microbiol, 9, (2018); Shi Y, Zhai Q, Li D, Mao B, Liu X, Zhao J, Et al., Restoration of cefixime-induced gut microbiota changes by Lactobacillus cocktails and fructooligosaccharides in a mouse model, Microbiol Res, 200, pp. 14-24, (2017); Ravisankar S, Tatum R, Garg PM, Herco M, Shekhawat PS, Chen YH., Necrotizing enterocolitis leads to disruption of tight junctions and increase in gut permeability in a mouse model, BMC Pediatr, 18, 1, (2018); Kim SW, Peck KR, Jung SI, Kim YS, Kim S, Lee NY, Et al., Pseudomonas aeruginosa as a potential cause of antibiotic-associated diarrhea, J Korean Med Sci, 16, 6, pp. 742-744, (2001); Chuang CH, Wang YH, Chang HJ, Chen HL, Huang YC, Lin TY, Et al., Shanghai fever: a distinct Pseudomonas aeruginosa enteric disease, Gut, 63, 5, pp. 736-743, (2014); Alnabhani Z, Montcuquet N, Biaggini K, Dussaillant M, Roy M, Ogier-Denis E, Et al., Pseudomonas fluorescens alters the intestinal barrier function by modulating IL-1β expression through hematopoietic NOD2 signaling, Inflamm Bowel Dis, 21, 3, pp. 543-555, (2015); von Klitzing E, Ekmekciu I, Kuhl AA, Bereswill S, Heimesaat MM., Multidrug-resistant Pseudomonas aeruginosa aggravates inflammatory responses in murine chronic colitis, Sci Rep, 8, 1, (2018); Tao S, Xiong Y, Han D, Pi Y, Zhang H, Wang J., N-(3-oxododecanoyl)-l-homoserine lactone disrupts intestinal epithelial barrier through triggering apoptosis and collapsing extracellular matrix and tight junction, J Cell Physiol, 236, 8, pp. 5771-5784, (2021); Tian P, Zhu H, Qian X, Chen Y, Wang Z, Zhao J, Et al., Consumption of Butylated Starch Alleviates the Chronic Restraint Stress-Induced Neurobehavioral and Gut Barrier Deficits Through Reshaping the Gut Microbiota, Front Immunol, 12, (2021); Wu T, Wang X, Xiong H, Deng Z, Peng X, Xiao L, Et al., Bioactives and their metabolites from Tetra-stigma hemsleyanum leaves ameliorate DSS-induced colitis via protecting the intestinal barrier, mitigating oxidative stress and regulating the gut microbiota, Food Funct, 12, 23, pp. 11760-11776, (2021); Luciano L, Hass R, Busche R, von Engelhardt W, Reale E., Withdrawal of butyrate from the colonic mucosa triggers ""mass apoptosis"" primarily in the G0/G1 phase of the cell cycle, Cell Tissue Res, 286, 1, pp. 81-92, (1996); Hass R, Busche R, Luciano L, Reale E, Engelhardt WV., Lack of butyrate is associated with induction of Bax and subsequent apoptosis in the proximal colon of guinea pig, Gastroenterology, 112, 3, pp. 875-881, (1997)","T. Kobayashi; Department of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Japan; email: takashik@oita-u.ac.jp","","Public Library of Science","","","","","","19326203","","POLNC","35704618","English","PLoS ONE","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85132155385"

"Wu H.; Zhan K.; Rao K.; Zheng H.; Qin S.; Tang X.; Huang S.","Wu, Haomeng (57211081140); Zhan, Kai (57220068150); Rao, Kehan (57491348600); Zheng, Huan (57210640207); Qin, Shumin (57189902334); Tang, Xudong (24339251100); Huang, Shaogang (56346213200)","57211081140; 57220068150; 57491348600; 57210640207; 57189902334; 24339251100; 56346213200","Comparison of five diarrhea-predominant irritable bowel syndrome (IBS-D) rat models in the brain-gut-microbiota axis","2022","Biomedicine and Pharmacotherapy","149","","112811","","","","10","10.1016/j.biopha.2022.112811","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85126529037&doi=10.1016%2fj.biopha.2022.112811&partnerID=40&md5=fc7a8943b11ed4b62caf8e9ad10ce460","Xiyuan Hospital China Academy of Chinese Medical Sciences, Beijing, 100091, China; The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China; State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China; Collaborative Innovation Team of Traditional Chinese Medicine in Prevention and Treatment of Functional Gastrointestinal Diseases, Guangzhou, 510120, China; Dongguan Hospital of Guangzhou University of Chinese Medicine, Dongguan, 523000, China","Wu H., Xiyuan Hospital China Academy of Chinese Medical Sciences, Beijing, 100091, China, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China, State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China, Collaborative Innovation Team of Traditional Chinese Medicine in Prevention and Treatment of Functional Gastrointestinal Diseases, Guangzhou, 510120, China; Zhan K., The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China; Rao K., The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China; Zheng H., The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China, Collaborative Innovation Team of Traditional Chinese Medicine in Prevention and Treatment of Functional Gastrointestinal Diseases, Guangzhou, 510120, China; Qin S., The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China, State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China, Collaborative Innovation Team of Traditional Chinese Medicine in Prevention and Treatment of Functional Gastrointestinal Diseases, Guangzhou, 510120, China; Tang X., Xiyuan Hospital China Academy of Chinese Medical Sciences, Beijing, 100091, China; Huang S., The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China, State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China, Collaborative Innovation Team of Traditional Chinese Medicine in Prevention and Treatment of Functional Gastrointestinal Diseases, Guangzhou, 510120, China, Dongguan Hospital of Guangzhou University of Chinese Medicine, Dongguan, 523000, China","The brain-gut-microbiota (BGM) axis is known to be essential for diarrhea-predominant irritable bowel syndrome (IBS-D). In order to evaluate the effects of IBS-D rat models (the central sensitization model, the peripheral sensitization model and the compound model) on the BGM axis, five models were induced in Wistar rats with 4% acetic acid (AD, dissolved 0.4 ml of AD in 9.6 ml of ultrapure water) + wrap restrain stress (WRS), 4% AD, colorectal distention (CRD), WRS, and neonatal maternal separation (NMS). Abdominal withdrawal reflex (AWR) scale scores and the moisture content of feces (MCF) were evaluated on the day of completing modeling. Body weight was measured every 7 days during modeling. Brain gut peptides, cytokine levels, the activity of spinal cord neurons, intestinal mucosal barrier function, and gut microbiota were determined after induction of IBS-D. We found intervention with 4% AD + WRS, 4% AD, CRD, WRS, and NMS induced a similar course of effects on the BGM axis. Among the five models, AWR scores (60 mmHg, 80 mmHg) were all increased. The levels of 5-hydroxytryptamine, corticotropin-releasing factor, substance P, and calcitonin gene-related protein in serum rapidly increased, whereas that of neuropeptide Y decreased. C-fos in the spinal cord showed increased neuronal activity. The intestinal permeability was increased and the composition and structure of gut microbiota were changed. In conclusion, the five models could cause changes in BGM axis, but the 4% AD + WRS model was closer to the changes BGM axis of post-inflammatory models of IBS-D. © 2022 The Authors","Acetic acid; Brain-gut-microbiota axis; Colorectal distention; Diarrhea predominant-irritable bowel syndrome; Neonatal maternal separation; Rat models; Wrap restrain stress","Animals; Brain; Diarrhea; Gastrointestinal Microbiome; Irritable Bowel Syndrome; Maternal Deprivation; Rats; Rats, Wistar; acetic acid; calcitonin; calcitonin gene related peptide; corticotropin releasing factor; interleukin 10; interleukin 2; interleukin 4; nuclear factor Y; serotonin; substance P; tumor necrosis factor; animal experiment; animal model; animal tissue; Article; body weight; brain-gut axis; controlled study; diarrhea; DNA extraction; enzyme linked immunosorbent assay; feces; immobilization stress; immunohistochemistry; irritable colon; male; maternal deprivation; moisture; newborn; nonhuman; rat; Western blotting; withdrawal reflex; animal; brain; diarrhea; intestine flora; metabolism; Wistar rat","","acetic acid, 127-08-2, 127-09-3, 64-19-7, 71-50-1, 6131-90-4; calcitonin, 12321-44-7, 21215-62-3, 9007-12-9; calcitonin gene related peptide, 83652-28-2; corticotropin releasing factor, 9015-71-8, 178359-01-8, 79804-71-0, 86297-72-5, 86784-80-7; interleukin 2, 85898-30-2; serotonin, 50-67-9; substance P, 33507-63-0","GeneAmp 9700, ABI, United States; NanoDrop 2000, Thermo, United States","ABI, United States; Thermo, United States","City School-College Union-Fundamentals and Application Fundamentals, (202102010207, 202102010226); Guangdong Medical Science and Technology Research Fund Project, (A2017394, A2020181); Traditional Chinese Medicine Research Project of Guangdong Provincial Bureau of Traditional Chinese Medicine, (20192024, 20222074); Traditional Chinese Medicine in Prevention and Treatment of Functional Gastrointestinal Diseases, (2021xk63); National Natural Science Foundation of China, NSFC, (81703992, 81974563); Natural Science Foundation of Beijing Municipality, (7192184); Guangzhou Municipal Science and Technology Project","Funding text 1: This work was supported by the National Natural Science Foundation of China (Grant nos. 81974563 and 81703992 ), Natural Science Foundation of Beijing Municipality ( 7192184 )， Guangzhou Science and Technology Project, City School-College Union-Fundamentals and Application Fundamentals ( 202102010226 , 202102010207 ), Guangdong Medical Science and Technology Research Fund Project (No. A2017394 , A2020181 ), and Traditional Chinese Medicine Research Project of Guangdong Provincial Bureau of Traditional Chinese Medicine ( 20192024 , 20222074 ). Project of Collaborative Innovation Team of Traditional Chinese Medicine in Prevention and Treatment of Functional Gastrointestinal Diseases ( 2021xk63 ). ; Funding text 2: This work was supported by the National Natural Science Foundation of China (Grant nos. 81974563 and 81703992), Natural Science Foundation of Beijing Municipality (7192184)?Guangzhou Science and Technology Project, City School-College Union-Fundamentals and Application Fundamentals (202102010226, 202102010207), Guangdong Medical Science and Technology Research Fund Project (No. A2017394, A2020181), and Traditional Chinese Medicine Research Project of Guangdong Provincial Bureau of Traditional Chinese Medicine (20192024, 20222074). Project of Collaborative Innovation Team of Traditional Chinese Medicine in Prevention and Treatment of Functional Gastrointestinal Diseases (2021xk63).","Zhan K., Zheng H., Li J., Wu H., Qin S., Luo L., Huang S., Gut microbiota-bile acid crosstalk in diarrhea-irritable bowel syndrome, Biomed. Res. Int., 2020, (2020); Garsed K., Chernova J., Hastings M., Lam C., Et al., A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea, Gut, 63, pp. 1617-1625, (2014); Black C.J., Burr N.E., Camilleri M., Earnest D.L., Et al., Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis, Gut, 69, pp. 74-82, (2020); Johnson A.C., Greenwood-Van Meerveld B., Critical evaluation of animal models of gastrointestinal disorders, Handb. Exp. Pharm., 239, pp. 289-317, (2017); Mayer E.A., Naliboff B.D., Chang L., Basic pathophysiologic mechanisms in irritable bowel syndrome, Dig. Dis., 19, pp. 212-218, (2001); Tsang S.W., Zhao M., Wu J., Sung J.J., Et al., Nerve growth factor-mediated neuronal plasticity in spinal cord contributes to neonatal maternal separation-induced visceral hypersensitivity in rats, Eur. J. Pain, 16, pp. 463-472, (2012); Williams C.L., Villar R.G., Peterson J.M., Burks T.F., Stress-induced changes in intestinal transit in the rat: a model for irritable bowel syndrome, Gastroenterology, 94, pp. 611-621, (1988); Vannucchi M.G., Evangelista S., Experimental models of irritable bowel syndrome and the role of the enteric neurotransmission, J. Clin. Med., 7, (2018); Qin H.Y., Wu J.C., Tong X.D., Sung J.J., Et al., Systematic review of animal models of post-infectious/post-inflammatory irritable bowel syndrome, J. Gastroenterol., 46, pp. 164-174, (2011); Al-Chaer E.D., Kawasaki M., Pasricha P.J., A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development, Gastroenterology, 119, pp. 1276-1285, (2000); Zhao L., Yang W., Chen Y., Huang F., Et al., A Clostridia-rich microbiota enhances bile acid excretion in diarrhea-predominant irritable bowel syndrome, J. Clin. Invest., 130, pp. 438-450, (2020); La J.H., Kim T.W., Sung T.S., Kang J.W., Et al., Visceral hypersensitivity and altered colonic motility after subsidence of inflammation in a rat model of colitis, World J. Gastroenterol., 9, pp. 2791-2795, (2003); Zou B.C., Dong L., Wang Y., Wang S.H., Et al., Expression and role of 5-HT7 receptor in brain and intestine in rats with irritable bowel syndrome, Chin. Med. J., 120, pp. 2069-2074, (2007); Zhang B., Xue H., Wang W., Chen T., Et al., Comparative proteomic analysis of the brain and colon in three rat models of irritable bowel syndrome, Proteome Sci., 18, 1, (2020); Ma J., Li J.H., Qian M.R., He N., Et al., The comprehensive pathophysiological changes in a novel rat model of postinflammatory visceral hypersensitivity, Faseb J., 33, pp. 13560-13571, (2019); Quigley E.M.M., The gut-brain axis and the microbiome: clues to pathophysiology and opportunities for novel management strategies in irritable bowel syndrome (IBS), J. Clin. Med., 7, (2018); Moloney R.D., Johnson A.C., O'Mahony S.M., Dinan T.G., Et al., Stress and the microbiota-gut-brain axis in visceral pain: relevance to irritable bowel syndrome, Cns Neurosci. Ther., 22, pp. 102-117, (2016); Martin C.R., Osadchiy V., Kalani A., Mayer E.A., The brain-gut-microbiome axis, Cell. Mol. Gastroenterol., 6, pp. 133-148, (2018); Holzer P., Farzi A., Neuropeptides and the microbiota-gut-brain axis, Adv. Exp. Med. Biol., 817, pp. 195-219, (2014); Monnikes H., Lauer G., Arnold R., Peripheral administration of cholecystokinin activates c-fos expression in the locus coeruleus/subcoeruleus nucleus, dorsal vagal complex and paraventricular nucleus via capsaicin-sensitive vagal afferents and CCK-A receptors in the rat, Brain Res., 770, pp. 277-288, (1997); Zhang R., Zou N., Li J., Lv H., Et al., Elevated expression of c-fos in central nervous system correlates with visceral hypersensitivity in irritable bowel syndrome (IBS): a new target for IBS treatment, Int. J. Colorectal Dis., 26, pp. 1035-1044, (2011); Darkoh C., Comer L., Zewdie G., Harold S., Et al., Chemotactic chemokines are important in the pathogenesis of irritable bowel syndrome, PLoS One, 9, (2014); Schmulson M., Pulido-London D., Rodriguez O., Morales-Rochlin N., Et al., Lower serum IL-10 is an independent predictor of IBS among volunteers in Mexico, Am. J. Gastroenterol., 107, pp. 747-753, (2012); Sun J.H., Wu X.L., Meng Y.F., Cheng J., Et al., Electro-acupuncture decreases 5-HT, CGRP and increases NPY in the brain-gut axis in two rat models of Diarrhea-predominant irritable bowel syndrome (D-IBS), Bmc Complement. Altern. Med., (2015); Sohnn W., Lee O.Y., Lee S.P., Lee K.N., Et al., Mast cell number, substance P and vasoactive intestinal peptide in irritable bowel syndrome with diarrhea, Scand. J. Gastroenterol., 49, pp. 43-51, (2014); Martinez C., Lobo B., Pigrau M., Ramos L., Et al., Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, pp. 1160-1168, (2013); Turner J.R., Intestinal mucosal barrier function in health and disease, Nat. Rev. Immunol., 9, pp. 799-809, (2009); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Lecleire S., Et al., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am. J. Gastroenterol., 106, pp. 2165-2173, (2011); Hou Q., Huang Y., Zhu Z., Liao L., Et al., Tong-Xie-Yao-Fang improves intestinal permeability in diarrhoea-predominant irritable bowel syndrome rats by inhibiting the NF-κB and notch signalling pathways, BMC Complement. Altern. Med., 19, (2019); Piche T., Barbara G., Aubert P., des Varannes S.B., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Martinez C., Vicario M., Ramos L., Lobo B., Et al., The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations, Am. J. Gastroenterol., 107, pp. 736-746, (2012); Zhao L., Huang Y., Lu L., Yang W., Et al., Saturated long-chain fatty acid-producing bacteria contribute to enhanced colonic motility in rats, Microbiome, 6, (2018); Traini C., Evangelista S., Girod V., Faussone-Pellegrini M.S., Et al., Changes of excitatory and inhibitory neurotransmitters in the colon of rats underwent to the wrap partial restraint stress, Neurogastroenterol. Motil., 28, pp. 1172-1185, (2016); Drossman D.A., Hasler W.L., Rome IV-functional GI disorders: disorders of gut-brain interaction introduction, Gastroenterology, 150, pp. 1257-1261, (2016); Ma X.X., Wang X.G., Kang N., Chen T., Et al., The effect of Tong-Xie-Yao-Fang on intestinal mucosal mast cells in postinfectious irritable bowel syndrome rats, Evid.-Based Complement. Altern. Med., 2017, (2017); Zhang C.R., Huang Y.Q., Li P.W., Chen X.L., Et al., Ginger relieves intestinal hypersensitivity of diarrhea predominant irritable bowel syndrome by inhibiting proinflammatory reaction, Bmc Complement. Med., 20, (2020); Hou Q.K., Zhu S.L., Zhang C.R., Huang Y.Q., Et al., Berberine improves intestinal epithelial tight junctions by upregulating A20 expression in IBS-D mice (vol. 118, 109206, 2019), Biomed. Pharmcother., (2019); Greenwood-Van Meerveld B., Prusator D.K., Johnson A.C., Animal models of gastrointestinal and liver diseases. Animal models of visceral pain: pathophysiology, translational relevance, and challenges, Am. J. Physiol.-Gastrointest. Liver, 308, pp. G885-G903, (2015); Fan M., Zhang X., Liu J., Wang S., Research progress in functional dyspepsia relevant to traditional Chinese medicine based on the theory of brain-gut axis, Zhong Nan Da Xue Xue Bao Yi Xue Ban., 44, pp. 1300-1305, (2019); Wu Y., He H.X., Cheng Z.B., Bai Y.Y., Et al., The role of neuropeptide Y and peptide YY in the development of obesity via gut-brain axis, Curr. Protein Pept. Sci., 20, pp. 750-758, (2019); Huang W., Jiang S.M., Jia L., You L.Q., Et al., Effect of amitriptyline on gastrointestinal function and brain-gut peptides: a double-blind trial, World J. Gastroenterol., 19, pp. 4214-4220, (2013); Camilleri M., Boeckxstaens G., Dietary and pharmacological treatment of abdominal pain in IBS, Gut, 66, pp. 966-974, (2017); Welgan P., Meshkinpour H., Hoehler F., The effect of stress on colon motor and electrical activity in irritable bowel syndrome, Psychosom. Med., 47, pp. 139-149, (1985); Schou W.S., Ashina S., Amin F.M., Goadsby P.J., Et al., Calcitonin gene-related peptide and pain: a systematic review, J. Headache Pain, (2017); Barreau F., Salvador-Cartier C., Houdeau E., Bueno L., Et al., Long-term alterations of colonic nerve-mast cell interactions induced by neonatal maternal deprivation in rats, Gut, 57, pp. 582-590, (2008); Chatoo M., Li Y., Ma Z., Coote J., Et al., Involvement of corticotropin-releasing factor and receptors in immune cells in irritable bowel syndrome, Front. Endocrinol., 9, (2018); Chang L., The role of stress on physiologic responses and clinical symptoms in irritable bowel syndrome, Gastroenterology, 140, pp. 761-U124, (2011); Kiank C., Tache Y., Larauche M., Stress-related modulation of inflammation in experimental models of bowel disease and post-infectious irritable bowel syndrome: role of corticotropin-releasing factor receptors, Brain Behav. Immun., 24, pp. 41-48, (2010); Gong Z.P., Chen Y., Zhang R.J., Yang Q., Et al., Pharmacokinetic difference of berberine between normal and chronic visceral hypersensitivity irritable bowel syndrome rats and its mechanism, Arch. Pharm. Res., 38, pp. 1888-1896, (2015); Ren T.H., Wu J., Yew D., Ziea E., Et al., Effects of neonatal maternal separation on neurochemical and sensory response to colonic distension in a rat model of irritable bowel syndrome, Am. J. Physiol.-Gastrointest. Liver, 292, pp. G849-G856, (2007); Bercik P., Verdu E.F., Collins S.M., Is irritable bowel syndrome a low-grade inflammatory bowel disease?, Gastroenterol. Clin. N. Am., 34, (2005); Ohman L., Simren M., Pathogenesis of IBs: role of inflammation, immunity and neuroimmune interactions, Nat. Rev. Gastroenterol. Hepat., 7, pp. 163-173, (2010); Ivashkin V., Poluektov Y., Kogan E., Shifrin O., Et al., Disruption of the pro-inflammatory, anti-inflammatory cytokines and tight junction proteins expression, associated with changes of the composition of the gut microbiota in patients with irritable bowel syndrome, PLoS One, 16, (2021); Hughes P.A., Zola H., Penttila I.A., Blackshaw L.A., Et al., Immune activation in irritable bowel syndrome: can neuroimmune interactions explain symptoms?, Am. J. Gastroenterol., 108, pp. 1066-1074, (2013); Dinan T.G., Quigley E.M., Ahmed S.M., Scully P., Et al., Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker?, Gastroenterology, 130, pp. 304-311, (2006); Scully P., McKernan D.P., Keohane J., Groeger D., Et al., Plasma cytokine profiles in females with irritable bowel syndrome and extra-intestinal co-morbidity, Am. J. Gastroenterol., 105, pp. 2235-2243, (2010); Chang L., Adeyemo M., Karagiannidis I., Videlock E.J., Et al., Serum and colonic mucosal immune markers in irritable bowel syndrome, Am. J. Gastroenterol., 107, pp. 262-272, (2012); Hughes P.A., Harrington A.M., Castro J., Liebregts T., Et al., Sensory neuro-immune interactions differ between irritable bowel syndrome subtypes, Gut, 62, pp. 1456-1465, (2013); Swan C., Duroudier N.P., Campbell E., Zaitoun A., Et al., Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNFα, Gut, 62, pp. 985-994, (2013); Malkin C.J., Pugh P.J., Jones R.D., Kapoor D., Et al., The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men, J. Clin. Endocr. Metab., 89, pp. 3313-3318, (2004); Lee J.Y., Kim N., Park J.H., Nam R.H., Et al., Expression of neurotrophic factors, tight junction proteins, and cytokines according to the irritable bowel syndrome subtype and sex, J. Neurogastroenterol., 26, pp. 106-116, (2020); Ganci M., Suleyman E., Butt H., Ball M., The role of the brain-gut-microbiota axis in psychology: the importance of considering gut microbiota in the development, perpetuation, and treatment of psychological disorders, Brain Behav., 9, (2019); Deng Y.Y., Zhou M.F., Wang J.F., Yao J.X., Et al., Involvement of the microbiota-gut-brain axis in chronic restraint stress: disturbances of the kynurenine metabolic pathway in both the gut and brain, Gut Microbes, (2021); Duan R.Q., Zhu S.W., Wang B., Duan L.P., Alterations of gut microbiota in patients with irritable bowel syndrome based on 16S rRNA-targeted sequencing: a systematic review, Clin. Transl. Gastroenterol., 10, (2019); Zhou C., Fang X., Xu J., Gao J., Et al., Bifidobacterium longum alleviates irritable bowel syndrome-related visceral hypersensitivity and microbiota dysbiosis via Paneth cell regulation, Gut Microbes, 12, (2020); Zhou X.Y., Li M., Li X., Long X., Et al., Visceral hypersensitive rats share common dysbiosis features with irritable bowel syndrome patients, World J. Gastroenterol., 22, pp. 5211-5227, (2016); Labus J.S., Hollister E.B., Jacobs J., Kirbach K., Et al., Differences in gut microbial composition correlate with regional brain volumes in irritable bowel syndrome, Microbiome, 5, (2017); Rajilic-Stojanovic M., Biagi E., Heilig H.G., Kajander K., Et al., Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome, Gastroenterology, 141, pp. 1792-1801, (2011); Saulnier D.M., Riehle K., Mistretta T.A., Diaz M.A., Et al., Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome, Gastroenterology, 141, pp. 1782-1791, (2011); Yi W., Cheng J., Wei Q., Pan R., Et al., Effect of temperature stress on gut-brain axis in mice: regulation of intestinal microbiome and central NLRP3 inflammasomes, Sci. Total Environ., 772, (2021); Shin N.R., Whon T.W., Bae J.W., Proteobacteria: microbial signature of dysbiosis in gut microbiota, Trends Biotechnol., 33, pp. 496-503, (2015); Becerra-Castro C., Macedo G., Silva A.M.T., Manaia C.M., Et al., Proteobacteria become predominant during regrowth after water disinfection, Sci. Total Environ., 573, pp. 313-323, (2016); Pittayanon R., Lau J.T., Yuan Y., Leontiadis G.I., Et al., Gut microbiota in patients with irritable bowel syndrome–a systematic review, Gastroenterology, 157, pp. 97-108, (2019); Bonfrate L., Di Palo D.M., Celano G., Albert A., Et al., Effects of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 in IBS patients, Eur. J. Clin. Invest., 50, (2020); Johnson A.C., Farmer A.D., Ness T.J., Greenwood-Van Meerveld B., Critical evaluation of animal models of visceral pain for therapeutics development: a focus on irritable bowel syndrome, Neurogastroenterol. Motil., 32, (2020)","X. Tang; Xiyuan Hospital China Academy of Chinese Medical Sciences, Beijing, 100091, China; email: txdly@sina.com; S. Huang; The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China; email: huangshaogang@gzucm.edu.cn","","Elsevier Masson s.r.l.","","","","","","07533322","","BIPHE","35303570","English","Biomed. Pharmacother.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85126529037"

"King A.J.; Chang L.; Li Q.; Liu L.; Zhu Y.; Pasricha P.J.; Wang J.; Siegel M.; Caldwell J.S.; Edelstein S.; Rosenbaum D.P.; Kozuka K.","King, Andrew J. (59037774100); Chang, Lin (55547137110); Li, Qian (58995049300); Liu, Liansheng (55614048500); Zhu, Yaohui (58995058200); Pasricha, Pankaj J. (7006094347); Wang, Ji (57203720593); Siegel, Matthew (8363955200); Caldwell, Jeremy S. (7402513807); Edelstein, Susan (58563156300); Rosenbaum, David P. (56533299600); Kozuka, Kenji (57073216200)","59037774100; 55547137110; 58995049300; 55614048500; 58995058200; 7006094347; 57203720593; 8363955200; 7402513807; 58563156300; 56533299600; 57073216200","NHE3 inhibitor tenapanor maintains intestinal barrier function, decreases visceral hypersensitivity, and attenuates TRPV1 signaling in colonic sensory neurons","2024","American Journal of Physiology - Gastrointestinal and Liver Physiology","326","5","","G543","G554","11","2","10.1152/AJPGI.00233.2023","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85190901865&doi=10.1152%2fAJPGI.00233.2023&partnerID=40&md5=4a97dcdb63e05fd98afb82a00341c9ca","Ardelyx, Inc., Waltham, MA, United States; Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States; Division of Gastroenterology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States","King A.J., Ardelyx, Inc., Waltham, MA, United States; Chang L., Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States; Li Q., Division of Gastroenterology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States; Liu L., Division of Gastroenterology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States; Zhu Y., Division of Gastroenterology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States; Pasricha P.J., Division of Gastroenterology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States; Wang J., Ardelyx, Inc., Waltham, MA, United States; Siegel M., Ardelyx, Inc., Waltham, MA, United States; Caldwell J.S., Ardelyx, Inc., Waltham, MA, United States; Edelstein S., Ardelyx, Inc., Waltham, MA, United States; Rosenbaum D.P., Ardelyx, Inc., Waltham, MA, United States; Kozuka K., Ardelyx, Inc., Waltham, MA, United States","The pathogenesis of irritable bowel syndrome (IBS) is multifactorial, characterized in part by increased intestinal permeability, and visceral hypersensitivity. Increased permeability is associated with IBS severity and abdominal pain. Tenapanor is FDA-approved for the treatment of IBS with constipation (IBS-C) and has demonstrated improvements in bowel motility and a reduction in IBS-related pain; however, the mechanism by which tenapanor mediates these functions remains unclear. Here, the effects of tenapanor on colonic pain signaling and intestinal permeability were assessed through behavioral, electrophysiological, and cell culture experiments. Intestinal motility studies in rats and humans demonstrated that tenapanor increased luminal sodium and water retention and gastrointestinal transit versus placebo. A significantly reduced visceral motor reflex (VMR) to colonic distension was observed with tenapanor treatment versus vehicle in two rat models of visceral hypersensitivity (neonatal acetic acid sensitization and partial restraint stress; both P < 0.05), returning VMR responses to that of nonsensitized controls. Whole cell voltage patch-clamp recordings of retrogradely labeled colonic dorsal root ganglia (DRG) neurons from sensitized rats found that tenapanor significantly reduced DRG neuron hyperexcitability to capsaicin versus vehicle (P < 0.05), an effect not mediated by epithelial cell secretions. Tenapanor also attenuated increases in intestinal permeability in human colon monolayer cultures caused by incubation with proinflammatory cytokines (P < 0.001) or fecal supernatants from patients with IBS-C (P < 0.005). These results support a model in which tenapanor reduces IBS-related pain by strengthening the intestinal barrier, thereby decreasing permeability to macromolecules and antigens and reducing DRG-mediated pain signaling. © 2024 The Authors.","dorsal root ganglia neurons; intestinal barrier permeability; tenapanor; TRPV1; visceral hypersensitivity","Abdominal Pain; Animals; Capsaicin; Colon; Cytokines; Humans; Intestinal Barrier Function; Irritable Bowel Syndrome; Isoquinolines; Rats; Sensory Receptor Cells; Sodium-Hydrogen Exchanger 3; Sulfonamides; TRPV Cation Channels; acetic acid; antigen; capsaicin; cytokine; macrogol 3350; phenobarbital; placebo; tenapanor; vanilloid receptor 1; capsaicin; isoquinoline derivative; sodium proton exchange protein 3; sulfonamide; tenapanor; TRPV1 protein, human; vanilloid receptor; abdominal pain; adult; animal cell; animal experiment; animal model; animal tissue; Article; cell culture; cellular secretion; colon; constipation; controlled study; electric potential; electromyography; electrophysiology; epithelium cell; female; gastrointestinal transit; human; human cell; hypersensitivity; immobilization stress; intestine motility; intestine mucosa permeability; macromolecule; male; monolayer culture; nerve cell; newborn; nonhuman; patch clamp technique; rat; spinal ganglion; visceral hyperalgesia; water retention; abdominal pain; animal; colon; irritable colon; metabolism; sensory nerve cell","","acetic acid, 127-08-2, 127-09-3, 64-19-7, 71-50-1, 6131-90-4; capsaicin, 404-86-4; phenobarbital, 50-06-6, 57-30-7, 8028-68-0; tenapanor, 1234423-95-0, 1234365-97-9; vanilloid receptor 1, 363242-41-5; sodium proton exchange protein 3, 170349-61-8; Capsaicin, ; Cytokines, ; Isoquinolines, ; Sodium-Hydrogen Exchanger 3, ; Sulfonamides, ; tenapanor, ; TRPV Cation Channels, ; TRPV1 protein, human, ","","","Ardelyx, Inc.; Gilead Sciences; Mayo Clinic","Funding text 1: Funding for medical writing and editorial assistance was provided by Ardelyx, Inc. Funding for the Phase 1 trial was provided by Ardelyx, Inc. Funding for the nonclinical studies was provided by Ardelyx, Inc.; Funding text 2: The authors thank Dr. Muriel Larauche for assisting with preparing fecal supernatants used in determining the cell models of permeability. Medical writing and editorial support were provided by Ashfield MedComms, an Inizio company. A. J. King is currently affiliated with Chinook Therapeutics, Oakland, CA. J. Wang is currently affiliated with Gilead Sciences, Foster City, CA. M. Siegel is currently affiliated with CARGO Therapeutics, San Mateo, CA. J. S. Caldwell is currently affiliated with Versant Ventures, San Diego, CA. Q. Li, L. Liu, and P. J Pasricha are currently affiliated with Mayo Clinic, Scottsdale, AZ. Funding for medical writing and editorial assistance was provided by Ardelyx, Inc. Funding for the Phase 1 trial was provided by Ardelyx, Inc. Funding for the nonclinical studies was provided by Ardelyx, Inc.","Palsson OS, Whitehead W, Tornblom H, Sperber AD, Simren M., Prevalence of Rome IV functional bowel disorders among adults in the United States, Canada, and the United Kingdom, Gastroenterology, 158, pp. 1262-1273, (2020); Lacy BE, Mearin F, Chang L, Chey WD, Lembo AJ, Simren M, Spiller R., Bowel disorders, Gastroenterology, 150, pp. 1393-1407, (2016); Ford AC, Sperber AD, Corsetti M, Camilleri M., Irritable bowel syndrome, Lancet, 396, pp. 1675-1688, (2020); Mishima Y, Ishihara S., Molecular mechanisms of microbiota-mediated pathology in irritable bowel syndrome, Int J Mol Sci, 21, (2020); Hanning N, Edwinson AL, Ceuleers H, Peters SA, De Man JG, Hassett LC, De Winter BY, Grover M., Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review, Therap Adv Gastroenterol, 14, (2021); Ghaffari P, Shoaie S, Nielsen LK., Irritable bowel syndrome and microbiome; Switching from conventional diagnosis and therapies to personalized interventions, J Transl Med, 20, (2022); Camilleri M, Madsen K, Spiller R, Greenwood-Van Meerveld B, Verne GN., Intestinal barrier function in health and gastrointestinal disease, Neurogastroenterol Motil, 24, pp. 503-512, (2012); Long Y, Du L, Kim JJ, Chen B, Zhu Y, Zhang Y, Yao S, He H, Zheng X, Huang Z, Dai N., MLCK-mediated intestinal permeability promotes immune activation and visceral hypersensitivity in PI-IBS mice, Neurogastroenterol Motil, 30, (2018); Park JH, Park DI, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Won KH, Park SM., The relationship between small-intestinal bacterial overgrowth and intestinal permeability in patients with irritable bowel syndrome, Gut Liver, 3, pp. 174-179, (2009); Piche T, Barbara G, Aubert P, Bruley Des Varannes S, Dainese R, Nano JL, Cremon C, Stanghellini V, De Giorgio R, Galmiche JP, Neunlist M., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Vivinus-Nebot M, Dainese R, Anty R, Saint-Paul MC, Nano JL, Gonthier N, Marjoux S, Frin-Mathy G, Bernard G, Hebuterne X, Tran A, Theodorou V, Piche T., Combination of allergic factors can worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells, Am J Gastroenterol, 107, pp. 75-81, (2012); Ait-Belgnaoui A, Bradesi S, Fioramonti J, Theodorou V, Bueno L., Acute stress-induced hypersensitivity to colonic distension depends upon increase in paracellular permeability: role of myosin light chain kinase, Pain, 113, pp. 141-147, (2005); Annahazi A, Ferrier L, Bezirard V, Leveque M, Eutamene H, Ait-Belgnaoui A, Coeffier M, Ducrotte P, Roka R, Inczefi O, Gecse K, Rosztoczy A, Molnar T, Ringel-Kulka T, Ringel Y, Piche T, Theodorou V, Wittmann T, Bueno L., Luminal cysteine-proteases degrade colonic tight junction structure and are responsible for abdominal pain in constipation-predominant IBS, Am J Gastroenterol, 108, pp. 1322-1331, (2013); Bertiaux-Vandaele N, Youmba SB, Belmonte L, Lecleire S, Antonietti M, Gourcerol G, Leroi AM, Dechelotte P, Menard JF, Ducrotte P, Coeffier M., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am J Gastroenterol, 106, pp. 2165-2173, (2011); Quigley EMM, Horn J, Kissous-Hunt M, Crozier RA, Harris LA., Better understanding and recognition of the disconnects, experiences, and needs of patients with irritable bowel syndrome with constipation (BURDEN IBS-C) study: results of an online questionnaire, Adv Ther, 35, pp. 967-980, (2018); Chang L, Sultan S, Lembo A, Verne GN, Smalley W, Heidelbaugh JJ., AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with constipation, Gastroenterology, 163, pp. 118-136, (2022); Trulance (Plecanatide) [Package Insert], (2021); LINZESS (Linaclotide) [Package Insert], (2023); AMITIZA (Lubiprostone) [Package Insert], (2020); ISBRELA (Tenapanor) [Package Insert], (2022); Chey WD, Lembo AJ, Rosenbaum DP., Efficacy of tenapanor in treating patients with irritable bowel syndrome with constipation: a 12-week, placebo-controlled phase 3 trial (T3MPO-1), Am J Gastroenterol, 115, pp. 281-293, (2020); Chey WD, Lembo AJ, Yang Y, Rosenbaum DP., Efficacy of tenapanor in treating patients with irritable bowel syndrome with constipation: a 26-week, placebo-controlled phase 3 trial (T3MPO-2), Am J Gastroenterol, 116, pp. 1294-1303, (2021); Jacobs JW, Leadbetter MR, Bell N, Koo-McCoy S, Carreras CW, He L, Kohler J, Kozuka K, Labonte ED, Navre M, Spencer AG, Charmot D., Discovery of tenapanor: a first-in-class minimally systemic inhibitor of intestinal Na <sup>þ</sup> /H <sup>þ</sup> exchanger isoform 3, ACS Med Chem Lett, 13, pp. 1043-1051, (2022); Spencer AG, Labonte ED, Rosenbaum DP, Plato CF, Carreras CW, Leadbetter MR, Kozuka K, Kohler J, Koo-McCoy S, He L, Bell N, Tabora J, Joly KM, Navre M, Jacobs JW, Charmot D., Intestinal inhibition of the Na <sup>þ</sup> /H <sup>þ</sup> exchanger 3 prevents cardiorenal damage in rats and inhibits Na <sup>þ</sup> uptake in humans, Sci Transl Med, 6, (2014); Johansson S, Rosenbaum DP, Knutsson M, Leonsson-Zachrisson M., A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers, Clin Exp Nephrol, 21, pp. 407-416, (2017); Rosenbaum DP, Yan A, Jacobs JW., Pharmacodynamics, safety, and tolerability of the NHE3 inhibitor tenapanor: two trials in healthy volunteers, Clin Drug Investig, 38, pp. 341-351, (2018); King AJ, Siegel M, He Y, Nie B, Wang J, Koo-McCoy S, Minassian NA, Jafri Q, Pan D, Kohler J, Kumaraswamy P, Kozuka K, Lewis JG, Dragoli D, Rosenbaum DP, O'Neill D, Plain A, Greasley PJ, Jonsson-Rylander AC, Karlsson D, Behrendt M, Stromstedt M, Ryden-Bergsten T, Knopfel T, Pastor Arroyo EM, Hernando N, Marks J, Donowitz M, Wagner CA, Alexander RT, Caldwell JS., Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability, Sci Transl Med, 10, (2018); Williams CL, Villar RG, Peterson JM, Burks TF., Stress-induced changes in intestinal transit in the rat: a model for irritable bowel syndrome, Gastroenterology, 94, pp. 611-621, (1988); Winston J, Shenoy M, Medley D, Naniwadekar A, Pasricha PJ., The vanilloid receptor initiates and maintains colonic hypersensitivity induced by neonatal colon irritation in rats, Gastroenterology, 132, pp. 615-627, (2007); Al-Chaer ED, Kawasaki M, Pasricha PJ., A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development, Gastroenterology, 119, pp. 1276-1285, (2000); Zhu Y, Colak T, Shenoy M, Liu L, Mehta K, Pai R, Zou B, Xie XS, Pasricha PJ., Transforming growth factor beta induces sensory neuronal hyperexcitability, and contributes to pancreatic pain and hyperalgesia in rats with chronic pancreatitis, Mol Pain, 8, (2012); Price TJ, Flores CM., Critical evaluation of the colocalization between calcitonin gene-related peptide, substance P, transient receptor potential vanilloid subfamily type 1 immunoreactivities, and isolectin B4 binding in primary afferent neurons of the rat and mouse, J Pain, 8, pp. 263-272, (2007); Phelps PT, Anthes JC, Correll CC., Cloning and functional characterization of dog transient receptor potential vanilloid receptor-1 (TRPV1), Eur J Pharmacol, 513, pp. 57-66, (2005); Kozuka K, He Y, Koo-McCoy S, Kumaraswamy P, Nie B, Shaw K, Chan P, Leadbetter M, He L, Lewis JG, Zhong Z, Charmot D, Balaa M, King AJ, Caldwell JS, Siegel M., Development and characterization of a human and mouse intestinal epithelial cell monolayer platform, Stem Cell Reports, 9, pp. 1976-1990, (2017); Vara EJ, Brokstad KA, Hausken T, Lied GA., Altered levels of cytokines in patients with irritable bowel syndrome are not correlated with fatigue, Int J Gen Med, 11, pp. 285-291, (2018); Marr EE, Mulhern TJ, Welch M, Keegan P, Caballero-Franco C, Johnson BG, Kasaian M, Azizgolshani H, Petrie T, Charest J, Wiellette E., A platform to reproducibly evaluate human colon permeability and damage, Sci Rep, 13, (2023); Bonetto S, Fagoonee S, Battaglia E, Grassini M, Saracco GM, Pellicano R., Recent advances in the treatment of irritable bowel syndrome, Pol Arch Intern Med, 131, pp. 709-715, (2021); Lembo A., Irritable bowel syndrome medications side effects survey, J Clin Gastroenterol, 38, pp. 776-781, (2004); Akbar A, Yiangou Y, Facer P, Walters JR, Anand P, Ghosh S., Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain, Gut, 57, pp. 923-929, (2008); Dlugosz A, Nowak P, D'Amato M, Mohammadian Kermani G, Nystrom J, Abdurahman S, Lindberg G., Increased serum levels of lipopolysaccharide and antiflagellin antibodies in patients with diarrhea-predominant irritable bowel syndrome, Neurogastroenterol Motil, 27, pp. 1747-1754, (2015); Zhou SY, Gillilland M, Wu X, Leelasinjaroen P, Zhang G, Zhou H, Ye B, Lu Y, Owyang C., FODMAP diet modulates visceral nociception by lipopolysaccharide-mediated intestinal inflammation and barrier dysfunction, J Clin Invest, 128, pp. 267-280, (2018); Turner JR, Black ED, Ward J, Tse CM, Uchwat FA, Alli HA, Donowitz M, Madara JL, Angle JM., Transepithelial resistance can be regulated by the intestinal brush-border Na <sup>þ</sup> /H <sup>þ</sup> exchanger NHE3, Am J Physiol Cell Physiol, 279, pp. C1918-C1924, (2000); Wang F, Sampogna RV, Ware BR., pH dependence of actin self-assembly, Biophys J, 55, pp. 293-298, (1989); Hartsock A, Nelson WJ., Adherens and tight junctions: structure, function and connections to the actin cytoskeleton, Biochim Biophys Acta, 1778, pp. 660-669, (2008); Qin HY, Cheng CW, Tang XD, Bian ZX., Impact of psychological stress on irritable bowel syndrome, World J Gastroenterol, 20, pp. 14126-14131, (2014)","K. Kozuka; Ardelyx, Inc., Waltham, United States; email: kkozuka@ardelyx.com","","American Physiological Society","","","","","","01931857","","APGPD","38252683","English","Am. J. Physiol. Gastrointest. Liver Physiol.","Article","Final","","Scopus","2-s2.0-85190901865"

"Filippone A.; Ardizzone A.; Bova V.; Lanza M.; Casili G.; Cuzzocrea S.; Esposito E.; Campolo M.; Paterniti I.","Filippone, Alessia (57200369301); Ardizzone, Alessio (57216888911); Bova, Valentina (57876785600); Lanza, Marika (57200363172); Casili, Giovanna (57189218376); Cuzzocrea, Salvatore (35492552100); Esposito, Emanuela (56417262900); Campolo, Michela (55364236100); Paterniti, Irene (26041018000)","57200369301; 57216888911; 57876785600; 57200363172; 57189218376; 35492552100; 56417262900; 55364236100; 26041018000","A Combination of Xyloglucan, Pea Protein and Chia Seed Ameliorates Intestinal Barrier Integrity and Mucosa Functionality in a Rat Model of Constipation-Predominant Irritable Bowel Syndrome","2022","Journal of Clinical Medicine","11","23","7073","","","","4","10.3390/jcm11237073","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85143588426&doi=10.3390%2fjcm11237073&partnerID=40&md5=7d01dfe4e75e7b61cf2ebe7c9757657d","Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D’ Alcontres, 31, Messina, 98166, Italy","Filippone A., Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D’ Alcontres, 31, Messina, 98166, Italy; Ardizzone A., Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D’ Alcontres, 31, Messina, 98166, Italy; Bova V., Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D’ Alcontres, 31, Messina, 98166, Italy; Lanza M., Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D’ Alcontres, 31, Messina, 98166, Italy; Casili G., Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D’ Alcontres, 31, Messina, 98166, Italy; Cuzzocrea S., Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D’ Alcontres, 31, Messina, 98166, Italy; Esposito E., Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D’ Alcontres, 31, Messina, 98166, Italy; Campolo M., Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D’ Alcontres, 31, Messina, 98166, Italy; Paterniti I., Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D’ Alcontres, 31, Messina, 98166, Italy","Irritable Bowel Syndrome is a gastrointestinal disorder that affects the large intestine, which encompasses several symptoms including, but not limited to, abdominal pain, bloating and dysmotility. In particular, IBS associated with constipation (IBS-C) is characterized by hard and dry stools and inadequate evacuation and difficulty in defecation. Although several drugs ameliorate intestinal modifications and constipation-associated features, management of IBS is still a challenge. Natural compounds including Xyloglucan and pea protein (XP) and Chia seed powder (CS) are widely known to possess beneficial effects in counteracting several gastrointestinal disorders. Here, we aimed to assess the combined effects of XP and CS to treat constipation-related alterations in an IBS-C rat model. IBS-C was induced by gastric instillation of 2 mL of cold water (0–4 °C) for 14 days and Xiloglucan, Pea protein and Chia seeds (XP + CS) treatment was orally administered for 7 days. On day 22, colon tissues were collected for histological analysis. Our results showed that XP + CS administration attenuated constipation-related parameters by increasing body weight and food and water intake. Upon XP + CS treatment, from day 14 to 22, stool moisture content was restored to physiological level. Colonic tissues from IBS-C rats depicted a disruption of the organ architecture accompanied by edema. Loss of colonic structure was reflected by the marked reduction of tight junction protein expression, Occludin and zona occludens-1 (ZO-1). Administration of XP + CS treatment in IBS-C rats significantly ameliorated the colonic histological parameters and exerted a positive effect on barrier integrity by restoring the expression of Occludin and zona occludens-1 (ZO-1). Our findings demonstrated that the efficacy of XP and CS in managing constipation in rats is due to the ability of these compounds to form a protective barrier fortifying intestinal integrity and gut functionality. © 2022 by the authors.","constipation; intestinal barrier; irritable bowel syndrome (IBS); natural compounds","laxative; occludin; pea protein; protein ZO1; tight junction protein; unclassified drug; xyloglucan; abdominal pain; adult; animal experiment; animal model; animal tissue; Article; body weight gain; chia; colon tissue; combination drug therapy; constipation; controlled study; drug efficacy; drug instillation; edema; fluid intake; food intake; intestine mucosa; irritable colon; male; moisture; nonhuman; protein expression; rat; urine volume; visceral sensitivity index","","occludin, 176304-61-3","","","","","Ardizzone A., Filippone A., Mannino D., Scuderi S.A., Casili G., Lanza M., Cucinotta L., Campolo M., Esposito E., Ulva pertusa, a Marine Green Alga, Attenuates DNBS-Induced Colitis Damage via NF-kappaB/Nrf2/SIRT1 Signaling Pathways, J. Clin. Med, 11, (2022); Li C., Nie S.P., Zhu K.X., Xiong T., Li C., Gong J., Xie M.Y., Effect of Lactobacillus plantarum NCU116 on loperamide-induced constipation in mice, Int. J. Food Sci. Nutr, 66, pp. 533-538, (2015); Lacy B.E., Patel N.K., Rome Criteria and a Diagnostic Approach to Irritable Bowel Syndrome, J. Clin. Med, 6, (2017); Kopczynska M., Mokros L., Pietras T., Malecka-Panas E., Quality of life and depression in patients with irritable bowel syndrome, Przegląd Gastroenterol, 13, pp. 102-108, (2018); Gillman P.K., Tricyclic antidepressant pharmacology and therapeutic drug interactions updated, Br. J. Pharmacol, 151, pp. 737-748, (2007); Marlicz W., Skonieczna-Zydecka K., Krynicka P., Loniewski I., Rydzewska G., Probiotics in irritable bowel syndrome—Is the quest for the right strain over? Rapid review of existing guidelines and recommendations, Przegląd Gastroenterol, 16, pp. 369-382, (2021); Roudsari N.M., Lashgari N.A., Momtaz S., Farzaei M.H., Marques A.M., Abdolghaffari A.H., Natural polyphenols for the prevention of irritable bowel syndrome: Molecular mechanisms and targets; a comprehensive review, Daru, 27, pp. 755-780, (2019); Cao P.Q., Li X.P., Ou-Yang J., Jiang R.G., Huang F.F., Wen B.B., Zhang X.N., Huang J.A., Liu Z.H., The protective effects of yellow tea extract against loperamide-induced constipation in mice, Food Funct, 12, pp. 5621-5636, (2021); Lanza M., Filippone A., Ardizzone A., Casili G., Paterniti I., Esposito E., Campolo M., SCFA Treatment Alleviates Pathological Signs of Migraine and Related Intestinal Alterations in a Mouse Model of NTG-Induced Migraine, Cells, 10, (2021); Soltanian N., Janghorbani M., Effect of flaxseed or psyllium vs. placebo on management of constipation, weight, glycemia, and lipids: A randomized trial in constipated patients with type 2 diabetes, Clin. Nutr. ESPEN, 29, pp. 41-48, (2019); Oh S.J., Fuller G., Patel D., Khalil C., Spalding W., Nag A., Spiegel B.M.R., Almario C.V., Chronic Constipation in the United States: Results From a Population-Based Survey Assessing Healthcare Seeking and Use of Pharmacotherapy, Am. J. Gastroenterol, 115, pp. 895-905, (2020); Campolo M., Casili G., Paterniti I., Filippone A., Lanza M., Ardizzone A., Scuderi S.A., Cuzzocrea S., Esposito E., Effect of a Product Containing Xyloglucan and Pea Protein on a Murine Model of Atopic Dermatitis, Int. J. Mol. Sci, 21, (2020); de Los Rios C.C., Falcon B.S., Arguelles-Arias F., Perez E., Teruel C., Geijo F., Rey E., Long-term safety and efficacy study of a medical device containing xyloglucan, pea protein reticulated with tannins and xylo-oligosaccharides, in patients with diarrhoea-predominant irritable bowel syndrome, Ther. Adv. Gastroenterol, 14, (2021); Emkani M., Oliete B., Saurel R., Pea Protein Extraction Assisted by Lactic Fermentation: Impact on Protein Profile and Thermal Properties, Foods, 10, (2021); Bellini M., Berti G., Bonfrate L., Ciranni F., Di Ciaula A., Di Ruscio M., Dell'Era A., Lambiase C., Noto A., Pancetti A., Et al., Use of GELSECTAN((R)) in Patients with Irritable Bowel Syndrome (IBS): An Italian Experience, Patient Prefer. Adherence, 15, pp. 1763-1774, (2021); Garland V., Herlitz L., Regunathan-Shenk R., Diet-induced oxalate nephropathy from excessive nut and seed consumption, BMJ Case Rep, 13, (2020); Kulczynski B., Kobus-Cisowska J., Taczanowski M., Kmiecik D., Gramza-Michalowska A., The Chemical Composition and Nutritional Value of Chia Seeds-Current State of Knowledge, Nutrients, 11, (2019); Ardizzone A., Lanza M., Casili G., Campolo M., Paterniti I., Cuzzocrea S., Esposito E., Efficacy of a Novel Therapeutic, Based on Natural Ingredients and Probiotics, in a Murine Model of Multiple Food Intolerance and Maldigestion, Nutrients, 14, (2022); Xu J.R., Luo J.Y., Shang L., Kong W.M., Effect of change in an inhibitory neurotransmitter of the myenteric plexus on the pathogenetic mechanism of irritable bowel syndrome subgroups in rat models, Chin. J. Dig. Dis, 7, pp. 89-96, (2006); Lee H.Y., Kim J.H., Jeung H.W., Lee C.U., Kim D.S., Li B., Lee G.H., Sung M.S., Ha K.C., Back H.I., Et al., Effects of Ficus carica paste on loperamide-induced constipation in rats, Food Chem. Toxicol, 50, pp. 895-902, (2012); Xie N., Cui Y., Yin Y.N., Zhao X., Yang J.W., Wang Z.G., Fu N., Tang Y., Wang X.H., Liu X.W., Et al., Effects of two Lactobacillus strains on lipid metabolism and intestinal microflora in rats fed a high-cholesterol diet, BMC Complement. Altern. Med, 11, (2011); Campolo M., Crupi R., Cordaro M., Cardali S.M., Ardizzone A., Casili G., Scuderi S.A., Siracusa R., Esposito E., Conti A., Et al., Co-Ultra PEALut Enhances Endogenous Repair Response Following Moderate Traumatic Brain Injury, Int. J. Mol. Sci, 22, (2021); Filippone A., Casili G., Ardizzone A., Lanza M., Mannino D., Paterniti I., Esposito E., Campolo M., Inhibition of Prolyl Oligopeptidase Prevents Consequences of Reperfusion following Intestinal Ischemia, Biomedicines, 9, (2021); Scuderi S.A., Casili G., Lanza M., Ardizzone A., Pantaleo L., Campolo M., Paterniti I., Cucinotta L., Cuzzocrea S., Esposito E., Efficacy of a Product Containing Xyloglucan and Pea Protein on Intestinal Barrier Function in a Partial Restraint Stress Animal Model, Int. J. Mol. Sci, 23, (2022); Lucarini E., Nocentini A., Bonardi A., Chiaramonte N., Parisio C., Micheli L., Toti A., Ferrara V., Carrino D., Pacini A., Et al., Carbonic Anhydrase IV Selective Inhibitors Counteract the Development of Colitis-Associated Visceral Pain in Rats, Cells, 10, (2021); Saha L., Irritable bowel syndrome: Pathogenesis, diagnosis, treatment, and evidence-based medicine, World J. Gastroenterol, 20, pp. 6759-6773, (2014); Qian Y., Suo H., Du M., Zhao X., Li J., Li G.J., Song J.L., Liu Z., Preventive effect of Lactobacillus fermentum Lee on activated carbon-induced constipation in mice, Exp. Ther. Med, 9, pp. 272-278, (2015); Meng J., Yu H., Ma J., Wang J., Banerjee S., Charboneau R., Barke R.A., Roy S., Morphine induces bacterial translocation in mice by compromising intestinal barrier function in a TLR-dependent manner, PLoS ONE, 8, (2013); Sharma A., Rao S., Constipation: Pathophysiology and Current Therapeutic Approaches, Handb. Exp. Pharmacol, 239, pp. 59-74, (2017); Vriesman M.H., Koppen I.J.N., Camilleri M., Di Lorenzo C., Benninga M.A., Management of functional constipation in children and adults, Nat. Rev. Gastroenterol. Hepatol, 17, pp. 21-39, (2020); Hossen I., Hua W., Ting L., Mehmood A., Jingyi S., Duoxia X., Yanping C., Hongqing W., Zhipeng G., Kaiqi Z., Et al., Phytochemicals and inflammatory bowel disease: A review, Crit. Rev. Food Sci. Nutr, 60, pp. 1321-1345, (2020); Hagan M., Hayee B.H., Rodriguez-Mateos A., (Poly)phenols in Inflammatory Bowel Disease and Irritable Bowel Syndrome: A Review, Molecules, 26, (2021); Pique N., Gomez-Guillen M.D.C., Montero M.P., Xyloglucan, a Plant Polymer with Barrier Protective Properties over the Mucous Membranes: An Overview, Int. J. Mol. Sci, 19, (2018); Campolo M., Lanza M., Filippone A., Paterniti I., Casili G., Scuderi S.A., Ardizzone A., Cuzzocrea S., Esposito E., Evaluation of a Product Containing Xyloglucan and Pea Protein on Skin Barrier Permeability, Skin Pharmacol. Physiol, 33, pp. 231-236, (2020); Gnessi L., Bacarea V., Marusteri M., Pique N., Xyloglucan for the treatment of acute diarrhea: Results of a randomized, controlled, open-label, parallel group, multicentre, national clinical trial, BMC Gastroenterol, 15, (2015); Cong L., Ma J.T., Jin Z.J., Duan L.W., Su W.P., Zheng J., Zhang L.J., Xu J., Li D.F., Efficacy and Safety of High Specific Volume Polysaccharide-A New Type of Dietary Fiber for Treatment of Functional Constipation and IBS-C, J. Nutr. Sci. Vitaminol. (Tokyo), 61, pp. 326-331, (2015); Tamargo A., Cueva C., Laguna L., Moreno-Arribas M.V., Munoz L.A., Understanding the impact of chia seed mucilage on human gut microbiota by using the dynamic gastrointestinal model simgi<sup>®</sup>, J. Funct. Foods, 50, pp. 104-111, (2018); Turner J.R., Intestinal mucosal barrier function in health and disease, Nat. Rev. Immunol, 9, pp. 799-809, (2009)","M. Campolo; Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Messina, Viale Ferdinando Stagno D’ Alcontres, 31, 98166, Italy; email: campolom@unime.it","","MDPI","","","","","","20770383","","","","English","J. Clin. Med.","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85143588426"

"Xing Y.; Xue S.; Wu J.; Zhou J.; Xing F.; Li T.; Nie X.","Xing, Ying (57225022309); Xue, Shan (57217102585); Wu, Jing (57270590000); Zhou, Jianhong (57225019948); Xing, Fangfang (57225021872); Li, Tianxing (57225022480); Nie, Xiaohu (58339464300)","57225022309; 57217102585; 57270590000; 57225019948; 57225021872; 57225022480; 58339464300","Serum Exosomes Derived from Irritable Bowel Syndrome Patient Increase Cell Permeability via Regulating miR-148b-5p/RGS2 Signaling in Human Colonic Epithelium Cells","2021","Gastroenterology Research and Practice","2021","","6655900","","","","8","10.1155/2021/6655900","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85108964495&doi=10.1155%2f2021%2f6655900&partnerID=40&md5=a4496a31db244c5b52cddc4110d7d0e4","Department of Gastroenterology, 72nd Group Army Hospital, Huzhou University, Zhejiang, Huzhou, 313000, China; Huzhou Central Hospital, Affiliated Central Hospital, Huzhou University, Zhejiang, Huzhou, 313000, China","Xing Y., Department of Gastroenterology, 72nd Group Army Hospital, Huzhou University, Zhejiang, Huzhou, 313000, China; Xue S., Department of Gastroenterology, 72nd Group Army Hospital, Huzhou University, Zhejiang, Huzhou, 313000, China; Wu J., Department of Gastroenterology, 72nd Group Army Hospital, Huzhou University, Zhejiang, Huzhou, 313000, China; Zhou J., Department of Gastroenterology, 72nd Group Army Hospital, Huzhou University, Zhejiang, Huzhou, 313000, China; Xing F., Department of Gastroenterology, 72nd Group Army Hospital, Huzhou University, Zhejiang, Huzhou, 313000, China; Li T., Department of Gastroenterology, 72nd Group Army Hospital, Huzhou University, Zhejiang, Huzhou, 313000, China; Nie X., Huzhou Central Hospital, Affiliated Central Hospital, Huzhou University, Zhejiang, Huzhou, 313000, China","Aim. Irritable bowel syndrome (IBS) is a multifactorial functional bowel disorder characterized by disruption of the intestinal barrier. Circulating exosomal microRNAs (miRNAs) are involved in regulating epithelial barrier function, and upregulation of miR-148b-5p has been detected in IBS. However, whether exosomal miR-148-5p is involved in the IBS pathogenesis remains unclear. This study was aimed at investigating the relationship of exosomal miR-148-5p with colonic epithelial permeability. Methods. Exosomes were isolated from the serum of IBS patients and healthy controls. HT-29 cells were cultured with the IBS-derived serum exosomes (IBS-exo). Exosome uptake assay was used to evaluate whether the IBS-exo could be absorbed by HT-29 cells. FITC-Dextran flux and transepithelial/endothelial electrical resistance were measured to evaluate epithelial permeability. A luciferase reporter assay was used to determine whether the regulator of G protein signaling- (RGS-) 2 is a target gene of miR-148b-5p. Results. miR-148b-5p was obviously elevated in the IBS-exo compared to the control-exo. Upregulation of miR-148b-5p was observed in the HT-29 cells cultured with IBS-exo. Exposure to IBS-exo increased cell permeability and decreased RGS2 expression. The IBS-exo-induced alterations were obviously reversed by interfering with the miR-148b-5p expression. Mimicking the IBS-exo treatment, miR-148b-5p overexpression increased cell permeability and downregulated RGS2 expression, which were abrogated by overexpressing RGS2. The luciferase reporter assay revealed that RGS2 was a direct target of miR-148b-5p. Conclusions. Serum-derived exosomes from IBS patients increase colonic epithelial permeability via miR-148b-5p/RGS2 signaling.  © 2021 Ying Xing et al.","","microRNA; microRNA 148b; RGS2 protein; unclassified drug; adult; Article; cell isolation; cell membrane permeability; colon cell line; colon epithelium; controlled study; exosome; human; human cell; intestine motility; irritable colon; pathophysiology; real time polymerase chain reaction; signal transduction; transepithelial resistance; upregulation","","","","","","","Adriani A., Ribaldone D.G., Astegiano M., Durazzo M., Saracco G., Pellicano R., Irritable bowel syndrome: The clinical approach, Panminerva Medica, 60, 4, pp. 213-222, (2018); Masuy I., Pannemans J., Tack J., Irritable bowel syndrome: Diagnosis and management, Minerva Gastroenterologica e Dietologica, 66, 2, pp. 136-150, (2020); Suzuki T., Regulation of the intestinal barrier by nutrients: The role of tight junctions, Animal Science Journal, 91, 1, (2020); Julio-Pieper M., Bravo J.A., Intestinal barrier and behavior, International Review of Neurobiology, 131, pp. 127-141, (2016); Gracie D.J., Ford A.C., Irritable bowel syndrome-type symptoms are associated with psychological comorbidity, reduced quality of life, and health care use in patients with inflammatory bowel disease, Gastroenterology, 153, 1, pp. 324-325, (2017); Hou Q., Huang Y., Zhu Z., Liao L., Chen X., Han Q., Liu F., Tong-Xie-Yao-Fang improves intestinal permeability in diarrhoea-predominant irritable bowel syndrome rats by inhibiting the NF- κ B and notch signalling pathways, BMC Complementary and Alternative Medicine, 19, 1, (2019); Martinez C., Rodino-Janeiro B.K., Lobo B., Stanifer M.L., Klaus B., Granzow M., Gonzalez-Castro A.M., Salvo-Romero E., Alonso-Cotoner C., MiR-16 and miR-125b are involved in barrier function dysregulation through the modulation of claudin-2 and cingulin expression in the jejunum in IBS with diarrhoea, Gut, 66, 9, pp. 1537-1538, (2017); Hou Q., Huang Y., Zhu S., Li P., Chen X., Hou Z., Liu F., MiR-144 increases intestinal permeability in IBS-D rats by targeting OCLN and ZO1, Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology, 44, 6, pp. 2256-2268, (2018); Neudecker V., Haneklaus M., Jensen O., Khailova L., Masterson J.C., Tye H., Biette K., Jedlicka P., Brodsky K.S., Gerich M.E., Myeloid-derived miR-223 regulates intestinal inflammation via repression of the NLRP3 inflammasome, Journal of Experimental Medicine, 214, 6, pp. 1737-1752, (2017); Jacenik D., Cygankiewicz A.I., Fichna J., Mokrowiecka A., Malecka-Panas E., Krajewska W.M., Estrogen signaling deregulation related with local immune response modulation in irritable bowel syndrome, Molecular and Cellular Endocrinology, 471, pp. 89-96, (2018); Van Niel G., D'Angelo G., Raposo G., Shedding light on the cell biology of extracellular vesicles, Nature Reviews Molecular Cell Biology, 19, 4, pp. 213-228, (2018); Pegtel D.M., Gould S.J., Exosomes, Annual Review of Biochemistry, 88, 1, pp. 487-514, (2019); Nedaeinia R., Manian M., Jazayeri M.H., Ranjbar M., Salehi R., Sharifi M., Circulating exosomes and exosomal microRNAs as biomarkers in gastrointestinal cancer, Cancer Gene Therapy, 24, 2, pp. 48-56, (2017); Bui T.M., Mascarenhas L.A., Sumagin R., Extracellular vesicles regulate immune responses and cellular function in intestinal inflammation and repair, Tissue Barriers, 6, 2, ARTICLE E1431038, (2018); Zhou Q., Souba W.W., Croce C.M., Verne G.N., MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome, Gut, 59, 6, pp. 775-784, (2010); Salaga M., Storr M., Martemyanov K.A., Fichna J., RGS proteins as targets in the treatment of intestinal inflammation and visceral pain: New insights and future perspectives, BioEssays, 38, 4, pp. 344-354, (2016); Kang J., Zhang Z., Wang J., Wang G., Yan Y., Qian H., Zhang X., Xu W., Mao F., HucMSCs attenuate IBD through releasing miR148b-5p to inhibit the expression of 15-lox-1 in macrophages, Mediators of Inflammation, 2019, (2019); Livak K.J., Schmittgen T., Analysis of relative gene expression data using real-time quantitative PCR and the 2- ΔΔ CT method, Methods, 25, 4, pp. 402-408, (2001); Thery C., Amigorena S., Raposo G., Clayton A., Isolation and characterization of exosomes from cell culture supernatants and biological fluids, Current Protocols in Cell Biology, 30, 1, (2006); Abels E.R., Breakefield X.O., Introduction to extracellular vesicles: Biogenesis, RNA cargo selection, content, release, and uptake, Cellular and Molecular Neurobiology, 36, 3, pp. 301-312, (2016); Mitsuhashi S., Feldbrugge L., Csizmadia E., Mitsuhashi M., Robson S.C., Moss A.C., Luminal extracellular vesicles (EVs) in inflammatory bowel disease (IBD) exhibit proinflammatory effects on epithelial cells and macrophages, Inflammatory Bowel Diseases, 22, 7, pp. 1587-1595, (2016); Valter M., Verstockt S., Finalet Ferreiro J.A., Cleynen I., Extracellular vesicles in inflammatory bowel disease: Small particles, big players, Journal of Crohn's & Colitis, 15, 3, pp. 499-510, (2021); Chang X., Wang S.-L., Zhao S.-B., Shi Y.-H., Pan P., Gu L., Yao J., Li Z.-S., Bai Y., Extracellular vesicles with possible roles in gut intestinal tract homeostasis and IBD, Mediators of Inflammation, 2020, (2020); Russano M., Napolitano A., Ribelli G., Iuliani M., Simonetti S., Citarella F., Pantano F., Dell'Aquila E., Anesi C., Silvestris N., Argentiero A., Solimando A.G., Vincenzi B., Tonini G., Santini D., Liquid biopsy and tumor heterogeneity in metastatic solid tumors: The potentiality of blood samples, Journal of Experimental & Clinical Cancer Research, 39, 1, (2020); Caterina V., Matteo F., Edoardo D., Vincenzo C., Nicola S., Gerard N., Aldo S., Clinical application of microRNA testing in neuroendocrine tumors of the gastrointestinal tract, Molecules, 19, 2, pp. 2458-2468, (2014); Desantis V., Saltarella I., Lamanuzzi A., Melaccio A., Frassanito M.A., MicroRNAs-based nano-strategies as new therapeutic approach in multiple myeloma to overcome disease progression and drug resistance, International Journal of Molecular Sciences, 21, 9, (2020); Friedrich M., Pracht K., Mashreghi M., Jack H., Radbruch A., Seliger B., The role of the miR-148/-152 family in physiology and disease, European Journal of Immunology, 47, 12, pp. 2026-2038, (2017); Zhuang Y., Peng H., Mastej V., Chen W., MicroRNA regulation of endothelial junction proteins and clinical consequence, Mediators of Inflammation, 2016, (2016); Linder A., Hagberg Thulin M., Damber J.-E., Welen K., Analysis of regulator of G-protein signalling 2 (RGS2) expression and function during prostate cancer progression, Scientific Reports, 8, 1, pp. 17259-17259, (2018); Lechuga S., Ivanov A.I., Disruption of the epithelial barrier during intestinal inflammation: Quest for new molecules and mechanisms, Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1864, 7, pp. 1183-1194, (2017); Martini E., Krug S.M., Siegmund B., Neurath M.F., Becker C., Mend your fences: The epithelial barrier and its relationship with mucosal immunity in inflammatory bowel disease, Cellular and Molecular Gastroenterology and Hepatology, 4, 1, pp. 33-46, (2017); Long Y., Du L., Kim J.J., Chen B., Zhu Y., Zhang Y., Yao S., He H., Zheng X., Huang Z., Dai N., MLCK-mediated intestinal permeability promotes immune activation and visceral hypersensitivity in PI-IBS mice, Neurogastroenterology & Motility, 30, 9, ARTICLE E13348, (2018); Papakonstantinou M.P., Karoussiotis C., Georgoussi Z., RGS2 and RGS4 proteins: New modulators of the κ -opioid receptor signaling, Cellular Signalling, 27, 1, pp. 104-114, (2015); George T., Bell M., Chakraborty M., Siderovski D.P., Giembycz M.A., Newton R., Protective roles for RGS2 in a mouse model of house dust mite-induced airway inflammation, PloS One, 12, (2017); Wu R., Zhang P.A., Liu X., Zhou Y., Xu M., Jiang X., Yan J., Xu G.Y., Decreased miR-325-5p contributes to visceral hypersensitivity through post-transcriptional upregulation of CCL2 in rat dorsal root ganglia, Neuroscience Bulletin, 35, 5, pp. 791-801, (2019)","X. Nie; Huzhou Central Hospital, Affiliated Central Hospital, Huzhou University, Huzhou, Zhejiang, 313000, China; email: xiaohunie1986@126.com","","Hindawi Limited","","","","","","16876121","","","","English","Gastroenterol. Res. Pract.","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85108964495"

"Maëva M.; Elodie B.; Nathalie R.; Manon D.; Marjolène S.; Valentine D.; Morgane M.; Ivan W.; Frédéric D.; Romain V.; Mathieu M.; Esther B.N.; Catherine G.; Nicolas B.; Denis A.; Philippe P.; Harry S.; Jean-Marc C.; Philippe L.; Valérie L.; Mathilde B.; Frédéric Antonio C.","Maëva, Meynier (57434423400); Elodie, Baudu (57434537800); Nathalie, Rolhion (57434460300); Manon, Defaye (57434479700); Marjolène, Straube (57434423500); Valentine, Daugey (57434479800); Morgane, Modoux (57434557400); Ivan, Wawrzyniak (57434537900); Frédéric, Delbac (57434557500); Romain, Villéger (57223197063); Mathieu, Méleine (57434423600); Esther, Borras Nogues (57434499900); Catherine, Godfraind (57434460400); Nicolas, Barnich (7801564380); Denis, Ardid (57434500000); Philippe, Poirier (57434479900); Harry, Sokol (57189696121); Jean-Marc, Chatel (57434519700); Philippe, Langella (57434423700); Valérie, Livrelli (57434460500); Mathilde, Bonnet (57223179033); Frédéric Antonio, Carvalho (16041688200)","57434423400; 57434537800; 57434460300; 57434479700; 57434423500; 57434479800; 57434557400; 57434537900; 57434557500; 57223197063; 57434423600; 57434499900; 57434460400; 7801564380; 57434500000; 57434479900; 57189696121; 57434519700; 57434423700; 57434460500; 57223179033; 16041688200","AhR/IL-22 pathway as new target for the treatment of post-infectious irritable bowel syndrome symptoms","2022","Gut Microbes","14","1","2022997","","","","26","10.1080/19490976.2021.2022997","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85123814767&doi=10.1080%2f19490976.2021.2022997&partnerID=40&md5=6293a6285a81e4ddecf194d6aa62683a","M2iSH, UMR 1071 INSERM, University of Clermont Auvergne, INRAE USC 2018, Clermont-Ferrand, 63001, France; NeuroDol, UMR 1107 INSERM, University of Clermont Auvergne, Clermont-Ferrand, 63001, France; Sorbonne University, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Saint Antoine Hospital, Gastroenterology Department, Paris, F-75012, France; Paris Centre for Microbiome Medicine FHU, Paris, France; Department of Physiology and Pharmacology, Inflammation Research Network, Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, T2N 4N1, AB, Canada; LMGE, CNRS 6023, University of Clermont Auvergne, Clermont-Ferrand, 63001, France; Université Paris-Saclay, Institut National de la Recherche Agronomique et Environnementale (INRAE), AgroParisTech UMR 1319 MICALIS, Jouy-en-Josas, France; CHU Clermont-Ferrand, Neuropathology Unit, Clermont-Ferrand, France; CHU Clermont-Ferrand, Laboratoire de Parasitologie et de Mycologie, Clermont-Ferrand, France","Maëva M., M2iSH, UMR 1071 INSERM, University of Clermont Auvergne, INRAE USC 2018, Clermont-Ferrand, 63001, France, NeuroDol, UMR 1107 INSERM, University of Clermont Auvergne, Clermont-Ferrand, 63001, France; Elodie B., M2iSH, UMR 1071 INSERM, University of Clermont Auvergne, INRAE USC 2018, Clermont-Ferrand, 63001, France, NeuroDol, UMR 1107 INSERM, University of Clermont Auvergne, Clermont-Ferrand, 63001, France; Nathalie R., Sorbonne University, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Saint Antoine Hospital, Gastroenterology Department, Paris, F-75012, France, Paris Centre for Microbiome Medicine FHU, Paris, France; Manon D., NeuroDol, UMR 1107 INSERM, University of Clermont Auvergne, Clermont-Ferrand, 63001, France, Department of Physiology and Pharmacology, Inflammation Research Network, Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, T2N 4N1, AB, Canada, LMGE, CNRS 6023, University of Clermont Auvergne, Clermont-Ferrand, 63001, France; Marjolène S., Sorbonne University, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Saint Antoine Hospital, Gastroenterology Department, Paris, F-75012, France; Valentine D., NeuroDol, UMR 1107 INSERM, University of Clermont Auvergne, Clermont-Ferrand, 63001, France; Morgane M., Sorbonne University, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Saint Antoine Hospital, Gastroenterology Department, Paris, F-75012, France; Ivan W., LMGE, CNRS 6023, University of Clermont Auvergne, Clermont-Ferrand, 63001, France; Frédéric D., LMGE, CNRS 6023, University of Clermont Auvergne, Clermont-Ferrand, 63001, France; Romain V., M2iSH, UMR 1071 INSERM, University of Clermont Auvergne, INRAE USC 2018, Clermont-Ferrand, 63001, France; Mathieu M., NeuroDol, UMR 1107 INSERM, University of Clermont Auvergne, Clermont-Ferrand, 63001, France; Esther B.N., Université Paris-Saclay, Institut National de la Recherche Agronomique et Environnementale (INRAE), AgroParisTech UMR 1319 MICALIS, Jouy-en-Josas, France; Catherine G., M2iSH, UMR 1071 INSERM, University of Clermont Auvergne, INRAE USC 2018, Clermont-Ferrand, 63001, France, CHU Clermont-Ferrand, Neuropathology Unit, Clermont-Ferrand, France; Nicolas B., M2iSH, UMR 1071 INSERM, University of Clermont Auvergne, INRAE USC 2018, Clermont-Ferrand, 63001, France; Denis A., NeuroDol, UMR 1107 INSERM, University of Clermont Auvergne, Clermont-Ferrand, 63001, France; Philippe P., M2iSH, UMR 1071 INSERM, University of Clermont Auvergne, INRAE USC 2018, Clermont-Ferrand, 63001, France, CHU Clermont-Ferrand, Laboratoire de Parasitologie et de Mycologie, Clermont-Ferrand, France; Harry S., Sorbonne University, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Saint Antoine Hospital, Gastroenterology Department, Paris, F-75012, France, Paris Centre for Microbiome Medicine FHU, Paris, France, Université Paris-Saclay, Institut National de la Recherche Agronomique et Environnementale (INRAE), AgroParisTech UMR 1319 MICALIS, Jouy-en-Josas, France; Jean-Marc C., Université Paris-Saclay, Institut National de la Recherche Agronomique et Environnementale (INRAE), AgroParisTech UMR 1319 MICALIS, Jouy-en-Josas, France; Philippe L., Université Paris-Saclay, Institut National de la Recherche Agronomique et Environnementale (INRAE), AgroParisTech UMR 1319 MICALIS, Jouy-en-Josas, France; Valérie L., M2iSH, UMR 1071 INSERM, University of Clermont Auvergne, INRAE USC 2018, Clermont-Ferrand, 63001, France, CHU Clermont-Ferrand, Laboratoire de Parasitologie et de Mycologie, Clermont-Ferrand, France; Mathilde B., M2iSH, UMR 1071 INSERM, University of Clermont Auvergne, INRAE USC 2018, Clermont-Ferrand, 63001, France; Frédéric Antonio C., NeuroDol, UMR 1107 INSERM, University of Clermont Auvergne, Clermont-Ferrand, 63001, France","Alterations in brain/gut/microbiota axis are linked to Irritable Bowel Syndrome (IBS) physiopathology. Upon gastrointestinal infection, chronic abdominal pain and anxio-depressive comorbidities may persist despite pathogen clearance leading to Post-Infectious IBS (PI-IBS). This study assesses the influence of tryptophan metabolism, and particularly the microbiota-induced AhR expression, on intestinal homeostasis disturbance following gastroenteritis resolution, and evaluates the efficacy of IL-22 cytokine vectorization on PI-IBS symptoms. The Citrobacter rodentium infection model in C57BL6/J mice was used to mimic Enterobacteria gastroenteritis. Intestinal homeostasis was evaluated as low-grade inflammation, permeability, mucosa-associated microbiota composition, and colonic sensitivity. Cognitive performances and emotional state of animals were assessed using several tests. Tryptophan metabolism was analyzed by targeted metabolomics. AhR activity was evaluated using a luciferase reporter assay method. One Lactococcus lactis strain carrying an eukaryotic expression plasmid for murine IL-22 (L. lactis IL−22) was used to induce IL-22 production in mouse colonic mucosa. C. rodentium-infected mice exhibited persistent colonic hypersensitivity and cognitive impairments and anxiety-like behaviors after pathogen clearance. These post-infectious disorders were associated with low-grade inflammation, increased intestinal permeability, decrease of Lactobacillaceae abundance associated with the colonic layer, and increase of short-chain fatty acids (SCFAs). During post-infection period, the indole pathway and AhR activity were decreased due to a reduction of tryptophol production. Treatment with L. lactis IL−22 restored gut permeability and normalized colonic sensitivity, restored cognitive performances and decreased anxiety-like behaviors. Data from the video-tracking system suggested an upgrade of welfare for mice receiving the L.lactis IL−22 strain. Our findings revealed that AhR/IL-22 signaling pathway is altered in a preclinical PI-IBS model. IL-22 delivering alleviate PI-IBS symptoms as colonic hypersensitivity, cognitive impairments, and anxiety-like behaviors by acting on intestinal mucosa integrity. Thus, therapeutic strategies targeting this pathway could be developed to treat IBS patients suffering from chronic abdominal pain and associated well-being disorders. © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.","ahr; citrobacter rodentium; colonic-associated microbiota; il-22; lactococcus lactis; Post-infectious ibs; tryptophan; well-being disorders","Animals; Bacteria; Cognition; Depression; Fatty Acids, Volatile; Gastrointestinal Microbiome; Humans; Interleukins; Intestines; Irritable Bowel Syndrome; Mice; Mice, Inbred C57BL; Receptors, Aryl Hydrocarbon; aromatic hydrocarbon receptor; interleukin 22; short chain fatty acid; aromatic hydrocarbon receptor; interleukin derivative; interleukin-22; volatile fatty acid; abdominal pain; animal experiment; animal model; animal tissue; anxiety; Article; behavioral test parameters; Citrobacter rodentium; cognitive function test; colorectal disease; controlled study; edema; enteropathy; epithelium lesion; forced swim test; gas chromatography; gastroenteritis; gastrointestinal infection; goblet cell; histopathology; hole board test; hyperplasia; infection complication; intestine mucosa; Lactobacillaceae; liquid chromatography; low grade inflammation; luciferase assay; male; mass spectrometry; mental performance; microflora; mouse; nonhuman; novel object recognition test; pathogen clearance; real time polymerase chain reaction; tail suspension test; tryptophan metabolism; Y-maze test; animal; bacterium; C57BL mouse; classification; cognition; complication; depression; genetics; human; intestine; intestine flora; irritable colon; isolation and purification; metabolism; microbiology; psychology","","interleukin 22, 457106-70-6, 478219-35-1, 554460-75-2; Fatty Acids, Volatile, ; interleukin-22, ; Interleukins, ; Receptors, Aryl Hydrocarbon, ","","","CPER; Ministère de la Recherche et de la Technologie; Plateforme Scientifique et Technologique; Institut National de la Santé et de la Recherche Médicale, Inserm, (UMR1071, UMR1107); Institut National de la Santé et de la Recherche Médicale, Inserm; Centre National de la Recherche Scientifique, CNRS, (UMR6023); Centre National de la Recherche Scientifique, CNRS; European Regional Development Fund, ERDF, (16-IDEX-0001-CAP 20-25); European Regional Development Fund, ERDF; Région Auvergne-Rhône-Alpes; Université Clermont-Auvergne, UCA; Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement, INRAE, (USC-2018); Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement, INRAE","This work was supported by co-financing from the Region Auvergne-Rhône-Alpes and FEDER in 2015 (“Thématiques émergentes”) and in 2018 (“Pack Ambition Recherche” CNSBACT and CPER Nex-N-Mob). It has also been funded by the French government IDEX-ISITE initiative (Grant number: 16-IDEX-0001-CAP 20-25) of the University of Clermont Auvergne. Maëva Meynier, Elodie Baudu, Romain Villéger and Manon Defaye received grants from the Auvergne-Rhône-Alpes Region, CPER and the FEDER. This work was supported by the « Ministère de la Recherche et de la Technologie », INSERM and University of Clermont Auvergne [UMR1071, UMR1107]; INRAE [USC-2018]; CNRS [UMR6023]. Virginie Bonnin, Gwenaelle Roche and Pierre Sauvanet for their technical assistance, the CICS platform from University of Clermont Auvergne for assistance with histopathology technics Abdelkrim Alloui (Animal Facilities) for animal care and Patrick Emond and Antoine Lefèvre (Plateforme Scientifique et Technologique, analyse des systèmes biologiques, Tours) for metabolomics analyses.","Drossman D.A., Hasler W.L., Rome IV - Functional GI disorders: disorders of gut-brain interaction, Gastroenterology, 150, 6, pp. 1257-1220, (2016); Cryan J.F., O'Riordan K.J., Cowan C.S.M., Sandhu K.V., Bastiaanssen T.F.S., Boehme M., Codagnone M.G., Cussotto S., Fulling C., Golubeva A.V., The microbiota-gut-brain axis, Physiol Rev, 99, 4, pp. 1877-2013, (2019); Card T., Enk P., Barbara G., Boeckxstaens G., Santos J., Azpiroz F., Mearin F., Aziz Q., Marshall J., Spiller R., Post-infectious IBS: defining its clinical features and prognosis using an internet-based survey, J United European Gastroenterology, 6, 8, pp. 1245-1253, (2018); Barbara G., Grover M., Bercik P., Corsetti M., Ghoshal U.C., Ohman L., Rajilic-Stojanovic M., Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome, Gastroenterology, 156, 1, pp. 46-58, (2019); Wang L., Alammar N., Singh R., Nanavati J., Song Y., Chaudhary R., Mullin G.E., Gut Microbial Dysbiosis in the Irritable Bowel Syndrome: a Systematic Review and Meta-Analysis of Case-Control Studies, Journal of the Academy of Nutrition and Dietetics, 120, 4, pp. 565-586, (2020); Crouzet L., Gaultier E., Del'Homme C., Cartier C., Delmas E., Dapoigny M., Fioramonti J., Bernalier-Donadille A., The hypersensitivity to colonic distension of IBS patients can be transferred to rats through their fecal microbiota, Neurogastroenterology & Motility, 25, 4, pp. 272-282, (2013); Zhou L., Zhang M., Wang Y., Dorfman R.G., Liu H., Yu T., Chen X., Tang D., Xu L., Yin Y., Faecalibacterium prausnitzii Produces Butyrate to Maintain Th17/Treg Balance and to Ameliorate Colorectal Colitis by Inhibiting Histone Deacetylase 1, Inflamm Bowel Dis, 24, 9, pp. 1926-1940, (2018); Sokol H., Pigneur B., Watterlot L., Lakhdari O., Bermudez-Humaran L.G., Gratadoux J.J., Blugeon S., Bridonneau C., Furet J.P., Corthier G., Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients, J PNAS, 162, pp. 323-327, (2008); Miquel S., Martin R., Lashermes A., Gillet M., Meleine M., Gelot A., Eschalier A., Ardid D., Bermudez-Humaran L.G., Sokol H., Anti-nociceptive effect of Faecalibacterium prausnitzii in non-inflammatory IBS-like models, Sci Rep, 6, 1, pp. 1-8, (2016); Agus A., Planchais J., Sokol H., Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease, Cell Host Microbe, 23, 6, pp. 716-724, (2018); Obata Y., Castano A., Boeing S., Bon-Frauches A.C., Fung C., Fallesen T., de Aguero M.G., Yilmaz B., Lopes R., Huseynova A., Neuronal programming by microbiota regulates intestinal physiology, Nature, 578, 7794, pp. 284-289, (2020); Benech N., Rolhion N., Sokol H., Tryptophan metabolites get the gut moving, Cell Host Microbe, 29, 2, pp. 145-147, (2021); Zhang L.S., Davies S.S., Microbial metabolism of dietary components to bioactive metabolites: opportunities for new therapeutic interventions, Genome Med, 8, 1, pp. 1-18, (2016); Lee J.S., Cella M., McDonald K.G., Garlanda C., Kennedy G.D., Nukaya M., Mantovani A., Kopan R., Bradfield C.A., Newberry R.D., AHR drives the development of gut ILC22 cells and postnatal lymphoid tissues via pathways dependent on and independent of Notch, J Nat Immunol, 13, pp. 144-151, (2012); Qiu J., Heller J., Guo X., Chen Z.-M., Fish K., Fu Y.-X., Zhou L., The Aryl Hydrocarbon Receptor Regulates Gut Immunity through Modulation of Innate Lymphoid Cells, Immunity, 36, 1, pp. 92-104, (2012); Lamas B., Adolph T.E., Card9 mediates susceptibility to intestinal pathogens through microbiota modulation and control of bacterial virulence, Gut, 67, 1, pp. 1-9, (2018); Zheng Y., Valdez P.A., Danilenko D.M., Hu Y., Sa S.M., Gong Q., Abbas A.R., Modrusan Z., Ghilardi N., de Sauvage F.J., Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens, Nat Med, 14, 3, pp. 282-289, (2008); Zenewicz L.A., Yin X., Wang G., Elinav E., Hao L., Zhao L., Flavell R.A., Interleukin-22 deficiency alters colonic microbiota to be transmissible and colitogenic, Journal of Immunology (Baltimore, Md. : 1950), 190, 10, pp. 5306-5312, (2013); Brawner K.M., Yeramilli V.A., Duck L.W., Van Der Pol W., Smythies L.E., Morrow C.D., Elson C.O., Martin C.A., Depletion of dietary aryl hydrocarbon receptor ligands alters microbiota composition and function, Sci Rep, 9, 1, pp. 1-12, (2019); Lupp C., Robertson M.L., Wickham M.E., Sekirov I., Champion O.L., Gaynor E.C., Finlay B.B., Host-Mediated Inflammation Disrupts the Intestinal Microbiota and Promotes the Overgrowth of Enterobacteriaceae, Cell Host Microbe, 2, 2, pp. 119-129, (2007); Enck P., Aziz Q., Barbara G., Farmer A.D., Fukudo S., Mayer E.A., Niesler B., Quigley E.M.M., Rajilic-Stojanovic M., Schemann M., Irritable bowel syndrome, J Nat Rev Dis Prim, 2, (2016); Mondelaers S.U., Theofanous S.A., Florens M.V., Perna E., Aguilera-Lizarraga J., Boeckxstaens G.E., Wouters M.M., Effect of genetic background and postinfectious stress on visceral sensitivity in Citrobacter rodentium -infected mice, Neurogastroenterol Motil, 28, 5, pp. 647-658, (2016); Ibeakanma C., Miranda-Morales M., Richards M., Bautista-Cruz F., Martin N., Hurlbut D., Vanner S., Citrobacter rodentium colitis evokes post-infectious hyperexcitability of mouse nociceptive colonic dorsal root ganglion neurons, J Physiol, 587, 14, pp. 3505-3521, (2009); Hoffmann C., Hill D.A., Minkah N., Kirn T., Troy A., Artis D., Bushman F., Community-Wide Response of the Gut Microbiota to Enteropathogenic Citrobacter rodentium Infection Revealed by Deep Sequencing, Infect Immun, 77, 10, pp. 4668-4678, (2009); Wiles S., Clare S., Harker J., Huett A., Young D., Dougan G., Frankel G., Organ specificity, colonization and clearance dynamics in vivo following oral challenges with the murine pathogen Citrobacter rodentium, J Cell Microbiol, 6, 10, pp. 963-972, (2004); Spreadbury I., Ochoa-Cortes F., Ibeakanma C., Martin N., Hurlbut D., Vanner S.J., Concurrent psychological stress and infectious colitis is key to sustaining enhanced peripheral sensory signaling, Neurogastroenterol Motil, 27, 3, pp. 347-355, (2015); Moloney R.D., Johnson A.C., O'Mahony S.M., Dinan T.G., Greenwood-Van Meerveld B., Cryan J.F., Stress and the Microbiota-Gut-Brain Axis in Visceral Pain: Relevance to Irritable Bowel Syndrome, J CNS Neurosci Ther, 22, 2, pp. 102-117, (2016); Crawley J.N., Belknap J.K., Collins A., Crabbe J.C., Frankel W., Henderson N., Hitzemann R.J., Maxson S.C., Miner L.L., Silva A.J., Behavioral phenotypes of inbred mouse strains, J Psychopharmacology (Berl), 132, 2, pp. 107-124, (1997); Lyte M., Li W., Opitz N., Gaykema R.P.A., Goehler L.E., Induction of anxiety-like behavior in mice during the initial stages of infection with the agent of murine colonic hyperplasia Citrobacter rodentium, Physiol Behav, 89, 3, pp. 350-357, (2006); Salameh E., Meleine M., Gourcerol G., do Rego J.C., do Rego J.L., Legrand R., Breton J., Aziz M., Guerin C., Coeffier M., Chronic colitis-induced visceral pain is associated with increased anxiety during quiescent phase, Am J Physiol - Gastrointest Liver Physiol, 316, 6, pp. G692-G700, (2019); Wei D., Zhao N., Xie L., Huang B., Zhuang Z., Tang Y., Yu S., Wu Q., Electroacupuncture and moxibustion improved anxiety behavior in DSS-induced colitis mice, Gastroenterol Res Pract, 2019, pp. 1-12, (2019); Gareau M.G., Wine E., Rodrigues D.M., Cho J.H., Whary M.T., Philpott D.J., MacQueen G., Sherman P.M., Bacterial infection causes stress-induced memory dysfunction in mice, Gut, 60, 3, pp. 307-317, (2011); Midenfjord I., Polster A., Sjovall H., Tornblom H., Simren M., Anxiety and depression in irritable bowel syndrome: exploring the interaction with other symptoms and pathophysiology using multivariate analyses, Neurogastroenterol Motil, 31, 8, pp. 1-14, (2019); Romero-Sandoval E.A., Depression and Pain, Anesthesiology, 115, 4, pp. 687-688, (2011); Yalcin I., Bohren Y., Waltisperger E., Sage-Ciocca D., Yin J.C., Freund-Mercier M.-J., Barrot M., A time-dependent history of mood disorders in a murine model of neuropathic pain, Biological Psychiatry, 70, 10, pp. 946-953, (2011); Gareau M.G., Gareau M.G., Lyte M., Cryan J.F., Microbiota-Gut-Brain Axis and Cognitive Function Abbreviations 5-HT Serotonin ANS Autonomic nervous system BDNF Brain derived neurotropic factor CD Crohn’s disease CREB cAMP response element binding protein CRF Corticotrophin-releasing factor DA Dopamine, Adv Exp Med Biol, 817, pp. 357-371, (2014); Schwarcz R., Bruno J.P., Muchowski P.J., Wu H.Q., Kynurenines in the mammalian brain: when physiology meets pathology, Nat Rev Neurosci, 13, 7, pp. 465-477, (2012); Stone T.W., Darlington L.G., The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders, Br J Pharmacol, 169, 6, pp. 1211-1227, (2013); McKernan D.P., Fitzgerald P., Dinan T.G., Cryan J.F., The probiotic Bifidobacterium infantis 35624 displays visceral antinociceptive effects in the rat, Neurogastroenterol Motil, 22, 9, pp. 1029-1036, (2010); Nestler E.J., Barrot M., DiLeone R.J., Eisch A.J., Gold S.J., Monteggia L.M., Neurology of Depression, Neuron, 34, 1, pp. 13-25, (2002); O'Mahony S.M., Felice V.D., Nally K., Savignac H.M., Claesson M.J., Scully P., Woznicki J., Hyland N.P., Shanahan F., Quigley E.M., Disturbance of the gut microbiota in early-life selectively affects visceral pain in adulthood without impacting cognitive or anxiety-related behaviors in male rats, J Neuroscience, 277, pp. 885-901, (2014); Jeffery I.B., O'Toole P.W., Ohman L., Claesson M.J., Deane J., Quigley E.M.M., Simren M., An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota, Gut, 61, 7, pp. 997-1006, (2012); Rodino-Janeiro B.K., Vicario M., Alonso-Cotoner C., Pascua-Garcia R., Santos J., A Review of Microbiota and Irritable Bowel Syndrome: future in Therapies, Adv Ther, 35, 3, pp. 289-310, (2018); Krogius-Kurikka L., Lyra A., Malinen E., Aarnikunnas J., Tuimala J., Paulin L., Makivuokko H., Kajander K., Pavla A., Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers, J BMC Gastroenterol, 9, 1, pp. 1-11, (2009); Osbelt L., Thiemann S., Smit N., Lesker T.R., Schroter M., Galvez E.J.C., Schmidt-Hohagen K., Pils M.C., Muhlen S., Dersch P., Variations in microbiota composition of laboratory mice influence Citrobacter rodentium infection via variable short-chain fatty acid production, PLoS Pathog, 16, 3, pp. 1-27, (2020); Brugiroux S., Beutler M., Pfann C., Garzetti D., Ruscheweyh H.-J., Ring D., Diehl M., Herp S., Lotscher Y., Hussain S., Genome-guided design of a defined mouse microbiota that confers colonization resistance against Salmonella enterica serovar Typhimurium, Nat Microbiol, 2, (2016); Chassaing B., Srinivasan G., Delgado M.A., Young A.N., Gewirtz A.T., Vijay-Kumar M., Fecal Lipocalin 2, a Sensitive and Broadly Dynamic Non-Invasive Biomarker for Intestinal Inflammation, J PLoS One, 7, 9, pp. 3-10, (2012); Collins J.W., Keeney K.M., Crepin V.F., Rathinam V.A.K., Fitzgerald K.A., Finlay B.B., Frankel G., Citrobacter rodentium: infection, inflammation and the microbiota, J Nat Rev Microbiol, 12, 9, pp. 612-623, (2014); Simpson C.A., Diaz-Arteche C., Eliby D., Schwartz O.S., Simmons J.G., Cowan C.S.M., The gut microbiota in anxiety and depression–a systematic review, J Clin Psychol Rev, 83, (2021); Farmer A.D., Aziz Q., Mechanisms of visceral pain in health and functional gastrointestinal disorders, Scand J Pain, 5, 2, pp. 51-60, (2014); Fitzgerald P., Cassidy Eugene M., Clarke G., Scully P., Barry S., Quigley Eamonn M.M., Shanahan F., Cryan J., Dinan Timothy G., Tryptophan catabolism in females with irritable bowel syndrome: relationship to interferon-gamma, severity of symptoms and psychiatric co-morbidity, Neurogastroenterol Motil, 20, 12, pp. 1291-1297, (2008); Clarke G., Fitzgerald P., Cryan J.F., Cassidy E.M., Quigley E.M., Dinan T.G., Tryptophan degradation in irritable bowel syndrome: evidence of indoleamine 2,3-dioxygenase activation in a male cohort, BMC Gastroenterol, 9, 1, pp. 1-7, (2009); Burr R.L., Gu H., Cain K., Djukovic D., Zhang X., Han C., Callan N., Raftery D., Heitkemper M., Tryptophan Metabolites in Irritable Bowel Syndrome: an Overnight Time-course Study, J Neurogastroenterol Motil, 25, 4, pp. 551-562, (2019); Berstad A., Raa J., Valeur J.T., Essential’ for the pathogenesis of irritable bowel syndrome?, Scand J Gastroenterol, 49, 12, pp. 1493-1498, (2014); Lamas B., Natividad J.M., Sokol H., Aryl hydrocarbon receptor and intestinal immunity review-article, Mucosal Immunol, 11, 4, pp. 1024-1038, (2018); De Moreno De Leblanc A., Del Carmen S., Chatel J.-M., Miyoshi A., Azevedo V., Langella P., Bermudez-Humaran L.G., LeBlanc J.G., Current Review of Genetically Modified Lactic Acid Bacteria for the Prevention and Treatment of Colitis Using Murine Models, Gastroenterol Res Pract, 2015, pp. 1-8, (2015); Mariat D., Robert V., Langella P., Chatel J.M., Plasmid transfer efficiency using Lactoccocus lactis strains depends on invasiveness status but also on plasmid copy number, FEMS Microbiol Lett, 364, 14, (2017); Guttman J.A., Li Y., Wickham M.E., Deng W., Vogl A.W., Finlay B.B., Attaching and effacing pathogen-induced tight junction disruption in vivo, Cell Microbiol, 8, 4, pp. 634-645, (2006); Dudakov J.A., Hanash A.M., van den Brink M.R.M., Interleukin-22: immunology and pathology, J Annu Rev Immunol, pp. 747-785, (2015); Prevot T.D., Misquitta K.A., Fee C., Newton D.F., Chatterjee D., Nikolova Y.S., Sibille E., Banasr M., Residual avoidance: a new, consistent and repeatable readout of chronic stress-induced conflict anxiety reversible by antidepressant treatment, Neuropharmacology, 153, pp. 98-110, (2019); Alameh M.-G., Weissman D., Pardi N., Messenger RNA-Based Vaccines Against Infectious Diseases, (2020); Zimmermann M., Ethical guidelines for invetigations of experimental pain in conscious animals, Pain, 16, 2, pp. 109-110, (1983); Defaye M., Nourrisson C., Baudu E., Lashermes A., Meynier M., Meleine M., Wawrzyniak I., Bonnin V., Barbier J., Chassaing B., Fecal dysbiosis associated with colonic hypersensitivity and behavioral alterations in chronically Blastocystis-infected rats, Sci Rep, 10, 1, pp. 1-12, (2020); Lefevre A., Mavel S., Nadal-Desbarats L., Galineau L., Attucci S., Dufour D., Sokol H., Emond P., Validation of a global quantitative analysis methodology of tryptophan metabolites in mice using LC-MS, Talanta, 195, pp. 593-598, (2019); Rodriguez Echandia E.L., Broitman S.T., Foscolo M.R., Effect of the chronic ingestion of chlorimipramine and desipramine on the hole board response to acute stresses in male rats, Pharmacol Biochem Behav, 26, 2, pp. 207-210, (1987); Sierksma A.S.R., van Den Hove D.L.A., Pfau F., Philippens M., Bruno O., Fedele E., Ricciarelli R., Steinbusch H.W.M., Vanmierlo T., Prickaerts J., Improvement of spatial memory function in APPswe/PS1dE9 mice after chronic inhibition of phosphodiesterase type 4D, Neuropharmacology, 77, pp. 120-130, (2014); Barre A., Berthoux C., De Bundel D., Valjent E., Bockaert J., Marin P., Becamel C., Presynaptic serotonin 2A receptors modulate thalamocortical plasticity and associative learning, J Proc Natl Acad Sci USA, 113, 10, pp. E1382-E1391, (2016); Steru L., Chermat R., Thierry B., Simon P., The tail suspension test: a new method for screening antidepressants in mice, Psychopharmacology (Berl), 85, 3, pp. 367-370, (1985); Porsolt R.D., Anton G., Blavet N., Jalfre M., Behavioural despair in rats: a new model sensitive to antidepressant treatments, Eur J Pharmacol, 47, 4, pp. 379-391, (1978); Larauche M., Gourcerol G., Million M., Adelson D.W., Tache Y., Repeated psychological stress-induced alterations of visceral sensitivity and colonic motor functions in mice: influence of surgery and postoperative single housing on visceromotor responses, Stress, 13, 4, pp. 343-354, (2010)","B. Mathilde; University of Clermont Auvergne, INSERM, 1071 M2iSH, INRAE USC 2018, Clermont-Ferrand, 28, place Henri Dunant, BP38, F-63001, France; email: mathilde.bonnet@uca.fr; C. Frédéric Antonio; UMR 1107 INSERM, University of Clermont Auvergne, 28 Place Henri, Dunant, BP38, F-63001, France; email: frederic.carvalho@inserm.fr","","Taylor and Francis Ltd.","","","","","","19490976","","","35090380","English","Gut Microbes","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85123814767"

"Nozu T.; Miyagishi S.; Nozu R.; Takakusaki K.; Okumura T.","Nozu, Tsukasa (12765917900); Miyagishi, Saori (56538237900); Nozu, Rintaro (57028157900); Takakusaki, Kaoru (7004150214); Okumura, Toshikatsu (7202327796)","12765917900; 56538237900; 57028157900; 7004150214; 7202327796","Losartan improves visceral sensation and gut barrier in a rat model of irritable bowel syndrome","2020","Neurogastroenterology and Motility","32","6","e13819","","","","13","10.1111/nmo.13819","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85079734611&doi=10.1111%2fnmo.13819&partnerID=40&md5=b54de525093cb94c5a52f87b5f3a1f36","Department of Regional Medicine and Education, Asahikawa Medical University, Asahikawa, Japan; Center for Medical Education, Asahikawa Medical University, Asahikawa, Japan; Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan; Research Center for Brain Function and Medical Engineering, Asahikawa Medical University, Asahikawa, Japan; Department of General Medicine, Asahikawa Medical University, Asahikawa, Japan","Nozu T., Department of Regional Medicine and Education, Asahikawa Medical University, Asahikawa, Japan, Center for Medical Education, Asahikawa Medical University, Asahikawa, Japan; Miyagishi S., Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan; Nozu R., Department of Regional Medicine and Education, Asahikawa Medical University, Asahikawa, Japan; Takakusaki K., Research Center for Brain Function and Medical Engineering, Asahikawa Medical University, Asahikawa, Japan; Okumura T., Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan, Department of General Medicine, Asahikawa Medical University, Asahikawa, Japan","Background: Lipopolysaccharide (LPS) or repeated water avoidance stress (WAS) induces visceral allodynia and colonic hyperpermeability via corticotropin-releasing factor (CRF) and proinflammatory cytokines, which is considered to be a rat irritable bowel syndrome (IBS) model. As losartan is known to inhibit proinflammatory cytokine release, we hypothesized that it improves these visceral changes. Methods: The threshold of visceromotor response (VMR), that is, abdominal muscle contractions induced by colonic balloon distention was electrophysiologically measured in rats. Colonic permeability was determined in vivo by quantifying the absorbed Evans blue in colonic tissue for 15 minutes spectrophotometrically. Key Results: Lipopolysaccharide (1 mg kg−1) subcutaneously (s.c.) reduced the threshold of VMR and increased colonic permeability. Losartan (5-25 mg kg−1 s.c.) for 3 days inhibited these changes in a dose-dependent manner. Moreover, repeated WAS (1 hour daily for 3 days) or intraperitoneal injection of CRF (50 µg kg−1) induced the similar visceral changes as LPS, which were also eliminated by losartan. These effects by losartan in LPS model were reversed by GW9662 (a peroxisome proliferator-activated receptor-γ [PPAR-γ] antagonist), NG-nitro-L-arginine methyl ester (a nitric oxide [NO] synthesis inhibitor), or naloxone (an opioid receptor antagonist). Moreover, it also inhibited by sulpiride (a dopamine D2 receptor antagonist) or domperidone (a peripheral dopamine D2 antagonist). Conclusion & Inferences: Losartan prevented visceral allodynia and colonic hyperpermeability in rat IBS models. These actions may be PPAR-γ–dependent and also mediated by the NO, opioid, and dopamine D2 pathways. Losartan may be useful for IBS treatment. © 2020 John Wiley & Sons Ltd","angiotensin II type 1 receptor; gut barrier; irritable bowel syndrome; lipopolysaccharide; visceral sensation","Animals; Colon; Corticotropin-Releasing Hormone; Disease Models, Animal; Hyperalgesia; Irritable Bowel Syndrome; Lipopolysaccharides; Losartan; Male; Permeability; Rats, Sprague-Dawley; Stress, Psychological; 2 chloro 5 nitrobenzanilide; corticotropin releasing factor; domperidone; lipopolysaccharide; losartan; n(g) nitroarginine methyl ester; naloxone; peroxisome proliferator activated receptor gamma; sulpiride; corticotropin releasing factor; lipopolysaccharide; losartan; abdominal wall musculature; allodynia; animal experiment; animal model; animal tissue; Article; colon tissue; controlled study; dose response; electrode implantation; experimental test; in vivo study; irritable colon; male; muscle contraction; nonhuman; permeability; priority journal; rat; visceral pain; water avoidance stress; animal; colon; disease model; drug effect; hyperalgesia; irritable colon; mental stress; pathophysiology; Sprague Dawley rat","","corticotropin releasing factor, 9015-71-8, 178359-01-8, 79804-71-0, 86297-72-5, 86784-80-7; domperidone, 57808-66-9; losartan, 114798-26-4; n(g) nitroarginine methyl ester, 50903-99-6; naloxone, 357-08-4, 465-65-6; sulpiride, 15676-16-1; Corticotropin-Releasing Hormone, ; Lipopolysaccharides, ; Losartan, ","","","Scientific Research on Innovative Areas, (26120012); Akiyama Life Science Foundation; Japan Society for the Promotion of Science, KAKEN, (18K07896, 26460287, 26460955)","This work was partially supported by Japan Society for the Promotion of Science KAKENHI, Grant-in-Aid for Scientific Research (C) (26460287 [TN] and 26460955 [TO]), Scientific Research on Innovative Areas (26120012 [KT]), and the research grant from the Akiyama Life Science Foundation (TN).","Mearin F., Lacy B.E., Chang L., Et al., Bowel disorders, Gastroenterology, 150, pp. 1393-1407, (2016); Tache Y., Kiank C., Stengel A., A role for corticotropin-releasing factor in functional gastrointestinal disorders, Curr Gastroenterol Rep, 11, pp. 270-277, (2009); Nozu T., Okumura T., Corticotropin-releasing factor receptor type 1 and type 2 interaction in irritable bowel syndrome, J Gastroenterol, 50, pp. 819-830, (2015); Dlugosz A., Nowak P., D'Amato M., Et al., Increased serum levels of lipopolysaccharide and antiflagellin antibodies in patients with diarrhea-predominant irritable bowel syndrome, Neurogastroenterol Motil, 27, pp. 1747-1754, (2015); Barbara G., Zecchi L., Barbaro R., Et al., Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome, J Clin Gastroenterol, 46, pp. S52-55, (2012); Nozu T., Miyagishi S., Nozu R., Takakusaki K., Okumura T., Lipopolysaccharide induces visceral hypersensitivity: role of interleukin-1, interleukin-6, and peripheral corticotropin-releasing factor in rats, J Gastroenterol, 52, pp. 72-80, (2017); Nozu T., Miyagishi S., Nozu R., Takakusaki K., Okumura T., Altered colonic sensory and barrier functions by CRF: roles of TLR4 and IL-1, J Endocrinol, 239, pp. 241-252, (2018); Nozu T., Miyagishi S., Nozu R., Takakusaki K., Okumura T., Repeated water avoidance stress induces visceral hypersensitivity; role of IL-1, IL-6 and peripheral corticotropin-releasing factor, J Gastroenterol Hepatol, 32, pp. 1958-1965, (2017); Goodfriend T.L., Elliott M.E., Catt K.J., Angiotensin receptors and their antagonists, N Engl J Med, 334, pp. 1649-1654, (1996); Satou R., Penrose H., Navar L.G., Inflammation as a regulator of the renin-angiotensin system and blood pressure, Curr Hypertens Rep, 20, (2018); Bali A., Singh N., Jaggi A.S., Renin-angiotensin system in pain: existing in a double life?, J Renin Angiotensin Aldosterone Syst, 15, pp. 329-340, (2014); Katada K., Yoshida N., Suzuki T., Et al., Dextran sulfate sodium-induced acute colonic inflammation in angiotensin II type 1a receptor deficient mice, Inflamm Res, 57, pp. 84-91, (2008); Arumugam S., Sreedhar R., Thandavarayan R.A., Et al., Telmisartan treatment targets inflammatory cytokines to suppress the pathogenesis of acute colitis induced by dextran sulphate sodium, Cytokine, 74, pp. 305-312, (2015); Nozu T., Miyagishi S., Nozu R., Takakusaki K., Okumura T., Dehydroepiandrosterone sulfate improves visceral sensation and gut barrier in a rat model of irritable bowel syndrome, Eur J Pharmacol, (2019); Ness T.J., Gebhart G.F., Colorectal distension as a noxious visceral stimulus: physiologic and pharmacologic characterization of pseudaffective reflexes in the rat, Brain Res, 450, pp. 153-169, (1988); Tang Q.L., Lai M.L., Zhong Y.F., Wang A.M., Su J.K., Zhang M.Q., Antinociceptive effect of berberine on visceral hypersensitivity in rats, World J Gastroenterol, 19, pp. 4582-4589, (2013); Martinez V., Rivier J., Wang L., Tache Y., Central injection of a new corticotropin-releasing factor (CRF) antagonist, astressin, blocks CRF- and stress-related alterations of gastric and colonic motor function, J Pharmacol Exp Ther, 280, pp. 754-760, (1997); An J., Nakajima T., Kuba K., Kimura A., Losartan inhibits LPS-induced inflammatory signaling through a PPARgamma-dependent mechanism in human THP-1 macrophages, Hypertens Res, 33, pp. 831-835, (2010); Cahill F.J., Ellenberger E.A., Mueller J.L., Tseng L.F., Quock R.M., Antagonism of nitrous oxide antinociception in mice by intrathecally administered antisera to endogenous opioid peptides, J Biomed Sci, 7, pp. 299-303, (2000); Chung E., Burke B., Bieber A.J., Doss J.C., Ohgami Y., Quock R.M., Dynorphin-mediated antinociceptive effects of L-arginine and SIN-1 (an NO donor) in mice, Brain Res Bull, 70, pp. 245-250, (2006); Satoh M., Fujimoto S., Arakawa S., Et al., Angiotensin II type 1 receptor blocker ameliorates uncoupled endothelial nitric oxide synthase in rats with experimental diabetic nephropathy, Nephrol Dial Transplant, 23, pp. 3806-3813, (2008); Imanishi M., Okada N., Konishi Y., Et al., Angiotensin II receptor blockade reduces salt sensitivity of blood pressure through restoration of renal nitric oxide synthesis in patients with diabetic nephropathy, J Renin Angiotensin Aldosterone Syst, 14, pp. 67-73, (2013); Larauche M., Mulak A., Kim Y.S., Labus J., Million M., Tache Y., Visceral analgesia induced by acute and repeated water avoidance stress in rats: sex difference in opioid involvement, Neurogastroenterol Motil, 24, pp. 1031-e1547, (2012); Okumura T., Nozu T., Kumei S., Takakusaki K., Miyagishi S., Ohhira M., Involvement of the dopaminergic system in the central orexin-induced antinociceptive action against colonic distension in conscious rats, Neurosci Lett, 605, pp. 34-38, (2015); Yu Y., Liu Z.Q., Liu X.Y., Et al., Stress-derived corticotropin releasing factor breaches epithelial endotoxin tolerance, PLoS ONE, 8, (2013); Obreja O., Rathee P.K., Lips K.S., Distler C., Kress M., IL-1 beta potentiates heat-activated currents in rat sensory neurons: involvement of IL-1RI, tyrosine kinase, and protein kinase C, FASEB J, 16, pp. 1497-1503, (2002); Creekmore A.L., Hong S., Zhu S., Xue J., Wiley J.W., Chronic stress-associated visceral hyperalgesia correlates with severity of intestinal barrier dysfunction, Pain, 159, pp. 1777-1789, (2018); Suzuki T., Yoshinaga N., Tanabe S., Interleukin-6 (IL-6) regulates claudin-2 expression and tight junction permeability in intestinal epithelium, J Biol Chem, 286, pp. 31263-31271, (2011); Azpiroz F., Bouin M., Camilleri M., Et al., Mechanisms of hypersensitivity in IBS and functional disorders, Neurogastroenterol Motil, 19, pp. 62-88, (2007); Groeschel M., Braam B., Connecting chronic and recurrent stress to vascular dysfunction: no relaxed role for the renin-angiotensin system, Am J Physiol Renal Physiol, 300, pp. F1-10, (2011); Saavedra J.M., Sanchez-Lemus E., Benicky J., Blockade of brain angiotensin II AT1 receptors ameliorates stress, anxiety, brain inflammation and ischemia: therapeutic implications, Psychoneuroendocrinology, 36, pp. 1-18, (2011); Ruiz-Ortega M., Ruperez M., Lorenzo O., Et al., Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney, Kidney Int Suppl, S12–22, (2002); Biancardi V.C., Bomfim G.F., Reis W.L., Al-Gassimi S., Nunes K.P., The interplay between Angiotensin II, TLR4 and hypertension, Pharmacol Res, 120, pp. 88-96, (2017); Benigni A., Cassis P., Remuzzi G., Angiotensin II revisited: new roles in inflammation, immunology and aging, EMBO Mol Med, 2, pp. 247-257, (2010); Kim E., Hwang S.H., Kim H.K., Abdi S., Kim H.K., Losartan, an Angiotensin II Type 1 receptor antagonist, alleviates mechanical hyperalgesia in a rat model of chemotherapy-induced neuropathic pain by inhibiting inflammatory cytokines in the dorsal root ganglia, Mol Neurobiol, 56, pp. 7408-7419, (2019); Inokuchi Y., Morohashi T., Kawana I., Nagashima Y., Kihara M., Umemura S., Amelioration of 2,4,6-trinitrobenzene sulphonic acid induced colitis in angiotensinogen gene knockout mice, Gut, 54, pp. 349-356, (2005); Okawada M., Koga H., Larsen S.D., Et al., Use of enterally delivered angiotensin II type Ia receptor antagonists to reduce the severity of colitis, Dig Dis Sci, 56, pp. 2553-2565, (2011); Jiang C., Ting A.T., Seed B., PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines, Nature, 391, pp. 82-86, (1998); Fajas L., Auboeuf D., Raspe E., Et al., The organization, promoter analysis, and expression of the human PPARgamma gene, J Biol Chem, 272, pp. 18779-18789, (1997); Su C.G., Wen X., Bailey S.T., Et al., A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response, J Clin Invest, 104, pp. 383-389, (1999); Nozu T., Miyagishi S., Nozu R., Takakusaki K., Okumura T., Pioglitazone improves visceral sensation and colonic permeability in a rat model of irritable bowel syndrome, J Pharmacol Sci, 139, pp. 46-49, (2018); Schupp M., Lee L.D., Frost N., Et al., Regulation of peroxisome proliferator-activated receptor gamma activity by losartan metabolites, Hypertension, 47, pp. 586-589, (2006); Kroncke K.D., Fehsel K., Suschek C., Kolb-Bachofen V., Inducible nitric oxide synthase-derived nitric oxide in gene regulation, cell death and cell survival, Int Immunopharmacol, 1, pp. 1407-1420, (2001); Kim Y.M., Talanian R.V., Li J., Billiar T.R., Nitric oxide prevents IL-1beta and IFN-gamma-inducing factor (IL-18) release from macrophages by inhibiting caspase-1 (IL-1beta-converting enzyme), J Immunol, 161, pp. 4122-4128, (1998); Kanwar S., Wallace J.L., Befus D., Kubes P., Nitric oxide synthesis inhibition increases epithelial permeability via mast cells, Am J Physiol, 266, pp. G222-229, (1994); Krazinski B.E., Koziorowski M., Brzuzan P., Okrasa S., The expression of genes encoding opioid precursors and the influence of opioid receptor agonists on steroidogenesis in porcine adrenocortical cells in vitro, J Physiol Pharmacol, 62, pp. 461-468, (2011); Kaneko S., Mori A., Tamura S., Satoh M., Takagi H., Intracerebroventricular administration of angiotensin II attenuates morphine-induced analgesia in mice, Neuropharmacology, 24, pp. 1131-1134, (1985); Ninkovic J., Roy S., Role of the mu-opioid receptor in opioid modulation of immune function, Amino Acids, 45, pp. 9-24, (2013); Pacifici R., di Carlo S., Bacosi A., Pichini S., Zuccaro P., Pharmacokinetics and cytokine production in heroin and morphine-treated mice, Int J Immunopharmacol, 22, pp. 603-614, (2000); Martinez-Pinilla E., Rodriguez-Perez A.I., Navarro G., Et al., Dopamine D2 and angiotensin II type 1 receptors form functional heteromers in rat striatum, Biochem Pharmacol, 96, pp. 131-142, (2015); Garrido-Gil P., Dominguez-Meijide A., Moratalla R., Guerra M.J., Labandeira-Garcia J.L., Aging-related dysregulation in enteric dopamine and angiotensin system interactions: implications for gastrointestinal dysfunction in the elderly, Oncotarget, 9, pp. 10834-10846, (2018); Durdagi S., Erol I., Salmas R.E., Aksoydan B., Kantarcioglu I., Oligomerization and cooperativity in GPCRs from the perspective of the angiotensin AT1 and dopamine D2 receptors, Neurosci Lett, 700, pp. 30-37, (2019); Arreola R., Alvarez-Herrera S., Perez-Sanchez G., Et al., Immunomodulatory effects mediated by dopamine, J Immunol Res, 2016, (2016); Beck G., Brinkkoetter P., Hanusch C., Et al., Clinical review: immunomodulatory effects of dopamine in general inflammation, Crit Care, 8, pp. 485-491, (2004); Han X., Li B., Ye X., Et al., Dopamine D2 receptor signalling controls inflammation in acute pancreatitis via a PP2A-dependent Akt/NF-kappaB signalling pathway, Br J Pharmacol, 174, pp. 4751-4770, (2017); Li Z., Bains J.S., Ferguson A.V., Functional evidence that the angiotensin antagonist losartan crosses the blood-brain barrier in the rat, Brain Res Bull, 30, pp. 33-39, (1993); Garrido-Gil P., Rodriguez-Perez A.I., Dominguez-Meijide A., Guerra M.J., Labandeira-Garcia J.L., Bidirectional neural interaction between central dopaminergic and gut lesions in Parkinson's disease models, Mol Neurobiol, 55, pp. 7297-7316, (2018); Zhang J.M., An J., Cytokines, inflammation, and pain, Int Anesthesiol Clin, 45, pp. 27-37, (2007); Tedgui A., Mallat Z., Cytokines in atherosclerosis: pathogenic and regulatory pathways, Physiol Rev, 86, pp. 515-581, (2006); Holtmann G.J., Ford A.C., Talley N.J., Pathophysiology of irritable bowel syndrome, Lancet Gastroenterol Hepatol, 1, pp. 133-146, (2016); Toth P.P., Pleiotropic effects of angiotensin receptor blockers: addressing comorbidities by optimizing hypertension therapy, J Clin Hypertens (Greenwich), 13, 1, pp. 42-51, (2011); Kamal A., Fain C., Park A., Et al., Angiotensin II receptor blockers and gastrointestinal adverse events of resembling sprue-like enteropathy: a systematic review, Gastroenterol Rep (Oxf), 7, pp. 162-167, (2019)","T. Nozu; Department of Regional Medicine and Education, Asahikawa Medical University, Asahikawa, Japan; email: tnozu@sea.plala.or.jp","","Blackwell Publishing Ltd","","","","","","13501925","","NMOTE","32056324","English","Neurogastroenterol. Motil.","Article","Final","","Scopus","2-s2.0-85079734611"

"Stepanov Y.M.; Budzak I.Ya.; Gaidar Y.A.","Stepanov, Yu.M. (57206899179); Budzak, I.Ya. (57365525600); Gaidar, Yu.A. (58178831400)","57206899179; 57365525600; 58178831400","Determination of intercellular contacts in patients with irritable bowel syndrome","2019","Gastroenterology (Ukraine)","53","2","","128","131","3","2","10.22141/2308-2097.53.2.2019.168987","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85107270591&doi=10.22141%2f2308-2097.53.2.2019.168987&partnerID=40&md5=2e053371a576d03a1f8fd9c958dadbcb","State Institution “Institute of Gastroenterology of the National Academy of Medical Sciences of Ukraine”, Dnipro, Ukraine; State Institution “Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine”, Dnipro, Ukraine","Stepanov Y.M., State Institution “Institute of Gastroenterology of the National Academy of Medical Sciences of Ukraine”, Dnipro, Ukraine; Budzak I.Ya., State Institution “Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine”, Dnipro, Ukraine; Gaidar Y.A., State Institution “Institute of Gastroenterology of the National Academy of Medical Sciences of Ukraine”, Dnipro, Ukraine","The article presents an analysis of literature data on the violation of intestinal permeability as one of the pathogenetic factors of irritable bowel syndrome. The structure of tight junctions is considered in detail as an impor-tant element of the normal functioning of the intestinal barrier. The researches that previously studied the expression of tight junction components in patients with irritable bowel syndrome were considered. The results of our own study with the evaluation of occludin expression in patients with irritable bowel syndrome are shown. It has been found that the expression of occludin is lower in patients with irritable bowel syndrome compared with healthy individuals. © «Gastroenterology» («Gastroenterologìa»), 2019.","immunohistochemical method; intestinal permeability; irritable bowel syndrome; occludin; tight junctions","","","","","","","","Martinez C, Gonzalez-Castro A, Vicario M, Santos J., Cellular and molecular basis of intestinal barrier dysfunction in the irritable bowel syn-drome, Gut Liver, 6, 3, pp. 305-315, (2012); Turner JR., Intestinal mucosal barrier function in health and dis-ease, Nat Rev Immunol, 9, 11, pp. 799-809, (2009); Garrett WS, Gordon JI, Glimcher LH., Homeostasis and inflammation in the intestine, Cell, 140, 6, pp. 859-870, (2010); Dunlop SP, Hebden J, Campbell E, Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syn-dromes, Am J Gastroenterol, 101, 6, pp. 1288-1294, (2006); Zhou Q, Zhang B, Verne GN., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, 1-2, pp. 41-46, (2009); Spiller RC, Jenkins D, Thornley JP, Et al., Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, 6, pp. 804-811, (2000); Marshall JK, Thabane M, Garg AX, Et al., Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario, Aliment Pharmacol Ther, 20, 11-12, pp. 1317-1322, (2004); Mujagic Z, Ludidi S, Keszthelyi D., Small intestinal permeability is increased in diarrhoea predominant IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to confounders, Aliment Pharmacol Ther, 40, 3, pp. 288-297, (2014); Cheng P, Yao J, Wang C, Zhang L, Kong W., Molecular and cellular mechanisms of tight junction dysfunction in the irritable bowel syndrome, Mol Med Rep, 12, 3, pp. 3257-3264, (2015); Kong WM, Gong J, Dong L, Xu JR., Changes of tight junction clau-din-1,-3,-4 protein expression in the intestinal mucosa in patients with irritable bowel syndrome, Nan Fang Yi Ke Da Xue Xue Bao, 27, 9, pp. 1345-1347, (2007); Martinez C, Vicario M, Ramos L, Et al., The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations, Am J Gastroenterol, 107, 5, pp. 736-746, (2012); Peters SA, Edogawa S, Sundt WJ, Et al., Constipation-Predominant Irritable Bowel Syndrome Females Have Normal Colonic Barrier and Secre-tory Function, Am J Gastroenterol, 112, 6, pp. 913-923, (2017); Bertiaux-Vandaele N, Youmba SB, Belmonte L, Et al., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am J Gastroenterol, 106, 12, pp. 2165-2173, (2011)","I.Ya. Budzak; Department of Therapy, Cardiology and Family Medicine, State Institution “Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine”, Dnipro, Vernadsky st., 9, 49044, Ukraine; email: igor.budzak@outlook.com","","Zaslavsky Publishing House","","","","","","23082097","","","","English","Gastroenterology.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85107270591"

"Edogawa S.; Edwinson A.L.; Peters S.A.; Chikkamenahalli L.L.; Sundt W.; Graves S.; Gurunathan S.V.; Breen-Lyles M.; Johnson S.; Dyer R.; Graham R.; Chen J.; Kashyap P.; Farrugia G.; Grover M.","Edogawa, Shoko (49861248700); Edwinson, Adam L (57207580613); Peters, Stephanie A (57193683015); Chikkamenahalli, Lakshmikanth L (57200100953); Sundt, Wendy (57148557200); Graves, Sara (58360669200); Gurunathan, Sakteesh V (57204856638); Breen-Lyles, Margaret (57195807544); Johnson, Stephen (57190584123); Dyer, Roy (7202532150); Graham, Rondell (53979541600); Chen, Jun (56640742100); Kashyap, Purna (24178249300); Farrugia, Gianrico (7006024784); Grover, Madhusudan (23012057300)","49861248700; 57207580613; 57193683015; 57200100953; 57148557200; 58360669200; 57204856638; 57195807544; 57190584123; 7202532150; 53979541600; 56640742100; 24178249300; 7006024784; 23012057300","Serine proteases as luminal mediators of intestinal barrier dysfunction and symptom severity in IBS","2020","Gut","69","1","","62","73","11","61","10.1136/gutjnl-2018-317416","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85063578049&doi=10.1136%2fgutjnl-2018-317416&partnerID=40&md5=7808ee1b2b729c760673135255233e30","Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, 55905, MN, United States; Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, United States; Immunochemical Core Laboratory, Mayo Clinic, Rochester, MN, United States; Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States; Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States","Edogawa S., Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, 55905, MN, United States; Edwinson A.L., Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, 55905, MN, United States; Peters S.A., Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, 55905, MN, United States; Chikkamenahalli L.L., Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, 55905, MN, United States; Sundt W., Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, 55905, MN, United States; Graves S., Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, 55905, MN, United States; Gurunathan S.V., Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, 55905, MN, United States; Breen-Lyles M., Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, 55905, MN, United States; Johnson S., Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, United States; Dyer R., Immunochemical Core Laboratory, Mayo Clinic, Rochester, MN, United States; Graham R., Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States; Chen J., Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States; Kashyap P., Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, 55905, MN, United States; Farrugia G., Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, 55905, MN, United States; Grover M., Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, 55905, MN, United States","Objective The intestinal lumen contains several proteases. Our aim was to determine the role of faecal proteases in mediating barrier dysfunction and symptoms in IBS. Design 39 patients with IBS and 25 healthy volunteers completed questionnaires, assessments of in vivo permeability, ex vivo colonic barrier function in Ussing chambers, tight junction (TJ) proteins, ultrastructural morphology and 16 s sequencing of faecal microbiota rRNA. A casein-based assay was used to measure proteolytic activity (PA) in faecal supernatants (FSNs). Colonic barrier function was determined in mice (ex-germ free) humanised with microbial communities associated with different human PA states. Results Patients with IBS had higher faecal PA than healthy volunteers. 8/20 postinfection IBS (PI-IBS) and 3/19 constipation- predominant IBS had high PA (>95th percentile). High-PA patients had more and looser bowel movements, greater symptom severity and higher in vivo and ex vivo colonic permeability. High-PA FSNs increased paracellular permeability, decreased occludin and increased phosphorylated myosin light chain (pMLC) expression. Serine but not cysteine protease inhibitor significantly blocked high-PA FSN effects on barrier. The effects on barrier were diminished by pharmacological or siRNA inhibition of protease activated receptor-2 (PAR-2). Patients with high-PA IBS had lower occludin expression, wider TJs on biopsies and reduced microbial diversity than patients with low PA. Mice humanised with high-PA IBS microbiota had greater in vivo permeability than those with low-PA microbiota. Conclusion A subset of patients with IBS, especially in PI-IBS, has substantially high faecal PA, greater symptoms, impaired barrier and reduced microbial diversity. Commensal microbiota affects luminal PA that can influence host barrier function. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.","Campylobacter; gastroenteritis; germ-free mice; microbiome; trypsin","Adult; Animals; Biopsy; Caco-2 Cells; Case-Control Studies; Colon; Dysbiosis; Feces; Female; Gastrointestinal Microbiome; Humans; Intestinal Absorption; Intestinal Mucosa; Irritable Bowel Syndrome; Male; Mice; Middle Aged; Permeability; Prospective Studies; Proteolysis; Serine Proteases; Severity of Illness Index; Tight Junction Proteins; bacterial RNA; cysteine proteinase; myosin light chain; occludin; proteinase activated receptor 2; ribosome RNA; serine proteinase; tight junction protein; serine proteinase; adult; animal experiment; animal model; animal tissue; Article; clinical article; colon; colon biopsy; constipation; controlled study; diarrhea; disease severity; enteropathy; ex vivo study; feces microflora; female; human; human cell; human tissue; in vivo study; intestinal barrier dysfunction; intestine mucosa permeability; irritable colon; male; microbial community; nonhuman; priority journal; protein degradation; protein expression; questionnaire; RNA sequence; supernatant; animal; biopsy; Caco-2 cell line; case control study; dysbiosis; enzymology; feces; intestine absorption; intestine flora; intestine mucosa; irritable colon; metabolism; microbiology; middle aged; mouse; pathology; pathophysiology; permeability; physiology; prospective study; severity of illness index","","cysteine proteinase, 37353-41-6; mucosa associated lymphoid tissue lymphoma translocation protein 1, ; occludin, 176304-61-3; proprotein convertase 9, ; serine protease HTRA1, ; serine proteinase, 37259-58-8; Serine Proteases, ; Tight Junction Proteins, ","","","National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK, (K23DK103911); Mayo Clinic; Center for Individualized Medicine, Mayo Clinic, CIM","Funding text 1: Funding this project was funded by niDDK K23 DK103911 to Dr. Madhusudan grover. Dr. Jun chen is supported by Mayo clinic center for individualized Medicine.; Funding text 2: This project was funded by NIDDK K23 DK103911 to Dr. Madhusudan Grover. Dr. Jun Chen is supported by Mayo Clinic Center for Individualized Medicine.","Vergnolle N., Protease inhibition as new therapeutic strategy for GI diseases, Gut, 65, pp. 1215-1224, (2016); Olland-Fourcade C.R., Denadai-Souza A., Cirillo C., Et al., Epithelial expression and function of trypsin-3 in irritable bowel syndrome, Gut, 66, pp. 1767-1778, (2017); Biancheri P., Di Sabatino A., Corazza G.R., Et al., Proteases and the gut barrier, Cell Tissue Res, 351, pp. 269-280, (2013); Maharshak N., Huh E.Y., Paiboonrungruang C., Et al., Enterococcus faecalis gelatinase mediates intestinal permeability via protease-activated receptor 2, Infect Immun, 83, pp. 2762-2770, (2015); Ao M.B.R., Tanksale A.M., Ghatge M.S., Et al., Molecular and biotechnological aspects of microbial proteases, Microbiol Mol Biol Rev, 62, pp. 597-635, (1998); Pruteanu M., Hyland N.P., Clarke D.J., Et al., Degradation of the extracellular matrix components by bacterial-derived metalloproteases: Implications for inflammatory bowel diseases, Inflamm Bowel Dis, 17, pp. 1189-1200, (2011); Shen W., Matsui T., Current knowledge of intestinal absorption of bioactive peptides, Food Funct, 8, pp. 4306-4314, (2017); Awlings N.D.R., Barrett A.J., Thomas P.D., Et al., The merops database of proteolytic enzymes, their substrates and inhibitors in 2017 and a comparison with peptidases in the panther database, Nucleic Acids Res, 46, 1 D, pp. D624-D632, (2018); Alipeau H.J.G., Wiepjes M., Motta J.P., Et al., Novel role of the serine protease inhibitor elafin in gluten-related disorders, Am J Gastroenterol, 109, pp. 748-756, (2014); Motta J.P., Magne L., Descamps D., Et al., Modifying the protease, antiprotease pattern by elafin overexpression protects mice from colitis, Gastroenterology, 140, pp. 1272-1282, (2011); Schmid M., Fellermann K., Fritz P., Et al., Attenuated induction of epithelial and leukocyte serine antiproteases elafin and secretory leukocyte protease inhibitor in Crohn's disease, J Leukoc Biol, 81, pp. 907-915, (2007); Macfarlane G.T., Allison C., Gibson S.A., Et al., Contribution of the microflora to proteolysis in the human large intestine, J Appl Bacteriol, 64, pp. 37-46, (1988); Ibson S.A.G., McFarlan C., Hay S., Et al., Significance of microflora in proteolysis in the colon, Appl Environ Microbiol, 55, pp. 679-683, (1989); Enell S.G., Gustafsson B.E., Ohlsson K., Immunochemical quanitation of pancreatic endopeptidases in the intestinal contents of germfree and conventional rats, Scand J Gastroenterol, 12, pp. 811-820, (1977); Enell S.G., Gustafsson B.E., Impaired enteric degradation of pancreatic endopeptidases in antibiotic-treated rats, Scand J Gastroenterol, 12, pp. 801-809, (1977); Enac N.C., Andrews C.N., Holzhausen M., Et al., Role for protease activity in visceral pain in irritable bowel syndrome, J Clin Invest, 117, pp. 636-647, (2007); Desormeaux C., Bautzova T., Garcia-Caraballo S., Et al., Protease-activated receptor 1 is implicated in irritable bowel syndrome mediators-induced signaling to thoracic human sensory neurons, Pain, 159, pp. 1257-1267, (2018); Nnahazi A.A., Ferrier L., Bezirard V., Et al., Luminal cysteine-proteases degrade colonic tight junction structure and are responsible for abdominal pain in constipation-predominant IBS, Am J Gastroenterol, 108, pp. 1322-1331, (2013); Buhner S., Hahne H., Hartwig K., Et al., Protease signaling through protease activated receptor 1 mediate nerve activation by mucosal supernatants from irritable bowel syndrome but not from ulcerative colitis patients, PLoS One, 13, (2018); Buhner S., Li Q., Vignali S., Et al., Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome, Gastroenterology, 137, pp. 1425-1434, (2009); Nnahazi A.A., Gecse K., Dabek M., Et al., Fecal proteases from diarrheic-IBS and ulcerative colitis patients exert opposite effect on visceral sensitivity in mice, Pain, 144, 1-2, pp. 209-217, (2009); Ecse K.G., Roka R., Ferrier L., Et al., Increased faecal serine protease activity in diarrhoeic IBS patients: A colonic lumenal factor impairing colonic permeability and sensitivity, Gut, 57, pp. 591-599, (2008); Beakanma C.I., Ochoa-Cortes F., Miranda-Morales M., Et al., Brain-gut interactions increase peripheral nociceptive signaling in mice with postinfectious irritable bowel syndrome, Gastroenterology, 141, pp. 2098-2108, (2011); Klem F., Wadhwa A., Prokop L.J., Et al., Prevalence, risk factors, and outcomes of irritable bowel syndrome after infectious enteritis: A systematic review and meta-analysis, Gastroenterology, 152, pp. 1042-1054, (2017); Rover M.G., Camilleri M., Smith K., Et al., On the fiftieth anniversary, Postinfectious Irritable Bowel Syndrome: Mechanisms Related to Pathogens. Neurogastroenterol Motil, 26, pp. 156-167, (2014); Vnin L.B.E., Vasquez J.R., Craik C.S., Substrate specificity of trypsin investigated by using a genetic selection, Proc Natl Acad Sci U S A, 87, pp. 6659-6663, (1990); DelMar E.G., Largman C., Brodrick J.W., Et al., A sensitive new substrate for chymotrypsin, Anal Biochem, 99, pp. 316-320, (1979); Dwards J.V.E., Prevost N.T., French A.D., Et al., Kinetic and structural analysis of fluorescent peptides on cotton cellulose nanocrystals as elastase sensors, Carbohydr Polym, 116, pp. 278-285, (2015); Sabotic J., Bleuler-Martinez S., Renko M., Et al., Structural basis of trypsin inhibition and entomotoxicity of cospin, serine protease inhibitor involved in defense of Coprinopsis cinerea fruiting bodies, J Biol Chem, 287, pp. 3898-3907, (2012); Morita T., Kato H., Iwanaga S., Et al., New fluorogenic substrates for alpha-thrombin, factor xa, kallikreins, and urokinase, J Biochem, 82, pp. 1495-1498, (1977); Euleers H.C., Hanning N., Heirbaut J., Et al., Newly developed serine protease inhibitors decrease visceral hypersensitivity in a post-inflammatory rat model for irritable bowel syndrome, Br J Pharmacol, 175, pp. 3516-3533, (2018); Denadai-Souza A., Bonnart C., Tapias N.S., Et al., Functional proteomic profiling of secreted serine proteases in health and inflammatory bowel disease, Sci Rep, 8, (2018); Dgington-Mitchell L.E.E., Barlow N., Aurelio L., Et al., Fluorescent diphenylphosphonate-based probes for detection of serine protease activity during inflammation, Bioorg Med Chem Lett, 27, pp. 254-260, (2017); Wegener J., Abrams D., Willenbrink W., Et al., Automated multi-well device to measure transepithelial electrical resistances under physiological conditions, Biotechniques, 37, 4, pp. 590-597, (2004); Rover M.G., Camilleri M., Hines J., Et al., 13) C mannitol as a novel biomarker for measurement of intestinal permeability, Neurogastroenterol Motil, 28, pp. 1114-1119, (2016); Szarka L.A., Camilleri M., Methods for the assessment of small-bowel and colonic transit, Semin Nucl Med, 42, pp. 113-123, (2012); Sai P.Y.T., Zhang B., He W.Q., Et al., IL-22 upregulates epithelial claudin-2 to drive diarrhea and enteric pathogen clearance, Cell Host Microbe, 21, pp. 671-681, (2017); Baldwin E.A., Walther-Antonio M., MacLean A.M., Et al., Persistent microbial dysbiosis in preterm premature rupture of membranes from onset until delivery, PeerJ, 3, (2015); Jeraldo P., Kalari K., Chen X., Et al., Im-tornado: A tool for comparison of 16s reads from paired-end libraries, PLoS One, 9, (2014); Arroll I.M.C., Ringel-Kulka T., Ferrier L., Et al., Fecal protease activity is associated with compositional alterations in the intestinal microbiota, PLoS One, 8, (2013); Oka R.R., Rosztoczy A., Leveque M., Et al., A pilot study of fecal serine-protease activity: A pathophysiologic factor in diarrhea-predominant irritable bowel syndrome, Clin Gastroenterol Hepatol, 5, pp. 550-555, (2007); Ooth D.T., Garsed K., Singh G., Et al., Characterisation of faecal protease activity in irritable bowel syndrome with diarrhoea: Origin and effect of gut transit, Gut, 63, pp. 753-760, (2014); Wilcz-Villega E.M., McClean S., O'Sullivan M.A., Mast cell tryptase reduces junctional adhesion molecule-A (jam-A ) expression in intestinal epithelial cells: Implications for the mechanisms of barrier dysfunction in irritable bowel syndrome, Am J Gastroenterol, 108, pp. 1140-1151, (2013); Oeffier M.C., Gloro R., Boukhettala N., Et al., Increased proteasome-mediated degradation of occludin in irritable bowel syndrome, Am J Gastroenterol, 105, pp. 1181-1188, (2010); Weber C.R., Raleigh D.R., Su L., Et al., Epithelial myosin light chain kinase activation induces mucosal interleukin-13 expression to alter tight junction ion selectivity, J Biol Chem, 285, pp. 12037-12046, (2010); Shen L., Weber C.R., Raleigh D.R., Et al., Tight junction pore and leak pathways: A dynamic duo, Annu Rev Physiol, 73, pp. 283-309, (2011); Oka R.R., Ait-Belgnaoui A., Salvador-Cartier C., Et al., Dexamethasone prevents visceral hyperalgesia but not colonic permeability increase induced by luminal protease-activated receptor-2 agonist in rats, Gut, 56, pp. 1072-1078, (2007); Reed D.E., Barajas-Lopez C., Cottrell G., Et al., Mast cell tryptase and proteinase-activated receptor 2 induce hyperexcitability of Guinea-pig submucosal neurons, J Physiol, 547, pp. 531-542, (2003); Sessenwein J.L., Baker C.C., Pradhananga S., Et al., Protease-mediated suppression of drg neuron excitability by commensal bacteria, J Neurosci, 37, pp. 11758-11768, (2017); McCarville J.L., Dong J., Caminero A., Et al., A commensal Bifidobacterium longum strain improves gluten-related immunopathology in mice through expression of a serine protease inhibitor, Appl Environ Microbiol, (2017); Mkaouar H., Akermi N., Mariaule V., Et al., Siropins, novel serine protease inhibitors from gut microbiota acting on human proteases involved in inflammatory bowel diseases, Microb Cell Fact, 15, (2016); Arcia-Ferrer I.G., Arede P., Gomez-Blanco J., Et al., Structural and functional insights into Escherichia coli α2-macroglobulin endopeptidase snap-trap inhibition, Proc Natl Acad Sci U S A, 112, pp. 8290-8295, (2015); Oulas T.G., Ksiazek M., Garcia-Ferrer I., Et al., A structure-derived snap-trap mechanism of a multispecific serpin from the dysbiotic human oral microbiome, J Biol Chem, 292, pp. 10883-10898, (2017); Ibson S.A.G., Macfarlane G.T., Characterization of proteases formed by Bacteroides fragilis, J Gen Microbiol, 134, pp. 2231-2240, (1988); Hornton R.F.T., Murphy E.C., Kagawa T.F., Et al., The effect of environmental conditions on expression of Bacteroides fragilis and Bacteroides thetaiotaomicron C10 protease genes, BMC Microbiol, 12, (2012); Uo C.J.G., Chang F.Y., Wyche T.P., Et al., Discovery of reactive microbiota-derived Metabolites that inhibit host proteases, Cell, 168, pp. 517-526, (2017); Leynen I.C., Vazeille E., Artieda M., Et al., Genetic and microbial factors modulating the ubiquitin proteasome system in inflammatory bowel disease, Gut, 63, pp. 1265-1274, (2014); Motta J.P., Bermudez-Humaran L.G., Deraison C., Et al., Food-grade bacteria expressing elafin protect against inflammation and restore colon homeostasis, Sci Transl Med, 4, (2012); Kobayashi H., Prevention of cancer and inflammation by soybean protease inhibitors, Front Biosci, 5, pp. 966-973, (2013); De Santis S., Galleggiante V., Scandiffio L., Et al., Secretory leukoprotease inhibitor (Slpi) expression is required for educating murine dendritic cells inflammatory response following quercetin exposure, Nutrients, 9, (2017)","M. Grover; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, 200 First Street SW, 55905, United States; email: grover.madhusudan@mayo.edu","","BMJ Publishing Group","","","","","","00175749","","GUTTA","30923071","English","Gut","Article","Final","All Open Access; Bronze Open Access; Green Open Access","Scopus","2-s2.0-85063578049"

"Liu F.; Zhang X.; Ji Y.","Liu, Feng (57214999843); Zhang, Xuesong (57214101168); Ji, Yong (57205438203)","57214999843; 57214101168; 57205438203","Total flavonoid extract from hawthorn (Crataegus pinnatifida) improves inflammatory cytokines-evoked epithelial barrier deficit","2020","Medical Science Monitor","26","","e920170","","","","21","10.12659/MSM.920170","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85079638923&doi=10.12659%2fMSM.920170&partnerID=40&md5=53b9aa441fbe5323e76646bbedddbbb9","Department of General Anorectal Surgery, Jingjiang People’s Hospital, Jingjiang, Jiangsu, China; Central Laboratory, Jingjiang People’s Hospital, Jingjiang, Jiangsu, China; Department of General Surgery, Jingjiang People’s Hospital, Jingjiang, Jiangsu, China","Liu F., Department of General Anorectal Surgery, Jingjiang People’s Hospital, Jingjiang, Jiangsu, China; Zhang X., Central Laboratory, Jingjiang People’s Hospital, Jingjiang, Jiangsu, China; Ji Y., Department of General Surgery, Jingjiang People’s Hospital, Jingjiang, Jiangsu, China","Background: Intestinal epithelial barrier dysfunction is involved in the development and pathogenesis of intestinal diseases, such as irritable bowel syndrome, inflammatory bowel disease, and celiac disease. This study was performed to evaluate the ability of total flavonoid extract from hawthorn (TFH) to improve TNF-a-evoked intestinal epithelial barrier deficit. Material/Methods: Caco-2 cells monolayers were exposed to TNF-a in different concentrations of TFH. Intestinal epithelial barrier function was evaluated using epithelial permeability and transepithelial electrical resistance (TER). Results: Our findings showed that TFH alleviated the increase of paracellular permeability and the decline of transepithelial electrical resistance (TER) evoked by TNF-a. Additionally, 24-h pre-incubation with TFH inhibited TNF-a-evoked secretion of pro-inflammatory factors (IL-6, IL-8, MCP-1, and IL-1b). Furthermore, TFH inhibited TNF-a-evoked overexpression of pMLC and MLCK and alleviated breakdown of TJs protein (ZO-1 and occludin). The activations of Elk-1 and NFkBp65 were inhibited by TFH pre-incubation. Conclusions: TFH can alleviate TNF-a-evoked intestinal epithelial barrier deficit via the NFkBp65-mediated MLCK-MLC signaling pathway. © Med Sci Monit.","Flavonoids; Gastrointestinal Diseases; Tight Junction Proteins","Caco-2 Cells; Cell Survival; Crataegus; Cytokines; Epithelial Cells; ets-Domain Protein Elk-1; Flavonoids; Humans; Inflammation Mediators; Intestines; Myosin Light Chains; Myosin-Light-Chain Kinase; Phosphorylation; Plant Extracts; Protective Agents; Tight Junction Proteins; Transcription Factor RelA; Tumor Necrosis Factor-alpha; chlorogenic acid; Crataegus pinnatifida extract; epicatechin; flavonoid; hyperin; interleukin 1beta; interleukin 6; interleukin 8; isoquercitrin; mitogen activated protein kinase 1; mitogen activated protein kinase 3; monocyte chemotactic protein 1; myosin light chain; myosin light chain kinase; occludin; plant extract; procyanidin; protein ZO1; transcription factor Elk 1; transcription factor RelA; tumor necrosis factor; unclassified drug; autacoid; cytokine; ELK1 protein, human; flavonoid; myosin light chain; myosin light chain kinase; plant extract; protective agent; tight junction protein; transcription factor Elk 1; transcription factor RelA; apoptosis; Article; cell membrane permeability; cell viability; controlled study; Crataegus pinnatifida; digestive system function disorder; enzyme linked immunosorbent assay; gastrointestinal epithelium; gene overexpression; high performance liquid chromatography; human; human cell; inflammation; MTT assay; protein expression; protein phosphorylation; signal transduction; transepithelial resistance; upregulation; Caco-2 cell line; cell survival; chemistry; Crataegus; drug effect; epithelium cell; intestine; metabolism; pathology; phosphorylation","","chlorogenic acid, 327-97-9; epicatechin, 490-46-0; hyperin, 482-36-0; interleukin 8, 114308-91-7; isoquercitrin, 21637-25-2, 482-35-9; mitogen activated protein kinase 1, 137632-08-7; mitogen activated protein kinase 3, 137632-07-6; myosin light chain kinase, 51845-53-5; occludin, 176304-61-3; procyanidin, 4852-22-6; Cytokines, ; ELK1 protein, human, ; ets-Domain Protein Elk-1, ; Flavonoids, ; Inflammation Mediators, ; Myosin Light Chains, ; Myosin-Light-Chain Kinase, ; Plant Extracts, ; Protective Agents, ; Tight Junction Proteins, ; Transcription Factor RelA, ; Tumor Necrosis Factor-alpha, ","","","","","Turner J.R., Intestinal mucosal barrier function in health and disease, Nat Rev Immunol, 9, 11, pp. 799-809, (2009); Arnott I.D., Kingstone K., Ghosh S., Abnormal intestinal permeability predicts relapse in inactive Crohn disease, Scand J Gastroenterol, 35, 11, pp. 1163-1169, (2000); Groschwitz K.R., Hogan S.P., Intestinal barrier function: Molecular regulation and disease pathogenesis, J Allergy Clin Immunol, 124, 1, pp. 3-20, (2009); Odenwald M.A., Turner J.R., Intestinal permeability defects: Is it time to treat?, Clin Gastroenterol Hepatol, 11, 9, pp. 1075-1083, (2013); Ye X., Sun M., AGR2 ameliorates tumor necrosis factor-alpha-induced epithelial barrier dysfunction via suppression of NF-kappaB p65-mediated MLCK/p-MLC pathway activation, Int J Mol Med, 39, 5, pp. 1206-1214, (2017); van Itallie C.M., Anderson J.M., Claudins and epithelial paracellular transport, Annu Rev Physiol, 68, pp. 403-429, (2006); Suzuki T., Regulation of intestinal epithelial permeability by tight junctions, Cell Mol Life Sci, 70, 4, pp. 631-659, (2013); Toumi R., Soufli I., Rafa H., Et al., Probiotic bacteria lactobacillus and bifidobacterium attenuate inflammation in dextran sulfate sodium-induced experimental colitis in mice, Int J Immunopathol Pharmacol, 27, 4, pp. 615-627, (2014); Wang F., Graham W.V., Wang Y., Et al., Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression, Am J Pathol, 166, 2, pp. 409-419, (2005); Sandborn W.J., Targan S.R., Biologic therapy of inflammatory bowel disease, Gastroenterology, 122, 6, pp. 1592-1608, (2002); van Deventer S.J., Anti-TNF antibody treatment of Crohn’s disease, Ann Rheum Dis, 58, pp. I114-I120, (1999); Ricart E., Panaccione R., Loftus E.V., Et al., Infliximab for Crohn’s disease in clinical practice at the Mayo Clinic: The first 100 patients, Am J Gastroenterol, 96, 3, pp. 722-729, (2001); Weber C.R., Raleigh D.R., Su L., Et al., Epithelial myosin light chain kinase activation induces mucosal interleukin-13 expression to alter tight junction ion selectivity, J Biol Chem, 285, 16, pp. 12037-12046, (2010); Cunningham K.E., Turner J.R., Myosin light chain kinase: Pulling the strings of epithelial tight junction function, Ann NY Acad Sci, 1258, pp. 34-42, (2012); Doecke J.D., Hartnell F., Bampton P., Et al., Infliximab vs. Adalimumab in Crohn’s disease: Results from 327 patients in an Australian and New Zealand observational cohort study, Aliment Pharmacol Ther, 45, 4, pp. 542-552, (2017); Vezza T., Rodriguez-Nogales A., Algieri F., Et al., Flavonoids in inflammatory bowel disease: A review, Nutrients, 8, 4, (2016); Wu J., Peng W., Qin R., Zhou H., Crataegus pinnatifida: Chemical constituents, pharmacology, and potential applications, Molecules, 19, 2, pp. 1685-1712, (2014); Liu P., Kallio H., Yang B., Phenolic compounds in hawthorn (Crataegus grayana) fruits and leaves and changes during fruit ripening, J Agric Food Chem, 59, 20, pp. 11141-11149, (2011); Zhang J., Liang R., Wang L., Et al., Effects of an aqueous extract of Crataegus pinnatifida Bge. Var. Major N.E.Br. Fruit on experimental atherosclerosis in rats, J Ethnopharmacol, 148, 2, pp. 563-569, (2013); Pathak N., Khandelwal S., Role of oxidative stress and apoptosis in cadmium induced thymic atrophy and splenomegaly in mice, Toxicol Lett, 169, 2, pp. 95-108, (2007); Fiocchi C., Inflammatory bowel disease: Evolutionary concepts in biology, epidemiology, mechanisms and therapy, Curr Opin Gastroenterol, 29, 4, pp. 347-349, (2013); Khor B., Gardet A., Xavier R.J., Genetics and pathogenesis of inflammatory bowel disease, Nature, 474, 7351, pp. 307-317, (2011); Siegel C.A., Review article: Explaining risks of inflammatory bowel disease therapy to patients, Aliment Pharmacol Ther, 33, 1, pp. 23-32, (2011); Li Y., Tian X., Li S., Et al., Total polysaccharides of adlay bran (Coix lachrymajobi L.) improve TNF-alpha induced epithelial barrier dysfunction in Caco-2 cells via inhibition of the inflammatory response, Food Funct, 10, 5, pp. 2906-2913, (2019); Salaritabar A., Darvishi B., Hadjiakhoondi F., Et al., Therapeutic potential of flavonoids in inflammatory bowel disease: A comprehensive review, World J Gastroenterol, 23, 28, pp. 5097-5114, (2017); Han X., Li W., Huang D., Yang X., Polyphenols from hawthorn peels and fleshes differently mitigate dyslipidemia, inflammation and oxidative stress in association with modulation of liver injury in high fructose diet-fed mice, Chem Biol Interact, 257, pp. 132-140, (2016); Wang Y., Lv M., Wang T., Et al., Research on mechanism of charred hawthorn on digestive through modulating “brain-gut” axis and gut flora, J Ethnopharmacol, 245, (2019); Fujisawa M., Oguchi K., Yamaura T., Et al., Protective effect of hawthorn fruit on murine experimental colitis, Am J Chin Med, 33, 2, pp. 167-180, (2005); Gibson P., Rosella O., Interleukin 8 secretion by colonic crypt cells in vitro: Response to injury suppressed by butyrate and enhanced in inflammatory bowel disease, Gut, 37, 4, pp. 536-543, (1995); Lu Y., Li L., Zhang J.W., Et al., Total polysaccharides of the Sijunzi decoction attenuate tumor necrosis factor-alpha-induced damage to the barrier function of a Caco-2 cell monolayer via the nuclear factor-kappaB-myosin light chain kinase-myosin light chain pathway, World J Gastroenterol, 24, 26, pp. 2867-2877, (2018); Shen L., Weber C.R., Raleigh D.R., Et al., Tight junction pore and leak pathways: A dynamic duo, Annu Rev Physiol, 73, pp. 283-309, (2011); Liang N., Kitts D.D., Chlorogenic acid (CGA) isomers alleviate interleukin 8 (IL-8) production in Caco-2 cells by decreasing phosphorylation of p38 and increasing cell integrity, Int J Mol Sci, 19, 12, (2018); Ma T.Y., Iwamoto G.K., Hoa N.T., Et al., TNF-alpha-induced increase in intestinal epithelial tight junction permeability requires NF-kappa B activation, Am J Physiol Gastrointest Liver Physiol, 286, 3, pp. G367-G376, (2004); Al-Sadi R., Guo S., Ye D., Ma T.Y., TNF-alpha modulation of intestinal epithelial tight junction barrier is regulated by ERK1/2 activation of Elk-1, Am J Pathol, 183, 6, pp. 1871-1884, (2013); Wang L., Yue Z., Guo M., Et al., Dietary flavonoid hyperoside induces apoptosis of activated human LX-2 hepatic stellate cell by suppressing canonical NF-kappaB signaling, Biomed Res Int, 2016, (2016)","Y. Ji; Department of General Surgery, Jingjiang People’s Hospital, Jingjiang, Jiangsu, China; email: jyong0909@126.com","","International Scientific Information, Inc.","","","","","","12341010","","MSMOF","32065826","English","Med. Sci. Monit.","Article","Final","All Open Access; Green Open Access","Scopus","2-s2.0-85079638923"

"Liu Y.; Xiao W.; Yu L.; Tian F.; Wang G.; Lu W.; Narbad A.; Chen W.; Zhai Q.","Liu, Yang (57208195491); Xiao, Wei (57222007753); Yu, Leilei (56510578800); Tian, Fengwei (19337981000); Wang, Gang (56190334700); Lu, Wenwei (55484329700); Narbad, Arjan (6603867601); Chen, Wei (55613230694); Zhai, Qixiao (55241436100)","57208195491; 57222007753; 56510578800; 19337981000; 56190334700; 55484329700; 6603867601; 55613230694; 55241436100","Evidence from comparative genomic analyses indicating that: Lactobacillus -mediated irritable bowel syndrome alleviation is mediated by conjugated linoleic acid synthesis","2021","Food and Function","12","3","","1121","1134","13","16","10.1039/d0fo02616f","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100945293&doi=10.1039%2fd0fo02616f&partnerID=40&md5=aed827bf8af5aa1cd478b28ab7e007b6","State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi Jiangsu, 214122, China; School of Food Science and Technology, Jiangnan University, Wuxi Jiangsu, 214122, China; International Joint Research Laboratory for Pharmabiotics and Antibiotic Resistance, Jiangnan University, Wuxi Jiangsu, 214122, China; (Yangzhou) Institute of Food Biotechnology, Jiangnan University, Yangzhou, 225004, China; National Engineering Research Center for Functional Food, Jiangnan University, Wuxi Jiangsu, 214122, China; Gut Health and Food Safety Programme, Quadram Institute Bioscience, Norwich Research Park, Norwich, United Kingdom; Beijing Innovation Center of Food Nutrition and Human Health, Beijing Technology and Business University (BTBU), Beijing, 100048, China","Liu Y., State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi Jiangsu, 214122, China, School of Food Science and Technology, Jiangnan University, Wuxi Jiangsu, 214122, China; Xiao W., State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi Jiangsu, 214122, China, School of Food Science and Technology, Jiangnan University, Wuxi Jiangsu, 214122, China; Yu L., State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi Jiangsu, 214122, China, School of Food Science and Technology, Jiangnan University, Wuxi Jiangsu, 214122, China; Tian F., State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi Jiangsu, 214122, China, School of Food Science and Technology, Jiangnan University, Wuxi Jiangsu, 214122, China, International Joint Research Laboratory for Pharmabiotics and Antibiotic Resistance, Jiangnan University, Wuxi Jiangsu, 214122, China; Wang G., State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi Jiangsu, 214122, China, School of Food Science and Technology, Jiangnan University, Wuxi Jiangsu, 214122, China, International Joint Research Laboratory for Pharmabiotics and Antibiotic Resistance, Jiangnan University, Wuxi Jiangsu, 214122, China, (Yangzhou) Institute of Food Biotechnology, Jiangnan University, Yangzhou, 225004, China; Lu W., State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi Jiangsu, 214122, China, School of Food Science and Technology, Jiangnan University, Wuxi Jiangsu, 214122, China, (Yangzhou) Institute of Food Biotechnology, Jiangnan University, Yangzhou, 225004, China, National Engineering Research Center for Functional Food, Jiangnan University, Wuxi Jiangsu, 214122, China; Narbad A., International Joint Research Laboratory for Pharmabiotics and Antibiotic Resistance, Jiangnan University, Wuxi Jiangsu, 214122, China, Gut Health and Food Safety Programme, Quadram Institute Bioscience, Norwich Research Park, Norwich, United Kingdom; Chen W., State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi Jiangsu, 214122, China, School of Food Science and Technology, Jiangnan University, Wuxi Jiangsu, 214122, China, National Engineering Research Center for Functional Food, Jiangnan University, Wuxi Jiangsu, 214122, China, Beijing Innovation Center of Food Nutrition and Human Health, Beijing Technology and Business University (BTBU), Beijing, 100048, China; Zhai Q., State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi Jiangsu, 214122, China, School of Food Science and Technology, Jiangnan University, Wuxi Jiangsu, 214122, China, International Joint Research Laboratory for Pharmabiotics and Antibiotic Resistance, Jiangnan University, Wuxi Jiangsu, 214122, China","Irritable bowel syndrome (IBS) is a chronic intestinal disorder accompanied by low-grade inflammation, visceral hypersensitivity, and gut microbiota dysbiosis. Several studies have indicated that Lactobacillus supplementation can help to alleviate IBS symptoms and that these effects are strain-specific. Therefore, this study aimed to investigate the key physiological characteristics and functional genes contributing to the IBS-alleviating effects of Lactobacillus. An IBS model was established by subjecting C57BL/6 mice to Citrobacter rodentium ingestion and water avoidance stress. Lactobacillus strains with different physiological characteristics were administered to mice intragastrically for 4 weeks (5 × 109 CFU/0.2 mL per mouse per day). Indicators of colonic inflammation, visceral hypersensitivity, and gut microbiota were also evaluated. Finally, differences in functional genes between Lactobacillus strains were analyzed by a comparative genomic analysis, and the relationships between the physiological characteristics, functional genes, and IBS-alleviating effects of the strains were quantified using correlation analysis. Among the eight tested Lactobacillus strains, only Lactobacillus plantarum CCFM8610 significantly inhibited the expression of IL-1β, IL-6, PAR-2, and mast cell tryptase. L. plantarum CCFM8610 also significantly increased the intestinal barrier function, inhibited visceral hypersensitivity symptoms, and modulated the gut microbiota diversity and composition. The correlation analysis of factors associated with the IBS-alleviating effects of Lactobacillus revealed the ability to synthesize conjugated linoleic acid as the most strongly associated physiological characteristic and COG1028-related genes as the most strongly associated functional genes. In conclusion, these findings can facilitate the rapid screening of Lactobacillus strains with IBS-alleviating effects and lay a foundation for studies of the related mechanisms. © The Royal Society of Chemistry.","","Animals; Citrobacter rodentium; Colon; Corticosterone; Enterobacteriaceae Infections; Humans; Inflammation; Irritable Bowel Syndrome; Lactobacillus; Linoleic Acids, Conjugated; Male; Mice; Mice, Inbred C57BL; Probiotics; Receptor, PAR-2; Tryptases; Correlation methods; Genes; Immunology; Mammals; Pathology; Physiology; Strain; conjugated linoleic acid; corticosterone; F2rl1 protein, mouse; probiotic agent; proteinase activated receptor 2; tryptase; Conjugated linoleic acid; Correlation analysis; Intestinal barriers; Irritable bowel syndromes; Lactobacillus plantarum; Lactobacillus strains; Physiological characteristics; Water avoidance stress; animal; blood; C57BL mouse; Citrobacter rodentium; colon; Enterobacteriaceae infection; genetics; human; inflammation; irritable colon; Lactobacillus; male; metabolism; microbiology; mouse; pathology; physiology; Linoleic acid","","corticosterone, 50-22-6; tryptase, 97501-93-4; Corticosterone, ; F2rl1 protein, mouse, ; Linoleic Acids, Conjugated, ; Receptor, PAR-2, ; Tryptases, ","","","National First-Class Discipline Program of Food Science and Technology, (JUFSTR20180102); Projects of Innovation and Development Pillar Program for Key Industries in Southern Xinjiang of Xinjiang Production and Construction Corps, (2018DB002); Biotechnology and Biological Sciences Research Council, BBSRC; National Key Research and Development Program of China, NKRDPC, (31820103010, 31871773); National Key Research and Development Program of China, NKRDPC; Collaborative Innovationcenter of Food Safety and Quality Control in Jiangsu Province","This work was supported by the National Natural Science Foundation of China Program [No. 31820103010 and No. 31871773]; the Projects of Innovation and Development Pillar Program for Key Industries in Southern Xinjiang of Xinjiang Production and Construction Corps [2018DB002]; the National First-Class Discipline Program of Food Science and Technology [JUFSTR20180102]; the BBSRC Newton Fund Joint Centre Award; and the Collaborative Innovation Center of Food Safety and Quality Control in Jiangsu Province.","Ford A.C., Lacy B.E., Talley N.J., Irritable Bowel Syndrome, N. Engl. J. Med., 376, pp. 2566-2578, (2017); Buono J.L., Carson R.T., Flores N.M., Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea, Health. Qual. Life. Outcomes, 15, (2017); Canavan C., West J., Card T., Review article: The economic impact of the irritable bowel syndrome, Aliment. Pharmacol. Ther., 40, pp. 1023-1034, (2014); Gwee K.A., Ghoshal U.C., Chen M., Irritable bowel syndrome in Asia: Pathogenesis, natural history, epidemiology, and management, J. Gastroenterol. Hepatol., 33, pp. 99-110, (2018); Staudacher H.M., Whelan K., The low FODMAP diet: Recent advances in understanding its mechanisms and efficacy in IBS, Gut, 66, pp. 1517-1527, (2017); Akehurst R.L., Brazier J.E., Mathers N., O'Keefe C., Kaltenthaler E., Morgan A., Platts M., Walters S.J., Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting, Pharmacoeconomics, 20, pp. 455-462, (2002); Ballou S., McMahon C., Lee H.-N., Katon J., Shin A., Rangan V., Singh P., Nee J., Camilleri M., Lembo A., Effects of irritable bowel syndrome on daily activities vary among subtypes based on results from the IBS in America Survey, Clin. Gastroenterol. Hepatol., 17, pp. 2471-2478, (2019); Brenner D.M., Sayuk G.S., Current US Food and Drug Administration-approved pharmacologic therapies for the treatment of irritable bowel syndrome with diarrhea, Adv. Ther., 37, pp. 83-96, (2020); Sayuk G.S., Wolf R., Chang L., Comparison of symptoms, healthcare utilization, and treatment in diagnosed and undiagnosed individuals with diarrhea-predominant irritable bowel syndrome, Am. J. Gastroenterol., 112, pp. 892-899, (2017); Sanders M.E., Merenstein D.J., Reid G., Gibson G.R., Rastall R.A., Probiotics and prebiotics in intestinal health and disease: From biology to the clinic, Nat. Rev. Gastroenterol. Hepatol., 16, pp. 605-616, (2019); De Filippis F., Pasolli E., Ercolini D., The food-gut axis: Lactic acid bacteria and their link to food, the gut microbiome and human health, FEMS Microbiol. Rev., 44, pp. 454-489, (2020); Do Carmo M.S., Itapary Dos Santos C., Araujo M.C., Giron J.A., Fernandes E.S., Monteiro-Neto V., Probiotics, mechanisms of action, and clinical perspectives for diarrhea management in children, Food Funct., 9, pp. 5074-5095, (2018); Zhao Q., Yang W.-R., Wang X.-H., Li G.-Q., Xu L.-Q., Cui X., Liu Y., Zuo X.-L., Clostridium butyricum alleviates intestinal low-grade inflammation in TNBS-induced irritable bowel syndrome in mice by regulating functional status of lamina propria dendritic cells, World J. Gastroenterol., 25, pp. 5469-5482, (2019); Ding R., Goh W., Wu R., Yue X., Luo X., Khine W.W.T., Wu J., Lee Y., Revisit gut microbiota and its impact on human health and disease, J. Food Drug Anal., 27, pp. 623-631, (2019); Ait-Belgnaoui A., Payard I., Rolland C., Harkat C., Braniste V., Theodorou V., Tompkins T.A., Bifidobacterium longum and Lactobacillus helveticus synergistically suppress stress-related visceral hypersensitivity through hypothalamic-pituitary-adrenal axis modulation, J. Neurogastroenterol., 24, pp. 138-146, (2018); Martoni C.J., Srivastava S., Leyer G.J., Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 improve abdominal pain severity and symptomology in irritable bowel syndrome: Randomized controlled trial, Nutrients, 12, (2020); Cremon C., Guglielmetti S., Gargari G., Taverniti V., Castellazzi A.M., Valsecchi C., Tagliacarne C., Fiore W., Bellini M., Bertani L., Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial, United Eur. Gastroenterol. J., 6, pp. 604-613, (2018); Shin S.P., Choi Y.M., Kim W.H., Hong S.P., Park J.-M., Kim J., Kwon O., Lee E.H., Hahm K.B., A double blind, placebo-controlled, randomized clinical trial that breast milk derived- Lactobacillus gasseri BNR17 mitigated diarrhea-dominant irritable bowel syndrome, J. Clin. Biochem. Nutr., 62, pp. 179-186, (2018); Stevenson C., Blaauw R., Fredericks E., Visser J., Roux S., Randomized clinical trial: Effect of Lactobacillus plantarum, 299v on symptoms of irritable bowel syndrome, Nutrition, 30, pp. 1151-1157, (2014); Hod K., Dekel R., Aviv Cohen N., Sperber A., Ron Y., Boaz M., Berliner S., Maharshak N., The effect of a multispecies probiotic on microbiota composition in a clinical trial of patients with diarrhea-predominant irritable bowel syndrome, Neurogastroenterol. Motil., 30, (2018); Begtrup L.M., De Muckadell O.B.S., Kjeldsen J., Jarbol D.E., Long-term treatment with probiotics in primary care patients with irritable bowel syndrome-a randomised, double-blind, placebo controlled trial, Scand. J. Gastroenterol., 48, pp. 1127-1135, (2013); Romijn A.R., Rucklidge J.J., Kuijer R.G., Frampton C., A double-blind, randomized, placebo-controlled trial of Lactobacillus helveticus and Bifidobacterium longum for the symptoms of depression, Aust. N. Z. J. Psychiat., 51, pp. 810-821, (2017); Dunne C., O'Mahony L., Murphy L., Thornton G., Morrissey D., O'Halloran S., Feeney M., Flynn S., Fitzgerald G., Daly C., In vitro selection criteria for probiotic bacteria of human origin: Correlation with in vivo findings, Am. J. Clin. Nutr., 73, pp. 386s-392s, (2001); Li R., Zhang Y., Polk D.B., Tomasula P.M., Yan F., Liu L., Preserving viability of Lactobacillus rhamnosus GG in vitro and in vivo by a new encapsulation system, J. Controlled Release, 230, pp. 79-87, (2016); Yan S., Yang B., Zhao J., Zhao J., Stanton C., Ross R.P., Zhang H., Chen W., A ropy exopolysaccharide producing strain Bifidobacterium longum subsp. longum YS108R alleviates DSS-induced colitis by maintenance of the mucosal barrier and gut microbiota modulation, Food Funct., 10, pp. 1595-1608, (2019); Wang J., Chen H., Yang B., Gu Z., Zhang H., Chen W., Chen Y.Q., Lactobacillus plantarum ZS2058 produces CLA to ameliorate DSS-induced acute colitis in mice, RSC Adv., 6, pp. 14457-14464, (2016); Subramaniyan V., Gurumurthy K., Diversity of probiotic adhesion genes in the gastrointestinal tract of goats, J. Cell. Biochem., 120, pp. 12422-12428, (2019); Lee I.-C., Caggianiello G., Van Swam I.I., Taverne N., Meijerink M., Bron P.A., Spano G., Kleerebezem M., Strain-specific features of extracellular polysaccharides and their impact on Lactobacillus plantarum -host interactions, Appl. Environ. Microbiol., 82, pp. 3959-3970, (2016); Ibeakanma C., Cortes F.O., Morales M.M., McDonald T., Spreadbury I., Cenac N., Cattaruzza F., Hurlbut D.J., Vanner S., Bunnett N.W., Brain-gut interactions increase peripheral nociceptive signaling in mice with postinfectious irritable bowel syndrome, Gastroenterology, 141, pp. 2098-2108, (2011); Chen Q., Ren Y., Lu J., Bartlett M., Chen L., Zhang Y., Guo X., Liu C., A novel prebiotic blend product prevents irritable bowel syndrome in mice by improving gut microbiota and modulating immune response, Nutrients, 9, (2017); Liu Y., Sheng Y., Pan Q., Xue Y., Yu L., Tian F., Zhao J., Zhang H., Zhai Q., Chen W., Identification of the key physiological characteristics of Lactobacillus plantarum strains for ulcerative colitis alleviation, Food Funct., 11, pp. 1279-1291, (2020); Zhao J., Tian F., Yan S., Zhai Q., Zhang H., Chen W., Lactobacillus plantarum CCFM10 alleviating oxidative stress and restoring the gut microbiota in d-galactose-induced aging mice, Food Funct., 9, pp. 917-924, (2018); Cen S., Yin R., Mao B., Zhao J., Zhang H., Zhai Q., Chen W., Comparative genomics shows niche-specific variations of Lactobacillus plantarum strains isolated from human, Drosophila melanogaster, vegetable and dairy sources, Food Biosci., 35, (2020); Liu Y., Li Y., Yu X., Yu L., Tian F., Zhao J., Zhang H., Zhai Q., Chen W., Physiological characteristics of Lactobacillus casei strains and their alleviation effects against inflammatory bowel disease, J. Microbiol. Biotechnol., 30, (2020); Choghakhori R., Abbasnezhad A., Hasanvand A., Amani R., Inflammatory cytokines and oxidative stress biomarkers in irritable bowel syndrome: Association with digestive symptoms and quality of life, Cytokine, 93, pp. 34-43, (2017); Bertiauxvandaele N., Youmba S.B., Belmonte L., Lecleire S., Antonietti M., Gourcerol G., Leroi A.M., Dechelotte P., Menard J., Ducrotte P., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am. J. Gastroenterol., 106, pp. 2165-2173, (2011); Duan R., Zhu S., Wang B., Duan L., Alterations of gut microbiota in patients with irritable bowel syndrome based on 16S rRNA-targeted sequencing: A systematic review, Clin. Transl. Gastroenterol., 10, (2019); Ringelkulka T., McRorie J.W., Ringel Y., Multi-Center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the benefit of the probiotic Bifidobacte rium infantis, 35624 in non-patients with symptoms of abdominal discomfort and bloating, Am. J. Gastroenterol., 112, pp. 145-151, (2017); Ludidi S., Jonkers D., Koning C.J.M., Kruimel J.W., Mulder L., Der Vaart I.B.V., Conchillo J.M., Masclee A.A.M., Randomized clinical trial on the effect of a multispecies probiotic on visceroperception in hypersensitive IBS patients, Neurogastroenterol. Motil., 26, pp. 705-714, (2014); Cui Y., Wei H., Lu F., Liu X., Liu D., Gu L., Ouyang C., Different effects of three selected Lactobacillus strains in dextran sulfate sodium-induced colitis in BALB/c mice, PLoS One, 11, (2016); Zheng B., Van Bergenhenegouwen J., Van De Kant H.J.G., Folkerts G., Garssen J., Vos A.P., Morgan M.E., Kraneveld A.D., Specific probiotic dietary supplementation leads to different effects during remission and relapse in murine chronic colitis, Benefic. Microbes, 7, pp. 205-213, (2016); Perezberezo T., Pujo J., Martin P., Faouder P.L., Galano J., Guy A., Knauf C., Tabet J., Tronnet S., Barreau F., Identification of an analgesic lipopeptide produced by the probiotic Escherichia coli strain Nissle 1917, Nat. Commun., 8, (2017); Zhang J., Song L., Wang Y., Liu C., Zhang L., Zhu S., Liu S., Duan L., Beneficial effect of butyrate-producing Lachnospiraceae on stress-induced visceral hypersensitivity in rats, J. Gastroenterol. Hepatol., 34, pp. 1368-1376, (2018); Yang B., Qi H., Gu Z., Zhang H., Chen W., Chen H., Chen Y., Characterization of the triple-component linoleic acid isomerase in Lactobacillus plantarum ZS2058 by genetic manipulation, J. Appl. Microbiol., 123, pp. 1263-1273, (2017); Evans N.P., Misyak S.A., Schmelz E.M., Guri A.J., Hontecillas R., Bassaganya-Riera J., Conjugated linoleic acid ameliorates inflammation-induced colorectal cancer in mice through activation of PPARγ, J. Nutr., 140, pp. 515-521, (2010); Borniquel S., Jadert C., Lundberg J.O., Dietary conjugated linoleic acid activates PPARγ and the intestinal trefoil factor in SW480 cells and mice with dextran sulfate sodium-induced colitis, J. Nutr., 142, pp. 2135-2140, (2012); Delerive P., Gervois P., Fruchart J.-C., Staels B., Induction of IκBα expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-α activators, J. Biol. Chem., 275, pp. 36703-36707, (2000); Belury M.A., Dietary conjugated linoleic acid in health: Physiological effects and mechanisms of action, Annu. Rev. Nutr., 22, pp. 505-531, (2002); Chen Y., Jin Y., Stanton C., Ross R.P., Zhao J., Zhan H., Yang B., Chen W., Alleviation effects of Bifidobacterium breve on DSS-induced colitis depends on intestinal tract barrier maintenance and gut microbiota modulation, Eur. J. Nutr., (2020); Bassaganya-Riera J., Viladomiu M., Pedragosa M., De Simone C., Carbo A., Shaykhutdinov R., Jobin C., Arthur J.C., Corl B.A., Vogel H., Probiotic bacteria produce conjugated linoleic acid locally in the gut that targets macrophage PPARγ to suppress colitis, PLoS One, 7, (2012); Cole M., Augustin M.A., Food Safety and Health, Engineering, 6, pp. 391-392, (2020); Den Hartigh L.J., Conjugated linoleic acid effects on cancer, obesity, and atherosclerosis: A review of pre-clinical and human trials with current perspectives, Nutrients, 11, (2019); Marques T.M., Wall R., O'Sullivan O., Fitzgerald G.F., Shanahan F., Quigley E.M., Cotter P.D., Cryan J.F., Dinan T.G., Ross R.P., Dietary trans-10, cis-12-conjugated linoleic acid alters fatty acid metabolism and microbiota composition in mice, Br. J. Nutr., 113, pp. 728-738, (2015); Chen Y., Yang B., Ross R.P., Jin Y., Stanton C., Zhao J., Zhang H., Chen W., Orally administered CLA ameliorates DSS-induced colitis in mice via intestinal barrier improvement, oxidative stress reduction, and inflammatory cytokine and gut microbiota modulation, J. Agric. Food Chem., 67, pp. 13282-13298, (2019); Queiroz M.P., Lima M.S., Melo M.F.F.T., Bertozzo C.C.D.S., Araujo D.F., Guerra G.C.B., Queiroga R.C.R.E., Soares J.K.B., Maternal suppplementation with conjugated linoleic acid reduce anxiety and lipid peroxidation in the offspring brain, J. Affective Disord., 243, pp. 75-82, (2019); Soares J.K.B., Melo A.P.R., Medeiros M.C., Queiroga R.C.R.E., Bomfim M.A.D., Santiago E.C.A., Guedes R.A., Anxiety behavior is reduced, and physical growth is improved in the progeny of rat dams that consumed lipids from goat milk: An elevated plus maze analysis, Neurosci. Lett., 552, pp. 25-29, (2013); Cigliano L., Spagnuolo M.S., Boscaino F., Ferrandino I., Monaco A., Capriello T., Cocca E., Iannotta L., Treppiccione L., Luongo D., Dietary supplementation with fish oil or conjugated linoleic acid relieves depression markers in mice by modulation of the Nrf2 pathway, Mol. Nutr. Food Res., 63, (2019); Cryan J.F., O'Riordan K.J., Cowan C.S., Sandhu K.V., Bastiaanssen T.F., Boehme M., Codagnone M.G., Cussotto S., Fulling C., Golubeva A.V., The microbiota-gut-brain axis, Physiol. Rev., 99, pp. 1877-2013, (2019); Fond G., Loundou A., Hamdani N., Boukouaci W., Dargel A., Oliveira J., Roger M., Tamouza R., Leboyer M., Boyer L., Anxiety and depression comorbidities in irritable bowel syndrome (IBS): A systematic review and meta-analysis, Eur. Arch. Psychiatry Clin. Neurosci., 264, pp. 651-660, (2014); Adam B., Liebregts T., Gschossmann J.M., Krippner C., Scholl F., Ruwe M., Holtmann G., Severity of mucosal inflammation as a predictor for alterations of visceral sensory function in a rat model, Pain, 123, pp. 179-186, (2006)","Q. Zhai; State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi Jiangsu, 214122, China; email: zhaiqixiao@sina.com","","Royal Society of Chemistry","","","","","","20426496","","","33427835","English","Food. Funct.","Article","Final","","Scopus","2-s2.0-85100945293"

"Xie Y.; Zhan X.; Tu J.; Xu K.; Sun X.; Liu C.; Ke C.; Cao G.; Zhou Z.; Liu Y.","Xie, Ying (57212653811); Zhan, Xin (57221843222); Tu, Jiyuan (57226021266); Xu, Kang (57823983500); Sun, Xiongjie (57211920167); Liu, Chunlian (57222076265); Ke, Chang (57220194096); Cao, Guosheng (56318632900); Zhou, Zhongshi (57212653191); Liu, Yanju (55414763400)","57212653811; 57221843222; 57226021266; 57823983500; 57211920167; 57222076265; 57220194096; 56318632900; 57212653191; 55414763400","Atractylodes oil alleviates diarrhea-predominant irritable bowel syndrome by regulating intestinal inflammation and intestinal barrier via SCF/c-kit and MLCK/MLC2 pathways","2021","Journal of Ethnopharmacology","272","","113925","","","","39","10.1016/j.jep.2021.113925","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85101287017&doi=10.1016%2fj.jep.2021.113925&partnerID=40&md5=a9523b378c34b3834f8e8360f54df42f","School of Pharmacy, Hubei University of Chinese Medicine, 1 Huangjia Lake West Road, Wuhan, 430065, China; Hubei Research Center of Chinese Materia Medica Processing Engineering and Technology, Hubei University of Chinese Medicine, 1 Huangjia Lake West Road, Wuhan, 430065, China","Xie Y., School of Pharmacy, Hubei University of Chinese Medicine, 1 Huangjia Lake West Road, Wuhan, 430065, China; Zhan X., School of Pharmacy, Hubei University of Chinese Medicine, 1 Huangjia Lake West Road, Wuhan, 430065, China; Tu J., School of Pharmacy, Hubei University of Chinese Medicine, 1 Huangjia Lake West Road, Wuhan, 430065, China, Hubei Research Center of Chinese Materia Medica Processing Engineering and Technology, Hubei University of Chinese Medicine, 1 Huangjia Lake West Road, Wuhan, 430065, China; Xu K., School of Pharmacy, Hubei University of Chinese Medicine, 1 Huangjia Lake West Road, Wuhan, 430065, China; Sun X., School of Pharmacy, Hubei University of Chinese Medicine, 1 Huangjia Lake West Road, Wuhan, 430065, China; Liu C., School of Pharmacy, Hubei University of Chinese Medicine, 1 Huangjia Lake West Road, Wuhan, 430065, China; Ke C., School of Pharmacy, Hubei University of Chinese Medicine, 1 Huangjia Lake West Road, Wuhan, 430065, China; Cao G., School of Pharmacy, Hubei University of Chinese Medicine, 1 Huangjia Lake West Road, Wuhan, 430065, China; Zhou Z., School of Pharmacy, Hubei University of Chinese Medicine, 1 Huangjia Lake West Road, Wuhan, 430065, China; Liu Y., School of Pharmacy, Hubei University of Chinese Medicine, 1 Huangjia Lake West Road, Wuhan, 430065, China, Hubei Research Center of Chinese Materia Medica Processing Engineering and Technology, Hubei University of Chinese Medicine, 1 Huangjia Lake West Road, Wuhan, 430065, China","Ethnopharmacological relevance: Atractylodes lancea (Thunb.) DC. is a widely used traditional herb that is well known for treating spleen deficiency and diarrhea. According to traditional Chinese medicine (TCM) theory, diarrhea-predominant irritable bowel syndrome (IBS-D) is caused by cold and dampness, resulting in diarrhea and abdominal pain. Nevertheless, the effect and mechanism of Atractylodes on IBS-D are still unclear. Aim of the study: This study was designed to confirm the therapeutic effect of Atractylodes lanceolata oil (AO) in a rat model of IBS-D, and to determine the mechanisms by which AO protects against the disease. Materials and methods: The chemical components in AO were determined using gas chromatography-mass spectrometry (GC-MS). The expression levels of 5-hydroxytryptamine (5-HT), vasoactive intestinal peptide (VIP), and surfactant protein (SP) in serum and colon tissue were measured using enzyme-linked immunosorbent assay (ELISA). Reverse transcription-polymerase chain reaction (RT-PCR), western blotting (WB), immunohistochemistry (IHC), and immunofluorescence (IF) were used to elucidate the mechanism of action of AO toward inflammation and the intestinal barrier in a rat model of IBS-D. Results: The 15 chemical substances of the highest concentration in AO were identified using GC-MS. AO was effective against IBS-D in the rat model, in terms of increased body weight, diarrhea grade score, levels of interleukin-10 (IL-10), aquaporin 3 (AQP3), and aquaporin 8 (AQP8), and reduced fecal moisture content, levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), 5-HT, VIP, and SP, while also reducing intestinal injury, as observed using hematoxylin-eosin (HE) staining. In addition, the results indicated that AO increased the mRNA and protein expression levels of stem cell factor (SCF) and c-kit and enhanced the levels of zonula occludens-1 (ZO-1) and occludin, as well as decreased the levels of myosin light chain kinase (MLCK) and inhibited the phosphorylation of myosin light chain 2 (p-MLC2). Conclusions: AO was found to be efficacious in the rat model of IBS-D. AO inhibited the SCF/c-kit pathway, thereby reducing inflammation and protecting against intestinal barrier damage via the MLCK/MLC2 pathway. © 2021 Elsevier B.V.","Atractylodes oil; IBS-D; Intestinal barrier; Intestinal inflammation; MLCK/MLC2; SCF/c-kit","Animals; Aquaporins; Atractylodes; Colitis; Cytokines; Diarrhea; Intestinal Mucosa; Irritable Bowel Syndrome; Myosin Light Chains; Myosin-Light-Chain Kinase; Plant Oils; Proto-Oncogene Proteins c-kit; Rats, Sprague-Dawley; Serotonin; Signal Transduction; Stem Cell Factor; Tight Junction Proteins; Vasoactive Intestinal Peptide; antidiarrheal agent; aquaporin 3; aquaporin 8; Atractylodes extract; Atractylodes lanceolata extract; interleukin 10; interleukin 6; myosin light chain 2; myosin light chain kinase; occludin; pinaverium bromide; protein ZO1; serotonin; stem cell factor; surfactant; tumor necrosis factor; unclassified drug; vasoactive intestinal polypeptide; aquaporin; cytokine; MYL2 protein, rat; myosin light chain; myosin light chain kinase; serotonin; stem cell factor; stem cell factor receptor; tight junction protein; vegetable oil; animal experiment; animal model; animal tissue; antidiarrheal activity; antiinflammatory activity; Article; Atractylodes; Atractylodes lanceolata; body weight; colon tissue; controlled study; diarrhea; drug mechanism; enteritis; enzyme linked immunosorbent assay; immunofluorescence; immunohistochemistry; intestine mucosa permeability; irritable colon; male; mass fragmentography; moisture; nonhuman; protein expression; protein phosphorylation; rat; real time polymerase chain reaction; regulatory mechanism; reverse transcription polymerase chain reaction; RNA isolation; scoring system; signal transduction; therapy effect; Western blotting; animal; Atractylodes; chemistry; colitis; diarrhea; drug effect; genetics; intestine mucosa; irritable colon; metabolism; pathology; signal transduction; Sprague Dawley rat","","myosin light chain kinase, 51845-53-5; occludin, 176304-61-3; pinaverium bromide, 53251-94-8; serotonin, 50-67-9; vasoactive intestinal polypeptide, 37221-79-7; aquaporin, 215587-75-0; Aquaporins, ; Cytokines, ; MYL2 protein, rat, ; Myosin Light Chains, ; Myosin-Light-Chain Kinase, ; Plant Oils, ; Proto-Oncogene Proteins c-kit, ; Serotonin, ; Stem Cell Factor, ; Tight Junction Proteins, ; Vasoactive Intestinal Peptide, ","","","Hubei Provincial Department of Education, (Q20202006); National Natural Science Foundation of China, NSFC, (2020ZYYD030, 82074018); Natural Science Foundation of Hubei Province, (2020CFB160)","This research was funded by the National Natural Science Foundation of China (No. 82074018 ); Central Support for Local Development Projects ( 2020ZYYD030 ); Natural Science Foundation of Hubei Province ( 2020CFB160 ), and Scientific Research Plan of Hubei Provincial Department of Education (No. Q20202006 ). ","Chai Y., Huang Y., Tang H., Tu X., He J., Wang T., Zhang Q., Xiong F., Li D., Qiu Z., Role of stem cell growth factor/c-Kit in the pathogenesis of irritable bowel syndrome, Exp Ther Med, 13, 4, pp. 1187-1193, (2017); Crespo M., Vilar E., Tsai S.Y., Chang K., Amin S., Srinivasan T., Zhang T., Pipalia N.H., Chen H.J., Witherspoon M., Gordillo M., Xiang J.Z., Maxfield F.R., Lipkin S., Evans T., Chen S., Colonic organoids derived from human induced pluripotent stem cells for modeling colorectal cancer and drug testing, Nat. Med., 23, 7, pp. 878-884, (2017); Das Roy L., Curry J.M., Sahraei M., Besmer D.M., Kidiyoor A., Gruber H.E., Mukherjee P., Arthritis augments breast cancer metastasis: role of mast cells and SCF/c-Kit signaling, Breast Cancer Res., 15, 2, (2013); Deng J., Zeng L., Lai X., Li J., Liu L., Lin Q., Chen Y., Metformin protects against intestinal barrier dysfunction via AMPKalpha1-dependent inhibition of JNK signalling activation, J. Cell Mol. Med., 22, 1, pp. 546-557, (2018); Fan H., Zheng L., Lai Y., Lu W., Yan Z., Xiao Q., Li B., Tang M., Huang D., Wang Y., Li Z., Mei Y., Jiang Z., Liu X., Tang Q., Zuo D., Ye J., Yang Y., Huang H., Tang Z., Xiao J., China Irritable Bowel Syndrome C., Tongxie formula reduces symptoms of irritable bowel syndrome, Clin. Gastroenterol. Hepatol., 15, 11, pp. 1724-1732, (2017); Garsed K., Chernova J., Hastings M., Lam C., Marciani L., Singh G., Henry A., Hall I., Whorwell P., Spiller R., A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea, Gut, 63, 10, pp. 1617-1625, (2014); Greenway F., Wang S., Heiman M., A novel cobiotic containing a prebiotic and an antioxidant augments the glucose control and gastrointestinal tolerability of metformin: a case report, Benef. Microbes, 5, 1, pp. 29-32, (2014); Guilarte M., Santos J., de Torres I., Alonso C., Vicario M., Ramos L., Martinez C., Casellas F., Saperas E., Malagelada J.R., Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum, Gut, 56, 2, pp. 203-209, (2007); Gwee K.A., Leong Y.L., Graham C., McKendrick M.W., Collins S.M., Walters S.J., Underwood J.E., Read N.W., The role of psychological and biological factors in postinfective gut dysfunction, Gut, 44, 3, pp. 400-406, (1999); Hou Q., Huang Y., Zhu S., Li P., Chen X., Hou Z., Liu F., MiR-144 increases intestinal permeability in IBS-D rats by targeting OCLN and ZO1, Cell. Physiol. Biochem., 44, 6, pp. 2256-2268, (2017); Hou Q., Huang Y., Zhu Z., Liao L., Chen X., Han Q., Liu F., Tong-Xie-Yao-Fang improves intestinal permeability in diarrhoea-predominant irritable bowel syndrome rats by inhibiting the NF-kappaB and notch signalling pathways, BMC Compl. Alternative Med., 19, 1, (2019); Hou Q., Zhu S., Zhang C., Huang Y., Guo Y., Li P., Chen X., Wen Y., Han Q., Liu F., Berberine improves intestinal epithelial tight junctions by upregulating A20 expression in IBS-D mice, Biomed. Pharmacother., 118, (2019); Hu R., Zhang T., Tang F., [Effect of Weichang'an pill on intestinal digestion enzymes and the AQP4 concentration in proximal colon in IBS-D rats], Zhongguo Zhongyao Zazhi, 35, 21, pp. 2899-2903, (2010); Huang S., Fu Y., Xu B., Liu C., Wang Q., Luo S., Nong F., Wang X., Huang S., Chen J., Zhou L., Luo X., Wogonoside alleviates colitis by improving intestinal epithelial barrier function via the MLCK/pMLC2 pathway, Phytomedicine, 68, (2020); Huizinga J.D., Thuneberg L., Kluppel M., Malysz J., Mikkelsen H.B., Bernstein A., W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity, Nature, 373, 6512, pp. 347-349, (1995); Kim H.J., Kim N., Kim Y.S., Nam R.H., Lee S.M., Park J.H., Choi D., Hwang Y.J., Lee J., Lee H.S., Kim M.S., Lee M.Y., Lee D.H., Changes in the interstitial cells of Cajal and neuronal nitric oxide synthase positive neuronal cells with aging in the esophagus of F344 rats, PloS One, 12, 11, (2017); Li B., Luo X.F., Liu S.W., Zhao N., Li H.N., Zhang W., Chen Y.Y., Bao A., Wang J.G., Wang Q.S., Abdominal massage reduces visceral hypersensitivity via regulating GDNF and PI3K/AKT signal pathway in a rat model of irritable bowel syndrome, Evid Based Complement Altern. Med., (2020); Li K., Kuang H.X., Yin Y., Zhang J.Y., Wang Z., Zhang Q.Y., Wang J.W., [Effect of Tongxie Yaofang on endogenous metabolites in serum of IBS model rats], Zhongguo Zhongyao Zazhi, 42, 5, pp. 970-981, (2017); Li S., Qian Y., Xie R., Li Y., Jia Z., Zhang Z., Huang R., Tuo L., Quan Y., Yu Z., Liu J., Xiang M., Exploring the protective effect of ShengMai-Yin and Ganmaidazao decoction combination against type 2 diabetes mellitus with nonalcoholic fatty liver disease by network pharmacology and validation in KKAy mice, J. Ethnopharmacol., 242, (2019); Li Y., Jin K., van Pelt G.W., van Dam H., Yu X., Mesker W.E., Ten Dijke P., Zhou F., Zhang L., c-Myb enhances breast cancer invasion and metastasis through the wnt/beta-catenin/axin2 pathway, Canc. Res., 76, 11, pp. 3364-3375, (2016); Linghang Q., Yiyi X., Guosheng C., Kang X., Jiyuan T., Xiong L., Guangzhong W., Shuiqing L., Yanju L., Effects of atractylodes oil on inflammatory response and serum metabolites in adjuvant arthritis rats, Biomed. Pharmacother., 127, (2020); Liu Y., Liu W., Peng Q.X., Peng J.L., Yu L.Z., Hu J.L., Protective effect of huoxiang zhengqi oral liquid on intestinal mucosal mechanical barrier of rats with postinfectious irritable bowel syndrome induced by acetic Acid, Evid. Based Complement Altern. Med., (2014); Lyu Z., Ji X., Chen G., An B., Atractylodin ameliorates lipopolysaccharide and d-galactosamine-induced acute liver failure via the suppression of inflammation and oxidative stress, Int. Immunopharm., 72, pp. 348-357, (2019); Moon P.D., Han N.R., Lee J.S., Kim H.Y., Hong S., Kim H.J., Yoo M.S., Kim H.M., Jeong H.J., beta-eudesmol inhibits thymic stromal lymphopoietin through blockade of caspase-1/NF-kappaB signal cascade in allergic rhinitis murine model, Chem. Biol. Interact., 294, pp. 101-106, (2018); Ng Q.X., Soh A.Y.S., Loke W., Lim D.Y., Yeo W.S., The role of inflammation in irritable bowel syndrome (IBS), J. Inflamm. Res., 11, pp. 345-349, (2018); Ohman L., Simren M., Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions, Nat. Rev. Gastroenterol. Hepatol., 7, 3, pp. 163-173, (2010); Seo M.J., Kim S.J., Kang T.H., Rim H.K., Jeong H.J., Um J.Y., Hong S.H., Kim H.M., The regulatory mechanism of beta-eudesmol is through the suppression of caspase-1 activation in mast cell-mediated inflammatory response, Immunopharmacol. Immunotoxicol., 33, 1, pp. 178-185, (2011); Shi K., Qu L., Lin X., Xie Y., Tu J., Liu X., Zhou Z., Cao G., Li S., Liu Y., Deep-fried Atractylodis rhizoma protects against spleen deficiency-induced diarrhea through regulating intestinal inflammatory response and gut microbiota, Int. J. Mol. Sci., 21, 1, (2019); Song H.P., Hou X.Q., Li R.Y., Yu R., Li X., Zhou S.N., Huang H.Y., Cai X., Zhou C., Atractylenolide I stimulates intestinal epithelial repair through polyamine-mediated Ca(2+) signaling pathway, Phytomedicine, 28, pp. 27-35, (2017); Tang F., Fan K., Wang K., Bian C., Atractylodin attenuates lipopolysaccharide-induced acute lung injury by inhibiting NLRP3 inflammasome and TLR4 pathways, J. Pharmacol. Sci., 136, 4, pp. 203-211, (2018)","Y. Liu; School of Pharmacy, Hubei University of Chinese Medicine, Wuhan, 1 Huangjia Lake West Road, 430065, China; email: lyj1965954@hbtcm.edu.cn; Z. Zhou; School of Pharmacy, Hubei University of Chinese Medicine, Wuhan, 1 Huangjia Lake West Road, 430065, China; email: 3161@hbtcm.edu.cn","","Elsevier Ireland Ltd","","","","","","03788741","","JOETD","33592255","English","J. Ethnopharmacol.","Article","Final","","Scopus","2-s2.0-85101287017"

"Hou Q.; Zhu S.; Zhang C.; Huang Y.; Guo Y.; Li P.; Chen X.; Wen Y.; Han Q.; Liu F.","Hou, Qiuke (35573727700); Zhu, Shuilian (57193834637); Zhang, Changrong (57203160104); Huang, Yongquan (57195074253); Guo, Yajuan (57226052042); Li, Peiwu (55757309300); Chen, Xinlin (55357650100); Wen, Yi (57193832229); Han, Quanbin (7202485341); Liu, Fengbin (55799656200)","35573727700; 57193834637; 57203160104; 57195074253; 57226052042; 55757309300; 55357650100; 57193832229; 7202485341; 55799656200","Berberine improves intestinal epithelial tight junctions by upregulating A20 expression in IBS-D mice","2019","Biomedicine and Pharmacotherapy","118","","109206","","","","47","10.1016/j.biopha.2019.109206","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85068662605&doi=10.1016%2fj.biopha.2019.109206&partnerID=40&md5=7a67f2e73589ba5e04ef334961771273","Department of Gastroenterology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China; School of Chinese Medicine, Hong Kong Baptist University, Hong Kong; Department of Orthopedics, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China; Inernational Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China; Department of Preventive Medicine and Health Statistics, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China","Hou Q., Department of Gastroenterology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong; Zhu S., Department of Gastroenterology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China; Zhang C., Department of Gastroenterology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China; Huang Y., Department of Orthopedics, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China; Guo Y., Inernational Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China; Li P., Department of Gastroenterology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China; Chen X., Department of Preventive Medicine and Health Statistics, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China; Wen Y., Department of Gastroenterology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China; Han Q., School of Chinese Medicine, Hong Kong Baptist University, Hong Kong; Liu F., Department of Gastroenterology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China","To investigate effects of berberine exerts on A20 expression and regulation of intestinal epithelial tight junctions via the TNF-α-NF-κB-MLCK pathway in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D). C57BL/6 wild type (WT) and A20 IEC-KO mice (48 each) were randomly divided into normal control (NC), model control (MC), rifaximin and berberine groups (12 mice per group). An experimental model of IBS-D was established using 4% acetic acid and evaluated by haematoxylin-eosin (HE) staining. rifaximin and berberine mice were treated with rifaximin and berberine, respectively. Intestinal epithelial space of WT berberine mice improved more than A20 IEC-KO berberine mice compared to MC mice. WT berberine mice exhibited greater expression of A20 compared with MC mice(P < 0.01). TNF-α, NF-kB p65, MLCK, MLC, TRAF6 and RIP1 levels in A20 IEC-KO and WT berberine mice were all decreased compared to MC mice(P all<0.05). NF-κB p65, MLCK and TRAF6 levels were increased in A20 IEC-KO berberine mice as compared to WT berberine mice (P all<0.05). Intestinal epithelial levels of occludin, claudin-1, ZO-1 and F-actin increased in all berberine mice (P all<0.01-0.05), while occludin, claudin-1, and ZO-1 levels were lower in A20 IEC-KO berberine mice(P < 0.05). Berberine downregulates abnormal activation of the TNF-α-NF-κB-MLCK pathway by upregulating expression of A20 in a mouse model of IBS-D, thereby protecting intestinal epithelial tight junctions and repairing the damage IBS-D causes to the intestinal epithelial barrier. © 2019 The Authors","A20; Berberine; IBS-D; Intestinal epithelial barrier; TNF-α-NF-κB-MLCK pathway","Animals; Berberine; Diarrhea; Disease Models, Animal; Intestinal Absorption; Intestinal Mucosa; Irritable Bowel Syndrome; Mice, Inbred C57BL; Mice, Knockout; Permeability; Tight Junctions; Tumor Necrosis Factor alpha-Induced Protein 3; Up-Regulation; acetic acid; berberine; claudin 1; F actin; immunoglobulin enhancer binding protein; myosin light chain kinase; occludin; protein ZO1; rifaximin; RNA; tight junction protein; tumor necrosis factor; tumor necrosis factor alpha induced protein 3; tumor necrosis factor receptor associated factor 6; berberine; Tnfaip3 protein, mouse; tumor necrosis factor alpha induced protein 3; animal experiment; animal model; animal tissue; Article; controlled study; diarrhea; drug effect; drug protein binding; enzyme linked immunosorbent assay; histology; immunohistochemistry; intestine epithelium; irritable colon; mouse; nonhuman; priority journal; protein blood level; protein expression; reverse transcription polymerase chain reaction; RNA extraction; tight junction; animal; C57BL mouse; diarrhea; disease model; drug effect; genetics; intestine absorption; intestine mucosa; irritable colon; knockout mouse; metabolism; permeability; tight junction; upregulation","","acetic acid, 127-08-2, 127-09-3, 64-19-7, 71-50-1; berberine, 2086-83-1, 633-65-8; claudin 1, 329338-06-9; F actin, 39409-31-9; myosin light chain kinase, 51845-53-5; occludin, 176304-61-3; rifaximin, 80621-81-4, 88747-56-2; RNA, 63231-63-0; tumor necrosis factor alpha induced protein 3, ; ubiquitin carboxyl terminal hydrolase 7, ; ubiquitin carboxyl terminal hydrolase CYLD, ; Berberine, ; Tnfaip3 protein, mouse, ; Tumor Necrosis Factor alpha-Induced Protein 3, ","","","Guangzhou University of Traditional Chinese Medicine's first-class discipline research key project, (A1-AFD018191A16); Innovative Research Team Project of “Innovative Strong Institute; National Natural Science Foundation, (81804047); Guangdong Provincial Hospital of Traditional Chinese Medicine, (20181095, XJ2018059); Guangzhou University of Chinese Medicine, GUCM, (2017TD05)","This study was supported by the National Natural Science Foundation (No. 81804047 ), Guangdong Provincial Traditional Chinese Medicine Research Project (No. 20181095 ), Hong Kong scholar program ( XJ2018059 ), Innovative Research Team Project of “Innovative Strong Institute”, the First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine ( 2017TD05 ) and Guangzhou University of Traditional Chinese Medicine's first-class discipline research key project ( A1-AFD018191A16 ).","Oshima T., Miwa H., Epidemiology of functional gastrointestinal disorders in Japan and in the world, J. Neurogastroenterol. Motil., 21, 3, pp. 320-329, (2015); Chen C., Lu M., Pan Q., Fichna J., Zheng L., Wang K., Yu Z., Li Y., Li K., Song A., Liu Z., Song Z., Kreis M., Berberine improves intestinal motility and visceral pain in the mouse models mimicking diarrhea-predominant irritable bowel syndrome (IBS-D) symptoms in an opioid-receptor dependent manner, PLoS One, 10, 12, (2015); Hou Q., Huang Y., Zhang C., Zhu S., Li P., Chen X., Hou Z., Liu F., MicroRNA-200a targets cannabinoid receptor 1 and serotonin transporter to increase visceral hyperalgesia in diarrhea-predominant irritable bowel syndrome rats, J. Neurogastroenterol. Motil., 24, 4, pp. 656-668, (2018); Zong Y., Zhu S., Zhang S., Zheng G., Wiley J.W., Hong S., Chronic stress and intestinal permeability: lubiprostone regulates glucocorticoid receptor-mediated changes in colon epithelial tight junction proteins, barrier function, and visceral pain in the rodent and human, Neurogastroenterol. Motil., 31, 2, (2019); Hou Q., Huang Y., Zhu S., Li P., Chen X., Hou Z., Liu F., MiR-144 increases intestinal permeability in IBS-D rats by targeting OCLN and ZO1, Cell. Physiol. Biochem., 44, 6, pp. 2256-2268, (2017); Wilcz-Villega E., McClean S., O'Sullivan M., Reduced E-cadherin expression is associated with abdominal pain and symptom duration in a study of alternating and diarrhea predominant IBS, Neurogastroenterol. Motil., 26, 3, pp. 316-325, (2014); Piche T., Tight junctions and IBS–the link between epithelial permeability, low-grade inflammation, and symptom generation?, Neurogastroenterol. Motil., 26, 3, pp. 296-302, (2014); Hossain Z., Hirata T., Molecular mechanism of intestinal permeability: interaction at tight junctions, Mol. Biosyst., 4, 12, pp. 1181-1185, (2008); Coeffier M., Gloro R., Boukhettala N., Aziz M., Lecleire S., Vandaele N., Antonietti M., Savoye G., Bole-Feysot C., Dechelotte P., Reimund J.M., Ducrotte P., Increased proteasome-mediated degradation of occludin in irritable bowel syndrome, Am. J. Gastroenterol., 105, 5, pp. 1181-1188, (2010); berberinetrand J., Ghouzali I., Guerin C., Bole-Feysot C., Gouteux M., Dechelotte P., Ducrotte P., Coeffier M., Glutamine restores tight junction protein Claudin-1 expression in colonic mucosa of patients with diarrhea-predominant irritable bowel syndrome, JPEN J. Parenter. Enteral Nutr., 40, 8, pp. 1170-1176, (2016); Barbara G., Zecchi L., Barbaro R., Cremon C., Bellacosa L., Marcellini M., De Giorgio R., Corinaldesi R., Stanghellini V., Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome, J. Clin. Gastroenterol., 46, pp. S52-5, (2012); Al-Khatib K., Lin H.C., Immune activation and gut microbes in irritable bowel syndrome, Gut Liver, 3, 1, pp. 14-19, (2009); Zhang A., Wang G., Jia L., Su T., Zhang L., Exosome-mediated microRNA-138 and vascular endothelial growth factor in endometriosis through inflammation and apoptosis via the nuclear factor-kappaB signaling pathway, Int. J. Mol. Med., 43, 1, pp. 358-370, (2019); Cuzzocrea S., Mazzon E., De Sarro A., Caputi A.P., Role of free radicals and poly(ADP-ribose) synthetase in intestinal tight junction permeability, Mol. Med., 6, 9, pp. 766-778, (2000); Long Y., Du L., Kim J.J., Chen B., Zhu Y., Zhang Y., Yao S., He H., Zheng X., Huang Z., Dai N., MLCK-mediated intestinal permeability promotes immune activation and visceral hypersensitivity in PI-IBS mice, Neurogastroenterol. Motil., 30, 9, (2018); Swan C., Duroudier N.P., Campbell E., Zaitoun A., Hastings M., Dukes G.E., Cox J., Kelly F.M., Wilde J., Lennon M.G., Neal K.R., Whorwell P.J., Hall I.P., Spiller R.C., Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNFalpha, Gut, 62, 7, pp. 985-994, (2013); Fletcher N.F., Clark A.R., Balfe P., McKeating J.A., TNF superfamily memberberines promote hepatitis C virus entry via an NF-kappaB and myosin light chain kinase dependent pathway, J. Gen. Virol., 98, 3, pp. 405-412, (2017); Cao M., Wang P., Sun C., He W., Wang F., Amelioration of IFN-gamma and TNF-alpha-induced intestinal epithelial barrier dysfunction by berberine via suppression of MLCK-MLC phosphorylation signaling pathway, PLoS One, 8, 5, (2013); Yang C., Jiang Q., Vitamin E delta-tocotrienol inhibits TNF-alpha-stimulated NF-kappaB activation by up-regulation of anti-inflammatory A20 via modulation of sphingolipid including elevation of intracellular dihydroceramides, J. Nutr. Biochem., 64, pp. 101-109, (2019); da Silva C.G., Maccariello E.R., Wilson S.W., Putheti P., Daniel S., Damrauer S.M., Peterson C.R., Siracuse J.J., Kaczmarek E., Ferran C., Hepatocyte growth factor preferentially activates the anti-inflammatory arm of NF-kappaB signaling to induce A20 and protect renal proximal tubular epithelial cells from inflammation, J. Cell. Physiol., 227, 4, pp. 1382-1390, (2012); Gong Z., Chen Y., Zhang R., Yang Q., Wang Y., Guo Y., Zhou B., Weng X., Liu X., Li Y., Zhu X., Dong Y., Pharmacokinetic difference of berberine between normal and chronic visceral hypersensitivity irritable bowel syndrome rats and its mechanism, Arch. Pharm. Res., 38, 10, pp. 1888-1896, (2015); Suzuki T., Regulation of intestinal epithelial permeability by tight junctions, Cell. Mol. Life Sci., 70, 4, pp. 631-659, (2013); Hung R.J., Yazdani U., Yoon J., Wu H., Yang T., Gupta N., Huang Z., van berberinekel W.J., Terman J.R., Mical links semaphorins to F-actin disassembly, Nature, 463, 7282, pp. 823-827, (2010); Bouwmeester T., Bauch A., Ruffner H., Angrand P.O., berberinegamini G., Croughton K., Cruciat C., Eberberinehard D., Gagneur J., Ghidelli S., Hopf C., Huhse B., Mangano R., Michon A.M., Schirle M., Schlegl J., Schwab M., Stein M.A., Bauer A., Casari G., Drewes G., Gavin A.C., Jackson D.B., Joberberinety G., Neubauer G., Rick J., Kuster B., Superti-Furga G., A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway, Nat. Cell Biol., 6, 2, pp. 97-105, (2004); Zou X.L., Pei D.A., Yan J.Z., Xu G., Wu P., A20 overexpression inhibits lipopolysaccharide-induced NF-kappaB activation, TRAF6 and CD40 expression in rat peritoneal mesothelial cells, Int. J. Mol. Sci., 15, 4, pp. 6592-6608, (2014); Heyninck K., Beyaert R., The cytokine-inducible zinc finger protein A20 inhibits IL-1-induced NF-kappaB activation at the level of TRAF6, FEBS Lett., 442, 2-3, pp. 147-150, (1999); Meng Z., Zhao T., Zhou K., Zhong Q., Wang Y., Xiong X., Wang F., Yang Y., Zhu W., Liu J., Liao M., Wu L., Duan C., Li J., Gong Q., Liu L., Xiong A., Yang M., Wang J., Yang Q., A20 ameliorates intracerebral hemorrhage-induced inflammatory injury by regulating TRAF6 polyubiquitination, J. Immunol., 198, 2, pp. 820-831, (2017); Ma T.Y., Iwamoto G.K., Hoa N.T., Akotia V., Pedram A., Boivin M.A., Said H.M., TNF-alpha-induced increase in intestinal epithelial tight junction permeability requires NF-kappa B activation, American journal of physiology, Gastrointest. Liver Physiol., 286, 3, pp. G367-76, (2004); Chen D., Li X., Zhai Z., Shu H.B., A novel zinc finger protein interacts with receptor-interacting protein (RIP) and inhibits tumor necrosis factor (TNF)- and IL1-induced NF-kappa B activation, J. Biol. Chem., 277, 18, pp. 15985-15991, (2002); Evans P.C., Ovaa H., Hamon M., Kilshaw P.J., Hamm S., Bauer S., Ploegh H.L., Smith T.S., Zinc-finger protein A20, a regulator of inflammation and cell survival, has de-ubiquitinating activity, Biochem. J., 378, pp. 727-734, (2004)","F. Liu; Department of Gastroenterology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China; email: liufb163@126.com","","Elsevier Masson SAS","","","","","","07533322","","BIPHE","31306972","English","Biomed. Pharmacother.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85068662605"

"Scuderi S.A.; Casili G.; Lanza M.; Filippone A.; Paterniti I.; Esposito E.; Campolo M.","Scuderi, Sarah Adriana (57216891177); Casili, Giovanna (57189218376); Lanza, Marika (57200363172); Filippone, Alessia (57200369301); Paterniti, Irene (26041018000); Esposito, Emanuela (56417262900); Campolo, Michela (55364236100)","57216891177; 57189218376; 57200363172; 57200369301; 26041018000; 56417262900; 55364236100","Modulation of nlrp3 inflammasome attenuated inflammatory response associated to diarrhea-predominant irritable bowel syndrome","2020","Biomedicines","8","11","519","1","16","15","22","10.3390/biomedicines8110519","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85096308936&doi=10.3390%2fbiomedicines8110519&partnerID=40&md5=d8f871351bbae45c205a6a7fc44472ff","Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D’ Alcontres, 31, Messina, 98166, Italy","Scuderi S.A., Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D’ Alcontres, 31, Messina, 98166, Italy; Casili G., Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D’ Alcontres, 31, Messina, 98166, Italy; Lanza M., Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D’ Alcontres, 31, Messina, 98166, Italy; Filippone A., Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D’ Alcontres, 31, Messina, 98166, Italy; Paterniti I., Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D’ Alcontres, 31, Messina, 98166, Italy; Esposito E., Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D’ Alcontres, 31, Messina, 98166, Italy; Campolo M., Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D’ Alcontres, 31, Messina, 98166, Italy","Diarrhea-predominant irritable bowel syndrome (IBS-D) is a multifactorial chronic gastrointestinal disorder characterized by inflammation and immune response. In this context, NLRP3 over-activation is associated with a breakdown of enteric-immune balance related to IBS-D. The aim of this study was to evaluate the effect of the inflammasome inhibitor, BAY 11-7082, in a rat model of IBS-D. Syndrome was induced by intracolonic instillation of 1 mL 4% acetic acid at 8 cm proximal to the anus for 30 s and sacrificed 2 weeks after IBS-D induction. BAY 11-7082 (10 and 30 mg/kg) was administered daily by oral gavage. The results obtained showed that the treatment with BAY 11-7082 (30 mg/kg) significantly reduced tissue injury characterized by edema, neutrophil infiltration, and loss of colon structure. We demonstrated that BAY 11-7082 treatment inhibited NLRP3 inflammasome activation and NF-kB translocation, reducing inflammatory mediators. Moreover, treatment with BAY 11-7082 restored tight junction alteration following IBS-D induction and reduced the restraint stress. Taken together, our data demonstrate that IBS-D induced NLRP3 inflammasome pathway activation, accompanied by the production of proinflammatory response. The modulation of the inflammosome pathway with BAY 11-7082 inhibitor significantly reduced pathological signs of IBS-D, therefore, can be considered a valuable strategy to reduce the development of IBS-D. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.","IBS-D; Inflammasome; Intestinal permeability; NF-κB; NLRP3; Stress","","","","","","","","Gracie D.J., Ford A.C., Irritable Bowel Syndrome-Type Symptoms Are Associated with Psychological Comorbidity, Reduced Quality of Life, and Health Care Use in Patients With Inflammatory Bowel Disease, Gastroenterology, 153, pp. 324-325, (2017); Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Abdalla M.I., Sandler R.S., Kappelman M.D., Martin C.F., Chen W., Anton K., Long M.D., Prevalence and Impact of Inflammatory Bowel Disease-Irritable Bowel Syndrome on Patient-reported Outcomes in CCFA Partners, Inflamm. Bowel Dis, 23, pp. 325-331, (2017); Ford A.C., Lacy B.E., Talley N.J., Irritable Bowel Syndrome, N. Engl. J. Med, 376, pp. 2566-2578, (2017); Lacy B.E., Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome, Int. J. Gen. Med, 9, pp. 7-17, (2016); Ghoshal U.C., Shukla R., Ghoshal U., Gwee K.A., Ng S.C., Quigley E.M., The gut microbiota and irritable bowel syndrome: Friend or foe?, Int. J. Inflam, 2012, (2012); Ortiz-Lucas M., Saz-Peiro P., Sebastian-Domingo J.J., Irritable bowel syndrome immune hypothesis. Part two: The role of cytokines, Rev. Esp. Enferm. Dig, 102, pp. 711-717, (2010); Corridoni D., Arseneau K.O., Cifone M.G., Cominelli F., The dual role of nod-like receptors in mucosal innate immunity and chronic intestinal inflammation, Front. Immunol, 5, (2014); Awad F., Assrawi E., Louvrier C., Jumeau C., Georgin-Lavialle S., Grateau G., Amselem S., Giurgea I., Karabina S.A., Inflammasome biology, molecular pathology and therapeutic implications, Pharmacol. Ther, 187, pp. 133-149, (2018); Kelley N., Jeltema D., Duan Y., He Y., The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation, Int. J. Mol. Sci, 20, (2019); Schroder K., Tschopp J., The inflammasomes, Cell, 140, pp. 821-832, (2010); Latz E., The inflammasomes: Mechanisms of activation and function, Curr. Opin. Immunol, 22, pp. 28-33, (2010); Pellegrini C., Antonioli L., Lopez-Castejon G., Blandizzi C., Fornai M., Canonical and Non-Canonical Activation of NLRP3 Inflammasome at the Crossroad between Immune Tolerance and Intestinal Inflammation, Front. Immunol, 8, (2017); Juliana C., Fernandes-Alnemri T., Wu J., Datta P., Solorzano L., Yu J.W., Meng R., Quong A.A., Latz E., Scott C.P., Et al., Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome, J. Biol. Chem, 285, pp. 9792-9802, (2010); Jiang W., Li M., He F., Zhou S., Zhu L., Targeting the NLRP3 inflammasome to attenuate spinal cord injury in mice, J. Neuroinflamm, 14, (2017); Chiazza F., Couturier-Maillard A., Benetti E., Mastrocola R., Nigro D., Cutrin J.C., Serpe L., Aragno M., Fantozzi R., Ryffel B., Et al., Targeting the NLRP3 Inflammasome to Reduce Diet-Induced Metabolic Abnormalities in Mice, Mol. Med, 21, pp. 1025-1037, (2016); Ghashghaeinia M., Cluitmans J.C., Toulany M., Saki M., Koberle M., Lang E., Dreischer P., Biedermann T., Duszenko M., Lang F., Et al., Age sensitivity of NFkappaB abundance and programmed cell death in erythrocytes induced by NFkappaB inhibitors, Cell Physiol. Biochem, 32, pp. 801-813, (2013); Rauert-Wunderlich H., Siegmund D., Maier E., Giner T., Bargou R.C., Wajant H., Stuhmer T., The IKK inhibitor Bay 11-7082 induces cell death independent from inhibition of activation of NFkappaB transcription factors, PLoS ONE, 8, (2013); Wang Y., Zhang X.L., Sun C.M., BAY-11-7082 induces apoptosis of multiple myeloma U266 cells through inhibiting NF-kappaB pathway, Eur. Rev. Med. Pharmacol. Sci, 22, pp. 2564-2571, (2018); Sasaki C.T., Doukas S.G., Vageli D.P., In Vivo Short-Term Topical Application of BAY 11-7082 Prevents the Acidic Bile-Induced mRNA and miRNA Oncogenic Phenotypes in Exposed Murine Hypopharyngeal Mucosa, Neoplasia, 20, pp. 374-386, (2018); Xu J.R., Luo J.Y., Shang L., Kong W.M., Effect of change in an inhibitory neurotransmitter of the myenteric plexus on the pathogenetic mechanism of irritable bowel syndrome subgroups in rat models, Chin. J. Dig. Dis, 7, pp. 89-96, (2006); Esposito E., Campolo M., Casili G., Lanza M., Franco D., Filippone A., Peritore A.F., Cuzzocrea S., Protective Effects of Xyloglucan in Association with the Polysaccharide Gelose in an Experimental Model of Gastroenteritis and Urinary Tract Infections, Int. J. Mol. Sci, 19, (2018); Asseman C., Mauze S., Leach M.W., Coffman R.L., Powrie F., An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation, J. Exp. Med, 190, pp. 995-1004, (1999); Casili G., Cordaro M., Impellizzeri D., Bruschetta G., Paterniti I., Cuzzocrea S., Esposito E., Dimethyl Fumarate Reduces Inflammatory Responses in Experimental Colitis, J. Crohns Colitis, 10, pp. 472-483, (2016); Al-Henhena N., Ying R.P., Ismail S., Najm W., Khalifa S.A., El-Seedi H., Ameen Abdulla M., Chemopreventive efficacy of Andrographis paniculata on azoxymethane-induced aberrant colon crypt foci in vivo, PLoS ONE, 9, (2014); Ding W., Zhang W., Hui F.M., Zhang Y.H., Zhang F.F., Li X.M., Shi F.X., Cell-specific expression and immunolocalization of nitric oxide synthase isoforms and soluble guanylyl cyclase alpha1 and beta1 subunits in the ovary of fetal, neonatal and immature pigs, Anim. Reprod. Sci, 131, pp. 172-180, (2012); Impellizzeri D., Bruschetta G., Di Paola R., Ahmad A., Campolo M., Cuzzocrea S., Esposito E., Navarra M., The anti-inflammatory and antioxidant effects of bergamot juice extract (BJe) in an experimental model of inflammatory bowel disease, Clin. Nutr, 34, pp. 1146-1154, (2015); Hwang I., An B.S., Yang H., Kang H.S., Jung E.M., Jeung E.B., Tissue-specific expression of occludin, zona occludens-1, and junction adhesion molecule A in the duodenum, ileum, colon, kidney, liver, lung, brain, and skeletal muscle of C57BL mice, J. Physiol. Pharmacol, 64, pp. 11-18, (2013); Kolodziej L.E., Lodolce J.P., Chang J.E., Schneider J.R., Grimm W.A., Bartulis S.J., Zhu X., Messer J.S., Murphy S.F., Reddy N., Et al., TNFAIP3 maintains intestinal barrier function and supports epithelial cell tight junctions, PLoS ONE, 6, (2011); Ziade F., Rungoe C., Kallemose T., Paerregaard A., Wewer A.V., Jakobsen C., Biochemical Markers, Genotype, and Inflammation in Pediatric Inflammatory Bowel Disease: A Danish Population-Based Study, Dig. Dis, 37, pp. 140-146, (2019); Nanini H.F., Bernardazzi C., Castro F., de Souza H.S.P., Damage-associated molecular patterns in inflammatory bowel disease: From biomarkers to therapeutic targets, World J. Gastroenterol, 24, pp. 4622-4634, (2018); Ringel-Scaia V.M., McDaniel D.K., Allen I.C., The Goldilocks Conundrum: NLR Inflammasome Modulation of Gastrointestinal Inflammation during Inflammatory Bowel Disease, Crit. Rev. Immunol, 36, pp. 283-314, (2016); Rashidian A., Muhammadnejad A., Dehpour A.R., Mehr S.E., Akhavan M.M., Shirkoohi R., Chamanara M., Mousavi S.E., Rezayat S.M., Atorvastatin attenuates TNBS-induced rat colitis: The involvement of the TLR4/NF-kB signaling pathway, Inflammopharmacology, 24, pp. 109-118, (2016); Li M.C., He S.H., IL-10 and its related cytokines for treatment of inflammatory bowel disease, World J. Gastroenterol, 10, pp. 620-625, (2004); Lee J.Y., Kim J.S., Kim J.M., Kim N., Jung H.C., Song I.S., Simvastatin inhibits NF-kappaB signaling in intestinal epithelial cells and ameliorates acute murine colitis, Int. Immunopharmacol, 7, pp. 241-248, (2007); Sands B.E., Biomarkers of Inflammation in Inflammatory Bowel Disease, Gastroenterology, 149, pp. 1275-1285, (2015); Xu Y., Li Y., Scott K., Lindh C.H., Jakobsson K., Fletcher T., Ohlsson B., Andersson E.M., Inflammatory bowel disease and biomarkers of gut inflammation and permeability in a community with high exposure to perfluoroalkyl substances through drinking water, Environ. Res, 181, (2020); Wallace J.L., Miller M.J., Nitric oxide in mucosal defense: A little goes a long way, Gastroenterology, 119, pp. 512-520, (2000); Alzoghaibi M.A., Al Mofleh I.A., Al-Jebreen A.M., Lipid peroxides in patients with inflammatory bowel disease, Saudi J. Gastroenterol, 13, pp. 187-190, (2007); Miller Y.I., Choi S.H., Wiesner P., Fang L., Harkewicz R., Hartvigsen K., Boullier A., Gonen A., Diehl C.J., Que X., Et al., Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity, Circ. Res, 108, pp. 235-248, (2011); Dudzinska E., Gryzinska M., Ognik K., Gil-Kulik P., Kocki J., Oxidative Stress and Effect of Treatment on the Oxidation Product Decomposition Processes in IBD, Oxid. Med. Cell. Longev, 2018, (2018); Wallace J.L., Devchand P.R., Emerging roles for cyclooxygenase-2 in gastrointestinal mucosal defense, Br. J. Pharmacol, 145, pp. 275-282, (2005); Barbara G., Zecchi L., Barbaro R., Cremon C., Bellacosa L., Marcellini M., De Giorgio R., Corinaldesi R., Stanghellini V., Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome, J. Clin. Gastroenterol, 46, pp. S52-S55, (2012); Strober W., Fuss I.J., Blumberg R.S., The immunology of mucosal models of inflammation, Annu. Rev. Immunol, 20, pp. 495-549, (2002); Atreya I., Atreya R., Neurath M.F., NF-kappaB in inflammatory bowel disease, J. Intern. Med, 263, pp. 591-596, (2008); Lamkanfi M., Dixit V.M., Mechanisms and functions of inflammasomes, Cell, 157, pp. 1013-1022, (2014); Lazaridis N., Germanidis G., Current insights into the innate immune system dysfunction in irritable bowel syndrome, Ann. Gastroenterol, 31, pp. 171-187, (2018); Liu J.J., Kay T.M., Davis E.M., Lou Y., Kao D., Claggett B., Fedorak R.N., Irvin R.T., Epithelial Cell Extrusion Zones Observed on Confocal Laser Endomicroscopy Correlates with Immunohistochemical Staining of Mucosal Biopsy Samples, Dig. Dis. Sci, 61, pp. 1895-1902, (2016); Mayer E.A., Naliboff B.D., Chang L., Coutinho S.V.V., Stress and irritable bowel syndrome, Am. J. Physiol. Gastrointest. Liver Physiol, 280, pp. G519-G524, (2001); Blake M.R., Raker J.M., Whelan K., Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome, Aliment. Pharmacol. Ther, 44, pp. 693-703, (2016); Walker J.R., Ediger J.P., Graff L.A., Greenfeld J.M., Clara I., Lix L., Rawsthorne P., Miller N., Rogala L., McPhail C.M., Et al., The Manitoba IBD cohort study: A population-based study of the prevalence of lifetime and 12-month anxiety and mood disorders, Am. J. Gastroenterol, 103, pp. 1989-1997, (2008); Hou Q., Zhu S., Zhang C., Huang Y., Guo Y., Li P., Chen X., Wen Y., Han Q., Liu F., Berberine improves intestinal epithelial tight junctions by upregulating A20 expression in IBS-D mice, Biomed. Pharmacother, 118, (2019); Sanchez de Medina F., Romero-Calvo I., Mascaraque C., Martinez-Augustin O., Intestinal inflammation and mucosal barrier function, Inflamm. Bowel Dis, 20, pp. 2394-2404, (2014); Dunlop S.P., Hebden J., Campbell E., Naesdal J., Olbe L., Perkins A.C., Spiller R.C., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am. J. Gastroenterol, 101, pp. 1288-1294, (2006); Gu Q.Y., Zhang J., Feng Y.C., Role of NLRP3 inflammasome in Bifidobacterium longum-regulated visceral hypersensitivity of postinfectious irritable bowel syndrome, Artif. Cells Nanomed. Biotechnol, 44, pp. 1933-1937, (2016); Zhen Y., Zhang H., NLRP3 Inflammasome and Inflammatory Bowel Disease, Front. Immunol, 10, (2019); Hausmann M., Obermeier F., Schreiter K., Spottl T., Falk W., Scholmerich J., Herfarth H., Saftig P., Rogler G., Cathepsin D is up-regulated in inflammatory bowel disease macrophages, Clin. Exp. Immunol, 136, pp. 157-167, (2004); Vallabhapurapu S., Karin M., Regulation and function of NF-kappaB transcription factors in the immune system, Annu. Rev. Immunol, 27, pp. 693-733, (2009); Neurath M.F., Cytokines in inflammatory bowel disease, Nat. Rev. Immunol, 14, pp. 329-342, (2014); Wang L.H., Fang X.C., Pan G.Z., Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis, Gut, 53, pp. 1096-1101, (2004); Takagi H., Kanai T., Okazawa A., Kishi Y., Sato T., Takaishi H., Inoue N., Ogata H., Iwao Y., Hoshino K., Et al., Contrasting action of IL-12 and IL-18 in the development of dextran sodium sulphate colitis in mice, Scand. J. Gastroenterol, 38, pp. 837-844, (2003); Singer I.I., Kawka D.W., Scott S., Weidner J.R., Mumford R.A., Riehl T.E., Stenson W.F., Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease, Gastroenterology, 111, pp. 871-885, (1996); Lih-Brody L., Powell S.R., Collier K.P., Reddy G.M., Cerchia R., Kahn E., Weissman G.S., Katz S., Floyd R.A., McKinley M.J., Et al., Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease, Dig. Dis. Sci, 41, pp. 2078-2086, (1996); Liu X., Moon S.H., Jenkins C.M., Sims H.F., Gross R.W., Cyclooxygenase-2 Mediated Oxidation of 2-Arachidonoyl-Lysophospholipids Identifies Unknown Lipid Signaling Pathways, Cell Chem. Biol, 23, pp. 1217-1227, (2016); Parks D.A., Bulkley G.B., Granger D.N., Role of oxygen-derived free radicals in digestive tract diseases, Surgery, 94, pp. 415-422, (1983)","E. Esposito; Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Messina, Viale Ferdinando Stagno D’ Alcontres, 31, 98166, Italy; email: eesposito@unime.it","","MDPI AG","","","","","","22279059","","","","English","Biomedicines","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85096308936"

"Ajamian M.; Rosella G.; Newnham E.D.; Biesiekierski J.R.; Muir J.G.; Gibson P.R.","Ajamian, Mary (55675396400); Rosella, Gennaro (57193555101); Newnham, Evan D. (15835231300); Biesiekierski, Jessica R. (36184914800); Muir, Jane G. (7202728581); Gibson, Peter R. (57226032608)","55675396400; 57193555101; 15835231300; 36184914800; 7202728581; 57226032608","Effect of Gluten Ingestion and FODMAP Restriction on Intestinal Epithelial Integrity in Patients with Irritable Bowel Syndrome and Self-Reported Non-Coeliac Gluten Sensitivity","2021","Molecular Nutrition and Food Research","65","5","1901275","","","","21","10.1002/mnfr.201901275","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85092933215&doi=10.1002%2fmnfr.201901275&partnerID=40&md5=17728620114819d435d92d16ecc115eb","Department of Gastroenterology, Monash University and Alfred Health, Melbourne, 3004, VIC, Australia; Department of Gastroenterology and Hepatology, Eastern Health, 3128, VIC, Australia","Ajamian M., Department of Gastroenterology, Monash University and Alfred Health, Melbourne, 3004, VIC, Australia; Rosella G., Department of Gastroenterology, Monash University and Alfred Health, Melbourne, 3004, VIC, Australia; Newnham E.D., Department of Gastroenterology and Hepatology, Eastern Health, 3128, VIC, Australia; Biesiekierski J.R., Department of Gastroenterology and Hepatology, Eastern Health, 3128, VIC, Australia; Muir J.G., Department of Gastroenterology, Monash University and Alfred Health, Melbourne, 3004, VIC, Australia, Department of Gastroenterology and Hepatology, Eastern Health, 3128, VIC, Australia; Gibson P.R., Department of Gastroenterology, Monash University and Alfred Health, Melbourne, 3004, VIC, Australia, Department of Gastroenterology and Hepatology, Eastern Health, 3128, VIC, Australia","Scope: Since epithelial barrier dysfunction has been associated with gluten and fermentable oligosaccharide, disaccharide, monosaccharide, and polyols (FODMAPs), the effect of alterations in FODMAP a gluten intake on epithelial barrier function in patients with irritable bowel syndrome (IBS) who self-reported gluten sensitivity. Methods and results: Circulating concentrations of markers of epithelial injury (syndecan-1 and intestinal fatty acid-binding protein) and bacterial translocation (lipopolysaccharide-binding protein and soluble CD14) are measured while consuming habitual gluten-free diet and during blinded challenges with gluten or placebo on a background of low FODMAP intake. In 33 patients, only syndecan-1 concentrations during their habitual diet are elevated (median 43 ng mL−1) compared with 23 ng mL−1 in 49 healthy subjects (p < 0.001). On a low FODMAP diet, symptoms are reduced and levels of syndecan-1 (but not other markers) fell by a median 3335% (p < 0.001) irrespective of whether gluten is present or not. Conclusion: Gluten ingestion has no specific effect on epithelial integrity or symptoms in this cohort, but reducing FODMAP intake concomitantly reduces symptoms and reverses apparent colonic epithelial injury. These findings highlight the heterogeneity of populations self-reporting gluten sensitivity and implicate FODMAPs in colonic injury in IBS. © 2020 Wiley-VCH GmbH","bacterial translocation; functional bowel disorders; gluten-free diet; intestinal epithelium","Acute-Phase Proteins; Adult; Carrier Proteins; Celiac Disease; Diet, Carbohydrate-Restricted; Double-Blind Method; Female; Glutens; Humans; Irritable Bowel Syndrome; Lipopolysaccharide Receptors; Malabsorption Syndromes; Male; Membrane Glycoproteins; Middle Aged; Self Report; Syndecan-1; Treatment Outcome; Young Adult; acute phase protein; carrier protein; CD14 protein, human; gluten; lipopolysaccharide receptor; lipopolysaccharide-binding protein; membrane protein; SDC1 protein, human; syndecan 1; adult; blood; celiac disease; controlled study; double blind procedure; female; human; irritable colon; low carbohydrate diet; malabsorption; male; middle aged; randomized controlled trial; self report; treatment outcome; young adult","","carrier protein, 80700-39-6; gluten, 8002-80-0; syndecan 1, 128559-86-4; Acute-Phase Proteins, ; Carrier Proteins, ; CD14 protein, human, ; Glutens, ; Lipopolysaccharide Receptors, ; lipopolysaccharide-binding protein, ; Membrane Glycoproteins, ; SDC1 protein, human, ; Syndecan-1, ","","","","","Catassi C., Elli L., Bonaz B., Bouma G., Carroccio A., Castillejo G., Cellier C., Cristofori F., de Magistris L., Dolinsek J., Dieterich W., Francavilla R., Hadjivassiliou M., Holtmeier W., Korner U., Leffler D.A., Lundin K.E.A., Mazzarella G., Mulder C.J., Pellegrini N., Rostami K., Sanders D., Skodje G.I., Schuppan D., Ullrich R., Volta U., Williams M., Zevallos V.F., Zopf Y., Fasano A., Nutrients, 7, (2015); Di Sabatino A., Volta U., Salvatore C., Biancheri P., Caio G., De Giorgio R., Di Stefano M., Corazza G.R., Clin. Gastroenterol. Hepatol., 13, (2015); Elli L., Tomba C., Branchi F., Roncoroni L., Lombardo V., Bardella M.T., Ferretti F., Conte D., Valiante F., Fini L., Forti E., Cannizzaro R., Maiero S., Londoni C., Lauri A., Fornaciari G., Lenoci N., Spagnuolo R., Basilisco G., Somalvico F., Borgatta B., Leandro G., Segato S., Barisani D., Morreale G., Buscarini E., Nutrients, 8, (2016); Zanini B., Basche R., Ferraresi A., Ricci C., Lanzarotto F., Marullo M., Villanacci V., Hidalgo A., Lanzini A., Aliment. Pharmacol. Ther., 42, (2015); Francavilla R., Cristofori F., Verzillo L., Gentile A., Castellaneta S., Polloni C., Giorgio V., Verduci E., D'Angelo E., Dellatte S., Indrio F., Am. J. Gastroenterol., 113, (2018); Skodje G.I., Sarna V.K., Minelle I.H., Rolfsen K.L., Muir J.G., Gibson P.R., Veierod M.B., Henriksen C., Lundin K.E.A., Gastroenterology, 154, (2018); Uhde M., Ajamian M., Caio G., De Giorgio R., Indart A., Green P.H., Verna E.C., Volta U., Alaedini A., Gut, 65, (2016); Biesiekierski J.R., Peters S.L., Newnham E.D., Rosella O., Muir J.G., Gibson P.R., Gastroenterology, 145, (2013); Gibson P.R., Halmos E.P., Muir J.G., Aliment. Pharmacol. Ther., 52, (2020); Argenzio R.A., Meuten D.J., Dig. Dis. Sci., 36, (1991); Bovee-Oudenhoven I.M., Ten Bruggencate S.J., Lettink-Wissink M.L., Van der Meer R., J. Nutr., 135, (2005); Ten Bruggencate S.J., Bovee-Oudenhoven I.M., Lettink-Wissink M.L., Van der Meer R., J. Nutr., 136, (2006); Petersen A., Heegaard P.M., Pedersen A.L., Andersen J.B., Sorensen R.B., Frokiaer H., Lahtinen S.J., Ouwehand A.C., Poulsen M., Licht T.R., BMC Microbiol., 9, (2009); Zhou S.Y., Gillilland M., Wu X., Leelasinjaroen P., Zhang G., Zhou H., Ye B., Lu Y., Owyang C., J. Clin. Invest., 128, (2017); Chen B.R., Du L.J., He H.Q., Kim J.J., Yan Zhao Y., Zhang Y., Luo L., Dai N., World J. Gastroenterol., 23, (2017); Palaiologou M., Delladetsima I., Tiniakos D., Histol. Histopathol., 29, (2014); Xu H., Diolintzi A., Storch J., Curr. Opin. Clin. Nutr. Metab. Care, 22, (2019); Alexopoulou A., Agiasotelli D., Vasilieva L.E., Dourakis S.P., Ann. Gastroenterol., 30, (2017); Gibson P.R., Skodje G.I., Lundin K.E., J. Gastroenterol. Hepatol., 32, (2017); Carroccio A., Giannone G., Mansueto P., Soresi M., La Blasca F., Fayer F., Iacobucci R., Porcasi R., Catalano T., Geraci G., Arini A., D'Alcamo A., Villanacci V., Florena A.M., Clin. Gastroenterol. Hepatol., 17, (2019); Furuhashi M., Hotamisligil G.S., Nat. Rev. Drug Discovery, 7, (2008); Derikx J.P., Schellekens D.H., Acosta S., Best Pract. Res. Clin. Gastroenterol., 31, (2017); Derikx J.P., Vreugdenhil A.C., Van den Neucker A.M., Grootjans J., van Bijnen A.A., Damoiseaux J.G.M.C., van Heurn L.W.E., Heineman E., Buurman W.A., J. Clin. Gastroenterol., 43, (2009); Adriaanse M.P., Tack G.J., Passos V.L., Damoiseaux J.G.M.C., Schreurs M.W.J., van Wijck K., Riedl R.G., Masclee A.A.M., Buurman W.A., Mulder C.J.J., Vreugdenhil A.C.E., Aliment. Pharmacol. Ther., 37, (2013); Hoffmanova I., Sanchez D., Habova V., Andel M., Tuckova L., Tlaskalova-Hogenova H., Physiol. Res., 64, (2015); B. Arias N.M., Garcia M., Bondar C., Guzman L., Redondo A., Chopita N., Corsico B., Chirdo F.G., Mediators Inflammation, 2015, (2015); Vreugdenhil A.C., Wolters V.M., Adriaanse M.P., Van den Neucker A.M., van Bijnen A.A., Houwen R., Buurman W.A., Scand. J. Gastroenterol., 46, (2011); Adriaanse M.P.M., Mubarak A., Riedl R.G., Ten Kate F.J.W., Damoiseaux J.G.M.C., Buurman W.A., Houwen R.H.J., Vreugdenhil A.C.E., Sci. Rep., 7, (2017); Oldenburger I.B., Wolters V.M., Kardol-Hoefnagel T., Houwen R.H.J., Otten H.G., APMIS, 126, (2018); Adriaanse M.P., Leffler D.A., Kelly C.P., Schuppan D., Najarian R.M., Goldsmith J.D., Buurman W.A., Vreugdenhil A.C.E., Am. J. Gastroenterol., 111, (2016); Bodelier A.G., Pierik M.J., Lenaerts K., de Boer E., Damink S.W.O., Hameeteman W.M., Masclee A.A.M., Jonkers D.M., Eur. J. Gastroenterol. Hepatol., 28, (2016); Wiercinska-Drapalo A., Jaroszewicz J., Siwak E., Pogorzelska J., Prokopowicz D., Regul. Pept., 147, (2008); Wang Z., Li R., Tan J., Peng L., Wang P., Liu J., Xiong H., Jiang B., Chen Y., Inflammatory Bowel Dis., 21, (2015); Alexopoulou A.N., Multhaupt H.A., Couchman J.R., Int. J. Biochem. Cell Biol., 39, (2007); Bode L., Salvestrini C., Park P.W., Li J.-P., Esko J.D., Yamaguchi Y., Murch S., Freeze H.H., J. Clin. Invest., 118, (2008); Gan X., Wong B., Wright S.D., Cai T.Q., J. Interferon Cytokine Res., 21, (2001); Klein R.D., Borchers A.H., Sundareshan P., Bougelet C., Berkman M.R., Nagle R.B., Bowden G.T., J. Biol. Chem., 272, (1997); Yablecovitch D., Stein A., Shabat-Simon M., Naftali T., Gabay G., Laish I., Oren A., Konikoff F.M., Dig. Dis. Sci., 60, (2015); Cekic C., Kirci A., Vatansever S., Aslan F., Yilmaz H.E., Alper E., Arabul M., Yuksel E.S., Unsal B., Gastroenterol. Res. Pract., 2015, (2015); Ierardi E., Giorgio F., Zotti M., Rosania R., Principi M., Marangi S., Valle N.D., De Francesco V., Di Leo A., Ingrosso M., Panella C., J. Clin. Pathol., 64, (2011); Tursi A., Elisei W., Principi M., Inchingolo D.D., Nenna R., Picchio M., Giorgio F., Ierardi E., Brandimarte G., J. Gastrointest. Liver Dis., 23, (2014); Grube B.J., Cochane C.G., Ye R.D., McPhail M.E., Ulevitch R.J., Tobias P.S., J. Biol. Chem., 269, (1994); Klein R.D., Su G.L., Aminlari A., Alarcon W.H., Wang S.C., J. Surg. Res., 78, (1998); Wright S.D., Ramos R.A., Tobias P.S., Ulevitch R.J., Mathison J.C., Science, 249, (1990); Tapping R.I., Tobias P.S., J. Biol. Chem., 272, (1997); Landmann R., Knopf H.P., Link S., Sansano S., Schumann R., Zimmerli W., Infect. Immun., 64, (1996); P. Rojo O., Lopez San Roman A., Arbizu E.A., de la Hera Martinez A., Sevillano E.R., Martinez A.A., Inflammatory Bowel Dis., 13, (2007); Sandler N.G., Douek D.C., Nat. Rev. Microbiol., 10, (2012); Benjamini Y., Hochberg Y., J. R. Stat. Soc., Ser. B, 57, (1995)","P.R. Gibson; Department of Gastroenterology, Monash University and Alfred Health, Melbourne, 3004, Australia; email: peter.gibson@monash.edu; P.R. Gibson; Department of Gastroenterology and Hepatology, Eastern Health, 3128, Australia; email: peter.gibson@monash.edu","","Wiley-VCH Verlag","","","","","","16134125","","","32902928","English","Mol. Nutr. Food Res.","Article","Final","","Scopus","2-s2.0-85092933215"

"Fritscher-Ravens A.; Pflaum T.; Mösinger M.; Ruchay Z.; Röcken C.; Milla P.J.; Das M.; Böttner M.; Wedel T.; Schuppan D.","Fritscher-Ravens, Annette (7003556738); Pflaum, Theresa (57209284188); Mösinger, Marie (57209284049); Ruchay, Zino (57209284428); Röcken, Christoph (57194578639); Milla, Peter J. (7006184499); Das, Melda (57209278870); Böttner, Martina (6602507256); Wedel, Thilo (56253065500); Schuppan, Detlef (35448732000)","7003556738; 57209284188; 57209284049; 57209284428; 57194578639; 7006184499; 57209278870; 6602507256; 56253065500; 35448732000","Many Patients With Irritable Bowel Syndrome Have Atypical Food Allergies Not Associated With Immunoglobulin E","2019","Gastroenterology","157","1","","109","118.e5","","163","10.1053/j.gastro.2019.03.046","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85067204898&doi=10.1053%2fj.gastro.2019.03.046&partnerID=40&md5=23dde4a9c36f7655cf66522888f2c9d8","Unit Experimental Endoscopy, Department of Internal Medicine I, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Department of Pathology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; UCL Institute of Child Health, University College London, London, United Kingdom; Department of Anatomy, Christian Albrecht University, Kiel, Germany; Institute of Translational Immunology, University Medical Center, Mainz, Germany; Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States","Fritscher-Ravens A., Unit Experimental Endoscopy, Department of Internal Medicine I, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Pflaum T., Unit Experimental Endoscopy, Department of Internal Medicine I, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Mösinger M., Unit Experimental Endoscopy, Department of Internal Medicine I, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Ruchay Z., Unit Experimental Endoscopy, Department of Internal Medicine I, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Röcken C., Department of Pathology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Milla P.J., UCL Institute of Child Health, University College London, London, United Kingdom; Das M., Unit Experimental Endoscopy, Department of Internal Medicine I, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Böttner M., Department of Anatomy, Christian Albrecht University, Kiel, Germany; Wedel T., Department of Anatomy, Christian Albrecht University, Kiel, Germany; Schuppan D., Institute of Translational Immunology, University Medical Center, Mainz, Germany, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States","Background & Aims: Confocal laser endomicroscopy (CLE) is a technique that permits real-time detection and quantification of changes in intestinal tissues and cells, including increases in intraepithelial lymphocytes and fluid extravasation through epithelial leaks. Using CLE analysis of patients with irritable bowel syndrome (IBS), we found that more than half have responses to specific food components. Exclusion of the defined food led to long-term symptom relief. We used the results of CLE to detect reactions to food in a larger patient population and analyzed duodenal biopsy samples and fluid from patients to investigate mechanisms of these reactions. Methods: In a prospective study, 155 patients with IBS received 4 challenges with each of 4 common food components via the endoscope, followed by CLE, at a tertiary medical center. Classical food allergies were excluded by negative results from immunoglobulin E serology analysis and skin tests for common food antigens. Duodenal biopsy samples and fluid were collected 2 weeks before and immediately after CLE and were analyzed by histology, immunohistochemistry, reverse transcription polymerase chain reaction, and immunoblots. Results from patients who had a response to food during CLE (CLE+) were compared with results from patients who did not have a reaction during CLE (CLE–) or healthy individuals (controls). Results: Of the 108 patients who completed the study, 76 were CLE+ (70%), and 46 of these (61%) reacted to wheat. CLE+ patients had a 4-fold increase in prevalence of atopic disorders compared with controls (P =.001). Numbers of intraepithelial lymphocytes were significantly higher in duodenal biopsy samples from CLE+ vs CLE– patients or controls (P =.001). Expression of claudin-2 increased from crypt to villus tip (P <.001) and was up-regulated in CLE+ patients compared with CLE– patients or controls (P =.023). Levels of occludin were lower in duodenal biopsy samples from CLE+ patients vs controls (P =.022) and were lowest in villus tips (P <.001). Levels of messenger RNAs encoding inflammatory cytokines were unchanged in duodenal tissues after CLE challenge, but eosinophil degranulation increased, and levels of eosinophilic cationic protein were higher in duodenal fluid from CLE+ patients than controls (P =.03). Conclusions: In a CLE analysis of patients with IBS, we found that more than 50% of patients could have nonclassical food allergy, with immediate disruption of the intestinal barrier upon exposure to food antigens. Duodenal tissues from patients with responses to food components during CLE had immediate increases in expression of claudin-2 and decreases in occludin. CLE+ patients also had increased eosinophil degranulation, indicating an atypical food allergy characterized by eosinophil activation. © 2019 AGA Institute","Diet; Eosinophil; Food Allergy; Tight Junction","Adolescent; Adult; Aged; Allergens; Animals; Biopsy; Cell Degranulation; Claudin-2; Cytokines; Duodenum; Egg Hypersensitivity; Egg White; Endoscopy, Digestive System; Eosinophil Cationic Protein; Eosinophils; Female; Food Hypersensitivity; Humans; Immunoglobulin E; Intestinal Mucosa; Intraepithelial Lymphocytes; Irritable Bowel Syndrome; Male; Microscopy, Confocal; Middle Aged; Milk; Milk Hypersensitivity; Occludin; Permeability; Prospective Studies; RNA, Messenger; Soybeans; Tight Junctions; Triticum; Wheat Hypersensitivity; Yeasts; Young Adult; claudin 2; eosinophil cationic protein; immunoglobulin E; messenger RNA; occludin; tryptase; allergen; claudin 2; cytokine; egg white; eosinophil cationic protein; immunoglobulin E; messenger RNA; occludin; adult; aged; Article; atopy; confocal laser scanning microscopy; controlled study; degranulation; duodenum biopsy; duodenum tissue; egg; eosinophil; female; food allergy; histopathology; human; human tissue; immunoblotting; immunohistochemistry; intestine crypt; intestine villus; intraepithelial lymphocyte; irritable colon; major clinical study; male; milk; priority journal; protein expression; provocation test; quantitative analysis; randomized controlled trial (topic); retrospective study; reverse transcription polymerase chain reaction; soy food; upregulation; wheat; yeast; adolescent; animal; biopsy; confocal microscopy; digestive tract endoscopy; duodenum; egg allergy; food allergy; intestine mucosa; irritable colon; metabolism; middle aged; milk allergy; pathology; permeability; prospective study; soybean; tight junction; wheat allergy; young adult","","immunoglobulin E, 37341-29-0; occludin, 176304-61-3; tryptase, 97501-93-4; egg white, 9006-50-2; Allergens, ; Claudin-2, ; Cytokines, ; Eosinophil Cationic Protein, ; Immunoglobulin E, ; Occludin, ; RNA, Messenger, ","","","Deutsche Forschungsgemeinschaft, DFG, (646/17-1, 646/20-1)","Funding The work was supported by the Rashid Hussein Charity Trust, Kuala Lumpur, Malaysia to Annette Fritscher-Ravens and by research grants from the German Research Foundation (DFG Schu 646/17-1, DFG Schu 646/20-1) and from the Leibniz Foundation (Wheatscan, SAW-2016-DFA-2) to Detlef Schuppan. The sponsor has no involvement in the study. Author contributions: Annette Fritscher-Ravens: study concept and design, oversaw study, performed endoscopies, wrote manuscript; Theresa Pflaum: immunohistochemistry and histology, clinical assessment of patients; Marie Mösinger: clinical patient assessment; performed eosinophil count, tryptase, ECP measurements; statistics: Zino Ruchai: clinical patient evaluation and follow-up, CLE image interpretation, questionnaire evaluation, statistics; Chirstoph Röcken: oversaw all histology, guided correlation CLE histology, corrected manuscript; Peter Milla: helped with study design and writing of manuscript; Melda Das: clinical patient evaluation and follow-up, oversaw all diets and follow-up; Martina Böttner: helped with study design and all immunohistochemistry; Thilo Wedel: corrected manuscript; Detlef Schuppan: study concept/design, wrote manuscript, provided conceptual strategy.","Lovell R.M., Ford A.C., Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis, Clin Gastroenterol Hepatol, 10, pp. 712-721, (2012); Longstreth G.F., Thompson W.G., Chey W.D., Et al., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Soares R.L., Irritable bowel syndrome: a clinical review, World J Gastroenterol, 20, pp. 12144-12160, (2014); Bohn L., Storsrud S., Tornblom H., Et al., Self-reported food related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life, Am J Gastroenterol, 108, pp. 634-641, (2013); Halmos E.P., Power V.A., Shepherd S.J., Et al., A diet low in FODMAPS reduces symptoms of irritable bowel syndrome, Gastroenterology, 146, pp. 67-75, (2014); Bohn L., Storsrud S., Liljebo T., Et al., Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial, Gastroenterology, 149, pp. 1399-1407, (2015); Eswaran S., Goel A., Chey W.D., What role does wheat play in the symptoms of irritable bowel syndrome?, Gastroenterol Hepatol, 9, pp. 85-91, (2013); Vazquez-Roque M.I., Camilleri M., Smyrk T., Et al., A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function, Gastroenterology, 144, pp. 903-911, (2013); Fritscher-Ravens A., Schuppan D., Erichmann M., Et al., Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome, Gastroenterology, 147, pp. 1012-1020, (2014); Guidelines—Rome III diagnostic criteria for functional gastrointestinal disorders, J Gastrointest Liver Dis, 15, pp. 307-312, (2006); Walker M.M., Murray J.A., Ronkainen J., Et al., Detection of celiac disease and lymphocytic enteropathy by parallel serology and histopathology in a population-based study, Gastroenterology, 139, pp. 112-119, (2010); Phillips A.D., Rice S.J., France N.E., Et al., Small intestinal intraepithelial lymphocyte levels in cow's milk protein intolerance, Gut, 20, pp. 509-512, (1979); Hayat M., Cairns A., Dixon M.F., Et al., Quantitation of intraepithelial lymphocytes in human duodenum: what is normal?, J Clin Pathol, 55, pp. 393-394, (2002); Hofmann S.R., Laass M.W., Fehrs A., Et al., IL10 promoter haplotypes may contribute to altered cytokine expression and systemic inflammation in celiac disease, Clin Immunol, 190, pp. 15-21, (2018); Rothenburg M.E., Eosinophilia. N Engl J Med, 338, pp. 1592-1600, (1998); Neumann H., Vieth M., Atreya R., Et al., Assessment of Crohn's disease activity by confocal laser endomicroscopy, Inflamm Bowel Dis, 12, pp. 2261-2269, (2012); Queneherve L., David G., Bourreille A., Et al., Quantitative assessment of mucosal architecture using computer-based analysis of confocal laser endomicroscopy in inflammatory bowel disease, Gastrointest Endosc, 89, pp. 626-636, (2019); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Vazquez-Roque M.I., Camilleri M., Smyrk T., Et al., Association of permeability measurements bowel transit, barrier function and inﬂammation in irritable bowel syndrome with diarrhea, Am J Physiol Gastrointest Liver Physiol, 303, pp. G1262-G1269, (2012); Martinez C., Lobo B., Pigrau M., Et al., Diarrhea-predominant irritable bowel syndrome. An organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, pp. 1160-1168, (2013); Piche T., Barbara G., Aubert P., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Gunzel D., Yu A.S.L., Claudins and the modulation of tight junction permeability, Physiol Rev, 93, pp. 525-569, (2013); Al-Sadi R., Khatib K., Guo S., Et al., Occludin regulates macromolecule flux across the intestinal epithelial tight junction barrier, Am J Physiol Gastrointest Liver Physiol, 300, pp. G1054-G1064, (2011); Martinez C., Gonzalez-Castro A., Vicario M., Santos J., Cellular and molecular basis of intestinal barrier dysfunction in the irritable bowel syndrome, Gut Liver, 6, pp. 305-315, (2012); Zeissig S., Burgel N., Gunzel D., Et al., Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease, Gut, 56, pp. 61-72, (2007); Landy J., Ronde E., English N., Et al., Tight junctions in inflammatory bowel diseases and inflammatory bowel disease associated colorectal cancer, World J Gastroenterol, 22, pp. 3117-3126, (2016); Rauhavirta T., Lindfors K., Koskinen O., Et al., Impaired epithelial integrity in the duodenal mucosa in early stages of celiac disease, Transl Res, 164, pp. 223-231, (2014); Wang F., Graham W.V., Wang Y., Et al., Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression, Am J Pathol, 166, pp. 409-419, (2005); Weber C.R., Raleigh D.R., Su L., Et al., Epithelial myosin light chain kinase activation induces mucosal interleukin-13 expression to alter tight junction ion selectivity, J Biol Chem, 285, pp. 12037-12046, (2010); Travers J., Rothenburg M.E., Eosinophils in mucosal immune responses, Mucosal Immunol, 8, pp. 464-475, (2015); Furuta G.T., Nieuwenhuis E.E., Karhausen J., Et al., Eosinophils alter colonic epithelial barrier function: role for major basic protein, Am J Physiol Gastrointest Liver Physiol, 289, pp. G890-G897, (2005); O'Shea K.M., Aceves S.S., Dellon E.S., Et al., Pathophysiology of eosinophilic esophagitis, Gastroenterology, 154, pp. 333-345, (2018); Kalach N., Kapel N., Waligora-Dupriet A.J., Et al., Intestinal permeability and fecal eosinophil-derived neurotoxin are the best diagnosis tools for digestive non-IgE-mediated cow's milk allergy in toddlers, Clin Chem Lab Med, 51, pp. 351-361, (2013); Warners M.J., Vlieg-Boerstra B.J., Verheij J., Et al., Esophageal and small intestinal mucosal integrity in eosinophilic esophagitis and response to an elemental diet, Am J Gastroenterol, 112, pp. 1061-1071, (2017); Vivinus-Nebot M., Frin-Mathy G., Bzioueche H., Et al., Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation, Gut, 63, pp. 744-752, (2014); Vanheel H., Vicario M., Vanuytsel T., Et al., Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia, Gut, 63, pp. 262-271, (2014); Gibson P.G., Inflammatory phenotypes in adult asthma: clinical applications, Clin Respir J, 3, pp. 198-206, (2009); Saitoh O., Kojima K., Sugi K., Et al., Fecal eosinophil granule-derived proteins reflect disease activity in inflammatory bowel disease, Am J Gastroenterol, 94, pp. 3513-3520, (1999); Zevallos V.F., Raker V.K., Maxeiner J., Et al.; Junker Y., Zeissig S., Kim S.J., Et al., Wheat amylase trypsin inhibitors drive intestinal inflammation via activation of toll-like receptor 4, J Exp Med, 209, pp. 2395-2408, (2012); Bellinghausen I., Weigmann B., Zevallos V., Et al., Wheat amylase-trypsin inhibitors exacerbate intestinal and airway allergic immune responses in humanized mice, J Allergy Clin Immunol, 143, pp. 201-212, (2019); Fritscher-Ravens A., Schuppan D., Erichmann M., Et al., Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome, Gastroenterology, 147, pp. 1012-1020, (2014); Francis C.Y., Morris J., Whorwell P.J., The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress, Alimentary Pharmacol Ther, 11, pp. 395-402, (2007); Coffin B., Dapoigny M., Cloarec D., Et al., Relationship between severity of symptoms and quality of life in 858 patients with irritable bowel syndrome, Gastroenterol Clin Biol, 28, pp. 11-15, (2004); Bengtsson M., Ohlsson B., Ulander K., Development and psychometric testing of the Visual Analogue Scale for Irritable Bowel Syndrome (VAS-IBS), BMC Gastroenterol, 7, (2007)","A. Fritscher-Ravens; Department of Internal Medicine I, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Arnold Heller Strasse 3, 24105, Germany; email: fri.rav@btopenworld.com","","W.B. Saunders","","","","","","00165085","","GASTA","31100380","English","Gastroenterology","Article","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-85067204898"

"Mahurkar-Joshi S.; Rankin C.R.; Videlock E.J.; Soroosh A.; Verma A.; Khandadash A.; Iliopoulos D.; Pothoulakis C.; Mayer E.A.; Chang L.","Mahurkar-Joshi, Swapna (57188692009); Rankin, Carl Robert (36627549600); Videlock, Elizabeth Jane (6506286261); Soroosh, Artin (56966623200); Verma, Abhishek (57218322918); Khandadash, Ariela (57222716697); Iliopoulos, Dimitrios (57204296530); Pothoulakis, Charalabos (7007088541); Mayer, Emeran A. (35500853900); Chang, Lin (55547137110)","57188692009; 36627549600; 6506286261; 56966623200; 57218322918; 57222716697; 57204296530; 7007088541; 35500853900; 55547137110","The Colonic Mucosal MicroRNAs, MicroRNA-219a-5p, and MicroRNA-338-3p Are Downregulated in Irritable Bowel Syndrome and Are Associated With Barrier Function and MAPK Signaling","2021","Gastroenterology","160","7","","2409","2422.e19","","27","10.1053/j.gastro.2021.02.040","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85106502906&doi=10.1053%2fj.gastro.2021.02.040&partnerID=40&md5=83a259e88ab49461a135421acc3e4d5c","G. Oppenheimer Center for Neurobiology of Stress and Resilience, Division of Digestive Diseases, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, United States; UCLA Center for Inflammatory Bowel Diseases, Division of Digestive Diseases, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, United States","Mahurkar-Joshi S., G. Oppenheimer Center for Neurobiology of Stress and Resilience, Division of Digestive Diseases, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, United States; Rankin C.R., UCLA Center for Inflammatory Bowel Diseases, Division of Digestive Diseases, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, United States; Videlock E.J., G. Oppenheimer Center for Neurobiology of Stress and Resilience, Division of Digestive Diseases, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, United States; Soroosh A., UCLA Center for Inflammatory Bowel Diseases, Division of Digestive Diseases, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, United States; Verma A., G. Oppenheimer Center for Neurobiology of Stress and Resilience, Division of Digestive Diseases, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, United States; Khandadash A., G. Oppenheimer Center for Neurobiology of Stress and Resilience, Division of Digestive Diseases, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, United States; Iliopoulos D., UCLA Center for Inflammatory Bowel Diseases, Division of Digestive Diseases, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, United States; Pothoulakis C., UCLA Center for Inflammatory Bowel Diseases, Division of Digestive Diseases, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, United States; Mayer E.A., G. Oppenheimer Center for Neurobiology of Stress and Resilience, Division of Digestive Diseases, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, United States; Chang L., G. Oppenheimer Center for Neurobiology of Stress and Resilience, Division of Digestive Diseases, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, United States","Background & Aims: Alterations in microRNA (miRNA) and in the intestinal barrier are putative risk factors for irritable bowel syndrome (IBS). We aimed to identify differentially expressed colonic mucosal miRNAs, their targets in IBS compared to healthy controls (HCs), and putative downstream pathways. Methods: Twenty-nine IBS patients (15 IBS with constipation [IBS-C], 14 IBS with diarrhea [IBS-D]), and 15 age-matched HCs underwent sigmoidoscopy with biopsies. A nCounter array was used to assess biopsy specimen-associated miRNA levels. A false discovery rate (FDR) < 10% was considered significant. Real-time polymerase chain reaction (PCR) was used to validate differentially expressed genes. To assess barrier function, trans-epithelial electrical resistance (TEER) and dextran flux assays were performed on Caco-2 intestinal epithelial cells that were transfected with miRNA-inhibitors or control inhibitors. Protein expression of barrier function associated genes was confirmed using western blots. Results: Four out of 247 miRNAs tested were differentially expressed in IBS compared to HCs (FDR < 10%). Real-time PCR validation suggested decreased levels of miR-219a-5p and miR-338-3p in IBS (P =.026 and P =.004), and IBS-C (P =.02 and P =.06) vs. HCs as the strongest associations. Inhibition of miR-219a-5p resulted in altered expression of proteasome/barrier function genes. Functionally, miR-219a-5p inhibition enhanced the permeability of intestinal epithelial cells as TEER was reduced (25-50%, P <.05) and dextran flux was increased (P <.01). Additionally, inhibition of miR-338-3p in cells caused alterations in the mitogen-activated protein kinase (MAPK) signaling pathway genes. Conclusion: Two microRNAs that potentially affect permeability and visceral nociception were identified to be altered in IBS patients. MiR-219a-5p and miR-338-3p potentially alter barrier function and visceral hypersensitivity via neuronal and MAPK signaling and could be therapeutic targets in IBS. © 2021 AGA Institute","Barrier Function; MAPK Signaling; miR-219a-5p; miR-338-3p; miRNA","Adolescent; Adult; Case-Control Studies; Colon; Constipation; Diarrhea; Down-Regulation; Female; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Male; MAP Kinase Signaling System; MicroRNAs; Middle Aged; Permeability; Young Adult; antidiarrheal agent; benzodiazepine; dextran; laxative; microRNA; microRNA 219a 5p; microRNA 338 3p; mitogen activated protein kinase; nonsteroid antiinflammatory agent; proteasome; unclassified drug; microRNA; MIRN219 microRNA, human; MIRN338 microRNA, human; abdominal pain; adult; anxiety; Article; bloating; Caco-2 cell line; clinical article; colon biopsy; colon mucosa; constipation; controlled study; defecation habit; depression; diarrhea; down regulation; electric resistance; false discovery rate; female; gene expression regulation; Hospital Anxiety and Depression Scale; human; human cell; human tissue; intestine epithelium cell; irritable colon; male; MAPK signaling; NCM460 cell line; nociception; numeric rating scale; permeability barrier; priority journal; protein expression; real time polymerase chain reaction; sigmoidoscopy; transepithelial electrical resistance; Western blotting; adolescent; case control study; colon; complication; genetics; intestine mucosa; irritable colon; metabolism; middle aged; permeability; young adult","","benzodiazepine, 12794-10-4; dextran, 87915-38-6, 9014-78-2; mitogen activated protein kinase, 142243-02-5; proteasome, 140879-24-9; MicroRNAs, ; MIRN219 microRNA, human, ; MIRN338 microRNA, human, ","","","National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases, (P50 DK64539, R21 DK104078); National Center for Advancing Translational Sciences, NCATS, (UL1TR000124); University of California, Los Angeles, UCLA, (P30 DK041301)","Funding Funding was received from National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases grants P50 DK64539, R21 DK104078, University of California, Los Angeles (UCLA)/Integrated Molecular Technologies (IMT) core Collaboration in Undergraduate Research Enrichment (CURE)/P30 DK041301, and National Center for Advancing translational Sciences grant UL1TR000124. ","Drossman D.A., Hasler W.L., Rome IV-functional GI disorders: disorders of gut-brain interaction, Gastroenterology, 150, pp. 1257-1261, (2016); Lovell R.M., Ford A.C., Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis, Clin Gastroenterol Hepatol, 10, pp. 712-721.e4, (2012); Camilleri M., Lasch K., Zhou W., Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome, Am J Physiol Gastrointest Liver Physiol, 303, pp. G775-G785, (2012); Barbara G., Stanghellini V., De Giorgio R., Et al., Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome, Gastroenterology, 126, pp. 693-702, (2004); Chadwick V.S., Chen W., Shu D., Et al., Activation of the mucosal immune system in irritable bowel syndrome, Gastroenterology, 122, pp. 1778-1783, (2002); Buhner S., Li Q., Vignali S., Et al., Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome, Gastroenterology, 137, pp. 1425-1434, (2009); Barbara G., Wang B., Stanghellini V., Et al., Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome, Gastroenterology, 132, pp. 26-37, (2007); Mahurkar-Joshi S., Chang L., Epigenetic mechanisms in irritable bowel syndrome, Front Psychiatry, 11, (2020); Camilleri M., Carlson P., Acosta A., Et al., Colonic mucosal gene expression and genotype in irritable bowel syndrome patients with normal or elevated fecal bile acid excretion, Am J Physiol Gastrointest Liver Physiol, 309, pp. G10-G20, (2015); Videlock E.J., Mahurkar-Joshi S., Iliopoulos D., Et al., Dysregulation of the long-noncoding RNA, GHRLOS, in irritable bowel syndrome, Gastroenterology, 152, (2017); Taft R.J., Pheasant M., Mattick J.S., The relationship between non-protein-coding DNA and eukaryotic complexity, Bioessays, 29, pp. 288-299, (2007); Fabian M.R., Sonenberg N., Filipowicz W., Regulation of mRNA translation and stability by microRNAs, Annu Rev Biochem, 79, pp. 351-379, (2010); Wohlfarth C., Schmitteckert S., Hartle J.D., Et al., miR-16 and miR-103 impact 5-HT 4 receptor signalling and correlate with symptom profile in irritable bowel syndrome, Sci Rep, 7, pp. 1-14, (2017); Martinez C., Rodino-Janeiro B.K., Lobo B., Et al., miR-16 and miR-125b are involved in barrier function dysregulation through the modulation of claudin-2 and cingulin expression in the jejunum in IBS with diarrhoea, Gut, 66, pp. 1537-1538, (2017); Zhou Q., Yang L., Larson S., Et al., Decreased miR-199 augments visceral pain in patients with IBS through translational upregulation of TRPV1, Gut, 65, pp. 797-805, (2016); Hou Q., Huang Y., Zhu S., Et al., MiR-144 increases intestinal permeability in IBS-D rats by targeting OCLN and ZO1, Cell Physiol Biochem, 44, pp. 2256-2268, (2017); Zhu H., Xiao X., Chai Y., Et al., MiRNA-29a modulates visceral hyperalgesia in irritable bowel syndrome by targeting HTR7, Biochem Biophys Res Commun, 511, pp. 671-678, (2019); Zhang Y., Li Y., Hao Z., Et al., Association of the serotonin receptor 3E gene as a functional variant in the microRNA-510 target site with diarrhea predominant irritable bowel syndrome in Chinese women, J Neurogastroenterol Motil, 22, pp. 272-281, (2016); Hou Q., Huang Y., Zhang C., Et al., MicroRNA-200a targets cannabinoid receptor 1 and serotonin transporter to increase visceral hyperalgesia in diarrhea-predominant irritable bowel syndrome rats, J Neurogastroenterol Motil, 24, pp. 656-668, (2018); Chao G., Wang Y., Zhang S., Et al., MicroRNA-29a increased the intestinal membrane permeability of colonic epithelial cells in irritable bowel syndrome rats, Oncotarget, 8, pp. 85828-85837, (2017); Stanisor O.I., van Diest S.A., Yu Z., Et al., Stress-induced visceral hypersensitivity in maternally separated rats can be reversed by peripherally restricted histamine-1-receptor antagonists, PLoS One, 8, (2013); Longstreth G.F., Thompson W.G., Chey W.D., Et al., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Sheehan D.V., Lecrubier Y., Sheehan K.H., Et al., The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10, J Clin Psychiatry, 59, pp. 22-33, (1998); Munakata J., Naliboff B., Harraf F., Et al., Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndrome, Gastroenterology, 112, pp. 55-63, (1997); Zigmond A.S., Snaith R.P., The hospital anxiety and depression scale, Acta Psychiatr Scand, 67, pp. 361-370, (1983); Moll P., Ante M., Seitz A., Et al., QuantSeq 3′ mRNA sequencing for RNA quantification, Nat Methods, 11, pp. i-iii, (2014); Waggott D., Chu K., Yin S., Et al., NanoStringNorm: an extensible R package for the pre-processing of NanoString mRNA and miRNA data, Bioinformatics, 28, pp. 1546-1548, (2012); Ritchie M.E., Phipson B., Wu D., Et al., limma powers differential expression analyses for RNA-sequencing and microarray studies, Nucleic Acids Res, 43, (2015); McDonald J.H., Handbook of Biological Statistics, pp. 254-260, (2014); Schmittgen T.D., Livak K.J., Analyzing real-time PCR data by the comparative C(T) method, Nat Protoc, 3, pp. 1101-1108, (2008); Vlachos I.S., Zagganas K., Paraskevopoulou M.D., Et al., DIANA-miRPath v3.0: deciphering microRNA function with experimental support, Nucleic Acids Res, 43, pp. W460-W466, (2015); Bindea G., Galon J., Mlecnik B., CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data, Bioinformatics, 29, pp. 661-663, (2013); Cattin A.-L., Le Beyec J., Barreau F., Et al., Hepatocyte nuclear factor 4alpha, a key factor for homeostasis, cell architecture, and barrier function of the adult intestinal epithelium, Mol Cell Biol, 29, pp. 6294-6308, (2009); Coeffier M., Gloro R., Boukhettala N., Et al., Increased proteasome-mediated degradation of occludin in irritable bowel syndrome, Am J Gastroenterol, 105, pp. 1181-1188, (2010); Smalley K.S.M., Brafford P., Haass N.K., Et al., Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion, Am J Pathol, 166, pp. 1541-1554, (2005); Schneider M.R., Dahlhoff M., Horst D., Et al., A key role for E-cadherin in intestinal homeostasis and paneth cell maturation, PLoS One, 5, (2010); Lea T., Caco-2 Cell Line, The Impact of Food Bioactives on Health: in vitro and ex vivo models, (2015); Tian T., Wang Z., Zhang J., Pathomechanisms of oxidative stress in inflammatory bowel disease and potential antioxidant therapies, Oxid Med Cell Longev, 2017, (2017); Poyton R.O., Castello P.R., Ball K.A., Et al., Mitochondria and hypoxic signaling, Ann N Y Acad Sci, 1177, pp. 48-56, (2009); Ramachandran K.V., Margolis S.S., A mammalian nervous system-specific plasma membrane proteasome complex that modulates neuronal function, Nat Struct Mol Biol, 24, pp. 419-430, (2017); Lockhart S.M., Saudek V., O'Rahilly S., GDF15: a hormone conveying somatic distress to the brain, Endocr Rev, 41, pp. 610-642, (2020); Ryu C.S., Klein K., Zanger U.M., Membrane associated progesterone receptors: promiscuous proteins with pleiotropic functions—focus on interactions with cytochromes P450, Front Pharmacol, 8, (2017); Kiss-Toth E., Bagstaff S.M., Sung H.Y., Et al., Human tribbles, a protein family controlling mitogen-activated protein kinase cascades, J Biol Chem, 279, pp. 42703-42708, (2004); Ji R.-R., Befort K., Brenner G.J., Et al., ERK MAP kinase activation in superficial spinal cord neurons induces prodynorphin and NK-1 upregulation and contributes to persistent inflammatory pain hypersensitivity, J Neurosci, 22, pp. 478-485, (2002); Nefla M., Sudre L., Denat G., Et al., The pro-inflammatory cytokine 14-3-3ε is a ligand of CD13 in cartilage, J Cell Sci, 128, pp. 3250-3262, (2015); Wollank Y., Ramer R., Ivanov I., Et al., Inhibition of FAAH confers increased stem cell migration via PPARα, J Lipid Res, 56, pp. 1947-1960, (2015); Booker L., Kinsey S.G., Abdullah R.A., Et al., The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice, Br J Pharmacol, 165, pp. 2485-2496, (2012); Ji Y., Tang B., Traub R.J., Spinal estrogen receptor alpha mediates estradiol-induced pronociception in a visceral pain model in the rat, Pain, 152, pp. 1182-1191, (2011); Naliboff B.D., Waters A.M., Labus J.S., Et al., Increased acoustic startle responses in IBS patients during abdominal and nonabdominal threat, Psychosom Med, 70, pp. 920-927, (2008); Martinez C., Rodino-Janeiro B.K., Lobo B., Et al., miR-16 and miR-125b are involved in barrier function dysregulation through the modulation of claudin-2 and cingulin expression in the jejunum in IBS with diarrhoea, Gut, 66, pp. 1537-1538, (2017); Zhou Q., Souba W.W., Croce C.M., Et al., MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome, Gut, 59, pp. 775-784, (2010); Videlock E.J., Mahurkar-Joshi S., Hoffman J.M., Et al., Sigmoid colon mucosal gene expression supports alterations of neuronal signaling in irritable bowel syndrome with constipation, Am J Physiol Gastrointest Liver Physiol, 315, pp. G140-157, (2018); Piche T., Barbara G., Aubert P., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Furuse M., Itoh M., Hirase T., Et al., Direct association of occludin with ZO-1 and its possible involvement in the localization of occludin at tight junctions, J Cell Biol, 127, pp. 1617-1626, (1994); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Et al., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am J Gastroenterol, 106, pp. 2165-2173, (2011); Kim S., Kim G.-H., Roles of claudin-2, ZO-1 and occludin in leaky HK-2 cells, PLoS One, 12, (2017); Camilleri M., Carlson P., Valentin N., Et al., Pilot study of small bowel mucosal gene expression in patients with irritable bowel syndrome with diarrhea, Am J Physiol Gastrointest Liver Physiol, 311, pp. G365-376, (2016); Fasano A., Visanji N.P., Liu L.W.C., Et al., Gastrointestinal dysfunction in Parkinson's disease, Lancet Neurol, 14, pp. 625-639, (2015); Zhu Y., Xu Q., Sha W.-P., Et al., MiR-219-5p promotes spinal cord injury recovery by inhibiting NEUROD2-regulated inflammation and oxidative stress, Eur Rev Med Pharmacol Sci, 23, pp. 37-43, (2019); Pan Z., Zhu L.-J., Li Y.-Q., Et al., Epigenetic modification of spinal miR-219 expression regulates chronic inflammation pain by targeting CaMKIIγ, J Neurosci, 34, pp. 9476-9483, (2014); Hu X.-M., Cao S.-B., Zhang H.-L., Et al., Downregulation of miR-219 enhances brain-derived neurotrophic factor production in mouse dorsal root ganglia to mediate morphine analgesic tolerance by upregulating CaMKIIγ, Mol Pain, 12, (2016); Mete R., Tulubas F., Oran M., Et al., The role of oxidants and reactive nitrogen species in irritable bowel syndrome: a potential etiological explanation, Med Sci Monit, 19, pp. 762-766, (2013); Mahurkar S., Polytarchou C., Iliopoulos D., Et al., Genome-wide DNA methylation profiling of peripheral blood mononuclear cells in irritable bowel syndrome, Neurogastroenterol Motil, 28, pp. 410-422, (2016); Yu Y., Elble R.C., Homeostatic signaling by cell-cell junctions and its dysregulation during cancer progression, J Clin Med, 5, (2016); Bhattacharyya A., Chattopadhyay R., Mitra S., Et al., Oxidative stress: an essential factor in the pathogenesis of gastrointestinal mucosal diseases, Physiol Rev, 94, pp. 329-354, (2014); Zhang H., Dai S.-D., Zhang D., Et al., Delta-catenin promotes the proliferation and invasion of colorectal cancer cells by binding to E-cadherin in a competitive manner with p120 catenin, Target Oncol, 9, pp. 53-61, (2014); Kim C.K., Saxena M., Maharjan K., Et al., Krüppel-like factor 5 regulates stemness, lineage specification, and regeneration of intestinal epithelial stem cells, Cell Mol Gastroenterol Hepatol, 9, pp. 587-609, (2020); Ocadiz-Ruiz R., Photenhauer A.L., Hayes M.M., Et al., ZBP-89 function in colonic stem cells and during butyrate-induced senescence, Oncotarget, 8, pp. 94330-94344, (2017); Citalan-Madrid A.F., Vargas-Robles H., Garcia-Ponce A., Et al., Cortactin deficiency causes increased RhoA/ROCK1-dependent actomyosin contractility, intestinal epithelial barrier dysfunction, and disproportionately severe DSS-induced colitis, Mucosal Immunol, 10, pp. 1237-1247, (2017); Gkika D., Lemonnier L., Shapovalov G., Et al., TRP channel-associated factors are a novel protein family that regulates TRPM8 trafficking and activity, J Cell Biol, 208, pp. 89-107, (2015); Weyer A.D., Lehto S.G., Development of TRPM8 antagonists to treat chronic pain and migraine, Pharmaceuticals (Basel), 10, (2017); Topham L., Gregoire S., Kang H., Et al., The transition from acute to chronic pain: dynamic epigenetic reprogramming of the mouse prefrontal cortex up to one year following nerve injury, Pain, 161, pp. 2394-2409, (2020); De Gregorio D., McLaughlin R.J., Posa L., Et al., Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain, Pain, 160, pp. 136-150, (2019); Olah A., Toth B.I., Borbiro I., Et al., Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes, J Clin Invest, 124, pp. 3713-3724, (2014); Baldari S., Ubertini V., Garufi A., Et al., Targeting MKK3 as a novel anticancer strategy: molecular mechanisms and therapeutical implications, Cell Death Dis, 6, (2015); Qu Y.-J., Jia L., Zhang X., Et al., MAPK pathways are involved in neuropathic pain in rats with chronic compression of the dorsal root ganglion, Evid Based Complement Alternat Med, 2016, (2016); Spiller R.C., Jenkins D., Thornley J.P., Et al., Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, pp. 804-811, (2000); Barbara G., Grover M., Bercik P., Et al., Rome Foundation Working Team report on post-infection irritable bowel syndrome, Gastroenterology, 156, pp. 46-58.e7, (2019); Moyer M.P., Manzano L.A., Merriman R.L., Stauffer J.S., Tanzer L.R., NCM460, a normal human colon mucosal epithelial cell line, Vitro Cell Dev Biol Anim, 32, pp. 315-317, (1996); Nguyen L.H., Ong W., Wang K., Et al., Effects of miR-219/miR-338 on microglia and astrocyte behaviors and astrocyte-oligodendrocyte precursor cell interactions, Neural Regen Res, 15, pp. 739-747, (2020); Dobin A., Gingeras T.R., Mapping RNA-seq Reads with STAR, Curr Protoc Bioinformatics, 51, pp. 11.14.1-11.14.19, (2015); Anders S., Pyl P.T., Huber W., HTSeq—a Python framework to work with high-throughput sequencing data, Bioinformatics, 31, pp. 166-169, (2015); Love M.I., Huber W., Anders S., Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2, Genome Biol, 15, (2014); Harding S.D., Sharman J.L., Faccenda E., Et al., The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY, Nucleic Acids Res, 46, pp. D1091-D1106, (2018); Breiman L., Random forests, Mach Learn, 45, pp. 5-32, (2001); Hoban A.E., Stilling R.M., M Moloney G., Et al., Microbial regulation of microRNA expression in the amygdala and prefrontal cortex, Microbiome, 5, (2017)","L. Chang; David Geffen School of Medicine at UCLA, Los Angeles, 10833 Le Conte Avenue, CHS 42-210, 90095-7378, United States; email: linchang@mednet.ucla.edu","","W.B. Saunders","","","","","","00165085","","GASTA","33617890","English","Gastroenterology","Article","Final","All Open Access; Green Open Access","Scopus","2-s2.0-85106502906"

"Martínez C.; Lasitschka F.; Thöni C.; Wohlfarth C.; Braun A.; Granzow M.; Röth R.; Dizdar V.; Rappold G.A.; Hausken T.; Langeland N.; Hanevik K.; Niesler B.","Martínez, Cristina (17534584700); Lasitschka, Felix (8320093700); Thöni, Cornelia (57218697315); Wohlfarth, Carolin (26435618400); Braun, Alexander (57196326503); Granzow, Martin (6603113998); Röth, Ralph (8609257700); Dizdar, Vernesa (23024561200); Rappold, Gudrun A. (56231566500); Hausken, Trygve (7006077847); Langeland, Nina (7004550853); Hanevik, Kurt (6507169429); Niesler, Beate (6602490382)","17534584700; 8320093700; 57218697315; 26435618400; 57196326503; 6603113998; 8609257700; 23024561200; 56231566500; 7006077847; 7004550853; 6507169429; 6602490382","Comparative expression profiling in the intestine of patients with Giardia-induced postinfectious functional gastrointestinal disorders","2020","Neurogastroenterology and Motility","32","9","e13868","","","","5","10.1111/nmo.13868","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85084489098&doi=10.1111%2fnmo.13868&partnerID=40&md5=dc07cb477d72bd1277024d59df809363","Department of Human Molecular Genetics, Institute of Human Genetics, Heidelberg University, Heidelberg, Germany; Lleida Institute for Biomedical Research Dr. Pifarré Foundation (IRBLleida), Lleida, Spain; Genes in Irritable Bowel Syndrome (GENIEUR) Research Network Europe, Heidelberg, Germany; Institute of Pathology, Heidelberg University, Heidelberg, Germany; Institute of Human Genetics, Heidelberg University, Heidelberg, Germany; nCounter Core Facility Heidelberg, Institute of Human Genetics, Heidelberg, Germany; Department of Clinical Science, University of Bergen, Bergen, Norway; Department of Medicine, Haukeland University Hospital, Bergen, Norway; Department of Medicine, National Advisory Center for Tropical Infectious Diseases, Haukeland University Hospital, Bergen, Norway","Martínez C., Department of Human Molecular Genetics, Institute of Human Genetics, Heidelberg University, Heidelberg, Germany, Lleida Institute for Biomedical Research Dr. Pifarré Foundation (IRBLleida), Lleida, Spain, Genes in Irritable Bowel Syndrome (GENIEUR) Research Network Europe, Heidelberg, Germany; Lasitschka F., Institute of Pathology, Heidelberg University, Heidelberg, Germany; Thöni C., Institute of Pathology, Heidelberg University, Heidelberg, Germany; Wohlfarth C., Department of Human Molecular Genetics, Institute of Human Genetics, Heidelberg University, Heidelberg, Germany; Braun A., Department of Human Molecular Genetics, Institute of Human Genetics, Heidelberg University, Heidelberg, Germany; Granzow M., Institute of Human Genetics, Heidelberg University, Heidelberg, Germany; Röth R., Department of Human Molecular Genetics, Institute of Human Genetics, Heidelberg University, Heidelberg, Germany, nCounter Core Facility Heidelberg, Institute of Human Genetics, Heidelberg, Germany; Dizdar V., Department of Clinical Science, University of Bergen, Bergen, Norway; Rappold G.A., Department of Human Molecular Genetics, Institute of Human Genetics, Heidelberg University, Heidelberg, Germany, nCounter Core Facility Heidelberg, Institute of Human Genetics, Heidelberg, Germany; Hausken T., Genes in Irritable Bowel Syndrome (GENIEUR) Research Network Europe, Heidelberg, Germany, Department of Medicine, Haukeland University Hospital, Bergen, Norway; Langeland N., Genes in Irritable Bowel Syndrome (GENIEUR) Research Network Europe, Heidelberg, Germany, Department of Clinical Science, University of Bergen, Bergen, Norway; Hanevik K., Genes in Irritable Bowel Syndrome (GENIEUR) Research Network Europe, Heidelberg, Germany, Department of Clinical Science, University of Bergen, Bergen, Norway, Department of Medicine, National Advisory Center for Tropical Infectious Diseases, Haukeland University Hospital, Bergen, Norway; Niesler B., Department of Human Molecular Genetics, Institute of Human Genetics, Heidelberg University, Heidelberg, Germany, Genes in Irritable Bowel Syndrome (GENIEUR) Research Network Europe, Heidelberg, Germany, nCounter Core Facility Heidelberg, Institute of Human Genetics, Heidelberg, Germany","Background: A Giardia outbreak in Bergen, Norway, caused postinfectious functional gastrointestinal disorders (PI-FGIDs). Despite the devastating effects of this outbreak, it presented a unique chance to investigate the implication on the dysregulation of genetic pathways in PI-FGID. Methods: We performed the first comparative expression profiling of miRNAs and their potential target genes in microdissected rectal biopsies from 20 Giardia-induced PI-FGID patients vs 18 healthy controls by nCounter analysis. Subsequently, candidates were validated on protein level by immunostaining. Key Results: miRNA profiling on rectal biopsy samples from 5 diarrhea-predominant PI-IBS cases compared to 10 healthy controls revealed differential expression in the epithelial layer. The top five regulated miRNAs were implicated in GI disease, inflammatory response, and immunological disease. Subsequently, these miRNAs and 100 potential mRNA targets were examined in 20 PI-FGID cases and 18 healthy controls in both the mucosal epithelium and the lamina propria. Although deregulation of the selected miRNAs could not be verified in the larger sample set, mRNAs involved in barrier function were downregulated in the epithelium. Pro-inflammatory genes and genes implicated in epigenetic modifications were upregulated in the lamina propria. Immunostaining for selected candidates on 17 PI-FGID cases and 16 healthy controls revealed increased tryptase levels as well as a decreased and aberrant subcellular expression of occludin. Conclusions and Inferences: Genes relevant to immune and barrier function as well as stress response and epigenetic modulation are differentially expressed in PI-FGIDs and may contribute to disease manifestation. © 2020 John Wiley & Sons Ltd","expression analysis; laser-capture microdissection; leaky gut; mast cells; occludin; postinfectious functional GI disorders; tight junctions; tryptase","Adult; Female; Gastrointestinal Diseases; Gene Expression Profiling; Giardiasis; Humans; Intestinal Mucosa; Male; MicroRNAs; Middle Aged; Young Adult; messenger RNA; microRNA; occludin; tryptase; microRNA; Article; controlled study; diarrhea; digestive system function disorder; epigenetics; gene expression profiling; giardiasis; human; human cell; human tissue; immune system; immunohistochemistry; immunopathology; inflammation; intestine; lamina propria; priority journal; protein expression; rectum biopsy; adult; complication; female; gastrointestinal disease; genetics; giardiasis; intestine mucosa; male; metabolism; microbiology; middle aged; young adult","","occludin, 176304-61-3; tryptase, 97501-93-4; MicroRNAs, ","","","","","Hanevik K., Hausken T., Morken M.H., Et al., Persisting symptoms and duodenal inflammation related to Giardia Duodenalis infection, JInfect, 55, 6, pp. 524-530, (2007); Hanevik K., Dizdar V., Langeland N., Hausken T., Development of functional gastrointestinal disorders after Giardia Lamblia infection, BMC Gastroenterol, 9, (2009); Morch K., Hanevik K., Rivenes A.C., Et al., Chronic fatigue syndrome 5 years after giardiasis: differential diagnoses, characteristics and natural course, BMC Gastroenterol, 13, (2013); Litleskare S., Rortveit G., Eide G.E., Hanevik K., Langeland N., Wensaas K.A., Prevalence of irritable bowel syndrome and chronic fatigue 10 years after giardia infection, Clin Gastroenterol Hepatol, 16, 7, pp. 1064-1072.e4, (2018); Marshall J.K., Thabane M., Garg A.X., Et al., Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery, Gastroenterology, 131, 2, pp. 445-450, (2006); Talley N.J., Functional gastrointestinal disorders as a public health problem, NeurogastroenterolMotil, 20, pp. 121-129, (2008); Gazouli M., Wouters M.M., Kapur-Pojskic L., Et al., Lessons learned–resolving the enigma of genetic factors in IBS, Nat Rev Gastroenterol Hepatol, 13, 2, pp. 77-87, (2016); Spiller R., Postinfectious functional dyspepsia and postinfectious irritable bowel syndrome: different symptoms but similar risk factors, Gastroenterology, 138, 5, pp. 1660-1663, (2010); Ford A.C., Forman D., Bailey A.G., Axon A.T., Moayyedi P., Fluctuation of gastrointestinal symptoms in the community: a 10-year longitudinal follow-up study, Aliment Pharmacol Ther, 28, 8, pp. 1013-1020, (2008); Olafsdottir L.B., Gudjonsson H., Jonsdottir H.H., Thjodleifsson B., Stability of the irritable bowel syndrome and subgroups as measured by three diagnostic criteria - a 10-year follow-up study, Aliment Pharmacol Ther, 32, 5, pp. 670-680, (2010); Spiller R., Significance of postinfectious irritable bowel syndrome?, Gastroenterology, 156, 1, pp. 14-17, (2019); Spiller R., Garsed K., Postinfectious irritable bowel syndrome, Gastroenterology, 136, 6, pp. 1979-1988, (2009); Thompson W.G., Longstreth G.F., Drossman D.A., Heaton K.W., Irvine E.J., Muller-Lissner S.A., Functional bowel disorders and functional abdominal pain, Gut, 45, pp. ii43-ii47, (1999); Villani A.C., Lemire M., Thabane M., Et al., Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis, Gastroenterology, 138, 4, pp. 1502-1513, (2009); Swan C., Duroudier N.P., Campbell E., Et al., Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNFalpha, Gut, 62, 7, pp. 985-994, (2013); Rodino-Janeiro B.K., Pardo-Camacho C., Santos J., Martinez C., Mucosal RNA and protein expression as the next frontier in IBS: abnormal function despite morphologically intact small intestinal mucosa, Am J Physiol Gastrointest Liver Physiol, 316, 6, pp. G701-G719, (2019); Kapeller J., Houghton L.A., Monnikes H., Et al., First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome, Hum Mol Genet, 17, 19, pp. 2967-2977, (2008); Liao X.J., Mao W.M., Wang Q., Yang G.G., Wu W.J., Shao S.X., MicroRNA-24 inhibits serotonin reuptake transporter expression and aggravates irritable bowel syndrome, Biochem Biophys Res Commun, 469, 2, pp. 288-293, (2016); Martinez C., Rodino-Janeiro B.K., Lobo B., Et al., miR-16 and miR-125b are involved in barrier function dysregulation through the modulation of claudin-2 and cingulin expression in the jejunum in IBS with diarrhoea, Gut, 66, 9, pp. 1537-1538, (2017); Wohlfarth C., Schmitteckert S., Hartle J.D., Et al., miR-16 and miR-103 impact 5-HT4 receptor signalling and correlate with symptom profile in irritable bowel syndrome, Sci Rep, 7, 1, (2017); Zhou Q., Costinean S., Croce C.M., Et al., MicroRNA 29 targets nuclear factor-kappaB-repressing factor and Claudin 1 to increase intestinal permeability, Gastroenterology, 148, 1, pp. 158-169 e158, (2015); Zhou Q., Souba W.W., Croce C.M., Verne G.N., MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome, Gut, 59, 6, pp. 775-784, (2010); Zhou Q., Yang L., Larson S., Et al., Decreased miR-199 augments visceral pain in patients with IBS through translational upregulation of TRPV1, Gut, 65, 5, pp. 797-805, (2016); Zhu H., Xiao X., Chai Y., Li D., Yan X., Tang H., MiRNA-29a modulates visceral hyperalgesia in irritable bowel syndrome by targeting HTR7, Biochem Biophys Res Commun, 511, 3, pp. 671-678, (2019); Fourie N.H., Peace R.M., Abey S.K., Et al., Elevated circulating miR-150 and miR-342-3p in patients with irritable bowel syndrome, Exp Mol Pathol, 96, 3, pp. 422-425, (2014); Zhang Y., Li Y., Hao Z., Li X., Bo P., Gong W., Association of the Serotonin Receptor 3E gene as a functional variant in the MicroRNA-510 target site with diarrhea predominant irritable bowel syndrome in Chinese Women, J Neurogastroenterol Motil, 22, 2, pp. 272-281, (2016); Chira A., Muresan M.S., Braicu C., Et al., Serum patterns of mir-23a and mir-181b in irritable bowel syndrome and colorectal cancer - A pilot study, Bosn J Basic Med Sci, 20, 2, pp. 254-261, (2020); Jacenik D., Cygankiewicz A.I., Fichna J., Mokrowiecka A., Malecka-Panas E., Krajewska W.M., Estrogen signaling deregulation related with local immune response modulation in irritable bowel syndrome, Mol Cell Endocrinol, 471, pp. 89-96, (2018); Zhang Y., Wu X., Wu J., Et al., Decreased expression of microRNA-510 in intestinal tissue contributes to post-infectious irritable bowel syndrome via targeting PRDX1, Am J Transl Res, 11, 12, pp. 7385-7397, (2019); Arisawa T., Tahara T., Fukuyama T., Et al., Genetic polymorphism of pri-microRNA 325, targeting SLC6A4 3'-UTR, is closely associated with the risk of functional dyspepsia in Japan, J Gastroenterol, 47, 10, pp. 1091-1098, (2012); Hanevik K., Dizdar V., Langeland N., Eide G.E., Hausken T., Tolerability and effect of mesalazine in postinfectious irritable bowel syndrome, Aliment Pharmacol Ther, 34, 2, pp. 259-260, (2011); Braun A., Martinez C., Schmitteckert S., Roth R., Lasitschka F., Niesler B., Site-specific gene expression analysis from archived human intestine samples combining laser-capture microdissection and multiplexed color-coded probes, Neurogastroenterol Motil, 30, 5, (2018); Vandesompele J., De Preter K., Pattyn F., Et al., Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes, Genome Biol, 3, 7, (2002); Andersen C.L., Jensen J.L., Orntoft T.F., Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets, Cancer Res, 64, 15, pp. 5245-5250, (2004); Waggott D., Chu K., Yin S., Wouters B.G., Liu F.F., Boutros P.C., NanoStringNorm: an extensible R package for the pre-processing of NanoString mRNA and miRNA data, Bioinformatics, 28, 11, pp. 1546-1548, (2012); Huber W., von Heydebreck A., Sultmann H., Poustka A., Vingron M., Variance stabilization applied to microarray data calibration and to the quantification of differential expression, Bioinformatics, 18, pp. S96-S104, (2002); Garmire L.X., Subramaniam S., Evaluation of normalization methods in mammalian microRNA-Seq data, RNA, 18, 6, pp. 1279-1288, (2012); Benjamini Y., Hochberg Y., Controlling the false discovery rate: a practical and powerful approach to multiple testing, J R Stat Soc Ser B Methodol, 57, pp. 289-300, (1995); Kraus J.A., Dabbs D.J., Beriwal S., Bhargava R., Semi-quantitative immunohistochemical assay versus oncotype DX((R)) qRT-PCR assay for estrogen and progesterone receptors: an independent quality assurance study, Mod Pathol, 25, 6, pp. 869-876, (2012); Ludwig N., Leidinger P., Becker K., Et al., Distribution of miRNA expression across human tissues, Nucleic Acids Res, 44, 8, pp. 3865-3877, (2016); Zhu W., Huang Y., Pan Q., Xiang P., Xie N., Yu H., MicroRNA-98 suppress Warburg effect by targeting HK2 in colon cancer cells, Dig Dis Sci, 62, 3, pp. 660-668, (2017); Wu Y.Z., Lin H.Y., Zhang Y., Chen W.F., miR-200b-3p mitigates oxaliplatin resistance via targeting TUBB3 in colorectal cancer, J Gene Med, (2020); Slattery M.L., Herrick J.S., Mullany L.E., Et al., An evaluation and replication of miRNAs with disease stage and colorectal cancer-specific mortality, Int J Cancer, 137, 2, pp. 428-438, (2015); Zhang S., Jin J., Tian X., Wu L., hsa-miR-29c-3p regulates biological function of colorectal cancer by targeting SPARC, Oncotarget, 8, 61, pp. 104508-104524, (2017); Cattin A.L., Le Beyec J., Barreau F., Et al., Hepatocyte nuclear factor 4alpha, a key factor for homeostasis, cell architecture, and barrier function of the adult intestinal epithelium, Mol Cell Biol, 29, 23, pp. 6294-6308, (2009); Battle M.A., Konopka G., Parviz F., Et al., Hepatocyte nuclear factor 4alpha orchestrates expression of cell adhesion proteins during the epithelial transformation of the developing liver, Proc Natl Acad Sci USA, 103, 22, pp. 8419-8424, (2006); Martinez C., Lobo B., Pigrau M., Et al., Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, 8, pp. 1160-1168, (2013); Keszthelyi D., Troost F.J., Jonkers D.M., Et al., Serotonergic reinforcement of intestinal barrier function is impaired in irritable bowel syndrome, Aliment Pharmacol Ther, 40, 4, pp. 392-402, (2014); Coeffier M., Gloro R., Boukhettala N., Et al., Increased proteasome-mediated degradation of occludin in irritable bowel syndrome, Am J Gastroenterol, 105, 5, pp. 1181-1188, (2010); Nasser Y., Boeckxstaens G.E., Wouters M.M., Schemann M., Vanner S., Using human intestinal biopsies to study the pathogenesis of irritable bowel syndrome, Neurogastroenterol Motil, 26, 4, pp. 455-469, (2014); Taki M., Oshima T., Li M., Et al., Duodenal low-grade inflammation and expression of tight junction proteins in functional dyspepsia, Neurogastroenterol Motil, 31, 10, (2019); Vanheel H., Vicario M., Vanuytsel T., Et al., Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia, Gut, 63, 2, pp. 262-271, (2014); Cotton J.A., Amat C.B., Buret A.G., Disruptions of host immunity and inflammation by Giardia Duodenalis: potential consequences for co-infections in the gastro-intestinal tract, Pathogens, 4, 4, pp. 764-792, (2015); Amat C.B., Motta J.-P., Chadee K., Buret A.G., Giardia Duodenalis directly depletes mucins in intestinal goblet cells, FASEB J, 30, 1_supplement, pp. 161-162, (2016); Rodriguez-Nogales A., Algieri F., Vezza T., Et al., Calcium pyruvate exerts beneficial effects in an experimental model of irritable bowel disease induced by DCA in rats, Nutrients, 11, 1, (2019); Kim H.S., Lim J.H., Park H., Lee S.I., Increased immunoendocrine cells in intestinal mucosa of postinfectious irritable bowel syndrome patients 3 years after acute Shigella infection–an observation in a small case control study, Yonsei Med J, 51, 1, pp. 45-51, (2010); Han W., Wang Z., Lu X., Guo C., Protease activated receptor 4 status of mast cells in post infectious irritable bowel syndrome, Neurogastroenterol Motil, 24, 2, pp. 113-119, (2012); Cenac N., Andrews C.N., Holzhausen M., Et al., Role for protease activity in visceral pain in irritable bowel syndrome, J Clin Invest, 117, 3, pp. 636-647, (2007); Wang L.H., Fang X.C., Pan G.Z., Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis, Gut, 53, 8, pp. 1096-1101, (2004); Gonzalez-Castro A.M., Martinez C., Salvo-Romero E., Et al., Mucosal pathobiology and molecular signature of epithelial barrier dysfunction in the small intestine in irritable bowel syndrome, J Gastroenterol Hepatol, 32, 1, pp. 53-63, (2017); Foley S., Garsed K., Singh G., Et al., Impaired uptake of serotonin by platelets from patients with irritable bowel syndrome correlates with duodenal immune activation, Gastroenterology, 140, 5, pp. 1434-1443.e1, (2011); Philpott H., Gibson P., Thien F., Irritable bowel syndrome - An inflammatory disease involving mast cells, Asia Pac Allergy, 1, 1, pp. 36-42, (2011); Barbara G., Wang B., Stanghellini V., Et al., Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome, Gastroenterology, 132, 1, pp. 26-37, (2007); He S.H., He Y.S., Xie H., Activation of human colon mast cells through proteinase activated receptor-2, World J Gastroenterol, 10, 3, pp. 327-331, (2004); Buhner S., Li Q., Vignali S., Et al., Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome, Gastroenterology, 137, 4, pp. 1425-1434, (2009); Dizdar V., Spiller R., Singh G., Et al., Relative importance of abnormalities of CCK and 5-HT (serotonin) in Giardia-induced post-infectious irritable bowel syndrome and functional dyspepsia, Aliment Pharmacol Ther, 31, 8, pp. 883-891, (2010); Halliez M.C., Motta J.P., Feener T.D., Et al., Giardia duodenalis induces paracellular bacterial translocation and causes postinfectious visceral hypersensitivity, Am J Physiol Gastrointest Liver Physiol, 310, 8, pp. G574-G585, (2016); Tran L., Chaloner A., Sawalha A.H., Greenwood V.-M., Importance of epigenetic mechanisms in visceral pain induced by chronic water avoidance stress, Psychoneuroendocrinology, 38, 6, pp. 898-906, (2013); Mahurkar S., Polytarchou C., Iliopoulos D., Pothoulakis C., Mayer E.A., Chang L., Genome-wide DNA methylation profiling of peripheral blood mononuclear cells in irritable bowel syndrome, Neurogastroenterol Motil, 28, 3, pp. 410-422, (2016); Mahurkar-Joshi S., Videlock E.J., Iliopoulos D., Pothoulakis C., Mayer E.A., Chang L., Epigenetic changes in blood cells and colonic mucosa are associated with irritable bowel syndrome (IBS), Gastroenterology, 154, (2018)","B. Niesler; Department of Human Molecular Genetics, Institute of Human Genetics, Heidelberg University, Heidelberg, Germany; email: beate.niesler@med.uni-heidelberg.de; B. Niesler; Genes in Irritable Bowel Syndrome (GENIEUR) Research Network Europe, Heidelberg, Germany; email: beate.niesler@med.uni-heidelberg.de; B. Niesler; nCounter Core Facility Heidelberg, Institute of Human Genetics, Heidelberg, Germany; email: beate.niesler@med.uni-heidelberg.de","","Blackwell Publishing Ltd","","","","","","13501925","","NMOTE","32391639","English","Neurogastroenterol. Motil.","Article","Final","","Scopus","2-s2.0-85084489098"

"Linsalata M.; Riezzo G.; Orlando A.; D’attoma B.; Prospero L.; Tutino V.; Notarnicola M.; Russo F.","Linsalata, Michele (6603600075); Riezzo, Giuseppe (7004144336); Orlando, Antonella (23767683100); D’attoma, Benedetta (57205751185); Prospero, Laura (57207799778); Tutino, Valeria (25646829800); Notarnicola, Maria (6701314744); Russo, Francesco (59133987400)","6603600075; 7004144336; 23767683100; 57205751185; 57207799778; 25646829800; 6701314744; 59133987400","The relationship between low serum vitamin d levels and altered intestinal barrier function in patients with ibs diarrhoea undergoing a long-term low-fodmap diet: Novel observations from a clinical trial","2021","Nutrients","13","3","1011","1","18","17","23","10.3390/nu13031011","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102709617&doi=10.3390%2fnu13031011&partnerID=40&md5=c4cb806f04caa475a0fd4d09c63053d1","Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte (Ba), 70013, Italy; Laboratory of Nutritional Biochemistry, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte (Ba), 70013, Italy","Linsalata M., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte (Ba), 70013, Italy; Riezzo G., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte (Ba), 70013, Italy; Orlando A., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte (Ba), 70013, Italy; D’attoma B., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte (Ba), 70013, Italy; Prospero L., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte (Ba), 70013, Italy; Tutino V., Laboratory of Nutritional Biochemistry, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte (Ba), 70013, Italy; Notarnicola M., Laboratory of Nutritional Biochemistry, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte (Ba), 70013, Italy; Russo F., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte (Ba), 70013, Italy","Decreased serum vitamin D (VD) levels have been associated with gastrointestinal (GI) disorders, including irritable bowel syndrome (IBS). VD can also modulate the intestinal barrier. Given the link between the GI barrier’s alterations and diet, attention has aroused the positive effects of the Low FODMAP Diet (LFD) on IBS patients’ symptom profile. We evaluated the GI symptoms and the urinary and circulating markers of GI barrier function, the markers of inflammation and intestinal dysbiosis in 36 IBS patients with predominant diarrhea (IBS-D) (5 men and 31 women, 43.1 ± 1.7 years) categorized for their circulating VD levels in low (L-VD) and normal (N-VD) (cutoff = 20 ng/mL). Evaluations were performed before and after 12 weeks of LFD. At the baseline, L-VD patients showed a significantly worse symptom profile and altered small intestinal permeability (s-IP) than N-VD. After LFD, a significant increase in the circulating VD levels in both the subgroups and a significant improvement of s-IP in L-VD patients occurred. Finally, VD levels negatively correlated with the symptom score and fecal zonulin. These data highlight the close relationship between VD and the intestinal barrier and support their involvement in IBS-D pathophysiology. Moreover, the potentially positive role of LFD in the management of IBS-D was confirmed. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.","Intestinal barrier; Irritable bowel syndrome; Low FODMAP diet; Symptom profile; Vitamin D","Adult; Biomarkers; Body Mass Index; Diarrhea; Diet, Carbohydrate-Restricted; Feces; Female; Fermentation; Gastrointestinal Diseases; Haptoglobins; Humans; Irritable Bowel Syndrome; Male; Middle Aged; Protein Precursors; Vitamin D; HLA DQ2 antigen; HLA DQ8 antigen; interleukin 6; interleukin 8; vitamin D; biological marker; haptoglobin; protein precursor; vitamin D; zonulin; abdominal circumference; abdominal distension; abdominal pain; adult; Article; bacterial translocation; basal metabolic rate; body mass; clinical article; clinical trial; colorimetry; comparative study; controlled study; diarrhea; disease duration; energy consumption; enzyme linked immunosorbent assay; feeding behavior; female; follicular phase; high performance liquid chromatography; human; human tissue; irritable colon; lifestyle; low FODMAP diet; male; nutrient intake; pain severity; physical activity; physical examination; questionnaire; vitamin blood level; waist circumference; blood; chemistry; complication; diarrhea; feces; fermentation; gastrointestinal disease; irritable colon; low carbohydrate diet; middle aged; pathophysiology; procedures","","interleukin 8, 114308-91-7; haptoglobin, 9087-69-8; Biomarkers, ; Haptoglobins, ; Protein Precursors, ; Vitamin D, ; zonulin, ","ELISA kits, Becton Dickinson Biosciences, United States; ELISA kits, Cloud-Clone, United States; ELISA kits, Thermo, United States; UltiMate 3000","Becton Dickinson Biosciences, United States; Cloud-Clone, United States; Thermo, United States","Italian Ministry of Health RC 2020, (700/2020); Italian Ministry of Health RC 2020?","Funding text 1: Funding: This research was funded by the Italian Ministry of Health RC 2020–2021, Prog. (D.D.G. n. 700/2020).; Funding text 2: This research was funded by the Italian Ministry of Health RC 2020?2021, Prog. N? 16 (D.D.G. n. 700/2020).","Brett N.R., Lavery P., Agellon S., Vanstone C.A., Goruk S., Field C.J., Weiler H.A., Vitamin D Status and Immune Health Outcomes in a Cross-Sectional Study and a Randomized Trial of Healthy Young Children, Nutrients, 10, (2018); Sassi F., Tamone C., D'Amelio P., Vitamin D: Nutrient, Hormone, and Immunomodulator, Nutrients, 10, (2018); Panarese A., Pesce F., Porcelli P., Riezzo G., Iacovazzi P.A., Leone C.M., De Carne M., Rinaldi C.M., Shahini E., Chronic functional constipation is strongly linked to vitamin D deficiency, World J. Gastroenterol, 25, pp. 1729-1740, (2019); Tazzyman S., Richards N., Trueman A.R., Evans A.L., Grant V.A., Garaiova I., Plummer S.F., Williams E.A., Corfe B.M., Vitamin D associates with improved quality of life in participants with irritable bowel syndrome: Outcomes from a pilot trial, BMJ Open Gastroenterol, 2, (2015); Abbasnezhad A., Amani R., Hajiani E., Alavinejad P., Cheraghian B., Ghadiri A., Effect of vitamin D on gastrointestinal symptoms and health-related quality of life in irritable bowel syndrome patients: A randomized double-blind clinical trial, Neurogastroenterol. Motil, 28, pp. 1533-1544, (2016); Gil A., Plaza-Diaz J., Mesa M.D., Vitamin D: Classic and Novel Actions, Ann. Nutr. Metab, 72, pp. 87-95, (2018); Williams C.E., Williams E.A., Corfe B.M., Vitamin D status in irritable bowel syndrome and the impact of supplementation on symptoms: What do we know and what do we need to know?, Eur. J. Clin. Nutr, 72, pp. 1358-1363, (2018); Katrinaki M., Kampa M., Margioris A., Castanas E., Malliaraki N., Vitamin D levels in a large Mediterranean cohort: Reconsidering normal cut-off values, Hormones (Athens), 15, pp. 205-223, (2016); Khalighi Sikaroudi M., Mokhtare M., Janani L., Faghihi Kashani A.H., Masoodi M., Agah S., Abbaspour N., Dehnad A., Shidfar F., Vitamin d3 supplementation in diarrhea-predominant irritable bowel syndrome patients: The effects on symptoms improvement, serum corticotropin-releasing hormone, and interleukin-6—A randomized clinical trial, Complementary Med. Res, 27, pp. 302-309, (2020); Silva M.C., Furlanetto T.W., Intestinal absorption of vitamin D: A systematic review, Nutr. Rev, 76, pp. 60-76, (2018); Assa A., Vong L., Pinnell L.J., Avitzur N., Johnson-Henry K.C., Sherman P.M., Vitamin d deficiency promotes epithelial barrier dysfunction and intestinal inflammation, J. Infect. Dis, 210, pp. 1296-1305, (2014); Fakhoury H.M.A., Kvietys P.R., Al Kattan W., Anouti F.A., Elahi M.A., Karras S.N., Grant W.B., Vitamin D and intestinal homeostasis: Barrier, microbiota, and immune modulation, J. Steroid Biochem. Mol. Biol, 200, (2020); Akimbekov N.S., Digel I., Sherelkhan D.K., Lutfor A.B., Razzaque M.S., Vitamin D and the Host-Gut Microbiome: A Brief Overview, Acta Histochem. Cytochem, 53, pp. 33-42, (2020); Linsalata M., Riezzo G., D'Attoma B., Clemente C., Orlando A., Russo F., Noninvasive biomarkers of gut barrier function identify two subtypes of patients suffering from diarrhoea predominant-ibs: A case-control study, BMC Gastroenterol, 18, (2018); Wells J.M., Brummer R.J., Derrien M., MacDonald T.T., Troost F., Cani P.D., Theodorou V., Dekker J., Meheust A., de Vos W.M., Et al., Homeostasis of the gut barrier and potential biomarkers, Am. J. Physiol. Gastrointest. Liver Physiol, 312, pp. G171-G193, (2017); Linsalata M., Riezzo G., Clemente C., D'Attoma B., Russo F., Noninvasive biomarkers of gut barrier function in patients suffering from diarrhea predominant-ibs: An update, Dis. Markers, 2020, (2020); Camilleri M., Leaky gut: Mechanisms, measurement and clinical implications in humans, Gut, 68, pp. 1516-1526, (2019); Fasano A., Zonulin and its regulation of intestinal barrier function: The biological door to inflammation, autoimmunity, and cancer, Physiol. Rev, 91, pp. 151-175, (2011); Pelsers M.M., Hermens W.T., Glatz J.F., Fatty acid-binding proteins as plasma markers of tissue injury, Clin. Chim. Acta, 352, pp. 15-35, (2005); Song W.B., Lv Y.H., Zhang Z.S., Li Y.N., Xiao L.P., Yu X.P., Wang Y.Y., Ji H.L., Ma L., Soluble intercellular adhesion molecule-1, D-lactate and diamine oxidase in patients with inflammatory bowel disease, World J. Gastroenterol, 15, pp. 3916-3919, (2009); Zhang L., Fan X., Zhong Z., Xu G., Shen J., Association of plasma diamine oxidase and intestinal fatty acid-binding protein with severity of disease in patient with heat stroke, Am. J. Emerg. Med, 33, pp. 867-871, (2015); Tuck C.J., Reed D.E., Muir J.G., Vanner S.J., Implementation of the low FODMAP diet in functional gastrointestinal symptoms: A real-world experience, Neurogastroenterol. Motil, 32, (2020); Orlando A., Tutino V., Notarnicola M., Riezzo G., Linsalata M., Clemente C., Prospero L., Martulli M., D'Attoma B., De Nunzio V., Et al., Improved Symptom Profiles and Minimal Inflammation in IBS-D Patients Undergoing a Long-Term Low-FODMAP Diet: A Lipidomic Perspective, Nutrients, 12, (2020); Francis C.Y., Morris J., Whorwell P.J., The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress, Aliment. Pharmacol. Ther, 11, pp. 395-402, (1997); Kulich K.R., Madisch A., Pacini F., Pique J.M., Regula J., Van Rensburg C.J., Ujszaszy L., Carlsson J., Halling K., Wiklund I.K., Reliability and validity of the Gastrointestinal Symptom Rating Scale (GSRS) and Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire in dyspepsia: A six-country study, Health Qual. Life Outcomes, 6, (2008); Schmulson M.J., Drossman D.A., What Is New in Rome IV, J. Neurogastroenterol. Motil, 23, pp. 151-163, (2017); Verdu E.F., Armstrong D., Murray J.A., Between celiac disease and irritable bowel syndrome: The “no man’s land” of gluten sensitivity, Am. J. Gastroenterol, 104, pp. 1587-1594, (2009); Blake M.R., Raker J.M., Whelan K., Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome, Aliment Pharmacol. Ther, 44, pp. 693-703, (2016); Maagaard L., Ankersen D.V., Vegh Z., Burisch J., Jensen L., Pedersen N., Munkholm P., Follow-up of patients with functional bowel symptoms treated with a low FODMAP diet, World J. Gastroenterol, 22, pp. 4009-4019, (2016); The Monash University Low FODMAP App, (2017); Linsalata M., D'Attoma B., Orlando A., Guerra V., Russo F., Comparison of an enzymatic assay with liquid chromatography-pulsed amperometric detection for the determination of lactulose and mannitol in urine of healthy subjects and patients with active celiac disease, Clin. Chem. Lab. Med, 52, pp. e61-e64, (2014); Hilsden R.J., Meddings J.B., Sutherland L.R., Intestinal permeability changes in response to acetylsalicylic acid in relatives of patients with Crohn’s disease, Gastroenterology, 110, pp. 1395-1403, (1996); Simeoni M., Citraro M.L., Cerantonio A., Deodato F., Provenzano M., Cianfrone P., Capria M., Corrado S., Libri E., Comi A., Et al., An open-label, randomized, placebo-controlled study on the effectiveness of a novel probiotics administration protocol (ProbiotiCKD) in patients with mild renal insufficiency (stage 3a of CKD), Eur. J. Nutr, 58, pp. 2145-2156, (2019); Meeker S., Seamons A., Maggio-Price L., Paik J., Protective links between vitamin D, inflammatory bowel disease and colon cancer, World J. Gastroenterol, 22, pp. 933-948, (2016); Barbalho S.M., Goulart R.A., Araujo A.C., Guiguer E.L., Bechara M.D., Irritable bowel syndrome: A review of the general aspects and the potential role of vitamin D, Expert Rev. Gastroenterol. Hepatol, 13, pp. 345-359, (2019); Eslamian G., Ardehali S.H., Hajimohammadebrahim-Ketabforoush M., Vahdat Shariatpanahi Z., Association of intestinal permeability with admission vitamin D deficiency in patients who are critically ill, J. Investig. Med, 68, pp. 397-402, (2020); Kong J., Zhang Z., Musch M.W., Ning G., Sun J., Hart J., Bissonnette M., Li Y.C., Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier, Am. J. Physiol. Gastrointest. Liver Physiol, 294, pp. G208-G216, (2008); Zhu T., Liu T.J., Shi Y.Y., Zhao Q., Vitamin D/VDR signaling pathway ameliorates 2,4,6-trinitrobenzene sulfonic acid-induced colitis by inhibiting intestinal epithelial apoptosis, Int. J. Mol. Med, 35, pp. 1213-1218, (2015); Raftery T., Martineau A.R., Greiller C.L., Ghosh S., McNamara D., Bennett K., Meddings J., O'Sullivan M., Effects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn’s disease: Results from a randomised double-blind placebo-controlled study, United Eur. Gastroenterol. J, 3, pp. 294-302, (2015); McCabe P.S., Pye S.R., Beth J.M., Lee D.M., Tajar A., Bartfai G., Boonen S., Bouillon R., Casanueva F., Finn J.D., Et al., Low vitamin D and the risk of developing chronic widespread pain: Results from the European male ageing study, BMC Musculoskelet. Disord, 17, (2016); Jalili M., Vahedi H., Poustchi H., Hekmatdoost A., Effects of Vitamin D Supplementation in Patients with Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Int. J. Prev. Med, 10, (2019); Bicikova M., Duskova M., Vitku J., Kalvachova B., Ripova D., Mohr P., Starka L., Vitamin D in anxiety and affective disorders, Physiol. Res, 64, pp. S101-S103, (2015); Ajamian M., Rosella G., Newnham E.D., Biesiekierski J.R., Muir J.G., Gibson P.R., Effect of Gluten Ingestion and FODMAP Restriction on Intestinal Epithelial Integrity in Patients with Irritable Bowel Syndrome and Self-Reported Non-Coeliac Gluten Sensitivity, Mol. Nutr. Food Res, (2020); Zhou S.Y., Gillilland M., Wu X., Leelasinjaroen P., Zhang G., Zhou H., Ye B., Lu Y., Owyang C., FODMAP diet modulates visceral nociception by lipopolysaccharide-mediated intestinal inflammation and barrier dysfunction, J. Clin. Investig, 128, pp. 267-280, (2018); Harvie R.M., Chisholm A.W., Bisanz J.E., Burton J.P., Herbison P., Schultz K., Schultz M., Long-term irritable bowel syndrome symptom control with reintroduction of selected FODMAPs, World J. Gastroenterol, 23, pp. 4632-4643, (2017); Gibson P.R., Shepherd S.J., Evidence-based dietary management of functional gastrointestinal symptoms: The FODMAP approach, J. Gastroenterol. Hepatol, 25, pp. 252-258, (2010); Bascunan K.A., Elli L., Pellegrini N., Scricciolo A., Lombardo V., Doneda L., Vecchi M., Scarpa C., Araya M., Roncoroni L., Impact of FODMAP Content Restrictions on the Quality of Diet for Patients with Celiac Disease on a Gluten-Free Diet, Nutrients, 11, (2019); Vincenzi M., Del Ciondolo I., Pasquini E., Gennai K., Paolini B., Effects of a Low FODMAP Diet and Specific Carbohydrate Diet on Symptoms and Nutritional Adequacy of Patients with Irritable Bowel Syndrome: Preliminary Results of a Single-blinded Randomized Trial, J. Transl. Int. Med, 5, pp. 120-126, (2017); Maes M., Kubera M., Leunis J.C., The gut-brain barrier in major depression: Intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression, Neuro Endocrinol. Lett, 29, pp. 117-124, (2008)","F. Russo; Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte (Ba), 70013, Italy; email: francesco.russo@irccsdebellis.it","","MDPI AG","","","","","","20726643","","","33801020","English","Nutrients","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85102709617"

"Jalili M.; Vahedi H.; Poustchi H.; Hekmatdoost A.","Jalili, Mahsa (54398609400); Vahedi, Homayoon (6602272096); Poustchi, Hossein (8622806500); Hekmatdoost, Azita (7801320384)","54398609400; 6602272096; 8622806500; 7801320384","Soy isoflavones and cholecalciferol reduce inflammation, and gut permeability, without any effect on antioxidant capacity in irritable bowel syndrome: A randomized clinical trial","2019","Clinical Nutrition ESPEN","34","","","50","54","4","20","10.1016/j.clnesp.2019.09.003","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85072757376&doi=10.1016%2fj.clnesp.2019.09.003&partnerID=40&md5=f9825ed6d170b79776d3b52b84c7f283","Cell, Molecular Biology Group (CMBG), Department of Biology, Faculty of Natural Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway; Digestive Disease Research Center, Digestive Disease Research Institute (DDRI), Tehran, Iran; Liver and Pancreatobiliary Research Group, Digestive Disease Research Institute (DDRI), Tehran, Iran; National Nutrition and Food Technology Research Institute (NFTRI), Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences (SBMU), Tehran, Iran","Jalili M., Cell, Molecular Biology Group (CMBG), Department of Biology, Faculty of Natural Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway; Vahedi H., Digestive Disease Research Center, Digestive Disease Research Institute (DDRI), Tehran, Iran; Poustchi H., Liver and Pancreatobiliary Research Group, Digestive Disease Research Institute (DDRI), Tehran, Iran; Hekmatdoost A., National Nutrition and Food Technology Research Institute (NFTRI), Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences (SBMU), Tehran, Iran","Background & aims: Irritable bowel syndrome (IBS) is a common gastrointestinal disorder that is more prevalent in women. Vitamin D deficiency and hormonal disorders are also prevalent in Iranian women, and may influence the severity of clinical outcomes mediated by microinflammation, oxidative stress and intestinal permeability pathways. Our objective was to investigate the effects of co-administration of soy and vitamin D on some inflammatory, antioxidant and gut permeability markers in women with IBS. Methods: In a randomized clinical trial, women (18–75 years of age) were randomly allocated into four groups to receive soy isoflavones (40 mg/day), cholecalciferol (50,000 IU/15 days), both soy isoflavones and cholecalciferol, or placebo for six weeks. The outcomes were plasma inflammatory markers, antioxidant status and fecal protease activity at week 0 and week 6. Results: After the intervention, plasma inflammatory markers and fecal protease activity were reduced significantly in all treatment groups compared to the placebo group; however, there was no significant effect on antioxidant status. Conclusion: This study suggests combined supplementation of soy isoflavones and active vitamin D can improve some biochemical parameters regarding inflammation and intestinal permeability of IBS in women. Trial registration: Clinical.Trials.gov NCT02026518. © 2019 European Society for Clinical Nutrition and Metabolism","Antioxidant; Cholecalciferol; Inflammation; Irritable bowel syndrome; Permeability; Soy; Women","Adolescent; Adult; Aged; Antioxidants; Biomarkers; Cholecalciferol; Dietary Supplements; Feces; Female; Gastrointestinal Tract; Humans; Inflammation; Iran; Irritable Bowel Syndrome; Isoflavones; Middle Aged; Permeability; Serine Proteases; Tumor Necrosis Factor-alpha; Vitamin D; Vitamin D Deficiency; Young Adult; 25 hydroxyvitamin D; antioxidant; biological marker; colecalciferol; daidzein; genistein; glycetin; immunoglobulin enhancer binding protein; isoflavone derivative; serine proteinase; tumor necrosis factor; unclassified drug; antioxidant; biological marker; colecalciferol; isoflavone derivative; serine proteinase; tumor necrosis factor; vitamin D; adult; aged; Article; clinical article; clinical outcome; controlled study; drug effect; enzyme activity; feces level; female; human; inflammation; intestine mucosa permeability; irritable colon; leukocyte; oxidative stress; protein blood level; randomized controlled trial; soybean; supplementation; vitamin blood level; adolescent; dietary supplement; feces; gastrointestinal tract; inflammation; Iran; irritable colon; metabolism; middle aged; permeability; vitamin D deficiency; young adult","","25 hydroxyvitamin D, 64719-49-9; colecalciferol, 1406-16-2, 67-97-0; daidzein, 486-66-8; genistein, 446-72-0; proprotein convertase 9, ; serine protease HTRA1, ; serine proteinase, 37259-58-8; Antioxidants, ; Biomarkers, ; Cholecalciferol, ; Isoflavones, ; Serine Proteases, ; Tumor Necrosis Factor-alpha, ; Vitamin D, ","","","National Nutrition and Food Technology Research Institute, NNFTRI","This study was financially supported by National Nutrition and Food Science Technology Research Institute, Tehran, Iran . ","Taft T., Guadagnoli L., Abbasi R., Ibrahim A., Doerfler B., Brenner D.M., Et al., Food related quality of life in patients with inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), Gastroenterology, 152, (2017); Holtmann G.J., Ford A.C., Talley N.J., Pathophysiology of irritable bowel syndrome, Lancet Gastroenterol Hepatol, 1, pp. 133-146, (2016); Mulak A., Tache Y., Larauche M., Sex hormones in the modulation of irritable bowel syndrome, World J Gastroenterol: WJG, 20, (2014); Van Der Veek P.P., Van Den Berg M., De Kroon Y.E., Verspaget H.W., Masclee A.A., Role of tumor necrosis factor-α and interleukin-10 gene polymorphisms in irritable bowel syndrome, Am J Gastroenterol, 100, pp. 2510-2516, (2005); Beutler B., The role of tumor necrosis factor in health and disease, J Rheumatol Suppl, 57, pp. 16-21, (1999); Rogler G., Brand K., Vogl D., Page S., Hofmeister R., Andus T., Et al., Nuclear factor κB is activated in macrophages and epithelial cells of inflamed intestinal mucosa, Gastroenterology, 115, pp. 357-369, (1998); Ma T.Y., Iwamoto G.K., Hoa N.T., Akotia V., Pedram A., Boivin M.A., Et al., TNF-α-induced increase in intestinal epithelial tight junction permeability requires NF-κB activation, Am J Physiol Gastrointest Liver Physiol, 286, pp. G367-G376, (2004); Neurath M.F., Fuss I., Pasparakis M., Alexopoulou L., Haralambous S., Meyer zum Buschenfelde K.H., Et al., Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice, Eur J Immunol, 27, pp. 1743-1750, (1997); A P., Caso J.R., Alou L., Colon A., Sevillano D., Moro M.A., Et al., The role of PPARγ on restoration of colonic homeostasis after experimental stress-induced inflammation and dysfunction, Gastroenterology, 132, pp. 1791-1803, (2007); Asadi-Shahmirzadi A., Mozaffari S., Sanei Y., Baeeri M., Hajiaghaee R., Monsef-Esfahani H.R., Et al., Benefit of Aloe vera and Matricaria recutita mixture in rat irritable bowel syndrome: combination of antioxidant and spasmolytic effects, Chin J Integr Med, pp. 1-9, (2012); Cenac N., Andrews C.N., Holzhausen M., Chapman K., Cottrell G., Andrade-Gordon P., Et al., Role for protease activity in visceral pain in irritable bowel syndrome, J Clin Investig, 117, pp. 636-647, (2007); Al-Sadi R., Boivin M., Ma T., Mechanism of cytokine modulation of epithelial tight junction barrier, Front Biosci – J Vis Lit, 14, (2009); Gecse K., Roka R., Ferrier L., Leveque M., Eutamene H., Cartier C., Et al., Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity, Gut, 57, pp. 591-599, (2008); Heitkemper M.M., Cain K.C., Jarrett M.E., Burr R.L., Hertig V., Bond E.F., Symptoms across the menstrual cycle in women with irritable bowel syndrome, Am J Gastroenterol, 98, pp. 420-430, (2003); Braniste V., Leveque M., Buisson-Brenac C., Bueno L., Fioramonti J., Houdeau E., Oestradiol decreases colonic permeability through oestrogen receptor β-mediated up-regulation of occludin and junctional adhesion molecule-A in epithelial cells, J Physiol, 587, pp. 3317-3328, (2009); Somjen D., Kohen F., Gayer B., Knoll E., Limor R., Baz M., Et al., A non-calcemic Vitamin D analog modulates both nuclear and putative membranal estrogen receptors in cultured human vascular smooth muscle cells, J Steroid Biochem Mol Biol, 89, pp. 397-399, (2004); Jalili M., Hekmatdoost A., Vahedi H., Poustchi H., Khademi B., Saadi M., Et al., Co-administration of soy isoflavones and vitamin D in management of irritable bowel disease, PLoS One, 11, (2016); Drossman D.A., Dumitrascu D.L., Rome III: new standard for functional gastrointestinal disorders, J Gastrointest Liver Dis, 15, (2006); Suh K.S., Koh G., Park C.Y., Woo J.T., Kim S.W., Kim J.W., Et al., Soybean isoflavones inhibit tumor necrosis factor-α-induced apoptosis and the production of interleukin-6 and prostaglandin E2 in osteoblastic cells, Phytochemistry, 63, pp. 209-215, (2003); Satsu H., Hyun J.S., Shin H.S., Shimizu M., Suppressive effect of an isoflavone fraction on tumor necrosis factor-α-induced interleukin-8 production in human intestinal epithelial Caco-2 cells, J Nutr Sci Vitaminol, 55, pp. 442-446, (2009); Moussa L., Bezirard V., Salvador-Cartier C., Bacquie V., Houdeau E., Theodorou V., A new soy germ fermented ingredient displays estrogenic and protease inhibitor activities able to prevent irritable bowel syndrome-like symptoms in stressed female rats, Clin Nutr, 32, pp. 51-58, (2013); Amani R., Abbasnezhad A., Hajiani E., Cheraghian B., Abdoli Z., RJIjoiI C., Vitamin D3 induced decrease in IL-17 and malondialdehyde, and increase in IL-10 and total antioxidant capacity levels in patients with irritable bowel syndrome, 15, pp. 186-196, (2018)","M. Jalili; Trondheim, Høgskoleringen 5, 7034, Norway; email: mahsa.jalili@ntnu.no","","Elsevier Ltd","","","","","","24054577","","","31677711","English","Clin. Nutr. ESPEN","Article","Final","","Scopus","2-s2.0-85072757376"

"Zhao D.-Y.; Qi Q.-Q.; Long X.; Li X.; Chen F.-X.; Yu Y.-B.; Zuo X.-L.","Zhao, D.-Y. (57218293182); Qi, Q.-Q. (55261413600); Long, X. (59046686500); Li, X. (58496676400); Chen, F.-X. (35204563200); Yu, Y.-B. (55561393800); Zuo, X.-L. (57204617174)","57218293182; 55261413600; 59046686500; 58496676400; 35204563200; 55561393800; 57204617174","Ultrastructure of intestinal mucosa in diarrhea-predominant irritable bowel syndrome","2019","Physiology International","106","3","","225","235","10","4","10.1556/2060.106.2019.20","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85073124407&doi=10.1556%2f2060.106.2019.20&partnerID=40&md5=18bc38119639bfcc695185f2404e3ab2","Department of Gastroenterology, Puyang Oilfield General Hospital, Puyang, China; Department of Gastroenterology, Qilu Hospital, Shandong University, Shandong Province, China","Zhao D.-Y., Department of Gastroenterology, Puyang Oilfield General Hospital, Puyang, China; Qi Q.-Q., Department of Gastroenterology, Qilu Hospital, Shandong University, Shandong Province, China; Long X., Department of Gastroenterology, Qilu Hospital, Shandong University, Shandong Province, China; Li X., Department of Gastroenterology, Qilu Hospital, Shandong University, Shandong Province, China; Chen F.-X., Department of Gastroenterology, Qilu Hospital, Shandong University, Shandong Province, China; Yu Y.-B., Department of Gastroenterology, Qilu Hospital, Shandong University, Shandong Province, China; Zuo X.-L., Department of Gastroenterology, Qilu Hospital, Shandong University, Shandong Province, China","Objectives: Impaired intestinal barrier function has been demonstrated in the pathophysiology of diarrheapredominant irritable bowel syndrome (IBS-D). This study aimed to describe the intestinal ultrastructural findings in the intestinal mucosal layer of IBS-D patients. Methods: In total, 10 healthy controls and 10 IBS-D patients were analyzed in this study. The mucosa of each patient's rectosigmoid colon was first assessed by confocal laser endomicroscopy (CLE); next, biopsied specimens of these sites were obtained. Intestinal tissues of IBS-D patients and healthy volunteers were examined to observe cellular changes by transmission electron microscopy (TEM). Results: CLE showed no visible epithelial damage or inflammatory changes in the colonic mucosa of IBS-D compared with healthy volunteers. On transmission electron microscopic examination, patients with IBS-D displayed a larger apical intercellular distance with a higher proportion of dilated (>20 nm) intercellular junctional complexes, which was indicative of impaired mucosal integrity. In addition, microvillus exfoliation, extracellular vesicle as well as increased presence of multivesicular bodies were visible in IBS-D patients. Single epithelial cells appeared necrotic, as characterized by cytoplasmic vacuolization, cytoplasmic swelling, and presence of autolysosome. A significant association between bowel habit, frequency of abdominal pain, and enlarged intercellular distance was found. Conclusion: This study showed ultrastructural alterations in the architecture of intestinal epithelial cells and intercellular junctional complexes in IBS-D patients, potentially representing a pathophysiological mechanism in IBS-D. © 2019 Akadémiai Kiadó, Budapest.","Diarrhea-predominant irritable bowel syndrome; Extracellular vesicles; Intercellular junctional complex; Intestinal barrier; Transmission electron microscopy","Abdominal Pain; Colon, Sigmoid; Cytoplasm; Diarrhea; Epithelial Cells; Female; Humans; Intercellular Junctions; Intestinal Mucosa; Irritable Bowel Syndrome; Male; Middle Aged; Rectum; fentanyl; fluorescein; midazolam; osmium tetraoxide; abdominal pain; adherens junction; adult; Article; autolysosome; cell junction; clinical article; clinical assessment; colon biopsy; colon epithelium; colon mucosa; colonoscopy; confocal laser scanning microscopy; controlled study; defecation measurement; desmosome; diarrhea; exosome; female; human; intestine biopsy; intestine epithelium cell; intestine mucosa; intestine tissue; irritable colon; male; microvillus; middle aged; multivesicular body; physical examination; questionnaire; sigmoid; transmission electron microscopy; ultrastructure; cytoplasm; diarrhea; epithelium cell; intestine mucosa; irritable colon; pathology; rectum; ultrastructure","","fentanyl, 437-38-7, 1443-54-5; fluorescein, 2321-07-5, 91316-42-6; midazolam, 59467-70-8, 59467-96-8; osmium tetraoxide, 16984-68-2, 20816-12-0","","","Key Laboratory of Cardiovascular Remodeling and Function Research in Qilu Hospital of Shandong University; Fundamental Research Fund of Shandong University, (2017JC036); Fundamental Research Fund of Shandong University; National Natural Science Foundation of China, NSFC, (NSFC 81670486); National Natural Science Foundation of China, NSFC","Funding text 1: The authors appreciate the considerable assistance from the Key Laboratory of Cardiovascular Remodeling and Function Research in Qilu Hospital of Shandong University. This work was supported by the National Natural Science Foundation of China (NSFC 81670486) and the Fundamental Research Funds of Shandong University (2017JC036). D-YZ contributed to analysis and interpretation of data, drafting of the manuscript, statistical analysis, and technical and material support. Q-QQ involved in participant enrollment and technical and material support. XLo and XLi involved in technical support and participant enrollment. F-XC contributed to analysis and interpretation of data and technical support. Y-BY involved in study concept and design, critical revision of the manuscript, procurement of funding, study supervision, and final approval of the version to be published. X-LZ contributed in study supervision, participant enrollment, and critical revision of the manuscript. All authors read and approved the final version of the manuscript.; Funding text 2: The authors appreciate the considerable assistance from the Key Laboratory of Cardiovascular Remodeling and Function Research in Qilu Hospital of Shandong University. This work was supported by the National Natural Science Foundation of China (NSFC 81670486) and the Fundamental Research Funds of Shandong University (2017JC036)","Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Lecleire S., Antonietti M., Gourcerol G., Leroi A.M., Dechelotte P., Menard J.F., Ducrotte P., Coeffier M., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am. J. Gastroenterol., 106, pp. 2165-2173, (2011); Bruewer M., Samarin S., Nusrat A., Inflammatory bowel disease and the apical junctional complex, Ann. N. Y. Acad. Sci., 1072, pp. 242-252, (2006); Buning J., Von Smolinski D., Tafazzoli K., Zimmer K.P., Strobel S., Apostolaki M., Kollias G., Heath J.K., Ludwig D., Gebert A., Multivesicular bodies in intestinal epithelial cells: Responsible for MHC class II-restricted antigen processing and origin of exosomes, Immunology, 125, pp. 510-521, (2008); Chang F.Y., Lu C.L., Irritable bowel syndrome in the 21st century: Perspectives from Asia or South-east Asia, J. Gastroenterol. Hepatol., 22, pp. 4-12, (2007); Demaude J., Salvador-Cartier C., Fioramonti J., Ferrier L., Bueno L., Phenotypic changes in colonocytes following acute stress or activation of mast cells in mice: Implications for delayed epithelial barrier dysfunction, Gut, 55, pp. 655-661, (2006); Dourmashkin R.R., Davies H., Wells C., Shah D., Price A., O'Morain C., Levi J., Epithelial patchy necrosis in Crohn's disease, Hum. Pathol., 14, pp. 643-648, (1983); Fritscher-Ravens A., Schuppan D., Ellrichmann M., Schoch S., Rocken C., Brasch J., Bethge J., Bottner M., Klose J., Milla P.J., Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome, Gastroenterology, 147, pp. 1012-1020, (2014); Groschwitz K.R., Hogan S.P., Intestinal barrier function: Molecular regulation and disease pathogenesis, J. Allergy Clin. Immunol., 124, pp. 3-20, (2009); Gunther C., Neumann H., Neurath M.F., Becker C., Apoptosis, necrosis and necroptosis: Cell death regulation in the intestinal epithelium, Gut, 62, pp. 1062-1071, (2013); Gwee K.A., Bak Y.T., Ghoshal U.C., Gonlachanvit S., Lee O.Y., Fock K.M., Chua A.S., Lu C.L., Goh K.L., Kositchaiwat C., Makharia G., Park H.J., Chang F.Y., Fukudo S., Choi M.G., Bhatia S., Ke M., Hou X., Hongo M., Asian consensus on irritable bowel syndrome, J. Gastroenterol. Hepatol., 25, pp. 1189-1205, (2010); Hartsock A., Nelson W.J., Adherens and tight junctions: Structure, function and connections to the actin cytoskeleton, Biochim. Biophys. Acta., 1778, pp. 660-669, (2008); Jeon M.K., Klaus C., Kaemmerer E., Gassler N., Intestinal barrier: Molecular pathways and modifiers, World J. Gastrointest. Pathophysiol., 4, pp. 94-99, (2013); Kiesslich R., Burg J., Vieth M., Gnaendiger J., Enders M., Delaney P., Polglase A., Mclaren W., Janell D., Thomas S., Nafe B., Galle P.R., Neurath M.F., Confocal laser endoscopy for diagnosing intraepithelial neoplasias and colorectal cancer in vivo, Gastroenterology, 127, pp. 706-713, (2004); Kiesslich R., Duckworth C.A., Moussata D., Gloeckner A., Lim L.G., Goetz M., Pritchard D.M., Galle P.R., Neurath M.F., Watson A.J., Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease, Gut, 61, pp. 1146-1153, (2012); Krug S.M., Schulzke J.D., Fromm M., Tight junction, selective permeability, and related diseases, Semin. Cell Dev. Biol., 36, pp. 166-176, (2014); Lewis S.J., Heaton K.W., Stool form scale as a useful guide to intestinal transit time, Scand. J. Gastroenterol., 32, pp. 920-924, (1997); Liu L., Xiao Q.F., Zhang Y.L., Yao S.K., A cross-sectional study of irritable bowel syndrome in nurses in China: Prevalence and associated psychological and lifestyle factors, J. Zhejiang Univ. Sci. B., 15, pp. 590-597, (2014); Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Mallegol J., Van Niel G., Heyman M., Phenotypic and functional characterization of intestinal epithelial exosomes, Blood Cells Mol. Dis., 35, pp. 11-16, (2005); Maloy K.J., Powrie F., Intestinal homeostasis and its breakdown in inflammatory bowel disease, Nature, 474, pp. 298-306, (2011); Martinez C., Lobo B., Pigrau M., Ramos L., Gonzalez-Castro A.M., Alonso C., Guilarte M., Guila M., De Torres I., Azpiroz F., Santos J., Vicario M., Diarrhoea-predominant irritable bowel syndrome: An organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, pp. 1160-1168, (2013); Perez-Moreno M., Jamora C., Fuchs E., Sticky business: Orchestrating cellular signals at adherens junctions, Cell, 112, pp. 535-548, (2003); Piche T., Barbara G., Aubert P., Des Varannes B.S., Dainese R., Nano J.L., Cremon C., Stanghellini V., De Giorgio R., Galmiche J.P., Neunlist M., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: Involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Potten C.S., Loeffler M., Stem cells: Attributes, cycles, spirals, pitfalls and uncertainties, Lessons for and from the Crypt. Development, 110, pp. 1001-1020, (1990); Than U.T.T., Guanzon D., Leavesley D., Parker T., Association of extracellular membrane vesicles with cutaneous wound healing, Int. J. Mol. Sci., 18, (2017); Tompkins A.J., Chatterjee D., Maddox M., Wang J., Arciero E., Camussi G., Quesenberry P.J., Renzulli J.F., The emergence of extracellular vesicles in urology: Fertility, cancer, biomarkers and targeted pharmacotherapy, J. Extracell. Vesicles, 4, (2015); Turcotte J.F., Kao D., Mah S.J., Claggett B., Saltzman J.R., Fedorak R.N., Liu J.J., Breaks in the wall: Increased gaps in the intestinal epithelium of irritable bowel syndrome patients identified by confocal laser endomicroscopy (with videos), Gastrointest. Endosc., 77, pp. 624-630, (2013); Vanheel H., Vicario M., Vanuytsel T., Van Oudenhove L., Martinez C., Keita A.V., Pardon N., Santos J., Soderholm J.D., Tack J., Farre R., Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia, Gut, 63, pp. 262-271, (2014); Xu R., Greening D.W., Zhu H.J., Takahashi N., Simpson R.J., Extracellular vesicle isolation and characterization: Toward clinical application, J. Clin. Invest., 126, pp. 1152-1162, (2016)","Y.-B. Yu; Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, Shandong Province, 107 Wenhuaxi Road, 250012, China; email: yuyanbo2000@126.com","","Akademiai Kiado ZRt.","","","","","","2498602X","","","31560236","English","Phys. Int.","Article","Final","All Open Access; Green Open Access","Scopus","2-s2.0-85073124407"

"Miglietta S.; Borghini R.; Relucenti M.; Sorrentino V.; Chen R.; Li X.; Fazi F.; Donato G.; Familiari G.; Petrozza V.; Picarelli A.","Miglietta, Selenia (56940649200); Borghini, Raffaele (39960970700); Relucenti, Michela (14011954100); Sorrentino, Veronica (57200959131); Chen, Rui (24824111000); Li, Xiaobo (35741076500); Fazi, Francesco (6505950816); Donato, Giuseppe (56396394000); Familiari, Giuseppe (35514590400); Petrozza, Vincenzo (6603788886); Picarelli, Antonio (7004609330)","56940649200; 39960970700; 14011954100; 57200959131; 24824111000; 35741076500; 6505950816; 56396394000; 35514590400; 6603788886; 7004609330","New insights into intestinal permeability in irritable bowel syndrome-like disorders: Histological and ultrastructural findings of duodenal biopsies","2021","Cells","10","10","2593","","","","10","10.3390/cells10102593","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85115852842&doi=10.3390%2fcells10102593&partnerID=40&md5=70fa57b55e6027e4326fe17eea557b7c","Department of Anatomical, Histological, Forensic and Orthopedic Sciences, Sapienza University of Rome, Rome, 00161, Italy; Department of Translation and Precision Medicine, Sapienza University of Rome, Rome, 00161, Italy; Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Rome, 00161, Italy; Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing, 218889, China","Miglietta S., Department of Anatomical, Histological, Forensic and Orthopedic Sciences, Sapienza University of Rome, Rome, 00161, Italy; Borghini R., Department of Translation and Precision Medicine, Sapienza University of Rome, Rome, 00161, Italy; Relucenti M., Department of Anatomical, Histological, Forensic and Orthopedic Sciences, Sapienza University of Rome, Rome, 00161, Italy; Sorrentino V., Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Rome, 00161, Italy; Chen R., Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing, 218889, China; Li X., Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing, 218889, China; Fazi F., Department of Anatomical, Histological, Forensic and Orthopedic Sciences, Sapienza University of Rome, Rome, 00161, Italy; Donato G., Department of Translation and Precision Medicine, Sapienza University of Rome, Rome, 00161, Italy; Familiari G., Department of Anatomical, Histological, Forensic and Orthopedic Sciences, Sapienza University of Rome, Rome, 00161, Italy; Petrozza V., Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Rome, 00161, Italy; Picarelli A., Department of Translation and Precision Medicine, Sapienza University of Rome, Rome, 00161, Italy","Background and Aim: Diarrhea, abdominal pain, and bloating are frequent in irritable bowel syndrome (IBS)-like disorders, although little is known about their intestinal ultrastructural alterations. The aim of the present study was to study duodenal biopsies from IBS-like patients to find ultrastructural alterations. Materials and Methods: Study design: descriptive comparative pilot study. Thirty outpatients (9 male and 21 female; median age 37.7 years; range, 20 to 65 years) complaining of IBS-like symptoms were enrolled between January 2015 to May 2019 and were divided into 6 groups, each equally consisting of 5 patients: (A) untreated celiac disease (uCD); (B) treated celiac disease (tCD); (C) wheat allergy (WA); (D) Non-celiac gluten sensitivity (NCGS); (E) Nickel allergic contact mucositis (Ni ACM); (F) controls affected by GERD. Transmission electron microscopy (TEM) morphological characteristics were: microvilli length, intermicrovillar distance, junctional complexes (JC) gap width, autophagic bodies, apoptosis, altered mitochondria, lipid/chylomicron droplets, and mast cells. Regarding JC, we focused on tight junctions (TJ), adherens junctions (AJ), and desmosomes. Results: Major alterations in microvilli length and intermicrovillar distance have been observed in the subjects affected by uCD. Microvilli of tCD patients showed marked recovery after adequate GFD, although not comparable to controls. Intermediate microvillar alterations were instead observed in NCGS and Ni ACM, while characteristics of WA subjects appeared more similar to tCD. Regarding JC, TJ did not show significant differences between all groups studied, including controls. The AJ were significantly more dilated in all groups compared to controls, while no significant differences were found between the pathological groups. The distance between desmosomes was greater in uCD, NCGS, and Ni ACM than in tCD, WA, and controls. Finally, intracellular alterations have been detected in most of the groups studied although they seemed more unspecific. Conclusions: TEM analysis confirmed damages to the intestinal barrier and defense mechanisms by enterocytes in IBS-like patients, probably linked to low-grade inflammation or adverse reactions triggered by food allergens, heavy metals, or other unknown. On the other hand, our study needs confirmation and further investigations with larger populations to facilitate diagnosis, therapy, and prevention of IBS-like disorders in the future. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.","Celiac disease; Diagnosis; Duodenal biopsies; IBS-like disorders; Intestinal permeability; Nickel allergy; Non-celiac gluten sensitivity; Transmission electron microscopy (TEM); Ultrastructure; Wheat allergy","Adult; Aged; Biopsy; Duodenum; Female; Humans; Irritable Bowel Syndrome; Male; Middle Aged; Pilot Projects; Young Adult; allergen; chylomicron; epoxy resin; heavy metal; immunoglobulin A; immunoglobulin E; nickel; propylene oxide; abdominal pain; adherens junction; adult; anemia; apoptosis; Article; asthenia; atopic dermatitis; autophagosome; bloating; capsule endoscopy; celiac disease; clinical article; colonoscopy; Creutzfeldt Jakob disease; defense mechanism; desmosome; diarrhea; duodenum biopsy; duodenum mucosa; dyspepsia; dysphagia; endoscopy; female; flow cytometry; gastroesophageal reflux; genetic polymorphism; gluten free diet; heartburn; histology; human; immunohistochemistry; inflammation; intestine cell; intestine flora; irritable colon; lamina propria; lymphocytosis; male; mast cell; mitochondrion; morphological trait; mucosa inflammation; nickel hypersensitivity; observational study; outpatient; pilot study; psoriasis; swelling; tight junction; transmission electron microscopy; ulcerative colitis; ultrastructure; wheat allergy; aged; biopsy; complication; duodenum; irritable colon; middle aged; procedures; surgery; ultrastructure; young adult","","immunoglobulin E, 37341-29-0; nickel, 7440-02-0; propylene oxide, 75-56-9","","","Ministry of Foreign Affairs and International Cooperation of Italy, (CN18GR10)","This research was funded by Ministry of Foreign Affairs and International Cooperation of Italy, grant number CN18GR10.","Spiller R., Irritable bowel syndrome: New insights into symptom mechanisms and advances in treatment, F1000Research, 29, (2016); Borghini R., Donato G., Alvaro D., Picarelli A., New insights in IBS-like disorders: Pandora’s box has been opened; a review, Gastroenterol. Hepatol. Bed Bench, 10, pp. 79-89, (2017); Elli L., Branchi F., Tomba C., Villalta D., Norsa L., Ferretti F., Roncoroni L., Bardella M.T., Diagnosis of gluten related disorders: Celiac disease, wheat allergy and non-celiac gluten sensitivity, World J. Gastroenterol, 21, pp. 7110-7119, (2015); Goswami P., Das P., Verma A.K., Prakash S., Das T.K., Nag T.C., Ahuja V., Gupta S.D., Makharia G.K., Are alterations of tight junctions at molecular and ultrastructural level different in duodenal biopsies of patients with celiac disease and Crohn’s disease?, Virchows Arch, 465, pp. 521-530, (2014); Valitutti F., Fasano A., Breaking Down Barriers: How Understanding Celiac Disease Pathogenesis Informed the Development of Novel Treatments, Dig. Dis. Sci, 64, pp. 1748-1758, (2019); Anderson J.M., Van Itallie C.M., Fanning A.S., Setting up a selective barrier at the apical junction complex, Curr. Opin. Cell Biol, 16, pp. 140-145, (2004); Visser J., Rozing J., Sapone A., Lammers K., Fasano A., Tight junctions, intestinal permeability, and autoimmunity: Celiac disease and type 1 diabetes paradigms, Ann. N. Y. Acad. Sci, 1165, pp. 195-205, (2009); Cukrowska B., Sowinska A., Bierla J.B., Czarnowska E., Rybak A., Grzybowska-Chlebowczyk U., Intestinal epithelium, intraepithelial lymphocytes and the gut microbiota-Key players in the pathogenesis of celiac disease, World J. Gastroenterol, 23, pp. 7505-7518, (2017); Schumann M., Siegmund B., Schulzke J.D., Fromm M., Celiac Disease: Role of the Epithelial Barrier, Cell Mol. Gastroenterol. Hepatol, 3, pp. 150-162, (2017); Schoultz I., Keita A.V., The Intestinal Barrier and Current Techniques for the Assessment of Gut Permeability, Cells, 9, (2020); Cardoso-Silva D., Delbue D., Itzlinger A., Moerkens R., Withoff S., Branchi F., Schumann M., Intestinal Barrier Function in Gluten-Related Disorders, Nutrients, 11, (2019); Hollon J., Puppa E.L., Greenwald B., Goldberg E., Guerrerio A., Fasano A., Effect of gliadin on permeability of intestinal biopsy explants from celiac disease patients and patients with non-celiac gluten sensitivity, Nutrients, 7, pp. 1565-1576, (2015); Lebwohl B., Sanders D.S., Green P.H.R., Coeliac disease, Lancet, 391, pp. 70-81, (2018); Picarelli A., Borghini R., Isonne C., Di Tola M., Reactivity to dietary gluten: New insights into differential diagnosis among gluten-related gastrointestinal disorders, Pol. Arch. Med. Wewn, 123, pp. 708-712, (2013); Borghini R., Di Tola M., Salvi E., Isonne C., Puzzono M., Marino M., Donato G., Picarelli A., Impact of gluten-free diet on quality of life in celiac patients, Acta Gastroenterol. Belg, 79, pp. 447-453, (2016); Shiner M., Birbeck M.S., The microvilli of the small intestinal surface epithelium in coeliac disease and in idiopathic steatorrhoea, Gut, 2, pp. 277-284, (1961); Serena G., D'Avino P., Fasano A., Celiac Disease and Non-celiac Wheat Sensitivity: State of Art of Non-dietary Therapies, Front. Nutr, 7, (2020); Picarelli A., Borghini R., Di Tola M., Marino M., Urciuoli C., Isonne C., Puzzono M., Porowska B., Rumi G., Lonardi S., Et al., Intestinal, Systemic, and Oral Gluten-related Alterations in Patients with Nonceliac Gluten Sensitivity, J. Clin. Gastroenterol, 50, pp. 849-858, (2016); Biesiekierski J.R., Peters S.L., Newnham E.D., Rosella O., Muir J.G., Gibson P.R., No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates, Gastroenterology, 145, pp. 320-328, (2013); Catassi C., Elli L., Bonaz B., Bouma G., Carroccio A., Castillejo G., Cellier C., Cristofori F., de Magistris L., Dolinsek J., Et al., Diagnosis of Non-Celiac Gluten Sensitivity (NCGS): The Salerno Experts’ Criteria, Nutrients, 7, pp. 4966-4977, (2015); Carroccio A., Giannone G., Mansueto P., Soresi M., La Blasca F., Fayer F., Iacobucci R., Porcasi R., Catalano T., Geraci G., Et al., Duodenal and Rectal Mucosa Inflammation in Patients with Non-celiacWheatSensitivity, Clin. Gastroenterol. Hepatol, 17, pp. 682-690, (2019); Pizzutelli S., Systemic nickel hypersensitivity and diet: Myth or reality?, Eur. Ann. Allergy Clin. Immunol, 43, pp. 5-18, (2011); Borghini R., Porpora M.G., Casale R., Marino M., Palmieri E., Greco N., Donato G., Picarelli A., Irritable Bowel Syndrome-Like Disorders in Endometriosis: Prevalence of Nickel Sensitivity and Effects of a Low-Nickel Diet. An Open-Label Pilot Study, Nutrients, 28, (2020); Borghini R., Puzzono M., Rosato E., Di Tola M., Marino M., Greco F., Picarelli A., Nickel-Related Intestinal Mucositis in IBS-Like Patients: Laser Doppler Perfusion Imaging and Oral Mucosa Patch Test in Use, Biol. Trace Elem. Res, 173, pp. 55-61, (2016); Di Tola M., Marino M., Amodeo R., Tabacco F., Casale R., Portaro L., Borghini R., Cristaudo A., Manna F., Rossi A., Et al., Immunologicalcharacterization of the allergiccontactmucositisrelated to the ingestion of nickel-richfoods, Immunobiology, 219, pp. 522-530, (2014); Al-Toma A., Volta U., Auricchio R., Castillejo G., Sanders D.S., Cellier C., Mulder C.J., Lundin K.E.A., European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders, United Eur. Gastroenterol. J, 7, pp. 583-613, (2019); Vitalone A., Di Sotto A., Mammola C.L., Heyn R., Miglietta S., Mariani P., Sciubba F., Passarelli F., Nativio P., Mazzanti G., Phytochemicalanalysis and effects on ingestivebehaviour of a Caralluma fimbriata extract, Food Chem. Toxicol, 108, pp. 63-73, (2017); Nabi A., Khalili M.A., Talebi A.R., Mangoli E., Yari N., Nottola S.A., Miglietta S., Taheri F., In-Vitro Application of Pentoxifylline Preserved Ultrastructure of Spermatozoa After Vitrification in Asthenozoospermic Patients, Urol. J, 14, pp. 4038-4043, (2017); Sowinska A., Morsy Y., Czarnowska E., Oralewska B., Konopka E., Woynarowski M., Szymanska S., Ejmont M., Scharl M., Bierla J.B., Et al., Transcriptional and Ultrastructural Analyses Suggest Novel Insightsinto Epithelial Barrier Impairment in Celiac Disease, Cells, 9, (2020); Canavan C., West J., Card T., The epidemiology of irritable bowel syndrome, Clin. Epidemiol, 6, pp. 71-80, (2014); Catassi C., Alaedini A., Bojarski C., Bonaz B., Bouma G., Carroccio A., Castillejo G., De Magistris L., Dieterich W., Di Liberto D., Et al., The Overlapping Area of Non-Celiac Gluten Sensitivity (NCGS) and Wheat-Sensitive Irritable Bowel Syndrome (IBS): An Update, Nutrients, 9, (2017); Granger B., Baker R.F., Electron microscope investigation of the striated border of intestinal epithelium, Anat. Rec, 107, pp. 423-441, (1950); Yardley J.H., Bayless T.M., Norton J.H., Hendrix T.R., Celiac disease. A study of the jejunal epithelium before and after a gluten-free diet, N. Engl. J. Med, 267, pp. 1173-1179, (1962); Trier J.S., Rubin C.E., Electron microscopy of the small intestine: A review, Gastroenterology, 49, pp. 574-603, (1965); Trier J.S., Structure of the mucosa of the small intestine as it relates to intestinal function, Fed. Proc, 26, pp. 1391-1404, (1967); Wehman H.J., Plantholt B.A., Lifshitz F., Microvillous anomalies induced by various conditions of stress in the small intestine of the rat, Exp. Mol. Pathol, 17, pp. 296-306, (1972); Borghini R., De Amicis N., Bella A., Greco N., Donato G., Picarelli A., Beneficial Effects of a Low-Nickel Diet on Relapsing IBS-Like and Extraintestinal Symptoms of Celiac Patients during a Proper Gluten-Free Diet: Nickel Allergic Contact Mucositis in Suspected Non-Responsive Celiac Disease, Nutrients, 12, (2020); Jing K., Lim K., Why is autophagy important in human diseases?, Exp. Mol. Med, 44, pp. 69-72, (2012); Klionsky D.J., Autophagy: From phenomenology to molecular understanding in less than a decade, Nat. Rev. Mol. Cell Biol, 8, pp. 931-937, (2007); Huett A., Xavier R.J., Autophagy at the gut interface: Mucosal responses to stress and the consequences for inflammatory bowel diseases, Inflamm. Bowel. Dis, 16, pp. 152-174, (2010); Barone M.V., Troncone R., Auricchio S., Gliadin Peptides as Triggers of the Proliferative and Stress/Innate Immune Response of the Celiac Small Intestinal Mucosa, Int. J. Mol. Sci, 15, pp. 20518-20537, (2014); Buret A.G., Bhargava A., Modulatory mechanisms of enterocyte apoptosis by viral, bacterial and parasitic pathogens, Crit. Rev. Microbiol, 40, pp. 1-17, (2014); Shalimar D.M., Das P., Sreenivas V., Gupta S.D., Panda S.K., Makharia G.K., Mechanism of villous atrophy in celiac disease: Role of apoptosis and epithelial regeneration, Arch. Pathol. Lab. Med, 137, pp. 1262-1269, (2013); Mazzarella G., Stefanile R., Camarca A., Giliberti P., Cosentini E., Marano C., Iaquinto G., Giardullo N., Auricchio S., Sette A., Et al., Gliadinactivates HLA class I-restricted CD8+ T cells in celiacdiseaseintestinal mucosa and induces the enterocyteapoptosis, Gastroenterology, 134, pp. 1017-1027, (2008); Novak E.A., Mollen K.P., Mitochondrial dysfunction in inflammatory bowel disease, Front. Cell Dev. Biol, 3, (2015); Bhonchal S., Nain C.K., Prasad K.K., Nada R., Sharma A.K., Sinha S.K., Singh K., Functional and morphological alterations in small intestine mucosa of chronic alcoholics, J. Gastroenterol. Hepatol, 23, pp. e43-e48, (2008); Beilstein F., Carriere V., Leturque A., Demignot S., Characteristics and functions of lipid droplets and associated proteins in enterocytes, Exp. Cell Res, 340, pp. 172-179, (2016); Demignot S., Beilstein F., Morel E., Triglyceride-rich lipoproteins and cytosolic lipid droplets in enterocytes: Key players in intestinal physiology and metabolic disorders, Biochimie, 96, pp. 48-55, (2014); Magrone T., Magrone M., Jirillo E., Mast Cells as a Double Edged Sword in Immunity: Disorders of Mast Cell Activation and Therapeutic Management. Second of Two Parts, Endocr. Metab. Immune Disord. Drug Targets, 20, pp. 670-686, (2019); Albert-Bayo M., Paracuellos I., Gonzalez-Castro A.M., Rodriguez-Urrutia A., Rodriguez-Lagunas M.J., Alonso-Cotoner C., Santos J., Vicario M., Intestinal Mucosal Mast Cells: Key Modulators of Barrier Function and Homeostasis, Cells, 8, (2019); Frossi B., De Carli M., Calabro A., Coeliac Disease and Mast Cells, Int. J. Mol. Sci, 20, (2019); Hiatt R.B., Katz L., Mast cells in inflammatory conditions of the gastrointestinal tract, Am. J. Gastroenterol, 37, pp. 541-545, (1962); Robles A., Perez Ingles D., Myneedu K., Deoker A., Sarosiek I., Zuckerman M.J., Schmulson M.J., Bashashati M., Mast cells are increased in the small intestinal mucosa of patients with irritable bowel syndrome: A systematic review and meta-analysis, Neurogastroenterol. Motil, 31, (2019); Vanheel H., Vicario M., Boesmans W., Vanuytsel T., Salvo-Romero E., Tack J., Farre R., Activation of Eosinophils and Mast Cells in Functional Dyspepsia: An Ultrastructural Evaluation, Sci. Rep, 8, (2018); Giancola F., Volta U., Repossi R., Latorre R., Beeckmans D., Carbone F., Van den Houte K., Bianco F., Bonora E., Gori A., Et al., Mast cell-nerve interactions correlate with bloating and abdominal pain severity in patients with non-celiac gluten/wheat sensitivity, Neurogastroenterol. Motil, 5, (2020); Galli S.J., Tsai M., IgE and mast cells in allergic disease, Nat. Med, 18, pp. 693-704, (2012); Kinbara M., Bando K., Shiraishi D., Kuroishi T., Nagai Y., Ohtsu H., Takano-Yamamoto T., Sugawara S., Endo Y., Mast cell histamine-mediated transient inflammation following exposure to nickel promotes nickel allergy in mice, Exp. Dermatol, 25, pp. 466-471, (2016); Walsh M.L., Smith V.H., King C.M., Type 1 and type IV hypersensitivity to nickel, Australas. J. Dermatol, 51, pp. 285-286, (2010); Ishii N., Sugita Y., Nakajima H., Tanaka S., Askenase P.W., Elicitation of nickel sulfate (NiSO4)-specific delayed-type hypersensitivity requires early-occurring and early-acting, NiSO4-specific DTH-initiating cells with an unusual mixed phenotype for an antigen-specific cell, Cell Immunol, 161, pp. 244-255, (1995)","S. Miglietta; Department of Anatomical, Histological, Forensic and Orthopedic Sciences, Sapienza University of Rome, Rome, 00161, Italy; email: selenia.miglietta@uniroma1.it; R. Borghini; Department of Translation and Precision Medicine, Sapienza University of Rome, Rome, 00161, Italy; email: raffaele.borghini@uniroma1.it","","MDPI","","","","","","20734409","","","34685576","English","Cells","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85115852842"

"Katinios G.; Casado-Bedmar M.; Walter S.A.; Vicario M.; González-Castro A.M.; Bednarska O.; Söderholm J.D.; Hjortswang H.; Keita Å.V.","Katinios, Georgios (57217208209); Casado-Bedmar, Maite (56951301500); Walter, Susanna A (23053245700); Vicario, Maria (6603267769); González-Castro, Ana M (54796498900); Bednarska, Olga (55789563900); Söderholm, Johan D (7004276501); Hjortswang, Henrik (6603103510); Keita, Åsa V (13104052600)","57217208209; 56951301500; 23053245700; 6603267769; 54796498900; 55789563900; 7004276501; 6603103510; 13104052600","Increased Colonic Epithelial Permeability and Mucosal Eosinophilia in Ulcerative Colitis in Remission Compared with Irritable Bowel Syndrome and Health","2020","Inflammatory Bowel Diseases","26","7","","974","984","10","37","10.1093/ibd/izz328","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85083096809&doi=10.1093%2fibd%2fizz328&partnerID=40&md5=256699a4aee83cd410bf93f2bf703cdf","Department of Gastroenterology, Linköping University, Linköping, Sweden; Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden; Laboratory of Translational Mucosal Immunology, Digestive Diseases Research, Unit. Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Surgery, Linköping Linköping University, Sweden","Katinios G., Department of Gastroenterology, Linköping University, Linköping, Sweden, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden; Casado-Bedmar M., Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden; Walter S.A., Department of Gastroenterology, Linköping University, Linköping, Sweden, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden; Vicario M., Laboratory of Translational Mucosal Immunology, Digestive Diseases Research, Unit. Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain; González-Castro A.M., Laboratory of Translational Mucosal Immunology, Digestive Diseases Research, Unit. Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain; Bednarska O., Department of Gastroenterology, Linköping University, Linköping, Sweden, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden; Söderholm J.D., Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden, Department of Surgery, Linköping Linköping University, Sweden; Hjortswang H., Department of Gastroenterology, Linköping University, Linköping, Sweden, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden; Keita Å.V., Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden","Barrier dysfunction is recognized as a pathogenic factor in ulcerative colitis (UC) and irritable bowel syndrome (IBS), but it is unclear to what extent the factors related to barrier dysfunction are disease-specific. The aim of this study was to compare these aspects in UC patients in remission, IBS patients, and healthy controls (HCs). Methods: Colonic biopsies were collected from 13 patients with UC in remission, 15 patients with IBS-mixed, and 15 HCs. Ulcerative colitis patients had recently been treated for relapse, and biopsies were taken from earlier inflamed areas. Biopsies were mounted in Ussing chambers for measurements of intestinal paracellular permeability to 51chromium (Cr)-ethylenediaminetetraacetic acid (EDTA). In addition, biopsies were analyzed for mast cells and eosinophils by histological procedures, and plasma tumor necrosis factor (TNF)-α was assessed by ELISA. Results: Ussing chamber experiments revealed an increased 51Cr-EDTA permeability in UC and IBS (P < 0.05). The 51Cr-EDTA permeability was higher in UC compared with IBS (P < 0.005). There were increased numbers of mucosal mast cells and eosinophils in UC and IBS and more eosinophils in UC compared with IBS (P < 0.05). Also, increased extracellular granule content was found in UC compared with HCs (P < 0.05). The 51Cr-EDTA permeability correlated significantly with eosinophils in all groups. Plasma TNF-α concentration was higher in UC compared with IBS and HCs (P < 0.0005). Conclusions: Results indicate a more permeable intestinal epithelium in inactive UC and IBS compared with HCs. Ulcerative colitis patients, even during remission, demonstrate a leakier barrier compared with IBS. Both eosinophil numbers and activation state might be involved in the increased barrier function seen in UC patients in remission. © 2020 Crohn's & Colitis Foundation. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.","eosinophils; intestinal permeability; irritable bowel syndrome; mast cells; ulcerative colitis","Adult; Biopsy; Case-Control Studies; Colitis, Ulcerative; Colon; Eosinophilia; Female; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Male; Middle Aged; Permeability; Remission Induction; Young Adult; chromium 51; edetic acid; eosinophil cationic protein; tumor necrosis factor; adult; aged; Article; clinical article; colon biopsy; controlled study; correlational study; enzyme linked immunosorbent assay; eosinophil; eosinophilia; female; histology; human; human tissue; intestine mucosa permeability; irritable colon; large intestine; male; mast cell; mucosa cell; priority journal; protein analysis; protein blood level; relapse; remission; ulcerative colitis; biopsy; case control study; colon; comparative study; complication; eosinophilia; intestine mucosa; irritable colon; metabolism; middle aged; pathology; permeability; ulcerative colitis; young adult","","chromium 51, 14392-02-0; edetic acid, 150-43-6, 60-00-4","","","Bengt-Ihre fonden; County Council of Östergötland; Fondo de Investigación Sanitaria, (PI16/00583); VR-Medicine and Health, (2017-02475); AGA Research Foundation; Ministerio de Ciencia, Innovación y Universidades, MCIU, (CIBER-EHD CB06/04/0021); Stiftelsen för Strategisk Forskning, SSF, (RB13-016); Vetenskapsrådet, VR; Instituto de Salud Carlos III, ISCIII","Supported by: This work was supported by grants from Bengt Ihre research Scholarship (ÅVK), AFA research foundation (SAW); Bengt-Ihre fonden, County Council of Östergötland (SAW), the Swedish Research Council (VR-Medicine and Health, 2017-02475) (JDS, ÅVK), and the Swedish Foundation For Strategic Research (RB13-016). It was upported in part by Instituto de Salud Carlos III, Fondo de Investigación Sanitaria (PI16/00583, MV), and Ministerio de Ciencia, Innovación y Universidades, Spain (CIBER-EHD CB06/04/0021, MV).","Mearin F, Lacy BE, Chang L, Et al., Bowel disorders, Gastroenterology, 150, pp. 1393-1407, (2016); Jenkins RT, Ramage JK, Jones DB, Et al., Small bowel and colonic permeability to 51Cr-EDTA in patients with active inflammatory bowel disease, Clin Invest Med, 11, pp. 151-155, (1988); Arslan G, Atasever T, Cindoruk M, Et al., (51)CrEDTA colonic permeability and therapy response in patients with ulcerative colitis, Nucl Med Commun, 22, pp. 997-1001, (2001); Teahon K, Somasundaram S, Smith T, Et al., Assessing the site of increased intestinal permeability in coeliac and inflammatory bowel disease, Gut, 38, pp. 864-869, (1996); Bednarska O, Walter SA, Casado-Bedmar M, Et al., Vasoactive intestinal polypeptide and mast cells regulate increased passage of colonic bacteria in patients with irritable bowel syndrome, Gastroenterology, 153, pp. 948-960, (2017); Dunlop SP, Hebden J, Campbell E, Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Piche T, Barbara G, Aubert P, Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Gecse K, Roka R, Sera T, Et al., Leaky gut in patients with diarrheapredominant irritable bowel syndrome and inactive ulcerative colitis, Digestion, 85, pp. 40-46, (2012); Vivinus-Nebot M, Frin-Mathy G, Bzioueche H, Et al., Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation, Gut, 63, pp. 744-752, (2014); Jonefjall B, Ohman L, Simren M, Et al., IBS-like symptoms in patients with ulcerative colitis in deep remission are associated with increased levels of serum cytokines and poor psychological well-being, Inflamm Bowel Dis, 22, pp. 2630-2640, (2016); Ohman L, Isaksson S, Lindmark AC, Et al., T-cell activation in patients with irritable bowel syndrome, Am J Gastroenterol, 104, pp. 1205-1212, (2009); An S, Zong G, Wang Z, Et al., Expression of inducible nitric oxide synthase in mast cells contributes to the regulation of inflammatory cytokines in irritable bowel syndrome with diarrhea, Neurogastroenterol Motil, 28, pp. 1083-1093, (2016); Ahn JY, Lee KH, Choi CH, Et al., Colonic mucosal immune activity in irritable bowel syndrome: comparison with healthy controls and patients with ulcerative colitis, Dig Dis Sci, 59, pp. 1001-1011, (2014); De Winter BY, van den Wijngaard RM, de Jonge WJ., Intestinal mast cells in gut inflammation and motility disturbances, Biochim Biophys Acta, 1822, pp. 66-73, (2012); He SH., Key role of mast cells and their major secretory products in inflammatory bowel disease, World J Gastroenterol, 10, pp. 309-318, (2004); Casado-Bedmar M, Heil SDS, Myrelid P, Et al., Upregulation of intestinal mucosal mast cells expressing VPAC1 in close proximity to vasoactive intestinal polypeptide in inflammatory bowel disease and murine colitis, Neurogastroenterol Motil, 31, (2019); Guilarte M, Santos J, de Torres I, Et al., Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum, Gut, 56, pp. 203-209, (2007); Cremon C, Gargano L, Morselli-Labate AM, Et al., Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms, Am J Gastroenterol, 104, pp. 392-400, (2009); Neunlist M, Toumi F, Oreschkova T, Et al., Human ENS regulates the intestinal epithelial barrier permeability and a tight junction-associated protein ZO-1 via VIPergic pathways, Am J Physiol Gastrointest Liver Physiol, 285, pp. G1028-G1036, (2003); Bakker R, Dekker K, De Jonge HR, Et al., VIP, serotonin, and epinephrine modulate the ion selectivity of tight junctions of goldfish intestine, Am J Physiol, 264, pp. R362-R368, (1993); Conlin VS, Wu X, Nguyen C, Et al., Vasoactive intestinal peptide ameliorates intestinal barrier disruption associated with Citrobacter rodentium-induced colitis, Am J Physiol Gastrointest Liver Physiol, 297, pp. G735-G750, (2009); Winterkamp S, Raithel M, Hahn EG., Secretion and tissue content of eosinophil cationic protein in Crohn's disease, J Clin Gastroenterol, 30, pp. 170-175, (2000); Lampinen M, Ronnblom A, Amin K, Et al., Eosinophil granulocytes are activated during the remission phase of ulcerative colitis, Gut, 54, pp. 1714-1720, (2005); Zheng PY, Feng BS, Oluwole C, Et al., Psychological stress induces eosinophils to produce corticotrophin releasing hormone in the intestine, Gut, 58, pp. 1473-1479, (2009); Wallon C, Persborn M, Jonsson M, Et al., Eosinophils express muscarinic receptors and corticotropin-releasing factor to disrupt the mucosal barrier in ulcerative colitis, Gastroenterology, 140, pp. 1597-1607, (2011); Park KS, Ahn SH, Hwang JS, Et al., A survey about irritable bowel syndrome in South Korea: prevalence and observable organic abnormalities in IBS patients, Dig Dis Sci, 53, pp. 704-711, (2008); De Silva AP, Nandasiri SD, Hewavisenthi J, Et al., Subclinical mucosal inflammation in diarrhea-predominant irritable bowel syndrome (IBS) in a tropical setting, Scand J Gastroenterol, 47, pp. 619-624, (2012); O'Sullivan M, Clayton N, Breslin NP, Et al., Increased mast cells in the irritable bowel syndrome, Neurogastroenterol Motil, 12, pp. 449-457, (2000); Longstreth GF, Thompson WG, Chey WD, Et al., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Keita AV, Gullberg E, Ericson AC, Et al., Characterization of antigen and bacterial transport in the follicle-associated epithelium of human ileum, Lab Invest, 86, pp. 504-516, (2006); Schroeder KW, Tremaine WJ, Ilstrup DM., Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study, N Engl J Med, 317, pp. 1625-1629, (1987); Francis CY, Morris J, Whorwell PJ., The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress, Aliment Pharmacol Ther, 11, pp. 395-402, (1997); Fukuba N, Ishihara S, Tada Y, Et al., Prevalence of irritable bowel syndrome-like symptoms in ulcerative colitis patients with clinical and endoscopic evidence of remission: prospective multicenter study, Scand J Gastroenterol, 49, pp. 674-680, (2014); Sasaki Y, Tanaka M, Kudo H., Differentiation between ulcerative colitis and Crohn's disease by a quantitative immunohistochemical evaluation of T lymphocytes, neutrophils, histiocytes and mast cells, Pathol Int, 52, pp. 277-285, (2002); Lloyd G, Green FH, Fox H, Et al., Mast cells and immunoglobulin E in inflammatory bowel disease, Gut, 16, pp. 861-865, (1975); Dvorak AM, Monahan RA, Osage JE, Et al., Crohn's disease: transmission electron microscopic studies. II. Immunologic inflammatory response. Alterations of mast cells, basophils, eosinophils, and the microvasculature, Hum Pathol, 11, pp. 606-619, (1980); Dvorak AM, McLeod RS, Onderdonk A, Et al., Ultrastructural evidence for piecemeal and anaphylactic degranulation of human gut mucosal mast cells in vivo, Int Arch Allergy Immunol, 99, pp. 74-83, (1992); Bischoff SC, Wedemeyer J, Herrmann A, Et al., Quantitative assessment of intestinal eosinophils and mast cells in inflammatory bowel disease, Histopathology, 28, pp. 1-13, (1996); Bystrom J, Amin K, Bishop-Bailey D., Analysing the eosinophil cationic protein-a clue to the function of the eosinophil granulocyte, Respir Res, 12, (2011); Filippone RT, Sahakian L, Apostolopoulos V, Et al., Eosinophils in inflammatory bowel disease, Inflamm Bowel Dis, 25, pp. 1140-1151, (2019); Inoue S, Matsumoto T, Iida M, Et al., Characterization of cytokine expression in the rectal mucosa of ulcerative colitis: correlation with disease activity, Am J Gastroenterol, 94, pp. 2441-2446, (1999); Mir A, Minguez M, Tatay J, Et al., Elevated serum eotaxin levels in patients with inflammatory bowel disease, Am J Gastroenterol, 97, pp. 1452-1457, (2002); Lampinen M, Waddell A, Ahrens R, Et al., CD14+CD33+ myeloid cell-CCL11-eosinophil signature in ulcerative colitis, J Leukoc Biol, 94, pp. 1061-1070, (2013); Carlson M, Raab Y, Peterson C, Et al., Increased intraluminal release of eosinophil granule proteins EPO, ECP, EPX, and cytokines in ulcerative colitis and proctitis in segmental perfusion, Am J Gastroenterol, 94, pp. 1876-1883, (1999); Lampinen M, Fredricsson A, Vessby J, Et al., Downregulated eosinophil activity in ulcerative colitis with concomitant primary sclerosing cholangitis, J Leukoc Biol, 104, pp. 173-183, (2018); Wilcz-Villega EM, McClean S, Et al., Mast cell tryptase reduces junctional adhesion molecule-A (JAM-A) expression in intestinal epithelial cells: implications for the mechanisms of barrier dysfunction in irritable bowel syndrome, Am J Gastroenterol, 108, pp. 1140-1151, (2013); Li Q, Zhang Q, Wang M, Et al., Interferon-gamma and tumor necrosis factoralpha disrupt epithelial barrier function by altering lipid composition in membrane microdomains of tight junction, Clin Immunol, 126, pp. 67-80, (2008); Jimenez-Saenz M, Gonzalez-Campora R, Linares-Santiago E, Et al., Bleeding colonic ulcer and eosinophilic colitis: a rare complication of nonsteroidal anti-inflammatory drugs, J Clin Gastroenterol, 40, pp. 84-85, (2006); Al Samman M, Haque S, Long JD., Strongyloidiasis colitis: a case report and review of the literature, J Clin Gastroenterol, 28, pp. 77-80, (1999); Alfadda AA, Storr MA, Shaffer EA., Eosinophilic colitis: epidemiology, clinical features, and current management, Therap Adv Gastroenterol, 4, pp. 301-309, (2011); Lucendo AJ., Cellular and molecular immunological mechanisms in eosinophilic esophagitis: an updated overview of their clinical implications, Expert Rev Gastroenterol Hepatol, 8, pp. 669-685, (2014); Corinaldesi R, Stanghellini V, Cremon C, Et al., Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proofof-concept study, Aliment Pharmacol Ther, 30, pp. 245-252, (2009); Bartal C, Sagy I, Barski L., Drug-induced eosinophilic pneumonia: a review of 196 case reports, Medicine (Baltimore), 97, (2018); Galdiero MR, Varricchi G, Seaf M, Et al., Bidirectional mast cell-eosinophil interactions in inflammatory disorders and cancer, Front Med (Lausanne), 4, (2017); Chang L, Adeyemo M, Karagiannides I, Et al., Serum and colonic mucosal immune markers in irritable bowel syndrome, Am J Gastroenterol, 107, pp. 262-272, (2012)","Å.V. Keita; Department of Biomedical and Clinical Sciences, Linköping University, Medical Faculty Campus Us, Linköping, 581 85, Sweden; email: asa.keita@liu.se","","Oxford University Press","","","","","","10780998","","IBDNB","31944236","English","Inflammatory Bowel Dis.","Article","Final","All Open Access; Green Open Access; Hybrid Gold Open Access","Scopus","2-s2.0-85083096809"

"Sundin J.; Nordlander S.; Eutamene H.; Alquier-Bacquie V.; Cartier C.; Theodorou V.; Le Nevé B.; Törnblom H.; Simrén M.; Öhman L.","Sundin, Johanna (56332687100); Nordlander, Sofia (24780774900); Eutamene, Helene (55926684800); Alquier-Bacquie, Valerie (57211261294); Cartier, Christel (24079526500); Theodorou, Vassilia (55410684700); Le Nevé, Boris (36668774300); Törnblom, Hans (7801453693); Simrén, Magnus (57202571330); Öhman, Lena (14820629200)","56332687100; 24780774900; 55926684800; 57211261294; 24079526500; 55410684700; 36668774300; 7801453693; 57202571330; 14820629200","Colonic mast cell numbers, symptom profile, and mucosal expression of elements of the epithelial barrier in irritable bowel syndrome","2019","Neurogastroenterology and Motility","31","11","e13701","","","","11","10.1111/nmo.13701","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85073182601&doi=10.1111%2fnmo.13701&partnerID=40&md5=ec75e993dcd5b1d7202e82572c30ba96","Institute of Medicine, University of Gothenburg, Gothenburg, Sweden; Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden; Neuro-Gastroenterology & Nutrition Group, UMR 1331 Toxalim INRA, INP-PURPAN, Université de Toulouse 3 Paul Sabatier, Toulouse, France; Endocrinology & Toxicology of the Intestinal Barrier Group, UMR 1331 Toxalim INRA, INP-PURPAN, Université de Toulouse 3 Paul Sabatier, Toulouse, France; Danone Nutricia Research, Innovation, Science and Nutrition, Palaiseau, France; Centre for Person-Centred Care, University of Gothenburg, Gothenburg, Sweden; Centre for Functional Gastrointestinal and Motility Disorders, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States","Sundin J., Institute of Medicine, University of Gothenburg, Gothenburg, Sweden, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden; Nordlander S., Institute of Medicine, University of Gothenburg, Gothenburg, Sweden, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden; Eutamene H., Neuro-Gastroenterology & Nutrition Group, UMR 1331 Toxalim INRA, INP-PURPAN, Université de Toulouse 3 Paul Sabatier, Toulouse, France; Alquier-Bacquie V., Neuro-Gastroenterology & Nutrition Group, UMR 1331 Toxalim INRA, INP-PURPAN, Université de Toulouse 3 Paul Sabatier, Toulouse, France; Cartier C., Endocrinology & Toxicology of the Intestinal Barrier Group, UMR 1331 Toxalim INRA, INP-PURPAN, Université de Toulouse 3 Paul Sabatier, Toulouse, France; Theodorou V., Neuro-Gastroenterology & Nutrition Group, UMR 1331 Toxalim INRA, INP-PURPAN, Université de Toulouse 3 Paul Sabatier, Toulouse, France; Le Nevé B., Danone Nutricia Research, Innovation, Science and Nutrition, Palaiseau, France; Törnblom H., Institute of Medicine, University of Gothenburg, Gothenburg, Sweden, Centre for Person-Centred Care, University of Gothenburg, Gothenburg, Sweden; Simrén M., Institute of Medicine, University of Gothenburg, Gothenburg, Sweden, Centre for Person-Centred Care, University of Gothenburg, Gothenburg, Sweden, Centre for Functional Gastrointestinal and Motility Disorders, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States; Öhman L., Institute of Medicine, University of Gothenburg, Gothenburg, Sweden, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden","Background: This study aimed to determine whether patients with IBS displayed altered mucosal mast cell (MC) numbers and proportions of MCs co-localizing with nerves compared with healthy subjects (HS) and whether these MC characteristics correlated with IBS symptoms, elements of the epithelial barrier, or visceral sensitivity. Methods: Mucosal MC characteristics were determined using immunoassay. IBS symptoms, gene expression of elements of the epithelial barrier, fecal serine protease activity, and visceral sensitivity were assessed. Key Results: The MC numbers per mm2 were 2.0 (0.0-6.0) in patients with IBS (n = 43) and 3.5 (1.1-9.1) in HS (n = 20, P =.26). Of these, MCs were 0.0 (0.0-20) % vs 3.1 (0.0-18) % (P =.76) in IBS and HS, respectively, in co-localization with nerve fibers. MC characteristics were equivalent in the different IBS subtypes. Hierarchical cluster analysis identified two distinct groups among patients with IBS: MC high (higher MC numbers and proportions of MCs co-localizing with nerves) and MC low (lower MC numbers and proportions of MCs co-localizing with nerves). The MC high and MC low groups could not be discriminated with regard to IBS symptoms, parameters of visceral sensitivity, gene expression of elements of the epithelial barrier, and fecal protease activity. Conclusion and Inferences: There was no evidence of increased infiltration or altered localization of MCs in the colonic mucosa of patients with IBS. These MC characteristics were not linked to global IBS symptoms or mucosal expression of elements of the epithelial barrier. These findings indicate that quantity and location of mucosal MCs are factors not involved in the pathophysiology of IBS. © 2019 John Wiley & Sons Ltd","barrier integrity; intestinal; irritable bowel syndrome; mast cells; symptom severity","Adult; Colon; Female; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Male; Mast Cells; claudin 1; mucin; occludin; protein ZO1; serine proteinase; adult; Article; cell count; clinical article; cohort analysis; colon biopsy; colon mucosa; controlled study; disease severity; enzyme activity; female; gastrointestinal symptom; gene expression; human; human cell; human tissue; immunoassay; immunohistochemistry; irritable colon; male; mast cell; mRNA expression level; nerve fiber; pain threshold; permeability barrier; priority journal; Swedish citizen; colon; immunology; intestine mucosa; irritable colon; mast cell; metabolism; pathology","","claudin 1, 329338-06-9; occludin, 176304-61-3; proprotein convertase 9, ; serine protease HTRA1, ; serine proteinase, 37259-58-8","","","Sahlgrenska Academy, University of Gothenburg; Shire; Alberta Foundation for the Arts, AFA, (140330); Alberta Foundation for the Arts, AFA; Nutricia Research Foundation; VINNOVA, (11-03475); VINNOVA; Ferring Pharmaceuticals; Medicinska Forskningsrådet, MFR, (13409, 21691, 21692); Medicinska Forskningsrådet, MFR; Centrum fÖr Personcentrerad Vård, GPCC; Faculty of Medicine, Assiut University, AUFOM; Marianne and Marcus Wallenberg Foundation","Funding text 1: Funding information This study was supported by The Swedish Medical Research Council (grants 13409, 21691 and 21692); AFA insurance (140330); VINNOVA (11-03475); The Marianne and Marcus Wallenberg Foundation; Centre for Person-Centred Care (GPCC), Sahlgrenska Academy, University of Gothenburg; and The Faculty of Medicine, University of Gothenburg. The study was partially funded by an unrestricted grant from Danone Nutricia Research.; Funding text 2:  Boris Le Nevé: Danone Nutricia Research employee. Hans Törnblom: Has served as a consultant/ advisory board member for Almirall, Allergan, and Shire, and as a speaker for Tillotts, Takeda, Shire, and Almirall. Magnus Simrén: Has received unrestricted research grants from Danone, Glycom, and Ferring Pharmaceuticals, and served as a consultant/ advisory board member for AstraZeneca, Danone, Nestlé, Almirall, Allergan, Albireo, Glycom, Menarini, and Shire, and as a speaker for Tillotts, Takeda, Shire, Menarini, Biocodex, AlfaSigma, and Almirall. Lena Öhman: Has received a financial support for research by Danone Research and AstraZeneca and served as an advisory board member for Genetic Analysis and as speaker for Abbvie, Takeda, Janssen, and Tillots. For other authors no conflict of interest exists.  ","Mearin F., Lacy B.E., Chang L., Et al., Bowel disorders, Gastroenterology, 150, pp. 1393-1407, (2016); Bednarska O., Walter S.A., Casado-Bedmar M., Et al., Vasoactive intestinal polypeptide and mast cells regulate increased passage of colonic bacteria in patients with irritable bowel syndrome, Gastroenterology, 153, 4, pp. 948-960, (2017); Grinsvall C., Tornblom H., Tack J., Van Oudenhove L., Simren M., Psychological factors selectively upregulate rectal pain perception in hypersensitive patients with irritable bowel syndrome, Neurogastroenterol Motil, 27, 12, pp. 1772-1782, (2015); Bennet S.M., Polster A., Tornblom H., Et al., Global cytokine profiles and association with clinical characteristics in patients with irritable bowel syndrome, Am J Gastroenterol, 111, 8, pp. 1165-1176, (2016); Marshall J.S., Mast-cell responses to pathogens, Nat Rev Immunol, 4, 10, pp. 787-799, (2004); Wernersson S., Pejler G., Mast cell secretory granules: armed for battle, Nat Rev Immunol, 14, 7, pp. 478-494, (2014); Siebenhaar F., Redegeld F.A., Bischoff S.C., Gibbs B.F., Maurer M., Mast cells as drivers of disease and therapeutic targets, Trends Immunol, 39, 2, pp. 151-162, (2018); Espinosa E., Valitutti S., New roles and controls of mast cells, Curr Opin Immunol, 50, pp. 39-47, (2017); Galli S.J., Tsai M., IgE and mast cells in allergic disease, Nat Med, 18, 5, pp. 693-704, (2012); Ramsay D.B., Stephen S., Borum M., Voltaggio L., Doman D.B., Mast cells in gastrointestinal disease, Gastroenterol Hepatol (N Y), 6, 12, pp. 772-777, (2010); Gecse K., Roka R., Ferrier L., Et al., Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity, Gut, 57, 5, pp. 591-599, (2008); Chatterjea D., Martinov T., Mast cells: versatile gatekeepers of pain, Mol Immunol, 63, 1, pp. 38-44, (2015); Sundin J., Rangel I., Kumawat A.K., Hultgren-Hornquist E., Brummer R.J., Aberrant mucosal lymphocyte number and subsets in the colon of post-infectious irritable bowel syndrome patients, Scand J Gastroenterol, 49, 9, pp. 1068-1075, (2014); Camilleri M., Oduyebo I., Halawi H., Chemical and molecular factors in irritable bowel syndrome: current knowledge, challenges, and unanswered questions, Am J Physiol Gastrointest Liver Physiol, 311, 5, pp. G777-G784, (2016); Chadwick V.S., Chen W., Shu D., Et al., Activation of the mucosal immune system in irritable bowel syndrome, Gastroenterology, 122, 7, pp. 1778-1783, (2002); Lee H., Park J.H., Park D.I., Et al., Mucosal mast cell count is associated with intestinal permeability in patients with diarrhea predominant irritable bowel syndrome, J Neurogastroenterol Motil, 19, 2, pp. 244-250, (2013); Chang L., Adeyemo M., Karagiannides I., Et al., Serum and colonic mucosal immune markers in irritable bowel syndrome, Am J Gastroenterol, 107, 2, pp. 262-272, (2012); Dunlop S.P., Jenkins D., Spiller R.C., Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome, Am J Gastroenterol, 98, 7, pp. 1578-1583, (2003); Barbara G., Stanghellini V., De Giorgio R., Et al., Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome, Gastroenterology, 126, 3, pp. 693-702, (2004); Cremon C., Carini G., Wang B., Et al., Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome, Am J Gastroenterol, 106, 7, pp. 1290-1298, (2011); Sohn W., Lee O.Y., Lee S.P., Et al., Mast cell number, substance P and vasoactive intestinal peptide in irritable bowel syndrome with diarrhea, Scand J Gastroenterol, 49, 1, pp. 43-51, (2014); Ahn J.Y., Lee K.H., Choi C.H., Et al., Colonic mucosal immune activity in irritable bowel syndrome: comparison with healthy controls and patients with ulcerative colitis, Dig Dis Sci, 59, 5, pp. 1001-1011, (2014); Barbara G., Wang B., Stanghellini V., Et al., Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome, Gastroenterology, 132, 1, pp. 26-37, (2007); Wang L.H., Fang X.C., Pan G.Z., Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis, Gut, 53, 8, pp. 1096-1101, (2004); Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C., Functional bowel disorders, Gastroenterology, 130, 5, pp. 1480-1491, (2006); Munch A., Aust D., Bohr J., Et al., Microscopic colitis: current status, present and future challenges: statements of the European Microscopic Colitis Group, J Crohns Colitis, 6, 9, pp. 932-945, (2012); Lewis S.J., Heaton K.W., Stool form scale as a useful guide to intestinal transit time, Scand J Gastroenterol, 32, 9, pp. 920-924, (1997); Simren M., Tornblom H., Palsson O.S., Et al., Visceral hypersensitivity is associated with GI symptom severity in functional GI disorders: consistent findings from five different patient cohorts, Gut, 67, 2, pp. 255-262, (2018); Cremonini F., Houghton L.A., Camilleri M., Et al., Barostat testing of rectal sensation and compliance in humans: comparison of results across two centres and overall reproducibility, Neurogastroenterol Motil, 17, 6, pp. 810-820, (2005); Nybacka S., Ohman L., Storsrud S., Et al., Neither self-reported atopy nor IgE-mediated allergy are linked to gastrointestinal symptoms in patients with irritable bowel syndrome, Neurogastroenterol Motil, 30, 10, (2018); Francis C.Y., Morris J., Whorwell P.J., The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress, Aliment Pharmacol Ther, 11, 2, pp. 395-402, (1997); Wiklund I.K., Fullerton S., Hawkey C.J., Et al., An irritable bowel syndrome-specific symptom questionnaire: development and validation, Scand J Gastroenterol, 38, 9, pp. 947-954, (2003); Jerndal P., Ringstrom G., Agerforz P., Et al., Gastrointestinal-specific anxiety: an important factor for severity of GI symptoms and quality of life in IBS, Neurogastroenterol Motil, 22, 6, pp. 646-179, (2010); Zigmond A.S., Snaith R.P., The hospital anxiety and depression scale, Acta Psychiatr Scand, 67, 6, pp. 361-370, (1983); Barreau F., Salvador-Cartier C., Houdeau E., Bueno L., Fioramonti J., Long-term alterations of colonic nerve-mast cell interactions induced by neonatal maternal deprivation in rats, Gut, 57, 5, pp. 582-590, (2008); Annahazi A., Ferrier L., Bezirard V., Et al., Luminal cysteine-proteases degrade colonic tight junction structure and are responsible for abdominal pain in constipation-predominant IBS, Am J Gastroenterol, 108, 8, pp. 1322-1331, (2013); Bashashati M., Moossavi S., Cremon C., Et al., Colonic immune cells in irritable bowel syndrome: A systematic review and meta-analysis, Neurogastroenterol Motil, 30, 1, (2018); Coeffier M., Gloro R., Boukhettala N., Et al., Increased proteasome-mediated degradation of occludin in irritable bowel syndrome, Am J Gastroenterol, 105, 5, pp. 1181-1188, (2010); Park J.H., Rhee P.L., Kim H.S., Et al., Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome, J Gastroenterol Hepatol, 21, 1, pp. 71-78, (2006); Akbar A., Yiangou Y., Facer P., Walters J.R., Anand P., Ghosh S., Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain, Gut, 57, 7, pp. 923-929, (2008); Liu D.R., Xu X.J., Yao S.K., Increased intestinal mucosal leptin levels in patients with diarrhea-predominant irritable bowel syndrome, World J Gastroenterol, 24, 1, pp. 46-57, (2018); Lepinoux-Chambaud C., Eyer J., Review on intermediate filaments of the nervous system and their pathological alterations, Histochem Cell Biol, 140, 1, pp. 13-22, (2013); Dorn S.D., Morris C.B., Hu Y., Et al., Irritable bowel syndrome subtypes defined by Rome II and Rome III criteria are similar, J Clin Gastroenterol, 43, 3, pp. 214-220, (2009); McDermott J.R., Bartram R.E., Knight P.A., Miller H.R., Garrod D.R., Grencis R.K., Mast cells disrupt epithelial barrier function during enteric nematode infection, Proc Natl Acad Sci U S A, 100, 13, pp. 7761-7766, (2003); Shah E., Rezaie A., Riddle M., Pimentel M., Psychological disorders in gastrointestinal disease: epiphenomenon, cause or consequence?, Ann Gastroenterol, 27, 3, pp. 224-230, (2014); Braak B., Klooker T.K., Wouters M.M., Et al., Mucosal immune cell numbers and visceral sensitivity in patients with irritable bowel syndrome: is there any relationship?, Am J Gastroenterol, 107, 5, pp. 715-726, (2012); Khalili H., Huang E.S., Ananthakrishnan A.N., Et al., Geographical variation and incidence of inflammatory bowel disease among US women, Gut, 61, 12, pp. 1686-1692, (2012)","L. Öhman; Institute of Medicine, University of Gothenburg, Gothenburg, Sweden; email: lena.ohman@microbio.gu.se","","Blackwell Publishing Ltd","","","","","","13501925","","NMOTE","31518490","English","Neurogastroenterol. Motil.","Article","Final","","Scopus","2-s2.0-85073182601"

"Playford R.J.; Choudhry N.; Kelly P.; Marchbank T.","Playford, Raymond J. (57201696491); Choudhry, Naheed (24503111700); Kelly, Paul (57210439233); Marchbank, Tania (6602122723)","57201696491; 24503111700; 57210439233; 6602122723","Effects of bovine colostrum with or without egg on in vitro bacterial-induced intestinal damage with relevance for sibo and infectious diarrhea","2021","Nutrients","13","3","1024","1","16","15","11","10.3390/nu13031024","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102766245&doi=10.3390%2fnu13031024&partnerID=40&md5=0ab05f7484ffe98ffc90f5dd27cb0dca","Centre of Immunobiology, Blizard Institute, Barts and The London School of Medicine, Queen Mary, University of London, London, E1 2AT, United Kingdom; Research & Development, Pantheryx Inc, Boulder, 80301, CO, United States","Playford R.J., Centre of Immunobiology, Blizard Institute, Barts and The London School of Medicine, Queen Mary, University of London, London, E1 2AT, United Kingdom, Research & Development, Pantheryx Inc, Boulder, 80301, CO, United States; Choudhry N., Centre of Immunobiology, Blizard Institute, Barts and The London School of Medicine, Queen Mary, University of London, London, E1 2AT, United Kingdom; Kelly P., Centre of Immunobiology, Blizard Institute, Barts and The London School of Medicine, Queen Mary, University of London, London, E1 2AT, United Kingdom; Marchbank T., Centre of Immunobiology, Blizard Institute, Barts and The London School of Medicine, Queen Mary, University of London, London, E1 2AT, United Kingdom","Small intestinal bacterial overgrowth (SIBO) occurs commonly, is difficult to treat, and frequently recurs. Bovine colostrum (BC) and chicken eggs contain immunoglobulins and other components that possess antimicrobial, immunoregulatory, and growth factor activities; however, it is not known if they have the ability to reduce injury caused by the presence of bacteria associated with SIBO (Streptococcus, Escherichia coli, Staphylococcus, Bacteroides, Klebsiella, Enterococcus, and Proteus) and infectious diarrhea (enteropathogenic Escherichia coli, Salmonella). We examined the effects of BC, egg, or the combination, on bacterial growth and bacteria-induced changes in transepithelial electrical resistance (TEER) and bacterial translocation across confluent Caco-2 monolayers. BC, egg, or the combination did not affect bacterial growth. Adding bacteria to monolayers reduced TEER and (with minor variations among species) increased bacterial translocation, increased monolayer apoptosis (increased caspase-3 and Baxα, reduced Bcl2), increased intercellular adhesion molecule 1 (ICAM-1), and reduced cell adhesion molecules zonulin1 (ZO1) and claudin-1. BC, egg, or the combination reduced these effects (all p < 0.01) and caused additional increases in vascular endothelial growth factor (VEGF) and Heat Shock Protein 70 (Hsp70) expression. We conclude that BC ± egg strength-ens mucosal integrity against a battery of bacteria relevant for SIBO and for infectious diarrhea. Oral BC ± egg may have clinical value for these conditions, especially SIBO where eradication of precipitating organisms may be difficult to achieve. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.","Antimicrobial; Irritable bowel syndrome; Leaky gut; Nutraceuticals; Repair; Small intestinal bacterial overgrowth (SIBO)","Animals; Bacterial Infections; Caco-2 Cells; Cattle; Colostrum; Dysentery; Humans; In Vitro Techniques; Intestinal Diseases; Intestine, Small; Ovum; caspase 3; claudin 1; heat shock protein 70; intercellular adhesion molecule 1; protein Bax; protein Bax alpha; protein bcl 2; protein ZO1; unclassified drug; vasculotropin; aged; apoptosis; apoptosis assay; Article; bacterial growth; bacterial translocation; Bacteroides; bovine colostrum; Caco-2 cell line; colostrum; controlled study; egg; Enterococcus; enteropathogenic Escherichia coli; Escherichia coli; human; human cell; in vitro study; infectious diarrhea; Klebsiella; male; nonhuman; protein expression; Proteus; Salmonella; small intestinal bacterial overgrowth; Streptococcus; transepithelial resistance; animal; bacterial infection; bovine; colostrum; complication; dysentery; enteropathy; metabolism; microbiology; ovum; small intestine","","caspase 3, 169592-56-7; claudin 1, 329338-06-9; intercellular adhesion molecule 1, 126547-89-5; protein bcl 2, 219306-68-0; vasculotropin, 127464-60-2","BF3100, R and D Systems, United States; Duoset, R and D Systems, United Kingdom; Graphpad Prism 8 version 8.3.1; Millicell-ERS, Millipore, United Kingdom","Millipore, United Kingdom; R and D Systems, United Kingdom; R and D Systems, United States","PanTheryx Inc.","This study was partially funded by PanTheryx Inc. The funder provided support in the form of salaries for R.J.P. and provided partial funding for T.M. in her role as an external consultant and a research grant support for N.C. PanTheryx did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.","Middleton S.J., Playford R.J., Bacterial overgrowth of the small intestine, Oxford Textbook of Medicine, pp. 2879-2883, (2020); Ghoshal U.C., Shukla R., Ghoshal U., Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic Dichotomy, Gut Liver, 11, pp. 196-208, (2017); Dukowicz A.C., Lacy B.E., Levine G.M., Small intestinal bacterial overgrowth: A comprehensive review, Gastroenterol. Hepatol, 3, pp. 112-122, (2007); Pimentel M., Chow E.J., Lin H.C., Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome, Am. J. Gastroenterol, 95, pp. 3503-3506, (2000); Mello C.S., Rodrigues M.S.D.C., Filho H.B.D.A., Melli L.C.F.L., Tahan S., Pignatari A.C.C., De Morais M.B., Fecal microbiota analysis of children with small intestinal bacterial overgrowth among residents of an urban slum in Brazil, J. Pediatr, 94, pp. 483-490, (2018); Jacobs C., Adame E.C., Attaluri A., Valestin J., Rao S.S.C., Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and/or fungal overgrowth, Aliment. Pharmacol. Ther, 37, pp. 1103-1111, (2013); Haboubi N.Y., Lee G.S., Montgomery R.D., Duodenal Mucosal Morphometry of Elderly Patients with Small Intestinal Bacterial Overgrowth: Response to Antibiotic Treatment, Age Ageing, 20, pp. 29-32, (1991); Gatta L., Scarpignato C., Systematic review with meta-analysis: Rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth, Aliment. Pharmacol. Ther, 45, pp. 604-616, (2017); Lauritano E.C., Gabrielli M., Scarpellini E., Lupascu A., Novi M., Sottili S., Vitale G., Cesario V., Serricchio M., Cammarota G., Et al., Small Intestinal Bacterial Overgrowth Recurrence After Antibiotic Therapy, Am. J. Gastroenterol, 103, pp. 2031-2035, (2008); Pimentel M., Saad R.J., Long M.D., Rao S.S.C., ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth, Am. J. Gastroenterol, 115, pp. 165-178, (2020); Panahi Y., Falahi G., Falahpour M., Moharamzad Y., Khorasgani M.R., Beiraghdar F., Naghizadeh M.M., Bovine Colostrum in the Management of Nonorganic Failure to Thrive: A Randomized Clinical Trial, J. Pediatr. Gastroenterol. Nutr, 50, pp. 551-554, (2010); Playford R.J., Macdonald C.E., Calnan D.P., Floyd D.N., Podas T., Johnson W., Wicks A.C., Bashir O., Marchbank T., Co-administration of the health food supplement, bovine colostrum, reduces the acute non-steroidal anti-inflammatory drug-induced increase in intestinal permeability, Clin. Sci, 100, pp. 627-633, (2001); Buckley J.D., Brinkworth G.D., Abbott M.J., Effect of bovine colostrum on anaerobic exercise performance and plasma insu-lin-like growth factor I, J. Sports Sci, 21, pp. 577-588, (2003); Rehault-Godbert S., Guyot N., Nys Y., The Golden Egg: Nutritional Value, Bioactivities, and Emerging Benefits for Human Health, Nutrients, 11, (2019); Kovacs-Nolan J., Phillips M., Mine Y., Advances in the Value of Eggs and Egg Components for Human Health, J. Agric. Food Chem, 53, pp. 8421-8431, (2005); Wang X., Song L., Tan W., Zhao W., Clinical efficacy of oral immunoglobulin Y in infant rotavirus enteritis: Systematic re-view and meta-analysis, Medicine, 98, (2019); Playford R.J., Garbowsky M., Marchbank T., Pasteurized Chicken Egg Powder Stimulates Proliferation and Migration of AGS, RIE1, and Caco-2 Cells and Reduces NSAID-Induced Injury in Mice and Colitis in Rats, J. Nutr, 150, pp. 1434-1442, (2020); Gaensbauer J.T., Melgar M.A., Calvimontes D.M., Lamb M.M., Asturias E.J., Contreras-Roldan I.L., Dominguez S.R., Rob-inson C.C., Berman S., Efficacy of a bovine colostrum and egg-based intervention in acute childhood diarrhoea in Guatemala: A randomised, double-blind, placebo-controlled trial, BMJ Glob. Health, 2, (2017); Playford R.J., Cattell M., Marchbank T., Marked variability in bioactivity between commercially available bovine colostrum for human use; implications for clinical trials, PLoS ONE, 15, (2020); Lee J., Paik H.-D., Anticancer and immunomodulatory activity of egg proteins and peptides: A review, Poult. Sci, 98, pp. 6505-6516, (2019); Fogh J., Fogh J.M., Orfeo T., One Hundred and Twenty-Seven Cultured Human Tumor Cell Lines Producing Tumors in Nude Mice23, J. Natl. Cancer Inst, 59, pp. 221-226, (1977); Srinivasan B., Kolli A.R., Esch M.B., Abaci H.E., Shuler M.L., Hickman J.J., TEER Measurement Techniques for In Vitro Barrier Model Systems, J. Lab. Autom, 20, pp. 107-126, (2015); Choudhry N., Scott F., Edgar M., Sanger G.J., Kelly P., Reversal of Pathogen-Induced Barrier Defects in Intestinal Epithelial Cells by Contra-pathogenicity Agents, Dig. Dis. Sci, 66, pp. 88-104, (2021); Marchbank T., Davison G., Oakes J.R., Ghatei M.A., Patterson M., Moyer M.P., Playford R.J., The nutriceutical bovine colostrum truncates the increase in gut permeability caused by heavy exercise in athletes, Am. J. Physiol. Liver Physiol, 300, pp. G477-G484, (2011); Playford R., Weiser M., Bovine Colostrum: Its Constituents and Uses, Nutrients, 13, (2021); Ebina T., Ohta M., Kanamaru Y., Yamamoto-Osumi Y., Baba K., Passive immunizations of suckling mice and infants with bovine colostrum containing antibodies to human rotavirus, J. Med. Virol, 38, pp. 117-123, (1992); Rump J., Arndt R., Arnold A., Bendick C., Dichtelmuller H., Franke M., Helm E., Jager H., Kampmann B., Kolb P., Et al., Treatment of diarrhoea in human immunodeficiency virus-infected patients with immunoglobulins from bovine colostrum, J. Mol. Med, 70, pp. 588-594, (1992); Brooks H.J., McConnell M.A., Corbett J., Buchan G.S., Fitzpatrick C.E., Broadbent R.S., Potential prophylactic value of bovine colostrum in necrotizing enterocolitis in neonates: An in vitro study on bacterial attachment, antibody levels and cytokine production, FEMS Immunol. Med. Microbiol, 48, pp. 347-354, (2006); Lissner R., Thurmann P.A., Merz G., Karch H., Antibody reactivity and fecal recovery of bovine immunoglobulins follow-ing oral administration of a colostrum concentrate from cows (Lactobin) to healthy volunteers, Int. J. Clin. Pharmacol. Ther, 36, pp. 239-245, (1998); Mahdavi A., Rahmani H., Nili N., Samie A., Soleimania S., Chicken Egg Yolk Antibody (IgY) Powder Against Escherichia coli O78:K80, J. Anim. Veter Adv, 9, pp. 366-373, (2010); Rokutan K., Role of heat shock proteins in gastric mucosal protection, J. Gastroenterol. Hepatol, 15, pp. 12-19, (2000); Duffy A.M., Bouchier-Hayes D.J., Harmey J.H., Vascular Endothelial Growth Factor (VEGF) and Its Role in Non-Endothelial Cells: Autocrine Signalling by VEGF, Madame Curie Bioscience Database, pp. 133-144, (2004); Hsu C.-R., Chang I.-W., Hsieh P.-F., Lin T.-L., Liu P.-Y., Huang C.-H., Li K.-T., Wang J.-T., A Novel Role for the Klebsiella pneumoniae Sap (Sensitivity to Antimicrobial Peptides) Transporter in Intestinal Cell Interactions, Innate Immune Responses, Liver Abscess, and Virulence, J. Infect. Dis, 219, pp. 1294-1306, (2019); Kwak Y.-K., Vikstrom E., Magnusson K.-E., Vecsey-Semjen B., Colque-Navarro P., Mollby R., The Staphylococcus aureus Alpha-Toxin Perturbs the Barrier Function in Caco-2 Epithelial Cell Monolayers by Altering Junctional Integrity, Infect. Immun, 80, pp. 1670-1680, (2012); Tang X., Liu H., Yang S., Li Z., Zhong J., Fang R., Epidermal Growth Factor and Intestinal Barrier Function, Mediat. Inflamm, 2016, pp. 1-9, (2016); McEntee C.P., Gunaltay S., Travis M.A., Regulation of barrier immunity and homeostasis by integrin-mediated transforming growth factor β activation, Immunology, 160, pp. 139-148, (2019); Hagiwara T., Shinoda I., Fukuwatari Y., Shimamura S., Effects of Lactoferrin and Its Peptides on Proliferation of Rat Intestinal Epithelial Cell Line, IEC-18, in the Presence of Epidermal Growth Factor, Biosci. Biotechnol. Biochem, 59, pp. 1875-1881, (1995); Otani K., Tanigawa T., Watanabe T., Shimada S., Nadatani Y., Nagami Y., Tanaka F., Kamata N., Yamagami H., Shiba M., Et al., Microbiota Plays a Key Role in Non-Steroidal Anti-Inflammatory Drug-Induced Small Intestinal Damage, Digestion, 95, pp. 22-28, (2017)","R.J. Playford; Centre of Immunobiology, Blizard Institute, Barts and The London School of Medicine, Queen Mary, University of London, London, E1 2AT, United Kingdom; email: r.playford@qmul.ac.uk; R.J. Playford; Research & Development, Pantheryx Inc, Boulder, 80301, United States; email: r.playford@qmul.ac.uk","","MDPI AG","","","","","","20726643","","","33809940","English","Nutrients","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85102766245"

"Russo F.; Riezzo G.; Linsalata M.; Orlando A.; Tutino V.; Prospero L.; D'Attoma B.; Giannelli G.","Russo, Francesco (59133987400); Riezzo, Giuseppe (7004144336); Linsalata, Michele (6603600075); Orlando, Antonella (23767683100); Tutino, Valeria (25646829800); Prospero, Laura (57207799778); D'Attoma, Benedetta (8554891800); Giannelli, Gianluigi (7005015716)","59133987400; 7004144336; 6603600075; 23767683100; 25646829800; 57207799778; 8554891800; 7005015716","Managing Symptom Profile of IBS-D Patients With Tritordeum-Based Foods: Results From a Pilot Study","2022","Frontiers in Nutrition","9","","797192","","","","8","10.3389/fnut.2022.797192","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85125645014&doi=10.3389%2ffnut.2022.797192&partnerID=40&md5=0ad826c23ec8b6c80ff1eb4bc2b2daab","Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte, Italy; Laboratory of Nutritional Biochemistry, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte, Italy; Scientific Direction, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte, Italy","Russo F., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte, Italy; Riezzo G., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte, Italy; Linsalata M., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte, Italy; Orlando A., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte, Italy; Tutino V., Laboratory of Nutritional Biochemistry, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte, Italy; Prospero L., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte, Italy; D'Attoma B., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte, Italy; Giannelli G., Scientific Direction, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte, Italy","In the past few years, increasing attention has been given to the pathologic role of specific foods in IBS, like wheat and other cereals. Recent literature describes IBS patients who may experience gastrointestinal (GI) and extra-GI symptoms precipitated by the ingestion of cereals. Tritordeum is a cereal of Spanish origin derived from the hybridization of durum wheat and wild barley. It is different from classic wheat for its gluten protein composition, with fewer carbohydrates and fructans and a higher content of proteins, dietary fibers, and antioxidants. This pilot study aimed to investigate the effects of a 12-week diet with Tritordeum-based foods in substitution of other cereals on the profile of GI symptoms (evaluated by appropriate questionnaire) and the health of the GI barrier (assessed by sugar absorption test and different markers of integrity and functions) in 16 diarrhea-predominant IBS (IBS-D) patients. The diet with Tritordeum-based foods (bread, bakery products, and pasta) significantly reduced IBS-D patients' symptoms. This amelioration appears to occur through an overall improvement of the GI barrier, as demonstrated by the reduced intestinal permeability and the decreased levels of markers of intestinal mucosal integrity, mucosal inflammation, and fermentative dysbiosis. Copyright © 2022 Russo, Riezzo, Linsalata, Orlando, Tutino, Prospero, D'Attoma and Giannelli.","diet; dysbiosis; gastrointestinal symptoms; inflammation; intestinal permeability; irritable bowel syndrome; Tritordeum","","","","","","Italian Ministry of Health RC 2020","This work was supported by the Italian Ministry of Health RC 2020–2021, Prog. N. 16 (DDG n. 700/2020). Tritordeum bread, bakery products, and pasta were provided by Intini& C. SAS di Intini Bartolomeo, Putignano, Bari, Italy.","Chey W.D., Olden K., Carter E., Boyle J., Drossman D., Chang L., Utility of the Rome I and Rome II criteria for irritable bowel syndrome in U, Am J Gastroenterol, 97, pp. 2803-2811, (2002); Schmulson M.J., Drossman D.A., What is new in Rome IV, J NeurogastroenterolMotil, 23, pp. 151-163, (2017); Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Tuck C.J., Reed D.E., Muir J.G., Vanner S.J., Implementation of the low FODMAP diet in functional gastrointestinal symptoms: a real-world experience, NeurogastroenterolMotil, 32, (2020); Linsalata M., Riezzo G., Orlando A., D'attoma B., Prospero L., Tutino V., Et al., The relationship between low serum vitamin D levels and altered intestinal barrier function in patients with IBS diarrhoea undergoing a long-term low-FODMAP diet: novel observations from a clinical trial, Nutrients, 13, (2021); Orlando A., Tutino V., Notarnicola M., Riezzo G., Linsalata M., Clemente C., Et al., Improved symptom profiles and minimal inflammation in IBS-D patients undergoing a long-term low-FODMAP diet: a lipidomic perspective, Nutrients, 12, (2020); RotondiAufiero V., Fasano A., Mazzarella G., Non-celiac gluten sensitivity: how its gut immune activation and potential dietary management differ from celiac disease, Mol Nutr Food Res, 62, (2018); Barmeyer C., Schumann M., Meyer T., Zielinski C., Zuberbier T., Siegmund B., Et al., Long-term response to gluten-free diet as evidence for non-celiac wheat sensitivity in one third of patients with diarrhea-dominant and mixed-type irritable bowel syndrome, Int J Colorectal Dis, 32, pp. 29-39, (2017); Aziz I., Trott N., Briggs R., North J.R., Hadjivassiliou M., Sanders D.S., Efficacy of a gluten- free diet in subjects with irritable bowel syndrome-diarrhea unaware of their HLA-DQ2/8 genotype, Clin Gastroenterol Hepatol, 14, pp. 696-703, (2016); Martin A., Alvarez J.B., Martin L.M., Barro F., Ballesteros J., The development of tritordeum: a novel cereal for food processing, J Cereal Sci, 30, pp. 85-95, (1999); Vaquero L., Comino I., Vivas S., Rodriguez-Martin L., Gimenez M.J., Pastor J., Et al., Tritordeum: a novel cereal for food processing with good acceptability and significant reduction in gluten immunogenic peptides in comparison with wheat, J Sci Food Agric, 98, pp. 2201-2209, (2018); Sanchez-Leon S., Haro C., Villatoro M., Vaquero L., Comino I., Gonzalez-Amigo A.B., Et al., Tritordeum breads are well tolerated with preference over gluten-free breads in non-celiac wheat-sensitive patients and its consumption induce changes in gut bacteria, J Sci Food Agric, 101, pp. 3508-3517, (2020); Cardoso-Silva D., Delbue D., Itzlinger A., Moerkens R., Withoff S., Branchi F., Et al., Intestinal barrier function in gluten-related disorders, Nutrients, 11, (2019); Linsalata M., Riezzo G., D'attoma B., Clemente C., Orlando A., Russo F., Noninvasive biomarkers of gut barrier function identify two subtypes of patients suffering from diarrhoea predominant-IBS: a case-control study, BMC Gastroenterol, 18, (2018); Linsalata M., Riezzo G., Clemente C., D'attoma B., Russo F., Noninvasive biomarkers of gut barrier function in patients suffering from diarrhea predominant-IBS: an update, Dis Markers, 2020, (2020); Leaky gut: mechanisms, measurement and clinical implications in humans, Gut, 68, pp. 1516-1526, (2019); Fasano A., Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer, Physiol Rev, 91, pp. 151-175, (2011); Pelsers M.M., Hermens W.T., Glatz J.F., Fatty acid-binding proteins as plasma markers of tissue injury, Clin Chim Acta, 352, pp. 15-35, (2005); Song W.B., Lv Y.H., Zhang Z.S., Li Y.N., Xiao L.P., Yu X.P., Et al., Soluble intercellular adhesion molecule-1, D-lactate and diamine oxidase in patients with inflammatory bowel disease, World J Gastroenterol, 15, pp. 3916-3919, (2009); Zhang L., Fan X., Zhong Z., Xu G., Shen J., Association of plasma diamine oxidase and intestinal fatty acid-binding protein with severity of disease in patient with heat stroke, Am J Emerg Med, 33, pp. 867-871, (2015); Francis C.Y., Morris J., Whorwell P.J., The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress, Aliment Pharmacol Ther, 11, pp. 395-402, (1997); Verdu E.F., Armstrong D., Murray J.A., Between celiac disease and irritable bowel syndrome: the no man's land of gluten sensitivity, Am J Gastroenterol, 104, pp. 1587-1594, (2009); Blake M.R., Raker J.M., Whelan K., Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome, Aliment PharmacolTher, 44, pp. 693-703, (2016); Maagaard L., Ankersen D.V., Vegh Z., Burisch J., Jensen L., Pedersen N., Et al., Follow-up of patients with functional bowel symptoms treated with a low FODMAP diet, World J Gastroenterol, 22, pp. 4009-4019, (2016); Linsalata M., D'attoma B., Orlando A., Guerra V., Russo F., Comparison of an enzymatic assay with liquid chromatography-pulsed amperometric detection for the determination of lactulose and mannitol in urine of healthy subjects and patients with active celiac disease, Clin Chem Lab Med, 52, pp. e61-e64, (2014); Hilsden R.J., Meddings J.B., Sutherland L.R., Intestinal permeability changes in response to acetylsalicylic acid in relatives of patients with Crohn's disease, Gastroenterology, 110, pp. 1395-1403, (1996); Simeoni M., Citraro M.L., Cerantonio A., Deodato F., Provenzano M., Cianfrone P., Et al., An open-label, randomized, placebo-controlled study on the effectiveness of a novel probiotics administration protocol (ProbiotiCKD) in patients with mild renal insufficiency (stage 3a of CKD), Eur J Nutr, 58, pp. 2145-2156, (2019); Lombardi F., Fiasca F., Minelli M., Maio D., Mattei A., Vergallo I., Et al., The effects of low-nickel diet combined with oral administration of selected probiotics on patients with systemic nickel allergy syndrome (SNAS) and gut dysbiosis, Nutrients, 12, (2020); Drossman D.A., Chang L., Bellamy N., Gallo-Torres H.E., Lembo A., Mearin F., Et al., Severity in irritable bowel syndrome: a Rome Foundation Working Team report, Am J Gastroenterol, (2011); De Giorgio R., Volta U., Gibson P.R., Sensitivity to wheat, gluten and FODMAPs in IBS: facts or fiction?, Gut, 65, pp. 169-178, (2016); Catassi C., Bai J.C., Bonaz B., Bouma G., Calabro A., Carroccio A., Et al., Non-Celiac Gluten sensitivity: the new frontier of gluten related disorders, Nutrients, 5, pp. 3839-3853, (2013); Dieterich W., Zopf Y., Gluten and FODMAPS-sense of a restriction/when is restriction necessary?, Nutrients, 11, (2019); Nilholm C., Larsson E., Roth B., Gustafsson R., Ohlsson B., Irregular dietary habits with a high intake of cereals and sweets are associated with more severe gastrointestinal symptoms in IBS patients, Nutrients, 11, (2019); Bohn L., Storsrud S., Liljebo T., Collin L., Lindfors P., Tornblom H., Et al., Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial, Gastroenterology, 149, pp. 1399-1407, (2015); Haro C., Villatoro M., Vaquero L., Pastor J., Gimenez M.J., Ozuna C.V., Et al., The dietary intervention of transgenic low-gliadin wheat bread in patients with non-celiac gluten sensitivity (NCGS) showed no differences with gluten free diet (GFD) but provides better gut microbiota profile, Nutrients, 10, (2018); Schwenk A., Eschner W., Kremer G., Ward L.C., Assessment of intracellular water by whole body bioelectrical impedance and total body potassium in HIV-positive patients, Clin Nutr, 19, pp. 109-113, (2000); Stapel S.N., Looijaard W., Dekker I.M., Girbes A.R.J., Weijs P.J.M., Oudemans-van Straaten H.M., Bioelectrical impedance analysis-derived phase angle at admission as a predictor of 90-day mortality in intensive care patients, Eur J Clin Nutr, 72, pp. 1019-1025, (2018); Ghosh S.S., Wang J., Yannie P.J., Ghosh S., Intestinal barrier dysfunction, LPS translocation, and disease development, J Endocr Soc, 4, (2020); Fritscher-Ravens A., Schuppan D., Ellrichmann M., Schoch S., Rocken C., Brasch J., Et al., Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome, Gastroenterology, 147, pp. 1012-1020, (2014); Wu R.L., Vazquez-Roque M.I., Carlson P., Burton D., Grover M., Camilleri M., Et al., Gluten-induced symptoms in diarrhea-predominant irritable bowel syndrome are associated with increased myosin light chain kinase activity and claudin-15 expression, Lab Invest, 97, pp. 14-23, (2017); Usai-Satta P., Bassotti G., Bellini M., Oppia F., Lai M., Cabras F., Irritable bowel syndrome and gluten-related disorders, Nutrients, 12, (2020); Elli L., Tomba C., Branchi F., Roncoroni L., Lombardo V., Bardella M.T., Et al., Evidence for the presence of non-celiac gluten sensitivity in patients with functional gastrointestinal symptoms: results from a multicenter randomized double-blind placebo-controlled gluten challenge, Nutrients, 8, (2016)","F. Russo; Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte, Italy; email: francesco.russo@irccsdebellis.it","","Frontiers Media S.A.","","","","","","2296861X","","","","English","Front. Nutr.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85125645014"

"Du L.; Long Y.; Kim J.J.; Chen B.; Zhu Y.; Dai N.","Du, Lijun (57190012632); Long, Yanqin (15846348900); Kim, John J. (7601384309); Chen, Binrui (57192066215); Zhu, Yubin (57204666814); Dai, Ning (57204509665)","57190012632; 15846348900; 7601384309; 57192066215; 57204666814; 57204509665","Protease Activated Receptor-2 Induces Immune Activation and Visceral Hypersensitivity in Post-infectious Irritable Bowel Syndrome Mice","2019","Digestive Diseases and Sciences","64","3","","729","739","10","24","10.1007/s10620-018-5367-y","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85056654571&doi=10.1007%2fs10620-018-5367-y&partnerID=40&md5=2c9b22428d8db89de7c461290ad8bc7c","Department of Gastroenterology, School of Medicine, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, 310016, China; Division of Gastroenterology & Hepatology, Loma Linda University Health, Loma Linda, 92354, CA, United States","Du L., Department of Gastroenterology, School of Medicine, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, 310016, China; Long Y., Department of Gastroenterology, School of Medicine, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, 310016, China; Kim J.J., Department of Gastroenterology, School of Medicine, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, 310016, China, Division of Gastroenterology & Hepatology, Loma Linda University Health, Loma Linda, 92354, CA, United States; Chen B., Department of Gastroenterology, School of Medicine, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, 310016, China; Zhu Y., Department of Gastroenterology, School of Medicine, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, 310016, China; Dai N., Department of Gastroenterology, School of Medicine, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, 310016, China","Background: The role of protease activated receptor-2 (PAR-2) in the pathogenesis of abdominal pain in irritable bowel syndrome (IBS) is not well defined. Aims: To investigate the role of PAR-2-mediated visceral hypersensitivity in a post-infectious IBS (PI-IBS) mouse model. Methods: T. spiralis-infected PI-IBS mouse model was used. Fecal serine protease activity and intestinal mast cells were evaluated. Intestinal permeability was assessed by urine lactulose/mannitol ratio, and colonic expressions of PAR-2 and tight junction (TJ) proteins were examined by Western blot. Intestinal immune profile was assessed by measuring Th (T helper) 1/Th2 cytokine expression. Visceral sensitivity was evaluated by abdominal withdrawal reflex in response to colorectal distention. Results: Colonic PAR-2 expression as well as fecal serine protease activity and intestinal mast cell counts were elevated in PI-IBS compared to the control mice. Decreased colonic TJ proteins expression, increased lactulose/mannitol ratio, elevated colonic Th1/Th2 cytokine ratio, and visceral hypersensitivity were observed in PI-IBS compared to the control mice. Administration of PAR-2 agonist in control mice demonstrated similar changes observed in PI-IBS mice, while PAR-2 antagonist normalized the increased intestinal permeability and reduced visceral hypersensitivity observed in PI-IBS mice. Conclusions: PAR-2 activation increases intestinal permeability leading to immune activation and visceral hypersensitivity in PI-IBS mouse model. © 2018, Springer Science+Business Media, LLC, part of Springer Nature.","Intestinal permeability; Post-infectious irritable bowel syndrome; Protease activated receptor-2; T helper; Tight junction","Abdominal Pain; Animals; Colon; Feces; Hyperalgesia; Irritable Bowel Syndrome; Male; Mast Cells; Mice; Oligopeptides; Permeability; Receptor, PAR-2; Serine Proteases; Signal Transduction; Th1 Cells; Th1-Th2 Balance; Tight Junctions; Trichinella spiralis; Trichinellosis; claudin 1; gamma interferon; interleukin 4; lactulose; mannitol; myeloperoxidase; occludin; protein ZO1; proteinase activated receptor 2; proteinase activated receptor 2 antagonist; serine proteinase; serine proteinase inhibitor; unclassified drug; oligopeptide; proteinase activated receptor 2; serine proteinase; seryl-leucyl-isoleucyl-glycyl--arginyl-leucinamide; abdominal pain; animal cell; animal experiment; animal model; animal tissue; Article; cell count; cell infiltration; controlled study; cytokine production; cytokine release; enzyme activity; hypersensitivity; infection complication; intestine distension; intestine mucosa permeability; irritable colon; male; mast cell; mouse; mouse model; nonhuman; pathogenesis; priority journal; protein expression; Th1 cell; Th1 Th2 balance; Th2 cell; Trichinella spiralis; trichinosis; urine level; visceral hypersensitivity; Western blotting; withdrawal reflex; abdominal pain; agonists; animal; chemically induced; colon; complication; drug effect; enzymology; feces; hyperalgesia; immunology; irritable colon; metabolism; parasitology; pathogenicity; pathophysiology; permeability; signal transduction; tight junction","","claudin 1, 329338-06-9; gamma interferon, 82115-62-6; lactulose, 4618-18-2; mannitol, 69-65-8, 87-78-5; myeloperoxidase, ; occludin, 176304-61-3; proprotein convertase 9, ; serine protease HTRA1, ; serine proteinase, 37259-58-8; Oligopeptides, ; Receptor, PAR-2, ; Serine Proteases, ; seryl-leucyl-isoleucyl-glycyl--arginyl-leucinamide, ","","","National Natural Science Foundation of China, NSFC, (81200274, 81670487)","Acknowledgments The study was granted and supported by the National Natural Science Foundation of China (No. 81200274, No. 81670487).","Enck P., Aziz Q., Barbara G., Et al., Irritable bowel syndrome, Nat Rev Dis Primers, 2, (2016); Spiller R., Garsed K., Postinfectious irritable bowel syndrome, Gastroenterology, 136, pp. 1979-1988, (2009); Bueno L., Fioramonti J., Effects of inflammatory mediators on gut sensitivity, Can J Gastroenterol, 13, pp. 42a-46a, (1999); Shulman R.J., Jarrett M.E., Cain K.C., Et al., Associations among gut permeability, inflammatory markers, and symptoms in patients with irritable bowel syndrome, J Gastroenterol, 49, pp. 1467-1476, (2014); Marshall J.K., Thabane M., Garg A.X., Et al., Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario, Aliment Pharmacol Ther, 20, pp. 1317-1322, (2004); Jacob C., Yang P.C., Darmoul D., Et al., Mast cell tryptase controls paracellular permeability of the intestine. Role of protease-activated receptor 2 and beta-arrestins, J Biol Chem, 280, pp. 31936-31948, (2005); Bao Y., Hou W., Hua B., Protease-activated receptor 2 signalling pathways: a role in pain processing, Expert Opin Ther Targets, 18, pp. 15-27, (2014); Barbara G., Wang B., Stanghellini V., Et al., Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome, Gastroenterology, 132, pp. 26-37, (2007); Buhner S., Li Q., Vignali S., Et al., Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome, Gastroenterology, 137, pp. 1425-1434, (2009); Lee J.W., Park J.H., Park D.I., Et al., Subjects with diarrhea-predominant IBS have increased rectal permeability responsive to tryptase, Dig Dis Sci, 55, pp. 2922-2928, (2010); Rolland-Fourcade C., Denadai-Souza A., Cirillo C., Et al., Epithelial expression and function of trypsin-3 in irritable bowel syndrome, Gut, 66, pp. 1767-1778, (2017); Liang W.J., Zhang G., Luo H.S., Et al., Tryptase and protease-activated receptor 2 expression levels in irritable bowel syndrome, Gut Liver, 10, pp. 382-390, (2015); Gecse K., Roka R., Ferrier L., Et al., Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity, Gut, 57, pp. 591-599, (2008); Guide for the Care and Use of Laboratory Animals, (2011); Nutrient Requirements of Laboratory Animals, (1995); Bercik P., Wang L., Verdu E.F., Et al., Visceral hyperalgesia and intestinal dysmotility in a mouse model of postinfective gut dysfunction, Gastroenterology, 127, pp. 179-187, (2004); Cenac N., Garcia-Villar R., Ferrier L., Et al., Proteinase-activated receptor-2-induced colonic inflammation in mice: possible involvement of afferent neurons, nitric oxide, and paracellular permeability, J Immunol, 170, pp. 4296-4300, (2003); Nguyen C., Coelho A.M., Grady E., Et al., Colitis induced by proteinase-activated receptor-2 agonists is mediated by a neurogenic mechanism, Can J Physiol Pharmacol, 81, pp. 920-927, (2003); Han S.K., Dong X., Hwang J.I., Et al., Orphan G protein-coupled receptors MrgA1 and MrgC11 are distinctively activated by RF-amide-related peptides through the Galpha q/11 pathway, Proc Natl Acad Sci USA, 99, pp. 14740-14745, (2002); Park Y., Yang J., Zhang H., Et al., Effect of PAR2 in regulating TNF-alpha and NAD(P)H oxidase in coronary arterioles in type 2 diabetic mice, Basic Res Cardiol, 106, pp. 111-123, (2011); Al-Ani B., Saifeddine M., Wijesuriya S.J., Et al., Modified proteinase-activated receptor-1 and -2 derived peptides inhibit proteinase-activated receptor-2 activation by trypsin, J Pharmacol Exp Ther, 300, pp. 702-708, (2002); Kamp E.H., Jones R.C., Tillman S.R., Et al., Quantitative assessment and characterization of visceral nociception and hyperalgesia in mice, Am J Physiol Gastrointest Liver Physiol, 284, pp. G434-G444, (2003); Al-Chaer E.D., Kawasaki M., Pasricha P.J., A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development, Gastroenterology, 119, pp. 1276-1285, (2000); Lan C., Sun X.N., Zhou X.C., Et al., Preinduced intestinal HSP70 improves visceral hypersensitivity and abnormal intestinal motility in PI-IBS mouse model, Asian Pac J Trop Med, 9, pp. 302-305, (2016); Long Y., Liu Y., Tong J., Et al., Effectiveness of trimebutine maleate on modulating intestinal hypercontractility in a mouse model of postinfectious irritable bowel syndrome, Eur J Pharmacol, 636, pp. 159-165, (2010); Krawisz J.E., Sharon P., Stenson W.F., Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models, Gastroenterology, 87, pp. 1344-1350, (1984); Barbara G., Vallance B.A., Collins S.M., Persistent intestinal neuromuscular dysfunction after acute nematode infection in mice, Gastroenterology, 113, pp. 1224-1232, (1997); Gecse K., Roka R., Ferrier L., Et al., Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity, Gut, 57, pp. 591-599, (2008); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Et al., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am J Gastroenterol, 106, pp. 2165-2173, (2011); Kong W., McConalogue K., Khitin L.M., Et al., Luminal trypsin may regulate enterocytes through proteinase-activated receptor 2, Proc Natl Acad Sci USA, 94, pp. 8884-8889, (1997); Wang P., Chen F.X., Du C., Et al., Increased production of BDNF in colonic epithelial cells induced by fecal supernatants from diarrheic IBS patients, Sci Rep, 5, (2015); Coelho A.M., Vergnolle N., Guiard B., Et al., Proteinases and proteinase-activated receptor 2: a possible role to promote visceral hyperalgesia in rats, Gastroenterology, 122, pp. 1035-1047, (2002); Kawao N., Ikeda H., Kitano T., Et al., Modulation of capsaicin-evoked visceral pain and referred hyperalgesia by protease-activated receptors 1 and 2, J Pharmacol Sci, 94, pp. 277-285, (2004); Valdez-Morales E.E., Overington J., Guerrero-Alba R., Et al., Sensitization of peripheral sensory nerves by mediators from colonic biopsies of diarrhea-predominant irritable bowel syndrome patients: a role for PAR2, Am J Gastroenterol, 108, pp. 1634-1643, (2013); Jinguji Y., Ishikawa H., Electron microscopic observations on the maintenance of the tight junction during cell division in the epithelium of the mouse small intestine, Cell Struct Funct., 17, pp. 27-37, (1992); Al-Sadi R., Boivin M., Ma T., Mechanism of cytokine modulation of epithelial tight junction barrier, Front Biosci (Landmark Ed), 14, pp. 2765-2778, (2009); Al-Sadi R., Ye D., Dokladny K., Et al., Mechanism of IL-1beta-induced increase in intestinal epithelial tight junction permeability, J Immunol, 180, pp. 5653-5661, (2008); He F., Peng J., Deng X.L., Et al., Mechanisms of tumor necrosis factor-alpha-induced leaks in intestine epithelial barrier, Cytokine, 59, pp. 264-272, (2012); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Et al., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am J Gastroenterol, 106, pp. 2165-2173, (2011); Liebregts T., Adam B., Bredack C., Et al., Immune activation in patients with irritable bowel syndrome, Gastroenterology, 132, pp. 913-920, (2007); Ohman L., Isaksson S., Lindmark A.C., Et al., T-cell activation in patients with irritable bowel syndrome, Am J Gastroenterol, 104, pp. 1205-1212, (2009); Lee K.J., Kim Y.B., Kim J.H., Et al., The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors, J Gastroenterol Hepatol, 23, pp. 1689-1694, (2008); Chen J., Zhang Y., Deng Z., Imbalanced shift of cytokine expression between T helper 1 and T helper 2 (Th1/Th2) in intestinal mucosa of patients with post-infectious irritable bowel syndrome, BMC Gastroenterol, 12, (2012); Hyun E., Andrade-Gordon P., Steinhoff M., Et al., Protease-activated receptor-2 activation: a major actor in intestinal inflammation, Gut, 57, pp. 1222-1229, (2008); Cenac N., Coelho A.M., Nguyen C., Et al., Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2, Am J Pathol, 161, pp. 1903-1915, (2002); Wang F., Graham W.V., Wang Y., Et al., Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression, Am J Pathol, 166, pp. 409-419, (2005); Richardson J.D., Vasko M.R., Cellular mechanisms of neurogenic inflammation, J Pharmacol Exp Ther, 302, pp. 839-845, (2002); Park J.H., Rhee P.L., Kim H.S., Et al., Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome, J Gastroenterol Hepatol, 21, pp. 71-78, (2006); Song J., Zhang L., Bai T., Et al., Mast cell-dependent mesenteric afferent activation by mucosal supernatant from different bowel segments of guinea pigs with post-infectious irritable bowel syndrome, J Neurogastroenterol Motil, 21, pp. 236-246, (2015); Dothel G., Barbaro M.R., Boudin H., Et al., Nerve fiber outgrowth is increased in the intestinal mucosa of patients with irritable bowel syndrome, Gastroenterology, 148, (2015); Long Y., Du L., Kim J.J., Et al., MLCK-mediated intestinal permeability promotes immune activation and visceral hypersensitivity in PI-IBS mice, Neurogastroenterol Motil, 30, (2018); Liu Q., Weng H.J., Patel K.N., Et al., The distinct roles of two GPCRs, MrgprC11 and PAR2, in itch and hyperalgesia, Sci Signal, 4, (2011); Hockley J.R.F., Taylor T.S., Callejo G., Et al., Single-cell RNAseq reveals seven classes of colonic sensory neuron, Gut, pp. 1-12, (2018); Langford D.J., Bailey A.L., Chanda M.L., Et al., Coding of facial expressions of pain in the laboratory mouse, Nat Methods, 7, pp. 447-449, (2010); Christianson J.A., Gebhart G.F., Assessment of colon sensitivity by luminal distension in mice, Nat Protoc, 2, pp. 2624-2631, (2007); Klem F., Wadhwa A., Prokop L.J., Et al., Prevalence, risk factors, and outcomes of irritable bowel syndrome after infectious enteritis: a systematic review and meta-analysis, Gastroenterology, 152, (2017); Heitkemper M.M., Chang L., Do fluctuations in ovarian hormones affect gastrointestinal symptoms in women with irritable bowel syndrome?, Gend Med, 6, pp. 152-167, (2009)","Y. Long; Department of Gastroenterology, School of Medicine, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, 310016, China; email: longyanqin@zju.edu.cn","","Springer New York LLC","","","","","","01632116","","DDSCD","30446929","English","Dig. Dis. Sci.","Article","Final","","Scopus","2-s2.0-85056654571"

"Hou Q.; Huang Y.; Wang Y.; Liao L.; Zhu Z.; Zhang W.; Liu Y.; Li P.; Chen X.; Liu F.","Hou, Qiuke (35573727700); Huang, Yongquan (57195074253); Wang, Yan (57218600505); Liao, Liu (57212027253); Zhu, Zhaoyang (57212018121); Zhang, Wenjie (57219718771); Liu, Yongshang (57219719424); Li, Peiwu (55757309300); Chen, Xinlin (55357650100); Liu, Fengbin (55799656200)","35573727700; 57195074253; 57218600505; 57212027253; 57212018121; 57219718771; 57219719424; 55757309300; 55357650100; 55799656200","Lactobacillus casei LC01 regulates intestinal epithelial permeability through miR-144 targeting of OCLN and ZO1","2020","Journal of Microbiology and Biotechnology","30","10","","1480","1487","7","18","10.4014/JMB.2002.02059","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85094933430&doi=10.4014%2fJMB.2002.02059&partnerID=40&md5=237eace54d3172f9566d6acc246d43a9","Department of Gastroenterology, First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510176, China; School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, Hong Kong; Department of Orthopedics, Guangzhou University of Chinese Medicine, Guangzhou, 510176, China; Department of Preventive Medicine and Health Statistics, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, 510176, China","Hou Q., Department of Gastroenterology, First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510176, China, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, Hong Kong; Huang Y., Department of Orthopedics, Guangzhou University of Chinese Medicine, Guangzhou, 510176, China; Wang Y., Department of Gastroenterology, First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510176, China; Liao L., Department of Gastroenterology, First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510176, China; Zhu Z., Department of Gastroenterology, First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510176, China; Zhang W., Department of Gastroenterology, First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510176, China; Liu Y., Department of Gastroenterology, First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510176, China; Li P., Department of Gastroenterology, First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510176, China; Chen X., Department of Preventive Medicine and Health Statistics, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, 510176, China; Liu F., Department of Gastroenterology, First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510176, China","Our previous report determined that miR-144 is a key regulator of intestinal epithelial permeability in irritable bowel syndrome with diarrhea (IBS-D) rats. Recent evidence has shown that lactobacilli play an important role in the relief of IBS-D symptoms. However, few studies have addressed the mechanisms by which microRNAs and lactobacilli exert their beneficial effects on intestinal epithelial permeability. Hence, to elucidate whether miRNAs and lactobacilli play roles in intestinal epithelial barrier regulation, we compared miRNA expression levels in intestinal epithelial cells (IECs) under Lactobacillus casei (L. casei LC01) treatment. IECs and L. casei LC01 were co-cultured and then subjected to microRNA microarray assay. qRT-PCR, western blot and ELISA were used to detect the expression of occludin (OCLN) and zonula occludens 1 (ZO1/TJP1). The interaction between miRNAs and L. casei LC01 acting in IECs was investigated through transfection of RNA oligoribonucleotides and pcDNA 3.1 plasmid. The results are as follows: 1) L. casei LC01 decreased the expression of miR-144 and FD4 and promoted OCLN and ZO1 expression in IECs; 2) L. casei LC01 enhanced the barrier function of IECs via downregulation of miR-144 and upregulation of OCLN and ZO1; 3) Under L. casei LC01 treatment, OCLN and ZO1 overexpression could partially eliminate the promoting effect of miR-144 on intestinal permeability in IECs. Our results demonstrate that L. casei LC01 regulates intestinal permeability of IECs through miR-144 targeting of OCLN and ZO1. L. casei LC01 can be a possible therapeutic target for managing dysfunction of the intestinal epithelial barrier. Copyright© 2020 by The Korean Society for Microbiology and Biotechnology","Intestinal epithelial permeability; Lactobacilli; MiR-144; Occludin (OCLN); Zonula occludens 1 (ZO1/TJP1)","Animals; Cell Line; Epithelial Cells; Gene Expression Regulation; Humans; Intestinal Mucosa; Intestines; Irritable Bowel Syndrome; Lactobacillus casei; MicroRNAs; Occludin; Permeability; Rats; Zonula Occludens-1 Protein; DNA; microRNA; microRNA 144; occludin; oligoribonucleotide; protein ZO1; unclassified drug; microRNA; MIRN144 microRNA, rat; occludin; Ocln protein, rat; protein ZO1; Tjp1 protein, rat; Article; coculture; controlled study; diarrhea; down regulation; enzyme linked immunosorbent assay; gene targeting; human; human cell; intestine epithelium; intestine mucosa permeability; irritable colon; Lactobacillus casei; microarray analysis; protein protein interaction; reverse transcription polymerase chain reaction; upregulation; Western blotting; animal; cell line; epithelium cell; gene expression regulation; genetics; intestine; intestine mucosa; irritable colon; Lactobacillus casei; metabolism; permeability; rat","","DNA, 9007-49-2; occludin, 176304-61-3; MicroRNAs, ; MIRN144 microRNA, rat, ; Occludin, ; Ocln protein, rat, ; Tjp1 protein, rat, ; Zonula Occludens-1 Protein, ","","","Guangzhou University of Traditional Chinese Medicine's first-class discipline research key project, (A1-AFD018191A16); Innovative Research Team Project of “Innovative Strong Institute; National Natural Science Foundation, (81804047); Guangdong Provincial Hospital of Traditional Chinese Medicine, (20181095, XJ2018059); Guangzhou University of Chinese Medicine, GUCM, (2017TD05)","This study was supported by the National Natural Science Foundation (No. 81804047), Guangdong Provincial Traditional Chinese Medicine Research Project (No. 20181095), Hong Kong Scholar Program (XJ2018059), Innovative Research Team Project of “Innovative Strong Institute”, the First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine (2017TD05) and Guangzhou University of Traditional Chinese Medicine's first-class discipline research key project (A1-AFD018191A16).","Quigley E., Gut permeability in irritable bowel syndrome: More leaks add to slightly inflamed bowel syndrome conspiracy theory, Gastroenterology, 137, pp. 728-730, (2009); Gracie DJ, Ford AC., Irritable bowel syndrome-type symptoms are associated with psychological comorbidity, reduced quality of life, and health care use in patients with inflammatory bowel disease, Gastroenterology, 153, pp. 324-325, (2017); Spiller R, Garsed K., Postinfectious irritable bowel syndrome, Gastroenterology, 136, pp. 1979-1988, (2009); Orr WC, Crowell MD, Lin B, Harnish MJ, Chen JD., Sleep and gastric function in irritable bowel syndrome: derailing the brain-gut axis, Gut, 41, pp. 390-393, (1997); Botschuijver S, Roeselers G, Levin E, Jonkers DM, Welting O, Heinsbroek SEM, Et al., Intestinal fungal dysbiosis is associated with visceral hypersensitivity in patients with irritable bowel syndrome and rats, Gastroenterology, 153, pp. 1026-1039, (2017); Kellow JE, Phillips SF, Miller LJ, Zinsmeister AR., Dysmotility of the small intestine in irritable bowel syndrome, Gut, 29, pp. 1236-1243, (1988); Sasaki D, Sutoh T, Abe T., Psychosomatic treatment of irritable bowel syndrome, Nihon Rinsho, 50, pp. 2758-2763, (1992); Drossman DA, McKee DC, Sandler RS, Mitchell CM, Cramer EM, Lowman BC, Et al., Psychosocial factors in the irritable bowel syndrome. A multivariate study of patients and nonpatients with irritable bowel syndrome, Gastroenterology, 95, pp. 701-708, (1988); Zhang H, Sun J, Liu X, Hong C, Zhu Y, Liu A, Et al., Lactobacillus paracasei subsp. Paracasei lc01 positively modulates intestinal microflora in healthy young adults, J. Microbiol, 51, pp. 777-782, (2013); Zhang H, Wang Y, Sun J, Guo Z, Guo H, Ren F., Safety evaluation of Lactobacillus paracasei subsp. paracasei LC-01, a probiotic bacterium, J. Microbiol, 51, pp. 633-638, (2013); Pahumunto N, Sophatha B, Piwat S, Teanpaisan R., Increasing salivary IgA and reducing Streptococcus mutans by probiotic Lactobacillus paracasei SD1: A double-blind, randomized, controlled study, J. Dent Sci, 14, pp. 178-184, (2019); Marttinen AM, Haukioja AL, Keskin M, Soderling EM., Effects of Lactobacillus reuteri PTA 5289 and L. paracasei DSMZ16671 on the adhesion and biofilm formation of Streptococcus mutans, Curr. Microbiol, 67, pp. 193-199, (2013); Zhou Q, Verne GN., Mirna-based therapies for the irritable bowel syndrome, Expert Opin. Biol. Ther, 11, pp. 991-995, (2011); Zhou Q, Souba WW, Croce CM, Verne GN., Microrna-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome, Gut, 59, pp. 775-784, (2010); Ye D, Guo S, Al-Sadi R, Ma TY., Microrna regulation of intestinal epithelial tight junction permeability, Gastroenterology, 141, pp. 1323-1333, (2011); Zhang L, Shen J, Cheng J, Fan X., MicroRNA-21 regulates intestinal epithelial tight junction permeability, Cell Biochem. Funct, 33, pp. 235-240, (2015); Hou Q, Huang Y, Zhu S, Li P, Chen X, Hou Z, Et al., MiR-144 increases intestinal permeability in IBS-D rats by targeting OCLN and ZO1, Cell Physiol. Biochem, 44, pp. 2256-2268, (2017); Compare D, Rocco A, Coccoli P, Angrisani D, Sgamato C, Iovine B, Et al., Lactobacillus casei dg and its postbiotic reduce the inflammatory mucosal response: an ex-vivo organ culture model of post-infectious irritable bowel syndrome, BMC Gastroenterol, 17, (2017); Lin X, Chen X, Tu Y, Wang S, Chen H., Effect of probiotic lactobacilli on the growth of streptococcus mutans and multispecies biofilms isolated from children with active caries, Med. Sci. Monit, 23, pp. 4175-4181, (2017); Williams MR, Stedtfeld RD, Tiedje JM, Hashsham SA., Micrornas-based inter-domain communication between the host and members of the gut microbiome, Front. Microbiol, 8, (2017); Singh N, Shirdel EA, Waldron L, Zhang RH, Jurisica I, Comelli EM., The murine caecal microrna signature depends on the presence of the endogenous microbiota, Int. J. Biol. Sci, 8, pp. 171-186, (2012); Dalmasso G, Nguyen HT, Yan Y, Laroui H, Charania MA, Ayyadurai S, Et al., Microbiota modulate host gene expression via micrornas, PLoS One, 6, (2011); Peterson LW, Artis D., Intestinalepithelialcells:regulatorsofbarrierfunctionandimmunehomeostasis, Nat.Rev.Immunol, 14, pp. 141-153, (2014); Pruteanu M, Shanahan F., Digestion of epithelial tight junction proteins by the commensal clostridium perfringens, Am. J. Physiol. Gastrointest. Liver Physiol, 305, pp. G740-G748, (2013); Liu C, Duan Z, Guan Y, Wu H, Hu K, Gao X, Et al., Increased expression of tight junction protein occludin is associated with the protective effect of mosapride against aspirin-induced gastric injury, Exp. Ther. Med, 15, pp. 1626-1632, (2018); Ye L, Martin TA, Parr C, Harrison GM, Mansel RE, Jiang WG., Biphasic effects of 17-beta-estradiol on expression of occludin and transendothelial resistance and paracellular permeability in human vascular endothelial cells, J. Cell. Physiol, 196, pp. 362-369, (2003); Caswell D, Jaggi S, Axis J, Amsler K., Src family kinases regulate renal epithelial paracellular permeability barrier through an occludin-independent mechanism, J. Cell. Physiol, 228, pp. 1210-1220, (2013); Buret AG, Mitchell K, Muench DG, Scott KG., Giardia lamblia disrupts tight junctional zo-1 and increases permeability in non-transformed human small intestinal epithelial monolayers: effects of epidermal growth factor, Parasitology, 125, pp. 11-19, (2002); Cario E, Gerken G, Podolsky DK., Toll-like receptor 2 enhances zo-1-associated intestinal epithelial barrier integrity via protein kinase c, Gastroenterology, 127, pp. 224-238, (2004)","F. Liu; Department of Gastroenterology, First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510176, China; email: liufb163@126.com","","Korean Society for Microbiolog and Biotechnology","","","","","","10177825","","JOMBE","32807750","English","J. Microbiol. Biotechnol.","Article","Final","All Open Access; Bronze Open Access; Green Open Access","Scopus","2-s2.0-85094933430"

"Bonfrate L.; Di Palo D.M.; Celano G.; Albert A.; Vitellio P.; De Angelis M.; Gobbetti M.; Portincasa P.","Bonfrate, Leonilde (34871403600); Di Palo, Domenica M. (57201761977); Celano, Giuseppe (56347019400); Albert, Adelin (7202794939); Vitellio, Paola (57208562405); De Angelis, Maria (7102614438); Gobbetti, Marco (7005775302); Portincasa, Piero (7007157491)","34871403600; 57201761977; 56347019400; 7202794939; 57208562405; 7102614438; 7005775302; 7007157491","Effects of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 in IBS patients","2020","European Journal of Clinical Investigation","50","3","e13201","","","","76","10.1111/eci.13201","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85079394559&doi=10.1111%2feci.13201&partnerID=40&md5=2b2de29e7945d4007a6ba97f0bddc71c","Clinica Medica “A. Murri”, Department of Biomedical Sciences & Human Oncology, University of Bari Medical School, Bari, Italy; Department of Soil, Plant and Food Sciences, Università degli Studi di Bari Aldo Moro, Bari, Italy; Department of Biostatistics, University Hospital of Liège, Liège, Belgium; Faculty of Science and Technology, Free University of Bolzano, Bolzano, Italy","Bonfrate L., Clinica Medica “A. Murri”, Department of Biomedical Sciences & Human Oncology, University of Bari Medical School, Bari, Italy; Di Palo D.M., Clinica Medica “A. Murri”, Department of Biomedical Sciences & Human Oncology, University of Bari Medical School, Bari, Italy, Department of Soil, Plant and Food Sciences, Università degli Studi di Bari Aldo Moro, Bari, Italy; Celano G., Department of Soil, Plant and Food Sciences, Università degli Studi di Bari Aldo Moro, Bari, Italy; Albert A., Department of Biostatistics, University Hospital of Liège, Liège, Belgium; Vitellio P., Clinica Medica “A. Murri”, Department of Biomedical Sciences & Human Oncology, University of Bari Medical School, Bari, Italy, Department of Soil, Plant and Food Sciences, Università degli Studi di Bari Aldo Moro, Bari, Italy; De Angelis M., Department of Soil, Plant and Food Sciences, Università degli Studi di Bari Aldo Moro, Bari, Italy; Gobbetti M., Faculty of Science and Technology, Free University of Bolzano, Bolzano, Italy; Portincasa P., Clinica Medica “A. Murri”, Department of Biomedical Sciences & Human Oncology, University of Bari Medical School, Bari, Italy","Background: Irritable bowel syndrome (IBS) is a common gastrointestinal disorder, which still lacks effective therapy. We aimed to investigate the effects of a novel formulation of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 with vitamin B6 (LBB) on symptoms, intestinal permeability, cultivable bacteria and metabolome in IBS subjects. Materials and methods: Twenty-five IBS patients (Rome IV criteria) (M:F = 8:17; age 48 years ± 11 SD) were randomized to treatment (LBB) or placebo (one month each) in a crossover randomized double-blind controlled trial. Symptoms, intestinal habits, disease severity, intestinal permeability and intestinal microbiota were analysed at 0, 30, 45 and 60 days. Results: Percentage decrease from baseline of abdominal pain (−48.8% vs −3.5%), bloating (−36.35% vs +7.35%) and severity of disease (−30.1% vs −0.4%) was significantly (P <.0001) greater with LBB than placebo, respectively. In IBS-D patients, the improvement from baseline of Bristol score was more consistent with LBB (from 6 ± 0.4 to 4.3 ± 1.1, P <.00001) than placebo (from 6.2 ± 0.7 to 5.3 ± 1.1, P =.04). In IBS-C patients, Bristol score tended to improve from baseline after LBB (2.6 ± 1.1 vs 3.2 ± 0.5, P =.06). LBB significantly improved the percentage of sucralose recovery (colonic permeability) (1.86 ± 0.1 vs 1.1 ± 0.2, P =.01). During treatment, presumptive lactic acid bacteria and bifidobacteria, relative abundance of propanoic, butanoic, pentanoic acids and hydrocarbons increased, while phenol decreased. Conclusions: The novel formulation of B. longum BB536 and L. rhamnosus HN001 with B6 vitamin improves symptoms and severity of disease, restores intestinal permeability and gut microbiota in IBS patients. © 2020 Stichting European Society for Clinical Investigation Journal Foundation","abdominal pain; bloating; functional gastrointestinal disorders; randomized placebo-controlled study","Adult; Bifidobacterium longum; Double-Blind Method; Female; Gastrointestinal Microbiome; Humans; Irritable Bowel Syndrome; Lactobacillus rhamnosus; Male; Metabolome; Middle Aged; butyric acid; hydrocarbon; phenol; placebo; propionic acid; pyridoxine; sucralose; valeric acid derivative; abdominal pain; adult; Article; Bifidobacteriaceae; Bifidobacterium longum; bloating; clinical article; controlled study; crossover procedure; disease severity; female; human; intestine flora; intestine mucosa permeability; irritable colon; lactic acid bacterium; Lactobacillus rhamnosus; male; metabolome; middle aged; nonhuman; population abundance; priority journal; randomized controlled trial; double blind procedure; irritable colon; microbiology","","butyric acid, 107-92-6, 156-54-7, 461-55-2; phenol, 108-95-2, 3229-70-7; propionic acid, 72-03-7, 79-09-4; pyridoxine, 12001-77-3, 58-56-0, 65-23-6, 8059-24-3; sucralose, 56038-13-2","","","Alfasigma S.p.A.","Alfasigma S.p.A. (Milano, Italy) provided the packets containing Zircombi® (LBB) and placebo.","Lovell R.M., Ford A.C., Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis, Clin Gastroenterol Hepatol, 10, 7, pp. 712-721, (2012); Lacy B.E., Mearin F., Chang L., Et al., Bowel Disorders, Gastroenterology, 150, 6, pp. 1393-1407, (2016); Bonfrate L., Tack J., Grattagliano I., Cuomo R., Portincasa P., Microbiota in health and irritable bowel syndrome: current knowledge, perspectives and therapeutic options, Scand J Gastroenterol, 48, 9, pp. 995-1009, (2013); Camilleri M., Peripheral mechanisms in irritable bowel syndrome, N Engl J Med, 367, 17, pp. 1626-1635, (2012); Hill C., Guarner F., Reid G., Et al., Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic, Nat Rev Gastroenterol Hepatol, 11, 8, (2014); Markowiak P., Slizewska K., Effects of probiotics, prebiotics, and synbiotics on human health, Nutrients, 9, 9, (2017); Milani C., Lugli G.A., Duranti S., Et al., Bifidobacteria exhibit social behavior through carbohydrate resource sharing in the gut, Sci Rep, 5, (2015); Akatsu H., Iwabuchi N., Xiao J.Z., Et al., Clinical effects of probiotic Bifidobacterium longum BB536 on immune function and intestinal microbiota in elderly patients receiving enteral tube feeding, JPEN J Parenter Enteral Nutr, 37, 5, pp. 631-640, (2013); Falony G., Vlachou A., Verbrugghe K., De Vuyst L., Cross-feeding between Bifidobacterium longum BB536 and acetate-converting, butyrate-producing colon bacteria during growth on oligofructose, Appl Environ Microbiol, 72, 12, pp. 7835-7841, (2006); Khailova L., Petrie B., Baird C.H., Dominguez Rieg J.A., Wischmeyer P.E., Lactobacillus rhamnosus GG and Bifidobacterium longum attenuate lung injury and inflammatory response in experimental sepsis, PLoS ONE, 9, 5, (2014); Toscano M., De Grandi R., Stronati L., De Vecchi E., Drago L., Effect of Lactobacillus rhamnosus HN001 and Bifidobacterium longum BB536 on the healthy gut microbiota composition at phyla and species level: A preliminary study, World J Gastroenterol, 23, 15, (2017); Parra M., Stahl S., Hellmann H., Vitamin B(6) and its role in cell metabolism and physiology, Cells, 7, 7, (2018); Qian B., Shen S., Zhang J., Jing P., Effects of vitamin B6 deficiency on the composition and functional potential of T cell populations, J Immunol Res, 2017, (2017); Bonfrate L., Krawczyk M., Lembo A., Grattagliano I., Lammert F., Portincasa P., Effects of dietary education, followed by a tailored fructose-restricted diet in adults with fructose malabsorption, Eur J Gastroenterol Hepatol, 27, 7, pp. 785-796, (2015); Francis C.Y., Morris J., Whorwell P.J., The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress, Aliment Pharmacol Ther, 11, 2, pp. 395-402, (1997); O'Donnell L.J., Virjee J., Heaton K.W., Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate, BMJ, 300, 6722, pp. 439-440, (1990); Sofi F., Macchi C., Abbate R., Gensini G.F., Casini A., Mediterranean diet and health status: an updated meta-analysis and a proposal for a literature-based adherence score, Public Health Nutr, 17, 12, pp. 2769-2782, (2014); Del Valle-Pinero A.Y., Van Deventer H.E., Fourie N.H., Et al., Gastrointestinal permeability in patients with irritable bowel syndrome assessed using a four probe permeability solution, Clin Chim Acta, 418, pp. 97-101, (2013); De Angelis M., Piccolo M., Vannini L., Et al., Fecal microbiota and metabolome of children with autism and pervasive developmental disorder not otherwise specified, PLoS ONE, 8, 10, (2013); De Angelis M., Montemurno E., Vannini L., Et al., Effect of whole-grain barley on the human fecal microbiota and metabolome, Appl Environ Microbiol, 81, 22, pp. 7945-7956, (2015); Zak J., Willig M., Moorhead D., Wildman H., Functional diversity of microbial communities: A quantitative approach, Soil Biol Biochem, 26, 9, pp. 1101-1108, (1994); Hintze J., NCSS 10 Statistical Software, (2015); Zeng J., Li Y.Q., Zuo X.L., Zhen Y.B., Yang J., Liu C.H., Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome, Aliment Pharmacol Ther, 28, 8, pp. 994-1002, (2008); Bogovic Matijasic B., Obermajer T., Lipoglavsek L., Et al., Effects of synbiotic fermented milk containing Lactobacillus acidophilus La-5 and Bifidobacterium animalis ssp. lactis BB-12 on the fecal microbiota of adults with irritable bowel syndrome: A randomized double-blind, placebo-controlled trial, J Dairy Sci, 99, 7, pp. 5008-5021, (2016); O'Sullivan M.A., O'Morain C.A., Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study, Dig Liver Dis, 32, 4, pp. 294-301, (2000); Whorwell P.J., Altringer L., Morel J., Et al., Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome, Am J Gastroenterol, 101, 7, pp. 1581-1590, (2006); Brenner D.M., Moeller M.J., Chey W.D., Schoenfeld P.S., The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review, Am J Gastroenterol, 104, 4, pp. 1033-1049, (2009); Giannetti E., Maglione M., Alessandrella A., Et al., A mixture of 3 bifidobacteria decreases abdominal pain and improves the quality of life in children with irritable bowel syndrome, J Clin Gastroenterol, 51, 1, pp. e5-e10, (2017); Irvine E.J., Tack J., Crowell M.D., Et al., Design of treatment trials for functional gastrointestinal disorders, Gastroenterology, 150, 6, pp. 1469-1480, (2016); Ringel Y., Carroll I.M., Alterations in the intestinal microbiota and functional bowel symptoms, Gastrointest Endosc Clin N Am, 19, 1, pp. 141-150, (2009); Piche T., Tight junctions and IBS–the link between epithelial permeability, low-grade inflammation, and symptom generation?, Neurogastroenterol Motil, 26, 3, pp. 296-302, (2014); Nebot-Vivinus M., Harkat C., Bzioueche H., Et al., Multispecies probiotic protects gut barrier function in experimental models, World J Gastroenterol, 20, 22, pp. 6832-6843, (2014); Agostini S., Goubern M., Tondereau V., Et al., A marketed fermented dairy product containing Bifidobacterium lactis CNCM I-2494 suppresses gut hypersensitivity and colonic barrier disruption induced by acute stress in rats, Neurogastroenterol Motil, 24, 4, (2012); Rosenberg J., Ischebeck T., Commichau F.M., Vitamin B6 metabolism in microbes and approaches for fermentative production, Biotechnol Adv, 35, 1, pp. 31-40, (2017); Pinto-Sanchez M.I., Hall G.B., Ghajar K., Et al., Probiotic bifidobacterium longum NCC3001 reduces depression scores and alters brain activity: a pilot study in patients with irritable bowel syndrome, Gastroenterology, 153, 2, pp. 448-459, (2017); Ahmed I., Greenwood R., Costello Bde L., Ratcliffe N.M., Probert C.S., An investigation of fecal volatile organic metabolites in irritable bowel syndrome, PLoS ONE, 8, 3, (2013); Portincasa P., Bonfrate L., de Bari O., Lembo A., Ballou S., Irritable bowel syndrome and diet, Gastroenterol Rep (Oxf), 5, 1, pp. 11-19, (2017); Duncan S.H., Louis P., Flint H.J., Lactate-utilizing bacteria, isolated from human feces, that produce butyrate as a major fermentation product, Appl Environ Microbiol, 70, 10, pp. 5810-5817, (2004); De Filippis F., Pellegrini N., Vannini L., Et al., High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome, Gut, 65, 11, pp. 1812-1821, (2016); Ahmed I., Greenwood R., Costello B., Ratcliffe N., Probert C.S., Investigation of faecal volatile organic metabolites as novel diagnostic biomarkers in inflammatory bowel disease, Aliment Pharmacol Ther, 43, 5, pp. 596-611, (2016)","P. Portincasa; Clinica Medica “A. Murri”, Department of Biomedical Sciences & Human Oncology, University of Bari Medical School, Bari, Italy; email: piero.portincasa@uniba.it","","Blackwell Publishing Ltd","","","","","","00142972","","EJCIB","31960952","English","Eur. J. Clin. Invest.","Article","Final","","Scopus","2-s2.0-85079394559"

"Prospero L.; Riezzo G.; Linsalata M.; Orlando A.; D’Attoma B.; Di Masi M.; Martulli M.; Russo F.","Prospero, Laura (57207799778); Riezzo, Giuseppe (7004144336); Linsalata, Michele (6603600075); Orlando, Antonella (23767683100); D’Attoma, Benedetta (57205751185); Di Masi, Marta (6506805689); Martulli, Manuela (36437204300); Russo, Francesco (59133987100)","57207799778; 7004144336; 6603600075; 23767683100; 57205751185; 6506805689; 36437204300; 59133987100","Somatization in patients with predominant diarrhoea irritable bowel syndrome: the role of the intestinal barrier function and integrity","2021","BMC Gastroenterology","21","1","235","","","","7","10.1186/s12876-021-01820-7","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85106719397&doi=10.1186%2fs12876-021-01820-7&partnerID=40&md5=003e0b41b049da995dd456b4db84413d","Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Via Turi 27, Castellana Grotte, 70013, BA, Italy; Scientific Direction, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte, 70013, BA, Italy","Prospero L., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Via Turi 27, Castellana Grotte, 70013, BA, Italy; Riezzo G., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Via Turi 27, Castellana Grotte, 70013, BA, Italy; Linsalata M., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Via Turi 27, Castellana Grotte, 70013, BA, Italy; Orlando A., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Via Turi 27, Castellana Grotte, 70013, BA, Italy; D’Attoma B., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Via Turi 27, Castellana Grotte, 70013, BA, Italy; Di Masi M., Scientific Direction, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte, 70013, BA, Italy; Martulli M., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Via Turi 27, Castellana Grotte, 70013, BA, Italy; Russo F., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Via Turi 27, Castellana Grotte, 70013, BA, Italy","Background: Irritable bowel syndrome (IBS) is characterised by gastrointestinal (GI) and psychological symptoms (e.g., depression, anxiety, and somatization). Depression and anxiety, but not somatization, have already been associated with altered intestinal barrier function, increased LPS, and dysbiosis. The study aimed to investigate the possible link between somatization and intestinal barrier in IBS with diarrhoea (IBS-D) patients. Methods: Forty-seven IBS-D patients were classified as having low somatization (LS = 19) or high somatization (HS = 28) according to the Symptom Checklist-90-Revised (SCL-90-R), (cut-off score = 63). The IBS Severity Scoring System (IBS-SSS) and the Gastrointestinal Symptom Rating Scale (GSRS) questionnaires were administered to evaluate GI symptoms. The intestinal barrier function was studied by the lactulose/mannitol absorption test, faecal and serum zonulin, serum intestinal fatty-acid binding protein, and diamine oxidase. Inflammation was assessed by assaying serum Interleukins (IL-6, IL-8, IL-10), and tumour necrosis factor-α. Dysbiosis was assessed by the urinary concentrations of indole and skatole and serum lipopolysaccharide (LPS). All data were analysed using a non-parametric test. Results: The GI symptoms profiles were significantly more severe, both as a single symptom and as clusters of IBS-SSS and GSRS, in HS than LS patients. This finding was associated with impaired small intestinal permeability and increased faecal zonulin levels. Besides, HS patients showed significantly higher IL-8 and lowered IL-10 concentrations than LS patients. Lastly, circulating LPS levels and the urinary concentrations of indole were higher in HS than LS ones, suggesting a more pronounced imbalance of the small intestine in the former patients. Conclusions: IBS is a multifactorial disorder needing complete clinical, psychological, and biochemical evaluations. Trial registration: https://clinicaltrials.gov/ct2/show/NCT03423069. © 2021, The Author(s).","Dysbiosis; Inflammation; Intestinal permeability; Irritable bowel syndrome; Somatization; Symptom questionnaire","Anxiety; Diarrhea; Gastrointestinal Diseases; Humans; Irritable Bowel Syndrome; Surveys and Questionnaires; amine oxidase (copper containing); cell protein; fatty acid binding protein 2; indole; interleukin 10; interleukin 6; interleukin 8; lactulose; lipopolysaccharide; mannitol; skatole; tumor necrosis factor; unclassified drug; zonulin; absorption; adult; Article; clinical article; cluster analysis; controlled study; diarrhea; dysbiosis; female; gastrointestinal symptom rating scale; human; irritable colon; kidney concentrating capacity; male; permeability barrier; protein blood level; rating scale; scoring system; somatization; Symptom Checklist 90-Revised; symptomatology; anxiety; complication; diarrhea; gastrointestinal disease; questionnaire","","amine oxidase (copper containing), 9001-53-0, 9014-75-9; indole, 120-72-9; interleukin 8, 114308-91-7; lactulose, 4618-18-2; mannitol, 69-65-8, 87-78-5; skatole, 83-34-1","","","Italian Ministry of Health RC 2020","Project supported by Italian Ministry of Health RC 2020–2021, Prog. N° 16 (D.D.G. n. 700/2020). ","Mearin F., Lacy B.E., Chang L., Et al., Bowel disorders, Gastroenterology, 150, pp. 1393-1407, (2016); Lydiard R.B., Falsetti S.A., Experience with anxiety and depression treatment studies: implications for designing irritable bowel syndrome clinical trials, Am J Med, 107, pp. 65S-73S, (1999); Johannes P., Fournier C., Durdevic M., Et al., A microbial signature of psychological distress in irritable bowel syndrome, Psychosom Med, 80, pp. 698-709, (2018); Barsky A.J., Borus J.F., Functional somatic syndromes, Ann Intern Med, 130, pp. 910-921, (1999); Clouse R.E., Lustman P.J., Use of psychopharmacological agents for functional gastrointestinal disorders, Gut, 54, pp. 1332-1341, (2005); Lipowski Z.J., Somatization: the concept and its clinical application, Am J Psychiatry, 145, pp. 1358-1368, (1988); Williams A.E., Czyzewski D.I., Self M.M., Shulman R.J., Are child anxiety and somatization associated with pain in pain-related functional gastrointestinal disorders?, J Health Psychol, 20, pp. 369-379, (2015); Hausteiner-Wiehle C., Henningsen P., Irritable bowel syndrome: relations with functional, mental, and somatoform disorders, World J Gastroenterol, 20, pp. 6024-6030, (2014); Heinrich T.W., Medically unexplained symptoms and the concept of somatization, WMJ, 103, pp. 83-87, (2004); Ketterer M.W., Buckholtz C.D., Somatization disorder, J Am Osteopath Assoc, 89, 489-90, pp. 495-499, (1989); Diagnostic and statistical manual of mental disorders, (2013); North C.S., Hong B.A., Alpers D.H., Relationship of functional gastrointestinal disorders and psychiatric disorders: implications for treatment, World J Gastroenterol, 13, pp. 2020-2027, (2007); North C.S., Downs D., Clouse R.E., Et al., The presentation of irritable bowel syndrome in the context of somatization disorder, Clin Gastroenterol Hepatol, 2, pp. 787-795, (2004); Miller A.R., North C.S., Clouse R.E., Wetzel R.D., Spitznagel E.L., Alpers D.H., The association of irritable bowel syndrome and somatization disorder, Ann Clin Psychiatry, 13, pp. 25-30, (2001); Arsie E., Coletta M., Cesana B.M., Basilisco G., Symptom-association probability between meal ingestion and abdominal pain in patients with irritable bowel syndrome. Does somatization play a role?, Neurogastroenterol Motil, 27, pp. 416-422, (2015); Hollier J.M., Van Tilburg M.A.L., Liu Y., Et al., Multiple psychological factors predict abdominal pain severity in children with irritable bowel syndrome, Neurogastroenterol Motil, 31, (2019); Wells J.M., Brummer R.J., Derrien M., Et al., Homeostasis of the gut barrier and potential biomarkers, Am J Physiol Gastrointest Liver Physiol, 312, pp. G171-G193, (2017); Khan I., Ullah N., Zha L., Et al., Alteration of gut microbiota in inflammatory bowel disease (IBD): cause or consequence? IBD treatment targeting the gut microbiome, Pathogens, 8, pp. 126-129, (2019); Stevens B.R., Goel R., Seungbum K., Et al., Increased human intestinal barrier permeability plasma biomarkers zonulin and FABP2 correlated with plasma LPS and altered gut microbiome in anxiety or depression, Gut, 67, pp. 1555-1557, (2018); Dunlop S.P., Coleman N.S., Blackshaw E., Et al., Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome, Clin Gastroenterol Hepatol, 3, pp. 349-357, (2005); Wang P., Chen F., Du C., Et al., Increased production of BDNF in colonic epithelial cells induced by fecal supernatants from diarrheic IBS patients, Sci Rep, 5, (2015); Liebregts T., Adam B., Bredack C., Et al., Immune activation in patients with irritable bowel syndrome, Gastroenterology, 132, pp. 913-920, (2007); Konturek P.C., Konturek K., Brzozowski T., Et al., Participation of the intestinal microbiota in the mechanism of beneficial effect of treatment with symbiotic Syngut on experimental colitis under stress conditions, J Physiol Pharmacol, 71, pp. 329-343, (2020); Bashier Eltayeb L., Shams D., Babikr N., Madani M., Abdelghani S., Ali W.H., Serum levels of interferon gamma INF-γ and interleukin 10 Il-10: an immunological aspect among irritable bowel syndrome patients, Pak J Biol Sci, 23, pp. 898-903, (2020); Chang L., Sundaresh S., Elliott J., Et al., Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis in irritable bowel syndrome, Neurogastroenterol Motil, 21, pp. 149-159, (2009); Eriksson E.M., Andren K.I., Eriksson H.T., Kurlberg G.K., Irritable bowel syndrome subtypes differ in body awareness, psychological symptoms and biochemical stress markers, World J Gastroenterol, 14, pp. 4889-4896, (2008); Linsalata M., Riezzo G., D'Attoma B., Clemente C., Orlando A., Russo F., Noninvasive biomarkers of gut barrier function identify two subtypes of patients suffering from diarrhoea predominant-IBS: a case-control study, BMC Gastroenterol, 18, (2018); Schmulson M., Lee O.Y., Chang L., Naliboff B., Mayer E.A., Symptom differences in moderate to severe IBS patients based on predominant bowel habit, Am J Gastroenterol, 94, pp. 2929-2935, (1999); Kulich K.R., Madisch A., Pacini F., Et al., Reliability and validity of the Gastrointestinal Symptom Rating Scale (GSRS) and Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire in dyspepsia: a six-country study, Health Qual Life Outcomes, 6, (2008); Verdu E.F., Armstrong D., Murray J.A., Between celiac disease and irritable bowel syndrome: the “no man's land” of gluten sensitivity, Am J Gastroenterol, 104, pp. 1587-1594, (2009); Derogatis L.R., Lipman R.S., Covi L., SCL-90: an outpatient psychiatric rating scale-preliminary report, Psychopharmacol Bull, 9, pp. 13-28, (1973); Hildenbrand A.K., Nicholls E.G., Aggarwall R., Brody-Bizar E., Daly B.P., Symptom Checklist-90-Revised (SCL-90-R), The encyclopedia of clinical psychology, pp. 1-5, (2015); Jensen H.H., Mortensen E.L., Lotz M., Scl-90-R symptom profiles and outcome of short-term psychodynamic group therapy, ISRN Psychiatry, 2013, (2013); Francis C.Y., Morris J., Whorwell P.J., The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress, Aliment Pharmacol Ther, 11, pp. 395-402, (1997); Miller L.E., Study design considerations for irritable bowel syndrome clinical trials, Ann Gastroenterol, 27, pp. 338-345, (2014); Russo F., Chimienti G., Riezzo G., Et al., Adipose tissue-derived biomarkers of intestinal barrier functions for the characterization of diarrhoea-predominant IBS, Dis Markers, 2018, (2018); Linsalata M., D'Attoma B., Orlando A., Guerra V., Russo F., Comparison of an enzymatic assay with liquid chromatography-pulsed amperometric detection for the determination of lactulose and mannitol in urine of healthy subjects and patients with active celiac disease, Clin Chem Lab Med, 52, pp. e61-e64, (2014); Simeoni M., Citraro M.L., Cerantonio A., Et al., An open-label, randomized, placebo-controlled study on the effectiveness of a novel probiotics administration protocol (Probioti CKD) in patients with mild renal insufficiency (stage 3a of CKD), Eur J Nutr, 58, pp. 2145-2156, (2019); Soncini M., Stasi C., Usai Satta P., Milazzo G., Bianco M., Leandro G., Montalbano L.M., Muscatiello N., Monica F., Galeazzi F., Bellini M., AIGO. IBS clinical management in Italy: the AIGO survey, Dig Liver Dis, 51, pp. 782-789, (2019); Stasi C., Caserta A., Nisita C., Cortopassi S., Fani B., Salvadori S., Pancetti A., Bertani L., Gambaccini D., de Bortoli N., Dell'Osso L., Blandizzi C., Marchi S., Bellini M., The complex interplay between gastrointestinal and psychiatric symptoms in irritable bowel syndrome: a longitudinal assessment, J Gastroenterol Hepatol, 34, pp. 713-719, (2019); Jones M.P., Maganti K., Symptoms, gastric function, and psychosocial factors in functional dyspepsia, J Clin Gastroenterol, 38, pp. 866-872, (2004); Padhy S.K., Sahoo S., Mahajan S., Sinha S.K., Irritable bowel syndrome: is it “irritable brain” or “irritable bowel”?, J Neurosci Rural Pract, 6, pp. 568-577, (2015); Maes M., Kubera M., Leunis J.C., The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from Gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression, Neuro Endocrinol Lett, 29, pp. 117-124, (2008); Barbaro M.R., Cremon C., Caio G., De Giorgio R., Volta U., Et al., Zonulin serum levels are increased in non-celiac gluten sensitivity and irritable bowel syndrome with diarrhea, Gastroenterology, 148, 1, (2015); Miller A.H., Raison C.L., The role of inflammation in depression: from evolutionary imperative to modern treatment target, Nat Rev Immunol, 16, pp. 22-34, (2015); Drago A., Crisafulli C., Calabro M., Serretti A., Enrichment pathway analysis. The inflammatory genetic background in bipolar disorder, J Affect Disord, 179, pp. 88-94, (2015); Russo F., Chimienti G., Clemente C., Et al., Adipokine profile in celiac patients: differences in comparison with patients suffering from diarrhea-predominant IBS and healthy subjects, Scand J Gastroenterol, 48, pp. 1377-1385, (2013); Patel S.R., Singh A., Misra V., Misra S.P., Dwivedi M., Trivedi P., Levels of interleukins 2, 6, 8, and 10 in patients with irritable bowel syndrome, Indian J Pathol Microbiol, 60, pp. 385-389, (2017); Bickel M., The role of interleukin-8 in inflammation and mechanisms of regulation, J Periodontol, 64, pp. 456-460, (1993); Shouval D.S., Biswas A., Goettel J.A., Et al., Interleukin-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and anti-inflammatory macrophage function, Immunity, 40, pp. 706-719, (2014); Hendrikx T., Schnabl B., Indoles: metabolites produced by intestinal bacteria capable of controlling liver disease manifestation, J Intern Med, 286, pp. 32-40, (2019); Garcia Regueiro J.A., Rius M.A., Rapid determination of skatole and indole in pig back fat by normal-phase liquid chromatography, J Chromatogr A, 809, pp. 246-251, (1998); Cassani E., Barichella M., Cancello R., Et al., Increased urinary indoxyl sulfate (indican): new insights into gut dysbiosis in Parkinson's disease, Parkinsonism Relat Disord, 21, pp. 389-393, (2015); Wang Z., Xu C.M., Liu Y.X., Et al., Characteristic dysbiosis of gut microbiota of Chinese patients with diarrhea-predominant irritable bowel syndrome by an insight into the pan-microbiome, Chin Med J (Engl), 132, pp. 889-904, (2019); Pinto-Sanchez M.I., Hall G.B., Ghajar K., Et al., Probiotic Bifidobacterium longum NCC3001 reduces depression scores and alters brain activity: a pilot study in patients with irritable bowel syndrome, Gastroenterology, 153, pp. 448-459.e8, (2017)","F. Russo; Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte, Via Turi 27, 70013, Italy; email: francesco.russo@irccsdebellis.it","","BioMed Central Ltd","","","","","","1471230X","","BGMAB","34022802","English","BMC Gastroenterol.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85106719397"

"Ma J.; Li J.; Qian M.; He N.; Cao Y.; Liu Y.; Wu K.; He S.","Ma, Jing (57738647200); Li, Jianhui (57606771600); Qian, Meirui (57201379135); He, Nan (57214454884); Cao, Ying (57751519100); Liu, Yaping (55985396400); Wu, Kaichun (8947728400); He, Shuixiang (7402691385)","57738647200; 57606771600; 57201379135; 57214454884; 57751519100; 55985396400; 8947728400; 7402691385","The comprehensive pathophysiological changes in a novel rat model of postinflammatory visceral hypersensitivity","2019","FASEB Journal","33","12","","13560","13571","11","13","10.1096/fj.201901489R","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85076123084&doi=10.1096%2ffj.201901489R&partnerID=40&md5=79a677dc4e779229391c697e7e816a8f","Department of Digestive Diseases, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China; State Key Laboratory of Cancer Biology and Institute of Digestive Diseases, Xijing Hospital, The Fourth Military Medical University, Xi'an, China; Department of Infectious Diseases, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China; School of Life Science, Northwest University, Xi'an, China","Ma J., Department of Digestive Diseases, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China, State Key Laboratory of Cancer Biology and Institute of Digestive Diseases, Xijing Hospital, The Fourth Military Medical University, Xi'an, China; Li J., Department of Digestive Diseases, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China, Department of Infectious Diseases, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China; Qian M., State Key Laboratory of Cancer Biology and Institute of Digestive Diseases, Xijing Hospital, The Fourth Military Medical University, Xi'an, China; He N., State Key Laboratory of Cancer Biology and Institute of Digestive Diseases, Xijing Hospital, The Fourth Military Medical University, Xi'an, China; Cao Y., School of Life Science, Northwest University, Xi'an, China; Liu Y., Department of Digestive Diseases, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China; Wu K., State Key Laboratory of Cancer Biology and Institute of Digestive Diseases, Xijing Hospital, The Fourth Military Medical University, Xi'an, China; He S., Department of Digestive Diseases, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China","So far, a comprehensive animal model that can mimic both the central and peripheral pathophysiological changes of irritable bowel syndrome (IBS) is lacking. Here, we developed a novel IBS rat model combining trinitro-benzene-sulfonic acid (TNBS) and chronic unpredictable mild stress (CUMS) (designated as TC-IBS) and compared it with the TNBS-induced and CUMS-induced models. TC-IBS showed a pronounced depression phenotype with increased corticotropin-releasing hormone receptor (CRHR)1 and CRHR2 expression at the frontal cortex and increased serum ACTH concentration. Visceral hypersensitivity (VH), as evidenced by colorectal distention (CRD) test, was highest in TC-IBS, accompanied by increased serum 5-hydroxytryptamine (5-HT) level and colonic 5-HT receptor 3A (5-HT3AR)/5-HT receptor 2B expression, impaired tight junction protein expression including occludin, zonula occludens-1, and phosphorylated myosin light chain. Palonosetron, a second generation of 5-HT3AR antagonist, alleviated VH significantly in TC-IBS. 16S rRNA sequencing showed that TNBS plus CUMS induced a significant disturbance of the gut microbiota. Cytokine profile analysis of TC-IBS model indicated an innate immune activation both in serum and colonic mucosa. Further, fecal microbiota transplantation improved VH and some pathophysiological changes in TC-IBS. In summary, we established a postinflammatory IBS model covering multifactorial pathophysiological changes, which may help to develop therapies that target specific IBS subtype.—Ma, J., Li, J., Qian, M., He, N., Cao, Y., Liu, Y., Wu, K., He, S. The comprehensive pathophysiological changes in a novel rat model of postinflammatory visceral hypersensitivity. FASEB J. 33, 13560-13571 (2019). www.fasebj.org. © FASEB.","CUMS; fecal microbiota transplantation; intestinal permeability","Animals; Behavior, Animal; Depression; Disease Models, Animal; Gastrointestinal Microbiome; Hyperalgesia; Intestinal Mucosa; Irritable Bowel Syndrome; Male; Rats; Rats, Sprague-Dawley; Receptors, Corticotropin-Releasing Hormone; Stress, Physiological; Trinitrobenzenesulfonic Acid; Visceral Pain; corticotropin releasing factor receptor; corticotropin releasing factor receptor 1; corticotropin releasing factor receptor 2; trinitrobenzenesulfonic acid; animal; animal behavior; depression; disease model; genetics; hyperalgesia; intestine flora; intestine mucosa; irritable colon; male; metabolism; pathology; pathophysiology; physiological stress; rat; Sprague Dawley rat; visceral pain","","trinitrobenzenesulfonic acid, 16655-63-3, 2508-19-2; CRF receptor type 1, ; CRF receptor type 2, ; Receptors, Corticotropin-Releasing Hormone, ; Trinitrobenzenesulfonic Acid, ","","","State Key Laboratory of Cancer Biology; National Institute of Agrobiological Sciences, NIAS","Funding text 1: The authors thank Prof. Huang Niu and Dr. Zhou Yu (both from National Institute of Biological Sciences, Beijing, China) for developing the animal model. This study was funded by State Key Laboratory of Cancer Biology. The authors declare no conflicts of interest. ; Funding text 2: The authors thank Prof. Huang Niu and Dr. Zhou Yu (both from National Institute of Biological Sciences, Beijing, China) for developing the animal model. This study was funded by State Key Laboratory of Cancer Biology. The authors declare no conflicts of interest.","Spiller R., Clinical update: irritable bowel syndrome, Lancet, 369, pp. 1586-1588, (2007); Mayer E.A., Savidge T., Shulman R.J., Brain-gut microbiome interactions and functional bowel disorders, Gastroenterology, 146, pp. 1500-1512, (2014); Chang L., The role of stress on physiologic responses and clinical symptoms in irritable bowel syndrome, Gastroenterology, 140, pp. 761-765, (2011); Jones M.P., Tack J., Van Oudenhove L., Walker M.M., Holtmann G., Koloski N.A., Talley N.J., Mood and anxiety disorders precede development of functional gastrointestinal disorders in patients but not in the population, Clin. Gastroenterol. Hepatol., 15, pp. 1014-1020, (2017); Spiller R., Garsed K., Postinfectious irritable bowel syndrome, Gastroenterology, 136, pp. 1979-1988, (2009); Tap J., Derrien M., Tornblom H., Brazeilles R., Cools-Portier S., Dore J., Storsrud S., Le Neve B., Ohman L., Simren M., Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome, Gastroenterology, 152, pp. 111-123, (2017); Bhattarai Y., Muniz Pedrogo D.A., Kashyap P.C., Irritable bowel syndrome: a gut microbiota-related disorder?, Am. J. Physiol. Gastrointest. Liver Physiol., 312, pp. G52-G62, (2017); Saito Y.A., The role of genetics in IBS, Gastroenterol. Clin. North Am., 40, pp. 45-67, (2011); Holtmann G.J., Ford A.C., Talley N.J., Pathophysiology of irritable bowel syndrome, Lancet Gastroenterol. Hepatol., 1, pp. 133-146, (2016); Qin H.Y., Xiao H.T., Wu J.C., Berman B.M., Sung J.J., Bian Z.X., Key factors in developing the trinitrobenzene sulfonic acid-induced post-inflammatory irritable bowel syndrome model in rats, World J. Gastroenterol., 18, pp. 2481-2492, (2012); Wu J., Cheng Y., Zhang R., Liu D., Luo Y.M., Chen K.L., Ren S., Zhang J., P2Y1R is involved in visceral hypersensitivity in rats with experimental irritable bowel syndrome, World J. Gastroenterol., 23, pp. 6339-6349, (2017); Williams C.L., Villar R.G., Peterson J.M., Burks T.F., Stress-induced changes in intestinal transit in the rat: a model for irritable bowel syndrome, Gastroenterology, 94, pp. 611-621, (1988); Szyf M., Weaver I., Meaney M., Maternal care, the epigenome and phenotypic differences in behavior, Reprod. Toxicol., 24, pp. 9-19, (2007); Mayer E.A., Collins S.M., Evolving pathophysiologic models of functional gastrointestinal disorders, Gastroenterology, 122, pp. 2032-2048, (2002); O'Mahony S.M., Tramullas M., Fitzgerald P., Cryan J.F., Rodent models of colorectal distension, Curr. Protoc. Neurosci., 9, (2012); Simpson J., Sundler F., Humes D.J., Jenkins D., Wakelin D., Scholefield J.H., Spiller R.C., Prolonged elevation of galanin and tachykinin expression in mucosal and myenteric enteric nerves in trinitrobenzene sulphonic acid colitis, Neurogastroenterol. Motil., 20, pp. 392-406, (2008); Sanovic S., Lamb D.P., Blennerhassett M.G., Damage to the enteric nervous system in experimental colitis, Am. J. Pathol., 155, pp. 1051-1057, (1999); Fond G., Loundou A., Hamdani N., Boukouaci W., Dargel A., Oliveira J., Roger M., Tamouza R., Leboyer M., Boyer L., Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis, Eur. Arch. Psychiatry Clin. Neurosci., 264, pp. 651-660, (2014); Traini C., Evangelista S., Girod V., Faussone-Pellegrini M.S., Vannucchi M.G., Repeated otilonium bromide administration prevents neurotransmitter changes in colon of rats underwent to wrap restraint stress, J. Cell. Mol. Med., 21, pp. 735-745, (2017); Overman E.L., Rivier J.E., Moeser A.J., CRF induces intestinal epithelial barrier injury via the release of mast cell proteases and TNF-a, PLoS One, 7, (2012); Smith G.W., Aubry J.M., Dellu F., Contarino A., Bilezikjian L.M., Gold L.H., Chen R., Marchuk Y., Hauser C., Bentley C.A., Sawchenko P.E., Koob G.F., Vale W., Lee K.F., Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development, Neuron, 20, pp. 1093-1102, (1998); Bale T.L., Picetti R., Contarino A., Koob G.F., Vale W.W., Lee K.F., Mice deficient for both corticotropin-releasing factor receptor 1 (CRFR1) and CRFR2 have an impaired stress response and display sexually dichotomous anxiety-like behavior, J. Neurosci., 22, pp. 193-199, (2002); Simren M., Tornblom H., Palsson O.S., van Tilburg M.A.L., Van Oudenhove L., Tack J., Whitehead W.E., Visceral hypersensitivity is associated with GI symptom severity in functional GI disorders: consistent findings from five different patient cohorts, Gut, 67, pp. 255-262, (2018); Ritchie J., Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome, Gut, 14, pp. 125-132, (1973); Gershon M.D., Tack J., The serotonin signaling system: from basic understanding to drug development for functional GI disorders, Gastroenterology, 132, pp. 397-414, (2007); Shao Y.Y., Huang J., Ma Y.R., Han M., Ma K., Qin H.Y., Rao Z., Wu X.A., Serum serotonin reduced the expression of hepatic transporter Mrp2 and P-gp via regulating nuclear receptor CAR in PI-IBS rats, Can. J. Physiol. Pharmacol., 93, pp. 633-639, (2015); Ford A.C., Brandt L.J., Young C., Chey W.D., Foxx-Orenstein A.E., Moayyedi P., Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis, Am. J. Gastroenterol., 104, pp. 1831-1843, (2009); Lin S.Y., Chang W.J., Lin C.S., Huang C.Y., Wang H.F., Sun W.H., Serotonin receptor 5-HT2B mediates serotonin-induced mechanical hyperalgesia, J. Neurosci., 31, pp. 1410-1418, (2011); Camilleri M., Lasch K., Zhou W., Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome, Am. J. Physiol. Gastrointest. Liver Physiol., 303, pp. G775-G785, (2012); Turner J.R., Rill B.K., Carlson S.L., Carnes D., Kerner R., Mrsny R.J., Madara J.L., Physiological regulation of epithelial tight junctions is associated with myosin light-chain phosphorylation, Am. J. Physiol., 273, pp. C1378-C1385, (1997); Walsh S.V., Hopkins A.M., Chen J., Narumiya S., Parkos C.A., Nusrat A., Rho kinase regulates tight junction function and is necessary for tight junction assembly in polarized intestinal epithelia, Gastroenterology, 121, pp. 566-579, (2001); Martinez C., Lobo B., Pigrau M., Ramos L., Gonzalez-Castro A.M., Alonso C., Guilarte M., Guila M., de Torres I., Azpiroz F., Santos J., Vicario M., Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, pp. 1160-1168, (2013); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Lecleire S., Antonietti M., Gourcerol G., Leroi A.M., Dechelotte P., Menard J.F., Ducrotte P., Coeffier M., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am. J. Gastroenterol., 106, pp. 2165-2173, (2011); Chadwick V.S., Chen W., Shu D., Paulus B., Bethwaite P., Tie A., Wilson I., Activation of the mucosal immune system in irritable bowel syndrome, Gastroenterology, 122, pp. 1778-1783, (2002); Liebregts T., Adam B., Bredack C., Roith A., Heinzel S., Lester S., Downie-Doyle S., Smith E., Drew P., Talley N.J., Holtmann G., Immune activation in patients with irritable bowel syndrome, Gastroenterology, 132, pp. 913-920, (2007); Bashashati M., Rezaei N., Shafieyoun A., McKernan D.P., Chang L., Ohman L., Quigley E.M., Schmulson M., Sharkey K.A., Simren M., Cytokine imbalance in irritable bowel syndrome: a systematic review and meta-analysis, Neurogastroenterol. Motil., 26, pp. 1036-1048, (2014); Barbara G., Feinle-Bisset C., Ghoshal U.C., Quigley E.M., Santos J., Vanner S., Vergnolle N., Zoetendal E.G., The intestinal microenvironment and functional gastrointestinal disorders. [E-pub ahead of print], Gastroenterology, (2016); Bennet S.M., Ohman L., Simren M., Gut microbiota as potential orchestrators of irritable bowel syndrome, Gut Liver, 9, pp. 318-331, (2015); Kelly C.R., Kahn S., Kashyap P., Laine L., Rubin D., Atreja A., Moore T., Wu G., Update on fecal microbiota transplantation 2015: indications, methodologies, mechanisms, and outlook, Gastroenterology, 149, pp. 223-237, (2015); Halkjaer S.I., Boolsen A.W., Gunther S., Christensen A.H., Petersen A.M., Can fecal microbiota transplantation cure irritable bowel syndrome?, World J. Gastroenterol., 23, pp. 4112-4120, (2017); Halkjaer S.I., Christensen A.H., Lo B.Z.S., Browne P.D., Gunther S., Hansen L.H., Petersen A.M., Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study, Gut, 67, pp. 2107-2115, (2018); Johnsen P.H., Hilpusch F., Cavanagh J.P., Leikanger I.S., Kolstad C., Valle P.C., Goll R., Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial, Lancet Gastroenterol. Hepatol., 3, pp. 17-24, (2018)","S. He; Department of Digestive Diseases, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China; email: dyyyjxk@mail.xjtu.edu.cn; K. Wu; State Key Laboratory of Cancer Biology and Institute of Digestive Diseases, Xijing Hospital, The Fourth Military Medical University, Xi'an, China; email: kaicwu@fmmu.edu.cn","","John Wiley and Sons Inc","","","","","","08926638","","FAJOE","31570003","English","FASEB J.","Article","Final","","Scopus","2-s2.0-85076123084"

"Nozu T.; Miyagishi S.; Ishioh M.; Takakusaki K.; Okumura T.","Nozu, Tsukasa (12765917900); Miyagishi, Saori (56538237900); Ishioh, Masatomo (57202513969); Takakusaki, Kaoru (7004150214); Okumura, Toshikatsu (7202327796)","12765917900; 56538237900; 57202513969; 7004150214; 7202327796","Phlorizin attenuates visceral hypersensitivity and colonic hyperpermeability in a rat model of irritable bowel syndrome","2021","Biomedicine and Pharmacotherapy","139","","111649","","","","14","10.1016/j.biopha.2021.111649","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85105052762&doi=10.1016%2fj.biopha.2021.111649&partnerID=40&md5=e57f578f7660ae16de124a1dc5b146eb","Department of Regional Medicine and Education, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Center for Medical Education, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Division of Neuroscience, Department of Physiology, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Department of General Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan","Nozu T., Department of Regional Medicine and Education, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan, Center for Medical Education, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Miyagishi S., Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Ishioh M., Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Takakusaki K., Division of Neuroscience, Department of Physiology, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Okumura T., Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan, Department of General Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan","Visceral hypersensitivity and impaired gut barrier are crucial contributors to the pathophysiology of irritable bowel syndrome (IBS), and those are mediated via corticotropin-releasing factor (CRF)−Toll like receptor 4–pro-inflammatory cytokine signaling. Phlorizin is an inhibitor of sodium-linked glucose transporters (SGLTs), and known to have anti-cytokine properties. Thus, we hypothesized that phlorizin may improve these gastrointestinal changes in IBS, and tested this hypothesis in rat IBS models, i.e., lipopolysaccharide (LPS) or CRF-induced visceral hypersensitivity and colonic hyperpermeability. The visceral pain threshold in response to colonic balloon distention was estimated by abdominal muscle contractions by electromyogram, and colonic permeability was measured by quantifying the absorbed Evans blue in colonic tissue. Subcutaneous (s.c.) injection of phlorizin inhibited visceral hypersensitivity and colonic hyperpermeability induced by LPS in a dose-dependent manner. Phlorizin also blocked CRF-induced these gastrointestinal changes. Phlorizin is known to inhibit both SGLT1 and SGLT2, but intragastric administration of phlorizin may only inhibit SGLT1 because gut mainly expresses SGLT1. We found that intragastric phlorizin did not display any effects, but ipragliflozin, an orally active and selective SGLT2 inhibitor improved the gastrointestinal changes in the LPS model. Compound C, an adenosine monophosphate-activated protein kinase (AMPK) inhibitor, NG-nitro-L-arginine methyl ester, a nitric oxide (NO) synthesis inhibitor and naloxone, an opioid receptor antagonist reversed the effects of phlorizin. In conclusions, phlorizin improved visceral hypersensitivity and colonic hyperpermeability in IBS models. These effects may result from inhibition of SGLT2, and were mediated via AMPK, NO and opioid pathways. Phlorizin may be effective for the treatment of IBS. © 2021 The Authors","Gut barrier; Irritable bowel syndrome; Sodium-linked glucose transporter; Visceral sensation","Abdominal Muscles; Animals; Colon; Corticotropin-Releasing Hormone; Dose-Response Relationship, Drug; Electromyography; Hyperalgesia; Injections, Subcutaneous; Irritable Bowel Syndrome; Lipopolysaccharides; Male; Naloxone; NG-Nitroarginine Methyl Ester; Permeability; Phlorhizin; Rats; Rats, Sprague-Dawley; butorphanol tartrate; compound C; corticotropin releasing factor; Evans blue; hydroxymethylglutaryl coenzyme A reductase kinase; ipragliflozin; lipopolysaccharide; medetomidine; midazolam; n(g) nitroarginine methyl ester; naloxone; nitric oxide; phlorizin; protein serine threonine kinase inhibitor; sodium glucose cotransporter 1; sodium glucose cotransporter 2; unclassified drug; corticotropin releasing factor; lipopolysaccharide; n(g) nitroarginine methyl ester; naloxone; phlorizin; abdominal wall musculature; adult; animal experiment; animal model; animal tissue; Article; colon disease; colon tissue; colonic hyperpermeability; colonic hyperpermeability; controlled study; dose response; drug absorption; drug antagonism; drug targeting; electromyogram; irritable colon; male; muscle contraction; nonhuman; pain threshold; priority journal; rat; visceral pain; animal; colon; drug effect; electromyography; hyperalgesia; irritable colon; metabolism; permeability; Sprague Dawley rat; subcutaneous drug administration","","butorphanol tartrate, 58786-99-5; corticotropin releasing factor, 9015-71-8, 178359-01-8, 79804-71-0, 86297-72-5, 86784-80-7; Evans blue, 314-13-6; hydroxymethylglutaryl coenzyme A reductase kinase, 172522-01-9, 72060-32-3; ipragliflozin, 761423-87-4; medetomidine, 119717-21-4, 86347-14-0; midazolam, 59467-70-8; n(g) nitroarginine methyl ester, 50903-99-6; naloxone, 357-08-4, 465-65-6; nitric oxide, 10102-43-9; phlorizin, 60-81-1, 7061-54-3; Corticotropin-Releasing Hormone, ; Lipopolysaccharides, ; Naloxone, ; NG-Nitroarginine Methyl Ester, ; Phlorhizin, ","","","Akiyama Life Science Foundation; Japan Society for the Promotion of Science, KAKEN, (26120012, 26460287, 26460955)","This work was partially supported by the Japan Society for the Promotion of Science KAKENHI, Grant-in-Aid for Scientific Research (C) [ 26460287 (TN) and 26460955 (TO)], Scientific Research on Innovative Areas [ 26120012 (KT) ], and the research grant from the Akiyama Life Science Foundation (TN).","Mearin F., Lacy B.E., Chang L., Chey W.D., Lembo A.J., Simren M., Spiller R., Bowel disorders, Gastroenterology, 150, 6, pp. 1393-1407, (2016); Mertz H., Naliboff B., Munakata J., Niazi N., Mayer E.A., Altered rectal perception is a biological marker of patients with irritable bowel syndrome, Gastroenterology, 109, 1, pp. 40-52, (1995); Bouin M., Plourde V., Boivin M., Riberdy M., Lupien F., Laganiere M., Verrier P., Poitras P., Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds, Gastroenterology, 122, 7, pp. 1771-1777, (2002); Kanazawa M., Hongo M., Fukudo S., Visceral hypersensitivity in irritable bowel syndrome, J. Gastroenterol. Hepatol., 26, pp. 119-121, (2011); Azpiroz F., Bouin M., Camilleri M., Mayer E.A., Poitras P., Serra J., Spiller R.C., Mechanisms of hypersensitivity in IBS and functional disorders, Neurogastroenterol. Motil., 19, 1, pp. 62-88, (2007); Tache Y., Kiank C., Stengel A., A role for corticotropin-releasing factor in functional gastrointestinal disorders, Curr. Gastroenterol. Rep., 11, 4, pp. 270-277, (2009); Nozu T., Kudaira M., Kitamori S., Uehara A., Repetitive rectal painful distention induces rectal hypersensitivity in patients with irritable bowel syndrome, J. Gastroenterol., 41, 3, pp. 217-222, (2006); Nozu T., Okumura T., Corticotropin-releasing factor receptor type 1 and type 2 interaction in irritable bowel syndrome, J. Gastroenterol., 50, 8, pp. 819-830, (2015); Piche T., Barbara G., Aubert P., Bruley des Varannes S., Dainese R., Nano J.L., Cremon C., Stanghellini V., De Giorgio R., Galmiche J.P., Neunlist M., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators, Gut, 58, 2, pp. 196-201, (2009); Nozu T., Miyagishi S., Nozu R., Takakusaki K., Okumura T., Lipopolysaccharide induces visceral hypersensitivity: role of interleukin-1, interleukin-6, and peripheral corticotropin-releasing factor in rats, J. Gastroenterol., 52, 1, pp. 72-80, (2017); Obreja O., Rathee P.K., Lips K.S., Distler C., Kress M., IL-1 beta potentiates heat-activated currents in rat sensory neurons: involvement of IL-1RI, tyrosine kinase, and protein kinase C, FASEB J., 16, 12, pp. 1497-1503, (2002); Nozu T., Miyagishi S., Nozu R., Takakusaki K., Okumura T., Repeated water avoidance stress induces visceral hypersensitivity; role of IL-1, IL-6 and peripheral corticotropin-releasing factor, J. Gastroenterol. Hepatol., 32, 12, pp. 1958-1965, (2017); Nozu T., Miyagishi S., Nozu R., Takakusaki K., Okumura T., Altered colonic sensory and barrier functions by CRF: roles of TLR4 and IL-1, J. Endocrinol., 239, 2, pp. 241-252, (2018); Gil-Cardoso K., Gines I., Pinent M., Ardevol A., Arola L., Blay M., Terra X., Chronic supplementation with dietary proanthocyanidins protects from diet-induced intestinal alterations in obese rats, Mol. Nutr. Food Res., 61, 8, (2017); Liu W., Zhao S., Wang J., Shi J., Sun Y., Wang W., Ning G., Hong J., Liu R., Grape seed proanthocyanidin extract ameliorates inflammation and adiposity by modulating gut microbiota in high-fat diet mice, Mol. Nutr. Food Res., 61, 9, (2017); Tian Y., Gao L., Guo Y., Xu Y., Short-term phlorizin treatment attenuates adipose tissue inflammation without alerting obesity in high-fat diet fed mice, J. Food Biochem., 41, 6, (2017); Ehrenkranz J.R., Lewis N.G., Kahn C.R., Roth J., Phlorizin: a review, Diabetes Metab. Res. Rev., 21, 1, pp. 31-38, (2005); Panchapakesan U., Pegg K., Gross S., Komala M.G., Mudaliar H., Forbes J., Pollock C., Mather A., Effects of SGLT2 inhibition in human kidney proximal tubular cells–renoprotection in diabetic nephropathy?, PLoS One, 8, 2, (2013); Abbas N.A.T., El Salem A., Awad M.M., Empagliflozin, SGLT2 inhibitor, attenuates renal fibrosis in rats exposed to unilateral ureteric obstruction: potential role of klotho expression, Naunyn Schmiede Arch. Pharm., 391, 12, pp. 1347-1360, (2018); Ashrafi Jigheh Z., Ghorbani Haghjo A., Argani H., Roshangar L., Rashtchizadeh N., Sanajou D., Nazari Soltan Ahmad S., Rashedi J., Dastmalchi S., Mesgari Abbasi M., Empagliflozin alleviates renal inflammation and oxidative stress in streptozotocin-induced diabetic rats partly by repressing HMGB1-TLR4 receptor axis, Iran. J. Basic Med. Sci., 22, 4, pp. 384-390, (2019); Imamura M., Nakanishi K., Suzuki T., Ikegai K., Shiraki R., Ogiyama T., Murakami T., Kurosaki E., Noda A., Kobayashi Y., Yokota M., Koide T., Kosakai K., Ohkura Y., Takeuchi M., Tomiyama H., Ohta M., Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus, Bioorg. Med. Chem., 20, 10, pp. 3263-3279, (2012); Katsuda Y., Sasase T., Tadaki H., Mera Y., Motohashi Y., Kemmochi Y., Toyoda K., Kakimoto K., Kume S., Ohta T., Contribution of hyperglycemia on diabetic complications in obese type 2 diabetic SDT fatty rats: effects of SGLT inhibitor phlorizin, Exp. Anim., 64, 2, pp. 161-169, (2015); Takakura S., Takasu T., First-dose effect of the SGLT2 inhibitor ipragliflozin on cardiovascular activity in spontaneously diabetic Torii fatty rats, Clin. Exp. Pharm. Physiol., 46, pp. 266-273, (2019); Nozu T., Miyagishi S., Nozu R., Takakusaki K., Okumura T., Butyrate inhibits visceral allodynia and colonic hyperpermeability in rat models of irritable bowel syndrome, Sci. Rep., 9, 1, (2019); Ness T.J., Gebhart G.F., Colorectal distension as a noxious visceral stimulus: physiologic and pharmacologic characterization of pseudaffective reflexes in the rat, Brain Res., 450, 1-2, pp. 153-169, (1988); Al-Chaer E.D., Kawasaki M., Pasricha P.J., A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development, Gastroenterology, 119, 5, pp. 1276-1285, (2000); Nozu T., Miyagishi S., Nozu R., Takakusaki K., Okumura T., Losartan improves visceral sensation and gut barrier in a rat model of irritable bowel syndrome, Neurogastroenterol. Motil., 32, 6, (2020); Yang J.P., Yao M., Jiang X.H., Wang L.N., Establishment of model of visceral pain due to colorectal distension and its behavioral assessment in rats, World J. Gastroenterol., 12, 17, pp. 2781-2784, (2006); Okumura T., Nozu T., Kumei S., Takakusaki K., Ohhira M., Ghrelin acts centrally to induce an antinociceptive action during colonic distension through the orexinergic, dopaminergic and opioid systems in conscious rats, Brain Res., 1686, pp. 48-54, (2018); Kellett G.L., Helliwell P.A., The diffusive component of intestinal glucose absorption is mediated by the glucose-induced recruitment of GLUT2 to the brush-border membrane, Biochem J., 350 Pt 1, pp. 155-162, (2000); Hawley S.A., Ford R.J., Smith B.K., Gowans G.J., Mancini S.J., Pitt R.D., Day E.A., Salt I.P., Steinberg G.R., Hardie D.G., The Na+/glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular amp levels, Diabetes, 65, 9, pp. 2784-2794, (2016); Nozu T., Miyagishi S., Kumei S., Nozu R., Takakusaki K., Okumura T., Metformin inhibits visceral allodynia and increased gut permeability induced by stress in rats, J. Gastroenterol. Hepatol., 34, 1, pp. 186-193, (2019); Li C.Y., Wang L.X., Dong S.S., Hong Y., Zhou X.H., Zheng W.W., Zheng C., Phlorizin exerts direct protective effects on palmitic acid (PA)-induced endothelial dysfunction by activating the PI3K/AKT/eNOS signaling pathway and increasing the levels of nitric oxide (NO), Med. Sci. Monit. Basic Res., 24, pp. 1-9, (2018); Nozu T., Miyagishi S., Nozu R., Takakusaki K., Okumura T., Dehydroepiandrosterone sulfate improves visceral sensation and gut barrier in a rat model of irritable bowel syndrome, Eur. J. Pharmacol., 852, pp. 198-206, (2019); Larauche M., Mulak A., Kim Y.S., Labus J., Million M., Tache Y., Visceral analgesia induced by acute and repeated water avoidance stress in rats: sex difference in opioid involvement, Neurogastroenterol. Motil., 24, 11, pp. 1031-e547, (2012); Mayer E.A., Naliboff B.D., Chang L., Coutinho S.V., V. Stress and irritable bowel syndrome, Am. J. Physiol. Gastrointest. Liver Physiol., 280, 4, pp. G519-G524, (2001); Fukudo S., Nomura T., Hongo M., Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome, Gut, 42, 6, pp. 845-849, (1998); Yu Y., Liu Z.Q., Liu X.Y., Yang L., Geng X.R., Yang G., Liu Z.G., Zheng P.Y., Yang P.C., Stress-derived corticotropin releasing factor breaches epithelial endotoxin tolerance, PLoS One, 8, 6, (2013); Suzuki T., Yoshinaga N., Tanabe S., Interleukin-6 (IL-6) regulates claudin-2 expression and tight junction permeability in intestinal epithelium, J. Biol. Chem., 286, 36, pp. 31263-31271, (2011); Faillie J.L., Pharmacological aspects of the safety of gliflozins, Pharmacol. Res., 118, pp. 71-81, (2017); Rieg T., Vallon V., Development of SGLT1 and SGLT2 inhibitors, Diabetologia, 61, 10, pp. 2079-2086, (2018); Patel D.K., Strong J., The pleiotropic effects of sodium-glucose cotransporter-2 inhibitors: beyond the glycemic benefit, Diabetes Ther., 10, 5, pp. 1771-1792, (2019); Verma S., McMurray J.J.V., SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review, Diabetologia, 61, 10, pp. 2108-2117, (2018); Chilton R., Tikkanen I., Cannon C.P., Crowe S., Woerle H.J., Broedl U.C., Johansen O.E., Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes, Diabetes Obes. Metab., 17, 12, pp. 1180-1193, (2015); Lopaschuk G.D., Verma S., Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review, JACC Basic Transl. Sci., 5, 6, pp. 632-644, (2020); Kaplan R.C., Frishman W.H., Systemic inflammation as a cardiovascular disease risk factor and as a potential target for drug therapy, Heart Dis., 3, 5, pp. 326-332, (2001); Yaribeygi H., Butler A.E., Atkin S.L., Katsiki N., Sahebkar A., Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways, J. Cell. Physiol., 234, 1, pp. 223-230, (2018); Han J.H., Oh T.J., Lee G., Maeng H.J., Lee D.H., Kim K.M., Choi S.H., Jang H.C., Lee H.S., Park K.S., Kim Y.B., Lim S., The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE (-/-) mice fed a western diet, Diabetologia, 60, 2, pp. 364-376, (2017); Kim J., Kwak H.J., Cha J.Y., Jeong Y.S., Rhee S.D., Kim K.R., Cheon H.G., Metformin suppresses lipopolysaccharide (LPS)-induced inflammatory response in murine macrophages via activating transcription factor-3 (ATF-3) induction, J. Biol. Chem., 289, 33, pp. 23246-23255, (2014); Kim Y.J., Greimel P., Hirabayashi Y., GPRC5B-mediated sphingomyelin synthase 2 phosphorylation plays a critical role in insulin resistance, iScience, 8, pp. 250-266, (2018); Kroncke K.D., Fehsel K., Suschek C., Kolb-Bachofen V., Inducible nitric oxide synthase-derived nitric oxide in gene regulation, cell death and cell survival, Int. Immunopharmacol., 1, 8, pp. 1407-1420, (2001); Kim Y.M., Talanian R.V., Li J., Billiar T.R., Nitric oxide prevents IL-1beta and IFN-gamma-inducing factor (IL-18) release from macrophages by inhibiting caspase-1 (IL-1beta-converting enzyme), J. Immunol., 161, 8, pp. 4122-4128, (1998); Ninkovic J., Roy S., Role of the mu-opioid receptor in opioid modulation of immune function, Amino Acids, 45, 1, pp. 9-24, (2013); Wang J., Barke R.A., Charboneau R., Roy S., Morphine impairs host innate immune response and increases susceptibility to Streptococcus pneumoniae lung infection, J. Immunol., 174, 1, pp. 426-434, (2005); Martucci C., Franchi S., Lattuada D., Panerai A.E., Sacerdote P., Differential involvement of RelB in morphine-induced modulation of chemotaxis, NO, and cytokine production in murine macrophages and lymphocytes, J. Leukoc. Biol., 81, 1, pp. 344-354, (2007); Pol O., Sasaki M., Jimenez N., Dawson V.L., Dawson T.M., Puig M.M., The involvement of nitric oxide in the enhanced expression of mu-opioid receptors during intestinal inflammation in mice, Br. J. Pharm., 145, 6, pp. 758-766, (2005); Ferreira S.H., Duarte I.D., Lorenzetti B.B., The molecular mechanism of action of peripheral morphine analgesia: stimulation of the cGMP system via nitric oxide release, Eur. J. Pharmacol., 201, 1, pp. 121-122, (1991); Nozaki-Taguchi N., Yamamoto T., The interaction of FK409, a novel nitric oxide releaser, and peripherally administered morphine during experimental inflammation, Anesth. Analg., 86, 2, pp. 367-373, (1998); Zhang J.M., An J., Cytokines, inflammation, and pain, Int. Anesthesiol. Clin., 45, 2, pp. 27-37, (2007); Lewis C.V., Taylor W.R., Intestinal barrier dysfunction as a therapeutic target for cardiovascular disease, Am. J. Physiol. Heart Circ. Physiol., 319, 6, pp. H1227-H1233, (2020); Lau W.L., Kalantar-Zadeh K., Vaziri N.D., The gut as a source of inflammation in chronic kidney disease, Nephron, 130, 2, pp. 92-98, (2015)","T. Nozu; Department of Regional Medicine and Education, Asahikawa Medical University, Asahikawa, 2-1-1-1 Midorigaoka-Higashi, 078-8510, Japan; email: tnozu@sea.plala.or.jp","","Elsevier Masson s.r.l.","","","","","","07533322","","BIPHE","33957565","English","Biomed. Pharmacother.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85105052762"

"Guilarte M.; Vicario M.; Martínez C.; De Torres I.; Lobo B.; Pigrau M.; González-Castro A.; Rodiño-Janeiro B.K.; Salvo-Romero E.; Fortea M.; Pardo-Camacho C.; Antolín M.; Saperas E.; Azpiroz F.; Santos J.; Alonso-Cotoner C.","Guilarte, Mar (18133405400); Vicario, María (6603267769); Martínez, Cristina (17534584700); De Torres, Inés (7003506754); Lobo, Beatriz (7003936898); Pigrau, Marc (37009212800); González-Castro, Ana (54796498900); Rodiño-Janeiro, Bruno K. (35729142300); Salvo-Romero, Eloísa (56830611700); Fortea, Marina (56830396500); Pardo-Camacho, Cristina (57192877965); Antolín, María (7004375048); Saperas, Esteban (7004148840); Azpiroz, Fernando (57207592894); Santos, Javier (7402389020); Alonso-Cotoner, Carmen (57220113655)","18133405400; 6603267769; 17534584700; 7003506754; 7003936898; 37009212800; 54796498900; 35729142300; 56830611700; 56830396500; 57192877965; 7004375048; 7004148840; 57207592894; 7402389020; 57220113655","Peripheral Corticotropin-Releasing Factor Triggers Jejunal Mast Cell Activation and Abdominal Pain in Patients with Diarrhea-Predominant Irritable Bowel Syndrome","2020","American Journal of Gastroenterology","115","12","","2047","2059","12","16","10.14309/ajg.0000000000000789","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85096709151&doi=10.14309%2fajg.0000000000000789&partnerID=40&md5=2281a5b0bc3be4fbbe7063eb2f94763b","Allergy Section, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Barcelona, Spain; Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Department of Gastroenterology, Barcelona, Spain; Spanish Research Network on Allergy, National Allergy Network ARADyAL: Asma Reacciones Adversas y Alérgicas, ISCIII, Madrid, Spain; Translational Mucosal Immunology Group, Digestive System Research Unit, Hospital Universitari Vall d'Hebron, Barcelona, Spain; Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas (CIBERehd, Madrid, Spain; Department of Pathology, Hospital Universitari Vall d'Hebron, Barcelona, Spain","Guilarte M., Allergy Section, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Barcelona, Spain, Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Department of Gastroenterology, Barcelona, Spain, Spanish Research Network on Allergy, National Allergy Network ARADyAL: Asma Reacciones Adversas y Alérgicas, ISCIII, Madrid, Spain; Vicario M., Translational Mucosal Immunology Group, Digestive System Research Unit, Hospital Universitari Vall d'Hebron, Barcelona, Spain, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas (CIBERehd, Madrid, Spain; Martínez C., Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Department of Gastroenterology, Barcelona, Spain; De Torres I., Department of Pathology, Hospital Universitari Vall d'Hebron, Barcelona, Spain; Lobo B., Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Department of Gastroenterology, Barcelona, Spain; Pigrau M., Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Department of Gastroenterology, Barcelona, Spain; González-Castro A., Translational Mucosal Immunology Group, Digestive System Research Unit, Hospital Universitari Vall d'Hebron, Barcelona, Spain; Rodiño-Janeiro B.K., Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Department of Gastroenterology, Barcelona, Spain; Salvo-Romero E., Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Department of Gastroenterology, Barcelona, Spain, Translational Mucosal Immunology Group, Digestive System Research Unit, Hospital Universitari Vall d'Hebron, Barcelona, Spain; Fortea M., Translational Mucosal Immunology Group, Digestive System Research Unit, Hospital Universitari Vall d'Hebron, Barcelona, Spain; Pardo-Camacho C., Translational Mucosal Immunology Group, Digestive System Research Unit, Hospital Universitari Vall d'Hebron, Barcelona, Spain; Antolín M., Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Department of Gastroenterology, Barcelona, Spain; Saperas E., Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Department of Gastroenterology, Barcelona, Spain; Azpiroz F., Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Department of Gastroenterology, Barcelona, Spain, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas (CIBERehd, Madrid, Spain; Santos J., Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Department of Gastroenterology, Barcelona, Spain, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas (CIBERehd, Madrid, Spain; Alonso-Cotoner C., Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Department of Gastroenterology, Barcelona, Spain, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas (CIBERehd, Madrid, Spain","INTRODUCTION:To determine the effect of peripheral CRF on intestinal barrier function in diarrhea-predominant IBS (IBS-D). Irritable bowel syndrome (IBS) pathophysiology has been linked to life stress, epithelial barrier dysfunction, and mast cell activation. Corticotropin-releasing factor (CRF) is a major mediator of stress responses in the gastrointestinal tract, yet its role on IBS mucosal function remains largely unknown.METHODS:Intestinal response to sequential i.v. 5-mL saline solution (placebo) and CRF (100 g) was evaluated in 21 IBS-D and 17 healthy subjects (HSs). A 20-cm jejunal segment was perfused with an isosmotic solution and effluents collected at baseline, 30 minutes after placebo, and 60 minutes after CRF. We measured water flux, albumin output, tryptase release, stress hormones, cardiovascular and psychological responses, and abdominal pain. A jejunal biopsy was obtained for CRF receptor expression assessment.RESULTS:Water flux did not change after placebo in IBS-D and HS but significantly increased after CRF in IBS-D (P = 0.007). Basal luminal output of albumin was higher in IBS-D and increased further after CRF in IBS-D (P = 0.042). Basal jejunal tryptase release was higher in IBS-D, and CRF significantly increased it in both groups (P = 0.004), the response being higher in IBS-D than in HS (P = 0.0023). Abdominal pain worsened only in IBS-D after CRF and correlated with jejunal tryptase release, water flux, and albumin output. IBS-D displayed jejunal up-regulation of CRF2 and down-regulation of CRF1 compared with HS.DISCUSSION:Stress via CRF-driven mast cell activation seems to be relevant in the pathophysiology of IBS-D. © 2020 Wolters Kluwer Health. All rights reserved.","","Abdominal Pain; Adult; Corticotropin-Releasing Hormone; Diarrhea; Female; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Jejunum; Male; Mast Cells; Middle Aged; Young Adult; albumin; barium; corticotropin; corticotropin releasing factor; histamine; sodium chloride; corticotropin releasing factor; abdominal pain; adult; Article; Beck Depression Inventory; chemiluminescence immunoassay; colorimetry; depression; diarrhea; disease assessment; dyspepsia; echography; female; fluoroscopy; gastrostomy; human; inflammatory disease; irritable colon; jejunal muscle; jejunum biopsy; major clinical study; male; mast cell; middle aged; modified social readjustment scale  of holmes rahe; numeric rating scale; prick test; questionnaire; respiratory tract allergy; scoring system; spectrophotometry; subjective stress rating scale; abdominal pain; diarrhea; drug effect; intestine mucosa; irritable colon; jejunum; mast cell; metabolism; pathology; young adult","","barium, 7440-39-3; corticotropin, 11136-52-0, 9002-60-2, 9061-27-2; corticotropin releasing factor, 9015-71-8, 178359-01-8, 79804-71-0, 86297-72-5, 86784-80-7; histamine, 51-45-6, 56-92-8, 93443-21-1; sodium chloride, 7647-14-5, 23724-87-0, 49658-21-1; Corticotropin-Releasing Hormone, ","AU5400, Olympus, Spain; Cobas Mira Plus, Hoffmann La Roche, Spain; Compat, Novartis; Immulite 2000, EUROIDPC, United Kingdom; m4 1, Omron, Netherlands","EUROIDPC, United Kingdom; Hoffmann La Roche, Spain; Novartis; Olympus, Spain; Omron, Netherlands","Fondo de Investigación Sanitaria; Ministerio de Economía y Competitividad, MINECO, (CD15/00010, CM08/00229, CM10/00155, CP10/00502, CP18/00116, CPII16/00031, EII2011-0035, FI12/00254, PI16/00583); Instituto de Salud Carlos III, ISCIII; European Regional Development Fund, ERDF; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, CIBEREHD","Financial Support : Supported in part by Fondo Europeo de Desarrollo Regional (FEDER), Fondo de Investigación Sanitaria and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Subdirección General de Investigación Sanitaria, Ministerio de Economía y Competitividad: CP10/00502, PI16/00583 & CPII16/00031 (M.V.); CP18/00116 (C.M.), CM08/00229 (B.L.); CM10/00155 (M.P.); EII2011-0035 & CD15/00010 (B.R-J.); FI12/00254 (E.S-R.), PI17/0190 (J.S.), PI12/00314 & PI15/00301 (C.A-C.), CIBEREHD CB06/04/0021 (F.A., M.V, J.S., C.A-C.); Ministerio de Educación, Dirección General de Investigación: SAF 2016-76648-R (F.A.); Agència de Gestió d’Ajuts Universitaris i de Recerca, de la Generalitat de Catalunya: 2017 SGR 1529 (F.A.); Vall d’Hebron Institut de Recerca, Programa de becas predoctorales Amics de Vall d’Hebron: PRED-VHIR-2014-018 (M.F.), PRED-VHIR-2016-53 34 (C.P-C.). FA serves as a consultant or advisory board member for Danone, Clasado, and Allergan; he has received research support from Danone, Clasado,and Noventure. ","Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndrome, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Guilarte M., Santos J., De Torres I., Et al., Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum, Gut, 56, pp. 203-209, (2007); Martinez C., Vicario M., Ramos L., Et al., The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction-signaling pathway that are associated with mucosal pathobiology and clinical manifestations, Am J Gastroenterol, 107, pp. 736-746, (2012); Wouters M.M., Vicario M., Santos J., The role of mast cells in functional GI disorders, Gut, 65, pp. 155-168, (2016); Marshall J.K., Thabane M., Garg A.X., Et al., Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario, Aliment Pharmacol Ther, 20, pp. 1317-1322, (2004); Rao A.S., Camilleri M., Eckert D.J., Et al., Urine sugars for in vivo gut permeability: Validation and comparisons in irritable bowel syndrome-diarrhea and controls, Am J Physiol Gastrointest Liver Physiol, 301, pp. G919-G928, (2011); Piche T., Barbara G., Aubert P., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: Involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Camilleri M., Lasch K., Zhou W., Irritable bowel syndrome: Methods, mechanisms, and pathophysiology. the confluence of increased permeability, inflammation, and pain in irritable bowel syndrome, Am J Physiol Gastrointest Liver Physiol, 303, pp. G775-G785, (2012); Zhou Q., Souba W.W., Croce C.M., Et al., MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome, Gut, 59, pp. 775-784, (2010); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Et al., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am J Gastroenterol, 106, pp. 2165-2173, (2011); Martinez C., Lobo B., Pigrau M., Et al., Diarrhoea-predominant irritable bowel syndrome: An organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, pp. 1160-1168, (2013); Lee J.W., Park J.H., Park D.I., Et al., Subjects with diarrhea-predominant IBS have increased rectal permeability responsive to tryptase, Dig Dis Sci, 55, pp. 2922-2928, (2010); Buhner S., Li Q., Vignali S., Et al., Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome, Gastroenterology, 137, pp. 1425-1434, (2009); Cenac N., Andrews C.N., Holzhausen M., Et al., Role for protease activity in visceral pain in irritable bowel syndrome, J Clin Invest, 117, pp. 636-647, (2007); Barbara G., Stanghellini V., De Giorgio R., Et al., Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome, Gastroenterology, 126, pp. 693-702, (2004); Klooker T.K., Braak B., Koopman K.E., Et al., The mast cell stabilizer ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome, Gut, 59, pp. 1213-1221, (2010); Lobo B., Ramos L., Martinez C., Et al., Downregulation of mucosal mast cell activation and immune response in diarrhoea-irritable bowel syndrome by oral disodium cromoglycate: A pilot study, United Eur Gastroenterol J, 5, pp. 887-897, (2017); Wang J., Wang Y., Zhou H., Et al., Clinical efficacy and safety of ketotifen in treating irritable bowel syndrome with diarrhea, Eur J Gastroenterol Hepatol, 32, pp. 706-712, (2020); Mayer E.A., Naliboff B.D., Chang L., Et al., Stress and irritable bowel syndrome, Am J Physiol, 280, pp. G519-G524, (2001); Qin H.Y., Cheng C.W., Tang X.D., Et al., Impact of psychological stress on irritable bowel syndrome, World J Gastroenterol, 20, pp. 14126-14131, (2014); Surdea-Blaga T., Bban A., Dumitrascu D.L., Psychosocial determinants of irritable bowel syndrome, World J Gastroenterol, 18, pp. 616-626, (2012); Whitehead W.E., Palsson O., Jones K.R., Systematic review of the comorbidity of irritable bowel syndrome with other disorders: What are the causes and implications?, Gastroenterology, 122, pp. 1140-1156, (2002); Naliboff B.D., Smith S.R., Serpa J.G., Et al., Mindfulness-based stress reduction improves irritable bowel syndrome (IBS) symptoms via specific aspects of mindfulness, Neurogastroenterol Motil, (2020); Barclay G.R., Turnberg L.A., Effect of psychological stress on salt and water transport in the human jejunum, Gastroenterology, 93, pp. 91-97, (1987); Barclay G.R., Turnberg L.A., Effect of cold-induced pain on salt and water transport in the human jejunum, Gastroenterology, 94, pp. 994-998, (1988); Santos J., Saperas E., Nogueiras C., Et al., Release of mast cell mediators into the jejunum by cold pain stress in humans, Gastroenterology, 114, pp. 640-648, (1998); Alonso C., Guilarte M., Vicario M., Et al., Maladaptive intestinal epithelial responses to life stress may predispose healthy women to gut mucosal inflammation, Gastroenterology, 135, pp. 163-172, (2008); Vanuytsel T., Van Wanrooy S., Vanheel H., Et al., Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism, Gut, 63, pp. 1293-1299, (2014); Koob G.F., Corticotropin-releasing factor, norepinephrine, and stress, Biol Psychiatry, 46, pp. 1167-1180, (1999); Tache Y., Perdue M.H., Role of peripheral CRF signalling pathways in stress-related alterations of gut motility and mucosal function, Neurogastroenterol Motil, 16, pp. 137-142, (2004); Larauche M., Kiank C., Tache Y., Corticotropin releasing factor signaling in colon and ileum: Regulation by stress and pathophysiological implications, J Physiol Pharmacol, 60, pp. 33-46, (2009); Kano M., Muratsubaki T., Van Oudenhove L., Et al., Altered brain and gut responses to corticotropin-releasing hormone (CRH) in patients with irritable bowel syndrome, Sci Rep, 7, pp. 124-125, (2017); Tayama J., Sagami Y., Shimada Y., Et al., Effect of alpha-helical CRH on quantitative electroencephalogram in patients with irritable bowel syndrome, Neurogastroenterol Motil, 19, pp. 471-483, (2007); Wallon C., Yang P.C., Keita A., Et al., Corticotropin-releasing hormone (CRH) regulates macromolecular permeability via mast cells in normal human colonic biopsies in vitro, Gut, 57, pp. 50-58, (2008); Holmes T.H., Rahe R.H., The social readjustment rating scale, J Psychosom Med, 11, pp. 213-218, (1967); Beck A.T., Ward C.H., Mendelson M., Et al., An inventory for measuring depression, Arch Gen Psychiatry, 4, pp. 561-571, (1961); Spiegel B., Bolus R., Harris L.A., Et al., Measuring irritable bowel syndrome patient-reported outcomes with an abdominal pain numeric rating scale, Aliment Pharmacol Ther, 30, pp. 1159-1170, (2009); Naliboff B.D., Benton D., Solomon G.F., Et al., Immunological changes in young and old adults during brief laboratory stress, Psychosom Med, 53, pp. 121-132, (1991); Muglia L., Jacobson L., Dikkes P., Et al., Corticotropin-releasing hormone deficiency reveals major fetal but not adult glucocorticoid need, Nature, 373, pp. 427-432, (1995); Heitkemper M., Jarrett M., Cain K., Et al., Increased urine catecholamines and cortisol in women with irritable bowel syndrome, Am J Gastroenterol, 91, pp. 906-913, (1996); Fukudo S., Nomura T., Hongo M., Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome, Gut, 42, pp. 845-849, (1998); Dinan T.G., Quigley E.M., Ahmed S.M., Et al., Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: Plasma cytokines as a potential biomarker?, Gastroenterology, 130, pp. 304-311, (2006); Bohmelt A.H., Nater U.M., Franke S., Et al., Basal and stimulated hypothalamic-pituitary-Adrenal axis activity in patients with functional gastrointestinal disorders and healthy controls, Psychosom Med, 67, pp. 288-294, (2005); Tanaka Y., Kanazawa M., Kano M., Et al., Differential activation in amygdala and plasma noradrenaline during colorectal distention by administration of corticotropin-releasing hormone between healthy individuals and patients with irritable bowel syndrome, PLoS One, 11, (2016); Murray K.A., Lam C., Rehman S., Et al., Corticotropin-releasing factor increases ascending colon volume after a fructose test meal in healthy humans: A randomized controlled trial, Am J Clin Nutr, 103, pp. 1318-1326, (2016); Camilleri M., Leaky gut: Mechanisms, measurement and clinical implications in humans, Gut, 68, pp. 1516-1526, (2019); Zuo L., Kuo W.T., Turner J.R., Tight junctions as targets and effectors of mucosal immune homeostasis, Cell Mol Gastroenterol Hepatol, 10, 2, pp. 327-340, (2020); Fihn B.M., Sjoqvist A., Jodal M., Permeability of the rat small intestinal epithelium along the villus-crypt axis: Effects of glucose transport, Gastroenterology, 119, pp. 1029-1036, (2000); Buschmann M.M., Shen L., Rajapakse H., Et al., Occludin OCEL-domain interactions are required for maintenance and regulation of the tight junction barrier to macromolecular flux, Mol Biol Cell, 24, pp. 3056-3068, (2013); Demaude J., Salvador-Cartier C., Fioramonti J., Et al., Phenotypic changes in colonocytes following acute stress or activation of mast cells in mice: Implications for delayed epithelial barrier dysfunction, Gut, 55, pp. 655-661, (2006); Yue H., Bin L., Chaoying C., Et al., Potential regulatory effects of corticotropin-releasing factor on tight junction-related intestinal epithelial permeability are partially mediated by CK8 upregulation, Cell Physiol Biochem, 44, pp. 1161-1173, (2017); Alpern R.J., Moe O.W., Caplan M., Seldin and Giebisch's the Kidney, 5th Edition. Physiology and Pathophysiology, (2012); Hashem L., Swedrowska M., Vllasaliu D., Intestinal uptake and transport of albumin nanoparticles: Potential for oral delivery, Nanomedicine (Lond), 13, pp. 1255-1265, (2018); Hartmann P., Chen P., Wang H.J., Et al., Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice, Hepatology, 58, pp. 108-119, (2013); Beeken W.L., Clearance of circulating radiochromated albumin and erythrocytes by the gastrointestinal tract of normal subjects, Gastroenterology, 52, pp. 35-41, (1967); Yuan P.Q., Wu S.V., Elliott J., Et al., Expression of corticotropin releasing factor receptor type 1 (CRF1) in the human gastrointestinal tract and upregulation in the colonic mucosa in patients with ulcerative colitis, Peptides, 38, pp. 62-69, (2012); Saunders P.R., Maillot C., Million M., Et al., Peripheral corticotropin-releasing factor induces diarrhea in rats: Role of CRF1 receptor in fecal watery excretion, Eur J Pharmacol, 435, pp. 231-235, (2002); Keita A.V., Soderholm J.D., Ericson A.C., Stress-induced barrier disruption of rat follicle-Associated epithelium involves corticotropin-releasing hormone, acetylcholine, substance P, and mast cells, Neurogastroenterol Motil, 22, pp. 770-778, (2010); Barreau F., Cartier C., Leveque M., Et al., Pathways involved in gut mucosal barrier dysfunction induced in adult rats by maternal deprivation: Corticotrophin-releasing factor and nerve growth factor interplay, J Physiol, 580, pp. 347-356, (2007); Overman E.L., Rivier J.E., Moeser A.J., CRF induces intestinal epithelial barrier injury via the release of mast cell proteases and TNF-α, PLoS One, 7, (2012); Santos J., Yates D., Guilarte M., Et al., Stress neuropeptides evoke epithelial responses via mast cell activation in the rat colon, Psychoneuroendocrinology, 33, pp. 1248-1256, (2008); Sato N., Suzuki N., Sasaki A., Et al., Corticotropin-releasing hormone receptor 1 gene variants in irritable bowel syndrome, PLoS One, 7, (2012); Komuro H., Sato N., Sasaki A., Et al., Corticotropin-releasing hormone receptor 2 gene variants in irritable bowel syndrome, PLoS One, 11, (2016); Udelsman R., Gallucci W.T., Bacher J., Et al., Hemodynamic effects of corticotropin releasing hormone in the anesthetized cynomolgus monkey, Peptides, 7, pp. 465-471, (1986); Muramatsu Y., Fukushima K., Iino K., Et al., Urocortin and corticotropin-releasing factor receptor expression in the human colonic mucosa, Peptides, 21, pp. 1799-1809, (2000); Yuan P.Q., Wu V., Chang L., Cellular localization of corticotropin-releasing factor (CRF) receptor 1 (CRF1) in human colon and its expression in the jejunum and colon of irritable bowel syndrome (IBS) female and male patients, Gastroenterology, 132, (2007); Sagami Y., Shimada Y., Tayama J., Et al., Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome, Gut, 53, pp. 958-964, (2004); D'Costa S., Ayyadurai S., Gibson A.J., Et al., Mast cell corticotropin-releasing factor subtype 2 suppresses mast cell degranulation and limits the severity of anaphylaxis and stress-induced intestinal permeability, J Allergy Clin Immunol, 143, pp. 1865-1877, (2019); Ayyadurai S., Gibson A.J., D'Costa S., Et al., Frontline science: Corticotropin-releasing factor receptor subtype 1 is a critical modulator of mast cell degranulation and stress-induced pathophysiology, J Leukoc Biol, 102, pp. 1299-1312, (2017); Greetfeld M., Schmidt M.V., Ganea K., Et al., A single episode of restraint stress regulates central corticotrophin-releasing hormone receptor expression and binding in specific areas of the mouse brain, J Neuroendocrinol, 21, pp. 473-480, (2009); Brunson K.L., Grigoriadis D.E., Lorang M.T., Et al., Corticotropin-releasing hormone (CRH) downregulates the function of its receptor (CRF1) and induces CRF1 expression in hippocampal and cortical regions of the immature rat brain, Exp Neurol, 176, pp. 75-86, (2002); Hauger R.L., Risbrough V., Oakley R.H., Et al., Role of CRF receptor signaling in stress vulnerability, anxiety, and depression, Ann N y Acad Sci, 1179, pp. 120-143, (2009); Waters R.P., Rivalan M., Bangasser D.A., Et al., Evidence for the role of corticotropin-releasing factor in major depressive disorder, Neurosci Biobehav Rev, 58, pp. 63-78, (2015); Pritchard S.E., Garsed K.C., Hoad C.L., Et al., Effect of experimental stress on the small bowel and colon in healthy humans, Neurogastroenterol Motil, 27, pp. 542-549, (2015); Keita A.V., Carlsson A.H., Cigehn M., Et al., Vasoactive intestinal polypeptide regulates barrier function via mast cells in human intestinal follicle-Associated epithelium and during stress in rats, Neurogastroenterol Motil, 25, pp. e406-e417, (2013); Masini E., Fantozzi R., Blandina P., Ellis G.P., West G.B., In E., Amsterdam A., Elsevier Science Publishers B.V., The riddle of cholinergic histamine release from mast cells, Progress in Medicinal Chemistry, 22, pp. 267-291, (1985); Wallon C., Persborn M., Jonsson M., Et al., Eosinophils express muscarinic receptors and corticotropin-releasing factor to disrupt the mucosal barrier in ulcerative colitis, Gastroenterology, 140, pp. 1597-1607, (2011); Zheng P.Y., Feng B.S., Oluwole C., Et al., Psychological stress induces eosinophils to produce corticotrophin releasing hormone in the intestine, Gut, 58, pp. 1473-1479, (2009)","J. Santos; Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Department of Gastroenterology, Barcelona, Spain; email: javier.santos@vhir.org; C. Alonso-Cotoner; Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas (CIBERehd, Madrid, Spain; email: carmen.alonso@vhir.org","","Wolters Kluwer Health","","","","","","00029270","","AJGAA","32740086","English","Am. J. Gastroenterol.","Article","Final","","Scopus","2-s2.0-85096709151"

"Piccione M.; Facchinello N.; Schrenk S.; Gasparella M.; Pathak S.; Ammar R.M.; Rabini S.; Valle L.D.; Di Liddo R.","Piccione, Monica (57212508634); Facchinello, Nicola (24179339600); Schrenk, Sandra (56294053400); Gasparella, Marco (7801539071); Pathak, Surajit (7203000636); Ammar, Ramy M. (57211509168); Rabini, Sabine (6507407620); Valle, Luisa Dalla (57577281500); Di Liddo, Rosa (8711748200)","57212508634; 24179339600; 56294053400; 7801539071; 7203000636; 57211509168; 6507407620; 57577281500; 8711748200","Stw 5 herbal preparation modulates wnt3a and claudin 1 gene expression in zebrafish ibs-like model","2021","Pharmaceuticals","14","12","1234","","","","0","10.3390/ph14121234","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85120932567&doi=10.3390%2fph14121234&partnerID=40&md5=d9ffec5078cd24faf174c01cf932cf4f","Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, 35131, Italy; Department of Biology, University of Padova, Padova, 35131, Italy; Department of Pediatric Surgery, Ca Foncello Hospital, Treviso, 31100, Italy; Department of Medical Biotechnology Faculty of Allied Health Sciences, Chettinad Hospital and Research Institute (CHRI), Chettinad Academy of Research and Education (CARE), Kelambakkam, 603103, India; BAYER Consumer Health, Global Medical Affairs, Darmstadt, 64295, Germany; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Kafrelsheikh University, Kafr-El Sheikh, 33516, Egypt","Piccione M., Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, 35131, Italy; Facchinello N., Department of Biology, University of Padova, Padova, 35131, Italy; Schrenk S., Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, 35131, Italy; Gasparella M., Department of Pediatric Surgery, Ca Foncello Hospital, Treviso, 31100, Italy; Pathak S., Department of Medical Biotechnology Faculty of Allied Health Sciences, Chettinad Hospital and Research Institute (CHRI), Chettinad Academy of Research and Education (CARE), Kelambakkam, 603103, India; Ammar R.M., BAYER Consumer Health, Global Medical Affairs, Darmstadt, 64295, Germany, Department of Pharmacology and Toxicology, Faculty of Pharmacy, Kafrelsheikh University, Kafr-El Sheikh, 33516, Egypt; Rabini S., BAYER Consumer Health, Global Medical Affairs, Darmstadt, 64295, Germany; Valle L.D., Department of Biology, University of Padova, Padova, 35131, Italy; Di Liddo R., Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, 35131, Italy","Aim: Irritable bowel syndrome (IBS) is a functional bowel disorder characterized by chronic abdominal pain and stool irregularities. STW 5 has proven clinical efficacy in functional gastrointestinal disorders, including IBS, targeting pathways that suppress inflammation and protect the mucosa. Wnt signaling is known to modulate NF-kβ-dependent inflammatory cytokine production. This sparked the idea of evaluating the impact of STW 5 on the expression of inflammatory-response and Wnt/β catenin-target genes in an IBS-like model. Main methods: We used zebrafish and dextran sodium sulfate (DSS) treatment to model IBS-like conditions in vivo and in vitro and examined the effects of subsequent STW 5 treatment on the intestines of DSS-treated fish and primary cultured intestinal and neuronal cells. Gross gut anatomy, histology, and the expression of Wnt-signaling and cytokine genes were analyzed in treated animals and/or cells, and in controls. Key findings: DSS treatment up-regulated the expression of interleukin-8, tumor necrosis factor-α, wnt3a, and claudin-1 in explanted zebrafish gut. Subsequent STW 5 treatment abolished both the macroscopic signs of gut inflammation, DSS-induced mucosecretory phenotype, and normalized the DSS-induced upregulated expression of il10 and Wnt signaling genes, such as wnt3a and cldn1 in explanted zebrafish gut. Under inflammatory conditions, STW 5 downregulated the expression of the pro-inflammatory cytokine genes il1β, il6, il8, and tnfα while it upregulated the expression of the anti-inflammatory genes il10 and wnt3a in enteric neuronal cells in vitro. Significance: Wnt signaling could be a novel target for the anti-inflammatory and intestinal permeability-restoring effects of STW 5, possibly explaining its clinical efficacy in IBS. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.","Claudin 1; IBS; NF-kβ; STW 5; Wnt signaling; Wnt3a; Zebrafish","claudin 1; dextran sulfate; herbaceous agent; stw 5; unclassified drug; Wnt3a protein; adult; animal cell; animal experiment; animal model; animal tissue; Article; cell culture; cldn1 gene; controlled study; down regulation; gene; gene expression; gene targeting; histology; in vitro study; in vivo study; intestine cell; irritable colon; male; nerve cell; nonhuman; protein expression; upregulation; Wnt3a gene; zebra fish","","claudin 1, 329338-06-9; dextran sulfate, 9011-18-1, 9042-14-2","","","Executive Program for Scientific and Technological Cooperation between the Italian Republic, (In17mo05); Steigerwald Arzneimittelwerk GmbH; Bayer Consumer Health","Funding: This study was funded by Bayer Consumer Health, Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany. The funding did not in any way influence the outcome or any part of the study. The collaboration with Professor Pathak Surajit was supported by the Executive Program for Scientific and Technological Cooperation between the Italian Republic and the Republic of India (In17mo05).","Drossman D.A., Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV, Gastroenterology, 150, pp. 1262-1279, (2016); Enck P., Aziz Q., Barbara G., Farmer A.D., Fukudo S., Mayer E.A., Niesler B., Quigley E.M., Rajilic-Stojanovic M., Schemann M., Et al., Irritable bowel syndrome, Nat. Rev. Dis. Primers, 2, (2016); Schmulson M.J., Drossman D.A., What Is New in Rome IV, J. Neurogastroenterol. Motil, 23, pp. 151-163, (2017); Lacy B.E., Chey W.D., Lembo A.J., New and Emerging Treatment Options for Irritable Bowel Syndrome, Gastroenterol. Hepatol, 11, pp. 1-19, (2015); Lembo A.J., Lacy B.E., Zuckerman M.J., Schey R., Dove L.S., Andrae D.A., Davenport J.M., McIntyre G., Lopez R., Turner L., Et al., Eluxadoline for Irritable Bowel Syndrome with Diarrhea, N. Engl. J. Med, 374, pp. 242-253, (2016); Chadwick V.S., Chen W., Shu D., Paulus B., Bethwaite P., Tie A., Wilson I., Activation of the mucosal immune system in irritable bowel syndrome, Gastroenterology, 122, pp. 1778-1783, (2002); Stasi C., Rosselli M., Bellini M., Laffi G., Milani S., Altered neuro-endocrine-immune pathways in the irritable bowel syndrome: The top-down and the bottom-up model, J. Gastroenterol, 47, pp. 1177-1185, (2012); Hughes P.A., Harrington A.M., Castro J., Liebregts T., Adam B., Grasby D.J., Isaacs N.J., Maldeniya L., Martin C.M., Persson J., Et al., Sensory neuro-immune interactions differ between irritable bowel syndrome subtypes, Gut, 62, pp. 1456-1465, (2013); Hughes K.R., Sablitzky F., Mahida Y.R., Expression profiling of Wnt family of genes in normal and inflammatory bowel disease primary human intestinal myofibroblasts and normal human colonic crypt epithelial cells, Inflamm. Bowel Dis, 17, pp. 213-220, (2011); Ford A.C., Moayyedi P., Lacy B.E., Lembo A.J., Saito Y.A., Schiller L.R., Soffer E.E., Spiegel B.M., Quigley E.M., The Task Force on the Management of Functional Bowel Disorders. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation, Am. J. Gastroenterol, 109, pp. S2-S26, (2014); Chey W.D., Kurlander J., Eswaran S., Irritable bowel syndrome: A clinical review, JAMA, 313, pp. 949-958, (2015); Liu J.P., Yang M., Liu Y.X., Wei M., Grimsgaard S., Herbal medicines for treatment of irritable bowel syndrome, Cochrane Database Syst. Rev, (2006); Holtmann G., Schrenk D., Madisch A., Allescher H.D., Ulrich-Merzenich G., Mearin F., Larrey D., Malfertheiner P., Use of Evidence-Based Herbal Medicines for Patients with Functional Gastrointestinal Disorders: A Conceptional Framework for Risk-Benefit Assessment and Regulatory Approaches, Dig. Dis, 38, pp. 269-279, (2020); Rosch W., Vinson B., Sassin I., A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia, Z. Gastroenterol, 40, pp. 401-408, (2002); Madisch A., Holtmann G., Mayr G., Vinson B., Hotz J., Treatment of functional dyspepsia with a herbal preparation. A double-blind, randomized, placebo-controlled, multicenter trial, Digestion, 69, pp. 45-52, (2004); Madisch A., Holtmann G., Plein K., Hotz J., Treatment of irritable bowel syndrome with herbal preparations: Results of a double-blind, randomized, placebo-controlled, multi-centre trial, Aliment. Pharmacol. Ther, 19, pp. 271-279, (2004); Raedsch R., Hanisch J., Bock P., Sibaev A., Vinson B., Gundermann K.J., Assessment of the efficacy and safety of the phytopharmacon STW 5 versus metoclopramide in functional dyspepsia—A retrolective cohort study, Z. Gastroenterol, 45, pp. 1041-1048, (2007); von Arnim U., Peitz U., Vinson B., Gundermann K.J., Malfertheiner P., STW 5, a phytopharmacon for patients with functional dyspepsia: Results of a multicenter, placebo-controlled double-blind study, Am. J. Gastroenterol, 102, pp. 1268-1275, (2007); Braden B., Caspary W., Borner N., Vinson B., Schneider A.R., Clinical effects of STW 5 (Iberogast) are not based on acceleration of gastric emptying in patients with functional dyspepsia and gastroparesis, Neurogastroenterol. Motil, 21, pp. 632-638, (2009); Abdel-Aziz H., Kelber O., Lorkowski G., Storr M., Evaluating the Multitarget Effects of Combinations through Multistep Clustering of Pharmacological Data: The Example of the Commercial Preparation Iberogast, Planta Med, 83, pp. 1130-1140, (2017); Allescher H.D., Abdel-Aziz H., Mechanism of Action of STW 5 in Functional Dyspepsia and IBS: The Origin of Multi-Target, Dig. Dis, 35, pp. 18-24, (2017); Allescher H.D., Wagner H., STW 5/Iberogast: Multi-target-action for treatment of functional dyspepsia and irritable bowel syndrome, Wien. Med. Wochenschr, 157, pp. 301-307, (2007); Ottillinger B., Storr M., Malfertheiner P., Allescher H.D., STW 5 (Iberogast®)--a safe and effective standard in the treatment of functional gastrointestinal disorders, Wien. Med. Wochenschr, 163, pp. 65-72, (2013); Malfertheiner P., STW 5 (Iberogast) Therapy in Gastrointestinal Functional Disorders, Dig. Dis, 35, pp. 25-29, (2017); Di Liddo R., Bertalot T., Schuster A., Schrenk S., Tasso A., Zanusso I., Conconi M.T., Schafer K.H., Anti-inflammatory activity of Wnt signaling in enteric nervous system: In vitro preliminary evidences in rat primary cultures, J. Neuroinflamm, 12, (2015); Le Guen L., Marchal S., Faure S., de Santa Barbara P., Mesenchymal-epithelial interactions during digestive tract development and epithelial stem cell regeneration, Cell Mol. Life Sci, 72, pp. 3883-3896, (2015); Simonetti M., Agarwal N., Stosser S., Bali K.K., Karaulanov E., Kamble R., Pospisilova B., Kurejova M., Birchmeier W., Niehrs C., Et al., Wnt-Fzd signaling sensitizes peripheral sensory neurons via distinct noncanonical pathways, Neuron, 83, pp. 104-121, (2014); Katoh M., WNT signaling in stem cell biology and regenerative medicine, Curr. Drug Targets, 9, pp. 565-570, (2008); Ratanasirintrawoot S., Israsena N., Stem Cells in the Intestine: Possible Roles in Pathogenesis of Irritable Bowel Syndrome, J. Neurogastroenterol. Motil, 22, pp. 367-382, (2016); Neumann J., Schaale K., Farhat K., Endermann T., Ulmer A.J., Ehlers S., Reiling N., Frizzled1 is a marker of inflammatory macrophages, and its ligand Wnt3a is involved in reprogramming Mycobacterium tuberculosis-infected macrophages, FASEB J, 24, pp. 4599-4612, (2010); Ma B., Hottiger M.O., Crosstalk between Wnt/β-Catenin and NF-κB Signaling Pathway during Inflammation, Front. Immunol, 7, (2016); Manicassamy S., Reizis B., Ravindran R., Nakaya H., Salazar-Gonzalez R.M., Wang Y.C., Pulendran B., Activation of beta-catenin in dendritic cells regulates immunity versus tolerance in the intestine, Science, 329, pp. 849-853, (2010); Di Liddo R., Bertalot T., Schuster A., Schrenk S., Muller O., Apfel J., Reischmann P., Rajendran S., Sfriso R., Gasparella M., Et al., Fluorescence-based gene reporter plasmid to track canonical Wnt signaling in ENS inflammation, Am. J. Physiol. Gastrointest. Liver Physiol, 310, pp. G337-G346, (2016); Sen M., Ghosh G., Transcriptional outcome of Wnt-Frizzled signal transduction in inflammation: Evolving concepts, J. Immunol, 181, pp. 4441-4445, (2008); Jridi I., Cante-Barrett K., Pike-Overzet K., Staal F.J.T., Inflammation and Wnt Signaling: Target for Immunomodulatory Therapy?, Front. Cell Dev. Biol, 8, (2020); Yang Y., Tomkovich S., Jobin C., Could a swimming creature inform us on intestinal diseases? Lessons from zebrafish, Inflamm. Bowel Dis, 20, pp. 956-966, (2014); Scanzi J., Accarie A., Muller E., Pereira B., Aissouni Y., Goutte M., Joubert-Zakeyh J., Picard E., Boudieu L., Mallet C., Et al., Colonic overexpression of the T-type calcium channel Ca, Neurogastroenterol. Motil, 28, pp. 1632-1640, (2016); Camilleri M., Carlson P., Valentin N., Acosta A., O'Neill J., Eckert D., Dyer R., Na J., Klee E.W., Murray J.A., Pilot study of small bowel mucosal gene expression in patients with irritable bowel syndrome with diarrhea, Am. J. Physiol. Gastrointest. Liver Physiol, 311, pp. G365-G376, (2016); D'Antongiovanni V., Pellegrini C., Fornai M., Colucci R., Blandizzi C., Antonioli L., Bernardini N., Intestinal epithelial barrier and neuromuscular compartment in health and disease, World J. Gastroenterol, 26, pp. 1564-1579, (2020); You J., Nguyen A.V., Albers C.G., Lin F., Holcombe R.F., Wnt pathway-related gene expression in inflammatory bowel disease, Dig. Dis. Sci, 53, pp. 1013-1019, (2008); Kim Y.S., Ho S.B., Intestinal goblet cells and mucins in health and disease: Recent insights and progress, Curr. Gastroenterol. Rep, 12, pp. 319-330, (2010); Dharmani P., Leung P., Chadee K., Tumor necrosis factor-α and Muc2 mucin play major roles in disease onset and progression in dextran sodium sulphate-induced colitis, PLoS ONE, 6, (2011); Cheng P., Yao J., Wang C., Zhang L., Kong W., Molecular and cellular mechanisms of tight junction dysfunction in the irritable bowel syndrome, Mol. Med. Rep, 12, pp. 3257-3264, (2015); Wallace K.N., Akhter S., Smith E.M., Lorent K., Pack M., Intestinal growth and differentiation in zebrafish, Mech. Dev, 122, pp. 157-173, (2005); Graham V., Khudyakov J., Ellis P., Pevny L., SOX2 functions to maintain neural progenitor identity, Neuron, 39, pp. 749-765, (2003); Heanue T.A., Pachnis V., Prospective identification and isolation of enteric nervous system progenitors using Sox2, Stem Cells, 29, pp. 128-140, (2011); Laranjeira C., Sandgren K., Kessaris N., Richardson W., Potocnik A., Vanden Berghe P., Pachnis V., Glial cells in the mouse enteric nervous system can undergo neurogenesis in response to injury, J. Clin. Investig, 121, pp. 3412-3424, (2011); Colomier E., Algera J., Melchior C., Pharmacological Therapies and Their Clinical Targets in Irritable Bowel Syndrome With Diarrhea, Front. Pharmacol, 11, (2020); Ohman L., Simren M., Pathogenesis of IBS: Role of inflammation, immunity and neuroimmune interactions, Nat. Rev. Gastroenterol. Hepatol, 7, pp. 163-173, (2010); Abdul Rani R., Raja Ali R.A., Lee Y.Y., Irritable bowel syndrome and inflammatory bowel disease overlap syndrome: Pieces of the puzzle are falling into place, Intest. Res, 14, pp. 297-304, (2016); Goldsmith J.R., Jobin C., Think small: Zebrafish as a model system of human pathology, J. Biomed. Biotechnol, 2012, (2012); Chassaing B., Srinivasan G., Delgado M.A., Young A.N., Gewirtz A.T., Vijay-Kumar M., Fecal lipocalin 2, a sensitive and broadly dynamic non-invasive biomarker for intestinal inflammation, PLoS ONE, 7, (2012); Spiller R., Garsed K., Infection, inflammation, and the irritable bowel syndrome, Dig. Liver Dis, 41, pp. 844-849, (2009); Buhner S., Li Q., Vignali S., Barbara G., De Giorgio R., Stanghellini V., Cremon C., Zeller F., Langer R., Daniel H., Et al., Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome, Gastroenterology, 137, pp. 1425-1434, (2009); Clarke G., Quigley E.M., Cryan J.F., Dinan T.G., Irritable bowel syndrome: Towards biomarker identification, Trends Mol. Med, 15, pp. 478-489, (2009); Dinan T.G., Quigley E.M., Ahmed S.M., Scully P., O'Brien S., O'Mahony L., O'Mahony S., Shanahan F., Keeling P.W., Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: Plasma cytokines as a potential biomarker?, Gastroenterology, 130, pp. 304-311, (2006); Liebregts T., Adam B., Bredack C., Roth A., Heinzel S., Lester S., Downie-Doyle S., Smith E., Drew P., Talley N.J., Et al., Immune activation in patients with irritable bowel syndrome, Gastroenterology, 132, pp. 913-920, (2007); Patel S.R., Singh A., Misra V., Misra S.P., Dwivedi M., Trivedi P., Levels of interleukins 2, 6, 8, and 10 in patients with irritable bowel syndrome, Indian J. Pathol. Microbiol, 60, pp. 385-389, (2017); Dinan T.G., Clarke G., Quigley E.M., Scott L.V., Shanahan F., Cryan J., Cooney J., Keeling P.W., Enhanced cholinergic-mediated increase in the pro-inflammatory cytokine IL-6 in irritable bowel syndrome: Role of muscarinic receptors, Am. J. Gastroenterol, 103, pp. 2570-2576, (2008); Xia Y., Hu H.Z., Liu S., Ren J., Zafirov D.H., Wood J.D., IL-1beta and IL-6 excite neurons and suppress nicotinic and noradrenergic neurotransmission in guinea pig enteric nervous system, J. Clin. Investig, 103, pp. 1309-1316, (1999); O'Malley D., Quigley E.M., Dinan T.G., Cryan J.F., Do interactions between stress and immune responses lead to symptom exacerbations in irritable bowel syndrome?, Brain Behav. Immun, 25, pp. 1333-1341, (2011); Natale L., Piepoli A.L., De Salvia M.A., De Salvatore G., Mitolo C.I., Marzullo A., Portincasa P., Moschetta A., Palasciano G., Mitolo-Chieppa D., Interleukins 1 beta and 6 induce functional alteration of rat colonic motility: An in vitro study, Eur. J. Clin. Investig, 33, pp. 704-712, (2003); Kindt S., Vanden Berghe P., Boesmans W., Roosen L., Tack J., Prolonged IL-1beta exposure alters neurotransmitter and electrically induced Ca(2+) responses in the myenteric plexus, Neurogastroenterol. Motil, 22, pp. 321-e385, (2010); McKernan D.P., Gaszner G., Quigley E.M., Cryan J.F., Dinan T.G., Altered peripheral toll-like receptor responses in the irritable bowel syndrome, Aliment. Pharmacol. Ther, 33, pp. 1045-1052, (2011); Buckley M.M., O'Halloran K.D., Rae M.G., Dinan T.G., O'Malley D., Modulation of enteric neurons by interleukin-6 and corticotropin-releasing factor contributes to visceral hypersensitivity and altered colonic motility in a rat model of irritable bowel syndrome, J. Physiol, 592, pp. 5235-5250, (2014); Kyoko O.O., Kono H., Ishimaru K., Miyake K., Kubota T., Ogawa H., Okumura K., Shibata S., Nakao A., Expressions of tight junction proteins Occludin and Claudin-1 are under the circadian control in the mouse large intestine: Implications in intestinal permeability and susceptibility to colitis, PLoS ONE, 9, (2014); Allescher H.D., Burgell R., Malfertheiner P., Mearin F., Multi-target Treatment for Irritable Bowel Syndrome with STW 5: Pharmacological Modes of Action, J. Gastrointestin. Liver Dis, 29, pp. 227-233, (2020); Dhawan P., Singh A.B., Deane N.G., No Y., Shiou S.R., Schmidt C., Neff J., Washington M.K., Beauchamp R.D., Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer, J. Clin. Investig, 115, pp. 1765-1776, (2005); Miwa N., Furuse M., Tsukita S., Niikawa N., Nakamura Y., Furukawa Y., Involvement of claudin-1 in the beta-catenin/Tcf signaling pathway and its frequent upregulation in human colorectal cancers, Oncol. Res, 12, pp. 469-476, (2001); O'Garra A., Vieira P., T(H)1 cells control themselves by producing interleukin-10, Nat. Rev. Immunol, 7, pp. 425-428, (2007); Krueger D., Gruber L., Buhner S., Zeller F., Langer R., Seidl S., Michel K., Schemann M., The multi-herbal drug STW 5 (Iberogast) has prosecretory action in the human intestine, Neurogastroenterol. Motil, 21, pp. 1203-e1110, (2009); Allam S., Krueger D., Demir I.E., Ceyhan G., Zeller F., Schemann M., Extracts from peppermint leaves, lemon balm leaves and in particular angelica roots mimic the pro-secretory action of the herbal preparation STW 5 in the human intestine, Phytomedicine, 22, pp. 1063-1070, (2015); Alestrom P., D'Angelo L., Midtlyng P.J., Schorderet D.F., Schulte-Merker S., Sohm F., Warner S., Zebrafish: Housing and husbandry recommendations, Lab. Anim, 54, pp. 213-224, (2020); Oehlers S.H., Flores M.V., Hall C.J., Okuda K.S., Sison J.O., Crosier K.E., Crosier P.S., Chemically induced intestinal damage models in zebrafish larvae, Zebrafish, 10, pp. 184-193, (2013); Chira A., Dumitrascu D.L., Serum biomarkers for irritable bowel syndrome, Clujul Med, 88, pp. 258-264, (2015); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Lecleire S., Antonietti M., Gourcerol G., Leroi A.M., Dechelotte P., Menard J.F., Ducrotte P., Et al., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am. J. Gastroenterol, 106, pp. 2165-2173, (2011); Kumar S., Shukla R., Ranjan P., Kumar A., Interleukin-10: A Compelling Therapeutic Target in Patients With Irritable Bowel Syndrome, Clin. Ther, 39, pp. 632-643, (2017); Schafer K.H., Saffrey M.J., Burnstock G., Mestres-Ventura P., A new method for the isolation of myenteric plexus from the newborn rat gastrointestinal tract, Brain Res. Brain Res. Protoc, 1, pp. 109-113, (1997)","R. Di Liddo; Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, 35131, Italy; email: rosa.diliddo@unipd.it","","MDPI","","","","","","14248247","","","","English","Pharmaceuticals","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85120932567"

"Bahlouli W.; Breton J.; Lelouard M.; L'Huillier C.; Tirelle P.; Salameh E.; Amamou A.; Atmani K.; Goichon A.; Bôle-Feysot C.; Ducrotté P.; Ribet D.; Déchelotte P.; Coëffier M.","Bahlouli, Wafa (57191848794); Breton, Jonathan (13611261000); Lelouard, Mauranne (57216769729); L'Huillier, Clément (56177469400); Tirelle, Pauline (57216763674); Salameh, Emmeline (57202534256); Amamou, Asma (57209071590); Atmani, Karim (57950265700); Goichon, Alexis (46861122700); Bôle-Feysot, Christine (55881037400); Ducrotté, Philippe (7006732860); Ribet, David (6506850472); Déchelotte, Pierre (57201760610); Coëffier, Moïse (6603081357)","57191848794; 13611261000; 57216769729; 56177469400; 57216763674; 57202534256; 57209071590; 57950265700; 46861122700; 55881037400; 7006732860; 6506850472; 57201760610; 6603081357","Stress-induced intestinal barrier dysfunction is exacerbated during diet-induced obesity","2020","Journal of Nutritional Biochemistry","81","","108382","","","","10","10.1016/j.jnutbio.2020.108382","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85084561213&doi=10.1016%2fj.jnutbio.2020.108382&partnerID=40&md5=501abba883a2fd234c63de5f501f8332","Normandie University, UNIROUEN, INSERM UMR 1073 “Nutrition, inflammation and gut-brain axis”, Rouen, 76183, France; Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Rouen, 76183, France; Department of Gastroenterology, Rouen University Hospital, Rouen, 76183, France; Department of Nutrition, Rouen University Hospital, Rouen, 76183, France","Bahlouli W., Normandie University, UNIROUEN, INSERM UMR 1073 “Nutrition, inflammation and gut-brain axis”, Rouen, 76183, France, Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Rouen, 76183, France; Breton J., Normandie University, UNIROUEN, INSERM UMR 1073 “Nutrition, inflammation and gut-brain axis”, Rouen, 76183, France, Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Rouen, 76183, France; Lelouard M., Normandie University, UNIROUEN, INSERM UMR 1073 “Nutrition, inflammation and gut-brain axis”, Rouen, 76183, France, Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Rouen, 76183, France; L'Huillier C., Normandie University, UNIROUEN, INSERM UMR 1073 “Nutrition, inflammation and gut-brain axis”, Rouen, 76183, France, Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Rouen, 76183, France; Tirelle P., Normandie University, UNIROUEN, INSERM UMR 1073 “Nutrition, inflammation and gut-brain axis”, Rouen, 76183, France, Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Rouen, 76183, France; Salameh E., Normandie University, UNIROUEN, INSERM UMR 1073 “Nutrition, inflammation and gut-brain axis”, Rouen, 76183, France, Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Rouen, 76183, France; Amamou A., Normandie University, UNIROUEN, INSERM UMR 1073 “Nutrition, inflammation and gut-brain axis”, Rouen, 76183, France, Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Rouen, 76183, France; Atmani K., Normandie University, UNIROUEN, INSERM UMR 1073 “Nutrition, inflammation and gut-brain axis”, Rouen, 76183, France, Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Rouen, 76183, France; Goichon A., Normandie University, UNIROUEN, INSERM UMR 1073 “Nutrition, inflammation and gut-brain axis”, Rouen, 76183, France, Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Rouen, 76183, France; Bôle-Feysot C., Normandie University, UNIROUEN, INSERM UMR 1073 “Nutrition, inflammation and gut-brain axis”, Rouen, 76183, France, Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Rouen, 76183, France; Ducrotté P., Normandie University, UNIROUEN, INSERM UMR 1073 “Nutrition, inflammation and gut-brain axis”, Rouen, 76183, France, Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Rouen, 76183, France, Department of Gastroenterology, Rouen University Hospital, Rouen, 76183, France; Ribet D., Normandie University, UNIROUEN, INSERM UMR 1073 “Nutrition, inflammation and gut-brain axis”, Rouen, 76183, France, Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Rouen, 76183, France; Déchelotte P., Normandie University, UNIROUEN, INSERM UMR 1073 “Nutrition, inflammation and gut-brain axis”, Rouen, 76183, France, Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Rouen, 76183, France, Department of Nutrition, Rouen University Hospital, Rouen, 76183, France; Coëffier M., Normandie University, UNIROUEN, INSERM UMR 1073 “Nutrition, inflammation and gut-brain axis”, Rouen, 76183, France, Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Rouen, 76183, France, Department of Nutrition, Rouen University Hospital, Rouen, 76183, France","Obesity and irritable bowel syndrome (IBS) are two major public health issues. Interestingly previous data report a marked increase of IBS prevalence in morbid obese subjects compared with non-obese subjects but underlying mechanisms remain unknown. Obesity and IBS share common intestinal pathophysiological mechanisms such as gut dysbiosis, intestinal hyperpermeability and low-grade inflammatory response. We thus aimed to evaluate the link between obesity and IBS using different animal models. Male C57Bl/6 mice received high fat diet (HFD) for 12 weeks and were then submitted to water avoidance stress (WAS). In response to WAS, HFD mice exhibited higher intestinal permeability and plasma corticosterone concentration than non-obese mice. We were not able to reproduce a similar response both in ob/ob mice and in leptin-treated non-obese mice. In addition, metformin, a hypoglycemic agent, limited fasting glycaemia both in unstressed and WAS diet-induced obese mice but only partially restored colonic permeability in unstressed HFD mice. Metformin failed to improve intestinal permeability in WAS HFD mice. Finally, cecal microbiota transplantation from HFD mice in antibiotics-treated recipient mice did not reproduce the effects observed in stressed HFD mice. In conclusion, stress induced a more marked intestinal barrier dysfunction in diet-induced obese mice compared with non-obese mice that seems to be independent of leptin, glycaemia and gut microbiota. These data should be further confirmed and the role of the dietary composition should be studied. © 2020 Elsevier Inc.","Gut barrier; Gut microbiota; Irritable bowel syndrome; Leptin; Metformin; Morbid obesity","Animals; Cecum; Colon; Corticosterone; Diet, High-Fat; Gastrointestinal Microbiome; Humans; Hypoglycemic Agents; Intestinal Mucosa; Irritable Bowel Syndrome; Leptin; Male; Metformin; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Permeability; Prevalence; Stress, Physiological; amphotericin B; ampicillin; claudin 1; corticosterone; genomic DNA; glucose; interleukin 1beta; leptin; messenger RNA; metformin; metronidazole; neomycin; occludin; vancomycin; antidiabetic agent; corticosterone; leptin; metformin; animal experiment; animal model; Article; cecum content; controlled study; corticosterone blood level; diet-induced obesity; disease exacerbation; dysbiosis; enteropathy; fasting; fecal microbiota transplantation; glucose blood level; intestine mucosa permeability; irritable colon; lipid diet; male; microbial community; mouse; nonhuman; obesity; stress; Western blotting; adverse event; animal; blood; C57BL mouse; cecum; colon; human; intestine flora; intestine mucosa; irritable colon; metabolism; microbiology; mouse mutant; obesity; permeability; physiological stress; prevalence","","amphotericin B, 1397-89-3, 30652-87-0; ampicillin, 69-52-3, 69-53-4, 7177-48-2, 74083-13-9, 94586-58-0; claudin 1, 329338-06-9; corticosterone, 50-22-6; glucose, 50-99-7, 84778-64-3; metformin, 1115-70-4, 657-24-9; metronidazole, 39322-38-8, 443-48-1; neomycin, 11004-65-2, 1404-04-2, 1405-10-3, 8026-22-0; occludin, 176304-61-3; vancomycin, 1404-90-6, 1404-93-9; Corticosterone, ; Hypoglycemic Agents, ; Leptin, ; Metformin, ","","","European Union and Normandie Regional Council; Microbiome foundation; Roquette foundation for health; European Regional Development Fund, FEDER","Funding text 1: This work was co-supported by the Microbiome foundation, the Roquette foundation for health and by European Union and Normandie Regional Council (to W.B. and for equipment). Europe gets involved in Normandie with European Regional Development Fund (ERDF). These funders did not participate in the design, implementation, analysis, and interpretation of the data. ; Funding text 2: This work was co-supported by the Microbiome foundation, the Roquette foundation for health and by European Union and Normandie Regional Council (to W.B. and for equipment). Europe gets involved in Normandie with European Regional Development Fund (ERDF). These funders did not participate in the design, implementation, analysis, and interpretation of the data. WB, JB, ML, CL, PT, ES, AA, KA, AG, CBF and DR performed experiments and analyses. WB, PDu and MC designed experiments. WB, DR, PDe and MC interpreted the data. WB and MC wrote the main manuscript text and prepared figures. All authors reviewed the manuscript.","Gallus S., Lugo A., Murisic B., Bosetti C., Boffetta P., La Vecchia C., Overweight and obesity in 16 European countries, Eur J Nutr, 54, 5, pp. 679-689, (2015); Marques A., Peralta M., Naia A., Loureiro N., de Matos M.G., Prevalence of adult overweight and obesity in 20 European countries, 2014, Eur J Pub Health, 28, 2, pp. 295-300, (2018); Turnbaugh P.J., Backhed F., Fulton L., Gordon J.I., Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome, Cell Host Microbe, 3, 4, pp. 213-223, (2008); Cani P.D., Bibiloni R., Knauf C., Waget A., Neyrinck A.M., Delzenne N.M., Et al., Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice, Diabetes, 57, 6, pp. 1470-1481, (2008); Teixeira T.F., Souza N.C., Chiarello P.G., Franceschini S.C., Bressan J., Ferreira C.L., Et al., Intestinal permeability parameters in obese patients are correlated with metabolic syndrome risk factors, Clin Nutr, 31, 5, pp. 735-740, (2012); Le Pluart D., Sabate J.M., Bouchoucha M., Hercberg S., Benamouzig R., Julia C., Functional gastrointestinal disorders in 35,447 adults and their association with body mass index, Aliment Pharmacol Ther, 41, 8, pp. 758-767, (2015); Ford A.C., Lacy B.E., Talley N.J., Irritable Bowel Syndrome, N Engl J Med, 376, 26, pp. 2566-2578, (2017); Bashashati M., Moossavi S., Cremon C., Barbaro M.R., Moraveji S., Talmon G., Et al., Colonic immune cells in irritable bowel syndrome: A systematic review and meta-analysis, Neurogastroenterol Motil, 30, (2018); Menees S., Chey W., The gut microbiome and irritable bowel syndrome, F1000Res, (2018); Piche T., Barbara G., Aubert P., Bruley S., Varannes D., Dainese R., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators, Gut, 58, 2, pp. 196-201, (2009); Dunlop S.P., Hebden J., Campbell E., Naesdal J., Olbe L., Perkins A.C., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, 6, pp. 1288-1294, (2006); Pickett-Blakely O., Obesity and irritable bowel syndrome: a comprehensive review, Gastroenterol Hepatol (N Y), 10, 7, pp. 411-416, (2014); Schneck A.S., Anty R., Tran A., Hastier A., Amor I.B., Gugenheim J., Et al., Increased Prevalence of Irritable Bowel Syndrome in a Cohort of French Morbidly Obese Patients Candidate for Bariatric Surgery, Obes Surg, 26, 7, pp. 1525-1530, (2016); Carter D., Beer-Gabel M., Tzur D., Levy G., Derazne E., Novis B., Et al., Predictive factors for the diagnosis of irritable bowel syndrome in a large cohort of 440,822 young adults, J Clin Gastroenterol, 49, 4, pp. 300-305, (2015); de La Serre C.B., Ellis C.L., Lee J., Hartman A.L., Rutledge J.C., Raybould H.E., Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation, Am J Physiol Gastrointest Liver Physiol, 299, 2, pp. G440-G448, (2010); Ghouzali I., Lemaitre C., Bahlouli W., Azhar S., Bole-Feysot C., Meleine M., Et al., Targeting immunoproteasome and glutamine supplementation prevent intestinal hyperpermeability, Biochim Biophys Acta, 1861, 1, pp. 3278-3288, (2017); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Lecleire S., Antonietti M., Gourcerol G., Et al., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am J Gastroenterol, 106, pp. 2165-2173, (2011); Pugliese G., Muscogiuri G., Barrea L., Laudisio D., Savastano S., Colao A., Irritable bowel syndrome: a new therapeutic target when treating obesity? Hormones (Athens), (2019); Le Drean G., Segain J.P., Connecting metabolism to intestinal barrier function: The role of leptin, Tissue Barriers, 2, 4, (2014); Thaiss C.A., Levy M., Grosheva I., Zheng D., Soffer E., Blacher E., Et al., Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection, Science, 359, 6382, pp. 1376-1383, (2018); Kilkenny C., Parsons N., Kadyszewski E., Festing M.F., Cuthill I.C., Fry D., Et al., Survey of the quality of experimental design, statistical analysis and reporting of research using animals, PLoS One, 4, 11, (2009); Goichon A., Bahlouli W., Ghouzali I., Chan P., Vaudry D., Dechelotte P., Et al., Colonic Proteome Signature in Immunoproteasome-Deficient Stressed Mice and Its Relevance for Irritable Bowel Syndrome, J Proteome Res, 18, 1, pp. 478-492, (2019); Maurya R., Bhattacharya P., Ismail N., Dagur P.K., Joshi A.B., Razdan K., Et al., Differential Role of Leptin as an Immunomodulator in Controlling Visceral Leishmaniasis in Normal and Leptin-Deficient Mice, Am J Trop Med Hyg, 95, 1, pp. 109-119, (2016); Zhou Z.Y., Ren L.W., Zhan P., Yang H.Y., Chai D.D., Yu Z.W., Metformin exerts glucose-lowering action in high-fat fed mice via attenuating endotoxemia and enhancing insulin signaling, Acta Pharmacol Sin, 37, 8, pp. 1063-1075, (2016); Herrmann J.R., Turner J.R., Beyond Ussing's chambers: contemporary thoughts on integration of transepithelial transport, Am J Phys Cell Physiol, 310, 6, pp. C423-C431, (2016); Coeffier M., Gloro R., Boukhettala N., Aziz M., Lecleire S., Vandaele N., Et al., Increased Proteasome-Mediated Degradation of Occludin in Irritable Bowel Syndrome, Am J Gastroenterol, 105, 5, pp. 1181-1188, (2010); Costea P.I., Zeller G., Sunagawa S., Pelletier E., Alberti A., Levenez F., Et al., Towards standards for human fecal sample processing in metagenomic studies, Nat Biotechnol, 35, 11, pp. 1069-1076, (2017); Queipo-Ortuno M.I., Seoane L.M., Murri M., Pardo M., Gomez-Zumaquero J.M., Cardona F., Et al., Gut microbiota composition in male rat models under different nutritional status and physical activity and its association with serum leptin and ghrelin levels, PLoS One, 8, 5, (2013); Fierer N., Jackson J.A., Vilgalys R., Jackson R.B., Assessment of soil microbial community structure by use of taxon-specific quantitative PCR assays, Appl Environ Microbiol, 71, 7, pp. 4117-4120, (2005); Jesus P., Ouelaa W., Francois M., Riachy L., Guerin C., Aziz M., Et al., Alteration of intestinal barrier function during activity-based anorexia in mice, Clin Nutr, 33, pp. 1046-1053, (2014); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, 1-2, pp. 41-46, (2009); Zhou Q., Verne M.L., Fields J.Z., Lefante J.J., Basra S., Salameh H., Et al., Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome, Gut, 68, 6, pp. 996-1002, (2019); Spiller R.C., Jenkins D., Thornley J.P., Hebden J.M., Wright T., Skinner M., Et al., Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, 6, pp. 804-811, (2000); Martinez C., Vicario M., Ramos L., Lobo B., Mosquera J.L., Alonso C., Et al., The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations, Am J Gastroenterol, 107, 5, pp. 736-746, (2012); Martinez C., Lobo B., Pigrau M., Ramos L., Gonzalez-Castro A.M., Alonso C., Et al., Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, 8, pp. 1160-1168, (2013); Annahazi A., Ferrier L., Bezirard V., Leveque M., Eutamene H., Ait-Belgnaoui A., Et al., Luminal Cysteine-Proteases Degrade Colonic Tight Junction Structure and Are Responsible for Abdominal Pain in Constipation-Predominant IBS, Am J Gastroenterol, 108, 8, pp. 1322-1331, (2013); Damms-Machado A., Louis S., Schnitzer A., Volynets V., Rings A., Basrai M., Et al., Gut permeability is related to body weight, fatty liver disease, and insulin resistance in obese individuals undergoing weight reduction, Am J Clin Nutr, 105, 1, pp. 127-135, (2017); Stenman L.K., Holma R., Gylling H., Korpela R., Genetically obese mice do not show increased gut permeability or faecal bile acid hydrophobicity, Br J Nutr, 110, 6, pp. 1157-1164, (2013); Nagpal R., Newman T.M., Wang S., Jain S., Lovato J.F., Yadav H., Obesity-Linked Gut Microbiome Dysbiosis Associated with Derangements in Gut Permeability and Intestinal Cellular Homeostasis Independent of Diet, J Diabetes Res, 2018, (2018); Johnson A.M., Costanzo A., Gareau M.G., Armando A.M., Quehenberger O., Jameson J.M., Et al., High fat diet causes depletion of intestinal eosinophils associated with intestinal permeability, PLoS One, 10, 4, (2015); Kim C.Y., Kim K.H., Curcumin prevents leptin-induced tight junction dysfunction in intestinal Caco-2 BBe cells, J Nutr Biochem, 25, 1, pp. 26-35, (2014); Le Drean G., Haure-Mirande V., Ferrier L., Bonnet C., Hulin P., de Coppet P., Et al., Visceral adipose tissue and leptin increase colonic epithelial tight junction permeability via a RhoA-ROCK-dependent pathway, FASEB J, 28, 3, pp. 1059-1070, (2014); Ye C., Wang R., Wang M., Huang Z., Tang C., Leptin alleviates intestinal mucosal barrier injury and inflammation in obese mice with acute pancreatitis, Int J Obes, 42, 8, pp. 1471-1479, (2018); Rena G., Hardie D.G., Pearson E.R., The mechanisms of action of metformin, Diabetologia, 60, 9, pp. 1577-1585, (2017); Zhou H.Y., Zhu H., Yao X.M., Qian J.P., Yang J., Pan X.D., Et al., Metformin regulates tight junction of intestinal epithelial cells via MLCK-MLC signaling pathway, Eur Rev Med Pharmacol Sci, 21, 22, pp. 5239-5246, (2017); Chen L., Wang J., You Q., He S., Meng Q., Gao J., Et al., Activating AMPK to Restore Tight Junction Assembly in Intestinal Epithelium and to Attenuate Experimental Colitis by Metformin, Front Pharmacol, 9, (2018); Deng J., Zeng L., Lai X., Li J., Liu L., Lin Q., Et al., Metformin protects against intestinal barrier dysfunction via AMPKalpha1-dependent inhibition of JNK signalling activation, J Cell Mol Med, 22, 1, pp. 546-557, (2018); Nozu T., Miyagishi S., Kumei S., Nozu R., Takakusaki K., Okumura T., Metformin inhibits visceral allodynia and increased gut permeability induced by stress in rats, J Gastroenterol Hepatol, 34, 1, pp. 186-193, (2019); Li Y., Yang T., Yao Q., Li S., Fang E., Li Y., Et al., Metformin prevents colonic barrier dysfunction by inhibiting mast cell activation in maternal separation-induced IBS-like rats, Neurogastroenterol Motil, 31, 5, (2019); Cotillard A., Kennedy S.P., Kong L.C., Prifti E., Pons N., Le Chatelier E., Et al., Dietary intervention impact on gut microbial gene richness, Nature, 500, 7464, pp. 585-588, (2013); Aasbrenn M., Valeur J., Farup P.G., Evaluation of a faecal dysbiosis test for irritable bowel syndrome in subjects with and without obesity, Scand J Clin Lab Invest, 78, 1-2, pp. 109-113, (2018); Francois M., Barde S., Legrand R., Lucas N., Azhar S., El Dhaybi M., Et al., High-fat diet increases ghrelin-expressing cells in stomach, contributing to obesity, Nutrition, 32, pp. 709-715, (2016); Gomez-Zorita S., Aguirre L., Milton-Laskibar I., Fernandez-Quintela A., Trepiana J., Kajarabille N., Et al., Relationship between Changes in Microbiota and Liver Steatosis Induced by High-Fat Feeding-A Review of Rodent Models, Nutrients, (2019); Zhao Y.J., Li J.H., Hu B., Wang Y., Chang X.F., Traub R.J., Et al., Extracellular signal-regulated kinase activation in the spinal cord contributes to visceral hypersensitivity induced by craniofacial injury followed by stress, Neurogastroenterol Motil, (2018); Agostini S., Goubern M., Tondereau V., Salvador-Cartier C., Bezirard V., Leveque M., Et al., A marketed fermented dairy product containing Bifidobacterium lactis CNCM I-2494 suppresses gut hypersensitivity and colonic barrier disruption induced by acute stress in rats, Neurogastroenterol Motil, 24, 4, pp. 376-e172, (2012); Miquel S., Martin R., Lashermes A., Gillet M., Meleine M., Gelot A., Et al., Anti-nociceptive effect of Faecalibacterium prausnitzii in non-inflammatory IBS-like models, Sci Rep, 6, (2016); Yu Y., Wu S., Li J., Wang R., Xie X., Yu X., Et al., The effect of curcumin on the brain-gut axis in rat model of irritable bowel syndrome: involvement of 5-HT-dependent signaling, Metab Brain Dis, 30, 1, pp. 47-55, (2015)","M. Coëffier; Normandie University, UNIROUEN, INSERM UMR 1073 “Nutrition, inflammation and gut-brain axis”, Rouen, 76183, France; email: moise.coeffier@univ-rouen.fr","","Elsevier Inc.","","","","","","09552863","","JNBIE","32417626","English","J. Nutr. Biochem.","Article","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-85084561213"

"Li Y.; Yang T.; Yao Q.; Li S.; Fang E.; Li Y.; Liu C.; Li W.","Li, Yong (57872415500); Yang, Tingting (57195372357); Yao, Qing (56643871700); Li, Songsong (57205755807); Fang, En (57205754352); Li, Yankun (55156208400); Liu, Chao (56938500200); Li, Weimin (57196302773)","57872415500; 57195372357; 56643871700; 57205755807; 57205754352; 55156208400; 56938500200; 57196302773","Metformin prevents colonic barrier dysfunction by inhibiting mast cell activation in maternal separation-induced IBS-like rats","2019","Neurogastroenterology and Motility","31","5","e13556","","","","14","10.1111/nmo.13556","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85061435811&doi=10.1111%2fnmo.13556&partnerID=40&md5=69babab51065cdc76119011059ed1aa9","Laboratory of Neuronal Network and Systems Biology, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, China; Hubei Key Laboratory of Cardiovascular, Cerebrovascular, and Metabolic Disorders, Hubei University of Science and Technology, Xianning, China; Xianning Institute for Drug Control, Xianning, China; College of Pharmacy, Hubei University of Science and Technology, Xianning, China","Li Y., Laboratory of Neuronal Network and Systems Biology, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, China, Hubei Key Laboratory of Cardiovascular, Cerebrovascular, and Metabolic Disorders, Hubei University of Science and Technology, Xianning, China; Yang T., Laboratory of Neuronal Network and Systems Biology, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, China; Yao Q., Hubei Key Laboratory of Cardiovascular, Cerebrovascular, and Metabolic Disorders, Hubei University of Science and Technology, Xianning, China; Li S., Xianning Institute for Drug Control, Xianning, China; Fang E., Xianning Institute for Drug Control, Xianning, China; Li Y., College of Pharmacy, Hubei University of Science and Technology, Xianning, China; Liu C., Hubei Key Laboratory of Cardiovascular, Cerebrovascular, and Metabolic Disorders, Hubei University of Science and Technology, Xianning, China; Li W., Laboratory of Neuronal Network and Systems Biology, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, China","Background: Intestinal barrier dysfunction is a key etiologic factor of irritable bowel syndrome (IBS). Metformin improves intestinal barrier function, although the underlying mechanism has yet to be fully explained. This study evaluates the protective effect of metformin on colonic barrier integrity and explores the underlying cellular mechanisms. Methods: IBS-like rats were induced by maternal separation. Metformin was administered daily by gavage at 08:30, and rat pups were then separated from their mother. Visceral hyperalgesia and depression-like behaviors were evaluated by colorectal distension, sucrose preference tests, and forced swimming tests. Intestinal integrity was analyzed using sugar probes and transmission electron microscopy. Inflammatory factors and the levels of corticotropin-releasing factor were assessed by PCR and ELISA. The number of mast cells was evaluated by toluidine blue staining. Protein expression and localization were determined using Western blot and immunochemistry. Key Results: Metformin pretreatment (a) reduced visceral hypersensitivity to colorectal distension, immobility time and enhanced sucrose consumption; (b) decreased urine lactulose/mannitol ratio and sucralose output; (c) inhibited the dilation of tight junction and prevented claudin-4 translocation; (d) inhibited mast cell activation and downregulated the expression of IL-6, IL-18, tryptase, PAR-2, and ERK activation; (e) inhibited claudin-4 phosphorylation at serine sites and interactions between clau-4 and ZO-1. Conclusions & Inferences: Metformin may block mast cell activation to reduce PAR-2 expression and subsequently inhibit ERK activation and clau-4 phosphorylation at serine sites to normalize the interaction of clau-4 and ZO-1 and clau-4 distribution. Metformin may be clinically beneficial for patients with IBS or IBS-like symptoms. © 2019 John Wiley & Sons Ltd","claudin-4; claudin-4; intestinal permeability; intestinal permeability; irritable bowel syndrome; irritable bowel syndrome; mast cell; mast cell; maternal separation; maternal separation; metformin; metformin","Animals; Disease Models, Animal; Hypoglycemic Agents; Intestinal Mucosa; Irritable Bowel Syndrome; Mast Cells; Maternal Deprivation; Metformin; Psychological Distress; Rats; Tight Junctions; beta n acetylhexosaminidase; claudin 4; corticotropin releasing factor; interleukin 18; interleukin 6; metformin; myeloperoxidase; protein ZO1; proteinase activated receptor 2; tryptase; antidiabetic agent; metformin; animal experiment; animal model; antigen retrieval; Article; cell activation; controlled study; depression; drug mechanism; enzyme activation; enzyme activity; enzyme linked immunosorbent assay; forced swim test; HMC-1 cell line; hyperalgesia; immobility time; immunochemistry; immunoprecipitation; irritable colon; male; mast cell; maternal deprivation; nonhuman; priority journal; protein expression; protein localization; protein phosphorylation; rat; reverse transcription polymerase chain reaction; sucrose preference test; tight junction; transmission electron microscopy; Western blotting; animal; disease model; distress syndrome; drug effect; immunology; intestine mucosa; irritable colon; mast cell; maternal deprivation; metabolism; pathophysiology","","beta n acetylhexosaminidase, 37211-57-7, 9012-33-3, 9027-52-5; corticotropin releasing factor, 9015-71-8, 178359-01-8, 79804-71-0, 86297-72-5, 86784-80-7; interleukin 18, 189304-55-0; metformin, 1115-70-4, 657-24-9; myeloperoxidase, ; tryptase, 97501-93-4; Hypoglycemic Agents, ; Metformin, ","metformin, Sangon, China","Sangon, China","National Natural Science Foundation of China, NSFC, (81373756); National Natural Science Foundation of China, NSFC","Funding text 1: This work was supported by grants from National Natural Science Foundation of China (81373756).; Funding text 2: This work was supported by grants from National Natural Science","Ford A.C., Lacy B.E., Talley N.J., Irritable bowel syndrome, N Engl J Med., 376, pp. 2566-2578, (2017); Ford A.C., Talley N.J., Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review, J Gastroenterol, 46, pp. 421-431, (2011); Labus J.S., Hollister E.B., Jacobs J., Et al., Differences in gut microbial composition correlate with regional brain volumes in irritable bowel syndrome, Microbiome, 5, (2017); Martinez C., Lobo B., Pigrau M., Et al., Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, pp. 1160-1168, (2013); Piche T., Tight junctions and IBS – the link between epithelial permeability, low-grade inflammation, and symptom generation?, Neurogastroenterol Motil, 26, pp. 296-302, (2014); Bischoff S.C., Barbara G., Buurman W., Et al., Intestinal permeability – a new target for disease prevention and therapy, BMC Gastroenterol, 14, (2014); Marchiando A.M., Graham W.V., Turner J.R., Epithelial barriers in homeostasis and disease, Annu Rev Pathol, 5, pp. 119-144, (2010); Camilleri M., Lasch K., Zhou W., Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome, Am J Physiol Gastrointest Liver Physiol, 303, pp. G775-G785, (2012); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Et al., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am J Gastroenterol, 106, pp. 2165-2173, (2011); Coeffier M., Gloro R., Boukhettala N., Et al., Increased proteasome-mediated degradation of occludin in irritable bowel syndrome, Am J Gastroenterol, 105, pp. 1181-1188, (2010); Lee H., Park J.H., Park D.I., Et al., Mucosal mast cell count is associated with intestinal permeability in patients with diarrhea predominant irritable bowel syndrome, J Neurogastroenterol Motil, 19, pp. 244-250, (2013); Lee K.N., Lee O.Y., The role of mast cells in irritable bowel syndrome, Gastroenterol Res Pract, 2016, (2016); Wouters M.M., Vicario M., Santos J., The role of mast cells in functional GI disorders, Gut, 65, pp. 155-168, (2016); Jacob C., Yang P.C., Darmoul D., Et al., Mast cell tryptase controls paracellular permeability of the intestine. Role of protease-activated receptor 2 and beta-arrestins, J Biol Chem, 280, pp. 31936-31948, (2005); Ma J., Yu H., Liu J., Et al., Metformin attenuates hyperalgesia and allodynia in rats with painful diabetic neuropathy induced by streptozotocin, Eur J Pharmacol, 764, pp. 599-606, (2015); Burton M.D., Tillu D.V., Mazhar K., Et al., Pharmacological activation of AMPK inhibits incision-evoked mechanical hypersensitivity and the development of hyperalgesic priming in mice, Neuroscience, 359, pp. 119-129, (2017); Bullon P., Alcocer-Gomez E., Carrion A.M., Et al., AMPK Phosphorylation modulates pain by activation of NLRP3 inflammasome, Antioxid Redox Signal, 24, pp. 157-170, (2016); Tsilchorozidou T., Mohamed-Ali V., Conway G.S., Determinants of interleukin-6 and C-reactive protein vary in polycystic ovary syndrome, as do effects of short- and long-term metformin therapy, Horm Res, 71, pp. 148-154, (2009); Cameron A.R., Morrison V.L., Levin D., Et al., Anti-inflammatory effects of metformin irrespective of diabetes status, Circ Res, 119, pp. 652-665, (2016); Liu Y., Tang G., Li Y., Et al., Metformin attenuates blood-brain barrier disruption in mice following middle cerebral artery occlusion, J Neuroinflammation, 11, (2014); Takata F., Dohgu S., Matsumoto J., Et al., Metformin induces up-regulation of blood-brain barrier functions by activating AMP-activated protein kinase in rat brain microvascular endothelial cells, Biochem Biophys Res Comm, 433, pp. 586-590, (2013); Spruss A., Kanuri G., Stahl C., Et al., Metformin protects against the development of fructose-induced steatosis in mice: role of the intestinal barrier function, Lab Invest, 92, pp. 1020-1032, (2012); Xue Y., Zhang H., Sun X., Et al., Metformin improves ileal epithelial barrier function in interleukin-10 deficient mice, PLoS ONE, 11, (2016); Barreau F., Salvador-Cartier C., Houdeau E., Et al., Long-term alterations of colonic nerve-mast cell interactions induced by neonatal maternal deprivation in rats, Gut, 57, pp. 582-590, (2008); Tsang S.W., Zhao M., Wu J., Et al., Nerve growth factor-mediated neuronal plasticity in spinal cord contributes to neonatal maternal separation-induced visceral hypersensitivity in rats, Eur J Pain, 16, pp. 463-472, (2012); Barone F.C., Deegan J.F., Price W.J., Et al., Cold-restraint stress increases rat fecal pellet output and colonic transit, Am J Physiol, 258, pp. G329-G337, (1990); Snyder J.S., Soumier A., Brewer M., Et al., Adult hippocampal neurogenesis buffers stress responses and depressive behaviour, Nature, 476, pp. 458-461, (2011); Iniguez S.D., Flores-Ramirez F.J., Riggs L.M., Et al., Vicarious social defeat stress induces depression-related outcomes in female mice, Biol Psychiat, 83, pp. 9-17, (2018); Slattery D.A., Cryan J.F., Using the rat forced swim test to assess antidepressant-like activity in rodents, Nat Protoc, 7, pp. 1009-1014, (2012); Qi D., Wu S., Zhang Y., Et al., Electroacupuncture analgesia with different frequencies is mediated via different opioid pathways in acute visceral hyperalgesia rats, Life Sci, 160, pp. 64-71, (2016); Farhadi A., Keshavarzian A., Fields J.Z., Et al., Resolution of common dietary sugars from probe sugars for test of intestinal permeability using capillary column gas chromatography, J Chromatogr B, 836, pp. 63-68, (2006); Radinger M., Jensen B.M., Swindle E., Et al., Assay of mast cell mediators, Meth Mol Biol, 1220, pp. 307-323, (2015); Chey W.D., Kurlander J., Eswaran S., Irritable bowel syndrome: a clinical review, JAMA, 313, pp. 949-958, (2015); Lee Y.J., Park K.S., Irritable bowel syndrome: emerging paradigm in pathophysiology, World J Gastroenterol, 20, pp. 2456-2469, (2014); Camilleri M., Gorman H., Intestinal permeability and irritable bowel syndrome, Neurogastroenterol Motil, 19, pp. 545-552, (2007); Piche T., Barbara G., Aubert P., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Rao A.S., Camilleri M., Eckert D.J., Et al., Urine sugars for in vivo gut permeability: validation and comparisons in irritable bowel syndrome-diarrhea and controls, Am J Physiol Gastrointest Liver Physiol, 301, pp. 919-928, (2011); Sinagra E., Morreale G.C., Mohammadian G., Et al., New therapeutic perspectives in irritable bowel syndrome: targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond, World J Gastroenterol, 23, pp. 6593-6627, (2017); Santos J., Yates D., Guilarte M., Et al., Stress neuropeptides evoke epithelial responses via mast cell activation in the rat colon, Psychoneuroendocrinology, 33, pp. 1248-1256, (2008); van den Wijngaard R.M., Klooker T.K., de Jonge W.J., Et al., Peripheral relays in stress-induced activation of visceral afferents in the gut, Auton Neurosci, 153, pp. 99-105, (2010); Wilcz-Villega E.M., McClean S., O'Sullivan M.A., Mast cell tryptase reduces junctional adhesion molecule-A (JAM-A) expression in intestinal epithelial cells: implications for the mechanisms of barrier dysfunction in irritable bowel syndrome, Am J Gastroenterol, 108, pp. 1140-1151, (2013); Groschwitz K.R., Ahrens R., Osterfeld H., Et al., Mast cells regulate homeostatic intestinal epithelial migration and barrier function by a chymase/Mcpt4-dependent mechanism, Proc Natl Acad Sci USA, 106, 52, pp. 22381-22386, (2009); Van Itallie C.M., Anderson J.M., Phosphorylation of tight junction transmembrane proteins: many sites, much to do, Tissue Barriers, 6, (2018); Shigetomi K., Ikenouchi J., Regulation of the epithelial barrier by post-translational modifications of tight junction membrane proteins, J Biochem, 163, pp. 265-272, (2018); Tan J.C., Cui W.X., Heng D., Et al., ERK1/2 participates in regulating the expression and distribution of tight junction proteins in the process of reflux esophagitis, J Dig Dis, 15, pp. 409-418, (2014); Kim B., Breton S., The MAPK/ERK-signaling pathway regulates the expression and distribution of tight junction proteins in the mouse proximal epididymis, Biol Reprod, 94, (2016); Cong X., Zhang Y., Li J., Et al., Claudin-4 is required for modulation of paracellular permeability by muscarinic acetylcholine receptor in epithelial cells, J Cell Sci, 128, pp. 2271-2286, (2015); Choi W., Yeruva S., Turner J.R., Contributions of intestinal epithelial barriers to health and disease, Exp Cell Res, 358, pp. 71-77, (2017); Fond G., Loundou A., Hamdani N., Et al., Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis, Eur Arch Psychiatry Clin Neurosci, 264, pp. 651-660, (2014); Akiho H., Ihara E., Nakamura K., Low-grade inflammation plays a pivotal role in gastrointestinal dysfunction in irritable bowel syndrome, World J Gastrointest Pathophysiol, 1, pp. 97-105, (2010); Zhang D., Tang Q., Zheng G., Et al., Metformin ameliorates BSCB disruption by inhibiting neutrophil infiltration and MMP-9 expression but not direct TJ proteins expression regulation, J Cell Mol Med, 21, pp. 3322-3336, (2017); Pandey A., Verma S., Kumar V.L., Metformin maintains mucosal integrity in experimental model of colitis by inhibiting oxidative stress and pro-inflammatory signaling, Biomed Pharmacother, 94, pp. 1121-1128, (2017); Bashashati M., Moossavi S., Cremon C., Et al., Colonic immune cells in irritable bowel syndrome: a systematic review and meta-analysis, Neurogastroenterol Motil, 30, (2018); Vanuytsel T., van Wanrooy S., Vanheel H., Et al., Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism, Gut, 63, pp. 1293-1299, (2014); O'Malley D., Dinan T.G., Cryan J.F., Altered expression and secretion of colonic interleukin-6 in a stress-sensitive animal model of brain-gut axis dysfunction, J Neuroimmunol, 235, pp. 48-55, (2011); Suzuki T., Yoshinaga N., Tanabe S., Interleukin-6 (IL-6) regulates claudin-2 expression and tight junction permeability in intestinal epithelium, J Biol Chem, 286, pp. 31263-31271, (2011); Nullens S., Staessens M., Peleman C., Et al., Beneficial effects of anti-interleukin-6 antibodies on impaired gastrointestinal motility, inflammation and increased colonic permeability in a murine model of sepsis are most pronounced when administered in a preventive setup, PLoS ONE, 11, (2016); Xiao Y.T., Yan W.H., Cao Y., Et al., Neutralization of IL-6 and TNF-alpha ameliorates intestinal permeability in DSS-induced colitis, Cytokine, 83, pp. 189-192, (2016); Li X., Akhtar S., Choudhry M.A., Alteration in intestine tight junction protein phosphorylation and apoptosis is associated with increase in IL-18 levels following alcohol intoxication and burn injury, Biochem Biophys Acta, 1822, pp. 196-203, (2012); Allam O., Samarani S., Mehraj V., Et al., HIV induces production of IL-18 from intestinal epithelial cells that increases intestinal permeability and microbial translocation, PLoS ONE, 13, (2018); Cottrell G.S., Amadesi S., Schmidlin F., Et al., Protease-activated receptor 2: activation, signalling and function, Biochem Soc Trans, 31, pp. 1191-1197, (2003); Soh U.J., Dores M.R., Chen B., Et al., Signal transduction by protease-activated receptors, Br J Pharmacol, 160, pp. 191-203, (2010); DeFea K.A., Zalevsky J., Thoma M.S., Et al., beta-arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2, J Cell Biol, 148, pp. 1267-1281, (2000); Kwapiszewska G., Markart P., Dahal B.K., Et al., PAR-2 inhibition reverses experimental pulmonary hypertension, Circ Res, 110, pp. 1179-1191, (2012); Jin G., Hayashi T., Kawagoe J., Et al., Deficiency of PAR-2 gene increases acute focal ischemic brain injury, J Cereb Blood Flow Metab, 25, pp. 302-313, (2005); Nozu T., Miyagishi S., Kumei S., Et al., Metformin inhibits visceral allodynia and increased gut permeability induced by stress in rats, J Gastroenterol Hepatol, (2018); Itoh M., Furuse M., Morita K., Et al., Direct binding of three tight junction-associated MAGUKs, ZO-1, ZO-2, and ZO-3, with the COOH termini of claudins, J Cell Biol, 147, pp. 1351-1363, (1999); Umeda K., Ikenouchi J., Katahira-Tayama S., Et al., ZO-1 and ZO-2 independently determine where claudins are polymerized in tight-junction strand formation, Cell, 126, pp. 741-754, (2006); Fanning A.S., Van Itallie C.M., Anderson J.M., Zonula occludens-1 and -2 regulate apical cell structure and the zonula adherens cytoskeleton in polarized epithelia, Mol Biol Cell, 23, pp. 577-590, (2012); Kale G., Naren A.P., Sheth P., Et al., Tyrosine phosphorylation of occludin attenuates its interactions with ZO-1, ZO-2, and ZO-3, Biochem Biophys Res Comm, 302, pp. 324-329, (2003); Tanaka M., Kamata R., Sakai R., EphA2 phosphorylates the cytoplasmic tail of Claudin-4 and mediates paracellular permeability, J Biol Chem, 280, pp. 42375-42382, (2005); Cabreiro F., Au C., Leung K.Y., Et al., Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism, Cell, 153, pp. 228-239, (2013); Wu H., Esteve E., Tremaroli V., Et al., Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug, Nat Med, 23, pp. 850-858, (2017); Shin N.R., Lee J.C., Lee H.Y., Et al., An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice, Gut, 63, pp. 727-735, (2014)","C. Liu; Hubei Key Laboratory of Cardiovascular, Cerebrovascular, and Metabolic Disorders, Hubei University of Science and Technology, Xianning, China; email: tnbsys_liuchao@126.com","","Blackwell Publishing Ltd","","","","","","13501925","","NMOTE","30740845","English","Neurogastroenterol. Motil.","Article","Final","","Scopus","2-s2.0-85061435811"

"Sun S.; Liu W.; Li Y.","Sun, Shengtao (56549233100); Liu, Wenlong (57219007894); Li, Yinfeng (57219012195)","56549233100; 57219007894; 57219012195","CADM1 enhances intestinal barrier function in a rat model of mild inflammatory bowel disease by inhibiting the STAT3 signaling pathway","2020","Journal of Bioenergetics and Biomembranes","52","5","","343","354","11","11","10.1007/s10863-020-09850-8","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85091012838&doi=10.1007%2fs10863-020-09850-8&partnerID=40&md5=087b59b719ff3cbc7661f1e2c542c8f7","Department of Pediatrics, Linyi People’s Hospital, No. 27, Eastern Jiefang Road, Lanshan District, Linyi, 276003, Shandong Province, China","Sun S., Department of Pediatrics, Linyi People’s Hospital, No. 27, Eastern Jiefang Road, Lanshan District, Linyi, 276003, Shandong Province, China; Liu W., Department of Pediatrics, Linyi People’s Hospital, No. 27, Eastern Jiefang Road, Lanshan District, Linyi, 276003, Shandong Province, China; Li Y., Department of Pediatrics, Linyi People’s Hospital, No. 27, Eastern Jiefang Road, Lanshan District, Linyi, 276003, Shandong Province, China","Cell adhesion molecule 1 (CADM1) is frequently silenced in lung, prostate, liver, stomach, pancreatic and breast carcinomas and other forms of human carcinomas. However, it is unclear regarding the role of CADM1 in irritable bowel syndrome with diarrhoea (IBS-D) that is the most common gastrointestinal diagnosis and may contribute to impaired intestinal barrier function. The aim of the present study is to explore the potential mechanism of CADM1 in regulating intestinal barrier function in IBS-D. A rat model with IBS-D induced by the combination method of mother-infant separation, acetic acid and restraint stress was initially established. The defecation frequency, faecal water content (FWC), total intestinal permeability, sIgA, endotoxin, D-lactic acid and diamine oxidase (DAO) were then measured. Next, positive expression of CADM1 protein was detected in distal colonic tissue of rats by immunohistochemistry. The expression of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in distal colonic mucosa, CADM1, Janus kinase 1 (JAK1), STAT3, p-JAK1, p-STAT3, Claudin-1and Claudin-2 were evaluated using ELISA, RT-qPCR and western blot analysis. IBS-D rats exhibited low CADM1 expression and activated STAT3 signaling pathway. Overexpression of CADM1 in rats was shown to increase Claudin-1 expression, while decreasing expression of STAT3, Claudin-2, TNF-α and IL-6. In addition, silencing of CADM1 or inhibition of the STAT3 signaling pathway was demonstrated to improve the intestinal barrier function. Our study provides evidence that CADM1 can potentially improve intestinal barrier function in rats with IBS-D by inhibiting the STAT3 signaling pathway. © 2020, Springer Science+Business Media, LLC, part of Springer Nature.","CADM1; Intestinal barrier function; Irritable bowel syndrome with diarrhoea; STAT3 signaling pathway","Animals; Case-Control Studies; Cell Adhesion Molecules; Disease Models, Animal; Female; HEK293 Cells; HeLa Cells; Humans; Immunoglobulins; Inflammatory Bowel Diseases; Intestinal Mucosa; Male; Rats; Rats, Sprague-Dawley; Signal Transduction; STAT3 Transcription Factor; acetic acid; amine oxidase (copper containing); cell adhesion molecule 1; claudin 1; claudin 2; endotoxin; immunoglobulin A; interleukin 6; Janus kinase 1; lactic acid; STAT3 protein; tumor necrosis factor; Cadm1 protein, rat; cell adhesion molecule; immunoglobulin; STAT3 protein; Stat3 protein, rat; animal experiment; animal model; Article; colon tissue; controlled study; defecation; enzyme linked immunosorbent assay; feces composition; female; immobilization stress; immunohistochemistry; inflammatory bowel disease; intestine mucosa permeability; newborn; nonhuman; protein expression; rat; real time polymerase chain reaction; regulatory mechanism; signal transduction; water content; Western blotting; animal; biosynthesis; case control study; disease model; genetics; HEK293 cell line; HeLa cell line; human; inflammatory bowel disease; intestine mucosa; male; metabolism; pathology; signal transduction; Sprague Dawley rat","","acetic acid, 127-08-2, 127-09-3, 64-19-7, 71-50-1; amine oxidase (copper containing), 9001-53-0, 9014-75-9; claudin 1, 329338-06-9; lactic acid, 113-21-3, 50-21-5; immunoglobulin, 9007-83-4; Cadm1 protein, rat, ; Cell Adhesion Molecules, ; Immunoglobulins, ; Stat3 protein, rat, ; STAT3 Transcription Factor, ","","","","","Abroun S., Saki N., Ahmadvand M., Asghari F., Salari F., Rahim F., STATs: an old story, yet mesmerizing, Cell J, 17, 3, pp. 395-411, (2015); Al-Chaer E.D., Kawasaki M., Pasricha P.J., A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development, Gastroenterology, 119, 5, pp. 1276-1285, (2000); Barbara G., Stanghellini V., de Giorgio R., Cremon C., Cottrell G.S., Santini D., Pasquinelli G., Morselli-Labate A.M., Grady E.F., Bunnett N.W., Collins S.M., Corinaldesi R., Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome, Gastroenterology, 126, 3, pp. 693-702, (2004); Berthenet K., Bokhari A., Lagrange A., Marcion G., Boudesco C., Causse S., de Thonel A., Svrcek M., Goloudina A.R., Dumont S., Hammann A., Biard D.S., Demidov O.N., Seigneuric R., Duval A., Collura A., Jego G., Garrido C., HSP110 promotes colorectal cancer growth through STAT3 activation, Oncogene, 36, 16, pp. 2328-2336, (2017); Cai H., Miao M., Wang Z., miR-214-3p promotes the proliferation, migration and invasion of osteosarcoma cells by targeting CADM1, Oncol Lett, 16, 2, pp. 2620-2628, (2018); Camilleri M., Gorman H., Intestinal permeability and irritable bowel syndrome, Neurogastroenterol Motil, 19, 7, pp. 545-552, (2007); Camilleri M., Madsen K., Spiller R., Greenwood-Van Meerveld B., Verne G.N., Intestinal barrier function in health and gastrointestinal disease, Neurogastroenterol Motil, 24, 6, pp. 503-512, (2012); Chang J.Y., Talley N.J., Current and emerging therapies in irritable bowel syndrome: from pathophysiology to treatment, Trends Pharmacol Sci, 31, 7, pp. 326-334, (2010); Chen K., Wang G., Peng L., Liu S., Fu X., Zhou Y., Yu H., Li A., Li J., Zhang S., Bai Y., Zhang Y., CADM1/TSLC1 inactivation by promoter hypermethylation is a frequent event in colorectal carcinogenesis and correlates with late stages of the disease, Int J Cancer, 128, 2, pp. 266-273, (2011); Chu X.Q., Wang J., Chen G.X., Zhang G.Q., Zhang D.Y., Cai Y.Y., Overexpression of microRNA-495 improves the intestinal mucosal barrier function by targeting STAT3 via inhibition of the JAK/STAT3 signaling pathway in a mouse model of ulcerative colitis, Pathol Res Pract, 214, 1, pp. 151-162, (2018); Cremonini F., Talley N.J., Irritable bowel syndrome: epidemiology, natural history, health care seeking and emerging risk factors, Gastroenterol Clin N Am, 34, 2, pp. 189-204, (2005); Dinkel K., MacPherson A., Sapolsky R.M., Novel glucocorticoid effects on acute inflammation in the CNS, J Neurochem, 84, 4, pp. 705-716, (2003); Dunlop S.P., Jenkins D., Spiller R.C., Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome, Am J Gastroenterol, 98, 7, pp. 1578-1583, (2003); Feng S., Et al., Impaired function of the intestinal barrier in a novel sub-health rat model, Mol Med Rep, 13, 4, pp. 3459-3465, (2016); Harvey J.M., Sibelli A., Chalder T., Everitt H., Moss-Morris R., Bishop F.L., Desperately seeking a cure: treatment seeking and appraisal in irritable bowel syndrome, Br J Health Psychol, 23, 3, pp. 561-579, (2018); Iraha A., Chinen H., Hokama A., Yonashiro T., Kinjo T., Kishimoto K., Nakamoto M., Hirata T., Kinjo N., Higa F., Tateyama M., Kinjo F., Fujita J., Fucoidan enhances intestinal barrier function by upregulating the expression of claudin-1, World J Gastroenterol, 19, 33, pp. 5500-5507, (2013); Ito T., Nakamura A., Tanaka I., Tsuboi Y., Morikawa T., Nakajima J., Takai D., Fukayama M., Sekido Y., Niki T., Matsubara D., Murakami Y., CADM1 associates with hippo pathway core kinases; membranous co-expression of CADM1 and LATS2 in lung tumors predicts good prognosis, Cancer Sci, 110, 7, pp. 2284-2295, (2019); Koukos G., Polytarchou C., Kaplan J.L., Morleyfletcher A., Grasmiralles B., Kokkotou E., Barildore M., Pothoulakis C., Winter H.S., Iliopoulos D., MicroRNA-124 regulates STAT3 expression and is down-regulated in colon tissues of pediatric patients with ulcerative colitis, Gastroenterology, 145, 4, pp. 842-852, (2013); Li Y., Chen Y., Zhang J., Zhu J.F., Liu Z.J., Liang S.Y., Sun K., Liao W.Y., Gong J.P., Protective effect of glutamine-enriched early enteral nutrition on intestinal mucosal barrier injury after liver transplantation in rats, Am J Surg, 199, 1, pp. 35-42, (2010); Liu X., Yang G., Geng X.R., Cao Y., Li N., Ma L., Chen S., Yang P.C., Liu Z., Microbial products induce claudin-2 to compromise gut epithelial barrier function, PLoS One, 8, 8, (2013); Lovell R.M., Ford A.C., Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis, Clin Gastroenterol Hepatol, 10, 7, pp. 712-721, (2012); Luyer M.D., Et al., Pretreatment with high-fat enteral nutrition reduces endotoxin and tumor necrosis factor-alpha and preserves gut barrier function early after hemorrhagic shock, Shock, 21, 1, pp. 65-71, (2004); Magadmi R., Meszaros J., Damanhouri Z.A., Seward E.P., Secretion of mast cell inflammatory mediators is enhanced by CADM1-dependent adhesion to sensory neurons, Front Cell Neurosci, 13, (2019); Mou K., Et al., LNMAT1 promotes invasion-metastasis Cascade in malignant melanoma by epigenetically suppressing CADM1 expression, Front Oncol, 9, (2019); Noth R., Stuber E., Hasler R., Nikolaus S., Kuhbacher T., Hampe J., Bewig B., Schreiber S., Arlt A., Anti-TNF-alpha antibodies improve intestinal barrier function in Crohn’s disease, J Crohns Colitis, 6, 4, pp. 464-469, (2012); Ohman L., Isaksson S., Lundgren A., Simren M., Sjovall H., A controlled study of colonic immune activity and beta7+ blood T lymphocytes in patients with irritable bowel syndrome, Clin Gastroenterol Hepatol, 3, 10, pp. 980-986, (2005); Saito M., Goto A., Abe N., Saito K., Maeda D., Ohtake T., Murakami Y., Takenoshita S., Decreased expression of CADM1 and CADM4 are associated with advanced stage breast cancer, Oncol Lett, 15, 2, pp. 2401-2406, (2018); Sun Y.J., Cao H.J., Song D.D., Diao Y.G., Zhou J., Zhang T.Z., Probiotics can alleviate cardiopulmonary bypass-induced intestinal mucosa damage in rats, Dig Dis Sci, 58, 6, pp. 1528-1536, (2013); Swan C., Duroudier N.P., Campbell E., Zaitoun A., Hastings M., Dukes G.E., Cox J., Kelly F.M., Wilde J., Lennon M.G., Neal K.R., Whorwell P.J., Hall I.P., Spiller R.C., Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): Association with TNFSF15 and TNFalpha, Gut, 62, 7, pp. 985-994, (2013); Vallath S., Et al., CADM1 inhibits squamous cell carcinoma progression by reducing STAT3 activity, Sci Rep, 6, (2016); van Der Weyden L., Arends M.J., Rust A.G., Poulogiannis G., McIntyre R.E., Adams D.J., Increased tumorigenesis associated with loss of the tumor suppressor gene Cadm1, Mol Cancer, 11, 29, (2012); Wei N., Li J., Fang C., Chang J., Xirou V., Syrigos N.K., Marks B.J., Chu E., Schmitz J.C., Targeting colon cancer with the novel STAT3 inhibitor bruceantinol, Oncogene, 38, 10, pp. 1676-1687, (2019); Xiao Y.T., Wang J., Lu W., Cao Y., Cai W., Downregulated expression of microRNA-124 in pediatric intestinal failure patients modulates macrophages activation by inhibiting STAT3 and AChE, Cell Death Dis, 7, 12, (2016); Yoneshige A., Hagiyama M., Fujita M., Ito A., Pathogenic actions of cell adhesion molecule 1 in pulmonary emphysema and atopic dermatitis, Front Cell. Dev Biol, 3, (2015)","Y. Li; Department of Pediatrics, Linyi People’s Hospital, Linyi, No. 27, Eastern Jiefang Road, Lanshan District, 276003, China; email: yinfengl@163.com","","Springer","","","","","","0145479X","","JBBID","32929607","English","J. Bioenerg. Biomembr.","Article","Final","","Scopus","2-s2.0-85091012838"

"Li Y.; Tian X.; Li S.; Chang L.; Sun P.; Lu Y.; Yu X.; Chen S.; Wu Z.; Xu Z.; Kang W.","Li, Yanlong (58448825500); Tian, Xudong (59050918700); Li, Shengcai (57208928842); Chang, Lijun (57208897486); Sun, Ping (57197836606); Lu, Yubei (57208920190); Yu, Xiaoyan (57208924520); Chen, Shiwang (57208922065); Wu, Zhengquan (57208924639); Xu, Zhong (57208922621); Kang, Wanrong (57208920328)","58448825500; 59050918700; 57208928842; 57208897486; 57197836606; 57208920190; 57208924520; 57208922065; 57208924639; 57208922621; 57208920328","Total polysaccharides of adlay bran (: Coix lachryma-jobi L.) improve TNF-α induced epithelial barrier dysfunction in Caco-2 cells via inhibition of the inflammatory response","2019","Food and Function","10","5","","2906","2913","7","43","10.1039/c9fo00590k","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85066123977&doi=10.1039%2fc9fo00590k&partnerID=40&md5=4fd0a9916930e1b5f7552f462149f091","Department of Spleen and Stomach Diseases, Gansu Hospital of TCM, Lanzhou, 730050, China; Gansu Provincial Center for Disease Control and Prevention, Lanzhou, 730000, China; SPF Animal Lab of Gansu University of TCM, Lanzhou, 730030, China","Li Y., Department of Spleen and Stomach Diseases, Gansu Hospital of TCM, Lanzhou, 730050, China; Tian X., Department of Spleen and Stomach Diseases, Gansu Hospital of TCM, Lanzhou, 730050, China; Li S., Department of Spleen and Stomach Diseases, Gansu Hospital of TCM, Lanzhou, 730050, China; Chang L., Gansu Provincial Center for Disease Control and Prevention, Lanzhou, 730000, China; Sun P., Department of Spleen and Stomach Diseases, Gansu Hospital of TCM, Lanzhou, 730050, China; Lu Y., Department of Spleen and Stomach Diseases, Gansu Hospital of TCM, Lanzhou, 730050, China; Yu X., Department of Spleen and Stomach Diseases, Gansu Hospital of TCM, Lanzhou, 730050, China; Chen S., Department of Spleen and Stomach Diseases, Gansu Hospital of TCM, Lanzhou, 730050, China; Wu Z., Department of Spleen and Stomach Diseases, Gansu Hospital of TCM, Lanzhou, 730050, China; Xu Z., Department of Spleen and Stomach Diseases, Gansu Hospital of TCM, Lanzhou, 730050, China; Kang W., SPF Animal Lab of Gansu University of TCM, Lanzhou, 730030, China","Dysfunction of the intestinal epithelial barrier plays an important role in the pathogenesis of several intestinal diseases, including celiac disease, inflammatory bowel disease, and irritable bowel syndrome. The present research was carried out to investigate the protective effect of total polysaccharides of adlay bran (TPA) on TNF-α-evoked epithelial barrier dysfunction in Caco-2 cells. Caco-2 cells were treated with or without TPA in the absence or presence of TNF-α, and transepithelial electrical resistance (TEER) and Phenol Red flux were assayed to evaluate the intestinal epithelial barrier function. The results indicated that TPA suppressed the TNF-α-induced release of pro-inflammatory factors. Furthermore, TPA obviously assuaged both the increased paracellular permeability and the decrease of TEER in TNF-α-challenged Caco-2 cells. Furthermore, TPA obviously assuaged TNF-α-evoked up-regulation of IL-8 and IL-6 expression, down-regulation of occludin and ZO-3 expression, and markedly suppressed the activation and protein expression of NF-κB p65. Our results indicated that TPA assuages the TNF-α-evoked dysfunction of the intestinal epithelial barrier by inhibiting the NF-κB p65-mediated inflammatory response. © 2019 The Royal Society of Chemistry.","","Caco-2 Cells; Coix; Epithelial Cells; Humans; Interleukin-6; Interleukin-8; Intestinal Mucosa; Occludin; Phosphorylation; Plant Extracts; Polysaccharides; Transcription Factor RelA; Tumor Necrosis Factor-alpha; Cytology; Polysaccharides; interleukin 6; interleukin 8; occludin; plant extract; polysaccharide; transcription factor RelA; tumor necrosis factor; Epithelial barrier; Inflammatory bowel disease; Inflammatory response; Irritable bowel syndromes; Paracellular permeability; Protective effects; Protein expressions; Transepithelial electrical resistances; Caco-2 cell line; chemistry; Coix; drug effect; epithelium cell; genetics; human; immunology; intestine mucosa; phosphorylation; Cells","","interleukin 8, 114308-91-7; occludin, 176304-61-3; Interleukin-6, ; Interleukin-8, ; Occludin, ; Plant Extracts, ; Polysaccharides, ; Transcription Factor RelA, ; Tumor Necrosis Factor-alpha, ","","","Science-Technology Foundation for Young Scientists of Gansu Province, (18JR3RA072)","The present work was financially supported by the Science-Technology Foundation for Young Scientists of Gansu Province, China (Grant No. 18JR3RA072).","Suzuki T., Regulation of intestinal epithelial permeability by tight junctions, Cell. Mol. Life Sci., 70, pp. 631-659, (2013); Turner J.R., Intestinal mucosal barrier function in health and disease, Nat. Rev. Immunol., 9, pp. 799-809, (2009); Arnott I.D., Kingstone K., Ghosh S., Abnormal intestinal permeability predicts relapse in inactive Crohn disease, Scand. J. Gastroenterol., 35, pp. 1163-1169, (2000); Groschwitz K.R., Hogan S.P., Intestinal barrier function: Molecular regulation and disease pathogenesis, J. Allergy Clin. Immunol., 124, pp. 3-20, (2009); Weber C.R., Dynamic properties of the tight junction barrier, Ann. N. Y. Acad. Sci., 1257, pp. 77-84, (2012); Liu Z., Li N., Neu J., Tight junctions, leaky intestines, and pediatric diseases, Acta Paediatr., 94, pp. 386-393, (2005); Neurath M.F., Cytokines in inflammatory bowel disease, Nat. Rev. Immunol., 14, pp. 329-342, (2014); Hoffmann E., Dittrich-Breiholz O., Holtmann H., Kracht M., Multiple control of interleukin-8 gene expression, J. Leukocyte Biol., 72, pp. 847-855, (2002); Gibson P., Rosella O., Interleukin 8 secretion by colonic crypt cells in vitro: Response to injury suppressed by butyrate and enhanced in inflammatory bowel disease, Gut, 37, pp. 536-543, (1995); Ranganathan P., Jayakumar C., Manicassamy S., Ramesh G., CXCR2 knockout mice are protected against DSS-colitis-induced acute kidney injury and inflammation, Am. J. Physiol.: Renal Physiol., 305, pp. F1422-F1427, (2013); Doecke J.D., Hartnell F., Bampton P., Bell S., Mahy G., Grover Z., Lewindon P., Jones L.V., Sewell K., Krishnaprasad K., Prosser R., Marr D., Fischer J., Thomas G.R., Tehan J.V., Ding N.S., Infliximab vs. Adalimumab in Crohn's disease: Results from 327 patients in an Australian and New Zealand observational cohort study, Aliment. Pharmacol. Ther., 45, pp. 542-552, (2017); Oyama M., Van Hung T., Yoda K., He F., Suzuki T., A novel whey tetrapeptide IPAV reduces interleukin-8 production induced by TNF-α in human intestinal Caco-2 cells, J. Funct. Foods, 35, pp. 376-383, (2017); Lu Y., Li L., Zhang J.W., Zhong X.Q., Wei J.A., Han L., Total polysaccharides of the Sijunzi decoction attenuate tumor necrosis factor-alpha-induced damage to the barrier function of a Caco-2 cell monolayer via the nuclear factor-kappaB-myosin light chain kinase-myosin light chain pathway, World J. Gastroenterol., 24, pp. 2867-2877, (2018); Chen H.J., Lo Y.C., Chiang W., Inhibitory effects of adlay bran (Coix lachryma-jobi L. Var. Ma-yuen Stapf) on chemical mediator release and cytokine production in rat basophilic leukemia cells, J. Ethnopharmacol., 141, pp. 119-127, (2012); Seo W.G., Pae H.O., Chai K.Y., Yun Y.G., Kwon T.H., Chung H.T., Inhibitory effects of methanol extract of seeds of Job's Tears (Coix lachryma-jobi L. Var. Ma-yuen) on nitric oxide and superoxide production in RAW 264.7 macrophages, Immunopharmacol. Immunotoxicol., 22, pp. 545-554, (2000); Chen H.J., Shih C.K., Hsu H.Y., Chiang W., Mast cell-dependent allergic responses are inhibited by ethanolic extract of adlay (Coix lachryma-jobi L. Var. Ma-yuen Stapf) testa, J. Agric. Food Chem., 58, pp. 2596-2601, (2010); Yao Y., Zhu Y., Gao Y., Ren G., Effect of ultrasonic treatment on immunological activities of polysaccharides from adlay, Int. J. Biol. Macromol., 80, pp. 246-252, (2015); Huang D.W., Wu C.H., Shih C.K., Liu C.Y., Shih P.H., Shieh T.M., Lin C.I., Chiang W., Hsia S.M., Application of the solvent extraction technique to investigation of the anti-inflammatory activity of adlay bran, Food Chem., 145, pp. 445-453, (2014); Pathak N., Khandelwal S., Role of oxidative stress and apoptosis in cadmium induced thymic atrophy and splenomegaly in mice, Toxicol. Lett., 169, pp. 95-108, (2007); Chen Q., Chen O., Martins I.M., Hou H., Zhao X., Blumberg J.B., Li B., Collagen peptides ameliorate intestinal epithelial barrier dysfunction in immunostimulatory Caco-2 cell monolayers via enhancing tight junctions, Food Funct., 8, pp. 1144-1151, (2017); Watari A., Sakamoto Y., Hisaie K., Iwamoto K., Fueta M., Yagi K., Kondoh M., Rebeccamycin Attenuates TNF-alpha-Induced Intestinal Epithelial Barrier Dysfunction by Inhibiting Myosin Light Chain Kinase Production, Cell. Physiol. Biochem., 41, pp. 1924-1934, (2017); Khor B., Gardet A., Xavier R.J., Genetics and pathogenesis of inflammatory bowel disease, Nature, 474, pp. 307-317, (2011); Amasheh M., Grotjohann I., Amasheh S., Fromm A., Soderholm J., Zeitz M., Fromm M., Schulzke J., Regulation of mucosal structure and barrier function in rat colon exposed to tumor necrosis factor alpha and interferon gamma in vitro: A novel model for studying the pathomechanisms of inflammatory bowel disease cytokines, Scand. J. Gastroenterol., 44, pp. 1226-1235, (2009); Sudirman S., Hsu Y.-H., He J.-L., Kong Z.-L., Dietary polysaccharide-rich extract from Eucheuma cottonii modulates the inflammatory response and suppresses colonic injury on dextran sulfate sodium-induced colitis in mice, PLoS One, 13, (2018); Zhang J., Lu Y., Wei J., Li L., Han L., Protective effect of carboxytmethylpachymaran on TNF-alpha-induced damage in Caco-2 cell monolayers, Int. J. Biol. Macromol., 93, pp. 506-511, (2016); Kim Y., Kim D.M., Kim J.Y., Ginger Extract Suppresses Inflammatory Response and Maintains Barrier Function in Human Colonic Epithelial Caco-2 Cells Exposed to Inflammatory Mediators, J. Food Sci., 82, pp. 1264-1270, (2017); Zhang Y., Wang Y., Zhang F., Wang K., Liu G., Yang M., Luan Y., Zhao Z., Zhang J., Cao X., Zhang D., Allyl methyl disulfide inhibits IL-8 and IP-10 secretion in intestinal epithelial cells via the NF-small ka, CyrillicB signaling pathway, Int. Immunopharmacol., 27, pp. 156-163, (2015); Puleston J., Cooper M., Murch S., Bid K., Makh S., Ashwood P., Bingham A.H., Green H., Moss P., Dhillon A., Morris R., Strobel S., Gelinas R., Pounder R.E., Platt A., A distinct subset of chemokines dominates the mucosal chemokine response in inflammatory bowel disease, Aliment. Pharmacol. Ther., 21, pp. 109-120, (2005); Sun S.C., Ley S.C., New insights into NF-kappaB regulation and function, Trends Immunol., 29, pp. 469-478, (2008); Mitchell S., Vargas J., Signaling via the NFkappaB system, Wiley Interdiscip. Rev.: Syst. Biol. Med., 8, pp. 227-241, (2016); Ma T.Y., Iwamoto G.K., Hoa N.T., Akotia V., Pedram A., Boivin M.A., Said H.M., TNF-alpha-induced increase in intestinal epithelial tight junction permeability requires NF-kappa B activation, Am. J. Physiol.: Gastrointest. Liver Physiol., 286, pp. G367-G376, (2004); Shen L., Weber C.R., Raleigh D.R., Yu D., Turner J.R., Tight junction pore and leak pathways: A dynamic duo, Annu. Rev. Physiol., 73, pp. 283-309, (2011)","","","Royal Society of Chemistry","","","","","","20426496","","","31070650","English","Food. Funct.","Article","Final","","Scopus","2-s2.0-85066123977"

"Singh P.; Silvester J.; Chen X.; Xu H.; Sawhney V.; Rangan V.; Iturrino J.; Nee J.; Duerksen D.R.; Lembo A.","Singh, Prashant (55503159600); Silvester, Jocelyn (7006743582); Chen, Xinhua (13002749600); Xu, Hua (57207839350); Sawhney, Veer (57205571278); Rangan, Vikram (57200561025); Iturrino, Johanna (6506490989); Nee, Judy (56673860400); Duerksen, Donald R. (7003683927); Lembo, Anthony (26426421700)","55503159600; 7006743582; 13002749600; 57207839350; 57205571278; 57200561025; 6506490989; 56673860400; 7003683927; 26426421700","Serum zonulin is elevated in IBS and correlates with stool frequency in IBS-D","2019","United European Gastroenterology Journal","7","5","","709","715","6","39","10.1177/2050640619826419","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85060583515&doi=10.1177%2f2050640619826419&partnerID=40&md5=aa9cfeef36d41827f1ee4d2cc4dcc1ae","Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, United States; Division of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, Boston, United States; Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada","Singh P., Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, United States; Silvester J., Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, United States, Division of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, Boston, United States; Chen X., Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, United States; Xu H., Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, United States; Sawhney V., Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, United States; Rangan V., Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, United States; Iturrino J., Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, United States; Nee J., Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, United States; Duerksen D.R., Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada; Lembo A., Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, United States","Background: Studies have shown increased intestinal permeability in irritable bowel syndrome. Validating serum biomarkers for altered intestinal permeability in irritable bowel syndrome will facilitate research and pathophysiology-based therapy. Objective: To measure serum zonulin and intestinal fatty acid binding protein levels in diarrhea-predominant irritable bowel syndrome and constipation-predominant irritable bowel syndrome and compare with healthy controls and celiac disease. Methods: Serum zonulin and intestinal fatty acid binding protein levels were measured using enzyme-linked immunosorbent assays in constipation-predominant irritable bowel syndrome (n = 50), diarrhea-predominant irritable bowel syndrome (n = 50), celiac disease (n = 53) and healthy controls (n = 42). Irritable bowel syndrome symptom severity was measured using the irritable bowel syndrome-symptom severity scale. Results: Patients with constipation-predominant irritable bowel syndrome and diarrhea-predominant irritable bowel syndrome had higher zonulin levels compared with healthy controls (p = 0.006 and 0.009 respectively), which was comparable to those with active celiac disease. Although zonulin levels did not correlate with the overall irritable bowel syndrome symptom severity scale, it positively correlated with stool frequency per week (p = 0.03) and dissatisfaction with bowel habits (p = 0.007) in diarrhea-predominant irritable bowel syndrome. Patients with diarrhea-predominant irritable bowel syndrome and constipation-predominant irritable bowel syndrome had lower intestinal fatty acid binding protein levels compared with celiac patients (p = 0.005 and p = 0.047 respectively). Conclusion: Serum zonulin is upregulated in irritable bowel syndrome and the levels are comparable to those in celiac disease. Zonulin levels correlated with severity of bowel habits in diarrhea-predominant irritable bowel syndrome. Intestinal fatty acid binding protein levels in irritable bowel syndrome patients were not increased suggesting no significant increase in enterocyte death. © Author(s) 2019.","gut barrier; Intestinal permeability; serine protease; tight junction","Adult; Biomarkers; Constipation; Diarrhea; Fatty Acid-Binding Proteins; Female; Haptoglobins; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Male; Middle Aged; Permeability; Protein Precursors; Young Adult; biological marker; fatty acid binding protein 2; tight junction protein; unclassified drug; zonulin; biological marker; fatty acid binding protein; haptoglobin; protein precursor; zonulin; adult; Article; celiac disease; constipation; controlled study; correlational study; diarrhea; duodenum biopsy; endoscopy; enzyme linked immunosorbent assay; feces analysis; female; gluten free diet; histology; human; human tissue; intestine mucosa permeability; intestine villus atrophy; irritable colon; major clinical study; male; middle aged; pain severity; priority journal; blood; intestine mucosa; irritable colon; metabolism; permeability; young adult","","haptoglobin, 9087-69-8; Biomarkers, ; Fatty Acid-Binding Proteins, ; Haptoglobins, ; Protein Precursors, ; zonulin, ","","","National Institutes of Health, NIH, (RO1 AT008573-03); National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK, (T32DK007760)","This work was supported in part by RO1 AT008573-03 (AL) and T32DK007760 (PS).","Mearin F., Lacy B.E., Chang L., Et al., Bowel disorders, Gastroenterol, (2016); Makharia G.K., Verma A.K., Amarchand R., Et al., Prevalence of irritable bowel syndrome: A community based study from northern India, J Neurogastroenterol Motil, 17, pp. 82-87, (2011); Hungin A.P.S., Chang L., Locke G.R., Et al., Irritable bowel syndrome in the United States: Prevalence, symptom patterns and impact, Aliment Pharmacol Ther, 21, pp. 1365-1375, (2005); Canavan C., West J and Card T., Review article: The economic impact of the irritable bowel syndrome, Aliment Pharmacol Ther, 40, pp. 1023-1034, (2014); Lovell R.M., Ford A.C., Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis, Clin Gastroenterol Hepatol, 10, pp. 712-721, (2012); Camilleri M., Lasch K., Zhou W., Irritable bowel syndrome: Methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome, Am J Physiol Gastrointest Liver Physiol, 303, pp. G775-G785, (2012); Camilleri M., Gorman H., Intestinal permeability and irritable bowel syndrome, Neurogastroenterol Motil, 19, pp. 545-552, (2007); Camilleri M., Madsen K., Spiller R., Et al., Intestinal barrier function in health and gastrointestinal disease, Neurogastroenterol Motil, 24, pp. 503-512, (2012); Camilleri M., Oduyebo I., Halawi H., Chemical and molecular factors in irritable bowel syndrome: Current knowledge, challenges, and unanswered questions, Am J Physiol Gastrointest Liver Physiol, 311, pp. G777-G784, (2016); Gecse K., Roka R., Sera T., Et al., Leaky gut in patients with diarrhea-predominant irritable bowel syndrome and inactive ulcerative colitis, Digestion, 85, pp. 40-46, (2012); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Rao A.S., Camilleri M., Eckert D.J., Et al., Urine sugars for in vivo gut permeability: Validation and comparisons in irritable bowel syndrome-diarrhea and controls, Am J Physiol Gastrointest Liver Physiol, 301, pp. G919-G928, (2011); Piche T., Barbara G., Aubert P., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: Involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Park J.H., Park D.I., Kim H.J., Et al., The relationship between small-intestinal bacterial overgrowth and intestinal permeability in patients with irritable bowel syndrome, Gut Liver, 3, pp. 174-179, (2009); Kerckhoffs A.P.M., Akkermans L.M.A., de Smet M.B.M., Et al., Intestinal permeability in irritable bowel syndrome patients: Effects of NSAIDs, Dig Dis Sci, 55, pp. 716-723, (2010); Bischoff S.C., Barbara G., Buurman W., Et al., Intestinal permeability: A new target for disease prevention and therapy, BMC Gastroenterol, 14, (2014); Fasano A., Zonulin, regulation of tight junctions, and autoimmune diseases, Ann N Y Acad Sci, 1258, pp. 25-33, (2012); Fasano A., Intestinal permeability and its regulation by zonulin: Diagnostic and therapeutic implications, Clin Gastroenterol Hepatol, 10, pp. 1096-1100, (2012); Visser J., Rozing J., Sapone A., Et al., Tight junctions, intestinal permeability, and autoimmunity: Celiac disease and type 1 diabetes paradigms, Ann N Y Acad Sci, 1165, pp. 195-205, (2009); Khaleghi S., Ju J.M., Lamba A., Et al., The potential utility of tight junction regulation in celiac disease: Focus on larazotide acetate, Ther Adv Gastroenterol, 9, pp. 37-49, (2016); Adriaanse M.P.M., Tack G.J., Passos V.L., Et al., Serum I-FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies, Aliment Pharmacol Ther, 37, pp. 482-490, (2013); Adriaanse M.P.M., Mubarak A., Riedl R.G., Et al., Progress towards non-invasive diagnosis and follow-up of celiac disease in children: A prospective multicentre study to the usefulness of plasma I-FABP, Sci Rep, 7, (2017); Barbaro M.R., Cremon C., Caio G., Et al., 247 Zonulin serum levels are increased in non-celiac gluten sensitivity and irritable bowel syndrome with diarrhea, Gastroenterol, 148, (2015); Undseth R., Berstad A., Valeur J., Systemic symptoms in irritable bowel syndrome: An investigative study on the role of enterocyte disintegrity, endotoxemia and inflammation, Mol Med Rep, 14, pp. 5072-5076, (2016); Francis C.Y., Morris J., Whorwell P.J., The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress, Aliment Pharmacol Ther, 11, pp. 395-402, (1997); Anbardan S.J., Daryani N.E., Fereshtehnejad S.-M., Et al., Gender role in irritable bowel syndrome: A comparison of irritable bowel syndrome module (ROME III) between male and female patients, J Neurogastroenterol Motil, 18, pp. 70-77, (2012); Li C., Gao M., Zhang W., Et al., Zonulin regulates intestinal permeability and facilitates enteric bacteria permeation in coronary artery disease, Sci Rep; Bueno L., Protease activated receptor 2: A new target for IBS treatment, Eur Rev Med Pharmacol Sci, 12, pp. 95-102, (2008); Roka R., Rosztoczy A., Leveque M., Et al., A pilot study of fecal serine-protease activity: A pathophysiologic factor in diarrhea-predominant irritable bowel syndrome, Clin Gastroenterol Hepatol, 5, pp. 550-555, (2007); Smecuol E., Bai J.C., Vazquez H., Et al., Gastrointestinal permeability in celiac disease, Gastroenterology, 112, pp. 1129-1136, (1997); Duerksen D.R., Wilhelm-Boyles C., Veitch R., Et al., A comparison of antibody testing, permeability testing, and zonulin levels with small-bowel biopsy in celiac disease patients on a gluten-free diet, Dig Dis Sci, 55, pp. 1026-1031, (2010); Peters S.A., Edogawa S., Sundt W.J., Et al., Constipation-predominant irritable bowel syndrome females have normal colonic barrier and secretory function, Am J Gastroenterol, 112, pp. 913-923, (2017); Vazquez-Roque M.I., Camilleri M., Smyrk T., Et al., A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: Effects on bowel frequency and intestinal function, Gastroenterol, 144, pp. 903-911, (2013); Scheffler L., Crane A., Heyne H., Et al., Widely used commercial ELISA does not detect precursor of haptoglobin2, but recognizes properdin as a potential second member of the zonulin family, Front Endocrinol","A. Lembo; Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, United States; email: alembo@bidmc.harvard.edu","","SAGE Publications Ltd","","","","","","20506406","","","31210949","English","United Eur. Gastroenterol. J.","Article","Final","All Open Access; Bronze Open Access; Green Open Access","Scopus","2-s2.0-85060583515"

"de los Ríos C.C.; Cabezudo M.A.; Vallés A.Z.; Díaz-Rubio E.R.","de los Ríos, Constanza Ciriza (6603114265); Cabezudo, Marta Aparicio (56562850800); Vallés, Ana Zaratain (57219449588); Díaz-Rubio, Enrique Rey (7103353498)","6603114265; 56562850800; 57219449588; 7103353498","Practical approach to irritable bowel syndrome-diarrhea beyond low-FODMAP diet","2022","Revista Espanola de Enfermedades Digestivas","114","","","","","","0","10.17235/reed.2022.8749/2022","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85133880910&doi=10.17235%2freed.2022.8749%2f2022&partnerID=40&md5=3459863f60334eec7ee574685bf2678d","Gastroenterology Department, Hospital Clínico San Carlos, Universidad Complutense, Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain","de los Ríos C.C., Gastroenterology Department, Hospital Clínico San Carlos, Universidad Complutense, Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain; Cabezudo M.A., Gastroenterology Department, Hospital Clínico San Carlos, Universidad Complutense, Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain; Vallés A.Z., Gastroenterology Department, Hospital Clínico San Carlos, Universidad Complutense, Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain; Díaz-Rubio E.R., Gastroenterology Department, Hospital Clínico San Carlos, Universidad Complutense, Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain","Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by abdominal pain and altered defecation, usually accompanied by abdominal bloating or distension. The integrated model of bidirectional interaction between the central, autonomic, enteric nervous system, the microbiome, and the gut barrier allows a better understanding of the pathophysiology of IBS, as well as consideration of potential therapeutic strategies. IBS with predominant diarrhea (IBS-D) represents a therapeutic challenge. Dietary changes or restrictions are most commonly used by patients in an attempt at symptom control. Therefore, a number of diets, especially low-FODMAP diet, have increasingly gained interest as a therapy for IBS-D or mixed IBS. However, this kind of diet, while effective, is not exempt of problems. It is therefore necessary that other therapeutic options be considered while bearing pathophysiological mechanisms and general symptom management in mind. © 2022 ARAN Ediciones S.A.. All rights reserved.","Irritable bowel syndrome; Low-FODMAP diet; Microbiota; Mucoprotective drugs; Neuromodulators; Peppermint essential oil","cromoglycate disodium; ebastine; essential oil; fructan; histamine; hydrocortisone; ondansetron; peppermint; prebiotic agent; pregabalin; probiotic agent; ramosetron; rifaximin; saponin; abdominal distension; abdominal pain; Article; Bifidobacterium; bloating; cholecystectomy; colonoscopy; columnar epithelium; constipation; cytokine release; defecation; diarrhea; down regulation; extracellular matrix; fecal microbiota transplantation; feces microflora; gastrointestinal motility; gastrointestinal tract; health care utilization; human; immune response; intestine flora; intestine innervation; irritable colon; Lactobacillus; low FODMAP diet; mast cell; Mentha piperita; microbiome; nausea and vomiting; neuromuscular function; Parkinson disease; pathophysiology; quality of life; systematic review; upregulation; vomiting","","cromoglycate disodium, 15826-37-6, 16110-51-3, 93356-79-7, 93356-84-4; ebastine, 90729-43-4; fructan, 9037-90-5; histamine, 51-45-6, 56-92-8, 93443-21-1; hydrocortisone, 50-23-7; ondansetron, 103639-04-9, 116002-70-1, 99614-01-4; pregabalin, 148553-50-8; ramosetron, 132036-88-5, 132907-72-3; rifaximin, 80621-81-4, 88747-56-2; saponin, 8047-15-2","","","","","Ford AC, Lacy BE, Talley NJ., Irritable Bowel Syndrome, N Engl J Med, 376, 26, pp. 2566-2578, (2017); Black CJ, Ford AC., Global burden of irritable bowel syndrome: trends, predictions and risk factors, Nat Rev Gastroenterol Hepatol, 17, 8, pp. 473-486, (2020); Martin CR, Osadchiy V, Kalani A, Et al., The Brain-Gut-Microbiome Axis, Cellular and molecular gastroenterology and hepatology, 6, 2, pp. 133-148, (2018); Ford AC, Sperber AD, Corsetti M, Et al., Irritable bowel syndrome, Lancet, 396, 10263, pp. 1675-1688, (2020); Bohn L, Storsrud S, Tornblom H, Et al., Self-reported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life, Am J Gastroenterol, 108, 5, pp. 634-641, (2013); McKenzie YA, Bowyer RK, Leach H, Et al., British Dietetic Association systematic review and evidence-based practice guidelines for the dietary management of irritable bowel syndrome in adults (2016 update), J Hum Nutr Diet, 29, 5, pp. 549-575, (2016); Bellini M, Tonarelli S, Nagy AG, Et al., Low FODMAP Diet: Evidence, Doubts, and Hopes, Nutrients, 12, 1, (2020); Portincasa P, Bonfrate L, de Bari O, Et al., Irritable bowel syndrome and diet, Gastroenterol Rep (Oxf), 5, 1, pp. 11-19, (2017); Casellas F, Burgos R, Marcos A, Et al., Consensus document on exclusion diets in irritable bowel syndrome (IBS), Rev Esp Enferm Dig, 110, 12, pp. 806-824, (2018); Biesiekierski JR, Rosella O, Rose R, Et al., Quantification of fructans, galactooligosacharides and other short-chain carbohydrates in processed grains and cereals, J Hum Nutr Diet, 24, 2, pp. 154-176, (2011); Hahn J, Choi J, Chang MJ., Effect of Low FODMAPs Diet on Irritable Bowel Syndromes: A Systematic Review and Meta-Analysis of Clinical Trials, Nutrients, 13, 7, (2021); Vasant DH, Paine PA, Black CJ, Et al., British Society of Gastroenterology guidelines on the management of irritable bowel syndrome, Gut, 70, 7, pp. 1214-1240, (2021); Lacy BE, Pimentel M, Brenner DM, Et al., ACG Clinical Guideline: Management of Irritable Bowel Syndrome, Am J Gastroenterol, 116, 1, pp. 17-44, (2021); Ancona A, Petito C, Iavarone I, Et al., The gut-brain axis in irritable bowel syndrome and inflammatory bowel disease, Dig Liver Dis, 53, 3, pp. 298-305, (2021); Alonso-Cotoner C, Abril-Gil M, Albert-Bayo M, Et al., The Role of Purported Mucoprotectants in Dealing with Irritable Bowel Syndrome, Functional Diarrhea, and Other Chronic Diarrheal Disorders in Adults, Adv Ther, 38, 5, pp. 2054-2076, (2021); Claesson MJ, Jeffery IB, Conde S, Et al., Gut microbiota composition correlates with diet and health in the elderly, Nature, 488, 7410, pp. 178-184, (2012); Mayer EA, Savidge T, Shulman RJ., Brain-gut microbiome interactions and functional bowel disorders, Gastroenterology, 146, 6, pp. 1500-1512, (2014); Gonzalez Olmo BM, Butler MJ, Barrientos RM., Evolution of the Human Diet and Its Impact on Gut Microbiota, Immune Responses, and Brain Health, Nutrients, 13, 1, (2021); O'Keeffe M, Jansen C, Martin L, Et al., Long-term impact of the low-FODMAP diet on gastrointestinal symptoms, dietary intake, patient acceptability, and healthcare utilization in irritable bowel syndrome, Neurogastroenterol Motil, 30, 1, (2018); Marsh A, Eslick EM, Eslick GD., Does a diet low in FODMAPs reduce symptoms associated with functional gastrointestinal disorders? A comprehensive systematic review and meta-analysis, Eur J Nutr, 55, 3, pp. 897-906, (2016); Schumann D, Klose P, Lauche R, Et al., Low fermentable, oligo-, di-, monosaccharides and polyol diet in the treatment of irritable bowel syndrome: A systematic review and meta-analysis, Nutrition, 45, pp. 24-31, (2018); Staudacher HM, Whelan K, Irving PM, Et al., Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome, J Hum Nutr Diet, 24, 5, pp. 487-495, (2011); Hill P, Muir JG, Gibson PR., Controversies and Recent Developments of the Low-FODMAP Diet, Gastroenterol Hepatol (NY), 13, 1, pp. 36-45, (2017); Black CJ, Staudacher HM, Ford AC., Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis, Gut, 71, 6, pp. 1117-1126, (2022); Dionne J, Ford AC, Yuan Y, Et al., A Systematic Review and Meta-Analysis Evaluating the Efficacy of a Gluten-Free Diet and a Low FODMAPs Diet in Treating Symptoms of Irritable Bowel Syndrome, Am J Gastroenterol, 113, 9, pp. 1290-1300, (2018); Skodje GI, Sarna VK, Minelle IH, Et al., Fructan, Rather Than Gluten, Induces Symptoms in Patients With Self-Reported Non-Celiac Gluten Sensitivity, Gastroenterology, 154, 3, pp. 529-539, (2018); Moshiree B, Zhou Q, Price DD, Et al., Central sensitisation in visceral pain disorders, Gut, 55, 7, pp. 905-908, (2006); Lambarth A, Zarate-Lopez N, Fayaz A., Oral and parenteral anti-neuropathic agents for the management of pain and discomfort in irritable bowel syndrome: A systematic review and meta-analysis, Neurogastroenterol Motil, 34, 1, (2022); Saito YA, Almazar AE, Tilkes KE, Et al., Randomised clinical trial: pregabalin vs placebo for irritable bowel syndrome, Aliment Pharmacol Ther, 49, 4, pp. 389-397, (2019); Edogawa S, Edwinson AL, Peters SA, Et al., Serine proteases as luminal mediators of intestinal barrier dysfunction and symptom severity in IBS, Gut, 69, 1, pp. 62-73, (2020); Alexea O, Bacarea V, Pique N., The combination of oligo- and polysaccharides and reticulated protein for the control of symptoms in patients with irritable bowel syndrome: Results of a randomised, placebo-controlled, double-blind, parallel group, multicentre clinical trial, United European Gastroenterol J, 4, 3, pp. 455-465, (2016); Trifan A, Burta O, Tiuca N, Et al., Efficacy and safety of Gelsectan for diarrhoea-predominant irritable bowel syndrome: A randomised, crossover clinical trial, United European Gastroenterol J, 7, 8, pp. 1093-1101, (2019); Ciriza de Los Rios C, Falcon BS, Arguelles-Arias F, Et al., Long-term safety and efficacy study of a medical device containing xyloglucan, pea protein reticulated with tannins and xylo-oligosaccharides, in patients with diarrhoea-predominant irritable bowel syndrome, Therap Adv Gastroenterol, 14, (2021); Ford AC, Harris LA, Lacy BE, Et al., Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome, Aliment Pharmacol Ther, 48, 10, pp. 1044-1060, (2018); Xu D, Chen VL, Steiner CA, Et al., Efficacy of Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis, Am J Gastroenterol, 114, 7, pp. 1043-1050, (2019); Ianiro G, Eusebi LH, Black CJ, Et al., Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome, Aliment Pharmacol Ther, 50, 3, pp. 240-248, (2019); Lembo A, Pimentel M, Rao SS, Et al., Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome, Gastroenterology, 151, 6, pp. 1113-1121, (2016); Alammar N, Wang L, Saberi B, Et al., The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data, BMC Complement Altern Med, 19, 1, (2019); Weerts Z, Masclee AAM, Witteman BJM, Et al., Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome, Gastroenterology, 158, 1, pp. 123-136, (2020); Hughes PA, Zola H, Penttila IA, Et al., Immune activation in irritable bowel syndrome: can neuroimmune interactions explain symptoms?, Am J Gastroenterol, 108, 7, pp. 1066-1074, (2013); Wouters MM, Vicario M, Santos J., The role of mast cells in functional GI disorders, Gut, 65, 1, pp. 155-168, (2016); Barbara G, Stanghellini V, De Giorgio R, Et al., Functional gastrointestinal disorders and mast cells: implications for therapy, Neurogastroenterol Motil, 18, 1, pp. 6-17, (2006); Ciriza de Los Rios C, Castel de Lucas I, Canga Rodriguez-Valcarcel F, Et al., Irritable bowel syndrome and basal serum tryptase: correlation between subtype, severity, and comorbidities. A pilot study, Rev Esp Enferm Dig, 114, 1, pp. 22-27, (2022); Wouters MM, Balemans D, Van Wanrooy S, Et al., Histamine Receptor H1-Mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome, Gastroenterology, 150, 4, pp. 875-887, (2016); Lobo B, Ramos L, Martinez C, Et al., Downregulation of mucosal mast cell activation and immune response in diarrhoea-irritable bowel syndrome by oral disodium cromoglycate: A pilot study, United European Gastroenterol J, 5, 6, pp. 887-897, (2017); Barshop K, Staller K., Eluxadoline in irritable bowel syndrome with diarrhea: rationale, evidence and place in therapy, Ther Adv Chronic Dis, 8, 11, pp. 153-160, (2017); Black CJ, Burr NE, Camilleri M, Et al., Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis, Gut, 69, 1, pp. 74-82, (2020); Cash BD, Lacy BE, Schoenfeld PS, Et al., Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea, Am J Gastroenterol, 112, 2, pp. 365-374, (2017); Brenner DM, Sayuk GS, Gutman CR, Et al., Efficacy and Safety of Eluxadoline in Patients With Irritable Bowel Syndrome With Diarrhea Who Report Inadequate Symptom Control With Loperamide: RELIEF Phase 4 Study, Am J Gastroenterol, 114, 9, pp. 1502-1511, (2019); Zheng Y, Yu T, Tang Y, Et al., Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials, PLoS One, 12, 3, (2017); Ford AC, Brandt LJ, Young C, Et al., Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis, Am J Gastroenterol, 104, 7, pp. 1831-1843, (2009); Lembo T, Wright RA, Bagby B, Et al., Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome, Am J Gastroenterol, 96, 9, pp. 2662-2670, (2001); Chang L, Chey WD, Harris L, Et al., Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data, Am J Gastroenterol, 101, 5, pp. 1069-1079, (2006); Garsed K, Chernova J, Hastings M, Et al., A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea, Gut, 63, 10, pp. 1617-1625, (2014); Plasse TF, Barton G, Davidson E, Et al., Bimodal Release Ondansetron Improves Stool Consistency and Symptomatology in Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Trial, Am J Gastroenterol","C.C. de los Ríos; Servicio de Aparato Digestivo, Hospital Clínico San Carlos, Madrid, Calle del Profesor Martín Lagos, s/n, 28040, Spain; email: constanzacarpa@gmail.com","","ARAN Ediciones S.L","","","","","","11300108","","REDIE","35694883","English","Rev. Esp. Enferm. Dig.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85133880910"

"Nozu T.; Miyagishi S.; Ishioh M.; Takakusaki K.; Okumura T.","Nozu, Tsukasa (12765917900); Miyagishi, Saori (56538237900); Ishioh, Masatomo (57202513969); Takakusaki, Kaoru (7004150214); Okumura, Toshikatsu (7202327796)","12765917900; 56538237900; 57202513969; 7004150214; 7202327796","Imipramine improves visceral sensation and gut barrier in rat models of irritable bowel syndrome","2020","European Journal of Pharmacology","887","","173565","","","","9","10.1016/j.ejphar.2020.173565","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85091091879&doi=10.1016%2fj.ejphar.2020.173565&partnerID=40&md5=5c26343747ee78c50b65200516fbb394","Department of Regional Medicine and Education, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Center for Medical Education, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Division of Neuroscience, Department of Physiology, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Department of General Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan","Nozu T., Department of Regional Medicine and Education, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan, Center for Medical Education, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Miyagishi S., Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Ishioh M., Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Takakusaki K., Division of Neuroscience, Department of Physiology, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Okumura T., Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan, Department of General Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan","An impaired gut barrier, possibly leading to visceral hypersensitivity has been recently recognized to be one of the pivotal pathophysiology of irritable bowel syndrome (IBS). We previously showed that lipopolysaccharide (LPS), corticotropin-releasing factor (CRF), and repeated water avoidance stress (WAS) induce visceral hypersensitivity and colonic hyperpermeability via pro-inflammatory cytokine signaling (rat IBS models). Although the precise mechanisms of action are unclear, imipramine, a tricyclic antidepressant, improves IBS symptoms, and also has anticytokine properties. In this study, we hypothesized that imipramine improves the gut barrier to ameliorate IBS symptoms. To test this hypothesis, we determined its effects on visceral hypersensitivity and colonic hyperpermeability in rat IBS models. The visceral pain threshold in response to colonic balloon distention was electrophysiologically estimated by abdominal muscle contractions, and colonic permeability was measured by quantifying the absorbed Evans blue in colonic tissue in vivo. Subcutaneous imipramine injection (7, 20, 50 mg/kg) dose-dependently inhibited LPS-induced (1 mg/kg, subcutaneously) visceral hypersensitivity and colonic hyperpermeability. Imipramine also blocked these gastrointestinal (GI) changes induced by CRF (50 μg/kg, intraperitoneally) or repeated WAS (1 h daily for 3 days). Yohimbine (an α2-adrenoceptors antagonist), sulpiride (a dopamine D2 receptor antagonist), and naloxone hydrochloride (an opioid receptor antagonist) reversed these effects of imipramine in the LPS model. Therefore, imipramine may block GI changes in IBS via α2-adrenoceptors, dopamine D2, and opioid signaling. The improvement in the gut barrier resulting in inhibition of visceral pain is considered a valid mechanism of imipramine to ameliorate IBS symptoms. © 2020 Elsevier B.V.","Gut barrier; Imipramine; Irritable bowel syndrome; Visceral pain","Abdominal Muscles; Animals; Antidepressive Agents, Tricyclic; Colon; Corticotropin-Releasing Hormone; Dose-Response Relationship, Drug; Imipramine; Intestines; Irritable Bowel Syndrome; Lipopolysaccharides; Male; Permeability; Rats; Rats, Sprague-Dawley; Sensation; Stress, Psychological; Visceral Pain; alpha 2 adrenergic receptor; dopamine 2 receptor; imipramine; n(g) nitroarginine methyl ester; naloxone; ondansetron; opiate receptor; sulpiride; corticotropin releasing factor; imipramine; lipopolysaccharide; tricyclic antidepressant agent; adult; animal experiment; animal model; animal tissue; antinociception; Article; colon dilatation; controlled study; dose response; drug dose comparison; intestine mucosa permeability; irritable colon; male; muscle contraction; nonhuman; pain threshold; priority journal; rat; visceral pain; abdominal wall musculature; animal; colon; complication; drug effect; intestine; irritable colon; mental stress; permeability; psychology; sensation; Sprague Dawley rat; visceral pain","","imipramine, 113-52-0, 50-49-7; n(g) nitroarginine methyl ester, 50903-99-6; naloxone, 357-08-4, 465-65-6; ondansetron, 103639-04-9, 116002-70-1, 99614-01-4; sulpiride, 15676-16-1; corticotropin releasing factor, 9015-71-8, 178359-01-8, 79804-71-0, 86297-72-5, 86784-80-7; Antidepressive Agents, Tricyclic, ; Corticotropin-Releasing Hormone, ; Imipramine, ; Lipopolysaccharides, ","","","Akiyama Life Science Foundation; Japan Society for the Promotion of Science, KAKEN, (26120012, 26460287, 26460955)","This work was partially supported by the Japan Society for the Promotion of Science KAKENHI , Grant-in-Aid for Scientific Research (C) [ 26460287 (TN) and 26460955 (TO)], Scientific Research on Innovative Areas [ 26120012 (KT)], and the research grant from the Akiyama Life Science Foundation (TN).","Al-Chaer E.D., Kawasaki M., Pasricha P.J., A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development, Gastroenterology, 119, pp. 1276-1285, (2000); Averill D.B., Tsuchihashi T., Khosla M.C., Ferrario C.M., Losartan, nonpeptide angiotensin II-type 1 (AT1) receptor antagonist, attenuates pressor and sympathoexcitatory responses evoked by angiotensin II and L-glutamate in rostral ventrolateral medulla, Brain Res., 665, pp. 245-252, (1994); Azpiroz F., Bouin M., Camilleri M., Mayer E.A., Poitras P., Serra J., Spiller R.C., Mechanisms of hypersensitivity in IBS and functional disorders, Neuro Gastroenterol. Motil., 19, pp. 62-88, (2007); Bilge S.S., Bozkurt A., Ilkaya F., Ciftcioglu E., Kesim Y., Uzbay T.I., The antinociceptive effects of intravenous tianeptine in colorectal distension-induced visceral pain in rats: the role of 5-HT<sub>3</sub> receptors, Eur. J. Pharmacol., 681, pp. 44-49, (2012); Bilge S.S., Ilkaya F., Darakci O., Ciftcioglu E., Bozkurt A., Opioid receptors contribute to antinociceptive effect of tianeptine on colorectal distension-induced visceral pain in rats, Pharmacology, 101, pp. 96-103, (2018); Bischoff S.C., Barbara G., Buurman W., Ockhuizen T., Schulzke J.D., Serino M., Tilg H., Watson A., Wells J.M., Intestinal permeability--a new target for disease prevention and therapy, BMC Gastroenterol., 14, (2014); Calarge C.A., Devaraj S., Shulman R.J., Gut permeability and depressive symptom severity in unmedicated adolescents, J. Affect. Disord., 246, pp. 586-594, (2019); de Gandarias J.M., Echevarria E., Acebes I., Silio M., Casis L., Effects of imipramine administration on mu-opioid receptor immunostaining in the rat forebrain, Arzneimittelforschung, 48, pp. 717-719, (1998); Dharmshaktu P., Tayal V., Kalra B.S., Efficacy of antidepressants as analgesics: a review, J. Clin. Pharmacol., 52, pp. 6-17, (2012); Ganta C.K., Blecha F., Ganta R.R., Helwig B.G., Parimi S., Lu N., Fels R.J., Musch T.I., Kenney M.J., Hyperthermia-enhanced splenic cytokine gene expression is mediated by the sympathetic nervous system, Physiol. Genom., 19, pp. 175-183, (2004); Garrido-Gil P., Rodriguez-Perez A.I., Dominguez-Meijide A., Guerra M.J., Labandeira-Garcia J.L., Bidirectional neural interaction between central dopaminergic and gut lesions in Parkinson's disease models, Mol. Neurobiol., 55, pp. 7297-7316, (2018); Giovannitti J.A., Thoms S.M., Crawford J.J., Alpha-2 adrenergic receptor agonists: a review of current clinical applications, Anesth. Prog., 62, pp. 31-39, (2015); Hirata T., Keto Y., Nakata M., Takeuchi A., Funatsu T., Akuzawa S., Sasamata M., Miyata K., Effects of serotonin 5-HT3 receptor antagonists on stress-induced colonic hyperalgesia and diarrhoea in rats: a comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer, Neuro Gastroenterol. Motil., 20, pp. 557-565, (2008); Ilkaya F., Bilge S.S., Bozkurt A., Bas D.B., Erdal A., Ciftcioglu E., Kesim Y., The antinociceptive effect of intravenous imipramine in colorectal distension-induced visceral pain in rats: the role of serotonergic and noradrenergic receptors, Pharmacol. Biochem. Behav., 122, pp. 1-6, (2014); Kenney M.J., Ganta C.K., Autonomic nervous system and immune system interactions, Compreh. Physiol., 4, pp. 1177-1200, (2014); Kim I.J., Park C.H., Lee S.H., Yoon M.H., The role of spinal adrenergic receptors on the antinociception of ginsenosides in a rat postoperative pain model, Korean J. Anesthesiol, 65, pp. 55-60, (2013); Kulak-Bejda A., Bejda G., Waszkiewicz N., Antidepressants for irritable bowel syndrome-A systematic review, Pharmacol. Rep., 69, pp. 1366-1379, (2017); Lee C., Doo E., Choi J.M., Jang S.H., Ryu H.S., Lee J.Y., Oh J.H., Park J.H., Kim Y.S., The increased level of depression and anxiety in irritable bowel syndrome patients compared with healthy controls: systematic review and meta-analysis, J. Neurogastroenterol. Motil, 23, pp. 349-362, (2017); Liu L., Zhu G., Gut-brain Axis and mood disorder, Front. Psychiatr., 9, (2018); Martinez V., Rivier J., Wang L., Tache Y., Central injection of a new corticotropin-releasing factor (CRF) antagonist, astressin, blocks CRF- and stress-related alterations of gastric and colonic motor function, J. Pharmacol. Exp. Therapeut., 280, pp. 754-760, (1997); Maruta S., Suzuki E., Yokoyama M., Sato T., Inada K., Watanabe S., Miyaoka H., Effects of intraperitoneally injected lithium, imipramine and diazepam on nitrate levels in rat amygdala, Psychiatr. Clin. Neurosci., 59, pp. 358-361, (2005); Mearin F., Lacy B.E., Chang L., Chey W.D., Lembo A.J., Simren M., Spiller R., Bowel disorders, Gastroenterology, 150, pp. 1393-1407, (2016); Muscat R., Sampson D., Willner P., Dopaminergic mechanism of imipramine action in an animal model of depression, Biol. Psychiatr., 28, pp. 223-230, (1990); Ness T.J., Gebhart G.F., Colorectal distension as a noxious visceral stimulus: physiologic and pharmacologic characterization of pseudaffective reflexes in the rat, Brain Res., 450, pp. 153-169, (1988); Ninkovic J., Roy S., Role of the mu-opioid receptor in opioid modulation of immune function, Amino Acids, 45, pp. 9-24, (2013); Nozu T., Kudaira M., Kitamori S., Uehara A., Repetitive rectal painful distention induces rectal hypersensitivity in patients with irritable bowel syndrome, J. Gastroenterol., 41, pp. 217-222, (2006); Nozu T., Miyagishi S., Nozu R., Takakusaki K., Okumura T., Lipopolysaccharide induces visceral hypersensitivity: role of interleukin-1, interleukin-6, and peripheral corticotropin-releasing factor in rats, J. Gastroenterol., 52, pp. 72-80, (2017); Nozu T., Miyagishi S., Nozu R., Takakusaki K., Okumura T., Repeated water avoidance stress induces visceral hypersensitivity; role of IL-1, IL-6 and peripheral corticotropin-releasing factor, J. Gastroenterol. Hepatol., 32, pp. 1958-1965, (2017); Nozu T., Miyagishi S., Nozu R., Takakusaki K., Okumura T., Altered colonic sensory and barrier functions by CRF: roles of TLR4 and IL-1, J. Endocrinol., 239, pp. 241-252, (2018); Nozu T., Miyagishi S., Nozu R., Takakusaki K., Okumura T., Butyrate inhibits visceral allodynia and colonic hyperpermeability in rat models of irritable bowel syndrome, Sci. Rep., 9, (2019); Nozu T., Miyagishi S., Nozu R., Takakusaki K., Okumura T., Dehydroepiandrosterone sulfate improves visceral sensation and gut barrier in a rat model of irritable bowel syndrome, Eur. J. Pharmacol., 852, pp. 198-206, (2019); Nozu T., Miyagishi S., Nozu R., Takakusaki K., Okumura T., Losartan improves visceral sensation and gut barrier in a rat model of irritable bowel syndrome, Neuro Gastroenterol. Motil., 32, (2020); Nozu T., Okumura T., Corticotropin-releasing factor receptor type 1 and type 2 interaction in irritable bowel syndrome, J. Gastroenterol., 50, pp. 819-830, (2015); Obreja O., Rathee P.K., Lips K.S., Distler C., Kress M., IL-1 beta potentiates heat-activated currents in rat sensory neurons: involvement of IL-1RI, tyrosine kinase, and protein kinase C, Faseb. J., 16, pp. 1497-1503, (2002); Okumura T., Nozu T., Kumei S., Takakusaki K., Ohhira M., Ghrelin acts centrally to induce an antinociceptive action during colonic distension through the orexinergic, dopaminergic and opioid systems in conscious rats, Brain Res., 1686, pp. 48-54, (2018); Reus G.Z., Dos Santos M.A., Abelaira H.M., Ribeiro K.F., Petronilho F., Vuolo F., Colpo G.D., Pfaffenseller B., Kapczinski F., Dal-Pizzol F., Quevedo J., Imipramine reverses alterations in cytokines and BDNF levels induced by maternal deprivation in adult rats, Behav. Brain Res., 242, pp. 40-46, (2013); Sierralta F., Pinardi G., Mendez M., Miranda H.F., Interaction of opioids with antidepressant-induced antinociception, Psychopharmacology (Berlin), 122, pp. 374-378, (1995); Sonohata M., Furue H., Katafuchi T., Yasaka T., Doi A., Kumamoto E., Yoshimura M., Actions of noradrenaline on substantia gelatinosa neurones in the rat spinal cord revealed by in vivo patch recording, J. Physiol., 555, pp. 515-526, (2004); Stevens B.R., Goel R., Seungbum K., Richards E.M., Holbert R.C., Pepine C.J., Raizada M.K., Increased human intestinal barrier permeability plasma biomarkers zonulin and FABP2 correlated with plasma LPS and altered gut microbiome in anxiety or depression, Gut, 67, pp. 1555-1557, (2018); Suzuki E., Nakaki T., Kanba S., Shintani F., Miyaoka H., Long-term imipramine treatment increases nitrate levels in the rat hypothalamus, Cell. Mol. Neurobiol., 23, pp. 953-962, (2003); Suzuki T., Yoshinaga N., Tanabe S., Interleukin-6 (IL-6) regulates claudin-2 expression and tight junction permeability in intestinal epithelium, J. Biol. Chem., 286, pp. 31263-31271, (2011); Tache Y., Kiank C., Stengel A., A role for corticotropin-releasing factor in functional gastrointestinal disorders, Curr. Gastroenterol. Rep., 11, pp. 270-277, (2009); Tanda G., Carboni E., Frau R., Di Chiara G., Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential?, Psychopharmacology (Berlin), 115, pp. 285-288, (1994); Vahedi H., Merat S., Momtahen S., Kazzazi A.S., Ghaffari N., Olfati G., Malekzadeh R., Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome, Aliment. Pharmacol. Ther., 27, pp. 678-684, (2008); Valdez G.R., CRF receptors as a potential target in the development of novel pharmacotherapies for depression, Curr. Pharmaceut. Des., 15, pp. 1587-1594, (2009); Vanuytsel T., Tack J.F., Boeckxstaens G.E., Treatment of abdominal pain in irritable bowel syndrome, J. Gastroenterol., 49, pp. 1193-1205, (2014); Wang J., Barke R.A., Charboneau R., Roy S., Morphine impairs host innate immune response and increases susceptibility to Streptococcus pneumoniae lung infection, J. Immunol., 174, pp. 426-434, (2005); Xia Z., DePierre J.W., Nassberger L., Tricyclic antidepressants inhibit IL-6, IL-1 beta and TNF-alpha release in human blood monocytes and IL-2 and interferon-gamma in T cells, Immunopharmacology, 34, pp. 27-37, (1996); Yang J.P., Yao M., Jiang X.H., Wang L.N., Establishment of model of visceral pain due to colorectal distension and its behavioral assessment in rats, World J. Gastroenterol., 12, pp. 2781-2784, (2006); Yu Y., Liu Z.Q., Liu X.Y., Yang L., Geng X.R., Yang G., Liu Z.G., Zheng P.Y., Yang P.C., Stress-derived corticotropin releasing factor breaches epithelial endotoxin tolerance, PloS One, 8, (2013)","T. Nozu; Department of Regional Medicine and Education, Asahikawa Medical University, Asahikawa, 2-1-1-1 Midorigaoka-Higashi, 078-8510, Japan; email: tnozu@sea.plala.or.jp","","Elsevier B.V.","","","","","","00142999","","EJPHA","32946869","English","Eur. J. Pharmacol.","Article","Final","","Scopus","2-s2.0-85091091879"

"Yu L.-M.; Mao L.-Q.; Wu C.-Y.; Ye W.; Wang X.","Yu, Lei-Min (23037841100); Mao, Li-Qi (57211849788); Wu, Chun-Yan (57226128693); Ye, Wei (57219147042); Wang, Xi (56998855200)","23037841100; 57211849788; 57226128693; 57219147042; 56998855200","Chlorogenic acid improves intestinal barrier function by downregulating CD14 to inhibit the NF-κB signaling pathway","2021","Journal of Functional Foods","85","","104640","","","","20","10.1016/j.jff.2021.104640","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85110520434&doi=10.1016%2fj.jff.2021.104640&partnerID=40&md5=66fe5354b289fa2054709f44f0f87f7d","Department of Gastroenterology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China; Department of Gastroenterology, The First People's Hospital of Huzhou, The First Affiliated Hospital of Huzhou Teachers College, Huzhou, Zhejiang Province, China; Key Laboratory of Digestive Pathophysiology of Zhejiang Province, The First Affiliated Hospital of Zhejiang Chinese Medicine, Zhejiang Chinese Medical University, Hangzhou, China","Yu L.-M., Department of Gastroenterology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China; Mao L.-Q., Department of Gastroenterology, The First People's Hospital of Huzhou, The First Affiliated Hospital of Huzhou Teachers College, Huzhou, Zhejiang Province, China; Wu C.-Y., Department of Gastroenterology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China; Ye W., Department of Gastroenterology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China; Wang X., Key Laboratory of Digestive Pathophysiology of Zhejiang Province, The First Affiliated Hospital of Zhejiang Chinese Medicine, Zhejiang Chinese Medical University, Hangzhou, China","Chlorogenic acid (CGA) is a polyphenol compound present in plant foods. CGA is a differentially excreted gut microbial metabolite in fecal samples of irritable bowel syndrome model mice and normal control mice. Here, we aimed to clarify the protective effect of CGA on intestinal barrier function. We used Caco-2 cells to create an intestinal epithelial cell barrier model, and evaluated tight-junctional permeability with fluorescein isothiocyanate–dextran. We treated Caco-2 cells with lipopolysaccharide and CGA, and measured tight-junction protein expression, TLR4/NF-κB pathway activation, and proinflammatory cytokine levels. CGA blocked the NF-κB pathway by downregulating CD14 and p65, and preventing phospho-p65 from entering cell nuclei. CGA showed anti-inflammatory effects by suppressing tumor necrosis factor-α, interleukin (IL)-1β, and IL-6 production, and thereby restored intestinal epithelial tight-junction integrity. In conclusion, CGA was highly effective at preserving cell membrane integrity, and inhibited proinflammatory cytokine secretion by downregulating CD14 to block the NF-kB pathway. © 2021","CD14; Chlorogenic acid; Intestinal barrier; NF-κB; Pro-inflammatory cytokines","","","","","","Natural Science Foundation of Zhejiang Province, ZJNSF, (LY21H030002); Medical Scientific Research Foundation of Zhejiang Province, China, (2019RC229, 2019RC250, 2021KY917)","This study was supported by grants from Zhejiang Provincial Natural Science Foundation of China (no. LY21H030002) and the Medical Scientific Research Foundation of Zhejiang Province (nos. 2019RC250, 2021KY917, and 2019RC229).","Abreu M.T., Vora P., Faure E., Thomas L.S., Arnold E.T., Arditi M., Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide, J Immunol, 167, 3, pp. 1609-1616, (2001); Artursson P., Palm K., Luthman K., Caco-2 monolayers in experimental and theoretical predictions of drug transport, Adv Drug Deliv Rev, 46, pp. 27-43, (2001); Brint E.K., MacSharry J., Fanning A., Shanahan F., Quigley E.M., Differential expression of toll-like receptors in patients with irritable bowel syndrome, Am J Gastroenterol, 106, pp. 329-336, (2011); Camilleri M., Lasch K., Zhou W., Irritable bowel syndrome: Methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome, Am J Physiol Gastrointest Liver Physiol, 303, 7, pp. G775-G785, (2012); Capaldo C.T., Nusrat A., Cytokine regulation of tight junctions, Biochim Biophys Acta, 1788, 4, pp. 864-871, (2009); Chen D., Pan D., Tang S., Tan Z., Zhang Y., Fu Y., Et al., Administration of chlorogenic acid alleviates spinal cord injury via TLR4/NF-κB and p38 signaling pathway anti-inflammatory activity, Mol Med Rep, (2018); Chen J., Yu B., Chen D., Huang Z., Mao X., Zheng P., Et al., Chlorogenic acid improves intestinal barrier functions by suppressing mucosa inflammation and improving antioxidant capacity in weaned pigs, J Nutr Biochem, 59, pp. 84-92, (2018); Chen L., Ilham S.J., Feng B., Pharmacological Approach for Managing Pain in Irritable Bowel Syndrome: A Review Article, Anesth Pain Med, 7, (2017); Collins S.M., Piche T., Rampal P., The putative role of inflammation in the irritable bowel syndrome, Gut, 49, pp. 743-745, (2001); da Silva Correia J., Soldau K., Christen U., Tobias P.S., Ulevitch R.J., Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex. transfer from CD14 to TLR4 and MD-2, J Biol Chem, 276, 24, pp. 21129-21135, (2001); De Palma G., Lynch M.D.J., Lu J., Dang V.T., Deng Y., Jury J., Et al., Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice, Sci Transl Med, 9, 379, (2017); Fitzgerald K.A., Rowe D.C., Golenbock D.T., Endotoxin recognition and signal transduction by the TLR4/MD2-complex, Microbes Infect, 6, 15, pp. 1361-1367, (2004); Galvez-Llompart M., Recio M.C., Garcia-Domenech R., Topological virtual screening: A way to find new compounds active in ulcerative colitis by inhibiting NF-κB, Mol Divers, 15, 4, pp. 917-926, (2011); Gao K., Mu C.L., Farzi A., Zhu W.Y., Tryptophan Metabolism: A Link Between the Gut Microbiota and Brain, Adv Nutr, 11, pp. 709-723, (2020); Gonzalez-Castro A.M., Martinez C., Salvo-Romero E., Fortea M., Pardo-Camacho C., Perez-Berezo T., Et al., Mucosal pathobiology and molecular signature of epithelial barrier dysfunction in the small intestine in irritable bowel syndrome, J Gastroenterol Hepatol, 32, 1, pp. 53-63, (2017); Guo S., Al-Sadi R., Said H.M., Ma T.Y., Lipopolysaccharide causes an increase in intestinal tight junction permeability in vitro and in vivo by inducing enterocyte membrane expression and localization of TLR-4 and CD14, Am J Pathol, 182, pp. 375-387, (2013); Haziot A., Ferrero E., Kontgen F., Hijiya N., Yamamoto S., Silver J., Et al., Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice, Immunity, 4, 4, pp. 407-414, (1996); Li G.Z., Wang Z.H., Cui W., Fu J.L., Wang Y.R., Liu P., Tumor necrosis factor alpha increases intestinal permeability in mice with fulminant hepatic failure, World J Gastroenterol, 18, pp. 5042-5050, (2012); Liang N., Kitts D., Role of Chlorogenic Acids in Controlling Oxidative and Inflammatory Stress Conditions, Nutrients, 8, 1, (2015); Luissint A.-C., Parkos C.A., Nusrat A., Inflammation and the Intestinal Barrier: Leukocyte-Epithelial Cell Interactions, Cell Junction Remodeling, and Mucosal Repair, Gastroenterology, 151, 4, pp. 616-632, (2016); Madden J.A., Hunter J.O., A review of the role of the gut microflora in irritable bowel syndrome and the effects of probiotics, Br J Nutr, 88, pp. S67-S72, (2002); Mankertz J., Tavalali S., Schmitz H., Mankertz A., Riecken E.O., Fromm M., Et al., pp. 2085-2090, (2000); Ng Q.X., Soh A.Y.S., Loke W., Lim D.Y., Yeo W.S., The role of inflammation in irritable bowel syndrome (IBS), J Inflamm Res, 11, pp. 345-349, (2018); Nicholson J.K., Holmes E., Wilson I.D., Gut microorganisms, mammalian metabolism and personalized health care, Nat Rev Microbiol, 3, 5, pp. 431-438, (2005); Noreen M., Shah M.A.A., Mall S.M., Choudhary S., Hussain T., Ahmed I., Et al., TLR4 polymorphisms and disease susceptibility, Inflamm Res, 61, 3, pp. 177-188, (2012); Plociennikowska A., Hromada-Judycka A., Borzecka K., Kwiatkowska K., Co-operation of TLR4 and raft proteins in LPS-induced pro-inflammatory signaling, Cell Mol Life Sci, 72, 3, pp. 557-581, (2015); Ponce de Leon-Rodriguez, Guyot J.P., Laurent-Babot C., Intestinal in vitro cell culture models and their potential to study the effect of food components on intestinal inflammation, Crit Rev Food Sci Nutr, 59, pp. 3648-3666, (2019); Ruan Z., Liu S., Zhou Y., Mi S., Liu G., Wu X., Et al., (2014); Ruan Z., Mi S., Zhou L., Zhou Y., Li J., Liu W., Et al., Chlorogenic acid enhances intestinal barrier by decreasing MLCK expression and promoting dynamic distribution of tight junction proteins in colitic rats, J Funct Foods, 26, pp. 698-708, (2016); Shariati A., Fallah F., Pormohammad A., Taghipour A., Safari H., chirani A.S., Et al., The possible role of bacteria, viruses, and parasites in initiation and exacerbation of irritable bowel syndrome, J Cell Physiol, 234, 6, pp. 8550-8569, (2019); Varadi J., Harazin A., Fenyvesi F., Reti-Nagy K., Gogolak P., Vamosi G., Et al., (2017); Vamadevan A.S., Fukata M., Arnold E.T., Thomas L.S., Hsu D., Abreu M.T., Regulation of Toll-like receptor 4-associated MD-2 in intestinal epithelial cells: A comprehensive analysis, Innate Immun, 16, 2, pp. 93-103, (2010); Van Spaendonk H., Ceuleers H., Witters L., Patteet E., Joossens J., Augustyns K., Et al., Regulation of intestinal permeability: The role of proteases, World J Gastroenterol, 23, 12, (2017); Volpe D.A., Permeability classification of representative fluoroquinolones by a cell culture method, Aaps j, 6, 2, pp. 1-6, (2004); Wang X., Lu B., Dai C., Fu Y., Hao K., Zhao B., Et al., (2020); Wullaert A., Role of NF-kappaB activation in intestinal immune homeostasis, Int J Med Microbiol, 300, pp. 49-56, (2010); Xavier R.J., Podolsky D.K., Unravelling the pathogenesis of inflammatory bowel disease, Nature, 448, 7152, pp. 427-434, (2007); Yu L.-M., Zhao K.-J., Wang S.-S., Wang X.I., Lu B., Gas chromatography/mass spectrometry based metabolomic study in a murine model of irritable bowel syndrome, World J Gastroenterol, 24, 8, pp. 894-904, (2018); Zeber-Lubecka N., Kulecka M., Ambrozkiewicz F., Paziewska A., Goryca K., Karczmarski J., Et al., Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome, Gut Microbes, 7, 5, pp. 397-413, (2016); Zhang S., Xu W., Wang H., Cao M., Li M., Zhao J., Et al., Inhibition of CREB-mediated ZO-1 and activation of NF-κB-induced IL-6 by colonic epithelial MCT4 destroys intestinal barrier function, Cell Prolif, 52, 6, (2019); Zhang Z., Wu X., Cao S., Cromie M., Shen Y., Feng Y., Et al., Chlorogenic Acid Ameliorates Experimental Colitis by Promoting Growth of Akkermansia in Mice, Nutrients, 9, 7, (2017); Zhu S., Liu S., Li H., Zhang Z., Zhang Q., Chen L., Et al., (2019)","X. Wang; Key Laboratory of Digestive Pathophysiology of Zhejiang Province, The First Affiliated Hospital of Zhejiang Chinese Medicine, Zhejiang Chinese Medical University, Hangzhou, Rm 20304, 20# Building, Binwen Campus, 548 Binwen Road, Binjiang District, 310053, China; email: wangxi@zcmu.edu.cn","","Elsevier Ltd","","","","","","17564646","","","","English","J. Funct. Foods","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85110520434"

"Chen T.; Yin X.-L.; Kang N.; Wang X.-G.; Li B.-S.; Ji H.-J.; Zhang Y.-Q.; Bian L.-Q.; Zhang B.-H.; Wang F.-Y.; Tang X.-D.","Chen, Ting (56580693700); Yin, Xiao-lan (57189897513); Kang, Nan (56581286200); Wang, Xiao-ge (56308893500); Li, Bao-shuang (36987650900); Ji, Hai-jie (58392478900); Zhang, Yin-qiang (24281929500); Bian, Li-qun (26651311200); Zhang, Bei-hua (56171115000); Wang, Feng-yun (55740508700); Tang, Xu-dong (24339251100)","56580693700; 57189897513; 56581286200; 56308893500; 36987650900; 58392478900; 24281929500; 26651311200; 56171115000; 55740508700; 24339251100","Chang’an II Decoction (肠安 II 号方)-Containing Serum Ameliorates Tumor Necrosis Factor-α-Induced Intestinal Epithelial Barrier Dysfunction via MLCK-MLC Signaling Pathway in Rats","2020","Chinese Journal of Integrative Medicine","26","10","","745","753","8","5","10.1007/s11655-019-3034-6","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85075610238&doi=10.1007%2fs11655-019-3034-6&partnerID=40&md5=b95d89e0a8a07b436a91a21f2256797a","Department of Gastroenterology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China; Graduate School of China Academy of Chinese Medical Sciences, Beijing, 100700, China; Department of Internal Medicine, Jining Medical College Affiliated Hospital, Jining, 272029, Shandong Province, China; Department of Gastroenterology, Henan University of Chinese Medicine Affiliated Hospital, Zhengzhou, 136300, China; Department of Liver Diseases, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China","Chen T., Department of Gastroenterology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China; Yin X.-L., Graduate School of China Academy of Chinese Medical Sciences, Beijing, 100700, China; Kang N., Department of Internal Medicine, Jining Medical College Affiliated Hospital, Jining, 272029, Shandong Province, China; Wang X.-G., Department of Gastroenterology, Henan University of Chinese Medicine Affiliated Hospital, Zhengzhou, 136300, China; Li B.-S., Department of Gastroenterology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China; Ji H.-J., Department of Gastroenterology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China; Zhang Y.-Q., Department of Liver Diseases, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China; Bian L.-Q., Department of Gastroenterology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China; Zhang B.-H., Department of Gastroenterology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China; Wang F.-Y., Department of Gastroenterology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China; Tang X.-D., Department of Gastroenterology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China","Objective: To investigate the effect of Chang’an II Decoction (肠安 II 号方))-containing serum on intestinal epithelial barrier dysfunction in rats. Methods: Tumor necrosis factor (TNF)-α-induced injury of Caco-2 monolayers were established as an inflammatory model of human intestinal epithelium. Caco-2 monolayers were treated with blank serum and Chang’an II Decoction-containing serum that obtained from the rats which were treated with distilled water and Chang’an II Decoction intragastrically at doses of 0.49, 0.98, 1.96 g/(kg·d) for 1 week, respectively. After preparation of containing serum, cells were divided into the normal group, the model group, the Chang’an II-H, M, and L groups (treated with 30 ng/mL TNF-α and medium plus 10% high, middle-, and low-doses Chang’an II serum, respectively). Epithelial barrier function was assessed by transepithelial electrical resistance (TER) and permeability of fluorescein isothiocyanate (FITC)-labeled dextran. Transmission electron microscopy was used to observe the ultrastructure of tight junctions (TJs). Immunofluorescence of zonula occludens-1 (ZO-1), claudin-1 and nuclear transcription factor-kappa p65 (NF-κ Bp65) were measured to determine the protein distribution. The mRNA expression of myosin light chain kinase (MLCK) was measured by real-time polymerase chain reaction. The expression levels of MLCK, myosin light chain (MLC) and p-MLC were determined by Western blot. Results: Chang’an II Decoction-containing serum significantly attenuated the TER and paracellular permeability induced by TNF-α. It alleviated TNF-α-induced morphological alterations in TJ proteins. The increases in MLCK mRNA and MLCK, MLC and p-MLC protein expressions induced by TNF-α were significantly inhibited in the Chang’an II-H group. Additionally, Chang’an II Decoction significantly attenuated translocation of NF-κ Bp65 into the nucleus. Conclusion: High-dose Chang’an II-containing serum attenuates TNF-α-induced intestinal barrier dysfunction. The underlying mechanism may be involved in inhibiting the MLCK-MLC phosphorylation signaling pathway mediated by NF-κ Bp65. © 2019, The Chinese Journal of Integrated Traditional and Western Medicine Press and Springer-Verlag GmbH Germany, part of Springer Nature.","Chang’an II Decoction; drug-containing serum; intestinal epithelial cells; myosin light chain kinase-myosin light chain; signaling pathway; tight junction; tumor necrosis factor-α","Animals; Caco-2 Cells; Disease Models, Animal; Drugs, Chinese Herbal; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Male; Myosin Light Chains; Myosin-Light-Chain Kinase; Rats; Rats, Sprague-Dawley; Tumor Necrosis Factor-alpha; changan ii decoction; Chinese medicinal formula; claudin 1; fluorescein isothiocyanate dextran; messenger RNA; myosin light chain; myosin light chain kinase; protein ZO1; tight junction protein; transcription factor RelA; tumor necrosis factor; unclassified drug; Chang'an II; herbaceous agent; myosin light chain; myosin light chain kinase; tumor necrosis factor; actin filament; animal experiment; animal model; Article; body surface; Caco-2 cell line; controlled study; drug megadose; human; human cell; immunofluorescence; intestine epithelium; intestine injury; low drug dose; male; nonhuman; priority journal; protein blood level; protein expression; protein localization; protein phosphorylation; rat model; real time polymerase chain reaction; signal transduction; transepithelial resistance; transmission electron microscopy; upregulation; Western blotting; animal; disease model; drug effect; intestine mucosa; irritable colon; metabolism; rat; Sprague Dawley rat","","claudin 1, 329338-06-9; fluorescein isothiocyanate dextran, 60842-46-8; myosin light chain kinase, 51845-53-5; Chang'an II, ; Drugs, Chinese Herbal, ; Myosin Light Chains, ; Myosin-Light-Chain Kinase, ; Tumor Necrosis Factor-alpha, ","","","","","Lacy B.E., Mearin F., Chang L., Chey W.D., Lembo A.J., Simren M., Et al., Bowel disorders, Gastroenterology, 150, pp. 1393-1407, (2016); Canavan C., West J., Card T., The epidemiology of irritable bowel syndrome, Clin Epidemiol, 6, pp. 71-80, (2014); Stasi C., Rosselli M., Bellini M., Laffi G., Milani S., Altered neuro-endocrine-immune pathways in the irritable bowel syndrome: the top-down and the bottom-up model, J Gastroenterol, 47, pp. 1177-1185, (2012); Bercik P., Wang L., Verdu E.F., Mao Y.K., Blennerhassett P., Khan W.I., Et al., Visceral hyperalgesia and Intestinal dysmotility in a mouse model of postinfective gut dysfunction, Gastroenterology, 127, pp. 179-187, (2004); Ledochowski M., Propst T., Fuchs D., The role of psychological and biological factors in post infective gut dysfunction, Gut, 46, pp. 140-141, (2000); Kimball E.S., Palmer J.M., D'Andrea M.R., Hornby P.J., Wade P.R., Acute colitis induction by oil of mustard results in later development of an IBS-like accelerated upper GI transit in mice, Amer J Physiol Gastrointest Liver Phys, 288, pp. G1266-G1273, (2005); Ohman L., Tornblom H., Simren M., Crosstalk at the mucosal border: importance of the gut microenvironment in IBS, Nat Rev Gastroenterol Hepatol, 12, pp. 36-49, (2015); Peterson L.W., Artis D., Intestinal epithelial cells: regulators of barrier function and immune homeostasis, Nature Review Immunol, 14, pp. 141-153, (2014); Bertiaux-Vandaele N., Youmba S.B., BeLmonte L., Lecleire S., Antonietti M., Gourcerol G., Et al., The expression and the cellular distribution of the tight junction proteins are altered in Irritable bowel syndrome patients with differences according to the disease subtype, Ame J Gastroenterol, 106, pp. 2165-2173, (2011); Piche T., Barbara G., Aubert P., Bruley des Varannes S., Dainese R., Nano J.L., Et al., Impaired Intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Bashashati M., Rezaei N., Andrews C.N., Chen C.Q., Daryani N.E., Sharkey K.A., Et al., Cytokines and irritable bowel syndrome: where do we stand?, Cytokine, 57, pp. 201-209, (2012); Darkoh C., Comer L., Zewdie G., HaroLd S., Snyder N., DuPont H.L., Chemotactic chemokines are important in the pathogenesis of irritable bowel syndrome, PLoS One, 9, pp. 1-8, (2014); Clark I.A., How TNF was recognized as a key mechanism of disease, Cytok Growth Factor Rev, 18, pp. 335-343, (2007); Ma T.Y., Boivin M.A., Ye D., Pedram A., Said H.M., Mechanism of TNF-α modulation of Caco-2 intestinal epithelial tight junction barrier: role of myosin light-chain kinase protein expression, Am J Physiol Gastrointest Liver Physiol, 288, pp. G422-G430, (2005); Hecht G., Pestic L., Nikcevic G., Koutsouris A., Tripuraneni J., Lorimer D.D., Et al., Expression of the catalytic domain of myosin light chain kinase increases paracellular permeability, Am J Physiol, 271, pp. C1678-C1684, (1996); Ivanov A.I., McCall I.C., Parkos C.A., Nusrat A., Role for actin filament turnover and a myosin II motor in cytoskeleton-driven disassembly of the epithelial apical junctional complex, Mol Biol Cell, 15, pp. 2639-2651, (2004); Ma T.Y., Tran D., Hoa N., Nguyen D., Merryfield M., Tarnawski A., Mechanism of extracellular calcium regulation of Intestinal epithelial tight junction permeability: role of cytoskeletal involvement, Microsc Res Tech, 51, pp. 156-168, (2000); Shen L., Black E.D., Witkowski E.D., Lencer W.I., Guerriero V., Schneeberger E.E., Et al., Myosin light chain phosphorylation regulates barrier function by remodeling tight junction structure, J Cell Sci, 119, pp. 2095-2106, (2006); Cao M., Wang P., Sun C.H., He W., Wang F.J., Amelioration of IFN-γ and TNF-α-induced intestinal epithelial barrier dysfunction by berberine via suppression of MLCK-MLC phosphorylation signaling pathway, PLoS One, 8, pp. 1-9, (2013); Liu H., Wang P., Cao M., Li M., Wang F., Protective role of oligomycin against intestinal epithelial barrier dysfunction caused by IFN-γ and TNF-α, Cell Physiol Biochem, 29, pp. 799-808, (2012); Bian Z., Wu T., Liu L., Miao J., Wong H., Song L., Et al., Effectiveness of the Chinese herbal formula TongXieYaoFang for irritable bowel syndrome: a systematic review, J Altern Complement Med, 12, pp. 401-407, (2006); Wang C.W., Shi J., Ke F., Meta-analysis of the effectiveness of Tong Xie Yao Fang in treating irritable bowel syndrome, World Chin J Digest (Chin), 15, pp. 1934-1939, (2007); Wang F.Y., Su M., Zheng Y.Q., Wang X.G., Kang N., Chen T., Et al., Herbal prescription Chang’an II repairs intestinal mucosal barrier in rats with post-inflammation irritable bowel syndrome, Acta Pharmacol Sin, 36, pp. 708-715, (2015); Turner J.R., Molecular basis of epithelial barrier regulation: from basic mechanisms to clinical application, Am J Pathol, 169, pp. 1901-1909, (2006); Zhang K., Hornef M.W., Dupont A., The intestinal epithelium as guardian of gut barrier integrity, Cell Microbiol, 17, pp. 1561-1569, (2015); Watson A.J., Hughes K.R., TNF-α -induced intestinal epithelial cell shedding: implications for intestinal barrier function, Ann N Y Acad Sci, 1258, pp. 1-8, (2012); Noth R., Stuber E., Hasler R., Anti-TNF-α antibodies improve intestinal barrier function in Crohn’s disease, J Crohns Colitis, 6, pp. 464-469, (2012); Forster C., Tight junctions and the modulation of barrier function in disease, Histochem Cell Biol, 130, pp. 55-70, (2008); Matter K., Balda M.S., Signaling to and from tight junctions, Nat Rev Mol Cell Biol, 4, pp. 225-236, (2003); Steed E., Balda M.S., Matter K., Dynamics and functions of tight junctions, Trends Cell Biol, 20, pp. 142-149, (2010); Suzuki T., Regulation of intestinal epithelial permeability by tight junctions, Cell Mol Life Sci, 70, pp. 631-659, (2013); Gu L., Li N., Li Q., Zhang Q., Wang C., Zhu W., Et al., The effect of berberine in vitro on tight junctions in human Caco-2 intestinal epithelial cells, Fitoterapia, 80, pp. 241-248, (2009); Grozdanovic M.M., Cavic M., Nesic A., Andjelkovic U., Akbari P., Smit J.J., Et al., Kiwifruit cysteine protease actinidin compromises the intestinal barrier by disrupting tight junctions, Biochim Biophys Acta, 1860, pp. 516-526, (2016); Jeong C.H., Seok J.S., Petriello M.C., Han S.G., Arsenic downregulates tight junction claudin proteins through p38 and NF-κ B in intestinal epithelial cell line, HT-29, Toxicology, 379, pp. 31-39, (2017); Vila L., Garcia-Rodriguez A., Cortes C., Marcos R., Hernandez A., Assessing the effects of silver nanoparticles on monolayers of differentiated Caco-2 cells, as a model of intestinal barrier, Food Chem Toxicol, 116, pp. 1-10, (2018); Wang F., Graham W.V., Wang Y., Witkowski E.D., Schwarz B.T., Turner J.R., Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression, Am J Pathol, 166, pp. 409-419, (2005); Ma T.Y., Iwamoto G.K., Hoa N.T., Akotia V., Pedram A., Boivin M.A., TNF-alpha-induced increase in intestinal epithelial tight junction permeability requires NF-kappa B activation, Am J Physiol Gastrointest Liver Physiol, 286, pp. G367-G376, (2004); Cunningham K.E., Turner J.R., Myosin light chain kinase: pulling the strings of epithelial tight junction function, Ann N Y Acad Sci, 1258, pp. 34-42, (2012); Ye D., Ma I., Ma T.Y., Molecular mechanism of tumor necrosis factor-alpha modulation of intestinal epithelial tight junction barrier, Am J Physiol Gastrointest Liver Physiol, 290, pp. G496-G504, (2006); Widera D., Mikenberg I., Elvers M., Kaltschmidt C., Kaltschmidt B., Tumor necrosis factor alpha triggers proliferation of adult neural stem cells via IKK/NF-kappa B signaling, BMC Neurosci, 7, pp. 64-82, (2006); Al-Sadi R., Guo S., Ye D., Rawat M., Ma T.Y., TNF-α modulation of intestinal tight junction permeability is mediated by NIK/IKK-α axis activation of the canonical NF-κB pathway, Am J Pathol, 186, pp. 1151-1165, (2016)","X.-D. Tang; Department of Gastroenterology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China; email: txdly@sina.com","","Springer Science and Business Media Deutschland GmbH","","","","","","16720415","","","31768870","English","Chin. J. Integr. Med.","Article","Final","","Scopus","2-s2.0-85075610238"

"Linsalata M.; Riezzo G.; Clemente C.; D'Attoma B.; Russo F.","Linsalata, Michele (6603600075); Riezzo, Giuseppe (7004144336); Clemente, Caterina (7005101585); D'Attoma, Benedetta (8554891800); Russo, Francesco (59133987100)","6603600075; 7004144336; 7005101585; 8554891800; 59133987100","Noninvasive Biomarkers of Gut Barrier Function in Patients Suffering from Diarrhea Predominant-IBS: An Update","2020","Disease Markers","2020","","2886268","","","","22","10.1155/2020/2886268","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85094831821&doi=10.1155%2f2020%2f2886268&partnerID=40&md5=654e45ac8a2a8f1daab9a46103a39d6e","Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology, S. de Bellis"" Research Hospital, Castellana Grotte, I-70013, Italy","Linsalata M., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology, S. de Bellis"" Research Hospital, Castellana Grotte, I-70013, Italy; Riezzo G., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology, S. de Bellis"" Research Hospital, Castellana Grotte, I-70013, Italy; Clemente C., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology, S. de Bellis"" Research Hospital, Castellana Grotte, I-70013, Italy; D'Attoma B., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology, S. de Bellis"" Research Hospital, Castellana Grotte, I-70013, Italy; Russo F., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology, S. de Bellis"" Research Hospital, Castellana Grotte, I-70013, Italy","The intestinal barrier plays a crucial role in the absorption of nutrients and in preventing the entry of pathogenic microorganisms and toxic molecules. Several studies have shown a compromised intestinal barrier associated with low-grade inflammation in the small intestinal mucosa in celiac disease, inflammatory bowel disease, and irritable bowel syndrome (IBS), particularly in IBS with diarrhea (IBS-D). In light of these new data, IBS is no longer considered a functional disease but rather a heterogeneous syndrome that has yet to be carefully studied. Therefore, investigating the integrity and function of the intestinal barrier is now essential to improving knowledge of the pathophysiology of IBS-D and to improving the management of IBS-D patients. However, the study of the intestinal barrier must clarify some still unsolved methodological aspects and propose standardised assays before becoming a useful diagnostic tool. In this framework, this review will discuss data about the tests that noninvasively evaluate the integrity and functionality of the human intestinal barrier, paying particular attention to patients with IBS-D, in both clinical and research situations.  © 2020 Michele Linsalata et al.","","Amine Oxidase (Copper-Containing); Biomarkers; Diarrhea; Dysbiosis; Fatty Acid-Binding Proteins; Gastrointestinal Microbiome; Humans; Intestinal Absorption; Irritable Bowel Syndrome; amine oxidase (copper containing); biological marker; chromium 51; claudin 2; edetate chromium; fatty acid binding protein 2; indican; lactic acid; skatole; sugar; tight junction protein; unclassified drug; zonulin; amine oxidase (copper containing); biological marker; FABP2 protein, human; fatty acid binding protein; adult; Article; cell damage; diarrhea; dysbiosis; epithelium cell; follow up; human; intestine mucosa permeability; irritable colon; non invasive procedure; pathophysiology; diarrhea; dysbiosis; intestine absorption; intestine flora; irritable colon; pathophysiology","","amine oxidase (copper containing), 9001-53-0, 9014-75-9; chromium 51, 14392-02-0; indican, 1336-79-4, 487-94-5; lactic acid, 113-21-3, 50-21-5; skatole, 83-34-1; Amine Oxidase (Copper-Containing), ; Biomarkers, ; FABP2 protein, human, ; Fatty Acid-Binding Proteins, ","","","","","Camilleri M., Madsen K., Spiller R., Van Meerveld B.G., Verne G.N., Intestinal barrier function in health and gastrointestinal disease, Neurogastroenterology and Motility, 24, 6, pp. 503-512, (2012); Galipeau H.J., Verdu E.F., The complex task of measuring intestinal permeability in basic and clinical science, Neurogastroenterology and Motility, 28, 7, pp. 957-965, (2016); Oshima T., Miwa H., Gastrointestinal mucosal barrier function and diseases, Journal of Gastroenterology, 51, 8, pp. 768-778, (2016); Fasano A., Zonulin, regulation of tight junctions, and autoimmune diseases, Annals of the New York Academy of Sciences, 1258, 1, pp. 25-33, (2012); Camilleri M., Leaky gut: Mechanisms, measurement and clinical implications in humans, Gut, 68, 8, pp. 1516-1526, (2019); Camilleri M., Gorman H., Intestinal permeability and irritable bowel syndrome, Neurogastroenterology and Motility, 19, 7, pp. 545-552, (2007); Martinez C., Gonzalez-Castro A., Vicario M., Santos J., Cellular and molecular basis of intestinal barrier dysfunction in the irritable bowel syndrome, Gut Liver, 6, 3, pp. 305-315, (2012); Canavan C., West J., Card T., The epidemiology of irritable bowel syndrome, Clinical Epidemiology, 6, pp. 71-80, (2014); Camilleri M., Lasch K., Zhou W., Irritable bowel syndrome: Methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome, American Journal of Physiology. Gastrointestinal and Liver Physiology, 303, 7, pp. G775-G785, (2012); Piche T., Tight junctions and IBS-The link between epithelial permeability, low-grade inflammation, and symptom generation?, Neurogastroenterology and Motility, 26, 3, pp. 296-302, (2014); Webb D.L., Tests of intestinal mucosal hyperpermeability: Many diseases, many biomarkers and a bright future, Best Practice & Research. Clinical Gastroenterology, (2019); Graziani C., Talocco C., De Sire R., Petito V., Lopetuso L.R., Gervasoni J., Persichilli S., Franceschi F., Ojetti V., Gasbarrini A., Scaldaferri F., Intestinal permeability in physiological and pathological conditions: Major determinants and assessment modalities, European Review for Medical and Pharmacological Sciences, 23, 2, pp. 795-810, (2019); Wang L., Llorente C., Hartmann P., Yang A.M., Chen P., Schnabl B., Methods to determine intestinal permeability and bacterial translocation during liver disease, Journal of Immunological Methods, 421, pp. 44-53, (2015); Gonzalez-Castro A.M., Martinez C., Salvo-Romero E., Fortea M., Pardo-Camacho C., Perez-Berezo T., Alonso-Cotoner C., Santos J., Vicario M., Mucosal pathobiology and molecular signature of epithelial barrier dysfunction in the small intestine in irritable bowel syndrome, Journal of Gastroenterology and Hepatology, 32, 1, pp. 53-63, (2017); Pelsers M.M., Hermens W.T., Glatz J.F., Fatty acid-binding proteins as plasma markers of tissue injury, Clinica Chimica Acta, 352, 1-2, pp. 15-35, (2005); Peoc'h K., Nuzzo A., Guedj K., Paugam C., Corcos O., Diagnosis biomarkers in acute intestinal ischemic injury: So close, yet so far, Clinical Chemistry and Laboratory Medicine, 56, 3, pp. 373-385, (2018); Sun D.L., Cen Y.Y., Li S.M., Li W.M., Lu Q.P., Xu P.Y., Accuracy of the serum intestinal fatty-acid-binding protein for diagnosis of acute intestinal ischemia: A meta-analysis, Scientific Reports, 6, 1, (2016); Besnard P., Niot I., Poirier H., Clement L., Bernard A., New insights into the fatty acid-binding protein (FABP) family in the small intestine, Molecular and Cellular Biochemistry, 239, 1-2, pp. 139-147, (2002); Bodelier A.G., Pierik M.J., Lenaerts K., De Boer E., Olde Damink S.W., Hameeteman W.M., Masclee A.A., Jonkers D.M., Plasma intestinal fatty acid-binding protein fails to predict endoscopic disease activity in inflammatory bowel disease patients, European Journal of Gastroenterology & Hepatology, 28, 7, pp. 807-813, (2016); Sarikaya M., Ergul B., Dogan Z., Filik L., Can M., Arslan L., Intestinal fatty acid binding protein (I-FABP) as a promising test for Crohn's disease: A preliminary study, Clinical Laboratory, 61, pp. 87-91, (2015); Vogt A., Reuken P.A., Stengel S., Stallmach A., Bruns T., Dual-sugar tests of small intestinal permeability are poor predictors of bacterial infections and mortality in cirrhosis: A prospective study, World Journal of Gastroenterology, 22, 11, pp. 3275-3284, (2016); Abu Faddan N.H., Sherif T.M., Mohammed O.A., Nasif K.A., El Gezawy E.M., Intestinal barrier integrity and function in infants with cholestasis, Intestinal Research, 15, 1, pp. 118-123, (2017); Adriaanse M.P., Tack G.J., Passos V.L., Damoiseaux J.G., Schreurs M.W., Van Wijck K., Riedl R.G., Masclee A.A., Buurman W.A., Mulder C.J., Vreugdenhil A.C., Serum I-FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies, Alimentary Pharmacology & Therapeutics, 37, 4, pp. 482-490, (2013); Adriaanse M.P., Leffler D.A., Kelly C.P., Schuppan D., Najarian R.M., Goldsmith J.D., Buurman W.A., Vreugdenhil A.C., Serum I-FABP detects gluten responsiveness in adult celiac disease patients on a short-term gluten challenge, The American Journal of Gastroenterology, 111, 7, pp. 1014-1022, (2016); Vreugdenhil A.C., Wolters V.M., Adriaanse M.P., Van Den Neucker A.M., Van Bijnen A.A., Houwen R., Buurman W.A., Additional value of serum I-FABP levels for evaluating celiac disease activity in children, Scandinavian Journal of Gastroenterology, 46, 12, pp. 1435-1441, (2011); Adriaanse M.P.M., Mubarak A., Riedl R.G., Ten Kate F.J.W., Damoiseaux J.G.M.C., Buurman W.A., Houwen R.H.J., Vreugdenhil A.C.E., Progress towards noninvasive diagnosis and follow-up of celiac disease in children; A prospective multicentre study to the usefulness of plasma I-FABP, Scientific Reports, 7, 1, (2017); Uhde M., Ajamian M., Caio G., De Giorgio R., Indart A., Green P.H., Verna E.C., Volta U., Alaedini A., Intestinal cell damage and systemic immune activation in individuals reporting sensitivity to wheat in the absence of coeliac disease, Gut, 65, 12, pp. 1930-1937, (2016); Shi H., Wan J., Liu W., Su B., An analysis for the clinical difference between post infectious irritable bowel syndrome and non post infectious irritable bowel syndrome, Zhonghua Nei Ke Za Zhi, 54, 4, pp. 326-329, (2015); Linsalata M., Riezzo G., D'Attoma B., Clemente C., Orlando A., Russo F., Noninvasive biomarkers of gut barrier function identify two subtypes of patients suffering from diarrhoea predominant-IBS: A case-control study, Bmc Gastroenterology, 18, 1, (2018); Luk G.D., Bayless T.M., Baylin S.B., Diamine oxidase (histaminase). A circulating marker for rat intestinal mucosal maturation and integrity, The Journal of Clinical Investigation, 66, 1, pp. 66-70, (1980); Zhang L., Fan X., Zhong Z., Xu G., Shen J., Association of plasma diamine oxidase and intestinal fatty acid-binding protein with severity of disease in patient with heat stroke, The American Journal of Emergency Medicine, 33, 7, pp. 867-871, (2015); Meng Y., Zhang Y., Liu M., Kun Huang Y., Zhang J., Yao Q., Ling Zhao Y., Jing Xiong J., Evaluating intestinal permeability by measuring plasma endotoxin and diamine oxidase in children with acute lymphoblastic leukemia treated with high-dose methotrexate, Anti-Cancer Agents in Medicinal Chemistry, 16, 3, pp. 387-392, (2016); Gu J., Hu J., Qian H., Shi Y., Zhang E., Guo Y., Xiao Z., Fang Z., Zhong M., Zhang H., Meng W., Intestinal barrier dysfunction: A novel therapeutic target for inflammatory response in acute Stanford type A aortic dissection, Journal of Cardiovascular Pharmacology and Therapeutics, 21, 1, pp. 64-69, (2015); D'Agostino L., Daniele B., Pignata S., Greco L., Mazzacca G., Postheparin plasma diamine oxidase in subjects with small bowel disease. Diagnostic efficiency of a simplified test, Digestion, 41, 1, pp. 46-54, (1988); Forget P., Grandfils C., Van Cutsem J.L., Dandrifosse G., Diamine oxidase in serum and small intestinal biopsy tissue in childhood celiac disease, Journal of Pediatric Gastroenterology and Nutrition, 5, 3, pp. 379-383, (1986); Corazza G.R., Falasca A., Strocchi A., Rossi C.A., Gasbarrini G., Decreased plasma postheparin diamine oxidase levels in celiac disease, Digestive Diseases and Sciences, 33, 8, pp. 956-961, (1988); Corazza G.R., Ginaldi L., Falasca A., Strocchi A., Rossi C.A., Quaglino D., Gasbarrini G., Diamine oxidase plasma activities after treatment with heparin and jejunal morphometry in untreated coeliac disease, Journal of Clinical Pathology, 42, 11, pp. 1136-1139, (1989); Rokkas T., Vaja S., Murphy G.M., Dowling R.H., Postheparin plasma diamine oxidase in health and intestinal disease, Gastroenterology, 98, 6, pp. 1493-1501, (1990); Honzawa Y., Nakase H., Matsuura M., Chiba T., Clinical significance of serum diamine oxidase activity in inflammatory bowel disease: Importance of evaluation of small intestinal permeability, Inflammatory Bowel Diseases, 17, 2, pp. E23-E25, (2011); Xu X.J., Zhang Y.L., Liu L., Pan L., Yao S.K., Increased expression of nerve growth factor correlates with visceral hypersensitivity and impaired gut barrier function in diarrhoea-predominant irritable bowel syndrome: A preliminary explorative study, Alimentary Pharmacology & Therapeutics, 45, 1, pp. 100-114, (2017); Assimakopoulos S.F., Papageorgiou I., Charonis A., Enterocytes' tight junctions: From molecules to diseases, World Journal of Gastrointestinal Pathophysiology, 2, 6, pp. 123-137, (2011); Liang G.H., Weber C.R., Molecular aspects of tight junction barrier function, Current Opinion in Pharmacology, 19, pp. 84-89, (2014); Lee S.H., Intestinal permeability regulation by tight junction: Implication on inflammatory bowel diseases, Intestinal Research, 13, 1, pp. 11-18, (2015); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Lecleire S., Antonietti M., Gourcerol G., Leroi A.M., Dechelotte P., Menard J.F., Ducrotte P., Coeffier M., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, The American Journal of Gastroenterology, 106, 12, pp. 2165-2173, (2011); Wu R.L., Vazquez-Roque M.I., Carlson P., Burton D., Grover M., Camilleri M., Turner J.R., Gluten-induced symptoms in diarrhea-predominant irritable bowel syndrome are associated with increased myosin light chain kinase activity and claudin-15 expression, Laboratory Investigation, 97, 1, pp. 14-23, (2017); Saliminejad K., Khorram Khorshid H.R., Soleymani Fard S., Ghaffari S.H., An overview of microRNAs: Biology, functions, therapeutics, and analysis methods, Journal of Cellular Physiology, 234, 5, pp. 5451-5465, (2019); Vicario M., Martinez C., Santos J., Role of microRNA in IBS with increased gut permeability, Gut, 59, 6, pp. 710-712, (2010); Capaldo C.T., Nusrat A., Claudin switching: Physiological plasticity of the tight junction, Seminars in Cell & Developmental Biology, 42, pp. 22-29, (2015); Ishimoto H., Oshima T., Sei H., Yamasaki T., Kondo T., Tozawa K., Tomita T., Ohda Y., Fukui H., Watari J., Miwa H., Claudin-2 expression is upregulated in the ileum of diarrhea predominant irritable bowel syndrome patients, Journal of Clinical Biochemistry and Nutrition, 60, 2, pp. 146-150, (2017); Martinez C., Vicario M., Ramos L., Lobo B., Mosquera J.L., Alonso C., Sanchez A., Guilarte M., Antolin M., De Torres I., Gonzalez-Castro A.M., Pigrau M., Saperas E., Azpiroz F., Santos J., The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations, The American Journal of Gastroenterology, 107, 5, pp. 736-746, (2012); Martinez C., Lobo B., Pigrau M., Ramos L., Gonzalez-Castro A.M., Alonso C., Guilarte M., Guila M., De Torres I., Azpiroz F., Santos J., Vicario M., Diarrhoea-predominant irritable bowel syndrome: An organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, 8, pp. 1160-1168, (2013); Thuijls G., Derikx J.P., De Haan J.J., Grootjans J., De Bruine A., Masclee A.A., Heineman E., Buurman W.A., Urine-based detection of intestinal tight junction loss, Journal of Clinical Gastroenterology, 44, 1, pp. e14-e19, (2010); Thomson A., Smart K., Somerville M.S., Lauder S.N., Appanna G., Horwood J., Sunder Raj L., Srivastava B., Durai D., Scurr M.J., Keita A.V., Gallimore A.M., Godkin A., The Ussing chamber system for measuring intestinal permeability in health and disease, Bmc Gastroenterology, 19, 1, (2019); Schoultz I., Keita A.V., The intestinal barrier and current techniques for the assessment of gut permeability, Cells, 9, 8, (2020); Van Wijck K., Verlinden T.J., Van Eijk H.M., Dekker J., Buurman W.A., Dejong C.H., Lenaerts K., Novel multi-sugar assay for site-specific gastrointestinal permeability analysis: A randomized controlled crossover trial, Clinical Nutrition, 32, 2, pp. 245-251, (2013); Arrieta M.C., Bistritz L., Meddings J.B., Alterations in intestinal permeability, Gut, 55, 10, pp. 1512-1520, (2006); Denno D.M., VanBuskirk K., Nelson Z.C., Musser C.A., Hay Burgess D.C., Tarr P.I., Use of the lactulose to mannitol ratio to evaluate childhood environmental enteric dysfunction: A systematic review, Clinical Infectious Diseases, 59, pp. S213-S219, (2014); Musa M.A., Kabir M., Hossain M.I., Ahmed E., Siddique A., Rashid H., Mahfuz M., Mondal D., Ahmed T., Petri W.A., Haque R., Measurement of intestinal permeability using lactulose and mannitol with conventional five hours and shortened two hours urine collection by two different methods: HPAE-PAD and LC-MSMS, PLoS One, 14, 8, (2019); Linsalata M., D'Attoma B., Orlando A., Guerra V., Russo F., Comparison of an enzymatic assay with liquid chromatography-pulsed amperometric detection for the determination of lactulose and mannitol in urine of healthy subjects and patients with active celiac disease, Clinical Chemistry and Laboratory Medicine, 52, 4, pp. e61-e64, (2014); Bischoff S.C., Barbara G., Buurman W., Ockhuizen T., Schulzke J.D., Serino M., Tilg H., Watson A., Wells J.M., Intestinal permeability-A new target for disease prevention and therapy, Bmc Gastroenterology, 14, 1, (2014); Konig J., Wells J., Cani P.D., Garcia-Rodenas C.L., Mac Donald T., Mercenier A., Whyte J., Troost F., Brummer R.J., Human intestinal barrier function in health and disease, Clinical and Translational Gastroenterology, 7, 10, (2016); Russo F., Chimienti G., Linsalata M., Clemente C., Orlando A., Riezzo G., The obestatin/ghrelin ratio and ghrelin genetics in adult celiac patients before and after a gluten-free diet, in irritable bowel syndrome patients and healthy individuals, European Journal of Gastroenterology & Hepatology, 29, 2, pp. 160-168, (2017); Del Valle-Pinero A.Y., Van Deventer H.E., Fourie N.H., Martino A.C., Patel N.S., Remaley A.T., Henderson W.A., Gastrointestinal permeability in patients with irritable bowel syndrome assessed using a four probe permeability solution, Clinica Chimica Acta, 418, pp. 97-101, (2013); Rao A.S., Camilleri M., Eckert D.J., Busciglio I., Burton D.D., Ryks M., Wong B.S., Lamsam J., Singh R., Zinsmeister A.R., Urine sugars for in vivo gut permeability: Validation and comparisons in irritable bowel syndrome-diarrhea and controls, American Journal of Physiology. Gastrointestinal and Liver Physiology, 301, 5, pp. G919-G928, (2011); Mujagic Z., Ludidi S., Keszthelyi D., Hesselink M.A., Kruimel J.W., Lenaerts K., Hanssen N.M., Conchillo J.M., Jonkers D.M., Masclee A.A., Small intestinal permeability is increased in diarrhoea predominant IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to confounders, Alimentary Pharmacology & Therapeutics, 40, 3, pp. 288-297, (2014); Wahnschaffe U., Schulzke J.D., Zeitz M., Ullrich R., Predictors of clinical response to gluten-free diet in patients diagnosed with diarrhea-predominant irritable bowel syndrome, Clinical Gastroenterology and Hepatology, 5, 7, pp. 844-850, (2007); Vazquez-Roque M.I., Camilleri M., Smyrk T., Murray J.A., Marietta E., O'Neill J., Carlson P., Lamsam J., Janzow D., Eckert D., Burton D., Zinsmeister A.R., A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: Effects on bowel frequency and intestinal function, Gastroenterology, 144, 5, pp. 903e3-911e3, (2013); Vazquez-Roque M.I., Camilleri M., Smyrk T., Murray J.A., O'Neill J., Carlson P., Lamsam J., Eckert D., Janzow D., Burton D., Ryks M., Rhoten D., Zinsmeister A.R., Association of HLA-DQ gene with bowel transit, barrier function, and inflammation in irritable bowel syndrome with diarrhea, American Journal of Physiology. Gastrointestinal and Liver Physiology, 303, 11, pp. G1262-G1269, (2012); Shulman R.J., Jarrett M.E., Cain K.C., Broussard E.K., Heitkemper M.M., Associations among gut permeability, inflammatory markers, and symptoms in patients with irritable bowel syndrome, Journal of Gastroenterology, 49, 11, pp. 1467-1476, (2014); Zhou Q., Zhang B., Verne N.G., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, 1, pp. 41-46, (2009); Zhou Q., Souba W.W., Croce C.M., Verne G.N., MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome, Gut, 59, 6, pp. 775-784, (2010); Li L., Xiong L., Yao J., Zhuang X., Zhang S., Yu Q., Xiao Y., Cui Y., Chen M., Increased small intestinal permeability and RNA expression profiles of mucosa from terminal ileum in patients with diarrhoea-predominant irritable bowel syndrome, Digestive and Liver Disease, 48, 8, pp. 880-887, (2016); Russo F., Chimienti G., Riezzo G., Linsalata M., D'Attoma B., Clemente C., Orlando A., Adipose tissue-derived biomarkers of intestinal barrier functions for the characterization of diarrhoea-predominant IBS, Disease Markers, 2018, (2018); Zhou Q., Verne M.L., Fields J.Z., Lefante J.J., Basra S., Salameh H., Verne G.N., Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome, Gut, 68, 6, pp. 996-1002, (2019); Ohland C.L., MacNaughton W.K., Probiotic bacteria and intestinal epithelial barrier function, American Journal of Physiology Gastrointestinal and Liver Physiology, 298, 6, pp. G807-G819, (2010); Zeng J., Li Y.Q., Zuo X.L., Zhen Y.B., Yang J., Liu C.H., Clinical trial: Effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome, Alimentary Pharmacology & Therapeutics, 28, 8, pp. 994-1002, (2008); Bjarnason I., Peters T.J., Veall N., 51Cr-EDTA test for intestinal permeability, The Lancet, 324, 8401, (1984); Zuckerman M.J., Watts M.T., Bhatt B.D., Ho H., Intestinal permeability to [51Cr] EDTA in infectious diarrhea, Digestive Diseases and Sciences, 38, 9, pp. 1651-1657, (1993); Horton F., Wright J., Smith L., Hinton P.J., Robertson M.D., Increased intestinal permeability to oral chromium (51 Cr)-EDTA in human type 2 diabetes, Diabetic Medicine, 31, 5, pp. 559-563, (2014); Gecse K., Roka R., Sera T., Rosztoczy A., Annahazi A., Izbeki F., Nagy F., Molnar T., Szepes Z., Pavics L., Bueno L., Wittmann T., Leaky gut in patients with diarrhea-predominant irritable bowel syndrome and inactive ulcerative colitis, Digestion, 85, 1, pp. 40-46, (2012); Dunlop S.P., Hebden J., Campbell E., Naesdal J., Olbe L., Perkins A.C., Spiller R.C., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, The American Journal of Gastroenterology, 101, 6, pp. 1288-1294, (2006); Peled Y., Watz C., Gilat T., Measurement of intestinal permeability using 51Cr-EDTA, The American Journal of Gastroenterology, 80, 10, pp. 770-773, (1985); Sundqvist T., Magnusson K.E., Sjodahl R., Stjernstrom I., Tagesson C., Passage of molecules through the wall of the gastrointestinal tract. II. Application of low-molecular weight polyethyleneglycol and a deterministic mathematical model for determining intestinal permeability in man, Gut, 21, 3, pp. 208-214, (1980); Bjarnason I., MacPherson A., Hollander D., Intestinal permeability: An overview, Gastroenterology, 108, 5, pp. 1566-1581, (1995); Parlesak A., Bode J.C., Bode C., Parallel determination of gut permeability in man with M <sub>r</sub>400, M <sub>r</sub>1500, M <sub>r</sub>4000 and M <sub>r</sub>10 000 polyethylene glycol, European Journal of Clinical Chemistry and Clinical Biochemistry, 32, 11, pp. 813-820, (1994); Magnusson K.E., Sundqvist T., Sjodahl R., Tagesson C., Altered intestinal permeability to low-molecular-weight polyethyleneglycols (PEG 400) in patients with Crohn's disease, Acta Chirurgica Scandinavica, 149, 3, pp. 323-327, (1983); Falth-Magnusson K., Kjellman N.I., Magnusson K.E., Sundqvist T., Intestinal permeability in healthy and allergic children before and after sodium-cromoglycate treatment assessed with different-sized polyethyleneglycols (PEG 400 and PEG 1000), Clinical Allergy, 14, 3, pp. 277-286, (1984); Falth-Magnusson K., Kjellman N.I., Odelram H., Sundqvist T., Magnusson K.E., Gastrointestinal permeability in children with cow's milk allergy: Effect of milk challenge and sodium cromoglycate as assessed with polyethyleneglycols (PEG 400 and PEG 1000), Clinical Allergy, 16, 6, pp. 543-551, (1986); Sundqvist T., Stenhammar L., Tjellstrom B., Magnusson K.E., Forslund T., Hogberg L., Oral immunoglobulin treatment improved intestinal permeability in children with active Crohn's disease, Acta Paediatrica, 106, 4, pp. 647-653, (2017); Van Wijck K., Bessems B.A., Van Eijk H.M., Buurman W.A., Dejong C.H., Lenaerts K., Polyethylene glycol versus dual sugar assay for gastrointestinal permeability analysis: Is it time to choose?, Clinical and Experimental Gastroenterology, 5, pp. 139-150, (2012); Stenhamma L., Falth-Magnusson K., Jansson G., Magnusson K.E., Sundqvist T., Intestinal permeability to inert sugars and different-sized polyethyleneglycols in children with celiac disease, Journal of Pediatric Gastroenterology and Nutrition, 9, 3, pp. 281-289, (1989); Kerckhoffs A.P., Akkermans L.M., De Smet M.B., Besselink M.G., Hietbrink F., Bartelink I.H., Busschers W.B., Samsom M., Renooij W., Intestinal permeability in irritable bowel syndrome patients: Effects of NSAIDs, Digestive Diseases and Sciences, 55, 3, pp. 716-723, (2010); Park J.H., Park D.I., Kim H.J., Cho Y.K., Sohn C.I., Jeon W.K., Kim B.I., Won K.H., Park S.M., The relationship between small-intestinal bacterial overgrowth and intestinal permeability in patients with irritable bowel syndrome, Gut Liver, 3, 3, pp. 174-179, (2009); Fasano A., Intestinal permeability and its regulation by zonulin: Diagnostic and therapeutic implications, Clinical Gastroenterology and Hepatology, 10, 10, pp. 1096-1100, (2012); Esnafoglu E., Cirrik S., Ayyildiz S.N., Erdil A., Erturk E.Y., Dagli A., Noyan T., Increased serum zonulin levels as an intestinal permeability marker in autistic subjects, The Journal of Pediatrics, 188, pp. 240-244, (2017); Sturgeon C., Fasano A., Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases, Tissue Barriers, 4, 4, (2016); Sapone A., De Magistris L., Pietzak M., Clemente M.G., Tripathi A., Cucca F., Lampis R., Kryszak D., Carteni M., Generoso M., Iafusco D., Prisco F., Laghi F., Riegler G., Carratu R., Counts D., Fasano A., Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives, Diabetes, 55, 5, pp. 1443-1449, (2006); Vorobjova T., Raikkerus H., Kadaja L., Talja I., Uibo O., Heilman K., Uibo R., Circulating zonulin correlates with density of enteroviruses and tolerogenic dendritic cells in the small bowel mucosa of celiac disease patients, Digestive Diseases and Sciences, 62, 2, pp. 358-371, (2017); Fasano A., Not T., Wang W., Uzzau S., Berti I., Tommasini A., Goldblum S.E., Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease, The Lancet, 355, 9214, pp. 1518-1519, (2000); Khaleghi S., Ju J.M., Lamba A., Murray J.A., The potential utility of tight junction regulation in celiac disease: Focus on larazotide acetate, Therapeutic Advances in Gastroenterology, 9, 1, pp. 37-49, (2015); Duerksen D.R., Wilhelm-Boyles C., Veitch R., Kryszak D., Parry D.M., A comparison of antibody testing, permeability testing, and zonulin levels with small-bowel biopsy in celiac disease patients on a gluten-free diet, Digestive Diseases and Sciences, 55, 4, pp. 1026-1031, (2010); Barbaro M.R., Cremon C., Caio G., De Giorgio R., Volta U., Stanghellini V., Barbara G., Zonulin serum levels are increased in non-celiac gluten sensitivity and irritable bowel syndrome with diarrhea, Gastroenterology, 11, pp. 5072-5076, (2015); Singh P., Silvester J., Chen X., Xu H., Sawhney V., Rangan V., Iturrino J., Nee J., Duerksen D.R., Lembo A., Serum zonulin is elevated in IBS and correlates with stool frequency in IBS-D, United European Gastroenterology Journal, 7, 5, pp. 709-715, (2019); Bueno L., Protease activated receptor 2: A new target for IBS treatment, European Review for Medical and Pharmacological Sciences, 12, pp. 95-102, (2008); Marchiando A.M., Graham W.V., Turner J.R., Epithelial barriers in homeostasis and disease, Annual Review of Pathology: Mechanisms of Disease, 5, 1, pp. 119-144, (2010); Moser A.M., Spindelboeck W., Halwachs B., Strohmaier H., Kump P., Gorkiewicz G., Hogenauer C., Effects of an oral synbiotic on the gastrointestinal immune system and microbiota in patients with diarrhea-predominant irritable bowel syndrome, European Journal of Nutrition, 58, 7, pp. 2767-2778, (2018); Moreno-Navarrete J.M., Sabater M., Ortega F., Ricart W., Fernandez-Real J.M., Circulating zonulin, a marker of intestinal permeability, is increased in association with obesity-associated insulin resistance, PLoS One, 7, 5, (2012); Kume T., Acar S., Tuhan H., Catli G., Anik A., Gursoy Calan O., Bober E., Abaci A., The relationship between serum zonulin level and clinical and laboratory parameters of childhood obesity, Journal of Clinical Research in Pediatric Endocrinology, 9, 1, pp. 31-38, (2017); Takiishi T., Fenero C.I.M., Camara N.O.S., Intestinal barrier and gut microbiota: Shaping our immune responses throughout life, Tissue Barriers, 5, 4, (2017); Adike A., DiBaise J.K., Small intestinal bacterial overgrowth: Nutritional implications, diagnosis, and management, Gastroenterology Clinics of North America, 47, 1, pp. 193-208, (2018); Raj A.S., Shanahan E.R., Tran C.D., Bhat P., Fletcher L.M., Vesey D.A., MacDonald G.A., Dysbiosis of the duodenal mucosal microbiota is associated with increased small intestinal permeability in chronic liver disease, Clinical and Translational Gastroenterology, 10, 8, (2019); Hawrelak J.A., Myers S.P., The causes of intestinal dysbiosis: A review, Alternative Medicine Review, 9, 2, pp. 180-197, (2004); Hendrikx T., Schnabl B., Indoles: Metabolites produced by intestinal bacteria capable of controlling liver disease manifestation, Journal of Internal Medicine, 286, 1, pp. 32-40, (2019); Lord R.S., Bralley J.A., Clinical applications of urinary organic acids. Part 2. Dysbiosis markers, Alternative Medicine Review, 13, 4, pp. 292-306, (2008); Garcia Regueiro J.A., Rius M.A., Rapid determination of skatole and indole in pig back fat by normal-phase liquid chromatography, Journal of Chromatography. A, 809, 1-2, pp. 246-251, (1998); Cassani E., Barichella M., Cancello R., Cavanna F., Iorio L., Cereda E., Bolliri C., Zampella Maria P., Bianchi F., Cestaro B., Pezzoli G., Increased urinary indoxyl sulfate (indican): New insights into gut dysbiosis in Parkinson's disease, Parkinsonism & Related Disorders, 21, 4, pp. 389-393, (2015); Simeoni M., Citraro M.L., Cerantonio A., Deodato F., Provenzano M., Cianfrone P., Capria M., Corrado S., Libri E., Comi A., Pujia A., Abenavoli L., Andreucci M., Cocchi M., Montalcini T., Fuiano G., An open-label, randomized, placebo-controlled study on the effectiveness of a novel probiotics administration protocol (ProbiotiCKD) in patients with mild renal insufficiency (stage 3a of CKD), European Journal of Nutrition, 58, 5, pp. 2145-2156, (2019); Wang Z., Xu C.M., Liu Y.X., Wang X.Q., Zhang L., Li M., Zhu S.W., Xie Z.J., Wang P.H., Duan L.P., Zhu H.Q., Characteristic dysbiosis of gut microbiota of Chinese patients with diarrhea-predominant irritable bowel syndrome by an insight into the pan-microbiome, Chinese Medical Journal, 132, 8, pp. 889-904, (2019); Cai J., Chen H., Weng M., Jiang S., Gao J., Diagnostic and clinical significance of serum levels of D-lactate and diamine oxidase in patients with Crohn's disease, Gastroenterology Research and Practice, 2019, (2019); Murray M.J., Barbose J.J., Cobb C.F., Serum D(-)-lactate levels as a predictor of acute intestinal ischemia in a rat model, The Journal of Surgical Research, 54, 5, pp. 507-509, (1993); Assadian A., Assadian O., Senekowitsch C., Rotter R., Bahrami S., Furst W., Jaksch W., Hagmuller G.W., Hubl W., Plasma D-lactate as a potential early marker for colon ischaemia after open aortic reconstruction, European Journal of Vascular and Endovascular Surgery, 31, 5, pp. 470-474, (2006); Sun X.Q., Fu X.B., Zhang R., Lu Y., Deng Q., Jiang X.G., Sheng Z.Y., Relationship between plasma D(-)-lactate and intestinal damage after severe injuries in rats, World Journal of Gastroenterology, 7, 4, pp. 555-558, (2001); Shi H., Wu B., Wan J., Liu W., Su B., The role of serum intestinal fatty acid binding protein levels and D-lactate levels in the diagnosis of acute intestinal ischemia, Clinics and Research in Hepatology and Gastroenterology, 39, 3, pp. 373-378, (2015); Song W.B., Lv Y.H., Zhang Z.S., Li Y.N., Xiao L.P., Yu X.P., Wang Y.Y., Ji H.L., Ma L., Soluble intercellular adhesion molecule-1, D-lactate and diamine oxidase in patients with inflammatory bowel disease, World Journal of Gastroenterology, 15, 31, pp. 3916-3919, (2009); Xu X., Liu L., Yao S., Zhang Y., Visceral sensitivity, gut barrier function and autonomic nerve function in patients with diarrhea-predominant irritable bowel syndrome, Zhong Nan da Xue Xue Bao Yi Xue Ban, 42, 5, pp. 522-528, (2017)","F. Russo; Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology, S. de Bellis"" Research Hospital, Castellana Grotte, I-70013, Italy; email: francesco.russo@irccsdebellis.it","","Hindawi Limited","","","","","","02780240","","DMARD","33110455","English","Dis. Markers","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85094831821"

"Laatikainen R.; Salmenkari H.; Sibakov T.; Vapaatalo H.; Turpeinen A.","Laatikainen, Reijo (57190220075); Salmenkari, Hanne (56856795200); Sibakov, Timo (57188649074); Vapaatalo, Heikki (7103390664); Turpeinen, Anu (7004546735)","57190220075; 56856795200; 57188649074; 7103390664; 7004546735","Randomised controlled trial: Partial hydrolysation of casein protein in milk decreases gastrointestinal symptoms in subjects with functional gastrointestinal disorders","2020","Nutrients","12","7","2140","1","11","10","8","10.3390/nu12072140","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85088159789&doi=10.3390%2fnu12072140&partnerID=40&md5=d993a2c7b4a83b9755bf23338449565b","Booston Oy Ltd., Viikinkaari 6, Helsinki, FI-00790, Finland; Pharmacology, Medical Faculty, University of Helsinki, P.O. Box 63, Helsinki, FI-00014, Finland; Valio Ltd., R&D, P.O. Box 30, Valio, FI-00039, Finland","Laatikainen R., Booston Oy Ltd., Viikinkaari 6, Helsinki, FI-00790, Finland; Salmenkari H., Pharmacology, Medical Faculty, University of Helsinki, P.O. Box 63, Helsinki, FI-00014, Finland; Sibakov T., Valio Ltd., R&D, P.O. Box 30, Valio, FI-00039, Finland; Vapaatalo H., Pharmacology, Medical Faculty, University of Helsinki, P.O. Box 63, Helsinki, FI-00014, Finland; Turpeinen A., Valio Ltd., R&D, P.O. Box 30, Valio, FI-00039, Finland","Unspecific gastrointestinal symptoms associated with milk consumption are common. In addition to lactose, also other components of milk may be involved. We studied whether the partial hydrolysation of milk proteins would affect gastrointestinal symptoms in subjects with functional gastrointestinal disorders. In a randomised, placebo-controlled crossover intervention, subjects (n = 41) were given ordinary or hydrolysed high-protein, lactose-free milkshakes (500 mL, 50 g protein) to be consumed daily for ten days. After a washout period of ten days, the other product was consumed for another ten days. Gastrointestinal symptoms were recorded daily during the study periods, and a validated irritable bowel syndrome-symptom severity scale (IBS-SSS) questionnaire was completed at the beginning of the study and at the end of both study periods. Blood and urine samples were analysed for markers of inflammation, intestinal permeability and immune activation. Both the IBS-SSS score (p = 0.001) and total symptom score reported daily (p = 0.002) were significantly reduced when participants consumed the hydrolysed product. Less bloating was reported during both study periods when compared with the baseline (p < 0.01 for both groups). Flatulence (p = 0.01) and heartburn (p = 0.03) decreased when consuming the hydrolysed product but not when drinking the control product. No significant differences in the levels of inflammatory markers (tumor necrosis factor alpha, TNF-α and interleukin 6, IL-6), intestinal permeability (fatty acid binding protein 2, FABP2) or immune activation (1-methylhistamine) were detected between the treatment periods. The results suggest that the partial hydrolysation of milk proteins (mainly casein) reduces subjective symptoms to some extent in subjects with functional gastrointestinal disorders. The mechanism remains to be resolved. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.","Bloating; Casein; Functional gastrointestinal disorder; Hydrolysation; IBS; Inflammation; Milk","Abdominal Pain; Adult; Animals; Caseins; Cross-Over Studies; Female; Flatulence; Gastrointestinal Diseases; Heartburn; Humans; Irritable Bowel Syndrome; Male; Middle Aged; Milk; Protein Hydrolysates; Severity of Illness Index; Surveys and Questionnaires; Symptom Assessment; Symptom Flare Up; casein; fatty acid binding protein 2; interleukin 6; milk protein; protein derivative; tele methylhistamine; tumor necrosis factor; casein; protein hydrolysate; adult; aged; Article; bloating; blood sampling; clinical article; controlled study; crossover procedure; diarrhea; diet restriction; dietary compliance; digestive system function disorder; digestive system inflammation; dyspepsia; female; fiber intake; flatulence; gastrointestinal symptom; heartburn; human; intestine mucosa permeability; irritable bowel syndrome symptom severity scale questionnaire; macronutrient intake; male; milkshake; protein hydrolysis; protein intake; questionnaire; randomized controlled trial; randomized controlled trial (topic); reversed phase high performance liquid chromatography; scoring system; telephone interview; ultrafiltration; urine sampling; visual analog scale; abdominal pain; animal; complication; flatulence; gastrointestinal disease; heartburn; irritable colon; middle aged; milk; pathophysiology; procedures; questionnaire; recurrent disease; severity of illness index; symptom assessment","","casein, 9000-71-9; tele methylhistamine, 501-75-7; protein hydrolysate, 76773-71-2, 9015-54-7; Caseins, ; Protein Hydrolysates, ","","","","","Simren M., Tack J., New treatments and therapeutic targets for IBS and other functional bowel disorders, Nat. Rev. Gastroenterol. Hepatol, 15, pp. 589-605, (2018); Palsson O.S., Whitehead W.E., van Tilburg M.A., Chang L., Chey W., Crowell M.D., Keefer L., Lembo A.J., Parkman H.P., Rao S.S., Et al., Development and validation of the Rome IV diagnostic questionnaire for adults, Gastroenterology, 150, pp. 1481-1491, (2016); Simren M., Mansson A., Langkilde A.M., Svedlund J., Abrahamsson H., Bengtsson U., Bjornsson E.S., Food-related gastrointestinal symptoms in the irritable bowel syndrome, Digestion, 63, pp. 108-115, (2001); Bohn L., Storsrud S., Tornblom H., Bengtsson U., Simren M., Self-reported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life, Am. J. Gastroenterol, 108, pp. 634-641, (2013); Staudacher H.M., Whelan K., The low FODMAP diet: Recent advances in understanding its mechanisms and efficacy in IBS, Gut, 66, pp. 1517-1527, (2017); Anthoni S., Cow’s Milk Related Gastrointestinal Symptoms in Adults, (2009); Sahi T., Launiala K., Laitinen H., Hypolactasia in a fixed cohort of young Finnish adults. A follow-up study, Scand. J. Gastroenterol, 18, pp. 865-870, (1983); Kristjansson G., Venge P., Hallgren R., Mucosal reactivity to cow’s milk protein in coeliac disease, Clin. Exp. Immunol, 147, pp. 449-455, (2007); Pelto L., Salminen S., Lilius E.M., Nuutila J., Isolauri E., Milk hypersensitivity—Key to poorly defined gastrointestinal symptoms in adults, Allergy, 53, pp. 307-310, (1998); Carroccio A., Mansueto P., Iacono G., Soresi M., D'Alcamo A., Cavataio F., Brusca I., Florena A.M., Ambrosiano G., Seidita A., Non-celiac wheat sensitivity diagnosed by double-blind placebo-controlled challenge: Exploring a new clinical entity, Am. J. Gastroenterol, 107, pp. 1898-1906, (2012); Turpeinen A., Kautiainen H., Tikkanen M.L., Sibakov T., Tossavainen O., Myllyluoma E., Mild protein hydrolysation of lactose-free milk further reduces milk-related gastrointestinal symptoms, J. Dairy Res, 83, pp. 256-260, (2016); Sibakov T., Tossavainen O., Milk Product and Preparation Method, (2013); Matsubara H., Hagihara B., Nakai M., Komaki T., Yonetani T., Okunuki K., Crystalline bacterial proteinase II. General properties of crystalline proteinase of Bacillus subtilis N, J. Biochem, 45, pp. 251-258, (1958); Bonfatti V., Grigoletto L., Cecchinato A., Gallo L., Carnier P., Validation of a new reversed phase high-performance liquid chromatography method for separation and quantification of bovine milk protein genetic variants, J. Chromatogr. A, 1195, pp. 101-106, (2008); Laemmli U.K., Cleavage of structural proteins during the assembly of the head of bacteriophage T4, Nature, 227, pp. 680-685, (1970); Francis C.Y., Morris J., Whorwell P.J., The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress, Aliment. Pharmacol. Ther, 11, pp. 395-402, (1997); Drossman D.A., Chang L., Bellamy N., Gallo-Torres H.E., Lembo A., Mearin F., Norton N.J., Whorwell P., Severity in irritable bowel syndrome: A Rome Foundation Working Team report, Am. J. Gastroenterol, 106, pp. 1749-1759, (2011); Nuora A., Tupasela T., Jokioja R., Tahvonen R., Kallio H., Yang B., Viitanen M., Linderborg K.M., The effect of heat treatments and homogenisation of cows’ milk on gastrointestinal symptoms, inflammation markers and postprandial lipid metabolism, Int. Dairy J, 85, pp. 184-190, (2018); Mummah S., Oelrich J., Hope Q., Vu C.D., Effect of raw milk on lactose intolerance: A randomized controlled pilot study, Ann. Fam. Med, 12, pp. 134-141, (2014); Korpela R., Paajanen L., Tuure T., Homogenization of milk has no effect on the gastrointestinal symptoms of lactose intolerant subjects, Milchwissenschaft, 6, pp. 3-6, (2005); Paajanen L., Tuure T., Poussa T., Korpela R., No difference in symptoms during challenges with homogenized and unhomogenized cow’s milk in subjects with subjective hypersensitivity to homogenized milk, J. Dairy Res, 70, pp. 175-179, (2003); Pelto L., Rantakokko H.-K., Lilius E.-M., Nuutila J., Salminen S., No difference in symptoms and receptor expression in lactose-intolerant and in milk-hypersensitive subjects following intake of homogenized and unhomogenized milk, Int. Dairy J, 10, pp. 799-803, (2000); Brooke-Taylor S., Dwyer K., Woodford K., Kost N., Systematic review of the gastrointestinal effects of a1 compared with a2 β-casein, Adv. Nutr, 8, pp. 739-748, (2017); Ho S., Woodford K., Kukuljan S., Pal S., Comparative effects of A1 versus A2 beta-casein on gastrointestinal measures: A blinded randomised cross-over pilot study, Eur. J. Clin. Nutr, 68, pp. 994-1000, (2014); Krammer L., Sowa A.S., Lorentz A., Mast cells in irritable bowel syndrome: A systematic review, J. Gastrointest. Liver Dis, 28, pp. 463-472, (2019); Robles A., Perez Ingles D., Myneedu K., Deoker A., Sarosiek I., Zuckerman M.J., Schmulson M.J., Bashashati M., Mast cells are increased in the small intestinal mucosa of patients with irritable bowel syndrome: A systematic review and metaanalysis, Neurogastroenterol. Motil, 31, (2019); McIntosh K., Reed D.E., Schneider T., Dang F., Keshteli A.H., De Palma G., Madsen K., Bercik P., Vanner S., FODMAPs alter symptoms and the metabolome of patients with IBS: A randomised controlled trial, Gut, 66, pp. 1241-1251, (2019); Wouters M.M., Balemans D., Van Wanrooy S., Dooley J., Cibert-Goton V., Alpizar Y.A., Valdez-Morales E.E., Nasser Y., Van Veldhoven P.P., Vanbrabant W., Et al., Histamine receptor H1-mediated sensitization of TRPV1 mediates visceral hypersensitivity and symptoms in patients with irritable bowel syndrome, Gastroenterology, 150, pp. 875-887, (2016); Staudacher H.M., Irving P.M., Lomer M.C.E., Whelan K., The challenges of control groups, placebos and blinding in clinical trials of dietary interventions, Proc. Nutr. Soc, 76, pp. 203-212, (2017)","R. Laatikainen; Booston Oy Ltd., Helsinki, Viikinkaari 6, FI-00790, Finland; email: reijo.laatikainen@booston.fi","","MDPI AG","","","","","","20726643","","","32708428","English","Nutrients","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85088159789"

"Zhou Q.; Verne M.L.; Fields J.Z.; Lefante J.J.; Basra S.; Salameh H.; Verne G.N.","Zhou, QiQi (13404854200); Verne, Meghan L (57203725585); Fields, Jeremy Z (7103238507); Lefante, John J (6602087100); Basra, Sarpreet (55970998300); Salameh, Habeeb (36574126600); Verne, G Nicholas (7004085639)","13404854200; 57203725585; 7103238507; 6602087100; 55970998300; 36574126600; 7004085639","Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome","2019","Gut","68","6","","996","1002","6","114","10.1136/gutjnl-2017-315136","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85052731357&doi=10.1136%2fgutjnl-2017-315136&partnerID=40&md5=3ec8f41a1a725b03c487ac6835e72b6b","Department of Medicine, Tulane University School of Medicine, New Orleans, 70112-2699, LA, United States; Department of Veteran Affairs, Malcom Randall VAMC, Gainesville, FL, United States; Health Sciences, Texas AandM University, College Station, TX, United States; Department of Global Biostatistics and Data Science, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, United States; Department of Medicine, University of Texas Medical Branch, Galveston, TX, United States","Zhou Q., Department of Medicine, Tulane University School of Medicine, New Orleans, 70112-2699, LA, United States, Department of Veteran Affairs, Malcom Randall VAMC, Gainesville, FL, United States; Verne M.L., Health Sciences, Texas AandM University, College Station, TX, United States; Fields J.Z., Department of Medicine, Tulane University School of Medicine, New Orleans, 70112-2699, LA, United States; Lefante J.J., Department of Global Biostatistics and Data Science, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, United States; Basra S., Department of Medicine, Tulane University School of Medicine, New Orleans, 70112-2699, LA, United States; Salameh H., Department of Medicine, University of Texas Medical Branch, Galveston, TX, United States; Verne G.N., Department of Medicine, Tulane University School of Medicine, New Orleans, 70112-2699, LA, United States","Background More effective treatments are needed for patients with postinfectious, diarrhoea-predominant, irritable bowel syndrome (IBS-D). Accordingly, we conducted a randomised, double-blind, placebo-controlled, 8-week-long trial to assess the efficacy and safety of oral glutamine therapy in patients who developed IBS-D with increased intestinal permeability following an enteric infection. Methods Eligible adults were randomised to glutamine (5 g/t.i.d.) or placebo for 8 weeks. The primary end point was a reduction of ≥50 points on the Irritable Bowel Syndrome Severity Scoring System (IBS-SS). Secondary endpoints included: raw IBS-SS scores, changes in daily bowel movement frequency, stool form (Bristol Stool Scale) and intestinal permeability. Results Fifty-four glutamine and 52 placebo subjects completed the 8-week study. The primary endpoint occurred in 43 (79.6%) in the glutamine group and 3 (5.8%) in the placebo group (a 14-fold difference). Glutamine also reduced all secondary endpoint means: IBS-SS score at 8 weeks (301 vs 181, p<0.0001), daily bowel movement frequency (5.4 vs 2.9±1.0, p<0.0001), Bristol Stool Scale (6.5 vs 3.9, p<0.0001) and intestinal permeability (0.11 vs 0.05; p<0.0001). 'Intestinal hyperpermeability' (elevated urinary lactulose/mannitol ratios) was normalised in the glutamine but not the control group. Adverse events and rates of study-drug discontinuation were low and similar in the two groups. No serious adverse events were observed. Conclusions In patients with IBS-D with intestinal hyperpermeability following an enteric infection, oral dietary glutamine supplements dramatically and safely reduced all major IBS-related endpoints. Large randomised clinical trials (RCTs) should now be done to validate these findings, assess quality of life benefits and explore pharmacological mechanisms. Trial registration number NCT 1414244; Results. © Author(s) (or their employer(s)) 2019.","diarrhoea; enteric infections; intestinal permeability; irritable bowel syndrome","Administration, Oral; Adult; Dietary Supplements; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Enteritis; Female; Glutamine; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Male; Reference Values; Risk Assessment; Severity of Illness Index; Treatment Outcome; glutamine; lactulose; mannitol; placebo; glutamine; abdominal distension; abdominal pain; adult; Article; bloating; Bristol Stool Scale; clinical article; controlled study; diarrhea; digestive system disease assessment; digestive tract parameters; double blind procedure; drug efficacy; drug safety; female; human; intestine infection; intestine mucosa permeability; Irritable Bowel Syndrome Severity Scoring System; irritable colon; male; patient compliance; patient satisfaction; priority journal; quality of life; randomized controlled trial; urinary lactulose mannitol ratio; complication; dietary supplement; dose response; drug administration; drug effect; enteritis; intestine mucosa; irritable colon; microbiology; oral drug administration; reference value; risk assessment; severity of illness index; treatment outcome","","glutamine, 56-85-9, 6899-04-3; lactulose, 4618-18-2; mannitol, 69-65-8, 87-78-5; Glutamine, ","","","National Institutes of Health, NIH, (NCT1414244); National Institute of General Medical Sciences, NIGMS, (U54GM104940); National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK, (DK099052); U.S. Department of Veterans Affairs, VA, (1 U54 gM104940, cX001477-01); National Center for Complementary and Integrative Health, NCCIH, (AT 005291); national, (at005291)","Funding text 1: Funding this study was supported by the national center for complementary and integrative Health (at005291); national institute of Diabetes and Digestive and Kidney Diseases (DK099052) and the Department of Veterans affairs (cX001477-01). Supported in part by 1 U54 gM104940 from the national institute of general Medical Sciences of the national institutes of Health, which funds the louisiana clinical and translational Science center. clinicaltrials.gov number, nct1414244. Competing interests none declared. Patient consent Obtained. ethics approval institutional review Board. Provenance and peer review not commissioned; externally peer reviewed.; Funding text 2: The authors would like to thank Wiley W Souba, MD, MBA, ScD, Professor of Surgery, Emeritus Dean, Dartmouth Geisel School of Medicine, Hanover, NH for help with the study design. This study was supported by the National Center for Complementary and Integrative Health (AT 005291); National Institute of Diabetes and Digestive and Kidney Diseases (DK099052) and the Department of Veterans Affairs (CX001477-01). Supported in part by 1 U54 GM104940 from the National Institute of General Medical Sciences of the National Institutes of Health, which funds the Louisiana Clinical and Translational Science Center. ClinicalTrials. gov number, NCT1414244.","Enck P., Aziz Q., Barbara G., Et al., Irritable bowel syndrome, Nat Rev Dis Primers, 2, (2016); Camilleri M., Peripheral mechanisms in irritable bowel syndrome, N Engl J Med, 367, pp. 1626-1635, (2012); Peery A.F., Dellon E.S., Lund J., Et al., Burden of gastrointestinal disease in the United States: 2012 update, Gastroenterology, 143, pp. 1179-1187, (2012); Pimentel M., Lembo A., Chey W.D., Et al., Rifaximin therapy for patients with irritable bowel syndrome without constipation, N Engl J Med, 364, pp. 22-32, (2011); Lembo A.J., Lacy B.E., Zuckerman M.J., Et al., Eluxadoline for irritable bowel syndrome with diarrhea, N Engl J Med, 374, pp. 242-253, (2016); Chang L., Heitkemper M.M., Wiley J.W., Et al., Freston single topic conference: A renaissance in the understanding and management of irritable bowel syndrome, Gastroenterology, 2016, pp. e1-8, (2015); Spiller R.C., Postinfectious irritable bowel syndrome, Gastroenterology, 124, pp. 1662-1671, (2003); Zhou Q., Souba W.W., Croce C.M., Et al., MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome, Gut, 59, pp. 775-784, (2010); Klimberg V.S., Souba W.W., The importance of intestinal glutamine metabolism in maintaining a healthy gastrointestinal tract and supporting the body's response to injury and illness, Surg Annu, 22, pp. 61-76, (1990); Labow B.I., Souba W.W., Glutamine, World J Surg, 24, pp. 1503-1513, (2000); Zhou Q., Verne G.N., Intestinal permeability in patients with diarrhea-predominant irritable bowel syndrome: Is there a place for glutamine supplementation?, Gastroenterology, 148, pp. 1080-1081, (2015); Longstreth G.F., Thompson W.G., Chey W.D., Et al., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Keshavarzian A., Fields J.Z., Vaeth J., Et al., The differing effects of acute and chronic alcohol on gastric and intestinal permeability, Am J Gastroenterol, 89, pp. 2205-2211, (1994); Rezaie A., Buresi M., Lembo A., Et al., Hydrogen and methane-based breath testing in gastrointestinal disorders: The North American Consensus, Am J Gastroenterol, 112, pp. 775-784, (2017); Francis C.Y., Morris J., Whorwell P.J., The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress, Aliment Pharmacol Ther, 11, pp. 395-402, (1997); Macdonald T.T., Monteleone G., Immunity, inflammation, and allergy in the gut, Science, 307, pp. 1920-1925, (2005); Zhou Q., Costinean S., Croce C., Et al., Targeted deletion of microRNA-29 reverses intestinal hyperpermeability, Gastroenterology, 148, pp. 158-169, (2015); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Wang L.H., Fang X.C., Pan G.Z., Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis, Gut, 53, pp. 1096-1101, (2004); Spiller R.C., Jenkins D., Thornley J.P., Et al., Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, pp. 804-811, (2000); Camilleri M., Madsen K., Spiller R., Et al., Intestinal barrier function in health and gastrointestinal disease, Neurogastroenterol Motil, 24, pp. 503-512, (2012); Maynard C.L., Elson C.O., Hatton R.D., Et al., Reciprocal interactions of the intestinal microbiota and immune system, Nature, 489, pp. 231-241, (2012); Heyland D., Muscedere J., Wischmeyer P.E., Et al., A randomized trial of glutamine and antioxidants in critically ill patients, N Engl J Med, 368, pp. 1489-1497, (2013); Yoshida S., Matsui M., Shirouzu Y., Et al., Effects of glutamine supplements and radiochemotherapy on systemic immune and gut barrier function in patients with advanced esophageal cancer, Ann Surg, 227, pp. 485-491, (1998); Sido B., Seel C., Hochlehnert A., Et al., Low intestinal glutamine level and low glutaminase activity in Crohn's disease: A rational for glutamine supplementation?, Dig Dis Sci, 51, pp. 2170-2179, (2006); Zhou Q., Verne G.N., New insights into visceral hypersensitivity-clinical implications in IBS, Nat Rev Gastroenterol Hepatol, 8, pp. 349-355, (2011); Hong S., Zheng G., Wiley J.W., Epigenetic regulation of genes that modulate chronic stress-induced visceral pain in the peripheral nervous system, Gastroenterology, 148, pp. 148-157, (2015); Ghishan F.K., Kiela P.R., Epithelial transport in inflammatory bowel diseases, Inflamm Bowel Dis, 20, pp. 1-109, (2014); Bertrand J., Ghouzali I., Guerin C., Et al., Glutamine restores tight junction protein Claudin-1 Expression in colonic mucosa of patients with diarrhea-predominant irritable bowel syndrome, J Parenter Enteral Nutr, 40, pp. 1170-1176, (2016)","G.N. Verne; Department of Medicine, Tulane University School of Medicine, New Orleans, 70112-2699, United States; email: gverne@tulane.edu","","BMJ Publishing Group","","","","","","00175749","","GUTTA","30108163","English","Gut","Article","Final","All Open Access; Green Open Access","Scopus","2-s2.0-85052731357"

"Caviglia G.P.; Tucci A.; Pellicano R.; Fagoonee S.; Rosso C.; Abate M.L.; Olivero A.; Armandi A.; Vanni E.; Saracco G.M.; Bugianesi E.; Astegiano M.; Ribaldone D.G.","Caviglia, Gian Paolo (24491739500); Tucci, Alessandra (56219805900); Pellicano, Rinaldo (7005853671); Fagoonee, Sharmila (6603221574); Rosso, Chiara (55613318800); Abate, Maria Lorena (7004963939); Olivero, Antonella (55369742700); Armandi, Angelo (57204445604); Vanni, Ester (6601986579); Saracco, Giorgio Maria (57205711772); Bugianesi, Elisabetta (6701433364); Astegiano, Marco (6701316557); Ribaldone, Davide Giuseppe (57195507877)","24491739500; 56219805900; 7005853671; 6603221574; 55613318800; 7004963939; 55369742700; 57204445604; 6601986579; 57205711772; 6701433364; 6701316557; 57195507877","Clinical response and changes of cytokines and zonulin levels in patients with diarrhoea-predominant irritable bowel syndrome treated with bifidobacterium longum es1 for 8 or 12 weeks: A preliminary report","2020","Journal of Clinical Medicine","9","8","2353","1","11","10","22","10.3390/jcm9082353","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85111770871&doi=10.3390%2fjcm9082353&partnerID=40&md5=221a59ad6ad0399edc19bc46e656c0ff","Department of Medical Sciences, University of Turin, Turin, 10124, Italy; Unit of Gastroenterology, Città della Salute e della Scienza di Torino—Molinette Hospital, Turin, 10126, Italy; Institute of Biostructure and Bioimaging, CNR c/o Molecular Biotechnology Centre, Turin, 10126, Italy","Caviglia G.P., Department of Medical Sciences, University of Turin, Turin, 10124, Italy; Tucci A., Unit of Gastroenterology, Città della Salute e della Scienza di Torino—Molinette Hospital, Turin, 10126, Italy; Pellicano R., Unit of Gastroenterology, Città della Salute e della Scienza di Torino—Molinette Hospital, Turin, 10126, Italy; Fagoonee S., Institute of Biostructure and Bioimaging, CNR c/o Molecular Biotechnology Centre, Turin, 10126, Italy; Rosso C., Department of Medical Sciences, University of Turin, Turin, 10124, Italy; Abate M.L., Department of Medical Sciences, University of Turin, Turin, 10124, Italy; Olivero A., Department of Medical Sciences, University of Turin, Turin, 10124, Italy; Armandi A., Unit of Gastroenterology, Città della Salute e della Scienza di Torino—Molinette Hospital, Turin, 10126, Italy; Vanni E., Unit of Gastroenterology, Città della Salute e della Scienza di Torino—Molinette Hospital, Turin, 10126, Italy; Saracco G.M., Department of Medical Sciences, University of Turin, Turin, 10124, Italy; Bugianesi E., Department of Medical Sciences, University of Turin, Turin, 10124, Italy; Astegiano M., Unit of Gastroenterology, Città della Salute e della Scienza di Torino—Molinette Hospital, Turin, 10126, Italy; Ribaldone D.G., Department of Medical Sciences, University of Turin, Turin, 10124, Italy","Bifidobacterium longum (B. longum) ES1 is a probiotic strain capable of modulating microbiome composition, anti-inflammatory activity and intestinal barrier function. We investigated the use of B. Longum ES1 in the treatment of patients with diarrhoea-predominant irritable bowel syndrome (IBS-D). Sixteen patients were treated for 8 or 12 weeks with B. Longum ES1 (1 × 109 CFU/day). Serum zonulin and cytokines were measured at baseline (T0) and at the end of therapy (T1). Clinical response to therapy was assessed by IBS Severity Scoring System. Interleukin (IL)-6, IL-8, IL-12p70 and tumor necrosis factor (TNF) α levels decreased from T0 to T1, irrespective of treatment duration (p < 0.05), while zonulin levels diminished only in patients treated for 12 weeks (p = 0.036). Clinical response was observed in 5/16 patients (31%): 4/8 (50%) treated for 12 weeks and 1/8 (13%) treated for 8 weeks. Abdominal pain improved only in patients treated for 12 weeks (5/8 vs. 0/8, p = 0.025), while stool consistency improved regardless of therapy duration (p < 0.001). In conclusion, the results of this pilot study showed, in IBS-D patients treated for 12 weeks with B. longum ES1, a reduction in the levels of pro-inflammatory cytokines, and intestinal permeability as well as an improvement in gastrointestinal symptoms, but further studies including a placebo-control group are necessary to prove a causal link. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.","IBS; IL-12p70; IL-6; IL-8; Intestinal permeability; Zonulin","Bifidobacterium longum ES1; interleukin 12p70; interleukin 6; interleukin 8; probiotic agent; tumor necrosis factor; unclassified drug; zonulin; abdominal pain; adult; Article; Bifidobacterium longum; clinical article; clinical outcome; diarrhea; disease severity; Disorder Severity Index questionnaire; enzyme linked immunosorbent assay; female; human; irritable colon; male; pain intensity; quality control; quality of life; questionnaire; scoring system; treatment duration","","interleukin 8, 114308-91-7","","","","","Adriani A., Ribaldone D.G., Astegiano M., Durazzo M., Saracco G.M., Pellicano R., Irritable bowel syndrome: The clinical approach, Panminerva Med, 60, pp. 213-222, (2018); Gonzalez-Castro A.M., Martinez C., Salvo-Romero E., Fortea M., Pardo-Camacho C., Perez-Berezo T., Alonso-Cotoner C., Santos J., Vicario M., Mucosal pathobiology and molecular signature of epithelial barrier dysfunction in the small intestine in irritable bowel syndrome, J. Gastroenterol. Hepatol, 32, pp. 53-63, (2017); Martinez C., Gonzalez-Castro A., Vicario M., Santos J., Cellular and molecular basis of intestinal barrier dysfunction in the irritable bowel syndrome, Gut Liver, 6, pp. 305-315, (2012); Barbara G., Wang B., Stanghellini V., de Giorgio R., Cremon C., Di Nardo G., Trevisani M., Campi B., Geppetti P., Tonini M., Et al., Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome, Gastroenterology, 132, pp. 26-37, (2007); Sturgeon C., Fasano A., Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases, Tissue Barriers, 4, (2016); Caviglia G.P., Rosso C., Ribaldone D.G., Dughera F., Fagoonee S., Asteigano M., Pellicano R., Physiopathology of intestinal barrier and the role of zonulin, Minerva Biotecnol, 31, pp. 83-92, (2019); Fasano A., All disease begins in the (leaky) gut: Role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases, F1000 Res, 9, (2020); Caviglia G.P., Dughera F., Ribaldone D.G., Rosso C., Abate M.L., Pellicano R., Bresso F., Smedile A., Saracco G.M., Astegiano M., Serum zonulin in patients with inflammatory bowel disease: A pilot study, Minerva Med, 110, pp. 95-100, (2019); Singh P., Silvester J., Chen X., Xu H., Sawhney V., Rangan V., Iturrino J., Nee J., Duerksen D.R., Lembo A., Serum zonulin is elevated in IBS and correlates with stool frequency in IBS-D, United Eur. Gastroenterol. J, 7, pp. 709-715, (2019); Barbara G., Cremon C., Carini G., Bellacosa L., Zecchi L., De Giorgio R., Corinaldesi R., Stanghellini V., The immune system in irritable bowel syndrome, J. Neurogastroenterol. Motil, 17, pp. 349-359, (2011); Barbara G., Grover M., Bercik P., Corsetti M., Ghoshal U.C., Ohman L., Rajilic-Stojanovic M., Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome, Gastroenterology, 156, pp. 46-58, (2019); Musch M.W., Clarke L.L., Mamah D., Gawenis L.R., Zhang Z., Ellsworth W., Shalowitz D., Mittal N., Efthimiou P., Alnadjim Z., Et al., T cell activation causes diarrhea by increasing intestinal permeability and inhibiting epithelial Na+/K+-ATPase, J. Clin. Invest, 110, pp. 1739-1747, (2002); Wang F., Graham W.V., Wang Y., Witkowski E.D., Schwarz B.T., Turner J.R., Interferon-γ and tumor necrosis factor-α synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression, Am. J. Pathol, 166, pp. 409-419, (2005); Parkes G.C., Rayment N.B., Hudspith B.N., Petrovska L., Lomer M.C., Brostoff J., Whelan K., Sanderson J.D., Distinct microbial populations exist in the mucosa-associated microbiota of sub-groups of irritable bowel syndrome, Neurogastroenterol. Motil, 24, pp. 31-39, (2012); Carroll I.M., Ringel-Kulka T., Siddle J.P., Ringel Y., Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome, Neurogastroenterol. Motil, 24, pp. 521-530, (2012); Abrams G.D., Bauer H., Sprinz H., Influence of the normal flora on mucosal morphology and cellular renewal in the ileum. A comparison of germ-free and conventional mice, Lab. Invest, 12, pp. 355-364, (1963); Fan W.T., Ding C., Xu N.N., Zong S., Ma P., Gu B., Close association between intestinal microbiota and irritable bowel syndrome, Eur. J. Clin. Microbiol. Infect. Dis, 36, pp. 2303-2317, (2017); Tojo R., Suarez A., Clemente M.G., De Los Reyes-Gavilan C.G., Margolles A., Gueimonde M., Ruas-Madiedo P., Intestinal microbiota in health and disease: Role of bifidobacteria in gut homeostasis, World J. Gastroenterol, 20, pp. 15163-15176, (2014); Chenoll E., Codoner F., Silva A., Ibanez A., Martinez-Blanch J., Bollati-Fogolin M., Crispo M., Ramirez S., Sanz Y., Ramon D., Et al., Genomic Sequence and Pre-Clinical Safety Assessment of Bifidobacterium longum CECT 7347, a Probiotic able to Reduce the Toxicity and Inflammatory Potential of Gliadin-Derived Peptides, J. Probiotics Heal, pp. 1-6, (2013); Izquierdo E., Medina M., Ennahar S., Marchioni E., Sanz Y., Resistance to simulated gastrointestinal conditions and adhesion to mucus as probiotic criteria for Bifidobacterium longum strains, Curr. Microbiol, 56, pp. 613-618, (2008); Olivares M., Castillejo G., Varea V., Sanz Y., Double-blind, randomised, placebo-controlled intervention trial to evaluate the effects of Bifidobacterium longum CECT 7347 in children with newly diagnosed coeliac disease, Br. J. Nutr, 112, pp. 30-40, (2014); Sultana R., McBain A.J., O'Neill C.A., Strain-dependent augmentation of tight-junction barrier function in human primary epidermal keratinocytes by Lactobacillus and Bifidobacterium lysates, Appl. Environ. Microbiol, 79, pp. 4887-4894, (2013); Takeda Y., Nakase H., Namba K., Inoue S., Ueno S., Uza N., Chiba T., Upregulation of T-bet and tight junction molecules by Bifidobactrium longum improves colonic inflammation of ulcerative colitis, Inflamm. Bowel Dis, 15, pp. 1617-1618, (2009); Zhang Y., Li L., Guo C., Mu D., Feng B., Zuo X., Li Y., Effects of probiotic type, dose and treatmenty duration on irritable bowel syndrome diagnosed by Rome III criteria: A meta-analysis, BMC Gastroenterolol, 16, (2016); Ford A.C., Harris L.A., Lucy B.E., Quigley E.M.M., Moayyedi P., Systematic review with meta-analysis: The efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome, Aliment. Pharmacol. Ther, 48, pp. 1044-1060, (2018); Ciacci C., Franceschi F., Purchiaroni F., Capone P., Buccelletti F., Iacomini P., Ranaudo A., Andreozzi P., Tondi P., Gentiloni Silveri N., Et al., Effect of beta-glucan, inositol and digestive enzymes in GI symptoms of patients with IBS, Eur. Rev. Med. Pharmacol. Sci, 15, pp. 637-643, (2011); Spaguolo R., Cosco C., Mancina R.M., Ruggiero G., Garieri P., Cosco V., Doldo P., Beta-glucan, inositol and digestive enzymes improve quality of life of patients with inflammatory bowel disease and irritable bowel syndrome, Eur. Rev. Med. Pharmacol. Sci, 21, pp. 102-107, (2017); Drossman D.A., Hasler W.L., Rome IV-Functional GI Disorders: Disorders of Gut-Brain Interaction, Gastroenterology, 150, pp. 1257-1261, (2016); Drossman D.A., Li Z., Toner B.B., Diamant N.E., Creed F.H., Thompson D., Read N.W., Babbs C., Barreiro M., Bank L., Et al., Functional bowel disorders. A multicenter comparison of health status and development of illness severity index, Dig. Dis. Sci, 40, pp. 986-995, (1995); Francis C.Y., Morris J., Whorwell P.J., The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress, Aliment. Pharmacol. Ther, 11, pp. 395-402, (1997); Patrick D.L., Drossman D.A., Frederick I.O., Di Cesare J., Puder K.L., Quality of life in persons with irritable bowel syndrome: Development and validation of a new measure, Dig. Dis. Sci, 43, pp. 400-411, (1998); Caviglia G.P., Rosso C., Stalla F., Rizzo M., Massano A., Abate M.L., Olivero A., Armandi A., Vanni E., Younes R., Et al., On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Dis, J. Clin. Med, 9, (2020); Andresen V., Gschossmann J., Layer P., Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN–HI–001) in the treatment of irritable bowel syndrome: A multicentre, randomised, double-blind, placebo-controlled clinical trial, Lancet Gastroenterol. Hepatol, 5, pp. 658-666, (2020); Lewis S.J., Heaton K.W., Stool form scale as a useful guide to intestinal transit time, Scand. J. Gastroenterol, 32, pp. 920-924, (1997); Drossman D., Morris C.B., Hu Y., Toner B.B., Diamant N., Whitehead W.E., Dalton C.B., Leserman J., Patrick D.L., Bangdiwala S.I., Characterization of health related quality of life (HRQOL) for patients with functional bowel disorder (FBD) and its response to treatment, Am. J. Gastroenterol, 102, pp. 1442-1453, (2007); Davis C., Bryan J., Hodgson J., Murphy K., Definition of the Mediterranean Diet; a Literature Review, Nutrients, 7, pp. 9139-9153, (2015); Ford A.C., Quigley E.M., Lacy B.E., Lembo A.J., Saito Y.A., Schiller L.R., Soffer E.E., Spiegel B.M., Moayyedi P., Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: Systematic review and meta-analysis, Am. J. Gastroenterol, 109, pp. 1547-1561, (2014); Duan R., Zhu S., Wang B., Duan L., Alterations of gut microbiota in patients with irritable bowel syndrome based on 16 rRNA-targeted sequencing: A systemic review, Clin. Gasteroenterol. Hepatol, 10, (2019); Pittayanon R., Lau J.T., Yuan Y., Leontiadis G.I., Tse F., Surette M., Moayyedi P., Gut microbiota in patients with irritable bowel syndrome—A systematic review, Gastroenterology, 157, pp. 97-108, (2019); Ki Cha B., Mun Jung S., Hwan Choi C., Song I.D., Woong Lee H., Joon Kim H., Hyuk J., Kyung Chang S., Kim K., Chung W.S., Et al., The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial, J. Clin. Gastroenterol, 46, pp. 220-227, (2012); Giannetti E., Maglione M., Alessandrella A., Strisciuglio C., De Giovanni D., Campanozzi A., Miele E., Staiano A., A Mixture of 3 Bifidobacteria Decreases Abdominal Pain and Improves the Quality of Life in Children With Irritable Bowel Syndrome: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Trial, J. Clin. Gastroenterol, 51, pp. e5-e10, (2017); Pinto-Sanchez M.I., Hall G.B., Ghajar K., Nardelli A., Bolino C., Lau J.T., Martin F.P., Cominetti O., Welsh C., Rieder A., Et al., Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome, Gastroenterology, 153, pp. 448-459, (2017); Barbara G., De Giorgio R., Stanghellini V., Cremon C., Corinaldesi R., A role for inflammation in irritable bowel syndrome?, Gut, 51, pp. i41-i44, (2002); Farzaei M.H., Bahramsoltani R., Abdollahi M., Rahimi R., The Role of Visceral Hypersensitivity in Irritable Bowel Syndrome: Pharmacological Targets and Novel Treatments, J. Neurogastroenterol. Motil, 22, pp. 558-574, (2016); Song D.D., Li Y., Tang D., Huang L.Y., Yuan Y.Z., Neuron-glial communication mediated by TNF-alfa and glial activation in dorsal root ganglia in visceral inflammatory hypersensitivity, Am. J. Physiol. Gastrointest. Liver Physiol, 306, pp. G788-G795, (2014); Bashashati M., Moradi M., Sarosiek I., Interleukin-6 in irritable bowel syndrome: A systematic review and meta-analysis of IL-(-G174C) and circulating IL-6 levels, Cytokine, 99, pp. 132-138, (2017); Patel S.R., Singh A., Misra V., Misra S.P., Dwivedi M., Trivedi P., Levels of interleukins 2, 6, 8, and 10 in patients with irritable bowel syndrome, Indian J. Pathol. Microbiol, 60, pp. 385-389, (2017); Bashashati M., Rezaei N., Shafieyoun A., McKernan D.P., Chang L., Ohman L., Quigley E.M., Schmulson M., Sharkey K.A., Simren M., Cytokine imbalance in irritable bowel syndrome: A systematic review and meta-analysis, Neurogastroenterol. Motil, 26, pp. 1036-1048, (2014); Ng Q.X., Soh A.Y.S., Loke W., Lim D.Y., Yeo W.S., The role of inflammation in irritable bowel syndrome (IBS), J. Inflamm. Res, 11, pp. 345-349, (2018); Mujagic Z., Ludidi S., Keszthelyi D., Hesselink M.A., Kruimel J.W., Lenaerts K., Hanssen N.M., Conchillo J.M., Jonkers D.M., Masclee A.A., Small intestinal permeability is increased in diarrhoea predominant IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to confounders, Aliment. Pharmacol. Ther, 40, pp. 288-297, (2014); Rao A.S., Camilleri M., Eckert D.J., Busciglio I., Burton D.D., Ryks M., Wong B.S., Lamsam J., Singh R., Zinsmeister A.R., Urine sugars for in vivo gut permeability: Validation and comparisons in irritable bowel syndrome-diarrhea and controls, Am. J. Physiol. Gastrointest. Liver. Physiol, 301, pp. 919-928, (2011); Linsalata M., Riezzo G., D'Attoma B., Clemente C., Orlando A., Russo F., Noninvasive biomarkers of gut barrier function identify two subtypes of patients suffering from diarrhoea predominant-IBS: A case-control study, BMC Gastroenterol, 18, (2018); Bonfrate L., Di Palo D.M., Celano G., Albert A., Vitellio P., De Angelis M., Gobbetti M., Portincasa P., Effects of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 in IBS patients, Eur. J. Clin. Invest, 50, (2020)","G.P. Caviglia; Department of Medical Sciences, University of Turin, Turin, 10124, Italy; email: gianpaolo.caviglia@unito.it; D.G. Ribaldone; Department of Medical Sciences, University of Turin, Turin, 10124, Italy; email: davidegiuseppe.ribaldone@unito.it","","MDPI","","","","","","20770383","","","","English","J. Clin. Med.","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85111770871"

"Wilms E.; Troost F.J.; Elizalde M.; Winkens B.; de Vos P.; Mujagic Z.; Jonkers D.M.A.E.; Masclee A.A.M.","Wilms, Ellen (57192382296); Troost, Freddy J. (6603454094); Elizalde, Montserrat (57188824676); Winkens, Bjorn (55885489100); de Vos, Paul (56435643800); Mujagic, Zlatan (56197282500); Jonkers, Daisy M. A. E. (6701864464); Masclee, Ad A. M. (7103116978)","57192382296; 6603454094; 57188824676; 55885489100; 56435643800; 56197282500; 6701864464; 7103116978","Intestinal barrier function is maintained with aging – a comprehensive study in healthy subjects and irritable bowel syndrome patients","2020","Scientific Reports","10","1","475","","","","45","10.1038/s41598-019-57106-2","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85077941476&doi=10.1038%2fs41598-019-57106-2&partnerID=40&md5=67dac6e1b8f5cd5e770f2a557de1a1f5","Division Gastroenterology-Hepatology, Department of Internal Medicine; NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, Netherlands; Top Institute Food and Nutrition, Wageningen, Netherlands; Food Innovation and Health Research, Centre for Healthy Eating and Food Innovation, Maastricht University, Venlo, Netherlands; Department of Methodology and Statistics; CAPHRI, Care and Public Health Research Institute, Maastricht University Medical Center, Maastricht, Netherlands; Department of Pathology and Medical Biology, section Immunoendocrinology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands","Wilms E., Division Gastroenterology-Hepatology, Department of Internal Medicine; NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, Netherlands, Top Institute Food and Nutrition, Wageningen, Netherlands; Troost F.J., Division Gastroenterology-Hepatology, Department of Internal Medicine; NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, Netherlands, Food Innovation and Health Research, Centre for Healthy Eating and Food Innovation, Maastricht University, Venlo, Netherlands; Elizalde M., Division Gastroenterology-Hepatology, Department of Internal Medicine; NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, Netherlands; Winkens B., Department of Methodology and Statistics; CAPHRI, Care and Public Health Research Institute, Maastricht University Medical Center, Maastricht, Netherlands; de Vos P., Top Institute Food and Nutrition, Wageningen, Netherlands, Department of Pathology and Medical Biology, section Immunoendocrinology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands; Mujagic Z., Division Gastroenterology-Hepatology, Department of Internal Medicine; NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, Netherlands; Jonkers D.M.A.E., Division Gastroenterology-Hepatology, Department of Internal Medicine; NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, Netherlands; Masclee A.A.M., Division Gastroenterology-Hepatology, Department of Internal Medicine; NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, Netherlands","Animal studies have shown that intestinal barrier function is compromised with aging. We aimed to assess the effects of aging on intestinal barrier function in humans in vivo and ex vivo. In this cross-sectional study, healthy subjects and subjects with irritable bowel syndrome (IBS) of older (65–75 years) and young adult age (18–40 years) were compared. In vivo gastrointestinal site-specific permeability was assessed by a multi-sugar test, taking into account potential confounders. Sigmoid biopsies were collected from subgroups of healthy young adults and elderly for ex vivo Ussing chamber experiments, gene transcription of barrier-related genes and staining of junctional proteins. No significant differences between healthy young adults and elderly were found for small intestinal, colonic and whole gut permeability (P ≥ 0.142). In IBS patients, gastroduodenal and colonic permeability did not differ significantly (P ≥ 0.400), but small intestinal and whole gut permeability were higher in elderly versus young adults (P ≤ 0.009), mainly driven by the IBS-diarrhea subtype. Ussing chamber experiments with or without stressor (P ≥ 0.052), and relative expression of intestinal barrier-related genes (P ≥ 0.264) showed no significant differences between healthy elderly and young adults, as confirmed by immunofluorescent stainings. Overall, the functional capacity of the intestinal barrier is maintained in elderly. © 2020, The Author(s).","","Adult; Aged; Aging; Case-Control Studies; Cell Membrane Permeability; Cross-Sectional Studies; Female; Healthy Volunteers; Humans; Intestinal Mucosa; Intestine, Small; Irritable Bowel Syndrome; Male; Middle Aged; Prognosis; Young Adult; adult; aged; aging; case control study; cell membrane permeability; cross-sectional study; female; human; intestine mucosa; irritable colon; male; middle aged; normal human; pathophysiology; physiology; prognosis; small intestine; young adult","","","","","TI Food and Nutrition, (GH002)","This research was funded by TI Food and Nutrition (project GH002), a public–private partnership on precompetitive research in food and nutrition. The funders had no role in the study design, data collection, data analyses, or manuscript related decisions. D.J. is partly funded by a Grant Top Knowledge Institute (Well on Wheat). All other authors disclose no competing interests.","Global Health and Aging, (2011); Britton E., McLaughlin J.T., Ageing and the gut, Proc. Nutr. Soc., 72, pp. 173-177, (2013); Maijo M., Clements S.J., Ivory K., Nicoletti C., Carding S.R., Nutrition, diet and immunosenescence, Mech. Ageing Dev., 136-137, pp. 116-128, (2014); An R., Et al., Age-dependent changes in GI physiology and microbiota: time to reconsider?, Gut., 67, pp. 2213-2222, (2018); Mabbott N.A., Et al., Aging and the mucosal immune system in the intestine, Biogerontology., 16, pp. 133-145, (2015); Katz D., Hollander D., Said H.M., Dadufalza V., Aging-associated increase in intestinal permeability to polyethylene glycol 900, Dig. Dis. Sci., 32, pp. 285-288, (1987); Ma T.Y., Hollander D., Dadufalza V., Krugliak P., Effect of aging and caloric restriction on intestinal permeability, Exp. Gerontol., 27, pp. 321-333, (1992); Tran L., Meerveld B.G.-V., Age-Associated Remodeling of the Intestinal Epithelial Barrier, J. Gerontol. A. Biol. Sci. Med. Sci., 68, pp. 1045-1056, (2013); Thevaranjan N., Et al., Age-Associated Microbial Dysbiosis Promotes Intestinal Permeability, Systemic Inflammation, and Macrophage Dysfunction, Cell Host Microbe., 21, pp. 455-466, (2017); Fukui H., Increased Intestinal Permeability and Decreased Barrier Function: Does It Really Influence the Risk of Inflammation?, Inflamm. Intest. Dis., 1, pp. 135-145, (2016); Saweirs W.M., Andrews D.J., Low-Beer T.S., The double sugar test of intestinal permeability in the elderly, Age Ageing, 14, pp. 312-315, (1985); Saltzman J.R., Kowdley K.V., Perrone G., Russell R.M., Changes in small-intestine permeability with aging, J. Am. Geriatr. Soc., 43, pp. 160-164, (1995); Valentini L., Et al., Small intestinal permeability in older adults, Physiol. Rep., 2, (2014); Ganda Mall J.P., Et al., Differential effects of dietary fibres on colonic barrier function in elderly individuals with gastrointestinal symptoms, Sci. Rep., 8, (2018); Mujagic Z., Et al., Small intestinal permeability is increased in diarrhoea predominant IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to confounders, Aliment. Pharmacol. Ther., 40, pp. 288-297, (2014); Suzuki T., Regulation of intestinal epithelial permeability by tight junctions, Cell. Mol. Life Sci. CMLS, 70, pp. 631-659, (2013); Mabbott N.A., A breakdown in communication? Understanding the effects of aging on the human small intestine epithelium, Clin. Sci. Lond. Engl. 1979, 129, pp. 529-531, (2015); van Wijck K., van Eijk H.M.H., Buurman W.A., Dejong C.H.C., Lenaerts K., Novel analytical approach to a multi-sugar whole gut permeability assay, J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 879, pp. 2794-2801, (2011); Wilms E., Et al., Effects of Supplementation of the Synbiotic Ecologic® 825/FOS P6 on Intestinal Barrier Function in Healthy Humans: A Randomized Controlled Trial, PLOS ONE., 11, (2016); Salden B.N., Et al., Reinforcement of intestinal epithelial barrier by arabinoxylans in overweight and obese subjects: A randomized controlled trial: Arabinoxylans in gut barrier, Clin. Nutr., 37, pp. 471-480, (2018); Dunlop S.P., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am. J. Gastroenterol., 101, pp. 1288-1294, (2006); Zhou Q., Souba W.W., Croce C.M., Verne G.N., MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome, Gut., 59, pp. 775-784, (2010); Man A.L., Et al., Age-associated modifications of intestinal permeability and innate immunity in human small intestine, Clin. Sci., 129, pp. 515-527, (2015); van Wijck K., Et al., Novel multi-sugar assay for site-specific gastrointestinal permeability analysis: A randomized controlled crossover trial, Clin. Nutr., 32, pp. 245-251, (2013); Rinsma N.F., Et al., Exploration of the Esophageal Mucosal Barrier in Non-Erosive Reflux Disease, Int. J. Mol. Sci., 18, (2017); Pijls K.E., Et al., Is intestinal oxidative stress involved in patients with compensated liver cirrhosis?, Ann. Hepatol., 15, pp. 402-409, (2016); Keszthelyi D., Et al., Does acute tryptophan depletion affect peripheral serotonin metabolism in the intestine?, Am. J. Clin. Nutr., 95, pp. 603-608, (2012); Elamin E., Et al., Ethanol Impairs Intestinal Barrier Function in Humans through Mitogen Activated Protein Kinase Signaling: A Combined In Vivo and In Vitro Approach, PLOS ONE., 9, (2014)","E. Wilms; Division Gastroenterology-Hepatology, Department of Internal Medicine; NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, Netherlands; email: e.wilms@maastrichtuniversity.nl","","Nature Research","","","","","","20452322","","","31949225","English","Sci. Rep.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85077941476"

"Li M.; Oshima T.; Ito C.; Yamada M.; Tomita T.; Fukui H.; Miwa H.","Li, Min (57195153535); Oshima, Tadayuki (7401663152); Ito, Chiyomi (57192162200); Yamada, Mayumi (57211095960); Tomita, Toshihiko (7403059566); Fukui, Hirokazu (7202565238); Miwa, Hiroto (56921458500)","57195153535; 7401663152; 57192162200; 57211095960; 7403059566; 7202565238; 56921458500","Glutamine Blocks Interleukin-13-Induced Intestinal Epithelial Barrier Dysfunction","2021","Digestion","102","2","","170","179","9","21","10.1159/000502953","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85072630140&doi=10.1159%2f000502953&partnerID=40&md5=18c45d297eb733d4bf77a1eaa5ce21d7","Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan; Department of Gastroenterology, The Third People's Hospital of Chengdu, Chengdu, China","Li M., Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan, Department of Gastroenterology, The Third People's Hospital of Chengdu, Chengdu, China; Oshima T., Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan; Ito C., Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan; Yamada M., Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan; Tomita T., Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan; Fukui H., Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan; Miwa H., Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan","Introduction: Impaired intestinal epithelial barrier function is a hallmark of a variety of pathological conditions such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). IBD patients with IBS-like symptoms show higher interleukin-13 (IL-13) serum levels and poor psychological well-being. Supplementary glutamine reduced the daily bowel movement frequency, improved the stool form, and normalized intestinal hyperpermeability. This study was aimed at assessing the effects of IL-13 and supplementary glutamine on human intestinal epithelial function in vitro. Methods: Caco-2 cells were grown on TranswellTM inserts. -IL-13 was added to the basolateral compartment, and transepithelial electrical resistance (TEER) and fluorescein isothiocyanate (FITC) labeled-dextran permeability measured. Effects of glutamine or the phosphatidylinositol-3-kinase inhibitor LY294002 were assessed. Involvement of tight junction proteins was assessed using Western blotting and immunofluorescence staining. Results: IL-13 significantly decreased TEER and increased FITC labeled-dextran epithelial permeability. IL-13 stimulation decreased the claudin-1 expression and increased the claudin-2 expression. Glutamine alleviated IL-13-induced decrease of TEER and increase of FITC labeled-dextran permeability. Further, the phosphatidylinositol-3-kinase inhibitor showed this alleviating effect while the signal transducer and activator of transcription 6 inhibitor did not. Conclusions: IL-13 induced barrier integrity impairment by decreasing claudin-1 and increasing claudin-2. Glutamine alleviated IL-13-induced barrier dysfunction by increasing claudin-1 expression, via disruption of the phosphatidylinositol-3-kinase/Akt signaling pathway.  © 2021 S. Karger AG. All rights reserved.","Glutamine; Interleukin-13; Intestinal barrier function; Phosphoinositide 3-kinase","Caco-2 Cells; Claudin-1; Epithelial Cells; Glutamine; Humans; Interleukin-13; Intestinal Mucosa; 2 morpholino 8 phenylchromone; claudin 1; claudin 2; glutamine; interleukin 13; tight junction protein; claudin 1; glutamine; interleukin 13; Article; Caco-2 cell line; controlled study; drug effect; electric resistance; immunofluorescence; in vitro study; intestine function disorder; intestine mucosa permeability; priority journal; protein expression; transepithelial resistance; Western blotting; epithelium cell; human; intestine mucosa","","2 morpholino 8 phenylchromone, 154447-36-6; claudin 1, 329338-06-9; glutamine, 56-85-9, 6899-04-3; interleukin 13, 148157-34-0; Claudin-1, ; Glutamine, ; Interleukin-13, ","Transwell","","","","Danese S., Fiocchi C., Ulcerative colitis, N Engl J Med., 365, 18, pp. 1713-1725, (2011); Strober W., Fuss I.J., Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases, Gastroenterology., 140, 6, pp. 1756-1767, (2011); Neurath M.F., Cytokines in inflammatory bowel disease, Nat Rev Immunol., 14, 5, pp. 329-342, (2014); Bennet S.M., Polster A., Tornblom H., Isaksson S., Capronnier S., Tessier A., Et al., Global cytokine profiles and association with clinical characteristics in patients with irritable bowel syndrome, Am J Gastroenterol., 111, 8, pp. 1165-1176, (2016); Heller F., Florian P., Bojarski C., Richter J., Christ M., Hillenbrand B., Et al., Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution, Gastroenterology., 129, 2, pp. 550-564, (2005); Jonefjall B., Ohman L., Simren M., Strid H., IBSlike symptoms in patients with ulcerative colitis in deep remission are associated with increased levels of serum cytokines and poor psychological well-being, Inflamm Bowel Dis., 22, 11, pp. 2630-2640, (2016); Ishihara S., Kawashima K., Fukuba N., Tada Y., Kotani S., Mishima Y., Et al., Irritable bowel syndrome-like symptoms in ulcerative colitis patients in clinical remission: Association with residual colonic inflammation, Digestion., 99, 1, pp. 46-51, (2019); Tomita T., Kato Y., Takimoto M., Yamasaki T., Kondo T., Kono T., Et al., Prevalence of irritable bowel syndrome-like symptoms in Japanese patients with inactive inflammatory bowel disease, J Neurogastroenterol Motil., 22, 4, pp. 661-669, (2016); Groschwitz K.R., Hogan S.P., Intestinal barrier function: Molecular regulation and disease pathogenesis, J Allergy Clin Immunol., 124, 1, pp. 3-20, (2009); Oshima T., Miwa H., Gastrointestinal mucosal barrier function and diseases, J Gastroenterol., 51, 8, pp. 768-778, (2016); Baumgart D.C., Sandborn W.J., Crohn's disease, Lancet., 380, 9853, pp. 1590-1605, (2012); Ordas I., Eckmann L., Talamini M., Baumgart D.C., Sandborn W.J., Ulcerative colitis, Lancet., 380, 9853, pp. 1606-1619, (2012); Ishimoto H., Oshima T., Sei H., Yamasaki T., Kondo T., Tozawa K., Et al., Claudin-2 expression is upregulated in the ileum of diarrhea predominant irritable bowel syndrome patients, J Clin Biochem Nutr., 60, 2, pp. 146-150, (2017); Van Der Hulst R.R., Von Meyenfeldt M.F., Soeters P.B., Glutamine: An essential amino acid for the gut, Nutrition., 12, 12, pp. S78-S81, (1996); Ueno P.M., Oria R.B., Maier E.A., Guedes M., De Azevedo O.G., Wu D., Et al., Alanyl-glutamine promotes intestinal epithelial cell homeostasis in vitro and in a murine model of weanling undernutrition, Am J Physiol Gastrointest Liver Physiol., 301, 4, pp. G612-G622, (2011); Ropeleski M.J., Riehm J., Baer K.A., Musch M.W., Chang E.B., Anti-apoptotic effects of L-glutamine-mediated transcriptional modulation of the heat shock protein 72 during heat shock, Gastroenterology., 129, 1, pp. 170-184, (2005); Chaudhry K.K., Shukla P.K., Mir H., Manda B., Gangwar R., Yadav N., Et al., Glutamine supplementation attenuates ethanol-induced disruption of apical junctional complexes in colonic epithelium and ameliorates gut barrier dysfunction and fatty liver in mice, J Nutr Biochem., 27, pp. 16-26, (2016); Ewaschuk J.B., Murdoch G.K., Johnson I.R., Madsen K.L., Field C.J., Glutamine supplementation improves intestinal barrier function in a weaned piglet model of Escherichia coli infection, Br J Nutr., 106, 6, pp. 870-877, (2011); Beutheu S., Ouelaa W., Guerin C., Belmonte L., Aziz M., Tennoune N., Et al., Glutamine supplementation, but not combined glutamine and arginine supplementation, improves gut barrier function during chemotherapy-induced intestinal mucositis in rats, Clin Nutr., 33, 4, pp. 694-701, (2014); Zhou Q., Verne M.L., Fields J.Z., Lefante J.J., Basra S., Salameh H., Et al., Randomised placebocontrolled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome, Gut., (2018); Artursson P., Karlsson J., Correlation between oral-drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells, Biochem Biophys Res Commun., 175, 3, pp. 880-885, (1991); Oshima T., Sasaki M., Kataoka H., Miwa H., Takeuchi T., Joh T., Wip1 protects hydrogen peroxide-induced colonic epithelial barrier dysfunction, Cell Mol Life Sci., 64, 23, pp. 3139-3147, (2007); Oshima T., Flores S.C., Vaitaitis G., Coe L.L., Joh T., Park J.H., Et al., HIV-1 Tat increases endothelial solute permeability through tyrosine kinase and mitogen-activated protein kinasedependent pathways, AIDS., 14, 5, pp. 475-482, (2000); Horikawa T., Oshima T., Li M., Kitayama Y., Eda H., Nakamura K., Et al., Chenodeoxycholic acid releases proinflammatory cytokines from small intestinal epithelial cells through the farnesoid X receptor, Digestion., 7, pp. 1-9, (2019); Mineta K., Yamamoto Y., Yamazaki Y., Tanaka H., Tada Y., Saito K., Et al., Predicted expansion of the claudin multigene family, Febs Lett., 585, 4, pp. 606-612, (2011); Amasheh S., Meiri N., Gitter A.H., Schoneberg T., Mankertz J., Schulzke J.D., Et al., Claudin-2 expression induces cation-selective channels in tight junctions of epithelial cells, J Cell Sci., 115, 24, pp. 4969-4976, (2002); Suzuki T., Yoshinaga N., Tanabe S., Interleukin-6 (IL-6) regulates claudin-2 expression and tight junction permeability in intestinal epithelium, J Biol Chem., 286, 36, pp. 31263-31271, (2011); Rosenthal R., Milatz S., Krug S.M., Oelrich B., Schulzke J.D., Amasheh S., Et al., Claudin-2, a component of the tight junction, forms a paracellular water channel, J Cell Sci., 123, 11, pp. 1913-1921, (2010); Sakakibara A., Furuse M., Saitou M., Ando-Akatsuka Y., Tsukita S., Possible involvement of phosphorylation of occludin in tight junction formation, J Cell Biol., 137, 6, pp. 1393-1401, (1997); Oshima T., Koseki J., Chen X., Matsumoto T., Miwa H., Acid modulates the squamous epithelial barrier function by modulating the localization of claudins in the superficial layers, Lab Invest., 92, 1, pp. 22-31, (2012); Ren W., Yin J., Wu M., Liu G., Yang G., Xion Y., Et al., Serum amino acids profile and the beneficial effects of L-arginine or L-glutamine supplementation in dextran sulfate sodium colitis, PLoS One., 9, 2, (2014); Beutheu S., Ghouzali I., Galas L., Dechelotte P., Coeffier M., Glutamine and arginine improve permeability and tight junction protein expression in methotrexate-treated Caco-2 cells, Clin Nutr., 32, 5, pp. 863-869, (2013); Wang H., Zhang C., Wu G.Y., Sun Y.L., Wang B., He B.B., Et al., Glutamine enhances tight junction protein expression and modulates corticotropin-releasing factor signaling in the jejunum of weanling piglets, J Nutr., 145, 1, pp. 25-31, (2015); Pugh J.N., Sage S., Hutson M., Doran D.A., Fleming S.C., Highton J., Et al., Glutamine supplementation reduces markers of intestinal permeability during running in the heat in a dose-dependent manner, Eur J Appl Physiol., 117, 12, pp. 2569-2577, (2017); Wang Z.E., Wu D., Zheng L.W., Shi Y., Wang C., Zh C., Et al., Effects of glutamine on intestinal mucus barrier after burn injury, Am J Transl Res., 10, pp. 3833-3846, (2018); Yi D., Hou Y., Wang L., Ouyang W., Long M., Zhao D., Et al., L-Glutamine enhances enterocyte growth via activation of the mTOR signaling pathway independently of AMPK, Amino Acids., 47, 1, pp. 65-78, (2015); Wang B., Wu Z., Ji Y., Sun K., Dai Z., Wu G., Lglutamine enhances tight junction integrity by activating CaMK kinase 2-AMP-activated protein kinase signaling in intestinal porcine epithelial cells, J Nutr., 146, 3, pp. 501-508, (2016); Li N., Neu J., Glutamine deprivation alters intestinal tight junctions via a PI3-K/Akt mediated pathway in Caco-2 cells, J Nutr., 139, 4, pp. 710-714, (2009); DeMarco V.G., Li N., Thomas J., West C.M., Neu J., Glutamine and barrier function in cultured Caco-2 epithelial cell monolayers, J Nutr., 133, 7, pp. 2176-2179, (2003); Hu X., Deng J., Yu T., Chen S., Ge Y., Zhou Z., Et al., ATF4 deficiency promotes intestinal inflammation in mice by reducing uptake of glutamine and expression of antimicrobial peptides, Gastroenterology., 156, 4, pp. 1098-1111, (2019); Sido B., Seel C., Hochlehnert A., Breitkreutz R., Droge W., Low intestinal glutamine level and low glutaminase activity in Crohn's disease: A rational for glutamine supplementation?, Dig Dis Sci., 51, 12, pp. 2170-2179, (2006); Noth R., Hasler R., Stuber E., Ellrichmann M., Schafer H., Geismann C., Et al., Oral glutamine supplementation improves intestinal permeability dysfunction in a murine acute graftvs.-host disease model, Am J Physiol Gastrointest Liver Physiol., 304, 7, pp. G646-G654, (2013); Zund G., Madara J.L., Dzus A.L., Awtrey C.S., Colgan S.P., Interleukin-4 and interleukin-13 differentially regulate epithelial chloride secretion, J Biol Chem., 271, 13, pp. 7460-7464, (1996); Krug S.M., Bojarski C., Fromm A., Lee I.M., Dames P., Richter J.F., Et al., Tricellulin is regulated via interleukin-13-receptor alpha 2, affects macromolecule uptake, and is decreased in ulcerative colitis, Mucosal Immunol., 11, 2, pp. 345-356, (2018); Weber C.R., Raleigh D.R., Su L., Shen L., Sullivan E.A., Wang Y., Et al., Epithelial myosin light chain kinase activation induces mucosal interleukin-13 expression to alter tight junction ion selectivity, J Biol Chem., 285, 16, pp. 12037-12046, (2010); Kelly-Welch A.E., Hanson E.M., Boothby M.R., Keegan A.D., Interleukin-4 and interleukin-13 signaling connections maps, Science., 300, 5625, pp. 1527-1528, (2003); Amasheh M., Fromm A., Krug S.M., Amasheh S., Andres S., Zeitz M., Et al., TNF alpha-induced and berberine-antagonized tight junction barrier impairment via tyrosine kinase, Akt and NF kappa B signaling, J Cell Sci., 123, 23, pp. 4145-4155, (2010); Ceponis P.J., Botelho F., Richards C.D., McKay D.M., Interleukins 4 and 13 increase intestinal epithelial permeability by a phosphatidylinositol 3-kinase pathway. Lack of evidence for STAT 6 involvement, J Biol Chem., 275, 37, pp. 29132-29137, (2000); Berin M.C., Yang P.C., Ciok L., Waserman S., Perdue M.H., Role for IL-4 in macromolecular transport across human intestinal epithelium, Am J Physiol., 276, 5, pp. C1046-C1052, (1999); Ma T.Y., Iwamoto G.K., Hoa N.T., Akotia V., Pedram A., Boivin M.A., Et al., TNF-alpha-induced increase in intestinal epithelial tight junction permeability requires NF-kappa B activation, Am J Physiol Gastrointest Liver Physiol., 286, 3, pp. G367-G376, (2004); Al-Sadi R.M., Ma T.Y., IL-1beta causes an increase in intestinal epithelial tight junction permeability, J Immunol., 178, 7, pp. 4641-4649, (2007); Prasad S., Mingrino R., Kaukinen K., Hayes K.L., Powell R.M., MacDonald T.T., Et al., Inflammatory processes have differential effects on claudins 2, 3 and 4 in colonic epithelial cells, Lab Invest., 85, 9, pp. 1139-1162, (2005)","T. Oshima; Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo, 1-1 Mukogawa-cho, 663-8501, Japan; email: t-oshima@hyo-med.ac.jp","","S. Karger AG","","","","","","00122823","","DIGEB","31533100","English","Digestion","Article","Final","","Scopus","2-s2.0-85072630140"

"Lobo de Sá F.D.; Heimesaat M.M.; Bereswill S.; Nattramilarasu P.K.; Schulzke J.D.; Bücker R.","Lobo de Sá, F.D. (57211078887); Heimesaat, M.M. (6602258464); Bereswill, S. (7003804266); Nattramilarasu, P.K. (57192703302); Schulzke, J.D. (35502556700); Bücker, R. (10043068400)","57211078887; 6602258464; 7003804266; 57192703302; 35502556700; 10043068400","Resveratrol Prevents Campylobacter jejuni-Induced Leaky gut by Restoring Occludin and Claudin-5 in the Paracellular Leak Pathway","2021","Frontiers in Pharmacology","12","","640572","","","","20","10.3389/fphar.2021.640572","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85104968577&doi=10.3389%2ffphar.2021.640572&partnerID=40&md5=4718299bda9abb66672a10fdcd867cbd","Medical Department, Division of Gastroenterology, Infectious Diseases, Rheumatology, Nutritional Medicine/Clinical Physiology, Charité–Universitätsmedizin Berlin, Berlin, Germany; Institute of Microbiology, Infectious Diseases, and Immunology, Gastrointestinal Microbiology Research Group, Charité - Universitätsmedizin Berlin, Berlin, Germany","Lobo de Sá F.D., Medical Department, Division of Gastroenterology, Infectious Diseases, Rheumatology, Nutritional Medicine/Clinical Physiology, Charité–Universitätsmedizin Berlin, Berlin, Germany; Heimesaat M.M., Institute of Microbiology, Infectious Diseases, and Immunology, Gastrointestinal Microbiology Research Group, Charité - Universitätsmedizin Berlin, Berlin, Germany; Bereswill S., Institute of Microbiology, Infectious Diseases, and Immunology, Gastrointestinal Microbiology Research Group, Charité - Universitätsmedizin Berlin, Berlin, Germany; Nattramilarasu P.K., Medical Department, Division of Gastroenterology, Infectious Diseases, Rheumatology, Nutritional Medicine/Clinical Physiology, Charité–Universitätsmedizin Berlin, Berlin, Germany; Schulzke J.D., Medical Department, Division of Gastroenterology, Infectious Diseases, Rheumatology, Nutritional Medicine/Clinical Physiology, Charité–Universitätsmedizin Berlin, Berlin, Germany; Bücker R., Medical Department, Division of Gastroenterology, Infectious Diseases, Rheumatology, Nutritional Medicine/Clinical Physiology, Charité–Universitätsmedizin Berlin, Berlin, Germany","Campylobacter jejuni is a bacterial human pathogen causing gastroenteritis and sequelae like irritable bowel syndrome. Epidemiologists count the human campylobacteriosis by C. jejuni as the most common foodborne zoonosis and bacterial diarrheal disease worldwide. Based on bioinformatics predictions for potential protective compounds in campylobacteriosis, the question was raised whether the plant-based polyphenol resveratrol is sufficient to attenuate intestinal epithelial damage induced by C. jejuni. We investigated this by performing experimental infection studies in an epithelial cell culture and the secondary abiotic IL-10−/− mouse model. In C. jejuni-infected human colonic HT-29/B6 cell monolayers, transepithelial electrical resistance (TER) was decreased and the paracellular marker flux of fluorescein (332 Da) increased. Concomitantly, the tight junction (TJ) proteins occludin and claudin-5 were re-distributed off the tight junction domain. This was accompanied by an increased induction of epithelial apoptosis, both changes contributing to compromised barrier function and the opening of the leak pathway induced by C. jejuni. In parallel, the recovery experiments with the application of resveratrol revealed a functional improvement of the disturbed epithelial barrier in both models in vitro and in vivo. During treatment with resveratrol, TJ localization of occludin and claudin-5 was fully restored in the paracellular domain of HT-29/B6 cells. Moreover, resveratrol decreased the rate of epithelial apoptosis. These resveratrol-induced molecular and cellular effects would therefore be expected to improve epithelial barrier function, thereby minimizing the so-called leaky gut phenomenon. In conclusion, the induction of the leak pathway by C. jejuni and the restoration of barrier function by resveratrol demonstrates its effectiveness as a potential preventive or therapeutic method of mitigating the leaky gut associated with campylobacteriosis. © Copyright © 2021 Lobo de Sá, Heimesaat, Bereswill, Nattramilarasu, Schulzke and Bücker.","epithelial apoptosis; epithelial barrier; leak flux; leak pathway; leaky gut model; mucosal permeability; tight junction","claudin 5; fluorescein; gamma interferon; interleukin 10; interleukin 1beta; occludin; resveratrol; tumor necrosis factor; animal experiment; animal model; animal tissue; apoptosis; Article; bioinformatics; Campylobacter enteritis; cellular distribution; controlled study; cytokine production; cytokine release; drug mechanism; epithelium cell; experimental infection; HT-29 cell line; human; human cell; in vitro study; in vivo study; infection prevention; intestine epithelium; intestine injury; intestine mucosa permeability; mouse; nonhuman; permeability barrier; protein expression; protein localization; tight junction; transepithelial resistance","","fluorescein, 2321-07-5, 91316-42-6; gamma interferon, 82115-62-6; occludin, 176304-61-3; resveratrol, 501-36-0","","","German Federal Ministries of Economy and Energy, (ZF4117904 AJ8); University of Leeds; Deutsche Forschungsgemeinschaft, DFG; Bundesministerium für Bildung und Forschung, BMBF, (DFG Schu559/11-3, IP7/ 01KI1725D, IP8/01KI2007D); Charité – Universitätsmedizin Berlin","Funding text 1: We acknowledge support from the German Research Foundation and the Open Access Publication Fund of the Charité–Universitätsmedizin Berlin. This work was supported by the German Federal Ministry of Education and Research (BMBF) in frame of the zoonoses research consortium PAC-Campylobacter to RB and JDS (project IP8/01KI2007D) and to MMH and SB (IP7/ 01KI1725D). This work was supported by the German Research Foundation (DFG Schu559/11-3) to JDS. Furthermore, MMH and SB received support from the German Federal Ministries of Economy and Energy (ZIM; ZF4117904 AJ8).; Funding text 2: We acknowledge the excellent technical support of Anja Fromm and In-Fah Maria Lee. We wish to thank Professor Geoffrey Sandle (University of Leeds, United Kingdom) for proof reading and editing the manuscript.","Al-Salloom F., Mahmeed A.A., Ismaeel A., Botta G.A., Bakhiet M., Campylobacter-stimulated INT407 cells produce dissociated cytokine profiles, J. Infect, 47, 3, pp. 217-224, (2003); Amasheh M., Fromm A., Krug S.M., Amasheh S., Andres S., Zeitz M., Et al., TNFα-induced and berberine-antagonized tight junction barrier impairment via tyrosine kinase, Akt and NFκB signaling, J. Cell Sci, 123, 23, pp. 4145-4155, (2010); Bereswill S., Munoz M., Fischer A., Plickert R., Haag L.-M., Otto B., Et al., Anti-inflammatory effects of resveratrol, curcumin and simvastatin in acute small intestinal inflammation, PLoS One, 5, 12, (2010); Bergann T., Ploger S., Fromm A., Zeissig S., Borden S.A., Fromm M., Et al., A colonic mineralocorticoid receptor cell model expressing epithelial Na+ channels, Biochem. Biophys. Res. Comm, 381, 2, pp. 280-285, (2009); Berman A.Y., Motechin R.A., Wiesenfeld M.Y., Holz M.K., The therapeutic potential of resveratrol: a review of clinical trials, npj Precision Onc, 1, (2017); Black R.E., Levine M.M., Clements M.L., Hughes T.P., Blaser M.J., Experimental Campylobacter jejuni infection in humans, J. Infect. Dis, 157, 3, pp. 472-479, (1988); Bojarski C., Weiske J., Schoneberg T., Schroder W., Mankertz J., Schulzke J.D., Et al., The specific fates of tight junction proteins in apoptotic epithelial cells, J. Cell Sci, 117, 10, pp. 2097-2107, (2004); Bucker R., Krug S.M., Fromm A., Nielsen H.L., Fromm M., Nielsen H., Et al., Campylobacter fetusimpairs barrier function in HT-29/B6 cells through focal tight junction alterations and leaks, Ann. N.Y. Acad. Sci, 1405, 1, pp. 189-201, (2017); Bucker R., Krug S.M., Moos V., Bojarski C., Schweiger M.R., Kerick M., Et al., Erratum: Campylobacter jejuni impairs sodium transport and epithelial barrier function via cytokine release in human colon, Mucosal Immunol, 11, 2, pp. 575-577, (2018); Bucker R., Schulz E., Gunzel D., Bojarski C., Lee I.F.M., John L.J., Et al., α-Haemolysin ofEscherichia coliin IBD: a potentiator of inflammatory activity in the colon, Gut, 63, 12, pp. 1893-1901, (2014); Butkevych E., Lobo de Sa F.D., Nattramilarasu P.K., Bucker R., Contribution of epithelial apoptosis and subepithelial immune responses in Campylobacter jejuni-induced barrier disruption, Front. Microbiol, 11, (2020); Cao S., Shen Z., Wang C., Zhang Q., Hong Q., He Y., Et al., Resveratrol improves intestinal barrier function, alleviates mitochondrial dysfunction and induces mitophagy in diquat challenged piglets1, Food Funct, 10, 1, pp. 344-354, (2019); Carrasco-Pozo C., Morales P., Gotteland M., Polyphenols protect the epithelial barrier function of Caco-2 cells exposed to indomethacin through the modulation of occludin and zonula occludens-1 expression, J. Agric. Food Chem, 61, 22, pp. 5291-5297, (2013); Chen M.L., Ge Z., Fox J.G., Schauer D.B., Disruption of tight junctions and induction of proinflammatory cytokine responses in colonic epithelial cells by Campylobacter jejuni, Iai, 74, 12, pp. 6581-6589, (2006); Chudzinska M., Rogowicz D., Wolowiec L., Banach J., Sielski S., Bujak R., Et al., Resveratrol and cardiovascular system-the unfulfilled hopes, Ir J. Med. Sci, (2020); Dampf Stone A., Batie S.F., Sabir M.S., Jacobs E.T., Lee J.H., Whitfield G.K., Et al., Resveratrol potentiates vitamin D and nuclear receptor signaling, J. Cell. Biochem, 116, 6, pp. 1130-1143, (2015); Edwards L.A., Nistala K., Mills D.C., Stephenson H.N., Zilbauer M., Wren B.W., Et al., Delineation of the innate and adaptive T-cell immune outcome in the human host in response to Campylobacter jejuni infection, PLoS One, 5, 11, (2010); El-Kott A.F., Shati A.A., Ali Al-Kahtani M., Alharbi S.A., The apoptotic effect of resveratrol in ovarian cancer cells is associated with downregulation of galectin-3 and stimulating miR-424-3p transcription, J. Food Biochem, 43, 12, (2019); Feng L., Yasmeen R., Schoene N.W., Lei K.Y., Wang T.T.Y., Resveratrol differentially modulates immune responses in human THP-1 monocytes and macrophages, Nutr. Res, 72, pp. 57-69, (2019); Gao X., Xu Y.X., Janakiraman N., Chapman R.A., Gautam∗ S.C., Immunomodulatory activity of resveratrol: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production11Abbreviations: CTLs, cytotoxic T lymphocytes; LAK cells, lymphokine activated killer cells; IL-2, interleukin-2; IFN-γ, interferon-gamma; TNF-α, tumor necrosis factor-α NF-κB, nuclear factor kappa B; Con A, concanavalin A; HBSS, Hanks' balanced salt solution; DTT, dithiothreitol; PMSF, phenylmethylsulfonyl fluoride; RT-PCR, reverse transcription-polymerase chain reaction; LPS, lipopolysaccharide; and EMSA, electrophoretic mobility shift assay, Biochem. Pharmacol, 62, pp. 1299-1308, (2001); Golz G., Karadas G., Alutis M.E., Fischer A., Kuhl A.A., Breithaupt A., Et al., Arcobacter butzleri induce colonic, extra-intestinal and systemic inflammatory responses in Gnotobiotic IL-10 deficient mice in a strain-dependent manner, PLoS One, 10, 9, (2015); Haag L.-M., Fischer A., Otto B., Plickert R., Kuhl A.A., Gobel U.B., Et al., Campylobacter jejuni induces acute enterocolitis in Gnotobiotic IL-10−/− mice via toll-like-receptor-2 and -4 signaling, PLoS One, 7, 7, (2012); Harrer A., Bucker R., Boehm M., Zarzecka U., Tegtmeyer N., Sticht H., Et al., Campylobacter jejuni enters gut epithelial cells and impairs intestinal barrier function through cleavage of occludin by serine protease HtrA, Gut Pathog, 11, (2019); Heimesaat M.M., Escher U., Grunau A., Kuhl A.A., Bereswill S., Multidrug-resistant Pseudomonas aeruginosa accelerate intestinal, extra-intestinal, and systemic inflammatory responses in human microbiota-associated mice with subacute ileitis, Front. Immunol, 10, (2019); Heimesaat M.M., Mousavi S., Escher U., Lobo de Sa F.D., Peh E., Schulzke J.-D., Et al., Resveratrol alleviates acute Campylobacter jejuni induced enterocolitis in a preclinical murine intervention study, Microorganisms, 8, 12, (2020); Hollander D., Intestinal permeability, leaky gut, and intestinal disorders, Curr. Gastroenterol. Rep, 1, 5, pp. 410-416, (1999); Klancnik A., Sikic Pogacar M., Trost K., Tusek Znidaric M., Mozetic Vodopivec B., Smole Mozina S., Anti-Campylobacter activity of resveratrol and an extract from waste Pinot noir grape skins and seeds, and resistance of Camp. jejuni planktonic and biofilm cells, mediated via the CmeABC efflux pump, J. Appl. Microbiol, 122, 1, pp. 65-77, (2017); Koushki M., Amiri-Dashatan N., Ahmadi N., Abbaszadeh H.A., Rezaei-Tavirani M., Resveratrol: a miraculous natural compound for diseases treatment, Food Sci. Nutr, 6, 8, pp. 2473-2490, (2018); Koushki M., Dashatan N.A., Meshkani R., Effect of resveratrol supplementation on inflammatory markers: a systematic review and meta-analysis of randomized controlled trials, Clin. Ther, 40, 7, pp. 1180-1192, (2018); Kundu J.K., Surh Y.-J., Molecular basis of chemoprevention by resveratrol: NF-κB and AP-1 as potential targets, Mutat. Research/Fundamental Mol. Mech. Mutagenesis, 555, 1-2, pp. 65-80, (2004); Ling K.-H., Wan M.L.Y., El-Nezami H., Wang M., Protective capacity of resveratrol, a natural polyphenolic compound, against deoxynivalenol-induced intestinal barrier dysfunction and bacterial translocation, Chem. Res. Toxicol, 29, 5, pp. 823-833, (2016); Liu J., Zhang X., Yan T., Wang F., Li J., Jia L., Et al., Screening of an endophyte transforming polydatin to resveratrol from Reynoutria japonica houtt and the optimization of its transformation parameters, Molecules, 25, 20, (2020); Lobo de Sa F.D., Butkevych E., Nattramilarasu P.K., Fromm A., Mousavi S., Moos V., Et al., Curcumin mitigates immune-induced epithelial barrier dysfunction by Campylobacter jejuni, Int. J. Mol. Sci, 20, 19, (2019); Lobo de Sa F.D., Schulzke J.D., Bucker R., Diarrheal mechanisms and the role of intestinal barrier dysfunction in Campylobacter infections, Curr. Top. Microbiol. Immunol, 431, pp. 203-231, (2021); Luettig J., Rosenthal R., Lee I.F.M., Krug S.M., Schulzke J.D., The ginger component 6-shogaol prevents TNF-α-induced barrier loss via inhibition of PI3K/Akt and NF-κB signaling, Mol. Nutr. Food Res, 60, 12, pp. 2576-2586, (2016); Mayangsari Y., Suzuki T., Resveratrol ameliorates intestinal barrier defects and inflammation in colitic mice and intestinal cells, J. Agric. Food Chem, 66, 48, pp. 12666-12674, (2018); Mousavi S., Bereswill S., Heimesaat M., Novel clinical Campylobacter jejuni infection models based on sensitization of mice to lipooligosaccharide, a major bacterial factor triggering innate immune responses in human campylobacteriosis, Microorganisms, 8, 4, (2020); Mousavi S., Lobo de Sa F.D., Schulzke J.-D., Bucker R., Bereswill S., Heimesaat M.M., Vitamin D in acute campylobacteriosis-results from an intervention study applying a clinical Campylobacter jejuni induced enterocolitis model, Front. Immunol, 10, (2019); Nielsen H.L., Engberg J., Ejlertsen T., Bucker R., Nielsen H., Short-term and medium-term clinical outcomes of Campylobacter concisus infection, Clin. Microbiol. Infect, 18, 11, pp. E459-E465, (2012); Otto B., Haag L.-M., Fischer A., Plickert R., Kuhl A.A., Gobel U.B., Et al., Campylobacter jejuniinduces extra-intestinal immune responses via toll-like-receptor-4 signaling in conventional IL-10 deficient mice with chronic colitis, Eur. J. Microbiol. Immunol. (Bp), 2, 3, pp. 210-219, (2012); Rees L.E.N., Cogan T.A., Dodson A.L., Birchall M.A., Bailey M., Humphrey T.J., Campylobacter and IFNγ interact to cause a rapid loss of epithelial barrier integrity, Inflamm. Bowel Dis, 14, 3, pp. 303-309, (2008); Rosenthal R., Luettig J., Hering N.A., Krug S.M., Albrecht U., Fromm M., Et al., Myrrh exerts barrier-stabilising and -protective effects in HT-29/B6 and Caco-2 intestinal epithelial cells, Int. J. Colorectal Dis, 32, 5, pp. 623-634, (2017); Salehi B., Mishra A., Nigam M., Sener B., Kilic M., Sharifi-Rad M., Et al., Resveratrol: a double-edged sword in health benefits, Biomedicines, 6, 3, (2018); Schulzke J.-D., Bojarski C., Zeissig S., Heller F., Gitter A.H., Fromm M., Disrupted barrier function through epithelial cell apoptosis, Ann. New York Acad. Sci, 1072, pp. 288-299, (2006); Shane S.M., The significance ofcampylobacter jejuniinfection in poultry: a review, Avian Pathol, 21, 2, pp. 189-213, (1992); Singh S.K., Banerjee S., Acosta E.P., Lillard J.W., Singh R., Resveratrol induces cell cycle arrest and apoptosis with docetaxel in prostate cancer cells via a p53/p21WAF1/CIP1 and p27KIP1 pathway, Oncotarget, 8, 10, pp. 17216-17228, (2017); Singh U.P., Singh N.P., Singh B., Hofseth L.J., Price R.L., Nagarkatti M., Et al., Resveratrol (Trans-3,5,4′-trihydroxystilbene) induces silent mating type information regulation-1 and down-regulates nuclear transcription factor-κb activation to abrogate dextran sulfate sodium-induced colitis, J. Pharmacol. Exp. Ther, 332, 3, pp. 829-839, (2010); Stahl M., Ries J., Vermeulen J., Yang H., Sham H.P., Crowley S.M., Et al., A novel mouse model of Campylobacter jejuni gastroenteritis reveals key pro-inflammatory and tissue protective roles for Toll-like receptor signaling during infection, Plos Pathog, 10, 7, (2014); Stahl M., Vallance B.A., Insights intoCampylobacter jejunicolonization of the mammalian intestinal tract using a novel mouse model of infection, Gut Microbes, 6, 2, pp. 143-148, (2015); Tsai S.H., Lin-Shiau S.Y., Lin J.K., Suppression of nitric oxide synthase and the down-regulation of the activation of NFκB in macrophages by resveratrol, Br. J. Pharmacol, 126, 3, pp. 673-680, (1999); Vandamme P., Falsen E., Rossau R., Hoste B., Segers P., Tytgat R., Et al., Revision of Campylobacter, Helicobacter, and Wolinella taxonomy: emendation of generic descriptions and proposal of Arcobacter gen. nov, Int. J. Syst. Bacteriol, 41, 1, pp. 88-103, (1991); von Klitzing E., Ekmekciu I., Kuhl A.A., Bereswill S., Heimesaat M.M., Intestinal, extra-intestinal and systemic sequelae of Toxoplasma gondii induced acute ileitis in mice harboring a human gut microbiota, PLoS One, 12, 4, (2017); Wang N., Han Q., Wang G., Ma W.P., Wang J., Wu W.X., Et al., Resveratrol protects oxidative stress-induced intestinal epithelial barrier dysfunction by upregulating heme oxygenase-1 expression, Dig. Dis. Sci, 61, 9, pp. 2522-2534, (2016); Wassenaar T.M., Blaser M.J., Pathophysiology of Campylobacter jejuni infections of humans, Microbes Infect, 1, 12, pp. 1023-1033, (1999); Weiskirchen S., Weiskirchen R., Resveratrol: how much wine do you have to drink to stay healthy?, Adv. Nutr, 7, 4, pp. 706-718, (2016); Yao J., Wang J.Y., Liu L., Li Y.X., Xun A.Y., Zeng W.S., Et al., Anti-oxidant effects of resveratrol on mice with DSS-induced ulcerative colitis, Arch. Med. Res, 41, 4, pp. 288-294, (2010); Yao J., Wei C., Wang J.Y., Zhang R., Li Y.X., Wang L.S., Effect of resveratrol on Treg/Th17 signaling and ulcerative colitis treatment in mice, Wjg, 21, 21, pp. 6572-6581, (2015); Zhang M., Xue Y., Chen H., Meng L., Chen B., Gong H., Et al., Resveratrol inhibits MMP3 and MMP9 expression and secretion by suppressing TLR4/NF-κB/STAT3 activation in ox-LDL-treated HUVECs, Oxid Med. Cell Longev, (2019); Zhao L., Lee J.Y., Hwang D.H., Inhibition of pattern recognition receptor-mediated inflammation by bioactive phytochemicals, Nutr. Rev, 69, 6, pp. 310-320, (2011); Zhong M., Cheng G.F., Wang W.J., Guo Y., Zhu X.Y., Zhang J.T., Inhibitory effect of resveratrol on interleukin 6 release by stimulated peritoneal macrophages of mice, Phytomedicine, 6, 2, pp. 79-84, (1999)","R. Bücker; Medical Department, Division of Gastroenterology, Infectious Diseases, Rheumatology, Nutritional Medicine/Clinical Physiology, Charité–Universitätsmedizin Berlin, Berlin, Germany; email: roland-felix.buecker@charite.de; ","","Frontiers Media S.A.","","","","","","16639812","","","","English","Front. Pharmacol.","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85104968577"

"Chao G.; Wang Z.; Yang Y.; Zhang S.","Chao, Guanqun (24780251800); Wang, Zhaojun (57220587874); Yang, Yi (57221747637); Zhang, Shuo (57171163400)","24780251800; 57220587874; 57221747637; 57171163400","LncRNA H19 as a Competing Endogenous RNA to Regulate AQP Expression in the Intestinal Barrier of IBS-D Patients","2021","Frontiers in Physiology","11","","602076","","","","9","10.3389/fphys.2020.602076","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100016787&doi=10.3389%2ffphys.2020.602076&partnerID=40&md5=edc87c5aefbb99c177443c3e0dffdb0c","Department of General Practice, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China; Department of Gastroenterology, The First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, China","Chao G., Department of General Practice, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China; Wang Z., Department of Gastroenterology, The First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, China; Yang Y., Department of Gastroenterology, The First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, China; Zhang S., Department of Gastroenterology, The First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, China","Objective: The study aimed to investigate the role of Long non-coding RNA (LncRNA) H19 in the pathogenesis of Diarrhea Irritable Bowel Syndrome (IBS-D), and further to the regulatory effect of LncRNA H19 on AQP1, 3 in the intestinal mucosa of IBS-D patients, so as to seek a new way to elucidate the mechanism of IBS in clinic. Methods: The levels of LncRNA H19, AQP1, and AQP3 were detected in colonic tissues of IBS-D patients, compared with that in healthy controls. Through RNA gene interference and activation methods, small activating RNA (saRNA) and small interfering (siRNA) were transfered into Caco-2 cells in vitro experiment, and sub-group for two control group, siH19 empty vector group, siH19 interference group, overexpression H19 vector group, and overexpression H19 empty vector group. Quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR) and Western blot were applied to evaluate the expression levels of LncRNA H19 and the amount of AQP1 and AQP3 protein expression, respectively. Results: Compared with healthy volunteers, the levels of LncRNA H19, AQP1, and AQP3 in the colonic mucosa of IBS-D patients were significantly decreased (P < 0.05). The results in vitro transfection experiment revealed that the level of LncRNA H19 in the siH19 interference group was significantly declined (P < 0.05), while there was a remarkable increase in the overexpression H19 vector group (P < 0.05), compared with the corresponding control groups. The expression of AQP1 and AQP3 in Caco-2 cells was of positive correlation with the level of LncRNA H19. Conclusion: That the down-regulation of LncRNA H19 resulted in the expression changes of AQP1 and AQP3 may play an important role in the occurrence and development of IBS-D. © Copyright © 2021 Chao, Wang, Yang and Zhang.","AQP1; AQP3; IBS-D; LncRNA H19; mechanism","aquaporin 1; aquaporin 3; RNA; RNA H19; small activating RNA; small interfering RNA; unclassified drug; adult; aged; Article; Caco-2 cell line; colon tissue; controlled study; diarrhea; down regulation; gene expression level; gene function; gene overexpression; genetic transfection; human; human tissue; in vitro study; intestine mucosa; irritable colon; pathogenesis; protein expression; real time reverse transcription polymerase chain reaction; RNA interference; Western blotting","","aquaporin 1, 146410-94-8, 149348-86-7; RNA, 63231-63-0","","","Medical Health Platform Plan Projects of Zhejiang Province, (2015RCA020, LY16H030010); Medicine and Health Science and Technology Plan Projects in Zhejiang Province, (2017KY413); Traditional Chinese Medicine Science and Technology Plan of Zhejiang Province, (2014ZA030, 2015ZZ012, 2016ZB071, 2017ZA089); Zhejiang Provincial Natural Science Foundation of China, (LY18H030001); National Natural Science Foundation of China, NSFC, (81573760, 81973598, 82074214)","This research was supported by funding from the National Natural Science Foundation of China (82074214, 81973598, and 81573760), Zhejiang Provincial Natural Science Foundation of China under Grant No. LY18H030001, the Medicine and Health Science and Technology Plan Projects in Zhejiang Province (2017KY413), Traditional Chinese Medicine Science and Technology Plan of Zhejiang Province (2017ZA089, 2016ZB071, 2015ZZ012, and 2014ZA030), Medical Health Platform Plan Projects of Zhejiang Province (2015RCA020), and Zhejiang Provincial Natural Science Foundation of China (LY16H030010).","Bartolomei M.S., Zemel S., Tilghman S.M., Parental imprinting of the mouse H19 gene, Nature, 351, pp. 153-155, (1991); Camilleri M., Carlson P., Chedid V., Vijayvargiya P., Burton D., Busciglio I., Aquaporin Expression in Colonic Mucosal Biopsies From Irritable Bowel Syndrome With Diarrhea, Clin. Transl. Gastroenterol, 10, e00019, (2019); Chao G.Q., Zhang S., Aquaporins 1, 3 and 8 expression and cytokines in irritable bowel syndrome rats’colon via cAMP-PKA pathway, Int. J. Clin. Exp. Pathol, 11, pp. 4117-4123, (2018); Chen S.W., Wang P.Y., Liu Y.C., Sun L., Zhu J., Zuo S., Et al., Effect of Long Noncoding RNA H19 Overexpression on Intestinal Barrier Function and Its Potential Role in the Pathogenesis of Ulcerative Colitis, Inflamm. Bowel Dis, 22, pp. 2582-2592, (2016); Drossman D.A., Hasler W.L., Rome IV-Functional GI Disorders: Disorders of Gut-Brain Interaction, Gastroenterology, 150, pp. 1257-1261, (2016); Fang Y., Hu J., Wang Z., Zong H., Zhang L., Zhang R., Et al., LncRNA H19 functions as an Aquaporin 1 competitive endogenous RNA to regulate microRNA-874 expression in LPS sepsis, Biomed. Pharmacother, 105, pp. 1183-1191, (2018); Finotti A., Fabbri E., Lampronti I., Gasparello J., Borgatti M., Gambari R., MicroRNAs and Long Non-coding RNAs in Genetic Diseases, Mol. Diagn. Ther, 23, pp. 155-171, (2019); Geng H., Bu H.F., Liu F., Wu L., Pfeifer K., Chou P.M., Et al., In Inflamed Intestinal Tissues and Epithelial Cells, Interleukin 22 Signaling Increases Expression of H19 Long Noncoding RNA, Which Promotes Mucosal Regeneration, Gastroenterology, 155, pp. 144-155, (2018); Gracie D.J., Ford A.C., Irritable Bowel Syndrome-Type Symptoms Are Associated With Psychological Comorbidity, Reduced Quality of Life, and Health Care Use in Patients With Inflammatory Bowel Disease, Gastroenterology, 153, pp. 324-325, (2017); Hou Q., Huang Y., Zhu S., Li P., Chen X., Hou Z., Et al., MiR-144 Increases Intestinal Permeability in IBS-D Rats by Targeting OCLN and ZO1, Cell Physiol. Biochem, 44, pp. 2256-2268, (2017); Hou Q., Zhu S., Zhang C., Huang Y., Guo Y., Li P., Et al., Berberine improves intestinal epithelial tight junctions by upregulating A20 expression in IBS-D mice, Biomed. Pharmacother, 118, (2019); Ikarashi N., Mizukami N., Kon R., Kaneko M., Uchino R., Fujisawa I., Et al., Study of the Mechanism Underlying the Onset of Diabetic Xeroderma Focusing on an Aquaporin-3 in a Streptozotocin-Induced Diabetic Mouse Model, Int. J. Mol. Sci, 20, 3782, (2019); Juan V., Crain C., Wilson C., Evidence for evolutionarily conserved secondary structure in the H19 tumor suppressor RNA, Nucleic Acids Res, 28, pp. 1221-1227, (2000); Kesuma Y., Firmansyah A., Bardosono S., Sari I.P., Kurniawan A., Blastocystis ST-1 is associated with Irritable Bowel Syndrome-diarrhoea (IBS-D) in Indonesian adolescences, Parasite Epidemiol. Control, 6, e00112, (2019); Lei Y., Guo W., Chen B., Chen L., Gong J., Li W., Tumor-released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in non-small cell lung cancer, Oncol Rep, 40, pp. 3438-3446, (2018); Leighton P.A., Ingram R.S., Eggenschwiler J., Efstratiadis A., Tilghman S.M., Disruption of imprinting caused by deletion of the H19 gene region in mice, Nature, 375, pp. 34-39, (1995); Li C., Zhuang M., Zhu B., Li Y., Zhang W., Yan H., Et al., Epidermal growth factor regulation by autophagy-mediated lncRNA H19 in murine intestinal tract after severe burn, J. Cell Mol. Med, 24, pp. 5878-5887, (2020); Ma T., Jayaraman S., Wang K.S., Song Y., Yang B., Li J., Et al., Defective dietary fat processing in transgenic mice lacking aquaporin-1 water channels, Am. J. Physiol. Cell. Physiol, 280, pp. C126-C134, (2001); Nielsen S., Smith B.L., Christensen E.I., Agre P., Distribution of the aquaporin CHIP in secretory and resorptive epithelia and capillary endothelia, Proc. Natl. Acad. Sci. USA, 90, pp. 7275-7279, (1993); Pan J.X., LncRNA H19 promotes atherosclerosis by regulating MAPK and NF-kB signaling pathway, Eur. Rev. Med. Pharmacol. Sci, 21, pp. 322-328, (2017); Pan L.Y., Chen Y.F., Li H.C., Bi L.M., Sun W.J., Sun G.F., Et al., Dachengqi Decoction Attenuates Intestinal Vascular Endothelial Injury in Severe Acute Pancreatitis in Vitro and in Vivo, Cell Physiol. Biochem, 44, pp. 2395-2406, (2017); Su Z., Zhi X., Zhang Q., Yang L., Xu H., Xu Z., LncRNA H19 functions as a competing endogenous RNA to regulate AQP3 expression by sponging miR-874 in the intestinal barrier, FEBS Lett, 590, pp. 1354-1364, (2016); Thomas A.A., Biswas S., Feng B., Chen S., Gonder J., Chakrabarti S., lncRNA H19 prevents endothelial-mesenchymal transition in diabetic retinopathy, Diabetologia, 62, pp. 517-530, (2019); Xiao Z., Qiu Y., Lin Y., Medina R., Zhuang S., Rosenblum J.S., Et al., Blocking lncRNA H19-miR-19a-Id2 axis attenuates hypoxia/ischemia induced neuronal injury, Aging, 11, pp. 3585-3600, (2019); Zhang W., Xu Y., Chen Z., Xu Z., Xu H., Knockdown of aquaporin 3 is involved in intestinal barrier integrity impairment, FEBS Lett, 585, pp. 3113-3119, (2011); Zhao G.X., Dong P.P., Peng R., Li J., Zhang D.Y., Wang J.Y., Et al., Expression, localization and possible functions of aquaporins 3 and 8 in rat digestive system, Biotech. Histochem, 91, pp. 269-276, (2016); Zhi X., Tao J., Li Z., Jiang B., Feng J., Yang L., Et al., MiR-874 promotes intestinal barrier dysfunction through targeting AQP3 following intestinal ischemic injury, FEBS Lett, 588, pp. 757-763, (2014); Zou T., Jaladanki S.K., Liu L., Xiao L., Chung H.K., Wang J.Y., Et al., H19 Long Noncoding RNA Regulates Intestinal Epithelial Barrier Function via MicroRNA 675 by Interacting with RNA-Binding Protein HuR, Mol. Cell Biol, 36, pp. 1332-1341, (2016)","S. Zhang; Department of Gastroenterology, The First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, China; email: zhangshuotcm@163.com","","Frontiers Media S.A.","","","","","","1664042X","","","","English","Front. Physiol.","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85100016787"

"Khoshbin K.; Khanna L.; Maselli D.; Atieh J.; Breen-Lyles M.; Arndt K.; Rhoten D.; Dyer R.B.; Singh R.J.; Nayar S.; Bjerkness S.; Harmsen W.S.; Busciglio I.; Camilleri M.","Khoshbin, Katayoun (57193934219); Khanna, Lehar (57220210306); Maselli, Daniel (57208710617); Atieh, Jessica (57217292842); Breen-Lyles, Margaret (57195807544); Arndt, Kayla (57215864406); Rhoten, Deborah (35765672600); Dyer, Roy B. (7202532150); Singh, Ravinder J. (55994265700); Nayar, Sunita (57194201242); Bjerkness, Sandra (14019050700); Harmsen, William S. (7005973985); Busciglio, Irene (17343569900); Camilleri, Michael (7102181053)","57193934219; 57220210306; 57208710617; 57217292842; 57195807544; 57215864406; 35765672600; 7202532150; 55994265700; 57194201242; 14019050700; 7005973985; 17343569900; 7102181053","Development and Validation of Test for “Leaky Gut” Small Intestinal and Colonic Permeability Using Sugars in Healthy Adults","2021","Gastroenterology","161","2","","463","475.e13","","30","10.1053/j.gastro.2021.04.020","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85109077620&doi=10.1053%2fj.gastro.2021.04.020&partnerID=40&md5=196f24d5006757425023190c8436047d","Clinical Enteric NeuroscienceTranslational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States; Clinical Research and Trials Unit, Mayo Clinic, Rochester, MN, United States; Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States","Khoshbin K., Clinical Enteric NeuroscienceTranslational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States; Khanna L., Clinical Enteric NeuroscienceTranslational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States; Maselli D., Clinical Enteric NeuroscienceTranslational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States; Atieh J., Clinical Enteric NeuroscienceTranslational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States; Breen-Lyles M., Clinical Enteric NeuroscienceTranslational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States; Arndt K., Clinical Enteric NeuroscienceTranslational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States; Rhoten D., Clinical Enteric NeuroscienceTranslational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States; Dyer R.B., Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States; Singh R.J., Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States; Nayar S., Clinical Research and Trials Unit, Mayo Clinic, Rochester, MN, United States; Bjerkness S., Clinical Research and Trials Unit, Mayo Clinic, Rochester, MN, United States; Harmsen W.S., Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States; Busciglio I., Clinical Enteric NeuroscienceTranslational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States; Camilleri M., Clinical Enteric NeuroscienceTranslational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States","Background: Oral monosaccharides and disaccharides are used to measure in vivo human gut permeability through urinary excretion. Aims: The aims were as follows: (1) to obtain normative data on small intestinal and colonic permeability; (2) to assess variance on standard 16 g fiber diet performed twice; (3) to determine whether dietary fiber influences gut permeability measurements; and (4) to present pilot data using 2 selected probes in patients with diarrhea-predominant irritable bowel syndrome (IBS-D). Methods: Sixty healthy female and male adults, age 18–70 years, participated in 3 randomized studies (2 studies on 16.25 g and 1 study on 32.5 g fiber) in otherwise standardized diets. At each test, the following sugars were ingested: 12C-mannitol, 13C-mannitol, rhamnose (monosaccharides), sucralose, and lactulose (disaccharides). Standardized meals were administered from 24 hours before and during 24 hours post-sugars with 3 urine collections: 0–2, 2–8, and 8–24 hours. Sugars were measured using high-performance liquid chromatography–tandem mass spectrometry. Eighteen patients with IBS-D underwent 24-hour excretion studies after oral 13C-mannitol and lactulose. Results: Baseline sugars (>3-fold above lower limits of quantitation) were identified in the 3 studies: 12C-mannitol in all participants; sucralose in 4–8, and rhamnose in 1–3. Median excretions/24 h (percentage of administered dose) for 13C-mannitol, rhamnose, lactulose, and sucralose were ∼30%, ∼15%, 0.32%, and 2.3%, respectively. 13C-mannitol and rhamnose reflected mainly small intestinal permeability. Intraindividual saccharide excretions were consistent, with minor differences with 16.25 g vs 32.5 g fiber diets. Median interindividual coefficient of variation was 76.5% (10–90 percentile: 34.6–111.0). There were no significant effects of sex, age, or body mass index on permeability measurements in health. 13C-mannitol measurements are feasible in IBS-D. Conclusions: Baseline 12C-mannitol excretion precludes its use; 13C-mannitol is the preferred probe for small intestinal permeability. © 2021 The Authors","Barrier; Lactulose; Mannitol; Sucralose","Administration, Oral; Adult; Aged; Biomarkers; Chromatography, High Pressure Liquid; Colon; Cross-Over Studies; Diagnostic Techniques, Digestive System; Diarrhea; Dietary Fiber; Disaccharides; Female; Healthy Volunteers; Humans; Intestinal Mucosa; Intestine, Small; Irritable Bowel Syndrome; Male; Middle Aged; Monosaccharides; Permeability; Pilot Projects; Predictive Value of Tests; Renal Elimination; Reproducibility of Results; Tandem Mass Spectrometry; Urinalysis; carbohydrate; lactulose; mannitol; rhamnose; sucralose; biological marker; disaccharide; monosaccharide; adult; age; aged; Article; body mass; clinical article; cohort analysis; colon; female; glucose urine level; high fiber diet; high performance liquid chromatography; human; human experiment; intestine mucosa permeability; irritable colon; male; normal human; pilot study; sex difference; small intestine; tandem mass spectrometry; urinary excretion; urine sampling; administration and dosage; colon; comparative study; complication; controlled study; crossover procedure; diarrhea; dietary fiber; digestive system examination; intestine mucosa; irritable colon; metabolism; middle aged; oral drug administration; permeability; predictive value; randomized controlled trial; reproducibility; small intestine; urinalysis; urine","","lactulose, 4618-18-2; mannitol, 69-65-8, 87-78-5; rhamnose, 10485-94-6, 3615-41-6; sucralose, 56038-13-2; Biomarkers, ; Dietary Fiber, ; Disaccharides, ; Monosaccharides, ","","","Institute for the Advancement of Food and Nutrition Sciences; National Institutes of Health, NIH, (R01 DK115950); National Institutes of Health, NIH; National Center for Advancing Translational Sciences, NCATS, (UL1TR002377); National Center for Advancing Translational Sciences, NCATS","Funding text 1: Funding This work was supported by the Institute for the Advancement of Food and Nutrition Sciences (IAFNS) (through an ILSI North America Carbohydrate Committee grant). IAFNS is a nonprofit science organization that pools funding from industry and advances science through the in-kind and financial contributions from private and public sector members. ILSI North America receives support primarily from its industry membership. ILSI North America had no role in the design, analysis, interpretation, or presentation of the data and results. Dr Camilleri receives funding for studies on intestinal permeability in irritable bowel syndrome (unrelated to current project) from the National Institutes of Health (R01 DK115950). The study was conducted in the Mayo Clinic Clinical Research Trials Unit, supported in part by nursing, dietetic, physiology, and immunochemistry laboratory components, which are supported by grant number UL1-TR002377 from the National Center for Advancing Translational Sciences. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.; Funding text 2: Funding This work was supported by the Institute for the Advancement of Food and Nutrition Sciences (IAFNS) (through an ILSI North America Carbohydrate Committee grant). IAFNS is a nonprofit science organization that pools funding from industry and advances science through the in-kind and financial contributions from private and public sector members. ILSI North America receives support primarily from its industry membership. ILSI North America had no role in the design, analysis, interpretation, or presentation of the data and results. Dr Camilleri receives funding for studies on intestinal permeability in irritable bowel syndrome (unrelated to current project) from the National Institutes of Health (R01 DK115950). The study was conducted in the Mayo Clinic Clinical Research Trials Unit, supported in part by nursing, dietetic, physiology, and immunochemistry laboratory components, which are supported by grant number UL1-TR002377 from the National Center for Advancing Translational Sciences . Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health. ","Odenwald M.A., Turner J.R., The intestinal epithelial barrier: a therapeutic target?, Nat Rev Gastroenterol Hepatol, 14, pp. 9-21, (2017); Quigley E.M., Leaky gut - concept or clinical entity?, Curr Opin Gastroenterol, 32, pp. 74-79, (2016); Camilleri M., Lyle B.J., Madsen K.L., Et al., Role for diet in normal gut barrier function: developing guidance within the framework of food labeling regulations, Am J Physiol, 317, pp. G17-G39, (2019); Camilleri M., Invited recent advances in basic science: the leaky gut: mechanisms, measurement and clinical implications in humans, Gut, 68, pp. 1516-1526, (2019); Guidance for Industry: Evidence-Based Review System for Scientific Evaluation of Health Claims (Online); Guidance for Industry: Substantiation for Dietary Supplement Claims Made Under Section 403(r) (6) of the Federal Food, Drug, and Cosmetic Act (Online); Rao A.S., Camilleri M., Eckert D.J., Et al., Urine sugars for in vivo gut permeability: validation and comparisons in irritable bowel syndrome-diarrhea and controls, Am J Physiol, 301, pp. G919-G928, (2011); Grover M., Camilleri M., Hines J., Et al., <sup>13</sup>C-mannitol as a novel biomarker for measurement of intestinal permeability, Neurogastroenterol Motil, 28, pp. 1114-1119, (2016); Faubion W.A., Camilleri M., Murray J.A., Et al., Improving the detection of environmental enteric dysfunction: a lactulose, rhamnose assay of intestinal permeability in children aged under 5 years exposed to poor sanitation and hygiene, BMJ Glob Health, 1, (2016); Dwyer J., Picciano M.F., Raiten D.J., Estimation of usual intakes: what we eat in America-NHANES, J Nutr, 133, pp. 609S-623S, (2003); Talley N.J., Phillips S.F., Wiltgen C.M., Et al., Assessment of functional gastrointestinal disease: the bowel disease questionnaire, Mayo Clin Proc, 65, pp. 1456-1479, (1990); Zigmond A.S., Snaith R.P., The hospital anxiety and depression scale, Acta Psychiatr Scand, 67, pp. 361-370, (1983); Camilleri M., Nadeau A., Lamsam J., Et al., Understanding measurements of intestinal permeability in healthy humans with urine lactulose and mannitol excretion, Neurogastroenterol Motil, 22, pp. e15-e26, (2010); Lostia A.M., Lionetto L., Principessa L., Et al., A liquid chromatography/mass spectrometry method for the evaluation of intestinal permeability, Clin Biochem, 41, pp. 887-892, (2008); Bjarnason I., Scarpignato C., Holmgren E., Et al., Mechanisms of damage to the gastrointestinal tract from nonsteroidal anti-inflammatory drugs, Gastroenterology, 154, pp. 500-514, (2018); Longstreth G.F., Thompson W.G., Chey W.D., Et al., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Camilleri M., Nadeau A., Tremaine W.J., Et al., Measurement of serum 7α-hydroxy-4-cholesten-3-one (or 7αC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry, Neurogastroenterol Motil, 21, pp. 734-743, (2009); Donato L.J., Lueke A., Kenyon S.M., Et al., Description of analytical method and clinical utility of measuring serum 7-alpha-hydroxy-4-cholesten-3-one (7aC4) by mass spectrometry, Clin Biochem, 52, pp. 106-111, (2018); Camilleri M., Busciglio I., Acosta A., Et al., Effect of increased bile acid synthesis or fecal excretion in irritable bowel syndrome-diarrhea, Am J Gastroenterol, 109, pp. 1621-1630, (2014); Meddings J., Gibbons I., Discrimination of site-specific alterations in gastrointestinal permeability in the rat, Gastroenterology, 114, pp. 83-92, (1998); Flint H.J., Scott K.P., Louis P., Et al., The role of the gut microbiota in nutrition and health, Nat Rev Gastroenterol Hepatol, 9, pp. 577-589, (2012); Sahota S.S., Bramley P.M., Menzies I.S., The fermentation of lactulose by colonic bacteria, J Gen Microbiol, 128, pp. 319-325, (1982); McOmber M.E., Ou C.-N., Shulman R.J., Effects of timing, sex, and age on site-specific gastrointestinal permeability testing in children and adults, J Pediatr Gastroenterol Nutr, 50, pp. 269-275, (2010); Karhu E., Forsgard R.A., Alanko L., Et al., Exercise and gastrointestinal symptoms: running-induced changes in intestinal permeability and markers of gastrointestinal function in asymptomatic and symptomatic runners, Eur J Appl Physiol, 117, pp. 2519-2526, (2017); Pires W., Veneroso C.E., Wanner S.P., Et al., Association between exercise-induced hyperthermia and intestinal permeability: a systematic review, Sports Med, 47, pp. 1389-1403, (2017); van Wijck K., Wijnands K.A., Meesters D.M., Et al., L-citrulline improves splanchnic perfusion and reduces gut injury during exercise, Med Sci Sports Exerc, 46, pp. 2039-2046, (2014); Man A.L., Bertelli E., Rentini S., Et al., Age-associated modifications of intestinal permeability and innate immunity in human small intestine, Clin Sci (Lond), 129, pp. 515-527, (2015); Bischoff S.C., Barbara G., Buurman W., Et al., Intestinal permeability--a new target for disease prevention and therapy, BMC Gastroenterol, 14, (2014)","M. Camilleri; Rochester, 200 First Street SW, Charlton Building, Room 8-110, 55905, United States; email: camilleri.michael@mayo.edu","","W.B. Saunders","","","","","","00165085","","GASTA","33865841","English","Gastroenterology","Article","Final","All Open Access; Hybrid Gold Open Access","Scopus","2-s2.0-85109077620"

"Nozu T.; Miyagishi S.; Nozu R.; Ishioh M.; Takakusaki K.; Okumura T.","Nozu, Tsukasa (12765917900); Miyagishi, Saori (56538237900); Nozu, Rintaro (57028157900); Ishioh, Masatomo (57202513969); Takakusaki, Kaoru (7004150214); Okumura, Toshikatsu (7202327796)","12765917900; 56538237900; 57028157900; 57202513969; 7004150214; 7202327796","EMA401, an angiotensin II type 2 receptor antagonist blocks visceral hypersensitivity and colonic hyperpermeability in rat model of irritable bowel syndrome","2021","Journal of Pharmacological Sciences","146","3","","121","124","3","5","10.1016/j.jphs.2021.04.001","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85105567543&doi=10.1016%2fj.jphs.2021.04.001&partnerID=40&md5=1295207efefb357ba3b4fc00b8bc9fa5","Department of Regional Medicine and Education, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Center for Medical Education, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Division of Neuroscience, Department of Physiology, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Department of General Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan","Nozu T., Department of Regional Medicine and Education, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan, Center for Medical Education, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Miyagishi S., Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Nozu R., Department of Regional Medicine and Education, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Ishioh M., Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Takakusaki K., Division of Neuroscience, Department of Physiology, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Okumura T., Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan, Department of General Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan","Visceral hypersensitivity and impaired gut barrier are crucial pathophysiology of irritable bowel syndrome (IBS), and injection of lipopolysaccharide or corticotropin-releasing factor, and repeated water avoidance stress simulate these gastrointestinal changes in rat (IBS models). We previously demonstrated that losartan, an angiotensin II type 1 (AT1) receptor antagonist prevented these changes, and we attempted to determine the effects of EMA401, an AT2 receptor antagonist in the current study. EMA401 blocked visceral hypersensitivity and colonic hyperpermeability in these models, and naloxone reversed the effects by EMA401. These results suggest that EMA401 may improve gut function via opioid signaling in IBS. © 2021 The Authors","Angiotensin II type 2 receptor; Colonic permeability; Visceral sensation","Angiotensin II Type 2 Receptor Blockers; Animals; Benzhydryl Compounds; Colon; Disease Models, Animal; Hyperalgesia; Irritable Bowel Syndrome; Isoquinolines; Male; Permeability; Rats, Sprague-Dawley; Visceral Pain; angiotensin 2 receptor; olodanrigan; angiotensin 2 receptor antagonist; benzhydryl derivative; EMA400; isoquinoline derivative; adult; animal experiment; animal model; animal tissue; Article; controlled study; drug determination; drug effect; drug mechanism; electromyography; hypersensitivity; intestine function; intestine mucosa permeability; irritable colon; male; muscle contraction; nonhuman; rat; signal transduction; animal; colon; disease model; drug effect; hyperalgesia; irritable colon; metabolism; pathophysiology; permeability; Sprague Dawley rat; visceral pain","","olodanrigan, 1316755-16-4; Angiotensin II Type 2 Receptor Blockers, ; Benzhydryl Compounds, ; EMA400, ; Isoquinolines, ","ema 401, MedChemexpress, United States","MedChemexpress, United States","Akiyama Life Science Foundation; Japan Society for the Promotion of Science, KAKEN, (26120012, 26460287, 26460955)","This work was partially supported by Japan Society for the Promotion of Science KAKENHI, Grant-in-Aid for Scientific Research (C) [ 26460287 (TN) and 26460955 (TO) ], Scientific Research on Innovative Areas [ 26120012 (KT) ], and the research grant from the Akiyama Life Science Foundation (TN).","Nozu T., Miyagishi S., Nozu R., Et al., Altered colonic sensory and barrier functions by CRF: roles of TLR4 and IL-1, J Endocrinol, 239, 2, pp. 241-252, (2018); Nozu T., Miyagishi S., Nozu R., Et al., Repeated water avoidance stress induces visceral hypersensitivity; role of IL-1, IL-6 and peripheral corticotropin-releasing factor, J Gastroenterol Hepatol, 32, 12, pp. 1958-1965, (2017); Tache Y., Kiank C., Stengel A., A role for corticotropin-releasing factor in functional gastrointestinal disorders, Curr Gastroenterol Rep, 11, 4, pp. 270-277, (2009); Nozu T., Miyagishi S., Nozu R., Et al., Lipopolysaccharide induces visceral hypersensitivity: role of interleukin-1, interleukin-6, and peripheral corticotropin-releasing factor in rats, J Gastroenterol, 52, 1, pp. 72-80, (2017); Garg M., Angus P.W., Burrell L.M., Et al., Review article: the pathophysiological roles of the renin-angiotensin system in the gastrointestinal tract, Aliment Pharmacol Ther, 35, 4, pp. 414-428, (2012); Nozu T., Miyagishi S., Nozu R., Et al., Losartan improves visceral sensation and gut barrier in a rat model of irritable bowel syndrome, Neuro Gastroenterol Motil, 32, 6, (2020); Yu Y., Liu Z.Q., Liu X.Y., Et al., Stress-derived corticotropin releasing factor breaches epithelial endotoxin tolerance, PLoS One, 8, 6, (2013); Obreja O., Rathee P.K., Lips K.S., Et al., IL-1 beta potentiates heat-activated currents in rat sensory neurons: involvement of IL-1RI, tyrosine kinase, and protein kinase C, Faseb J, 16, 12, pp. 1497-1503, (2002); Suzuki T., Yoshinaga N., Tanabe S., Interleukin-6 (IL-6) regulates claudin-2 expression and tight junction permeability in intestinal epithelium, J Biol Chem, 286, 36, pp. 31263-31271, (2011); Zizzo M.G., Caldara G., Bellanca A., Et al., PD123319, angiotensin II type II receptor antagonist, inhibits oxidative stress and inflammation in 2, 4-dinitrobenzene sulfonic acid-induced colitis in rat and ameliorates colonic contractility, Inflammopharmacology, 28, 1, pp. 187-199, (2020); Yoshikawa M., Ohinata K., Yamada Y., The pharmacological effects of novokinin; a designed peptide agonist of the angiotensin AT2 receptor, Curr Pharmaceut Des, 19, 17, pp. 3009-3012, (2013); Saavedra J.M., Benicky J., Brain and peripheral angiotensin II play a major role in stress, Stress, 10, 2, pp. 185-193, (2007); Ninkovic J., Roy S., Role of the mu-opioid receptor in opioid modulation of immune function, Amino Acids, 45, 1, pp. 9-24, (2013); Alicea C., Belkowski S., Eisenstein T.K., Et al., Inhibition of primary murine macrophage cytokine production in vitro following treatment with the kappa-opioid agonist U50,488H, J Neuroimmunol, 64, 1, pp. 83-90, (1996)","T. Nozu; Department of Regional Medicine and Education, Asahikawa Medical University, Asahikawa, 2-1-1-1 Midorigaoka-Higashi, 078-8510, Japan; email: tnozu@asahikawa-med.ac.jp","","Japanese Pharmacological Society","","","","","","13478613","","JPSTG","34030794","English","J. Pharmacol. Sci.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85105567543"

"Zhan Y.; Tang X.; Xu H.; Tang S.","Zhan, Yu (56443385600); Tang, Xuegui (56443026000); Xu, Hong (59121210300); Tang, Shiyu (57218488690)","56443385600; 56443026000; 59121210300; 57218488690","Maren Pills Improve Constipation via Regulating AQP3 and NF- B Signaling Pathway in Slow Transit Constipation in Vitro and in Vivo","2020","Evidence-based Complementary and Alternative Medicine","2020","","9837384","","","","25","10.1155/2020/9837384","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85089306667&doi=10.1155%2f2020%2f9837384&partnerID=40&md5=fc0257d458feb05390580d7a467e2159","Department of Anus and Intestine Surgery, Chengdu Integrated TCM andWestern Medicine Hospital, Chengdu First People's Hospital, Chengdu, China; Department of Anus and Intestine Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, China","Zhan Y., Department of Anus and Intestine Surgery, Chengdu Integrated TCM andWestern Medicine Hospital, Chengdu First People's Hospital, Chengdu, China; Tang X., Department of Anus and Intestine Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, China; Xu H., Department of Anus and Intestine Surgery, Chengdu Integrated TCM andWestern Medicine Hospital, Chengdu First People's Hospital, Chengdu, China; Tang S., Department of Anus and Intestine Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, China","Background. Maren pills have been used to treat constipation. Aquaporin 3 (AQP3) plays a vital role in regulating water transfer in the colon. It has been reported that the downregulation of AQP3 can regulate liquid water metabolism and intestinal permeability in irritable bowel syndrome (IBS) rats' colon via NF-κB pathway. In this study, we investigated whether the laxative effect of Maren pills is associated with the regulation of AQP3 and NF-κB signaling pathway in the colon. Methods. The compound diphenoxylate suspension-induced STC rats received Maren pills intragastrically for 1 consecutive week to evaluate the laxative effect of Maren pills involving the regulation of AQP3 and NF-κB signaling pathway. Moreover, human intestinal epithelial cells (HT-29) were treated with drug serum to obtain in vitro data. Results. Our results revealed that treatment with Maren pills increased the stool number, moisture content of feces, and intestinal transit rate in a dose-dependent manner. Maren pills significantly increased the AQP3, fibrosis transmembrane conductance regulator (CFTR), and protein kinase A (PKA) proteins in the colon of rats and in HT-29 cells. Mechanistically, Maren pills obviously inhibited the activation of NF-κB pathway in the colon of rats and in HT-29 cells. Conclusion. These results suggest that the laxative effect of Maren pills is associated with the increased expression of AQP3 by downregulating NF-κB signal pathway. © 2020 Yu Zhan et al.","","aquaporin 3; cyclic AMP dependent protein kinase; cystic fibrosis transmembrane conductance regulator; diphenoxylate; immunoglobulin enhancer binding protein; Kampo medicine (drug); laxative; maren pill; unclassified drug; animal experiment; animal model; animal tissue; Article; colon motility; constipation; controlled study; diarrhea; human; human cell; in vitro study; in vivo study; inflammation; intestine epithelium cell; moisture; nonhuman; rat; signal transduction","","cyclic AMP dependent protein kinase, ; cystic fibrosis transmembrane conductance regulator, 126880-72-6; diphenoxylate, 3810-80-8, 915-30-0","","","National Natural Science Foundation of China 81573990 Education Department of Sichuan Province, (18ZA0160)"," Background . Maren pills have been used to treat constipation. Aquaporin 3 (AQP3) plays a vital role in regulating water transfer in the colon. It has been reported that the downregulation of AQP3 can regulate liquid water metabolism and intestinal permeability in irritable bowel syndrome (IBS) rats’ colon via NF- κ B pathway. In this study, we investigated whether the laxative effect of Maren pills is associated with the regulation of AQP3 and NF- κ B signaling pathway in the colon. Methods . The compound diphenoxylate suspension-induced STC rats received Maren pills intragastrically for 1 consecutive week to evaluate the laxative effect of Maren pills involving the regulation of AQP3 and NF- κ B signaling pathway. Moreover, human intestinal epithelial cells (HT-29) were treated with drug serum to obtain in vitro data. Results . Our results revealed that treatment with Maren pills increased the stool number, moisture content of feces, and intestinal transit rate in a dose-dependent manner. Maren pills significantly increased the AQP3, fibrosis transmembrane conductance regulator (CFTR), and protein kinase A (PKA) proteins in the colon of rats and in HT-29 cells. Mechanistically, Maren pills obviously inhibited the activation of NF- κ B pathway in the colon of rats and in HT-29 cells. Conclusion . These results suggest that the laxative effect of Maren pills is associated with the increased expression of AQP3 by downregulating NF- κ B signal pathway.  National Natural Science Foundation of China 81573990 Education Department of Sichuan Province 18ZA0160","Chang J.Y., Locke R.G., McNally M.A., Impact of functional gastrointestinal disorders on survival in the community, American Journal of Gastroenterology, 105, 4, pp. 822-832, (2010); Mugie S.M., Benninga M.A., Lorenzo C.D., Epidemiology of constipation in children and adults: A?systematic review, Best Practice & Research Clinical Gastroenterology, 25, 1, pp. 3-18, (2011); Chu H., Zhong L., Li H., Zhang X., Zhang J., Hou X., Epidemiology characteristics of constipation for general population, pediatric population, and elderly population in China, Gastroenterology Research and Practice, 2014, pp. 1-11, (2014); Tsukamoto A., Ohno K., Maeda S., Prokinetic effect of the 5-HT4R agonist mosapride on canine gastric motility, Journal of Veterinary Medical Science, 73, 12, pp. 1635-1637, (2011); Singh S., Heady S., Adame E.C., Rao S.S.C., Clinical utility of colonic manometry in slow transit constipation, Neurogastroenterology & Motility the Official Journal of the European Gastrointestinal Motility Society, 25, 6, pp. e487-e367, (2013); Xue J., Effect of Maren Pills Combined with Lactulose Preventing Opioid-Induced Constipation in Cancer Pain Patients, (2015); Yin D., Clinical Observation of 92 Cases of Functional Constipation Treated by Maren Pills Combined with Retention Enema of Traditional Chinese Medicine, (2016); Nobutomo I., Risako K., Kiyoshi S., Aquaporins in the colon as a new therapeutic target in diarrhea and constipation, International Journal of Molecular Sciences, 17, 7, (2016); Ishibashi K., Tanaka Y., Morishita Y., The role of mammalian superaquaporins inside the cell, Biochimica et Biophysica Acta (BBA)-General Subjects, 1840, 5, pp. 1507-1512, (2014); Zheng Y.F., Liu C.-F., Lai W.-F., The laxative effect of emodin is attributable to increased aquaporin 3 expression in the colon of mice and HT-29 cells, Fitoterapia, 96, pp. 25-32, (2014); Chao G., Zhang S., Aquaporins 1, 3 and 8 expression in irritable bowel syndrome rats' colon via NF- B pathway, Oncotarget, 8, 29, pp. 47175-47183, (2017); Chikuma M.H., Satooka H., Watanabe S., Aquaporin-3-mediated hydrogen peroxide transport is required for NF- B signalling in keratinocytes and development of psoriasis, Nature Communications, 6, 1, (2015); Satitsri S., Pathophysiological mechanisms of diarrhea caused by the Vibrio cholerae O1 El Tor variant: an in vivo study in mice, Virulence, 7, 7, pp. 789-805, (2016); Tian H., Ge X., Ne Y., Fecal microbiota transplantation in patients with slow-transit constipation: a randomized, clinical trial, PLoS One, 12, 2, (2017); Gao F., Sheng H.-M., Zhang T.-N., Wu S.-B., Cao J., Zhou M.-Q., Effect of manual acupuncture stimulation of single acupoint or acupoints combination on intestinal movement in slow transit constipation mice, Zhen Ci Yan Jiu, 42, 1, (2017); Dong-Bing L.I., Effect and Safety of Maren Soft Capsule on Constipation, (2013); Koyama Y., Yamamoto T., Tani T., Expression and localization of aquaporins in rat gastrointestinal tract, American Journal of Physiology-Cell Physiology, 276, 3, pp. 621-627, (1999); Niu T., Expression of aquaporin-3 in colon mucosa of rats with slow transit constipation, Journal of Gansu University of Chinese Medicine, (2017); Wu M., Li Y., Gu Y., Hesperidin improves colonic motility in loeramide-induced constipation rat model via 5-hydroxytryptamine 4R/cAMP signaling pathway, Digestion, 27, 8, pp. 1-14, (2019); Zhou Y., Wang Y., Zhang H., Yan S., Wang B., Xie P., Effect of vasoactive intestinal peptide on defecation and VIP-cAMP-PKA-AQP3 signaling pathway #br# in rats with constipation, Randomized Controlled Trial, 41, 11, pp. 1175-1180, (2016); Cil O., Phuan P.-W., Lee S., CFTR activator increases intestinal fluid secretion and normalizes stool output in a mouse model of constipation, Cellular & Molecular Gastroenterology & Hepatology., 2, 3, pp. 317-327, (2016); Harada Y., Iizuka S., Saegusa Y., Mogami S., Fujitsuka N., Hattori T., Mashiningan improves opioid-induced constipation in rats by activating cystic fibrosis transmembrane conductance regulator chloride channel, Journal of Pharmacology & Experimental Therapeutics, 362, 1, pp. 78-84, (2017); Peplowski M.A., Vegso A.J., Iablokov V., Tumor necrosis factor α decreases aquaporin 3 expression in intestinal epithelial cells through inhibition of constitutive transcription, Physiological Reports, 5, 19, (2017); Hasler U., Leroy V., Jeon U.S., NF- B modulates aquaporin-2 transcription in renal collecting duct principal cells, Journal of Biological Chemistry, 283, 42, pp. 28095-28105, (2008)","","","Hindawi Limited","","","","","","1741427X","","","","English","Evid.-Based Complement. Altern. Med.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85089306667"

"Goichon A.; Bahlouli W.; Ghouzali I.; Chan P.; Vaudry D.; Déchelotte P.; Ducrotté P.; Coëffier M.","Goichon, Alexis (46861122700); Bahlouli, Wafa (57191848794); Ghouzali, Ibtissem (55534510300); Chan, Philippe (7403498126); Vaudry, David (6603869843); Déchelotte, Pierre (57201760610); Ducrotté, Philippe (7006732860); Coëffier, Moïse (6603081357)","46861122700; 57191848794; 55534510300; 7403498126; 6603869843; 57201760610; 7006732860; 6603081357","Colonic Proteome Signature in Immunoproteasome-Deficient Stressed Mice and Its Relevance for Irritable Bowel Syndrome","2019","Journal of Proteome Research","18","1","","478","492","14","4","10.1021/acs.jproteome.8b00793","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85057820070&doi=10.1021%2facs.jproteome.8b00793&partnerID=40&md5=19ea078d95aa02f6dacf745098fe522b","INSERM Unit 1073, Normandie University, UNIROUEN, 22 boulevard Gambetta, Rouen, F-76183, France; Institute for Research and Innovation in Biomedicine (IRIB), Normandie University, UNIROUEN, Rouen, F-76183, France; Platform in Proteomics PISSARO, Normandie University, UNIROUEN, Rouen, F-76821, France; INSERM Unit 1239, Normandie University, UNIROUEN, Rouen, F-76821, France; Nutrition Department, Rouen University Hospital, Rouen, F-76031, France; Gastroenterology Department, Rouen University Hospital, Rouen, F-76031, France","Goichon A., INSERM Unit 1073, Normandie University, UNIROUEN, 22 boulevard Gambetta, Rouen, F-76183, France, Institute for Research and Innovation in Biomedicine (IRIB), Normandie University, UNIROUEN, Rouen, F-76183, France; Bahlouli W., INSERM Unit 1073, Normandie University, UNIROUEN, 22 boulevard Gambetta, Rouen, F-76183, France, Institute for Research and Innovation in Biomedicine (IRIB), Normandie University, UNIROUEN, Rouen, F-76183, France; Ghouzali I., INSERM Unit 1073, Normandie University, UNIROUEN, 22 boulevard Gambetta, Rouen, F-76183, France, Institute for Research and Innovation in Biomedicine (IRIB), Normandie University, UNIROUEN, Rouen, F-76183, France; Chan P., Institute for Research and Innovation in Biomedicine (IRIB), Normandie University, UNIROUEN, Rouen, F-76183, France, Platform in Proteomics PISSARO, Normandie University, UNIROUEN, Rouen, F-76821, France; Vaudry D., Institute for Research and Innovation in Biomedicine (IRIB), Normandie University, UNIROUEN, Rouen, F-76183, France, Platform in Proteomics PISSARO, Normandie University, UNIROUEN, Rouen, F-76821, France, INSERM Unit 1239, Normandie University, UNIROUEN, Rouen, F-76821, France; Déchelotte P., INSERM Unit 1073, Normandie University, UNIROUEN, 22 boulevard Gambetta, Rouen, F-76183, France, Institute for Research and Innovation in Biomedicine (IRIB), Normandie University, UNIROUEN, Rouen, F-76183, France, Nutrition Department, Rouen University Hospital, Rouen, F-76031, France; Ducrotté P., INSERM Unit 1073, Normandie University, UNIROUEN, 22 boulevard Gambetta, Rouen, F-76183, France, Institute for Research and Innovation in Biomedicine (IRIB), Normandie University, UNIROUEN, Rouen, F-76183, France, Gastroenterology Department, Rouen University Hospital, Rouen, F-76031, France; Coëffier M., INSERM Unit 1073, Normandie University, UNIROUEN, 22 boulevard Gambetta, Rouen, F-76183, France, Institute for Research and Innovation in Biomedicine (IRIB), Normandie University, UNIROUEN, Rouen, F-76183, France, Nutrition Department, Rouen University Hospital, Rouen, F-76031, France","A role for immunoproteasome in the regulation of intestinal permeability has been previously suggested both in mice during water avoidance stress (WAS) and in patients with irritable bowel syndrome (IBS). Here, we provide evidence that the ubiquitin-proteasome system (UPS) contributes to the pathophysiology of IBS. Indeed, we report that colonic proteome is altered in WAS mice and that β2i subunit deficiency modifies the proteome response that is associated with a limitation of colonic hyperpermeability. Interestingly, we show specific alterations of proteins involved in UPS, mitochondrial, and energy metabolism. We also report changes in the pattern of colonic ubiquitome in diarrhea-predominant IBS (IBS-D) patients and particularly a reduced expression of ubiquitinated proteins involved in the nuclear factor-kappa B (NF-κB) inflammatory signaling pathway. All these data suggest that immunoproteasome targeting may represent a new therapeutic strategy for the treatment of IBS patients with increased intestinal permeability. © Copyright 2018 American Chemical Society.","colonic proteome; immunoproteasome; irritable bowel syndrome; water avoidance stress","immunoglobulin enhancer binding protein; proteasome; proteome; ubiquitin; ubiquitinated protein; animal experiment; animal model; Article; chronic stress; controlled study; energy metabolism; irritable colon; male; mitochondrial respiration; mouse; nonhuman; pathophysiology; priority journal; protein expression; signal transduction; water avoidance stress","","proteasome, 140879-24-9; ubiquitin, 60267-61-0","","","","","Le Pluart D., Sabate J.-M., Bouchoucha M., Hercberg S., Benamouzig R., Julia C., Functional Gastrointestinal Disorders in 35,447 Adults and Their Association with Body Mass Index, Aliment. Pharmacol. Ther., 41, 8, pp. 758-767, (2015); Ford A.C., Lacy B.E., Talley N.J., Irritable Bowel Syndrome, N. Engl. J. Med., 376, 26, pp. 2566-2578, (2017); Drossman D.A., Camilleri M., Mayer E.A., Whitehead W.E., AGA Technical Review on Irritable Bowel Syndrome, Gastroenterology, 123, 6, pp. 2108-2131, (2002); Simren M., Axelsson J., Gillberg R., Abrahamsson H., Svedlund J., Bjornsson E.S., Quality of Life in Inflammatory Bowel Disease in Remission: The Impact of IBS-like Symptoms and Associated Psychological Factors, Am. J. Gastroenterol., 97, 2, pp. 389-396, (2002); Camilleri M., Madsen K., Spiller R., Van Meerveld B.G., Verne G.N., Intestinal Barrier Function in Health and Gastrointestinal Disease, Neurogastroenterol. Motil., 24, 6, pp. 503-512, (2012); Zhou Q., Verne G.N., New Insights into Visceral Hypersensitivity - Clinical Implications in IBS, Nat. Rev. Gastroenterol. Hepatol., 8, 6, pp. 349-355, (2011); Spiller R.C., Jenkins D., Thornley J.P., Hebden J.M., Wright T., Skinner M., Neal K.R., Increased Rectal Mucosal Enteroendocrine Cells, T Lymphocytes, and Increased Gut Permeability Following Acute Campylobacter Enteritis and in Post-Dysenteric Irritable Bowel Syndrome, Gut, 47, 6, pp. 804-811, (2000); Dunlop S.P., Hebden J., Campbell E., Naesdal J., Olbe L., Perkins A.C., Spiller R.C., Abnormal Intestinal Permeability in Subgroups of Diarrhea-Predominant Irritable Bowel Syndromes, Am. J. Gastroenterol., 101, 6, pp. 1288-1294, (2006); Zhou Q., Zhang B., Verne G.N., Intestinal Membrane Permeability and Hypersensitivity in the Irritable Bowel Syndrome, Pain, 146, 12, pp. 41-46, (2009); Coeffier M., Gloro R., Boukhettala N., Aziz M., Lecleire S., Vandaele N., Antonietti M., Savoye G., Bole-Feysot C., Dechelotte P., Et al., Increased Proteasome-Mediated Degradation of Occludin in Irritable Bowel Syndrome, Am. J. Gastroenterol., 105, 5, pp. 1181-1188, (2010); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Lecleire S., Antonietti M., Gourcerol G., Leroi A.-M., Dechelotte P., Menard J.-F., Ducrotte P., Et al., The Expression and the Cellular Distribution of the Tight Junction Proteins Are Altered in Irritable Bowel Syndrome Patients with Differences According to the Disease Subtype, Am. J. Gastroenterol., 106, 12, pp. 2165-2173, (2011); Martinez C., Vicario M., Ramos L., Lobo B., Mosquera J.L., Alonso C., Sanchez A., Guilarte M., Antolin M., De Torres I., Et al., The Jejunum of Diarrhea-Predominant Irritable Bowel Syndrome Shows Molecular Alterations in the Tight Junction Signaling Pathway That Are Associated with Mucosal Pathobiology and Clinical Manifestations, Am. J. Gastroenterol., 107, 5, pp. 736-746, (2012); Zhou Q., Souba W.W., Croce C.M., Verne G.N., MicroRNA-29a Regulates Intestinal Membrane Permeability in Patients with Irritable Bowel Syndrome, Gut, 59, 6, pp. 775-784, (2010); Traweger A., Fang D., Liu Y.-C., Stelzhammer W., Krizbai I.A., Fresser F., Bauer H.-C., Bauer H., The Tight Junction-Specific Protein Occludin Is a Functional Target of the E3 Ubiquitin-Protein Ligase Itch, J. Biol. Chem., 277, 12, pp. 10201-10208, (2002); Visekruna A., Joeris T., Seidel D., Kroesen A., Loddenkemper C., Zeitz M., Kaufmann S.H.E., Schmidt-Ullrich R., Steinhoff U., Proteasome-Mediated Degradation of IkappaBalpha and Processing of P105 in Crohn Disease and Ulcerative Colitis, J. Clin. Invest., 116, 12, pp. 3195-3203, (2006); Leblond J., Hubert-Buron A., Bole-Feysot C., Ducrotte P., Dechelotte P., Coeffier M., Regulation of Proteolysis by Cytokines in the Human Intestinal Epithelial Cell Line HCT-8: Role of IFNgamma, Biochimie, 88, 7, pp. 759-765, (2006); Kloetzel P.M., Antigen Processing by the Proteasome, Nat. Rev. Mol. Cell Biol., 2, 3, pp. 179-187, (2001); Inoue S., Nakase H., Matsuura M., Mikami S., Ueno S., Uza N., Chiba T., The Effect of Proteasome Inhibitor MG132 on Experimental Inflammatory Bowel Disease, Clin. Exp. Immunol., 156, 1, pp. 172-182, (2009); Schmidt N., Gonzalez E., Visekruna A., Kuhl A.A., Loddenkemper C., Mollenkopf H., Kaufmann S.H.E., Steinhoff U., Joeris T., Targeting the Proteasome: Partial Inhibition of the Proteasome by Bortezomib or Deletion of the Immunosubunit LMP7 Attenuates Experimental Colitis, Gut, 59, 7, pp. 896-906, (2010); Basler M., Dajee M., Moll C., Groettrup M., Kirk C.J., Prevention of Experimental Colitis by a Selective Inhibitor of the Immunoproteasome, J. Immunol., 185, 1, pp. 634-641, (2010); Ghouzali I., Lemaitre C., Bahlouli W., Azhar S., Bole-Feysot C., Meleine M., Ducrotte P., Dechelotte P., Coeffier M., Targeting Immunoproteasome and Glutamine Supplementation Prevent Intestinal Hyperpermeability, Biochim. Biophys. Acta, Gen. Subj., 1861, 1, pp. 3278-3288, (2017); Kilkenny C., Parsons N., Kadyszewski E., Festing M.F.W., Cuthill I.C., Fry D., Hutton J., Altman D.G., Survey of the Quality of Experimental Design, Statistical Analysis and Reporting of Research Using Animals, PLoS One, 4, 11, (2009); Bradesi S., Schwetz I., Ennes H.S., Lamy C.M.R., Ohning G., Fanselow M., Pothoulakis C., McRoberts J.A., Mayer E.A., Repeated Exposure to Water Avoidance Stress in Rats: A New Model for Sustained Visceral Hyperalgesia, Am. J. Physiol. Gastrointest. Liver Physiol., 289, 1, pp. G42-53, (2005); Lee J.Y., Kim N., Kim Y.S., Nam R.H., Ham M.H., Lee H.S., Jo W., Shim Y., Choi Y.J., Yoon H., Et al., Repeated Water Avoidance Stress Alters Mucosal Mast Cell Counts, Interleukin-1β Levels with Sex Differences in the Distal Colon of Wistar Rats, J. Neurogastroenterol. Motil., 22, 4, pp. 694-704, (2016); Larauche M., Gourcerol G., Million M., Adelson D.W., Tache Y., Repeated Psychological Stress-Induced Alterations of Visceral Sensitivity and Colonic Motor Functions in Mice: Influence of Surgery and Postoperative Single Housing on Visceromotor Responses, Stress, 13, 4, pp. 343-354, (2010); Jesus P., Ouelaa W., Francois M., Riachy L., Guerin C., Aziz M., Do Rego J.-C., Dechelotte P., Fetissov S.O., Coeffier M., Alteration of Intestinal Barrier Function during Activity-Based Anorexia in Mice, Clin. Nutr., 33, 6, pp. 1046-1053, (2014); Coeffier M., Claeyssens S., Hecketsweiler B., Lavoinne A., Ducrotte P., Dechelotte P., Enteral Glutamine Stimulates Protein Synthesis and Decreases Ubiquitin MRNA Level in Human Gut Mucosa, Am. J. Physiol. Gastrointest. Liver Physiol., 285, 2, pp. G266-273, (2003); Goichon A., Coeffier M., Claeyssens S., Lecleire S., Cailleux A.-F., Bole-Feysot C., Chan P., Donnadieu N., Lerebours E., Lavoinne A., Et al., Effects of an Enteral Glucose Supply on Protein Synthesis, Proteolytic Pathways, and Proteome in Human Duodenal Mucosa, Am. J. Clin. Nutr., 94, 3, pp. 784-794, (2011); Bertrand J., Marion-Letellier R., Azhar S., Chan P., Legrand R., Goichon A., Ghouzali I., Aziz M., Vaudry D., Savoye G., Et al., Glutamine Enema Regulates Colonic Ubiquitinated Proteins but Not Proteasome Activities during TNBS-Induced Colitis Leading to Increased Mitochondrial Activity, Proteomics, 15, 13, pp. 2198-2210, (2015); Goichon A., Bertrand J., Chan P., Lecleire S., Coquard A., Cailleux A.-F., Vaudry D., Dechelotte P., Coeffier M., Enteral Delivery of Proteins Enhances the Expression of Proteins Involved in the Cytoskeleton and Protein Biosynthesis in Human Duodenal Mucosa, Am. J. Clin. Nutr., 102, 2, pp. 359-367, (2015); Vizcaino J.A., Csordas A., Del-Toro N., Dianes J.A., Griss J., Lavidas I., Mayer G., Perez-Riverol Y., Reisinger F., Ternent T., Et al., 2016 Update of the PRIDE Database and Its Related Tools, Nucleic Acids Res., 44, D1, pp. D447-456, (2016); Huang D.W., Sherman B.T., Lempicki R.A., Systematic and Integrative Analysis of Large Gene Lists Using DAVID Bioinformatics Resources, Nat. Protoc., 4, 1, pp. 44-57, (2009); Bertrand J., Tennoune N., Marion-Letellier R., Goichon A., Chan P., Mbodji K., Vaudry D., Dechelotte P., Coeffier M., Evaluation of Ubiquitinated Proteins by Proteomics Reveals the Role of the Ubiquitin Proteasome System in the Regulation of Grp75 and Grp78 Chaperone Proteins during Intestinal Inflammation, Proteomics, 13, 22, pp. 3284-3292, (2013); Visekruna A., Joeris T., Schmidt N., Lawrenz M., Ritz J.-P., Buhr H.J., Steinhoff U., Comparative Expression Analysis and Characterization of 20S Proteasomes in Human Intestinal Tissues: The Proteasome Pattern as Diagnostic Tool for IBD Patients, Inflamm. Bowel Dis., 15, 4, pp. 526-533, (2009); Rolland-Fourcade C., Denadai-Souza A., Cirillo C., Lopez C., Jaramillo J.O., Desormeaux C., Cenac N., Motta J.-P., Larauche M., Tache Y., Et al., Epithelial Expression and Function of Trypsin-3 in Irritable Bowel Syndrome, Gut, 66, 10, pp. 1767-1778, (2017); Moloney R.D., O'Mahony S.M., Dinan T.G., Cryan J.F., Stress-Induced Visceral Pain: Toward Animal Models of Irritable-Bowel Syndrome and Associated Comorbidities, Front. Psychiatry, 6, (2015); Seifert U., Bialy L.P., Ebstein F., Bech-Otschir D., Voigt A., Schroter F., Prozorovski T., Lange N., Steffen J., Rieger M., Et al., Immunoproteasomes Preserve Protein Homeostasis upon Interferon-Induced Oxidative Stress, Cell, 142, 4, pp. 613-624, (2010); Nathan J.A., Spinnenhirn V., Schmidtke G., Basler M., Groettrup M., Goldberg A.L., Immuno- and Constitutive Proteasomes Do Not Differ in Their Abilities to Degrade Ubiquitinated Proteins, Cell, 152, 5, pp. 1184-1194, (2013); Setsuie R., Suzuki M., Tsuchiya Y., Wada K., Skeletal Muscles of Uchl3 Knockout Mice Show Polyubiquitinated Protein Accumulation and Stress Responses, Neurochem. Int., 56, 8, pp. 911-918, (2010); Kim J.Y., Lee J.-M., Cho J.-Y., Ubiquitin C-Terminal Hydrolase-L3 Regulates Smad1 Ubiquitination and Osteoblast Differentiation, FEBS Lett., 585, 8, pp. 1121-1126, (2011); Sano Y., Furuta A., Setsuie R., Kikuchi H., Wang Y.-L., Sakurai M., Kwon J., Noda M., Wada K., Photoreceptor Cell Apoptosis in the Retinal Degeneration of Uchl3-Deficient Mice, Am. J. Pathol., 169, 1, pp. 132-141, (2006); Song H.M., Lee J.E., Kim J.H., Ubiquitin C-Terminal Hydrolase-L3 Regulates EMT Process and Cancer Metastasis in Prostate Cell Lines, Biochem. Biophys. Res. Commun., 452, 3, pp. 722-727, (2014); Rolen U., Kobzeva V., Gasparjan N., Ovaa H., Winberg G., Kisseljov F., Masucci M.G., Activity Profiling of Deubiquitinating Enzymes in Cervical Carcinoma Biopsies and Cell Lines, Mol. Carcinog., 45, 4, pp. 260-269, (2006); Miyoshi Y., Nakayama S., Torikoshi Y., Tanaka S., Ishihara H., Taguchi T., Tamaki Y., Noguchi S., High Expression of Ubiquitin Carboxy-Terminal Hydrolase-L1 and -L3MRNA Predicts Early Recurrence in Patients with Invasive Breast Cancer, Cancer Sci., 97, 6, pp. 523-529, (2006); Zhao P., Guo T., Qian L., Wang X., Yuan Y., Cheng Q., Zuo Y., Liu J., Miao Y., Feng Q., Et al., Ubiquitin C-Terminal Hydrolase-L3 Promotes Interferon Antiviral Activity by Stabilizing Type I-Interferon Receptor, Antiviral Res., 144, pp. 120-129, (2017); Kanarek N., Ben-Neriah Y., Regulation of NF-B by Ubiquitination and Degradation of the IκBs, Immunol. Rev., 246, 1, pp. 77-94, (2012); Coeffier M., Marion-Letellier R., Dechelotte P., Potential for Amino Acids Supplementation during Inflammatory Bowel Diseases, Inflamm. Bowel Dis., 16, 3, pp. 518-524, (2010); Singleton K.D., Wischmeyer P.E., Glutamine Attenuates Inflammation and NF-KappaB Activation via Cullin-1 Deneddylation, Biochem. Biophys. Res. Commun., 373, 3, pp. 445-449, (2008); Beutheu S., Ouelaa W., Guerin C., Belmonte L., Aziz M., Tennoune N., Bole-Feysot C., Galas L., Dechelotte P., Coeffier M., Glutamine Supplementation, but Not Combined Glutamine and Arginine Supplementation, Improves Gut Barrier Function during Chemotherapy-Induced Intestinal Mucositis in Rats, Clin. Nutr., 33, 4, pp. 694-701, (2014); Beutheu S., Ghouzali I., Galas L., Dechelotte P., Coeffier M., Glutamine and Arginine Improve Permeability and Tight Junction Protein Expression in Methotrexate-Treated Caco-2 Cells, Clin. Nutr., 32, 5, pp. 863-869, (2013); Choi K., Lee S.S., Oh S.J., Lim S.Y., Lim S.Y., Jeon W.K., Oh T.Y., Kim J.W., The Effect of Oral Glutamine on 5-Fluorouracil/Leucovorin-Induced Mucositis/Stomatitis Assessed by Intestinal Permeability Test, Clin. Nutr., 26, 1, pp. 57-62, (2007); Daniele B., Perrone F., Gallo C., Pignata S., De Martino S., De Vivo R., Barletta E., Tambaro R., Abbiati R., D'Agostino L., Oral Glutamine in the Prevention of Fluorouracil Induced Intestinal Toxicity: A Double Blind, Placebo Controlled, Randomised Trial, Gut, 48, 1, pp. 28-33, (2001); Hubert-Buron A., Leblond J., Jacquot A., Ducrotte P., Dechelotte P., Coeffier M., Glutamine Pretreatment Reduces IL-8 Production in Human Intestinal Epithelial Cells by Limiting IkappaBalpha Ubiquitination, J. Nutr., 136, 6, pp. 1461-1465, (2006); Bertrand J., Ghouzali I., Guerin C., Bole-Feysot C., Gouteux M., Dechelotte P., Ducrotte P., Coeffier M., Glutamine Restores Tight Junction Protein Claudin-1 Expression in Colonic Mucosa of Patients with Diarrhea-Predominant Irritable Bowel Syndrome, JPEN, J. Parenter. Enteral Nutr., 40, 8, pp. 1170-1176, (2016); Zhou Q., Costinean S., Croce C.M., Brasier A.R., Merwat S., Larson S.A., Basra S., Verne G.N., MicroRNA 29 Targets Nuclear Factor-B-Repressing Factor and Claudin 1 to Increase Intestinal Permeability, Gastroenterology, 148, 1, pp. 158-158e8, (2015); Zhou Q., Verne M.L., Fields J.Z., Lefante J.J., Basra S., Salameh H., Verne G.N., Randomised Placebo-Controlled Trial of Dietary Glutamine Supplements for Postinfectious Irritable Bowel Syndrome, Gut, (2018); Li N., Neu J., Glutamine Deprivation Alters Intestinal Tight Junctions via a PI3-K/Akt Mediated Pathway in Caco-2 Cells, J. Nutr., 139, 4, pp. 710-714, (2009); Coeffier M., Dechelotte P., Ducrotte P., Intestinal Permeability in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: Is There a Place for Glutamine Supplementation?, Gastroenterology, 148, 5, pp. 1079-1080, (2015); Zhou Q., Verne G.N., Reply: To PMID 25277410, Gastroenterology, 148, 5, pp. 1080-1081, (2015); Cleynen I., Vazeille E., Artieda M., Verspaget H.W., Szczypiorska M., Bringer M.-A., Lakatos P.L., Seibold F., Parnell K., Weersma R.K., Et al., Genetic and Microbial Factors Modulating the Ubiquitin Proteasome System in Inflammatory Bowel Disease, Gut, 63, 8, pp. 1265-1274, (2014)","M. Coëffier; INSERM Unit 1073, Normandie University, UNIROUEN, Rouen, 22 boulevard Gambetta, F-76183, France; email: moise.coeffier@univ-rouen.fr","","American Chemical Society","","","","","","15353893","","JPROB","30475625","English","J. Proteome Res.","Article","Final","All Open Access; Green Open Access","Scopus","2-s2.0-85057820070"

"Ji S.; Zhang Q.","Ji, Shanyun (57684583400); Zhang, Qing (57221696943)","57684583400; 57221696943","Momordica charantia polysaccharides alleviate diarrhea-predominant irritable bowel syndrome by regulating intestinal inflammation and barrier via NF-kB pathway","2022","Allergologia et Immunopathologia","50","3","","62","70","8","16","10.15586/aei.v50i3.584","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85130004534&doi=10.15586%2faei.v50i3.584&partnerID=40&md5=58042952ad93d7d6267e7c4e12361fad","Department of Digestive Internal Medicine, Lianyungang Hospital of Traditional Chinese Medicine, Jiangsu, Lianyungang, China","Ji S., Department of Digestive Internal Medicine, Lianyungang Hospital of Traditional Chinese Medicine, Jiangsu, Lianyungang, China; Zhang Q., Department of Digestive Internal Medicine, Lianyungang Hospital of Traditional Chinese Medicine, Jiangsu, Lianyungang, China","Background: Momordica charantia exerts anti-inflammatory effect against ulcerative colitis. Momordica charantia polysaccharides (MCPs) attenuate gastritis through inhibition of ethanol-induced inflammatory response. Objective: The role of MCPs in diarrhea-predominant irritable bowel syndrome (IBS-D) is investigated. Materials and Methods: Chemical stimulation followed by acute and chronic pressure stimulation was used to establish rats model with IBS-D. The model rats were then administrated with MCPs. Defecation frequency, fecal water content and abdominal withdrawal reflex (AWR) score were then recorded. Pathologic changes in the colonic tissues were evaluated by hematoxylin and eosin staining. Inflammation was detected by ELISA and qRT-PCR, and immunohistochemistry was used to assess intestinal mucosal permeability. Results: First, IBS-D of mice wasIBS-D ratsmice exhibited many abnormal clinical manifestations, including increased frequency of defecation, fecal water content, and abdominal withdrawal reflex (AWR) score. Second, the mice were administrated with MCPs, which reduced frequency of defecation, fecal water content, and AWR score, and 100-mg/kg MCPs indicated therapeutic effect on IBS-D mice equivalent to rifaximin. Moreover, MCPs also ameliorated pathologic changes in the colonic tissues of IBS-D mice. Third, inflammatory response in IBS-D mice was also suppressed by MCPs through up-regulation of Interleukin (IL)-10, and downregulation of tumor necrosis factor-a (TNF-a), Interleukin(IL)-1B, and IL-6. MCPs enhanced levels of occludin (OCLN) and zona occludens protein-1 (ZO-1) in IBS-D mice to improve intestinal mucosal permeability. Finally, phosphorylation of p65 in IBS-D mice was reduced by MCP treatment. Conclusion: MCPs ameliorated intestinal permeability and repressed intestinal inflammation to attenuate IBS-D by inactivating nuclear factor kappa B (NF-kB) signaling © 2022. Codon Publications. Published by Codon Publications. All Rights Reserved.","diarrhea-predominant irritable bowel syndrome; intestinal inflammation; intestinal permeability; momordica charantia polysaccharides; NF-kB","Animals; Diarrhea; Humans; Inflammation; Irritable Bowel Syndrome; Mice; Momordica charantia; NF-kappa B; Polysaccharides; Rats; Water; immunoglobulin enhancer binding protein; interleukin 1; interleukin 10; interleukin 1beta; interleukin 6; Momordica charantia extract; occludin; pentobarbital; protein ZO1; rifaximin; synaptotagmin I; tumor necrosis factor; immunoglobulin enhancer binding protein; polysaccharide; water; animal cell; animal experiment; animal model; animal tissue; antiinflammatory activity; Article; cell protection; chemical stimulation; colon tissue; controlled study; defecation habit; diarrhea; dose response; down regulation; drug efficacy; drug isolation; edema; enteritis; enzyme linked immunosorbent assay; feces analysis; histopathology; immunohistochemistry; inflammatory infiltrate; intestine mucosa permeability; intestine pressure; irritable colon; mouse; mRNA expression level; NF kB signaling; nonhuman; protein phosphorylation; real time reverse transcription polymerase chain reaction; upregulation; water content; withdrawal reflex; animal; diarrhea; human; inflammation; metabolism; Momordica charantia; pathology; rat","","occludin, 176304-61-3; pentobarbital, 57-33-0, 76-74-4; rifaximin, 80621-81-4, 88747-56-2; water, 7732-18-5; NF-kappa B, ; Polysaccharides, ; Water, ","","","","","Weaver KR, Melkus GD, Henderson WA., Irritable Bowel syndrome, Am J Nurs, 117, 6, pp. 48-55, (2017); Greenwood-Van Meerveld B, Johnson AC., Stress-induced chronic visceral pain of gastrointestinal origin, Front Syst Neurosci, 11, (2017); Chen YJ, Wu H, Wu SD, Lu N, Wang YT, Liu HN, Et al., Parasutterella, in association with irritable bowel syndrome and intestinal chronic inflammation, J Gastroenterol Hepatol, 33, 11, pp. 1844-1852, (2018); Canavan C, West J, Card T., The epidemiology of irritable bowel syndrome, Clin Epidemiol, 6, pp. 71-80, (2014); Altomare A, Di Rosa C, Imperia E, Emerenziani S, Cicala M, Guarino MPL., Diarrhea predominant-irritable bowel syndrome (IBS-D): Effects of different nutritional patterns on intestinal dysbiosis and symptoms, Nutrients, 13, 5, (2021); Weber HC., New treatment options for irritable bowel syndrome with predominant diarrhea, Curr Opinion Endocrinol Diabetes Obesity, 24, 1, pp. 25-30, (2017); Farrell DJ., Rifaximin in the treatment of irritable bowel syndrome: Is there a high risk for development of antimicrobial resistance?, J Clin Gastroenterol, 47, 3, pp. 205-211, (2013); Mei L, Zhou J, Su Y, Mao K, Wu J, Zhu C, Et al., Gut microbiota composition and functional prediction in diarrhea-predominant irritable bowel syndrome, BMC Gastroenterol, 21, 1, (2021); Bortolotti M, Mercatelli D, Polito L., Momordica charantia, a nutraceutical approach for inflammatory related diseases, Front Pharmacol, 10, (2019); Li Z, Xia A, Li S, Yang G, Jin W, Zhang M, Et al., The pharmacological properties and therapeutic use of bitter melon (Momordica charantia L.), Curr Pharmacol Rep, 6, 3, pp. 103-109, (2020); Deng Z, Yuan C, Yang J, Peng Y, Wang W, Wang Y, Et al., Behavioral defects induced by chronic social defeat stress are protected by Momordica charantia polysaccharides via attenuation of JNK3/PI3K/AKT neuroinflammatory pathway, Ann Transl Med, 7, 1, (2019); Wen J-J, Li M-Z, Gao H, Hu J-L, Nie Q-X, Chen H-H, Et al., Polysaccharides from fermented Momordica charantia L. with Lactobacillus plantarum NCU116 ameliorate metabolic disorders and gut microbiota change in obese rats, Food Funct, 12, 6, pp. 2617-2630, (2021); Semiz A, Ozgun Acar O, Cetin H, Semiz G, Sen A., Suppression of inflammatory cytokines expression with bitter melon (Momordica Charantia) in TNBS-instigated ulcerative colitis, J Transl Inter Med, 8, 3, pp. 177-187, (2020); Zhang C, Huang Y, Li P, Chen X, Liu F, Hou Q., Ginger relieves intestinal hypersensitivity of diarrhea predominant irritable bowel syndrome by inhibiting proinflammatory reaction, BMC Compl Med Ther, 20, 1, (2020); Hou Q, Huang Y, Zhu Z, Liao L, Chen X, Han Q, Et al., Tong- Xie-Yao-Fang improves intestinal permeability in diarrhoea-predominant irritable bowel syndrome rats by inhibiting the NF-kB and notch signalling pathways, BMC Complement Altern Med, 19, 1, (2019); Ng QX, Soh AYS, Loke W, Lim DY, Yeo W-S., The role of inflammation in irritable bowel syndrome (IBS), J Inflamm Res, 11, pp. 345-349, (2018); Choghakhori R, Abbasnezhad A, Hasanvand A, Amani R., Inflammatory cytokines and oxidative stress biomarkers in irritable bowel syndrome: Association with digestive symptoms and quality of life, Cytokine, 93, pp. 34-43, (2017); Kumar S, Singh P, Kumar A., Targeted therapy of irritable bowel syndrome with anti-inflammatory cytokines, Clin J Gastroenterol, 15, 1, pp. 1-10, (2022); Guo D, Zhou J, Zhang M, Taximaimaiti R, Wang X, Wang H., Momordica Charantia polysaccharides attenuates MPP<sup>+</sup>-induced injury in Parkinson's disease mice and cell models by regulating TLR4/MyD88/NF-KB patway, Int J Polym Sci, 2021, (2021); Cojocariu RO, Balmus IM, Lefter R, Ababei DC, Ciobica A, Hritcu L, Et al., Behavioral and oxidative stress changes in mice subjected to combinations of multiple stressors relevant to irritable bowel syndrome, Brain Sci, 10, 11, (2020); Raish M., Momordica charantia polysaccharides ameliorate oxidative stress, hyperlipidemia, inflammation, and apoptosis during myocardial infarction by inhibiting the NF-kB signaling pathway, Int J Biol Macromol, 97, pp. 544-551, (2017); He X, Cui L-H, Wang X-H, Yan Z-H, Li C, Gong S-D, Et al., Modulation of inflammation by toll-like receptor 4/nuclear factor-kappa B in diarrhea-predominant irritable bowel syndrome, Oncotarget, 8, 69, pp. 113957-113965, (2017); Coeffier M, Dechelotte P, Ducrotte P., Intestinal permeability in patients with diarrhea-predominant irritable bowel syndrome: Is there a place for glutamine supplementation?, Gastroenterology, 148, 5, pp. 1079-1080, (2015); Raish M, Ahmad A, Ansari MA, Alkharfy KM, Aljenoobi FI, Jan BL, Et al., Momordica charantia polysaccharides ameliorate oxidative stress, inflammation, and apoptosis in ethanol-induced gastritis in mucosa through NF-kB signaling pathway inhibition, Int J Biol Macromol, 111, pp. 193-199, (2018); Scalera A, Di Minno MN, Tarantino G., What does irritable bowel syndrome share with non-alcoholic fatty liver disease?, World J Gastroenterol, 19, 33, pp. 5402-5420, (2013); Fan M, Lee JI, Ryu YB, Choi YJ, Tang Y, Oh M, Et al., Comparative analysis of metabolite profiling of momordica charantia leaf and the anti-obesity effect through regulating lipid metabolism, Int J Environ Res Public Health, 18, 11, (2021)","","","Codon Publications","","","","","","03010546","","AGIMB","35527657","English","Allergol. Immunopathol.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85130004534"

"McOmber M.; Rafati D.; Cain K.; Devaraj S.; Weidler E.M.; Heitkemper M.; Shulman R.J.","McOmber, Mark (22035812700); Rafati, Danny (57225289310); Cain, Kevin (7103341073); Devaraj, Sridevi (7004533440); Weidler, Erica M. (26424158700); Heitkemper, Margaret (7005514887); Shulman, Robert J. (56961627200)","22035812700; 57225289310; 7103341073; 7004533440; 26424158700; 7005514887; 56961627200","Increased Gut Permeability in First-degree Relatives of Children with Irritable Bowel Syndrome or Functional Abdominal Pain","2020","Clinical Gastroenterology and Hepatology","18","2","","375","384.e1","","9","10.1016/j.cgh.2019.05.011","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85076375407&doi=10.1016%2fj.cgh.2019.05.011&partnerID=40&md5=8f00313f19c0d76649b10522ca5e8c43","Department of Pediatrics, Phoenix Children's Hospital, Phoenix, AZ, United States; Cook Children's Health Care System, Fort Worth, TX, United States; University of Washington, Seattle, WA, United States; Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, United States; Department of Pediatrics, Baylor College of Medicine, Houston, TX, United States; Texas Children's Hospital, Houston, TX, United States; Children's Nutrition Research Center, Houston, TX, United States","McOmber M., Department of Pediatrics, Phoenix Children's Hospital, Phoenix, AZ, United States; Rafati D., Cook Children's Health Care System, Fort Worth, TX, United States; Cain K., University of Washington, Seattle, WA, United States; Devaraj S., Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, United States, Department of Pediatrics, Baylor College of Medicine, Houston, TX, United States; Weidler E.M., Department of Pediatrics, Baylor College of Medicine, Houston, TX, United States, Texas Children's Hospital, Houston, TX, United States, Children's Nutrition Research Center, Houston, TX, United States; Heitkemper M., University of Washington, Seattle, WA, United States; Shulman R.J., Department of Pediatrics, Baylor College of Medicine, Houston, TX, United States, Texas Children's Hospital, Houston, TX, United States, Children's Nutrition Research Center, Houston, TX, United States","Background & Aims: Increased gut permeability might contribute to the pathogenesis of irritable bowel syndrome or functional abdominal pain (IBS or FAP). We investigated whether siblings and parents of children with IBS or FAP have increased gut permeability. Methods: We performed permeability tests (using sucrose, lactulose, mannitol, and sucralose) on 29 siblings and 43 parents of children with IBS or FAP, and 43 children (controls) and 42 parents of controls, from primary and secondary care. Permeability studies were repeated in 7 siblings and 37 parents of children with IBS or FAP and 23 controls and 36 parents of controls following ingestion of 400 mg of ibuprofen. Percent recovery of sucrose was calculated based on analyses of urine collected overnight; the lactulose/mannitol ratio and percent recovery of sucralose were based on analyses of urine samples collected over a 24-hour period. Results: When we controlled for age, sex, and family membership, siblings of children with IBS or FAP had increased small bowel permeability (urinary lactulose/mannitol ratio) vs controls (P =.004). There was no difference in gastroduodenal (percent sucrose recovery) or colonic (percent sucralose recovery) permeability between groups. Similarly, parents of children with IBS or FAP also had increased small bowel permeability, compared with parents of controls (P =.015), with no differences in gastric or colonic permeability. After administration of ibuprofen, gastroduodenal and small bowel permeability tended to be greater in IBS or FAP siblings (P =.08) and gastroduodenal permeability tended to be greater in IBS or FAP parents (P =.086). Conclusions: Siblings and parents of children with IBS or FAP have increased baseline small intestinal permeability compared with control children and their parents. These results indicate that there are familial influences on gastrointestinal permeability in patients with IBS or FAP. © 2020 AGA Institute","Environmental Factor; Genetics; Intestinal Barrier; NSAID","Abdominal Pain; Child; Humans; Irritable Bowel Syndrome; Lactulose; Permeability; ibuprofen; lactulose; mannitol; sucralose; sucrose; abdominal pain; age distribution; Article; child; controlled study; family; female; functional abdominal pain; human; intestine mucosa permeability; irritable colon; major clinical study; male; pathogenesis; primary medical care; secondary health care; sex difference; sibling; urine level; urine sampling; abdominal pain; irritable colon; permeability","","ibuprofen, 15687-27-1, 79261-49-7, 31121-93-4, 527688-20-6; lactulose, 4618-18-2; mannitol, 69-65-8, 87-78-5; sucralose, 56038-13-2; sucrose, 122880-25-5, 57-50-1; Lactulose, ","","","Baylor College of Medicine and Texas Children's Hospital; Daffy's Foundation; Texas Medical Center Digestive Disease Center; U.S. Government; USDA/ARS, (6250-51000-043, P30 DK56338); National Institutes of Health, NIH; National Institute of Nursing Research, NINR, (R01NR005337); National Institute of Nursing Research, NINR; U.S. Department of Agriculture, USDA","Funding Supported in part by R01 NR05337 from the National Institutes of Health, the Daffy's Foundation, the USDA/ARS under Cooperative Agreement No. 6250-51000-043, and P30 DK56338, which funds the Texas Medical Center Digestive Disease Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This work is a publication of the USDA/ARS Children's Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital. The contents do not necessarily reflect the views or policies of the USDA, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.","Saps M., Seshadri R., Sztainberg M., Et al., A prospective school-based study of abdominal pain and other common somatic complaints in children, J Pediatr, 154, pp. 322-326, (2009); Rosen J.M., Saps M., British secondary school students report frequent abdominal pain with associated physical and emotional symptoms, Evidence-based Nursing, 17, pp. 15-16, (2014); Hyams J.S., Di Lorenzo C., Saps M., Et al., Functional disorders: children and adolescents, Gastroenterology, 150, pp. 1456-1468, (2016); Rutten J.M., Benninga M.A., Vlieger A.M., IBS and FAP(S) in children: a comparison of psychological and clinical characteristics, J Pediatr Gastroenterol Nutr, 59, pp. 493-499, (2014); Lembo A., Zaman M., Jones M., Et al., Influence of genetics on irritable bowel syndrome, gastro-oesophageal reflux and dyspepsia: a twin study, Aliment Pharmacol Ther, 25, pp. 1343-1350, (2007); Keszthelyi D., Troost F.J., Masclee A.A., Irritable bowel syndrome: methods, mechanisms, and pathophysiology—methods to assess visceral hypersensitivity in irritable bowel syndrome, Am J Physiol Gastrointest Liver Physiol, 303, pp. G141-G154, (2012); El-Salhy M., Ostgaard H., Gundersen D., Et al., The role of diet in the pathogenesis and management of irritable bowel syndrome (review), Int J Mol Med, 29, pp. 723-731, (2012); Camilleri M., Lasch K., Zhou W., The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome, Am J Physiol Gastrointest Liver Physiol, 303, pp. G775-G785, (2012); Soderholm J.D., Olaison G., Lindberg E., Et al., Different intestinal permeability patterns in relatives and spouses of patients with Crohn's disease: an inherited defect in mucosal defence?, Gut, 44, pp. 96-100, (1999); Miki K., Moore D.J., Butler R.N., Et al., The sugar permeability test reflects disease activity in children and adolescents with inflammatory bowel disease, J Pediatr, 133, pp. 750-754, (1998); Lee J.Y., Wasinger V.C., Yau Y.Y., Et al., Molecular pathophysiology of epithelial barrier dysfunction in inflammatory bowel diseases, Proteomes, 6, (2018); Arrieta M.C., Madsen K., Doyle J., Et al., Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse, Gut, 58, pp. 41-48, (2009); Teshima C.W., Goodman K.J., El-Kalla M., Et al., Increased intestinal permeability in relatives of patients with crohn's disease is not associated with small bowel ulcerations, Clin Gastroenterol Hepatol, 15, pp. 1413-1418 e1, (2017); Shulman R.J., Eakin M.N., Czyzewski D.I., Et al., Increased gastrointestinal permeability and gut inflammation in children with functional abdominal pain and irritable bowel syndrome, J Pediatr, 153, pp. 646-650, (2008); Saulnier D.M., Riehle K., Mistretta T.A., Et al., Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome, Gastroenterology, 141, pp. 1782-1791, (2011); Williams A.E., Heitkemper M., Self M.M., Et al., Endogenous inhibition of somatic pain is impaired in girls with irritable bowel syndrome compared with healthy girls, J Pain, 14, pp. 921-930, (2013); Shulman R.J., Eakin M.N., Jarrett M., Et al., Characteristics of pain and stooling in children with recurrent abdominal pain, J Pediatr Gastroenterol Nutr, 44, pp. 203-208, (2007); Erlacher L., Wyatt J., Pflugbeil S., Et al., Sucrose permeability as a marker for NSAID-induced gastroduodenal injury, Clin Exp Rheumatol, 16, pp. 69-71, (1998); McOmber M.E., Ou C.N., Shulman R.J., Effects of timing, sex, and age on site-specific gastrointestinal permeability testing in children and adults, J Pediatr Gastroenterol Nutr, 50, pp. 269-275, (2010); Smecuol E., Bai J.C., Sugai E., Et al., Acute gastrointestinal permeability responses to different non-steroidal anti-inflammatory drugs, Gut, 49, pp. 650-655, (2001); Bjarnason I., Hayllar J., MacPherson A.J., Et al., Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans, Gastroenterology, 104, pp. 1832-1847, (1993); Maiden L., Thjodleifsson B., Theodors A., Et al., A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy, Gastroenterology, 128, pp. 1172-1178, (2005); Conover W.J.I., Iman R.L., Rank transformations as a bridge between parametric and nonparametric statistics, The American Statistician, 35, pp. 124-129, (1981); Rodriguez-Fandino O., Hernandez-Ruiz J., Schmulson M., From cytokines to toll-like receptors and beyond: current knowledge and future research needs in irritable bowel syndrome, J Neurogastroenterol Motil, 16, pp. 363-373, (2010); Matricon J., Meleine M., Gelot A., Et al., Review article: associations between immune activation, intestinal permeability and the irritable bowel syndrome, Aliment Pharmacol Ther, 36, pp. 1009-1031, (2012); Gonzalez-Castro A.M., Martinez C., Salvo-Romero E., Et al., Mucosal pathobiology and molecular signature of epithelial barrier dysfunction in the small intestine in irritable bowel syndrome, J Gastroenterol Hepatol, 32, pp. 53-63, (2017); Francavilla R., Miniello V., Magista A.M., Et al., A randomized controlled trial of Lactobacillus GG in children with functional abdominal pain, Pediatrics, 126, pp. e1445-e1452, (2010); Lostia A.M., Lionetto L., Principessa L., Et al., A liquid chromatography/mass spectrometry method for the evaluation of intestinal permeability, Clin Biochem, 41, pp. 887-892, (2008); Del Valle-Pinero A.Y., Van Deventer H.E., Fourie N.H., Et al., Gastrointestinal permeability in patients with irritable bowel syndrome assessed using a four probe permeability solution, Clin Chim Acta, 418, pp. 97-101, (2013); Kosek M.N., Lee G.O., Guerrant R.L., Et al., Age and sex normalization of intestinal permeability measures for the improved assessment of enteropathy in infancy and early childhood: results from the MAL-ED study, J Pediatr Gastroenterol Nutr, 65, pp. 31-39, (2017); Meleine M., Matricon J., Gender-related differences in irritable bowel syndrome: potential mechanisms of sex hormones, World J Gastroenterol, 20, pp. 6725-6743, (2014); Pigrau M., Rodino-Janeiro B.K., Casado-Bedmar M., Et al., The joint power of sex and stress to modulate brain-gut-microbiota axis and intestinal barrier homeostasis: implications for irritable bowel syndrome, Neurogastroenterol Motil, 28, pp. 463-486, (2016); Diebel M.E., Diebel L.N., Manke C.W., Liberati D.M., Estrogen modulates intestinal mucus physiochemical properties and protects against oxidant injury, J Trauma Acute Care Surg, 78, pp. 94-99, (2015); Li J.Y., Chassaing B., Tyagi A.M., Et al., Sex steroid deficiency-associated bone loss is microbiota dependent and prevented by probiotics, J Clin Invest, 126, pp. 2049-2063, (2016); Kerckhoffs A.P., Akkermans L.M., de Smet M.B., Et al., Intestinal permeability in irritable bowel syndrome patients: effects of NSAIDs, Dig Dis Sci, 55, pp. 716-723, (2010); Meddings J.B., Gibbons L., Descrimination of site-specific alterations in gastrointestinal permeability in the rat, Gastroenterology, 114, pp. 83-92, (1998); Vera J.F., Gotteland M., Chavez E., Et al., Sucrose permeability in children with gastric damage and Helicobacter pylori infection, J Pediatr Gastroenterol Nutr, 24, pp. 506-511, (1997); Meddings J.B., Sutherland L.R., Byles N.I., Et al., Sucrose: a novel permeability marker for gastroduodenal disease, Gastroenterology, 104, pp. 1619-1626, (1993); Rao A.S., Camilleri M., Eckert D.J., Et al., Urine sugars for in vivo gut permeability: validation and comparisons in irritable bowel syndrome-diarrhea and controls, Am J Physiol Gastrointest Liver Physiol, 301, pp. G919-G928, (2011); Read N.W., Al-Janabi M.N., Bates T.E., Et al., Interpretation of the breath hydrogen profile obtained after ingesting a solid meal containing unabsorbable carbohydrate, Gut, 26, pp. 834-842, (1985); Peled Y., Gilat T., The metabolism of lactulose by the fecal flora, Gastroenterology, 77, pp. 821-823, (1979); Saunders D.R., Wiggins H.S., Conservation of mannitol, lactulose, and raffinose by the human colon, Am J Physiol, 241, pp. G397-G402, (1981); Maxton D.G., Bjarnason I., Reynolds A.P., Et al., Lactulose, 51Cr-labelled ethylenediaminetetra-acetate, L-rhamnose and polyethyleneglycol 400 [corrected] as probe markers for assessment in vivo of human intestinal permeability, Clin Sci, 71, pp. 71-80, (1986); Jenkins A.P., Menzies I.S., Nukajam W.S., Et al., The effect of ingested lactulose on absorption of L-rhamnose, D-xylose, and 3-O-methyl-D-glucose in subjects with ileostomies, Scand J Gastroenterol, 29, pp. 820-825, (1994); Elia M., Behrens R., Northrop C., Et al., Evaluation of mannitol, lactulose and 51Cr-labelled ethylenediaminetetra-acetate as markers of intestinal permeability in man, Clin Sci, 73, pp. 197-204, (1987); Laker M.F., Bull H.J., Menzies I.S., Evaluation of mannitol for use as a probe marker of gastrointestinal permeability in man, Eur J Clin Invest, 12, pp. 485-491, (1982); Calarge C.A., Devaraj S., Shulman R.J., Gut permeability and depressive symptom severity in unmedicated adolescents, J Affect Disord, 246, pp. 586-594, (2019); Grice H.C., Goldsmith L.A., Sucralose: an overview of the toxicity data, Food Chem Toxicol, 38, pp. S1-S6, (2000); Farhadi A., Gundlapalli S., Shaikh M., Et al., Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis, Liver Int, 28, pp. 1026-1033, (2008); Varni J.W., Shulman R.J., Self M.M., Et al., Symptom profiles in patients with irritable bowel syndrome or functional abdominal pain compared with healthy controls, J Pediatr Gastroenterol Nutr, 61, pp. 323-329, (2015); Czyzewski D.I., Lane M.M., Weidler E.M., Et al., The interpretation of Rome III criteria and method of assessment affect the irritable bowel syndrome classification of children, Aliment Pharmacol Ther, 33, pp. 403-411, (2011); Mishra A., Makharia G.K., Techniques of functional and motility test: how to perform and interpret intestinal permeability, J Neurogastroenterol Motil, 18, pp. 443-447, (2012); Menzies I.S.C.R., Assessing intestinal absorptive capacity and permeability in vivo, Methods in disease: investigating the gastrointestinal tract, pp. 41-63, (1998); Goodgame R.W., Malaty H.M., el-Zimaity H.M., Et al., Decrease in gastric permeability to sucrose following cure of Helicobacter pylori infection, Helicobacter, 2, pp. 44-47, (1997); van Wijck K., Verlinden T.J., van Eijk H.M., Et al., Novel multi-sugar assay for site-specific gastrointestinal permeability analysis: a randomized controlled crossover trial, Clin Nutr, 32, pp. 245-251, (2013); Akram S., Mourani S., Ou C.N., Et al., Assessment of intestinal permeability with a two-hour urine collection, Dig Dis Sci, 43, pp. 1946-1950, (1998); Anderson A.D., Jain P.K., Fleming S., Et al., Evaluation of a triple sugar test of colonic permeability in humans, Acta Physiol Scand, 182, pp. 171-177, (2004); Li X., Kan E.M., Lu J., Et al., Combat-training increases intestinal permeability, immune activation and gastrointestinal symptoms in soldiers, Aliment Pharmacol Ther, 37, pp. 799-809, (2013)","R.J. Shulman; Houston, 1100 Bates Avenue, Room 8072, 77030, United States; email: rshulman@bcm.edu","","W.B. Saunders","","","","","","15423565","","CGHLA","31100459","English","Clin. Gastroenterol. Hepatol.","Article","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-85076375407"

"Meira de-Faria F.; Bednarska O.; Ström M.; Söderholm J.D.; Walter S.A.; Keita Å.V.","Meira de-Faria, Felipe (36450289100); Bednarska, Olga (55789563900); Ström, Magnus (7005995994); Söderholm, Johan D. (7004276501); Walter, Susanna A. (23053245700); Keita, Åsa V. (13104052600)","36450289100; 55789563900; 7005995994; 7004276501; 23053245700; 13104052600","Colonic paracellular permeability and circulating zonulin-related proteins","2021","Scandinavian Journal of Gastroenterology","56","4","","424","431","7","17","10.1080/00365521.2021.1879247","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100537095&doi=10.1080%2f00365521.2021.1879247&partnerID=40&md5=f3c51ec0cc51d7129d04066481bc1d62","Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden; Department of Gastroenterology, Linköping University, Linköping, Sweden; Department of Surgery, Linköping University, Linköping, Sweden","Meira de-Faria F., Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden; Bednarska O., Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden, Department of Gastroenterology, Linköping University, Linköping, Sweden; Ström M., Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden, Department of Gastroenterology, Linköping University, Linköping, Sweden; Söderholm J.D., Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden, Department of Surgery, Linköping University, Linköping, Sweden; Walter S.A., Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden, Department of Gastroenterology, Linköping University, Linköping, Sweden; Keita Å.V., Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden","Objective: Irritable bowel syndrome (IBS) is a gut-brain disorder associated with increased gut permeability. Zonulin has been suggested to regulate the gut barrier and claimed to be pre-haptoglobin 2 (pre-HP2) and circulating zonulin is often used as a proxy for gastrointestinal permeability. This study investigated the correlation between colonic paracellular permeability and levels of circulating zonulin and pre-HP2. Materials and Methods: Colonic biopsies from 32 patients with IBS and 15 healthy controls (HC) were used to measure permeability in Ussing chambers and levels of zonulin (Cusabio ELISA). Zonulin was also measured in blood samples from 40 HC, 78 patients with IBS and 20 patients with celiac disease (CeD), before and after a gluten-free diet. In addition, we verified HP genotype and circulating pre-HP2 using a monoclonal pre-HP2 antibody (Bio-Rad) by ELISA. Results: Increased colonic paracellular permeability correlated positively with zonulin levels in IBS biopsies, but negatively with plasma zonulin. We found no agreement between circulating zonulin and pre-HP2. Genotyping revealed non-specificity of the zonulin kit, as all pre-HP2 non-producers presented detectable levels. Patients with CeD displayed higher pre-HP2 and zonulin levels compared to HC. A gluten-free diet in patients with CeD led to lower serum zonulin and pre-HP2 concentrations. Conclusions: Our study suggests that neither circulating zonulin nor pre-HP2 mirror colonic permeability. Our data corroborate previous reports showing the inability of the Cusabio zonulin kit to target zonulin and highlights that the results of studies using this kit must be re-examined with caution. © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.","Colonic paracellular permeability; ELISA; irritable bowel syndrome; pre-haptoglobin 2; zonulin","Haptoglobins; Humans; Intestinal Mucosa; Permeability; Protein Precursors; DNA; genomic DNA; haptoglobin; nonsteroid antiinflammatory agent; unclassified drug; zonulin; haptoglobin; protein precursor; zonulin; adult; Article; blood sampling; celiac disease; clinical assessment; colon biopsy; colonic paracellular permeability; comparative study; concentration process; controlled study; correlation analysis; enzyme linked immunosorbent assay; female; genotype; gluten free diet; human; human tissue; intestine mucosa permeability; irritable colon; major clinical study; male; priority journal; protein blood level; protein expression; intestine mucosa; permeability","","DNA, 9007-49-2; haptoglobin, 9087-69-8; Haptoglobins, ; Protein Precursors, ; zonulin, ","Cusabio, Biotech, United States; QIAamp, Qiagen; Softmax pro 5, Molecular Devices; Thermal Cycler, Biorad","Biorad; Biotech, United States; Molecular Devices; Qiagen","","","Oswiecimska J., Szymlak A., Roczniak W., Et al., New insights into the pathogenesis and treatment of irritable bowel syndrome, Adv Med Sci, 62, 1, pp. 17-30, (2017); Barbara G., Mucosal barrier defects in irritable bowel syndrome. Who left the door open?, Am J Gastroenterol, 101, 6, pp. 1295-1298, (2006); Camilleri M., Gorman H., Intestinal permeability and irritable bowel syndrome, Neurogastroenterol Motil, 19, 7, pp. 545-552, (2007); Del Valle-Pinero A.Y., Van Deventer H.E., Fourie N.H., Et al., Gastrointestinal permeability in patients with irritable bowel syndrome assessed using a four probe permeability solution, Clin Chim Acta, 418, pp. 97-101, (2013); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, 6, pp. 1288-1294, (2006); Gecse K., Roka R., Sera T., Et al., Leaky gut in patients with diarrhea-predominant irritable bowel syndrome and inactive ulcerative colitis, Digestion, 85, 1, pp. 40-46, (2012); Piche T., Barbara G., Aubert P., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators, Gut, 58, 2, pp. 196-201, (2009); Quigley E., Gut permeability in irritable bowel syndrome: more leaks add to slightly inflamed bowel syndrome conspiracy theory, Gastroenterology, 137, 2, pp. 728-730, (2009); Turcotte J.F., Kao D., Mah S.J., Et al., Breaks in the wall: increased gaps in the intestinal epithelium of irritable bowel syndrome patients identified by confocal laser endomicroscopy (with videos), Gastrointest Endosc, 77, 4, pp. 624-630, (2013); Bednarska O., Walter S.A., Casado-Bedmar M., Et al., Vasoactive intestinal polypeptide and mast cells regulate increased passage of colonic bacteria in patients with irritable bowel syndrome, Gastroenterology, 153, 4, pp. 948-960, (2017); Marshall J.K., Thabane M., Garg A.X., Et al., Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario, Aliment Pharmacol Ther, 20, 11-12, pp. 1317-1322, (2004); Spiller R.C., Jenkins D., Thornley J.P., Et al., Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, 6, pp. 804-811, (2000); Sturgeon C., Fasano A., Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases, Tissue Barriers, 4, 4, (2016); Fasano A., Intestinal zonulin: open sesame!, Gut, 49, 2, pp. 159-162, (2001); Suzuki T., Regulation of intestinal epithelial permeability by tight junctions, Cell Mol Life Sci, 70, 4, pp. 631-659, (2013); Stevens B.R., Goel R., Seungbum K., Et al., Increased human intestinal barrier permeability plasma biomarkers zonulin and FABP2 correlated with plasma LPS and altered gut microbiome in anxiety or depression, Gut, 67, 8, pp. 1555-1557, (2018); Fasano A., Not T., Wang W., Et al., Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease, Lancet, 355, 9214, pp. 1518-1519, (2000); El Asmar R., Panigrahi P., Bamford P., Et al., Host-dependent zonulin secretion causes the impairment of the small intestine barrier function after bacterial exposure, Gastroenterology, 123, 5, pp. 1607-1615, (2002); Smecuol E., Sugai E., Niveloni S., Et al., Permeability, zonulin production, and enteropathy in dermatitis herpetiformis, Clin Gastroenterol Hepatol, 3, 4, pp. 335-341, (2005); Arrieta M.C., Bistritz L., Meddings J.B., Alterations in intestinal permeability, Gut, 55, 10, pp. 1512-1520, (2006); Tripathi A., Lammers K.M., Goldblum S., Et al., Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2, Proc Natl Acad Sci USA, 106, 39, pp. 16799-16804, (2009); Koch W., Latz W., Eichinger M., Et al., Haptoglobin gene subtyping by restriction enzyme analysis, Clin Chem, 49, 11, pp. 1937-1940, (2003); Vanuytsel T., Vermeire S., Cleynen I., The role of Haptoglobin and its related protein, Zonulin, in inflammatory bowel disease, Tissue Barriers, 1, 5, (2013); Scheffler L., Crane A., Heyne H., Et al., Widely used commercial ELISA does not detect precursor of haptoglobin2, but recognizes properdin as a potential second member of the zonulin family, Front Endocrinol, 9, (2018); Ajamian M., Steer D., Rosella G., Et al., Serum zonulin as a marker of intestinal mucosal barrier function: may not be what it seems, PLoS One, 14, 1, (2019); Talley N.J., Holtmann G.J., Jones M., Et al., Zonulin in serum as a biomarker fails to identify the IBS, functional dyspepsia and non-coeliac wheat sensitivity, Gut, 69, 9, pp. 1-3, (2020); Witt S.T., Bednarska O., Keita A.V., Et al., Interactions between gut permeability and brain structure and function in health and irritable bowel syndrome, Neuroimage Clin, 21, (2019); Longstreth G.F., Thompson W.G., Chey W.D., Et al., Functional bowel disorders, Gastroenterology, 130, 5, pp. 1480-1491, (2006); Keita A.V., Gullberg E., Ericson A.C., Et al., Characterization of antigen and bacterial transport in the follicle-associated epithelium of human ileum, Lab Invest, 86, 5, pp. 504-516, (2006); Koch W., Latz W., Eichinger M., Et al., Genotyping of the common haptoglobin Hp 1/2 polymorphism based on PCR, Clin Chem, 48, 9, pp. 1377-1382, (2002); Flanagan J.J., Arjomandi A., Delanoy M.L., Et al., Development of monoclonal antibodies to pre-haptoglobin 2 and their use in an enzyme-linked immunosorbent assay (ELISA), J Immunol Methods, 406, pp. 34-42, (2014); Duerksen D.R., Wilhelm-Boyles C., Veitch R., Et al., A comparison of antibody testing, permeability testing, and zonulin levels with small-bowel biopsy in celiac disease patients on a gluten-free diet, Dig Dis Sci, 55, 4, pp. 1026-1031, (2010); Fasano A., Regulation of intercellular tight junctions by zonula occludens toxin and its eukaryotic analogue zonulin, Ann NY Acad Sci, 915, pp. 214-222, (2000); Ganda Mall J.P., Ostlund-Lagerstrom L., Lindqvist C.M., Et al., Are self-reported gastrointestinal symptoms among older adults associated with increased intestinal permeability and psychological distress?, BMC Geriatr, 18, 1, (2018); Langlois M.R., Delanghe J.R., Biological and clinical significance of haptoglobin polymorphism in humans, Clin Chem, 42, 10, pp. 1589-1600, (1996); Wang W., Uzzau S., Goldblum S.E., Et al., Human zonulin, a potential modulator of intestinal tight junctions, J Cell Sci, 113, 24, pp. 4435-4440, (2000); Paterson B.M., Lammers K.M., Arrieta M.C., Et al., The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study, Aliment Pharmacol Ther, 26, 5, pp. 757-766, (2007); Clemente M.G., De Virgiliis S., Kang J.S., Et al., Early effects of gliadin on enterocyte intracellular signalling involved in intestinal barrier function, Gut, 52, 2, pp. 218-223, (2003); Barbaro M.R., Cremon C., Caio G., Et al., 247 zonulin serum levels are increased in non-celiac gluten sensitivity and irritable bowel syndrome with diarrhea, Gastroenterology, 148, 4, (2015); Barbaro M.R., Cremon C., Morselli-Labate A.M., Et al., Serum zonulin and its diagnostic performance in non-coeliac gluten sensitivity, Gut, 69, 11, pp. 1966-1974, (2020); Fasano A., Uzzau S., Fiore C., Et al., The enterotoxic effect of zonula occludens toxin on rabbit small intestine involves the paracellular pathway, Gastroenterology, 112, 3, pp. 839-846, (1997); Drago S., El Asmar R., Di Pierro M., Et al., Gliadin, zonulin and gut permeability: effects on celiac and non-celiac intestinal mucosa and intestinal cell lines, Scand J Gastroenterol, 41, 4, pp. 408-419, (2006); Cenac N., Chin A.C., Garcia-Villar R., Et al., PAR2 activation alters colonic paracellular permeability in mice via IFN-gamma-dependent and -independent pathways, J Physiol, 558, 3, pp. 913-925, (2004); Pontarollo G., Mann A., Brandao I., Et al., Protease-activated receptor signaling in intestinal permeability regulation, FEBS J, 287, 4, pp. 645-658, (2020); Fasano A., Shea-Donohue T., Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases, Nat Clin Pract Gastroenterol Hepatol, 2, 9, pp. 416-422, (2005); Leffler D.A., Kelly C.P., Abdallah H.Z., Et al., A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge, Am J Gastroenterol, 107, 10, pp. 1554-1562, (2012); Kelly C.P., Green P.H., Murray J.A., Et al., Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study, Aliment Pharmacol Ther, 37, 2, pp. 252-262, (2013); Tajik N., Frech M., Schulz O., Et al., Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis, Nat Commun, 11, 1, (2020)","","","Taylor and Francis Ltd.","","","","","","00365521","","SJGRA","33535002","English","Scand. J. Gastroenterol.","Article","Final","All Open Access; Hybrid Gold Open Access","Scopus","2-s2.0-85100537095"

"Han X.; Lee A.; Huang S.; Gao J.; Spence J.R.; Owyang C.","Han, Xu (57693782200); Lee, Allen (36551221400); Huang, Sha (56454526600); Gao, Jun (58834228300); Spence, Jason R. (57203253681); Owyang, Chung (7102742637)","57693782200; 36551221400; 56454526600; 58834228300; 57203253681; 7102742637","Lactobacillus rhamnosus GG prevents epithelial barrier dysfunction induced by interferon-gamma and fecal supernatants from irritable bowel syndrome patients in human intestinal enteroids and colonoids","2019","Gut Microbes","10","1","","59","76","17","100","10.1080/19490976.2018.1479625","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85052073234&doi=10.1080%2f19490976.2018.1479625&partnerID=40&md5=bcfff31d243db2f8e2de3d1ca22ff2f5","University of Michigan, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Ann Arbor, MI, United States","Han X., University of Michigan, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Ann Arbor, MI, United States; Lee A., University of Michigan, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Ann Arbor, MI, United States; Huang S., University of Michigan, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Ann Arbor, MI, United States; Gao J., University of Michigan, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Ann Arbor, MI, United States; Spence J.R., University of Michigan, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Ann Arbor, MI, United States; Owyang C., University of Michigan, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Ann Arbor, MI, United States","Disruption of intestinal barrier homeostasis is an important pathogenic factor in conditions such as irritable bowel syndrome (IBS). Lactobacillus rhamnosus GG (LGG) improves IBS symptoms through unclear mechanisms. Previous studies utilizing colorectal adenocarcinoma cell lines showed that LGG metabolites prevented interferon gamma (IFN-gamma) induced barrier damage but the model employed limited these findings. We aimed to interrogate the protective effects of LGG on epithelial barrier function using human intestinal epithelial cultures (enteroids and colonoids) as a more physiologic model. To investigate how LGG affects epithelial barrier function, we measured FITC-Dextran (FD4) flux across the epithelium as well as tight junction zonula occludens 1 (ZO-1) and occludin (OCLN) expression. Colonoids were incubated with fecal supernatants from IBS patients (IBS-FSN) and healthy controls in the presence or absence of LGG to examine changes in gut permeability. Enteroids incubated with IFN-gamma demonstrated a downregulation of OCLN and ZO-1 expression by 67% and 50%, respectively (p<0.05). This was accompanied by increased paracellular permeability as shown by leakage of FD4. Pretreatment of enteroids with LGG prevented these changes and normalized OCLN and ZO-1 to control levels. These actions were independent of its action against apoptosis. However, these protective effects were not seen with LGG cell wall extracts, LGG DNA, or denatured (boiled) LGG. Intriguingly, IBS-FSN injected into colonoids increased paracellular permeability, which was prevented by LGG. LGG, likely due to secreted proteins, protects against epithelial barrier dysfunction. Bacterial-derived factors to modulate gut barrier function may be a treatment option in disorders such as IBS. © 2018, © 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.","epithelial barrier function; human colonoids; human intestinal enteroids; IFN-gamma; irritable bowel syndrome; Lactobacillus rhamnosus GG metabolites; tight junction","Cell Culture Techniques; Colon; Culture Media, Conditioned; Feces; Gene Expression Regulation; Humans; Interferon-gamma; Intestinal Mucosa; Intestines; Irritable Bowel Syndrome; Lactobacillus rhamnosus; Permeability; Tight Junction Proteins; Tight Junctions; 4 (3 chloroanilino) 6,7 dimethoxyquinazoline; caspase 3; epidermal growth factor; epidermal growth factor receptor; fluorescein isothiocyanate; gamma interferon; messenger RNA; occludin; protein ZO1; gamma interferon; tight junction protein; apoptosis; Article; bright field microscopy; colonoid; colonoscopy; controlled study; digestive system function disorder; DNA extraction; down regulation; enteroid; epithelial barrier dysfunction; fecal supernatant; feces analysis; fluorescence microscopy; gene expression; human; human cell; immunofluorescence; immunofluorescence test; intestine; intestine mucosa permeability; irritable colon; Lactobacillus crispatus; Lactobacillus rhamnosus; MAPK signaling; nonhuman; numeric rating scale; permeability barrier; protein expression; protein localization; real time polymerase chain reaction; spectrophotometry; supernatant; tight junction; Western blotting; cell culture technique; chemistry; colon; conditioned medium; cytology; drug effect; feces; gene expression regulation; genetics; intestine mucosa; irritable colon; Lactobacillus rhamnosus; metabolism; microbiology; pathophysiology; permeability","","4 (3 chloroanilino) 6,7 dimethoxyquinazoline, 153436-53-4; caspase 3, 169592-56-7; epidermal growth factor, 59459-45-9, 62229-50-9; epidermal growth factor receptor, 79079-06-4; fluorescein isothiocyanate, 25168-13-2, 27072-45-3, 3326-32-7; gamma interferon, 82115-62-6; occludin, 176304-61-3; Culture Media, Conditioned, ; Interferon-gamma, ; Tight Junction Proteins, ","","","National Institute of Allergy and Infectious Diseases, NIAID, (U19AI116482); National Institute of Allergy and Infectious Diseases, NIAID; National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK, (P30-DK34933, R01-DK048419); National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK","This work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Grants R01-DK048419 (C. Owyang) and P30-DK34933 (C. Owyang).","Konig J., Wells J., Cani P.D., Garcia-Rodenas C.L., MacDonald T., Mercenier A., Whyte J., Troost F., Brummer R.-J., Human Intestinal Barrier Function in Health and Disease, Clin Transl Gastroenterol, 7, (2016); Turner J.R., Intestinal mucosal barrier function in health and disease, Nat Rev Immunol, 9, pp. 799-809, (2009); Arrieta M.C., Bistritz L., Jb M., Alterations in intestinal permeability, Gut, 55, pp. 1512-1520, (2006); Madara J.L., Stafford J., Interferon-gamma directly affects barrier function of cultured intestinal epithelial monolayers, J Clin Invest, 83, pp. 724-727, (1989); Mullin J.M., Laughlin K.V., Marano C.W., Russo L.M., Soler A.P., Modulation of tumor necrosis factor-induced increase in renal (LLC-PK1) transepithelial permeability, Am J Physiol, 263, pp. F915-F924, (1992); Cash H.L., Whitham C.V., Behrendt C.L., Lv H., Symbiotic bacteria direct expression of an intestinal bactericidal lectin, Science, 313, pp. 1126-1130, (2006); Chung H., Pamp S.J., Hill J.A., Surana N.K., Edelman S.M., Troy E.B., Reading N.C., Villablanca E.J., Wang S., Mora J.R., Et al., Gut immune maturation depends on colonization with a host-specific microbiota, Cell, 149, pp. 1578-1593, (2012); Wells J.M., Brummer R.J., Derrien M., MacDonald T.T., Troost F., Cani P.D., Theodorou V., Dekker J., Meheust A., de V.W.M., Et al., Homeostasis of the gut barrier and potential biomarkers, Am J Physiol Gastrointest Liver Physiol, 312, pp. G171-G193, (2017); Abreu M.T., Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function, Nat Rev Immunol, 10, pp. 131-144, (2010); Wells J.M., Loonen L.M.P., Karczewski J.M., The role of innate signaling in the homeostasis of tolerance and immunity in the intestine, Int J Med Microbiol IJMM, 300, pp. 41-48, (2010); Wells J.M., Rossi O., Meijerink M., Baarlen P.V., Epithelial crosstalk at the microbiota–mucosal interface, Proc Natl Acad Sci, 108, pp. 4607-4614, (2011); Cario E., Gerken G., Podolsky D.K., Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function, Gastroenterology, 132, pp. 1359-1374, (2007); Ewaschuk J.B., Diaz H., Meddings L., Diederichs B., Dmytrash A., Backer J., Looijer-van Langen M., Madsen K.L., Secreted bioactive factors from Bifidobacterium infantis enhance epithelial cell barrier function, Am J Physiol Gastrointest Liver Physiol, 295, pp. G1025-G1034, (2008); Fasano A., Fiorentini C., Donelli G., Uzzau S., Kaper J.B., Margaretten K., Ding X., Guandalini S., Comstock L., Goldblum S.E., Zonula occludens toxin modulates tight junctions through protein kinase C-dependent actin reorganization, in vitro, J Clin Invest, 96, pp. 710-720, (1995); Fukuda S., Toh H., Hase K., Oshima K., Nakanishi Y., Yoshimura K., Tobe T., Clarke J.M., Topping D.L., Suzuki T., Et al., Bifidobacteria can protect from enteropathogenic infection through production of acetate, Nature, 469, pp. 543-547, (2011); Hamer H.M., Jonkers D., Venema K., Vanhoutvin S., Troost F.J., Brummer R.-J., Review article: the role of butyrate on colonic function, Aliment Pharmacol Ther, 27, pp. 104-119, (2008); Piche T., Barbara G., Aubert P., Bruley des Varannes S., Dainese R., Jl N., Cremon C., Stanghellini V., De G.R., Jp G., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Salim S.Y., Soderholm J.D., Importance of disrupted intestinal barrier in inflammatory bowel diseases, Inflamm Bowel Dis, 17, pp. 362-381, (2011); Camilleri M., Madsen K., Spiller R., Van M.B.G., Verne G.N., Intestinal barrier function in health and gastrointestinal disease, 24, pp. 503-512, (2012); Chassaing B., Darfeuille-Michaud A., The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases, Gastroenterology, 140, pp. 1720-1728, (2011); Vijay-Kumar M., Aitken J.D., Carvalho F.A., Cullender T.C., Mwangi S., Srinivasan S., Sitaraman S.V., Knight R., Ley R.E., At G., Metabolic Syndrome and Altered Gut Microbiota in Mice Lacking Toll-Like Receptor 5, Science, 328, pp. 228-231, (2010); Kalliomaki M., Satokari R., Lahteenoja H., Vahamiko S., Gronlund J., Routi T., Salminen S., Expression of Microbiota, Toll-like Receptors, and Their Regulators in the Small Intestinal Mucosa in Celiac Disease, J Pediatr Gastroenterol Nutr, 54, pp. 727-732, (2012); Hill C., Guarner F., Reid G., Gibson G.R., Merenstein D.J., Pot B., Morelli L., Canani R.B., Flint H.J., Salminen S., Et al., Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic, Nat Rev Gastroenterol Hepatol, 11, pp. 506-514, (2014); Segers M.E., Lebeer S., Towards a better understanding of Lactobacillus rhamnosus GG–host interactions, Microb Cell Factories, 13, (2014); Doron S., Snydman D.R., Gorbach S.L., Lactobacillus GG: Bacteriology and Clinical Applications, Gastroenterol Clin North Am, 34, pp. 483-498, (2005); Yan F., Polk D.B., Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells, J Biol Chem, 277, pp. 50959-50965, (2002); Tao Y., Drabik K.A., Waypa T.S., Musch M.W., Alverdy J.C., Schneewind O., Chang E.B., Petrof E.O., Soluble factors from Lactobacillus GG activate MAPKs and induce cytoprotective heat shock proteins in intestinal epithelial cells, Am J Physiol–Cell Physiol, 290, pp. C1018-C1030, (2006); Yan F., Cao H., Cover T.L., Whitehead R., Washington M.K., Polk D.B., Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth, Gastroenterology, 132, pp. 562-575, (2007); Chen R.-C., Xu L.-M., Du S.-J., Huang S.-S., Wu H., Dong J.-J., Huang J.-R., Wang X.-D., Feng W.-K., Chen Y.-P., Lactobacillus rhamnosus GG supernatant promotes intestinal barrier function, balances Treg and TH17 cells and ameliorates hepatic injury in a mouse model of chronic-binge alcohol feeding, Toxicol Lett, 241, pp. 103-110, (2016); Bauserman M., Bausserman M., Michail S., The use of Lactobacillus GG in irritable bowel syndrome in children: A double-blind randomized control trial, J Pediatr, 147, pp. 197-201, (2005); Gosselink M.P., Schouten W.R., Lmc V.L., Hop W.C.J., Laman J.D., Ruseler-van E.J.G.H., Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG, Dis Colon Rectum, 47, pp. 876-884, (2004); Zocco M.A., dal Verme L.Z., Cremonini F., Piscaglia A.C., Nista E.C., Candelli M., Novi, M, Rigante D., Cazzato I.A., Ojetti V., Et al., Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis, Aliment Pharmacol Ther, 23, pp. 1567-1574, (2006); Seth A., Yan F., Polk D.B., Rao R.K., Probiotics ameliorate the hydrogen peroxide-induced epithelial barrier disruption by a PKC- and MAP kinase-dependent mechanism, Am J Physiol Gastrointest Liver Physiol, 294, pp. G1060-G1069, (2008); Donato K.A., Gareau M.G., Wang Y.J.J., Sherman P.M., Lactobacillus rhamnosus GG attenuates interferon-{gamma} and tumour necrosis factor-alpha-induced barrier dysfunction and pro-inflammatory signalling, Microbiol Read Engl, 156, pp. 3288-3297, (2010); Ettayebi K., Crawford S.E., Murakami K., Broughman J.R., Karandikar U., Tenge V.R., Neill F.H., Blutt S.E., Zeng X.-L., Qu L., Et al., Replication of human noroviruses in stem cell–derived human enteroids, Science, 353, pp. 1387-1393, (2016); Spence J.R., Mayhew C.N., Rankin S.A., Kuhar M.F., Vallance J.E., Tolle K., Hoskins E.E., Kalinichenko V.V., Wells S.I., Zorn A.M., Et al., Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro, Nature, 470, pp. 105-109, (2011); Barbaro M.R., Di Sabatino A., Cremon C., Giuffrida P., Fiorentino M., Altimari A., Bellacosa L., Stanghellini V., Barbara G., Interferon-γ is increased in the gut of patients with irritable bowel syndrome and modulates serotonin metabolism, Am J Physiol Gastrointest Liver Physiol, 310, pp. G439-G447, (2016); Yang S., Yu M., Sun L., Xiao W., Yang X., Sun L., Zhang C., Ma Y., Yang H., Liu Y., Et al., Interferon-γ-induced intestinal epithelial barrier dysfunction by NF-κB/HIF-1α pathway, J Interferon Cytokine Res, 34, pp. 195-203, (2014); Alhouayek M., Rankin L., Gouveia-Figueira S., Fowler C.J., Interferon γ treatment increases endocannabinoid and related N-acylethanolamine levels in T84 human colon carcinoma cells, Br J Pharmacol, (2018); Zhou S.-Y., Gillilland M., Wu X., Leelasinjaroen P., Zhang G., Zhou H., Ye B., Lu Y., Owyang C., FODMAP diet modulates visceral nociception by lipopolysaccharide-mediated intestinal inflammation and barrier dysfunction, J Clin Invest, 128, pp. 267-280, (2018); Sato T., Vries R.G., Snippert H.J., van de Wetering M., Barker N., Stange D.E., van Es J.H., Abo A., Kujala P., Peters P.J., Et al., Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche, Nature, 459, pp. 262-265, (2009); Juuti-Uusitalo K., Klunder L.J., Sjollema K.A., Mackovicova K., Ohgaki R., Hoekstra D., Dekker J., van Ijzendoorn S.C.D., Differential effects of TNF (TNFSF2) and IFN-γ on intestinal epithelial cell morphogenesis and barrier function in three-dimensional culture, PloS One, 6, (2011); Leslie J.L., Huang S., Opp J.S., Nagy M.S., Kobayashi M., Young V.B., Spence J.R., Persistence and toxin production by Clostridium difficile within human intestinal organoids result in disruption of epithelial paracellular barrier function, 83, pp. 138-145, (2015); Li Q., Zhang Q., Wang M., Zhao S., Ma J., Luo N., Li N., Li Y., Xu G., Li J., Interferon-gamma and tumor necrosis factor-alpha disrupt epithelial barrier function by altering lipid composition in membrane microdomains of tight junction, Clin Immunol Orlando Fla, 126, pp. 67-80, (2008); Osset J., Bartolome R.M., Garcia E., Andreu A., Assessment of the capacity of Lactobacillus to inhibit the growth of uropathogens and block their adhesion to vaginal epithelial cells, J Infect Dis, 183, pp. 485-491, (2001); Stapleton A.E., Au-Yeung M., Hooton T.M., Fredricks D.N., Roberts P.L., Czaja C.A., Yarova-Yarovaya Y., Fiedler T., Cox M., Stamm W.E., Randomized, Placebo-Controlled Phase 2 Trial of a Lactobacillus crispatus Probiotic Given Intravaginally for Prevention of Recurrent Urinary Tract Infection, Clin Infect Dis Off Publ Infect Dis Soc Am, 52, pp. 1212-1217, (2011); Zhou F.-X., Chen L., Liu X.-W., Ouyang C.-H., Wu X.-P., Wang X.-H., Wang C.-L., Lu F.-G., Lactobacillus crispatus M206119 exacerbates murine DSS-colitis by interfering with inflammatory responses, World J Gastroenterol WJG, 18, pp. 2344-2356, (2012); Szajewska H., Kolodziej M., Systematic review with meta-analysis: Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults, Aliment Pharmacol Ther, 42, pp. 1149-1157, (2015); Boyle R.J., Robins-Browne R.M., Tang M.L.K., Probiotic use in clinical practice: what are the risks?, Am J Clin Nutr, 83, (2006); Besselink M.G., van Santvoort H.C., Buskens E., Boermeester M.A., van Goor H., Timmerman H.M., Nieuwenhuijs V.B., Bollen T.L., van Ramshorst B., Witteman B.J., Et al., Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial, Lancet Lond Engl, 371, pp. 651-659, (2008); Yan F., Liu L., Dempsey P.J., Tsai Y.-H., Raines E.W., Wilson C.L., Cao H., Z C., Liu L., Polk D.B.A., Lactobacillus rhamnosus GG-derived soluble protein, p40, stimulates ligand release from intestinal epithelial cells to transactivate epidermal growth factor receptor, J Biol Chem, 288, pp. 30742-30751, (2013); Wang L., Cao H., Liu L., B W., Walker W.A., Acra S.A., Yan F., Activation of epidermal growth factor receptor mediates mucin production stimulated by p40, a Lactobacillus rhamnosus GG-derived protein, J Biol Chem, 289, pp. 20234-20244, (2014); Palma G.D., Mdj L., Lu J., Dang V.T., Y D., Jury J., Umeh G., Miranda P.M., Pastor M.P., Sidani S., Et al., Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice, Sci Transl Med, 9, (2017); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Desmarais S.M., Cava F., de Pedro M.A., Huang K.C., Isolation and Preparation of Bacterial Cell Walls for Compositional Analysis by Ultra Performance Liquid Chromatography, (2014); Alimolaei M., Golchin M., An Efficient DNA Extraction Method for Lactobacillus casei, a Difficult-to-Lyse Bacterium, Int J Enteric Pathog, 4, pp. 7-32472, (2016); Mahe M.M., Sundaram N., Watson C.L., Shroyer N.F., Helmrath M.A., Establishment of human epithelial enteroids and colonoids from whole tissue and biopsy, J Vis Exp JoVE, (2015); Miyoshi H., Stappenbeck T.S., In vitro expansion and genetic modification of gastrointestinal stem cells as organoids, Nat Protoc, 8, pp. 2471-2482, (2013); Miyoshi H., Ajima R., Luo C.T.-Y., Yamaguchi T.P., Stappenbeck T.S., Wnt5a Potentiates TGF-β Signaling to Promote Colonic Crypt Regeneration after Tissue Injury, Science, 338, pp. 108-113, (2012); Watanabe K., Ueno M., Kamiya D., Nishiyama A., Matsumura M., Wataya T., Takahashi J.B., Nishikawa S., Nishikawa S., Muguruma K., Et al., A ROCK inhibitor permits survival of dissociated human embryonic stem cells, Nat Biotechnol, 25, pp. 681-686, (2007); Heaton K.W., Radvan J., Cripps H., Mountford R.A., Braddon F.E., Hughes A.O., Defecation frequency and timing, and stool form in the general population: a prospective study, Gut, 33, pp. 818-824, (1992); Spiegel B., Bolus R., Harris L., Lucak S., Naliboff B., Esrailian E., Chey W., Lembo A., Karsan H., Tillisch K., Et al., Measuring IBS patient reported outcomes with an abdominal pain numeric rating scale: results from the proof cohort, Aliment Pharmacol Ther, 30, pp. 1159-1170, (2009); Schneider C.A., Rasband W.S., Eliceiri K.W.N.I.H., Image to ImageJ: 25 years of image analysis, Nat Methods, 9, pp. 671-675, (2012)","C. Owyang; 3912 Taubman Center, 1500 E. Medical Center Dr, Ann Arbor, 48109-5362, United States; email: cowyang@med.umich.edu","","Taylor and Francis Inc.","","","","","","19490976","","","30040527","English","Gut Microbes","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85052073234"

"Grover M.; Berumen A.; Peters S.; Wei T.; Breen-Lyles M.; Harmsen W.S.; Busciglio I.; Burton D.; Vazquez Roque M.; DeVault K.R.; Camilleri M.; Wallace M.; Dasari S.; Neumann H.; Houghton L.A.","Grover, Madhusudan (23012057300); Berumen, Antonio (57219021765); Peters, Stephanie (57193683015); Wei, Ting (57221674305); Breen-Lyles, Margaret (57195807544); Harmsen, William S. (7005973985); Busciglio, Irene (17343569900); Burton, Duane (35453351900); Vazquez Roque, Maria (8983380500); DeVault, Kenneth R. (7006660502); Camilleri, Michael (7102181053); Wallace, Michael (7401942875); Dasari, Surendra (8393836400); Neumann, Helmut (23100999100); Houghton, Lesley A. (7007135913)","23012057300; 57219021765; 57193683015; 57221674305; 57195807544; 7005973985; 17343569900; 35453351900; 8983380500; 7006660502; 7102181053; 7401942875; 8393836400; 23100999100; 7007135913","Intestinal chemosensitivity in irritable bowel syndrome associates with small intestinal TRPV channel expression","2021","Alimentary Pharmacology and Therapeutics","54","9","","1179","1192","13","19","10.1111/apt.16591","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85114013455&doi=10.1111%2fapt.16591&partnerID=40&md5=06eebe44491e99310ad5694e4e167ded","Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States; Health Sciences Research, Mayo Clinic, Rochester, MN, United States; Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, United States; Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, United States; Department of Medicine I, University Medical Center Mainz, Mainz, Germany; GastroZentrum Lippe, Bad Salzuflen, Germany; Leeds Institute of Medical Research at St James’s, University of Leeds, Leeds, United Kingdom","Grover M., Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States; Berumen A., Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States; Peters S., Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States; Wei T., Health Sciences Research, Mayo Clinic, Rochester, MN, United States; Breen-Lyles M., Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States; Harmsen W.S., Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, United States; Busciglio I., Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States; Burton D., Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States; Vazquez Roque M., Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, United States; DeVault K.R., Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, United States; Camilleri M., Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States; Wallace M., Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, United States; Dasari S., Health Sciences Research, Mayo Clinic, Rochester, MN, United States; Neumann H., Department of Medicine I, University Medical Center Mainz, Mainz, Germany, GastroZentrum Lippe, Bad Salzuflen, Germany; Houghton L.A., Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, United States, Leeds Institute of Medical Research at St James’s, University of Leeds, Leeds, United Kingdom","Background: Irritable bowel syndrome (IBS) patients often experience meal-associated symptoms. However, the underlying mechanisms are unclear. Aim: To determine small intestinal mechanisms of lipid-induced symptoms and rectal hypersensitivity in IBS. Methods: We recruited 26 IBS patients (12 IBS-C, 14 IBS-D) and 15 healthy volunteers (HV). In vivo permeability was assessed using saccharide excretion assay. Rectal sensitivity was assessed using a barostat before and after small bowel lipid infusion; symptoms were assessed throughout. Next, an extended upper endoscopy with probe-based confocal laser endomicroscopy (pCLE) was performed with changes induced by lipids. Duodenal and jejunal mucosal biopsies were obtained for transcriptomics. Results: Following lipid infusion, a higher proportion of HV than IBS patients reported no pain, no nausea, no fullness and no urgency (P < 0.05 for all). In a model adjusted for sex and anxiety, IBS-C and IBS-D patients had lower thresholds for first rectal sensation (P = 0.0007) and pain (P = 0.004) than HV. In vivo small intestinal permeability and mean pCLE scores were similar between IBS patients and HV. Post-lipid, pCLE scores were higher than pre-lipid but were not different between groups. Baseline duodenal transient receptor potential vanilloid (TRPV) 1 and 3 expression was increased in IBS-D, and TRPV3 in IBS-C. Duodenal TRPV1 expression correlated with abdominal pain (r = 0.51, FDR = 0.01), and inversely with first rectal sensation (r = −0.48, FDR = 0.01) and pain (r = −0.41, FDR = 0.02) thresholds. Conclusion: Lipid infusion elicits a greater symptom response in IBS patients than HV, which is associated with small intestinal expression of TRPV channels. TRPV-mediated small intestinal chemosensitivity may mediate post-meal symptoms in IBS. © 2021 John Wiley & Sons Ltd","","Abdominal Pain; Humans; Intestine, Small; Irritable Bowel Syndrome; Rectum; Transient Receptor Potential Channels; lipid; vanilloid receptor 1; vanilloid receptor 3; transient receptor potential channel; abdominal pain; adult; Article; chemosensitivity; clinical article; controlled study; defecation urgency; duodenum; epigastric fullness; female; human; in vivo study; intestine mucosa permeability; irritable colon; jejunum; male; meal; nausea; protein expression; rectum; sensation; small intestine; transcriptomics; irritable colon; small intestine","","lipid, 66455-18-3; vanilloid receptor 1, 363242-41-5; Transient Receptor Potential Channels, ","","","National Institutes of Health, NIH; U.S. Department of Defense, DOD; Takeda Pharmaceutical Company, TPC","Funding text 1: : MG has received funding from NIH, DoD, Donga and Alexza pharmaceuticals. Declaration of funding interest ; Funding text 2: Investigator-initiated grant from Takeda Pharmaceuticals, USA. The authors thank Ms Lori Anderson for administrative support. Declaration of personal interest: None. Declaration of funding interest: MG has received funding from NIH, DoD, Donga and Alexza pharmaceuticals.","Black C.J., Ford A.C., Global burden of irritable bowel syndrome: trends, predictions and risk factors, Nat Rev Gastroenterol Hepatol, 17, pp. 473-486, (2020); Mearin F., Lacy B.E., Chang L., Et al., Bowel disorders, Gastroenterology, 150, pp. 1393-1407, (2016); Bouin M., Plourde V., Boivin M., Et al., Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds, Gastroenterology, 122, pp. 1771-1777, (2002); Mertz H., Naliboff B., Munakata J., Niazi N., Mayer E.A., Altered rectal perception is a biological marker of patients with irritable bowel syndrome, Gastroenterology, 109, pp. 40-52, (1995); Ragnarsson G., Bodemar G., Pain is temporally related to eating but not to defaecation in the irritable bowel syndrome (IBS). Patients' description of diarrhea, constipation and symptom variation during a prospective 6-week study, Eur J Gastroenterol Hepatol, 10, pp. 415-421, (1998); Aguilera-Lizarraga J., Florens M.V., Viola M.F., Et al., Local immune response to food antigens drives meal-induced abdominal pain, Nature, (2021); Bohn L., Storsrud S., Tornblom H., Bengtsson U., Simren M., Self-reported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life, Am J Gastroenterol, 108, pp. 634-641, (2013); Simren M., Agerforz P., Bjornsson E.S., Abrahamsson H., Nutrient-dependent enhancement of rectal sensitivity in irritable bowel syndrome (IBS), Neurogastroenterol Motil, 19, pp. 20-29, (2007); Simren M., Abrahamsson H., Bjornsson E.S., Lipid-induced colonic hypersensitivity in the irritable bowel syndrome: the role of bowel habit, sex, and psychologic factors, Clin Gastroenterol Hepatol, 5, pp. 201-208, (2007); Simren M., Abrahamsson H., Bjornsson E.S., An exaggerated sensory component of the gastrocolonic response in patients with irritable bowel syndrome, Gut, 48, pp. 20-27, (2001); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Edogawa S., Edwinson A.L., Peters S.A., Et al., Serine proteases as luminal mediators of intestinal barrier dysfunction and symptom severity in IBS, Gut, 69, pp. 62-73, (2020); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Rao A.S., Camilleri M., Eckert D.J., Et al., Urine sugars for in vivo gut permeability: validation and comparisons in irritable bowel syndrome-diarrhea and controls, Am J Physiol Gastrointest Liver Physiol, 301, pp. G919-G928, (2011); Grover M., Camilleri M., Hines J., Et al., (13) C mannitol as a novel biomarker for measurement of intestinal permeability, Neurogastroenterol Motil, 28, pp. 1114-1119, (2016); Peters S.A., Edogawa S., Sundt W.J., Et al., Constipation-predominant irritable bowel syndrome females have normal colonic barrier and secretory function, Am J Gastroenterol, 112, pp. 913-923, (2017); Kiesslich R., Goetz M., Angus E.M., Et al., Identification of epithelial gaps in human small and large intestine by confocal endomicroscopy, Gastroenterology, 133, pp. 1769-1778, (2007); Robles-Medranda C., Oleas R., Valero M., Et al., Confocal laser endomicroscopy detects colonic inflammation in patients with irritable bowel syndrome: a prospective study, Endosc Int Open, 8, pp. E550-E557, (2020); Fritscher-Ravens A., Schuppan D., Ellrichmann M., Et al., Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome, Gastroenterology, 147, (2014); Turcotte J.F., Kao D., Mah S.J., Et al., Breaks in the wall: increased gaps in the intestinal epithelium of irritable bowel syndrome patients identified by confocal laser endomicroscopy (with videos), Gastrointest Endosc, 77, pp. 624-630, (2013); Kasim A., Shkedy Z., Lin D., Et al., Translation of disease associated gene signatures across tissues, Int J Data Min Bioinform, 11, pp. 301-313, (2015); Martinez C., Vicario M., Ramos L., Et al., The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations, Am J Gastroenterol, 107, pp. 736-746, (2012); Martinez C., Rodino-Janeiro B.K., Lobo B., Et al., miR-16 and miR-125b are involved in barrier function dysregulation through the modulation of claudin-2 and cingulin expression in the jejunum in IBS with diarrhoea, Gut, 66, pp. 1537-1538, (2017); Camilleri M., Carlson P., Valentin N., Et al., Pilot study of small bowel mucosal gene expression in patients with irritable bowel syndrome with diarrhea, Am J Physiol Gastrointest Liver Physiol, 311, pp. G365-G376, (2016); Talley N.J., Phillips S.F., Wiltgen C.M., Zinsmeister A.R., Melton L.J., Assessment of functional gastrointestinal disease: the bowel disease questionnaire, Mayo Clin Proc, 65, pp. 1456-1479, (1990); Becker V., von Delius S., Bajbouj M., Karagianni A., Schmid R.M., Meining A., Intravenous application of fluorescein for confocal laser scanning microscopy: evaluation of contrast dynamics and image quality with increasing injection-to-imaging time, Gastrointest Endosc, 68, pp. 319-323, (2008); Kalari K.R., Nair A.A., Bhavsar J.D., Et al., MAP-RSeq: mayo analysis pipeline for RNA sequencing, BMC Bioinformatics, 15, (2014); McCarthy D.J., Chen Y., Smyth G.K., Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation, Nucleic Acids Res, 40, pp. 4288-4297, (2012); Subramanian A., Tamayo P., Mootha V.K., Et al., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles, Proc Natl Acad Sci U S A, 102, pp. 15545-15550, (2005); Edogawa S., Peters S.A., Jenkins G.D., Et al., Sex differences in NSAID-induced perturbation of human intestinal barrier function and microbiota, FASEB J, 32, pp. 6615-6625, (2018); Kong W.M., Gong J., Dong L., Xu J.R., Changes of tight junction claudin-1,-3,-4 protein expression in the intestinal mucosa in patients with irritable bowel syndrome, Nan Fang Yi Ke Da Xue Xue Bao, 27, pp. 1345-1347, (2007); Balemans D., Boeckxstaens G.E., Talavera K., Wouters M.M., Transient receptor potential ion channel function in sensory transduction and cellular signaling cascades underlying visceral hypersensitivity, Am J Physiol Gastrointest Liver Physiol, 312, pp. G635-G648, (2017); Rizopoulos T., Papadaki-Petrou H., Assimakopoulou M., Expression profiling of the transient receptor potential vanilloid (TRPV) channels 1, 2, 3 and 4 in mucosal epithelium of human ulcerative colitis, Cells, 7, (2018); Rodino-Janeiro B.K., Pardo-Camacho C., Santos J., Martinez C., Mucosal RNA and protein expression as the next frontier in IBS: abnormal function despite morphologically intact small intestinal mucosa, Am J Physiol Gastrointest Liver Physiol, 316, pp. G701-G719, (2019); Lievin-Le Moal V., Servin A.L., Coconnier-Polter M.-H., The increase in mucin exocytosis and the upregulation of MUC genes encoding for membrane-bound mucins induced by the thiol-activated exotoxin listeriolysin O is a host cell defence response that inhibits the cell-entry of Listeria monocytogenes, Cell Microbiol, 7, pp. 1035-1048, (2005); Yamamoto-Furusho J.K., Ascano-Gutierrez I., Furuzawa-Carballeda J., Fonseca-Camarillo G., Differential expression of MUC12, MUC16, and MUC20 in patients with active and remission ulcerative colitis, Mediators Inflamm, 2015, (2015); Camilleri M., Intestinal secretory mechanisms in irritable bowel syndrome-diarrhea, Clin Gastroenterol Hepatol, 13, pp. 1051-1057, (2015); Beckers A.B., Weerts Z., Helyes Z., Masclee A.A.M., Keszthelyi D., Review article: transient receptor potential channels as possible therapeutic targets in irritable bowel syndrome, Aliment Pharmacol Ther, 46, pp. 938-952, (2017); Simren M., Simms L., D'Souza D., Abrahamsson H., Bjornsson E.S., Lipid-induced colonic hypersensitivity in irritable bowel syndrome: the role of 5-HT3 receptors, Aliment Pharmacol Ther, 17, pp. 279-287, (2003); Saffouri G.B., Shields-Cutler R.R., Chen J., Et al., Small intestinal microbial dysbiosis underlies symptoms associated with functional gastrointestinal disorders, Nat Commun, 10, (2019); Vazquez-Roque M.I., Camilleri M., Smyrk T., Et al., Association of HLA-DQ gene with bowel transit, barrier function, and inflammation in irritable bowel syndrome with diarrhea, Am J Physiol Gastrointest Liver Physiol, 303, pp. G1262-G1269, (2012); Valentin N., Camilleri M., Carlson P., Harrington S.C., Eckert D., O'Neill J., Burton D., Chen J., Shaw A.L., Acosta A., Potential mechanisms of effects of serum-derived bovine immunoglobulin/protein isolate therapy in patients with diarrhea-predominant irritable bowel syndrome, Physiol Rep, 5, (2017); Camilleri M., Shin A., Busciglio I., Et al., Validating biomarkers of treatable mechanisms in irritable bowel syndrome, Neurogastroenterol Motil, 26, pp. 1677-1685, (2014); Mujagic Z., Ludidi S., Keszthelyi D., Et al., Small intestinal permeability is increased in diarrhoea predominant IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to confounders, Aliment Pharmacol Ther, 40, pp. 288-297, (2014); Zhou Q., Zhang B., Nicholas V.G., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Gecse K., Roka R., Sera T., Et al., Leaky gut in patients with diarrhea-predominant irritable bowel syndrome and inactive ulcerative colitis, Digestion, 85, pp. 40-46, (2012); Li L., Xiong L., Yao J., Et al., Increased small intestinal permeability and RNA expression profiles of mucosa from terminal ileum in patients with diarrhoea-predominant irritable bowel syndrome, Dig Liver Dis, 48, pp. 880-887, (2016); Zhao D.Y., Qi Q.Q., Long X., Et al., Ultrastructure of intestinal mucosa in diarrhea-predominant irritable bowel syndrome, Physiol Int, 106, pp. 225-235, (2019); Martinez C., Lobo B., Pigrau M., Et al., Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, pp. 1160-1168, (2013); Fritscher-Ravens A., Pflaum T., Mosinger M., Et al., Many patients with irritable bowel syndrome have atypical food allergies not associated with immunoglobulin E, Gastroenterology, 157, pp. 109-118, (2019); Balemans D., Aguilera-Lizarraga J., Florens M.V., Et al., Histamine-mediated potentiation of transient receptor potential (TRP) ankyrin 1 and TRP vanilloid 4 signaling in submucosal neurons in patients with irritable bowel syndrome, Am J Physiol Gastrointest Liver Physiol, 316, pp. G338-G349, (2019); Wouters M.M., Balemans D., Van Wanrooy S., Et al., Histamine receptor H1-mediated sensitization of TRPV1 mediates visceral hypersensitivity and symptoms in patients with irritable bowel syndrome, Gastroenterology, 150, (2016); Akbar A., Yiangou Y., Facer P., Walters J.R., Anand P., Ghosh S., Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain, Gut, 57, pp. 923-929, (2008); Akbar A., Yiangou Y., Facer P., Et al., Expression of the TRPV1 receptor differs in quiescent inflammatory bowel disease with or without abdominal pain, Gut, 59, pp. 767-774, (2010); Gonlachanvit S., Mahayosnond A., Kullavanijaya P., Effects of chili on postprandial gastrointestinal symptoms in diarrhoea predominant irritable bowel syndrome: evidence for capsaicin-sensitive visceral nociception hypersensitivity, Neurogastroenterol Motil, 21, pp. 23-32, (2009); Lapointe T.K., Basso L., Iftinca M.C., Et al., TRPV1 sensitization mediates postinflammatory visceral pain following acute colitis, Am J Physiol Gastrointest Liver Physiol, 309, pp. G87-99, (2015); Ueda T., Yamada T., Ugawa S., Ishida Y., Shimada S., TRPV3, a thermosensitive channel is expressed in mouse distal colon epithelium, Biochem Biophys Res Commun, 383, pp. 130-134, (2009); Toledo Maurino J.J., Fonseca-Camarillo G., Furuzawa-Carballeda J., Et al., TRPV subfamily (TRPV2, TRPV3, TRPV4, TRPV5, and TRPV6) gene and protein expression in patients with ulcerative colitis, J Immunol Res, 2020, (2020); De Petrocellis L., Orlando P., Moriello A.S., Et al., Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation, Acta Physiol, 204, pp. 255-266, (2012); Camilleri M., Carlson P., Acosta A., Et al., RNA sequencing shows transcriptomic changes in rectosigmoid mucosa in patients with irritable bowel syndrome-diarrhea: a pilot case-control study, Am J Physiol Gastrointest Liver Physiol, 306, pp. G1089-G1098, (2014); Coates M.D., Mahoney C.R., Linden D.R., Et al., Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome, Gastroenterology, 126, pp. 1657-1664, (2004); Kerckhoffs A.P., ter Linde J.J., Akkermans L.M., Samsom M., SERT and TPH-1 mRNA expression are reduced in irritable bowel syndrome patients regardless of visceral sensitivity state in large intestine, Am J Physiol Gastrointest Liver Physiol, 302, pp. G1053-G1060, (2012); Mars R.A.T., Yang Y., Ward T., Et al., Longitudinal multi-omics reveals subset-specific mechanisms underlying irritable bowel syndrome, Cell, 182, (2020)","M. Grover; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, United States; email: grover.madhusudan@mayo.edu","","John Wiley and Sons Inc","","","","","","02692813","","APTHE","34472640","English","Aliment. Pharmacol. Ther.","Article","Final","All Open Access; Green Open Access","Scopus","2-s2.0-85114013455"

"Dale H.F.; Johannessen J.C.H.; Brønstad I.; Lied G.A.","Dale, Hanna Fjeldheim (57202963187); Johannessen, Julianne C. H. (57369012400); Brønstad, Ingeborg (36449808400); Lied, Gülen Arslan (26030494000)","57202963187; 57369012400; 36449808400; 26030494000","Assessment of markers of gut integrity and inflammation in non-celiac gluten sensitivity after a gluten free-diet","2021","International Journal of General Medicine","14","","","9459","9470","11","1","10.2147/IJGM.S333078","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85120965314&doi=10.2147%2fIJGM.S333078&partnerID=40&md5=b2cbf1fcb33fb76134174d0d9f103dd8","Centre for Nutrition, Department of Clinical Medicine, University of Bergen, Bergen, Norway; Division of Gastroenterology, Department of Medicine, Haukeland University Hospital, Bergen, Norway; National Centre of Functional Gastrointestinal Disorders, Haukeland University Hospital, Bergen, Norway","Dale H.F., Centre for Nutrition, Department of Clinical Medicine, University of Bergen, Bergen, Norway, Division of Gastroenterology, Department of Medicine, Haukeland University Hospital, Bergen, Norway, National Centre of Functional Gastrointestinal Disorders, Haukeland University Hospital, Bergen, Norway; Johannessen J.C.H., Centre for Nutrition, Department of Clinical Medicine, University of Bergen, Bergen, Norway; Brønstad I., Division of Gastroenterology, Department of Medicine, Haukeland University Hospital, Bergen, Norway, National Centre of Functional Gastrointestinal Disorders, Haukeland University Hospital, Bergen, Norway; Lied G.A., Centre for Nutrition, Department of Clinical Medicine, University of Bergen, Bergen, Norway, Division of Gastroenterology, Department of Medicine, Haukeland University Hospital, Bergen, Norway, National Centre of Functional Gastrointestinal Disorders, Haukeland University Hospital, Bergen, Norway","Purpose: Markers for gut integrity and inflammation have received increasing interest as intestinal permeability and innate immune system activation are suggested as possible pathophysiological mechanisms in non-celiac gluten sensitivity (NCGS). We aimed to assess relevant biomarkers in NCGS by analyzing serum levels of gut integrity and permeability markers, pro-inflammatory cytokines and antigliadin IgG in patients with suspected NCGS on a gluten-free diet (GFD), and compare them to serum levels in patients with irritable bowel syndrome (IBS) and healthy controls (HC). Patients and Methods: Serum samples collected from patients with suspected NCGS on a GFD (n=20, 14 women, 21–62 years), IBS (n=20, 16 women, 24–67 years) and HC (n=20, 14 women, 21–54 years) were analyzed. IBS severity scoring system (IBS-SSS) was applied to evaluate gastrointestinal symptoms. Results: The IBS-SSS score was higher in subjects with suspected NCGS and IBS patients compared to HC (p<0.0001). No significant differences were found in the serum levels of any of the gut integrity and permeability markers, cytokines or antigliadin IgG antibodies between the three groups. However, positive correlations were observed between claudin-1 and i-FABP, and between claudin-1 and antigliadin IgG antibodies. Conclusion: No differences in serum levels of gut integrity and permeability markers, proinflammatory cytokines or antigliadin IgG antibodies were found among patients with suspected NCGS on a GFD, IBS and HC. © 2021 Dale et al.","Gluten; Irritable bowel syndrome; Permeability; Pro-inflammatory cytokines","claudin 1; cytokine; fatty acid binding protein 2; gliadin antibody; immunoglobulin G antibody; interleukin 8; lipopolysaccharide binding protein; membrane protein; occludin; unclassified drug; zonulin family peptide; adult; antibody blood level; Article; clinical article; controlled study; descriptive research; digestive system disease assessment; enteritis; female; gastrointestinal symptom; gluten free diet; gut integrity; human; intestine mucosa permeability; intestine parameters; Irritable Bowel Syndrome Quality of Life; Irritable Bowel Syndrome Severity Scoring System; irritable colon; male; non-celiac gluten sensitivity; population research; protein blood level","","claudin 1, 329338-06-9; interleukin 8, 114308-91-7; lipopolysaccharide binding protein, 203946-66-1; occludin, 176304-61-3","","","","","Catassi C, Elli L, Bonaz B, Et al., Diagnosis of Non-Celiac Gluten Sensitivity (NCGS): the salerno experts’ criteria, Nutrients, 7, 6, pp. 4966-4977, (2015); Biesiekierski RJ, Newnham DE, Irving MP, Et al., Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial, Am J Gastroenterol, 106, 3, pp. 508-514, (2011); Volta U, Bardella MT, CalabrA A, Troncone R, Corazza GR., An Italian prospective multicenter survey on patients suspected of having non-celiac gluten sensitivity, BMC Med, 12, 1, (2014); Junker Y, Zeissig S, Kim S-J, Et al., Wheat amylase trypsin inhibitors drive intestinal inflammation via activation of toll-like receptor 4, J Exp Med, 209, (2012); Biesiekierski JR, Peters SL, Newnham ED, Rosella O, Muir JG, Gibson PR., No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates, Gastroenterology, 145, 2, pp. 320-328, (2013); Pellegrina CD, Perbellini O, Scupoli MT, Et al., Effects of wheat germ agglutinin on human gastrointestinal epithelium: insights from an experimental model of immune/epithelial cell interaction, Toxicol Appl Pharmacol, 237, 2, pp. 146-153, (2009); Elli L, Roncoroni L, Bardella MT., Non-celiac gluten sensitivity: time for sifting the grain, World J Gastroenterol, 21, 27, (2015); Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG, Diet A., Low in FODMAPs reduces symptoms of irritable bowel syndrome, Gastroenterology, 146, 1, pp. 67-75, (2014); Barrett JS, Gearry RB, Muir JG, Et al., Dietary poorly absorbed, short-chain carbohydrates increase delivery of water and fermentable substrates to the proximal colon. (Clinical report), Aliment Pharmacol Ther, 31, 8, (2010); Skodje GI, Sarna VK, Minelle IH, Et al., Fructan, rather than gluten, induces symptoms in patients with self-reported non-celiac gluten sensitivity, Gastroenterology, 154, 3, pp. 529-539, (2018); Dale HF, Hatlebakk JG, Hovdenak N, Ystad SO, Lied GA., The effect of a controlled gluten challenge in a group of patients with suspected noncoeliac gluten sensitivity: a randomized, double-blind placebo-controlled challenge, Neurogastroenterol Motility, 30, 8, (2018); Vazquez-Roque M, Oxentenko A., Nonceliac Gluten Sensitivity, Mayo Clin Proc, 90, 9, pp. 1272-1277, (2015); Carroccio A, Giannone G, Mansueto P, Et al., Duodenal and rectal mucosa inflammation in patients with non-celiac wheat sensitivity, Clin Gastroenterol Hepatol, 17, 4, pp. 682-690, (2019); Margit B, Ann-Christin RB, Stig T, Et al., Mucosal cytokine response after short-term gluten challenge in celiac disease and non-celiac gluten sensitivity, Am J Gastroenterol, 108, 5, (2013); Uhde M, Ajamian M, Caio G, Et al., Intestinal cell damage and systemic immune activation in individuals reporting sensitivity to wheat in the absence of coeliac disease, Gut, 65, 12, pp. 1930-1937, (2016); Fritscher-Ravens A, Pflaum T, Mosinger M, Et al., Many patients with irritable bowel syndrome have atypical food allergies not associated with immunoglobulin E, Gastroenterology, 157, 1, pp. 109-118, (2019); Barbaro M, Cremon C, Caio G, Et al., Zonulin serum levels are increased in non-celiac gluten sensitivity and irritable bowel syndrome with diarrhea, Gastroenterology, 148, 4, pp. S56-S56, (2015); Sapone A, Lammers K, Casolaro V, Et al., Divergence of gut permeability and mucosal immune gene expression in two gluten-associated conditions: celiac disease and gluten sensitivity, BMC Med, 9, (2011); Wang W, Uzzau S, Goldblum SE, Fasano A., Human zonulin, a potential modulator of intestinal tight junctions, J Cell Sci, 113, (2000); Lammers KM, Lu R, Brownley J, Et al., Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3, Gastroenterology, 135, 1, pp. 194-204, (2008); Fasano A., All disease begins in the (leaky) gut: role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases, F1000Res, 9, (2020); Schumann RR., Function of lipopolysaccharide (LPS)-binding protein (LBP) and CD14, the receptor for LPS/LBP complexes: a short review, Res Immunol, 143, 1, pp. 11-15, (1992); Adriaanse MP, Tack GJ, Passos VL, Et al., Serum I-FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies, Aliment Pharmacol Ther, 37, 4, pp. 482-490, (2013); Cardoso-Silva D, Delbue D, Itzlinger A, Et al., Intestinal barrier function in gluten-related disorders, Nutrients, 11, 10, (2019); Barmeyer C, Schulzke JD, Fromm M., Claudin-related intestinal diseases, Semin Cell Dev Biol, 42, pp. 30-38, (2015); Dale HF, Jensen C, Hausken T, Valeur J, Hoff DAL, Lied GA., Effects of a cod protein hydrolysate supplement on symptoms, gut integrity markers and fecal fermentation in patients with irritable bowel syndrome, Nutrients, 11, 7, (2019); Francis CY, Morris J, Whorwell PJ., The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress, Aliment Pharmacol Ther, 11, 2, pp. 395-402, (1997); Barbaro MR, Cremon C, Morselli-Labate AM, Et al., Serum zonulin and its diagnostic performance in non-coeliac gluten sensitivity, Gut, 69, 11, pp. 1966-1974, (2020); Vazquez-Roque MI, Camilleri M, Smyrk T, Et al., A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function, Gastroenterology, 144, 5, pp. 903-911, (2013); Kleiner G, Marcuzzi A, Zanin V, Monasta L, Zauli G., Cytokine levels in the serum of healthy subjects, Mediators Inflamm, 2013, (2013); Justin H, Elaine Leonard P, Bruce G, Eric G, Anthony G, Alessio F., Effect of gliadin on permeability of intestinal biopsy explants from celiac disease patients and patients with non-celiac gluten sensitivity, Nutrients, 7, 3, pp. 1565-1576, (2015); Lau E, Marques C, Pestana D, Et al., The role of I-FABP as a biomarker of intestinal barrier dysfunction driven by gut microbiota changes in obesity, Nutr Metab, 13, (2016); Molina-Infante J, Carroccio A., Suspected nonceliac gluten sensitivity confirmed in few patients after gluten challenge in double-blind, placebo-controlled trials, Clin Gastroenterol Hepatol, 15, 3, pp. 339-348, (2017)","H.F. Dale; Department of Clinical Medicine, University of Bergen, Bergen, Jonas Lies vei 65, 0521, Norway; email: hanna.dale@outlook.com","","Dove Medical Press Ltd","","","","","","11787074","","","","English","Int. J. Gen. Med.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85120965314"

"Caviglia G.P.; Rosso C.; Stalla F.; Rizzo M.; Massano A.; Abate M.L.; Olivero A.; Armandi A.; Vanni E.; Younes R.; Fagoonee S.; Pellicano R.; Astegiano M.; Saracco G.M.; Bugianesi E.; Ribaldone D.G.","Caviglia, Gian Paolo (24491739500); Rosso, Chiara (55613318800); Stalla, Francesco (57246805400); Rizzo, Martina (57218370997); Massano, Alessandro (57222495882); Abate, Maria Lorena (7004963939); Olivero, Antonella (55369742700); Armandi, Angelo (57204445604); Vanni, Ester (6601986579); Younes, Ramy (57195953766); Fagoonee, Sharmila (6603221574); Pellicano, Rinaldo (7005853671); Astegiano, Marco (6701316557); Saracco, Giorgio Maria (57205711772); Bugianesi, Elisabetta (6701433364); Ribaldone, Davide Giuseppe (57195507877)","24491739500; 55613318800; 57246805400; 57218370997; 57222495882; 7004963939; 55369742700; 57204445604; 6601986579; 57195953766; 6603221574; 7005853671; 6701316557; 57205711772; 6701433364; 57195507877","On-treatment decrease of serum interleukin-6 as a predictor of clinical response to biologic therapy in patients with inflammatory bowel diseases","2020","Journal of Clinical Medicine","9","3","800","","","","32","10.3390/jcm9030800","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85087289059&doi=10.3390%2fjcm9030800&partnerID=40&md5=68dbef23e8868ef47b07a4322aa67cf7","Department of Medical Sciences, University of Turin, Turin, 1016, Italy; Unit of Gastroenterology, Città della Salute e della Scienza di Torino-Molinette Hospital, Turin, 10126, Italy; Institute of Biostructure and Bioimaging, CNR c/o Molecular Biotechnology Centre, Turin, 10126, Italy","Caviglia G.P., Department of Medical Sciences, University of Turin, Turin, 1016, Italy; Rosso C., Department of Medical Sciences, University of Turin, Turin, 1016, Italy; Stalla F., Unit of Gastroenterology, Città della Salute e della Scienza di Torino-Molinette Hospital, Turin, 10126, Italy; Rizzo M., Unit of Gastroenterology, Città della Salute e della Scienza di Torino-Molinette Hospital, Turin, 10126, Italy; Massano A., Unit of Gastroenterology, Città della Salute e della Scienza di Torino-Molinette Hospital, Turin, 10126, Italy; Abate M.L., Department of Medical Sciences, University of Turin, Turin, 1016, Italy; Olivero A., Department of Medical Sciences, University of Turin, Turin, 1016, Italy; Armandi A., Unit of Gastroenterology, Città della Salute e della Scienza di Torino-Molinette Hospital, Turin, 10126, Italy; Vanni E., Unit of Gastroenterology, Città della Salute e della Scienza di Torino-Molinette Hospital, Turin, 10126, Italy; Younes R., Department of Medical Sciences, University of Turin, Turin, 1016, Italy; Fagoonee S., Institute of Biostructure and Bioimaging, CNR c/o Molecular Biotechnology Centre, Turin, 10126, Italy; Pellicano R., Unit of Gastroenterology, Città della Salute e della Scienza di Torino-Molinette Hospital, Turin, 10126, Italy; Astegiano M., Unit of Gastroenterology, Città della Salute e della Scienza di Torino-Molinette Hospital, Turin, 10126, Italy; Saracco G.M., Department of Medical Sciences, University of Turin, Turin, 1016, Italy; Bugianesi E., Department of Medical Sciences, University of Turin, Turin, 1016, Italy; Ribaldone D.G., Department of Medical Sciences, University of Turin, Turin, 1016, Italy","In patients with inflammatory bowel diseases (IBD) undergoing biologic therapy, biomarkers of treatment response are still scarce. This study aimed to evaluate whether serum zonulin, a biomarker of intestinal permeability; soluble CD163 (sCD163), a macrophage activation marker; and a panel of serum cytokines could predict the response to biologic treatment in patients with IBD. For this purpose, we prospectively enrolled 101 patients with IBD and 19 patients with irritable bowel syndrome (IBS) as a control group; 60 out of 101 patients underwent treatment with biologics. Zonulin, sCD163, and cytokines were measured at the baseline in all patients and after 10 weeks of treatment in the 60 patients who underwent biologic therapy. We observed that zonulin levels were higher in IBD patients with active disease compared to those in remission (p = 0.035), and that sCD163 values were higher in patients with IBD compared to those with IBS (p = 0.042), but no association with therapy response was observed for either biomarker. Conversely, interleukin (IL)-6, IL-8, IL-10, and tumor necrosis factor-alpha showed a significant reduction from baseline to week 10 of treatment, particularly in responder patients. By multivariate logistic regression analysis corrected for disease (Crohn’s disease or ulcerative colitis), type of biologic drug (Infliximab, Adalimumab, Vedolizumab, or Ustekinumab) and disease activity, the reduction in IL-6 values was associated with a clinical response at 12 months of biological therapy (odds ratio (OR) = 4.75, 95% confidence interval (CI) 1.25–18.02, p = 0.022). In conclusion, the measurement of serum IL-6 in biologics-treated IBD patients may allow for the prediction of response to treatment at 12 months of therapy and thus may help with tailoring personalized treatment strategies. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.","Adalimumab; Crohn’s disease; Cytokines; IL-6; SCD163; Ulcerative colitis; Ustekinumab; Vedolizumab; Zonulin","adalimumab; C reactive protein; CD163 antigen; corticosteroid; epstein Barr virus antibody; gamma interferon; hepatitis B core antigen; hepatitis B surface antigen; hepatitis C antigen; Human immunodeficiency virus antibody; infliximab; interleukin 10; interleukin 12p70; interleukin 17; interleukin 1beta; interleukin 23; interleukin 33; interleukin 4; interleukin 6; interleukin 8; mercaptopurine; mesalazine; steroid; tumor necrosis factor alpha receptor; tumor necrosis factor inhibitor; unclassified drug; unindexed drug; ustekinumab; varicella zoster virus antibody; vedolizumab; virus antibody; adult; aged; algorithm; Article; biological therapy; cohort analysis; colitis; colon disease; controlled study; Crohn disease; cross-sectional study; diarrhea; disease activity; enzyme linked immunosorbent assay; erythrocyte sedimentation rate; evaluation and follow up; female; Harvey Bradshaw index; human; ileocolic intussusception; ileum disease; inflammation; inflammatory bowel disease; intestine mucosa permeability; longitudinal study; macrophage activation; major clinical study; male; middle aged; Montreal cognitive assessment; multivariate logistic regression analysis; pancolitis; partial Mayo score; proctitis; prospective study; scoring system; treatment response time; ulcerative colitis; upper gastrointestinal tract; very elderly; young adult","","adalimumab, 331731-18-1, 1446410-95-2; C reactive protein, 9007-41-4; gamma interferon, 82115-62-6; infliximab, 170277-31-3; interleukin 8, 114308-91-7; mercaptopurine, 31441-78-8, 50-44-2, 6112-76-1; mesalazine, 89-57-6; ustekinumab, 815610-63-0, 949907-93-1; vedolizumab, 943609-66-3","Bio Plex, Biorad, United States; IDK Zonulin ELISA Kit, Immunodiagnostik, Germany; Luminex 200, Luminex, United States; Quantikine, R and D Systems, United States","Biorad, United States; Immunodiagnostik, Germany; Luminex, United States; R and D Systems, United States","","","Torres J., Mehandru S., Colombel J.F., Peyrin-Biroulet L., Crohn’s disease, Lancet, 389, pp. 1741-1755, (2017); Gargallo C.J., Lue A., Gomollon F., Biosimilars in inflammatory bowel disease, Minerva Med, 108, pp. 239-254, (2017); Caviglia G.P., Rosso C., Ribaldone D.G., Dughera F., Fagoonee S., Astegiano M., Pellicano R., Physiopathology of intestinal barrier and the role of zonulin, Minerva Biotecnol, 31, pp. 83-92, (2019); Khan I., Ullah N., Zha L., Bai Y., Khan A., Zhao T., Che T., Zhang C., Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome, Pathogens, 8, (2019); Actis G.C., Pellicano R., Fagoonee S., Ribaldone D.G., History of Inflammatory Bowel Diseases, J. Clin. Med., 8, (2019); Fasano A., Zonulin and its regulation of intestinal barrier function: The biological door to inflammation, autoimmunity, and cancer, Physiol. Rev., 91, pp. 151-175, (2011); Kim D.H., Cheon J.H., Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic Therapies, Immune Netw, 17, pp. 25-40, (2017); Caviglia G.P., Dughera F., Ribaldone D.G., Rosso C., Abate M.L., Pellicano R., Bresso F., Smedile A., Saracco G.M., Astegiano M., Serum zonulin in patients with inflammatory bowel disease: A pilot study, Minerva Med, 110, pp. 95-100, (2019); Ahluwalia B., Moraes L., Magnusson M.K., Ohman L., Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies, Scand. J. Gastroenterol., 53, pp. 379-389, (2018); Fasano A., All disease begins in the (Leaky) gut: Role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases, F1000res., 9, (2020); Dige A., Stoy S., Thomsen K.L., Hvas C.L., Agnholt J., Dahlerup J.F., Moller H.J., Gronbaek H., Soluble CD163, a specific macrophage activation marker, is decreased by anti-TNF-α antibody treatment in active inflammatory bowel disease, Scand. J. Immunol., 80, pp. 417-423, (2014); Schreiner P., Neurath M.F., Ng S.C., El-Omar E.M., Sharara A.I., Kobayashi T., Hisamatsu T., Hibi T., Rogler G., Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More, Inflamm. Intest. Dis., 4, pp. 79-96, (2019); Kayal M., Shah S., Ulcerative Colitis: Current and Emerging Treatment Strategies, J. Clin. Med., 9, (2020); Berg D.R., Colombel J.F., Ungaro R., The Role of Early Biologic Therapy in Inflammatory Bowel Disease, Inflamm. Bowel. Dis., 25, pp. 1896-1905, (2019); Yanai H., Hanauer S.B., Assessing response and loss of response to biological therapies in IBD, Am. J. Gastroenterol., 106, pp. 685-698, (2011); Magro F., Gionchetti P., Eliakim R., Ardizzone S., Armuzzi A., Barreiro-De Acosta M., Burisch J., Gecse K.B., Hart A.L., Hindryckx P., Et al., Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders, J. Crohns Colitis, 11, pp. 649-670, (2017); Gomollon F., Dignass A., Annese V., Tilg H., van Assche G., Lindsay J.O., Peyrin-Biroulet L., Cullen G.J., Daperno M., Kucharzik T., Et al., 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: Part 1: Diagnosis and medical management, J. Crohn Colitis, 11, pp. 3-25, (2017); Silverberg M.S., Satsangi J., Ahmad T., Arnott I.D., Bernstein C.N., Brant S.R., Caprilli R., Colombel J.F., Gasche C., Geboes K., Et al., Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a working party of the 2005 Montreal world congress of gastroenterology, Can. J. Gastroenterol., 19, pp. 5-36, (2005); Harvey R.F., Bradshaw M.J., Measuring Crohn’s disease activity, Lancet, 1, pp. 1134-1135, (1980); Lewis J.D., Chuai S., Nessel L., Lichtenstein G.R., Aberra F.N., Ellenberg J.H., Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis, Inflamm. Bowel. Dis., 14, pp. 1660-1666, (2008); Peyrin-Biroulet L., Sandborn W., Sands B.E., Reinisch W., Bemelman W., Bryant R.V., D'Haens G., Dotan I., Dubinsky M., Feagan B., Et al., Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target, Am. J. Gastroenterol, 110, (2015); Arrieta M.C., Madsen K., Doyle J., Meddings J., Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse, Gut, 58, pp. 41-48, (2009); Singh P., Silvester J., Chen X., Xu H., Sawhney V., Rangan V., Iturrino J., Nee J., Duerksen D.R., Lembo A., Serum zonulin is elevated in IBS and correlates with stool frequency in IBS-D, United Eur. Gastroenterol. J., 7, pp. 709-715, (2019); Linsalata M., Riezzo G., D'Attoma B., Clemente C., Orlando A., Russo F., Noninvasive biomarkers of gut barrier function identify two subtypes of patients suffering from diarrhoea predominant-IBS: A case-control study, BMC Gastroenterol, 18, (2018); Kamada N., Hisamatsu T., Okamoto S., Chinen H., Kobayashi T., Sato T., Sakuraba A., Kitazume M.T., Sugita A., Koganei K., Et al., Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis, J. Clin. Invest., 118, pp. 2269-2280, (2008); Wallace K.L., Zheng L.B., Kanazawa Y., Shih D.Q., Immunopathology of inflammatory bowel disease, World J. Gastroenterol, 20, pp. 6-21, (2014); Huang Y., Chen Z., Inflammatory bowel disease related innate immunity and adaptive immunity, Am. J. Transl. Res, 8, pp. 2490-2497, (2016); Franze E., Caruso R., Stolfi C., Sarra M., Cupi M.L., Caprioli F., Monteleone I., Zorzi F., de Nitto D., Colantoni A., Et al., Lesional accumulation of CD163-expressing cells in the gut of patients with inflammatory bowel disease, Plos One, 8, (2013); Marafini I., Sedda S., Dinallo V., Monteleone G., Inflammatory cytokines: From discoveries to therapies in IBD, Expert. Opin. Biol., 19, pp. 1207-1217, (2019); Bertani L., Antonioli L., Fornai M., Tapete G., Baiano Svizzero G., Marchi S., Blandizzi C., Costa F., Evaluation of cytokine levels as putative biomarkers to predict the pharmacological response to biologic therapy in inflammatory bowel diseases, Minerva Gastroenterol. Dietol., 65, pp. 298-308, (2019); Bertani L., Baglietto L., Antonioli L., Fornai M., Tapete G., Albano E., Ceccarelli L., Mumolo M.G., Pellegrini C., Lucenteforte E., Et al., Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients, Br. J. Clin. Pharm., (2020); Suzuki Y., Matsui T., Ito H., Ashida T., Nakamura S., Motoya S., Matsumoto T., Sato N., Ozaki K., Watanabe M., Et al., Circulating Interleukin 6 and Albumin, and Infliximab Levels Are Good Predictors of Recovering Efficacy After Dose Escalation Infliximab Therapy in Patients with Loss of Response to Treatment for Crohn’s Disease: A Prospective Clinical Trial, Inflamm. Bowel. Dis., 21, pp. 2114-2122, (2015); Nishida Y., Hosomi S., Watanabe K., Watanabe K., Yukawa T., Otani K., Nagami Y., Tanaka F., Taira K., Kamata N., Et al., Serum interleukin-6 level is associated with response to infliximab in ulcerative colitis, Scand. J. Gastroenterol., 53, pp. 579-585, (2018); Wine E., Mack D.R., Hyams J., Otley A.R., Markowitz J., Crandall W.V., Leleiko N., Muise A.M., Griffiths A.M., Turner D., Interleukin-6 is associated with steroid resistance and reflects disease activity in severe pediatric ulcerative colitis, J. Crohns Colitis, 7, pp. 916-922, (2013)","G.P. Caviglia; Department of Medical Sciences, University of Turin, Turin, 1016, Italy; email: gianpaolo.caviglia@unito.it","","MDPI","","","","","","20770383","","","","English","J. Clin. Med.","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85087289059"

"Jiang Y.; Song J.; Xu Y.; Liu C.; Qian W.; Bai T.; Hou X.","Jiang, Yudong (57194091337); Song, Jun (56226572400); Xu, Yan (57208548375); Liu, Caiyuan (57221305306); Qian, Wei (35238189900); Bai, Tao (7101922692); Hou, Xiaohua (7402838898)","57194091337; 56226572400; 57208548375; 57221305306; 35238189900; 7101922692; 7402838898","Piezo1 regulates intestinal epithelial function by affecting the tight junction protein claudin-1 via the ROCK pathway","2021","Life Sciences","275","","119254","","","","56","10.1016/j.lfs.2021.119254","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102872771&doi=10.1016%2fj.lfs.2021.119254&partnerID=40&md5=4be09a2d2a85c7d253c22fffcab377b8","Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, Hubei Province, China","Jiang Y., Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, Hubei Province, China; Song J., Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, Hubei Province, China; Xu Y., Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, Hubei Province, China; Liu C., Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, Hubei Province, China; Qian W., Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, Hubei Province, China; Bai T., Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, Hubei Province, China; Hou X., Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, Hubei Province, China","Aims: Defective tight junctions (TJs) can induce intestinal epithelial dysfunction, which participates in various diseases such as irritable bowel syndrome. However, the mechanisms of TJ defects remain unclear. Our study revealed the role of Piezo1 in regulating intestinal epithelial function and TJs. Materials and methods: The human colonic adenocarcinoma cell line Caco-2 were cultured on Transwell plate to form an epithelial barrier in vitro, and Piezo1 expression was manipulated using a lentivirus vector. Epithelial function was evaluated by measuring transepithelial electronic resistance (TEER) and 4-kDa FITC-dextran (FD4) transmission. TJ proteins (claudin-1, occludin, ZO-1) were evaluated by RT-PCR, western blot, and immunostaining analysis. Potential signal pathways, including the ROCK and Erk pathways, were detected. Moreover, to explore the regulatory effect of Piezo1 activity on epithelial function, inhibitors (ruthenium red, GsMTx4) and an agonist (Yoda1) were introduced both ex vivo and in vitro. Key findings: Alteration of Piezo1 expression altered epithelial function and the expression of the tight junction protein claudin-1. Piezo1 expression regulated phosphorylated ROCK1/2 expression, whereas interference on ROCK1/2 prevented the regulation of claudin-1 by Piezo1. In both Caco-2 monolayer and mouse colon epithelium, Piezo1 activity directly modulated epithelial function and permeability. Significance: Piezo1 negatively regulates epithelial barrier function by affecting the expression of claudin-1. Such regulation may be achieved partially via the ROCK1/2 pathway. Moreover, activating Piezo1 can induce epithelial dysfunction. © 2021 Elsevier Inc.","Claudin-1; Claudin-1; Erk; FITC-dextran; GsMTx4; Intestinal epithelial function; Occludin; Piezo1; ROCK; ROCK; Tight junction; U46619; Y-27632; Yoda1; ZO-1","Animals; Blotting, Western; Caco-2 Cells; Claudin-1; Humans; Intestinal Mucosa; Ion Channels; Male; Mice; Mice, Inbred C57BL; Occludin; Real-Time Polymerase Chain Reaction; rho-Associated Kinases; Signal Transduction; Zonula Occludens-1 Protein; cell protein; claudin 1; dextran; fluorescein isothiocyanate; mitogen activated protein kinase; occludin; Piezo1 protein; protein ZO1; ROCK1 protein; ruthenium; unclassified drug; claudin 1; CLDN1 protein, human; ion channel; occludin; OCLN protein, human; PIEZO1 protein, human; protein ZO1; Rho kinase; ROCK1 protein, human; ROCK2 protein, human; TJP1 protein, human; animal tissue; Article; Caco-2 cell line; cell culture; controlled study; ex vivo study; human; human cell; immunohistochemistry; in vitro study; intestine epithelium; mouse; nonhuman; protein expression; protein phosphorylation; reverse transcription polymerase chain reaction; signal transduction; transepithelial resistance; Western blotting; animal; C57BL mouse; intestine mucosa; male; metabolism; physiology; real time polymerase chain reaction","","claudin 1, 329338-06-9; dextran, 87915-38-6, 9014-78-2; fluorescein isothiocyanate, 25168-13-2, 27072-45-3, 3326-32-7; mitogen activated protein kinase, 142243-02-5; occludin, 176304-61-3; ruthenium, 7440-18-8; Claudin-1, ; CLDN1 protein, human, ; Ion Channels, ; Occludin, ; OCLN protein, human, ; PIEZO1 protein, human, ; rho-Associated Kinases, ; ROCK1 protein, human, ; ROCK2 protein, human, ; TJP1 protein, human, ; Zonula Occludens-1 Protein, ","","","National Natural Science Foundation of China, NSFC, (81670488, 81873553)","Our research was supported and sponsored by two general projects of National Natural Science Foundation of China (No. 81670488 , NO. 81873553 ).","Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Lecleire S., Antonietti M., Gourcerol G., Leroi A.M., Dechelotte P., Menard J.F., Ducrotte P., Coeffier M., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am. J. Gastroenterol., 106, 12, pp. 2165-2173, (2011); Piche T., Barbara G., Aubert P., Bruley D.V.S., Dainese R., Nano J.L., Cremon C., Stanghellini V., De Giorgio R., Galmiche J.P., Neunlist M., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators, Gut, 58, 2, pp. 196-201, (2009); Overman E.L., Rivier J.E., Moeser A.J., CRF induces intestinal epithelial barrier injury via the release of mast cell proteases and TNF-alpha, PLoS One, 7, 6, (2012); Vivinus-Nebot M., Dainese R., Anty R., Saint-Paul M.C., Nano J.L., Gonthier N., Marjoux S., Frin-Mathy G., Bernard G., Hebuterne X., Tran A., Theodorou V., Piche T., Combination of allergic factors can worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells, Am. J. Gastroenterol., 107, 1, pp. 75-81, (2012); Coeffier M., Gloro R., Boukhettala N., Aziz M., Lecleire S., Vandaele N., Antonietti M., Savoye G., Bole-Feysot C., Dechelotte P., Reimund J.M., Ducrotte P., Increased proteasome-mediated degradation of occludin in irritable bowel syndrome, Am. J. Gastroenterol., 105, 5, pp. 1181-1188, (2010); Coste B., Mathur J., Schmidt M., Earley T.J., Ranade S., Petrus M.J., Dubin A.E., Patapoutian A., Piezo1 and Piezo2 are essential components of distinct mechanically activated cation channels, Science, 330, 6000, pp. 55-60, (2010); Michishita M., Yano K., Tomita K.I., Matsuzaki O., Kasahara K.I., Piezo1 expression increases in rat bladder after partial bladder outlet obstruction, Life Sci., 166, pp. 1-7, (2016); Jetta D., Gottlieb P.A., Verma D., Sachs F., Hua S.Z., Shear stress-induced nuclear shrinkage through activation of Piezo1 channels in epithelial cells, J. Cell Sci., 132, 11, (2019); Hyman A.J., Tumova S., Beech D.J., Piezo1 channels in vascular development and the sensing of shear stress, Curr. Top. Membr., 79, pp. 37-57, (2017); Eisenhoffer G.T., Loftus P.D., Yoshigi M., Otsuna H., Chien C.B., Morcos P.A., Rosenblatt J., Crowding induces live cell extrusion to maintain homeostatic cell numbers in epithelia, Nature, 484, 7395, pp. 546-549, (2012); Alcaino C., Knutson K.R., Treichel A.J., Yildiz G., Strege P.R., Linden D.R., Li J.H., Leiter A.B., Szurszewski J.H., Farrugia G., Beyder A., A population of gut epithelial enterochromaffin cells is mechanosensitive and requires Piezo2 to convert force into serotonin release, Proc. Natl. Acad. Sci. U. S. A., 115, 32, (2018); Bai T., Li Y., Xia J., Jiang Y., Zhang L., Wang H., Qian W., Song J., Hou X., Piezo2: a candidate biomarker for visceral hypersensitivity in irritable bowel syndrome?, J. Neurogastroenterol. Motil., (2017); Friedrich E.E., Hong Z., Xiong S., Zhong M., Di A., Rehman J., Komarova Y.A., Malik A.B., Endothelial cell Piezo1 mediates pressure-induced lung vascular hyperpermeability via disruption of adherens junctions, Proc. Natl. Acad. Sci. U. S. A., 116, 26, pp. 12980-12985, (2019); Kwon J., Kim N.H., Choi I., ROCK activity regulates functional tight junction assembly during blastocyst formation in porcine parthenogenetic embryos, PeerJ., 4, (2016); Elamin E., Masclee A., Dekker J., Jonkers D., Ethanol disrupts intestinal epithelial tight junction integrity through intracellular calcium-mediated Rho/ROCK activation, Am. J. Physiol. Gastrointest. Liver Physiol., 306, 8, (2014); Utech M., Ivanov A.I., Samarin S.N., Bruewer M., Turner J.R., Mrsny R.J., Parkos C.A., Nusrat A., Mechanism of IFN-gamma-induced endocytosis of tight junction proteins: myosin II-dependent vacuolarization of the apical plasma membrane, Mol. Biol. Cell, 16, 10, pp. 5040-5052, (2005); Al-Sadi R., Guo S., Ye D., Ma T.Y., TNF-alpha modulation of intestinal epithelial tight junction barrier is regulated by ERK1/2 activation of Elk-1, Am. J. Pathol., 183, 6, pp. 1871-1884, (2013); Ishizaki T., Uehata M., Tamechika I., Keel J., Nonomura K., Maekawa M., Narumiya S., Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases, Mol. Pharmacol., 57, 5, pp. 976-983, (2000); Pang H., Guo Z., Su W., Xie Z., Eto M., Gong M.C., RhoA-Rho kinase pathway mediates thrombin- and U-46619-induced phosphorylation of a myosin phosphatase inhibitor, CPI-17, in vascular smooth muscle cells, Am. J. Phys. Cell Physiol., 289, 2, (2005); Coste B., Xiao B., Santos J.S., Syeda R., Grandl J., Spencer K.S., Kim S.E., Schmidt M., Mathur J., Dubin A.E., Montal M., Patapoutian A., Piezo proteins are pore-forming subunits of mechanically activated channels, Nature, 483, 7388, pp. 176-181, (2012); Gnanasambandam R., Ghatak C., Yasmann A., Nishizawa K., Sachs F., Ladokhin A.S., Sukharev S.I., Suchyna T.M., GsMTx4: mechanism of inhibiting mechanosensitive ion channels, Biophys. J., 112, 1, pp. 31-45, (2017); Syeda R., Xu J., Dubin A.E., Coste B., Mathur J., Huynh T., Matzen J., Lao J., Tully D.C., Engels I.H., Petrassi H.M., Schumacher A.M., Montal M., Bandell M., Patapoutian A., Chemical activation of the mechanotransduction channel Piezo1, Elife, (2015); Lacroix J.J., Botello-Smith W.M., Luo Y., Probing the gating mechanism of the mechanosensitive channel Piezo1 with the small molecule Yoda1, Nat. Commun., 9, 1, (2018); Li M., Oshima T., Ito C., Yamada M., Tomita T., Fukui H., Miwa H., Glutamine blocks interleukin-13-induced intestinal epithelial barrier dysfunction, Digestion, pp. 1-10, (2019); Wilcz-Villega E.M., Mcclean S., O'Sullivan M.A., Mast cell tryptase reduces junctional adhesion molecule-A (JAM-A) expression in intestinal epithelial cells: implications for the mechanisms of barrier dysfunction in irritable bowel syndrome, Am. J. Gastroenterol., 108, 7, pp. 1140-1151, (2013); Piche T., Tight junctions and IBS—the link between epithelial permeability, low-grade inflammation, and symptom generation?, Neurogastroenterol. Motil., 26, 3, pp. 296-302, (2014); Wang Y., Wang X., Yang W., Zhao X., Zhang R., Effect of simvastatin on the intestinal Rho/ROCK signaling pathway in rats with sepsis, J. Surg. Res., 232, pp. 531-538, (2018); Li Z., Gao M., Yang B., Zhang H., Wang K., Liu Z., Xiao X., Yang M., Naringin attenuates MLC phosphorylation and NF-kappaB activation to protect sepsis-induced intestinal injury via RhoA/ROCK pathway, Biomed. Pharmacother., 103, pp. 50-58, (2018); Walsh S.V., Hopkins A.M., Chen J., Narumiya S., Parkos C.A., Nusrat A., Rho kinase regulates tight junction function and is necessary for tight junction assembly in polarized intestinal epithelia, Gastroenterology, 121, 3, pp. 566-579, (2001); Mousawi F., Peng H., Li J., Sreenivasan P., Roger S., Zhao H., Yang X., Jiang L.H., Chemical activation of the Piezo1 channel drives mesenchymal stem cell migration via inducing ATP release and activation of P2 receptor purinergic signalling, Stem Cells, (2019); Velasco I., Moran J., Tapia R., Selective neurotoxicity of ruthenium red in primary cultures, Neurochem. Res., 20, 5, pp. 599-604, (1995); Hamilton M.G., Lundy P.M., Effect of ruthenium red on voltage-sensitive Ca++ channels, J. Pharmacol. Exp. Ther., 273, 2, pp. 940-947, (1995); Corbalan-Garcia S., Teruel J.A., Gomez-Fernandez J.C., Characterization of ruthenium red-binding sites of the Ca(2+)-ATPase from sarcoplasmic reticulum and their interaction with Ca(2+)-binding sites, Biochem. J., 287, pp. 767-774, (1992); Gottlieb P.A., Suchyna T.M., Sachs F., Properties and mechanism of the mechanosensitive ion channel inhibitor GsMTx4, a therapeutic peptide derived from tarantula venom, Curr. Top. Membr., 59, pp. 81-109, (2007)","T. Bai; Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 1277 Jiefang Avenue, 430022, China; email: drbaitao@126.com","","Elsevier Inc.","","","","","","00243205","","LIFSA","33636174","English","Life Sci.","Article","Final","","Scopus","2-s2.0-85102872771"

"Horie H.; Handa O.; Naito Y.; Majima A.; Yasuda-Onozawa Y.; Uehara Y.; Kamada K.; Katada K.; Uchiyama K.; Ishikawa T.; Takagi T.; Itoh Y.; Shiotani A.","Horie, Hideki (56326369100); Handa, Osamu (6602192347); Naito, Yuji (55138675100); Majima, Atsushi (57189716076); Yasuda-Onozawa, Yuriko (57196355795); Uehara, Yukiko (56326133700); Kamada, Kazuhiro (8380912900); Katada, Kazuhiro (7006665029); Uchiyama, Kazuhiko (7201456543); Ishikawa, Takeshi (34770511800); Takagi, Tomohisa (7403554058); Itoh, Yoshito (7403646430); Shiotani, Akiko (55559820600)","56326369100; 6602192347; 55138675100; 57189716076; 57196355795; 56326133700; 8380912900; 7006665029; 7201456543; 34770511800; 7403554058; 7403646430; 55559820600","Subepithelial Serotonin Reduces Small Intestinal Epithelial Cell Tightness via Reduction of Occluding Expression","2022","Turkish Journal of Gastroenterology","33","1","","74","79","5","2","10.5152/tjg.2022.20691","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85123567658&doi=10.5152%2ftjg.2022.20691&partnerID=40&md5=3669ae5094b97f4a6e70ef9b5c6b6bc4","Horie Internal Medicine Clinic, Kyoto, Kyoto-city, Japan; Division of Gastroenterology, Department of Internal Medicine, Kawasaki Medical School, Okayama, Kurashiki-city, Japan; Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Kyoto-city, Japan","Horie H., Horie Internal Medicine Clinic, Kyoto, Kyoto-city, Japan; Handa O., Division of Gastroenterology, Department of Internal Medicine, Kawasaki Medical School, Okayama, Kurashiki-city, Japan; Naito Y., Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Kyoto-city, Japan; Majima A., Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Kyoto-city, Japan; Yasuda-Onozawa Y., Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Kyoto-city, Japan; Uehara Y., Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Kyoto-city, Japan; Kamada K., Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Kyoto-city, Japan; Katada K., Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Kyoto-city, Japan; Uchiyama K., Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Kyoto-city, Japan; Ishikawa T., Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Kyoto-city, Japan; Takagi T., Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Kyoto-city, Japan; Itoh Y., Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Kyoto-city, Japan; Shiotani A., Division of Gastroenterology, Department of Internal Medicine, Kawasaki Medical School, Okayama, Kurashiki-city, Japan","Background: The precise pathogenesis of irritable bowel syndrome (IBS) remains unresolved; however, recent studies have reported that patients with diarrhea-predominant IBS exhibit an increased small intestinal permeability and increased number of enterochromaffin cells containing high 5-hydroxytryptamine (5HT; serotonin) levels. In this study, we investigated whether 5HT has the potential to modulate small intestinal epithelial cell permeability, focusing on tight junction-associated proteins. Methods: The differentiated Caco-2 cell monolayer on porous filters (Millicell) was used. Then, 5HT was added to the lower Millicell compartment for 7 days. Intestinal epithelial cell permeability was assessed by measuring the flux of paracellular permeability markers. We further assessed the expression of occludin in the 5HT-stimulated Caco-2 monolayer. Results: We found that 5HT did not affect the viability of Caco-2 cells at concentrations up to 100 µM during the experimental period. Administration of 5HT to the basal side of Caco-2 cells increased the flux of 3H-labeled mannitol (182 Da) but did not increase that of FITC-dextran (4000 Da). Among the tight junction proteins, the expression of occludin was specifically decreased by stimulation with 5HT at a concentration of 100 µM. Conclusion: In conclusion, excessive 5HT in the basal side increased the permeability of intestinal epithelial cells via reduction of occludin expression. © Copyright 2022 by The Turkish Society of Gastroenterology","epithelial cell; Irritable bowel syndrome; permeability; serotonin; tight junction","Caco-2 Cells; Epithelial Cells; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Occludin; Serotonin; Tight Junctions; occludin; serotonin; tight junction protein; occludin; Article; Caco-2 cell line; cell differentiation; cell membrane permeability; cell viability; clinical effectiveness; controlled study; drug effect; drug efficacy; drug mechanism; drug response; human; human cell; intestine epithelium cell; protein expression; small intestine epithelium; epithelium cell; intestine mucosa; irritable colon; metabolism; tight junction","","occludin, 176304-61-3; serotonin, 50-67-9; Occludin, ; Serotonin, ","","","","","El-Salhy M., Irritable bowel syndrome: diagnosis and pathogenesis, World J Gastroenterol, 18, 37, pp. 5151-5163, (2012); Garakani A, Win T, Virk S, Et al., Comorbidity of irritable bowel syndrome in psychiatric patients: a review, Am J Ther, 10, 1, pp. 61-67, (2003); Zhou H, Li D, Cheng G, Fan J, Lu H., An epidemiologic study of irritable bowel syndrome in adolescents and children in South China: a school-based study, Child Care Health Dev, 36, 6, pp. 781-786, (2010); Bai T, Xia J, Jiang Y, Et al., Comparison of the Rome IV and Rome III criteria for IBS diagnosis: a cross-sectional survey, J Gastroenterol Hepatol, 32, 5, pp. 1018-1025, (2017); Matricon J, Meleine M, Gelot A, Et al., Review article: associations between immune activation, intestinal permeability and the irritable bowel syndrome, Aliment Pharmacol Ther, 36, 11-12, pp. 1009-1031, (2012); Camilleri M., Serotonin in the gastrointestinal tract, Curr Opin Endocrinol Diabetes Obes, 16, 1, pp. 53-59, (2009); Dizdar V, Spiller R, Singh G, Et al., Relative importance of abnormalities of CCK and 5-HT (serotonin) in Giardia-induced post-infectious irritable bowel syndrome and functional dyspepsia, Aliment Pharmacol Ther, 31, 8, pp. 883-891, (2010); Wang SH, Dong L, Luo JY, Et al., Decreased expression of serotonin in the jejunum and increased numbers of mast cells in the terminal ileum in patients with irritable bowel syndrome, World J Gastroenterol, 13, 45, pp. 6041-6047, (2007); Costa JL, Murphy DL, Stark H., Applicability of models for carrier-mediated serotonin transport to pools of serotonin in intact human platelets, J Physiol, 316, pp. 153-161, (1981); Gershon MD, Tack J., The serotonin signaling system: from basic understanding to drug development for functional GI disorders, Gastroenterology, 132, 1, pp. 397-414, (2007); Cooke HJ., Neurotransmitters in neuronal reflexes regulating intestinal secretion, Ann N Y Acad Sci, 915, pp. 77-80, (2000); Chin A, Svejda B, Gustafsson BI, Et al., The role of mechanical forces and adenosine in the regulation of intestinal enterochromaffin cell serotonin secretion, Am J Physiol Gastrointest Liver Physiol, 302, 3, pp. G397-G405, (2012); Latorre E, Mendoza C, Matheus N, Et al., IL-10 modulates serotonin transporter activity and molecular expression in intestinal epithelial cells, Cytokine, 61, 3, pp. 778-784, (2013); Dunlop SP, Hebden J, Campbell E, Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, 6, pp. 1288-1294, (2006); Piche T, Barbara G, Aubert P, Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: Involvement of soluble mediators, Gut, 58, 2, pp. 196-201, (2009); Wilcz-Villega EM, McClean S, O'Sullivan MA., Mast cell tryptase reduces junctional adhesion molecule-A (JAM-A) expression in intestinal epithelial cells: Implications for the mechanisms of barrier dysfunction in irritable bowel syndrome, Am J Gastroenterol, 108, 7, pp. 1140-1151, (2013); Ma TY, Tran D, Hoa N, Et al., Mechanism of extracellular calcium regulation of intestinal epithelial tight junction permeability: role of cytoskeletal involvement, Microsc Res Tech, 51, 2, pp. 156-168, (2000); Beaurepaire C, Smyth D, McKay DM., Interferon-gamma regulation of intestinal epithelial permeability, J Interferon Cytokine Res, 29, 3, pp. 133-144, (2009); Suzuki T., Regulation of intestinal epithelial permeability by tight junctions, Cell Mol Life Sci, 70, 4, pp. 631-659, (2013); Bhattacharyya S, Jagroop A, Gujral DM, Et al., Circulating plasma and platelet 5-hydroxytryptamine in carcinoid heart disease: a pilot study, J Heart Valve Dis, 22, 3, pp. 400-407, (2013); Wendelbo I, Mazzawi T, El-Salhy M., Increased serotonin transporter immunoreactivity intensity in the ileum of patients with irritable bowel disease, Mol Med Rep, 9, 1, pp. 180-184, (2014); Filip M, Bader M., Overview on 5-HT receptors and their role in physiology and pathology of the central nervous system, Pharmacol Rep, 61, 5, pp. 761-777, (2009); Coates MD, Mahoney CR, Linden DR, Et al., Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome, Gastroenterology, 126, 7, pp. 1657-1664, (2004); Majima A, Handa O, Naito Y, Et al., Real-time monitoring of trans-epithelial electrical resistance in cultured intestinal epithelial cells: The barrier protection of water-soluble dietary fiber, J Dig Dis, 18, 3, pp. 151-159, (2017); Eigenmann DE, Xue G, Kim KS, Et al., Comparative study of four immortalized human brain capillary endothelial cell lines, hCMEC/D3, hBMEC, TY10, and BB19, and optimization of culture conditions, for an in vitro blood-brain barrier model for drug permeability studies, Fluids Barriers CNS, 10, 1, (2013); Handa O, Stephen J, Cepinskas G., Role of endothelial nitric oxide synthase-derived nitric oxide in activation and dysfunction of cerebrovascular endothelial cells during early onsets of sepsis, Am J Physiol Heart Circ Physiol, 295, 4, pp. H1712-H1719, (2008); Ezraty B, Gennaris A, Barras F, Collet JF., Oxidative stress, protein damage and repair in bacteria, Nat Rev Microbiol, 15, 7, pp. 385-396, (2017); Walter JK, Castro V, Voss M, Et al., Redox-sensitivity of the dimerization of occludin, Cell Mol Life Sci, 66, 22, pp. 3655-3662, (2009); Fukui A, Naito Y, Handa O, Et al., Acetyl salicylic acid induces damage to intestinal epithelial cells by oxidation-related modifications of ZO-1, Am J Physiol Gastrointest Liver Physiol, 303, 8, pp. G927-G936, (2012); Takehara M, Nishimura T, Mima S, Hoshino T, Mizushima T., Effect of claudin expression on paracellular permeability, migration and invasion of colonic cancer cells, Biol Pharm Bull, 32, 5, pp. 825-831, (2009)","O. Handa; Division of Gastroenterology, Department of Internal Medicine, Kawasaki Medical School, Kurashiki-city, Okayama, Japan; email: handao@med.kawasaki-m.ac.jp","","AVES","","","","","","13004948","","TJGAF","35040791","English","Turk. J. Gastroenterol.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85123567658"

"Shao Y.-Y.; Guo Y.; Feng X.-J.; Liu J.-J.; Chang Z.-P.; Deng G.-F.; Xu D.; Gao J.-P.; Hou R.-G.","Shao, Yun-yun (56115863000); Guo, Yao (57219669923); Feng, Xiao-juan (57205376120); Liu, Jun-jin (57204922883); Chang, Zhuang-peng (57204922510); Deng, Gui-feng (57219670458); Xu, Ding (57209321374); Gao, Jian-ping (55702680000); Hou, Rui-gang (57204916820)","56115863000; 57219669923; 57205376120; 57204922883; 57204922510; 57219670458; 57209321374; 55702680000; 57204916820","Oridonin Attenuates TNBS-induced Post-inflammatory Irritable Bowel Syndrome via PXR/NF-κB Signaling","2021","Inflammation","44","2","","645","658","13","18","10.1007/s10753-020-01364-0","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85094671313&doi=10.1007%2fs10753-020-01364-0&partnerID=40&md5=aee47c89e635f7fe509ba8905d884dd3","School of Pharmaceutical, Shanxi Medical University, Taiyuan, 030000, Shanxi, China; Department of Pharmacy, Second Hospital of Shanxi Medical University, No.382 Wuyi Road, Xinghualing District, Taiyuan City, 030000, Shanxi Province, China","Shao Y.-Y., School of Pharmaceutical, Shanxi Medical University, Taiyuan, 030000, Shanxi, China, Department of Pharmacy, Second Hospital of Shanxi Medical University, No.382 Wuyi Road, Xinghualing District, Taiyuan City, 030000, Shanxi Province, China; Guo Y., School of Pharmaceutical, Shanxi Medical University, Taiyuan, 030000, Shanxi, China, Department of Pharmacy, Second Hospital of Shanxi Medical University, No.382 Wuyi Road, Xinghualing District, Taiyuan City, 030000, Shanxi Province, China; Feng X.-J., School of Pharmaceutical, Shanxi Medical University, Taiyuan, 030000, Shanxi, China, Department of Pharmacy, Second Hospital of Shanxi Medical University, No.382 Wuyi Road, Xinghualing District, Taiyuan City, 030000, Shanxi Province, China; Liu J.-J., School of Pharmaceutical, Shanxi Medical University, Taiyuan, 030000, Shanxi, China, Department of Pharmacy, Second Hospital of Shanxi Medical University, No.382 Wuyi Road, Xinghualing District, Taiyuan City, 030000, Shanxi Province, China; Chang Z.-P., School of Pharmaceutical, Shanxi Medical University, Taiyuan, 030000, Shanxi, China, Department of Pharmacy, Second Hospital of Shanxi Medical University, No.382 Wuyi Road, Xinghualing District, Taiyuan City, 030000, Shanxi Province, China; Deng G.-F., School of Pharmaceutical, Shanxi Medical University, Taiyuan, 030000, Shanxi, China, Department of Pharmacy, Second Hospital of Shanxi Medical University, No.382 Wuyi Road, Xinghualing District, Taiyuan City, 030000, Shanxi Province, China; Xu D., School of Pharmaceutical, Shanxi Medical University, Taiyuan, 030000, Shanxi, China, Department of Pharmacy, Second Hospital of Shanxi Medical University, No.382 Wuyi Road, Xinghualing District, Taiyuan City, 030000, Shanxi Province, China; Gao J.-P., School of Pharmaceutical, Shanxi Medical University, Taiyuan, 030000, Shanxi, China; Hou R.-G., School of Pharmaceutical, Shanxi Medical University, Taiyuan, 030000, Shanxi, China, Department of Pharmacy, Second Hospital of Shanxi Medical University, No.382 Wuyi Road, Xinghualing District, Taiyuan City, 030000, Shanxi Province, China","To investigate the beneficial effects of oridonin, a diterpenoid compound isolated from Rabdosia rubescens, on the inflammatory response in TNBS-induced post-inflammatory irritable bowel syndrome (PI-IBS) model and the underlying mechanism. Using the PI-IBS rat model and Caco-2 cell lines, we found that intestinal barrier function reflected by lactulose/mannitol (L/M) ratio and tight junction protein level was significantly ameliorated by oridonin. We also demonstrated that oridonin abrogated inflammation through inhibiting the phosphorylation of NF-κBp65 as well as its downstream gene (iNOS, COX-2, IL-1β, and IL-6) level. Molecular docking studies confirmed the good binding activity between oridonin and PXR. In Caco-2 cell lines, oridonin markedly inhibited LPS-induced NF-κB activation in a PXR-dependent manner. Meanwhile, PXR and its target genes CYP3A4 and P-gp were induced by oridonin, which was associated with the decreased expression of NF-κB and the recovery of intestinal barrier. This study indicated that the therapeutic effect of oridonin on experimental PI-IBS through repairing intestinal barrier function may be closely associated with the regulatory role of PXR/NF-κB signaling pathway. Oridonin may serve as a PXR ligand for the development of drugs in the therapy for PI-IBS. © 2020, Springer Science+Business Media, LLC, part of Springer Nature.","chronic low-grade inflammation; intestinal barrier function; oridonin; post-inflammatory irritable bowel syndrome; PXR/NF-κB","Animals; Anti-Inflammatory Agents; Biomarkers; Blotting, Western; Caco-2 Cells; Diterpenes, Kaurane; Humans; Inflammation; Irritable Bowel Syndrome; Male; NF-kappa B; Permeability; Pregnane X Receptor; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Signal Transduction; Tight Junctions; Treatment Outcome; Trinitrobenzenesulfonic Acid; ABC transporter subfamily B; beta actin; claudin 1; complementary DNA; cyclooxygenase 2; cytochrome P450 3A4; glyceraldehyde 3 phosphate dehydrogenase; immunoglobulin enhancer binding protein; inducible nitric oxide synthase; interleukin 1beta; interleukin 6; ketoconazole; lactulose; mannitol; occludin; oridonin; pregnane X receptor; protein ZO1; rifampicin; tight junction protein; transcription factor RelA; trinitrobenzenesulfonic acid; antiinflammatory agent; biological marker; immunoglobulin enhancer binding protein; kaurane derivative; oridonin; pregnane X receptor; trinitrobenzenesulfonic acid; animal cell; animal experiment; animal model; animal tissue; Article; binding affinity; Caco-2 cell line; cell viability assay; chemiluminescence immunoassay; colon tissue; controlled study; disease activity; disease association; drug effect; drug mechanism; electrospray mass spectrometry; gene targeting; high performance liquid chromatography; human; inflammation; intestine function; intestine tissue; irritable colon; male; molecular docking; nonhuman; post inflammatory irritable bowel syndrome; protein expression; protein phosphorylation; rat; real time polymerase chain reaction; signal transduction; software; therapy effect; Western blotting; animal; inflammation; irritable colon; metabolism; pathophysiology; permeability; Sprague Dawley rat; tight junction; treatment outcome","","ABC transporter subfamily B, 149200-37-3, 208997-77-7; claudin 1, 329338-06-9; cytochrome P450 3A4, 329736-03-0; glyceraldehyde 3 phosphate dehydrogenase, 9001-50-7; inducible nitric oxide synthase, 501433-35-8; ketoconazole, 65277-42-1; lactulose, 4618-18-2; mannitol, 69-65-8, 87-78-5; occludin, 176304-61-3; oridonin, 28957-04-2; pregnane X receptor, 259206-22-9; rifampicin, 13292-46-1; trinitrobenzenesulfonic acid, 16655-63-3, 2508-19-2; Anti-Inflammatory Agents, ; Biomarkers, ; Diterpenes, Kaurane, ; NF-kappa B, ; oridonin, ; Pregnane X Receptor, ; Trinitrobenzenesulfonic Acid, ","ImageJ, National Institute of Health; MultiQuant 3.0.2, AB Sciex; StepOnePlus, Applied Biosystems","AB Sciex; Applied Biosystems; National Institute of Health","Shanxi Basic Applied Research Program, (201901D111389); Shanxi Medical University, (201802-1, 201902-2)","We thank the Youth fund of the second affiliated hospital of Shanxi medical university (grant: 201802-1 and 201902-2) and Shanxi Basic Applied Research Program (201901D111389). ","Wang H., Gu J., Hou X., Chen J., Yang N., Liu Y., Wang G., du M., Qiu H., Luo Y., Jiang Z., Feng L., Anti-inflammatory effect of miltirone on inflammatory bowel disease via TLR4/NF-kappaB/IQGAP2 signaling pathway, Biomedicine & Pharmacotherapy, 85, pp. 531-540, (2017); Du L., Long Y., Kim J.J., Chen B., Zhu Y., Dai N., Protease Activated Receptor-2 Induces Immune Activation and Visceral Hypersensitivity in Post-infectious Irritable Bowel Syndrome Mice, Digestive Diseases and Sciences, 64, 3, pp. 729-739, (2019); Zhang S., Xu W., Wang H., Cao M., Li M., Zhao J., Hu Y., Wang Y., Li S., Xie Y., Chen G., Liu R., Cheng Y., Xu Z., Zou K., Gong S., Geng L., Inhibition of CREB-mediated ZO-1 and activation of NF-kappaB-induced IL-6 by colonic epithelial MCT4 destroys intestinal barrier function, Cell Proliferation, 52, 6, (2019); Robertson M.D., Pedersen C., Hinton P.J., Asjr M., Cani P.D., Griffin B.A., Elevated high density lipoprotein cholesterol and low grade systemic inflammation is associated with increased gut permeability in normoglycemic men, Nutrition, Metabolism, and Cardiovascular Diseases, 28, 12, pp. 1296-1303, (2018); Fukui H., Increased Intestinal Permeability and Decreased Barrier Function: Does It Really Influence the Risk of Inflammation?, Inflammatory Intestinal Diseases, 1, 3, pp. 135-145, (2016); Lan C., Sun X.N., Zhou X.C., Yang B., Huang B.L., Deng T.Z., He Z.T., Han X.Y., Preinduced intestinal HSP70 improves visceral hypersensitivity and abnormal intestinal motility in PI-IBS mouse model, Asian Pacific Journal of Tropical Medicine, 9, 3, pp. 302-305, (2016); Tao J.H., Duan J.A., Zhang W., Jiang S., Guo J.M., Wei D.D., Polysaccharides From Chrysanthemum morifolium Ramat Ameliorate Colitis Rats via Regulation of the Metabolic Profiling and NF-kappa B/TLR4 and IL-6/JAK2/STAT3 Signaling Pathways, Frontiers in Pharmacology, 9, (2018); Jiang F., Liu M., Wang H., Shi G., Chen B., Chen T., Yuan X., Zhu P., Zhou J., Wang Q., Chen Y., Wu Mei Wan attenuates CAC by regulating gut microbiota and the NF-kB/IL6-STAT3 signaling pathway, Biomedicine & Pharmacotherapy, 125, (2020); Chen S., Ye J., Chen X., Shi J., Wu W., Lin W., Lin W., Li Y., Fu H., Li S., Valproic acid attenuates traumatic spinal cord injury-induced inflammation via STAT1 and NF-kappaB pathway dependent of HDAC3, Journal of Neuroinflammation, 15, 1, (2018); Li F., Liang D., Yang Z., Wang T., Wang W., Song X., Guo M., Zhou E., Li D., Cao Y., Zhang N., Astragalin suppresses inflammatory responses via down-regulation of NF-kappaB signaling pathway in lipopolysaccharide-induced mastitis in a murine model, International Immunopharmacology, 17, 2, pp. 478-482, (2013); Deuring J.J., Li M., Cao W., Chen S., Wang W., de Haar C., van der Woude C.J., Peppelenbosch M., Pregnane X receptor activation constrains mucosal NF-kappaB activity in active inflammatory bowel disease, PLoS One, 14, 10, (2019); Wahli W., A gut feeling of the PXR, PPAR and NF-kappaB connection, Journal of Internal Medicine, 263, 6, pp. 613-619, (2008); Xu C., Huang M., Bi H., PXR- and CAR-mediated herbal effect on human diseases, Biochimica et Biophysica Acta, 1859, 9, pp. 1121-1129, (2016); Xu L., Li L., Zhang C.Y., Schluesener H., Zhang Z.Y., Natural Diterpenoid Oridonin Ameliorates Experimental Autoimmune Neuritis by Promoting Anti-inflammatory Macrophages Through Blocking Notch Pathway, Frontiers in Neuroscience, 13, (2019); Yang H., Lv H., Li H., Ci X., Peng L., Oridonin protects LPS-induced acute lung injury by modulating Nrf2-mediated oxidative stress and Nrf2-independent NLRP3 and NF-kappaB pathways, Cell Communication and Signaling: CCS, 17, 1, (2019); Zang K.H., Shao Y.Y., Zuo X., Rao Z., Qin H.Y., Oridonin alleviates visceral hyperalgesia in a rat model of postinflammatory irritable bowel syndrome: Role of colonic enterochromaffin cell and serotonin availability, Journal of Medicinal Food, 19, 6, pp. 586-592, (2016); Qin H.-Y., Key factors in developing the trinitrobenzene sulfonic acid-induced post-inflammatory irritable bowel syndrome model in rats, World Journal of Gastroenterology, 18, 20, pp. 2481-2492, (2012); Hou Q., Huang Y., Zhu Z., Liao L., Chen X., Han Q., Liu F., Tong-Xie-Yao-Fang improves intestinal permeability in diarrhoea-predominant irritable bowel syndrome rats by inhibiting the NF-kappaB and notch signalling pathways, BMC Complementary and Alternative Medicine, 19, 1, (2019); Sanchez de Medina F., Romero-Calvo I., Mascaraque C., Martinez-Augustin O., Intestinal inflammation and mucosal barrier function, Inflammatory Bowel Diseases, 20, 12, pp. 2394-2404, (2014); Zhang W., Huang Q., Hua Z.-C., Oridonin: A promising anticancer drug from China, Frontiers in Biology, 5, 6, pp. 540-545, (2010); Xu X.J., Zhang Y.L., Liu L., Pan L., Yao S.K., Increased expression of nerve growth factor correlates with visceral hypersensitivity and impaired gut barrier function in diarrhoea-predominant irritable bowel syndrome: A preliminary explorative study, Alimentary Pharmacology & Therapeutics, 45, 1, pp. 100-114, (2017); Wang Q., Ning L., Niu Y., Liu H., Yao X., Molecular mechanism of the inhibition and remodeling of human islet amyloid polypeptide (hIAPP(1-37)) oligomer by resveratrol from molecular dynamics simulation, The Journal of Physical Chemistry. B, 119, 1, pp. 15-24, (2015); Yang M., Jia W., Wang D., Han F., Niu W., Zhang H., Shih D.Q., Zhang X., Effects and mechanism of constitutive TL1A expression on intestinal mucosal barrier in DSS-induced colitis, Digestive Diseases and Sciences, 64, 7, pp. 1844-1856, (2019); Ning L., Lou X., Zhang F., Xu G., Nuclear receptors in the pathogenesis and management of inflammatory bowel disease, Mediators of Inflammation, 2019, pp. 2624941-2624913, (2019); Gabbia D., Pozzo L., Zigiotto G., Roverso M., Sacchi D., Dalla Pozza A., Carrara M., Bogialli S., Floreani A., Guido M., de Martin S., Dexamethasone counteracts hepatic inflammation and oxidative stress in cholestatic rats via CAR activation, PLoS One, 13, 9, (2018); Guo M.Z., Meng M., Feng C.C., Wang X., Wang C.L., A novel polysaccharide obtained from Craterellus cornucopioides enhances immunomodulatory activity in immunosuppressive mice models via regulation of the TLR4-NF-kappaB pathway, Food & Function, 10, 8, pp. 4792-4801, (2019); Zhang J., Zhao Z., Bai H., Wang M., Jiao L., Peng W., Wu T., Liu T., Chen H., Song X., Wu L., Hu X., Wu Q., Zhou J., Song J., Lyv M., Ying B., Genetic polymorphisms in PXR and NF-kappaB1 influence susceptibility to anti-tuberculosis drug-induced liver injury, PLoS One, 14, 9, (2019)","J.-J. Liu; Department of Pharmacy, Second Hospital of Shanxi Medical University, Taiyuan City, No.382 Wuyi Road, Xinghualing District, 030000, China; email: liujunjin326@163.com; J.-P. Gao; School of Pharmaceutical, Shanxi Medical University, Taiyuan, 030000, China; email: jpgao123@163.com; R.-G. Hou; Department of Pharmacy, Second Hospital of Shanxi Medical University, Taiyuan City, No.382 Wuyi Road, Xinghualing District, 030000, China; email: Ruiganghou9966@163.com","","Springer","","","","","","03603997","","INFLD","33125572","English","Inflammation","Article","Final","","Scopus","2-s2.0-85094671313"

"Hou Q.; Huang Y.; Zhu Z.; Liao L.; Chen X.; Han Q.; Liu F.","Hou, Qiuke (35573727700); Huang, Yongquan (57195074253); Zhu, Zhaoyang (57212018121); Liao, Liu (57212027253); Chen, Xinlin (55357650100); Han, Quanbin (7202485341); Liu, Fengbin (55799656200)","35573727700; 57195074253; 57212018121; 57212027253; 55357650100; 7202485341; 55799656200","Tong-Xie-Yao-Fang improves intestinal permeability in diarrhoea-predominant irritable bowel syndrome rats by inhibiting the NF-κB and notch signalling pathways","2019","BMC Complementary and Alternative Medicine","19","1","337","","","","39","10.1186/s12906-019-2749-4","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85075737852&doi=10.1186%2fs12906-019-2749-4&partnerID=40&md5=e36c8064278cb35fd0b0c85bc774f0ff","Department of Gastroenterology, Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, 510405, China; School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, Hong Kong; Department of Orthopaedics, Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China; Department of Preventive Medicine and Health Statistics, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China","Hou Q., Department of Gastroenterology, Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, 510405, China, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, Hong Kong; Huang Y., Department of Orthopaedics, Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China; Zhu Z., Department of Gastroenterology, Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, 510405, China; Liao L., Department of Gastroenterology, Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, 510405, China; Chen X., Department of Preventive Medicine and Health Statistics, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China; Han Q., School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, Hong Kong; Liu F., Department of Gastroenterology, Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, 510405, China","Background: Tong-Xie-Yao-Fang (TXYF) has been shown to be effective in diarrhoea-predominant irritable bowel syndrome (IBS-D) patients. However, the underlying mechanism remains to be clarified. The aim of this study was to investigate the efficacy and related mechanisms of TXYF in an IBS-D rat model. Methods: The IBS-D rat model was established with 4% acetic acid and evaluated by haematoxylin-eosin (HE) staining. Then, IBS-D rats were divided into control, TXYF and rifaximin groups and treated intragastrically with normal saline, TXYF and rifaximin, respectively, for 14 days. The following indicators were measured before and after treatment: defecation frequency, faecal water content (FWC) and colorectal distension (CRD). Histopathological changes in the distal colon were observed after treatment. The expression of OCLN and ZO1 in the distal colon of IBS-D rats reflected the intestinal mucosal permeability, as measured by qRT-PCR, western blot, and enzyme-linked immunosorbent assays (ELISAs). The NF-κB and Notch signalling pathways and inflammation-related factors were investigated. Results: After treatment with TXYF, the defecation frequency, FWC and CRD were significantly lower than those in the model group (P < 0.05). HE staining showed that colonic epithelial cells (CECs) in the IBS-D rats displayed significant oedema, impaired intestinal mucosal integrity and an increased influx of inflammatory cells. A significant reduction in granulocyte and CEC oedema was observed after the administration of TXYF and rifaximin compared to that of the model group and blank group (P < 0.05). TXYF significantly upregulated the expression of OCLN and ZO-1 and downregulated inflammation-related factors (IL-6, IL-1β, and TNF-α and the chemokine KC) in IBS-D rats compared to those in the model group rats (P < 0.05). In terms of the NF-κB and Notch signalling pathways, the expression of NICD, p-ERK, Hes-1 and p-P65 decreased significantly in the TXYF and rifaximin groups, while the expression of ATOH1 increased significantly compared to that in the model group (P < 0.05). Conclusion: TXYF can effectively improve intestinal permeability and enhance intestinal mucosal barrier function, which may be related to inhibition of the inflammatory cascade and the NF-κB and Notch signalling pathways. © 2019 The Author(s).","Diarrhoea predominant-irritable bowel syndrome; Intestinal permeability; NF-κB Signalling; Notch Signalling; Tong-Xie-Yao-fang","Animals; Cytokines; Diarrhea; Disease Models, Animal; Drugs, Chinese Herbal; Female; Intestinal Absorption; Intestinal Mucosa; Irritable Bowel Syndrome; Male; NF-kappa B; Rats; Receptors, Notch; Signal Transduction; chemokine; Chinese drug; herbaceous agent; immunoglobulin enhancer binding protein; interleukin 1beta; interleukin 6 receptor; rifaximin; tong xie yao fang; transcription factor HES 1; tumor necrosis factor; unclassified drug; cytokine; herbaceous agent; immunoglobulin enhancer binding protein; Notch receptor; tongxie-yaofang; animal cell; animal experiment; animal model; animal tissue; Article; China; colon dilatation; controlled study; defecation; diarrhea; drug efficacy; edema; enzyme linked immunosorbent assay; epithelial cell line; female; granulocyte; histopathology; inflammatory cell; intermethod comparison; intestine mucosa permeability; irritable colon; male; nonhuman; Notch signaling; rat; real time polymerase chain reaction; receptor down regulation; receptor upregulation; Western blotting; animal; diarrhea; disease model; drug effect; intestine absorption; intestine mucosa; irritable colon; metabolism; pathology; signal transduction","","rifaximin, 80621-81-4, 88747-56-2; Cytokines, ; Drugs, Chinese Herbal, ; NF-kappa B, ; Receptors, Notch, ; tongxie-yaofang, ","","","Guangzhou University of Traditional Chinese Medicine’s first-class discipline research key project, (A1-AFD018191A16); Guangdong Provincial Hospital of Traditional Chinese Medicine, (20181095, XJ2018059); National Natural Science Foundation of China, NSFC, (81804047); Guangzhou University of Chinese Medicine, GUCM, (2017TD05)","This study was supported by the National Natural Science Foundation (No. 81804047) (design of the study), Guangdong Provincial Traditional Chinese Medicine Research Project (No. 20181095) (writing the manuscript), Hong Kong scholar programme (XJ2018059) (interpretation of data), Innovative Research Team Project of “Innovative Strong Institute”, the First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine (2017TD05) (collection of data) and Guangzhou University of Traditional Chinese Medicine’s first-class discipline research key project (A1-AFD018191A16) (analysis of data).","Oshima T., Miwa H., Epidemiology of functional gastrointestinal disorders in Japan and in the world, J Neurogastroenterol Motil, 21, 3, pp. 320-329, (2015); Chen C., Lu M., Pan Q., Et al., Berberine improves intestinal motility and visceral pain in the mouse models mimicking diarrhea-predominant irritable bowel syndrome (IBS-D) symptoms in an opioid-receptor dependent manner, PLoS One, 10, 12, (2015); Hou Q., Huang Y., Zhang C., Et al., MicroRNA-200a targets cannabinoid receptor 1 and serotonin transporter to increase visceral Hyperalgesia in diarrhea-predominant irritable bowel syndrome rats, J Neurogastroenterol Motility, 24, 4, pp. 656-668, (2018); Hou Q., Huang Y., Zhu S., Et al., MiR-144 increases intestinal permeability in IBS-D rats by targeting OCLN and ZO1, Cell Physiol Biochem, 44, 6, pp. 2256-2268, (2017); De Arcangelis A., Hamade H., Alpy F., Et al., Hemidesmosome integrity protects the colon against colitis and colorectal cancer, Gut., 66, 10, pp. 1748-1760, (2017); Chang J., Leong R.W., Wasinger V.C., Et al., Impaired intestinal permeability contributes to ongoing bowel symptoms in patients with inflammatory bowel disease and mucosal healing, Gastroenterology., 153, 3, pp. 723-731, (2017); Chen M., Tang T.C., Wang Y., Et al., Randomised clinical trial: Tong-Xie-Yao-fang granules versus placebo for patients with diarrhoea-predominant irritable bowel syndrome, Aliment Pharmacol Ther, 48, 2, pp. 160-168, (2018); Pan F., Zhang T., Zhang Y.H., Et al., Effect of Tongxie Yaofang granule in treating diarrhea-predominate irritable bowel syndrome, Chin J Integr Med, 15, 3, pp. 216-219, (2009); Zheng L., Zhang Y.L., Dai Y.C., Et al., Jianpi Qingchang decoction alleviates ulcerative colitis by inhibiting nuclear factor-kappaB activation, World J Gastroenterol, 23, 7, pp. 1180-1188, (2017); Lu L., Yan L., Yuan J., Et al., Shuganyin decoction improves the intestinal barrier function in a rat model of irritable bowel syndrome induced by water-avoidance stress, Chinas Med, 13, (2018); Li B., Rui J., Ding X., Et al., Exploring the multicomponent synergy mechanism of Banxia Xiexin decoction on irritable bowel syndrome by a systems pharmacology strategy, J Ethnopharmacol, 233, pp. 158-168, (2019); Wang F.Y., Su M., Zheng Y.Q., Et al., Herbal prescription Chang'an II repairs intestinal mucosal barrier in rats with post-inflammation irritable bowel syndrome, Acta Pharmacol Sin, 36, 6, pp. 708-715, (2015); Yin Y., Zhong L., Wang J.W., Et al., Tong Xie Yao Fang relieves irritable bowel syndrome in rats via mechanisms involving regulation of 5-hydroxytryptamine and substance P, World J Gastroenterol, 21, 15, pp. 4536-4546, (2015); Ma X., Wang X., Kang N., Et al., The effect of Tong-Xie-Yao-fang on intestinal mucosal mast cells in postinfectious irritable bowel syndrome rats, Evid Based Complement Alternat Med, 2017, (2017); Blanpain C., Horsley V., Fuchs E., Epithelial stem cells: Turning over new leaves, Cell., 128, 3, pp. 445-458, (2007); Vallabhapurapu S., Karin M., Regulation and function of NF-kappaB transcription factors in the immune system, Annu Rev Immunol, 27, pp. 693-733, (2009); Thakur E.R., Shapiro J., Chan J., Et al., A systematic review of the effectiveness of psychological treatments for IBS in gastroenterology settings: Promising but in need of further study, Dig Dis Sci, 63, 9, pp. 2189-2201, (2018); Blanchard E.B., Lackner J.M., Jaccard J., Et al., The role of stress in symptom exacerbation among IBS patients, J Psychosom Res, 64, 2, pp. 119-128, (2008); Piche T., Tight junctions and IBS - The link between epithelial permeability, low-grade inflammation, and symptom generation?, Neurogastroenterol Motil, 26, 3, pp. 296-302, (2014); Odenwald M.A., Turner J.R., Intestinal permeability defects: Is it time to treat?, Clin Gastroenterol Hepatol, 11, 9, pp. 1075-1083, (2013); Stevens B.R., Goel R., Seungbum K., Et al., Increased human intestinal barrier permeability plasma biomarkers zonulin and FABP2 correlated with plasma LPS and altered gut microbiome in anxiety or depression, Gut., 67, 8, pp. 1555-1557, (2018); Zeisel M.B., Dhawan P., Baumert T.F., Tight junction proteins in gastrointestinal and liver disease, Gut., pp. 1-15, (2018); Gonzalez-Castro A.M., Martinez C., Salvo-Romero E., Et al., Mucosal pathobiology and molecular signature of epithelial barrier dysfunction in the small intestine in irritable bowel syndrome, J Gastroenterol Hepatol, 32, 1, pp. 53-63, (2017); Yan Z., Yang X., Wu J., Et al., Qualitative and quantitative analysis of chemical constituents in traditional Chinese medicinal formula Tong-Xie-Yao-Fang by high-performance liquid chromatography/diode array detection/electrospray ionization tandem mass spectrometry, Anal Chim Acta, 691, 1-2, pp. 110-118, (2011); Shamshiri H., Paragomi P., Paydar M.J., Et al., Antinociceptive effect of chronic lithium on visceral hypersensitivity in a rat model of diarrhea-predominant irritable bowel syndrome: The role of nitric oxide pathway, J Gastroenterol Hepatol, 24, 4, pp. 672-680, (2009); Kufe D.W., Mucins in cancer: Function, prognosis and therapy, Nat Rev Cancer, 9, 12, pp. 874-885, (2009); Zheng X., Tsuchiya K., Okamoto R., Et al., Suppression of hath1 gene expression directly regulated by hes1 via notch signaling is associated with goblet cell depletion in ulcerative colitis, Inflamm Bowel Dis, 17, 11, pp. 2251-2260, (2011); Pope J.L., Bhat A.A., Sharma A., Et al., Claudin-1 regulates intestinal epithelial homeostasis through the modulation of notch-signalling, Gut., 63, 4, pp. 622-634, (2014); Kovall R.A., Gebelein B., Sprinzak D., Et al., The canonical notch signaling pathway: Structural and biochemical insights into shape, sugar, and force, Dev Cell, 41, 3, pp. 228-241, (2017); Zeng L., Li K., Wei H., Et al., A novel EphA2 inhibitor exerts beneficial effects in PI-IBS in vivo and in vitro models via Nrf2 and NF-kappaB signaling pathways, Front Pharmacol, 9, (2018); Burbach B.J., Srivastava R., Medeiros R.B., Et al., Distinct regulation of integrin-dependent T cell conjugate formation and NF-kappa B activation by the adapter protein ADAP, J Immunol, 181, 7, pp. 4840-4851, (2008); Neurath M.F., Cytokines in inflammatory bowel disease, Nat Rev Immunol, 14, 5, pp. 329-342, (2014)","Q. Han; School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, Hong Kong; email: simonhan74@126.com","","BioMed Central Ltd.","","","","","","14726882","","BCAMC","31775739","English","BMC Complement. Altern. Med.","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85075737852"

"Barbaro M.R.; Cremon C.; Morselli-Labate A.M.; Di Sabatino A.; Giuffrida P.; Corazza G.R.; Di Stefano M.; Caio G.; Latella G.; Ciacci C.; Fuschi D.; Mastroroberto M.; Bellacosa L.; Stanghellini V.; Volta U.; Barbara G.","Barbaro, Maria Raffaella (56235164100); Cremon, Cesare (6507319921); Morselli-Labate, Antonio Maria (35458723700); Di Sabatino, Antonio (6603698114); Giuffrida, Paolo (55018594900); Corazza, Gino Roberto (57205413845); Di Stefano, Michele (7005484843); Caio, Giacomo (36005480000); Latella, Giovanni (6603914614); Ciacci, Carolina (7004873608); Fuschi, Daniele (57202989311); Mastroroberto, Marianna (54585720400); Bellacosa, Lara (34972669400); Stanghellini, Vincenzo (7006377452); Volta, Umberto (35780792400); Barbara, Giovanni (7004311418)","56235164100; 6507319921; 35458723700; 6603698114; 55018594900; 57205413845; 7005484843; 36005480000; 6603914614; 7004873608; 57202989311; 54585720400; 34972669400; 7006377452; 35780792400; 7004311418","Serum zonulin and its diagnostic performance in non-coeliac gluten sensitivity","2020","Gut","69","11","","1966","1974","8","51","10.1136/gutjnl-2019-319281","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85080046102&doi=10.1136%2fgutjnl-2019-319281&partnerID=40&md5=0ef4cc5278daf2a07e24ed8043c621ff","Department of Medical and Surgical Sciences, University of Bologna, Bologna, Emilia-Romagna, 40138, Italy; First Department of Internal Medicine, San Matteo Hospital Foundation, University of Pavia, Pavia, Lombardia, Italy; Department of Clinical Medicine Public Health Life Sciences and Environment, University of l'Aquila, L'Aquila, Abruzzo, Italy; Department of Medicine, Surgery, and Dentistry Scuola Medica Salernitana, University of Salerno, Salerno, Campania, Italy","Barbaro M.R., Department of Medical and Surgical Sciences, University of Bologna, Bologna, Emilia-Romagna, 40138, Italy; Cremon C., Department of Medical and Surgical Sciences, University of Bologna, Bologna, Emilia-Romagna, 40138, Italy; Morselli-Labate A.M., Department of Medical and Surgical Sciences, University of Bologna, Bologna, Emilia-Romagna, 40138, Italy; Di Sabatino A., First Department of Internal Medicine, San Matteo Hospital Foundation, University of Pavia, Pavia, Lombardia, Italy; Giuffrida P., First Department of Internal Medicine, San Matteo Hospital Foundation, University of Pavia, Pavia, Lombardia, Italy; Corazza G.R., First Department of Internal Medicine, San Matteo Hospital Foundation, University of Pavia, Pavia, Lombardia, Italy; Di Stefano M., First Department of Internal Medicine, San Matteo Hospital Foundation, University of Pavia, Pavia, Lombardia, Italy; Caio G., Department of Medical and Surgical Sciences, University of Bologna, Bologna, Emilia-Romagna, 40138, Italy; Latella G., Department of Clinical Medicine Public Health Life Sciences and Environment, University of l'Aquila, L'Aquila, Abruzzo, Italy; Ciacci C., Department of Medicine, Surgery, and Dentistry Scuola Medica Salernitana, University of Salerno, Salerno, Campania, Italy; Fuschi D., Department of Medical and Surgical Sciences, University of Bologna, Bologna, Emilia-Romagna, 40138, Italy; Mastroroberto M., Department of Medical and Surgical Sciences, University of Bologna, Bologna, Emilia-Romagna, 40138, Italy; Bellacosa L., Department of Medical and Surgical Sciences, University of Bologna, Bologna, Emilia-Romagna, 40138, Italy; Stanghellini V., Department of Medical and Surgical Sciences, University of Bologna, Bologna, Emilia-Romagna, 40138, Italy; Volta U., Department of Medical and Surgical Sciences, University of Bologna, Bologna, Emilia-Romagna, 40138, Italy; Barbara G., Department of Medical and Surgical Sciences, University of Bologna, Bologna, Emilia-Romagna, 40138, Italy","Objective Non-coeliac gluten sensitivity (NCGS) is characterised by intestinal and extraintestinal symptoms related to the ingestion of gluten-containing foods, in the absence of coeliac disease (CD) and wheat allergy. No biomarkers are available to diagnose NCGS and the gold standard double-blind placebo-controlled gluten challenge is clinically impractical. The aim of our work was to investigate the role of serum zonulin as a diagnostic biomarker of NCGS and to develop a diagnostic algorithm. Design In a multicentre study, we enrolled 86 patients with either self-reported or double-blind confirmed NCGS, 59 patients with diarrhoea-predominant IBS (IBS-D), 15 patients with CD and 25 asymptomatic controls (AC). Zonulin serum levels were assessed and the associated diagnostic power calculated. Clinical and symptomatic data were recorded. The effect of diet on zonulin levels was evaluated in a subgroup of patients with NCGS. Results Compared with ACs, the NCGS, irrespective of modality of diagnosis, and patients with CD had significantly increased levels of zonulin, as did both NCGS and patients with CD compared with participants with IBS-D. Self-reported NCGS showed increased zonulin levels compared with double-blind confirmed and not-confirmed NCGS. Six-month wheat avoidance significantly reduced zonulin levels only in HLA-DQ2/8-positive participants with NCGS. The diagnostic accuracy of zonulin levels in distinguishing NCGS from IBS-D was 81%. After exclusion of CD, a diagnostic algorithm combining zonulin levels, symptoms and gender improved the accuracy to 89%. Conclusion Zonulin can be considered a diagnostic biomarker in NCGS and combined with demographic and clinical data differentiates NCGS from IBS-D with high accuracy. Wheat withdrawal was associated with a reduction in zonulin levels only in NCGS carrying HLA genotype.  © ","epithelial barrier; functional bowel disorder; irritable bowel syndrome; nutrition","Adult; Algorithms; Biomarkers; Case-Control Studies; Celiac Disease; Female; Glutens; Haptoglobins; Humans; Irritable Bowel Syndrome; Male; Middle Aged; Predictive Value of Tests; Protein Precursors; ROC Curve; Wheat Hypersensitivity; HLA DQ2 antigen; HLA DQ8 antigen; HLA DQA1 antigen; HLA DQB1 antigen; membrane protein; unclassified drug; zonulin; biological marker; gluten; haptoglobin; protein precursor; zonulin; adult; Article; asymptomatic disease; celiac disease; controlled study; diagnostic accuracy; diagnostic value; diet; differential diagnosis; enzyme linked immunosorbent assay; female; gender; genotype; human; irritable colon; major clinical study; malabsorption; male; non celiac gluten sensitivity; nutritional intolerance; priority journal; protein blood level; receiver operating characteristic; self report; sensitivity and specificity; wheat; algorithm; blood; case control study; celiac disease; irritable colon; middle aged; predictive value; wheat allergy","","gluten, 8002-80-0; haptoglobin, 9087-69-8; Biomarkers, ; Glutens, ; Haptoglobins, ; Protein Precursors, ; zonulin, ","NanoDrop 2000, Thermo, Italy","Thermo, Italy","Fondazione del Monte di Bologna; University; Ministry of Education, MOE; Ministero dell’Istruzione, dell’Università e della Ricerca, MIUR; Fondazione del Monte di Bologna e Ravenna; Università di Bologna, UNIBO","Funding text 1: Funding The study was supported by the italian Ministry of education, University and research, the University of Bologna and Fondazione del Monte di Bologna e ravenna.; Funding text 2: The study was supported by the Italian Ministry of Education, University and Research, the University of Bologna and Fondazione del Monte di Bologna e Ravenna.","Catassi C., Elli L., Bonaz B., Et al., Diagnosis of non-celiac gluten sensitivity (NCGS): The Salerno experts' criteria, Nutrients, 7, pp. 4966-4977, (2015); Ford A.C., Lacy B.E., Talley N.J., Irritable bowel syndrome, N Engl J Med, 376, pp. 2566-2578, (2017); Volta U., Bardella M.T., Calabro A., Et al., An Italian prospective multicenter survey on patients suspected of having non-celiac gluten sensitivity, BMC Med, 12, (2014); Carroccio A., D'Alcamo A., Cavataio F., Et al., High proportions of people with Nonceliac wheat sensitivity have autoimmune disease or antinuclear antibodies, Gastroenterology, 149, pp. 596-603, (2015); Hollon J., Puppa E.L., Greenwald B., Et al., Effect of gliadin on permeability of intestinal biopsy explants from celiac disease patients and patients with non-celiac gluten sensitivity, Nutrients, 7, pp. 1565-1576, (2015); Wang W., Uzzau S., Goldblum S.E., Et al., Human zonulin, a potential modulator of intestinal tight junctions, J Cell Sci, 113, pp. 4435-4440, (2000); Tripathi A., Lammers K.M., Goldblum S., Et al., Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2, Proc Natl Acad Sci U S A, 106, pp. 16799-16804, (2009); Sapone A., De Magistris L., Pietzak M., Et al., Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives, Diabetes, 55, pp. 1443-1449, (2006); Vazquez-Roque M.I., Camilleri M., Smyrk T., Et al., A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: Effects on bowel frequency and intestinal function, Gastroenterology, 144, pp. 903-911, (2013); El Asmar R., Panigrahi P., Bamford P., Et al., Host-dependent zonulin secretion causes the impairment of the small intestine barrier function after bacterial exposure, Gastroenterology, 123, pp. 1607-1615, (2002); Lammers K.M., Lu R., Brownley J., Et al., Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3, Gastroenterology, 135, pp. 194-204, (2008); Fasano A., Not T., Wang W., Et al., Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease, The Lancet, 355, pp. 1518-1519, (2000); Caio G., Volta U., Tovoli F., Et al., Effect of gluten free diet on immune response to gliadin in patients with non-celiac gluten sensitivity, BMC Gastroenterol, 14, (2014); Volta U., Caio G., De Giorgio R., Et al., Non-celiac gluten sensitivity: A work-in-progress entity in the spectrum of wheat-related disorders, Best Pract Res Clin Gastroenterol, 29, pp. 477-491, (2015); Di Sabatino A., Volta U., Salvatore C., Et al., Small amounts of gluten in subjects with suspected Nonceliac gluten sensitivity: A randomized, double-blind, placebo-controlled, cross-over trial, Clin Gastroenterol Hepatol, 13, pp. 1604-1612, (2015); Elli L., Tomba C., Branchi F., Et al., Evidence for the presence of non-celiac gluten sensitivity in patients with functional gastrointestinal symptoms: Results from a multicenter randomized double-blind placebo-controlled gluten challenge, Nutrients, 8, (2016); Longstreth G.F., Thompson W.G., Chey W.D., Et al., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Rubio-Tapia A., Hill I.D., Kelly C.P., Et al., ACG clinical guidelines: Diagnosis and management of celiac disease, Am J Gastroenterol, 108, pp. 656-676, (2013); Oberhuber G., Granditsch G., Vogelsang H., The histopathology of coeliac disease: Time for a standardized report scheme for pathologists, Eur J Gastroenterol Hepatol, 11, pp. 1185-1194, (1999); Barbara G., Stanghellini V., De Giorgio R., Et al., Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome, Gastroenterology, 126, pp. 693-702, (2004); Barbaro M.R., Cremon C., Caio G., Et al., The role of zonulin in non-celiac gluten sensitivity and irritable bowel syndrome, United Eur Gastroenterol J, 3, (2015); Dupont W.D., Plummer W.D., PS: Power and Sample Size Calculation; Dupont W.D., Plummer W.D., Power and sample size calculations. A review and computer program, Control Clin Trials, 11, pp. 116-128, (1990); Dupont W.D., Plummer W.D., Power and sample size calculations for studies involving linear regression, Control Clin Trials, 19, pp. 589-601, (1998); Pezzilli R., Billi P., Miniero R., Et al., Serum interleukin-6, interleukin-8, and beta 2-microglobulin in early assessment of severity of acute pancreatitis. Comparison with serum C-reactive protein, Dig Dis Sci, 40, pp. 2341-2348, (1995); Uhde M., Ajamian M., Caio G., Et al., Intestinal cell damage and systemic immune activation in individuals reporting sensitivity to wheat in the absence of coeliac disease, Gut, 65, pp. 1930-1937, (2016); De Punder K., Pruimboom L., The dietary intake of wheat and other cereal grains and their role in inflammation, Nutrients, 5, pp. 771-787, (2013); Skodje G.I., Sarna V.K., Minelle I.H., Et al., Fructan, rather than gluten, induces symptoms in patients with self-reported non-celiac gluten sensitivity, Gastroenterology, 154, pp. 529-539, (2018); Pinto-Sanchez M.I., Verdu E.F., Non-coeliac gluten sensitivity: Are we closer to separating the wheat from the chaff?, Gut, 65, pp. 1921-1922, (2016); Junker Y., Zeissig S., Kim S.-J., Et al., Wheat amylase trypsin inhibitors drive intestinal inflammation via activation of Toll-like receptor 4, J Exp Med, 209, pp. 2395-2408, (2012); Singh P., Silvester J., Chen X., Et al., Serum zonulin is elevated in IBS and correlates with stool frequency in IBS-D, United European Gastroenterol J, 7, pp. 709-715, (2019); Zhou Q., Zhang B., Verne N.G., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Piche T., Barbara G., Aubert P., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: Involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Martinez C., Lobo B., Pigrau M., Et al., Diarrhoea-predominant irritable bowel syndrome: An organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, pp. 1160-1168, (2013); Martinez C., Vicario M., Ramos L., Et al., The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations, Am J Gastroenterol, 107, pp. 736-746, (2012); Carroccio A., Mansueto P., Iacono G., Et al., Non-C eliac wheat sensitivity diagnosed by double-blind placebo-controlled challenge: Exploring a new clinical entity, Am J Gastroenterol, 107, pp. 1898-1906, (2012); Stevens B.R., Goel R., Seungbum K., Et al., Increased human intestinal barrier permeability plasma biomarkers zonulin and FABP2 correlated with plasma LPS and altered gut microbiome in anxiety or depression, Gut, 67, pp. 1555-1557, (2018); Perrier C., Corthesy B., Gut permeability and food allergies, Clin Exp Allergy, 41, pp. 20-28, (2011); Barbara G., Wang B., Stanghellini V., Et al., Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome, Gastroenterology, 132, pp. 26-37, (2007); Buhner S., Li Q., Vignali S., Et al., Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome, Gastroenterology, 137, pp. 1425-1434, (2009); Volta U., Tovoli F., Cicola R., Et al., Serological tests in gluten sensitivity (nonceliac gluten intolerance), J Clin Gastroenterol, 46, pp. 680-685, (2012); Carroccio A., Giannone G., Mansueto P., Et al., Duodenal and rectal mucosa inflammation in patients with non-celiac wheat sensitivity, Clin Gastroenterol Hepatol, 17, pp. 682-690, (2019); Barbara G., IBS: Biomarkers for IBS: Ready for prime time?, Nat Rev Gastroenterol Hepatol, 12, pp. 9-10, (2015)","","","BMJ Publishing Group","","","","","","00175749","","GUTTA","32060130","English","Gut","Article","Final","","Scopus","2-s2.0-85080046102"

"Arie H.; Shibata H.; Nozu T.; Miyagishi S.; Ida M.; Izumo T.","Arie, Hideyuki (57210962418); Shibata, Hiroshi (59096504300); Nozu, Tsukasa (57214214134); Miyagishi, Saori (57226207036); Ida, Masayuki (57214214779); Izumo, Takayuki (6701385201)","57210962418; 59096504300; 57214214134; 57226207036; 57214214779; 6701385201","Grape seed extract eliminates visceral allodynia and colonic hyperpermeability induced by repeated water avoidance stress in rats","2019","Nutrients","11","11","2646","","","","16","10.3390/nu11112646","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85074564749&doi=10.3390%2fnu11112646&partnerID=40&md5=41c8bd1bae82b117fd3cdb3c12ae7796","Institute for Health Care Science, Suntory Wellness Limited, Seikadai 8-1-1, Seika-cho, Soraku-gun, Kyoto, 619-0284, Japan; Department of Regional Medicine and Education, Asahikawa Medical University, Midorigaoka Higashi 2-1-1-1, Asahikawa, 078-8510, Japan; Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Midorigaoka Higashi 2-1-1-1, Asahikawa, 078-8510, Japan","Arie H., Institute for Health Care Science, Suntory Wellness Limited, Seikadai 8-1-1, Seika-cho, Soraku-gun, Kyoto, 619-0284, Japan; Shibata H., Institute for Health Care Science, Suntory Wellness Limited, Seikadai 8-1-1, Seika-cho, Soraku-gun, Kyoto, 619-0284, Japan; Nozu T., Department of Regional Medicine and Education, Asahikawa Medical University, Midorigaoka Higashi 2-1-1-1, Asahikawa, 078-8510, Japan; Miyagishi S., Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Midorigaoka Higashi 2-1-1-1, Asahikawa, 078-8510, Japan; Ida M., Institute for Health Care Science, Suntory Wellness Limited, Seikadai 8-1-1, Seika-cho, Soraku-gun, Kyoto, 619-0284, Japan; Izumo T., Institute for Health Care Science, Suntory Wellness Limited, Seikadai 8-1-1, Seika-cho, Soraku-gun, Kyoto, 619-0284, Japan","Grape seed extract (GSE) is rich in polyphenols composed mainly of proanthocyanidins, which are known to attenuate proinflammatory cytokine production. Repeated water avoidance stress (WAS) induces visceral allodynia and colonic hyperpermeability via toll-like receptor 4 (TLR4) and proinflammatory cytokine pathways, which is a rat irritable bowel syndrome (IBS) model. Thus, we explored the effects of GSE on repeated WAS (1 h for 3 days)-induced visceral allodynia and colonic hyperpermeability in Sprague-Dawley rats. Paracellular permeability, as evaluated by transepithelial electrical resistance and flux of carboxyfluorescein, was analyzed in Caco-2 cell monolayers treated with interleukin-6 (IL-6) and IL-1β. WAS caused visceral allodynia and colonic hyperpermeability, and intragastric administration of GSE (100 mg/kg, once daily for 11 days) inhibited these changes. Furthermore, GSE also suppressed the elevated colonic levels of IL-6, TLR4, and claudin-2 caused by WAS. Paracellular permeability was increased in Caco-2 cell monolayers in the presence of IL-6 and IL-1β, which was inhibited by GSE. Additionally, GSE suppressed the claudin-2 expression elevated by cytokine stimulation. The effects of GSE on visceral changes appear to be evoked by suppressing colonic TLR4-cytokine signaling and maintaining tight junction integrity. GSE may be useful for treating IBS. © 2019 by the authors. Licensee MDPI, Basel, Switzerland.","Grape seed extract; Gut barrier; Gut permeability; Inflammation; Tight junction; Toll-like receptor 4; Visceral hypersensitivity","Animals; Caco-2 Cells; Colon; Cytokines; Gene Expression Regulation; Grape Seed Extract; Humans; Hyperalgesia; Intestinal Mucosa; Irritable Bowel Syndrome; Male; Permeability; Rats; Rats, Sprague-Dawley; Stress, Physiological; Water; carboxyfluorescein; claudin 2; cytokine; grape seed extract; interleukin 1beta; interleukin 6; protein ZO1; toll like receptor 4; grape seed extract; water; abdominal wall musculature; allodynia; animal cell; animal experiment; animal model; animal tissue; Article; colonic hyperpermeability; controlled study; electric resistance; electrode implantation; electromyogram; enzyme linked immunosorbent assay; gastrointestinal disease; intestine distension; irritable colon; male; nociception; nonhuman; protein expression; rat; sensation; tight junction; visceral allodynia; water avoidance stress; animal; Caco-2 cell line; colon; drug effect; gene expression regulation; genetics; human; hyperalgesia; intestine mucosa; irritable colon; metabolism; permeability; physiological stress; Sprague Dawley rat","","carboxyfluorescein, 72088-94-9; toll like receptor 4, 203811-83-0; water, 7732-18-5; Cytokines, ; Grape Seed Extract, ; Water, ","","","Suntory Wellness Limited","Funding: T.N. received research grants from Suntory Wellness Limited.","Mearin F., Lacy B.E., Chang L., Chey W.D., Lembo A.J., Simren M., Spiller R., Bowel Disorders, Gastroenterology, 150, pp. 1393-1407, (2016); Kanazawa M., Hongo M., Fukudo S., Visceral hypersensitivity in irritable bowel syndrome, J. Gastroenterol. Hepatol., 26, pp. 119-121, (2011); Tache Y., Kiank C., Stengel A., A role for corticotropin-releasing factor in functional gastrointestinal disorders, Curr. Gastroenterol. Rep., 11, pp. 270-277, (2009); Nozu T., Miyagishi S., Nozu R., Takakusaki K., Toshikatsu O., Altered colonic sensory and barrier functions by CRF: Roles of TLR4 and IL-1, J. Endocrinol., 239, pp. 241-252, (2018); Dlugosz A., Nowak P., D'Amato M., Mohammadian Kermani G., Nystrom J., Abdurahman S., Lindberg G., Increased serum levels of lipopolysaccharide and antiflagellin antibodies in patients with diarrhea-predominant irritable bowel syndrome, Neurogastroenterol. Motil., 27, pp. 1747-1754, (2015); Barbara G., Zecchi L., Barbaro R., Cremon C., Bellacosa L., Marcellini M., de Giorgio R., Corinaldesi R., Stanghellini V., Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome, J. Clin. Gastroenterol., 46, pp. S52-S55, (2012); Nozu T., Miyagishi S., Nozu R., Takakusaki K., Okumura T., Lipopolysaccharide induces visceral hypersensitivity: Role of interleukin-1, interleukin-6, and peripheral corticotropin-releasing factor in rats, J. Gastroenterol., 52, pp. 72-80, (2017); Scully P., McKernan D.P., Keohane J., Groeger D., Shanahan F., Dinan T.G., Quigley E.M., Plasma cytokine profiles in females with irritable bowel syndrome and extra-intestinal co-morbidity, Am. J. Gastroenterol., 105, pp. 2235-2243, (2010); Dinan T.G., Quigley E.M., Ahmed S.M., Scully P., O'Brien S., O'Mahony L., O'Mahony S., Shanahan F., Keeling P.W., Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: Plasma cytokines as a potential biomarker?, Gastroenterology, 130, pp. 304-311, (2006); Ortiz-Lucas M., Saz-Peiro P., Sebastian-Domingo J.J., Irritable bowel syndrome immune hypothesis. Part two: The role of cytokines, Rev. Esp. Enferm. Dig., 102, pp. 711-717, (2010); Larauche M., Mulak A., Tache Y., Stress and visceral pain: From animal models to clinical therapies, Exp. Neurol., 233, pp. 49-67, (2012); Nozu T., Miyagishi S., Nozu R., Takakusaki K., Okumura T., Repeated water avoidance stress induces visceral hypersensitivity: Role of interleukin-1, interleukin-6, and peripheral corticotropin-releasing factor, J. Gastroenterol. Hepatol., 32, pp. 1958-1965, (2017); Liebregts T., Adam B., Bredack C., Roth A., Heinzel S., Lester S., Downie-Doyle S., Smith E., Drew P., Talley N.J., Et al., Immune activation in patients with irritable bowel syndrome, Gastroenterology, 132, pp. 913-920, (2007); Fine A.M., Oligomeric proanthocyanidin complexes: History, structure, and phytopharmaceutical applications, Altern. Med. Rev., 5, pp. 144-151, (2000); Weseler A.R., Bast A., Masquelier’s grape seed extract: From basic flavonoid research to a well-characterized food supplement with health benefits, Nutr. J., 16, 5, (2017); Wang H., Xue Y., Zhang H., Huang Y., Yang G., Du M., Zhu M.J., Dietary grape seed extract ameliorates symptoms of inflammatory bowel disease in IL10-deficient mice, Mol. Nutr. Food Res., 57, pp. 2253-2257, (2013); Yang G., Xue Y., Zhang H., Du M., Zhu M.J., Favourable effects of grape seed extract on intestinal epithelial differentiation and barrier function in IL10-deficient mice, Br. J. Nutr., 114, pp. 15-23, (2015); Liu W., Zhao S., Wang J., Shi J., Sun Y., Wang W., Ning G., Hong J., Liu R., Grape seed proanthocyanidin extract ameliorates inflammation and adiposity by modulating gut microbiota in high-fat diet mice, Mol. Nutr. Food Res., 61, (2017); Gil-Cardoso K., Gines I., Pinent M., Ardevol A., Arola L., Blay M., Terra X., Chronic supplementation with dietary proanthocyanidins protects from diet-induced intestinal alterations in obese rats, Mol. Nutr. Food Res., 61, (2017); Yamakoshi J., Tokutate S., Kikuchi M., Kubota Y., Konishi H., Mitsuoka T., Effect of proanthocyanidin-rich extract from grape seeds on human fecal flora and fecal odor, Microb. Ecol. Health Dis., 13, pp. 25-31, (2001); Nozu T., Miyagishi S., Kumei S., Nozu R., Takakusaki K., Okumura T., Lovastatin inhibits visceral allodynia and increased colonic permeability induced by lipopolysaccharide or repeated water avoidance stress in rats, Eur. J. Pharmacol., 818, pp. 228-234, (2018); Suzuki T., Yoshinaga N., Tanabe S., Interleukin-6 (IL-6) regulates claudin-2 expression and tight junction permeability in intestinal epithelium, J. Biol. Chem., 286, pp. 31263-31271, (2011); Haines R.J., Beard R.S., Chen L., Eitnier R.A., Wu M.H., Interleukin-1beta Mediates beta-Catenin-Driven Downregulation of Claudin-3 and Barrier Dysfunction in Caco2 Cells, Dig. Dis. Sci., 61, pp. 2252-2261, (2016); Yu D., Marchiando A.M., Weber C.R., Raleigh D.R., Wang Y., Shen L., Turner J.R., MLCK-dependent exchange and actin binding region-dependent anchoring of ZO-1 regulate tight junction barrier function, Proc. Natl. Acad. Sci. USA, 107, pp. 8237-8241, (2010); Tanaka H., Takechi M., Kiyonari H., Shioi G., Tamura A., Tsukita S., Intestinal deletion of Claudin-7 enhances paracellular organic solute flux and initiates colonic inflammation in mice, Gut, 64, pp. 1529-1538, (2015); Bradesi S., Eutamene H., Garcia-Villar R., Fioramonti J., Bueno L., Acute and chronic stress differently affect visceral sensitivity to rectal distension in female rats, Neurogastroenterol. Motil., 14, pp. 75-82, (2002); Kocak E., Akbal E., Koklu S., Ergul B., Can M., The Colonic Tissue Levels of TLR2, TLR4 and Nitric Oxide in Patients with Irritable Bowel Syndrome, Intern. Med., 55, pp. 1043-1048, (2016); Belmonte L., Beutheu Youmba S., Bertiaux-Vandaele N., Antonietti M., Lecleire S., Zalar A., Gourcerol G., Leroi A.M., Dechelotte P., Coeffier M., Et al., Role of toll like receptors in irritable bowel syndrome: Differential mucosal immune activation according to the disease subtype, Plos ONE, 7, (2012); Obreja O., Rathee P.K., Lips K.S., Distler C., Kress M., IL-1 beta potentiates heat-activated currents in rat sensory neurons: Involvement of IL-1RI, tyrosine kinase, and protein kinase C, FASEB J, 16, pp. 1497-1503, (2002); von Banchet G.S., Kiehl M., Schaible H.G., Acute and long-term effects of IL-6 on cultured dorsal root ganglion neurones from adult rat, J. Neurochem., 94, pp. 238-248, (2005); Creekmore A.L., Hong S., Zhu S., Xue J., Wiley J.W., Chronic stress-associated visceral hyperalgesia correlates with severity of intestinal barrier dysfunction, Pain, 159, pp. 1777-1789, (2018); Ishimoto H., Oshima T., Sei H., Yamasaki T., Kondo T., Tozawa K., Tomita T., Ohda Y., Fukui H., Watari J., Et al., Claudin-2 expression is upregulated in the ileum of diarrhea predominant irritable bowel syndrome patients, J. Clin. Biochem. Nutr., 60, pp. 146-150, (2017); Nagpal R., Yadav H., Bacterial Translocation from the Gut to the Distant Organs: An Overview, Ann. Nutr. Metab, 71, pp. 11-16, (2017); Fukui H., Increased Intestinal Permeability and Decreased Barrier Function: Does It Really Influence the Risk of Inflammation?, Inflamm. Intest. Dis., 1, pp. 135-145, (2016); Nozu T., Okumura T., Corticotropin-releasing factor receptor type 1 and type 2 interaction in irritable bowel syndrome, J. Gastroenterol., 50, pp. 819-830, (2015); Tsatsanis C., Androulidaki A., Alissafi T., Charalampopoulos I., Dermitzaki E., Roger T., Gravanis A., Margioris A.N., Corticotropin-releasing factor and the urocortins induce the expression of TLR4 in macrophages via activation of the transcription factors PU.1 and AP-1, J. Immunol., 176, pp. 1869-1877, (2006); Agelaki S., Tsatsanis C., Gravanis A., Margioris A.N., Corticotropin-releasing hormone augments proinflammatory cytokine production from macrophages in vitro and in lipopolysaccharide-induced endotoxin shock in mice, Infect. Immun., 70, pp. 6068-6074, (2002); Yu Y., Liu Z.Q., Liu X.Y., Yang L., Geng X.R., Yang G., Liu Z.G., Zheng P.Y., Yang P.C., Stress-Derived Corticotropin Releasing Factor Breaches Epithelial Endotoxin Tolerance, Plos ONE, 8, (2013); Terra X., Valls J., Vitrac X., Merrillon J.M., Arola L., Ardevol A., Blade C., Fernandez-Larrea J., Pujadas G., Salvado J., Et al., Grape-seed procyanidins act as antiinflammatory agents in endotoxin-stimulated RAW 264.7 macrophages by inhibiting NFkB signaling pathway, J. Agric. Food Chem., 55, pp. 4357-4365, (2007); Chu H., Tang Q., Huang H., Hao W., Wei X., Grape-seed proanthocyanidins inhibit the lipopolysaccharide-induced inflammatory mediator expression in RAW264.7 macrophages by suppressing MAPK and NF-kappab signal pathways, Environ. Toxicol. Pharmacol., 41, pp. 159-166, (2016); Wan J., Shan Y., Fan Y., Fan C., Chen S., Sun J., Zhu L., Qin L., Yu M., Lin Z., NF-kappaB inhibition attenuates LPS-induced TLR4 activation in monocyte cells, Mol. Med. Rep., 14, pp. 4505-4510, (2016); Liu T., Zhang L., Joo D., Sun S.C., NF-kappaB signaling in inflammation, Signal Transduct. Target. Ther., 2, (2017); Overman E.L., Rivier J.E., Moeser A.J., CRF induces intestinal epithelial barrier injury via the release of mast cell proteases and TNF-alpha, Plos ONE, 7, (2012); Piche T., Tight junctions and IBS–the link between epithelial permeability, low-grade inflammation, and symptom generation?, Neurogastroenterol. Motil., 26, pp. 296-302, (2014); Wang Y.H., Ge B., Yang X.L., Zhai J., Yang L.N., Wang X.X., Liu X., Shi J.C., Wu Y.J., Proanthocyanidins from grape seeds modulates the nuclear factor-kappa B signal transduction pathways in rats with TNBS-induced recurrent ulcerative colitis, Int. Immunopharmacol., 11, pp. 1620-1627, (2011)","H. Arie; Institute for Health Care Science, Suntory Wellness Limited, Kyoto, Seikadai 8-1-1, Seika-cho, Soraku-gun, 619-0284, Japan; email: Hideyuki_Arie@suntory.co.jp","","MDPI AG","","","","","","20726643","","","31689935","English","Nutrients","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85074564749"

"Yin S.; Sun C.; Ji Y.; Abdolmaleky H.; Zhou J.-R.","Yin, Sheng (57218525830); Sun, Chao (57746230900); Ji, Yi (57208291852); Abdolmaleky, Hamid (8744606800); Zhou, Jin-Rong (7405549563)","57218525830; 57746230900; 57208291852; 8744606800; 7405549563","Herbal medicine WangShiBaoChiWan improves gastrointestinal health in mice via modulation of intestinal tight junctions and gut microbiota and inhibition of inflammation","2021","Biomedicine and Pharmacotherapy","138","","111426","","","","12","10.1016/j.biopha.2021.111426","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103005687&doi=10.1016%2fj.biopha.2021.111426&partnerID=40&md5=7cf23bef2e2ea6def52d869777d95367","Nutrition/Metabolism Laboratory, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, 02215, MA, United States; Department of Acupuncture-Moxibustion and Tuina, Qilu Hospital of Shangdong University, Jinan, 250012, Shangdong, China; Department of Oncology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210028, Jiangsu, China","Yin S., Nutrition/Metabolism Laboratory, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, 02215, MA, United States; Sun C., Nutrition/Metabolism Laboratory, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, 02215, MA, United States, Department of Acupuncture-Moxibustion and Tuina, Qilu Hospital of Shangdong University, Jinan, 250012, Shangdong, China; Ji Y., Nutrition/Metabolism Laboratory, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, 02215, MA, United States, Department of Oncology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210028, Jiangsu, China; Abdolmaleky H., Nutrition/Metabolism Laboratory, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, 02215, MA, United States; Zhou J.-R., Nutrition/Metabolism Laboratory, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, 02215, MA, United States","WangShiBoChiWan (WSBCW) is a commonly used Chinese herbal medicine for the treatment of functional gastrointestinal disorders. However, its preclinical efficacy and the mechanisms of action have not been adequately studied. The goals of this study were to evaluate the effects of WSBCW on gastrointestinal health and modulation of related biomarkers. Female C57BL mice were randomly assigned into one of the experimental groups consisting of the control, drug controls, and WSBCW at 40, 120, and 360 mg/kg BW. Whole gut transit, small intestinal motility, and intestinal barrier permeability were determined. The castor oil-induced diarrhea mouse model was used to determine the effect of WSBCW on the diarrhea type of irritable bowel syndrome (IBS-D). WSBCW increased whole gut transit and intestinal motility, improved intestinal permeability in healthy animals and alleviated diarrhea symptoms in IBS-D mice. WSBCW upregulated intestinal junction proteins, increased the abundance of Bifidobacterium genus, Desulfovibrio genus and inhibited Bacteroides fragillis group in the gut microbiota, increased intestinal villi lengths, and decreased blood levels of inflammatory cytokines. Our study provided preclinical evidence to verify the effectiveness of WSBCW in gastrointestinal health and elucidate mechanistic insights. The results warrant further investigations to evaluate the therapeutic efficacy of WSBCW on gastrointestinal disorders, such as IBS and IBD. © 2021 The Authors","Gastrointestinal; Inflammation; Junction; Microbiota; Motility; Permeability","Animals; Diarrhea; Drugs, Chinese Herbal; Female; Gastrointestinal Microbiome; Gastrointestinal Motility; Gastrointestinal Tract; Herbal Medicine; Inflammation Mediators; Intestinal Mucosa; Irritable Bowel Syndrome; Mice; Mice, Inbred C57BL; Tight Junctions; agents used in inflammatory bowel disease; antidiarrheal agent; biological marker; Chinese drug; claudin; claudin 1; claudin 15; claudin 4; claudin 7; gamma interferon; genomic DNA; herbaceous agent; interleukin 12p40; interleukin 12p70; interleukin 6; junctional adhesion molecule; junctional adhesion molecule 4; junctional adhesion molecule A; linaclotide; loperamide; membrane protein; messenger RNA; monocyte chemotactic protein 1; protein ZO1; protein ZO2; protein ZO3; tumor necrosis factor; unclassified drug; uvomorulin; wangshibaochiwan; autacoid; herbaceous agent; adherens junction; adult; animal cell; animal experiment; animal model; animal tissue; antidiarrheal activity; Article; Atopobium; Bacteroides; Bacteroides fragilis; Bacteroides fragillis; Bifidobacterium; castor oil-induced diarrhea; Chinese medicine; Clostridium; Clostridium coccoides; Clostridium leptum; controlled study; Desulfovibrio; digestive system function disorder; DNA extraction; female; gastrointestinal tract function; gastrointestinal transit; inflammatory bowel disease; intestine flora; intestine motility; intestine mucosa permeability; intestine villus; irritable colon; Lactobacillus; mouse; mRNA expression level; nonhuman; Prevotella; priority journal; protein blood level; real time polymerase chain reaction; small intestine; tight junction; upregulation; animal; C57BL mouse; diarrhea; drug effect; gastrointestinal motility; gastrointestinal tract; herbal medicine; intestine mucosa; pathophysiology; physiology; procedures","","claudin 1, 329338-06-9; gamma interferon, 82115-62-6; linaclotide, 851199-59-2, 851199-60-5; loperamide, 34552-83-5, 53179-11-6; uvomorulin, 112956-45-3; Drugs, Chinese Herbal, ; Inflammation Mediators, ","","","Jinghua Pharmaceuticals Group","This research was funded by Beth Israel Deaconess Medical Center Research Project (#A10164) sponsored by Jinghua Pharmaceuticals Group, China.","Bischoff S.C., ‘Gut health’: a new objective in medicine?, BMC Med., 9, (2011); Noddin L., Callahan M., Lacy B.E., Irritable bowel syndrome and functional dyspepsia: different diseases or a single disorder with different manifestations?, MedGenMed, 7, 3, (2005); Chogle A., Velasco-Benitez C.A., Koppen I.J., Moreno J.E., Ramirez Hernandez C.R., Saps M., A population-based study on the epidemiology of functional gastrointestinal disorders in young children, J. Pediatr., 179, pp. 139-143 e1, (2016); Boronat A.C., Ferreira-Maia A.P., Matijasevich A., Wang Y.P., Epidemiology of functional gastrointestinal disorders in children and adolescents: a systematic review, World J. Gastroenterol., 23, 21, pp. 3915-3927, (2017); Avramidou M., Angst F., Angst J., Aeschlimann A., Rossler W., Schnyder U., Epidemiology of gastrointestinal symptoms in young and middle-aged Swiss adults: prevalences and comorbidities in a longitudinal population cohort over 28 years, BMC Gastroenterol., 18, 1, (2018); Dale H.F., Rasmussen S.H., Asiller O.O., Lied G.A., Probiotics in irritable bowel syndrome: an up-to-date systematic review, Nutrients, 11, 9, (2019); Masuy I., Pannemans J., Tack J., Irritable bowel syndrome: diagnosis and management, Minerva Gastroenterol. Dietol., 66, 2, pp. 136-150, (2020); Vegh Z., Kurti Z., Lakatos P.L., Epidemiology of inflammatory bowel diseases from west to east, J. Dig. Dis., 18, 2, pp. 92-98, (2017); Hu S.Y., Ma R., Guang J.X., Feng Z.W., Xu H.F., Li X.M., Bai X.H., Ma Q.P., Xiang X.X., Zhu F.L., Li W.W., Liu P.D., Cai J.X., Zhang H., Treatment of functional dyspepsia in children with WangshiBaochi Pills: a randomized double-blind multicenter clinical trial, Chin. J. New Drugs, 28, pp. 179-183, (2019); He L.X., Abdolmaleky H.M., Yin S., Wang Y., Zhou J.R., Dietary fermented soy extract and oligo-lactic acid alleviate chronic kidney disease in mice via inhibition of inflammation and modulation of gut microbiota, Nutrients, 12, 8, (2020); Gunzel D., Yu A.S., Claudins and the modulation of tight junction permeability, Physiol. Rev., 93, 2, pp. 525-569, (2013); Lee S.H., Intestinal permeability regulation by tight junction: implication on inflammatory bowel diseases, Intest. Res., 13, 1, pp. 11-18, (2015); Luettig J., Rosenthal R., Barmeyer C., Schulzke J.D., Claudin-2 as a mediator of leaky gut barrier during intestinal inflammation, Tissue Barriers, 3, 1-2, (2015); Tokuda S., Hirai T., Furuse M., Claudin-4 knockout by TALEN-mediated gene targeting in MDCK cells: Claudin-4 is dispensable for the permeability properties of tight junctions in wild-type MDCK cells, PLoS One, 12, 8, (2017); Nishiguchi Y., Fujiwara-Tani R., Sasaki T., Luo Y., Ohmori H., Kishi S., Mori S., Goto K., Yasui W., Sho M., Kuniyasu H., Targeting claudin-4 enhances CDDP-chemosensitivity in gastric cancer, Oncotarget, 10, 22, pp. 2189-2202, (2019); Fujiwara-Tani R., Sasaki T., Luo Y., Goto K., Kawahara I., Nishiguchi Y., Kishi S., Mori S., Ohmori H., Kondoh M., Kuniyasu H., Anti-claudin-4 extracellular domain antibody enhances the antitumoral effects of chemotherapeutic and antibody drugs in colorectal cancer, Oncotarget, 9, 100, pp. 37367-37378, (2018); Duarte G.M., Almeida N.R., Tocchet F., Espinola J., Barreto C.T.R., Pinto G.A., Soares F.A., Marshall P., Russano de Paiva Silva G., Claudin-4 expression is associated with disease-free survival in breast carcinoma-in-situ: mean follow-up of 8.2 years, Clin. Breast Cancer, 18, 5, pp. e1111-e1116, (2018); Martin de la Fuente L., Malander S., Hartman L., Jonsson J.M., Ebbesson A., Nilbert M., Masback A., Hedenfalk I., Claudin-4 expression is associated with survival in ovarian cancer but not with chemotherapy response, Int. J. Gynecol. Pathol., 37, 2, pp. 101-109, (2018); Breed C., Hicks D.A., Webb P.G., Galimanis C.E., Bitler B.G., Behbakht K., Baumgartner H.K., Ovarian tumor cell expression of claudin-4 reduces apoptotic response to paclitaxel, Mol. Cancer Res., 17, 3, pp. 741-750, (2019); Mehta S., Nijhuis A., Kumagai T., Lindsay J., Silver A., Defects in the adherens junction complex (E-cadherin/beta-catenin) in inflammatory bowel disease, Cell Tissue Res., 360, 3, pp. 749-760, (2015); Hermiston M.L., Gordon J.I., Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin, Science, 270, 5239, pp. 1203-1207, (1995); Satokari R., Modulation of gut microbiota for health by current and next-generation probiotics, Nutrients, 11, 8, (2019); Hirano A., Umeno J., Okamoto Y., Shibata H., Ogura Y., Moriyama T., Torisu T., Fujioka S., Fuyuno Y., Kawarabayasi Y., Matsumoto T., Kitazono T., Esaki M., Comparison of the microbial community structure between inflamed and non-inflamed sites in patients with ulcerative colitis, J. Gastroenterol. Hepatol., 33, pp. 1590-1597, (2018); Blandford L.E., Johnston E.L., Sanderson J.D., Wade W.G., Lax A.J., Promoter orientation of the immunomodulatory Bacteroides fragilis capsular polysaccharide A (PSA) is off in individuals with inflammatory bowel disease (IBD), Gut Microbes, 10, 5, pp. 569-577, (2019); Rashidan M., Azimirad M., Alebouyeh M., Ghobakhlou M., Asadzadeh Aghdaei H., Zali M.R., Detection of B. fragilis group and diversity of bft enterotoxin and antibiotic resistance markers cepA, cfiA and nim among intestinal Bacteroides fragilis strains in patients with inflammatory bowel disease, Anaerobe, 50, pp. 93-100, (2018); Aomatsu T., Imaeda H., Takahashi K., Fujimoto T., Kasumi E., Yoden A., Tamai H., Fujiyama Y., Andoh A., Tacrolimus (FK506) suppresses TNF-alpha-induced CCL2 (MCP-1) and CXCL10 (IP-10) expression via the inhibition of p38 MAP kinase activation in human colonic myofibroblasts, Int. J. Mol. Med., 30, 5, pp. 1152-1158, (2012); Mazzucchelli L., Hauser C., Zgraggen K., Wagner H.E., Hess M.W., Laissue J.A., Mueller C., Differential in situ expression of the genes encoding the chemokines MCP-1 and RANTES in human inflammatory bowel disease, J. Pathol., 178, 2, pp. 201-206, (1996); Spoettl T., Hausmann M., Herlyn M., Gunckel M., Dirmeier A., Falk W., Herfarth H., Schoelmerich J., Rogler G., Monocyte chemoattractant protein-1 (MCP-1) inhibits the intestinal-like differentiation of monocytes, Clin. Exp. Immunol., 145, 1, pp. 190-199, (2006); Neurath M.F., IL-23 in inflammatory bowel diseases and colon cancer, Cytokine Growth Factor Rev., 45, pp. 1-8, (2019); Shim H.H., Chan P.W., Chuah S.W., Schwender B.J., Kong S.C., Ling K.L., A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases, JGH Open, 2, 5, pp. 223-234, (2018)","J.-R. Zhou; Nutrition/Metabolism Laboratory, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, ST-8M10D, 330 Brookline Avenue, 02215, United States; email: jrzhou@bidmc.harvard.edu","","Elsevier Masson s.r.l.","","","","","","07533322","","BIPHE","33762124","English","Biomed. Pharmacother.","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85103005687"

"Palombo G.; Merone M.; Altomare A.; Gori M.; Terradura C.; Bacco L.; Del Chierico F.; Putignani L.; Cicala M.; Guarino M.P.L.; Piemonte V.","Palombo, Giovanni (56203913300); Merone, Mario (56102657200); Altomare, Annamaria (11539354000); Gori, Manuele (56284669400); Terradura, Carlotta (57224948092); Bacco, Luca (57220927387); Del Chierico, Federica (8976163900); Putignani, Lorenza (6603168130); Cicala, Michele (6701721784); Guarino, Michele Pier Luca (35901989300); Piemonte, Vincenzo (8706417000)","56203913300; 56102657200; 11539354000; 56284669400; 57224948092; 57220927387; 8976163900; 6603168130; 6701721784; 35901989300; 8706417000","The impact of the intestinal microbiota and the mucosal permeability on three different antibiotic drugs","2021","European Journal of Pharmaceutical Sciences","164","","105869","","","","3","10.1016/j.ejps.2021.105869","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85108726646&doi=10.1016%2fj.ejps.2021.105869&partnerID=40&md5=71d385932adca8f55a79dbf095fd66a1","Unit of Chemical-physics Fundamentals in Chemical Engineering, Department of Engineering, University Campus Bio-Medico of Rome, Italy; Computer Systems and Bioinformatics Laboratory, Department of Engineering, University Campus Bio-Medico of Rome, Italy; Istituto di Analisi dei Sistemi ed Informatica “A. Ruberti”, IASI-CNR (National Research Council of Italy), Rome, Italy; Unit of Gastroenterology Campus Bio-Medico University, Rome, Italy; Institute of Biochemistry and Cell Biology (IBBC) - National Research Council (CNR), Monterotondo Scalo, Rome, Italy; Multimodal Laboratory Medicine Research Area, Unit of Human Microbiome, Bambino Gesú Children's Hospital, IRCCS, Rome, Italy; Department of Diagnostic and Laboratory Medicine, Unit of Parasitology and Multimodal Laboratory Medicine Research Area, Unit of Human Microbiome, Bambino Gesú Children's Hospital, IRCCS, Rome, Italy; Istituto di Linguistica Computazionale “Antonio Zampolli” (IL-CNR), ItaliaNLP Lab, Pisa, Italy; SYSBIO/ISBE.IT, Centre of System Biology, Rome, Italy","Palombo G., Istituto di Analisi dei Sistemi ed Informatica “A. Ruberti”, IASI-CNR (National Research Council of Italy), Rome, Italy, SYSBIO/ISBE.IT, Centre of System Biology, Rome, Italy; Merone M., Computer Systems and Bioinformatics Laboratory, Department of Engineering, University Campus Bio-Medico of Rome, Italy; Altomare A., Unit of Gastroenterology Campus Bio-Medico University, Rome, Italy; Gori M., Unit of Gastroenterology Campus Bio-Medico University, Rome, Italy, Institute of Biochemistry and Cell Biology (IBBC) - National Research Council (CNR), Monterotondo Scalo, Rome, Italy; Terradura C., Unit of Chemical-physics Fundamentals in Chemical Engineering, Department of Engineering, University Campus Bio-Medico of Rome, Italy; Bacco L., Computer Systems and Bioinformatics Laboratory, Department of Engineering, University Campus Bio-Medico of Rome, Italy, Istituto di Linguistica Computazionale “Antonio Zampolli” (IL-CNR), ItaliaNLP Lab, Pisa, Italy; Del Chierico F., Multimodal Laboratory Medicine Research Area, Unit of Human Microbiome, Bambino Gesú Children's Hospital, IRCCS, Rome, Italy; Putignani L., Department of Diagnostic and Laboratory Medicine, Unit of Parasitology and Multimodal Laboratory Medicine Research Area, Unit of Human Microbiome, Bambino Gesú Children's Hospital, IRCCS, Rome, Italy; Cicala M., Unit of Gastroenterology Campus Bio-Medico University, Rome, Italy; Guarino M.P.L., Unit of Gastroenterology Campus Bio-Medico University, Rome, Italy; Piemonte V., Unit of Chemical-physics Fundamentals in Chemical Engineering, Department of Engineering, University Campus Bio-Medico of Rome, Italy","BackgroundThe totality of bacteria, protozoa, viruses and fungi that lives in the human body is called microbiota. Human microbiota specifically colonizes the skin, the respiratory and urinary tract, the urogenital tract and the gastrointestinal system. This study focuses on the intestinal microbiota to explore the drug-microbiota relationship and, therefore, how the drug bioavailability changes in relation to the microbiota biodiversity to identify more personalized therapies, with the minimum risk of side effects. MethodsTo achieve this goal, we developed a new mathematical model with two compartments, the intestine and the blood, which takes into account the colonic mucosal permeability variation - measured by Ussing chamber system on human colonic mucosal biopsies - and the fecal microbiota composition, determined through microbiota 16S rRNA sequencing analysis. Both of the clinical parameters were evaluated in a group of Irritable Bowel Syndrome patients compared to a group of healthy controls. Key ResultsThe results show that plasma drug concentration increases as bacterial concentration decreases, while it decreases as intestinal length decreases too. ConclusionsThe study provides interesting data since in literature there are not yet mathematical models with these features, in which the importance of intestinal microbiota, the ”forgotten organ”, is considered both for the subject health state and in the nutrients and drugs metabolism. © 2021","Compartmental models; Drug bioavailability; Gut barrier function; Intestinal microbiota","Anti-Bacterial Agents; Feces; Gastrointestinal Microbiome; Humans; Intestinal Mucosa; Permeability; Pharmaceutical Preparations; RNA, Ribosomal, 16S; ampicillin; antibiotic agent; antihypertensive agent; beta adrenergic receptor blocking agent; ciprofloxacin; hydroxymethylglutaryl coenzyme A reductase inhibitor; RNA 16S; tetracycline; antiinfective agent; drug; RNA 16S; adult; Article; blood; clinical article; colon biopsy; colon mucosa; compartment model; computer simulation; controlled study; data analysis software; drug bioavailability; drug blood level; feces microflora; female; human; human tissue; intestine; intestine flora; intestine mucosa permeability; irritable colon; length; male; microbial diversity; nonhuman; prospective study; RNA sequencing; species composition; feces; genetics; intestine mucosa; permeability","","ampicillin, 69-52-3, 69-53-4, 7177-48-2, 74083-13-9, 94586-58-0; ciprofloxacin, 85721-33-1, 86393-32-0, 128074-72-6, 128074-76-0, 192934-52-4, 93107-08-5, 86483-48-9, 96186-80-0; tetracycline, 23843-90-5, 60-54-8, 64-75-5, 8021-86-1; Anti-Bacterial Agents, ; Pharmaceutical Preparations, ; RNA, Ribosomal, 16S, ","FastStart High Fidelity, Hoffmann La Roche, United States; GS sequencer software v.2.7, Hoffmann La Roche, Germany; Infinite M200-Pro, Tecan, Switzerland; QIAamp DNA Stool Mini Kit, Qiagen, Germany; QIIME 1.9.0; Quant-iT PicoGreen, Life Technologies, United States; Roche 454, Life Science","Hoffmann La Roche, Germany; Hoffmann La Roche, United States; Life Science; Life Technologies, United States; Qiagen, Germany; Tecan, Switzerland","","","Acetate G., Livertox: Clinical and Research Information on Drug-induced Liver Injury, (2012); Agoram B., Woltosz W.S., Bolger M.B., Predicting the impact of physiological and biochemical processes on oral drug bioavailability, Adv. Drug Deliv. Rev., 50, pp. S41-S67, (2001); Alegria A., Garcia-Llatas G., Cilla A., Static digestion models: general introduction, The impact of food bioactives on health, pp. 3-12, (2015); Altomare A., Gori M., Cocca S., Carotti S., Francesconi M., Ribolsi M., Emerenziani S., Perrone G., Morini S., Cicala M., Et al., Impaired colonic contractility and intestinal permeability in symptomatic uncomplicated diverticular disease, J. Neurogastroenterol. Motil., (2021); Anson N.M., Havenaar R., Bast A., Haenen G.R., Antioxidant and anti-inflammatory capacity of bioaccessible compounds from wheat fractions after gastrointestinal digestion, J. Cereal Sci., 51, 1, pp. 110-114, (2010); den Besten G., van Eunen K., Groen A.K., Venema K., Reijngoud D.-J., Bakker B.M., The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism, J. Lipid Research, 54, 9, pp. 2325-2340, (2013); Blaser J., Stone B.B., Groner M.C., Zinner S.H., Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to mic for bactericidal activity and emergence of resistance., Antimicrob. Agents Chemother., 31, 7, pp. 1054-1060, (1987); Bowker K., Wootton M., Rogers C., Lewis R., Holt H., MacGowan A., Comparison of in-vitro pharmacodynamics of once and twice daily ciprofloxacin, J. Antimicrob. Chemother., 44, 5, pp. 661-667, (1999); Caporaso J.G., Kuczynski J., Stombaugh J., Bittinger K., Bushman F.D., Costello E.K., Fierer N., Pena A.G., Goodrich J.K., Gordon J.I., Et al., Qiime allows analysis of high-throughput community sequencing data, Nat. Methods, 7, 5, (2010); Carabotti M., Scirocco A., Maselli M.A., Severi C., The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems, Ann. Gastroenterol., 28, 2, (2015); Carinci P., Marinozzi G., Gaudio E., Anatomia umana e istologia, (2015); Craig W.A., Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men, Clin. Infect. Dis., pp. 1-10, (1998); Dinan T., Borre Y., Cryan J., Genomics of schizophrenia: time to consider the gut microbiome?, Mol. Psychiatry, 19, 12, pp. 1252-1257, (2014); Dona D., Barbieri E., Daverio M., Lundin R., Giaquinto C., Zaoutis T., Sharland M., Implementation and impact of pediatric antimicrobial stewardship programs: a systematic scoping review, Antimicrob. Resist. Infect. Control, 9, 1, (2020); Dressman J., Amidon G., Fleisher D., Absorption potential: estimating the fraction absorbed for orally administered compounds, J. Pharm. Sci., 74, 5, pp. 588-589, (1985); Edgar R.C., Search and clustering orders of magnitude faster than blast, Bioinformatics, 26, 19, pp. 2460-2461, (2010); Ekmekcioglu C., A physiological approach for preparing and conducting intestinal bioavailability studies using experimental systems, Food Chem., 76, 2, pp. 225-230, (2002); Ercolini D., De Filippis F., La Storia A., Iacono M., “remake” by high-throughput sequencing of the microbiota involved in the production of water buffalo mozzarella cheese, Appl. Environ. Microbiol., 78, 22, pp. 8142-8145, (2012); (2016); Fasano A., All disease begins in the (leaky) gut: Role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases, F1000Research, 9, (2020); Fernandez-Garcia E., Carvajal-Lerida I., Perez-Galvez A., In vitro bioaccessibility assessment as a prediction tool of nutritional efficiency, Nutr. Res., 29, 11, pp. 751-760, (2009); Ferrua M.J., Singh R.P., Human gastric simulator (riddet model), The Impact of Food Bioactives on Health, pp. 61-71, (2015); Finnah A., Pineiro S., Reuss R., Sanders P.; Fouchecourt M.-O., Beliveau M., Krishnan K., Quantitative structure–pharmacokinetic relationship modelling, Sci. Total Environ., 274, 1-3, pp. 125-135, (2001); Guarino M.P.L., Altomare A., Stasi E., Marignani M., Severi C., Alloni R., Dicuonzo G., Morelli L., Coppola R., Cicala M., Effect of acute mucosal exposure to lactobacillus rhamnosus gg on human colonic smooth muscle cells, J. Clin. Gastroenterol., 42, pp. S185-S190, (2008); Haggard H.W., The absorption, distribution, and elimination of ethyl ether ii. analysis of the mechanism of absorption and elimination of such a gas or vapor as ethyl ether, J. Biol. Chem., 59, 3, pp. 753-770, (1924); Haggard H.W., The absorption, distribution, and elimination of ethyl ether. III. The relation of the concentration of ether, or any similar volatile substance, in the central nervous system to the concentration in the arterial blood, and the buffer action of the body, J. Biol. Chem., 59, 3, pp. 771-781, (1924); Hellstrom P.M., Benno P., The rome iv: irritable bowel syndrome-a functional disorder, Best Pract. Res. Clin. Gastroenterol., (2019); Hiippala K., Kainulainen V., Kalliomaki M., Arkkila P., Satokari R., Mucosal prevalence and interactions with the epithelium indicate commensalism of sutterella spp., Front. Microbiol., 7, (2016); Holz M., Fahr A., Compartment modeling, Adv. Drug Deliv. Rev., 48, 2-3, pp. 249-264, (2001); Jeffery I.B., O'toole P.W., Ohman L., Claesson M.J., Deane J., Quigley E.M., Simren M., An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota, Gut, 61, 7, pp. 997-1006, (2012); Kim S., Covington A., Pamer E.G., The intestinal microbiota: antibiotics, colonization resistance, and enteric pathogens, Immunol. Rev., 279, 1, pp. 90-105, (2017); Klinke R., Silbernagl S., Fisiologia, (1999); Kong F., Singh R.P., A human gastric simulator (HGS) to study food digestion in human stomach, J. Food Sci., 75, 9, pp. E627-E635, (2010); Labus J.S., Hollister E.B., Jacobs J., Kirbach K., Oezguen N., Gupta A., Acosta J., Luna R.A., Aagaard K., Versalovic J., Et al., Differences in gut microbial composition correlate with regional brain volumes in irritable bowel syndrome, Microbiome, 5, 1, (2017); Lacy B.E., Patel N.K., Rome criteria and a diagnostic approach to irritable bowel syndrome, J. Clin. Med., 6, 11, (2017); Larsson M., Minekus M., Havenaar R., Estimation of the bioavailability of iron and phosphorus in cereals using a dynamic in vitro gastrointestinal model, J. Sci. Food Agric., 74, 1, pp. 99-106, (1997); Lawrence X.Y., Crison J.R., Amidon G.L., Compartmental transit and dispersion model analysis of small intestinal transit flow in humans, Int. J. Pharm., 140, 1, pp. 111-118, (1996); Lennernas H., Human in vivo regional intestinal permeability: importance for pharmaceutical drug development, Mol. Pharm., 11, 1, pp. 12-23, (2014); Lin J.H., Sugiyama Y., Awazu S., Hanano M., In vitro andin vivo evaluation of the tissue-to-blood partition coefficient for physiological pharmacokinetic models, J. Pharmacokinet. Biopharm., 10, 6, pp. 637-647, (1982); Lin L., Wong H., Predicting oral drug absorption: mini review on physiologically-based pharmacokinetic models, Pharmaceutics, 9, 4, (2017); Liu L., Pang K.S., An integrated approach to model hepatic drug clearance, Eur. J. Pharm. Sci., 29, 3-4, pp. 215-230, (2006); Lo Presti A., Zorzi F., Del Chierico F., Altomare A., Cocca S., Avola A., De Biasio F., Russo A., Cella E., Reddel S., Et al., Fecal and mucosal microbiota profiling in irritable bowel syndrome and inflammatory bowel disease, Front. Microbiol., 10, (2019); Maier L., Pruteanu M., Kuhn M., Zeller G., Telzerow A., Anderson E.E., Brochado A.R., Fernandez K.C., Dose H., Mori H., Et al., Extensive impact of non-antibiotic drugs on human gut bacteria, Nature, 555, 7698, pp. 623-628, (2018); Mann J.C., Pygall S.R., A formulation case study comparing the dynamic gastric model with conventional dissolution methods, Dissolut. Technol., 19, 4, pp. 14-19, (2012); Menard O., Picque D., Dupont D., The didgi® system, The Impact of Food Bioactives on Health, pp. 73-81, (2015); Menees S., Chey W., The gut microbiome and irritable bowel syndrome, F1000Research, 7, (2018); Minekus M., The tno gastro-intestinal model (tim), The impact of food bioactives on health, pp. 37-46, (2015); Minekus M., Marteau P., Havenaar R., Et al., Multicompartmental dynamic computer-controlled model simulating the stomach and small intestine, Altern. Lab. Anim., (1995); Moreda-Pineiro J., Moreda-Pineiro A., Romaris-Hortas V., Moscoso-Perez C., Lopez-Mahia P., Muniategui-Lorenzo S., Bermejo-Barrera P., Prada-Rodriguez D., In-vivo and in-vitro testing to assess the bioaccessibility and the bioavailability of arsenic, selenium and mercury species in food samples, TrAC Trends Anal. Chem., 30, 2, pp. 324-345, (2011); Nestorov I., Whole body pharmacokinetic models, Clin. Pharmacokinet., 42, 10, pp. 883-908, (2003); Ohlsson A., Shah V.S., Intrapartum antibiotics for known maternal group b streptococcal colonization, Cochrane Database Syst. Rev., 6, (2014); Peng H., Cheung B., A Review on Pharmacokinetic Modeling and the Effects of Environmental Stressors on Pharmacokinetics for Operational Medicine: Operational Pharmacokinetics, Technical Report, (2009); Pompa M., Capocelli M., Piemonte V., A new gastro-intestinal mathematical model to study drug bioavailability, Med. Eng. Phys., 74, pp. 106-114, (2019); Recenti R., Il microbiota intestinale, Recenti Prog. Med., 107, 6, pp. 257-266, (2016); Reeder J., Knight R., Rapidly denoising pyrosequencing amplicon reads by exploiting rank-abundance distributions, Nat. Methods, 7, 9, pp. 668-669, (2010); Regoes R.R., Wiuff C., Zappala R.M., Garner K.N., Baquero F., Levin B.R., Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens, Antimicrob. Agents Chemother., 48, 10, pp. 3670-3676, (2004); Ruan W., Engevik M.A., Spinler J.K., Versalovic J., Healthy human gastrointestinal microbiome: composition and function after a decade of exploration, Digest. Dis. Sci., pp. 1-11, (2020); S Darwich A., Neuhoff S., Jamei M., Rostami-Hodjegan A., Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the “advanced dissolution, absorption, metabolism (adam)- model, Curr. Drug Metab., 11, 9, pp. 716-729, (2010); Sanchez Navarro M.D., Sayalero Marinero M.L., Sanchez Navarro A., Pharmacokinetic/pharmacodynamic modelling of ciprofloxacin 250 mg/12 h versus 500 mg/24 h for urinary infections, J. Antimicrob. Chemother., 50, 1, pp. 67-72, (2002); Sarkar S.R., Banerjee S., Gut microbiota in neurodegenerative disorders, J. Neuroimmunol., 328, pp. 98-104, (2019); Sjogren E., Westergren J., Grant I., Hanisch G., Lindfors L., Lennernas H., Abrahamsson B., Tannergren C., In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-SIM, Eur. J. Pharm. Sci., 49, 4, pp. 679-698, (2013); Steelant B., Farre R., Wawrzyniak P., Belmans J., Dekimpe E., Vanheel H., Van Gerven L., Krohn I.K., Bullens D.M., Ceuppens J.L., Et al., Impaired barrier function in patients with house dust mite–induced allergic rhinitis is accompanied by decreased occludin and zonula occludens-1 expression, J. Allergy Clin. Immunol., 137, 4, pp. 1043-1053, (2016); Sugano K., Introduction to computational oral absorption simulation, Expert Opin. Drug Metab. Toxicol., 5, 3, pp. 259-293, (2009); Tang H., Mayersohn M., pp. 1297-1303, (2005); Teorell T., Kinetics of distribution of substances administered to the body, I: the extravascular modes of administration, Arch. Internatl. Pharm.Ther., 57, pp. 205-225, (1937); Thelen K., Coboeken K., Willmann S., Burghaus R., Dressman J.B., Lippert J., Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part 1: oral solutions, J. Pharm. Sci., 100, 12, pp. 5324-5345, (2011); Thuenemann E.C., Mandalari G., Rich G.T., Faulks R.M., Dynamic gastric model (DGM), The impact of food bioactives on health, pp. 47-59, (2015); Ungell A.-L., Nylander S., Bergstrand S., Sjoberg A., Lennernas H., Membrane transport of drugs in different regions of the intestinal tract of the rat, J. Pharm. Sci., 87, 3, pp. 360-366, (1998); Unno T., Choi J.-H., Hur H.-G., Sadowsky M.J., Ahn Y.-T., Huh C.-S., Kim G.-B., Cha C.-J., Changes in human gut microbiota influenced by probiotic fermented milk ingestion, J. Dairy Sci., 98, 6, pp. 3568-3576, (2015); Vanheel H., Vicario M., Vanuytsel T., Van Oudenhove L., Martinez C., Keita A.V., Pardon N., Santos J., Soderholm J.D., Tack J., Et al., Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia, Gut, 63, 2, pp. 262-271, (2014); Wallon C., Braaf Y., Wolving M., Olaison G., Soderholm J.D., Endoscopic biopsies in ussing chambers evaluated for studies of macromolecular permeability in the human colon, Scand. J. Gastroenterol., 40, 5, pp. 586-595, (2005); Wickham M., Faulks R., Mann J., Mandalari G., The design, operation, and application of a dynamic gastric model, Dissolut. Technol., 19, 3, pp. 15-22, (2012); Wickham M., Faulks R., Mills C., In vitro digestion methods for assessing the effect of food structure on allergen breakdown, Mol. Nutr. Food Res., 53, 8, pp. 952-958, (2009); Williams L., Leggett R., Reference values for resting blood flow to organs of man, Clin. Phys. Physiol. Meas., 10, 3, (1989); Willmann S., Schmitt W., Keldenich J., Lippert J., Dressman J.B., A physiological model for the estimation of the fraction dose absorbed in humans, J. Med. Chem., 47, 16, pp. 4022-4031, (2004); Wu H., Tremaroli V., Backhed F., Linking microbiota to human diseases: a systems biology perspective, Trends Endocrinol. Metab., 26, 12, pp. 758-770, (2015); Yu L.C.-H., Microbiota dysbiosis and barrier dysfunction in inflammatory bowel disease and colorectal cancers: exploring a common ground hypothesis, J. Biomed. Sci., 25, 1, pp. 1-14, (2018); Zimmermann M., Zimmermann-Kogadeeva M., Wegmann R., Goodman A.L., Separating host and microbiome contributions to drug pharmacokinetics and toxicity, Science, 363, 6427, (2019)","M. Merone; Computer Systems and Bioinformatics Laboratory, Department of Engineering, University Campus Bio-Medico of Rome, Italy; email: m.merone@unicampus.it","","Elsevier B.V.","","","","","","09280987","","EPSCE","34020000","English","Eur. J. Pharm. Sci.","Article","Final","","Scopus","2-s2.0-85108726646"

"Nozu T.; Miyagishi S.; Nozu R.; Takakusaki K.; Okumura T.","Nozu, Tsukasa (12765917900); Miyagishi, Saori (56538237900); Nozu, Rintaro (57028157900); Takakusaki, Kaoru (7004150214); Okumura, Toshikatsu (7202327796)","12765917900; 56538237900; 57028157900; 7004150214; 7202327796","Dehydroepiandrosterone sulfate improves visceral sensation and gut barrier in a rat model of irritable bowel syndrome","2019","European Journal of Pharmacology","852","","","198","206","8","11","10.1016/j.ejphar.2019.03.037","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85063618578&doi=10.1016%2fj.ejphar.2019.03.037&partnerID=40&md5=b0fbf139a48d5ca3896ba47083dae3fd","Department of Regional Medicine and Education, Asahikawa Medical University, Midorigaoka Higashi 2-1-1-1, Asahikawa, 078-8510, Japan; Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Research Center for Brain Function and Medical Engineering, Asahikawa Medical University, Midorigaoka Higashi 2-1-1-1, Asahikawa, 078-8510, Japan; Department of General Medicine, Asahikawa Medical University, Midorigaoka Higashi 2-1-1-1, Asahikawa, 078-8510, Japan","Nozu T., Department of Regional Medicine and Education, Asahikawa Medical University, Midorigaoka Higashi 2-1-1-1, Asahikawa, 078-8510, Japan; Miyagishi S., Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Nozu R., Department of Regional Medicine and Education, Asahikawa Medical University, Midorigaoka Higashi 2-1-1-1, Asahikawa, 078-8510, Japan; Takakusaki K., Research Center for Brain Function and Medical Engineering, Asahikawa Medical University, Midorigaoka Higashi 2-1-1-1, Asahikawa, 078-8510, Japan; Okumura T., Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan, Department of General Medicine, Asahikawa Medical University, Midorigaoka Higashi 2-1-1-1, Asahikawa, 078-8510, Japan","Stress-induced altered visceral sensation and impaired gut barrier play an important role in the pathophysiology of irritable bowel syndrome (IBS). These responses were demonstrated to be peripheral corticotropin-releasing factor (CRF) dependent and also mediated via proinflammatory cytokine in animal IBS model. Dehydroepiandrosterone sulfate (DHEA-S) is known to have anti-inflammatory properties by suppressing proinflammatory cytokine release. We hypothesized that DHEA-S improves stress-induced visceral changes and is beneficial for IBS treatment. We explored the effects of DHEA-S on lipopolysaccharide (LPS)- or repeated water avoidance stress (WAS)-induced visceral allodynia and increased colonic permeability (rat IBS models). The threshold of visceromotor response, i.e. abdominal muscle contractions induced by colonic balloon distention was electrophysiologically measured. Colonic permeability was estimated in vivo by quantifying the absorbed Evans blue in colonic tissue. DHEA-S abolished visceral allodynia and colonic hyperpermeability induced by LPS in a dose-dependent manner. It also blocked repeated WAS- or peripheral injection of CRF-induced visceral changes. These effects by DHEA-S in LPS model were reversed by bicuculline, a γ-aminobutyric acid (GABA)A receptor antagonist, NG-nitro-L-arginine methyl ester, a nitric oxide (NO) synthesis inhibitor, naloxone, an opioid receptor antagonist, or sulpiride, a dopamine D2 receptor antagonist. However, domperidone, a peripheral dopamine D2 receptor antagonist did not modify the effects. Peripheral injection of astressin2-B, a selective CRF receptor subtype 2 (CRF2) antagonist also reversed these effects. In conclusion, DHEA-S blocked stress-induced visceral changes via GABAA, NO, opioid, central dopamine D2 and peripheral CRF2 signaling. DHEA-S may be useful for IBS treating. © 2019 Elsevier B.V.","Dehydroepiandrosterone sulfate; Gut barrier; Irritable bowel syndrome; Visceral pain","Animals; Colon; Cytokines; Dehydroepiandrosterone Sulfate; Irritable Bowel Syndrome; Male; Permeability; Rats; Rats, Sprague-Dawley; Stress, Psychological; Visceral Pain; astressin; bicuculline; domperidone; Evans blue; lipopolysaccharide; n(g) nitroarginine methyl ester; prasterone sulfate; sulpiride; cytokine; prasterone sulfate; adult; allodynia; animal experiment; animal model; animal tissue; antiinflammatory activity; antinociception; Article; colonic permeability; controlled study; cytokine release; electrophysiology; experimental behavioral test; in vivo study; intestine mucosa permeability; irritable colon; limit of quantitation; male; nonhuman; priority journal; rat; signal transduction; visceral allodynia; visceral allodynia; water avoidance stress test; animal; colon; complication; drug effect; irritable colon; mental stress; metabolism; permeability; psychology; Sprague Dawley rat; visceral pain","","astressin, 170809-51-5; bicuculline, 485-49-4; domperidone, 57808-66-9; Evans blue, 314-13-6; n(g) nitroarginine methyl ester, 50903-99-6; prasterone sulfate, 651-48-9; sulpiride, 15676-16-1; Cytokines, ; Dehydroepiandrosterone Sulfate, ","","","Akiyama Life Science Foundation; Japan Society for the Promotion of Science, KAKEN, (18K07896, 26120012, 26460287, 26460955)","This work was partially supported by Japan Society for the Promotion of Science KAKENHI , Grant-in-Aid for Scientific Research (C) [ 26460287 (TN) and 26460955 (TO)], Scientific Research on Innovative Areas [ 26120012 (KT)], and the research grant from the Akiyama Life Science Foundation (TN).","Barbara G., Zecchi L., Barbaro R., Cremon C., Bellacosa L., Marcellini M., De Giorgio R., Corinaldesi R., Stanghellini V., Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome, J. Clin. Gastroenterol., 46, pp. S52-S55, (2012); Baulieu E.E., Corpechot C., Dray F., Emiliozzi R., Lebeau M.C., Mauvais Jarvis P., Robel P., An adrenal-secreted “androgen”: dehydroisoandrosterone sulfate. Its metabolism and a tentative generalization on the metabolism of other steroid conjugates in man, Recent Prog. Horm. Res., 21, pp. 411-500, (1965); Ben-Nathan D., Padgett D.A., Loria R.M., Androstenediol and dehydroepiandrosterone protect mice against lethal bacterial infections and lipopolysaccharide toxicity, J. Med. Microbiol., 48, pp. 425-431, (1999); Branda E.M., Ramza J.T., Cahill F.J., Tseng L.F., Quock R.M., Role of brain dynorphin in nitrous oxide antinociception in mice, Pharmacol. Biochem. Behav., 65, pp. 217-221, (2000); Capasso R., Orlando P., Pagano E., Aveta T., Buono L., Borrelli F., Di Marzo V., Izzo A.A., Palmitoylethanolamide normalizes intestinal motility in a model of post-inflammatory accelerated transit: involvement of CB(1) receptors and TRPV1 channels, Br. J. Pharmacol., 171, pp. 4026-4037, (2014); Chakraborti A., Gulati K., Ray A., Involvement of nitric oxide in the protective effects of dehydroepiandrosterone sulphate on stress induced neurobehavioral suppression and brain oxidative injury in rats, Eur. J. Pharmacol., 652, pp. 55-59, (2011); Chrousos G.P., Stress and disorders of the stress system, Nat. Rev. Endocrinol., 5, pp. 374-381, (2009); Chung E., Burke B., Bieber A.J., Doss J.C., Ohgami Y., Quock R.M., Dynorphin-mediated antinociceptive effects of L-arginine and SIN-1 (an NO donor) in mice, Brain Res. Bull., 70, pp. 245-250, (2006); Danenberg H.D., Alpert G., Lustig S., Ben-Nathan D., Dehydroepiandrosterone protects mice from endotoxin toxicity and reduces tumor necrosis factor production, Antimicrob. Agents Chemother., 36, pp. 2275-2279, (1992); Dlugosz A., Nowak P., D'Amato M., Mohammadian Kermani G., Nystrom J., Abdurahman S., Lindberg G., Increased serum levels of lipopolysaccharide and antiflagellin antibodies in patients with diarrhea-predominant irritable bowel syndrome, Neuro Gastroenterol. Motil., 27, pp. 1747-1754, (2015); Du C., Khalil M.W., Sriram S., Administration of dehydroepiandrosterone suppresses experimental allergic encephalomyelitis in SJL/J mice, J. Immunol., 167, pp. 7094-7101, (2001); Eser D., Schule C., Romeo E., Baghai T.C., di Michele F., Pasini A., Zwanzger P., Padberg F., Rupprecht R., Neuropsychopharmacological properties of neuroactive steroids in depression and anxiety disorders, Psychopharmacology (Berlin), 186, pp. 373-387, (2006); Garrido-Gil P., Rodriguez-Perez A.I., Dominguez-Meijide A., Guerra M.J., Labandeira-Garcia J.L., Bidirectional neural interaction between central dopaminergic and gut lesions in Parkinson's disease models, Mol. Neurobiol., 55, pp. 7297-7316, (2018); Gladkevich A., Korf J., Hakobyan V.P., Melkonyan K.V., The peripheral GABAergic system as a target in endocrine disorders, Auton. Neurosci., 124, pp. 1-8, (2006); Hillhouse E.W., Grammatopoulos D.K., The molecular mechanisms underlying the regulation of the biological activity of corticotropin-releasing hormone receptors: implications for physiology and pathophysiology, Endocr. Rev., 27, pp. 260-286, (2006); Hong S., Zheng G., Wu X., Snider N.T., Owyang C., Wiley J.W., Corticosterone mediates reciprocal changes in CB 1 and TRPV1 receptors in primary sensory neurons in the chronically stressed rat, Gastroenterology, 140, pp. 627-637, (2011); Kamin H.S., Kertes D.A., Cortisol and DHEA in development and psychopathology, Horm. Behav., 89, pp. 69-85, (2017); Kanwar S., Wallace J.L., Befus D., Kubes P., Nitric oxide synthesis inhibition increases epithelial permeability via mast cells, Am. J. Physiol., 266, pp. G222-G229, (1994); Kibaly C., Meyer L., Patte-Mensah C., Mensah-Nyagan A.G., Biochemical and functional evidence for the control of pain mechanisms by dehydroepiandrosterone endogenously synthesized in the spinal cord, FASEB J., 22, pp. 93-104, (2008); Kim Y.M., Talanian R.V., Li J., Billiar T.R., Nitric oxide prevents IL-1beta and IFN-gamma-inducing factor (IL-18) release from macrophages by inhibiting caspase-1 (IL-1beta-converting enzyme), J. Immunol., 161, pp. 4122-4128, (1998); Kroncke K.D., Fehsel K., Suschek C., Kolb-Bachofen V., Inducible nitric oxide synthase-derived nitric oxide in gene regulation, cell death and cell survival, Int. Immunopharmacol., 1, pp. 1407-1420, (2001); Lapchak P.A., Chapman D.F., Nunez S.Y., Zivin J.A., Dehydroepiandrosterone sulfate is neuroprotective in a reversible spinal cord ischemia model: possible involvement of GABA(A) receptors, Stroke, 31, pp. 1953-1956, (2000); Lee C., Doo E., Choi J.M., Jang S.H., Ryu H.S., Lee J.Y., Oh J.H., Park J.H., Kim Y.S., The increased level of depression and anxiety in irritable bowel syndrome patients compared with healthy controls: systematic review and meta-analysis, J. Neurogastroenterol. Motil., 23, pp. 349-362, (2017); Majewska M.D., Harrison N.L., Schwartz R.D., Barker J.L., Paul S.M., Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor, Science, 232, pp. 1004-1007, (1986); Maninger N., Capitanio J.P., Mason W.A., Ruys J.D., Mendoza S.P., Acute and chronic stress increase DHEAS concentrations in rhesus monkeys, Psychoneuroendocrinology, 35, pp. 1055-1062, (2010); Martinez V., Rivier J., Wang L., Tache Y., Central injection of a new corticotropin-releasing factor (CRF) antagonist, astressin, blocks CRF- and stress-related alterations of gastric and colonic motor function, J. Pharmacol. Exp. Ther., 280, pp. 754-760, (1997); Mearin F., Lacy B.E., Chang L., Chey W.D., Lembo A.J., Simren M., Spiller R., Bowel disorders, Gastroenterology, 150, pp. 1393-1407, (2016); Melchior C.L., Ritzmann R.F., Dehydroepiandrosterone is an anxiolytic in mice on the plus maze, Pharmacol. Biochem. Behav., 47, pp. 437-441, (1994); Ness T.J., Gebhart G.F., Colorectal distension as a noxious visceral stimulus: physiologic and pharmacologic characterization of pseudaffective reflexes in the rat, Brain Res., 450, pp. 153-169, (1988); Ninkovic J., Roy S., Role of the mu-opioid receptor in opioid modulation of immune function, Amino Acids, 45, pp. 9-24, (2013); Nozu T., Miyagishi S., Kumei S., Nozu R., Takakusaki K., Okumura T., Lovastatin inhibits visceral allodynia and increased colonic permeability induced by lipopolysaccharide or repeated water avoidance stress in rats, Eur. J. Pharmacol., 818, pp. 228-234, (2017); Nozu T., Miyagishi S., Kumei S., Nozu R., Takakusaki K., Okumura T., Metformin inhibits visceral allodynia and increased gut permeability induced by stress in rats, J. Gastroenterol. Hepatol., 34, pp. 186-193, (2019); Nozu T., Miyagishi S., Nozu R., Takakusaki K., Okumura T., Lipopolysaccharide induces visceral hypersensitivity: role of interleukin-1, interleukin-6, and peripheral corticotropin-releasing factor in rats, J. Gastroenterol., 52, pp. 72-80, (2017); Nozu T., Miyagishi S., Nozu R., Takakusaki K., Okumura T., Repeated water avoidance stress induces visceral hypersensitivity; role of IL-1, IL-6 and peripheral corticotropin-releasing factor, J. Gastroenterol. Hepatol., 32, pp. 1958-1965, (2017); Nozu T., Miyagishi S., Nozu R., Takakusaki K., Okumura T., Altered colonic sensory and barrier functions by CRF: roles of TLR4 and IL-1, J. Endocrinol., 239, pp. 241-252, (2018); Nozu T., Okumura T., Corticotropin-releasing factor receptor type 1 and type 2 interaction in irritable bowel syndrome, J. Gastroenterol., 50, pp. 819-830, (2015); Nozu T., Takakusaki K., Okumura T., A balance theory of peripheral corticotropin-releasing factor receptor type 1 and type 2 signaling to induce colonic contractions and visceral hyperalgesia in rats, Endocrinology, 155, pp. 4655-4664, (2014); Obreja O., Rathee P.K., Lips K.S., Distler C., Kress M., IL-1 beta potentiates heat-activated currents in rat sensory neurons: involvement of IL-1RI, tyrosine kinase, and protein kinase C, FASEB J., 16, pp. 1497-1503, (2002); Obut T.A., Saryg S.K., Ovsukova M.V., Dementeva T.U., Obut E.T., Erdinieva T.A., Effect of dehydroepiandrosterone sulfate on aldosterone level during stress exposures: role of mu-opioid receptors, Bull. Exp. Biol. Med., 152, pp. 696-698, (2012); Okumura T., Nozu T., Kumei S., Takakusaki K., Miyagishi S., Ohhira M., Involvement of the dopaminergic system in the central orexin-induced antinociceptive action against colonic distension in conscious rats, Neurosci. Lett., 605, pp. 34-38, (2015); Pacifici R., di Carlo S., Bacosi A., Pichini S., Zuccaro P., Pharmacokinetics and cytokine production in heroin and morphine-treated mice, Int. J. Immunopharmacol., 22, pp. 603-614, (2000); Pagano E., Capasso R., Piscitelli F., Romano B., Parisi O.A., Finizio S., Lauritano A., Marzo V.D., Izzo A.A., Borrelli F., An orally active cannabis extract with high content in cannabidiol attenuates chemically-induced intestinal inflammation and hypermotility in the mouse, Front. Pharmacol., 7, (2016); Patte-Mensah C., Meyer L., Kibaly C., Mensah-Nyagan A.G., Regulatory effect of dehydroepiandrosterone on spinal cord nociceptive function, Front. Biosci. (Elite edition), 2, pp. 1528-1537, (2010); Perez-Neri I., Montes S., Ojeda-Lopez C., Ramirez-Bermudez J., Rios C., Modulation of neurotransmitter systems by dehydroepiandrosterone and dehydroepiandrosterone sulfate: mechanism of action and relevance to psychiatric disorders, Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 32, pp. 1118-1130, (2008); Perrin M.H., Vale W.W., Corticotropin releasing factor receptors and their ligand family, Ann. N. Y. Acad. Sci., 885, pp. 312-328, (1999); Poynter M.E., Daynes R.A., Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging, J. Biol. Chem., 273, pp. 32833-32841, (1998); Reddy D.S., Kulkarni S.K., Possible role of nitric oxide in the nootropic and antiamnesic effects of neurosteroids on aging- and dizocilpine-induced learning impairment, Brain Res., 799, pp. 215-229, (1998); Reiss D., Ceredig R.A., Secher T., Boue J., Barreau F., Dietrich G., Gaveriaux-Ruff C., Mu and delta opioid receptor knockout mice show increased colonic sensitivity, Eur. J. Pain, 21, pp. 623-634, (2017); Reyes-Garcia M.G., Hernandez-Hernandez F., Hernandez-Tellez B., Garcia-Tamayo F., GABA (A) receptor subunits RNA expression in mice peritoneal macrophages modulate their IL-6/IL-12 production, J. Neuroimmunol., 188, pp. 64-68, (2007); Rode F., Jensen D.G., Blackburn-Munro G., Bjerrum O.J., Centrally-mediated antinociceptive actions of GABA(A) receptor agonists in the rat spared nerve injury model of neuropathic pain, Eur. J. Pharmacol., 516, pp. 131-138, (2005); Samardzic J., Hencic B., Jancic J., Jadzic D., Djuric M., Obradovic D.I., Svob Strac D., Neurosteroid dehydroepiandrosterone improves active avoidance retrieval and induces antidepressant-like behavior in rats, Neurosci. Lett., 660, pp. 17-21, (2017); Suzuki T., Yoshinaga N., Tanabe S., Interleukin-6 (IL-6) regulates claudin-2 expression and tight junction permeability in intestinal epithelium, J. Biol. Chem., 286, pp. 31263-31271, (2011); Tache Y., Kiank C., Stengel A., A role for corticotropin-releasing factor in functional gastrointestinal disorders, Curr. Gastroenterol. Rep., 11, pp. 270-277, (2009); Tang Q.L., Lai M.L., Zhong Y.F., Wang A.M., Su J.K., Zhang M.Q., Antinociceptive effect of berberine on visceral hypersensitivity in rats, World J. Gastroenterol., 19, pp. 4582-4589, (2013); von Banchet G.S., Kiehl M., Schaible H.G., Acute and long-term effects of IL-6 on cultured dorsal root ganglion neurones from adult rat, J. Neurochem., 94, pp. 238-248, (2005); Wiley J.W., Higgins G.A., Athey B.D., Stress and glucocorticoid receptor transcriptional programming in time and space: implications for the brain-gut axis, Neuro Gastroenterol. Motil., 28, pp. 12-25, (2016); Woda A., Picard P., Dutheil F., Dysfunctional stress responses in chronic pain, Psychoneuroendocrinology, 71, pp. 127-135, (2016); Zong Y., Zhu S., Zhang S., Zheng G., Wiley J.W., Hong S., Chronic stress and intestinal permeability: lubiprostone regulates glucocorticoid receptor-mediated changes in colon epithelial tight junction proteins, barrier function, and visceral pain in the rodent and human, Neuro Gastroenterol. Motil., (2018)","T. Nozu; Department of Regional Medicine and Education, Asahikawa Medical University, Asahikawa, 2-1-1-1 Midorigaoka-Higashi, 078-8510, Japan; email: tnozu@sea.plala.or.jp","","Elsevier B.V.","","","","","","00142999","","EJPHA","30935894","English","Eur. J. Pharmacol.","Article","Final","All Open Access; Green Open Access","Scopus","2-s2.0-85063618578"

"Meira de-Faria F.; Casado-Bedmar M.; Mårten Lindqvist C.; Jones M.P.; Walter S.A.; Keita Å.V.","Meira de-Faria, Felipe (36450289100); Casado-Bedmar, Maite (56951301500); Mårten Lindqvist, Carl (57222602406); Jones, Michael P. (57005805200); Walter, Susanna A. (23053245700); Keita, Åsa V. (13104052600)","36450289100; 56951301500; 57222602406; 57005805200; 23053245700; 13104052600","Altered interaction between enteric glial cells and mast cells in the colon of women with irritable bowel syndrome","2021","Neurogastroenterology and Motility","33","11","e14130","","","","17","10.1111/nmo.14130","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103388083&doi=10.1111%2fnmo.14130&partnerID=40&md5=1f9dcea476b32320495daefcf7b6f953","Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden; Department of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; Macquarie University, Sydney, NSW, Australia; Department of Gastroenterology, Linköping University, Linköping, Sweden","Meira de-Faria F., Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden; Casado-Bedmar M., Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden; Mårten Lindqvist C., Department of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; Jones M.P., Macquarie University, Sydney, NSW, Australia; Walter S.A., Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden, Department of Gastroenterology, Linköping University, Linköping, Sweden; Keita Å.V., Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden","Background: Enteric glial cells (EGC) and mast cells (MC) are intimately associated with gastrointestinal physiological functions. We aimed to investigate EGC-MC interaction in irritable bowel syndrome (IBS), a gut-brain disorder linked to increased intestinal permeability, and MC. Methods: Parallel approaches were used to quantify EGC markers in colonic biopsies from healthy controls (HC) and patients with IBS. Data were correlated with MC, vasoactive intestinal polypeptide (VIP) and VIP receptors (VPAC1/VPAC2) expressions, and bacterial translocation through biopsies mounted in Ussing chambers. In addition, we investigated the effects of EGC mediators on colonic permeability and the pharmacological-induced responses of EGC and MC cell lines. Key Results: Immunofluorescence of IBS colonic mucosa, as well as Western blotting and ELISA of IBS biopsy lysates, revealed increased glial fibrillary intermediate filament (GFAP) expression, indicating EGC activation. Mucosal GFAP correlated with increased MC and VPAC1+MC numbers and decreased VIP+MC, which seemed to control bacterial translocation in HC. In the contrary, EGC activation in IBS correlated with less MC and VPAC1+ MC numbers, and more VIP+ MC. In vitro, MC and EGC cell lines showed intracellular calcium responses to each other's mediators. Furthermore, EGC mediators prevented VIP-induced MC degranulation, while MC mediators induced a reactive EGC phenotype. In Ussing chambers, EGC mediators decreased paracellular passage through healthy colonic biopsies. Conclusions & Inferences: Findings suggest the involvement of EGC and MC in the control of barrier function in the human colon and indicate a potential EGC-MC interaction that seems altered in IBS, with detrimental consequences to colonic permeability. Altogether, results suggest that imbalanced EGC-MC communication contributes to the pathophysiology of IBS. © 2021 The Authors. Neurogastroenterology & Motility published by John Wiley & Sons Ltd.","bacterial translocation; enteric glial cells; enteric nervous system; mast cell; mucosal immunology","Adult; Colon; Enteric Nervous System; Female; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Mast Cells; Middle Aged; Neuroglia; Receptors, Vasoactive Intestinal Peptide, Type II; Receptors, Vasoactive Intestinal Polypeptide, Type I; Young Adult; calcium; glial cell line derived neurotrophic factor; tryptase; vasoactive intestinal polypeptide receptor; vasoactive intestinal polypeptide receptor 1; vasoactive intestinal polypeptide receptor 2; VIPR1 protein, human; VIPR2 protein, human; abdominal pain; Actinomycetales; adult; anxiety; Article; bacterial translocation; bloating; calcium cell level; calcium mobilization assay; cell lysate; colon biopsy; colon mucosa; controlled study; degranulation; depression; disease severity; enteric glial cell; enzyme linked immunosorbent assay; feces microflora; female; glia cell; Hospital Anxiety and Depression Scale; human; human cell; human tissue; immunofluorescence assay; in vitro study; irritable colon; male; mast cell; prospective study; protein expression; Western blotting; colon; glia; intestine innervation; intestine mucosa; irritable colon; mast cell; metabolism; middle aged; young adult","","calcium, 7440-70-2, 14092-94-5; tryptase, 97501-93-4; Receptors, Vasoactive Intestinal Peptide, Type II, ; Receptors, Vasoactive Intestinal Polypeptide, Type I, ; VIPR1 protein, human, ; VIPR2 protein, human, ","","","AFA Insurance Research Foundation; Apotekare Hedberg Foundation; County Council; County Council of Östergötland, (Lio‐902661, Lio‐934618); Mucosa Infection and Inflammation Center-MIIC; Mucosa Infection and Inflammation Center‐MIIC, (ÅVK/SAW); Magnus Bergvalls Stiftelse; Bengt Ihres Foundation, (SLS‐882561 ÅVK); Ruth och Richard Julins Stiftelse, (2017‐00350, 2019‐00347 ÅVK)","Funding text 1: This work was supported by grants from the Apotekare Hedberg Foundation (ÅVK), Magnus Bergwall Foundation (2018‐02604 ÅVK), Bengt Ihre Foundation (SLS‐788111, SLS‐882561 ÅVK), Ruth and Richard Julin Foundation (2017‐00350, 2019‐00347 ÅVK), Mucosa Infection and Inflammation Center‐MIIC (ÅVK/SAW), AFA Insurance Research Foundation (SAW), and County Council of Östergötland (ÅVK; Lio‐934618 and SAW; Lio‐902661). ; Funding text 2: This work was supported by grants from the Apotekare Hedberg Foundation (?VK), Magnus Bergwall Foundation (2018-02604 ?VK), Bengt Ihre Foundation (SLS-788111, SLS-882561 ?VK), Ruth and Richard Julin Foundation (2017-00350, 2019-00347 ?VK), Mucosa Infection and Inflammation Center-MIIC (?VK/SAW), AFA Insurance Research Foundation (SAW), and County Council of ?sterg?tland (?VK; Lio-934618 and SAW; Lio-902661). The authors thank all healthy volunteers and patients for their participation and contribution; Olga Bednarska who performed sigmoidoscopies; the Microscopy Core Facility at Link?ping University and Vesa Loitto, Link?ping, for assisting with imaging gearing and expertise; Martin Tinnerfelt Winberg and Lena Svensson, Link?ping, for excellent technical assistance; and Pieter Vanden Bergh, Laboratory for Enteric Neuroscience, University of Leuven, Belgium, for invaluable help and comments on live cell imaging.","Simren M., Tack J., New treatments and therapeutic targets for IBS and other functional bowel disorders, Nat Rev Gastroenterol Hepatol, 15, pp. 589-605, (2018); Camilleri M., Gorman H., Intestinal permeability and irritable bowel syndrome, Neurogastroenterol Motil, 19, pp. 545-552, (2007); Del Valle-Pinero A.Y., Van Deventer H.E., Fourie N.H., Et al., Gastrointestinal permeability in patients with irritable bowel syndrome assessed using a four probe permeability solution, Clin Chim Acta, 418, pp. 97-101, (2013); Piche T., Barbara G., Aubert P., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Vales S., Touvron M., Van Landeghem L., Enteric glia: diversity or plasticity?, Brain Res, 1693, pp. 140-145, (2018); Breit S., Kupferberg A., Rogler G., Et al., Vagus nerve as modulator of the brain-gut axis in psychiatric and inflammatory disorders, Front Psychiatry, 9, (2018); Gulbransen B.D., Sharkey K.A., Novel functional roles for enteric glia in the gastrointestinal tract, Nat Rev Gastroenterol Hepatol, 9, pp. 625-632, (2012); Boesmans W., Lasrado R., Vanden Berghe P., Et al., Heterogeneity and phenotypic plasticity of glial cells in the mammalian enteric nervous system, Glia, 63, pp. 229-241, (2015); Vergnolle N., Cirillo C., Neurons and glia in the enteric nervous system and epithelial barrier function, Physiology (Bethesda), 33, pp. 269-280, (2018); Savidge T.C., Newman P., Pothoulakis C., Et al., Enteric glia regulate intestinal barrier function and inflammation via release of S-nitrosoglutathione, Gastroenterology, 132, pp. 1344-1358, (2007); MacEachern S.J., Patel B.A., McKay D.M., Et al., Nitric oxide regulation of colonic epithelial ion transport: a novel role for enteric glia in the myenteric plexus, J Physiol, 589, pp. 3333-3348, (2011); Rao M., Rastelli D., Dong L., Et al., Enteric glia regulate gastrointestinal motility but are not required for maintenance of the epithelium in mice, Gastroenterology, 153, pp. 1068-1081.e7, (2017); Grubisic V., Verkhratsky A., Zorec R., Et al., Enteric glia regulate gut motility in health and disease, Brain Res Bull, 136, pp. 109-117, (2018); Fujikawa Y., Tominaga K., Tanaka F., Et al., Enteric glial cells are associated with stress-induced colonic hyper-contraction in maternally separated rats, Neurogastroenterol Motil, 27, pp. 1010-1023, (2015); Wang P., Du C., Chen F.X., Et al., BDNF contributes to IBS-like colonic hypersensitivity via activating the enteroglia-nerve unit, Sci Rep, 6, (2016); Lilli N.L., Queneherve L., Haddara S., Et al., Glioplasticity in irritable bowel syndrome, Neurogastroenterol Motil, 30, (2018); Stead R.H., Innervation of mucosal immune cells in the gastrointestinal tract, Reg Immunol, 4, pp. 91-99, (1992); Boeckxstaens G.E., Wouters M.M., Neuroimmune factors in functional gastrointestinal disorders: a focus on irritable bowel syndrome, Neurogastroenterol Motil, 29, 6, (2017); Klooker T.K., Braak B., Koopman K.E., Et al., The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome, Gut, 59, pp. 1213-1221, (2010); Keita A.V., Carlsson A.H., Cigehn M., Et al., Vasoactive intestinal polypeptide regulates barrier function via mast cells in human intestinal follicle-associated epithelium and during stress in rats, Neurogastroenterol Motil, 25, pp. e406-e417, (2013); Bednarska O., Walter S.A., Casado-Bedmar M., Et al., Vasoactive intestinal polypeptide and mast cells regulate increased passage of colonic bacteria in patients with irritable bowel syndrome, Gastroenterology, 153, 4, pp. 948-960.e3, (2017); Skaper S.D., Facci L., Giusti P., Mast cells, glia and neuroinflammation: partners in crime?, Immunology, 141, pp. 314-327, (2014); Skaper S.D., Facci L., Zusso M., Et al., An inflammation-centric view of neurological disease: beyond the neuron, Front Cell Neurosci, 12, (2018); Buhner S., Barki N., Greiter W., Et al., Calcium imaging of nerve-mast cell signaling in the human intestine, Front Physiol, 8, (2017); Cirillo C., Bessissow T., Desmet A.S., Et al., Evidence for neuronal and structural changes in submucous ganglia of patients with functional dyspepsia, Am J Gastroenterol, 110, pp. 1205-1215, (2015); Turco F., Sarnelli G., Cirillo C., Et al., Enteroglial-derived S100B protein integrates bacteria-induced Toll-like receptor signalling in human enteric glial cells, Gut, 63, pp. 105-115, (2014); Ragnarsson G., Bodemar G., Division of the irritable bowel syndrome into subgroups on the basis of daily recorded symptoms in two outpatients samples, Scand J Gastroenterol, 34, pp. 993-1000, (1999); Francis C.Y., Morris J., Whorwell P.J., The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress, Aliment Pharmacol Ther, 11, pp. 395-402, (1997); Zigmond A.S., Snaith R.P., The hospital anxiety and depression scale, Acta Psychiatr Scand, 67, pp. 361-370, (1983); Keita A.V., Gullberg E., Ericson A.C., Et al., Characterization of antigen and bacterial transport in the follicle-associated epithelium of human ileum, Lab Invest, 86, pp. 504-516, (2006); Casen C., Vebo H.C., Sekelja M., Et al., Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD, Aliment Pharmacol Ther, 42, pp. 71-83, (2015); Hagbom M., De Faria F.M., Winberg M.E., Et al., Neurotrophic factors protect the intestinal barrier from rotavirus insult in mice, MBio, 11, (2020); Meir M., Flemming S., Burkard N., Et al., Glial cell line-derived neurotrophic factor promotes barrier maturation and wound healing in intestinal epithelial cells in vitro, Am J Physiol Gastrointest Liver Physiol, 309, pp. G613-G624, (2015); Schindelin J., Arganda-Carreras I., Frise E., Et al., Fiji: an open-source platform for biological-image analysis, Nat Methods, 9, pp. 676-682, (2012); Zack G.W., Rogers W.E., Latt S.A., Automatic measurement of sister chromatid exchange frequency, J Histochem Cytochem, 25, pp. 741-753, (1977); Keita A.V., Alkaissi L.Y., Holm E.B., Et al., Enhanced E. coli LF82 translocation through the follicle-associated epithelium in Crohn's disease is dependent on long polar fimbriae and CEACAM6 expression, and increases paracellular permeability, J Crohns Colitis, 14, pp. 216-229, (2020); Ruhl A., Trotter J., Stremmel W., Isolation of enteric glia and establishment of transformed enteroglial cell lines from the myenteric plexus of adult rat, Neurogastroenterol Motil, 13, pp. 95-106, (2001); Van Landeghem L., Mahe M.M., Teusan R., Et al., Regulation of intestinal epithelial cells transcriptome by enteric glial cells: impact on intestinal epithelial barrier functions, BMC Genom, 10, (2009); Casado-Bedmar M., Heil S.D.S., Myrelid P., Et al., Upregulation of intestinal mucosal mast cells expressing VPAC1 in close proximity to vasoactive intestinal polypeptide in inflammatory bowel disease and murine colitis, Neurogastroenterol Motil, 31, (2019); Middeldorp J., Hol E.M., GFAP in health and disease, Prog Neurogibol, 93, pp. 421-443, (2011); Yang Z., Wang K.K., Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker, Trends Neurosci, 38, pp. 364-374, (2015); Tarassishin L., Suh H.S., Lee S.C., LPS and IL-1 differentially activate mouse and human astrocytes: role of CD14, Glia, 62, pp. 999-1013, (2014); Cirillo C., Sarnelli G., Turco F., Et al., Proinflammatory stimuli activates human-derived enteroglial cells and induces autocrine nitric oxide production, Neurogastroenterol Motil, 23, pp. e372-e382, (2011); Bassotti G., Villanacci V., Nascimbeni R., Et al., Increase of colonic mast cells in obstructed defecation and their relationship with enteric glia, Dig Dis Sci, 57, pp. 65-71, (2012); Nogueira L.T., Costa D.V., Gomes A.S., Et al., The involvement of mast cells in the irinotecan-induced enteric neurons loss and reactive gliosis, J Neuroinflammation, 14, (2017); Schemann M., Kugler E.M., Buhner S., Et al., The mast cell degranulator compound 48/80 directly activates neurons, PLoS One, 7, (2012); Skaper S.D., Facci L., Zusso M., Et al., Neuroinflammation, mast cells, and glia: dangerous liaisons, Neuroscientist, 23, pp. 478-498, (2017); Linan-Rico A., Turco F., Ochoa-Cortes F., Et al., Molecular signaling and dysfunction of the human reactive enteric glial cell phenotype: implications for GI infection, IBD, POI, neurological, motility, and GI disorders, Inflamm Bowel Dis, 22, pp. 1812-1834, (2016); Park C.H., Joo Y.E., Choi S.K., Et al., Activated mast cells infiltrate in close proximity to enteric nerves in diarrhea-predominant irritable bowel syndrome, J Korean Med Sci, 18, pp. 204-210, (2003); Barbara G., Stanghellini V., De Giorgio R., Et al., Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome, Gastroenterology, 126, pp. 693-702, (2004); Buhner S., Schemann M., Mast cell-nerve axis with a focus on the human gut, Biochim Biophys Acta, 1822, pp. 85-92, (2012); Ochoa-Cortes F., Turco F., Linan-Rico A., Et al., Enteric glial cells: a new frontier in neurogastroenterology and clinical target for inflammatory bowel diseases, Inflamm Bowel Dis, 22, pp. 433-449, (2016); Enck P., Aziz Q., Barbara G., Et al., Irritable bowel syndrome, Nat Rev Dis Primers, 2, (2016); Couvineau A., Laburthe M., VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins, Br J Pharmacol, 166, pp. 42-50, (2012); Delgado M., Ganea D., Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions, Amino Acids, 45, pp. 25-39, (2013); Delgado M., Ganea D., Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation, FASEB J, 17, pp. 944-946, (2003); Fung C., Boesmans W., Cirillo C., Et al., VPAC receptor subtypes tune purinergic neuron-to-glia communication in the murine submucosal plexus, Front Cell Neurosci, 11, (2017); Lin L., Feng B., Zhou R., Et al., Acute stress disrupts intestinal homeostasis via GDNF-RET, Cell Prolif, 53, (2020); Lee J.Y., Kim N., Park J.H., Et al., Expression of neurotrophic factors, tight junction proteins, and cytokines according to the irritable bowel syndrome subtype and sex, J Neurogastroenterol Motil, 26, pp. 106-116, (2020); Liu Y., Beyer A., Aebersold R., On the dependency of cellular protein levels on mRNA abundance, Cell, 165, pp. 535-550, (2016); Pochard C., Coquenlorge S., Jaulin J., Et al., Defects in 15-HETE production and control of epithelial permeability by human enteric glial cells from patients with Crohn's disease, Gastroenterology, 150, pp. 168-180, (2016); Godinho-Silva C., Cardoso F., Veiga-Fernandes H., Neuro-immune cell units: a new paradigm in physiology, Annu Rev Immunol, 37, pp. 19-46, (2019); Fettucciari K., Ponsini P., Gioe D., Et al., Enteric glial cells are susceptible to Clostridium difficile toxin B, Cell Mol Life Sci, 74, pp. 1527-1551, (2017); Fettucciari K., Macchioni L., Davidescu M., Et al., Clostridium difficile toxin B induces senescence in enteric glial cells: a potential new mechanism of Clostridium difficile pathogenesis, Biochim Biophys Acta Mol Cell Res, 1865, pp. 1945-1958, (2018); Garcia-Gutierrez E., Mayer M.J., Cotter P.D., Et al., Gut microbiota as a source of novel antimicrobials, Gut Microbes, 10, pp. 1-21, (2019); Krogius-Kurikka L., Lyra A., Malinen E., Et al., Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers, BMC Gastroenterol, 9, (2009); Verma A.K., Manohar M., Upparahalli Venkateshaiah S., Et al., Neuroendocrine cells derived chemokine vasoactive intestinal polypeptide (VIP) in allergic diseases, Cytokine Growth Factor Rev, 38, pp. 37-48, (2017); Gulubova M., Vodenicharov A., Structural examination of tryptase-, and VIP-positive mast cells in the common bile duct of patients with lithiasis, Acta Histochem, 103, pp. 437-452, (2001); Cutz E., Chan W., Track N.S., Et al., Release of vasoactive intestinal polypeptide in mast cells by histamine liberators, Nature, 275, pp. 661-662, (1978)","Å.V. Keita; Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden; email: asa.keita@liu.se","","John Wiley and Sons Inc","","","","","","13501925","","NMOTE","33797165","English","Neurogastroenterol. Motil.","Article","Final","All Open Access; Green Open Access","Scopus","2-s2.0-85103388083"

"Zhao L.; Ren P.; Wang M.; Wang J.; He X.; Gu J.; Lu Y.; Wu Y.; Liu J.; Wang L.; Li H.","Zhao, Li (57204010143); Ren, Peipei (59052929800); Wang, Miaolei (57363605300); Wang, Jingjing (57363605400); He, Xueyun (57362880500); Gu, Jingyan (57363022800); Lu, Yanyu (57198799385); Wu, Yana (57363317400); Liu, Junhong (56508997100); Wang, Longde (7409176358); Li, Hongfang (36066477500)","57204010143; 59052929800; 57363605300; 57363605400; 57362880500; 57363022800; 57198799385; 57363317400; 56508997100; 7409176358; 36066477500","Changes in intestinal barrier protein expression and intestinal flora in a rat model of visceral hypersensitivity","2022","Neurogastroenterology and Motility","34","4","e14299","","","","12","10.1111/nmo.14299","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85120653040&doi=10.1111%2fnmo.14299&partnerID=40&md5=185e1cdc1304f72021252393f4a6ea6e","Department of Physiology, College of Basic Medicine, Lanzhou University, Lanzhou, China; Affiliated Hospital, Gansu University of Chinese Medicine, Lanzhou, China; Function Laboratory in College of Basic Medicine, Lanzhou University, Gansu Province, Lanzhou, China; Key Laboratory of Preclinical Study for New Drugs of Gansu Province, Lanzhou, China","Zhao L., Department of Physiology, College of Basic Medicine, Lanzhou University, Lanzhou, China; Ren P., Affiliated Hospital, Gansu University of Chinese Medicine, Lanzhou, China; Wang M., Affiliated Hospital, Gansu University of Chinese Medicine, Lanzhou, China; Wang J., Department of Physiology, College of Basic Medicine, Lanzhou University, Lanzhou, China; He X., Department of Physiology, College of Basic Medicine, Lanzhou University, Lanzhou, China; Gu J., Department of Physiology, College of Basic Medicine, Lanzhou University, Lanzhou, China; Lu Y., Function Laboratory in College of Basic Medicine, Lanzhou University, Gansu Province, Lanzhou, China; Wu Y., Affiliated Hospital, Gansu University of Chinese Medicine, Lanzhou, China; Liu J., Affiliated Hospital, Gansu University of Chinese Medicine, Lanzhou, China; Wang L., Affiliated Hospital, Gansu University of Chinese Medicine, Lanzhou, China; Li H., Department of Physiology, College of Basic Medicine, Lanzhou University, Lanzhou, China, Key Laboratory of Preclinical Study for New Drugs of Gansu Province, Lanzhou, China","Background: Destruction of the intestinal mucosal barrier and visceral hypersensitivity are main pathogenesis of irritable bowel syndrome (IBS). The study aimed to establish a rat model of visceral hypersensitivity and explore mechanisms involved the changes of the intestinal barrier protein expression and intestinal flora. Methods: A rat model of visceral hypersensitivity was established and evaluated using abdominal withdrawal reflex (AWR) scores, colonic paracellular permeability, and gastrointestinal motility. The expression of tight junction proteins, aquaporin proteins (AQPs), phosphorylated ERK, and proteinase-activated receptor-2 (PAR-2) was determined. The intestinal microflora was evaluated by high-throughput sequencing of the 16S rRNA gene. Key results: In model rats, AWR score and fecal water content were significantly increased, gastrointestinal motilities were disorder and characterized by an inhibition of gastric motility and an enhancement of small intestinal and colonic movement. The expressions of colonic occludin, ZO-1, AQP3, and AQP8 were decreased but claudin-2 and claudin-4 were markedly increased. Imbalance of intestinal flora appeared and showed an obvious decrease of Lactobacillus and an increase of Clostridiales_bacterium. Additionally, the total serine protease activity in feces, the expressions of PAR2 and phosphorylated ERK in the colon tissues were increased significantly. Conclusion and inferences: The model rats of visceral hypersensitivity possess the decreased expression of occludin, ZO-1, AQP3, AQP8, and the increased expression of claudin-2 and claudin-4, meanwhile develop an imbalance of intestinal flora which probably increase serine protease activity, thereby activating the PAR2/ERK signaling and causing the intestinal barrier disorder. © 2021 John Wiley & Sons Ltd.","aquaporin; intestinal flora; serine protease activity; tight junction proteins; visceral hypersensitivity","Animals; Claudin-2; Claudin-4; Gastrointestinal Microbiome; Intestinal Mucosa; Irritable Bowel Syndrome; Occludin; Rats; RNA, Ribosomal, 16S; Serine Proteases; aquaporin 3; aquaporin 8; buprenorphine; cefazolin; claudin 2; claudin 4; eosin; hematoxylin; mitogen activated protein kinase 1; occludin; petrolatum; protein ZO1; proteinase activated receptor 2; RNA 16S; serine proteinase; tight junction protein; claudin 2; claudin 4; occludin; RNA 16S; serine proteinase; adult; animal experiment; animal model; Article; ascending colon; Clostridiales; colon tissue; controlled study; data analysis software; diarrhea; diarrhea predominant irritable bowel syndrome; electrode implantation; enzyme activity; feces microflora; gastrointestinal motility; gastrointestinal motility disorder; high throughput sequencing; hypersensitivity; immunofluorescence assay; immunohistochemistry; in vitro study; intestine flora; intestine motility; intestine mucosa permeability; irritable colon; Lactobacillus; latent period; male; myoelectricity; nonhuman; permeability barrier; postoperative analgesia; postoperative infection; postoperative pain; protein expression; protein phosphorylation; rat; rat model; signal transduction; small intestine; stomach emptying; stomach motility; visceral hypersensitivity; water content; Western blotting; withdrawal reflex; animal; intestine mucosa; irritable colon; metabolism","","buprenorphine, 52485-79-7, 53152-21-9; cefazolin, 25953-19-9, 27164-46-1; eosin, 17372-87-1, 51395-88-1, 548-26-5; hematoxylin, 517-28-2; mitogen activated protein kinase 1, 137632-08-7; occludin, 176304-61-3; petrolatum, 8009-03-8; proprotein convertase 9, ; serine protease HTRA1, ; serine proteinase, 37259-58-8; Claudin-2, ; Claudin-4, ; Occludin, ; RNA, Ribosomal, 16S, ; Serine Proteases, ","HiSeq, Novogene; Phusion, New England Biolabs; QIAamp, Qiagen","New England Biolabs; Novogene; Qiagen","National Natural Science Foundation of China, NSFC, (NSFC81660773, NSFC82160883); National Natural Science Foundation of China, NSFC","This work was supported by the National Natural Science Foundation of China (NSFC81660773) and (NSFC82160883). ","Drossman D.A., Chang L., Bellamy N., Et al., Severity in irritable bowel syndrome: a Rome Foundation Working Team report, Am J Gastroenterol, 106, pp. 1749-1759, (2011); Ford A.C., Lacy B.E., Talley N.J., Irritable bowel syndrome, N Engl J Med, 376, pp. 2566-2578, (2017); Shariati A., Fallah F., Pormohammad A., Et al., The possible role of bacteria, viruses, and parasites in initiation and exacerbation of irritable bowel syndrome, J Cell Physiol, 234, pp. 8550-8569, (2019); Fu R., Chen M., Chen Y.U., Et al., Expression and clinical significance of 5-HT and 5-HT3R in the intestinal mucosa of patient with diarrhea-type irritable bowel syndrome, Exp Ther Med, 17, pp. 3077-3082, (2019); Ohman L., Tornblom H., Simren M., Et al., the mucosal border: importance of the gut microenvironment in IBS, Nat Rev Gastroenterol Hepatol, 12, pp. 36-49, (2015); Sundin J., Ohman L., Simren M., Understanding the gut microbiota in inflammatory and functional gastrointestinal diseases, Psychosom Med, 79, pp. 857-867, (2017); Sundin J., Rangel I., Fuentes S., Et al., Altered faecal and mucosal microbial composition in post-infectious irritable bowel syndrome patients correlates with mucosal lymphocyte phenotypes and psychological distress, Aliment Pharmacol Ther, 41, pp. 342-351, (2015); Malikowski T., Khanna S., Pardi D.S., Fecal microbiota transplantation for gastrointestinal disorders, Curr Opin Gastroenterol, 33, pp. 8-13, (2017); Martinez C., Rodino-Janeiro B.K., Lobo B., Et al., miR-16 and miR-125b are involved in barrier function dysregulation through the modulation of claudin-2 and cingulin expression in the jejunum in IBS with diarrhoea, Gut, 66, pp. 1537-1538, (2017); Chao G., Wang Y., Zhang S., Et al., MicroRNA-29a increased the intestinal membrane permeability of colonic epithelial cells in irritable bowel syndrome rats, Oncotarget, 8, pp. 85828-85837, (2017); Zhi X., Tao J., Li Z., Et al., MiR-874 promotes intestinal barrier dysfunction through targeting AQP3 following intestinal ischemic injury, FEBS Lett, 588, pp. 757-763, (2014); Edwinson A.L., Grover M., Measurement of novel intestinal secretory and barrier pathways and effects of proteases, Neurogastroenterol Motil, 31, (2019); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Spiller R.C., Jenkins D., Thornley J.P., Et al., Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, pp. 804-811, (2000); Hartsock A., Nelson W.J., Adherens and tight junctions: structure, function and connections to the actin cytoskeleton, Biochim Biophys Acta, 1778, pp. 660-669, (2008); Marchiando A.M., Graham W.V., Turner J.R., Epithelial barriers in homeostasis and disease, Annu Rev Pathol, 5, pp. 119-144, (2010); Ishimoto H., Oshima T., Sei H., Et al., Claudin-2 expression is upregulated in the ileum of diarrhea predominant irritable bowel syndrome patients, J Clin Biochem Nutr, 60, pp. 146-150, (2017); Wardill H.R., Gibson R.J., Logan R.M., Et al., TLR4/PKC-mediated tight junction modulation: a clinical marker of chemotherapy-induced gut toxicity?, Int J Cancer, 135, pp. 2483-2492, (2014); Agre P., Kozono D., Aquaporin water channels: molecular mechanisms for human diseases, FEBS Lett, 555, pp. 72-78, (2003); Cao C., Sun Y., Healey S., Et al., EGFR-mediated expression of aquaporin-3 is involved in human skin fibroblast migration, Biochem J, 400, pp. 225-234, (2006); Zhang W., Xu Y., Chen Z., Et al., Knockdown of aquaporin 3 is involved in intestinal barrier integrity impairment, FEBS Lett, 585, pp. 3113-3119, (2011); Chao G., Zhang S., Aquaporins 1, 3 and 8 expression in irritable bowel syndrome rats’ colon via NF-kappaB pathway, Oncotarget, 8, pp. 47175-47183, (2017); Carco C., Young W., Gearry R.B., Et al., Increasing evidence that irritable bowel syndrome and functional gastrointestinal disorders have a microbial pathogenesis, Front Cell Infect Microbiol, 10, (2020); Nishikawa H., Kawai K., Nishimura S., Et al., Suppression by protease-activated receptor-2 activation of gastric acid secretion in rats, Eur J Pharmacol, 447, pp. 87-90, (2002); Li Y., Yang T., Yao Q., Et al., Metformin prevents colonic barrier dysfunction by inhibiting mast cell activation in maternal separation-induced IBS-like rats, Neurogastroenterol Motil, 31, (2019); Hou Q., Huang Y., Zhu S., Et al., MiR-144 increases intestinal permeability in IBS-D rats by targeting OCLN and ZO1, Cell Physiol Biochem, 44, pp. 2256-2268, (2017); Sun S., Liu W., Li Y., CADM1 enhances intestinal barrier function in a rat model of mild inflammatory bowel disease by inhibiting the STAT3 signaling pathway, J Bioenerg Biomembr, 52, pp. 343-354, (2020); Du L., Long Y., Kim J.J., Et al., Protease activated receptor-2 induces immune activation and visceral hypersensitivity in post-infectious irritable bowel syndrome mice, Dig Dis Sci, 64, pp. 729-739, (2019); Li Y.J., Li J., Dai C., The role of intestinal microbiota and mast cell in a rat model of visceral hypersensitivity, J Neurogastroenterol Motil, 26, pp. 529-538, (2020); Zhang C., Huang Y., Li P., Et al., Ginger relieves intestinal hypersensitivity of diarrhea predominant irritable bowel syndrome by inhibiting proinflammatory reaction, BMC Complement Med Ther, 20, (2020); Cavin J.-B., Cuddihey H., MacNaughton W.K., Et al., Acute regulation of intestinal ion transport and permeability in response to luminal nutrients: the role of the enteric nervous system, Am J Physiol Gastrointest Liver Physiol, 318, 2, pp. G254-G264, (2020); Liang Q., Yan Y., Mao L., Et al., Evaluation of a modified rat model for functional dyspepsia, Saudi J Gastroenterol, 24, pp. 228-235, (2018); Chai X.-Y., Diwakarla S., Pustovit R.V., Et al., Investigation of nerve pathways mediating colorectal dysfunction in Parkinson's disease model produced by lesion of nigrostriatal dopaminergic neurons, Neurogastroenterol Motil, 32, (2020); Gecse K., Roka R., Ferrier L., Et al., Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity, Gut, 57, pp. 591-599, (2008); Rolland-Fourcade C., Denadai-Souza A., Cirillo C., Et al., Epithelial expression and function of trypsin-3 in irritable bowel syndrome, Gut, 66, pp. 1767-1778, (2017); Vannucchi M.G., Evangelista S., Experimental models of irritable bowel syndrome and the role of the enteric neurotransmission, J Clin Med, 7, (2018); Bhattarai Y., Muniz Pedrogo D.A., Kashyap P.C., Irritable bowel syndrome: a gut microbiota-related disorder?, Am J Physiol Gastrointest Liver Physiol, 312, pp. G52-G62, (2017); Matsuzaki T., Tajika Y., Ablimit A., Et al., Aquaporins in the digestive system, Med Electron Microsc, 37, pp. 71-80, (2004); Mobasheri A., Wray S., Marples D., Distribution of AQP2 and AQP3 water channels in human tissue microarrays, J Mol Histol, 36, pp. 1-14, (2005); Wang J.P., Hou X.H., Expression of aquaporin 8 in colonic epithelium with diarrhoea-predominant irritable bowel syndrome, Chin Med J (Engl), 120, pp. 313-316, (2007); Laforenza U., Water channel proteins in the gastrointestinal tract, Mol Aspects Med, 33, pp. 642-650, (2012); Kawedia J.D., Jiang M., Kulkarni A., Et al., The protein kinase A pathway contributes to Hg<sup>2+</sup>-induced alterations in phosphorylation and subcellular distribution of occludin associated with increased tight junction permeability of salivary epithelial cell monolayers, J Pharmacol Exp Ther, 326, pp. 829-837, (2008); Fukatsu K., Kudsk K.A., Nutrition and gut immunity, Surg Clin North Am, 91, pp. 755-770, (2011); Camilleri M., Lasch K., Zhou W., Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome, Am J Physiol Gastrointest Liver Physiol, 303, pp. G775-G785, (2012); Nobaek S., Johansson M.-L., Molin G., Et al., Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome, Am J Gastroenterol, 95, pp. 1231-1238, (2000); Simren M., Barbara G., Flint H.J., Et al., Intestinal microbiota in functional bowel disorders: a Rome foundation report, Gut, 62, pp. 159-176, (2013); Hyland N.P., Quigley E.M., Brint E., Microbiota-host interactions in irritable bowel syndrome: epithelial barrier, immune regulation and brain-gut interactions, World J Gastroenterol, 20, pp. 8859-8866, (2014); Lee K.N., Lee O.Y., Intestinal microbiota in pathophysiology and management of irritable bowel syndrome, World J Gastroenterol, 20, pp. 8886-8897, (2014); Zyrek A.A., Cichon C., Helms S., Et al., Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair, Cell Microbiol, 9, pp. 804-816, (2007); Natividad J.M., Verdu E.F., Modulation of intestinal barrier by intestinal microbiota: pathological and therapeutic implications, Pharmacol Res, 69, pp. 42-51, (2013); Liu L., Saitz-Rojas W., Smith R., Et al., Mucus layer modeling of human colonoids during infection with enteroaggragative E. coli, Sci Rep, 10, 1, (2020); Zhu D., Sun Y.U., Liu F., Et al., Identification of surface-associated proteins of Bifidobacterium animalis ssp. lactis KLDS 2.0603 by enzymatic shaving, J Dairy Sci, 99, pp. 5155-5172, (2016); Carabotti M., Scirocco A., Maselli M.A., Et al., The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems, Ann Gastroenterol, 28, pp. 203-209, (2015); Rao R.K., Samak G., Protection and restitution of gut barrier by probiotics: nutritional and clinical implications, Curr Nutr Food Sci, 9, pp. 99-107, (2013); Nebot-Vivinus M., Harkat C., Bzioueche H., Et al., Multispecies probiotic protects gut barrier function in experimental models, World J Gastroenterol, 20, pp. 6832-6843, (2014); Bailey M.T., Influence of stressor-induced nervous system activation on the intestinal microbiota and the importance for immunomodulation, Adv Exp Med Biol, 817, pp. 255-276, (2014); Distrutti E., Monaldi L., Ricci P., Et al., Gut microbiota role in irritable bowel syndrome: new therapeutic strategies, World J Gastroenterol, 22, pp. 2219-2241, (2016); Zhao L., Yang W., Chen Y., Et al., A Clostridia-rich microbiota enhances bile acid excretion in diarrhea-predominant irritable bowel syndrome, J Clin Invest, 130, pp. 438-450, (2020); Jacob C., Yang P.-C., Darmoul D., Et al., Mast cell tryptase controls paracellular permeability of the intestine. Role of protease-activated receptor 2 and beta-arrestins, J Biol Chem, 280, pp. 31936-31948, (2005); Kim D.H., Cho Y.J., Kim J.H., Et al., Stress-induced alterations in mast cell numbers and proteinase-activated receptor-2 expression of the colon: role of corticotrophin-releasing factor, J Korean Med Sci, 25, 9, pp. 1330-1335, (2010); Buhner S., Li Q., Vignali S., Et al., Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome, Gastroenterology, 137, pp. 1425-1434, (2009); Cenac N., Bautzova T., Le Faouder P., Et al., Quantification and potential functions of endogenous agonists of transient receptor potential channels in patients with irritable bowel syndrome, Gastroenterology, 149, pp. 433-447, (2015); Valdez-Morales E.E., Overington J., Guerrero-Alba R., Et al., Sensitization of peripheral sensory nerves by mediators from colonic biopsies of diarrhea-predominant irritable bowel syndrome patients: a role for PAR2, Am J Gastroenterol, 108, pp. 1634-1643, (2013)","H. Li; Department of Physiology, College of Basic Medicine, Lanzhou University, Lanzhou, China; email: lihf@lzu.edu.cn","","John Wiley and Sons Inc","","","","","","13501925","","NMOTE","34821442","English","Neurogastroenterol. Motil.","Article","Final","","Scopus","2-s2.0-85120653040"

"Prospero L.; Riezzo G.; Linsalata M.; Orlando A.; D’attoma B.; Russo F.","Prospero, Laura (57207799778); Riezzo, Giuseppe (7004144336); Linsalata, Michele (6603600075); Orlando, Antonella (23767683100); D’attoma, Benedetta (57205751185); Russo, Francesco (59133987400)","57207799778; 7004144336; 6603600075; 23767683100; 57205751185; 59133987400","Psychological and gastrointestinal symptoms of patients with irritable bowel syndrome undergoing a low-fodmap diet: The role of the intestinal barrier","2021","Nutrients","13","7","2469","","","","16","10.3390/nu13072469","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85110358153&doi=10.3390%2fnu13072469&partnerID=40&md5=8e03f6f1717c1d7236329b434e4a02cc","Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, BA, Castellana Grotte, 70013, Italy","Prospero L., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, BA, Castellana Grotte, 70013, Italy; Riezzo G., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, BA, Castellana Grotte, 70013, Italy; Linsalata M., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, BA, Castellana Grotte, 70013, Italy; Orlando A., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, BA, Castellana Grotte, 70013, Italy; D’attoma B., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, BA, Castellana Grotte, 70013, Italy; Russo F., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, BA, Castellana Grotte, 70013, Italy","A diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (LFD) improves both gastrointestinal (GI) symptoms and the psychological profile of patients with irritable bowel syndrome with diarrhea (IBS-D). The effects of 12 weeks of LFD on GI symptom and psychological profiles in relation to inflammation and the involvement of the intestinal barrier were studied in twenty IBS-D patients. The IBS Severity Scoring System, the Symptom Checklist-90-Re-vised, the Italian version of the 36-Item Short-Form Health Survey, the IBS-Quality of Life (QoL) questionnaire, and the Psychophysiological questionnaire were administered. The GI barrier function was assessed by sugar absorption test, the serum and fecal zonulin levels, and the serum levels of intestinal fatty-acid binding protein and diamine oxidase. Interleukins (ILs) and lipopolysaccha-ride (LPS) serum levels were evaluated along with dysbiosis. At the end of LFD, GI symptoms, psychological state (mainly anxiety, somatization, psychoticism, and interpersonal sensitivity), and QoL significantly improved in these patients. Simultaneously, an improvement in small intestinal permeability and intestinal mucosal integrity occurred, while IL-6, Il-10, LPS, and fermentative dysbiosis significantly decreased. The LFD can modify the immune-inflammatory features and en-hance intestinal permeability and mucosal integrity, thus determining a concurrent improvement in the clinical and psychological conditions. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.","Gastrointestinal symptom profile; Intestinal barrier; Irritable bowel syndrome; Low FODMAP diet; Psychological profile","Adult; Diarrhea; Diet, Carbohydrate-Restricted; Disaccharides; Female; Fermentation; Gastrointestinal Tract; Humans; Inflammation; Intestinal Absorption; Intestinal Mucosa; Intestines; Irritable Bowel Syndrome; Male; Mental Disorders; Middle Aged; Monosaccharides; Oligosaccharides; Polymers; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; amine oxidase (copper containing); fatty acid binding protein 2; indican; interleukin 10; interleukin 6; lipopolysaccharide; skatole; disaccharide; monosaccharide; oligosaccharide; polymer; polyol; abdominal circumference; abdominal distension; abdominal pain; adult; anxiety; arm circumference; Article; bacterial translocation; blood level; blood sampling; body mass; clinical article; controlled study; defecation habit; depression; digestive system disease assessment; disease severity assessment; dysbiosis; female; gastrointestinal symptom; hip circumference; human; intestine flora; intestine mucosa permeability; Irritable Bowel Syndrome Severity Scoring System; irritable colon; low FODMAP diet; male; mental disease; mental health; obsessive compulsive disorder; paranoia; phobia; physical activity; psychosis; quality of life; Short Form 36; shoulder; somatization; Symptom Checklist 90; urine level; urine sampling; waist circumference; diarrhea; fermentation; gastrointestinal tract; inflammation; intestine; intestine absorption; intestine mucosa; irritable colon; low carbohydrate diet; mental disease; middle aged; pathophysiology; physiology; psychology; questionnaire; severity of illness index","","amine oxidase (copper containing), 9001-53-0, 9014-75-9; indican, 1336-79-4, 487-94-5; skatole, 83-34-1; Disaccharides, ; Monosaccharides, ; Oligosaccharides, ; Polymers, ; polyol, ","","","Ministero della Salute, (RC 2020-2021); Ministero della Salute","Funding: The research was funded by the Italian Ministry of Health RC 2020-2021, Prog. N° 16 (D.D.G. n. 700/2020).","Chey W.D., Kurlander J., Eswaran S., Irritable bowel syndrome: A clinical review, JAMA, 313, pp. 949-958, (2015); Whitehead W.E., Palsson O., Jones K.R., Systematic review of the comorbidity of irritable bowel syndrome with other disorders: What are the causes and implications?, Gastroenterology, 122, pp. 1140-1156, (2002); Hu Z., Li M., Yao L., Wang Y., Wang E., Yuan J., Wang F., Yang K., Bian Z., Zhong L.L.D., The level and prevalence of depression and anxiety among patients with different subtypes of irritable bowel syndrome: A network meta-analysis, BMC Gastroenterol, 21, pp. 1-18, (2021); Zamani M., Alizadeh-Tabari S., Zamani V., Systematic review with meta-analysis: The prevalence of anxiety and depression in patients with irritable bowel syndrome, Aliment. Pharmacol. Ther, 50, pp. 132-143, (2019); Kabra N., Nadkarni A., Prevalence of depression and anxiety in irritable bowel syndrome: A clinic based study from India, Indian J. Psychiatry, 55, pp. 77-80, (2013); Tanaka Y., Kanazawa M., Fukudo S., Drossman D.A., Biopsychosocial model of irritable bowel syndrome, J. Neurogastroenterol. Motil, 17, pp. 131-139, (2011); Bai T., Xia J., Jiang Y., Cao H., Zhao Y., Zhang L., Wang H., Song J., Hou X., Comparison of the Rome IV and Rome III criteria for IBS diagnosis: A cross-sectional survey, J. Gastroenterol. Hepatol, 32, pp. 1018-1025, (2017); Tornblom H., Van Oudenhove L., Sadik R., Abrahamsson H., Tack J., Simren M., Colonic transit time and IBS symptoms: what's the link?, Am. J. Gastroenterol, 107, pp. 754-760, (2012); Simren M., Tornblom H., Palsson O.S., van Tilburg M.A.L., Van Oudenhove L., Tack J., Whitehead W.E., Visceral hypersensitivity is associated with GI symptom severity in functional GI disorders: Consistent findings from five different patient cohorts, Gut, 67, pp. 255-262, (2018); Martinez C., Gonzalez-Castro A., Vicario M., Santos J., Cellular and molecular basis of intestinal barrier dysfunction in the irritable bowel syndrome, Gut Liver, 6, pp. 305-315, (2012); Martin-Vinas J.J., Quigley E.M., Immune response in irritable bowel syndrome: A systematic review of systemic and mucosal inflammatory mediators, J. Dig. Dis, 17, pp. 572-581, (2016); Lee K.N., Lee O.Y., Intestinal microbiota in pathophysiology and management of irritable bowel syndrome, World J. Gastroenterol, 20, pp. 8886-8897, (2014); Powell N., Walker M.M., Talley N.J., The mucosal immune system: Master regulator of bidirectional gut-brain communications, Nat. Rev. Gastroenterol. Hepatol, 14, pp. 143-159, (2017); Mayer E.A., Gut feelings: The emerging biology of gut-brain communication, Nat. Rev. Neurosci, 12, pp. 453-466, (2011); Bashashati M., Rezaei N., Shafieyoun A., McKernan D.P., Chang L., Ohman L., Quigley E.M., Schmulson M., Sharkey K.A., Simren M., Cytokine imbalance in irritable bowel syndrome: A systematic review and meta-analysis, Neurogastroenterol. Motil, 26, pp. 1036-1048, (2014); Liebregts T., Adam B., Bredack C., Roth A., Heinzel S., Lester S., Downie-Doyle S., Smith E., Drew P., Talley N.J., Et al., Immune activation in patients with irritable bowel syndrome, Gastroenterology, 132, pp. 913-920, (2007); Orlando A., Tutino V., Notarnicola M., Riezzo G., Linsalata M., Clemente C., Prospero L., Martulli M., D'Attoma B., De Nunzio V., Et al., Improved Symptom Profiles and Minimal Inflammation in IBS-D Patients Undergoing a Long-Term Low-FODMAP Diet: A Lipidomic Perspective, Nutrients, 12, (2020); Wells J.M., Brummer R.J., Derrien M., MacDonald T.T., Troost F., Cani P.D., Theodorou V., Dekker J., Meheust A., de Vos W.M., Et al., Homeostasis of the gut barrier and potential biomarkers, Am. J. Physiol.-Gastrointest. Liver Physiology, 312, pp. G171-G193, (2017); Hughes P.A., Zola H., Penttila I.A., Blackshaw L.A., Andrews J.M., Krumbiegel D., Immune activation in irritable bowel syndrome: Can neuroimmune interactions explain symptoms?, Am. J. Gastroenterol, 108, pp. 1066-1074, (2013); Linsalata M., Riezzo G., D'Attoma B., Clemente C., Orlando A., Russo F., Noninvasive biomarkers of gut barrier function identify two subtypes of patients suffering from diarrhoea predominant-IBS: A case-control study, BMC Gastroenterol, 18, (2018); Stevens B.R., Goel R., Seungbum K., Richards E.M., Holbert R.C., Pepine C.J., Raizada M.K., Increased human intestinal barrier permeability plasma biomarkers zonulin and FABP2 correlated with plasma LPS and altered gut microbiome in anxiety or depression, Gut, 67, pp. 1555-1557, (2018); Camilleri M., Lyle B.J., Madsen K.L., Sonnenburg J., Verbeke K., Wu G.D., Role for diet in normal gut barrier function: Developing guidance within the framework of food-labeling regulations, Am. J. Physiol.-Gastrointest. Liver Physiol, 317, pp. G17-G39, (2019); Tuck C.J., Reed D.E., Muir J.G., Vanner S.J., Implementation of the low FODMAP diet in functional gastrointestinal symptoms: A real-world experience, Neurogastroenterol. Motil, 32, (2020); Linsalata M., Riezzo G., Orlando A., D'Attoma B., Prospero L., Tutino V., Notarnicola M., Russo F., The Relationship between Low Serum Vitamin D Levels and Altered Intestinal Barrier Function in Patients with IBS Diarrhoea Undergoing a Long-Term Low-FODMAP Diet: Novel Observations from a Clinical Trial, Nutrients, 13, (2021); Kortlever T.L., Ten Bokkel Huinink S., Offereins M., Hebblethwaite C., O'Brien L., Leeper J., Mulder C.J.J., Barrett J.S., Gearry R.B., Low-FODMAP Diet Is Associated With Improved Quality of Life in IBS Patients-A Prospective Observational Study, Nutr. Clin. Pract, 34, pp. 623-630, (2019); Hayes P.A., Fraher M.H., Quigley E.M., Irritable bowel syndrome: The role of food in pathogenesis and management, Gastroenterol. Hepatol, 10, pp. 164-174, (2014); Mearin F., Lacy B.E., Chang L., Chey W.D., Lembo A.J., Simren M., Spiller R., Bowel Disorders, Gastroenterology, 150, pp. 1393-1407, (2016); Francis C.Y., Morris J., Whorwell P.J., The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress, Aliment. Pharmacol. Ther, 11, pp. 395-402, (1997); Miller L.E., Study design considerations for irritable bowel syndrome clinical trials, Ann. Gastroenterol, 27, pp. 338-345, (2014); Blake M.R., Raker J.M., Whelan K., Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome, Aliment. Pharmacol. Ther, 44, pp. 693-703, (2016); Derogatis L.R., Lipman R.S., Covi L., SCL-90: An outpatient psychiatric rating scale--preliminary report, Psychopharmacol. Bull, 9, pp. 13-28, (1973); Jensen H.H., Mortensen E.L., Lotz M., Scl-90-R symptom profiles and outcome of short-term psychodynamic group therapy, ISRN Psychiatry, 2013, (2013); Bertolotti G., Zotti A.M., Michielin P., Vidotto G., Sanavio E., A computerized approach to cognitive behavioural assessment: An introduction to CBA-2.0 primary scales, J. Behav. Ther. Exp. psychiatry, 21, pp. 21-27, (1990); Ware J.E., Sherbourne C.D., The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection, Med. Care, 30, pp. 473-483, (1992); Patrick D.L., Drossman D.A., Frederick I.O., DiCesare J., Puder K.L., Quality of life in persons with irritable bowel syndrome: Development and validation of a new measure, Dig. Dis. Sci, 43, pp. 400-411, (1998); Hilsden R.J., Meddings J.B., Sutherland L.R., Intestinal permeability changes in response to acetylsalicylic acid in relatives of patients with Crohn's disease, Gastroenterology, 110, pp. 1395-1403, (1996); Hendrikx T., Schnabl B., Indoles: Metabolites produced by intestinal bacteria capable of controlling liver disease manifestation, J. Intern. Med, 286, pp. 32-40, (2019); Garcia Regueiro J.A., Rius M.A., Rapid determination of skatole and indole in pig back fat by normal-phase liquid chromatography, J. Chromatography. A, 809, pp. 246-251, (1998); Zhou Q., Verne M.L., Fields J.Z., Lefante J.J., Basra S., Salameh H., Verne G.N., Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome, Gut, 68, pp. 996-1002, (2019); Prospero L., Riezzo G., Linsalata M., Orlando A., D'Attoma B., Di Masi M., Martulli M., Russo F., Somatization in patients with predominant diarrhoea irritable bowel syndrome: The role of the intestinal barrier function and integrity, BMC Gastroenterol, 21, pp. 1-10, (2021); Cingolani A., Paduano D., Vecchiarelli V., Demelas M., Corrias P.T., Casula L., Usai P., Feasibility of Low Fermentable Oligosaccharide, Disaccharide, Monosaccharide, and Polyol Diet and Its Effects on Quality of Life in an Italian Cohort, Nutrients, 12, (2020); Kumar S., Shukla R., Ranjan P., Kumar A., Interleukin-10: A Compelling Therapeutic Target in Patients With Irritable Bowel Syndrome, Clin. Ther, 39, pp. 632-643, (2017); Holzer P., Hassan A.M., Jain P., Reichmann F., Farzi A., Neuroimmune pharmacological approaches, Curr. Opin. Pharmacol, 25, pp. 13-22, (2015); Gonsalkorale W.M., Perrey C., Pravica V., Whorwell P.J., Hutchinson I.V., Interleukin 10 genotypes in irritable bowel syndrome: Evidence for an inflammatory component?, Gut, 52, pp. 91-93, (2003); Li C.C., Gan L., Tan Y., Yan M.Z., Liu X.M., Chang Q., Pan R.L., Chronic restraint stress induced changes in colonic homeostasis-related indexes and tryptophan-kynurenine metabolism in rats, J. Proteom, 240, (2021); Zhou S.Y., Gillilland M., Wu X., Leelasinjaroen P., Zhang G., Zhou H., Ye B., Lu Y., Owyang C., FODMAP diet modulates visceral nociception by lipopolysaccharide-mediated intestinal inflammation and barrier dysfunction, J. Clin. Investig, 128, pp. 267-280, (2018); Sperandeo P., Martorana A.M., Polissi A., Lipopolysaccharide Biosynthesis and Transport to the Outer Membrane of Gram-Negative Bacteria, Bact. Cell Walls Membr, 92, pp. 9-37, (2019); Wang Z., Xu C.M., Liu Y.X., Wang X.Q., Zhang L., Li M., Zhu S.W., Xie Z.J., Wang P.H., Duan L.P., Et al., Characteristic dysbiosis of gut microbiota of Chinese patients with diarrhea-predominant irritable bowel syndrome by an insight into the pan-microbiome, Chin. Med. J, 132, pp. 889-904, (2019); Maes M., Kubera M., Leunis J.C., The gut-brain barrier in major depression: Intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression, Neuroendocrinol. Lett, 29, pp. 117-124, (2008); Rogers G.B., Keating D.J., Young R.L., Wong M.L., Licinio J., Wesselingh S., From gut dysbiosis to altered brain function and mental illness: Mechanisms and pathways, Mol. Psychiatry, 21, pp. 738-748, (2016); Hollier J.M., van Tilburg M.A.L., Liu Y., Czyzewski D.I., Self M.M., Weidler E.M., Heitkemper M., Shulman R.J., Multiple psychological factors predict abdominal pain severity in children with irritable bowel syndrome, Neurogastroenterol. Motil, 31, (2019); Boem F., Amedei A., Healthy axis: Towards an integrated view of the gut-brain health, World J. Gastroenterol, 25, pp. 3838-3841, (2019); van Lanen A.S., de Bree A., Greyling A., Efficacy of a low-FODMAP diet in adult irritable bowel syndrome: A systematic review and meta-analysis, Eur. J. Nutr, (2021)","F. Russo; Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte, BA, 70013, Italy; email: francesco.russo@irccsdebellis.it","","MDPI AG","","","","","","20726643","","","34371976","English","Nutrients","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85110358153"

"Beatty J.K.; Akierman S.V.; Motta J.-P.; Muise S.; Workentine M.L.; Harrison J.J.; Bhargava A.; Beck P.L.; Rioux K.P.; McKnight G.W.; Wallace J.L.; Buret A.G.","Beatty, Jennifer K. (37761071500); Akierman, Sarah V. (26646301000); Motta, Jean-Paul (36098189300); Muise, Stacy (54788177600); Workentine, Matthew L. (12788559500); Harrison, Joe J. (7402743258); Bhargava, Amol (55976378200); Beck, Paul L. (7201483589); Rioux, Kevin P. (6603085314); McKnight, Gordon Webb (7005826710); Wallace, John L. (55634626300); Buret, Andre G. (7007101465)","37761071500; 26646301000; 36098189300; 54788177600; 12788559500; 7402743258; 55976378200; 7201483589; 6603085314; 7005826710; 55634626300; 7007101465","Giardia duodenalis induces pathogenic dysbiosis of human intestinal microbiota biofilms","2017","International Journal for Parasitology","47","6","","311","326","15","115","10.1016/j.ijpara.2016.11.010","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85014144288&doi=10.1016%2fj.ijpara.2016.11.010&partnerID=40&md5=b19e20b0c31176839ac3428ee5fbbc1a","Department of Biological Sciences, University of Calgary, 2500 University Drive NW, Calgary, T2N 4N1, Alberta, Canada; Department of Physiology & Pharmacology, University of Calgary, 3330 Hospital Drive NW, Calgary, T2N 4N1, Alberta, Canada; Department of Medicine, Division of Gastroenterology, University of Calgary, 3330 Hospital Drive NW, Calgary, T2N 4N1, Alberta, Canada; Department of Medicine, McMaster University, 1280 Main Street West, Hamilton, L8S 4K1, Ontario, Canada","Beatty J.K., Department of Biological Sciences, University of Calgary, 2500 University Drive NW, Calgary, T2N 4N1, Alberta, Canada; Akierman S.V., Department of Biological Sciences, University of Calgary, 2500 University Drive NW, Calgary, T2N 4N1, Alberta, Canada; Motta J.-P., Department of Biological Sciences, University of Calgary, 2500 University Drive NW, Calgary, T2N 4N1, Alberta, Canada, Department of Physiology & Pharmacology, University of Calgary, 3330 Hospital Drive NW, Calgary, T2N 4N1, Alberta, Canada; Muise S., Department of Biological Sciences, University of Calgary, 2500 University Drive NW, Calgary, T2N 4N1, Alberta, Canada; Workentine M.L., Department of Biological Sciences, University of Calgary, 2500 University Drive NW, Calgary, T2N 4N1, Alberta, Canada; Harrison J.J., Department of Biological Sciences, University of Calgary, 2500 University Drive NW, Calgary, T2N 4N1, Alberta, Canada; Bhargava A., Department of Biological Sciences, University of Calgary, 2500 University Drive NW, Calgary, T2N 4N1, Alberta, Canada; Beck P.L., Department of Medicine, Division of Gastroenterology, University of Calgary, 3330 Hospital Drive NW, Calgary, T2N 4N1, Alberta, Canada; Rioux K.P., Department of Medicine, Division of Gastroenterology, University of Calgary, 3330 Hospital Drive NW, Calgary, T2N 4N1, Alberta, Canada; McKnight G.W., Department of Medicine, McMaster University, 1280 Main Street West, Hamilton, L8S 4K1, Ontario, Canada; Wallace J.L., Department of Physiology & Pharmacology, University of Calgary, 3330 Hospital Drive NW, Calgary, T2N 4N1, Alberta, Canada; Buret A.G., Department of Biological Sciences, University of Calgary, 2500 University Drive NW, Calgary, T2N 4N1, Alberta, Canada, Department of Physiology & Pharmacology, University of Calgary, 3330 Hospital Drive NW, Calgary, T2N 4N1, Alberta, Canada","Giardia duodenalis is a prevalent cause of acute diarrheal disease worldwide. However, recent outbreaks in Italy and Norway have revealed a link between giardiasis and the subsequent development of chronic post-infectious irritable bowel syndrome. While the mechanisms underlying the causation of post-infectious irritable bowel syndrome remain obscure, recent findings suggest that alterations in gut microbiota communities are linked to the pathophysiology of irritable bowel syndrome. In the present study, we use a laboratory biofilm system to culture and enrich mucosal microbiota from human intestinal biopsies. Subsequently, we show that co-culture with Giardia induces disturbances in biofilm species composition and biofilm structure resulting in microbiota communities that are intrinsically dysbiotic – even after the clearance of Giardia. These microbiota abnormalities were mediated in part by secretory-excretory Giardia cysteine proteases. Using in vitro cell culture and germ-free murine infection models, we show that Giardia-induced disruptions of microbiota promote bacterial invasion, resulting in epithelial apoptosis, tight junctional disruption, and bacterial translocation across an intestinal epithelial barrier. Additionally, these dysbiotic microbiota communities resulted in increased activation of the Toll-like receptor 4 signalling pathway, and overproduction of the pro-inflammatory cytokine IL-1beta in humanized germ-free mice. Previous studies that have sought explanations and risk factors for the development of post-infectious irritable bowel syndrome have focused on features of enteropathogens and attributes of the infected host. We propose that polymicrobial interactions involving Giardia and gut microbiota may cause persistent dysbiosis, offering a new interpretation of the reasons why those afflicted with giardiasis are predisposed to gastrointestinal disorders post-infection. © 2017 The Author(s)","Biofilm; Gastrointestinal microbiome; Giardia duodenalis; Post-infectious irritable bowel syndrome","Animals; Apoptosis; Biofilms; Biopsy; Caco-2 Cells; Colon; Cysteine Proteases; Feces; Gastrointestinal Microbiome; Germ-Free Life; Giardia lamblia; Giardiasis; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Mice; Microscopy, Electron, Scanning; Rabbits; Rats; Symbiosis; Italy; Norway; Bacteria (microorganisms); Giardia; Giardia intestinalis; Murinae; Mus; toll like receptor 4; cysteine proteinase; biofilm; diarrheal disease; digestive system disorder; disease incidence; disease severity; infectivity; microbial community; parasite; pathology; physiology; adult; animal experiment; animal model; animal tissue; apoptosis; Article; bacterial translocation; biofilm; controlled study; culture medium; disease association; enzyme activation; Giardia intestinalis; giardiasis; human; human cell; human tissue; in vitro study; in vivo study; intestine epithelium cell; intestine flora; irritable colon; limit of detection; limit of quantitation; mouse; nonhuman; parasite clearance; pathophysiology; risk factor; signal transduction; tight junction; animal; biofilm; biopsy; Caco-2 cell line; colon; complication; enzymology; feces; germfree animal; giardiasis; growth, development and aging; intestine flora; intestine mucosa; irritable colon; Leporidae; metabolism; microbiology; parasitology; pathology; physiology; rat; scanning electron microscopy; symbiosis; ultrastructure","","toll like receptor 4, 203811-83-0; cysteine proteinase, 37353-41-6; Cysteine Proteases, ","","","","","Abreu M.T., Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function, Nature Rev. Immunol., 10, pp. 131-144, (2010); Amat C., Motta J.-P., Bhargava A., Chadee K., Buret A., Giardia duodenalis depletes goblet cell mucins and degrades MUC2, Facilitating bacterial translocation, FASEB J., 29, (2015); Abreu M.T., Arnold E.T., Thomas L.S., Gonsky R., Zhou Y., Hu B., Arditi M., TLR4 and MD-2 expression is regulated by immune-mediated signals in human intestinal epithelial cells, J. Biol. Chem., 277, pp. 20431-20437, (2002); Barbara G., De Giorgio R., Stanghellini V., Cremon C., Corinaldesi R., A role for inflammation in irritable bowel syndrome?, Gut, 51, pp. i41-i44, (2002); Barrett A.J., Fluorimetric assays for cathepsin B and cathepsin H with methylcoumarylamide substrates, Biochem, J187, pp. 909-912, (1980); Belmonte L., Beutheu Youmba S., Bertiaux-Vandaele N., Antonietti M., Lecleire S., Zalar A., Gourcerol G., Leroi A.M., Dechelotte P., Coeffier M., Ducrotte P., Role of toll like receptors in irritable bowel syndrome: differential mucosal immune activation according to the disease subtype, PLoS ONE, 7, (2012); Bhargava A., Cotton J.A., Dixon B.R., Gedamu L., Yates R.M., Buret A.G., Giardia duodenalis Surface Cysteine Proteases Induce Cleavage of the Intestinal Epithelial Cytoskeletal Protein Villin via Myosin Light Chain Kinase, PLoS ONE, 10, (2015); Buret A.G., Mechanisms of epithelial dysfunction in giardiasis, Gut, 56, pp. 316-317, (2007); Buret A.G., Bhargava A., Modulatory mechanisms of enterocyte apoptosis by viral, bacterial and parasitic pathogens, Crit. Rev. Microbiol., 40, pp. 1-17, (2014); Cario E., Podolsky D.K., Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease, Infect. Immun., 68, pp. 7010-7017, (2000); Carroll I.M., Ringel-Kulka T., Keku T.O., Chang Y.H., Packey C.D., Sartor R.B., Ringel Y., Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome, Am. J. Physiol. Gastrointest. Liver Physiol., 301, pp. G799-G807, (2011); Ceri H., Olson M.E., Stremick C., Read R.R., Morck D., Buret A., The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms, J. Clin. Microbiol., 37, pp. 1771-1776, (1999); Chadwick V.S., Chen W., Shu D., Paulus B., Bethwaite P., Tie A., Wilson I., Activation of the mucosal immune system in irritable bowel syndrome, Gastroenterology, 122, pp. 1778-1783, (2002); Chen J., Ng C.P., Tsang L.L., Ho L.S., Xu P.H., Rowlands D.K., Gao J.Y., Chung Y.W., Li T.Y., Chan H.C., Altered expression of inflammatory cytokine receptors in response to LPS challenge through interaction between intestinal epithelial cells and lymphocytes of Peyer's patch, Cell Biol. Int., 33, pp. 369-375, (2009); Chua S.L., Liu Y., Yam J.K., Chen Y., Vejborg R.M., Tan B.G., Kjelleberg S., Tolker-Nielsen T., Givskov M., Yang L., Dispersed cells represent a distinct stage in the transition from bacterial biofilm to planktonic lifestyles, Nat. Commun., 5, (2014); Cotton J.A., Amat C.B., Buret A.G., Disruptions of Host Immunity and Inflammation by Giardia Duodenalis: Potential Consequences for Co-Infections in the Gastro-Intestinal Tract, Pathog, 4, pp. 764-792, (2015); Cotton J.A., Bhargava A., Ferraz J.G., Yates R.M., Beck P.L., Buret A.G., Giardia duodenalis cathepsin B proteases degrade intestinal epithelial interleukin-8 and attenuate interleukin-8-induced neutrophil chemotaxis, Infect. Immun., 82, pp. 2772-2787, (2014); Cremon C., Gargano L., Morselli-Labate A.M., Santini D., Cogliandro R.F., De Giorgio R., Stanghellini V., Corinaldesi R., Barbara G., Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms, Am. J. Gastroenterol., 104, pp. 392-400, (2009); Cremon C., Stanghellini V., Pallotti F., Fogacci E., Bellacosa L., Morselli-Labate A.M., Paccapelo A., Di Nardo G., Cogliandro R.F., De Giorgio R., Corinaldesi R., Barbara G., Salmonella gastroenteritis during childhood is a risk factor for irritable bowel syndrome in adulthood, Gastroenterology, 147, pp. 69-77, (2014); David E.B., de Carvalho T.B., Oliveira C.M., Coradi S.T., Sforcin J.M., Guimaraes S., Characterisation of protease activity in extracellular products secreted by Giardia duodenalis trophozoites treated with propolis, Nat. Prod. Res., 26, pp. 370-374, (2012); Dongari-Bagtzoglou A., Pathogenesis of mucosal biofilm infections: challenges and progress, Expert Rev. Anti Infect. Ther., 6, pp. 201-208, (2008); DuBois K.N., Abodeely M., Sajid M., Engel J.C., McKerrow J.H., Giardia lamblia cysteine proteases, Parasitol. Res., 99, pp. 313-316, (2006); Edgar R.C., UPARSE: highly accurate OTU sequences from microbial amplicon reads, Nat. Methods, 10, pp. 996-998, (2013); Fahlgren A., Hammarstrom S., Danielsson A., Hammarstrom M.L., Increased expression of antimicrobial peptides and lysozyme in colonic epithelial cells of patients with ulcerative colitis, Clin. Exp. Immunol., 131, pp. 90-101, (2003); Gerbaba T.K., Gupta P., Rioux K., Hansen D., Buret A.G., Giardia duodenalis-induced alterations of commensal bacteria kill Caenorhabditis elegans: a new model to study microbial-microbial interactions in the gut, Am. J. Physiol. Gastrointest. Liver Physiol., 308, pp. G550-G561, (2015); Green M.R., Sambrook J., Molecular Cloning: A Laboratory Manual, (2012); Gwee K.A., Collins S.M., Read N.W., Rajnakova A., Deng Y., Graham J.C., McKendrick M.W., Moochhala S.M., Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome, Gut, 52, pp. 523-526, (2003); Halliez M.C., Buret A.G., Extra-intestinal and long term consequences of Giardia duodenalis infections, World J. Gastroenterol., 19, pp. 8974-8985, (2013); Halliez M.C., Motta J.P., Feener T.D., Guerin G., LeGoff L., Francois A., Colasse E., Favennec L., Gargala G., Lapointe T.K., Altier C., Buret A.G., Giardia duodenalis induces para-cellular bacterial translocation and causes post-infectious visceral hypersensitivity, Am. J. Physiol. Gastrointest. Liver Physiol., 144, (2016); Hanevik K., Dizdar V., Langeland N., Hausken T., Development of functional gastrointestinal disorders after Giardia lamblia infection, BMC Gastroenterol., 9, (2009); Hare D.F., Jarroll E.L., Lindmark D.G., Giardia lamblia: characterization of proteinase activity in trophozoites, Exp. Parasitol., 68, pp. 168-175, (1989); Harrison J.J., Ceri H., Yerly J., Stremick C.A., Hu Y., Martinuzzi R., Turner R.J., The use of microscopy and three-dimensional visualization to evaluate the structure of microbial biofilms cultivated in the Calgary Biofilm Device, Biol. Proc. Online, 8, pp. 194-215, (2006); Harrison J.J., Stremick C.A., Turner R.J., Allan N.D., Olson M.E., Ceri H., Microtiter susceptibility testing of microbes growing on peg lids: a miniaturized biofilm model for high-throughput screening, Nat. Protoc., 5, pp. 1236-1254, (2010); Kalischuk L.D., Inglis G.D., Buret A.G., Campylobacter jejuni induces transcellular translocation of commensal bacteria via lipid rafts, Gut Pathog, 1, (2009); Kalischuk L.D., Leggett F., Inglis G.D., Campylobacter jejuni induces transcytosis of commensal bacteria across the intestinal epithelium through M-like cells, Gut Pathog, 2, (2010); Kassinen A., Krogius-Kurikka L., Makivuokko H., Rinttila T., Paulin L., Corander J., Malinen E., Apajalahti J., Palva A., The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects, Gastroenterology, 133, pp. 24-33, (2007); Keselman A., Li E., Maloney J., Singer S.M., The microbiota contributes to CD8+ T cell activation and nutrient malabsorption following intestinal infection with giardia duodenalis, Infect. Immun., 84, pp. 2853-2860, (2016); Kleessen B., Blaut M., Modulation of gut mucosal biofilms, T Brit J Nutr, 93, pp. S35-S40, (2005); Klindworth A., Pruesse E., Schweer T., Peplies J., Quast C., Horn M., Glockner F.O., Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation sequencing-based diversity studies, Nucleic Acids Res., 41, (2013); Konig J., Brummer R.J., Alteration of the intestinal microbiota as a cause of and a potential therapeutic option in irritable bowel syndrome, Beneficial Microb., 3, pp. 1-15, (2014); Koster J., Rahmann S., Snakemake—a scalable bioinformatics workflow engine, Bioinformatics, 28, pp. 2520-2522, (2012); Kozlowski C., Jeet S., Beyer J., Guerrero S., Lesch J., Wang X., Devoss J., Diehl L., An entirely automated method to score DSS-induced colitis in mice by digital image analysis of pathology slides, Dis. Models Mech., 6, pp. 855-865, (2013); Lapointe T.K., Buret A.G., Interleukin-18 facilitates neutrophil transmigration via myosin light chain kinase-dependent disruption of occludin, without altering epithelial permeability, Am. J. Physiol. Gastrointest. Liver Physiol., 302, pp. G343-G351, (2012); Liebregts T., Adam B., Bredack C., Roth A., Heinzel S., Lester S., Downie-Doyle S., Smith E., Drew P., Talley N.J., Holtmann G., Immune activation in patients with irritable bowel syndrome, Gastroenterology, 132, pp. 913-920, (2007); Love M.I., Huber W., Anders S., Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2, Genome Biol., 15, (2014); Macfarlane G.T., Macfarlane S., Human colonic microbiota: ecology, physiology and metabolic potential of intestinal bacteria, Scand. J. Gastroenterol. Suppl., 222, pp. 3-9, (1997); Macfarlane S., Woodmansey E.J., Macfarlane G.T., Colonization of mucin by human intestinal bacteria and establishment of biofilm communities in a two-stage continuous culture system, Appl. Environ. Microbiol., 71, pp. 7483-7492, (2005); Marshall J.K., Thabane M., Garg A.X., Clark W.F., Moayyedi P., Collins S.M., Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery, Gut, 59, pp. 605-611, (2010); Mason K.L., Stepien T.A., Blum J.E., Holt J.F., Labbe N.H., Rush J.S., Raffa K.F., Handelsman J., From commensal to pathogen: translocation of Enterococcus faecalis from the midgut to the hemocoel of Manduca sexta, mBio, 2, (2011); McMurdie P.J., Holmes S., Phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data, PLoS ONE, 8, (2013); McMurdie P.J., Holmes S., Waste not, want not: why rarefying microbiome data is inadmissible, PLoS Comput. Biol., 10, (2014); Noronha A.M., Liang Y., Hetzel J.T., Hasturk H., Kantarci A., Stucchi A., Zhang Y., Nikolajczyk B.S., Farraye F.A., Ganley-Leal L.M., Hyperactivated B cells in human inflammatory bowel disease, J. Leuk. Biol., 86, pp. 1007-1016, (2009); O'Hara J.R., Buret A.G., Mechanisms of intestinal tight junctional disruption during infection, Front. Biosci., 13, pp. 7008-7021, (2008); O'Neil D.A., Porter E.M., Elewaut D., Anderson G.M., Eckmann L., Ganz T., Kagnoff M.F., Expression and regulation of the human beta-defensins hBD-1 and hBD-2 in intestinal epithelium, J. Immunol., 163, pp. 6718-6724, (1999); Ohman L., Isaksson S., Lindmark A.C., Posserud I., Stotzer P.O., Strid H., Sjovall H., Simren M., T-cell activation in patients with irritable bowel syndrome, Am. J. Gastroenterol., 104, pp. 1205-1212, (2009); Perez-Mendoza D., Coulthurst S.J., Sanjuan J., Salmond G.P., N-Acetylglucosamine-dependent biofilm formation in Pectobacterium atrosepticum is cryptic and activated by elevated c-di-GMP levels, Microbiology, 157, pp. 3340-3348, (2011); Rajilic-Stojanovic M., Biagi E., Heilig H.G., Kajander K., Kekkonen R.A., Tims S., de Vos W.M., Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome, Gastroenterology, 141, pp. 1792-1801, (2011); Ramachandran A., Madesh M., Balasubramanian K.A., Apoptosis in the intestinal epithelium: its relevance in normal and pathophysiological conditions, J. Gastroenterol. Hepatol., 15, pp. 109-120, (2000); Reti K.L., Tymensen L.D., Davis S.P., Amrein M.W., Buret A.G., Campylobacter jejuni increases flagellar expression and adhesion of noninvasive Escherichia coli: effects on enterocytic Toll-like receptor 4 and CXCL-8 expression, Infect. Immun., 83, pp. 4571-4581, (2015); Roberts-Thomson I.C., Stevens D.P., Mahmoud A.A., Warren K.S., Giardiasis in the mouse: an animal model, Gastroenterology, 71, pp. 57-61, (1976); Rodriguez-Fuentes G.B., Cedillo-Rivera R., Fonseca-Linan R., Arguello-Garcia R., Munoz O., Ortega-Pierres G., Yepez-Mulia L., Giardia duodenalis: analysis of secreted proteases upon trophozoite-epithelial cell interaction in vitro, Mem. Inst. Oswaldo Cruz, 101, pp. 693-696, (2006); Roslev P., King G.M., Application of a tetrazolium salt with a water-soluble formazan as an indicator of viability in respiring bacteria, Appl. Environ. Microbiol., 59, pp. 2891-2896, (1993); Round J.L., Mazmanian S.K., The gut microbiota shapes intestinal immune responses during health and disease, Nat. Rev. Immunol., 9, pp. 313-323, (2009); Salonen A., de Vos W.M., Palva A., Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives, Microbiology, 156, pp. 3205-3215, (2010); Sambuy Y., De Angelis I., Ranaldi G., Scarino M.L., Stammati A., Zucco F., The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics, Cell Biol. Toxicol., 21, pp. 1-26, (2005); Sawada N., Tight junction-related human diseases, Pathol. Int., 63, pp. 1-12, (2013); Scully P., McKernan D.P., Keohane J., Groeger D., Shanahan F., Dinan T.G., Quigley E.M., Plasma cytokine profiles in females with irritable bowel syndrome and extra-intestinal co-morbidity, Am. J. Gastroenterol., 105, pp. 2235-2243, (2010); Sepehri S., Kotlowski R., Bernstein C.N., Krause D.O., Microbial diversity of inflamed and noninflamed gut biopsy tissues in inflammatory bowel disease, Inflamm. Bowel Dis., 13, pp. 675-683, (2007); Spiller R., Campbell E., Post-infectious irritable bowel syndrome, Curr. Opin. Gastroenterol., 22, pp. 13-17, (2006); Spiller R.C., Jenkins D., Thornley J.P., Hebden J.M., Wright T., Skinner M., Neal K.R., Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, pp. 804-811, (2000); Sproule-Willoughby K.M., Stanton M.M., Rioux K.P., McKay D.M., Buret A.G., Ceri H., In vitro anaerobic biofilms of human colonic microbiota, J. Microbiol. Methods, 83, pp. 296-301, (2010); Stevens D.P., Roberts-Thompson I.C., Animal model of human disease: giardiasis, Am. J. Pathol., 90, pp. 529-532, (1978); Sutherland I.W., The biofilm matrix–an immobilized but dynamic microbial environment, Trends Microbiol., 9, pp. 222-227, (2001); Tchoupe J.R., Moreau T., Gauthier F., Bieth J.G., Photometric or fluorometric assay of cathepsin B, L and H and papain using substrates with an aminotrifluoromethylcoumarin leaving group, Biochim. Biophys. Acta, 1076, pp. 149-151, (1991); Teoh D.A., Kamieniecki D., Pang G., Buret A.G., Giardia lamblia rearranges F-actin and alpha-actinin in human colonic and duodenal monolayers and reduces transepithelial electrical resistance, J. Parasitol., 86, pp. 800-806, (2000); Thabane M., Marshall J.K., Post-infectious irritable bowel syndrome, World J. Gastroenterol., 15, pp. 3591-3596, (2009); Tornblom H., Lindberg G., Nyberg B., Veress B., Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome, Gastroenterology, 123, pp. 1972-1979, (2002); Toyofuku M., Roschitzki B., Riedel K., Eberl L., Identification of proteins associated with the Pseudomonas aeruginosa biofilm extracellular matrix, J. Proteo Res., 11, pp. 4906-4915, (2012); von Rosenvinge E.C., O'May G.A., Macfarlane S., Macfarlane G.T., Shirtliff M.E., Microbial biofilms and gastrointestinal diseases, Pathog Dis., 67, pp. 25-38, (2013); Vora P., Youdim A., Thomas L.S., Fukata M., Tesfay S.Y., Lukasek K., Michelsen K.S., Wada A., Hirayama T., Arditi M., Abreu M.T., Beta-defensin-2 expression is regulated by TLR signaling in intestinal epithelial cells, J. Immunol., 173, pp. 5398-5405, (2004); Wang D., Dubois R.N., Richmond A., The role of chemokines in intestinal inflammation and cancer, Curr. Opin. Pharmacol., 9, pp. 688-696, (2009); Wensaas K.A., Langeland N., Hanevik K., Morch K., Eide G.E., Rortveit G., Irritable bowel syndrome and chronic fatigue 3 years after acute giardiasis: historic cohort study, Gut, 61, pp. 214-219, (2012); Williams A.G., Coombs G.H., Multiple protease activities in Giardia intestinalis trophozoites, Int. J. Parasitol., 25, pp. 771-778, (1995); Yu L.C., Flynn A.N., Turner J.R., Buret A.G., SGLT-1-mediated glucose uptake protects intestinal epithelial cells against LPS-induced apoptosis and barrier defects: a novel cellular rescue mechanism?, FASEB J., 19, pp. 1822-1835, (2005); Zoetendal E.G., Rajilic-Stojanovic M., de Vos W.M., High-throughput diversity and functionality analysis of the gastrointestinal tract microbiota, Gut, 57, pp. 1605-1615, (2008)","A.G. Buret; Department of Biological Sciences, Faculty of Sciences, University of Calgary, Calgary, 2500 University Drive NW, T2N 4N1, Canada; email: aburet@ucalgary.ca","","Elsevier Ltd","","","","","","00207519","","IJPYB","28237889","English","Int. J. Parasitol.","Article","Final","All Open Access; Hybrid Gold Open Access","Scopus","2-s2.0-85014144288"

"Yu Y.-B.; Zhao D.-Y.; Qi Q.-Q.; Long X.; Li X.; Chen F.-X.; Zuo X.-L.","Yu, Y.-B. (55561393800); Zhao, D.-Y. (57218293182); Qi, Q.-Q. (55261413600); Long, X. (57191658481); Li, X. (57191651709); Chen, F.-X. (35204563200); Zuo, X.-L. (57204617174)","55561393800; 57218293182; 55261413600; 57191658481; 57191651709; 35204563200; 57204617174","BDNF modulates intestinal barrier integrity through regulating the expression of tight junction proteins","2017","Neurogastroenterology and Motility","29","3","e12967","","","","24","10.1111/nmo.12967","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84992418573&doi=10.1111%2fnmo.12967&partnerID=40&md5=a74a59bd2febe782f455c6c435158b97","Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, China; Laboratory of Translational Gastroenterology, Qilu Hospital, Shandong University, Jinan, China; Department of Gastroenterology, General Hospital of Puyang Oilfield, Puyang, China","Yu Y.-B., Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, China; Zhao D.-Y., Laboratory of Translational Gastroenterology, Qilu Hospital, Shandong University, Jinan, China, Department of Gastroenterology, General Hospital of Puyang Oilfield, Puyang, China; Qi Q.-Q., Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, China; Long X., Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, China; Li X., Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, China; Chen F.-X., Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, China; Zuo X.-L., Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, China","Background: Brain-derived neurotrophic factor (BDNF) may play a vital role in the homeostatic regulation of intestinal barrier integrity. We aimed to investigate the physiological role of BDNF in maintaining the intestinal epithelial barrier using postinflammatory irritable bowel syndrome (PI-IBS) mice and explore the underlying molecular mechanisms using intestinal epithelial cells in vitro. Methods: Postinflammatory-IBS mice were induced by intrarectal administration of trinitrobenzene sulfonic acid and allowed to recover for 28 days. Frequency of defecation, fecal water content, colonic epithelial integrity and expressions of BDNF and tight junction (TJ) proteins (occludin, ZO-1, claudin-1, claudin-2) of the PI-IBS mice were investigated. Based on the results of animal studies, we further performed RT-PCR and Western blots to assess how BDNF stimulation and BDNF knockdown impacted TJ proteins in the ht-29 intestinal epithelial cells. Key Results: Water content of stools was significantly increased in the PI-IBS mice compared with controls. Colonic mucosa from the PI-IBS mice displayed epithelial barrier defects and exhibited increased protein expressions of BDNF and claudin-2 and decreased protein expressions of occludin, ZO-1 and claudin-1. Furthermore, a siRNA against BDNF in the ht-29 cells could effectively suppress BDNF gene and protein expressions, and subsequently reduce TJ gene and protein levels. When the ht-29 cells were incubated with different doses of exogenous BDNF, significant increases of occludin, ZO-1 and claudin-1 and decreases of claudin-2 protein were observed. Conclusions & Inferences: BDNF may play a role in regulating intestinal epithelial barrier via affecting the expression of TJ proteins. © 2016 John Wiley & Sons Ltd","BDNF; IBS; intestinal barrier; tight junction proteins","Animals; Brain-Derived Neurotrophic Factor; Dose-Response Relationship, Drug; Gene Expression; HT29 Cells; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Male; Mice; Mice, Inbred C57BL; Tight Junction Proteins; brain derived neurotrophic factor; claudin 1; claudin 2; occludin; protein ZO1; small interfering RNA; tight junction protein; trinitrobenzenesulfonic acid; brain derived neurotrophic factor; tight junction protein; adult; animal experiment; animal model; animal tissue; Article; colon epithelium; colon mucosa; controlled study; defecation; feces; gene expression; gene silencing; HT-29 cell line; human; human cell; in vitro study; intestine epithelium cell; irritable colon; male; mouse; nonhuman; permeability barrier; priority journal; protein expression; reverse transcription polymerase chain reaction; water content; Western blotting; animal; biosynthesis; C57BL mouse; dose response; drug effects; genetics; intestine mucosa; irritable colon; metabolism; pathology","","brain derived neurotrophic factor, 218441-99-7; claudin 1, 329338-06-9; occludin, 176304-61-3; trinitrobenzenesulfonic acid, 16655-63-3, 2508-19-2; Brain-Derived Neurotrophic Factor, ; Tight Junction Proteins, ","","","Scientific Research Foundation for Outstanding Young Scientist of Shandong Province, (BS2012SW012); Shangdong Province Science and Technology Committee, (2013GEF11833); National Natural Science Foundation of China, NSFC, (81200270, 81330012, 81370495); National Natural Science Foundation of China, NSFC","This work was supported by the National Natural Science Foundation of China (NSFC; 81200270, 81330012, and 81370495), the Shangdong Province Science and Technology Committee (no. 2013GEF11833) and the Scientific Research Foundation for Outstanding Young Scientist of Shandong Province (BS2012SW012).","Shen L., Turner J.R., Role of epithelial cells in initiation and propagation of intestinal inflammation. Eliminating the static: tight junction dynamics exposed, Am J Physiol Gastrointest Liver Physiol, 290, pp. G577-G582, (2006); Turner J.R., Intestinal mucosal barrier function in health and disease, Nat Rev Immunol, 9, pp. 799-809, (2009); Vijendravarma R.K., Narasimha S., Chakrabarti S., Et al., Gut physiology mediates a trade-off between adaptation to malnutrition and susceptibility to food-borne pathogens, Ecol Lett, 18, pp. 1078-1086, (2015); Musch M.W., Clarke L.L., Mamah D., Et al., T cell activation causes diarrhea by increasing intestinal permeability and inhibiting epithelial Na<sup>+</sup>/K<sup>+</sup>-ATPase, J Clin Invest, 110, pp. 1739-1748, (2002); Gecse K., Roka R., Ferrier L., Et al., Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity, Gut, 57, pp. 591-599, (2008); Annahazi A., Ferrier L., Bezirard V., Et al., Luminal cysteine-proteases degrade colonic tight junction structure and are responsible for abdominal pain in constipation-predominant IBS, Am J Gastroenterol, 108, pp. 1322-1331, (2013); Martinez C., Lobo B., Pigrau M., Et al., Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, pp. 1160-1168, (2013); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Et al., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am J Gastroenterol, 106, pp. 2165-2173, (2011); Piche T., Barbara G., Aubert P., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Hartsock A., Nelson W.J., Adherens and tight junctions: structure, function and connections to the actin cytoskeleton, Biochim Biophys Acta, 1778, pp. 660-669, (2008); Krug S.M., Schulzke J.D., Fromm M., Tight junction, selective permeability, and related diseases, Semin Cell Dev Biol, 36, pp. 166-176, (2014); Shen L., Weber C.R., Raleigh D.R., Yu D., Turner J.R., Tight junction pore and leak pathways: a dynamic duo, Annu Rev Physiol, 73, pp. 283-309, (2011); Rosenthal R., Milatz S., Krug S.M., Et al., Claudin-2, a component of the tight junction, forms a paracellular water channel, J Cell Sci, 123, pp. 1913-1921, (2010); Piche T., Tight junctions and IBS-the link between epithelial permeability, low-grade inflammation, and symptom generation?, Neurogastroenterol Motil, 26, pp. 296-302, (2014); Arevalo J.C., Wu S.H., Neurotrophin signaling: many exciting surprises!, Cell Mol Life Sci, 63, pp. 1523-1537, (2006); Lommatzsch M., Braun A., Mannsfeldt A., Et al., Abundant production of brain-derived neurotrophic factor by adult visceral epithelia: implications for paracrine and target-derived neurotrophic functions, Am J Pathol, 155, pp. 1183-1193, (1999); Anastasia A., Deinhardt K., Wang S., Et al., Trkb signaling in pericytes is required for cardiac microvessel stabilization, PLoS ONE, 9, (2014); Kurihara H., Shinohara H., Yoshino H., Takeda K., Shiba H., Neurotrophins in cultured cells from periodontal tissues, J Periodontol, 74, pp. 76-84, (2003); Shimizu F., Sano Y., Ma A., Et al., Peripheral nerve pericytes modify the blood–nerve barrier function and tight junctional molecules through the secretion of various soluble factors, J Cell Physiol, 226, pp. 255-266, (2011); Matsuda S., Fujita T., Kajiya M., Et al., Brain-derived neurotrophic factor prevents the endothelial barrier dysfunction induced by interleukin-1β and tumor necrosis factor-α, J Periodontal Res, 50, pp. 444-451, (2015); Lampugnani M.-G., Resnati M., Raiteri M., Et al., A novel endothelial-specific membrane protein is a marker of cell-cell contacts, J Cell Biol, 118, pp. 1511-1522, (1992); Barreau F., Cartier C., Ferrier L., Fioramonti J., Bueno L., Nerve growth factor mediates alterations of colonic sensitivity and mucosal barrier induced by neonatal stress in rats, Gastroenterology, 127, pp. 524-534, (2004); Reinshagen M., Rohm H., Steinkamp M., Et al., Protective role of neurotrophins in experimental inflammation of the rat gut, Gastroenterology, 119, pp. 368-376, (2000); Yu Y.B., Zuo X.L., Zhao Q.J., Et al., Brain-derived neurotrophic factor contributes to abdominal pain in irritable bowel syndrome, Gut, 61, pp. 685-694, (2012); Hughes P.A., Brierley S.M., Martin C.M., Brookes S.J., Linden D.R., Blackshaw L.A., Post-inflammatory colonic afferent sensitisation: different subtypes, different pathways and different time courses, Gut, 58, pp. 1333-1341, (2009); Qin H.-Y., Wu J.C., Tong X.-D., Sung J.J., Xu H.-X., Bian Z.-X., Systematic review of animal models of post-infectious/post-inflammatory irritable bowel syndrome, J Gastroenterol, 46, pp. 164-174, (2011); Matricon J., Meleine M., Gelot A., Et al., Review article: associations between immune activation, intestinal permeability and the irritable bowel syndrome, Aliment Pharmacol Ther, 36, pp. 1009-1031, (2012); Stadelmann C., Kerschensteiner M., Misgeld T., Bruck W., Hohlfeld R., Lassmann H., BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells?, Brain, 125, pp. 75-85, (2002); Donovan M.J., Miranda R.C., Kraemer R., Et al., Neurotrophin and neurotrophin receptors in vascular smooth muscle cells: regulation of expression in response to injury, Am J Pathol, 147, (1995); Donovan M.J., Lin M.I., Wiegn P., Et al., Brain derived neurotrophic factor is an endothelial cell survival factor required for intramyocardial vessel stabilization, Development, 127, pp. 4531-4540, (2000); Amasheh S., Fromm M., Gunzel D., Claudins of intestine and nephron–a correlation of molecular tight junction structure and barrier function, Acta Physiol, 201, pp. 133-140, (2011); Zhang Y., Wu S., Xia Y., Sun J., Salmonella infection upregulates the leaky protein claudin-2 in intestinal epithelial cells, PLoS ONE, 8, (2013); de Farias C.B., Heinen T.E., dos Santos R.P., Abujamra A.L., Schwartsmann G., Roesler R., BDNF/TrkB signaling protects HT-29 human colon cancer cells from EGFR inhibition, Biochem Biophys Res Commun, 425, pp. 328-332, (2012); Yang X., Martin T.A., Jiang W.G., Biological influence of brain-derived neurotrophic factor (BDNF) on colon cancer cells, Exp Ther Med, 6, pp. 1475-1481, (2013); Johansson M., Norrgard O., Forsgren S., Study of expression patterns and levels of neurotrophins and neurotrophin receptors in ulcerative colitis, Inflamm Bowel Dis, 13, pp. 398-409, (2007); Gunther C., Neumann H., Neurath M.F., Becker C., Apoptosis, necrosis and necroptosis: cell death regulation in the intestinal epithelium, Gut, 62, pp. 1062-1071, (2013); Zhang C., Sheng Z.-Y., Hu S., Gao J.-C., Yu S., Liu Y., The influence of apoptosis of mucosal epithelial cells on intestinal barrier integrity after scald in rats, Burns, 28, pp. 731-737, (2002)","X.-L. Zuo; Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, China; email: zuoxiuli@sina.com","","Blackwell Publishing Ltd","","","","","","13501925","","NMOTE","27747999","English","Neurogastroenterol. Motil.","Article","Final","","Scopus","2-s2.0-84992418573"

"Chao G.; Zhang S.","Chao, Guanqun (24780251800); Zhang, Shuo (57171163400)","24780251800; 57171163400","Aquaporins 1, 3 and 8 expression in irritable bowel syndrome rats' colon via NF-κB pathway","2017","Oncotarget","8","29","","47175","47183","8","19","10.18632/oncotarget.17565","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85024397541&doi=10.18632%2foncotarget.17565&partnerID=40&md5=92038bfd51f5e3bcdebedaf2905a2692","Department of Family Medicine, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China; Department of Gastroenterology, The First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, China","Chao G., Department of Family Medicine, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China; Zhang S., Department of Gastroenterology, The First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, China","Objective: Our research was to detect the expression of aquaporins. NF-κB in Irritable bowel syndrome (IBS) rat models' colon so as to find novel pathogenesisof IBS. Results: The expression of AQP1, AQP3, and AQP8 of IBS model group was downregulated while NF-κB p65 was up-regulated comparing with control group (p < 0.05), and the expression of AQP1, AQP3, and AQP8 of inhibitor group was up-regulated while NF-κB p65 was down-regulated comparing with IBS model group (p < 0.05). Materials and Methods: 18 adult female SD big rats were divided into three groups:the rats in control group were normal rats,the rats in IBS model group and the rats of inhibitor group were injected with the inhibitor of NF-κB (PDTC). Immunohistochemical technique and western blot were performed to detect the expression of AQP1, AQP3, AQP8 and NF-κB p65. RT-PCR was performed to detect the expression of AQP1, AQP3, and AQP8. Conclusions: Liquid water metabolic abnormalities and intestine permeability alteration might be the mechanism of IBS by down-regulating AQP1, AQP3 and AQP8 via NF-κB pathway. © Chao et al.","Aquaporins; Irritable bowel syndrome; NF-κB","Animals; Aquaporin 1; Aquaporin 3; Aquaporins; Colon; Disease Models, Animal; Female; Gene Expression; Immunohistochemistry; Irritable Bowel Syndrome; NF-kappa B; Permeability; Rats; Signal Transduction; Water; aquaporin 1; aquaporin 3; aquaporin 8; immunoglobulin enhancer binding protein; aquaporin; aquaporin 1; aquaporin 3; aquaporin 8; immunoglobulin enhancer binding protein; water; adult; animal experiment; animal model; animal tissue; Article; controlled study; down regulation; female; immunohistochemistry; irritable colon; nonhuman; pathogenesis; protein expression; rat; reverse transcription polymerase chain reaction; upregulation; Western blotting; animal; colon; disease model; gene expression; genetics; irritable colon; metabolism; pathology; permeability; signal transduction","","aquaporin 1, 146410-94-8, 149348-86-7; aquaporin, 215587-75-0; water, 7732-18-5; Aquaporin 1, ; Aquaporin 3, ; aquaporin 8, ; Aquaporins, ; NF-kappa B, ; Water, ","","","Fund of Medicine and health science and technology plan projectsin Zhejiang province, (2017179719); Traditional Chinese medicine science and technology plan of Zhejiang province, (2017ZA089); Traditional Chinese medicine science and technology plan projects of Zhejiang province, (2016ZB071); National Natural Science Foundation of China, NSFC, (2015ZZ012, 81573760); Natural Science Foundation of Zhejiang Province, ZJNSF, (LY16H030010); medical health platform plan projects of Zhejiang province, (2015RCA020)","This work was partially supported by the Fund of Medicine and health science and technology plan projectsin Zhejiang province (2017179719); Traditional Chinese medicine science and technology plan of Zhejiang province (2017ZA089); Traditional Chinese medicine science and technology plan projects of Zhejiang province (2016ZB071); and National Natural Science Foundation of China (81573760); and Traditional Chinese medicine science and technology plan projects of Zhejiang province (2015ZZ012); and medical health platform plan projects of Zhejiang province (2015RCA020); Zhejiang Provincial Natural Science Foundation of China (LY16H030010).","Jarrett M.E., Han C.J., Cain K.C., Burr R.L., Shulman R.J., Barney P.G., Naliboff B.D., Zia J., Heitkemper M.M., Relationships of abdominal pain, reports to visceral and temperature pain sensitivity, conditioned pain modulation, and heart rate variability in irritable bowel syndrome, Neurogastroenterol Motil, 28, pp. 1094-1103, (2016); Drossman D.A., Camilleri M., Mayer E.A., Whitehead W.E., AGA technical review on irritable bowel syndrome, Gastroenterology, 123, pp. 2108-2131, (2002); Naeem S.S., Siddiqui E.U., Kazi A.N., Memon A.A., Khan S.T., Ahmed B., Prevalence and factors associated with irritable bowel syndrome among medical students of Karachi, Pakistan: a cross-sectional study, BMC Res Notes, 5, (2012); Basandra S., Bajaj D., Epidemiology of Dyspepsia and Irritable Bowel Syndrome (IBS) in Medical Students of Northern India, J Clin Diagn Res, 8, pp. JC13-JC16, (2014); Fallah M., Pourrasouli Z., Ghasemipour R., Heidarzadeh A., Joukar F., Hammami P., Arami M., Keyhanian S., Keyhanian M., Masoudnia N., Ziaratban R., Irritable bowel syndrome (IBS) prevalence in medical students of Gilan University of Medical Sciences, Govaresh, 11, pp. 7-11, (2006); Loo D.D., Wright E.M., Zeuthen T., Water pumps, J Physiol, 542, pp. 53-60, (2002); Matsuzaki T., Tajika Y., Ablimit A., Aoki T., Hagiwara H., Takata K., Aquaporins in the digestive system, Med Electron Microsc, 37, pp. 71-80, (2004); Mobasheri A., Wray S., Marples D., Distribution of AQP2 and AQP3 water channels in human tissue microarrays, J Mol Histol, 36, pp. 1-14, (2005); Wang J.P., Hou X.H., Expression of aquaporin 8 in colonic epithelium with diarrhoea-predominant irritable bowel syndrome, Chin Med J (Engl), 120, pp. 313-316, (2007); Laforenza U., Water channel proteins in the gastrointestinal tract, Mol Aspects Med, 33, pp. 642-650, (2012); Matsuzaki T., Tajika Y., Ablimit A., Aoki T., Hagiwara H., Takata K., Aquaporins in the digestive system, Medical Molecular Morphology, 37, pp. 71-80, (2004); Yde J., Keely S., Wu Q., Borg J.F., Lajczak N., O'Dwyer A., Dalsgaard P., Fenton R.A., Moeller H.B., Characterization of AQPs in Mouse, Rat, and Human Colon and Their Selective Regulation by Bile Acids, Frontiers in Nutrition, (2016); DiDonato J.A., Mercurio F., Karin M., NF-κB and the link between inflammation and cancer, Immunol Rev, 246, pp. 379-400, (2012); Yao C., Purwanti N., Karabasil M.R., Azlina A., Javkhlan P., Hasegawa T., Akamatsu T., Hosoi T., Ozawa K., Hosoi K., Potential down-regulation of salivary gland AQP5 by LPS via cross-coupling of NF-kappaB and p-c-Jun/c-Fos, Am J Pathol, 177, pp. 724-734, (2010); Hocherl K., Schmidt C., Kurt B., Bucher M., Inhibition of NF-kappaB ameliorates sepsis-induced downregulation of aquaporin-2/V2 receptor expression and acute renal failure in vivo, Am J Physiol Renal Physiol, 298, pp. F196-F204, (2010); Schmulson M.J., Drossman D.A., What Is New in Rome IV, J Neurogastroenterol Motil, 23, pp. 151-163, (2017); Qureshi S.R., Abdelaal A.M., Janjua Z.A., Alasmari H.A., Obad A.S., Alamodi A., Shareef M.A., Irritable Bowel Syndrome: A Global Challenge Among Medical Students, Cureus, 8, (2016); Ringel Y., Drossman D.A., Irritable bowel syndrome: classification and conceptualization, J Clin Gastroenterol, 35, pp. S7-S10, (2002); El-Matary W., Spray C., Sandhu B., Irritable bowel syndrome: the commonest cause of recurrent abdominal pain in children, Eur J Pediatr, 163, pp. 584-588, (2004); Ghoshal U.C., Shukla R., Ghoshal U., Gwee K.A., Ng S.C., Quigley E.M., The gut microbiota and irritable bowel syndrome: friend or foe?, Int J Inflam, 2012, (2012); Zhu C., Chen Z., Jiang Z., Expression, Distribution and Role of Aquaporin Water Channels in Human and Animal Stomach and Intestines, Int J Mol Sci, (2016); Matsuzaki T., Tajika Y., Ablimit A., Aoki T., Hagiwara H., Takata K., Aquaporins in the digestive system, Med Electron Microsc, 37, pp. 71-80, (2004); Laforenza U., Water channel proteins in the gastrointestinal tract, Mol Aspects Med, 33, pp. 642-650, (2012); Zhao G.X., Dong P.P., Peng R., Li J., Zhang D.Y., Wang J.Y., Shen X.Z., Dong L., Sun J.Y., Expression, localization and possible functions of aquaporins 3 and 8 in rat digestive system, Biotech Histochem, 91, pp. 269-276, (2016); Huebert R.C., Vasdev M.M., Shergill U., Das A., Huang B.Q., Charlton M.R., LaRusso N.F., Shah V.H., Aquaporin-1 facilitates angiogenic invasion in the pathological neovasculature that accompanies cirrhosis, Hepatology, 52, pp. 238-248, (2010); Ikarashi N., Kon R., Iizasa T., Suzuki N., Hiruma R., Suenaga K., Toda T., Ishii M., Hoshino M., Ochiai W., Sugiyama K., Inhibition of aquaporin-3 water channel in the colon induces diarrhea, Biol Pharm Bull, 35, pp. 957-962, (2012); Prasad S., Ravindran J., Aggarwal B.B., NF-kappaB and cancer: how intimate is this relationship, Mol Cell Biochem, 336, pp. 25-37, (2010); Maruyama W., Shirakawa K., Matsui H., Matsumoto T., Yamazaki H., Sarca A.D., Kazuma Y., Kobayashi M., Shindo K., Takaori-Kondo A., Classical NF-κB pathway is responsible for APOBEC3B expression in cancer cells, Biochem Biophys Res Commun, 478, pp. 1466-1471, (2016); Vlantis K., Wullaert A., Polykratis A., Kondylis V., Dannappel M., Schwarzer R., Welz P., Corona T., Walczak H., Weih F., Klein U., Kelliher M., Pasparakis M., NEMO Prevents RIP Kinase 1-Mediated Epithelial Cell Death and Chronic Intestinal Inflammation by NF-κB-Dependent and-Independent Functions, Immunity, 44, pp. 553-567, (2016); Koh S.J., Choi Y., Kim B.G., Lee K.L., Kim D.W., Kim J.H., Kim J.W., Kim J.S., Matricellular Protein Periostin Mediates Intestinal Inflammation through the Activation of Nuclear Factor κB Signaling, PLoS One, 11, (2016); Yuan B., Tang W.H., Lu L.J., Zhou Y., Zhu H.Y., Zhou Y.L., Zhang H.H., Hu C.Y., Xu G.Y., TLR4 upregulates CBS expression through NF-κB activation in a rat model of irritable bowel syndrome with chronic visceral hypersensitivity, World J Gastroenterol, 21, pp. 8615-8628, (2015); Hasler U., Leroy V., Jeon U.S., Bouley R., Dimitrov M., Kim J.A., Brown D., Kwon H.M., Martin P.Y., Feraille E., NF-κB modulates aquaporin-2 transcription in renal collecting duct principal cells, J Biol Chem, 283, pp. 28095-28105, (2008); Ito H., Yamamoto N., Arima H., Hirate H., Morishima T., Umenishi F., Tada T., Asai K., Katsuya H., Sobue K., Interleukin-1beta induces the expression of aquaporin-4 through a nuclear factor-kappaB pathway in rat astrocytes, J Neurochem, 99, pp. 107-118, (2006); Zhang Z.Q., Song Y.L., Chen Z.H., Shen Y., Bai C.X., Deletion of aquaporin 5 aggravates acute lung injury induced by Pseudomonas aeruginosa, J Trauma, 71, pp. 1305-1311, (2011); Zhao J.M., Chen L., Zhou C.L., Shi Y., Li Y.W., Shang H.X., Wu L.Y., Bao C.H., Dou C.Z., Wu H.G., Comparison of Electroacupuncture and Moxibustion for Relieving Visceral Hypersensitivity in Rats with Constipation-Predominant Irritable Bowel Syndrome, Evid Based Complement Alternat Med, 2016, (2016); Wang W.A., Qian J.M., Pan G.Z., Development of irritable bowel syndrome animal model induced by brain gut interaction directed conditioned stress, Chinese Journal of Digestion, 24, pp. 592-593, (2004); Naliboff B.D., Chang L., Munakata J., Mayer E.A., Towards an integrative model of irritable bowel syndrome, Prog Brain Res, 122, pp. 413-423, (2000)","S. Zhang; Department of Gastroenterology, The First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, China; email: zhangshuotcm@163.com","","Impact Journals LLC","","","","","","19492553","","","28525373","English","Oncotarget","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85024397541"

"Li L.; Xiong L.; Yao J.; Zhuang X.; Zhang S.; Yu Q.; Xiao Y.; Cui Y.; Chen M.","Li, Li (56148413500); Xiong, Lishou (8305776200); Yao, Junhua (35560043800); Zhuang, Xiaojun (57189377798); Zhang, Shenghong (29967471700); Yu, Qiao (59097060300); Xiao, Yinglian (23500436000); Cui, Yi (35200410400); Chen, Minhu (8642044500)","56148413500; 8305776200; 35560043800; 57189377798; 29967471700; 59097060300; 23500436000; 35200410400; 8642044500","Increased small intestinal permeability and RNA expression profiles of mucosa from terminal ileum in patients with diarrhoea-predominant irritable bowel syndrome","2016","Digestive and Liver Disease","48","8","","880","887","7","19","10.1016/j.dld.2016.05.002","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84969959941&doi=10.1016%2fj.dld.2016.05.002&partnerID=40&md5=2c55b2fc9b0f0c441c7c1d87bfed53de","Department of Gastroenterology and Hepatology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China; Instrumental Analysis and Research Centre, Sun Yat-Sen University, Guangzhou, China","Li L., Department of Gastroenterology and Hepatology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China; Xiong L., Department of Gastroenterology and Hepatology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China; Yao J., Instrumental Analysis and Research Centre, Sun Yat-Sen University, Guangzhou, China; Zhuang X., Department of Gastroenterology and Hepatology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China; Zhang S., Department of Gastroenterology and Hepatology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China; Yu Q., Department of Gastroenterology and Hepatology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China; Xiao Y., Department of Gastroenterology and Hepatology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China; Cui Y., Department of Gastroenterology and Hepatology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China; Chen M., Department of Gastroenterology and Hepatology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China","Background Altered intestinal permeability in diarrhoea-predominant irritable bowel syndrome (IBS-D) has been reported in some studies. Aims The study aimed to investigate the altered intestinal permeability and its associated clinical characteristics and RNA expression profiles in IBS-D. Methods We stratified IBS-D patients into two groups according to the P95 value of the permeability in controls. The clinical characteristics of the two groups were evaluated, and two biopsy cases from each of the two groups were selected for the RNA-seq analysis. Results IBS-D patients had a significant increase in the small intestinal permeability compared with controls [0.0245 (0.0229) median (interquartile range)] versus 0.0156 (0.0098), P = 0.010), but no significant difference was found in the colonic permeability [23.286 (10.470) versus 21.650 (6.650), P = 0.574]. The IBS-D patients with increased small intestinal permeability had worse psychological effects (P = 0.027) and quality of life (P = 0.044). Analysis of RNA-seq data revealed 185 genes differentially expressed, many of which were related to mucosal inflammation and immunity. Conclusions Small intestinal permeability, but not colonic permeability, is increased in IBS-D patients. IBS-D patients with increased small intestinal permeability tend to be more severely impaired in terms of psychological effects and quality of life, and analysis of RNA-seq data reveals that increased small intestinal permeability is related to mucosal inflammation and immunity. © 2016 Editrice Gastroenterologica Italiana S.r.l.","Diarrhoea-predominant irritable bowel syndrome; Intestinal permeability; RNA-seq analysis","Adult; Case-Control Studies; China; Colonoscopy; Diarrhea; Female; Humans; Ileum; Immunity, Mucosal; Intestinal Mucosa; Irritable Bowel Syndrome; Male; Middle Aged; Permeability; Quality of Life; RNA, Messenger; Surveys and Questionnaires; Transcriptome; Young Adult; claudin 4; messenger RNA; occludin; protein ZO1; protein ZO2; protein ZO3; RNA; unclassified drug; zonula occludens protein; messenger RNA; transcriptome; adult; anxiety; Article; clinical article; comparative study; controlled study; depression; diarrhea; female; gene expression profiling; human; intestine biopsy; intestine mucosa permeability; irritable colon; male; priority journal; protein expression; quality of life; RNA sequence; small intestine; terminal ileum; case control study; China; colonoscopy; diarrhea; genetics; ileum; intestine mucosa; irritable colon; metabolism; middle aged; mucosal immunity; pathophysiology; permeability; questionnaire; young adult","","occludin, 176304-61-3; RNA, 63231-63-0; RNA, Messenger, ","","","Inner Mongolia Shuangqi Pharmaceutical Company; Medical Research Foundation Project of Guangdong Province, (A2015317)","This study was funded by the Medical Research Foundation Project of Guangdong Province ( A2015317 ) and Inner Mongolia Shuangqi Pharmaceutical Company .  ","Spiller R., Aziz Q., Creed F., Et al., Guidelines on the irritable bowel syndrome: mechanisms and practical management, Gut, 56, pp. 1770-1798, (2007); El-Serag H.B., Olden K., Bjorkman D., Health-related quality of life among persons with irritable bowel syndrome: a systematic review, Alimentary Pharmacology & Therapeutics, 16, pp. 1171-1185, (2002); Gracie D.J., Ford A.C., Functional bowel symptoms in quiescent inflammatory bowel disease: more than just irritable bowel syndrome?, Gastroenterology, 147, pp. 1176-1177, (2014); Vivinus-Nebot M., Frin-Mathy G., Bzioueche H., Et al., Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation, Gut, 63, pp. 744-752, (2014); Gecse K., Roka R., Sera T., Et al., Leaky gut in patients with diarrhea-predominant irritable bowel syndrome and inactive ulcerative colitis, Digestion, 85, pp. 40-46, (2012); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Camilleri M., Lasch K., Zhou W., Irritable bowel syndrome: methods, mechanisms, and pathophysiology, the confluence of increased permeability, inflammation, and pain in irritable bowel syndrome, American Journal of Physiology – Gastrointestinal and Liver Physiology, 303, pp. G775-G785, (2012); Zhou Q., Souba W.W., Croce C.M., Et al., MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome, Gut, 59, pp. 775-784, (2010); Mujagic Z., Ludidi S., Keszthelyi D., Et al., Small intestinal permeability is increased in diarrhoea predominant IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to confounders, Alimentary Pharmacology & Therapeutics, 40, pp. 288-297, (2014); Piche T., Barbara G., Aubert P., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Vivinus-Nebot M., Dainese R., Anty R., Et al., Combination of allergic factors can worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells, American Journal of Gastroenterology, 107, pp. 75-81, (2012); Longstreth G.F., Thompson W.G., Chey W.D., Et al., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Smecuol E., Bai J.C., Sugai E., Et al., Acute gastrointestinal permeability responses to different non-steroidal anti-inflammatory drugs, Gut, 49, pp. 650-655, (2001); Odenwald M.A., Turner J.R., Intestinal permeability defects: is it time to treat?, Clinical Gastroenterology and Hepatology, 11, pp. 1075-1083, (2013); Svedlund J., Sjodin I., Dotevall G., GSRS – a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease, Digestive Diseases and Sciences, 33, pp. 129-134, (1988); Zigmond A.S., Snaith R.P., The hospital anxiety and depression scale, Acta Psychiatrica Scandinavica, 67, pp. 361-370, (1983); Patrick D.L., Drossman D.A., Frederick I.O., Et al., Quality of life in persons with irritable bowel syndrome: development and validation of a new measure, Digestive Diseases and Sciences, 43, pp. 400-411, (1998); Li R., Zhu H., Ruan J., Et al., De novo assembly of human genomes with massively parallel short read sequencing, Genome Research, 20, pp. 265-272, (2010); Mortazavi A., Williams B.A., Mccue K., Et al., Mapping and quantifying mammalian transcriptomes by RNA-Seq, Nature Methods, 5, pp. 621-628, (2008); Ye J., Fang L., Zheng H., Et al., WEGO: a web tool for plotting GO annotations, Nucleic Acids Research, 34, pp. W293-W297, (2006); Kanehisa M., Araki M., Goto S., Et al., KEGG for linking genomes to life and the environment, Nucleic Acids Research, 36, pp. D480-D484, (2008); De Hoon M.J., Imoto S., Kobayashi K., Et al., Predicting the operon structure of Bacillus subtilis using operon length, intergene distance, and gene expression information, Pacific Symposium on Biocomputing, pp. 276-287, (2004); Martinez C., Vicario M., Ramos L., Et al., The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations, American Journal of Gastroenterology, 107, pp. 736-746, (2012); Vanuytsel T., van Wanrooy S., Vanheel H., Et al., Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism, Gut, 63, pp. 1293-1299, (2014); Ferrier L., Mazelin L., Cenac N., Et al., Stress-induced disruption of colonic epithelial barrier: role of interferon-γ and myosin light chain kinase in mice, Gastroenterology, 125, pp. 795-804, (2003); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, American Journal of Gastroenterology, 101, pp. 1288-1294, (2006); Aerssens J., Camilleri M., Talloen W., Et al., Alterations in mucosal immunity identified in the colon of patients with irritable bowel syndrome, Clinical Gastroenterology and Hepatology, 6, pp. 194-205, (2008); Macsharry J., O'Mahony L., Fanning A., Et al., Mucosal cytokine imbalance in irritable bowel syndrome, Scandinavian Journal of Gastroenterology, 43, pp. 1467-1476, (2008); Kerckhoffs A.P.M., Akkermans L.M.A., de Smet M.B.M., Et al., Intestinal permeability in irritable bowel syndrome patients: effects of NSAIDs, Digestive Diseases and Sciences, 55, pp. 716-723, (2010)","L. Xiong; Department of Gastroenterology and Hepatology, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, China; email: xionglishou@263.net","","Elsevier B.V.","","","","","","15908658","","DLDIF","27246797","English","Dig. Liver Dis.","Article","Final","","Scopus","2-s2.0-84969959941"

"Barbaro M.R.; Fuschi D.; Cremon C.; Carapelle M.; Dino P.; Marcellini M.M.; Dothel G.; De Ponti F.; Stanghellini V.; Barbara G.","Barbaro, M.R. (56235164100); Fuschi, D. (57202989311); Cremon, C. (6507319921); Carapelle, M. (57202987898); Dino, P. (57189630336); Marcellini, M.M. (55358259100); Dothel, G. (37107414200); De Ponti, F. (55992097200); Stanghellini, V. (7006377452); Barbara, G. (7004311418)","56235164100; 57202989311; 6507319921; 57202987898; 57189630336; 55358259100; 37107414200; 55992097200; 7006377452; 7004311418","Escherichia coli Nissle 1917 restores epithelial permeability alterations induced by irritable bowel syndrome mediators","2018","Neurogastroenterology and Motility","30","8","e13388","","","","23","10.1111/nmo.13388","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85050077165&doi=10.1111%2fnmo.13388&partnerID=40&md5=e123a1cd2fed989ed8d1ef61d9a1f1f9","Department of Medical and Surgical Sciences (DIMEC), Center for Applied Biomedical Research (CRBA), Alma Mater Studiorum - University of Bologna and S. Orsola-Malpighi Hospital, Bologna, Italy","Barbaro M.R., Department of Medical and Surgical Sciences (DIMEC), Center for Applied Biomedical Research (CRBA), Alma Mater Studiorum - University of Bologna and S. Orsola-Malpighi Hospital, Bologna, Italy; Fuschi D., Department of Medical and Surgical Sciences (DIMEC), Center for Applied Biomedical Research (CRBA), Alma Mater Studiorum - University of Bologna and S. Orsola-Malpighi Hospital, Bologna, Italy; Cremon C., Department of Medical and Surgical Sciences (DIMEC), Center for Applied Biomedical Research (CRBA), Alma Mater Studiorum - University of Bologna and S. Orsola-Malpighi Hospital, Bologna, Italy; Carapelle M., Department of Medical and Surgical Sciences (DIMEC), Center for Applied Biomedical Research (CRBA), Alma Mater Studiorum - University of Bologna and S. Orsola-Malpighi Hospital, Bologna, Italy; Dino P., Department of Medical and Surgical Sciences (DIMEC), Center for Applied Biomedical Research (CRBA), Alma Mater Studiorum - University of Bologna and S. Orsola-Malpighi Hospital, Bologna, Italy; Marcellini M.M., Department of Medical and Surgical Sciences (DIMEC), Center for Applied Biomedical Research (CRBA), Alma Mater Studiorum - University of Bologna and S. Orsola-Malpighi Hospital, Bologna, Italy; Dothel G., Department of Medical and Surgical Sciences (DIMEC), Center for Applied Biomedical Research (CRBA), Alma Mater Studiorum - University of Bologna and S. Orsola-Malpighi Hospital, Bologna, Italy; De Ponti F., Department of Medical and Surgical Sciences (DIMEC), Center for Applied Biomedical Research (CRBA), Alma Mater Studiorum - University of Bologna and S. Orsola-Malpighi Hospital, Bologna, Italy; Stanghellini V., Department of Medical and Surgical Sciences (DIMEC), Center for Applied Biomedical Research (CRBA), Alma Mater Studiorum - University of Bologna and S. Orsola-Malpighi Hospital, Bologna, Italy; Barbara G., Department of Medical and Surgical Sciences (DIMEC), Center for Applied Biomedical Research (CRBA), Alma Mater Studiorum - University of Bologna and S. Orsola-Malpighi Hospital, Bologna, Italy","Background: Intestinal permeability is altered in a subgroup of irritable bowel syndrome (IBS) patients and may contribute to symptom development. The aim of this study was to evaluate the in vitro effect of the probiotic Escherichia coli Nissle 1917 (EcN) on Caco-2 permeability alterations induced by mediators released by IBS mucosal biopsies compared to asymptomatic controls (AC). Methods: Caco-2 cells were used as an in vitro model of intestinal permeability. Seven AC and 28 well-phenotyped IBS (9 IBS-D, 8 IBS-C, and 11 IBS-M) patients were enrolled. Mucosal mediators spontaneously released (SUP) by IBS and AC biopsies were collected. Two concentrations of EcN (108 and 106) were applied to Caco-2 with or without SUP or SLIGRL (a protease-activated receptor-2 activating peptide), tumor necrosis factor-α, and interferon-γ. Paracellular permeability was assessed by evaluating the flow of sulfonic-acid conjugated to fluorescein through Caco-2 monolayer. Key Results: EcN 108 significantly reinforced Caco-2 monolayer compared to cells incubated with medium alone. IBS SUP induced a significant increase in paracellular permeability compared to AC SUP, independently of IBS bowel habit. EcN 108 induced a significant recovery of permeability rate compared to IBS SUP. Permeability increase induced by IBS SUP significantly correlated with severity and frequency of abdominal pain and abdominal distension. The co-incubation of EcN and IBS SUP abolished the above significant correlations. Conclusions and Inferences: EcN reinforces the integrity of Caco-2 monolayer and reverts the increase of permeability induced by mediators released by IBS biopsies. Future studies should investigate EcN therapeutic potentials in IBS. © 2018 John Wiley & Sons Ltd","Escherichia coli Nissle 1917; irritable bowel syndrome; permeability; probiotics","fluorescein; gamma interferon; probiotic agent; proteinase activated receptor 2; sligrl protein; sup protein; tumor necrosis factor; unclassified drug; adult; aged; Article; Caco-2 cell line; cell membrane permeability; clinical article; controlled study; epithelium cell; Escherichia coli; Escherichia coli nissle 1917; female; human; human cell; human tissue; in vitro study; intestine biopsy; irritable colon; male; nonhuman; oral biopsy; phenotype; priority journal","","fluorescein, 2321-07-5, 91316-42-6; gamma interferon, 82115-62-6","","","Ministero dell’Istruzione, dell’Università e della Ricerca, MIUR; Fondazione del Monte di Bologna e Ravenna; Università di Bologna, UNIBO","The study was supported in part by the Italian Ministry of Education, University and Research and funds from the University of Bologna RFO to GB. GB is a recipient of an educational grant from Fondazione del Monte di Bologna e Ravenna, Bologna, Italy. GB is recipient of a research support from Ca.Di.Group S.r.l., Rome, Italy.","Mearin F., Lacy B.E., Chang L., Et al., Bowel disorders, Gastroenterology, 150, pp. 1393-1407, (2016); Ford A.C., Lacy B.E., Talley N.J., Irritable bowel syndrome, N Engl J Med, 376, pp. 2566-2578, (2017); Barbara G., Stanghellini V., De Giorgio R., Et al., Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome, Gastroenterology, 126, pp. 693-702, (2004); Cremon C., Carini G., Wang B., Et al., Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome, Am J Gastroenterol, 106, pp. 1290-1298, (2011); Barbara G., Wang B., Stanghellini V., Et al., Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome, Gastroenterology, 132, pp. 26-37, (2007); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Piche T., Barbara G., Aubert P., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Vivinus-Nebot M., Dainese R., Anty R., Et al., Combination of allergic factors can worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells, Am J Gastroenterol, 107, pp. 75-81, (2012); Simren M., Barbara G., Flint H.J., Et al., Intestinal microbiota in functional bowel disorders: a Rome foundation report, Gut, 62, pp. 159-176, (2013); Nusrat A., Turner J.R., Madara J.L., Molecular physiology and pathophysiology of tight junctions. IV. Regulation of tight junctions by extracellular stimuli: nutrients, cytokines, and immune cells, Am J Physiol Gastrointest Liver Physiol, 279, pp. G851-G857, (2000); Tsukita S., Furuse M., Itoh M., Structural and signalling molecules come together at tight junctions, Curr Opin Cell Biol, 11, pp. 628-633, (1999); Cunningham K.E., Turner J.R., Myosin light chain kinase: pulling the strings of epithelial tight junction function, Ann N Y Acad Sci, 1258, pp. 34-42, (2012); Coeffier M., Claeyssens S., Bensifi M., Et al., Influence of leucine on protein metabolism, phosphokinase expression, and cell proliferation in human duodenum1,3, Am J Clin Nutr, 93, pp. 1255-1262, (2011); Hill C., Guarner F., Reid G., Et al., Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic, Nat Rev Gastroenterol Hepatol, 11, pp. 506-514, (2014); Kumar M., Nagpal R., Verma V., Et al., Probiotic metabolites as epigenetic targets in the prevention of colon cancer, Nutr Rev, 71, pp. 23-34, (2013); Reid G., Younes J.A., Van der Mei H.C., Gloor G.B., Knight R., Busscher H.J., Microbiota restoration: natural and supplemented recovery of human microbial communities, Nat Rev Microbiol, 9, pp. 27-38, (2011); Ukena S.N., Singh A., Dringenberg U., Et al., Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity, PLoS ONE, 2, (2007); Mennigen R., Nolte K., Rijcken E., Et al., Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis, Am J Physiol Gastrointest Liver Physiol, 296, pp. G1140-G1149, (2009); Llopis M., Antolin M., Carol M., Et al., Lactobacillus casei downregulates commensals’ inflammatory signals in Crohn’s disease mucosa, Inflamm Bowel Dis, 15, pp. 275-283, (2009); Patzer S.I., Baquero M.R., Bravo D., Moreno F., Hantke K., The colicin G, H and X determinants encode microcins M and H47, which might utilize the catecholate siderophore receptors FepA, Cir, Fiu and IroN, Microbiology, 149, pp. 2557-2570, (2003); Altenhoefer A., Oswald S., Sonnenborn U., Et al., The probiotic Escherichia coli strain Nissle 1917 interferes with invasion of human intestinal epithelial cells by different enteroinvasive bacterial pathogens, FEMS Immunol Med Microbiol, 40, pp. 223-229, (2004); Lodinova-Zadnikova R., Sonnenborn U., Effect of preventive administration of a nonpathogenic Escherichia coli strain on the colonization of the intestine with microbial pathogens in newborn infants, Biol Neonate, 71, pp. 224-232, (1997); Wehkamp J., Harder J., Wehkamp K., Et al., NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium, Infect Immun, 72, pp. 5750-5758, (2004); Westendorf A.M., Gunzer F., Deppenmeier S., Et al., Intestinal immunity of Escherichia coli NISSLE 1917: a safe carrier for therapeutic molecules, FEMS Immunol Med Microbiol, 43, pp. 373-384, (2005); Zyrek A.A., Cichon C., Helms S., Enders C., Sonnenborn U., Schmidt M.A., Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair, Cell Microbiol, 9, pp. 804-816, (2007); Kruis W., Schutz E., Fric P., Fixa B., Judmaier G., Stolte M., Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis, Aliment Pharmacol Ther, 11, pp. 853-858, (1997); Rembacken B.J., Snelling A.M., Hawkey P.M., Chalmers D.M., Axon A.T., Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial, Lancet, 354, pp. 635-639, (1999); Dignass A., Lindsay J.O., Sturm A., Et al., Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management, J Crohns Colitis, 6, pp. 991-1030, (2012); Talley N.J., Phillips S.F., Melton J., Wiltgen C., Zinsmeister A.R., A patient questionnaire to identify bowel disease, Ann Intern Med, 111, pp. 671-674, (1989); Moayyedi P., Ford A.C., Talley N.J., Et al., The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review, Gut, 59, pp. 325-332, (2010); Ford A.C., Quigley E.M., Lacy B.E., Et al., Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis, Am J Gastroenterol, 109, pp. 1547-1561, (2014); Cremon C., Gargano L., Morselli-Labate A.M., Et al., Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms, Am J Gastroenterol, 104, pp. 392-400, (2009); Wang H., Bastian S.E., Cheah K.Y., Lawrence A., Howarth G.S., Escherichia coli Nissle 1917-derived factors reduce cell death and late apoptosis and increase transepithelial electrical resistance in a model of 5-fluorouracil-induced intestinal epithelial cell damage, Cancer Biol Ther, 15, pp. 560-569, (2014); Veltman K., Hummel S., Cichon C., Sonnenborn U., Schmidt M.A., Identification of specific miRNAs targeting proteins of the apical junctional complex that simulate the probiotic effect of E. coli Nissle 1917 on T84 epithelial cells, Int J Biochem Cell Biol, 2012, 44, pp. 341-349, (1917); Kruis W., Chrubasik S., Boehm S., Stange C., Schulze J., A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome, Int J Colorectal Dis, 27, pp. 467-474, (2012); Faghihi A.H., Agah S., Masoudi M., Ghafoori S.M., Eshraghi A., Efficacy of probiotic Escherichia coli Nissle 1917 in patients with irritable bowel syndrome: a double blind placebo-controlled randomized trial, Acta Med Indones, 47, pp. 201-208, (2015); Nasser Y., Boeckxstaens G.E., Wouters M.M., Schemann M., Vanner S., Using human intestinal biopsies to study the pathogenesis of irritable bowel syndrome, Neurogastroenterol Motil, 26, pp. 455-469, (2014); Coelho A.M., Vergnolle N., Guiard B., Fioramonti J., Bueno L., Proteinases and proteinase-activated receptor 2: a possible role to promote visceral hyperalgesia in rats, Gastroenterology, 122, pp. 1035-1047, (2002); Jacob C., Yang P.C., Darmoul D., Et al., Mast cell tryptase controls paracellular permeability of the intestine. Role of protease-activated receptor 2 and beta-arrestins, J Biol Chem, 280, pp. 31936-31948, (2005); Wang F., Graham W.V., Wang Y., Witkowski E.D., Schwarz B.T., Turner J.R., Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression, Am J Pathol, 166, pp. 409-419, (2005); Utech M., Ivanov A.I., Samarin S.N., Et al., Mechanism of IFN-gamma-induced endocytosis of tight junction proteins: myosin II-dependent vacuolarization of the apical plasma membrane, Mol Biol Cell, 16, pp. 5040-5052, (2005); Gecse K., Roka R., Ferrier L., Et al., Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity, Gut, 57, pp. 591-599, (2008); Hughes P.A., Harrington A.M., Castro J., Et al., Sensory neuro-immune interactions differ between irritable bowel syndrome subtypes, Gut, 62, pp. 1456-1465, (2013); Bashashati M., Rezaei N., Shafieyoun A., Et al., Cytokine imbalance in irritable bowel syndrome: a systematic review and meta-analysis, Neurogastroenterol Motil, 26, pp. 1036-1048, (2014); Barbaro M.R., Di Sabatino A., Cremon C., Et al., Interferon-gamma is increased in the gut of patients with irritable bowel syndrome and modulates serotonin metabolism, Am J Physiol Gastrointest Liver Physiol, 310, pp. G439-G447, (2016); O'Neill L.A., The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress, Immunol Rev, 226, pp. 10-18, (2008); Dlugosz A., Zakikhany K., Acevedo N., D'Amato M., Lindberg G., Increased expression of toll-like receptors 4, 5, and 9 in small bowel mucosa from patients with irritable bowel syndrome, Biomed Res Int, 2017, (2017); Brint E.K., MacSharry J., Fanning A., Shanahan F., Quigley E.M., Differential expression of toll-like receptors in patients with irritable bowel syndrome, Am J Gastroenterol, 106, pp. 329-336, (2011); Ohman L., Isaksson S., Lindmark A.C., Et al., T-cell activation in patients with irritable bowel syndrome, Am J Gastroenterol, 104, pp. 1205-1212, (2009); Schoepfer A.M., Schaffer T., Seibold-Schmid B., Muller S., Seibold F., Antibodies to flagellin indicate reactivity to bacterial antigens in IBS patients, Neurogastroenterol Motil, 20, pp. 1110-1118, (2008); Langhorst J., Junge A., Rueffer A., Et al., Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome, Am J Gastroenterol, 104, pp. 404-410, (2009); Hafez M., Hayes K., Goldrick M., Grencis R.K., Roberts I.S., The K5 capsule of Escherichia coli strain Nissle 1917 is important in stimulating expression of Toll-like receptor 5, CD14, MyD88, and TRIF together with the induction of interleukin-8 expression via the mitogen-activated protein kinase pathway in epithelial cells, Infect Immun, 78, pp. 2153-2162, (2010); Cross M.L., Ganner A., Teilab D., Fray L.M., Patterns of cytokine induction by gram-positive and gram-negative probiotic bacteria, FEMS Immunol Med Microbiol, 42, pp. 173-180, (2004); Ukena S.N., Westendorf A.M., Hansen W., Et al., The host response to the probiotic Escherichia coli strain Nissle 1917: specific up-regulation of the proinflammatory chemokine MCP-1, BMC Med Genet, 6, (2005); Sturm A., Rilling K., Baumgart D.C., Et al., Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling, Infect Immun, 73, pp. 1452-1465, (2005); Perez-Berezo T., Pujo J., Martin P., Et al., Identification of an analgesic lipopeptide produced by the probiotic Escherichia coli strain Nissle 1917, Nat Commun, 8, (2017); Martinez C., Lobo B., Pigrau M., Et al., Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, pp. 1160-1168, (2013)","G. Barbara; Department of Medical and Surgical Sciences (DIMEC), Center for Applied Biomedical Research (CRBA), Alma Mater Studiorum - University of Bologna and S. Orsola-Malpighi Hospital, Bologna, Italy; email: giovanni.barbara@unibo.it","","Blackwell Publishing Ltd","","","","","","13501925","","NMOTE","","English","Neurogastroenterol. Motil.","Article","Final","","Scopus","2-s2.0-85050077165"

"Ludidi S.; Jonkers D.; Elamin E.; Pieters H.-J.; Schaepkens E.; Bours P.; Kruimel J.; Conchillo J.; Masclee A.","Ludidi, Samefko (53984561400); Jonkers, Daisy (6701864464); Elamin, Elhaseen (55189305700); Pieters, Harm-Jan (55625655500); Schaepkens, Esther (56644710000); Bours, Paul (36162832800); Kruimel, Joanna (56036414600); Conchillo, José (12766784800); Masclee, Ad (7103116978)","53984561400; 6701864464; 55189305700; 55625655500; 56644710000; 36162832800; 56036414600; 12766784800; 7103116978","The intestinal barrier in irritable bowel syndrome: Subtype-specific effects of the systemic compartment in an In Vitro model","2015","PLoS ONE","10","5","0123498","","","","21","10.1371/journal.pone.0123498","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84929346679&doi=10.1371%2fjournal.pone.0123498&partnerID=40&md5=13531909137383de5438c89be4aa6e76","Division of Gastroenterology-Hepatology, Department of Internal Medicine, NUTRIM School for Nutrition, Maastricht, Netherlands","Ludidi S., Division of Gastroenterology-Hepatology, Department of Internal Medicine, NUTRIM School for Nutrition, Maastricht, Netherlands; Jonkers D., Division of Gastroenterology-Hepatology, Department of Internal Medicine, NUTRIM School for Nutrition, Maastricht, Netherlands; Elamin E., Division of Gastroenterology-Hepatology, Department of Internal Medicine, NUTRIM School for Nutrition, Maastricht, Netherlands; Pieters H.-J., Division of Gastroenterology-Hepatology, Department of Internal Medicine, NUTRIM School for Nutrition, Maastricht, Netherlands; Schaepkens E., Division of Gastroenterology-Hepatology, Department of Internal Medicine, NUTRIM School for Nutrition, Maastricht, Netherlands; Bours P., Division of Gastroenterology-Hepatology, Department of Internal Medicine, NUTRIM School for Nutrition, Maastricht, Netherlands; Kruimel J., Division of Gastroenterology-Hepatology, Department of Internal Medicine, NUTRIM School for Nutrition, Maastricht, Netherlands; Conchillo J., Division of Gastroenterology-Hepatology, Department of Internal Medicine, NUTRIM School for Nutrition, Maastricht, Netherlands; Masclee A., Division of Gastroenterology-Hepatology, Department of Internal Medicine, NUTRIM School for Nutrition, Maastricht, Netherlands","Background Irritable bowel syndrome (IBS) is a disorder with multifactorial pathophysiology. Intestinal barrier may be altered, especially in diarrhea-predominant IBS (IBS-D). Several mediators may contribute to increased intestinal permeability in IBS. Aim We aimed to assess effects of tryptase and LPS on in vitro permeability using a 3- dimensional cell model after basolateral cell exposure. Furthermore, we assessed the extent to which these mediators in IBS plasma play a role in intestinal barrier function. Materials and Methods Caco-2 cells were grown in extracellular matrix to develop into polarized spheroids and were exposed to tryptase (10 - 50 mU), LPS (1 - 50 ng/mL) and two-fold diluted plasma samples of 7 patients with IBS-D, 7 with constipation-predominant IBS (IBS-C) and 7 healthy controls (HC). Barrier function was assessed by the flux of FITC-dextran (FD4) using live cell imaging. Furthermore, plasma tryptase and LPS were determined. Results Tryptase (20 and 50 mU) and LPS (6.25 - 50 ng/mL) significantly increased Caco-2 permeability versus control (all P< 0.05). Plasma of IBS-D only showed significantly elevated median tryptase concentrations (7.1 [3.9 - 11.0] vs. 4.2 [2.2 - 7.0] vs. 4.2 [2.5 - 5.9] μg/mL; P<0.05) and LPS concentrations (3.65 [3.00 - 6.10] vs. 3.10 [2.60-3.80] vs. 2.65 [2.40 - 3.40] EU/ml; P< 0.05) vs. IBS-C and HC. Also, plasma of IBS-D increased Caco-2 permeability versus HC (0.14450 ± 0.00472 vs. 0.00021 ± 0.00003; P < 0.001), which was attenuated by selective inhibition of tryptase and LPS (P< 0.05). Conclusion Basolateral exposure of spheroids to plasma of IBS-D patients resulted in a significantly increased FD4 permeation, which was partially abolished by selective inhibition of tryptase and LPS. These findings point to a role of systemic tryptase and LPS in the epithelial barrier alterations observed in patients with IBS-D.  © 2015 Ludidi et al.","","Caco-2 Cells; Extracellular Matrix; Humans; Intestines; Irritable Bowel Syndrome; Lipopolysaccharides; Tryptases; fluorescein isothiocyanate dextran; lipopolysaccharide; tryptase; lipopolysaccharide; tryptase; Article; CACO 2 cell line; cell viability; clinical article; constipation; controlled study; enzyme blood level; enzyme inhibition; exposure; female; human; human cell; in vitro study; intestinal barrier; intestine mucosa permeability; irritable colon; male; permeability barrier; plasma; Caco-2 cell line; drug effects; extracellular matrix; intestine; irritable colon; metabolism","","fluorescein isothiocyanate dextran, 60842-46-8; tryptase, 97501-93-4; Lipopolysaccharides, ; Tryptases, ","","","","","Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C., Functional bowel disorders, Gastroenterology., 130, 5, pp. 1480-1491, (2006); Drossman D.A., Camilleri M., Mayer E.A., Whitehead W.E., Aga technical review on irritable bowel syndrome, Gastroenterology., 123, 6, pp. 2108-2131, (2002); Azpiroz F., Bouin M., Camilleri M., Mayer E.A., Poitras P., Serra J., Et al., Mechanisms of hypersensitivity in ibs and functional disorders, Neurogastroenterol Motil., 19, 1, pp. 62-88, (2007); Cremon C., Gargano L., Morselli-Labate A.M., Santini D., Cogliandro R.F., De Giorgio R., Et al., Mucosal immune activation in irritable bowel syndrome: Gender-dependence and association with digestive symptoms, Am J Gastroenterol., 104, 2, pp. 392-400, (2009); Barbara G., Stanghellini V., De Giorgio R., Cremon C., Cottrell G.S., Santini D., Et al., Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome, Gastroenterology., 126, 3, pp. 693-702, (2004); Ringel Y., Maharshak N., The intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome, Am J Physiol Gastrointest Liver Physiol., 305, 8, pp. G529-541, (2013); Chadwick V.S., Chen W., Shu D., Paulus B., Bethwaite P., Tie A., Et al., Activation of the mucosal immune system in irritable bowel syndrome, Gastroenterology., 122, 7, pp. 1778-1783, (2002); Mertz H., Naliboff B., Munakata J., Niazi N., Mayer E.A., Altered rectal perception is a biological marker of patients with irritable bowel syndrome, Gastroenterology., 109, 1, pp. 40-52, (1995); Camilleri M., Lasch K., Zhou W., The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome, Am J Physiol Gastrointest Liver Physiol., (2012); Barbara G., Mucosal barrier defects in irritable bowel syndrome. Who left the door open?, Am J Gastroenterol., 101, 6, pp. 1295-1298, (2006); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Lecleire S., Antonietti M., Gourcerol G., Et al., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am J Gastroenterol., 106, 12, pp. 2165-2173, (2011); Dunlop S.P., Hebden J., Campbell E., Naesdal J., Olbe L., Perkins A.C., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol., 101, 6, pp. 1288-1294, (2006); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain., 146, 1-2, pp. 41-46, (2009); Marshall J.K., Thabane M., Garg A.X., Clark W., Meddings J., Collins S.M., Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in walkerton ontario, Aliment Pharmacol Ther., 20, 11-12, pp. 1317-1322, (2004); Ossovskaya V.S., Bunnett N.W., Protease-Activated receptors: Contribution to physiology and disease, Physiol Rev., 84, 2, pp. 579-621, (2004); Annahazi A., Ferrier L., Bezirard V., Leveque M., Eutamene H., Ait-Belgnaoui A., Et al., Luminal cysteine-proteases degrade colonic tight junction structure and are responsible for abdominal pain in constipation-predominant ibs, Am J Gastroenterol., 108, 8, pp. 1322-1331, (2013); Gecse K., Roka R., Ferrier L., Leveque M., Eutamene H., Cartier C., Et al., Increased faecal serine protease activity in diarrhoeic ibs patients: A colonic lumenal factor impairing colonic permeability and sensitivity, Gut., 57, 5, pp. 591-599, (2008); Roka R., Rosztoczy A., Leveque M., Izbeki F., Nagy F., Molnar T., Et al., A pilot study of fecal serineprotease activity: A pathophysiologic factor in diarrhea-predominant irritable bowel syndrome, Clin Gastroenterol Hepatol., 5, 5, pp. 550-555, (2007); Lee J.W., Park J.H., Park D.I., Park J.H., Kim H.J., Cho Y.K., Et al., Subjects with diarrhea-predominant ibs have increased rectal permeability responsive to tryptase, Dig Dis Sci., 55, 10, pp. 2922-2928, (2010); Benoit R., Rowe S., Watkins S.C., Boyle P., Garrett M., Alber S., Et al., Pure endotoxin does not pass across the intestinal epithelium in vitro, Shock., 10, 1, pp. 43-48, (1998); Ge Y., Ezzell R.M., Warren H.S., Localization of endotoxin in the rat intestinal epithelium, J Infect Dis., 182, 3, pp. 873-881, (2000); Elamin E., Jonkers D., Juuti-Uusitalo K., Van Ijzendoorn S., Troost F., Duimel H., Et al., Effects of ethanol and acetaldehyde on tight junction integrity: In vitro study in a three dimensional intestinal epithelial cell culture model, PLoS One., 7, 4, (2012); Elamin E., Masclee A., Juuti-Uusitalo K., Van Ijzendoorn S., Troost F., Pieters H.J., Et al., Fatty acid ethyl esters induce intestinal epithelial barrier dysfunction via a reactive oxygen species-dependent mechanism in a three-dimensional cell culture model, PLoS One., 8, 3, (2013); Collins T.J., Imagej for microscopy, Biotechniques., 43, 1, pp. 25-30, (2007); Cuellar A., Fonseca A., Gomez A., Effect of lipopolysaccharides on human dendritic cell cultures and its inhibition by polymyxin b, Biomedica., 24, 4, pp. 413-422, (2004); Zhou Q., Souba W.W., Croce C.M., Verne G.N., Microrna-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome, Gut., 59, 6, pp. 775-784, (2010); Spiller R.C., Jenkins D., Thornley J.P., Hebden J.M., Wright T., Skinner M., Et al., Increased rectal mucosal enteroendocrine cells t lymphocytes and increased gut permeability following acute campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut., 47, 6, pp. 804-811, (2000); Matricon J., Meleine M., Gelot A., Piche T., Dapoigny M., Muller E., Et al., Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome, Aliment Pharmacol Ther., 36, 11-12, pp. 1009-1031, (2012); Lee H., Park J.H., Park D.I., Kim H.J., Cho Y.K., Sohn C.I., Jet al. Mucosal mast cell count is associated with intestinal permeability in patients with diarrhea predominant irritable bowel syndrome, J Neurogastroenterol Motil., 19, 2, pp. 244-250, (2013); Amadesi S., Nie J., Vergnolle N., Cottrell G.S., Grady E.F., Trevisani M., Et al., Protease-Activated receptor 2 sensitizes the capsaicin receptor transient receptor potential vanilloid receptor 1 to induce hyperalgesia, J Neurosci., 24, 18, pp. 4300-4312, (2004); Bohm S.K., Kong W., Bromme D., Smeekens S.P., Anderson D.C., Connolly A., Et al., Molecular cloning, expression and potential functions of the human proteinase-Activated receptor-2, Biochem J., 314, pp. 1009-1016, (1996); Maltman D.J., Przyborski S.A., Developments in three-dimensional cell culture technology aimed at improving the accuracy of in vitro analyses, Biochem Soc Trans., 38, 4, pp. 1072-1075, (2010); Juuti-Uusitalo K., Klunder L.J., Sjollema K.A., Mackovicova K., Ohgaki R., Hoekstra D., Et al., Differential effects of tnf (tnfsf2) and ifn-gamma on intestinal epithelial cell morphogenesis and barrier function in three-dimensional culture, PLoS One., 6, 8, (2011); Elamin E., Masclee A., Troost F., Dekker J., Jonkers D., Activation of the epithelial-To-mesenchymal transition factor snail mediates acetaldehyde-induced intestinal epithelial barrier disruption, Alcohol Clin Exp Res., (2013); Elamin E., Masclee A., Dekker J., Jonkers D., Ethanol disrupts intestinal epithelial tight junction integrity through intracellular calcium-mediated rho/rock activation, Am J Physiol Gastrointest Liver Physiol., 306, 8, pp. G677-685, (2014); Wilcz-Villega E.M., McClean S., O'Sullivan M.A., Mast cell tryptase reduces junctional adhesion molecule-A (jam-A) expression in intestinal epithelial cells: Implications for the mechanisms of barrier dysfunction in irritable bowel syndrome, Am J Gastroenterol., 108, 7, pp. 1140-1151, (2013); Taira M., Tamaoki J., Kondo M., Kawatani K., Nagai A., Serum b12 tryptase level as a marker of allergic airway inflammation in asthma, J Asthma., 39, 4, pp. 315-322, (2002); Hanson P.J., Moran A.P., Butler K., Paracellular permeability is increased by basal lipopolysaccharide in a primary culture of colonic epithelial cells; an effect prevented by an activator of toll-like receptor-2, Innate Immun., (2007); Guo S., Al-Sadi R., Said H.M., Ma T.Y., Lipopolysaccharide causes an increase in intestinal tight junction permeability in vitro and in vivo by inducing enterocyte membrane expression and localization of tlr-4 and cd14, Am J Pathol., 182, 2, pp. 375-387, (2013); Pastor Rojo O., Lopez San Roman A., Albeniz Arbizu E., De La Hera Martinez A., Ripoll Sevillano E., Albillos Martinez A., Serum lipopolysaccharide-binding protein in endotoxemic patients with inflammatory bowel disease, Inflamm Bowel Dis., 13, 3, pp. 269-277, (2007); O'Dwyer S.T., Michie H.R., Ziegler T.R., Revhaug A., Smith R.J., Wilmore D.W., A single dose of endotoxin increases intestinal permeability in healthy humans, Arch Surg., 123, 12, pp. 1459-1464, (1988); Keszthelyi D., Masclee A.A., Effects of proton pump inhibitor therapy in the distal gut: Putting the pieces together, Dig Dis Sci., 57, 10, pp. 2487-2489, (2012); Keszthelyi D., Dackus G.H., Masclee G.M., Kruimel J.W., Masclee A.A., Increased proton pump inhibitor and nsaid exposure in irritable bowel syndrome: Results from a case-control study, BMC Gastroenterol., 12, (2012); Ohmori T., Yang J.L., Price J.O., Arteaga C.L., Blockade of tumor cell transforming growth factor-betas enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy, Exp Cell Res., 245, 2, pp. 350-359, (1998); Kim J.B., Three-dimensional tissue culture models in cancer biology, Semin Cancer Biol., 15, 5, pp. 365-377, (2005)","","","Public Library of Science","","","","","","19326203","","POLNC","25978614","English","PLoS ONE","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-84929346679"

"Shulman R.J.; Hollister E.B.; Cain K.; Czyzewski D.I.; Self M.M.; Weidler E.M.; Devaraj S.; Luna R.A.; Versalovic J.; Heitkemper M.","Shulman, Robert J. (56961627200); Hollister, Emily B. (35224866500); Cain, Kevin (7103341073); Czyzewski, Danita I. (6701585207); Self, Mariella M. (55695874800); Weidler, Erica M. (26424158700); Devaraj, Sridevi (7004533440); Luna, Ruth Ann (15019309900); Versalovic, James (7003744341); Heitkemper, Margaret (7005514887)","56961627200; 35224866500; 7103341073; 6701585207; 55695874800; 26424158700; 7004533440; 15019309900; 7003744341; 7005514887","Psyllium Fiber Reduces Abdominal Pain in Children With Irritable Bowel Syndrome in a Randomized, Double-Blind Trial","2017","Clinical Gastroenterology and Hepatology","15","5","","712","719.e4","","72","10.1016/j.cgh.2016.03.045","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84994662238&doi=10.1016%2fj.cgh.2016.03.045&partnerID=40&md5=05c2286a7f26652e01ae7b698229cea7","Department of Pediatrics, Baylor College of Medicine, United States; Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, United States; Department of Pathology and Immunology, Baylor College of Medicine, United States; Children's Nutrition Research Center, United States; Department of Pathology, Texas Children's Hospital, United States; Texas Children's Hospital, United States; Texas Children's Microbiome Center, United States; Department of Biostatistics and Office of Nursing Research, University of Washington, Seattle, Washington, United States; Department of Biobehavioral Nursing and Health Systems, University of Washington, Seattle, Washington, United States","Shulman R.J., Department of Pediatrics, Baylor College of Medicine, United States, Children's Nutrition Research Center, United States, Texas Children's Hospital, United States; Hollister E.B., Department of Pathology and Immunology, Baylor College of Medicine, United States, Department of Pathology, Texas Children's Hospital, United States, Texas Children's Hospital, United States, Texas Children's Microbiome Center, United States; Cain K., Department of Biostatistics and Office of Nursing Research, University of Washington, Seattle, Washington, United States; Czyzewski D.I., Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, United States, Texas Children's Hospital, United States; Self M.M., Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, United States, Texas Children's Hospital, United States; Weidler E.M., Department of Pediatrics, Baylor College of Medicine, United States, Children's Nutrition Research Center, United States, Texas Children's Hospital, United States; Devaraj S., Department of Pathology and Immunology, Baylor College of Medicine, United States, Department of Pathology, Texas Children's Hospital, United States, Texas Children's Hospital, United States, Texas Children's Microbiome Center, United States; Luna R.A., Department of Pathology and Immunology, Baylor College of Medicine, United States, Department of Pathology, Texas Children's Hospital, United States, Texas Children's Hospital, United States, Texas Children's Microbiome Center, United States; Versalovic J., Department of Pathology and Immunology, Baylor College of Medicine, United States, Department of Pathology, Texas Children's Hospital, United States, Texas Children's Hospital, United States, Texas Children's Microbiome Center, United States; Heitkemper M., Department of Biobehavioral Nursing and Health Systems, University of Washington, Seattle, Washington, United States","Background & Aims We sought to determine the efficacy of psyllium fiber treatment on abdominal pain and stool patterns in children with irritable bowel syndrome (IBS). We evaluated effects on breath hydrogen and methane production, gut permeability, and microbiome composition. We also investigated whether psychological characteristics of children or parents affected the response to treatment. Methods We performed a randomized, double-blind trial of 103 children (mean age, 13 ± 3 y) with IBS seen at primary or tertiary care settings. After 2 weeks on their habitual diet, children began an 8-day diet excluding carbohydrates thought to cause symptoms of IBS. Children with ≥75% improvement in abdominal pain were excluded (n = 17). Children were assigned randomly to groups given psyllium (n = 37) or placebo (maltodextrin, n = 47) for 6 weeks. Two-week pain and stool diaries were compared at baseline and during the final 2 weeks of treatment. We assessed breath hydrogen and methane production, intestinal permeability, and the composition of the microbiome before and after administration of psyllium or placebo. Psychological characteristics of children were measured at baseline. Results Children in the psyllium group had a greater reduction in the mean number of pain episodes than children in the placebo group (mean reduction of 8.2 ± 1.2 after receiving psyllium vs mean reduction of 4.1 ± 1.3 after receiving placebo; P = .03); the level of pain intensity did not differ between the groups. Psychological characteristics were not associated with response. At the end of the study period, the percentage of stools that were normal (Bristol scale scores, 3–5), breath hydrogen or methane production, intestinal permeability, and microbiome composition were similar between groups. Conclusions Psyllium fiber reduced the number of abdominal pain episodes in children with IBS, independent of psychological factors. Psyllium did not alter breath hydrogen or methane production, gut permeability, or microbiome composition. ClinicalTrials.gov no: NCT00526903. © 2017 AGA Institute","Abdominal Pain; Fiber; Irritable Bowel Syndrome; Microbiome; Psyllium","Abdominal Pain; Adolescent; Breath Tests; Child; Dietary Fiber; Double-Blind Method; Female; Humans; Irritable Bowel Syndrome; Male; Placebos; Psyllium; Treatment Outcome; carbohydrate; hydrogen; ispagula; maltodextrin; methane; placebo; ispagula; placebo; abdominal pain; adolescent; adult; Article; Bristol scale score; child; controlled study; dietary intake; double blind procedure; feces analysis; feeding behavior; female; human; hydrogen breath test; intestine flora; intestine mucosa permeability; irritable colon; major clinical study; male; nonhuman; outcome assessment; pain intensity; preschool child; psychological aspect; randomized controlled trial; rating scale; school child; scoring system; species composition; tertiary health care; treatment duration; treatment response; abdominal pain; administration and dosage; breath analysis; dietary fiber; irritable colon; treatment outcome","","hydrogen, 12385-13-6, 1333-74-0; ispagula, 77462-61-4, 8063-16-9; maltodextrin, 9050-36-6; methane, 74-82-8; Dietary Fiber, ; Placebos, ; Psyllium, ","","","National Institute of Nursing Research, NINR, (R01NR005337); National Institute of Nursing Research, NINR","","Saps M., Seshadri R., Sztainberg M., Et al., A prospective school-based study of abdominal pain and other common somatic complaints in children, J Pediatr, 154, pp. 322-326, (2009); Mobley A.R., Jones J.M., Rodriguez J., Et al., Identifying practical solutions to meet America's fiber needs: proceedings from the Food & Fiber Summit, Nutrients, 6, pp. 2540-2551, (2014); Moayyedi P., Quigley E.M., Lacy B.E., Et al., The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis, Am J Gastroenterol, 109, pp. 1367-1374, (2014); Ruepert L., Quartero A.O., de Wit N.J., Et al., Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome, Cochrane Database Syst Rev, 8, (2011); Czyzewski D.I., Lane M.M., Weidler E.M., Et al., The interpretation of Rome III criteria and method of assessment affect the irritable bowel syndrome classification of children, Aliment Pharmacol Ther, 33, pp. 403-411, (2011); Barrett J.S., Gibson P.R., Fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) and nonallergic food intolerance: FODMAPs or food chemicals?, Therap Adv Gastroenterol, 5, pp. 261-268, (2012); Clemens R., Kranz S., Mobley A.R., Et al., Filling America's fiber intake gap: summary of a roundtable to probe realistic solutions with a focus on grain-based foods, J Nutr, 142, pp. 1390S-1401S, (2012); Von Baeyer C.L., Spagrud L.J., McCormick J.C., Et al., Three new datasets supporting use of the Numerical Rating Scale (NRS-11) for children's self-reports of pain intensity, Pain, 143, pp. 223-227, (2009); Lewis S.J., Heaton K.W., Stool form scale as a useful guide to intestinal transit time, Scand J Gastroenterol, 32, pp. 920-924, (1997); Longstreth G.F., Thompson W.G., Chey W.D., Et al., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Niu H.C., Schoeller D.A., Klein P.D., Improved gas chromatographic quantitation of breath hydrogen by normalization to respiratory carbon dioxide, J Lab Clin Med, 94, pp. 755-763, (1979); McOmber M.E., Ou C.N., Shulman R.J., Effects of timing, sex, and age on site-specific gastrointestinal permeability testing in children and adults, J Pediatr Gastroenterol Nutr, 50, pp. 269-275, (2010); Reynolds C.R., Kamphaus R.W., Behavior assessment system for children, (2004); Walker L.S., Garber J., Greene J.W., Somatization symptoms in pediatric abdominal pain patients: relation to chronicity of abdominal pain and parent somatization, J Abnorm Child Psychol, 19, pp. 379-394, (1991); Van Slyke D.A., Walker L.S., Mothers' responses to children's pain, Clin J Pain, 22, pp. 387-391, (2006); Walker L.S., Smith C.A., Garber J., Et al., Testing a model of pain appraisal and coping in children with chronic abdominal pain, Health Psychol, 24, pp. 364-374, (2005); Varni J.W., Bendo C.B., Denham J., Et al., PedsQL Gastrointestinal Symptoms Scales and Gastrointestinal Worry Scales in pediatric patients with functional and organic gastrointestinal diseases in comparison to healthy controls, Qual Life Res, 24, pp. 363-378, (2015); Derogatis L.R., Lipman R.S., Covi L., SLC-90: an outpatient psychiatric rating scale–preliminary report, Psychopharmacol Bull, 9, pp. 13-28, (1973); Aagaard K., Petrosino J., Keitel W., Et al., The Human Microbiome Project strategy for comprehensive sampling of the human microbiome and why it matters, FASEB J, 27, pp. 1012-1022, (2013); Caporaso J.G., Kuczynski J., Stombaugh J., Et al., QIIME allows analysis of high-throughput community sequencing data, Nat Methods, 7, pp. 335-336, (2010); Edgar R.C., Search and clustering orders of magnitude faster than BLAST, Bioinformatics, 26, pp. 2460-2461, (2010); DeSantis T.Z., Hugenholtz P., Larsen N., Et al., Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB, Appl Environ Microbiol, 72, pp. 5069-5072, (2006); Haas B.J., Gevers D., Earl A.M., Et al., Chimeric 16S rRNA sequence formation and detection in Sanger and 454-pyrosequenced PCR amplicons, Genome Res, 21, pp. 494-504, (2011); Carlson M.J., Moore C.E., Tsai C.M., Et al., Child and parent perceived food-induced gastrointestinal symptoms and quality of life in children with functional gastrointestinal disorders, J Acad Nutr Diet, 114, pp. 403-413, (2014); Feldman W., McGrath P., Hodgson C., Et al., The use of dietary fiber in the management of simple, childhood, idiopathic, recurrent abdominal pain. Results in a prospective, double-blind, randomized, controlled trial, Am J Dis Child, 139, pp. 1216-1218, (1985); Ford A.C., Talley N.J., Spiegel B.M., Et al., Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis, BMJ, 337, (2008); Christensen M.F., Recurrent abdominal pain and dietary fiber, Am J Dis Child, 140, pp. 738-739, (1986); Huertas-Ceballos A.A., Logan S., Bennett C., Et al., Dietary interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood, Cochrane Database Syst Rev, 2, (2014); Marlett J.A., Fischer M.H., The active fraction of psyllium seed husk, Proc Nutr Soc, 62, pp. 207-209, (2003); Marteau P., Flourie B., Cherbut C., Et al., Digestibility and bulking effect of ispaghula husks in healthy humans, Gut, 35, pp. 1747-1752, (1994); Elli M., Cattivelli D., Soldi S., Et al., Evaluation of prebiotic potential of refined psyllium (Plantago ovata) fiber in healthy women, J Clin Gastroenterol, 42, pp. S174-S176, (2008); Shulman R.J., Eakin M.N., Czyzewski D.I., Et al., Increased gastrointestinal permeability and gut inflammation in children with functional abdominal pain and irritable bowel syndrome, J Pediatr, 153, pp. 646-650, (2008); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Kim H., Bartley G.E., Young S.A., Et al., Altered hepatic gene expression profiles associated with improved fatty liver, insulin resistance, and intestinal permeability after hydroxypropyl methylcellulose (HPMC) supplementation in diet-induced obese mice, J Agric Food Chem, 61, pp. 6404-6411, (2013); van Tilburg M.A., Levy R.L., Walker L.S., Et al., Psychosocial mechanisms for the transmission of somatic symptoms from parents to children, World J Gastroenterol, 21, pp. 5532-5541, (2015); Fales J.L., Essner B.S., Harris M.A., Et al., When helping hurts: miscarried helping in families of youth with chronic pain, J Pediatr Psychol, 39, pp. 427-437, (2014); Rao S.S., Yu S., Fedewa A., Systematic review: dietary fibre and FODMAP-restricted diet in the management of constipation and irritable bowel syndrome, Aliment Pharmacol Ther, 41, pp. 1256-1270, (2015); Shulman R.J., Kerzner B., Sloan H.R., Et al., Absorption and oxidation of glucose polymers of different lengths in young infants, Pediatr Res, 20, pp. 740-743, (1986); Shulman R.J., Feste A., Ou C., Absorption of lactose, glucose polymers, or combination in premature infants, J Pediatr, 127, pp. 626-631, (1995); Varni J.W., Shulman R.J., Self M.M., Et al., Symptom profiles in patients with irritable bowel syndrome or functional abdominal pain compared with healthy controls, J Pediatr Gastroenterol Nutr, 61, pp. 323-329, (2015); Cain K.C., Headstrom P., Jarrett M.E., Et al., Abdominal pain impacts quality of life in women with irritable bowel syndrome, Am J Gastroenterol, 101, pp. 124-132, (2006)","R.J. Shulman; Children's Nutrition Research Center, Houston, 1100 Bates Avenue, Room 8072, 77030, United States; email: rshulman@bcm.edu","","W.B. Saunders","","","","","","15423565","","CGHLA","27080737","English","Clin. Gastroenterol. Hepatol.","Article","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-84994662238"

"De Palma G.; Lynch M.D.J.; Lu J.; Dang V.T.; Deng Y.; Jury J.; Umeh G.; Miranda P.M.; Pastor M.P.; Sidani S.; Pinto-Sanchez M.I.; Philip V.; McLean P.G.; Hagelsieb M.-G.; Surette M.G.; Bergonzelli G.E.; Verdu E.F.; Britz-McKibbin P.; Neufeld J.D.; Collins S.M.; Bercik P.","De Palma, Giada (26029304200); Lynch, Michael D.J. (57202459599); Lu, Jun (57199237883); Dang, Vi T. (57191579889); Deng, Yikang (7401531040); Jury, Jennifer (7004287397); Umeh, Genevieve (55931080300); Miranda, Pedro M. (57193534210); Pastor, Marc Pigrau (57193537742); Sidani, Sacha (57206175564); Pinto-Sanchez, Maria Ines (26649598100); Philip, Vivek (57204255186); McLean, Peter G. (57206423778); Hagelsieb, Moreno-Gabriel (57193533839); Surette, Michael G. (7006624110); Bergonzelli, Gabriela E. (6602847479); Verdu, Elena F. (8109011300); Britz-McKibbin, Philip (57203382441); Neufeld, Josh D. (7005470596); Collins, Stephen M. (57203291674); Bercik, Premysl (6602481586)","26029304200; 57202459599; 57199237883; 57191579889; 7401531040; 7004287397; 55931080300; 57193534210; 57193537742; 57206175564; 26649598100; 57204255186; 57206423778; 57193533839; 7006624110; 6602847479; 8109011300; 57203382441; 7005470596; 57203291674; 6602481586","Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice","2017","Science Translational Medicine","9","379","eaaf6397","","","","374","10.1126/scitranslmed.aaf6397","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85014649400&doi=10.1126%2fscitranslmed.aaf6397&partnerID=40&md5=00bf204efe04fccd7c283fba44abc4fa","Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, ON, Canada; Department of Biology, University of Waterloo, Waterloo, ON, Canada; Department of Chemistry and Chemical Biology, McMaster University, Hamilton, ON, Canada; Nestlé Research Center, Lausanne, Switzerland; Department of Biology, Wilfrid Laurier University, Waterloo, ON, Canada","De Palma G., Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, ON, Canada; Lynch M.D.J., Department of Biology, University of Waterloo, Waterloo, ON, Canada; Lu J., Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, ON, Canada; Dang V.T., Department of Chemistry and Chemical Biology, McMaster University, Hamilton, ON, Canada; Deng Y., Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, ON, Canada; Jury J., Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, ON, Canada; Umeh G., Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, ON, Canada; Miranda P.M., Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, ON, Canada; Pastor M.P., Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, ON, Canada; Sidani S., Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, ON, Canada; Pinto-Sanchez M.I., Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, ON, Canada; Philip V., Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, ON, Canada; McLean P.G., Nestlé Research Center, Lausanne, Switzerland; Hagelsieb M.-G., Department of Biology, Wilfrid Laurier University, Waterloo, ON, Canada; Surette M.G., Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, ON, Canada; Bergonzelli G.E., Nestlé Research Center, Lausanne, Switzerland; Verdu E.F., Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, ON, Canada; Britz-McKibbin P., Department of Chemistry and Chemical Biology, McMaster University, Hamilton, ON, Canada; Neufeld J.D., Department of Biology, University of Waterloo, Waterloo, ON, Canada; Collins S.M., Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, ON, Canada; Bercik P., Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, ON, Canada","Irritable bowel syndrome (IBS) is a common disorder characterized by altered gut function and often is accompanied by comorbid anxiety. Although changes in the gut microbiota have been documented, their relevance to the clinical expression of IBS is unknown. To evaluate a functional role for commensal gut bacteria in IBS, we colonized germ-free mice with the fecal microbiota from healthy control individuals or IBS patients with diarrhea (IBS-D), with or without anxiety, and monitored gut function and behavior in the transplanted mice. Microbiota profiles in recipient mice clustered according to the microbiota profiles of the human donors. Mice receiving the IBS-D fecal microbiota showed a taxonomically similar microbial composition to that of mice receiving the healthy control fecal microbiota. However, IBS-D mice showed different serum metabolomic profiles. Mice receiving the IBS-D fecal microbiota, but not the healthy control fecal microbiota, exhibited faster gastrointestinal transit, intestinal barrier dysfunction, innate immune activation, and anxiety-like behavior. These results indicate the potential of the gut microbiota to contribute to both intestinal and behavioral manifestations of IBS-D and suggest the potential value of microbiota-directed therapies in IBS patients. © 2017 The Authors, some rights reserved.","","Adult; Animals; Anxiety; Behavior, Animal; Case-Control Studies; Colon; Fecal Microbiota Transplantation; Feces; Female; Gastrointestinal Microbiome; Gastrointestinal Tract; Gastrointestinal Transit; Germ-Free Life; Humans; Irritable Bowel Syndrome; Male; Metabolomics; Mice; Tissue Donors; beta defensin 3; C reactive protein; chemokine receptor CCR2; chemokine receptor CXCR3; chemokine receptor CXCR4; complement component C3; gamma interferon; glucocorticoid receptor; glycerophosphorylcholine; immunoglobulin enhancer binding protein; interleukin 10; interleukin 1beta; interleukin 2; interleukin 6; interleukin 8; lysophosphatidylcholine; mitogen activated protein kinase p38; monocyte chemotactic protein 1; oleic acid; palmitic acid; pattern recognition receptor; phosphatidylserine; stearic acid; tumor necrosis factor; adult; animal experiment; animal tissue; anxiety; Article; CD3+ T lymphocyte; clinical article; controlled study; diarrhea; fecal microbiota transplantation; female; gastrointestinal transit; gene expression regulation; germfree mouse; human; innate immunity; intestine function; intestine motility; intestine mucosa permeability; irritable colon; lymphocyte count; male; mouse; nonhuman; recipient; Swiss Webster mouse; upregulation; animal; animal behavior; anxiety; blood; case control study; colon; donor; feces; gastrointestinal tract; germfree animal; immunology; intestine flora; irritable colon; metabolism; metabolomics; microbiology; pathophysiology","","C reactive protein, 9007-41-4; chemokine receptor CXCR4, 188900-71-2; complement component C3, 80295-41-6; gamma interferon, 82115-62-6; glycerophosphorylcholine, 4217-84-9, 563-24-6; interleukin 2, 85898-30-2; interleukin 8, 114308-91-7; lysophosphatidylcholine, 93794-93-5; oleic acid, 112-80-1, 115-06-0; palmitic acid, 57-10-3; stearic acid, 57-11-4, 646-29-7","","","Canadian Institutes of Health Research, IRSC; Canadian Association of Gastroenterology, CAG","This study was supported by grants from Canadian Institutes of Health Research (CIHR) and Nestlé Switzerland. P.B. is a recipient of a Hamilton Health Sciences Early Career Research Award. G.D.P. is a recipient of a CIHR-Canadian Association of Gastroenterology Postdoctoral Fellowship.","Sekirov I., Russell S.L., Antunes L.C.M., Finlay B.B., Gut microbiota in health and disease, Physiol. Rev., 90, pp. 859-904, (2010); Hooper L.V., Littman D.R., Macpherson A.J., Interactions between the microbiota and the immune system, Science, 336, pp. 1268-1273, (2012); Husebye E., Hellstrom P.M., Sundler F., Chen J., Midtvedt T., Influence of microbial species on small intestinal myoelectric activity and transit in germ-free rats, Am. J. Physiol. Gastrointest. Liver Physiol., 280, pp. G368-G380, (2001); Ridaura V.K., Faith J.J., Rey F.E., Cheng J., Duncan A.E., Kau A.L., Griffin N.W., Lombard V., Henrissat B., Bain J.R., Muehlbauer M.J., Ilkayeva O., Semenkovich C.F., Funai K., Hayashi D.K., Lyle B.J., Martini M.C., Ursell L.K., Clemente J.C., Van Treuren W., Walters W.A., Knight R., Newgard C.B., Heath A.C., Gordon J.I., Gut microbiota from twins discordant for obesity modulate metabolism in mice, Science, 341, (2013); Verdu E.F., Bercik P., Verma-Gandhu M., Huang X.-X., Blennerhassett P., Jackson W., Mao Y., Wang L., Rochat F., Collins S.M., Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice, Gut, 55, pp. 182-190, (2006); Nieuwdorp M., Gilijamse P.W., Pai N., Kaplan L.M., Role of the microbiome in energy regulation and metabolism, Gastroenterology, 146, pp. 1525-1533, (2014); Schnabl B., Brenner D.A., Interactions between the intestinal microbiome and liver diseases, Gastroenterology, 146, pp. 1513-1524, (2014); Amaral F.A., Sachs D., Costa V.V., Fagundes C.T., Cisalpino D., Cunha T.M., Ferreira S.H., Cunha F.Q., Silva T.A., Nicoli J.R., Vieira L.Q., Souza D.G., Teixeira M.M., Commensal microbiota is fundamental for the development of inflammatory pain, Proc. Natl. Acad. Sci. U.S.A., 105, pp. 2193-2197, (2008); Heijtz R.D., Wang S., Anuar F., Qian Y., Bjorkholm B., Samuelsson A., Hibberd M.L., Forssberg H., Pettersson S., Normal gut microbiota modulates brain development and behavior, Proc. Natl. Acad. Sci. U.S.A., 108, pp. 3047-3052, (2011); Bercik P., Denou E., Collins J., Jackson W., Lu J., Jury J., Deng Y., Blennerhassett P., Macri J., McCoy K.D., Verdu E.F., Collins S.M., The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice, Gastroenterology, 141, pp. 599-609e3, (2011); Gareau M.G., Wine E., Rodrigues D.M., Cho J.H., Whary M.T., Philpott D.J., Macqueen G., Sherman P.M., Bacterial infection causes stress-induced memory dysfunction in mice, Gut, 60, pp. 307-317, (2011); Bravo J.A., Forsythe P., Chew M.V., Escaravage E., Savignac H.M., Dinan T.G., Bienenstock J., Cryan J.F., Ingestion of lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve, Proc. Natl. Acad. Sci. U.S.A., 108, pp. 16050-16055, (2011); Collins S.M., Surette M., Bercik P., The interplay between the intestinal microbiota and the brain, Nat. Rev. Microbiol., 10, pp. 735-742, (2012); Peterson D.A., Frank D.N., Pace N.R., Gordon J.I., Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases, Cell Host Microbe, 3, pp. 417-427, (2008); Bhargava P., Mowry E.M., Gut microbiome and multiple sclerosis, Curr. Neurol. Neurosci. Rep., 14, (2014); Mulle J.G., Sharp W.G., Cubells J.F., The gut microbiome: A new frontier in autism research, Curr. Psychiatry Rep., 15, (2013); Hanage W.P., Microbiology: Microbiome science needs a healthy dose of scepticism, Nature, 512, pp. 247-248, (2014); Drossman D.A., Camilleri M., Mayer E.A., Whitehead W.E., AGA technical review on irritable bowel syndrome, Gastroenterology, 123, pp. 2108-2131, (2002); Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Fond G., Loundou A., Hamdani N., Boukouaci W., Dargel A., Oliveira J., Roger M., Tamouza R., Leboyer M., Boyer L., Anxiety and depression comorbidities in irritable bowel syndrome (IBS): A systematic review and meta-analysis, Eur. Arch. Psychiatry Clin. Neurosci., 264, pp. 651-660, (2014); Simren M., Barbara G., Flint H.J., Spiegel B.M.R., Spiller R.C., Vanner S., Verdu E.F., Whorwell P.J., Zoetendal E.G., Intestinal microbiota in functional bowel disorders: A Rome foundation report, Gut, 62, pp. 159-176, (2013); Matto J., Maunuksela L., Kajander K., Palva A., Korpela R., Kassinen A., Saarela M., Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome - A longitudinal study in IBS and control subjects, FEMS Immunol. Med. Microbiol., 43, pp. 213-222, (2005); Tana Y.C., Umesaki A., Imaoka T., Handa M., Kanazawa S., Fukudo, altered profiles of intestinal microbiota and organic acids May be the origin of symptoms in irritable bowel syndrome, Neurogastroenterol. Motil., 22, pp. 512-519, (2010); Jeffery I.B., O'Toole P.W., Ohman L., Claesson M.J., Deane J., Quigley E.M.M., Simren M., An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota, Gut, 61, pp. 997-1006, (2012); Carroll I.M., Ringel-Kulka T., Siddle J.P., Ringel Y., Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome, Neurogastroenterol. Motil., 24, pp. 521-530e248, (2012); Krogius-Kurikka L., Lyra A., Malinen E., Aarnikunnas J., Tuimala J., Paulin L., Makivuokko H., Kajander K., Palva A., Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers, BMC Gastroenterol., 9, (2009); Spiller R., Garsed K., Postinfectious irritable bowel syndrome, Gastroenterology, 136, pp. 1979-1988, (2009); Villarreal A.A., Aberger F.J., Benrud R., Gundrum J.D., Use of broad-spectrum antibiotics and the development of irritable bowel syndrome, WMJ, 111, pp. 17-20, (2012); El-Salhy M., Ostgaard H., Gundersen D., Hatlebakk J.G., Hausken T., The role of diet in the pathogenesis and management of irritable bowel syndrome (Review), Int. J. Mol. Med., 29, pp. 723-731, (2012); Dunlop S.P., Coleman N.S., Blackshaw E., Perkins A.C., Singh G., Marsden C.A., Spiller R.C., Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome, Clin. Gastroenterol. Hepatol., 3, pp. 349-357, (2005); Ford A.C., Talley N.J., Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: A systematic review, J. Gastroenterol., 46, pp. 421-431, (2011); Liebregts T., Adam B., Bredack C., Roth A., Heinzel S., Lester S., Downie-Doyle S., Smith E., Drew P., Talley N.J., Holtmann G., Immune activation in patients with irritable bowel syndrome, Gastroenterology, 132, pp. 913-920, (2007); Reed D.E., Pigrau M., Lu J., Mayyedi P., Collins S.M., Bercik P., Beads study: A novel method to measure gastrointestinal transit in mice, Neurogastroenterol. Motil., 26, pp. 1663-1668, (2014); Talley N.J., Functional gastrointestinal disorders in 2007 and Rome III: Something new, something borrowed, something objective, Rev. Gastroenterol. Disord., 7, pp. 97-105, (2007); Whitehead W.E., Palsson O., Jones K.R., Systematic review of the comorbidity of irritable bowel syndrome with other disorders: What are the causes and implications?, Gastroenterology, 122, pp. 1140-1156, (2002); Voss E., Wehkamp J., Wehkamp K., Stange E.F., Schroder J.M., Harder J., NOD2/CARD15 mediates induction of the antimicrobial peptide human beta-defensin-2, J. Biol. Chem., 281, pp. 2005-2011, (2006); Wehkamp J., Fellermann K., Herrlinger K.R., Baxmann S., Schmidt K., Schwind B., Duchrow M., Wohlschlager C., Feller A.C., Stange E.F., Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease, Eur. J. Gastroenterol. Hepatol., 14, pp. 745-752, (2002); Langhorst J., Junge A., Rueffer A., Wehkamp J., Foell D., Michalsen A., Musial F., Dobos G.J., Elevated human β-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome, Am. J. Gastroenterol., 104, pp. 404-410, (2009); Cohen S.B., Maurer K.J., Egan C.E., Oghumu S., Satoskar A.R., Denkers E.Y., CXCR3-dependent CD4<sup>+</sup> T cells are required to activate inflammatory monocytes for defense against intestinal infection, PLOS Pathog., 9, (2013); Ostvik A.E., Granlund A.V., Bugge M., Nilsen N.J., Torp S.H., Waldum H.L., Damas J.K., Espevik T., Sandvik A.K., Enhanced expression of CXCL10 in inflammatory bowel disease: Potential role of mucosal toll-like receptor 3 stimulation, Inflamm. Bowel Dis., 19, pp. 265-274, (2013); Moloney G., Fanning A., Sharry J.M., Craig O.F., Edelstein E., Dinan T.G., Cryan J.F., Shanahan F., Quigley E.M., Melgar S., Nally K., Evidence of on-going activation of the CXCR3 chemokine system in irritable bowel syndrome (IBS), Gastroenterology, 146, pp. S530-S531, (2014); Salonen A., De Vos W.M., Palva A., Gastrointestinal microbiota in irritable bowel syndrome: Present state and perspectives, Microbiology, 156, pp. 3205-3215, (2010); Martinez C., Vicario M., Ramos L., Lobo B., Mosquera J.L., Alonso C., Sanchez A., Guilarte M., Antolin M., De Torres I., Gonzalez-Castro A.M., Pigrau M., Saperas E., Azpiroz F., Santos J., The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations, Am. J. Gastroenterol., 107, pp. 736-746, (2012); Bercik P., Verdu E.F., Foster J.A., Macri J., Potter M., Huang X., Malinowski P., Jackson W., Blennerhassett P., Neufeld K.A., Lu J., Khan W.I., Corthesy-Theulaz I., Cherbut C., Bergonzelli G.E., Collins S.M., Chronic gastrointestinal inflammation induces anxiety-like behavior and alters central nervous system biochemistry in mice, Gastroenterology, 139, pp. 2102-2112e1, (2010); Tillisch K., Labus J., Kilpatrick L., Jiang Z., Stains J., Ebrat B., Guyonnet D., Legrain-Raspaud S., Trotin B., Naliboff B., Mayer E.A., Consumption of fermented milk product with probiotic modulates brain activity, Gastroenterology, 144, pp. 1394-1401e4, (2013); Pinto-Sanchez M.I., Hall G., Gajar K., Nardelli A., Bolino C., Welch C., Rieder A., Traynor J., Gregory C., Lau J., Ford A.C., Bergonzelli G., Surette M.G., Collins S.M., Moayyedi P., Bercik P., Bifidobacterium longum NCC3001 improves depression scores and alters brain activity in patients with irritable bowel syndrome: A randomized, double blind, placebo-controlled trial, UEG Proc. J., 3, (2015); Camilleri M., Peripheral mechanisms in irritable bowel syndrome, N. Engl. J. Med., 367, pp. 1626-1635, (2012); Radojevic N., McKay D.M., Merger M., Vallance B.A., Collins S.M., Croitoru K., Characterization of enteric functional changes evoked by in vivo anti-CD3 T cell activation, Am. J. Physiol., 276, pp. R715-R723, (1999); Ibeakanma C., Ochoa-Cortes F., Miranda-Morales M., McDonald T., Spreadbury I., Cenac N., Cattaruzza F., Hurlbut D., Vanner S., Bunnett N., Vergnolle N., Vanner S., Brain-gut interactions increase peripheral nociceptive signaling in mice with postinfectious irritable bowel syndrome, Gastroenterology, 141, pp. 2098-2108e5, (2011); Tran L., Chaloner A., Sawalha A.H., Greenwood Van-Meerveld B., Importance of epigenetic mechanisms in visceral pain induced by chronic water avoidance stress, Psychoneuroendocrinology, 38, pp. 898-906, (2013); Rohrl J., Yang D., Oppenheim J.J., Hehlgans T., Human β-defensin 2 and 3 and their mouse orthologs induce chemotaxis through interaction with CCR2, J. Immunol., 184, pp. 6688-6694, (2010); Oeckinghaus A., Hayden M.S., Ghosh S., Crosstalk in NF-κB signaling pathways, Nat. Immunol., 12, pp. 695-708, (2011); Avula L.R., Knapen D., Buckinx R., Vergauwen L., Adriaensen D., Van Nassauw L., Timmermans J.-P., Whole-genome microarray analysis and functional characterization reveal distinct gene expression profiles and patterns in two mouse models of ileal inflammation, BMC Genomics, 13, (2012); Barbara G., De Giorgio R., Stanghellini V., Cremon C., Salvioli B., Corinaldesi R., New pathophysiological mechanisms in irritable bowel syndrome, Aliment. Pharmacol. Ther., 20, pp. 1-9, (2004); Al-Sadi R., Guo S., Ye D., Dokladny K., Alhmoud T., Ereifej L., Said H.M., Ma T.Y., Mechanism of IL-1β modulation of intestinal epithelial barrier involves p38 kinase and activating transcription factor-2 activation, J. Immunol., 190, pp. 6596-6606, (2013); Sano R., Reed J.C., ER stress-induced cell death mechanisms, Biochim. Biophys. Acta, 1833, pp. 3460-3470, (2013); Wohleb E.S., Powell N.D., Godbout J.P., Sheridan J.F., Stress-induced recruitment of bone marrow-derived monocytes to the brain promotes anxiety-like behavior, J. Neurosci., 33, pp. 13820-13833, (2013); Rajilic-Stojanovic M., Biagi E., Heilig H.G.H.J., Kajander K., Kekkonen R.A., Tims S., De Vos W.M., Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome, Gastroenterology, 141, pp. 1792-1801, (2011); Saulnier D.M., Riehle K., Mistretta T.-A., Diaz M.-A., Mandal D., Raza S., Weidler E.M., Qin X., Coarfa C., Milosavljevic A., Petrosino J.F., Highlander S., Gibbs R., Lynch S.V., Shulman R.J., Versalovic J., Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome, Gastroenterology, 141, pp. 1782-1791, (2011); Fuchs B., Muller K., Paasch U., Schiller J., Lysophospholipids: Potential markers of diseases and infertility?, Mini Rev. Med. Chem., 12, pp. 74-86, (2012); Fan H., Zingarelli B., Harris V., Tempel G.E., Halushka P.V., Cook J.A., Lysophosphatidic acid inhibits bacterial endotoxin-induced pro-inflammatory response: Potential anti-inflammatory signaling pathways, Mol. Med., 14, pp. 422-428, (2008); Frey B., Gaipl U.S., The immune functions of phosphatidylserine in membranes of dying cells and microvesicles, Semin. Immunopathol., 33, pp. 497-516, (2011); Hellhammer J., Fries E., Buss C., Engert V., Tuch A., Rutenberg D., Hellhammer D., Effects of soy lecithin phosphatidic acid and phosphatidylserine complex (PAS) on the endocrine and psychological responses to mental stress, Stress, 7, pp. 119-126, (2004); Funfgeld E.W., Baggen M., Nedwidek P., Richstein B., Mistlberger G., Double-blind study with phosphatidylserine (PS) in parkinsonian patients with senile dementia of Alzheimer's type (SDAT), Prog. Clin. Biol. Res., 317, pp. 1235-1246, (1989); Castilho J.C., Perry J.C., Andreatini R., Vital M.A.B.F., Phosphatidylserine: An antidepressive or a cognitive enhancer?, Prog. Neuropsychopharmacol. Biol. Psychiatry, 28, pp. 731-738, (2004); Brambilla F., Maggioni M., Blood levels of cytokines in elderly patients with major depressive disorder, Acta Psychiatr. Scand., 97, pp. 309-313, (1998); Vanotti A., Osio M., Mailland E., Nascimbene C., Capiluppi E., Mariani C., Overview on pathophysiology and newer approaches to treatment of peripheral neuropathies, CNS Drugs, 21, pp. 3-12, (2007); Pettegrew J.W., Levine J., McClure R.J., Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: Relevance for its mode of action in Alzheimer's disease and geriatric depression, Mol. Psychiatry, 5, pp. 616-632, (2000); Benoit S.C., Kemp C.J., Elias C.F., Abplanalp W., Herman J.P., Migrenne S., Lefevre A.-L., Cruciani-Guglielmacci C., Magnan C., Yu F., Niswender K., Irani B.G., Holland W.L., Clegg D.J., Palmitic acid mediates hypothalamic insulin resistance by altering PKC-θ subcellular localization in rodents, J. Clin. Invest., 119, pp. 2577-2589, (2009); De Jesus Moreno Moreno M., Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: A multicenter, double-blind, randomized, placebo-controlled trial, Clin. Ther., 25, pp. 178-193, (2003); Parnetti L., Mignini F., Tomassoni D., Traini E., Amenta F., Cholinergic precursors in the treatment of cognitive impairment of vascular origin: Ineffective approaches or need for re-evaluation?, J. Neurol. Sci., 257, pp. 264-269, (2007); Bailey M.T., Dowd S.E., Parry N.M.A., Galley J.D., Schauer D.B., Lyte M., Stressor exposure disrupts commensal microbial populations in the intestines and leads to increased colonization by citrobacter rodentium, Infect. Immun., 78, pp. 1509-1519, (2010); Park A.J., Collins J., Blennerhassett P.A., Ghia J.E., Verdu E.F., Bercik P., Collins S.M., Altered colonic function and microbiota profile in a mouse model of chronic depression, Neurogastroenterol. Motil., 25, pp. 733-1575, (2013); Anisman H., Hayley S., Kelly O., Borowski T., Merali Z., Psychogenic, neurogenic, and systemic stressor effects on plasma corticosterone and behavior: Mouse strain-dependent outcomes, Behav. Neurosci., 115, pp. 443-454, (2001); Bourin M., Hascoet M., The mouse light/dark box test, Eur. J. Pharmacol., 463, pp. 55-65, (2003); Sakic B., Szechtman H., Talangbayan H., Denburg S.D., Carbotte R.M., Denburg J.A., Disturbed emotionality in autoimmune MRL-lpr mice, Physiol. Behav., 56, pp. 609-617, (1994); Galipeau H.J., Rulli N.E., Jury J., Huang X., Araya R., Murray J.A., David C.S., Chirdo F.G., McCoy K.D., Verdu E.F., Sensitization to gliadin induces moderate enteropathy and insulitis in nonobese diabetic-DQ8 mice, J. Immunol., 187, pp. 4338-4346, (2011); Kennedy K., Hall M.W., Lynch M.D.J., Moreno-Hagelsieb G., Neufeld J.D., Evaluating bias of illumina-based bacterial 16S rRNA gene profiles, Appl. Environ. Microbiol., 80, pp. 5717-5722, (2014); Bartram A.K., Lynch M.D.J., Stearns J.C., Moreno-Hagelsieb G., Neufeld J.D., Generation of multimillion-sequence 16S rRNA gene libraries from complex microbial communities by assembling paired-end illumina reads, Appl. Environ. Microbiol., 77, pp. 3846-3852, (2011); Lynch M.D.J., Masella A.P., Hall M.W., Bartram A.K., Neufeld J.D., AXIOME: Automated exploration of microbial diversity, GigaScience, 2, (2013); Caporaso J.G., Kuczynski J., Stombaugh J., Bittinger K., Bushman F.D., Costello E.K., Fierer N., Pena A.G., Goodrich J.K., Gordon J.I., Huttley G.A., Kelley S.T., Knights D., Koenig J.E., Ley R.E., Lozupone C.A., McDonald D., Muegge B.D., Pirrung M., Reeder J., Sevinsky J.R., Turnbaugh P.J., Walters W.A., Widmann J., Yatsunenko T., Zaneveld J., Knight R., QIIME allows analysis of high-throughput community sequencing data, Nat. Methods, 7, pp. 335-336, (2010); Masella A.P., Bartram A.K., Truszkowski J.M., Brown D.G., Neufeld J.D., PANDAseq: Paired-end assembler for illumina sequences, BMC Bioinformatics, 13, (2012); Edgar R.C., UPARSE: Highly accurate OTU sequences from microbial amplicon reads, Nat. Methods, 10, pp. 996-998, (2013); Wang Q., Garrity G.M., Tiedje J.M., Cole J.R., Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy, Appl. Environ. Microbiol., 73, pp. 5261-5267, (2007); DeSantis T.Z., Hugenholtz P., Larsen N., Rojas M., Brodie E.L., Keller K., Huber T., Dalevi D., Hu P., Andersen G.L., Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB, Appl. Environ. Microbiol., 72, pp. 5069-5072, (2006); McDonald D., Price M.N., Goodrich J., Nawrocki E.P., DeSantis T.Z., Probst A., Andersen G.L., Knight R., Hugenholtz P., An improved greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea, ISME J., 6, pp. 610-618, (2012); Edgar R.C., Haas B.J., Clemente J.C., Quince C., Knight R., UCHIME improves sensitivity and speed of chimera detection, Bioinformatics, 27, pp. 2194-2200, (2011); Mielke P.W., Meteorological applications of permutation techniques based on distance function, Handbook of Statistics, 4, pp. 813-830, (1984); Lozupone C., Knight R., UniFrac: A new phylogenetic method for comparing microbial communities, Appl. Environ. Microbiol., 71, pp. 8228-8235, (2005); Price M.N., Dehal P.S., Arkin A.P., FastTree 2-approximately maximum-likelihood trees for large alignments, PLOS ONE, 5, (2010); Price M.N., Dehal P.S., Arkin A.P., FastTree: Computing large minimum evolution trees with profiles instead of a distance matrix, Mol. Biol. Evol., 26, pp. 1641-1650, (2009); Caporaso J.G., Bittinger K., Bushman F.D., DeSantis T.Z., Andersen G.L., Knight R., PyNAST: A flexible tool for aligning sequences to a template alignment, Bioinformatics, 26, pp. 266-267, (2010); Dufrene M., Legendre P., Species assemblages and indicator species: The need for a flexible asymmetrical approach, Ecol. Monogr., 67, pp. 345-366, (1997); Walter J., Tannock G.W., Tilsala-Timisjarvi A., Rodtong S., Loach D.M., Munro K., Alatossava T., Detection and identification of gastrointestinal lactobacillus species by using denaturing gradient gel electrophoresis and species-specific PCR primers, Appl. Environ. Microbiol., 66, pp. 297-303, (2000); Chalcraft K.R., McCarry B.E., Tandem LC columns for the simultaneous retention of polar and nonpolar molecules in comprehensive metabolomics analysis, J. Sep. Sci., 36, pp. 3478-3485, (2013); Smith C.A., Want E.J., O'Maille G., Abagyan R., Siuzdak G., XCMS: Processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification, Anal. Chem., 78, pp. 779-787, (2006)","P. Bercik; Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, Canada; email: bercikp@mcmaster.ca","","American Association for the Advancement of Science","","","","","","19466234","","","28251905","English","Sci. Transl. Med.","Article","Final","","Scopus","2-s2.0-85014649400"

"Fukui H.; Oshima T.; Tanaka Y.; Oikawa Y.; Makizaki Y.; Ohno H.; Tomita T.; Watari J.; Miwa H.","Fukui, Hirokazu (7202565238); Oshima, Tadayuki (7401663152); Tanaka, Yoshiki (57206614122); Oikawa, Yosuke (57193748394); Makizaki, Yutaka (57193749174); Ohno, Hiroshi (59065099100); Tomita, Toshihiko (7403059566); Watari, Jiro (56682679100); Miwa, Hiroto (56921458500)","7202565238; 7401663152; 57206614122; 57193748394; 57193749174; 59065099100; 7403059566; 56682679100; 56921458500","Effect of probiotic Bifidobacterium bifidum G9-1 on the relationship between gut microbiota profile and stress sensitivity in maternally separated rats","2018","Scientific Reports","8","1","12384","","","","58","10.1038/s41598-018-30943-3","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85051757460&doi=10.1038%2fs41598-018-30943-3&partnerID=40&md5=20daa26723279863940e8b0c52ff7480","Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan; R&D Center, Biofermin Pharmaceutical Co., Ltd, Kobe, Japan; Medical Science Department, Biofermin Pharmaceutical Co., Ltd, Kobe, Japan","Fukui H., Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan; Oshima T., Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan; Tanaka Y., R&D Center, Biofermin Pharmaceutical Co., Ltd, Kobe, Japan; Oikawa Y., R&D Center, Biofermin Pharmaceutical Co., Ltd, Kobe, Japan; Makizaki Y., Medical Science Department, Biofermin Pharmaceutical Co., Ltd, Kobe, Japan; Ohno H., R&D Center, Biofermin Pharmaceutical Co., Ltd, Kobe, Japan; Tomita T., Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan; Watari J., Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan; Miwa H., Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan","Although gut microbiota and early life events are likely involved in the development of irritable bowel syndrome (IBS), it remains unclear how these factors interact in the pathophysiology of IBS. In the present study, using rats subjected to maternal separation (MS) as a model of IBS, we investigated interrelationships among gut microbiota, stress susceptibility and intestinal permeability, and examined the effect of the probiotic Bifidobacterium bifidum G9-1 (BBG9-1) on those interrelationships. When compared with the controls at postnatal day 20, MS rats showed hypercorticosteronemia, enhanced intestinal permeability and changes in gut microbiota structure. All of these changes in MS rats were prevented by treatment with BBG9-1. Although the gut microbiota profile and basal serum corticosterone level did not differ between MS and control rats at postnatal day 56, MS rats showed hypersensitivity to restraint stress in terms of serum corticosterone level and fecal frequency. However, such hypersensitivity was not observed in MS rats treated with BBG9-1. These findings suggest that MS initiates the link between gut microbiota alteration and hypersensitivity to stress and that the triggering of this process can be prevented by the treatment with the probiotic BBG9-1. © 2018, The Author(s).","","Animals; Bifidobacterium bifidum; Biodiversity; Biomarkers; Body Weight; Corticosterone; Gastrointestinal Microbiome; Intestinal Mucosa; Permeability; Probiotics; Rats; Stress, Physiological; biological marker; corticosterone; probiotic agent; animal; Bifidobacterium bifidum; biodiversity; blood; body weight; intestine flora; intestine mucosa; metabolism; microbiology; permeability; physiological stress; rat","","corticosterone, 50-22-6; Biomarkers, ; Corticosterone, ","","","Biofermin Pharmaceutical Co., Ltd.; Japan Society for the Promotion of Science, JSPS, (17K09363); Japan Society for the Promotion of Science, JSPS; Ministry of Education, Culture, Sports, Science and Technology, MEXT","This work was supported in part by Grants-in-aid for Scientific Research 17K09363 (H.F) from the Ministry of Education, Culture, Sports, Science and Technology, Japan. This work was also funded by Biofermin Pharmaceutical Co., Ltd. This funder provided support in the form of salaries for Y.T., Y.O., Y.M. and H.O.","Longstreth G.F., Et al., Functional bowel disorders, Gastroenterology, 130, pp. 480-1491, (2006); Enck P., Et al., Irritable bowel syndrome, Nat Rev Dis Primers, 2, (2016); Simren M., Et al., Intestinal microbiota in functional bowel disorders: a Rome foundation report, Gut, 62, pp. 159-176, (2013); Barbara G., Et al., Interactions between commensal bacteria and gut sensorimotor function in health and disease, Am J Gastroenterol, 100, pp. 2560-2568, (2005); Collins S.M., Bercik P., The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease, Gastroenterology, 136, pp. 2003-2014, (2009); Ford A.C., Et al., Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis, Am J Gastroenterol, 109, pp. 1547-1561, (2014); Mazurak N., Broelz E., Storr M., Enck P., Probiotic therapy in the irritable bowel syndrome — why is the evidence for clinical efficacy still poor and what can be done about it?, J Neurogastroeterol Motil, 21, pp. 471-485, (2015); Didari T., Mozaffari S., Nikfar S., Abdollahi M., Effectiveness of probiotics in irritable bowel syndrome: updated systematic review with meta-analysis, World J Gastroenterol, 21, pp. 3072-3084, (2015); Brenner D.M., Moeller M.J., Chey W.D., Schoenfeld P.S., The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review, Am J Gastroenterol, 104, pp. 1033-1049, (2009); Moayyedi P., Et al., The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review, Gut, 59, pp. 325-332, (2010); Kawahara T., Et al., Oral administration of Bifidobacterium bifidum G9-1 alleviates rotavirus gastroenteritis through regulation of intestinal homeostasis by inducing mucosal protective factors, PLoS One, 12, (2017); Kato S., Et al., Probiotic Bifidobacterium bifidum G9-1 attenuates 5-fluorouracil-induced intestinal mucositis in mice via suppression of dysbiosis-related secondary inflammatory responses, Clin Exp Pharmacol Physiol, 44, pp. 1017-1025, (2017); Coutinho S.V., Et al., Neonatal maternal separation alters stress-induced responses to viscerosomatic nociceptive stimuli in rat, Am J Physiol Gastrointest Liver Physiol, 282, pp. G307-G316, (2002); Rosztoczy A., Et al., Influence of sex and experimental protocol on the effect of maternal deprivation on rectal sensitivity to distension in the adult rat, Neurogastroenterol Motil, 15, pp. 679-686, (2003); Barreau F., Ferrier L., Fioramonti J., Bueno L., New insights in the etiology and pathophysiology of irritable bowel syndrome: contribution of neonatal stress models, Pediatr Res, 62, pp. 240-245, (2007); Oshima T., Fukui H., Watari J., Miwa H., Childhood abuse history is associated with the development of dyspepsia: a population-based survey in Japan, J Gastroenterol, 50, pp. 744-750, (2015); Delvaux M., Denis P., Allemand H., Sexual abuse is more frequently reported by IBS patients than by patients with organic digestive diseases or controls. Results of a multicentre inquiry, French club of digestive motility. Eur J Gastroenterol Hepatol, 9, pp. 345-352, (1997); Gareau M.G., Jury J., MacQueen G., Sherman P.M., Perdue M.H., Probiotic treatment of rat pups normalises corticosterone release and ameliorates colonic dysfunction induced by maternal separation, Gut, 56, pp. 1522-1528, (2007); Matsuki T., Et al., Quantitative PCR with 16S rRNA-gene-targeted species-specific primers for analysis of human intestinal bifidobacteria, Appl Environ Microbiol, 70, pp. 167-173, (2004); Fadrosh D.W., Et al., An improved dual-indexing approach for multiplexed 16S rRNA gene sequencing on the Illumina MiSeq platform, Microbiome, 2, (2014); Caporaso J.G., Et al., QIIME allows analysis of high-throughput community sequencing data, Nat Methods, 27, pp. 335-336, (2010); Lozupone C., Knight R., UniFrac: a new phylogenetic method for comparing microbial communities, Appl Environ Microbiol, 71, pp. 8228-8235, (2005); Moussaoui N., Et al., Changes in intestinal glucocorticoid sensitivity in early life shape the risk of epithelial barrier defect in maternal-deprived rats, PLoS One, 9, (2014); Lehmann J., Russig H., Feldon J., Pryce C.R., Effect of a single maternal separation at different pup ages on the corticosterone stress response in adult and aged rats, Pharmacol Biochem Behav, 73, pp. 141-145, (2002); R: A language and environment for statistical computing, R Foundation for Statistical Computing, (2016); Sekirov I., Russell S.L., Antunes L.C., Finlay B.B., Gut microbiota in health and disease, Physiol Rev, 90, pp. 859-904, (2010); Schroeder B.O., Backhed F., Signals from the gut microbiota to distant organs in physiology and disease, Nat Med, 22, pp. 1079-1089, (2016); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Matricon J., Et al., Associations between immune activation, intestinal permeability and the irritable bowel syndrome, Aliment Pharmacol Ther, 36, pp. 1009-1031, (2012); Rajilic-Stojanovic M., Et al., Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome, Gastroenterology, 141, pp. 1792-1801, (2011); Crost E.H., Et al., Utilisation of mucin glycans by the human gut symbiont Ruminococcus gnavus is strain-dependent, PLoS One, 8, (2013); Takeshita K., Et al., A single species of Clostridium subcluster XIVa decreased in ulcerative colitis patients, Inflamm Bowel Dis, 22, pp. 2802-2810, (2016); Ostuka Y., Et al., Effect of Bifidobacterium breve on inflammatory gene expression I neonatal and weaning rat intestine, Pediatr Res, 71, pp. 46-53, (2012); Jalanka-Tuovinen J., Et al., Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome, Gut, 63, pp. 1737-1745, (2014); Pozuelo M., Et al., Reduction of butyrate- and methane-producing microorganisms in patients with irritable bowel syndrome, Sci Rep, 5, (2015); Tap J., Et al., Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome, Gastroenterology, 152, pp. 111-123, (2017); Shade A., Et al., Fundamentals of microbial community resistance and resilience, Front Microbiol, 3, (2012); David L.A., Et al., Diet rapidly and reproducibly alters the human gut microbiome, Nature, 505, pp. 559-563, (2014); Dethlefsen L., Relman D.A., Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation, Proc Natl Acad Sci USA, 108, pp. 4554-4561, (2011); Barouei J., Moussavi M., Hodgson D.M., Effect of maternal probiotic intervention on HPA axis, immunity and gutmicrobiota in a rat mode of irritable bowel syndrome, PLoS One, 7, (2012); De Palma G., Et al., Microbiota and host determinants of behavioural phenotype in maternally separated mice, Nat Commun, 6, (2015); Lehmann J., Feldon J., Long-term biobehavioral effects of maternal separation in the rat: consistent or confusing?, Rev Neurosci, 11, pp. 383-408, (2000)","H. Fukui; Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan; email: hfukui@hyo-med.ac.jp","","Nature Publishing Group","","","","","","20452322","","","30120330","English","Sci. Rep.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85051757460"

"Russo F.; Chimienti G.; Riezzo G.; Linsalata M.; D’Attoma B.; Clemente C.; Orlando A.","Russo, Francesco (59133988500); Chimienti, Guglielmina (57210207419); Riezzo, Giuseppe (7004144336); Linsalata, Michele (6603600075); D’Attoma, Benedetta (57205751185); Clemente, Caterina (7005101585); Orlando, Antonella (23767683100)","59133988500; 57210207419; 7004144336; 6603600075; 57205751185; 7005101585; 23767683100","Adipose tissue-derived biomarkers of intestinal barrier functions for the characterization of diarrhoea-predominant IBS","2018","Disease Markers","2018","","1827937","","","","17","10.1155/2018/1827937","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85059795293&doi=10.1155%2f2018%2f1827937&partnerID=40&md5=8d500bd6a29f407fedb726470ca02d7e","Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis”, Research Hospital, Castellana Grotte, Bari, Italy; Department of Biosciences, Biotechnology and Biopharmaceutics, University of Bari, Bari, Italy","Russo F., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis”, Research Hospital, Castellana Grotte, Bari, Italy; Chimienti G., Department of Biosciences, Biotechnology and Biopharmaceutics, University of Bari, Bari, Italy; Riezzo G., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis”, Research Hospital, Castellana Grotte, Bari, Italy; Linsalata M., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis”, Research Hospital, Castellana Grotte, Bari, Italy; D’Attoma B., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis”, Research Hospital, Castellana Grotte, Bari, Italy; Clemente C., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis”, Research Hospital, Castellana Grotte, Bari, Italy; Orlando A., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis”, Research Hospital, Castellana Grotte, Bari, Italy","Background. Alterations of the small-intestinal permeability (s-IP) might play an essential role in a subgroup of diarrhoea-predominant IBS (D-IBS) patients. Goals. (a) To analyse in D-IBS patients the symptom profile in relation to the altered (+) or not (−) s-IP using the Gastrointestinal Symptom Rating Scale (GSRS). (b) To assess the circulating levels of the adipokines IL-6, IL-8, TNF-α, leptin, and adiponectin, along with LPS, TLR-4, neurotensin, and brain-derived neurotrophic factor (BDNF). The frequency distribution of SNPs at the loci for the investigated molecules and leptin receptor was evaluated. Study. The study included 34 D-IBS patients and 17 healthy controls (HC). s-IP permeability was assayed by high-performance liquid chromatography determination in the urine of the lactulose to mannitol ratio. Concentrations of IL-6, IL-8, TNF-α, LPS, TLR-4, leptin, adiponectin, neurotensin, and BDNF were assayed by ELISA. Screening of genetic variants was done employing the restriction fragment length polymorphism-polymerase chain reaction method. Results. D-IBS(−) patients had a significantly higher GSRS cluster pain and diarrhoea profile than D-IBS(+) ones. Significant correlations were found between the symptoms clusters and immune activation and inflammation markers. The levels of adipo(cyto)kines in D-IBS(+) patients were higher than those of controls, and IL-6 levels correlated with those of LPS. Leptin and BDNF were significantly higher, and neurotensin levels were significantly lower in D-IBS(+) than in controls. No differences were found in the frequency distribution of genotypes among the study groups. Conclusions. Results from this study could be of some help in the characterization of the DIBS and highlight the contribution of an altered intestinal barrier in the pathogenesis of this syndrome. Besides, a role could be ascribed to molecules secreted by the visceral adipose tissue that can impact on barrier functions. Copyright © 2018 Francesco Russo et al.","","Adipose Tissue; Adult; Biomarkers; Brain-Derived Neurotrophic Factor; Case-Control Studies; Cytokines; Diarrhea; Female; Humans; Intestine, Small; Irritable Bowel Syndrome; Leptin; Male; Polymorphism, Single Nucleotide; adiponectin; biological marker; brain derived neurotrophic factor; interleukin 6; interleukin 8; leptin; leptin receptor; neurotensin; toll like receptor 4; tumor necrosis factor; BDNF protein, human; biological marker; brain derived neurotrophic factor; cytokine; leptin; adipose tissue; adult; Article; clinical article; controlled study; diarrhea; enzyme linked immunosorbent assay; female; genetic variability; high performance liquid chromatography; human; intestine function; intestine mucosa permeability; irritable colon; male; polymerase chain reaction; rating scale; restriction fragment length polymorphism; single nucleotide polymorphism; symptom assessment; adipose tissue; blood; case control study; complication; diarrhea; genetics; irritable colon; metabolism; physiology; small intestine","","adiponectin, 283182-39-8; brain derived neurotrophic factor, 218441-99-7; interleukin 8, 114308-91-7; neurotensin, 39379-15-2; toll like receptor 4, 203811-83-0; BDNF protein, human, ; Biomarkers, ; Brain-Derived Neurotrophic Factor, ; Cytokines, ; Leptin, ","","","Italian Ministry of Health, (RC21-2015)","The authors thank Dr. Marianna Annese, HCA, and Dr Manuela Martulli, BScT (IRCCS “Saverio de Bellis”), for their valuable technical assistance. This study was supported by the Italian Ministry of Health (RC21-2015).","Oswiecimska J., Szymlak A., Roczniak W., Girczys-Poledniok K., Kwiecien J., New insights into the pathogenesis and treatment of irritable bowel syndrome, Advances in Medical Sciences, 62, 1, pp. 17-30, (2017); Schmulson M.J., Drossman D.A., What is new in Rome IV, Journal of Neurogastroenterology and Motility, 23, 2, pp. 151-163, (2017); Borghini R., Donato G., Alvaro D., Picarelli A., New insights in IBS-like disorders: Pandora's box has been opened; a review, Gastroenterology and Hepatology from Bed to Bench, 10, 2, pp. 79-89, (2017); Drossman D.A., Dumitrascu D.L., Rome III: New standard for functional gastrointestinal disorders, Journal of Gastrointestinal and Liver Diseases, 15, 3, pp. 237-241, (2006); Blake M.R., Raker J.M., Whelan K., Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome, Alimentary Pharmacology & Therapeutics, 44, 7, pp. 693-703, (2016); Piche T., Tight junctions and IBS–the link between epithelial permeability, low-grade inflammation, and symptom generation?, Neurogastroenterology & Motility, 26, 3, pp. 296-302, (2014); Mujagic Z., Ludidi S., Keszthelyi D., Et al., Small intestinal permeability is increased in diarrhoea predominant IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to confounders, Alimentary Pharmacology & Therapeutics, 40, 3, pp. 288-297, (2014); Cummings J.H., Antoine J.-M., Azpiroz F., Et al., PAS-SCLAIM–gut health and immunity, European Journal of Nutrition, 43, pp. II118-II173, (2004); Russo F., Chimienti G., Clemente C., Et al., Adipokine profile in celiac patients: Differences in comparison with patients suffering from diarrhea-predominant IBS and healthy subjects, Scandinavian Journal of Gastroenterology, 48, 12, pp. 1377-1385, (2013); Yu Y.B., Zhao D.Y., Qi Q.Q., Et al., BDNF modulates intestinal barrier integrity through regulating the expression of tight junction proteins, Neurogastroenterology & Motility, 29, 3, (2017); O'Malley D., Neuroimmune cross talk in the gut. Neuroendo-crine and neuroimmune pathways contribute to the pathophysiology of irritable bowel syndrome, American Journal of Physiology Gastrointestinal and Liver Physiology, 311, 5, pp. G934-G941, (2016); Bischoff S.C., Barbara G., Buurman W., Et al., Intestinal permeability–a new target for disease prevention and therapy, BMC Gastroenterology, 14, 1, (2014); Gummesson A., Carlsson L.M.S., Storlien L.H., Et al., Intestinal permeability is associated with visceral adiposity in healthy women, Obesity, 19, 11, pp. 2280-2282, (2011); Matafome P., Eickhoff H., Letra L., Seica R., Neuroendo-crinology of adipose tissue and gut-brain axis, Advances in Neurobiology, 19, pp. 49-70, (2017); Svedlund J., Sjodin I., Dotevall G., GSRS–a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease, Digestive Diseases and Sciences, 33, 2, pp. 129-134, (1988); Kopp A., Buechler C., Neumeier M., Et al., Innate immunity and adipocyte function: Ligand-specific activation of multiple Toll-like receptors modulates cytokine, adipokine, and chemo-kine secretion in adipocytes, Obesity, 17, 4, pp. 648-656, (2009); Kahraman R., Calhan T., Sahin A., Et al., Are adipocyto-kines inflammatory or metabolic mediators in patients with inflammatory bowel disease?, Therapeutics and Clinical Risk Management, 13, pp. 1295-1301, (2017); Koon H.-W., Kim Y.S., Xu H., Et al., Neurotensin induces IL-6 secretion in mouse preadipocytes and adipose tissues during 2, 4, 6,-trinitrobenzensulphonic acid-induced colitis, Proceedings of The National Academy of Sciences of The United States of America, 106, 21, pp. 8766-8771, (2009); Sornelli F., Fiore M., Chaldakov G.N., Aloe L., Adipose tissue-derived nerve growth factor and brain-derived neurotrophic factor: Results from experimental stress and diabetes, General Physiology and Biophysics, 28, pp. 179-183, (2009); Makker J., Chilimuri S., Bella J.N., Genetic epidemiology of irritable bowel syndrome, World Journal of Gastroenterology, 21, 40, pp. 11353-11361, (2015); Schmulson M., Lee O.Y., Chang L., Naliboff B., Mayer E.A., Symptom differences in moderate to severe IBS patients based on predominant bowel habit, The American Journal of Gastroenterology, 94, 10, pp. 2929-2935, (1999); Verdu E.F., Armstrong D., Murray J.A., Between celiac disease and irritable bowel syndrome: The ""no man's land"" of gluten sensitivity, The American Journal of Gastroenterology, 104, 6, pp. 1587-1594, (2009); Linsalata M., D'Attoma B., Orlando A., Guerra V., Russo F., Comparison of an enzymatic assay with liquid chromatography-pulsed amperometric detection for the determination of lactulose and mannitol in urine of healthy subjects and patients with active celiac disease, Clinical Chemistry and Laboratory Medicine, 52, 4, pp. e61-e64, (2014); Ludidi S., Mujagic Z., Jonkers D., Et al., Markers for visceral hypersensitivity in patients with irritable bowel syndrome, Neurogastroenterology & Motility, 26, 8, pp. 1104-1111, (2014); Undseth R., Berstad A., Valeur J., Systemic symptoms in irritable bowel syndrome: An investigative study on the role of enterocyte disintegrity, endotoxemia and inflammation, Molecular Medicine Reports, 14, 6, pp. 5072-5076, (2016); Zhen Y., Chu C., Zhou S., Qi M., Shu R., Imbalance of tumor necrosis factor-α, interleukin-8 and interleukin-10 production evokes barrier dysfunction, severe abdominal symptoms and psychological disorders in patients with irritable bowel syndrome-associated diarrhea, Molecular Medicine Reports, 12, 4, pp. 5239-5245, (2015); Bashashati M., Rezaei N., Shafieyoun A., Et al., Cytokine imbalance in irritable bowel syndrome: A systematic review and meta-analysis, Neurogastroenterology & Motility, 26, 7, pp. 1036-1048, (2014); Holtmann G.J., Talley N.J., Inconsistent symptom clusters for functional gastrointestinal disorders in Asia: Is Rome burning?, Gut, 67, 11, pp. 1911-1915, (2018); Qin H.-Y., Cheng C.-W., Tang X.-D., Bian Z.-X., Impact of psychological stress on irritable bowel syndrome, World Journal of Gastroenterology, 20, 39, pp. 14126-14131, (2014); Camilleri M., Madsen K., Spiller R., Van Meerveld B.G., Verne G.N., Intestinal barrier function in health and gastrointestinal disease, Neurogastroenterology & Motility, 24, 6, pp. 503-512, (2012); Camilleri M., Halawi H., Oduyebo I., Biomarkers as a diagnostic tool for irritable bowel syndrome: Where are we?, Expert Review of Gastroenterology & Hepatology, 11, 4, pp. 303-316, (2017); Bennet S.M.P., Polster A., Tornblom H., Et al., Global cytokine profiles and association with clinical characteristics in patients with irritable bowel syndrome, The American Journal of Gastroenterology, 111, 8, pp. 1165-1176, (2016); Perez-Perez A., Vilarino-Garcia T., Fernandez-Riejos P., Martin-Gonzalez J., Segura-Egea J.J., Sanchez-Marga-Let V., Role of leptin as a link between metabolism and the immune system, Cytokine & Growth Factor Reviews, 35, pp. 71-84, (2017); Anty R., Marjoux S., Bekri S., Et al., Plasma carnitine is associated with fatigue in chronic hepatitis C but not in the irritable bowel syndrome, Alimentary Pharmacology & Therapeutics, 33, 8, pp. 961-968, (2011); Semnani S., Roshandel G., Keshtkar A., Et al., Serum leptin levels and irritable bowel syndrome: A new hypothesis, Journal of Clinical Gastroenterology, 43, 9, pp. 826-830, (2009); Le Drean G., Segain J.-P., Connecting metabolism to intestinal barrier function: The role of leptin, Tissue Barriers, 2, 4, (2014); Le Drean G., Haure-Mirande V., Ferrier L., Et al., Visceral adipose tissue and leptin increase colonic epithelial tight junction permeability via a RhoA-ROCK-dependent pathway, The FASEB Journal, 28, 3, pp. 1059-1070, (2014); Sitaraman S., Liu X., Charrier L., Et al., Colonic leptin: Source of a novel proinflammatory cytokine involved in IBD, The FASEB Journal, 18, 6, pp. 696-698, (2004); Karrasch T., Schaeffler A., Adipokines and the role of visceral adipose tissue in inflammatory bowel disease, Annals of Gastroenterology, 29, 4, pp. 424-438, (2016); Karmiris K., Koutroubakis I.E., Xidakis C., Polychronaki M., Voudouri T., Kouroumalis E.A., Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease, Inflammatory Bowel Diseases, 12, 2, pp. 100-105, (2006); Matsuda N.M., Miller S.M., Non-adrenergic non-cholinergic inhibition of gastrointestinal smooth muscle and its intracellular mechanism(s), Fundamental & Clinical Pharmacology, 24, 3, pp. 261-268, (2010); Riezzo G., Chimienti G., Clemente C., Et al., Colonic transit time and gut peptides in adult patients with slow and normal colonic transit constipation, BioMed Research International, 2017, (2017); Barchetta I., Cimini F., Capoccia D., Et al., Neurotensin is a lipid-induced gastrointestinal peptide associated with visceral adipose tissue inflammation in obesity, Nutrients, 10, 4, (2018); Assimakopoulos S.F., Alexandris I.H., Scopa C.D., Et al., Effect of bombesin and neurotensin on gut barrier function in partially hepatectomized rats, World Journal of Gastroenterology, 11, 43, pp. 6757-6764, (2005); Wang P., Du C., Chen F.-X., Et al., BDNF contributes to IBS-like colonic hypersensitivity via activating the enteroglia-nerve unit, Scientific Reports, 6, 1, (2016); Bathina S., Das U.N., Brain-derived neurotrophic factor and Its clinical implications, Archives of Medical Science, 11, 6, pp. 1164-1178, (2015); Cheung C.K.Y., Wu J.C.Y., Genetic polymorphism in pathogenesis of irritable bowel syndrome, World Journal of Gastroenterology, 20, 47, pp. 17693-17698, (2014)","F. Russo; Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis”, Research Hospital, Castellana Grotte, Bari, Italy; email: francesco.russo@irccsdebellis.it","","Hindawi Limited","","","","","","02780240","","DMARD","30622656","English","Dis. Markers","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85059795293"

"Ohlsson B.; Orho-Melander M.; Nilsson P.M.","Ohlsson, Bodil (7005252394); Orho-Melander, Marju (6701619781); Nilsson, Peter M. (56388244600)","7005252394; 6701619781; 56388244600","Higher levels of serum zonulin may rather be associated with increased risk of obesity and hyperlipidemia, than with gastrointestinal symptoms or disease manifestations","2017","International Journal of Molecular Sciences","18","3","582","","","","94","10.3390/ijms18030582","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85014830587&doi=10.3390%2fijms18030582&partnerID=40&md5=acb0c22940705da2c5fe11e2e6d13141","Department of Internal Medicine, Skane University Hospital, Lund University, Malmö, 205 02, Sweden; Genetic Epidemiology, Diabetes and Cardiovascular Disease, Lund University, Malmö, 205 02, Sweden","Ohlsson B., Department of Internal Medicine, Skane University Hospital, Lund University, Malmö, 205 02, Sweden; Orho-Melander M., Genetic Epidemiology, Diabetes and Cardiovascular Disease, Lund University, Malmö, 205 02, Sweden; Nilsson P.M., Department of Internal Medicine, Skane University Hospital, Lund University, Malmö, 205 02, Sweden","Zonulin is considered a biomarker of increased intestinal permeability, and elevated levels have been found in celiac disease. The primary aim of this study was to examine the association between serum zonulin levels and gastrointestinal (GI) symptoms, and secondarily, between zonulin levels and anthropometric and metabolic factors. The offspring (n = 363) of the participants of the Malmö Diet and Cancer cardiovascular cohort (MDC-CV) were invited to an anthropometric and clinical examination, where fasting plasma glucose levels were measured. Questionnaires about lifestyle factors and medical history were completed along with the Visual Analog Scale for Irritable Bowel Syndrome (VAS-IBS). Zonulin levels were measured in serum by ELISA. Neither GI symptoms nor GI diseases had any influence on zonulin levels. Higher zonulin levels were associated with higher waist circumference (p = 0.003), diastolic blood pressure (p = 0.003), and glucose levels (p = 0.036). Higher zonulin levels were associated with increased risk of overweight (p < 0.001), obesity (p = 0.047), and hyperlipidemia (p = 0.048). We cannot detect altered zonulin levels among individuals reporting GI symptoms or GI diseases, but higher zonulin levels are associated with higher waist circumference, diastolic blood pressure, fasting glucose, and increased risk of metabolic diseases. © 2017 by the authors. Licensee MDPI, Basel, Switzerland.","Blood pressure; Gastrointestinal disorders; Gastrointestinal symptoms; Hyperlipidemia; Obesity; Overweight; Zonulin","Adult; Biomarkers; Blood Glucose; Blood Pressure; Body Weights and Measures; Cholera Toxin; Female; Gastrointestinal Diseases; Humans; Hyperlipidemias; Male; Middle Aged; Obesity; Phenotype; Population Surveillance; Risk; regulator protein; unclassified drug; zonulin; biological marker; cholera toxin; glucose blood level; zonulin; adult; age; Article; blood level; body height; controlled study; diabetes mellitus; diastolic blood pressure; enzyme linked immunosorbent assay; female; gastrointestinal disease; gastrointestinal symptom; gender; glucose blood level; human; hyperlipidemia; hypertension; irritable colon; major clinical study; male; middle aged; obesity; observational study; prospective study; questionnaire; visual analog scale; waist circumference; blood; blood pressure; Gastrointestinal Diseases; health survey; Hyperlipidemias; morphometry; obesity; phenotype; risk","","Biomarkers, ; Blood Glucose, ; Cholera Toxin, ; zonulin, ","","","","","Chiba H., Osanai M., Murata M., Kojima T., Sawada N., Transmembrane proteins of tight junctions, Biochim. Biophys. Acta, 1778, pp. 588-600, (2008); Fasano A., Intestinal permeability and its regulation by zonulin: Diagnostic and therapeutic implications, Ann. N. Y. Acad. Sci, 1258, pp. 25-33, (2012); Sapone A., De Magistris L., Pietzak M., Clemente M.G., Tripathi A., Cucca F., Lampis R., Kryszak D., Carteni M., Generoso M., Et al., Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives, Diabetes, 55, pp. 1443-1449, (2006); Fasano A., Regulation of intercellular tight junctions by zonula occludens toxin and its eujaryotic analogue zonulin, Ann. N. Y. Acad. Sci, 915, pp. 214-222, (2000); Tripathi A., Lammers K.M., Goldblum S., Shea-Donohue T., Netzel-Arnett S., Buzza M.S., Antalis T.M., Vogel S.N., Zhao A., Yang S., Et al., Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2, Proc. Natl. Acad. Sci. USA, 106, pp. 16799-16804, (2009); Wang W., Uzzau S., Goldblum S.E., Fasano A., Human zonulin, a potential modulator of intestinal tight junctions, J. Cell Sci, 113, pp. 4435-4440, (2000); Vanuytsel T., Vermeire S., Cleynen I., The role of haptoglobin and its related protein, zonulin, in inflammatory bowel disease, Tissue Barriers, 1, (2013); El Asmar R., Panigrahi P., Bamford P., Berti I., Not T., Coppa G.V., Catassi C., Fasano A., Host-dependent zonulin secretion causes the impairment of the small intestine barrier function after bacterial exposure, Gastroenterology, 123, pp. 1607-1615, (2002); Lacy B.E., Mearin F., Chang L., Chey W.D., Lembo A.J., Simren M., Spiller R., Bowel disorders, Gastroenterology, 150, pp. 1393-1407, (2016); Walsham N.E., Sherwood R.A., Fecal calprotectin in inflammatory bowel disease. Clin. Exp, Gastroenterol, 9, pp. 21-29, (2016); Zhou Q., Souba W.W., Croce C., Verne G.N., MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome, Gut, 59, pp. 775-784, (2010); Fasano A., Zonulin and its regulation of intestinal barrier function: The biological door to inflammation, autoimmunity, and cancer, Physiol. Rev, 91, pp. 151-175, (2011); Zak-Golab A., Kocelak P., Aptekorz M., Zientara M., Juszczyk L., Martirosian G., Chudek J., Olszanecka-Glinianowicz M., Gut microbiota, microinflammation, metabolic profile, and zonulin concentration in obese and normal weight subjects, Int. J. Endocrinol, 2013, (2013); Zhang D., Zhang L., Zheng Y., Yue F., Russell R.D., Zeng Y., Circulating zonulin levels in newly diagnosed Chinese type 2 diabetes patients, Diabetes Res. Clin. Pract, 106, pp. 312-318, (2014); Ohlsson B., Darwiche G., Roth B., Hoglund P., Two meals with different carbohydrate-, fat-, and protein contents render equivalent postprandial plasma levels of calprotectin, cortisol, triglycerides, and zonulin, Int. J. Food Sci. Nutr, 67, pp. 872-880, (2016); Pacifico L., Bonci E., Marandola L., Romaggioli S., Bascetta S., Chiesa C., Increased circulating zonuln in children with biopsy-proven nonalcoholoic fatty liver disease, World J. Gastroenterol, 20, pp. 17107-17114, (2014); Ohlsson B., Roth B., Larsson E., Hoglund P., Calprotectin in serum and zonulin in serum and feces are elevated after introduction of a diet with lower carbohydrate content and higher fiber, fat and protein contents, Biomed. Rep, (2017); Levy A.P., Asleh R., Blum S., Levy N.S., Miller-Lotan R., Kalet-Litman S., Anbinder Y., Lache O., Nakhoul F.M., Asaf R., Et al., Haptoglobin: Basic and clinical aspects, Antioxid. Redox Signal, 12, pp. 293-304, (2010); Quaye I.K., Haptoglobin, inflammation and disease, Trans. R. Soc. Trop. Med. Hyg, 12, pp. 735-742, (2008); Malyszko J., Koc-Zorawska E., Levin-Laina N., Malyszko J., Zonulin, iron status, and anemia in kidney transplant recipients: Are they related?, Transplant. Proc, 46, pp. 2644-2646, (2014); Chiellini C., Santini F., Marsili A., Berti P., Bertacca A., Pelosini C., Scartabelli G., Pardini E., Lopez-Soriano J., Centoni R., Et al., Serum haptoglobin: A novel marker of adiposity in humans, J. Clin. Endocrinol. Metab, 89, pp. 2678-2683, (2004); Hamalainen P., Saltevo J., Kautiainen H., Mantyselka P., Vanhala M., Erythropoietin, ferritin, haptoglobin, hemoglobin and transferrin receptor in metabolic syndrome: A case control study, Cardiovasc. Diabetol, 11, (2012); Qi L., Hu F.B., Dietary glycemic load, whole grains, and systemic inflammation in diabetes: The epidemiological evidence, Curr. Opin. Lipidol, 18, pp. 3-8, (2007); Rittirsch D., Flieri M.A., Nadeau B.A., Day D.E., Huber-Lang M.S., Grailer J.J., Zetoune F.S., Andjelkovic A.V., Fasano A., Ward P.A., Zonulin as prehaptoglobin-2 regulates lung permeability and activates the complement system, Am. J. Physiol. Lung Cell. Mol. Physiol, 304, pp. L863-L872, (2013); Chagnac A., Weinstein T., Herman M., Hirsh J., Gafter U., Ori Y., The effects of weight loss on renal function in patients with severe obesity, J. Am. Soc. Nephrol, 14, pp. 1480-1486, (2003); Visser J.T., Lammers K., Hoogendijk A., Boer M.W., Brugman S., Beijer-Liefers S., Zandvoort A., Harmsen H., Welling G., Stellaard F., Et al., Restoration of impaired intestinal barrier function by the hydrolysed casein diet contributes to the prevention of type 1 diabetes in the diabetes-prone BioBreeding rat, Diabetologia, 53, pp. 2621-2628, (2010); Madara J.L., Stafford J., Interferon-gamma directly affects barrier function of cultured intestinal epithelial monolayers, J. Clin. Investig, 83, pp. 724-727, (1989); Skardelly M., Armbruster F.P., Meixensberger J., Hilbig H., Expression of zonulin, c-kit, and glial fibrillary acidic protein in human gliomas, Transl. Oncol, 2, pp. 117-120, (2009); Giacco F., Brownlee M., Oxidative stress and diabetic complications, Circ. Res, 107, pp. 1058-1070, (2010); Griendling K.K., Fitzgerald G., Oxidative stress and cardiovascular injury: Part I: Basic mechanisms and in vivo monitoring of ROS, Circulation, 108, pp. 1912-1916, (2003); Casas R., Sacanella E., Estruch R., The immune protective effect of the Mediterranean diet against chronic low-grade inflammatory diseases, Endocr. Metab. Immune Disord. Drug Targets, 14, pp. 245-254, (2014); Manjer J., Carlsson S., Elmstahl S., Gullberg B., Janzon L., Lindstrom M., Mattisson I., Berglund G., The Malmö Diet and Cancer Study: Representativity, cancer incidence and mortality in participants and non-participants, Eur. J. Cancer Prev, 10, pp. 489-499, (2001); Bengtsson M., Ohlsson B., Ulander K., Development and psychometric testing of the visual analogue scale for irritable bowel syndrome (VAS-IBS), BMC Gastroenterol, 7, (2007); Bengtsson M., Persson J., Sjolund K., Ohlsson B., Further validation of the visual analogue scale for irritable bowel syndrome after use in clinical practice, Gastroenterol. Nurs, 36, pp. 188-198, (2013); Global Database on Body Mass Index, (2015); Bengtsson M., Hammar O., Mandl T., Ohlsson B., Evaluation of gastrointestinal symptoms in different patient groups using the visual analogue scale for irritable bowel syndrome (VAS-IBS), BMC Gastroenterol, 11, (2011)","B. Ohlsson; Department of Internal Medicine, Skane University Hospital, Lund University, Malmö, 205 02, Sweden; email: bodil.ohlsson@med.lu.se","","MDPI AG","","","","","","16616596","","","28282855","English","Int. J. Mol. Sci.","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85014830587"

"Lu L.; Yan L.; Yuan J.; Ye Q.; Lin J.","Lu, Lu (57199037564); Yan, Liang (57200518219); Yuan, Jianye (15521575500); Ye, Qing (58593833800); Lin, Jiang (55710026200)","57199037564; 57200518219; 15521575500; 58593833800; 55710026200","Shuganyin decoction improves the intestinal barrier function in a rat model of irritable bowel syndrome induced by water-avoidance stress","2018","Chinese Medicine (United Kingdom)","13","1","6","","","","10","10.1186/s13020-017-0161-x","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85041481394&doi=10.1186%2fs13020-017-0161-x&partnerID=40&md5=4962314ce041793ac11646df14499c40","Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Department of Gastroenterology, Shanghai, 200032, China; Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Department of General Surgery, Shanghai, 201203, China; Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Research Institute of the Spleen and Stomach Disease, Shanghai, 200032, China; Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Department of Neurology, Shanghai, 200032, China","Lu L., Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Department of Gastroenterology, Shanghai, 200032, China; Yan L., Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Department of General Surgery, Shanghai, 201203, China; Yuan J., Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Research Institute of the Spleen and Stomach Disease, Shanghai, 200032, China; Ye Q., Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Department of Neurology, Shanghai, 200032, China; Lin J., Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Department of Gastroenterology, Shanghai, 200032, China","Background: To determine the effect of Shuganyin decoction (SGD) on the intestinal barrier function in an irritable bowel syndrome (IBS) rat model induced by water-avoidance stress. Methods: Forty male Wistar rats were divided into control, water-avoidance stress (WAS) group, WAS plus Shuganyin decoction (SGD) group and WAS plus dicetel (Dicetel) group. IBS was induced in rats by subjecting them to water-avoidance stress for 7 days. On day 4 of the WAS protocol, the rats were treated for 7 consecutive days (days 4-11) with SGD, dicetel or a negative control (saline). The number of feces granules, histopathological changes of the intestine and mast cell (MC) morphometry were determined. Intestinal permeability was approximated by measuring the absorption of FITC-dextran 4400 (FD-4) from the lumen into the bloodstream in vivo and in vitro experiments. Also, the expression of protease active receptor-2 (PAR-2) and tumor necrosis factor-α (TNF-α) was estimated using immunohistochemical staining and ELISA, respectively. Tight junction (TJ) protein abundance was measured following a quantitative immunofluorescent analysis of intestinal sections and western blotting. Results: In vivo, WAS elicited a significantly increase in the transfer of FD-4 from the intestine to blood about threefold in 30 min compared with control group. After treated with SGD, the intestinal permeability to FD-4 of WAS-induced rats was significantly attenuated (P < 0.05). In vitro, the permeability coefficient (Papp) values were measured for FD-4 absorption across the excised intestine. WAS was shown to increase the intestinal permeability to (4.695 ± 0.3629) × 10-7 cm/s in 120 min, which was 2.6-fold higher than the control group. Rats treated with SGD showed a significant decrease in Papp values of FD-4 as compared to WAS group (P < 0.05). Furthermore, by immunofluorescent detection we found that WAS elicited the irregular distribution of TJ proteins. Using the quantitative analysis software of the medical image, the average optical density and protein abundance of TJ proteins was shown to be lower in the WAS group as compared to control group, (P < 0.05). SGD could attenuate this response and improve TJ distribution (P < 0.05). Western blot analysis confirmed that TJ protein abundance was significantly decreased in WAS group and that they could be returned to control levels following an SGD treatment. WAS also induced an increase in number of MCs, their area and diameter as compared to controls. These observations were attenuated with an SGD or dicetel treatment. Similarly, the expression of PAR-2 and TNF-α exceeded control values in the WAS group and were shown to be successfully attenuated with an SGD treatment. Conclusion: WAS-induced IBS rat model exhibited intestinal barrier dysfunction, which was manifested as tight junction damage and structural rearrangements that increased the intestinal permeability. Under these conditions, MCs were activated and degranulated in the intestinal mucosa leading to the activation of PAR-2. Our data showed that SGD could inhibit the activation of MCs and down-regulate the expression of both PAR-2 and TNF-α. In turn, this was shown to improve the expression and structural arrangement of TJ proteins in the intestinal mucosa, thereby regulating the intestinal permeability. It was concluded that Shuganyin could protect the intestinal barrier. © 2018 The Author(s).","Intestinal barrier function; Mast cell; Protease activated preceptor-2; Rat model; Shuganyin decoction; Water-avoidance stress","fluorescein isothiocyanate dextran; pinaverium bromide; plant extract; proteinase activated receptor 2; shuganyin extract; tight junction protein; tumor necrosis factor; unclassified drug; animal cell; animal experiment; animal model; animal tissue; Article; cell size; controlled study; diarrhea; drug effect; drug protein binding; enzyme linked immunosorbent assay; feces; histopathology; immunofluorescence; immunohistochemistry; in vitro study; in vivo study; intestine mucosa permeability; irritable colon; male; mast cell; mast cell degranulation; morphometry; nonhuman; permeability barrier; physically induced stress; protein expression; quantitative analysis; rat; Western blotting","","fluorescein isothiocyanate dextran, 60842-46-8; pinaverium bromide, 53251-94-8","","","National Natural Science Foundation of China, NSFC, (81202665)","This manuscript was supported by Natural Science Foundation of China (Grant No. 81202665).","Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Thompson W.G., Longstreth G.F., Drossman D.A., Heaton K.W., Irvine E.J., Muller-Lissner S.A., Functional bowel disorders and functional abdominal pain, Gut, 45, pp. 43-47, (1999); Piche T., Barbara G., Aubert P., Bruley des Varannes S., Dainese R., Nano J.L., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Park J.H., Park D.I., Kim H.J., Cho Y.K., Sohn C.I., Jeon W.K., Et al., The relationship between small-intestinal bacterial overgrowth and intestinal permeability in patients with irritable bowel syndrome, Gut Liver, 3, pp. 174-179, (2009); Dunlop S.P., Hebden J., Campbell E., Naesdal J., Olbe L., Perkins A.C., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Zhou Q., Souba W.W., Croce C.M., Verne G.N., MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome, Gut, 59, pp. 775-784, (2010); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Halland M., Saito Y.A., Irritable bowel syndrome: new and emerging treatments, BMJ, 18, 350, (2015); Gershon M.D., Nerves, reflexes, and the enteric nervous system: pathogenesis of the irritable bowel syndrome, J Clin Gastroenterol, 39, pp. S184-S193, (2005); Barbara G., Stanghellini V., Giorgio R., Corinaldesi R., Functional gastrointestinal disorders and mast cells: implications for therapy, Neurogastroenterol Motil, 18, pp. 6-17, (2006); Bradesi S., Schwetz I., Ennes H.S., Lamy C.M., Ohning G., Fanselow M., Pothoulakis C., McRoberts J.A., Mayer E.A., Repeated exposure to water avoidance stress in rats: a new model for sustained visceral hyperalgesia, Am J Physiol Gastrointest Liver Physiol, 289, pp. G42-G53, (2005); Shi H.L., Liu C.H., Ding L.L., Et al., Alterations in serotonin, transient receptor potential channels and protease-activated receptors in rats with irritable bowel syndrome attenuated by Shugan decoction, World J Gastroenterol., 21, 16, pp. 4852-4863, (2015); Xiao D.T., Hong C., Xiao W.Q., Et al., Platelet-activating factor increases mucosal permeability in rat intestine via tyrosine phosphorylation of E-cadherin, Br J Pharmacol, 129, 7, pp. 1522-1529, (2000); Fan Y., Wu D.Z., Gong Y.Q., Et al., Effects of calycosin on the impairment of barrier function induced by hypoxia in human umbilical vein endothelial cells, Eur J Pharmacol, 481, 1, pp. 33-40, (2003); Saunders P.R., Santos J., Hanssen N.P., Yates D., Groot J.A., Perdue M.H., Physical and psychological stress in rats enhances colonic epithelial permeability via peripheral CRH, Dig Dis Sci, 47, pp. 208-215, (2002); Kiliaan A.J., Saunders P.R., Bijlsma P.B., Berin M.C., Taminiau J.A., Et al., Stress stimulates transepithelial macromolecular uptake in rat jejunum, Am J Physiol, 275, pp. G1037-G1044, (1998); Collins S.M., Piche T., Rampal P., The putative role of inflammation in the irritable bowel syndrome, Gut, 49, pp. 743-745, (2001); Piche T., Tight junctions and IBS-the link between epithelial permeability, low-grade inflammation, and symptom generation?, Neurogastroenterol Motil, 26, pp. 296-302, (2014); Gassler N., Rohr C., Schneider A., Kartenbeck J., Bach A., Et al., Inflammatory bowel disease is associated with changes of enterocytic junctions, Am J Physiol Gastrointest Liver Physiol, 281, pp. G216-G228, (2001); Vanuytsel T., Wanrooy S., Vanheel H., Vanormelingen C., Verschueren S., Houben E., Et al., Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism, Gut, 63, pp. 1293-1299, (2014); Madara J.L., Loosening tight junction lessons from the intestine, J Clin Invest, 83, 4, pp. 1089-1094, (1989); Ivanov A.I., Nusrat A., Parkos C.A., Endocytosis of the apical junctional complex: mechanisms and possible roles in regulation of epithelial barriers, BioEssays, 27, pp. 356-365, (2005); Usami Y., Chiba H., Nakayama F., Ueda J., Matsuda Y., Sawada N., Komori T., Ito A., Yokozaki H., Reduced expression of claudin-7 correlates with invasion and metastasis in squamous cell carcinoma of the esophagus, Hum Pathol, 37, pp. 569-577, (2006); Anderson J.M., Itallie C.M., Tight junctions and the molecular basis for regulation of paracellular permeability, Am J Physiol, 269, pp. 467-475, (1995); Ma T.Y., Iwamoto G.K., Hoa N.T., Et al., TNF-alpha-induce increase in intestinal epithelial tight junction permeability requires NF-KappaB activation, Am J Physiol Gastrointest Liver Physiol, 286, pp. G367-G376, (2004); Martinez C., Lobo B., Pigrau M., Ramos L., Gonzalez-Castro A.M., Alonso C., Guilarte M., Guila M., Et al., Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, pp. 1160-1168, (2013); Martinez C., Vicario M., Ramos L., Lobo B., Mosquera J.L., Alonso C., Sanchez A., Guilarte M., Et al., The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations, Am J Gastroenterol, 107, pp. 736-746, (2012); Cenac N., Chin A.C., Garcia-Villar R., Salvador-Cartier C., Ferrier L., Vergnolle N., Buret A.G., Fioramonti J., Bueno L., PAR2 activation alters colonic paracellular permeability in mice via IFN-gamma-dependent and -independent pathways, J Physiol, 558, pp. 913-925, (2004); Anton P.A., Stress and mind-body impact on the course of inflammatory bowel diseases, Semin Gastrointest Dis., 10, 1, pp. 14-19, (1999); Levenstein S., Prantera C., Varvo V., Scribano M.L., Andreoli A., Luzi C., Arca M., Berto E., Milite G., Marcheggiano A., Stress and exacerbation in ulcerative colitis: a prospective study of patients enrolled in remission, Am J Gastroenterol, 95, pp. 1213-1220, (2000); Lohman R.J., Cotterell A.J., Suen J., Et al., Antagonism of protease-activated receptor 2 protects against experimental colitis, J Pharmacol Exp Ther, 340, 2, pp. 256-265, (2012)","Q. Ye; Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Department of Neurology, Shanghai, 200032, China; email: yeqing1982889@126.com","","BioMed Central Ltd.","","","","","","17498546","","","","English","Chin. Med","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85041481394"

"Rizzi A.; Nucera E.; Laterza L.; Gaetani E.; Valenza V.; Corbo G.M.; Inchingolo R.; Buonomo A.; Schiavino D.; Gasbarrini A.","Rizzi, Angela (24537318700); Nucera, Eleonora (57192332998); Laterza, Lucrezia (55428675300); Gaetani, Eleonora (7003631094); Valenza, Venanzio (7004161175); Corbo, Giuseppe M (7005355725); Inchingolo, Riccardo (57837086500); Buonomo, Alessandro (7004415698); Schiavino, Domenico (7004829829); Gasbarrini, Antonio (58589716200)","24537318700; 57192332998; 55428675300; 7003631094; 7004161175; 7005355725; 57837086500; 7004415698; 7004829829; 58589716200","Irritable bowel syndrome and nickel allergy: What is the role of the low nickel diet?","2017","Journal of Neurogastroenterology and Motility","23","1","","101","108","7","31","10.5056/jnm16027","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85010402999&doi=10.5056%2fjnm16027&partnerID=40&md5=58021232b8b5dc827300278019939a62","Department of Rheumatology, Immunology, Dermatology and Uro-Nefrological Sciences, Allergy Unit, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy; Division of Gastroenterology, Department of Internal Medicine, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy; Department of Nuclear Medicine, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy; Department of Pulmonary Medicine, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy","Rizzi A., Department of Rheumatology, Immunology, Dermatology and Uro-Nefrological Sciences, Allergy Unit, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy; Nucera E., Department of Rheumatology, Immunology, Dermatology and Uro-Nefrological Sciences, Allergy Unit, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy; Laterza L., Division of Gastroenterology, Department of Internal Medicine, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy; Gaetani E., Division of Gastroenterology, Department of Internal Medicine, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy; Valenza V., Department of Nuclear Medicine, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy; Corbo G.M., Department of Pulmonary Medicine, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy; Inchingolo R., Department of Pulmonary Medicine, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy; Buonomo A., Department of Rheumatology, Immunology, Dermatology and Uro-Nefrological Sciences, Allergy Unit, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy; Schiavino D., Department of Rheumatology, Immunology, Dermatology and Uro-Nefrological Sciences, Allergy Unit, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy; Gasbarrini A., Division of Gastroenterology, Department of Internal Medicine, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy","Background/Aims Irritable bowel syndrome (IBS) is characterized by chronic abdominal pain or discomfort accompanied by abnormal bowel movements. In sensitized subjects, ingested nickel (Ni) may induce gastrointestinal symptoms similar to IBS, in addition to typical systemic cutaneous lesions (systemic nickel allergy syndrome [SNAS]). A low nickel diet could improve the systemic manifestations. We evaluated prevalence of nickel allergy in IBS and effects of low Ni diet on (1) gastrointestinal symptoms control, (2) intestinal barrier function, (3) quality of life, and (4) psychological status of patients with IBS and Ni-sensitized patients. Methods Twenty consecutive patients affected by IBS and suspected SNAS underwent intestinal permeability tests. Gastrointestinal symptoms were evaluated using the visual analogue scale before and after 3 months low Ni diet. Subjects with increased intestinal permeability at baseline repeated nuclear examination after the diet. Results The most frequent profile was diarrhea-predominant IBS (8/20). The low Ni diet induced a significant and constant improvement of gastrointestinal symptoms and an equally significant improvement of visual analogue scale. Mean urinary output of 51Chromium ethylene-diamine-tetra-acetate (51Cr-EDTA) was 5.91%/24 hr (± 2.08), significantly different from the control group (2.20%/24 hr ± 0.60, P < 0.0001). Conclusion This pilot study shows that low Ni diet improves gastrointestinal symptoms in patients with IBS and SNAS. © 2017 The Korean Society of Neurogastroenterology and Motility.","Diet; Hypersensitivity; Irritable bowel syndrome; Nickel; Permeability","edetate chromium cr 51; adult; Article; clinical article; controlled clinical trial; controlled study; diarrhea; diet; female; gastrointestinal symptom; human; intestine barrier; intestine function; intestine mucosa permeability; irritable colon; low nickel diet; male; nickel hypersensitivity; permeability barrier; pilot study; prevalence; prospective study; quality of life; systemic nickel allergy syndrome; urine volume; visual analog scale","","edetate chromium cr 51, 11063-42-6","","","","","Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Oshima T., Miwa H., Epidemiology of functional gastrointestinal disorders in Japan and in the world, J Neurogastroenterol Motil, 21, pp. 320-329, (2015); Lackner J.M., Gudleski G.D., Thakur E.R., Stewart T.J., Iacobucci G.J., Spiegel B.M., The impact of physical complaints, social environment, and psychological functioning on IBS patients' health perceptions: looking beyond GI symptom severity, Am J Gastroenterol, 109, pp. 224-233, (2014); Ohman L., Simren M., Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions, Nat Rev Gastroenterol Hepatol, 7, pp. 163-173, (2010); Falagiani P., Di Gioacchino M., Ricciardi L., Et al., Systemic nickel allergy syndrome (SNAS): a review, Rev Port Imunoalergologia, 16, pp. 135-147, (2008); Pizzutelli S., Systemic nickel hypersensitivity and diet: myth or reality?, Eur Ann Allergy Clin Immunol, 43, pp. 5-18, (2011); Veien N.K., Menne T., Nickel contact allergy and a nickel-restricted diet, Semin Dermatol, 9, pp. 197-205, (1990); Piche T., Barbara G., Aubert P., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Di Gioacchino M., Masci S., Cavallucci E., Et al., [Immunohistopathologic changes in the gastrointestinal mucosa in patients with nickel contact allergy.], G Ital Med Lav, 17, (1995); Minelli M., Schiavino D., Musca F., Et al., Oral hyposensitization to nickel induces clinical improvement and a decrease in TH1 and TH2 cytokines in patients with systemic nickel allergy syndrome, Int J Immunopathol Pharmacol, 23, pp. 193-201, (2010); Drossman D.A., The functional Gastrointestinal Disorders and the Rome III process, Gastroenterology, 130, pp. 1377-1390, (2006); Calnan C.D., Fregert S., Magnusson B., The international contact dermatitis research group, Cutis, 18, pp. 708-710, (1976); Spiewak R., Patch Testing for contact allergy and allergic contact dermatitis, Open Allergy Journal, 1, pp. 42-51, (2008); Braga M., Quecchia C., Perotta C., Et al., Systemic nickel allergy syndrome: nosologic framework and diet regimen, Int J Immunopathol Pharmacol, 26, pp. 707-716, (2013); Bengtsson M., Ohlsson B., Ulander K., Development and psychometric testing of the Visual Analogue Scale for Irritable Bowel Syndrome (VASIBS), BMC Gastroenterol, 7, (2007); Ware J.E., Sherbourne C.D., The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection, Med Care, 30, pp. 473-483, (1992); Dupy H., The psychological general well-being (PGWB) index, Assessment of quality of life in clinical trials of cardiovascular therapies, (1984); Butcher J.N., Dahlstrom W.G., Graham J.R., Tellegen A., Kaemmer B., MMPI-2: manual for administration and scoring, (1989); Balimane P.V., Chong S., Morrison R.A., Current methodologies used for the evaluation of the intestinal permeability and absorption, J Pharmacol Toxicol Methods, 44, pp. 301-312, (2000); Rossi M., Sganga G., Mazzone M., Et al., Cardiopulmonary bypass in man: role of the intestine in a self-limiting inflammatory response with demonstrable bacterial translocation, Ann Thorac Surg, 77, pp. 612-618, (2004); Perino A., Nickel and food, Int J Immunopathol Pharmacol, 18, 4, pp. 15-17, (2005); Simren M., Mansson A., Langkilde A.M., Et al., Food-related gastrointestinal symptoms in the irritable bowel syndrome, Digestion, 63, pp. 108-115, (2001); Lovell R.M., Ford A.C., Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis, Am J Gastroenterol, 107, pp. 991-1000, (2012); Hayes P.A., Fraher M.H., Quigley E.M., Irritable bowel syndrome: the role of food in pathogenesis and management, Gastroenterol Hepatol (NY), 10, pp. 164-174, (2014); Iacovou M., Tan V., Muir J.G., Gibson P.R., The Low FODMAP diet and its application in east and southeast Asia, J Neurogastroenterol Motil, 21, pp. 459-470, (2015); Staudacher H.M., Whelan K., Irving P.M., Lomer M.C., Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome, J Hum Nutr Diet, 24, pp. 487-495, (2011); Bohn L., Storsrud S., Liljebo T., Et al., Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial, Gastroenterology, 149, pp. 1399.e2-1407.e2, (2015); McKenzie Y.A., Alder A., Anderson W., Et al., British Dietetic Association evidence-based guidelines for the dietary management of irritable bowel syndrome in adults, J Hum Nutr Diet, 25, pp. 260-274, (2012); Cazzato I.A., Vadrucci E., Cammarota G., Minelli M., Gasbarrini A., Lactose intolerance in systemic nickel allergy syndrome, Int J Immunopathol Pharmacol, 24, pp. 535-537, (2011); Camilleri M., Madsen K., Spiller R., Greenwood-Van Meerveld B., Verne G.N., Intestinal barrier function in health and gastrointestinal disease, Neurogastroenterol Motil, 24, pp. 503-512, (2012); Lackner J.M., Ma C.X., Keefer L., Et al., Type, rather than number, of mental and physical comorbidities increases the severity of symptoms in patients with irritable bowel syndrome, Clin Gastroenterol Hepatol, 11, pp. 1147-1157, (2013); Folks D.G., The interface of psychiatry and irritable bowel syndrome, Curr Psychiatry Rep, 6, pp. 210-215, (2004)","A. Rizzi; Department of Rheumatology, Immunology, Dermatology and Uro-Nefrological Sciences, Allergy Unit, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Largo A. Gemelli 8, 00168, Italy; email: angelarizzi81@gmail.com","","Journal of Neurogastroenterology and Motility","","","","","","20930879","","","","English","J. Neurogastroenterology Motil.","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85010402999"

"Xu X.J.; Zhang Y.L.; Liu L.; Pan L.; Yao S.K.","Xu, X.J. (57148762100); Zhang, Y.L. (55312584900); Liu, L. (56261197400); Pan, L. (58425847400); Yao, S.K. (8370458800)","57148762100; 55312584900; 56261197400; 58425847400; 8370458800","Increased expression of nerve growth factor correlates with visceral hypersensitivity and impaired gut barrier function in diarrhoea-predominant irritable bowel syndrome: a preliminary explorative study","2017","Alimentary Pharmacology and Therapeutics","45","1","","100","114","14","59","10.1111/apt.13848","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85000956295&doi=10.1111%2fapt.13848&partnerID=40&md5=fecebf40450a65a19c0075f65f0a451b","Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China; Gastroenterology Department, China-Japan Friendship Hospital, Beijing, China; Jinan Central Hospital Affiliated to Shandong University, Jinan, China; Immunohistochemistry Laboratory of Clinical Medical Research Institute, China-Japan Friendship Hospital, Beijing, China","Xu X.J., Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China, Gastroenterology Department, China-Japan Friendship Hospital, Beijing, China; Zhang Y.L., Gastroenterology Department, China-Japan Friendship Hospital, Beijing, China; Liu L., Jinan Central Hospital Affiliated to Shandong University, Jinan, China; Pan L., Immunohistochemistry Laboratory of Clinical Medical Research Institute, China-Japan Friendship Hospital, Beijing, China; Yao S.K., Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China, Gastroenterology Department, China-Japan Friendship Hospital, Beijing, China","Background: Neural-immune-endocrine network mechanism has attracted increased attention in diarrhoea-predominant irritable bowel syndrome (IBS-D). Pre-clinical evidence indicates that nerve growth factor (NGF) mediates visceral hypersensitivity and gut barrier dysfunction, via interactions with mast cells and sensory nerve fibres. Aim: To explore the role of nerve growth factor, as well as mast cell–nerve growth factor–nerve interaction in IBS-D pathophysiology. Methods: In this cross-sectional study, IBS-D patients and healthy controls first underwent clinical and psychological assessments. Visceral sensitivity to rectal distension was tested. As gut barrier function markers, serum diamine oxidase and d-lactate were detected. Rectosigmoid biopsies were taken for the analyses of nerve growth factor expression, mast cell count and activation, and sensory nerve fibres expressing transient receptor potential vanilloid 1 and calcitonin gene-related peptide. Correlations between these parameters were examined in patients. Results: Thirty-eight IBS-D patients (28 males, 10 females; average age 30.2 years) and 20 healthy controls (12 males, 8 females; average age 26.8 years) participated in the study. The patients presented increased psychological symptoms, visceral hypersensitivity and impaired gut barrier function. NGF gene expression, mast cell count and sensory nerve fibres were significantly increased in the patients (P < 0.05). In correlation analysis, NGF expression was positively correlated with the disease severity, anxiety and serum diamine oxidase; visceral sensitivity thresholds were negatively associated with NGF expression (Bonferroni corrected P < 0.0029). Conclusions: Elevated mucosal NGF may interact with mast cells and sensory nerve fibres, contributing to visceral hypersensitivity and impaired gut barrier function in IBS-D. © 2016 John Wiley & Sons Ltd","","Adult; Cross-Sectional Studies; Diarrhea; Female; Gastric Mucosa; Gastrointestinal Absorption; Gene Expression; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Male; Middle Aged; Nerve Growth Factor; Pain Measurement; Visceral Pain; Young Adult; amine oxidase (copper containing); lactic acid; messenger RNA; nerve growth factor; vanilloid receptor 1; nerve growth factor; NGF protein, human; adult; Article; cell count; clinical article; controlled study; cross-sectional study; diarrhea; female; gene; gene expression; human; human tissue; immunohistochemistry; impaired gut barrier function; intestine distension; intestine function disorder; intestine mucosa permeability; irritable colon; lactate blood level; male; mast cell; mast cell degranulation; molecular pathology; NGF gene; priority journal; protein expression; protein function; rectum biopsy; visceral hypersensitivity; blood; diarrhea; gastrointestinal absorption; intestine mucosa; Irritable Bowel Syndrome; metabolism; middle aged; pain measurement; pathology; pathophysiology; physiology; procedures; stomach mucosa; visceral pain; young adult","","amine oxidase (copper containing), 9001-53-0, 9014-75-9; lactic acid, 113-21-3, 50-21-5; nerve growth factor, 9061-61-4; vanilloid receptor 1, 363242-41-5; Nerve Growth Factor, ; NGF protein, human, ","","","","","Yao X., Yang Y.S., Zhao K.B., Sun G., Liu Y.S., Wang W.F., Clinical features and subtypes of irritable bowel syndrome based on Rome III diagnostic criteria, World Chinese J Digestol, 16, pp. 563-566, (2008); Shen F., Li D.G., Zhou H.Q., Et al., An epidemiological investigation of irritable bowel syndrome in Shanghai Songjiang communities, Chin J Dig, 31, pp. 663-668, (2011); Camilleri M., Peripheral mechanisms in irritable bowel syndrome, N Engl J Med, 367, pp. 1626-1635, (2012); Wang W.L., Wu W.C., Nerve growth factor and irritable bowel syndrome, Chin J Gastroenterol Hepatol, 19, pp. 285-287, (2010); Lewin G.R., Lechner S.G., Smith E.S., Nerve growth factor and nociception: from experimental embryology to new analgesic therapy, Handb Exp Pharmacol, 220, pp. 251-282, (2014); Coelho A., Wolf-Johnston A.S., Shinde S., Et al., Urinary bladder inflammation induces changes in urothelial nerve growth factor and vanilloid receptor 1, Br J Pharmacol, 172, pp. 1691-1699, (2015); Barreau F., Cartier C., Ferrier L., Fioramonti J., Bueno L., Nerve growth factor mediates alterations of colonic sensitivity and mucosal barrier induced by neonatal stress in rats, Gastroenterology, 127, pp. 524-534, (2004); van den Wijngaard R.M., Klooker T.K., Welting O., Et al., Essential role for TRPV1 in stress-induced (mast cell-dependent) colonic hypersensitivity in maternally separated rats, Neurogastroenterol Motil, 21, pp. e94-1107, (2009); Willot S., Gauthier C., Patey N., Faure C., Nerve growth factor content is increased in the rectal mucosa of children with diarrhea-predominant irritable bowel syndrome, Neurogastroenterol Motil, 24, pp. e347-734, (2012); Dothel G., Barbaro M.R., Boudin H., Et al., Nerve fiber outgrowth is increased in the intestinal mucosa of patients with irritable bowel syndrome, Gastroenterology, 148, pp. 1002-1011, (2015); Francis C.Y., Morris J., Whorwell P.J., The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress, Aliment Pharmacol Ther, 11, pp. 395-402, (1997); Drossman D.A., Patrick D.L., Whitehead W.E., Et al., Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire, Am J Gastroenterol, 95, pp. 999-1007, (2000); Hamilton M., The assessment of anxiety states by rating, Br J Med Psychol, 32, pp. 50-55, (1959); Hamilton M., Development of a psychiatric rating scale for primary depression, Brit J Soc Chin Psychol, 6, pp. 278-296, (1967); Labus J.S., Bolus R., Chang L., Et al., The visceral sensitivity index: development and validation of a gastrointestinal symptom-specific anxiety scale, Aliment Pharmacol Ther, 20, pp. 89-97, (2004); Saigo T., Tayama J., Hamaguchi T., Et al., Gastrointestinal specific anxiety in irritable bowel syndrome: validation of the Japanese version of the visceral sensitivity index for university students, Biopsychosoc Med, 8, (2014); Buysse D.J., Reynolds C.F., Monk T.H., Berman S.R., Kupfer D.J., The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research, Psychiatric Res, 28, pp. 193-213, (1989); Zhang Y.L., Yang D.S., Life event scale, Handb Behav Med Scales, 10, pp. 245-247, (2005); Jiang Q.J., Trait coping style questionnaire, Handb Behav Med Scales, 10, pp. 255-256, (2005); Jiang Q.J., Zhu Y.H., Further explorations for a coping style questionnaire, Chin J Behav Med Sci, 8, pp. 1-5, (1999); Schmittgen T.D., Livak K.J., Analyzing real-time PCR data by the comparative C(T) method, Nat Protoc, 3, pp. 1101-1108, (2008); Jones R., Latinovic R., Charlton J., Gulliford M., Physical and psychological co-morbidity in irritable bowel syndrome: a matched cohort study using the General Practice Research Database, Aliment Pharmacol Ther, 24, pp. 879-886, (2006); Lee S., Wu J., Ma Y.L., Et al., Irritable bowel syndrome is strongly associated with generalized anxiety disorder: a community study, Aliment Pharmacol Ther, 30, pp. 643-651, (2009); Patel P., Bercik P., Morgan D.G., Et al., Irritable bowel syndrome is significantly associated with somatisation in 840 patients, which may drive bloating, Aliment Pharmacol Ther, 41, pp. 449-458, (2015); Elsenbruch S., Abdominal pain in irritable bowel syndrome: a review of putative psychological, neural and neuro-immune mechanisms, Brain Behav Immu, 25, pp. 386-394, (2011); Kennedy P.J., Cryan J.F., Quigley E.M., Dinan T.G., Clarke G., A sustained hypothalamic-pituitary-adrenal axis response to acute psychosocial stress in irritable bowel syndrome, Psychol Med, 44, pp. 3123-3134, (2014); Surdea-Blaga T., Baban A., Dumitrascu D.L., Psychosocial determinants of irritable bowel syndrome, World J Gastroenterol, 18, pp. 616-626, (2012); Xiong L.S., Chen M.H., Chen H.X., Et al., A population-based epidemiologic study of irritable bowel syndrome in South China: stratified randomized study by cluster sampling, Aliment Pharmacol Ther, 19, pp. 1217-1224, (2004); Liu L., Liu B.N., Chen S., Et al., Visceral and somatic hypersensitivity, autonomic cardiovascular dysfunction and low-grade inflammation in a subset of irritable bowel syndrome patients, J Zhejiang Univ Sci B, 15, pp. 907-914, (2014); Piche M., Arsenault M., Poitras P., Rainville P., Bouin M., Widespread hypersensitivity is related to altered pain inhibition processes in irritable bowel syndrome, Pain, 148, pp. 49-58, (2010); Zhou Q.Q., Verne G.N., New insights into visceral hypersensitivity—clinical implications in IBS, Nat Rev Gastroenterol Hepatol, 8, pp. 349-355, (2011); Zhou X.P., Li X.L., Advances in studies on visceral hypersensitivity of irritable bowel syndrome, Chin J Gastroenterol, 19, pp. 117-119, (2014); Whitehead W.E., Palsson O.S., Is rectal pain sensitivity a biological marker for irritable bowel syndrome: psychological influences on pain perception, Gastroenterology, 115, pp. 1263-1271, (1998); Whitehead W.E., Delvaux M., Standardization of barostat procedures for testing smooth muscle tone and sensory thresholds in the gastrointestinal tract, Dig Dis Sci, 42, pp. 223-241, (1997); Sabate J.M., Veyrac M., Mion F., Et al., Relationship between rectal sensitivity, symptoms intensity and quality of life in patients with irritable bowel syndrome, Aliment Pharmacol Ther, 28, pp. 484-490, (2008); Klooker T.K., Kuiken S.D., Lei A., Boeckxstaens G.E., Effect of long-term treatment with octreotide on rectal sensitivity in patients with non-constipated irritable bowel syndrome, Aliment Pharmacol Ther, 26, pp. 605-615, (2007); Hammer H.F., Phillips S.F., Camilleri M., Hanson R.B., Rectal tone, distensibility, and perception: reproducibility and response to different distensions, Am J Physiol, 274, pp. G584-G590, (1998); Zhu Y., Zheng X., Cong Y., Et al., Bloating and distention in irritable bowel syndrome: the role of gas production and visceral sensation after lactose ingestion in a population with lactase deficiency, Am J Gastroenterol, 108, pp. 1516-1525, (2013); Bischoff S.C., Barbara G., Buurman W., Et al., Intestinal permeability—a new target for disease prevention and therapy, BMC Gastroenterol, 14, (2014); Mujagic Z., Ludidi S., Keszthelyi D., Et al., Small intestinal permeability is increased in diarrhoea predominant IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to confounders, Aliment Pharmacol Ther, 40, pp. 288-297, (2014); Shulman R.J., Jarrett M.E., Cain K.C., Broussard E.K., Heitkemper M.M., Associations among gut permeability, inflammatory markers, and symptoms in patients with irritable bowel syndrome, J Gastroenterol, 49, pp. 1467-1476, (2014); Marshall J.K., Thabane M., Garg A.X., Et al., Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario, Aliment Pharmacol Ther, 20, pp. 1317-1322, (2004); Martinez C., Lobo B., Pigrau M., Et al., Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, pp. 1160-1168, (2013); Keszthelyi D., Troost F.J., Jonkers D.M., Et al., Serotonergic reinforcement of intestinal barrier function is impaired in irritable bowel syndrome, Aliment Pharmacol Ther, 40, pp. 392-402, (2014); Jin X., Yu C.H., Lv G.C., Li Y.M., Increased intestinal permeability in pathogenesis and progress of nonalcoholic steatohepatitis in rats, World J Gastroenterol, 13, pp. 1732-1736, (2007); Li J.Y., Lu Y., Hu S., Et al., Preventive effect of glutamine on intestinal barrier dysfunction induced by severe trauma, World J Gastroenterol, 8, pp. 168-171, (2002); Sun Y.J., Chen W.M., Zhang T.Z., Cao H.J., Zhou J., Effects of cardiopulmonary bypass on tight junction protein expressions in intestinal mucosa of rats, World J Gastroenterol, 14, pp. 5868-5875, (2008); Ying C., Chunmin Y., Qingsen L., Et al., Effects of simulated weightlessness on tight junction protein occludin and Zonula Occluden-1 expression levels in the intestinal mucosa of rats, J Huazhong Univ Sci Technol Med Sci, 31, pp. 26-32, (2011); Song W.B., Lv Y.H., Zhang Z.S., Et al., Soluble intercellular adhesion molecule-1, D-lactate and diamine oxidase in patients with inflammatory bowel syndrome, World J Gastroenterol, 15, pp. 3916-3919, (2009); Assadian A., Assadian O., Senekowitsch C., Et al., Plasma D-lactate as a potential early marker for colon ischaemia after open aortic reconstruction, Eur J Vasc Endovasc Surg, 31, pp. 470-474, (2005); Ruan P., Gong Z.J., Zhang Q.R., Changes of plasma D-lactate, diamine oxidase and endotoxin in patients with liver cirrhosis, Hepatobiliary Pancreat Dis Int, 3, pp. 58-61, (2004); Barbara G., Stanghellini V., de Giorgio R., Et al., Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome, Gastroenterology, 126, pp. 693-702, (2004); Leon A., Buriani A., Dal Toso R., Et al., Mast cells synthesize, store, and release nerve growth factor, Proc Natl Acad Sci, 91, pp. 3739-3743, (1994); Levi-Montalcini R., Skaper S.D., Dal Toso R., Petrelli L., Leon A., Nerve growth factor: from neurotrophin to neurokine, Trends Neurosci, 19, pp. 514-520, (1996); Skaper S.D., Pollock M., Facci L., Mast cells differentially express and release active high molecular weight neurotrophins, Brain Res Mol Brain Res, 97, pp. 177-185, (2001); Park C.H., Joo Y.E., Choi S.K., Activated mast cell infiltrate in close proximity to enteric nerves in diarrhea-predominant irritable bowel syndrome, J Korean Med Sci, 18, pp. 204-210, (2003); Bonnington J.K., Mc Naughton P.A., Signalling pathways involved in the sensitisation of mouse nociceptive neurones by nerve growth factor, J Physiol, 551, pp. 433-446, (2003); Barbara G., de Giorgio R., Stanghellini V., Et al., New pathophysiological mechanisms in irritable bowel syndrome, Aliment Pharmacol Ther, 20, pp. 1-9, (2004); Akbar A., Walters J.R., Ghosh S., Review article: visceral hypersensitivity in irritable bowel syndrome: molecular mechanisms and therapeutic agents, Aliment Pharmacol Ther, 30, pp. 423-435, (2009); Xu X.J., Liu L., Yao S.K., Nerve growth factor and diarrhea-predominant irritable bowel syndrome (IBS-D): a potential therapeutic target?, J Zhejiang Univ Sci B, 17, pp. 1-9, (2016); Adeyemo M.A., Spiegel B.M., Chang L., Meta-analysis: do irritable bowel syndrome symptoms vary between men and women?, Aliment Pharmacol Ther, 32, pp. 738-755, (2010); Lu C.L., Chang F.Y., Lang H.C., Et al., Gender difference on the symptoms, health-seeking behaviour, social impact and sleep quality in irritable bowel syndrome: a Rome II-based survey in an apparent healthy adult Chinese population in Taiwan, Aliment Pharmacol Ther, 21, pp. 1497-1505, (2005)","S.K. Yao; Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China; email: yaosk123@126.com","","Blackwell Publishing Ltd","","","","","","02692813","","APTHE","27862119","English","Aliment. Pharmacol. Ther.","Article","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-85000956295"

"Nozu T.; Miyagishi S.; Nozu R.; Takakusaki K.; Okumura T.","Nozu, Tsukasa (12765917900); Miyagishi, Saori (56538237900); Nozu, Rintaro (57028157900); Takakusaki, Kaoru (7004150214); Okumura, Toshikatsu (7202327796)","12765917900; 56538237900; 57028157900; 7004150214; 7202327796","Pioglitazone improves visceral sensation and colonic permeability in a rat model of irritable bowel syndrome","2019","Journal of Pharmacological Sciences","139","1","","46","49","3","12","10.1016/j.jphs.2018.11.006","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85057557082&doi=10.1016%2fj.jphs.2018.11.006&partnerID=40&md5=f1fdbdadb87cdc35e7597d4997c938ca","Department of Regional Medicine and Education, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Department of General Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Research Center for Brain Function and Medical Engineering, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan","Nozu T., Department of Regional Medicine and Education, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Miyagishi S., Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Nozu R., Department of Regional Medicine and Education, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Takakusaki K., Research Center for Brain Function and Medical Engineering, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan; Okumura T., Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan, Department of General Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Hokkaido, Japan","Visceral hypersensitivity and impaired gut barrier with minor inflammation are considered to play an important role in the pathophysiology of irritable bowel syndrome (IBS). Since pioglitazone is known to have anti-inflammatory property, we hypothesized that pioglitazone is beneficial for treating IBS. In this study, the effect was tested in rat IBS models such as lipopolysaccharide or repeated water avoidance stress-induced visceral allodynia and increased colonic permeability. Pioglitazone blocked these visceral changes, and GW9662, a peroxisome proliferator-activated receptor gamma (PPAR-γ) antagonist fully reversed the effect by pioglitazone. These results suggest that PPAR-γ activation by pioglitazone may be useful for IBS treatment. © 2018 The Authors","Gut permeability; Pioglitazone; Visceral sensation","Animals; Colon; Disease Models, Animal; Hyperalgesia; Hypoglycemic Agents; Irritable Bowel Syndrome; Lipopolysaccharides; Male; Permeability; Pioglitazone; PPAR gamma; Rats, Sprague-Dawley; Stress, Physiological; 2 chloro 5 nitrobenzanilide; peroxisome proliferator activated receptor gamma; pioglitazone; antidiabetic agent; lipopolysaccharide; peroxisome proliferator activated receptor gamma; pioglitazone; adult; allodynia; animal experiment; animal model; Article; controlled study; intestine mucosa permeability; irritable colon; male; nonhuman; rat; rat model; agonists; animal; colon; disease model; drug effect; hyperalgesia; metabolism; pathophysiology; permeability; physiological stress; physiology; Sprague Dawley rat","","pioglitazone, 105355-27-9, 111025-46-8; Hypoglycemic Agents, ; Lipopolysaccharides, ; Pioglitazone, ; PPAR gamma, ","","","Akiyama Life Science Foundation; Japan Society for the Promotion of Science, KAKEN, (18K07896, 26120012, 26460287, 26460955)","This work was partially supported by Japan Society for the Promotion of Science, KAKENHI, Grant-in-Aid for Scientific Research (C) [ 26460287 (TN) and 26460955 (TO)], Scientific Research on Innovative Areas [ 26120012 (KT)] and the research grant from the Akiyama Life Science Foundation (TN).","Tache Y., Kiank C., Stengel A., A role for corticotropin-releasing factor in functional gastrointestinal disorders, Curr Gastroenterol Rep, 11, 4, pp. 270-277, (2009); Liebregts T., Adam B., Bredack C., Et al., Immune activation in patients with irritable bowel syndrome, Gastroenterology, 132, 3, pp. 913-920, (2007); Jia H., Xu S., Liu Q., Et al., Effect of pioglitazone on neuropathic pain and spinal expression of TLR-4 and cytokines, Exp Ther Med, 12, 4, pp. 2644-2650, (2016); Cani P.D., Bibiloni R., Knauf C., Et al., Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice, Diabetes, 57, 6, pp. 1470-1481, (2008); Nozu T., Miyagishi S., Nozu R., Et al., Lipopolysaccharide induces visceral hypersensitivity: role of interleukin-1, interleukin-6, and peripheral corticotropin-releasing factor in rats, J Gastroenterol, 52, 1, pp. 72-80, (2017); Nozu T., Miyagishi S., Nozu R., Et al., Repeated water avoidance stress induces visceral hypersensitivity: role of IL-1, IL-6 and peripheral corticotropin-releasing factor, J Gastroenterol Hepatol, 32, 12, pp. 1958-1965, (2017); Nozu T., Miyagishi S., Nozu R., Et al., Altered colonic sensory and barrier functions by CRF: roles of TLR4 and IL-1, J Endocrinol, 239, 2, pp. 241-252, (2018); Paragomi P., Rahimian R., Kazemi M.H., Et al., Antinociceptive and antidiarrheal effects of pioglitazone in a rat model of diarrhoea-predominant irritable bowel syndrome: role of nitric oxide, Clin Exp Pharmacol Physiol, 41, 2, pp. 118-126, (2014); Sukhotnik I., Nissimov N., Ben Shahar Y., Et al., Fenofibrate reduces intestinal damage and improves intestinal recovery following intestinal ischemia-reperfusion injury in a rat, Pediatr Surg Int, 32, 12, pp. 1193-1200, (2016); Nozu T., Miyagishi S., Kumei S., Et al., Lovastatin inhibits visceral allodynia and increased colonic permeability induced by lipopolysaccharide or repeated water avoidance stress in rats, Eur J Pharmacol, 818, pp. 228-234, (2017); Larauche M., Mulak A., Tache Y., Stress and visceral pain: from animal models to clinical therapies, Exp Neurol, 233, 1, pp. 49-67, (2012); Zingarelli B., Sheehan M., Hake P.W., Et al., Peroxisome proliferator activator receptor-gamma ligands, 15-deoxy-delta(12,14)-prostaglandin J2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsis by modulation of signal transduction pathways, J Immunol, 171, 12, pp. 6827-6837, (2003); Zhang W.Y., Schwartz E.A., Permana P.A., Et al., Pioglitazone inhibits the expression of inflammatory cytokines from both monocytes and lymphocytes in patients with impaired glucose tolerance, Arterioscler Thromb Vasc Biol, 28, 12, pp. 2312-2318, (2008); Larauche M., Mulak A., Kim Y.S., Et al., Visceral analgesia induced by acute and repeated water avoidance stress in rats: sex difference in opioid involvement, Neurogastroenterol Motil, 24, 11, (2012)","T. Nozu; Department of Regional Medicine and Education, Asahikawa Medical University, Asahikawa, 2-1-1-1 Midorigaoka-Higashi, 078-8510, Japan; email: tnozu@sea.plala.or.jp","","Japanese Pharmacological Society","","","","","","13478613","","JPSTG","30522964","English","J. Pharmacol. Sci.","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85057557082"

"Hou Q.; Huang Y.; Zhu S.; Li P.; Chen X.; Hou Z.; Liu F.","Hou, Qiuke (35573727700); Huang, Yongquan (57195074253); Zhu, Shuilian (57193834637); Li, Peiwu (55757309300); Chen, Xinlin (55357650100); Hou, Zhengkun (36055683600); Liu, Fengbin (55799656200)","35573727700; 57195074253; 57193834637; 55757309300; 55357650100; 36055683600; 55799656200","MiR-144 Increases Intestinal Permeability in IBS-D Rats by Targeting OCLN and ZO1","2018","Cellular Physiology and Biochemistry","44","6","","2256","2268","12","60","10.1159/000486059","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85040792061&doi=10.1159%2f000486059&partnerID=40&md5=3cacc6690603976a5f33c109c4e4ecaa","Department of Gastroenterology, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China; Department of Orthopedics, Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China; Department of Preventive Medicine and Health Statistics, Guangzhou University of Chinese Medicine, Guangzhou, China","Hou Q., Department of Gastroenterology, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China; Huang Y., Department of Orthopedics, Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China; Zhu S., Department of Gastroenterology, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China; Li P., Department of Gastroenterology, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China; Chen X., Department of Preventive Medicine and Health Statistics, Guangzhou University of Chinese Medicine, Guangzhou, China; Hou Z., Department of Gastroenterology, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China; Liu F., Department of Gastroenterology, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China","Background/Aims: Irritable bowel syndrome with diarrhoea (IBS-D) is a chronic, functional bowel disorder characterized by abdominal pain or diarrhoea and altered bowel habits, which correlate with intestinal hyperpermeability. MicroRNAs (miRNAs) are involved in regulating intestinal permeability in IBS-D. However, the role of miRNAs in regulating intestinal permeability and protecting the epithelial barrier remains unclear. Our goals were to (i) identify differential expression of miRNAs and their targets in the distal colon of IBS-D rats; (ii) verify in vitro whether occludin (OCLN) and zonula occludens 1 (ZO1/TJP1) were direct targets of miR-144 and were down-regulated in IBS-D rats; and (iii) determine whether down-regulation of miR-144 in vitro could reverse the pathological hallmarks of intestinal hyperpermeability via targeting OCLN and ZO1. Methods: The IBS-D rat model was established using 4% acetic acid and evaluated by haematoxylin-eosin (HE) staining. The distal colon was obtained in order to perform miRNA microarray analysis and to isolate and culture colonic epithelial cells. When differential expression of miRNA was found, the results were verified by qRT-PCR, and the target genes were further explored by bioinformatics analysis. Correlation analyses were carried out to compare the expression of miRNA and target genes. Then, mutants, miRNA mimics and inhibitors of the target genes were constructed and transfected to colonic epithelial cells. qRT-PCR, western blotting, enzyme-linked immunosorbent assays (ELISAs) and dual-luciferase assays were used to investigate the expression of miR-144 and OCLN, ZO1 in IBS-D rats. Results: There were 8 up-regulated and 18 down-regulated miRNAs identified in the IBS-D rat model. Of these, miR-144 was markedly up-regulated and resulted in the down-regulation of OCLN and ZO1 expression. Overexpression of miR-144 by transfection of miR-144 precursor markedly inhibited the expression of OCLN and ZO1. Further studies confirmed that OCLN and ZO1 were direct targets of miR-144. Additionally, intestinal hyperpermeability was enhanced by miR-144 up-regulation and attenuated by miR-144 down-regulation in IBS-D rat colonic epithelial cells. Moreover, rescue experiments showed that overexpression of OCLN and ZO1 significantly eliminated the inhibitory effect of miR-144, which showed a stronger effect on the attenuation of intestinal hyperpermeability. Conclusion: Up-regulation of miR-144 could promote intestinal hyperpermeability and impair the protective effect of the epithelial barrier by directly targeting OCLN and ZO1. miR-144 is likely a key regulator of intestinal hyperpermeability and could be a potential therapeutic target for IBS-D. © 2017 The Author(s).","Intestinal permeability; Irritable bowel syndrome with diarrhoea (IBS-D); MiR-144; Occludin(OCLN); Zonula occludens 1 (ZO1/TJP1)","Animals; Colon; Diarrhea; Down-Regulation; Female; Gene Expression Regulation; Intestinal Absorption; Irritable Bowel Syndrome; Male; MicroRNAs; Occludin; Rats, Sprague-Dawley; Up-Regulation; Zonula Occludens-1 Protein; acetic acid; eosin; hematoxylin; microRNA; microRNA 144; occludin; protein ZO1; unclassified drug; microRNA; MIRN144 microRNA, rat; occludin; protein ZO1; animal cell; animal experiment; animal model; animal tissue; Article; bioinformatics; cell culture; cell isolation; colon epithelium; controlled study; correlation analysis; diarrhea; disease model; down regulation; enzyme linked immunosorbent assay; epithelium cell; female; gene overexpression; gene targeting; genetic transfection; immunohistochemistry; in vitro study; intestine mucosa permeability; irritable colon; luciferase assay; male; microarray analysis; nonhuman; priority journal; protein expression; protein targeting; quantitative analysis; rat; reverse transcription polymerase chain reaction; upregulation; Western blotting; animal; colon; complication; gene expression regulation; genetics; intestine absorption; irritable colon; metabolism; pathology; Sprague Dawley rat","","acetic acid, 127-08-2, 127-09-3, 64-19-7, 71-50-1; eosin, 17372-87-1, 51395-88-1, 548-26-5; hematoxylin, 517-28-2; occludin, 176304-61-3; MicroRNAs, ; MIRN144 microRNA, rat, ; Occludin, ; Zonula Occludens-1 Protein, ","","","China Postdoctoral Science Foundation, (2017M612641)","This study was supported by the China Postdoctoral Science Foundation (No. 2017M612641).","Gracie D.J., Ford A.C., Irritable Bowel Syndrome-Type Symptoms Are Associated with Psychological Comorbidity, Reduced Quality of Life, and Health Care Use in Patients with Inflammatory Bowel Disease, Gastroenterology, 153, pp. 324-325, (2017); Coeffier M., Dechelotte P., Ducrotte P., Intestinal permeability in patients with diarrhea-predominant irritable bowel syndrome: Is there a place for glutamine supplementation, Gastroenterology, 148, pp. 1079-1080, (2015); Ikemura K., Iwamoto T., Okuda M., MicroRNAs as regulators of drug transporters, drug-metabolizing enzymes, and tight junctions: Implication for intestinal barrier function, Pharmacol Ther, 143, pp. 217-224, (2014); Kolodziej L.E., Lodolce J.P., Chang J.E., Schneider J.R., Grimm W.A., Bartulis S.J., Zhu X., Messer J.S., Murphy S.F., Reddy N., Turner J.R., Boone D.L., TNFAIP3 maintains intestinal barrier function and supports epithelial cell tight junctions, PLoS One, 6, (2011); Grozdanovic M.M., Cavic M., Nesic A., Andjelkovic U., Akbari P., Smit J.J., Gavrovic-Jankulovic M., Kiwifruit cysteine protease actinidin compromises the intestinal barrier by disrupting tight junctions, Biochim Biophys Acta, 1860, pp. 516-526, (2016); Visser J., Rozing J., Sapone A., Lammers K., Fasano A., Tight junctions, intestinal permeability, and autoimmunity: Celiac disease and type 1 diabetes paradigms, Ann N y Acad Sci, 1165, pp. 195-205, (2009); Vanuytsel T., Vanormelingen C., Vanheel H., Masaoka T., Salim Rasoel S., Toth J., Houben E., Verbeke K., De Hertogh G., Vanden Berghe P., Tack J., Farre R., From intestinal permeability to dysmotility: The biobreeding rat as a model for functional gastrointestinal disorders, PLoS One, 9, (2014); McKenna L.B., Schug J., Vourekas A., McKenna J.B., Bramswig N.C., Friedman J.R., Kaestner K.H., MicroRNAs control intestinal epithelial differentiation, architecture, and barrier function, Gastroenterology, 139, pp. 1654-1664, (2010); O'Hara S.P., Mott J.L., Splinter P.L., Gores G.J., LaRusso N.F., MicroRNAs: Key modulators of posttranscriptional gene expression, Gastroenterology, 136, pp. 17-25, (2009); Kalla R., Ventham N.T., Kennedy N.A., MicroRNAs: New players in inflammatory bowel disease, Gut, 64, (2015); Zhang L., Cheng J., Fan X.M., MicroRNAs: New therapeutic targets for intestinal barrier dysfunction, World J Gastroenterol, 20, pp. 5818-5825, (2014); Wu F., Zikusoka M., Trindade A., Dassopoulos T., Harris M.L., Bayless T.M., Brant S.R., Chakravarti S., Kwon J.H., MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha, Gastroenterology, 135, pp. 1624-1635, (2008); Neesse A., Gress T.M., Emerging role of microRNAs to tackle drug resistance in pancreatic cancer, Gut, 64, pp. 1842-1843, (2015); Kalla R., Ventham N.T., Kennedy N.A., Quintana J.F., Nimmo E.R., Buck A.H., Satsangi J., MicroRNAs: New players in IBD, Gut, 64, pp. 504-517, (2015); Nguyen H.T., Dalmasso G., Muller S., Carriere J., Seibold F., Darfeuille-Michaud A., Crohn's disease-associated adherent invasive Escherichia coli modulate levels of microRNAs in intestinal epithelial cells to reduce autophagy, Gastroenterology, 146, pp. 508-519, (2014); Shamshiri H., Paragomi P., Paydar M.J., Moezi L., Bahadori M., Behfar B., Ardalan F.A., Dehpour A.R., Antinociceptive effect of chronic lithium on visceral hypersensitivity in a rat model of diarrhea-predominant irritable bowel syndrome: The role of nitric oxide pathway, J Gastroenterol Hepatol, 24, pp. 672-680, (2009); Booth C., Patel S., Bennion G.R., Potten C.S., The isolation and culture of adult mouse colonic epithelium, Epithelial Cell Biol, 4, pp. 76-86, (1995); Duan B., Hu J., Zhang T., Luo X., Zhou Y., Liu S., Zhu L., Wu C., Liu W., Chen C., Gao H., MiRNA-338-3p/CDK4 signaling pathway suppressed hepatic stellate cell activation and proliferation, BMC Gastroenterol, 17, (2017); Toffanin S., Villanueva A., Llovet J.M., MiRNA delivery: Emerging therapy for hepatocellular carcinoma, Gastroenterology, 138, pp. 1202-1204, (2010); Hanin G., Yayon N., Tzur Y., Haviv R., Bennett E.R., Udi S., Krishnamoorthy Y.R., Kotsiliti E., Zangen R., Efron B., Tam J., Pappo O., Shteyer E., Pikarsky E., Heikenwalder M., Greenberg D.S., Soreq H., MiRNA-132 induces hepatic steatosis and hyperlipidaemia by synergistic multitarget suppression, Gut; Yi T., Arthanari H., Akabayov B., Song H., Papadopoulos E., Qi H.H., Jedrychowski M., Guttler T., Guo C., Luna R.E., Gygi S.P., Huang S.A., Wagner G., EIF1A augments Ago2-mediated Dicer-independent miRNA biogenesis and RNA interference, Nat Commun, 6, (2015); Zhou Q., Costinean S., Croce C.M., Brasier A.R., Merwat S., Larson S.A., Basra S., Verne G.N., MicroRNA 29 targets nuclear factor-κB-repressing factor and Claudin 1 to increase intestinal permeability, Gastroenterology, 148, pp. 158-169, (2015); Pope J.L., Bhat A.A., Sharma A., Ahmad R., Krishnan M., Washington M.K., Beauchamp R.D., Singh A.B., Dhawan P., Claudin-1 regulates intestinal epithelial homeostasis through the modulation of Notch-signalling, Gut, 63, pp. 622-634, (2014); Lunardi C., Bason C., Dolcino M., Navone R., Simone R., Saverino D., Frulloni L., Tinazzi E., Peterlana D., Corrocher R., Puccetti A., Antiflagellin antibodies recognize the autoantigens Toll-Like Receptor 5 and Pals 1-associated tight junction protein and induce monocytes activation and increased intestinal permeability in Crohn's disease, J Intern Med, 265, pp. 250-265, (2009); Piche T., Barbara G., Aubert P., Bruley Des Varannes S., Dainese R., Nano J.L., Cremon C., Stanghellini V., De Giorgio R., Galmiche J.P., Neunlist M., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: Involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Chen T., Xue H., Lin R., Huang Z., MiR-34c and PlncRNA1 mediated the function of intestinal epithelial barrier by regulating tight junction proteins in inflammatory bowel disease, Biochem Biophys Res Commun, 486, pp. 6-13, (2017); Buret A.G., Mitchell K., Muench D.G., Scott K.G., Giardia lamblia disrupts tight junctional ZO-1 and increases permeability in non-transformed human small intestinal epithelial monolayers: Effects of epidermal growth factor, Parasitology, 125, pp. 11-19, (2002); Cario E., Gerken G., Podolsky D.K., Toll-like receptor 2 enhances ZO-1-associated intestinal epithelial barrier integrity via protein kinase C, Gastroenterology, 127, pp. 224-238, (2004); Liao X.J., Mao W.M., Wang Q., Yang G.G., Wu W.J., Shao S.X., MicroRNA-24 inhibits serotonin reuptake transporter expression and aggravates irritable bowel syndrome, Biochem Biophys Res Commun, 469, pp. 288-293, (2016); Fourie N.H., Peace R.M., Abey S.K., Sherwin L.B., Rahim-Williams B., Smyser P.A., Wiley J.W., Henderson W.A., Elevated circulating miR-150 and miR-342-3p in patients with irritable bowel syndrome, Exp Mol Pathol, 96, pp. 422-425, (2014); Bitar A., De R., Melgar S., Aung K.M., Rahman A., Qadri F., Wai S.N., Shirin T., Hammarstrom M.L., Induction of immunomodulatory miR-146a and miR-155 in small intestinal epithelium of Vibrio cholerae infected patients at acute stage of cholera, PLoS One, 12, (2017); Mansour M.A., Sabbah N.A., Mansour S.A., Ibrahim A.M., MicroRNA-199b expression level and coliform count in irritable bowel syndrome, IUBMB Life, 68, pp. 335-342, (2016); Martinez C., Rodino-Janeiro B.K., Lobo B., Stanifer M.L., Klaus B., Granzow M., Gonzalez-Castro A.M., Salvo-Romero E., Alonso-Cotoner C., Pigrau M., Roeth R., Rappold G., Huber W., Gonzalez-Silos R., Lorenzo J., De Torres I., Azpiroz F., Boulant S., Vicario M., Niesler B., Santos J., MiR-16 and miR-125b are involved in barrier function dysregulation through the modulation of claudin-2 and cingulin expression in the jejunum in IBS with diarrhoea, Gut, 66, pp. 1537-1538, (2017)","","","S. Karger AG","","","","","","10158987","","CEPBE","29258088","English","Cell. Physiol. Biochem.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85040792061"

"Ishimoto H.; Oshima T.; Sei H.; Yamasaki T.; Kondo T.; Tozawa K.; Tomita T.; Ohda Y.; Fukui H.; Watari J.; Miwa H.","Ishimoto, Haruka (57193511156); Oshima, Tadayuki (7401663152); Sei, Hiroo (56921743400); Yamasaki, Takahisa (35274045200); Kondo, Takashi (56587253600); Tozawa, Katsuyuki (14527805100); Tomita, Toshihiko (7403059566); Ohda, Yoshio (8425938700); Fukui, Hirokazu (7202565238); Watari, Jiro (56682679100); Miwa, Hiroto (56921458500)","57193511156; 7401663152; 56921743400; 35274045200; 56587253600; 14527805100; 7403059566; 8425938700; 7202565238; 56682679100; 56921458500","Claudin-2 expression is upregulated in the ileum of diarrhea predominant irritable bowel syndrome patients","2017","Journal of Clinical Biochemistry and Nutrition","60","2","","146","150","4","23","10.3164/jcbn.16-92","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85014481386&doi=10.3164%2fjcbn.16-92&partnerID=40&md5=115755960064af54dd9eaa5c27df2350","Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan","Ishimoto H., Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan; Oshima T., Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan; Sei H., Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan; Yamasaki T., Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan; Kondo T., Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan; Tozawa K., Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan; Tomita T., Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan; Ohda Y., Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan; Fukui H., Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan; Watari J., Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan; Miwa H., Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan","Intestinal epithelial barrier function is impaired in irritable bowel syndrome patients. Claudins are highly expressed in cells with tight junctions and are involved in the intestinal epithelial barrier function. The expression pattern of tight junction proteins in diarrhea-predominant irritable bowel syndrome have not been fully elucidated. We therefore recruited 17 diarrhea-predominant irritable bowel syndrome patients and 20 healthy controls. The expression of the tight junction-related proteins was examined in the ileal, cecal, and rectal mucosa of diarrhea-predominant irritable bowel syndrome patients using real-time PCR and immunofluorescence. Claudin-2 expression was high in the ileum of diarrhea-predominant irritable bowel syndrome patients. Claudin-2 expression was the same in cecum and rectal mucosa of control and diarrhea-predominant irritable bowel syndrome patients. Similarly, the expression of clauidn-1, claudin-7, JAM-A, occludin, and ZO-1 in the ileal, cecal, and rectal mucosa did not change between control and diarrhea-predominant irritable bowel syndrome samples. Infiltration of eosinophil and mast cells in the mucosa of ileum, cecum and rectum was evaluated using immunohistochemical staining and was not affected by diarrhea-predominant irritable bowel syndrome. Claudin-2 was expressed on the apical side of villi and crypts of ileal mucosal epithelial cells. Clauidn-2 expression is upregulated in diarrhea-predominant irritable bowel syndrome patients and may contribute to the pathogenesis of this condition. © 2017 JCBN.","Claudins; Eosinophil; Irritable bowel syndrome; Mast cell; Tight junction","claudin 1; claudin 2; claudin 7; junctional adhesion molecule A; occludin; protein ZO1; tight junction protein; adult; Article; cecum; cell infiltration; clinical article; controlled study; diarrhea; eosinophil; female; human; ileum; immunofluorescence; immunohistochemistry; inflammatory cell; intestine crypt; intestine epithelium cell; intestine villus; irritable colon; male; mast cell; protein expression; real time polymerase chain reaction; rectum mucosa; upregulation","","claudin 1, 329338-06-9; occludin, 176304-61-3","","","Japan Society for the Promotion of Science, JSPS, (17K09363)","","Lovell R.M., Ford A.C., Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis, Clin Gastroenterol Hepatol, 10, pp. 712-712e4, (2012); Fukudo S., Kaneko H., Akiho H., Et al., Evidence-based clinical practice guidelines for irritable bowel syndrome, J Gastroenterol, 50, pp. 11-30, (2015); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Gecse K., Roka R., Sera T., Et al., Leaky gut in patients with diarrheapredominant irritable bowel syndrome and inactive ulcerative colitis, Digestion, 85, pp. 40-46, (2012); Martinez C., Lobo B., Pigrau M., Et al., Diarrhoea-predominant irritable bowel syndrome: An organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, pp. 1160-1168, (2013); Piche T., Barbara G., Aubert P., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: Involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Coeffier M., Gloro R., Boukhettala N., Et al., Increased proteasome-mediated degradation of occludin in irritable bowel syndrome, Am J Gastroenterol, 105, pp. 1181-1188, (2010); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Et al., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am J Gastroenterol, 106, pp. 2165-2173, (2011); Vivinus-Nebot M., Frin-Mathy G., Bzioueche H., Et al., Functional bowel symptoms in quiescent inflammatory bowel diseases: Role of epithelial barrier disruption and low-grade inflammation, Gut, 63, pp. 744-752, (2014); Wang Y., Gao Y., Liu Q., Et al., Effect of Vitamin A and Zn supplementation on indices of Vitamin A status, haemoglobin level and defecation of children with persistent diarrhea, J Clin Biochem Nutr, 59, pp. 58-64, (2016); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Chadwick V.S., Chen W., Shu D., Et al., Activation of the mucosal immune system in irritable bowel syndrome, Gastroenterology, 122, pp. 1778-1783, (2002); Barbara G., Stanghellini V., De Giorgio R., Et al., Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome, Gastroenterology, 126, pp. 693-702, (2004); Park J.H., Rhee P.L., Kim H.S., Et al., Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome, J Gastroenterol Hepatol, 21, 1, pp. 71-78, (2006); Tornblom H., Lindberg G., Nyberg B., Veress B., Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome, Gastroenterology, 123, pp. 1972-1979, (2002); Weston A.P., Biddle W.L., Bhatia P.S., Miner P.B., Terminal ileal mucosal mast cells in irritable bowel syndrome, Dig Dis Sci, 38, pp. 1590-1595, (1993); Piche T., Saint-Paul M.C., Dainese R., Et al., Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome, Gut, 57, pp. 468-473, (2008); Vanuytsel T., Van Wanrooy S., Vanheel H., Et al., Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism, Gut, 63, pp. 1293-1299, (2014); Wallon C., Yang P.C., Keita A.V., Et al., Corticotropin-releasing hormone (CRH) regulates macromolecular permeability via mast cells in normal human colonic biopsies in vitro, Gut, 57, pp. 50-58, (2008); Oshima T., Miwa H., Gastrointestinal mucosal barrier function and diseases, J Gastroenterol, 51, pp. 768-778, (2016); Kanazawa M., Nakajima S., Oshima T., Et al., Validity and reliability of the Japanese version of the Rome III diagnostic questionnaire for irritable bowel syndrome and functional dyspepsia, J Neurogastroenterol Motil, 21, pp. 537-544, (2015); Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Tsukita S., Furuse M., Pores in the wall: Claudins constitute tight junction strands containing aqueous pores, J Cell Biol, 149, pp. 13-16, (2000); Yu Y., Liu Z.Q., Liu X.Y., Et al., Stress-derived corticotropin releasing factor breaches epithelial endotoxin tolerance, PLoS One, 8, (2013); Liu X., Yang G., Geng X.R., Et al., Microbial products induce claudin-2 to compromise gut epithelial barrier function, PLoS One, 8, (2013); Zheng P.Y., Feng B.S., Oluwole C., Et al., Psychological stress induces eosinophils to produce corticotrophin releasing hormone in the intestine, Gut, 58, pp. 1473-1479, (2009); Martinez C., Vicario M., Ramos L., Et al., The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations, Am J Gastroenterol, 107, pp. 736-746, (2012); Nasser Y., Boeckxstaens G.E., Wouters M.M., Schemann M., Vanner S., Using human intestinal biopsies to study the pathogenesis of irritable bowel syndrome, Neurogastroenterol Motil, 26, pp. 455-469, (2014); Rodrigo L., Lauret E., Perez I., Suarez A., Comments on ""the jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations, Am J Gastroenterol, 109, pp. 1290-1291, (2014); Mineta K., Yamamoto Y., Yamazaki Y., Et al., Predicted expansion of the claudin multigene family, FEBS Lett, 585, pp. 606-612, (2011); Amasheh S., Meiri N., Gitter A.H., Et al., Claudin-2 expression induces cationselective channels in tight junctions of epithelial cells, J Cell Sci, 115, pp. 4969-4976, (2002); Suzuki T., Yoshinaga N., Tanabe S., Interleukin-6 (IL-6) regulates claudin-2 expression and tight junction permeability in intestinal epithelium, J Biol Chem, 286, pp. 31263-31271, (2011); Rosenthal R., Milatz S., Krug S.M., Et al., Claudin-2, a component of the tight junction, forms a paracellular water channel, J Cell Sci, 123, pp. 1913-1921, (2010); Prasad S., Mingrino R., Kaukinen K., Et al., Inflammatory processes have differential effects on claudins 2, 3 and 4 in colonic epithelial cells, Lab Invest, 85, pp. 1139-1162, (2005); Oshima T., Miwa H., Joh T., Changes in the expression of claudins in active ulcerative colitis, J Gastroenterol Hepatol, 23, pp. S146-S150, (2008); Wilcz-Villega E.M., McClean S., O'Sullivan M.A., Mast cell tryptase reduces junctional adhesion molecule-A (JAM-A) expression in intestinal epithelial cells: Implications for the mechanisms of barrier dysfunction in irritable bowel syndrome, Am J Gastroenterol, 108, pp. 1140-1151, (2013); Wilcz-Villega E., McClean S., O'Sullivan M., Reduced E-cadherin expression is associated with abdominal pain and symptom duration in a study of alternating and diarrhea predominant IBS, Neurogastroenterol Motil, 26, pp. 316-325, (2014)","T. Oshima; Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo, 1-1 Mukogawa-cho, 663-8501, Japan; email: t-oshima@hyo-med.ac.jp","","The Society for Free Radical Research Japan","","","","","","09120009","","JCBNE","","English","J. Clin. Biochem. Nutr.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85014481386"

"Wu R.L.; Vazquez-Roque M.I.; Carlson P.; Burton D.; Grover M.; Camilleri M.; Turner J.R.","Wu, Richard L (57192836146); Vazquez-Roque, Maria I (8983380500); Carlson, Paula (7103028430); Burton, Duane (35453351900); Grover, Madhusudan (23012057300); Camilleri, Michael (7102181053); Turner, Jerrold R. (7404249336)","57192836146; 8983380500; 7103028430; 35453351900; 23012057300; 7102181053; 7404249336","Gluten-induced symptoms in diarrhea-predominant irritable bowel syndrome are associated with increased myosin light chain kinase activity and claudin-15 expression","2017","Laboratory Investigation","97","1","","14","23","9","42","10.1038/labinvest.2016.118","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85008311673&doi=10.1038%2flabinvest.2016.118&partnerID=40&md5=8930e090192f8b975a3b3f2e6d1b0652","Department of Pathology, University of Chicago, Chicago, IL, United States; Department of Pathology and Laboratory Medicine, Jackson Memorial Hospital, University of Miami, Miami, FL, United States; Division of Gastroenterology and Hepatology, Clinical Enteric Neuroscience Translational and Epidemiological Research, College of Medicine, Mayo Clinic, Rochester, MN, United States; Departments of Pathology and Medicine (GI), Brigham and Women's Hospital, Harvard Medical School, 20 Shattuck Street, TH1428, Boston, 02115, MA, United States","Wu R.L., Department of Pathology, University of Chicago, Chicago, IL, United States, Department of Pathology and Laboratory Medicine, Jackson Memorial Hospital, University of Miami, Miami, FL, United States; Vazquez-Roque M.I., Division of Gastroenterology and Hepatology, Clinical Enteric Neuroscience Translational and Epidemiological Research, College of Medicine, Mayo Clinic, Rochester, MN, United States; Carlson P., Division of Gastroenterology and Hepatology, Clinical Enteric Neuroscience Translational and Epidemiological Research, College of Medicine, Mayo Clinic, Rochester, MN, United States; Burton D., Division of Gastroenterology and Hepatology, Clinical Enteric Neuroscience Translational and Epidemiological Research, College of Medicine, Mayo Clinic, Rochester, MN, United States; Grover M., Division of Gastroenterology and Hepatology, Clinical Enteric Neuroscience Translational and Epidemiological Research, College of Medicine, Mayo Clinic, Rochester, MN, United States; Camilleri M., Division of Gastroenterology and Hepatology, Clinical Enteric Neuroscience Translational and Epidemiological Research, College of Medicine, Mayo Clinic, Rochester, MN, United States; Turner J.R., Department of Pathology, University of Chicago, Chicago, IL, United States, Departments of Pathology and Medicine (GI), Brigham and Women's Hospital, Harvard Medical School, 20 Shattuck Street, TH1428, Boston, 02115, MA, United States","The mechanisms underlying diarrhea-predominant irritable bowel syndrome (IBS-D) are poorly understood, but increased intestinal permeability is thought to contribute to symptoms. A recent clinical trial of gluten-free diet (GFD) demonstrated symptomatic improvement, relative to gluten-containing diet (GCD), which was associated with reduced intestinal permeability in non-celiac disease IBS-D patients. The aim of this study was to characterize intestinal epithelial tight junction composition in IBS-D before and after dietary gluten challenge. Biopsies from 27 IBS-D patients (13 GFD and 14 GCD) were examined by H&E staining and semiquantitative immunohistochemistry for phosphorylated myosin II regulatory light chain (MLC), MLC kinase, claudin-2, claudin-8 and claudin-15. Diet-induced changes were assessed and correlated with urinary mannitol excretion (after oral administration). In the small intestine, epithelial MLC phosphorylation was increased or decreased by GCD or GFD, respectively, and this correlated with increased intestinal permeability (P<0.03). Colonocyte expression of the paracellular Na + channel claudin-15 was also markedly augmented following GCD challenge (P<0.05). Conversely, colonic claudin-2 expression correlated with reduced intestinal permeability (P<0.03). Claudin-8 expression was not affected by dietary challenge. These data show that alterations in MLC phosphorylation and claudin-15 and claudin-2 expression are associated with gluten-induced symptomatology and intestinal permeability changes in IBS-D. The results provide new insight into IBS-D mechanisms and can explain permeability responses to gluten challenge in these patients. © 2017 USCAP, Inc All rights reserved.","","Adult; Claudin-2; Claudins; Colon; Diarrhea; Diet, Gluten-Free; Female; Glutens; Humans; Immunohistochemistry; Intestines; Irritable Bowel Syndrome; Male; Middle Aged; Myosin Light Chains; Myosin-Light-Chain Kinase; Permeability; Phosphorylation; Tight Junctions; claudin; claudin 15; claudin 2; claudin 8; gluten; myosin II; myosin light chain kinase; sodium channel; unclassified drug; claudin; claudin 15; claudin 2; claudin 8; gluten; myosin light chain; myosin light chain kinase; Article; body mass; clinical article; colon biopsy; colon cell; controlled study; diarrhea; double blind procedure; duodenum biopsy; enzyme phosphorylation; human; immunohistochemistry; intestine cell; irritable colon; priority journal; protein analysis; protein expression; protein function; randomized controlled trial; tight junction; adult; colon; diarrhea; drug effects; female; gluten free diet; intestine; Irritable Bowel Syndrome; male; metabolism; middle aged; pathology; permeability; phosphorylation","","gluten, 8002-80-0; myosin light chain kinase, 51845-53-5; claudin 15, ; claudin 8, ; Claudin-2, ; Claudins, ; Glutens, ; Myosin Light Chains, ; Myosin-Light-Chain Kinase, ","","","National Institutes of Health, NIH, (R01DK61931, R01DK68271, R24DK099803); National Institutes of Health, NIH; National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK, (R01DK092179); National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK","ACKNOWLEDGMENTS This study was supported by National Institute of Health Grants R01DK61931 (JRT); R01DK68271 (JRT); R24DK099803 (JRT); and R01DK092179 (MC).","Drossman D.A., Chang L., Bellamy N., Et al., Severity in irritable bowel syndrome: A Rome Foundation Working Team report, Am J Gastroenterol, 106, pp. 1749-1759, (2011); Sood R., Law G.R., Ford A.C., Diagnosis of IBS: Symptoms, symptom-based criteria, biomarkers or 'psychomarkers'?, Nat Rev Gastroenterol Hepatol, 11, (2014); Peery A.F., Dellon E.S., Lund J., Et al., Burden of gastrointestinal disease in the United States: 2012 update, Gastroenterol, 143, pp. 1179-1187, (2012); Camilleri M., Katzka D.A., Irritable bowel syndrome: Methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome, Am J Physiol Gastrointest Liver Physiol, 302, pp. G1075-G1084, (2012); Vazquez-Roque M.I., Camilleri M., Smyrk T., Et al., Association of HLA-DQ gene with bowel transit, barrier function, and inflammation in irritable bowel syndrome with diarrhea, Am J Physiol Gastrointest Liver Physiol, 303, pp. G1262-G1269, (2012); Camilleri M., Madsen K., Spiller R., Et al., Intestinal barrier function in health and gastrointestinal disease, Neurogastroenterol Motil, 24, pp. 503-512, (2012); Marchiando A.M., Shen L., Graham W.V., Et al., Caveolin-1-dependent occludin endocytosis is required for TNF-induced tight junction regulation in vivo, J Cell Biol, 189, pp. 111-126, (2010); Saitou M., Furuse M., Sasaki H., Et al., Complex phenotype of mice lacking occludin, a component of tight junction strands, Mol Biol Cell, 11, pp. 4131-4142, (2000); Schulzke J.D., Gitter A.H., Mankertz J., Et al., Epithelial transport and barrier function in occludin-deficient mice, Biochim Biophys Acta, 1669, pp. 34-42, (2005); Marchiando A.M., Graham W.V., Turner J.R., Epithelial barriers in homeostasis and disease, Annu Rev Pathol, 5, pp. 119-144, (2010); Muto S., Hata M., Taniguchi J., Et al., Claudin-2-deficient mice are defective in the leaky and cation-selective paracellular permeability properties of renal proximal tubules, Proc Natl Acad Sci USA, 107, pp. 8011-8016, (2010); Tamura A., Hayashi H., Imasato M., Et al., Loss of claudin-15, but not claudin-2, causes Na+ deficiency and glucose malabsorption in mouse small intestine, Gastroenterol, 140, pp. 913-923, (2011); Tamura A., Kitano Y., Hata M., Et al., Megaintestine in claudin-15-deficient mice, Gastroenterol, 134, pp. 523-534, (2008); Bagherie-Lachidan M., Wright S.I., Kelly S.P., Claudin-8 and -27 tight junction proteins in puffer fish Tetraodon nigroviridis acclimated to freshwater and seawater, J Comp Physiol B, 179, pp. 419-431, (2009); Hou J., Renigunta A., Yang J., Et al., Claudin-4 forms paracellular chloride channel in the kidney and requires claudin-8 for tight junction localization, Proc Natl Acad Sci USA, 107, pp. 18010-18015, (2010); Wada M., Tamura A., Takahashi N., Et al., Loss of claudins 2 and 15 from mice causes defects in paracellular Na+ flow and nutrient transport in gut and leads to death from malnutrition, Gastroenterol, 144, pp. 369-380, (2013); Clayburgh D.R., Musch M.W., Leitges M., Et al., Coordinated epithelial NHE3 inhibition and barrier dysfunction are required for TNF-mediated diarrhea in vivo, J Clin Invest, 116, pp. 2682-2694, (2006); Vazquez-Roque M.I., Camilleri M., Smyrk T., Et al., A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: Effects on bowel frequency and intestinal function, Gastroenterol, 144, pp. 903-911, (2013); Rao A.S., Camilleri M., Eckert D.J., Et al., Urine sugars for in vivo gut permeability: Validation and comparisons in irritable bowel syndrome-diarrhea and controls, Am J Physiol Gastrointest Liver Physiol, 301, pp. G919-G928, (2011); Blair S.A., Kane S.V., Clayburgh D.R., Et al., Epithelial myosin light chain kinase expression and activity are upregulated in inflammatory bowel disease, Lab Invest, 86, pp. 191-201, (2006); Weber C.R., Nalle S.C., Tretiakova M., Et al., Claudin-1 and claudin-2 expression is elevated in inflammatory bowel disease and may contribute to early neoplastic transformation, Lab Invest, 88, pp. 1110-1120, (2008); Russo J.M., Florian P., Shen L., Et al., Distinct temporal-spatial roles for rho kinase and myosin light chain kinase in epithelial purse-string wound closure, Gastroenterol, 128, pp. 987-1001, (2005); Clayburgh D.R., Rosen S., Witkowski E.D., Et al., A differentiation-dependent splice variant of myosin light chain kinase, MLCK1, regulates epithelial tight junction permeability, J Biol Chem, 279, pp. 55506-55513, (2004); Clayburgh D.R., Barrett T.A., Tang Y., Et al., Epithelial myosin light chain kinase-dependent barrier dysfunction mediates T cell activation-induced diarrhea in vivo, J Clin Invest, 115, pp. 2702-2715, (2005); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Van Itallie C.M., Holmes J., Bridges A., Et al., The density of small tight junction pores varies among cell types and is increased by expression of claudin-2, J Cell Sci, 121, pp. 298-305, (2008); Li J., Zhuo M., Pei L., Et al., Comprehensive cysteine-scanning mutagenesis reveals claudin-2 pore-lining residues with different intrapore locations, J Biol Chem, 289, pp. 6475-6484, (2014); Yu A.S., Cheng M.H., Angelow S., Et al., Molecular basis for cation selectivity in claudin-2-based paracellular pores: Identification of an electrostatic interaction site, J Gen Physiol, 133, pp. 111-127, (2009); Weber C.R., Liang G.H., Wang Y., Et al., Claudin-2-dependent paracellular channels are dynamically gated, ELife, 4, (2015); Angelow S., Schneeberger E.E., Yu A.S., Claudin-8 expression in renal epithelial cells augments the paracellular barrier by replacing endogenous claudin-2, J Membr Biol, 215, pp. 147-159, (2007); Angelow S., Kim K.J., Yu A.S., Claudin-8 modulates paracellular permeability to acidic and basic ions in MDCK II cells, J Physiol, 571, pp. 15-26, (2006); Yu A.S., Enck A.H., Lencer W.I., Et al., Claudin-8 expression in Madin-Darby canine kidney cells augments the paracellular barrier to cation permeation, J Biol Chem, 278, pp. 17350-17359, (2003); Colegio O.R., Van Itallie C., Rahner C., Et al., Claudin extracellular domains determine paracellular charge selectivity and resistance but not tight junction fibril architecture, Am J Physiol Cell Physiol, 284, pp. C1346-C1354, (2003); Capaldo C.T., Farkas A.E., Hilgarth R.S., Et al., Proinflammatory cytokine-induced tight junction remodeling through dynamic self-assembly of claudins, Mol Biol Cell, 25, pp. 2710-2719, (2014); Szakal D.N., Gyorffy H., Arato A., Et al., Mucosal expression of claudins 2, 3 and 4 in proximal and distal part of duodenum in children with coeliac disease, Virchows Arch, 456, pp. 245-250, (2010); Zeissig S., Burgel N., Gunzel D., Et al., Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease, Gut, 56, pp. 61-72, (2007); Heller F., Florian P., Bojarski C., Et al., Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution, Gastroenterol, 129, pp. 550-564, (2005); Su L., Nalle S.C., Shen L., Et al., TNFR2 activates MLCK-dependent tight junction dysregulation to cause apoptosis-mediated barrier loss and experimental colitis, Gastroenterol, 145, pp. 407-415, (2013); Suzuki H., Nishizawa T., Tani K., Et al., Crystal structure of a claudin provides insight into the architecture of tight junctions, Science, 344, pp. 304-307, (2014); Abiko Y., Kojima T., Murata M., Et al., Changes of tight junction protein claudins in small intestine and kidney tissues of mice fed a DDC diet, J Toxicol Pathol, 26, pp. 433-438, (2013); Arimura Y., Nagaishi K., Hosokawa M., Dynamics of claudins expression in colitis and colitis-associated cancer in rat, Methods Mol Biol, 762, pp. 409-425, (2011); Darsigny M., Babeu J.P., Dupuis A.A., Et al., Loss of hepatocyte-nuclear-factor-4alpha affects colonic ion transport and causes chronic inflammation resembling inflammatory bowel disease in mice, PLoS One, 4, (2009); Tipsmark C.K., Sorensen K.J., Madsen S.S., Aquaporin expression dynamics in osmoregulatory tissues of Atlantic salmon during smoltification and seawater acclimation, J Exp Biol, 213, pp. 368-379, (2010); Holmes J.L., Van Itallie C.M., Rasmussen J.E., Et al., Claudin profiling in the mouse during postnatal intestinal development and along the gastrointestinal tract reveals complex expression patterns, Gene Expr Patterns, 6, pp. 581-588, (2006); Turner J.R., De C., Mrsny R.J., Et al., Noninvasive in vivo analysis of human small intestinal paracellular absorption: Regulation by Na +-glucose cotransport, Dig Dis Sci, 45, pp. 2122-2126, (2000); Rosenthal R., Gunzel D., Krug S.M., Et al., Claudin-2-mediated cation and water transport share a common pore, Acta Physiol (Oxf), (2016); Amasheh S., Meiri N., Gitter A.H., Et al., Claudin-2 expression induces cation-selective channels in tight junctions of epithelial cells, J Cell Sci, 115, pp. 4969-4976, (2002); Turner J.R., Buschmann M.M., Romero-Calvo I., Et al., The role of molecular remodeling in differential regulation of tight junction permeability, Semin Cell Dev Biol, 36, pp. 204-212, (2014); Edelblum K.L., Shen L., Weber C.R., Et al., Dynamic migration of gammadelta intraepithelial lymphocytes requires occludin, Proc Natl Acad Sci USA, 109, pp. 7097-7102, (2012); Edelblum K.L., Singh G., Ma O., Et al., Gammadelta intraepithelial lymphocyte migration limits transepithelial pathogen invasion and systemic disease in mice, Gastroenterol, 148, pp. 1417-1426, (2015); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Et al., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am J Gastroenterol, 106, pp. 2165-2173, (2011); Cheng P., Yao J., Wang C., Et al., Molecular and cellular mechanisms of tight junction dysfunction in the irritable bowel syndrome, Mol Med Rep, 12, pp. 3257-3264, (2015); Furuse M., Hata M., Furuse K., Et al., Claudin-based tight junctions are crucial for the mammalian epidermal barrier: A lesson from claudin-1-deficient mice, J Cell Biol, 156, pp. 1099-1111, (2002); Saeedi B.J., Kao D.J., Kitzenberg D.A., Et al., HIF-dependent regulation of claudin-1 is central to intestinal epithelial tight junction integrity, Mol Biol Cell, 26, pp. 2252-2262, (2015); Martinez C., Lobo B., Pigrau M., Et al., Diarrhoea-predominant irritable bowel syndrome: An organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, pp. 1160-1168, (2013); Bertrand J., Ghouzali I., Guerin C., Et al., Glutamine restores tight junction protein claudin-1 expression in colonic mucosa of patients with diarrhea-predominant irritable bowel syndrome, J Parenter Enteral Nutr, (2015); Umeda K., Ikenouchi J., Katahira-Tayama S., Et al., ZO-1 and ZO-2 independently determine where claudins are polymerized in tight-junction strand formation, Cell, 126, pp. 741-754, (2006); Wilcz-Villega E., McClean S., O'Sullivan M., Reduced E-cadherin expression is associated with abdominal pain and symptom duration in a study of alternating and diarrhea predominant IBS, Neurogastroenterol Motil, 26, pp. 316-325, (2014); Piche T., Barbara G., Aubert P., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: Involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Nalle S.C., Turner J.R., Intestinal barrier loss as a critical pathogenic link between inflammatory bowel disease and graft-versus-host disease, Mucosal Immunol, 8, pp. 720-730, (2015); Turner J.R., Madara J.L., Physiological regulation of tight junction permeability by Na+-nutrient cotransport, Tight Junctions, pp. 333-347, (2001); Turner J.R., Rill B.K., Carlson S.L., Et al., Physiological regulation of epithelial tight junctions is associated with myosin light-chain phosphorylation, Am J Physiol-Cell Physiol, 273, pp. C1378-C1385, (1997); Atisook K., Carlson S., Madara J.L., Effects of phlorizin and sodium on glucose-elicited alterations of cell junctions in intestinal epithelia, Am J Physiol, 258, pp. C77-C85, (1990); Zolotarevsky Y., Hecht G., Koutsouris A., Et al., A membrane-permeant peptide that inhibits MLC kinase restores barrier function in in vitro models of intestinal disease, Gastroenterol, 123, pp. 163-172, (2002); Berglund J.J., Riegler M., Zolotarevsky Y., Et al., Regulation of human jejunal transmucosal resistance and MLC phosphorylation by Na<sup>+</sup>-glucose cotransport, Am J Physiol Gastrointest Liver Physiol, 281, pp. G1487-G1493, (2001); Shen L., Black E.D., Witkowski E.D., Et al., Myosin light chain phosphorylation regulates barrier function by remodeling tight junction structure, J Cell Sci, 119, pp. 2095-2106, (2006); Su L., Shen L., Clayburgh D.R., Et al., Targeted epithelial tight junction dysfunction causes immune activation and contributes to development of experimental colitis, Gastroenterol, 136, pp. 551-563, (2009); Wang F., Graham W.V., Wang Y., Et al., Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression, Am J Pathol, 166, pp. 409-419, (2005); Graham W.V., Wang F., Clayburgh D.R., Et al., Tumor necrosis factor-induced long myosin light chain kinase transcription is regulated by differentiation-dependent signaling events. Characterization of the human long myosin light chain kinase promoter, J Biol Chem, 281, pp. 26205-26215, (2006); Wang F., Schwarz B.T., Graham W.V., Et al., IFN-gamma-induced TNFR2 expression is required for TNF-dependent intestinal epithelial barrier dysfunction, Gastroenterol, 131, pp. 1153-1163, (2006); Rosenthal R., Milatz S., Krug S.M., Et al., Claudin-2, a component of the tight junction, forms a paracellular water channel, J Cell Sci, 123, pp. 1913-1921, (2010); Turner J.R., Intestinal mucosal barrier function in health and disease, Nat Rev Immunol, 9, pp. 799-809, (2009); Anderson J.M., Van Itallie C.M., Physiology and function of the tight junction, Cold Spring Harb Perspect Biol, 1, (2009); Weber C.R., Raleigh D.R., Su L., Et al., Epithelial myosin light chain kinase activation induces mucosal interleukin-13 expression to alter tight junction ion selectivity, J Biol Chem, 285, pp. 12037-12046, (2010); Marciani L., Cox E.F., Hoad C.L., Et al., Postprandial changes in small bowel water content in healthy subjects and patients with irritable bowel syndrome, Gastroenterol, 138, pp. 469-477, (2010); Wilcz-Villega E.M., McClean S., Ma O., Mast cell tryptase reduces junctional adhesion molecule-A (JAM-A) expression in intestinal epithelial cells: Implications for the mechanisms of barrier dysfunction in irritable bowel syndrome, Am J Gastroenterol, 108, pp. 1140-1151, (2013); Vetrano S., Rescigno M., Cera M.R., Et al., Unique role of junctional adhesion molecule-a in maintaining mucosal homeostasis in inflammatory bowel disease, Gastroenterol, 135, pp. 173-184, (2008); Swan C., Duroudier N.P., Campbell E., Et al., Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): Association with TNFSF15 and TNFalpha, Gut, 62, pp. 985-994, (2013)","J.R. Turner; Departments of Pathology and Medicine (GI), Brigham and Women's Hospital, Harvard Medical School, Boston, 20 Shattuck Street, TH1428, 02115, United States; email: jrturner@bwh.harvard.edu","","Nature Publishing Group","","","","","","00236837","","LAINA","27869798","English","Lab. Investig.","Article","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-85008311673"

"Valentin N.; Camilleri M.; Carlson P.; Harrington S.C.; Eckert D.; O'Neill J.; Burton D.; Chen J.; Shaw A.L.; Acosta A.","Valentin, Nelson (56644402100); Camilleri, Michael (7102181053); Carlson, Paula (7103028430); Harrington, Sean C. (12770653200); Eckert, Deborah (25121346500); O'Neill, Jessica (9043435800); Burton, Duane (35453351900); Chen, Jun (56640742100); Shaw, Audrey L. (7402249214); Acosta, Andres (55844615900)","56644402100; 7102181053; 7103028430; 12770653200; 25121346500; 9043435800; 35453351900; 56640742100; 7402249214; 55844615900","Potential mechanisms of effects of serum-derived bovine immunoglobulin/protein isolate therapy in patients with diarrhea-predominant irritable bowel syndrome","2017","Physiological Reports","5","5","e13170","","","","20","10.14814/phy2.13170","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85015177828&doi=10.14814%2fphy2.13170&partnerID=40&md5=8aa584af02a499f180bb31b0494dcf07","Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, MN, United States; Entera Health Inc., Cary, NC, United States","Valentin N., Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, MN, United States; Camilleri M., Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, MN, United States; Carlson P., Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, MN, United States; Harrington S.C., Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, MN, United States; Eckert D., Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, MN, United States; O'Neill J., Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, MN, United States; Burton D., Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, MN, United States; Chen J., Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, MN, United States; Shaw A.L., Entera Health Inc., Cary, NC, United States; Acosta A., Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, MN, United States","Serum-derived bovine immunoglobulin/protein isolate (SBI), an oral nutritional therapy, is efficacious in diverse diarrheal diseases. In an open-label study in 15 patients with irritable bowel syndrome-diarrhea (IBS-D), we evaluated effects of SBI (5.0 g, twice a day) for 8 weeks on safety, on bowel function and abdominal pain, tryptophan metabolism (K:T ratio), intestinal permeability (13C-mannitol and lactulose excretion), bile acid synthesis (fasting serum FGF-19 and C4), duodenal and stool microbiome, and the expression of 90 genes related to inflammation, immune function, and tight junctions in duodenal mucosa. Statistical analysis (paired tests, baseline vs. treatment) was based on intention to treat (ITT) principles. One of 15 Caucasian patients (13F, 2M, age 40.3 ± 2.3y, BMI 34.3 ± 3.0 kg/m2) withdrew without completing studies. There were improvements in stools/day (decrease, P < 0.001), ease of passage (P = 0.035), and evacuation (P = 0.004) with SBI therapy. Worst pain severity was numerically reduced in last 2 weeks' treatment (P = 0.078). Duodenal mucosal mRNA expression; serum C4, FGF-19, and KT ratio; small bowel or colon permeability; and stool microbiome were not significantly different after SBI therapy, compared to baseline. In duodenal brushings, there was considerable microbiota structure difference (β diversity analysis P = 0.072, UniFrac) and, on taxonomic analysis, increased abundance of Proteobacteria Burkholderiales, Firmicutes Catonella, and unclassified genus organisms with SBI therapy. Thus, SBI therapy for 8 weeks in IBS-D patients is associated with improved bowel function; the mechanism of benefit is unclear, though there were microbiota structure differences in duodenal brushings. Further studies in patients with low-grade inflammation and intestinal barrier dysfunction at baseline are indicated. © 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of The Physiological Society and the American Physiological Society.","Bile acids; gene expression; permeability; tryptophan","Abdominal Pain; Adult; Animals; Cattle; Diarrhea; Female; Humans; Immunoglobulins; Intestinal Mucosa; Intestine, Small; Irritable Bowel Syndrome; Male; Pain Measurement; Permeability; Treatment Outcome; bovine immunoglobulin; chemokine; complement component C4; fibroblast growth factor 19; lactulose; mannitol; tight junction protein; immunoglobulin; abdominal pain; adult; aged; anastomosis leakage; Article; backache; bacterium isolation; bile acid synthesis; bloating; clinical article; clinical trial; defecation habit; diarrhea; drug withdrawal; duodenum biopsy; enzyme linked immunosorbent assay; feces analysis; female; Firmicutes; gastroesophageal reflux; gastrointestinal endoscopy; gene expression; headache; high performance liquid chromatography; human; human tissue; inflammation; influenza; intestine flora; intestine function; intestine mucosa permeability; irritable colon; liquid chromatography-mass spectrometry; male; meteorism; molecular therapy; mouth pain; muscle cramp; nausea; nonhuman; pain severity; patient compliance; protein expression; protein isolate therapy; Proteobacteria; real time polymerase chain reaction; taste disorder; taxonomy; tryptophan metabolism; abdominal pain; animal; bovine; diarrhea; intestine mucosa; irritable colon; metabolism; pain measurement; permeability; small intestine; treatment outcome","","complement component C4, 80295-48-3, 80295-71-2; lactulose, 4618-18-2; mannitol, 69-65-8, 87-78-5; immunoglobulin, 9007-83-4; Immunoglobulins, ","","","Department of Bioengineering; EnteraHealth, (R01-DK92179, UL1-TR000135); National Institutes of Health, NIH; National Center for Advancing Translational Sciences, NCATS; University of California, San Francisco, UCSF, (CA 94143)","Funding Information This study was supported by a research grant from EnteraHealth. Dr. Camilleri is supported by NIH grant R01-DK92179. The study was made possible by CCaTS grant UL1-TR000135 from the National Center for Advancing Translational Sciences (NCATS), a component of National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NIH. We thank Mrs. Cindy Stanislav for excellent secretarial assistance. K/T analyses were conducted by a contract lab (Dr. Yong Huang at the University of California, San Francisco Drug Studies Unit, Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, UCSF, CA 94143).","Asmuth D.M., Ma Z.M., Albanese A., Sandler N.G., Devaraj S., Knight T.H., Et al., Oral serum-derived bovine immunoglobulin improves duodenal immune reconstitution and absorption function in patients with HIV enteropathy, AIDS, 27, pp. 2207-2217, (2013); Bischoff S.C., Barbara G., Buurman W., Ockhuizen T., Schulzke J.D., Serino M., Et al., Intestinal permeability–a new target for disease prevention and therapy, BMC Gastroenterol., 14, (2014); Camilleri M., Peripheral mechanisms in irritable bowel syndrome, N. Engl. J. Med., 367, pp. 1626-1635, (2012); Camilleri M., Katzka D.A., Invited Review. irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome, Am. J. Physiol., 302, pp. G1075-G1084, (2012); Camilleri M., Nadeau A., Tremaine W.J., Lamsam J., Burton D., Odunsi S., Et al., Measurement of serum 7 α -hydroxy-4-cholesten-3-one (or 7 α C4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry, Neurogastroenterol. Motil., 21, pp. 734-743, (2009); Camilleri M., Nadeau A., Lamsam J., Nord S.L., Ryks M., Burton D., Et al., Understanding measurements of intestinal permeability in healthy humans with urine lactulose and mannitol excretion, Neurogastroenterol. Motil., 22, pp. e15-e26, (2010); Camilleri M., Acosta A., Busciglio I., Boldingh A., Dyer R.B., Zinsmeister A.R., Et al., Effect of colesevelam on fecal bile acids and bowel functions in diarrhea-predominant irritable bowel syndrome, Aliment. Pharmacol. Ther., 41, pp. 438-448, (2015); Camilleri M., Carlson P., Acosta A., Busciglio I., Colonic mucosal gene expression and genotype in irritable bowel syndrome with normal or elevated fecal bile acid excretion, Am. J. Physiol. Gastrointest. Liver Physiol., 309, pp. G10-G20, (2015); Camilleri M., Carlson P., Valentin N., Acosta A., O'Neill J., Eckert D., Et al., Pilot study of small mucosal gene expression in patients with irritable bowel syndrome and diarrhea, Am. J. Physiol., 311, pp. G365-G376, (2016); Camilleri M., Oduyebo I., Halawi H., Chemical and molecular factors in irritable bowel syndrome: current knowledge, challenges and unanswered questions, Am. J. Physiol. Gastrointest. Liver Physiol., 311, pp. G777-G784, (2016); Campbell J.M., Polo J., Russell L.E., Crenshaw J.D., Review of spray-dried plasma's impact on intestinal barrier function, Livestock. Sci., 133, pp. 239-241, (2010); Caporaso J.G., Kuczynski J., Stombaugh J., Bittinger K., Bushman F.D., Costello E.K., Et al., QIIME allows analysis of high-throughput community sequencing data, Nat. Methods, 7, pp. 335-336, (2010); Caporaso J.G., Lauber C.L., Walters W.A., Berg-Lyons D., Huntley J., Fierer N., Et al., Ultra-high-throughput microbial community analysis on the Illumina HiSeq platforms, ISME J., 6, pp. 1621-1624, (2012); Carretti N., Florio P., Bertolin A., Costa C.V., Allegri G., Zilli G., Serum fluctuations of total and free tryptophan levels during the menstrual cycle are related to gonadotrophins and reflect brain serotonin utilization, Hum. Reprod., 20, pp. 1548-1553, (2005); Clarke G., Fitzgerald P., Cryan J.F., Cassidy E.M., Quigley E.M., Dinan T.G., Tryptophan degradation in irritable bowel syndrome: evidence of indoleamine 2,3-dioxygenase activation in a male cohort, BMC Gastroenterol., 9, (2009); Crawford C., Panas R., Post-infectious irritable bowel syndrome with functional diarrhea following C. difficile infections: case studies of responses using serum-derived bovine immunoglobulin, J. Gastroenterol. Hepatol. Res., 4, pp. 1577-1581, (2015); Dawson J., Hodgson H.J., Pepys M.B., Peters T.J., Chadwick V.S., Immunodeficiency, malabsorption and secretory diarrhea a new syndrome, Am. J. Med., 67, pp. 540-546, (1979); Dethlefsen L., Relman D.A., Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation, Proc. Natl Acad. Sci. USA, 108, pp. 4554-4561, (2011); Dethlefsen L., Huse S., Sogin M.L., Relman D.A., The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing, PLoS Biol., 6, (2008); Detzel C.J., Horgan A., Henderson A.L., Petschow B.W., Warner C.D., Maas K.J., Et al., Bovine immunoglobulin/protein isolate binds pro-inflammatory bacterial compounds and prevents immune activation in an intestinal co-culture model, PLoS ONE, 10, (2015); Gohl D.M., Vangay P., Garbe J., MacLean A., Hauge A., Becker A., Et al., Systematic improvement of amplicon marker gene methods for increased accuracy in microbiome studies, Nat. Biotechnol., 34, pp. 942-949, (2016); Good L., Rosario R., Panas R., New therapeutic option for irritable bowel syndrome: serum-derived bovine immunoglobulin, World J. Gastroenterol., 21, pp. 3361-3366, (2015); Grover M., Camilleri M., Hines J., Burton D., Ryks M., Wadhwa A., Et al.,            <sup>13</sup>C mannitol as a novel biomarker for measurement of intestinal permeability, Neurogastroenterol. Motil., 28, pp. 1114-1119, (2016); Huang Y., Louie A., Yang Q., Massenkoff N., Xu C., Hunt P.W., Et al., A simple LC-MS/MS method for determination of kynurenine and tryptophan concentrations in human plasma from HIV-infected patients, Bioanalysis, 5, pp. 1397-1407, (2013); Jatoi A., Anti-inflammatory therapy: exploring exercise, serum-derived bovine immunoglobulin/protein isolates, and ruxolitinib for the cancer-associated weight loss syndrome, Curr. Opin. Support Palliat. Care., 7, pp. 339-341, (2013); Jeffery I.B., O'Toole P.W., Ohman L., Claesson M.J., Deane J., Quigley E.M., Et al., An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota, Gut, 61, pp. 997-1006, (2012); Jenabian M.A., El-Far M., Vyboh K., Kema I., Costiniuk C.T., Thomas R., Immunosuppressive tryptophan catabolism and gut mucosal dysfunction following early HIV infection, J. Infect. Dis., 212, pp. 355-366, (2015); Jeraldo P., Kalari K., Chen X., Bhavsar J., Mangalam A., White B., Et al., IM-TORNADO: a tool for comparison of 16S reads from paired-end libraries, PLoS ONE, 9, (2014); Kuchibhatla R., Petschow B.W., Odle J., Weaver E.M., Nutritional impact of dietary plasma proteins in animals undergoing experimental challenge and implications for patients with inflammatory bowel disorders: a meta-analysis, Adv. Nutr., 6, pp. 541-551, (2015); Lewis S.J., Heaton K.W., Stool form scale as a useful guide to intestinal transit time, Scand. J. Gastroenterol., 32, pp. 920-924, (1997); Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Lostia A.M., Lionetto L., Principessa L., Evangelisti M., Gamba A., Villa M.P., Et al., A liquid chromatography/mass spectrometry method for the evaluation of intestinal permeability, Clin. Biochem., 41, pp. 887-892, (2008); Martinez C., Vicario M., Ramos L., Lobo B., Mosquera J.L., Alonso C., Et al., The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations, Am. J. Gastroenterol., 107, pp. 736-746, (2012); Martinez C., Lobo B., Pigrau M., Ramos L., Gonzalez-Castro A.M., Alonso C., Et al., Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, pp. 1160-1168, (2013); Moreto M., Perez-Bosque A., Dietary plasma proteins, the intestinal immune system, and the barrier functions of the intestinal mucosa, J. Anim. Sci., 87, 14, pp. E92-E100, (2009); Navarro A., Eslava C., de Garcia la Torre G., Leon L.A., Licona D., Leon L., Zarco L.A., Cravioto A., Common epitopes in LPS of different Enterobacteriaceae are associated with an immune response against Escherichia coli O157 in bovine serum samples, J Med Microbiol, 56, pp. 1447-1454, (2007); Ohman L., Simren M., Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions, Nat. Rev. Gastroenterol. Hepatol., 7, pp. 163-173, (2010); Perez-Bosque A., Miro L., Maijo M., Polo J., Campbell J., Russell L., Et al., Dietary intervention with serum-derived bovine immunoglobulins protects barrier function in a mouse model of colitis, Am. J. Physiol. Gastrointest. Liver Physiol., 308, pp. G1012-G1018, (2015); Perez-Pantoja D., Donoso R., Agullo L., Cordova M., Seeger M., Pieper D.H., Et al., Genomic analysis of the potential for aromatic compounds biodegradation in Burkholderiales, Environ. Microbiol., 14, pp. 1091-1117, (2012); Rao A.S., Camilleri M., Eckert D.J., Busciglio I., Burton D.D., Ryks M., Et al., Urine sugars for in vivo gut permeability: validation and comparisons in irritable bowel syndrome-diarrhea and controls, Am. J. Physiol., 301, pp. G919-G928, (2011); Shafran I., Burgunder P., Wei D., Young H.E., Klein G., Burnett B.P., Management of inflammatory bowel disease with oral serum-derived bovine immunoglobulin, Therap. Adv. Gastroenterol., 8, pp. 331-339, (2015); Simren M., Barbara G., Flint H.J., Spiegel B.M., Spiller R.C., Vanner S., Et al., Rome Foundation Committee. Intestinal microbiota in functional bowel disorders: a Rome foundation report, Gut, 62, pp. 159-176, (2013); Teahon K., Smethurst P., Pearson M., Levi A.J., Bjarnason I., The effect of elemental diet on intestinal permeability and inflammation in Crohn's disease, Gastroenterology, 101, pp. 84-89, (1991); Tomita G.M., Todhunter D.A., Hogan J.S., Smith K.L., Antigenic crossreactivity and lipopolysaccharide neutralization properties of bovine immunoglobulin G, J. Dairy Sci., 78, pp. 2745-2752, (1995); Torrallardona D., Spray dried animal plasma as an alternative to antibiotics in weanling pigs – A review, Asian-Aust. J. Anim. Sci., 23, pp. 131-148, (2010); Torres M.I., Lopez-Casado M.A., Lorite P., Rios A., Tryptophan metabolism and indoleamine 2,3-dioxygenase expression in coeliac disease, Clin. Exp. Immunol., 148, pp. 419-424, (2007); Valentin N., Camilleri M., Altayar O., Vijayvargiya P., Acosta A., Nelson A.D., Et al., Biomarkers for bile acid diarrhoea in functional bowel disorder with diarrhoea: a systematic review and meta-analysis, Gut, 65, pp. 1951-1959, (2016); Vazquez-Roque M.I., Camilleri M., Smyrk T., Murray J.A., O'Neill J., Carlson P., Et al., Association of HLA-DQ gene with bowel transit, barrier function and inflammation in irritable bowel syndrome with diarrhea, Am. J. Physiol., 303, pp. G1262-G1269, (2012); Wilson D., Evans M.D., Weaver E., Shaw A.L., Klein G.L., Evaluation of serum-derived bovine immunoglobulin protein isolate in subjects with diarrhea-predominant irritable bowel syndrome, Clin. Med. Insights Gastroenterol., 6, pp. 49-60, (2013); Yu Z., Morrison M., Comparisons of different hypervariable regions of rrs genes for use in fingerprinting of microbial communities by PCR-denaturing gradient gel electrophoresis, Appl. Environ. Microbiol., 70, pp. 4800-4806, (2004)","M. Camilleri; Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, United States; email: camilleri.michael@mayo.edu","","American Physiological Society","","","","","","2051817X","","","28275113","English","Physiol. Rep.","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85015177828"

"Ren Y.-J.; Lei Z.; Bai T.; Yu H.-L.; Li Y.; Qian W.; Jin S.; Xiong Z.-F.; Huan W.; Hou X.-H.","Ren, Ya-Jun (59098767000); Lei, Zhang (35262133900); Bai, Tao (7101922692); Yu, Hong-Lu (57192251321); Li, Ying (57872790600); Qian, Wei (35238189900); Jin, Si (16506684100); Xiong, Zhi-Fan (57198974790); Huan, Wang (57194288118); Hou, Xiao-Hua (7402838898)","59098767000; 35262133900; 7101922692; 57192251321; 57872790600; 35238189900; 16506684100; 57198974790; 57194288118; 7402838898","Transfer of CD11c+ lamina propria mononuclear phagocytes from post-infectious irritable bowel syndrome causes mucosal barrier dysfunction and visceral hypersensitivity in recipient mice","2017","International Journal of Molecular Medicine","39","6","","1555","1563","8","5","10.3892/ijmm.2017.2966","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85019624878&doi=10.3892%2fijmm.2017.2966&partnerID=40&md5=b08b20072398f97b41a12b7a1e0da6ac","Division of Gastroenterology, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, 39 Yanhu Street, Wuhan, Hubei, 430077, China; Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, China; Department of Endocrinology, Institute of Geriatric Medicine, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430077, China","Ren Y.-J., Division of Gastroenterology, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, 39 Yanhu Street, Wuhan, Hubei, 430077, China; Lei Z., Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, China; Bai T., Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, China; Yu H.-L., Division of Gastroenterology, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, 39 Yanhu Street, Wuhan, Hubei, 430077, China; Li Y., Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, China; Qian W., Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, China; Jin S., Department of Endocrinology, Institute of Geriatric Medicine, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430077, China; Xiong Z.-F., Division of Gastroenterology, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, 39 Yanhu Street, Wuhan, Hubei, 430077, China; Huan W., Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, China; Hou X.-H., Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, China","The role of low-grade inflammation in the development of post-infectious irritable bowel syndrome (PI-IBS) has attracted increasing attention. Abnormal CD11c+ mononuclear phagocytes, such as dendritic cells (DCs), macrophages, and monocytes, are involved in the disruption of immune tolerance in organisms, which can lead to the development of chronic inflammatory diseases. The present study tested the hypothesis that CD11c+ lamina propria mononuclear phagocytes (CD11c+ LPMPs) contribute to increased mucosal permeability and visceral hypersensitivity in a PI-IBS mouse model. CD11c+ LPMPs were isolated and purified via the digestion of intestinal tissues and magnetic-activated cell sorting. We detected increased mucosal permeability, visceral hypersensitivity and intestinal inflammation during both the acute and chronic stages of Trichinella infection. Following the transfer of CD11c+ LPMPs from PI-IBS mice into normal mice, low-grade inflammation was detected, as demonstrated by increased IL-4 expression in the ileum, as well as enhanced mucosal permeability, as indicated by decreased transepithelial electrical resistance and the presence of ultrastructural alterations. More importantly, the mice that underwent adoptive transfer of CD11c+ LPMPs from the PI-IBS mice also exhibited increased abdominal withdrawal reflex scores and a decreased threshold. Our data demonstrated that the CD11c+ LPMPs from this PI-IBS mouse model were not only able to transfer enteric inflammation to the normal mice but also caused abnormal intestinal function, characterized by epithelial barrier disruption and visceral hyperalgesia.","CD11c+ lamina propria mononuclear phagocytes; Mild inflammation; Mucosal barrier dysfunction; Post-infectious irritable bowel syndrome model; Visceral hypersensitivity","Animals; CD11c Antigen; Cells, Cultured; Hyperalgesia; Inflammation; Intestinal Absorption; Intestinal Mucosa; Irritable Bowel Syndrome; Male; Mice; Mononuclear Phagocyte System; Mucous Membrane; Trichinella spiralis; Trichinellosis; Viscera; glycoprotein p 15095; interleukin 4; glycoprotein p 15095; adoptive transfer; animal experiment; animal model; animal tissue; Article; cell function; cell isolation; cell selection; controlled study; dendritic cell; electric resistance; immunological tolerance; irritable colon; lamina propria; macrophage; male; membrane permeability; monocyte; mononuclear phagocyte; mouse; mucosal barrier dysfunction; nonhuman; priority journal; protein expression; stomach mucosa lesion; trichinosis; visceral hypersensitivity; animal; cell culture; cytology; hyperalgesia; immunology; inflammation; intestine absorption; intestine mucosa; irritable colon; mononuclear phagocyte; mucosa; parasitology; pathology; Trichinella spiralis; viscera","","CD11c Antigen, ","","","National Natural Science Foundation of China, NSFC, (81330014, 81500415); National Natural Science Foundation of China, NSFC","The present study was supported by the National Natural Science Foundation of China (grant nos. 81500415 and 81330014). The website is http://www.nsfc.gov.cn/.","Shen L., Turner J.R., Role of epithelial cells in initiation and propagation of intestinal inflammation, Eliminating the Static: Tight Junction Dynamics Exposed. Am J Physiol Gastrointest Liver Physiol, 290, pp. G577-G582, (2006); Turner J.R., Intestinal mucosal barrier function in health and disease, Nat Rev Immunol, 9, pp. 799-809, (2009); Martinez C., Lobo B., Pigrau M., Ramos L., Gonzalez-Castro A.M., Alonso C., Guilarte M., Guila M., Torres I., Azpiroz F., Et al., Diarrhoea-predominant irritable bowel syndrome: An organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, pp. 1160-1168, (2013); Keszthelyi D., Troost F.J., Jonkers D.M., Van Eijk H.M., Lindsey P.J., Dekker J., Buurman W.A., Masclee A.A., Serotonergic reinforcement of intestinal barrier function is impaired in irritable bowel syndrome, Aliment Pharmacol Ther, 40, pp. 392-402, (2014); Cheng P., Yao J., Wang C., Zhang L., Kong W., Molecular and cellular mechanisms of tight junction dysfunction in the irritable bowel syndrome, Mol Med Rep, 12, pp. 3257-3264, (2015); Barbara G., Mucosal barrier defects in irritable bowel syndrome, Who Left the Door Open?. Am J Gastroenterol, 101, pp. 1295-1298, (2006); Camilleri M., Gorman H., Intestinal permeability and irritable bowel syndrome, Neurogastroenterol Motil, 19, pp. 545-552, (2007); Dunlop S.P., Hebden J., Campbell E., Naesdal J., Olbe L., Perkins A.C., Spiller R.C., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Piche T., Barbara G., Aubert P., Bruley V.S., Dainese R., Nano J.L., Cremon C., Stanghellini V., De Giorgio R., Galmiche J.P., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: Involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Thabane M., Marshall J.K., Post-infectious irritable bowel syndrome, World J Gastroenterol, 15, pp. 3591-3596, (2009); Spiller R.C., Jenkins D., Thornley J.P., Hebden J.M., Wright T., Skinner M., Neal K.R., Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, pp. 804-811, (2000); Guilarte M., Santos J., Torres I., Alonso C., Vicario M., Ramos L., Martinez C., Casellas F., Saperas E., Malagelada J.R., Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum, Gut, 56, pp. 203-209, (2007); Walker M.M., Talley N.J., Prabhakar M., Pennaneac'H C.J., Aro P., Ronkainen J., Storskrubb T., Harmsen W.S., Zinsmeister A.R., Agreus L., Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia, Aliment Pharmacol Ther, 29, pp. 765-773, (2009); Ohman L., Simren M., Pathogenesis of IBS: Role of inflammation, immunity and neuroimmune interactions, Nat Rev Gastroenterol Hepatol, 7, pp. 163-173, (2010); Sundin J., Rangel I., Kumawat A.K., Hultgren-Hornquist E., Brummer R.J., Aberrant mucosal lymphocyte number and subsets in the colon of post-infectious irritable bowel syndrome patients, Scand J Gastroenterol, 49, pp. 1068-1075, (2014); Bhuiyan M.R., Majumder T.K., Raihan A.A., Roy P.K., Farha N., Kamal M., Histopathological alterations in post-infectious irritable bowel syndrome in Bangladeshi population, Mymensingh Med J, 19, pp. 275-281, (2010); Kirsch R., Riddell R.H., Histopathological alterations in irritable bowel syndrome, Mod Pathol, 19, pp. 1638-1645, (2006); Gwee K.A., Collins S.M., Read N.W., Rajnakova A., Deng Y., Graham J.C., McKendrick M.W., Moochhala S.M., Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome, Gut, 52, pp. 523-526, (2003); Chen J., Zhang Y., Deng Z., Imbalanced shift of cytokine expression between T helper 1 and T helper 2 (Th1/Th2) in intestinal mucosa of patients with post-infectious irritable bowel syndrome, BMC Gastroenterol, 12, (2012); Feng B., La J.H., Schwartz E.S., Gebhart G.F., Irritable bowel syndrome: Methods, mechanisms, and pathophysiology, Neural and Neuro-immune Mechanisms of Visceral Hypersensitivity in Irritable Bowel Syndrome. Am J Physiol Gastrointest Liver Physiol, 302, pp. G1085-G1098, (2012); Scott C.L., Henri S., Guilliams M., Mononuclear phagocytes of the intestine, the skin, and the lung, Immunol Rev, 262, pp. 9-24, (2014); Huang H., Liu J.Q., Yu Y., Mo L.H., Ge R.T., Zhang H.P., Liu Z.G., Zheng P.Y., Yang P.C., Regulation of TWIK-related potassium channel-1 (Trek1) restitutes intestinal epithelial barrier function, Cell Mol Immunol, 13, pp. 110-118, (2016); Arnold I.C., Mathisen S., Schulthess J., Danne C., Hegazy A.N., Powrie F., CD11c(+) monocyte/macrophages promote chronic Helicobacter hepaticus-induced intestinal inflammation through the production of IL-23, Mucosal Immunol, 9, pp. 352-363, (2016); Aychek T., Mildner A., Yona S., Kim K.W., Lampl N., Reich-Zeliger S., Boon L., Yogev N., Waisman A., Cua D.J., Et al., IL-23-mediated mononuclear phagocyte crosstalk protects mice from Citrobacter rodentium-induced colon immunopathology, Nat Commun, 6, (2015); Hart A.L., Al-Hassi H.O., Rigby R.J., Bell S.J., Emmanuel A.V., Knight S.C., Kamm M.A., Stagg A.J., Characteristics of intestinal dendritic cells in inflammatory bowel diseases, Gastroenterology, 129, pp. 50-65, (2005); Silva M.A., Lopez C.B., Riverin F., Oligny L., Menezes J., Seidman E.G., Characterization and distribution of colonic dendritic cells in Crohn's disease, Inflamm Bowel Dis, 10, pp. 504-512, (2004); Krajina T., Leithauser F., Moller P., Trobonjaca Z., Reimann J., Colonic lamina propria dendritic cells in mice with CD4+ T cell-induced colitis, Eur J Immunol, 33, pp. 1073-1083, (2003); Karlis J., Penttila I., Tran T.B., Jones B., Nobbs S., Zola H., Flesch I.E., Characterization of colonic and mesenteric lymph node dendritic cell subpopulations in a murine adoptive transfer model of inflammatory bowel disease, Inflamm Bowel Dis, 10, pp. 834-847, (2004); Long Y., Wang W., Wang H., Hao L., Qian W., Hou X., Characteristics of intestinal lamina propria dendritic cells in a mouse model of postinfectious irritable bowel syndrome, J Gastroenterol Hepatol, 27, pp. 935-944, (2012); Li M., Zhang L., Lu B., Chen Z., Chu L., Meng L., Fan Y., Role of dendritic cell-mediated abnormal immune response in visceral hypersensitivity, J Clin Exp Med, 8, pp. 13243-13250, (2015); Jones R.C., Otsuka E., Wagstrom E., Jensen C.S., Price M.P., Gebhart G.F., Short-term sensitization of colon mechanoreceptors is associated with long-term hypersensitivity to colon distention in the mouse, Gastroenterology, 133, pp. 184-194, (2007); Al-Chaer E.D., Kawasaki M., Pasricha P.J., A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development, Gastroenterology, 119, pp. 1276-1285, (2000); Velin A.K., Ericson A.C., Braaf Y., Wallon C., Soderholm J.D., Increased antigen and bacterial uptake in follicle associated epithelium induced by chronic psychological stress in rats, Gut, 53, pp. 494-500, (2004); Keita A.V., Soderholm J.D., Ericson A.C., Stress-induced barrier disruption of rat follicle-associated epithelium involves corticotropin-releasing hormone, acetylcholine, substance P, and mast cells, Neurogastroenterol Motil, 22, pp. 770-778, (2010); Overman E.L., Rivier J.E., Moeser A.J., CRF induces intestinal epithelial barrier injury via the release of mast cell proteases and TNF-and alpha, PLoS One, 7, (2012); Pozzo Miller L.D., Landis D.M., Cytoplasmic structure in organotypic cultures of rat hippocampus prepared by rapid freezing and freeze-substitution fixation, Synapse, 13, pp. 195-205, (1993); Siddiqui K.R., Laffont S., Powrie F., E-cadherin marks a subset of inflammatory dendritic cells that promote T cell-mediated colitis, Immunity, 32, pp. 557-567, (2010); McDole J.R., Wheeler L.W., McDonald K.G., Wang B., Konjufca V., Knoop K.A., Newberry R.D., Miller M.J., Goblet cells deliver luminal antigen to CD103+ dendritic cells in the small intestine, Nature, 483, pp. 345-349, (2012); Cascio J.A., Haymaker C.L., Divekar R.D., Zaghouani S., Khairallah M.T., Wan X., Rowland L.M., Dhakal M., Chen W., Zaghouani H., Antigen-specific effector CD4 T lymphocytes school lamina propria dendritic cells to transfer innate tolerance, J Immunol, 190, pp. 6004-6014, (2013); Poritz L.S., Garver K.I., Tilberg A.F., Koltun W.A., Tumor necrosis factor alpha disrupts tight junction assembly, J Surg Res, 116, pp. 14-18, (2004); McDermott J.R., Bartram R.E., Knight P.A., Miller H.R., Garrod D.R., Grencis R.K., Mast cells disrupt epithelial barrier function during enteric nematode infection, Proc Natl Acad Sci USA, 100, pp. 7761-7766, (2003); Edelblum K.L., Turner J.R., The tight junction in inflammatory disease: Communication breakdown, Curr Opin Pharmacol, 9, pp. 715-720, (2009); Al-Sadi R., Ye D., Boivin M., Guo S., Hashimi M., Ereifej L., Ma T.Y., Interleukin-6 modulation of intestinal epithelial tight junction permeability is mediated by JNK pathway activation of claudin-2 gene, PLoS One, 9, (2014); Al-Sadi R., Boivin M., Ma T., Mechanism of cytokine modulation of epithelial tight junction barrier, Front Biosci (Landmark Ed), 14, pp. 2765-2778, (2009); Bercik P., Wang L., Verdu E.F., Mao Y.K., Blennerhassett P., Khan W.I., Kean I., Tougas G., Collins S.M., Visceral hyperalgesia and intestinal dysmotility in a mouse model of postinfective gut dysfunction, Gastroenterology, 127, pp. 179-187, (2004); Fu Y., Wang W., Tong J., Pan Q., Long Y., Qian W., Hou X., Th17 cells influence intestinal muscle contraction during Trichinella spiralis infection, J Huazhong Univ Sci Technolog Med Sci, 29, pp. 481-485, (2009)","Z.-F. Xiong; Division of Gastroenterology, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 39 Yanhu Street, 430077, China; email: xiongzhifan@126.com","","Spandidos Publications","","","","","","11073756","","IJMMF","28440501","English","Int. J. Mol. Med.","Article","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-85019624878"

"Zhou S.-Y.; Gillilland M., III; Wu X.; Leelasinjaroen P.; Zhang G.; Zhou H.; Ye B.; Lu Y.; Owyang C.","Zhou, Shi-Yi (38062671900); Gillilland, Merritt (6603428978); Wu, Xiaoyin (7407063918); Leelasinjaroen, Pornchai (55697991200); Zhang, Guanpo (56023790100); Zhou, Hui (57215083667); Ye, Bo (57200207528); Lu, Yuanxu (7405480526); Owyang, Chung (7102742637)","38062671900; 6603428978; 7407063918; 55697991200; 56023790100; 57215083667; 57200207528; 7405480526; 7102742637","FODMAP diet modulates visceral nociception by lipopolysaccharide-mediated intestinal inflammation and barrier dysfunction","2018","Journal of Clinical Investigation","128","1","","267","280","13","143","10.1172/JCI92390","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85040180220&doi=10.1172%2fJCI92390&partnerID=40&md5=6862ed490e58e9f2526747d28fd4cc0b","Division of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, United States; 3912 Taubman Center, SPC 5362, Ann Arbor, 48109, MI, United States","Zhou S.-Y., Division of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, United States; Gillilland M., III, Division of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, United States; Wu X., Division of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, United States; Leelasinjaroen P., Division of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, United States; Zhang G., Division of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, United States; Zhou H., Division of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, United States; Ye B., Division of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, United States; Lu Y., Division of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, United States; Owyang C., Division of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, United States, 3912 Taubman Center, SPC 5362, Ann Arbor, 48109, MI, United States","Foods high in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) exacerbate symptoms of irritable bowel syndrome (IBS); however, their mechanism of action is unknown. We hypothesized that a high-FODMAP (HFM) diet increases visceral nociception by inducing dysbiosis and that the FODMAP-altered gut microbial community leads to intestinal pathology. We fed rats an HFM and showed that HFM increases rat fecal Gram-negative bacteria, elevates lipopolysaccharides (LPS), and induces intestinal pathology, as indicated by inflammation, barrier dysfunction, and visceral hypersensitivity (VH). These manifestations were prevented by antibiotics and reversed by low-FODMAP (LFM) diet. Additionally, intracolonic administration of LPS or fecal supernatant (FS) from HFM-fed rats caused intestinal barrier dysfunction and VH, which were blocked by the LPS antagonist LPS-RS or by TLR4 knockdown. Fecal LPS was higher in IBS patients than in healthy subjects (HS), and IBS patients on a 4-week LFM diet had improved IBS symptoms and reduced fecal LPS levels. Intracolonic administration of FS from IBS patients, but not FS from HS or LFM-treated IBS patients, induced VH in rats, which was ameliorated by LPS-RS. Our findings indicate that HFM-associated gut dysbiosis and elevated fecal LPS levels induce intestinal pathology, thereby modulating visceral nociception and IBS symptomatology, and might provide an explanation for the success of LFM diet in IBS patients.","","Animals; Dietary Carbohydrates; Dysbiosis; Gastrointestinal Microbiome; Gene Knockdown Techniques; Intestines; Irritable Bowel Syndrome; Lipopolysaccharides; Male; Nociception; Rats; Rats, Wistar; Toll-Like Receptor 4; antibiotic agent; disaccharide; endotoxin; fluorescein isothiocyanate dextran; gamma interferon; genomic DNA; interleukin 17; interleukin 1beta; interleukin 6; lipopolysaccharide; messenger RNA; monosaccharide; occludin; oligosaccharide; polyol; protein ZO1; rifaximin; small interfering RNA; toll like receptor 4; tumor necrosis factor; lipopolysaccharide; Tlr4 protein, mouse; toll like receptor 4; abdominal pain; animal experiment; animal model; Article; ascending colon; Bacteroidetes; bloating; colon epithelium; colon mucosa; colon tissue; controlled study; diet; diet therapy; DNA isolation; dysbiosis; endotoxemia; enteritis; ex vivo study; fecal supernatant; feces; Firmicutes; FODMAP diet; gene expression; Gram negative bacterium; Gram positive bacterium; high FODMAP diet; histology; human; human cell; hyperalgesia; hypersensitivity; immobilization stress; intestine cell; intestine flora; intestine mucosa permeability; intracolonic drug administration; irritable colon; lamina propria; low FODMAP diet; mast cell; microbial community; mononuclear cell; neutrophil; nociception; nonhuman; priority journal; Proteobacteria; quantitative analysis; rat; real time polymerase chain reaction; supernatant; tight junction; Verrucomicrobia; visceral hyperalgesia; visceral hypersensitivity; Western blotting; Wistar rat; animal; carbohydrate diet; chemically induced; dysbiosis; gene knockdown; genetics; intestine; intestine flora; irritable colon; male; metabolism; microbiology; pharmacology","","fluorescein isothiocyanate dextran, 60842-46-8; gamma interferon, 82115-62-6; occludin, 176304-61-3; rifaximin, 80621-81-4, 88747-56-2; toll like receptor 4, 203811-83-0; Dietary Carbohydrates, ; Lipopolysaccharides, ; Tlr4 protein, mouse, ; Toll-Like Receptor 4, ","","","National Institutes of Health, NIH, (R01DK058913); National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK, (P30DK034933)","The studies were supported by NIH grants R01DK058913 and P30DK34933.","Shepherd S.J., Lomer M.C., Gibson P.R., Short-chain carbohydrates and functional gastrointestinal disorders, Am J Gastroenterol, 108, 5, pp. 707-717, (2013); Ong D.K., Et al., Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome, JGastroenterolHepatol, 25, 8, pp. 1366-1373, (2010); Shepherd S.J., Parker F.C., Muir J.G., Gibson P.R., Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: Randomized placebo-controlled evidence, Clin Gastroenterol Hepatol, 6, 7, pp. 765-771, (2008); Staudacher H.M., Et al., Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome, JNutr, 142, 8, pp. 1510-1518, (2012); Staudacher H.M., Whelan K., Irving P.M., Lomer M.C., Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome, J Hum Nutr Diet, 24, 5, pp. 487-495, (2011); Halmos E.P., Power V.A., Shepherd S.J., Gibson P.R., Muir J.G., A diet low in FODMAPs reduces symptoms of irritable bowel syndrome, Gastroenterology, 146, 1, pp. 67-75, (2014); Raetz C.R., Whitfield C., Lipopolysaccharide endotoxins, Annu Rev Biochem, 71, pp. 635-700, (2002); Pastor Rojo O., Lopez San Roman A., Albeniz Arbizu E., de la Hera Martinez A., Ripoll Sevillano E., Albillos Martinez A., Serum lipopolysaccharide-binding protein in endotoxemic patients with inflammatory bowel disease, Inflamm Bowel Dis, 13, 3, pp. 269-277, (2007); van Deventer S.J., Buller H.R., Ten Cate J.W., Aarden L.A., Hack C.E., Sturk A., Experimental endotoxemia in humans: Analysis of cytokine release and coagulation, fibrinolytic, and complement pathways, Blood, 76, 12, pp. 2520-2526, (1990); Dlugosz A., Et al., Increased serum levels of lipopolysaccharide and antiflagellin antibodies in patients with diarrhea-predominant irritable bowel syndrome, NeurogastroenterolMotil, 27, 12, pp. 1747-1754, (2015); Jalanka-Tuovinen J., Et al., Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome, Gut, 63, 11, pp. 1737-1745, (2014); Abreu M.T., Toll-like receptor signalling in the intestinal epithelium: How bacterial recognition shapes intestinal function, Nat Rev Immunol, 10, 2, pp. 131-144, (2010); Bhattacharyya S., Dudeja P.K., Tobacman J.K., Lipopolysaccharide activates NF-kappaB by TLR4-Bcl10-dependent and independent pathways in colonic epithelial cells, Am J Physiol Gas-Trointest Liver Physiol, 295, 4, pp. G784-G790, (2008); Lenoir C., Et al., MD-2 controls bacterial lipopolysaccharide hyporesponsiveness in human intestinal epithelial cells, Life Sci, 82, 9-10, pp. 519-528, (2008); Guo S., Al-Sadi R., Said H.M., Ma T.Y., Lipopolysaccharide causes an increase in intestinal tight junction permeability in vitro and in vivo by inducing enterocyte membrane expression and localization of TLR-4 and CD14, Am J Pathol, 182, 2, pp. 375-387, (2013); Xu D., Et al., Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats, Gastroenterology, 146, 2, (2014); Symons P., Jones M.P., Kellow J.E., Symptom provocation in irritable bowel syndrome. Effects of differing doses of fructose-sorbitol, Scand J Gastroenterol, 27, 11, pp. 940-944, (1992); Ravich W.J., Bayless T.M., Carbohydrate absorption and malabsorption, Clin Gastroenterol, 12, 2, pp. 335-356, (1983); Ford A.C., Talley N.J., Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: A systematic review, JGastroenterol, 46, 4, pp. 421-431, (2011); Dunlop S.P., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, 6, pp. 1288-1294, (2006); Bertiaux-Vandaele N., Et al., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am J Gastroenterol, 106, 12, pp. 2165-2173, (2011); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, 1-2, pp. 41-46, (2009); Ait-Belgnaoui A., Bradesi S., Fioramonti J., Theodorou V., Bueno L., Acute stress-induced hypersensitivity to colonic distension depends upon increase in paracellular permeability: Role of myosin light chain kinase, Pain, 113, 1-2, pp. 141-147, (2005); Ludidi S., Et al., The intestinal barrier in irritable bowel syndrome: Subtype-specific effects of the systemic compartment in an in vitro model, PLoS ONE, 10, 5, (2015); Neuman M.G., Immune dysfunction in inflammatory bowel disease, TranslRes, 149, 4, pp. 173-186, (2007); van Deventer S.J., Ten Cate J.W., Tytgat G.N., Intestinal endotoxemia. Clinical significance, Gastroenterology, 94, 3, pp. 825-831, (1988); Halmos E.P., Christophersen C.T., Bird A.R., Shepherd S.J., Gibson P.R., Muir J.G., Diets that differ in their FODMAP content alter the colonic luminal microenvironment, Gut, 64, 1, pp. 93-100, (2015); Derrien M., Vaughan E.E., Plugge C.M., De Vos W.M., Akkermansia muciniphila gen. Nov., sp. Nov., a human intestinal mucin-degrading bacterium, Int JSystEvolMicrobiol, 54, pp. 1469-1476, (2004); Collado M.C., Derrien M., Isolauri E., De Vos W.M., Salminen S., Intestinal integrity and Akkermansia muciniphila, a mucin-degrading member of the intestinal microbiota present in infants, adults, and the elderly, Appl Environ Microbiol, 73, 23, pp. 7767-7770, (2007); Everard A., Et al., Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice, Diabetes, 60, 11, pp. 2775-2786, (2011); Kang C.S., Et al., Extracellular vesicles derived from gut microbiota, especially Akkermansia muciniphila, protect the progression of dextran sulfate sodium-induced colitis, PLoS ONE, 8, 10, (2013); Vatanen T., Et al., Variation in microbiome LPS immunogenicity contributes to autoimmunity in humans, Cell, 165, 6, (2016); Saulnier D.M., Et al., Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome, Gastroenterology, 141, 5, pp. 1782-1791, (2011); Rajilic-Stojanovic M., Et al., Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome, Gastroenterology, 141, 5, pp. 1792-1801, (2011); Nahid M.A., Satoh M., Chan E.K., MicroRNA in TLR signaling and endotoxin tolerance, CellMol Immunol, 8, 5, pp. 388-403, (2011); Kang D.J., Et al., Rifaximin exerts beneficial effects independent of its ability to alter microbiota composition, Clin Transl Gastroenterol, 7, 8, (2016); Bailey M.T., Dowd S.E., Parry N.M., Galley J.D., Schauer D.B., Lyte M., Stressor exposure disrupts commensal microbial populations in the intestines and leads to increased colonization by Citrobacter rodentium, Infect Immun, 78, 4, pp. 1509-1519, (2010); Bailey M.T., Dowd S.E., Galley J.D., Hufnagle A.R., Allen R.G., Lyte M., Exposure to a social stressor alters the structure of the intestinal microbiota: Implications for stressor-induced immunomodu-lation, Brain Behav Immun, 25, 3, pp. 397-407, (2011); Soderholm J.D., Et al., Chronic stress induces mast cell-dependent bacterial adherence and initiates mucosal inflammation in rat intestine, Gastroenterology, 123, 4, pp. 1099-1108, (2002); Bhunia A., Mohanram H., Domadia P.N., Torres J., Bhattacharjya S., Designed beta-boomerang antiendotoxic and antimicrobial peptides: Structures and activities in lipopolysaccharide, JBiol Chem, 284, 33, pp. 21991-22004, (2009); El Asmar R., Et al., Host-dependent zonulin secretion causes the impairment of the small intestine barrier function after bacterial exposure, Gastroenterology, 123, 5, pp. 1607-1615, (2002); Tripathi A., Et al., Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2, Proc Natl Acad Sci USA, 106, 39, pp. 16799-16804, (2009); Buzza M.S., Et al., Membrane-anchored serine protease matriptase regulates epithelial barrier formation and permeability in the intestine, Proc Natl Acad Sci U S A, 107, 9, pp. 4200-4205, (2010); Coutinho S.V., Et al., Neonatal maternal separation alters stress-induced responses to viscerosomatic nociceptive stimuli in rat, Am J Physiol Gastroin-Test Liver Physiol, 282, 2, pp. G307-G316, (2002); Chen S.L., Et al., Subdiaphragmatic vagal afferent nerves modulate visceral pain, Am J Physiol Gastro-Intest Liver Physiol, 294, 6, pp. G1441-G1449, (2008); Bradesi S., Et al., Repeated exposure to water avoidance stress in rats: A new model for sustained visceral hyperalgesia, Am J Physiol Gastro-Intest Liver Physiol, 289, 1, pp. G42-G53, (2005); Dabek M., Et al., Intracolonic infusion of fecal supernatants from ulcerative colitis patients triggers altered permeability and inflammation in mice: Role of cathepsin G and protease-activated receptor-4, InflammBowelDis, 17, 6, pp. 1409-1414, (2011); Zhang Y., Et al., Engineering mucosal RNA interference in vivo, MolTher, 14, 3, pp. 336-342, (2006); Palliser D., Et al., An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection, Nature, 439, 7072, pp. 89-94, (2006); Sato T., Et al., Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche, Nature, 459, 7244, pp. 262-265, (2009); Jung P., Et al., Isolation and in vitro expansion of human colonic stem cells, Nat Med, 17, 10, pp. 1225-1227, (2011); Leslie J.L., Et al., Persistence and toxin production by Clostridium difficile within human intestinal organoids result in disruption of epithelial paracellular barrier function, Infect Immun, 83, 1, pp. 138-145, (2015)","C. Owyang; Division of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, United States; email: cowyang@med.umich.edu","","American Society for Clinical Investigation","","","","","","00219738","","JCINA","29202473","English","J. Clin. Invest.","Article","Final","All Open Access; Bronze Open Access; Green Open Access","Scopus","2-s2.0-85040180220"

"Long Y.; Du L.; Kim J.J.; Chen B.; Zhu Y.; Zhang Y.; Yao S.; He H.; Zheng X.; Huang Z.; Dai N.","Long, Y. (15846348900); Du, L. (57190012632); Kim, J.J. (7601384309); Chen, B. (57192066215); Zhu, Y. (55808317900); Zhang, Y. (57193677882); Yao, S. (59077758100); He, H. (57193685244); Zheng, X. (56692016800); Huang, Z. (56658086200); Dai, N. (57204509665)","15846348900; 57190012632; 7601384309; 57192066215; 55808317900; 57193677882; 59077758100; 57193685244; 56692016800; 56658086200; 57204509665","MLCK-mediated intestinal permeability promotes immune activation and visceral hypersensitivity in PI-IBS mice","2018","Neurogastroenterology and Motility","30","9","e13348","","","","30","10.1111/nmo.13348","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85053613472&doi=10.1111%2fnmo.13348&partnerID=40&md5=7588890c3892a0313a679c40c7c9bb14","Department of Gastroenterology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China; Division of Gastroenterology, Loma Linda University Medical Center, Loma Linda, CA, United States","Long Y., Department of Gastroenterology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China; Du L., Department of Gastroenterology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China; Kim J.J., Department of Gastroenterology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China, Division of Gastroenterology, Loma Linda University Medical Center, Loma Linda, CA, United States; Chen B., Department of Gastroenterology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China; Zhu Y., Department of Gastroenterology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China; Zhang Y., Department of Gastroenterology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China; Yao S., Department of Gastroenterology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China; He H., Department of Gastroenterology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China; Zheng X., Department of Gastroenterology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China; Huang Z., Department of Gastroenterology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China; Dai N., Department of Gastroenterology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China","Background: Alterations in intestinal permeability regulated by tight junctions (TJs) are associated with immune activation and visceral hypersensitivity in irritable bowel syndrome (IBS). Myosin light chain kinase (MLCK) is an important mediator of epithelial TJ. The aim of this study is to investigate the role of MLCK in the pathogenesis of IBS using a post infectious IBS (PI-IBS) mouse model. Methods: Trichinella spiralis-infected PI-IBS mouse model was used. Urine lactulose/mannitol ratio was measured to assess intestinal epithelial permeability. Western blotting was used to evaluate intestinal TJ protein (zonula occludens-1) and MLCK-associated protein expressions. Immune profile was assessed by measuring Th (T helper) 1/Th2 cytokine expression. Visceral sensitivity was determined by abdominal withdrawal reflex in response to colorectal distension. Results: Eight weeks after inoculation with T. spiralis, PI-IBS mice developed decreased pain and volume thresholds during colorectal distention, increased urine lactulose/mannitol ratio, elevated colonic Th1/Th2 cytokine ratio, and decreased zonula occludens-1 expression compared to the control mice. MLCK expression was dramatically elevated in the colonic mucosa of PI-IBS mice compared to the control mice, alongside increased pMLC/MLC and decreased MLCP expression. Administration of MLCK inhibitor and TJ blocker both reversed the increased intestinal permeability, visceral hypersensitivity, and Th1-dominant immune profile in PI-IBS mice. Conclusion: MLCK is a pivotal step in inducing increased intestinal permeability promoting low-grade intestinal immune activation and visceral hypersensitivity in PI-IBS mice. MLCK inhibitor may provide a potential therapeutic option in the treatment of IBS. © 2018 John Wiley & Sons Ltd","immune activation; intestinal permeability; myosin light chain kinase; post infectious irritable bowel syndrome; visceral hypersensitivity","Animals; Hyperalgesia; Intestinal Mucosa; Intestines; Irritable Bowel Syndrome; Male; Mice; Myosin-Light-Chain Kinase; Permeability; Tight Junctions; myosin light chain kinase; animal; hyperalgesia; immunology; intestine; intestine mucosa; irritable colon; male; metabolism; mouse; pathophysiology; permeability; tight junction","","myosin light chain kinase, 51845-53-5; Myosin-Light-Chain Kinase, ","","","National Natural Science Foundation; National Natural Science Foundation of China, NSFC, (81200274, 81670487); National Natural Science Foundation of China, NSFC","Funding text 1: Funding Information The study was granted and supported by National Natural Science Foundation of China (no. 81200274, no. 81670487).; Funding text 2: The study was granted and supported by National Natural Science Foundation of","Karantanos T., Markoutsaki T., Gazouli M., Anagnou N.P., Karamanolis D.G., Current insights in to the pathophysiology of irritable bowel syndrome, Gut Pathog, 2, (2010); Chey W.D., Kurlander J., Eswaran S., Irritable bowel syndrome: a clinical review, JAMA, 313, pp. 949-958, (2015); Elsenbruch S., Abdominal pain in irritable bowel syndrome: a review of putative psychological, neural and neuro-immune mechanisms, Brain Behav Immun, 25, pp. 386-394, (2011); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Lee H., Park J.H., Park D.I., Et al., Mucosal mast cell count is associated with intestinal permeability in patients with diarrhea predominant irritable bowel syndrome, J Neurogastroenterol Motil, 19, pp. 244-250, (2013); Perdue M.H., Mucosal immunity and inflammation. III. The mucosal antigen barrier: cross talk with mucosal cytokines, Am J Physiol, 277, pp. G1-G5, (1999); Bueno L., Fioramonti J., Protease-activated receptor 2 and gut permeability: a review, Neurogastroenterol Motil, 20, pp. 580-587, (2008); Adelstein R.S., Calmodulin and the regulation of the actin-myosin interaction in smooth muscle and nonmuscle cells, Cell, 30, pp. 349-350, (1982); Chen C., Wang P., Su Q., Wang S., Wang F., Myosin light chain kinase mediates intestinal barrier disruption following burn injury, PLoS ONE, 7, (2012); Blair S.A., Kane S.V., Clayburgh D.R., Turner J.R., Epithelial myosin light chain kinase expression and activity are upregulated in inflammatory bowel disease, Lab Invest, 86, pp. 191-201, (2006); Su L., Nalle S.C., Shen L., Et al., TNFR2 activates MLCK-dependent tight junction dysregulation to cause apoptosis-mediated barrier loss and experimental colitis, Gastroenterology, 145, pp. 407-415, (2013); Gong Z., Chen Y., Zhang R., Et al., Pharmacokinetic difference of berberine between normal and chronic visceral hypersensitivity irritable bowel syndrome rats and its mechanism, Arch Pharm Res, 38, pp. 1888-1896, (2015); Ait-Belgnaoui A., Bradesi S., Fioramonti J., Theodorou V., Bueno L., Acute stress-induced hypersensitivity to colonic distension depends upon increase in paracellular permeability: role of myosin light chain kinase, Pain, 113, pp. 141-147, (2005); Martinez C., Lobo B., Pigrau M., Et al., Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, pp. 1160-1168, (2013); Turner J.R., Rill B.K., Carlson S.L., Et al., Physiological regulation of epithelial tight junctions is associated with myosin light-chain phosphorylation, Am J Physiol, 273, pp. C1378-C1385, (1997); Scott K.G., Meddings J.B., Kirk D.R., Lees-Miller S.P., Buret A.G., Intestinal infection with Giardia spp. reduces epithelial barrier function in a myosin light chain kinase-dependent fashion, Gastroenterology, 123, pp. 1179-1190, (2002); Saitoh M., Ishikawa T., Matsushima S., Naka M., Hidaka H., Selective inhibition of catalytic activity of smooth muscle myosin light chain kinase, J Biol Chem, 262, pp. 7796-7801, (1987); Krejs G.J., Seelig L.L., Fordtran J.S., Effect of protonated 2,4,6-triaminopyrimidine, a tight junction blocker, on intestinal transport in dog ileum in vivo, Gastroenterology, 72, pp. 685-691, (1977); Bercik P., Wang L., Verdu E.F., Et al., Visceral hyperalgesia and intestinal dysmotility in a mouse model of postinfective gut dysfunction, Gastroenterology, 127, pp. 179-187, (2004); Ferrier L., Mazelin L., Cenac N., Et al., Stress-induced disruption of colonic epithelial barrier: role of interferon-gamma and myosin light chain kinase in mice, Gastroenterology, 125, pp. 795-804, (2003); Cenac N., Garcia-Villar R., Ferrier L., Et al., Proteinase-activated receptor-2-induced colonic inflammation in mice: possible involvement of afferent neurons, nitric oxide, and paracellular permeability, J Immunol, 170, pp. 4296-4300, (2003); Jones R.C., Otsuka E., Wagstrom E., Jensen C.S., Price M.P., Gebhart G.F., Short-term sensitization of colon mechanoreceptors is associated with long-term hypersensitivity to colon distention in the mouse, Gastroenterology, 133, pp. 184-194, (2007); Al-Chaer E.D., Kawasaki M., Pasricha P.J., A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development, Gastroenterology, 119, pp. 1276-1285, (2000); Liu H., Zhang S., Yu A., Et al., Studies on intestinal permeability of cirrhotic patients by analysis lactulose and mannitol in urine with HPLC/RID/MS, Bioorg Med Chem Lett, 14, pp. 2339-2344, (2004); Smith J.W., Castro G.A., Relation of peroxidase activity in gut mucosa to inflammation, Am J Physiol, 234, pp. R72-R79, (1978); Krawisz J.E., Sharon P., Stenson W.F., Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models, Gastroenterology, 87, pp. 1344-1350, (1984); Miranda A., Nordstrom E., Mannem A., Smith C., Banerjee B., Sengupta J.N., The role of transient receptor potential vanilloid 1 in mechanical and chemical visceral hyperalgesia following experimental colitis, Neuroscience, 148, pp. 1021-1032, (2007); Barbara G., Vallance B.A., Collins S.M., Persistent intestinal neuromuscular dysfunction after acute nematode infection in mice, Gastroenterology, 113, pp. 1224-1232, (1997); Tan J.L., Ravid S., Spudich J.A., Control of nonmuscle myosins by phosphorylation, Annu Rev Biochem, 61, pp. 721-759, (1992); Ikebe M., Hartshorne D.J., Phosphorylation of smooth muscle myosin at two distinct sites by myosin light chain kinase, J Biol Chem, 260, pp. 10027-10031, (1985); Wang H., Gong J., Wang W., Et al., Are there any different effects of Bifidobacterium, Lactobacillus and Streptococcus on intestinal sensation, barrier function and intestinal immunity in PI-IBS mouse model?, PLoS ONE, 9, (2014); Tsukita S., Furuse M., Itoh M., Multifunctional strands in tight junctions, Nat Rev Mol Cell Biol, 2, pp. 285-293, (2001); Turner J.R., Intestinal mucosal barrier function in health and disease, Nat Rev Immunol, 9, pp. 799-809, (2009); Clayburgh D.R., Shen L., Turner J.R., A porous defense: the leaky epithelial barrier in intestinal disease, Lab Invest, 84, pp. 282-291, (2004); Spiller R.C., Jenkins D., Thornley J.P., Et al., Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, pp. 804-811, (2000); Lee K.J., Kim Y.B., Kim J.H., Kwon H.C., Kim D.K., Cho S.W., The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors, J Gastroenterol Hepatol, 23, pp. 1689-1694, (2008); Cremon C., Gargano L., Morselli-Labate A.M., Et al., Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms, Am J Gastroenterol, 104, pp. 392-400, (2009); Scully P., McKernan D.P., Keohane J., Et al., Plasma cytokine profiles in females with irritable bowel syndrome and extra-intestinal co-morbidity, Am J Gastroenterol, 105, pp. 2235-2243, (2010); Chen J., Zhang Y., Deng Z., Imbalanced shift of cytokine expression between T helper 1 and T helper 2 (Th1/Th2) in intestinal mucosa of patients with post-infectious irritable bowel syndrome, BMC Gastroenterol, 12, (2012); Yang S., Yu M., Sun L., Et al., Interferon-gamma-induced intestinal epithelial barrier dysfunction by NF-kappaB/HIF-1alpha pathway, J Interferon Cytokine Res, 34, pp. 195-203, (2014); Cenac N., Chin A.C., Garcia-Villar R., Et al., PAR2 activation alters colonic paracellular permeability in mice via IFN- -dependent and -independent pathways, J Physiol, 558, pp. 913-925, (2004); Martinez C., Vicario M., Ramos L., Et al., The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations, Am J Gastroenterol, 107, pp. 736-746, (2012); Zahs A., Bird M.D., Ramirez L., Turner J.R., Choudhry M.A., Kovacs E.J., Inhibition of long myosin light-chain kinase activation alleviates intestinal damage after binge ethanol exposure and burn injury, Am J Physiol Gastrointest Liver Physiol, 303, pp. G705-G712, (2012); Ness T.J., Gebhart G.F., Inflammation enhances reflex and spinal neuron responses to noxious visceral stimulation in rats, Am J Physiol Gastrointest Liver Physiol, 280, pp. G649-G657, (2001); Demaude J., Leveque M., Chaumaz G., Et al., Acute stress increases colonic paracellular permeability in mice through a mast cell-independent mechanism: involvement of pancreatic trypsin, Life Sci, 84, pp. 847-852, (2009); Moreno J.H., Blockage of gallbladder tight junction cation-selective channels by 2,4,6-triaminopyrimidinium (TAP), J Gen Physiol, 66, pp. 97-115, (1975)","N. Dai; Department of Gastroenterology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China; email: ndaicn@zju.edu.cn","","Blackwell Publishing Ltd","","","","","","13501925","","NMOTE","29644768","English","Neurogastroenterol. Motil.","Article","Final","","Scopus","2-s2.0-85053613472"

"Russo F.; Chimienti G.; Linsalata M.; Clemente C.; Orlando A.; Riezzo G.","Russo, Francesco (59133987400); Chimienti, Guglielmina (57210207419); Linsalata, Michele (6603600075); Clemente, Caterina (7005101585); Orlando, Antonella (23767683100); Riezzo, Giuseppe (7004144336)","59133987400; 57210207419; 6603600075; 7005101585; 23767683100; 7004144336","The obestatin/ghrelin ratio and ghrelin genetics in adult celiac patients before and after a gluten-free diet, in irritable bowel syndrome patients and healthy individuals","2017","European Journal of Gastroenterology and Hepatology","29","2","","160","168","8","9","10.1097/MEG.0000000000000760","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84991454129&doi=10.1097%2fMEG.0000000000000760&partnerID=40&md5=32daad7904fb78112eddea5ddd815962","Laboratory of Nutritional Pathophysiology, Department of Clinical Pathology, National Institute of Digestive Diseases, IRCCS Saverio de Bellis, Via Turi 27, Castellana Grotte, Bari, I-70013, Italy; Department of Biosciences, Biotechnology and Biopharmaceutics, University of Bari, Bari, Italy","Russo F., Laboratory of Nutritional Pathophysiology, Department of Clinical Pathology, National Institute of Digestive Diseases, IRCCS Saverio de Bellis, Via Turi 27, Castellana Grotte, Bari, I-70013, Italy; Chimienti G., Department of Biosciences, Biotechnology and Biopharmaceutics, University of Bari, Bari, Italy; Linsalata M., Laboratory of Nutritional Pathophysiology, Department of Clinical Pathology, National Institute of Digestive Diseases, IRCCS Saverio de Bellis, Via Turi 27, Castellana Grotte, Bari, I-70013, Italy; Clemente C., Laboratory of Nutritional Pathophysiology, Department of Clinical Pathology, National Institute of Digestive Diseases, IRCCS Saverio de Bellis, Via Turi 27, Castellana Grotte, Bari, I-70013, Italy; Orlando A., Laboratory of Nutritional Pathophysiology, Department of Clinical Pathology, National Institute of Digestive Diseases, IRCCS Saverio de Bellis, Via Turi 27, Castellana Grotte, Bari, I-70013, Italy; Riezzo G., Laboratory of Nutritional Pathophysiology, Department of Clinical Pathology, National Institute of Digestive Diseases, IRCCS Saverio de Bellis, Via Turi 27, Castellana Grotte, Bari, I-70013, Italy","Background: Ghrelin levels and obestatin/ghrelin ratio have been proposed as activity markers in ulcerative colitis, but no data are available in celiac disease (CD) and irritable bowel syndrome (IBS). Our aims were as follows: (a) to assess obestatin and ghrelin concentrations in adult active CD patients, diarrhea-predominant IBS (IBS-d), and healthy controls (HC) in relation to intestinal permeability; (b) to evaluate the ghrelin-obestatin profile in CD patients after a 1-year gluten-free diet (GFD); and (c) to establish the impact of ghrelin genetics. Methods: The study included 31 CD patients, 28 IBS-d patients, and 19 HC. Intestinal permeability, assayed by highperformance liquid chromatography determination of urinary lactulose (La)/mannitol (Ma), and circulating concentrations of obestatin, ghrelin, and their ratio were evaluated at enrollment and after GFD. The ghrelin single nucleotide polymorphisms Arg51Gln (rs34911341), Leu72Met (rs696217), and Gln90Leu (rs4684677) were analyzed. Results: Intestinal permeability was impaired in CD patients and ameliorated after GFD. Ghrelin was significantly (P =0.048) higher and the obestatin/ghrelin ratio was significantly (P= 0.034) lower in CD patients compared with both IBS-d and HC, and GFD reduced the peptide levels, but without reaching the concentrations in HC. Significant differences (P< 0.05) were found in the Leu72Met polymorphism among groups, with the reduction of the GT genotype and the T allele in both CD and IBS-d patients compared with HC. Conclusion: Intestinal permeability is altered in CD, but not in IBS-d patients, and ghrelin levels increase in CD patients as observed in other inflammatory conditions. Moreover, a role for ghrelin genetics is hypothesized in sustaining the many pathogenetic components of these different pathologies, but with a similar symptom profile. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.","Celiac disease; Ghrelin; GHRL; Gluten-free diet; Irritable bowel syndrome; Obestatin","Adult; Celiac Disease; Diarrhea; Diet, Gluten-Free; Female; Genetic Predisposition to Disease; Genotype; Ghrelin; Healthy Volunteers; Humans; Intestines; Irritable Bowel Syndrome; Lactulose; Male; Mannitol; Permeability; Polymorphism, Single Nucleotide; ghrelin; obestatin; sugar; ghrelin; lactulose; mannitol; obestatin, human; absorption; adult; allele; Article; celiac disease; clinical article; dietary compliance; female; genotype; gluten free diet; high performance liquid chromatography; human; intestine mucosa permeability; irritable colon; male; priority journal; sample size; single nucleotide polymorphism; blood; celiac disease; diarrhea; diet therapy; genetic predisposition; genetics; gluten free diet; intestine; irritable colon; metabolism; normal human; permeability; urine","","ghrelin, 304853-26-7; lactulose, 4618-18-2; mannitol, 69-65-8, 87-78-5; Ghrelin, ; Lactulose, ; Mannitol, ; obestatin, human, ","","","","","Gujral N., Freeman H.J., Thomson A.B., Celiac disease: Prevalence, diagnosis, pathogenesis and treatment, World J Gastroenterol, 18, pp. 6036-6059, (2012); Shahbazkhani B., Forootan M., Merat S., Akbari M.R., Nasserimoghadam S., Vahedi H., Et al., Coeliac disease presenting with symptoms of irritable bowel syndrome, Aliment Pharmacol Ther, 18, pp. 231-235, (2003); Barbara G., Zecchi L., Barbaro R., Cremon C., Bellacosa L., Marcellini M., Et al., Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome, J Clin Gastroenterol, 46, pp. S52-S55, (2012); Russo F., Chimienti G., Clemente C., D'Attoma B., Linsalata M., Orlando A., Et al., Adipokine profile in celiac patients: Differences in comparison with patients suffering from diarrhea-predominant IBS and healthy subjects, Scand J Gastroenterol, 48, pp. 1377-1385, (2013); El-Salhy M., Seim I., Chopin L., Gundersen D., Hatlebakk J.G., Hausken T., Irritable bowel syndrome: The role of gut neuroendocrine peptides, Front Biosci (Elite Ed), 4, pp. 2783-2800, (2012); Lanzini A., Magni P., Petroni M.L., Motta M., Lanzarotto F., Villanacci V., Et al., Circulating ghrelin level is increased in coeliac disease as in functional dyspepsia and reverts to normal during gluten-free diet, Aliment Pharmacol Ther, 23, pp. 907-913, (2006); Capristo E., Farnetti S., Mingrone G., Certo M., Greco A.V., Addolorato G., Et al., Reduced plasma ghrelin concentration in celiac disease after gluten-free diet treatment, Scand J Gastroentero, 40, pp. 430-436, (2005); Otto B., Spranger J., Benoit S.C., Clegg D.J., Tschop M.H., The many faces of ghrelin: New perspectives for nutrition research?, Br J Nutr, 93, pp. 765-771, (2005); Eissa N., Ghia J.E., Immunomodulatory effect of ghrelin in the intestinal mucosa, Neurogastroent Motil, 27, pp. 1519-1527, (2015); Jung J.Y., Jeong J.B., Kim J.W., Kim S.H., Koh S.J., Kim B.G., Et al., Circulating ghrelin levels and obestatin/ghrelin ratio as a marker of activity in ulcerative colitis, Intest Res, 13, pp. 68-73, (2015); Russo F., Linsalata M., Clemente C., D'Attoma B., Orlando A., Campanella G., Et al., The effects of fluorouracil, epirubicin, and cyclophosphamide (FEC60) on the intestinal barrier function and gut peptides in breast cancer patients: An observational study, BMC Cancer, 13, (2013); Pamukcu O., Kumral Z.N., Ercan F., Yegen B.C., Ertem D., Antiinflammatory effect of obestatin and ghrelin in dextran sulfate sodiuminduced colitis in rats, J Pediatr Gastroenterol Nutr, 57, pp. 211-218, (2013); Nikoukar L.R., Nabavizadeh F., Mohamadi S.M., Moslehi A., Hassanzadeh G., Nahrevanian H., Et al., Protective effect of ghrelin in a rat model of celiac disease, Acta Physiol Hung, 101, pp. 438-447, (2014); Seim I., Walpole C., Amorim L., Josh P., Herington A., Chopin L., The expanding roles of the ghrelin-gene derived peptide obestatin in health and disease, Mol Cell Endocrinol, 340, pp. 111-117, (2011); Ghalandari H., Hosseini-Esfahani F., Mirmiran P., The association of polymorphisms in leptin/leptin receptor genes and ghrelin/ghrelin receptor genes with overweight/obesity and the related metabolic disturbances: A review, Int J Endocrinol Metab, 13, (2015); Futagami S., Shimpuku M., Kawagoe T., Izumi N., Ohishi N., Yamawaki H., Et al., The preproghrelin 3056 TT genotype is associated with the feeling of hunger and low acylated ghrelin levels in Japanese patients with Helicobacter pylori-negative functional dyspepsia, Internal Med, 52, pp. 1155-1163, (2013); Pabalan N.A., Seim I., Jarjanazi H., Chopin L.K., Associations between ghrelin and ghrelin receptor polymorphisms and cancer in Caucasian populations: A meta-analysis, BMC Genet, 15, (2014); Yamawaki H., Futagami S., Shimpuku M., Shindo T., Maruki Y., Nagoya H., Et al., Leu72Met408 polymorphism of the ghrelin gene is associated with early phase of gastric emptying in the patients with functional dyspepsia in Japan, J Neurogastroenterol Motil, 21, pp. 93-102, (2015); Hassouna R., Zizzari P., Tolle V., The ghrelin/obestatin balance in the physiological and pathological control of growth hormone secretion, body composition and food intake, J Neuroendocrinol, 22, pp. 793-804, (2010); Trovato L., Gallo D., Settanni F., Gesmundo I., Ghigo E., Granata R., Obestatin: Is it really doing something?, Front Horm Res, 42, pp. 175-185, (2014); Ates Y., Degertekin B., Erdil A., Yaman H., Dagalp K., Serum ghrelin levels in inflammatory bowel disease with relation to disease activity and nutritional status, Digest Dis Sci, 53, pp. 2215-2221, (2008); Schmulson M., Lee O.Y., Chang L., Naliboff B., Mayer E.A., Symptom differences in moderate to severe IBS patients based on predominant bowel habit, Am J Gastroenterol, 94, pp. 2929-2935, (1999); Svedlund J., Sjodin I., Dotevall G., GSRS - A clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease, Dig Dis Sci, 33, pp. 129-134, (1988); Verdu E.F., Armstrong D., Murray J.A., Between celiac disease and irritable bowel syndrome: The 'no man's land' of gluten sensitivity, Am J Gastroenterol, 104, pp. 1587-1594, (2009); El-Salhy M., Hatlebakk J.G., Gilja O.H., Hausken T., The relation between celiac disease, nonceliac gluten sensitivity and irritable bowel syndrome, Nutr J, 14, (2015); Antonioli D.A., Celiac disease: A progress report, Mod Pathol, 16, pp. 342-346, (2003); Ozgen M., Koca S.S., Etem E.O., Yuce H., Aydin S., Isik A., Ghrelin gene polymorphisms in rheumatoid arthritis, Joint Bone Spine, 78, pp. 368-373, (2011); Linsalata M., D'Attoma B., Orlando A., Guerra V., Russo F., Comparison of an enzymatic assay with liquid chromatography-pulsed amperometric detection for the determination of lactulose and mannitol in urine of healthy subjects and patients with active celiac disease, Clin Chem Lab Med, 52, pp. E61-E64, (2014); Gaunt T.R., Rodriguez S., Day I.N.M., Cubic exact solutions for the estimation of pairwise haplotype frequencies: Implications for linkage disequilibrium analyses and a web tool 'CubeX, BMC Bioinformatics, 8, (2007); Mearin F., Balboa A., Badia X., Baro E., Caldwell E., Cucala M., Et al., Irritable bowel syndrome subtypes according to bowel habit: Revisiting the alternating subtype, Eur J Gastroenterol Hepatol, 15, pp. 165-172, (2003); Spiller R., Lam C., The shifting interface between IBS and IBD, Curr Opin Pharmacol, 11, pp. 586-592, (2011); Camilleri M., Gorman H., Intestinal permeability and irritable bowel syndrome, Neurogastroenterol Motil, 19, pp. 545-552, (2007); Kempinski R., Demissie M., Jasinska M., Paradowski L., Plasma ghrelin concentration in celiac patients, Gastroenterol Pol, 15, pp. 375-377, (2008); Janas R.M., Rybak A., Wierzbicka-Rucinska A., Socha P., Nitko R., Szaflarska-Poplawska A., Et al., Serum concentrations of insulin, ghrelin, adiponectin, leptin, leptin receptor and lipocalin-2 in children with celiac disease who do and do not adhere to a gluten-free diet, Gut Liver, 10, pp. 587-594, (2016); Manavalan J.S., Hernandez L., Shah J.G., Konikkara J., Naiyer A.J., Lee A.R., Et al., Serum cytokine elevations in celiac disease: Association with disease presentation, Hum Immunol, 71, pp. 50-57, (2010); Cheung C.K., Wu J.C.Y., Role of ghrelin in the pathophysiology of gastrointestinal disease, Gut Liver, 7, pp. 505-512, (2013); Sung E.Z., Da Silva N.F., Goodyear S., McTernan P.G., Sanger G.J., Nwokolo C.U., Increased plasma ghrelin following infliximab in Crohn's disease, Aliment Pharmacol Ther, 29, pp. 83-89, (2009); Hosomi S., Oshitani N., Kamata N., Sogawa M., Yamagami H., Watanabe K., Et al., Phenotypical and functional study of ghrelin and its receptor in the pathogenesis of Crohn's disease, Inflamm Bowel Dis, 14, pp. 1205-1213, (2008); Poykko S.M., Kellokoski E., Horkko S., Kauma H., Kesaniemi Y.A., Ukkola O., Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes, Diabetes, 52, pp. 2546-2553, (2003); Zhang X.L., Zhai L.M., Rong C.Z., Qin X., Li S., Association of ghrelin gene polymorphisms and serum ghrelin levels with the risk of hepatitis B virus-related liver diseases in a Chinese population, PLoS One, 10, (2015); Mora M., Adam V., Palomera E., Blesa S., Diaz G., Buquet X., Et al., Ghrelin gene variants influence on metabolic syndrome components in aged Spanish population, PLoS One, 10, (2015); Ukkola O., Genetic variants of ghrelin in metabolic disorders, Peptides, 32, pp. 2319-2322, (2011)","F. Russo; Laboratory of Nutritional Pathophysiology, Department of Clinical Pathology, National Institute of Digestive Diseases, IRCCS Saverio de Bellis, Castellana Grotte, Bari, Via Turi 27, I-70013, Italy; email: francesco.russo@irccsdebellis.it","","Lippincott Williams and Wilkins","","","","","","0954691X","","EJGHE","27750262","English","Eur. J. Gastroenterol. Hepatol.","Article","Final","","Scopus","2-s2.0-84991454129"

"Heitkemper M.M.; Cain K.C.; Shulman R.J.; Burr R.L.; Ko C.; Hollister E.B.; Callen N.; Zia J.; Han C.J.; Jarrett M.E.","Heitkemper, M.M. (7005514887); Cain, K.C. (7103341073); Shulman, R.J. (56961627200); Burr, R.L. (7005552308); Ko, C. (7202596492); Hollister, E.B. (35224866500); Callen, N. (57201998997); Zia, J. (6507732284); Han, C.J. (56493706700); Jarrett, M.E. (59045458700)","7005514887; 7103341073; 56961627200; 7005552308; 7202596492; 35224866500; 57201998997; 6507732284; 56493706700; 59045458700","Stool and urine trefoil factor 3 levels: Associations with symptoms, intestinal permeability, and microbial diversity in irritable bowel syndrome","2018","Beneficial Microbes","9","3","","345","355","10","12","10.3920/bm2017.0059","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85046725288&doi=10.3920%2fbm2017.0059&partnerID=40&md5=f7f8daa3dd294b9aa8c0d021597da56e","Department of Biobehavioral Nursing and Health Informatics, University of Washington, 1959 NE Pacific Street, Seattle, 98195-7266, WA, United States; Department of Biostatistics and Office of Nursing Research, University of Washington, 1959 NE Pacific Street, Seattle, WA, United States; Children's Nutrition Research Center, Baylor College of Medicine, Texas Children's Hospital, 6621 Fannin Street, Houston, 77030, TX, United States; University of Washington Medical Center, 1959 NE Pacific Street, Seattle, 98195, WA, United States; Department of Pathology and Immunology, Baylor College of Medicine, Texas Children's Microbiome Center, Texas Children's Hospital, 6621 Fannin Street, Houston, 77030, TX, United States; Department of Family and Child Nursing, University of Washington, 1959 NE Pacific Street, Seattle, 98195, WA, United States","Heitkemper M.M., Department of Biobehavioral Nursing and Health Informatics, University of Washington, 1959 NE Pacific Street, Seattle, 98195-7266, WA, United States; Cain K.C., Department of Biostatistics and Office of Nursing Research, University of Washington, 1959 NE Pacific Street, Seattle, WA, United States; Shulman R.J., Children's Nutrition Research Center, Baylor College of Medicine, Texas Children's Hospital, 6621 Fannin Street, Houston, 77030, TX, United States; Burr R.L., Department of Biobehavioral Nursing and Health Informatics, University of Washington, 1959 NE Pacific Street, Seattle, 98195-7266, WA, United States; Ko C., University of Washington Medical Center, 1959 NE Pacific Street, Seattle, 98195, WA, United States; Hollister E.B., Department of Pathology and Immunology, Baylor College of Medicine, Texas Children's Microbiome Center, Texas Children's Hospital, 6621 Fannin Street, Houston, 77030, TX, United States; Callen N., Department of Family and Child Nursing, University of Washington, 1959 NE Pacific Street, Seattle, 98195, WA, United States; Zia J., University of Washington Medical Center, 1959 NE Pacific Street, Seattle, 98195, WA, United States; Han C.J., Department of Biobehavioral Nursing and Health Informatics, University of Washington, 1959 NE Pacific Street, Seattle, 98195-7266, WA, United States; Jarrett M.E., Department of Biobehavioral Nursing and Health Informatics, University of Washington, 1959 NE Pacific Street, Seattle, 98195-7266, WA, United States","Previously we showed that urine trefoil factor 3 (TFF3) levels were higher in females with irritable bowel syndrome (IBS) compared to non-IBS females. To assess if TFF3 is associated with symptoms and/or reflect alterations in gastrointestinal permeability and gut microbiota in an IBS population, we correlated stool and urine TFF3 levels with IBS symptoms, intestinal permeability, stool microbial diversity and relative abundance of predominant bacterial families and genera. We also tested the relationship of stool TFF3 to urine TFF3, and compared results based on hormone contraception use. Samples were obtained from 93 females meeting Rome III IBS criteria and completing 4-week symptom diaries. TFF3 levels were measured by ELISA. Permeability was assessed with the urine lactulose/mannitol (L/M) ratio. Stool microbiota was assessed using 16S rRNA. Stool TFF3, but not urine TFF3, was associated positively with diarrhoea and loose stool consistency. Higher stool TFF3 was also associated with lower L/M ratio and microbial diversity. Of the 20 most abundant bacterial families Mogibacteriaceae and Christensenellaceae were inversely related to stool TFF3, with only Christensenellaceae remaining significant after multiple comparison adjustment. There were no significant relationships between stool or urine TFF3 levels and other symptoms, nor between stool and urine levels. In premenopausal females, urine TFF3 levels were higher in those reporting hormone contraception. Collectively these results suggest that higher stool TFF3 levels are associated with IBS symptoms (loose/diarrhoeal stools), lower gut permeability, and altered stool bacteria composition (decreased diversity and decreased Christensenellaceae), which further suggests that TFF3 may be an important marker of host-bacteria interaction. © 2018 Wageningen Academic Publishers.","Anti-microbial peptide; Christensenellaceae; Diarrhoea; Hormone contraception","Adult; Aged; DNA, Bacterial; DNA, Ribosomal; Enzyme-Linked Immunosorbent Assay; Feces; Female; Gastrointestinal Microbiome; Humans; Irritable Bowel Syndrome; Microbiota; Middle Aged; Permeability; Phylogeny; RNA, Ribosomal, 16S; Sequence Analysis, DNA; Trefoil Factor-3; Urine; Young Adult; lactulose; mannitol; RNA 16S; trefoil factor 3; bacterial DNA; ribosome DNA; RNA 16S; TFF3 protein, human; trefoil factor 3; abdominal pain; adult; aged; Article; behavior therapy; Christensenellaceae; constipation; controlled study; diarrhea; disease association; disease severity; enzyme linked immunosorbent assay; feces analysis; female; gastrointestinal tract; genetic variability; Gram negative bacterium; human; intestine flora; intestine mucosa permeability; irritable colon; major clinical study; microbial diversity; Mogibacteriaceae; randomized controlled trial; symptomatology; urinalysis; chemistry; DNA sequence; feces; genetics; intestine flora; irritable colon; microflora; middle aged; pathology; permeability; phylogeny; urine; young adult","","lactulose, 4618-18-2, 58166-24-8; mannitol, 69-65-8, 87-78-5; DNA, Bacterial, ; DNA, Ribosomal, ; RNA, Ribosomal, 16S, ; TFF3 protein, human, ; Trefoil Factor-3, ","","","National Institutes of Health, NIH; National Institute of Nursing Research, NINR, (R21NR014331); National Institute of Nursing Research, NINR","Work was supported by a grant from the National Institute of Nursing Research, National Institutes of Health R21NR014331.","Aagaard K., Petrosino J., Keitel W., Watson M., Katancik J., Garcia N., Patel S., Cutting M., Madden T., Hamilton H., Harris E., Gevers D., Simone G., McInnes P., Versalovic J., The Human Microbiome Project strategy for comprehensive sampling of the human microbiome and why it matters, FASEB Journal, 27, pp. 1012-1022, (2013); Aronesty E., Command-line tools for processing biological sequencing data, (2011); Beck P.L., Ihara E., Hirota S.A., MacDonald J.A., Meng D., Nanthakumar N.N., Podolsky D.K., Xavier R.J., Exploring the interplay of barrier function and leukocyte recruitment in intestinal inflammation by targeting fucosyltransferase VII and trefoil factor 3, American Journal of Physiology, Gastrointestinal and Liver Physiology, 299, pp. G43-53, (2010); Bennet S.M., Polster A., Tornblom H., Isaksson S., Capronnier S., Tessier A., Le Neve B., Simren M., Ohman L., Global cytokine profiles and association with clinical characteristics in patients with irritable bowel syndrome, American Journal of Gastroenterology, 111, pp. 1165-1176, (2016); Biagi E., Franceschi C., Rampelli S., Severgnini M., Ostan R., Turroni S., Consolandi C., Quercia S., Scurti M., Monti D., Capri M., Brigidi P., Candela M., Gut microbiota and extreme longevity, Current Biology, 26, pp. 1480-1485, (2016); Bradford M.M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding, Analytical Biochemistry, 72, pp. 248-254, (1976); Buda A., Jepson M.A., Pignatelli M., Regulatory function of trefoil peptides (TFF) on intestinal cell junctional complexes, Cell Communication and Adhesion, 19, pp. 63-68, (2012); Camilleri M., Lasch K., Zhou W., Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome, American Journal of Physiology, Gastrointestinal and Liver Physiology, 303, pp. G775-G785, (2012); Caporaso J.G., Kuczynski J., Stombaugh J., Bittinger K., Bushman F.D., Costello E.K., Fierer N., Pena A.G., Goodrich J.K., Gordon J.I., Huttley G.A., Kelley S.T., Knights D., Koenig J.E., Ley R.E., Lozupone C.A., McDonald D., Muegge B.D., Pirrung M., Reeder J., Sevinsky J.R., Turnbaugh P.J., Walters W.A., Widmann J., Yatsunenko T., Zaneveld J., Knight R., QIIME allows analysis of high-throughput community sequencing data, Nature Methods, 7, pp. 335-336, (2010); Caporaso J.G., Lauber C.L., Walters W.A., Berg-Lyons D., Lozupone C.A., Turnbaugh P.J., Fierer N., Knight R., Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample, Proceedings of the National Academy of Sciences of the USA, 108, pp. 4516-4522, (2011); Catassi C., Pierani P., Natalini G., Gabrielli O., Coppa G.V., Giorgi P.L., Clinical application of a simple HPLC method for the sugar intestinal permeability test, Journal of Pediatric Gastroenterology and Nutrition, 12, pp. 209-212, (1991); Chaiyarit P., Chayasadom A., Wara-Aswapati N., Hormdee D., Sittisomwong S., Nakaresisoon S., Samson M.H., Pitiphat W., Giraud A.S., Trefoil factors in saliva and gingival tissues of patients with chronic periodontitis, Journal of Periodontology, 83, pp. 1129-1138, (2012); Chang R., Wang Y., Chang J., Wen L., Jiang Z., Yang T., Yu K., LPS preconditioning ameliorates intestinal injury in a rat model of hemorrhagic shock, Inflammation Research, 63, pp. 675-682, (2014); Comelli E.M., Simmering R., Faure M., Donnicola D., Mansourian R., Rochat F., Corthesy-Theulaz I., Cherbut C., Multifaceted transcriptional regulation of the murine intestinal mucus layer by endogenous microbiota, Genomics, 91, pp. 70-77, (2008); DeSantis T.Z., Hugenholtz P., Larsen N., Rojas M., Brodie E.L., Keller K., Huber T., Dalevi D., Hu P., Andersen G.L., Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB, Applied and Environmental Microbiology, 72, pp. 5069-5072, (2006); Drossman D.A., Dumitrascu D.L., Rome III: new standard for functional gastrointestinal disorders, Journal of Gastrointestinal and Liver Diseases, 15, pp. 237-241, (2006); Edgar R.C., Search and clustering orders of magnitude faster than BLAST, Bioinformatics, 26, pp. 2460-2461, (2010); Edgar R.C., UPARSE: highly accurate OTU sequences from microbial amplicon reads, Nature Methods, 10, pp. 996-998, (2013); Ek M., Roth B., Ekstrom P., Valentin L., Bengtsson M., Ohlsson B., Gastrointestinal symptoms among endometriosis patients - a case-cohort study, BMC Women's Health, 15, (2015); Fu T., Znalesniak E.B., Kalinski T., Mohle L., Biswas A., Salm F., Dunay I.R., Hoffmann W., TFF peptides play a role in the immune response following oral infection of mice with Toxoplasma gondii, European Journal of Microbiology and Immunology, 5, pp. 221-231, (2015); Goo Y.A., Cain K., Jarrett M., Smith L., Voss J., Tolentino E., Tsuji J., Tsai Y.S., Panchaud A., Goodlett D.R., Shulman R.J., Heitkemper M., Urinary proteome analysis of irritable bowel syndrome (IBS) symptom subgroups, Journal of Proteome Research, 11, pp. 5650-5662, (2012); Gronbaek H., Vestergaard E.M., Hey H., Nielsen J.N., Nexo E., Serum trefoil factors in patients with inflammatory bowel disease, Digestion, 74, pp. 33-39, (2006); Haas B.J., Gevers D., Earl A.M., Feldgarden M., Ward D.V., Giannoukos G., Ciulla D., Tabbaa D., Highlander S.K., Sodergren E., Methe B., DeSantis T.Z., Petrosino J.F., Knight R., Birren B.W., Chimeric 16S rRNA sequence formation and detection in Sanger and 454-pyrosequenced PCR amplicons, Genome Research, 21, pp. 494-504, (2011); Henze D., Doecke W.D., Hornung D., Agueusop I., Von Ahsen O., Machens K., Schmitz A.A., Gashaw I., Endometriosis leads to an increased trefoil factor 3 concentration in the peritoneal cavity but does not alter systemic levels, Reproductive Sciences, 24, pp. 258-267, (2016); Hildebrand F., Tadeo R., Voigt A.Y., Bork P., Raes J., LotuS: an efficient and user-friendly OTU processing pipeline, Microbiome, 2, (2014); Jarrett M.E., Cain K.C., Barney P.G., Burr R.L., Naliboff B.D., Shulman R., Zia J., Heitkemper M.M., Balance of autonomic nervous system predicts who benefits from a self-management intervention program for irritable bowel syndrome, Journal of Neurogastroenterology and Motility, 22, pp. 102-111, (2016); Jeffery I.B., O'Toole P.W., Ohman L., Claesson M.J., Deane J., Quigley E.M., Simren M., An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota, Gut, 61, pp. 997-1006, (2012); Johansson P.A., Farup P.G., Bracco A., Vandvik P.O., How does comorbidity affect cost of health care in patients with irritable bowel syndrome? A cohort study in general practice, BMC Gastroenterology, 10, (2010); Kasai C., Sugimoto K., Moritani I., Tanaka J., Oya Y., Inoue H., Tameda M., Shiraki K., Ito M., Takei Y., Takase K., Comparison of the gut microbiota composition between obese and non-obese individuals in a Japanese population, as analyzed by terminal restriction fragment length polymorphism and next-generation sequencing, BMC Gastroenterology, 15, (2015); Khailova L., Dvorak K., Arganbright K.M., Halpern M.D., Kinouchi T., Yajima M., Dvorak B., Bifidobacterium bifidum improves intestinal integrity in a rat model of necrotizing enterocolitis, American Journal of Physiology, Gastrointestinal and Liver Physiology, 297, pp. G940-G949, (2009); May F.E., Westley B.R., TFF3 is a valuable predictive biomarker of endocrine response in metastatic breast cancer, Endocrine-Related Cancer, 22, pp. 465-479, (2015); McOmber M.E., Ou C.N., Shulman R.J., Effects of timing, sex, and age on site-specific gastrointestinal permeability testing in children and adults, Journal of Pediatric Gastroenterology and Nutrition, 50, pp. 269-275, (2010); Mhawech-Fauceglia P., Wang D., Samrao D., Liu S., DuPont N.C., Pejovic T., Trefoil factor family 3 (TFF3) expression and its interaction with estrogen receptor (ER) in endometrial adenocarcinoma, Gynecologic Oncology, 130, pp. 174-180, (2013); Morotomi M., Nagai F., Watanabe Y., Description of Christensenella minuta gen. nov., sp. nov., isolated from human faeces, which forms a distinct branch in the order Clostridiales, and proposal of Christensenellaceae fam. nov., International Journal of Systematic and Evolutionary Microbiology, 62, pp. 144-149, (2012); Podolsky D.K., Gerken G., Eyking A., Cario E., Colitis-associated variant of TLR2 causes impaired mucosal repair because of TFF3 deficiency, Gastroenterology, 137, pp. 209-220, (2009); Pozuelo M., Panda S., Santiago A., Mendez S., Accarino A., Santos J., Guarner F., Azpiroz F., Manichanh C., Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel Syndrome, Scientific Reports, 5, (2015); Renes I.B., Verburg M., Van Nispen D.J., Taminiau J.A., Buller H.A., Dekker J., Einerhand A.W., Epithelial proliferation, cell death, and gene expression in experimental colitis: alterations in carbonic anhydrase I, mucin MUC2, and trefoil factor 3 expression, International Journal of Colorectal Disease, 17, pp. 317-326, (2002); Ritari J., Salojarvi J., Lahti L., De Vos W.M., Improved taxonomic assignment of human intestinal 16S rRNA sequences by a dedicated reference database, BMC Genomics, 16, (2015); Rognes T., Flouri T., Nichols B., Quince C., Mahe F., VSEARCH: a versatile open source tool for metagenomics, PeerJ, 4, (2016); Saulnier D.M., Riehle K., Mistretta T.A., Diaz M.A., Mandal D., Raza S., Weidler E.M., Qin X., Coarfa C., Milosavljevic A., Petrosino J.F., Highlander S., Gibbs R., Lynch S.V., Shulman R.J., Versalovic J., Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome, Gastroenterology, 141, pp. 1782-1791, (2011); Shulman R.J., Jarrett M.E., Cain K.C., Broussard E., Heitkemper M.M., Associations among gut permeability, inflammatory markers and symptoms in patients with irritable bowel syndrome, Journal of Gastroenterology, 49, pp. 1467-1476, (2014); Shulman R.J., Jarrett M.E., Cain K.C., Broussard E.K., Heitkemper M.M., Associations among gut permeability, inflammatory markers, and symptoms in patients with irritable bowel syndrome, Journal of Gastroenterology, 49, pp. 1467-1476, (2014); Shulman R.J., Schanler R.J., Lau C., Heitkemper M., Ou C.N., Smith E.O., Early feeding, antenatal glucocorticoids, and human milk decrease intestinal permeability in preterm infants, Pediatric Research, 44, pp. 519-523, (1998); Srivastava S., Kedia S., Kumar S., Pratap Mouli V., Dhingra R., Sachdev V., Tiwari V., Kurrey L., Pradhan R., Ahuja V., Serum human trefoil factor 3 is a biomarker for mucosal healing in ulcerative colitis patients with minimal disease activity, Journal of Crohn's and Colitis, 9, pp. 575-579, (2015); Tap J., Derrien M., Tornblom H., Brazeilles R., Cools-Portier S., Dore J., Storsrud S., Le Neve B., Ohman L., Simren M., Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome, Gastroenterology, 152, pp. 111-123, (2016); Taupin D., Podolsky D.K., Trefoil factors: initiators of mucosal healing, Nature Reviews, Molecular Cell Biology, 4, pp. 721-732, (2003); Thim L., Madsen F., Poulsen S.S., Effect of trefoil factors on the viscoelastic properties of mucus gels, European Journal of Clinical Investigation, 32, pp. 519-527, (2002); Verey F., Nexo E., Greenwood R., Berry M., Corfield A.P., Trefoil factor family peptides are increased in the saliva of children with mucositis, Clinical Chemistry and Laboratory Medicine, 49, pp. 2051-2055, (2011)","M.M. Heitkemper; Department of Biobehavioral Nursing and Health Informatics, University of Washington, Seattle, 1959 NE Pacific Street, 98195-7266, United States; email: heit@uw.edu","","Wageningen Academic Publishers","","","","","","18762883","","","29633639","English","Benefic. Microbes","Article","Final","All Open Access; Green Open Access","Scopus","2-s2.0-85046725288"

"Zhen Y.; Chu C.; Zhou S.; Qi M.; Shu R.","Zhen, Yanbo (24391635600); Chu, Chuanlian (7404345660); Zhou, Shiqing (56809824400); Qi, Ming (56504617900); Shu, Ronghua (56735851500)","24391635600; 7404345660; 56809824400; 56504617900; 56735851500","Imbalance of tumor necrosis factor-α, interleukin-8 and interleukin-10 production evokes barrier dysfunction, severe abdominal symptoms and psychological disorders in patients with irritable bowel syndrome-associated diarrhea","2015","Molecular Medicine Reports","12","4","","5239","5245","6","33","10.3892/mmr.2015.4079","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84940495158&doi=10.3892%2fmmr.2015.4079&partnerID=40&md5=7498dc2f6ffbebe5c68d705663135074","Department of Gastroenterology, Jinan Central Hospital, 105 Jiefang Road, Jinan, Shandong, 250013, China","Zhen Y., Department of Gastroenterology, Jinan Central Hospital, 105 Jiefang Road, Jinan, Shandong, 250013, China; Chu C., Department of Gastroenterology, Jinan Central Hospital, 105 Jiefang Road, Jinan, Shandong, 250013, China; Zhou S., Department of Gastroenterology, Jinan Central Hospital, 105 Jiefang Road, Jinan, Shandong, 250013, China; Qi M., Department of Gastroenterology, Jinan Central Hospital, 105 Jiefang Road, Jinan, Shandong, 250013, China; Shu R., Department of Gastroenterology, Jinan Central Hospital, 105 Jiefang Road, Jinan, Shandong, 250013, China","The present study aimed to explore the correlation between cytokine expression of tumor necrosis factor α (TNF.-α), interleukin (IL).-8 and IL.-10 with occludin production, abdominal symptoms and psychological factors in patients with irritable bowel syndrome.-associated diarrhea (IBS.-D). A total of 42 IBS.-D patients and 20 healthy controls were included, which were recruited from QiLu Hospital in China. ELISA and immunohistochemical analysis were performed for evaluating the cytokines (TNF.-α, IL.-8 and IL.-10) and occludin protein levels in the peripheral blood mononuclear cells (PBMCs) of all subjects. In addition, the abdominal symptoms and psychological status were assessed in IBS.-D patients. Levels of TNF.-α and IL.-8 in the PBMCs of patients with IBS.D were significantly higher than those in the controls (P<0.001 and P=0.007, respectively), while IL.-10 levels were significantly reduced in patients with IBS.-D (P=0.047). Occludin production was significantly reduced in patients with IBS.-D as compared with that in the controls (P<0.001). In patients with IBS.-D, levels of TNF.-α and IL.-8 were negatively correlated with occludin levels (r=0.34, P=0.028; r=0.52, P<0.001, respectively). IL.-10 showed a negative correlation with occludin production (r=0.05, P=0.748). Furthermore, TNF.-α, IL.8 and IL.10 levels were significantly correlated with symptoms scores (r=0.74, P<0.001; r=0.55, P<0.001; r=0.80, P<0.001, respectively) in patients with IBS.-D. Within the IBS.-D group, TNF.-α expression was significantly increased in patients with a self.rating depression scale (SDS) score.50 (P=0.004) as compared with that in patients with an SDS score <50. Furthermore, IL.8 was significantly increased in IBS.D patients with a self.-rating anxiety scale (SAS) or SDS score.50 (P=0.016, P=0.008, respectively) as compared with that in patients scoring <50. In conclusion, the results of the present study suggested that in IBS.-D, an imbalance of cytokine production evoked colonic epithelial barrier dysfunction, abdominal symptoms and psychological disorders.","Abdominal symptoms; Cytokines; Irritable bowel syndrome; Occludin; Psychological factor","Adolescent; Adult; Cytokines; Diarrhea; Female; Gene Expression; Humans; Immunohistochemistry; Interleukin-10; Interleukin-8; Irritable Bowel Syndrome; Leukocytes, Mononuclear; Male; Middle Aged; Occludin; Stress, Psychological; Tumor Necrosis Factor-alpha; Young Adult; interleukin 10; interleukin 8; occludin; tumor necrosis factor alpha; cytokine; interleukin 10; interleukin 8; occludin; tumor necrosis factor alpha; abdominal disease; adult; Article; clinical article; colon; controlled study; cytokine production; diarrhea; distress syndrome; enzyme linked immunosorbent assay; female; human; human cell; human tissue; immunohistochemistry; irritable bowel syndrome associated diarrhea; irritable colon; male; peripheral blood mononuclear cell; Self-rating Anxiety Scale; Self-rating Depression Scale; Western blotting; adolescent; complication; diarrhea; gene expression; genetics; irritable colon; mental stress; metabolism; middle aged; mononuclear cell; young adult","","interleukin 8, 114308-91-7; occludin, 176304-61-3; Cytokines, ; Interleukin-10, ; Interleukin-8, ; Occludin, ; Tumor Necrosis Factor-alpha, ","","","","","Schmulson M.W., Chang L., Diagnostic approach to the patient with irritable bowel syndrome, Am J Med, 107, pp. 20S-26S, (1999); Holten K.B., Wetherington A., Bankston L., Diagnosing the patient with abdominal pain and altered bowel habits: Is it irritable bowel syndrome?, Am Fam Physician, 67, pp. 2157-2164, (2003); Andresen V., Camilleri M., Irritable bowel syndrome: Recent and novel therapeutic approaches, Drugs, 66, pp. 1073-1088, (2006); Van Der Veek P.P., Van Den Berg M., De Kroon Y.E., Verspaget H.W., Masclee A.A., Role of tumor necrosis factor-alpha and inter-leukin-10 gene polymorphisms in irritable bowel syndrome, Am J Gastroenterol, 100, pp. 2510-2516, (2005); Gonsalkorale W.M., Perrey C., Pravica V., Whorwell P.J., Hutchinson I.V., Interleukin 10 genotypes in irritable bowel syndrome: Evidence for an infammatory component?, Gut, 52, pp. 91-93, (2003); Nielsen O.H., Rudiger N., Gaustadnes M., Horn T., Intestinal interleukin-8 concentration and gene expression in infammatory bowel disease, Scand J Gastroenterol, 32, pp. 1028-1034, (1997); Coeffier M., Gloro R., Boukhettala N., Et al., Increased proteasome-mediated degradation of occludin in irritable bowel syndrome, Am J Gastroenterol, 105, pp. 1181-1188, (2010); Simren M., Abrahamsson H., Svedlund J., Bjornsson E., Quality of life in patients with irritable bowel syndrome seen in referral centers versus primary care: The impact of gender and predominant bowel pattern, Scand J Gastroenterol, 36, pp. 545-552, (2001); Piche T., Huet P.M., Gelsi E., Et al., Fatigue in irritable bowel syndrome: Characterization and putative role of leptin, Eur J Gastroenterol Hepatol, 19, pp. 237-243, (2007); Piche T., Saint-Paul M.C., Dainese R., Et al., Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome, Gut, pp. 57468-57473, (2008); Drossman D.A., Dumitrascu D.L., Rome III: New standard for functional gastrointestinal disorders, J Gastrointestin Liver Dis, 15, pp. 237-241, (2006); Lewis S.J., Heaton K.W., Stool form scale as a useful guide to intestinal transit time, Scand J Gastroenterol, 32, pp. 920-924, (1997); Endo Y., Yoshizawa M., Fukudo S., Sasaki M., Hongo M., Panic disorder in irritable bowel syndrome, Jpn J Psychosom Med, 40, pp. 339-346, (2000); Liebregts T., Adam B., Bredack C., Et al., Immune activation in patients with irritable bowel syndrome, Gastroenterology, 132, pp. 913-920, (2007); Zung W.W., A rating instrument for anxiety disorders, Psychosomatics, 12, pp. 371-379, (1971); Zung W.W., A self-rating depression scale, Arch Gen Psychiatry, 12, pp. 63-70, (1965); Chang L., Ameen V.Z., Dukes G.E., McSorley D.J., Carter E.G., Mayer E.A., A dose-ranging, phase II study of the effcacy and safety of alosetron in men with diarrhea-predominant IBS, Am J Gastroenterol, 100, pp. 115-123, (2005); Ohman L., Simren M., Pathogenesis of IBS: Role of infam-mation, immunity and neuroimmune interactions, Nat Rev Gastroenterol Hepatol, 7, pp. 163-173, (2010); Nakamura M., Saito H., Kasanuki J., Tamura Y., Yoshida S., Cytokine production in patients with inflammatory bowel disease, Gut, 33, pp. 933-937, (1992); Gecse K., Roka R., Ferrier L., Et al., Increased faecal serine protease activity in diarrhoeic IBS patients: A colonic lumenal factor impairing colonic permeability and sensitivity, Gut, 57, pp. 591-599, (2008); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Et al., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am J Gastroenterol, 106, pp. 2165-2173, (2011); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Chadwick V.S., Chen W., Shu D., Et al., Activation of the mucosal immune system in irritable bowel syndrome, Gastroenterology, 122, pp. 1778-1783, (2002); Woolf C., Allchorne A., Safieh-Garabedian B., Poole S., Cytokines, nerve growth factor and inflammatory hyperalgesia: The contribution of tumour necrosis factor alpha, Br J Pharmacol, 121, pp. 417-424, (1997); Gao J., Correlation between anxiety-depression status and cytokines in diarrhea-predominant irritable bowel syndrome, Exp Ther Med, 6, pp. 93-96, (2013); Nicholl B.I., Halder S.L., MacFarlane G.J., Et al., Psychosocial risk markers for new onset irritable bowel syndrome-results of a large prospective population-based study, Pain, 137, pp. 147-155, (2008); Qiu B.S., Vallance B.A., Blennerhassett P.A., Collins S.M., The role of CD4+ lymphocytes in the susceptibility of mice to stress-induced reactivation of experimental colitis, Nat Med, 5, pp. 1178-1182, (1999); Kiliaan A.J., Saunders P.R., Bijlsma P.B., Et al., Stress stimulates transepithelial macromolecular uptake in rat jejunum, Am J Physiol, 275, 5, pp. G1037-G1044, (1998)","Y. Zhen; Department of Gastroenterology, Jinan Central Hospital, Jinan, Shandong, 105 Jiefang Road, 250013, China; email: yanbo0213y@gmail.com","","Spandidos Publications","","","","","","17912997","","","26180016","English","Mol. Med. Rep.","Article","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-84940495158"

"Bednarska O.; Walter S.A.; Casado-Bedmar M.; Ström M.; Salvo-Romero E.; Vicario M.; Mayer E.A.; Keita Å.V.","Bednarska, Olga (55789563900); Walter, Susanna A. (23053245700); Casado-Bedmar, Maite (56951301500); Ström, Magnus (7005995994); Salvo-Romero, Eloísa (56830611700); Vicario, Maria (6603267769); Mayer, Emeran A. (35500853900); Keita, Åsa V. (13104052600)","55789563900; 23053245700; 56951301500; 7005995994; 56830611700; 6603267769; 35500853900; 13104052600","Vasoactive Intestinal Polypeptide and Mast Cells Regulate Increased Passage of Colonic Bacteria in Patients With Irritable Bowel Syndrome","2017","Gastroenterology","153","4","","948","960.e3","","101","10.1053/j.gastro.2017.06.051","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85031665143&doi=10.1053%2fj.gastro.2017.06.051&partnerID=40&md5=fb57fd6cd8739f231ee7f28d3bb9ce95","Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden; Department of Gastroenterology, Linköping University, Linköping, Sweden; Laboratory of Translational Mucosal Immunology, Digestive Diseases Research Unit, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; G Oppenheimer Center for Neurobiology of Stress & Resilience, Division of Digestive Diseases, David Geffen School of Medicine at UCLA, Los Angeles, California, United States","Bednarska O., Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, Department of Gastroenterology, Linköping University, Linköping, Sweden; Walter S.A., Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, Department of Gastroenterology, Linköping University, Linköping, Sweden; Casado-Bedmar M., Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden; Ström M., Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, Department of Gastroenterology, Linköping University, Linköping, Sweden; Salvo-Romero E., Laboratory of Translational Mucosal Immunology, Digestive Diseases Research Unit, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; Vicario M., Laboratory of Translational Mucosal Immunology, Digestive Diseases Research Unit, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; Mayer E.A., G Oppenheimer Center for Neurobiology of Stress & Resilience, Division of Digestive Diseases, David Geffen School of Medicine at UCLA, Los Angeles, California, United States; Keita Å.V., Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden","Background & Aims Irritable bowel syndrome (IBS) is associated with intestinal dysbiosis and symptoms of IBS develop following gastroenteritis. We aimed to study the passage of live bacteria through the colonic epithelium, and determine the role of mast cells (MCs) and vasoactive intestinal polypeptide (VIP) in barrier regulation in IBS and healthy individuals. Methods Colon biopsies from 32 women with IBS and 15 age-matched healthy women (controls) were mounted in Ussing chambers; we measured numbers of fluorescently labeled Escherichia coli HS and Salmonella typhimurium that passed through from the mucosal side to the serosal side of the tissue. Some biopsies were exposed to agents that block the VIP receptors (VPAC1 and VPAC2) or MCs. Levels of VIP and tryptase were measured in plasma and biopsy lysates. Number of MCs and MCs that express VIP or VIP receptors were quantified by immunofluorescence. Biopsies from an additional 5 patients with IBS and 4 controls were mounted in chambers and Salmonella were added; we studied passage routes through the epithelium by transmission electron microscopy and expression of tight junctions by confocal microscopy. Results In colon biopsies from patients with IBS, larger numbers of E coli HS and S typhimurium passed through the epithelium than in biopsies from controls (P <.0005). In transmission electron microscopy analyses, bacteria were found to cross the epithelium via only the transcellular route. Bacterial passage was reduced in biopsies from patients with IBS and controls after addition of antibodies against VPACs or ketotifen, which inhibits MCs. Plasma samples from patients with IBS had higher levels of VIP than plasma samples from controls. Biopsies from patients with IBS had higher levels of tryptase, larger numbers of MCs, and a higher percentage of MCs that express VPAC1 than biopsies from controls. In biopsies from patients with IBS, addition of Salmonella significantly reduced levels of occludin; subsequent addition of ketotifen significantly reversed this effect. Conclusions We found that colonic epithelium tissues from patients with IBS have increased translocation of commensal and pathogenic live bacteria compared with controls. The mechanisms of increased translocation include MCs and VIP. © 2017 AGA Institute","Bacteria; Inflammation; Intestinal Permeability; Ketotifen","Adult; Bacterial Translocation; Biopsy; Case-Control Studies; Colon; Dysbiosis; Electric Impedance; Escherichia coli; Female; Fluorescent Antibody Technique; Gastrointestinal Microbiome; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Mast Cells; Microscopy, Confocal; Microscopy, Electron, Transmission; Middle Aged; Receptors, Vasoactive Intestinal Peptide, Type II; Receptors, Vasoactive Intestinal Polypeptide, Type I; Salmonella typhimurium; Symbiosis; Tight Junctions; Vasoactive Intestinal Peptide; Young Adult; fluorescent dye; occludin; tight junction protein; tryptase; vasoactive intestinal polypeptide; vasoactive intestinal polypeptide receptor 1; vasoactive intestinal polypeptide receptor 2; vasoactive intestinal polypeptide; adult; Article; cell function; clinical article; colon biopsy; colon epithelium; colon flora; colon mucosa; comparative study; confocal microscopy; controlled study; digestive system electrophysiology; enzyme blood level; Escherichia coli; female; human; immunofluorescence; intestinal barrier function; intestine function; irritable colon; mast cell; nonhuman; priority journal; protein blood level; Salmonella; Salmonella enterica serovar Typhimurium; tight junction; transmission electron microscopy; bacterial translocation; biopsy; case control study; colon; dysbiosis; fluorescent antibody technique; impedance; intestine flora; intestine mucosa; Irritable Bowel Syndrome; mast cell; metabolism; microbiology; middle aged; pathogenicity; physiology; symbiosis; ultrastructure; young adult","","occludin, 176304-61-3; tryptase, 97501-93-4; vasoactive intestinal polypeptide, 37221-79-7; Receptors, Vasoactive Intestinal Peptide, Type II, ; Receptors, Vasoactive Intestinal Polypeptide, Type I, ; Vasoactive Intestinal Peptide, ","","","National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK, (R01DK048351)","","Sperber A.D., Dumitrascu D., Fukudo S., Et al., The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review, Gut, 66, pp. 1075-1082, (2017); Mayer E.A., Tillisch K., Gupta A., Gut/brain axis and the microbiota, J Clin Invest, 125, pp. 926-938, (2015); Ahn J.Y., Lee K.H., Choi C.H., Et al., Colonic mucosal immune activity in irritable bowel syndrome: comparison with healthy controls and patients with ulcerative colitis, Dig Dis Sci, 59, pp. 1001-1011, (2014); Chaudhary N.A., Truelove S.C., The irritable colon syndrome. A study of the clinical features, predisposing causes, and prognosis in 130 cases, Q J Med, 31, pp. 307-322, (1962); Barbara G., Feinle-Bisset C., Ghoshal U.C., Et al., The intestinal microenvironment and functional gastrointestinal disorders, Gastroenterology, (2016); Mearin F., Perez-Oliveras M., Perello A., Et al., Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study, Gastroenterology, 129, pp. 98-104, (2005); Keithlin J., Sargeant J.M., Thomas M.K., Et al., Systematic review and meta-analysis of the proportion of non-typhoidal Salmonella cases that develop chronic sequelae, Epidemiol Infect, 143, pp. 1333-1351, (2015); Ohman L., Tornblom H., Simren M., Crosstalk at the mucosal border: importance of the gut microenvironment in IBS, Nat Rev Gastroenterol Hepatol, 12, pp. 36-49, (2015); Casen C., Vebo H.C., Sekelja M., Et al., Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD, Aliment Pharmacol Ther, 42, pp. 71-83, (2015); Dior M., Delagreverie H., Duboc H., Et al., Interplay between bile acid metabolism and microbiota in irritable bowel syndrome, Neurogastroenterol Motil, 28, pp. 1339-1340, (2016); Vandeputte D., Falony G., Vieira-Silva S., Et al., Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates, Gut, 65, pp. 57-62, (2016); Coeffier M., Gloro R., Boukhettala N., Et al., Increased proteasome-mediated degradation of occludin in irritable bowel syndrome, Am J Gastroenterol, 105, pp. 1181-1188, (2010); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Et al., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am J Gastroenterol, 106, pp. 2165-2173, (2011); Vanheel H., Vicario M., Vanuytsel T., Et al., Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia, Gut, 63, pp. 262-271, (2014); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Shulman R.J., Eakin M.N., Czyzewski D.I., Et al., Increased gastrointestinal permeability and gut inflammation in children with functional abdominal pain and irritable bowel syndrome, J Pediatr, 153, pp. 646-650, (2008); Piche T., Barbara G., Aubert P., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Matricon J., Meleine M., Gelot A., Et al., Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome, Aliment Pharmacol Ther, 36, pp. 1009-1031, (2012); Longstreth G.F., Thompson W.G., Chey W.D., Et al., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Kerckhoffs A.P., Akkermans L.M., de Smet M.B., Et al., Intestinal permeability in irritable bowel syndrome patients: effects of NSAIDs, Dig Dis Sci, 55, pp. 716-723, (2010); Annahazi A., Ferrier L., Bezirard V., Et al., Luminal cysteine-proteases degrade colonic tight junction structure and are responsible for abdominal pain in constipation-predominant IBS, Am J Gastroenterol, 108, pp. 1322-1331, (2013); Halliez M.C., Motta J.P., Feener T.D., Et al., Giardia duodenalis induces paracellular bacterial translocation and causes postinfectious visceral hypersensitivity, Am J Physiol Gastrointest Liver Physiol, 310, pp. G574-G585, (2016); Ottaway C.A., Lewis D.L., Asa S.L., Vasoactive intestinal peptide-containing nerves in Peyer's patches, Brain Behav Immun, 1, pp. 148-158, (1987); Keita A.V., Carlsson A.H., Cigehn M., Et al., Vasoactive intestinal polypeptide regulates barrier function via mast cells in human intestinal follicle-associated epithelium and during stress in rats, Neurogastroenterol Motil, 25, pp. e406-e417, (2013); Quin J.A., Sgambati S.A., Goldenring J.R., Et al., PYY inhibition of VIP-stimulated ion transport in the rabbit distal ileum, J Surg Res, 58, pp. 111-115, (1995); Izu L.T., McCulle S.L., Ferreri-Jacobia M.T., Et al., Vasoactive intestinal peptide-stimulated Cl- secretion: activation of cAMP-dependent K+ channels, J Membr Biol, 186, pp. 145-157, (2002); Neunlist M., Toumi F., Oreschkova T., Et al., Human ENS regulates the intestinal epithelial barrier permeability and a tight junction-associated protein ZO-1 via VIPergic pathways, Am J Physiol Gastrointest Liver Physiol, 285, pp. G1028-G1036, (2003); Bakker R., Dekker K., De Jonge H.R., Et al., VIP, serotonin, and epinephrine modulate the ion selectivity of tight junctions of goldfish intestine, Am J Physiol, 264, pp. R362-R368, (1993); Conlin V.S., Wu X., Nguyen C., Et al., Vasoactive intestinal peptide ameliorates intestinal barrier disruption associated with Citrobacter rodentium-induced colitis, Am J Physiol Gastrointest Liver Physiol, 297, pp. G735-G750, (2009); Zhang H., Yan Y., Shi R., Et al., Correlation of gut hormones with irritable bowel syndrome, Digestion, 78, pp. 72-76, (2008); Wu H.G., Jiang B., Zhou E.H., Et al., Regulatory mechanism of electroacupuncture in irritable bowel syndrome: preventing MC activation and decreasing SP VIP secretion, Dig Dis Sci, 53, pp. 1644-1651, (2008); Lee H., Park J.H., Park D.I., Et al., Mucosal mast cell count is associated with intestinal permeability in patients with diarrhea predominant irritable bowel syndrome, J Neurogastroenterol Motil, 19, pp. 244-250, (2013); O'Sullivan M., Clayton N., Breslin N.P., Et al., Increased mast cells in the irritable bowel syndrome, Neurogastroenterol Motil, 12, pp. 449-457, (2000); Guilarte M., Santos J., de Torres I., Et al., Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum, Gut, 56, pp. 203-209, (2007); Francis C.Y., Morris J., Whorwell P.J., The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress, Aliment Pharmacol Ther, 11, pp. 395-402, (1997); Keita A.V., Gullberg E., Ericson A.C., Et al., Characterization of antigen and bacterial transport in the follicle-associated epithelium of human ileum, Lab INvest, 86, pp. 504-516, (2006); Grass G.M., Sweetana S.A., In vitro measurement of gastrointestinal tissue permeability using a new diffusion cell, Pharm Res, 5, pp. 372-376, (1988); Keita A.V., Salim S.Y., Jiang T., Et al., Increased uptake of non-pathogenic E coli via the follicle-associated epithelium in longstanding ileal Crohn's disease, J Pathol, 215, pp. 135-144, (2008); Rautava S., Luoto R., Salminen S., Et al., Microbial contact during pregnancy, intestinal colonization and human disease, Nat Rev Gastroenterol Hepatol, 9, pp. 565-576, (2012); Klooker T.K., Braak B., Koopman K.E., Et al., The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome, Gut, 59, pp. 1213-1221, (2010); Hyland N.P., Quigley E.M., Brint E., Microbiota-host interactions in irritable bowel syndrome: epithelial barrier, immune regulation and brain-gut interactions, World J Gastroenterol, 20, pp. 8859-8866, (2014); Braak B., Klooker T.K., Wouters M.M., Et al., Mucosal immune cell numbers and visceral sensitivity in patients with irritable bowel syndrome: is there any relationship?, Am J Gastroenterol, 107, pp. 715-726, (2012); An S., Zong G., Wang Z., Et al., Expression of inducible nitric oxide synthase in mast cells contributes to the regulation of inflammatory cytokines in irritable bowel syndrome with diarrhea, Neurogastroenterol Motil, 28, pp. 1083-1093, (2016); Ohman L., Isaksson S., Lindmark A.C., Et al., T-cell activation in patients with irritable bowel syndrome, Am J Gastroenterol, 104, pp. 1205-1212, (2009); Park J.H., Rhee P.L., Kim H.S., Et al., Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome, J Gastroenterol Hepatol, 21, pp. 71-78, (2006); Cremon C., Gargano L., Morselli-Labate A.M., Et al., Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms, Am J Gastroenterol, 104, pp. 392-400, (2009); Ohman L., Simren M., Intestinal microbiota and its role in irritable bowel syndrome (IBS), Cur Gastroenterol Rep, 15, (2013); Tillisch K., The effects of gut microbiota on CNS function in humans, Gut Microbes, 5, pp. 404-410, (2014); Rasko D.A., Rosovitz M.J., Myers G.S., Et al., The pangenome structure of Escherichia coli: comparative genomic analysis of E coli commensal and pathogenic isolates, J Bacteriol, 190, pp. 6881-6893, (2008); Mayer E.A., Labus J.S., Tillisch K., Et al., Towards a systems view of IBS, Nat Rev Gastroenterol Hepatol, 12, pp. 592-605, (2015); Johansson M.E., Phillipson M., Petersson J., Et al., The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria, Proc Natl Acad Sci U S A, 105, pp. 15064-15069, (2008); Ermund A., Gustafsson J.K., Hansson G.C., Et al., Mucus properties and goblet cell quantification in mouse, rat and human ileal Peyer's patches, PLoS One, 8, (2013); Peters S.A., Edogawa S., Sundt W.J., Et al., Constipation-predominant irritable bowel syndrome females have normal colonic barrier and secretory function, Am J Gastroenterol, 112, pp. 913-923, (2017); Marchiando A.M., Shen L., Graham W.V., Et al., Caveolin-1-dependent occludin endocytosis is required for TNF-induced tight junction regulation in vivo, J Cell Biol, 189, pp. 111-126, (2010); Marshall J.K., Thabane M., Garg A.X., Et al., Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery, Gastroenterology, 131, pp. 445-450, (2006); Halvorson H.A., Schlett C.D., Riddle M.S., Postinfectious irritable bowel syndrome–a meta-analysis, Am J Gastroenterol, 101, pp. 1894-1899, (2006); Cremon C., Stanghellini V., Pallotti F., Et al., Salmonella gastroenteritis during childhood is a risk factor for irritable bowel syndrome in adulthood, Gastroenterology, 147, pp. 69-77, (2014); Crowley S.M., Knodler L.A., Vallance B.A., Salmonella and the Inflammasome: Battle for Intracellular Dominance, Curr Top Microbiol Immunol, 397, pp. 43-67, (2016); Berkes J., Viswanathan V.K., Savkovic S.D., Et al., Intestinal epithelial responses to enteric pathogens: effects on the tight junction barrier, ion transport, and inflammation, Gut, 52, pp. 439-451, (2003); Zareie M., Riff J., Donato K., Et al., Novel effects of the prototype translocating Escherichia coli, strain C25 on intestinal epithelial structure and barrier function, Cell Microbiol, 7, pp. 1782-1797, (2005); Yu Q., Yuan L., Deng J., Et al., Lactobacillus protects the integrity of intestinal epithelial barrier damaged by pathogenic bacteria, Front Cell Infect Microbiol, 5, (2015); Shen L., Weber C.R., Raleigh D.R., Et al., Tight junction pore and leak pathways: a dynamic duo, Annu Rev Physiol, 73, pp. 283-309, (2011); Tobin M.C., Moparty B., Farhadi A., Et al., Atopic irritable bowel syndrome: a novel subgroup of irritable bowel syndrome with allergic manifestations, Ann Allergy Asthma Immunol, 100, pp. 49-53, (2008); Vivinus-Nebot M., Dainese R., Anty R., Et al., Combination of allergic factors can worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells, Am J Gastroenterol, 107, pp. 75-81, (2012)","V. Keita; Department of Clinical and Experimental Medicine, Division of Surgery, Orthopedics and Oncology, Medical Faculty, Linköping University, Linköping, 581 85, United States; email: asa.keita@liu.se","","W.B. Saunders","","","","","","00165085","","GASTA","28711627","English","Gastroenterology","Article","Final","All Open Access; Green Open Access","Scopus","2-s2.0-85031665143"

"Xu L.; Cai J.; Tian A.; Qian K.; Qin R.; Qi S.; Tan X.; Qiu Y.; Gong M.; Han B.; Hu X.","Xu, Lu (57203714331); Cai, Jieyi (58592393200); Tian, Aofei (57203712789); Qian, Kai (57203715572); Qin, Renan (55227256300); Qi, Shaoyun (57203715049); Tan, Xupeng (57203718746); Qiu, Yuqin (24171757300); Gong, Mengjuan (55973940800); Han, Bin (55867926500); Hu, Xuguang (55496170100)","57203714331; 58592393200; 57203712789; 57203715572; 55227256300; 57203715049; 57203718746; 24171757300; 55973940800; 55867926500; 55496170100","The effect of prim-O-glucosylcimifugin on tryptase-induced intestinal barrier dysfunction in Caco-2 cells","2018","Biological and Pharmaceutical Bulletin","41","9","","1355","1361","6","11","10.1248/bpb.b18-00059","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85052678436&doi=10.1248%2fbpb.b18-00059&partnerID=40&md5=2805dec5a28a7613cb5973e6565bdf50","School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, HigherEducation Mega Center, No. 280, East Ring Road, Guangzhou, 510006, China; First Affiliated Hospital of Guangdong PharmaceuticalUniversity, No. 19, Nong Lin Road, Yuexiu District, Guangzhou, 510080, China; Guangzhou Baiyun MountainHutchison Whampoa Traditional Chinese Medicine Co., Ltd., Guangzhou, 510515, China","Xu L., School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, HigherEducation Mega Center, No. 280, East Ring Road, Guangzhou, 510006, China; Cai J., First Affiliated Hospital of Guangdong PharmaceuticalUniversity, No. 19, Nong Lin Road, Yuexiu District, Guangzhou, 510080, China; Tian A., School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, HigherEducation Mega Center, No. 280, East Ring Road, Guangzhou, 510006, China; Qian K., School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, HigherEducation Mega Center, No. 280, East Ring Road, Guangzhou, 510006, China; Qin R., Guangzhou Baiyun MountainHutchison Whampoa Traditional Chinese Medicine Co., Ltd., Guangzhou, 510515, China; Qi S., School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, HigherEducation Mega Center, No. 280, East Ring Road, Guangzhou, 510006, China; Tan X., School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, HigherEducation Mega Center, No. 280, East Ring Road, Guangzhou, 510006, China; Qiu Y., School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, HigherEducation Mega Center, No. 280, East Ring Road, Guangzhou, 510006, China; Gong M., School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, HigherEducation Mega Center, No. 280, East Ring Road, Guangzhou, 510006, China; Han B., School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, HigherEducation Mega Center, No. 280, East Ring Road, Guangzhou, 510006, China; Hu X., School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, HigherEducation Mega Center, No. 280, East Ring Road, Guangzhou, 510006, China","The intestinal barrier dysfunction is a critical pathological change in irritable bowel syndrome (IBS). The objective of this study was to evaluate the effect of Prim-O-glucosylcimifugin (POG) on intestinal barrier dysfunction and reveal possible molecular mechanisms. Human colon adenocarcinoma cell line (Caco-2) cell monolayers induced by tryptase (TRYP) were used to establish an intestinal barrier dysfunction model. Caco-2 cell monolayers from both functional and dysfunctional samples were treated with POG (30, 60 and 120µg/mL) for 2, 8, 24, 36, 48 and 72h. The Caco-2 cell monolayers were assessed by measurement of transepithelial electrical resistance (TEER) and percentage of fluorescein permeation (PFP). The expression of Protease Activated Receptor 2 (PAR-2) and myosin light chain kinase (MLCK) mRNA was analyzed by RT-PCR and the level of Zonula Occludens-1 (ZO-1) protein expression was determined by Western blot. In addition, the impact of POG on the distribution of the tight juction protein of Occludin was performed by immunofluorescence. Our results showed that POG elevated the TEER and decreased the PFP of the functional Caco-2 cell monolayers, as well as the dysfunctional Caco-2 cell monolayers. Furthermore, POG inhibited the expression of PAR-2 mRNA and MLCK mRNA and increased the level of ZO-1 protein expression in dysfunctional Caco-2 cells. The distribution of the Occludin proteins was ameliorated simultaneously. This study demonstrates that POG can enhance the intestinal barrier function of Caco-2 cell monolayers by inhibiting the expression of PAR-2 and MLCK and up-regulating the expression of ZO-1 protein, and ameliorated the distribution of Occludin protein. © 2018 The Pharmaceutical Society of Japan","Barrier dysfunction; Human colon adenocarcinoma cell line (Caco-2) cell; Intestinal barrier; Irritable bowel syndrome; Prim-O-glucosylcimifugin (POG)","Anti-Inflammatory Agents, Non-Steroidal; Caco-2 Cells; Cell Survival; Dose-Response Relationship, Drug; Humans; Inflammation Mediators; Intestinal Absorption; Intestinal Mucosa; Monosaccharides; Tight Junctions; Tryptases; Xanthenes; gastrointestinal agent; messenger RNA; myosin light chain kinase; occludin; prim o glucosylcimifugin; protein ZO1; proteinase activated receptor 2; tryptase; unclassified drug; autacoid; monosaccharide; nonsteroid antiinflammatory agent; prim-O-glucosylcimifugin; tryptase; xanthene derivative; Article; Caco-2 cell line; cell viability; controlled study; dose response; down regulation; human; human cell; immunofluorescence; intestine mucosa permeability; measurement; percentage of fluorescein permeation; protein expression; reverse transcription polymerase chain reaction; transepithelial electrical resistance; upregulation; Western blotting; agonists; antagonists and inhibitors; cell survival; chemistry; drug effect; intestine absorption; intestine mucosa; metabolism; physiology; tight junction","","myosin light chain kinase, 51845-53-5; occludin, 176304-61-3; tryptase, 97501-93-4; Anti-Inflammatory Agents, Non-Steroidal, ; Inflammation Mediators, ; Monosaccharides, ; prim-O-glucosylcimifugin, ; Tryptases, ; Xanthenes, ","","","First Affiliated Hospital of Guangdong Pharmaceutical University; Department of Natural Resources and the Environment, University of New Hampshire; National Natural Science Foundation of China, NSFC, (81673620); National Natural Science Foundation of China, NSFC; Department of Science and Technology, Government of Kerala; Naturvidenskab og Teknologi, Aarhus Universitet; Guangdong Pharmaceutical University, GDPU, (GYFYLH201328); Guangdong Pharmaceutical University, GDPU","Funding text 1: This study was supported by the National Natural Science Foundation of China (No. 81673620) and the Joint Natural Sciences Fund of the Department of Science and Technology and the First Affiliated Hospital of Guangdong Pharmaceutical University (No. GYFYLH201328).; Funding text 2: Acknowledgments This study was supported by the National Natural Science Foundation of China (No. 81673620) and the Joint Natural Sciences Fund of the Department of Science and Technology and the First Affiliated Hospital of Guangdong Pharmaceutical University (No. GYFYLH201328).","Halpern M.D., Denning P.W., The role of intestinal epithelial barrier function in the development of necrotizing enterocolitis, Tissue Barriers, 3, (2015); Coskun M., Intestinal epithelium in inflammatory bowel disease, Front. Med., 1, (2014); Saha L., Irritable bowel syndrome: Pathogenesis, diagnosis, treatment, and evidence based medicine, World J. Gastroenterol., 20, pp. 6759-6773, (2014); Beatty J.K., Bhargava A., Buret A.G., Post-infectious irritable bowel syndrome: Mechanistic insights into chronic disturbances following enteric infection, World J. Gastroenterol., 20, pp. 3976-3985, (2014); Liang W.J., Zhang G., Luo H.S., Liang L.X., Huang D., Zhang F.C., Tryptase and protease-activated receptor 2 expression levels in irritable bowel syndrome, Gut & Liver, 10, pp. 382-390, (2016); Lee J.W., Park J.H., Park D.I., Park J.H., Kim H.J., Cho Y.K., Sohn C.I., Jeon W.K., Kim B.I., Subjects with diarrheapredominant IBS have increased rectal permeability responsive to tryptase, Dig. Dis. Sci., 55, pp. 2922-2928, (2010); Amadesi S., Bunnett N., Protease-activated receptors: Protease signaling in the gastrointestinal tract, Curr. Opin. Pharmacol., 4, pp. 551-556, (2004); Gonzalez-Mariscal L., Tapia R., Chamorro D., Crosstalk of tight junction components with signaling pathways, Biochim. Biophys. Acta, 1778, pp. 729-756, (2008); Shen L., Tight junctions on the move: Molecular mechanisms forepi-thelial barrier regulation, Ann. N. Y. Acad. Sci., 1258, pp. 9-18, (2012); Yu D., Marchiando A.M., Weber C.R., Raleigh D.R., Wang Y., Shen L., Turner J.R., MLCK-dependent exchange and actin binding regionde-pendent anchoring of ZO-1 regulate tight junction barrier function, Proc. Natl. Acad. Sci. U.S.A., 107, pp. 8237-8241, (2010); Lee S.H., Intestinal permeability regulation by tight junction: Implication on inflammatory bowel diseases, Intest Res, 13, pp. 11-18, (2015); Pharmacopoeia of The People’S Republic of China, (2010); Zhao B., Yang X., Yang X., Zhang L., Biotransformation of prim-O-glucosylcimifugin by human intestinal flora and its inhibition on NO production and DPPH free radical, Chung Kuo Chung Yao TSA Chih, 35, pp. 1569-1572, (2010); Chun J.M., Kim H.S., Lee A.Y., Kim S.H., Kim H.K., Anti-inflammatory and antiosteoarthritis effects of Saposhnikovia divaricata ethanol extract: In vitro and in vivo studies, Evidence-Based Complemen-Tray and Alternative Medicine, (2016); Kong X., Liu C., Zhang C., Zhao J., Wang J., Wan H., Zhu H., Zhang P., Chen W., Xiao Y., Lin N., The suppressive effects of Saposhnikovia divaricata (POG) chromone extract on rheumatoid arthritis via inhibition of nuclear factor-κB and mitogen activated proteinkinases activation on collagen-induced arthritis model, J. Ethnopharmacol., 148, pp. 842-850, (2013); Hu X., Xu D., Zhao Y., Yang X., Meng J., Shen H., Guo J., The alleviating pain effect of aqueous extract from tong-xie-yao-fang, on experimental visceral hypersensitivity and its mechanism, Biol. Pharm. Bull., 32, pp. 1075-1079, (2009); Tan X., Han Z., Wen Y., Liu D., Hu X., Effects of tongxie yaofang and radix saposhnikoviae on the barrier functions of human intestinal Caco-2 cell, Shenzhen J. Trad. Chi. Med., 24, pp. 1-3, (2014); Qi S., Cai J., Zhou L., Yang T., Tan X., Li M., Han B., Hu X., Effect of radix saposhnikoviae on intestinal flora and serine protease signal in rats with post-infection irritable bowel syndrome, Trad. Chi. Dru. Res. Cli. Pharmacol., 26, pp. 790-796, (2015); Hu X., Liao S., Wang Y., Gong M., Wang M., Liu S., Han B., Effect of Radix Saposhnikoviae in Tongxie Yaofang on PAR2 mRNA expression and inflammatory mediators in the colon of rats with postinfection irritable bowel syndrome, Trad. Chi. Dru. Res. Cli. Pharmacol., 24, pp. 1-7, (2013); Gui Y., Tsao R., Li L., Liu C.M., Wang J., Zong X., Preparative separation of chromones in plant extract of Saposhnikovia divaricata by high-performance counter-current chromatography, J. Sep. Sci., 34, pp. 520-526, (2011); Chen L., Chen X., Su L., Jiang Y., Liu B., Rapid characterisation and identification of compounds in Saposhnikoviae Radix by high-performance liquid chromatography coupled with electrospray ioni-sation quadrupole time-of-flight mass spectrometry, Nat. Prod. Res., 32, pp. 898-901, (2018); Scherubl R., Beggs A., Franz G., Heilmann J., Manns D., Analysis of chromone glycosides in saposhnikovia divaricata for the establishment of a monograph of the German pharmacopoeia, Planta Med, 78, (2012); Jiang Y.Y., Liu B., Shi R.B., Tu G.Z., Isolation and structure identification of chemical constituents from Saposhnikovia divaricata (Turcz.) Schischk, Yao Xue Xue Bao, 42, pp. 505-510, (2007); Li Y.Y., Wang X.X., Zhao L., Zhang H., Lv L., Zhou G.C., Chai Y.F., Zhang G.Q., High-performance liquid chromatography-electrospray ionization time-of-flight mass spectrometry analysis of radix saposhnikoviae for metabolomic research, J. Chromatogr. Sci., 51, pp. 99-106, (2013); Li N., Gu L., Qu L., Gong J., Li Q., Zhu W., Li J., Berberine attenuates pro-inflammatory cytokine-induced tight junction disruption in an in vitro model of intestinal epithelial cells, Eur. J. Pharm. Sci., 40, pp. 1-8, (2010); Bueno L., Fioramonti J., Protease-activated receptor 2 and gut permeability: A review, Neurogastroenterol. Motil., 20, pp. 580-587, (2008); Hidalgo I.J., Raub T.J., Borchardt R.T., Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability, Gastroenterology, 96, pp. 736-749, (1989); Sambuy Y., De Angelis I., Ranaldi G., Scarino M.L., Stammati A., Zucco F., The Caco-2 cell line as a model of the intestinal barrier: Influence of cell and culture-related factors on Caco-2 cell functional characteristics, Cell Biol. Toxicol., 21, pp. 1-26, (2005); Elamin E.E., Masclee A.A., Dekker J., Pieters H.J., Jonkers D.M., Short-chain fatty acids activate AMP-activated protein kinase and ameliorate ethanol-induced intestinal barrier dysfunction in Caco-2 cell monolayers, J. Nutr., 143, pp. 1872-1881, (2013); Lee J.W., Park J.H., Park D.I., Park J.H., Kim H.J., Cho Y.K., Sohn C.I., Jeon W.K., Kim B.I., Subjects with diarrhea-predominant IBS have increased rectal permeability responsive to tryptase, Dig. Dis. Sci., 55, pp. 2922-2928, (2010); Roka R., Rosztoczy A., Leveque M., Izbeki F., Nagy F., Molnar T., Lonovics J., Garcia-Villar R., Fioramonti J., Wittmann T., Bueno L., A pilot study of Fecal serine-protease activity: A pathophysiologic factor in diarrhea-predominant irritable bowel syndrome, Clin. Gastroenterol. Hepatol., 5, pp. 550-555, (2007); Ludidi S., Jonkers L., Elamin E., Pieters H.J., Schaepkens E., Bours P., Kruimel J., Conchillo J., Masclee A., The intestinal barrier in irritable bowel syndrome: Subtype-specific effects of the systemic compartment in an in vitro model, PLOS ONE, 10, (2015); Zhao B., Yang X.B., Yang X.W., Liu J.X., Biotransformation of prim-O-glucosylcimifugin by human intestinal flora and its inhibition on NO production and DPPH free radical, J. Asian Nat. Prod. Res., 14, pp. 886-896, (2012); Salim S.Y., Soderholm J.D., Importance of disrupted intestinal barrier in inflammatory bowel diseases, Inflamm. Bowel Dis., 17, pp. 362-381, (2011); Cenac N., Coelho A.M., Nguyen C., Compton S., Andrade-Gordon P., MacNaughton W.K., Wallace J.L., Hollenberg M.D., Bunnett N.W., Garcia-Villar R., Bueno L., Vergnolle N., Induction of intestinal inflammationin mouse by activation of proteinase-activated receptor-2, Am. J. Pathol., 161, pp. 1903-1915, (2002); Wilcz-Villega E.M., McClean S., O'Sullivan M.A., Mast cell tryptase reduces junctional adhesion molecule-A (JAM-A) expression in intestinal epithelial cells: Implications for the mechanisms of barrier dysfunction in irritable bowel syndrome, Am. J. Gastroenterol., 108, pp. 1140-1151, (2013); Piche T., Barbara G., Aubert P., Bruley des Varannes S., Dainese R., Nano J.L., Cremon C., Stanghellini V., De Giorgio R., Galmiche J.P., Neunlist M., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: Involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Nusrat A., Turner J.R., Madara J.L., Regulation of tight junctions by extracellular stimuli: Nutrients, cytokines, and immune cells, Am. J. Physiol. Gastrointest. Liver Physiol., 279, pp. G851-G857, (2000); Shen L., Black E.D., Witkowski E.D., Lencer W.I., Guerriero V., Schneeberger E.E., Turner J.R., Myosin light chain phosphorylation regulates barrier function by remodeling tight junction structure, J. Cell Sci., 119, pp. 2095-2106, (2006); Clayburgh D.R., Barrett T.A., Tang Y., Meddings J.B., Van Eldik L.J., Watterson D.M., Clarke L.L., Mrsny R.J., Turner J.R., Epithelial myosin light chain kinase-dependent barrier dysfunction mediates T cell activation-induced diarrhea in vivo, J. Clin. Invest., 115, pp. 2702-2715, (2005); Furuse M., Itoh M., Hirase T., Nagafuchi A., Yonemura S., Tsukita S., Tsukita S., Direct association of occludin with ZO-1 and its possible involvement in the localization of occludin at tight junctions, J. Cell Biol., 127, pp. 1617-1626, (1994)","X. Hu; School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, HigherEducation Mega Center, Guangzhou, No. 280, East Ring Road, 510006, China; email: D19973434@163.com","","Pharmaceutical Society of Japan","","","","","","09186158","","BPBLE","29910215","English","Biol. Pharm. Bull.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85052678436"

"Bertrand J.; Ghouzali I.; Guérin C.; Bôle-Feysot C.; Gouteux M.; Déchelotte P.; Ducrotté P.; Coëffier M.","Bertrand, Julien (57198107366); Ghouzali, Ibtissem (55534510300); Guérin, Charlène (55319308600); Bôle-Feysot, Christine (55881037400); Gouteux, Mélodie (57191954126); Déchelotte, Pierre (57201760610); Ducrotté, Philippe (7006732860); Coëffier, Moïse (6603081357)","57198107366; 55534510300; 55319308600; 55881037400; 57191954126; 57201760610; 7006732860; 6603081357","Glutamine Restores Tight Junction Protein Claudin-1 Expression in Colonic Mucosa of Patients with Diarrhea-Predominant Irritable Bowel Syndrome","2016","Journal of Parenteral and Enteral Nutrition","40","8","","1170","1176","6","36","10.1177/0148607115587330","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84995387494&doi=10.1177%2f0148607115587330&partnerID=40&md5=baaf2170f8882c3a995153148d17eaf6","INSERM UMR1073, University of Rouen, 22 boulevard Gambetta, Rouen Cedex 1, 76183, France; Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, Rouen, France; Department of Nutrition, Rouen University Hospital, Rouen, France; Department of Gastroenterology, Rouen University Hospital, Rouen, France","Bertrand J., INSERM UMR1073, University of Rouen, 22 boulevard Gambetta, Rouen Cedex 1, 76183, France, Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, Rouen, France; Ghouzali I., INSERM UMR1073, University of Rouen, 22 boulevard Gambetta, Rouen Cedex 1, 76183, France, Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, Rouen, France; Guérin C., INSERM UMR1073, University of Rouen, 22 boulevard Gambetta, Rouen Cedex 1, 76183, France, Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, Rouen, France; Bôle-Feysot C., INSERM UMR1073, University of Rouen, 22 boulevard Gambetta, Rouen Cedex 1, 76183, France, Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, Rouen, France; Gouteux M., INSERM UMR1073, University of Rouen, 22 boulevard Gambetta, Rouen Cedex 1, 76183, France, Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, Rouen, France; Déchelotte P., INSERM UMR1073, University of Rouen, 22 boulevard Gambetta, Rouen Cedex 1, 76183, France, Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, Rouen, France, Department of Nutrition, Rouen University Hospital, Rouen, France; Ducrotté P., INSERM UMR1073, University of Rouen, 22 boulevard Gambetta, Rouen Cedex 1, 76183, France, Department of Gastroenterology, Rouen University Hospital, Rouen, France; Coëffier M., INSERM UMR1073, University of Rouen, 22 boulevard Gambetta, Rouen Cedex 1, 76183, France, Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, Rouen, France, Department of Nutrition, Rouen University Hospital, Rouen, France","Background:Recent studies showed that patients with diarrhea-predominant irritable bowel syndrome (IBS-D) had an increased intestinal permeability as well as a decreased expression of tight junctions. Glutamine, the major substrate of rapidly dividing cells, is able to modulate intestinal permeability and tight junction expression in other diseases. We aimed to evaluate, ex vivo, glutamine effects on tight junction proteins, claudin-1 and occludin, in the colonic mucosa of patients with IBS-D. Materials and Methods: Twelve patients with IBS-D, diagnosed with the Rome III criteria, were included (8 women/4 men, aged 40.7 ± 6.9 years). Colonic biopsy specimens were collected and immediately incubated for 18 hours in culture media with increasing concentrations of glutamine from 0.6-10 mmol/L. Claudin-1 and occludin expression was then measured by immunoblot, and concentrations of cytokines were assessed by multiplex technology. Claudin-1 expression was affected by glutamine (P <.05, analysis of variance). In particularly, 10 mmol/L glutamine increased claudin-1 expression compared with 0.6 mmol/L glutamine (0.47 ± 0.04 vs 0.33 ± 0.03, P <.05). In contrast, occludin expression was not significantly modified by glutamine. Interestingly, glutamine effect was negatively correlated to claudin-1 (Pearson r = -0.83, P <.001) or occludin basal expression (Pearson r = -0.84, P <.001), suggesting that glutamine had more marked effects when tight junction protein expression was altered. Cytokine concentrations in culture media were not modified by glutamine treatment. Conclusion: Glutamine increased claudin-1 expression in the colonic mucosa of patients with IBS-D. In addition, glutamine effect seems to be dependent on basal expression of tight junction proteins. © 2015 The American Society for Parenteral and Enteral Nutrition.","claudin; diarrhea; glutamine; irritable bowel syndrome; occludin; tight junctions","Adult; Claudin-1; Diarrhea; Female; Glutamine; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Male; Middle Aged; Occludin; Permeability; claudin 1; glutamine; occludin; tight junction protein; claudin 1; glutamine; occludin; adult; Article; clinical article; colon biopsy; colon mucosa; culture medium; cytokine production; diarrhea; drug effect; ex vivo study; female; human; human tissue; immunoblotting; incubation time; intestine mucosa permeability; irritable colon; male; pilot study; priority journal; protein expression; diarrhea; genetics; intestine mucosa; irritable colon; metabolism; middle aged; permeability","","claudin 1, 329338-06-9; glutamine, 56-85-9, 6899-04-3; occludin, 176304-61-3; Claudin-1, ; Glutamine, ; Occludin, ","","","","","Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Thompson W.G., Longstreth G.F., Drossman D.A., Heaton K.W., Irvine E.J., Muller-Lissner S.A., Functional bowel disorders and functional abdominal pain, Gut, 45, pp. II43-II47, (1999); Drossman D.A., Camilleri M., Mayer E.A., Whitehead W.E., AGA technical review on irritable bowel syndrome, Gastroenterology, 123, pp. 2108-2131, (2002); Zhou Q., Souba W.W., Croce C.M., Verne G.N., MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome, Gut, 59, pp. 775-784, (2010); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Bertiaux-Vandaele N., Beutheu Youmba S., Et al., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am J Gastroenterol, 166, pp. 2165-2173, (2011); Coeffier M., Gloro R., Boukhettala N., Et al., Increased proteasome-mediated degradation of occludin in irritable bowel syndrome, Am J Gastroenterol, 105, pp. 1181-1188, (2010); Piche T., Barbara G., Aubert P., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: Involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Martinez C., Vicario M., Ramos L., Et al., The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations, Am J Gastroenterol, 107, pp. 736-746, (2012); Sido B., Seel C., Hochlehnert A., Breitkreutz R., Droge W., Low intestinal glutamine level and low glutaminase activity in Crohn's disease: A rational for glutamine supplementation?, Dig Dis Sci, 51, pp. 2170-2179, (2006); De-Souza D.A., Greene L.J., Intestinal permeability and systemic infections in critically ill patients: Effect of glutamine, Crit Care Med, 33, pp. 1125-1135, (2005); Boukhettala N., Claeyssens S., Bensifi M., Et al., Effects of essential amino acids or glutamine deprivation on intestinal permeability and protein synthesis in HCT-8 cells: Involvement of GCN2 and mTOR pathways, Amino Acids, 42, pp. 375-383, (2012); Le Bacquer O., Laboisse C., Darmaun D., Glutamine preserves protein synthesis and paracellular permeability in Caco-2 cells submitted to ""luminal fasting., Am J Physiol Gastrointest Liver Physiol, 285, pp. G128-G136, (2003); Li N., Lewis P., Samuelson D., Liboni K., Neu J., Glutamine regulates Caco-2 cell tight junction proteins, Am J Physiol Gastrointest Liver Physiol, 287, pp. G726-G733, (2004); Beutheu S., Ghouzali I., Galas L., Dechelotte P., Coeffier M., Glutamine and arginine improve permeability and tight junction protein expression in methotrexate-treated Caco-2 cells, Clin Nutr, 32, pp. 863-869, (2013); Beutheu S., Ouelaa W., Guerin C., Et al., Glutamine supplementation, but not combined glutamine and arginine supplementation, improves gut barrier function during chemotherapy-induced intestinal mucositis in rats, Clin Nutr, 33, pp. 694-701, (2014); Choi K., Lee S.S., Oh S.J., Et al., The effect of oral glutamine on 5-fluorouracil/leucovorin-induced mucositis/stomatitis assessed by intestinal permeability test, Clin Nutr, 26, pp. 57-62, (2007); Daniele B., Perrone F., Gallo C., Et al., Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: A double blind, placebo controlled, randomised trial, Gut, 48, pp. 28-33, (2001); Coeffier M., Dechelotte P., Ducrotte P., Intestinal permeability in patients with diarrhea predominant irritable bowel syndrome: Is there a place for glutamine supplementation?, Gastroenterology, 148, 5, pp. 1079-1080, (2015); Coeffier M., Marion R., Ducrotte P., Dechelotte P., Modulating effect of glutamine on IL-1beta-induced cytokine production by human gut, Clin Nutr, 22, pp. 407-413, (2003); Belmonte L., Beutheu Youmba S., Bertiaux-Vandaele N., Et al., Role of Toll like receptors in irritable bowel syndrome: Differential mucosal immune activation according to the disease subtype, PLoS One, 7, (2012); Bradford M.M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding, Anal Biochem, 72, pp. 248-254, (1976); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Zhou Q., Costinean S., Croce C.M., Et al., MicroRNA 29 targets nuclear factor-kappaB-repressing factor and claudin 1 to increase intestinal permeability, Gastroenterology, 148, pp. 158-169, (2015); Smith M.W., James P.S., Amino acid transport by the helicoidal colon of the new-born pig, Biochim Biophys Acta, 419, pp. 391-394, (1976); Blachier F., Boutry C., Bos C., Tome D., Metabolism and functions of L-glutamate in the epithelial cells of the small and large intestines, Am J Clin Nutr, 90, pp. 814S-821S, (2009); Bertrand J., Marion-Letellier R., Et al., Glutamine enema regulates colonic ubiquitinated-proteins but not proteasome activities during TNBS-induced colitis leading to increased mitochondrial activity, Proteomics, (2015); Kretzmann N.A., Fillmann H., Mauriz J.L., Et al., Effects of glutamine on proinflammatory gene expression and activation of nuclear factor kappa B and signal transducers and activators of transcription in TNBS-induced colitis, Inflamm Bowel Dis, 14, pp. 1504-1513, (2008); Wischmeyer P., Pemberton J.H., Phillips S.F., Chronic pouchitis after ileal pouch-anal anastomosis: Responses to butyrate and glutamine suppositories in a pilot study, Mayo Clin Proc, 68, pp. 978-981, (1993); Coeffier M., Marion-Letellier R., Dechelotte P., Potential for amino acids supplementation during inflammatory bowel diseases, Inflamm Bowel Dis, 16, pp. 518-524, (2010); Darcy-Vrillon B., Morel M.T., Cherbuy C., Et al., Metabolic characteristics of pig colonocytes after adaptation to a high fiber diet, J Nutr, 123, pp. 234-243, (1993); Vermeulen M.A., De Jong J., Vaessen M.J., Van Leeuwen P.A., Houdijk A.P., Glutamate reduces experimental intestinal hyperpermeability and facilitates glutamine support of gut integrity, World J Gastroenterol, 17, pp. 1569-1573, (2011); Seth A., Basuroy S., Sheth P., Rao R.K., L-Glutamine ameliorates acetaldehyde-induced increase in paracellular permeability in Caco-2 cell monolayer, Am J Physiol Gastrointest Liver Physiol, 287, pp. G510-G517, (2004); Barbara G., Stanghellini V., De Giorgio R., Et al., Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome, Gastroenterology, 126, pp. 693-702, (2004); Barkhordari E., Rezaei N., Mahmoudi M., Et al., T-helper 1, T-helper 2, and T-regulatory cytokines gene polymorphisms in irritable bowel syndrome, Inflammation, 33, pp. 281-286, (2010); O'Loughlin E.V., Pang G.P., Noltorp R., Koina C., Batey R., Clancy R., Interleukin 2 modulates ion secretion and cell proliferation in cultured human small intestinal enterocytes, Gut, 49, pp. 636-643, (2001); Epple H.J., Schneider T., Troeger H., Et al., Impairment of the intestinal barrier is evident in untreated but absent in suppressively treated HIV-infected patients, Gut, 58, pp. 220-227, (2009)","M. Coëffier; INSERM UMR1073, University of Rouen, Rouen Cedex 1, 22 boulevard Gambetta, 76183, France; email: moise.coeffier@univ-rouen.fr","","SAGE Publications Inc.","","","","","","01486071","","JPEND","25972430","English","J. Parenter. Enter. Nutr.","Article","Final","","Scopus","2-s2.0-84995387494"

"Martínez C.; Rodinõ-Janeiro B.K.; Lobo B.; Stanifer M.L.; Klaus B.; Granzow M.; González-Castro A.M.; Salvo-Romero E.; Alonso-Cotoner C.; Pigrau M.; Roeth R.; Rappold G.; Huber W.; González-Silos R.; Lorenzo J.; De Torres I.; Azpiroz F.; Boulant S.; Vicario M.; Niesler B.; Santos J.","Martínez, Cristina (17534584700); Rodinõ-Janeiro, Bruno K (35729142300); Lobo, Beatriz (7003936898); Stanifer, Megan L (6507953984); Klaus, Bernd (56349662200); Granzow, Martin (6603113998); González-Castro, Ana M (54796498900); Salvo-Romero, Eloisa (56830611700); Alonso-Cotoner, Carmen (56411082400); Pigrau, Marc (37009212800); Roeth, Ralph (8609257700); Rappold, Gudrun (56231566500); Huber, Wolfgang (22135017800); González-Silos, Rosa (57193141691); Lorenzo, Justo (57193136007); De Torres, Inés (7003506754); Azpiroz, Fernando (57207592894); Boulant, Steeve (8070197900); Vicario, Mariá (6603267769); Niesler, Beate (6602490382); Santos, Javier (7402389020)","17534584700; 35729142300; 7003936898; 6507953984; 56349662200; 6603113998; 54796498900; 56830611700; 56411082400; 37009212800; 8609257700; 56231566500; 22135017800; 57193141691; 57193136007; 7003506754; 57207592894; 8070197900; 6603267769; 6602490382; 7402389020","MiR-16 and miR-125b are involved in barrier function dysregulation through the modulation of claudin-2 and cingulin expression in the jejunum in IBS with diarrhoea","2017","Gut","66","9","","1597","1610","13","110","10.1136/gutjnl-2016-311477","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85011049801&doi=10.1136%2fgutjnl-2016-311477&partnerID=40&md5=500c3ccd47e891ccc1eeedc2a55117e9","Department of Human Molecular Genetics, Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany; Digestive System Research Unit, Institut de Recerca Vall d'Hebron, Barcelona, Spain; Facultat de Medicina, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain; Schaller Research Group at CellNetworks, Department of Infectious Diseases Virology, University of Heidelberg, Heidelberg, Germany; European Molecular Biology Laboratory (EMBL), Heidelberg, Germany; Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany, Germany; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Spain; COST Action BM1106 Genes in Irritable Bowel Syndrome European Research Network, Spain; NCounter Core Facility, Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany; Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany; Department of Pathology, Facultat de Medicina, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain; Research Group 'Cellular Polarity and Viral Infection', German Cancer Research Center, Heidelberg, Germany","Martínez C., Department of Human Molecular Genetics, Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany, Digestive System Research Unit, Institut de Recerca Vall d'Hebron, Barcelona, Spain, Facultat de Medicina, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain; Rodinõ-Janeiro B.K., Digestive System Research Unit, Institut de Recerca Vall d'Hebron, Barcelona, Spain, Facultat de Medicina, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain; Lobo B., Digestive System Research Unit, Institut de Recerca Vall d'Hebron, Barcelona, Spain, Facultat de Medicina, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain; Stanifer M.L., Schaller Research Group at CellNetworks, Department of Infectious Diseases Virology, University of Heidelberg, Heidelberg, Germany; Klaus B., European Molecular Biology Laboratory (EMBL), Heidelberg, Germany; Granzow M., Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany, Germany; González-Castro A.M., Digestive System Research Unit, Institut de Recerca Vall d'Hebron, Barcelona, Spain; Salvo-Romero E., Digestive System Research Unit, Institut de Recerca Vall d'Hebron, Barcelona, Spain; Alonso-Cotoner C., Digestive System Research Unit, Institut de Recerca Vall d'Hebron, Barcelona, Spain, Facultat de Medicina, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Spain, COST Action BM1106 Genes in Irritable Bowel Syndrome European Research Network, Spain; Pigrau M., Digestive System Research Unit, Institut de Recerca Vall d'Hebron, Barcelona, Spain, Facultat de Medicina, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain; Roeth R., Department of Human Molecular Genetics, Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany, NCounter Core Facility, Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany; Rappold G., Department of Human Molecular Genetics, Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany; Huber W., European Molecular Biology Laboratory (EMBL), Heidelberg, Germany; González-Silos R., Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany; Lorenzo J., Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany; De Torres I., Department of Pathology, Facultat de Medicina, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain; Azpiroz F., Digestive System Research Unit, Institut de Recerca Vall d'Hebron, Barcelona, Spain, Facultat de Medicina, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Spain, COST Action BM1106 Genes in Irritable Bowel Syndrome European Research Network, Spain; Boulant S., Schaller Research Group at CellNetworks, Department of Infectious Diseases Virology, University of Heidelberg, Heidelberg, Germany, Research Group 'Cellular Polarity and Viral Infection', German Cancer Research Center, Heidelberg, Germany; Vicario M., Digestive System Research Unit, Institut de Recerca Vall d'Hebron, Barcelona, Spain, Facultat de Medicina, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Spain, COST Action BM1106 Genes in Irritable Bowel Syndrome European Research Network, Spain; Niesler B., Department of Human Molecular Genetics, Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany, COST Action BM1106 Genes in Irritable Bowel Syndrome European Research Network, Spain, NCounter Core Facility, Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany; Santos J., Digestive System Research Unit, Institut de Recerca Vall d'Hebron, Barcelona, Spain, Facultat de Medicina, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Spain, COST Action BM1106 Genes in Irritable Bowel Syndrome European Research Network, Spain","Objective Micro-RNAs (miRNAs) play a crucial role in controlling intestinal epithelial barrier function partly by modulating the expression of tight junction (TJ) proteins. We have previously shown differential messenger RNA (mRNA) expression correlated with ultrastructural abnormalities of the epithelial barrier in patients with diarrhoea-predominant IBS (IBS-D). However, the participation of miRNAs in these differential mRNA-associated findings remains to be established. Our aims were (1) to identify miRNAs differentially expressed in the small bowel mucosa of patients with IBS-D and (2) to explore putative target genes specifically involved in epithelial barrier function that are controlled by specific dysregulated IBS-D miRNAs. Design Healthy controls and patients meeting Rome III IBS-D criteria were studied. Intestinal tissue samples were analysed to identify potential candidates by: (a) miRNA-mRNA profiling; (b) miRNA-mRNA pairing analysis to assess the co-expression profile of miRNA-mRNA pairs; (c) pathway analysis and upstream regulator identification; (d) miRNA and target mRNA validation. Candidate miRNA-mRNA pairs were functionally assessed in intestinal epithelial cells. Results IBS-D samples showed distinct miRNA and mRNA profiles compared with healthy controls. TJ signalling was associated with the IBS-D transcriptional profile. Further validation of selected genes showed consistent upregulation in 75% of genes involved in epithelial barrier function. Bioinformatic analysis of putative miRNA binding sites identified hsa-miR-125b-5p and hsa-miR-16 as regulating expression of the TJ genes CGN (cingulin) and CLDN2 (claudin-2), respectively. Consistently, protein expression of CGN and CLDN2 was upregulated in IBS-D, while the respective targeting miRNAs were downregulated. In addition, bowel dysfunction, perceived stress and depression and number of mast cells correlated with the expression of hsa-miR-125b-5p and hsa-miR-16 and their respective target proteins. Conclusions Modulation of the intestinal epithelial barrier function in IBS-D involves both transcriptional and post-transcriptional mechanisms. These molecular mechanisms include miRNAs as master regulators in controlling the expression of TJ proteins and are associated with major clinical symptoms. © 2017 Published by the BMJ Publishing Group Limited.","Gene Expression; Intestinal Barrier Function; Irritable Bowel Syndrome; Molecular Biology; Rna Expression","Adult; Claudins; Diarrhea; Down-Regulation; Female; Gene Expression Profiling; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Jejunum; Male; Membrane Proteins; Microfilament Proteins; MicroRNAs; Middle Aged; Up-Regulation; cingulin; claudin 2; microRNA 125b; microRNA 16; tight junction protein; unclassified drug; actin binding protein; CGN protein, human; claudin; CLDN2 protein, human; membrane protein; microRNA; MIRN125 microRNA, human; MIRN16 microRNA, human; adult; Article; binding site; bioinformatics; cell count; CGN gene; chronic stress; CLDN2 gene; clinical article; controlled study; correlation analysis; defecation habit; depression; diarrhea; down regulation; enteropathy; female; gene; gene expression; human; human cell; human tissue; humoral immunity; intestinal epithelial barrier; intestine mucosa permeability; irritable colon; jejunum; male; mast cell; priority journal; protein expression; protein structure; RNA sequence; signal transduction; upregulation; diarrhea; gene expression profiling; genetics; intestine mucosa; metabolism; middle aged; pathology; pathophysiology","","CGN protein, human, ; Claudins, ; CLDN2 protein, human, ; Membrane Proteins, ; Microfilament Proteins, ; MicroRNAs, ; MIRN125 microRNA, human, ; MIRN16 microRNA, human, ","","","","","Martinez C., Lobo B., Pigrau M., Et al., Diarrhoea-predominant irritable bowel syndrome: An organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, pp. 1160-1168, (2013); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Piche T., Barbara G., Aubert P., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: Involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Martinez C., Gonzalez-Castro A., Vicario M., Et al., Cellular and molecular basis of intestinal barrier dysfunction in the irritable bowel syndrome, Gut Liver, 6, pp. 305-315, (2012); Guilarte M., Santos J., De Torres I., Et al., Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum, Gut, 56, pp. 203-209, (2007); Matricon J., Meleine M., Gelot A., Et al., Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome, Aliment Pharmacol Ther, 36, pp. 1009-1031, (2012); Cenac N., Andrews C.N., Holzhausen M., Et al., Role for protease activity in visceral pain in irritable bowel syndrome, J Clin Invest, 117, pp. 636-647, (2007); Foley S., Garsed K., Singh G., Et al., Impaired uptake of serotonin by platelets from patients with irritable bowel syndrome correlates with duodenal immune activation, Gastroenterology, 140, pp. 1434-1443, (2011); Barbara G., Wang B., Stanghellini V., Et al., Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome, Gastroenterology, 132, pp. 26-37, (2007); MacSharry J., O'Mahony L., Fanning A., Et al., Mucosal cytokine imbalance in irritable bowel syndrome, Scand J Gastroenterol, 43, pp. 1467-1476, (2008); Aerssens J., Camilleri M., Talloen W., Et al., Alterations in mucosal immunity identified in the colon of patients with irritable bowel syndrome, Clin Gastroenterol Hepatol, 6, pp. 194-205, (2008); Camilleri M., Carlson P., Acosta A., Et al., RNA sequencing shows transcriptomic changes in rectosigmoid mucosa in patients with irritable bowel syndrome-diarrhea: A pilot case-control study, Am J Physiol Gastrointest Liver Physiol, 306, pp. G1089-G1098, (2014); Martinez C., Vicario M., Ramos L., Et al., The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations, Am J Gastroenterol, 107, pp. 736-746, (2012); Vicario M., Gonzalez-Castro A.M., Martinez C., Et al., Increased humoral immunity in the jejunum of diarrhoea-predominant irritable bowel syndrome associated with clinical manifestations, Gut, 64, pp. 1379-1388, (2015); Khalil A.M., Rinn J.L., RNA-protein interactions in human health and disease, Semin Cell Dev Biol, 22, pp. 359-365, (2011); Taft R.J., Pheasant M., Mattick J.S., The relationship between non-protein-coding DNA and eukaryotic complexity, Bioessays, 29, pp. 288-299, (2007); Morris K.V., The emerging role of RNA in the regulation of gene transcription in human cells, Semin Cell Dev Biol, 22, pp. 351-358, (2011); Bi Y., Liu G., Yang R., MicroRNAs: Novel regulators during the immune response, J Cell Physiol, 218, pp. 467-472, (2009); Sheedy F.J., O'Neill L.A.J., Adding fuel to fire: MicroRNAs as a new class of mediators of inflammation, Ann Rheum Dis, 67, pp. iii50-iii55, (2008); Kapeller J., Houghton L.A., Monnikes H., Et al., First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome, Hum Mol Genet, 17, pp. 2967-2977, (2008); Wohlfarth C., Hartle J.D., Becker P., Et al., Impaired MiRNA Regulation May Lead to Altered 5-HT4 Receptor Levels in IBS-D Patients, (2013); Zhou Q., Souba W.W., Croce C.M., Et al., MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome, Gut, 59, pp. 775-784, (2010); Fourie N.H., Peace R.M., Abey S.K., Et al., Elevated circulating miR-150 and miR-342-3p in patients with irritable bowel syndrome, Exp Mol Pathol, 96, pp. 422-425, (2014); McKenna L.B., Schug J., Vourekas A., Et al., MicroRNAs control intestinal epithelial differentiation, architecture, and barrier function, Gastroenterology, 139, pp. 1654-1664, (2010); Longstreth G.F., Thompson W.G., Chey W.D., Et al., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Lewis S.J., Heaton K.W., Stool form scale as a useful guide to intestinal transit time, Scand J Gastroenterol, 32, pp. 920-924, (1997); Holmes T.H., Rahe R.H., The social readjustment rating scale, J Psychosom Res, 11, pp. 213-218, (1967); Cohen S., Kamarck T., Mermelstein R., A global measure of perceived stress, J Health Soc Behav, 24, pp. 385-396, (1983); Beck A.T., Ward C.H., Mendelson M., Et al., An inventory for measuring depression, Arch Gen Psychiatry, 4, pp. 561-571, (1961); Madara J.L., Stafford J., Dharmsathaphorn K., Et al., Structural analysis of a human intestinal epithelial cell line, Gastroenterology, 92, pp. 1133-1145, (1987); Ebert M.S., Neilson J.R., Sharp P.A., MicroRNA sponges: Competitive inhibitors of small RNAs in mammalian cells, Nat Methods, 4, pp. 721-726, (2007); Anders S., Huber W., Differential expression analysis for sequence count data, Genome Biol, 11, (2010); Benjamini Y., Hochberg Y., Controlling the false discovery rate: A practical and powerful approach to multiple testing, J R Stat Soc Ser B Methodol, 57, pp. 289-300, (1995); Dweep H., Sticht C., Pandey P., Et al., MiRWalk-database: Prediction of possible miRNA binding sites by 'walking' the genes of three genomes, J Biomed Inform, 44, pp. 839-847, (2011); Biton M., Levin A., Slyper M., Et al., Epithelial microRNAs regulate gut mucosal immunity via epithelium-T cell crosstalk, Nat Immunol, 12, pp. 239-246, (2011); Cichon C., Sabharwal H., Ruter C., Et al., MicroRNAs regulate tight junction proteins and modulate epithelial/endothelial barrier functions, Tissue Barriers, 2, (2014); Yang H., Rao J.N., Wang J.-Y., Posttranscriptional regulation of intestinal epithelial tight junction barrier by RNA-binding proteins and microRNAs, Tissue Barriers, 2, (2014); Zhou Q., Costinean S., Croce C.M., Et al., MicroRNA 29 targets nuclear factor-?B-repressing factor and claudin 1 to increase intestinal permeability, Gastroenterology, 148, pp. 158-169, (2015); Zhou Q., Yang L., Larson S., Et al., Decreased miR-199 augments visceral pain in patients with IBS through translational upregulation of TRPV1, Gut, 65, pp. 797-805, (2016); Ludwig N., Leidinger P., Becker K., Et al., Distribution of miRNA expression across human tissues, Nucleic Acids Res, 44, pp. 3865-3877, (2016); Nasser Y., Boeckxstaens G.E., Wouters M.M., Et al., Using human intestinal biopsies to study the pathogenesis of irritable bowel syndrome, Neurogastroenterol Motil, 26, pp. 455-469, (2014); Mestdagh P., Hartmann N., Baeriswyl L., Et al., Evaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study, Nat Methods, 11, pp. 809-815, (2014); Citi S., Sabanay H., Jakes R., Et al., Cingulin, a new peripheral component of tight junctions, Nature, 333, pp. 272-276, (1988); Cordenonsi M., D'Atri F., Hammar E., Et al., Cingulin contains globular and coiled-coil domains and interacts with Zo-1, Zo-2, Zo-3, and Myosin, J Cell Biol, 147, pp. 1569-1582, (1999); Guillemot L., Hammar E., Kaister C., Et al., Disruption of the cingulin gene does not prevent tight junction formation but alters gene expression, J Cell Sci, 117, pp. 5245-5256, (2004); Guillemot L., Citi S., Cingulin regulates claudin-2 expression and cell proliferation through the small GTPase RhoA, Mol Biol Cell, 17, pp. 3569-3577, (2006); Guillemot L., Schneider Y., Brun P., Et al., Cingulin is dispensable for epithelial barrier function and tight junction structure, and plays a role in the control of claudin-2 expression and response to duodenal mucosa injury, J Cell Sci, 125, pp. 5005-5014, (2012); Guillemot L., Spadaro D., Citi S., The junctional proteins cingulin and paracingulin modulate the expression of tight junction protein genes through GATA-4, PLoS ONE, 8, (2013); Boyd M., Bressendorff S., Moller J., Et al., Mapping of HNF4? Target genes in intestinal epithelial cells, BMC Gastroenterol, 9, (2009); Barmeyer C., Schulzke J.D., Fromm M., Claudin-related intestinal diseases, Semin Cell Dev Biol, 42, pp. 30-38, (2015); Cheng P., Yao J., Wang C., Et al., Molecular and cellular mechanisms of tight junction dysfunction in the irritable bowel syndrome, Mol Med Rep, 12, pp. 3257-3264, (2015); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Et al., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am J Gastroenterol, 106, pp. 2165-2173, (2011); Camilleri M., Gorman H., Intestinal permeability and irritable bowel syndrome, Neurogastroenterol Motil, 19, pp. 545-552, (2007); Vicario M., Guilarte M., Alonso C., Et al., Chronological assessment of mast cell-mediated gut dysfunction and mucosal inflammation in a rat model of chronic psychosocial stress, Brain Behav Immun, 24, pp. 1166-1175, (2010); Vanuytsel T., Van Wanrooy S., Vanheel H., Et al., Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism, Gut, 63, pp. 1293-1299, (2014); Ekstrom K., Valadi H., Sjostrand M., Et al., Characterization of mRNA and microRNA in human mast cell-derived exosomes and their transfer to other mast cells and blood CD34 progenitor cells, J Extracell Vesicles, (2012); O'Connor R.M., D'Inan T.G., Cryan J.F., Little things on which happiness depends: MicroRNAs as novel therapeutic targets for the treatment of anxiety and depression, Mol Psychiatry, 17, pp. 359-376, (2012); Baudry A., Mouillet-Richard S., Schneider B., Et al., MiR-16 targets the serotonin transporter: A new facet for adaptive responses to antidepressants, Science, 329, pp. 1537-1541, (2010); Moya P.R., Wendland J.R., Salemme J., Et al., MiR-15a and miR-16 regulate serotonin transporter expression in human placental and rat brain raphe cells, Int J Neuropsychopharmacol, 16, pp. 621-629, (2013); Dwivedi Y., Pathogenetic and therapeutic applications of microRNAs in major depressive disorder, Prog Neuropsychopharmacol Biol Psychiatry, 64, pp. 341-348, (2016); Launay J.M., Mouillet-Richard S., Baudry A., Et al., Raphe-mediated signals control the hippocampal response to SRI antidepressants via miR-16, Transl Psychiatry, 1, (2011); Honda M., Kuwano Y., Katsuura-Kamano S., Et al., Chronic academic stress increases a group of microRNAs in peripheral blood, PLoS ONE, 8, (2013)","C. Martínez; email: cristina.martinez@med.uniheidelberg.de","","BMJ Publishing Group","","","","","","00175749","","GUTTA","28082316","English","Gut","Article","Final","All Open Access; Green Open Access; Hybrid Gold Open Access","Scopus","2-s2.0-85011049801"

"Linsalata M.; Riezzo G.; D'Attoma B.; Clemente C.; Orlando A.; Russo F.","Linsalata, Michele (6603600075); Riezzo, Giuseppe (7004144336); D'Attoma, Benedetta (8554891800); Clemente, Caterina (7005101585); Orlando, Antonella (23767683100); Russo, Francesco (59133987100)","6603600075; 7004144336; 8554891800; 7005101585; 23767683100; 59133987100","Noninvasive biomarkers of gut barrier function identify two subtypes of patients suffering from diarrhoea predominant-IBS: A case-control study","2018","BMC Gastroenterology","18","1","167","","","","64","10.1186/s12876-018-0888-6","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85056120858&doi=10.1186%2fs12876-018-0888-6&partnerID=40&md5=4e1bce2571d3308a3b49cf90f44c0155","Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology, S. de Bellis, Research Hospital, Via Turi 27, Castellana Grotte, Bari, I-70013, Italy","Linsalata M., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology, S. de Bellis, Research Hospital, Via Turi 27, Castellana Grotte, Bari, I-70013, Italy; Riezzo G., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology, S. de Bellis, Research Hospital, Via Turi 27, Castellana Grotte, Bari, I-70013, Italy; D'Attoma B., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology, S. de Bellis, Research Hospital, Via Turi 27, Castellana Grotte, Bari, I-70013, Italy; Clemente C., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology, S. de Bellis, Research Hospital, Via Turi 27, Castellana Grotte, Bari, I-70013, Italy; Orlando A., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology, S. de Bellis, Research Hospital, Via Turi 27, Castellana Grotte, Bari, I-70013, Italy; Russo F., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology, S. de Bellis, Research Hospital, Via Turi 27, Castellana Grotte, Bari, I-70013, Italy","Background: Alterations of the small-intestinal permeability (s-IP) might play an essential role in both diarrhoea-predominant IBS (D-IBS) and celiac disease (CD) patients. Our aims were to analyse in D-IBS patients the symptom profile along with the levels of urinary sucrose (Su), lactulose (La), mannitol (Ma), and circulating biomarkers (zonulin, intestinal fatty acid binding protein - I-FABP, and diamine oxidase - DAO) of the gastrointestinal (GI) barrier function. The pro-inflammatory interleukins 6 and 8 (IL-6 and IL-8), the plasma values of lipopolysaccharide (LPS), and Toll-like receptor 4 (TLR-4) were also investigated. Besides, these biomarkers were compared with those in CD and healthy controls (HC). Finally, comparisons were performed between D-IBS patients with [D-IBS(+)] and without [D-IBS(-)] increased s-IP according to normal or altered La/Ma ratio. Methods: The study included 39 D-IBS patients, 32 CD patients, and 20 HC. GI permeability was assayed by high-performance liquid chromatography determination in the urine of Su and La/Ma ratio. ELISA kits assayed circulating concentrations of zonulin, I-FABP, DAO, IL-6, IL-8, LPS, and TLR-4. The Mann-Whitney or the Kruskal-Wallis with Dunn's post-test was used to assess differences among the groups. Results: As for the La/Ma ratio, %Su, and I-FABP levels, D-IBS patients were significantly different from CD, but not HC. IL-6 levels were significantly higher in CD than HC, whereas IL-8 levels were significantly higher in both D-IBS and CD patients than HC. By opposite, LPS, and TLR-4 concentrations did not differ significantly among the groups. When D-IBS patients were categorised according to normal or altered s-IP, D-IBS(+) patients had %La, %Su, I-FABP, and DAO levels significantly higher than D-IBS(-) ones. The inflammatory parameters and markers of bacterial translocation (namely, IL-6 and LPS) were significantly higher in D-IBS(+) patients than D-IBS(-) ones. Conclusions: The present study suggests that two distinct D-IBS subtypes could be identified. The investigation of possible s-IP alterations (i.e., considering the La/Ma ratio) might be useful to assess better and categorise this heterogeneous D-IBS population. Trial registration: NCT01574209. Registered March 2012. First recruitment started in April 2012. © 2018 The Author(s).","Celiac disease; Diarrhoea-predominant irritable bowel syndrome; Gut barrier; Interleukins; Intestinal permeability; Lipopolysaccharide","Adult; Amine Oxidase (Copper-Containing); Biomarkers; Case-Control Studies; Celiac Disease; Cholera Toxin; Diarrhea; Fatty Acid-Binding Proteins; Female; Humans; Interleukins; Intestines; Irritable Bowel Syndrome; Lactulose; Lipopolysaccharides; Male; Mannitol; Middle Aged; Permeability; Sucrose; Surveys and Questionnaires; Toll-Like Receptor 4; amine oxidase (copper containing); biological marker; fatty acid binding protein 2; interleukin 6; interleukin 8; lactulose; lipopolysaccharide; mannitol; sucrose; toll like receptor 4; unclassified drug; zonulin; amine oxidase (copper containing); biological marker; cholera toxin; FABP1 protein, human; fatty acid binding protein; interleukin derivative; lactulose; mannitol; sucrose; toll like receptor 4; zonulin; adult; Article; bacterial translocation; case control study; clinical feature; controlled clinical trial; controlled study; diarrhea; disease association; enzyme linked immunosorbent assay; female; gastrointestinal tract function; high performance liquid chromatography; human; inflammatory bowel disease; intestine mucosa permeability; male; urine level; blood; celiac disease; classification; complication; diarrhea; intestine; irritable colon; metabolism; middle aged; permeability; questionnaire; urine","","amine oxidase (copper containing), 9001-53-0, 9014-75-9; interleukin 8, 114308-91-7; lactulose, 4618-18-2; mannitol, 69-65-8, 87-78-5; sucrose, 122880-25-5, 57-50-1; toll like receptor 4, 203811-83-0; Amine Oxidase (Copper-Containing), ; Biomarkers, ; Cholera Toxin, ; FABP1 protein, human, ; Fatty Acid-Binding Proteins, ; Interleukins, ; Lactulose, ; Lipopolysaccharides, ; Mannitol, ; Sucrose, ; Toll-Like Receptor 4, ; zonulin, ","","","","","Usai P., Manca R., Lai M.A., Russo L., Boi M.F., Ibba I., Giolitto G., Cuomo R., Prevalence of irritable bowel syndrome in Italian rural and urban areas, Eur J Intern Med, 21, 4, pp. 324-326, (2010); Drossman D.A., Dumitrascu D.L., Rome I.I.I., New standard for functional gastrointestinal disorders, J Gastrointestin Liver Dis, 15, 3, pp. 237-241, (2006); Mearin F., Irritable bowel syndrome (IBS) subtypes: Nothing resembles less an IBS than another IBS, Rev Esp Enferm Dig, 108, 2, pp. 57-58, (2016); Blake M.R., Raker J.M., Whelan K., Validity and reliability of the Bristol stool form scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome, Aliment Pharmacol Ther, 44, 7, pp. 693-703, (2016); Shahbazkhani B., Forootan M., Merat S., Akbari M.R., Nasserimoghadam S., Vahedi H., Malekzadeh R., Coeliac disease presenting with symptoms of irritable bowel syndrome, Aliment Pharmacol Ther, 18, 2, pp. 231-235, (2003); Lebwohl B., Sanders D.S., Green P.H.R., Coeliac disease, Lancet, 391, pp. 70-81, (2018); Heyman M., Abed J., Lebreton C., Cerf-Bensussan N., Intestinal permeability in coeliac disease: Insight into mechanisms and relevance to pathogenesis, Gut, 61, 9, pp. 1355-1364, (2012); Gonzalez-Castro A.M., Martinez C., Salvo-Romero E., Fortea M., Pardo-Camacho C., Perez-Berezo T., Alonso-Cotoner C., Santos J., Vicario M., Mucosal pathobiology and molecular signature of epithelial barrier dysfunction in the small intestine in irritable bowel syndrome, J Gastroenterol Hepatol, 32, 1, pp. 53-63, (2017); Schumann M., Siegmund B., Schulzke J.D., Fromm M., Celiac disease: Role of the epithelial barrier, Cell Mol Gastroenterol Hepatol, 3, 2, pp. 150-162, (2017); Piche T., Tight junctions and IBS - The link between epithelial permeability, low-grade inflammation, and symptom generation?, Neurogastroenterol Motil, 26, 3, pp. 296-302, (2014); Lopetuso L.R., Scaldaferri F., Bruno G., Petito V., Franceschi F., Gasbarrini A., The therapeutic management of gut barrier leaking: The emerging role for mucosal barrier protectors, Eur Rev Med Pharmacol Sci, 19, 6, pp. 1068-1076, (2015); Van Wijck K., Bessems B.A., Van Eijk H.M., Buurman W.A., Dejong C.H., Lenaerts K., Polyethylene glycol versus dual sugar assay for gastrointestinal permeability analysis: Is it time to choose?, Clin Exp Gastroenterol, 5, pp. 139-150, (2012); Bischoff S., Bischoff S.C., Barbara G., Buurman W., Ockhuizen T., Schulzke J.D., Serino M., Tilg H., Watson A., Wells J.M., Intestinal permeability - A new target for disease prevention and therapy, BMC Gastroenterol, 14, (2014); Van Wijck K., Verlinden T.J., Van Eijk H.M., Dekker J., Buurman W.A., Dejong C.H., Lenaerts K., Novel multi-sugar assay for site-specific gastrointestinal permeability analysis: A randomized controlled crossover trial, Clin Nutr, 32, 2, pp. 245-251, (2013); Aguirre Valadez J.M., Rivera-Espinosa L., Mendez-Guerrero O., Chavez-Pacheco J.L., Garcia Juarez I., Torre A., Intestinal permeability in a patient with liver cirrhosis, Ther Clin Risk Manag, 12, pp. 1729-1748, (2016); Sturgeon C., Fasano A., Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases, Tissue Barriers, 4, 4, (2016); Pelsers M.M., Hermens W.T., Glatz J.F., Fatty acid-binding proteins as plasma markers of tissue injury, Clin Chim Acta, 352, 1-2, pp. 15-35, (2005); Honzawa Y., Nakase H., Matsuura M., Chiba T., Clinical significance of serum diamine oxidase activity in inflammatory bowel disease: Importance of evaluation of small intestinal permeability, Inflamm Bowel Dis, 17, 2, pp. E23-E25, (2011); Xu X.J., Zhang Y.L., Liu L., Pan L., Yao S.K., Increased expression of nerve growth factor correlates with visceral hypersensitivity and impaired gut barrier function in diarrhoea-predominant irritable bowel syndrome: A preliminary explorative study, Aliment Pharmacol Ther, 45, 1, pp. 100-114, (2017); Svedlund J., Sjodin I., Dotevall G., GSRS - A clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease, Dig Dis Sci, 33, 2, pp. 129-134, (1988); Schmulson M., Lee O.Y., Chang L., Naliboff B., Mayer E.A., Symptom differences in moderate to severe IBS patients based on predominant bowel habit, Am J Gastroenterol, 94, 10, pp. 2929-2935, (1999); Verdu E.F., Armstrong D., Murray J.A., Between celiac disease and irritable bowel syndrome: The ""no man's land"" of gluten sensitivity, Am J Gastroenterol, 104, 6, pp. 1587-1594, (2009); El-Salhy M., Hatlebakk J.G., Gilja O.H., Hausken T., The relation between celiac disease, nonceliac gluten sensitivity and irritable bowel syndrome, Nutr J, 14, (2015); Antonioli D.A., Celiac disease: A progress report, Mod Pathol, 16, 4, pp. 342-346, (2003); Russo F., Linsalata M., Clemente C., D'Attoma B., Orlando A., Campanella G., Giotta F., Riezzo G., The effects of fluorouracil, epirubicin, and cyclophosphamide (FEC60) on the intestinal barrier function and gut peptides in breast cancer patients: An observational study, BMC Cancer, 13, (2013); Linsalata M., D'Attoma B., Orlando A., Guerra V., Russo F., Comparison of an enzymatic assay with liquid chromatography-pulsed amperometric detection for the determination of lactulose and mannitol in the urine of healthy subjects and patients with active celiac disease, Clin Chem Lab Med, 52, 4, pp. e61-e64, (2014); Martinez C., Gonzalez-Castro A., Vicario M., Santos J., Cellular and molecular basis of intestinal barrier dysfunction in the irritable bowel syndrome, Gut Liver, 6, 3, pp. 305-315, (2012); Mujagic Z., Ludidi S., Keszthelyi D., Hesselink M.A., Kruimel J.W., Lenaerts K., Hanssen N.M., Conchillo J.M., Jonkers D.M., Masclee A.A., Small intestinal permeability is increased in diarrhoea predominant IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to confounders, Aliment Pharmacol Ther, 40, 3, pp. 288-297, (2014); Russo F., Chimienti G., Clemente C., Riezzo G., D'Attoma B., Martulli M., Gastric activity and gut peptides in patients with functional dyspepsia: Postprandial distress syndrome versus epigastric pain syndrome, J Clin Gastroenterol, 51, 2, pp. 136-144, (2017); Vogelsang H., Schwarzenhofer M., Oberhuber G., Changes in gastrointestinal permeability in celiac disease, Dig Dis, 16, 6, pp. 333-336, (1998); Vorobjova T., Raikkerus H., Kadaja L., Talja I., Uibo O., Heilman K., Uibo R., Circulating Zonulin correlates with density of enteroviruses and Tolerogenic dendritic cells in the small bowel mucosa of celiac disease patients, Dig Dis Sci, 62, 2, pp. 358-371, (2017); Del Valle-Pinero A.Y., Van Deventer H.E., Fourie N.H., Martino A.C., Patel N.S., Remaley A.T., Henderson W.A., Gastrointestinal permeability in patients with irritable bowel syndrome assessed using a four probe permeability solution, Clin Chim Acta, 418, pp. 97-101, (2013); Kerckhoffs A.P., Akkermans L.M., De Smet M.B., Besselink M.G., Hietbrink F., Bartelink I.H., Busschers W.B., Samsom M., Renooij W., Intestinal permeability in irritable bowel syndrome patients: Effects of NSAIDs, Dig Dis Sci, 55, 3, pp. 716-723, (2010); Gecse K., Roka R., Sera T., Rosztoczy A., Annahazi A., Izbeki F., Nagy F., Molnar T., Szepes Z., Pavics L., Et al., Leaky gut in patients with diarrhea-predominant irritable bowel syndrome and inactive ulcerative colitis, Digestion, 85, 1, pp. 40-46, (2012); Rao A.S., Camilleri M., Eckert D.J., Busciglio I., Burton D.D., Ryks M., Wong B.S., Lamsam J., Singh R., Zinsmeister A.R., Urine sugars for in vivo gut permeability: Validation and comparisons in irritable bowel syndrome-diarrhea and controls, Am J Physiol Gastrointest Liver Physiol, 301, 5, pp. G919-G928, (2011); Dunlop S.P., Hebden J., Campbell E., Naesdal J., Olbe L., Perkins A.C., Spiller R.C., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, 6, pp. 1288-1294, (2006); Li L., Xiong L., Yao J., Zhuang X., Zhang S., Yu Q., Xiao Y., Cui Y., Chen M., Increased small intestinal permeability and RNA expression profiles of mucosa from terminal ileum in patients with diarrhoea-predominant irritable bowel syndrome, Dig Liver Dis, 48, 8, pp. 880-887, (2016); Ohlsson B., Orho-Melander M., Nilsson P., Higher Levels of Serum Zonulin May Rather Be Associated with Increased Risk of Obesity and Hyperlipidemia, Than with Gastrointestinal Symptoms or Disease Manifestations, International Journal of Molecular Sciences, 18, 3, (2017); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, 1-2, pp. 41-46, (2009); De Punder K., Pruimboom L., Stress induces endotoxemia and low-grade inflammation by increasing barrier permeability, Front Immunol, 6, (2015); March D.S., Marchbank T., Playford R.J., Jones A.W., Thatcher R., Davison G., Intestinal fatty acid-binding protein and gut permeability responses to exercise, Eur J Appl Physiol, 117, 5, pp. 931-941, (2017); Mulak A., Tache Y., Sex difference in irritable bowel syndrome: Do gonadal hormones play a role?, Gastroenterol Pol, 17, 2, pp. 89-97, (2010); Rubio-Tapia A., Jansson-Knodell C.L., Rahim M.W., See J.A., Murray J.A., Influence of gender on the clinical presentation and associated diseases in adults with celiac disease, Gac Med Mex, 152, pp. 38-46, (2016)","F. Russo; Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology, S. de Bellis, Research Hospital, Castellana Grotte, Bari, Via Turi 27, I-70013, Italy; email: francesco.russo@irccsdebellis.it","","BioMed Central Ltd.","","","","","","1471230X","","BGMAB","30400824","English","BMC Gastroenterol.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85056120858"

"Peters S.A.; Edogawa S.; Sundt W.J.; Dyer R.B.; Dalenberg D.A.; Mazzone A.; Singh R.J.; Moses N.; Smyrk T.C.; Weber C.; Linden D.R.; Macnaughton W.K.; Turner J.R.; Camilleri M.; Katzka D.A.; Farrugia G.; Grover M.","Peters, Stephanie A (57193683015); Edogawa, Shoko (49861248700); Sundt, Wendy J. (57148557200); Dyer, Roy B (7202532150); Dalenberg, Daniel A (40261111500); Mazzone, Amelia (7102461894); Singh, Ravinder J (55994265700); Moses, Natalie (57193686053); Smyrk, Thomas C (7006123619); Weber, Christopher (35786862900); Linden, David R (7102905426); Macnaughton, Wallace K (7003388325); Turner, Jerrold R (7404249336); Camilleri, Michael (7102181053); Katzka, David A (7004142785); Farrugia, Gianrico (7006024784); Grover, Madhusudan (23012057300)","57193683015; 49861248700; 57148557200; 7202532150; 40261111500; 7102461894; 55994265700; 57193686053; 7006123619; 35786862900; 7102905426; 7003388325; 7404249336; 7102181053; 7004142785; 7006024784; 23012057300","Constipation-Predominant Irritable Bowel Syndrome Females Have Normal Colonic Barrier and Secretory Function","2017","American Journal of Gastroenterology","112","6","","913","923","10","30","10.1038/ajg.2017.48","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85015743578&doi=10.1038%2fajg.2017.48&partnerID=40&md5=5c537b7bb6f996b4db9cd0ddfad3e243","Enteric NeuroScience Program, Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, 55905, MN, United States; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States; Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, United States; Department of Pathology, University of Chicago, Chicago, IL, United States; Department of Physiology and Pharmacology, University of Calgary, Calgary, AB, Canada; Departments of Pathology and Medicine, Brigham and Women's Hospital, Boston, MA, United States","Peters S.A., Enteric NeuroScience Program, Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, 55905, MN, United States; Edogawa S., Enteric NeuroScience Program, Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, 55905, MN, United States; Sundt W.J., Enteric NeuroScience Program, Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, 55905, MN, United States; Dyer R.B., Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States; Dalenberg D.A., Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States; Mazzone A., Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, United States; Singh R.J., Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States; Moses N., Enteric NeuroScience Program, Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, 55905, MN, United States; Smyrk T.C., Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States; Weber C., Department of Pathology, University of Chicago, Chicago, IL, United States; Linden D.R., Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, United States; Macnaughton W.K., Department of Physiology and Pharmacology, University of Calgary, Calgary, AB, Canada; Turner J.R., Departments of Pathology and Medicine, Brigham and Women's Hospital, Boston, MA, United States; Camilleri M., Enteric NeuroScience Program, Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, 55905, MN, United States; Katzka D.A., Enteric NeuroScience Program, Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, 55905, MN, United States; Farrugia G., Enteric NeuroScience Program, Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, 55905, MN, United States; Grover M., Enteric NeuroScience Program, Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, 55905, MN, United States","OBJECTIVES:The objective of this study was to determine whether constipation-predominant irritable bowel syndrome (IBS-C) is associated with changes in intestinal barrier and secretory function.METHODS:A total of 19 IBS-C patients and 18 healthy volunteers (all females) underwent saccharide excretion assay (0.1 g 13 C mannitol and 1 g lactulose), measurements of duodenal and colonic mucosal barrier (transmucosal resistance (TMR), macromolecular and Escherichia coli Bio-Particle translocation), mucosal secretion (basal and acetylcholine (Ach)-evoked short-circuit current (Isc)), in vivo duodenal mucosal impedance, circulating endotoxins, and colonic tight junction gene expression.RESULTS:There were no differences in the in vivo measurements of barrier function between IBS-C patients and healthy controls: cumulative excretion of 13 C mannitol (0-2 h mean (s.e.m.); IBS-C: 12.1 (0.9) mg vs. healthy: 13.2 (0.8) mg) and lactulose (8-24 h; IBS-C: 0.9 (0.5) mg vs. healthy: 0.5 (0.2) mg); duodenal impedance IBS-C: 729 (65) Ω vs. healthy: 706 (43) Ω; plasma mean endotoxin activity level IBS-C: 0.36 (0.03) vs. healthy: 0.35 (0.02); and in colonic mRNA expression of occludin, zonula occludens (ZO) 1-3, and claudins 1-12 and 14-19. The ex vivo findings were consistent, with no group differences: duodenal TMR (IBS-C: 28.2 (1.9) Ω cm 2 vs. healthy: 29.8 (1.9) Ω cm 2) and colonic TMR (IBS-C: 19.1 (1.1) Ω cm 2 vs. healthy: 17.6 (1.7) Ω cm 2); fluorescein isothiocyanate (FITC)-dextran (4 kDa) and E. coli Bio-Particle flux. Colonic basal Isc was similar, but duodenal basal Isc was lower in IBS-C (43.5 (4.5) μA cm -2) vs. healthy (56.9 (4.9) μA cm -2), P=0.05. Ach-evoked Î ""Isc was similar.CONCLUSIONS:Females with IBS-C have normal colonic barrier and secretory function. Basal duodenal secretion is decreased in IBS-C. © 2017 by the American College of Gastroenterology.","","Acetylcholine; Adult; Case-Control Studies; Cholinergic Agonists; Claudins; Colon; Constipation; Duodenum; Electric Impedance; Endotoxins; Female; Gene Expression; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Lactulose; Mannitol; Middle Aged; Occludin; Permeability; RNA, Messenger; Tight Junctions; Zonula Occludens Proteins; acetylcholine; claudin; endotoxin; fluorescein isothiocyanate dextran; lactulose; mannitol; occludin; acetylcholine; cholinergic receptor stimulating agent; claudin; messenger RNA; occludin; zonula occludens protein; adult; Article; bacterial translocation; carbohydrate analysis; clinical article; colon biopsy; colon tissue; colonic secretion; colony forming unit; constipation; controlled study; duodenal secretion; duodenum biopsy; duodenum tissue; endotoxemia; Escherichia coli; ex vivo study; female; frozen section; gene expression; human; human tissue; impedance; in vivo study; irritable colon; macromolecule; middle aged; permeability barrier; priority journal; quality of life; short circuit current; tight junction; blood; case control study; colon; complication; constipation; drug effects; duodenum; genetics; intestine mucosa; irritable colon; metabolism; pathology; pathophysiology; permeability","","acetylcholine, 51-84-3, 60-31-1, 66-23-9; fluorescein isothiocyanate dextran, 60842-46-8; lactulose, 4618-18-2; mannitol, 69-65-8, 87-78-5; occludin, 176304-61-3; Acetylcholine, ; Cholinergic Agonists, ; Claudins, ; Endotoxins, ; Lactulose, ; Mannitol, ; Occludin, ; RNA, Messenger, ; Zonula Occludens Proteins, ","","","National Institutes of Health, NIH, (DK103911); National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK, (R01DK068271); Mayo Clinic, (P30DK084567); Takeda Pharmaceutical Company, TPC","This project was funded by an investigatorinitiated grant by Takeda Pharmaceuticals to Dr Grover. In addition, Dr Grover is supported by NIH K23 (DK103911) and Pilot and Feasibility Award from Mayo Clinic Center for Cell Signaling in Gastroenterology (NIH P30DK084567).","Enck P., Aziz Q., Barbara G., Et al., Irritable bowel syndrome, Nat Rev Dis Primers, 2, (2016); Piche T., Tight junctions and IBS-the link between epithelial permeability, low-grade inflammation, and symptom generation?, Neurogastroenterol Motil, 26, pp. 296-302, (2014); Piche T., Barbara G., Aubert P., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: Involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Vivinus-Nebot M., Dainese R., Anty R., Et al., Combination of allergic factors can worsen diarrheic irritable bowel syndrome: Role of barrier defects and mast cells, Am J Gastroenterol, 107, pp. 75-81, (2012); Annahazi A., Ferrier L., Bezirard V., Et al., Luminal cysteine-proteases degrade colonic tight junction structure and are responsible for abdominal pain in constipation-predominant IBS, Am J Gastroenterol, 108, pp. 1322-1331, (2013); Coeffi Er M., Gloro R., Boukhettala N., Et al., Increased proteasome-mediated degradation of occludin in irritable bowel syndrome, Am J Gastroenterol, 105, pp. 1181-1188, (2010); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Et al., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with diff erences according to the disease subtype, Am J Gastroenterol, 106, pp. 2165-2173, (2011); Park J.H., Park D.I., Kim H.J., Et al., The relationship between small-intestinal bacterial overgrowth and intestinal permeability in patients with irritable bowel syndrome, Gut Liver, 3, pp. 174-179, (2009); Kerckhoff S.A.P., Akkermans L.M., De Smet M.B., Et al., Intestinal permeability in irritable bowel syndrome patients: Effects of NSAIDs, Dig Dis Sci, 55, pp. 716-723, (2010); Gecse K., Roka R., Sera T., Et al., Leaky gut in patients with diarrhea-predominant irritable bowel syndrome and inactive ulcerative colitis, Digestion, 85, pp. 40-46, (2012); Rao A.S., Camilleri M., Eckert D.J., Et al., Urine sugars for in vivo gut permeability: Validation and comparisons in irritable bowel syndrome-diarrhea and controls, Am J Physiol Gastrointest Liver Physiol, 301, pp. G919-G928, (2011); Grover M., Camilleri M., Hines J., Et al., (13) C mannitol as a novel biomarker for measurement of intestinal permeability, Neurogastroenterol Motil, 28, pp. 1114-1119, (2016); Francis C.Y., Morris J., Whorwell P.J., The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress, Aliment Pharmacol Ther, 11, pp. 395-402, (1997); Drossman D.A., Patrick D.L., Whitehead W.E., Et al., Further validation of the IBS-QOL: A disease-specifi c quality-of-life questionnaire, Am J Gastroenterol, 95, pp. 999-1007, (2000); Katzka D.A., Ravi K., Geno D.M., Et al., Endoscopic mucosal impedance measurements correlate with eosinophilia and dilation of intercellular spaces in patients with eosinophilic esophagitis, Clin Gastroenterol Hepatol, 13, pp. 1242-1248, (2015); Camilleri M., Lasch K., Zhou W., Irritable bowel syndrome: Methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome, Am J Physiol Gastrointest Liver Physiol, 303, pp. G775-G785, (2012); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Bjarnason I., Macpherson A., Hollander D., Intestinal permeability: An overview, Gastroenterology, 108, pp. 1566-1581, (1995); Swan C., Duroudier N.P., Campbell E., Et al., Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): Association with TNFSF15 and TNFalpha, Gut, 62, pp. 985-994, (2013); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Spiller R.C., Jenkins D., Thornley J.P., Et al., Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, pp. 804-811, (2000); Marshall J.K., Thabane M., Garg A.X., Et al., Intestinal permeability in patients with irritable bowel syndrome aft er a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario, Aliment Pharmacol Ther, 20, pp. 1317-1322, (2004); Kelly C.P., Green P.H., Murray J.A., Et al., Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: A randomised placebocontrolled study, Aliment Pharmacol Ther, 37, pp. 252-262, (2013); Ortiz M.E., Raya R.R., Mozzi F., Effi cient mannitol production by wild-type Lactobacillus reuteri CRL 1101 is attained at constant pH using a simplifi ed culture medium, Appl Microbiol Biotechnol, 99, pp. 8717-8729, (2015); Menard S., Cerf-Bensussan N., Heyman M., Multiple facets of intestinal permeability and epithelial handling of dietary antigens, Mucosal Immunol, 3, pp. 247-259, (2010); Overman E.L., Rivier J.E., Moeser A.J., CRF induces intestinal epithelial barrier injury via the release of mast cell proteases and TNF-alpha, PLoS ONE, 7, (2012); Wallon C., Yang P.C., Keita A.V., Et al., Corticotropin-releasing hormone (CRH) regulates macromolecular permeability via mast cells in normal human colonic biopsies in vitro, Gut, 57, pp. 50-58, (2008); Shen L., Weber C.R., Turner J.R., The tight junction protein complex undergoes rapid and continuous molecular remodeling at steady state, J Cell Biol, 181, pp. 683-695, (2008); Uhde M., Ajamian M., Caio G., Et al., Intestinal cell damage and systemic immune activation in individuals reporting sensitivity to wheat in the absence of coeliac disease, Gut, 65, pp. 1930-1937, (2016); Tulic M.K., Vivinus-Nebot M., Rekima A., Et al., Presence of commensal house dust mite allergen in human gastrointestinal tract: A potential contributor to intestinal barrier dysfunction, Gut, 65, pp. 757-766, (2016); Guerville M., Boudry G., Gastrointestinal and hepatic mechanisms limiting entry and dissemination of lipopolysaccharide into the systemic circulation, Am J Physiol Gastrointest Liver Physiol, 311, pp. G1-G15, (2016); Ohman L., Tornblom H., Simren M., Crosstalk at the mucosal border: Importance of the gut microenvironment in IBS, Nat Rev Gastroenterol Hepatol, 12, pp. 36-49, (2015); Munford R.S., Endotoxemia-menace, marker, or mistake?, J Leukoc Biol, 100, pp. 687-688, (2016); Cil O., Phuan P.W., Lee S., Et al., CFTR activator increases intestinal fluid secretion and normalizes stool output in a mouse model of constipation, Cell Mol Gastroenterol Hepatol, 2, pp. 317-327, (2016); Larsson M.H., Simren M., Thomas E.A., Et al., Elevated motility-related transmucosal potential diff erence in the upper small intestine in the irritable bowel syndrome, Neurogastroenterol Motil, 19, pp. 812-820, (2007); Krueger D., Michel K., Zeller F., Et al., Neural influences on human intestinal epithelium in vitro, J Physiol, 594, pp. 357-372, (2016)","M. Grover; Enteric NeuroScience Program, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, 200 First Street SW, 55905, United States; email: grover.madhusudan@mayo.edu","","Nature Publishing Group","","","","","","00029270","","AJGAA","28323272","English","Am. J. Gastroenterol.","Article","Final","All Open Access; Green Open Access","Scopus","2-s2.0-85015743578"

"Vicario M.; Gonzàlez-Castro A.M.; Martnez C.; Lobo B.; Pigrau M.; Guilarte M.; De Torres I.; Mosquera J.L.; Fortea M.; Sevillano-Aguilera C.; Salvo-Romero E.; Alonso C.; Rodiño-Janeiro B.K.; Söderholm J.D.; Azpiroz F.; Santos J.","Vicario, Maria (6603267769); Gonzàlez-Castro, Ana M. (54796498900); Martnez, Cristina (17534584700); Lobo, Beatriz (7003936898); Pigrau, Marc (37009212800); Guilarte, Mar (18133405400); De Torres, Inés (7003506754); Mosquera, Jose L. (57354626500); Fortea, Marina (56830396500); Sevillano-Aguilera, César (56830477300); Salvo-Romero, Eloisa (56830611700); Alonso, Carmen (56411082400); Rodiño-Janeiro, Bruno K. (35729142300); Söderholm, Johan D. (7004276501); Azpiroz, Fernando (57207592894); Santos, Javier (7402389020)","6603267769; 54796498900; 17534584700; 7003936898; 37009212800; 18133405400; 7003506754; 57354626500; 56830396500; 56830477300; 56830611700; 56411082400; 35729142300; 7004276501; 57207592894; 7402389020","Increased humoral immunity in the jejunum of diarrhoea-predominant irritable bowel syndrome associated with clinical manifestations","2015","Gut","64","9","","1379","1388","9","87","10.1136/gutjnl-2013-306236","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84941299655&doi=10.1136%2fgutjnl-2013-306236&partnerID=40&md5=10fc8639efaf5febaf0af9e4155ee4f4","Neuro-immuno-gastroenterology Laboratory, Digestive Diseases Research Unit, Vall d'Hebron Institut de Recerca, Department of Gastroenterolog, Hospital Universitario Vall d'Hebron, Paseo Vall d'Hebro 119-129, Barcelona, 08035, Spain; Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Facultat de Medicina, Universitat Autónoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepàticas y Digestivas, Spain; Department of Human Molecular Genetics, Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany; Department of Allergy, Hospital Universitari Vall d'Hebron, Facultat de Medicina, Universitat Autónoma de Barcelona, Barcelona, Spain; Department of Pathology, Hospital Universitari Vall d'Hebron, Facultat de Medicina, Universitat Autónoma de Barcelona, Barcelona, Spain; Department of Statistics, University of Barcelona, Barcelona, Spain; Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden","Vicario M., Neuro-immuno-gastroenterology Laboratory, Digestive Diseases Research Unit, Vall d'Hebron Institut de Recerca, Department of Gastroenterolog, Hospital Universitario Vall d'Hebron, Paseo Vall d'Hebro 119-129, Barcelona, 08035, Spain, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Facultat de Medicina, Universitat Autónoma de Barcelona, Barcelona, Spain, Centro de Investigación Biomédica en Red de Enfermedades Hepàticas y Digestivas, Spain; Gonzàlez-Castro A.M., Neuro-immuno-gastroenterology Laboratory, Digestive Diseases Research Unit, Vall d'Hebron Institut de Recerca, Department of Gastroenterolog, Hospital Universitario Vall d'Hebron, Paseo Vall d'Hebro 119-129, Barcelona, 08035, Spain, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Facultat de Medicina, Universitat Autónoma de Barcelona, Barcelona, Spain; Martnez C., Department of Human Molecular Genetics, Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany; Lobo B., Neuro-immuno-gastroenterology Laboratory, Digestive Diseases Research Unit, Vall d'Hebron Institut de Recerca, Department of Gastroenterolog, Hospital Universitario Vall d'Hebron, Paseo Vall d'Hebro 119-129, Barcelona, 08035, Spain, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Facultat de Medicina, Universitat Autónoma de Barcelona, Barcelona, Spain; Pigrau M., Neuro-immuno-gastroenterology Laboratory, Digestive Diseases Research Unit, Vall d'Hebron Institut de Recerca, Department of Gastroenterolog, Hospital Universitario Vall d'Hebron, Paseo Vall d'Hebro 119-129, Barcelona, 08035, Spain, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Facultat de Medicina, Universitat Autónoma de Barcelona, Barcelona, Spain; Guilarte M., Department of Allergy, Hospital Universitari Vall d'Hebron, Facultat de Medicina, Universitat Autónoma de Barcelona, Barcelona, Spain; De Torres I., Department of Pathology, Hospital Universitari Vall d'Hebron, Facultat de Medicina, Universitat Autónoma de Barcelona, Barcelona, Spain; Mosquera J.L., Department of Statistics, University of Barcelona, Barcelona, Spain; Fortea M., Neuro-immuno-gastroenterology Laboratory, Digestive Diseases Research Unit, Vall d'Hebron Institut de Recerca, Department of Gastroenterolog, Hospital Universitario Vall d'Hebron, Paseo Vall d'Hebro 119-129, Barcelona, 08035, Spain, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Facultat de Medicina, Universitat Autónoma de Barcelona, Barcelona, Spain; Sevillano-Aguilera C., Neuro-immuno-gastroenterology Laboratory, Digestive Diseases Research Unit, Vall d'Hebron Institut de Recerca, Department of Gastroenterolog, Hospital Universitario Vall d'Hebron, Paseo Vall d'Hebro 119-129, Barcelona, 08035, Spain, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Facultat de Medicina, Universitat Autónoma de Barcelona, Barcelona, Spain; Salvo-Romero E., Neuro-immuno-gastroenterology Laboratory, Digestive Diseases Research Unit, Vall d'Hebron Institut de Recerca, Department of Gastroenterolog, Hospital Universitario Vall d'Hebron, Paseo Vall d'Hebro 119-129, Barcelona, 08035, Spain, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Facultat de Medicina, Universitat Autónoma de Barcelona, Barcelona, Spain; Alonso C., Neuro-immuno-gastroenterology Laboratory, Digestive Diseases Research Unit, Vall d'Hebron Institut de Recerca, Department of Gastroenterolog, Hospital Universitario Vall d'Hebron, Paseo Vall d'Hebro 119-129, Barcelona, 08035, Spain, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Facultat de Medicina, Universitat Autónoma de Barcelona, Barcelona, Spain; Rodiño-Janeiro B.K., Neuro-immuno-gastroenterology Laboratory, Digestive Diseases Research Unit, Vall d'Hebron Institut de Recerca, Department of Gastroenterolog, Hospital Universitario Vall d'Hebron, Paseo Vall d'Hebro 119-129, Barcelona, 08035, Spain, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Facultat de Medicina, Universitat Autónoma de Barcelona, Barcelona, Spain; Söderholm J.D., Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden; Azpiroz F., Neuro-immuno-gastroenterology Laboratory, Digestive Diseases Research Unit, Vall d'Hebron Institut de Recerca, Department of Gastroenterolog, Hospital Universitario Vall d'Hebron, Paseo Vall d'Hebro 119-129, Barcelona, 08035, Spain, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Facultat de Medicina, Universitat Autónoma de Barcelona, Barcelona, Spain, Centro de Investigación Biomédica en Red de Enfermedades Hepàticas y Digestivas, Spain; Santos J., Neuro-immuno-gastroenterology Laboratory, Digestive Diseases Research Unit, Vall d'Hebron Institut de Recerca, Department of Gastroenterolog, Hospital Universitario Vall d'Hebron, Paseo Vall d'Hebro 119-129, Barcelona, 08035, Spain, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Facultat de Medicina, Universitat Autónoma de Barcelona, Barcelona, Spain, Centro de Investigación Biomédica en Red de Enfermedades Hepàticas y Digestivas, Spain","Background and aims Altered intestinal barrier is associated with immune activation and clinical symptoms in diarrhoea-predominant IBS (IBS-D). Increased mucosal antigen load may induce specific responses; however, local antibody production and its contribution to IBS aetiopathogenesis remain undefined. This study evaluated the role of humoral activity in IBS-D. Methods A single mucosal jejunal biopsy, luminal content and blood were obtained from healthy volunteers (H; n=30) and IBS-D (n=49; Rome III criteria) participants. Intraepithelial lymphocytes, mast cells, B lymphocytes and plasma cells were studied by imaging techniques. Differential gene expression and pathway analysis were assessed by microarray and PCR techniques. Blood and luminal immunoglobulins (Igs) were quantified. Gastrointestinal symptoms, respiratory atopy and stress and depression were also recorded. Results Patients with IBS-D showed a higher number and activation of mucosal B lymphocytes and plasma cells (p<0.05). Mast cell density was increased in patients with IBS-D (non-atopic) and in close proximity to plasma cells ( p<0.05). Microarray profiling identified differential humoral activity in IBS-D, involving proliferation and activation of B lymphocytes and Igs production ( p<0.001). Mucosal humoral activity was higher in IBS-D, with upregulation of germline transcripts and Ig genes (1.3-fold1.7-fold increase; p<0.05), and increased IgG+ cells and luminal IgG compared with H ( p<0.05), with no differences in blood. Biological markers of humoral activity correlated positively with bowel movements, stool form and depression. Conclusions Enhanced small bowel humoral immunity is a distinctive feature of IBS-D. Mucosal Ig production contributes to local inflammation and clinical manifestations in IBS-D.","","Adult; Analysis of Variance; Biopsy, Needle; Case-Control Studies; Diarrhea; Disease Progression; Female; Fluorescent Antibody Technique; Humans; Immunity, Humoral; Immunoglobulins; Immunohistochemistry; Intestinal Mucosa; Irritable Bowel Syndrome; Jejunum; Male; Microscopy, Electron, Transmission; Middle Aged; Prospective Studies; Severity of Illness Index; Statistics, Nonparametric; T-Lymphocytes; Young Adult; immunoglobulin G; immunoglobulin; adult; Article; B lymphocyte activation; clinical article; clinical evaluation; clinical feature; controlled study; depression; diarrhea; disease association; female; gastrointestinal symptom; gene expression; germ line; human; human cell; human tissue; humoral immunity; immunoglobulin gene; immunoglobulin production; irritable colon; jejunum disease; male; mast cell; microarray analysis; polymerase chain reaction; priority journal; respiratory atopy; respiratory tract disease; signal transduction; stress; upregulation; analysis of variance; case control study; comparative study; diarrhea; disease course; fluorescent antibody technique; humoral immunity; immunohistochemistry; immunology; intestine mucosa; irritable colon; jejunum; metabolism; middle aged; needle biopsy; nonparametric test; pathology; pathophysiology; procedures; prospective study; severity of illness index; T lymphocyte; transmission electron microscopy; young adult","","immunoglobulin G, 97794-27-9; immunoglobulin, 9007-83-4; Immunoglobulins, ","","","","","Martinez C., Vicario M., Ramos L., Et al., The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations, Am J Gastroenterol, 107, pp. 736-746, (2012); Martinez C., Lobo B., Pigrau M., Et al., Diarrhoea-predominant irritable bowel syndrome: An organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, pp. 1160-1168, (2013); Sansonetti P.J., War and peace at mucosal surfaces, Nat Rev Immunol, 4, pp. 953-964, (2004); Matricon J., Meleine M., Gelot A., Et al., Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome, Aliment Pharmacol Ther, 36, pp. 1009-1031, (2012); Foley S., Garsed K., Singh G., Et al., Impaired uptake of serotonin by platelets from patients with irritable bowel syndrome correlates with duodenal immune activation, Gastroenterology, 140, pp. 1434-1443e1, (2011); Reed D.E., Barajas-Lopez C., Cottrell G., Et al., Mast cell tryptase and proteinase-activated receptor 2 induce hyperexcitability of Guinea-pig submucosal neurons, J Physiol, 547, pp. 531-542, (2003); Cenac N., Andrews C.N., Holzhausen M., Et al., Role for protease activity in visceral pain in irritable bowel syndrome, J Clin Invest, 117, pp. 636-647, (2007); Barbara G., Wang B., Stanghellini V., Et al., Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome, Gastroenterology, 132, pp. 26-37, (2007); Brandtzaeg P., Mucosal immunity: Induction, dissemination, and effector functions, Scand J Immunol, 70, pp. 505-515, (2009); Cerutti A., Chen K., Chorny A., Immunoglobulin responses at the mucosal interface, Annu Rev Immunol, 29, pp. 273-293, (2011); Honjo T., Kinoshita K., Muramatsu M., Molecular mechanism of class switch recombination: Linkage with somatic hypermutation, Annu Rev Immunol, 20, pp. 165-196, (2002); Moisini I., Davidson A., BAFF: A local and systemic target in autoimmune diseases, Clin Exp Immunol, 158, pp. 155-163, (2009); Schoepfer A.M., Schaffer T., Seibold-Schmid B., Et al., Antibodies to flagellin indicate reactivity to bacterial antigens in IBS patients, Neurogastroenterol Motil, 20, pp. 1110-1118, (2008); Ohman L., Lindmark A.C., Isaksson S., Et al., B-cell activation in patients with irritable bowel syndrome (IBS), Neurogastroenterol Motil, 21, pp. 644-650, (2009); Zar S., Mincher L., Benson M.J., Et al., Food-specific IgG4 antibody-guided exclusion diet improves symptoms and rectal compliance in irritable bowel syndrome, Scand J Gastroenterol, 40, pp. 800-807, (2005); Atkinson W., Sheldon T.A., Shaath N., Et al., Food elimination based on IgG antibodies in irritable bowel syndrome: A randomised controlled trial, Gut, 53, pp. 1459-1464, (2004); Ligaarden S.C., Lydersen S., Farup P.G., IgG and IgG4 antibodies in subjects with irritable bowel syndrome: A case control study in the general population, BMC Gastroenterol, 12, (2012); Vivinus-Nebot M., Dainese R., Anty R., Et al., Combination of allergic factors can worsen diarrheic irritable bowel syndrome: Role of barrier defects and mast cells, Am J Gastroenterol, 107, pp. 75-81, (2012); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Longstreth G.F., Thompson W.G., Chey W.D., Et al., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Guilarte M., Santos J., De Torres I., Et al., Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum, Gut, 56, pp. 203-209, (2007); Francis C.Y., Morris J., Whorwell P.J., The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress, Aliment Pharmacol Ther, 11, pp. 395-402, (1997); Lewis S.J., Heaton K.W., Stool form scale as a useful guide to intestinal transit time, Scand J Gastroenterol, 32, (1997); Tack J., Talley N.J., Camilleri M., Et al., Functional gastroduodenal disorders, Gastroenterology, 130, pp. 1466-1479, (2006); Holmes T.H., Rahe R.H., The social readjustment rating scale, J Psychosom Med, 11, pp. 213-218, (1967); Cohen S., Kamarck T., Mermelstein R., A global measure of perceived stress, J Health Soc Behav, 24, pp. 385-396, (1983); Beck A.T., Ward C.H., Mendelson M., Et al., An inventory for measuring depression, Arch Gen Psychiatry, 4, pp. 561-571, (1961); Heinzerling L., Mari A., Bergmann K.C., Et al., The skin prick test-European standards, Clin Transl Allergy, 3, (2013); Cerutti A., Zan H., Schaffer A., Et al., CD40 ligand and appropriate cytokines induce switching to IgG, IgA, and IgE and coordinated germinal center and plasmacytoid phenotypic differentiation in a human monoclonal IgM+IgD+ B cell line, J Immunol, 160, pp. 2145-2157, (1998); Vicario M., Blanchard C., Stringer K.F., Et al., Local B cells and IgE production in the oesophageal mucosa in eosinophilic oesophagitis, Gut, 59, pp. 12-20, (2010); Schmittgen T.D., Livak K.J., Analyzing real-time PCR data by the comparative CT method, Nat Protoc, 3, pp. 1101-1108, (2008); Benjamini Y., Hochberg Y., Controlling the false discovery rate: A practical and powerful approach to multiple testing, J Roy Statist Soc B, 85, pp. 289-300, (1995); Maindonald J., Braun J., Data Analysis and Graphics Using R, (2007); Magnusson J., Lin X.P., Dahlman-Hoglund A., Et al., Seasonal intestinal inflammation in patients with birch pollen allergy, J Allergy ClinImmunol, 112, pp. 45-50, (2003); Wu K.C., Mahida Y.R., Priddle J.D., Et al., Immunoglobulin production by isolated intestinal mononuclear cells from patients with ulcerative colitis and Crohn's disease, Clin Exp Immunol, 78, pp. 37-41, (1989); Macpherson A., Khoo U.Y., Forgacs I., Et al., Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria, Gut, 38, pp. 365-375, (1996); Fagarasan S., Kinoshita K., Muramatsu M., Et al., In situ class switching and differentiation to IgA-producing cells in the gut lamina propria, Nature, 413, pp. 639-643, (2001); He B., Xu W., Santini P.A., Et al., Intestinal bacteria trigger T cell-independent immunoglobulin A(2) class switching by inducing epithelial-cell secretion of the cytokine April, Immunity, 26, pp. 812-826, (2007); He B., Santamaria R., Xu W., Et al., The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88, Nat Immunol, 11, pp. 836-845, (2010); Lobo B., Vicario M., Martinez C., Et al., Clinical benefit in IBS after disodium cromoglycate involves mast cell-mediated recovery of healthy-like innate immunity genes expression profile in the jejunal mucosa, Gastroenterology, 136, S1, (2009); Sanderson I.R., Walker W.A., TLRs in the Gut I. the role of TLRs/Nods in intestinal development and homeostasis, Am J Physiol Gastrointest Liver Physiol, 292, pp. G6-10, (2007); Carroll I.M., Ringel-Kulka T., Keku T.O., Et al., Molecular analysis of the luminal-and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome, Am J Physiol Gastrointest Liver Physiol, 301, pp. G799-807, (2011); Sachdev A.H., Pimentel M., Antibiotics for irritable bowel syndrome: Rationale and current evidence, Curr Gastroenterol Rep, 14, pp. 439-445, (2012); Jefferis R., Kumararatne D.S., Selective IgG subclass deficiency: Quantification and clinical relevance, Clin Exp Immunol, 81, pp. 357-367, (1990); Kinoshita K., Harigai M., Fagarasan S., Et al., A hallmark of active class switch recombination: Transcripts directed by i promoters on looped-out circular DNAs, Proc Natl Acad Sci USA, 98, pp. 12620-12623, (2001); Coe C.L., Rosenberg L.T., Fischer M., Et al., Psychological factors capable of preventing the inhibition of antibody responses in separated infant monkeys, Child Dev, 58, pp. 1420-1430, (1987); Cohen S., Miller G.E., Rabin B.S., Psychological stress and antibody response to immunization: A critical review of the human literature, Psychosom Med, 63, pp. 7-18, (2001)","","","BMJ Publishing Group","","","","","","00175749","","GUTTA","25209656","English","Gut","Article","Final","","Scopus","2-s2.0-84941299655"

"Hou Q.; Huang Y.; Zhang C.; Zhu S.; Li P.; Chen X.; Hou Z.; Liu F.","Hou, Qiuke (35573727700); Huang, Yongquan (57195074253); Zhang, Changrong (57203160104); Zhu, Shuilian (57193834637); Li, Peiwu (55757309300); Chen, Xinlin (55357650100); Hou, Zhengkun (36055683600); Liu, Fengbin (55799656200)","35573727700; 57195074253; 57203160104; 57193834637; 55757309300; 55357650100; 36055683600; 55799656200","MicroRNA-200a targets cannabinoid receptor 1 and serotonin transporter to increase visceral hyperalgesia in diarrhea-predominant irritable bowel syndrome rats","2018","Journal of Neurogastroenterology and Motility","24","4","","656","668","12","31","10.5056/jnm18037","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85054696426&doi=10.5056%2fjnm18037&partnerID=40&md5=47c46a5d476b731addfff021c288012b","Department of Gastroenterology, First Affiliated Hospital, Guangzhou University of Chinese Medicine, Qiuke Hou, No.12, Jichang Road, Guangzhou, Guangdong, 510405, China; Department of Orthopedics, Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China; Department of Preventive Medicine and Health Statistics, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China","Hou Q., Department of Gastroenterology, First Affiliated Hospital, Guangzhou University of Chinese Medicine, Qiuke Hou, No.12, Jichang Road, Guangzhou, Guangdong, 510405, China; Huang Y., Department of Orthopedics, Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China; Zhang C., Department of Gastroenterology, First Affiliated Hospital, Guangzhou University of Chinese Medicine, Qiuke Hou, No.12, Jichang Road, Guangzhou, Guangdong, 510405, China; Zhu S., Department of Gastroenterology, First Affiliated Hospital, Guangzhou University of Chinese Medicine, Qiuke Hou, No.12, Jichang Road, Guangzhou, Guangdong, 510405, China; Li P., Department of Gastroenterology, First Affiliated Hospital, Guangzhou University of Chinese Medicine, Qiuke Hou, No.12, Jichang Road, Guangzhou, Guangdong, 510405, China; Chen X., Department of Preventive Medicine and Health Statistics, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China; Hou Z., Department of Gastroenterology, First Affiliated Hospital, Guangzhou University of Chinese Medicine, Qiuke Hou, No.12, Jichang Road, Guangzhou, Guangdong, 510405, China; Liu F., Department of Gastroenterology, First Affiliated Hospital, Guangzhou University of Chinese Medicine, Qiuke Hou, No.12, Jichang Road, Guangzhou, Guangdong, 510405, China","Background/Aims: MicroRNAs (miRNAs) were reported to be responsible for intestinal permeability in diarrhea-predominant irritable bowel syndrome (IBS-D) rats in our previous study. However, whether and how miRNAs regulate visceral hypersensitivity in IBS-D remains largely unknown. Methods: We established the IBS-D rat model and evaluated it using the nociceptive visceral hypersensitivity test, myeloperoxidase activity assay, restraint stress-induced defecation, and electromyographic (EMG) activity. The distal colon was subjected to miRNA microarray analysis followed by isolation and culture of colonic epithelial cells (CECs). Bioinformatic analysis and further experiments, including dual luciferase assays, quantitative real-time polymerase chain reaction, western blot, and enzyme-linked immunosorbent assay, were used to detect the expression of miRNAs and how it regulates visceral hypersensitivity in IBS-D rats. Results: The IBS-D rat model was successfully established. A total of 24 miRNAs were differentially expressed in the distal colon of IBS-D rats; 9 were upregulated and 15 were downregulated. Among them, the most significant upregulation was miR-200a, accompanied by downregulation of cannabinoid receptor 1 (CNR1) and serotonin transporter (SERT). MiR-200a mimic markedly inhibited the expression of CNR1/SERT. Bioinformatic analysis and luciferase assay confirmed that CNR1/SERT are direct targets of miR-200a. Rescue experiments that overexpressed CNR1/SERT significantly abolished the inhibitory effect of miR-200a on the IBS-D rats CECs. Conclusions: This study suggests that miR-200a could induce visceral hyperalgesia by targeting the downregulation of CNR1 and SERT, aggravating or leading to the development and progression of IBS-D. MiR-200a may be a regulator of visceral hypersensitivity, which provides potential targets for the treatment of IBS-D. © 2018 The Korean Society of Neurogastroenterology and Motility.","CNR1; Diarrhea; Hypersensitivity; Irritable bowel syndrome; MiR-200a; SERT","","","","","","Chinese Medicine Science Research Project of Guangdong Province, (20181095); China Postdoctoral Science Foundation, (2017M612641)","Financial support: This study was supported by the China Postdoctoral Science Foundation (No. 2017M612641) and the Chinese Medicine Science Research Project of Guangdong Province (No. 20181095).","Drossman D.A., Hasler W.L., Rome IV-functional GI disorders: Disorders of gut-brain interaction, Gastroenterology, 150, pp. 1257-1261, (2016); Oshima T., Miwa H., Epidemiology of functional gastrointestinal disorders in Japan and in the world, J Neurogastroenterol Motil, 21, pp. 320-329, (2015); Asano T., Tanaka K.I., Tada A., Et al., Aminophylline suppresses stressinduced visceral hypersensitivity and defecation in irritable bowel syndrome, Sci Rep, 7, (2017); Chen M.X., Chen Y., Fu R., Liu S.Y., Yang Q.Q., Shen T.B., Activation of 5-HT and NR2B contributes to visceral hypersensitivity in irritable bowel syndrome in rats, Am J Transl Res, 8, pp. 5580-5590, (2016); Camilleri M., Is there a SERT-ain association with IBS?, Gut, 53, pp. 1396-1399, (2004); Jiang Y., Nie Y., Li Y., Zhang L., Association of cannabinoid type 1 receptor and fatty acid amide hydrolase genetic polymorphisms in Chinese patients with irritable bowel syndrome, J Gastroenterol Hepatol, 29, pp. 1186-1191, (2014); Storr M., Emmerdinger D., Diegelmann J., Et al., The cannabinoid 1 receptor (CNR1) 1359 G/A polymorphism modulates susceptibility to ulcerative colitis and the phenotype in Crohn's disease, PLoS One, 5, (2010); Abalo R., Chen C., Vera G., Et al., In vitro and non-invasive in vivo effects of the cannabinoid-1 receptor agonist AM841 on gastrointestinal motor function in the rat, Neurogastroenterol Motil, 27, pp. 1721-1735, (2015); McKenna L.B., Schug J., Vourekas A., Et al., MicroRNAs control intestinal epithelial differentiation, architecture, and barrier function, Gastroenterology, 139, pp. 1654-1664, (2010); O'Hara S.P., Mott J.L., Splinter P.L., Gores G.J., LaRusso N.F., MicroRNAs: Key modulators of posttranscriptional gene expression, Gastroenterology, 136, pp. 17-25, (2009); Kalla R., Ventham N.T., Kennedy N.A., MicroRNAs: New players in inflammatory bowel disease, Gut, 64, (2015); Zhang L., Cheng J., Fan X.M., MicroRNAs: New therapeutic targets for intestinal barrier dysfunction, World J Gastroenterol, 20, pp. 5818-5825, (2014); Wu F., Zikusoka M., Trindade A., Et al., MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha, Gastroenterology, 135, pp. 1624-1635, (2008); Neesse A., Gress T.M., Emerging role of microRNAs to tackle drug resistance in pancreatic cancer, Gut, 64, pp. 1842-1843, (2015); Kalla R., Ventham N.T., Kennedy N.A., Et al., MicroRNAs: New players in IBD, Gut, 64, pp. 504-517, (2015); Nguyen H.T., Dalmasso G., Muller S., Carriere J., Seibold F., Darfeuille-Michaud A., Crohn's disease-associated adherent invasive Escherichia coli modulate levels of microRNAs in intestinal epithelial cells to reduce autophagy, Gastroenterology, 146, pp. 508-519, (2014); Hou Q., Huang Y., Zhu S., Et al., MiR-144 increases intestinal permeability in IBS-D rats by targeting OCLN and ZO1, Cell Physiol Biochem, 44, pp. 2256-2268, (2017); Sun J., Wu X., Meng Y., Et al., Electro-acupuncture decreases 5-HT, CGRP and increases NPY in the brain-gut axis in two rat models of diarrhea-predominant irritable bowel syndrome (D-IBS), BMC Complement Altern Med, 15, (2015); Zhou Q., Price D.D., Dreher K.L., Et al., Localized colonic stem cell transplantation enhances tissue regeneration in murine colitis, J Cell Mol Med, 16, pp. 1900-1915, (2012); Winston J., Shenoy M., Medley D., Naniwadekar A., Pasricha P.J., The vanilloid receptor initiates and maintains colonic hypersensitivity induced by neonatal colon irritation in rats, Gastroenterology, 132, pp. 615-627, (2007); Krawisz J.E., Sharon P., Stenson W.F., Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models, Gastroenterology, 87, pp. 1344-1350, (1984); Booth C., Patel S., Bennion G.R., Potten C.S., The isolation and culture of adult mouse colonic epithelium, Epithelial Cell Biol, 4, pp. 76-86, (1995); Ren H.X., Zhang F.C., Luo H.S., Zhang G., Liang L.X., Role of mast cell-miR-490-5p in irritable bowel syndrome, World J Gastroenterol, 23, pp. 93-102, (2017); Zhou Q., Verne G.N., MiRNA-based therapies for the irritable bowel syndrome, Expert Opin Biol Ther, 11, pp. 991-995, (2011); Fourie N.H., Peace R.M., Abey S.K., Et al., Elevated circulating miR-150 and miR-342-3p in patients with irritable bowel syndrome, Exp Mol Pathol, 96, pp. 422-425, (2014); Koukos G., Polytarchou C., Kaplan J.L., Et al., A microRNA signature in pediatric ulcerative colitis: Deregulation of the miR-4284/CXCL5 pathway in the intestinal epithelium, Inflamm Bowel Dis, 21, pp. 996-1005, (2015); Zhou Q., Costinean S., Croce C.M., Et al., MicroRNA 29 targets nuclear factor-κB-repressing factor and claudin 1 to increase intestinal permeability, Gastroenterology, 148, pp. 158-169, (2015); Zhou Q., Yang L., Larson S., Et al., Decreased miR-199 augments visceral pain in patients with IBS through translational upregulation of TRPV1, Gut, 65, pp. 797-805, (2016); Liao X.J., Mao W.M., Wang Q., Yang G.G., Wu W.J., Shao S.X., MicroRNA-24 inhibits serotonin reuptake transporter expression and aggravates irritable bowel syndrome, Biochem Biophys Res Commun, 469, pp. 288-293, (2016); Baudry A., Mouillet-Richard S., Schneider B., Launay J.M., Kellermann O., MiR-16 targets the serotonin transporter: A new facet for adaptive responses to antidepressants, Science, 329, pp. 1537-1541, (2010); Vianna C.R., Donato J., Rossi J., Et al., Cannabinoid receptor 1 in the vagus nerve is dispensable for body weight homeostasis but required for normal gastrointestinal motility, J Neurosci, 30, pp. 10331-10337, (2012); Hong S., Fan J., Kemmerer E.S., Evans S., Li Y., Wiley J.W., Reciprocal changes in vanilloid (TRPV1) and endocannabinoid (CB1) receptors contribute to visceral hyperalgesia in the water avoidance stressed rat, Gut, 58, pp. 202-210, (2009); Hong S., Zheng G., Wiley J.W., Epigenetic regulation of genes that modulate chronic stress-induced visceral pain in the peripheral nervous system, Gastroenterology, 148, pp. 148-157, (2015); Reigstad C.S., Linden D.R., Szurszewski J.H., Sonnenburg J.L., Farrugia G., Kashyap P.C., Correlated gene expression encoding serotonin (5-HT) receptor 4 and 5-HT transporter in proximal colonic segments of mice across different colonization states and sexes, Neurogastroenterol Motil, 28, pp. 1443-1448, (2016); Gutierrez B., Bellon J.A., Rivera M., Et al., The risk for major depression conferred by childhood maltreatment is multiplied by BDNF and SERT genetic vulnerability: A replication study, J Psychiatry Neurosci, 40, pp. 187-196, (2015); De W W., Brand L., Stein D.J., Harvey B.H., Reappraisal of spontaneous stereotypy in the deer mouse as an animal model of obsessivecompulsive disorder (OCD): Response to escitalopram treatment and basal serotonin transporter (SERT) density, Behav Brain Res, 256, pp. 545-553, (2013); Charoenphandhu J., Teerapornpuntakit J., Nuntapornsak A., Krishnamra N., Charoenphandhu N., Anxiety-like behaviors and expression of SERT and TPH in the dorsal raphé of estrogen- and fluoxetine-treated ovariectomized rats, Pharmacol Biochem Behav, 98, pp. 503-510, (2011); Cui X.F., Zhou W.M., Yang Y., Et al., Epidermal growth factor upregulates serotonin transporter and its association with visceral hypersensitivity in irritable bowel syndrome, World J Gastroenterol, 37, pp. 13521-13529, (2014); Sikander A., Rana S.V., Sinha S.K., Et al., Serotonin transporter promoter variant: Analysis in Indian IBS patients and control population, J Clin Gastroenterol, 43, pp. 957-961, (2009); Galligan J.J., Patel B.A., Schneider S.P., Et al., Visceral hypersensitivity in female but not in male serotonin transporter knockout rats, Neurogastroenterol Motil, 25, pp. e373-e381, (2013)","F. Liu; Department of Gastroenterology, First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, Qiuke Hou, No.12, Jichang Road, 510405, China; email: liufb163@126.com","","Korean Society of Neurogastroenterology and Motility","","","","","","20930879","","","","English","J. Neurogastroenterology Motil.","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85054696426"

"Bücker R.; Krug S.M.; Moos V.; Bojarski C.; Schweiger M.R.; Kerick M.; Fromm A.; Janßen S.; Fromm M.; Hering N.A.; Siegmund B.; Schneider T.; Barmeyer C.; Schulzke J.D.","Bücker, R. (10043068400); Krug, S.M. (25641099900); Moos, V. (6602224334); Bojarski, C. (8764110100); Schweiger, M.R. (9240082000); Kerick, M. (26632263800); Fromm, A. (13106110800); Janßen, S. (57201777066); Fromm, M. (55605772841); Hering, N.A. (35332178600); Siegmund, B. (7006254804); Schneider, T. (56835063000); Barmeyer, C. (6506742657); Schulzke, J.D. (35502556700)","10043068400; 25641099900; 6602224334; 8764110100; 9240082000; 26632263800; 13106110800; 57201777066; 55605772841; 35332178600; 7006254804; 56835063000; 6506742657; 35502556700","Campylobacter jejuni impairs sodium transport and epithelial barrier function via cytokine release in human colon","2018","Mucosal Immunology","11","2","","474","485","11","30","10.1038/mi.2017.66","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85046102198&doi=10.1038%2fmi.2017.66&partnerID=40&md5=8c939468424e149a2bf017b6220145fc","Institute of Clinical Physiology, Nutritional Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany; Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité-Universitätsmedizin Berlin, Berlin, Germany; Laboratory of Functional Epigenomics, Functional Epigenomics, CCG, University Hospital of Cologne, Cologne, Germany; Department of General, Visceral and Vascular Surgery, Charité-Universitätsmedizin Berlin, Berlin, Germany","Bücker R., Institute of Clinical Physiology, Nutritional Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany; Krug S.M., Institute of Clinical Physiology, Nutritional Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany; Moos V., Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité-Universitätsmedizin Berlin, Berlin, Germany; Bojarski C., Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité-Universitätsmedizin Berlin, Berlin, Germany; Schweiger M.R., Laboratory of Functional Epigenomics, Functional Epigenomics, CCG, University Hospital of Cologne, Cologne, Germany; Kerick M., Laboratory of Functional Epigenomics, Functional Epigenomics, CCG, University Hospital of Cologne, Cologne, Germany; Fromm A., Institute of Clinical Physiology, Nutritional Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany; Janßen S., Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité-Universitätsmedizin Berlin, Berlin, Germany; Fromm M., Institute of Clinical Physiology, Nutritional Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany; Hering N.A., Department of General, Visceral and Vascular Surgery, Charité-Universitätsmedizin Berlin, Berlin, Germany; Siegmund B., Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité-Universitätsmedizin Berlin, Berlin, Germany; Schneider T., Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité-Universitätsmedizin Berlin, Berlin, Germany; Barmeyer C., Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité-Universitätsmedizin Berlin, Berlin, Germany; Schulzke J.D., Institute of Clinical Physiology, Nutritional Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany","Campylobacter jejuni is the most prevalent cause of foodborne bacterial enteritis worldwide. Patients present with diarrhea and immune responses lead to complications like arthritis and irritable bowel syndrome. Although studies exist in animal and cell models, we aimed at a functional and structural characterization of intestinal dysfunction and the involved regulatory mechanisms in human colon. First, in patients' colonic biopsies, sodium malabsorption was identified as an important diarrheal mechanism resulting from hampered epithelial ion transport via impaired epithelial sodium channel (ENaC) β- and γ-subunit. In addition, barrier dysfunction from disrupted epithelial tight junction proteins (claudin-1, -3, -4, -5, and -8), epithelial apoptosis, and appearance of lesions was detected, which cause leak-flux diarrhea and can perpetuate immune responses. Importantly, these effects in human biopsies either represent direct action of Campylobacter jejuni (ENaC impairment) or are caused by proinflammatory signaling (barrier dysfunction). This was revealed by regulator analysis from RNA-sequencing (cytometric bead array-checked) and confirmed in cell models, which identified interferon-γ, TNFα, IL-13, and IL-1β. Finally, bioinformatics' predictions yielded additional information on protective influences like vitamin D, which was confirmed in cell models. Thus, these are candidates for intervention strategies against C. jejuni infection and post-infectious sequelae, which result from the permissive barrier defect along the leaky gut. © 2018 Nature Publishing Group. All rights reserved.","","Adult; Apoptosis; Campylobacter Infections; Campylobacter jejuni; Cells, Cultured; Colon; Computational Biology; Cytokines; Enteritis; Epithelial Sodium Channels; Female; Humans; Inflammation Mediators; Intestinal Mucosa; Ion Transport; Malabsorption Syndromes; Male; Middle Aged; Signal Transduction; Sodium; Tight Junction Proteins; Vitamin D; claudin 1; claudin 3; claudin 4; claudin 5; claudin 8; epithelial sodium channel; gamma interferon; interleukin 13; interleukin 1beta; tumor necrosis factor; autacoid; cytokine; epithelial sodium channel; sodium; tight junction protein; vitamin D; adult; apoptosis; Article; Campylobacter jejuni; campylobacteriosis; clinical article; colon biopsy; controlled study; cytokine release; diarrhea; female; human; human cell; immune response; in vitro study; ion transport; male; nonhuman; pathogenesis; priority journal; protein localization; regulatory mechanism; RNA sequence; signal transduction; sodium transport; biology; Campylobacter jejuni; campylobacteriosis; cell culture; colon; enteritis; genetics; immunology; intestine mucosa; malabsorption; metabolism; microbiology; middle aged; pathology; physiology","","claudin 1, 329338-06-9; gamma interferon, 82115-62-6; interleukin 13, 148157-34-0; sodium, 7440-23-5; Cytokines, ; Epithelial Sodium Channels, ; Inflammation Mediators, ; Sodium, ; Tight Junction Proteins, ; Vitamin D, ","","","Deutsche Forschungsgemeinschaft, DFG, (DFG Schu559/11)","In-Fah Maria Lee and Diana Bösel are gratefully acknowledged for their technical support. Funding for this study was supported by the Deutsche Forschungsgemeinschaft (DFG Schu559/11) to J.D.S; the Volkswagen Foundation (Lichtenberg program) to M.R.S. and the German Federal Ministry of Education and Research (BMBF) PAC-CAMPY consortium (IP8) to R.B. and J.D.S.","Blaser M.J., Et al., Experimental Campylobacter jejuni infection of adult mice, Infect. Immun, 39, pp. 908-916, (1983); Russell R.G., Et al., Experimental Campylobacter jejuni infection in Macaca nemestrina, Infect. Immun, 57, pp. 1438-1444, (1989); Fox J.G., Et al., Gastroenteritis in NF-kappaB-deficient mice is produced with wild-type Camplyobacter jejuni but not with C. jejuni lacking cytolethal distending toxin despite persistent colonization with both strains, Infect. Immun, 72, pp. 1116-1125, (2004); Hickey T.E., Et al., Intracellular survival of Campylobacter jejuni in human monocytic cells and induction of apoptotic death by cytholethal distending toxin, Infect. Immun, 73, pp. 5194-5197, (2005); Elmi A., Et al., Campylobacter jejuni outer membrane vesicles play an important role in bacterial interactions with human intestinal epithelial cells, Infect. Immun, 80, pp. 4089-4098, (2012); Black R.E., Et al., Experimental Campylobacter jejuni infection in humans, J. Infect. Dis, 157, pp. 472-479, (1988); Spiller R.C., Et al., Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, pp. 804-811, (2000); Van Spreeuwel J.P., Et al., Campylobacter colitis: Histological immunohistochemical and ultrastructural findings, Gut, 26, pp. 945-951, (1985); Boehm M., Et al., Rapid paracellular transmigration of Campylobacter jejuni across polarized epithelial cells without affecting TER: Role of proteolyticactive HtrA cleaving E-cadherin but not fibronectin, Gut Pathog, 4, (2012); Backert S., Et al., Transmigration route of Campylobacter jejuni across polarized intestinal epithelial cells: Paracellular, transcellular or both?, Cell Commun. Signal, 11, (2013); Chen M.L., Et al., Disruption of tight junctions and induction of proinflammatory cytokine responses in colonic epithelial cells by Campylobacter jejuni, Infect. Immun, 74, pp. 6581-6589, (2006); Lamb-Rosteski J.M., Et al., Epidermal growth factor inhibits Campylobacter jejuni-induced claudin-4 disruption, loss of epithelial barrier function, and Escherichia coli translocation, Infect. Immun, 76, pp. 3390-3398, (2008); Rees L.E., Et al., Campylobacter and IFNgamma interact to cause a rapid loss of epithelial barrier integrity, Inflamm. Bowel Dis, 14, pp. 303-309, (2008); Soler A.P., Et al., Activation of NF-kappaB is necessary for the restoration of the barrier function of an epithelium undergoing TNF-alpha-induced apoptosis, Eur. J. Cell Biol, 78, pp. 56-66, (1999); Negoro S., Et al., Campylobacter jejuni infection suppressed Cl- secretion induced by CFTR activation in T-84 cells, J. Infect. Chemother, 20, pp. 682-688, (2014); Zeissig S., Et al., Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease, Gut, 56, pp. 61-72, (2007); Bergann T., Et al., Glucocorticoid receptor is indispensable for physiological responses to aldosterone in epithelial Na+ channel induction via the mineralocorticoid receptor in a human colonic cell line, Eur. J. Cell Biol, 90, pp. 432-439, (2011); Kreusel K.M., Et al., Cl- secretion in epithelial monolayers of mucusforming human colon cells (HT-29/B6), Am. J. Physiol, 261, pp. C574-C582, (1991); Dames P., Et al., Interleukin-13 affects the epithelial sodium channel in the intestine by coordinated modulation of STAT6 and p38 MAPK activity, J. Physiol, 593, pp. 5269-5282, (2015); Lissner D., Et al., Monocyte and M1 macrophage-induced barrier defect contributes to chronic intestinal inflammation in IBD, Inflamm. Bowel Dis, 21, pp. 1297-1305, (2015); Barmeyer C., Et al., ENaC dysregulation through activation of MEK1/2 contributes to impaired Na+ absorption in lymphocytic colitis, Inflamm. Bowel Dis, 22, pp. 539-547, (2016); Barmeyer C., Et al., IL-1beta and TNFalpha regulate sodium absorption in rat distal colon, Biochem. Biophys. Res. Commun, 317, pp. 500-507, (2004); Marchelletta R.R., Et al., Altered expression and localization of ion transporters contribute to diarrhea in mice with Salmonella-induced enteritis, Gastroenterology, 145, pp. 1358-1368, (2013); Bachmann O., Seidler U., News from the end of the gut - How the highly segmental pattern of colonic HCO- transport relates to absorptive function and mucosal integrity, Biol. Pharm. Bull, 34, pp. 794-802, (2011); Bucker R., Et al., Arcobacter butzleri induces barrier dysfunction in intestinal HT-29/B6 cells, J. Infect. Dis, 200, pp. 756-764, (2009); Nielsen H.L., Et al., Oral and fecal Campylobacter concisus strains perturb barrier function by apoptosis induction in HT-29/B6 intestinal epithelial cells, PLoS ONE, 6, (2011); Amasheh M., Et al., TNFalpha-induced and berberine-antagonized tight junction barrier impairment via tyrosine kinase, Akt and NFkappaB signaling, J. Cell. Sci, 123, pp. 4145-4155, (2010); Weber C.R., Et al., Claudin-1 and claudin-2 expression is elevated in inflammatory bowel disease and may contribute to early neoplastic transformation, Lab. Invest, 88, pp. 1110-1120, (2008); Poritz L.S., Et al., Increase in the tight junction protein claudin-1 in intestinal inflammation, Dig. Dis. Sci, 56, pp. 2802-2809, (2011); Mankertz J., Et al., TNFalpha up-regulates claudin-2 expression in epithelial HT-29/B6 cells via phosphatidylinositol-3-kinase signaling, Cell. Tissue Res, 336, pp. 67-77, (2009); Bojarski C., Et al., Apoptosis and intestinal barrier function, Ann. N.Y. Acad. Sci, 915, pp. 270-274, (2000); Bojarski C., Et al., Permeability of human HT-29/B6 colonic epithelium as a function of apoptosis, J. Physiol, 535, pp. 541-552, (2001); Troeger H., Et al., Effect of chronic Giardia lamblia infection on epithelial transport and barrier function in human duodenum, Gut, 56, pp. 328-335, (2007); Troeger H., Et al., Structural and functional changes of the duodenum in human norovirus infection, Gut, 58, pp. 1070-1077, (2009); Weber C.R., Et al., Epithelial myosin light chain kinase activation induces mucosal interleukin-13 expression to alter tight junction ion selectivity, J. Biol. Chem, 285, pp. 12037-12046, (2010); Heller F., Et al., Epithelial apoptosis is a prominent feature of the epithelial barrier disturbance in intestinal inflammation: Effect of pro-inflammatory interleukin-13 on epithelial cell function, Mucosal Immunol, 1, pp. S58-S61, (2008); Suzuki T., Et al., Interleukin-6 (IL-6) regulates claudin-2 expression and tight junction permeability in intestinal epithelium, J. Biol. Chem, 286, pp. 31263-31271, (2011); Bucker R., Et al., A-Haemolysin of Escherichia coli in IBD: A potentiator of inflammatory activity in the colon, Gut, 63, pp. 1893-1901, (2014); Amasheh M., Et al., Quercetin enhances epithelial barrier function and increases claudin-4 expression in Caco-2 cells, J. Nutr, 138, pp. 1067-1073, (2008); Sun X., Et al., Campylobacter jejuni induces colitis through activation of mammalian target of rapamycin signaling, Gastroenterology, 142, pp. 86-95, (2012); Daniel C., Et al., Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile, J. Pharmacol. Exp. Ther, 324, pp. 23-33, (2008); De Haes P., Et al., Molecular pathways involved in the anti-apoptotic effect of 1, 25-dihydroxyvitamin D3 in primary human keratinocytes, J. Cell Biochem, 93, pp. 951-967, (2004); Stio M., Et al., Vitamin D regulates the tight-junction protein expression in active ulcerative colitis, Scand. J. Gastroenterol, 20, pp. 1-7, (2016); Burgel N., Et al., Mechanisms of diarrhea in collagenous colitis, Gastroenterology, 123, pp. 433-443, (2002); Dobin A., Et al., STAR: Ultrafast universal RNA-seq aligner, Bioinformatics, 29, pp. 15-21, (2013); Schneider T., Et al., Increased immunoglobulin G production by short term cultured duodenal biopsy samples from HIV infected patients, Gut, 42, pp. 357-361, (1998)","J.D. Schulzke; Institute of Clinical Physiology, Nutritional Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany; email: joerg.schulzke@charite.de","","Nature Publishing Group","","","","","","19330219","","","28766554","English","Mucosal Immunol.","Article","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-85046102198"

"Gervasoni J.; Schiattarella A.; Giorgio V.; Primiano A.; Russo C.; Tesori V.; Scaldaferri F.; Urbani A.; Zuppi C.; Persichilli S.","Gervasoni, Jacopo (25922119000); Schiattarella, Arcangelo (56668644400); Giorgio, Valentina (56919461700); Primiano, Aniello (56508446700); Russo, Consuelo (57300900700); Tesori, Valentina (8599490700); Scaldaferri, Franco (8222069100); Urbani, Andrea (55198663000); Zuppi, Cecilia (7004679403); Persichilli, Silvia (6602941489)","25922119000; 56668644400; 56919461700; 56508446700; 57300900700; 8599490700; 8222069100; 55198663000; 7004679403; 6602941489","Validation of an LC-MS/MS Method for Urinary Lactulose and Mannitol Quantification: Results in Patients with Irritable Bowel Syndrome","2016","Disease Markers","2016","","5340386","","","","13","10.1155/2016/5340386","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85008625181&doi=10.1155%2f2016%2f5340386&partnerID=40&md5=61b8bbf8bf4ad561059babec039861fe","UOC Laboratorio Analisi i, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy; Pediatria, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy; UOC di Medicina Interna Gastroenterologia e Malattie Del Fegato, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy","Gervasoni J., UOC Laboratorio Analisi i, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy; Schiattarella A., UOC Laboratorio Analisi i, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy; Giorgio V., Pediatria, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy; Primiano A., UOC Laboratorio Analisi i, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy; Russo C., Pediatria, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy; Tesori V., UOC di Medicina Interna Gastroenterologia e Malattie Del Fegato, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy; Scaldaferri F., UOC di Medicina Interna Gastroenterologia e Malattie Del Fegato, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy; Urbani A., UOC Laboratorio Analisi i, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy; Zuppi C., UOC Laboratorio Analisi i, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy; Persichilli S., UOC Laboratorio Analisi i, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy","Aim. Lactulose/mannitol ratio is used to assess intestinal barrier function. Aim of this work was to develop a robust and rapid method for the analysis of lactulose and mannitol in urine by liquid chromatography coupled to tandem mass spectrometry. Lactulose/mannitol ratio has been measured in pediatric patients suffering from irritable bowel syndrome. Methods. Calibration curves and raffinose, used as internal standard, were prepared in water: acetonitrile 20: 80. Fifty μL of urine sample was added to 450 μL of internal standard solution. The chromatographic separation was performed using a Luna NH2 column operating at a flow rate of 200 μL/min and eluted with a linear gradient from 20% to 80% water in acetonitrile. Total run time is 9 minutes. The mass spectrometry operates in electrospray negative mode. Method was fully validated according to European Medicine Agency guidelines. Results and Conclusions. Linearity ranged from 10 to 1000 mg/L for mannitol and 2.5 to 1000 mg/L for lactulose. Imprecision in intra- and interassay was lower than 15% for both analytes. Accuracy was higher than 85%. Lactulose/mannitol ratio in pediatric patients is significantly higher than that measured in controls. The presented method, rapid and sensitive, is suitable in a clinical laboratory. Copyright © 2016 Jacopo Gervasoni et al.","","Adolescent; Case-Control Studies; Child; Chromatography, Liquid; Female; Humans; Irritable Bowel Syndrome; Lactulose; Male; Mannitol; Mass Spectrometry; Urinalysis; lactulose; mannitol; raffinose; lactulose; mannitol; adolescent; Article; calibration; child; clinical article; clinical laboratory; comparative study; controlled study; diagnostic accuracy; female; flow rate; high performance liquid chromatography; human; irritable colon; limit of quantitation; liquid chromatograph; liquid chromatography-mass spectrometry; male; mass spectrometer; mass spectrometry; tandem mass spectrometry; urine sampling; case control study; irritable colon; liquid chromatography; procedures; urinalysis; urine; validation study","","lactulose, 4618-18-2; mannitol, 69-65-8, 87-78-5; raffinose, 512-69-6; Lactulose, ; Mannitol, ","TSQ Quantum Access, Thermo, United States","Thermo, United States","","","Marchesi J., Shanahan F., The normal intestinal microbiota, Current Opinion in Infectious Diseases, 20, 5, pp. 508-513, (2007); Lovell R.M., Ford A.C., Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis, Clinical Gastroenterology AndHepatology, 10, 7, pp. 712-721, (2012); Canavan C., West J., Card T., The epidemiology of irritable bowel syndrome, Clinical Epidemiology, 6, pp. 71-80, (2014); Camilleri M., Gorman H., Intestinal permeability and irritable bowel syndrome, Neurogastroenterology and Motility, 19, 7, pp. 545-552, (2007); Shulman R.J., Eakin M.N., Czyzewski D.I., Jarrett M.M., Ou C.N., Increased gastrointestinal permeability and gut inflammation in children with functional abdominal pain and irritable bowel syndrome, Journal of Pediatrics, 153, 5, pp. 646-650, (2008); Tibble J.A., Sigthorsson G., Foster R., Forgacs I., Bjarnason I., Use of surrogate markers of inflammation and Rome criteria to distinguish organic fromnonorganic intestinal disease, Gastroenterology, 123, 2, pp. 450-460, (2002); Sun Z., Wang X., Andersson R., Role of intestinal permeability in monitoring mucosal barrier function. History, methodology, and significance of pathophysiology, Digestive Surgery, 15, 5, pp. 386-397, (1998); Camilleri M., Nadeau A., Lamsam J., Et al., Understandingmeasurements of intestinal permeability in healthy humans with urine lactulose and mannitol excretion, Neurogastroenterology and Motility, 22, 1, pp. e15-e26, (2010); Bjarnason I., MacPherson A., Hollander D., Intestinal permeability: An overview, Gastroenterology, 108, 5, pp. 1566-1581, (1995); Tibble J.A., Bjarnason I., Non-invasive investigation of inflammatory bowel disease, World Journal OfGastroenterology, 7, 4, pp. 460-465, (2001); Denno D.M., VanBuskirk K., Nelson Z.C., Musser C.A., Hay Burgess D.C., Tarr P.I., Use of the lactulose to mannitol ratio to evaluate childhood environmental enteric dysfunction: A systematic review, Clinical Infectious Diseases, 59, S4, pp. S213-S219, (2014); Zhang Y., Lee B., Thompson M., Et al., Lactulose-mannitol intestinal permeability test in children with diarrhea caused by Rotavirus and Cryptosporidium, Journal of Pediatric Gastroenterology and Nutrition, 31, 1, pp. 16-21, (2000); Northrop C.A., Lunn P.G., Behrens R.H., Automated enzymatic assays for the determination of intestinal permeability probes in urine. 1. Lactulose and lactose, Clinica Chimica Acta, 187, 2, pp. 79-87, (1990); Lunn P.G., Northrop C.A., Northrop A.J., Automated enzymatic assays for the determination of intestinal permeability probes in urine. 2. Mannitol, Clinica Chimica Acta, 183, 2, pp. 163-170, (1989); Hessels J., Snoeyink E.J.M., Platenkamp A.J., Voortman G., Steggink J., Eidhof H.H.M., Assessment of intestinal permeability: Enzymatic determination of urinary mannitol, raffinose, sucrose and lactose on hitachi analyzer, Clinical Chemistry and Laboratory Medicine, 41, 1, pp. 33-38, (2003); Farhadi A., Keshavarzian A., Holmes E.W., Fields J., Zhang L., Banan A., Gas chromatographic method for detection of urinary sucralose: Application to the assessment of intestinal permeability, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 784, 1, pp. 145-154, (2003); Delahunty T., Hollander D., Liquid-chromatographic method for estimating urinary sugars: Applicability to studies of intestinal permeability, Clinical Chemistry, 32, 8, pp. 1542-1544, (1986); Marsilio R., D'Antiga L., Zancan L., Dussini N., Zacchello F., Simultaneous HPLC determination with lightscattering detection of lactulose and mannitol in studies of intestinal permeability in pediatrics, Clinical Chemistry, 44, 8, pp. 1685-1691, (1998); Lostia A.M., Lionetto L., Principessa L., Et al., A liquid chromatography/mass spectrometry method for the evaluation of intestinal permeability, Clinical Biochemistry, 41, 10-11, pp. 887-892, (2008); Drossman D.A., The functional gastrointestinal disorders and the Rome III process, Gastroenterology, 130, 5, pp. 1377-1390, (2006); Taylor P.J., Matrix effects: The Achilles heel of quantitative high-performance liquid chromatography-electrospray-tandem mass spectrometry, Clinical Biochemistry, 38, 4, pp. 328-334, (2005); Zhou Q., Zhang B., Nicholas Verne G., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, 1-2, pp. 41-46, (2009); Welcker K., Martin A., Kolle O., Siebeck M., Gross M., Increased intestinal permeability in patients with inflammatory bowel disease, European Journal of Medical Research, 9, 10, pp. 456-460, (2004); Guideline on Bioanalytical Method Validation, (2009)","S. Persichilli; UOC Laboratorio Analisi i, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy; email: spersichilli@rm.unicatt.it","","Hindawi Limited","","","","","","02780240","","DMARD","28070137","English","Dis. Markers","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85008625181"

"Halliez M.C.M.; Motta J.-P.; Feener T.D.; Guérin G.; Legoff L.; François A.; Colasse E.; Favennec L.; Gargala G.; Lapointe T.K.; Altier C.; Buret A.G.","Halliez, Marie C. M. (55974377400); Motta, Jean-Paul (36098189300); Feener, Troy D. (55212252700); Guérin, Gaetan (57190882760); Legoff, Laetitia (57190880075); François, Arnaud (8374814700); Colasse, Elodie (57189379984); Favennec, Loic (7004223448); Gargala, Gilles (56046059900); Lapointe, Tamia K. (9737021500); Altier, Christophe (6603697246); Buret, André G. (7007101465)","55974377400; 36098189300; 55212252700; 57190882760; 57190880075; 8374814700; 57189379984; 7004223448; 56046059900; 9737021500; 6603697246; 7007101465","Giardia duodenalis induces paracellular bacterial translocation and causes postinfectious visceral hypersensitivity","2016","American Journal of Physiology - Gastrointestinal and Liver Physiology","310","8","","G574","G585","11","58","10.1152/ajpgi.00144.2015","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84983802563&doi=10.1152%2fajpgi.00144.2015&partnerID=40&md5=1627af634298a483435c2d07587d91e5","Protozooses transmises par l’alimentation, Rouen University Hospital, University of Rouen and University of Reims Champagne-Ardennes, Institute for Biomedical Research, Rouen and Reims, France; Department of Biological Sciences, Inflammation Research Network, Host-Parasite Interaction NSERC-CREATE, University of Calgary, Calgary, AB, Canada; Service d’Anatomie et de Cytologie Pathologique CHU Rouen, Rouen cedex, France; Snyder Institute for Chronic Diseases, Inflammation Research Network, Department of Physiology and Pharmacology, University of Calgary, Calgary, AB, Canada","Halliez M.C.M., Protozooses transmises par l’alimentation, Rouen University Hospital, University of Rouen and University of Reims Champagne-Ardennes, Institute for Biomedical Research, Rouen and Reims, France, Department of Biological Sciences, Inflammation Research Network, Host-Parasite Interaction NSERC-CREATE, University of Calgary, Calgary, AB, Canada; Motta J.-P., Department of Biological Sciences, Inflammation Research Network, Host-Parasite Interaction NSERC-CREATE, University of Calgary, Calgary, AB, Canada; Feener T.D., Department of Biological Sciences, Inflammation Research Network, Host-Parasite Interaction NSERC-CREATE, University of Calgary, Calgary, AB, Canada; Guérin G., Protozooses transmises par l’alimentation, Rouen University Hospital, University of Rouen and University of Reims Champagne-Ardennes, Institute for Biomedical Research, Rouen and Reims, France; Legoff L., Protozooses transmises par l’alimentation, Rouen University Hospital, University of Rouen and University of Reims Champagne-Ardennes, Institute for Biomedical Research, Rouen and Reims, France; François A., Protozooses transmises par l’alimentation, Rouen University Hospital, University of Rouen and University of Reims Champagne-Ardennes, Institute for Biomedical Research, Rouen and Reims, France, Service d’Anatomie et de Cytologie Pathologique CHU Rouen, Rouen cedex, France; Colasse E., Service d’Anatomie et de Cytologie Pathologique CHU Rouen, Rouen cedex, France; Favennec L., Protozooses transmises par l’alimentation, Rouen University Hospital, University of Rouen and University of Reims Champagne-Ardennes, Institute for Biomedical Research, Rouen and Reims, France; Gargala G., Protozooses transmises par l’alimentation, Rouen University Hospital, University of Rouen and University of Reims Champagne-Ardennes, Institute for Biomedical Research, Rouen and Reims, France; Lapointe T.K., Snyder Institute for Chronic Diseases, Inflammation Research Network, Department of Physiology and Pharmacology, University of Calgary, Calgary, AB, Canada; Altier C., Snyder Institute for Chronic Diseases, Inflammation Research Network, Department of Physiology and Pharmacology, University of Calgary, Calgary, AB, Canada; Buret A.G., Department of Biological Sciences, Inflammation Research Network, Host-Parasite Interaction NSERC-CREATE, University of Calgary, Calgary, AB, Canada","Irritable bowel syndrome (IBS) is the most frequent functional gastrointestinal disorder. It is characterized by abdominal hypersensitivity, leading to discomfort and pain, as well as altered bowel habits. While it is common for IBS to develop following the resolution of infectious gastroenteritis [then termed postinfectious IBS (PI-IBS)], the mechanisms remain incompletely understood. Giardia duodenalis is a cosmopolitan water-borne enteropathogen that causes intestinal malabsorption, diarrhea, and postinfectious complications. Cause-and-effect studies using a human enteropathogen to help investigate the mechanisms of PI-IBS are sorely lacking. In an attempt to establish causality between giardiasis and postinfectious visceral hypersensitivity, this study describes a new model of PI-IBS in neonatal rats infected with G. duodenalis. At 50 days postinfection with G. duodenalis (assemblage A or B), long after the parasite was cleared, rats developed visceral hypersensitivity to luminal balloon distension in the jejunum and rectum, activation of the nociceptive signaling pathway (increased c-fos expression), histological modifications (villus atrophy and crypt hyperplasia), and proliferation of mucosal intraepithelial lymphocytes and mast cells in the jejunum, but not in the rectum. G. duodenalis infection also disrupted the intestinal barrier, in vivo and in vitro, which in turn promoted the translocation of commensal bacteria. Giardia-induced bacterial paracellular translocation in vitro correlated with degradation of the tight junction proteins occludin and claudin-4. The extensive observations associated with gut hypersensitivity described here demonstrate that, indeed, in this new model of postgiardiasis IBS, alterations to the gut mucosa and c-fos are consistent with those associated with PI-IBS and, hence, offer avenues for new mechanistic research in the field. © 2016 the American Physiological Society.","Bacterial translocation; Irritable bowel syndrome; Tight junctions; Visceral hypersensitivity","Animals; Caco-2 Cells; Escherichia coli; Female; Gastrointestinal Microbiome; Giardiasis; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Male; Nociception; Rats; Rats, Sprague-Dawley; Tight Junction Proteins; Transcellular Cell Migration; claudin 4; occludin; protein c fos; tight junction protein; animal experiment; animal model; animal tissue; Article; bacterial translocation; CACO 2 cell line; cell proliferation; commensal; controlled study; Escherichia coli; female; Giardia intestinalis; giardiasis; histology; human; human cell; hyperplasia; hypersensitivity; immunocompetence; in vitro study; in vivo study; infection complication; internalization; intestine crypt; intestine distension; intestine flora; intestine mucosa; intestine villus atrophy; irritable colon; jejunum; lymphocyte; mast cell; monolayer culture; newborn; nociception; nonhuman; parasite clearance; permeability barrier; postinfectious visceral hypersensitivity; priority journal; protein expression; rat; rectum; signal transduction; spinal cord dorsal horn; trophozoite; animal; Caco-2 cell line; complication; intestine flora; Irritable Bowel Syndrome; male; metabolism; microbiology; parasitology; pathogenicity; pathology; physiology; Sprague Dawley rat; transcellular cell migration","","occludin, 176304-61-3; Tight Junction Proteins, ","","","Natural Sciences and Engineering Research Council of Canada, NSERC","These studies were funded by the Natural Sciences and Engineering Research Council of Canada (Discovery and CREATE grant programs) and the French-Canada Collaborative Research Program. M. C. M. Halliez was sponsored by a French National Research Scholarship.","Arebi N., Gurmany S., Bullas D., Hobson A., Stagg A., Kamm M., The psychoneuroimmunology of irritable bowel syndrome—an exploration of interactions between psychological, neurological and immunological observations, Aliment Pharmacol Ther, 28, pp. 830-840, (2008); Arevalo F., Aragon V., Montes P., Guzman E., Monge E., [Increase of intraepithelial lymphocytes in patients with irritable bowel syndrome], Rev Gastroenterol Perú, 31, pp. 315-318, (2011); Azpiroz F., Bouin M., Camilleri M., Mayer E.A., Poitras P., Serra J., Spiller R.C., Mechanisms of hypersensitivity in IBS and functional disorders, Neurogastroenterol Motil, 19, pp. 62-88, (2007); Balestra B., Vicini R., Cremon C., Zecchi L., Dothel G., Vasina V., de Giorgio R., Paccapelo A., Pastoris O., Stanghellini V., Corinaldesi R., de Ponti F., Tonini M., Barbara G., Colonic mucosal mediators from patients with irritable bowel syndrome excite enteric cholinergic motor neurons, Neurogastroenterol Motil, 24, (2012); Barbara G., Stanghellini V., de Giorgio R., Cremon C., Cottrell G.S., Santini D., Pasquinelli G., Morselli-Labate A.M., Grady E.F., Bunnett N.W., Collins S.M., Corinaldesi R., Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome, Gastroenterology, 126, pp. 693-702, (2004); Beatty J.K., Akierman S., Rioux K., Beck P., McKnight W., Feener T., Wallace J., Buret A., Gut microbiota biofilm disruptions by Giardia: Pathology in human enterocytes and germ-free mice (Abstract), FASEB J, 27, 131, (2013); Beatty J.K., Bhargava A., Buret A.G., Post-infectious irritable bowel syndrome: Mechanistic insights into chronic disturbances following enteric infection, World J Gastroenterol, 20, pp. 3976-3985, (2014); Benere E., van Assche T., van Ginneken C., Peulen O., Cos P., Maes L., Intestinal growth and pathology of Giardia duodenalis assemblage subtype AI, AII, B and, E in the Gerbil Model. Parasitology, 139, pp. 424-433, (2012); Bercik P., Wang L., Verdu E.F., Mao Y.K., Blennerhassett P., Khan W.I., Kean I., Tougas G., Collins S.M., Visceral hyperalgesia and intestinal dysmotility in a mouse model of postinfective gut dysfunction, Gastroenterology, 127, pp. 179-187, (2004); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Lecleire S., Antonietti M., Gourcerol G., Leroi A.M., Dechelotte P., Menard J.F., Ducrotte P., Coeffier M., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am J Gastroenterol, 106, pp. 2165-2173, (2011); Buret A., Denhollander N., Wallis P.M., Befus D., Olson M.E., Zoonotic potential of giardiasis in domestic ruminants, J Infect Dis, 162, pp. 231-237, (1990); Buret A., Gall D.G., Olson M.E., Effects of murine giardiasis on growth, intestinal morphology, and disaccharidase activity, J Parasitol, 76, pp. 403-409, (1990); Buret A., Gall D.G., Olson M.E., Growth, activities of enzymes in the small intestine, and ultrastructure of microvillous border in gerbils infected with Giardia duodenalis, Parasitol Res, 77, pp. 109-114, (1991); Buret A., Hardin J.A., Olson M.E., Gall D.G., Pathophysiology of small intestinal malabsorption in gerbils infected with Giardia lamblia, Gastroenterology, 103, pp. 506-513, (1992); Camilleri M., Lasch K., Zhou W., Irritable bowel syndrome: Methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome, Am J Physiol Gastrointest Liver Physiol, 303, pp. G775-G785, (2012); Cenac N., Rews C.N., Holzhausen M., Chapman K., Cottrell G., Rade-Gordon P., Steinhoff M., Barbara G., Beck P., Bunnett N.W., Sharkey K.A., Ferraz J.G., Shaffer E., Vergnolle N., Role for protease activity in visceral pain in irritable bowel syndrome, J Clin Invest, 117, pp. 636-647, (2007); Cevallos A., Carnaby S., James M., Farthing J.G., Small intestinal injury in a neonatal rat model of giardiasis is strain dependent, Gastroenterology, 109, pp. 766-773, (1995); Chen T.L., Chen S., Wu H.W., Lee T.C., Lu Y.Z., Wu L.L., Ni Y.H., Sun C.H., Yu W.H., Buret A.G., Yu L.C., Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice, Gut Pathog, 5, (2013); Clarke G., Quigley E.M., Cryan J.F., Dinan T.G., Irritable bowel syndrome: Towards biomarker identification, Trends Mol Med, 15, pp. 478-489, (2009); Coelho A.M., Fioramonti J., Bueno L., Systemic lipopolysaccharide influences rectal sensitivity in rats: Role of mast cells, cytokines, and vagus nerve, Am J Physiol Gastrointest Liver Physiol, 279, pp. G781-G790, (2000); Collins S.M., A role for the gut microbiota in IBS, Nat Rev Gastroenterol, 11, pp. 497-505, (2014); Costantini M., Sturniolo G.C., Zaninotto G., D'Inca R., Polo R., Naccarato R., Ancona E., Altered esophageal pain threshold in irritable bowel syndrome, Dig Dis Sci, 38, pp. 206-212, (1993); Cotton J.A., Beatty J.K., Buret A.G., Host parasite interactions and pathophysiology in Giardia infections, Int J Parasitol, 41, pp. 925-933, (2011); Diamond L.S., Harlow D.R., Cunnick C.C., A new medium for the axenic cultivation of Entamoeba histolytica and other Entamoeba, Trans R Soc Trop Med Hyg, 72, pp. 431-432, (1978); Evans P.R., Bennett E.J., Bak Y.T., Tennant C.C., Kellow J.E., Jejunal sensorimotor dysfunction in irritable bowel syndrome: Clinical and psychosocial features, Gastroenterology, 110, pp. 393-404, (1996); Evans P.R., Piesse C., Bak Y.T., Kellow J.E., Fructose-sorbitol malabsorption and symptom provocation in irritable bowel syndrome: Relationship to enteric hypersensitivity and dysmotility, Scand J Gastroenterol, 33, pp. 1158-1163, (1998); Fent J., Balazs L., Buzas G., Erasmus L.P., Holzl R., Kovacs A., Weisz J., Adam G., Colonic sensitivity in irritable bowel syndrome and normal subjects according to their hemispheric preference and cognitive style, Integr Physiol Behav Sci, 34, pp. 54-62, (1999); Gaykema R.P., Goehler L.E., Tilders F.J., Bol J.G., McGorry M., Fleshner M., Maier S.F., Watkins L.R., Bacterial endotoxin induces fos immunoreactivity in primary afferent neurons of the vagus nerve, Neuroimmunomodulation, 5, pp. 234-240, (1998); Geurden T., Geldhof P., Levecke B., Martens C., Berkvens D., Casaert S., Vercruysse J., Claerebout E., Mixed Giardia duodenalis assemblage A and, E Infections in Calves. Int J Parasitol, 38, pp. 259-264, (2008); Gibney S.M., Gosselin R.D., Dinan T.G., Cryan J.F., Colorectal distensioninduced prefrontal cortex activation in the Wistar-Kyoto rat: Implications for irritable bowel syndrome, Neuroscience, 165, pp. 675-683, (2010); Gillon J., Al Thamery D., Ferguson A., Features of small intestinal pathology (Epithelial cell kinetics, intraepithelial lymphocytes, disaccharidases) in a primary Giardia muris infection, Gut, 23, pp. 498-506, (1982); Goldstein R., Braverman D., Stankiewicz H., Carbohydrate malabsorption and the effect of dietary restriction on symptoms of irritable bowel syndrome and functional bowel complaints, Isr Med Assoc J, 2, pp. 583-587, (2000); Halliez M.C., Buret A.G., Extra-intestinal and long term consequences of Giardia duodenalis infections, World J Gastroenterol, 19, pp. 8974-8985, (2013); Halvorson H.A., Schlett C.D., Riddle M.S., Postinfectious irritable bowel syndrome—a meta-analysis, Am J Gastroenterol, 101, (2006); Hanevik K., Dizdar V., Langeland N., Hausken T., Development of functional gastrointestinal disorders after Giardia lamblia infection, BMC Gastroenterol, 9, (2009); Hanevik K., Wensaas K.A., Rortveit G., Eide G.E., Morch K., Langeland N., Irritable bowel syndrome and chronic fatigue 6 years after Giardia infection: A controlled prospective cohort study, Clin Infect Dis, 59, pp. 1394-1400, (2014); Hardin J.A., Buret A.G., Olson M.E., Kimm M.H., Gall D.G., Mast cell hyperplasia and increased macromolecular uptake in an animal model of giardiasis, J Parasitol, 83, pp. 908-912, (1997); Ibeakanma C., Ochoa-Cortes F., Miranda-Morales M., McDonald T., Spreadbury I., Cenac N., Cattaruzza F., Hurlbut D., Vanner S., Bunnett N., Vergnolle N., Vanner S., Brain-gut interactions increase peripheral nociceptive signaling in mice with postinfectious irritable bowel syndrome, Gastroenterology, 141, pp. 2098-2108, (2011); Jacobson K., McHugh K., Collins S., The mechanism of altered neural function in a rat model of acute colitis, Gastroenterology, 112, pp. 156-162, (1997); Jawed H., Jamall S., Shah S.U., Perveen K., Hanif F., Simjee S.U., N-(2-hydroxy phenyl) acetamide produces profound inhibition of c-Fos protein and mRNA expression in the brain of adjuvant-induced arthritic rats, Mol Cell Biochem, 387, pp. 81-90, (2014); Jones R., Lydeard S., Irritable bowel syndrome in the general population, BMJ, 304, pp. 87-90, (1992); Kalischuk L.D., Inglis G.D., Buret A.G., Campylobacter jejuni induces transcellular translocation of commensal bacteria via lipid rafts, Gut Pathog, 1, (2009); Kassinen A., Krogius-Kurikka L., Makivuokko H., Rinttila T., Paulin L., Corander J., Malinen E., Apajalahti J., Palva A., The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects, Gastroenterology, 133, pp. 24-33, (2007); Keister D.B., Axenic culture of Giardia lamblia in TYI-S-33 medium supplemented with bile, Trans R Soc Trop Med Hyg, 77, pp. 487-488, (1983); Kellow J.E., Phillips S.F., Miller L.J., Zinsmeister A.R., Dysmotility of the small intestine in irritable bowel syndrome, Gut, 29, pp. 1236-1243, (1988); Khaldi S., Gargala G., Le Goff L., Parey S., Francois A., Fioramonti J., Ballet J.J., Dupont J.P., Ducrotte P., Favennec L., Cryptosporidium parvum isolate-dependent postinfectious jejunal hypersensitivity and mast cell accumulation in an immunocompetent rat model, Infect Immun, 77, pp. 5163-5169, (2009); Levecke B., Geldhof P., Claerebout E., Dorny P., Vercammen F., Caccio S.M., Vercruysse J., Geurden T., Molecular characterisation of Giardia duodenalis in captive non-human primates reveals mixed assemblage A and B infections and novel polymorphisms, Int J Parasitol, 39, pp. 1595-1601, (2009); Levy D., Kainz V., Burstein R., Strassman A.M., Mast cell degranulation distinctly activates trigemino-cervical and lumbosacral pain pathways and elicits widespread tactile pain hypersensitivity, Brain Behav Immun, 26, pp. 311-317, (2012); Li E., Zhao A., Shea-Donohue T., Singer S.M., Mast cell-mediated changes in smooth muscle contractility during mouse giardiasis, Infect Immun, 75, pp. 4514-4518, (2007); Li W.M., Suzuki A., Cui K.M., Responses of blood pressure and renal sympathetic nerve activity to colorectal distension in anesthetized rats, J Physiol Sci, 56, pp. 153-156, (2006); Lovell R.M., Ford A.C., Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis, Clin Gastroenterol Hepatol, 10, pp. 712-721, (2012); Maia-Brigagao C., Morgado-Diaz J.A., de Souza W., Giardia disrupts the arrangement of tight, adherens and desmosomal junction proteins of intestinal cells, Parasitol Int, 61, pp. 280-287, (2012); Marshall J.K., Thabane M., Borgaonkar M.R., James C., Postinfectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attributed to a viral pathogen, Clin Gastroenterol Hepatol, 5, pp. 457-460, (2007); Marshall J.K., Thabane M., Garg A.X., Clark W.F., Moayyedi P., Collins S.M., Walkerton Health Study Investigators. Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery, Gut, 59, pp. 605-611, (2010); Marshall J.K., Thabane M., Garg A.X., Clark W.F., Salvadori M., Collins S.M., Walkerton Health Study Investigators. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery, Gastroenterology, 131, pp. 445-450, (2006); Martinez C., Vicario M., Ramos L., Lobo B., Mosquera J.L., Alonso C., Sanchez A., Guilarte M., Antolin M., de Torres I., Gonzalez-Castro A.M., Pigrau M., Saperas E., Azpiroz F., Santos J., The jejunum of diarrheapredominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations, Am J Gastroenterol, 107, pp. 736-746, (2012); McLean P.G., Picard C., Garcia-Villar R., More J., Fioramonti J., Bueno L., Effects of nematode infection on sensitivity to intestinal distension: Role of tachykinin NK2 receptors, Eur J Pharmacol, 337, pp. 279-282, (1997); Mearin F., Perez-Oliveras M., Perello A., Vinyet J., Ibanez A., Coderch J., Perona M., Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: One-year follow-up cohort study, Gastroenterology, 129, pp. 98-104, (2005); Meleine M., Matricon J., Gender-related differences in irritable bowel syndrome: Potential mechanisms of sex hormones, World J Gastroenterol, 20, pp. 6725-6743, (2014); Mertz H., Naliboff B., Munakata J., Niazi N., Mayer E.A., Altered rectal perception is a biological marker of patients with irritable bowel syndrome, Gastroenterology, 109, pp. 40-52, (1995); Morgan J.I., Curran T., Inducible proto-oncogenes of the nervous system: Their contribution to transcription factors and neuroplasticity, Prog Brain Res, 86, pp. 287-294, (1990); O'Leary C., Quigley E.M., Small bowel bacterial overgrowth, celiac disease, and IBS: What are the real associations?, Am J Gastroenterol, 98, pp. 720-722, (2003); Piche T., Barbara G., Aubert P., Bruley Des Varannes S., Dainese R., Nano J.L., Cremon C., Stanghellini V., de Giorgio R., Galmiche J.P., Neunlist M., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: Involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Png C.W., Linden S.K., Gilshenan K.S., Zoetendal E.G., McSweeney C.S., Sly L.I., McGuckin M.A., Florin T.H., Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria, Am J Gastroenterol, 105, pp. 2420-2428, (2010); Posserud I., Stotzer P.O., Bjornsson E.S., Abrahamsson H., Simren M., Small intestinal bacterial overgrowth in patients with irritable bowel syndrome, Gut, 56, pp. 802-808, (2007); Ritchie J., Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome, Gut, 14, pp. 125-132, (1973); Romero-Calvo I., Ocon B., Martinez-Moya P., Suarez M.D., Zarzuelo A., Martinez-Augustin O., de Medina F.S., Reversible Ponceau staining as a loading control alternative to actin in Western blots, Anal Biochem, 401, pp. 318-320, (2010); Roxstrom-Lindquist K., Palm D., Reiner D., Ringqvist E., Svard S.G., Giardia immunity—an update, Trends Parasitol, 22, pp. 26-31, (2006); Saleh T.M., Connell B.J., Allen G.V., Visceral afferent activation-induced changes in sympathetic nerve activity and baroreflex sensitivity, Am J Physiol Regul Integr Comp Physiol, 276, pp. R1780-R1791, (1999); Schmittgen T.D., Livak K.J., Analyzing real-time PCR data by the comparative CT method, Nat Protoc, 3, pp. 1101-1108, (2008); Scott K.G., Meddings J.B., Kirk D.R., Lees-Miller S.P., Buret A.G., Intestinal infection with Giardia spp. Reduces epithelial barrier function in a myosin light chain kinase-dependent fashion, Gastroenterology, 123, pp. 1179-1190, (2002); Sekirov I., Russell S.L., Antunes L.C., Finlay B.B., Gut microbiota in health and disease, Physiol Rev, 90, pp. 859-904, (2010); Sohn W., Lee O.Y., Lee S.P., Lee K.N., Jun D.W., Lee H.L., Yoon B.C., Choi H.S., Sim J., Jang K.S., Mast cell number, substance P and vasoactive intestinal peptide in irritable bowel syndrome with diarrhea, Scand J Gastroenterol, 49, pp. 43-51, (2014); Sundin J., Rangel I., Kumawat A.K., Hultgren-Hornquist E., Brummer R.J., Aberrant mucosal lymphocyte number and subsets in the colon of post-infectious irritable bowel syndrome patients, Scand J Gastroenterol, 49, pp. 1068-1075, (2014); Teoh D.A., Kamieniecki D., Pang G., Buret A.G., Giardia lamblia rearranges F-actin and α-actinin in human colonic and duodenal monolayers and reduces transepithelial electrical resistance, J Parasitol, 86, pp. 800-806, (2000); Thabane M., Kottachchi D.T., Marshall J.K., Systematic review and meta-analysis: The incidence and prognosis of post-infectious irritable bowel syndrome, Aliment Pharmacol Ther, 26, pp. 535-544, (2007); Thabane M., Simunovic M., Akhtar-Danesh N., Garg A.X., Clark W.F., Collins S.M., Salvadori M., Marshall J.K., An outbreak of acute bacterial gastroenteritis is associated with an increased incidence of irritable bowel syndrome in children, Am J Gastroenterol, 105, pp. 933-939, (2010); Walker M.M., Talley N.J., Prabhakar M., Pennaneac'H C.J., Aro P., Ronkainen J., Storskrubb T., Harmsen W.S., Zinsmeister A.R., Agreus L., Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia, Aliment Pharmacol Ther, 29, pp. 765-773, (2009); Wang B., Glatzle J., Mueller M.H., Kreis M., Enck P., Grundy D., Lipopolysaccharide-induced changes in mesenteric afferent sensitivity of rat jejunum in vitro: Role of prostaglandins, Am J Physiol Gastrointest Liver Physiol, 289, pp. G254-G260, (2005); Willot S., Gauthier C., Patey N., Faure C., Nerve growth factor content is increased in the rectal mucosa of children with diarrhea-predominant irritable bowel syndrome, Neurogastroenterol Motil 24, 734-739, (2012); Guidelines for Drinking-Water Quality — Volume 1: Recommendations, (2008); Zhang R., Zou N., Li J., Lv H., Wei J., Fang X.C., Qian J.M., Elevated expression of c-fos in central nervous system correlates with visceral hypersensitivity in irritable bowel syndrome (IBS): A new target for IBS treatment, Int J Colorectal Dis, 26, pp. 1035-1044, (2011)","A.G. Buret; Dept. of Biological Sciences, Inflammation Research Network, Univ. of Calgary, Calgary, 2500 Univ. Dr. NW, T2N 1N4, Canada; email: aburet@ucalgary.ca","","American Physiological Society","","","","","","01931857","","APGPD","26744469","English","Am. J. Physiol. Gastrointest. Liver Physiol.","Article","Final","All Open Access; Bronze Open Access; Green Open Access","Scopus","2-s2.0-84983802563"

"Pereira M.T.; Malik M.; Nostro J.A.; Mahler G.J.; Musselman L.P.","Pereira, Matthew T. (57205378239); Malik, Mridu (57205380237); Nostro, Jillian A. (57205379350); Mahler, Gretchen J. (24544410300); Musselman, Laura Palanker (54584141300)","57205378239; 57205380237; 57205379350; 24544410300; 54584141300","Effect of dietary additives on intestinal permeability in both Drosophila and a human cell co-culture","2018","DMM Disease Models and Mechanisms","11","12","dmm034520","","","","32","10.1242/dmm.034520","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85059811172&doi=10.1242%2fdmm.034520&partnerID=40&md5=46405a89180361ded4a18245b90c2f78","Department of Biological Sciences, Binghamton University, Binghamton, 13902, NY, United States; Department of Biomedical Engineering, Binghamton University, Binghamton, 13902, NY, United States","Pereira M.T., Department of Biological Sciences, Binghamton University, Binghamton, 13902, NY, United States; Malik M., Department of Biomedical Engineering, Binghamton University, Binghamton, 13902, NY, United States; Nostro J.A., Department of Biological Sciences, Binghamton University, Binghamton, 13902, NY, United States; Mahler G.J., Department of Biomedical Engineering, Binghamton University, Binghamton, 13902, NY, United States; Musselman L.P., Department of Biological Sciences, Binghamton University, Binghamton, 13902, NY, United States","Increased intestinal barrier permeability has been correlated with aging and disease, including type 2 diabetes, Crohn’s disease, celiac disease, multiple sclerosis and irritable bowel syndrome. The prevalence of these ailments has risen together with an increase in industrial food processing and food additive consumption. Additives, including sugar, metal oxide nanoparticles, surfactants and sodium chloride, have all been suggested to increase intestinal permeability. We used two complementary model systems to examine the effects of food additives on gut barrier function: a Drosophila in vivo model and an in vitro human cell co-culture model. Of the additives tested, intestinal permeability was increased most dramatically by high sugar. High sugar also increased feeding but reduced gut and overall animal size. We also examined how food additives affected the activity of a gut mucosal defense factor, intestinal alkaline phosphatase (IAP), which fluctuates with bacterial load and affects intestinal permeability. We found that high sugar reduced IAP activity in both models. Artificial manipulation of the microbiome influenced gut permeability in both models, revealing a complex relationship between the two. This study extends previous work in flies and humans showing that diet can play a role in the health of the gut barrier. Moreover, simple models can be used to study mechanisms underlying the effects of diet on gut permeability and function. © 2018. Published by The Company of Biologists Ltd.","Alkaline phosphatase; Drosophila; Gut barrier function; Intestinal permeability","Alkaline Phosphatase; Animals; Cell Line; Coculture Techniques; Diet; Dietary Sugars; Drosophila melanogaster; Drosophila Proteins; Food Additives; Humans; Intestines; Microbiota; Permeability; Phenotype; Polysorbates; Sodium Chloride, Dietary; Sugars; Ubiquitin-Protein Ligases; alkaline phosphatase; food additive; alkaline phosphatase; carbohydrate; Drosophila protein; food additive; polysorbate; Smurf protein, Drosophila; ubiquitin protein ligase; animal tissue; Article; bacterial load; Caco-2 cell line; coculture; controlled study; Drosophila; human; human cell; human cell culture; intestine flora; intestine mucosa permeability; nonhuman; priority journal; animal; cell line; coculture; cytology; diet; Drosophila melanogaster; drug effect; intestine; metabolism; microbiology; microflora; permeability; pharmacology; phenotype; salt intake; sugar intake","","alkaline phosphatase, 9001-78-9; polysorbate, 9005-63-4; ubiquitin protein ligase, 134549-57-8; Alkaline Phosphatase, ; Dietary Sugars, ; Drosophila Proteins, ; Food Additives, ; Polysorbates, ; Smurf protein, Drosophila, ; Sodium Chloride, Dietary, ; Sugars, ; Ubiquitin-Protein Ligases, ","","","National Institutes of Health, NIH; National Institute of Environmental Health Sciences, NIEHS, (R15ES022828); State University of New York, SUNY","We thank Thécla Lesuffleur for the HT29-MTX intestinal epithelial cell line, the Vienna Drosophila Resource Center for the flies, and Paul Pereira for technical support. Funding for this work was provided by the National Institutes of Health (1R15 ES022828) and the Research Foundation of the State University of New York through a Transdisciplinary Area of Excellence Award.","Akiba Y., Mizumori M., Guth P.H., Engel E., Kaunitz J.D., Duodenal brush border intestinal alkaline phosphatase activity affects bicarbonate secretion in rats, Am. J. Physiol. Gastrointest. Liver Physiol., 293, pp. G1223-G1233, (2007); Al-Saraf A., Holm R., Nielsen C.U., Tween 20 increases intestinal transport of doxorubicin in vitro but not in vivo, Int. J. Pharm., 498, pp. 66-69, (2016); Arrieta M.C., Bistritz L., Meddings J.B., Alterations in intestinal permeability, Gut, 55, pp. 1512-1520, (2006); Bamba T., Vaja S., Murphy G.M., Dowling R.H., Effect of fasting and feeding on polyamines and related enzymes along the villus: Crypt axis, Digestion, 46, pp. 424-429, (1990); Barone S., Fussell S.L., Singh A.K., Lucas F., Xu J., Kim C., Wu X., Yu Y., Amlal H., Seidler U., Et al., Slc2a5 (Glut5) is essential for the absorption of fructose in the intestine and generation of fructose-induced hypertension, J. Biol. Chem., 284, pp. 5056-5066, (2009); Bettini S., Boutet-Robinet E., Cartier C., Comera C., Gaultier E., Dupuy J., Naud N., Tache S., Grysan P., Reguer S., Et al., Food-grade TiO2 impairs intestinal and systemic immune homeostasis, initiates preneoplastic lesions and promotes aberrant crypt development in the rat colon, Sci. Rep., 7, (2017); Beumer C., Wulferink M., Raaben W., Fiechter D., Brands R., Seinen W., Calf intestinal alkaline phosphatase, a novel therapeutic drug for lipopolysaccharide (LPS)-mediated diseases, attenuates LPS toxicity in mice and piglets, J. Pharmacol. Exp. Ther., 307, (2003); Biteau B., Hochmuth C.E., Jasper H., JNK activity in somatic stem cells causes loss of tissue homeostasis in the aging drosophila gut, Cell Stem Cell, 3, pp. 442-455, (2008); Brummel T., Ching A., Seroude L., Simon A.F., Benzer S., Drosophila lifespan enhancement by exogenous bacteria, Proc. Natl. Acad. Sci. USA, 101, pp. 12974-12979, (2004); Brun E., Barreau F., Veronesi G., Fayard B., Sorieul S., Chaneac C., Carapito C., Rabilloud T., Mabondzo A., Herlin-Boime N., Et al., Titanium dioxide nanoparticle impact and translocation through ex vivo, in vivo and in vitro gut epithelia, Part. Fibre Toxicol., 11, (2014); Buchon N., Osman D., All for one and one for all: Regionalization of the Drosophila intestine, Insect Biochem. Mol. Biol., 67, pp. 2-8, (2015); Cheng J., Palva A.M., De Vos W.M., Satokari R., Contribution of the intestinal microbiota to human health: From birth to 100 years of age, Curr. Top. Microbiol. Immunol., 358, pp. 323-346, (2013); Chiba H., Osanai M., Murata M., Kojima T., Sawada N., Transmembrane proteins of tight junctions, Biochim. Biophys. Acta, 1778, pp. 588-600, (2007); Choi N.-H., Kim J.-G., Yang D.-J., Kim Y.-S., Yoo M.-A., Age-related changes in Drosophila midgut are associated with PVF2, a PDGF/VEGF-like growth factor, Aging Cell, 7, pp. 318-334, (2008); Chung H.Y., Cesari M., Anton S., Marzetti E., Giovannini S., Seo A.Y., Carter C., Yu B.P., Leeuwenburgh C., Molecular inflammation: Underpinnings of aging and age-related diseases, Ageing Res. Rev., 8, pp. 18-30, (2009); Clark R.I., Salazar A., Yamada R., Fitz-Gibbon S., Morselli M., Alcaraz J., Rana A., Rera M., Pellegrini M., Ja W.W., Et al., Distinct shifts in microbiota composition during drosophila aging impair intestinal function and drive mortality, Cell Rep, 12, pp. 1656-1667, (2015); Dambroise E., Monnier L., Ruisheng L., Aguilaniu H., Joly J.-S., Tricoire H., Rera M., Two phases of aging separated by the Smurf transition as a public path to death, Nat. Publ. Gr., 6, (2016); Das S., Chaudhury A., Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery, AAPS PharmSciTech, 12, pp. 62-76, (2011); De Lisle R.C., Mueller R., Boyd M., Impaired mucosal barrier function in the small intestine of the cystic fibrosis mouse, J. Pediatr. Gastroenterol. Nutr., 53, pp. 371-379, (2011); DeSesso J.M., Jacobson C.F., Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats, Food Chem. Toxicol., 39, pp. 209-228, (2001); Deshpande G., Mapanga R.F., Essop M.F., Frequent sugar-sweetened beverage consumption and the onset of cardiometabolic diseases: Cause for concern?, J. Endocr. Soc., 1, pp. 1372-1385, (2017); D'Souza V.M., Shertzer H.G., Menon A.G., Pauletti G.M., High glucose concentration in isotonic media alters Caco-2 cell permeability, AAPS PharmSci, 5, pp. 17-25, (2003); Dus M., Ai M., Suh G.S.B., Taste-independent nutrient selection is mediated by a brain-specific Na+ /solute co-transporter in Drosophila, Nat. Neurosci., 16, pp. 526-528, (2013); Economopoulos K.P., Ward N.L., Phillips C.D., Teshager A., Patel P., Mohamed M.M., Hakimian S., Cox S.B., Ahmed R., Moaven O., Et al., Prevention of antibiotic-associated metabolic syndrome in mice by intestinal alkaline phosphatase, Diabetes Obes. Metab., 18, pp. 519-527, (2016); Eliakim R., DeSchryver-Kecskemeti K., Nogee L., Stenson W.F., Alpers D.H., Isolation and characterization of a small intestinal surfactant-like particle containing alkaline phosphatase and other digestive enzymes, J. Biol. Chem., 264, pp. 20614-20619, (1989); Engle M.J., Mahmood A., Alpers D.H., Regulation of surfactant-like particle secretion by Caco-2 cells, Biochim. Biophys. Acta Biomembr., 1511, pp. 369-380, (2001); Farhadi A., Banan A., Fields J., Keshavarzian A., Intestinal barrier: An interface between health and disease, J. Gastroenterol. Hepatol., 18, pp. 479-497, (2003); Fasano A., Shea-Donohue T., Mechanisms of disease: The role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases, Nat. Clin. Pract. Gastroenterol. Hepatol., 2, pp. 416-422, (2005); Faust J.J., Doudrick K., Yang Y., Westerhoff P., Capco D.G., Food grade titanium dioxide disrupts intestinal brush border microvilli in vitro independent of sedimentation, Cell Biol. Toxicol., 30, pp. 169-188, (2014); Fihn B.M., Sjoqvist A., Jodal M., Permeability of the rat small intestinal epithelium along the villus-crypt axis: Effects of glucose transport, Gastroenterology, 119, pp. 1029-1036, (2000); Francavilla R., Miniello V., Magista A.M., De Canio A., Bucci N., Gagliardi F., Lionetti E., Castellaneta S., Polimeno L., Peccarisi L., Et al., A randomized controlled trial of lactobacillus GG in children with functional abdominal pain, Pediatrics, 126, pp. e1445-e1452, (2010); Glahn R.P., Lee O.A., Yeung A., Goldman M.I., Miller D.D., Caco-2 cell ferritin formation predicts nonradiolabeled food iron availability in an in vitro digestion/Caco-2 cell culture model, J. Nutr., 128, pp. 1555-1561, (1998); Goldberg R.F., Austen W.G., Zhang X., Munene G., Mostafa G., Biswas S., McCormack M., Eberlin K.R., Nguyen J.T., Tatlidede H.S., Et al., Intestinal alkaline phosphatase is a gut mucosal defense factor maintained by enteral nutrition, Proc. Natl. Acad. Sci. USA, 105, pp. 3551-3556, (2008); Gouyon F., Caillaud L., Carriere V., Klein C., Dalet V., Citadelle D., Kellett G.L., Thorens B., Leturque A., Brot-Laroche E., Simple-sugar meals target GLUT2 at enterocyte apical membranes to improve sugar absorption: A study in GLUT2-null mice, J. Physiol., 552, pp. 823-832, (2003); Guan G., Wang H., Chen S., Liu G., Xiong X., Tan B., Duraipandiyan V., Al-Dhabi N.A., Fang J., Dietary chitosan supplementation increases microbial diversity and attenuates the severity of citrobacter rodentium infection in mice, Mediators Inflamm, 2016, (2016); Guo Z., Martucci N.J., Moreno-Olivas F., Tako E., Mahler G.J., Titanium dioxide nanoparticle ingestion alters nutrient absorption in an in vitro model of the small intestine, NanoImpact, 5, pp. 70-82, (2017); Guo Z., Martucci N.J., Liu Y., Yoo E., Tako E., Mahler G.J., Silicon dioxide nanoparticle exposure affects small intestine function in an in vitro model, Nanotoxicology, 12, pp. 485-508, (2018); Guthmann F., Maehl P., Preiss J., Kolleck I., Rustow B., Ectoprotein kinase-mediated phosphorylation of FAT/CD36 regulates palmitate uptake by human platelets, Cell. Mol. Life Sci., 59, pp. 1999-2003, (2002); Hamid K.A., Katsumi H., Sakane T., Yamamoto A., The effects of common solubilizing agents on the intestinal membrane barrier functions and membrane toxicity in rats, Int. J. Pharm., 379, pp. 100-108, (2009); Han G., Lee H.J., Jeong S.E., Jeon C.O., Hyun S., Comparative analysis of Drosophila Melanogaster gut microbiota with respect to host strain, sex, and age, Microb. Ecol., 74, pp. 207-216, (2017); Hansen G.H., Niels-Christiansen L.-L., Immerdal L., Nystrom B.T., Danielsen E.M., Intestinal alkaline phosphatase: Selective endocytosis from the enterocyte brush border during fat absorption, AJP Gastrointest. Liver Physiol., 293, pp. G1325-G1332, (2007); Harris C.E., Griffiths R.D., Freestone N., Billington D., Atherton S.T., Macmillan R.R., Intestinal permeability in the critically ill, Intensive Care Med, 18, pp. 38-41, (1992); Hidalgo I.J., Raub T.J., Borchardt R.T., Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability, Gastroenterology, 96, pp. 736-749, (1989); Hopfer U., Nelson K., Perrotto J., Isselbacher K.J., Glucose transport in isolated brush border membrane from rat small intestine, J. Biol. Chem., 248, pp. 25-32, (1973); Huygelen V., De Vos M., Willemen S., Fransen E., Casteleyn C., Van Cruchten S., Van Ginneken C., Age-related differences in mucosal barrier function and morphology of the small intestine in low and normal birth weight piglets, J. Anim. Sci., 92, pp. 3398-3406, (2014); Izumi Y., Furuse M., Molecular organization and function of invertebrate occluding junctions, Semin. Cell Dev. Biol., 36, pp. 186-193, (2014); Jang I., Jung K., Cho J., Influence of age on duodenal brush border membrane and specific activities of brush border membrane enzymes in wistar rats, Exp. Anim, 49, pp. 281-287, (2000); Jonusaite S., Donini A., Kelly S.P., Occluding junctions of invertebrate epithelia, J. Comp. Physiol. B, 186, pp. 17-43, (2016); Kabeerdoss J., Shobana Devi R., Regina Mary R., Ramakrishna B.S., Faecal microbiota composition in vegetarians: Comparison with omnivores in a cohort of young women in southern India, Br. J. Nutr., 108, pp. 953-957, (2012); Kaliannan K., Hamarneh S.R., Economopoulos K.P., Nasrin Alam S., Moaven O., Patel P., Malo N.S., Ray M., Abtahi S.M., Muhammad N., Et al., Intestinal alkaline phosphatase prevents metabolic syndrome in mice, Proc. Natl. Acad. Sci. USA, 110, pp. 7003-7008, (2013); Kang M.J., Kim H.S., Jeon H.S., Park J.H., Lee B.S., Ahn B.K., Moon K.Y., Choi Y.W., In situ intestinal permeability and in vivo absorption characteristics of olmesartan medoxomil in self-microemulsifying drug delivery system, Drug Dev. Ind. Pharm., 38, pp. 587-596, (2012); Katz D., Hollander D., Said H.M., Dadufalza V., Aging-associated increase in intestinal permeability to polyethylene glycol 900, Dig. Dis. Sci., 32, pp. 285-288, (1987); Katzenberger R.J., Chtarbanova S., Rimkus S.A., Fischer J.A., Kaur G., Seppala J.M., Swanson L.C., Zajac J.E., Ganetzky B., Wassarman D.A., Death following traumatic brain injury in Drosophila is associated with intestinal barrier dysfunction, Elife, 4, (2015); Kayanos T., Burants C.F., Fukumotoq H., Gouldll G.W., Fanll Y.-S., Eddy R.L., Byersii M.G., Shows T.B., Seinos S., Bell G.I., Human facilitative glucose transporters. Isolation, functional characterization, and gene localization of cDNAs encoding an isoform (GLUT5) expressed in small intestine, kidney, muscle, and adipose tissue and an unusual glucose transporter pseudogene-like, J. Biol. Chem., 265, pp. 13276-13282, (1990); Kellett G.L., Brot-Laroche E., Apical GLUT2: A major pathway of intestinal sugar absorption, Diabetes, 54, pp. 3056-3062, (2005); Kirkwood T.B.L., Intrinsic ageing of gut epithelial stem cells, Mech. Ageing Dev., 125, pp. 911-915, (2004); Kuraishi T., Binggeli O., Opota O., Buchon N., Lemaitre B., Genetic evidence for a protective role of the peritrophic matrix against intestinal bacterial infection in Drosophila melanogaster, Proc. Natl. Acad. Sci. USA, 108, pp. 15966-15971, (2011); Landis G.N., Abdueva D., Skvortsov D., Yang J., Rabin B.E., Carrick J., Tavare S., Tower J., Similar gene expression patterns characterize aging and oxidative stress in Drosophila melanogaster, Proc. Natl. Acad. Sci. USA, 101, pp. 7663-7668, (2004); Lane E.R., Zisman T.L., Suskind D.L., The microbiota in inflammatory bowel disease: Current and therapeutic insights, J. Inflamm. Res., 10, pp. 63-73, (2017); Lesuffleur T., Barbat A., Dussaulx E., Zweibaum A., Growth adaptation to methotrexate of HT-29 human colon carcinoma cells is associated with their ability to differentiate into columnar absorptive and mucus-secreting cells, Cancer Res, 50, pp. 6334-6343, (1990); Lesuffleur T., Roche F., Hill A.S., Lacasa M., Fox M., Swallow D.M., Zweibaum A., Real F.X., Characterization of a mucin cDNA clone isolated from HT-29 mucus-secreting cells. The 3’ end of MUC5AC?, J. Biol. Chem., 270, pp. 13665-13673, (1995); Liu W., Hu D., Huo H., Zhang W., Adiliaghdam F., Morrison S., Ramirez J.M., Gul S.S., Hamarneh S.R., Hodin R.A., Intestinal alkaline phosphatase regulates tight junction protein levels, J. Am. Coll. Surg., 222, pp. 1009-1017, (2016); Lo Y., Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines, J. Control. Release, 90, pp. 37-48, (2003); Loo Y., Grigsby C.L., Yamanaka Y.J., Chellappan M.K., Jiang X., Mao H.-Q., Leong K.W., Comparative study of nanoparticle-mediated transfection in different GI epithelium co-culture models, J. Control. Release, 160, pp. 48-56, (2012); Lopez-Otin C., Blasco M.A., Partridge L., Serrano M., Kroemer G., The hallmarks of aging Europe PMC funders group, Cell June, 6, pp. 1194-121705, (2013); Lushchak V.I., Dissection of the hormetic curve: Analysis of components and mechanisms, Dose-Response, 12, pp. 466-479, (2014); Lusis A.J., Attie A.D., Reue K., Metabolic syndrome: From epidemiology to systems biology, Nat. Rev. Genet., 9, pp. 819-830, (2008); Lv L.-Z., Tong C.-Q., Yu J., Han M., Gao J.-Q., Mechanism of enhanced oral absorption of hydrophilic drug incorporated in hydrophobic nanoparticles, Int. J. Nanomedicine, 8, pp. 2709-2717, (2013); Ma T.Y., Anderson J.M., Tight junctions and the intestinal barrier, Physiology of The Gastrointestinal Tract, pp. 1559-1594, (2006); MacMillan H.A., Yerushalmi G.Y., Jonusaite S., Kelly S.P., Donini A., Thermal acclimation mitigates cold-induced paracellular leak from the Drosophila gut, Sci. Rep., 7, (2017); Madara J.L., Carlson S., Supraphysiologic L-tryptophan elicits cytoskeletal and macromolecular permeability alterations in hamster small intestinal epithelium in vitro, J. Clin. Invest., 87, pp. 454-462, (1991); Madara J.L., Pappenheimer J.R., Structural basis for physiological regulation of paracellular pathways in intestinal epithelia, J. Membr. Biol., 100, pp. 149-164, (1987); Madara J.L., Moore R., Carlson S., Alteration of intestinal tight junction structure and permeability by cytoskeletal contraction, Am. J. Physiol., 253, pp. C854-C861, (1987); Madara J.L., Carlson S., Anderson J.M., ZO-1 maintains its spatial distribution but dissociates from junctional fibrils during tight junction regulation, Am. J. Physiol., 264, pp. C1096-C1101, (1993); Mahler G.J., Shuler M.L., Glahn R.P., Characterization of Caco-2 and HT29-MTX cocultures in an in vitro digestion/cell culture model used to predict iron bioavailability, J. Nutr. Biochem., 20, pp. 494-502, (2009); Mahler G.J., Esch M.B., Tako E., Southard T.L., Archer S.D., Glahn R.P., Shuler M.L., Oral exposure to polystyrene nanoparticles affects iron absorption, Nat. Nanotechnol., 7, pp. 264-271, (2012); Manzel A., Muller D.N., Hafler D.A., Erdman S.E., Linker R.A., Kleinewietfeld M., Role of “Western Diet” in inflammatory autoimmune diseases, Curr. Allergy Asthma Rep., 14, (2014); Matijasic B.B., Obermajer T., Lipoglavsek L., Grabnar I., Avgustin G., Rogelj I., Association of dietary type with fecal microbiota in vegetarians and omnivores in Slovenia, Eur. J. Nutr., 53, pp. 1051-1064, (2014); Micchelli C.A., Perrimon N., Evidence that stem cells reside in the adult Drosophila midgut epithelium, Nature, 439, pp. 475-479, (2006); Mine Y., Zhang J.W., Surfactants enhance the tight-junction permeability of food allergens in human intestinal epithelial Caco-2 cells, Int. Arch. Allergy Immunol., 130, pp. 135-142, (2003); Mizumori M., Ham M., Guth P.H., Engel E., Kaunitz J.D., Akiba Y., Intestinal alkaline phosphatase regulates protective surface microclimate pH in rat duodenum, J. Physiol., 587, pp. 3651-3663, (2009); Molnar K., Vannay A., Sziksz E., Banki N.F., Gyo rffy H., Arato A., Dezso fi A., Veres G., Decreased mucosal expression of intestinal alkaline phosphatase in children with coeliac disease, Virchows Arch, 460, pp. 157-161, (2012); Montoya C.A., Leterme P., Lalles J.-P., A protein-free diet alters small intestinal architecture and digestive enzyme activities in rats, Reprod. Nutr. Dev., 46, pp. 49-56, (2006); Morley J.E., Decreased food intake with aging, J. Gerontol. Ser. A Biol. Sci. Med. Sci., 56, pp. 81-88, (2001); Morris S.N.S., Coogan C., Chamseddin K., Fernandez-Kim S.O., Kolli S., Keller J.N., Bauer J.H., Development of diet-induced insulin resistance in adult Drosophila melanogaster, Biochim. Biophys. Acta. Mol. Basis Dis., 1822, pp. 1230-1237, (2012); Moskalev A., Shaposhnikov M., Proshkina E., Belyi A., Fedintsev A., Zhikrivetskaya S., Guvatova Z., Sadritdinova A., Snezhkina A., Krasnov G., Et al., The influence of pro-longevity gene Gclc overexpression on the age-dependent changes in Drosophila transcriptome and biological functions, BMC Genomics, 17, (2016); Musselman L.P., Fink J.L., Narzinski K., Ramachandran P.V., Hathiramani S.S., Cagan R.L., Baranski T.J., A high-sugar diet produces obesity and insulin resistance in wild-type Drosophila, Dis. Model. Mech., 4, pp. 842-849, (2011); Na J., Musselman L.P., Pendse J., Baranski T.J., Bodmer R., Ocorr K., Cagan R., A drosophila model of high sugar diet-induced cardiomyopathy, PLoS Genet, 9, (2013); Narisawa S., Huang L., Iwasaki A., Hasegawa H., Alpers D.H., Millan J.L., Accelerated fat absorption in intestinal alkaline phosphatase knockout mice, Mol. Cell. Biol., 23, pp. 7525-7530, (2003); Narisawa S., Hoylaerts M.F., Doctor K.S., Fukuda M.N., Alpers D.H., Millan J.L., A novel phosphatase upregulated in Akp3 knockout mice, Am. J. Physiol. Gastrointest. Liver Physiol., 293, pp. G1068-G1077, (2007); Nusrat A., Turner J.R., Madara J.L., Molecular physiology and pathophysiology of tight junctions. IV. Regulation of tight junctions by extracellular stimuli: Nutrients, cytokines, and immune cells, Am. J. Physiol. Gastrointest. Liver Physiol., 279, pp. G851-G857, (2000); O'Flaherty S., Klaenhammer T.R., Influence of exposure time on gene expression by human intestinal epithelial cells exposed to Lactobacillus acidophilus, Appl. Environ. Microbiol., 78, pp. 5028-5032, (2012); Pappenheimer J.R., Physiological regulation of transepithelial impedance in the intestinal mucosa of rats and hamsters, J. Membr. Biol., 100, pp. 137-148, (1987); Pappenheimer J.R., Reiss K.Z., Contribution of solvent drag through intercellular junctions to absorption of nutrients by the small intestine of the rat, J. Membr. Biol., 100, pp. 123-136, (1987); Pappenheimer J.R., Volpp K., Transmucosal impedance of small intestine: Correlation with transport of sugars and amino acids, Am. J. Physiol., 263, pp. C480-C493, (1992); Park J.-S., Kim Y.-S., Yoo M.-A., The role of p38b MAPK in age-related modulation of intestinal stem cell proliferation and differentiation in Drosophila, Aging (Albany. NY), 1, pp. 637-651, (2009); Pletcher S.D., Macdonald S.J., Marguerie R., Certa U., Stearns S.C., Goldstein D.B., Partridge L., Genome-wide transcript profiles in aging and calorically restricted Drosophila melanogaster, Curr. Biol., 12, pp. 712-723, (2002); Poelstra K., Bakker W.W., Klok P.A., Kamps J.A.A.M., Hardonk M.J., Meijer D.K.F., Dephosphorylation of endotoxin by alkaline phosphatase in vivo, Am. J. Pathol., 151, pp. 1163-1169, (1997); Pueyo J.I., Magny E.G., Sampson C.J., Amin U., Evans I.R., Bishop S.A., Couso J.P., Hemotin, a regulator of phagocytosis encoded by a small ORF and conserved across metazoans, PLoS Biol, 14, (2016); Rapin J.R., Wiernsperger N., Possible links between intestinal permeability and food processing: A potential therapeutic niche for glutamine, Clinics, 65, pp. 635-643, (2010); Regan J.C., Khericha M., Dobson A.J., Bolukbasi E., Rattanavirotkul N., Partridge L., Sex difference in pathology of the ageing gut mediates the greater response of female lifespan to dietary restriction, Elife, 5, (2016); Ren C., Webster P., Finkel S.E., Tower J., Increased internal and external bacterial load during drosophila aging without life-span trade-off, Cell Metab, 6, pp. 144-152, (2007); Rera M., Bahadorani S., Cho J., Koehler C.L., Ulgherait M., Hur J.H., Ansari W.S., Lo T., Jones D.L., Walker D.W., Modulation of longevity and tissue homeostasis by the drosophila PGC-1 homolog, Cell Metab, 14, pp. 623-634, (2011); Rera M., Clark R.I., Walker D.W., Intestinal barrier dysfunction links metabolic and inflammatory markers of aging to death in Drosophila, Proc. Natl. Acad. Sci. USA, 109, pp. 21528-21533, (2012); Richter J.W., Shull G.M., Fountain J.H., Guo Z., Musselman L.P., Fiumera A.C., Mahler G.J., Titanium dioxide nanoparticle exposure alters metabolic homeostasis in a cell culture model of the intestinal epithelium and drosophila melanogaster, Nanotoxicology, 12, pp. 390-406, (2018); Roder P.V., Geillinger K.E., Zietek T.S., Thorens B., Koepsell H., Daniel H., The role of SGLT1 and GLUT2 in intestinal glucose transport and sensing, PLoS ONE, 9, (2014); Liu R., Drug delivery applications, Water-Insoluble Drug Formulation, pp. 293-295, (2008); Round J.L., Mazmanian S.K., The gut microbiota shapes intestinal immune responses during health and disease, Nat. Rev. Immunol., 9, pp. 313-323, (2009); Sadowski D.C., Meddings J.B., Luminal nutrients alter tight-junction permeability in the rat jejunum: An in vivo perfusion model, Can. J. Physiol. Pharmacol., 71, pp. 835-839, (1993); Sandek A., Rauchhaus M., Anker S.D., Von Haehling S., The emerging role of the gut in chronic heart failure, Curr. Opin. Clin. Nutr. Metab. Care, 11, pp. 632-639, (2008); Saremi S., Dinarvand R., Kebriaeezadeh A., Ostad S.N., Atyabi F., Enhanced oral delivery of docetaxel using thiolated chitosan nanoparticles: Preparation, in vitro and in vivo studies, Biomed Res. Int., 2013, (2013); Selmi C., The worldwide gradient of autoimmune conditions, Autoimmun. Rev., 9, pp. A247-A250, (2010); Sha X., Yan G., Wu Y., Li J., Fang X., Effect of self-microemulsifying drug delivery systems containing Labrasol on tight junctions in Caco-2 cells, Eur. J. Pharm. Sci., 24, pp. 477-486, (2005); Shanbhag S., Tripathi S., Electrogenic H+ transport and pH gradients generated by a V-H+-ATPase in the isolated perfused larval drosophila midgut, J. Membr. Biol., 206, pp. 61-72, (2005); Singh G.M., Micha R., Khatibzadeh S., Lim S., Ezzati M., Mozaffarian D., Estimated global, regional, and national disease burdens related to sugar-sweetened beverage consumption in 2010CLINICAL PERSPECTIVE, Circulation, 132, pp. 639-666, (2015); Sogabe N., Mizoi L., Asahi K., Ezawa I., Goseki-Sone M., Enhancement by lactose of intestinal alkaline phosphatase expression in rats, Bone, 35, pp. 249-255, (2004); Sogabe N., Maruyama R., Hosori T., Goseki-Sone M., Enhancement effects of vitamin K1 (phylloquinone) or vitamin K2 (menaquinone-4) on intestinal alkaline phosphatase activity in rats, J. Nutr. Sci. Vitaminol., 53, pp. 219-224, (2007); Stergiopoulos K., Cabrero P., Davies S.-A., Dow J.A.T., Salty dog, an SLC5 symporter, modulates Drosophila response to salt stress, Physiol. Genomics, 37, pp. 1-11, (2009); Strand M., Micchelli C.A., Regional control of Drosophila gut stem cell proliferation: EGF establishes GSSC proliferative set point controls emergence from quiescence, PLoS ONE, 8, (2013); Thaiss C.A., Levy M., Grosheva I., Zheng D., Soffer E., Blacher E., Braverman S., Tengeler A.C., Barak O., Elazar M., Et al., Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection, Science, 359, pp. 1376-1383, (2018); Tricoire H., Rera M., A new, discontinuous 2 phases of aging model: Lessons from Drosophila melanogaster, PLoS ONE, 10, (2015); Turner J.R., Cohen D.E., Mrsny R.J., Madara J.L., Noninvasive in vivo analysis of human small intestinal paracellular absorption: Regulation by Na+-glucose cotransport, Dig. Dis. Sci., 45, pp. 2122-2126, (2000); Uhing M.R., Kimura R.E., Active transport of 3-O-methyl-glucose by the small intestine in chronically catheterized rats, J. Clin. Invest., 95, pp. 2799-2805, (1995); CFR - Code of Federal Regulations Title 21, (2017); Ventura E.E., Davis J.N., Goran M.I., Sugar content of popular sweetened beverages based on objective laboratory analysis: Focus on fructose content, Obesity, 19, pp. 868-874, (2011); Wang W., Chen S.W., Zhu J., Zuo S., Ma Y.Y., Chen Z.Y., Zhang J.L., Chen G.W., Liu Y.C., Wang P.Y., Intestinal alkaline phosphatase inhibits the translocation of bacteria of gut-origin in mice with peritonitis: Mechanism of action, PLoS ONE, 10, (2015); Watts T., Berti I., Sapone A., Gerarduzzi T., Not T., Zielke R., Fasano A., Role of the intestinal tight junction modulator zonulin in the pathogenesis of type I diabetes in BB diabetic-prone rats, Proc. Natl. Acad. Sci. USA, 102, pp. 2916-2921, (2005); Webster J.L., Dunford E.K., Neal B.C., A systematic survey of the sodium contents of processed foods, Am. J. Clin. Nutr., 91, pp. 413-420, (2010); Weir A., Westerhoff P., Fabricius L., Hristovski K., Von Goetz N., Titanium dioxide nanoparticles in food and personal care products, Environ. Sci. Technol., 46, pp. 2242-2250, (2012); Welsh J.D., Stevenson D.E., Poley J.R., Walker A.W., Intestinal alkaline phosphatase activity in relation to age in humans, J. Pediatr. Gastroenterol. Nutr., 4, pp. 954-959, (1985); Welsh J.A., Sharma A.J., Grellinger L., Vos M.B., Consumption of added sugars is decreasing in the United States, Am. J. Clin. Nutr., 94, pp. 726-734, (2011); Wong R., Piper M.D.W., Wertheim B., Partridge L., Quantification of food intake in Drosophila, PLoS ONE, 4, (2009); Wray L., The diabetic patient and dental treatment: An update, Br. Dent. J., 211, pp. 209-215, (2011); Yu Q., Wang Z., Li P., Yang Q., The effect of various absorption enhancers on tight junction in the human intestinal Caco-2 cell line, Drug Dev. Ind. Pharm., 39, pp. 587-592, (2013); Zackular J.P., Moore J.L., Jordan A.T., Juttukonda L.J., Noto M.J., Nicholson M.R., Crews J.D., Semler M.W., Zhang Y., Ware L.B., Et al., Dietary zinc alters the microbiota and decreases resistance to Clostridium difficile infection, Nat. Med., 22, pp. 1330-1334, (2016); Zhang L., Li N., Des Robert C., Fang M., Liboni K., McMahon R., Caicedo R.A., Neu J., Lactobacillus rhamnosus GG decreases lipopolysaccharide-induced systemic inflammation in a gastrostomy-fed infant rat model, J. Pediatr. Gastroenterol. Nutr., 42, pp. 545-552, (2006); Zhang J., Zhu X., Jin Y., Shan W., Huang Y., Mechanism study of cellular uptake and tight junction opening mediated by goblet cell-specific trimethyl chitosan nanoparticles, Mol. Pharm., 11, pp. 1520-1532, (2014); Zhang X., Jin Q., Jin L.H., High sugar diet disrupts gut homeostasis though JNK and STAT pathways in Drosophila, Biochem. Biophys. Res. Commun., 487, pp. 910-916, (2017); Zhao H., Zhao C., Dong Y., Zhang M., Wang Y., Li F., Li X., McClain C., Yang S., Feng W., Inhibition of miR122a by Lactobacillus rhamnosus GG culture supernatant increases intestinal occludin expression and protects mice from alcoholic liver disease, Toxicol. Lett., 234, pp. 194-200, (2015)","G.J. Mahler; Department of Biomedical Engineering, Binghamton University, Binghamton, 13902, United States; email: gmahler@binghamton.edu","","Company of Biologists Ltd","","","","","","17548403","","","30504122","English","DNM Dis. Models Mech.","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85059811172"

"Jin Y.; Ren X.; Li G.; Li Y.; Zhang L.; Wang H.; Qian W.; Hou X.","Jin, Yu (56727028600); Ren, Xiaoyang (57200383199); Li, Gangping (56726862100); Li, Ying (57872790600); Zhang, Lei (56562609800); Wang, Huan (53986862000); Qian, Wei (35238189900); Hou, Xiaohua (7402838898)","56727028600; 57200383199; 56726862100; 57872790600; 56562609800; 53986862000; 35238189900; 7402838898","Beneficial effects of Rifaximin in post-infectious irritable bowel syndrome mouse model beyond gut microbiota","2018","Journal of Gastroenterology and Hepatology (Australia)","33","2","","443","452","9","34","10.1111/jgh.13841","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85041079292&doi=10.1111%2fjgh.13841&partnerID=40&md5=ba9d4895b7e1dffb5e4f097d1de3ec51","Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China","Jin Y., Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Ren X., The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China; Li G., Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Li Y., Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Zhang L., Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Wang H., Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Qian W., Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Hou X., Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China","Background and Aims: Rifaximin is a minimally absorbed antibiotic, which has shown efficacy in irritable bowel syndrome (IBS) patients. However, the mechanism on how it effects in IBS is still incompletely defined. In this study, Trichinella spiralis-infected post-infectious (PI) IBS mouse model was used, to assess the action of rifaximin on visceral hypersensitivity, barrier function, gut inflammation, and microbiota. Methods: Post-infectious IBS model was established by T. spiralis infection in mice. Rifaximin were administered to PI-IBS mice for seven consecutive days. The abdominal withdrawal reflex and threshold of colorectal distention were employed to evaluate visceral sensitivity. Smooth muscle contractile response was recorded in the organ bath. Intestinal permeability was measured by Ussing chamber. Expression of tight junction protein and cytokines were measured by Western blotting. Ilumina miseq platform was used to analyze bacterial 16S ribosomal RNA. Results: Post-infectious IBS mice treated with rifaximin exhibited decreased abdominal withdrawal reflex score, increased threshold, reduced contractile response, and intestinal permeability. Rifaximin also suppressed the expression of interleukin-12 and interleukin-17 and promoted the expression of the major tight junction protein occludin. Furthermore, rifaximin did not change the composition and diversity, and the study reavealed that rifaximin had a tiny effect on the relative abundance of Lactobacillus and Bifidobacterium in this PI-IBS model. Conclusions: Rifaximin alleviated visceral hypersensitivity, recovered intestinal barrier function, and inhibited low-grade inflammation in colon and ileum of PI-IBS mouse model. Moreover, rifaximin exerts anti-inflammatory effects with only a minimal effect on the overall composition and diversity of the gut microbiota in this model. © 2017 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd","anti-inflammatory effect; barrier function; gut microbiota; irritable bowel syndrome; rifaximin","Animals; Anti-Infective Agents; Bifidobacterium; Disease Models, Animal; Gastrointestinal Microbiome; Interleukin-12; Interleukin-17; Irritable Bowel Syndrome; Lactobacillus; Male; Mice; Occludin; Rifamycins; Trichinella spiralis; Trichinellosis; claudin 1; gamma interferon; interleukin 12; interleukin 17; interleukin 22; occludin; rifaximin; tight junction protein; antiinfective agent; interleukin 12; interleukin 17; occludin; rifamycin; rifaximin; abdominal wall; animal experiment; animal model; Article; colonic muscle; controlled study; down regulation; intestine flora; intestine infection; intestine mucosa; irritable colon; male; mouse; nonhuman; pain threshold; priority journal; protein expression; surface property; transepithelial resistance; Trichinella spiralis; trichinosis; upregulation; animal; Bifidobacterium; complication; disease model; irritable colon; Lactobacillus; metabolism; microbiology; Trichinella spiralis; trichinosis","","claudin 1, 329338-06-9; gamma interferon, 82115-62-6; interleukin 12, 138415-13-1; interleukin 22, 457106-70-6, 478219-35-1, 554460-75-2; occludin, 176304-61-3; rifaximin, 80621-81-4, 88747-56-2; rifamycin, 6998-60-3, 14897-39-3, 15105-92-7; Anti-Infective Agents, ; Interleukin-12, ; Interleukin-17, ; Occludin, ; Rifamycins, ; rifaximin, ","","","","","Weber H.C., New treatment options for irritable bowel syndrome with predominant diarrhea, Curr. Opin. Endocrinol. Diabetes Obes., 24, pp. 25-30, (2016); Pimentel M., Park S., Mirocha J., Kane S.V., Kong Y., The effect of a nonabsorbed oral antibiotic (Rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial, Ann. Intern. Med., 145, pp. 557-563, (2006); Pimentel M., Lembo A., Chey W.D., Et al., Rifaximin therapy for patients with irritable bowel syndrome without constipation, N. Engl. J. Med., 364, pp. 22-32, (2011); Meyrat P., Safroneeva E., Schoepfer A.M., Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months, Aliment. Pharmacol. Ther., 36, pp. 1084-1093, (2012); Pimentel M., Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea, Aliment. Pharmacol. Ther., 43, pp. 37-49, (2016); Sharara A.I., Aoun E., Abdul-Baki H., Mounzer R., Sidani S., Elhajj I., A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence, Am. J. Gastroenterol., 101, pp. 326-333, (2006); Pistiki A., Galani I., Pyleris E., Barbatzas C., Pimentel M., Giamarellos-Bourboulis E.J., In vitro activity of rifaximin against isolates from patients with small intestinal bacterial overgrowth, Int. J. Antimicrob. Agents, 43, pp. 236-241, (2014); Di Stefano M., Malservisi S., Veneto G., Ferrieri A., Corazza G.R., Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth, Aliment. Pharmacol. Ther., 14, pp. 551-556, (2000); Jeffery I.B., O'Toole P.W., Ohman L., Et al., An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota, Gut, 61, pp. 997-1006, (2012); Adachi J.A., DuPont H.L., Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders, Clin. Infect. Dis., 42, pp. 541-547, (2006); DuPont H.L., Jiang Z.D., Okhuysen P.C., Et al., A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea, Ann. Intern. Med., 142, pp. 805-812, (2005); Calanni F., Renzulli C., Barbanti M., Viscomi G.C., Rifaximin: beyond the traditional antibiotic activity, J. Antibiot., 67, pp. 667-670, (2014); Collins S.M., Bercik P., The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease, Gastroenterology, 136, pp. 2003-2014, (2009); Raskov H., Burcharth J., Pommergaard H.C., Rosenberg J., Irritable bowel syndrome, the microbiota and the gut-brain axis, Gut Microbes, 29, pp. 1-19, (2016); Long Y., Wang W., Wang H., Hao L., Qian W., Hou X., Characteristics of intestinal lamina propria dendritic cells in a mouse model of postinfectious irritable bowel syndrome, J. Gastroenterol. Hepatol., 27, pp. 935-944, (2012); Fu Y., Wang W., Tong J., Et al., Th17: a new participant in gut dysfunction in mice infected with Trichinella spiralis, Mediat. Inflamm., 2009, pp. 1-7, (2009); Wang H., Gong J., Wang W., Et al., Are there any different effects of Bifidobacterium, Lactobacillus and Streptococcus on intestinal sensation, barrier function and intestinal immunity in PI-IBS mouse model?, PLoS One, 9, (2014); Castro G.A., Fairbairn D., Carbohydrates and lipids in Trichinella spiralis larvae and their utilization in vitro, J. Parasitol., 55, pp. 51-58, (1969); Jones Iii R.C.W., Otsuka E., Wagstrom E., Jensen C.S., Price M.P., Gebhart G.F., Short-term sensitization of colon mechanoreceptors is associated with long-term hypersensitivity to colon distention in the mouse, Gastroenterology, 133, pp. 184-194, (2007); Carroll I.M., Ringel-Kulka T., Siddle J.P., Ringel Y., Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome, Neurogastroenterol. Motil., 24, pp. 521-530, (2012); Quast C., Pruesse E., Yilmaz P., Et al., The SILVA ribosomal RNA gene database project: improved data processing and web-based tools, Nucleic Acids Res., 41, pp. D590-D596, (2013); Xu D., Gao J., Gillilland M., Et al., Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats, Gastroenterology, 146, pp. 484-496, (2014); Akiho H., Deng Y., Blennerhassett P., Kanbayashi H., Collins S.M., Mechanisms underlying the maintenance of muscle hypercontractility in a model of postinfective gut dysfunction, Gastroenterology, 129, pp. 131-141, (2005); Bercik P., Wang L., Verdu E.F., Et al., Visceral hyperalgesia and intestinal dysmotility in a mouse model of postinfective gut dysfunction, Gastroenterology, 127, pp. 179-187, (2004); Qin H.Y., Wu J.C., Tong X.D., Sung J.J., Xu H.X., Bian Z.X., Systematic review of animal models of post-infectious/post-inflammatory irritable bowel syndrome, J. Gastroenterol., 46, pp. 164-174, (2011); Talley N.J., Spiller R., Irritable bowel syndrome: a little understood organic bowel disease?, Lancet, 360, pp. 555-564, (2002); Ludidi S., Conchillo J.M., Keszthelyi D., Et al., Rectal hypersensitivity as hallmark for irritable bowel syndrome: defining the optimal cutoff, Neurogastroenterol. Motil., 24, pp. 729-733, (2012); Barbara G., Cremon C., De Giorgio R., Et al., Mechanisms underlying visceral hypersensitivity in irritable bowel syndrome, Curr. Gastroenterol. Rep., 13, pp. 308-315, (2011); Farzaei M.H., Bahramsoltani R., Abdollahi M., Rahimi R., The role of visceral hypersensitivity in irritable bowel syndrome: pharmacological targets and novel treatments, J. Neurogastroenterol. Motil., 22, pp. 558-574, (2016); Lee H., Park J.H., Park D.I., Et al., Mucosal mast cell count is associated with intestinal permeability in patients with diarrhea predominant irritable bowel syndrome, J. Neurogastroenterol. Motil., 19, pp. 244-250, (2013); Matricon J., Meleine M., Gelot A., Et al., Review article: associations between immune activation, intestinal permeability and the irritable bowel syndrome, Aliment. Pharmacol. Ther., 36, pp. 1009-1031, (2012); Spiller R., Lam C., An update on post-infectious irritable bowel syndrome: Role of genetics, immune activation, serotonin and altered microbiome, J. Neurogastroenterol. Motil., 18, pp. 258-268, (2012); Ford A.C., Talley N.J., Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review, J. Gastroenterol., 46, pp. 421-431, (2011); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am. J. Gastroenterol., 101, pp. 1288-1294, (2006); Zhou Q., Zhang B., Nicholas V.G., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Piche T., Barbara G., Aubert P., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Ait-Belgnaoui A., Bradesi S., Fioramonti J., Theodorou V., Bueno L., Acute stress-induced hypersensitivity to colonic distension depends upon increase in paracellular permeability: role of myosin light chain kinase, Pain, 113, pp. 141-147, (2005); Wullaert A., Heyninck K., Beyaert R., Mechanisms of crosstalk between TNF-induced NF-κB and JNK activation in hepatocytes, Biochem. Pharmacol., 72, pp. 1090-1101, (2006); Spiller R., Garsed K., Postinfectious irritable bowel syndrome, Gastroenterology, 136, pp. 1979-1988, (2009); Elsenbruch S., Holtmann G., Oezcan D., Et al., Are there alterations of neuroendocrine and cellular immune responses to nutrients in women with irritable bowel syndrome?, Am. J. Gastroenterol., 99, pp. 703-710, (2004); Liebregts T., Adam B., Bredack C., Et al., Immune activation in patients with irritable bowel syndrome, Gastroenterology, 132, pp. 913-920, (2007); Blaschitz C., Raffatellu M., Th17 cytokines and the gut mucosal barrier, J. Clin. Immunol., 30, pp. 196-203, (2010); Guslandi M., Rifaximin in the treatment of inflammatory bowel disease, World J Gastroenterol: WJG, 17, pp. 4643-4646, (2011); Bajaj J.S., Hylemon P.B., Ridlon J.M., Et al., Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation, Am. J. Physiol. Gastrointest. Liver Physiol., 303, pp. G675-G685, (2012); Cheng J., Shah Y.M., Gonzalez F.J., Pregnane X receptor as a target for treatment of inflammatory bowel disorders, Trends Pharmacol. Sci., 33, pp. 323-330, (2012); Cheng J., Shah Y.M., Ma X., Et al., Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation, J. Pharmacol. Exp. Ther., 335, pp. 32-41, (2010)","X. Hou; Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; email: houxh@medmail.com.cn","","Blackwell Publishing","","","","","","08159319","","JGHEE","28573746","English","J. Gastroenterol. Hepatol.","Article","Final","","Scopus","2-s2.0-85041079292"

"Miquel S.; Martín R.; Lashermes A.; Gillet M.; Meleine M.; Gelot A.; Eschalier A.; Ardid D.; Bermúdez-Humarán L.G.; Sokol H.; Thomas M.; Theodorou V.; Langella P.; Carvalho F.A.","Miquel, S. (23009469300); Martín, R. (24179115600); Lashermes, A. (57070458900); Gillet, M. (56384183500); Meleine, M. (53464003400); Gelot, A. (14419858000); Eschalier, A. (7006766529); Ardid, D. (6603953203); Bermúdez-Humarán, L.G. (6602243913); Sokol, H. (14421842400); Thomas, M. (55472010300); Theodorou, V. (55410684700); Langella, P. (7003598187); Carvalho, F.A. (16041688200)","23009469300; 24179115600; 57070458900; 56384183500; 53464003400; 14419858000; 7006766529; 6603953203; 6602243913; 14421842400; 55472010300; 55410684700; 7003598187; 16041688200","Anti-nociceptive effect of Faecalibacterium prausnitzii in non-inflammatory IBS-like models","2016","Scientific Reports","6","","19399","","","","65","10.1038/srep19399","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84955084589&doi=10.1038%2fsrep19399&partnerID=40&md5=4f673f40771e956eb05622fc58673d0a","INRA, Commensal and Probiotics-Host Interactions Laboratory, UMR 1319 Micalis, Jouy-en-Josas, F-78350, France; AgroParisTech, UMR1319 Micalis, Jouy-en-Josas, F-78350, France; Laboratoire Microorganismes: Génome et Environnement, UMR CNRS 6023, Clermont-Ferrand, 63000, France; Université d'Auvergne, Clermont- Ferrand, 63000, France; INSERM 1107 Neuro-Dol, Clermont-Ferrand, 630000, France; Neuro-Gastroenterology and Nutrition Team, TOXALIM, UMR 1331-INRA/INP/UPS, Toulouse, F-31931, France; APHP, Hôpital Saint Antoine, Service de Gastroentérologie et nutrition, Paris, F-75012, France; Sorbonne Universités, UPMC Univ Paris 06, LBM, 27 rue de Chaligny, Paris, F-75012, France; INSERM-ERL 1157, Inflammation-Immunopathology-Biotherapy Department (DHU i2B), CHU Saint-Antoine, 27 rue de Chaligny, Paris, F-75012, France; CNRS, UMR 7203 LBM, Paris, F-75005, France","Miquel S., INRA, Commensal and Probiotics-Host Interactions Laboratory, UMR 1319 Micalis, Jouy-en-Josas, F-78350, France, AgroParisTech, UMR1319 Micalis, Jouy-en-Josas, F-78350, France, Laboratoire Microorganismes: Génome et Environnement, UMR CNRS 6023, Clermont-Ferrand, 63000, France, Université d'Auvergne, Clermont- Ferrand, 63000, France; Martín R., INRA, Commensal and Probiotics-Host Interactions Laboratory, UMR 1319 Micalis, Jouy-en-Josas, F-78350, France, AgroParisTech, UMR1319 Micalis, Jouy-en-Josas, F-78350, France; Lashermes A., Université d'Auvergne, Clermont- Ferrand, 63000, France, INSERM 1107 Neuro-Dol, Clermont-Ferrand, 630000, France; Gillet M., Neuro-Gastroenterology and Nutrition Team, TOXALIM, UMR 1331-INRA/INP/UPS, Toulouse, F-31931, France; Meleine M., Université d'Auvergne, Clermont- Ferrand, 63000, France, INSERM 1107 Neuro-Dol, Clermont-Ferrand, 630000, France; Gelot A., Université d'Auvergne, Clermont- Ferrand, 63000, France, INSERM 1107 Neuro-Dol, Clermont-Ferrand, 630000, France; Eschalier A., Université d'Auvergne, Clermont- Ferrand, 63000, France, INSERM 1107 Neuro-Dol, Clermont-Ferrand, 630000, France; Ardid D., Université d'Auvergne, Clermont- Ferrand, 63000, France, INSERM 1107 Neuro-Dol, Clermont-Ferrand, 630000, France; Bermúdez-Humarán L.G., INRA, Commensal and Probiotics-Host Interactions Laboratory, UMR 1319 Micalis, Jouy-en-Josas, F-78350, France, AgroParisTech, UMR1319 Micalis, Jouy-en-Josas, F-78350, France; Sokol H., INRA, Commensal and Probiotics-Host Interactions Laboratory, UMR 1319 Micalis, Jouy-en-Josas, F-78350, France, AgroParisTech, UMR1319 Micalis, Jouy-en-Josas, F-78350, France, APHP, Hôpital Saint Antoine, Service de Gastroentérologie et nutrition, Paris, F-75012, France, Sorbonne Universités, UPMC Univ Paris 06, LBM, 27 rue de Chaligny, Paris, F-75012, France, INSERM-ERL 1157, Inflammation-Immunopathology-Biotherapy Department (DHU i2B), CHU Saint-Antoine, 27 rue de Chaligny, Paris, F-75012, France, CNRS, UMR 7203 LBM, Paris, F-75005, France; Thomas M., INRA, Commensal and Probiotics-Host Interactions Laboratory, UMR 1319 Micalis, Jouy-en-Josas, F-78350, France, AgroParisTech, UMR1319 Micalis, Jouy-en-Josas, F-78350, France; Theodorou V., Neuro-Gastroenterology and Nutrition Team, TOXALIM, UMR 1331-INRA/INP/UPS, Toulouse, F-31931, France; Langella P., INRA, Commensal and Probiotics-Host Interactions Laboratory, UMR 1319 Micalis, Jouy-en-Josas, F-78350, France, AgroParisTech, UMR1319 Micalis, Jouy-en-Josas, F-78350, France; Carvalho F.A., Université d'Auvergne, Clermont- Ferrand, 63000, France, INSERM 1107 Neuro-Dol, Clermont-Ferrand, 630000, France","Visceral pain and intestinal dysbiosis are associated with Irritable Bowel Syndrome (IBS), a common functional gastrointestinal disorder without available efficient therapies. In this study, a decrease of Faecalibacterium prausnitzii presence has been observed in an IBS-like rodent model induced by a neonatal maternal separation (NMS) stress. Moreover, it was investigated whether F. prausnitzii may have an impact on colonic sensitivity. The A2-165 reference strain, but not its supernatant, significantly decreased colonic hypersensitivity induced by either NMS in mice or partial restraint stress in rats. This effect was associated with a reinforcement of intestinal epithelial barrier. Thus, F. prausnitzii exhibits anti-nociceptive properties, indicating its potential to treat abdominal pain in IBS patients.","","Animals; Colon; Disease Models, Animal; Faecalibacterium prausnitzii; Intestinal Mucosa; Irritable Bowel Syndrome; Male; Maternal Deprivation; Mice; Permeability; Stress, Physiological; animal; colon; disease model; Faecalibacterium prausnitzii; immunology; intestine mucosa; Irritable Bowel Syndrome; male; maternal deprivation; metabolism; microbiology; mouse; permeability; physiological stress; physiology","","","","","ANR-09-MNPS-037-01; Conseil Régional d’Auvergne; Merck Médication Familiale; Saint Etienne de Chomeil; Vitagora Competitive Cluster; Agence Nationale de la Recherche, ANR; Fonds Unique Interministériel, FUI, (F1010012D); Fonds Unique Interministériel, FUI; European Regional Development Fund, FEDER, (32025, 34606); European Regional Development Fund, FEDER","Authors would like to thank Jean-Marc Chatel and Chantal Bridonneau for their advices during this work and M2ISH team for their help concerning Claudin-2 experiments. This study was a part of FPARIS collaborative project selected and supported by the Vitagora Competitive Cluster and funded by the French FUI (Fond Unique Interministériel; FUI: n°F1010012D), the FEDER (Fonds Européen de Développement Régional; Bourgogne: 34606, and Auvergne: 32025), the Burgundy Region, the Conseil Général 21, the Grand Dijon, ANR VISCERALGY (ANR-09-MNPS-037-01) and the Conseil Régional d’Auvergne (MHIB grant). This work was also supported by Merck Médication Familiale (Dijon, France) and Biovitis (Saint Etienne de Chomeil, France).","Marshall J.K., Et al., Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Aliment. Pharmacol. Ther, 20, pp. 1317-1322, (2004); Ritchie J., Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome, Gut, 14, pp. 125-132, (1973); Kiank C., Tache Y., Larauche M., Stress-related modulation of inflammation in experimental models of bowel disease and postinfectious irritable bowel syndrome: Role of corticotropin-releasing factor receptors, Brain. Behav. Immun, 24, pp. 41-48, (2010); Collins S.M., Denou E., Verdu E.F., Bercik P., The putative role of the intestinal microbiota in the irritable bowel syndrome, Dig. Liver Dis. Off. J. Ital. Soc. Gastroenterol. Ital. Assoc. Study Liver, 41, pp. 850-853, (2009); Bixquert Jimenez M., Treatment of irritable bowel syndrome with probiotics An etiopathogenic approach at last?, Rev. Esp. Enfermedades Dig. Organo Of. Soc. Esp. Patol. Dig, 101, pp. 553-564, (2009); Bennet S.M.P., Ohman L., Simren M., Gut microbiota as potential orchestrators of irritable bowel syndrome, Gut Liver, 9, pp. 318-331, (2015); Bonfrate L., Tack J., Grattagliano I., Cuomo R., Portincasa P., Microbiota in health and irritable bowel syndrome: Current knowledge, perspectives and therapeutic options, Scand. J. Gastroenterol, 48, pp. 995-1009, (2013); Rajilic-Stojanovic M., Et al., Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome, Gastroenterology, 141, pp. 1792-1801, (2011); Miquel S., Et al., Faecalibacterium prausnitzii and human intestinal health, Curr. Opin. Microbiol, 16, pp. 255-261, (2013); Sokol H., Et al., Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients, Proc. Natl. Acad. Sci. USA, 105, pp. 16731-16736, (2008); Miquel S., Et al., Identification of metabolic signatures linked to anti-inflammatory effects of Faecalibacterium prausnitzii, MBio, 6, (2015); Martin R., Et al., The commensal bacterium Faecalibacterium prausnitzii is protective in DNBS-induced chronic moderate and severe colitis models, Inflamm. Bowel Dis, 20, pp. 417-430, (2014); Coutinho S.V., Et al., Neonatal maternal separation alters stress-induced responses to viscerosomatic nociceptive stimuli in rat, Am. J. Physiol. Gastrointest. Liver Physiol, 282, pp. G307-316, (2002); Ait-Belgnaoui A., Et al., Lactobacillus farciminis treatment suppresses stress induced visceral hypersensitivity: A possible action through interaction with epithelial cell cytoskeleton contraction, Gut, 55, pp. 1090-1094, (2006); Rosztoczy A., Et al., Influence of sex and experimental protocol on the effect of maternal deprivation on rectal sensitivity to distension in the adult rat, Neurogastroenterol. Motil. Off. J. Eur. Gastrointest. Motil. Soc, 15, pp. 679-686, (2003); Williams C.L., Peterson J.M., Villar R.G., Burks T.F., Corticotropin-releasing factor directly mediates colonic responses to stress, Am. J. Physiol, 253, pp. G582-586, (1987); Lee B.J., Bak Y.-T., Irritable bowel syndrome, gut microbiota and probiotics, J. Neurogastroenterol. Motil, 17, pp. 252-266, (2011); Christianson J.A., Gebhart G.F., Assessment of colon sensitivity by luminal distension in mice, Nat. Protoc, 2, pp. 2624-2631, (2007); Eutamene H., Et al., Involvement of interleukin-1, prostaglandins and mast cells in rectal distension-induced colonic water secretion in rats, J. Physiol, 506, PT1, pp. 245-252, (1998); Rochat T., Et al., Anti-inflammatory effects of lactobacillus casei bl23 producing or not a manganese-dependant catalase on dssinduced colitis in mice, Microb. Cell Factories, 6, (2007); Ameho C.K., Et al., Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumour necrosis factor alpha production in trinitrobenzene sulphonic acid induced colitis, Gut, 41, pp. 487-493, (1997); Kechaou N., Et al., Identification of one novel candidate probiotic Lactobacillus plantarum strain active against influenza virus infection in mice by a large-scale screening, Appl. Environ. Microbiol, 79, pp. 1491-1499, (2013); Tambuwala M.M., Et al., Loss of prolyl hydroxylase-1 protects against colitis through reduced epithelial cell apoptosis and increased barrier function, Gastroenterology, 139, pp. 2093-2101, (2010); Denizot J., Et al., Adherent-invasive Escherichia coli induce claudin-2 expression and barrier defect in CEABAC10 mice and Crohn?s disease patients, Inflamm. Bowel Dis, 18, pp. 294-304, (2012); Miquel S., Et al., Ecology and metabolism of the beneficial intestinal commensal bacterium Faecalibacterium prausnitzii, Gut Microbes, 5, pp. 146-151, (2014); Balamurugan R., Janardhan H.P., George S., Chittaranjan S.P., Ramakrishna B.S., Bacterial succession in the colon during childhood and adolescence: Molecular studies in a southern Indian village, Am. J. Clin. Nutr, 88, pp. 1643-1647, (2008); Barreau F., Ferrier L., Fioramonti J., Bueno L., New insights in the etiology and pathophysiology of irritable bowel syndrome: Contribution of neonatal stress models, Pediatr. Res, 62, pp. 240-245, (2007); Khan S., Chang L., Diagnosis and management of IBS, Nat. Rev. Gastroenterol. Hepatol, 7, pp. 565-581, (2010); Thabane M., Marshall J.K., Post-infectious irritable bowel syndrome, World J. Gastroenterol. WJG, 15, pp. 3591-3596, (2009); Nourrisson C., Et al., Blastocystis is associated with decrease of fecal microbiota protective bacteria: Comparative analysis between patients with irritable bowel syndrome and control subjects, Plos One, 9, (2014); Crouzet L., Et al., The hypersensitivity to colonic distension of IBS patients can be transferred to rats through their fecal microbiota, Neurogastroenterol. Motil. Off. J. Eur. Gastrointest. Motil. Soc, 25, pp. e272-282, (2013); Duboc H., Et al., Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome, Neurogastroenterol. Motil. Off. J. Eur. Gastrointest. Motil. Soc, 24, pp. 513-520, (2012); Rigsbee L., Et al., Quantitative profiling of gut microbiota of children with diarrhea-predominant irritable bowel syndrome, Am. J. Gastroenterol, 107, pp. 1740-1751, (2012); Pozuelo M., Et al., Reduction of butyrate-and methane-producing microorganisms in patients with irritable bowel syndrome, Sci. Rep, 5, (2015); Ait-Belgnaoui A., Bradesi S., Fioramonti J., Theodorou V., Bueno L., Acute stress-induced hypersensitivity to colonic distension depends upon increase in paracellular permeability: Role of myosin light chain kinase, Pain 113, pp. 141-147, (2005); Agostini S., Et al., Peripheral anti-nociceptive effect of nociceptin/orphanin FQ in inflammation and stress-induced colonic hyperalgesia in rats, Pain, 141, pp. 292-299, (2009); Eutamene H., Et al., Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain, Neurogastroenterol. Motil. Off. J. Eur. Gastrointest. Motil. Soc, 22, pp. e312-e384, (2010); Agostini S., Et al., A marketed fermented dairy product containing Bifidobacterium lactis CNCM I-2494 suppresses gut hypersensitivity and colonic barrier disruption induced by acute stress in rats, Neurogastroenterol. Motil. Off. J. Eur. Gastrointest. Motil. Soc, 24, (2012); Zhao J., Et al., A protease inhibitor against acute stress-induced visceral hypersensitivity and paracellular permeability in rats, Eur. J. Pharmacol, 654, pp. 289-294, (2011); Wrzosek L., Et al., Bacteroides thetaiotaomicron and Faecalibacterium prausnitzii influence the production of mucus glycans and the development of goblet cells in the colonic epithelium of a gnotobiotic model rodent, BMC Biol, 11, (2013); Laval L., Et al., Lactobacillus rhamnosus cncm i-3690 and the commensal bacterium faecalibacterium prausnitzii a2-165 exhibit similar protective effects to induced barrier hyper-permeability in mice, Gut Microbes, 6, pp. 1-9, (2015); Carlsson A.H., Et al., Faecalibacterium prausnitzii supernatant improves intestinal barrier function in mice DSS colitis, Scand. J. Gastroenterol, 48, pp. 1136-1144, (2013); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Miquel S., Et al., A proposed framework for an appropriate evaluation scheme for microorganisms as novel foods with a health claim in Europe, Microb. Cell Factories, 14, (2015)","S. Miquel; INRA, Commensal and Probiotics-Host Interactions Laboratory, UMR 1319 Micalis, Jouy-en-Josas, F-78350, France; email: sylmiquel@gmail.com","","Nature Publishing Group","","","","","","20452322","","","26775847","English","Sci. Rep.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-84955084589"

"Mackey E.; Ayyadurai S.; Pohl C.S.; D’Costa S.; Li Y.; Moeser A.J.","Mackey, Emily (57192081205); Ayyadurai, Saravanan (25224580000); Pohl, Calvin S. (57004435400); D’Costa, Susan (57192090426); Li, Yihang (57189060962); Moeser, Adam J. (6602410975)","57192081205; 25224580000; 57004435400; 57192090426; 57189060962; 6602410975","Sexual dimorphism in the mast cell transcriptome and the pathophysiological responses to immunological and psychological stress","2016","Biology of Sex Differences","7","1","","1","19","18","59","10.1186/s13293-016-0113-7","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84996843278&doi=10.1186%2fs13293-016-0113-7&partnerID=40&md5=cb0daa05c338122274d631847831b0c8","Gastrointestinal Stress Biology Laboratory, Michigan State University, East Lansing, 48824, MI, United States; Department of Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, 48824, MI, United States; Neuroscience Program, Michigan State University, East Lansing, 48824, MI, United States; Department of Physiology, Michigan State University, East Lansing, 48824, MI, United States; Comparative Biomedical Sciences Program, College of Veterinary Medicine, North Carolina State University, Raleigh, 27603, NC, United States; Department of Medicine, University of North Carolina, Chapel Hill, 27599, NC, United States","Mackey E., Gastrointestinal Stress Biology Laboratory, Michigan State University, East Lansing, 48824, MI, United States, Comparative Biomedical Sciences Program, College of Veterinary Medicine, North Carolina State University, Raleigh, 27603, NC, United States; Ayyadurai S., Gastrointestinal Stress Biology Laboratory, Michigan State University, East Lansing, 48824, MI, United States, Department of Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, 48824, MI, United States; Pohl C.S., Gastrointestinal Stress Biology Laboratory, Michigan State University, East Lansing, 48824, MI, United States, Department of Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, 48824, MI, United States; D’Costa S., Department of Medicine, University of North Carolina, Chapel Hill, 27599, NC, United States; Li Y., Gastrointestinal Stress Biology Laboratory, Michigan State University, East Lansing, 48824, MI, United States, Department of Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, 48824, MI, United States; Moeser A.J., Gastrointestinal Stress Biology Laboratory, Michigan State University, East Lansing, 48824, MI, United States, Department of Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, 48824, MI, United States, Neuroscience Program, Michigan State University, East Lansing, 48824, MI, United States, Department of Physiology, Michigan State University, East Lansing, 48824, MI, United States","Background: Biological sex plays a prominent role in the prevalence and severity of a number of important stress-related gastrointestinal and immune-related diseases including IBS and allergy/anaphylaxis. Despite the establishment of sex differences in these diseases, the underlying mechanisms contributing to sex differences remain poorly understood. The objective of this study was to define the role of biological sex on mast cells (MCs), an innate immune cell central to the pathophysiology of many GI and allergic disorders. Methods: Twelve-week-old C57BL/6 male and female mice were exposed to immunological stress (2 h of IgE-mediated passive systemic anaphylaxis (PSA)) or psychological stress (1 h of restraint stress (RS)) and temperature, clinical scores, serum histamine, and intestinal permeability (for RS) were measured. Primary bone marrow-derived MCs (BMMCs) were harvested from male and female mice and analyzed for MC degranulation, signaling pathways, mediator content, and RNA transcriptome analysis. Results: Sexually dimorphic responses were observed in both models of PSA and RS and in primary MCs. Compared with male mice, female mice exhibited increased clinical scores, hypothermia, and serum histamine levels in response to PSA and had greater intestinal permeability and serum histamine responses to RS. Primary BMMCs from female mice exhibited increased release of β-hexosaminidase, histamine, tryptase, and TNF-α upon stimulation with IgE/DNP and A23187. Increased mediator release in female BMMCs was not associated with increased upstream phospho-tyrosine signaling pathways or downstream Ca2+ mobilization. Instead, increased mediator release in female MCs was associated with markedly increased capacity for synthesis and storage of MC granule-associated immune mediators as determined by MC mediator content and RNA transcriptome analysis. Conclusions: These results provide a new understanding of sexual dimorphic responses in MCs and have direct implications for stress-related diseases associated with a female predominance and MC hyperactivity including irritable bowel syndrome, allergy, and anaphylaxis. © 2016 The Author(s).","Allergy; Females; Intestine; Mast cells; Sexual dimorphism; Stress","","","","","","National Institutes of Health, NIH, (DK097462, HD072968, OD011070)","This work was supported by grants from the National Institutes of Health HD072968 (to A.J.M.), DK097462 (to A.J.M.), R03 DK097462 (to A.J.M), and OD011070 (T32 support for EM).","Osman M., Hansell A.L., Simpson C.R., Hollowell J., Helms P.J., Gender-specific presentations for asthma, allergic rhinitis and eczema in primary care, Prim Care Respir J, 16, 1, pp. 28-35, (2007); Dorner T., Lawrence K., Rieder A., Kunze M., Epidemiology of allergies in Austria. Results of the first Austrian allergy report, Wiener Med Wochenschr, 157, 11-12, pp. 235-242, (2007); Poulos L.M., Waters A., Correll P.K., Loblay R.H., Marks G.B., Trends in hospitalizations for anaphylaxis, angioedema, and urticaria in Australia, 1993-1994 to 2004-2005, J Allergy Clin Immunol, 120, 4, pp. 878-884, (2007); Brown A.F., Mckinnon D., Chu K., Emergency department anaphylaxis: a review of 142 patients in a single year, J Allergy Clin Immunol, 108, 5, pp. 861-866, (2001); De Marco R., Locatelli F., Cerveri I., Bugiani M., Marinoni A., Giammanco G., Incidence and remission of asthma: a retrospective study on the natural history of asthma in Italy, J Allergy Clin Immunol, 110, 2, pp. 228-235, (2002); Moorman J.E., Akinbami L.J., Bailey C.M., Zahran H.S., King M.E., Johnson C.A., Liu X., National surveillance of asthma: United States, 2001-2010, Vital Health Stat 3, 35, pp. 1-67, (2012); Webb L.M., Lieberman P., Anaphylaxis: a review of 601 cases, Ann Allergy Asthma Immunol, 97, 1, pp. 39-43, (2006); Gonzalez-Perez A., Aponte Z., Vidaurre C.F., Rodriguez L.A.G., Anaphylaxis epidemiology in patients with and patients without asthma: a United Kingdom database review, J Allergy Clin Immunol, 125, 5, pp. 1098-1104, (2010); Ross M.P., Ferguson M., Street D., Klontz K., Schroeder T., Luccioli S., Analysis of food-allergic and anaphylactic events in the National Electronic Injury Surveillance System, J Allergy Clin Immunol, 121, 1, pp. 166-171, (2008); Lovell R.M., Ford A.C., Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis, Am J Gastroenterol, 107, 7, pp. 991-1000, (2012); Beery A.K., Zucker I., Sex bias in neuroscience and biomedical research, Neurosci Biobehav Rev, 35, 3, pp. 565-572, (2011); Marts S.A., Keitt S., Foreword: a historical overview of advocacy for research in sex-based biology, Adv Mol Cell Biol, 34, pp. v-xii, (2004); Lundequist A., Pejler G., Biological implications of preformed mast cell mediators, Cell Mol Life Sci, 68, 6, pp. 965-975, (2011); Gilfillan A.M., Tkaczyk C., Integrated signalling pathways for mast-cell activation, Nat Rev Immunol, 6, 3, pp. 218-230, (2006); Wernersson S., Pejler G., Mast cell secretory granules: armed for battle, Nat Rev Immunol, 14, pp. 478-494, (2014); Galli S.J., Tsai M., Piliponsky A.M., The development of allergic inflammation, Nature, 454, 7203, pp. 445-454, (2008); Ohman L., Simren M., Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions, Nat Rev Gastroenterol Hepatol, 7, 3, pp. 163-173, (2010); Munoz-Cruz S., Mendoza-Rodriguez Y., Nava-Castro K.E., Yepez-Mulia L., Morales-Montor J., Gender-Related Effects of Sex Steroids on Histamine Release and FcεRI Expression in Rat Peritoneal Mast Cells, J Immunol Res, 2014, (2015); Narita S., Goldblum R.M., Watson C.S., Brooks E.G., Estes D.M., Curran E.M., Midoro-Horiuti T., Environmental estrogens induce mast cell degranulation and enhance IgE-mediated release of allergic mediators, Environ Health Perspect, 115, pp. 48-52, (2007); Kim M., Chae H., Shin T., Kim H., Kim H., Estrogen regulates cytokine release in human mast cells, Immunopharmacol Immunotoxicol, 23, 4, pp. 495-504, (2001); Zaitsu M., Narita S., Lambert K.C., Grady J.J., Estes D.M., Curran E.M., Brooks E.G., Watson C.S., Goldblum R.M., Midoro-Horiuti T., Estradiol activates mast cells via a non-genomic estrogen receptor-α and calcium influx, Mol Immunol, 44, 8, pp. 1977-1985, (2007); Vliagoftis H., Dimitriadou V., Boucher W., Rozniecki J., Correia I., Raam S., Theoharides T., Estradiol augments while tamoxifen inhibits rat mast cell secretion, Int Arch Allergy Immunol, 98, 4, pp. 398-409, (1992); Vasiadi M., Kempuraj D., Boucher W., Kalogeromitros D., Theoharides T., Progesterone inhibits mast cell secretion, Int J Immunopathol Pharmacol, 19, 4, pp. 787-794, (2006); Chen W., Beck I., Schober W., Brockow K., Effner R., Buters J., Behrendt H., Ring J., Human mast cells express androgen receptors but treatment with testosterone exerts no influence on IgE-independent mast cell degranulation elicited by neuromuscular blocking agents, Exp Dermatol, 19, 3, pp. 302-304, (2010); Chen X., Lau K.W., Yang F., Sun S.S., Fung M., An adjuvant free mouse model of oral allergenic sensitization to rice seeds protein, BMC Gastroenterol, 11, 1, (2011); Haisenleder D.J., Schoenfelder A.H., Marcinko E.S., Geddis L.M., Marshall J.C., Estimation of estradiol in mouse serum samples: evaluation of commercial estradiol immunoassays, Endocrinology, 152, 11, pp. 4443-4447, (2011); Jensen B.M., Swindle E.J., Iwaki S., Gilfillan A.M., Generation, isolation, and maintenance of rodent mast cells and mast cell lines, Curr Protoc Immunol, 3, (2006); Krishnaswamy G., Ajitawi O., Chi D.S., The human mast cell: an overview, Methods Mol Biol, 315, pp. 13-34, (2006); McDowell E.M., Trump B.F., Histologic fixatives suitable for diagnostic light and electron microscopy, Arch Pathol Lab Med, 100, 8, pp. 405-414, (1976); Reynolds E.S., The use of lead citrate at high pH as an electron-opaque stain in electron microscopy, J Cell Biol, 17, pp. 208-212, (1963); Caligioni C.S., Assessing reproductive status/stages in mice, Curr Protoc Neurosci, Appendix 4, (2009); Moloney R.D., Sajjad J., Foley T., Felice V.D., Dinan T.G., Cryan J.F., O'Mahony S.M., Estrous cycle influences excitatory amino acid transport and visceral pain sensitivity in the rat: effects of early-life stress, Biol Sex Differ, 7, 1, (2016); Finkelman F.D., Anaphylaxis: lessons from mouse models, J Allergy Clin Immunol, 120, 3, pp. 506-515, (2007); Zhao L., Cui X., Yuan H., Liang B., Zheng L., Liu Y., Luo M., Tan J., Restraint stress inhibits mouse implantation: temporal window and the involvement of HB-EGF, estrogen and progesterone, PLoS One, 8, 11, (2013); Andersen M.L., Bignotto M., Machado R.B., Tufik S., Different stress modalities result in distinct steroid hormone responses by male rats, Braz J Med Biol Res, 37, 6, pp. 791-797, (2004); Nishida K., Yamasaki S., Ito Y., Kabu K., Hattori K., Tezuka T., Nishizumi H., Kitamura D., Goitsuka R., Geha R.S., Yamamoto T., Yagi T., Hirano T., Fc{epsilon}RI-mediated mast cell degranulation requires calcium-independent microtubule-dependent translocation of granules to the plasma membrane, J Cell Biol, 170, 1, pp. 115-126, (2005); Aydin Y., Tuncel N., Gurer F., Tuncel M., Kosar M., Oflaz G., Ovarian, uterine and brain mast cells in female rats: cyclic changes and contribution to tissue histamine, Comp Biochem Physiol A Mol Integr Physiol, 120, 2, pp. 255-262, (1998); Boes T., Levy D., Influence of sex, estrous cycle, and estrogen on intracranial dural mast cells, Cephalalgia, 32, 12, pp. 924-931, (2012); Jing H., Wang Z., Chen Y., Effect of oestradiol on mast cell number and histamine level in the mammary glands of rat, Anat Histol Embryol, 41, 3, pp. 170-176, (2012); Hewagama A., Patel D., Yarlagadda S., Strickland F.M., Richardson B.C., Stronger inflammatory/cytotoxic T-cell response in women identified by microarray analysis, Genes Immun, 10, 5, pp. 509-516, (2009); Pemberton A., Brown J., Wright S., Knight P., Mcphee M., Mceuen A., Forse P., Miller H., Purification and characterization of mouse mast cell proteinase-2 and the differential expression and release of mouse mast cell proteinase-1 and-2 in vivo, Clin Exp Allergy, 33, 7, pp. 1005-1012, (2003); Vogel C., Marcotte E.M., Insights into the regulation of protein abundance from proteomic and transcriptomic analyses, Nat Rev Genet, 13, 4, pp. 227-232, (2012); Caughey G.H., Mast cell proteases as pharmacological targets, Eur J Pharmacol, 778, pp. 44-55, (2015); Hove-Jensen B., Mutation in the phosphoribosylpyrophosphate synthetase gene (prs) that results in simultaneous requirements for purine and pyrimidine nucleosides, nicotinamide nucleotide, histidine, and tryptophan in Escherichia coli, J Bacteriol, 170, 3, pp. 1148-1152, (1988); Nowak E.C., De Vries V.C., Wasiuk A., Ahonen C., Bennett K.A., Le Mercier I., Ha D.G., Noelle R.J., Tryptophan hydroxylase-1 regulates immune tolerance and inflammation, J Exp Med, 209, 11, pp. 2127-2135, (2012); Ringvall M., Ronnberg E., Wernersson S., Duelli A., Henningsson F., Abrink M., Garcia-Faroldi G., Fajardo I., Pejler G., Serotonin and histamine storage in mast cell secretory granules is dependent on serglycin proteoglycan, J Allergy Clin Immunol, 121, 4, pp. 1020-1026, (2008); Garcia-Faroldi G., Rodriguez C.E., Urdiales J.L., Perez-Pomares J.M., Davila J.C., Pejler G., Sanchez-Jimenez F., Fajardo I., Polyamines are present in mast cell secretory granules and are important for granule homeostasis, PLoS One, 5, 11, (2010); Azouz N.P., Zur N., Efergan A., Ohbayashi N., Fukuda M., Amihai D., Hammel I., Rothenberg M.E., Sagi-Eisenberg R., Rab5 is a novel regulator of mast cell secretory granules: impact on size, cargo, and exocytosis, J Immunol, 192, 9, pp. 4043-4053, (2014); Bonnemaison M., Back N., Lin Y., Bonifacino J.S., Mains R., Eipper B., AP-1A Controls Secretory Granule Biogenesis and Trafficking of Membrane Secretory Granule Proteins, Traffic, 15, 10, pp. 1099-1121, (2014); Coutinho M.F., Prata M.J., Alves S., A shortcut to the lysosome: the mannose-6-phosphate-independent pathway, Mol Genet Metab, 107, 3, pp. 257-266, (2012); Borges R., Dominguez N., Estevez-Herrera J., Pereda D., Machado J.D., Vesicular Ca 2 mediates granule motion and exocytosis, Cell Calcium, 51, 3, pp. 338-341, (2012); Hammel I., Lagunoff D., Galli S.J., Regulation of secretory granule size by the precise generation and fusion of unit granules, J Cell Mol Med, 14, 7, pp. 1904-1916, (2010); Travis E.R., Wang Y.M., Michael D.J., Caron M.G., Wightman R.M., Differential quantal release of histamine and 5-hydroxytryptamine from mast cells of vesicular monoamine transporter 2 knockout mice, Proc Natl Acad Sci U S A, 97, 1, pp. 162-167, (2000); Mulak A., Tache Y., Larauche M., Sex hormones in the modulation of irritable bowel syndrome, World J Gastroenterol, 20, 10, (2014); Meleine M., Matricon J., Gender-related differences in irritable bowel syndrome: Potential mechanisms of sex hormones, World J Gastroenterol, 20, 22, (2014); Clayton J.A., Collins F.S., NIH to balance sex in cell and animal studies, Nature, 509, 7500, pp. 282-283, (2014); Hox V., Desai A., Bandara G., Gilfillan A.M., Metcalfe D.D., Olivera A., Estrogen increases the severity of anaphylaxis in female mice through enhanced endothelial nitric oxide synthase expression and nitric oxide production, J Allergy Clin Immunol, 135, 3, pp. 729-736, (2015); Oskeritzian C.A., Price M.M., Hait N.C., Kapitonov D., Falanga Y.T., Morales J.K., Ryan J.J., Milstien S., Spiegel S., Essential roles of sphingosine-1-phosphate receptor 2 in human mast cell activation, anaphylaxis, and pulmonary edema, J Exp Med, 207, 3, pp. 465-474, (2010); Csaba G., Kovacs P., Pallinger E., Gender differences in the histamine and serotonin content of blood, peritoneal and thymic cells: a comparison with mast cells, Cell Biol Int, 27, 4, pp. 387-389, (2003); Vrieze A., Postma D.S., Kerstjens H.A., Perimenstrual asthma: a syndrome without known cause or cure, J Allergy Clin Immunol, 112, 2, pp. 271-282, (2003); Bauer C.S., Kampitak T., Messieh M.L., Kelly K.J., Vadas P., Heterogeneity in presentation and treatment of catamenial anaphylaxis, Ann Allergy Asthma Immunol, 111, 2, pp. 107-111, (2013); Spanos C., El-Mansoury M., Letourneau R., Minogiannis P., Greenwood J., Siri P., Sant G.R., Theoharides T.C., Carbachol-induced bladder mast cell activation: augmentation by estradiol and implications for interstitial cystitis, Urology, 48, 5, pp. 809-816, (1996); Ober C., Loisel D.A., Gilad Y., Sex-specific genetic architecture of human disease, Nat Rev Genet, 9, 12, pp. 911-922, (2008); Yang X., Schadt E.E., Wang S., Wang H., Arnold A.P., Ingram-Drake L., Drake T.A., Lusis A.J., Tissue-specific expression and regulation of sexually dimorphic genes in mice, Genome Res, 16, 8, pp. 995-1004, (2006); Jansen R., Batista S., Brooks A.I., Tischfield J.A., Willemsen G., Van Grootheest G., Hottenga J.J., Milaneschi Y., Mbarek H., Madar V., Peyrot W., Vink J.M., Verweij C.L., De Geus E.J., Smit J.H., Wright F.A., Sullivan P.F., Boomsma D.I., Penninx B.W., Sex differences in the human peripheral blood transcriptome, BMC Genomics, 15, (2014); Lindholm M.E., Huss M., Solnestam B.W., Kjellqvist S., Lundeberg J., Sundberg C.J., The human skeletal muscle transcriptome: sex differences, alternative splicing, and tissue homogeneity assessed with RNA sequencing, FASEB J, 28, 10, pp. 4571-4581, (2014); Sankaran-Walters S., Macal M., Grishina I., Nagy L., Goulart L., Coolidge K., Li J., Fenton A., Williams T., Miller M.K., Sex differences matter in the gut: effect on mucosal immune activation and inflammation, Biol Sex Differ, 4, 10, (2013); Ames B.N., Garry B.J., Martin R.G., The first step of histidine biosynthesis, J Biol Chem, 236, pp. 2019-2026, (1961); Ahmed M., Taylor W., Smith P.R., Becker M.A., Accelerated transcription of PRPS1 in X-linked overactivity of normal human phosphoribosylpyrophosphate synthetase, J Biol Chem, 274, 11, pp. 7482-7488, (1999); Nakazawa S., Sakanaka M., Furuta K., Natsuhara M., Takano H., Tsuchiya S., Okuno Y., Ohtsu H., Nishibori M., Thurmond R.L., Histamine synthesis is required for granule maturation in murine mast cells, Eur J Immunol, 44, 1, pp. 204-214, (2014); Childs A., Mehta D., Gerner E., Polyamine-dependent gene expression, Cell Mol Life Sci, 60, 7, pp. 1394-1406, (2003); Tian X., Jin R.U., Bredemeyer A.J., Oates E.J., Blazewska K.M., McKenna C.E., Mills J.C., RAB26 and RAB3D are direct transcriptional targets of MIST1 that regulate exocrine granule maturation, Mol Cell Biol, 30, 5, pp. 1269-1284, (2010); Olszewski M.B., Trzaska D., Knol E.F., Adamczewska V., Dastych J., Efficient sorting of TNF-alpha to rodent mast cell granules is dependent on N-linked glycosylation, Eur J Immunol, 36, 4, pp. 997-1008, (2006); Xiao Y., Word B., Starlard-Davenport A., Haefele A., Lyn-Cook B.D., Hammons G., Age and gender affect DNMT3a and DNMT3b expression in human liver, Cell Biol Toxicol, 24, 3, pp. 265-272, (2008); McCarthy M.M., Auger A.P., Bale T.L., De Vries G.J., Dunn G.A., Forger N.G., Murray E.K., Nugent B.M., Schwarz J.M., Wilson M.E., The epigenetics of sex differences in the brain, J Neurosci, 29, 41, pp. 12815-12823, (2009); Jadhav R.R., Ye Z., Huang R.L., Liu J., Hsu P.Y., Huang Y.W., Rangel L.B., Lai H.C., Roa J.C., Kirma N.B., Huang T.H., Jin V.X., Genome-wide DNA methylation analysis reveals estrogen-mediated epigenetic repression of metallothionein-1 gene cluster in breast cancer, Clin Epigenetics, 7, 1, (2015); Wijchers P.J., Festenstein R.J., Epigenetic regulation of autosomal gene expression by sex chromosomes, Trends Genet, 27, 4, pp. 132-140, (2011); Libert C., Dejager L., Pinheiro I., The X chromosome in immune functions: when a chromosome makes the difference, Nat Rev Immunol, 10, 8, pp. 594-604, (2010); Berletch J.B., Ma W., Yang F., Shendure J., Noble W.S., Disteche C.M., Deng X., Escape from X inactivation varies in mouse tissues, PLoS Genet, 11, 3, (2015); Carrel L., Willard H.F., X-inactivation profile reveals extensive variability in X-linked gene expression in females, Nature, 434, 7031, pp. 400-404, (2005); Gordon J.R., Burd P.R., Galli S.J., Mast cells as a source of multifunctional cytokines, Immunol Today, 11, pp. 458-464, (1990); Wastling J.M., Knight P., Ure J., Wright S., Thornton E.M., Scudamore C.L., Mason J., Smith A., Miller H.R., Histochemical and ultrastructural modification of mucosal mast cell granules in parasitized mice lacking the β-chymase, mouse mast cell protease-1, Am J Pathol, 153, 2, pp. 491-504, (1998); Caughey G.H., Mast cell proteases as protective and inflammatory mediators, Mast Cell Biology, pp. 212-234, (2011); Lutzelschwab C., Huang M.R., Kullberg M.C., Aveskogh M., Hellman L., Characterization of mouse mast cell protease-8, the first member of a novel subfamily of mouse mast cell serine proteases, distinct from both the classical chymases and tryptases, Eur J Immunol, 28, 3, pp. 1022-1033, (1998); Payne V., Kam P., Mast cell tryptase: a review of its physiology and clinical significance, Anaesthesia, 59, 7, pp. 695-703, (2004); Le Q.T., Gomez G., Zhao W., Hu J., Xia H.Z., Fukuoka Y., Katunuma N., Schwartz L.B., Processing of human protryptase in mast cells involves cathepsins L, B, and C, J Immunol, 187, 4, pp. 1912-1918, (2011); Caughey G.H., Mast cell tryptases and chymases in inflammation and host defense, Immunol Rev, 217, 1, pp. 141-154, (2007); Schweiger A., Christensen I.J., Nielsen H.J., Sorensen S., Brunner N., Kos J., Serum cathepsin H as a potential prognostic marker in patients with colorectal cancer, Int J Biol Markers, 19, 4, pp. 289-294, (2004); Bone H.G., McClung M.R., Roux C., Recker R.R., Eisman J.A., Verbruggen N., Hustad C.M., DaSilva C., Santora A.C., Ince B.A., Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density, J Bone Miner Res, 25, 5, pp. 937-947, (2004); Wang J., Chen L., Li Y., Guan X., Overexpression of cathepsin Z contributes to tumor metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma, PLoS One, 6, 9, (2011); Henningsson F., Yamamoto K., Saftig P., Reinheckel T., Peters C., Knight S.D., Pejler G., A role for cathepsin E in the processing of mast-cell carboxypeptidase A, J Cell Sci, 118, pp. 2035-2042, (2005); Tang C.H., Lee J.W., Galvez M.G., Robillard L., Mole S.E., Chapman H.A., Murine cathepsin F deficiency causes neuronal lipofuscinosis and late-onset neurological disease, Mol Cell Biol, 26, 6, pp. 2309-2316, (2006); Zhang K., Su J., Chen S., Yu S., Tan J., Xu M., Liang H., Zhao Y., Chao H., Yang L., Molecular cloning, characterization and expression analysis of cathepsin O in silkworm Bombyx mori related to bacterial response, Mol Immunol, 66, 2, pp. 409-417, (2015); Fukuishi N., Murakami S., Ohno A., Yamanaka N., Matsui N., Fukutsuji K., Yamada S., Itoh K., Akagi M., Does beta-hexosaminidase function only as a degranulation indicator in mast cells? The primary role of betahexosaminidase in mast cell granules, J Immunol, 193, 4, pp. 1886-1894, (2014); Durchfort N., Verhoef S., Vaughn M.B., Shrestha R., Adam D., Kaplan J., Ward D.M., The enlarged lysosomes in beigej cells result from decreased lysosome fission and not increased lysosome fusion, Traffic, 13, 1, pp. 108-119, (2012); Merickel A., Edwards R., Transport of histamine by vesicular monoamine transporter-2, Neuropharmacology, 34, 11, pp. 1543-1547, (1995)","A.J. Moeser; Gastrointestinal Stress Biology Laboratory, Michigan State University, East Lansing, 48824, United States; email: moeserad@cvm.msu.edu","","BioMed Central Ltd.","","","","","","20426410","","","","English","Biol. Sex Differ.","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-84996843278"

"Yue H.; Bin L.; Chaoying C.; Meng Z.; Meng L.; Xi W.","Yue, Hu (56911799200); Bin, Lu (24780310000); Chaoying, Chen (57197866425); Meng, Zhang (57197867322); Meng, Li (57217647912); Xi, Wang (57197868376)","56911799200; 24780310000; 57197866425; 57197867322; 57217647912; 57197868376","Potential Regulatory Effects of Corticotropin-Releasing Factor on Tight Junction-Related Intestinal Epithelial Permeability are Partially Mediated by CK8 Upregulation","2017","Cellular Physiology and Biochemistry","44","3","","1161","1173","12","7","10.1159/000485420","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85035770355&doi=10.1159%2f000485420&partnerID=40&md5=db0b4514f0d95a6fc11e01db2edaeb7d","Department of Gastroenterology, First Affiliated Hospital, Zhejiang Chinese Medical University, 54 Youdian Road, Hangzhou, China","Yue H., Department of Gastroenterology, First Affiliated Hospital, Zhejiang Chinese Medical University, 54 Youdian Road, Hangzhou, China; Bin L., Department of Gastroenterology, First Affiliated Hospital, Zhejiang Chinese Medical University, 54 Youdian Road, Hangzhou, China; Chaoying C., Department of Gastroenterology, First Affiliated Hospital, Zhejiang Chinese Medical University, 54 Youdian Road, Hangzhou, China; Meng Z., Department of Gastroenterology, First Affiliated Hospital, Zhejiang Chinese Medical University, 54 Youdian Road, Hangzhou, China; Meng L., Department of Gastroenterology, First Affiliated Hospital, Zhejiang Chinese Medical University, 54 Youdian Road, Hangzhou, China; Xi W., Department of Gastroenterology, First Affiliated Hospital, Zhejiang Chinese Medical University, 54 Youdian Road, Hangzhou, China","Background/Aims: Intestinal permeability and stress have been implicated in the pathophysiology of irritable bowel syndrome (IBS). Cytokeratin 8 (CK8), for the first time, has been shown to mediate corticotropin-releasing factor (CRF)-induced changes in intestinal permeability in animal models of IBS. In this study, we investigated the regulatory effects of CRF on the permeability of human intestinal epithelial cells through the CK8-mediated tight junction. Methods: The expression levels of corticotropin-releasing factor receptor 1 (CRFR1) and corticotropin-releasing factor receptor 2 (CRFR2) on the HT29 cell surface were determined by immunofluorescence, RT-PCR, and Western blotting. After treatment with 100 nM CRF for 72 h, the translocation of FITC-labelled dextran was measured in a transwell chamber; the structural changes of tight junctions were observed under transmission electron microscopy; the expression levels of CK8, F-actin and tight junction proteins ZO-1, claudin-1, and occludin were detected by immunoblotting and immunofluorescence. The activity of RhoA was detected by immunoprecipitation. Furthermore, the effects of CRF on intestinal epithelial permeability were examined in CK8-silenced HT29 cells, which were constructed by shRNA interference. Results: CRF treatment increased FITC-labelled dextran permeability, caused the opening of tight junctions, induced increased fluorescence intensity of CK8 and decreased the intensities of ZO-1, claudin-1, and occludin, together with structural disruption. The expression levels of F-actin, occludin, claudin-1, and ZO-1 were downregulated. RhoA activity peaked at 30 min after CRF treatment. CRF-induced increased permeability, and downregulation of claudin-1 and occludin were not blocked by CK8 silencing. Nevertheless, CK8 silencing blocked the effects of CRF regarding the decrease in the expression levels of F-action and ZO-1 and increase in RhoA activity. Conclusion: CRF may increase intestinal epithelial permeability by upregulating CK8 expression, activating the RhoA signalling pathway, promoting intestinal epithelial actin remodelling, and decreasing the expression of the tight junction protein ZO-1. Other CK8-independent pathways may be involved in the downregulation of claudin-1 and occludin, which might also contribute to increased intestinal epithelial permeability. © 2017 The Author(s). Published by S. Karger AG, Basel.","Corticotropin-releasing factor; Cytokeratin 8; Intestinal epithelial permeability; RhoA; Tight junction protein","Actins; Claudin-1; Corticotropin-Releasing Hormone; HT29 Cells; Humans; Intestinal Mucosa; Keratin-8; Microscopy, Electron; Microscopy, Fluorescence; Occludin; Permeability; Real-Time Polymerase Chain Reaction; Receptors, Corticotropin-Releasing Hormone; rhoA GTP-Binding Protein; RNA Interference; RNA, Small Interfering; Tight Junctions; Up-Regulation; Zonula Occludens-1 Protein; claudin 1; corticotropin releasing factor; cytokeratin 8; F actin; occludin; tight junction protein; actin; claudin 1; corticotropin releasing factor; corticotropin releasing factor receptor; corticotropin releasing factor receptor 1; corticotropin releasing factor receptor 2; cytokeratin 8; occludin; protein ZO1; RhoA guanine nucleotide binding protein; small interfering RNA; analysis of variance; Article; cell culture; cell viability; controlled study; down regulation; electron microscopy; human; human cell; immunoblotting; immunofluorescence; immunoprecipitation; intestine epithelium cell; intestine mucosa permeability; priority journal; protein analysis; protein expression; protein function; reverse transcription polymerase chain reaction; Western blotting; antagonists and inhibitors; cytology; drug effects; fluorescence microscopy; genetics; HT-29 cell line; intestine mucosa; metabolism; permeability; real time polymerase chain reaction; RNA interference; tight junction; ultrastructure; upregulation","","claudin 1, 329338-06-9; corticotropin releasing factor, 9015-71-8, 178359-01-8, 79804-71-0, 86297-72-5, 86784-80-7; F actin, 39409-31-9; occludin, 176304-61-3; RhoA guanine nucleotide binding protein, ; RhoB guanine nucleotide binding protein, ; RhoC guanine nucleotide binding protein, ; Actins, ; Claudin-1, ; Corticotropin-Releasing Hormone, ; CRF receptor type 1, ; CRF receptor type 2, ; Keratin-8, ; Occludin, ; Receptors, Corticotropin-Releasing Hormone, ; rhoA GTP-Binding Protein, ; RNA, Small Interfering, ; Zonula Occludens-1 Protein, ","","","National Natural Science Foundation of China, NSFC, (81470814)","This study was supported by the Natural Science Foundation of China (No.81470814).","Chang J.Y., Locke G.R., McNally M.A., Halder S.L., Schleck C.D., Zinsmeister A.R., Talley N.J., 2010 Impact of functional gastrointestinal disorders on survival in the community, Am J Gastroenterol, 105, pp. 822-832, (2010); Piche T., Barbara G., Aubert P., Bruley Des Varannes S., Dainese R., Nano J.L., Cremon C., Stanghellini V., De Giorgio R., Galmiche J.P., Neunlist M., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: Involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Vivinus-Nebot M., Frin-Mathy G., Bzioueche H., Dainese R., Bernard G., Anty R., Filippi J., Saint-Paul M.C., Tulic M.K., Verhasselt V., Hebuterne X., Piche T., Functional bowel symptoms in quiescent inflammatory bowel diseases: Role of epithelial barrier disruption and low-grade inflammation, Gut, 63, pp. 744-752, (2014); Xiao L., Rao J.N., Cao S., Liu L., Chung H.K., Zhang Y., Zhang J., Liu Y., Gorospe M., Wang J.Y., Long noncoding RNA SPRY4-IT1 regulates intestinal epithelial barrier function by modulating the expression levels of tight junction proteins, Mol Biol Cell, 27, pp. 617-626, (2016); Forster C., Tight junctions and the modulation of barrier function in disease, Histochem Cell Biol, 130, pp. 55-70, (2008); Turner J.R., Molecular basis of epithelial barrier regulation: From basic mechanisms to clinical application, Am J Pathol, 169, pp. 1901-1909, (2006); Steed E., Balda M.S., Matter K., Dynamics and functions of tight junctions, Trends Cell Biol, 20, pp. 142-149, (2010); Citi S., Denisenko N., Phosphorylation of the tight junction protein cingulin and the effects of protein kinase inhibitors and activators in MDCK epithelial cells, J Cell Sci, 108, pp. 2917-2926, (1995); Dai C., Guandalini S., Zhao D.H., Jiang M., Antinociceptive effect of VSL#3 on visceral hypersensitivity in a rat model of irritable bowel syndrome: A possible action through nitric oxide pathway and enhance barrier function, Mol Cell Biochem, 362, pp. 43-53, (2012); Matsuo K., Zhang X., Ono Y., Nagatomi R., Acute stress-induced colonic tissue HSP70 expression requires commensal bacterial components and intrinsic glucocorticoid, Brain Behav Immun, 23, pp. 108-115, (2009); Zhou Q., Souba W.W., Croce C.M., Verne G.N., MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome, Gut, 59, pp. 775-784, (2010); Martinez C., Rodino-Janeiro B.K., Lobo B., Stanifer M.L., Klaus B., Granzow M., Gonzalez-Castro A.M., Salvo-Romero E., Alonso-Cotoner C., Pigrau M., Roeth R., Rappold G., Huber W., Gonzalez-Silos R., Lorenzo J., De Torres I., Azpiroz F., Boulant S., Vicario M., Niesler B., Santos J., MiR-16 and miR-125b are involved in barrier function dysregulation through the modulation of claudin-2 and cingulin expression in the jejunum in IBS with diarrhoea, Gut, 66, pp. 1537-1538, (2017); Zupancic T., Stojan J., Lane E.B., Komel R., Bedina-Zavec A., Liovic M., Intestinal cell barrier function in vitro is severely compromised by keratin 8 and 18 mutations identified in patients with inflammatory bowel disease, PLoS One, 9, (2014); Alam H., Kundu S.T., Dalal S.N., Vaidya M.M., Loss of keratins 8 and 18 leads to alterations in alpha6beta4-integrin-mediated signalling and decreased neoplastic progression in an oral-tumour-derived cell line, J Cell Sci, 124, pp. 2096-2106, (2011); Beil M., Leser J., Lutz M.P., Gukovskaya A., Seufferlein T., Lynch G., Pandol S.J., Adler G., Caspase 8-mediated cleavage of plectin precedes F-actin breakdown in acinar cells during pancreatitis, Am J Physiol Gastrointest Liver Physiol, 282, pp. G450-460, (2002); Bordeleau F., Myrand Lapierre M.E., Sheng Y., Marceau N., Keratin 8/18 regulation of cell stiffness-extracellular matrix interplay through modulation of Rho-mediated actin cytoskeleton dynamics, PLoS One, 7, (2012); Wald F.A., Oriolo A.S., Casanova M.L., Salas P.J., Intermediate filaments interact with dormant ezrin in intestinal epithelial cells, Mol Biol Cell, 16, pp. 4096-4107, (2005); Fortier A.M., Asselin E., Cadrin M., Keratin 8 and 18 loss in epithelial cancer cells increases collective cell migration and cisplatin sensitivity through claudin1 up-regulation, J Biol Chem, 288, pp. 11555-11571, (2013); Ding Y., Lu B., Chen D., Meng L., Shen Y., Chen S., Proteomic analysis of colonic mucosa in a rat model of irritable bowel syndrome, Proteomics, 10, pp. 2620-2630, (2010); Larauche M., Mulak A., Tache Y., Stress and visceral pain: From animal models to clinical therapies, Exp Neurol, 233, pp. 49-67, (2012); O'Malley D., Quigley E.M., Dinan T.G., Cryan J.F., Do interactions between stress and immune responses lead to symptom exacerbations in irritable bowel syndrome?, Brain Behav Immun, 25, pp. 1333-1341, (2011); Zhou H., Lv B., Zhang L., Li M., Chu L., Chen M.Y., Chen H.Q., The effect of antagonizing corticotropin releasing factor receptor 1/activating corticotropin releasing factor receptor 2 on visceral sensitivity and colonic motility of irritable bowel syndrome rats, Chin J Dig, 31, pp. 372-376, (2011); Nozu T., Okumura T., Corticotropin-releasing factor receptor type 1 and type 2 interaction in irritable bowel syndrome, J Gastroenterol, 50, pp. 819-830, (2015); Overman E.L., Rivier J.E., Moeser A.J., CRF induces intestinal epithelial barrier injury via the release of mast cell proteases and TNF-alpha, PLoS One, 7, (2012); Buckley M.M., O'Halloran K.D., Rae M.G., Dinan T.G., O'Malley D., Modulation of enteric neurons by interleukin-6 and corticotropin-releasing factor contributes to visceral hypersensitivity and altered colonic motility in a rat model of irritable bowel syndrome, J Physiol, 592, pp. 5235-5250, (2014); Wallon C., Persborn M., Jonsson M., Wang A., Phan V., Lampinen M., Vicario M., Santos J., Sherman P.M., Carlson M., Ericson A.C., McKay D.M., Soderholm J.D., Eosinophils express muscarinic receptors and corticotropin-releasing factor to disrupt the mucosal barrier in ulcerative colitis, Gastroenterology, 140, pp. 1597-1607, (2011); Zbytek B., Pikula M., Slominski R.M., Mysliwski A., Wei E., Wortsman J., Slominski A.T., Corticotropin-releasing hormone triggers differentiation in HaCaT keratinocytes, Br J Dermatol, 152, pp. 474-480, (2005); Zoumakis E., Margioris A.N., Stournaras C., Dermitzaki E., Angelakis E., Makrigiannakis A., Koumantakis E., Gravanis A., Corticotrophin-releasing hormone (CRH) interacts with inflammatory prostaglandins and interleukins and affects the decidualization of human endometrial stroma, Mol Hum Reprod, 6, pp. 344-351, (2000); Keita A.V., Soderholm J.D., Ericson A.C., Stress-induced barrier disruption of rat follicle-associated epithelium involves corticotropin-releasing hormone, acetylcholine, substance P, and mast cells, Neurogastroenterol Motil, 22, pp. 770-778, (2010); Teitelbaum A.A., Gareau M.G., Jury J., Yang P.C., Perdue M.H., Chronic peripheral administration of corticotropin-releasing factor causes colonic barrier dysfunction similar to psychological stress, Am J Physiol Gastrointest Liver Physiol, 295, pp. G452-459, (2008); Hesse M., Magin T.M., Weber K., Genes for intermediate filament proteins and the draft sequence of the human genome: Novel keratin genes and a surprisingly high number of pseudogenes related to keratin genes 8 and 18, J Cell Sci, 114, pp. 2569-2575, (2001); Kimura K., Ito M., Amano M., Chihara K., Fukata Y., Nakafuku M., Yamamori B., Feng J., Nakano T., Okawa K., Iwamatsu A., Kaibuchi K., Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase), Science, 273, pp. 245-248, (1996); Ma T., Liu L., Wang P., Xue Y., Evidence for involvement of ROCK signaling in bradykinin-induced increase in murine blood-tumor barrier permeability, J Neurooncol, 106, pp. 291-301, (2012); Gonzalez-Mariscal L., Quiros M., Diaz-Coranguez M., ZO proteins and redox-dependent processes, Antioxid Redox Signal, 15, pp. 1235-1253, (2011); Van Hinsbergh V.W., Van Nieuw Amerongen G.P., Intracellular signalling involved in modulating human endothelial barrier function, J Anat, 200, pp. 549-560, (2002); Arnold T.R., Stephenson R.E., Miller A.L., Rho GTPases and actomyosin: Partners in regulating epithelial cell-cell junction structure and function, Exp Cell Res, 358, pp. 20-30, (2017); Torres-Cruz F.M., Rodriguez-Cruz F., Escobar-Herrera J., Barragan-Andrade N., Basurto-Islas G., Ripova D., Avila J., Garcia-Sierra F., Expression of tau produces aberrant plasma membrane blebbing in glial cells through RhoA-ROCK-dependent F-actin remodeling, J Alzheimers Dis, 52, pp. 463-482, (2016); Wettschureck N., Offermanns S., Rho/Rho-kinase mediated signaling in physiology and pathophysiology, J Mol Med (Berl), 80, pp. 629-638, (2002); Wallon C., Persborn M., Jonsson M., Wang A., Phan V., Lampinen M., Vicario M., Santos J., Sherman P.M., Carlson M., Ericson A.C., McKay D.M., Soderholm J.D., Eosinophils express muscarinic receptors and corticotropin-releasing factor to disrupt the mucosal barrier in ulcerative colitis, Gastroenterology, 140, pp. 1597-1607, (2011)","","","S. Karger AG","","","","","","10158987","","CEPBE","29179184","English","Cell. Physiol. Biochem.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85035770355"

"Zhang J.; Song L.; Wang Y.; Liu C.; Zhang L.; Zhu S.; Liu S.; Duan L.","Zhang, Jindong (57205127895); Song, Lijin (57200651228); Wang, Yujing (57201739138); Liu, Chang (57203359455); Zhang, Lu (15040157300); Zhu, Shiwei (57205130831); Liu, Shuangjiang (7409461413); Duan, Liping (10539575000)","57205127895; 57200651228; 57201739138; 57203359455; 15040157300; 57205130831; 7409461413; 10539575000","Beneficial effect of butyrate-producing Lachnospiraceae on stress-induced visceral hypersensitivity in rats","2019","Journal of Gastroenterology and Hepatology (Australia)","34","8","","1368","1376","8","179","10.1111/jgh.14536","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85058708876&doi=10.1111%2fjgh.14536&partnerID=40&md5=07b6758174e4ac7483a6bff73613c78c","Department of Gastroenterology, Peking University Third Hospital, Beijing, China; State Key Laboratory of Microbial Resources, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China","Zhang J., Department of Gastroenterology, Peking University Third Hospital, Beijing, China; Song L., Department of Gastroenterology, Peking University Third Hospital, Beijing, China; Wang Y., State Key Laboratory of Microbial Resources, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China; Liu C., State Key Laboratory of Microbial Resources, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China; Zhang L., Department of Gastroenterology, Peking University Third Hospital, Beijing, China; Zhu S., Department of Gastroenterology, Peking University Third Hospital, Beijing, China; Liu S., State Key Laboratory of Microbial Resources, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China; Duan L., Department of Gastroenterology, Peking University Third Hospital, Beijing, China","Background and Aim: Emerging evidence indicates that psychological stress is involved in the pathogenesis of irritable bowel syndrome, which is characterized by visceral hypersensitivity and may be accompanied by gut dysbiosis. However, how such stress contributes to the development of visceral hypersensitivity is incompletely understood. Here, we aimed to investigate the influence that stress-induced microbial changes exert on visceral sensitivity, as well as the possible underlying mechanisms associated with this effect. Methods: Male Sprague–Dawley rats underwent chronic water avoidance stress (WAS) to induce visceral hypersensitivity. Visceral sensitivity, colonic tight junction protein expression, and short-chain fatty acids of cecal contents were measured. Fecal samples were collected to characterize microbiota profiles. In a separate study, oral gavage of Roseburia in WAS rats was conducted to verify its potential role in the effectiveness on visceral hypersensitivity. Results: Repeated WAS caused visceral hypersensitivity, altered fecal microbiota composition and function, and decreased occludin expression in the colon. Stressed rats exhibited reduced representation of pathways involved in the metabolism of butyrate and reduced abundance of several operational taxonomic units associated with butyrate-producing bacteria, such as Lachnospiraceae. Consistently, supplementation with Roseburia hominis, a species belonging to Lachnospiraceae, significantly increased cecal butyrate content. Moreover, Roseburia supplementation alleviated visceral hypersensitivity and prevented the decreased expression of occludin. Conclusions: Reduction in the abundance of butyrate-producing Lachnospiraceae, which is beneficial for the intestinal barrier, was involved in the formation of visceral hypersensitivity. R. hominis is a potential probiotic for treating stress-induced visceral hypersensitivity. © 2018 The Authors. Journal of Gastroenterology and Hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd","butyrate; intestinal barrier; microbiota; stress; visceral hypersensitivity","Animals; Butyrates; Clostridiales; Colon; Disease Models, Animal; Feces; Gastrointestinal Microbiome; Hyperalgesia; Male; Occludin; Pain Perception; Pain Threshold; Probiotics; Rats, Sprague-Dawley; Stress, Psychological; Tight Junctions; Visceral Pain; beta actin; butyric acid; complementary DNA; corticotropin releasing factor; occludin; probiotic agent; RNA 16S; short chain fatty acid; butyric acid derivative; occludin; Ocln protein, rat; probiotic agent; animal experiment; animal model; Article; avoidance behavior; drug efficacy; feces microflora; hypersensitivity; male; mental stress; nonhuman; priority journal; protein blood level; protein expression; rat; Roseburia; Roseburia hominis; animal; Clostridiales; colon; complication; disease model; feces; hyperalgesia; intestine flora; mental stress; metabolism; microbiology; nociception; pain threshold; pathophysiology; Sprague Dawley rat; tight junction; visceral pain","","butyric acid, 107-92-6, 156-54-7, 461-55-2; corticotropin releasing factor, 9015-71-8, 178359-01-8, 79804-71-0, 86297-72-5, 86784-80-7; occludin, 176304-61-3; Butyrates, ; Occludin, ; Ocln protein, rat, ","","","Capital’s Funds for Health Improvement and Research, (2016-2-4093); Institute of Acupuncture and Moxibustion China Academy of Chinese Medical Sciences; National Natural Science Foundation of China, NSFC, (81670491)","Funding text 1: We are greatly thankful for the support of Institute of Acupuncture and Moxibustion China Academy of Chinese Medical Sciences, as well as Metabolomics Facility at Technology Center for Protein Sciences in Tsinghua University.; Funding text 2: disclosed no financial relationships relevant to this publication. Financial support: This work was supported by the National Natural Science Foundation of China (grant number 81670491) and Capital’s Funds for Health Improvement and Research (grant number 2016-2-4093).","Liu Y., Zhang L., Wang X., Et al., Similar fecal microbiota signatures in patients with diarrhea-predominant irritable bowel syndrome and patients with depression, Clin. Gastroenterol. Hepatol., 14, pp. 1602-1611, (2016); Tap J., Derrien M., Tornblom H., Brazeilles R., Cools-Portier S., Dore J., Et al., Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology, (2016); Luczynski P., Tramullas M., Viola M., Et al., Microbiota regulates visceral pain in the mouse, Elife, 6, (2017); O'Mahony S.M., Felice V.D., Nally K., Et al., Disturbance of the gut microbiota in early-life selectively affects visceral pain in adulthood without impacting cognitive or anxiety-related behaviors in male rats, Neuroscience, 277, pp. 885-901, (2014); Sisson G., Ayis S., Sherwood R.A., Bjarnason I., Randomised clinical trial: a liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome—a 12 week double-blind study, Aliment Pharmacol. Ther., 40, pp. 51-62, (2014); Acosta A., Camilleri M., Shin A., Et al., Effects of rifaximin on transit, permeability, fecal microbiome, and organic acid excretion in irritable bowel syndrome, Clin. Transl. Gastroenterol., 7, (2016); Bailey M.T., Dowd S.E., Galley J.D., Hufnagle A.R., Allen R.G., Lyte M., Exposure to a social stressor alters the structure of the intestinal microbiota: implications for stressor-induced immunomodulation, Brain Behav. Immun., 25, pp. 397-407, (2011); Bharwani A., Mian M.F., Foster J.A., Surette M.G., Bienenstock J., Forsythe P., Structural & functional consequences of chronic psychosocial stress on the microbiome & host, Psychoneuroendocrinology, 63, pp. 217-227, (2016); Szyszkowicz J.K., Wong A., Anisman H., Merali Z., Audet M.C., Implications of the gut microbiota in vulnerability to the social avoidance effects of chronic social defeat in male mice, Brain Behav. Immun., 66, pp. 45-55, (2017); de Theije C.G., Wopereis H., Ramadan M., Et al., Altered gut microbiota and activity in a murine model of autism spectrum disorders, Brain Behav. Immun., 37, pp. 197-206, (2014); Tan J., McKenzie C., Potamitis M., Thorburn A.N., Mackay C.R., Macia L., The role of short-chain fatty acids in health and disease, Adv. Immunol., 121, pp. 91-119, (2014); Kannampalli P., Shaker R., Sengupta J.N., Colonic butyrate- algesic or analgesic?, Neurogastroenterol. Motil., 23, pp. 975-979, (2011); Farup P.G., Rudi K., Hestad K., Fecal short-chain fatty acids—a diagnostic biomarker for irritable bowel syndrome?, BMC Gastroenterol, 16, (2016); Gil D.W., Wang J., Gu C., Donello J.E., Cabrera S., Al-Chaer E.D., Role of sympathetic nervous system in rat model of chronic visceral pain, Neurogastroenterol. Motil., 28, pp. 423-431, (2016); Hong S., Fan J., Kemmerer E.S., Evans S., Li Y., Wiley J.W., Reciprocal changes in vanilloid (TRPV1) and endocannabinoid (CB1) receptors contribute to visceral hyperalgesia in the water avoidance stressed rat, Gut, 58, pp. 202-210, (2009); Al-Chaer E.D., Kawasaki M., Pasricha P.J., A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development, Gastroenterology, 119, pp. 1276-1285, (2000); Langille M.G.I., Zaneveld J., Caporaso J.G., McDonald D., Knights D., Reyes J.A., Et al., Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences, Nat. Biotechnol., 31, pp. 814-821, (2013); Han J., Lin K., Sequeira C., Borchers C.H., An isotope-labeled chemical derivatization method for the quantitation of short-chain fatty acids in human feces by liquid chromatography-tandem mass spectrometry, Anal. Chim. Acta., 854, pp. 86-94, (2015); Chung C.S., Chang P.F., Liao C.H., Et al., Differences of microbiota in small bowel and faeces between irritable bowel syndrome patients and healthy subjects, Scand. J. Gastroenterol., 51, pp. 410-419, (2016); Elinav E., Strowig T., Kau A.L., Et al., NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis, Cell, 145, pp. 745-757, (2011); Chen W., Liu F., Ling Z., Tong X., Xiang C., Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer, PLoS One, 7, (2012); Harmsen H.J.M., Wildeboer-Veloo A.C.M., Grijpstra J., Knol J., Degener J.E., Welling G.W., Development of 16S rRNA-based probes for the Coriobacterium group and the Atopobium cluster and their application for enumeration of Coriobacteriaceae in human feces from volunteers of different age groups, Appl. Environ. Microbiol., 66, pp. 4523-4527, (2000); Bangsgaard Bendtsen K.M., Krych L., Sorensen D.B., Et al., Gut microbiota composition is correlated to grid floor induced stress and behavior in the BALB/c mouse, PLoS One, 7, (2012); Flint H.J., Duncan S.H., Scott K.P., Louis P., Links between diet, gut microbiota composition and gut metabolism, Proc Nutr Soc, 74, pp. 13-22, (2015); Dehingia M., Devi K.T., Talukdar N.C., Et al., Gut bacterial diversity of the tribes of India and comparison with the worldwide data, Sci. Rep., 5, (2015); Tamanai-Shacoori Z., Smida I., Bousarghin L., Et al., Roseburia spp.: a marker of health?, Future Microbiol., 12, pp. 157-170, (2017); Kumari R., Ahuja V., Paul J., Fluctuations in butyrate-producing bacteria in ulcerative colitis patients of North India, World J. Gastroenterol., 19, pp. 3404-3414, (2013); Machiels K., Joossens M., Sabino J., Et al., A decrease of the butyrate-producing species Roseburia hominis and Fecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis, Gut, 63, pp. 1275-1283, (2014); Chassard C., Dapoigny M., Scott K.P., Et al., Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome, Aliment Pharm. Ther., 35, pp. 828-838, (2012); Wang T.T., Cai G.X., Qiu Y.P., Et al., Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers, ISME J, 6, pp. 320-329, (2012); Takahashi K., Nishida A., Fujimoto T., Et al., Reduced abundance of butyrate-producing bacteria species in the fecal microbial community in Crohn's disease, Digestion, 93, pp. 59-65, (2016); Undseth R., Jakobsdottir G., Nyman M., Berstad A., Valeur J., Low serum levels of short-chain fatty acids after lactulose ingestion may indicate impaired colonic fermentation in patients with irritable bowel syndrome, Clin. Exp. Gastroenterol., 8, pp. 303-308, (2015); Banasiewicz T., Krokowicz L., Stojcev Z., Et al., Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome, Colorectal Dis., 15, pp. 204-209, (2013); Vanhoutvin S.A., Troost F.J., The effects of butyrate enemas on visceral perception in healthy volunteers, Neurogastroenterol. Motil., 21, pp. 952-e76, (2009); Treem W.R., Ahsan N., Kastoff G., Hyams J.S., Fecal short-chain fatty acids in patients with diarrhea-predominant irritable bowel syndrome: in vitro studies of carbohydrate fermentation, J. Pediatr. Gastroenterol. Nutr., 23, pp. 280-286, (1996); Bourdu S., Dapoigny M., Chapuy E., Et al., Rectal instillation of butyrate provides a novel clinically relevant model of noninflammatory colonic hypersensitivity in rats, Gastroenterology, 128, pp. 1996-2008, (2005); Long X., Li M., Li L.X., Et al., Butyrate promotes visceral hypersensitivity in an IBS-like model via enteric glial cell-derived nerve growth factor, Neurogastroenterol. Motil., 30, (2018); Ringel-Kulka T., Choi C.H., Temas D., Et al., Altered colonic bacterial fermentation as a potential pathophysiological factor in irritable bowel syndrome, Am. J. Gastroenterol., 110, pp. 1339-1346, (2015); Patterson A.M., Mulder I.E., Travis A.J., Et al., Human gut symbiont Roseburia hominis promotes and regulates innate immunity, Front. Immunol., 8, (2017); Burger-van Paassen N., Vincent A., Puiman P.J., Et al., The regulation of intestinal mucin MUC2 expression by short-chain fatty acids: implications for epithelial protection, Biochem. J., 420, pp. 211-219, (2009); Peng L., Li Z.R., Green R.S., Holzman I.R., Lin J., Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers, J. Nutr., 139, pp. 1619-1625, (2009)","L. Duan; Department of Gastroenterology, Peking University Third Hospital, Beijing, China; email: duanlp@bjmu.edu.cn","","Blackwell Publishing","","","","","","08159319","","JGHEE","30402954","English","J. Gastroenterol. Hepatol.","Article","Final","All Open Access; Green Open Access; Hybrid Gold Open Access","Scopus","2-s2.0-85058708876"

"Rodiño-Janeiro B.K.; Martínez C.; Fortea M.; Lobo B.; Pigrau M.; Nieto A.; González-Castro A.M.; Salvo-Romero E.; Guagnozzi D.; Pardo-Camacho C.; Iribarren C.; Azpiroz F.; Alonso-Cotoner C.; Santos J.; Vicario M.","Rodiño-Janeiro, Bruno K. (35729142300); Martínez, Cristina (17534584700); Fortea, Marina (56830396500); Lobo, Beatriz (7003936898); Pigrau, Marc (37009212800); Nieto, Adoración (57191341801); González-Castro, Ana María (54796498900); Salvo-Romero, Eloísa (56830611700); Guagnozzi, Danila (6506135584); Pardo-Camacho, Cristina (57192877965); Iribarren, Cristina (57200549137); Azpiroz, Fernando (57207592894); Alonso-Cotoner, Carmen (56411082400); Santos, Javier (7402389020); Vicario, Maria (6603267769)","35729142300; 17534584700; 56830396500; 7003936898; 37009212800; 57191341801; 54796498900; 56830611700; 6506135584; 57192877965; 57200549137; 57207592894; 56411082400; 7402389020; 6603267769","Decreased TESK1-mediated cofilin 1 phosphorylation in the jejunum of IBS-D patients may explain increased female predisposition to epithelial dysfunction","2018","Scientific Reports","8","1","2255","","","","12","10.1038/s41598-018-20540-9","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85041620756&doi=10.1038%2fs41598-018-20540-9&partnerID=40&md5=4d0fba7fae4e63b19377c4f03de22a62","Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d'Hebron Institut de Recerca, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona (Facultat de Medicina), Barcelona, Spain; Translational Mucosal Immunology, Digestive System Research Unit, Vall d'Hebron Institut de Recerca; Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona (Facultat de Medicina), Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Instituto de Salud Carlos III, Subdirección General de Investigación Sanitaria, Ministerio de Economía, Industria y Competitividad, Madrid, Spain","Rodiño-Janeiro B.K., Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d'Hebron Institut de Recerca, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona (Facultat de Medicina), Barcelona, Spain; Martínez C., Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d'Hebron Institut de Recerca, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona (Facultat de Medicina), Barcelona, Spain; Fortea M., Translational Mucosal Immunology, Digestive System Research Unit, Vall d'Hebron Institut de Recerca; Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona (Facultat de Medicina), Barcelona, Spain; Lobo B., Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d'Hebron Institut de Recerca, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona (Facultat de Medicina), Barcelona, Spain; Pigrau M., Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d'Hebron Institut de Recerca, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona (Facultat de Medicina), Barcelona, Spain; Nieto A., Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d'Hebron Institut de Recerca, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona (Facultat de Medicina), Barcelona, Spain; González-Castro A.M., Translational Mucosal Immunology, Digestive System Research Unit, Vall d'Hebron Institut de Recerca; Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona (Facultat de Medicina), Barcelona, Spain; Salvo-Romero E., Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d'Hebron Institut de Recerca, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona (Facultat de Medicina), Barcelona, Spain, Translational Mucosal Immunology, Digestive System Research Unit, Vall d'Hebron Institut de Recerca; Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona (Facultat de Medicina), Barcelona, Spain; Guagnozzi D., Translational Mucosal Immunology, Digestive System Research Unit, Vall d'Hebron Institut de Recerca; Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona (Facultat de Medicina), Barcelona, Spain; Pardo-Camacho C., Translational Mucosal Immunology, Digestive System Research Unit, Vall d'Hebron Institut de Recerca; Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona (Facultat de Medicina), Barcelona, Spain; Iribarren C., Translational Mucosal Immunology, Digestive System Research Unit, Vall d'Hebron Institut de Recerca; Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona (Facultat de Medicina), Barcelona, Spain; Azpiroz F., Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d'Hebron Institut de Recerca, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona (Facultat de Medicina), Barcelona, Spain, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Instituto de Salud Carlos III, Subdirección General de Investigación Sanitaria, Ministerio de Economía, Industria y Competitividad, Madrid, Spain; Alonso-Cotoner C., Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d'Hebron Institut de Recerca, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona (Facultat de Medicina), Barcelona, Spain, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Instituto de Salud Carlos III, Subdirección General de Investigación Sanitaria, Ministerio de Economía, Industria y Competitividad, Madrid, Spain; Santos J., Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d'Hebron Institut de Recerca, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona (Facultat de Medicina), Barcelona, Spain, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Instituto de Salud Carlos III, Subdirección General de Investigación Sanitaria, Ministerio de Economía, Industria y Competitividad, Madrid, Spain; Vicario M., Translational Mucosal Immunology, Digestive System Research Unit, Vall d'Hebron Institut de Recerca; Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona (Facultat de Medicina), Barcelona, Spain, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Instituto de Salud Carlos III, Subdirección General de Investigación Sanitaria, Ministerio de Economía, Industria y Competitividad, Madrid, Spain","Disturbed intestinal epithelial barrier and mucosal micro-inflammation characterize irritable bowel syndrome (IBS). Despite intensive research demonstrating ovarian hormones modulation of IBS severity, there is still limited knowledge on the mechanisms underlying female predominance in this disorder. Our aim was to identify molecular pathways involved in epithelial barrier dysfunction and female predominance in diarrhea-predominant IBS (IBS-D) patients. Total RNA and protein were obtained from jejunal mucosal biopsies from healthy controls and IBS-D patients meeting the Rome III criteria. IBS severity was recorded based on validated questionnaires. Gene and protein expression profiles were obtained and data integrated to explore biological and molecular functions. Results were validated by western blot. Tight junction signaling, mitochondrial dysfunction, regulation of actin-based motility by Rho, and cytoskeleton signaling were differentially expressed in IBS-D. Decreased TESK1-dependent cofilin 1 phosphorylation (pCFL1) was confirmed in IBS-D, which negatively correlated with bowel movements only in female participants. In conclusion, deregulation of cytoskeleton dynamics through TESK1/CFL1 pathway underlies epithelial intestinal dysfunction in the small bowel mucosa of IBS-D, particularly in female patients. Further understanding of the mechanisms involving sex-mediated regulation of mucosal epithelial integrity may have significant preventive, diagnostic, and therapeutic implications for IBS. © 2018 The Author(s).","","Adult; Biopsy; Blotting, Western; Cofilin 1; Disease Susceptibility; Female; Gene Expression Profiling; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Jejunum; Male; Middle Aged; Phosphorylation; Protein Processing, Post-Translational; Protein-Serine-Threonine Kinases; Proteins; Proteome; RNA; Sex Factors; Surveys and Questionnaires; Young Adult; cofilin 1; protein; protein serine threonine kinase; proteome; RNA; testis-specific protein kinase 1; adult; biopsy; disease predisposition; female; gene expression profiling; human; intestine mucosa; irritable colon; isolation and purification; jejunum; male; metabolism; middle aged; pathology; pathophysiology; phosphorylation; protein processing; questionnaire; sex factor; Western blotting; young adult","","protein, 67254-75-5; protein serine threonine kinase, ; RNA, 63231-63-0; Cofilin 1, ; Protein-Serine-Threonine Kinases, ; Proteins, ; Proteome, ; RNA, ; testis-specific protein kinase 1, ","","","Generalitat de Catalunya, (2014 SGR 1285, PRED-VHIR-2014-018, PRED-VHIR-2016-34); Agència de Gestió d'Ajuts Universitaris i de Recerca, AGAUR; Ministerio de Economía y Competitividad, MINECO, (CD15/00010, CIBER-EHD CB06/04/0021, CPII16/00031, FI12/00254, IJCI-2015-26099, PI11/00716, PI12/00314, PI13/00935, PI14/00994, PI15/00301, PI16/00583); Instituto de Salud Carlos III, ISCIII; Dirección General de Investigación Científica y Técnica, DGICT; Ministerio de Educación de la Nación; European Regional Development Fund, FEDER; INCLIVA Instituto de Investigación Sanitaria; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, CIBEREHD","Grant Support. Supported in part by Fondo Europeo de Desarrollo Regional (FEDER), Fondo de Investigación Sanitaria and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas-CIBERehd, Instituto de Salud Carlos III, Subdirección General de Investigación Sanitaria, Ministerio de Economía y Competitividad: CD15/00010 (B. Rodiño-Janeiro), IJCI-2015-26099 (C. Martínez), FI12/00254 (E. Salvo-Romero), PI12/00314 & PI15/00301 (C. Alonso-Cotoner), PI11/00716 & PI14/00994 (J. Santos), CPII16/00031, PI13/00935 & PI16/00583 (M. Vicario); CIBER-EHD CB06/04/0021 (FA, CAC, JS, MV); Ministerio de Educación, Dirección General de Investigación: SAF 2016-76648-R (F. Azpiroz); Agència de Gestió d’Ajuts Universitaris i de Recerca, de la Generalitat de Catalunya: 2014 SGR 1285 (F. Azpiroz); Vall d’Hebron Institut de Recerca, Programa de becas predoctorales “Amics de Vall d’Hebron”: PRED-VHIR-2014-018 (M. Fortea), PRED-VHIR-2016-34 (C. Pardo-Camacho).","Enck P., Et al., Irritable bowel syndrome, Nat. Rev. Dis. Prime, 2, (2016); Hughes P.A., Et al., Immune activation in irritable bowel syndrome: Can neuroimmune interactions explain symptoms?, Am. J. Gastroenterol, 108, pp. 1066-1074, (2013); Vicario M., Et al., Increased humoral immunity in the jejunum of diarrhoea-predominant irritable bowel syndrome associated with clinical manifestations, Gu, 64, pp. 1379-1388, (2015); Wouters M.M., Vicario M., Santos J., The role of mast cells in functional GI disorders, Gu, 65, pp. 155-168, (2016); Fiocchi C., Intestinal inflammation: A complex interplay of immune and nonimmune cell interactions, Am. J. Physiol, 273, pp. G769-775, (1997); Martinez C., Et al., The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations, Am. J. Gastroenterol, 107, pp. 736-746, (2012); Martinez C., Et al., Diarrhoea-predominant irritable bowel syndrome: An organic disorder with structural abnormalities in the jejunal epithelial barrier, Gu, 62, pp. 1160-1168, (2013); Martinez C., Gonzalez-Castro A., Vicario M., Santos J., Cellular and molecular basis of intestinal barrier dysfunction in the irritable bowel syndrome, Gut Live, 6, pp. 305-315, (2012); Bueno L., Fioramonti J., Protease-activated receptor 2 and gut permeability: A review, Neurogastroenterol. Motil, 20, pp. 580-587, (2008); Rolland-Fourcade C., Et al., Epithelial expression and function of trypsin-3 in irritable bowel syndrome, (2017); Lau C., Lytle C., Straus D.S., DeFea K.A., Apical and basolateral pools of proteinase-activated receptor-2 direct distinct signaling events in the intestinal epithelium, Am. J. Physiol. Cell Physiol, 300, pp. C113-123, (2011); Ressad F., Didry D., Egile C., Pantaloni D., Carlier M.F., Control of actin filament length and turnover by actin depolymerizing factor (ADF/cofilin) in the presence of capping proteins and ARP2/3 complex, J. Biol. Chem, 274, pp. 20970-20976, (1999); Nagumo Y., Han J., Arimoto M., Isoda H., Tanaka T., Capsaicin induces cofilin dephosphorylation in human intestinal cells: The triggering role of cofilin in tight-junction signaling, Biochem. Biophys. Res. Commun, 355, pp. 520-525, (2007); Nagumo Y., Han J., Bellila A., Isoda H., Tanaka T., Cofilin mediates tight-junction opening by redistributing actin and tightjunction proteins, Biochem. Biophys. Res. Commun, 377, pp. 921-925, (2008); Dai S., Et al., Extracellular high mobility group box-1 (HMGB1) inhibits enterocyte migration via activation of Toll-like receptor-4 and increased cell-matrix adhesiveness, J. Biol. Chem, 285, pp. 4995-5002, (2010); Arber S., Et al., Regulation of actin dynamics through phosphorylation of cofilin by LIM-kinase, Natur, 393, pp. 805-809, (1998); Rosok O., Pedeutour F., Ree A.H., Aasheim H.C., Identification and characterization of TESK2, a novel member of the LIMK/ TESK family of protein kinases, predominantly expressed in testis, Genomic, 61, pp. 44-54, (1999); Toshima J., Et al., Cofilin phosphorylation by protein kinase testicular protein kinase 1 and its role in integrin-mediated actin reorganization and focal adhesion formation, Mol. Biol. Cel, 12, pp. 1131-1145, (2001); Aerssens J., Et al., Alterations in mucosal immunity identified in the colon of patients with irritable bowel syndrome, Clin. Gastroenterol. Hepatol, 6, pp. 194-205, (2008); Camilleri M., Et al., RNA sequencing shows transcriptomic changes in rectosigmoid mucosa in patients with irritable bowel syndrome-diarrhea: A pilot case-control study, Am. J. Physiol. Gastrointest. Liver Physiol, 306, pp. G1089-1098, (2014); Li L., Et al., Increased small intestinal permeability and RNA expression profiles of mucosa from terminal ileum in patients with diarrhoea-predominant irritable bowel syndrome, Dig. Liver Dis, 48, pp. 880-887, (2016); Macsharry J., Et al., Mucosal cytokine imbalance in irritable bowel syndrome, Scand. J. Gastroenterol, 43, pp. 1467-1476, (2008); Martinez C., Et al., MIR-16 and MIR-125b are involved in barrier function dysregulation through the modulation of claudin-2 and cingulin expression in the jejunum in IBS with diarrhoea, Gu, 66, pp. 1537-1538, (2017); Goo Y.A., Et al., Urinary proteome analysis of irritable bowel syndrome (IBS) symptom subgroups, J. Proteome Res, 11, pp. 5650-5662, (2012); Ding Y., Et al., Proteomic analysis of colonic mucosa in a rat model of irritable bowel syndrome, Proteomic, 10, pp. 2620-2630, (2010); Lopes L.V., Et al., Maternal deprivation affects the neuromuscular protein profile of the rat colon in response to an acute stressor later in life, J. Proteomic, 71, pp. 80-88, (2008); Zhou Q., Et al., MicroRNA 29 targets nuclear factor-kB-repressing factor and Claudin 1 to increase intestinal permeability, Gastroenterolog, 148, pp. 158-169e8, (2015); Cavey M., Lecuit T., Molecular bases of cell-cell junctions stability and dynamics, Cold Spring Harb. Perspect. Biol, 1, (2009); Davidson A.J., Wood W., Unravelling the actin cytoskeleton: A new competitive edge?, Trends Cell Biol, 26, pp. 569-576, (2016); Bamburg J.R., Wiggan O.P., ADF/cofilin and actin dynamics in disease, Trends Cell Biol, 12, pp. 598-605, (2002); Ono S., Mechanism of depolymerization and severing of actin filaments and its significance in cytoskeletal dynamics, Int. Rev. Cytol, 258, pp. 1-82, (2007); Agnew B.J., Minamide L.S., Bamburg J.R., Reactivation of phosphorylated actin depolymerizing factor and identification of the regulatory site, J. Biol. Chem, 270, pp. 17582-17587, (1995); Moriyama K., Iida K., Yahara I., Phosphorylation of Ser-3 of cofilin regulates its essential function on actin, Genes Cells Devoted Mol. Cell. Mech, 1, pp. 73-86, (1996); Shen L., Turner J.R., Actin depolymerization disrupts tight junctions via caveolae-mediated endocytosis, Mol. Biol. Cel, 16, pp. 3919-3936, (2005); Terai T., Nishimura N., Kanda I., Yasui N., Sasaki T., JRAB/MICAL-L2 is a junctional Rab13-binding protein mediating the endocytic recycling of occludin, Mol. Biol. Cel, 17, pp. 2465-2475, (2006); Niwa R., Nagata-Ohashi K., Takeichi M., Mizuno K., Uemura T., Control of actin reorganization by Slingshot, a family of phosphatases that dephosphorylate ADF/cofilin, Cel, 108, pp. 233-246, (2002); Gohla A., Birkenfeld J., Bokoch G.M., Chronophin, a novel HAD-type serine protein phosphatase, regulates cofilin-dependent actin dynamics, Nat. Cell Biol, 7, pp. 21-29, (2005); Amano M., Nakayama M., Kaibuchi K., Rho-kinase/ROCK: A key regulator of the cytoskeleton and cell polarity, Cytoskelet. Hoboken N, 67, pp. 545-554, (2010); Kile B.T., Et al., Mutations in the cofilin partner Aip1/Wdr1 cause autoinflammatory disease and macrothrombocytopenia, Bloo, 110, pp. 2371-2380, (2007); Lechuga S., Baranwal S., Ivanov A.I., Actin-interacting protein 1 controls assembly and permeability of intestinal epithelial apical junctions, Am. J. Physiol. Gastrointest. Liver Physiol, 308, pp. G745-756, (2015); Ferraro A., Boni T., Pintzas A., EZH2 regulates cofilin activity and colon cancer cell migration by targeting ITGA2 gene, PloS on, 9, (2014); Hansberg-Pastor V., Gonzalez-Arenas A., Pina-Medina A.G., Camacho-Arroyo I., Sex hormones regulate cytoskeletal proteins involved in brain plasticity, Front. Psychiatr, 6, (2015); Kramar E.A., Et al., Cytoskeletal changes underlie estrogen's acute effects on synaptic transmission and plasticity, J. Neurosci. Off. J. Soc. Neurosci, 29, pp. 12982-12993, (2009); Simoncini T., Et al., Estrogen receptor alpha interacts with Galpha13 to drive actin remodeling and endothelial cell migration via the RhoA/Rho kinase/moesin pathway, Mol. Endocrinol. Baltim. M, 20, pp. 1756-1771, (2006); Briz V., Baudry M., Estrogen regulates protein synthesis and actin polymerization in hippocampal neurons through different molecular mechanisms, Front. Endocrinol, 5, (2014); Ludidi S., Et al., The intestinal barrier in irritable bowel syndrome: Subtype-specific effects of the systemic compartment in an in vitro model, PloS on, 10, (2015); Dlugosz A., Et al., Increased serum levels of lipopolysaccharide and antiflagellin antibodies in patients with diarrhea-predominant irritable bowel syndrome, Neurogastroenterol. Motil, 27, pp. 1747-1754, (2015); Srivastava D., Ghoshal U., Mittal R.D., Ghoshal U.C., Associations between IL-1RA polymorphisms and small intestinal bacterial overgrowth among patients with irritable bowel syndrome from India, Neurogastroenterol. Motil, 26, pp. 1408-1416, (2014); Hughes P.A., Et al., Sensory neuro-immune interactions differ between irritable bowel syndrome subtypes, Gu, 62, pp. 1456-1465, (2013); Vicario M., Et al., Chronic psychosocial stress induces reversible mitochondrial damage and corticotropin-releasing factor receptor type-1 upregulation in the rat intestine and IBS-like gut dysfunction, Psychoneuroendocrinolog, 37, pp. 65-77, (2012); Vicario M., Et al., Chronological assessment of mast cell-mediated gut dysfunction and mucosal inflammation in a rat model of chronic psychosocial stress, Brain. Behav. Immun, 24, pp. 1166-1175, (2010); Felty Q., Et al., Estrogen-induced mitochondrial reactive oxygen species as signal-transducing messengers, Biochemistry (Mosc., 44, pp. 6900-6909, (2005); Shiobara T., Usui T., Han J., Isoda H., Nagumo Y., The reversible increase in tight junction permeability induced by capsaicin is mediated via cofilin-actin cytoskeletal dynamics and decreased level of occludin, PloS on, 8, (2013); Wang D., Et al., Actin-Depolymerizing factor and cofilin-1 have unique and overlapping functions in regulating intestinal epithelial junctions and mucosal inflammation, Am. J. Pathol, 186, pp. 844-858, (2016); Coeffier M., Et al., Increased proteasome-mediated degradation of occludin in irritable bowel syndrome, Am. J. Gastroenterol, 105, pp. 1181-1188, (2010); Drossman D.A., The functional gastrointestinal disorders and the Rome III process, Gastroenterolog, 130, pp. 1377-1390, (2006); Lewis S.J., Heaton K.W., Stool form scale as a useful guide to intestinal transit time, Scand. J. Gastroenterol, 32, pp. 920-924, (1997); Guilarte M., Et al., Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum, Gu, 56, pp. 203-209, (2007); May C., Brosseron F., Chartowski P., Meyer H.E., Marcus K., Differential proteome analysis using 2D-DIGE, Methods Mol. Biol. Clifton N, 893, pp. 75-82, (2012); Shevchenko A., Wilm M., Vorm O., Mann M., Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels, Anal. Chem, 68, pp. 850-858, (1996); Hirosawa M., Hoshida M., Ishikawa M., Toya T., MASCOT: Multiple alignment system for protein sequences based on three-way dynamic programming, Comput. Appl. Biosci. CABIO, 9, pp. 161-167, (1993)","B.K. Rodiño-Janeiro; Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d'Hebron Institut de Recerca, Department of Gastroenterology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona (Facultat de Medicina), Barcelona, Spain; email: bruno.rodino@vhir.org","","Nature Publishing Group","","","","","","20452322","","","29396473","English","Sci. Rep.","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85041620756"

"Neilan N.A.; Garg U.C.; Schurman J.V.; Friesen C.A.","Neilan, Nancy A. (26644315200); Garg, Uttam C. (7004837688); Schurman, Jennifer Verrill (8730319500); Friesen, Craig A. (57210554273)","26644315200; 7004837688; 8730319500; 57210554273","Intestinal permeability in children/adolescents with functional dyspepsia","2014","BMC Research Notes","7","1","275","","","","13","10.1186/1756-0500-7-275","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84901045700&doi=10.1186%2f1756-0500-7-275&partnerID=40&md5=9a0cd39a1487305033a1040497edb0a6","Division of Pathology and Laboratory Medicine, Children's Mercy Hospitals and Clinics, Kansas City, United States; Division of Developmental and Behavioral Sciences, Children's Mercy Hospitals and Clinics, Kansas City, United States; Division of Gastroenterology, Hepatology, and Nutrition, Children's Mercy Hospitals and Clinics, Kansas City, MO 64108, 2401 Gillham Road, United States","Neilan N.A., Division of Gastroenterology, Hepatology, and Nutrition, Children's Mercy Hospitals and Clinics, Kansas City, MO 64108, 2401 Gillham Road, United States; Garg U.C., Division of Pathology and Laboratory Medicine, Children's Mercy Hospitals and Clinics, Kansas City, United States; Schurman J.V., Division of Developmental and Behavioral Sciences, Children's Mercy Hospitals and Clinics, Kansas City, United States; Friesen C.A., Division of Gastroenterology, Hepatology, and Nutrition, Children's Mercy Hospitals and Clinics, Kansas City, MO 64108, 2401 Gillham Road, United States","Background: An altered intestinal mucosal barrier has been demonstrated in subsets of patients with IBS and FAP and may be an additional biological factor contributing to symptom generation in children with FD. The objective of this study was to determine if intestinal permeability is increased in children/adolescents with functional dyspepsia (FD) and whether intestinal permeability is correlated with mucosal inflammation and/or symptoms of anxiety or depression in this population. Methods. A sugar absorption test was performed in 19 patients with FD and 19 controls. Anxiety and depression were assessed in both groups utilizing a standard questionnaire. In FD patients, duodenal mean and peak mast cell and eosinophil densities were determined. Results: Intestinal permeability as measured by the sugar absorption test did not differ between children with FD and controls. In children with FD, there was no correlation between permeability and mast cell density, eosinophil density, anxiety scores, or depression scores, respectively. Conclusions: Pediatric FD does not appear to be associated with increased small bowel intestinal permeability, however, there are some limitations to the current study. Trial registration. ClinicalTrials.gov; NCT00363597. © 2014 Neilan et al.; licensee BioMed Central Ltd.","Eosinophilic duodenitis; Functional dyspepsia; Intestinal permeability; Sugar absorption test","Adolescent; Anxiety; Case-Control Studies; Cell Count; Child; Depression; Dyspepsia; Eosinophils; Female; Humans; Intestines; Male; Mast Cells; Permeability; adolescent; anxiety; case control study; cell count; child; clinical trial; complication; depression; dyspepsia; eosinophil; female; human; intestine; male; mast cell; pathology; pathophysiology; permeability","","","","","","","Hyams J.S., Burke G., Davis P.M., Rzepski B., Andrulonis P.A., Abdominal pain and irritable bowel syndrome in adolescents: A community- based study, Journal of Pediatrics, 129, 2, pp. 220-226, (1996); Walker L.S., Lipani T.A., Greene J.W., Caines K., Stutts J., Polk D.B., Caplan A., Rasquin-Weber A., Recurrent abdominal pain: Symptom subtypes based on Rome II criteria for pediatric functional gastrointestinal disorders, J Pediatr Gastroenterol Nutr, 38, pp. 187-191, (2004); Schurman J.V., Friesen C.A., Danda C.E., Andre L., Welchert E., Lavenbarg T., Cocjin J.T., Hyman P.E., Diagnosing functional abdominal pain with the Rome II criteria: Parent, child, and clinician agreement, Journal of Pediatric Gastroenterology and Nutrition, 41, 3, pp. 291-295, (2005); Rasquin A., Dilorenzo C., Forbes D., Guiraldes E., Hyams J.S., Staiano A., Walker L.S., Childhood functional gastrointestinal disorders: Child/adolescent, Gastroenterology, 130, pp. 1527-1537, (2006); Camilleri M., Gorman H., Intestinal permeability and irritable bowel syndrome, Neurogastroenterology and Motility, 19, 7, pp. 545-552, (2007); Schulman R.J., Eakin M.N., Czyzewski D.I., Jarrett M., Ou C.-N., Increased gastrointestinal permeability and gut inflammation in children with functional abdominal pain and irritable bowel syndrome, J Pediatr, 153, pp. 646-650, (2008); Francavilla R., Miniello V., Magista A.M., De Canio A., Bucci N., Gagliardi F., Lionetti E., Castellaneta S., Polimeno L., Peccarisi L., Indrio F., Cavallo L., A randomized controlled trial of lactobacillus GG in children with functional abdominal pain, Pediatrics, 126, (2010); Jarvinen K.M., Konstantinou G.N., Pilapil M., Arrieta M.C., Noone S., Sampson H.A., Meddings J., Nowak-Wegrzyn A., Intestinal permeability in children with food allergy on specific elimination diets, Pediatr Allergy Immunol, 24, pp. 589-595, (2013); Reynolds C.R., Kamphaus R.W., Behavior Assessment for Children (BASC), (1992); Keita A., Soderholm J.D., The intestinal barrier and its regulation by neuroimmune factors, Neurogastroenterol Motil, 22, pp. 718-733, (2010); Wyatt J., Oberhuber G., Pongratz S., Puspok A., Moser G., Novacek G., Lochs H., Vogelsang H., Increased gastric and intestinal permeability in patients with Crohn's disease, American Journal of Gastroenterology, 92, 10, pp. 1891-1896, (1997); Sanderson I.R., Boulton P., Menzies I., Walker-Smith J.A., Improvement of abnormal lactulose/rhamnose permeability in active Crohn's disease of the small bowel by an elemental diet, Gut, 28, 9, pp. 1073-1076, (1987); Duerksen D.R., Wilhelm-Boyles C., Parry D.M., Intestinal permeability in long-term follow-up of patients with celiac disease on a gluten-free diet, Digestive Diseases and Sciences, 50, 4, pp. 785-790, (2005); Talley N.J., Walker M.M., Aro P., Ronkainen J., Storskrubb T., Hindley L.A., Harmsen W.S., Zinsmeister A.R., Agreus L., Non-ulcer Dyspepsia and Duodenal Eosinophilia: An Adult Endoscopic Population-Based Case-Control Study, Clinical Gastroenterology and Hepatology, 5, 10, pp. 1175-1183, (2007); Friesen C.A., Neilan N.A., Schurman J.V., Taylor D.L., Kearns G.L., Abdel-Rahman S.M., Montelukast in the treatment of duodenal eosinophilia in children with dyspepsia: Effect on eosinophil density and activation in relation to pharmacokinetics, BMC Gastroenterol, 9, (2009); Hall W., Buckley M., Crotty P., O'Morain C.A., Gastric mucosal mast cells are increased in Helicobacter pylori-negative functional dyspepsia, Clinical Gastroenterology and Hepatology, 1, 5, pp. 363-369, (2003); Yang P.-C., Jury J., Soderholm J.D., Sherman P.M., McKay D.M., Perdue M.H., Chronic psychological stress in rats induces intestinal sensitization to luminal antigens, American Journal of Pathology, 168, 1, pp. 104-114, (2006); Vicario M., Guilarte M., Alonso C., Yang P., Martinez C., Ramos L., Lobo B., Gonzalez A., Guila M., Pigrau M., Saperas E., Azpiroz F., Santos J., Chronological assessment of mast cell-mediated gut dysfunction and mucosal inflammation in a rat model of chronic psychosocial stress, Brain Behav Immun, 24, pp. 1166-1175, (2010); Santos J., Benjamin M., Yang P.-C., Prior T., Perdue M.H., Chronic stress impairs rat growth and jejunal epithelial barrier function: Role of mast cells, Am J Physiol Gastrointest Liver Physiol, 278, (2000); Soderholm J.D., Yang P.C., Ceponis P., Vohra A., Riddell R., Sherman P.M., Perdue M.H., Chronic stress induces mast cell-dependent bacterial adherence and initiates mucosal inflammation in rat intestine, Gastroenterology, 123, pp. 1099-1108, (2002); Santos J., Saperas E., Nogueiras C., Mourelle M., Antolin M., Cadahia A., Malagelada J.-R., Release of mast cell mediators into the jejunum by cold pain stress in humans, Gastroenterology, 114, 4 I, pp. 640-648, (1998)","C.A. Friesen; Division of Gastroenterology, Hepatology, and Nutrition, Children's Mercy Hospitals and Clinics, Kansas City, MO 64108, 2401 Gillham Road, United States; email: cfriesen@cmh.edu","","BioMed Central Ltd.","","","","","","17560500","","","24886078","English","BMC Res. Notes","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-84901045700"

"Barbara G.; Zecchi L.; Barbaro R.; Cremon C.; Bellacosa L.; Marcellini M.; De Giorgio R.; Corinaldesi R.; Stanghellini V.","Barbara, Giovanni (7004311418); Zecchi, Lisa (36098678300); Barbaro, Raffaella (56235164100); Cremon, Cesare (6507319921); Bellacosa, Lara (34972669400); Marcellini, Marco (55358259100); De Giorgio, Roberto (7005471207); Corinaldesi, Roberto (7004571215); Stanghellini, Vincenzo (7006377452)","7004311418; 36098678300; 56235164100; 6507319921; 34972669400; 55358259100; 7005471207; 7004571215; 7006377452","Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome","2012","Journal of Clinical Gastroenterology","46","SUPPL. 1","","S52","S55","3","84","10.1097/MCG.0b013e318264e918","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84866264998&doi=10.1097%2fMCG.0b013e318264e918&partnerID=40&md5=eb69ab61d42c096a9356fb82a0d5958c","Department of Clinical Medicine, Centre for Applied Biomedical Research, University of Bologna, Bologna, Italy","Barbara G., Department of Clinical Medicine, Centre for Applied Biomedical Research, University of Bologna, Bologna, Italy; Zecchi L., Department of Clinical Medicine, Centre for Applied Biomedical Research, University of Bologna, Bologna, Italy; Barbaro R., Department of Clinical Medicine, Centre for Applied Biomedical Research, University of Bologna, Bologna, Italy; Cremon C., Department of Clinical Medicine, Centre for Applied Biomedical Research, University of Bologna, Bologna, Italy; Bellacosa L., Department of Clinical Medicine, Centre for Applied Biomedical Research, University of Bologna, Bologna, Italy; Marcellini M., Department of Clinical Medicine, Centre for Applied Biomedical Research, University of Bologna, Bologna, Italy; De Giorgio R., Department of Clinical Medicine, Centre for Applied Biomedical Research, University of Bologna, Bologna, Italy; Corinaldesi R., Department of Clinical Medicine, Centre for Applied Biomedical Research, University of Bologna, Bologna, Italy; Stanghellini V., Department of Clinical Medicine, Centre for Applied Biomedical Research, University of Bologna, Bologna, Italy","There is increasingly convincing evidence supporting the participation of the gut microenvironment in the pathophysiology of irritable bowel syndrome (IBS). Studies particularly suggest an interplay between luminal factors (eg, foods and bacteria residing in the intestine), the epithelial barrier, and the mucosal immune system. Decreased expression and structural rearrangement of tight junction proteins in the small bowel and colon leading to increased intestinal permeability have been observed, particularly in postinfectious IBS and in IBS with diarrhea. These abnormalities are thought to contribute to the outflow of antigens through the leaky epithelium, causing overstimulation of the mucosal immune system. Accordingly, subsets of patients with IBS show higher numbers and an increased activation of mucosal immunocytes, particularly mast cells. Immune factors, released by these cells, including proteases, histamine, and prostanoids, participate in the perpetuation of the permeability dysfunction and contribute to the activation of abnormal neural responses involved in abdominal pain perception and changes in bowel habits. All these mechanisms represent new targets for therapeutic approaches in IBS. Probiotics are an attractive therapeutic option in IBS given their recognized safety and by virtue of positive biological effects they can exert on the host. Of importance for the IBS pathophysiology is that preclinical studies have shown that selective probiotic strains exhibit potentially useful properties including anti-inflammatory effects, improvement of mucosal barrier homeostasis, beneficial effects on intestinal microbiota, and a reduction of visceral hypersensitivity. The effect of probiotics on IBS is positive in most randomized, controlled studies, although the gain over the placebo is small. Identifying tailored probiotic approaches for subgroups of IBS patients represents a challenge for the future. © 2012 by Lippincott Williams & Wilkins.","abdominal pain; immune activation; irritable bowel syndrome; mast cells; mucosal barrier","Abdominal Pain; Bifidobacterium; Gastrointestinal Tract; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Lactobacillus; Mast Cells; Permeability; Probiotics; Randomized Controlled Trials as Topic; beta defensin 2; immunoglobulin A; ketotifen; mesalazine; messenger RNA; mucin 1; mucin 2; mucin 3; probiotic agent; protein ZO1; RNA 16S; abdominal pain; antiinflammatory activity; article; Bifidobacterium breve; Bifidobacterium longum infantis; disease severity; drug safety; feces microflora; human; hypersensitivity; immune response; intestine flora; intestine mucosa permeability; irritable colon; Lactobacillus rhamnosus; Lactobacillus salivarius; mast cell; pathophysiology; priority journal; quality of life; symptom","","ketotifen, 34580-13-7; mesalazine, 89-57-6; mucin 1, 212255-06-6; mucin 3, 199543-31-2","","","","","Longstreth G.F., Thompson W.G., Chey W.D., Et al., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Barbara G., De Giorgio R., Stanghellini V., Cremon C., Salvioli B., Corinaldesi R., New pathophysiological mechanisms in irritable bowel syndrome, Alimentary Pharmacology and Therapeutics, 20, SUPPL.2, pp. 1-9, (2004); Barbara G., Stanghellini V., Biomarkers in IBS: When will they replace symptoms for diagnosis and management?, Gut, 58, pp. 1571-1575, (2009); Barbara G., Stanghellini V., Cremon C., Et al., Probiotics and irritable bowel syndrome: Rationale and clinical evidence for their use, J Clin Gastroenterol, 42, SUPPL. 3, (2008); Turner J.R., Intestinal mucosal barrier function in health and disease, Nat Rev Immunol, 9, pp. 799-809, (2009); Nusrat A., Turner J.R., Madara J.L., Molecular physiology and pathophysiology of tight junctions IV Regulation of tight junctions by extracellular stimuli: Nutrients, cytokines, and immune cells, Am J Physiol Gastrointest Liver Physiol, 279, (2000); Barbara G., Mucosal barrier defects in irritable bowel syndrome. Who left the door open?, American Journal of Gastroenterology, 101, 6, pp. 1295-1298, (2006); Camilleri M., Gorman H., Intestinal permeability and irritable bowel syndrome, Neurogastroenterology and Motility, 19, 7, pp. 545-552, (2007); Rao A.S., Camilleri M., Eckert D.J., Et al., Urine sugars for in vivo gut permeability: Validation and comparisons in irritable bowel syndrome-diarrhea and controls, Am J Physiol Gastrointest Liver Physiol, 301, (2011); Piche T., Barbara G., Aubert P., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: Involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Dunlop S.P., Hebden J., Campbell E., Naesdal J., Olbe L., Perkins A.C., Spiller R.C., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, American Journal of Gastroenterology, 101, 6, pp. 1288-1294, (2006); Martnez C., Vicario M., Ramos L., Et al., The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations, Am J Gastroenterol, 107, pp. 736-746, (2012); Coe Ffier M., Gloro R., Boukhettala N., Et al., Increased proteasome-mediated degradation of occludin in irritable bowel syndrome, Am J Gastroenterol, 105, pp. 1181-1188, (2010); Bertiaux-Vandaelse N., Youmba S.B., Et al., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am J Gastroenterol, 106, pp. 2165-2173, (2011); Lee J.W., Park J.H., Park D.I., Et al., Subjects with diarrheapredominant IBS have increased rectal permeability responsive to tryptase, Dig Dis Sci, 55, pp. 2922-2928, (2010); Barbara G., Cremon C., Carini G., Et al., The immune system in irritable bowel syndrome, J Neurogastroenterol Motil, 17, pp. 349-359, (2011); Chadwick V.S., Chen W., Shu D., Paulus B., Bethwaite P., Tie A., Wilson I., Activation of the mucosal immune system in irritable bowel syndrome, Gastroenterology, 122, 7, pp. 1778-1783, (2002); Guilarte M., Santos J., De Torres I., Et al., Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum, Gut, 56, pp. 203-209, (2007); Weston A.P., Biddle W.L., Bhatia P.S., Miner Jr. P.B., Terminal ileal mucosal mast cells in irritable bowel syndrome, Digestive Diseases and Sciences, 38, 9, pp. 1590-1595, (1993); Walker M.M., Talley N.J., Prabhakar M., Et al., Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia, Aliment Pharmacol Ther, 29, pp. 765-773, (2009); Barbara G., Stanghellini V., De Giorgio R., Cremon C., Cottrell G.S., Santini D., Pasquinelli G., Morselli-Labate A.M., Grady E.F., Bunnett N.W., Collins S.M., Corinaldesi R., Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome, Gastroenterology, 126, 3, pp. 693-702, (2004); Piche T., Saint-Paul M.C., Dainese R., Marine-Barjoan E., Iannelli A., Montoya M.L., Peyron J.F., Czerucka D., Cherikh F., Filippi J., Tran A., Hebuterne X., Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome, Gut, 57, 4, pp. 468-473, (2008); Cremon C., Gargano L., Morselli-Labate A.M., Et al., Mucosal immune activation in irritable bowel syndrome: Genderdependence and association with digestive symptoms, Am J Gastroenterol, 104, pp. 392-400, (2009); Cenac N., Andrews C.N., Holzhausen M., Chapman K., Cottrell G., Andrade-Gordon P., Steinhoff M., Barbara G., Beck P., Bunnett N.W., Sharkey K.A., Ferraz J.G.P., Shaffer E., Vergnolle N., Role for protease activity in visceral pain in irritable bowel syndrome, Journal of Clinical Investigation, 117, 3, pp. 636-647, (2007); Barbara G., Wang B., Stanghellini V., De Giorgio R., Cremon C., Di Nardo G., Trevisani M., Campi B., Geppetti P., Tonini M., Bunnett N.W., Grundy D., Corinaldesi R., Mast Cell-Dependent Excitation of Visceral-Nociceptive Sensory Neurons in Irritable Bowel Syndrome, Gastroenterology, 132, 1, pp. 26-37, (2007); MacSharry J., O'mahony L., Fanning A., Et al., Mucosal cytokine imbalance in irritable bowel syndrome, Scand J Gastroenterol, 43, pp. 1467-1476, (2008); Buhner S., Li Q., Vignali S., Et al., Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome, Gastroenterology, 137, pp. 1425-1434, (2009); Salim S.Y., So Derholm J.D., Importance of disrupted intestinal barrier in inflammatory bowel diseases, Inflamm Bowel Dis, 17, pp. 362-381, (2011); Schoepfer A.M., Schaffer T., Seibold-Schmid B., Et al., Antibodies to flagellin indicate reactivity to bacterial antigens in IBS patients, Neurogastroenterol Motil, 20, pp. 1110-1118, (2008); Preidis G.A., Versalovic J., Targeting the human microbiome with antibiotics, probiotics, and prebiotics: Gastroenterology enters the metagenomics era, Gastroenterology, 136, pp. 2015-2031, (2009); Moayyedi P., Ford A.C., Talley N.J., Et al., The efficacy of probiotics in the treatment of irritable bowel syndrome: A systematic review, Gut, 59, pp. 325-332, (2010); Pimentel M., Lembo A., Chey W.D., Et al., Rifaximin therapy for patients with irritable bowel syndrome without constipation, N Engl J Med, 364, pp. 22-32, (2011); Lyra A., Rinttila T., Nikkila J., Et al., Diarrhoea-predominant irritable bowel syndrome distinguishable by 16S rRNA gene phylotype quantification, World J Gastroenterol, 15, pp. 5936-5945, (2009); Kassinen A., Krogius-Kurikka L., Makivuokko H., Rinttila T., Paulin L., Corander J., Malinen E., Apajalahti J., Palva A., The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects, Gastroenterology, 133, 1, pp. 24-33, (2007); Malinen E., Rinttila T., Kajander K., Matto J., Kassinen A., Krogius L., Saarela M., Korpela R., Palva A., Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR, American Journal of Gastroenterology, 100, 2, pp. 373-382, (2005); Swidsinski A., Weber J., Loening-Baucke V., Hale L.P., Lochs H., Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease, Journal of Clinical Microbiology, 43, 7, pp. 3380-3389, (2005); Langhorst J., Junge A., Rueffer A., Et al., Elevated human betadefensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome, Am J Gastroenterol, 104, pp. 404-410, (2009); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Ohman L., Isaksson S., Lindmark A.C., Et al., T-cell activation in patients with irritable bowel syndrome, Am J Gastroenterol, 104, pp. 1205-1212, (2009); Corinaldesi R., Stanghellini V., Cremon C., Et al., Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: A randomized controlled proof-of-concept study, Aliment Pharmacol Ther, 30, pp. 245-252, (2009); Lunardi C., Bambara L.M., Biasi D., Et al., Double-blind crossover trial of oral sodium cromoglycate in patients with irritable bowel syndrome due to food intolerance, Clin Exp Allergy, 21, pp. 569-572, (1991); Stefanini G.F., Saggioro A., Alvisi V., Et al., Oral cromolyn sodium in comparison with elimination diet in the irritable bowel syndrome, diarrheic type: Multicenter study of 428 patients, Scand J Gastroenterol, 30, pp. 535-541, (1995); Klooker T.K., Braak B., Koopman K.E., Et al., The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome, Gut, 59, pp. 1213-1221, (2010); Ohland C.L., MacNaughton W.K., Probiotic bacteria and intestinal epithelial barrier function, Am J Physiol Gastrointest Liver Physiol, 298, (2010); Lyra A., Krogius-Kurikka L., Nikkila J., Et al., Effect of a multispecies probiotic supplement on quantity of irritable bowel syndrome-related intestinal microbial phylotypes, BMC Gastroenterol, 10, pp. 110-119, (2010); O'Mahony L., Mccarthy J., Kelly P., Hurley G., Luo F., Chen K., O'Sullivan G.C., Kiely B., Collins J.K., Shanahan F., Quigley E.M.M., Lactobacillus and Bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles, Gastroenterology, 128, 3, pp. 541-551, (2005); Halpern G.M., Prindiville T., Blankenburg M., Hsia T., Gershwin M.E., Treatment of irritable bowel syndrome with lacteol fort: A randomized, double-blind, cross-over trial, American Journal of Gastroenterology, 91, 8, pp. 1579-1585, (1996); Nobaek S., Johansson M.-L., Molin G., Ahrne S., Jeppsson B., Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome, American Journal of Gastroenterology, 95, 5, pp. 1231-1238, (2000); O'sullivan M.A., O'morain C.A., Bacterial supplementation in the irritable bowel syndrome; A randomised double blind placebo-controlled crossover study, Dig Liver Dis, 32, pp. 294-301, (2000); Niedzielin K., Kordecki H., Birkenfeld B., A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome, European Journal of Gastroenterology and Hepatology, 13, 10, pp. 1143-1147, (2001); Sen S., Mullan M.M., Parker T.J., Woolner J.T., Tarry S.A., Hunter J.O., Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome, Digestive Diseases and Sciences, 47, 11, pp. 2615-2620, (2002); Niv E., Naftali T., Hallak R., Vaisman N., The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome - A double blind, placebo-controlled, randomized study, Clinical Nutrition, 24, 6, pp. 925-931, (2005); Whorwell P.J., Altringer L., Morel J., Bond Y., Charbonneau D., O'Mahony L., Kiely B., Shanahan F., Quigley E.M.M., Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome, American Journal of Gastroenterology, 101, 7, pp. 1581-1590, (2006); Guyonnet D., Chassany O., Ducrotte P., Picard C., Mouret M., Mercier C.-H., Matuchansky C., Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: A multicentre, randomized, double-blind, controlled trial, Alimentary Pharmacology and Therapeutics, 26, 3, pp. 475-486, (2007); Spiller R., Review article: Probiotics and prebiotics in irritable bowel syndrome, Alimentary Pharmacology and Therapeutics, 28, 4, pp. 385-396, (2008); Kim H.J., Camilleri M., McKinzie S., Lempke M.B., Burton D.D., Thomforde G.M., Zinsmeister A.R., A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome, Alimentary Pharmacology and Therapeutics, 17, 7, pp. 895-904, (2003); Kim H.J., Vazquez Roque M.I., Camilleri M., Stephens D., Burton D.D., Baxter K., Thomforde G., Zinsmeister A.R., A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating, Neurogastroenterology and Motility, 17, 5, pp. 687-696, (2005); Kajander K., Hatakka K., Poussa T., Farkkila M., Korpela R., A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: A controlled 6-month intervention, Alimentary Pharmacology and Therapeutics, 22, 5, pp. 387-394, (2005)","G. Barbara; Department of Clinical Medicine, University of Bologna, S. Orsola-Malpighi Hospital, I-40138 Bologna, Via Massarenti 9, Italy; email: giovanni.barbara@unibo.it","","","","","","","","15392031","","JCGAD","22955358","English","J. Clin. Gastroenterol.","Article","Final","","Scopus","2-s2.0-84866264998"

"Del Valle-Pinero A.Y.; Van Deventer H.E.; Fourie N.H.; Martino A.C.; Patel N.S.; Remaley A.T.; Henderson W.A.","Del Valle-Pinero, Arseima Y. (13404797500); Van Deventer, Hendrick E. (57103111000); Fourie, Nicolaas H. (19640057500); Martino, Angela C. (36461365400); Patel, Nayan S. (54682102400); Remaley, Alan T. (7006511029); Henderson, Wendy A. (32367603100)","13404797500; 57103111000; 19640057500; 36461365400; 54682102400; 7006511029; 32367603100","Gastrointestinal permeability in patients with irritable bowel syndrome assessed using a four probe permeability solution","2013","Clinica Chimica Acta","418","","","97","101","4","45","10.1016/j.cca.2012.12.032","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84873308035&doi=10.1016%2fj.cca.2012.12.032&partnerID=40&md5=e3211b95c2ba974c67c16de22ec62f53","Biobehavioral Branch, Intramural Research Program, NINR, NIH, DHHS, Bethesda, MD, United States; Department of Laboratory Medicine, NIH, DHHS, Bethesda, MD, United States; Warren Grant Magnuson Clinical Center, NIH, DHHS, Bethesda, MD, United States","Del Valle-Pinero A.Y., Biobehavioral Branch, Intramural Research Program, NINR, NIH, DHHS, Bethesda, MD, United States; Van Deventer H.E., Department of Laboratory Medicine, NIH, DHHS, Bethesda, MD, United States, Warren Grant Magnuson Clinical Center, NIH, DHHS, Bethesda, MD, United States; Fourie N.H., Biobehavioral Branch, Intramural Research Program, NINR, NIH, DHHS, Bethesda, MD, United States; Martino A.C., Biobehavioral Branch, Intramural Research Program, NINR, NIH, DHHS, Bethesda, MD, United States; Patel N.S., Biobehavioral Branch, Intramural Research Program, NINR, NIH, DHHS, Bethesda, MD, United States; Remaley A.T., Department of Laboratory Medicine, NIH, DHHS, Bethesda, MD, United States, Warren Grant Magnuson Clinical Center, NIH, DHHS, Bethesda, MD, United States; Henderson W.A., Biobehavioral Branch, Intramural Research Program, NINR, NIH, DHHS, Bethesda, MD, United States","Background: Abnormal gastrointestinal permeability has been linked to irritable bowel syndrome (IBS). The lactulose-to-mannitol ratio is traditionally used to assess small intestine permeability while sucralose and sucrose are used to assess colonic and gastric permeability respectively. We used a single 4-probe test solution to assess permeability throughout the gastrointestinal tract in IBS patients and healthy controls by measuring the recovery of the probes in urine after ingestion using a modified liquid chromatography mass spectrometry protocol. Methods: Fasting participants (N = 59) drank a permeability test solution (100. ml: sucralose, sucrose, mannitol, and lactulose). Urine was collected over a 5-h period and kept frozen until analysis. Urinary sugar concentrations were measured using a liquid chromatography/triple quadruple mass spectrometer. Results: Colonic permeability was significantly lower in IBS patients when compared to healthy controls (p = 0.011). Gastric and small intestinal permeability did not significantly differ between the groups. Conclusions: The study demonstrates the clinical potential of this non-invasive method for assessing alterations in gastrointestinal permeability in patients with IBS. © 2013 .","Intestinal permeability; Lactulose-to-mannitol ratio; Mass spectrometry; Multiple reaction monitoring; Sucralose; Sucrose","Adult; Female; Gastrointestinal Tract; Humans; Irritable Bowel Syndrome; Lactulose; Male; Mannitol; Permeability; Solutions; Sucrose; lactulose; mannitol; sucralose; sucrose; adult; article; controlled study; female; functional assessment; human; intestine function; intestine mucosa permeability; irritable colon; liquid chromatography; major clinical study; male; mass spectrometry; oligonucleotide probe; priority journal; urinalysis; urinary excretion","","lactulose, 4618-18-2; mannitol, 69-65-8, 87-78-5; sucralose, 56038-13-2; sucrose, 122880-25-5, 57-50-1; Lactulose, 4618-18-2; Mannitol, 3OWL53L36A; Solutions, ; Sucrose, 57-50-1; trichlorosucrose, 56038-13-2","","","National Institute of Nursing Research, NINR, (ZIANR000018)","The authors thank the study participants, NIH Clinical Center and NIDDK Metabolic Program of Care (Dr. Kong Chen). We also thank Dr. Robert Shulman for the formulation of the test solution and Dr. Margaret Heitkemper for her mentorship. This study was funded by NINR's Intramural Research Training Awards (Del Valle-Pinero, Fourie, and Patel) and 1ZIANR000018-03 award (PI: Henderson).","Drossman D.A., Corazziari E., Delvaux M., Spiller R.C., Rome III: the functional gastrointestinal disorders, (2006); Drossman D.A., Dumitrascu D.L., Drossman D.A., Dumitrascu D.L., Rome III: new standard for functional gastrointestinal disorders, J Gastrointestin Liver Dis, 15, pp. 237-241, (2006); Saito Y.A., Schoenfeld P., Locke G.R., The epidemiology of irritable bowel syndrome in North America: a systematic review, Am J Gastroenterol, 97, pp. 1910-1915, (2002); Thompson W.G., Longstreth G.F., Drossman D.A., Et al., Functional bowel disorders and functional abdominal pain, Gut, 45, SUPPL. 2, (1999); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Et al., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am J Gastroenterol, 106, pp. 2165-2173, (2011); Camilleri M., Gorman H., Intestinal permeability and irritable bowel syndrome, Neurogastroenterol Motil, 19, pp. 545-552, (2007); Gecse K., Roka R., Sera T., Et al., Leaky gut in patients with diarrhea-predominant irritable bowel syndrome and inactive ulcerative colitis, Digestion, 85, pp. 40-46, (2011); Rao A.S., Camilleri M., Eckert D.J., Et al., Urine sugars for in vivo gut permeability: validation and comparisons in irritable bowel syndrome-diarrhea and controls, Am J Physiol Gastrointest Liver Physiol, 301, (2011); Tibble J.A., Sigthorsson G., Foster R., Et al., Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease, Gastroenterology, 123, pp. 450-460, (2002); Bjarnason I., Cederborg A., Akvist A., Smale S., Intestinal barrier function, Biology of the intestine in growing animals, pp. 657-693, (2002); Bjarnason I., MacPherson A., Hollander D., Intestinal permeability: an overview, Gastroenterology, 108, pp. 1566-1581, (1995); Nakamura R.M., Matsutani M., Barry M., Advances in clinical laboratory tests for inflammatory bowel disease, Clin Chim Acta, 335, pp. 9-20, (2003); Fleming S.C., Kapembwa M.S., Laker M.F., Et al., Rapid and simultaneous determination of lactulose and mannitol in urine, by HPLC with pulsedamperometric detection, for use in studies of intestinal permeability, Clin Chem, 36, pp. 797-799, (1990); Spiller R.C., Jenkins D., Thornley J.P., Et al., Increased rectal mucosal enteroendocrine cells, t lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, pp. 804-811, (2000); Marshall J.K., Thabane M., Garg A.X., Et al., Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkteron Ontario, Aliment Pharmacol Ther, 20, pp. 1317-1322, (2004); Zhou Q., Souba W.W., Croce C.M., Verne G.N., MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome, Gut, 59, pp. 775-784, (2010); Haas V., Buning C., Buhner S., Et al., Clinical relevance of measuring colonic permeability, Eur J Clin Invest, 39, pp. 139-144, (2009); van Wijck K., van Eijk H.M., Buurman W.A., Et al., Analytical approach to a multi-sugar whole gut permeability assay, J Chromatogr B Analyt Technol Biomed Life Sci, 879, pp. 2794-2801, (2011); Shulman R.J., Eakin M.N., Czyzewski D.I., Jarrett M., Ou C.N., Increased gastrointestinal permeability and gut inflammation in children with functional abdominal pain and irritable bowel syndrome, J Pediatr, 153, pp. 646-650, (2008); Willems D., Cadranel S., Jacobs W., Measurement of urinary sugars by HPLC in the estimation of intestinal permeability: evaluation in pediatric clinical practice, Clin Chem, 39, pp. 888-890, (1993); Lostia A.M., Lionetto L., Principessa L., Et al., A liquid chromatography/mass spectrometry method for the evaluation of intestinal permeability, Clin Biochem, 41, pp. 887-892, (2008); Buning C., Geissler N., Prager M., Et al., Increased small intestinal permeability in ulcerative colitis: rather genetic than environmental and a risk factor for extensive disease?, Inflamm Bowel Dis, (2012); Berstad A., Arslan G., Folvik G., Relationship between intestinal permeability and calprotectin concentration in gut lavage fluid, Scand J Gastroenterol, 35, pp. 64-69, (2000); Braniste V., Leveque M., Buisson-Brenac C., Et al., Oestradiol decreases colonic permeability through oestrogen receptor betamediated up-regulation of occludin and junctional adhesion molecule-a in epithelial cells, J Physiol, 587, pp. 3317-3328, (2009); Schepens M.A., Rijnierse A., Schonewille A.J., Et al., Dietary calcium decreases but short-chain fructo-oligosaccharides increase colonic permeability in rats, Br J Nutr, 104, pp. 1780-1786, (2010); Zakostelska Z., Kverka M., Klimesova K., Et al., Lysate of probiotic Lactobacillus casei dn-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment, PLoS One, 6, (2011); Obinna F.C., Cook G., Beale T., Et al., Comparative assessment of small intestinal and colonic permeability in HIV infected homosexual men, AIDS, 9, pp. 1009-1016, (1995); Dainese R., Galliani E.A., De Lazzari F., Et al., Discrepancies between reported food intolerance and sensitization test findings in irritable bowel syndrome patients, Am J Gastroenterol, 94, pp. 1892-1897, (1999); Fleming S.C., Duncan A., Russell R.I., Laker M.F., Measurement of sugar probes in serum: an alternative to urine measurement in intestinal permeability testing, Clin Chem, 42, pp. 445-448, (1996); Katouzian F., Sblattero D., Not T., Et al., Dual sugar gut-permeability testing on blood drop on animal models, Clin Chim Acta, 352, 1-2, pp. 191-197, (2005); Seimiya M., Osawa S., Hisae N., Shishido T., Yamaguchi T., Nomura F., A sensitive enzymatic assay for the determination of sucrose in serum and urine, Clin Chim Acta, 343, 1-2, pp. 195-199, (2004)","W.A. Henderson; Biobehavioral Unit, NINR, NIH, DHHS, Bethesda, MD 20892, Building 10, 2-1339, United States; email: hendersw@mail.nih.gov","","","","","","","","18733492","","CCATA","23328210","English","Clin. Chim. Acta","Article","Final","All Open Access; Green Open Access","Scopus","2-s2.0-84873308035"

"Liu L.; Cai X.; Yan J.; Luo Y.; Shao M.; Lu Y.; Sun Z.; Cao P.","Liu, Lina (56547600200); Cai, Xueting (36571457900); Yan, Jing (55551894800); Luo, Yi (56979692400); Shao, Ming (57207173847); Lu, Yin (35277440800); Sun, Zhiguang (36082067200); Cao, Peng (7103379975)","56547600200; 36571457900; 55551894800; 56979692400; 57207173847; 35277440800; 36082067200; 7103379975","In vivo and in vitro antinociceptive effect of fagopyrum cymosum (Trev.) meisn extracts: A possible action by recovering intestinal barrier dysfunction","2012","Evidence-based Complementary and Alternative Medicine","2012","","983801","","","","13","10.1155/2012/983801","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84872142110&doi=10.1155%2f2012%2f983801&partnerID=40&md5=66c0f591f60f803a8e7d64c5e45a9969","Institute of First Clinical Medicine, Nanjing University of Chinese Medicine, Jiangsu, Nanjing 210046, China; Department of Liver Disease, Affiliated Hospital, Nanjing University of Chinese Medicine, Jiangsu, Nanjing 210029, China; Laboratory of Cellular and Molecular Biology, Jiangsu Province Institute of Traditional Chinese Medicine, Jiangsu, Nanjing 210028, China; Institute of Pharmacy, Nanjing University of Chinese Medicine, Jiangsu, Nanjing 210046, China","Liu L., Institute of First Clinical Medicine, Nanjing University of Chinese Medicine, Jiangsu, Nanjing 210046, China, Department of Liver Disease, Affiliated Hospital, Nanjing University of Chinese Medicine, Jiangsu, Nanjing 210029, China; Cai X., Laboratory of Cellular and Molecular Biology, Jiangsu Province Institute of Traditional Chinese Medicine, Jiangsu, Nanjing 210028, China; Yan J., Institute of First Clinical Medicine, Nanjing University of Chinese Medicine, Jiangsu, Nanjing 210046, China; Luo Y., Institute of First Clinical Medicine, Nanjing University of Chinese Medicine, Jiangsu, Nanjing 210046, China; Shao M., Department of Liver Disease, Affiliated Hospital, Nanjing University of Chinese Medicine, Jiangsu, Nanjing 210029, China; Lu Y., Institute of Pharmacy, Nanjing University of Chinese Medicine, Jiangsu, Nanjing 210046, China; Sun Z., Institute of First Clinical Medicine, Nanjing University of Chinese Medicine, Jiangsu, Nanjing 210046, China; Cao P., Laboratory of Cellular and Molecular Biology, Jiangsu Province Institute of Traditional Chinese Medicine, Jiangsu, Nanjing 210028, China","Fagopyrum cymosum (Trev.) Meisn (Fag) is a herb rhizome which has been widely used to treat diseases. To investigate the effects and mechanisms of the Fag on irritable bowel syndrome (IBS), in vivo neonatal pups maternal separation (NMS) combined with intracolonic infusion of acetic acid (AA) was employed to establish IBS rat models. Fag reduced their visceral hyperalgesia and the whole gut permeability, ameliorated colonic mucosa inflammation and injury, and upregulated the expression of decreased tight junction proteins (TJs) of claudin-1, occludin, and ZO-1 (except ZO-2) in colonic epithelium. Caco-2 monolayer cells were incubated with TNF-α and IFN-γ in vitro to establish an epithelial barrier dysfunction model whose transepithelial electrical resistance (TER) depended more on dose of Fag than that of the controls, and whose TJs levels were lower than those of the controls. Fag upregulated the NP-40 insoluble and soluble components of the four TJs markedly in a dose-dependent manner. These data suggest that Fag alleviated the hyperalgesia of IBS rats by reducing intestinal inflammation and enhancing mucosal epithelial function after regulating the structure and function of TJs. © 2012 Lina Liu et al.","","acetic acid; antinociceptive agent; claudin 1; Fagopyrum cymosum extract; gamma interferon; occludin; plant extract; protein ZO1; tight junction protein; tumor necrosis factor alpha; unclassified drug; abdominal pain; animal experiment; animal model; animal tissue; antinociception; article; colon injury; colon mucosa; controlled study; Fagopyrum; fagopyrum cymosum; hyperalgesia; in vitro study; in vivo study; irritable colon; maternal deprivation; nonhuman; priority journal; protein expression; pup (rodent); rhizome; upregulation","","acetic acid, 127-08-2, 127-09-3, 64-19-7, 71-50-1; claudin 1, 329338-06-9; gamma interferon, 82115-62-6; occludin, 176304-61-3","","","","","Camilleri M., Management of the irritable bowel syndrome, Gastroenterology, 120, 3, pp. 652-668, (2001); Mearin F., Perello A., Balboa A., Perona M., Sans M., Salas A., Angulo S., Lloreta J., Benasayag R., Garcia-Gonzalez M.A., Perez-Oliveras M., Coderch J., Pathogenic mechanisms of postinfectious functional gastrointestinal disorders: Results 3 years after gastroenteritis, Scandinavian Journal of Gastroenterology, 44, 10, pp. 1173-1185, (2009); Gwee K.-A., Collins S.M., Read N.W., Rajnakova A., Deng Y., Graham J.C., McKendrick M.W., Moochhala S.M., Increased rectal mucosal expression of interleukin 1β in recently acquired post-infectious irritable bowel syndrome, Gut, 52, 4, pp. 523-526, (2003); Chadwick V.S., Chen W., Shu D., Paulus B., Bethwaite P., Tie A., Wilson I., Activation of the mucosal immune system in irritable bowel syndrome, Gastroenterology, 122, 7, pp. 1778-1783, (2002); Cenac N., Andrews C.N., Holzhausen M., Chapman K., Cottrell G., Andrade-Gordon P., Steinhoff M., Barbara G., Beck P., Bunnett N.W., Sharkey K.A., Ferraz J.G.P., Shaffer E., Vergnolle N., Role for protease activity in visceral pain in irritable bowel syndrome, Journal of Clinical Investigation, 117, 3, pp. 636-647, (2007); Gecse K., Roka R., Ferrier L., Leveque M., Eutamene H., Cartier C., Ait-Belgnaoui A., Rosztoczy A., Izbeki F., Fioramonti J., Wittmann T., Bueno L., Increased faecal serine protease activity in diarrhoeic IBS patients: A colonic lumenal factor impairing colonic permeability and sensitivity, Gut, 57, 5, pp. 591-598, (2008); Ferrier L., Mazelin L., Cenac N., Desreumaux P., Janin A., Emilie D., Colombel J.-F., Garcia-Villar R., Fioramonti J., Bueno L., Stress-induced disruption of colonic epithelial barrier: Role of interferon-γ and myosin light chain kinase in mice, Gastroenterology, 125, 3, pp. 795-804, (2003); Capaldo C.T., Nusrat A., Cytokine regulation of tight junctions, Biochimica et Biophysica Acta, 1788, 4, pp. 864-871, (2009); Piche T., Barbara G., Aubert P., Des Varannes S.B., Dainese R., Nano J.L., Cremon C., Stanghellini V., De Giorgio R., Galmiche J.P., Neunlist M., Impaired Intestinal barrier integrity in the colon of patients with irritable bowel syndrome: Involvement of soluble mediators, Gut, 58, 2, pp. 196-201, (2009); Dunlop S.P., Hebden J., Campbell E., Naesdal J., Olbe L., Perkins A.C., Spiller R.C., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, American Journal of Gastroenterology, 101, 6, pp. 1288-1294, (2006); Spiller R.C., Jenkins D., Thornley J.P., Hebden J.M., Wright T., Skinner M., Neal K.R., Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, 6, pp. 804-811, (2000); Kong W.M., Gong J., Dong L., Chen M.X., Changes in tight junction of intestinal mucosa in patients with irritable bowel syndrome: A study with tracing electron microscope, Nan Fang Yi Ke da Xue Xue Bao, 27, 8, pp. 1167-1172, (2007); Kong W.M., Gong J., Dong L., Xu J.R., Changes of tight junction claudin-1,-3,-4 protein expression in the intestinal mucosa in patients with irritable bowel syndrome, Nan Fang Yi Ke da Xue Xue Bao, 27, 9, pp. 1345-1347, (2007); Barreau F., Ferrier L., Fioramonti J., Bueno L., Neonatal maternal deprivation triggers long term alterations in colonic epithelial barrier and mucosal immunity in rats, Gut, 53, 4, pp. 501-506, (2004); Winston J., Shenoy M., Medley D., Naniwadekar A., Pasricha P.J., The Vanilloid Receptor Initiates and Maintains Colonic Hypersensitivity Induced by Neonatal Colon Irritation in Rats, Gastroenterology, 132, 2, pp. 615-627, (2007); Al-Chaer E.D., A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development, Gastroenterology, 119, 5, pp. 1276-1285, (2000); Bradley P.P., Christensen R.D., Rothstein G., Cellular and extracellular myeloperoxidase in pyogenic inflammation, Blood, 60, 3, pp. 618-622, (1982); Keohane J., O'Mahony C., O'Mahony L., O'Mahony S., Quigley E.M., Shanahan F., Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: A real association or reflection of occult inflammation?, The American Journal of Gastroenterology, 105, 8, pp. 1788-1795, (2010); Ma T.Y., Hoa N.T., Tran D.D., Bui V., Pedram A., Mills S., Merryfield M., Cytochalasin B modulation of Caco-2 tight junction barrier: Role of myosin light chain kinase, American Journal of Physiology, 279, 5, (2000); Ma T.Y., Nguyen D., Bui V., Nguyen H., Hoa N., Ethanol modulation of intestinal epithelial tight junction barrier, American Journal of Physiology - Gastrointestinal and Liver Physiology, 276, 4, (1999); Basuroy S., Seth A., Elias B., Naren A.P., Rao R., MAPK interacts with occludin and mediates EGF-induced prevention of tight junction disruption by hydrogen peroxide, Biochemical Journal, 393, 1, pp. 69-77, (2006); Soderholm J.D., Yates D.A., Gareau M.G., Yang P.-C., MacQueen G., Perdue M.H., Neonatal maternal separation predisposes adult rats to colonic barrier dysfunction in response to mild stress, American Journal of Physiology - Gastrointestinal and Liver Physiology, 283, 6, (2002); Rosztoczy A., Fioramonti J., Jarmay K., Barreau F., Wittmann T., Bueno L., Influence of sex and experimental protocol on the effect of maternal deprivation on rectal sensitivity to distension in the adult rat, Neurogastroenterology and Motility, 15, 6, pp. 679-686, (2003); Ando T., Brown R.F., Berg R.D., Dunn A.J., Bacterial translocation can increase plasma corticosterone and brain catecholamine and indoleamine metabolism, American Journal of Physiology, 279, 6, (2000); Quigley E.M.M., Disturbances of motility and visceral hypersensitivity in irritable bowel syndrome: Biological markers or epiphenomenon, Gastroenterology Clinics of North America, 34, SPEC. ISS. 2, pp. 221-233, (2005); Furuse M., Molecular basis of the core structure of tight junctions, Cold Spring Harbor Perspectives in Biology, 2, 1, (2010); Ulluwishewa D., Anderson R.C., McNabb W.C., Moughan P.J., Wells J.M., Roy N.C., Regulation of tight junction permeability by intestinal bacteria and dietary components, Journal of Nutrition, 141, 5, pp. 769-776, (2011); Suzuki T., Elias B.C., Seth A., Shen L., Turner J.R., Giorgianni F., Desiderio D., Guntaka R., Rao R., PKC η regulates occludin phosphorylation and epithelial tight junction integrity, Proceedings of the National Academy of Sciences of the United States of America, 106, 1, pp. 61-66, (2009); Morgado-Diaz J.A., De Souza W., Evidence that increased tyrosine phosphorylation causes disassembly of adherens junctions but does not perturb paracellular permeability in Caco-2 cells, Tissue and Cell, 33, 5, pp. 500-513, (2001); Sakakibara A., Furuse M., Saitou M., Ando-Akatsuka Y., Tsukita S., Possible involvement of phosphorylation of occludin in tight junction formation, Journal of Cell Biology, 137, 6, pp. 1393-1401, (1997); Fujibe M., Chiba H., Kojima T., Soma T., Wada T., Yamashita T., Sawada N., Thr<sup>203</sup> of claudin-1, a putative phosphorylation site for MAP kinase, is required to promote the barrier function of tight junctions, Experimental Cell Research, 295, 1, pp. 36-47, (2004); Zareie M., McKay D.M., Kovarik G.G., Perdue M.H., Monocyte/macrophages evoke epithelial dysfunction: Indirect role of tumor necrosis factor- α, American Journal of Physiology, 275, 4, (1998); Mashukova A., Wald F.A., Salas P.J., Tumor necrosis factor alpha and inflammation disrupt the polarity complex in intestinal epithelial cells by a posttranslational mechanism, Molecular and Cellular Biology, 31, 4, pp. 756-765, (2011); Graham W.V., Wang F., Clayburgh D.R., Cheng J.X., Yoon B., Wang Y., Lin A., Turner J.R., Tumor necrosis factor-induced long myosin light chain kinase transcription is regulated by differentiation-dependent signaling events: Characterization of the human long myosin light chain kinase promoter, Journal of Biological Chemistry, 281, 36, pp. 26205-26215, (2006); Wang F., Graham W.V., Wang Y., Witkowski E.D., Schwarz B.T., Turner J.R., Interferon-γ and tumor necrosis factor-α synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression, American Journal of Pathology, 166, 2, pp. 409-419, (2005); Sappington P.L., Han X., Yang R., Delude R.L., Fink M.P., Ethyl pyruvate ameliorates intestinal epithelial barrier dysfunction in endotoxemic mice and immunostimulated caco-2 enterocytic monolayers, Journal of Pharmacology and Experimental Therapeutics, 304, 1, pp. 464-476, (2003); Han X., Fink M.P., Delude R.L., Proinflammatory cytokines cause NO-dependent and -independent changes in expression and localization of tight junction proteins in intestinal epithelial cells, Shock, 19, 3, pp. 229-237, (2003); Dai C., Guandalini S., Zhao D.-H., Jiang M., Antinociceptive effect of VSL#3 on visceral hypersensitivity in a rat model of irritable bowel syndrome: A possible action through nitric oxide pathway and enhance barrier function, Molecular and Cellular Biochemistry, 361, 1-2, pp. 43-53, (2012); Zyrek A.A., Cichon C., Helms S., Enders C., Sonnenborn U., Schmidt M.A., Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCζ redistribution resulting in tight junction and epithelial barrier repair, Cellular Microbiology, 9, 3, pp. 804-816, (2007); Anderson R.C., Cookson A.L., McNabb W.C., Park Z., McCann M.J., Kelly W.J., Roy N.C., Lactobacillus plantarum MB452 enhances the function of the intestinal barrier by increasing the expression levels of genes involved in tight junction formation, BMC Microbiology, 10, (2010); Putaala H., Salusjarvi T., Nordstrom M., Saarinen M., Ouwehand A.C., Bech Hansen E., Rautonen N., Effect of four probiotic strains and Escherichia coli O157:H7 on tight junction integrity and cyclo-oxygenase expression, Research in Microbiology, 159, 9-10, pp. 692-698, (2008); Resta-Lenert S., Barrett K.E., Probiotics and commensals reverse TNF-α- and IFN-γ-induced dysfunction in human intestinal epithelial cells, Gastroenterology, 130, 3, pp. 731-746, (2006); Quettier-Deleu C., Gressier B., Vasseur J., Dine T., Brunet C., Luyckx M., Cazin M., Cazin J.C., Bailleul F., Trotin F., Phenolic compounds and antioxidant activities of buckwheat (Fagopyrum esculentum Moench) hulls and flour, Journal of Ethnopharmacology, 72, 1-2, pp. 35-42, (2000); Da Silva Porto P.A.L., Laranjinha J.A.N., De Freitas V.A.P., Antioxidant protection of low density lipoprotein by procyanidins: Structure/activity relationships, Biochemical Pharmacology, 66, 6, pp. 947-954, (2003); Mao T.K., Van De Water J., Keen C.L., Schmitz H.H., Gershwin M.E., Effect of cocoa flavanols and their related oligomers on the secretion of interleukin-5 in peripheral blood mononuclear cells, Journal of Medicinal Food, 5, 1, pp. 17-22, (2002); Takano F., Takata T., Yoshihara A., Nakamura Y., Arima Y., Ohta T., Aqueous extract of peanut skin and its main constituent procyanidin A1 suppress serum IgE and IgG1 levels in mice-immunized with ovalbumin, Biological and Pharmaceutical Bulletin, 30, 5, pp. 922-927, (2007); Watson J.L., Ansari S., Cameron H., Wang A., Akhtar M., McKay D.M., Green tea polyphenol (-)-epigallocatechin gallate blocks epithelial barrier dysfunction provoked by IFN-γ but not by IL-4, American Journal of Physiology - Gastrointestinal and Liver Physiology, 287, 5, (2004); Obara K., Ukai K., Ishikawa T., Mechanism of potentiation by tea epigallocatechin of contraction in porcine coronary artery: The role of protein kinase Cdelta-mediated CPI-17 phosphorylation, European Journal of Pharmacology, 668, 3, pp. 414-418, (2011); Kaneko-Kawano T., Takasu F., Naoki H., Sakumura Y., Ishii S., Ueba T., Eiyama A., Okada A., Kawano Y., Suzuki K., Dynamic regulation of myosin light chain phosphorylation by Rho-kinase, PLoS One, 7, 6, (2012); Ihme N., Kiesewetter H., Jung F., Hoffmann K.H., Birk A., Muller A., Grutzner K.I., Leg oedema protection from a buckwheat herb tea in patients with chronic venous insufficiency: A single-centre, randomised, double-blind, placebo controlled clinical trial, European Journal of Clinical Pharmacology, 50, 6, pp. 443-447, (1996); Santana D.G., Santos C.A., Santos A.D.C., Nogueira P.C.L., Thomazzi S.M., Estevam C.S., Antoniolli A.R., Camargo E.A., Beneficial effects of the ethanol extract of Caesalpinia pyramidalis on the inflammatory response and abdominal hyperalgesia in rats with acute pancreatitis, Journal of Ethnopharmacology, 142, 2, pp. 445-455, (2012); Schmitz H., Fromm M., Bentzel C.J., Scholz P., Detjen K., Mankertz J., Bode H., Epple H.-J., Riecken E.-O., Schulzke J.-D., Tumor necrosis factor-alpha (TNFα) regulates the epithelial barrier in the human intestinal cell line HT-29/B6, Journal of Cell Science, 112, 1, pp. 137-146, (1999); Suzuki T., Hara H., Quercetin enhances intestinal barrier function through the assembly of zonnula occludens-2, occludin, and claudin-1 and the expression of claudin-4 in caco-2 cells, Journal of Nutrition, 139, 5, pp. 965-974, (2009); Amasheh M., Schlichter S., Amasheh S., Mankertz J., Zeitz M., Fromm M., Schulzke J.D., Quercetin enhances epithelial barrier function and increases claudin-4 expression in Caco-2 cells, Journal of Nutrition, 138, 6, pp. 1067-1073, (2008)","Z. Sun; Institute of First Clinical Medicine, Nanjing University of Chinese Medicine, Jiangsu, Nanjing 210046, China; email: pr_zhiguangsun@163.com","","","","","","","","17414288","","","","English","Evid.-Based Complement. Altern. Med.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-84872142110"

"Zhou Q.; Zhang B.; Nicholas Verne G.","Zhou, QiQi (13404854200); Zhang, Buyi (24777452100); Nicholas Verne, G. (7004085639)","13404854200; 24777452100; 7004085639","Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome","2009","Pain","146","1-2","","41","46","5","320","10.1016/j.pain.2009.06.017","https://www.scopus.com/inward/record.uri?eid=2-s2.0-70349799526&doi=10.1016%2fj.pain.2009.06.017&partnerID=40&md5=7de8aebde1ce13fbefc36404784ce6e4","Department of Medicine, Ohio State University, Columbus, OH, United States; Research Service, Cincinnati VA Medical Center, Cincinnati, OH, United States","Zhou Q., Department of Medicine, Ohio State University, Columbus, OH, United States, Research Service, Cincinnati VA Medical Center, Cincinnati, OH, United States; Zhang B., Department of Medicine, Ohio State University, Columbus, OH, United States; Nicholas Verne G., Department of Medicine, Ohio State University, Columbus, OH, United States, Research Service, Cincinnati VA Medical Center, Cincinnati, OH, United States","Irritable bowel syndrome (IBS) is a common gastrointestinal disorder in which the underlying pathophysiology is poorly understood; however, increased intestinal permeability in diarrhea-predominant IBS patients has been reported. Here we demonstrate that diarrhea-predominant IBS (D-IBS) patients display increased intestinal permeability. We have also found that increased intestinal membrane permeability is associated with visceral and thermal hypersensitivity in this subset of D-IBS patients. We evaluated 54 D-IBS patients and 22 controls for intestinal membrane permeability using the lactulose/mannitol method. All subjects ingested 5 g of lactulose and 2 g of mannitol in 100 ml of water after which their urine was collected. We also evaluated the mean mechanical visual analogue scale (M-VAS) pain rating to nociceptive thermal and visceral stimulation in all subjects. All study participants also completed the FBDSI scale. Approximately 39% of diarrhea-predominant IBS patients had increased intestinal membrane permeability as measured by the lactulose/mannitol ratio. These IBS patients also demonstrated higher M-VAS pain intensity reading scale. Interestingly, the IBS patients with hypersensitivity and increased intestinal permeability had a higher FBDSI score (100.8 ± 5.4) than IBS patients with normal membrane permeability and sensitivity (51.6 ± 12.7) and controls (6.1 ± 5.6) (p < 0.001). A subset of D-IBS patients had increased intestinal membrane permeability that was associated with an increased FBDSI score and increased hypersensitivity to visceral and thermal nociceptive pain stimuli. Thus, increased intestinal membrane permeability in D-IBS patients may lead to more severe IBS symptoms and hypersensitivity to somatic and visceral stimuli. © 2009 International Association for the Study of Pain.","Functional Bowel Disorder Severity Index (FBDSI); Intestinal membrane permeability; Irritable bowel syndrome (IBS); Visceral and thermal hypersensitivity","Adult; Balloon Dilatation; Cell Membrane Permeability; Diarrhea; Female; Hot Temperature; Humans; Hypersensitivity; Intestinal Mucosa; Irritable Bowel Syndrome; Male; Pain; Pain Measurement; Physical Stimulation; Severity of Illness Index; lactulose; mannitol; adult; article; controlled study; diarrhea; disease severity; female; Functional Bowel Disorder Severity Index; human; hypersensitivity; intestine mucosa permeability; irritable colon; major clinical study; male; pain assessment; priority journal; rating scale; visceral pain; visual analog scale","","lactulose, 4618-18-2; mannitol, 69-65-8, 87-78-5","","","Medical Research Service; National Institutes of Health, NIH, (RO1-NS053090); National Center for Research Resources, NCRR, (M01RR000082); U.S. Department of Veterans Affairs, VA","This study was supported by a NIH RO1-NS053090 award (PI: GN Verne) and a VA Merit Review Award (PI: GN Verne) from the Medical Research Service at the Department of Veterans Affairs. The authors have no financial or other relationship to report that might lead to a conflict of interest.","Accarino A.M., Azpiroz F., Malagelada J.R., Selective dysfunction of mechanosensitive intestinal afferents in irritable bowel syndrome, Gastroenterology, 108, pp. 636-643, (1995); Al Chaer E.D., Kawasaki M., Pasricha P.J., A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development, Gastroenterology, 119, pp. 1276-1285, (2000); Bjarnason I., MacPherson A., Hollander D., Intestinal permeability: an overview, Gastroenterology, 108, pp. 1566-1581, (1995); Bouin M., Meunier P., Riberdy-Poitras M., Poitras P., Pain hypersensitivity in patients with functional gastrointestinal disorders: a gastrointestinal-specific defect or a general systemic condition?, Dig Dis Sci, 46, pp. 2542-2548, (2001); Camilleri M., Gorman H., Intestinal permeability and irritable bowel syndrome, Neurogastroenterol Motil, 19, pp. 545-552, (2007); Castilloux J., Noble A., Faure C., Is visceral hypersensitivity correlated with symptom severity in children with functional gastrointestinal disorders?, J Pediatr Gastroenterol Nutr, 45, pp. 272-278, (2008); Chang L., Mayer E.A., Johnson T., FitzGerald L.Z., Naliboff B., Differences in somatic perception in female patients with irritable bowel syndrome with and without fibromyalgia, Pain, 84, pp. 297-307, (2000); Cook I.J., van Eeden A., Collins S.M., Patients with irritable bowel syndrome have greater pain tolerance than normal subjects, Gastroenterology, 93, pp. 727-733, (1987); Dunlop S.P., Hebden J., Campbell E., Naesdal J., Olbe L., Perkins A.C., Spiller R.C., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Dunphy R.C., Bridgewater L., Price D.D., Robinson M.E., Zeilman III C.J., Verne G.N., Visceral and cutaneous hypersensitivity in Persian Gulf War veterans with chronic gastrointestinal symptoms, Pain, 102, pp. 79-85, (2003); Fillingim R.B., Ness T.J., Sex-related hormonal influences on pain and analgesic responses, Neurosci Biobehav Rev, 24, pp. 485-501, (2000); Gebhart G.F., Pathobiology of visceral pain: molecular mechanisms and therapeutic implications IV Visceral afferent contributions to the pathobiology of visceral pain, Am J Gastrointest Liver Physiol, 278, (2000); Geel S.E., The fibromyalgia syndrome: musculoskeletal pathophysiology, Semin Arthritis Rheum, 23, pp. 347-353, (1994); Geisser M.E., Robinson M.E., Pickwren W.E., Differences in cognitive coping strategies among pain-sensitive and pain-tolerant individuals on the cold pressor test, Behav Ther, 23, pp. 31-42, (1992); Gwee K.A., Graham J.C., McKendrick M.W., Collins S.M., Marshall J.S., Walters S.J., Read N.W., Psychometric scores and persistence of irritable bowel after infectious diarrhoea, Lancet, 347, pp. 150-153, (1996); Heitkemper M.M., Jarrett M., Pattern of gastrointestinal and somatic symptoms across the menstrual cycle, Gastroenterology, 102, pp. 505-513, (1992); Keshavarzian A., Fields J.Z., Vaeth J., Holmes E.W., The differing effects of acute and chronic alcohol on gastric and intestinal permeability, Am J Gastroenterol, 89, pp. 2205-2211, (1994); Keshavarzian A., Holmes E.W., Patel M., Iber F., Fields J.Z., Pethkar S., Leaky gut in alcoholic cirrhosis: a possible mechanism for alcohol-induced liver damage, Am J Gastroenterol, 94, pp. 200-207, (1999); Kuiken S.D., Lindeboom R., Tytgat G.N., Boeckxstaens G.E., Relationship between symptoms and hypersensitivity to rectal distension in patients with irritable bowel syndrome, Aliment Pharmacol Ther, 22, pp. 157-164, (2005); Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Macdonald T.T., Montelenone G., Immunity, inflammation, and allergy in the gut, Science, 307, pp. 1920-1925, (2005); Mayer E.A., Bradesi S., Chang L., Spiegel B.M., Bueller J.A., Naliboff B.D., Functional GI disorders: from animal models to drug development, Gut, 57, pp. 384-404, (2008); Mayer E.A., Collins S.M., Evolving pathophysiologic models of functional gastrointestinal disorders, Gastroenterology, 122, pp. 2032-2048, (2002); Mayer E.A., Gebhart G.F., Basic and clinical aspects of visceral hyperalgesia, Gastroenterology, 107, pp. 271-293, (1994); McKendrick M.W., Read N.W., Irritable bowel-syndrome-post salmonella infection, J Infect, 29, pp. 1-3, (1994); Mearin F., Perez-Oliveras M., Perello A., Vinyet J., Ibanez A., Coderch J., Perona M., Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study, Gastroenterology, 129, pp. 98-104, (2005); Naliboff B.D., Munakata J., Fullerton S., Gracely R.H., Kodner A., Harraf F., Mayer E.A., Evidence for two distinct perceptual alterations in irritable bowel syndrome, Gut, 41, pp. 505-512, (1997); Porras M., Martin M.T., Yang P.C., Jury J., Perdue M.H., Vergara P., Correlation between cyclical epithelial barrier dysfunction and bacterial translocation in the relapses of intestinal inflammation, Inflamm Bowel Dis, 12, pp. 843-852, (2006); Posserud I., Syrous A., Lindstrom L., Tack J., Abrahamsson H., Simren M., Altered rectal perception in irritable bowel syndrome is associated with symptom severity, Gastroenterology, 133, pp. 1113-1123, (2007); Price D.D., Bush F.M., Long S., Harkins S.W., A comparison of pain measurement characteristics of mechanical visual analogue and simple numerical rating scales, Pain, 56, pp. 217-226, (1994); Sabate J.M., Veyrac M., Mion F., Siproudhis L., Ducrotte P., Zerbib F., Grimaud J.C., Dapoigny M., Dyard F., Coffin B., Relationship between rectal sensitivity, symptoms intensity and quality of life in patients with the irritable bowel syndrome, Aliment Pharmacol Ther, 28, pp. 484-490, (2008); Sarlani E., Greenspan J.D., Evidence for generalized hyperalgesia in temoromandibular disorders patients, Pain, 102, pp. 221-226, (2003); Sperber A.D., Carmel S., Atzmon Y., Weisberg I., Shalit Y., Neumann L., Fich A., Friger M., Buskila D., Use of the Functional Bowel Disorder Severity Index (FBDSI) in a study of patients with the irritable bowel syndrome and fibromyalgia, Am J Gastroenterol, 95, pp. 995-998, (2000); Spiller R.C., Postinfectious irritable bowel syndrome, Gastroenterology, 124, pp. 1662-1671, (2003); Spiller R.C., Role of infection in irritable bowel syndrome, J Gastroenterol, 42, pp. 41-47, (2007); Spiller R.C., Jenkins D., Thornley J.P., Hebden J.M., Wright T., Skinner M., Neal K.R., Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, pp. 804-811, (2000); Van der Veek P.P., Van Rood Y.R., Masclee A.A., Symptom severity but not psychopathology predicts visceral hypersensitivity in irritable bowel syndrome, Clin Gastroenterol Hepatol, 6, pp. 321-328, (2008); Verne G.N., Cerda J.J., Irritable bowel syndrome. Streamlining the diagnosis, Postgrad Med, 102, pp. 197-208, (1997); Verne G.N., Himes N.C., Robinson M.E., Gopinath K.S., Briggs R.W., Crosson B., Price D.D., Central representation of visceral and cutaneous hypersensitivity in the irritable bowel syndrome, Pain, 103, pp. 99-110, (2003); Verne G.N., Price D.D., Irritable bowel syndrome as a common precipitant of central sensitization, Curr Rheumatol Rep, 4, pp. 322-328, (2002); Verne G.N., Robinson M.E., Price D.D., Hypersensitivity to visceral and cutaneous pain in the irritable bowel syndrome, Pain, 93, pp. 7-14, (2001); Whitehead W.E., Holtkotter B., Enck P., Hoelzl R., Holmes K.D., Anthony J., Shabsin H.S., Schuster M., Tolerance for rectosigmoid distention in irritable bowel syndrome, Gastroenterology, 98, pp. 1187-1192, (1990); Wilder-Smith C.H., Robert-Yap J., Abnormal endogenous pain modulation and somatic and visceral hypersensitivity in female patients with irritable bowel syndrome, World J Gastroeneterol, 13, pp. 3699-3704, (2007); Zhou Q., Price D.D., Caudle R.M., Verne G.N., Visceral and somatic hypersensitivity in a subset of rats of rats following TNBS-induced colitis, Pain, 134, pp. 9-15, (2008); Zighelboim J., Talley N.J., Phillips S.F., Harmsen W.S., Zinsmeister A.R., Visceral perception in irritable bowel syndrome. Rectal and gastric responses to distension and serotonin type 3 antagonism, Dig Dis Sci, 40, pp. 819-827, (1995)","G. Nicholas Verne; Department of Medicine, Ohio State University, Columbus, OH, United States; email: ginick@gmail.com","","","","","","","","03043959","","PAIND","19595511","English","Pain","Article","Final","All Open Access; Green Open Access","Scopus","2-s2.0-70349799526"

"Martínez C.; Vicario M.; Ramos L.; Lobo B.; Mosquera J.L.; Alonso C.; Sánchez A.; Guilarte M.; Antolín M.; De Torres I.; González-Castro A.M.; Pigrau M.; Saperas E.; Azpiroz F.; Santos J.","Martínez, Cristina (17534584700); Vicario, María (6603267769); Ramos, Laura (57206530978); Lobo, Beatriz (7003936898); Mosquera, Jose Luis (57354626500); Alonso, Carmen (56411082400); Sánchez, Alex (36910493800); Guilarte, Mar (18133405400); Antolín, María (7004375048); De Torres, Inés (7003506754); González-Castro, Ana M. (54796498900); Pigrau, Marc (37009212800); Saperas, Esteban (7004148840); Azpiroz, Fernando (57207592894); Santos, Javier (7402389020)","17534584700; 6603267769; 57206530978; 7003936898; 57354626500; 56411082400; 36910493800; 18133405400; 7004375048; 7003506754; 54796498900; 37009212800; 7004148840; 57207592894; 7402389020","The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations","2012","American Journal of Gastroenterology","107","5","","736","746","10","174","10.1038/ajg.2011.472","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84862336762&doi=10.1038%2fajg.2011.472&partnerID=40&md5=f27596a5816f67df91ce1ede37d2a64b","Department of Gastroenterology, Institut de Recerca Vall d'Hebron, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Paseo Vall d'Hebron 119-129, Spain; Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas Y Digestivas (CIBERehd), Barcelona, Spain; Statistics and Bioinformatics Unit, Institut de Recerca Vall d'Hebron, Barcelona, Spain; Statistics Department, Facultad de Biología, Universidad de Barcelona, Barcelona, Spain; Department of Allergy, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona (Departmento de Medicina), Barcelona, Spain; Department of Pathology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona (Departmento de Medicina), Barcelona, Spain","Martínez C., Department of Gastroenterology, Institut de Recerca Vall d'Hebron, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Paseo Vall d'Hebron 119-129, Spain; Vicario M., Department of Gastroenterology, Institut de Recerca Vall d'Hebron, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Paseo Vall d'Hebron 119-129, Spain, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas Y Digestivas (CIBERehd), Barcelona, Spain; Ramos L., Department of Gastroenterology, Institut de Recerca Vall d'Hebron, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Paseo Vall d'Hebron 119-129, Spain; Lobo B., Department of Gastroenterology, Institut de Recerca Vall d'Hebron, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Paseo Vall d'Hebron 119-129, Spain; Mosquera J.L., Statistics and Bioinformatics Unit, Institut de Recerca Vall d'Hebron, Barcelona, Spain; Alonso C., Department of Gastroenterology, Institut de Recerca Vall d'Hebron, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Paseo Vall d'Hebron 119-129, Spain; Sánchez A., Statistics and Bioinformatics Unit, Institut de Recerca Vall d'Hebron, Barcelona, Spain, Statistics Department, Facultad de Biología, Universidad de Barcelona, Barcelona, Spain; Guilarte M., Department of Gastroenterology, Institut de Recerca Vall d'Hebron, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Paseo Vall d'Hebron 119-129, Spain, Department of Allergy, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona (Departmento de Medicina), Barcelona, Spain; Antolín M., Department of Gastroenterology, Institut de Recerca Vall d'Hebron, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Paseo Vall d'Hebron 119-129, Spain, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas Y Digestivas (CIBERehd), Barcelona, Spain; De Torres I., Department of Pathology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona (Departmento de Medicina), Barcelona, Spain; González-Castro A.M., Department of Gastroenterology, Institut de Recerca Vall d'Hebron, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Paseo Vall d'Hebron 119-129, Spain; Pigrau M., Department of Gastroenterology, Institut de Recerca Vall d'Hebron, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Paseo Vall d'Hebron 119-129, Spain; Saperas E., Department of Gastroenterology, Institut de Recerca Vall d'Hebron, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Paseo Vall d'Hebron 119-129, Spain; Azpiroz F., Department of Gastroenterology, Institut de Recerca Vall d'Hebron, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Paseo Vall d'Hebron 119-129, Spain, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas Y Digestivas (CIBERehd), Barcelona, Spain; Santos J., Department of Gastroenterology, Institut de Recerca Vall d'Hebron, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Paseo Vall d'Hebron 119-129, Spain, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas Y Digestivas (CIBERehd), Barcelona, Spain","OBJECTIVES: Diarrhea-predominant irritable bowel syndrome (IBS-D) patients show altered epithelial permeability and mucosal micro-inflammation in both proximal and distal regions of the intestine. The objective of this study was to determine the molecular events and mechanisms and the clinical role of upper small intestinal alterations. METHODS: Clinical assessment and a jejunal biopsy was obtained in IBS-D patients and healthy subjects. Routine histology and immunohistochemistry was performed in all participants to assess the number of mast cells (MCs) and intraepithelial lymphocytes. RNA in tissue samples was isolated to identify genes showing consistent differential expression by microarray analysis followed by pathway and network analysis in order to identify the biological functions of the differentially expressed genes in IBS-D. Gene and protein expression of tight junction (TJ) components was also assessed by quantitative real-time polymerase chain reaction and confocal microscopy to evaluate the pathways identified by gene expression analysis. RESULTS: The analysis reveals a strong association between the transcript signature of the jejunal mucosa of IBS-D and intestinal permeability, MC biology, and TJ signaling. The expression of zonula occludens 1 (ZO-1) was reduced in IBS-D at both gene and protein level, with protein redistribution from the TJ to the cytoplasm. Remarkably, our analysis disclosed significant correlation between ZO proteins, MC activation, and clinical symptoms. CONCLUSIONS: IBS-D manifestations are linked to molecular alterations involving MC-related dysregulation of TJ functioning in the jejunal mucosa. © 2012 by the American College of Gastroenterology.","","Adult; Diarrhea; Female; Gene Expression; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Jejunum; Lymphocytes; Male; Mast Cells; Microarray Analysis; Middle Aged; Permeability; Real-Time Polymerase Chain Reaction; Signal Transduction; Tight Junctions; Young Adult; protein ZO1; adult; article; cell activation; cell count; clinical article; clinical assessment; confocal microscopy; controlled study; cytoplasm; diarrhea; disease association; female; gene expression; gene identification; histopathology; human; human cell; human tissue; immunohistochemistry; intestine mucosa permeability; irritable colon; jejunum biopsy; jejunum mucosa; lymphocyte; male; mast cell; microarray analysis; priority journal; protein expression; protein localization; quantitative analysis; real time polymerase chain reaction; RNA isolation; signal transduction; tight junction; diarrhea; genetics; intestine mucosa; irritable colon; jejunum; metabolism; middle aged; pathology; permeability; signal transduction; tight junction","","","","","","","Faresjo A., Grodzinsky E., Johansson S., Wallander M.-A., Timpka T., Akerlind I., Psychosocial factors at work and in every day life are associated with irritable bowel syndrome, European Journal of Epidemiology, 22, 7, pp. 473-480, (2007); Bennett E.J., Tennant C.C., Piesse C., Badcock C.-A., Kellow J.E., Level of chronic life stress predicts clinical outcome in irritable bowel syndrome, Gut, 43, 2, pp. 256-261, (1998); Nicholl B.I., Halder S.L., Macfarlane G.J., Thompson D.G., O'Brien S., Musleh M., McBeth J., Psychosocial risk markers for new onset irritable bowel syndrome - Results of a large prospective population-based study, Pain, 137, 1, pp. 147-155, (2008); Spiller R., Garsed K., Postinfectious irritable bowel syndrome, Gastroenterology, 136, pp. 1979-1988, (2009); Dunlop S.P., Hebden J., Campbell E., Naesdal J., Olbe L., Perkins A.C., Spiller R.C., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, American Journal of Gastroenterology, 101, 6, pp. 1288-1294, (2006); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Spiller R.C., Jenkins D., Thornley J.P., Et al., Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, pp. 804-811, (2000); Marshall J.K., Thabane M., Garg A.X., Clark W., Meddings J., Collins S.M., Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario, Alimentary Pharmacology and Therapeutics, 20, 11-12, pp. 1317-1322, (2004); Piche T., Barbara G., Aubert P., Et al., Impaired intestinal integrity in the colon of irritable bowel syndrome patients: Involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Coeffier M., Gloro R., Boukhettala N., Et al., Increased proteasome-mediated degradation of occludin in irritable bowel syndrome, Am J Gastroenterol, 105, pp. 1181-1188, (2010); Turner J.R., Intestinal mucosal barrier function in health and disease, Nat Rev Immunol, 9, pp. 799-809, (2009); Garrett W.S., Gordon J.I., Glimcher L.H., Homeostasis and inflammation in the intestine, Cell, 140, pp. 859-870, (2010); Alonso C., Guilarte M., Vicario M., Et al., Maladaptive intestinal epithelial responses to life stress, Gastroenterology, 135, pp. 163-172, (2008); Soderholm J.D., Yang P.C., Ceponis P., Et al., Chronic stress induces mast cell dependent bacterial adherence and initiates mucosal inflammation in rat intestine, Gastroenterology, 123, pp. 1099-1108, (2002); Qiu B.S., Vallance B.A., Blennerhassett P.A., Collins S.M., The role of CD4 <sup>+</sup> lymphocytes in the susceptibility of mice to stress- induced reactivation of experimental colitis, Nature Medicine, 5, 10, pp. 1178-1182, (1999); Cenac N., Andrews C.N., Holzhausen M., Chapman K., Cottrell G., Andrade-Gordon P., Steinhoff M., Barbara G., Beck P., Bunnett N.W., Sharkey K.A., Ferraz J.G.P., Shaffer E., Vergnolle N., Role for protease activity in visceral pain in irritable bowel syndrome, Journal of Clinical Investigation, 117, 3, pp. 636-647, (2007); Klooker T.K., Braak B., Koopman K.E., Et al., The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome, Gut, 59, pp. 1213-1221, (2010); Gwee K.-A., Collins S.M., Read N.W., Rajnakova A., Deng Y., Graham J.C., McKendrick M.W., Moochhala S.M., Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome, Gut, 52, 4, pp. 523-526, (2003); Chadwick V.S., Chen W., Shu D., Paulus B., Bethwaite P., Tie A., Wilson I., Activation of the mucosal immune system in irritable bowel syndrome, Gastroenterology, 122, 7, pp. 1778-1783, (2002); Barbara G., Stanghellini V., De Giorgio R., Cremon C., Cottrell G.S., Santini D., Pasquinelli G., Morselli-Labate A.M., Grady E.F., Bunnett N.W., Collins S.M., Corinaldesi R., Activated Mast Cells in Proximity to Colonic Nerves Correlate with Abdominal Pain in Irritable Bowel Syndrome, Gastroenterology, 126, 3, pp. 693-702, (2004); Guilarte M., Santos J., De Torres I., Et al., Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum, Gut, 56, pp. 203-209, (2007); Ohman L., Simren M., Pathogenesis of IBS: Role of inflammation, immunity and neuroimmune interactions, Nat Rev Gastroenterol Hepatol, 7, pp. 163-173, (2010); Barbara G., Wang B., Stanghellini V., De Giorgio R., Cremon C., Di N.G., Trevisani M., Campi B., Geppetti P., Tonini M., Bunnett N.W., Grundy D., Corinaldesi R., Mast Cell-Dependent Excitation of Visceral-Nociceptive Sensory Neurons in Irritable Bowel Syndrome, Gastroenterology, 132, 1, pp. 26-37, (2007); Buhner S., Li Q., Vignali S., Et al., Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome, Gastroenterology, 137, pp. 1425-1434, (2009); Aerssens J., Camilleri M., Talloen W., Thielemans L., Gohlmann H.W.H., Van Den W.I., Thielemans T., De Hoogt R., Andrews C.N., Bharucha A.E., Carlson P.J., Busciglio I., Burton D.D., Smyrk T., Urrutia R., Coulie B., Alterations in Mucosal Immunity Identified in the Colon of Patients With Irritable Bowel Syndrome, Clinical Gastroenterology and Hepatology, 6, 2, pp. 194-205, (2008); Macsharry J., O'Mahony L., Fanning A., Et al., Mucosal cytokine imbalance in irritable bowel syndrome, Scand J Gastroenterol, 43, pp. 1467-1476, (2008); Talley N.J., Stanghellini V., Heading R.C., Et al., Functional gastroduodenal disorders, Gut, 45, pp. 1137-1142, (1999); Holmes T.H., Rahe R.H., The social readjustment rating scale, J Psychosom Med, 11, pp. 213-218, (1967); Lewis S.J., Heaton K.W., Stool form scale as a useful guide to intestinal transit time, Scandinavian Journal of Gastroenterology, 32, 9, pp. 920-924, (1997); Schmittgen T.D., Livak K.J., Analyzing real-time PCR data by the comparative C <sub>T</sub> method, Nature Protocols, 3, 6, pp. 1101-1108, (2008); Benjamini Y., Hochberg Y., Controlling the false discovery rate: A practical and powerful approach to multiple testing, J Roy Statist Soc B, 85, pp. 289-300, (1995); Guillemot L., Paschoud S., Pulimeno P., Et al., The cytoplasmic plaque of tight junctions: A scaffolding and signalling center, Biochim Biophys Acta, 1778, pp. 601-613, (2008); Gecse K., Roka R., Ferrier L., Et al., Increased faecal serine protease activity in diarrhoeic IBS patients: A colonic lumenal factor impairing colonic permeability and sensitivity, Gut, 57, pp. 591-599, (2008); Utech M., Mennigen R., Bruewer M., Endocytosis and recycling of tight junction proteins in inflammation, J Biomed Biotechnol, 2010, (2010); Hopkins A.M., Walsh S.V., Verkade P., Boquet P., Nusrat A., Constitutive activation of Rho proteins by CNF-1 influences tight junction structure and epithelial barrier function, Journal of Cell Science, 116, 4, pp. 725-742, (2003); Marchiando A.M., Shen L., Graham W.V., Et al., Caveolin-1-dependent occludin endocytosis is required for TNF-induced tight junction regulation in vivo, J Cell Biol, 189, pp. 111-126, (2010); Galli S.J., Grimbaldeston M., Tsai M., Immunomodulatory mast cells: Negative, as well as positive, regulators of immunity, Nature Reviews Immunology, 8, 6, pp. 478-486, (2008); Aichberger K.J., Mayerhofer M., Gleixner K.V., Krauth M.-T., Gruze A., Pickl W.F., Wacheck V., Selzer E., Mullauer L., Agis H., Sillaber C., Valent P., Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: Inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412, Blood, 109, 7, pp. 3031-3041, (2007); Moller C., Alfredsson J., Engstrom M., Wootz H., Xiang Z., Lennartsson J., Jonsson J.-I., Nilsson G., Stem cell factor promotes mast cell survival via inactivation of FOXO3a-mediated transcriptional induction and MEK-regulated phosphorylation of the proapoptotic protein Bim, Blood, 106, 4, pp. 1330-1336, (2005); Berent-Maoz B., Piliponsky A.M., Daigle I., Simon H.-U., Levi-Schaffer F., Human mast cells undergo TRAIL-induced apoptosis, Journal of Immunology, 176, 4, pp. 2272-2278, (2006); Cremon C., Gargano L., Morselli-Labate A.M., Et al., Mucosal immune activation in irritable bowel syndrome: Gender-dependence and association with digestive symptoms, Am J Gastroenterol, 104, pp. 392-400, (2009); Bercik P., Verdu E.F., Collins S.M., Is irritable bowel syndrome a low-grade inflammatory bowel disease?, Gastroenterology Clinics of North America, 34, 2 SPEC. ISS., pp. 235-245, (2005); Kirsch R.H., Riddell R., Histopathological alterations in irritable bowel syndrome, Modern Pathology, 19, 12, pp. 1638-1645, (2006)","J. Santos; Department of Gastroenterology, Institut de Recerca Vall d'Hebron, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Paseo Vall d'Hebron 119-129, Spain; email: jsantos@ir.vhebron.net","","","","","","","","15720241","","AJGAA","22415197","English","Am. J. Gastroenterol.","Article","Final","","Scopus","2-s2.0-84862336762"

"Brown D.","Brown, Donald (55738763900)","55738763900","Probiotics effectively treat irritable bowel syndrome in children","2011","Alternative Medicine Alert","14","3","","28","30","2","0","","https://www.scopus.com/inward/record.uri?eid=2-s2.0-79955911537&partnerID=40&md5=04d7d20b62f6a1d2f4c0c54324d53b5a","Natural Products Research Consultants, Seattle, WA, United States","Brown D., Natural Products Research Consultants, Seattle, WA, United States","Results of this 8-week clinical trial demonstrated the efficacy of Lactobacillus rhamnosus strain GG (LGG) in reducing the frequency and severity of pain in children with irritable bowel syndrome or functional abdominal pain. Benefits persisted for 8 weeks after cessation of treatment. Additionally, small intestinal permeability was decreased in children with IBS treated with LGG.","","","","","","","","","Saps M., Et al., A prospective school-based study of abdominal pain and other common somatic complaints in children, J Pediatr, 154, pp. 322-326, (2009); Rasquin A., Et al., Childhood functional gastrointestinal disorders :child/adolescent, Gastroenterology, 130, pp. 1527-1537, (2006); Hoveyda N., Et al., A systematic review and metaanalysis: Probiotics in the treatment of irritable bowel syndrome, BMC Gastroenterol, 9, (2009); Mertz H.R., Iritable bowel syndrome, N Engl J Med, 349, pp. 2136-2146, (2003); Everheart J.E., Et al., Irritable bowel syndrome in office-based practice in the United States, Gastroenterol, 100, pp. 998-1005, (1991); Weydert J.A., Et al., Systematic review of treatments for recurrent abdominal pain, Pediatrics, 111, (2003); Baussermann M., Et al., The use of Lactobacillus GG in irritable bowel syndrome in children: A double-blind randomized control trial, J Pediatr, 147, pp. 197-201, (2005); Gawronska A., Dziechciarz P., Horvath A., Szajewska H., A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children, Alimentary Pharmacology and Therapeutics, 25, 2, pp. 177-184, (2007); Dunlop S.P., Hebden J., Campbell E., Naesdal J., Olbe L., Perkins A.C., Spiller R.C., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, American Journal of Gastroenterology, 101, 6, pp. 1288-1294, (2006); Stratiki Z., Costalos C., Sevastiadou S., Kastanidou O., Skouroliakou M., Giakoumatou A., Petrohilou V., The effect of a bifidobacter supplemented bovine milk on intestinal permeability of preterm infants, Early Human Development, 83, 9, pp. 575-579, (2007); Mohammad M., Hussein L., Yamamah G., Rawi S., The impact of probiotic and/or honey supplements on gut permeability among Egyptian children, Journal of Nutritional and Environmental Medicine, 16, 1, pp. 10-15, (2007); Shulman R.J., Et al., Increased gastrointestinal permeability and gut inflammation in children with functional abdominal pain and irritable bowel syndrome, J Pediatr, 153, pp. 646-650, (2008); Lin H.C., Small intestinal bacterial overgrowth: A framework for understanding irritable bowel syndrome, Journal of the American Medical Association, 292, 7, pp. 852-858, (2004)","","","","","","","","","1096942X","","","","English","Altern.Med. Alert","Article","Final","","Scopus","2-s2.0-79955911537"

"Ghoshal U.C.; Ranjan P.","Ghoshal, Uday C. (7005966711); Ranjan, Prabhat (57200595370)","7005966711; 57200595370","Post-infectious irritable bowel syndrome: The past, the present and the future","2011","Journal of Gastroenterology and Hepatology (Australia)","26","SUPPL. 3","","94","101","7","64","10.1111/j.1440-1746.2011.06643.x","https://www.scopus.com/inward/record.uri?eid=2-s2.0-79953093222&doi=10.1111%2fj.1440-1746.2011.06643.x&partnerID=40&md5=e0166dce0ee13a7971e78966354dd5bc","Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India","Ghoshal U.C., Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India; Ranjan P., Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India","Background: Irritable bowel syndrome (IBS), once thought to be a psychosomatic disease, is being considered to be more organic. Post-infectious IBS (PI-IBS), defined as acute onset IBS (by Rome criteria) after gastrointestinal infection in an individual without prior IBS with two or more of the followings: fever, vomiting, diarrhea, a positive stool culture. The recent and old literature of PI-IBS will be reviewed. Future directions for research will be presented. Methods: Literature on PI-IBS was reviewed by electronic search and cross references of these papers. Results: Interest in studies on PI-IBS, which was described five to six decades ago, re-surfaced recently. 3.6 to 32% patients with acute gastroenteritis develop PI-IBS during 3-12 month follow-up. PI-IBS is commonly diarrhea predominant. Factors implicated in development include nature of pathogens, duration and severity of diarrhea, younger age, female gender and psychological co-morbidities like anxiety and depression. The pathogenesis of PI-IBS is largely related to continuing gut inflammation due to inability of the host to contain the inflammatory reaction, altered gut microbiota, increased intestinal permeability, muscle hyper-contractility and visceral hypersensitivity. There could be an overlap between PI-IBS and post-infectious malabsorption syndrome (PI-MAS), popularly known as tropical sprue. Conclusions: Development of IBS in a subset of patients with acute gastroenteritis is uncontested. This is expected to open a paradigm shift in understanding the pathogenesis of IBS. Future studies should address the issue of overlap of PI-IBS and PI-MAS. Exploring the molecular mechanisms of pathogenesis of PI-IBS may help to design preventive and therapeutic strategies. © 2011 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd.","Chronic diarrhea; Dysentery; Functional bowel disease; Gastroenteritis; Tropical sprue","toll like receptor 9; acute gastroenteritis; anxiety; article; bacterial flora; comorbidity; depression; diarrhea; disease severity; DNA polymorphism; enteritis; follow up; groups by age; Helicobacter pylori; human; innate immunity; irritable colon; malabsorption; membrane permeability; microflora; muscle contraction; pathogenesis; post infection irritable bowel syndrome; post infection malabsorption syndrome; priority journal; psychological aspect; risk factor; sex difference","","toll like receptor 9, 352486-49-8, 390883-32-6","","","","","Gwee K.A., Lu C.L., Ghoshal U.C., Epidemiology of irritable bowel syndrome in Asia: something old, something new, something borrowed, J. Gastroenterol. Hepatol., 24, pp. 1601-1607, (2009); Ghoshal U.C., Park H., Gwee K.A., Bugs and irritable bowel syndrome: the good, the bad and the ugly, J. Gastroenterol. Hepatol., 25, pp. 244-251, (2010); Collins S., Verdu E., Denou E., Bercik P., The role of pathogenic microbes and commensal bacteria in irritable bowel syndrome, Dig. Dis., 27, SUPPL. 1, pp. 85-89, (2009); Cuomo R., Savarese M.F., Gargano R., Almost all irritable bowel syndromes are post-infectious and respond to probiotics: consensus issues, Dig. Dis., 25, pp. 241-244, (2007); Spiller R.C., Infection, immune function, and functional gut disorders, Clin. Gastroenterol. Hepatol., 2, pp. 445-455, (2004); Spiller R.C., Overlap between irritable bowel syndrome and inflammatory bowel disease, Dig. Dis., 27, SUPPL. 1, pp. 48-54, (2009); Stewart G.T., Post-dysenteric colitis, Br. Med. J., 1, pp. 405-409, (1950); Chaudhary N.A., Truelove S.C., The irritable colon syndrome. A study of the clinical features, predisposing causes, and prognosis in 130 cases, Q. J. Med., 31, pp. 307-322, (1962); Mathan V.I., Baker S.J., Epidemic tropical sprue and other epidemics of diarrhea in South Indian villages, Am. J. Clin. Nutr., 21, pp. 1077-1087, (1968); Montgomery R.D., Shearer A.C., The cell population of the upper jejunal mucosa in tropical sprue and postinfective malabsorption, Gut, 15, pp. 387-391, (1974); Lindenbaum J., Malabsorption during and after recovery from acute intestinal infection, Br. Med. J., 2, pp. 326-329, (1965); Ramakrishna B.S., Venkataraman S., Mukhopadhya A., Tropical malabsorption, Postgrad. Med. J., 82, pp. 779-787, (2006); Gwee K.A., Graham J.C., McKendrick M.W., Et al., Psychometric scores and persistence of irritable bowel after infectious diarrhoea, Lancet, 347, pp. 150-153, (1996); McKendrick M.W., Read N.W., Irritable bowel syndrome-post salmonella infection, J. Infect., 29, pp. 1-3, (1994); Neal K.R., Hebden J., Spiller R., Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients, BMJ, 314, pp. 779-782, (1997); Gwee K.A., Leong Y.L., Graham C., Et al., The role of psychological and biological factors in postinfective gut dysfunction, Gut, 44, pp. 400-406, (1999); Rodriguez L.A., Ruigomez A., Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study, BMJ, 318, pp. 565-566, (1999); Mearin F., Badia X., Balboa A., Et al., Irritable bowel syndrome prevalence varies enormously depending on the employed diagnostic criteria: comparison of Rome II versus previous criteria in a general population, Scand. J. Gastroenterol., 36, pp. 1155-1161, (2001); Ilnyckyj A., Balachandra B., Elliott L., Choudhri S., Duerksen D.R., Post-traveler's diarrhea irritable bowel syndrome: a prospective study, Am. J. Gastroenterol., 98, pp. 596-599, (2003); Dunlop S.P., Jenkins D., Spiller R.C., Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome, Am. J. Gastroenterol., 98, pp. 1578-1583, (2003); Parry S.D., Stansfield R., Jelley D., Et al., Does bacterial gastroenteritis predispose people to functional gastrointestinal disorders? A prospective, community-based, case-control study, Am. J. Gastroenterol., 98, pp. 1970-1975, (2003); Wang L.H., Fang X.C., Pan G.Z., Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis, Gut, 53, pp. 1096-1101, (2004); Okhuysen P.C., Jiang Z.D., Carlin L., Forbes C., DuPont H.L., Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico, Am. J. Gastroenterol., 99, pp. 1774-1778, (2004); Ji S., Park H., Lee D., Song Y.K., Choi J.P., Lee S.I., Post-infectious irritable bowel syndrome in patients with Shigella infection, J. Gastroenterol. Hepatol., 20, pp. 381-386, (2005); Kim H.S., Kim M.S., Ji S.W., Park H., The development of irritable bowel syndrome after Shigella infection: 3year follow-up study, Korean J. Gastroenterol., 47, pp. 300-305, (2006); Jung I.S., Kim H.S., Park H., Lee S.I., The clinical course of postinfectious irritable bowel syndrome: a five-year follow-up study, J. Clin. Gastroenterol., 43, pp. 534-540, (2009); Marshall J.K., Thabane M., Garg A.X., Clark W.F., Salvadori M., Collins S.M., Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery, Gastroenterology, 131, pp. 445-450, (2006); Borgaonkar M.R., Ford D.C., Marshall J.K., Churchill E., Collins S.M., The incidence of irritable bowel syndrome among community subjects with previous acute enteric infection, Dig. Dis. Sci., 51, pp. 1026-1032, (2006); Moss-Morris R., Spence M., To ""lump"" or to ""split"" the functional somatic syndromes: can infectious and emotional risk factors differentiate between the onset of chronic fatigue syndrome and irritable bowel syndrome?, Psychosom. Med., 68, pp. 463-469, (2006); Stermer E., Lubezky A., Potasman I., Paster E., Lavy A., Is traveler's diarrhea a significant risk factor for the development of irritable bowel syndrome? A prospective study, Clin. Infect. Dis., 43, pp. 898-901, (2006); Marshall J.K., Thabane M., Borgaonkar M.R., James C., Postinfectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attributed to a viral pathogen, Clin. Gastroenterol. Hepatol., 5, pp. 457-460, (2007); Spence M.J., Moss-Morris R., The cognitive behavioural model of irritable bowel syndrome: a prospective investigation of patients with gastroenteritis, Gut, 56, pp. 1066-1071, (2007); Hanevik K., Dizdar V., Langeland N., Hausken T., Development of functional gastrointestinal disorders after Giardia lamblia infection, BMC Gastroenterol., 9, (2009); Haagsma J.A., Siersema P.D., De Wit N.J., Havelaar A.H., Disease burden of post-infectious irritable bowel syndrome in The Netherlands, Epidemiol. Infect., 138, pp. 1650-1656, (2010); Thabane M., Kottachchi D.T., Marshall J.K., Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome, Aliment. Pharmacol. Ther., 26, pp. 535-544, (2007); Halvorson H.A., Schlett C.D., Riddle M.S., Postinfectious irritable bowel syndrome-a meta-analysis, Am. J. Gastroenterol., 101, pp. 1894-1899, (2006); Grazioli B., Matera G., Laratta C., Et al., Giardia lamblia infection in patients with irritable bowel syndrome and dyspepsia: a prospective study, World J. Gastroenterol., 12, pp. 1941-1944, (2006); D'Anchino M., Orlando D., De Feudis L., Giardia lamblia infections become clinically evident by eliciting symptoms of irritable bowel syndrome, J. Infect., 45, pp. 169-172, (2002); Sinha P., Ghoshal U.C., Choudhuri G., Naik S., Ayyagari A., Naik S.R., Does Entamoeba histolytica cause irritable bowel syndrome?, Indian J. Gastroenterol., 16, pp. 130-133, (1997); Anand A.C., Reddy P.S., Saiprasad G.S., Kher S.K., Does non-dysenteric intestinal amoebiasis exist?, Lancet, 349, pp. 89-92, (1997); Pan G., Lu S., Ke M., Han S., Guo H., Fang X., Epidemiologic study of the irritable bowel syndrome in Beijing: stratified randomized study by cluster sampling, Chin. Med. J. (Engl.), 113, pp. 35-39, (2000); Tuteja A.K., Talley N.J., Gelman S.S., Et al., Development of functional diarrhea, constipation, irritable bowel syndrome, and dyspepsia during and after traveling outside the USA, Dig. Dis. Sci., 53, pp. 271-276, (2008); Sykes M.A., Blanchard E.B., Lackner J., Keefer L., Krasner S., Psychopathology in irritable bowel syndrome: support for a psychophysiological model, J. Behav. Med., 26, pp. 361-372, (2003); Thabane M., Simunovic M., Akhtar-Danesh N., Marshall J.K., Development and validation of a risk score for post-infectious irritable bowel syndrome, Am. J. Gastroenterol., 104, pp. 2267-2274, (2009); Xiong L.S., Chen M.H., Chen H.X., Xu A.G., Wang W.A., Hu P.J., A population-based epidemiologic study of irritable bowel syndrome in Guangdong province, Zhonghua Yi Xue Za Zhi, 84, pp. 278-281, (2004); Xiong L.S., Chen M.H., Chen H.X., Xu A.G., Wang W.A., Hu P.J., A population-based epidemiologic study of irritable bowel syndrome in South China: stratified randomized study by cluster sampling, Aliment. Pharmacol. Ther., 19, pp. 1217-1224, (2004); Park K.S., Ahn S.H., Hwang J.S., Et al., A survey about irritable bowel syndrome in South Korea: prevalence and observable organic abnormalities in IBS patients, Dig. Dis. Sci., 53, pp. 704-711, (2008); Ghoshal U.C., Abraham P., Bhatt C., Et al., Epidemiological and clinical profile of irritable bowel syndrome in India: report of the Indian society of gastroenterology task force, Indian J. Gastroenterol., 27, pp. 22-28, (2008); Danivat D., Tankeyoon M., Sriratanaban A., Prevalence of irritable bowel syndrome in a non-Western population, Br. Med. J. (Clin. Res. Ed), 296, (1988); Masud M.A., Hasan M., Khan A.K., Irritable bowel syndrome in a rural community in Bangladesh: prevalence, symptoms pattern, and health care seeking behavior, Am. J. Gastroenterol., 96, pp. 1547-1552, (2001); Husain N., Chaudhry I.B., Jafri F., Niaz S.K., Tomenson B., Creed F., A population-based study of irritable bowel syndrome in a non-Western population, Neurogastroenterol. Motil., 20, pp. 1022-1029, (2008); Pearce E.J., M Kane C., Sun J., J Taylor J., McKee A.S., Cervi L., Th2 response polarization during infection with the helminth parasite Schistosoma mansoni, Immunol. Rev., 201, pp. 117-126, (2004); Baker S.J., Mathan V.I., An epidemic of tropical sprue in southern India. II. Epidemiology, Ann. Trop. Med. Parasitol., 64, pp. 453-467, (1970); Mathan V.I., Baker S.J., An epidemic of tropical sprue in southern India. I. Clinical features, Ann. Trop. Med. Parasitol., 64, pp. 439-451, (1970); Sheeby T.W., Digestive disease as a national problem. VI. Enteric disease among United States troops in Vietnam, Gastroenterology, 55, pp. 105-112, (1968); Lim M.L., A perspective on tropical sprue, Curr. Gastroenterol. Rep., 3, pp. 322-327, (2001); Ghoshal U.C., Ghoshal U., Ayyagari A., Et al., Tropical sprue is associated with contamination of small bowel with aerobic bacteria and reversible prolongation of orocecal transit time, J. Gastroenterol. Hepatol., 18, pp. 540-547, (2003); Gorbach S.L., Mitra R., Jacobs B., Banwell J.G., Chatterjee B.D., Mazumder D.N., Bacterial contamination of the upper small bowel in tropical sprue, Lancet, 1, pp. 74-77, (1969); Rana S.V., Sinha S.K., Sikander A., Bhasin D.K., Singh K., Study of small intestinal bacterial overgrowth in North Indian patients with irritable bowel syndrome: a case control study, Trop. Gastroenterol., 29, pp. 23-25, (2008); Gupta D., Ghoshal U.C., Misra A., Choudhuri G., Singh K., Lactose intolerance in patients with irritable bowel syndrome from northern India: a case-control study, J. Gastroenterol. Hepatol., 22, pp. 2261-2265, (2007); Spiller R., Garsed K., Postinfectious irritable bowel syndrome, Gastroenterology, 136, pp. 1979-1988, (2009); Ghoshal U.C., Kumar S., Mehrotra M., Lakshmi C., Misra A., Frequency of small intestinal bacterial overgrowth in patients with irritable bowel syndrome and chronic non-specific diarrhea, J. Neurogastroenterol. Motil., 16, pp. 40-46, (2010); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am. J. Gastroenterol., 101, pp. 1288-1294, (2006); Kumar S., Ghoshal U.C., Jayalakshmi K., Roy R., Misra A., Khetrapal C.L., Abnormal small intestinal permeability in patients with idiopathic malabsorption in tropics (tropical Sprue) does not change even after successful treatment, Dig. Dis. Sci., 56, pp. 161-169, (2011); Gorbach S.L., Neale G., Levitan R., Hepner G.W., Alterations in human intestinal microflora during experimental diarrhoea, Gut, 11, pp. 1-6, (1970); Malinen E., Rinttila T., Kajander K., Et al., Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR, Am. J. Gastroenterol., 100, pp. 373-382, (2005); Krogius-Kurikka L., Lyra A., Malinen E., Et al., Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers, BMC Gastroenterol., 9, (2009); Malinen E., Krogius-Kurikka L., Lyra A., Et al., Association of symptoms with gastrointestinal microbiota in irritable bowel syndrome, World J. Gastroenterol., 16, pp. 4532-4540, (2010); Pimentel M., Chatterjee S., Chang C., Et al., A new rat model links two contemporary theories in irritable bowel syndrome, Dig. Dis. Sci., 53, pp. 982-989, (2008); Pimentel M., Mayer A.G., Park S., Chow E.J., Hasan A., Kong Y., Methane production during lactulose breath test is associated with gastrointestinal disease presentation, Dig. Dis. Sci., 48, pp. 86-92, (2003); Rana S.V., Sharma S., Sinha S.K., Kaur H., Sikander A., Singh K., Incidence of predominant methanogenic flora in irritable bowel syndrome patients and apparently healthy controls from North India, Dig. Dis. Sci., 54, pp. 132-135, (2009); Kumar S., Misra A., Ghoshal U.C., Patients with irritable bowel syndrome exhale more hydrogen than healthy subjects in fasting state, J. Neurogastroenterol. Motil., 16, pp. 299-305, (2010); Austin G.L., Dalton C.B., Hu Y., Et al., A very low-carbohydrate diet improves symptoms and quality of life in diarrhea-predominant irritable bowel syndrome, Clin. Gastroenterol. Hepatol., 7, (2009); Goldstein R., Braverman D., Stankiewicz H., Carbohydrate malabsorption and the effect of dietary restriction on symptoms of irritable bowel syndrome and functional bowel complaints, Isr. Med. Assoc. J., 2, pp. 583-587, (2000); Haderstorfer B., Psycholgin D., Whitehead W.E., Schuster M.M., Intestinal gas production from bacterial fermentation of undigested carbohydrate in irritable bowel syndrome, Am. J. Gastroenterol., 84, pp. 375-378, (1989); Afdhal N.H., Piggott C., Long A.A., O'Donoghue D.P., Carbohydrate handling by colonic flora-is it pathogenic in the irritable bowel syndrome?, Ir. J. Med. Sci., 155, pp. 197-201, (1986); Mortensen P.B., Andersen J.R., Arffmann S., Krag E., Short-chain fatty acids and the irritable bowel syndrome: the effect of wheat bran, Scand. J. Gastroenterol., 22, pp. 185-192, (1987); Treem W.R., Ahsan N., Kastoff G., Hyams J.S., Fecal short-chain fatty acids in patients with diarrhea-predominant irritable bowel syndrome: in vitro studies of carbohydrate fermentation, J. Pediatr. Gastroenterol. Nutr., 23, pp. 280-286, (1996); Spiller R.C., Jenkins D., Thornley J.P., Et al., Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, pp. 804-811, (2000); Marshall J.K., Thabane M., Garg A.X., Clark W., Meddings J., Collins S.M., Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario, Aliment. Pharmacol. Ther., 20, pp. 1317-1322, (2004); Gwee K.A., Collins S.M., Read N.W., Et al., Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome, Gut, 52, pp. 523-526, (2003); Dumoulin V., Moro F., Barcelo A., Dakka T., Cuber J.C., Peptide YY, glucagon-like peptide-1, and neurotensin responses to luminal factors in the isolated vascularly perfused rat ileum, Endocrinology, 139, pp. 3780-3786, (1998); Cherbut C., Aube A.C., Blottiere H.M., Galmiche J.P., Effects of short-chain fatty acids on gastrointestinal motility, Scand. J. Gastroenterol. Suppl., 222, pp. 58-61, (1997); Akiho H., Deng Y., Blennerhassett P., Kanbayashi H., Collins S.M., Mechanisms underlying the maintenance of muscle hypercontractility in a model of postinfective gut dysfunction, Gastroenterology, 129, pp. 131-141, (2005); Long Y.Q., Tong J.J., Qian W., Hou X.H., Altered expression of intestinal cytokines in development of postinfectious irritable bowel syndrome mouse model, Zhonghua Yi Xue Za Zhi, 90, pp. 2415-2419, (2010); Dunlop S.P., Jenkins D., Neal K.R., Spiller R.C., Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS, Gastroenterology, 125, pp. 1651-1659, (2003); Villani A.C., Lemire M., Thabane M., Et al., Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis, Gastroenterology, 138, pp. 1502-1513, (2010)","U.C. Ghoshal; Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, India; email: udayghoshal@gmail.com","","Blackwell Publishing","","","","","","08159319","","JGHEE","","English","J. Gastroenterol. Hepatol.","Article","Final","","Scopus","2-s2.0-79953093222"

"Dunlop S.P.; Hebden J.; Campbell E.; Naesdal J.; Olbe L.; Perkins A.C.; Spiller R.C.","Dunlop, Simon P. (35802259600); Hebden, John (7004407753); Campbell, Eugene (7402063635); Naesdal, Jorgen (55900963000); Olbe, Lars (7006954993); Perkins, Alan C. (55586059800); Spiller, Robin C. (7005287882)","35802259600; 7004407753; 7402063635; 55900963000; 7006954993; 55586059800; 7005287882","Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes","2006","American Journal of Gastroenterology","101","6","","1288","1294","6","406","10.1111/j.1572-0241.2006.00672.x","https://www.scopus.com/inward/record.uri?eid=2-s2.0-33744830627&doi=10.1111%2fj.1572-0241.2006.00672.x&partnerID=40&md5=f355ab0e52c9cfcfae91d46de6c1c464","Wolfson Digestive Diseases Centre, Division of Medical Physics, University Hospital, Nottingham, United Kingdom; Division of Gastroenterology, University Hospital, Nottingham, NG7 2UH, United Kingdom","Dunlop S.P., Wolfson Digestive Diseases Centre, Division of Medical Physics, University Hospital, Nottingham, United Kingdom; Hebden J., Wolfson Digestive Diseases Centre, Division of Medical Physics, University Hospital, Nottingham, United Kingdom; Campbell E., Wolfson Digestive Diseases Centre, Division of Medical Physics, University Hospital, Nottingham, United Kingdom; Naesdal J., Wolfson Digestive Diseases Centre, Division of Medical Physics, University Hospital, Nottingham, United Kingdom; Olbe L., Wolfson Digestive Diseases Centre, Division of Medical Physics, University Hospital, Nottingham, United Kingdom; Perkins A.C., Wolfson Digestive Diseases Centre, Division of Medical Physics, University Hospital, Nottingham, United Kingdom; Spiller R.C., Wolfson Digestive Diseases Centre, Division of Medical Physics, University Hospital, Nottingham, United Kingdom, Division of Gastroenterology, University Hospital, Nottingham, NG7 2UH, United Kingdom","OBJECTIVES: Irritable bowel syndrome (IBS) is a heterogeneous condition and defined according to symptoms. Low-grade inflammation has been associated with IBS, particularly that following infection, but whether altered intestinal permeability profiles relate to irritable bowel subtype or onset is uncertain. Our aim was to compare small and large intestinal permeability in various subtypes of IBS to healthy controls. METHODS: Intestinal permeability was measured using 1.8 MBq of 51Cr-EDTA and collecting urine over 24 h; Study 1: patients with diarrhea-predominant postinfectious IBS (N = 15), constipation-predominant IBS (N = 15), and healthy controls (N = 15); Study 2: two groups of diarrhea-predominant IBS (D-IBS), one with a history of onset after acute gastroenteritis (postinfectious) (N = 15) and the other without such a history (nonpostinfectious) (N = 15) both compared with healthy controls (N = 12). RESULTS: Permeability expressed as percentage of total dose excreted in urine (median [inter-quartile range]). Study 1: Proximal small intestinal permeability was increased in postinfectious IBS (0.19 [0.12-0.23]) in contrast to constipated IBS (0.085 [0.043-0.13]) and controls (0.07 [0.035-0.19]) (p = 0.02). IBS patients with eczema, asthma, or hayfever had increased proximal small intestinal permeability compared with IBS patients without atopy (p = 0.02). Study 2: Small intestinal permeability was greater in nonpostinfectious diarrhea-predominant IBS (0.84 [0.69-1.49]) compared with postinfectious IBS (0.43 [0.29-0.63], p = 0.028) or controls (0.27 [0.2-0.39]), p = 0.001). CONCLUSIONS: Small intestinal permeability is frequently abnormal in diarrhea-predominant IBS. Those without a history of infectious onset appear to have a more severe defect. © 2006 by Am. Coll. of Gastroenterology Published by Blackwell Publishing.","","Adolescent; Adult; Analysis of Variance; Case-Control Studies; Chromium Isotopes; Diarrhea; Edetic Acid; Enzyme-Linked Immunosorbent Assay; Female; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Male; Middle Aged; Permeability; Questionnaires; Statistics, Nonparametric; edetate chromium cr 51; acute gastroenteritis; adult; article; asthma; atopy; clinical article; colon biopsy; constipation; controlled study; diarrhea; eczema; enterochromaffin cell; female; hay fever; high risk patient; human; intestine mucosa permeability; irritable colon; male; priority journal; small intestine","","edetate chromium cr 51, 11063-42-6; Chromium Isotopes, ; Edetic Acid, 60-00-4","","","","","Drossman D.A., Creed F.H., Olden K.W., Psychosocial aspects of functional gastrointestinal disorders, Gut, 45, 2, (1999); Atkinson W., Sheldon T.A., Shaath N., Food elimation based on IgG antibodies in irritable bowel syndrome: A randomised controlled trial, Gut, 53, pp. 1459-64, (2004); Francis C.Y., Whorwell P.J., Bran and irritable bowel syndrome: Time for reappraisal, Lancet, 344, pp. 39-40, (1994); Spiller R.C., Postinfectious irritable bowel syndrome, Gastroenterology, 124, pp. 1662-71, (2003); Salzmann J.L., Peltier-Koch F., Bloch F., Et al., Morphometric study of colonic biopsies: A new method of estimating inflammatory diseases, Lab Invest, 60, pp. 847-51, (1989); Weston A.P., Biddle W.L., Bhatia P.S., Et al., Terminal ileal mucosal mast cells in irritable bowel syndrome, Dig Dis Sci, 38, pp. 1590-5, (1993); Gwee K.A., Leong Y.L., Graham C., Et al., The role of psychological and biological factors in postinfective gut dysfunction, Gut, 44, pp. 400-6, (1999); O'Sullivan M., Clayton N., Breslin N.P., Et al., Increased mast cells in the irritable bowel syndrome, Neurogastroenterol Motil, 12, pp. 449-57, (2000); Spiller R.C., Jenkins D., Thornley J.P., Et al., Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, pp. 804-11, (2000); Chadwick V.S., Chen W., Shu D., Et al., Activation of the mucosal immune system in irritable bowel syndrome, Gastroenterology, 122, pp. 1778-83, (2002); Collins S.M., Piche T., Rampal P., The putative role of inflammation in the irritable bowel syndrome, Gut, 49, pp. 743-5, (2001); Dunlop S.P., Jenkins D., Spiller R.C., Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome, Am J Gastroenterol, 98, pp. 1578-83, (2003); Forget P., Sodoyez-Goffaux F., Zappitelli A., Permeability of the small intestine to [51Cr]EDTA in children with acute gastroenteritis or eczema, J Pediatr Gastroenterol Nutr, 4, pp. 393-6, (1985); Zuckerman M.J., Watts M.T., Bhatt B.D., Et al., Intestinal permeability to [51Cr]EDTA in infectious diarrhea, Dig Dis Sci, 38, pp. 1651-7, (1993); Bjarnason I., Peters T.J., Veall N., A persistent defect in intestinal permeability in coeliac disease demonstrated by a 51Cr-labelled EDTA absorption test, Lancet, 1, pp. 323-5, (1983); Bjarnason I., O'Morain C., Levi A.J., Et al., Absorption of 51chromium-labeled ethylenediaminetetraacetate in inflammatory bowel disease, Gastroenterology, 85, pp. 318-22, (1983); Barau E., Dupont C., Modifications of intestinal permeability during food provocation procedures in pediatric irritable bowel syndrome, J Pediatr Gastroenterol Nutr, 11, pp. 72-7, (1990); Paganelli R., Fagiolo U., Cancian M., Et al., Intestinal permeability in irritable bowel syndrome. Effect of diet and sodium cromoglycate administration, Ann Allergy, 64, pp. 377-80, (1990); Peled Y., Watz C., Gilat T., Measurement of intestinal permeability using 51Cr-EDTA, Am J Gastroenterol, 80, pp. 770-3, (1985); Dainese R., Galliani E.A., De Lazzari F., Et al., Discrepancies between reported food intolerance and sensitization test findings in irritable bowel syndrome patients, Am J Gastroenterol, 94, pp. 1892-7, (1999); D'Inca R., Sturniolo G.C., Martines D., Et al., Functional and morphological changes in small bowel of Crohn's disease patients. Influence of site of disease, Dig Dis Sci, 40, pp. 1388-93, (1995); Thompson W.G., Creed F.H., Drossman D.A., Et al., Functional bowel disease and functional abdominal pain, Gastroenterol Int, 5, pp. 75-91, (1992); Thompson W.G., Longstreth G.F., Drossman D.A., Et al., Functional bowel disorders and functional abdominal pain, Gut, 45, 2, (1999); Dunlop S.P., Jenkins D., Spiller R.C., Distinctive histological patterns of chronic inflammatory cells in rectal biopsies of patients with different clinical subtypes of IBS, Gastroenterology, 122, (2002); Dunlop S.P., Jenkins D., Neal K.R., Et al., Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome, Aliment Pharmacol Ther, 18, pp. 77-84, (2003); Svedlund J., Sjodin I., Dotevall G., GSRS - A clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease, Dig Dis Sci, 33, pp. 129-34, (1988); Dimenas E., Glise H., Hallerback B., Et al., Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer, Scand J Gastroenterol, 30, pp. 1046-52, (1995); Wong E., Guyatt G.H., Cook D.J., Et al., Development of a questionnaire to measure quality of life in patients with irritable bowel syndrome, Eur J Surg Suppl, pp. 50-6, (1998); Talley N.J., Phillips S.F., Wiltgen C.M., Et al., Assessment of functional gastrointestinal disease: The bowel disease questionnaire, Mayo Clin Proc, 65, pp. 1456-79, (1990); Zigmond A.S., Snaith R.P., The Hospital Anxiety and Depression scale, Acta Psychiatr Scand, 67, pp. 361-70, (1983); Peeters M., Hiele M., Ghoos Y., Et al., Test conditions greatly influence permeation of water soluble molecules through the intestinal mucosa: Need for standardisation, Gut, 35, pp. 1404-8, (1994); Maxton D.G., Bjarnason I., Reynolds A.P., Et al., Lactulose, 51Cr-labelled ethylenediaminetetra-acetate, L-rhamnose and polyethyleneglycol 400 [corrected] as probe markers for assessment in vivo of human intestinal permeability, Clin Sci (Lond), 71, pp. 71-80, (1986); Metcalf A.M., Phillips S.F., Zinsmeister A.R., Et al., Simplified assessment of segmental colonic transit, Gastroenterology, 92, pp. 40-7, (1987); Dunlop S.P., Coleman N.S., Blackshaw E., Et al., Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome., Clin Gastroenterol Hepatol, 3, pp. 349-57, (2005); Roseth A.G., Fagerhol M.K., Aadland E., Et al., Assessment of the neutrophil dominating protein calprotectin in feces: A methodologic study, Scand J Gastroenterol, 27, pp. 793-8, (1992); Elia M., Behrens R., Northrop C., Et al., Evaluation of mannitol, lactulose and 51Cr-labelled ethylenediaminetetra- acetate as markers of intestinal permeability in man, Clin Sci (Lond), 73, pp. 197-204, (1987); Jenkins D., Balsitis M., Gallivan S., Et al., Guidelines for the initial biopsy diagnosis of suspected chronic idiopathic inflammatory bowel disease. the British Society of Gastroenterology initiative, J Clin Pathol, 50, pp. 93-105, (1997); Talley N.J., Spiller R., Irritable bowel syndrome: A little understood organic bowel disease?, Lancet, 360, pp. 555-64, (2002); Ma C., Collins S.M., Disparity between mucosal inflammatory changes and muscle contractility in hapten-induced colitis in mice post colitis, Gastroenterology, 118, (2000); Hiatt R.B., Katz L., Mast cells in inflammatory conditions of the gastrointestinal tract, Am J Gastroenterol, 37, pp. 541-5, (1962); Tornblom H., Lindberg G., Nyberg B., Et al., Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome, Gastroenterology, 123, pp. 1972-9, (2002); Hebden J.M., Blackshaw E., D'Amato M., Et al., Abnormalities of GI transit in bloated irritable bowel syndrome: Effect of bran on transit and symptoms, Am J Gastroenterol, 97, pp. 2315-20, (2002); Madsen J.L., Scharff O., Rabol A., Relationship between small-intestinal transit rate and intestinal absorption of (14)C-labelled mannitol and (51)Cr labelled ethylenediaminetetraacetate acid in healthy subjects, Scand J Gastroenterol, 31, pp. 254-9, (1996); Dunlop S.P., Coleman N.S., Blackshaw E., Et al., Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome, Clin Gastroenterol Hepatol, 3, pp. 349-57, (2005); Dunlop S.P., Jenkins D., Neal K.R., Et al., Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS, Gastroenterology, 125, pp. 1651-9, (2003); Marshall J.K., Thabane M., Garg A.X., Et al., Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario, Aliment Pharmacol Ther, 20, pp. 1317-22, (2004); Berin M.C., Kiliaan A.J., Yang P.C., Et al., The influence of mast cells on pathways of transepithelial antigen transport in rat intestine, J Immunol, 161, pp. 2561-6, (1998); Perdue M.H., Masson S., Wershil B.K., Et al., Role of mast cells in ion transport abnormalities associated with intestinal anaphylaxis. Correction of the diminished secretory response in genetically mast cell-deficient W/Wv mice by bone marrow transplantation, J Clin Invest, 87, pp. 687-93, (1991); Wershil B.K., Castagliuolo I., Pothoulakis C., Direct evidence of mast cell involvement in Clostridium difficile toxin A-induced enteritis in mice, Gastroenterology, 114, pp. 956-64, (1998); Crowe S.E., Luthra G.K., Perdue M.H., Mast cell mediated ion transport in intestine from patients with and without inflammatory bowel disease, Gut, 41, pp. 785-92, (1997); Barbara G., Stanghellini V., De Giorgio R., Et al., Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome, Gastroenterology, 126, pp. 693-702, (2004); Santos J., Benjamin M., Yang P.C., Et al., Chronic stress impairs rat growth and jejunal epithelial barrier function: Role of mast cells, Am J Physiol Gastrointest Liver Physiol, 278, (2000); Santos J., Yang P.C., Soderholm J.D., Et al., Role of mast cells in chronic stress induced colonic epithelial barrier dysfunction in the rat, Gut, 48, pp. 630-6, (2001); Guilarte M., Santos J., Alonso C., Et al., Corticotrophin-releasing hormone (CRH) triggers jejunal mast cell and eosinophil activation in IBS patients, Gastroenterology, 126, 2, (2004); Menzies I.S., Zuckerman M.J., Nukajam W.S., Et al., Geography of intestinal permeability and absorption, Gut, 44, pp. 483-9, (1999)","","","","","","","","","15720241","","AJGAA","16771951","English","Am. J. Gastroenterol.","Article","Final","","Scopus","2-s2.0-33744830627"

"Jung H.P.; Dong I.P.; Hong J.K.; Yong K.C.; Chong I.S.; Woo K.J.; Byung I.K.; Kyoung H.W.; Soon M.P.","Jung, Ho Park (57206477427); Dong, Il Park (14036952200); Hong, Joo Kim (57214743139); Yong, Kyun Cho (35261851400); Chong, Il Sohn (7102538401); Woo, Kyu Jeon (16687173900); Byung, Ik Kim (24477301500); Kyoung, Hee Won (35368715700); Soon, Min Park (35369253800)","57206477427; 14036952200; 57214743139; 35261851400; 7102538401; 16687173900; 24477301500; 35368715700; 35369253800","The relationship between small-intestinal bacterial overgrowth and intestinal permeability in patients with irritable bowel syndrome","2009","Gut and Liver","3","3","","174","179","5","38","10.5009/gnl.2009.3.3.174","https://www.scopus.com/inward/record.uri?eid=2-s2.0-70349327608&doi=10.5009%2fgnl.2009.3.3.174&partnerID=40&md5=4f309f73c94c78d2fb6f51229ed7d542","Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul 110-746, 108, Pyeong-dong, Jongno-gu, South Korea; Suwon Health Screening Center, Kangbuk Samsung Hospital, Suwon, South Korea","Jung H.P., Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul 110-746, 108, Pyeong-dong, Jongno-gu, South Korea; Dong I.P., Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul 110-746, 108, Pyeong-dong, Jongno-gu, South Korea; Hong J.K., Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul 110-746, 108, Pyeong-dong, Jongno-gu, South Korea; Yong K.C., Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul 110-746, 108, Pyeong-dong, Jongno-gu, South Korea; Chong I.S., Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul 110-746, 108, Pyeong-dong, Jongno-gu, South Korea; Woo K.J., Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul 110-746, 108, Pyeong-dong, Jongno-gu, South Korea; Byung I.K., Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul 110-746, 108, Pyeong-dong, Jongno-gu, South Korea; Kyoung H.W., Suwon Health Screening Center, Kangbuk Samsung Hospital, Suwon, South Korea; Soon M.P., Suwon Health Screening Center, Kangbuk Samsung Hospital, Suwon, South Korea","Background/Aims: Small-intestinal bacterial overgrowth (SIBO) is a frequent finding in patients with irritable bowel syndrome (IBS). Many patients with IBS also have abnormal intestinal permeability, which is probably due to low-grade inflammation in the intestinal mucosa. Our aim was to verify the relationship between SIBO and small-intestinal permeability in IBS patients. Methods: A cohort of 38 IBS patients (20 women and 18 men; age range 16-70 years; mean age 40.2 years) with symptoms that fulfilled Rome-II criteria, and 12 healthy controls (5 women and 7 men; age range 25-52 years; mean age: 37.8 years) were recruited. All subjects underwent lactulose breath tests (LBTs) and intestinal permeability tests using the polyethylene glycol (PEG) 3350/400 retrieval ratio. Results: A positive LBT was found in 18.4% (7/38) of patients with IBS and 8.3% (1/12) of control subjects. Intestinal permeability was significantly increased in patients with IBS compared with the normal controls (0.82±0.09 vs 0.41±0.05 [mean±SD], respectively; p<0.05). However, the intestinal permeability did not differ significantly between IBS patients with a positive LBT and those with a negative LBT (0.90±0.13 and 0.80±0.11, respectively; p>0.05). Conclusions: Intestinal permeability was increased in patients with IBS, but this finding did not correlated with the occurrence of SIBO.","Intestinal permeability; Irritable bowel syndrome; Small intestinal bacterial overgrowth","adolescent; adult; aged; article; bacterial overgrowth; breath analysis; clinical article; constipation; controlled study; correlation analysis; diarrhea; disease association; female; human; immunostimulation; intestine mucosa permeability; irritable colon; male; small intestine","","","","","","","Lin H.C., Small intestinal bacterial overgrowth: A framework for understanding irritable bowel syndrome, Journal of the American Medical Association, 292, 7, pp. 852-858, (2004); Pimentel M., Chow E.J., Lin H.C., Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: A double-blind, randomized, placebo-controlled study, American Journal of Gastroenterology, 98, 2, pp. 412-419, (2003); Posserud I., Stotzer P.-O., Bjornsson E.S., Abrahamsson H., Simren M., Small intestinal bacterial overgrowth in patients with irritable bowel syndrome, Gut, 56, 6, pp. 802-808, (2007); Lupascu A., Gabrielli M., Lauritano E.C., Scarpellini E., Santoliquido A., Cammarota G., Flore R., Tondi P., Pola P., Gasbarrini G., Gasbarrini A., Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: A prevalence case-control study in irritable bowel syndrome, Alimentary Pharmacology and Therapeutics, 22, 11-12, pp. 1157-1160, (2005); Walters B., Vanner S.J., Detection of bacterial overgrowth in IBS using the lactulose H <sub>2</sub> breath test: Comparison with<sup>14</sup>C-D-xylose and healthy controls, American Journal of Gastroenterology, 100, 7, pp. 1566-1570, (2005); Pimentel M., Chow E.J., Lin H.C., Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome, Am J Gastroenterol, 95, pp. 3503-3506, (2000); Hong K.S., Kang H.W., Im J.P., Et al., Effect of probiotics on symptoms in Korean adults with irritable bowel syndrome, Gut Liver, 3, pp. 101-107, (2009); Berg R.D., Garlington A.W., Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model, Infect Immun, 23, pp. 403-411, (1979); Woodcock N.P., Robertson J., Morgan D.R., Gregg K.L., Mitchell C.J., MacFie J., Bacterial translocation and immunohistochemical measurement of gut immune function, Journal of Clinical Pathology, 54, 8, pp. 619-623, (2001); Nieuwenhuijs V.B., Verheem A., Van Duijvenbode-Beumer H., Visser M.R., Verhoef J., Gooszen H.G., Akkermans L.M.A., The role of interdigestive small bowel motility in the regulation of gut microflora, bacterial overgrowth, and bacterial translocation in rats, Annals of Surgery, 228, 2, pp. 188-193, (1998); Weston A.P., Biddle W.L., Bhatia P.S., Miner Jr. P.B., Terminal ileal mucosal mast cells in irritable bowel syndrome, Dig Dis Sci, 38, pp. 1590-1595, (1993); O'Sullivan, Clayton, Breslin, Harman, Bountra, Mclaren, O'Morain, Increased mast cells in the irritable bowel syndrome, Neurogastroenterology and Motility, 12, 5, pp. 449-457, (2000); Gwee K.-A., Leong Y.-L., Graham C., McKendrick M.W., Collins S.M., Walters S.J., Underwood J.E., Read N.W., The role of psychological and biological factors in postinfective gut dysfunction, Gut, 44, 3, pp. 400-406, (1999); Salzmann J.L., Peltier-Koch F., Bloch F., Petite J.P., Camilleri J.P., Morphometric study of colonic biopsies: A new method of estimating inflammatory diseases, Laboratory Investigation, 60, 6, pp. 847-851, (1989); O'Mahony L., Mccarthy J., Kelly P., Hurley G., Luo F., Chen K., O'Sullivan G.C., Kiely B., Collins J.K., Shanahan F., Quigley E.M.M., Lactobacillus and Bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles, Gastroenterology, 128, 3, pp. 541-551, (2005); Al-Khatib K., Lin H.C., Immune activation and gut microbes in irritable bowel syndrome, Gut Liver, 3, pp. 14-19, (2009); Forget P., Sodoyez-Goffaux F., Zappitelli A., Permeability of the small intestine to [<sup>51</sup>Cr]EDTA in children with acute gastroenteritis or eczema, Journal of Pediatric Gastroenterology and Nutrition, 4, 3, pp. 393-396, (1985); Bjarnson I., O'Morain C., Levi A.J., Peters T.J., Absorption of 51chromium-labeled ethylenediaminetetraacetate in inflammatory bowel disease, Gastroenterology, 85, pp. 318-322, (1983); Dunlop S.P., Hebden J., Campbell E., Naesdal J., Olbe L., Perkins A.C., Spiller R.C., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, American Journal of Gastroenterology, 101, 6, pp. 1288-1294, (2006); Tibble J.A., Sigthorsson G., Foster R., Forgacs I., Bjarnason I., Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease, Gastroenterology, 123, 2, pp. 450-460, (2002); Dainese R., Galliani E.A., De Lazzari F., Di Leo V., Naccarato R., Discrepancies between reported food intolerance and sensitization test findings in irritable bowel syndrome patients, American Journal of Gastroenterology, 94, 7, pp. 1892-1897, (1999); American Gastroenterological Association medical position statement: Irritable bowel syndrome, Gastroenterology, 123, 6, pp. 2105-2107, (2002); Spiller R.C., Postinfectious irritable bowel syndrome, Gastroenterology, 124, pp. 1662-1671, (2003); Beck A., Ward C.H., Mendelson M., Mock J., Erbaugh J., An inventory for measuring depression, Arch Gen Psychiatry, 4, pp. 561-571, (1961); Spielberger C., Manual for the State-trait Anxiety Inventory, (1983); Peled Y., Weinberg D., Hallak A., Gilat T., Factors affecting methane production in humans. Gastrointestinal diseases and alterations of colonic flora, Digestive Diseases and Sciences, 32, 3, pp. 267-271, (1987); Dipalma J.A., Brady III C.E., Stewart D.L., Et al., Comparison of colon cleansing methods in preparation for colonoscopy, Gastroenterology, 86, pp. 856-860, (1984); Schiller L.R., Santa Ana C.A., Porter J., Fordtran J.S., Validation of polyethylene glycol 3350 as a poorly absorbable marker for intestinal perfusion studies, Digestive Diseases and Sciences, 42, 1, pp. 1-5, (1997); Winne D., Gorig H., Appearance of<sup>14</sup>C-polyethylene glycol 4000 in intestinal venous blood: Influence of osmolarity and laxatives, effect on net water flux determination, Naunyn-Schmiedeberg's Archives of Pharmacology, 321, 2, pp. 149-156, (1982); Ameno H., Tani T., Hanasawa K., Kodama M., New method for the detection of bacterial translocation using intestinal permeability with polyethylene glycol 4000, European Surgical Research, 32, 1, pp. 23-29, (2000); Loret S., Nollevaux G., Remacle R., Et al., Analysis of PEG 400 and 4000 in urine for gut permeability assessment using solid phase extraction and gel permeation chromatography with refractometric detection, J Chromatogr B Analyt Technol Biomed Life Sci, 805, pp. 195-202, (2004); Bjarnason I., MacPherson A., Hollander D., Intestinal permeability: An overview, Gastroenterology, 108, pp. 1566-1581, (1995); Chadwick V.S., Chen W., Shu D., Paulus B., Bethwaite P., Tie A., Wilson I., Activation of the mucosal immune system in irritable bowel syndrome, Gastroenterology, 122, 7, pp. 1778-1783, (2002); Jacob C., Yang P.-C., Darmoul D., Amadesi S., Saito T., Cottrell G.S., Coelho A.-M., Singh P., Grady E.F., Perdue M., Bunnett N.W., Mast cell tryptase controls paracellular permeability of the intestine: Role of protease-activated receptor 2 and beta-arrestins, Journal of Biological Chemistry, 280, 36, pp. 31936-31948, (2005)","H. P. Jung; Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul 110-746, 108, Pyeong-dong, Jongno-gu, South Korea; email: pjho3@hotmail.com","","","","","","","","19762283","","","","English","Gut Liver","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-70349327608"

"Lee H.; Park J.H.; Park D.I.; Kim H.J.; Cho Y.K.; Sohn C.I.; Jeon W.K.; Kim B.I.; Chae S.W.","Lee, Hyuk (54896123100); Park, Jung Ho (57206477427); Park, Dong Il (56524839700); Kim, Hong Joo (57185160200); Cho, Yong Kyun (35261851400); Sohn, Chong Il (7102538401); Jeon, Woo Kyu (25947504400); Kim, Byung Ik (59110894000); Chae, Seoung Wan (57203550986)","54896123100; 57206477427; 56524839700; 57185160200; 35261851400; 7102538401; 25947504400; 59110894000; 57203550986","Mucosal mast cell count is associated with intestinal permeability in patients with diarrhea predominant irritable bowel syndrome","2013","Journal of Neurogastroenterology and Motility","19","2","","244","250","6","84","10.5056/jnm.2013.19.2.244","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84876719598&doi=10.5056%2fjnm.2013.19.2.244&partnerID=40&md5=4f6b013eda335e4e47f9b6773072182c","Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, South Korea; Departments of Internal Medicine, Seoul, South Korea; Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University College of Medicine, Seoul, South Korea","Lee H., Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, South Korea; Park J.H., Departments of Internal Medicine, Seoul, South Korea; Park D.I., Departments of Internal Medicine, Seoul, South Korea; Kim H.J., Departments of Internal Medicine, Seoul, South Korea; Cho Y.K., Departments of Internal Medicine, Seoul, South Korea; Sohn C.I., Departments of Internal Medicine, Seoul, South Korea; Jeon W.K., Departments of Internal Medicine, Seoul, South Korea; Kim B.I., Departments of Internal Medicine, Seoul, South Korea; Chae S.W., Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University College of Medicine, Seoul, South Korea","Background/Aims: Although mucosal mast cell tryptase is known to significantly increase intestinal permeability, the relationship between mucosal mast cells and intestinal permeability remains unclear. The objective of this study was to evaluate the correlation among intestinal permeability, tryptase activity and mucosal mast cell count. Methods Rectal biopsies from 16 patients with diarrhea-predominant irritable bowel syndrome (IBS-D) and 7 normal subjects were assessed for tryptase activity and macromolecular permeability using horseradish peroxidase in Ussing chambers. In addition, mucosal mast cell levels were immunohistochemically quantified via image analysis. Results Rectal biopsy of tissues from IBS-D patients showed significantly increased permeability compared with those from normal controls (0.644 ± 0.08 and 0.06 ± 0.00 ng/2 hr/mm2, P < 0.01). Tryptase activity was also substantially higher in rectal biopsy samples from IBS-D patients than those from normal controls (0.86 ± 0.18 and 0.28 ± 0.04 mU/mg protein, P < 0.05). Mucosal mast cell counts were not significantly different between the 2 groups (P > 0.05). However, correlation analysis revealed that only mucosal mast cell count was significantly correlated with intestinal permeability in IBS-D patients (r = 0.558, P < 0.05). Conclusions This study demonstrated a positive correlation between the number of mucosal mast cells and intestinal permeability, suggesting that mucosal mast cells play an important role for increased intestinal permeability in patients with IBS-D. © 2013 The Korean Society of Neurogastroenterology and Motility.","Irritable bowel syndrome; Mast cell, Permeability; Tryptase","tryptase; adult; aged; article; cell count; clinical article; diarrhea; disease association; enzyme activity; female; histopathology; human; human tissue; image analysis; intestine mucosa permeability; irritable colon; male; mast cell; rectum biopsy","","tryptase, 97501-93-4","","","","","Marshall J.K., Thabane M., Garg A.X., Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario., Aliment Pharmacol Ther, 20, pp. 1317-1322, (2004); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes., Am J Gastroenterol, 101, pp. 1288-1294, (2006); Santos J., Yang P.C., Soderholm J.D., Benjamin M., Perdue M.H., Role of mast cells in chronic stress induced colonic epithelial barrier dysfunction in the rat., Gut, 48, pp. 630-636, (2001); Demaude J., Salvador-Cartier C., Fioramonti J., Ferrier L., Bueno L., Phenotypic changes in colonocytes following acute stress or activation of mast cells in mice: implications for delayed epithelial barrier dysfunction., Gut, 55, pp. 655-661, (2006); Jacob C., Yang P.C., Darmoul D., Et al., Mast cell tryptase controls paracellular permeability of the intestine., Role of protease-activated receptor 2 and beta-arrestins. J Biol Chem, 280, pp. 31936-31948, (2005); Park J.H., Rhee P.L., Kim H.S., Et al., Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome., J Gastroenterol Hepatol, 21, pp. 71-78, (2006); Chadwick V.S., Chen W., Shu D., Et al., Activation of the mucosal immune system in irritable bowel syndrome., Gastroenterology, 122, pp. 1778-1783, (2002); Barbara G., Stanghellini V., De Giorgio R., Et al., Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome., Gastroenterology, 126, pp. 693-702, (2004); Lee J.W., Park J.H., Park D.I., Et al., Subjects with diarrhea-predominant IBS have increased rectal permeability responsive to tryptase., Dig Dis Sci, 55, pp. 2922-2928, (2010); Dunlop S.P., Jenkins D., Spiller R.C., Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome., Am J gastroenterol, 98, pp. 1578-1583, (2003); O'Sullivan M., Clayton N., Breslin N.P., Et al., Increased mast cells in the irritable bowel syndrome., Neurogastroenterol Motil, 12, pp. 449-457, (2000); Talley N.J., Butterfield J.H., Mast cell infiltration and degranulation in colonic mucosa in the irritable bowel syndrome., Am J gastroenterol, 91, pp. 1675-1676, (1996); Spiller R.C., Jenkins D., Thornley J.P., Et al., Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome., Gut, 47, pp. 804-811, (2000); Schwartz L.B., Metcalfe D.D., Miller J.S., Earl H., Sullivan T., Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis., N Eng J Med, 316, pp. 1622-1626, (1987); Butrus S.I., Ochsner K.I., Abelson M.B., Schwartz L.B., The level of tryptase in human tears., An indicator of activation of conjunctival mast cells. Ophthalmology, 97, pp. 1678-1683, (1990); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome., Pain, 146, pp. 41-46, (2009); Ait-Belgnaoui A., Bradesi S., Fioramonti J., Theodorou V., Bueno L., Acute stress-induced hypersensitivity to colonic distension depends upon increase in paracellular permeability: role of myosin light chain kinase., Pain, 113, pp. 141-147, (2005); Miller H.R., Pemberton A.D., Tissue-specific expression of mast cell granule serine proteinases and their role in inflammation in the lung and gut., Immunology, 105, pp. 375-390, (2002); Cenac N., Coelho A.M., Nguyen C., Et al., Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2., Am J pathol, 161, pp. 1903-1915, (2002); Chin A.C., Vergnolle N., MacNaughton W.K., Wallace J.L., Hollenberg M.D., Buret A.G., Proteinase-activated receptor 1 activation induces epithelial apoptosis and increases intestinal permeability., Proc Nat Acad Sci USA, 100, pp. 11104-11109, (2003); Santos J., Saunders P.R., Hanssen N.P., Et al., Corticotropin-releasing hormone mimics stress-induced colonic epithelial pathophysiology in the rat., Am J Physiol, 277, 2 PART 1, (1999)","J.H. Park; Departments of Internal Medicine, Sungkyunkwan University School of Medicine, Kangbuk Samsung Hospital, Jongno-gu, Seoul, 29, Saemunan-ro, South Korea; email: pjho3@hotmail.com","","","","","","","","20930887","","","","English","J. Neurogastroenterology Motil.","Article","Final","All Open Access; Hybrid Gold Open Access","Scopus","2-s2.0-84876719598"

"Martínez C.; Lobo B.; Pigrau M.; Ramos L.; González-Castro A.M.; Alonso C.; Guilarte M.; Guilá M.; De Torres I.; Azpiroz F.; Santos J.; Vicario M.","Martínez, Cristina (17534584700); Lobo, Beatriz (7003936898); Pigrau, Marc (37009212800); Ramos, Laura (57206530978); González-Castro, Ana Maria (54796498900); Alonso, Carmen (56411082400); Guilarte, Mar (18133405400); Guilá, Meritxell (8566782700); De Torres, Ines (7003506754); Azpiroz, Fernando (57207592894); Santos, Javier (7402389020); Vicario, María (6603267769)","17534584700; 7003936898; 37009212800; 57206530978; 54796498900; 56411082400; 18133405400; 8566782700; 7003506754; 57207592894; 7402389020; 6603267769","Diarrhoea-predominant irritable bowel syndrome: An organic disorder with structural abnormalities in the jejunal epithelial barrier","2013","Gut","62","8","","1160","1168","8","220","10.1136/gutjnl-2012-302093","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84877575913&doi=10.1136%2fgutjnl-2012-302093&partnerID=40&md5=cc4fa0a0a60f6f8334396e95fc579aa5","Digestive System Research Unit, Laboratory of Neuro-Immuno-Gastroenterology, Department of Gastroenterology, 08035, Barcelona, Paseo Vall d'Hebron 119-129, Spain; Allergy Unit, Hospital Universitari Vall D'Hebron and Vall D'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain; Pathology Department, Hospital Universitari Vall D'Hebron and Vall D'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Barcelona, Spain","Martínez C., Digestive System Research Unit, Laboratory of Neuro-Immuno-Gastroenterology, Department of Gastroenterology, 08035, Barcelona, Paseo Vall d'Hebron 119-129, Spain; Lobo B., Digestive System Research Unit, Laboratory of Neuro-Immuno-Gastroenterology, Department of Gastroenterology, 08035, Barcelona, Paseo Vall d'Hebron 119-129, Spain; Pigrau M., Digestive System Research Unit, Laboratory of Neuro-Immuno-Gastroenterology, Department of Gastroenterology, 08035, Barcelona, Paseo Vall d'Hebron 119-129, Spain; Ramos L., Digestive System Research Unit, Laboratory of Neuro-Immuno-Gastroenterology, Department of Gastroenterology, 08035, Barcelona, Paseo Vall d'Hebron 119-129, Spain; González-Castro A.M., Digestive System Research Unit, Laboratory of Neuro-Immuno-Gastroenterology, Department of Gastroenterology, 08035, Barcelona, Paseo Vall d'Hebron 119-129, Spain; Alonso C., Digestive System Research Unit, Laboratory of Neuro-Immuno-Gastroenterology, Department of Gastroenterology, 08035, Barcelona, Paseo Vall d'Hebron 119-129, Spain, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Barcelona, Spain; Guilarte M., Digestive System Research Unit, Laboratory of Neuro-Immuno-Gastroenterology, Department of Gastroenterology, 08035, Barcelona, Paseo Vall d'Hebron 119-129, Spain, Allergy Unit, Hospital Universitari Vall D'Hebron and Vall D'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain; Guilá M., Digestive System Research Unit, Laboratory of Neuro-Immuno-Gastroenterology, Department of Gastroenterology, 08035, Barcelona, Paseo Vall d'Hebron 119-129, Spain; De Torres I., Pathology Department, Hospital Universitari Vall D'Hebron and Vall D'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain; Azpiroz F., Digestive System Research Unit, Laboratory of Neuro-Immuno-Gastroenterology, Department of Gastroenterology, 08035, Barcelona, Paseo Vall d'Hebron 119-129, Spain, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Barcelona, Spain; Santos J., Digestive System Research Unit, Laboratory of Neuro-Immuno-Gastroenterology, Department of Gastroenterology, 08035, Barcelona, Paseo Vall d'Hebron 119-129, Spain, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Barcelona, Spain; Vicario M., Digestive System Research Unit, Laboratory of Neuro-Immuno-Gastroenterology, Department of Gastroenterology, 08035, Barcelona, Paseo Vall d'Hebron 119-129, Spain, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Barcelona, Spain","Objective Recently, the authors demonstrated altered gene expression in the jejunal mucosa of diarrhoeapredominant irritable bowel syndrome patients (IBS-D); specifically, the authors showed that genes related to mast cells and the intercellular apical junction complex (AJC) were expressed differently than in healthy subjects. The aim of the authors here was to determine whether these alterations are associated with structural abnormalities in AJC and their relationship with mast cell activation and IBS-D clinical manifestations. Design A clinical assessment and a jejunal biopsy were obtained in IBS-D patients (n=45) and healthy subjects (n=30). Mucosal mast cell number and activation were determined by quantifying CD117+ cells/hpf and tryptase expression, respectively. Expression and distribution of AJC specific proteins were evaluated by western blot and confocal microscopy. AJC ultrastructure was assessed by transmission electron microscopy. Results Compared with healthy subjects, IBS-D patients exhibited: (a) increased mast cell counts and activation; (b) increased protein expression of claudin-2, reduced occludin phosphorylation and enhanced redistribution from the membrane to the cytoplasm; and (c) increased myosin kinase expression, reduced myosin phosphatase and, consequently, enhanced phosphorylation of myosin. These molecular alterations were associated with ultrastructural abnormalities at the AJC, specifically, perijunctional cytoskeleton condensation and enlarged apical intercellular distance. Moreover, AJC structural alterations positively correlated both with mast cell activation and clinical symptoms. Conclusion The jejunal mucosa of IBS-D patients displays disrupted apical junctional complex integrity associated with mast cell activation and clinical manifestations. These results provide evidence for the organic nature of IBS-D, a heretofore model disease of functional gastrointestinal disorders.","","Adolescent; Adult; Biopsy; Diarrhea; Female; Humans; Intercellular Junctions; Intestinal Mucosa; Irritable Bowel Syndrome; Jejunum; Male; Mast Cells; Middle Aged; Myosin Light Chains; Phosphorylation; Prospective Studies; Sex Factors; Stress, Psychological; Tight Junction Proteins; Young Adult; anorectal function; antibacterial mucosal immunity; brain-gut interaction; enteric bacterial microflora; functional bowel disorder; gas physiology; gastrointestinal motility; gene expression; gut immunology; gut inflammation; IBS-D; intestinal barrier function; intestinal mast cells; intestinal permeability; motility disorders; mucosal mast cells; neural-immune interactions; neurogastroenterology; serotonin; small bowel disease; stress; tight junction signalling; visceral sensitivity; claudin 2; myosin; myosin kinase; myosin phosphatase; occludin; tryptase; unclassified drug; adult; apical junction complex; article; cell activation; cell count; cell hyperplasia; cell junction; clinical article; clinical assessment; confocal microscopy; controlled study; diarrhea; disease association; female; human; human tissue; irritable colon; jejunum biopsy; male; mast cell; molecular mechanics; priority journal; protein expression; protein localization; protein phosphorylation; transmission electron microscopy; Western blotting","","occludin, 176304-61-3; tryptase, 97501-93-4; Myosin Light Chains, ; Tight Junction Proteins, ","","","","","Shen L., Turner J.R., Role of epithelial cells in initiation and propagation of intestinal inflammation. Eliminating the static: Tight junction dynamics exposed, Am J Physiol Gastrointest Liver Physiol, 290, (2006); Turner J.R., Intestinal mucosal barrier function in health and disease, Nat Rev Immunol, 9, pp. 799-809, (2009); Spiller R., Clinical update: Irritable bowel syndrome, Lancet, 369, pp. 1586-1588, (2007); Guilarte M., Santos J., De Torres I., Et al., Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum, Gut, 56, pp. 203-209, (2007); Gwee K.A., Collins S.M., Read N.W., Et al., Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome, Gut, 52, pp. 523-526, (2003); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndrome, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Piche T., Barbara G., Aubert P., Et al., Impaired intestinal integrity in the colon of irritable bowel syndrome patients: Involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Dinan T.G., Quigley E.M., Ahmed S.M., Et al., Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: Plasma cytokines as a potential biomarker?, Gastroenterology, 130, pp. 304-311, (2006); Chadwick V.S., Chen W., Shu D., Et al., Activation of the mucosal immune system in irritable bowel syndrome, Gastroenterology, 122, pp. 1778-1783, (2002); Barbara G., Stanghellini V., De Giorgio R., Et al., Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome, Gastroenterology, 126, pp. 693-702, (2004); Martinez C., Vicario M., Ramos L., Et al., The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations, Am J Gastroenterol; Bueno L., Fioramonti J., Protease-activated receptor 2 and gut permeability: A review, Neurogastroenterol Motil, 20, pp. 580-587, (2008); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Coeffier M., Gloro R., Boukhettala N., Et al., Increased proteasome-mediated degradation of occludin in irritable bowel syndrome, Am J Gastroenterol, 105, pp. 1181-1188, (2010); Aerssens J., Camilleri M., Talloen W., Et al., Alterations in mucosal immunity identified in the colon of patients with irritable bowel syndrome, Clin Gastroenterol Hepatol, 6, pp. 194-205, (2008); Walker M.M., Talley N.J., Prabhakar M., Et al., Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia, Aliment Pharmacol Ther, 29, pp. 765-773, (2009); Foley S., Garsed K., Singh G., Et al., Impaired uptake of serotonin by platelets from patients with irritable bowel syndrome correlates with duodenal immune activation, Gastroenterology, 140, pp. 1434-1443, (2011); Salvioli B., Serra J., Azpiroz F., Et al., Origin of gas retention and symptoms in patients with bloating, Gastroenterology, 128, pp. 574-579, (2005); Salvioli B., Serra J., Azpiroz F., Et al., Impaired small bowel gas propulsion in patients with bloating during intestinal lipid infusion, Am J Gastroenterol, 101, pp. 1853-1857, (2006); Malagelada C., De Lorio F., Segui S., Et al., Functional gut disorders or disordered gut function? Small bowel dysmotility evidenced by an original technique, Neurogastroenterol Motil, 24, pp. 223-228, (2012); Talley N.J., Stanghellini V., Heading R.C., Et al., Functional gastroduodenal disorders, Gut, 45, pp. 1137-1142, (1999); Lewis S.J., Heaton K.W., Stool form scale as a useful guide to intestinal transit time, Scand J Gastroenterol, 32, pp. 920-924, (1997); Holmes T.H., Rahe R.H., The social readjustment rating scale, J Psychosom Med, 11, pp. 213-218, (1967); Demaude J., Salvador-Cartier C., Fioramonti J., Et al., Phenotypic changes in colonocytes following acute stress or activation of mast cells in mice: Implications for delayed barrier dysfunction, Gut, 55, pp. 655-661, (2006); Soderholm J.D., Olaison G., Peterson K.H., Et al., Augmented increase in tight junction permeability by luminal stimuli in the non-inflamed ileum of Crohn's disease, Gut, 50, pp. 307-313, (2002); Graham W.V., Marchiando A.M., Shen L., Et al., No static at all. A new perspective on molecular architecture of the tight junction, Ann N y Acad Sci, 1165, pp. 314-322, (2009); Benjamini Y., Hochberg Y., Controlling the false discovery rate: A practical and powerful approach to multiple testing, J R Statist Soc B, 57, pp. 289-300, (1995); Simonovic I., Rosenberg J., Koutsouris A., Et al., Enteropathogenic Escherichia coli dephosphorylates and dissociates occludin from intestinal epithelial tight junctions, Cell Microbiol, 2, pp. 305-315, (2000); Barbara G., Wang B., Stanghellini V., Et al., Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome, Gastroenterology, 132, pp. 26-37, (2007); Jacob C., Yang P.C., Darmoul D., Et al., Mast cell tryptase controls paracellular permeability of the intestine. Role of protease-activated receptor 2 and beta-arrestins, J Biol Chem, 280, pp. 31936-31948, (2005); Lee J.W., Park J.H., Park D.I., Et al., Subjects with diarrhea-predominant IBS have increased rectal permeability responsive to tryptase, Dig Dis Sci, 55, pp. 2922-2928, (2010); Balda M.S., Matter K., Tight junctions at a glance, J Cell Sci, 121, pp. 3677-3682, (2008); Amasheh S., Meiri N., Gitter A.H., Et al., Claudin-2 expression induces cation-selective channels in tight junctions of epithelial cells, J Cell Sci, 115, pp. 4969-4976, (2002); Van Itallie C.M., Anderson J.M., Claudins and epithelial paracellular transport, Annu Rev Physiol, 68, pp. 403-429, (2006); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Et al., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am J Gastroenterol, 106, pp. 2165-2173, (2011); Rao R., Occludin phosphorylation in regulation of epithelial tight junctions, Ann N y Acad Sci, 1165, pp. 62-68, (2009); Sakakibara A., Furuse M., Saitou M., Et al., Possible involvement of phosphorylation of occludin in tight junction formation, J Cell Biol, 137, pp. 1393-1401, (1997); Marchiando A.M., Shen L., Graham W.V., Et al., Caveolin-1-dependent occludin endocytosis is required for TNF-induced tight junction regulation in vivo, J Cell Biol, 189, pp. 111-126, (2010); Clayburgh D.R., Barrett T.A., Tang Y., Et al., Epithelial myosin light chain kinase-dependent barrier dysfunction mediates T cell activation-induced diarrhea in vivo, J Clin Invest, 115, pp. 2702-2715, (2005); Turner J.R., Show me the pathway! Regulation of paracellular permeability by Na+/ glucose cotransport, Adv Drug Deliv Rev, 41, pp. 265-281, (2000); Gecse K., Roka R., Ferrier L., Et al., Increased faecal serine protease activity in diarrhoeic IBS patients: A colonic lumenal factor impairing colonic permeability and sensitivity, Gut, 57, pp. 591-599, (2008); Santos J., Saunders P.R., Hanssen N.P., Et al., Corticotropin-releasing hormone mimics stress-induced colonic epithelialpathophysiology in the rat, Am J Physiol, 277, (1999); Santos J., Yang P.C., Soderholm J.D., Et al., Role of mast cells in chronicstress induced colonic epithelial barrier dysfunction in the rat, Gut, 48, pp. 630-636, (2001)","M. Vicario; Digestive System Research Unit, Laboratory of Neuro-Immuno-Gastroenterology, Department of Gastroenterology, 08035, Barcelona, Paseo Vall d'Hebron 119-129, Spain; email: maria.vicario@vhir.org","","","","","","","","14683288","","GUTTA","22637702","English","Gut","Article","Final","","Scopus","2-s2.0-84877575913"

"Zhou Q.; Costinean S.; Croce C.M.; Brasier A.R.; Merwat S.; Larson S.A.; Basra S.; Verne G.N.","Zhou, Qiqi (13404854200); Costinean, Stefan (12041762100); Croce, Carlo M. (7202975031); Brasier, Alan R. (7007058345); Merwat, Shehzad (12771714600); Larson, Scott A. (7202795423); Basra, Sarpreet (55970998300); Verne, G. Nicholas (7004085639)","13404854200; 12041762100; 7202975031; 7007058345; 12771714600; 7202795423; 55970998300; 7004085639","MicroRNA 29 targets nuclear factor-κB-repressing factor and claudin 1 to increase intestinal permeability","2015","Gastroenterology","148","1","","158","169.e8","","141","10.1053/j.gastro.2014.09.037","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84922899761&doi=10.1053%2fj.gastro.2014.09.037&partnerID=40&md5=6ed2af79a7de4840a6883025794b3759","Department of Medicine, University of Texas Medical Branch, Galveston, TX, United States; Department of Veteran Affairs, Cincinnati VA Medical Center, Cincinnati, OH, United States; Comprehensive Cancer Center, Ohio State University, Columbus, OH, United States; Department of Medicine, Tulane University School of Medicine, New Orleans, LA, United States; Tulane University School of Medicine, 1430 Tulane Ave., SL 8512, New Orleans, 70112-2699, LA, United States","Zhou Q., Department of Medicine, University of Texas Medical Branch, Galveston, TX, United States, Department of Veteran Affairs, Cincinnati VA Medical Center, Cincinnati, OH, United States; Costinean S., Comprehensive Cancer Center, Ohio State University, Columbus, OH, United States; Croce C.M., Comprehensive Cancer Center, Ohio State University, Columbus, OH, United States; Brasier A.R., Department of Medicine, University of Texas Medical Branch, Galveston, TX, United States; Merwat S., Department of Medicine, University of Texas Medical Branch, Galveston, TX, United States; Larson S.A., Department of Medicine, University of Texas Medical Branch, Galveston, TX, United States; Basra S., Department of Medicine, University of Texas Medical Branch, Galveston, TX, United States; Verne G.N., Department of Medicine, Tulane University School of Medicine, New Orleans, LA, United States, Tulane University School of Medicine, 1430 Tulane Ave., SL 8512, New Orleans, 70112-2699, LA, United States","BACKGROUND & AIMS: Some patients with irritable bowel syndrome with diarrhea (IBS-D) have intestinal hyperpermeability, which contributes to their diarrhea and abdominal pain. MicroRNA 29 (MIR29) regulates intestinal permeability in patients with IBS-D. We investigated and searched for targets of MIR29 and investigated the effects of disrupting Mir29 in mice. METHODS: We investigated expression MIR29A and B in intestinal biopsies collected during endoscopy from patients with IBS (n = 183) and without IBS (controls) (n = 36). Levels were correlated with disease phenotype. We also generated and studied Mir29-/- mice, in which expression of Mir29a and b, but not c, is lost. Colitis was induced by administration of 2,4,6-trinitrobenzenesulfonic acid; intestinal tissues were collected and permeability was assessed. Microarray analysis was performed using tissues from Mir29-/- mice. Changes in levels of target genes were measured in human colonic epithelial cells and small intestinal epithelial cells after knockdown of MIR29 with anti-MIRs. RESULTS: Intestinal tissues from patients with IBS-D (but not IBS with constipation or controls) had increased levels of MIR29A and B, but reduced levels of Claudin-1 (CLDN1) and nuclear factor-κB-repressing factor (NKRF). Induction of colitis and water avoidance stress increased levels of Mir29a and Mir29b and intestinal permeability in wild-type mice; these increased intestinal permeability in colons of far fewer Mir29-/- mice. In microarray and knockdown experiments, MIR29A and B were found to reduce levels of NKRF and CLDN1 messenger RNA, and alter levels of other messenger RNAs that regulate intestinal permeability. CONCLUSIONS: Based on experiments in knockout mice and analyses of intestinal tissue samples from patients with IBS-D, MIR29 targets and reduces expression of CLDN1 and NKRF to increase intestinal permeability. Strategies to block MIR29 might be developed to restore intestinal permeability in patients with IBS-D. © 2015 AGA Institute.","Gene Regulation; Intestinal Barrier Function; Mouse Model; mRNA Processing","Animals; Case-Control Studies; Cell Line; Claudin-1; Colitis; Colon; Disease Models, Animal; Down-Regulation; Gene Knockdown Techniques; Genetic Predisposition to Disease; Humans; Inflammatory Bowel Diseases; Male; Mice, Inbred C57BL; Mice, Knockout; MicroRNAs; Permeability; Phenotype; Repressor Proteins; RNA, Messenger; Signal Transduction; Trinitrobenzenesulfonic Acid; claudin 1; immunoglobulin enhancer binding protein; microRNA 29; claudin 1; CLDN1 protein, human; Cldn1 protein, mouse; messenger RNA; microRNA; MIRN29 microRNA, human; MIRN29 microRNA, mouse; NKRF protein, human; NKRF protein, mouse; repressor protein; trinitrobenzenesulfonic acid; adult; animal experiment; animal model; Article; controlled study; electric resistance; female; gene expression; gene function; human; human cell; intestine mucosa permeability; irritable colon; knockout mouse; major clinical study; male; microarray analysis; mouse; mouse model; nonhuman; priority journal; signal transduction; animal; C57BL mouse; case control study; cell line; chemically induced; colitis; colon; disease model; down regulation; gene silencing; genetic predisposition; genetics; inflammatory bowel disease; metabolism; pathology; permeability; phenotype","","claudin 1, 329338-06-9; trinitrobenzenesulfonic acid, 16655-63-3, 2508-19-2; Claudin-1, ; CLDN1 protein, human, ; Cldn1 protein, mouse, ; MicroRNAs, ; MIRN29 microRNA, human, ; MIRN29 microRNA, mouse, ; NKRF protein, human, ; NKRF protein, mouse, ; Repressor Proteins, ; RNA, Messenger, ; Trinitrobenzenesulfonic Acid, ","","","National Institutes of Health, NIH; National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK, (DK099052); National Center for Complementary and Alternative Medicine, NCCAM; U.S. Department of Veterans Affairs, VA; National Center for Complementary and Integrative Health, NCCIH, (R21AT005291)","Funding This work was supported by grants from the National Institutes of Health from National Institute of Diabetes and Digestive and Kidney Diseases ( DK099052 ); National Center for Complementary and Alternative Medicine ( AT005291 ); and from the Department of Veteran Affairs. ","Mayer E.A., Irritable bowel syndrome, N Engl J Med, 358, pp. 1692-1699, (2008); Simren M., Axelsson J., Gillberg H., Quality of life in inflammatory bowel disease in remission: The impact of IBS-like symptoms and associated factors, Am J Gastroenterol, 97, pp. 389-396, (2002); Camilleri M., Madsen K., Spiller R., Intestinal barrier function in health and gastrointestinal disease, Neurogastroenterol Motil, 24, pp. 503-512, (2012); Zhou Q., Verne G.N., New insights into visceral hypersensitivity-clinical implications in IBS, Nat Rev Gastroenterol Hepatol, 8, pp. 349-355, (2011); Spiller R.C., Jenkins D., Thornley J.P., Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, pp. 804-811, (2000); Dunlap S.P., Hebden J., Campbell E., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndrome, Am J Gastroenterol, 101, pp. 1288-1294, (2007); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Bjarnason I., MacPherson A., Hollander D., Intestinal permeability: An overview, Gastroenterology, 108, pp. 1566-1581, (1995); Keshavarzian A., Holmes E.W., Patel M., Leaky gut in alcoholic cirrhosis: A possible mechanism for alcohol-induced liver damage, Am J Gastroenterol, 94, pp. 200-207, (1999); Zhou Q., Souba W.W., Croce C., MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome, Gut, 59, pp. 775-784, (2010); Zhou Q., Price D.D., Caudle R.M., Visceral and somatic hypersensitivity in a subset of rats following TNBS-induced colitis, Pain, 134, pp. 9-15, (2008); Bradesi S., Schwetz I., Ennes H.S., Repeated exposure to water avoidance stress in rats: A new model for sustained visceral hyperalgesia, Am J Physiol Gastrointest Liver Physiol, 289, pp. G42-G53, (2005); Zhou Q., Price D.D., Dreher K.L., Localized colonic stem cell transplantation enhances tissue regeneration in murine colitis, J Cell Mol Med, 16, pp. 1900-1915, (2012); Park S.Y., Lee J.H., Ha M., MiR-29 miRNAs activate p53 by targeting p85 alpha and CDC42, Nat Struct Mol Biol, 16, pp. 23-29, (2009); Zhao J.J., Lin J., Lwin T., MicroRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma, Blood, 115, pp. 2630-2639, (2010); Li Y., Wang F., Xu J., Progressive miRNA expression profiles in cervical carcinogenesis and identification of HPV-related target genes for miR-29, J Pathol, 224, pp. 484-495, (2011); Sekiya Y., Ogawa T., Yoshizato K., Suppression of hepatic stellate cell activation by microRNA-29b, Biochem Biophys Res Commun, 412, pp. 74-79, (2011); Li Z., Hassan M.Q., Jafferji M., Biological functions of miR-29b contribute to positive regulation of osteoblast differentiation, J Biol Chem, 284, pp. 15676-15684, (2009); Meunier L., Siddeek B., Vega A., Perinatal programming of adult rat germ cell death after exposure to xenoestrogens: Role of microRNA miR-29 family in the down-regulation of DNA methyltransferases and Mcl-1, Endocrinology, 153, pp. 1936-1947, (2012); Fabbri M., Garzon A., Cimmino Z., MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltranferases 3A and 3B, PNAS, 104, pp. 15805-15810, (2007); Koturbash I., Zemp F., Kolb B., Sex-specific radiation-induced microRNAome responses in the hippocampus, cerebellum and frontal cortex in a mouse model, Mutat Res, 722, pp. 114-118, (2011); Creighton C.J., Hernandez-Herrera A., Jacobsen A., Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma, PLOS ONE, 7, (2012); Nguyen T., Kuo C., Nicholl M.B., Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma, Epigenetics, 6, pp. 388-394, (2011); Hand N.J., Horner A.M., Master Z.R., MicroRNA profiling identifies miR-29 as a regulator of disease-associated pathways in experimental biliary atresia, J Pediatr Gastroenterol Nutr, 54, pp. 186-192, (2012); Roggli E., Gattesco S., Caille D., Changes in microRNA expression contribute to pancreatic β-cell dysfunction in prediabetic NOD mice, Diabetes, 61, pp. 1742-1751, (2012); Kovalchuk O., Zemp F.J., Filkowski J.N., MicroRNAome changes in bystander three-dimensional human tissue models suggest priming of apoptotic pathways, Carcinogenesis, 31, pp. 1882-1888, (2010); Ding Q., Chang C.J., Xie X., APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal cancer and predicts human hepatic metastasis, J Clin Invest, 121, pp. 4526-4536, (2011); Kwiecinski M., Elfimova N., Noetel A., Expression of platelet-derived growth factor-C and insulin-like growth factor I in hepatic stellate cells is inhibited by miR-29, Lab Invest, 92, pp. 978-987, (2012); Wu F., Zikusoka M., Trindale A., MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha, Gastroenterology, 135, pp. 1624-1635, (2008); Kapeller J., Houghton L.A., Monnikes H., First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome, Hum Mol Genet, 17, pp. 2967-2977, (2008); Haberle J., Gorg B., Rutsch F., Congenital glutamine deficiency with glutamine synthetase mutations, N Engl J Med, 353, pp. 1926-1933, (2005); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., The expression and cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am J Gastroenterol, 106, pp. 2165-2173, (2011); Inai T., Kobayashi J., Shibata Y., Claudin-1 contributes to the epithelial barrier function in MDCK cells, Eur J Cell Biol, 78, pp. 849-855, (1999); Nourbakhsh M., Hauser H., Constitutive silencing of IBF-beta promoter is mediated by NRF (NF-kappaB-repressing factor), a nuclear inhibitor of NF-kappaB, EMBO J, 18, pp. 6415-6425, (1999); Brasier A.R., The nuclear factor-kappaB-interleukin-6 signaling pathway mediating vascular inflammation, Cardiovasc Res, 86, pp. 211-218, (2010); Sen R., Baltimore D., Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism, Cell, 47, pp. 921-928, (1986); Ma T.Y., Iwamoto G.K., Hoa N.T., TNF-α-induced increase in intestinal epithelial tight junction permeability requires NF-κB activation, Am J Physiol Gastrointest Liver Physiol, 286, pp. G367-G376, (2004); Bamias G., Corridoni D., Pizarro T.T., New insights into the dichotomous role of innate cytokines gut homeostasis and inflammation, Cytokine, 59, pp. 451-459, (2012); Majewski P.M., Thurston R.D., Ramalingam R., Cooperative role of NF-{kappa}B and poly(ADP-ribose) polymerase 1 (PARP-1) in the TNF-induced inhibition of PHEX expression in osteoblasts, J Biol Chem, 285, pp. 34828-34838, (2010); Zhou Q., Verne G.N., MiRNA-based therapies for the Irritable Bowel Syndrome, Exp Opin Biol Ther, 8, pp. 991-995, (2011)","G.N. Verne; Tulane University School of Medicine, New Orleans, 1430 Tulane Ave., SL 8512, 70112-2699, United States; email: gverne@tulane.edu","","W.B. Saunders","","","","","","00165085","","GASTA","25277410","English","Gastroenterology","Article","Final","All Open Access; Green Open Access","Scopus","2-s2.0-84922899761"

"Lin H.C.; Pimentel M.","Lin, Henry C. (56919981500); Pimentel, Mark (7006799213)","56919981500; 7006799213","Bacterial concepts in irritable bowel syndrome","2005","Reviews in Gastroenterological Disorders","5","SUPPL. 3","","S3","S9","6","20","","https://www.scopus.com/inward/record.uri?eid=2-s2.0-31144467842&partnerID=40&md5=d0e3d42a3dba284763525522c7f9f152","Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States; Gastrointestinal Motility Program, Cedars-Sinai Medical Center, Los Angeles, CA, United States","Lin H.C., Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States; Pimentel M., Gastrointestinal Motility Program, Cedars-Sinai Medical Center, Los Angeles, CA, United States","An overlap of symptoms in irritable bowel syndrome (IBS) exists across subtype groups. Symptoms include intestinal gas, diarrhea, dyspepsia, bloating, abdominal pain, and constipation. The unifying symptom may be excessive intestinal gas as a by-product of intestinal microbial fermentation. Abnormal fermentation of food takes place when gut microbes expand proximally into the small intestine instead of being confined predominantly to the colon. Such proximal expansion of indigenous gut microbes or small intestinal bacterial overgrowth (SIBO) may lead to activation of host mucosal immunity and an increase in intestinal permeability to result in flu-like extra-intestinal symptoms that accompany the classic IBS symptoms of altered bowels. The presence of methane on lactulose breath testing is associated with constipation-predominant IBS. Antibiotic therapy may be appropriate to treat underlying SIBO in IBS patients. Seventy-five percent improvement of IBS symptoms was reported in a double-blind, placebo-controlled study once antibiotics succeeded in treating bacterial overgrowth. Once a good clinical response and normalization of the lactulose breath test are achieved, a prokinetic agent may be used to stimulate phase III of interdigestive motility to delay relapse of bacterial overgrowth. © 2005 MedReviews, LLC.","Constipation; Diarrhea; Gut microbes; Intestinal gas; Irritable bowel syndrome","Anti-Bacterial Agents; Bacteria; Humans; Intestine, Small; Irritable Bowel Syndrome; Prognosis; erythromycin; lactulose; methane; tegaserod; article; bacterial overgrowth; breath analysis; host pathogen interaction; host resistance; host susceptibility; human; immunological tolerance; infection prevention; intestine flora; intestine motility; irritable colon; mucosal immunity; small intestine; symptomatology","","erythromycin, 114-07-8, 70536-18-4; lactulose, 4618-18-2; methane, 74-82-8; tegaserod, 145158-71-0, 189188-57-6; Anti-Bacterial Agents, ","","","","","Thompson W.G., Creed F.H., Drossman D.A., Et al., Functional bowel disorders and functional abdominal pain, Gastroenterol Int., 5, pp. 75-91, (1992); Thompson W.G., Longstretch G.F., Drossman D.A., Et al., Functional bowel disorders and functional abdominal pain, Gut, 45, SUPPL. II, pp. 1143-1147, (1999); Locke G.R., Zinsmeister A.R., Fett S., Et al., Overlap of gastrointestinal symptom complexes in a US community, Neurogastroenterol Motil., 17, pp. 29-34, (2005); Chami T.N., Schuster M.M., Bohlman M.E., Et al., A simple radiologic method to estimate the quantity of bowel gas, Am J Gastroenterol., 86, pp. 599-602, (1991); Dotevall G., Svedlund J., Sjodin I., Symptoms in irritable bowel syndrome, Scand J Gastroenterol Suppl., 79, pp. 16-19, (1982); Lin H.C., Small intestinal bacterial overgrowth: A framework for understanding IBS, JAMA, 292, pp. 852-858, (2004); Lasser R.B., Bond J.H., Levitt M.D., The role of intestinal gas in functional abdominal pain, N Engl J Med., 293, pp. 524-525, (1975); Serra J., Azpiroz F., Malagelada J.R., Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome, Gut, 48, pp. 14-19, (2001); Lea R., Houghton L.A., Reilly B., Whorwell P.J., Abdominal distension in irritable bowel syndrome (IBS): Is there a relationship to visceral sensitivity, Gastroenterology, 124, (2003); Koide A., Yamaguchi T., Odaka T., Et al., Quantitative analysis of bowel gas using plain abdominal radiograph in patients with irritable bowel syndrome, Am J Gastroenterol., 95, pp. 735-741, (2000); King T.S., Ekua M., Hunter J.O., Abnormal colonic fermentation in irritable bowel syndrome, Lancet, 352, pp. 1187-1189, (1998); Levitt M.D., Production and excretion of hydrogen gas in man, N Engl J Med., 281, pp. 122-127, (1969); Strocchi A., Furne J., Ellis C., Levitt M.D., Methanogens outcompetes sulphate reducing bacteria for H2 in the human colon, Gut, 35, pp. 1098-1101, (1994); Eckburg P.B., Bik E.M., Bernstein C.N., Et al., Diversity of the human intestinal microbial flora, Science, 308, pp. 1635-1638, (2005); Brandtzaeg P., History of oral tolerance and mucosal immunity, Ann NY Acad Sci., 778, pp. 1-27, (1996); Gorbach S.L., Intestinal microflora, Gastroenterology, 60, pp. 1110-1129, (1971); Plaut A.G., Gorbach S.L., Nahas L., Et al., Intestinal microflora. 3. The microbial flora of human small intestinal mucosa, Gastroenterology, 53, pp. 868-873, (1967); Dear K.L., Elia M., Hunter J.O., Do interventions which reduce colonic bacterial fermentation improve symptoms of irritable bowel syndrome?, Dig Dis Sci., 50, pp. 758-766, (2005); Riordan S.M., McIver C.J., Thomas D.H., Et al., Luminal bacteria and small intestinal permeability, Scand J Gastroenterol Suppl., 32, pp. 556-563, (1997); Woodcock N.P., Robertson J., Morgan D.R., Et al., Bacterial translocation and immunohistochemical measurement of gut immune function, J Clin Pathol., 54, pp. 619-623, (2001); Gwee K.A., Collins S.M., Read N.W., Et al., Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome, Gut, 52, pp. 523-526, (2003); Dunlop S.P., Jenkins D., Spiller R.C., Distinctive clinical, psychological, and histological features of post-infective bowel syndrome, Am J Gastroenterol., 98, pp. 1578-1583, (2003); O'Sullivan M., Clayton N., Breslin N.P., Et al., Increased mast cells in the irritable bowel syndrome, Neurogastroenterol Motil., 12, pp. 449-457, (2000); Spiller R.C., Jenkins D., Thomley J.P., Et al., Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, pp. 804-811, (2000); Tornblom H., Lindberg G., Nyberg B., Veress B., Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome, Gastroenterology, 123, pp. 1972-1979, (2002); Weston A.P., Biddle W.L., Bhatia P.S., Miner P.B.J., Terminal ileal mucosal mast cells in irritable bowel syndrome, Dig Dis Sci., 38, pp. 1590-1595, (1993); Chadwick V., Chen W., Shu D., Et al., Activation of the mucosal immune system in irritable bowel syndrome, Gastroenterology, 122, pp. 1778-1783, (2002); Marshall J.K., Thabane M., Meddings J., Et al., Increased intestinal permeability (IP) in subjects with irritable bowel syndrome (IBS) two years after the Walkerton outbreak of waterborne gastroenteritis, Gastroenterology, 126, (2004); O'Mahony L., McCarthy J., Kelly P., Et al., Lactobacillus and Bifidobacterium in irritable bowel syndrome: Symptom response and relationship to cytokine profiles, Gastroenterology, 128, pp. 541-551, (2005); Van der Veek P., DeKoon Y., Van den Berg M., Et al., Tumor necrosis factor alpha and interleukin 10 gene polymorphisms in irritable bowel syndrome, Gastroenterology, 126, (2004); Toskes P.P., Small intestinal bacterial overgrowth, Sleisinger and Fortran Textbook of Gastroenterology, (1989); Matsuo K., Ota H., Akamatsu T., Et al., Histochemistry of the surface mucous gel layer of the human colon, Gut, 40, pp. 782-789, (1997); Levitt M.D., Donaldson R.M., Use of respiratory hydrogen (H2) excretion to detect carbohydrate malabsorption, J Lab Clin Med., 75, pp. 937-945, (1970); Riordan S.M., McIver C.J., Walker B.M., Et al., The lactulose breath hydrogen test and small intestinal bacterial overgrowth, Am J Gastroenterol., 91, pp. 1795-1803, (1996); Galatola G., Grosso M., Barlotta A., Et al., Diagnosis of bacterial contamination of the small intestine using the 1 g [14C] xylose breath test in various gastrointestinal diseases, Minerva Gastroenterol Dietol., 37, pp. 169-175, (1991); Pimentel M., Chow E.J., Lin H.C., Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study, Am J Gastroenterol., 98, pp. 412-419, (2003); Nucera G., Gabrielli M., Lupascu A., Et al., Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth, Aliment Pharmacol Ther., 21, pp. 1391-1395, (2005); Walters B., Vanner S.J., Detection of bacterial overgrowth in IBS using the lactulose H2 breath test: Comparison with 14C-D-xylose and healthy controls, Am J Gastroenterol., 100, pp. 1566-1570, (2005); Lupascu A., Lauritano C., Gabrielli M., Et al., Small intestinal bacterial overgrowth prevalence in irritable bowel syndrome, Gastroenterology, 128, (2005); McCallum R., Schultz C., Sostarich S., Evaluating the role of small intestinal bacterial overgrowth (sibo) in diarrhea predominant irritable bowel syndrome (IBS-D) patients utilizing the glucose breath test (gbt), Gastroenterology, 128, (2005); Simren M., Ringstrom G., Agerforz P., Et al., Small intestinal bacterial overgrowth is not of major importance in irritable bowel syndrome, Gastroenterology, 124, (2003); Robson K.M., Kakullavarapu J., Lembo T., Bacterial overgrowth and irritable bowel syndrome: A look at prevalence, symptoms and quality of life, Am J Gastroenterol., 98, (2003); Pimentel M., Park S., Kong Y., Et al., Rifaximin, a non-absorbable antibiotic, improves the symptoms of irritable bowel syndrome: A double-blind randomized controlled study, Am J Gastroenterol., 100, 9, (2005); Vantrappen G., Jannssen J., Hellemans J., Ghoos Y., The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine, J Clin Invest., 59, pp. 1158-1166, (1977); Pimentel M., Soffer E.E., Chow E.J., Lin H.C., Lower frequency of MMC is found in IBS subjects with abnormal breath test suggesting bacterial overgrowth, Dig Dis Sci., 47, pp. 2639-2643, (2002); Pimentel M., Mayer A.G., Park S., Et al., Methane production during lactulose breath test is associated with gastrointestinal disease presentation, Dig Dis Sci., 48, pp. 86-92, (2003); Lin H.C., Pimentel M., Chen J.H., Intestinal transit is slowed by luminal methane, Neurogastroenterol Motil., 4, (2002); Pimentel M., Chatterjee S., Chow E.J., Et al., Neomycin improves C-IBS in a fashion that is dependent on the presence of methane gas: Sub-analysis of a double-blind randomized controlled study, Am J Gastroenterol","","","","","","","","","1533001X","","RGDEA","17713456","English","Rev. Gastroenterol. Disord.","Article","Final","","Scopus","2-s2.0-31144467842"

"Vicario M.; Guilarte M.; Alonso C.; Yang P.; Martínez C.; Ramos L.; Lobo B.; González A.; Guilà M.; Pigrau M.; Saperas E.; Azpiroz F.; Santos J.","Vicario, María (6603267769); Guilarte, Mar (18133405400); Alonso, Carmen (56411082400); Yang, Pinchang (35279014900); Martínez, Cristina (17534584700); Ramos, Laura (57206530978); Lobo, Beatriz (7003936898); González, Ana (54796498900); Guilà, Meritxell (8566782700); Pigrau, Marc (37009212800); Saperas, Esteban (7004148840); Azpiroz, Fernando (57207592894); Santos, Javier (7402389020)","6603267769; 18133405400; 56411082400; 35279014900; 17534584700; 57206530978; 7003936898; 54796498900; 8566782700; 37009212800; 7004148840; 57207592894; 7402389020","Chronological assessment of mast cell-mediated gut dysfunction and mucosal inflammation in a rat model of chronic psychosocial stress","2010","Brain, Behavior, and Immunity","24","7","","1166","1175","9","90","10.1016/j.bbi.2010.06.002","https://www.scopus.com/inward/record.uri?eid=2-s2.0-79959831052&doi=10.1016%2fj.bbi.2010.06.002&partnerID=40&md5=0d765b127079aa9d6f51811e1575931c","Digestive Diseases Research Unit, Lab Neuro-Immuno-Gastroenterology, Institut de Recerca Vall d'Hebron, CIBERehd, Department of Gastroenterology, Barcelona, Spain; Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Department of Medicine, Barcelona, Spain; Allergy Unit, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Department of Medicine, Barcelona, Spain; Department of Pathology, McMaster University, Hamilton, ON, Canada","Vicario M., Digestive Diseases Research Unit, Lab Neuro-Immuno-Gastroenterology, Institut de Recerca Vall d'Hebron, CIBERehd, Department of Gastroenterology, Barcelona, Spain, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Department of Medicine, Barcelona, Spain; Guilarte M., Allergy Unit, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Department of Medicine, Barcelona, Spain; Alonso C., Digestive Diseases Research Unit, Lab Neuro-Immuno-Gastroenterology, Institut de Recerca Vall d'Hebron, CIBERehd, Department of Gastroenterology, Barcelona, Spain, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Department of Medicine, Barcelona, Spain; Yang P., Department of Pathology, McMaster University, Hamilton, ON, Canada; Martínez C., Digestive Diseases Research Unit, Lab Neuro-Immuno-Gastroenterology, Institut de Recerca Vall d'Hebron, CIBERehd, Department of Gastroenterology, Barcelona, Spain, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Department of Medicine, Barcelona, Spain; Ramos L., Digestive Diseases Research Unit, Lab Neuro-Immuno-Gastroenterology, Institut de Recerca Vall d'Hebron, CIBERehd, Department of Gastroenterology, Barcelona, Spain, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Department of Medicine, Barcelona, Spain; Lobo B., Digestive Diseases Research Unit, Lab Neuro-Immuno-Gastroenterology, Institut de Recerca Vall d'Hebron, CIBERehd, Department of Gastroenterology, Barcelona, Spain, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Department of Medicine, Barcelona, Spain; González A., Digestive Diseases Research Unit, Lab Neuro-Immuno-Gastroenterology, Institut de Recerca Vall d'Hebron, CIBERehd, Department of Gastroenterology, Barcelona, Spain, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Department of Medicine, Barcelona, Spain; Guilà M., Digestive Diseases Research Unit, Lab Neuro-Immuno-Gastroenterology, Institut de Recerca Vall d'Hebron, CIBERehd, Department of Gastroenterology, Barcelona, Spain, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Department of Medicine, Barcelona, Spain; Pigrau M., Digestive Diseases Research Unit, Lab Neuro-Immuno-Gastroenterology, Institut de Recerca Vall d'Hebron, CIBERehd, Department of Gastroenterology, Barcelona, Spain, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Department of Medicine, Barcelona, Spain; Saperas E., Digestive Diseases Research Unit, Lab Neuro-Immuno-Gastroenterology, Institut de Recerca Vall d'Hebron, CIBERehd, Department of Gastroenterology, Barcelona, Spain, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Department of Medicine, Barcelona, Spain; Azpiroz F., Digestive Diseases Research Unit, Lab Neuro-Immuno-Gastroenterology, Institut de Recerca Vall d'Hebron, CIBERehd, Department of Gastroenterology, Barcelona, Spain, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Department of Medicine, Barcelona, Spain; Santos J., Digestive Diseases Research Unit, Lab Neuro-Immuno-Gastroenterology, Institut de Recerca Vall d'Hebron, CIBERehd, Department of Gastroenterology, Barcelona, Spain, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Department of Medicine, Barcelona, Spain","Life stress and mucosal inflammation may influence symptom onset and severity in certain gastrointestinal disorders, particularly irritable bowel syndrome (IBS), in connection with dysregulated intestinal barrier. However, the mechanism responsible remains unknown. Crowding is a validated animal model reproducing naturalistic psychosocial stress, whose consequences on gut physiology remain unexplored. Our aims were to prove that crowding stress induces mucosal inflammation and intestinal dysfunction, to characterize dynamics in time, and to evaluate the implication of stress-induced mast cell activation on intestinal dysfunction. Wistar-Kyoto rats were submitted to 15 days of crowding stress (8 rats/cage) or sham-crowding (2 rats/cage). We measured spontaneous and corticotropin-releasing factor-mediated release of plasma corticosterone. Stress-induced intestinal chrono-pathobiology was determined by measuring intestinal inflammation, epithelial damage, mast cell activation and infiltration, and intestinal barrier function. Corticosterone release was higher in crowded rats throughout day 15. Stress-induced mild inflammation, manifested earlier in the ileum and the colon than in the jejunum. While mast cell counts remained mostly unchanged, piecemeal degranulation increased along time, as the mucosal content and luminal release of rat mast cell protease-II. Stress-induced mitochondrial injury and increased jejunal permeability, both events strongly correlated with mast cell activation at day 15. Taken together, we have provided evidences that long-term exposure to psychosocial stress promotes mucosal inflammation and mast cell-mediated barrier dysfunction in the rat bowel. The notable resemblance of these findings with those in some IBS patients, support the potential interest and translational validity of this experimental model for the research of stress-sensitive intestinal disorders, particularly IBS. © 2010 Elsevier Inc.","Irritable bowel syndrome; Mast cells; Psychosocial stress","Animals; Cell Count; Colon; Corticosterone; Corticotropin-Releasing Hormone; Crowding; Disease Models, Animal; Flow Cytometry; Gastrointestinal Tract; Housing, Animal; Ileum; Immunohistochemistry; Intestinal Mucosa; Irritable Bowel Syndrome; Jejunum; Male; Mast Cells; Mitochondria; Permeability; Rats; Rats, Inbred WKY; Social Environment; Stress, Psychological; Time Factors; animal cell; animal experiment; animal model; animal tissue; article; cell activation; cell infiltration; cell permeabilization; crowding; enteritis; gastrointestinal disease; histopathology; hypothalamus hypophysis adrenal system; leukocyte count; male; mast cell; mental stress; mitochondrial membrane; nonhuman; priority journal; rat","","Corticosterone, 50-22-6; Corticotropin-Releasing Hormone, 9015-71-8","","","Spanish Ministerio de Ciencia e Innovación; Generalitat de Catalunya, (2009 SGR 219); Generalitat de Catalunya; Agència de Gestió d'Ajuts Universitaris i de Recerca, AGAUR; Instituto de Salud Carlos III, ISCIII; INCLIVA Instituto de Investigación Sanitaria, (CD05/00060, CM04/00019, CM05/00055, CM08/00229, EC07/90148, PI01/3134, PI02/0190, PI05/1423, PI08/0940); INCLIVA Instituto de Investigación Sanitaria; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, CIBEREHD, (CB06/04/0021); Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, CIBEREHD","Supported by Spanish Ministerio de Ciencia e Innovación, Instituto de Salud Carlos III, Fondo de Investigación Sanitaria (CD05/00060 to MV; CM04/00019 to CA; CM05/00055 to LR; CM08/00229 to BL; and PI02/0190 & PI01/3134 & PI05/1423 & PI08/0940 & EC07/90148 to JS), and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CB06/04/0021 to FA and JS); Agència de Gestió d’Ajuts Universitaris i de Recerca, Generalitat de Catalunya (2009 SGR 219 to FA- & JS-Digestive Diseases Research Unit). ","Adzic M., Djordjevic A., Demonacos C., Krstic-Demonacos M., Radojcic M.B., The role of phosphorylated glucocorticoid receptor in mitochondrial functions and apoptotic signalling in brain tissue of stressed Wistar rats, Int. J. Biochem. Cell. Biol., 41, pp. 2181-2188, (2009); Al-Chaer E.D., Kawasaki M., Pasricha P.J., A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development, Gastroenterology, 119, pp. 1276-1285, (2000); Alonso C., Santos J., A closer look at mucosal inflammation in irritable bowel syndrome: sex- and gender-related disparities-quantity, quality, or both?, Am. J. Gastroenterol., 104, pp. 401-403, (2009); Armario A., Ortiz R., Balasch J., Effect of crowding on some physiological and behavioral variables in adult male rats, Physiol. Behav., 32, pp. 35-37, (1984); Barbara G., Wang B., Stanghellini V., de Giorgio R., Cremon C., Di Nardo G., Trevisani M., Campi B., Geppetti P., Tonini M., Bunnett N.W., Grundy D., Corinaldesi R., Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome, Gastroenterology, 132, pp. 26-37, (2007); Bennett E.J., Tennant C.C., Piesse C., Badcock C.A., Kellow J.E., Level of chronic life stress predicts clinical outcome in irritable bowel syndrome, Gut, 43, pp. 256-261, (1998); Bhatnagar S., Dallman M.F., Neuroanatomical basis for facilitation of hypothalamic-pituitary-adrenal responses to a novel stressor after chronic stress, Neuroscience, 84, pp. 1025-1039, (1998); Bhatnagar S., Vining C., Iyer V., Kinni V., Changes in hypothalamic-pituitary-adrenal function, body temperature, body weight and food intake with repeated social stress exposure in rats, J. Neuroendocrinol., 18, pp. 13-24, (2006); Bohmelt A.H., Nater U.M., Franke S., Hellhammer D.H., Ehlert U., Basal and stimulated hypothalamic-pituitary-adrenal axis activity in patients with functional gastrointestinal disorders and healthy controls, Psychosom. Med., 67, pp. 288-294, (2005); Boudry G., Jury J., Yang P.C., Perdue M.H., Chronic psychological stress alters epithelial cell turn-over in rat ileum, Am. J. Physiol. Gastrointest. Liver Physiol., 292, (2007); Bowers S.L., Bilbo S.D., Dhabhar F.S., Nelson R.J., Stressor-specific alterations in corticosterone and immune responses in mice, Brain. Behav. Immun., 22, pp. 105-113, (2008); Bugajski J., Gadek-Michalska A., Effect of cyclooxygenase inhibitors on the vasopressin induced ACTH and corticosterone response during crowding stress, J. Physiol. Pharmacol., 54, pp. 247-256, (2003); Caso J.R., Leza J.C., Menchen L., The effects of physical and psychological stress on the gastrointestinal tract: lessons from animal models, Curr. Mol. Med., 8, pp. 299-312, (2008); Chang L., Sundaresh S., Elliott J., Anton P.A., Baldi P., Licudine A., Mayer M., Vuong T., Hirano M., Naliboff B.D., Ameen V.Z., Mayer E.A., Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis in irritable bowel syndrome, Neurogastroenterol. Motil., 21, pp. 149-159, (2009); Chin A.C., Lee W.Y., Nusrat A., Vergnolle N., Parkos C.A., Neutrophil-mediated activation of epithelial protease-activated receptors-1 and -2 regulates barrier function and transepithelial migration, J. Immunol., 181, pp. 5702-5710, (2008); Chin A.C., Parkos C.A., Pathobiology of neutrophil transepithelial migration: implications in mediating epithelial injury, Annu. Rev. Pathol., 2, pp. 111-143, (2007); Chrousos G.P., Stress and disorders of the stress system, Nat. Rev. Endocrinol., 5, pp. 374-381, (2009); Collins S.M., Bercik P., The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease, Gastroenterology, 136, pp. 2003-2014, (2009); Collins S.M., McHugh K., Jacobson K., Khan I., Riddell R., Murase K., Weingarten H.P., Previous inflammation alters the response of the rat colon to stress, Gastroenterology, 111, pp. 1509-1515, (1996); Dinan T.G., Quigley E.M., Ahmed S.M., Scully P., O'Brien S., O'Mahony L., O'Mahony S., Shanahan F., Keeling P.W., Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker?, Gastroenterology, 130, pp. 304-311, (2006); Engler H., Dawils L., Hoves S., Kurth S., Stevenson J.R., Schauenstein K., Stefanski V., Effects of social stress on blood leukocyte distribution: the role of alpha- and beta-adrenergic mechanisms, J. Neuroimmunol., 156, pp. 153-162, (2004); Faresjo A., Grodzinsky E., Johansson S., Wallander M.A., Timpka T., Akerlind I., Psychosocial factors at work and in every day life are associated with irritable bowel syndrome, Eur. J. Epidemiol., 22, pp. 473-480, (2007); Fukudo S., Role of corticotropin-releasing hormona in irritable bowel syndrome and intestinal inflammation, J. Gastroenterol., 42, pp. 48-51, (2007); Fukudo S., Nomura T., Hongo M., Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome, Gut, 42, pp. 845-849, (1998); Gadek-Michalska A., Bugajski J., Repeated handling, restraint, or chronic crowding impair the hypothalamic-pituitary-adrenocortical response to acute restraint stress, J. Physiol. Pharmacol., 54, pp. 449-459, (2003); Gamallo A., Villanua A., Trancho G., Fraile A., Stress adaptation and adrenal activity in isolated and crowded rats, Physiol. Behav., 36, pp. 217-221, (1986); Gareau M.G., Silva M.A., Perdue M.H., Pathophysiological mechanisms of stress-induced intestinal damage, Curr. Mol. Med., 8, pp. 274-281, (2008); Gay J., Kokkotou E., O'Brien M., Pothoulakis C., Karalis K.P., Corticotropin-releasing hormone deficiency is associated with reduced local inflammation in a mouse model of experimental colitis, Endocrinology, 149, pp. 3403-3409, (2008); Guilarte M., Santos J., de Torres I., Alonso C., Vicario M., Ramos L., Martinez C., Casellas F., Saperas E., Malagelada J.R., Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum, Gut, 56, pp. 203-209, (2007); Karalis K., Sano H., Redwine J., Listwak S., Wilder R.L., Chrousos G.P., Autocrine or paracrine inflammatory actions of corticotropin-releasing hormone in vivo, Science, 254, pp. 421-423, (1991); Kaushik S., Kaur J., Effect of chronic cold stress on intestinal epithelial cell proliferation and inflammation in rats, Stress, 8, pp. 191-197, (2005); Keita A.V., Soderholm J.D., Ericson A.C., (2010); Kiank C., Tache Y., Larauche M., Stress-related modulation of inflammation in experimental models of bowel disease and post-infectious irritable bowel syndrome: role of corticotropin-releasing factor receptors, Brain. Behav. Immun., 24, pp. 41-48, (2010); Kokkotou E., Torres D., Moss A.C., O'Brien M., Grigoriadis D.E., Karalis K., Pothoulakis C., Corticotropin-releasing hormone receptor 2-deficient mice have reduced intestinal inflammatory responses, J. Immunol., 177, pp. 3355-3361, (2006); La Fleur S.E., Wick E.C., Idumalla P.S., Grady E.F., Bhargava A., Role of peripheral corticotropin-releasing factor and urocortin II in intestinal inflammation and motility in terminal ileum, Proc. Natl. Acad. Sci., 102, pp. 7647-7652, (2005); Levine S., Maternal and environmental influences on the adrenocortical response to stress in weaning rats, Science, 156, pp. 258-260, (1967); Lipkin M., Bell B., Sherlock P., Cell proliferation kinetics in the gastrointestinal tract of man. I. Cell renewal in colon and rectum, J. Clin. Invest., 42, pp. 767-776, (1963); Ma S., Morilak D.A., Chronic intermittent cold stress sensitises the hypothalamic-pituitary-adrenal response to a novel acute stress by enhancing noradrenergic influence in the rat paraventricular nucleus, J. Neuroendocrinol., 17, pp. 761-769, (2005); Maehly A.C., Chance B., The assay of catalases and peroxidases, Methods of Biochemical analysis, (1954); Maunder R.G., Levenstein S., The role of stress in the development and clinical course of inflammatory bowel disease: epidemiological evidence, Curr. Mol. Med., 8, pp. 247-252, (2008); McLean P.G., Picard C., Garcia-Villar R., Ducos de Lahitte R., More J., Fioramonti J., Bueno L., Effects of nematode infection on sensitivity to intestinal distension: role of tachykinin NK2 receptors, Eur. J. Pharmacol., 337, pp. 279-282, (1997); Monnikes H., Tebbe J.J., Hildebrandt M., Arck P., Osmanoglou E., Rose M., Klapp B., Wiedenmann B., Heymann-Monnikes I., Role of stress in functional gastrointestinal disorders. Evidence for stress-induced alterations in gastrointestinal motility and sensitivity, Digest. Dis., 19, pp. 201-211, (2001); Murray C.D.R., Flynn J., Ratcliffe L., Jacyna M.R., Kamm M.A., Emmanuel A.V., Effect of acute physical and psychological stress on gut autonomic innervation in irritable bowel syndrome, Gastroenterology, 127, pp. 1695-1703, (2004); Nicholl B.I., Halder S.L., Macfarlane G.J., Thompson D.G., O'Brien S., Musleh M., McBeth J., Psychosocial risk markers for new onset irritable bowel syndrome - results of a large prospective population-based study, Pain, 137, pp. 147-155, (2008); O'Mahony S.M., Marchesi J.R., Scully P., Codling C., Ceolho A.M., Quigley E.M., Cryan J.F., Dinan T.G., Early life stress alters behaviour, immunity, and microbiota in rats: implications for irritable bowel syndrome and psychiatric illnesses, Biol. Psychiat., 65, pp. 263-267, (2009); O'Malley D., Julio-Pieper M., Gibney S.M., Gosselin R.D., Dinan T.G., Cryan J.F., Differential stress-induced alterations of colonic corticotropin-releasing factor receptors in the Wistar Kyoto rat, Neurogastroenterol. Motil., 22, pp. 301-311, (2010); Palsson O.S., Drossman D.A., Psychiatric and psychological dysfunction in irritable bowel syndrome and the role of psychological treatments, Gastroenterol. Clin. N. Am., 34, pp. 281-303, (2005); Piche T., Barbara G., Aubert P., Bruley des Varannes S., Dainese R., Nano J.L., Cremon C., Stanghellini V., De Giorgio R., Galmiche J.P., Neunlist M., Impaired intestinal integrity in the colon of irritable bowel syndrome patients: involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Ponferrada A., Caso J.R., Alou L., Colon A., Sevillano D., Moro M.A., Lizasoain I., Menchen P., Gomez-Lus M.L., Lorenzo P., Cos E., Leza J.C., Menchen L., The role of PPARgamma on restoration of colonic homeostasis after experimental stress-induced inflammation and dysfunction, Gastroenterology, 132, pp. 1791-1803, (2007); Psarra A.M.G., Solakidi S., Sekeris C.E., The mitochondrion as a primary site of action of regulatory agents involved in neuroimmunomodulation, Ann. N.Y. Acad. Sci., 1088, pp. 12-22, (2006); Reber S.O., Birkeneder L., Veenema A.H., Obermeier F., Falk W., Straub R.H., Neumann I.D., Adrenal insufficiency and colonic inflammation after a novel chronic psycho-social stress paradigm in mice. implications and mechanisms, Endocrinology, 148, pp. 670-682, (2007); Reber S.O., Obermeier F., Straub H.R., Falk W., Neumann I.D., Chronic intermittent psychosocial stress (social defeat/overcrowding) in mice increases the severity of an acute DSS-induced colitis and impairs regeneration, Endocrinology, 147, pp. 4968-4976, (2006); Santos J., Alonso C., Vicario M., Ramos L., Lobo B., Malagelada J.R., Neuropharmacology of stress-induced mucosal inflammation: implications for inflammatory bowel disease and irritable bowel syndrome, Curr. Mol. Med., 8, pp. 258-273, (2008); Santos J., Benjamin M., Yang P.C., Prior T., Perdue M.H., Chronic stress impairs rat growth and jejunal epithelial barrier function: role of mast cells, Am. J. Physiol. Gastrointest. Liver Physiol., 278, (2000); Santos J., Bienenstock J., Perdue M.H., Innervation of lymphoid tissue and functional consequences of neurotransmitter and neuropeptide release, Food Allergy and Intolerance, pp. 51-67, (2002); Santos J., Yang P.C., Soderholm J.D., Benjamin M., Perdue M.H., Role of mast cells in chronic stress induced colonic epithelial barrier dysfunction in the rat, Gut, 48, pp. 630-636, (2001); Santos J., Yates D., Guilarte M., Vicario M., Alonso C., Perdue M.H., Stress neuropeptides evoke epithelial responses via mast cell activation in the rat colon, Psychoneuroendocrinology, 33, pp. 1248-1256, (2008); Saunders P.R., Miceli P., Vallance B.A., Wang L., Pinto S., Tougas G., Kamath M., Jacobson K., Noradrenergic and cholinergic neural pathways mediate stress-induced reactivation of colitis in the rat, Auton. Neurosci., 124, pp. 56-68, (2006); Savkovic S.D., Koutsouris A., Hecht G., Attachment of a noninvasive enteric pathogen, enteropathogenic Escherichia coli, to cultured human intestinal epithelial monolayers induces transmigration of neutrophils, Infect. Immun., 64, pp. 4480-4487, (1996); Smith F., Clark J.E., Overman B.L., Tozel C.C., Huang J.H., Rivier J.E., Blikslager A.T., Moeser A.J., Early weaning stress impairs development of mucosal barrier function in the porcine intestine, Am. J. Physiol. Gastrointest. Liver Physiol., 298, (2010); Soderholm J.D., Yang P.C., Ceponis P., Vohra A., Riddell R., Sherman P.M., Perdue M.H., Chronic stress induces mast cell-dependent bacterial adherence and initiates mucosal inflammation in the rat intestine, Gastroenterology, 123, pp. 1099-1108, (2002); Soderholm J.D., Yates D.A., Gareau M.G., Yang P.C., MacQueen G., Perdue M.H., Neonatal maternal separation predisposes adult rats to colonic barrier dysfunction in response to mild stress, Am. J. Physiol. Gastrointest. Liver Physiol., 283, (2002); Somasundaram S., Rafi S., Hayllar J., Sigthorsson G., Jacob M., Price A.B., Macpherson A., Mahmod T., Scott D., Wrigglesworth J.M., Bjarnason I., Mitochondrial damage: a possible mechanism of the ""topical"" phase of NSAID induced injury to the rat intestine, Gut, 41, pp. 344-353, (1997); Stefanski V., Peschel A., Reber S., Social stress affects migration of blood T cells into lymphoid organs, J. Neuroimmunol., 138, pp. 17-24, (2003); Tache Y., Bonaz B., Corticotropin-releasing factor receptors and stress-related alterations of gut motor function, J. Clin. Invest., 117, pp. 33-40, (2007); Tamashiro K.L., Nguyen M.M., Sakai R.R., Social stress: from rodents to primates, Front. Neuroendocrinol., 26, pp. 27-40, (2005); Teitelbaum A.A., Gareau M.G., Jury J., Yang P.C., Perdue M.H., Chronic peripheral administration of corticotropin-releasing factor causes colonic barrier dysfunction similar to psychological stress, Am. J. Physiol. Gastrointest. Liver Physiol., 295, (2008); Vicario M., Crespi M., Franch A., Amat C., Pelegri C., Moreto M., Induction of colitis in young rats by dextran sulfate sodium, Digest. Dis. Sci., 50, pp. 143-150, (2005); Wallon C., Yang P.C., Keita A.V., Ericson A.C., McKay D.M., Sherman P.M., Perdue M.H., Soderholm J.D., Corticotropin-releasing hormone (CRH) regulates macromolecular permeability via mast cells in normal human colonic biopsies in vitro, Gut, 57, pp. 50-58, (2008)","J. Santos; Neuro-Immuno-Gastroenterology Lab, Digestive Diseases Research Unit, Institut de Recerca Vall d'Hebron, 08035 Barcelona, Paseo Vall d'Hebron 119-129, Spain; email: jsantos@ir.vhebron.net","","","","","","","","08891591","","BBIME","20600818","English","Brain Behav. Immun.","Article","Final","","Scopus","2-s2.0-79959831052"

"Wilcz-Villega E.M.; McClean S.; O'Sullivan M.A.","Wilcz-Villega, Ewa M. (55650650000); McClean, Siobhán (16425720600); O'Sullivan, Maria A (35616329200)","55650650000; 16425720600; 35616329200","Mast cell tryptase reduces junctional adhesion molecule-A (JAM-A) expression in intestinal epithelial cells: Implications fo. The mechanisms of barrier dysfunction in irritable bowel syndrome","2013","American Journal of Gastroenterology","108","7","","1140","1151","11","99","10.1038/ajg.2013.92","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84880235634&doi=10.1038%2fajg.2013.92&partnerID=40&md5=13ce4f1acafaa33d13820f335c2f8e69","Department of Clinical Medicine, Trinity Centre for Health Sciences, Adelaide and Meath Hospital, Dublin, Ireland; Centre for Microbial Host Interactions, Institute of Technology Tallaght, Dublin, Ireland; School of Medicine, Trinity Centre for Health Sciences, St James's Hospital, Dublin 8, Ireland","Wilcz-Villega E.M., Department of Clinical Medicine, Trinity Centre for Health Sciences, Adelaide and Meath Hospital, Dublin, Ireland; McClean S., Centre for Microbial Host Interactions, Institute of Technology Tallaght, Dublin, Ireland; O'Sullivan M.A., Department of Clinical Medicine, Trinity Centre for Health Sciences, Adelaide and Meath Hospital, Dublin, Ireland, School of Medicine, Trinity Centre for Health Sciences, St James's Hospital, Dublin 8, Ireland","OBJECTIVES:The objective of this study was to investigate how mast cell tryptase may influence intestinal permeability and tight junction (TJ) proteins in vitro and explore translation to irritable bowel syndrome (IBS).METHODS:We investigate. The effect of: (1) tryptase on Caco-2 monolayers, (2) mast cell degranulation in a Caco-2/human mast cell-1 (HMC-1) co-culture model, (3) mast cell degranulation±tryptase inhibition with nafamostat mesilate (NM). Epithelial integrity was assessed by transepithelial resistance (TER), permeability to fluorescein isothiocyanate (FITC)-dextran and transmission electron microscopy (TEM). The expression of junctional proteins zonula occludens-1 (ZO-1), junctional adhesion molecule-A (JAM-A), claudin-1 (CLD-1), CLD-2, CLD-3, occludin and E-cadherin was determined by western blot analysis and immunofluorescence confocal microscopy. Based o. The in vitro results, we further assessed JAM-A expression in biopsy tissue (cecum) from 34 IBS patients, 12 controls, and 8 inflammatory controls using immunofluorescence confocal microscopy and explored associations between JAM-A and IBS symptoms.RESULTS: ptase disrupted epithelial integrity in Caco-2 monolayers as shown by a significant decrease in TER, an increase in permeability to FITC-dextran, and a decrease i. The expression of junctional proteins JAM-A, CLD-1, and ZO-1 within 24 h. Correspondingly, i. The Caco-2/HMC-1 co-culture model we showed a significant decrease in TER, an increase in permeability to FITC-dextran, an. The presence of open TJs (TEM) in response to mast cell degranulation within 24 h. In this co-culture model, mast cell degranulation significantly decreased JAM-A and CLD-1 protein expression at 24 h. Tryptase inhibition (NM) significantly reduce. The effect of mast cell degranulation o. The junctional protein JAM-A, TER, and FITC-dextran flux. In IBS, epithelial JAM-A protein expression was significantly reduced in IBS tissue compared with controls. Lower JAM-A expression was associated with more severe abdominal pain (r s =-0.69, P=0.018) and longer duration of symptoms (r s =-0.7, P=0.012) in IBS-alternating subtype.CONCLUSIONS:uced JAM-A expression in vitro appears to contribute t. The underlying mechanisms of altered epithelial integrity in response to tryptase released from degranulating mast cells. In IBS, JAM-A expression was significantly reduced i. The cecal epithelium and associated with abdominal pain severity. JAM-A may provide new insights int. The underlying mechanisms in IBS.","","Abdominal Pain; Adult; Caco-2 Cells; Cadherins; Cell Adhesion Molecules; Claudins; Coculture Techniques; Dextrans; Female; Fluorescein-5-isothiocyanate; Humans; Intercellular Junctions; Irritable Bowel Syndrome; Male; Mast Cells; Microscopy, Electron, Transmission; Middle Aged; Occludin; Permeability; Receptors, Cell Surface; Severity of Illness Index; Time Factors; Tryptases; Zonula Occludens-1 Protein; claudin 1; claudin 3; fluorescein isothiocyanate; junctional adhesion molecule A; nafamstat mesilate; occludin; protein ZO1; tryptase; uvomorulin; article; cell membrane permeability; cell strain CACO 2; coculture; confocal microscopy; human; human cell; human cell culture; human tissue; immunofluorescence; in vitro study; intestine biopsy; intestine epithelium cell; irritable colon; mast cell degranulation; priority journal; protein expression; transmission electron microscopy; Western blotting","","claudin 1, 329338-06-9; fluorescein isothiocyanate, 25168-13-2, 27072-45-3, 3326-32-7; nafamstat mesilate, 82956-11-4; occludin, 176304-61-3; tryptase, 97501-93-4; uvomorulin, 112956-45-3; Cadherins, ; Cell Adhesion Molecules, ; Claudins, ; Dextrans, 9004-54-0; F11R protein, human, ; Fluorescein-5-isothiocyanate, 3326-32-7; Occludin, ; Receptors, Cell Surface, ; Tryptases, 3.4.21.59; Zonula Occludens-1 Protein, ; fluorescein isothiocyanate dextran, ","","","","","Longstreth G.F., Th Ompson W.G., Chey W.D., Et al., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Pichet, Barbara G., Aubert P., Et al., Impaired intestinal barrier integrity i. The colon of patients with irritable bowel syndrome: Involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Marshall J., Th Abane M., Garg A., Et al., Intestinal permeability in patients with irritable bowel syndrome aft er a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario, Aliment Pharmacol Th Er, 20, pp. 1317-1322, (2004); Dunlop S., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Maher S., Brayden D.J., Feighery L., Et al., Crackin. The junction: Update o. The progress of gastrointestinal absorption enhancement i. The delivery of poorly absorbed drugs, Crit Rev Th Er Drug Carrier Syst, 25, pp. 117-168, (2008); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity i. The irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Bertiaux-Vanda Le E.N., Youmba S.B., Belmonte L., Et al., The expression an. The cellular distribution of thetight junction proteins are altered in irritable bowel syndrome patients with diff erences according t. The disease subtype, Am J Gastroenterol, 106, pp. 2165-2173, (2011); Villani A., Lemire M., Th Abane M., Et al., Genetic risk factors for postinfectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis, Gastroenterology, 138, pp. 1502-1513, (2010); Laukoetter M., Nava P., Lee W., Et al., JAM-A regulates permeability and infl ammation i. The intestine in vivo, J Exp Med, 204, pp. 3067-3076, (2007); Vetrano S., Rescigno M., Cera M., Et al., Unique role of junctional adhesion molecule- A in maintaining mucosal homeostasis in infl ammatory bowel disease, Gastroenterology, 135, pp. 173-184, (2008); Vetrano S., Danese S., The role of JAM-A in infl ammatory bowel disease: Unrevealing theties that bind, Ann N y Acad Sci, 1165, pp. 308-313, (2009); Sullivan M.O., Clayton N., Breslin N., Et al., Increased mast cells i. The irritable bowel syndrome, Neurogastroenterol Motil, 12, pp. 449-457, (2000); Barbara G., Stanghellini V., De Giorgio R., Et al., Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome, Gastroenterology, 126, pp. 693-702, (2004); Park J., Rhee P., Kim H., Et al., Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome, J Gastroenterol Hepatol, 21, pp. 71-78, (2006); Cremon C., Gargano L., Morselli-Labate A.M., Et al., Mucosal immune activation in irritable bowel syndrome: Gender-dependence and association with digestive symptoms, Am J Gastroenterol, 104, pp. 392-400, (2009); Lee K.J., Kim Y.B., Kim J.H., Et al., The alteration of enterochromaffi n cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors, J Gastroenterol Hepatol, 23, pp. 1689-1694, (2008); Ford A.C., Talley N.J., Mucosal infl ammation as a potential etiological factor in irritable bowel syndrome: A systematic review, J Gastroenterol, 46, pp. 421-431, (2011); Braak B., Klooker T.K., Wouters M.M., Et al., Mucosal immune cell numbers and visceral sensitivity in patients with irritable bowel syndrome: Is there any relationship, Am J Gastroenterol, 107, pp. 715-726, (2012); Santos J., Yang P.C., Soderholm J.D., Et al., Role of mast cells in chronic stress induced colonic epithelial barrier dysfunction i. The rat, Gut, 48, pp. 630-636, (2001); Lee J., Park J., Park D., Et al., Subjects with diarrhea-predominant IBS have increased rectal permeability responsiveto tryptase, Dig Dis Sci, (2010); Jacob C., Yang P., Darmoul D., Et al., Mast cell tryptase controls paracellular permeability o. The intestine. Role of protease-activated receptor 2 and beta-arrestins, J Biol Chem, 280, pp. 31936-31948, (2005); Artursson P., Karlsson J., Correlation between oral drug absorption in humans and apparent drug permeability coeffi cients in human intestinal epithelial (Caco-2) cells, Biochem Biophys Res Commun, 175, pp. 880-885, (1991); Mori S., Itoh Y., Shinohata R., Et al., Nafamostat mesilate is an extremely potent inhibitor of human tryptase, J Pharmacol Sci, 92, pp. 420-423, (2003); Isozaki Y., Yoshida N., Kuroda M., Et al., Anti-tryptasetreatment using nafamostat mesilate has a therapeutic eff ect on experimental colitis, Scand J Gastroenterol, 41, pp. 944-953, (2006); Lennard-Jones J.E., Classifi cation of infl ammatory bowel disease, Scand J Gastroenterol Suppl, 170, pp. 2-6, (1989); Th Ompson W.G., Longstreth G.F., Drossman D.A., Et al., Functional bowel disorders and functional abdominal pain, Gut, 45, SUPPL. 2, (1999); Jensen M.P., Turner L.R., Turner J.A., Et al., The use of multiple-item scales for pain intensity measurement in chronic pain patients, Pain, 67, pp. 35-40, (1996); Best W.R., Becktel J.M., Singleton J.W., Et al., Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study, Gastroenterology, 70, pp. 439-444, (1976); Camilleri M., Gorman H., Intestinal permeability and irritable bowel syndrome, Neurogastroenterol Motil, 19, pp. 545-552, (2007); Molino M., Barnathan E.S., Numerof R., Et al., Interactions of mast cell tryptase with thrombin receptors and PAR-2, J Biol Chem, 272, pp. 4043-4049, (1997); Kong W., McConalogue K., Khitin L.M., Et al., Luminal trypsin may regulate enterocytes through proteinase-activated receptor 2, Proc Natl Acad Sci USA, 94, pp. 8884-8889, (1997); Mart Nez I.C., Lobo B., Pigrau M., Et al., Diarrhea-predominant irritable bowel syndrome: An organic disorder with structural abnormalities i. The jejunal epithelial barrier, Gut, (2012); Mart Nez I.C., Vicario M., Ramos L., Et al., Th e jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in thetight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations, Am J Gastroenterol, (2012); Barbara G., Wang B., Stanghellini V., Et al., Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome, Gastroenterology, 132, pp. 26-37, (2007)","M.A. O'Sullivan; School of Medicine, Trinity Centre for Health Sciences, St James's Hospital, Dublin 8, Ireland; email: Maria.osullivan@tcd.ie","","","","","","","","15720241","","AJGAA","23588236","English","Am. J. Gastroenterol.","Article","Final","","Scopus","2-s2.0-84880235634"

"Odenwald M.A.; Turner J.R.","Odenwald, Matthew A. (55547160100); Turner, Jerrold R. (7404249336)","55547160100; 7404249336","Intestinal Permeability Defects: Is It Time to Treat?","2013","Clinical Gastroenterology and Hepatology","11","9","","1075","1083","8","276","10.1016/j.cgh.2013.07.001","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84882797836&doi=10.1016%2fj.cgh.2013.07.001&partnerID=40&md5=8ea48d5958d6f2463044eaa29446fa3e","Department of Pathology, The University of Chicago, Chicago, IL, United States","Odenwald M.A., Department of Pathology, The University of Chicago, Chicago, IL, United States; Turner J.R., Department of Pathology, The University of Chicago, Chicago, IL, United States","An essential role of the intestinal epithelium is to separate luminal contents from the interstitium, a function primarily determined by the integrity of the epithelium and the tight junction that seals the paracellular space. Intestinal tight junctions are selectively permeable, and intestinal permeability can be increased physiologically in response to luminal nutrients or pathologically by mucosal immune cells and cytokines, the enteric nervous system, and pathogens. Compromised intestinal barrier function is associated with an array of clinical conditions, both intestinal and systemic. Although most available data are correlative, some studies support a model where cycles of increased intestinal permeability, intestinal immune activation, and subsequent immune-mediated barrier loss contribute to disease progression. This model is applicable to intestinal and systemic diseases. However, it has not been proven, and both mechanistic and therapeutic studies are ongoing. Nevertheless, the correlation between increased intestinal permeability and disease has caught the attention of the public, leading to a rise in popularity of the diagnosis of ""leaky gut syndrome,"" which encompasses a range of systemic disorders. Proponents claim that barrier restoration will cure underlying disease, but this has not been demonstrated in clinical trials. Moreover, human and mouse studies show that intestinal barrier loss alone is insufficient to initiate disease. It is therefore uncertain whether increased permeability in these patients is a cause or effect of the underlying disorder. Although drug targets that may mediate barrier restoration have been proposed, none have been proven effective. As such, current treatments for barrier dysfunction should target the underlying disease. © 2013 AGA Institute.","Claudin; Graft vs Host Disease; Inflammatory Bowel Disease; Irritable Bowel Syndrome; Leaky Gut Syndrome; Myosin Light Chain Kinase; Tight Junction","Gastrointestinal Diseases; Humans; Intestinal Mucosa; Permeability; CA-MLCK; CD; Claudin; constitutively active-myosin light chain kinase; Crohn's disease; Graft vs Host Disease; graft-versus-host disease; GVHD; IBD; IBS; IL; Inflammatory Bowel Disease; inflammatory bowel disease; interleukin; irritable bowel syndrome; Irritable Bowel Syndrome; Leaky Gut Syndrome; MLCK; Myosin Light Chain Kinase; myosin light chain kinase; Tight Junction; TNF; tumor necrosis factor; acute pancreatitis; alcoholism; article; asthma; celiac disease; chronic fatigue syndrome; Crohn disease; depression; disease activity; disease association; disease course; disease severity; eczema; enteropathy; fibromyalgia; gastrointestinal disease; graft versus host reaction; human; insulin dependent diabetes mellitus; intestinal permeability defect; kwashiorkor; liver cirrhosis; multiple organ failure; multiple sclerosis; nonalcoholic fatty liver; nonhuman; Parkinson disease; pathogenesis; psoriasis; rheumatic disease; ulcerative colitis","","","","","National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK, (R01DK068271)","","Turner J.R., Intestinal mucosal barrier function in health and disease, Nat Rev Immunol, 9, pp. 799-809, (2009); Johansson M.E., Phillipson M., Petersson J., Et al., The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria, Proc Natl Acad Sci U S A, 105, pp. 15064-15069, (2008); Levitt M.D., Furne J.K., Strocchi A., Et al., Physiological measurements of luminal stirring in the dog and human small bowel, J Clin Invest, 86, pp. 1540-1547, (1990); Van der Sluis M., De Koning B.A., De Bruijn A.C., Et al., Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection, Gastroenterology, 131, pp. 117-129, (2006); Kottra G., Fromter E., Functional properties of the paracellular pathway in some leaky epithelia, J Exp Biol, 106, pp. 217-229, (1983); Shen L., Weber C.R., Raleigh D.R., Et al., Tight junction pore and leak pathways: a dynamic duo, Annu Rev Physiol, 73, pp. 283-309, (2011); Francis S.A., Kelly J.M., McCormack J., Et al., Rapid reduction of MDCK cell cholesterol by methyl-beta-cyclodextrin alters steady state transepithelial electrical resistance, Eur J Cell Biol, 78, pp. 473-484, (1999); Marchiando A.M., Graham W.V., Turner J.R., Epithelial barriers in homeostasis and disease, Annu Rev Pathol, 5, pp. 119-144, (2010); Schulzke J.D., Ploeger S., Amasheh M., Et al., Epithelial tight junctions in intestinal inflammation, Ann N Y Acad Sci, 1165, pp. 294-300, (2009); Anderson J.M., Van Itallie C.M., Physiology and function of the tight junction, Cold Spring Harb Perspect Biol, 1, (2009); Van Itallie C.M., Anderson J.M., Claudins and epithelial paracellular transport, Annu Rev Physiol, 68, pp. 403-429, (2006); Tang V.W., Goodenough D.A., Paracellular ion channel at the tight junction, Biophys J, 84, pp. 1660-1673, (2003); Madara J.L., Increases in guinea pig small intestinal transepithelial resistance induced by osmotic loads are accompanied by rapid alterations in absorptive-cell tight-junction structure, J Cell Biol, 97, pp. 125-136, (1983); Madara J.L., Barenberg D., Carlson S., Effects of cytochalasin D on occluding junctions of intestinal absorptive cells: further evidence that the cytoskeleton may influence paracellular permeability and junctional charge selectivity, J Cell Biol, 102, pp. 2125-2136, (1986); Fihn B.M., Sjoqvist A., Jodal M., Permeability of the rat small intestinal epithelium along the villus-crypt axis: effects of glucose transport, Gastroenterology, 119, pp. 1029-1036, (2000); Clayburgh D.R., Barrett T.A., Tang Y., Et al., Epithelial myosin light chain kinase-dependent barrier dysfunction mediates T cell activation-induced diarrhea in vivo, J Clin Invest, 115, pp. 2702-2715, (2005); Weber C.R., Raleigh D.R., Su L., Et al., Epithelial myosin light chain kinase activation induces mucosal interleukin-13 expression to alter tight junction ion selectivity, J Biol Chem, 285, pp. 12037-12046, (2010); Jodal M., Fihn B.-M., Sjoqvist A., Effect of glucose on passive transport of extracellular probes across the rat small intestinal epithelium in vivo, Gastroenterology, 107, (1994); Watson C.J., Hoare C.J., Garrod D.R., Et al., Interferon-gamma selectively increases epithelial permeability to large molecules by activating different populations of paracellular pores, J Cell Sci, 118, pp. 5221-5230, (2005); Watson C.J., Rowland M., Warhurst G., Functional modeling of tight junctions in intestinal cell monolayers using polyethylene glycol oligomers, Am J Physiol Cell Physiol, 281, (2001); Van Itallie C.M., Holmes J., Bridges A., Et al., The density of small tight junction pores varies among cell types and is increased by expression of claudin-2, J Cell Sci, 121, pp. 298-305, (2008); Heller F., Florian P., Bojarski C., Et al., Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution, Gastroenterology, 129, pp. 550-564, (2005); Amasheh S., Meiri N., Gitter A.H., Et al., Claudin-2 expression induces cation-selective channels in tight junctions of epithelial cells, J Cell Sci, 115, pp. 4969-4976, (2002); Rosenthal R., Milatz S., Krug S.M., Et al., Claudin-2, a component of the tight junction, forms a paracellular water channel, J Cell Sci, 123, pp. 1913-1921, (2010); Zolotarevsky Y., Hecht G., Koutsouris A., Et al., A membrane-permeant peptide that inhibits MLC kinase restores barrier function in in vitro models of intestinal disease, Gastroenterology, 123, pp. 163-172, (2002); Blair S.A., Kane S.V., Clayburgh D.R., Et al., Epithelial myosin light chain kinase expression and activity are upregulated in inflammatory bowel disease, Lab Invest, 86, pp. 191-201, (2006); Krug S.M., Fromm M., Gunzel D., Two-path impedance spectroscopy for measuring paracellular and transcellular epithelial resistance, Biophys J, 97, pp. 2202-2211, (2009); Meddings J.B., Gibbons I., Discrimination of site-specific alterations in gastrointestinal permeability in the rat, Gastroenterology, 114, pp. 83-92, (1998); Camilleri M., Lasch K., Zhou W., Irritable bowel syndrome: methods, mechanisms, and pathophysiology-the confluence of increased permeability, inflammation, and pain in irritable bowel syndrome, Am J Physiol Gastrointest Liver Physiol, 303, (2012); Rao A.S., Camilleri M., Eckert D.J., Et al., Urine sugars for in vivo gut permeability: validation and comparisons in irritable bowel syndrome-diarrhea and controls, Am J Physiol Gastrointest Liver Physiol, 301, (2011); Turner J.R., Cohen D.E., Mrsny R.J., Et al., Noninvasive in vivo analysis of human small intestinal paracellular absorption: regulation by Na<sup>+</sup>-glucose cotransport, Dig Dis Sci, 45, pp. 2122-2126, (2000); Turner J.R., Rill B.K., Carlson S.L., Et al., Physiological regulation of epithelial tight junctions is associated with myosin light-chain phosphorylation, Am J Physiol, 273, (1997); Meddings J.B., Westergaard H., Intestinal glucose transport using perfused rat jejunum in vivo: model analysis and derivation of corrected kinetic constants, Clin Sci (Lond), 76, pp. 403-413, (1989); Atisook K., Carlson S., Madara J.L., Effects of phlorizin and sodium on glucose-elicited alterations of cell junctions in intestinal epithelia, Am J Physiol, 258, (1990); Ramakrishna B.S., Venkataraman S., Srinivasan P., Et al., Amylase-resistant starch plus oral rehydration solution for cholera, N Engl J Med, 342, pp. 308-313, (2000); Hollander D., Vadheim C.M., Brettholz E., Et al., Increased intestinal permeability in patients with Crohn's disease and their relatives: a possible etiologic factor, Ann Intern Med, 105, pp. 883-885, (1986); May G.R., Sutherland L.M., Meddings J.B., Lactulose/mannitol permeability is increased in relatives of patients with Crohn's disease, Gastroenterology, 102, (1992); Buhner S., Buning C., Genschel J., Et al., Genetic basis for increased intestinal permeability in families with Crohn's disease: role of CARD15 3020insC mutation?, Gut, 55, pp. 342-347, (2006); Wyatt J., Vogelsang H., Hubl W., Et al., Intestinal permeability and the prediction of relapse in Crohn's disease, Lancet, 341, pp. 1437-1439, (1993); D'Inca R., Di Leo V., Corrao G., Et al., Intestinal permeability test as a predictor of clinical course in Crohn's disease, Am J Gastroenterol, 94, pp. 2956-2960, (1999); Bitton A., Dobkin P., Edwardes M.D., Et al., Predicting relapse in Crohn's disease: a biopsychosocial model, Gut, 57, pp. 1386-1392, (2008); Meddings J.B., Swain M.G., Environmental stress-induced gastrointestinal permeability is mediated by endogenous glucocorticoids in the rat, Gastroenterology, 119, pp. 1019-1028, (2000); Boirivant M., Amendola A., Butera A., Et al., A transient breach in the epithelial barrier leads to regulatory T-cell generation and resistance to experimental colitis, Gastroenterology, 135, pp. 1612-1623, (2008); Arrieta M.C., Madsen K., Doyle J., Et al., Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse, Gut, 58, pp. 41-48, (2009); Watts T., Berti I., Sapone A., Et al., Role of the intestinal tight junction modulator zonulin in the pathogenesis of type I diabetes in BB diabetic-prone rats, Proc Natl Acad Sci U S A, 102, pp. 2916-2921, (2005); Kelly C.P., Green P.H.R., Murray J.A., Et al., Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study, Aliment Pharmacol Ther, 37, pp. 252-262, (2013); Su L., Shen L., Clayburgh D.R., Et al., Targeted epithelial tight junction dysfunction causes immune activation and contributes to development of experimental colitis, Gastroenterology, 136, pp. 551-563, (2009); May G.R., Sutherland L.R., Meddings J.B., Is small intestinal permeability really increased in relatives of patients with Crohn's disease?, Gastroenterology, 104, pp. 1627-1632, (1993); Gradel K.O., Nielsen H.L., Schonheyder H.C., Et al., Increased short- and long-term risk of inflammatory bowel disease after salmonella or campylobacter gastroenteritis, Gastroenterology, 137, pp. 495-501, (2009); Villani A.C., Lemire M., Thabane M., Et al., Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis, Gastroenterology, 138, pp. 1502-1513, (2010); Su L., Nalle S.C., Shen L., Et al., TNFR2 activates MLCK-dependent tight junction dysregulation to cause apoptosis-mediated barrier loss and experimental colitis, Gastroenterology, 145, pp. 407-415, (2013); Borody T.J., Warren E.F., Leis S., Et al., Treatment of ulcerative colitis using fecal bacteriotherapy, J Clin Gastroenterol, 37, pp. 42-47, (2003); Summers R.W., Elliott D.E., Qadir K., Et al., Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease, Am J Gastroenterol, 98, pp. 2034-2041, (2003); Madsen K.L., Malfair D., Gray D., Et al., Interleukin-10 gene-deficient mice develop a primary intestinal permeability defect in response to enteric microflora, Inflamm Bowel Dis, 5, pp. 262-270, (1999); Suenaert P., Bulteel V., Lemmens L., Et al., Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease, Am J Gastroenterol, 97, pp. 2000-2004, (2002); Scheinin T., Butler D.M., Salway F., Et al., Validation of the interleukin-10 knockout mouse model of colitis: antitumour necrosis factor-antibodies suppress the progression of colitis, Clin Exp Immunol, 133, pp. 38-43, (2003); Johansson J.E., Ekman T., Gut toxicity during hemopoietic stem cell transplantation may predict acute graft-versus-host disease severity in patients, Dig Dis Sci, 52, pp. 2340-2345, (2007); Brown G.R., Lindberg G., Meddings J., Et al., Tumor necrosis factor inhibitor ameliorates murine intestinal graft-versus-host disease, Gastroenterology, 116, pp. 593-601, (1999); Heidt P.J., Vossen J.M., Experimental and clinical gnotobiotics: influence of the microflora on graft-versus-host disease after allogeneic bone marrow transplantation, J Med, 23, pp. 161-173, (1992); Beelen D.W., Elmaagacli A., Muller K.D., Et al., Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-label prospective randomized trial, Blood, 93, pp. 3267-3275, (1999); Bosi E., Molteni L., Radaelli M.G., Et al., Increased intestinal permeability precedes clinical onset of type 1 diabetes, Diabetologia, 49, pp. 2824-2827, (2006); Meddings J.B., Jarand J., Urbanski S.J., Et al., Increased gastrointestinal permeability is an early lesion in the spontaneously diabetic BB rat, Am J Physiol, 276, (1999); Wen L., Ley R.E., Volchkov P.Y., Et al., Innate immunity and intestinal microbiota in the development of Type 1 diabetes, Nature, 455, pp. 1109-1113, (2008); Pozzilli P., Signore A., Williams A.J., Et al., NOD mouse colonies around the world: recent facts and figures, Immunol Today, 14, pp. 193-196, (1993); Sharpstone D., Neild P., Crane R., Et al., Small intestinal transit, absorption, and permeability in patients with AIDS with and without diarrhoea, Gut, 45, pp. 70-76, (1999); Keating J., Bjarnason I., Somasundaram S., Et al., Intestinal absorptive capacity, intestinal permeability and jejunal histology in HIV and their relation to diarrhoea, Gut, 37, pp. 623-629, (1995); Brenchley J.M., Price D.A., Schacker T.W., Et al., Microbial translocation is a cause of systemic immune activation in chronic HIV infection, Nat Med, 12, pp. 1365-1371, (2006); Epple H.J., Schneider T., Troeger H., Et al., Impairment of the intestinal barrier is evident in untreated but absent in suppressively treated HIV-infected patients, Gut, 58, pp. 220-227, (2009); Doig C.J., Sutherland L.R., Sandham J.D., Et al., Increased intestinal permeability is associated with the development of multiple organ dysfunction syndrome in critically ill ICU patients, Am J Respir Crit Care Med, 158, pp. 444-451, (1998); Fink M.P., Antonsson J.B., Wang H.L., Et al., Increased intestinal permeability in endotoxic pigs: mesenteric hypoperfusion as an etiologic factor, Arch Surg, 126, pp. 211-218, (1991); Deitch E.A., Morrison J., Berg R., Et al., Effect of hemorrhagic shock on bacterial translocation, intestinal morphology, and intestinal permeability in conventional and antibiotic-decontaminated rats, Crit Care Med, 18, pp. 529-536, (1990); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Marshall J.K., Thabane M., Garg A.X., Et al., Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario, Aliment Pharmacol Ther, 20, pp. 1317-1322, (2004); Smecuol E., Bai J.C., Vazquez H., Et al., Gastrointestinal permeability in celiac disease, Gastroenterology, 112, pp. 1129-1136, (1997); van Elburg R.M., Uil J.J., Mulder C.J., Et al., Intestinal permeability in patients with coeliac disease and relatives of patients with coeliac disease, Gut, 34, pp. 354-357, (1993); Natividad J.M., Huang X., Slack E., Et al., Host responses to intestinal microbial antigens in gluten-sensitive mice, PLoS One, 4, (2009); Verdu E.F., Huang X., Natividad J., Et al., Gliadin-dependent neuromuscular and epithelial secretory responses in gluten-sensitive HLA-DQ8 transgenic mice, Am J Physiol Gastrointest Liver Physiol, 294, (2008); de Magistris L., Familiari V., Pascotto A., Et al., Alterations of the intestinal barrier in patients with autism spectrum disorders and in their first-degree relatives, J Pediatr Gastroenterol Nutr, 51, pp. 418-424, (2010); Pike M.G., Heddle R.J., Boulton P., Et al., Increased intestinal permeability in atopic eczema, J Invest Dermatol, 86, pp. 101-104, (1986); Jackson P.G., Lessof M.H., Baker R.W., Et al., Intestinal permeability in patients with eczema and food allergy, Lancet, 1, pp. 1285-1286, (1981); Ammori B.J., Leeder P.C., King R.F., Et al., Early increase in intestinal permeability in patients with severe acute pancreatitis: correlation with endotoxemia, organ failure, and mortality, J Gastrointest Surg, 3, pp. 252-262, (1999); Foitzik T., Fernandez-del Castillo C., Ferraro M.J., Et al., Pathogenesis and prevention of early pancreatic infection in experimental acute necrotizing pancreatitis, Ann Surg, 222, pp. 179-185, (1995); Ryan C.M., Schmidt J., Lewandrowski K., Et al., Gut macromolecular permeability in pancreatitis correlates with severity of disease in rats, Gastroenterology, 104, pp. 890-895, (1993); Foitzik T., Stufler M., Hotz H.G., Et al., Glutamine stabilizes intestinal permeability and reduces pancreatic infection in acute experimental pancreatitis, J Gastrointest Surg, 1, pp. 40-47, (1997); Salat-Foix D., Tran K., Ranawaya R., Et al., Increased intestinal permeability and Parkinson disease patients: chicken or egg?, Can J Neurol Sci, 39, pp. 185-188, (2012); Davies K.N., King D., Billington D., Et al., Intestinal permeability and orocaecal transit time in elderly patients with Parkinson's disease, Postgrad Med J, 72, pp. 164-167, (1996); Goebel A., Buhner S., Schedel R., Et al., Altered intestinal permeability in patients with primary fibromyalgia and in patients with complex regional pain syndrome, Rheumatology (Oxford), 47, pp. 1223-1227, (2008); Pimentel M., Wallace D., Hallegua D., Et al., A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath testing, Ann Rheum Dis, 63, pp. 450-452, (2004); Hijazi Z., Molla A.M., Al-Habashi H., Et al., Intestinal permeability is increased in bronchial asthma, Arch Dis Child, 89, pp. 227-229, (2004); Umetsu D.T., McIntire J.J., Akbari O., Et al., Asthma: an epidemic of dysregulated immunity, Nat Immunol, 3, pp. 715-720, (2002); Yacyshyn B., Meddings J., Sadowski D., Et al., Multiple sclerosis patients have peripheral blood CD45RO+ B cells and increased intestinal permeability, Dig Dis Sci, 41, pp. 2493-2498, (1996); Lee Y.K., Menezes J.S., Umesaki Y., Et al., Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis, Proc Natl Acad Sci U S A, 108, S1, pp. 4615-4622, (2011); Martinez-Gonzalez O., Cantero-Hinojosa J., Paule-Sastre P., Et al., Intestinal permeability in patients with ankylosing spondylitis and their healthy relatives, Br J Rheumatol, 33, pp. 644-647, (1994); Morris A.J., Howden C.W., Robertson C., Et al., Increased intestinal permeability in ankylosing spondylitis: primary lesion or drug effect?, Gut, 32, pp. 1470-1472, (1991); Taurog J.D., Richardson J.A., Croft J.T., Et al., The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats, J Exp Med, 180, pp. 2359-2364, (1994); Wu H.J., Ivanov I.I., Darce J., Et al., Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells, Immunity, 32, pp. 815-827, (2010); Wigg A.J., Roberts-Thomson I.C., Dymock R.B., Et al., The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis, Gut, 48, pp. 206-211, (2001); Farhadi A., Gundlapalli S., Shaikh M., Et al., Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis, Liver Int, 28, pp. 1026-1033, (2008); Cope K., Risby T., Diehl A.M., Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis, Gastroenterology, 119, pp. 1340-1347, (2000); Bergheim I., Weber S., Vos M., Et al., Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin, J Hepatol, 48, pp. 983-992, (2008); Keshavarzian A., Holmes E.W., Patel M., Et al., Leaky gut in alcoholic cirrhosis: a possible mechanism for alcohol-induced liver damage, Am J Gastroenterol, 94, pp. 200-207, (1999); Cesaro C., Tiso A., Del Prete A., Et al., Gut microbiota and probiotics in chronic liver diseases, Dig Liver Dis, 43, pp. 431-438, (2011); Kukuruzovic R.H., Brewster D.R., Small bowel intestinal permeability in Australian aboriginal children, J Pediatr Gastroenterol Nutr, 35, pp. 206-212, (2002); Kukuruzovic R., Robins-Browne R.M., Anstey N.M., Et al., Enteric pathogens, intestinal permeability and nitric oxide production in acute gastroenteritis, Pediatr Infect Dis J, 21, pp. 730-739, (2002); Ritchie B.K., Brewster D.R., Davidson G.P., Et al., 13C-sucrose breath test: novel use of a noninvasive biomarker of environmental gut health, Pediatrics, 124, pp. 620-626, (2009); Korpe P.S., Petri W.A., Environmental enteropathy: critical implications of a poorly understood condition, Trends Mol Med, 18, pp. 328-336, (2012); Kelly P., Menzies I., Crane R., Et al., Responses of small intestinal architecture and function over time to environmental factors in a tropical population, Am J Trop Med Hyg, 70, pp. 412-419, (2004); Brewster D.R., Manary M.J., Menzies I.S., Et al., Intestinal permeability in kwashiorkor, Arch Dis Child, 76, pp. 236-241, (1997); Lunn P.G., Northrop C.A., Wainwright M., Hypoalbuminemia in energy-malnourished rats infected with Nippostrongylus brasiliensis (Nematoda), J Nutr, 118, pp. 121-127, (1988); Smith M.I., Yatsunenko T., Manary M.J., Et al., Gut microbiomes of Malawian twin pairs discordant for Kwashiorkor, Science, 339, pp. 548-554, (2013)","J.R. Turner; Department of Pathology, The University of Chicago, Chicago, IL 60637, 5841 South Maryland, MC 1089, United States; email: jturner@bsd.uchicago.edu","","","","","","","","15423565","","CGHLA","23851019","English","Clin. Gastroenterol. Hepatol.","Article","Final","All Open Access; Hybrid Gold Open Access","Scopus","2-s2.0-84882797836"

"Daguet D.; Pinheiro I.; Verhelst A.; Possemiers S.; Marzorati M.","Daguet, David (6506368748); Pinheiro, Iris (56441265800); Verhelst, An (6602779093); Possemiers, Sam (6506792414); Marzorati, Massimo (12545508300)","6506368748; 56441265800; 6602779093; 6506792414; 12545508300","Acacia gum improves the gut barrier functionality in vitro","2015","Agro Food Industry Hi-Tech","26","4","","29","33","4","4","","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84943802525&partnerID=40&md5=4efd1d1c445e09f6deda5ca15dcf8106","NEXIRA SAS, 129 Chemin de Croisset, BP 4151, Rouen Cedex 3, 76723, France; ProDigest BVBA, Technologiepark 4, Ghent, 9052, Belgium; Laboratory of Microbial Ecology and Technology (LabMET), Ghent University, Coupure Links 653, Ghent, 9000, Belgium","Daguet D., NEXIRA SAS, 129 Chemin de Croisset, BP 4151, Rouen Cedex 3, 76723, France; Pinheiro I., ProDigest BVBA, Technologiepark 4, Ghent, 9052, Belgium; Verhelst A., ProDigest BVBA, Technologiepark 4, Ghent, 9052, Belgium; Possemiers S., ProDigest BVBA, Technologiepark 4, Ghent, 9052, Belgium; Marzorati M., Laboratory of Microbial Ecology and Technology (LabMET), Ghent University, Coupure Links 653, Ghent, 9000, Belgium","The Leaky Gut Syndrome - impairment of the gut wall functionality - is involved in many inflammatory diseases, among them IBS. The aim of this work was to evaluate the effect of arabinogalactan (AG) and fructo-oligosaccharides (FOS) on gut wall modulation using a Simulator of the Human Intestinal Microbial Ecosystem (SHIME®) - inoculated with faecal material from an IBS donor - coupled with co-cultures of enterocytes and macrophages (transwell approach using Caco-2 and THP1 cells). AG and FOS showed a different fermentation profile (more proximal for FOS and distal for AG) and both fibres exerted a potential positive effect on gut barrier (increased TEER parameter) and inflammation (modulation of cytokines IL-8, IL-6, IL-10 and NF-κB) in their main area of fermentation. AG could be an interesting nutritional supplement for the treatment of those conditions characterized by inflammation and increased permeability in the distal colon.","Colonic fermentation; Fibregum; Gut inflammation; Gut permeability; IBS; SHIME®","Fermentation; Modulation; Pathology; Arabinogalactan; Fibregum; Fructo-oligosaccharides; Gut inflammation; IBS; Inflammatory disease; Microbial eco system; Nutritional supplements; Food additives","","","","","","","Chey W.D., Maneerattaporn M., Saad R., Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome, Gut and Liver, 5, 3, pp. 253-266, (2011); Heitkemper M., Jarrett M., Jun S.E., Update on irritable bowel syndrome program of research, Journal of Korean Academy of Nursing, 43, 5, pp. 579-586, (2013); Guarner F., Casellas F., Borruel N., Et al., Role of microecology in chronic inflammatory bowel diseases, European Journal of Clinical Nutrition, 56, pp. S34-S38, (2002); Rescigno M., The intestinal epithelial barrier in the control of homeostasis and immunity, Trends Immunol, 32, 6, pp. 256-264, (2011); Gecse K., Roka R., Sera T., Et al., Leaky gut in patients with diarrhea-predominant irritable bowel syndrome and inactive ulcerative colitis, Digestion, 85, 1, pp. 40-46, (2012); Groschwitz K.R., Hogan S.P., Intestinal barrier function: Molecular regulation and disease pathogenesis, Journal of Allergy and Clinical Immunology, 124, 1, pp. 3-20, (2009); Maes M., Wisk F T., Chronic Fatigue Syndrome: La bete noire of the Belgian Health Care System, Neuroendocrinology Letters, 30, 3, pp. 300-311, (2009); Fasano A., Zonulin and its regulation of intestinal barrier function: The biological door to inflammation, autoimmunity, and cancer, Physiological Reviews, 91, 1, pp. 151-175, (2011); Camilleri M., Madsen K., Spiller R., Et al., Intestinal barrier function in health and gastrointestinal disease, Neurogastroenterology and Motility, 24, 6, pp. 503-512, (2012); Vaarala O., Atkinson M.A., Neu J., The ""perfect storm"" for type 1 diabetes - The complex interplay between intestinal microbiota, gut permeability, and mucosal immunity, Diabetes, 57, 10, pp. 2555-2562, (2008); Hartmann P., Chen P., Wang H.J., Et al., Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice, Hepatology, 58, 1, pp. 108-119, (2013); Fasano A., Leaky gut and autoimmune diseases, Clinical Reviews in Allergy & Immunology, 42, 1, pp. 71-78, (2012); Zhang Y.Z., Li Y.Y., Inflammatory bowel disease: Pathogenesis, World Journal of Gastroenterology, 20, 1, pp. 91-99, (2014); Major G., Spiller R., Irritable bowel syndrome, inflammatory bowel disease and the microbiome, Current Opinion in Endocrinology Diabetes and Obesity, 21, 1, pp. 15-21, (2014); Terpend K., Possemiers S., Daguet D., Et al., Arabinogalactan and fructo-oligosaccharides have a different fermentation profile in the Simulator of the Human Intestinal Microbial Ecosystem (SHIME), Environmental Microbiology Reports, 5, 4, pp. 595-603, (2013); Marzorati M., Qin B., Hildebrand F., Et al., Addition of acacia gum to a FOS/inulin blend improves its fermentation profile in the Simulator of the Human Intestinal Microbial Ecosystem (SHIME®), J Funct Food, 16, pp. 211-222, (2015); Possemiers S., Pinheiro I., Verhelst A., Et al., A Dried Yeast Fermentate Selectively Modulates both the Luminal and Mucosal Gut Microbiota and Protects against Inflammation, As Studied in an Integrated in Vitro Approach, Journal of Agricultural and Food Chemistry, 61, 39, pp. 9380-9392, (2013); Menzies A.R., Osman M.E., Malik A.A., Et al., A comparison of the physicochemical and immunological properties of the plant gum exudates of Acacia Senegal (gum Arabic) and Acacia seyal (gum tahla), Food Additives and Contaminants, 13, 8, pp. 991-999, (1996); Van De Wiel E.T., Boon N., Possemiers S., Et al., Prebiotic effects of chicory inulin in the simulator of the human intestinal microbial ecosystem, FEMS Microbiology Ecology, 51, pp. 143-153, (2004); Tsuchiya S., Kobayashi Y., Goto Y., Et al., Induction of Maturation in Cultured Human Monocytic Leukemia-Cells by a Phorbol Diester, Cancer Research, 42, 4, pp. 1530-1536, (1982); Schwende H., Fitzke E., Ambs P., Et al., Differences in the state of differentiation of THP-1 cells induced by phorbol ester and 1,25-dihydroxyvitamin D-3, Journal of Leukocyte Biology, 59, 4, pp. 555-561, (1996); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, 1-2, pp. 41-46, (2009); Wullaert A., Bonnet M.C., Pasparakis M., NF-kappa B in the regulation of epithelial homeostasis and inflammation, Cell Research, 21, 1, pp. 146-158, (2011); Pasparakis M., IKK/NF-kappa B signaling in intestinal epithelial cells controls immune homeostasis in the gut, Mucosal Immunology, 1, pp. S54-S57, (2008); Wong J.M.W., De Souza R., Kendall C.W.C., Et al., Colonic health: Fermentation and short chain fatty acids, Journal of Clinical Gastroenterology, 40, 3, pp. 235-243, (2006); Vinolo M.A.R., Rodrigues H.G., Nachbar R.T., Et al., Regulation of inflammation by short chain fatty acids, Nutrients, 3, 10, pp. 858-876, (2011); Puertollano E., Kolida S., Yaqoob P., Biological significance of shortchain fatty acid metabolism by the intestinal microbiome, Curr Opin Clin Nutr Metab Care, 17, 2, pp. 139-144, (2014)","","","TeknoScienze","","","","","","17226996","","","","English","Agro Food Ind. Hi-Tech","Article","Final","","Scopus","2-s2.0-84943802525"

"Martín R.; Chain F.; Miquel S.; Natividad J.M.; Sokol H.; Verdu E.F.; Langella P.; Bermúdez-Humarán L.G.","Martín, Rebeca (24179115600); Chain, Florian (15070399500); Miquel, Sylvie (23009469300); Natividad, Jane M. (23470366600); Sokol, Harry (14421842400); Verdu, Elena F. (8109011300); Langella, Philippe (7003598187); Bermúdez-Humarán, Luis G. (6602243913)","24179115600; 15070399500; 23009469300; 23470366600; 14421842400; 8109011300; 7003598187; 6602243913","Effects in the use of a genetically engineered strain of Lactococcus lactis delivering in situ IL-10 as a therapy to treat low-grade colon inflammation","2014","Human Vaccines and Immunotherapeutics","10","6","","1611","1621","10","68","10.4161/hv.28549","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84899876481&doi=10.4161%2fhv.28549&partnerID=40&md5=5ba60f9be4eef23f300f1b567ab9c6ce","INRA, Commensal and Probiotics-Host Interactions Laboratory, UMR 1319 Micalis, Jouy-en-Josas, France; AgroParisTech, UMR1319 Micalis, Jouy-en-Josas, France; Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada; Department of Gastroenterology and Nutrition, Hôpital Saint-Antoine F-75012, UPMC Univ Paris, Paris, France; INSERM, Equipe AVENIR U1057, UMR CNRS 7203, Paris, France","Martín R., INRA, Commensal and Probiotics-Host Interactions Laboratory, UMR 1319 Micalis, Jouy-en-Josas, France, AgroParisTech, UMR1319 Micalis, Jouy-en-Josas, France; Chain F., INRA, Commensal and Probiotics-Host Interactions Laboratory, UMR 1319 Micalis, Jouy-en-Josas, France, AgroParisTech, UMR1319 Micalis, Jouy-en-Josas, France; Miquel S., INRA, Commensal and Probiotics-Host Interactions Laboratory, UMR 1319 Micalis, Jouy-en-Josas, France, AgroParisTech, UMR1319 Micalis, Jouy-en-Josas, France; Natividad J.M., Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada; Sokol H., INRA, Commensal and Probiotics-Host Interactions Laboratory, UMR 1319 Micalis, Jouy-en-Josas, France, AgroParisTech, UMR1319 Micalis, Jouy-en-Josas, France, Department of Gastroenterology and Nutrition, Hôpital Saint-Antoine F-75012, UPMC Univ Paris, Paris, France, INSERM, Equipe AVENIR U1057, UMR CNRS 7203, Paris, France; Verdu E.F., Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada; Langella P., INRA, Commensal and Probiotics-Host Interactions Laboratory, UMR 1319 Micalis, Jouy-en-Josas, France, AgroParisTech, UMR1319 Micalis, Jouy-en-Josas, France; Bermúdez-Humarán L.G., INRA, Commensal and Probiotics-Host Interactions Laboratory, UMR 1319 Micalis, Jouy-en-Josas, France, AgroParisTech, UMR1319 Micalis, Jouy-en-Josas, France","Irritable bowel syndrome (IBS) is a gastrointestinal disorder characterized by chronic abdominal pain, discomfort, and bloating. Interestingly, there is now evidence of the presence of a low-grade inflammatory status in many IBS patients, including histopathological and mucosal cytokine levels in the colon, as well as the presence of IBS-like symptoms in quiescent inflammatory bowel disease (IBD). The use of a genetically engineered food-grade bacterium, such as Lactococcus lactis, secreting the anti-inflammatory cytokine IL-10 has been proven by many pre-clinical studies to be a successful therapy to treat colon inflammation. In this study, we first reproduced the recovery-recurrence periods observed in IBS-patients in a new chronic model characterized by 2 episodes of DiNitro-BenzeneSulfonic-acid (DNBS)-challenge and we tested the effects of a recombinant strain of L. lactis secreting IL-10 under a Stress-Inducible Controlled Expression (SICE) system. In vivo gut permeability, colonic serotonin levels, cytokine profiles, and spleen cell populations were then measured as readouts of a low-grade inflammation. In addition, since there is increasing evidence that gut microbiota tightly regulates gut barrier function, tight junction proteins were also measured by qRT-PCR after administration of recombinant L. lactis in DNBS-treated mice. Strikingly, oral administration of L. lactis secreting active IL-10 in mice resulted in significant protective effects in terms of permeability, immune activation, and gut-function parameters. Although genetically engineered bacteria are, for now, used only as a ""proof-of-concept,"" our study validates the interest in the use of the novel SICE system in L. lactis to express therapeutic molecules, such as IL-10, locally at mucosal surfaces. © 2014 Landes Bioscience.","Genetically engineered bacteria; Gut hyperpermeability; IBS; IL-10; Lactococcis lactis; Probiotic","Animals; Biological Therapy; Colitis; Cytokines; Disease Models, Animal; Gene Expression Profiling; Humans; Immunologic Factors; Immunotherapy; Interleukin-10; Lactococcus lactis; Male; Mice, Inbred C57BL; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Serotonin; Spleen; Treatment Outcome; claudin 4; interleukin 10; occludin; protein ZO1; serotonin; tight junction protein; uvomorulin; cytokine; immunologic factor; interleukin 10; recombinant protein; serotonin; animal cell; animal experiment; animal model; animal tissue; article; bacterial strain; cell population; colitis; controlled study; cytokine production; drug effect; immunostimulation; in vivo study; intestine mucosa permeability; Lactococcus lactis; male; mouse; nonhuman; nucleotide sequence; quantitative analysis; reverse transcription polymerase chain reaction; spleen cell; animal; biological therapy; C57BL mouse; colitis; disease model; gene expression profiling; genetics; growth, development and aging; human; immunology; immunotherapy; Lactococcus lactis; metabolism; pathology; procedures; real time polymerase chain reaction; spleen; treatment outcome","GENBANK: NM_008084, NM_008756, NM_009864, NM_009902, NM_009903, NM_013805, NM_016674, NM_016675, NM_021719, NM_172647","occludin, 176304-61-3; serotonin, 50-67-9; uvomorulin, 112956-45-3; Cytokines, ; Immunologic Factors, ; Interleukin-10, ; Recombinant Proteins, ; Serotonin, ","","","Merck Médication Familiale; Saint Etienne de Chomeil; Vitagora Competitive Cluster; Crohn's and Colitis Foundation of Canada, CCFC; Fonds Unique Interministériel, FUI, (F1010012D); Fonds Unique Interministériel, FUI; European Regional Development Fund, ERDF, (34606); European Regional Development Fund, ERDF","This study was a part of FPARIS collaborative project selected and supported by the Vitagora Competitive Cluster and funded by the French FUI (Fond Unique Interministériel; FUI: n°F1010012D), the FEDER (Fonds Européen de Développement Régional; Bourgogne: 34606), the Burgundy Region, the Conseil Général 21, and the Grand Dijon. This work was also supported by Merck Médication Familiale (Dijon, France) and Biovitis (Saint Etienne de Chomeil, France). R.M. receives a salary from the same grants. E.F.V. holds a Canada Research Chair. The work was partially funded by a CCFC grant to P.L. and E.F.V. Authors would like to thank Jean Jacques Gratadoux and all UEAR personal for their technical help.","Collins S.M., Is the irritable gut an inflamed gut?, Scand J Gastroenterol Suppl, 192, pp. 102-105, (1992); Khan S., Chang L., Diagnosis and management of IBS, Nat Rev Gastroenterol Hepatol, 7, pp. 565-581, (2010); Ford A.C., Talley N.J., Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: A systematic review, J Gastroenterol, 46, pp. 421-431, (2011); Ohman L., Simren M., New insights into the pathogenesis and pathophysiology of irritable bowel syndrome, Dig Liver Dis, 39, pp. 201-215, (2007); Marshall J.K., Thabane M., Garg A.X., Clark W., Meddings J., Collins S.M., Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario, Aliment Pharmacol Ther, 20, pp. 1317-1322, (2004); Akiho H., Ihara E., Nakamura K., Low-grade inflammation plays a pivotal role in gastrointestinal dysfunction in irritable bowel syndrome, World J Gastrointest Pathophysiol, 1, pp. 97-105, (2010); Vivinus-Nebot M., Frin-Mathy G., Bzioueche H., Dainese R., Bernard G., Anty R., Filippi J., Saint-Paul M.C., Tulic M.K., Verhasselt V., Et al., Functional bowel symptoms in quiescent inflammatory bowel diseases: Role of epithelial barrier disruption and low-grade inflammation, Gut, (2013); Halpin S.J., Ford A.C., Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: Systematic review and meta-analysis, Am J Gastroenterol, 107, pp. 1474-1482, (2012); Simren M., Axelsson J., Gillberg R., Abrahamsson H., Svedlund J., Bjornsson E.S., Quality of life in inflammatory bowel disease in remission: The impact of IBS-like symptoms and associated psychological factors, Am J Gastroenterol, 97, pp. 389-396, (2002); Bermudez-Humaran L.G., Aubry C., Motta J.P., Deraison C., Steidler L., Vergnolle N., Chatel J.M., Langella P., Engineering lactococci and lactobacilli for human health, Curr Opin Microbiol, 16, pp. 278-283, (2013); Seegers J.F., Lactobacilli as live vaccine delivery vectors: Progress and prospects, Trends Biotechnol, 20, pp. 508-515, (2002); Lee S.F., Halperin S.A., Salloum D.F., MacMillan A., Morris A., Mucosal immunization with a genetically engineered pertussis toxin S1 fragment-cholera toxin subunit B chimeric protein, Infect Immun, 71, pp. 2272-2275, (2003); Cortes-Perez N.G., Bermudez-Humaran L.G., Le Loir Y., Rodriguez-Padilla C., Gruss A., Saucedo-Cardenas O., Langella P., Montes-de-Oca-Luna R., Mice immunization with live lactococci displaying a surface anchored HPV-16 E7 oncoprotein, FEMS Microbiol Lett, 229, pp. 37-42, (2003); Bermudez-Humaran L.G., Langella P., Cortes-Perez N.G., Gruss A., Tamez-Guerra R.S., Oliveira S.C., Saucedo-Cardenas O., Montes De Oca-Luna R., Le Loir Y., Intranasal immunization with recombinant Lactococcus lactis secreting murine interleukin-12 enhances antigen-specific Th1 cytokine production, Infect Immun, 71, pp. 1887-1896, (2003); Bermudez-Humaran L.G., Cortes-Perez N.G., Le Loir Y., Alcocer-Gonzalez J.M., Tamez-Guerra R.S., De Oca-Luna R.M., Langella P., An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci, J Med Microbiol, 53, pp. 427-433, (2004); Grangette C., Muller-Alouf H., Goudercourt D., Geoffroy M.C., Turneer M., Mercenier A., Mucosal immune responses and protection against tetanus toxin after intranasal immunization with recombinant Lactobacillus plantarum, Infect Immun, 69, pp. 1547-1553, (2001); Kruger C., Hu Y., Pan Q., Marcotte H., Hultberg A., Delwar D., Van Dalen P.J., Pouwels P.H., Leer R.J., Kelly C.G., Et al., In situ delivery of passive immunity by lactobacilli producing single-chain antibodies, Nat Biotechnol, 20, pp. 702-706, (2002); Robinson K., Chamberlain L.M., Schofield K.M., Wells J.M., Le Page R.W., Oral vaccination of mice against tetanus with recombinant Lactococcus lactis, Nat Biotechnol, 15, pp. 653-657, (1997); Steidler L., Neirynck S., Huyghebaert N., Snoeck V., Vermeire A., Goddeeris B., Cox E., Remon J.P., Remaut E., Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10, Nat Biotechnol, 21, pp. 785-789, (2003); Steidler L., Hans W., Schotte L., Neirynck S., Obermeier F., Falk W., Fiers W., Remaut E., Treatment of murine colitis by Lactococcus lactis secreting interleukin-10, Science, 289, pp. 1352-1355, (2000); Schotte L., Steidler L., Vandekerckhove J., Remaut E., Secretion of biologically active murine interleukin-10 by Lactococcus lactis, Enzyme Microb Technol, 27, pp. 761-765, (2000); Benbouziane B., Ribelles P., Aubry C., Martin R., Kharrat P., Riazi A., Langella P., Bermudez-Humaran L.G., Development of a Stress-Inducible Controlled Expression (SICE) system in Lactococcus lactis for the production and delivery of therapeutic molecules at mucosal surfaces, J Biotechnol, 168, pp. 120-129, (2013); Martin R., Chain F., Miquel S., Lu J., Gratadoux J.J., Sokol H., Verdu E.F., Bercik P., Bermudez-Humaran L.G., Langella P., The commensal bacterium Faecalibacterium prausnitzii is protective in DNBS-induced chronic moderate and severe colitis models, Inflamm Bowel Dis, 20, pp. 417-430, (2014); Martin R., Miquel S., Ulmer J., Kechaou N., Langella P., Bermudez-Humaran L.G., Role of commensal and probiotic bacteria in human health: A focus on inflammatory bowel disease, Microb Cell Fact, 12, (2013); Motta J.P., Bermudez-Humaran L.G., Deraison C., Martin L., Rolland C., Rousset P., Boue J., Dietrich G., Chapman K., Kharrat P., Et al., Food-grade bacteria expressing elafin protect against inflammation and restore colon homeostasis, Sci Transl Med, 4, (2012); Galipeau H.J., Wiepjes M., Motta J.P., Schulz J.D., Jury J., Natividad J.M., Pinto-Sanchez I., Sinclair D., Rousset P., Martin-Rosique R., Et al., Novel Role of the Serine Protease Inhibitor Elafin in Gluten-Related Disorders, Am J Gastroenterol, (2014); Foligne B., Dessein R., Marceau M., Poiret S., Chamaillard M., Pot B., Simonet M., Daniel C., Prevention and treatment of colitis with Lactococcus lactis secreting the immunomodulatory Yersinia LcrV protein, Gastroenterology, 133, pp. 862-874, (2007); Smelt M.J., De Haan B.J., Bron P.A., Van Swam I., Meijerink M., Wells J.M., Faas M.M., De Vos P., L. Plantarum, L. Salivarius, and L. Lactis attenuate Th2 responses and increase Treg frequencies in healthy mice in a strain dependent manner, PLoS One, 7, (2012); Bermudez-Humaran L.G., Cortes-Perez N.G., Lefevre F., Guimaraes V., Rabot S., Alcocer-Gonzalez J.M., Gratadoux J.J., Rodriguez-Padilla C., Tamez-Guerra R.S., Corthier G., Et al., A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors, J Immunol, 175, pp. 7297-7302, (2005); Shashidharamurthy R., Machiah D., Aitken J.D., Putty K., Srinivasan G., Chassaing B., Parkos C.A., Selvaraj P., Vijay-Kumar M., Differential role of lipocalin 2 during immune complex-mediated acute and chronic inflammation in mice, Arthritis Rheum, 65, pp. 1064-1073, (2013); Vijay-Kumar M., Wu H., Jones R., Grant G., Babbin B., King T.P., Kelly D., Gewirtz A.T., Neish A.S., Flagellin suppresses epithelial apoptosis and limits disease during enteric infection, Am J Pathol, 169, pp. 1686-1700, (2006); Miyauchi E.M.H., Morita H., Tanabe S., Lactobacillus rhamnosus alleviates intestinal barrier dysfunction in part by increasing expression of zonula occludens-1 and myosin light-chain kinase in vivo, J Dairy Sci, 92, pp. 2400-2408, (2009); Mennigen R.N.K., Nolte K., Rijcken E., Utech M., Loeffler B., Senninger N., Bruewer M., Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis, Am J Physiol Gastrointest Liver Physiol, 296, (2009); Coates M.D., Johnson A.C., Greenwood-Van Meerveld B., Mawe G.M., Effects of serotonin transporter inhibition on gastrointestinal motility and colonic sensitivity in the mouse, Neurogastroenterol Motil, 18, pp. 464-471, (2006); Khan W.I., Ghia J.E., Gut hormones: Emerging role in immune activation and inflammation, Clin Exp Immunol, 161, pp. 19-27, (2010); Bertrand P.P., Barajas-Espinosa A., Neshat S., Bertrand R.L., Lomax A.E., Analysis of real-time serotonin (5-HT) availability during experimental colitis in mouse, Am J Physiol Gastrointest Liver Physiol, 298, (2010); Qin H.Y., Xiao H.T., Wu J.C., Berman B.M., Sung J.J., Bian Z.X., Key factors in developing the trinitrobenzene sulfonic acid-induced post-inflammatory irritable bowel syndrome model in rats, World J Gastroenterol, 18, pp. 2481-2492, (2012); Wallace J.L., Le T., Carter L., Appleyard C.B., Beck P.L., Hapten-induced chronic colitis in the rat: Alternatives to trinitrobenzene sulfonic acid, J Pharmacol Toxicol Methods, 33, pp. 237-239, (1995); Appleyard C.B., Wallace J.L., Reactivation of hapten-induced colitis and its prevention by anti-inflammatory drugs, Am J Physiol, 269, (1995); Qiu B.S., Vallance B.A., Blennerhassett P.A., Collins S.M., The role of CD4+ lymphocytes in the susceptibility of mice to stress-induced reactivation of experimental colitis, Nat Med, 5, pp. 1178-1182, (1999); Cooper H.S., Murthy S.N., Shah R.S., Sedergran D.J., Clinicopathologic study of dextran sulfate sodium experimental murine colitis, Lab Invest, 69, pp. 238-249, (1993); Bradley P.P., Priebat D.A., Christensen R.D., Rothstein G., Measurement of cutaneous inflammation: Estimation of neutrophil content with an enzyme marker, J Invest Dermatol, 78, pp. 206-209, (1982); Tambuwala M.M., Cummins E.P., Lenihan C.R., Kiss J., Stauch M., Scholz C.C., Fraisl P., Lasitschka F., Mollenhauer M., Saunders S.P., Et al., Loss of prolyl hydroxylase-1 protects against colitis through reduced epithelial cell apoptosis and increased barrier function, Gastroenterology, 139, pp. 2093-2101, (2010)","L.G. Bermúdez-Humarán; INRA, Commensal and Probiotics-Host Interactions Laboratory, UMR 1319 Micalis, Jouy-en-Josas, France; email: luis.bermudez@jouy.inra.fr","","Landes Bioscience","","","","","","21645515","","","24732667","English","Hum. Vaccines Immunother.","Article","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-84899876481"

"Ko S.J.; Ryu B.; Kim J.; Hong B.G.; Yeo I.; Lee B.J.; Lee J.M.; Park J.W.","Ko, Seok-Jae (52363719300); Ryu, Bongha (36444287400); Kim, Jinsung (57203251776); Hong, Beom-Gi (52363710000); Yeo, Inkwon (8209765300); Lee, Beom-Joon (35299944200); Lee, Jin-Moo (54792039400); Park, Jae-Woo (57193414960)","52363719300; 36444287400; 57203251776; 52363710000; 8209765300; 35299944200; 54792039400; 57193414960","Effect of herbal extract granules combined with probiotic mixture on irritable bowel syndrome with diarrhea: study protocol for a randomized controlled trial.","2011","Trials","12","","219","219","","","18","10.1186/1745-6215-12-219","https://www.scopus.com/inward/record.uri?eid=2-s2.0-80053532829&doi=10.1186%2f1745-6215-12-219&partnerID=40&md5=2c054747cf3c9a7bf0b7a89bbeea16d6","Department of Internal Medicine, College of Oriental Medicine, Kyung Hee University, Seoul, Republic of Korea.","Ko S.J., Department of Internal Medicine, College of Oriental Medicine, Kyung Hee University, Seoul, Republic of Korea.; Ryu B.; Kim J.; Hong B.G.; Yeo I.; Lee B.J.; Lee J.M.; Park J.W.","Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by abdominal pain and change of bowel habits without organic disease. Many patients seek alternative IBS treatments because of the limitations of conventional treatments. Gwakhyangjeonggisan (GJS), a herbal formula, has long been used for alleviating diarrhea-predominant IBS (D-IBS) in traditional medicine. Duolac7S, which comprises 7 bacterial species as probiotics, has been frequently used for D-IBS. Although GJS and Duolac7S have been administered simultaneously in many D-IBS patients, no study has investigated the effects of GJS and Duolac7S combination therapy on D-IBS. The current trial is a randomized, double-blinded, placebo-controlled, 4-arm study. After a 2-week run-in period, 60 patients with D-IBS will be randomly assigned to one of the 4 combination groups consisting of GJS (water extract granules, 3 g/pack, 3 times a day) with Duolac7S (powder form, 1 capsule, 2 times a day) or their placebos and followed up for 2 weeks. The assigned treatments will last for 8 weeks. The primary outcomes are adequate relief of IBS pain and discomfort and the proportion of responders (on a weekly basis). The secondary outcomes are visual analog scale for IBS symptoms (on a daily basis), quality of life (at 0, 8, and 10 weeks), intestinal permeability, and composition of intestinal microbiota (at 0 and 8 weeks). The present study is designed to examine the safety and efficacy of GJS and Duolac7S combination therapy on D-IBS. Our study provides the clinical evidence of a new therapeutic strategy for D-IBS.","","Adolescent; Adult; Aged; Clinical Protocols; Diarrhea; Double-Blind Method; Humans; Intestines; Irritable Bowel Syndrome; Middle Aged; Outcome Assessment (Health Care); Permeability; Plant Extracts; Probiotics; plant extract; probiotic agent; MLCS; MLOWN; adolescent; adult; aged; article; clinical protocol; clinical trial; controlled clinical trial; controlled study; diarrhea; double blind procedure; human; intestine; irritable colon; metabolism; microbiology; middle aged; outcome assessment; permeability; randomized controlled trial","","Plant Extracts, ","","","Cell Biotech Co., Ltd., (2011CBT-001)","The study was sponsored by Cell Biotech Co., Ltd., Seoul, Korea (2011CBT-001).","","","","","","","","","","17456215","","","21978382","English","Trials","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-80053532829"

"Jalanka-Tuovinen J.; Salojärvi J.; Salonen A.; Immonen O.; Garsed K.; Kelly F.M.; Zaitoun A.; Palva A.; Spiller R.C.; De Vos W.M.","Jalanka-Tuovinen, Jonna (56502248200); Salojärvi, Jarkko (12140977600); Salonen, Anne (22935234500); Immonen, Outi (36193970000); Garsed, Klara (15845718400); Kelly, Fiona M. (14830570700); Zaitoun, Abed (35497124700); Palva, Airi (7005149835); Spiller, Robin C. (7005287882); De Vos, Willem M. (35495729400)","56502248200; 12140977600; 22935234500; 36193970000; 15845718400; 14830570700; 35497124700; 7005149835; 7005287882; 35495729400","Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome","2014","Gut","63","11","","1737","1745","8","252","10.1136/gutjnl-2013-305994","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84890985732&doi=10.1136%2fgutjnl-2013-305994&partnerID=40&md5=34b859625838f56aaaa35f2cd26d7a13","Department of Veterinary Biosciences, Microbiology, University of Helsinki, PO Box 66, Helsinki, FI-00014, Finland; Department of Bacteriology and Immunology, University of Helsinki, Helsinki, Finland; NIHR Biomedical Research Unit, Nottingham Digestive Diseases Centre, University Hospital, Nottingham, United Kingdom; GSK Research and Development Ltd., GlaxoSmithKline, Stevenage, United Kingdom; Laboratory of Microbiology, Wageningen University, Wageningen, Netherlands","Jalanka-Tuovinen J., Department of Veterinary Biosciences, Microbiology, University of Helsinki, PO Box 66, Helsinki, FI-00014, Finland; Salojärvi J., Department of Veterinary Biosciences, Microbiology, University of Helsinki, PO Box 66, Helsinki, FI-00014, Finland; Salonen A., Department of Bacteriology and Immunology, University of Helsinki, Helsinki, Finland; Immonen O., Department of Veterinary Biosciences, Microbiology, University of Helsinki, PO Box 66, Helsinki, FI-00014, Finland; Garsed K., NIHR Biomedical Research Unit, Nottingham Digestive Diseases Centre, University Hospital, Nottingham, United Kingdom; Kelly F.M., GSK Research and Development Ltd., GlaxoSmithKline, Stevenage, United Kingdom; Zaitoun A., NIHR Biomedical Research Unit, Nottingham Digestive Diseases Centre, University Hospital, Nottingham, United Kingdom; Palva A., Department of Veterinary Biosciences, Microbiology, University of Helsinki, PO Box 66, Helsinki, FI-00014, Finland; Spiller R.C., NIHR Biomedical Research Unit, Nottingham Digestive Diseases Centre, University Hospital, Nottingham, United Kingdom; De Vos W.M., Department of Veterinary Biosciences, Microbiology, University of Helsinki, PO Box 66, Helsinki, FI-00014, Finland, Department of Bacteriology and Immunology, University of Helsinki, Helsinki, Finland, Laboratory of Microbiology, Wageningen University, Wageningen, Netherlands","Results Microbiota analysis revealed a bacterial profile of 27 genus-like groups, providing an Index of Microbial Dysbiosis (IMD), which significantly separated patient groups and controls. Within this profile, several members of Bacteroidetes phylum were increased 12-fold in patients, while healthy controls had 35-fold more uncultured Clostridia. We showed correlations between the IMD and expression of several host gene pathways, including amino acid synthesis, cell junction integrity and inflammatory response, suggesting an impaired epithelial barrier function in IBS.; Background About 10% of patients with IBS report the start of the syndrome after infectious enteritis. The clinical features of postinfectious IBS (PI-IBS) resemble those of diarrhoea-predominant IBS (IBS-D). While altered faecal microbiota has been identified in other IBS subtypes, composition of the microbiota in patients with PI-IBS remains uncharacterised.; Objective To characterise the microbial composition of patients with PI-IBS, and to examine the associations between the faecal microbiota and a patient's clinical features.; Design Using a phylogenetic microarray and selected qPCR assays, we analysed differences in the faecal microbiota of 57 subjects from five study groups: patients with diagnosed PI-IBS, patients who 6 months after gastroenteritis had either persisting bowel dysfunction or no IBS symptoms, benchmarked against patients with IBS-D and healthy controls. In addition, the associations between the faecal microbiota and health were investigated by correlating the microbial profiles to immunological markers, quality of life indicators and host gene expression in rectal biopsies.; Conclusions The faecal microbiota of patients with PI-IBS differs from that of healthy controls and resembles that of patients with IBS-D, suggesting a common pathophysiology. Moreover, our analysis suggests a variety of host-microbe associations that may underlie intestinal symptoms, initiated by gastroenteritis.","","Adult; Feces; Female; Gastroenteritis; Gene Expression Profiling; Humans; Irritable Bowel Syndrome; Male; Microbiota; Middle Aged; Receptor Cross-Talk; adult; feces; female; gastroenteritis; gene expression profiling; human; Irritable Bowel Syndrome; male; microbiology; microflora; middle aged; pathophysiology; physiology; signal transduction","","","","","GlaxoSmithKline; Suomen Akatemia, (1141130, 118602, 137389, 141140)","","Spiller R., Aziz Q., Creed F., Et al., Guidelines on the irritable bowel syndrome: Mechanisms and practical management, Gut, 56, pp. 1770-1798, (2007); Camilleri M., Peripheral mechanisms in irritable bowel syndrome, N Engl J Med, 367, pp. 1626-1635, (2012); Saito Y.A., Mitra N., Mayer E.A., Genetic approaches to functional gastrointestinal disorders, Gastroenterology, 138, pp. 1276-1285, (2010); Koloski N.A., Jones M., Kalantar J., Et al., The brain-gut pathway in functional gastrointestinal disorders is bidirectional: A 12-year prospective population-based study, Gut, 61, pp. 1284-1290, (2012); Rodriguez L.A., Ruigomez A., Increased risk of irritable bowel syndrome after bacterial gastroenteritis: Cohort study, BMJ, 318, pp. 565-566, (1999); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Camilleri M., Madsen K., Spiller R., Et al., Intestinal barrier function in health and gastrointestinal disease, Neurogastroenterol Motil, 24, pp. 503-512, (2012); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Lupp C., Robertson M.L., Wickham M.E., Et al., Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae, Cell Host Microbe, 2, pp. 119-129, (2007); Rao S.S., Edwards C.A., Austen C.J., Et al., Impaired colonic fermentation of carbohydrate after ampicillin, Gastroenterology, 94, pp. 928-932, (1988); Dunlop S.P., Jenkins D., Neal K.R., Et al., Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS, Gastroenterology, 125, pp. 1651-1659, (2003); Neal K.R., Barker L., Spiller R.C., Prognosis in post-infective irritable bowel syndrome: A six year follow up study, Gut, 51, pp. 410-413, (2002); Salonen A., De Vos W.M., Palva A., Gastrointestinal microbiota in irritable bowel syndrome: Present state and perspectives, Microbiology, 156, pp. 3205-3215, (2010); Jeffery I.B., O'toole P.W., Ohman L., Et al., An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota, Gut, 61, pp. 997-1006, (2012); Swan C., Duroudier N.P., Campbell E., Et al., Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): Association with TNFSF15 and TNFalpha, Gut, 62, pp. 985-994, (2013); Melzack R., The McGill Pain Questionnaire: Major properties and scoring methods, Pain, 1, pp. 277-299, (1975); Zigmond A.S., Snaith R.P., The hospital anxiety and depression scale, Acta Psychiatr Scand, 67, pp. 361-370, (1983); Spiller R.C., Humes D.J., Campbell E., Et al., The Patient Health Questionnaire 12 Somatic Symptom scale as a predictor of symptom severity and consulting behaviour in patients with irritable bowel syndrome and symptomatic diverticular disease, Aliment Pharmacol Ther, 32, pp. 811-820, (2010); Talley N.J., Phillips S.F., Melton J., Et al., A patient questionnaire to identify bowel disease, Ann Intern Med, 111, pp. 671-674, (1989); Irizarry R.A., Bolstad B.M., Collin F., Et al., Summaries of Affymetrix GeneChip probe level data, Nucleic Acids Res, 31, (2003); Dai M., Wang P., Boyd A.D., Et al., Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data, Nucleic Acids Res, 33, (2005); Salonen A., Nikkila J., Jalanka-Tuovinen J., Et al., Comparative analysis of fecal DNA extraction methods with phylogenetic microarray: Effective recovery of bacterial and archaeal DNA using mechanical cell lysis, J Microbiol Methods, 81, pp. 127-134, (2010); Rajilic-Stojanovic M., Heilig H.G., Molenaar D., Et al., Development and application of the human intestinal tract chip, a phylogenetic microarray: Analysis of universally conserved phylotypes in the abundant microbiota of young and elderly adults, Environ Microbiol, 11, pp. 1736-1751, (2009); Jalanka-Tuovinen J., Salonen A., Nikkila J., Et al., Intestinal microbiota in healthy adults: Temporal analysis reveals individual and common core and relation to intestinal symptoms, PLoS ONE, 6, (2011); Claesson M.J., O'sullivan O., Wang Q., Et al., Comparative analysis of pyrosequencing and a phylogenetic microarray for exploring microbial community structures in the human distal intestine, PLoS ONE, 4, (2009); Ufnar J.A., Wang S.Y., Christiansen J.M., Et al., Detection of the nifH gene of Methanobrevibacter smithii: A potential tool to identify sewage pollution in recreational waters, J Appl Microbiol, 101, pp. 44-52, (2006); Rinttila T., Kassinen A., Malinen E., Et al., Development of an extensive set of 16S rDNA-targeted primers for quantification of pathogenic and indigenous bacteria in faecal samples by real-time PCR, J Appl Microbiol, 97, pp. 1166-1177, (2004); Kassinen A., Krogius-Kurikka L., Makivuokko H., Et al., The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects, Gastroenterology, 133, pp. 24-33, (2007); Development C.T., R: A language and environment for statistical computing, Vienna Austria: R Foundation for Statistical Computing, (2012); Efron B., Tibshirani R., Improvements on cross-validation: The .632+ bootstrap method, J Am Stat Assoc, 92, pp. 548-560, (1997); Lozupone C., Knight R., UniFrac: A new phylogenetic method for comparing microbial communities, Appl Environ Microbiol, 71, pp. 8228-8235, (2005); Efron B., Tibshirani R., On testing the significance of sets of genes, Ann Appl Stat, 1, pp. 107-129, (2007); Subramanian A., Tamayo P., Mootha V.K., Et al., Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles, Proc Natl Acad Sci USA, 102, pp. 15545-15550, (2005); Caldas J., Gehlenborg N., Faisal A., Et al., Probabilistic retrieval and visualization of biologically relevant microarray experiments, Bioinformatics, 25, pp. i145-i153, (2009); Hansson G.C., Role of mucus layers in gut infection and inflammation, Curr Opin Microbiol, 15, pp. 57-62, (2012); Cunningham K.E., Turner J.R., Myosin light chain kinase: Pulling the strings of epithelial tight junction function, Ann N y Acad Sci, 1258, pp. 34-42, (2012); Gwee K.A., Leong Y.L., Graham C., Et al., The role of psychological and biological factors in postinfective gut dysfunction, Gut, 44, pp. 400-406, (1999); Kashyap P.C., Marcobal A., Ursell L.K., Et al., Complex interactions among diet, gastrointestinal transit, and gut microbiota in humanized mice, Gastroenterology, 144, pp. 967-977, (2013); Kunkel D., Basseri R.J., Makhani M.D., Et al., Methane on breath testing is associated with constipation: A systematic review, Dig Dis Sci, 56, pp. 1612-1618, (2011); Ponnusamy K., Choi J.N., Kim J., Et al., Microbial community and metabolomic comparison of irritable bowel syndrome faeces, J Med Microbiol, 60, pp. 817-827, (2011); Parkes G.C., Rayment N.B., Hudspith B.N., Et al., Distinct microbial populations exist in the mucosa-associated microbiota of sub-groups of irritable bowel syndrome, Neurogastroenterol Motil, 24, pp. 31-39, (2012); Manichanh C., Eck A., Varela E., Et al., Anal gas evacuation and colonic microbiota in patients with flatulence: Effect of diet, Gut, 63, pp. 401-408, (2014); Rajilic-Stojanovic M., Biagi E., Heilig H.G., Et al., Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome, Gastroenterology, 141, pp. 1792-1801, (2011); Krogius-Kurikka L., Lyra A., Malinen E., Et al., Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers, BMC Gastroenterol, 9, (2009); Malinen E., Krogius-Kurikka L., Lyra A., Et al., Association of symptoms with gastrointestinal microbiota in irritable bowel syndrome, World J Gastroenterol, 16, pp. 4532-4540, (2010); Chadwick V.S., Chen W., Shu D., Et al., Activation of the mucosal immune system in irritable bowel syndrome, Gastroenterology, 122, pp. 1778-1783, (2002); Spiller R., Garsed K., Postinfectious irritable bowel syndrome, Gastroenterology, 136, pp. 1979-1988, (2009); Mudter J., Neurath M.F., Apoptosis of T cells and the control of inflammatory bowel disease: Therapeutic implications, Gut, 56, pp. 293-303, (2007); Faure M., Moennoz D., Montigon F., Et al., Dietary threonine restriction specifically reduces intestinal mucin synthesis in rats, J Nutr, 135, pp. 486-491, (2005); Wrzosek L., Miquel S., Noordine M.L., Et al., Bacteroides thetaiotaomicron and Faecalibacterium prausnitzii influence the production of mucus glycans and the development of goblet cells in the colonic epithelium of a gnotobiotic model rodent, BMC Biology, 11, (2013); Manning A.P., Thompson W.G., Heaton K.W., Et al., Towards positive diagnosis of the irritable bowel, Br Med J, 2, pp. 653-654, (1978); O'malley D., Julio-Pieper M., Gibney S.M., Et al., Distinct alterations in colonic morphology and physiology in two rat models of enhanced stress-induced anxiety and depression-like behaviour, Stress, 13, pp. 114-122, (2010)","","","BMJ Publishing Group","","","","","","00175749","","GUTTA","24310267","English","Gut","Article","Final","","Scopus","2-s2.0-84890985732"

"Fernández-Blanco J.A.; Hollenberg M.D.; Martínez V.; Vergara P.","Fernández-Blanco, Juan A. (53981356600); Hollenberg, Morley D. (35458973200); Martínez, Vicente (35466861100); Vergara, Patri (7006757890)","53981356600; 35458973200; 35466861100; 7006757890","PAR-2-mediated control of barrier function and motility differs between early and late phases of postinfectious gut dysfunction in the rat","2013","American Journal of Physiology - Gastrointestinal and Liver Physiology","304","4","","G390","G400","10","17","10.1152/ajpgi.00387.2012","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84874056757&doi=10.1152%2fajpgi.00387.2012&partnerID=40&md5=56f4c9ee1c09f810897c9a708a8b81c9","Department of Cell Biology, Physiology and Immunology, Veterinary School, Universitat Autònoma de Barcelona, Barcelona, Spain; School of Biosciences, Universitat Autònoma de Barcelona, Barcelona, Spain; Instituto de Neurociencias, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Physiology and Pharmacology and Department of Medicine, Faculty of Medicine, University of Calgary, AB, Canada; Centro de Investigacion Biomédica en Red de Enfermedades Hepaticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain","Fernández-Blanco J.A., Department of Cell Biology, Physiology and Immunology, Veterinary School, Universitat Autònoma de Barcelona, Barcelona, Spain; Hollenberg M.D., Department of Physiology and Pharmacology and Department of Medicine, Faculty of Medicine, University of Calgary, AB, Canada; Martínez V., Department of Cell Biology, Physiology and Immunology, Veterinary School, Universitat Autònoma de Barcelona, Barcelona, Spain, School of Biosciences, Universitat Autònoma de Barcelona, Barcelona, Spain, Instituto de Neurociencias, Universitat Autònoma de Barcelona, Barcelona, Spain, Centro de Investigacion Biomédica en Red de Enfermedades Hepaticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain; Vergara P., Department of Cell Biology, Physiology and Immunology, Veterinary School, Universitat Autònoma de Barcelona, Barcelona, Spain, Instituto de Neurociencias, Universitat Autònoma de Barcelona, Barcelona, Spain, Centro de Investigacion Biomédica en Red de Enfermedades Hepaticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain","Proteinase-activated receptor-2 (PAR-2) and mast cell (MC) mediators contribute to inflammatory and functional gastrointestinal disorders. We aimed to characterize jejunal PAR-2-mediated responses and the potential MC involvement in the early and late phases of a rat model of postinfectious gut dysfunction. Jejunal tissues of control and Trichinella spiralis-infected (14 and 30 days postinfection) rats, treated or not with the MC stabilizer, ketotifen, were used. Histopathology and immunostaining were used to characterize inflammation, PAR-2 expression, and mucosal and connective tissue MCs. Epithelial barrier function (hydroelectrolytic transport and permeability) and motility were assessed in vitro in basal conditions and after PAR-2 activation. Intestinal inflammation on day 14 postinfection (early phase) was significantly resolved by day 30 (late phase) although MC counts and epithelial permeability remained increased. PAR-2-mediated ion transport (Ussing chambers, in vitro) and epithelial surface PAR-2 expression were reduced in the early phase, with a trend toward normalization during the late phase. In control conditions, PAR-2 activation (organ bath) induced biphasic motor responses (relaxation followed by excitation). At 14 days postinfection, spontaneous contractility and PAR-2-mediated relaxations were enhanced; motor responses were normalized on day 30. Postinfectious changes in PAR-2 functions were not affected by ketotifen treatment. We concluded that, in the rat model of Trichinella spiralis infection, alterations of intestinal PAR-2 function and expression depend on the inflammatory phase considered. A lack of a ketotifen effect suggests no interplay between MCs and PAR-2-mediated motility and ion transport alterations. These observations question the role of MC mediators in PAR-2-modulating postinfectious gut dysfunction. © 2013 the American Physiological Society.","Functional gastrointestinal disorders; Irritable bowel syndrome; Ketotifen; Mast cell; Proteinase-activated receptors","Animals; Gastroenteritis; Gastrointestinal Motility; Gastrointestinal Tract; Ketotifen; Male; Mast Cells; Muscle Contraction; Permeability; Rats; Rats, Sprague-Dawley; Receptor, PAR-2; Trichinella spiralis; Trichinellosis; ketotifen; proteinase activated receptor 2; animal experiment; animal model; animal tissue; article; controlled study; enteritis; enteropathy; histopathology; immunohistochemistry; inflammation; intestine motility; ion transport; male; mast cell; nonhuman; postinfectious gut dysfunction; priority journal; protein expression; rat; Trichinella spiralis; trichinosis","","ketotifen, 34580-13-7; Ketotifen, 34580-13-7; Receptor, PAR-2, ","","","","","Adams M.N., Ramachandran R., Yau M.K., Suen J.Y., Fairlie D.P., Hollenberg M.D., Hooper J.D., Structure, function and pathophysiology of protease activated receptors, Pharmacol Ther, 130, pp. 248-282, (2011); Al-Ani B., Saifeddine M., Kawabata A., Renaux B., Mokashi S., Hollenberg M.D., Proteinase-activated receptor 2 (PAR2): Development of a ligand-binding assay correlating with activation of PAR(2) by PAR(1)-and PAR(2)-derived peptide ligands, J Pharmacol Exp Ther, 290, pp. 753-760, (1999); Bures J., Cyrany J., Kohoutova D., Forstl M., Rejchrt S., Kvetina J., Vorisek V., Kopacova M., Small intestinal bacterial overgrowth syndrome, World J Gastroenterol, 16, pp. 2978-2990, (2010); Castro G.A., Fairbairn D., Carbohydrates and lipids in Trichinella spiralis larvae and their utilization in vitro, J Parasitol, 55, pp. 51-58, (1969); Cenac N., Andrews C.N., Holzhausen M., Chapman K., Cottrell G., Andrade-Gordon P., Steinhoff M., Barbara G., Beck P., Bunnett N.W., Sharkey K.A., Ferraz J.G., Shaffer E., Vergnolle N., Role for protease activity in visceral pain in irritable bowel syndrome, J Clin Invest, 117, pp. 636-647, (2007); Compton S.J., McGuire J.J., Saifeddine M., Hollenberg M.D., Restricted ability of human mast cell tryptase to activate proteinase-activated receptor-2 in rat aorta, Can J Physiol Pharmacol, 80, pp. 987-992, (2002); de Giorgio R., Barbara G., Blennerhassett P., Wang L., Stanghellini V., Corinaldesi R., Collins S.M., Tougas G., Intestinal inflammation and activation of sensory nerve pathways: A functional and morphological study in the nematode infected rat, Gut, 49, pp. 822-827, (2001); de Jonge W.J., The F.O., van der Coelen D., Bennink R.J., Reitsma P.H., van Deventer S.J., van den Wijngaard R.M., Boeckxstaens G.E., Mast cell degranulation during abdominal surgery initiates postoperative ileus in mice, Gastroenterology, 127, pp. 535-545, (2004); Devlin M.G., Gasser R.B., Cocks T.M., Initial support for the hypothesis that PAR2 is involved in the immune response to Nippostrongylus brasiliensis in mice, Parasitol Res, 101, pp. 105-109, (2007); Fernandez-Blanco J.A., Barbosa S., de Sanchez Medina F., Martinez V., Vergara P., Persistent epithelial barrier alterations in a rat model of postinfectious gut dysfunction, Neurogastroenterol Motil, 23, (2011); Guilarte M., Santos J., de Torres I., Alonso C., Vicario M., Ramos L., Martinez C., Casellas F., Saperas E., Malagelada J.R., Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum, Gut, 56, pp. 203-209, (2007); Gunther C., Neumann H., Neurath M.F., Becker C., Apoptosis, necrosis and necroptosis: Cell death regulation in the intestinal epithelium, Gut.; Hansen K.K., Sherman P.M., Cellars L., Andrade-Gordon P., Pan Z., Baruch A., Wallace J.L., Hollenberg M.D., Vergnolle N., A major role for proteolytic activity and proteinase-activated receptor-2 in the pathogenesis of infectious colitis, Proc Natl Acad Sci USA, 102, pp. 8363-8368, (2005); Juanola C., Giralt M., Jimenez M., Mourelle M., Vergara P., Mucosal mast cells are involved in CCK disruption of MMC in the rat intestine, Am J Physiol Gastrointest Liver Physiol, 275, (1998); Kawabata A., Kuroda R., Nagata N., Kawao N., Masuko T., Nishikawa H., Kawai K., In vivo evidence that protease-activated receptors 1 and 2 modulate gastrointestinal transit in the mouse, Br J Pharmacol, 133, pp. 1213-1218, (2001); Kerckhoffs A.P., ter Linde J.J., Akkermans L.M., Samsom M., Trypsinogen IV, serotonin transporter transcript levels and serotonin content are increased in small intestine of irritable bowel syndrome patients, Neurogastroenterol Motil, 20, pp. 900-907, (2008); Khan W.I., Collins S.M., Immune-mediated alteration in gut physiology and its role in host defence in nematode infection, Parasite Immunol, 26, pp. 319-326, (2004); Kim J.A., Choi S.C., Yun K.J., Kim D.K., Han M.K., Seo G.S., Yeom J.J., Kim T.H., Nah Y.H., Lee Y.M., Expression of protease-activated receptor 2 in ulcerative colitis, Inflamm Bowel Dis, 9, pp. 224-229, (2003); Klooker T.K., Braak B., Koopman K.E., Welting O., Wouters M.M., van der Heide S., Schemann M., Bischoff S.C., van den Wijngaard R.M., Boeckxstaens G.E., The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome, Gut, 59, pp. 1213-1221, (2010); Knecht W., Cottrell G.S., Amadesi S., Mohlin J., Skaregarde A., Gedda K., Peterson A., Chapman K., Hollenberg M.D., Vergnolle N., Bunnett N.W., Trypsin IV or mesotrypsin and p23 cleave protease-activated receptors 1 and 2 to induce inflammation and hyperalgesia, J Biol Chem, 282, pp. 26089-26100, (2007); Kong W., McConalogue K., Khitin L.M., Hollenberg M.D., Payan D.G., Bohm S.K., Bunnett N.W., Luminal trypsin may regulate enterocytes through proteinase-activated receptor 2, Proc Natl Acad Sci USA, 94, pp. 8884-8889, (1997); Lee J.W., Park J.H., Park D.I., Park J.H., Kim H.J., Cho Y.K., Sohn C.I., Jeon W.K., Kim B.I., Subjects with diarrhea-predominant IBS have increased rectal permeability responsive to tryptase, Dig Dis Sci, 55, pp. 2922-2928, (2010); Martinez-Augustin O., Romero-Calvo I., Suarez M.D., Zarzuelo A., de Medina F.S., Molecular bases of impaired water and ion movements in inflammatory bowel diseases, Inflamm Bowel Dis, 15, pp. 114-127, (2009); McDermott J.R., Bartram R.E., Knight P.A., Miller H.R., Garrod D.R., Grencis R.K., Mast cells disrupt epithelial barrier function during enteric nematode infection, Proc Natl Acad Sci USA, 100, pp. 7761-7766, (2003); Mule F., Baffi M.C., Capparelli A., Pizzuti R., Involvement of nitric oxide and tachykinins in the effects induced by protease-activated receptors in rat colon longitudinal muscle, Br J Pharmacol, 139, pp. 598-604, (2003); Mule F., Baffi M.C., Cerra M.C., Dual effect mediated by proteaseactivated receptors on the mechanical activity of rat colon, Br J Pharmacol, 136, pp. 367-374, (2002); Norkina O., Burnett T.G., de Lisle R.C., Bacterial overgrowth in the cystic fibrosis transmembrane conductance regulator null mouse small intestine, Infect Immun, 72, pp. 6040-6049, (2004); Pejler G., Abrink M., Ringvall M., Wernersson S., Mast cell proteases, Adv Immunol, 95, pp. 167-255, (2007); Reed D.E., Barajas-Lopez C., Cottrell G., Velazquez-Rocha S., Dery O., Grady E.F., Bunnett N.W., Vanner S.J., Mast cell tryptase and proteinaseactivated receptor 2 induce hyperexcitability of guinea-pig submucosal neurons, J Physiol, 547, pp. 531-542, (2003); Rijnierse A., Nijkamp F.P., Kraneveld A.D., Mast cells and nerves tickle in the tummy: Implications for inflammatory bowel disease and irritable bowel syndrome, Pharmacol Ther, 116, pp. 207-235, (2007); Roka R., Ait-Belgnaoui A., Salvador-Cartier C., Garcia-Villar R., Fioramonti J., Eutamene H., Bueno L., Dexamethasone prevents visceral hyperalgesia but not colonic permeability increase induced by luminal protease-activated receptor-2 agonist in rats, Gut, 56, pp. 1072-1078, (2007); Roka R., Demaude J., Cenac N., Ferrier L., Salvador-Cartier C., Garcia-Villar R., Fioramonti J., Bueno L., Colonic luminal proteases activate colonocyte proteinase-activated receptor-2 and regulate paracellular permeability in mice, Neurogastroenterol Motil, 19, pp. 57-65, (2007); Roka R., Wittmann T., Bueno L., Altered protease signalling in the gut: A novel pathophysiological factor in irritable bowel syndrome, Neurogastroenterol Motil, 20, pp. 853-856, (2008); Schepens M.A., Rijnierse A., Schonewille A.J., Vink C., Brummer R.J., Willemsen L.E., van der Meer R., Bovee-Oudenhoven I.M., Dietary calcium decreases but short-chain fructo-oligosaccharides increase colonic permeability in rats, Br J Nutr, 104, pp. 1780-1786, (2010); Serna H., Porras M., Vergara P., Mast cell stabilizer ketotifen [4-(1-methyl-4-piperidylidene)-4h-benzo[4,5]cyclohepta[1,2-b]thiophen-10(9H)-one fumarate] prevents mucosal mast cell hyperplasia and intestinal dysmotility in experimental Trichinella spiralis inflammation in the rat, J Pharmacol Exp Ther, 319, pp. 1104-1111, (2006); Shea-Donohue T., Notari L., Stiltz J., Sun R., Madden K.B., Urban Jr. J.F., Zhao A., Role of enteric nerves in immune-mediated changes in proteaseactivated receptor 2 effects on gut function, Neurogastroenterol Motil, 22, (2010); Stewart G.L., Na H., Smart L., Seelig Jr. L.L., The temporal relationship among anti-parasite immune elements expressed during the early phase of infection of the rat with Trichinella spiralis, Parasitol Res, 85, pp. 672-677, (1999); Stoyanova I.I., Gulubova M.V., Mast cells and inflammatory mediators in chronic ulcerative colitis, Acta Histochem, 104, pp. 185-192, (2002); Swystun V.A., Renaux B., Moreau F., Wen S., Peplowski M.A., Hollenberg M.D., McNaughton W.K., Serine proteases decrease intestinal epithelial ion permeability by activation of protein kinase Czeta, Am J Physiol Gastrointest Liver Physiol, 297, (2009); Tahara T., Shibata T., Nakamura M., Yamashita H., Yoshioka D., Okubo M., Maruyama N., Kamano T., Kamiya Y., Fujita H., Nakagawa Y., Nagasaka M., Iwata M., Takahama K., Watanabe M., Nakano H., Hirata I., Arisawa T., Promoter methylation of protease-activated receptor (PAR2) is associated with severe clinical phenotypes of ulcerative colitis (UC), Clin Exp Med, 9, pp. 125-130, (2009); Tanovic A., Jimenez M., Fernandez E., Changes in the inhibitory responses to electrical field stimulation of intestinal smooth muscle from Trichinella spiralis infected rats, Life Sci, 71, pp. 3121-3136, (2002); The F.O., Buist M.R., Lei A., Bennink R.J., Hofland J., van den Wijngaard R.M., de Jonge W.J., Boeckxstaens G.E., The role of mast cell stabilization in treatment of postoperative ileus: A pilot study, Am J Gastroenterol, 104, pp. 2257-2266, (2009); Torrents D., Vergara P., In vivo changes in the intestinal reflexes and the response to CCK in the inflamed small intestine of the rat, Am J Physiol Gastrointest Liver Physiol, 279, (2000); Trap C., Fu B., Le Guerhier F., Liu M., Le Rhun D., Romand T., Perret C., Blaga R., Boireau P., Cloning and analysis of a cDNA encoding a putative serine protease comprising two trypsin-like domains of Trichinella spiralis, Parasitol Res, 98, pp. 288-294, (2006); Traver E., Torres R., de Mora F., Vergara P., Mucosal mast cells mediate motor response induced by chronic oral exposure to ovalbumin in the rat gastrointestinal tract, Neurogastroenterol Motil, 22, (2010); Tremaine W.J., Brzezinski A., Katz J.A., Wolf D.C., Fleming T.J., Mordenti J., Strenkoski-Nix L.C., Kurth M.C., Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): An open-label pilot study, Aliment Pharmacol Ther, 16, pp. 407-413, (2002); Vergnolle N., McNaughton W.K., Al-Ani B., Saifeddine M., Wallace J.L., Hollenberg M.D., Proteinase-activated receptor 2 (PAR2)-activating peptides: Identification of a receptor distinct from PAR2 that regulates intestinal transport, Proc Natl Acad Sci USA, 95, pp. 766-7771, (1998)","V. Martínez; Unit of Physiology, Veterinary School, Dept. of Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona, 08193 - Bellaterra, Barcelona, Spain; email: vicente.martinez@uab.es","","","","","","","","15221547","","APGPD","23238933","English","Am. J. Physiol. Gastrointest. Liver Physiol.","Article","Final","","Scopus","2-s2.0-84874056757"

"Piche T.; Barbara G.; Aubert P.; Des Varannes S.B.; Dainese R.; Nano J.L.; Cremon C.; Stanghellini V.; De Giorgio R.; Galmiche J.P.; Neunlist M.","Piche, T. (7004658977); Barbara, G. (7004311418); Aubert, P. (56652397900); Des Varannes, S. Bruley (57193752746); Dainese, R. (23479438000); Nano, J.L. (6701832616); Cremon, C. (6507319921); Stanghellini, V. (7006377452); De Giorgio, R. (7005471207); Galmiche, J.P. (55950901200); Neunlist, M. (6701416352)","7004658977; 7004311418; 56652397900; 57193752746; 23479438000; 6701832616; 6507319921; 7006377452; 7005471207; 55950901200; 6701416352","Impaired Intestinal barrier integrity in the colon of patients with irritable bowel syndrome: Involvement of soluble mediators","2009","Gut","58","2","","196","201","5","454","10.1136/gut.2007.140806","https://www.scopus.com/inward/record.uri?eid=2-s2.0-58849136276&doi=10.1136%2fgut.2007.140806&partnerID=40&md5=df8bd2e183cf1ad7ff1b5ec5c5064354","INSERM, U913, Nantes, France; Université de Nantes, Faculté de Médecine, Nantes, France; CHU Nantes, Hôtel Dieu, Institut des Maladies de i'Appareil Digestif, Nantes, France; Service de Gastroentérologie and Inserm U895, Pôle Digestif Médicochirurgical, Hôpital de i'Archet II, Nice, France; Department of Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy; CRBA, Centro Unificato di Ricerca BioMedica Applicata, St. Orsola Hospital, Bologna, Italy; INSERM U 913, Hôspital Hôtel Dieu, 44035 Nantes, 1, place Alexis Ricordeau, France","Piche T., INSERM, U913, Nantes, France, Université de Nantes, Faculté de Médecine, Nantes, France, CHU Nantes, Hôtel Dieu, Institut des Maladies de i'Appareil Digestif, Nantes, France, Service de Gastroentérologie and Inserm U895, Pôle Digestif Médicochirurgical, Hôpital de i'Archet II, Nice, France; Barbara G., Department of Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy, CRBA, Centro Unificato di Ricerca BioMedica Applicata, St. Orsola Hospital, Bologna, Italy; Aubert P., INSERM, U913, Nantes, France, Université de Nantes, Faculté de Médecine, Nantes, France, CHU Nantes, Hôtel Dieu, Institut des Maladies de i'Appareil Digestif, Nantes, France; Des Varannes S.B., INSERM, U913, Nantes, France, Université de Nantes, Faculté de Médecine, Nantes, France, CHU Nantes, Hôtel Dieu, Institut des Maladies de i'Appareil Digestif, Nantes, France; Dainese R., Service de Gastroentérologie and Inserm U895, Pôle Digestif Médicochirurgical, Hôpital de i'Archet II, Nice, France; Nano J.L., Service de Gastroentérologie and Inserm U895, Pôle Digestif Médicochirurgical, Hôpital de i'Archet II, Nice, France; Cremon C., Department of Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy, CRBA, Centro Unificato di Ricerca BioMedica Applicata, St. Orsola Hospital, Bologna, Italy; Stanghellini V., Department of Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy, CRBA, Centro Unificato di Ricerca BioMedica Applicata, St. Orsola Hospital, Bologna, Italy; De Giorgio R., Department of Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy, CRBA, Centro Unificato di Ricerca BioMedica Applicata, St. Orsola Hospital, Bologna, Italy; Galmiche J.P., INSERM, U913, Nantes, France, Université de Nantes, Faculté de Médecine, Nantes, France, CHU Nantes, Hôtel Dieu, Institut des Maladies de i'Appareil Digestif, Nantes, France; Neunlist M., INSERM, U913, Nantes, France, Université de Nantes, Faculté de Médecine, Nantes, France, CHU Nantes, Hôtel Dieu, Institut des Maladies de i'Appareil Digestif, Nantes, France, INSERM U 913, Hôspital Hôtel Dieu, 44035 Nantes, 1, place Alexis Ricordeau, France","Background: Growing evidence suggests that patients with irritable bowel syndrome (IBS) have increased intestinal permeability. In addition, mucosal soluble mediators are involved in the pathophysiology of pain in IBS. We aimed to investigate (1) paracellular permeability in colonic biopsies of patients with IBS; and (2) the ability of soluble factors from colonic biopsies to reproduce these alterations in vitro. Methods: Paracellular permeability in colonic biopsies of healthy subjects and patients with IBS was measured by mounting the biopsies in Ussing chambers. Cleared supernatant (SUP) of the culture from colonic biopsies was collected and applied to Caco-2 cells for 48 h. Paracellular permeability and transepithelial resistance (TER) were evaluated. mRNA expression of the tight junction proteins, zonula occludens (Z0)-1 and occludin, was assessed in colonic biopsies. Abdominal pain was assessed using a validated questionnaire. Results: Permeability of colonic biopsies was significantly higher in patients with IBS compared to healthy subjects. These changes were associated with significantly lower expression of ZO-1 mRNA in biopsies of IBS as compared to healthy subjects. Compared to healthy subjects, SUP of IBS markedly reduced TER and significantly increased permeability in Caco-2 cells. SUP of IBS patients induced a significant decrease of ZO-1 mRNA in Caco-2 as compared to healthy subjects. SUP-induced increased paracellular permeability correlated with the severity of abdominal pain. Conclusions: Our study shows that colonic soluble mediators are able to reproduce functional (permeability) and molecular (ZO-1 mRNA expression) alterations observed in IBS patients. These findings might pave the way both to identify novel biomarkers as well as new therapeutic targets in IBS.","","Adult; Aged; Analysis of Variance; Biopsy; Caco-2 Cells; Case-Control Studies; Cell Membrane; Cell Membrane Permeability; Colon; Electric Impedance; Female; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Male; Membrane Proteins; Middle Aged; Phosphoproteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Statistics, Nonparametric; Young Adult; biological marker; messenger RNA; abdominal pain; adult; aged; article; cell strain CACO 2; colon biopsy; controlled study; disease severity; female; human; human cell; intestine mucosa permeability; irritable colon; major clinical study; male; mediator release; priority journal; protein expression; questionnaire; supernatant; tight junction","","Membrane Proteins, ; occludin, ; Phosphoproteins, ; RNA, Messenger, ; zonula occludens-1 protein, ","","","","","Collins S.M., Piche T., Rampal P., The putative role of inflammation in the irritable bowel syndrome, Gut, 49, pp. 743-745, (2001); Barbara G., Mucosal barrier defects in irritable bowel syndrome. Who left the door open?, Am J Gastroenterol, 101, pp. 1295-1298, (2006); Nusrat A., Turner J.R., Madara J.L., Molecular physiology and pathophysiology of tight junctions. IV. Regulation of tight junctions by extracellular stimuli: Nutrients, cytokines, and immune cells, Am J Physiol Gastrointest Liver Physiol, 279, (2000); Tsukita S., Furuse M., Itoh M., Structural and signaling molecules come together at tight junctions, Curr Opin Cell Biol, 11, pp. 628-633, (1999); Spiller R.C., Jenkins D., Thornley J.P., Et al., Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, pp. 804-811, (2000); Marshall J.K., Thabane M., Carg A.X., Et al., Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario, Aliment Pharmacol Ther, 20, pp. 1317-1322, (2004); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1295-1304, (2006); Geese K., Roka R., Ferrier L., Et al., Increased faecal serine protease activity in diarrhoeic IBS patients: A colonic lumenal factor impairing permeability and sensitivity, Gut, 57, pp. 591-598, (2008); Cenac N., Andrews C.N., Holzhausen M., Et al., Role of protease activity in visceral pain in irritable bowel syndrome, J Clin Invest, 117, pp. 636-637, (2007); Barbara G., Wang B., Stanghellini V., Et al., Mast cell-dependent excitation of visceralnociceptive sensory neurons in irritable bowel syndrome, Gastroenterology, 132, pp. 26-37, (2007); Barbara G., Stanghellini V., De Giorgio R., Et al., Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome, Gastroenterology, 126, pp. 693-702, (2004); Savidge T.C., Newman P., Pothoulakis C., Et al., Enteric glia regulate intestinal barrier function and inflammation via release of S-nitroglutathione, Gastroenterology, 132, pp. 1344-1358, (2007); Neunlist M., Toumi F., Oresschkova T., Et al., Human ENS regulates the intestinal epithelial barrier permeability and a tight junction-associated protein ZO-1 via VIPergic pathways, Am J Physiol Gastrointest Liver Physiol, 285, (2003); Livak K.J., Schmittgen T.D., Analysis of relative gene expression data using real-time quantitative PCR and the 2-DDCt Method, Methods, 25, pp. 402-408, (2001); Spiller R.C., Jenkins D., Thornley J.P., Et al., Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, pp. 804-811, (2002); Dainese R., Galliani E.A., De Lazzari F., Et al., Discrepancies between reported food intolerance and sensitization test findings in irritable bowel syndrome patients, Am J Gastroenterol, 94, pp. 1892-1897, (1999); Vogelsang H., Wyatt J., Penner E., Et al., Screening for celiac disease in first-degree relatives of patients with celiac disease by lactulose/mannitol test, Am J Gastroenterol, 90, pp. 1838-1842, (1995); Barau E., Dupont C., Modifications of intestinal permeability during food provocation procedures in pediatric irritable bowel syndrome, J Pediatr Gastroenterol Nutr, 11, pp. 72-77, (1990); Wallon C., Braaf Y., Wolving M., Et al., Endoscopic biopsies in Ussing chambers evaluated for studies of macromolecular permeability in the human colon, Scand J Gastroenterol, 40, pp. 586-595, (2005); Neunlist M., Van Landeghem L., Boureille A., Et al., Neuro-glial crosstalk in inflammatory bowel disease, J Intern Med, 263, pp. 577-583, (2008); Soderholm J.D., Peterson K.H., Olaison G., Et al., Epithelial permeability to proteins in the noninflamed ileum of Crohn's disease?, Gastroenterology, 117, pp. 65-72, (1999); Cobden I., Rothwell J., Axon A.T., Intestinal permeability and screening tests for coeliac disease, Gut, 21, pp. 512-518, (1980); Zuckerman M.J., Watts M.T., Bhatt B.D., Et al., Intestinal permeability to (<sup>51</sup>Cr)EDTA in infectious diarrhea, Dig Dis Sci, 38, pp. 1651-1657, (1993); Ait-Belgnaoui A., Bradesi S., Fioramonti J., Et al., Acute stress-induced hypersensitivity to colonic distension depends upon increase in paracellular permeability: Role of myosin light chain kinase, Pain, 113, pp. 141-147, (2005); Kucharzik T., Walsh S.V., Chen J., Et al., Neutrophil transmigration in inflammatory bowel disease is associated with differential expression of epithelial intercellular junction proteins, Am J Pathol, 159, pp. 2001-2009, (2001); Crowe S.E., Luthra G.K., Perdue M.H., Mast cell mediated transport in intestine from patients with and without inflammatory bowel disease, Gut, 41, pp. 785-792, (1997); Xie H., He S.H., Role of histamine and its receptors in allergic and inflammatory bowel diseases, World J Gastroenterol, 21, pp. 2851-2857, (2005); Oprins J.C., van der Burg C., Meijer H.P., Et al., Tumor necrosis factor alpha potentiates ion secretion induced by histamine in a human intestinal epithelial cell line and in mouse colon: Involvement of the phospholipase D pathway, Gut, 50, pp. 314-321, (2002); Hirase T., Kawashima S., Wong A.Y.M., Et al., Regulation of tight junction permeability and occludin phosphorylation by RhoA-p160R0CK-dependant and independent mechanisms, J Biol Chem, 276, pp. 10423-10431, (2001); Guo Y., Ramachandran C., Satpathy M., Et al., Histamine-induced myosin light chain phosphorylation breaks down the barrier integrity of cultured corneal epithelial cells, Pharm Res, 24, pp. 1824-1833, (2007); Devalia J.L., Godfrey R.W., Sapsford R.J., Et al., No effect of histamine on human bronchial epithelial cell permeability and tight junctional integrity in vitro, Eur J Resp, 7, pp. 1958-1965, (1994); Gan L.S., Souzan Y., Thakker D.R., Modulation of the tight junctions of the Caco-2 cell monolayers by H<sub>2</sub>-antagonists, Pharm Res, 15, pp. 53-57, (1998)","M. Neunlist; INSERM U 913, Hôspital Hôtel Dieu, 44035 Nantes, 1, place Alexis Ricordeau, France; email: michel.neunlist@univnantes.fr","","","","","","","","14683288","","GUTTA","18824556","English","Gut","Article","Final","All Open Access; Green Open Access","Scopus","2-s2.0-58849136276"

"Camilleri M.; Shin A.; Busciglio I.; Carlson P.; Acosta A.; Bharucha A.E.; Burton D.; Lamsam J.; Lueke A.; Donato L.J.; Zinsmeister A.R.","Camilleri, M. (7102181053); Shin, A. (54996506000); Busciglio, I. (17343569900); Carlson, P. (7103028430); Acosta, A. (55844615900); Bharucha, A.E. (7004518505); Burton, D. (35453351900); Lamsam, J. (6505919871); Lueke, A. (55813166100); Donato, L.J. (8950442500); Zinsmeister, A.R. (36043887800)","7102181053; 54996506000; 17343569900; 7103028430; 55844615900; 7004518505; 35453351900; 6505919871; 55813166100; 8950442500; 36043887800","Validating biomarkers of treatable mechanisms in irritable bowel syndrome","2014","Neurogastroenterology and Motility","26","12","","1677","1685","8","45","10.1111/nmo.12421","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84911481455&doi=10.1111%2fnmo.12421&partnerID=40&md5=611784f144bc8a0bae0bf1837b041b95","Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, MN, United States; Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN, United States; Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN, United States","Camilleri M., Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, MN, United States; Shin A., Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, MN, United States; Busciglio I., Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, MN, United States; Carlson P., Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, MN, United States; Acosta A., Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, MN, United States; Bharucha A.E., Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, MN, United States; Burton D., Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, MN, United States; Lamsam J., Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, MN, United States; Lueke A., Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN, United States; Donato L.J., Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN, United States; Zinsmeister A.R., Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN, United States","Background: A valid biomarker is 'an indicator of normal biologic or pathogenic processes, or pharmacological responses to a therapeutic intervention'. There is no validated biomarker for irritable bowel syndrome (IBS). The aim of the study was to assess ability of three quantitative traits to identify treatable processes to discriminate between IBS-diarrhea (IBS-D) patients, IBS-constipation (IBS-C) patients and healthy volunteers (HV). Methods: In 30 HV, 30 IBS-C patients and 64 IBS-D patients, we characterized bowel symptoms and quantitated pathophysiological mechanisms: bile acid (BA) synthesis (serum C4 and FGF19), fecal BA and fat, colonic transit (CT), and intestinal permeability (IP). We used multiple logistic regression and receiver-operating characteristic (ROCAUC) to appraise three factors (fecal BA, CT, and IP) individually and in combination to identify discriminant targets for treatment in IBS. Key Results: There were significant associations between the three subgroups and symptoms reflecting bowel function and the quantitative traits. There were significant associations between fecal BA and CT at 48 h (r = 0.43; p < 0.001) and between fecal BA and IP (r = 0.23; p = 0.015). Individually, fecal BA and CT48 (but not IP) were significant independent predictors for distinguishing HV from IBS. In combination, they discriminated HV from IBS-D patients (ROCAUC 0.70), HV from IBS-C patients (ROCAUC 0.73), and IBS-C patients from IBS-D patients (ROCAUC 0.86). Colonic transit and fecal BA excretion together discriminate between healthy volunteers and IBS-C patients or IBS-D patients, or between the IBS subgroups with 75-90% specificity at 60% sensitivity. Conclusions & Inferences: Colonic transit and fecal BA individually and together constitute useful biomarkers to identify treatable mechanisms in IBS and to differentiate subgroups of IBS. We assessed the ability of three quantitative traits to identify treatable processes to discriminate between IBS-D patients, IBS-C patients, and healthy volunteers. Colonic transit and fecal BA individually and together constitute useful biomarkers to identify treatable mechanisms in IBS and to differentiate subgroups of IBS. © 2014 John Wiley & Sons Ltd.","Bile acid; Colon; Permeability; Transit","Adult; Area Under Curve; Bile Acids and Salts; Biomarkers; Chromatography, High Pressure Liquid; Complement C4; Constipation; Diarrhea; Feces; Female; Fibroblast Growth Factors; Gastrointestinal Transit; Humans; Irritable Bowel Syndrome; Male; Middle Aged; Permeability; ROC Curve; Sensitivity and Specificity; bile acid; biological marker; complement component C4; FGF19 protein, human; fibroblast growth factor; adult; area under the curve; biosynthesis; blood; chemistry; complication; constipation; diarrhea; feces; female; gastrointestinal transit; high performance liquid chromatography; human; Irritable Bowel Syndrome; male; middle aged; pathophysiology; permeability; physiology; receiver operating characteristic; sensitivity and specificity; validation study","","complement component C4, 80295-48-3, 80295-71-2; fibroblast growth factor, 62031-54-3; Bile Acids and Salts, ; Biomarkers, ; Complement C4, ; FGF19 protein, human, ; Fibroblast Growth Factors, ","","","National Institutes of Health, NIH; National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK, (R01DK092179)","","Engsbro A.L., Begtrup L.M., Kjeldsen J., Larsen P.V., de Muckadell O.S., Jarbol D.E., Bytzer P., Patients suspected of irritable bowel syndrome-cross-sectional study exploring the sensitivity of Rome III criteria in primary care, Am J Gastroenterol, 108, pp. 972-980, (2013); Manning A.P., Thompson W.G., Heaton K.W., Morris A.F., Towards positive diagnosis of the irritable bowel, Br Med J, 277, pp. 653-654, (1978); Kruis W., Thieme C., Weinzierl M., Schussler P., Holl J., Paulus W., A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease, Gastroenterology, 87, pp. 1-7, (1984); Camilleri M., Do the symptom-based, Rome criteria of irritable bowel syndrome lead to better diagnosis and treatment outcomes? The con argument, Clin Gastroenterol Hepatol, 8, (2009); Sainsbury A., Sanders D.S., Ford A.C., Prevalence of irritable bowel syndrome-type symptoms in patients with celiac disease: a meta-analysis, Clin Gastroenterol Hepatol, 11, pp. 359-365, (2013); Ford A.C., Bercik P., Morgan D.G., Bolino C., Pintos-Sanchez M.I., Moayyedi P., Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care, Gastroenterology, 145, pp. 1262-1270, (2013); Camilleri M., Peripheral mechanisms in irritable bowel syndrome, N Engl J Med, 367, pp. 1626-1635, (2012); Biomarkers and surrogate endpoints: preferred definitions and conceptual framework, Clin Pharmacol Ther, 69, pp. 89-95, (2001); Le Neve B., Posserud I., Bohn L., Guyonnet D., Rondeau P., Tillisch K., Naliboff B., Mayer E.A., Et al., A combined nutrient and lactulose challenge test allows symptom-based clustering of patients with irritable bowel syndrome, Am J Gastroenterol, 108, pp. 786-795, (2013); Hwang L., Low K., Khoshini R., Melmed G., Sahakian A., Makhani M., Pokkunuri V., Pimentel M., Evaluating breath methane as a diagnostic test for constipation-predominant IBS, Dig Dis Sci, 55, pp. 398-403, (2010); Mertz H., Naliboff B., Munakata J., Niazi N., Mayer E.A., Altered rectal perception is a biological marker of patients with irritable bowel syndrome, Gastroenterology, 109, pp. 40-52, (1995); Kindt S., Van Oudenhove L., Broekaert D., Kasran A., Ceuppens J.L., Bossuyt X., Fischler B., Tack J., Immune dysfunction in patients with functional gastrointestinal disorders, Neurogastroenterol Motil, 21, pp. 389-398, (2009); Chang L., Adeyemo M., Karagiannides I., Videlock E.J., Bowe C., Shih W., Presson A.P., Yuan P.Q., Et al., Serum and colonic mucosal immune markers in irritable bowel syndrome, Am J Gastroenterol, 107, pp. 262-272, (2012); Ohman L., Stridsberg M., Isaksson S., Jerlstad P., Simren M., Altered levels of fecal chromogranins and secretogranins in IBS: relevance for pathophysiology and symptoms?, Am J Gastroenterol, 107, pp. 440-447, (2012); El-Salhy M., Seim I., Chopin L., Gundersen D., Hatlebakk J.G., Hausken T., Irritable bowel syndrome: the role of gut neuroendocrine peptides, Front Biosci (Elite Ed), 4, pp. 2783-2800, (2012); Goepp J., Fowler E., McBride T., Landis D., Frequency of abnormal fecal biomarkers in irritable bowel syndrome, Glob Adv Health Med, 3, pp. 9-15, (2014); Dabritz J., Musci J., Foell D., Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome, World J Gastroenterol, 20, pp. 363-375, (2014); Pavlidis P., Chedgy F.J., Tibble J.A., Diagnostic accuracy and clinical application of faecal calprotectin in adult patients presenting with gastrointestinal symptoms in primary care, Scand J Gastroenterol, 48, pp. 1048-1054, (2013); Jones M.P., Chey W.D., Singh S., Gong H., Shringarpure R., Hoe N., Chuang E., Talley N.J., A biomarker panel and psychological morbidity differentiates the irritable bowel syndrome from health and provides novel pathophysiological leads, Aliment Pharmacol Ther, 39, pp. 426-437, (2014); Camilleri M., McKinzie S., Busciglio I., Low P.A., Sweetser S., Burton D., Baxter K., Ryks M., Et al., Prospective study of motor, sensory, psychological and autonomic functions in 119 patients with irritable bowel syndrome, Clin Gastroenterol Hepatol, 6, pp. 772-781, (2008); Manabe N., Wong B.S., Camilleri M., Burton D., McKinzie S., Zinsmeister A.R., Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort, Neurogastroenterol Motil, 22, (2010); Deiteren A., Camilleri M., Bharucha A.E., Burton D., McKinzie S., Rao A.S., Zinsmeister A.R., Performance characteristics of scintigraphic colon transit measurement in health and irritable bowel syndrome and relationship to bowel functions, Neurogastroenterol Motil, 22, pp. 415-423, (2010); Camilleri M., Scintigraphic biomarkers for colonic dysmotility, Clin Pharmacol Ther, 87, pp. 748-753, (2010); Wedlake L., A'Hern R., Russell D., Thomas K., Walters J.R., Andreyev H.J., Systematic Review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome, Aliment Pharmacol Ther, 30, pp. 707-717, (2009); Wong B.S., Camilleri M., Carlson P., McKinzie S., Busciglio I., Bondar O., Dyer R.B., Lamsam J., Et al., Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea, Clin Gastroenterol Hepatol, 10, pp. 1009-1015, (2012); Shin A., Camilleri M., Vijayvargiya P., Busciglio I., Burton D., Ryks M., Rhoten D., Lueke A., Et al., Bowel functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome, Clin Gastroenterol Hepatol, 11, pp. 1270-1275, (2013); Camilleri M., Nadeau A., Tremaine W.J., Lamsam J., Burton D., Odunsi S., Sweetser S., Singh R., Measurement of serum 7alpha-hydroxy-4-cholesten-3-one (or 7alphaC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry, Neurogastroenterol Motil, 21, (2009); Rao A.S., Wong B.S., Camilleri M., Odunsi-Shiyanbade S.T., McKinzie S., Ryks M., Burton D., Carlson P., Et al., Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis, Gastroen-terology, 139, pp. 1549-1558, (2010); Camilleri M., Lasch K., Zhou W., Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome, Am J Physiol, 303, pp. G775-G785, (2012); Vazquez-Roque M.I., Camilleri M., Smyrk T., Murray J., Marietta E., O'Neill J., Carlson P., Lamsam J., Et al., A controlled trial of gluten-free diet in irritable bowel syndrome-diarrhea: effect on bowel frequency and intestinal functions, Gastroenterology, 144, pp. 903-911, (2013); Talley N.J., Phillips S.F., Wiltgen C.M., Zinsmeister A.R., Melton III L.J., Assessment of functional gastrointestinal disease: the bowel disease questionnaire, Mayo Clin Proc, 65, pp. 1456-1479, (1990); Zigmond A.S., Snaith R.P., The hospital anxiety and depression scale, Acta Psychiatr Scand, 67, pp. 361-370, (1983); Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Sauter G.H., Munzing W., von Ritter C., Paumgartner G., Bile acid malabsorption as a cause of chronic diarrhea: diagnostic value of 7alpha-hydroxy-4-cholesten-3-one in serum, Dig Dis Sci, 44, pp. 14-19, (1999); Brydon W.G., Nyhlin H., Eastwood M.A., Merrick M.V., Serum 7 alpha-hydroxy-4-cholesten-3-one and seleno-homocholyltaurine (SeHCAT) whole body retention in the assessment of bile acid induced diarrhoea, Eur J Gastroenterol Hepatol, 8, pp. 117-123, (1996); Galman C., Arvidsson I., Angelin B., Rudling M., Monitoring hepatic cholesterol 7alpha-hydroxylase activity by assay of the stable bile acid intermediate 7alpha-hydroxy-4-cholesten-3-one in peripheral blood, J Lipid Res, 44, pp. 859-866, (2003); Tagliacozzi D., Mozzi A.F., Casetta B., Bertucci P., Bernardini S., Di Ilio C., Urbani A., Federici G., Quantitative analysis of bile acids in human plasma by liquid chromatography-electrospray tandem mass spectrometry: a simple and rapid one-step method, Clin Chem Lab Med, 41, pp. 1633-1641, (2003); Walters J.R., Tasleem A.M., Omer O.S., Brydon W.G., Dew T., le Roux C.W., A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis, Clin Gastroenterol Hepatol, 7, pp. 1189-1194, (2009); Odunsi S.T., Camilleri M., McKinzie S., Burton D., Carlson P., Busciglio I.A., Lamsam J., Singh R., Et al., Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function, Clin Gastroenterol Hepatol, 8, pp. 159-165, (2010); Camilleri M., Nadeau A., Lamsam J., Linker-Nord S., Ryks M., Burton D., Sweetser S., Zinsmeister A.R., Et al., Understanding measurements of intestinal permeability in healthy humans with urine lactulose and mannitol excretion, Neurogastroenterol Motil, 22, pp. e15-e26, (2010); Rao A.S., Camilleri M., Eckert D.J., Burton D.D., Ryks M., Wong B.S., Lamsam J., Singh R., Et al., Urine sugars for in vivo gut permeability: validation and comparisons in irritable bowel syndrome-diarrhea and controls, Am J Physiol, 301, pp. G919-G928, (2011); Bjarnason I., O'Morain C., Levi A.J., Peters T.J., Absorption of 51chromium-labeled ethylenediaminetetraacetate in inflammatory bowel disease, Gastroenterology, 85, pp. 318-322, (1983); Miki K., Moore D.J., Butler R.N., Southcott E., Couper R.T., Davidson G.P., The sugar permeability test reflects disease activity in children and adolescents with inflammatory bowel disease, J Pediatr, 133, pp. 750-754, (1998); Peeters M., Ghoos Y., Maes B., Hiele M., Geboes K., Vantrappen G., Rutgeerts P., Increased permeability of macroscopically normal small bowel in Crohn's disease, Dig Dis Sci, 39, pp. 2170-2176, (1994); Kolar G.J., Camilleri M., Burton D., Nadeau A., Zinsmeister A.R., Prevalence of colonic motor or evacuation disorders in patients presenting with chronic nausea and vomiting evaluated by a single gastroenterologist in a tertiary referral practice, Neurogastroenterol Motil, 26, pp. 131-138, (2014); Johnston I.M., Nolan J.D., Dew T., Brydon W.G., Walters J.R., A new therapy for chronic diarrhea? A proof of concept study of the FXR agonist obeticholic acid in patients with primary bile acid diarrhea, Gastroenterology, 144, (2013); Camilleri M., Pharmacological agents currently in clinical trials for disorders of neurogastroenterology, J Clin Invest, 123, pp. 4111-4120, (2013); Tornblom H., Van Oudenhove L., Sadik R., Abrahamsson H., Tack J., Simren M., Colonic transit time and IBS symptoms: what's the link?, Am J Gastroenterol, 107, pp. 754-760, (2012); Gracie D.J., Kane J.S., Mumtaz S., Scarsbrook A.F., Chowdhury F.U., Ford A.C., Prevalence of, and predictors of, bile acid malabsorption in outpatients with chronic diarrhea, Neurogastroenterol Motil, 24, (2012); Pattni S.S., Brydon W.G., Dew T., Johnston I.M., Nolan J.D., Srinivas M., Basumani P., Bardhan K.D., Et al., Fibroblast growth factor 19 in patients with bile acid diarrhoea: a prospective comparison of FGF19 serum assay and SeHCAT retention, Aliment Pharmacol Ther, 38, pp. 967-976, (2013)","","","Blackwell Publishing Ltd","","","","","","13501925","","NMOTE","25244349","English","Neurogastroenterol. Motil.","Article","Final","All Open Access; Green Open Access","Scopus","2-s2.0-84911481455"

"Camilleri M.; Shin A.; Busciglio I.; Carlson P.; Acosta A.; Bharucha A.E.; Burton D.; Lamsam J.; Lueke A.; Donato L.J.; Zinsmeister A.R.","Camilleri, Michael (7102181053); Shin, Andrea (54996506000); Busciglio, Irene (17343569900); Carlson, Paula (7103028430); Acosta, Andres (55844615900); Bharucha, Adil E. (7004518505); Burton, Duane (35453351900); Lamsam, Jesse (6505919871); Lueke, Alan (55813166100); Donato, Leslie J. (8950442500); Zinsmeister, Alan R. (36043887800)","7102181053; 54996506000; 17343569900; 7103028430; 55844615900; 7004518505; 35453351900; 6505919871; 55813166100; 8950442500; 36043887800","Genetic variation in GPBAR1 predisposes to quantitative changes in colonic transit and bile acid excretion","2014","American Journal of Physiology - Gastrointestinal and Liver Physiology","307","5","","G508","G516","8","48","10.1152/ajpgi.00178.2014","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84907305689&doi=10.1152%2fajpgi.00178.2014&partnerID=40&md5=0b1ea1e7ea5f9c1818c417295de65583","Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, MN, United States; Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN, United States; Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN, United States","Camilleri M., Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, MN, United States; Shin A., Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, MN, United States; Busciglio I., Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, MN, United States; Carlson P., Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, MN, United States; Acosta A., Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, MN, United States; Bharucha A.E., Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, MN, United States; Burton D., Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, MN, United States; Lamsam J., Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, MN, United States; Lueke A., Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN, United States; Donato L.J., Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN, United States; Zinsmeister A.R., Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN, United States","The pathobiology of irritable bowel syndrome (IBS) is multifaceted. We aimed to identify candidate genes predisposing to quantitative traits in IBS. In 30 healthy volunteers, 30 IBS-constipation, and 64 IBS-diarrhea patients, we measured bowel symptoms, bile acid (BA) synthesis (serum 7α-hydroxy-4-cholesten-3-one and FGF19), fecal BA and fat, colonic transit (CT by scintigraphy), and intestinal permeability (IP by 2-sugar excretion). We assessed associations of candidate genes controlling BA metabolism (KLB rs17618244 and FGFR4 rs351855), BA receptor (GPBAR1 rs11554825), serotonin (5-HT) reuptake (SLC6A4 through rs4795541 which encodes for the 44-bp insert in 5HTTLPR), or immune activation (TNFSF15 rs4263839) with three primary quantitative traits of interest: colonic transit, BA synthesis, and fecal BA excretion. There were significant associations between fecal BA and CT at 48 h (r = 0.43; P < 0.001) and IP (r = 0.23; P = 0.015). GPBAR1 genotype was associated with CT48 (P = 0.003) and total fecal BA [P = 0.030, false detection rate (FDR) P = 0.033]. Faster CT48 observed with both CC and TT GPBAR1 genotypes was due to significant interaction with G allele of KLB, which increases BA synthesis and excretion. Other univariate associations (P < 0.05, without FDR correction) observed between GPBAR1 and symptom phenotype and gas sensation ratings support the role of GPBAR1 receptor. Associations between SLC6A4 and stool consistency, ease of passage, postprandial colonic tone, and total fecal BA excretion provide data in support of future hypothesis-testing studies. Genetic control of GPBAR1 receptor predisposing to pathobiological mechanisms in IBS provides evidence from humans in support of the importance of GPBAR1 to colonic motor and secretory functions demonstrated in animal studies. © 2014 the American Physiological Society.","Bile acid; Immune; Serotonin; Transit","Adolescent; Adult; Aged; Bile Acids and Salts; Biological Transport; Case-Control Studies; Cholestenones; Colon; Constipation; Diarrhea; Feces; Female; Fibroblast Growth Factors; Glucuronidase; Humans; Irritable Bowel Syndrome; Lipids; Male; Middle Aged; Polymorphism, Single Nucleotide; Quantitative Trait, Heritable; Receptors, G-Protein-Coupled; Serotonin Plasma Membrane Transport Proteins; Tumor Necrosis Factor Ligand Superfamily Member 15; bile acid; immune; serotonin; transit; 7alpha hydroxycholest 4 en 3 one; bile acid; cholesterol derivative; feces lipid; fibroblast growth factor 19; fibroblast growth factor receptor 4; unclassified drug; vascular endothelial growth inhibitor; adult; article; bile acid metabolism; bile acid synthesis; colon motility; controlled study; excretion; feces; female; FGFR4 gene; gastrointestinal tract scintiscanning; gene; gene interaction; genetic predisposition; genetic regulation; genetic variability; genotype; genotype phenotype correlation; GPBAR1 gene; human; human cell; intestine mucosa permeability; irritable colon; major clinical study; male; priority journal; quantitative trait; real time polymerase chain reaction; single nucleotide polymorphism; SLC6A4 gene; tnfsf15 gene","","fibroblast growth factor receptor 4, 147573-63-5","","","National Institutes of Health, (RO1-DK92179); National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK, (T32DK007198)","","Alemi F., Poole D.P., Chiu J., Schoonjans K., Cattaruzza F., Grider J.R., Bunnett N.W., Corvera C.U., The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice, Gastroenterology, 144, pp. 145-154, (2013); Alrefai W.A., Saksena S., Tyagi S., Gill R.K., Ramaswamy K., Dudeja P.K., Taurodeoxycholate modulates apical Cl<sup>-</sup>/OH<sup>-</sup> exchange activity in Caco2 cells, Dig Dis Sci, 52, pp. 1270-1278, (2007); Areeshi M.Y., Haque S., Panda A.K., Mandal R.K., A serotonin transporter gene (SLC6A4). Polymorphism is associated with reduced risk of irritable bowel syndrome in American and Asian population: A meta-analysis, PLoS One, 8, (2013); Bampton P.A., Dinning P.G., Kennedy M.L., Lubowski D.Z., Cook I.J., The proximal colonic motor response to rectal mechanical and chemical stimulation, Am J Physiol Gastrointest Liver Physiol, 282, (2002); Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework, Clin Pharmacol Ther, 69, pp. 89-95, (2001); Brydon W.G., Nyhlin H., Eastwood M.A., Merrick M.V., Serum 7 alphahydroxy-4-cholesten-3-one and seleno-homocholyltaurine (SeHCAT) whole body retention in the assessment of bile acid induced diarrhoea, Eur J Gastroenterol Hepatol, 8, pp. 117-123, (1996); Camilleri M., Peripheral mechanisms in irritable bowel syndrome, N Engl J Med, 367, pp. 1626-1635, (2012); Camilleri M., Physiological underpinnings of irritable bowel syndrome: Neurohormonal mechanisms, J Physiol, (2014); Camilleri M., Busciglio I., Carlson P., McKinzie S., Burton D., Baxter K., Ryks M., Zinsmeister A.R., Candidate genes and sensory functions in health and irritable bowel syndrome, Am J Physiol Gastrointest Liver Physiol, 295, (2008); Camilleri M., Carlson P., McKinzie S., Zucchelli M., D'Amato M., Busciglio I., Burton D., Zinsmeister A.R., Genetic susceptibility to inflammation and colonic transit in lower functional gastrointestinal disorders: Preliminary analysis, Neurogastroenterol Motil, 23, pp. 935-943, (2011); Camilleri M., Katzka D.A., Irritable bowel syndrome: Methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome, Am J Physiol Gastrointest Liver Physiol, 302, (2012); Camilleri M., McKinzie S., Busciglio I., Low P.A., Sweetser S., Burton D., Baxter K., Ryks M., Zinsmeister A.R., Prospective study of motor, sensory, psychological and autonomic functions in 119 patients with irritable bowel syndrome, Clin Gastroenterol Hepatol, 6, pp. 772-781, (2008); Camilleri M., Nadeau A., Lamsam J., Nord S.L., Ryks M., Burton D., Sweetser S., Zinsmeister A.R., Singh R., Understanding measurements of intestinal permeability in healthy humans with urine lactulose and mannitol excretion, Neurogastroenterol Motil, 22, (2010); Camilleri M., Nadeau A., Tremaine W.J., Lamsam J., Burton D., Odunsi S., Sweetser S., Singh R., Measurement of serum 7alpha-hydroxy-4-cholesten-3-one (or 7alphaC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry, Neurogastroenterol Motil, 21, (2009); Camilleri M., Shin A., Busciglio I., Acosta A., Burton D., Lamsam J., Lueke A., Donato L., Zinsmeister A.R., Validating a biomarker for irritable bowel syndrome, Gastroenterology 146, Suppl, 1, (2014); Camilleri M., Vazquez-Roque M.I., Carlson P., Burton D., Wong B.S., Zinsmeister A.R., Association of bile acid receptor TGR5 variation and transit in health and lower functional gastrointestinal disorders, Neurogastroenterol Motil, 23, (2011); Chadwick V.S., Gaginella T.S., Carlson G.L., Debongnie J.C., Phillips S.F., Hofmann A.F., Effect of molecular structure on bile acid-induced alterations in absorptive function, permeability, and morphology in the perfused rabbit colon, J Lab Clin Med, 94, pp. 661-674, (1979); Colucci R., Gambaccini D., Ghisu N., Rossi G., Costa F., Tuccori M., De Bortoli N., Fornai M., Antonioli L., Ricchiuti A., Mumolo M.G., Marchi S., Blandizzi C., Bellini M., Influence of the serotonin transporter 5HTTLPR polymorphism on symptom severity in irritable bowel syndrome, PLoS One, 8, (2013); Deiteren A., Camilleri M., Bharucha A.E., Burton D., McKinzie S., Rao A.S., Zinsmeister A.R., Performance characteristics of scintigraphic colon transit measurement in health and irritable bowel syndrome and relationship to bowel functions, Neurogastroenterol Motil, 22, pp. 415-423, (2010); Fukudo S., Kanazawa M., Mizuno T., Hamaguchi T., Kano M., Watanabe S., Sagami Y., Shoji T., Endo Y., Hongo M., Itoyama Y., Yanai K., Tashiro M., Aoki M., Impact of serotonin transporter gene polymorphism on brain activation by colorectal distention, Neuroimage, 47, pp. 946-951, (2009); Galman C., Arvidsson I., Angelin B., Rudling M., Monitoring hepatic cholesterol 7alpha-hydroxylase activity by assay of the stable bile acid intermediate 7alpha-hydroxy-4-cholesten-3-one in peripheral blood, J Lipid Res, 44, pp. 859-866, (2003); Gonenne J., Esfandyari T., Camilleri M., Burton D.D., Stephens D.A., Baxter K.L., Zinsmeister A.R., Bharucha A.E., Effect of female sex hormone supplementation and withdrawal on gastrointestinal and colonic transit in postmenopausal women, Neurogastroenterol Motil, 18, pp. 911-918, (2006); Gullikson G.W., Cline W.S., Lorenzsonn V., Benz L., Olsen W.A., Bass P., Effects of anionic surfactants on hamster small intestinal membrane structure and function: Relationship to surface activity, Gastroenterology, 73, pp. 501-511, (1977); Hinds J.P., Stoney B., Wald A., Does gender or the menstrual cycle affect colonic transit?, Am J Gastroenterol, 84, pp. 123-126, (1989); Hov J.R., Keitel V., Laerdahl J.K., Spomer L., Ellinghaus E., ElSharawy A., Melum E., Boberg K.M., Manke T., Balschun T., Schramm C., Bergquist A., Weismuller T., Gotthardt D., Rust C., Henckaerts L., Onnie C.M., Weersma R.K., Sterneck M., Teufel A., Runz H., Stiehl A., Ponsioen C.Y., Wijmenga C., Vatn M.H., Stokkers P.C., Vermeire S., Mathew C.G., Lie B.A., Beuers U., Manns M.P., Schreiber S., Schrumpf E., Haussinger D., Franke A., Karlsen T.H., Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis, PLoS One, 5, (2010); Jang J.H., Rickenbacher A., Humar B., Weber A., Raptis D.A., Lehmann K., Stieger B., Moritz W., Soll C., Georgiev P., Fischer D., Laczko E., Graf R., Clavien P.A., Serotonin protects mouse liver from cholestatic injury by decreasing bile salt pool after bile duct ligation, Hepatology, 56, pp. 209-218, (2012); Kawamata Y., Fujii R., Hosoya M., Harada M., Yoshida H., Miwa M., Fukusumi S., Habata Y., Itoh T., Shintani Y., Hinuma S., Fujisawa Y., Fujino M., A G protein-coupled receptor responsive to bile acids, J Biol Chem, 278, pp. 9435-9440, (2003); Kim H.J., Camilleri M., Carlson P.J., Cremonini F., Ferber I., Stephens D., McKinzie S., Zinsmeister A.R., Urrutia R., Association of distinct α2 adrenoceptor and serotonin-transporter polymorphisms associated with constipation and somatic symptoms in functional gastrointestinal disorders, Gut, 53, pp. 829-837, (2004); Kumar S., Ranjan P., Mittal B., Ghoshal U.C., Serotonin transporter gene (SLC6A4) polymorphism in patients with irritable bowel syndrome and healthy controls, J Gastrointestin Liver Dis, 21, pp. 31-38, (2012); Lieu T., Jayaweera G., Bunnett N.W., GPBA: A GPCR for bile acids and an emerging therapeutic target for disorders of digestion and sensation, Br J Pharmacol, 171, pp. 1156-1166, (2014); Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Manabe N., Wong B.S., Camilleri M., Burton D., McKinzie S., Zinsmeister A.R., Lower functional gastrointestinal disorders: Evidence of abnormal colonic transit in a 287 patient cohort, Neurogastroenterol Motil, 22, (2010); Maruyama T., Tanaka K., Suzuki J., Miyoshi H., Harada N., Nakamura T., Miyamoto Y., Kanatani A., Tamai Y., Targeted disruption of G protein-coupled bile acid receptor 1 (Gpbar1/M-Bar) in mice, J Endocrinol, 191, pp. 197-205, (2006); Odunsi S.T., Camilleri M., McKinzie S., Burton D., Carlson P., Busciglio I.A., Lamsam J., Singh R., Zinsmeister A.R., Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function, Clin Gastroenterol Hepatol, 8, pp. 159-165, (2010); Poole D.P., Godfrey C., Cattaruzza F., Cottrell G.S., Kirkland J.G., Pelayo J.C., Bunnett N.W., Corvera C.U., Expression and function of the bile acid receptor GpBAR1 (TGR5) in the murine enteric nervous system, Neurogastroenterol Motil, 22, pp. 814-825, (2010); Rajagopal S., Kumar D.P., Mahavadi S., Bhattacharya S., Zhou R., Corvera C.U., Bunnett N.W., Grider J.R., Murthy K.S., Activation of G protein-coupled bile acid receptor, TGR5, induces smooth muscle relaxation via both Epac-and PKA-mediated inhibition of RhoA/Rho kinase pathway, Am J Physiol Gastrointest Liver Physiol, 304, (2013); Rao A.S., Camilleri M., Eckert D.J., Busciglio I., Burton D.D., Ryks M., Wong B.S., Lamsam J., Singh R., Zinsmeister A.R., Urine sugars for in vivo gut permeability: Validation and comparisons in irritable bowel syndrome-diarrhea and controls, Am J Physiol Gastrointest Liver Physiol, 301, (2011); Sauter G.H., Munzing W., von Ritter C., Paumgartner G., Bile acid malabsorption as a cause of chronic diarrhea: Diagnostic value of 7alphahydroxy-4-cholesten-3-one in serum, Dig Dis Sci, 44, pp. 14-19, (1999); Shin A., Camilleri M., Vijayvargiya P., Busciglio I., Burton D., Ryks M., Rhoten D., Lueke A., Saenger A., Girtman A., Zinsmeister A.R., Bowel functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome, Clin Gastroenterol Hepatol, 11, pp. 1270-1275, (2013); Suenaert P., Bulteel V., Den Hond E., Hiele M., Peeters M., Monsuur F., Ghoos Y., Rutgeerts P., The effects of smoking and indomethacin on small intestinal permeability, Aliment Pharmacol Ther, 14, pp. 819-822, (2000); Swan C., Duroudier N.P., Campbell E., Zaitoun A., Hastings M., Dukes G.E., Cox J., Kelly F.M., Wilde J., Lennon M.G., Neal K.R., Whorwell P.J., Hall I.P., Spiller R.C., Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): Association with TNFSF15 and TNFα, Gut, 62, pp. 985-994, (2013); Tagliacozzi D., Mozzi A.F., Casetta B., Bertucci P., Bernardini S., Di Ilio C., Urbani A., Federici G., Quantitative analysis of bile acids in human plasma by liquid chromatography-electrospray tandem mass spectrometry: A simple and rapid one-step method, Clin Chem Lab Med, 41, pp. 1633-1641, (2003); Talley N.J., Phillips S.F., Wiltgen C.M., Zinsmeister A.R., Melton III L.J., Assessment of functional gastrointestinal disease: The bowel disease questionnaire, Mayo Clin Proc, 65, pp. 1456-1479, (1990); Thompson W.G., Gender differences in irritable bowel symptoms, Eur J Gastroenterol Hepatol, 9, pp. 299-302, (1997); Wald A., Van Thiel D.H., Hoechstetter L., Gavaler J.S., Egler K.M., Verm R., Scott L., Lester R., Gastrointestinal transit: The effect of the menstrual cycle, Gastroenterology, 80, pp. 1497-1500, (1981); Walters J.R., Tasleem A.M., Omer O.S., Brydon W.G., Dew T., le Roux C.W., A new mechanism for bile acid diarrhea: Defective feedback inhibition of bile acid biosynthesis, Clin Gastroenterol Hepatol, 7, pp. 1189-1194, (2009); Watanabe H., Akasaka D., Ogasawara H., Sato K., Miyake M., Saito K., Takahashi Y., Kanaya T., Takakura I., Hondo T., Chao G., Rose M.T., Ohwada S., Watanabe K., Yamaguchi T., Aso H., Peripheral serotonin enhances lipid metabolism by accelerating bile acid turnover, Endocrinology, 151, pp. 4776-4786, (2010); Wedlake L., A'Hern R., Russell D., Thomas K., Walters J.R., Andreyev H.J., Systematic Review: The prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoeapredominant irritable bowel syndrome, Aliment Pharmacol Ther, 30, pp. 707-717, (2009); Wong B.S., Camilleri M., Carlson P., McKinzie S., Busciglio I., Bondar O., Dyer R.B., Lamsam J., Zinsmeister A.R., Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea, Clin Gastroenterol Hepatol, 10, pp. 1009-1015, (2012); Wong B.S., Camilleri M., Carlson P.J., Guicciardi M.E., Burton D., McKinzie S., Rao A.S., Zinsmeister A.R., Gores G.J., A klothoβ variant mediates protein stability and associates with colon transit in irritable bowel syndrome with diarrhea, Gastroenterology, 140, pp. 1934-1942, (2011); Yuan J., Kang C., Wang M., Wang Q., Li P., Liu H., Hou Y., Su P., Yang F., Wei Y., Yang J., Association study of serotonin transporter SLC6A4 gene with Chinese Han irritable bowel syndrome, PLoS One, 9, (2014); Zhang Z.F., Duan Z.J., Wang L.X., Yang D., Zhao G., Zhang L., The serotonin transporter gene polymorphism (5-HTTLPR), and irritable bowel syndrome: A meta-analysis of 25 studies, BMC Gastroenterol, 14, pp. 23-34, (2014); Zigmond A.S., Snaith R.P., The hospital anxiety and depression scale, Acta Psychiatr Scand, 67, pp. 361-370, (1983); Zucchelli M., Camilleri M., Nixon Andreasson A., Bresso F., Dlugosz A., Halfvarson J., Torkvist L., Schmidt P.T., Karling P., Ohlsson B., Duerr R.H., Simren M., Lindberg G., Agreus L., Carlson P., Zinsmeister A.R., D'Amato M., Association of TNFSF15 polymorphism with irritable bowel syndrome, Gut, 60, pp. 1671-1677, (2011)","M. Camilleri; Mayo Clinic, Rochester, MN 55905, Charlton 8-110, 200 First St. S.W, United States; email: camilleri.michael@mayo.edu","","American Physiological Society","","","","","","01931857","","APGPD","25012842","English","Am. J. Physiol. Gastrointest. Liver Physiol.","Article","Final","All Open Access; Green Open Access","Scopus","2-s2.0-84907305689"

"Gecse K.; Róka R.; Séra T.; Rosztóczy A.; Annaházi A.; Izbéki F.; Nagy F.; Molnár T.; Szepes Z.; Pávics L.; Bueno L.; Wittmann T.","Gecse, Krisztina (24080248600); Róka, Richárd (8512636100); Séra, Teréz (7004305751); Rosztóczy, András (6602312658); Annaházi, Anita (8252873800); Izbéki, Ferenc (6602337283); Nagy, Ferenc (55551993200); Molnár, Tamás (7006518154); Szepes, Zoltán (6603073928); Pávics, László (7003477581); Bueno, Lionel (36043988100); Wittmann, Tibor (7004015774)","24080248600; 8512636100; 7004305751; 6602312658; 8252873800; 6602337283; 55551993200; 7006518154; 6603073928; 7003477581; 36043988100; 7004015774","Leaky gut in patients with diarrhea-predominant irritable bowel syndrome and inactive ulcerative colitis","2012","Digestion","85","1","","40","46","6","69","10.1159/000333083","https://www.scopus.com/inward/record.uri?eid=2-s2.0-83455164987&doi=10.1159%2f000333083&partnerID=40&md5=fa0dd3f320648dd8ed760df6fa3521c5","First Department of Internal Medicine, University of Szeged, Szeged, Hungary; Department of Nuclear Medicine, University of Szeged, Szeged, Hungary; INRA, UMR 1054 INRA-EI Purpan, Neuro-Gastroenterology and Nutrition Unit, Toulouse, France; First Department of Internal Medicine, University of Szeged, HU-6720 Szeged, Korányi fasor 8-10, Hungary","Gecse K., First Department of Internal Medicine, University of Szeged, Szeged, Hungary, First Department of Internal Medicine, University of Szeged, HU-6720 Szeged, Korányi fasor 8-10, Hungary; Róka R., First Department of Internal Medicine, University of Szeged, Szeged, Hungary; Séra T., Department of Nuclear Medicine, University of Szeged, Szeged, Hungary; Rosztóczy A., First Department of Internal Medicine, University of Szeged, Szeged, Hungary; Annaházi A., First Department of Internal Medicine, University of Szeged, Szeged, Hungary; Izbéki F., First Department of Internal Medicine, University of Szeged, Szeged, Hungary; Nagy F., First Department of Internal Medicine, University of Szeged, Szeged, Hungary; Molnár T., First Department of Internal Medicine, University of Szeged, Szeged, Hungary; Szepes Z., First Department of Internal Medicine, University of Szeged, Szeged, Hungary; Pávics L., Department of Nuclear Medicine, University of Szeged, Szeged, Hungary; Bueno L., INRA, UMR 1054 INRA-EI Purpan, Neuro-Gastroenterology and Nutrition Unit, Toulouse, France; Wittmann T., First Department of Internal Medicine, University of Szeged, Szeged, Hungary","Background/Aims: Defective epithelial barrier has been implicated in the pathogenesis of irritable bowel syndrome (IBS) and inflammatory bowel diseases. The aim of this study was to investigate gut permeability in patients with inactive ulcerative colitis (UC) and in patients with IBS. Methods: IBS patients of the diarrhea-predominant (IBS-D) and of the constipation-predominant subgroup (IBS-C), patients with inactive UC and healthy subjects were enrolled. Gut permeability was evaluated by measuring 24-hour urine excretion of orally administered 51Cr-EDTA. Clinical symptoms were evaluated in IBS-D patients and correlated to colonic permeability. Results: There was a significant decrease in the proximal small intestinal permeability in IBS-C patients compared to controls (0.26 ± 0.05 vs. 0.63 ± 0.1%; p < 0.05). Distal small intestinal permeability showed no significant difference in the studied group of patients compared to controls. Colonic permeability of IBS-D and inactive UC patients was significantly increased compared to controls (2.68 ± 0.35 and 3.74 ± 0.49 vs. 1.04 ± 0.18%; p < 0.05, p < 0.001). Colonic permeability of IBS-D patients correlated with stool frequency. Conclusions: Elevated gut permeability is localized to the colon both in IBS-D and in inactive UC patients. © 2011 S. Karger AG, Basel.","Intestinal barrier; Irritable bowel syndrome; Permeability; Ulcerative colitis","Adult; Aged; Case-Control Studies; Colitis, Ulcerative; Colon; Diarrhea; Edetic Acid; Female; Humans; Irritable Bowel Syndrome; Male; Middle Aged; Permeability; edetate chromium cr 51; adult; aged; article; clinical article; constipation; controlled study; diarrhea; feces; female; human; intestine mucosa permeability; irritable colon; male; priority journal; ulcerative colitis","","edetate chromium cr 51, 11063-42-6; Edetic Acid, 60-00-4","","","","","Chadwick V.S., Chen W., Shu D., Paulus B., Bethwaite P., Tie A., Wilson I., Activation of the mucosal immune system in irritable bowel syndrome, Gastroenterology, 122, 7, pp. 1778-1783, (2002); Barbara G., Stanghellini V., De Giorgio R., Cremon C., Cottrell G.S., Santini D., Pasquinelli G., Morselli-Labate A.M., Grady E.F., Bunnett N.W., Collins S.M., Corinaldesi R., Activated Mast Cells in Proximity to Colonic Nerves Correlate with Abdominal Pain in Irritable Bowel Syndrome, Gastroenterology, 126, 3, pp. 693-702, (2004); Park J.H., Rhee P.L., Kim H.S., Lee J.H., Kim Y.H., Kim J.J., Rhee J.C., Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome, J Gastroenterol Hepatol, 21, pp. 71-78, (2006); Tornblom H., Lindberg G., Nyberg B., Veress B., Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome, Gastroenterology, 123, 6, pp. 1972-1979, (2002); Porras M., Martin M.T., Yang P.-C., Jury J., Perdue M.H., Vergara P., Correlation between cyclical epithelial barrier dysfunction and bacterial translocation in the relapses of intestinal inflammation, Inflammatory Bowel Diseases, 12, 9, pp. 843-852, (2006); Spiller R.C., Jenkins D., Thornley J.P., Hebden J.M., Wright T., Skinner M., Neal K.R., Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, pp. 804-811, (2000); Dunlop S.P., Hebden J., Campbell E., Naesdal J., Olbe L., Perkins A.C., Spiller R.C., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, American Journal of Gastroenterology, 101, 6, pp. 1288-1294, (2006); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Marshall J.K., Thabane M., Garg A.X., Clark W., Meddings J., Collins S.M., Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario, Alimentary Pharmacology and Therapeutics, 20, 11-12, pp. 1317-1322, (2004); Piche T., Barbara G., Aubert P., Bruley Des Varannes S., Dainese R., Nano J.L., Cremon C., Stanghellini V., De Giorgio R., Galmiche J.P., Neunlist M., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: Involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Jenkins R.T., Ramage J.K., Jones D.B., Collins S.M., Goodacre R.L., Hunt R.H., Small bowel and colonic permeability to 51Cr-EDTA in patients with active inflammatory bowel disease, Clin Invest Med, 11, pp. 151-155, (1988); Soderholm J.D., Peterson K.H., Olaison G., Franzen L.E., Westrom B., Magnusson K.E., Sjodahl R., Epithelial Permeability to Proteins in the Noninflamed Ileum of Crohn's Disease? Gastroenterology, 117, pp. 65-72, (1999); Peeters M., Ghoos Y., Maes B., Hiele M., Geboes K., Vantrappen G., Rutgeerts P., Increased permeability of macroscopically normal small bowel in Crohn's disease, Digestive Diseases and Sciences, 39, 10, pp. 2170-2176, (1994); Hollander D., Vadheim C.M., Brettholz E., Increased intestinal permeability in patients with Crohn's disease and their relatives: A possible etiologic factor, Annals of Internal Medicine, 105, 6, pp. 883-885, (1986); Wyatt J., Vogelsang H., Hubl W., Waldhoer T., Lochs H., Intestinal permeability and the prediction of relapse in Crohn's disease, Lancet, 341, 8858, pp. 1437-1439, (1993); Tibble J.A., Sigthorsson G., Bridger S., Fagerhol M.K., Bjarnason I., Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease, Gastroenterology, 119, 1, pp. 15-22, (2000); Arslan G., Atasever T., Cindoruk M., Yildirim I.S.,  <sup>51</sup>CrEDTA colonic permeability and therapy response in patients with ulcerative colitis, Nuclear Medicine Communications, 22, 9, pp. 997-1001, (2001); Teahon K., Somasundaram S., Smith T., Menzies I., Bjarnason I., Assessing the site of increased intestinal permeability in coeliac and inflammatory bowel disease, Gut, 38, 6, pp. 864-869, (1996); Bjarnason I., Peters T.J., Veall N., A persistent defect in intestinal permeability in coeliac disease demonstrated by a <sup>51</sup>Cr-labelled EDTA absorption test, Lancet, 1, 8320, pp. 323-325, (1983); Bjarnason I., O'Morain C., Levi A.J., Peters T.J., Absorption of <sup>51</sup>Chromium-labeled ethylenediaminetetraacetate in inflammatory bowel disease, Gastroenterology, 85, 2, pp. 318-322, (1983); McGuckin M.A., Eri R., Simms L.A., Florin T.H., Radford-Smith G., Intestinal barrier dysfunction in inflammatory bowel diseases, Inflamm Bowel Dis, 15, pp. 100-113, (2009); Gecse K., Roka R., Ferrier L., Leveque M., Eutamene H., Cartier C., Ait-Belgnaoui A., Rosztoczy A., Izbeki F., Fioramonti J., Wittmann T., Bueno L., Increased faecal serine protease activity in diarrhoeic IBS patients: A colonic luminal factor impairing colonic permeability and sensitivity, Gut, 57, pp. 591-599, (2008); Schmitz H., Barmeyer C., Fromm M., Runkel N., Foss H.-D., Bentzel C.J., Riecken E.-O., Schulzke J.-D., Altered tight junction structure contributes to the impaired epithelial barrier function in ulcerative colitis, Gastroenterology, 116, 2, pp. 301-309, (1999); Zeissig S., Burgel N., Gunzel D., Richter J., Mankertz J., Wahnschaffe U., Kroesen A.J., Zeitz M., Fromm M., Schulzke J.-D., Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease, Gut, 56, 1, pp. 61-72, (2007); Roka R., Rosztoczy A., Leveque M., Izbeki F., Nagy F., Molnar T., Lonovics J., Garcia-Villar R., Fioramonti J., Wittmann T., Bueno L., A Pilot Study of Fecal Serine-Protease Activity: A Pathophysiologic Factor in Diarrhea-Predominant Irritable Bowel Syndrome, Clinical Gastroenterology and Hepatology, 5, 5, pp. 550-555, (2007); Kerckhoffs A.P., Akkermans L.M., De Smet M.B., Besselink M.G., Hietbrink F., Bartelink I.H., Busschers W.B., Samsom M., Renooij W., Intestinal permeability in irritable bowel syndrome patients: Effects of NSAIDs, Dig Dis Sci, 2010, 55, pp. 716-723; Camilleri M., Gorman H., Intestinal permeability and irritable bowel syndrome, Neurogastroenterology and Motility, 19, 7, pp. 545-552, (2007); Philipsen E.K., Batsberg W., Christensen A.B., Gastrointestinal permeability to polyethylene glycol: An evaluation of urinary recovery of an oral load of polyethylene glycol as a parameter of intestinal permeability in man, Eur J Clin Invest, 18, pp. 139-145, (1988); Jenkins A.P., Nukajam W.S., Menzies I.S., Creamer B., Simultaneous administration of lactulose and 51 Cr- ethylenediaminetetraacetic acid: A test to distinguish colonic from small-intestinal permeability change, Scand J Gastroenterol, 27, pp. 769-773, (1992); Weston A.P., Biddle W.L., Bhatia P.S., Miner Jr. P.B., Terminal ileal mucosal mast cells in irritable bowel syndrome, Digestive Diseases and Sciences, 38, 9, pp. 1590-1595, (1993); Van Wijk H.J., Smout A.J., Akkermans L.M., Roelofs J.M., Ten Thije O.J., Gastric emptying and dyspeptic symptoms in the irritable bowel syndrome, Scand J Gastroenterol, 27, pp. 99-102, (1992); Shulman R.J., Eakin M.N., Czyzewski D.I., Jarrett M., Ou C.N., Increased gastrointestinal permeability and gut inflammation in children with functional abdominal pain and irritable bowel syndrome, J Pediatr, 153, pp. 646-650, (2008); Gitter A.H., Wullstein F., Fromm M., Schulzke J.D., Epithelial barrier defects in ulcerative colitis: Characterization and quantification by electrophysiological imaging, Gastroenterology, 121, 6, pp. 1320-1328, (2001); Strater J., Wellisch I., Riedl S., Walczak H., Koretz K., Tandara A., Krammer P.H., Moller P., CD95 (APO-1/Fas)-mediated apoptosis in colon epithelial cells: A possible role in ulcerative colitis, Gastroenterology, 113, 1, pp. 160-167, (1997); Blair S.A., Kane S.V., Clayburgh D.R., Turner J.R., Epithelial myosin light chain kinase expression and activity are upregulated in inflammatory bowel disease, Laboratory Investigation, 86, 2, pp. 191-201, (2006); Dabek M., Ferrier L., Roka R., Gecse K., Annahazi A., Moreau J., Escourrou J., Cartier C., Chaumaz G., Leveque M., Ait-Belgnaoui A., Wittmann T., Theodorou V., Bueno L., Luminal cathepsin G and protease-activated receptor 4: A duet involved in alterations of the colonic epithelial barrier in ulcerative colitis, Am J Pathol, 175, pp. 207-214, (2009)","K. Gecse; First Department of Internal Medicine, University of Szeged, Szeged, Hungary; email: krisztina.gecse@gmail.com","","","","","","","","14219867","","DIGEB","22179430","English","Digestion","Article","Final","","Scopus","2-s2.0-83455164987"

"Hyland N.P.; Quigley E.M.M.; Brint E.","Hyland, Niall P. (15762604000); Quigley, Eamonn M.M. (7103105068); Brint, Elizabeth (6507920898)","15762604000; 7103105068; 6507920898","Microbiota-host interactions in irritable bowel syndrome: Epithelial barrier, immune regulation and brain-gut interactions","2014","World Journal of Gastroenterology","","27","","8859","8866","7","87","10.3748/wjg.v20.i27.8859","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84905376185&doi=10.3748%2fwjg.v20.i27.8859&partnerID=40&md5=7b84ead0284004de556b3a44e5204758","Alimentary Pharmabiotic Centre, University College Cork, Cork, 30, Ireland; Department of Pharmacology and Therapeutics, University College Cork, Cork, 30, Ireland; Houston Methodist Hospital, Houston, 77030, TX, United States; Department of Pathology, University College Cork, Coláiste Na Hollscoile, Bóthar an Choláiste, Co. Corcaigh, Cork, 30, Ireland","Hyland N.P., Alimentary Pharmabiotic Centre, University College Cork, Cork, 30, Ireland, Department of Pharmacology and Therapeutics, University College Cork, Cork, 30, Ireland; Quigley E.M.M., Alimentary Pharmabiotic Centre, University College Cork, Cork, 30, Ireland, Houston Methodist Hospital, Houston, 77030, TX, United States; Brint E., Alimentary Pharmabiotic Centre, University College Cork, Cork, 30, Ireland, Department of Pathology, University College Cork, Coláiste Na Hollscoile, Bóthar an Choláiste, Co. Corcaigh, Cork, 30, Ireland","Irritable bowel syndrome (IBS) is a common, sometimes debilitating, gastrointestinal disorder worldwide. While altered gut motility and sensation, as well as aberrant brain perception of visceral events, are thought to contribute to the genesis of symptoms in IBS, a search for an underlying aetiology has, to date, proven unsuccessful. Recently, attention has been focused on the microbiota as a possible factor in the pathogenesis of IBS. Prompted by a number of clinical observations, such as the recognition of the de novo development of IBS following enteric infections, as well as descriptions of changes in colonic bacterial populations in IBS and supported by clinical responses to interventions, such as antibiotics and probiotics, that modify the microbiota, various approaches have been taken to investigating the microbiota-host response in IBS, as well as in animal models thereof. From such studies a considerable body of evidence has accumulated to indicate the activation or upregulation of both factors involved in bacterial engagement with the host as well host defence mechanisms against bacteria. Alterations in gut barrier function, occurring in response, or in parallel, to changes in the microbiota, have also been widely described and can be seen to play a pivotal role in generating and sustaining host immune responses both within and beyond the gut. In this manner a plausible hypothesis, based on an altered microbiota and/or an aberrant host response, for the pathogenesis, of at least some instances of IBS, can be generated. © 2014 Baishideng Publishing Group Inc. All rights reserved.","Epithelial barrier; Gut-brain axis; Irritable bowel syndrome; Microbiota; Toll-like receptor","Animals; Bacteria; Brain; Host-Pathogen Interactions; Humans; Immunity, Mucosal; Intestinal Mucosa; Intestines; Irritable Bowel Syndrome; Microbiota; Permeability; Signal Transduction; G protein coupled receptor; G protein coupled receptor 41; G protein coupled receptor 43; interleukin 10; interleukin 12; short chain fatty acid; toll like receptor; toll like receptor 2; toll like receptor 4; unclassified drug; uvomorulin; Article; commensal ; host pathogen interaction ; host resistance ; immune response ; immunological tolerance ; immunoregulation ; intestine epithelium cell ; intestine innervation ; irritable colon ; mucosal immunity ; nerve cell plasticity ; neuromuscular function ; nonhuman; upregulation ; animal; Bacteria; brain; host pathogen interaction; human; immunology; innervation; intestine; intestine mucosa; irritable colon; metabolism; microbiology; microflora; mucosal immunity; pathophysiology; permeability; signal transduction","","interleukin 12, 138415-13-1; toll like receptor, 409141-78-2; toll like receptor 2, 203811-81-8; toll like receptor 4, 203811-83-0; uvomorulin, 112956-45-3","","","","","Guarner F., Malagelada J.R., Gut flora in health and disease, Lancet, 361, pp. 512-519, (2003); Codling C., O'Mahony L., Shanahan F., Quigley E.M., Marchesi J.R., A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome, Dig Dis Sci, 55, pp. 392-397, (2010); Jeffery I.B., Quigley E.M., Ohman L., Simren M., O'Toole P.W., The microbiota link to irritable bowel syndrome: An emerging story, Gut Microbes, 3, pp. 572-576, (2012); Quigley E.M., Therapies aimed at the gut microbiota and inflammation: Antibiotics, prebiotics, probiotics, synbiotics, anti-inflammatory therapies, Gastroenterol Clin North Am, 40, pp. 207-222, (2011); Choung R.S., Locke G.R., Epidemiology of IBS, Gastroenterol Clin North Am, 40, pp. 1-10, (2011); Clarke G., Quigley E.M., Cryan J.F., Dinan T.G., Irritable bowel syndrome: Towards biomarker identification, Trends Mol Med, 15, pp. 478-489, (2009); Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Quigley E.M., Abdel-Hamid H., Barbara G., Bhatia S.J., Boeckxstaens G., De Giorgio R., Delvaux M., Drossman D.A., Foxx-Orenstein A.E., Guarner F., Gwee K.A., Harris L.A., Hungin A.P., Hunt R.H., Kellow J.E., Khalif I.L., Kruis W., Lindberg G., Olano C., Moraes-Filho J.P., Schiller L.R., Schmulson M., Simren M., Tzeuton C., A global perspective on irritable bowel syndrome: A consensus statement of the World Gastroenterology Organisation Summit Task Force on irritable bowel syndrome, J Clin Gastroenterol, 46, pp. 356-366, (2012); Quigley E.M., Bugs on the brain; brain in the gut - Seeking explanations for common gastrointestinal symptoms, Ir J Med Sci, 182, pp. 1-6, (2013); Thabane M., Kottachchi D.T., Marshall J.K., Systematic review and meta-analysis: The incidence and prognosis of post-infectious irritable bowel syndrome, Aliment Pharmacol Ther, 26, pp. 535-544, (2007); Farhadi A., Banan A., Fields J., Keshavarzian A., Intestinal barrier: An interface between health and disease, J Gastroenterol Hepatol, 18, pp. 479-497, (2003); Goto Y., Ivanov I.I., Intestinal epithelial cells as mediators of the commensal-host immune crosstalk, Immunol Cell Biol, 91, pp. 204-214, (2013); Zyrek A.A., Cichon C., Helms S., Enders C., Sonnenborn U., Schmidt M.A., Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair, Cell Microbiol, 9, pp. 804-816, (2007); Ulluwishewa D., Anderson R.C., McNabb W.C., Moughan P.J., Wells J.M., Roy N.C., Regulation of tight junction permeability by intestinal bacteria and dietary components, J Nutr, 141, pp. 769-776, (2011); Petersson J., Schreiber O., Hansson G.C., Gendler S.J., Velcich A., Lundberg J.O., Roos S., Holm L., Phillipson M., Importance and regulation of the colonic mucus barrier in a mouse model of colitis, Am J Physiol Gastrointest Liver Physiol, 300, pp. G327-G333, (2011); Ohland C.L., Macnaughton W.K., Probiotic bacteria and intestinal epithelial barrier function, Am J Physiol Gastrointest Liver Physiol, 298, pp. G807-G819, (2010); Natividad J.M., Verdu E.F., Modulation of intestinal barrier by intestinal microbiota: Pathological and therapeutic implications, Pharmacol Res, 69, pp. 42-51, (2013); Dunlop S.P., Hebden J., Campbell E., Naesdal J., Olbe L., Perkins A.C., Spiller R.C., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Frese S.A., Benson A.K., Tannock G.W., Loach D.M., Kim J., Zhang M., Oh P.L., Heng N.C., Patil P.B., Juge N., Mackenzie D.A., Pearson B.M., Lapidus A., Dalin E., Tice H., Goltsman E., Land M., Hauser L., Ivanova N., Kyrpides N.C., Walter J., The evolution of host specialization in the vertebrate gut symbiont Lactobacillus reuteri, PLoS Genet, 7, (2011); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Lecleire S., Antonietti M., Gourcerol G., Leroi A.M., Dechelotte P., Menard J.F., Ducrotte P., Coeffier M., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am J Gastroenterol, 106, pp. 2165-2173, (2011); Martinez C., Lobo B., Pigrau M., Ramos L., Gonzalez-Castro A.M., Alonso C., Guilarte M., Guila M., De Torres I., Azpiroz F., Santos J., Vicario M., Diarrhoea-predominant irritable bowel syndrome: An organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, pp. 1160-1168, (2013); Villani A.C., Lemire M., Thabane M., Belisle A., Geneau G., Garg A.X., Clark W.F., Moayyedi P., Collins S.M., Franchimont D., Marshall J.K., Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis, Gastroenterology, 138, pp. 1502-1513, (2010); Nicholson J.K., Holmes E., Lindon J.C., Wilson I.D., The challenges of modeling mammalian biocomplexity, Nat Biotechnol, 22, pp. 1268-1274, (2004); Zeng J., Li Y.Q., Zuo X.L., Zhen Y.B., Yang J., Liu C.H., Clinical trial: Effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome, Aliment Pharmacol Ther, 28, pp. 994-1002, (2008); Vivinus-Nebot M., Frin-Mathy G., Bzioueche H., Dainese R., Bernard G., Anty R., Filippi J., Saint-Paul M.C., Tulic M.K., Verhasselt V., Hebuterne X., Piche T., Functional bowel symptoms in quiescent inflammatory bowel diseases: Role of epithelial barrier disruption and low-grade inflammation, Gut, 63, pp. 744-752, (2014); Magalhaes J.G., Tattoli I., Girardin S.E., The intestinal epithelial barrier: How to distinguish between the microbial flora and pathogens, Semin Immunol, 19, pp. 106-115, (2007); Medzhitov R., Origin and physiological roles of inflammation, Nature, 454, pp. 428-435, (2008); O'Hara A.M., Shanahan F., Gut microbiota: Mining for therapeutic potential, Clin Gastroenterol Hepatol, 5, pp. 274-284, (2007); Thomas C.M., Versalovic J., Probiotics-host communication: Modulation of signaling pathways in the intestine, Gut Microbes, 1, pp. 148-163, (2010); Lyons A., O'Mahony D., O'Brien F., MacSharry J., Sheil B., Ceddia M., Russell W.M., Forsythe P., Bienenstock J., Kiely B., Shanahan F., O'Mahony L., Bacterial strain-specific induction of Foxp3+ T regulatory cells is protective in murine allergy models, Clin Exp Allergy, 40, pp. 811-819, (2010); Sibartie S., O'Hara A.M., Ryan J., Fanning A., O'Mahony J., O'Neill S., Sheil B., O'Mahony L., Shanahan F., Modulation of pathogen-induced CCL20 secretion from HT-29 human intestinal epithelial cells by commensal bacteria, BMC Immunol, 10, (2009); McCarthy J., O'Mahony L., O'Callaghan L., Sheil B., Vaughan E.E., Fitzsimons N., Fitzgibbon J., O'Sullivan G.C., Kiely B., Collins J.K., Shanahan F., Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance, Gut, 52, pp. 975-980, (2003); Rachmilewitz D., Katakura K., Karmeli F., Hayashi T., Reinus C., Rudensky B., Akira S., Takeda K., Lee J., Takabayashi K., Raz E., Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis, Gastroenterology, 126, pp. 520-528, (2004); Jijon H., Backer J., Diaz H., Yeung H., Thiel D., McKaigney C., De Simone C., Madsen K., DNA from probiotic bacteria modulates murine and human epithelial and immune function, Gastroenterology, 126, pp. 1358-1373, (2004); Sheil B., McCarthy J., O'Mahony L., Bennett M.W., Ryan P., Fitzgibbon J.J., Kiely B., Collins J.K., Shanahan F., Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis, Gut, 53, pp. 694-700, (2004); O'Mahony L., O'Callaghan L., McCarthy J., Shilling D., Scully P., Sibartie S., Kavanagh E., Kirwan W.O., Redmond H.P., Collins J.K., Shanahan F., Differential cytokine response from dendritic cells to commensal and pathogenic bacteria in different lymphoid compartments in humans, Am J Physiol Gastrointest Liver Physiol, 290, pp. G839-G845, (2006); Abreu M.T., Toll-like receptor signalling in the intestinal epithelium: How bacterial recognition shapes intestinal function, Nat Rev Immunol, 10, pp. 131-144, (2010); Kamdar K., Nguyen V., DePaolo R.W., Toll-like receptor signaling and regulation of intestinal immunity, Virulence, 4, pp. 207-212, (2013); Neish A.S., Gewirtz A.T., Zeng H., Young A.N., Hobert M.E., Karmali V., Rao A.S., Madara J.L., Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination, Science, 289, pp. 1560-1563, (2000); Round J.L., Lee S.M., Li J., Tran G., Jabri B., Chatila T.A., Mazmanian S.K., The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota, Science, 332, pp. 974-977, (2011); Wang Y., Devkota S., Musch M.W., Jabri B., Nagler C., Antonopoulos D.A., Chervonsky A., Chang E.B., Regional mucosaassociated microbiota determine physiological expression of TLR2 and TLR4 in murine colon, PLoS One, 5, (2010); Brint E.K., MacSharry J., Fanning A., Shanahan F., Quigley E.M., Differential expression of toll-like receptors in patients with irritable bowel syndrome, Am J Gastroenterol, 106, pp. 329-336, (2011); Belmonte L., Beutheu Youmba S., Bertiaux-Vandaele N., Antonietti M., Lecleire S., Zalar A., Gourcerol G., Leroi A.M., Dechelotte P., Coeffier M., Ducrotte P., Role of toll like receptors in irritable bowel syndrome: Differential mucosal immune activation according to the disease subtype, PLoS One, 7, (2012); McKernan D.P., Nolan A., Brint E.K., O'Mahony S.M., Hyland N.P., Cryan J.F., Dinan T.G., Toll-like receptor mRNA expression is selectively increased in the colonic mucosa of two animal models relevant to irritable bowel syndrome, PLoS One, 4, (2009); Tattoli I., Petitta C., Scirocco A., Ammoscato F., Cicenia A., Severi C., Microbiota, innate immune system, and gastrointestinal muscle: Ongoing studies, J Clin Gastroenterol, 46, pp. S6-S11, (2012); Macsharry J., O'Mahony L., Fanning A., Bairead E., Sherlock G., Tiesman J., Fulmer A., Kiely B., Dinan T.G., Shanahan F., Quigley E.M., Mucosal cytokine imbalance in irritable bowel syndrome, Scand J Gastroenterol, 43, pp. 1467-1476, (2008); Lee B.J., Bak Y.T., Irritable bowel syndrome, gut microbiota and probiotics, J Neurogastroenterol Motil, 17, pp. 252-266, (2011); Rousseaux C., Thuru X., Gelot A., Barnich N., Neut C., Dubuquoy L., Dubuquoy C., Merour E., Geboes K., Chamaillard M., Ouwehand A., Leyer G., Carcano D., Colombel J.F., Ardid D., Desreumaux P., Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors, Nat Med, 13, pp. 35-37, (2007); Kuhn K.A., Stappenbeck T.S., Peripheral education of the immune system by the colonic microbiota, Semin Immunol, 25, pp. 364-369, (2013); Falk P.G., Hooper L.V., Midtvedt T., Gordon J.I., Creating and maintaining the gastrointestinal ecosystem: What we know and need to know from gnotobiology, Microbiol Mol Biol Rev, 62, pp. 1157-1170, (1998); O'Mahony C., Scully P., O'Mahony D., Murphy S., O'Brien F., Lyons A., Sherlock G., MacSharry J., Kiely B., Shanahan F., O'Mahony L., Commensal-induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB activation, PLoS Pathog, 4, (2008); Ochoa-Reparaz J., Mielcarz D.W., Ditrio L.E., Burroughs A.R., Begum-Haque S., Dasgupta S., Kasper D.L., Kasper L.H., Central nervous system demyelinating disease protection by the human commensal Bacteroides fragilis depends on polysaccharide A expression, J Immunol, 185, pp. 4101-4108, (2010); Corr S.C., Li Y., Riedel C.U., O'Toole P.W., Hill C., Gahan C.G., Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118, Proc Natl Acad Sci USA, 104, pp. 7617-7621, (2007); Rea M.C., Sit C.S., Clayton E., O'Connor P.M., Whittal R.M., Zheng J., Vederas J.C., Ross R.P., Hill C., Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against Clostridium difficile, Proc Natl Acad Sci USA, 107, pp. 9352-9357, (2010); Castagliuolo I., Riegler M.F., Valenick L., LaMont J.T., Pothoulakis C., Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa, Infect Immun, 67, pp. 302-307, (1999); Ohman L., Lindmark A.C., Isaksson S., Posserud I., Strid H., Sjovall H., Simren M., B-cell activation in patients with irritable bowel syndrome (IBS), Neurogastroenterol Motil, 21, pp. 644-650, (2009); Ohman L., Isaksson S., Lindmark A.C., Posserud I., Stotzer P.O., Strid H., Sjovall H., Simren M., T-cell activation in patients with irritable bowel syndrome, Am J Gastroenterol, 104, pp. 1205-1212, (2009); Cremon C., Pallotti F., Bacchilega M., Stanghellini V., Corinaldesi R., Barbara G., Antiflagellin antibodies suggest infective participation in irritable bowel syndrome pathogenesis, Expert Rev Gastroenterol Hepatol, 2, pp. 735-740, (2008); Schoepfer A.M., Schaffer T., Seibold-Schmid B., Muller S., Seibold F., Antibodies to flagellin indicate reactivity to bacterial antigens in IBS patients, Neurogastroenterol Motil, 20, pp. 1110-1118, (2008); Langhorst J., Junge A., Rueffer A., Wehkamp J., Foell D., Michalsen A., Musial F., Dobos G.J., Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome, Am J Gastroenterol, 104, pp. 404-410, (2009); O'Mahony L., McCarthy J., Kelly P., Hurley G., Luo F., Chen K., O'Sullivan G.C., Kiely B., Collins J.K., Shanahan F., Quigley E.M., Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles, Gastroenterology, 128, pp. 541-551, (2005); Diaz Heijtz R., Wang S., Anuar F., Qian Y., Bjorkholm B., Samuelsson A., Hibberd M.L., Forssberg H., Pettersson S., Normal gut microbiota modulates brain development and behavior, Proc Natl Acad Sci USA, 108, pp. 3047-3052, (2011); Neufeld K.M., Kang N., Bienenstock J., Foster J.A., Reduced anxiety-like behavior and central neurochemical change in germ-free mice, Neurogastroenterol Motil, 23, pp. 255-264, (2011); Cryan J.F., O'Mahony S.M., The microbiome-gut-brain axis: From bowel to behavior, Neurogastroenterol Motil, 23, pp. 187-192, (2011); Fleshner M., The gut microbiota: A new player in the innate immune stress response?, Brain Behav Immun, 25, pp. 395-396, (2011); Wang S.X., Wu W.C., Effects of psychological stress on small intestinal motility and bacteria and mucosa in mice, World J Gastroenterol, 11, pp. 2016-2021, (2005); Cryan J.F., Dinan T.G., Mind-altering microorganisms: The impact of the gut microbiota on brain and behaviour, Nat Rev Neurosci, 13, pp. 701-712, (2012); Desbonnet L., Garrett L., Clarke G., Kiely B., Cryan J.F., Dinan T.G., Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression, Neuroscience, 170, pp. 1179-1188, (2010); Bravo J.A., Forsythe P., Chew M.V., Escaravage E., Savignac H.M., Dinan T.G., Bienenstock J., Cryan J.F., Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve, Proc Natl Acad Sci USA, 108, pp. 16050-16055, (2011); Clarke G., Grenham S., Scully P., Fitzgerald P., Moloney R.D., Shanahan F., Dinan T.G., Cryan J.F., The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner, Mol Psychiatry, 18, pp. 666-673, (2013); Tillisch K., Labus J., Kilpatrick L., Jiang Z., Stains J., Ebrat B., Guyonnet D., Legrain-Raspaud S., Trotin B., Naliboff B., Mayer E.A., Consumption of fermented milk product with probiotic modulates brain activity, Gastroenterology, 144, pp. 1394-1401, (2013); Barajon I., Serrao G., Arnaboldi F., Opizzi E., Ripamonti G., Balsari A., Rumio C., Toll-like receptors 3, 4, and 7 are expressed in the enteric nervous system and dorsal root ganglia, J Histochem Cytochem, 57, pp. 1013-1023, (2009); Scirocco A., Matarrese P., Petitta C., Cicenia A., Ascione B., Mannironi C., Ammoscato F., Cardi M., Fanello G., Guarino M.P., Malorni W., Severi C., Exposure of Toll-like receptors 4 to bacterial lipopolysaccharide (LPS) impairs human colonic smooth muscle cell function, J Cell Physiol, 223, pp. 442-450, (2010); Hooper L.V., Wong M.H., Thelin A., Hansson L., Falk P.G., Gordon J.I., Molecular analysis of commensal host-microbial relationships in the intestine, Science, 291, pp. 881-884, (2001); Verdu E.F., Bercik P., Bergonzelli G.E., Huang X.X., Blennerhasset P., Rochat F., Fiaux M., Mansourian R., Corthesy-Theulaz I., Collins S.M., Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of postinfective gut dysfunction, Gastroenterology, 127, pp. 826-837, (2004); Husebye E., Hellstrom P.M., Sundler F., Chen J., Midtvedt T., Influence of microbial species on small intestinal myoelectric activity and transit in germ-free rats, Am J Physiol Gastrointest Liver Physiol, 280, pp. G368-G380, (2001); Kim G., Deepinder F., Morales W., Hwang L., Weitsman S., Chang C., Gunsalus R., Pimentel M., Methanobrevibacter smithii is the predominant methanogen in patients with constipation-predominant IBS and methane on breath, Dig Dis Sci, 57, pp. 3213-3218, (2012); Pimentel M., Lin H.C., Enayati P., Van Den Burg B., Lee H.R., Chen J.H., Park S., Kong Y., Conklin J., Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity, Am J Physiol Gastrointest Liver Physiol, 290, pp. G1089-G1095, (2006); Lee H.R., Pimentel M., Bacteria and irritable bowel syndrome: The evidence for small intestinal bacterial overgrowth, Curr Gastroenterol Rep, 8, pp. 305-311, (2006); Linden D.R., Levitt M.D., Farrugia G., Szurszewski J.H., Endogenous production of H2S in the gastrointestinal tract: Still in search of a physiologic function, Antioxid Redox Signal, 12, pp. 1135-1146, (2010); Fiorucci S., Distrutti E., Cirino G., Wallace J.L., The emerging roles of hydrogen sulfide in the gastrointestinal tract and liver, Gastroenterology, 131, pp. 259-271, (2006); Carbonero F., Benefiel A.C., Gaskins H.R., Contributions of the microbial hydrogen economy to colonic homeostasis, Nat Rev Gastroenterol Hepatol, 9, pp. 504-518, (2012); Teague B., Asiedu S., Moore P.K., The smooth muscle relaxant effect of hydrogen sulphide in vitro: Evidence for a physiological role to control intestinal contractility, Br J Pharmacol, 137, pp. 139-145, (2002); Gallego D., Clave P., Donovan J., Rahmati R., Grundy D., Jimenez M., Beyak M.J., The gaseous mediator, hydrogen sulphide, inhibits in vitro motor patterns in the human, rat and mouse colon and jejunum, Neurogastroenterol Motil, 20, pp. 1306-1316, (2008); Salminen S., Bouley C., Boutron-Ruault M.C., Cummings J.H., Franck A., Gibson G.R., Isolauri E., Moreau M.C., Roberfroid M., Rowland I., Functional food science and gastrointestinal physiology and function, Br J Nutr, 80, pp. S147-S171, (1998); Thompson J.S., Quigley E.M., Adrian T.E., Qualitative changes in enteric flora and short-chain fatty acids after intestinal resection, Dig Dis Sci, 43, pp. 624-631, (1998); Canani R.B., Costanzo M.D., Leone L., Pedata M., Meli R., Calignano A., Potential beneficial effects of butyrate in intestinal and extraintestinal diseases, World J Gastroenterol, 17, pp. 1519-1528, (2011); Treem W.R., Ahsan N., Kastoff G., Hyams J.S., Fecal short-chain fatty acids in patients with diarrhea-predominant irritable bowel syndrome: In vitro studies of carbohydrate fermentation, J Pediatr Gastroenterol Nutr, 23, pp. 280-286, (1996); Soret R., Chevalier J., De Coppet P., Poupeau G., Derkinderen P., Segain J.P., Neunlist M., Short-chain fatty acids regulate the enteric neurons and control gastrointestinal motility in rats, Gastroenterology, 138, pp. 1772-1782, (2010); Haschke G., Schafer H., Diener M., Effect of butyrate on membrane potential, ionic currents and intracellular Ca2+ concentration in cultured rat myenteric neurones, Neurogastroenterol Motil, 14, pp. 133-142, (2002); Tazoe H., Otomo Y., Kaji I., Tanaka R., Karaki S.I., Kuwahara A., Roles of short-chain fatty acids receptors, GPR41 and GPR43 on colonic functions, J Physiol Pharmacol, 59, pp. 251-262, (2008); Lesniewska V., Rowland I., Laerke H.N., Grant G., Naughton P.J., Relationship between dietary-induced changes in intestinal commensal microflora and duodenojejunal myoelectric activity monitored by radiotelemetry in the rat in vivo, Exp Physiol, 91, pp. 229-237, (2006); Durban A., Abellan J.J., Jimenez-Hernandez N., Artacho A., Garrigues V., Ortiz V., Ponce J., Latorre A., Moya A., Instability of the faecal microbiota in diarrhoea-predominant irritable bowel syndrome, FEMS Microbiol Ecol, 86, pp. 581-589, (2013)","","","WJG Press","","","","","","10079327","","WJGAF","25083059","English","World J. Gastroenterol.","Article","Final","","Scopus","2-s2.0-84905376185"

"Nébot-Vivinus M.; Harkat C.; Bzioueche H.; Cartier C.; Plichon-Dainese R.; Moussa L.; Eutamene H.; Pishvaie D.; Holowacz S.; Seyrig C.; Piche T.; Theodorou V.","Nébot-Vivinus, Mylene (57217982819); Harkat, Cherryl (56199620800); Bzioueche, Hanene (55810625700); Cartier, Christel (24079526500); Plichon-Dainese, Raffaella (56199913100); Moussa, Lara (55255554900); Eutamene, Helene (55926684800); Pishvaie, Dorsa (56201065700); Holowacz, Sophie (56200615700); Seyrig, Christian (15833116800); Piche, Thierry (7004658977); Theodorou, Vassilia (55410684700)","57217982819; 56199620800; 55810625700; 24079526500; 56199913100; 55255554900; 55926684800; 56201065700; 56200615700; 15833116800; 7004658977; 55410684700","Multispecies probiotic protects gut barrier function in experimental models","2014","World Journal of Gastroenterology","20","22","","6832","6843","11","52","10.3748/wjg.v20.i22.6832","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84902182868&doi=10.3748%2fwjg.v20.i22.6832&partnerID=40&md5=b1376f860bff1b2d9b3d2ffab57f8774","Department of Immunology Pole of Biology, CHU de Nice, 06103 Nice, France; EA 6302 'Tolérance immunitaire', Université de Nice Sophia Antipolis, 06103 Nice, France; Neuro-Gastroenterology and Nutrition Group, Toxalim UMR 1331 INRA/INPT/UPS, F-31027 Toulouse, France; Department of Gastroenterology, CHU de Nice, 06103 Nice, France; Groupe PiLeJe, 75015 Paris Cedex 15, 37 Quai de Grenelle, France","Nébot-Vivinus M., Department of Immunology Pole of Biology, CHU de Nice, 06103 Nice, France, EA 6302 'Tolérance immunitaire', Université de Nice Sophia Antipolis, 06103 Nice, France; Harkat C., Neuro-Gastroenterology and Nutrition Group, Toxalim UMR 1331 INRA/INPT/UPS, F-31027 Toulouse, France; Bzioueche H., Department of Immunology Pole of Biology, CHU de Nice, 06103 Nice, France, EA 6302 'Tolérance immunitaire', Université de Nice Sophia Antipolis, 06103 Nice, France; Cartier C., Neuro-Gastroenterology and Nutrition Group, Toxalim UMR 1331 INRA/INPT/UPS, F-31027 Toulouse, France; Plichon-Dainese R., EA 6302 'Tolérance immunitaire', Université de Nice Sophia Antipolis, 06103 Nice, France, Department of Gastroenterology, CHU de Nice, 06103 Nice, France; Moussa L., Neuro-Gastroenterology and Nutrition Group, Toxalim UMR 1331 INRA/INPT/UPS, F-31027 Toulouse, France; Eutamene H., Neuro-Gastroenterology and Nutrition Group, Toxalim UMR 1331 INRA/INPT/UPS, F-31027 Toulouse, France; Pishvaie D., Department of Gastroenterology, CHU de Nice, 06103 Nice, France; Holowacz S., Groupe PiLeJe, 75015 Paris Cedex 15, 37 Quai de Grenelle, France; Seyrig C., Groupe PiLeJe, 75015 Paris Cedex 15, 37 Quai de Grenelle, France; Piche T., EA 6302 'Tolérance immunitaire', Université de Nice Sophia Antipolis, 06103 Nice, France, Department of Gastroenterology, CHU de Nice, 06103 Nice, France; Theodorou V., Neuro-Gastroenterology and Nutrition Group, Toxalim UMR 1331 INRA/INPT/UPS, F-31027 Toulouse, France","Aim: To investigate the effect of the probiotic combination Lactibiane Tolerance® (LT) on epithelial barrier function in vitro and in vivo Methods: The effect of the multispecies probiotic LT was assessed on several models of epithelial barrier function both in vitro (in basal and inflammatory conditions) and in vivo [visceral hypersensitivity induced by chronic stress or by colonic perfusion of a fecal supernatant (FSN) from patients with irritable bowel syndrome (IBS)]. In vitro, we measured the permeability of confluent T84 cell monolayers incubated with or without LT by evaluating the paracellular flux of macromolecules, in basal conditions and after stimulation with lipopolysaccharide (LPS) or with conditioned medium of colonic biopsies from IBS patients (IBS-CM). In vivo, male C57/Bl6 mice received orally NaCl or LT for 15 d and were submitted to water avoidance stress (WAS) before evaluating visceral sensitivity by measuring the myoelectrical activity of the abdominal muscle and the paracellular permeability with 51Cr-EDTA. Permeability and sensitivity were also measured after colonic instillation of FSN. Tight-junctions were assessed by immunoblotting and TLR-4 expression was evaluated by immunohistochemistry Results: Incubation of T84 cell monolayers with LT in basal conditions had no significant effect on permeability (P > 0.05 vs culture medium). By contrast, addition of LT bacterial bodies (LT) completely prevented the LPS-induced increase in paracellular permeability (P < 0.01 vs LPS 10 ng/mL (LPS 10); P < 0.01 vs LPS 100 ng/mL (LPS 100), P > 0.05 vs culture medium). The effect was dose dependent as addition of 109 LT bacterial bodies induced a stronger decrease in absorbance than 106 LT (109 LT + LPS 10: -20.1% ± 13.4, P < 0.01 vs LPS 10; 106 LT + LPS 10: -11.6% ± 6.2, P < 0.01 vs LPS 10; 109 LT + LPS 100: -14.4% ± 5.5, P < 0.01 vs LPS 100; 106 LT + LPS 100: -11.6% ± 7.3, P < 0.05 vs LPS 100). Moreover, the increase in paracellular permeability induced by culturing T84 cells with conditioned medium of colonic biopsies from IBS patients (IBS-CM) was completely inhibited in the presence of 109 LT (P< 0.01 vs IBS-CM). LT also significantly prevented the epithelial disruption induced by intracolonic infusion of fecal supernatant from IBS patients (P < 0.01 vs IBS FSN) or water avoidance stress P < 0.01 vs WAS) in C57/Bl6 mice and increased the expression of occludin in vitro and in vivo, as assessed by immnunoblotting. The WAS-induced effect on visceral sensitivity was prevented by LT treatment since values obtained for all steps of colorectal distension were significantly (P < 0.01) different from the WAS group. Finally, LT downregulated the response mediated through TLR-4 in vitro (decrease in tumor necrosis factor α secretion in response to LPS: -65.8% for 109 LT and -52.5% for 106 LT, P < 0.01 vs LPS) and in vivo (inhibition of WAS induced an increase in TLR-4 expression in the LT treated mice colon, P < 0.01 vs WAS). Conclusion: The probiotic LT mix prevented the disruption to the epithelial barrier induced by LPS, stress or colonic soluble factors from IBS patients and prevented visceral hypersensitivity. © 2014 Baishideng Publishing Group Inc. All rights reserved.","Hypersensitivity; Intestinal epithelial barrier permeability; Irritable bowel syndrome; Probiotic","Animals; Cell Line; Colon; Culture Media, Conditioned; Disease Models, Animal; Dose-Response Relationship, Drug; Epithelial Cells; Feces; Humans; Hyperalgesia; Inflammation Mediators; Intestinal Mucosa; Irritable Bowel Syndrome; Lipopolysaccharides; Male; Mice, Inbred C57BL; Permeability; Probiotics; Tight Junction Proteins; Tight Junctions; Time Factors; Tissue Culture Techniques; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha; Visceral Pain; Lactibiane Tolerance; lipopolysaccharide; occludin; probiotic agent; protein ZO1; toll like receptor 4; tumor necrosis factor alpha; unclassified drug; autacoid; culture medium; lipopolysaccharide; probiotic agent; tight junction protein; Tlr4 protein, mouse; toll like receptor 4; tumor necrosis factor alpha; article; cell culture; cell membrane permeability; clinical assessment; colon biopsy; controlled study; feces analysis; human; human cell; hypersensitivity; immunoblotting; immunohistochemistry; intestine epithelium; intestine flora; irritable colon; myoelectric control; pathophysiology; permeability barrier; protein expression; quantitative assay; treatment outcome; animal; C57BL mouse; cell line; colon; culture medium; disease model; dose response; drug effects; epithelium cell; feces; hyperalgesia; intestine mucosa; Irritable Bowel Syndrome; male; metabolism; microbiology; permeability; tight junction; time; tissue culture technique; visceral pain","","occludin, 176304-61-3; toll like receptor 4, 203811-83-0; Culture Media, Conditioned, ; Inflammation Mediators, ; Lipopolysaccharides, ; Tight Junction Proteins, ; Tlr4 protein, mouse, ; Toll-Like Receptor 4, ; Tumor Necrosis Factor-alpha, ","Lactibiane Tolerance","","","","Brint E.K., McSharry J., Fanning A., Shanahan F., Quigley E.M., Differential expression of toll-like receptors in patients with irritable bowel syndrome, Am J Gastroenterol, 106, pp. 329-336, (2011); Belmonte L., Beutheu Youmba S., Bertiaux-Vandaele N., Antonietti M., Lecleire S., Zalar A., Gourcerol G., Leroi A.M., Dechelotte P., Coeffier M., Ducrotte P., Role of toll like receptors in irritable bowel syndrome: Differential mucosal immune activation according to the disease subtype, PLoS One, 7, (2012); Dai C., Zheng C.Q., Jiang M., Ma X.Y., Jiang L.J., Probiotics and irritable bowel syndrome, World J Gastroenterol, 19, pp. 5973-5980, (2013); Simren M., Barbara G., Flint H.J., Spiegel B.M., Spiller R.C., Vanner S., Verdu E.F., Whorwell P.J., Zoetendal E.G., Intestinal microbiota in functional bowel disorders: A Rome foundation report, Gut, 62, pp. 159-176, (2013); Sanders M.E., Guarner F., Guerrant R., Holt P.R., Quigley E.M., Sartor R.B., Sherman P.M., Mayer E.A., An update on the use and investigation of probiotics in health and disease, Gut, 62, pp. 787-796, (2013); Zareie M., Johnson-Henry K., Jury J., Yang P.C., Ngan B.Y., McKay D.M., Soderholm J.D., Perdue M.H., Sherman P.M., Probiotics prevent bacterial translocation and improve intestinal barrier function in rats following chronic psychological stress, Gut, 55, pp. 1553-1560, (2006); Ait-Belgnaoui A., Durand H., Cartier C., Chaumaz G., Eutamene H., Ferrier L., Houdeau E., Fioramonti J., Bueno L., Theodorou V., Prevention of gut leakiness by a probiotic treatment leads to attenuated HPA response to an acute psychological stress in rats, Psychoneuroendocrinology, 37, pp. 1885-1895, (2012); Ait-Belgnaoui A., Han W., Lamine F., Eutamene H., Fioramonti J., Bueno L., Theodorou V., Lactobacillus farciminis treatment suppresses stress induced visceral hypersensitivity: A possible action through interaction with epithelial cell cytoskeleton contraction, Gut, 55, pp. 1090-1094, (2006); Eutamene H., Lamine F., Chabo C., Theodorou V., Rochat F., Bergonzelli G.E., Corthesy-Theulaz I., Fioramonti J., Bueno L., Synergy between Lactobacillus paracasei and its bacterial products to counteract stress-induced gut permeability and sensitivity increase in rats, J Nutr, 137, pp. 1901-1907, (2007); Ki Cha B., Mun Jung S., Hwan Choi C., Song I.D., Woong Lee H., Joon Kim H., Hyuk J., Kyung Chang S., Kim K., Chung W.S., Seo J.G., The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: A randomized, double-blind, placebocontrolled trial, J Clin Gastroenterol, 46, pp. 220-227, (2012); Lyra A., Krogius-Kurikka L., Nikkila J., Malinen E., Kajander K., Kurikka K., Korpela R., Palva A., Effect of a multispecies probiotic supplement on quantity of irritable bowel syndromerelated intestinal microbial phylotypes, BMC Gastroenterol, 10, (2010); Drouault-Holowacz S., Foligne B., Dennin V., Goudercourt D., Terpend K., Burckel A., Pot B., Anti-inflammatory potential of the probiotic dietary supplement Lactibiane Tolérance: In vitro and in vivo considerations, Clin Nutr, 25, pp. 994-1003, (2006); Hayasaka D., Maeda K., Ennis F.A., Terajima M., Increased permeability of human endothelial cell line EA. hy926 induced by hantavirus-specific cytotoxic T lymphocytes, Virus Res, 123, pp. 120-127, (2007); Piche T., Barbara G., Aubert P., Bruley des Varannes S., Dainese R., Nano J.L., Cremon C., Stanghellini V., De Giorgio R., Galmiche J.P., Neunlist M., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: Involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Larauche M., Bradesi S., Million M., McLean P., Tache Y., Mayer E.A., McRoberts J.A., Corticotropin-releasing factor type 1 receptors mediate the visceral hyperalgesia induced by repeated psychological stress in rats, Am J Physiol Gastrointest Liver Physiol, 294, (2008); Bjarnason I., Peters T.J., Veall N., 51Cr-EDTA test for intestinal permeability, Lancet, 2, (1984); Mangell P., Nejdfors P., Wang M., Ahrne S., Westrom B., Thorlacius H., Jeppsson B., Lactobacillus plantarum 299v inhibits Escherichia coli-induced intestinal permeability, Dig Dis Sci, 47, pp. 511-516, (2002); Behzadian M.A., Windsor L.J., Ghaly N., Liou G., Tsai N.T., Caldwell R.B., VEGF-induced paracellular permeability in cultured endothelial cells involves urokinase and its receptor, FASEB J, 17, pp. 752-754, (2003); Traweger A., Fang D., Liu Y.C., Stelzhammer W., Krizbai I.A., Fresser F., Bauer H.C., Bauer H., The tight junction-specific protein occludin is a functional target of the E3 ubiquitinprotein ligase itch, J Biol Chem, 277, pp. 10201-10208, (2002); Gecse K., Roka R., Ferrier L., Leveque M., Eutamene H., Cartier C., Ait-Belgnaoui A., Rosztoczy A., Izbeki F., Fioramonti J., Wittmann T., Bueno L., Increased faecal serine protease activity in diarrhoeic IBS patients: A colonic lumenal factor impairing colonic permeability and sensitivity, Gut, 57, pp. 591-599, (2008); Silva M.A., Porras M., Jury J., Vergara P., Perdue M.H., Characterization of ileal dendritic cell distribution in a rat model of acute and chronic inflammation, Inflamm Bowel Dis, 12, pp. 457-470, (2006); Annahazi A., Gecse K., Dabek M., Ait-Belgnaoui A., Rosztoczy A., Roka R., Molnar T., Theodorou V., Wittmann T., Bueno L., Eutamene H., Fecal proteases from diarrheic-IBS and ulcerative colitis patients exert opposite effect on visceral sensitivity in mice, Pain, 144, pp. 209-217, (2009); Cenac N., Andrews C.N., Holzhausen M., Chapman K., Cottrell G., Andrade-Gordon P., Steinhoff M., Barbara G., Beck P., Bunnett N.W., Sharkey K.A., Ferraz J.G., Shaffer E., Vergnolle N., Role for protease activity in visceral pain in irritable bowel syndrome, J Clin Invest, 117, pp. 636-647, (2007); Cenac N., Chin A.C., Garcia-Villar R., Salvador-Cartier C., Ferrier L., Vergnolle N., Buret A.G., Fioramonti J., Bueno L., PAR2 activation alters colonic paracellular permeability in mice via IFN-gamma-dependent and-independent pathways, J Physiol, 558, pp. 913-925, (2004); Roka R., Demaude J., Cenac N., Ferrier L., Salvador-Cartier C., Garcia-Villar R., Fioramonti J., Bueno L., Colonic luminal proteases activate colonocyte proteinase-activated receptor-2 and regulate paracellular permeability in mice, Neurogastroenterol Motil, 19, pp. 57-65, (2007); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Ait-Belgnaoui A., Bradesi S., Fioramonti J., Theodorou V., Bueno L., Acute stress-induced hypersensitivity to colonic distension depends upon increase in paracellular permeability: Role of myosin light chain kinase, Pain, 113, pp. 141-147, (2005); Rajilic-Stojanovic M., Biagi E., Heilig H.G., Kajander K., Kekkonen R.A., Tims S., de Vos W.M., Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome, Gastroenterology, 141, pp. 1792-1801, (2011); Kassinen A., Krogius-Kurikka L., Makivuokko H., Rinttila T., Paulin L., Corander J., Malinen E., Apajalahti J., Palva A., The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects, Gastroenterology, 133, pp. 24-33, (2007); Anderson R.C., Cookson A.L., McNabb W.C., Park Z., McCann M.J., Kelly W.J., Roy N.C., Lactobacillus plantarum MB452 enhances the function of the intestinal barrier by increasing the expression levels of genes involved in tight junction formation, BMC Microbiol, 10, (2010); Iemoli E., Trabattoni D., Parisotto S., Borgonovo L., Toscano M., Rizzardini G., Clerici M., Ricci E., Fusi A., De Vecchi E., Piconi S., Drago L., Probiotics reduce gut microbial translocation and improve adult atopic dermatitis, J Clin Gastroenterol, 46, SUPPL., (2012); Paturi G., Phillips M., Kailasapathy K., Effect of probiotic strains Lactobacillus acidophilus LAFTI L10 and Lactobacillus paracasei LAFTI L26 on systemic immune functions and bacterial translocation in mice, J Food Prot, 71, pp. 796-801, (2008); Agostini S., Goubern M., Tondereau V., Salvador-Cartier C., Bezirard V., Leveque M., Keranen H., Theodorou V., Bourdu-Naturel S., Goupil-Feuillerat N., Legrain-Raspaud S., Eutamene H., A marketed fermented dairy product containing Bifidobacterium lactis CNCM I-2494 suppresses gut hypersensitivity and colonic barrier disruption induced by acute stress in rats, Neurogastroenterol Motil, 24, (2012)","T. Piche; Department of Gastroenterology, CHU de Nice, 06103 Nice, Hôpital Archet 2, France; email: piche.t@chu-nice.fr","","Baishideng Publishing Group Co","","","","","","10079327","","WJGAF","24944474","English","World J. Gastroenterol.","Article","Final","All Open Access; Green Open Access","Scopus","2-s2.0-84902182868"

"Lee J.W.; Park J.H.; Park D.I.L.; Park J.-H.; Kim H.J.; Cho Y.K.; Sohn C.I.L.; Jeon W.K.; Kim B.I.","Lee, Jae Woong (36013167300); Park, Jung Ho (57206477427); Park, Dong I. L. (56524839700); Park, Jung-Hwan (8917443800); Kim, Hong Joo (57185160200); Cho, Yong Kyun (35261851400); Sohn, Chong I. L. (7102538401); Jeon, Woo Kyu (25947504400); Kim, Byung Ik (24477301500)","36013167300; 57206477427; 56524839700; 8917443800; 57185160200; 35261851400; 7102538401; 25947504400; 24477301500","Subjects with diarrhea-predominant IBS have increased rectal permeability responsive to tryptase","2010","Digestive Diseases and Sciences","55","10","","2922","2928","6","51","10.1007/s10620-009-1094-8","https://www.scopus.com/inward/record.uri?eid=2-s2.0-77957929507&doi=10.1007%2fs10620-009-1094-8&partnerID=40&md5=03194730671ec7b6cd8a96dd4e760754","Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea; Department of BioNano Technology, Gaehon BioNano Research Institute, Kyungwon University, Seongnam, Gyeonggi-Do 461-701, South Korea","Lee J.W., Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea; Park J.H., Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea; Park D.I.L., Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea; Park J.-H., Department of BioNano Technology, Gaehon BioNano Research Institute, Kyungwon University, Seongnam, Gyeonggi-Do 461-701, South Korea; Kim H.J., Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea; Cho Y.K., Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea; Sohn C.I.L., Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea; Jeon W.K., Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea; Kim B.I., Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea","Background and Aims Patients with diarrhea-predominant irritable bowel syndrome (IBS-D) appear to have increased intestinal permeability; it has been suggested that activation of protease-activated receptor-2 (PAR-2) receptors is responsible for this alteration. The aims of this study are to evaluate (1) if rectal (large bowel) permeability is increased in IBS-D and (2) if tryptase plays a critical role in the altered permeability. Methods Rectal biopsies from 20 patients with IBS-D and 30 subjects without the condition (normal controls) were assessed for macromolecular permeability using horseradish peroxidase in Ussing chambers in the basal state and after addition of drugs to the basolateral side. Reversetranscription polymerase chain reaction (RT-PCR) was performed using colonic biopsy tissues from patients with IBS-D and normal subjects. Results When tryptase was added to the basolateral (not mucosal) side of normal rectal biopsy tissues, permeability appeared to be proportional to the increase in tryptase concentration (P ≤ 0.05) and was abolished by the addition of tryptase inhibitor (100 μM nafamostat; 1.568 ± 0.874 ng/2 h/mm2 to 0.766 ± 0.661 ng/2 h/mm2, n = 14, respectively, P ≤ 0.01). Intestinal permeability in patients with IBS-D was significantly increased compared with controls (0.848 ± 0.0.600 ng/2 h/mm2, n = 21, P ≤ 0.01). Nafamostat significantly reduced the enhanced permeability in IBS-D (0.934 ± 0.589 ng/2 h/mm2 to 0.247 ± 0.263 ng/ 2 h/mm2, n = 14, respectively, P ≤ 0.05). Transcription levels of PAR2 measured by RT-PCR did not differ between IBS-D and normal subjects. Conclusion Tryptase seems to play an important role in the control of human colonic mucosal permeability, and enhanced tryptase activity was responsible for the increased permeability of rectal mucosa in IBS patients. © Springer Science+Business Media, LLC 2009.","Irritable bowel syndrome; PAR-2; Tryptase","Biopsy; Cell Membrane Permeability; Cell Polarity; Colon; Diarrhea; Diffusion Chambers, Culture; Dose-Response Relationship, Drug; Horseradish Peroxidase; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Receptor, PAR-2; Rectum; Reverse Transcriptase Polymerase Chain Reaction; Tryptases; horseradish peroxidase; nafamstat; tryptase; proteinase activated receptor 2; tryptase; article; clinical article; colon biopsy; controlled study; diarrhea; human; human tissue; intestine mucosa permeability; irritable colon; priority journal; protein blood level; rectum biopsy; reverse transcription polymerase chain reaction; biopsy; cell membrane permeability; cell polarity; colon; diarrhea; diffusion chamber; dose response; drug effect; enzymology; genetics; in vitro study; intestine mucosa; irritable colon; metabolism; pathology; physiology; rectum","","nafamstat, 81525-10-2; tryptase, 97501-93-4; Horseradish Peroxidase, 1.11.1.-; Receptor, PAR-2, ; Tryptases, 3.4.21.59","","","","","Marshall J.K., Thabane M., Garg A.X., Clark W., Meddings J., Collins S.M., Investigators WEL: Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in walkerton Ontario, Aliment Pharmacol Ther., 20, pp. 1317-1322, (2004); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol., 101, pp. 1288-1294, (2006); Gecse K., Roka R., Ferrier L., Et al., Increased faecal serine protease activity in diarrhoeic IBS patients: A colonic lumenal factor impairing colonic permeability and sensitivity, Gut., 57, pp. 591-599, (2008); Barbara G., Stanghellini V., De Giorgio R., Et al., Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome, Gastroenterology., 126, pp. 693-702, (2004); Jacob C., Yang P.C., Darmoul D., Et al., Mast cell tryptase controls paracellular permeability of the intestine. Role of protease-activated receptor 2 and beta-arrestins, J Biol Chem., 280, pp. 31936-31948, (2005); Miller H.R., Pemberton A.D., Tissue-specific expression of mast cell granule serine proteinases and their role in inflammation in the lung and gut, Immunology., 105, pp. 375-390, (2002); O'Sullivan M., Clayton N., Breslin N.P., Et al., Increased mast cells in the irritable bowel syndrome, Neurogastroenterol Motil., 12, pp. 449-457, (2000); Park J.H., Rhee P.L., Kim H.S., Et al., Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome, J Gastroenterol Hepatol., 21, pp. 71-78, (2006); Hollander D., Intestinal permeability, leaky gut, and intestinal disorders, Curr Gastroenterol Rep., 1, pp. 410-416, (1999); Bajka B.H., Gillespie C.M., Steeb C.B., Read L.C., Howarth G.S., Applicability of the using chamber technique to permeability determinations in functionally distinct regions of the gastrointestinal tract in the rat, Scand J Gastroenterol., 38, pp. 732-741, (2003); Deitch E.A., Xu D., Naruhn M.B., Deitch D.C., Lu Q., Marino A.A., Elemental diet and IV-TPN-induced bacterial translocation is associated with loss of intestinal mucosal barrier function against bacteria, Ann Surg., 221, pp. 299-307, (1995); Mishima S., Xu D., Lu Q., Deitch E.A., Bacterial translocation is inhibited in inducible nitric oxide synthase knockout mice after endotoxin challenge but not in a model of bacterial overgrowth, Arch Surg., 132, pp. 1190-1195, (1997); Langeler E.G., Van Hinsbergh V.W., Characterization of an in vitro model to study the permeability of human arterial endothelial cell monolayers, Thromb Haemost., 60, pp. 240-246, (1988); Brun P., Castagliuolo I., Di Leo V., Et al., Increased intestinal permeability in obese mice: New evidence in the pathogenesis of nonalcoholic steatohepatitis, Am J Physiol Gastrointest Liver Physiol., 292, (2007); Willemsen L.E., Hoetjes J.P., Van Deventer S.J., Van Tol E.A., Abrogation of IFN-gamma mediated epithelial barrier disruption by serine protease inhibition, Clin Exp Immunol., 142, pp. 275-284, (2005); Park J.H., Rhee P.L., Lee J.H., Et al., Segmental heterogeneity of electrogenic secretions in human ascending colon and rectum, Int J Colorectal Dis., 21, pp. 357-364, (2006); Egan W.J., Lauri G., Egan W.J., Lauri G., Prediction of intestinal permeability, Adv Drug Deliv Rev., 54, pp. 273-289, (2002); Cenac N., Chin A.C., Garcia-Villar R., Et al., PAR2 activation alters colonic paracellular permeability in mice via IFN-gamma-dependent and -independent pathways, J Physiol., 558, pp. 913-925, (2004); Cenac N., Garcia-Villar R., Ferrier L., Et al., Proteinase-activated receptor-2-induced colonic inflammation in mice: Possible involvement of afferent neurons, nitric oxide, and paracellular permeability, J Immunol., 170, pp. 4296-4300, (2003); Talley N.J., Spiller R., Irritable bowel syndrome: A little understood organic bowel disease?, Lancet., 360, pp. 555-564, (2002); Dunlop S.P., Jenkins D., Spiller R.C., Distinctive histological patterns of chronic inflammtory cells in rectal biopsies of patients with different clinical subtypes of IBS, Gastroenterology., 122, (2002); Dunlop S.P., Jenkins D., Spiller R.C., Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome, Am J Gastroenterol., 98, pp. 1578-1583, (2003); Cenac N., Andrews C.N., Holzhausen M., Et al., Role for protease activity in visceral pain in irritable bowel syndrome, J Clin Invest., 117, pp. 636-647, (2007); Barbara G., Proteases in irritable bowel syndrome: A lot more than just digestive enzymes, Clin Gastroenterol Hepatol., 5, pp. 548-549, (2007); Roka R., Ait-Belgnaoui A., Salvador-Cartier C., Et al., Dexamethasone prevents visceral hyperalgesia but not colonic permeability increase induced by luminal protease-activated receptor-2 agonist in rats, Gut., 56, pp. 1072-1078, (2007); Cenac N., Coelho A.M., Nguyen C., Et al., Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2, Am J Pathol., 161, pp. 1903-1915, (2002); Chin A.C., Vergnolle N., MacNaughton W.K., Wallace J.L., Hollenberg M.D., Buret A.G., Proteinase-activated receptor 1 activation induces epithelial apoptosis and increases intestinal permeability, Proc Natl Acad Sci USA., 100, pp. 11104-11109, (2003); Coelho A.M., Vergnolle N., Guiard B., Fioramonti J., Bueno L., Proteinases and proteinase-activated receptor 2: A possible role to promote visceral hyperalgesia in rats, Gastroenterology., 122, pp. 1035-1047, (2002); Schmidlin F., Amadesi S., Dabbagh K., Et al., Protease-activated receptor 2 mediates eosinophil infiltration and hyperreactivity in allergic inflammation of the airway, J Immunol., 169, pp. 5315-5321, (2002); Mori S., Itoh Y., Shinohata R., Sendo T., Oishi R., Nishibori M., Nafamostat mesilate is an extremely potent inhibitor of human tryptase, J Pharmacol Sci., 92, pp. 420-423, (2003); Sendo T., Itoh Y., Goromaru T., Et al., A potent tryptase inhibitor nafamostat mesilate dramatically suppressed pulmonary dysfunction induced in rats by a radiographic contrast medium, Br J Pharmacol., 138, pp. 959-967, (2003); Spiller R.C., Jenkins D., Thornley J.P., Et al., Increased rectal mucosal enteroendocrine cells T lymphocytes and increased gut permeability following acute campylobacter enteritis and in postdysenteric irritable bowel syndrome, Gut., 47, pp. 804-811, (2000); Kingham J.G., Loehry C.A., Permeability of the small intestine after intra-arterial injection of histamine-type mediators and irradiation, Gut., 17, pp. 517-526, (1976); Wallon C., Braaf Y., Wolving M., Olaison G., Soderholm J.D., Endoscopic biopsies in ussing chambers evaluated for studies of macromolecular permeability in the human colon, Scand J Gastroenterol., 40, pp. 586-595, (2005); Weston A.P., Biddle W.L., Bhatia P.S., Miner P.B. Jr., Terminal ileal mucosal mast cells in irritable bowel syndrome, Dig Dis Sci., 38, pp. 1590-1595, (1993)","J. H. Park; Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea; email: pjho3@hotmail.com","","","","","","","","01632116","","DDSCD","20087660","English","Dig. Dis. Sci.","Article","Final","","Scopus","2-s2.0-77957929507"

"Mattioli F.; Fucile C.; Marini V.; Isola L.; Montanaro F.; Savarino V.; Martelli A.","Mattioli, Francesca (34880495600); Fucile, Carmen (55233713600); Marini, Valeria (6602400192); Isola, Luca (14037430000); Montanaro, Fabio (6604060422); Savarino, Vincenzo (7102084533); Martelli, Antonietta (57212532269)","34880495600; 55233713600; 6602400192; 14037430000; 6604060422; 7102084533; 57212532269","Assessment of intestinal permeability using sugar probes: Influence of urinary volume","2011","Clinical Laboratory","57","11-12","","909","918","9","11","","https://www.scopus.com/inward/record.uri?eid=2-s2.0-83455217925&partnerID=40&md5=c46993c54350092f8cdf9b38488be41c","Department of Internal Medicine, Clinical Pharmacology and Toxicology Unit, University of Genoa, Genoa 1-16132, Viale Benedetto XV 2, Italy; Department of Internal Medicine, Gastroenterology Unit, University of Genoa, Italy","Mattioli F., Department of Internal Medicine, Clinical Pharmacology and Toxicology Unit, University of Genoa, Genoa 1-16132, Viale Benedetto XV 2, Italy; Fucile C., Department of Internal Medicine, Clinical Pharmacology and Toxicology Unit, University of Genoa, Genoa 1-16132, Viale Benedetto XV 2, Italy; Marini V., Department of Internal Medicine, Clinical Pharmacology and Toxicology Unit, University of Genoa, Genoa 1-16132, Viale Benedetto XV 2, Italy; Isola L., Department of Internal Medicine, Gastroenterology Unit, University of Genoa, Italy; Montanaro F.; Savarino V., Department of Internal Medicine, Gastroenterology Unit, University of Genoa, Italy; Martelli A., Department of Internal Medicine, Clinical Pharmacology and Toxicology Unit, University of Genoa, Genoa 1-16132, Viale Benedetto XV 2, Italy","Background: As the accuracy of the ""Sugar Test"" is currently debated, this study was conducted to focus on how urine volumes may impact the test results. Methods: Fifty-five subjects, 23 healthy and 32 with Irritable Bowel Syndrome (IBS), were enrolled. Lactulose and D-mannitol dissolved in water were administered to all the participating subjects; the urine excreted was collected and the total urine volume was measured. The urine samples were analyzed by High Performance Liquid Chromatography (HPLC). The results were expressed as percentage of urine recovery of lactulose and D-mannitol and lactulose/D-mannitol ratio (LMR). Results: All subjects were divided into two groups: subjects with urine volume <500 mL and subjects with urine volume ≥500 mL. Urine analysis showed that the mean LMR was significantly lower in subjects with urine volume ≥500 mL than in subjects with urine volume <500 mL (0.02 ± 0.02 vs 0.04 ± 0.04; p <0.05). A significant increase in D-mannitol recovery was found to be associated with greater urine volumes (p <0.001). Conclusions: The urine volume may influence urinary excretion of sugar probes. Intake of liquids should therefore be carefully monitored before and during the test and the volume of urine produced over the period of collection should be precisely measured.","High Performance Liquid Chromatography (HPLC); Intestinal permeability; Irritable Bowel Syndrome (IBS); Lactulose/D-mannitol ratio (LMR); Sugar test","Adult; Chromatography, High Pressure Liquid; Confounding Factors (Epidemiology); Diffusion; Diuresis; Female; Humans; Intestinal Absorption; Intestinal Mucosa; Irritable Bowel Syndrome; Lactulose; Male; Mannitol; Microvilli; Middle Aged; Molecular Weight; Permeability; acetylsalicylic acid; duloxetine; lactulose; lansoprazole; lorazepam; mannitol; article; clinical article; controlled study; drug excretion; drug urine level; high performance liquid chromatography; human; intestine mucosa permeability; irritable colon; urinalysis; urinary excretion; urine volume","","acetylsalicylic acid, 493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1; duloxetine, 116539-59-4, 136434-34-9; lactulose, 4618-18-2; lansoprazole, 103577-45-3, 138530-94-6, 138530-95-7; lorazepam, 846-49-1; mannitol, 69-65-8, 87-78-5; Lactulose, 4618-18-2; Mannitol, 69-65-8","aspirin","","","","Vilela E.G., De Abreu F.M.D.L., De Gama T.H.O., Martins F.P., Goulart E.M.A., Lima A.S., Da C.A.S., Intestinal permeability and antigliadin antibody test for monitoring adult patients with celiac disease, Digestive Diseases and Sciences, 52, 5, pp. 1304-1309, (2007); Duerksen D.R., Wilhelm-Boyles C., Parry D.M., Intestinal permeability in long-term follow-up of patients with celiac disease on a gluten-free diet, Digestive Diseases and Sciences, 50, 4, pp. 785-790, (2005); Vilela E.G., Torres H.O.G., Ferrari M.L.A., Lima A.S., Cunha A.S., Gut permeability to lactulose and mannitol differs in treated Crohn's disease and celiac disease patients and healthy subjects. Intestinal permeability in intestinal diseases, Braz J Med Biol Res, 41, pp. 1105-1109, (2008); Puspok A., Oberhuber G., Wyatt J., Maier-Dobersberger T., Hammer J., Pfeffel F., Wrba F., Potzi R., Vogelsang H., Gastroduodenal permeability in Crohn's disease, European Journal of Clinical Investigation, 28, 1, pp. 67-71, (1998); Haase A.M., Kukuruzovic R.H., Dunn K., Bright A., Brewster D.R., Dual sugar permeability testing in diarrheal disease, Journal of Pediatrics, 136, 2, pp. 232-237, (2000); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, 1-2, pp. 41-46, (2009); Camilleri M., Gorman H., Intestinal permeability and irritable bowel syndrome, Neurogastroenterology and Motility, 19, 7, pp. 545-552, (2007); Ancel D., Barraud H., Peyrin-Biroulet L., Bronowicki J.P., Perméabilité intestinale et cirrhose, Gastroenterol Clin Biol, 30, pp. 460-468, (2006); Zuckerman M.J., Menzies I.S., Ho H., Gregory G.G., Casner N.A., Crane R.S., Hernandez J.A., Assessment of intestinal permeability and absorption in cirrhotic patients with ascites using combined sugar probes, Digestive Diseases and Sciences, 49, 4, pp. 621-626, (2004); Hendriks H.J.E., Van Kreel B., Forget P.P., Effects of therapy with lansoprazole on intestinal permeability and inflammation in young cystic fibrosis patients, Journal of Pediatric Gastroenterology and Nutrition, 33, 3, pp. 260-265, (2001); Penny D.J., Ingall C.B., Boulton P., Intestinal malabsorption in cystic fibrosis, Archives of Disease in Childhood, 61, 11, pp. 1127-1128, (1986); Menzies I.S., Laker M.F., Pounder R., Abnormal intestinal permeability to sugars in villous atrophy, Lancet, 2, 8152, pp. 1107-1109, (1979); Travis S., Menzies I., Intestinal permeability: Functional assessment and significance, Clin Sci (London), 82, 5, pp. 471-488, (1992); Strobel S., Brydon W.G., Ferguson A., Cellobiose/mannitol sugar permeability test complements biopsy histopathology in clinical investigation of the jejunum, Gut, 25, 11, pp. 1241-1246, (1984); Bjamason I., Macpherson A., Hollander D., Intestinal permeability: An overview, Gastroenterology, 108, pp. 1566-1581, (1995); Demeo M.T., Mutlu E.A., Keshavarzian A., Mary C.T., Intestinal permeation and gastrointestinal disease, J Clin Gastroenterol, 34, 4, pp. 385-396, (2002); Andre F., Andre C., Emery Y., Forichon J., Descos L., Minaire Y., Assessment of the lactulose - Mannitol test in Crohn's disease, Gut, 29, pp. 511-515, (1988); Miki K., Butler R., Moore D., Davidson G., Rapid and simultaneous quantification of rhamnose, mannitol, and lactulose in urine by HPLC for estimating intestinal permeability in pediatric practice, Clinical Chemistry, 42, 1, pp. 71-75, (1996); Hallemeesch M.M., Lamers W.H., Soeters P.B., Deutz N.E.P., Increased lactulose/rhamnose ratio during fluid load is caused by increased urinary lactulose excretion, American Journal of Physiology - Gastrointestinal and Liver Physiology, 278, 1, (2000); Willems D., Cadranel S., Jacobs W., Measurement of urinary sugars by HPLC in the estimation of intestinal permeability: Evaluation in pediatric clinical practice, Clinical Chemistry, 39, 5, pp. 888-890, (1993); Marsilio R., D'Antiga L., Zancan L., Dussini N., Zacchello F., Simultaneous HPLC determination with light-scattering detection of lactulose and mannitol in studies of intestinal permeability in pediatrics, Clinical Chemistry, 44, 8 I, pp. 1685-1691, (1998); Benjamin J., Makharia G.K., Ahuja V., Kalaivani M., Joshi Y.K., Intestinal permeability and its association with the patient and disease characteristics in Crohn's disease, World J Gastroenterol, 14, 9, pp. 1399-1405, (2008); Shah V.P., Midha K.K., Dighe S., Et al., Conference Report: Analytical Methods Validation: Bioavailability, Bioequivalence, and Pharmacocinetic Studies, J Pharm Sci-US, 81, 3, pp. 309-312, (1992); ICH Harmonised Tripartite Guideline: Validation of analytical procedures: Methodology. 6 Nov 1996, FDA Federal Register, 62, 90, pp. 25634-25635, (1997); Davies N.M., Non-steroidal anti-inflammatory drug-induced gastrointestinal permeability, Alimentary Pharmacology and Therapeutics, 12, 4, pp. 303-320, (1998); Camilleri M., Nadeau A., Lamsam J., Et al., Understanding measurements of intestinal permeability in healthy humans with urine lactulose and mannitol excretion, Neurogastroenterol Motil, 22, 1, (2010); Oudemans-van S.H.M., Van Der V.P.H., Hoek F.J., Bosman R.J., Van Der S.J.I., Zandstra D.F., Pitfalls in gastrointestinal permeability measurement in ICU patients with multiple organ failure using differential sugar absorption, Intensive Care Medicine, 28, 2, pp. 130-138, (2002); Parviainen I., Takala J., Jakob S.M., Does fluid loading influence measurements of intestinal permeability?, Critical Care, 9, 3, (2005); Blomquist L., Bark T., Hedemborg G., Norman A., Evaluation of the Lactulose/Mannitol and <sup>51</sup>Cr- Ethylenediaminetetracetic acid/ <sup>14</sup>C-Mannitol methods for intestinal permeability, Scand J Gastroenterol, 32, 8, pp. 805-812, (1997); Dunlop S.P., Hebden J., Campbell E., Naesdal J., Olbe L., Perkins A.C., Spiller R.C., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, American Journal of Gastroenterology, 101, 6, pp. 1288-1294, (2006)","F. Mattioli; Department of Internal Medicine, Clinical Pharmacology and Toxicology Unit, University of Genoa, Genoa 1-16132, Viale Benedetto XV 2, Italy; email: francesca.mattioli@unige.it","","","","","","","","14336510","","CLLAF","22239021","English","Clin. Lab.","Article","Final","","Scopus","2-s2.0-83455217925"

"Belmonte L.; Beutheu Youmba S.; Bertiaux-Vandaële N.; Antonietti M.; Lecleire S.; Zalar A.; Gourcerol G.; Leroi A.-M.; Déchelotte P.; Coëffier M.; Ducrotté P.","Belmonte, Liliana (6602674697); Beutheu Youmba, Stéphanie (55152209200); Bertiaux-Vandaële, Nathalie (53363278400); Antonietti, Michel (7103185148); Lecleire, Stéphane (6602495158); Zalar, Alberto (7005655226); Gourcerol, Guillaume (6506887187); Leroi, Anne-Marie (16555385000); Déchelotte, Pierre (57201760610); Coëffier, Moïse (6603081357); Ducrotté, Philippe (7006732860)","6602674697; 55152209200; 53363278400; 7103185148; 6602495158; 7005655226; 6506887187; 16555385000; 57201760610; 6603081357; 7006732860","Role of toll like receptors in irritable bowel syndrome: Differential mucosal immune activation according to the disease subtype","2012","PLoS ONE","7","8","e42777","","","","120","10.1371/journal.pone.0042777","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84865066764&doi=10.1371%2fjournal.pone.0042777&partnerID=40&md5=3e940dfa54f78eda58039c2c321f700f","INSERM Unit U1073, Rouen University, Rouen, France; Institute for Research and Innovation in Biomedicine, Rouen University, Rouen, France; Laboratory of Immunology, IIHema, Consejo Nacional de Investigaciones Científicas y Técnicas, Academy National of Medicine, Buenos Aires, Argentina; Gastroenterology Department, Rouen University Hospital, Rouen, France; Physiology Department, Rouen University Hospital, Rouen, France; Nutrition Unit, Rouen University Hospital, Rouen, France","Belmonte L., INSERM Unit U1073, Rouen University, Rouen, France, Institute for Research and Innovation in Biomedicine, Rouen University, Rouen, France, Laboratory of Immunology, IIHema, Consejo Nacional de Investigaciones Científicas y Técnicas, Academy National of Medicine, Buenos Aires, Argentina; Beutheu Youmba S., INSERM Unit U1073, Rouen University, Rouen, France, Institute for Research and Innovation in Biomedicine, Rouen University, Rouen, France; Bertiaux-Vandaële N., Gastroenterology Department, Rouen University Hospital, Rouen, France; Antonietti M., Gastroenterology Department, Rouen University Hospital, Rouen, France; Lecleire S., INSERM Unit U1073, Rouen University, Rouen, France, Institute for Research and Innovation in Biomedicine, Rouen University, Rouen, France, Gastroenterology Department, Rouen University Hospital, Rouen, France; Zalar A., Gastroenterology Department, Rouen University Hospital, Rouen, France; Gourcerol G., INSERM Unit U1073, Rouen University, Rouen, France, Institute for Research and Innovation in Biomedicine, Rouen University, Rouen, France, Physiology Department, Rouen University Hospital, Rouen, France; Leroi A.-M., INSERM Unit U1073, Rouen University, Rouen, France, Institute for Research and Innovation in Biomedicine, Rouen University, Rouen, France, Physiology Department, Rouen University Hospital, Rouen, France; Déchelotte P., INSERM Unit U1073, Rouen University, Rouen, France, Institute for Research and Innovation in Biomedicine, Rouen University, Rouen, France, Nutrition Unit, Rouen University Hospital, Rouen, France; Coëffier M., INSERM Unit U1073, Rouen University, Rouen, France, Institute for Research and Innovation in Biomedicine, Rouen University, Rouen, France, Nutrition Unit, Rouen University Hospital, Rouen, France; Ducrotté P., INSERM Unit U1073, Rouen University, Rouen, France, Institute for Research and Innovation in Biomedicine, Rouen University, Rouen, France, Gastroenterology Department, Rouen University Hospital, Rouen, France","Background: The irritable bowel syndrome (IBS) is a functional gastrointestinal disorder whose pathogenesis is not completely understood. Its high prevalence and the considerable effects on quality of life make IBS a disease with high social cost. Recent studies suggest that low grade mucosal immune activation, increased intestinal permeability and the altered host-microbiota interactions that modulate innate immune response, contribute to the pathophysiology of IBS. However, the understanding of the precise molecular pathophysiology remains largely unknown. Methodology and Findings: In this study our objective was to evaluate the TLR expression as a key player in the innate immune response, in the colonic mucosa of IBS patients classified into the three main subtypes (with constipation, with diarrhea or mixed). TLR2 and TLR4 mRNA expression was assessed by real time RT-PCR while TLRs protein expression in intestinal epithelial cells was specifically assessed by flow cytometry and immunofluorescence. Mucosal inflammatory cytokine production was investigated by the multiplex technology. Here we report that the IBS-Mixed subgroup displayed a significant up-regulation of TLR2 and TLR4 in the colonic mucosa. Furthermore, these expressions were localized in the epithelial cells, opening new perspectives for a potential role of epithelial cells in host-immune interactions in IBS. In addition, the increased TLR expression in IBS-M patients elicited intracellular signaling pathways resulting in increased expression of the mucosal proinflammatory cytokines IL-8 and IL1β. Conclusions: Our results provide the first evidence of differential expression of TLR in IBS patients according to the disease subtype. These results offer further support that microflora plays a central role in the complex pathophysiology of IBS providing novel pharmacological targets for this chronic gastrointestinal disorder according to bowel habits. © 2012 Belmonte et al.","","Adult; Aged; Antigens, CD14; Case-Control Studies; Colon; Cytokines; Female; Gene Expression; Humans; Inflammation Mediators; Intestinal Mucosa; Irritable Bowel Syndrome; Male; Middle Aged; PPAR gamma; RNA, Messenger; Toll-Like Receptor 2; Toll-Like Receptor 4; Up-Regulation; gamma interferon; interleukin 1beta; interleukin 6; interleukin 8; messenger RNA; peroxisome proliferator activated receptor gamma; toll like receptor; toll like receptor 2; toll like receptor 4; tumor necrosis factor alpha; adult; aged; article; cellular distribution; clinical article; colon mucosa; constipation; controlled study; cytokine production; diarrhea; female; flow cytometry; human; human cell; human tissue; immunofluorescence test; immunostimulation; inflammation; innate immunity; intestine epithelium cell; irritable colon; male; pathophysiology; protein expression; protein function; protein localization; real time polymerase chain reaction; reverse transcription polymerase chain reaction; signal transduction; upregulation","","gamma interferon, 82115-62-6; interleukin 8, 114308-91-7; toll like receptor, 409141-78-2; toll like receptor 2, 203811-81-8; toll like receptor 4, 203811-83-0; Antigens, CD14, ; Cytokines, ; Inflammation Mediators, ; PPAR gamma, ; RNA, Messenger, ; TLR2 protein, human, ; TLR4 protein, human, ; Toll-Like Receptor 2, ; Toll-Like Receptor 4, ","","","","","Thompson W.G., Longstreth G.F., Drossman D.A., Heaton K.W., Irvine E.J., Et al., Functional bowel disorders and functional abdominal pain, Gut, 45, SUPPL. 2, (1999); Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Et al., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Ohman L., Isaksson S., Lindmark A.C., Posserud I., Stotzer P.O., Et al., T-cell activation in patients with irritable bowel syndrome, Am J Gastroenterol, 104, pp. 1205-1212, (2009); Cremon C., Gargano L., Morselli-Labate A.M., Santini D., Cogliandro R.F., Et al., Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms, Am J Gastroenterol, 104, pp. 392-400, (2009); Barbara G., de Giorgio R., Stanghellini V., Cremon C., Corinaldesi R., A role for inflammation in irritable bowel syndrome?, Gut, 51, SUPPL. 1, (2002); Kassinen A., Krogius-Kurikka L., Makivuokko H., Rinttila T., Paulin L., Et al., The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects, Gastroenterology, 133, pp. 24-33, (2007); Camilleri M., Gorman H., Intestinal permeability and irritable bowel syndrome, Neurogastroenterol Motil, 19, pp. 545-552, (2007); Dunlop S.P., Hebden J., Campbell E., Naesdal J., Olbe L., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Srikanth C.V., McCormick B.A., Interactions of the intestinal epithelium with the pathogen and the indigenous microbiota: a three-way crosstalk, Interdiscip Perspect Infect Dis, 2008, (2008); Takeuchi O., Hoshino K., Kawai T., Sanjo H., Takada H., Et al., Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components, Immunity, 11, pp. 443-451, (1999); Medzhitov R., Toll-like receptors and innate immunity, Nat Rev Immunol, 1, pp. 135-145, (2001); Takeda K., Kaisho T., Akira S., Toll-like receptors, Annu Rev Immunol, 21, pp. 335-376, (2003); Gribar S.C., Richardson W.M., Sodhi C.P., Hackam D.J., No longer an innocent bystander: epithelial toll-like receptor signaling in the development of mucosal inflammation, Mol Med, 14, pp. 645-659, (2008); Lien E., Sellati T.J., Yoshimura A., Flo T.H., Rawadi G., Et al., Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products, J Biol Chem, 274, pp. 33419-33425, (1999); Kawai T., Akira S., TLR signaling, Cell Death Differ, 13, pp. 816-825, (2006); Podolsky D.K., Inflammatory bowel disease, N Engl J Med, 347, pp. 417-429, (2002); Hausmann M., Kiessling S., Mestermann S., Webb G., Spottl T., Et al., Toll-like receptors 2 and 4 are up-regulated during intestinal inflammation, Gastroenterology, 122, pp. 1987-2000, (2002); Cario E., Podolsky D.K., Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease, Infect Immun, 68, pp. 7010-7017, (2000); Szebeni B., Veres G., Dezsofi A., Rusai K., Vannay A., Et al., Increased mucosal expression of Toll-like receptor (TLR)2 and TLR4 in coeliac disease, J Pediatr Gastroenterol Nutr, 45, pp. 187-193, (2007); Shibolet O., Podolsky D.K., TLRs in the Gut. IV. Negative regulation of Toll-like receptors and intestinal homeostasis: addition by subtraction, Am J Physiol Gastrointest Liver Physiol, 292, (2007); Su C.G., Wen X., Bailey S.T., Jiang W., Rangwala S.M., Et al., A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response, J Clin Invest, 104, pp. 383-389, (1999); Dubuquoy L., Jansson E.A., Deeb S., Rakotobe S., Karoui M., Et al., Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis, Gastroenterology, 124, pp. 1265-1276, (2003); Coeffier M., Claeyssens S., Hecketsweiler B., Lavoinne A., Ducrotte P., Et al., Enteral glutamine stimulates protein synthesis and decreases ubiquitin mRNA level in human gut mucosa, Am J Physiol Gastrointest Liver Physiol, 285, (2003); Zalar A., Figueroa M.I., Ruibal-Ares B., Bare P., Cahn P., Et al., Macrophage HIV-1 infection in duodenal tissue of patients on long term HAART, Antiviral Res, 87, pp. 269-271, (2010); Lecleire S., Hassan A., Marion-Letellier R., Antonietti M., Savoye G., Et al., Combined glutamine and arginine decrease proinflammatory cytokine production by biopsies from Crohn's patients in association with changes in nuclear factor-kappaB and p38 mitogen-activated protein kinase pathways, J Nutr, 138, pp. 2481-2486, (2008); Frolova L., Drastich P., Rossmann P., Klimesova K., Tlaskalova-Hogenova H., Expression of Toll-like receptor 2 (TLR2), TLR4, and CD14 in biopsy samples of patients with inflammatory bowel diseases: upregulated expression of TLR2 in terminal ileum of patients with ulcerative colitis, J Histochem Cytochem, 56, pp. 267-274, (2008); Brint E.K., MacSharry J., Fanning A., Shanahan F., Quigley E.M., Differential expression of toll-like receptors in patients with irritable bowel syndrome, Am J Gastroenterol, 106, pp. 329-336, (2010); McKernan D.P., Gaszner G., Quigley E.M., Cryan J.F., Dinan T.G., Altered peripheral toll-like receptor responses in the irritable bowel syndrome, Aliment Pharmacol Ther, 33, pp. 1045-1052, (2011); Sato S., Nomura F., Kawai T., Takeuchi O., Muhlradt P.F., Et al., Synergy and cross-tolerance between toll-like receptor (TLR) 2- and TLR4-mediated signaling pathways, J Immunol, 165, pp. 7096-7101, (2000); Jung H.C., Eckmann L., Yang S.K., Panja A., Fierer J., Et al., A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion, J Clin Invest, 95, pp. 55-65, (1995); Drossman D.A., Morris C.B., Hu Y., Toner B.B., Diamant N., Et al., A prospective assessment of bowel habit in irritable bowel syndrome in women: defining an alternator, Gastroenterology, 128, pp. 580-589, (2005); O'Hara A.M., Shanahan F., The gut flora as a forgotten organ, EMBO Rep, 7, pp. 688-693, (2006)","L. Belmonte; INSERM Unit U1073, Rouen University, Rouen, France; email: liliana.belmonte-zalar@inv.univ-rouen.fr","","","","","","","","19326203","","","23028414","English","PLoS ONE","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-84865066764"

"Shulman R.J.; Eakin M.N.; Czyzewski D.I.; Jarrett M.; Ou C.-N.","Shulman, Robert J. (56961627200); Eakin, Michelle N. (15834401200); Czyzewski, Danita I. (6701585207); Jarrett, Monica (7005047885); Ou, Ching-Nan (7103373731)","56961627200; 15834401200; 6701585207; 7005047885; 7103373731","Increased Gastrointestinal Permeability and Gut Inflammation in Children with Functional Abdominal Pain and Irritable Bowel Syndrome","2008","Journal of Pediatrics","153","5","","646","650","4","137","10.1016/j.jpeds.2008.04.062","https://www.scopus.com/inward/record.uri?eid=2-s2.0-55549142198&doi=10.1016%2fj.jpeds.2008.04.062&partnerID=40&md5=9e83e9908a517b611c309a24c44e6aa0","Department of Pediatrics, Houston, TX, United States; Menninger Department of Psychiatry and Behavioral Sciences, Houston, TX, United States; Baylor College of Medicine, Houston, TX, United States; Texas Children's Hospital, Houston, TX, United States; Children's Nutrition Research Center, Wilmington, DE, United States; A.I. duPont Hospital for Children, Wilmington, DE, United States; Department of Biobehavioral Nursing and Health Systems, University of Washington, Seattle, WA, United States","Shulman R.J., Department of Pediatrics, Houston, TX, United States, Baylor College of Medicine, Houston, TX, United States, Texas Children's Hospital, Houston, TX, United States, Children's Nutrition Research Center, Wilmington, DE, United States; Eakin M.N., A.I. duPont Hospital for Children, Wilmington, DE, United States; Czyzewski D.I., Department of Pediatrics, Houston, TX, United States, Menninger Department of Psychiatry and Behavioral Sciences, Houston, TX, United States, Baylor College of Medicine, Houston, TX, United States, Texas Children's Hospital, Houston, TX, United States; Jarrett M., Department of Biobehavioral Nursing and Health Systems, University of Washington, Seattle, WA, United States; Ou C.-N., Department of Pediatrics, Houston, TX, United States, Baylor College of Medicine, Houston, TX, United States, Texas Children's Hospital, Houston, TX, United States","Objectives: To determine gastrointestinal (GI) permeability and fecal calprotectin concentration in children 7 to 10 years of age with functional abdominal pain and irritable bowel syndrome (FAP/IBS) versus control subjects and ascertain potential relationships with pain symptoms and stooling. Study design: GI permeability and fecal calprotectin concentration were measured. Children kept a 2-week diary of pain episodes and stooling pattern. Results: Proximal GI permeability was greater in the FAP/IBS group (n = 93) compared with control subjects (n = 52) (0.59 ± 0.50 vs 0.36 ± 0.26, respectively; mean ± SD; P < .001) as was colonic permeability (1.01 ± 0.67 vs 0.81 ± 0.43, respectively; P < .05). Gastric and small intestinal permeability were similar. Fecal calprotectin concentration was greater in children with FAP/IBS compared with control children (65.5 ± 75.4 μg/g stool vs 43.2 ± 39.4, respectively; P < .01). Fecal calprotectin concentration correlated with pain interference with activities (P = .01, r2 = 0.36). There was no correlation between GI permeability and pain related symptoms. Neither permeability nor fecal calprotectin correlated with stool form. Conclusions: Children with FAP/IBS have evidence of increased GI permeability and low-grade GI inflammation, with the latter relating to the degree to which pain interferes with activities. © 2008 Mosby, Inc. All rights reserved.","","Abdominal Pain; Case-Control Studies; Child; Feces; Female; Gastrointestinal Tract; Humans; Inflammation; Irritable Bowel Syndrome; Leukocyte L1 Antigen Complex; Male; Permeability; Regression Analysis; calgranulin; calgranulin; abdominal pain; article; clinical feature; controlled study; disease association; disease severity; female; gastritis; human; irritable colon; major clinical study; male; membrane permeability; pain assessment; priority journal; school child; case control study; child; feces; gastrointestinal tract; inflammation; irritable colon; metabolism; pathology; pathophysiology; permeability; regression analysis","","Leukocyte L1 Antigen Complex, ","","","Daffy's Foundation, (P30 DK56338); Texas Medical Center Digestive Disease Center; National Institute of Nursing Research, NINR, (R01NR005337); U.S. Department of Agriculture, USDA; Agricultural Research Service, USDA ARS, (6250-51000-043)","Supported by R01 05337 to RJS, the Daffy's Foundation, P30 DK56338 which funds the Texas Medical Center Digestive Disease Center, Daffy's Foundation, and the USDA/ARS under Cooperative Agreement No. 6250-51000-043. This work is a publication of the USDA/ARS Children's Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine, and Texas Children's Hospital, Houston, TX. The contents of this publication do not necessarily reflect the views or policies of the USDA, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government. ","Liebman W.M., Recurrent abdominal pain in children: a retrospective survey of 119 patients, Clin Pediatr, 17, pp. 149-153, (1978); Hyams J.S., Treem W.R., Justinich C.J., Davis P., Shoup M., Burke G., Characterization of symptoms in children with recurrent abdominal pain: resemblance to irritable bowel syndrome, J Pediatr Gastroenterol Nutr, 20, pp. 209-214, (1995); Hyams J.S., Burke G., Davis P.M., Rzepski B., Andrulonis P.A., Abdominal pain and irritable bowel syndrome in adolescents: a community-based study, J Pediatr, 129, pp. 220-226, (1996); Rasquin A., Di L.C., Forbes D., Guiraldes E., Hyams J.S., Staiano A., Et al., Childhood functional gastrointestinal disorders: child/adolescent, Gastroenterology, 130, pp. 1527-1537, (2006); DiLorenzo C., Colletti R.B., Lehmann H.P., Boyle J.T., Gerson W.T., Hyams J.S., Et al., Chronic abdominal pain in children: a technical report of the American Academy of Pediatrics and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, J Pediatr Gastroenterol Nutr, 40, pp. 249-261, (2005); Jarrett M., Heitkemper M., Czyzewski D.I., Shulman R.J., Recurrent abdominal pain in children: forerunner to adult irritable bowel syndrome?, J Soc Pediatr Nurs, 8, pp. 81-89, (2003); Burke P., Elliott M., Fleissner R., Irritable bowel syndrome and recurrent abdominal pain. A comparative review, Psychosomatics, 40, pp. 277-285, (1999); DiLorenzo C., Youssef N.N., Sigurdsson L., Scharff L., Griffiths J., Wald A., Visceral hyperalgesia in children with functional abdominal pain, J Pediatr, 139, pp. 838-843, (2001); Tibble J.A., Sigthorsson G., Foster R., Forgacs I., Bjarnason I., Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease, Gastroenterology, 123, pp. 450-460, (2002); Dunlop S.P., Hebden J., Campbell E., Naesdal J., Olbe L., Perkins A.C., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Olafsdottir E., Aksnes L., Fluge G., Berstad A., Faecal calprotectin levels in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children, Acta Paediatr, 91, pp. 45-50, (2002); Berni Canani R., Rapacciuolo L., Romano M.T., Tanturri de H.L., Terrin G., Manguso F., Et al., Diagnostic value of faecal calprotectin in paediatric gastroenterology clinical practice, Dig Liver Dis, 36, pp. 467-470, (2004); Rasquin-Weber A., Hyman P.E., Cucchiara S., Fleisher D.R., Hyams J.S., Milla P.J., Et al., Childhood functional gastrointestinal disorders, Gut, 45, SUPPL. 2, (1999); Von Baeyer C.L., Walker L.S., Children with recurrent abdominal pain: issues in the selection and description of research participants, Develop Behav Pediatr, 20, pp. 307-313, (1999); Research Diagnostic Questions for Functional Gastrointestinal Disorders: Rome II Modular Questionnaire, Rome II The Functional Gastrointestinal Disorders. 2nd ed., pp. 670-688, (2000); Clinical Diagnostic Questionnaire for Pediatric Functional Gastrointestinal Disorders, Rome II The Functional Gastrointestinal Disorders. 2nd ed., pp. 715-722, (2000); Shulman R.J., Schanler R.J., Lau C., Heitkemper M., Ou C.-N., Smith E.O., Early feeding, antenatal glucocorticoids, and human milk decrease intestinal permeability in preterm infants, Pediatr Res, 44, pp. 519-523, (1998); Shulman R.J., Eakin M.N., Jarrett M., Czyzewski D.I., Zeltzer L.K., Characteristics of pain and stooling in children with recurrent abdominal pain, J Pediatr Gastroenterol Nutr, 44, pp. 203-208, (2007); McGrath P.J., Beyer J., Cleeland C., Eland J., McGrath P.A., Portenoy R., American Academy of Pediatrics Report of the Subcommittee on Assessment and Methodologic Issues in the Management of Pain in Childhood Cancer, Pediatrics, 86, PART 2, pp. 814-817, (1990); Varni J.W., Walco G.A., Katz E.R., A cognitive-behavioral approach to pain associated with pediatric chronic diseases, J Pain Symptom Manage, 4, pp. 238-241, (1989); Sanders M.R., Shepherd R.W., Cleghorn G., Woolford H., The treatment of recurrent abdominal pain in children: a controlled comparison of cognitive-behavioral family intervention and standard pediatric care, J Consult Clin Psychol, 62, pp. 306-314, (1994); Wong D.I., Baker C.M., Pain in children: comparison of assessment scales, Pediatr Nurs, 14, pp. 9-17, (1988); Gaylord N., Carson S., Assessing recurrent abdominal pain in children, Nurse Pract, 8, pp. 19-24, (1983); Lewis S.J., Heaton K.W., Stool form scale as a useful guide to intestinal transit time, Scand J Gastroenterol, 32, pp. 920-924, (1997); Marshall J.K., Thabane M., Garg A.X., Clark W., Meddings J., Collins S.M., Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario, Aliment Pharmacol Ther, 20, pp. 1317-1322, (2004); Spiller R.C., Jenkins D., Thornley J.P., Hebden J.M., Wright T., Skinner M., Et al., Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, pp. 804-811, (2000); Amery W.K., Forget P.P., The role of the gut in migraine: The oral 51-Cr EDTA test in recurrent abdominal pain, Cephalalgia, 9, pp. 227-229, (1989); van der Meer S.B., Forget P.P., Heidendal G.A.K., Abnormal small bowel permeability and duodenitis in recurrent abdominal pain, Arch Dis Child, 65, pp. 1311-1314, (1990); van der Meer S.B., Forget P.P., Arends J.W., Small bowel permeability to 51Cr-EDTA in children with recurrent abdominal pain, Acta Paediatr Scand, 79, pp. 422-426, (1990); Barau E., Dupont C., Modifications of intestinal permeability during food provocation procedures in pediatric irritable bowel syndrome, J Pediatr Gastroenterol Nutr, 11, pp. 72-77, (1990); Bercik P., Verdu E.F., Collins S.M., Is irritable bowel syndrome a low-grade inflammatory bowel disease?, Gastroenterol Clin North Am, 34, pp. 235-237, (2005); Roseth A.G., Fagerhol M.K., Aadland E., Schjonsby H., Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study, Scand J Gastroenterol, 27, pp. 793-798, (1992); Barreau F., Ferrier L., Fioramonti J., Bueno L., New insights in the etiology and pathophysiology of irritable bowel syndrome: contribution of neonatal stress models, Pediatr Res, 62, pp. 240-245, (2007); Anand K.J., Runeson B., Jacobson B., Gastric suction at birth associated with long-term risk for functional intestinal disorders in later life, J Pediatr, 144, pp. 449-454, (2004); Andrews K.A., Desai D., Dhillon H.K., Wilcox D.T., Fitzgerald M., Abdominal sensitivity in the first year of life: comparison of infants with and without prenatally diagnosed unilateral hydronephrosis, Pain, 100, pp. 35-46, (2002); Bengtson M.B., Ronning T., Vatn M.H., Harris J.R., Irritable bowel syndrome in twins: genes and environment, Gut, 55, pp. 1754-1759, (2006)","R.J. Shulman; Department of Pediatrics, Houston, TX, United States; email: rshulman@bcm.edu","","","","","","","","00223476","","JOPDA","18538790","English","J. Pediatr.","Article","Final","All Open Access; Green Open Access","Scopus","2-s2.0-55549142198"

"Wilcz-Villega E.; Mcclean S.; O'Sullivan M.","Wilcz-Villega, E. (55650650000); Mcclean, S. (16425720600); O'Sullivan, M. (35616329200)","55650650000; 16425720600; 35616329200","Reduced E-cadherin expression is associated with abdominal pain and symptom duration in a study of alternating and diarrhea predominant IBS","2014","Neurogastroenterology and Motility","26","3","","316","325","9","40","10.1111/nmo.12262","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84894231578&doi=10.1111%2fnmo.12262&partnerID=40&md5=6fce97a0555140aa36a9d9ce3d6c0f71","Department of Clinical Medicine, Trinity Centre for Health Sciences, Adelaide and Meath Hospital, Dublin, Ireland; Centre for Microbial Host Interactions, Institute of Technology Tallaght, Dublin, Ireland; Department of Clinical Medicine, Trinity Centre for Health Sciences, St James's Hospital, Dublin, Ireland","Wilcz-Villega E., Department of Clinical Medicine, Trinity Centre for Health Sciences, Adelaide and Meath Hospital, Dublin, Ireland; Mcclean S., Centre for Microbial Host Interactions, Institute of Technology Tallaght, Dublin, Ireland; O'Sullivan M., Department of Clinical Medicine, Trinity Centre for Health Sciences, St James's Hospital, Dublin, Ireland","Background: Increased intestinal permeability and altered expression of tight junction (TJ) proteins may be implicated in the pathogenesis of irritable bowel syndrome (IBS). This study aimed to investigate the expression of adherens junction (AJ) protein E-cadherin and TJ proteins zonula occludens (ZO)-1 and claudin (CLD)-1 and associations with IBS symptoms. Methods: Junctional proteins were immunostained in cecal biopsy tissue of Rome II IBS patients (n = 34) comprising both alternating (IBS-A) and diarrhea predominant (IBS-D) subtypes, and controls (n = 12). IBS symptom duration, abdominal pain severity and stool frequency were assessed for IBS patients. Protein expression was determined by immunofluorescence. Key Results: E-cadherin and ZO-1 protein expression was significantly lower (p = 0.03 and p = 0.016, respectively) in the cecal surface epithelium of the IBS group comprising both IBS-A and IBS-D subtypes. CLD-1 expression was not significantly altered compared with controls. On subtype analysis, ZO-1 expression was significantly reduced in both IBS-A and IBS-D compared with controls, whereas E-cadherin was reduced only in IBS-A. Lower E-cadherin expression was associated with longer symptoms duration specifically in IBS-A patients (rs = -0.76, p = 0.004). Reduced E-cadherin associated with abdominal pain severity in the overall IBS group (rs = -0.36, p = 0.041), but this association was unrelated to IBS subtype. Conclusions & Inferences: E-cadherin protein expression in the cecum was significantly lower in IBS-A compared with controls and associated with longstanding symptoms. E-cadherin was further associated with abdominal pain severity in the IBS group overall, but unrelated to IBS subtype. Altered E-cadherin expression may provide novel insights into mechanisms underlying intestinal barrier dysfunction in IBS. In this study, comprising IBS-A and IBS-D subtypes, E-cadherin and ZO-1 protein expression was significantly lower in the cecal surface epithelium compared with controls. Furthermore, reduced E-cadherin expressed in the IBS group was associated with more severe abdominal pain, and in IBS-A with longer duration of symptoms. Altered E-cadherin expression may provide novel insights into mechanisms underlying intestinal barrier dysfunction in IBS. © 2013 John Wiley & Sons Ltd.","Adherens junction proteins; E-cadherin; Intestinal permeability; Irritable bowel syndrome (IBS); Tight junction proteins; ZO-1","Abdominal Pain; Adult; Cadherins; Cecum; Claudin-1; Diarrhea; Female; Humans; Irritable Bowel Syndrome; Male; Middle Aged; Zonula Occludens-1 Protein; adherens junction proteins; E-cadherin; intestinal permeability; irritable bowel syndrome (IBS); tight junction proteins; ZO-1","","","","","","","Chang F.Y., Lu C.L., Chen T.S., The current prevalence of irritable bowel syndrome in Asia, J Neurogastroenterol Motil, 16, pp. 389-400, (2010); Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Camilleri M., Lasch K., Zhou W., Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome, Am J Physiol Gastrointest Liver Physiol, 303, (2012); Marshall J., Thabane M., Garg A., Et al., Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario, Aliment Pharmacol Ther, 20, pp. 1317-1322, (2004); Zhou Q., Souba W.W., Croce C.M., Verne G.N., MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome, Gut, 59, pp. 775-784, (2010); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Dainese R., Galliani E.A., De Lazzari F., Di Leo V., Naccarato R., Discrepancies between reported food intolerance and sensitization test findings in irritable bowel syndrome patients, Am J Gastroenterol, 94, pp. 1892-1897, (1999); Spiller R.C., Jenkins D., Thornley J.P., Et al., Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, pp. 804-811, (2000); Gecse K., Roka R., Sera T., Et al., Leaky gut in patients with diarrhea-predominant irritable bowel syndrome and inactive ulcerative colitis, Digestion, 85, pp. 40-46, (2012); Dunlop S., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Piche T., Barbara G., Aubert P., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Vivinus-Nebot M., Dainese R., Anty R., Et al., Combination of allergic factors can worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells, Am J Gastroenterol, 107, pp. 75-81, (2012); Maher S., Brayden D.J., Feighery L., McClean S., Cracking the junction: update on the progress of gastrointestinal absorption enhancement in the delivery of poorly absorbed drugs, Crit Rev Ther Drug Carrier Syst, 25, pp. 117-168, (2008); Wilcz-Villega E.M., McClean S., O'Sullivan M.A., Mast cell tryptase reduces junctional adhesion molecule-A (JAM-A) expression in intestinal epithelial cells: implications for the mechanisms of barrier dysfunction in irritable bowel syndrome, Am J Gastroenterol, 108, pp. 1140-1151, (2013); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Et al., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am J Gastroenterol, 106, pp. 2165-2173, (2011); Martinez C., Vicario M., Ramos L., Et al., The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations, Am J Gastroenterol, 107, pp. 736-746, (2012); Coeffier M., Gloro R., Boukhettala N., Et al., Increased proteasome-mediated degradation of occludin in irritable bowel syndrome, Am J Gastroenterol, 105, pp. 1181-1188, (2010); Martinez C., Lobo B., Pigrau M., Et al., Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, pp. 1160-1168, (2013); Hermiston M.L., Gordon J.I., In vivo analysis of cadherin function in the mouse intestinal epithelium: essential roles in adhesion, maintenance of differentiation, and regulation of programmed cell death, J Cell Biol, 129, pp. 489-506, (1995); Sasaki M., Sitaraman S.V., Babbin B.A., Et al., Invasive Escherichia coli are a feature of Crohn's disease, Lab Invest, 87, pp. 1042-1054, (2007); Kucharzik T., Walsh S., Chen J., Parkos C., Nusrat A., Neutrophil transmigration in inflammatory bowel disease is associated with differential expression of epithelial intercellular junction proteins, Am J Pathol, 159, pp. 2001-2009, (2001); Bruewer M., Samarin S., Nusrat A., Inflammatory bowel disease and the apical junctional complex, Ann N Y Acad Sci, 1072, pp. 242-252, (2006); Gassler N., Rohr C., Schneider A., Et al., Inflammatory bowel disease is associated with changes of enterocytic junctions, Am J Physiol Gastrointest Liver Physiol, 281, (2001); Vanheel H., Vicario M., Vanuytsel T., Et al., Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia, Gut, (2013); Villani A., Lemire M., Thabane M., Et al., Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis, Gastroenterology, 138, pp. 1502-1513, (2010); Thompson W.G., Longstreth G.F., Drossman D.A., Heaton K.W., Irvine E.J., Muller-Lissner S.A., Functional bowel disorders and functional abdominal pain, Gut, 45, SUPPL. 2, (1999); Jensen M.P., Turner L.R., Turner J.A., Romano J.M., The use of multiple-item scales for pain intensity measurement in chronic pain patients, Pain, 67, pp. 35-40, (1996); Best W.R., Becktel J.M., Singleton J.W., Kern F., Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study, Gastroenterology, 70, pp. 439-444, (1976); Qureshi H.S., Linden M.D., Divine G., Raju U.B., E-cadherin status in breast cancer correlates with histologic type but does not correlate with established prognostic parameters, Am J Clin Pathol, 125, pp. 377-385, (2006); Barshack I., Goldberg I., Chowers Y., Weiss B., Horowitz A., Kopolovic J., Immunohistochemical analysis of candidate gene product expression in the duodenal epithelium of children with coeliac sprue, J Clin Pathol, 54, pp. 684-688, (2001); Wu S., Rhee K.J., Zhang M., Franco A., Sears C.L., Bacteroides fragilis toxin stimulates intestinal epithelial cell shedding and gamma-secretase-dependent E-cadherin cleavage, J Cell Sci, 120, PART 11, pp. 1944-1952, (2007); Frank C.F., Hostetter M.K., Cleavage of E-cadherin: a mechanism for disruption of the intestinal epithelial barrier by Candida albicans, Transl Res, 149, pp. 211-222, (2007); Li L.C., Chui R.M., Sasaki M., Et al., A single nucleotide polymorphism in the E-cadherin gene promoter alters transcriptional activities, Cancer Res, 60, pp. 873-876, (2000); Spiller R., Garsed K., Postinfectious irritable bowel syndrome, Gastroenterology, 136, pp. 1979-1988, (2009); Ford A.C., Talley N.J., Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review, J Gastroenterol, 46, pp. 421-431, (2011); O'Sullivan M., Clayton N., Breslin N., Et al., Increased mast cells in the irritable bowel syndrome, Neurogastroenterol Motil, 12, pp. 449-457, (2000)","M. O'Sullivan; School of Medicine, Trinity Centre for Health Sciences, St James's Hospital, Dublin 8, Ireland; email: Maria.osullivan@tcd.ie","","","","","","","","13652982","","NMOTE","24286617","English","Neurogastroenterol. Motil.","Article","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-84894231578"

"Xu D.; Gao J.; Gillilland III M.; Wu X.; Song I.; Kao J.Y.; Owyang C.","Xu, Dabo (55856882500); Gao, Jun (58834228300); Gillilland III, Merritt (6603428978); Wu, Xiaoyin (7407063918); Song, Il (57217272417); Kao, John Y. (55383842700); Owyang, Chung (7102742637)","55856882500; 58834228300; 6603428978; 7407063918; 57217272417; 55383842700; 7102742637","Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats","2014","Gastroenterology","146","2","","484","496.e4","","233","10.1053/j.gastro.2013.10.026","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84892825869&doi=10.1053%2fj.gastro.2013.10.026&partnerID=40&md5=2d76559b3e6bd1a63cc2770f86698883","Gastroenterology Research Unit, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, 3912 Taubman Center, SPC 5362, United States","Xu D., Gastroenterology Research Unit, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, 3912 Taubman Center, SPC 5362, United States; Gao J., Gastroenterology Research Unit, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, 3912 Taubman Center, SPC 5362, United States; Gillilland III M., Gastroenterology Research Unit, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, 3912 Taubman Center, SPC 5362, United States; Wu X., Gastroenterology Research Unit, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, 3912 Taubman Center, SPC 5362, United States; Song I., Gastroenterology Research Unit, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, 3912 Taubman Center, SPC 5362, United States; Kao J.Y., Gastroenterology Research Unit, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, 3912 Taubman Center, SPC 5362, United States; Owyang C., Gastroenterology Research Unit, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, 3912 Taubman Center, SPC 5362, United States","Background & Aims Rifaximin is used to treat patients with functional gastrointestinal disorders, but little is known about its therapeutic mechanism. We propose that rifaximin modulates the ileal bacterial community, reduces subclinical inflammation of the intestinal mucosa, and improves gut barrier function to reduce visceral hypersensitivity. Methods We induced visceral hyperalgesia in rats, via chronic water avoidance or repeat restraint stressors, and investigated whether rifaximin altered the gut microbiota, prevented intestinal inflammation, and improved gut barrier function. Quantitative polymerase chain reaction (PCR) and 454 pyrosequencing were used to analyze bacterial 16S ribosomal RNA in ileal contents from the rats. Reverse transcription, immunoblot, and histologic analyses were used to evaluate levels of cytokines, the tight junction protein occludin, and mucosal inflammation, respectively. Intestinal permeability and rectal sensitivity were measured. Results Water avoidance and repeat restraint stress each led to visceral hyperalgesia, accompanied by mucosal inflammation and impaired mucosal barrier function. Oral rifaximin altered the composition of bacterial communities in the ileum (Lactobacillus species became the most abundant) and prevented mucosal inflammation, impairment to intestinal barrier function, and visceral hyperalgesia in response to chronic stress. Neomycin also changed the composition of the ileal bacterial community (Proteobacteria became the most abundant species). Neomycin did not prevent intestinal inflammation or induction of visceral hyperalgesia induced by water avoidance stress. Conclusions Rifaximin alters the bacterial population in the ileum of rats, leading to a relative abundance of Lactobacillus. These changes prevent intestinal abnormalities and visceral hyperalgesia in response to chronic psychological stress. © 2014 by the AGA Institute.","Antibiotic; Gut Flora; Intestine; Irritable Bowel Syndrome","Administration, Oral; Animals; Biological Markers; Blotting, Western; Cytokines; DNA, Bacterial; Drug Administration Schedule; Gastrointestinal Agents; Hyperalgesia; Ileitis; Ileum; Immunohistochemistry; Intestinal Mucosa; Male; Microbiota; Neomycin; Occludin; Rats; Rats, Wistar; Restraint, Physical; Reverse Transcriptase Polymerase Chain Reaction; Rifamycins; Sequence Analysis, DNA; Stress, Psychological; Antibiotic; colorectal distention; CRD; electromyographic; EMG; Gut Flora; IBS; IFN-gamma; IL; interferon-gamma; interleukin; Intestine; irritable bowel syndrome; Irritable Bowel Syndrome; PCR; polymerase chain reaction; pregnane X receptor; PXR; RF; ribosomal RNA; rifaximin; rRNA; TNF-α; tumor necrosis factor-α; visceromotor response; VMR; WAS; water avoidance stress; interleukin 10; interleukin 17; interleukin 6; neomycin; occludin; rifaximin; RNA 16S; tight junction protein; tumor necrosis factor alpha; animal experiment; animal model; animal tissue; article; avoidance behavior; chronic stress; controlled study; enteritis; immobilization stress; immunoblotting; intestine flora; intestine mucosa; Lactobacillus; male; microbial community; nonhuman; polymerase chain reaction; priority journal; pyrosequencing; rat; reverse transcription; visceral pain","","neomycin, 11004-65-2, 1404-04-2, 1405-10-3, 8026-22-0; occludin, 176304-61-3; rifaximin, 80621-81-4, 88747-56-2","","","National Institutes of Health, NIH, (R01DK058913); National Institutes of Health, NIH; National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK, (P30DK034933); National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK","Funding The studies were supported by the National Institutes of Health grants R01DK058913 and P30DK34933 . ","Pimentel M., Lembo A., Chey W.D., Et al., Rifaximin therapy for patients with irritable bowel syndrome without constipation, N Engl J Med, 364, pp. 22-32, (2011); Menees S.B., Maneerattannaporn M., Kim H.M., Et al., The efficacy and safety of rifaximin for the irritable bowel syndrome: A systematic review and meta-analysis, Am J Gastroenterol, 107, pp. 28-35, (2012); Pimentel M., Park S., Mirocha J., Et al., The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: A randomized trial, Ann Intern Med, 145, pp. 557-563, (2006); Ford A.C., Talley N.J., Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: A systematic review, J Gastroenterol, 46, pp. 421-431, (2011); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Piche T., Barbara G., Aubert P., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: Involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Lauritano E.C., Valenza V., Sparano L., Et al., Small intestinal bacterial overgrowth and intestinal permeability, Scand J Gastroenterol, 45, pp. 1131-1132, (2010); Camilleri M., Madsen K., Spiller R., Et al., Intestinal barrier function in health and gastrointestinal disease, Neurogastroenterol Motil, 24, pp. 503-512, (2012); Marshall J.K., Thabane M., Garg A.X., Et al., Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario, Aliment Pharmacol Ther, 20, pp. 1317-1322, (2004); Nobaek S., Johansson M.L., Molin G., Et al., Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome, Am J Gastroenterol, 95, pp. 1231-1238, (2000); Bennett E.J., Tennant C.C., Piesse C., Et al., Level of chronic life stress predicts clinical outcome in irritable bowel syndrome, Gut, pp. 256-261, (1998); Gwee K.A., Leong Y.L., Graham C., Et al., The role of psychological and biological factors in postinfective gut dysfunction, Gut, 44, pp. 400-406, (1999); Elenkov I.J., Chrousos G.P., Stress system - Organization, physiology and immunoregulation, Neuroimmunomodulation, 13, pp. 257-267, (2006); Coutinho S.V., Plotsky P.M., Sablad M., Et al., Neonatal maternal separation alters stress-induced responses to viscerosomatic nociceptive stimuli in rat, Am J Physiol Gastrointest Liver Physiol, 282, (2002); Bradesi S., Schwetz I., Ennes H.S., Et al., Repeated exposure to water avoidance stress in rats: A new model for sustained visceral hyperalgesia, Am J Physiol Gastrointest Liver Physiol, 289, (2005); Eutamene H., Lamine F., Chabo C., Et al., Synergy between Lactobacillus paracasei and its bacterial products to counteract stress-induced gut permeability and sensitivity increase in rats, J Nutr, 137, pp. 1901-1907, (2007); O'Mahony S.M., Marchesi J.R., Scully P., Et al., Early life stress alters behavior, immunity, and microbiota in rats: Implications for irritable bowel syndrome and psychiatric illnesses, Biol Psychiatry, 65, pp. 263-267, (2009); Bailey M.T., Dowd S.E., Parry N.M., Et al., Stressor exposure disrupts commensal microbial populations in the intestines and leads to increased colonization by Citrobacter rodentium, Infect Immunity, 78, pp. 1509-1519, (2010); Scarpignato C., Pelosini I., Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic, Digestion, 73, SUPPL. 1, pp. 13-27, (2006); Jahraus C.D., Schemera B., Rynders P., Et al., Rifaximin diminishes neutropenia following potentially lethal whole-body radiation, Exp Biol Med (Maywood), 235, pp. 900-905, (2010); Zelena D., Mergl Z., Foldes A., Et al., Role of hypothalamic inputs in maintaining pituitary-adrenal responsiveness in repeated restraint, Am J Physiol Endocrin Metab, 285, (2003); Schloss P.D., Westcott S.L., Ryabin T., Et al., Introducing mothur: Open-source, platform-independent, community-supported software for describing and comparing microbial communities, Appl Environ Microbiol, 75, pp. 7537-7541, (2009); Wang Q., Fang C.H., Hasselgren P.O., Intestinal permeability is reduced and IL-10 levels are increased in septic IL-6 knockout mice, Am J Physiol Regul Integr Comp Physiol, 281, (2001); Brun P., Castagliuolo I., Di Leo V., Et al., Increased intestinal permeability in obese mice: New evidence in the pathogenesis of nonalcoholic steatohepatitis, Am J Physiol Gastrointest Liver Physiol, 292, (2007); Ait-Belgnaoui A., Bradesi S., Fioramonti J., Et al., Acute stress-induced hypersensitivity to colonic distension depends upon increase in paracellular permeability: Role of myosin light chain kinase, Pain, 113, pp. 141-147, (2005); Grabauskas G., Xu D., Wu X., Et al., HCN2 ion channel in dorsal root ganglion neurons is responsible for visceral hypersensitivity in chronically stressed rat, Gastroenterology, 142, SUPPL. 1, (2012); Grabauskas G., Xu D., Song I., Et al., PGE<sub>2</sub> which activates HCN2 ion channel in dorsal root ganglia mediates visceral hypersensitivity in chronically stressed rats, Gastroenterology, 144, SUPPL. 1, (2013); Bailey M.T., Dowd S.E., Galley J.D., Et al., Exposure to a social stressor alters the structure of the intestinal microbiota: Implications for stressor-induced immunomodulation, Brain Behav Immunity, 25, pp. 397-407, (2011); Hooper L.V., Wong M.H., Thelin A., Et al., Molecular analysis of commensal host-microbial relationships in the intestine, Science, 291, pp. 881-884, (2001); Rajilic-Stojanovic M., Biagi E., Heilig H.G., Et al., Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome, Gastroenterology, 141, pp. 1792-1801, (2011); Malinen E., Rinttila T., Kajander K., Et al., Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR, Am J Gastroenterol, 100, pp. 373-382, (2005); Kassinen A., Krogius-Kurikka L., Makivuokko H., Et al., The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects, Gastroenterology, 133, pp. 24-33, (2007); Jeffery I.B., O'Toole P.W., Ohman L., Et al., An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota, Gut, 61, pp. 997-1006, (2012); Collins S.M., Bercik P., The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease, Gastroenterology, 136, pp. 2003-2014, (2009); Zareie M., Johnson-Henry K., Jury J., Et al., Probiotics prevent bacterial translocation and improve intestinal barrier function in rats following chronic psychological stress, Gut, 55, pp. 1553-1560, (2006); Borruel N., Carol M., Casellas F., Et al., Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria, Gut, 51, pp. 659-664, (2002); Llopis M., Antolin M., Carol M., Et al., Lactobacillus casei downregulates commensals' inflammatory signals in Crohn's disease mucosa, Inflamm Bowel Dis, 15, pp. 275-283, (2009); Verdu E.F., Bercik P., Verma-Gandhu M., Et al., Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice, Gut, 55, pp. 182-190, (2006); Mencarelli A., Renga B., Palladino G., Et al., Inhibition of NF-Κβ by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells, Eur J Pharmacol, 668, pp. 317-324, (2011); Jones S.A., Moore L.B., Shenk J.L., Et al., The pregnane X receptor: A promiscuous xenobiotic receptor that has diverged during evolution, Mol Endocrinol, 14, pp. 27-39, (2000); Sharara A.I., Aoun E., Abdul-Baki H., Et al., A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence, Am J Gastroenterol, 101, pp. 326-333, (2006); Lembo A., Zakko S.F., Ferreira N.L., Et al., Rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: Short-term treatment leading to long-term sustained response, Gastroenterology, 134, SUPPL. 1, (2008); Tsiotsias A., Voidarou C., Skoufos J., Et al., Stress-induced alterations in intestinal microflora, Microb Ecol Health Dis, 16, pp. 28-31, (2004); Zelena D., Mergl Z., Foldes A., Et al., Role of hypothalamic inputs in maintaining pituitary-adrenal responsiveness in repeated restraint, Am J Physiol Endocrinol Metab, 285, (2003); Schloss P.D., Westcott S.L., Ryabin T., Et al., Introducing mothur: Open-source, platform-independent, community-supported software for describing and comparing microbial communities, Appl Environ Microbiol, 75, pp. 7537-7541, (2009); Mayer E.A., The neurobiology of stress and gastrointestinal disease, Gut, 47, pp. 861-869, (2000); Coutinho S.V., Plotsky P.M., Sablad M., Et al., Neonatal maternal separation alters stress-induced responses to viscerosomatic nociceptive stimuli in rat, Am J Physiol Gastrointest Liver Physiol, 282, (2002); Bradesi S., Schwetz I., Ennes H.S., Et al., Repeated exposure to water avoidance stress in rats: A new model for sustained visceral hyperalgesia, Am J Physiol Gastrointest Liver Physiol, 289, (2005)","C. Owyang; Gastroenterology Research Unit, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, 3912 Taubman Center, SPC 5362, United States; email: cowyang@med.umich.edu","","W.B. Saunders","","","","","","00165085","","GASTA","24161699","English","Gastroenterology","Article","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-84892825869"

"Mujagic Z.; Ludidi S.; Keszthelyi D.; Hesselink M.A.M.; Kruimel J.W.; Lenaerts K.; Hanssen N.M.J.; Conchillo J.M.; Jonkers D.M.A.E.; Masclee A.A.M.","Mujagic, Z. (56197282500); Ludidi, S. (53984561400); Keszthelyi, D. (15020799500); Hesselink, M.A.M. (7004164829); Kruimel, J.W. (56036414600); Lenaerts, K. (8580080500); Hanssen, N.M.J. (55184082200); Conchillo, J.M. (12766784800); Jonkers, D.M.A.E. (6701864464); Masclee, A.A.M. (7103116978)","56197282500; 53984561400; 15020799500; 7004164829; 56036414600; 8580080500; 55184082200; 12766784800; 6701864464; 7103116978","Small intestinal permeability is increased in diarrhoea predominant IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to confounders","2014","Alimentary Pharmacology and Therapeutics","40","3","","288","297","9","94","10.1111/apt.12829","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84904066325&doi=10.1111%2fapt.12829&partnerID=40&md5=6c4b4571569972dd17a6b73a3b2239a8","Department of Internal Medicine, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Center+, Maastricht, Netherlands; Department of Surgery, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Center+, Maastricht, Netherlands; Department of Internal Medicine, CARIM School for Cardiovascular Diseases, Maastricht University Medical Center+, Maastricht, Netherlands","Mujagic Z., Department of Internal Medicine, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Center+, Maastricht, Netherlands; Ludidi S., Department of Internal Medicine, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Center+, Maastricht, Netherlands; Keszthelyi D., Department of Internal Medicine, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Center+, Maastricht, Netherlands; Hesselink M.A.M., Department of Internal Medicine, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Center+, Maastricht, Netherlands; Kruimel J.W., Department of Internal Medicine, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Center+, Maastricht, Netherlands; Lenaerts K., Department of Surgery, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Center+, Maastricht, Netherlands; Hanssen N.M.J., Department of Internal Medicine, CARIM School for Cardiovascular Diseases, Maastricht University Medical Center+, Maastricht, Netherlands; Conchillo J.M., Department of Internal Medicine, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Center+, Maastricht, Netherlands; Jonkers D.M.A.E., Department of Internal Medicine, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Center+, Maastricht, Netherlands; Masclee A.A.M., Department of Internal Medicine, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Center+, Maastricht, Netherlands","Background Intestinal permeability has been studied in small groups of IBS patients with contrasting findings. Aims To assess intestinal permeability at different sites of the GI tract in different subtypes of well-characterised IBS patients and healthy controls (HC), and to assess potential confounding factors. Methods IBS patients and HC underwent a multi-sugar test to assess site-specific intestinal permeability. Sucrose excretion and lactulose/rhamnose ratio in 0-5 h urine indicated gastroduodenal and small intestinal permeability, respectively. Sucralose/erythritol ratio in 0-24 h and 5-24 h urine indicated whole gut and colonic permeability, respectively. Linear regression analysis was used to assess the association between IBS groups and intestinal permeability and to adjust for age, sex, BMI, anxiety or depression, smoking, alcohol intake and use of medication. Results Ninety-one IBS patients, i.e. 37% IBS-D, 23% IBS-C, 33% IBS-M and 7% IBS-U and 94 HC were enrolled. Urinary sucrose excretion was significantly increased in the total IBS group [μmol, median (Q1;Q3): 5.26 (1.82;11.03) vs. 2.44 (0.91;5.85), P < 0.05], as well as in IBS-C and IBS-D vs. HC. However, differences attenuated when adjusting for confounders. The lactulose/rhamnose ratio was increased in IBS-D vs. HC [0.023 (0.013;0.038) vs. 0.014 (0.008;0.025), P < 0.05], which remained significant after adjustment for confounders. No difference was found in 0-24 and 5-24 h sucralose/erythritol ratio between groups. Conclusions Small intestinal permeability is increased in patients with IBS-D compared to healthy controls, irrespective of confounding factors. Adjustment for confounders is necessary when studying intestinal permeability, especially in a heterogeneous disorder such as IBS. © 2014 John Wiley & Sons Ltd.","","Adolescent; Adult; Aged; Diarrhea; Erythritol; Female; Humans; Intestines; Irritable Bowel Syndrome; Lactulose; Male; Middle Aged; Permeability; Rhamnose; Sucrose; Young Adult; erythritol; lactulose; rhamnose; sucralose; sucrose; adult; age; aged; alcohol consumption; anxiety; article; body mass; causal attribution; clinical feature; controlled study; correlational study; depression; diarrhea; disease association; drug use; female; gastroduodenal permeability; gastrointestinal tract; human; inflammatory bowel disease; intestine mucosa permeability; major clinical study; male; priority journal; sex difference; small intestine permeability; smoking; urinary excretion","","erythritol, 149-32-6, 7541-59-5; lactulose, 4618-18-2; rhamnose, 10485-94-6, 3615-41-6; sucralose, 56038-13-2; sucrose, 122880-25-5, 57-50-1","","","","","Simren M., Brazier J., Coremans G., Et al., Quality of life and illness costs in irritable bowel syndrome, Digestion, 69, pp. 254-261, (2004); Spiegel B.M., The burden of IBS: Looking at metrics, Curr Gastroenterol Rep, 11, pp. 265-269, (2009); Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Camilleri M., Peripheral mechanisms in irritable bowel syndrome, N Engl J Med, 367, pp. 1626-1635, (2012); Rao A.S., Camilleri M., Eckert D.J., Et al., Urine sugars for in vivo gut permeability: Validation and comparisons in irritable bowel syndrome-diarrhea and controls, Am J Physiol Gastrointest Liver Physiol, 301, (2011); Del Valle-Pinero A.Y., Van Deventer H.E., Fourie N.H., Et al., Gastrointestinal permeability in patients with irritable bowel syndrome assessed using a four probe permeability solution, Clin Chim Acta, 418, pp. 97-101, (2013); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Marshall J.K., Thabane M., Garg A.X., Et al., Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario, Aliment Pharmacol Ther, 20, pp. 1317-1322, (2004); Spiller R.C., Jenkins D., Thornley J.P., Et al., Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, pp. 804-811, (2000); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Zhou Q., Souba W.W., Croce C.M., Verne G.N., MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome, Gut, 59, pp. 775-784, (2010); Kerckhoffs A.P., Akkermans L.M., De Smet M.B., Et al., Intestinal permeability in irritable bowel syndrome patients: Effects of NSAIDs, Dig Dis Sci, 55, pp. 716-723, (2010); Gecse K., Roka R., Sera T., Et al., Leaky gut in patients with diarrhea-predominant irritable bowel syndrome and inactive ulcerative colitis, Digestion, 85, pp. 40-46, (2012); Park J.H., Park D.I., Kim H.J., Et al., The Relationship between Small-Intestinal Bacterial Overgrowth and Intestinal Permeability in Patients with Irritable Bowel Syndrome, Gut Liver, 3, pp. 174-179, (2009); Ersryd A., Posserud I., Abrahamsson H., Simren M., Subtyping the irritable bowel syndrome by predominant bowel habit: Rome II versus Rome III, Aliment Pharmacol Ther, 26, pp. 953-961, (2007); Meddings J.B., Gibbons I., Discrimination of site-specific alterations in gastrointestinal permeability in the rat, Gastroenterology, 114, pp. 83-92, (1998); Van Wijck K., Van Eijk H.M., Buurman W.A., Dejong C.H., Lenaerts K., Novel analytical approach to a multi-sugar whole gut permeability assay, J Chromatogr B Analyt Technol Biomed Life Sci, 879, pp. 2794-2801, (2011); Van Wijck K., Verlinden T.J., Van Eijk H.M., Et al., Novel multi-sugar assay for site-specific gastrointestinal permeability analysis: A randomized controlled crossover trial, Clin Nutr, 32, pp. 245-251, (2013); Svedlund J., Sjodin I., Dotevall G., GSRS-a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease, Dig Dis Sci, 33, pp. 129-134, (1988); Thijssen A.Y., Jonkers D.M., Leue C., Et al., Dysfunctional cognitions, anxiety and depression in irritable bowel syndrome, J Clin Gastroenterol, 44, (2010); Zigmond A.S., Snaith R.P., The hospital anxiety and depression scale, Acta Psychiatr Scand, 67, pp. 361-370, (1983); Bjelland I., Dahl A.A., Haug T.T., Neckelmann D., The validity of the Hospital Anxiety and Depression Scale. An updated literature review, J Psychosom Res, 52, pp. 69-77, (2002); Sutherland L.R., Verhoef M., Wallace J.L., Van Rosendaal G., Crutcher R., Meddings J.B., A simple, non-invasive marker of gastric damage: Sucrose permeability, Lancet, 343, pp. 998-1000, (1994); Pijls K.E., Koek G.H., Elamin E.E., De Vries H., Masclee A.A., Jonkers D.M., Large intestine permeability is increased in patients with compensated liver cirrhosis, Am J Physiol Gastrointest Liver Physiol, 306, (2014); Rutten E.P., Lenaerts K., Buurman W.A., Wouters E.F., Disturbed intestinal integrity in patients with COPD; Effects of activities of daily living, Chest, 145, pp. 245-252, (2014); Lambert G.P., Schmidt A., Schwarzkopf K., Lanspa S., Effect of aspirin dose on gastrointestinal permeability, Int J Sports Med, 33, pp. 421-425, (2012); Troost F.J., Saris W.H., Brummer R.J., Recombinant human lactoferrin ingestion attenuates indomethacin-induced enteropathy in vivo in healthy volunteers, Eur J Clin Nutr, 57, pp. 1579-1585, (2003); Roberts A., Renwick A.G., Sims J., Snodin D.J., Sucralose metabolism and pharmacokinetics in man, Food Chem Toxicol, 38, SUPPL. 2, (2000); Arrigoni E., Brouns F., Amado R., Human gut microbiota does not ferment erythritol, British J Nutr, 94, pp. 643-646, (2005); Suenaert P., Bulteel V., Den Hond E., Et al., The effects of smoking and indomethacin on small intestinal permeability, Aliment Pharmacol Ther, 14, pp. 819-822, (2000); Teixeira T.F., Souza N.C., Chiarello P.G., Et al., Intestinal permeability parameters in obese patients are correlated with metabolic syndrome risk factors, Clin Nutr, 31, pp. 735-740, (2012); Zhang X., Jiang X., Effects of Enteral Nutrition on the Barrier Function of the Intestinal Mucosa and Dopamine Receptor Expression in Rats with Traumatic Brain Injury, JPEN J Parenter Enteral Nutr, (2013); Rummel W., [Biologic membrane functions in health and disease. Effects of bile acids and laxatives on the mucosal transfer], Bull Schweiz Akad Med Wiss, 6, pp. 233-250, (1976); Mullin J.M., Valenzano M.C., Whitby M., Et al., Esomeprazole induces upper gastrointestinal tract transmucosal permeability increase, Aliment Pharmacol Ther, 28, pp. 1317-1325, (2008); Gotteland M., Cruchet S., Frau V., Et al., Effect of acute cigarette smoking, alone or with alcohol, on gastric barrier function in healthy volunteers, Dig Liver Dis, 34, pp. 702-706, (2002); Benoni C., Prytz H., Effects of smoking on the urine excretion of oral 51Cr EDTA in ulcerative colitis, Gut, 42, pp. 656-658, (1998); Martinez C., Gonzalez-Castro A., Vicario M., Santos J., Cellular and molecular basis of intestinal barrier dysfunction in the irritable bowel syndrome, Gut Liver, 6, pp. 305-315, (2012); Martinez C., Lobo B., Pigrau M., Et al., Diarrhoea-predominant irritable bowel syndrome: An organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, pp. 1160-1168, (2013); Barbara G., Stanghellini V., De Giorgio R., Et al., Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome, Gastroenterology, 126, pp. 693-702, (2004); Turner J.R., Intestinal mucosal barrier function in health and disease, Nat Rev Immunol, 9, pp. 799-809, (2009); Belmonte L., Beutheu Youmba S., Bertiaux-Vandaele N., Et al., Role of toll like receptors in irritable bowel syndrome: Differential mucosal immune activation according to the disease subtype, PLoS ONE, 7, (2012); Camilleri M., Madsen K., Spiller R., Greenwood-Van Meerveld B., Verne G.N., Intestinal barrier function in health and gastrointestinal disease, Neurogastroenterol Motil, 24, pp. 503-512, (2012); Gwee K.A., Collins S.M., Read N.W., Et al., Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome, Gut, 52, pp. 523-526, (2003); Chadwick V.S., Chen W., Shu D., Et al., Activation of the mucosal immune system in irritable bowel syndrome, Gastroenterology, 122, pp. 1778-1783, (2002); Keszthelyi D., Troost F.J., Jonkers D.M., Et al., Serotonergic reinforcement of intestinal barrier function is impaired in irritable bowel syndrome, Aliment Pharmacol Ther, (2014); Vanuytsel T., Van Wanrooy S., Vanheel H., Et al., Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism, Gut, (2013); Barreau F., Cartier C., Leveque M., Et al., Pathways involved in gut mucosal barrier dysfunction induced in adult rats by maternal deprivation: Corticotrophin-releasing factor and nerve growth factor interplay, J Physiol, 580, PART 1, pp. 347-356, (2007); Demaude J., Salvador-Cartier C., Fioramonti J., Ferrier L., Bueno L., Phenotypic changes in colonocytes following acute stress or activation of mast cells in mice: Implications for delayed epithelial barrier dysfunction, Gut, 55, pp. 655-661, (2006); Snoek S.A., Verstege M.I., Boeckxstaens G.E., Van Den Wijngaard R.M., De Jonge W.J., The enteric nervous system as a regulator of intestinal epithelial barrier function in health and disease, Expert Rev Gastroenterol Hepatol, 4, pp. 637-651, (2010); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Et al., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am J Gastroenterol, 106, pp. 2165-2173, (2011)","A.A.M. Masclee; Division of Gastroenterology and Hepatology, Maastricht University Medical Center+, 6202 AZ Maastricht, P.O. Box 5800, Netherlands; email: a.masclee@mumc.nl","","Blackwell Publishing Ltd","","","","","","02692813","","APTHE","24943095","English","Aliment. Pharmacol. Ther.","Article","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-84904066325"

"Coëffier M.; Gloro R.; Boukhettala N.; Aziz M.; Lecleire S.; Vandaele N.; Antonietti M.; Savoye G.; Ble-Feysot C.; Déchelotte P.; Reimund J.M.; Ducrotté P.","Coëffier, Mose (6603081357); Gloro, Romain (8984342900); Boukhettala, Nabile (25958924200); Aziz, Moutaz (35195190900); Lecleire, Stéphane (6602495158); Vandaele, Nathalie (26632390600); Antonietti, Michel (7103185148); Savoye, Guillaume (7004262370); Ble-Feysot, Christine (36016177500); Déchelotte, Pierre (57201760610); Reimund, Jean Marie (7005726551); Ducrotté, Philippe (7006732860)","6603081357; 8984342900; 25958924200; 35195190900; 6602495158; 26632390600; 7103185148; 7004262370; 36016177500; 57201760610; 7005726551; 7006732860","Increased proteasome-mediated degradation of occludin in irritable bowel syndrome","2010","American Journal of Gastroenterology","105","5","","1181","1188","7","163","10.1038/ajg.2009.700","https://www.scopus.com/inward/record.uri?eid=2-s2.0-77951975962&doi=10.1038%2fajg.2009.700&partnerID=40&md5=813ddb45be9d3ca72caa2632ebc81780","Nutrition Unit, Rouen University Hospital, Rouen University, 76183 Rouen Cedex, 22 Bd Gambetta, France; Appareil Digestif Environnement Nutrition (ADEN EA4311), Institute for Biomedical Research, Rouen University, Rouen, France; Department of Gastroenterology, Caen University Hospital, Caen, France; Laboratory of Anatomo-Pathology, Rouen University Hospital, Rouen, France; Department of Gastroenterology, Rouen University Hospital, Rouen, France; Biologie Moléculaire et Cellulaire de la Signalisation (EA 3919), IFR 146 ICORE (Interactions Cellules Organismes Environnement), Caen University, Caen, France","Coëffier M., Nutrition Unit, Rouen University Hospital, Rouen University, 76183 Rouen Cedex, 22 Bd Gambetta, France, Appareil Digestif Environnement Nutrition (ADEN EA4311), Institute for Biomedical Research, Rouen University, Rouen, France; Gloro R., Department of Gastroenterology, Caen University Hospital, Caen, France; Boukhettala N., Appareil Digestif Environnement Nutrition (ADEN EA4311), Institute for Biomedical Research, Rouen University, Rouen, France; Aziz M., Laboratory of Anatomo-Pathology, Rouen University Hospital, Rouen, France; Lecleire S., Appareil Digestif Environnement Nutrition (ADEN EA4311), Institute for Biomedical Research, Rouen University, Rouen, France, Department of Gastroenterology, Rouen University Hospital, Rouen, France; Vandaele N., Department of Gastroenterology, Rouen University Hospital, Rouen, France; Antonietti M., Department of Gastroenterology, Rouen University Hospital, Rouen, France; Savoye G., Appareil Digestif Environnement Nutrition (ADEN EA4311), Institute for Biomedical Research, Rouen University, Rouen, France, Department of Gastroenterology, Rouen University Hospital, Rouen, France; Ble-Feysot C., Appareil Digestif Environnement Nutrition (ADEN EA4311), Institute for Biomedical Research, Rouen University, Rouen, France; Déchelotte P., Nutrition Unit, Rouen University Hospital, Rouen University, 76183 Rouen Cedex, 22 Bd Gambetta, France, Appareil Digestif Environnement Nutrition (ADEN EA4311), Institute for Biomedical Research, Rouen University, Rouen, France; Reimund J.M., Department of Gastroenterology, Caen University Hospital, Caen, France, Biologie Moléculaire et Cellulaire de la Signalisation (EA 3919), IFR 146 ICORE (Interactions Cellules Organismes Environnement), Caen University, Caen, France; Ducrotté P., Appareil Digestif Environnement Nutrition (ADEN EA4311), Institute for Biomedical Research, Rouen University, Rouen, France, Department of Gastroenterology, Rouen University Hospital, Rouen, France","OBJECTIVES: Proteasome-mediated protein degradation may contribute to the regulation of intestinal inflammation. At the same time, low-grade inflammation and increased intestinal permeability seem to be involved in the pathophysiology of irritable bowel syndrome (IBS). Thus, we aimed to evaluate proteasome composition and activities in colonic mucosa of IBS patients and its putative pathogenic role.METHODS: Proteasome activities and proteasome subunit expression were measured in colonic mucosa of IBS, Crohn's disease (CD), and control patients by fluorometric assays and western blot, respectively. Expression of inhibitor of kappa B factor (IBα) and occludin, a tight junction protein, was also evaluated in colonic biopsies. The degradation of recombinant occludin incubated with protein extracts from colonic mucosa was evaluated in the presence or absence of proteasome inhibitor, MG132.RESULTS: Proteasome trypsin-like activity was increased in IBS patients compared with CD and controls, whereas chymotrypsin-like activity was upregulated in CD patients only. Caspase-like activity was reduced both in IBS and CD patients. IBα expression was similar between IBS and controls. In contrast, occludin expression was lower in IBS than in controls, but occludin mRNA level was similar. Protein extracts from IBS patients but not from controls degraded recombinant occludin (20% over 160 min), which was blocked by MG132. Although mast cell number was increased in IBS patients, no correlation was found between this number and proteasome alterations.CONCLUSIONS: Our study shows that proteasome alterations are present in the colonic mucosa of IBS patients and may contribute to the pathophysiology of IBS by increasing occludin degradation. © 2010 by the American College of Gastroenterology.","","Adult; Analysis of Variance; Biopsy, Needle; Blotting, Western; Case-Control Studies; Cell Membrane Permeability; Crohn Disease; Cytokines; Female; Humans; Immunohistochemistry; Intestinal Mucosa; Irritable Bowel Syndrome; Male; Mast Cells; Membrane Proteins; Middle Aged; Probability; Proteasome Endopeptidase Complex; Reference Values; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Severity of Illness Index; Statistics, Nonparametric; Young Adult; benzyloxycarbonylleucylleucylleucinal; caspase; chymotrypsin; I kappa B alpha; occludin; proteasome; protein subunit; adult; article; colon biopsy; colon mucosa; controlled study; Crohn disease; enzyme activity; female; human; irritable colon; major clinical study; male; mast cell; pathophysiology; priority journal; protein degradation","","I kappa B alpha, 151217-48-0; benzyloxycarbonylleucylleucylleucinal, 133407-82-6; caspase, 186322-81-6; chymotrypsin, 9004-07-3, 9014-64-6; occludin, 176304-61-3; proteasome, 140879-24-9; Cytokines, ; Membrane Proteins, ; Proteasome Endopeptidase Complex, 3.4.25.1; occludin, ","","","","","Thompson W.G., Longstreth G.F., Drossman D.A., Et al., Functional bowel disorders and functional abdominal pain, Gut, 45, SUPPL. 2, (1999); Brandt L.J., Chey W.D., Foxx-Orenstein A.E., Et al., An evidence-based position statement on the management of irritable bowel syndrome, Am J Gastroenterol, 104, SUPPL. 1, (2009); Drossman D.A., Camilleri M., Mayer E.A., Whitehead W.E., AGA technical review on irritable bowel syndrome, Gastroenterology, 123, 6, pp. 2108-2131, (2002); Piche T., Barbara G., Aubert P., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: Involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Barbara G., Cremon C., Serine proteases: New players in diarrhoea-predominant irritable bowel syndrome, Gut, 57, pp. 1035-1037, (2008); Glickman M.H., Ciechanover A., The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction, Physiol Rev, 82, pp. 373-428, (2002); Hubert-Buron A., Leblond J., Jacquot A., Et al., Glutamine pretreatment reduces IL-8 production in human intestinal epithelial cells by limiting IkappaBalpha ubiquitination, J Nutr, 136, pp. 1461-1465, (2006); Traweger A., Fang D., Liu Y.C., Et al., The tight junction-specifi c protein occludin is a functional target of the E3 ubiquitin-protein ligase itch, J Biol Chem, 277, pp. 10201-10208, (2002); Weerasooriya V., Rennie M.J., Anant S., Et al., Dietary fi ber decreases colonic epithelial cell proliferation and protein synthetic rates in human subjects, Am J Physiol Endocrinol Metab, 290, (2006); Coeffier M., Claeyssens S., Lecleire S., Et al., Combined enteral infusion of glutamine, carbohydrates, and antioxidants modulates gut protein metabolism in humans, Am J Clin Nutr, 88, pp. 1284-1290, (2008); Nakshabendi I.M., Downie S., Russell R.I., Et al., Increased rates of duodenal mucosal protein synthesis in vivo in patients with untreated coelia disease, Gut, 39, pp. 176-179, (1996); Boes B., Hengel H., Ruppert T., Et al., Interferon gamma stimulation modulates the proteolytic activity and cleavage site preference of 20S mouse proteasomes, J Exp Med, 179, pp. 901-909, (1994); Leblond J., Hubert-Buron A., Bole-Feysot C., Et al., Regulation of proteolysis by cytokines in the human intestinal epithelial cell line HCT-8: Role of IFNgamma, Biochimie, 88, pp. 759-765, (2006); Visekruna A., Joeris T., Seidel D., Et al., Proteasome-mediated degradation of IkappaBalpha and processing of p105 in Crohn disease and ulcerative colitis, J Clin Invest, 116, pp. 3195-3203, (2006); Fitzpatrick L.R., Khare V., Small J.S., Et al., Dextran sulfate sodium-induced colitis is associated wiThenhanced low molecular mass polypeptide 2 (LMP2) expression and is attenuated in LMP2 knockout mice, Dig Dis Sci, 51, pp. 1269-1276, (2006); Visekruna A., Joeris T., Schmidt N., Et al., Comparative expression analysis and characterization of 20S proteasomes in human intestinal tissues: The proteasome pattern as diagnostic tool for IBD patients, Infl Amm Bowel Dis, 15, pp. 526-533, (2009); Fitzpatrick L.R., Small J.S., Poritz L.S., Et al., Enhanced intestinal expression of the proteasome subunit low molecular mass polypeptide 2 in patients with infl ammatory bowel disease, Dis Colon Rectum, 50, pp. 337-48, (2007); Inoue S., Nakase H., Matsuura M., Et al., The eff ect of proteasome inhibitor MG132 on experimental infl ammatory bowel disease, Clin Exp Immunol, 156, pp. 172-182, (2009); Gecse K., Roka R., Ferrier L., Et al., Increased faecal serine protease activity in diarrhoeic IBS patients: A colonic lumenal factor impairing colonic permeability and sensitivity, Gut, 57, pp. 591-599, (2008); Coeffier M., Le Pessot F., Leplingard A., Et al., Acute enteral glutamine infusion enhances heme oxygenase-1 expression in human duodenal mucosa, J Nutr, 132, pp. 2570-2573, (2002); Boukhettala N., Leblond J., Claeyssens S., Et al., Methotrexate induces intestinal mucositis and alters gut protein metabolism independently of reduced food intake, Am J Physiol Endocrinol Metab, 296, (2009); Lecleire S., Hassan A., Marion-Letellier R., Et al., Combined glutamine and arginine decrease proinfl ammatory cytokine production by biopsies from Crohn's patients in association with changes in nuclear factor-kappaB and p38 mitogen-activated protein kinase pathways, J Nutr, 138, pp. 2481-2486, (2008); Coeffier M., Claeyssens S., Hecketsweiler B., Et al., Enteral glutamine stimulates protein synthesis and decreases ubiquitin mRNA level in human gut mucosa, Am J Physiol Gastrointest Liver Physiol, 285, (2003); Jung T., Catalgol B., Grune T., The proteasomal system, Mol Aspects Med, 30, pp. 191-296, (2009); Barcelo-Batllori S., Andre M., Servis C., Et al., Proteomic analysis of cytokine induced proteins in human intestinal epithelial cells: Implications for infl ammatory bowel diseases, Proteomics, 2, pp. 551-560, (2002); Hallermalm K., Seki K., Wei C., Et al., Tumor necrosis factor-alpha induces coordinated changes in major histocompatibility class i presentation pathway, resulting in increased stability of class i complexes at the cell surface, Blood, 98, pp. 1108-1115, (2001); Marshall J.K., Th Abane M., Garg A.X., Et al., Intestinal permeability in patients with irritable bowel syndrome aft er a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario, Aliment Pharmacol Ther, 20, pp. 1317-1322, (2004); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Spiller R.C., Jenkins D., Thornley J.P., Et al., Increased rectal mucosal enteroendocrine cells T lymphocytes and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, pp. 804-811, (2000); Jobin C., Sartor R.B., The i kappa B/NF-kappa B system: A key determinant of mucosalinfl ammation and protection, Am J Physiol Cell Physiol, 278, (2000); Lui W.Y., Lee W.M., CAMP perturbs inter-Sertoli tight junction permeability barrier in vitro via its eff ect on proteasome-sensitive ubiquitination of occludin, J Cell Physiol, 203, pp. 564-572, (2005)","M. Coëffier; Nutrition Unit, Rouen University Hospital, Rouen University, 76183 Rouen Cedex, 22 Bd Gambetta, France; email: moise.coeffier@univ-rouen.fr","","","","","","","","15720241","","AJGAA","19997094","English","Am. J. Gastroenterol.","Article","Final","","Scopus","2-s2.0-77951975962"

"Alonso C.; Guilarte M.; Vicario M.; Ramos L.; Rezzi S.; Martínez C.; Lobo B.; Martin F.-P.; Pigrau M.; González-Castro A.M.; Gallart M.; Malagelada J.R.; Azpiroz F.; Kochhar S.; Santos J.","Alonso, C. (56411082400); Guilarte, M. (18133405400); Vicario, M. (6603267769); Ramos, L. (57206530978); Rezzi, S. (16025274500); Martínez, C. (17534584700); Lobo, B. (7003936898); Martin, F.-P. (57710926500); Pigrau, M. (37009212800); González-Castro, A.M. (54796498900); Gallart, M. (57213292987); Malagelada, J.R. (35481774600); Azpiroz, F. (57207592894); Kochhar, S. (7007153522); Santos, J. (7402389020)","56411082400; 18133405400; 6603267769; 57206530978; 16025274500; 17534584700; 7003936898; 57710926500; 37009212800; 54796498900; 57213292987; 35481774600; 57207592894; 7007153522; 7402389020","Acute experimental stress evokes a differential gender-determined increase in human intestinal macromolecular permeability","2012","Neurogastroenterology and Motility","24","8","","740","e349","-391","57","10.1111/j.1365-2982.2012.01928.x","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84863854311&doi=10.1111%2fj.1365-2982.2012.01928.x&partnerID=40&md5=153ff50c4ea385014f2c7859d9860156","Laboratory of Neuro-Immuno-Gastroenterology, Digestive Diseases Research Unit, Institut de Recerca Vall d'Hebron, Hospital Universitari Vall d'Hebron, Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigacion Biomedica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain; Allergy Unit, Institut de Recerca Vall d'Hebron, Hospital Universitari Vall d'Hebron; Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain; Nestlé Research Center, Bioanalytical Science Department, Metabonomics and Biomarkers Group, Lausanne, Switzerland","Alonso C., Laboratory of Neuro-Immuno-Gastroenterology, Digestive Diseases Research Unit, Institut de Recerca Vall d'Hebron, Hospital Universitari Vall d'Hebron, Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain, Centro de Investigacion Biomedica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain; Guilarte M., Allergy Unit, Institut de Recerca Vall d'Hebron, Hospital Universitari Vall d'Hebron; Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain; Vicario M., Centro de Investigacion Biomedica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain; Ramos L., Centro de Investigacion Biomedica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain; Rezzi S., Nestlé Research Center, Bioanalytical Science Department, Metabonomics and Biomarkers Group, Lausanne, Switzerland; Martínez C., Centro de Investigacion Biomedica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain; Lobo B., Centro de Investigacion Biomedica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain; Martin F.-P., Nestlé Research Center, Bioanalytical Science Department, Metabonomics and Biomarkers Group, Lausanne, Switzerland; Pigrau M., Centro de Investigacion Biomedica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain; González-Castro A.M., Centro de Investigacion Biomedica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain; Gallart M., Centro de Investigacion Biomedica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain; Malagelada J.R., Centro de Investigacion Biomedica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain; Azpiroz F., Centro de Investigacion Biomedica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain; Kochhar S., Nestlé Research Center, Bioanalytical Science Department, Metabonomics and Biomarkers Group, Lausanne, Switzerland; Santos J., Centro de Investigacion Biomedica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain","Background Intestinal epithelial dysfunction is a common pathophysiologic feature in irritable bowel syndrome (IBS) patients and might be the link to its clinical manifestations. We previously showed that chronic psychosocial stress induces jejunal epithelial barrier dysfunction; however, whether this epithelial response is gender-specific and might thus explain the enhanced female susceptibility to IBS remains unknown. Methods Intestinal responses to acute stress were compared in age-matched groups of healthy women and men (n=10 each) experiencing low background stress. A 20-cm jejunal segment, was perfused with an isosmotic solution, and intestinal effluents were collected under basal conditions, for 15min during cold pain stress and for a 45-min recovery period. Epithelial function (net water flux and albumin output), changes in stress hormones, and cardiovascular and psychologic responses to cold stress were measured. Key Results Heart rate and blood pressure significantly increased during cold pain stress with no differences between men and women. Adrenocorticotropic hormone and cortisol levels during cold pain stress were significantly higher in men. Basal net water flux and epithelial permeability were similar in men and women. Cold pain stress increased water flux in both groups (72±23 and 107±18μLmin-1cm-1, respectively; F(5, 90)=5.5; P=0.003 for Time) and, interestingly, this was associated with a marked increase of albumin permeability in women but not in men (0.8±0.2 vs.-0.7±0.2mg/15min; P<0.0001). Conclusions & Inferences Intestinal macromolecular permeability in response to acute experimental stress is increased in healthy women, a mechanism that may contribute to female oversusceptibility to IBS. © 2012 Blackwell Publishing Ltd.","Acute stress; Barrier defect; Epithelial response; Functional diseases; Gender; Intestinal inflammation","Female; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Male; Permeability; Sex Characteristics; Stress, Psychological; Young Adult; albumin; corticotropin; hydrocortisone; stress hormone; water; acute stress; adult; article; cold stress; controlled study; corticotropin blood level; diastolic blood pressure; disease predisposition; effluent; female; heart rate; human; human experiment; hydrocortisone blood level; intestine epithelium; intestine mucosa permeability; irritable colon; jejunum; male; mental stress; normal human; osmosis; priority journal; prospective study; sex difference; systolic blood pressure","","corticotropin, 11136-52-0, 9002-60-2, 9061-27-2; hydrocortisone, 50-23-7; water, 7732-18-5","","","","","Payne S., Sex, gender, and irritable bowel syndrome: making the connections, Gend Med, 1, pp. 18-28, (2004); Marshall J.K., Thabane M., Garg A.X., Clark W.F., Moayyedi P., Collins S.M., Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery, Gut, 59, pp. 605-611, (2010); Mearin F., Perez-Oliveras M., Perello A., Et al., Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study, Gastroenterology, 129, pp. 98-104, (2005); Ruigomez A., Garcia Rodriguez L.A., Panes J., Risk of irritable bowel syndrome after an episode of bacterial gastroenteritis in general practice: influence of comorbidities, Clin Gastroenterol Hepatol, 5, pp. 465-469, (2007); Gwee K.A., Leong Y.L., Graham C., Et al., The role of psychological and biological factors in postinfective gut dysfunction, Gut, 44, pp. 400-406, (1999); Spiller R., Garsed K., Postinfectious irritable bowel syndrome, Gastroenterology, 136, pp. 1979-1988, (2009); Levy R.L., Cain K.C., Jarrett M., Heitkemper M.M., The relationship between daily life stress and gastrointestinal symptoms in women with irritable bowel syndrome, J Behav Med, 20, pp. 177-193, (1997); Levy R.L., Olden K.W., Naliboff B.D., Et al., Psychosocial aspects of the functional gastrointestinal disorders, Gastroenterology, 130, pp. 1447-1458, (2006); Spence M.J., Moss-Morris R., The cognitive behavioural model of irritable bowel syndrome: a prospective investigation of patients with gastroenteritis, Gut, 56, pp. 1066-1071, (2007); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Guilarte M., Santos J., de T I., Et al., Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum, Gut, 56, pp. 203-209, (2007); Alonso C., Guilarte M., Vicario M., Et al., Maladaptive intestinal epithelial responses to life stress may predispose healthy women to gut mucosal inflammation, Gastroenterology, 135, pp. 163-172, (2008); Vicario M., Alonso C., Santos J., Impaired intestinal molecular tightness in the mucosa of irritable bowel syndrome: what are the mediators?, Gut, 58, pp. 161-162, (2009); Vicario M., Guilarte M., Alonso C., Et al., Chronological assessment of mast cell-mediated gut dysfunction and mucosal inflammation in a rat model of chronic psychosocial stress, Brain Behav Immun, 24, pp. 1166-1175, (2010); Santos J., Saperas E., Nogueiras C., Et al., Release of mast cell mediators into the jejunum by cold pain stress in humans, Gastroenterology, 114, pp. 640-648, (1998); Holmes T.H., Rahe R.H., The Social Readjustment Rating Scale, J Psychosom Res, 11, pp. 213-218, (1967); Beck A.T., Ward C.H., Mendelson M., Mock J., Erbaugh J., An inventory for measuring depression, Arch Gen Psychiatry, 4, pp. 561-571, (1961); Talley N.J., Stanghellini V., Heading R.C., Koch K.L., Malagelada J.R., Tytgat G.N., Functional gastroduodenal disorders, Gut, 45, SUPPL. 2, (1999); Thompson W.G., Longstreth G.F., Drossman D.A., Heaton K.W., Irvine E.J., Muller-Lissner S.A., Functional bowel disorders and functional abdominal pain, Gut, 45, SUPPL. 2, (1999); Lovallo W., The cold pressor test and autonomic function: a review and integration, Psychophysiology, 12, pp. 268-282, (1975); Naliboff B.D., Benton D., Solomon G.F., Et al., Immunological changes in young and old adults during brief laboratory stress, Psychosom Med, 53, pp. 121-132, (1991); Barclay G.R., Turnberg L.A., Effect of psychological stress on salt and water transport in the human jejunum, Gastroenterology, 93, pp. 91-97, (1987); Barclay G.R., Turnberg L.A., Effect of cold-induced pain on salt and water transport in the human jejunum, Gastroenterology, 94, pp. 994-998, (1988); Xue J., Askwith C., Javed N.H., Cooke H.J., Autonomic nervous system and secretion across the intestinal mucosal surface, Auton Neurosci, 133, pp. 55-63, (2007); Santos J., Benjamin M., Yang P.C., Prior T., Perdue M.H., Chronic stress impairs rat growth and jejunal epithelial barrier function: role of mast cells, Am J Physiol Gastrointest Liver Physiol, 278, (2000); Saunders P.R., Kosecka U., McKay D.M., Perdue M.H., Acute stressors stimulate ion secretion and increase epithelial permeability in rat intestine, Am J Physiol, 267, 5 PART 1, (1994); Meddings J.B., Swain M.G., Environmental stress-induced gastrointestinal permeability is mediated by endogenous glucocorticoids in the rat, Gastroenterology, 119, pp. 1019-1028, (2000); Soderholm J.D., Perdue M.H., Stress and gastrointestinal tract. II. Stress and intestinal barrier function, Am J Physiol Gastrointest Liver Physiol, 280, (2001); Santos J., Perdue M.H., Stress and neuroimmune regulation of gut mucosal function, Gut, 47, SUPPL. 4, (2000); Ferrier L., Mazelin L., Cenac N., Et al., Stress-induced disruption of colonic epithelial barrier: role of interferon-gamma and myosin light chain kinase in mice, Gastroenterology, 125, pp. 795-804, (2003); Wallon C., Yang P.C., Keita A.V., Et al., Corticotropin-releasing hormone (CRH) regulates macromolecular permeability via mast cells in normal human colonic biopsies in vitro, Gut, 57, pp. 50-58, (2008); Persson C.G., Gustafsson B., Erjefalt J.S., Sundler F., Mucosal exudation of plasma is a noninjurious intestinal defense mechanism, Allergy, 48, pp. 581-586, (1993); Demaude J., Salvador-Cartier C., Fioramonti J., Ferrier L., Bueno L., Phenotypic changes in colonocytes following acute stress or activation of mast cells in mice: implications for delayed epithelial barrier dysfunction, Gut, 55, pp. 655-661, (2006); Santos J., Saunders P.R., Hanssen N.P., Et al., Corticotropin-releasing hormone mimics stress-induced colonic epithelial pathophysiology in the rat, Am J Physiol, 277, 2 PART 1, (1999); Santos J., Yang P.C., Soderholm J.D., Benjamin M., Perdue M.H., Role of mast cells in chronic stress induced colonic epithelial barrier dysfunction in the rat, Gut, 48, pp. 630-636, (2001); Oztas B., Camurcu S., Kaya M., Influence of sex on the blood brain barrier permeability during bicuculline-induced seizures, Int J Neurosci, 65, pp. 131-139, (1992); Moro P.J., Flavian A., Jacquier A., Et al., Gender differences in response to cold pressor test assessed with velocity-encoded cardiovascular magnetic resonance of the coronary sinus, J Cardiovasc Magn Reson, 13, (2011); Kawedia J.D., Nieman M.L., Boivin G.P., Et al., Interaction between transcellular and paracellular water transport pathways through Aquaporin 5 and the tight junction complex, Proc Natl Acad Sci U S A, 104, pp. 3621-3626, (2007); Condliffe S.B., Doolan C.M., Harvey B.J., 17beta-oestradiol acutely regulates Cl- secretion in rat distal colonic epithelium, J Physiol, 530, PART 1, pp. 47-54, (2001); Braniste V., Leveque M., Buisson-Brenac C., Bueno L., Fioramonti J., Houdeau E., Oestradiol decreases colonic permeability through oestrogen receptor beta-mediated up-regulation of occludin and junctional adhesion molecule-A in epithelial cells, J Physiol, 587, PART 13, pp. 3317-3328, (2009); Wada-Hiraike O., Imamov O., Hiraike H., Et al., Role of estrogen receptor beta in colonic epithelium, Proc Natl Acad Sci U S A, 103, pp. 2959-2964, (2006); Kudielka B.M., Buske-Kirschbaum A., Hellhammer D.H., Kirschbaum C., Differential heart rate reactivity and recovery after psychosocial stress (TSST) in healthy children, younger adults, and elderly adults: the impact of age and gender, Int J Behav Med, 11, pp. 116-121, (2004); Kajantie E., Phillips D.I., The effects of sex and hormonal status on the physiological response to acute psychosocial stress, Psychoneuroendocrinology, 31, pp. 151-178, (2006); Kudielka B.M., Kirschbaum C., Sex differences in HPA axis responses to stress: a review, Biol Psychol, 69, pp. 113-132, (2005); Kelly M.M., Tyrka A.R., Anderson G.M., Price L.H., Carpenter L.L., Sex differences in emotional and physiological responses to the Trier Social Stress Test, J Behav Ther Exp Psychiatry, 39, pp. 87-98, (2008)","J. Santos; Laboratory of Neuro-Immuno-Gastroenterology, Digestive Diseases Research Unit, Institut de Recerca Vall d'Hebron, 08035 Barcelona, Paseo Vall d'Hebron 119-129, Spain; email: javier.santos@vhir.org","","","","","","","","13652982","","NMOTE","22625665","English","Neurogastroenterol. Motil.","Article","Final","","Scopus","2-s2.0-84863854311"

"Shulman R.J.; Jarrett M.E.; Cain K.C.; Broussard E.K.; Heitkemper M.M.","Shulman, Robert J. (56961627200); Jarrett, Monica E. (59045458700); Cain, Kevin C. (7103341073); Broussard, Elizabeth K. (6603445454); Heitkemper, Margaret M. (7005514887)","56961627200; 59045458700; 7103341073; 6603445454; 7005514887","Associations among gut permeability, inflammatory markers, and symptoms in patients with irritable bowel syndrome","2014","Journal of Gastroenterology","49","11","","1467","1476","9","66","10.1007/s00535-013-0919-6","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84926666952&doi=10.1007%2fs00535-013-0919-6&partnerID=40&md5=7789e4dac3e0d4cf09c8691144e869d8","Department of Pediatrics, Baylor College of Medicine, Children’s Nutrition Research Center, and Texas Children’s Hospital, 1100 Bates Ave, Houston, 77030, TX, United States; Department of Biobehavioral Nursing and Health Systems, University of Washington, Seattle, WA, United States; Department of Biostatistics and Office of Nursing Research, University of Washington, Seattle, WA, United States; Department of Medicine, University of Washington, Seattle, WA, United States","Shulman R.J., Department of Pediatrics, Baylor College of Medicine, Children’s Nutrition Research Center, and Texas Children’s Hospital, 1100 Bates Ave, Houston, 77030, TX, United States; Jarrett M.E., Department of Biobehavioral Nursing and Health Systems, University of Washington, Seattle, WA, United States; Cain K.C., Department of Biostatistics and Office of Nursing Research, University of Washington, Seattle, WA, United States; Broussard E.K., Department of Medicine, University of Washington, Seattle, WA, United States; Heitkemper M.M., Department of Biobehavioral Nursing and Health Systems, University of Washington, Seattle, WA, United States","Background Alterations in gastrointestinal (GI) permeability and immune measures are present in some patients with irritable bowel syndrome (IBS) but the relationship to symptoms is poorly defined. In adults with IBS, we compared permeability, unstimulated peripheral blood monocyte (PBMC) interleukin-10 (IL-10) levels, IBS life interference, and GI and psychological distress symptoms. Methods In 88 women and 18 men with IBS, GI permeability was quantitated as percent recovery of urinary sucrose and the lactulose/mannitol (L/M) ratio. IL-10 was measured in supernatants from 72-h incubated, unstimulated PBMCs. Participants completed a 4-week daily diary recording IBS life interference on daily activities and work, IBS symptoms, and psychological distress symptoms. They also completed the Brief Symptom Inventory. Results The L/M ratio but not percent sucrose recovery was significantly correlated with IBS interference with activities and work and retrospectively measured anxiety and depression. Unstimulated PBMC production of IL-10 correlated significantly with IBS interference with daily work, IBS symptom score, and abdominal pain. We identified a subgroup of IBS subjects with higher IL-10 and/or higher L/M ratio who had substantially higher IBS interference and IBS symptom scores. Conclusions Our findings suggest a distinct subgroup of IBS patients with alterations in gut barrier function. This subgroup is characterized by increased GI permeability and/or increased PBMC production of IL-10. These physiologic alterations reflect more severe IBS as measured by interference of IBS with daily activities and daily IBS symptoms. © 2014 Springer Japan.","Cytokine; Irritable bowel syndrome; Permeability; Symptoms","Abdominal Pain; Activities of Daily Living; Adolescent; Adult; Aged; Biomarkers; Female; Humans; Interleukin-10; Intestinal Mucosa; Irritable Bowel Syndrome; Leukocytes, Mononuclear; Male; Middle Aged; Permeability; Prospective Studies; Retrospective Studies; Self Report; Severity of Illness Index; Stress, Psychological; Young Adult; interleukin 10; lactulose; mannitol; marker; sucrose; biological marker; IL10 protein, human; abdominal pain; adult; aged; anxiety; Article; blood; controlled study; depression; disease association; distress syndrome; female; human; intestine mucosa permeability; irritable colon; major clinical study; male; monocyte; peripheral blood mononuclear cell; priority journal; randomized controlled trial; scoring system; supernatant; abdominal pain; adolescent; blood; daily life activity; immunology; intestine mucosa; irritable colon; mental stress; metabolism; middle aged; mononuclear cell; pathophysiology; permeability; prospective study; psychology; retrospective study; self report; severity of illness index; young adult","","lactulose, 4618-18-2; mannitol, 69-65-8, 87-78-5; sucrose, 122880-25-5, 57-50-1; Biomarkers, ; IL10 protein, human, ; Interleukin-10, ","","","Anaesthetics Research Society; Daffy’s Foundation; National Institutes of Health, (R01 NR05337); Texas Medical Center Digestive Disease Center; U.S. Department of Agriculture; National Institutes of Health, NIH; National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK, (P30DK056338); National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK; U.S. Department of Agriculture, USDA; Agricultural Research Service, USDA ARS, (6250-51000-043); Agricultural Research Service, USDA ARS","This study was supported in part by R01 NR004142 and R01 NR05337 from the National Institutes of Health, the Daffy’s Foundation, the US Department of Agriculture/Agricultural Research Service (USDA/ARS) under Cooperative Agreement No. 6250-51000-043, and P30 DK56338 which funds the Texas Medical Center Digestive Disease Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This work is a publication of the University of Washington and the USDA/ARS Children’s Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine and Texas Children’s Hospital. The contents do not necessarily reflect the views or policies of the USDA, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government. ","Maxion-Bergemann S., Thielecke F., Abel F., Bergemann R., Costs of irritable bowel syndrome in the UK and US, Pharmacoeconomics, 24, 1, pp. 21-37, (2006); Agarwal N., Spiegel B.M., The effect of irritable bowel syndrome on health-related quality of life and health care expenditures, Gastroenterol Clin North Am, 40, 1, pp. 11-19, (2011); Graham D.P., Savas L., White D., El-Serag R., Laday-Smith S., Tan G., Et al., Irritable bowel syndrome symptoms and health related quality of life in female veterans, Aliment Pharmacol Ther, 31, 2, pp. 261-273, (2010); Drossman D., Corazziari E., Delvaux M., Spiller R., Talley N., Thompson W., Et al., Rome III: The functional gastrointestinal disorders, (2006); Qin H.Y., Wu J.C., Tong X.D., Sung J.J., Xu H.X., Bian Z.X., Systematic review of animal models of post-infectious/post-inflammatory irritable bowel syndrome, J Gastroenterol, 46, 2, pp. 164-174, (2011); Stasi C., Rosselli M., Bellini M., Laffi G., Milani S., Altered neuroendocrine-immune pathways in the irritable bowel syndrome: The top-down and the bottom-up model, J Gastroenterol, 47, 11, pp. 1177-1185, (2012); Adam B., Tsopelas C., Liebregts T., Bartholomeusz F.D., Holtmann G., Host immune response determines visceral hyperalgesia in a rat model of post-inflammatory irritable bowel syndrome, J Gastroenterol, 48, 10, pp. 1119-1127, (2013); Ford A.C., Talley N.J., Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: A systematic review, J Gastroenterol, 46, 4, pp. 421-431, (2011); Matricon J., Meleine M., Gelot A., Piche T., Dapoigny M., Muller E., Et al., Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome, Aliment Pharmacol Ther, 36, 11-12, pp. 1009-1031, (2012); Camilleri M., Lasch K., Zhou W., Irritable bowel syndrome: Methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome, Am J Physiol Gastrointest Liver Physiol, 303, 7, pp. G775-G785, (2012); Scully P., McKernan D.P., Keohane J., Groeger D., Shanahan F., Dinan T.G., Et al., Plasma cytokine profiles in females with irritable bowel syndrome and extra-intestinal co-morbidity, Am J Gastroenterol, 105, 10, pp. 2235-2243, (2010); Ortiz-Lucas M., Saz-Peiro P., Sebastian-Domingo J.J., Irritable bowel syndrome immune hypothesis. Part one: The role of lymphocytes and mast cells, Rev Esp Enferm Dig, 102, 11, pp. 637-647, (2010); Zhu H., Lei X., Liu Q., Wang Y., Interleukin-10-1082A/G polymorphism and inflammatory bowel disease susceptibility: A metaanalysis based on 17,585 subjects, Cytokine, 61, 1, pp. 146-153, (2013); Banchereau J., Pascual V., O'Garra A., From IL-2 to IL-37: The expanding spectrum of anti-inflammatory cytokines, Nat Immunol, 13, 10, pp. 925-931, (2012); Vignali D.A., Kuchroo V.K., IL-12 family cytokines: Immunological playmakers, Nat Immunol, 13, 8, pp. 722-728, (2012); Barreau F., Ferrier L., Fioramonti J., Bueno L., New insights in the etiology and pathophysiology of irritable bowel syndrome: Contribution of neonatal stress models, Pediatr Res, 62, 3, pp. 240-245, (2007); Li X., Kan E.M., Lu J., Cao Y., Wong R.K., Keshavarzian A., Et al., Combat-training increases intestinal permeability, immune activation and gastrointestinal symptoms in soldiers, Aliment Pharmacol Ther, 37, 8, pp. 799-809, (2013); Catassi C., Pierani P., Natalini G., Gabrielli O., Coppa G.V., Giorgi P.L., Clinical application of a simple HPLC method for the sugar intestinal permeability test, J Pediatr Gastroenterol Nutr, 12, 2, pp. 209-212, (1991); Shulman R.J., Schanler R.J., Lau C., Heitkemper M., Ou C.N., Smith E.O., Early feeding, antenatal glucocorticoids, and human milk decrease intestinal permeability in preterm infants, Pediatr Res, 44, pp. 519-523, (1998); McOmber M.E., Ou C.N., Shulman R.J., Effects of timing, sex, and age on site-specific gastrointestinal permeability testing in children and adults, J Pediatr Gastroenterol Nutr, 50, 3, pp. 269-275, (2010); O'Mahony L., McCarthy J., Kelly P., Hurley G., Luo F., Chen K., Et al., Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles, Gastroenterology, 128, 3, pp. 541-551, (2005); Reilly M.C., Zbrozek A.S., Dukes E.M., The validity and reproducibility of a work productivity and activity impairment instrument, Pharmacoeconomics, 4, 5, pp. 353-365, (1993); Jarrett M.E., Cain K.C., Burr R.L., Hertig V.L., Rosen S.N., Heitkemper M.M., Comprehensive self-management for irritable bowel syndrome: Randomized trial of in-person vs. combined in-person and telephone sessions, Am J Gastroenterol, 104, 12, pp. 3004-3014, (2009); Derogatis L., BSI: Brief Symptom Inventory; administration, scoring and procedures manual, (1993); Camilleri M., Lasch K., Zhou W., The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome, Am J Physiol Gastrointest Liver Physiol, 303, pp. G775-G785, (2012); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, 1-2, pp. 41-46, (2009); Marshall J.K., Thabane M., Garg A.X., Clark W., Meddings J., Collins S.M., Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario, Aliment Pharmacol Ther, 20, 11-12, pp. 1317-1322, (2004); Dunlop S.P., Hebden J., Campbell E., Naesdal J., Olbe L., Perkins A.C., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, AmJ Gastroenterol, 101, 6, pp. 1288-1294, (2006); Kamada N., Seo S.U., Chen G.Y., Nunez G., Role of the gut microbiota in immunity and inflammatory disease, Nat Rev Immunol, 13, 5, pp. 321-335, (2013); Kaji I., Yasuoka Y., Karaki S., Kuwahara A., Activation of TRPA1 by luminal stimuli induces EP4-mediated anion secretion in human and rat colon, Am J Physiol Gastrointest Liver Physiol, 302, 7, pp. G690-G701, (2012); Saulnier D.M., Riehle K., Mistretta T.A., Diaz M.A., Mandal D., Raza S., Et al., Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome, Gastroenterology, 141, 5, pp. 1782-1791, (2011); Langhorst J., Junge A., Rueffer A., Wehkamp J., Foell D., Michalsen A., Et al., Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome, Am J Gastroenterol, 104, 2, pp. 404-410, (2009); Suzuki T., Regulation of intestinal epithelial permeability by tight junctions. Cellular and molecular life sciences, CMLS, 70, 4, pp. 631-659, (2013); Chang L., Adeyemo M., Karagiannides I., Videlock E.J., Bowe C., Shih W., Et al., Serum and colonic mucosal immune markers in irritable bowel syndrome, Am J Gastroenterol, 107, 2, pp. 262-272, (2012); Schmulson M., Pulido-London D., Rodriguez O., Morales-Rochlin N., Martinez-Garcia R., Gutierrez-Ruiz M.C., Et al., Lower serum IL-10 is an independent predictor of IBS among volunteers in Mexico, Am J Gastroenterol, 107, 5, pp. 747-753, (2012); Kindt S., Van Oudenhove L., Broekaert D., Kasran A., Ceuppens J.L., Bossuyt X., Et al., Immune dysfunction in patients with functional gastrointestinal disorders, Neurogastroenterol Motil, 21, 4, pp. 389-398, (2009); Hughes P.A., Harrington A.M., Castro J., Liebregts T., Adam B., Grasby D.J., Et al., Sensory neuro-immune interactions differ between irritable bowel syndrome subtypes, Gut, 62, pp. 1456-1465, (2012); Liebregts T., Adam B., Bredack C., Roth A., Heinzel S., Lester S., Et al., Immune activation in patients with irritable bowel syndrome, Gastroenterology, 132, 3, pp. 913-920, (2007); Hua M.C., Lai M.W., Kuo M.L., Yao T.C., Huang J.L., Chen S.M., Decreased interleukin-10 secretion by peripheral blood mononuclear cells in children with irritable bowel syndrome, J Pediatr Gastroenterol Nutr, 52, 4, pp. 376-381, (2011); Chogle A., Sztainberg M., Bass L., Youssef N.N., Miranda A., Nurko S., Et al., Accuracy of pain recall in children, J Pediatr Gastroenterol Nutr, 55, 3, pp. 288-291, (2012); Engsbro A.L., Simren M., Bytzer P., The Rome II and Rome III criteria identify the same subtype-populations in irritable bowel syndrome: Agreement depends on the method used for symptom report, Neurogastroenterol Motil, 24, 7, (2012); Weinland S.R., Morris C.B., Hu Y., Leserman J., Bangdiwala S.I., Drossman D.A., Characterization of episodes of irritable bowel syndrome using ecological momentary assessment, Am J Gastroenterol, 106, 10, pp. 1813-1820, (2011)","R.J. Shulman; Department of Pediatrics, Baylor College of Medicine, Children’s Nutrition Research Center, and Texas Children’s Hospital, Houston, 1100 Bates Ave, 77030, United States; email: rshulman@bcm.edu","","Springer Tokyo","","","","","","09441174","","JOGAE","24435814","English","J. Gastroenterol.","Article","Final","All Open Access; Green Open Access","Scopus","2-s2.0-84926666952"

"Ko S.-J.; Han G.; Kim S.-K.; Seo J.-G.; Chung W.-S.; Ryu B.; Kim J.; Yeo I.; Lee B.-J.; Lee J.-M.; Park J.-W.","Ko, Seok-Jae (52363719300); Han, Gajin (36443612500); Kim, Seul-Ki (55551947100); Seo, Jae-Gu (7401784267); Chung, Won-Seok (54416964300); Ryu, Bongha (36444287400); Kim, Jinsung (57203251776); Yeo, Inkwon (8209765300); Lee, Beom-Joon (35299944200); Lee, Jin-Moo (54792039400); Park, Jae-Woo (57193414960)","52363719300; 36443612500; 55551947100; 7401784267; 54416964300; 36444287400; 57203251776; 8209765300; 35299944200; 54792039400; 57193414960","Effect of Korean herbal medicine combined with a probiotic mixture on diarrhea-dominant irritable bowel syndrome: A double-blind, randomized, placebo-controlled trial","2013","Evidence-based Complementary and Alternative Medicine","2013","","824605","","","","50","10.1155/2013/824605","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84893753857&doi=10.1155%2f2013%2f824605&partnerID=40&md5=aa816b5d9fc88d4cca2a26fd98da7622","College of Korean Medicine, Kyung Hee University, Dongdaemun-gu, Seoul 130-701, 26 Kyungheedae-ro, South Korea; Cell Biotech, Co., Ltd., Gyeonggi-do, Gimpo-si 415-871, Gaegok-Ri, Wolgot-myeon, South Korea; College of Sookmyung Women's University, Yongsan-gu, Seoul 140-742, Cheongpa-dong 2-ga, South Korea; Kangnam Korean Hospital, Kyung Hee University, Dongdaemun-gu, Seoul 130-701, 26 Kyungheedae-ro, South Korea","Ko S.-J., College of Korean Medicine, Kyung Hee University, Dongdaemun-gu, Seoul 130-701, 26 Kyungheedae-ro, South Korea; Han G., College of Korean Medicine, Kyung Hee University, Dongdaemun-gu, Seoul 130-701, 26 Kyungheedae-ro, South Korea; Kim S.-K., College of Korean Medicine, Kyung Hee University, Dongdaemun-gu, Seoul 130-701, 26 Kyungheedae-ro, South Korea; Seo J.-G., Cell Biotech, Co., Ltd., Gyeonggi-do, Gimpo-si 415-871, Gaegok-Ri, Wolgot-myeon, South Korea; Chung W.-S., Cell Biotech, Co., Ltd., Gyeonggi-do, Gimpo-si 415-871, Gaegok-Ri, Wolgot-myeon, South Korea; Ryu B., College of Korean Medicine, Kyung Hee University, Dongdaemun-gu, Seoul 130-701, 26 Kyungheedae-ro, South Korea; Kim J., College of Korean Medicine, Kyung Hee University, Dongdaemun-gu, Seoul 130-701, 26 Kyungheedae-ro, South Korea; Yeo I., College of Sookmyung Women's University, Yongsan-gu, Seoul 140-742, Cheongpa-dong 2-ga, South Korea; Lee B.-J., Kangnam Korean Hospital, Kyung Hee University, Dongdaemun-gu, Seoul 130-701, 26 Kyungheedae-ro, South Korea; Lee J.-M., College of Korean Medicine, Kyung Hee University, Dongdaemun-gu, Seoul 130-701, 26 Kyungheedae-ro, South Korea; Park J.-W., College of Korean Medicine, Kyung Hee University, Dongdaemun-gu, Seoul 130-701, 26 Kyungheedae-ro, South Korea","Introduction. Although combination therapy with herbal medicine and probiotics is gaining popularity for controlling diarrhea-dominant irritable bowel syndrome (D-IBS) symptoms, few studies have investigated its clinical effects. Materials and Methods. Fifty-three patients with D-IBS were randomly allocated into 1 of the following 4 groups: herbal medicine (Gwakhyangjeonggisan; GJS) plus probiotics (Duolac7S; DUO), GJS plus placebo DUO, placebo GJS plus DUO, and placebo GJS plus placebo DUO. The study period consisted of a 2-week run-in, 8 weeks of administration, and 2 weeks of follow-up. The primary outcomes were weekly adequate relief (AR) of overall IBS symptoms and the proportion of responders (PR) during the administration period. The secondary outcomes included individual IBS symptoms, stool assessment, and quality of life. Changes of intestinal microbiota and intestinal permeability were also analyzed. Results and Discussion. Weekly AR was not different among the 4 groups throughout the treatment period. However, the 3 treatment groups exhibited significant improvements in PR compared to the findings in the placebo group. In the intestinal microbiota assessment, herbal medicine and probiotics synergistically increased beneficial bacteria counts. Conclusion. Combination therapy with herbal medicine and probiotics appears to relieve overall IBS symptoms by synergistically increasing beneficial intestinal microbe counts. © 2013 Seok-Jae Ko et al.","","","","","","","","","Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C., Functional bowel disorders, Gastroenterology, 130, 5, pp. 1480-1491, (2006); Chang F.Y., The current prevalence of irritable bowel syndrome in Asia, Journal of Neurogastroenterology and Motility, 16, 4, pp. 389-400, (2010); Duracinsky M., Chassany O., How can an effective drug to treat irritable bowel syndrome be successfully developed?, Gastroenterologie Clinique et Biologique, 33, 1, (2009); Rajilic-Stojanovic M., Biagi E., Heilig H.G.H.J., Kajander K., Kekkonen R.A., Tims S., De Vos W.M., Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome, Gastroenterology, 141, 5, pp. 1792-1801, (2011); Dunlop S.P., Hebden J., Campbell E., Naesdal J., Olbe L., Perkins A.C., Spiller R.C., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, American Journal of Gastroenterology, 101, 6, pp. 1288-1294, (2006); Wu J.C.Y., Complementary and alternative medicine modalities for the treatment of irritable bowel syndrome: Facts or myths?, Gastroenterology and Hepatology, 6, 11, pp. 705-711, (2010); Kim Y.B., Kim J.H., Chae B.Y., Effects on Koakhyangieonggisan and Gamikoahyangieonggisan on the digestive and anti-allergic function, Journal of Korean Medical Society, 10, pp. 11-23, (1993); Ryu K.W., Ryu B.H., Yun H.S., Park D.W., Experimental comparative studies on the effects of Kwakhyangjeonggisan and Souminkwakhyang-jeonggisan, Journal of Korean Medical College of KyungHee University, 21, (1998); Han J.H., Kim G.B., Han I.S., Shim Y.S., Kim E.G., A clinical report of chronic diarrhea treated with GwakHyang-JungGiSan, Journal of Korean Internal Medicine, 26, pp. 889-896, (2005); Liu J.P., Yang M., Liu Y.X., Wei M.L., Grimsgaard S., Herbal medicines for treatment of irritable bowel syndrome, Cochrane Database of Systematic Reviews, 1, (2006); Cha B.K., Jung S.M., Choi C.H., Song I.-D., Lee H.W., Kim H.J., Hyuk J., Chang S.K., Kim K., Chung W.-S., Seo J.-G., The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial, Journal of Clinical Gastroenterology, 46, 3, pp. 220-227, (2012); Herbal Formula and Lactic Acid Bacteria; Ko S.-J., Ryu B., Kim J., Hong B.-G., Yeo I., Lee B.-J., Lee J.-M., Park J.-W., Effect of herbal extract granules combined with probiotic mixture on irritable bowel syndrome with diarrhea: Study protocol for a randomized controlled trial, Trials, (2011); Kim H.J., Camilleri M., McKinzie S., Lempke M.B., Burton D.D., Thomforde G.M., Zinsmeister A.R., A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome, Alimentary Pharmacology and Therapeutics, 17, 7, pp. 895-904, (2003); Vejdani R., Shalmani H.R.M., Mir-Fattahi M., Sajed-Nia F., Abdollahi M., Zali M.R., Alizadeh A.H.M., Bahari A., Amin G., The efficacy of an herbal medicine, Carmint, on the relief of abdominal pain and bloating in patients with irritable bowel syndrome: A pilot study, Digestive Diseases and Sciences, 51, 8, pp. 1501-1507, (2006); Kim H.J., Vazquez Roque M.I., Camilleri M., Stephens D., Burton D.D., Baxter K., Thomforde G., Zinsmeister A.R., A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating, Neurogastroenterology and Motility, 17, 5, pp. 687-696, (2005); Lewis S.J., Heaton K.W., Stool form scale as a useful guide to intestinal transit time, Scandinavian Journal of Gastroenterology, 32, 9, pp. 920-924, (1997); Coulie B., Szarka L.A., Camilleri M., Burton D.D., McKinzie S., Stambler N., Cedarbaum J.M., Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans, Gastroenterology, 119, 1, pp. 41-50, (2000); Drossman D.A., Patrick D.L., Whitehead W.E., Toner B.B., Diamant N.E., Hu Y., Jia H., Bangdiwala S.I., Further validation of the IBS-QOL: A disease-specific quality-of-life questionnaire, American Journal of Gastroenterology, 95, 4, pp. 999-1007, (2000); Park J.M., Choi M.-G., Oh J.H., Cho Y.K., Lee I.S., Kim S.W., Choi K.Y., Chung I.-S., Cross-cultural validation of irritable bowel syndrome quality of life in Korea, Digestive Diseases and Sciences, 51, 8, pp. 1478-1484, (2006); Zhou Q., Zhang B., Nicholas Verne G., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, 1-2, pp. 41-46, (2009); Hollander D., Intestinal permeability, leaky gut, and intestinal disorders, Current Gastroenterology Reports, 1, 5, pp. 410-416, (1999); Camilleri M., Gorman H., Intestinal permeability and irritable bowel syndrome, Neurogastroenterology and Motility, 19, 7, pp. 545-552, (2007); Malinen E., Krogius-Kurikka L., Lyra A., Nikkila J., Jaaskelainen A., Rinttila T., Vilpponen-Salmela T., Von Wright A.J., Palva A., Association of symptoms with gastrointestinal microbiota in irritable bowel syndrome, World Journal of Gastroenterology, 16, 36, pp. 4532-4540, (2010); Wang C., Nishino N., Presence of sourdough lactic acid bacteria in commercial total mixed ration silage as revealed by denaturing gradient gel electrophoresis analysis, Letters in Applied Microbiology, 51, 4, pp. 436-442, (2010); Hoveyda N., Heneghan C., Mahtani K.R., Perera R., Roberts N., Glasziou P., A systematic review and meta-analysis: Probiotics in the treatment of irritable bowel syndrome, BMC Gastroenterology, 915, (2009); Rahimi R., Abdollahi M., Herbal medicines for the management of irritable bowel syndrome: A comprehensive review, World Journal of Gastroenterology, 18, 7, pp. 589-600, (2012); Leung W.K., Wu J.C.Y., Liang S.M., Chan L.S., Chan F.K.L., Xie H., Fung S.S.L., Hui A.J., Wong V.W.S., Che C.-T., Sung J.J.Y., Treatment of diarrhea-predominant irritable bowel syndrome with traditional Chinese herbal medicine: A randomized placebo-controlled trial, American Journal of Gastroenterology, 101, 7, pp. 1574-1580, (2006); O'Mahony L., Mccarthy J., Kelly P., Hurley G., Luo F., Chen K., O'Sullivan G.C., Kiely B., Collins J.K., Shanahan F., Quigley E.M.M., Lactobacillus and Bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles, Gastroenterology, 128, 3, pp. 541-551, (2005); Camilleri M., Is there a role for probiotics in irritable bowel syndrome?, Digestive and Liver Disease, 38, SUPPL. 2, (2006); Pathmakanthan S., Li C.K.F., Cowie J., Hawkey C.J., Lactobacillus plantarum 299: Beneficial in vitro immunomodulation in cells extracted from inflamed human colon, Journal of Gastroenterology and Hepatology, 19, 2, pp. 166-173, (2004); Menard S., Candalh C., Bambou J.C., Terpend K., Cerf-Bensussan N., Heyman M., Lactic acid bacteria secrete metabolites retaining anti-inflammatory properties after intestinal transport, Gut, 53, 6, pp. 821-828, (2004); Chapman C.M.C., Gibson G.R., Rowland I., Health benefits of probiotics: Are mixtures more effective than single strains?, European Journal of Nutrition, 50, 1, pp. 1-17, (2011); Enck P., Zimmermann K., Menke G., Muller-Lissner S., Martens U., Klosterhalfen S., A mixture of Escherichia coli (DSM 17252) and Enterococcus faecalis (DSM 16440) for treatment of the irritable bowel syndrome - A randomized controlled trial with primary care physicians, Neurogastroenterology and Motility, 20, 10, pp. 1103-1109, (2008); Whorwell P.J., Altringer L., Morel J., Bond Y., Charbonneau D., O'Mahony L., Kiely B., Shanahan F., Quigley E.M.M., Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome, American Journal of Gastroenterology, 101, 7, pp. 1581-1590, (2006); Niv E., Naftali T., Hallak R., Vaisman N., The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome - A double blind, placebo-controlled, randomized study, Clinical Nutrition, 24, 6, pp. 925-931, (2005); O'Sullivan M.A., O'Morain C.A., Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study, Digestive and Liver Disease, 32, 4, pp. 294-301, (2000); Madisch A., Holtmann G., Plein K., Hotz J., Treatment of irritable bowel syndrome with herbal preparations: Results of a double-blind, randomized, placebo-controlled, multi-centre trial, Alimentary Pharmacology and Therapeutics, 19, 3, pp. 271-279, (2004); Wang G., Li T.-Q., Wang L., Xia Q., Chang J., Zhang Y., Wan M.-H., Guo J., Cheng Y., Huang X., Zhang R.-M., Tong-xie-ning, a Chinese herbal formula, in treatment of diarrhea-predominant irritable bowel syndrome: A prospective, randomized, double-blind, placebo-controlled trial, Chinese Medical Journal, 119, 24, pp. 2114-2119, (2006); Pan F., Zhang T., Zhang Y.-H., Xu J.-J., Chen F.-M., Effect of Tongxie Yaofang granule in treating diarrhea-predominate irritable bowel syndrome, Chinese Journal of Integrative Medicine, 15, 3, pp. 216-219, (2009); Si J.-M., Yu Y.-C., Fan Y.-J., Chen S.-J., Intestinal microecology and quality of life in irritable bowel syndrome patients, World Journal of Gastroenterology, 10, 12, pp. 1802-1805, (2004); Kassinen A., Krogius-Kurikka L., Makivuokko H., Rinttila T., Paulin L., Corander J., Malinen E., Apajalahti J., Palva A., The Fecal Microbiota of Irritable Bowel Syndrome Patients Differs Significantly From That of Healthy Subjects, Gastroenterology, 133, 1, pp. 24-33, (2007); Fan Y.-J., Chen S.-J., Yu Y.-C., Si J.-M., Liu B., A probiotic treatment containing Lactobacillus, Bifidobacterium and Enterococcus improves IBS symptoms in an open label trial, Journal of Zhejiang University Science B, 7, 12, pp. 987-991, (2006); Rajilic-Stojanovic M., Biagi E., Heilig H.G.H.J., Kajander K., Kekkonen R.A., Tims S., De Vos W.M., Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome, Gastroenterology, 141, 5, pp. 1792-1801, (2011); Di Leo V., D'Inca R., Diaz-Granado N., Fries W., Venturi C., D'Odorico A., Martines D., Sturniolo G.C., Lactulose/Mannitol Test Has High Efficacy for Excluding Organic Causes of Chronic Diarrhea, American Journal of Gastroenterology, 98, 10, pp. 2245-2252, (2003); Xie Y.-C., Tang F., Experimental study on protecting intestinal barrier function of Huoxiang Zhengqi soft capsule, Zhongguo Zhong Yao Za Zhi, 29, 5, pp. 456-458, (2004)","J.-W. Park; College of Korean Medicine, Kyung Hee University, Dongdaemun-gu, Seoul 130-701, 26 Kyungheedae-ro, South Korea; email: pjw2907@khu.ac.kr","","","","","","","","17414288","","","","English","Evid.-Based Complement. Altern. Med.","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-84893753857"

"Mbodji K.; Torre S.; Haas V.; Déchelotte P.; Marion-Letellier R.","Mbodji, Khaly (36572131900); Torre, Stéphanie (54394666300); Haas, Verena (9737047300); Déchelotte, Pierre (57201760610); Marion-Letellier, Rachel (22951234400)","36572131900; 54394666300; 9737047300; 57201760610; 22951234400","Alanyl-glutamine restores maternal deprivation-induced TLR4 levels in a rat neonatal model","2011","Clinical Nutrition","30","5","","672","677","5","13","10.1016/j.clnu.2011.04.002","https://www.scopus.com/inward/record.uri?eid=2-s2.0-80053629198&doi=10.1016%2fj.clnu.2011.04.002&partnerID=40&md5=36bdaf7c717c2f26a7995224f6125bc9","Appareil Digestif Environnement Nutrition (ADEN EA 4311), University of Rouen, I.F.R. 23, Institute of Biomedical Research, 76183 Rouen cedex, 22, boulevard Gambetta, France; Department of Neonatal Medicine, Rouen University Hospital, 76000 Rouen, 1 rue de Germont, France; 10117 Berlin, Charitéplatz 1, Germany; Nutrition Unit, Rouen University Hospital, 76031 Rouen cedex, 1 rue de Germont, France","Mbodji K., Appareil Digestif Environnement Nutrition (ADEN EA 4311), University of Rouen, I.F.R. 23, Institute of Biomedical Research, 76183 Rouen cedex, 22, boulevard Gambetta, France; Torre S., Appareil Digestif Environnement Nutrition (ADEN EA 4311), University of Rouen, I.F.R. 23, Institute of Biomedical Research, 76183 Rouen cedex, 22, boulevard Gambetta, France, Department of Neonatal Medicine, Rouen University Hospital, 76000 Rouen, 1 rue de Germont, France; Haas V., 10117 Berlin, Charitéplatz 1, Germany; Déchelotte P., Appareil Digestif Environnement Nutrition (ADEN EA 4311), University of Rouen, I.F.R. 23, Institute of Biomedical Research, 76183 Rouen cedex, 22, boulevard Gambetta, France, Nutrition Unit, Rouen University Hospital, 76031 Rouen cedex, 1 rue de Germont, France; Marion-Letellier R., Appareil Digestif Environnement Nutrition (ADEN EA 4311), University of Rouen, I.F.R. 23, Institute of Biomedical Research, 76183 Rouen cedex, 22, boulevard Gambetta, France","Background & aims: Increased intestinal permeability of Irritable bowel syndrome (IBS) patients has been recently associated with a decreased level of glutamine synthetase. Neonatal maternal deprivation (NMD) is considered as an IBS-like model. The aim of our study was to investigate whether early nutritional intervention with glutamine may attenuate the deleterious impact of early life stress on gut barrier function in NMD. Methods: 124 rat pups were separated from their dam 3 h daily during postnatal days 2-14, or left undisturbed (NS). Separated rats received by gavage either with alanyl-glutamine (GLN), an isonitrogenous amino acid mix (AA, control) or an equal amount of drinking water (H2O). Production of cytokines was measured by multiplex, expression of COX-2, PPARγ, tight junction proteins and TLR4 by western blot. Intestinal permeability was studied by Lactulose/Mannitol test. Results: Treatment of pups with GLN or AA abolished the decrease in body weight observed in NMD. Treatment with GLN decreased in the colon (i) TLR4 expression at D20, (ii) IL-2 and -10 productions at D60 (iii) protein expression of occludin at D20 compared to AA. GLN also decreased colon expression of COX2 and PPARγ at D60 compared to NS. Colon production of IFNγ is significantly reduced by GLN compared to H2O. No significant change in intestinal permeability was observed. Conclusions: These results showed that an early nutritional intervention with alanyl-glutamine specifically abolished the up-regulation of TLR4 expression in NMD. Glutamine may be evaluated as a potential treatment for IBS patients. © 2011 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism.","Alanyl-glutamine; Irritable bowel syndrome; Maternal deprivation; Toll-like receptor","alanylglutamine; amino acid; claudin 1; cyclooxygenase 2; cytokine; interleukin 10; interleukin 2; lactulose; mannitol; occludin; peroxisome proliferator activated receptor gamma; toll like receptor 4; animal cell; animal experiment; animal tissue; article; controlled study; cytokine production; early intervention; early life stress; female; intestine mucosa permeability; maternal deprivation; maternal nutrition; newborn; nonhuman; protein expression; protein function; protein localization; pup (rodent); rat; Western blotting","","alanylglutamine, 39537-23-0; amino acid, 65072-01-7; claudin 1, 329338-06-9; interleukin 2, 85898-30-2; lactulose, 4618-18-2; mannitol, 69-65-8, 87-78-5; occludin, 176304-61-3; toll like receptor 4, 203811-83-0","","","","","Dapoigny M., Bellanger J., Bonaz B., Bruley des Varannes S., Bueno L., Coffin B., Et al., Irritable bowel syndrome in France: a common, debilitating and costly disorder, Eur J Gastroenterol Hepatol, 16, pp. 995-1001, (2004); Marion R., Baishanbo A., Gargala G., Francois A., Ducrotte P., Duclos C., Et al., Transient neonatal Cryptosporidium parvum infection triggers long-term jejunal hypersensitivity to distension in immunocompetent rats, Infect Immun, 74, pp. 4387-4389, (2006); Barreau F., Ferrier L., Fioramonti J., Bueno L., New insights in the etiology and pathophysiology of irritable bowel syndrome: contribution of neonatal stress models, Pediatr Res, 62, pp. 240-245, (2007); Soderholm J.D., Yates D.A., Gareau M.G., Yang P.C., MacQueen G., Perdue M.H., Neonatal maternal separation predisposes adult rats to colonic barrier dysfunction in response to mild stress, Am J Physiol Gastrointest Liver Physiol, 283, (2002); Gareau M.G., Jury J., Perdue M.H., Neonatal maternal separation of rat pups results in abnormal cholinergic regulation of epithelial permeability, Am J Physiol Gastrointest Liver Physiol, 293, (2007); McKernan D.P., Nolan A., Brint E.K., O'Mahony S.M., Hyland N.P., Cryan J.F., Et al., Toll-like receptor mRNA expression is selectively increased in the colonic mucosa of two animal models Relevant to irritable bowel syndrome, PLoS ONE, 4, (2009); Le Mandat Schultz A., Bonnard A., Barreau F., Aigrain Y., Pierre-Louis C., Berrebi D., Et al., Expression of TLR-2, TLR-4, NOD2 and pNF-kappaB in a neonatal rat model of necrotizing enterocolitis, PLoS ONE, 2, (2007); Jilling T., Simon D., Lu J., Meng F.J., Li D., Schy R., Et al., The roles of bacteria and TLR4 in rat and murine models of necrotizing enterocolitis, J Immunol, 177, pp. 3273-3282, (2006); Zhou Q., Souba W.W., Croce C.M., Verne G.N., MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome, Gut, 59, pp. 775-784, (2010); Klimberg V.S., Souba W.W., The importance of intestinal glutamine metabolism in maintaining a healthy gastrointestinal tract and supporting the body's response to injury and illness, Surg Annu, 22, pp. 61-76, (1990); Souba W.W., Klimberg V.S., Plumley D.A., Salloum R.M., Flynn T.C., Bland K.I., Et al., The role of glutamine in maintaining a healthy gut and supporting the metabolic response to injury and infection, J Surg Res, 48, pp. 383-391, (1990); Lacey J.M., Wilmore D.W., Is glutamine a conditionally essential amino acid?, Nutr Rev, 48, pp. 297-309, (1990); DeMarco V.G., Li N., Thomas J., West C.M., Neu J., Glutamine and barrier function in cultured Caco-2 epithelial cell monolayers, J Nutr, 133, pp. 2176-2179, (2003); Coeffier M., Marion-Letellier R., Dechelotte P., Potential for amino acids supplementation during inflammatory bowel diseases, Inflamm Bowel Dis, 16, pp. 518-524, (2010); Clark E.C., Patel S.D., Chadwick P.R., Warhurst G., Curry A., Carlson G.L., Glutamine deprivation facilitates tumour necrosis factor induced bacterial translocation in Caco-2 cells by depletion of enterocyte fuel substrate, Gut, 52, pp. 224-230, (2003); Coeffier M., Marion R., Ducrotte P., Dechelotte P., Modulating effect of glutamine on IL-1beta-induced cytokine production by human gut, Clin Nutr, 22, pp. 407-413, (2003); Coeffier M., Marion R., Leplingard A., Lerebours E., Ducrotte P., Dechelotte P., Glutamine decreases interleukin-8 and interleukin-6 but not nitric oxide and prostaglandins e(2) production by human gut in-vitro, Cytokine, 18, pp. 92-97, (2002); Marion R., Coeffier M.M., Gargala G., Ducrotte P., Dechelotte P.P., Glutamine and CXC chemokines IL-8, Mig, IP-10 and I-TAC in human intestinal epithelial cells, Clin Nutr, 23, pp. 579-585, (2004); Barreau F., Ferrier L., Fioramonti J., Bueno L., Neonatal maternal deprivation triggers long term alterations in colonic epithelial barrier and mucosal immunity in rats, Gut, 53, pp. 501-506, (2004); Garcia-Rodenas C.L., Bergonzelli G.E., Nutten S., Schumann A., Cherbut C., Turini M., Et al., Nutritional approach to restore impaired intestinal barrier function and growth after neonatal stress in rats, J Pediatr Gastroenterol Nutr, 43, pp. 16-24, (2006); Gareau M.G., Jury J., MacQueen G., Sherman P.M., Perdue M.H., Probiotic treatment of rat pups normalises corticosterone release and ameliorates colonic dysfunction induced by maternal separation, Gut, 56, pp. 1522-1528, (2007); Eutamene H., Lamine F., Chabo C., Theodorou V., Rochat F., Bergonzelli G.E., Et al., Synergy between Lactobacillus paracasei and its bacterial products to counteract stress-induced gut permeability and sensitivity increase in rats, J Nutr, 137, pp. 1901-1907, (2007); Gareau M.G., Jury J., Yang P.C., MacQueen G., Perdue M.H., Neonatal maternal separation causes colonic dysfunction in rat pups including impaired host resistance, Pediatr Res, 59, pp. 83-88, (2006); Cario E., Podolsky D.K., Toll-like receptor signaling and its relevance to intestinal inflammation, Ann N Y Acad Sci, 1072, pp. 332-338, (2006); Kessel A., Toubi E., Pavlotzky E., Mogilner J., Coran A.G., Lurie M., Et al., Treatment with glutamine is associated with down-regulation of Toll-like receptor-4 and myeloid differentiation factor 88 expression and decrease in intestinal mucosal injury caused by lipopolysaccharide endotoxaemia in a rat, Clin Exp Immunol, 151, pp. 341-347, (2008); Asehnoune K., Strassheim D., Mitra S., Kim J.Y., Abraham E., Involvement of reactive oxygen species in Toll-like receptor 4-Dependent activation of NF-{kappa}B, J Immunol, 172, pp. 2522-2529, (2004); Abreu M.T., Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function, Nat Rev Immunol, 10, pp. 131-144, (2010); Coeffier M., Gloro R., Boukhettala N., Aziz M., Lecleire S., Vandaele N., Et al., Increased proteasome-mediated degradation of occludin in irritable bowel syndrome, Am J Gastroenterol, 105, pp. 1181-1188, (2010); Piche T., Barbara G., Aubert P., Bruley des Varannes S., Dainese R., Nano J.L., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Li N., Lassman B.J., Liu Z., Liboni K., Neu J., Effects of protein deprivation on growth and small intestine morphology are not improved by glutamine or glutamate in gastrostomy-fed rat pups, J Pediatr Gastroenterol Nutr, 39, pp. 28-33, (2004); Dubuquoy L., Jansson E.A., Deeb S., Rakotobe S., Karoui M., Colombel J.F., Et al., Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis, Gastroenterology, 124, pp. 1265-1276, (2003); Dubuquoy L., Rousseaux C., Thuru X., Peyrin-Biroulet L., Romano O., Chavatte P., Et al., PPARgamma as a new therapeutic target in inflammatory bowel diseases, Gut, 55, pp. 1341-1349, (2006); Marion-Letellier R., Dechelotte P., Iacucci M., Ghosh S., Dietary modulation of peroxisome proliferator-activated receptor gamma, Gut, 58, pp. 586-593, (2009); Sato N., Moore F.A., Kone B.C., Zou L., Smith M.A., Childs M.A., Et al., Differential induction of PPAR-{gamma} by luminal glutamine and iNOS by luminal arginine in the rodent postischemic small bowel, Am J Physiol Gastrointest Liver Physiol, 290, (2006); Ponferrada A., Caso J.R., Alou L., Colon A., Sevillano D., Moro M.A., Et al., The role of PPAR[gamma] on restoration of colonic Homeostasis after experimental stress-induced inflammation and dysfunction, Gastroenterology, 132, pp. 1791-1803, (2007); Fiatte C., Huin C., Collet P., Plenat F., Dauca M., Schohn H., Expression of PPARgamma is reduced by medium supplementation with L-glutamine in human colorectal Caco-2 cells, Int J Mol Med, 22, pp. 825-832, (2008); Anderson L., Seilhamer J., A comparison of selected mRNA and protein abundances in human liver, Electrophoresis, 18, pp. 533-537, (1997); Durand M., Sarrieau A., Aguerre S., Mormede P., Chaouloff F., Differential effects of neonatal handling on anxiety, corticosterone response to stress, and hippocampal, glucocorticoid and serotonin (5HT)2A receptors in Lewis rats, Psychoneuroendocrinology, 23, pp. 323-335, (1998); Yamasu K., Shimada Y., Sakaizumi M., Soma G., Mizuno D., Activation of the systemic production of tumor necrosis factor after exposure to acute stress, Eur Cytokine Netw, 3, pp. 391-398, (1992); Arrieta M.C., Bistritz L., Meddings J.B., Alterations in intestinal permeability, Gut, 55, pp. 1512-1520, (2006); Sodhi C.P., Shi X.H., Richardson W.M., Grant Z.S., Shapiro R.A., Prindle T., Et al., Toll-like receptor-4 inhibits enterocyte proliferation via impaired beta-catenin signaling in necrotizing enterocolitis, Gastroenterology, 138, pp. 185-196, (2010); Kul M., Vurucu S., Demirkaya E., Tunc T., Aydinoz S., Meral C., Et al., Enteral glutamine and/or arginine supplementation have favorable effects on oxidative stress parameters in neonatal rat intestine, J Pediatr Gastroenterol Nutr, 49, pp. 85-89, (2009); Akisu M., Baka M., Huseyinov A., Kultursay N., The role of dietary supplementation with L-glutamine in inflammatory mediator release and intestinal injury in hypoxia/reoxygenation-induced experimental necrotizing enterocolitis, Ann Nutr Metab, 47, pp. 262-266, (2003)","R. Marion-Letellier; Appareil Digestif Environnement Nutrition (ADEN EA 4311), University of Rouen, I.F.R. 23, Institute of Biomedical Research, 76183 Rouen cedex, 22, boulevard Gambetta, France; email: marion_rachel@hotmail.com","","Churchill Livingstone","","","","","","02615614","","CLNUD","21570752","English","Clin. Nutr.","Article","Final","","Scopus","2-s2.0-80053629198"

"Bertiaux-Vandaële N.; Youmba S.B.; Belmonte L.; Lecleire S.; Antonietti M.; Gourcerol G.; Leroi A.-M.; Déchelotte P.; Ménard J.-F.; Ducrotté P.; Coëffier M.","Bertiaux-Vandaële, Nathalie (53363278400); Youmba, Stéphanie Beutheu (53364891200); Belmonte, Liliana (6602674697); Lecleire, Stéphane (6602495158); Antonietti, Michel (7103185148); Gourcerol, Guillaume (6506887187); Leroi, Anne-Marie (16555385000); Déchelotte, Pierre (57201760610); Ménard, Jean-François (37122443100); Ducrotté, Philippe (7006732860); Coëffier, Mose (6603081357)","53363278400; 53364891200; 6602674697; 6602495158; 7103185148; 6506887187; 16555385000; 57201760610; 37122443100; 7006732860; 6603081357","The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype","2011","American Journal of Gastroenterology","106","12","","2165","2173","8","237","10.1038/ajg.2011.257","https://www.scopus.com/inward/record.uri?eid=2-s2.0-82955233025&doi=10.1038%2fajg.2011.257&partnerID=40&md5=8fe41b1383c80ae6fc275fe51fe7ac2c","Department of Gastroenterology, Rouen University Hospital, Rouen, France; ADEN EA4311, Institute for Biomedical Research, Rouen University, 76183, Rouen Cedex 1, 22 Boulevard Gambetta, France; Department of Physiology, Rouen University Hospital, Rouen, France; Nutrition Unit, Rouen University Hospital, Rouen, France; Biostatistics Unit, Rouen University Hospital, Rouen, France","Bertiaux-Vandaële N., Department of Gastroenterology, Rouen University Hospital, Rouen, France; Youmba S.B., ADEN EA4311, Institute for Biomedical Research, Rouen University, 76183, Rouen Cedex 1, 22 Boulevard Gambetta, France; Belmonte L., ADEN EA4311, Institute for Biomedical Research, Rouen University, 76183, Rouen Cedex 1, 22 Boulevard Gambetta, France; Lecleire S., Department of Gastroenterology, Rouen University Hospital, Rouen, France, ADEN EA4311, Institute for Biomedical Research, Rouen University, 76183, Rouen Cedex 1, 22 Boulevard Gambetta, France; Antonietti M., Department of Gastroenterology, Rouen University Hospital, Rouen, France; Gourcerol G., ADEN EA4311, Institute for Biomedical Research, Rouen University, 76183, Rouen Cedex 1, 22 Boulevard Gambetta, France, Department of Physiology, Rouen University Hospital, Rouen, France; Leroi A.-M., ADEN EA4311, Institute for Biomedical Research, Rouen University, 76183, Rouen Cedex 1, 22 Boulevard Gambetta, France, Department of Physiology, Rouen University Hospital, Rouen, France; Déchelotte P., ADEN EA4311, Institute for Biomedical Research, Rouen University, 76183, Rouen Cedex 1, 22 Boulevard Gambetta, France, Nutrition Unit, Rouen University Hospital, Rouen, France; Ménard J.-F., Biostatistics Unit, Rouen University Hospital, Rouen, France; Ducrotté P., Department of Gastroenterology, Rouen University Hospital, Rouen, France, ADEN EA4311, Institute for Biomedical Research, Rouen University, 76183, Rouen Cedex 1, 22 Boulevard Gambetta, France; Coëffier M., ADEN EA4311, Institute for Biomedical Research, Rouen University, 76183, Rouen Cedex 1, 22 Boulevard Gambetta, France, Nutrition Unit, Rouen University Hospital, Rouen, France","Objectives: Recent studies have suggested that an increased intestinal permeability is involved in the pathophysilogy of irritable bowel syndrome (IBS). However, the differential expression of tight junctions (TJs) proteins according to IBS subtypes and symptoms remained unknown. The objective of this study was to study zonula occludens-1 (ZO-1), occludin, and claudin-1 in the colonic mucosa of patients with IBS. Methods: Fifty IBS patients fulfilling the Rome III criteria and 31 controls were included. All types of IBS patients participated with predominant diarrhea (IBS-D, n=19), predominant constipation (IBS-C, n=14), constipation alternating with diarrhea (IBS-A, n=15), or unclassified (IBS-U, n=2). IBS symptom intensity was quantified on 10-cm Visual Analog Scale (VAS). TJ proteins (claudin-1, ZO-1, occludin) were quantified by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR), western blot, while their localization was determined by immunofluorescence. Results: ZO-1 and occludin expression was lower in IBS patients compared with controls, whereas only a trend for a decrease of claudin-1 was observed. The mRNA levels remained unaffected. In the subgroup analyses, occludin and claudin-1 expression was decreased in IBS-D patients but not in IBS-C and IBS-A patients. The subcellular distribution of these three proteins was altered in IBS-C and IBS-D patients. Occludin (r=0.40, P<0.01) and claudin-1 (r=0.46, P<0.01) expression was correlated with the duration of symptoms. The expression of occludin was lower in patients with an abdominal pain intensity higher than 6 on the VAS (P<0.05). Conclusions: Occludin and claudin-1 appeared markedly affected in IBS-D patients. In addition, our results suggest that alteration of TJ proteins may be involved in the initiation of IBS and contribute to visceral hypersensitivity. © 2011 by the American College of Gastroenterology.","","Abdominal Pain; Adult; Aged; Blotting, Western; Case-Control Studies; Colon; DNA Primers; Female; Fluorescent Antibody Technique; Gene Expression; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Male; Membrane Proteins; Middle Aged; Pain Measurement; Phosphoproteins; Questionnaires; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tight Junctions; Time Factors; claudin 1; messenger RNA; occludin; protein ZO1; abdominal pain; adult; article; cellular distribution; colon mucosa; constipation; diarrhea; female; human; hypersensitivity; immunofluorescence; irritable colon; major clinical study; priority journal; protein expression; quantitative analysis; questionnaire; symptom; tight junction; visual analog scale; Western blotting","","claudin 1, 329338-06-9; occludin, 176304-61-3; DNA Primers, ; Membrane Proteins, ; Phosphoproteins, ; RNA, Messenger, ; claudin 1, ; occludin, ; zonula occludens-1 protein, ","","","","","Longstreth G.F., Thompson W.G., Chey W.D., Et al., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Thompson W.G., Longstreth G.F., Drossman D.A., Heaton K.W., Irvine E.J., Muller-Lissner S.A., Functional bowel disorders and functional abdominal pain, Gut, 45, SUPPL. 2, (1999); Barbara G., Mucosal barrier defects in irritable bowel syndrome. Who left the door open?, American Journal of Gastroenterology, 101, 6, pp. 1295-1298, (2006); Camilleri M., Gorman H., Intestinal permeability and irritable bowel syndrome, Neurogastroenterology and Motility, 19, 7, pp. 545-552, (2007); Dunlop S.P., Hebden J., Campbell E., Naesdal J., Olbe L., Perkins A.C., Spiller R.C., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, American Journal of Gastroenterology, 101, 6, pp. 1288-1294, (2006); Spiller R.C., Jenkins D., Thornley J.P., Et al., Increased rectal mucosal enteroendocrine cells T lymphocytes and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, pp. 804-811, (2000); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Piche T., Barbara G., Aubert P., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: Involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Park J.H., Park D.I., Kim H.J., Et al., The relationship between small-intestinal bacterial overgrowth and intestinal permeability in patients with irritable bowel syndrome, Gut Liver, 3, pp. 174-179, (2009); Zhou Q., Souba W.W., Croce C.M., Et al., MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome, Gut, 59, pp. 775-784, (2010); Marshall J.K., Thabane M., Garg A.X., Clark W., Meddings J., Collins S.M., Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario, Alimentary Pharmacology and Therapeutics, 20, 11-12, pp. 1317-1322, (2004); Nusrat A., Turner J.R., Madara J.L., Molecular physiology and pathophysiology of tight junctions. IV. Regulation of tight junctions by extracellular stimuli: Nutrients, cytokines, and immune cells, Am J Physiol Gastrointest Liver Physiol, 279, (2000); Tsukita S., Furuse M., Itoh M., Structural and signalling molecules come together at tight junctions, Current Opinion in Cell Biology, 11, 5, pp. 628-633, (1999); Coeffier M., Gloro R., Boukhettala N., Et al., Increased proteasome-mediated degradation of occludin in irritable bowel syndrome, Am J Gastroenterol, 105, pp. 1181-1188, (2010); Lecleire S., Hassan A., Marion-Letellier R., Et al., Combined glutamine and arginine decrease proinfl ammatory cytokine production by biopsies from Crohn's patients in association with changes in nuclear factorkappaB and p38 mitogen-activated protein kinase pathways, J Nutr, 138, pp. 2481-2486, (2008); Coeffier M., Claeyssens S., Hecketsweiler B., Lavoinne A., Ducrotte P., Dechelotte P., Enteral glutamine stimulates protein synthesis and decreases ubiquitin mRNA level in human gut mucosa, American Journal of Physiology - Gastrointestinal and Liver Physiology, 285, 2-48, (2003); Gecse K., Roka R., Ferrier L., Et al., Increased faecal serine protease activity in diarrhoeic IBS patients: A colonic lumenal factor impairing colonic permeability and sensitivity, Gut, 57, pp. 591-599, (2008); Ivanov A.I., Young C., Den Beste K., Et al., Tumor suppressor scribble regulates assembly of tight junctions in the intestinal epithelium, Am J Pathol, 176, pp. 134-145, (2010); Marchiando A.M., Shen L., Graham W.V., Et al., Caveolin-1-dependent occludin endocytosis is required for TNF-induced tight junction regulation in vivo, J Cell Biol, 189, pp. 111-126, (2010); Delgado-Aros S., Locke III G.R., Camilleri M., Talley N.J., Fett S., Zinsmeister A.R., Melton III L.J., Obesity is associated with increased risk of gastrointestinal symptoms: A population-based study, American Journal of Gastroenterology, 99, 9, pp. 1801-1806, (2004); Talley N.J., Howell S., Poulton R., Obesity and chronic gastrointestinal tract symptoms in young adults: A birth cohort study, American Journal of Gastroenterology, 99, 9, pp. 1807-1814, (2004); Talley N.J., Quan C., Jones M.P., Horowitz M., Association of upper and lower gastrointestinal tract symptoms with body mass index in an Australian cohort, Neurogastroenterology and Motility, 16, 4, pp. 413-419, (2004); Teitelbaum J.E., Sinha P., Micale M., Et al., Obesity is related to multiple functional abdominal diseases, J Pediatr, 154, pp. 444-446, (2009); Brun P., Castagliuolo I., Di Leo V., Et al., Increased intestinal permeability in obese mice: New evidence in the pathogenesis of nonalcoholic steatohepatitis, Am J Physiol Gastrointest Liver Physiol, 292, (2007); De La Serre C.B., Ellis C.L., Lee J., Et al., Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut infl ammation, Am J Physiol Gastrointest Liver Physiol, 299, (2010); Brignardello J., Morales P., Diaz E., Et al., Pilot study: Alterations of intestinal microbiota in obese humans are not associated with colonic infl ammation or disturbances of barrier function, Aliment Pharmacol Th Er, 32, pp. 1307-1314, (2010); Alonso C., Guilarte M., Vicario M., Et al., Maladaptive intestinal epithelial responses to life stress may predispose healthy women to gut mucosal infl ammation, Gastroenterology, 135, pp. 163-172, (2008); Demaude J., Leveque M., Chaumaz G., Et al., Acute stress increases colonic paracellular permeability in mice through a mast cell-independent mechanism: Involvement of pancreatic trypsin, Life Sci, 84, pp. 847-852, (2009); Zheng P.Y., Feng B.S., Oluwole C., Et al., Psychological stress induces eosinophils to produce corticotrophin releasing hormone in the intestine, Gut, 58, pp. 1473-1479, (2009); Mazzon E., Sturniolo G.C., Puzzolo D., Et al., Eff ect of stress on the paracellular barrier in the rat ileum, Gut, 51, pp. 507-513, (2002)","M. Coëffier; ADEN EA4311, Institute for Biomedical Research, Rouen University, 76183, Rouen Cedex 1, 22 Boulevard Gambetta, France; email: moise.coeffier@univ-rouen.fr","","","","","","","","15720241","","AJGAA","22008894","English","Am. J. Gastroenterol.","Article","Final","","Scopus","2-s2.0-82955233025"

"Francavilla R.; Miniello V.; Magistà A.M.; De Canio A.; Bucci N.; Gagliardi F.; Lionetti E.; Castellaneta S.; Polimeno L.; Peccarisi L.; Indrio F.; Cavallo L.","Francavilla, Ruggiero (7003676833); Miniello, Vito (6602500979); Magistà, Anna Maria (6507379244); De Canio, Angela (23970240100); Bucci, Nunzia (23969840700); Gagliardi, Francesca (7005612084); Lionetti, Elena (9247230200); Castellaneta, Stefania (6506514036); Polimeno, Lorenzo (6603697344); Peccarisi, Lucia (6505945818); Indrio, Flavia (6507823589); Cavallo, Luciano (35562814400)","7003676833; 6602500979; 6507379244; 23970240100; 23969840700; 7005612084; 9247230200; 6506514036; 6603697344; 6505945818; 6507823589; 35562814400","A randomized controlled trial of lactobacillus GG in children with functional abdominal pain","2010","Pediatrics","126","6","","e1445","e1452","7","186","10.1542/peds.2010-0467","https://www.scopus.com/inward/record.uri?eid=2-s2.0-78649684470&doi=10.1542%2fpeds.2010-0467&partnerID=40&md5=a287c2586d1ac6fa9f93ef0f2f6aa0e5","Department of Developmental Biomedicine, University of Bari, Bari, Italy; Department of Emergency and Organ Transplantation, Gastroenterology Section, University of Bari, Bari, Italy; Department of Pediatrics, University of Catania, Catania, Italy; Department of Pediatrics, San Paolo Hospital, Bari, Italy; ASL-Bari, Bari, Italy","Francavilla R., Department of Developmental Biomedicine, University of Bari, Bari, Italy; Miniello V., Department of Developmental Biomedicine, University of Bari, Bari, Italy; Magistà A.M., Department of Developmental Biomedicine, University of Bari, Bari, Italy; De Canio A., Department of Developmental Biomedicine, University of Bari, Bari, Italy; Bucci N., Department of Developmental Biomedicine, University of Bari, Bari, Italy; Gagliardi F., Department of Developmental Biomedicine, University of Bari, Bari, Italy; Lionetti E., Department of Pediatrics, University of Catania, Catania, Italy; Castellaneta S., Department of Pediatrics, San Paolo Hospital, Bari, Italy; Polimeno L., Department of Emergency and Organ Transplantation, Gastroenterology Section, University of Bari, Bari, Italy; Peccarisi L., ASL-Bari, Bari, Italy; Indrio F., Department of Developmental Biomedicine, University of Bari, Bari, Italy; Cavallo L., Department of Developmental Biomedicine, University of Bari, Bari, Italy","OBJECTIVE: Our aim was to determine whether Lactobacillus rhamnosus GG (LGG) relieves symptoms in children with recurrent abdominal pain. PATIENTS AND METHODS: A total of 141 children with irritable bowel syndrome (IBS) or functional pain were enrolled in 9 primary care sites and a referral center. Children entered a randomized, double-blind, placebo-controlled trial and received LGG or placebo for 8 weeks and entered follow-up for 8 weeks. The primary outcome was overall pain at the end of the intervention period. At entry and at the end of the trial, children underwent a double-sugar intestinal permeability test. RESULTS: Compared with baseline, LGG, but not placebo, caused a significant reduction of both frequency (P < .01) and severity (P < .01) of abdominal pain. These differences still were significant at the end of follow-up (P < .02 and P < .001, respectively). At week 12, treatment success was achieved in 48 children in the LGG group compared with 37 children in the placebo group (P < .03); this difference still was present at the end of follow-up (P < .03). At entry, 59% of the children had abnormal results from the intestinal permeability test; LGG, but not placebo, determined a significant decrease in the number of patients with abnormal results from the intestinal permeability testing (P < .03). These effects mainly were in children with IBS. CONCLUSIONS: LGG significantly reduces the frequency and severity of abdominal pain in children with IBS; this effect is sustained and may be secondary to improvement of the gut barrier. Copyright © 2010 by the American Academy of Pediatrics.","Abdominal pain; Intestinal barrier function; Lactobacillus rhamnosus GG; Pediatric gastroenterology; Probiotics","Abdominal Pain; Adolescent; Child; Child, Preschool; Double-Blind Method; Female; Follow-Up Studies; Humans; Irritable Bowel Syndrome; Lactobacillus rhamnosus; Male; Probiotics; Retrospective Studies; Treatment Outcome; placebo; probiotic agent; sugar; abdominal pain; article; child; clinical trial; controlled clinical trial; controlled study; disease severity; double blind procedure; drug effect; female; follow up; human; intestine mucosa permeability; irritable colon; Lactobacillus rhamnosus; major clinical study; male; priority journal; randomized controlled trial; recurrent disease","","","","","","","Scharff L., Recurrent abdominal pain in children: A review of psychological factors and treatment, Clinical Psychology Review, 17, 2, pp. 145-166, (1997); Saps M., Seshadri R., Sztainberg M., Schaffer G., Marshall B.M., Di Lorenzo C., A prospective school-based study of abdominal pain and other common somatic complaints in children, J Pediatr, 154, 3, pp. 322-326, (2009); Rasquin A., Di Lorenzo C., Forbes D., Et al., Childhood functional gastrointestinal disorders: Child/adolescent, Gastroenterology, 130, 5, pp. 1527-1537, (2006); Sanders M.R., Shepherd R.W., Cleghorn G., Woolford H., The treatment of recurrent abdominal pain in children: A controlled comparison of cognitive-behavioral family intervention and standard pediatric care, J Consult Clin Psychol, 62, 2, pp. 306-314, (1994); Weydert J.A., Ball T.M., Davis M.F., Systematic review of treatments for recurrent abdominal pain, Pediatrics, 111, 1, (2003); Huertas-Ceballos A., Logan S., Bennett C., Macarthur C., Pharmacological interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood, Cochrane Database Syst Rev, 1, (2008); Huertas-Ceballos A.A., Logan S., Bennett C., Macarthur C., Dietaryinterventionsforrecurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood, Cochrane Database Syst Rev, 21, (2009); Saps M., Youssef N., Miranda A., Et al., Multicenter, randomized, placebo-controlled trial of amitriptyline in children with functional gastrointestinal disorders, Gastroenterology, 137, 4, pp. 1261-1269, (2009); Walker W.A., Goulet O., Morelli L., Antoine J.-M., Progress in the science of probiotics: From cellular microbiology and applied immunology to clinical nutrition, European Journal of Nutrition, 45, SUPPL. 9, pp. 1-18, (2006); Brown A.C., Valiere A., Probiotics and medical nutrition therapy, Nutr Clin Care, 7, 2, pp. 56-68, (2004); Lemberg D.A., Ooi C.Y., Day A.S., Probiotics in paediatric gastrointestinal diseases, J Paediatr Child Health, 43, 5, pp. 331-336, (2007); Silva M., Jacobus N.V., Deneke C., Gorbach S.L., Antimicrobial substance from a human Lactobacillus strain, Antimicrob Agents Chemother, 31, 8, pp. 1311-2233, (1987); O'Mahony L., McCarthy J., Kelly P., Et al., Lactobacillus and Bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles, Gastroenterology, 128, 3, pp. 415-551, (2005); Doron S., Snydman D.R., Gorbach L., Lactobacillus GG: Bacteriology and clinical applications, Gastroenterol Clin N Am, 34, 3, pp. 483-498, (2005); Bausserman M., Michail S., The use of Lactobacillus GG in irritable bowel syndrome in children: A double-blind randomized control trial, J Pediatr, 147, 2, pp. 197-201, (2005); Gawronska A., Dziechciarz P., Horvath A., Szajewska H., A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children, Aliment Pharmacol Ther, 25, 2, pp. 177-184, (2007); Corazziari E., Bytzer P., Delvauz M., Et al., Consensus report: Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome, Aliment Pharmcol Ther, 18, 6, pp. 569-580, (2003); Rasquin-Weber A., Hyman P.E., Cucchiara S., Et al., Childhood functional gastrointestinal disorder, Gut, 45, SUPPL. 2, (1999); McGrath P.A., Seifert C.E., Speechley K.N., Booth J.C., Stitt L., Gibson M.C., A new analogue scale for assessing children's pain: An initial validation study, Pain, 64, 3, pp. 435-443, (1996); Von Baeyer C.L., Children's self-reports of pain intensity: Scale selection, limitations and interpretation, Pain Res Manag. Autumn, 11, 3, pp. 157-162, (2006); Generoso M., De Rosa M., De Rosa R., De Magistris L., Secondulfo M., Fiandra R., Carratu R., Carteni M., Cellobiose and lactulose coupled with mannitol and determined using ion-exchange chromatography with pulsed amperometric detection, are reliable probes for investigation of intestinal permeability, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 783, 2, pp. 349-357, (2003); Secondulfo M., Iafusco D., Carratu R., Et al., Ultrastructural mucosal alterations and increased intestinal permeability in nonceliac, type 1 diabetic patients, Digest Liver Dis, 36, 1, pp. 35-45, (2004); Barbara G., Stanghellini V., Cremon C., Et al., Probiotics and irritable bowel syndrome: Rationale and clinical evidence for their use, J Clin Gastroenterol, 42, SUPPL. 3, (2008); Jarrett M., Heitkemper M., Czyzewski D.I., Shulman R., Recurrent abdominal pain in children: Forerunner to adult irritable bowel syndrome?, J Soc Pediatr Nurs, 8, 3, pp. 81-89, (2003); Hotopf M., Carr S., Mayou R., Wadsworth M., Wessely S., Why do children have chronic abdominal pain, and what happens to them when they grow up? Population based cohort study, BMJ, 316, 7139, pp. 1196-2000, (1998); Di Lorenzo C., Youssef N.N., Sigurdsson L., Scharff L., Griffiths J., Wald A., Visceral hyperalgesia in children with functional abdominal pain, Journal of Pediatrics, 139, 6, pp. 838-843, (2001); Wyatt G.M., Bayliss C.E., Lakey A.F., Bradley H.K., Hunter J.O., Jones V.A., The faecal flora of two patients with food-related irritable bowel syndrome during challenge with symptomprovoking foods, J Med Microbiol, 26, 4, pp. 295-299, (1988); Kassinen A., Krogius-Kurikka L., Makivuokko H., Et al., The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects, Gastroenterology, 133, 1, pp. 24-33, (2007); Matto J., Maunuksela L., Kajander K., Palva A., Riitta K., Anna K., Saarela M., Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome - A longitudinal study in IBS and control subjects, FEMS Immunology and Medical Microbiology, 43, 2, pp. 213-222, (2005); Lammers K.M., Brigidi P., Vitali B., Gionchetti P., Rizzello F., Caramelli E., Matteuzzi D., Campieri M., Immunomodulatory effects of probiotic bacteria DNA: IL-1 and IL-10 response in human peripheral blood mononuclear cells, FEMS Immunology and Medical Microbiology, 38, 2, pp. 165-172, (2003); Chen C.C., Louie S., Shi H.N., Walker W.A., Preinoculation with the probiotic Lactobacillus acidophilus early in life effectively inhibits murine Citrobacter rodentium colitis, Pediatr Res, 58, 6, pp. 1185-1191, (2005); Rousseaux C., Thuru X., Gelot A., Et al., Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors, Nat Med, 13, 1, pp. 35-37, (2007); Berger M.J., Gieteling M.J., Benninga M.A., Chronic abdominal pain in children, BMJ, 334, 7601, pp. 997-1002, (2007); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, 6, pp. 1288-1294, (2006); Marshall J.K., Thabane M., Garg A.X., Et al., Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario, Aliment Pharmacol Ther, 20, 11-12, pp. 1317-1322, (2004); Camilleri M., Gorman H., Intestinal permeability and irritable bowel syndrome, Neurogastroenterology and Motility, 19, 7, pp. 545-552, (2007); Shulman R.J., Eakin M.N., Czyzewski D.I., Jarrett M., Ou C.N., Increased gastrointestinal permeability and gut inflammation in children with functional abdominal pain and irritable bowel syndrome, J Pediatr, 153, 5, pp. 646-650, (2008); Johnson-Henry K.C., Donato K.A., Shen-Tu G., Gordanpour M., Sherman P.M., Lactobacillus rhamnosus strain GG prevents enterohemorrhagic Escherichia coli O157:H7-induced changes in epithelial barrier function, Infection and Immunity, 76, 4, pp. 1340-1348, (2008); Seth A., Yan F., Polk D.B., Rao R.K., Probiotics ameliorate the hydrogen peroxide-induced epithelial barrier disruption by a PKC- and MAP kinase-dependent mechanism, Am J Physiol Gastrointest Liver Physiol, 294, 4, (2008); Isolauri E., Majamaa H., Arvola T., Rantala I., Virtanen E., Arvilommi H., Lactobacillus casei strain GGreversesincreasedintestinal permeability induced by cow milk in suckling rats, Gastroenterology, 105, 6, pp. 1643-1650, (1993); Forsyth C.B., Farhadi A., Jakate S.M., Tang Y., Shaikh M., Keshavarzian A., Lactobacillus GG treatment ameliorates alcohol-induced intestinal oxidative stress, gut leakiness, and liver injury in a rat model of alcoholic steatohepatitis, Alcohol, 43, 2, pp. 163-172, (2009); Madsen K., Cornish A., Soper P., Et al., Probiotic bacteria enhance murine and human intestinal epithelial barrier function, Gastroenterology, 121, 3, pp. 580-591, (2001); Preidis G.A., Versalovic J., Targeting the human microbiome with antibiotics, probiotics, and prebiotics: Gastroenterology enters the metagenomics era, Gastroenterology, 136, 6, pp. 2015-2031, (2009)","R. Francavilla; Clinica Pediatrica B. Trambusti, 11-Policlinico, Bari, Piazza Giulio Cesare, Italy; email: rfrancavilla@libero.it","","","","","","","","10984275","","PEDIA","21078735","English","Pediatrics","Article","Final","","Scopus","2-s2.0-78649684470"

"Wang H.; Gong J.; Wang W.; Long Y.; Fu X.; Fu Y.; Qian W.; Hou X.","Wang, Huan (53986862000); Gong, Jing (57037621500); Wang, Wenfeng (35239196900); Long, Yanqin (15846348900); Fu, Xiaochao (57219232777); Fu, Yu (55227977000); Qian, Wei (35238189900); Hou, Xiaohua (7402838898)","53986862000; 57037621500; 35239196900; 15846348900; 57219232777; 55227977000; 35238189900; 7402838898","Are there any different effects of Bifidobacterium, Lactobacillus and Streptococcus on intestinal sensation, barrier function and intestinal immunity in PI-IBS mouse model?","2014","PLoS ONE","9","3","e90153","","","","95","10.1371/journal.pone.0090153","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84896918001&doi=10.1371%2fjournal.pone.0090153&partnerID=40&md5=2762c7e02c8a556af1eaeb3d70c9526e","Division of Gastroenterology, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; Division of Gastroenterology, Hospital of Dongfeng Motor Company of Hubei University of Medicine, Shiyan, Hubei, China; Division of Gastroenterology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China; Division of Culture Collection, Hubei Center of Industrial Culture Collection and Research, Wuhan, Hubei, China","Wang H., Division of Gastroenterology, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; Gong J., Division of Gastroenterology, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; Wang W., Division of Gastroenterology, Hospital of Dongfeng Motor Company of Hubei University of Medicine, Shiyan, Hubei, China; Long Y., Division of Gastroenterology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China; Fu X., Division of Culture Collection, Hubei Center of Industrial Culture Collection and Research, Wuhan, Hubei, China; Fu Y., Division of Gastroenterology, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; Qian W., Division of Gastroenterology, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; Hou X., Division of Gastroenterology, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China","Background and Aims: Research has increasingly suggested that gut flora plays an important role in the development of post-infectious irritable bowel syndrome (PI-IBS). Studies of the curative effect of probiotics for IBS have usually been positive but not always. However, the differences of treatment effects and mechanisms among probiotic stains, or mixture of them, are not clear. In this study, we compared the effects of different probiotics (Befidobacterium, Lactobacillus, Streptococcus or mixture of the three) on intestinal sensation, barrier function and intestinal immunity in PI-IBS mouse model. Methods: PI-IBS model was induced by Trichinella spiralis infection in mice. Different probiotics were administered to mice after 8 weeks infection. Visceral sensitivity was measured by scores of abdominal withdrawal reflex (AWR) and the threshold intensity of colorectal distention. Colonic smooth muscle contractile response was assessed by contraction of the longitudinal muscle strips. Plasma diamine oxidase (DAO) and d-lactate were determined by an enzymatic spectrophotometry. Expression of tight junction proteins and cytokines in ileum were measured by Western blotting. Results: Compared to control mice, PI-IBS mice treated either alone with Befidobacterium or Lactobacillus (but not Streptococcus), or the mixture of the three exhibited not only decreased AWR score and contractile response, but also reduced plasma DAO and D-lactate. These probiotic treatments also suppressed the expression of proinflammatory cytokine IL-6 and IL-17 and promoted the expression of major tight junction proteins claudin-1 and occludin. The mixture of the three probiotic strains performed better than the individual in up-regulating these tight junction proteins and suppressing IL-17 expression. Conclusions: Bifidobacterium and Lactobacillus, but not Streptococcus, alleviated visceral hypersensitivity and recovered intestinal barrier function as well as inflammation in PI-IBS mouse model, which correlated with an increase of major tight junction proteins. In addition, Mixture of three species was indicated to be superior to a single one. © 2014 Wang et al.","","Animals; Bifidobacterium; Blotting, Western; Cytokines; Intestinal Mucosa; Intestines; Lactobacillus; Mice; Permeability; Probiotics; Species Specificity; Streptococcus; amine oxidase (copper containing); claudin 1; interleukin 17; interleukin 6; lactic acid; occludin; probiotic agent; cytokine; probiotic agent; animal experiment; animal model; animal tissue; article; Bifidobacterium; colon motility; controlled study; drug effect; enzyme blood level; ileum; intestine distension; intestine mucosa permeability; irritable colon; lactate blood level; Lactobacillus; male; mouse; mucosal immunity; nonhuman; protein expression; Streptococcus; trichinosis; upregulation; withdrawal reflex; animal; immunology; intestine; intestine mucosa; metabolism; permeability; physiology; species difference; Western blotting","","amine oxidase (copper containing), 9001-53-0, 9014-75-9; claudin 1, 329338-06-9; lactic acid, 113-21-3, 50-21-5; occludin, 176304-61-3; Cytokines, ","","","","","Wilson S., Roberts L., Roalfe A., Bridge P., Singh S., Prevalence of irritable bowel syndrome: A community survey, British Journal of General Practice, 54, 504, pp. 495-502, (2004); Gwee K.-A., Wee S., Wong M.-L., Png D.J.C., The prevalence, symptom characteristics, and impact of irritable bowel syndrome in an Asian urban community, American Journal of Gastroenterology, 99, 5, pp. 924-931, (2004); Drossman D.A., Camilleri M., Mayer E.A., Whitehead W.E., AGA technical review on irritable bowel syndrome, Gastroenterology, 123, 6, pp. 2108-2131, (2002); Gwee K.A., Graham J.C., McKendrick M.W., Collins S.M., Marshall J.S., Walters S.J., Read N.W., Psychometric scores and persistence of irritable bowel after infectious diarrhoea, Lancet, 347, 8995, pp. 150-153, (1996); Garcia R.L.A., Ruigomez A., Increased risk of irritable bowel syndrome after bacterial gastroenteritis: Cohort study, British Medical Journal, 318, 7183, pp. 565-566, (1999); Dunlop S.P., Jenkins D., Spiller R.C., Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome, American Journal of Gastroenterology, 98, 7, pp. 1578-1583, (2003); Spiller R., Garsed K., Postinfectious irritable bowel syndrome, Gastroenterology, 136, pp. 1979-1988, (2009); Saulnier D.M., Riehle K., Mistretta T.A., Diaz M.A., Mandal D., Et al., Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome, Gastroenterology, 141, pp. 1782-1791, (2011); Jeffery I.B., O'Toole P.W., Ohman L., Claesson M.J., Deane J., Et al., An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota, Gut, 61, pp. 997-1006, (2012); Rajilic-Stojanovic M., Biagi E., Heilig H.G., Kajander K., Kekkonen R.A., Et al., Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome, Gastroenterology, 141, pp. 1792-1801, (2011); Moayyedi P., Ford A.C., Talley N.J., Cremonini F., Foxx-Orenstein A.E., Et al., The efficacy of probiotics in the treatment of irritable bowel syndrome: A systematic review, Gut, 59, pp. 325-332, (2010); Whelan K., Probiotics and prebiotics in the management of irritable bowel syndrome: A review of recent clinical trials and systematic reviews, Curr Opin Clin Nutr Metab Care, 14, pp. 581-587, (2011); Clarke G., Cryan J.F., Dinan T.G., Quigley E.M., Review article: Probiotics for the treatment of irritable bowel syndrome-focus on lactic acid bacteria, Aliment Pharmacol Ther, 35, pp. 403-413, (2012); Hoveyda N., Heneghan C., Mahtani K.R., Perera R., Roberts N., Et al., A systematic review and meta-analysis: Probiotics in the treatment of irritable bowel syndrome, BMC Gastroenterol, 9, (2009); McFarland L.V., Dublin S., Meta-analysis of probiotics for the treatment of irritable bowel syndrome, World J Gastroenterol, 14, pp. 2650-2661, (2008); Ortiz-Lucas M., Tobias A., Saz P., Sebastian J.J., Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis, Rev Esp Enferm Dig, 105, pp. 19-36, (2013); Niedzielin K., Kordecki H., Birkenfeld B., A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome, European Journal of Gastroenterology and Hepatology, 13, 10, pp. 1143-1147, (2001); O'Mahony L., Mccarthy J., Kelly P., Hurley G., Luo F., Chen K., O'Sullivan G.C., Kiely B., Collins J.K., Shanahan F., Quigley E.M.M., Lactobacillus and Bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles, Gastroenterology, 128, 3, pp. 541-551, (2005); Nobaek S., Johansson M.-L., Molin G., Ahrne S., Jeppsson B., Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome, American Journal of Gastroenterology, 95, 5, pp. 1231-1238, (2000); Niv E., Naftali T., Hallak R., Vaisman N., The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome - A double blind, placebo-controlled, randomized study, Clinical Nutrition, 24, 6, pp. 925-931, (2005); Bixquert Jimenez M., Treatment of irritable bowel syndrome with probiotics. An etiopathogenic approach at last?, Rev Esp Enferm Dig, 101, pp. 553-564, (2009); Verdu E.F., Bercik P., Bergonzelli G.E., Huang X.-X., Blennerhasset P., Rochat F., Fiaux M., Mansourian R., Corthesy-Theulaz I., Collins S.M., Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of postinfective gut dysfunction, Gastroenterology, 127, 3, pp. 826-837, (2004); Distrutti E., Cipriani S., Mencarelli A., Renga B., Fiorucci S., Probiotics VSL#3 protect against development of visceral pain in murine model of irritable bowel syndrome, PLoS ONE, 8, (2013); Fu Y., Wang W., Tong J., Pan Q., Long Y., Et al., Th17: A New Participant in Gut Dysfunction in Mice Infected with Trichinella spiralis, Mediators of Inflammation, 2009, pp. 1-7, (2009); Long Y., Wang W., Wang H., Hao L., Qian W., Et al., Characteristics of intestinal lamina propria dendritic cells in a mouse model of postinfectious irritable bowel syndrome, J Gastroenterol Hepatol, 27, pp. 935-944, (2012); Castro G.A., Fairbairn D., Carbohydrates and lipids in Trichinella spiralis larvae and their utilization in vitro, J Parasitol, 55, pp. 51-58, (1969); Wolvekamp M.C., De Bruin R.W., Diamine oxidase: An overview of historical, biochemical and functional aspects, Dig Dis, 12, pp. 2-14, (1994); Nakayama M., Yajima M., Hatano S., Yajima T., Kuwata T., Intestinal adherent bacteria and bacterial translocation in breast-fed and formula-fed rats in relation to susceptibility to infection, Pediatric Research, 54, 3, pp. 364-371, (2003); Ewaschuk J.B., Naylor J.M., Palmer R., Whiting S.J., Zello G.A., D-lactate production and excretion in diarrheic calves, Journal of Veterinary Internal Medicine, 18, 5, pp. 744-747, (2004); Anderson J.M., Van Itallie C.M., Tight junctions and the molecular basis for regulation of paracellular permeability, Am J Physiol, 269, (1995); Jones III R.C.W., Otsuka E., Wagstrom E., Jensen C.S., Price M.P., Gebhart G.F., Short-Term Sensitization of Colon Mechanoreceptors Is Associated With Long-Term Hypersensitivity to Colon Distention in the Mouse, Gastroenterology, 133, 1, pp. 184-194, (2007); Li J.-Y., Lu Y., Hu S., Sun D., Yao Y.-M., Preventive effect of glutamine on intestinal barrier dysfunction induced by severe trauma, World Journal of Gastroenterology, 8, 1, pp. 168-171, (2002); Brandt R.B., Siegel S.A., Waters M.G., Bloch M.H., Spectrophotometric assay for D-(-)-lactate in plasma, Analytical Biochemistry, 102, 1, pp. 39-46, (1980); Singh N., Arioli S., Wang A., Villa C.R., Jahani R., Et al., Impact of Bifidobacterium bifidum MIMBb75 on mouse intestinal microorganisms, FEMS Microbiol Ecol, 85, pp. 369-375, (2013); Matsuki T., Pedron T., Regnault B., Mulet C., Hara T., Et al., Epithelial cell proliferation arrest induced by lactate and acetate from Lactobacillus casei and Bifidobacterium breve, PLoS ONE, 8, (2013); Fanning S., Hall L.J., Cronin M., Zomer A., MacSharry J., Et al., Bifidobacterial surface-exopolysaccharide facilitates commensal-host interaction through immune modulation and pathogen protection, Proc Natl Acad Sci U S a, 109, pp. 2108-2113, (2012); Brenner D.M., Chey W.D., Bifidobacterium infantis 35624: A novel probiotic for the treatment of irritable bowel syndrome, Rev Gastroenterol Disord, 9, pp. 7-15, (2009); Guyonnet D., Chassany O., Ducrotte P., Picard C., Mouret M., Mercier C.-H., Matuchansky C., Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: A multicentre, randomized, double-blind, controlled trial, Alimentary Pharmacology and Therapeutics, 26, 3, pp. 475-486, (2007); Whorwell P.J., Altringer L., Morel J., Bond Y., Charbonneau D., O'Mahony L., Kiely B., Shanahan F., Quigley E.M.M., Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome, American Journal of Gastroenterology, 101, 7, pp. 1581-1590, (2006); Vanderhoof J.A., Probiotics: Future directions, Am J Clin Nutr, 73, (2001); Martens U., Enck P., Zieseniss E., Probiotic treatment of irritable bowel syndrome in children, Ger Med Sci, 8, (2010); Enck P., Zimmermann K., Menke G., Muller-Lissner S., Martens U., Et al., A mixture of Escherichia coli (DSM 17252) and Enterococcus faecalis (DSM 16440) for treatment of the irritable bowel syndrome-a randomized controlled trial with primary care physicians, Neurogastroenterol Motil, 20, pp. 1103-1109, (2008); Kim H.J., Vazquez R.M.I., Camilleri M., Stephens D., Burton D.D., Baxter K., Thomforde G., Zinsmeister A.R., A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating, Neurogastroenterology and Motility, 17, 5, pp. 687-696, (2005); Guandalini S., Magazzu G., Chiaro A., La Balestra V., Di Nardo G., Et al., VSL#3 improves symptoms in children with irritable bowel syndrome: A multicenter, randomized, placebo-controlled, double-blind, crossover study, J Pediatr Gastroenterol Nutr, 51, pp. 24-30, (2010); Michail S., Kenche H., Gut microbiota is not modified by Randomized, Double-blind, Placebo-controlled Trial of VSL#3 in Diarrhea-predominant Irritable Bowel Syndrome, Probiotics Antimicrob Proteins, 3, pp. 1-7, (2011); Kim H.J., Camilleri M., McKinzie S., Lempke M.B., Burton D.D., Thomforde G.M., Zinsmeister A.R., A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome, Alimentary Pharmacology and Therapeutics, 17, 7, pp. 895-904, (2003)","","","Public Library of Science","","","","","","19326203","","POLNC","24595218","English","PLoS ONE","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-84896918001"

"Keszthelyi D.; Troost F.J.; Jonkers D.M.; Van Eijk H.M.; Lindsey P.J.; Dekker J.; Buurman W.A.; Masclee A.A.M.","Keszthelyi, D. (15020799500); Troost, F.J. (6603454094); Jonkers, D.M. (6701864464); Van Eijk, H.M. (7006591660); Lindsey, P.J. (7004729231); Dekker, J. (17338202900); Buurman, W.A. (7102710940); Masclee, A.A.M. (7103116978)","15020799500; 6603454094; 6701864464; 7006591660; 7004729231; 17338202900; 7102710940; 7103116978","Serotonergic reinforcement of intestinal barrier function is impaired in irritable bowel syndrome","2014","Alimentary Pharmacology and Therapeutics","40","4","","392","402","10","45","10.1111/apt.12842","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84904466231&doi=10.1111%2fapt.12842&partnerID=40&md5=4d51cb77e9f988da014eadc736f7e25a","Top Institute Food and Nutrition, Wageningen, Netherlands; Division of Gastroenterology-Hepatology, Department of Internal Medicine, Maastricht University Medical Centre+, 6202 AZ Maastricht, PO Box 5800, Netherlands; Department of Surgery, Maastricht University Medical Centre+, Maastricht, Netherlands; Department of Clinical Genetics and Bioinformatics, Maastricht University Medical Centre+, Maastricht, Netherlands; Host-Microbe Interomics Group, Department of Animal Sciences, Wageningen University, Wageningen, Netherlands; School for Mental Health and Neurosciences, Maastricht University Medical Center+, Maastricht, Netherlands","Keszthelyi D., Top Institute Food and Nutrition, Wageningen, Netherlands, Division of Gastroenterology-Hepatology, Department of Internal Medicine, Maastricht University Medical Centre+, 6202 AZ Maastricht, PO Box 5800, Netherlands; Troost F.J., Top Institute Food and Nutrition, Wageningen, Netherlands, Division of Gastroenterology-Hepatology, Department of Internal Medicine, Maastricht University Medical Centre+, 6202 AZ Maastricht, PO Box 5800, Netherlands; Jonkers D.M., Top Institute Food and Nutrition, Wageningen, Netherlands, Division of Gastroenterology-Hepatology, Department of Internal Medicine, Maastricht University Medical Centre+, 6202 AZ Maastricht, PO Box 5800, Netherlands; Van Eijk H.M., Department of Surgery, Maastricht University Medical Centre+, Maastricht, Netherlands; Lindsey P.J., Department of Clinical Genetics and Bioinformatics, Maastricht University Medical Centre+, Maastricht, Netherlands; Dekker J., Top Institute Food and Nutrition, Wageningen, Netherlands, Host-Microbe Interomics Group, Department of Animal Sciences, Wageningen University, Wageningen, Netherlands; Buurman W.A., School for Mental Health and Neurosciences, Maastricht University Medical Center+, Maastricht, Netherlands; Masclee A.A.M., Top Institute Food and Nutrition, Wageningen, Netherlands, Division of Gastroenterology-Hepatology, Department of Internal Medicine, Maastricht University Medical Centre+, 6202 AZ Maastricht, PO Box 5800, Netherlands","Background Alterations in serotonergic (5-HT) metabolism and/or intestinal integrity have been associated with irritable bowel syndrome (IBS). Aims To assess the effects of the precursor of 5-HT, 5-hydroxytryptophan (5-HTP), on mucosal 5-HT availability and intestinal integrity, and to assess potential differences between healthy controls and IBS patients. Methods Fifteen IBS patients and 15 healthy volunteers participated in this randomised double-blind placebo-controlled study. Intestinal integrity was assessed by dual-sugar test and by determining the mucosal expression of tight junction proteins after ingestion of an oral bolus of 100 mg 5-HTP or placebo. Mucosal serotonergic metabolism was assessed in duodenal biopsy samples. Results 5-HTP administration significantly increased mucosal levels of 5-HIAA, the main metabolite of 5-HT, in both healthy controls (7.1 ± 1.7 vs. 2.5 ± 0.7 pmol/mg, 5-HTP vs. placebo, P = 0.02) and IBS patients (20.0 ± 4.8 vs. 8.1 ± 1.3 pmol/mg, 5-HTP vs. placebo, P = 0.02), with the latter group showing a significantly larger increase. Lactulose/L-rhamnose ratios were significantly lower after administration of 5-HTP (P < 0.05) in healthy controls and were accompanied by redistribution of zonula occludens-1 (ZO-1), pointing to reinforcement of the barrier. In IBS, expression of the tight junction proteins was significantly lower compared to healthy controls, and 5-HTP resulted in a further decrease in occludin expression. Conclusions Oral 5-HTP induced alterations in mucosal 5-HT metabolism. In healthy controls, a reinforcement of the intestinal barrier was seen whereas such reaction was absent in IBS patients. This could indicate the presence of a serotonin-mediated mechanism aimed to reinforce intestinal barrier function, which seems to dysfunction in IBS patients. © 2014 John Wiley & Sons Ltd.","","5-Hydroxytryptophan; Adolescent; Adult; Case-Control Studies; Cross-Over Studies; Double-Blind Method; Female; Humans; Hydroxyindoleacetic Acid; Intestinal Mucosa; Intestines; Irritable Bowel Syndrome; Male; Middle Aged; Serotonin; Tight Junctions; Young Adult; 5 hydroxytryptophan; lactulose; occludin; protein ZO1; rhamnose; serotonin; adult; article; clinical article; controlled study; female; human; human tissue; intestine mucosa; intestine mucosa permeability; irritable colon; male; priority journal; serotonin metabolism; tight junction","","5 hydroxytryptophan, 4350-09-8, 56-69-9; lactulose, 4618-18-2; occludin, 176304-61-3; rhamnose, 10485-94-6, 3615-41-6; serotonin, 50-67-9","","","","","Drossman D.A., Camilleri M., Mayer E.A., Whitehead W.E., AGA technical review on irritable bowel syndrome, Gastroenterology, 123, pp. 2108-2131, (2002); Camilleri M., Lasch K., Zhou W., The Confluence of Increased Permeability, Inflammation, and Pain in Irritable Bowel Syndrome, Am J Physiol Gastrointest Liver Physiol, 303, (2012); Matricon J., Meleine M., Gelot A., Et al., Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome, Aliment Pharmacol Ther, 36, pp. 1009-1031, (2012); Barbara G., Mucosal barrier defects in irritable bowel syndrome. Who left the door open?, Am J Gastroenterol, 101, pp. 1295-1298, (2006); Camilleri M., Gorman H., Intestinal permeability and irritable bowel syndrome, Neurogastroenterol Motil, 19, pp. 545-552, (2007); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Et al., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am J Gastroenterol, 106, pp. 2165-2173, (2011); Martinez C., Lobo B., Pigrau M., Et al., Diarrhoea-predominant irritable bowel syndrome: An organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, pp. 1160-1168, (2013); Martinez C., Vicario M., Ramos L., Et al., The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations, Am J Gastroenterol, 107, pp. 736-746, (2012); Coeffier M., Gloro R., Boukhettala N., Et al., Increased proteasome-mediated degradation of occludin in irritable bowel syndrome, Am J Gastroenterol, 105, pp. 1181-1188, (2010); Gecse K., Roka R., Ferrier L., Et al., Increased faecal serine protease activity in diarrhoeic IBS patients: A colonic lumenal factor impairing colonic permeability and sensitivity, Gut, 57, pp. 591-599, (2008); Camilleri M., Serotonin in the gastrointestinal tract, Curr Opin Endocrinol Diabetes Obes, 16, pp. 53-59, (2009); Spiller R., Serotonin and GI clinical disorders, Neuropharmacology, 55, pp. 1072-1080, (2008); Keszthelyi D., Troost F.J., Masclee A.A., Understanding the role of tryptophan and serotonin metabolism in gastrointestinal function, Neurogastroenterol Motil, 21, pp. 1239-1249, (2009); Coates M.D., Mahoney C.R., Linden D.R., Et al., Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome, Gastroenterology, 126, pp. 1657-1664, (2004); Kerckhoffs A.P., Ter Linde J.J., Akkermans L.M., Trypsinogen S.M., Serotonin transporter transcript levels and serotonin content are increased in small intestine of irritable bowel syndrome patients, Neurogastroenterol Motil, 20, pp. 900-907, (2008); Camilleri M., Andrews C.N., Bharucha A.E., Et al., Alterations in expression of p11 and SERT in mucosal biopsy specimens of patients with irritable bowel syndrome, Gastroenterology, 132, pp. 17-25, (2007); Foley S., Garsed K., Singh G., Et al., Impaired uptake of serotonin by platelets from patients with irritable bowel syndrome correlates with duodenal immune activation, Gastroenterology, 140, pp. 1434-1443, (2011); Haub S., Kanuri G., Volynets V., Brune T., Bischoff S.C., Bergheim I., Serotonin reuptake transporter (SERT) plays a critical role in the onset of fructose-induced hepatic steatosis in mice, Am J Physiol Gastrointest Liver Physiol, 298, (2010); Pai V.P., Horseman N.D., Multiple cellular responses to serotonin contribute to epithelial homeostasis, PLoS ONE, 6, (2011); Zeng J., Li Y.Q., Zuo X.L., Zhen Y.B., Yang J., Liu C.H., Clinical trial: Effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome, Aliment Pharmacol Ther, 28, pp. 994-1002, (2008); Gijsman H.J., Van Gerven J.M., De Kam M.L., Et al., Placebo-controlled comparison of three dose-regimens of 5-hydroxytryptophan challenge test in healthy volunteers, J Clin Psychopharmacol, 22, pp. 183-189, (2002); Van Wijck K., Van Eijk H.M., Buurman W.A., Dejong C.H., Lenaerts K., Novel analytical approach to a multi-sugar whole gut permeability assay, J Chromatogr B Analyt Technol Biomed Life Sci, 879, pp. 2794-2801, (2011); Keszthelyi D., Troost F.J., Jonkers D.M., Et al., Does acute tryptophan depletion affect peripheral serotonin metabolism in the intestine?, Am J Clin Nutr, 95, pp. 603-608, (2012); Ihaka R., Gentleman R., R: A language for data analysis and graphics, J Comput Graph Stat, 5, (1996); Lindsey J.K., Nonlinear Models in Medical Statistics, (2001); Atkinson W., Lockhart S., Whorwell P.J., Keevil B., Houghton L.A., Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome, Gastroenterology, 130, pp. 34-43, (2006); Bulbring E., Lin R.C., The effect of intraluminal application of 5-hydroxytryptamine and 5-hydroxytryptophan on peristalsis; The local production of 5-HT and its release in relation to intraluminal pressure and propulsive activity, J Physiol, 140, pp. 381-407, (1958); Bulbring E., Crema A., The action of 5-hydroxytryptamine, 5-hydroxytryptophan and reserpine on intestinal peristalsis in anaesthetized guinea-pigs, J Physiol, 146, pp. 29-53, (1959); Cremon C., Carini G., Wang B., Et al., Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome, Am J Gastroenterol, 106, pp. 1290-1298, (2011); Gill R.K., Pant N., Saksena S., Et al., Function, expression, and characterization of the serotonin transporter in the native human intestine, Am J Physiol Gastrointest Liver Physiol, 294, (2008); Wang S.H., Dong L., Luo J.Y., Et al., Decreased expression of serotonin in the jejunum and increased numbers of mast cells in the terminal ileum in patients with irritable bowel syndrome, World J Gastroenterol, 13, pp. 6041-6047, (2007); Kerckhoffs A.P., Ter Linde J.J., Akkermans L.M., Samsom M., SERT and TPH-1 mRNA expression are reduced in irritable bowel syndrome patients regardless of visceral sensitivity state in large intestine, Am J Physiol Gastrointest Liver Physiol, 302, (2012); Dizdar V., Spiller R., Singh G., Et al., Relative importance of abnormalities of CCK and 5-HT (serotonin) in Giardia-induced post-infectious irritable bowel syndrome and functional dyspepsia, Aliment Pharmacol Ther, 31, pp. 883-891, (2010); Bose M., Nickols C., Greenwald S., Feakins R., Perrett D., Farthing M., 5-Hydroxytryptamine (5-HT) levels in colonic mucosa in the irritable bowel syndrome (IBS): Assessment by high performance liquid chromatography (HPLC), Gut, 48, (2001); Shen L., Weber C.R., Raleigh D.R., Yu D., Turner J.R., Tight junction pore and leak pathways: A dynamic duo, Annu Rev Physiol, 73, pp. 283-309, (2011); Grundy D., 5-HT system in the gut: Roles in the regulation of visceral sensitivity and motor functions, Eur Rev Med Pharmacol Sci, 12, SUPPL.. 1, pp. 63-67, (2008); Stull M.A., Pai V., Vomachka A.J., Marshall A.M., Jacob G.A., Horseman N.D., Mammary gland homeostasis employs serotonergic regulation of epithelial tight junctions, Proc Natl Acad Sci USA, 104, pp. 16708-16713, (2007); Shen L., Turner J.R., Role of epithelial cells in initiation and propagation of intestinal inflammation. Eliminating the static: Tight junction dynamics exposed, Am J Physiol Gastrointest Liver Physiol, 290, (2006); Dupont H.L., Review article: Evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets, Aliment Pharmacol Ther, 39, pp. 1033-1042, (2014); Van Wijck K., Verlinden T.J., Van Eijk H.M., Et al., Novel multi-sugar assay for site-specific gastrointestinal permeability analysis: A randomized controlled crossover trial, Clin Nutr, 32, pp. 245-251, (2013)","D. Keszthelyi; Division of Gastroenterology-Hepatology, Department of Internal Medicine, Maastricht University Medical Centre+, 6202 AZ Maastricht, PO Box 5800, Netherlands; email: daniel.keszthelyi@maastrichtuniversity.nl","","Blackwell Publishing Ltd","","","","","","02692813","","APTHE","24943480","English","Aliment. Pharmacol. Ther.","Article","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-84904466231"

"Thabane M.; Marshall J.K.","Thabane, Marroon (14036433600); Marshall, John K. (7404858353)","14036433600; 7404858353","Post-infectious irritable bowel syndrome","2009","World Journal of Gastroenterology","15","29","","3591","3596","5","143","10.3748/wjg.15.3591","https://www.scopus.com/inward/record.uri?eid=2-s2.0-70349566856&doi=10.3748%2fwjg.15.3591&partnerID=40&md5=91c2eb4db62e120f9d17ab9fad2109be","Division of Gastroenterology, McMaster University Medical Centre, Hamilton, ON L8N 3Z5, 1200 Main Street West, Canada; Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON L8N 3Z5, Canada; Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON L8N 3Z5, Canada","Thabane M., Division of Gastroenterology, McMaster University Medical Centre, Hamilton, ON L8N 3Z5, 1200 Main Street West, Canada, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON L8N 3Z5, Canada, Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON L8N 3Z5, Canada; Marshall J.K., Division of Gastroenterology, McMaster University Medical Centre, Hamilton, ON L8N 3Z5, 1200 Main Street West, Canada, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON L8N 3Z5, Canada","Post-infectious irritable bowel syndrome (PI-IBS) is a common disorder wherein symptoms of IBS begin after an episode of acute gastroenteritis. Published studies have reported incidence of PI-IBS to range between 5% and 32%. The mechanisms underlying the development of PI-IBS are not fully understood, but are believed to include persistent sub-clinical inflammation, changes in intestinal permeability and alteration of gut flora. Individual studies have suggested that risk factors for PI-IBS include patients' demographics, psychological disorders and the severity of enteric illness. However, PI-IBS remains a diagnosis of exclusion with no specific disease markers and, to date, no definitive therapy exists. The prognosis of PI-IBS appears favorable with spontaneous and gradual resolution of symptoms in most patients. © 2009 The WJG Press and Baishideng. All rights reserved.","Functional bowel disorder; Functional colonic disease; Gastroenteritis; Irritable bowel syndrome","Gastroenteritis; Humans; Irritable Bowel Syndrome; Prognosis; corticosteroid derivative; prednisolone; probiotic agent; acute gastroenteritis; article; Campylobacter jejuni; clinical trial; demography; disease severity; drug efficacy; Escherichia coli; gastroenteritis; human; incidence; infection complication; mental disease; nonhuman; pathophysiology; postinfectious irritable bowel syndrome; postinfectious neuromuscular dysfunction; prognosis; risk factor","","prednisolone, 50-24-8","","","","","Drossman D.A., The functional gastrointestinal disorders and the Rome III process, Gastroenterology, 130, pp. 1377-1390, (2006); Hasler W.L., Owyang C., Irritable bowel syndrome, Textbook of Gastroenterology, pp. 1832-1855, (1995); Dunlop S.P., Jenkins D., Spiller R.C., Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome, Am J Gastroenterol, 98, pp. 1578-1583, (2003); Kim H.S., Kim M.S., Ji S.W., Park H., The development of irritable bowel syndrome after Shigella infection: 3 year follow-up study], Korean J Gastroenterol, 47, pp. 300-305, (2006); Ilnyckyj A., Balachandra B., Elliott L., Choudhri S., Duerksen D.R., Post-traveler's diarrhea irritable bowel syndrome: A prospective study, Am J Gastroenterol, 98, pp. 596-599, (2003); Rodriguez L.A., Ruigomez A., Increased risk of irritable bowel syndrome after bacterial gastroenteritis: Cohort study, BMJ, 318, pp. 565-566, (1999); Ruigomez A., Garcia Rodriguez L.A., Panes J., Risk of irritable bowel syndrome after an episode of bacterial gastroenteritis in general practice: Influence of comorbidities, Clin Gastroenterol Hepatol, 5, pp. 465-469, (2007); Soyturk M., Akpinar H., Gurler O., Pozio E., Sari I., Akar S., Akarsu M., Birlik M., Onen F., Akkoc N., Irritable bowel syndrome in persons who acquired trichinellosis, Am J Gastroenterol, 102, pp. 1064-1069, (2007); Piche T., Vanbiervliet G., Pipau F.G., Dainese R., Hebuterne X., Rampal P., Collins S.M., Low risk of irritable bowel syndrome after Clostridium difficile infection, Can J Gastroenterol, 21, pp. 727-731, (2007); Marshall J.K., Thabane M., Borgaonkar M.R., James C., Postinfectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attributed to a viral pathogen, Clin Gastroenterol Hepatol, 5, pp. 457-460, (2007); Marshall J.K., Thabane M., Garg A.X., Clark W.F., Salvadori M., Collins S.M., Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery, Gastroenterology, 131, pp. 445-450, (2006); Wang L.H., Fang X.C., Pan G.Z., Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis, Gut, 53, pp. 1096-1101, (2004); Neal K.R., Hebden J., Spiller R., Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: Postal survey of patients, BMJ, 314, pp. 779-782, (1997); Stermer E., Lubezky A., Potasman I., Paster E., Lavy A., Is traveler's diarrhea a significant risk factor for the development of irritable bowel syndrome? A prospective study, Clin Infect Dis, 43, pp. 898-901, (2006); Okhuysen P.C., Jiang Z.D., Carlin L., Forbes C., DuPont H.L., Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico, Am J Gastroenterol, 99, pp. 1774-1778, (2004); Thabane M., Kottachchi D.T., Marshall J.K., Systematic review and meta-analysis: The incidence and prognosis of post-infectious irritable bowel syndrome, Aliment Pharmacol Ther, 26, pp. 535-544, (2007); Wheatcroft J., Wakelin D., Smith A., Mahoney C.R., Mawe G., Spiller R., Enterochromaffin cell hyperplasia and decreased serotonin transporter in a mouse model of postinfectious bowel dysfunction, Neurogastroenterol Motil, 17, pp. 863-870, (2005); Spiller R.C., Jenkins D., Thornley J.P., Hebden J.M., Wright T., Skinner M., Neal K.R., Inc reased rec tal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, pp. 804-811, (2000); Stewart G.T., Post-dysenteric colitis, Br Med J, 1, pp. 405-409, (1950); Chaudhary N.A., Truelove S.C., The irritable colon syndrome. A study of the clinical features, predisposing causes, and prognosis in 130 cases, Q J Med, 31, pp. 307-322, (1962); Borgaonkar M.R., Ford D.C., Marshall J.K., Churchill E., Collins S.M., The incidence of irritable bowel syndrome among community subjects with previous acute enteric infection, Dig Dis Sci, 51, pp. 1026-1032, (2006); Gwee K.A., Leong Y.L., Graham C., McKendrick M.W., Collins S.M., Walters S.J., Underwood J.E., Read N.W., The role of psychological and biological factors in postinfective gut dysfunction, Gut, 44, pp. 400-406, (1999); Ji S., Park H., Lee D., Song Y.K., Choi J.P., Lee S.I., Post-infectious irritable bowel syndrome in patients with Shigella infection, J Gastroenterol Hepatol, 20, pp. 381-386, (2005); McKendrick M.W., Read N.W., Irritable bowel syndrome - post salmonella infection, J Infect, 29, pp. 1-3, (1994); Mearin F., Badia X., Balbao A., Baro E., Caldwell E., Cucala M., Diaz-Rubio M., Fueyo A., Ponce J., Roset M., Talley N.J., Irritable bowel syndrome prevalence varies enormously depending on the employed diagnostic criteria: Comparison of Rome II versus previous criteria in a general population, Scand J Gastroenterol, 36, pp. 1155-1161, (2001); Gwee K.A., Graham J.C., McKendrick M.W., Collins S.M., Marshall J.S., Walters S.J., Read N.W., Psychometric scores and persistence of irritable bowel after infectious diarrhoea, Lancet, 347, pp. 150-153, (1996); Tuteja A.K., Talley N.J., Gelman S.S., Alder S.C., Thompson C., Tolman K., Hale D.C., Development of functional diarrhea, constipation, irritable bowel syndrome, and dyspepsia during and after traveling outside the USA, Dig Dis Sci, 53, pp. 271-276, (2008); Spence M.J., Moss-Morris R., The cognitive behavioural model of irritable bowel syndrome: A prospective investigation of patients with gastroenteritis, Gut, 56, pp. 1066-1071, (2007); Dunlop S.P., Jenkins D., Spiller R.C., Age-related decline in rectal mucosal lymphocytes and mast cells, Eur J Gastroenterol Hepatol, 16, pp. 1011-1015, (2004); Sykes M.A., Blanchard E.B., Lackner J., Keefer L., Krasner S., Psychopathology in irritable bowel syndrome: Support for a psychophysiological model, J Behav Med, 26, pp. 361-372, (2003); Dunlop S.P., Jenkins D., Neal K.R., Spiller R.C., Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS, Gastroenterology, 125, pp. 1651-1659, (2003); Coates M.D., Mahoney C.R., Linden D.R., Sampson J.E., Chen J., Blaszyk H., Crowell M.D., Sharkey K.A., Gershon M.D., Mawe G.M., Moses P.L., Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome, Gastroenterology, 126, pp. 1657-1664, (2004); Dunlop S.P., Coleman N.S., Blackshaw E., Perkins A.C., Singh G., Marsden C.A., Spiller R.C., Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome, Clin Gastroenterol Hepatol, 3, pp. 349-357, (2005); Gwee K.A., Collins S.M., Read N.W., Rajnakova A., Deng Y., Graham J.C., McKendrick M.W., Moochhala S.M., Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome, Gut, 52, pp. 523-526, (2003); Marshall J.K., Thabane M., Garg A.X., Clark W., Meddings J., Collins S.M., Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario, Aliment Pharmacol Ther, 20, pp. 1317-1322, (2004); Villani A., Lemire M., Thabane M., Genetic risk factors for post-infectious IBS in the E. coli 0157:H7 outbreak in Walkerton (Canada) in 2000, Gastroenterology, 134, (2008); Marshall J.K., Thabane M., Garg A.X., Clark W.F., Prognosis in post-infectious irritable bowel syndrome: A four year follow up after the Walkerton waterborne outbreak of gastroenteritis, Gastroenterology, 130, (2006); Marshall J.K., Thabane M., Garg A.X., Clark W.F., Collins S.M., Prognosis in post-infectious irritable bowel syndrome: A six year follow up after the Walkerton waterborne outbreak of gastroenteritis, Gastroenterology, 132, (2007); Jung I.S., Kim H.S., Park H., Lee S.I., The clinical course of postinfectious irritable bowel syndrome: A five-year followup study, J Clin Gastroenterol, 43, pp. 534-540, (2009); Neal K.R., Barker L., Spiller R.C., Prognosis in post-infective irritable bowel syndrome: A six year follow up study, Gut, 51, pp. 410-413, (2002); Mearin F., Perez-Oliveras M., Perello A., Vinyet J., Ibanez A., Coderch J., Perona M., Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: One-year follow-up cohort study, Gastroenterology, 129, pp. 98-104, (2005); Verdu E.F., Bercik P., Bergonzelli G.E., Huang X.X., Blennerhasset P., Rochat F., Fiaux M., Mansourian R., Corthesy-Theulaz I., Collins S.M., Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of postinfective gut dysfunction, Gastroenterology, 127, pp. 826-837, (2004); Verdu E.F., Bercik P., Verma-Gandhu M., Huang X.X., Blennerhassett P., Jackson W., Mao Y., Wang L., Rochat F., Collins S.M., Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice, Gut, 55, pp. 182-190, (2006); Camilleri M., Probiotics and irritable bowel syndrome: Rationale, putative mechanisms, and evidence of clinical efficacy, J Clin Gastroenterol, 40, pp. 264-269, (2006); Camilleri M., Probiotics and irritable bowel syndrome: Rationale, mechanisms, and efficacy, J Clin Gastroenterol, 42, SUPPL. 3, (2008); Medici M., Vinderola C.G., Weill R., Perdigon G., Effect of fermented milk containing probiotic bacteria in the prevention of an enteroinvasive Escherichia coli infection in mice, J Dairy Res, 72, pp. 243-249, (2005); Attar A., Flourie B., Rambaud J.C., Franchisseur C., Ruszniewski P., Bouhnik Y., Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: A crossover, randomized trial, Gastroenterology, 117, pp. 794-797, (1999); Di Stefano M., Malservisi S., Veneto G., Ferrieri A., Corazza G.R., Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth, Aliment Pharmacol Ther, 14, pp. 551-556, (2000); Rohde C.L., Bartolini V., Jones N., The use of probiotics in the prevention and treatment of antibiotic-associated diarrhea with special interest in Clostridium difficile-associated diarrhea, Nutr Clin Pract, 24, pp. 33-40, (2009); Shukla G., Devi P., Sehgal R., Effect of Lactobacillus casei as a probiotic on modulation of giardiasis, Dig Dis Sci, 53, pp. 2671-2679, (2008); Resta-Lenert S., Barrett K.E., Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC), Gut, 52, pp. 988-997, (2003); Camilleri M., Chey W.Y., Mayer E.A., Northcutt A.R., Heath A., Dukes G.E., McSorley D., Mangel A.M., A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome, Arch Intern Med, 161, pp. 1733-1740, (2001); Camilleri M., Northcutt A.R., Kong S., Dukes G.E., McSorley D., Mangel A.W., Efficacy and safety of alosetron in women with irritable bowel syndrome: A randomised, placebo-controlled trial, Lancet, 355, pp. 1035-1040, (2000); Camilleri M., Mayer E.A., Drossman D.A., Heath A., Dukes G.E., McSorley D., Kong S., Mangel A.W., Northcutt A.R., Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist, Aliment Pharmacol Ther, 13, pp. 1149-1159, (1999); Chang L., Ameen V.Z., Dukes G.E., McSorley D.J., Carter E.G., Mayer E.A., A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS, Am J Gastroenterol, 100, pp. 115-123, (2005); Krause R., Ameen V., Gordon S.H., West M., Heath A.T., Perschy T., Carter E.G., A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS, Am J Gastroenterol, 102, pp. 1709-1719, (2007); Lembo A.J., Olden K.W., Ameen V.Z., Gordon S.L., Heath A.T., Carter E.G., Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: Analysis of two controlled trials, Clin Gastroenterol Hepatol, 2, pp. 675-682, (2004); Jones R.H., Holtmann G., Rodrigo L., Ehsanullah R.S., Crompton P.M., Jacques L.A., Mills J.G., Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients, Aliment Pharmacol Ther, 13, pp. 1419-1427, (1999); Chey W.D., Chey W.Y., Heath A.T., Dukes G.E., Carter E.G., Northcutt A., Ameen V.Z., Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome, Am J Gastroenterol, 99, pp. 2195-2203, (2004); Bardhan K.D., Bodemar G., Geldof H., Schutz E., Heath A., Mills J.G., Jacques L.A., A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome, Aliment Pharmacol Ther, 14, pp. 23-34, (2000); Muller-Lissner S., Holtmann G., Rueegg P., Weidinger G., Loffler H., Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation, Aliment Pharmacol Ther, 21, pp. 11-20, (2005); Chey W.D., Pare P., Viegas A., Ligozio G., Shetzline M.A., Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: A randomized controlled trial, Am J Gastroenterol, 103, pp. 1217-1225, (2008); Di Stefano M., Miceli E., Mazzocchi S., Tana P., Missanelli A., Corazza G.R., Effect of tegaserod on recto-sigmoid tonic and phasic activity in constipation-predominant irritable bowel syndrome, Am J Gastroenterol, 102, pp. 1720-1726, (2007); Fock K.M., Wagner A., Safety, tolerability and satisfaction with tegaserod therapy in Asia-Pacific patients with irritable bowel syndrome with constipation, J Gastroenterol Hepatol, 22, pp. 1190-1198, (2007); Harish K., Hazeena K., Thomas V., Kumar S., Jose T., Narayanan P., Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome, J Gastroenterol Hepatol, 22, pp. 1183-1189, (2007); Tack J., Muller-Lissner S., Bytzer P., Corinaldesi R., Chang L., Viegas A., Schnekenbuehl S., Dunger-Baldauf C., Rueegg P., A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation, Gut, 54, pp. 1707-1713, (2005); Muller-Lissner S.A., Fumagalli I., Bardhan K.D., Pace F., Pecher E., Nault B., Ruegg P., Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation, Aliment Pharmacol Ther, 15, pp. 1655-1666, (2001); Novick J., Miner P., Krause R., Glebas K., Bliesath H., Ligozio G., Ruegg P., Lefkowitz M., A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation, Aliment Pharmacol Ther, 16, pp. 1877-1888, (2002); Kellow J., Lee O.Y., Chang F.Y., Thongsawat S., Mazlam M.Z., Yuen H., Gwee K.A., Bak Y.T., Jones J., Wagner A., An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome, Gut, 52, pp. 671-676, (2003); Nyhlin H., Bang C., Elsborg L., Silvennoinen J., Holme I., Ruegg P., Jones J., Wagner A., A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome, Scand J Gastroenterol, 39, pp. 119-126, (2004); Dunlop S.P., Jenkins D., Neal K.R., Naesdal J., Borgaonker M., Collins S.M., Spiller R.C., Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome, Aliment Pharmacol Ther, 18, pp. 77-84, (2003); Barbara G., De Giorgio R., Deng Y., Vallance B., Blennerhassett P., Collins S.M., Role of immunologic factors and cyclooxygenase 2 in persistent postinfective enteric muscle dysfunction in mice, Gastroenterology, 120, pp. 1729-1736, (2001); Sukhdeo M.V., Croll N.A., Gut propulsion in mice infected with Trichinella spiralis, J Parasitol, 67, pp. 906-910, (1981)","J.K. Marshall; Division of Gastroenterology, McMaster University Medical Centre, Hamilton, ON L8N 3Z5, 1200 Main Street West, Canada; email: marshllj@mcmaster.ca","","Baishideng Publishing Group Co","","","","","","10079327","","WJGAF","19653335","English","World J. Gastroenterol.","Article","Final","All Open Access; Green Open Access; Hybrid Gold Open Access","Scopus","2-s2.0-70349566856"

"Gecse K.; Róka R.; Ferrier L.; Leveque M.; Eutamene H.; Cartier C.; Ait-Belgnaoui A.; Rosztóczy A.; Izbéki F.; Fioramonti J.; Wittmann T.; Bueno L.","Gecse, K. (24080248600); Róka, R. (8512636100); Ferrier, L. (7003733489); Leveque, M. (16047756000); Eutamene, H. (55926684800); Cartier, C. (24079526500); Ait-Belgnaoui, A. (24079568900); Rosztóczy, A. (6602312658); Izbéki, F. (6602337283); Fioramonti, J. (7102570340); Wittmann, T. (7004015774); Bueno, L. (36043988100)","24080248600; 8512636100; 7003733489; 16047756000; 55926684800; 24079526500; 24079568900; 6602312658; 6602337283; 7102570340; 7004015774; 36043988100","Increased faecal serine protease activity in diarrhoeic IBS patients: A colonic lumenal factor impairing colonic permeability and sensitivity","2008","Gut","57","5","","591","598","7","280","10.1136/gut.2007.140210","https://www.scopus.com/inward/record.uri?eid=2-s2.0-42549168553&doi=10.1136%2fgut.2007.140210&partnerID=40&md5=4d505d94fdfa7f8e572346c884151bfb","Neuro-Gastroenterology and Nutrition Unit, INRA, Toulouse, France; First Department of Internal Medicine, University of Szeged, Szeged, Hungary; Neuro-Gastroenterology and Nutrition Unit, Institut National de la Recherche Agronomique, 31931 Toulouse Cedex 9, 180 Chemin de Tournefeuille, France","Gecse K., Neuro-Gastroenterology and Nutrition Unit, INRA, Toulouse, France; Róka R., First Department of Internal Medicine, University of Szeged, Szeged, Hungary; Ferrier L., Neuro-Gastroenterology and Nutrition Unit, INRA, Toulouse, France; Leveque M., Neuro-Gastroenterology and Nutrition Unit, INRA, Toulouse, France; Eutamene H., Neuro-Gastroenterology and Nutrition Unit, INRA, Toulouse, France; Cartier C., Neuro-Gastroenterology and Nutrition Unit, INRA, Toulouse, France; Ait-Belgnaoui A., Neuro-Gastroenterology and Nutrition Unit, INRA, Toulouse, France; Rosztóczy A., First Department of Internal Medicine, University of Szeged, Szeged, Hungary; Izbéki F., First Department of Internal Medicine, University of Szeged, Szeged, Hungary; Fioramonti J., Neuro-Gastroenterology and Nutrition Unit, INRA, Toulouse, France; Wittmann T., First Department of Internal Medicine, University of Szeged, Szeged, Hungary; Bueno L., Neuro-Gastroenterology and Nutrition Unit, INRA, Toulouse, France, Neuro-Gastroenterology and Nutrition Unit, Institut National de la Recherche Agronomique, 31931 Toulouse Cedex 9, 180 Chemin de Tournefeuille, France","Objectives: Diarrhoea-predominant irritable bowel syndrome (IBS-D) is characterised by elevated colonic lumenal serine protease activity. The aims of this study were (1) to investigate the origin of this elevated serine protease activity, (2) to evaluate if it may be sufficient to trigger alterations in colonic paracellular permeability (CPP) and sensitivity, and (3) to examine the role of the proteinase-activated receptor-2 (PAR-2) activation and signalling cascade in this process. Patients and methods: Faecal enzymatic activities were assayed in healthy subjects and patients with IBS, ulcerative colitis and acute infectious diarrhoea. Following mucosal exposure to supernatants from control subjects and IBS-D patients, electromyographic response to colorectal balloon distension was recorded in wild-type and PAR-2-/- mice, and CPP was evaluated on colonic strips in Ussing chambers. Zonula occludens-1 (ZO-1) and phosphorylated myosin light chain were detected by immunohistochemistry. Results: The threefold increase in faecal serine protease activity seen in IBS-D patients compared with constipation-predominant IBS (IBS-C) or infectious diarrhoea is of neither epithelial nor inflammatory cell origin, nor is it coupled with antiprotease activity of endogenous origin. Mucosal application of faecal supernatants from IBS-D patients in mice evoked allodynia and increased CPP by 92%, both of which effects were prevented by serine protease inhibitors and dependent on PAR-2 expression. In mice, colonic exposure to supernatants from IBS-D patients resulted in a rapid increase in the phosphorylation of myosin light chain and delayed redistribution of ZO-1 in colonocytes. Conclusions: Elevated colonic lumenal serine protease activity of IBS-D patients evokes a PAR-2-mediated colonic epithelial barrier dysfunction and subsequent allodynia in mice, suggesting a novel organic background in the pathogenesis of IBS.","","Adult; Aged; Aged, 80 and over; Animals; Biological Markers; Colon; Diarrhea; Feces; Female; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Male; Mice; Mice, Inbred C57BL; Middle Aged; Permeability; Receptor, PAR-2; Serine Endopeptidases; myosin; protein ZO1; proteinase activated receptor 2; serine proteinase; serine proteinase inhibitor; adult; aged; allodynia; animal experiment; animal model; animal tissue; article; balloon dilatation; colon mucosa; constipation; controlled study; diarrhea; electromyography; enzyme activity; enzyme assay; epithelium cell; feces; female; human; immunohistochemistry; infectious diarrhea; inflammatory cell; intestine cell; intestine mucosa permeability; irritable colon; light chain; major clinical study; male; mouse; nonhuman; priority journal; protein analysis; protein expression; protein function; protein localization; protein phosphorylation; recording; signal transduction; supernatant; ulcerative colitis; wild type","","serine proteinase, 37259-58-8; Biological Markers, ; Receptor, PAR-2, ; Serine Endopeptidases, EC 3.4.21.-","","","","","Corazziari E., Definition and epidemiology of functional gastrointestinal disorders, Best Pract Res Clin Gastroenterol, 18, pp. 613-631, (2004); Roka B., Rosztoczy A., Leveque M., Et al., A pilot study of fecal serine-protease activity: A pathophysiologic factor in diarrhea-predominant irritable bowel syndrome, Clin Gastroenterol Hepatol, 5, pp. 550-555, (2007); Amadesi S., Bunnett N., Protease-activated receptors: Protease signaling in the gastrointestinal tract, Cure Opin Pharmacol, 4, pp. 551-556, (2004); Bohm S.K., Kong W., Bromme D., Et al., Molecular cloning, expression and potential functions of the human proteinase-activated receptor-2, Biochem J, 314, pp. 1009-1016, (1996); Kong W., McConalogue K., Khitin L.M., Et al., Luminal trypsin may regulate enterocytes through proteinase-activated receptor 2, Proc Natl Acad Sci USA, 94, pp. 8884-8889, (1997); Vergnolle N., Clinical relevance of proteinase activated receptors (PARs) in the gut, Gut, 54, pp. 867-874, (2005); Ait-Belgnaoui A., Bradesi S., Fioramonti J., Et al., Acute stress-induced hypersensitivity to colonic distension depends upon increase in paracellular permeability: Role of myosin light chain kinase, Pain, 113, pp. 141-147, (2005); Cenac N., Andrews C.N., Holzhausen M., Et al., Role for protease activity in visceral pain in irritable bowel syndrome, J Clin Invest, 117, pp. 636-647, (2007); Coelho A.M., Vergnolle N., Guiard B., Et al., Proteinases and proteinase-activated receptor 2: A possible role to promote visceral hyperalgesia in rats, Gastroenterology, 122, pp. 1035-1047, (2002); Mertz H., Naliboff B., Munakata J., Et al., Altered rectal perception is a biological marker of patients with irritable bowel syndrome, Gastroenterology, 109, pp. 40-52, (1995); Ritchie J., Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome, Gut, 14, pp. 125-132, (1973); Trimble K.C., Farouk R., Pryde A., Et al., Heightened visceral sensation in functional gastrointestinal disease is not site-specific. Evidence for a generalized disorder of gut sensitivity, Dig Dis Sci, 40, pp. 1607-1613, (1995); Marshall J.K., Thabane M., Garg A.X., Et al., Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario, Aliment Pharmacol Ther, 20, pp. 1317-1322, (2004); Spider R.C., Jenkins D., Thomley J.P., Et al., Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, pp. 804-811, (2000); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Turner J.R., Rill B.K., Carlson S.L., Et al., Physiological regulation of epithelial tight junctions is associated with myosin light-chain phosphorylation, Am J Physiol, 273, (1997); Weber C.R., Turner J.R., Inflammatory bowel disease: Is it really just another break in the wall?, Gut, 56, pp. 6-8, (2007); Thompson W.G., Longstreth G.F., Drossman D.A., Et al., Functional bowel disorders and functional abdominal pain, Gut, 45, SUPPL. 2, (1999); Bradley P.P., Priebat D.A., Christensen R.D., Et al., Measurement of cutaneous inflammation: Estimation of neutrophil content with an enzyme marker, J Invest Dermatol, 78, pp. 206-209, (1982); Larsson M., Arvidsson S., Ekman C., Et al., A model for chronic quantitative studies of colorectal sensitivity using balloon distension in conscious mice - effects of opioid receptor agonists, Neurogastroenterol Motil, 15, pp. 371-381, (2003); Laemmli U.K., Cleavage of structural proteins during the assembly of the head of bacteriophage T4, Nature, 227, pp. 680-685, (1970); Carroccio A., Iacono G., Cottone M., Et al., Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: A prospective study in adults and children, Clin Chem, 49, pp. 861-867, (2003); Lettesjo H., Hansson T., Peterson C., Et al., Detection of inflammatory markers in stools from patients with irritable bowel syndrome and collagenous colitis, Scand J Gastroenterol, 41, pp. 54-59, (2006); Silberer H., Kuppers B., Mickisch O., Et al., Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome, Clin Lab, 51, pp. 117-126, (2005); Cenac N., Chin A.C., Garcia-Villar R., Et al., PAR2 activation alters colonic paracellular permeability in mice via IFN-gamma-dependent and -independent pathways, J Physiol, 558, pp. 913-925, (2004); Macfarlane G.T., Allison C., Gibson S.A., Et al., Contribution of the microflora to proteolysis in the human large intestine, J Appl Bacteriol, 64, pp. 37-46, (1988); Malinen E., Rinttila T., Kajander K., Et al., Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR, Am J Gastroenterol, 100, pp. 373-382, (2005); Kassinen A., Krogius-Kurikka L., Makivuokko H., Et al., The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects, Gastroenterology, 133, pp. 24-33, (2007); Roka R., Demaude J., Cenac N., Et al., Colonic luminal proteases activate colonocyte proteinase-activated receptor-2 and regulate paracellular permeability in mice, Neurogastroenterol Motil, 19, pp. 57-65, (2007); Lourbakos A., Chinni C., Thompson P., Et al., Cleavage and activation of proteinase-activated receptor-2 on human neutrophils by gingipain-R from Porphyromonas gingivalis, FEBS Lett, 435, pp. 45-48, (1998); Kwan C.L., Diamant N.E., Mikula K., Et al., Characteristics of rectal perception are altered in irritable bowel syndrome, Pain, 113, pp. 160-171, (2005); Barbara G., Stanghellini V., De Giorgio R., Et al., Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome, Gastroenterology, 126, pp. 693-702, (2004); Chadwick V.S., Chen W., Shu D., Et al., Activation of the mucosal immune system in irritable bowel syndrome, Gastroenterology, 122, pp. 1778-1783, (2002); Park J.H., Rhee P.L., Kim H.S., Et al., Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome, J Gastroenterol Hepatol, 21, pp. 71-78, (2006); Tornblom H., Lindberg G., Nyberg B., Et al., Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome, Gastroenterology, 123, pp. 1972-1979, (2002); Wang L.H., Fang X.C., Pan G.Z., Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis, Gut, 53, pp. 1096-1101, (2004); Weston A.P., Biddle W.L., Bhatia P.S., Et al., Terminal ileal mucosal mast cells in irritable bowel syndrome, Dig Dis Sci, 38, pp. 1590-1595, (1993)","L. Bueno; Neuro-Gastroenterology and Nutrition Unit, Institut National de la Recherche Agronomique, 31931 Toulouse Cedex 9, 180 Chemin de Tournefeuille, France; email: lbueno@toulouse.inra.fr","","","","","","","","00175749","","GUTTA","18194983","English","Gut","Article","Final","","Scopus","2-s2.0-42549168553"

"Dai C.; Guandalini S.; Zhao D.-H.; Jiang M.","Dai, Cong (53663341300); Guandalini, Stefano (7006380751); Zhao, De-Hui (55475700100); Jiang, Min (34971185300)","53663341300; 7006380751; 55475700100; 34971185300","Antinociceptive effect of VSL#3 on visceral hypersensitivity in a rat model of irritable bowel syndrome: A possible action through nitric oxide pathway and enhance barrier function","2012","Molecular and Cellular Biochemistry","362","1-2","","43","53","10","57","10.1007/s11010-011-1126-5","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84857062675&doi=10.1007%2fs11010-011-1126-5&partnerID=40&md5=cc5de969fa95df8ea5dfd2abc10e3959","Department of Gastroenterology, First Affiliated Hospital, Medical University, Shenyang City, Liaoning Province, China; Section of Gastroenterology, Celiac Disease Center, University of Chicago Comer Children's Hospital, Chicago, United States","Dai C., Department of Gastroenterology, First Affiliated Hospital, Medical University, Shenyang City, Liaoning Province, China; Guandalini S., Section of Gastroenterology, Celiac Disease Center, University of Chicago Comer Children's Hospital, Chicago, United States; Zhao D.-H., Department of Gastroenterology, First Affiliated Hospital, Medical University, Shenyang City, Liaoning Province, China; Jiang M., Department of Gastroenterology, First Affiliated Hospital, Medical University, Shenyang City, Liaoning Province, China","Irritable bowel syndrome (IBS) is a functional bowel disorder characterized by visceral hypersensitivity and altered bowel function. There are increasing evidences suggested that VSL#3 probiotics therapy has been recognized as an effective method to relieve IBS-induced symptoms. The aim of this study was to examine the effects of VSL#3 probiotics on visceral hypersensitivity (VH), nitric oxide (NO), fecal character, colonic epithelium permeability, and tight junction protein expression. IBS model was induced by intracolonic instillation of 4% acetic acid and restraint stress in rats. After subsidence of inflammation on the seventh experimental day, the rats were subjected to rectal distension, and then the abdominal withdrawal reflex and the number of fecal output were measured, respectively. Also, colonic permeability to Evans blue was measured in vivo, and tight junction protein expression was studied by immunohistochemistry and immunoblotting method. Rats had been pretreated with VSL#3 or aminoguanidine (NOS inhibitor) or VSL#3? aminoguanidine before measurements. The rats at placebo group showed hypersensitive response to rectal distension (P<0.05) and defecated more stools than control rats (P<0.05), whereas VSL#3 treatment significantly attenuated VH and effectively reduced defecation. Aminoguanidine reduced the protective effects of VSL#3 on VH. A pronounced increase in epithelial permeability and decreased expression of tight junction proteins (occludin, ZO-1) in placebo group were prevented by VSL#3, but not aminoguanidine. VSL#3 treatment reduce the hypersensitivity, defecation, colonic permeability and increase the expression of tight junction proteins (occludin, ZO-1). As the part of this effect was lowered by NOS inhibitor, NO might play a role in the protective effect of VSL#3 to some extent. © 2011 Springer Science+Business Media, LLC.","Intestinal barrier; Irritable bowel syndrome; Nitric oxide; Probiotic; Tight junction; Visceral hypersensitivity; VSL#3","Animals; Biological Transport; Colon; Defecation; Guanidines; Intestinal Mucosa; Irritable Bowel Syndrome; Male; Membrane Proteins; Nitric Oxide; Pain Management; Permeability; Phosphoproteins; Probiotics; Rats; Rats, Wistar; Tight Junctions; Rattus; Rattus; aminoguanidine; nitric oxide; occludin; protein ZO1; VSL3; acetic acid; aminoguanidine; Evans blue; nitric oxide; occludin; placebo; protein ZO1; VSL3; analgesic activity; animal cell; animal experiment; animal model; animal tissue; antinociception; article; colon dilatation; colon mucosa; controlled study; drug effect; drug efficacy; drug inhibition; feces analysis; immobilization stress; immunoblotting; immunohistochemistry; in vivo study; intestine mucosa permeability; irritable colon; male; nonhuman; protein expression; rat; rectal distension; tight junction; treatment response; visceral hypersensitivity; visceral pain; defecation; experimental animal; hypersensitivity reaction; inflammation; intestine distension; irritable colon; withdrawal reflex","","aminoguanidine, 1068-42-4, 2582-30-1, 79-17-4; nitric oxide, 10102-43-9; occludin, 176304-61-3; Evans blue, 314-13-6; acetic acid, 127-08-2, 127-09-3, 64-19-7, 71-50-1; Guanidines, ; Membrane Proteins, ; Nitric Oxide, 10102-43-9; Phosphoproteins, ; occludin, ; pimagedine, 79-17-4; zonula occludens-1 protein, ","","","","","Quigley E.M.M., Flourie B., Probiotics and irritable bowel syndrome: A rationale for their use and an assessment of the evidence to date, Neurogastroenterology and Motility, 19, 3, pp. 166-172, (2007); McCarthy J., O'Mahony L., O'Callaghan L., Sheil B., Vaughan E.E., Fitzsimons N., Fitzgibbon J., O'Sullivan G.C., Kiely B., Collins J.K., Shanahan F., Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance, Gut, 52, 7, pp. 975-980, (2003); O'Mahony L., Mccarthy J., Kelly P., Hurley G., Luo F., Chen K., O'Sullivan G.C., Kiely B., Collins J.K., Shanahan F., Quigley E.M.M., Lactobacillus and Bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles, Gastroenterology, 128, 3, pp. 541-551, (2005); Verdu E.F., Bercik P., Verma-Gandhu M., Huang X.-X., Blennerhassett P., Jackson W., Mao Y., Wang L., Rochat F., Collins S.M., Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice, Gut, 55, 2, pp. 182-190, (2006); Rembacken B.J., Snelling A.M., Hawkey P.M., Chalmers D.M., Axon A.T.R., Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: A randomised trial, Lancet, 354, 9179, pp. 635-639, (1999); Gionchetti P., Rizzello F., Venturi A., Campieri M., Probiotics in infective diarrhoea and inflammatory bowel diseases, Journal of Gastroenterology and Hepatology, 15, 5, pp. 489-493, (2000); Sullivan A., Nord C.E., Probiotics and gastrointestinal diseases, Journal of Internal Medicine, 257, 1, pp. 78-92, (2005); Lamine F., Fioramonti J., Bueno L., Nepveu F., Cauquil E., Lobysheva I., Eutamene H., Theodorou V., Nitric Oxide Released by Lactobacillus farciminis Improves TNBS-induced Colitis in Rats, Scandinavian Journal of Gastroenterology, 39, 1, pp. 37-45, (2004); Isolauri E., Majamaa H., Arvola T., Rantala I., Virtanen E., Arvilommi H., Lactobacillus casei strain GG reverses increased intestinal permeability induced by cow milk in suckling rats, Gastroenterology, 105, 6, pp. 1643-1650, (1993); Salminen S., Clinical uses of probiotics for stabilizing the gut mucosal barrier: Successful strains and future challenges, Antonie van Leeuwenhoek, International Journal of General and Molecular Microbiology, 70, 2-4, pp. 347-358, (1996); Lu L., Walker W.A., Pathologic and physiologic interactions of bacteria with the gastrointestinal epithelium, American Journal of Clinical Nutrition, 73, 6, (2001); Resta-Lenert S., Barrett K.E., Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC), Gut, 52, 7, pp. 988-997, (2003); Montalto M., Maggiano N., Ricci R., Curigliano V., Santoro L., Di Nicuolo F., Vecchio F.M., Gasbarrini A., Gasbarrini G., Lactobacillus acidophilus protects tight junctions from aspirin damage in HT-29 cells, Digestion, 69, 4, pp. 225-228, (2004); Gaudier E., Michel C., Segain J.-P., Cherbut C., Hoebler C., The VSL# 3 probiotic mixture modifies microflora but does not heal chronic dextran-sodium sulfate-induced colitis or reinforce the mucus barrier in mice, Journal of Nutrition, 135, 12, pp. 2753-2761, (2005); Mennigen R., Nolte K., Rijcken E., Utech M., Loeffler B., Senninger N., Bruewer M., Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis, Am J Physiol Gastrointest Liver Physiol, 296, 5, (2009); Kim H.J., Camilleri M., McKinzie S., Lempke M.B., Burton D.D., Thomforde G.M., Zinsmeister A.R., A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome, Alimentary Pharmacology and Therapeutics, 17, 7, pp. 895-904, (2003); Kim H.J., Vazquez Roque M.I., Camilleri M., Stephens D., Burton D.D., Baxter K., Thomforde G., Zinsmeister A.R., A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating, Neurogastroenterology and Motility, 17, 5, pp. 687-696, (2005); Guandalini S., Magazzu G., Chiaro A., La Balestra V., Di Nardo G., Gopalan S., Sibal A., Romano C., Canani R.B., Lionetti P., Setty M., VSL#3 improves symptoms in children with irritable bowel syndrome: A multicenter, randomized, placebo-controlled, double-blind, crossover study, J Pediatr Gastroenterol Nutr, 51, 1, pp. 24-30, (2010); Camilleri M., Heading R.C., Thompson W.G., Consensus report: Clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome, Alimentary Pharmacology and Therapeutics, 16, 8, pp. 1407-1430, (2002); Alaradi O., Barkin J.S., Irritable bowel syndrome: Update on pathogenesis and management, Medical Principles and Practice, 11, 1, pp. 2-17, (2002); Frieling T., Functional and inflammatory bowel disorders, Med Klin (Munich), 101, SUPPL. 1, pp. 139-142, (2006); Crentsil V., Will corticosteroids and other anti-inflammatory agents be effective for diarrhea-predominant irritable bowel syndrome?, Medical Hypotheses, 65, 1, pp. 97-102, (2005); Kuiken S.D., Klooker T.K., Tytgat G.N., Lei A., Boeckxstaens G.E., Possible role of nitric oxide in visceral hypersensitivity in patients with irritable bowel syndrome, Neurogastroenterol Motil, 18, 2, pp. 115-122, (2006); Delvaux M., Role of visceral sensitivity in the pathophysiology of irritable bowel syndrome, Gut, 51, SUPPL. 1, (2002); Coutinho S.V., Urban M.O., Gebhart G.F., Role of glutamate receptors and nitric oxide in the rostral ventromedial medulla in visceral hyperalgesia, Pain, 78, 1, pp. 59-69, (1998); Coutinho S.V., Gebhart G.F., A role for spinal nitric oxide in mediating visceral hyperalgesia in the rat, Gastroenterology, 116, 6, pp. 1399-1408, (1999); Barbara G., Mucosal barrier defects in irritable bowel syndrome. Who left the door open?, American Journal of Gastroenterology, 101, 6, pp. 1295-1298, (2006); Barbara G., Cremon C., Pallotti F., De Giorgio R., Stanghellini V., Corinaldesi R., Postinfectious irritable bowel syndrome, J Pediatr Gastroenterol Nutr, 48, SUPPL. 2, (2009); Fanning A.S., Jameson B.J., Jesaitis L.A., Anderson J.M., The tight junction protein ZO-1 establishes a link between the transmembrane protein occludin and the actin cytoskeleton, Journal of Biological Chemistry, 273, 45, pp. 29745-29753, (1998); Gonzalez-Mariscal L., Betanzos A., Nava P., Jaramillo B.E., Tight junction proteins, Progress in Biophysics and Molecular Biology, 81, 1, pp. 1-44, (2003); Brookes S.J.H., Classes of enteric nerve cells in the guinea-pig small intestine, Anatomical Record, 262, 1, pp. 58-70, (2001); La Kim J.H.T.W., Sung T.S., Kang J.W., Kim H.J., Yang I.S., Visceral hypersensitivity and altered colonic motility after subsidence of inflammation in a rat model of colitis, World J Gastroenterol, 9, 12, pp. 2791-2795, (2003); Al-Chaer E.D., Kawasaki M., Pasricha P.J., A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development, Gastroenterology, 119, 5, pp. 1276-1285, (2000); Kitajima S., Takuma S., Morimoto M., Changes in colonic mucosal permeability in mouse colitis induced with dextran sulfate sodium, Experimental Animals, 48, 3, pp. 137-143, (1999); Ukena S.N., Singh A., Dringenberg U., Engelhardt R., Seidler U., Hansen W., Bleich A., Bruder D., Franzke A., Rogler G., Suerbaum S., Buer J., Gunzer F., Westendorf A.M., Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity, PLoS One, 2, 12, (2007); Kreiss C., Toegel S., Bauer A.J., α<sub>2</sub>-adrenergic regulation of NO production alters postoperative intestinal smooth muscle dysfunction in rodents, American Journal of Physiology - Gastrointestinal and Liver Physiology, 287, 3, (2004); Hierholzer C., Kalff J.C., Billiar T.R., Bauer A.J., Tweardy D.J., Harbrecht B.G., Induced nitric oxide promotes intestinal inflammation following hemorrhagic shock, American Journal of Physiology - Gastrointestinal and Liver Physiology, 286, 2, (2004); Garthwaite J., Charles S.L., Chess-Williams R., Endothelium- derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain, Nature, 336, 6197, pp. 385-388, (1988); Fritz E., Hammer J., Schmidt B., Eherer A.J., Hammer H.F., Stimulation of the Nitric Oxide-Guanosine 3′, 5′-Cyclic Monophosphate Pathway by Sildenafil: Effect on Rectal Muscle Tone, Distensibility, and Perception in Health and in Irritable Bowel Syndrome, American Journal of Gastroenterology, 98, 10, pp. 2253-2260, (2003); Kuiken S.D., Vergeer M., Heisterkamp S.H., Tytgat G.N.J., Boeckxstaens G.E.E., Role of nitric oxide in gastric motor and sensory functions in healthy subjects, Gut, 51, 2, pp. 212-218, (2002); Rodella L., Rezzani R., Agostini C., Bianchi R., Induction of NADPH-diaphorase activity in the rat periaqueductal gray matter after nociceptive visceral stimulation, Brain Research, 793, 1-2, pp. 333-336, (1998); Vizzard M.A., Erdman S.L., De Groat W.C., Increased expression of neuronal nitric oxide synthase (NOS) in visceral neurons after nerve injury, J Neurosci, 15, 5 PART 2, pp. 4033-4045, (1995); Bonaz B., Visceral sensitivity perturbation integration in the brain-gut axis in functional digestive disorders, J Physiol Pharmacol, 54, SUPPL. 4, pp. 27-42, (2003); Fooks L.J., Gibson G.R., Probiotics as modulators of the gut flora, British Journal of Nutrition, 88, SUPPL. 1, (2002); Verdu E.F., Bercik P., Collins S.M., Effect of probiotics on gastrointestinal function: Evidence from animal models, Therap Adv Gastroenterol, 2, 4, pp. 31-35, (2009); Matsuo K., Zhang X., Ono Y., Nagatomi R., Acute stressinduced colonic tissue HSP70 expression requires commensal bacterial components and intrinsic glucocorticoid, Brain Behav Immun, 23, 1, pp. 108-115, (2009)","M. Jiang; Department of Gastroenterology, First Affiliated Hospital, Medical University, Shenyang City, Liaoning Province, China; email: congdai2006@126.com","","Kluwer Academic Publishers","","","","","","03008177","","MCBIB","22020749","English","Mol. Cell. Biochem.","Article","Final","","Scopus","2-s2.0-84857062675"

"Zeng J.; Li Y.-Q.; Zuo X.-L.; Zhen Y.-B.; Yang J.; Liu C.-H.","Zeng, J. (58337271600); Li, Y.-Q. (57210136710); Zuo, X.-L. (13908131900); Zhen, Y.-B. (24391635600); Yang, J. (58372820400); Liu, C.-H. (7409787404)","58337271600; 57210136710; 13908131900; 24391635600; 58372820400; 7409787404","Clinical trial: Effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome","2008","Alimentary Pharmacology and Therapeutics","28","8","","994","1002","8","171","10.1111/j.1365-2036.2008.03818.x","https://www.scopus.com/inward/record.uri?eid=2-s2.0-52149114013&doi=10.1111%2fj.1365-2036.2008.03818.x&partnerID=40&md5=320ccc4954080106b25448d38fb3cdc4","Department of Gastroenterology, Qilu Hospital, Shandong University School of Medicine, Jinan, Shandong Province, China; Center of Medical Molecular Biology, Shandong University School of Medicine, Jinan, Shandong Province, China; Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, Shandong Province 250012, No. 107, Wenhua Xi Road, China","Zeng J., Department of Gastroenterology, Qilu Hospital, Shandong University School of Medicine, Jinan, Shandong Province, China; Li Y.-Q., Department of Gastroenterology, Qilu Hospital, Shandong University School of Medicine, Jinan, Shandong Province, China, Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, Shandong Province 250012, No. 107, Wenhua Xi Road, China; Zuo X.-L., Department of Gastroenterology, Qilu Hospital, Shandong University School of Medicine, Jinan, Shandong Province, China; Zhen Y.-B., Department of Gastroenterology, Qilu Hospital, Shandong University School of Medicine, Jinan, Shandong Province, China; Yang J., Department of Gastroenterology, Qilu Hospital, Shandong University School of Medicine, Jinan, Shandong Province, China; Liu C.-H., Center of Medical Molecular Biology, Shandong University School of Medicine, Jinan, Shandong Province, China","Background: The intestinal permeability is increased in patients with diarrhoea-predominant irritable bowel syndrome (D-IBS). Aim: To determine the possible efficacy of lactic acid bacteria on the increased intestinal permeability in D-IBS. Methods: Treatment was employed for 4 weeks in a randomized single blind placebo controlled study with 30 D-IBS patients. Patients were given either probiotic fermented milk (Streptococcus thermophilus, Lactobacillus bulgaricus, Lactobacillus acidophilus and Bifidobacterium Longum) or milk beverage containing no bacteria. The clinical symptoms were scored and intestinal permeability was measured by a triple sugar test before and after treatment. Results: Small bowel permeability was measured as the ratio of lactulose and mannitol recovery and colonic permeability was measured as the total mass of sucralose excretion (mg). After probiotics treatment, small bowel permeability decreased significantly from 0.038 (0.024) at baseline to 0.023 (0.020) (P = 0.004), the proportion of patients with increased small bowel permeability was lower than baseline (28.6% vs. 64.3%, P = 0.023). However, colonic permeability improved neither in the probiotics group nor in the placebo group at week 4. Treatment with probiotics significantly decreased the mean global IBS scores compared with the baseline scores (9.62 ± 1.05 vs. 7.64 ± 1.24, P < 0.001). Conclusion: Short-term active lactic acid bacteria treatment for D-IBS improved mucosal barrier function. © 2008 The Authors.","","Adult; Bifidobacterium; Diarrhea; Female; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Lactobacillus; Male; Middle Aged; Mucous Membrane; Probiotics; Single-Blind Method; Streptococcus thermophilus; ab100 jianneng; dudu; lactulose; placebo; probiotic agent; sucralose; unclassified drug; article; beverage; Bifidobacterium longum; clinical article; clinical trial; controlled clinical trial; controlled study; diarrhea; fermented product; human; intestine mucosa; intestine mucosa permeability; irritable colon; lactic acid bacterium; Lactobacillus acidophilus; lactobacillus bulgaricus; milk; nonhuman; priority journal; randomized controlled trial; scoring system; single blind procedure; small intestine; Streptococcus thermophilus; symptomatology; treatment response","","lactulose, 4618-18-2; sucralose, 56038-13-2","ab100 jianneng, Bright Dairy, China; dudu, Bright Dairy, China","Bright Dairy, China; Bright Dairy, China","","","Spiller R.C., Jenkins D., Thornley J.P., Et al., Increased rectal mucosal enteroendocrine cells, T lymphocytes and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, pp. 804-11, (2000); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-94, (2006); Marshall J.K., Thabane M., Garg A.X., Et al., Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario, Aliment Pharmacol Ther, 20, pp. 1317-22, (2004); Barbara G., Mucosal barrier defects in irritable bowel syndrome. Who left the door open?, Am J Gastroenterol, 101, pp. 1295-8, (2006); Chadwick V.S., Chen W., Shu D., Et al., Activation of the mucosal immune system in irritable bowel syndrome, Gastroenterology, 122, pp. 1178-83, (2002); Barbara G., Stanghellini V., De Giorgio R., Et al., Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome, Gastroenterology, 126, pp. 693-702, (2004); Tornblom H., Lindberg G., Nyberg B., Veress B., Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome, Gastroenterology, 123, pp. 1972-9, (2002); Dunlop S.P., Jenkins D., Spiller R.C., Distinctive histological patterns of chronic inflammatory cells in rectal biopsies of patients with different clinical subtypes of IBS, Gastroenterology, 122, (2002); Barbara G., Stanghellini V., De Giorgio R., Et al., Functional gastrointestinal disorders and mast cells: Implications for therapy, Neurogastroenterol Motil, 18, pp. 6-17, (2006); Denker B.M., Nigam S.K., Molecular structure and assembly of the tight junction, Am J Physiol, 274, (1998); Stevenson B.R., Understanding tight junction clinical physiology at the molecular level, J Clin Invest, 104, pp. 3-4, (1999); Dunlop S.P., Jenkins D., Neal K.R., Et al., Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome, Aliment Pharmacol Ther, 18, pp. 77-84, (2003); Lilly D.M., Stillwell R.H., Probiotics: Growth promoting factors produced by microorganisms, Science, 147, pp. 747-8, (1965); Gill H.S., Guarner F., Probiotics and human health: A clinical perspective, Postgrad Med J, 80, pp. 516-26, (2004); Rolfe R.D., The role of probiotic cultures in the control of gastrointestinal health, J Nutr, 130, (2000); Borowiec A.M., Fedorak R.N., The role of probiotics in management of irritable bowel syndrome, Curr Gastroenterol Rep, 9, pp. 393-400, (2007); Kim H.J., Camilleri M., McKinzie S., Et al., A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome, Aliment Pharmacol Ther, 17, pp. 895-904, (2003); O'Mahony L., McCarthy J., Kelly P., Et al., Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles, Gastroenterology, 128, pp. 541-51, (2005); Guyonnet D., Chassany O., Ducrotte P., Et al., Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: A multicentre, randomized, double-blind, controlled trial, Aliment Pharmacol Ther, 26, pp. 475-86, (2007); Kajander K., Myllyluoma E., Rajilic-Stojanovic M., Et al., Clinical trial: Multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota, Aliment Pharmacol Ther, 27, pp. 48-57, (2008); Svedlund J., Sjodin I., Dotevall G., GSRS - A clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease, Dig Dis Sci, 33, pp. 129-34, (1988); Smecuol E., Bai J.C., Sugai E., Et al., Acute gastrointestinal permeability responses to different non-steroidal anti-inflammatory drugs, Gut, 49, pp. 650-5, (2001); Celli M., D'Eufemia P., Dommarco R., Et al., Rapid gas-chromatographic assay of lactulose and mannitol for estimating intestinal permeability, Clin Chem, 41, pp. 752-6, (1995); Farhadi A., Keshavarzian A., Holmes E.W., Fields J., Zhang L., Banan A., Gas chromatographic method for detection of urinary sucralose: Application to the assessment of intestinal permeability, J Chromatogr B Analyt Technol Biomed Life Sci, 784, pp. 145-54, (2003); Abe T., Sugano E., Saigo Y., Tamai M., Interleukin-1beta and barrier function of retinal pigment epithelial cells (ARPE-19): Aberrant expression of junctional complex molecules, Invest Ophthalmol Vis Sci, 44, pp. 4097-104, (2003); Galante N.Z., Camara N.O., Kallas E.G., Salomao R., Pacheco-Silva A., Medina-Pestana J.O., Noninvasive immune monitoring assessed by flow cytometry and real time RT-PCR in urine of renal transplantation recipients, Transpl Immunol, 16, pp. 73-80, (2006); Kennedy R.J., The Effect of Lactobacillus Plantarum Species 299 on Intestinal Inflammation and Associated Gut Mucosal Barrier Dysfunction., (2000); Madsen K., Cornish A., Soper P., Et al., Probiotic bacteria enhance murine and human intestinal epithelial barrier function, Gastroenterology, 121, pp. 580-91, (2001); Furrie E., Is Bifidobacterium a more effective probiotic therapy than Lactobacillus for patients with irritable bowel syndrome?, Nat Clin Pract Gastroenterol Hepatol, 2, pp. 304-5, (2005); Luyer M.D., Buurman W.A., Hadfoune M., Et al., Strain-specific effects of probiotics on gut barrier integrity following hemorrhagic shock, Infect Immun, 73, pp. 3686-92, (2005); Jain P.K., McNaught C.E., Anderson A.D., MacFie J., Mitchell C.J., Influence of symbiotic containing Lactobacillus acidophilus La5, Bifidobacterium lactis Bb 12, Streptococcus thermophilus, Lactobacillus bulgaricus and oligofructose on gut barrier function and sepsis in critically ill patients: A randomized controlled trial, Clin Nutr, 23, pp. 467-75, (2004); McNaught C.E., Woodcock N.P., Anderson A.D., MacFie J., A prospective randomized trial of probiotics in critically ill patients, Clin Nutr, 24, pp. 211-9, (2005); Caballero-Franco C., Keller K., De Simone C., Chadee K., The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells, Am J Physiol Gastrointest Liver Physiol, 292, (2007); MacK D.R., Ahrne S., Hyde L., Wei S., Hollingsworth M.A., Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro, Gut, 52, pp. 827-33, (2003); Zyrek A.A., Cichon C., Helms S., Enders C., Sonnenborn U., Schmidt M.A., Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair, Cell Microbiol, 9, pp. 804-16, (2007); Ukena S.N., Singh A., Dringenberg U., Et al., Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity, PLoS ONE, 2, (2007); Hebden J.M., Erah P.O., Blackshaw P.E., Perkins A.C., Spiller R.C., Increased small bowel but not colonic permeability in post-infectious irritable bowel syndrome, Gastroenterology, 114, (1998); Gassler N., Rohr C., Schneider A., Et al., Inflammatory bowel disease is associated with changes of enterocytic junctions, Am J Physiol Gastrointest Liver Physiol, 281, (2001)","Y.-Q. Li; Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, Shandong Province 250012, No. 107, Wenhua Xi Road, China; email: liyanqing@sdu.edu.cn","","","","","","","","13652036","","APTHE","18671775","English","Aliment. Pharmacol. Ther.","Article","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-52149114013"

"Liu Y.; Liu W.; Peng Q.-X.; Peng J.-L.; Yu L.-Z.; Hu J.-L.","Liu, Yao (56707769100); Liu, Wei (56373373600); Peng, Qiu-Xian (54993074000); Peng, Jiang-Li (56585122200); Yu, Lin-Zhong (8322621700); Hu, Jian-Lan (56065781600)","56707769100; 56373373600; 54993074000; 56585122200; 8322621700; 56065781600","Protective effect of huoxiang zhengqi oral liquid on intestinal mucosal mechanical barrier of rats with postinfectious irritable bowel syndrome induced by acetic acid","2014","Evidence-based Complementary and Alternative Medicine","2014","","218383","","","","24","10.1155/2014/218383","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84926348314&doi=10.1155%2f2014%2f218383&partnerID=40&md5=6a1f02876f392141fe6d5d046f93a20e","School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China; New Drug Research and Development Center, Guangdong Institute of Traditional Chinese Medicine, Guangzhou, 510520, China; Department of Biology, Hong Kong Baptist University, Kowloon Tong, Hong Kong; College of Pharmacy, Hunan University of Traditional Chinese Medicine, Changsha, 410028, China","Liu Y., School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China, New Drug Research and Development Center, Guangdong Institute of Traditional Chinese Medicine, Guangzhou, 510520, China; Liu W., School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China; Peng Q.-X., School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China, Department of Biology, Hong Kong Baptist University, Kowloon Tong, Hong Kong; Peng J.-L., College of Pharmacy, Hunan University of Traditional Chinese Medicine, Changsha, 410028, China; Yu L.-Z., School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China; Hu J.-L., School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China","In this study, a rat model with acetic acid-induced PI-IBS was used to study the role of HXZQ oral liquid in repairing the colonic epithelial barrier and reducing intestinal permeability. Pathomorphism of colonic tissue, epithelial ultrastructure, DAO activity in serum, and the protein expression of ZO-1 and occludin were examined to investigate protective effect mechanisms of HXZQ on intestinal mucosa barrier and then present experimental support for its use for prevention and cure of PI-IBS. © 2014 Yao Liu et al.","","acetic acid; huoxiang shengqi; occludin; protective agent; protein ZO1; unclassified drug; animal experiment; animal model; animal tissue; Article; colon mucosa; controlled study; drug effect; drug mechanism; drug megadose; intestine mucosa; investigative procedures; irritable colon; low drug dose; nonhuman; postinfectious irritable bowel syndrome; priority journal; protein expression; rat; ultrastructure","","acetic acid, 127-08-2, 127-09-3, 64-19-7, 71-50-1; occludin, 176304-61-3","","","","","Marshall J.K., Post-infectious irritable bowel syndrome following water contamination, Kidney International, Supplement, 112, pp. S42-S43, (2009); Neal K.R., Barker L., Spiller R.C., Prognosis in post-infective irritable bowel syndrome: A six year follow up study, Gut, 51, 3, pp. 410-413, (2002); Akbar A., Yiangou Y., Facer P., Walters J.R.F., Anand P., Ghosh S., Increased capsaicin receptor TRPV1-expressing sensory fbres in irritable bowel syndrome and their correlation with abdominal pain, Gut, 57, 7, pp. 923-929, (2008); Lupp C., Robertson M.L., Wickham M.E., Et al., Hostmediated infammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae, Cell Host & Microbe, 2, 2, pp. 119-129, (2007); Motomura Y., Ghia J.-E., Wang H., Et al., Enterochromafn cell and 5-hydroxytryptamine responses to the same infectious agent difer in T1 and T2 dominant environments, Gut, 57, 4, pp. 475-481, (2008); O'Hara J.R., Skinn A.C., MacNaughton W.K., Sherman P.M., Sharkey K.A., Consequences of Citrobacter rodentium infection on enteroendocrine cells and the enteric nervous system in the mouse colon, Cellular Microbiology, 8, 4, pp. 646-660, (2006); Wang L.-H., Fang X.-C., Pan G.-Z., Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis, Gut, 53, 8, pp. 1096-1101, (2004); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, The American Journal of Gastroenterology, 101, 6, pp. 1288-1294, (2006); Spiller R.C., Jenkins D., Tornley J.P., Et al., Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, 6, pp. 804-811, (2000); Maher S., Brayden D.J., Feighery L., McClean S., Cracking the junction: Update on the progress of gastrointestinal absorption enhancement in the delivery of poorly absorbed drugs, Critical Reviews in Terapeutic Drug Carrier Systems, 25, 2, pp. 117-168, (2008); Martinez C., Lobo B., Pigrau M., Et al., Diarrhoea-predominant irritable bowel syndrome: An organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, 8, pp. 1160-1168, (2013); Dupont A.W., Postinfectious irritable bowel syndrome, Clinical Infectious Diseases, 46, 4, pp. 594-599, (2008); Spiller R., Garsed K., Postinfectious irritable bowel syndrome, Gastroenterology, 136, 6, pp. 1979-1988, (2009); Li H., Lu C.-Z., Tang K.-C., Clinical observation on treatment of SARS with combination of chaihu droplet pill and huoxiang zhengqi droplet pill, Zhongguo Zhong Xi Yi Jie He Za Zhi, 24, 4, pp. 321-324, (2004); He Y.-H., Zhao H.-Y., Liu Z.-L., Et al., Efects of huoxianzhengqi liquid on enteric mucosal immune responses in mice with Bacillus dysenteriae and Salmonella typhimurium induced diarrhea, World Journal of Gastroenterology, 12, 45, pp. 7346-7349, (2006); Lu Y., Li D., Tang F., Mechanism of huoxiang zhengqi extract for regulating the intestinal motility in rat model of diarrhea-predominant irritable bowel syndrome, Zhongguo Zhong Xi Yi Jie He Za Zhi, 31, 7, pp. 941-945, (2011); Wang Z.Z., Yang Z.H., Grinchuk V., Et al., Anti-infammatory and intestinal function-modulating activities of a traditional Chinese herbal formula Houxiang Zhengqi, Gastroenterology, 142, 5, (2012); Xie Y.C., Tang F., Experimental study on protecting intestinal barrier function of Huoxiang Zhengqi sof capsule, Zhongguo Zhong Yao Za Zhi, 29, 5, pp. 456-458, (2004); He Y.-H., Luo X.-J., Qian X.-W., Wu Z.-P., Lv A.-P., Efects of Huoxiang Zhengqi liquid on enteric mucosal immune responses in mice with Bacillus dysenteriae and Salmonella typhimurium induced diarrhea, Zhongguo Zhongyao Zazhi, 32, 22, pp. 2397-2400, (2007); Xie C., Wang X.F., Qi X.J., Lu L.L., Chan H.C., Efect of Huoxiang-zhengqi liquid on HCO(3)(-) secretion by intact porcine distal airway epithelium, Sheng Li Xue Bao, 60, 1, pp. 90-96, (2008); La J.-H., Kim T.-W., Sung T.-S., Kang J.-W., Kim H.-J., Yang I.-S., Visceral hypersensitivity and altered colonic motilty afer subsidence of infammation in a rat model of colitis, World Journal of Gastroenterology, 9, 12, pp. 2791-2795, (2003); Peng Q.X., Cai H.B., Sun X.G., Li X., Mo Z.X., Shi J., Alocasia cucullata exhibits strong antitumor efect in vivo by activating antitumor immunity, PLoS ONE, 8, 9, (2013); Lee K.J., Kim Y.B., Kim J.H., Kwon H.C., Kim D.K., Cho S.W., The alteration of enterochromafn cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors, Journal of Gastroenterology and Hepatology, 23, 11, pp. 1689-1694, (2008); Guilarte M., Santos J., De Torres I., Et al., Diarrhoea-predominant IBS patients show mast cell activation and hyper-plasia in the jejunum, Gut, 56, 2, pp. 203-209, (2007); Piche T., Barbara G., Aubert P., Et al., Impaired Intestinal barrier integrity in the colon of patients with irritable bowel syndrome: Involvement of soluble mediators, Gut, 58, 2, pp. 196-201, (2009); Qin H.-Y., Wu J.C.Y., Tong X.-D., Sung J.J.Y., Xu H.-X., Bian Z.-X., Systematic review of animal models of post-infectious/post-infammatory irritable bowel syndrome, Journal of Gastroenterology, 46, 2, pp. 164-174, (2011); Tominaga K., Arakawa T., Kampo medicines for gastrointestinal tract disorders: A review of basic science and clinical evidence and their future application, Journal of Gastroenterology, 48, 4, pp. 452-462, (2013); Luk G.D., Bayless T.M., Baylin S.B., Diamine oxidase (histaminase). A circulating marker for rat intestinal mucosal maturation and integrity, Journal of Clinical Investigation, 66, 1, pp. 66-70, (1980); Takagi K., Nakao M., Ogura Y., Nabeshima T., Kunii A., Sensitive colorimetric assay of serum diamine oxidase, Clinica Chimica Acta, 226, 1, pp. 67-75, (1994); Song W.-B., Lv Y.-H., Zhang Z.-S., Et al., Soluble intercellular adhesion molecule-1, D-lactate and diamine oxidase in patients with infammatory bowel disease, World Journal of Gastroenterology, 15, 31, pp. 3916-3919, (2009); Tompson J.S., Vaughan W.P., Forst C.F., Jacobs D.L., Weekly J.S., Rikkers L.F., The efect of the route of nutrient delivery on gut structure and diamine oxidase levels, Journal of Parenteral and Enteral Nutrition, 11, 1, pp. 28-32, (1987); Edelblum K.L., Turner J.R., The tight junction in infam-matory disease: Communication breakdown, Current Opinion in Pharmacology, 9, 6, pp. 715-720, (2009); Marshall J.K., Tabane M., Garg A.X., Clark W., Meddings J., Collins S.M., Intestinal permeability in patients with irritable bowel syndrome afer a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario, Alimentary Pharmacology and Terapeutics, 20, 11-12, pp. 1317-1322, (2004); Barbara G., Mucosal barrier defects in irritable bowel syndrome. Who lef the door open?, The American Journal of Gastroenterology, 101, 6, pp. 1295-1298, (2006); Balda M.S., Flores-Maldonado C., Cereijido M., Matter K., Multiple domains of occludin are involved in the regulation of paracellular permeability, Journal of Cellular Biochemistry, 78, 1, pp. 85-96, (2000); Rao R., Occludin phosphorylation in regulation of epithelial tight junctions, Annals of the New York Academy of Sciences, 1165, pp. 62-68, (2009); Fioramonti J., Bueno L., Centrally acting agents and visceral sensitivity, Gut, 51, pp. i91-i95, (2002); Poynard T., Regimbeau C., Benhamou Y., Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome, Alimentary Pharmacology and Terapeutics, 15, 3, pp. 355-361, (2001); Long Y., Liu Y., Tong J., Qian W., Hou X., Efectiveness of trimebutine maleate on modulating intestinal hypercon-tractility in a mouse model of postinfectious irritable bowel syndrome, European Journal of Pharmacology, 636, 1-3, pp. 159-165, (2010); Taniyama K., Sano I., Nakayama S., Et al., Dual efect of trimebutine on contractility of the guinea pig ileum via the opioid receptors, Gastroenterology, 101, 6, pp. 1579-1587, (1991)","","","Hindawi Limited","","","","","","1741427X","","","","English","Evid.-Based Complement. Altern. Med.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-84926348314"

"Kerckhoffs A.P.M.; Akkermans L.M.A.; De Smet M.B.M.; Besselink M.G.H.; Hietbrink F.; Bartelink I.H.; Busschers W.B.; Samsom M.; Renooij W.","Kerckhoffs, Angèle P. M. (24473265600); Akkermans, Louis M. A. (7005121187); De Smet, Martin B. M. (7006682777); Besselink, Marc G. H. (6603166269); Hietbrink, Falco (15070626000); Bartelink, Imke H. (15043594800); Busschers, Wim B. (14824540700); Samsom, Melvin (7006144417); Renooij, Willem (7003705969)","24473265600; 7005121187; 7006682777; 6603166269; 15070626000; 15043594800; 14824540700; 7006144417; 7003705969","Intestinal permeability in irritable bowel syndrome patients: Effects of NSAIDs","2010","Digestive Diseases and Sciences","55","3","","716","723","7","54","10.1007/s10620-009-0765-9","https://www.scopus.com/inward/record.uri?eid=2-s2.0-77949317353&doi=10.1007%2fs10620-009-0765-9&partnerID=40&md5=d4f3097bbacdc274d8f3408f6768d54e","Departments of Gastroenterology, Gastrointestinal Research Unit, University Medical Center Utrecht, Utrecht 3584CX, Heidelberglaan 100, F02.618, Netherlands; Departments of Surgery, Gastrointestinal Research Unit, University Medical Center Utrecht, Utrecht, Netherlands; Department of Pharmacy, University Medical Center Utrecht, Utrecht, Netherlands; Center for Biostatistics, Utrecht University, Utrecht, Netherlands","Kerckhoffs A.P.M., Departments of Gastroenterology, Gastrointestinal Research Unit, University Medical Center Utrecht, Utrecht 3584CX, Heidelberglaan 100, F02.618, Netherlands; Akkermans L.M.A., Departments of Surgery, Gastrointestinal Research Unit, University Medical Center Utrecht, Utrecht, Netherlands; De Smet M.B.M., Departments of Surgery, Gastrointestinal Research Unit, University Medical Center Utrecht, Utrecht, Netherlands; Besselink M.G.H., Departments of Surgery, Gastrointestinal Research Unit, University Medical Center Utrecht, Utrecht, Netherlands; Hietbrink F., Departments of Surgery, Gastrointestinal Research Unit, University Medical Center Utrecht, Utrecht, Netherlands; Bartelink I.H., Department of Pharmacy, University Medical Center Utrecht, Utrecht, Netherlands; Busschers W.B., Center for Biostatistics, Utrecht University, Utrecht, Netherlands; Samsom M., Departments of Gastroenterology, Gastrointestinal Research Unit, University Medical Center Utrecht, Utrecht 3584CX, Heidelberglaan 100, F02.618, Netherlands; Renooij W., Departments of Surgery, Gastrointestinal Research Unit, University Medical Center Utrecht, Utrecht, Netherlands","Intestinal permeability and the effect of NSAIDs on permeability were investigated in 14 irritable bowel syndrome (IBS) patients and 15 healthy subjects. In the study, 24-h urinary recoveries of orally administered polyethylene glycols (PEGs 400, 1500, and 4000) were not significantly different in healthy subjects and IBS patients before or after NSAID ingestion. Lactulose mannitol ratios in healthy subjects and IBS patients were not significantly different. Only time-dependent monitoring of PEG excretion showed that NSAIDs enhanced intestinal permeability for PEG 4000 in healthy subjects (P = 0.050) and for PEGs 400, 1500, and 4000 in IBS patients (P = 0.012, P = 0.041, and P = 0.012, respectively). These results show that intestinal permeability in IBS patients is not different from that in healthy subjects; NSAIDs compromise intestinal permeability in IBS patients to a greater extent than in healthy subjects, which suggests that IBS is associated with an altered response of the intestinal barrier to noxious agents. © 2009 Springer Science+Business Media, LLC.","IBS; Intestinal permeability; NSAIDs; PEG; Polyethylene glycol","Adult; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Male; Middle Aged; Permeability; Polyethylene Glycols; lactulose; macrogol; macrogol 1500; macrogol 400; macrogol 4000; mannitol; naproxen; unclassified drug; diagnostic agent; macrogol derivative; nonsteroid antiinflammatory agent; adult; aged; article; clinical article; controlled study; digestive function; drug response; female; human; intestine mucosa permeability; irritable colon; male; priority journal; urinalysis; urinary excretion; drug effect; intestine mucosa; irritable colon; middle aged; pathophysiology; permeability","","lactulose, 4618-18-2; macrogol, 25322-68-3; macrogol 4000, 88747-22-2; mannitol, 69-65-8, 87-78-5; naproxen, 22204-53-1, 26159-34-2; Anti-Inflammatory Agents, Non-Steroidal, ; Polyethylene Glycols, ","","","AstraZeneca R&D; Netherlands Society of Gastroenterology; Numico Research BV","Acknowledgments We acknowledge the staff of the Department of Pharmacy of the UMC Utrecht for production and supply of PEG and L/M test solutions. We thank M. van Loon, BSc, R. Voorbij, PhD, and coworkers of the Central Diagnostic Laboratory of the UMC Utrecht for the measurements of lactulose, mannitol, and creatinine. This work was funded in part by a Gastrostart grant from the Netherlands Society of Gastroenterology. APM Kerckhoffs was financially supported by Numico Research BV. LMA Akkermans received financial support from AstraZeneca R&D, Mölndal, Sweden. Supporting institutions were not involved in design, performance, or publication of this study.","Mayer E.A., Collins S.M., Evolving pathophysiologic models of functional gastrointestinal disorders, Gastroenterology, 122, 7, pp. 2032-2048, (2002); Rodriguez L.A., Ruigomez A., Increased risk of irritable bowel syndrome after bacterial gastroenteritis: Cohort study, British Medical Journal, 318, 7183, pp. 565-566, (1999); Barbara G., Stanghellini V., De Giorgio R., Cremon C., Cottrell G.S., Santini D., Pasquinelli G., Morselli-Labate A.M., Grady E.F., Bunnett N.W., Collins S.M., Corinaldesi R., Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome, Gastroenterology, 126, 3, pp. 693-702, (2004); Spiller R.C., Jenkins D., Thornley J.P., Hebden J.M., Wright T., Skinner M., Neal K.R., Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, 6, pp. 804-811, (2000); Marshall J.K., Thabane M., Garg A.X., Clark W., Meddings J., Collins S.M., Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario, Alimentary Pharmacology and Therapeutics, 20, 11-12, pp. 1317-1322, (2004); Parry S., Forgacs I., Intestinal infection and irritable bowel syndrome, European Journal of Gastroenterology and Hepatology, 17, 1, pp. 5-9, (2005); Minocha A., Johnson W.D., Abell T.L., Wigington W.C., Prevalence, sociodemography, and quality of life of older versus younger patients with irritable bowel syndrome: A population-based study, Dig Dis Sci, 51, 3, pp. 446-453, (2006); Dunlop S.P., Hebden J., Campbell E., Naesdal J., Olbe L., Perkins A.C., Spiller R.C., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, American Journal of Gastroenterology, 101, 6, pp. 1288-1294, (2006); Tibble J.A., Sigthorsson G., Foster R., Forgacs I., Bjarnason I., Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease, Gastroenterology, 123, 2, pp. 450-460, (2002); Di Leo V., D'Inca R., Diaz-Granado N., Fries W., Venturi C., D'Odorico A., Martines D., Sturniolo G.C., Lactulose/mannitol test has high efficacy for excluding organic causes of chronic diarrhea, American Journal of Gastroenterology, 98, 10, pp. 2245-2252, (2003); Hollen E., Peterson K.H., Sundqvist T., Grodzinsky E., Hogberg L., Laurin P., Stenhammar L., Falth-Magnusson K., Magnusson K.-E., Coeliac children on a gluten-free diet with or without oats display equal anti-avenin antibody titres, Scandinavian Journal of Gastroenterology, 41, 1, pp. 42-47, (2006); Locke III G.R., Zinsmeister A.R., Talley N.J., Fett S.L., Melton III L.J., Risk factors for irritable bowel syndrome: Role of analgesics and food sensitivities, American Journal of Gastroenterology, 95, 1, pp. 157-165, (2000); Kalantar J.S., Locke III G.R., Talley N.J., Zinsmeister A.R., Fett S.L., Melton III L.J., Is irritable bowel syndrome more likely to be persistent in those with relatives who suffer from gastrointestinal symptoms? A population-based study at three time points, Alimentary Pharmacology and Therapeutics, 17, 11, pp. 1389-1397, (2003); Talley N.J., Spiller R., Irritable bowel syndrome: A little understood organic bowel disease?, Lancet, 360, 9332, pp. 555-564, (2002); Holtmann G., Gschossmann J., Buenger L., Gerken G., Talley N.J., Do changes in visceral sensory function determine the development of dyspepsia during treatment with aspirin?, Gastroenterology, 123, 5, pp. 1451-1458, (2002); Brunsden A.M., Grundy D., Sensitization of visceral afferents to bradykinin in rat jejunum in vitro, Journal of Physiology, 521, 2, pp. 517-527, (1999); Bjarnason I., Williams P., Smethurst P., Effect of non-steroidal anti-inflammatory drugs and prostaglandins on the permeability of the human small intestine, Gut, 27, 11, pp. 1292-1297, (1986); Bjarnason I., Hayllar J., MacPherson A.J., Russell A.S., Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans, Gastroenterology, 104, 6, pp. 1832-1847, (1993); Tonini M., Cipollina L., De Giorgio R., Barbara G., De Ponti F., Serotonergic drugs for the treatment of irritable bowel syndrome, Journal of Functional Syndromes, 2, 2, pp. 104-109, (2002); Smecuol E., Bai J.C., Sugai E., Vazquez H., Niveloni S., Pedreira S., Maurino E., Meddings J., Acute gastrointestinal permeability responses to different non-steroidal anti-inflammatory drugs, Gut, 49, 5, pp. 650-655, (2001); Bjarnason I., MacPherson A., Hollander D., Intestinal permeability: An overview, Gastroenterology, 108, 5, pp. 1566-1581, (1995); Parlesak A., Bode Ch. J., Bode C., Parallel determination of gut permeability in man with M(r) 400, M(r) 1500, M(r) 4000 and M(r) 10000 polyethylene glycol, European Journal of Clinical Chemistry and Clinical Biochemistry, 32, 11, pp. 813-820, (1994); Parlesak A., Schafer C., Schutz T., Bode J.C., Bode C., Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease, Journal of Hepatology, 32, 5, pp. 742-747, (2000); Goldman R.C., Leive L., Heterogeneity of antigenic-side-chain length in lipopolysaccharide from Escherichia coli 0111 and Salmonella typhimurium LT2, Eur J Biochem, 107, 1, pp. 145-153, (1980); Kanda T., Fujii H., Tani T., Murakami H., Suda T., Sakai Y., Ono T., Hatakeyama K., Intestinal fatty acid-binding protein is a useful diagnostic marker for mesenteric infarction in humans, Gastroenterology, 110, 2, pp. 339-343, (1996); Kanda T., Fujii H., Fujita M., Sakai Y., Ono T., Hatakeyama K., Intestinal fatty acid binding protein is available for diagnosis of intestinal ischaemia: Immunochemical analysis of two patients with ischaemic intestinal diseases, Gut, 36, 5, pp. 788-791, (1995); Kanda T., Nakatomi Y., Ishikawa H., Hitomi M., Matsubara Y., Ono T., Muto T., Intestinal fatty acid-binding protein as a sensitive marker of intestinal ischemia, Dig Dis Sci, 37, 9, pp. 1362-1367, (1992); Thompson W.G., Longstreth G.F., Drossman D.A., Heaton K.W., Irvine E.J., Muller-Lissner S.A., Functional bowel disorders and functional abdominal pain, Gut, 45, SUPPL 2, (1999); Uil J.J., Van Elburg R.M., Van Overbeek F.M., Mulder C.J., Vanberge-Henegouwen G.P., Heymans H.S., Clinical implications of the sugar absorption test: Intestinal permeability test to assess mucosal barrier function, Scand J Gastroenterol Suppl, 223, pp. 70-78, (1997); Rissler K., Improved separation of polyethylene glycols widely differing in molecular weight range by reversed-phase high performance liquid chromatography and evaporative light scattering detection, Chromatographia, 49, 11-12, pp. 615-620, (1999); Megoulas N.C., Koupparis M.A., Twenty years of evaporative light scattering detection, Critical Reviews in Analytical Chemistry, 35, 4, pp. 301-316, (2005); Duerksen D.R., Wilhelm-Boyles C., Parry D.M., Intestinal permeability in long-term follow-up of patients with celiac disease on a gluten-free diet, Digestive Diseases and Sciences, 50, 4, pp. 785-790, (2005); Pearson A.D.J., Eastham E.J., Laker M.F., Intestinal permeability in children with Crohn's disease and coeliac disease, British Medical Journal, 285, 6334, pp. 20-21, (1982); Shah A.A., Thjodleifsson B., Murray F.E., Kay E., Barry M., Sigthorsson G., Gudjonsson H., Oddsson E., Price A.B., Fitzgerald D.J., Bjarnason I., Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: A comparison of nimesulide and naproxen, Gut, 48, 3, pp. 339-346, (2001); Berni Canani R., Terrin G., Rapacciuolo L., Miele E., Siani M.C., Puzone C., Cosenza L., Staiano A., Troncone R., Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease, Dig Liver Dis, 40, 7, pp. 533-547, (2008); Berkes J., Viswanathan V.K., Savkovic S.D., Hecht G., Intestinal epithelial responses to enteric pathogens: Effects on the tight junction barrier, ion transport, and inflammation, Gut, 52, 3, pp. 439-451, (2003); Serrander R., Magnusson K.-E., Kihlstrom E., Sundqvist T., Acute yersinia infections in man increase intestinal permeability for low-molecular weight polyethylene glycols (PEG 400), Scandinavian Journal of Infectious Diseases, 18, 5, pp. 409-413, (1986); Santos J., Yang P.-C., Soderholm J.D., Benjamin M., Perdue M.H., Role of mast cells in chronic stress induced colonic epithelial barrier dysfunction in the rat, Gut, 48, 5, pp. 630-636, (2001); Soderholm J.D., Yang P.C., Ceponis P., Vohra A., Riddell R., Sherman P.M., Perdue M.H., Chronic stress induces mast cell-dependent bacterial adherence and initiates mucosal inflammation in rat intestine, Gastroenterology, 123, 4, pp. 1099-1108, (2002); McDermott J.R., Bartram R.E., Knight P.A., Miller H.R.P., Garrod D.R., Grencis R.K., Mast cells disrupt epithelial barrier function during enteric nematode infection, Proceedings of the National Academy of Sciences of the United States of America, 100, 13, pp. 7761-7766, (2003); O'Sullivan M., Clayton N., Breslin N.P., Harman I., Bountra C., McLaren A., O'Morain C.A., Increased mast cells in the irritable bowel syndrome, Neurogastroenterol Motil, 12, 5, pp. 449-457, (2000); Weston A.P., Biddle W.L., Bhatia P.S., Miner Jr P.B., Terminal ileal mucosal mast cells in irritable bowel syndrome, Dig Dis Sci, 38, 9, pp. 1590-1595, (1993); Dunlop S.P., Jenkins D., Spiller R.C., Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome, American Journal of Gastroenterology, 98, 7, pp. 1578-1583, (2003); Jacob C., Yang P.-C., Darmoul D., Amadesi S., Saito T., Cottrell G.S., Coelho A.-M., Singh P., Grady E.F., Perdue M., Bunnett N.W., Mast cell tryptase controls paracellular permeability of the intestine: Role of protease-activated receptor 2 and β-arrestins, Journal of Biological Chemistry, 280, 36, pp. 31936-31948, (2005); Serrander R., Magnusson K.-E., Sundqvist T., Acute infections with Giardia lamblia and rotavirus decrease intestinal permeability to low-molecular weight polyethylene glycols (PEG 400), Scandinavian Journal of Infectious Diseases, 16, 4, pp. 339-344, (1984); Krugliak P., Hollander D., Le K., Ma T., Dadufalza V.D., Katz K.D., Regulation of polyethylene glycol 400 intestinal permeability by endogenous and exogenous prostanoids. Influence of non-steroidal anti-inflammatory drugs, Gut, 31, 4, pp. 417-421, (1990); Allen A., Hutton D.A., Leonard A.J., The role of mucus in the protection of the gastroduodenal mucosa, Scandinavian Journal of Gastroenterology, Supplement, 21, SUPPL. 125, pp. 71-78, (1986); Somasundaram S., Sigthorsson G., Simpson R.J., Watts J., Jacob M., Tavares I.A., Rafi S., Roseth A., Foster R., Price A.B., Wrigglesworth J.M., Bjarnason I., Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID-enteropathy in the rat, Alimentary Pharmacology and Therapeutics, 14, 5, pp. 639-650, (2000); Bjarnason I., Takeuchi K., Bjarnason A., Adler S.N., Teahon K., The G.U.T. of gut, Scandinavian Journal of Gastroenterology, 39, 9, pp. 807-815, (2004)","A. P. M. Kerckhoffs; Departments of Gastroenterology, Gastrointestinal Research Unit, University Medical Center Utrecht, Utrecht 3584CX, Heidelberglaan 100, F02.618, Netherlands; email: Angelekerckhoffs@hotmail.com","","","","","","","","01632116","","DDSCD","19255843","English","Dig. Dis. Sci.","Article","Final","","Scopus","2-s2.0-77949317353"

"Camilleri M.; Busciglio I.; Acosta A.; Shin A.; Carlson P.; Burton D.; Ryks M.; Rhoten D.; Lamsam J.; Lueke A.; Donato L.J.; Zinsmeister A.R.","Camilleri, Michael (7102181053); Busciglio, Irene (17343569900); Acosta, Andres (55844615900); Shin, Andrea (54996506000); Carlson, Paula (7103028430); Burton, Duane (35453351900); Ryks, Michael (23470927200); Rhoten, Deborah (35765672600); Lamsam, Jesse (6505919871); Lueke, Alan (55813166100); Donato, Leslie J. (8950442500); Zinsmeister, Alan R. (36043887800)","7102181053; 17343569900; 55844615900; 54996506000; 7103028430; 35453351900; 23470927200; 35765672600; 6505919871; 55813166100; 8950442500; 36043887800","Effect of increased bile acid synthesis or fecal excretion in irritable bowel syndrome-diarrhea","2014","The American journal of gastroenterology","109","10","","1621","1630","9","88","10.1038/ajg.2014.215","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84924925529&doi=10.1038%2fajg.2014.215&partnerID=40&md5=325f5c157b4bc076bb1ecf76340cea0d","Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, Minnesota, United States; Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, Minnesota, United States; Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, Minnesota, United States; Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, Minnesota, United States; Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, Minnesota, United States; Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, Minnesota, United States; Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, Minnesota, United States; Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, Minnesota, United States; Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, Minnesota, United States; Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, Minnesota, United States; Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, Minnesota, United States; Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, Minnesota, United States","Camilleri M., Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, Minnesota, United States; Busciglio I., Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, Minnesota, United States; Acosta A., Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, Minnesota, United States; Shin A., Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, Minnesota, United States; Carlson P., Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, Minnesota, United States; Burton D., Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, Minnesota, United States; Ryks M., Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, Minnesota, United States; Rhoten D., Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, Minnesota, United States; Lamsam J., Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, Minnesota, United States; Lueke A., Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, Minnesota, United States; Donato L.J., Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, Minnesota, United States; Zinsmeister A.R., Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, Rochester, Minnesota, United States","OBJECTIVES: Approximately 25% of patients with irritable bowel syndrome-diarrhea (IBS-D) have increased total fecal bile acids (BA) and serum C4 (surrogate for BA synthesis). BA synthesis-related genes (KLB and FGFR4) are associated with colonic transit (CT) in IBS-D. Our aims were: (i) to compare phenotype and pathophysiology in IBS-D patients with increased or normal fecal excretion or synthesis of BA; and (ii) to explore association of variations in two candidate bile-acid synthesis genes (KLB and FGFR4) in these two subgroups of IBS-D.; METHODS: A total of 64 IBS-D patients underwent on one occasion: fasting serum C4 and FGF19, total fecal fat and BA excretion, CT, intestinal and colonic permeability, and candidate genotyping (rs17618244 (KLB), rs351855 (FGFR4)). Colonic sensation and tone were measured in 47 of the IBS-D patients. IBS-D subgroups were identified by fecal BA >2,337 mM per 48 h or by serum C4 >47.1 ng/ml.; RESULTS: IBS-D patients with fecal BA >2,337 mM per 48 h (19/54) had significantly greater body mass index, fecal fat, percent chenodeoxycholic acid (CDCA) in feces, and intestinal permeability, and borderline increased CT (P=0.13). Those IBS-D patients with serum C4 >47.1 ng/ml (13/54) had increased total fecal BA excretion and borderline increased colonic permeability. Variants in genes involved in feedback regulation of BA synthesis (KLB, P=0.06 and FGFR4, P=0.09) were potentially associated with the subgroup with elevated serum C4.; CONCLUSIONS: IBS-D with increased BA excretion or synthesis is associated with significant pathophysiological changes relative to patients with normal BA profile. BA diarrhea is identified more effectively with total fecal BA than with serum C4.","","Adult; Bile Acids and Salts; Cholestenones; Diarrhea; Feces; Female; Fibroblast Growth Factors; Gastrointestinal Transit; Humans; Irritable Bowel Syndrome; Male; Membrane Proteins; Middle Aged; Receptor, Fibroblast Growth Factor, Type 4; 7 alpha-hydroxy-4-cholesten-3-one; bile acid; cholest 4 en 3 one; FGF19 protein, human; FGFR4 protein, human; fibroblast growth factor; fibroblast growth factor receptor 4; KLB protein, human; membrane protein; adult; blood; chemistry; diarrhea; feces; female; gastrointestinal transit; genetics; human; Irritable Bowel Syndrome; male; metabolism; middle aged; pathophysiology; physiology","","cholest 4 en 3 one, 601-57-0; fibroblast growth factor, 62031-54-3; fibroblast growth factor receptor 4, 147573-63-5; 7 alpha-hydroxy-4-cholesten-3-one, ; Bile Acids and Salts, ; Cholestenones, ; FGF19 protein, human, ; FGFR4 protein, human, ; Fibroblast Growth Factors, ; KLB protein, human, ; Membrane Proteins, ; Receptor, Fibroblast Growth Factor, Type 4, ","","","Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic College of Medicine, (R01-DK92179, UL1 TR000135); National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK, (R01DK092179)","","","","","","","","","","","15720241","","","25070056","English","Am. J. Gastroenterol.","Article","Final","All Open Access; Green Open Access","Scopus","2-s2.0-84924925529"

"Zhou Q.; Souba W.W.; Croce C.M.; Verne G.N.","Zhou, QiQi (13404854200); Souba, Wiley W. (7102268896); Croce, Carlo M. (7202975031); Verne, G. Nicholas (7004085639)","13404854200; 7102268896; 7202975031; 7004085639","MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome","2010","Gut","59","6","","775","784","9","233","10.1136/gut.2009.181834","https://www.scopus.com/inward/record.uri?eid=2-s2.0-77953721053&doi=10.1136%2fgut.2009.181834&partnerID=40&md5=8e6d4b22869d489534f7530549f2dd6e","Department of Medicine, Ohio State University, Columbus, OH, United States; Research Service, Cincinnati VA Medical Center, Cincinnati, OH, United States; Department of Surgery, Ohio State University, Columbus, OH, United States; Department of Physiology and Cell Biology, Ohio State University, Columbus, OH, United States; Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University, Columbus, OH, United States","Zhou Q., Department of Medicine, Ohio State University, Columbus, OH, United States, Research Service, Cincinnati VA Medical Center, Cincinnati, OH, United States; Souba W.W., Department of Surgery, Ohio State University, Columbus, OH, United States; Croce C.M., Department of Medicine, Ohio State University, Columbus, OH, United States, Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University, Columbus, OH, United States; Verne G.N., Department of Medicine, Ohio State University, Columbus, OH, United States, Research Service, Cincinnati VA Medical Center, Cincinnati, OH, United States, Department of Physiology and Cell Biology, Ohio State University, Columbus, OH, United States","Background: The molecular mechanisms underlying the pathophysiology of irritable bowel syndrome (IBS) are poorly understood. One mechanism may involve increased intestinal permeability that is reversed with glutamine supplementation. Our goal was to evaluate the expression of glutamine synthetase and its complementary miRNA in blood microvesicles and gut tissues of IBS patients with increased intestinal membrane permeability. Methods: We evaluated 19 diarrhoea-predominant IBS patients and 10 controls for intestinal membrane permeability using the lactulose/mannitol method. miRNA expression was evaluated in blood microvesicles and gut tissue. To further confirm the relationship between miRNA and glutamine synthetase expression, cell culture experiments were conducted. Glutamine synthetase was also evaluated in the gut tissues of patients. Results: A subset of patients with IBS (8/19, 42%) had increased intestinal membrane permeability and decreased glutamine synthetase expression compared to patients with IBS normal membrane permeability, and to controls. Expression of miR-29a was increased in blood microvesicles, small bowel and colon tissues of IBS patients with increased intestinal membrane permeability. Increased intestinal permeability was modulated by miR-29a which has a complementary site in the 3′-UTR of the GLUL gene. Conclusions: The results support the conclusion that GLUL regulates intestinal membrane permeability and miR-29a regulates both GLUL and intestinal membrane permeability. The data suggests that miR-29a effects on intestinal membrane permeability may be due to its regulation of GLUL. Targeting this signalling pathway could lead to a new therapeutic approach to the treatment of patients with IBS, especially because small molecules that mimic or inhibit miRNA-based mechanisms are readily available.","","Adult; Base Sequence; Cells, Cultured; Colon; Cytoplasmic Vesicles; Enzyme Activation; Female; Gene Expression Regulation, Enzymologic; Glutamate-Ammonia Ligase; Humans; Intestinal Absorption; Irritable Bowel Syndrome; Male; MicroRNAs; Permeability; Signal Transduction; Tissue Array Analysis; Young Adult; glutamate ammonia ligase; lactulose; mannitol; microRNA; microRNA 29a; unclassified drug; 3' untranslated region; adult; article; cell membrane permeability; clinical article; controlled study; diarrhea; female; gene expression; gene silencing; human; human cell; human tissue; intestine epithelium cell; intestine mucosa permeability; irritable colon; membrane microparticle; priority journal; regulatory mechanism","","glutamate ammonia ligase, 9023-70-5; lactulose, 4618-18-2; mannitol, 69-65-8, 87-78-5; Glutamate-Ammonia Ligase, 6.3.1.2; MIRN29 microRNA, human, ; MicroRNAs, ","","","National Institute of Neurological Disorders and Stroke, NINDS, (R01NS053090)","","Verne G.N., Cerda J.J., Irritable bowel syndrome. Streamlining the diagnosis, Postgrad Med, 102, pp. 197-208, (1997); Verne G.N., Himes N.C., Robinson M.E., Et al., Central representation of visceral and cutaneous hypersensitivity in the irritable bowel syndrome, Pain, 103, pp. 99-110, (2003); Verne G.N., Robinson M.E., Price D.D., Hypersensitivity to visceral and cutaneous pain in the irritable bowel syndrome, Pain, 93, pp. 7-14, (2001); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Spiller R.C., Jenkins D., Thornley J.P., Et al., Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, pp. 804-811, (2000); Spiller R.C., Role of infection in irritable bowel syndrome, J Gastroenterol, 42, SUPPL. 17, pp. 41-47, (2007); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hyper-sensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Bjarnason I., MacPherson A., Hollander D., Intestinal permeability: An overview, Gastroenterology, 108, pp. 1566-1581, (1995); Keshavarzian A., Holmes E.W., Patel M., Et al., Leaky gut in alcoholic cirrhosis: A possible mechanism for alcohol-induced liver damage, Am J Gastroenterol, 94, pp. 200-207, (1999); Keshavarzian A., Fields J.Z., Vaeth J., Holmes E.W., The differing effects of acute and chronic alcohol on gastric and intestinal permeability, American Journal of Gastroenterology, 89, 12, pp. 2205-2211, (1994); Al Chaer E.D., Kawasaki M., Pasricha P.J., A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development, Gastroenterology, 119, pp. 1276-1285, (2000); Mayer E.A., Collins S.M., Evolving pathophysiologic models of functional gastrointestinal disorders, Gastroenterology, 122, pp. 2032-2048, (2002); Zhou Q., Price D.D., Caudle R.M., Verne G.N., Visceral and somatic hypersensitivity in a subset of rats following TNBS-induced colitis, Pain, 134, 1-2, pp. 9-15, (2008); Haberle J., Gorg B., Rutsch F., Et al., Congenital glutamine deficiency with glutamine synthetase mutations, N Engl J Med, 353, pp. 1926-1933, (2005); Souba W.W., Klimberg V.A., Plumley D.A., Et al., The role of glutamine in maintaning a healthy gut and supporting the metabolic response to injury and infection, J Surg Res, 48, pp. 383-391, (1990); Klimberg V.A., Souba W.W., The importance of intestinal glutamine metabolism in maintaining a healthy gastrointestinal tract and supporting the body's response to injury and illness, Surg Annu, 22, pp. 61-76, (1990); Labow B.I., Souba W.W., Glutamine, World J Surg, 24, pp. 1503-1513, (2000); Valadi H., Ekstrom K., Bossios A., Et al., Exosome-mediated transfer of mRNA and microRNAs is a novel mechanism of genetic exchange between cells, Nat Cell Biol, 9, pp. 654-659, (2007); Fevrier B., Raposo G., Exosomes: Endosomal-derived vesicles shipping extracellular messages, Curr Opin Cell Biol, 16, pp. 415-421, (2004); Greenwalt T.J., The how and why of exocytic vesicles, Transfusion, 46, pp. 143-152, (2006); Hugel B., Martinez M.C., Kunzelmann C., Freyssinet J.-M., Membrane microparticles: Two sides of the coin, Physiology, 1, pp. 22-27, (2005); Pap E., Pallinger E., Paszoi M., Et al., Highlights of a new type of intercellular communication microvesicle-based information transfer review, Inflamm Res, 58, pp. 1-8, (2009); Geijnen H.F., Schiel A.E., Fijnheer R., Et al., Activated platelets release two types of membrane vesicles: Micrivesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules, Blood, 94, pp. 3791-3799, (1999); VanWijk M.J., VanBavel E., Sturk A., Et al., Microparticles in cardiovascular diseases, Cardiovasc Res, 59, pp. 277-287, (2003); Horstmann L.L., Jy W., Jimenez J.J., Et al., New horizons in the analysis of circulating cell-derived microparticles, Keio J Med, 53, pp. 210-230, (2004); Ratajczak J., Wysoczynski M., Hayek F., Et al., Membrane-derived microvesicles: Important and underappreciated mediators of cell-to-cell communication, Leukemia, 20, pp. 1487-1495, (2006); Sloand E.M., Mainwaring L., Keyvanfar L., Et al., Transfer of glycosylphosphatidylinositol-anchored proteins to deficient cells after erythrocyte transfusion in paroxysmal nocturnal hemoglobinuria, Blood, 104, pp. 3782-3788, (2004); Kim J., Krichevsky A., Grad Y., Et al., Identification of many microRNAs that copurify with polyribomes in mammalian neurons, Proc Natl Acad Sci U S A, 101, pp. 360-365, (2004); Farh K.K., Grimson A., Jan C., Et al., The widespread impact of mammalian microRNA on mRNA repression and evolution, Science, 310, pp. 1817-1821, (2005); Fabbri M., Garzon R., Cimmino A., Et al., MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltranferases 3A and 3B, Proc Natl Acad Sci USA, 104, pp. 15805-15810, (2007); Vanner S., The lactulose breath test for diagnosing SIBO in IBS patients: Another nail in the coffin, Am J Gastroenterol, 103, pp. 964-965, (2008); Bratten J.R., Spainer J., Jones M.P., Lactulose breath testing does not discriminate patients with irritable bowel syndrome from healthy controls, Am J Gastroenterol, 103, pp. 958-963, (2008); Longstreth G.F., Thompson W.G., Chey W.D., Et al., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Camilleri M., Nadeau A., Lamsam J., Et al., Understanding measurements of intestinal permeability in healthy humans with urine lactulose and mannitol exretion, Neurogastroenterol Motil, 22, (2010); Leonards K.S., Ohki S., Isolation and characterization of large (0.5-1.0 μm) cytoskeleton-free vesicles from human and rabbit erythrocytes, Biochimica et Biophysica Acta, 728, 3, pp. 383-393, (1983); Victoria E.J., Branks M.J., Masouredis S.P., Immunoreactivity of the Rh<sub>o</sub>(D) antigen in cytoskeleton-free vesicles, Transfusion, 27, pp. 32-35, (1987); Liu C., Calin G.A., Volinia S., Et al., MicroRNA expression profiling using microarrays, Nat Protoc, 3, pp. 563-578, (2008); Siddiqui K.M., Chopra D.P., Primary and long term epithelial cell cultures from human fetal normal colonic mucosa, In Vitro, 20, pp. 859-868, (1984); Smith H.S., In vitro properties of epithelial cell lines established from human carcinomas and nonmalignant tissue, J Natl Cancer Inst, 62, pp. 225-230, (1979); Macdonald T.T., Montelenone G., Immunity, inflammation, and allergy in the gut, Science, 307, pp. 1920-1925, (2005); Porras M., Martin M.T., Yang P.C., Et al., Correlation between cyclical epithelial barrier dysfunction and bacterial translocation in the relapses of intestinal inflammation, Inflamm Bowel Dis, 12, pp. 843-852, (2006); Camilleri M., Gorman H., Intestinal permeability and irritable bowel syndrome, Neurogastroenterol Motil, 19, pp. 545-552, (2007); Spiller R.C., Postinfectious irritable bowel syndrome, Gastroenterology, 124, pp. 1662-1671, (2003); Dupont A.W., Post-infectious irritable bowel syndrome, Curr Gastroenterol Rep, 9, pp. 378-384, (2007); Wang L.H., Fang X.C., Pan G.Z., Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis, Gut, 53, pp. 1096-2011, (2004); Yoshida S., Matsui M., Shirouzu Y., Et al., Effects of glutamine supplements and radiochemotherapy on the systemic immune and gut barrier function in patients with advanced esophageal cancer, Ann Surg, 227, pp. 485-491, (1998); Sido B., Seel C., Hochlehnert A., Et al., Low intestinal glutamine level and low glutaminase activity in Crohn's disease: A rational for glutamine supplementation?, Dig Dis Sci, 51, pp. 2170-2179, (2006); Demarco V., Dyess K., Strauss D., West C.M., Neu J., Inhibition of glutamine synthetase decreases proliferation of cultured rat intestinal epithelial cells, Journal of Nutrition, 129, 1, pp. 57-62, (1999); Halicka H.D., Bedner E., Darzynkiewicz Z., Segregation of RNA and separate packaging of DNA and RNA in apoptotic bodies during apoptosis, Exp Cell Res, 260, pp. 248-256, (2000); Levine S.J., Mechanisms of soluble cytokine receptor generation, J Immunol, 173, pp. 5343-5348, (2004); Taback B., Hoon D.S., Circulating nucleic acids and proteomics of plasma/serum: Clinical utility, Ann N Y Acad Sci, 1022, pp. 1-8, (2004); Wu F., Zikusoka M., Trindade A., Et al., MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2α, Gastroenterology, 135, pp. 1624-1635, (2008); Kapeller J., Houghton L.A., Monnikes H., Et al., First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome, Hum Mol Genet, 17, pp. 2967-2977, (2008)","G. N. Verne; Department of Medicine, Ohio State University, Columbus, OH, United States; email: verne.6@osu.edu","","","","","","","","14683288","","GUTTA","19951903","English","Gut","Article","Final","All Open Access; Green Open Access","Scopus","2-s2.0-77953721053"

"Agostini S.; Goubern M.; Tondereau V.; Salvador-Cartier C.; Bezirard V.; Lévèque M.; Keränen H.; Theodorou V.; Bourdu-Naturel S.; Goupil-Feuillerat N.; Legrain-Raspaud S.; Eutamene H.","Agostini, S. (9244386700); Goubern, M. (7004069256); Tondereau, V. (8399121800); Salvador-Cartier, C. (8399122000); Bezirard, V. (8935204200); Lévèque, M. (16047756000); Keränen, H. (57224298846); Theodorou, V. (55410684700); Bourdu-Naturel, S. (26425020400); Goupil-Feuillerat, N. (6507037312); Legrain-Raspaud, S. (26534380300); Eutamene, H. (55926684800)","9244386700; 7004069256; 8399121800; 8399122000; 8935204200; 16047756000; 57224298846; 55410684700; 26425020400; 6507037312; 26534380300; 55926684800","A marketed fermented dairy product containing Bifidobacterium lactis CNCM I-2494 suppresses gut hypersensitivity and colonic barrier disruption induced by acute stress in rats","2012","Neurogastroenterology and Motility","24","4","","376","e172","-204","91","10.1111/j.1365-2982.2011.01865.x","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84858290900&doi=10.1111%2fj.1365-2982.2011.01865.x&partnerID=40&md5=ed6d82de1a136b405ca0468db04e2441","Neuro-Gastroenterology and Nutrition Unit, Toxalim, UMR 1331, Toulouse, France; Danone Research Centre Carasso, Palaiseau, France; Medical Nutrition Physiology, Institute of Biomedicine, University of Helsinki, Helsinki, Finland","Agostini S., Neuro-Gastroenterology and Nutrition Unit, Toxalim, UMR 1331, Toulouse, France; Goubern M., Danone Research Centre Carasso, Palaiseau, France; Tondereau V., Neuro-Gastroenterology and Nutrition Unit, Toxalim, UMR 1331, Toulouse, France; Salvador-Cartier C., Neuro-Gastroenterology and Nutrition Unit, Toxalim, UMR 1331, Toulouse, France; Bezirard V., Neuro-Gastroenterology and Nutrition Unit, Toxalim, UMR 1331, Toulouse, France; Lévèque M., Neuro-Gastroenterology and Nutrition Unit, Toxalim, UMR 1331, Toulouse, France; Keränen H., Neuro-Gastroenterology and Nutrition Unit, Toxalim, UMR 1331, Toulouse, France, Medical Nutrition Physiology, Institute of Biomedicine, University of Helsinki, Helsinki, Finland; Theodorou V., Neuro-Gastroenterology and Nutrition Unit, Toxalim, UMR 1331, Toulouse, France; Bourdu-Naturel S., Danone Research Centre Carasso, Palaiseau, France; Goupil-Feuillerat N., Danone Research Centre Carasso, Palaiseau, France; Legrain-Raspaud S., Danone Research Centre Carasso, Palaiseau, France; Eutamene H., Neuro-Gastroenterology and Nutrition Unit, Toxalim, UMR 1331, Toulouse, France","Background Fermented milk (FM) containing Bifidobacterium lactis CNCM I-2494 and yogurt strains improves irritable bowel syndrome (IBS) symptoms in constipated IBS patients. In rats, stressful events exacerbate IBS symptoms and result in the alteration of gut sensitivity and permeability via epithelial cell cytoskeleton contraction. In a stress model, we aimed at evaluating the effect of B. lactis CNCM I-2494 as a pure strain or contained in an FM product on visceral sensitivity and the impact of this FM on intestinal barrier integrity. Methods Visceral sensitivity was analyzed in rats subjected to partial restraint stress (PRS). Rats received during 15days the B. lactis as a pure strain (10 6 to 10 10CFUmL -1), B. lactis in an FM product (10 8CFUg -1, diluted or not), or a control product. Gut paracellular permeability, colonic occluding and Jam-A proteins, and blood endotoxin levels were determined in rats receiving B. lactis in an FM product submitted or not to a PRS. Key Results The FM product showed a dose-dependent inhibitory effect on stress-induced visceral hypersensitivity. A similar antihyperalgesic effect was observed at 10 10CFUmL -1 of pure B. lactis administration. The FM product prevented the increase in intestinal permeability induced by PRS and restored occludin and JAM-A expressions to control levels. The FM product abolished the increase concentration of blood endotoxin induced by PRS. Conclusions & Inferences This study illustrates that a probiotic food containing B. lactis CNCM I-2494 strain reduces visceral hypersensitivity associated with acute stress by normalizing intestinal epithelial barrier via a synergistic interplay with the different probiotic strains and/or metabolites contained in this product. © 2012 Blackwell Publishing Ltd.","Fermented milk; Gut barrier; Irritable bowel syndrome; Pain; Probiotics","Animals; Bifidobacterium; Colon; Cultured Milk Products; Disease Models, Animal; Female; Hyperesthesia; Immobilization; Intestinal Mucosa; Irritable Bowel Syndrome; Pain Threshold; Probiotics; Rats; Rats, Wistar; Stress, Psychological; endotoxin; junctional adhesion molecule A; occludin; probiotic agent; acute stress; analgesia; animal cell; animal experiment; animal tissue; article; bacterial strain; Bifidobacterium animalis; colony forming unit; controlled study; dairy product; dose response; female; fermented product; hyperalgesia; immobilization stress; intestinal dysmotility; intestine mucosa permeability; nonhuman; permeability barrier; priority journal; protein expression; rat","","occludin, 176304-61-3","","","","","Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Whitehead W.E., Psychosocial aspects of functional gastrointestinal disorders, Gastroenterol Clin North Am, 25, pp. 21-34, (1996); Piche T., Barbara G., Aubert P., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Ait-Belgnaoui A., Bradesi S., Fioramonti J., Theodorou V., Bueno L., Acute stress-induced hypersensitivity to colonic distension depends upon increase in paracellular permeability: role of myosin light chain kinase, Pain, 113, pp. 141-147, (2005); Tsukita S., Furuse M., Itoh M., Structural and signalling molecules come together at tight junctions, Curr Opin Cell Biol, 11, pp. 628-633, (1999); Nusrat A., Turner J.R., Madara J.L., Molecular physiology and pathophysiology of tight junctions IV. Regulation of tight junctions by extracellular stimuli: nutrients, cytokines, and immune cells, Am J Physiol Gastrointest Liver Physiol, 279, (2000); Spiller R.C., Postinfectious irritable bowel syndrome, Gastroenterology, 124, pp. 1662-1671, (2003); Shanahan F., Irritable bowel syndrome: shifting the focus toward the gut microbiota, Gastroenterology, 133, pp. 340-342, (2007); Rhee S.H., Pothoulakis C., Mayer E.A., Principles and clinical implications of the brain-gut-enteric microbiota axis, Nat Rev Gastroenterol Hepatol, 6, pp. 306-314, (2009); Kassinen A., Krogius-Kurikka L., Makivuokko H., Et al., The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects, Gastroenterology, 133, pp. 24-33, (2007); Spiller R.C., Potential biomarkers, Gastroenterol Clin North Am, 40, pp. 121-139, (2011); Fuller R., Probiotics in human medicine, Gut, 32, pp. 439-442, (1991); Mack D.R., Lebel S., Role of probiotics in the modulation of intestinal infections and inflammation, Curr Opin Gastroenterol, 20, pp. 22-26, (2004); Gionchetti P., Rizzello F., Helwig U., Et al., Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial, Gastroenterology, 124, pp. 1202-1209, (2003); Mimura T., Rizzello F., Helwig U., Et al., Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis, Gut, 53, pp. 108-114, (2004); Quigley E.M., Flourie B., Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date, Neurogastroenterol Motil, 19, pp. 166-172, (2007); Parkes G.C., Brostoff J., Whelan K., Sanderson J.D., Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment, Am J Gastroenterol, 103, pp. 1557-1567, (2008); Eutamene H., Lamine F., Chabo C., Et al., Synergy between Lactobacillus paracasei and its bacterial products to counteract stress-induced gut permeability and sensitivity increase in rats, J Nutr, 137, pp. 1901-1907, (2007); O'Mahony L., McCarthy J., Kelly P., Et al., Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles, Gastroenterology, 128, pp. 541-551, (2005); Whorwell P.J., Altringer L., Morel J., Et al., Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome, Am J Gastroenterol, 101, pp. 1581-1590, (2006); Agrawal A., Houghton L.A., Morris J., Et al., Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173-010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation, Aliment Pharmacol Ther, 29, pp. 104-114, (2009); Marteau P., Cuillerier E., Meance S., Et al., Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study, Aliment Pharmacol Ther, 16, pp. 587-593, (2002); Guyonnet D., Chassany O., Ducrotte P., Et al., Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial, Aliment Pharmacol Ther, 26, pp. 475-486, (2007); Guyonnet D., Schlumberger A., Mhamdi L., Jakob S., Chassany O., Fermented milk containing Bifidobacterium lactis DN-173 010 improves gastrointestinal well-being and digestive symptoms in women reporting minor digestive symptoms: a randomised, double-blind, parallel, controlled study, Br J Nutr, 102, pp. 1654-1662, (2009); Williams C.L., Peterson J.M., Villar R.G., Burks T.F., Corticotropin-releasing factor directly mediates colonic responses to stress, Am J Physiol, 253, (1987); Morteau O., Hachet T., Caussette M., Bueno L., Experimental colitis alters visceromotor response to colorectal distension in awake rats, Dig Dis Sci, 39, pp. 1239-1248, (1994); Bjarnason I., MacPherson A., Hollander D., Intestinal permeability: an overview, Gastroenterology, 108, pp. 1566-1581, (1995); Agrawal A., Houghton L.A., Reilly B., Morris J., Whorwell P.J., Bloating and distension in irritable bowel syndrome: the role of gastrointestinal transit, Am J Gastroenterol, 104, pp. 1998-2004, (2009); Houghton L.A., Whorwell P.J., Towards a better understanding of abdominal bloating and distension in functional gastrointestinal disorders, Neurogastroenterol Motil, 17, pp. 500-511, (2005); Verdu E.F., Bercik P., Bergonzelli G.E., Et al., Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of postinfective gut dysfunction, Gastroenterology, 127, pp. 826-837, (2004); Kamiya T., Wang L., Forsythe P., Et al., Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats, Gut, 55, pp. 191-196, (2006); Donnet-Hughes A., Rochat F., Serrant P., Aeschlimann J.M., Schiffrin E.J., Modulation of nonspecific mechanisms of defense by lactic acid bacteria: effective dose, J Dairy Sci, 82, pp. 863-869, (1999); Sharp M.D., McMahon D.J., Broadbent J.R., Comparative evaluation of yogurt and low-fat cheddar cheese as delivery media for probiotic Lactobacillus casei, J Food Sci, 73, (2008); Saxelin M., Lassig A., Karjalainen H., Et al., Persistence of probiotic strains in the gastrointestinal tract when administered as capsules, yoghurt, or cheese, Int J Food Microbiol, 144, pp. 293-300, (2010); Pochart P., Marteau P., Bouhnik Y., Goderel I., Bourlioux P., Rambaud J.C., Survival of bifidobacteria ingested via fermented milk during their passage through the human small intestine: an in vivo study using intestinal perfusion, Am J Clin Nutr, 55, pp. 78-80, (1992); Rochet V., Rigottier-Gois L., Ledaire A., Et al., Survival of Bifidobacterium animalis DN-173 010 in the faecal microbiota after administration in lyophilised form or in fermented product - a randomised study in healthy adults, J Mol Microbiol Biotechnol, 14, pp. 128-136, (2008); Berrada N., Lemeland J.F., Laroche G., Thouvenot P., Piaia M., Bifidobacterium from fermented milks: survival during gastric transit, J Dairy Sci, 74, pp. 409-413, (1991); Resta-Lenert S., Barrett K.E., Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC), Gut, 52, pp. 988-997, (2003); Ferrier L., Mazelin L., Cenac N., Et al., Stress-induced disruption of colonic epithelial barrier: role of interferon-gamma and myosin light chain kinase in mice, Gastroenterology, 125, pp. 795-804, (2003); Barbara G., Stanghellini V., De Giorgio R., Et al., Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome, Gastroenterology, 126, pp. 693-702, (2004); Barreau F., Ferrier L., Fioramonti J., Bueno L., Neonatal maternal deprivation triggers long term alterations in colonic epithelial barrier and mucosal immunity in rats, Gut, 53, pp. 501-506, (2004)","H. Eutamene; Toxalim UMR 1331, Neuro-Gastroenterology and Nutrition Group, Toulouse 31027, 180 chemin de Tournefeuille, France; email: heutamen@toulouse.inra.fr","","","","","","","","13652982","","NMOTE","22272920","English","Neurogastroenterol. Motil.","Article","Final","","Scopus","2-s2.0-84858290900"

"Turcotte J.-F.; Kao D.; Mah S.J.; Claggett B.; Saltzman J.R.; Fedorak R.N.; Liu J.J.","Turcotte, Jean-Francois (57201786834); Kao, Dina (54793138500); Mah, Stephanie J. (7004406761); Claggett, Brian (36871489900); Saltzman, John R. (7007101192); Fedorak, Richard N. (7005513192); Liu, Julia J. (24471706200)","57201786834; 54793138500; 7004406761; 36871489900; 7007101192; 7005513192; 24471706200","Breaks in the wall: Increased gaps in the intestinal epithelium of irritable bowel syndrome patients identified by confocal laser endomicroscopy (with videos)","2013","Gastrointestinal Endoscopy","77","4","","624","630","6","47","10.1016/j.gie.2012.11.006","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84875212395&doi=10.1016%2fj.gie.2012.11.006&partnerID=40&md5=337418ed77ac7241be77d3b4265f2db3","Division of Gastroenterology, Department of Pediatrics, University of Alberta, Edmonton, AB, Canada; Division of Gastroenterology, Department of Medicine, University of Alberta Campus, Edmonton, AB T6G 2X8, Canada; Department of Biostatstics, Harvard School of Public Health, Boston, MA, United States; Gastroenterology Division, Brigham and Women's Hospital, Boston, MA, United States","Turcotte J.-F., Division of Gastroenterology, Department of Pediatrics, University of Alberta, Edmonton, AB, Canada; Kao D., Division of Gastroenterology, Department of Medicine, University of Alberta Campus, Edmonton, AB T6G 2X8, Canada; Mah S.J., Division of Gastroenterology, Department of Medicine, University of Alberta Campus, Edmonton, AB T6G 2X8, Canada; Claggett B., Department of Biostatstics, Harvard School of Public Health, Boston, MA, United States; Saltzman J.R., Gastroenterology Division, Brigham and Women's Hospital, Boston, MA, United States; Fedorak R.N., Division of Gastroenterology, Department of Medicine, University of Alberta Campus, Edmonton, AB T6G 2X8, Canada; Liu J.J., Division of Gastroenterology, Department of Medicine, University of Alberta Campus, Edmonton, AB T6G 2X8, Canada","Background: Altered intestinal permeability and mucosal inflammation have been reported in irritable bowel syndrome (IBS) patients. Increased cell extrusion in the epithelium as measured by epithelial gaps may be associated with barrier dysfunction and may lead to mucosal inflammation. Confocal laser endomicroscopy can be used to identify and quantitate epithelial gaps in the small intestine. Objective: To determine the epithelial gap density in IBS and healthy control patients. Design: Prospective, controlled cohort study. Setting: A tertiary referral center. Patients: In IBS and control patients undergoing routine colonoscopy, probe-based confocal laser endomicroscopy was used to image the terminal ileum. Main Outcome Measurements: The primary outcome was the density of epithelial gaps (gaps/cells counted) in adequately imaged villi using pCLE. Images were reviewed by 2 blinded reviewers. Results: We recruited 18 healthy controls and 16 IBS patients. The median epithelial gap densities for control and IBS patients were 6 and 32 gaps per 1000 cells, respectively (P <.001). There was a trend toward higher gap density in female (P =.07) and younger (ρ = -0.43, P =.07) patients. Using 3% (90% of the control population) as the cutoff for abnormal gap density, we found the diagnostic accuracy for IBS to be as follows: 62% sensitivity, 89% specificity, 83% positive predictive value, and 73% negative predictive value. Limitations: A single-center study, small number of patients. Conclusions: IBS patients have significantly more epithelial gaps in their small intestine compared with healthy controls, which suggests that increased epithelial cell extrusion may be a cause of altered intestinal permeability observed in IBS. © 2013 American Society for Gastrointestinal Endoscopy.","","Adult; Cohort Studies; Endoscopy, Gastrointestinal; Female; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Male; Microscopy, Confocal; Middle Aged; Prospective Studies; adult; article; clinical article; clinical trial; colonoscopy; confocal laser microscopy; controlled study; diagnostic accuracy; diagnostic imaging; digestive endoscope; female; human; intestine mucosa permeability; irritable colon; male; outcome assessment; predictive value; priority journal; prospective study; sensitivity and specificity","","","","","University of Alberta Hospital Foundation; Canada Foundation for Innovation, CFI","DISCLOSURE: The authors disclosed no financial relationships relevant to this publication. Dr Turcotte is a recipient of the Alberta Innovates Health Solutions (AIHS) Clinician Researcher Fellowship. Stephanie Mah is a recipient of the AIHS Summer Studentship. Dr Liu is a recipient of the Canadian Institutes of Health Research New Investigator Salary award. This work was supported in part by a grant to Dr Liu from the University of Alberta Hospital Foundation and a grant to Dr. Fedorak from the Canadian Foundation for Innovation . ","Drossman D.A., The functional gastrointestinal disorders and the Rome III process, Gastroenterology, 130, pp. 1377-1390, (2006); Choung R.S., Locke III G.R., Epidemiology of IBS, Gastroenterol Clin North Am, 40, pp. 1-10, (2011); Lovell R.M., Ford A.C., Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis, Clin Gastroenterol Hepatol, 10, pp. 712-721, (2012); Park D.W., Lee O.Y., Shim S.G., The differences in prevalence and sociodemographic characteristics of irritable bowel syndrome according to Rome II and Rome III, J Neurogastroenterol Motil, 16, pp. 186-193, (2010); Lacy B.E., Weiser K., De Lee R., The treatment of irritable bowel syndrome, Ther Adv Gastroenterol, 2, pp. 221-238, (2009); Carroll I.M., Ringel-Kulka T., Keku T.O., Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome, Am J Physiol Gastrointest Liver Physiol, 301, (2011); Rajilic-Stojanovic M., Biagi E., Heilig H.G., Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome, Gastroenterology, 141, pp. 1792-1801, (2011); Saulnier D.M., Riehle K., Mistretta T.A., Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome, Gastroenterology, 141, pp. 1782-1791, (2011); Marshall J.K., Thabane M., Garg A.X., Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery, Gastroenterology, 131, pp. 445-450, (2006); Porter C.K., Gormley R., Tribble D.R., The incidence and gastrointestinal infectious risk of functional gastrointestinal disorders in a healthy US adult population, Am J Gastroenterol, 106, pp. 130-138, (2011); Ramage J.K., Stanisz A., Scicchitano R., Effect of immunologic reactions on rat intestinal epithelium Correlation of increased permeability to chromium 51-labeled ethylenediaminetetraacetic acid and ovalbumin during acute inflammation and anaphylaxis, Gastroenterology, 94, pp. 1368-1375, (1988); Saunders P.R., Kosecka U., McKay D.M., Acute stressors stimulate ion secretion and increase epithelial permeability in rat intestine, Am J Physiol, 267, (1994); Gwee K.A., Collins S.M., Read N.W., Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome, Gut, 52, pp. 523-526, (2003); Khan W.I., Collins S.M., Gut motor function: Immunological control in enteric infection and inflammation, Clin Exp Immunol, 143, pp. 389-397, (2006); Buhner S., Li Q., Vignali S., Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome, Gastroenterology, 137, pp. 1425-1434, (2009); Tornblom H., Lindberg G., Nyberg B., Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome, Gastroenterology, 123, pp. 1972-1979, (2002); Montrose M.H., The future of GI and liver research: Editorial perspectives: I. Visions of epithelial research, Am J Physiol Gastrointest Liver Physiol, 284, (2003); Clayburgh D.R., Shen L., Turner J.R., A porous defense: The leaky epithelial barrier in intestinal disease, Lab Invest, 84, pp. 282-291, (2004); Wilson T.J., Ponder B.A., Wright N.A., Use of a mouse chimaeric model to study cell migration patterns in the small intestinal epithelium, Cell Tissue Kinet, 18, pp. 333-344, (1985); Guan Y., Watson A.J., Marchiando A.M., Redistribution of the tight junction protein ZO-1 during physiological shedding of mouse intestinal epithelial cells, Am J Physiol Cell Physiol, 300, (2011); Kiesslich R., Goetz M., Angus E.M., Identification of epithelial gaps in human small and large intestine by confocal endomicroscopy, Gastroenterology, 133, pp. 1769-1778, (2007); Liu J.J., Madsen K.L., Boulanger P., Mind the gaps: Confocal endomicroscopy showed increased density of small bowel epithelial gaps in inflammatory bowel disease, J Clin Gastroenterol, 45, pp. 240-245, (2011); Liu J.J., Rudzinski J.K., Mah S.J., Epithelial gaps in a rodent model of inflammatory bowel disease: A quantitative validation study, Clin Trans Gastroenterol, 2, (2011); Liu J.J., Wong K., Thiesen A.L., Increased epithelial gaps in the small intestines of patients with inflammatory bowel disease: Density matters, Gastrointest Endosc, 73, pp. 1174-1180, (2011); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am J Gastroenterol, 106, pp. 2165-2173, (2011); Bashashati M., Rezaei N., Andrews C.N., Cytokines and irritable bowel syndrome: Where do we stand?, Cytokine, 57, pp. 201-209, (2012); Dunlop S.P., Hebden J., Campbell E., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Furman D.L., Cash B.D., The role of diagnostic testing in irritable bowel syndrome, Gastroenterol Clin North Am, 40, pp. 105-119, (2011)","J.J. Liu; Division of Gastroenterology, Department of Medicine, University of Alberta Campus, Edmonton, AB T6G 2X8, Canada; email: julia.liu@ualberta.ca","","","","","","","","10976779","","GAENB","23357497","English","Gastrointest. Endosc.","Article","Final","","Scopus","2-s2.0-84875212395"

"Marshall J.K.; Thabane M.; Garg A.X.; Clark W.; Meddings J.; Collins S.M.","Marshall, J.K. (7404858353); Thabane, M. (14036433600); Garg, A.X. (55616238600); Clark, W. (7403516130); Meddings, J. (7005250322); Collins, S.M. (7402535948)","7404858353; 14036433600; 55616238600; 7403516130; 7005250322; 7402535948","Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario","2004","Alimentary Pharmacology and Therapeutics","20","11-12","","1317","1322","5","248","10.1111/j.1365-2036.2004.02284.x","https://www.scopus.com/inward/record.uri?eid=2-s2.0-11144330063&doi=10.1111%2fj.1365-2036.2004.02284.x&partnerID=40&md5=4b41f28be698a4e9b81fca9cca59ae3a","Department of Medicine, Division of Gastroenterology, McMaster University, Hamilton, Ont., Canada; Department of Medicine, Division of Nephrology, University of Western Ontario, London, Ont., Canada; Department of Medicine, Division of Gastroenterology, University of Calgary, Calgary, Alta., Canada; Division of Gastroentrology (4W8), McMaster University Medical Centre, Hamilton, Ont. LSN 3Z5, 1200 Main Street West, Canada","Marshall J.K., Department of Medicine, Division of Gastroenterology, McMaster University, Hamilton, Ont., Canada, Division of Gastroentrology (4W8), McMaster University Medical Centre, Hamilton, Ont. LSN 3Z5, 1200 Main Street West, Canada; Thabane M., Department of Medicine, Division of Gastroenterology, McMaster University, Hamilton, Ont., Canada; Garg A.X., Department of Medicine, Division of Nephrology, University of Western Ontario, London, Ont., Canada; Clark W., Department of Medicine, Division of Nephrology, University of Western Ontario, London, Ont., Canada; Meddings J., Department of Medicine, Division of Gastroenterology, University of Calgary, Calgary, Alta., Canada; Collins S.M., Department of Medicine, Division of Gastroenterology, McMaster University, Hamilton, Ont., Canada","Background: Post-infectious irritable bowel syndrome is a common clinical phenomenon of uncertain aetiology. Aim: To test the association between intestinal permeability and irritable bowel syndrome symptoms 2 years after a large waterborne outbreak of bacterial gastroenteritis. Methods: Consecutive adults with Rome I irritable bowel syndrome and controls without irritable bowel syndrome attending a community clinic were enrolled. Intestinal permeability was measured as the ratio of fractional urinary excretions of lactulose and mannitol, and compared among cases vs. controls and predictors of abnormal intestinal permeability were assessed. Results: A total of 218 subjects (132 irritable bowel syndrome cases and 86 non-irritable bowel syndrome controls) completed the study protocol. About 27 (12%) had been diagnosed with the irritable bowel syndrome before the outbreak and 115 (53%) had been ill during the outbreak. Lactulose-mannitol ratios were increased among cases vs. controls (Mann-Whitney mean rank 118.8 vs. 95.3, P = 0.007), and cases were more likely to have a ratio >0.020 (P = 0.007). Among cases, those with increased intestinal permeability were more likely to report increased stool frequency. Both irritable bowel syndrome symptoms and male gender, but not diarrhoeal illness during the outbreak, were significant predictors of abnormal permeability. Conclusions: Irritable bowel syndrome symptoms are associated with a subtle increase in intestinal permeability irrespective of prior gastroenteritis. This may improve understanding of the aetiology of both sporadic and post-infectious irritable bowel syndrome.","","Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Disease Outbreaks; Female; Gastroenteritis; Humans; Irritable Bowel Syndrome; Lactulose; Male; Mannitol; Middle Aged; Ontario; Permeability; lactulose; mannitol; acute gastroenteritis; adult; aged; article; Canada; clinical protocol; disease association; epidemic; female; human; intestine mucosa permeability; irritable colon; major clinical study; male; priority journal; rank sum test; urinary excretion","","lactulose, 4618-18-2; mannitol, 69-65-8, 87-78-5; Lactulose, 4618-18-2; Mannitol, 69-65-8","","","","","Marshall J.K., Thabane M., James C., Borgaonkar M., Collins S.M., Incidence of post-infectious irritable bowel syndrome following a food-borne outbreak of acute gastroenteritis attributed to a viral pathogen, Am J Gastroenterol, 98, (2003); Borgaonkar M.R., Ford D., Marshall J.K., Churchill E., Collins S.M., The incidence of irritable bowel syndrome following infectious gastroenteritis, Am J Gastroenterol, 96, (2001); Gwee K.A., Graham J.C., McKendrick M.W., Et al., Psychometric scores and persistence of irritable bowel after infectious diarrhoea, Lancet, 347, pp. 150-153, (1996); Gwee K.-A., Leong Y.-L., Graham C., Et al., The role of psychological and biological factors in post-infective gut dysfunction, Gut, 44, pp. 400-406, (1999); McKendrick M.W., Read N.W., Irritable bowel syndrome: Post salmonella infection, J Infect, 29, pp. 1-3, (1994); Neal K.R., Hebden J., Spiller R., Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: Postal survey of patients, BMJ, 314, pp. 779-782, (1997); Stewart G.T., Post-dysenteric colitis, BMJ, 1, pp. 405-409, (1950); Collins S.M., A case for an immunological basis for irritable bowel syndrome, Gastroenterology, 122, pp. 2078-2080, (2002); Irvine E.J., Marshall J.K., Increased intestinal permeability precedes the onset of Crohn's disease in a subject with familial risk, Gastroenterology, 119, pp. 1740-1744, (2000); Spiller R.C., Jenkins D., Thornley J.P., Et al., Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, pp. 804-811, (2000); The Investigative Report of the Walkerton Outbreak of Waterborne Gastroenteritis May-June 2000, (2000); Talley N.J., Phillips S.F., Melton J., Wiltgen C., Zinsmeister A.R., A patient questionnaire to identify bowel disease, Ann Intern Med, 111, pp. 671-674, (1989); Thompson W.G., Creed F.H., Drossman D.A., Et al., Functional bowel disorders and functional abdominal pain, Gastroenterol Int, 5, pp. 75-91, (1992); Meddings J.B., Review article: Intestinal permeability in Crohn's disease, Aliment Pharmacol Ther, 11, pp. 47-56, (1997); Hilsden R.J., Meddings J.B., Sutherland L.R., Intestinal permeability changes in response to acetylsalicylic acid in relatives of patients with Crohn's disease, Gastroenterology, 110, pp. 1395-1403, (1996); Gonsalkorale W.M., Perrey C., Pravica V., Whorwell P.J., Hutchinson I.V., Interleukin 10 genotypes in irritable bowel syndrome: Evidence for an inflammatory component?, Gut, 52, pp. 91-93, (2003); Chadwick V.S., Chen W., Shu D., Et al., Activation of the mucosal immune system in irritable bowel syndrome, Gastroenterology, 122, pp. 1778-1783, (2002); Dunlop S.P., Jenkins D., Neal K.R., Et al., Randomized double-blind placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome, Aliment Pharmacol Ther, 18, pp. 77-84, (2003); Whorwell P.J., Holdstock G., Whorwell G.M., Wright R., Bottle feeding, early gastroenteritis and inflammatory bowel disease, BMJ, 1, (1979); Rodriguez L.A., Ruigomez A., Increased risk of irritable bowel syndrome after bacterial gastroenteritis: Cohort study, BMJ, 318, pp. 565-566, (1999); Tagore A., Gonsalkorale W.M., Pravica V., Et al., Interleukin-10 genotypes in inflammatory bowel disease, Tissue Antigens, 54, pp. 386-390, (1999); Killiaan A.J., Saunders P.R., Bijlsma P.B., Et al., Stress stimulates transepithelial macromolecular uptake in rat jejunum, Am J Physiol, 275, (1998); Dunlop S.P., Jenkins D., Spiller R.C., Distinctive clinical psychological and histological features of post-infective irritable bowel syndrome, Am J Gastroenterol, 98, pp. 1578-1583, (2003)","J.K. Marshall; Division of Gastroentrology (4W8), McMaster University Medical Centre, Hamilton, Ont. LSN 3Z5, 1200 Main Street West, Canada; email: marshllj@mcmaster.ca","","","","","","","","02692813","","APTHE","15606393","English","Aliment. Pharmacol. Ther.","Article","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-11144330063"

"Dainese R.; Galliani E.A.; De Lazzari F.; Di Leo V.; Naccarato R.","Dainese, Raffaella (23479438000); Galliani, Ermenegildo A. (35481544600); De Lazzari, Franca (6701728949); Di Leo, Vincenza (6603861235); Naccarato, Remo (36047524800)","23479438000; 35481544600; 6701728949; 6603861235; 36047524800","Discrepancies between reported food intolerance and sensitization test findings in irritable bowel syndrome patients","1999","American Journal of Gastroenterology","94","7","","1892","1897","5","129","10.1111/j.1572-0241.1999.01226.x","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033051598&doi=10.1111%2fj.1572-0241.1999.01226.x&partnerID=40&md5=617eb574a70661ad798fe80cf87685d7","Gastroenterology Unit, Dept. Surg. Gastroenterological S., Padua, Italy","Dainese R., Gastroenterology Unit, Dept. Surg. Gastroenterological S., Padua, Italy; Galliani E.A., Gastroenterology Unit, Dept. Surg. Gastroenterological S., Padua, Italy; De Lazzari F., Gastroenterology Unit, Dept. Surg. Gastroenterological S., Padua, Italy; Di Leo V., Gastroenterology Unit, Dept. Surg. Gastroenterological S., Padua, Italy; Naccarato R., Gastroenterology Unit, Dept. Surg. Gastroenterological S., Padua, Italy","OBJECTIVE: Irritable bowel syndrome (IBS) is a common gastrointestinal disorder with clinical signs typical of 'intestinal' food allergies or intolerance. The aim of this study was to characterize the clinical features of IBS patients suspected of suffering from adverse reactions to food. METHODS: The study involved 128 consecutive IBS patients divided into four groups according to their main symptom on presentation at our outpatient clinic. A detailed medical history was recorded, paying particular attention to any allergies and reported intolerance to food. Each patient was screened for allergies; intestinal permeability tests was performed in randomly selected patients from different groups. Findings were analyzed using the X2 test. RESULTS: Adverse reactions to one or more foods were reported by 80 patients (62.5%); skin prick tests (SPT) were positive in 67 patients (52.3%) with no significant differences between patients complaining of different symptoms. Patients who reported a food intolerance had more positive SPTs than those who did not (47 of 80 [58.7%] vs 20 of 48 [41.7%]); this difference was not statistically significant, although it suggests a trend (p < 0.0610). There was little consistency between the specific foods reported to cause intolerance and those resulting from the tests (11 of 80 patients, 13.7%). The intestinal permeability test was normal in 29 of 33 patients (87.9%). CONCLUSIONS: More than 50% of IBS patients were found sensitized to some food or inhalant without any typical clinical signs. Patients were unable to identify potentially offending foods. The lack of a correlation between SPT results and reported food allergies needs further investigation to clarify the pathophysiology and improve the diagnosis of intestinal food allergies.","","Adolescent; Adult; Aged; Allergens; Colonic Diseases, Functional; Female; Food; Food Hypersensitivity; Humans; Intestinal Absorption; Male; Middle Aged; Sensitivity and Specificity; Skin Tests; adolescent; adult; aged; anamnesis; article; clinical examination; female; food allergy; gastrointestinal symptom; human; irritable colon; major clinical study; male; nutritional intolerance; priority journal; skin test; statistical analysis","","Allergens, ","","","","","Thompson W.G., Symptomatic presentations of the irritable bowel syndrome, Gastroenterol Clin North Am, 20, pp. 235-247, (1991); Thompson W.G., Irritable bowel syndrome: Pathogenesis and management, Lancet, 341, pp. 1569-1572, (1993); Moreno-Osset E., Calvo B., Tomas-Ridocci M., Et al., The irritable bowel syndrome: Diagnostic strategies, Ital J Gastroenterol, 23, SUPPL. 1, pp. 41-47, (1991); Barbara I., Baldi F., Longanesi A., Pathogenesis of irritable bowel syndrome, Ital J Gastroenterol, 23, SUPPL. 1, pp. 36-38, (1991); Addolorato G., Gasbarrini G., Marsigli L., Et al., Irritable bowel syndrome and food allergy: An association via anxiety-depression?, Gastroenterology, 11, pp. 833-834, (1996); Alun Jones V., Shorthouse M., McLaughlan P., Et al., Food intolerance: A major factor in the pathogenesis of irritable bowel syndrome, Lancet, 1, pp. 1115-1117, (1982); Bentley S.J., Pearson D.J., Rix K.J., Food hypersensitivity in irritable bowel syndrome, Lancet, 2, pp. 295-297, (1983); Petitpierre M., Gumowski P., Girard J.P., Irritable bowel syndrome and hypersensitivity to food, Ann Allergy, 54, pp. 538-540, (1985); Zwetchkenbaum J.F., Burakoff R., Food allergy and the irritable bowel syndrome, Am J Gastroenterol, 83, pp. 901-904, (1988); Bayliss C.E., Bradley H.K., Alun Jones V., Et al., Some aspects of colonic microbial activity in irritable bowel syndrome associated with food intolerance, Ann Ist Super Sanita, 22, pp. 959-963, (1986); Hunter J.O., Food allergy or enterometabolic disorder?, Lancet, 338, pp. 495-496, (1991); McKee A.M., Prior A., Whorwell P.J., Exclusion diets in irritable bowel syndrome: Are they worthwhile?, J Clin Gastroenterol, 9, pp. 526-528, (1987); Nanda R., James R., Smith H., Et al., Food intolerance and the irritable bowel syndrome, Gut, 30, pp. 1099-1104, (1989); Schmidt M., Floch M.H., Food hypersensitivity and the irritable bowel syndrome, Am J Gastroenterol, 87, pp. 18-19, (1992); Edwards A.M., Food allergic disease, Clin Exp Allergy, 25, SUPPL. 1, pp. 16-19, (1995); Stefanini G.F., Prati E., Albini M.C., Et al., Oral disodium cromoglycate treatment on irritable bowel syndrome: An open study on 101 subjects with diarrheic type, Am J Gastroenterol, 87, pp. 55-57, (1992); Stefanini G.F., Saggioro A., Alvisi V., Et al., Oral cromolyn sodium in comparison with elimination diet in the irritable bowel syndrome, diarrheic type, Scan J Gastroenterol, 30, pp. 535-541, (1995); Bischoff S.C., Mayer J., Wedemeyer J., Et al., Colonoscopic allergen provocation (COLAP): A new diagnosic approach for gastrointestinal food allergy, Gut, 40, pp. 745-753, (1997); Bruijnzeel-Koomen C., Ortolani C., Aas K., Et al., Adverse reactions to food, Allergy, 50, pp. 623-635, (1995); Shanahan F., Food allergy: Fact, fiction, and fatality, Gastroenterology, 104, pp. 1229-1231, (1993); Young E., Stoneham M.D., Petruckevitch A., Et al., A population study of food intolerance, Lancet, 343, pp. 1127-1130, (1994); Bischoff S.C., Herrmann A., Manns M.P., Prevalence of adverse reactions to food in patients with gastrointestinal disease, Allergy, 51, pp. 811-818, (1996); Talley N.J., Zinsmeister A.R., Van Dyke C., Et al., Epidemiology of colonic symptoms and the irritable bowel syndrome, Gastroenterology, 101, pp. 927-934, (1991); King T.S., Elia M., Hunter J.O., Rapid colonic fermentation associated with symptoms in irritable bowel syndrome is corrected by exclusion diet, Gastroenterology, 112, (1997); Majamaa H., Isolauri E., Probiotics: A novel approach in the management of food allergy, J Allergy Clin Immunol, 1, pp. 1-8, (1997); Farah D.A., Calder I., Benson L., Et al., Specific food intolerance: Its place as a cause of gastrointestinal symptoms, Gut, 26, pp. 164-168, (1985); Gwee K.A., Graham J.C., Mckendrick M.W., Et al., Psychometric scores and persistence of irritable bowel after infectious diarrhoea, Lancet, 347, pp. 150-153, (1996); Farthing M.J.G., Irritable bowel, irritable body, or irritable brain?, BMJ, 310, pp. 171-175, (1995); Aziz Q., Thompson D.G., Brain-gut axis in health and disease, Gastroenterology, 114, pp. 559-578, (1998); Frieling T., Strohmeyer G., Neuroimmune Interaktionen im Gastrointestinaltrakt, Z Gastroenterol, 33, pp. 219-224, (1995); Bjarnason I., Macpherson A., Hollander D., Intestinal permeability: An overview, Gastroenterology, 108, pp. 1556-1581, (1995); Crowe S.E., Perdue M.H., Gastrointestinal food hypersensitivity: Basic mechanism of pathophysiology, Gastroenterology, 103, pp. 1075-1095, (1992); Bischoff S.C., Mucosal allergy: Role of mast cells and eosinophil granulocytes in the gut, Baillières Clin Gastroenterol, 10, pp. 443-459, (1996); Andre C., Andre A., Colin L., Et al., IgE in stools as indicator of food sensitization, Allergy, 50, pp. 328-333, (1995); Bischoff S.C., Grabowsky J., Manns M.P., Quantification of inflammatory mediators in stool samples of patients with inflammatory bowel disorders and controls, Dig Dis Sci, 42, pp. 394-403, (1997); Talley N.J., Butterfield J.H., Mast cell infiltration and degranulation in colonic mucosa in the irritable bowel syndrome, Am J Gastroenterol, 91, pp. 1675-1676, (1996); Baentkler H.W., Lux G., Antigen-induced histamine release from duodenal biopsy in gastrointestinal food allergy, Ann Allergy, 62, pp. 449-452, (1989); De Lazzari F., Venturi C., Fregona I., Et al., Ige Specifiche Nella Mucosa Gastrica e Duodenale. Minerva Gastroenterol Dietol, 40, pp. 1-9, (1994); Horauf A.M., Matek M., Raithel M., Et al., Histamine release from human colonic mucosa in response to anti-IgE, Agents Actions, 27, pp. 89-91, (1989); Raithel M., Matek M., Baennkler H.W., Et al., Mucosal histamine content and histamine secretion in Crohn's disease, ulcerative colitis and allergic enteropathy, Int Arch Allergy Immunol, 108, pp. 127-133, (1995)","","","","","","","","","00029270","","AJGAA","10406255","English","Am. J. Gastroenterol.","Article","Final","","Scopus","2-s2.0-0033051598"

"Tibble J.A.; Sigthorsson G.; Foster R.; Forgacs I.; Bjarnason I.","Tibble, Jeremy A. (15736416500); Sigthorsson, Gudmundur (36108978400); Foster, Russell (36643868600); Forgacs, Ian (7007046231); Bjarnason, Ingvar (35186773100)","15736416500; 36108978400; 36643868600; 7007046231; 35186773100","Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease","2002","Gastroenterology","123","2","","450","460","10","361","10.1053/gast.2002.34755","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036320081&doi=10.1053%2fgast.2002.34755&partnerID=40&md5=8b233a7ecde892e1c9fca86f97bbc941","Department of Medicine, Guy’s, Kings, St. Thomas’ Medical School, London, United Kingdom; Department of Gastroenterology, Kings College Hospital, London, United Kingdom","Tibble J.A., Department of Medicine, Guy’s, Kings, St. Thomas’ Medical School, London, United Kingdom; Sigthorsson G., Department of Medicine, Guy’s, Kings, St. Thomas’ Medical School, London, United Kingdom; Foster R., Department of Medicine, Guy’s, Kings, St. Thomas’ Medical School, London, United Kingdom; Forgacs I., Department of Gastroenterology, Kings College Hospital, London, United Kingdom; Bjarnason I., Department of Medicine, Guy’s, Kings, St. Thomas’ Medical School, London, United Kingdom","Background and Aims: Differentiating symptoms of irritable bowel syndrome (IBS) from those of organic intestinal disease is a familiar problem for physicians. The aim of this study was to assess the sensitivity, specificity, and odds ratios (ORs) of fecal calprotectin, small intestinal permeability, Rome I criteria, and laboratory markers of inflammation (erythrocyte sedimentation rate [ESR], C-reactive protein [CRP], blood count) in distinguishing organic from nonorganic intestinal disease. Methods: A total of 602 new referrals to a gastroenterology clinic who had symptoms suggestive of IBS or organic intestinal disease were studied for these parameters. All patients underwent invasive imaging (barium/endoscopic examination) and other investigations as appropriate, with physicians blinded to the results of fecal calprotectin and intestinal permeability. Results: A total of 263 patients were diagnosed with organic disease and 339 with IBS. At 10 mg/L, the sensitivity and specificity of calprotectin for organic disease were 89% and 79%, respectively, and that of intestinal permeability for small intestinal disease were 63% and 87%, respectively. Sensitivity of positive Rome criteria for IBS was 85% with a specificity of 71%. An abnormal calprotectin test had an OR for disease of 27.8 (95% confidence interval [CI], 17.6-43.7; P < 0.0001) compared with ORs of 4.2 (95% Cl, 2.9-6.1; P < 0.0001) and 3.2 (95% CI, 2.2-4.6; P < 0.0001) for elevated CRP and ESR values. An abnormal permeability test gave an OR of 8.9 (95% CI, 5.8-14.0; P < 0.0001) for small intestinal disease. The OR for IBS with positive Rome criteria was 13.3 (95% CI, 8.9-20.0). Conclusions: Fecal calprotectin, intestinal permeability, and positive Rome I criteria provide a safe and noninvasive means of helping differentiate between patients with organic and nonorganic intestinal disease. © 2002 Elsevier Science Ltd. All rights reserved.","","barium; C reactive protein; calprotectin; adult; aged; article; blood cell count; confidence interval; diagnostic imaging; differential diagnosis; disease classification; disease marker; endoscopy; enteritis; enteropathy; erythrocyte sedimentation rate; female; human; intestine mucosa permeability; irritable colon; laboratory diagnosis; major clinical study; male; priority journal; safety; sensitivity and specificity; symptom","","barium, 7440-39-3; C reactive protein, 9007-41-4","","","NHS Executive South Thames Regional Office, (RDF 039)","Supported by NHS Executive South Thames Regional Office grant RDF 039 (to J.A.T.). ","Drossman D.A., Whitehead W.E., Camilleri M., Irritable bowel syndrome: A technical review for practice guideline development, Gastroenterology, 112, pp. 2120-2137, (1997); Manning A.P., Thompson W.G., Heaton K.W., Morris A.F., Towards positive diagnosis of the irritable bowel, Br Med J, 6138, pp. 653-664, (1978); Drossman D.A., Sandier R.S., McKee D.C., Lovitz A.J., Bowel patterns among subjects not seeking health care. Use of a questionnaire to identify a population with bowel dysfunction, Gastroenterology, 83, pp. 529-534, (1982); Kruis W., Thieme C., Weinzierl M., Schussler P., Holl J., Paulus W., A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease, Gastroenterology, 87, pp. 1-7, (1984); Whitehead W.E., Bosmajian L., Zonderman A.B., Costa P.T., Schuster M.M., Symptoms of psychologic distress associated with irritable bowel syndrome. Comparison of community and medical clinic samples, Gastroenterology, 95, pp. 709-714, (1988); Talley N.J., Phillips S.F., Melton J., Wiltgen C., Zinsmeister A.R., A patient questionnaire to identify bowel disease, Ann Intern Med, 111, pp. 671-674, (1989); Talley N.J., Phillips S.F., Melton J., Mulvihill C., Wiltgen C., Zinsmeister A.R., Diagnostic value of the Manning criteria in irritable bowel syndrome, Gut, 31, pp. 77-81, (1990); Smith R.C., Greenbaum D.S., Vancouver J.B., Henry R.C., Reinhart M.A., Greenbaum R.B., Dean H.A., Mayle J.E., Gender differences in Manning criteria in the irritable bowel syndrome, Gastroenterology, 100, pp. 591-595, (1991); Thompson W.G., Drossman D.A., Richter J.E., Talley N.J., Corazziari E., Whitehead W.E., Functional bowel disorders and functional abdominal pain, Functional gastrointestinal disorders: diagnosis, pathophysiology and treatment, pp. 115-173, (1994); Appendix B., Functional gastrointestinal disorders: diagnosis, pathophysiology and treatment, pp. 339-345, (1994); Harris M.S., Irritable bowel syndrome. A cost-effective approach for primary care physicians, Postgrad Med, 101, pp. 215-216, (1997); Camilleri M., Prather C.M., The irritable bowel syndrome: Mechanisms and a practical approach to management, Ann Intern Med, 116, pp. 1001-1008, (1992); Drossman D.A., Thompson W.G., The irritable bowel syndrome: Review and a graduated multicomponent treatment approach, Ann Intern Med, 116, pp. 1009-1016, (1992); Tolliver B.A., Herrera J.L., DiPalma J.A., Evaluation of patients who meet clinical criteria for irritable bowel syndrome, Am J Gastroenterol, 89, pp. 176-178, (1994); Dale I., Brandtzaeg P., Fagerhol M.K., Scott H., Distribution of a new myelomonocytic antigen (L1) in human peripheral blood leukocytes. Immunofluorescence and immunoperoxidase staining features in comparison with lysozyme and lactoferrin, Am J Clin Pathol, 84, pp. 24-34, (1985); Fagerhol M.K., Andersson K.B., Naess-Andresen C.F., Brandtzaeg P., Dale I., Calprotectin (the L1 leukocyte protein), Stimulus response coupling: the role of intracellular calcium-binding proteins, pp. 187-210, (1990); Roseth A.G., Aadland E., Jahnsen J., Raknerud N., Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein, Digestion, 58, pp. 176-180, (1997); Roseth A.G., Fagerhol M.K., Aadland E., Schjonsby H., Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study, Scand J Gastroenterol, 27, pp. 793-798, (1992); Kristinsson J., Roseth A., Fagerhol M.K., Aadland E., Schjonsby H., Bormer O.P., Raknerud N., Nygaard K., Fecal calprotectin concentration in patients with colorectal carcinoma, Dis Colon Rectum, 41, pp. 316-321, (1998); Meling T.R., Aabakken L., Roseth A., Osnes M., Faecal calprotectin shedding after short-term treatment with non-steroidal anti-inflammatory drugs, Scand J Gastroenterol, 31, pp. 339-344, (1996); Teahon K., Roseth A., Foster R., Bjarnason I., Faecal calprotectin: A simple sensitive quantitative measure of intestinal inflammation in man, Gastroenterology, 112, (1997); Tibble J., Sigthorsson G., Foster R., Sherwood R., Fagerhol M., Bjarnason I., Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma, Gut, 49, pp. 402-408, (2001); Tibble J.A., Sigthorsson G., Foster R., Scott D., Fagerhol M.K., Roseth A., Bjarnason I., High prevalence of NSAID enteropathy as demonstrated by a simple faecal test, Gut, 45, pp. 362-366, (1999); Bjarnason I., MacPherson A., Hollander D., Intestinal permeability: An overview, Gastroenterology, 108, pp. 1566-1581, (1995); Drossman D.A., The functional gastrointestinal disorders and the Rome II process, Gut, 45, pp. 1-5, (1999); Sigthorsson G., Tibble J., Hayllar J., Menzies I., Macpherson A., Moots R., Scott D., Gumpel M.J., Bjarnason I., Intestinal permeability and inflammation in patients on NSAID’s, Gut, 43, pp. 506-511, (1998); Teahon K., Smethurst P., Levi A.J., Menzies I.S., Bjarnason I., Intestinal permeability in patients with Crohn’s disease and their first degree relatives, Gut, 33, pp. 320-323, (1992); Henderson A.R., Assessing test accuracy on its clinical consequence: A primer for receiver operating characteristics curve analysis, Ann Clin Biochem, 30, pp. 521-539, (1993); Royston P., Estimating departure from normality, Stat Med, 10, pp. 1283-1294, (1991); Cox D.R., Regression models and life tables, J Royal Stat Soc, B34, pp. 187-202, (1972); Morris A.J., Madhok R., Sturrock R.D., Capell H.A., MacKenzie J.F., Enteroscopic diagnosis of small bowel ulceration in patients receiving non-steroidal anti-inflammatory drugs, Lancet, 337, (1991); Drossman D.A., McKee D.C., Sandier R.S., Mitchell C.M., Cramer E.M., Lowman B.C., Burger A.L., Psychosocial factors in the irritable bowel syndrome. A multivariate study of patients and nonpatients with irritable bowel syndrome, Gastroenterology, 95, pp. 701-708, (1988); Thompson W.G., Heaton K.W., Functional bowel disorders in apparently healthy people, Gastroenterology, 79, pp. 283-288, (1980); Bommelaer G., Rouch M., Dapoigny M., Pais D., Loisy P., Gualino M., Tournut R., Epidemiology of intestinal functional disorders in an apparently healthy population, Gastroenterol Clin Biol, 10, pp. 7-12, (1986); Mitchell C.M., Drossman D.A., Survey of the AGA membership relating to patients with functional gastrointestinal disorders, Gastroenterology, 92, pp. 1282-1284, (1987); Thompson W.G., Heaton K.W., Smyth G.T., Smyth C., Irritable bowel syndrome in general practice: Prevalence, characteristics and referral, Gut, 46, pp. 78-82, (2000); Thompson W.G., Irritable bowel syndrome: Pathogenesis and management, Lancet, 341, pp. 1569-1572, (1993); Bennett E.J., Tennant C.C., Piesse C., Badcock C.A., Kellow J.E., Level of chronic life stress predicts clinical outcome in irritable bowel syndrome, Gut, 43, pp. 256-261, (1998); Shaw M., Talley N.J., Adlis S., Beebe T., Tomshine P., Healey M., Development of a digestive health status instrument: Tests of scaling assumptions, structure and reliability in a primary care population, Aliment Pharmacol Ther, 12, pp. 1067-1078, (1998); Kay L., Jorgensen T., Lanng C., Irritable bowel syndrome: Which definitions are consistent?, J Intern Med, 244, pp. 489-494, (1998); Bensoussan A., Talley N.J., Hing M., Menzies R., Guo A., Ngu M., Treatment of irritable bowel syndrome with Chinese herbal medicine: A randomized controlled trial, JAMA, 280, pp. 1585-1589, (1998); Patrick D.L., Drossman D.A., Frederick I.O., DiCesare J., Puder K.L., Quality of life in persons with irritable bowel syndrome: Development and validation of a new measure, Dig Dis Sci, 43, pp. 400-411, (1998); Tibble J.A., Teahon K., Roseth A., Sigthorsson G., Bridger S., Foster R., Sherwood R., Fagerhol M., Bjarnason I., A simple method for assessing intestinal inflammation in Crohn’s disease, Gut, 47, pp. 506-513, (2000); Tibble J.A., Sigthorsson G., Bridger S., Fagerhol M., Bjarnason I., Surrogate markers of intestinal inflammation are predictive of relapse in patients with quiescent inflammatory bowel disease, Gastroenterology, 119, pp. 15-22, (2000); Gilbert J.A., Ahlquist D.A., Mahoney D.W., Zinsmeister A.R., Rubin J., Ellefson R.D., Fecal marker variability in colorectal cancer: Calprotectin versus hemoglobin, Scand J Gastroenterol, 31, pp. 1001-1005, (1996); Allison M.C., Howatson A.G., Torrance C.J., Lee F.D., Russell R.I., Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs, N Engl J Med, 327, pp. 749-754, (1992); Morris A.J., Wasson L.A., MacKenzie J.F., Small bowel enteroscopy in undiagnosed gastrointestinal blood loss, Gut, 33, pp. 887-889, (1992); Somasundaram S., Hayllar H., Rafi S., Wrigglesworth J.M., Macpherson A.J., Bjarnason I., The biochemical basis of non-steroidal antiinflammatory drug-induced damage to the gastrointestinal tract: A review and a hypothesis, Scand J Gastroenterol, 30, pp. 289-299, (1995)","J.A. Tibble; Digestive Diseases Centre, Royal Sussex County Hospital, Brighton, East Sussex BN2 5BE, Eastern Road, United Kingdom; email: jeremy.tibble@virgin.net","","","","","","","","00165085","","","12145798","English","Gastroenterology","Article","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-0036320081"

"Berstad A.; Arslan G.; Folvik G.","Berstad, Arnold (16071042800); Arslan, G. (26030494000); Folvik, G. (21645364800)","16071042800; 26030494000; 21645364800","Relationship between intestinal permeability and calprotectin concentration in gut lavage fluid","2000","Scandinavian Journal of Gastroenterology","35","1","","64","69","5","88","10.1080/003655200750024551","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033965041&doi=10.1080%2f003655200750024551&partnerID=40&md5=f3e83c1503a7091f3a654844184c4e1b","Division of Gastroenterology, Dept. of Medicine, Haukeland University Hospital, Bergen, Norway; Institute of Medicine, Haukeland University Hospital, NO-5021 Bergen, Norway","Berstad A., Division of Gastroenterology, Dept. of Medicine, Haukeland University Hospital, Bergen, Norway, Institute of Medicine, Haukeland University Hospital, NO-5021 Bergen, Norway; Arslan G., Division of Gastroenterology, Dept. of Medicine, Haukeland University Hospital, Bergen, Norway; Folvik G., Division of Gastroenterology, Dept. of Medicine, Haukeland University Hospital, Bergen, Norway","Background: Calprotectin is released from neutrophils and monocytes, and increased calprotectin levels in stool may serve as a marker of intestinal inflammation. Intestinal permeability is increased in inflammatory bowel diseases, especially in Crohn disease. We studied the relationship between intestinal permeability and calprotectin concentration in intestinal lavage fluid in patients with known or suspected inflammatory bowel disease (IBD). Methods: Thirty-eight patients were examined; 17 had Crohn disease; 3, ulcerative colitis; and 18, irritable bowel syndrome. Intestinal lavage was performed by means of a nasojejunal tube positioned by gastroduodenoscopy. By means of a peristaltic pump 2 1 isotonic polyethylene glycol solution (MW, 3350) containing 50 μCi51 Cr-labelled ethylenediaminetetraacetic acid (EDTA) were administered through the tube over a period of 40 min. The first clear fluid passed per rectum was collected and analysed for calprotectin levels with an enzyme-linked immunosorbent assay method. Urine was collected for 5 h and analysed for gamma radioactivity. 51Cr-EDTA excretion in urine was expressed as percentage of dose administered (that is, intestinal permeability). Results: Both intestinal permeability and calprotectin concentration were significantly higher in patients with IBD than in patients with functional conditions. In Crohn disease the values depended on disease activity but not on whether the disease was located in the small or in the large bowel. There was a highly significant correlation between calprotectin concentration in gut lavage fluid and intestinal permeability (r = 0.79, P < 0.0001). Conclusion: The significant correlation between calprotectin concentration in gut lavage fluid and intestinal permeability supports the view that increased intestinal permeability in IBD might at least in part, be a consequence of increased transepithelial migration of neutrophils.","Calprotectin; Inflammatory bowel disease; Intestinal permeability","calprotectin; chromium 51; edetic acid; macrogol; adult; article; cell migration; clinical article; controlled study; Crohn disease; disease activity; enzyme linked immunosorbent assay; female; gastrointestinal endoscopy; human; intestine lavage; intestine mucosa permeability; irritable colon; male; neutrophil; priority journal; ulcerative colitis; urinalysis","","chromium 51, 14392-02-0; edetic acid, 150-43-6, 60-00-4; macrogol, 25322-68-3","","","","","Johne B., Fagerhol M.K., Lyberg T., Prydz H., Brandtzaeg P., Naess-Andresen C.F., Et al., Functional and clinical aspects of the myelomonocyte protein calprotectin, Molec Pathol, 50, SUPPL. 3, pp. 113-123, (1997); Lugering N., Stoll R., Kucharzik T., Schmid K.W., Rohlmann G., Burmeister G., Immunohistochemical distribution and serum levels of the Ca<sup>2+</sup>-binding proteins MRP8, MRP14 and their heterodimeric form MRP8/14 in Crohn's disease, Digestion, 56, pp. 406-414, (1995); Roseth A.G., Aadland E., Jahnsen J., Raknerud N., Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein, Digestion, 58, pp. 176-180, (1997); Roseth A.G., Fagerhol M.K., Aadland E., Schjoonsby H., Assessment of the neutrophil dominating protein calprotectin in feces. A methodological study, Scand J Gastroenterol, 27, pp. 793-798, (1992); Roseth A.G., Schmidt P.N., Fagerhol M.K., Correlation between faecal excretion of indium-I I I-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease, Scand J Gastroenterol, 34, pp. 50-54, (1999); Bjarnason I., Macpherson A., Hollander D., Intestinal permeability: An overview, Gastroenterology, 108, pp. 1566-1581, (1995); Hollander D., Vadheim C.M., Brettholz E., Petersen G.M., Delahunty T., Rotter J.I., Increased intestinal permeability in patients with Crohn's disease and their relatives, Ann Intern Med, 105, pp. 883-885, (1986); Jenkins R.T., Ramage J.K., Jones D.B., Collins S.M., Goodacre R.L., Hunt R.H., Small bowel and colonic permeability to <sup>51</sup>CrEDTA in patients with active inflammatory bowel disease, Clin Invest Med, 11, pp. 151-155, (1988); Milks L.C., Brontoli M.J., Cramer E.B., Epithelial permeability and the transepithelial migration of human neutrophils, J Cell Biol, 96, pp. 1241-1247, (1983); Gumbier B.M., Breaking through the tight junction barrier, J Cell Biol, 123, pp. 1631-1633, (1993); Parkos A.C., Colgan S.P., Delp C., Arnaout M., Madara J.L., Neutrophil migration across a cultured epithelial monolayer elicits a biphasic resistance response representing sequential effects on transcellular and paracellular pathways, J Cell Biol, 117, pp. 757-764, (1992); Nash S., Stafford J., Madara L., Effects of polymorphonuclear leucocyte transmigration on the barrier function of cultured intestinal epithelial monolayers, J Clin Invest, 80, pp. 1104-1113, (1987); Harvey R.F., Bradshaw J.M., A simple index of Crohn's-disease activity, Lancet, 1, (1980); Handy M.L., Ghosh S., Ferguson A., Investigation of neutrophil migration into the gut by cytology of whole gut lavage fluid, Eur J Gastroenterol Hepatol, 7, pp. 53-58, (1995); Acciuffi S., Ghosh S., Ferguson A., Strengths and limitations of the Crohn's disease activity index, revealed by an objective gut lavage test of gastrointestinal protein loss, Aliment Pharmacol Ther, 10, pp. 321-326, (1996); Bjarnason I., O'Morain C., Levi A.J., Peters T.J., Absorption of <sup>51</sup>Cr EDTA in inflammatory bowel disease, Gastroenterology, 85, pp. 318-322, (1983); Thomas Y.M.A., Intestinal epithelial dysfunction in Crohn's disease, Proc Soc Exp Biol Med, 214, pp. 318-326, (1997); Issenman R.M., Jenkins R.T., Radoja C., Intestinal permeability compared in pediatric and adults patients with inflammatory bowel disease, Clin Invest Med, 16, pp. 187-196, (1992); Casellas F., Soriano A.B., Accarino A., Molero J., Guarner L., Intestinal permeability to <sup>99m</sup>Tc-diethylenetriaminopentaacetic acid in inflammatory bowel disease, Am J Gastroenterol, 81, pp. 767-770, (1986); O'Morain C.A., Abelow A.C., Chervu L.R., Fleischner G.M., Das K.M., Chromium 51-ethylenediaminetetraacetate test: A useful test in the assessment of inflammatory bowel disease, J Lab Clin Med, 108, pp. 430-435, (1986); Behrens R.H., Szaz K.F., Northrop C., Elia M., Neale G., Radio-nuclide testes for the assessment of intestinal permeability, Eur J Clin Invest, 17, pp. 100-105, (1987); McKay D.M., Baird A.W., Cytokine regulation of epithelial permeability and ion transport, Gut, 44, pp. 283-289, (1999); Mahraoui L., Heyman M., Plique O., Droy-Lefaix M.T., Desjeux J.F., Apical effect of diosmectite on damage to the intestinal barrier induced by basal tumor necrosis factor-α, Gut, 40, pp. 339-343, (1997); Nash S., Stafford J., Madara J.L., The selective and superoxide-independent disruption of intestinal epithelial tight junctions during leukocyte transmigration, Lab Invest, 59, pp. 531-537, (1988); Ma T.Y., Intestinal epithelial barrier dysfunction in Crohn's disease, Proc Soc Exp Biol Med, 214, pp. 318-327, (1997); Parsons P.E., Sugahara K., Cott G.R., Mason R.J., Henson P.M., The effect of neutrophil migration and prolonged neutrophil contact on epithelial permeability, Am J Pathol, 129, pp. 302-312, (1987); Wakefield A.J., Sawyerr A.M., Dhillon A.P., Pittilo R.M., Rowles P.M., Lewis A.A., Et al., Pathogenesis of Crohn's disease: Multifocal gastrointestinal infarcation, Lancet, 2, pp. 1057-1062, (1989); Sankey E.A., Dhillon A.P., Anthony A., Wakefield A.J., Sim R., More R., Et al., Early mucosal changes in Crohn's disease, Gut, 34, pp. 375-381, (1993); Taylor C.T., Dzus A.L., Colgan S.P., Automne regulation of epithelial permeability by hypoxia: Role for polarized release of TNF-α, Gastroenterology, 114, pp. 657-668, (1998); Iqbal T.H., Lewis K.O., Cooper B.T., Diffusion of polyethylene glycol.400 across lipid barriers in vitro, Clin Sci, 85, pp. 111-115, (1993); Cox M.A., Iqbal T.H., Lewis K.O., Cooper B.T., Viewpoints in intestinal permeability, Gastroenterology, 112, pp. 669-670, (1997); Fotherby K.J., Wraight E.P., Neale G., <sup>51</sup>Cr-EDTA/<sup>14</sup>C-mannitol intestinal permeability test. Clinical use in screening for coeliac disease, Scand J Gastroenterol, 23, pp. 171-177, (1988)","","","Scandinavian University Press","","","","","","00365521","","SJGRA","10672837","English","Scand. J. Gastroenterol.","Article","Final","","Scopus","2-s2.0-0033965041"

"Ferrier L.; Mazelin L.; Cenac N.; Desreumaux P.; Janin A.; Emilie D.; Colombel J.-F.; Garcia-Villar R.; Fioramonti J.; Bueno L.","Ferrier, Laurent (7003733489); Mazelin, Ludmilla (6602837050); Cenac, Nicolas (6602478958); Desreumaux, Pierre (7005437152); Janin, Anne (7101748658); Emilie, Dominique (7102190264); Colombel, Jean-Frederic (7102945104); Garcia-Villar, Rafael (7003755916); Fioramonti, Jean (7102570340); Bueno, Lionel (36043988100)","7003733489; 6602837050; 6602478958; 7005437152; 7101748658; 7102190264; 7102945104; 7003755916; 7102570340; 36043988100","Stress-induced disruption of colonic epithelial barrier: Role of interferon-γ and myosin light chain kinase in mice","2003","Gastroenterology","125","3","","795","804","9","171","10.1016/S0016-5085(03)01057-6","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0042324629&doi=10.1016%2fS0016-5085%2803%2901057-6&partnerID=40&md5=8cb976e12da2c55b2c44c2bfe8a0bc44","Neuro-Gastroenterology/Nutr. Unit, Inst. Natl. de la Rech. Agronomique, Toulouse, France; Inst. Natl. S./la Rech. Med. EPI114, Centre Hospitalier Universitaire, Lille, France; Inst. Natl. S./Rech. Med. ERM 0220, Université Paris VII, Hôpital Saint Louis, Paris, France; Institut Paris Sud sur les Cytokines, INSERM U131, Clamart, France; Neuro-Gastroenterology/Nutr. Unit, Inst. Natl. de la Rech. Agronomique, 31931 Toulouse Cedex 9, 180 chemin de Tournefeuille, France","Ferrier L., Neuro-Gastroenterology/Nutr. Unit, Inst. Natl. de la Rech. Agronomique, Toulouse, France; Mazelin L., Neuro-Gastroenterology/Nutr. Unit, Inst. Natl. de la Rech. Agronomique, Toulouse, France; Cenac N., Neuro-Gastroenterology/Nutr. Unit, Inst. Natl. de la Rech. Agronomique, Toulouse, France; Desreumaux P., Inst. Natl. S./la Rech. Med. EPI114, Centre Hospitalier Universitaire, Lille, France; Janin A., Inst. Natl. S./Rech. Med. ERM 0220, Université Paris VII, Hôpital Saint Louis, Paris, France; Emilie D., Institut Paris Sud sur les Cytokines, INSERM U131, Clamart, France; Colombel J.-F., Inst. Natl. S./la Rech. Med. EPI114, Centre Hospitalier Universitaire, Lille, France; Garcia-Villar R., Neuro-Gastroenterology/Nutr. Unit, Inst. Natl. de la Rech. Agronomique, Toulouse, France; Fioramonti J., Neuro-Gastroenterology/Nutr. Unit, Inst. Natl. de la Rech. Agronomique, Toulouse, France; Bueno L., Neuro-Gastroenterology/Nutr. Unit, Inst. Natl. de la Rech. Agronomique, Toulouse, France, Neuro-Gastroenterology/Nutr. Unit, Inst. Natl. de la Rech. Agronomique, 31931 Toulouse Cedex 9, 180 chemin de Tournefeuille, France","Background & Aims: Stressful life events are supposed to be involved in various diseases such as inflammatory bowel diseases and irritable bowel syndrome. Impairment of the intestinal epithelial barrier function is a suspected consequence of stress, but the underlying mechanisms remain unclear. This study aimed to determine the mechanisms through which stress modulates the colonic epithelial barrier. Methods: Cytokine messenger RNA (mRNA) expression was evaluated in murine colon, liver, and spleen by competitive reverse-transcription polymerase chain reaction after 1-4 days of daily 2-hour stress sessions. Colonic paracellular permeability was measured as the in vivo lumen-to-blood ratio of 51Cr-ethylenediaminetetraacetic acid. The effect of a myosin light chain (MLC) kinase inhibitor (ML-7) was assessed on stress-induced interferon (IFN)-γ mRNA expression and colonic epithelial barrier impairment, and MLC phosphorylation was determined by immunoblot. Finally, the incidence of repeated stress sessions on bacterial translocation was determined. Results: Repeated stress induced an overexpression of colonic IFN-γ. In the liver, higher levels of IFN-γ, interleukin (IL)-4, and IL-10 mRNAs were detected and were associated with bacterial translocation, inflammation, and apoptosis. Stress increased colonic permeability of control mice, but not of SCID and IFN-γ-deficient mice. ML-7 inhibited the stress-induced increased permeability, bacterial translocation, and cytokine overexpression in the liver and restored a normal histology. Larger amounts of phosphorylated MLC were detected in stressed animals. Conclusions: Repeated stress sessions drive organ-specific cytokine expression patterns and alter colonic mucosal barrier functions associated with bacterial translocation. This effect depends on the presence of CD4+ T cells and requires IFN-γ production and MLC phosphorylation.","","chromium 51; edetic acid; gamma interferon; interleukin 10; interleukin 4; myosin light chain kinase; myosin light chain kinase inhibitor; animal experiment; animal tissue; apoptosis; article; bacterial translocation; colon mucosa; controlled study; cytokine release; enteritis; enzyme phosphorylation; helper cell; intestine mucosa permeability; irritable colon; knockout mouse; liver histology; mesentery lymph node; mouse; nonhuman; priority journal; reverse transcription polymerase chain reaction; SCID mouse; spleen; stress; Western blotting","","chromium 51, 14392-02-0; edetic acid, 150-43-6, 60-00-4; gamma interferon, 82115-62-6; myosin light chain kinase, 51845-53-5","","","Institut de Recherche sur les Maladies de l’Affareil Digestif; Fondation pour la Recherche Médicale, FRM; Institut National de la Recherche Agronomique, INRA","Supported by Institut de Recherche sur les Maladies de l’Affareil Digestif (IRMAD), Fondation pour la Recherche Médicale, and an institutional grant of Institut National de la Recherche Agronomique. L.M. is a recipient of the Ministère de l’Education Nationale, de l’Enseignement Supérieur, de la Recherche, et de la Technologie. ","Chrousos G.P., The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation, N Engl J Med, 332, pp. 1351-1362, (1995); Ottaviani E., Franceschi C., The neuroimmunology of stress from invertebrates to man, Prog Neurobiol, 48, pp. 421-440, (1996); Webster E.L., Torpy D.J., Elenkov I.J., Chrousos G.P., Corticotropin-releasing hormone and inflammation, Ann N Y Acad Sci, 840, pp. 21-32, (1998); Millan S., Gonzalez-Quijano M.I., Giordano M., Soto L., Martin A.I., Lopez-Calderon A., Short and long restraint differentially affect humoral and cellular immune functions, Life Sci, 59, pp. 1431-1442, (1996); Perdue M.H., Mucosal immunity and inflammation. III. The mucosal antigen barrier: Cross talk with mucosal cytokines, Am J Physiol, 277, (1999); Turner J.R., Rill B.K., Carlson S.L., Carnes D., Kerner R., Mrsny R.J., Madara J.L., Physiological regulation of epithelial tight junctions is associated with myosin light-chain phosphorylation, Am J Physiol, 273, (1997); Saunders P.R., Santos J., Hanssen N.P., Yates D., Groot J.A., Perdue M.H., Physical and psychological stress in rats enhances colonic epithelial permeability via peripheral CRH, Dig Dis Sci, 47, pp. 208-215, (2002); Meddings J.B., Swain M.G., Environmental stress-induced gastrointestinal permeability is mediated by endogenous glucocorticoids in the rat, Gastroenterology, 119, pp. 1019-1028, (2000); Santos J., Saunders P.R., Hanssen N.P., Yang P.C., Yates D., Groot J.A., Perdue M.H., Corticotropin-releasing hormone mimics stress-induced colonic epithelial pathophysiology in the rat, Am J Physiol, 277, (1999); Schmitz H., Barmeyer C., Gitter A.H., Wullstein F., Bentzel C.J., Fromm M., Riecken E.O., Schulzke J.D., Epithelial barrier and transport function of the colon in ulcerative colitis, Ann N Y Acad Sci, 915, pp. 312-326, (2000); Soderholm J.D., Olaison G., Peterson K.H., Franzen L.E., Lindmark T., Wiren M., Tagesson C., Sjodahl R., Augmented increase in tight junction permeability by luminal stimuli in the non-inflamed ileum of Crohn's disease, Gut, 50, pp. 307-313, (2002); Gassler N., Rohr C., Schneider A., Kartenbeck J., Bach A., Obermuller N., Otto H.F., Autschbach F., Inflammatory bowel disease is associated with changes of enterocytic junctions, Am J Physiol, 281, (2001); Gue M., Bonbonne C., Fioramonti J., More J., Del Rio-Lacheze C., Comera C., Bueno L., Stress-induced enhancement of colitis in rats: CRF and arginine vasopressin are not involved, Am J Physiol, 272, (1997); Qiu B.S., Vallance B.A., Blennerhassett P.A., Collins S.M., The role of CD4+ lymphocytes in the susceptibility of mice to stress-induced reactivation of experimental colitis, Nat Med, 5, pp. 1178-1182, (1999); Keshavarzian A., Holmes E.W., Patel M., Iber F., Fields J.Z., Pethkar S., Leaky gut in alcoholic cirrhosis: A possible mechanism for alcohol-induced liver damage, Am J Gastroenterol, 94, pp. 200-207, (1999); Ceponis P.J., Botelho F., Richards C.D., McKay D.M., Interleukins 4 and 13 increase intestinal epithelial permeability by a phosphatidylinositol 3-kinase pathway: Lack of evidence for STAT 6 involvement, J Biol Chem, 275, pp. 29132-29137, (2000); Youakim A., Ahdieh M., Interferon-gamma decreases barrier function in T84 cells by reducing ZO-1 levels and disrupting apical actin, Am J Physiol, 276, (1999); Mankertz J., Tavalali S., Schmitz H., Mankertz A., Riecken E.O., Fromm M., Schulzke J.D., Expression from the human occludin promoter is affected by tumor necrosis factor alpha and interferon gamma, J Cell Sci, 113, pp. 2085-2090, (2000); Nusrat A., Turner J.R., Madara J.L., Molecular physiology and pathophysiology of tight junctions. IV. Regulation of tight junctions by extracellular stimuli: Nutrients, cytokines, and immune cells, Am J Physiol, 279, (2000); Dalton D.K., Pitts-Meek S., Keshav S., Figari I.S., Bradley A., Stewart T.A., Multiple defects of immune cell function in mice with disrupted interferon-gamma genes, Science, 259, pp. 1739-1742, (1993); Bradley P.P., Priebat D.A., Christensen R.D., Rothstein G., Measurement of cutaneous inflammation: Estimation of neutrophil content with an enzyme marker, J Invest Dermatol, 78, pp. 206-209, (1982); Ma T.Y., Nguyen D., Bui V., Nguyen H., Hoa N., Ethanol modulation of intestinal epithelial tight junction barrier, Am J Physiol, 276, (1999); Northrop J.P., Crabtree G.R., Mattila P.S., Negative regulation of interleukin 2 transcription by the glucocorticoid receptor, J Exp Med, 175, pp. 1235-1245, (1992); DeKruyff R.H., Fang Y., Umetsu D.T., Corticosteroids enhance the capacity of macrophages to induce Th2 cytokine synthesis in CD4+ lymphocytes by inhibiting IL-12 production, J Immunol, 160, pp. 2231-2237, (1998); Million M., Tache Y., Anton P., Susceptibility of Lewis and Fischer rats to stress-induced worsening of TNB-colitis: Protective role of brain CRF, Am J Physiol, 276, (1999); Levenstein S., Prantera C., Varvo V., Scribano M.L., Andreoli A., Luzi C., Arca M., Berto E., Milite G., Marcheggiano A., Stress and exacerbation in ulcerative colitis: A prospective study of patients enrolled in remission, Am J Gastroenterol, 95, pp. 1213-1220, (2000); Peeters M., Ghoos Y., Maes B., Hiele M., Geboes K., Vantrappen G., Rutgeerts P., Increased permeability of macroscopically normal small bowel in Crohn's disease, Dig Dis Sci, 39, pp. 2170-2176, (1994); Everding B., Wilhelm S., Averesch S., Scherdin U., Holzel F., Steffen M., IFN-gamma-induced change in microtubule organization and alpha-tubulin expression during growth inhibition of lung squamous carcinoma cells, J Interferon Cytokine Res, 20, pp. 983-990, (2000); Zolotarevsky Y., Hecht G., Koutsouris A., Gonzalez D.E., Quan C., Tom J., Mrsny R.J., Turner J.R., A membrane-permeant peptide that inhibits MLC kinase restores barrier function in in vitro models of intestinal disease, Gastroenterology, 123, pp. 163-172, (2002); Keshavarzian A., Choudhary S., Holmes E.W., Yong S., Banan A., Jakate S., Fields J.Z., Preventing gut leakiness by oats supplementation ameliorates alcohol-induced liver damage in rats, J Pharmacol Exp Ther, 299, pp. 442-448, (2001); Howell C.D., Li J., Chen W., Role of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1 during nonsuppurative destructive cholangitis in a mouse graft-versus-host disease model, Hepatology, 29, pp. 766-776, (1999); Shindo M., Mullin G.E., Braun-Elwert L., Bergasa N.V., Jones E.A., James S.P., Cytokine mRNA expression in the liver of patients with primary biliary cirrhosis (PBC) and chronic hepatitis B (CHB), Clin Exp Immunol, 105, pp. 254-259, (1996); Olsson T., Critical influences of the cytokine orchestration on the outcome of myelin antigen-specific T-cell autoimmunity in experimental autoimmune encephalomyelitis and multiple sclerosis, Immunol Rev, 144, pp. 245-268, (1995); Farah I.O., Mola P.W., Kariuki T.M., Nyindo M., Blanton R.E., King C.L., Repeated exposure induces periportal fibrosis in Schistosoma mansoni-infected baboons: Role of TGF-beta and IL-4, J Immunol, 164, pp. 5337-5343, (2000); Mola P.W., Farah I.O., Kariuki T.M., Nyindo M., Blanton R.E., King C.L., Cytokine control of the granulomatous response in Schistosoma mansoni-infected baboons: Role of exposure and treatment, Infect Immun, 67, pp. 6565-6571, (1999); Jarvelainen H.A., Fang C., Ingelman-Sundberg M., Lindros K.O., Effect of chronic coadministration of endotoxin and ethanol on rat liver pathology and proinflammatory and anti-inflammatory cytokines, Hepatology, 29, pp. 1503-1510, (1999); Thompson K., Maltby J., Fallowfield J., McAulay M., Millward-Sadler H., Sheron N., Interleukin-10 expression and function in experimental murine liver inflammation and fibrosis, Hepatology, 28, pp. 1597-1606, (1998); Benedetti A., Marucci L., The significance of apoptosis in the liver, Liver, 19, pp. 453-463, (1999); Geller D.A., Nussler A.K., Di Silvio M., Lowenstein C.J., Shapiro R.A., Wang S.C., Simmons R.L., Billiar T.R., Cytokines, endotoxin, and glucocorticoids regulate the expression of inducible nitric oxide synthase in hepatocytes, Proc Natl Acad Sci U S A, 90, pp. 522-526, (1993)","","","W.B. Saunders","","","","","","00165085","","GASTA","12949725","English","Gastroenterology","Article","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-0042324629"

"Barau E.; Dupont C.","Barau, Edith (6603210881); Dupont, Christophe (35986193400)","6603210881; 35986193400","Modifications of intestinal permeability during food provocation procedures in pediatric irritable bowel syndrome","1990","Journal of Pediatric Gastroenterology and Nutrition","11","1","","72","77","5","64","10.1097/00005176-199007000-00015","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0025371557&doi=10.1097%2f00005176-199007000-00015&partnerID=40&md5=da7248dcf0bbcdf895995286cd6f580c","Hôpital Saint-Vincent de Paul, Paris, France","Barau E., Hôpital Saint-Vincent de Paul, Paris, France; Dupont C., Hôpital Saint-Vincent de Paul, Paris, France","An intestinal permeability test analyzing the differential urinary elimination of lactulose and mannitol orally ingested at the same dosage was carried out first in fasting condition, then combined with specific food ingestion, in 17 children with clinical symptoms of irritable bowel syndrome (IBS). Foods were selected based on a suggestive clinical history or on a positive radioaller-gosorbent or prick test. Comparison of the results with those of a control population reported in a previous study showed that in nine IBS patients, specific food ingestion was associated with a modification of intestinal permeability. The nine children all had a personal and/or familial history of allergy and/or raised total IgE. The symptoms disappeared in the nine patients after food exclusion either alone (seven patients) or together with further treatment by cromolyn (two patients). We conclude that, at least in some children, symptoms of IBS may be related to food hypersensitivity. © 1990 Raven Press, Ltd., New York.","Food allergy; Intestinal permeability; Irritable bowel syndrome","Adolescent; Child; Child, Preschool; Colonic Diseases, Functional; Diet; Female; Food Hypersensitivity; Human; Intestinal Absorption; Lactulose; Male; Mannitol; lactulose; mannitol; article; child; clinical article; female; food; food allergy; human; intestine absorption; intestine function; intestine mucosa permeability; male; oral drug administration; priority journal; urinary excretion","","Lactulose, 4618-18-2; Mannitol, 69-65-8","duphalac, duphar, France","duphar, France","","","Dupont C., Barau E., Molkhou P., Barbet J.P., Dehennin L., Food-induced alterations of intestinal permeability in children with cow’s milk sensitive enteropathy and atopic dermatitis, J Pediatr Gastroenterol Nutr, 8, pp. 459-465, (1989); Walker-Smith J.A., Ford R.P., Philips A.D., The spectrum of gastrointestinal allergies to food, Ann Allergy, 53, pp. 629-636, (1984); Davidson M., Wasserman R., The irritable colon of childhood (Chronic non specific diarrhea syndrome), J Pediatr, 69, pp. 1027-1038, (1986); Snape W.J., Carlson G.M., Matarazzo S.A., Cohen S., Evidence that abdominal myoelectrical activity produces colonic motor dysfunction in the irritable bowel syndrome, Gastroen-Terology, 72, pp. 383-387, (1977); Cohen S.A., Hendricks K.M., Mathis R.K., Laramee S., Walker W.A., Chronic non specific diarrhea: Dietary relationships, Pediatrics, 64, pp. 402-407, (1979); Ghisolfi J., Olives J.P., Familiades J., Rives J.J., Rives-Tocaven M., Diarchies chroniques des colopathies non spécifiques de l’enfant. Essai de déemembrement étiologique, Arch Fr Pediatr, 40, pp. 531-536, (1983); Chang E.B., Fedorak R.N., Prostaglandins in diarrheal disease, J Pediatr Gastroenterol Nutr, 4, pp. 341-344, (1985); Jonas A., Diver-Haber A., Stool output and composition in the chronic non-specific diarrhoea syndrome, Arch Dis Child, 57, pp. 35-39, (1982); Alun Jones V., Me Laughlan P., Shorthouse M., Workman E., Hunter J.O., Food intolerance: A major factor in the pathogenesis of irritable bowel syndrome, Lancet, 2, pp. 1115-1117, (1982); Bentley S.J., Pearson D.J., Rix K.G., Food hypersensitivity in irritable bowel syndrome, Lancet, 2, pp. 295-297, (1983); Petitpierre M., Gumowski P., Girard J.P., Irritable bowel syndrome and hypersensitivity to food, Ann Allergy, 54, pp. 538-540, (1985); Savilahti E., Simell O., Chronic non-specific diarrhoea, Arch Dis Child, 60, pp. 452-456, (1985); Cohen S.A., Hendricks K.M., Eastham E.J., Mathis R.K., Walker W.A., Chronic nonspecific diarrhea. A complication of dietary fat restriction, Am J Dis Child, 133, pp. 490-492, (1979); Lloyd-Still J.D., Chronic diarrhea of childhood and the misuse of elimination diets, J Pediatr, 95, pp. 10-13, (1979); Juby L.D., Rothwell J., Axon A., Lactulose/mannitol test: An ideal screen for celiac disease, Gastroenterology, 96, pp. 79-85, (1989); Dupont C., Dehennin L., Navarro J., Canlorbe P., Identification des syndromes de malabsorption par mesure de la per-m£abilit£ intestinale. Son application k la maladie coeliaque de l’enfant, Presse Med, 16, pp. 777-778, (1987); Fenton T.R., The irritable bowel syndrome: A paediatric entity, Disorders of Gastrointestinal Motility in Childhood, pp. 101-109, (1988)","","","","","","","","","02772116","","","2117653","English","J. Pediatr. Gastroenterol. Nutr.","Article","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-0025371557"

"Strobel S.; Brydon W.G.; Ferguson A.","Strobel, S. (57208158895); Brydon, W.G. (57201271435); Ferguson, A. (16050168700)","57208158895; 57201271435; 16050168700","Cellobiose/mannitol sugar permeability test complements biopsy histopathology in clinical investigation of the jejunum","1984","Gut","25","11","","1241","1246","5","111","10.1136/gut.25.11.1241","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0021723161&doi=10.1136%2fgut.25.11.1241&partnerID=40&md5=b6043f3fffabff2b86d25605b8b1cf3e","United Kingdom","Strobel S., United Kingdom; Brydon W.G., United Kingdom; Ferguson A., United Kingdom","Intestinal permeability to probe molecules has been shown to correlate closely with the presence or absence of villous atrophy in a jejunal biopsy. The purpose of this study was to establish if there exist groups of patients with functional derangement of intestinal permeability but normal histopathology of the small bowel mucosa. In 135 patients a cellobiose/mannitol permeability test was performed at the same time as jejunal biopsy. Diagnosis included coeliac disease, Crohn's disease, irritable bowel syndrome, idiopathic diarrhoea, self diagnosed food allergy, atrophic eczema and postinfectious malabsorption. The value of the cellobiose/mannitol test in identifying patients with abnormal jejunal biopsy histopathology was confirmed. The permeability test was abnormal in all 28 patients with partial or subtotal villous atrophy, and also in all 10 in whom there was a high intraepithelial lymphocyte count despite normal villi and crypts. Functional abnormality of the small intestine has not previously been reported in patients with this jejunal biopsy abnormality. Abnormalities of permeability were also found in patients with idiopathic diarrhoea, folate deficiency, postinfectious or traveller's diarrhoea, small bowel Crohn's disease, and atopic eczema. These results show that sugar permeability tests have more potential in clinical investigation that merely serving as screening tests before jejunal biopsy. There are groups of patients without morphological changes in the small bowel in whom intestinal permeability is abnormal.","","biopsy; controlled study; diagnosis; histology; histopathology; human; intestine villus atrophy; jejunum; jejunum biopsy; major clinical study; priority journal; small intestine","","","","","","","","","","","","","","","","00175749","","GUTTA","6437913","English","GUT","Article","Final","All Open Access; Bronze Open Access; Green Open Access","Scopus","2-s2.0-0021723161"

